The	O
relationship	O
of	O
glycosylation	O
and	O
isoelectric	O
point	O
with	O
tumor	O
accumulation	O
of	O
avidin	B-Protein
.	O
<EOS>	B-X
Radiolabeled	B-X
avidin	B-X
markedly	B-X
accumulated	B-X
in	B-X
intraperitoneal	B-X
tumors	B-X
and	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
circulation	B-X
when	B-X
given	B-X
intraperitoneally	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
tumor	B-X
localization	B-X
of	B-X
avidin	B-X
.	B-X

Radiolabeled	O
avidin	B-Protein
markedly	O
accumulated	O
in	O
intraperitoneal	O
tumors	O
and	O
was	O
cleared	O
rapidly	O
from	O
circulation	O
when	O
given	O
intraperitoneally	O
.	O
<EOS>	B-X
Radiolabeled	B-X
avidin	B-X
markedly	B-X
accumulated	B-X
in	B-X
intraperitoneal	B-X
tumors	B-X
and	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
circulation	B-X
when	B-X
given	B-X
intraperitoneally	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
tumor	B-X
localization	B-X
of	B-X
avidin	B-X
.	B-X

This	O
study	O
investigated	O
the	O
mechanisms	O
of	O
the	O
tumor	O
localization	O
of	O
avidin	B-Protein
.	O
<EOS>	B-X
Radiolabeled	B-X
avidin	B-X
markedly	B-X
accumulated	B-X
in	B-X
intraperitoneal	B-X
tumors	B-X
and	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
circulation	B-X
when	B-X
given	B-X
intraperitoneally	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
tumor	B-X
localization	B-X
of	B-X
avidin	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
effect	B-X
of	B-X
sex	B-X
hormones	B-X
on	B-X
breast	B-X
tumorigenesis	B-X
and	B-X
prognosis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
on	B-X
the	B-X
development	B-X
of	B-X
breast	B-X
cancer	B-X
metastases	B-X
,	B-X
modification	B-X
of	B-X
the	B-X
steroid	B-X
skeleton	B-X
is	B-X
a	B-X
hotspot	B-X
of	B-X
research	B-X
for	B-X
novel	B-X
anticancer	B-X
agents	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
antitumor	B-X
and	B-X
antimetastatic	B-X
properties	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
a	B-X
D-ring-modified	B-X
exo-heterocyclic	B-X
androstadiene	B-X
derivative	B-X
named	B-X
17APAD	B-X
.	B-X
Inhibitory	B-X
effects	B-X
on	B-X
metastasis	B-X
formation	B-X
,	B-X
including	B-X
the	B-X
inhibition	B-X
of	B-X
migration	B-X
,	B-X
invasion	B-X
and	B-X
intravasation	B-X
were	B-X
investigated	B-X
in	B-X
2D	B-X
and	B-X
3D	B-X
models	B-X
.	B-X
These	B-X
findings	B-X
support	B-X
that	B-X
substitution	B-X
of	B-X
the	B-X
androsta-5,16-diene	B-X
framework	B-X
with	B-X
a	B-X
N-containing	B-X
heterocyclic	B-X
moiety	B-X
at	B-X
C17	B-X
position	B-X
yields	B-X
a	B-X
molecular	B-X
entity	B-X
rational	B-X
to	B-X
be	B-X
considered	B-X
for	B-X
design	B-X
and	B-X
synthesis	B-X
of	B-X
novel	B-X
,	B-X
effective	B-X
antitumor	B-X
agents	B-X
,	B-X
and	B-X
17APAD	B-X
is	B-X
worth	B-X
further	B-X
investigation	B-X
as	B-X
a	B-X
promising	B-X
anticancer	B-X
drug	B-X
candidate	B-X
.	B-X

METHODS	O
:	O
Avidin	B-Protein
was	O
deglycosylated	O
through	O
endoglycosydase	B-Protein
-	I-Protein
H	I-Protein
digestion	O
and	O
/	O
or	O
neutralized	O
by	O
acetylation	O
of	O
its	O
lysine	O
amino	O
acids	O
with	O
acetic	O
acid	O
N	O
-	O
hydroxysuccinimide	O
ester	O
.	O

Avidin	B-Protein
and	O
modified	O
avidins	B-Protein
were	O
analyzed	O
using	O
sodium	O
dodecylsulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
/	O
PAGE	O
)	O
and	O
isoelectric	O
focusing	O
.	O
<EOS>	B-X
To	B-X
optimize	B-X
blood	B-X
clearance	B-X
kinetics	B-X
,	B-X
SA	B-X
and	B-X
avidin	B-X
were	B-X
biochemically	B-X
modified	B-X
and	B-X
analyzed	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

A	O
tumor	O
model	O
was	O
established	O
by	O
intraperitoneal	O
injection	O
of	O
human	O
colon	O
cancer	O
cells	O
,	O
LS180	O
,	O
in	O
nude	O
mice	O
.	O
<EOS>	B-X
Radiolabeled	B-X
avidin	B-X
markedly	B-X
accumulated	B-X
in	B-X
intraperitoneal	B-X
tumors	B-X
and	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
circulation	B-X
when	B-X
given	B-X
intraperitoneally	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
tumor	B-X
localization	B-X
of	B-X
avidin	B-X
.	B-X

Avidin	B-Protein
and	O
modified	O
avidins	B-Protein
were	O
labeled	O
with	O
111In	O
using	O
diethyleneamine	O
pentaacetic	O
acid	O
-	O
biotin	O
and	O
were	O
administered	O
intraperitoneally	O
into	O
the	O
tumor	O
-	O
bearing	O
mice	O
.	O
<EOS>	B-X
Radiolabeled	B-X
avidin	B-X
markedly	B-X
accumulated	B-X
in	B-X
intraperitoneal	B-X
tumors	B-X
and	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
circulation	B-X
when	B-X
given	B-X
intraperitoneally	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
tumor	B-X
localization	B-X
of	B-X
avidin	B-X
.	B-X

The	O
biodistribution	O
of	O
radioactivity	O
was	O
examined	O
2	O
and	O
24	O
h	O
postinjection	O
.	O
<EOS>	B-X
Treatment	B-X
with	B-X
amyloid-β	B-X
(	B-X
Aβ	B-X
)	B-X
targeting	B-X
antibodies	B-X
is	B-X
a	B-X
promising	B-X
approach	B-X
to	B-X
remove	B-X
Aβ	B-X
brain	B-X
pathology	B-X
in	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
and	B-X
possibly	B-X
even	B-X
slow	B-X
down	B-X
or	B-X
stop	B-X
progression	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
One	B-X
of	B-X
the	B-X
main	B-X
challenges	B-X
of	B-X
brain	B-X
immunotherapy	B-X
is	B-X
the	B-X
restricted	B-X
delivery	B-X
of	B-X
antibodies	B-X
to	B-X
the	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
bispecific	B-X
antibodies	B-X
that	B-X
utilize	B-X
the	B-X
transferrin	B-X
receptor	B-X
(	B-X
TfR	B-X
)	B-X
as	B-X
a	B-X
shuttle	B-X
for	B-X
transport	B-X
across	B-X
the	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
can	B-X
access	B-X
the	B-X
brain	B-X
better	B-X
than	B-X
traditional	B-X
monospecific	B-X
antibodies	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
bispecific	B-X
Aβ	B-X
targeting	B-X
antibodies	B-X
have	B-X
higher	B-X
brain	B-X
distribution	B-X
,	B-X
and	B-X
can	B-X
remove	B-X
Aβ	B-X
pathology	B-X
more	B-X
efficiently	B-X
than	B-X
monospecific	B-X
antibodies	B-X
.	B-X
Yet	B-X
,	B-X
there	B-X
is	B-X
only	B-X
limited	B-X
information	B-X
available	B-X
on	B-X
brain	B-X
pharmacokinetics	B-X
,	B-X
especially	B-X
regarding	B-X
differences	B-X
between	B-X
mono-	B-X
and	B-X
bispecific	B-X
antibodies	B-X
.	B-X

RESULTS	O
:	O
Deglycosylated	O
avidins	B-Protein
revealed	O
a	O
major	O
band	O
of	O
smaller	O
molecules	O
on	O
SDS	O
/	O
PAGE	O
.	O

The	O
isoelectric	O
point	O
of	O
neutralized	O
avidins	B-Protein
was	O
reduced	O
to	O
less	O
than	O
5	O
,	O
whereas	O
that	O
of	O
unneutralized	O
avidins	B-Protein
was	O
more	O
than	O
9	O
.	O
5	O
.	O

Biodistribution	O
study	O
demonstrated	O
that	O
liver	O
uptake	O
was	O
decreased	O
by	O
deglycosylation	O
and	O
kidney	O
accumulation	O
was	O
decreased	O
by	O
neutralization	O
,	O
respectively	O
.	O
<EOS>	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
tumor	B-X
localization	B-X
of	B-X
avidin	B-X
.	B-X

The	O
blood	O
clearance	O
was	O
remarkably	O
slowed	O
by	O
combined	O
modification	O
of	O
deglycosylation	O
and	O
neutralization	O
.	O

The	O
tumor	O
uptake	O
of	O
radioactivity	O
was	O
reduced	O
by	O
either	O
deglycosylation	O
or	O
neutralization	O
and	O
was	O
further	O
decreased	O
with	O
combined	O
modification	O
.	O
<EOS>	B-X
A	B-X
YTE	B-X
modification	B-X
was	B-X
introduced	B-X
to	B-X
the	B-X
fragment	B-X
crystallizable	B-X
(	B-X
Fc	B-X
)	B-X
region	B-X
of	B-X
both	B-X
mAbs	B-X
to	B-X
prolong	B-X
serum	B-X
half-life	B-X
and	B-X
reduce	B-X
effector	B-X
function	B-X
.	B-X
The	B-X
amubarvimab	B-X
and	B-X
romlusevimab	B-X
combination	B-X
retained	B-X
activity	B-X
against	B-X
most	B-X
mutations	B-X
associated	B-X
with	B-X
reduced	B-X
susceptibility	B-X
to	B-X
previously	B-X
authorized	B-X
mAbs	B-X
and	B-X
against	B-X
variants	B-X
containing	B-X
amino	B-X
acid	B-X
substitutions	B-X
in	B-X
their	B-X
epitope	B-X
regions	B-X
.	B-X
Radiolabeled	B-X
avidin	B-X
markedly	B-X
accumulated	B-X
in	B-X
intraperitoneal	B-X
tumors	B-X
and	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
circulation	B-X
when	B-X
given	B-X
intraperitoneally	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
tumor	B-X
localization	B-X
of	B-X
avidin	B-X
.	B-X

CONCLUSION	O
:	O
Both	O
high	O
glycosylation	O
and	O
positive	O
charge	O
of	O
avidin	B-Protein
contributed	O
to	O
its	O
accumulation	O
in	O
tumor	O
.	O
<EOS>	B-X
Radiolabeled	B-X
avidin	B-X
markedly	B-X
accumulated	B-X
in	B-X
intraperitoneal	B-X
tumors	B-X
and	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
circulation	B-X
when	B-X
given	B-X
intraperitoneally	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
tumor	B-X
localization	B-X
of	B-X
avidin	B-X
.	B-X

This	O
study	O
may	O
facilitate	O
development	O
of	O
a	O
new	O
vehicle	O
for	O
the	O
delivery	O
of	O
therapeutic	O
agents	O
to	O
intraperitoneal	O
tumors	O
.	O
<EOS>	B-X
Radiolabeled	B-X
avidin	B-X
markedly	B-X
accumulated	B-X
in	B-X
intraperitoneal	B-X
tumors	B-X
and	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
circulation	B-X
when	B-X
given	B-X
intraperitoneally	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
tumor	B-X
localization	B-X
of	B-X
avidin	B-X
.	B-X

A	O
novel	O
aromatic	O
-	O
ring	O
-	O
hydroxylating	O
dioxygenase	O
from	O
the	O
diterpenoid	O
-	O
degrading	O
bacterium	O
Pseudomonas	O
abietaniphila	O
BKME	O
-	O
9	O
.	O
<EOS>	B-X
Pseudomonas	B-X
abietaniphila	B-X
BKME-9	B-X
is	B-X
able	B-X
to	B-X
degrade	B-X
dehydroabietic	B-X
acid	B-X
(	B-X
DhA	B-X
)	B-X
via	B-X
ring	B-X
hydroxylation	B-X
by	B-X
a	B-X
novel	B-X
dioxygenase	B-X
.	B-X
The	B-X
ditA1	B-X
,	B-X
ditA2	B-X
,	B-X
and	B-X
ditA3	B-X
genes	B-X
,	B-X
which	B-X
encode	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
the	B-X
oxygenase	B-X
and	B-X
the	B-X
ferredoxin	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
isolated	B-X
and	B-X
sequenced	B-X
.	B-X
The	B-X
ferredoxin	B-X
gene	B-X
is	B-X
9	B-X
.	B-X
2	B-X
kb	B-X
upstream	B-X
of	B-X
the	B-X
oxygenase	B-X
genes	B-X
and	B-X
872	B-X
bp	B-X
upstream	B-X
of	B-X
a	B-X
putative	B-X
meta	B-X
ring	B-X
cleavage	B-X
dioxygenase	B-X
gene	B-X
,	B-X
ditC	B-X
.	B-X
A	B-X
Tn5	B-X
insertion	B-X
in	B-X
the	B-X
alpha	B-X
subunit	B-X
gene	B-X
,	B-X
ditA1	B-X
,	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
by	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
of	B-X
the	B-X
pathway	B-X
intermediate	B-X
,	B-X
7-oxoDhA	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
ferredoxin	B-X
gene	B-X
,	B-X
ditA3	B-X
,	B-X
in	B-X
wild-type	B-X
BKME-9	B-X
by	B-X
mutant-allele	B-X
exchange	B-X
resulted	B-X
in	B-X
a	B-X
strain	B-X
(	B-X
BKME-91	B-X
)	B-X
with	B-X
a	B-X
phenotype	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
.	B-X
Sequence	B-X
analysis	B-X
of	B-X
the	B-X
putative	B-X
ferredoxin	B-X
indicated	B-X
that	B-X
it	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
a	B-X
[	B-X
4Fe-4S	B-X
]	B-X
-	B-X
or	B-X
[	B-X
3Fe-4S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
and	B-X
not	B-X
a	B-X
[	B-X
2Fe-2S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
,	B-X
as	B-X
found	B-X
in	B-X
all	B-X
previously	B-X
described	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X
Expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
of	B-X
ditA1A2A3	B-X
,	B-X
encoding	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
without	B-X
its	B-X
putative	B-X
reductase	B-X
component	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
functional	B-X
enzyme	B-X
.	B-X
The	B-X
diterpenoid	B-X
dioxygenase	B-X
attacks	B-X
7-oxoDhA	B-X
,	B-X
and	B-X
not	B-X
DhA	B-X
,	B-X
at	B-X
C-11	B-X
and	B-X
C-12	B-X
,	B-X
producing	B-X
7-oxo-11	B-X
,	B-X
12-dihydroxy-8,13-abietadien	B-X
acid	B-X
,	B-X
which	B-X
was	B-X
identified	B-X
by	B-X
1H	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
,	B-X
UV-visible	B-X
light	B-X
,	B-X
and	B-X
high-resolution	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
the	B-X
genes	B-X
encoding	B-X
the	B-X
various	B-X
components	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
the	B-X
phylogenetic	B-X
distinctiveness	B-X
of	B-X
both	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
the	B-X
ferredoxin	B-X
component	B-X
,	B-X
and	B-X
the	B-X
unusual	B-X
Fe-S	B-X
cluster	B-X
of	B-X
the	B-X
ferredoxin	B-X
all	B-X
suggest	B-X
that	B-X
this	B-X
enzyme	B-X
belongs	B-X
to	B-X
a	B-X
new	B-X
class	B-X
of	B-X
aromatic	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X

Pseudomonas	O
abietaniphila	O
BKME	O
-	O
9	O
is	O
able	O
to	O
degrade	O
dehydroabietic	O
acid	O
(	O
DhA	O
)	O
via	O
ring	O
hydroxylation	O
by	O
a	O
novel	O
dioxygenase	O
.	O
<EOS>	B-X
Pseudomonas	B-X
abietaniphila	B-X
BKME-9	B-X
is	B-X
able	B-X
to	B-X
degrade	B-X
dehydroabietic	B-X
acid	B-X
(	B-X
DhA	B-X
)	B-X
via	B-X
ring	B-X
hydroxylation	B-X
by	B-X
a	B-X
novel	B-X
dioxygenase	B-X
.	B-X
The	B-X
ditA1	B-X
,	B-X
ditA2	B-X
,	B-X
and	B-X
ditA3	B-X
genes	B-X
,	B-X
which	B-X
encode	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
the	B-X
oxygenase	B-X
and	B-X
the	B-X
ferredoxin	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
isolated	B-X
and	B-X
sequenced	B-X
.	B-X
The	B-X
ferredoxin	B-X
gene	B-X
is	B-X
9	B-X
.	B-X
2	B-X
kb	B-X
upstream	B-X
of	B-X
the	B-X
oxygenase	B-X
genes	B-X
and	B-X
872	B-X
bp	B-X
upstream	B-X
of	B-X
a	B-X
putative	B-X
meta	B-X
ring	B-X
cleavage	B-X
dioxygenase	B-X
gene	B-X
,	B-X
ditC	B-X
.	B-X
A	B-X
Tn5	B-X
insertion	B-X
in	B-X
the	B-X
alpha	B-X
subunit	B-X
gene	B-X
,	B-X
ditA1	B-X
,	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
by	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
of	B-X
the	B-X
pathway	B-X
intermediate	B-X
,	B-X
7-oxoDhA	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
ferredoxin	B-X
gene	B-X
,	B-X
ditA3	B-X
,	B-X
in	B-X
wild-type	B-X
BKME-9	B-X
by	B-X
mutant-allele	B-X
exchange	B-X
resulted	B-X
in	B-X
a	B-X
strain	B-X
(	B-X
BKME-91	B-X
)	B-X
with	B-X
a	B-X
phenotype	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
.	B-X
Sequence	B-X
analysis	B-X
of	B-X
the	B-X
putative	B-X
ferredoxin	B-X
indicated	B-X
that	B-X
it	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
a	B-X
[	B-X
4Fe-4S	B-X
]	B-X
-	B-X
or	B-X
[	B-X
3Fe-4S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
and	B-X
not	B-X
a	B-X
[	B-X
2Fe-2S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
,	B-X
as	B-X
found	B-X
in	B-X
all	B-X
previously	B-X
described	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X
Expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
of	B-X
ditA1A2A3	B-X
,	B-X
encoding	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
without	B-X
its	B-X
putative	B-X
reductase	B-X
component	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
functional	B-X
enzyme	B-X
.	B-X
The	B-X
diterpenoid	B-X
dioxygenase	B-X
attacks	B-X
7-oxoDhA	B-X
,	B-X
and	B-X
not	B-X
DhA	B-X
,	B-X
at	B-X
C-11	B-X
and	B-X
C-12	B-X
,	B-X
producing	B-X
7-oxo-11	B-X
,	B-X
12-dihydroxy-8,13-abietadien	B-X
acid	B-X
,	B-X
which	B-X
was	B-X
identified	B-X
by	B-X
1H	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
,	B-X
UV-visible	B-X
light	B-X
,	B-X
and	B-X
high-resolution	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
the	B-X
genes	B-X
encoding	B-X
the	B-X
various	B-X
components	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
the	B-X
phylogenetic	B-X
distinctiveness	B-X
of	B-X
both	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
the	B-X
ferredoxin	B-X
component	B-X
,	B-X
and	B-X
the	B-X
unusual	B-X
Fe-S	B-X
cluster	B-X
of	B-X
the	B-X
ferredoxin	B-X
all	B-X
suggest	B-X
that	B-X
this	B-X
enzyme	B-X
belongs	B-X
to	B-X
a	B-X
new	B-X
class	B-X
of	B-X
aromatic	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X

The	O
ditA1	B-Protein
,	O
ditA2	B-Protein
,	O
and	O
ditA3	B-Protein
genes	O
,	O
which	O
encode	O
the	O
alpha	O
and	O
beta	O
subunits	O
of	O
the	O
oxygenase	O
and	O
the	O
ferredoxin	O
of	O
the	O
diterpenoid	O
dioxygenase	O
,	O
respectively	O
,	O
were	O
isolated	O
and	O
sequenced	O
.	O
<EOS>	B-X
Pseudomonas	B-X
abietaniphila	B-X
BKME-9	B-X
is	B-X
able	B-X
to	B-X
degrade	B-X
dehydroabietic	B-X
acid	B-X
(	B-X
DhA	B-X
)	B-X
via	B-X
ring	B-X
hydroxylation	B-X
by	B-X
a	B-X
novel	B-X
dioxygenase	B-X
.	B-X
The	B-X
ditA1	B-X
,	B-X
ditA2	B-X
,	B-X
and	B-X
ditA3	B-X
genes	B-X
,	B-X
which	B-X
encode	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
the	B-X
oxygenase	B-X
and	B-X
the	B-X
ferredoxin	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
isolated	B-X
and	B-X
sequenced	B-X
.	B-X
The	B-X
ferredoxin	B-X
gene	B-X
is	B-X
9	B-X
.	B-X
2	B-X
kb	B-X
upstream	B-X
of	B-X
the	B-X
oxygenase	B-X
genes	B-X
and	B-X
872	B-X
bp	B-X
upstream	B-X
of	B-X
a	B-X
putative	B-X
meta	B-X
ring	B-X
cleavage	B-X
dioxygenase	B-X
gene	B-X
,	B-X
ditC	B-X
.	B-X
A	B-X
Tn5	B-X
insertion	B-X
in	B-X
the	B-X
alpha	B-X
subunit	B-X
gene	B-X
,	B-X
ditA1	B-X
,	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
by	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
of	B-X
the	B-X
pathway	B-X
intermediate	B-X
,	B-X
7-oxoDhA	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
ferredoxin	B-X
gene	B-X
,	B-X
ditA3	B-X
,	B-X
in	B-X
wild-type	B-X
BKME-9	B-X
by	B-X
mutant-allele	B-X
exchange	B-X
resulted	B-X
in	B-X
a	B-X
strain	B-X
(	B-X
BKME-91	B-X
)	B-X
with	B-X
a	B-X
phenotype	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
.	B-X
Sequence	B-X
analysis	B-X
of	B-X
the	B-X
putative	B-X
ferredoxin	B-X
indicated	B-X
that	B-X
it	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
a	B-X
[	B-X
4Fe-4S	B-X
]	B-X
-	B-X
or	B-X
[	B-X
3Fe-4S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
and	B-X
not	B-X
a	B-X
[	B-X
2Fe-2S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
,	B-X
as	B-X
found	B-X
in	B-X
all	B-X
previously	B-X
described	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X
Expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
of	B-X
ditA1A2A3	B-X
,	B-X
encoding	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
without	B-X
its	B-X
putative	B-X
reductase	B-X
component	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
functional	B-X
enzyme	B-X
.	B-X
The	B-X
diterpenoid	B-X
dioxygenase	B-X
attacks	B-X
7-oxoDhA	B-X
,	B-X
and	B-X
not	B-X
DhA	B-X
,	B-X
at	B-X
C-11	B-X
and	B-X
C-12	B-X
,	B-X
producing	B-X
7-oxo-11	B-X
,	B-X
12-dihydroxy-8,13-abietadien	B-X
acid	B-X
,	B-X
which	B-X
was	B-X
identified	B-X
by	B-X
1H	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
,	B-X
UV-visible	B-X
light	B-X
,	B-X
and	B-X
high-resolution	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
the	B-X
genes	B-X
encoding	B-X
the	B-X
various	B-X
components	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
the	B-X
phylogenetic	B-X
distinctiveness	B-X
of	B-X
both	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
the	B-X
ferredoxin	B-X
component	B-X
,	B-X
and	B-X
the	B-X
unusual	B-X
Fe-S	B-X
cluster	B-X
of	B-X
the	B-X
ferredoxin	B-X
all	B-X
suggest	B-X
that	B-X
this	B-X
enzyme	B-X
belongs	B-X
to	B-X
a	B-X
new	B-X
class	B-X
of	B-X
aromatic	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X

The	O
ferredoxin	O
gene	O
is	O
9	O
.	O
<EOS>	B-X
Matrix	B-X
metalloproteinases	B-X
9	B-X
(	B-X
MMP-9	B-X
)	B-X
is	B-X
a	B-X
zinc-dependent	B-X
gelatinase	B-X
,	B-X
which	B-X
could	B-X
decrease	B-X
the	B-X
expression	B-X
of	B-X
extracellular	B-X
matrix	B-X
proteins	B-X
and	B-X
influence	B-X
the	B-X
metastatic	B-X
behavior	B-X
of	B-X
tumors	B-X
.	B-X
In	B-X
order	B-X
to	B-X
draw	B-X
a	B-X
comprehensive	B-X
and	B-X
precise	B-X
result	B-X
about	B-X
the	B-X
relationship	B-X
of	B-X
MMP-9	B-X
and	B-X
urinary	B-X
cancers	B-X
,	B-X
we	B-X
presented	B-X
the	B-X
current	B-X
meta-analysis	B-X
.	B-X
The	B-X
unicellular	B-X
green	B-X
alga	B-X
Chlamydomonas	B-X
reinhardtii	B-X
has	B-X
a	B-X
complex	B-X
anaerobic	B-X
metabolism	B-X
and	B-X
reacts	B-X
to	B-X
hypoxic	B-X
or	B-X
anaerobic	B-X
conditions	B-X
with	B-X
the	B-X
induced	B-X
expression	B-X
of	B-X
many	B-X
genes	B-X
.	B-X
One	B-X
gene	B-X
which	B-X
is	B-X
upregulated	B-X
particularly	B-X
strongly	B-X
is	B-X
the	B-X
FDX5	B-X
gene	B-X
,	B-X
encoding	B-X
one	B-X
of	B-X
at	B-X
least	B-X
six	B-X
ferredoxin	B-X
isoforms	B-X
in	B-X
C.	B-X
reinhardtii	B-X
.	B-X
This	B-X
study	B-X
shows	B-X
that	B-X
two	B-X
of	B-X
these	B-X
GTAC	B-X
sites	B-X
are	B-X
essential	B-X
to	B-X
confer	B-X
oxygen	B-X
and	B-X
also	B-X
copper	B-X
responsiveness	B-X
to	B-X
a	B-X
reporter	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
clearly	B-X
indicate	B-X
that	B-X
Crr1	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
FDX5	B-X
gene	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
oxygen	B-X
or	B-X
copper	B-X
.	B-X

2	O
kb	O
upstream	O
of	O
the	O
oxygenase	O
genes	O
and	O
872	O
bp	O
upstream	O
of	O
a	O
putative	O
meta	O
ring	O
cleavage	O
dioxygenase	O
gene	O
,	O
ditC	B-Protein
.	O
<EOS>	B-X
Pseudomonas	B-X
abietaniphila	B-X
BKME-9	B-X
is	B-X
able	B-X
to	B-X
degrade	B-X
dehydroabietic	B-X
acid	B-X
(	B-X
DhA	B-X
)	B-X
via	B-X
ring	B-X
hydroxylation	B-X
by	B-X
a	B-X
novel	B-X
dioxygenase	B-X
.	B-X
The	B-X
ditA1	B-X
,	B-X
ditA2	B-X
,	B-X
and	B-X
ditA3	B-X
genes	B-X
,	B-X
which	B-X
encode	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
the	B-X
oxygenase	B-X
and	B-X
the	B-X
ferredoxin	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
isolated	B-X
and	B-X
sequenced	B-X
.	B-X
The	B-X
ferredoxin	B-X
gene	B-X
is	B-X
9	B-X
.	B-X
2	B-X
kb	B-X
upstream	B-X
of	B-X
the	B-X
oxygenase	B-X
genes	B-X
and	B-X
872	B-X
bp	B-X
upstream	B-X
of	B-X
a	B-X
putative	B-X
meta	B-X
ring	B-X
cleavage	B-X
dioxygenase	B-X
gene	B-X
,	B-X
ditC	B-X
.	B-X
A	B-X
Tn5	B-X
insertion	B-X
in	B-X
the	B-X
alpha	B-X
subunit	B-X
gene	B-X
,	B-X
ditA1	B-X
,	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
by	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
of	B-X
the	B-X
pathway	B-X
intermediate	B-X
,	B-X
7-oxoDhA	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
ferredoxin	B-X
gene	B-X
,	B-X
ditA3	B-X
,	B-X
in	B-X
wild-type	B-X
BKME-9	B-X
by	B-X
mutant-allele	B-X
exchange	B-X
resulted	B-X
in	B-X
a	B-X
strain	B-X
(	B-X
BKME-91	B-X
)	B-X
with	B-X
a	B-X
phenotype	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
.	B-X
Sequence	B-X
analysis	B-X
of	B-X
the	B-X
putative	B-X
ferredoxin	B-X
indicated	B-X
that	B-X
it	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
a	B-X
[	B-X
4Fe-4S	B-X
]	B-X
-	B-X
or	B-X
[	B-X
3Fe-4S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
and	B-X
not	B-X
a	B-X
[	B-X
2Fe-2S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
,	B-X
as	B-X
found	B-X
in	B-X
all	B-X
previously	B-X
described	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X
Expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
of	B-X
ditA1A2A3	B-X
,	B-X
encoding	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
without	B-X
its	B-X
putative	B-X
reductase	B-X
component	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
functional	B-X
enzyme	B-X
.	B-X
The	B-X
diterpenoid	B-X
dioxygenase	B-X
attacks	B-X
7-oxoDhA	B-X
,	B-X
and	B-X
not	B-X
DhA	B-X
,	B-X
at	B-X
C-11	B-X
and	B-X
C-12	B-X
,	B-X
producing	B-X
7-oxo-11	B-X
,	B-X
12-dihydroxy-8,13-abietadien	B-X
acid	B-X
,	B-X
which	B-X
was	B-X
identified	B-X
by	B-X
1H	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
,	B-X
UV-visible	B-X
light	B-X
,	B-X
and	B-X
high-resolution	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
the	B-X
genes	B-X
encoding	B-X
the	B-X
various	B-X
components	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
the	B-X
phylogenetic	B-X
distinctiveness	B-X
of	B-X
both	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
the	B-X
ferredoxin	B-X
component	B-X
,	B-X
and	B-X
the	B-X
unusual	B-X
Fe-S	B-X
cluster	B-X
of	B-X
the	B-X
ferredoxin	B-X
all	B-X
suggest	B-X
that	B-X
this	B-X
enzyme	B-X
belongs	B-X
to	B-X
a	B-X
new	B-X
class	B-X
of	B-X
aromatic	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X

A	O
Tn5	O
insertion	O
in	O
the	O
alpha	O
subunit	O
gene	O
,	O
ditA1	B-Protein
,	O
resulted	O
in	O
the	O
accumulation	O
by	O
the	O
mutant	O
strain	O
BKME	O
-	O
941	O
of	O
the	O
pathway	O
intermediate	O
,	O
7	O
-	O
oxoDhA	O
.	O
<EOS>	B-X
Pseudomonas	B-X
abietaniphila	B-X
BKME-9	B-X
is	B-X
able	B-X
to	B-X
degrade	B-X
dehydroabietic	B-X
acid	B-X
(	B-X
DhA	B-X
)	B-X
via	B-X
ring	B-X
hydroxylation	B-X
by	B-X
a	B-X
novel	B-X
dioxygenase	B-X
.	B-X
The	B-X
ditA1	B-X
,	B-X
ditA2	B-X
,	B-X
and	B-X
ditA3	B-X
genes	B-X
,	B-X
which	B-X
encode	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
the	B-X
oxygenase	B-X
and	B-X
the	B-X
ferredoxin	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
isolated	B-X
and	B-X
sequenced	B-X
.	B-X
The	B-X
ferredoxin	B-X
gene	B-X
is	B-X
9	B-X
.	B-X
2	B-X
kb	B-X
upstream	B-X
of	B-X
the	B-X
oxygenase	B-X
genes	B-X
and	B-X
872	B-X
bp	B-X
upstream	B-X
of	B-X
a	B-X
putative	B-X
meta	B-X
ring	B-X
cleavage	B-X
dioxygenase	B-X
gene	B-X
,	B-X
ditC	B-X
.	B-X
A	B-X
Tn5	B-X
insertion	B-X
in	B-X
the	B-X
alpha	B-X
subunit	B-X
gene	B-X
,	B-X
ditA1	B-X
,	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
by	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
of	B-X
the	B-X
pathway	B-X
intermediate	B-X
,	B-X
7-oxoDhA	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
ferredoxin	B-X
gene	B-X
,	B-X
ditA3	B-X
,	B-X
in	B-X
wild-type	B-X
BKME-9	B-X
by	B-X
mutant-allele	B-X
exchange	B-X
resulted	B-X
in	B-X
a	B-X
strain	B-X
(	B-X
BKME-91	B-X
)	B-X
with	B-X
a	B-X
phenotype	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
.	B-X
Expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
of	B-X
ditA1A2A3	B-X
,	B-X
encoding	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
without	B-X
its	B-X
putative	B-X
reductase	B-X
component	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
functional	B-X
enzyme	B-X
.	B-X
The	B-X
diterpenoid	B-X
dioxygenase	B-X
attacks	B-X
7-oxoDhA	B-X
,	B-X
and	B-X
not	B-X
DhA	B-X
,	B-X
at	B-X
C-11	B-X
and	B-X
C-12	B-X
,	B-X
producing	B-X
7-oxo-11	B-X
,	B-X
12-dihydroxy-8,13-abietadien	B-X
acid	B-X
,	B-X
which	B-X
was	B-X
identified	B-X
by	B-X
1H	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
,	B-X
UV-visible	B-X
light	B-X
,	B-X
and	B-X
high-resolution	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
the	B-X
genes	B-X
encoding	B-X
the	B-X
various	B-X
components	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
the	B-X
phylogenetic	B-X
distinctiveness	B-X
of	B-X
both	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
the	B-X
ferredoxin	B-X
component	B-X
,	B-X
and	B-X
the	B-X
unusual	B-X
Fe-S	B-X
cluster	B-X
of	B-X
the	B-X
ferredoxin	B-X
all	B-X
suggest	B-X
that	B-X
this	B-X
enzyme	B-X
belongs	B-X
to	B-X
a	B-X
new	B-X
class	B-X
of	B-X
aromatic	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X

Disruption	O
of	O
the	O
ferredoxin	O
gene	O
,	O
ditA3	B-Protein
,	O
in	O
wild	O
-	O
type	O
BKME	O
-	O
9	O
by	O
mutant	O
-	O
allele	O
exchange	O
resulted	O
in	O
a	O
strain	O
(	O
BKME	O
-	O
91	O
)	O
with	O
a	O
phenotype	O
identical	O
to	O
that	O
of	O
the	O
mutant	O
strain	O
BKME	O
-	O
941	O
.	O

Sequence	O
analysis	O
of	O
the	O
putative	O
ferredoxin	O
indicated	O
that	O
it	O
is	O
likely	O
to	O
be	O
a	O
[	O
4Fe	O
-	O
4S	O
]	O
-	O
or	O
[	O
3Fe	O
-	O
4S	O
]	O
-	O
type	O
ferredoxin	O
and	O
not	O
a	O
[	O
2Fe	O
-	O
2S	O
]	O
-	O
type	O
ferredoxin	O
,	O
as	O
found	O
in	O
all	O
previously	O
described	O
ring	O
-	O
hydroxylating	O
dioxygenases	O
.	O
<EOS>	B-X
The	B-X
thermal	B-X
and	B-X
chemical	B-X
stability	B-X
of	B-X
24mer	B-X
ferritins	B-X
has	B-X
led	B-X
to	B-X
attempts	B-X
to	B-X
exploit	B-X
their	B-X
naturally	B-X
occurring	B-X
nanoscale	B-X
(	B-X
8	B-X
nm	B-X
)	B-X
internal	B-X
cavities	B-X
for	B-X
biotechnological	B-X
applications	B-X
.	B-X
Three	B-X
types	B-X
of	B-X
hydrogenases	B-X
have	B-X
been	B-X
isolated	B-X
from	B-X
the	B-X
sulfate-reducing	B-X
bacteria	B-X
of	B-X
the	B-X
genus	B-X
Desulfovibrio	B-X
.	B-X
The	B-X
iron-sulfur-containing	B-X
hydrogenase	B-X
(	B-X
[	B-X
Fe	B-X
]	B-X
hydrogenase	B-X
)	B-X
contains	B-X
two	B-X
ferredoxin-type	B-X
(	B-X
4Fe-4S	B-X
)	B-X
clusters	B-X
and	B-X
an	B-X
atypical	B-X
iron-sulfur	B-X
center	B-X
believed	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
H2	B-X
.	B-X
The	B-X
nickel-	B-X
(	B-X
iron-sulfur	B-X
)	B-X
-containing	B-X
hydrogenases	B-X
[	B-X
(	B-X
NiFe	B-X
]	B-X
hydrogenases	B-X
)	B-X
possess	B-X
two	B-X
(	B-X
4Fe-4S	B-X
)	B-X
centers	B-X
and	B-X
one	B-X
(	B-X
3Fe-xS	B-X
)	B-X
cluster	B-X
in	B-X
addition	B-X
to	B-X
nickel	B-X
and	B-X
have	B-X
been	B-X
found	B-X
in	B-X
all	B-X
species	B-X
of	B-X
Desulfovibrio	B-X
so	B-X
far	B-X
investigated	B-X
.	B-X
The	B-X
third	B-X
class	B-X
is	B-X
represented	B-X
by	B-X
the	B-X
nickel-	B-X
(	B-X
iron-sulfur	B-X
)	B-X
-selenium-containing	B-X
hydrogenases	B-X
[	B-X
(	B-X
NiFe-Se	B-X
]	B-X
hydrogenases	B-X
)	B-X
which	B-X
contain	B-X
nickel	B-X
and	B-X
selenium	B-X
in	B-X
equimolecular	B-X
amounts	B-X
plus	B-X
(	B-X
4Fe-4S	B-X
)	B-X
centers	B-X
and	B-X
are	B-X
only	B-X
found	B-X
in	B-X
some	B-X
species	B-X
of	B-X
Desulfovibrio	B-X
.	B-X

Expression	O
in	O
Escherichia	O
coli	O
of	O
ditA1A2A3	B-Protein
,	O
encoding	O
the	O
diterpenoid	O
dioxygenase	O
without	O
its	O
putative	O
reductase	O
component	O
,	O
resulted	O
in	O
a	O
functional	O
enzyme	O
.	O

The	O
diterpenoid	O
dioxygenase	O
attacks	O
7	O
-	O
oxoDhA	O
,	O
and	O
not	O
DhA	O
,	O
at	O
C	O
-	O
11	O
and	O
C	O
-	O
12	O
,	O
producing	O
7	O
-	O
oxo	O
-	O
11	O
,	O
12	O
-	O
dihydroxy	O
-	O
8	O
,	O
13	O
-	O
abietadien	O
acid	O
,	O
which	O
was	O
identified	O
by	O
1H	O
nuclear	O
magnetic	O
resonance	O
,	O
UV	O
-	O
visible	O
light	O
,	O
and	O
high	O
-	O
resolution	O
mass	O
spectrometry	O
.	O
<EOS>	B-X
Pseudomonas	B-X
abietaniphila	B-X
BKME-9	B-X
is	B-X
able	B-X
to	B-X
degrade	B-X
dehydroabietic	B-X
acid	B-X
(	B-X
DhA	B-X
)	B-X
via	B-X
ring	B-X
hydroxylation	B-X
by	B-X
a	B-X
novel	B-X
dioxygenase	B-X
.	B-X
The	B-X
ditA1	B-X
,	B-X
ditA2	B-X
,	B-X
and	B-X
ditA3	B-X
genes	B-X
,	B-X
which	B-X
encode	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
the	B-X
oxygenase	B-X
and	B-X
the	B-X
ferredoxin	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
isolated	B-X
and	B-X
sequenced	B-X
.	B-X
2	B-X
kb	B-X
upstream	B-X
of	B-X
the	B-X
oxygenase	B-X
genes	B-X
and	B-X
872	B-X
bp	B-X
upstream	B-X
of	B-X
a	B-X
putative	B-X
meta	B-X
ring	B-X
cleavage	B-X
dioxygenase	B-X
gene	B-X
,	B-X
ditC	B-X
.	B-X
A	B-X
Tn5	B-X
insertion	B-X
in	B-X
the	B-X
alpha	B-X
subunit	B-X
gene	B-X
,	B-X
ditA1	B-X
,	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
by	B-X
the	B-X
mutant	B-X
strain	B-X
BKME-941	B-X
of	B-X
the	B-X
pathway	B-X
intermediate	B-X
,	B-X
7-oxoDhA	B-X
.	B-X
Sequence	B-X
analysis	B-X
of	B-X
the	B-X
putative	B-X
ferredoxin	B-X
indicated	B-X
that	B-X
it	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
a	B-X
[	B-X
4Fe-4S	B-X
]	B-X
-	B-X
or	B-X
[	B-X
3Fe-4S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
and	B-X
not	B-X
a	B-X
[	B-X
2Fe-2S	B-X
]	B-X
-type	B-X
ferredoxin	B-X
,	B-X
as	B-X
found	B-X
in	B-X
all	B-X
previously	B-X
described	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X
Expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
of	B-X
ditA1A2A3	B-X
,	B-X
encoding	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
without	B-X
its	B-X
putative	B-X
reductase	B-X
component	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
functional	B-X
enzyme	B-X
.	B-X
The	B-X
diterpenoid	B-X
dioxygenase	B-X
attacks	B-X
7-oxoDhA	B-X
,	B-X
and	B-X
not	B-X
DhA	B-X
,	B-X
at	B-X
C-11	B-X
and	B-X
C-12	B-X
,	B-X
producing	B-X
7-oxo-11	B-X
,	B-X
12-dihydroxy-8,13-abietadien	B-X
acid	B-X
,	B-X
which	B-X
was	B-X
identified	B-X
by	B-X
1H	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
,	B-X
UV-visible	B-X
light	B-X
,	B-X
and	B-X
high-resolution	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
the	B-X
genes	B-X
encoding	B-X
the	B-X
various	B-X
components	B-X
of	B-X
the	B-X
diterpenoid	B-X
dioxygenase	B-X
,	B-X
the	B-X
phylogenetic	B-X
distinctiveness	B-X
of	B-X
both	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
the	B-X
ferredoxin	B-X
component	B-X
,	B-X
and	B-X
the	B-X
unusual	B-X
Fe-S	B-X
cluster	B-X
of	B-X
the	B-X
ferredoxin	B-X
all	B-X
suggest	B-X
that	B-X
this	B-X
enzyme	B-X
belongs	B-X
to	B-X
a	B-X
new	B-X
class	B-X
of	B-X
aromatic	B-X
ring-hydroxylating	B-X
dioxygenases	B-X
.	B-X

The	O
organization	O
of	O
the	O
genes	O
encoding	O
the	O
various	O
components	O
of	O
the	O
diterpenoid	O
dioxygenase	O
,	O
the	O
phylogenetic	O
distinctiveness	O
of	O
both	O
the	O
alpha	O
subunit	O
and	O
the	O
ferredoxin	O
component	O
,	O
and	O
the	O
unusual	O
Fe	O
-	O
S	O
cluster	O
of	O
the	O
ferredoxin	O
all	O
suggest	O
that	O
this	O
enzyme	O
belongs	O
to	O
a	O
new	O
class	O
of	O
aromatic	O
ring	O
-	O
hydroxylating	O
dioxygenases	O
.	O

DNA	O
methylation	O
and	O
chromatin	O
modification	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
cytosine	B-X
in	B-X
CpG	B-X
dinucleotides	B-X
and	B-X
histone	B-X
lysine	B-X
and	B-X
arginine	B-X
residues	B-X
is	B-X
a	B-X
chromatin	B-X
modification	B-X
that	B-X
critically	B-X
contributes	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
genome	B-X
integrity	B-X
,	B-X
replication	B-X
,	B-X
and	B-X
accessibility	B-X
.	B-X
A	B-X
strong	B-X
correlation	B-X
exists	B-X
between	B-X
the	B-X
genome-wide	B-X
distribution	B-X
of	B-X
DNA	B-X
and	B-X
histone	B-X
methylation	B-X
,	B-X
suggesting	B-X
an	B-X
intimate	B-X
relationship	B-X
between	B-X
these	B-X
epigenetic	B-X
marks	B-X
.	B-X
Indeed	B-X
,	B-X
accumulating	B-X
literature	B-X
reveals	B-X
complex	B-X
mechanisms	B-X
underlying	B-X
the	B-X
molecular	B-X
crosstalk	B-X
between	B-X
DNA	B-X
and	B-X
histone	B-X
methylation	B-X
.	B-X
These	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
discoveries	B-X
are	B-X
further	B-X
supported	B-X
by	B-X
the	B-X
finding	B-X
that	B-X
genes	B-X
encoding	B-X
DNA-	B-X
and	B-X
histone-modifying	B-X
enzymes	B-X
are	B-X
often	B-X
mutated	B-X
in	B-X
overlapping	B-X
human	B-X
diseases	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
advances	B-X
in	B-X
understanding	B-X
how	B-X
DNA	B-X
and	B-X
histone	B-X
methylation	B-X
cooperate	B-X
to	B-X
maintain	B-X
the	B-X
cellular	B-X
epigenomic	B-X
landscape	B-X
.	B-X
We	B-X
will	B-X
also	B-X
discuss	B-X
the	B-X
potential	B-X
implication	B-X
of	B-X
these	B-X
insights	B-X
for	B-X
understanding	B-X
the	B-X
etiology	B-X
of	B-X
,	B-X
and	B-X
developing	B-X
biomarkers	B-X
and	B-X
therapies	B-X
for	B-X
,	B-X
human	B-X
congenital	B-X
disorders	B-X
and	B-X
cancers	B-X
that	B-X
are	B-X
driven	B-X
by	B-X
chromatin	B-X
abnormalities	B-X
.	B-X

DNA	O
methylation	O
and	O
chromatin	O
modification	O
are	O
two	O
global	O
mechanisms	O
that	O
regulate	O
gene	O
expression	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
(	B-X
5-methylcytosine	B-X
,	B-X
5mC	B-X
)	B-X
is	B-X
a	B-X
major	B-X
form	B-X
of	B-X
DNA	B-X
modification	B-X
in	B-X
the	B-X
mammalian	B-X
genome	B-X
that	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
chromatin	B-X
structure	B-X
and	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
general	B-X
,	B-X
DNA	B-X
methylation	B-X
is	B-X
stably	B-X
maintained	B-X
in	B-X
somatic	B-X
tissues	B-X
.	B-X
However	B-X
,	B-X
DNA	B-X
methylation	B-X
patterns	B-X
and	B-X
levels	B-X
show	B-X
dynamic	B-X
changes	B-X
during	B-X
development	B-X
.	B-X
Specifically	B-X
,	B-X
the	B-X
genome	B-X
undergoes	B-X
two	B-X
waves	B-X
of	B-X
global	B-X
demethylation	B-X
and	B-X
remethylation	B-X
for	B-X
the	B-X
purpose	B-X
of	B-X
producing	B-X
the	B-X
next	B-X
generation	B-X
.	B-X
The	B-X
first	B-X
wave	B-X
occurs	B-X
in	B-X
the	B-X
germline	B-X
,	B-X
initiated	B-X
with	B-X
the	B-X
erasure	B-X
of	B-X
global	B-X
methylation	B-X
in	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
and	B-X
completed	B-X
with	B-X
the	B-X
establishment	B-X
of	B-X
sex-specific	B-X
methylation	B-X
patterns	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
germ	B-X
cell	B-X
development	B-X
.	B-X
The	B-X
second	B-X
wave	B-X
occurs	B-X
after	B-X
fertilization	B-X
,	B-X
including	B-X
the	B-X
erasure	B-X
of	B-X
most	B-X
methylation	B-X
marks	B-X
inherited	B-X
from	B-X
the	B-X
gametes	B-X
and	B-X
the	B-X
subsequent	B-X
establishment	B-X
of	B-X
the	B-X
embryonic	B-X
methylation	B-X
pattern	B-X
.	B-X
The	B-X
two	B-X
waves	B-X
of	B-X
DNA	B-X
methylation	B-X
reprogramming	B-X
involve	B-X
both	B-X
distinct	B-X
and	B-X
shared	B-X
mechanisms	B-X
.	B-X
In	B-X
this	B-X
review	B-X
article	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
key	B-X
reprogramming	B-X
events	B-X
,	B-X
focusing	B-X
on	B-X
the	B-X
important	B-X
players	B-X
in	B-X
these	B-X
processes	B-X
,	B-X
including	B-X
DNA	B-X
methyltransferases	B-X
(	B-X
DNMTs	B-X
)	B-X
and	B-X
ten-eleven	B-X
translocation	B-X
(	B-X
TET	B-X
)	B-X
family	B-X
of	B-X
5mC	B-X
dioxygenases	B-X
.	B-X

Recent	O
studies	O
provide	O
insight	O
into	O
the	O
mechanism	O
of	O
transcriptional	O
silencing	O
by	O
a	O
methyl	O
-	O
CpG	O
binding	O
protein	O
,	O
MeCP2	B-Protein
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
and	B-X
chromatin	B-X
modification	B-X
are	B-X
two	B-X
global	B-X
mechanisms	B-X
that	B-X
regulate	B-X
gene	B-X
expression	B-X
.	B-X
Recent	B-X
studies	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
transcriptional	B-X
silencing	B-X
by	B-X
a	B-X
methyl-CpG	B-X
binding	B-X
protein	B-X
,	B-X
MeCP2	B-X
.	B-X
MeCP2	B-X
is	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
Sin3/histone	B-X
deacetylase	B-X
co-repressor	B-X
complex	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
interaction	B-X
can	B-X
provide	B-X
a	B-X
mechanistic	B-X
explanation	B-X
for	B-X
the	B-X
long-known	B-X
relationship	B-X
between	B-X
DNA	B-X
methylation	B-X
and	B-X
chromatin	B-X
structure	B-X
.	B-X
Moreover	B-X
,	B-X
several	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
inhibition	B-X
of	B-X
histone	B-X
deacetylases	B-X
by	B-X
specific	B-X
inhibitors	B-X
can	B-X
reactivate	B-X
endogenous	B-X
genes	B-X
or	B-X
reporter	B-X
constructs	B-X
previously	B-X
silenced	B-X
by	B-X
DNA	B-X
methylation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
DNA	B-X
methylation	B-X
can	B-X
pattern	B-X
chromatin	B-X
modification	B-X
.	B-X

MeCP2	B-Protein
is	O
shown	O
to	O
interact	O
with	O
the	O
Sin3	B-Protein
/	O
histone	B-Protein
deacetylase	O
co	O
-	O
repressor	O
complex	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
transcriptional	B-X
silencing	B-X
by	B-X
a	B-X
methyl-CpG	B-X
binding	B-X
protein	B-X
,	B-X
MeCP2	B-X
.	B-X
MeCP2	B-X
is	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
Sin3/histone	B-X
deacetylase	B-X
co-repressor	B-X
complex	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
interaction	B-X
can	B-X
provide	B-X
a	B-X
mechanistic	B-X
explanation	B-X
for	B-X
the	B-X
long-known	B-X
relationship	B-X
between	B-X
DNA	B-X
methylation	B-X
and	B-X
chromatin	B-X
structure	B-X
.	B-X
Moreover	B-X
,	B-X
several	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
inhibition	B-X
of	B-X
histone	B-X
deacetylases	B-X
by	B-X
specific	B-X
inhibitors	B-X
can	B-X
reactivate	B-X
endogenous	B-X
genes	B-X
or	B-X
reporter	B-X
constructs	B-X
previously	B-X
silenced	B-X
by	B-X
DNA	B-X
methylation	B-X
.	B-X

Thus	O
,	O
this	O
interaction	O
can	O
provide	O
a	O
mechanistic	O
explanation	O
for	O
the	O
long	O
-	O
known	O
relationship	O
between	O
DNA	O
methylation	O
and	O
chromatin	O
structure	O
.	O

Moreover	O
,	O
several	O
studies	O
have	O
shown	O
that	O
inhibition	O
of	O
histone	B-Protein
deacetylases	O
by	O
specific	O
inhibitors	O
can	O
reactivate	O
endogenous	O
genes	O
or	O
reporter	O
constructs	O
previously	O
silenced	O
by	O
DNA	O
methylation	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
and	B-X
chromatin	B-X
modification	B-X
are	B-X
two	B-X
global	B-X
mechanisms	B-X
that	B-X
regulate	B-X
gene	B-X
expression	B-X
.	B-X
Recent	B-X
studies	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
transcriptional	B-X
silencing	B-X
by	B-X
a	B-X
methyl-CpG	B-X
binding	B-X
protein	B-X
,	B-X
MeCP2	B-X
.	B-X
MeCP2	B-X
is	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
Sin3/histone	B-X
deacetylase	B-X
co-repressor	B-X
complex	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
interaction	B-X
can	B-X
provide	B-X
a	B-X
mechanistic	B-X
explanation	B-X
for	B-X
the	B-X
long-known	B-X
relationship	B-X
between	B-X
DNA	B-X
methylation	B-X
and	B-X
chromatin	B-X
structure	B-X
.	B-X
Moreover	B-X
,	B-X
several	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
inhibition	B-X
of	B-X
histone	B-X
deacetylases	B-X
by	B-X
specific	B-X
inhibitors	B-X
can	B-X
reactivate	B-X
endogenous	B-X
genes	B-X
or	B-X
reporter	B-X
constructs	B-X
previously	B-X
silenced	B-X
by	B-X
DNA	B-X
methylation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
DNA	B-X
methylation	B-X
can	B-X
pattern	B-X
chromatin	B-X
modification	B-X
.	B-X

Taken	O
together	O
,	O
the	O
data	O
strongly	O
suggest	O
that	O
DNA	O
methylation	O
can	O
pattern	O
chromatin	O
modification	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
and	B-X
chromatin	B-X
modification	B-X
are	B-X
two	B-X
global	B-X
mechanisms	B-X
that	B-X
regulate	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
interaction	B-X
can	B-X
provide	B-X
a	B-X
mechanistic	B-X
explanation	B-X
for	B-X
the	B-X
long-known	B-X
relationship	B-X
between	B-X
DNA	B-X
methylation	B-X
and	B-X
chromatin	B-X
structure	B-X
.	B-X
Moreover	B-X
,	B-X
several	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
inhibition	B-X
of	B-X
histone	B-X
deacetylases	B-X
by	B-X
specific	B-X
inhibitors	B-X
can	B-X
reactivate	B-X
endogenous	B-X
genes	B-X
or	B-X
reporter	B-X
constructs	B-X
previously	B-X
silenced	B-X
by	B-X
DNA	B-X
methylation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
DNA	B-X
methylation	B-X
can	B-X
pattern	B-X
chromatin	B-X
modification	B-X
.	B-X

Cr	O
(	O
IV	O
)	O
causes	O
activation	O
of	O
nuclear	O
transcription	O
factor	O
-	O
kappa	O
B	O
,	O
DNA	O
strand	O
breaks	O
and	O
dG	O
hydroxylation	O
via	O
free	O
radical	O
reactions	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
activation	B-X
while	B-X
superoxide	B-X
dismutase	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
Deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
inhibited	B-X
the	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
The	B-X
relative	B-X
magnitude	B-X
of	B-X
8-OHdG	B-X
formation	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
.OH	B-X
radicals	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
This	B-X
reactive	B-X
chromium	B-X
intermediate	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

Electrophoretic	O
mobility	O
shift	O
,	O
DNA	O
strand	O
breakage	O
assays	O
and	O
electron	O
spin	O
resonance	O
(	O
ESR	O
)	O
spin	O
trapping	O
were	O
used	O
to	O
investigate	O
the	O
activation	O
of	O
nuclear	O
transcription	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
,	O
DNA	O
strand	O
breakage	O
and	O
2	O
'	O
-	O
deoxyguanosine	O
hydroxylation	O
induced	O
by	O
Cr	O
(	O
IV	O
)	O
,	O
as	O
well	O
the	O
role	O
of	O
free	O
radical	O
reactions	O
in	O
these	O
processes	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
activation	B-X
while	B-X
superoxide	B-X
dismutase	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
Deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
inhibited	B-X
the	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
The	B-X
relative	B-X
magnitude	B-X
of	B-X
8-OHdG	B-X
formation	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
.OH	B-X
radicals	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
This	B-X
reactive	B-X
chromium	B-X
intermediate	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

Incubation	O
of	O
synthesized	O
Cr	O
(	O
IV	O
)	O
-	O
glutathione	O
complex	O
with	O
cultured	O
Jurkat	O
cells	O
resulted	O
in	O
activation	O
of	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
activation	B-X
while	B-X
superoxide	B-X
dismutase	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
Deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
inhibited	B-X
the	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
This	B-X
reactive	B-X
chromium	B-X
intermediate	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

Cr	O
(	O
VI	O
)	O
is	O
also	O
able	O
to	O
induce	O
NF	O
-	O
kappa	O
B	O
activation	O
through	O
Cr	O
(	O
V	O
)	O
and	O
Cr	O
(	O
IV	O
)	O
intermediates	O
generated	O
during	O
the	O
reduction	O
of	O
Cr	O
(	O
VI	O
)	O
by	O
the	O
cells	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
activation	B-X
while	B-X
superoxide	B-X
dismutase	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
This	B-X
reactive	B-X
chromium	B-X
intermediate	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

Cr	O
(	O
III	O
)	O
did	O
not	O
cause	O
observable	O
NF	O
-	O
kappa	O
B	O
activation	O
due	O
to	O
its	O
inability	O
to	O
cross	O
cell	O
membranes	O
.	O
<EOS>	B-X
POLE/POLD1	B-X
exonuclease	B-X
domain	B-X
mutations	B-X
lead	B-X
to	B-X
loss	B-X
of	B-X
proofreading	B-X
function	B-X
,	B-X
which	B-X
causes	B-X
the	B-X
accumulation	B-X
of	B-X
mutant	B-X
genes	B-X
in	B-X
cells	B-X
.	B-X
Pembrolizumab	B-X
,	B-X
which	B-X
targets	B-X
PD-1	B-X
,	B-X
has	B-X
been	B-X
approved	B-X
as	B-X
a	B-X
first-line	B-X
treatment	B-X
for	B-X
advanced	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
patients	B-X
with	B-X
positive	B-X
PD-L1	B-X
expression	B-X
.	B-X
However	B-X
,	B-X
PD-1/PD-L1	B-X
checkpoint	B-X
blockades	B-X
have	B-X
not	B-X
achieved	B-X
breakthroughs	B-X
in	B-X
treating	B-X
glioblastoma	B-X
because	B-X
glioblastoma	B-X
has	B-X
a	B-X
low	B-X
immunogenic	B-X
response	B-X
and	B-X
an	B-X
immunosuppressive	B-X
microenvironment	B-X
caused	B-X
by	B-X
the	B-X
precise	B-X
crosstalk	B-X
between	B-X
cytokines	B-X
and	B-X
immune	B-X
cells	B-X
.	B-X
A	B-X
phase	B-X
III	B-X
clinical	B-X
trial	B-X
,	B-X
Checkmate	B-X
143	B-X
,	B-X
reported	B-X
that	B-X
nivolumab	B-X
,	B-X
which	B-X
targets	B-X
PD-1	B-X
,	B-X
did	B-X
not	B-X
demonstrate	B-X
survival	B-X
benefits	B-X
compared	B-X
with	B-X
bavacizumab	B-X
in	B-X
recurrent	B-X
glioblastoma	B-X
patients	B-X
.	B-X

Cr	O
(	O
IV	O
)	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
dose	O
-	O
dependent	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
activation	B-X
while	B-X
superoxide	B-X
dismutase	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
This	B-X
reactive	B-X
chromium	B-X
intermediate	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

Catalase	B-Protein
inhibited	O
the	O
activation	O
while	O
superoxide	O
dismutase	O
enhanced	O
it	O
.	O
<EOS>	B-X
All	B-X
curcumin-treated	B-X
groups	B-X
exhibited	B-X
increased	B-X
activity	B-X
of	B-X
catalase	B-X
(	B-X
CAT	B-X
)	B-X
,	B-X
superoxide	B-X
dismutase	B-X
(	B-X
SOD	B-X
)	B-X
and	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GSH-PX	B-X
)	B-X
.	B-X
The	B-X
middle-dose	B-X
curcumin-treated	B-X
group	B-X
also	B-X
exhibited	B-X
enhanced	B-X
expression	B-X
of	B-X
glutamate-cysteine	B-X
ligase	B-X
,	B-X
a	B-X
modifier	B-X
subunit	B-X
(	B-X
GLCM	B-X
)	B-X
,	B-X
but	B-X
inhibited	B-X
transcription	B-X
of	B-X
glutamate-cysteine	B-X
ligase	B-X
,	B-X
a	B-X
catalytic	B-X
subunit	B-X
(	B-X
GCLC	B-X
)	B-X
.	B-X
The	B-X
activities	B-X
of	B-X
superoxide	B-X
dismutase	B-X
(	B-X
SOD	B-X
)	B-X
,	B-X
peroxidase	B-X
(	B-X
POD	B-X
)	B-X
,	B-X
catalase	B-X
(	B-X
CAT	B-X
)	B-X
,	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GPX	B-X
)	B-X
,	B-X
glutathione	B-X
S	B-X
transferase	B-X
(	B-X
GST	B-X
)	B-X
,	B-X
and	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
and	B-X
the	B-X
contents	B-X
of	B-X
protein	B-X
(	B-X
TP	B-X
)	B-X
,	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
,	B-X
and	B-X
malondialdehyde	B-X
(	B-X
MDA	B-X
)	B-X
in	B-X
earthworms	B-X
were	B-X
determined	B-X
.	B-X
Combined	B-X
exposure	B-X
to	B-X
MPs	B-X
and	B-X
Cd	B-X
enhanced	B-X
the	B-X
activities	B-X
of	B-X
SOD	B-X
,	B-X
POD	B-X
,	B-X
CAT	B-X
,	B-X
GPX	B-X
and	B-X
GST	B-X
,	B-X
MDA	B-X
and	B-X
GSH	B-X
contents	B-X
also	B-X
increased	B-X
,	B-X
while	B-X
the	B-X
AChE	B-X
activities	B-X
were	B-X
inhibited	B-X
.	B-X

The	O
metal	O
chelator	O
,	O
deferoxamine	O
,	O
and	O
hydroxyl	O
(	O
.	O
OH	O
)	O
radical	O
scavengers	O
,	O
sodium	O
formate	O
and	O
aspirin	O
,	O
also	O
inhibited	O
the	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
activation	B-X
while	B-X
superoxide	B-X
dismutase	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
inhibited	B-X
the	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
The	B-X
relative	B-X
magnitude	B-X
of	B-X
8-OHdG	B-X
formation	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
.OH	B-X
radicals	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

Electrophoretic	O
assays	O
using	O
lambda	O
Hind	O
III	O
linear	O
DNA	O
showed	O
that	O
,	O
in	O
the	O
presence	O
of	O
H2O2	O
,	O
Cr	O
(	O
IV	O
)	O
is	O
capable	O
of	O
causing	O
DNA	O
strand	O
breaks	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
Deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
inhibited	B-X
the	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
This	B-X
reactive	B-X
chromium	B-X
intermediate	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

Deferoxamine	O
,	O
sodium	O
formate	O
and	O
aspirin	O
inhibited	O
the	O
DNA	O
strand	O
breaks	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
activation	B-X
while	B-X
superoxide	B-X
dismutase	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
Deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
inhibited	B-X
the	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X

HPLC	O
measurements	O
also	O
show	O
that	O
.	O
OH	O
radical	O
generated	O
by	O
the	O
Cr	O
(	O
IV	O
)	O
-	O
mediated	O
reaction	O
with	O
H2O2	O
was	O
capable	O
of	O
causing	O
2	O
'	O
-	O
deoxyguanosine	O
(	O
dG	O
)	O
hydroxylation	O
to	O
generate	O
8	O
-	O
hydroxyguanosine	O
(	O
8	O
-	O
OHdG	O
)	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
The	B-X
relative	B-X
magnitude	B-X
of	B-X
8-OHdG	B-X
formation	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
.OH	B-X
radicals	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
This	B-X
reactive	B-X
chromium	B-X
intermediate	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

The	O
relative	O
magnitude	O
of	O
8	O
-	O
OHdG	O
formation	O
correlated	O
with	O
the	O
generation	O
of	O
.	O
OH	O
radicals	O
.	O
<EOS>	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
The	B-X
relative	B-X
magnitude	B-X
of	B-X
8-OHdG	B-X
formation	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
.OH	B-X
radicals	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X

ESR	O
spin	O
trapping	O
measurements	O
showed	O
that	O
reaction	O
of	O
Cr	O
(	O
IV	O
)	O
with	O
H2O2	O
generated	O
.	O
OH	O
radicals	O
,	O
which	O
were	O
inhibited	O
by	O
deferoxamine	O
,	O
sodium	O
formate	O
and	O
aspirin	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
activation	B-X
while	B-X
superoxide	B-X
dismutase	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
Deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
inhibited	B-X
the	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
The	B-X
relative	B-X
magnitude	B-X
of	B-X
8-OHdG	B-X
formation	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
.OH	B-X
radicals	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
This	B-X
reactive	B-X
chromium	B-X
intermediate	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

The	O
results	O
show	O
that	O
Cr	O
(	O
IV	O
)	O
can	O
cause	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
DNA	O
strand	O
breaks	O
and	O
dG	O
hydroxylation	O
through	O
.	O
OH	O
radical	O
-	O
initiated	O
reactions	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
assays	B-X
and	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
spin	B-X
trapping	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
,	B-X
DNA	B-X
strand	B-X
breakage	B-X
and	B-X
2'-deoxyguanosine	B-X
hydroxylation	B-X
induced	B-X
by	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
role	B-X
of	B-X
free	B-X
radical	B-X
reactions	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Incubation	B-X
of	B-X
synthesized	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
with	B-X
cultured	B-X
Jurkat	B-X
cells	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
is	B-X
also	B-X
able	B-X
to	B-X
induce	B-X
NF-kappa	B-X
B	B-X
activation	B-X
through	B-X
Cr	B-X
(	B-X
V	B-X
)	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
intermediates	B-X
generated	B-X
during	B-X
the	B-X
reduction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
by	B-X
the	B-X
cells	B-X
.	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
did	B-X
not	B-X
cause	B-X
observable	B-X
NF-kappa	B-X
B	B-X
activation	B-X
due	B-X
to	B-X
its	B-X
inability	B-X
to	B-X
cross	B-X
cell	B-X
membranes	B-X
.	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
dose-dependent	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
activation	B-X
while	B-X
superoxide	B-X
dismutase	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
metal	B-X
chelator	B-X
,	B-X
deferoxamine	B-X
,	B-X
and	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
scavengers	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
Electrophoretic	B-X
assays	B-X
using	B-X
lambda	B-X
Hind	B-X
III	B-X
linear	B-X
DNA	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
H2O2	B-X
,	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
Deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
inhibited	B-X
the	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
HPLC	B-X
measurements	B-X
also	B-X
show	B-X
that	B-X
.OH	B-X
radical	B-X
generated	B-X
by	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
reaction	B-X
with	B-X
H2O2	B-X
was	B-X
capable	B-X
of	B-X
causing	B-X
2'-deoxyguanosine	B-X
(	B-X
dG	B-X
)	B-X
hydroxylation	B-X
to	B-X
generate	B-X
8-hydroxyguanosine	B-X
(	B-X
8-OHdG	B-X
)	B-X
.	B-X
The	B-X
relative	B-X
magnitude	B-X
of	B-X
8-OHdG	B-X
formation	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
.OH	B-X
radicals	B-X
.	B-X
ESR	B-X
spin	B-X
trapping	B-X
measurements	B-X
showed	B-X
that	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
with	B-X
H2O2	B-X
generated	B-X
.OH	B-X
radicals	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
deferoxamine	B-X
,	B-X
sodium	B-X
formate	B-X
and	B-X
aspirin	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
can	B-X
cause	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
dG	B-X
hydroxylation	B-X
through	B-X
.OH	B-X
radical-initiated	B-X
reactions	B-X
.	B-X
This	B-X
reactive	B-X
chromium	B-X
intermediate	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-glutathione	B-X
complex	B-X
may	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenicity	B-X
.	B-X

This	O
reactive	O
chromium	O
intermediate	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
mechanism	O
of	O
Cr	O
(	O
VI	O
)	O
-	O
induced	O
carcinogenesis	O
.	O
<EOS>	B-X
Current	B-X
models	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
carcinogenesis	B-X
suggest	B-X
an	B-X
important	B-X
role	B-X
for	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
as	B-X
an	B-X
intermediate	B-X
,	B-X
toxic	B-X
,	B-X
carcinogenic	B-X
species	B-X
,	B-X
but	B-X
direct	B-X
chemical	B-X
evidence	B-X
has	B-X
been	B-X
lacking	B-X
.	B-X
This	B-X
is	B-X
because	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
reactive	B-X
oxidation	B-X
state	B-X
of	B-X
Cr	B-X
and	B-X
few	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-based	B-X
compounds	B-X
are	B-X
known	B-X
that	B-X
can	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
containing	B-X
a	B-X
biological	B-X
ligand	B-X
.	B-X
This	B-X
study	B-X
reports	B-X
the	B-X
isolation	B-X
of	B-X
such	B-X
a	B-X
stable	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
complex	B-X
.	B-X
The	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-GSH	B-X
complex	B-X
has	B-X
been	B-X
synthesized	B-X
through	B-X
the	B-X
reaction	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
with	B-X
GSH	B-X
.	B-X
Magnetic	B-X
susceptibility	B-X
measurements	B-X
showed	B-X
that	B-X
the	B-X
compound	B-X
has	B-X
a	B-X
magnetic	B-X
moment	B-X
of	B-X
2.53	B-X
Bohr	B-X
magneton	B-X
per	B-X
Cr	B-X
,	B-X
establishing	B-X
that	B-X
the	B-X
Cr	B-X
ion	B-X
has	B-X
two	B-X
unpaired	B-X
electrons	B-X
,	B-X
hence	B-X
its	B-X
identity	B-X
as	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
.	B-X
The	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-GSH	B-X
complex	B-X
is	B-X
able	B-X
to	B-X
generate	B-X
hydroxyl	B-X
(	B-X
.OH	B-X
)	B-X
radical	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
molecular	B-X
oxygen	B-X
in	B-X
aqueous	B-X
medium	B-X
.	B-X
Catalase	B-X
inhibited	B-X
the	B-X
.OH	B-X
radical	B-X
generation	B-X
while	B-X
H2O2	B-X
enhanced	B-X
it	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
.OH	B-X
radical	B-X
was	B-X
generated	B-X
via	B-X
a	B-X
Fenton-like	B-X
reaction	B-X
,	B-X
H2O2	B-X
being	B-X
generated	B-X
as	B-X
an	B-X
intermediate	B-X
in	B-X
the	B-X
reduction	B-X
of	B-X
molecular	B-X
oxygen	B-X
.	B-X
Metal	B-X
ion	B-X
chelators	B-X
,	B-X
deferoxamine	B-X
and	B-X
1,10-phenanthroline	B-X
,	B-X
attenuated	B-X
the	B-X
generation	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-mediated	B-X
.OH	B-X
radical	B-X
.	B-X
The	B-X
results	B-X
imply	B-X
that	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
Cr	B-X
(	B-X
VI	B-X
)	B-X
-induced	B-X
carcinogenesis	B-X
and	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
-GSH	B-X
can	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
compound	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
Cr	B-X
(	B-X
IV	B-X
)	B-X
in	B-X
this	B-X
mechanism	B-X
.	B-X

The	O
results	O
also	O
suggest	O
that	O
the	O
Cr	O
(	O
IV	O
)	O
-	O
glutathione	O
complex	O
may	O
be	O
used	O
as	O
a	O
model	O
compound	O
to	O
study	O
the	O
role	O
of	O
Cr	O
(	O
IV	O
)	O
in	O
Cr	O
(	O
VI	O
)	O
carcinogenicity	O
.	O

Overhydroxylation	O
of	O
lysyl	O
residues	O
is	O
the	O
initial	O
step	O
for	O
altered	O
collagen	O
cross	O
-	O
links	O
and	O
fibril	O
architecture	O
in	O
fibrotic	O
skin	O
.	O
<EOS>	B-X
In	B-X
fibrotic	B-X
skin	B-X
of	B-X
lipodermatosclerosis	B-X
a	B-X
substantial	B-X
increase	B-X
of	B-X
the	B-X
cross-link	B-X
hydroxylysylpyridinoline	B-X
is	B-X
observed	B-X
.	B-X
Hydroxylysylpyridinoline	B-X
is	B-X
a	B-X
typical	B-X
cross-link	B-X
of	B-X
skeletal	B-X
tissue	B-X
and	B-X
is	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
hardening	B-X
of	B-X
sclerotic	B-X
tissue	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
increase	B-X
in	B-X
hydroxylysylpyridinoline	B-X
is	B-X
due	B-X
to	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
in	B-X
the	B-X
collagen	B-X
molecule	B-X
,	B-X
which	B-X
may	B-X
also	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysine	B-X
residues	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
collagen	B-X
fibrils	B-X
in	B-X
lipodermatosclerosis	B-X
showed	B-X
a	B-X
decrease	B-X
of	B-X
the	B-X
diameter	B-X
in	B-X
the	B-X
tissue	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vitro	B-X
after	B-X
fibrillogenesis	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
Isolated	B-X
alpha-chains	B-X
of	B-X
pepsin	B-X
solubilized	B-X
collagen	B-X
I	B-X
showed	B-X
an	B-X
increase	B-X
in	B-X
lysyl	B-X
hydroxylation	B-X
(	B-X
hyl/	B-X
(	B-X
hyl	B-X
+	B-X
lys	B-X
)	B-X
)	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
control	B-X
[	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.18	B-X
+/-	B-X
0.01	B-X
;	B-X
control	B-X
0.12	B-X
+/-	B-X
0.01	B-X
;	B-X
alpha2	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.36	B-X
+/-	B-X
0.02	B-X
;	B-X
control	B-X
0	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
content	B-X
of	B-X
enzymatic	B-X
glycosylated	B-X
hydroxlysine	B-X
residues	B-X
increased	B-X
.	B-X
This	B-X
increase	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
fibril	B-X
diameter	B-X
of	B-X
both	B-X
tissue	B-X
and	B-X
fibrils	B-X
formed	B-X
in	B-X
vitro	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
In	B-X
the	B-X
same	B-X
pool	B-X
of	B-X
collagens	B-X
an	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
was	B-X
observed	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
(	B-X
lipodermatosclerosis	B-X
14.5	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
control	B-X
10.3	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
hydroxylysylpyridinoline	B-X
,	B-X
is	B-X
not	B-X
only	B-X
restricted	B-X
to	B-X
the	B-X
telopeptides	B-X
but	B-X
also	B-X
affects	B-X
the	B-X
helical	B-X
part	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
This	B-X
process	B-X
is	B-X
further	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysyl	B-X
residues	B-X
.	B-X
These	B-X
changes	B-X
along	B-X
with	B-X
the	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
seem	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
alteration	B-X
in	B-X
the	B-X
architecture	B-X
of	B-X
collagen	B-X
fibrils	B-X
in	B-X
sclerotic	B-X
skin	B-X
.	B-X

In	O
fibrotic	O
skin	O
of	O
lipodermatosclerosis	O
a	O
substantial	O
increase	O
of	O
the	O
cross	O
-	O
link	O
hydroxylysylpyridinoline	O
is	O
observed	O
.	O
<EOS>	B-X
In	B-X
fibrotic	B-X
skin	B-X
of	B-X
lipodermatosclerosis	B-X
a	B-X
substantial	B-X
increase	B-X
of	B-X
the	B-X
cross-link	B-X
hydroxylysylpyridinoline	B-X
is	B-X
observed	B-X
.	B-X
Hydroxylysylpyridinoline	B-X
is	B-X
a	B-X
typical	B-X
cross-link	B-X
of	B-X
skeletal	B-X
tissue	B-X
and	B-X
is	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
hardening	B-X
of	B-X
sclerotic	B-X
tissue	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
increase	B-X
in	B-X
hydroxylysylpyridinoline	B-X
is	B-X
due	B-X
to	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
in	B-X
the	B-X
collagen	B-X
molecule	B-X
,	B-X
which	B-X
may	B-X
also	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysine	B-X
residues	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
collagen	B-X
fibrils	B-X
in	B-X
lipodermatosclerosis	B-X
showed	B-X
a	B-X
decrease	B-X
of	B-X
the	B-X
diameter	B-X
in	B-X
the	B-X
tissue	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vitro	B-X
after	B-X
fibrillogenesis	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
Isolated	B-X
alpha-chains	B-X
of	B-X
pepsin	B-X
solubilized	B-X
collagen	B-X
I	B-X
showed	B-X
an	B-X
increase	B-X
in	B-X
lysyl	B-X
hydroxylation	B-X
(	B-X
hyl/	B-X
(	B-X
hyl	B-X
+	B-X
lys	B-X
)	B-X
)	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
control	B-X
[	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.18	B-X
+/-	B-X
0.01	B-X
;	B-X
control	B-X
0.12	B-X
+/-	B-X
0.01	B-X
;	B-X
alpha2	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.36	B-X
+/-	B-X
0.02	B-X
;	B-X
control	B-X
0	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
content	B-X
of	B-X
enzymatic	B-X
glycosylated	B-X
hydroxlysine	B-X
residues	B-X
increased	B-X
.	B-X
This	B-X
increase	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
fibril	B-X
diameter	B-X
of	B-X
both	B-X
tissue	B-X
and	B-X
fibrils	B-X
formed	B-X
in	B-X
vitro	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
In	B-X
the	B-X
same	B-X
pool	B-X
of	B-X
collagens	B-X
an	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
was	B-X
observed	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
(	B-X
lipodermatosclerosis	B-X
14.5	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
control	B-X
10.3	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
hydroxylysylpyridinoline	B-X
,	B-X
is	B-X
not	B-X
only	B-X
restricted	B-X
to	B-X
the	B-X
telopeptides	B-X
but	B-X
also	B-X
affects	B-X
the	B-X
helical	B-X
part	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
This	B-X
process	B-X
is	B-X
further	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysyl	B-X
residues	B-X
.	B-X
These	B-X
changes	B-X
along	B-X
with	B-X
the	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
seem	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
alteration	B-X
in	B-X
the	B-X
architecture	B-X
of	B-X
collagen	B-X
fibrils	B-X
in	B-X
sclerotic	B-X
skin	B-X
.	B-X

Hydroxylysylpyridinoline	O
is	O
a	O
typical	O
cross	O
-	O
link	O
of	O
skeletal	O
tissue	O
and	O
is	O
thought	O
to	O
play	O
a	O
major	O
part	O
in	O
the	O
hardening	O
of	O
sclerotic	O
tissue	O
.	O

We	O
investigated	O
whether	O
the	O
increase	O
in	O
hydroxylysylpyridinoline	O
is	O
due	O
to	O
overhydroxylation	O
of	O
lysyl	O
residues	O
in	O
the	O
collagen	O
molecule	O
,	O
which	O
may	O
also	O
be	O
associated	O
with	O
an	O
increase	O
of	O
glycosylated	O
hydroxylysine	O
residues	O
.	O
<EOS>	B-X
In	B-X
fibrotic	B-X
skin	B-X
of	B-X
lipodermatosclerosis	B-X
a	B-X
substantial	B-X
increase	B-X
of	B-X
the	B-X
cross-link	B-X
hydroxylysylpyridinoline	B-X
is	B-X
observed	B-X
.	B-X
Hydroxylysylpyridinoline	B-X
is	B-X
a	B-X
typical	B-X
cross-link	B-X
of	B-X
skeletal	B-X
tissue	B-X
and	B-X
is	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
hardening	B-X
of	B-X
sclerotic	B-X
tissue	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
increase	B-X
in	B-X
hydroxylysylpyridinoline	B-X
is	B-X
due	B-X
to	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
in	B-X
the	B-X
collagen	B-X
molecule	B-X
,	B-X
which	B-X
may	B-X
also	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysine	B-X
residues	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
collagen	B-X
fibrils	B-X
in	B-X
lipodermatosclerosis	B-X
showed	B-X
a	B-X
decrease	B-X
of	B-X
the	B-X
diameter	B-X
in	B-X
the	B-X
tissue	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vitro	B-X
after	B-X
fibrillogenesis	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
Isolated	B-X
alpha-chains	B-X
of	B-X
pepsin	B-X
solubilized	B-X
collagen	B-X
I	B-X
showed	B-X
an	B-X
increase	B-X
in	B-X
lysyl	B-X
hydroxylation	B-X
(	B-X
hyl/	B-X
(	B-X
hyl	B-X
+	B-X
lys	B-X
)	B-X
)	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
control	B-X
[	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.18	B-X
+/-	B-X
0.01	B-X
;	B-X
control	B-X
0.12	B-X
+/-	B-X
0.01	B-X
;	B-X
alpha2	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.36	B-X
+/-	B-X
0.02	B-X
;	B-X
control	B-X
0	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
content	B-X
of	B-X
enzymatic	B-X
glycosylated	B-X
hydroxlysine	B-X
residues	B-X
increased	B-X
.	B-X
This	B-X
increase	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
fibril	B-X
diameter	B-X
of	B-X
both	B-X
tissue	B-X
and	B-X
fibrils	B-X
formed	B-X
in	B-X
vitro	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
In	B-X
the	B-X
same	B-X
pool	B-X
of	B-X
collagens	B-X
an	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
was	B-X
observed	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
(	B-X
lipodermatosclerosis	B-X
14.5	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
control	B-X
10.3	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
hydroxylysylpyridinoline	B-X
,	B-X
is	B-X
not	B-X
only	B-X
restricted	B-X
to	B-X
the	B-X
telopeptides	B-X
but	B-X
also	B-X
affects	B-X
the	B-X
helical	B-X
part	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
This	B-X
process	B-X
is	B-X
further	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysyl	B-X
residues	B-X
.	B-X
These	B-X
changes	B-X
along	B-X
with	B-X
the	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
seem	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
alteration	B-X
in	B-X
the	B-X
architecture	B-X
of	B-X
collagen	B-X
fibrils	B-X
in	B-X
sclerotic	B-X
skin	B-X
.	B-X

Furthermore	O
,	O
we	O
determined	O
whether	O
the	O
collagen	O
fibrils	O
in	O
lipodermatosclerosis	O
showed	O
a	O
decrease	O
of	O
the	O
diameter	O
in	O
the	O
tissue	O
as	O
well	O
as	O
in	O
vitro	O
after	O
fibrillogenesis	O
of	O
pepsin	O
-	O
solubilized	O
collagens	O
.	O
<EOS>	B-X
In	B-X
fibrotic	B-X
skin	B-X
of	B-X
lipodermatosclerosis	B-X
a	B-X
substantial	B-X
increase	B-X
of	B-X
the	B-X
cross-link	B-X
hydroxylysylpyridinoline	B-X
is	B-X
observed	B-X
.	B-X
Hydroxylysylpyridinoline	B-X
is	B-X
a	B-X
typical	B-X
cross-link	B-X
of	B-X
skeletal	B-X
tissue	B-X
and	B-X
is	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
hardening	B-X
of	B-X
sclerotic	B-X
tissue	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
increase	B-X
in	B-X
hydroxylysylpyridinoline	B-X
is	B-X
due	B-X
to	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
in	B-X
the	B-X
collagen	B-X
molecule	B-X
,	B-X
which	B-X
may	B-X
also	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysine	B-X
residues	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
collagen	B-X
fibrils	B-X
in	B-X
lipodermatosclerosis	B-X
showed	B-X
a	B-X
decrease	B-X
of	B-X
the	B-X
diameter	B-X
in	B-X
the	B-X
tissue	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vitro	B-X
after	B-X
fibrillogenesis	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
Isolated	B-X
alpha-chains	B-X
of	B-X
pepsin	B-X
solubilized	B-X
collagen	B-X
I	B-X
showed	B-X
an	B-X
increase	B-X
in	B-X
lysyl	B-X
hydroxylation	B-X
(	B-X
hyl/	B-X
(	B-X
hyl	B-X
+	B-X
lys	B-X
)	B-X
)	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
control	B-X
[	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.18	B-X
+/-	B-X
0.01	B-X
;	B-X
control	B-X
0.12	B-X
+/-	B-X
0.01	B-X
;	B-X
alpha2	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.36	B-X
+/-	B-X
0.02	B-X
;	B-X
control	B-X
0	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
content	B-X
of	B-X
enzymatic	B-X
glycosylated	B-X
hydroxlysine	B-X
residues	B-X
increased	B-X
.	B-X
This	B-X
increase	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
fibril	B-X
diameter	B-X
of	B-X
both	B-X
tissue	B-X
and	B-X
fibrils	B-X
formed	B-X
in	B-X
vitro	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
In	B-X
the	B-X
same	B-X
pool	B-X
of	B-X
collagens	B-X
an	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
was	B-X
observed	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
(	B-X
lipodermatosclerosis	B-X
14.5	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
control	B-X
10.3	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
hydroxylysylpyridinoline	B-X
,	B-X
is	B-X
not	B-X
only	B-X
restricted	B-X
to	B-X
the	B-X
telopeptides	B-X
but	B-X
also	B-X
affects	B-X
the	B-X
helical	B-X
part	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
These	B-X
changes	B-X
along	B-X
with	B-X
the	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
seem	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
alteration	B-X
in	B-X
the	B-X
architecture	B-X
of	B-X
collagen	B-X
fibrils	B-X
in	B-X
sclerotic	B-X
skin	B-X
.	B-X

Isolated	O
alpha	O
-	O
chains	O
of	O
pepsin	O
solubilized	O
collagen	O
I	O
showed	O
an	O
increase	O
in	O
lysyl	O
hydroxylation	O
(	O
hyl	O
/	O
(	O
hyl	O
+	O
lys	O
)	O
)	O
as	O
compared	O
with	O
normal	O
control	O
[	O
alpha1	O
(	O
I	O
)	O
:	O
lipodermatosclerosis	O
0	O
.	O
18	O
+	O
/	O
-	O
0	O
.	O
01	O
;	O
control	O
0	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
01	O
;	O
alpha2	O
(	O
I	O
)	O
:	O
lipodermatosclerosis	O
0	O
.	O
36	O
+	O
/	O
-	O
0	O
.	O
02	O
;	O
control	O
0	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
03	O
,	O
p	O
<	O
0	O
.	O
001	O
]	O
.	O

Furthermore	O
,	O
the	O
content	O
of	O
enzymatic	O
glycosylated	O
hydroxlysine	O
residues	O
increased	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
increase	B-X
in	B-X
hydroxylysylpyridinoline	B-X
is	B-X
due	B-X
to	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
in	B-X
the	B-X
collagen	B-X
molecule	B-X
,	B-X
which	B-X
may	B-X
also	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysine	B-X
residues	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
collagen	B-X
fibrils	B-X
in	B-X
lipodermatosclerosis	B-X
showed	B-X
a	B-X
decrease	B-X
of	B-X
the	B-X
diameter	B-X
in	B-X
the	B-X
tissue	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vitro	B-X
after	B-X
fibrillogenesis	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
content	B-X
of	B-X
enzymatic	B-X
glycosylated	B-X
hydroxlysine	B-X
residues	B-X
increased	B-X
.	B-X
In	B-X
the	B-X
same	B-X
pool	B-X
of	B-X
collagens	B-X
an	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
was	B-X
observed	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
(	B-X
lipodermatosclerosis	B-X
14.5	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
control	B-X
10.3	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
hydroxylysylpyridinoline	B-X
,	B-X
is	B-X
not	B-X
only	B-X
restricted	B-X
to	B-X
the	B-X
telopeptides	B-X
but	B-X
also	B-X
affects	B-X
the	B-X
helical	B-X
part	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
This	B-X
process	B-X
is	B-X
further	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysyl	B-X
residues	B-X
.	B-X
These	B-X
changes	B-X
along	B-X
with	B-X
the	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
seem	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
alteration	B-X
in	B-X
the	B-X
architecture	B-X
of	B-X
collagen	B-X
fibrils	B-X
in	B-X
sclerotic	B-X
skin	B-X
.	B-X

This	O
increase	O
is	O
associated	O
with	O
a	O
decrease	O
of	O
fibril	O
diameter	O
of	O
both	O
tissue	O
and	O
fibrils	O
formed	O
in	O
vitro	O
of	O
pepsin	O
-	O
solubilized	O
collagens	O
.	O
<EOS>	B-X
In	B-X
fibrotic	B-X
skin	B-X
of	B-X
lipodermatosclerosis	B-X
a	B-X
substantial	B-X
increase	B-X
of	B-X
the	B-X
cross-link	B-X
hydroxylysylpyridinoline	B-X
is	B-X
observed	B-X
.	B-X
Hydroxylysylpyridinoline	B-X
is	B-X
a	B-X
typical	B-X
cross-link	B-X
of	B-X
skeletal	B-X
tissue	B-X
and	B-X
is	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
hardening	B-X
of	B-X
sclerotic	B-X
tissue	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
increase	B-X
in	B-X
hydroxylysylpyridinoline	B-X
is	B-X
due	B-X
to	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
in	B-X
the	B-X
collagen	B-X
molecule	B-X
,	B-X
which	B-X
may	B-X
also	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysine	B-X
residues	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
collagen	B-X
fibrils	B-X
in	B-X
lipodermatosclerosis	B-X
showed	B-X
a	B-X
decrease	B-X
of	B-X
the	B-X
diameter	B-X
in	B-X
the	B-X
tissue	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vitro	B-X
after	B-X
fibrillogenesis	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
Isolated	B-X
alpha-chains	B-X
of	B-X
pepsin	B-X
solubilized	B-X
collagen	B-X
I	B-X
showed	B-X
an	B-X
increase	B-X
in	B-X
lysyl	B-X
hydroxylation	B-X
(	B-X
hyl/	B-X
(	B-X
hyl	B-X
+	B-X
lys	B-X
)	B-X
)	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
control	B-X
[	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.18	B-X
+/-	B-X
0.01	B-X
;	B-X
control	B-X
0.12	B-X
+/-	B-X
0.01	B-X
;	B-X
alpha2	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.36	B-X
+/-	B-X
0.02	B-X
;	B-X
control	B-X
0	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
content	B-X
of	B-X
enzymatic	B-X
glycosylated	B-X
hydroxlysine	B-X
residues	B-X
increased	B-X
.	B-X
This	B-X
increase	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
fibril	B-X
diameter	B-X
of	B-X
both	B-X
tissue	B-X
and	B-X
fibrils	B-X
formed	B-X
in	B-X
vitro	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
In	B-X
the	B-X
same	B-X
pool	B-X
of	B-X
collagens	B-X
an	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
was	B-X
observed	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
(	B-X
lipodermatosclerosis	B-X
14.5	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
control	B-X
10.3	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
This	B-X
process	B-X
is	B-X
further	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysyl	B-X
residues	B-X
.	B-X
These	B-X
changes	B-X
along	B-X
with	B-X
the	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
seem	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
alteration	B-X
in	B-X
the	B-X
architecture	B-X
of	B-X
collagen	B-X
fibrils	B-X
in	B-X
sclerotic	B-X
skin	B-X
.	B-X

In	O
the	O
same	O
pool	O
of	O
collagens	O
an	O
increase	O
in	O
collagen	B-Protein
III	I-Protein
content	O
was	O
observed	O
as	O
compared	O
with	O
controls	O
(	O
lipodermatosclerosis	O
14	O
.	O
5	O
%	O
+	O
/	O
-	O
1	O
.	O
6	O
,	O
control	O
10	O
.	O
3	O
%	O
+	O
/	O
-	O
1	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Our	O
results	O
showed	O
that	O
the	O
overhydroxylation	O
of	O
lysyl	O
residues	O
,	O
which	O
is	O
required	O
for	O
the	O
generation	O
of	O
hydroxylysylpyridinoline	O
,	O
is	O
not	O
only	O
restricted	O
to	O
the	O
telopeptides	O
but	O
also	O
affects	O
the	O
helical	O
part	O
of	O
the	O
molecule	O
.	O
<EOS>	B-X
In	B-X
fibrotic	B-X
skin	B-X
of	B-X
lipodermatosclerosis	B-X
a	B-X
substantial	B-X
increase	B-X
of	B-X
the	B-X
cross-link	B-X
hydroxylysylpyridinoline	B-X
is	B-X
observed	B-X
.	B-X
Hydroxylysylpyridinoline	B-X
is	B-X
a	B-X
typical	B-X
cross-link	B-X
of	B-X
skeletal	B-X
tissue	B-X
and	B-X
is	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
hardening	B-X
of	B-X
sclerotic	B-X
tissue	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
increase	B-X
in	B-X
hydroxylysylpyridinoline	B-X
is	B-X
due	B-X
to	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
in	B-X
the	B-X
collagen	B-X
molecule	B-X
,	B-X
which	B-X
may	B-X
also	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysine	B-X
residues	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
collagen	B-X
fibrils	B-X
in	B-X
lipodermatosclerosis	B-X
showed	B-X
a	B-X
decrease	B-X
of	B-X
the	B-X
diameter	B-X
in	B-X
the	B-X
tissue	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vitro	B-X
after	B-X
fibrillogenesis	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
Isolated	B-X
alpha-chains	B-X
of	B-X
pepsin	B-X
solubilized	B-X
collagen	B-X
I	B-X
showed	B-X
an	B-X
increase	B-X
in	B-X
lysyl	B-X
hydroxylation	B-X
(	B-X
hyl/	B-X
(	B-X
hyl	B-X
+	B-X
lys	B-X
)	B-X
)	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
control	B-X
[	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.18	B-X
+/-	B-X
0.01	B-X
;	B-X
control	B-X
0.12	B-X
+/-	B-X
0.01	B-X
;	B-X
alpha2	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.36	B-X
+/-	B-X
0.02	B-X
;	B-X
control	B-X
0	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
content	B-X
of	B-X
enzymatic	B-X
glycosylated	B-X
hydroxlysine	B-X
residues	B-X
increased	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
hydroxylysylpyridinoline	B-X
,	B-X
is	B-X
not	B-X
only	B-X
restricted	B-X
to	B-X
the	B-X
telopeptides	B-X
but	B-X
also	B-X
affects	B-X
the	B-X
helical	B-X
part	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
This	B-X
process	B-X
is	B-X
further	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysyl	B-X
residues	B-X
.	B-X

This	O
process	O
is	O
further	O
associated	O
with	O
an	O
increase	O
of	O
glycosylated	O
hydroxylysyl	O
residues	O
.	O
<EOS>	B-X
In	B-X
fibrotic	B-X
skin	B-X
of	B-X
lipodermatosclerosis	B-X
a	B-X
substantial	B-X
increase	B-X
of	B-X
the	B-X
cross-link	B-X
hydroxylysylpyridinoline	B-X
is	B-X
observed	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
increase	B-X
in	B-X
hydroxylysylpyridinoline	B-X
is	B-X
due	B-X
to	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
in	B-X
the	B-X
collagen	B-X
molecule	B-X
,	B-X
which	B-X
may	B-X
also	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysine	B-X
residues	B-X
.	B-X
Isolated	B-X
alpha-chains	B-X
of	B-X
pepsin	B-X
solubilized	B-X
collagen	B-X
I	B-X
showed	B-X
an	B-X
increase	B-X
in	B-X
lysyl	B-X
hydroxylation	B-X
(	B-X
hyl/	B-X
(	B-X
hyl	B-X
+	B-X
lys	B-X
)	B-X
)	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
control	B-X
[	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.18	B-X
+/-	B-X
0.01	B-X
;	B-X
control	B-X
0.12	B-X
+/-	B-X
0.01	B-X
;	B-X
alpha2	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.36	B-X
+/-	B-X
0.02	B-X
;	B-X
control	B-X
0	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
content	B-X
of	B-X
enzymatic	B-X
glycosylated	B-X
hydroxlysine	B-X
residues	B-X
increased	B-X
.	B-X
This	B-X
increase	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
fibril	B-X
diameter	B-X
of	B-X
both	B-X
tissue	B-X
and	B-X
fibrils	B-X
formed	B-X
in	B-X
vitro	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
In	B-X
the	B-X
same	B-X
pool	B-X
of	B-X
collagens	B-X
an	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
was	B-X
observed	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
(	B-X
lipodermatosclerosis	B-X
14.5	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
control	B-X
10.3	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
hydroxylysylpyridinoline	B-X
,	B-X
is	B-X
not	B-X
only	B-X
restricted	B-X
to	B-X
the	B-X
telopeptides	B-X
but	B-X
also	B-X
affects	B-X
the	B-X
helical	B-X
part	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
This	B-X
process	B-X
is	B-X
further	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysyl	B-X
residues	B-X
.	B-X
These	B-X
changes	B-X
along	B-X
with	B-X
the	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
seem	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
alteration	B-X
in	B-X
the	B-X
architecture	B-X
of	B-X
collagen	B-X
fibrils	B-X
in	B-X
sclerotic	B-X
skin	B-X
.	B-X

These	O
changes	O
along	O
with	O
the	O
increase	O
in	O
collagen	B-Protein
III	I-Protein
content	O
seem	O
to	O
be	O
responsible	O
for	O
the	O
observed	O
alteration	O
in	O
the	O
architecture	O
of	O
collagen	O
fibrils	O
in	O
sclerotic	O
skin	O
.	O
<EOS>	B-X
In	B-X
fibrotic	B-X
skin	B-X
of	B-X
lipodermatosclerosis	B-X
a	B-X
substantial	B-X
increase	B-X
of	B-X
the	B-X
cross-link	B-X
hydroxylysylpyridinoline	B-X
is	B-X
observed	B-X
.	B-X
Hydroxylysylpyridinoline	B-X
is	B-X
a	B-X
typical	B-X
cross-link	B-X
of	B-X
skeletal	B-X
tissue	B-X
and	B-X
is	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
hardening	B-X
of	B-X
sclerotic	B-X
tissue	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
increase	B-X
in	B-X
hydroxylysylpyridinoline	B-X
is	B-X
due	B-X
to	B-X
overhydroxylation	B-X
of	B-X
lysyl	B-X
residues	B-X
in	B-X
the	B-X
collagen	B-X
molecule	B-X
,	B-X
which	B-X
may	B-X
also	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysine	B-X
residues	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
collagen	B-X
fibrils	B-X
in	B-X
lipodermatosclerosis	B-X
showed	B-X
a	B-X
decrease	B-X
of	B-X
the	B-X
diameter	B-X
in	B-X
the	B-X
tissue	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vitro	B-X
after	B-X
fibrillogenesis	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
Isolated	B-X
alpha-chains	B-X
of	B-X
pepsin	B-X
solubilized	B-X
collagen	B-X
I	B-X
showed	B-X
an	B-X
increase	B-X
in	B-X
lysyl	B-X
hydroxylation	B-X
(	B-X
hyl/	B-X
(	B-X
hyl	B-X
+	B-X
lys	B-X
)	B-X
)	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
control	B-X
[	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.18	B-X
+/-	B-X
0.01	B-X
;	B-X
control	B-X
0.12	B-X
+/-	B-X
0.01	B-X
;	B-X
alpha2	B-X
(	B-X
I	B-X
)	B-X
:	B-X
lipodermatosclerosis	B-X
0.36	B-X
+/-	B-X
0.02	B-X
;	B-X
control	B-X
0	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
content	B-X
of	B-X
enzymatic	B-X
glycosylated	B-X
hydroxlysine	B-X
residues	B-X
increased	B-X
.	B-X
This	B-X
increase	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
fibril	B-X
diameter	B-X
of	B-X
both	B-X
tissue	B-X
and	B-X
fibrils	B-X
formed	B-X
in	B-X
vitro	B-X
of	B-X
pepsin-solubilized	B-X
collagens	B-X
.	B-X
In	B-X
the	B-X
same	B-X
pool	B-X
of	B-X
collagens	B-X
an	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
was	B-X
observed	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
(	B-X
lipodermatosclerosis	B-X
14.5	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
control	B-X
10.3	B-X
%	B-X
+/-	B-X
1.6	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
This	B-X
process	B-X
is	B-X
further	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glycosylated	B-X
hydroxylysyl	B-X
residues	B-X
.	B-X
These	B-X
changes	B-X
along	B-X
with	B-X
the	B-X
increase	B-X
in	B-X
collagen	B-X
III	B-X
content	B-X
seem	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
alteration	B-X
in	B-X
the	B-X
architecture	B-X
of	B-X
collagen	B-X
fibrils	B-X
in	B-X
sclerotic	B-X
skin	B-X
.	B-X

ER	O
/	O
Golgi	O
intermediates	O
acquire	O
Golgi	O
enzymes	O
by	O
brefeldin	O
A	O
-	O
sensitive	O
retrograde	O
transport	O
in	O
vitro	O
.	O
<EOS>	B-X
Secretory	B-X
proteins	B-X
exit	B-X
the	B-X
ER	B-X
in	B-X
transport	B-X
vesicles	B-X
that	B-X
fuse	B-X
to	B-X
form	B-X
vesicular	B-X
tubular	B-X
clusters	B-X
(	B-X
VTCs	B-X
)	B-X
which	B-X
move	B-X
along	B-X
microtubule	B-X
tracks	B-X
to	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
Using	B-X
the	B-X
well-characterized	B-X
in	B-X
vitro	B-X
approach	B-X
to	B-X
study	B-X
the	B-X
properties	B-X
of	B-X
Golgi	B-X
membranes	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
Golgi	B-X
enzyme	B-X
NAGT	B-X
I	B-X
is	B-X
transported	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
.	B-X
Secretory	B-X
cargo	B-X
was	B-X
arrested	B-X
at	B-X
distinct	B-X
steps	B-X
of	B-X
the	B-X
secretory	B-X
pathway	B-X
of	B-X
a	B-X
glycosylation	B-X
mutant	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
vitro	B-X
complementation	B-X
of	B-X
the	B-X
glycosylation	B-X
defect	B-X
was	B-X
determined	B-X
.	B-X
Complementation	B-X
yield	B-X
increased	B-X
after	B-X
ER	B-X
exit	B-X
of	B-X
secretory	B-X
cargo	B-X
and	B-X
was	B-X
optimal	B-X
when	B-X
transport	B-X
was	B-X
blocked	B-X
at	B-X
an	B-X
ER/Golgi	B-X
intermediate	B-X
step	B-X
.	B-X
The	B-X
rapid	B-X
drop	B-X
of	B-X
the	B-X
complementation	B-X
yield	B-X
as	B-X
secretory	B-X
cargo	B-X
progresses	B-X
into	B-X
the	B-X
stack	B-X
suggests	B-X
that	B-X
Golgi	B-X
enzymes	B-X
are	B-X
preferentially	B-X
targeted	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
and	B-X
not	B-X
to	B-X
membranes	B-X
of	B-X
the	B-X
Golgi	B-X
stack	B-X
.	B-X
Two	B-X
mechanisms	B-X
for	B-X
in	B-X
vitro	B-X
complementation	B-X
could	B-X
be	B-X
distinguished	B-X
due	B-X
to	B-X
their	B-X
different	B-X
sensitivities	B-X
to	B-X
brefeldin	B-X
A	B-X
(	B-X
BFA	B-X
)	B-X
.	B-X
Transport	B-X
occurred	B-X
either	B-X
by	B-X
direct	B-X
fusion	B-X
of	B-X
preexisting	B-X
transport	B-X
intermediates	B-X
with	B-X
ER/Golgi	B-X
intermediates	B-X
,	B-X
or	B-X
it	B-X
occurred	B-X
as	B-X
a	B-X
BFA-sensitive	B-X
and	B-X
most	B-X
likely	B-X
COP	B-X
I-mediated	B-X
step	B-X
.	B-X
Direct	B-X
fusion	B-X
of	B-X
ER/Golgi	B-X
intermediates	B-X
with	B-X
cisternal	B-X
membranes	B-X
of	B-X
the	B-X
Golgi	B-X
stack	B-X
was	B-X
not	B-X
observed	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X

Secretory	O
proteins	O
exit	O
the	O
ER	O
in	O
transport	O
vesicles	O
that	O
fuse	O
to	O
form	O
vesicular	O
tubular	O
clusters	O
(	O
VTCs	O
)	O
which	O
move	O
along	O
microtubule	O
tracks	O
to	O
the	O
Golgi	O
apparatus	O
.	O

Using	O
the	O
well	O
-	O
characterized	O
in	O
vitro	O
approach	O
to	O
study	O
the	O
properties	O
of	O
Golgi	O
membranes	O
,	O
we	O
determined	O
whether	O
the	O
Golgi	O
enzyme	O
NAGT	B-Protein
I	I-Protein
is	O
transported	O
to	O
ER	O
/	O
Golgi	O
intermediates	O
.	O

Secretory	O
cargo	O
was	O
arrested	O
at	O
distinct	O
steps	O
of	O
the	O
secretory	O
pathway	O
of	O
a	O
glycosylation	O
mutant	O
cell	O
line	O
,	O
and	O
in	O
vitro	O
complementation	O
of	O
the	O
glycosylation	O
defect	O
was	O
determined	O
.	O
<EOS>	B-X
Secretory	B-X
proteins	B-X
exit	B-X
the	B-X
ER	B-X
in	B-X
transport	B-X
vesicles	B-X
that	B-X
fuse	B-X
to	B-X
form	B-X
vesicular	B-X
tubular	B-X
clusters	B-X
(	B-X
VTCs	B-X
)	B-X
which	B-X
move	B-X
along	B-X
microtubule	B-X
tracks	B-X
to	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
Using	B-X
the	B-X
well-characterized	B-X
in	B-X
vitro	B-X
approach	B-X
to	B-X
study	B-X
the	B-X
properties	B-X
of	B-X
Golgi	B-X
membranes	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
Golgi	B-X
enzyme	B-X
NAGT	B-X
I	B-X
is	B-X
transported	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
.	B-X
Secretory	B-X
cargo	B-X
was	B-X
arrested	B-X
at	B-X
distinct	B-X
steps	B-X
of	B-X
the	B-X
secretory	B-X
pathway	B-X
of	B-X
a	B-X
glycosylation	B-X
mutant	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
vitro	B-X
complementation	B-X
of	B-X
the	B-X
glycosylation	B-X
defect	B-X
was	B-X
determined	B-X
.	B-X
Complementation	B-X
yield	B-X
increased	B-X
after	B-X
ER	B-X
exit	B-X
of	B-X
secretory	B-X
cargo	B-X
and	B-X
was	B-X
optimal	B-X
when	B-X
transport	B-X
was	B-X
blocked	B-X
at	B-X
an	B-X
ER/Golgi	B-X
intermediate	B-X
step	B-X
.	B-X
The	B-X
rapid	B-X
drop	B-X
of	B-X
the	B-X
complementation	B-X
yield	B-X
as	B-X
secretory	B-X
cargo	B-X
progresses	B-X
into	B-X
the	B-X
stack	B-X
suggests	B-X
that	B-X
Golgi	B-X
enzymes	B-X
are	B-X
preferentially	B-X
targeted	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
and	B-X
not	B-X
to	B-X
membranes	B-X
of	B-X
the	B-X
Golgi	B-X
stack	B-X
.	B-X
Two	B-X
mechanisms	B-X
for	B-X
in	B-X
vitro	B-X
complementation	B-X
could	B-X
be	B-X
distinguished	B-X
due	B-X
to	B-X
their	B-X
different	B-X
sensitivities	B-X
to	B-X
brefeldin	B-X
A	B-X
(	B-X
BFA	B-X
)	B-X
.	B-X

Complementation	O
yield	O
increased	O
after	O
ER	O
exit	O
of	O
secretory	O
cargo	O
and	O
was	O
optimal	O
when	O
transport	O
was	O
blocked	O
at	O
an	O
ER	O
/	O
Golgi	O
intermediate	O
step	O
.	O
<EOS>	B-X
Secretory	B-X
proteins	B-X
exit	B-X
the	B-X
ER	B-X
in	B-X
transport	B-X
vesicles	B-X
that	B-X
fuse	B-X
to	B-X
form	B-X
vesicular	B-X
tubular	B-X
clusters	B-X
(	B-X
VTCs	B-X
)	B-X
which	B-X
move	B-X
along	B-X
microtubule	B-X
tracks	B-X
to	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
Using	B-X
the	B-X
well-characterized	B-X
in	B-X
vitro	B-X
approach	B-X
to	B-X
study	B-X
the	B-X
properties	B-X
of	B-X
Golgi	B-X
membranes	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
Golgi	B-X
enzyme	B-X
NAGT	B-X
I	B-X
is	B-X
transported	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
.	B-X
Secretory	B-X
cargo	B-X
was	B-X
arrested	B-X
at	B-X
distinct	B-X
steps	B-X
of	B-X
the	B-X
secretory	B-X
pathway	B-X
of	B-X
a	B-X
glycosylation	B-X
mutant	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
vitro	B-X
complementation	B-X
of	B-X
the	B-X
glycosylation	B-X
defect	B-X
was	B-X
determined	B-X
.	B-X
Complementation	B-X
yield	B-X
increased	B-X
after	B-X
ER	B-X
exit	B-X
of	B-X
secretory	B-X
cargo	B-X
and	B-X
was	B-X
optimal	B-X
when	B-X
transport	B-X
was	B-X
blocked	B-X
at	B-X
an	B-X
ER/Golgi	B-X
intermediate	B-X
step	B-X
.	B-X
The	B-X
rapid	B-X
drop	B-X
of	B-X
the	B-X
complementation	B-X
yield	B-X
as	B-X
secretory	B-X
cargo	B-X
progresses	B-X
into	B-X
the	B-X
stack	B-X
suggests	B-X
that	B-X
Golgi	B-X
enzymes	B-X
are	B-X
preferentially	B-X
targeted	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
and	B-X
not	B-X
to	B-X
membranes	B-X
of	B-X
the	B-X
Golgi	B-X
stack	B-X
.	B-X
Transport	B-X
occurred	B-X
either	B-X
by	B-X
direct	B-X
fusion	B-X
of	B-X
preexisting	B-X
transport	B-X
intermediates	B-X
with	B-X
ER/Golgi	B-X
intermediates	B-X
,	B-X
or	B-X
it	B-X
occurred	B-X
as	B-X
a	B-X
BFA-sensitive	B-X
and	B-X
most	B-X
likely	B-X
COP	B-X
I-mediated	B-X
step	B-X
.	B-X
Direct	B-X
fusion	B-X
of	B-X
ER/Golgi	B-X
intermediates	B-X
with	B-X
cisternal	B-X
membranes	B-X
of	B-X
the	B-X
Golgi	B-X
stack	B-X
was	B-X
not	B-X
observed	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X

The	O
rapid	O
drop	O
of	O
the	O
complementation	O
yield	O
as	O
secretory	O
cargo	O
progresses	O
into	O
the	O
stack	O
suggests	O
that	O
Golgi	O
enzymes	O
are	O
preferentially	O
targeted	O
to	O
ER	O
/	O
Golgi	O
intermediates	O
and	O
not	O
to	O
membranes	O
of	O
the	O
Golgi	O
stack	O
.	O

Two	O
mechanisms	O
for	O
in	O
vitro	O
complementation	O
could	O
be	O
distinguished	O
due	O
to	O
their	O
different	O
sensitivities	O
to	O
brefeldin	O
A	O
(	O
BFA	O
)	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
well-characterized	B-X
in	B-X
vitro	B-X
approach	B-X
to	B-X
study	B-X
the	B-X
properties	B-X
of	B-X
Golgi	B-X
membranes	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
Golgi	B-X
enzyme	B-X
NAGT	B-X
I	B-X
is	B-X
transported	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
.	B-X
Secretory	B-X
cargo	B-X
was	B-X
arrested	B-X
at	B-X
distinct	B-X
steps	B-X
of	B-X
the	B-X
secretory	B-X
pathway	B-X
of	B-X
a	B-X
glycosylation	B-X
mutant	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
vitro	B-X
complementation	B-X
of	B-X
the	B-X
glycosylation	B-X
defect	B-X
was	B-X
determined	B-X
.	B-X
The	B-X
rapid	B-X
drop	B-X
of	B-X
the	B-X
complementation	B-X
yield	B-X
as	B-X
secretory	B-X
cargo	B-X
progresses	B-X
into	B-X
the	B-X
stack	B-X
suggests	B-X
that	B-X
Golgi	B-X
enzymes	B-X
are	B-X
preferentially	B-X
targeted	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
and	B-X
not	B-X
to	B-X
membranes	B-X
of	B-X
the	B-X
Golgi	B-X
stack	B-X
.	B-X
Two	B-X
mechanisms	B-X
for	B-X
in	B-X
vitro	B-X
complementation	B-X
could	B-X
be	B-X
distinguished	B-X
due	B-X
to	B-X
their	B-X
different	B-X
sensitivities	B-X
to	B-X
brefeldin	B-X
A	B-X
(	B-X
BFA	B-X
)	B-X
.	B-X
Transport	B-X
occurred	B-X
either	B-X
by	B-X
direct	B-X
fusion	B-X
of	B-X
preexisting	B-X
transport	B-X
intermediates	B-X
with	B-X
ER/Golgi	B-X
intermediates	B-X
,	B-X
or	B-X
it	B-X
occurred	B-X
as	B-X
a	B-X
BFA-sensitive	B-X
and	B-X
most	B-X
likely	B-X
COP	B-X
I-mediated	B-X
step	B-X
.	B-X

Transport	O
occurred	O
either	O
by	O
direct	O
fusion	O
of	O
preexisting	O
transport	O
intermediates	O
with	O
ER	O
/	O
Golgi	O
intermediates	O
,	O
or	O
it	O
occurred	O
as	O
a	O
BFA	O
-	O
sensitive	O
and	O
most	O
likely	O
COP	O
I	O
-	O
mediated	O
step	O
.	O
<EOS>	B-X
Secretory	B-X
proteins	B-X
exit	B-X
the	B-X
ER	B-X
in	B-X
transport	B-X
vesicles	B-X
that	B-X
fuse	B-X
to	B-X
form	B-X
vesicular	B-X
tubular	B-X
clusters	B-X
(	B-X
VTCs	B-X
)	B-X
which	B-X
move	B-X
along	B-X
microtubule	B-X
tracks	B-X
to	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
Using	B-X
the	B-X
well-characterized	B-X
in	B-X
vitro	B-X
approach	B-X
to	B-X
study	B-X
the	B-X
properties	B-X
of	B-X
Golgi	B-X
membranes	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
the	B-X
Golgi	B-X
enzyme	B-X
NAGT	B-X
I	B-X
is	B-X
transported	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
.	B-X
Secretory	B-X
cargo	B-X
was	B-X
arrested	B-X
at	B-X
distinct	B-X
steps	B-X
of	B-X
the	B-X
secretory	B-X
pathway	B-X
of	B-X
a	B-X
glycosylation	B-X
mutant	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
vitro	B-X
complementation	B-X
of	B-X
the	B-X
glycosylation	B-X
defect	B-X
was	B-X
determined	B-X
.	B-X
Complementation	B-X
yield	B-X
increased	B-X
after	B-X
ER	B-X
exit	B-X
of	B-X
secretory	B-X
cargo	B-X
and	B-X
was	B-X
optimal	B-X
when	B-X
transport	B-X
was	B-X
blocked	B-X
at	B-X
an	B-X
ER/Golgi	B-X
intermediate	B-X
step	B-X
.	B-X
The	B-X
rapid	B-X
drop	B-X
of	B-X
the	B-X
complementation	B-X
yield	B-X
as	B-X
secretory	B-X
cargo	B-X
progresses	B-X
into	B-X
the	B-X
stack	B-X
suggests	B-X
that	B-X
Golgi	B-X
enzymes	B-X
are	B-X
preferentially	B-X
targeted	B-X
to	B-X
ER/Golgi	B-X
intermediates	B-X
and	B-X
not	B-X
to	B-X
membranes	B-X
of	B-X
the	B-X
Golgi	B-X
stack	B-X
.	B-X
Two	B-X
mechanisms	B-X
for	B-X
in	B-X
vitro	B-X
complementation	B-X
could	B-X
be	B-X
distinguished	B-X
due	B-X
to	B-X
their	B-X
different	B-X
sensitivities	B-X
to	B-X
brefeldin	B-X
A	B-X
(	B-X
BFA	B-X
)	B-X
.	B-X
Transport	B-X
occurred	B-X
either	B-X
by	B-X
direct	B-X
fusion	B-X
of	B-X
preexisting	B-X
transport	B-X
intermediates	B-X
with	B-X
ER/Golgi	B-X
intermediates	B-X
,	B-X
or	B-X
it	B-X
occurred	B-X
as	B-X
a	B-X
BFA-sensitive	B-X
and	B-X
most	B-X
likely	B-X
COP	B-X
I-mediated	B-X
step	B-X
.	B-X
Direct	B-X
fusion	B-X
of	B-X
ER/Golgi	B-X
intermediates	B-X
with	B-X
cisternal	B-X
membranes	B-X
of	B-X
the	B-X
Golgi	B-X
stack	B-X
was	B-X
not	B-X
observed	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X

Direct	O
fusion	O
of	O
ER	O
/	O
Golgi	O
intermediates	O
with	O
cisternal	O
membranes	O
of	O
the	O
Golgi	O
stack	O
was	O
not	O
observed	O
under	O
these	O
conditions	O
.	O

Immunofluorescent	O
studies	O
of	O
human	O
chromosomes	O
with	O
antibodies	O
against	O
phosphorylated	O
H1	B-Protein
histone	I-Protein
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
prominent	B-X
cell	B-X
cycle-related	B-X
modifications	B-X
of	B-X
histone	B-X
proteins	B-X
whose	B-X
function	B-X
remains	B-X
unresolved	B-X
is	B-X
the	B-X
phosphorylation	B-X
of	B-X
linker	B-X
histone	B-X
H1	B-X
.	B-X
In	B-X
this	B-X
work	B-X
we	B-X
have	B-X
used	B-X
indirect	B-X
immunofluorescence	B-X
on	B-X
human	B-X
cells	B-X
with	B-X
antibodies	B-X
that	B-X
are	B-X
specific	B-X
for	B-X
phosphorylated	B-X
histone	B-X
H1	B-X
to	B-X
examine	B-X
the	B-X
cellular	B-X
distribution	B-X
and	B-X
chromosome	B-X
association	B-X
patterns	B-X
of	B-X
this	B-X
protein	B-X
.	B-X
With	B-X
confocal	B-X
microscopy	B-X
on	B-X
whole	B-X
cells	B-X
,	B-X
strong	B-X
immunofluorescence	B-X
was	B-X
seen	B-X
in	B-X
association	B-X
with	B-X
mitotic	B-X
chromosomes	B-X
as	B-X
well	B-X
as	B-X
a	B-X
prominent	B-X
punctate	B-X
pattern	B-X
of	B-X
labeling	B-X
throughout	B-X
the	B-X
mitotic	B-X
cell	B-X
,	B-X
whereas	B-X
interphase	B-X
cells	B-X
showed	B-X
very	B-X
little	B-X
,	B-X
if	B-X
any	B-X
,	B-X
specific	B-X
fluorescence	B-X
.	B-X
Multiple	B-X
patterns	B-X
of	B-X
fluorescence	B-X
distribution	B-X
were	B-X
detected	B-X
with	B-X
metaphase	B-X
chromosomes	B-X
,	B-X
ranging	B-X
from	B-X
apparent	B-X
tight	B-X
colocalization	B-X
with	B-X
the	B-X
DNA	B-X
to	B-X
expanded	B-X
``	B-X
puffy	B-X
''	B-X
mitotic	B-X
figures	B-X
to	B-X
an	B-X
amorphous	B-X
network	B-X
of	B-X
staining	B-X
.	B-X
It	B-X
was	B-X
also	B-X
shown	B-X
that	B-X
the	B-X
ability	B-X
to	B-X
label	B-X
chromosomes	B-X
could	B-X
vary	B-X
drastically	B-X
with	B-X
different	B-X
fixation	B-X
procedures	B-X
,	B-X
adding	B-X
further	B-X
complications	B-X
to	B-X
interpretation	B-X
of	B-X
the	B-X
potentially	B-X
complex	B-X
role	B-X
of	B-X
phosphorylated	B-X
histone	B-X
H1	B-X
in	B-X
chromatin	B-X
condensation	B-X
or	B-X
decondensation	B-X
.	B-X

One	O
of	O
the	O
prominent	O
cell	O
cycle	O
-	O
related	O
modifications	O
of	O
histone	B-Protein
proteins	O
whose	O
function	O
remains	O
unresolved	O
is	O
the	O
phosphorylation	O
of	O
linker	O
histone	B-Protein
H1	I-Protein
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
prominent	B-X
cell	B-X
cycle-related	B-X
modifications	B-X
of	B-X
histone	B-X
proteins	B-X
whose	B-X
function	B-X
remains	B-X
unresolved	B-X
is	B-X
the	B-X
phosphorylation	B-X
of	B-X
linker	B-X
histone	B-X
H1	B-X
.	B-X
In	B-X
this	B-X
work	B-X
we	B-X
have	B-X
used	B-X
indirect	B-X
immunofluorescence	B-X
on	B-X
human	B-X
cells	B-X
with	B-X
antibodies	B-X
that	B-X
are	B-X
specific	B-X
for	B-X
phosphorylated	B-X
histone	B-X
H1	B-X
to	B-X
examine	B-X
the	B-X
cellular	B-X
distribution	B-X
and	B-X
chromosome	B-X
association	B-X
patterns	B-X
of	B-X
this	B-X
protein	B-X
.	B-X
With	B-X
confocal	B-X
microscopy	B-X
on	B-X
whole	B-X
cells	B-X
,	B-X
strong	B-X
immunofluorescence	B-X
was	B-X
seen	B-X
in	B-X
association	B-X
with	B-X
mitotic	B-X
chromosomes	B-X
as	B-X
well	B-X
as	B-X
a	B-X
prominent	B-X
punctate	B-X
pattern	B-X
of	B-X
labeling	B-X
throughout	B-X
the	B-X
mitotic	B-X
cell	B-X
,	B-X
whereas	B-X
interphase	B-X
cells	B-X
showed	B-X
very	B-X
little	B-X
,	B-X
if	B-X
any	B-X
,	B-X
specific	B-X
fluorescence	B-X
.	B-X
It	B-X
was	B-X
also	B-X
shown	B-X
that	B-X
the	B-X
ability	B-X
to	B-X
label	B-X
chromosomes	B-X
could	B-X
vary	B-X
drastically	B-X
with	B-X
different	B-X
fixation	B-X
procedures	B-X
,	B-X
adding	B-X
further	B-X
complications	B-X
to	B-X
interpretation	B-X
of	B-X
the	B-X
potentially	B-X
complex	B-X
role	B-X
of	B-X
phosphorylated	B-X
histone	B-X
H1	B-X
in	B-X
chromatin	B-X
condensation	B-X
or	B-X
decondensation	B-X
.	B-X

In	O
this	O
work	O
we	O
have	O
used	O
indirect	O
immunofluorescence	O
on	O
human	O
cells	O
with	O
antibodies	O
that	O
are	O
specific	O
for	O
phosphorylated	O
histone	B-Protein
H1	I-Protein
to	O
examine	O
the	O
cellular	O
distribution	O
and	O
chromosome	O
association	O
patterns	O
of	O
this	O
protein	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
prominent	B-X
cell	B-X
cycle-related	B-X
modifications	B-X
of	B-X
histone	B-X
proteins	B-X
whose	B-X
function	B-X
remains	B-X
unresolved	B-X
is	B-X
the	B-X
phosphorylation	B-X
of	B-X
linker	B-X
histone	B-X
H1	B-X
.	B-X
In	B-X
this	B-X
work	B-X
we	B-X
have	B-X
used	B-X
indirect	B-X
immunofluorescence	B-X
on	B-X
human	B-X
cells	B-X
with	B-X
antibodies	B-X
that	B-X
are	B-X
specific	B-X
for	B-X
phosphorylated	B-X
histone	B-X
H1	B-X
to	B-X
examine	B-X
the	B-X
cellular	B-X
distribution	B-X
and	B-X
chromosome	B-X
association	B-X
patterns	B-X
of	B-X
this	B-X
protein	B-X
.	B-X
With	B-X
confocal	B-X
microscopy	B-X
on	B-X
whole	B-X
cells	B-X
,	B-X
strong	B-X
immunofluorescence	B-X
was	B-X
seen	B-X
in	B-X
association	B-X
with	B-X
mitotic	B-X
chromosomes	B-X
as	B-X
well	B-X
as	B-X
a	B-X
prominent	B-X
punctate	B-X
pattern	B-X
of	B-X
labeling	B-X
throughout	B-X
the	B-X
mitotic	B-X
cell	B-X
,	B-X
whereas	B-X
interphase	B-X
cells	B-X
showed	B-X
very	B-X
little	B-X
,	B-X
if	B-X
any	B-X
,	B-X
specific	B-X
fluorescence	B-X
.	B-X
Multiple	B-X
patterns	B-X
of	B-X
fluorescence	B-X
distribution	B-X
were	B-X
detected	B-X
with	B-X
metaphase	B-X
chromosomes	B-X
,	B-X
ranging	B-X
from	B-X
apparent	B-X
tight	B-X
colocalization	B-X
with	B-X
the	B-X
DNA	B-X
to	B-X
expanded	B-X
``	B-X
puffy	B-X
''	B-X
mitotic	B-X
figures	B-X
to	B-X
an	B-X
amorphous	B-X
network	B-X
of	B-X
staining	B-X
.	B-X
It	B-X
was	B-X
also	B-X
shown	B-X
that	B-X
the	B-X
ability	B-X
to	B-X
label	B-X
chromosomes	B-X
could	B-X
vary	B-X
drastically	B-X
with	B-X
different	B-X
fixation	B-X
procedures	B-X
,	B-X
adding	B-X
further	B-X
complications	B-X
to	B-X
interpretation	B-X
of	B-X
the	B-X
potentially	B-X
complex	B-X
role	B-X
of	B-X
phosphorylated	B-X
histone	B-X
H1	B-X
in	B-X
chromatin	B-X
condensation	B-X
or	B-X
decondensation	B-X
.	B-X

With	O
confocal	O
microscopy	O
on	O
whole	O
cells	O
,	O
strong	O
immunofluorescence	O
was	O
seen	O
in	O
association	O
with	O
mitotic	O
chromosomes	O
as	O
well	O
as	O
a	O
prominent	O
punctate	O
pattern	O
of	O
labeling	O
throughout	O
the	O
mitotic	O
cell	O
,	O
whereas	O
interphase	O
cells	O
showed	O
very	O
little	O
,	O
if	O
any	O
,	O
specific	O
fluorescence	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
prominent	B-X
cell	B-X
cycle-related	B-X
modifications	B-X
of	B-X
histone	B-X
proteins	B-X
whose	B-X
function	B-X
remains	B-X
unresolved	B-X
is	B-X
the	B-X
phosphorylation	B-X
of	B-X
linker	B-X
histone	B-X
H1	B-X
.	B-X
In	B-X
this	B-X
work	B-X
we	B-X
have	B-X
used	B-X
indirect	B-X
immunofluorescence	B-X
on	B-X
human	B-X
cells	B-X
with	B-X
antibodies	B-X
that	B-X
are	B-X
specific	B-X
for	B-X
phosphorylated	B-X
histone	B-X
H1	B-X
to	B-X
examine	B-X
the	B-X
cellular	B-X
distribution	B-X
and	B-X
chromosome	B-X
association	B-X
patterns	B-X
of	B-X
this	B-X
protein	B-X
.	B-X
With	B-X
confocal	B-X
microscopy	B-X
on	B-X
whole	B-X
cells	B-X
,	B-X
strong	B-X
immunofluorescence	B-X
was	B-X
seen	B-X
in	B-X
association	B-X
with	B-X
mitotic	B-X
chromosomes	B-X
as	B-X
well	B-X
as	B-X
a	B-X
prominent	B-X
punctate	B-X
pattern	B-X
of	B-X
labeling	B-X
throughout	B-X
the	B-X
mitotic	B-X
cell	B-X
,	B-X
whereas	B-X
interphase	B-X
cells	B-X
showed	B-X
very	B-X
little	B-X
,	B-X
if	B-X
any	B-X
,	B-X
specific	B-X
fluorescence	B-X
.	B-X
Multiple	B-X
patterns	B-X
of	B-X
fluorescence	B-X
distribution	B-X
were	B-X
detected	B-X
with	B-X
metaphase	B-X
chromosomes	B-X
,	B-X
ranging	B-X
from	B-X
apparent	B-X
tight	B-X
colocalization	B-X
with	B-X
the	B-X
DNA	B-X
to	B-X
expanded	B-X
``	B-X
puffy	B-X
''	B-X
mitotic	B-X
figures	B-X
to	B-X
an	B-X
amorphous	B-X
network	B-X
of	B-X
staining	B-X
.	B-X
It	B-X
was	B-X
also	B-X
shown	B-X
that	B-X
the	B-X
ability	B-X
to	B-X
label	B-X
chromosomes	B-X
could	B-X
vary	B-X
drastically	B-X
with	B-X
different	B-X
fixation	B-X
procedures	B-X
,	B-X
adding	B-X
further	B-X
complications	B-X
to	B-X
interpretation	B-X
of	B-X
the	B-X
potentially	B-X
complex	B-X
role	B-X
of	B-X
phosphorylated	B-X
histone	B-X
H1	B-X
in	B-X
chromatin	B-X
condensation	B-X
or	B-X
decondensation	B-X
.	B-X

Multiple	O
patterns	O
of	O
fluorescence	O
distribution	O
were	O
detected	O
with	O
metaphase	O
chromosomes	O
,	O
ranging	O
from	O
apparent	O
tight	O
colocalization	O
with	O
the	O
DNA	O
to	O
expanded	O
"	O
puffy	O
"	O
mitotic	O
figures	O
to	O
an	O
amorphous	O
network	O
of	O
staining	O
.	O

It	O
was	O
also	O
shown	O
that	O
the	O
ability	O
to	O
label	O
chromosomes	O
could	O
vary	O
drastically	O
with	O
different	O
fixation	O
procedures	O
,	O
adding	O
further	O
complications	O
to	O
interpretation	O
of	O
the	O
potentially	O
complex	O
role	O
of	O
phosphorylated	O
histone	B-Protein
H1	I-Protein
in	O
chromatin	O
condensation	O
or	O
decondensation	O
.	O
<EOS>	B-X
As	B-X
part	B-X
of	B-X
their	B-X
anti-microbial	B-X
defense	B-X
,	B-X
neutrophils	B-X
form	B-X
extracellular	B-X
traps	B-X
(	B-X
NETs	B-X
)	B-X
by	B-X
releasing	B-X
decondensed	B-X
chromatin	B-X
lined	B-X
with	B-X
cytotoxic	B-X
proteins	B-X
.	B-X
NETs	B-X
,	B-X
however	B-X
,	B-X
can	B-X
also	B-X
induce	B-X
tissue	B-X
damage	B-X
.	B-X
Expression	B-X
of	B-X
peptidylarginine	B-X
deiminase	B-X
4	B-X
(	B-X
PAD4	B-X
,	B-X
encoded	B-X
by	B-X
Padi4	B-X
in	B-X
mice	B-X
)	B-X
,	B-X
an	B-X
enzyme	B-X
important	B-X
in	B-X
chromatin	B-X
decondensation	B-X
,	B-X
was	B-X
elevated	B-X
in	B-X
neutrophils	B-X
from	B-X
individuals	B-X
with	B-X
diabetes	B-X
.	B-X
In	B-X
diabetic	B-X
mice	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
citrullinated	B-X
histone	B-X
H3	B-X
(	B-X
H3Cit	B-X
,	B-X
a	B-X
NET	B-X
marker	B-X
)	B-X
were	B-X
found	B-X
in	B-X
their	B-X
wounds	B-X
than	B-X
in	B-X
normoglycemic	B-X
mice	B-X
and	B-X
healing	B-X
was	B-X
delayed	B-X
.	B-X

Clinical	O
and	O
biochemical	O
characteristics	O
of	O
congenital	O
disorder	O
of	O
glycosylation	O
type	O
Ic	O
,	O
the	O
first	O
recognized	O
endoplasmic	O
reticulum	O
defect	O
in	O
N	O
-	O
glycan	O
synthesis	O
.	O

We	O
report	O
on	O
8	O
patients	O
with	O
a	O
recently	O
described	O
novel	O
subtype	O
of	O
congenital	O
disorder	O
of	O
glycosylation	O
type	O
Ic	O
(	O
CDG	O
-	O
Ic	O
)	O
.	O
<EOS>	B-X
We	B-X
report	B-X
on	B-X
8	B-X
patients	B-X
with	B-X
a	B-X
recently	B-X
described	B-X
novel	B-X
subtype	B-X
of	B-X
congenital	B-X
disorder	B-X
of	B-X
glycosylation	B-X
type	B-X
Ic	B-X
(	B-X
CDG-Ic	B-X
)	B-X
.	B-X
Several	B-X
symptoms	B-X
commonly	B-X
seen	B-X
in	B-X
CDG-Ia	B-X
such	B-X
as	B-X
inverted	B-X
nipples	B-X
,	B-X
abnormal	B-X
fat	B-X
distribution	B-X
,	B-X
and	B-X
cerebellar	B-X
hypoplasia	B-X
were	B-X
not	B-X
observed	B-X
.	B-X
The	B-X
clinical	B-X
course	B-X
is	B-X
milder	B-X
overall	B-X
,	B-X
with	B-X
a	B-X
better	B-X
neurological	B-X
outcome	B-X
,	B-X
than	B-X
in	B-X
CDG-Ia	B-X
.	B-X
The	B-X
isoelectric	B-X
focusing	B-X
pattern	B-X
of	B-X
serum	B-X
transferrin	B-X
in	B-X
CDG-Ia	B-X
and	B-X
CDG-Ic	B-X
is	B-X
indistinguishable	B-X
.	B-X
Interestingly	B-X
,	B-X
beta-trace	B-X
protein	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
derived	B-X
from	B-X
immunoblot	B-X
analysis	B-X
of	B-X
the	B-X
brain	B-X
showed	B-X
a	B-X
less	B-X
pronounced	B-X
hypoglycosylation	B-X
pattern	B-X
in	B-X
CDG-Ic	B-X
patients	B-X
than	B-X
in	B-X
CDG-Ia	B-X
patients	B-X
.	B-X
All	B-X
patients	B-X
were	B-X
homozygous	B-X
for	B-X
an	B-X
A333V	B-X
mutation	B-X
.	B-X

Their	O
clinical	O
presentation	O
was	O
mainly	O
neurological	O
with	O
developmental	O
retardation	O
,	O
muscular	O
hypotonia	O
,	O
and	O
epilepsy	O
.	O
<EOS>	B-X
[	B-X
Analysis	B-X
of	B-X
6	B-X
cases	B-X
with	B-X
hepatocerebral	B-X
mitochondrial	B-X
DNA	B-X
depletion	B-X
syndrome	B-X
and	B-X
literature	B-X
review	B-X
]	B-X
.	B-X
Their	B-X
clinical	B-X
presentation	B-X
was	B-X
mainly	B-X
neurological	B-X
with	B-X
developmental	B-X
retardation	B-X
,	B-X
muscular	B-X
hypotonia	B-X
,	B-X
and	B-X
epilepsy	B-X
.	B-X
The	B-X
clinical	B-X
course	B-X
is	B-X
milder	B-X
overall	B-X
,	B-X
with	B-X
a	B-X
better	B-X
neurological	B-X
outcome	B-X
,	B-X
than	B-X
in	B-X
CDG-Ia	B-X
.	B-X

Several	O
symptoms	O
commonly	O
seen	O
in	O
CDG	O
-	O
Ia	O
such	O
as	O
inverted	O
nipples	O
,	O
abnormal	O
fat	O
distribution	O
,	O
and	O
cerebellar	O
hypoplasia	O
were	O
not	O
observed	O
.	O

The	O
clinical	O
course	O
is	O
milder	O
overall	O
,	O
with	O
a	O
better	O
neurological	O
outcome	O
,	O
than	O
in	O
CDG	O
-	O
Ia	O
.	O
<EOS>	B-X
We	B-X
report	B-X
on	B-X
8	B-X
patients	B-X
with	B-X
a	B-X
recently	B-X
described	B-X
novel	B-X
subtype	B-X
of	B-X
congenital	B-X
disorder	B-X
of	B-X
glycosylation	B-X
type	B-X
Ic	B-X
(	B-X
CDG-Ic	B-X
)	B-X
.	B-X
Their	B-X
clinical	B-X
presentation	B-X
was	B-X
mainly	B-X
neurological	B-X
with	B-X
developmental	B-X
retardation	B-X
,	B-X
muscular	B-X
hypotonia	B-X
,	B-X
and	B-X
epilepsy	B-X
.	B-X
Several	B-X
symptoms	B-X
commonly	B-X
seen	B-X
in	B-X
CDG-Ia	B-X
such	B-X
as	B-X
inverted	B-X
nipples	B-X
,	B-X
abnormal	B-X
fat	B-X
distribution	B-X
,	B-X
and	B-X
cerebellar	B-X
hypoplasia	B-X
were	B-X
not	B-X
observed	B-X
.	B-X
The	B-X
clinical	B-X
course	B-X
is	B-X
milder	B-X
overall	B-X
,	B-X
with	B-X
a	B-X
better	B-X
neurological	B-X
outcome	B-X
,	B-X
than	B-X
in	B-X
CDG-Ia	B-X
.	B-X
The	B-X
isoelectric	B-X
focusing	B-X
pattern	B-X
of	B-X
serum	B-X
transferrin	B-X
in	B-X
CDG-Ia	B-X
and	B-X
CDG-Ic	B-X
is	B-X
indistinguishable	B-X
.	B-X
Interestingly	B-X
,	B-X
beta-trace	B-X
protein	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
derived	B-X
from	B-X
immunoblot	B-X
analysis	B-X
of	B-X
the	B-X
brain	B-X
showed	B-X
a	B-X
less	B-X
pronounced	B-X
hypoglycosylation	B-X
pattern	B-X
in	B-X
CDG-Ic	B-X
patients	B-X
than	B-X
in	B-X
CDG-Ia	B-X
patients	B-X
.	B-X

The	O
isoelectric	O
focusing	O
pattern	O
of	O
serum	O
transferrin	B-Protein
in	O
CDG	O
-	O
Ia	O
and	O
CDG	O
-	O
Ic	O
is	O
indistinguishable	O
.	O
<EOS>	B-X
We	B-X
report	B-X
on	B-X
8	B-X
patients	B-X
with	B-X
a	B-X
recently	B-X
described	B-X
novel	B-X
subtype	B-X
of	B-X
congenital	B-X
disorder	B-X
of	B-X
glycosylation	B-X
type	B-X
Ic	B-X
(	B-X
CDG-Ic	B-X
)	B-X
.	B-X
Several	B-X
symptoms	B-X
commonly	B-X
seen	B-X
in	B-X
CDG-Ia	B-X
such	B-X
as	B-X
inverted	B-X
nipples	B-X
,	B-X
abnormal	B-X
fat	B-X
distribution	B-X
,	B-X
and	B-X
cerebellar	B-X
hypoplasia	B-X
were	B-X
not	B-X
observed	B-X
.	B-X
The	B-X
clinical	B-X
course	B-X
is	B-X
milder	B-X
overall	B-X
,	B-X
with	B-X
a	B-X
better	B-X
neurological	B-X
outcome	B-X
,	B-X
than	B-X
in	B-X
CDG-Ia	B-X
.	B-X
The	B-X
isoelectric	B-X
focusing	B-X
pattern	B-X
of	B-X
serum	B-X
transferrin	B-X
in	B-X
CDG-Ia	B-X
and	B-X
CDG-Ic	B-X
is	B-X
indistinguishable	B-X
.	B-X
Interestingly	B-X
,	B-X
beta-trace	B-X
protein	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
derived	B-X
from	B-X
immunoblot	B-X
analysis	B-X
of	B-X
the	B-X
brain	B-X
showed	B-X
a	B-X
less	B-X
pronounced	B-X
hypoglycosylation	B-X
pattern	B-X
in	B-X
CDG-Ic	B-X
patients	B-X
than	B-X
in	B-X
CDG-Ia	B-X
patients	B-X
.	B-X

Interestingly	O
,	O
beta	B-Protein
-	I-Protein
trace	I-Protein
protein	I-Protein
in	O
cerebrospinal	O
fluid	O
derived	O
from	O
immunoblot	O
analysis	O
of	O
the	O
brain	O
showed	O
a	O
less	O
pronounced	O
hypoglycosylation	O
pattern	O
in	O
CDG	O
-	O
Ic	O
patients	O
than	O
in	O
CDG	O
-	O
Ia	O
patients	O
.	O
<EOS>	B-X
We	B-X
report	B-X
on	B-X
8	B-X
patients	B-X
with	B-X
a	B-X
recently	B-X
described	B-X
novel	B-X
subtype	B-X
of	B-X
congenital	B-X
disorder	B-X
of	B-X
glycosylation	B-X
type	B-X
Ic	B-X
(	B-X
CDG-Ic	B-X
)	B-X
.	B-X
Several	B-X
symptoms	B-X
commonly	B-X
seen	B-X
in	B-X
CDG-Ia	B-X
such	B-X
as	B-X
inverted	B-X
nipples	B-X
,	B-X
abnormal	B-X
fat	B-X
distribution	B-X
,	B-X
and	B-X
cerebellar	B-X
hypoplasia	B-X
were	B-X
not	B-X
observed	B-X
.	B-X
The	B-X
clinical	B-X
course	B-X
is	B-X
milder	B-X
overall	B-X
,	B-X
with	B-X
a	B-X
better	B-X
neurological	B-X
outcome	B-X
,	B-X
than	B-X
in	B-X
CDG-Ia	B-X
.	B-X
The	B-X
isoelectric	B-X
focusing	B-X
pattern	B-X
of	B-X
serum	B-X
transferrin	B-X
in	B-X
CDG-Ia	B-X
and	B-X
CDG-Ic	B-X
is	B-X
indistinguishable	B-X
.	B-X
Interestingly	B-X
,	B-X
beta-trace	B-X
protein	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
derived	B-X
from	B-X
immunoblot	B-X
analysis	B-X
of	B-X
the	B-X
brain	B-X
showed	B-X
a	B-X
less	B-X
pronounced	B-X
hypoglycosylation	B-X
pattern	B-X
in	B-X
CDG-Ic	B-X
patients	B-X
than	B-X
in	B-X
CDG-Ia	B-X
patients	B-X
.	B-X
All	B-X
patients	B-X
were	B-X
homozygous	B-X
for	B-X
an	B-X
A333V	B-X
mutation	B-X
.	B-X

Analysis	O
of	O
lipid	O
-	O
linked	O
oligosaccharides	O
revealed	O
an	O
accumulation	O
of	O
Man9GlcNAc2	O
intermediates	O
due	O
to	O
dolichol	B-Protein
pyrophosphate	I-Protein
-	I-Protein
Man9GlcNAc2	I-Protein
alpha	I-Protein
-	I-Protein
1	I-Protein
,	I-Protein
3	I-Protein
glucosyltransferase	I-Protein
deficiency	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
lipid-linked	B-X
oligosaccharides	B-X
revealed	B-X
an	B-X
accumulation	B-X
of	B-X
Man9GlcNAc2	B-X
intermediates	B-X
due	B-X
to	B-X
dolichol	B-X
pyrophosphate-Man9GlcNAc2	B-X
alpha-1,3	B-X
glucosyltransferase	B-X
deficiency	B-X
.	B-X
All	B-X
patients	B-X
were	B-X
homozygous	B-X
for	B-X
an	B-X
A333V	B-X
mutation	B-X
.	B-X

All	O
patients	O
were	O
homozygous	O
for	O
an	O
A333V	O
mutation	O
.	O
<EOS>	B-X
Congenital	B-X
disorder	B-X
of	B-X
glycosylation	B-X
type	B-X
Ic	B-X
(	B-X
CDG-Ic	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
ALG6	B-X
,	B-X
encoding	B-X
an	B-X
alpha	B-X
1,3-glucosyltransferase	B-X
.	B-X
The	B-X
most	B-X
frequent	B-X
mutation	B-X
found	B-X
in	B-X
this	B-X
gene	B-X
(	B-X
C998T	B-X
resulting	B-X
in	B-X
an	B-X
A333V	B-X
substitution	B-X
)	B-X
has	B-X
until	B-X
now	B-X
been	B-X
found	B-X
only	B-X
in	B-X
patients	B-X
of	B-X
European	B-X
origin	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
first	B-X
occurrence	B-X
of	B-X
this	B-X
CDG-Ic	B-X
mutation	B-X
in	B-X
patients	B-X
of	B-X
Indian	B-X
origin	B-X
.	B-X
Of	B-X
three	B-X
Indian	B-X
patients	B-X
described	B-X
in	B-X
this	B-X
study	B-X
,	B-X
patient	B-X
1	B-X
was	B-X
homozygous	B-X
and	B-X
patient	B-X
2	B-X
heterozygous	B-X
for	B-X
the	B-X
A333V	B-X
mutation	B-X
.	B-X
In	B-X
patient	B-X
2	B-X
we	B-X
also	B-X
found	B-X
a	B-X
new	B-X
mutation	B-X
,	B-X
IVS3+2_3insT	B-X
,	B-X
just	B-X
3bp	B-X
away	B-X
from	B-X
the	B-X
previously	B-X
described	B-X
IVS3+5G	B-X
>	B-X
A	B-X
substitution	B-X
;	B-X
both	B-X
mutations	B-X
resulted	B-X
in	B-X
exon	B-X
3	B-X
skipping	B-X
.	B-X
We	B-X
screened	B-X
a	B-X
panel	B-X
of	B-X
>	B-X
350	B-X
genomic	B-X
DNA	B-X
samples	B-X
from	B-X
an	B-X
ethnically	B-X
diverse	B-X
American	B-X
population	B-X
to	B-X
determine	B-X
the	B-X
frequency	B-X
of	B-X
the	B-X
A333V	B-X
mutation	B-X
.	B-X
None	B-X
of	B-X
the	B-X
samples	B-X
carried	B-X
this	B-X
mutation	B-X
,	B-X
indicating	B-X
the	B-X
frequency	B-X
of	B-X
patients	B-X
carrying	B-X
this	B-X
homozygous	B-X
mutation	B-X
should	B-X
be	B-X
<	B-X
1	B-X
in	B-X
5x10	B-X
(	B-X
5	B-X
)	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
the	B-X
common	B-X
CDG-Ic	B-X
mutation	B-X
A333V	B-X
in	B-X
an	B-X
Indian	B-X
population	B-X
raises	B-X
questions	B-X
as	B-X
to	B-X
its	B-X
ethnic	B-X
origin	B-X
.	B-X

Phosphorylation	O
of	O
RTP	B-Protein
,	O
an	O
ER	O
stress	O
-	O
responsive	O
cytoplasmic	O
protein	O
.	O
<EOS>	B-X
RTP	B-X
,	B-X
also	B-X
called	B-X
Drg1/Cap43/rit42/TDD5/Ndr1	B-X
,	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
homocysteine-responsive	B-X
gene	B-X
product	B-X
,	B-X
and	B-X
is	B-X
now	B-X
considered	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
stress	B-X
responses	B-X
,	B-X
atherosclerosis	B-X
,	B-X
carcinogenesis	B-X
,	B-X
differentiation	B-X
,	B-X
androgen	B-X
responses	B-X
,	B-X
hypoxia	B-X
,	B-X
and	B-X
N-myc	B-X
pathways	B-X
.	B-X
We	B-X
raised	B-X
an	B-X
antiserum	B-X
against	B-X
a	B-X
recombinant	B-X
human	B-X
RTP	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
RTP	B-X
expression	B-X
was	B-X
induced	B-X
in	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
under	B-X
conditions	B-X
causing	B-X
endoplasmic	B-X
reticulum	B-X
stress	B-X
.	B-X
RTP	B-X
was	B-X
partially	B-X
phosphorylated	B-X
at	B-X
seven	B-X
or	B-X
more	B-X
sites	B-X
.	B-X
The	B-X
phosphorylation	B-X
was	B-X
reversible	B-X
,	B-X
and	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
intracellular	B-X
cAMP	B-X
and	B-X
inhibited	B-X
by	B-X
both	B-X
a	B-X
protein	B-X
kinase	B-X
A	B-X
inhibitor	B-X
and	B-X
a	B-X
calmodulin	B-X
kinase	B-X
inhibitor	B-X
.	B-X
Protein	B-X
kinase	B-X
A	B-X
directly	B-X
phosphorylated	B-X
recombinant	B-X
RTP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
data	B-X
demonstrated	B-X
that	B-X
RTP	B-X
is	B-X
a	B-X
phosphorylated	B-X
stress-responsive	B-X
protein	B-X
,	B-X
and	B-X
its	B-X
phosphorylation	B-X
may	B-X
be	B-X
related	B-X
to	B-X
cell	B-X
growth	B-X
.	B-X

RTP	B-Protein
,	O
also	O
called	O
Drg1	B-Protein
/	O
Cap43	B-Protein
/	O
rit42	B-Protein
/	O
TDD5	B-Protein
/	O
Ndr1	B-Protein
,	O
was	O
originally	O
identified	O
as	O
a	O
homocysteine	O
-	O
responsive	O
gene	O
product	O
,	O
and	O
is	O
now	O
considered	O
to	O
be	O
involved	O
in	O
stress	O
responses	O
,	O
atherosclerosis	O
,	O
carcinogenesis	O
,	O
differentiation	O
,	O
androgen	O
responses	O
,	O
hypoxia	O
,	O
and	O
N	B-Protein
-	I-Protein
myc	I-Protein
pathways	O
.	O

We	O
raised	O
an	O
antiserum	O
against	O
a	O
recombinant	O
human	O
RTP	B-Protein
.	O
<EOS>	B-X
RTP	B-X
,	B-X
also	B-X
called	B-X
Drg1/Cap43/rit42/TDD5/Ndr1	B-X
,	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
homocysteine-responsive	B-X
gene	B-X
product	B-X
,	B-X
and	B-X
is	B-X
now	B-X
considered	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
stress	B-X
responses	B-X
,	B-X
atherosclerosis	B-X
,	B-X
carcinogenesis	B-X
,	B-X
differentiation	B-X
,	B-X
androgen	B-X
responses	B-X
,	B-X
hypoxia	B-X
,	B-X
and	B-X
N-myc	B-X
pathways	B-X
.	B-X
We	B-X
raised	B-X
an	B-X
antiserum	B-X
against	B-X
a	B-X
recombinant	B-X
human	B-X
RTP	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
RTP	B-X
expression	B-X
was	B-X
induced	B-X
in	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
under	B-X
conditions	B-X
causing	B-X
endoplasmic	B-X
reticulum	B-X
stress	B-X
.	B-X
RTP	B-X
was	B-X
partially	B-X
phosphorylated	B-X
at	B-X
seven	B-X
or	B-X
more	B-X
sites	B-X
.	B-X
Protein	B-X
kinase	B-X
A	B-X
directly	B-X
phosphorylated	B-X
recombinant	B-X
RTP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
data	B-X
demonstrated	B-X
that	B-X
RTP	B-X
is	B-X
a	B-X
phosphorylated	B-X
stress-responsive	B-X
protein	B-X
,	B-X
and	B-X
its	B-X
phosphorylation	B-X
may	B-X
be	B-X
related	B-X
to	B-X
cell	B-X
growth	B-X
.	B-X

Western	O
blot	O
analysis	O
showed	O
that	O
RTP	B-Protein
expression	O
was	O
induced	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
under	O
conditions	O
causing	O
endoplasmic	O
reticulum	O
stress	O
.	O
<EOS>	B-X
RTP	B-X
,	B-X
also	B-X
called	B-X
Drg1/Cap43/rit42/TDD5/Ndr1	B-X
,	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
homocysteine-responsive	B-X
gene	B-X
product	B-X
,	B-X
and	B-X
is	B-X
now	B-X
considered	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
stress	B-X
responses	B-X
,	B-X
atherosclerosis	B-X
,	B-X
carcinogenesis	B-X
,	B-X
differentiation	B-X
,	B-X
androgen	B-X
responses	B-X
,	B-X
hypoxia	B-X
,	B-X
and	B-X
N-myc	B-X
pathways	B-X
.	B-X
We	B-X
raised	B-X
an	B-X
antiserum	B-X
against	B-X
a	B-X
recombinant	B-X
human	B-X
RTP	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
RTP	B-X
expression	B-X
was	B-X
induced	B-X
in	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
under	B-X
conditions	B-X
causing	B-X
endoplasmic	B-X
reticulum	B-X
stress	B-X
.	B-X
RTP	B-X
was	B-X
partially	B-X
phosphorylated	B-X
at	B-X
seven	B-X
or	B-X
more	B-X
sites	B-X
.	B-X
Protein	B-X
kinase	B-X
A	B-X
directly	B-X
phosphorylated	B-X
recombinant	B-X
RTP	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
phosphorylated	B-X
forms	B-X
were	B-X
abundant	B-X
in	B-X
cells	B-X
at	B-X
the	B-X
early	B-X
log	B-X
phase	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
with	B-X
increasing	B-X
cell	B-X
density	B-X
.	B-X
These	B-X
data	B-X
demonstrated	B-X
that	B-X
RTP	B-X
is	B-X
a	B-X
phosphorylated	B-X
stress-responsive	B-X
protein	B-X
,	B-X
and	B-X
its	B-X
phosphorylation	B-X
may	B-X
be	B-X
related	B-X
to	B-X
cell	B-X
growth	B-X
.	B-X

RTP	B-Protein
was	O
partially	O
phosphorylated	O
at	O
seven	O
or	O
more	O
sites	O
.	O
<EOS>	B-X
We	B-X
aim	B-X
to	B-X
review	B-X
concordance	B-X
between	B-X
primary	B-X
CRC	B-X
and	B-X
its	B-X
metastatic	B-X
sites	B-X
.	B-X
Within	B-X
any	B-X
molecule	B-X
or	B-X
cluster	B-X
containing	B-X
one	B-X
or	B-X
more	B-X
positively	B-X
charged	B-X
sites	B-X
,	B-X
families	B-X
of	B-X
Rydberg	B-X
orbitals	B-X
exist	B-X
.	B-X
Different	B-X
phosphorylation	B-X
sites	B-X
on	B-X
Dnmt1	B-X
can	B-X
change	B-X
its	B-X
activity	B-X
or	B-X
ability	B-X
to	B-X
bind	B-X
DNA	B-X
target	B-X
sites	B-X
.	B-X
This	B-X
article	B-X
explores	B-X
gay	B-X
porn	B-X
's	B-X
``	B-X
bareback	B-X
momentum	B-X
''	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
displacement	B-X
of	B-X
condoms	B-X
in	B-X
the	B-X
10	B-X
most	B-X
visited	B-X
gay	B-X
porn	B-X
Web	B-X
sites	B-X
(	B-X
that	B-X
have	B-X
operated	B-X
for	B-X
10	B-X
years	B-X
or	B-X
more	B-X
)	B-X
.	B-X
The	B-X
sites	B-X
analyzed	B-X
are	B-X
,	B-X
in	B-X
order	B-X
of	B-X
popularity	B-X
:	B-X
Sean	B-X
Cody	B-X
,	B-X
Helix	B-X
Studios	B-X
,	B-X
Lucas	B-X
Entertainment	B-X
,	B-X
Corbin	B-X
Fisher	B-X
,	B-X
Bel	B-X
Ami	B-X
,	B-X
Next	B-X
Door	B-X
Studios	B-X
,	B-X
Randy	B-X
Blue	B-X
,	B-X
Falcon	B-X
Studios	B-X
,	B-X
Cocky	B-X
Boys	B-X
,	B-X
and	B-X
Chaos	B-X
Men	B-X
.	B-X
Textual	B-X
analysis	B-X
reads	B-X
each	B-X
site	B-X
's	B-X
transition	B-X
individually	B-X
,	B-X
yet	B-X
connections	B-X
between	B-X
the	B-X
sites	B-X
are	B-X
the	B-X
article	B-X
's	B-X
central	B-X
concern	B-X
,	B-X
from	B-X
which	B-X
an	B-X
emphasis	B-X
on	B-X
couples	B-X
and	B-X
break-up	B-X
narratives	B-X
is	B-X
revealed	B-X
.	B-X

The	O
phosphorylation	O
was	O
reversible	O
,	O
and	O
was	O
enhanced	O
by	O
an	O
increased	O
level	O
of	O
intracellular	O
cAMP	O
and	O
inhibited	O
by	O
both	O
a	O
protein	O
kinase	O
A	O
inhibitor	O
and	O
a	O
calmodulin	O
kinase	O
inhibitor	O
.	O

Protein	O
kinase	O
A	O
directly	O
phosphorylated	O
recombinant	O
RTP	B-Protein
in	O
vitro	O
.	O
<EOS>	B-X
RTP	B-X
,	B-X
also	B-X
called	B-X
Drg1/Cap43/rit42/TDD5/Ndr1	B-X
,	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
homocysteine-responsive	B-X
gene	B-X
product	B-X
,	B-X
and	B-X
is	B-X
now	B-X
considered	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
stress	B-X
responses	B-X
,	B-X
atherosclerosis	B-X
,	B-X
carcinogenesis	B-X
,	B-X
differentiation	B-X
,	B-X
androgen	B-X
responses	B-X
,	B-X
hypoxia	B-X
,	B-X
and	B-X
N-myc	B-X
pathways	B-X
.	B-X
We	B-X
raised	B-X
an	B-X
antiserum	B-X
against	B-X
a	B-X
recombinant	B-X
human	B-X
RTP	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
RTP	B-X
expression	B-X
was	B-X
induced	B-X
in	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
under	B-X
conditions	B-X
causing	B-X
endoplasmic	B-X
reticulum	B-X
stress	B-X
.	B-X
RTP	B-X
was	B-X
partially	B-X
phosphorylated	B-X
at	B-X
seven	B-X
or	B-X
more	B-X
sites	B-X
.	B-X
The	B-X
phosphorylation	B-X
was	B-X
reversible	B-X
,	B-X
and	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
intracellular	B-X
cAMP	B-X
and	B-X
inhibited	B-X
by	B-X
both	B-X
a	B-X
protein	B-X
kinase	B-X
A	B-X
inhibitor	B-X
and	B-X
a	B-X
calmodulin	B-X
kinase	B-X
inhibitor	B-X
.	B-X
Protein	B-X
kinase	B-X
A	B-X
directly	B-X
phosphorylated	B-X
recombinant	B-X
RTP	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
phosphorylated	B-X
forms	B-X
were	B-X
abundant	B-X
in	B-X
cells	B-X
at	B-X
the	B-X
early	B-X
log	B-X
phase	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
with	B-X
increasing	B-X
cell	B-X
density	B-X
.	B-X
These	B-X
data	B-X
demonstrated	B-X
that	B-X
RTP	B-X
is	B-X
a	B-X
phosphorylated	B-X
stress-responsive	B-X
protein	B-X
,	B-X
and	B-X
its	B-X
phosphorylation	B-X
may	B-X
be	B-X
related	B-X
to	B-X
cell	B-X
growth	B-X
.	B-X

The	O
phosphorylated	O
forms	O
were	O
abundant	O
in	O
cells	O
at	O
the	O
early	O
log	O
phase	O
,	O
and	O
then	O
decreased	O
with	O
increasing	O
cell	O
density	O
.	O
<EOS>	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
RTP	B-X
expression	B-X
was	B-X
induced	B-X
in	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
under	B-X
conditions	B-X
causing	B-X
endoplasmic	B-X
reticulum	B-X
stress	B-X
.	B-X
RTP	B-X
was	B-X
partially	B-X
phosphorylated	B-X
at	B-X
seven	B-X
or	B-X
more	B-X
sites	B-X
.	B-X
The	B-X
phosphorylation	B-X
was	B-X
reversible	B-X
,	B-X
and	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
intracellular	B-X
cAMP	B-X
and	B-X
inhibited	B-X
by	B-X
both	B-X
a	B-X
protein	B-X
kinase	B-X
A	B-X
inhibitor	B-X
and	B-X
a	B-X
calmodulin	B-X
kinase	B-X
inhibitor	B-X
.	B-X
Protein	B-X
kinase	B-X
A	B-X
directly	B-X
phosphorylated	B-X
recombinant	B-X
RTP	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
phosphorylated	B-X
forms	B-X
were	B-X
abundant	B-X
in	B-X
cells	B-X
at	B-X
the	B-X
early	B-X
log	B-X
phase	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
with	B-X
increasing	B-X
cell	B-X
density	B-X
.	B-X
These	B-X
data	B-X
demonstrated	B-X
that	B-X
RTP	B-X
is	B-X
a	B-X
phosphorylated	B-X
stress-responsive	B-X
protein	B-X
,	B-X
and	B-X
its	B-X
phosphorylation	B-X
may	B-X
be	B-X
related	B-X
to	B-X
cell	B-X
growth	B-X
.	B-X

These	O
data	O
demonstrated	O
that	O
RTP	B-Protein
is	O
a	O
phosphorylated	O
stress	O
-	O
responsive	O
protein	O
,	O
and	O
its	O
phosphorylation	O
may	O
be	O
related	O
to	O
cell	O
growth	O
.	O
<EOS>	B-X
RTP	B-X
,	B-X
also	B-X
called	B-X
Drg1/Cap43/rit42/TDD5/Ndr1	B-X
,	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
homocysteine-responsive	B-X
gene	B-X
product	B-X
,	B-X
and	B-X
is	B-X
now	B-X
considered	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
stress	B-X
responses	B-X
,	B-X
atherosclerosis	B-X
,	B-X
carcinogenesis	B-X
,	B-X
differentiation	B-X
,	B-X
androgen	B-X
responses	B-X
,	B-X
hypoxia	B-X
,	B-X
and	B-X
N-myc	B-X
pathways	B-X
.	B-X
We	B-X
raised	B-X
an	B-X
antiserum	B-X
against	B-X
a	B-X
recombinant	B-X
human	B-X
RTP	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
RTP	B-X
expression	B-X
was	B-X
induced	B-X
in	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
under	B-X
conditions	B-X
causing	B-X
endoplasmic	B-X
reticulum	B-X
stress	B-X
.	B-X
RTP	B-X
was	B-X
partially	B-X
phosphorylated	B-X
at	B-X
seven	B-X
or	B-X
more	B-X
sites	B-X
.	B-X
The	B-X
phosphorylation	B-X
was	B-X
reversible	B-X
,	B-X
and	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
intracellular	B-X
cAMP	B-X
and	B-X
inhibited	B-X
by	B-X
both	B-X
a	B-X
protein	B-X
kinase	B-X
A	B-X
inhibitor	B-X
and	B-X
a	B-X
calmodulin	B-X
kinase	B-X
inhibitor	B-X
.	B-X
Protein	B-X
kinase	B-X
A	B-X
directly	B-X
phosphorylated	B-X
recombinant	B-X
RTP	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
phosphorylated	B-X
forms	B-X
were	B-X
abundant	B-X
in	B-X
cells	B-X
at	B-X
the	B-X
early	B-X
log	B-X
phase	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
with	B-X
increasing	B-X
cell	B-X
density	B-X
.	B-X
These	B-X
data	B-X
demonstrated	B-X
that	B-X
RTP	B-X
is	B-X
a	B-X
phosphorylated	B-X
stress-responsive	B-X
protein	B-X
,	B-X
and	B-X
its	B-X
phosphorylation	B-X
may	B-X
be	B-X
related	B-X
to	B-X
cell	B-X
growth	B-X
.	B-X

A	O
method	O
for	O
determining	O
the	O
in	O
vivo	O
topology	O
of	O
yeast	O
polytopic	O
membrane	O
proteins	O
demonstrates	O
that	O
Gap1p	B-Protein
fully	O
integrates	O
into	O
the	O
membrane	O
independently	O
of	O
Shr3p	B-Protein
.	O
<EOS>	B-X
The	B-X
general	B-X
amino	B-X
acid	B-X
permease	B-X
(	B-X
Gap1p	B-X
)	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
is	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
that	B-X
contains	B-X
12	B-X
hydrophobic	B-X
regions	B-X
predicted	B-X
to	B-X
be	B-X
membrane-spanning	B-X
segments	B-X
.	B-X
A	B-X
topological	B-X
reporter	B-X
construct	B-X
,	B-X
encoding	B-X
an	B-X
internal	B-X
53-amino	B-X
acid	B-X
peptide	B-X
of	B-X
invertase	B-X
(	B-X
Suc2p	B-X
)	B-X
containing	B-X
three	B-X
Asp-X-Ser/Thr	B-X
glycosylation	B-X
sites	B-X
,	B-X
was	B-X
inserted	B-X
in-frame	B-X
into	B-X
the	B-X
hydrophilic	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
-	B-X
and	B-X
COOH-terminal	B-X
domains	B-X
and	B-X
each	B-X
of	B-X
the	B-X
11	B-X
hydrophilic	B-X
loops	B-X
that	B-X
separate	B-X
the	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
.	B-X
The	B-X
resulting	B-X
13	B-X
gene	B-X
sandwich	B-X
fusion	B-X
proteins	B-X
were	B-X
expressed	B-X
in	B-X
a	B-X
gap1Delta	B-X
null	B-X
mutant	B-X
strain	B-X
;	B-X
9	B-X
of	B-X
these	B-X
retain	B-X
amino	B-X
acid	B-X
transport	B-X
activity	B-X
and	B-X
are	B-X
folded	B-X
and	B-X
correctly	B-X
targeted	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
glycosylation	B-X
state	B-X
of	B-X
each	B-X
of	B-X
the	B-X
fusion	B-X
proteins	B-X
was	B-X
monitored	B-X
;	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
all	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
span	B-X
the	B-X
membrane	B-X
,	B-X
and	B-X
the	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
COOH	B-X
termini	B-X
are	B-X
cytoplasmically	B-X
oriented	B-X
.	B-X
These	B-X
results	B-X
were	B-X
independently	B-X
tested	B-X
by	B-X
isolating	B-X
sealed	B-X
right-side-out	B-X
microsomes	B-X
from	B-X
sec12-1	B-X
strains	B-X
expressing	B-X
six	B-X
different	B-X
Gap1p	B-X
constructs	B-X
containing	B-X
functional	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
sites	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
was	B-X
found	B-X
to	B-X
be	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
12	B-X
membrane-spanning	B-X
domains	B-X
.	B-X
Gap1p	B-X
exhibited	B-X
the	B-X
same	B-X
membrane	B-X
topology	B-X
in	B-X
strains	B-X
lacking	B-X
Shr3p	B-X
;	B-X
therefore	B-X
,	B-X
Gap1p	B-X
fully	B-X
integrates	B-X
into	B-X
the	B-X
ER	B-X
membrane	B-X
independently	B-X
of	B-X
this	B-X
permease-specific	B-X
packaging	B-X
chaperone	B-X
.	B-X

The	O
general	O
amino	O
acid	O
permease	O
(	O
Gap1p	B-Protein
)	O
of	O
Saccharomyces	O
cerevisiae	O
is	O
an	O
integral	O
membrane	O
protein	O
that	O
contains	O
12	O
hydrophobic	O
regions	O
predicted	O
to	O
be	O
membrane	O
-	O
spanning	O
segments	O
.	O
<EOS>	B-X
The	B-X
general	B-X
amino	B-X
acid	B-X
permease	B-X
(	B-X
Gap1p	B-X
)	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
is	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
that	B-X
contains	B-X
12	B-X
hydrophobic	B-X
regions	B-X
predicted	B-X
to	B-X
be	B-X
membrane-spanning	B-X
segments	B-X
.	B-X
A	B-X
topological	B-X
reporter	B-X
construct	B-X
,	B-X
encoding	B-X
an	B-X
internal	B-X
53-amino	B-X
acid	B-X
peptide	B-X
of	B-X
invertase	B-X
(	B-X
Suc2p	B-X
)	B-X
containing	B-X
three	B-X
Asp-X-Ser/Thr	B-X
glycosylation	B-X
sites	B-X
,	B-X
was	B-X
inserted	B-X
in-frame	B-X
into	B-X
the	B-X
hydrophilic	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
-	B-X
and	B-X
COOH-terminal	B-X
domains	B-X
and	B-X
each	B-X
of	B-X
the	B-X
11	B-X
hydrophilic	B-X
loops	B-X
that	B-X
separate	B-X
the	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
.	B-X
The	B-X
resulting	B-X
13	B-X
gene	B-X
sandwich	B-X
fusion	B-X
proteins	B-X
were	B-X
expressed	B-X
in	B-X
a	B-X
gap1Delta	B-X
null	B-X
mutant	B-X
strain	B-X
;	B-X
9	B-X
of	B-X
these	B-X
retain	B-X
amino	B-X
acid	B-X
transport	B-X
activity	B-X
and	B-X
are	B-X
folded	B-X
and	B-X
correctly	B-X
targeted	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
glycosylation	B-X
state	B-X
of	B-X
each	B-X
of	B-X
the	B-X
fusion	B-X
proteins	B-X
was	B-X
monitored	B-X
;	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
all	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
span	B-X
the	B-X
membrane	B-X
,	B-X
and	B-X
the	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
COOH	B-X
termini	B-X
are	B-X
cytoplasmically	B-X
oriented	B-X
.	B-X
These	B-X
results	B-X
were	B-X
independently	B-X
tested	B-X
by	B-X
isolating	B-X
sealed	B-X
right-side-out	B-X
microsomes	B-X
from	B-X
sec12-1	B-X
strains	B-X
expressing	B-X
six	B-X
different	B-X
Gap1p	B-X
constructs	B-X
containing	B-X
functional	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
sites	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
was	B-X
found	B-X
to	B-X
be	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
12	B-X
membrane-spanning	B-X
domains	B-X
.	B-X
Gap1p	B-X
exhibited	B-X
the	B-X
same	B-X
membrane	B-X
topology	B-X
in	B-X
strains	B-X
lacking	B-X
Shr3p	B-X
;	B-X
therefore	B-X
,	B-X
Gap1p	B-X
fully	B-X
integrates	B-X
into	B-X
the	B-X
ER	B-X
membrane	B-X
independently	B-X
of	B-X
this	B-X
permease-specific	B-X
packaging	B-X
chaperone	B-X
.	B-X

A	O
topological	O
reporter	O
construct	O
,	O
encoding	O
an	O
internal	O
53	O
-	O
amino	O
acid	O
peptide	O
of	O
invertase	O
(	O
Suc2p	B-Protein
)	O
containing	O
three	O
Asp	O
-	O
X	O
-	O
Ser	O
/	O
Thr	O
glycosylation	O
sites	O
,	O
was	O
inserted	O
in	O
-	O
frame	O
into	O
the	O
hydrophilic	O
NH	O
(	O
2	O
)	O
-	O
and	O
COOH	O
-	O
terminal	O
domains	O
and	O
each	O
of	O
the	O
11	O
hydrophilic	O
loops	O
that	O
separate	O
the	O
12	O
hydrophobic	O
segments	O
of	O
Gap1p	B-Protein
.	O

The	O
resulting	O
13	O
gene	O
sandwich	O
fusion	O
proteins	O
were	O
expressed	O
in	O
a	O
gap1Delta	B-Protein
null	O
mutant	O
strain	O
;	O
9	O
of	O
these	O
retain	O
amino	O
acid	O
transport	O
activity	O
and	O
are	O
folded	O
and	O
correctly	O
targeted	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
glycosylation	O
state	O
of	O
each	O
of	O
the	O
fusion	O
proteins	O
was	O
monitored	O
;	O
the	O
results	O
indicate	O
that	O
all	O
12	O
hydrophobic	O
segments	O
of	O
Gap1p	B-Protein
span	O
the	O
membrane	O
,	O
and	O
the	O
NH	O
(	O
2	O
)	O
and	O
COOH	O
termini	O
are	O
cytoplasmically	O
oriented	O
.	O
<EOS>	B-X
Protein	B-X
fusion	B-X
with	B-X
an	B-X
unconventionally	B-X
secreted	B-X
chitinase	B-X
mediates	B-X
export	B-X
of	B-X
heterologous	B-X
proteins	B-X
.	B-X
The	B-X
unique	B-X
feature	B-X
of	B-X
this	B-X
pathway	B-X
is	B-X
the	B-X
circumvention	B-X
of	B-X
N-glycosylation	B-X
.	B-X
Different	B-X
heterologous	B-X
proteins	B-X
could	B-X
already	B-X
be	B-X
secreted	B-X
via	B-X
this	B-X
novel	B-X
mechanism	B-X
in	B-X
their	B-X
active	B-X
state	B-X
.	B-X
However	B-X
,	B-X
the	B-X
system	B-X
still	B-X
suffers	B-X
from	B-X
low	B-X
yields	B-X
mainly	B-X
attributed	B-X
to	B-X
the	B-X
degradation	B-X
of	B-X
exported	B-X
recombinant	B-X
proteins	B-X
by	B-X
proteases	B-X
.	B-X
Using	B-X
the	B-X
Respiration	B-X
Activity	B-X
Monitoring	B-X
System	B-X
we	B-X
discovered	B-X
that	B-X
a	B-X
pH	B-X
drop	B-X
during	B-X
prolonged	B-X
incubation	B-X
results	B-X
in	B-X
loss	B-X
of	B-X
activity	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
target	B-X
protein	B-X
.	B-X
The	B-X
two	B-X
approaches	B-X
overall	B-X
strongly	B-X
improved	B-X
the	B-X
stability	B-X
of	B-X
heterologous	B-X
proteins	B-X
in	B-X
this	B-X
fungal	B-X
system	B-X
.	B-X

These	O
results	O
were	O
independently	O
tested	O
by	O
isolating	O
sealed	O
right	O
-	O
side	O
-	O
out	O
microsomes	O
from	O
sec12	O
-	O
1	O
strains	O
expressing	O
six	O
different	O
Gap1p	B-Protein
constructs	O
containing	O
functional	O
factor	O
Xa	O
protease	O
cleavage	O
sites	O
.	O
<EOS>	B-X
The	B-X
general	B-X
amino	B-X
acid	B-X
permease	B-X
(	B-X
Gap1p	B-X
)	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
is	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
that	B-X
contains	B-X
12	B-X
hydrophobic	B-X
regions	B-X
predicted	B-X
to	B-X
be	B-X
membrane-spanning	B-X
segments	B-X
.	B-X
A	B-X
topological	B-X
reporter	B-X
construct	B-X
,	B-X
encoding	B-X
an	B-X
internal	B-X
53-amino	B-X
acid	B-X
peptide	B-X
of	B-X
invertase	B-X
(	B-X
Suc2p	B-X
)	B-X
containing	B-X
three	B-X
Asp-X-Ser/Thr	B-X
glycosylation	B-X
sites	B-X
,	B-X
was	B-X
inserted	B-X
in-frame	B-X
into	B-X
the	B-X
hydrophilic	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
-	B-X
and	B-X
COOH-terminal	B-X
domains	B-X
and	B-X
each	B-X
of	B-X
the	B-X
11	B-X
hydrophilic	B-X
loops	B-X
that	B-X
separate	B-X
the	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
.	B-X
The	B-X
resulting	B-X
13	B-X
gene	B-X
sandwich	B-X
fusion	B-X
proteins	B-X
were	B-X
expressed	B-X
in	B-X
a	B-X
gap1Delta	B-X
null	B-X
mutant	B-X
strain	B-X
;	B-X
9	B-X
of	B-X
these	B-X
retain	B-X
amino	B-X
acid	B-X
transport	B-X
activity	B-X
and	B-X
are	B-X
folded	B-X
and	B-X
correctly	B-X
targeted	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
glycosylation	B-X
state	B-X
of	B-X
each	B-X
of	B-X
the	B-X
fusion	B-X
proteins	B-X
was	B-X
monitored	B-X
;	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
all	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
span	B-X
the	B-X
membrane	B-X
,	B-X
and	B-X
the	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
COOH	B-X
termini	B-X
are	B-X
cytoplasmically	B-X
oriented	B-X
.	B-X
These	B-X
results	B-X
were	B-X
independently	B-X
tested	B-X
by	B-X
isolating	B-X
sealed	B-X
right-side-out	B-X
microsomes	B-X
from	B-X
sec12-1	B-X
strains	B-X
expressing	B-X
six	B-X
different	B-X
Gap1p	B-X
constructs	B-X
containing	B-X
functional	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
sites	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
was	B-X
found	B-X
to	B-X
be	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
12	B-X
membrane-spanning	B-X
domains	B-X
.	B-X
Gap1p	B-X
exhibited	B-X
the	B-X
same	B-X
membrane	B-X
topology	B-X
in	B-X
strains	B-X
lacking	B-X
Shr3p	B-X
;	B-X
therefore	B-X
,	B-X
Gap1p	B-X
fully	B-X
integrates	B-X
into	B-X
the	B-X
ER	B-X
membrane	B-X
independently	B-X
of	B-X
this	B-X
permease-specific	B-X
packaging	B-X
chaperone	B-X
.	B-X

The	O
pattern	O
of	O
factor	O
Xa	O
protease	O
cleavage	O
was	O
found	O
to	O
be	O
consistent	O
with	O
the	O
presence	O
of	O
12	O
membrane	O
-	O
spanning	O
domains	O
.	O
<EOS>	B-X
The	B-X
general	B-X
amino	B-X
acid	B-X
permease	B-X
(	B-X
Gap1p	B-X
)	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
is	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
that	B-X
contains	B-X
12	B-X
hydrophobic	B-X
regions	B-X
predicted	B-X
to	B-X
be	B-X
membrane-spanning	B-X
segments	B-X
.	B-X
A	B-X
topological	B-X
reporter	B-X
construct	B-X
,	B-X
encoding	B-X
an	B-X
internal	B-X
53-amino	B-X
acid	B-X
peptide	B-X
of	B-X
invertase	B-X
(	B-X
Suc2p	B-X
)	B-X
containing	B-X
three	B-X
Asp-X-Ser/Thr	B-X
glycosylation	B-X
sites	B-X
,	B-X
was	B-X
inserted	B-X
in-frame	B-X
into	B-X
the	B-X
hydrophilic	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
-	B-X
and	B-X
COOH-terminal	B-X
domains	B-X
and	B-X
each	B-X
of	B-X
the	B-X
11	B-X
hydrophilic	B-X
loops	B-X
that	B-X
separate	B-X
the	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
.	B-X
The	B-X
resulting	B-X
13	B-X
gene	B-X
sandwich	B-X
fusion	B-X
proteins	B-X
were	B-X
expressed	B-X
in	B-X
a	B-X
gap1Delta	B-X
null	B-X
mutant	B-X
strain	B-X
;	B-X
9	B-X
of	B-X
these	B-X
retain	B-X
amino	B-X
acid	B-X
transport	B-X
activity	B-X
and	B-X
are	B-X
folded	B-X
and	B-X
correctly	B-X
targeted	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
glycosylation	B-X
state	B-X
of	B-X
each	B-X
of	B-X
the	B-X
fusion	B-X
proteins	B-X
was	B-X
monitored	B-X
;	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
all	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
span	B-X
the	B-X
membrane	B-X
,	B-X
and	B-X
the	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
COOH	B-X
termini	B-X
are	B-X
cytoplasmically	B-X
oriented	B-X
.	B-X
These	B-X
results	B-X
were	B-X
independently	B-X
tested	B-X
by	B-X
isolating	B-X
sealed	B-X
right-side-out	B-X
microsomes	B-X
from	B-X
sec12-1	B-X
strains	B-X
expressing	B-X
six	B-X
different	B-X
Gap1p	B-X
constructs	B-X
containing	B-X
functional	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
sites	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
was	B-X
found	B-X
to	B-X
be	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
12	B-X
membrane-spanning	B-X
domains	B-X
.	B-X
Gap1p	B-X
exhibited	B-X
the	B-X
same	B-X
membrane	B-X
topology	B-X
in	B-X
strains	B-X
lacking	B-X
Shr3p	B-X
;	B-X
therefore	B-X
,	B-X
Gap1p	B-X
fully	B-X
integrates	B-X
into	B-X
the	B-X
ER	B-X
membrane	B-X
independently	B-X
of	B-X
this	B-X
permease-specific	B-X
packaging	B-X
chaperone	B-X
.	B-X

Gap1p	B-Protein
exhibited	O
the	O
same	O
membrane	O
topology	O
in	O
strains	O
lacking	O
Shr3p	B-Protein
;	O
therefore	O
,	O
Gap1p	B-Protein
fully	O
integrates	O
into	O
the	O
ER	O
membrane	O
independently	O
of	O
this	O
permease	O
-	O
specific	O
packaging	O
chaperone	O
.	O
<EOS>	B-X
The	B-X
general	B-X
amino	B-X
acid	B-X
permease	B-X
(	B-X
Gap1p	B-X
)	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
is	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
that	B-X
contains	B-X
12	B-X
hydrophobic	B-X
regions	B-X
predicted	B-X
to	B-X
be	B-X
membrane-spanning	B-X
segments	B-X
.	B-X
A	B-X
topological	B-X
reporter	B-X
construct	B-X
,	B-X
encoding	B-X
an	B-X
internal	B-X
53-amino	B-X
acid	B-X
peptide	B-X
of	B-X
invertase	B-X
(	B-X
Suc2p	B-X
)	B-X
containing	B-X
three	B-X
Asp-X-Ser/Thr	B-X
glycosylation	B-X
sites	B-X
,	B-X
was	B-X
inserted	B-X
in-frame	B-X
into	B-X
the	B-X
hydrophilic	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
-	B-X
and	B-X
COOH-terminal	B-X
domains	B-X
and	B-X
each	B-X
of	B-X
the	B-X
11	B-X
hydrophilic	B-X
loops	B-X
that	B-X
separate	B-X
the	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
.	B-X
The	B-X
resulting	B-X
13	B-X
gene	B-X
sandwich	B-X
fusion	B-X
proteins	B-X
were	B-X
expressed	B-X
in	B-X
a	B-X
gap1Delta	B-X
null	B-X
mutant	B-X
strain	B-X
;	B-X
9	B-X
of	B-X
these	B-X
retain	B-X
amino	B-X
acid	B-X
transport	B-X
activity	B-X
and	B-X
are	B-X
folded	B-X
and	B-X
correctly	B-X
targeted	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
glycosylation	B-X
state	B-X
of	B-X
each	B-X
of	B-X
the	B-X
fusion	B-X
proteins	B-X
was	B-X
monitored	B-X
;	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
all	B-X
12	B-X
hydrophobic	B-X
segments	B-X
of	B-X
Gap1p	B-X
span	B-X
the	B-X
membrane	B-X
,	B-X
and	B-X
the	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
COOH	B-X
termini	B-X
are	B-X
cytoplasmically	B-X
oriented	B-X
.	B-X
These	B-X
results	B-X
were	B-X
independently	B-X
tested	B-X
by	B-X
isolating	B-X
sealed	B-X
right-side-out	B-X
microsomes	B-X
from	B-X
sec12-1	B-X
strains	B-X
expressing	B-X
six	B-X
different	B-X
Gap1p	B-X
constructs	B-X
containing	B-X
functional	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
sites	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
factor	B-X
Xa	B-X
protease	B-X
cleavage	B-X
was	B-X
found	B-X
to	B-X
be	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
12	B-X
membrane-spanning	B-X
domains	B-X
.	B-X
Gap1p	B-X
exhibited	B-X
the	B-X
same	B-X
membrane	B-X
topology	B-X
in	B-X
strains	B-X
lacking	B-X
Shr3p	B-X
;	B-X
therefore	B-X
,	B-X
Gap1p	B-X
fully	B-X
integrates	B-X
into	B-X
the	B-X
ER	B-X
membrane	B-X
independently	B-X
of	B-X
this	B-X
permease-specific	B-X
packaging	B-X
chaperone	B-X
.	B-X

Exploring	O
the	O
glycan	O
repertoire	O
of	O
genetically	O
modified	O
mice	O
by	O
isolation	O
and	O
profiling	O
of	O
the	O
major	O
glycan	O
classes	O
and	O
nano	O
-	O
NMR	O
analysis	O
of	O
glycan	O
mixtures	O
.	O
<EOS>	B-X
The	B-X
production	B-X
of	B-X
mice	B-X
with	B-X
genetic	B-X
alterations	B-X
in	B-X
glycosyltransferases	B-X
has	B-X
highlighted	B-X
the	B-X
need	B-X
to	B-X
isolate	B-X
and	B-X
study	B-X
complex	B-X
mixtures	B-X
of	B-X
the	B-X
major	B-X
classes	B-X
of	B-X
oligosaccharides	B-X
(	B-X
glycans	B-X
)	B-X
from	B-X
intact	B-X
tissues	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
nano-NMR	B-X
spectroscopy	B-X
of	B-X
whole	B-X
mixtures	B-X
of	B-X
N-	B-X
and	B-X
O-glycans	B-X
can	B-X
complement	B-X
HPLC	B-X
profiling	B-X
methods	B-X
for	B-X
elucidating	B-X
structural	B-X
details	B-X
.	B-X
Working	B-X
toward	B-X
obtaining	B-X
such	B-X
glycan	B-X
mixtures	B-X
from	B-X
mouse	B-X
tissues	B-X
,	B-X
we	B-X
decided	B-X
to	B-X
develop	B-X
an	B-X
approach	B-X
to	B-X
isolate	B-X
not	B-X
only	B-X
N-	B-X
and	B-X
O-glycans	B-X
,	B-X
but	B-X
also	B-X
to	B-X
separate	B-X
out	B-X
glycosphingolipids	B-X
,	B-X
glycosaminoglycans	B-X
and	B-X
glycosylphosphatidylinositol	B-X
anchors	B-X
.	B-X
Using	B-X
radiolabeled	B-X
internal	B-X
tracers	B-X
,	B-X
we	B-X
show	B-X
that	B-X
recovery	B-X
of	B-X
each	B-X
major	B-X
class	B-X
of	B-X
glycans	B-X
is	B-X
as	B-X
good	B-X
or	B-X
better	B-X
than	B-X
with	B-X
conventional	B-X
approaches	B-X
for	B-X
isolating	B-X
individual	B-X
classes	B-X
,	B-X
and	B-X
that	B-X
cross-contamination	B-X
is	B-X
minimal	B-X
.	B-X
The	B-X
recovered	B-X
glycans	B-X
are	B-X
of	B-X
sufficient	B-X
purity	B-X
to	B-X
provide	B-X
a	B-X
``	B-X
glycoprofile	B-X
''	B-X
of	B-X
a	B-X
cell	B-X
type	B-X
or	B-X
tissue	B-X
.	B-X
We	B-X
applied	B-X
this	B-X
approach	B-X
to	B-X
compare	B-X
the	B-X
N-	B-X
and	B-X
O-glycans	B-X
from	B-X
wild	B-X
type	B-X
mouse	B-X
tissues	B-X
with	B-X
those	B-X
from	B-X
mice	B-X
genetically	B-X
deficient	B-X
in	B-X
glycosyltransferases	B-X
.	B-X
N-	B-X
and	B-X
O-glycan	B-X
mixtures	B-X
from	B-X
organs	B-X
of	B-X
mice	B-X
deficient	B-X
in	B-X
ST6Gal-I	B-X
(	B-X
CMP-Sia	B-X
:	B-X
Galbeta1-4GlcNAc	B-X
alpha2-6	B-X
sialyltransferase	B-X
)	B-X
were	B-X
studied	B-X
by	B-X
the	B-X
nano-NMR	B-X
spectroscopy	B-X
approach	B-X
,	B-X
showing	B-X
no	B-X
detectable	B-X
alpha2-6-linked	B-X
sialic	B-X
acids	B-X
.	B-X
Thus	B-X
,	B-X
ST6Gal-I	B-X
is	B-X
likely	B-X
responsible	B-X
for	B-X
generating	B-X
most	B-X
or	B-X
all	B-X
of	B-X
these	B-X
residues	B-X
in	B-X
normal	B-X
mice	B-X
.	B-X
Similar	B-X
studies	B-X
indicate	B-X
that	B-X
this	B-X
linkage	B-X
is	B-X
very	B-X
rare	B-X
in	B-X
ganglioside	B-X
glycans	B-X
,	B-X
even	B-X
in	B-X
wild-type	B-X
tissues	B-X
.	B-X
In	B-X
mice	B-X
deficient	B-X
in	B-X
GalNAcT-8	B-X
(	B-X
UDP-GalNAc	B-X
:	B-X
polypeptide	B-X
O-Ser/Thr	B-X
GalNAc	B-X
transferase	B-X
8	B-X
)	B-X
,	B-X
HPLC	B-X
profiling	B-X
indicates	B-X
that	B-X
O-glycans	B-X
persist	B-X
in	B-X
the	B-X
thymus	B-X
in	B-X
large	B-X
amounts	B-X
,	B-X
without	B-X
a	B-X
major	B-X
change	B-X
in	B-X
overall	B-X
profile	B-X
,	B-X
suggesting	B-X
that	B-X
other	B-X
enzymes	B-X
can	B-X
synthesize	B-X
the	B-X
GalNAc-O-Ser/Thr	B-X
linkage	B-X
in	B-X
this	B-X
tissue	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
the	B-X
applicability	B-X
of	B-X
nano-NMR	B-X
spectroscopy	B-X
to	B-X
complex	B-X
glycan	B-X
mixtures	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
versatility	B-X
of	B-X
the	B-X
Glycan	B-X
Isolation	B-X
Protocol	B-X
,	B-X
which	B-X
makes	B-X
possible	B-X
the	B-X
concurrent	B-X
examination	B-X
of	B-X
multiple	B-X
glycan	B-X
classes	B-X
from	B-X
intact	B-X
vertebrate	B-X
tissues	B-X
.	B-X

The	O
production	O
of	O
mice	O
with	O
genetic	O
alterations	O
in	O
glycosyltransferases	O
has	O
highlighted	O
the	O
need	O
to	O
isolate	O
and	O
study	O
complex	O
mixtures	O
of	O
the	O
major	O
classes	O
of	O
oligosaccharides	O
(	O
glycans	O
)	O
from	O
intact	O
tissues	O
.	O
<EOS>	B-X
The	B-X
production	B-X
of	B-X
mice	B-X
with	B-X
genetic	B-X
alterations	B-X
in	B-X
glycosyltransferases	B-X
has	B-X
highlighted	B-X
the	B-X
need	B-X
to	B-X
isolate	B-X
and	B-X
study	B-X
complex	B-X
mixtures	B-X
of	B-X
the	B-X
major	B-X
classes	B-X
of	B-X
oligosaccharides	B-X
(	B-X
glycans	B-X
)	B-X
from	B-X
intact	B-X
tissues	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
nano-NMR	B-X
spectroscopy	B-X
of	B-X
whole	B-X
mixtures	B-X
of	B-X
N-	B-X
and	B-X
O-glycans	B-X
can	B-X
complement	B-X
HPLC	B-X
profiling	B-X
methods	B-X
for	B-X
elucidating	B-X
structural	B-X
details	B-X
.	B-X
Working	B-X
toward	B-X
obtaining	B-X
such	B-X
glycan	B-X
mixtures	B-X
from	B-X
mouse	B-X
tissues	B-X
,	B-X
we	B-X
decided	B-X
to	B-X
develop	B-X
an	B-X
approach	B-X
to	B-X
isolate	B-X
not	B-X
only	B-X
N-	B-X
and	B-X
O-glycans	B-X
,	B-X
but	B-X
also	B-X
to	B-X
separate	B-X
out	B-X
glycosphingolipids	B-X
,	B-X
glycosaminoglycans	B-X
and	B-X
glycosylphosphatidylinositol	B-X
anchors	B-X
.	B-X
Using	B-X
radiolabeled	B-X
internal	B-X
tracers	B-X
,	B-X
we	B-X
show	B-X
that	B-X
recovery	B-X
of	B-X
each	B-X
major	B-X
class	B-X
of	B-X
glycans	B-X
is	B-X
as	B-X
good	B-X
or	B-X
better	B-X
than	B-X
with	B-X
conventional	B-X
approaches	B-X
for	B-X
isolating	B-X
individual	B-X
classes	B-X
,	B-X
and	B-X
that	B-X
cross-contamination	B-X
is	B-X
minimal	B-X
.	B-X
The	B-X
recovered	B-X
glycans	B-X
are	B-X
of	B-X
sufficient	B-X
purity	B-X
to	B-X
provide	B-X
a	B-X
``	B-X
glycoprofile	B-X
''	B-X
of	B-X
a	B-X
cell	B-X
type	B-X
or	B-X
tissue	B-X
.	B-X
We	B-X
applied	B-X
this	B-X
approach	B-X
to	B-X
compare	B-X
the	B-X
N-	B-X
and	B-X
O-glycans	B-X
from	B-X
wild	B-X
type	B-X
mouse	B-X
tissues	B-X
with	B-X
those	B-X
from	B-X
mice	B-X
genetically	B-X
deficient	B-X
in	B-X
glycosyltransferases	B-X
.	B-X
N-	B-X
and	B-X
O-glycan	B-X
mixtures	B-X
from	B-X
organs	B-X
of	B-X
mice	B-X
deficient	B-X
in	B-X
ST6Gal-I	B-X
(	B-X
CMP-Sia	B-X
:	B-X
Galbeta1-4GlcNAc	B-X
alpha2-6	B-X
sialyltransferase	B-X
)	B-X
were	B-X
studied	B-X
by	B-X
the	B-X
nano-NMR	B-X
spectroscopy	B-X
approach	B-X
,	B-X
showing	B-X
no	B-X
detectable	B-X
alpha2-6-linked	B-X
sialic	B-X
acids	B-X
.	B-X
Thus	B-X
,	B-X
ST6Gal-I	B-X
is	B-X
likely	B-X
responsible	B-X
for	B-X
generating	B-X
most	B-X
or	B-X
all	B-X
of	B-X
these	B-X
residues	B-X
in	B-X
normal	B-X
mice	B-X
.	B-X
Similar	B-X
studies	B-X
indicate	B-X
that	B-X
this	B-X
linkage	B-X
is	B-X
very	B-X
rare	B-X
in	B-X
ganglioside	B-X
glycans	B-X
,	B-X
even	B-X
in	B-X
wild-type	B-X
tissues	B-X
.	B-X
In	B-X
mice	B-X
deficient	B-X
in	B-X
GalNAcT-8	B-X
(	B-X
UDP-GalNAc	B-X
:	B-X
polypeptide	B-X
O-Ser/Thr	B-X
GalNAc	B-X
transferase	B-X
8	B-X
)	B-X
,	B-X
HPLC	B-X
profiling	B-X
indicates	B-X
that	B-X
O-glycans	B-X
persist	B-X
in	B-X
the	B-X
thymus	B-X
in	B-X
large	B-X
amounts	B-X
,	B-X
without	B-X
a	B-X
major	B-X
change	B-X
in	B-X
overall	B-X
profile	B-X
,	B-X
suggesting	B-X
that	B-X
other	B-X
enzymes	B-X
can	B-X
synthesize	B-X
the	B-X
GalNAc-O-Ser/Thr	B-X
linkage	B-X
in	B-X
this	B-X
tissue	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
the	B-X
applicability	B-X
of	B-X
nano-NMR	B-X
spectroscopy	B-X
to	B-X
complex	B-X
glycan	B-X
mixtures	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
versatility	B-X
of	B-X
the	B-X
Glycan	B-X
Isolation	B-X
Protocol	B-X
,	B-X
which	B-X
makes	B-X
possible	B-X
the	B-X
concurrent	B-X
examination	B-X
of	B-X
multiple	B-X
glycan	B-X
classes	B-X
from	B-X
intact	B-X
vertebrate	B-X
tissues	B-X
.	B-X

We	O
have	O
found	O
that	O
nano	O
-	O
NMR	O
spectroscopy	O
of	O
whole	O
mixtures	O
of	O
N	O
-	O
and	O
O	O
-	O
glycans	O
can	O
complement	O
HPLC	O
profiling	O
methods	O
for	O
elucidating	O
structural	O
details	O
.	O

Working	O
toward	O
obtaining	O
such	O
glycan	O
mixtures	O
from	O
mouse	O
tissues	O
,	O
we	O
decided	O
to	O
develop	O
an	O
approach	O
to	O
isolate	O
not	O
only	O
N	O
-	O
and	O
O	O
-	O
glycans	O
,	O
but	O
also	O
to	O
separate	O
out	O
glycosphingolipids	O
,	O
glycosaminoglycans	O
and	O
glycosylphosphatidylinositol	O
anchors	O
.	O
<EOS>	B-X
The	B-X
production	B-X
of	B-X
mice	B-X
with	B-X
genetic	B-X
alterations	B-X
in	B-X
glycosyltransferases	B-X
has	B-X
highlighted	B-X
the	B-X
need	B-X
to	B-X
isolate	B-X
and	B-X
study	B-X
complex	B-X
mixtures	B-X
of	B-X
the	B-X
major	B-X
classes	B-X
of	B-X
oligosaccharides	B-X
(	B-X
glycans	B-X
)	B-X
from	B-X
intact	B-X
tissues	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
nano-NMR	B-X
spectroscopy	B-X
of	B-X
whole	B-X
mixtures	B-X
of	B-X
N-	B-X
and	B-X
O-glycans	B-X
can	B-X
complement	B-X
HPLC	B-X
profiling	B-X
methods	B-X
for	B-X
elucidating	B-X
structural	B-X
details	B-X
.	B-X
Working	B-X
toward	B-X
obtaining	B-X
such	B-X
glycan	B-X
mixtures	B-X
from	B-X
mouse	B-X
tissues	B-X
,	B-X
we	B-X
decided	B-X
to	B-X
develop	B-X
an	B-X
approach	B-X
to	B-X
isolate	B-X
not	B-X
only	B-X
N-	B-X
and	B-X
O-glycans	B-X
,	B-X
but	B-X
also	B-X
to	B-X
separate	B-X
out	B-X
glycosphingolipids	B-X
,	B-X
glycosaminoglycans	B-X
and	B-X
glycosylphosphatidylinositol	B-X
anchors	B-X
.	B-X
Using	B-X
radiolabeled	B-X
internal	B-X
tracers	B-X
,	B-X
we	B-X
show	B-X
that	B-X
recovery	B-X
of	B-X
each	B-X
major	B-X
class	B-X
of	B-X
glycans	B-X
is	B-X
as	B-X
good	B-X
or	B-X
better	B-X
than	B-X
with	B-X
conventional	B-X
approaches	B-X
for	B-X
isolating	B-X
individual	B-X
classes	B-X
,	B-X
and	B-X
that	B-X
cross-contamination	B-X
is	B-X
minimal	B-X
.	B-X
The	B-X
recovered	B-X
glycans	B-X
are	B-X
of	B-X
sufficient	B-X
purity	B-X
to	B-X
provide	B-X
a	B-X
``	B-X
glycoprofile	B-X
''	B-X
of	B-X
a	B-X
cell	B-X
type	B-X
or	B-X
tissue	B-X
.	B-X
We	B-X
applied	B-X
this	B-X
approach	B-X
to	B-X
compare	B-X
the	B-X
N-	B-X
and	B-X
O-glycans	B-X
from	B-X
wild	B-X
type	B-X
mouse	B-X
tissues	B-X
with	B-X
those	B-X
from	B-X
mice	B-X
genetically	B-X
deficient	B-X
in	B-X
glycosyltransferases	B-X
.	B-X
N-	B-X
and	B-X
O-glycan	B-X
mixtures	B-X
from	B-X
organs	B-X
of	B-X
mice	B-X
deficient	B-X
in	B-X
ST6Gal-I	B-X
(	B-X
CMP-Sia	B-X
:	B-X
Galbeta1-4GlcNAc	B-X
alpha2-6	B-X
sialyltransferase	B-X
)	B-X
were	B-X
studied	B-X
by	B-X
the	B-X
nano-NMR	B-X
spectroscopy	B-X
approach	B-X
,	B-X
showing	B-X
no	B-X
detectable	B-X
alpha2-6-linked	B-X
sialic	B-X
acids	B-X
.	B-X
Similar	B-X
studies	B-X
indicate	B-X
that	B-X
this	B-X
linkage	B-X
is	B-X
very	B-X
rare	B-X
in	B-X
ganglioside	B-X
glycans	B-X
,	B-X
even	B-X
in	B-X
wild-type	B-X
tissues	B-X
.	B-X
In	B-X
mice	B-X
deficient	B-X
in	B-X
GalNAcT-8	B-X
(	B-X
UDP-GalNAc	B-X
:	B-X
polypeptide	B-X
O-Ser/Thr	B-X
GalNAc	B-X
transferase	B-X
8	B-X
)	B-X
,	B-X
HPLC	B-X
profiling	B-X
indicates	B-X
that	B-X
O-glycans	B-X
persist	B-X
in	B-X
the	B-X
thymus	B-X
in	B-X
large	B-X
amounts	B-X
,	B-X
without	B-X
a	B-X
major	B-X
change	B-X
in	B-X
overall	B-X
profile	B-X
,	B-X
suggesting	B-X
that	B-X
other	B-X
enzymes	B-X
can	B-X
synthesize	B-X
the	B-X
GalNAc-O-Ser/Thr	B-X
linkage	B-X
in	B-X
this	B-X
tissue	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
the	B-X
applicability	B-X
of	B-X
nano-NMR	B-X
spectroscopy	B-X
to	B-X
complex	B-X
glycan	B-X
mixtures	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
versatility	B-X
of	B-X
the	B-X
Glycan	B-X
Isolation	B-X
Protocol	B-X
,	B-X
which	B-X
makes	B-X
possible	B-X
the	B-X
concurrent	B-X
examination	B-X
of	B-X
multiple	B-X
glycan	B-X
classes	B-X
from	B-X
intact	B-X
vertebrate	B-X
tissues	B-X
.	B-X

We	O
describe	O
here	O
a	O
comprehensive	O
Glycan	O
Isolation	O
Protocol	O
that	O
is	O
based	O
primarily	O
upon	O
the	O
physicochemical	O
characteristics	O
of	O
the	O
molecules	O
,	O
and	O
requires	O
only	O
commonly	O
available	O
reagents	O
and	O
equipment	O
.	O

Using	O
radiolabeled	O
internal	O
tracers	O
,	O
we	O
show	O
that	O
recovery	O
of	O
each	O
major	O
class	O
of	O
glycans	O
is	O
as	O
good	O
or	O
better	O
than	O
with	O
conventional	O
approaches	O
for	O
isolating	O
individual	O
classes	O
,	O
and	O
that	O
cross	O
-	O
contamination	O
is	O
minimal	O
.	O
<EOS>	B-X
The	B-X
production	B-X
of	B-X
mice	B-X
with	B-X
genetic	B-X
alterations	B-X
in	B-X
glycosyltransferases	B-X
has	B-X
highlighted	B-X
the	B-X
need	B-X
to	B-X
isolate	B-X
and	B-X
study	B-X
complex	B-X
mixtures	B-X
of	B-X
the	B-X
major	B-X
classes	B-X
of	B-X
oligosaccharides	B-X
(	B-X
glycans	B-X
)	B-X
from	B-X
intact	B-X
tissues	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
nano-NMR	B-X
spectroscopy	B-X
of	B-X
whole	B-X
mixtures	B-X
of	B-X
N-	B-X
and	B-X
O-glycans	B-X
can	B-X
complement	B-X
HPLC	B-X
profiling	B-X
methods	B-X
for	B-X
elucidating	B-X
structural	B-X
details	B-X
.	B-X
Working	B-X
toward	B-X
obtaining	B-X
such	B-X
glycan	B-X
mixtures	B-X
from	B-X
mouse	B-X
tissues	B-X
,	B-X
we	B-X
decided	B-X
to	B-X
develop	B-X
an	B-X
approach	B-X
to	B-X
isolate	B-X
not	B-X
only	B-X
N-	B-X
and	B-X
O-glycans	B-X
,	B-X
but	B-X
also	B-X
to	B-X
separate	B-X
out	B-X
glycosphingolipids	B-X
,	B-X
glycosaminoglycans	B-X
and	B-X
glycosylphosphatidylinositol	B-X
anchors	B-X
.	B-X
Using	B-X
radiolabeled	B-X
internal	B-X
tracers	B-X
,	B-X
we	B-X
show	B-X
that	B-X
recovery	B-X
of	B-X
each	B-X
major	B-X
class	B-X
of	B-X
glycans	B-X
is	B-X
as	B-X
good	B-X
or	B-X
better	B-X
than	B-X
with	B-X
conventional	B-X
approaches	B-X
for	B-X
isolating	B-X
individual	B-X
classes	B-X
,	B-X
and	B-X
that	B-X
cross-contamination	B-X
is	B-X
minimal	B-X
.	B-X
The	B-X
recovered	B-X
glycans	B-X
are	B-X
of	B-X
sufficient	B-X
purity	B-X
to	B-X
provide	B-X
a	B-X
``	B-X
glycoprofile	B-X
''	B-X
of	B-X
a	B-X
cell	B-X
type	B-X
or	B-X
tissue	B-X
.	B-X
We	B-X
applied	B-X
this	B-X
approach	B-X
to	B-X
compare	B-X
the	B-X
N-	B-X
and	B-X
O-glycans	B-X
from	B-X
wild	B-X
type	B-X
mouse	B-X
tissues	B-X
with	B-X
those	B-X
from	B-X
mice	B-X
genetically	B-X
deficient	B-X
in	B-X
glycosyltransferases	B-X
.	B-X
N-	B-X
and	B-X
O-glycan	B-X
mixtures	B-X
from	B-X
organs	B-X
of	B-X
mice	B-X
deficient	B-X
in	B-X
ST6Gal-I	B-X
(	B-X
CMP-Sia	B-X
:	B-X
Galbeta1-4GlcNAc	B-X
alpha2-6	B-X
sialyltransferase	B-X
)	B-X
were	B-X
studied	B-X
by	B-X
the	B-X
nano-NMR	B-X
spectroscopy	B-X
approach	B-X
,	B-X
showing	B-X
no	B-X
detectable	B-X
alpha2-6-linked	B-X
sialic	B-X
acids	B-X
.	B-X
Similar	B-X
studies	B-X
indicate	B-X
that	B-X
this	B-X
linkage	B-X
is	B-X
very	B-X
rare	B-X
in	B-X
ganglioside	B-X
glycans	B-X
,	B-X
even	B-X
in	B-X
wild-type	B-X
tissues	B-X
.	B-X
In	B-X
mice	B-X
deficient	B-X
in	B-X
GalNAcT-8	B-X
(	B-X
UDP-GalNAc	B-X
:	B-X
polypeptide	B-X
O-Ser/Thr	B-X
GalNAc	B-X
transferase	B-X
8	B-X
)	B-X
,	B-X
HPLC	B-X
profiling	B-X
indicates	B-X
that	B-X
O-glycans	B-X
persist	B-X
in	B-X
the	B-X
thymus	B-X
in	B-X
large	B-X
amounts	B-X
,	B-X
without	B-X
a	B-X
major	B-X
change	B-X
in	B-X
overall	B-X
profile	B-X
,	B-X
suggesting	B-X
that	B-X
other	B-X
enzymes	B-X
can	B-X
synthesize	B-X
the	B-X
GalNAc-O-Ser/Thr	B-X
linkage	B-X
in	B-X
this	B-X
tissue	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
the	B-X
applicability	B-X
of	B-X
nano-NMR	B-X
spectroscopy	B-X
to	B-X
complex	B-X
glycan	B-X
mixtures	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
versatility	B-X
of	B-X
the	B-X
Glycan	B-X
Isolation	B-X
Protocol	B-X
,	B-X
which	B-X
makes	B-X
possible	B-X
the	B-X
concurrent	B-X
examination	B-X
of	B-X
multiple	B-X
glycan	B-X
classes	B-X
from	B-X
intact	B-X
vertebrate	B-X
tissues	B-X
.	B-X

The	O
recovered	O
glycans	O
are	O
of	O
sufficient	O
purity	O
to	O
provide	O
a	O
"	O
glycoprofile	O
"	O
of	O
a	O
cell	O
type	O
or	O
tissue	O
.	O
<EOS>	B-X
During	B-X
the	B-X
last	B-X
decades	B-X
,	B-X
research	B-X
on	B-X
adipose	B-X
tissues	B-X
has	B-X
spread	B-X
in	B-X
parallel	B-X
with	B-X
the	B-X
extension	B-X
of	B-X
obesity	B-X
.	B-X
Several	B-X
observations	B-X
converged	B-X
on	B-X
the	B-X
idea	B-X
that	B-X
adipose	B-X
tissues	B-X
are	B-X
organized	B-X
in	B-X
a	B-X
large	B-X
organ	B-X
with	B-X
endocrine	B-X
and	B-X
plastic	B-X
properties	B-X
.	B-X
Two	B-X
parenchymal	B-X
components	B-X
:	B-X
white	B-X
(	B-X
WATs	B-X
)	B-X
and	B-X
brown	B-X
adipose	B-X
tissues	B-X
(	B-X
BATs	B-X
)	B-X
are	B-X
contained	B-X
in	B-X
subcutaneous	B-X
and	B-X
visceral	B-X
compartments	B-X
.	B-X
During	B-X
pregnancy	B-X
and	B-X
lactation	B-X
breast	B-X
WAT	B-X
transdifferentiates	B-X
into	B-X
milk-secreting	B-X
glands	B-X
,	B-X
composed	B-X
by	B-X
cells	B-X
with	B-X
abundant	B-X
cytoplasmic	B-X
lipids	B-X
(	B-X
pink	B-X
adipocytes	B-X
)	B-X
and	B-X
in	B-X
the	B-X
postlactation	B-X
period	B-X
pink	B-X
adipocytes	B-X
transdifferentiate	B-X
back	B-X
into	B-X
WAT	B-X
and	B-X
BAT	B-X
.	B-X
The	B-X
plastic	B-X
properties	B-X
of	B-X
mature	B-X
adipocytes	B-X
are	B-X
supported	B-X
also	B-X
by	B-X
a	B-X
liposecretion	B-X
process	B-X
in	B-X
vitro	B-X
where	B-X
adult	B-X
cell	B-X
in	B-X
culture	B-X
transdifferentiate	B-X
to	B-X
differentiated	B-X
fibroblast-like	B-X
elements	B-X
able	B-X
to	B-X
give	B-X
rise	B-X
to	B-X
different	B-X
phenotypes	B-X
(	B-X
rainbow	B-X
adipocytes	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
inflammasome	B-X
system	B-X
is	B-X
activated	B-X
in	B-X
stressed	B-X
adipocytes	B-X
from	B-X
obese	B-X
adipose	B-X
tissue	B-X
.	B-X

We	O
applied	O
this	O
approach	O
to	O
compare	O
the	O
N	O
-	O
and	O
O	O
-	O
glycans	O
from	O
wild	O
type	O
mouse	O
tissues	O
with	O
those	O
from	O
mice	O
genetically	O
deficient	O
in	O
glycosyltransferases	O
.	O

N	O
-	O
and	O
O	O
-	O
glycan	O
mixtures	O
from	O
organs	O
of	O
mice	O
deficient	O
in	O
ST6Gal	B-Protein
-	I-Protein
I	I-Protein
(	O
CMP	O
-	O
Sia	O
:	O
Galbeta1	O
-	O
4GlcNAc	O
alpha2	O
-	O
6	O
sialyltransferase	O
)	O
were	O
studied	O
by	O
the	O
nano	O
-	O
NMR	O
spectroscopy	O
approach	O
,	O
showing	O
no	O
detectable	O
alpha2	O
-	O
6	O
-	O
linked	O
sialic	O
acids	O
.	O

Thus	O
,	O
ST6Gal	B-Protein
-	I-Protein
I	I-Protein
is	O
likely	O
responsible	O
for	O
generating	O
most	O
or	O
all	O
of	O
these	O
residues	O
in	O
normal	O
mice	O
.	O
<EOS>	B-X
The	B-X
mammalian	B-X
two	B-X
superaquaporins	B-X
,	B-X
AQP11	B-X
and	B-X
AQP12	B-X
,	B-X
are	B-X
present	B-X
inside	B-X
the	B-X
cell	B-X
and	B-X
their	B-X
null	B-X
phenotypes	B-X
in	B-X
mice	B-X
suggest	B-X
their	B-X
unusual	B-X
functions	B-X
.	B-X
The	B-X
human	B-X
cellular	B-X
prion	B-X
protein	B-X
(	B-X
PrP	B-X
(	B-X
C	B-X
)	B-X
)	B-X
is	B-X
a	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
anchored	B-X
membrane	B-X
glycoprotein	B-X
with	B-X
two	B-X
N-glycosylation	B-X
sites	B-X
at	B-X
residues	B-X
181	B-X
and	B-X
197	B-X
.	B-X
Nevertheless	B-X
,	B-X
there	B-X
is	B-X
a	B-X
strong	B-X
correlation	B-X
between	B-X
the	B-X
neurotoxicity	B-X
caused	B-X
by	B-X
prion	B-X
proteins	B-X
and	B-X
the	B-X
blockade	B-X
of	B-X
their	B-X
normal	B-X
proteolysis	B-X
.	B-X
For	B-X
example	B-X
,	B-X
expression	B-X
of	B-X
non-cleavable	B-X
PrP	B-X
(	B-X
C	B-X
)	B-X
mutants	B-X
in	B-X
transgenic	B-X
mice	B-X
generates	B-X
neurotoxicity	B-X
,	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
infectious	B-X
prions	B-X
,	B-X
suggesting	B-X
that	B-X
PrP	B-X
(	B-X
C	B-X
)	B-X
proteolysis	B-X
is	B-X
physiologically	B-X
and	B-X
pathologically	B-X
important	B-X
.	B-X
As	B-X
many	B-X
mouse	B-X
models	B-X
of	B-X
prion	B-X
diseases	B-X
have	B-X
recently	B-X
been	B-X
developed	B-X
and	B-X
the	B-X
knowledge	B-X
about	B-X
the	B-X
proteases	B-X
responsible	B-X
for	B-X
the	B-X
PrP	B-X
(	B-X
C	B-X
)	B-X
proteolysis	B-X
is	B-X
accumulating	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
historical	B-X
experimental	B-X
evidence	B-X
and	B-X
highlight	B-X
recent	B-X
studies	B-X
that	B-X
shed	B-X
new	B-X
light	B-X
on	B-X
this	B-X
issue	B-X
.	B-X

Similar	O
studies	O
indicate	O
that	O
this	O
linkage	O
is	O
very	O
rare	O
in	O
ganglioside	O
glycans	O
,	O
even	O
in	O
wild	O
-	O
type	O
tissues	O
.	O
<EOS>	B-X
The	B-X
production	B-X
of	B-X
mice	B-X
with	B-X
genetic	B-X
alterations	B-X
in	B-X
glycosyltransferases	B-X
has	B-X
highlighted	B-X
the	B-X
need	B-X
to	B-X
isolate	B-X
and	B-X
study	B-X
complex	B-X
mixtures	B-X
of	B-X
the	B-X
major	B-X
classes	B-X
of	B-X
oligosaccharides	B-X
(	B-X
glycans	B-X
)	B-X
from	B-X
intact	B-X
tissues	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
nano-NMR	B-X
spectroscopy	B-X
of	B-X
whole	B-X
mixtures	B-X
of	B-X
N-	B-X
and	B-X
O-glycans	B-X
can	B-X
complement	B-X
HPLC	B-X
profiling	B-X
methods	B-X
for	B-X
elucidating	B-X
structural	B-X
details	B-X
.	B-X
Working	B-X
toward	B-X
obtaining	B-X
such	B-X
glycan	B-X
mixtures	B-X
from	B-X
mouse	B-X
tissues	B-X
,	B-X
we	B-X
decided	B-X
to	B-X
develop	B-X
an	B-X
approach	B-X
to	B-X
isolate	B-X
not	B-X
only	B-X
N-	B-X
and	B-X
O-glycans	B-X
,	B-X
but	B-X
also	B-X
to	B-X
separate	B-X
out	B-X
glycosphingolipids	B-X
,	B-X
glycosaminoglycans	B-X
and	B-X
glycosylphosphatidylinositol	B-X
anchors	B-X
.	B-X
Using	B-X
radiolabeled	B-X
internal	B-X
tracers	B-X
,	B-X
we	B-X
show	B-X
that	B-X
recovery	B-X
of	B-X
each	B-X
major	B-X
class	B-X
of	B-X
glycans	B-X
is	B-X
as	B-X
good	B-X
or	B-X
better	B-X
than	B-X
with	B-X
conventional	B-X
approaches	B-X
for	B-X
isolating	B-X
individual	B-X
classes	B-X
,	B-X
and	B-X
that	B-X
cross-contamination	B-X
is	B-X
minimal	B-X
.	B-X
The	B-X
recovered	B-X
glycans	B-X
are	B-X
of	B-X
sufficient	B-X
purity	B-X
to	B-X
provide	B-X
a	B-X
``	B-X
glycoprofile	B-X
''	B-X
of	B-X
a	B-X
cell	B-X
type	B-X
or	B-X
tissue	B-X
.	B-X
We	B-X
applied	B-X
this	B-X
approach	B-X
to	B-X
compare	B-X
the	B-X
N-	B-X
and	B-X
O-glycans	B-X
from	B-X
wild	B-X
type	B-X
mouse	B-X
tissues	B-X
with	B-X
those	B-X
from	B-X
mice	B-X
genetically	B-X
deficient	B-X
in	B-X
glycosyltransferases	B-X
.	B-X
Similar	B-X
studies	B-X
indicate	B-X
that	B-X
this	B-X
linkage	B-X
is	B-X
very	B-X
rare	B-X
in	B-X
ganglioside	B-X
glycans	B-X
,	B-X
even	B-X
in	B-X
wild-type	B-X
tissues	B-X
.	B-X
In	B-X
mice	B-X
deficient	B-X
in	B-X
GalNAcT-8	B-X
(	B-X
UDP-GalNAc	B-X
:	B-X
polypeptide	B-X
O-Ser/Thr	B-X
GalNAc	B-X
transferase	B-X
8	B-X
)	B-X
,	B-X
HPLC	B-X
profiling	B-X
indicates	B-X
that	B-X
O-glycans	B-X
persist	B-X
in	B-X
the	B-X
thymus	B-X
in	B-X
large	B-X
amounts	B-X
,	B-X
without	B-X
a	B-X
major	B-X
change	B-X
in	B-X
overall	B-X
profile	B-X
,	B-X
suggesting	B-X
that	B-X
other	B-X
enzymes	B-X
can	B-X
synthesize	B-X
the	B-X
GalNAc-O-Ser/Thr	B-X
linkage	B-X
in	B-X
this	B-X
tissue	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
the	B-X
applicability	B-X
of	B-X
nano-NMR	B-X
spectroscopy	B-X
to	B-X
complex	B-X
glycan	B-X
mixtures	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
versatility	B-X
of	B-X
the	B-X
Glycan	B-X
Isolation	B-X
Protocol	B-X
,	B-X
which	B-X
makes	B-X
possible	B-X
the	B-X
concurrent	B-X
examination	B-X
of	B-X
multiple	B-X
glycan	B-X
classes	B-X
from	B-X
intact	B-X
vertebrate	B-X
tissues	B-X
.	B-X

In	O
mice	O
deficient	O
in	O
GalNAcT	B-Protein
-	I-Protein
8	I-Protein
(	O
UDP	B-Protein
-	I-Protein
GalNAc	I-Protein
:	I-Protein
polypeptide	I-Protein
O	I-Protein
-	I-Protein
Ser	I-Protein
/	I-Protein
Thr	I-Protein
GalNAc	I-Protein
transferase	I-Protein
8	I-Protein
)	O
,	O
HPLC	O
profiling	O
indicates	O
that	O
O	O
-	O
glycans	O
persist	O
in	O
the	O
thymus	O
in	O
large	O
amounts	O
,	O
without	O
a	O
major	O
change	O
in	O
overall	O
profile	O
,	O
suggesting	O
that	O
other	O
enzymes	O
can	O
synthesize	O
the	O
GalNAc	O
-	O
O	O
-	O
Ser	O
/	O
Thr	O
linkage	O
in	O
this	O
tissue	O
.	O

These	O
results	O
demonstrate	O
the	O
applicability	O
of	O
nano	O
-	O
NMR	O
spectroscopy	O
to	O
complex	O
glycan	O
mixtures	O
,	O
as	O
well	O
as	O
the	O
versatility	O
of	O
the	O
Glycan	O
Isolation	O
Protocol	O
,	O
which	O
makes	O
possible	O
the	O
concurrent	O
examination	O
of	O
multiple	O
glycan	O
classes	O
from	O
intact	O
vertebrate	O
tissues	O
.	O
<EOS>	B-X
The	B-X
production	B-X
of	B-X
mice	B-X
with	B-X
genetic	B-X
alterations	B-X
in	B-X
glycosyltransferases	B-X
has	B-X
highlighted	B-X
the	B-X
need	B-X
to	B-X
isolate	B-X
and	B-X
study	B-X
complex	B-X
mixtures	B-X
of	B-X
the	B-X
major	B-X
classes	B-X
of	B-X
oligosaccharides	B-X
(	B-X
glycans	B-X
)	B-X
from	B-X
intact	B-X
tissues	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
nano-NMR	B-X
spectroscopy	B-X
of	B-X
whole	B-X
mixtures	B-X
of	B-X
N-	B-X
and	B-X
O-glycans	B-X
can	B-X
complement	B-X
HPLC	B-X
profiling	B-X
methods	B-X
for	B-X
elucidating	B-X
structural	B-X
details	B-X
.	B-X
Working	B-X
toward	B-X
obtaining	B-X
such	B-X
glycan	B-X
mixtures	B-X
from	B-X
mouse	B-X
tissues	B-X
,	B-X
we	B-X
decided	B-X
to	B-X
develop	B-X
an	B-X
approach	B-X
to	B-X
isolate	B-X
not	B-X
only	B-X
N-	B-X
and	B-X
O-glycans	B-X
,	B-X
but	B-X
also	B-X
to	B-X
separate	B-X
out	B-X
glycosphingolipids	B-X
,	B-X
glycosaminoglycans	B-X
and	B-X
glycosylphosphatidylinositol	B-X
anchors	B-X
.	B-X
We	B-X
describe	B-X
here	B-X
a	B-X
comprehensive	B-X
Glycan	B-X
Isolation	B-X
Protocol	B-X
that	B-X
is	B-X
based	B-X
primarily	B-X
upon	B-X
the	B-X
physicochemical	B-X
characteristics	B-X
of	B-X
the	B-X
molecules	B-X
,	B-X
and	B-X
requires	B-X
only	B-X
commonly	B-X
available	B-X
reagents	B-X
and	B-X
equipment	B-X
.	B-X
Using	B-X
radiolabeled	B-X
internal	B-X
tracers	B-X
,	B-X
we	B-X
show	B-X
that	B-X
recovery	B-X
of	B-X
each	B-X
major	B-X
class	B-X
of	B-X
glycans	B-X
is	B-X
as	B-X
good	B-X
or	B-X
better	B-X
than	B-X
with	B-X
conventional	B-X
approaches	B-X
for	B-X
isolating	B-X
individual	B-X
classes	B-X
,	B-X
and	B-X
that	B-X
cross-contamination	B-X
is	B-X
minimal	B-X
.	B-X
The	B-X
recovered	B-X
glycans	B-X
are	B-X
of	B-X
sufficient	B-X
purity	B-X
to	B-X
provide	B-X
a	B-X
``	B-X
glycoprofile	B-X
''	B-X
of	B-X
a	B-X
cell	B-X
type	B-X
or	B-X
tissue	B-X
.	B-X
We	B-X
applied	B-X
this	B-X
approach	B-X
to	B-X
compare	B-X
the	B-X
N-	B-X
and	B-X
O-glycans	B-X
from	B-X
wild	B-X
type	B-X
mouse	B-X
tissues	B-X
with	B-X
those	B-X
from	B-X
mice	B-X
genetically	B-X
deficient	B-X
in	B-X
glycosyltransferases	B-X
.	B-X
N-	B-X
and	B-X
O-glycan	B-X
mixtures	B-X
from	B-X
organs	B-X
of	B-X
mice	B-X
deficient	B-X
in	B-X
ST6Gal-I	B-X
(	B-X
CMP-Sia	B-X
:	B-X
Galbeta1-4GlcNAc	B-X
alpha2-6	B-X
sialyltransferase	B-X
)	B-X
were	B-X
studied	B-X
by	B-X
the	B-X
nano-NMR	B-X
spectroscopy	B-X
approach	B-X
,	B-X
showing	B-X
no	B-X
detectable	B-X
alpha2-6-linked	B-X
sialic	B-X
acids	B-X
.	B-X
Similar	B-X
studies	B-X
indicate	B-X
that	B-X
this	B-X
linkage	B-X
is	B-X
very	B-X
rare	B-X
in	B-X
ganglioside	B-X
glycans	B-X
,	B-X
even	B-X
in	B-X
wild-type	B-X
tissues	B-X
.	B-X
In	B-X
mice	B-X
deficient	B-X
in	B-X
GalNAcT-8	B-X
(	B-X
UDP-GalNAc	B-X
:	B-X
polypeptide	B-X
O-Ser/Thr	B-X
GalNAc	B-X
transferase	B-X
8	B-X
)	B-X
,	B-X
HPLC	B-X
profiling	B-X
indicates	B-X
that	B-X
O-glycans	B-X
persist	B-X
in	B-X
the	B-X
thymus	B-X
in	B-X
large	B-X
amounts	B-X
,	B-X
without	B-X
a	B-X
major	B-X
change	B-X
in	B-X
overall	B-X
profile	B-X
,	B-X
suggesting	B-X
that	B-X
other	B-X
enzymes	B-X
can	B-X
synthesize	B-X
the	B-X
GalNAc-O-Ser/Thr	B-X
linkage	B-X
in	B-X
this	B-X
tissue	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
the	B-X
applicability	B-X
of	B-X
nano-NMR	B-X
spectroscopy	B-X
to	B-X
complex	B-X
glycan	B-X
mixtures	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
versatility	B-X
of	B-X
the	B-X
Glycan	B-X
Isolation	B-X
Protocol	B-X
,	B-X
which	B-X
makes	B-X
possible	B-X
the	B-X
concurrent	B-X
examination	B-X
of	B-X
multiple	B-X
glycan	B-X
classes	B-X
from	B-X
intact	B-X
vertebrate	B-X
tissues	B-X
.	B-X

Protein	O
N	O
-	O
arginine	O
methylation	O
in	O
subcellular	O
fractions	O
of	O
lymphoblastoid	O
cells	O
.	O
<EOS>	B-X
Arginine	B-X
methylation	B-X
in	B-X
RNA-binding	B-X
proteins	B-X
containing	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
RGG	B-X
motifs	B-X
is	B-X
catalyzed	B-X
by	B-X
specific	B-X
protein	B-X
arginine	B-X
N-methyltransferase	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
fractionated	B-X
the	B-X
lymphoblastoid	B-X
cells	B-X
to	B-X
locate	B-X
the	B-X
methyltransferases	B-X
and	B-X
the	B-X
substrates	B-X
in	B-X
cells	B-X
.	B-X
Different	B-X
sets	B-X
of	B-X
hypomethylated	B-X
methyl-accepting	B-X
polypeptides	B-X
with	B-X
wide	B-X
range	B-X
of	B-X
molecular	B-X
masses	B-X
were	B-X
present	B-X
in	B-X
cytosolic	B-X
,	B-X
ribosomal	B-X
,	B-X
and	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
methylated	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
methyl-accepting	B-X
proteins	B-X
in	B-X
these	B-X
fractions	B-X
were	B-X
determined	B-X
.	B-X
In	B-X
all	B-X
three	B-X
fractions	B-X
,	B-X
dimethylarginine	B-X
was	B-X
the	B-X
most	B-X
abundant	B-X
methylated	B-X
amino	B-X
acid	B-X
.	B-X
The	B-X
protein-arginine	B-X
methyltransferase	B-X
activities	B-X
in	B-X
the	B-X
three	B-X
fractions	B-X
were	B-X
analyzed	B-X
using	B-X
recombinant	B-X
fibrillarin	B-X
(	B-X
a	B-X
nucleolar	B-X
RGG	B-X
protein	B-X
)	B-X
as	B-X
the	B-X
methyl-accepting	B-X
substrate	B-X
.	B-X
Fibrillarin	B-X
methylation	B-X
was	B-X
strongest	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
ribosomal	B-X
and	B-X
then	B-X
the	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

Arginine	O
methylation	O
in	O
RNA	O
-	O
binding	O
proteins	O
containing	O
arginine	O
-	O
and	O
glycine	O
-	O
rich	O
RGG	O
motifs	O
is	O
catalyzed	O
by	O
specific	O
protein	O
arginine	O
N	O
-	O
methyltransferase	O
in	O
cells	O
.	O
<EOS>	B-X
Arginine	B-X
methylation	B-X
in	B-X
RNA-binding	B-X
proteins	B-X
containing	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
RGG	B-X
motifs	B-X
is	B-X
catalyzed	B-X
by	B-X
specific	B-X
protein	B-X
arginine	B-X
N-methyltransferase	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
fractionated	B-X
the	B-X
lymphoblastoid	B-X
cells	B-X
to	B-X
locate	B-X
the	B-X
methyltransferases	B-X
and	B-X
the	B-X
substrates	B-X
in	B-X
cells	B-X
.	B-X
The	B-X
methylated	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
methyl-accepting	B-X
proteins	B-X
in	B-X
these	B-X
fractions	B-X
were	B-X
determined	B-X
.	B-X
In	B-X
all	B-X
three	B-X
fractions	B-X
,	B-X
dimethylarginine	B-X
was	B-X
the	B-X
most	B-X
abundant	B-X
methylated	B-X
amino	B-X
acid	B-X
.	B-X
The	B-X
protein-arginine	B-X
methyltransferase	B-X
activities	B-X
in	B-X
the	B-X
three	B-X
fractions	B-X
were	B-X
analyzed	B-X
using	B-X
recombinant	B-X
fibrillarin	B-X
(	B-X
a	B-X
nucleolar	B-X
RGG	B-X
protein	B-X
)	B-X
as	B-X
the	B-X
methyl-accepting	B-X
substrate	B-X
.	B-X
Fibrillarin	B-X
methylation	B-X
was	B-X
strongest	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
ribosomal	B-X
and	B-X
then	B-X
the	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

We	O
previously	O
showed	O
that	O
lymphoblastoid	O
cells	O
grown	O
in	O
the	O
presence	O
of	O
an	O
indirect	O
methyltransferase	O
inhibitor	O
,	O
adenosine	O
dialdehyde	O
(	O
AdOx	O
)	O
,	O
accumulated	O
high	O
level	O
of	O
hypomethylated	O
protein	O
substrates	O
for	O
the	O
endogenous	O
protein	O
methyltransferases	O
or	O
recombinant	O
yeast	O
arginine	O
methyltransferase	O
[	O
Li	O
,	O
C	O
.	O
et	O
al	O
.	O
(	O
1998	O
)	O
Arch	O
.	O
Biochem	O
.	O
Biophys	O
.	O
351	O
,	O
53	O
-	O
59	O
]	O
.	O
<EOS>	B-X
Arginine	B-X
methylation	B-X
in	B-X
RNA-binding	B-X
proteins	B-X
containing	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
RGG	B-X
motifs	B-X
is	B-X
catalyzed	B-X
by	B-X
specific	B-X
protein	B-X
arginine	B-X
N-methyltransferase	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
(	B-X
1998	B-X
)	B-X
Arch	B-X
.	B-X
Biochem	B-X
.	B-X
Biophys	B-X
.	B-X
351	B-X
,	B-X
53-59	B-X
]	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
fractionated	B-X
the	B-X
lymphoblastoid	B-X
cells	B-X
to	B-X
locate	B-X
the	B-X
methyltransferases	B-X
and	B-X
the	B-X
substrates	B-X
in	B-X
cells	B-X
.	B-X
Different	B-X
sets	B-X
of	B-X
hypomethylated	B-X
methyl-accepting	B-X
polypeptides	B-X
with	B-X
wide	B-X
range	B-X
of	B-X
molecular	B-X
masses	B-X
were	B-X
present	B-X
in	B-X
cytosolic	B-X
,	B-X
ribosomal	B-X
,	B-X
and	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
methylated	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
methyl-accepting	B-X
proteins	B-X
in	B-X
these	B-X
fractions	B-X
were	B-X
determined	B-X
.	B-X
In	B-X
all	B-X
three	B-X
fractions	B-X
,	B-X
dimethylarginine	B-X
was	B-X
the	B-X
most	B-X
abundant	B-X
methylated	B-X
amino	B-X
acid	B-X
.	B-X
The	B-X
protein-arginine	B-X
methyltransferase	B-X
activities	B-X
in	B-X
the	B-X
three	B-X
fractions	B-X
were	B-X
analyzed	B-X
using	B-X
recombinant	B-X
fibrillarin	B-X
(	B-X
a	B-X
nucleolar	B-X
RGG	B-X
protein	B-X
)	B-X
as	B-X
the	B-X
methyl-accepting	B-X
substrate	B-X
.	B-X
Fibrillarin	B-X
methylation	B-X
was	B-X
strongest	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
ribosomal	B-X
and	B-X
then	B-X
the	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

In	O
this	O
study	O
we	O
fractionated	O
the	O
lymphoblastoid	O
cells	O
to	O
locate	O
the	O
methyltransferases	O
and	O
the	O
substrates	O
in	O
cells	O
.	O
<EOS>	B-X
Arginine	B-X
methylation	B-X
in	B-X
RNA-binding	B-X
proteins	B-X
containing	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
RGG	B-X
motifs	B-X
is	B-X
catalyzed	B-X
by	B-X
specific	B-X
protein	B-X
arginine	B-X
N-methyltransferase	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
fractionated	B-X
the	B-X
lymphoblastoid	B-X
cells	B-X
to	B-X
locate	B-X
the	B-X
methyltransferases	B-X
and	B-X
the	B-X
substrates	B-X
in	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

Different	O
sets	O
of	O
hypomethylated	O
methyl	O
-	O
accepting	O
polypeptides	O
with	O
wide	O
range	O
of	O
molecular	O
masses	O
were	O
present	O
in	O
cytosolic	O
,	O
ribosomal	O
,	O
and	O
nucleus	O
fractions	O
.	O
<EOS>	B-X
Arginine	B-X
methylation	B-X
in	B-X
RNA-binding	B-X
proteins	B-X
containing	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
RGG	B-X
motifs	B-X
is	B-X
catalyzed	B-X
by	B-X
specific	B-X
protein	B-X
arginine	B-X
N-methyltransferase	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
fractionated	B-X
the	B-X
lymphoblastoid	B-X
cells	B-X
to	B-X
locate	B-X
the	B-X
methyltransferases	B-X
and	B-X
the	B-X
substrates	B-X
in	B-X
cells	B-X
.	B-X
Different	B-X
sets	B-X
of	B-X
hypomethylated	B-X
methyl-accepting	B-X
polypeptides	B-X
with	B-X
wide	B-X
range	B-X
of	B-X
molecular	B-X
masses	B-X
were	B-X
present	B-X
in	B-X
cytosolic	B-X
,	B-X
ribosomal	B-X
,	B-X
and	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
methylated	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
methyl-accepting	B-X
proteins	B-X
in	B-X
these	B-X
fractions	B-X
were	B-X
determined	B-X
.	B-X
In	B-X
all	B-X
three	B-X
fractions	B-X
,	B-X
dimethylarginine	B-X
was	B-X
the	B-X
most	B-X
abundant	B-X
methylated	B-X
amino	B-X
acid	B-X
.	B-X
The	B-X
protein-arginine	B-X
methyltransferase	B-X
activities	B-X
in	B-X
the	B-X
three	B-X
fractions	B-X
were	B-X
analyzed	B-X
using	B-X
recombinant	B-X
fibrillarin	B-X
(	B-X
a	B-X
nucleolar	B-X
RGG	B-X
protein	B-X
)	B-X
as	B-X
the	B-X
methyl-accepting	B-X
substrate	B-X
.	B-X
Fibrillarin	B-X
methylation	B-X
was	B-X
strongest	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
ribosomal	B-X
and	B-X
then	B-X
the	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

The	O
methylated	O
amino	O
acid	O
residues	O
of	O
the	O
methyl	O
-	O
accepting	O
proteins	O
in	O
these	O
fractions	O
were	O
determined	O
.	O
<EOS>	B-X
Arginine	B-X
methylation	B-X
in	B-X
RNA-binding	B-X
proteins	B-X
containing	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
RGG	B-X
motifs	B-X
is	B-X
catalyzed	B-X
by	B-X
specific	B-X
protein	B-X
arginine	B-X
N-methyltransferase	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
fractionated	B-X
the	B-X
lymphoblastoid	B-X
cells	B-X
to	B-X
locate	B-X
the	B-X
methyltransferases	B-X
and	B-X
the	B-X
substrates	B-X
in	B-X
cells	B-X
.	B-X
Different	B-X
sets	B-X
of	B-X
hypomethylated	B-X
methyl-accepting	B-X
polypeptides	B-X
with	B-X
wide	B-X
range	B-X
of	B-X
molecular	B-X
masses	B-X
were	B-X
present	B-X
in	B-X
cytosolic	B-X
,	B-X
ribosomal	B-X
,	B-X
and	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
methylated	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
methyl-accepting	B-X
proteins	B-X
in	B-X
these	B-X
fractions	B-X
were	B-X
determined	B-X
.	B-X
In	B-X
all	B-X
three	B-X
fractions	B-X
,	B-X
dimethylarginine	B-X
was	B-X
the	B-X
most	B-X
abundant	B-X
methylated	B-X
amino	B-X
acid	B-X
.	B-X
The	B-X
protein-arginine	B-X
methyltransferase	B-X
activities	B-X
in	B-X
the	B-X
three	B-X
fractions	B-X
were	B-X
analyzed	B-X
using	B-X
recombinant	B-X
fibrillarin	B-X
(	B-X
a	B-X
nucleolar	B-X
RGG	B-X
protein	B-X
)	B-X
as	B-X
the	B-X
methyl-accepting	B-X
substrate	B-X
.	B-X
Fibrillarin	B-X
methylation	B-X
was	B-X
strongest	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
ribosomal	B-X
and	B-X
then	B-X
the	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

In	O
all	O
three	O
fractions	O
,	O
dimethylarginine	O
was	O
the	O
most	O
abundant	O
methylated	O
amino	O
acid	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
Different	B-X
sets	B-X
of	B-X
hypomethylated	B-X
methyl-accepting	B-X
polypeptides	B-X
with	B-X
wide	B-X
range	B-X
of	B-X
molecular	B-X
masses	B-X
were	B-X
present	B-X
in	B-X
cytosolic	B-X
,	B-X
ribosomal	B-X
,	B-X
and	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
methylated	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
methyl-accepting	B-X
proteins	B-X
in	B-X
these	B-X
fractions	B-X
were	B-X
determined	B-X
.	B-X
In	B-X
all	B-X
three	B-X
fractions	B-X
,	B-X
dimethylarginine	B-X
was	B-X
the	B-X
most	B-X
abundant	B-X
methylated	B-X
amino	B-X
acid	B-X
.	B-X
The	B-X
protein-arginine	B-X
methyltransferase	B-X
activities	B-X
in	B-X
the	B-X
three	B-X
fractions	B-X
were	B-X
analyzed	B-X
using	B-X
recombinant	B-X
fibrillarin	B-X
(	B-X
a	B-X
nucleolar	B-X
RGG	B-X
protein	B-X
)	B-X
as	B-X
the	B-X
methyl-accepting	B-X
substrate	B-X
.	B-X
Fibrillarin	B-X
methylation	B-X
was	B-X
strongest	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
ribosomal	B-X
and	B-X
then	B-X
the	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

The	O
protein	O
-	O
arginine	O
methyltransferase	O
activities	O
in	O
the	O
three	O
fractions	O
were	O
analyzed	O
using	O
recombinant	O
fibrillarin	B-Protein
(	O
a	O
nucleolar	O
RGG	O
protein	O
)	O
as	O
the	O
methyl	O
-	O
accepting	O
substrate	O
.	O
<EOS>	B-X
Arginine	B-X
methylation	B-X
in	B-X
RNA-binding	B-X
proteins	B-X
containing	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
RGG	B-X
motifs	B-X
is	B-X
catalyzed	B-X
by	B-X
specific	B-X
protein	B-X
arginine	B-X
N-methyltransferase	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
fractionated	B-X
the	B-X
lymphoblastoid	B-X
cells	B-X
to	B-X
locate	B-X
the	B-X
methyltransferases	B-X
and	B-X
the	B-X
substrates	B-X
in	B-X
cells	B-X
.	B-X
Different	B-X
sets	B-X
of	B-X
hypomethylated	B-X
methyl-accepting	B-X
polypeptides	B-X
with	B-X
wide	B-X
range	B-X
of	B-X
molecular	B-X
masses	B-X
were	B-X
present	B-X
in	B-X
cytosolic	B-X
,	B-X
ribosomal	B-X
,	B-X
and	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
methylated	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
methyl-accepting	B-X
proteins	B-X
in	B-X
these	B-X
fractions	B-X
were	B-X
determined	B-X
.	B-X
In	B-X
all	B-X
three	B-X
fractions	B-X
,	B-X
dimethylarginine	B-X
was	B-X
the	B-X
most	B-X
abundant	B-X
methylated	B-X
amino	B-X
acid	B-X
.	B-X
The	B-X
protein-arginine	B-X
methyltransferase	B-X
activities	B-X
in	B-X
the	B-X
three	B-X
fractions	B-X
were	B-X
analyzed	B-X
using	B-X
recombinant	B-X
fibrillarin	B-X
(	B-X
a	B-X
nucleolar	B-X
RGG	B-X
protein	B-X
)	B-X
as	B-X
the	B-X
methyl-accepting	B-X
substrate	B-X
.	B-X
Fibrillarin	B-X
methylation	B-X
was	B-X
strongest	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
ribosomal	B-X
and	B-X
then	B-X
the	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

Fibrillarin	B-Protein
methylation	O
was	O
strongest	O
in	O
the	O
presence	O
of	O
the	O
cytosolic	O
fraction	O
,	O
followed	O
by	O
the	O
ribosomal	O
and	O
then	O
the	O
nucleus	O
fractions	O
.	O
<EOS>	B-X
Arginine	B-X
methylation	B-X
in	B-X
RNA-binding	B-X
proteins	B-X
containing	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
RGG	B-X
motifs	B-X
is	B-X
catalyzed	B-X
by	B-X
specific	B-X
protein	B-X
arginine	B-X
N-methyltransferase	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
fractionated	B-X
the	B-X
lymphoblastoid	B-X
cells	B-X
to	B-X
locate	B-X
the	B-X
methyltransferases	B-X
and	B-X
the	B-X
substrates	B-X
in	B-X
cells	B-X
.	B-X
Different	B-X
sets	B-X
of	B-X
hypomethylated	B-X
methyl-accepting	B-X
polypeptides	B-X
with	B-X
wide	B-X
range	B-X
of	B-X
molecular	B-X
masses	B-X
were	B-X
present	B-X
in	B-X
cytosolic	B-X
,	B-X
ribosomal	B-X
,	B-X
and	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
methylated	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
methyl-accepting	B-X
proteins	B-X
in	B-X
these	B-X
fractions	B-X
were	B-X
determined	B-X
.	B-X
In	B-X
all	B-X
three	B-X
fractions	B-X
,	B-X
dimethylarginine	B-X
was	B-X
the	B-X
most	B-X
abundant	B-X
methylated	B-X
amino	B-X
acid	B-X
.	B-X
The	B-X
protein-arginine	B-X
methyltransferase	B-X
activities	B-X
in	B-X
the	B-X
three	B-X
fractions	B-X
were	B-X
analyzed	B-X
using	B-X
recombinant	B-X
fibrillarin	B-X
(	B-X
a	B-X
nucleolar	B-X
RGG	B-X
protein	B-X
)	B-X
as	B-X
the	B-X
methyl-accepting	B-X
substrate	B-X
.	B-X
Fibrillarin	B-X
methylation	B-X
was	B-X
strongest	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
ribosomal	B-X
and	B-X
then	B-X
the	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

The	O
results	O
demonstrated	O
that	O
protein	O
-	O
arginine	O
methyltransferases	O
as	O
well	O
as	O
their	O
methyl	O
-	O
accepting	O
substrates	O
were	O
widely	O
distributed	O
in	O
different	O
subcellular	O
fractions	O
of	O
lymphoblastoid	O
cells	O
.	O
<EOS>	B-X
Arginine	B-X
methylation	B-X
in	B-X
RNA-binding	B-X
proteins	B-X
containing	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
RGG	B-X
motifs	B-X
is	B-X
catalyzed	B-X
by	B-X
specific	B-X
protein	B-X
arginine	B-X
N-methyltransferase	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
lymphoblastoid	B-X
cells	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
indirect	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
adenosine	B-X
dialdehyde	B-X
(	B-X
AdOx	B-X
)	B-X
,	B-X
accumulated	B-X
high	B-X
level	B-X
of	B-X
hypomethylated	B-X
protein	B-X
substrates	B-X
for	B-X
the	B-X
endogenous	B-X
protein	B-X
methyltransferases	B-X
or	B-X
recombinant	B-X
yeast	B-X
arginine	B-X
methyltransferase	B-X
[	B-X
Li	B-X
,	B-X
C.	B-X
et	B-X
al	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
fractionated	B-X
the	B-X
lymphoblastoid	B-X
cells	B-X
to	B-X
locate	B-X
the	B-X
methyltransferases	B-X
and	B-X
the	B-X
substrates	B-X
in	B-X
cells	B-X
.	B-X
Different	B-X
sets	B-X
of	B-X
hypomethylated	B-X
methyl-accepting	B-X
polypeptides	B-X
with	B-X
wide	B-X
range	B-X
of	B-X
molecular	B-X
masses	B-X
were	B-X
present	B-X
in	B-X
cytosolic	B-X
,	B-X
ribosomal	B-X
,	B-X
and	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
methylated	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
methyl-accepting	B-X
proteins	B-X
in	B-X
these	B-X
fractions	B-X
were	B-X
determined	B-X
.	B-X
In	B-X
all	B-X
three	B-X
fractions	B-X
,	B-X
dimethylarginine	B-X
was	B-X
the	B-X
most	B-X
abundant	B-X
methylated	B-X
amino	B-X
acid	B-X
.	B-X
The	B-X
protein-arginine	B-X
methyltransferase	B-X
activities	B-X
in	B-X
the	B-X
three	B-X
fractions	B-X
were	B-X
analyzed	B-X
using	B-X
recombinant	B-X
fibrillarin	B-X
(	B-X
a	B-X
nucleolar	B-X
RGG	B-X
protein	B-X
)	B-X
as	B-X
the	B-X
methyl-accepting	B-X
substrate	B-X
.	B-X
Fibrillarin	B-X
methylation	B-X
was	B-X
strongest	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
ribosomal	B-X
and	B-X
then	B-X
the	B-X
nucleus	B-X
fractions	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
protein-arginine	B-X
methyltransferases	B-X
as	B-X
well	B-X
as	B-X
their	B-X
methyl-accepting	B-X
substrates	B-X
were	B-X
widely	B-X
distributed	B-X
in	B-X
different	B-X
subcellular	B-X
fractions	B-X
of	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X

Dynamic	O
associations	O
of	O
heterochromatin	O
protein	O
1	O
with	O
the	O
nuclear	O
envelope	O
.	O
<EOS>	B-X
To	B-X
study	B-X
the	B-X
dynamics	B-X
of	B-X
mammalian	B-X
HP1	B-X
proteins	B-X
we	B-X
have	B-X
microinjected	B-X
recombinant	B-X
forms	B-X
of	B-X
mHP1alpha	B-X
,	B-X
M31	B-X
and	B-X
M32	B-X
into	B-X
the	B-X
cytoplasm	B-X
of	B-X
living	B-X
cells	B-X
.	B-X
As	B-X
could	B-X
be	B-X
expected	B-X
from	B-X
previous	B-X
studies	B-X
,	B-X
the	B-X
three	B-X
fusion	B-X
proteins	B-X
were	B-X
efficiently	B-X
transported	B-X
into	B-X
the	B-X
nucleus	B-X
and	B-X
targeted	B-X
specific	B-X
chromatin	B-X
areas	B-X
.	B-X
However	B-X
,	B-X
before	B-X
incorporation	B-X
into	B-X
these	B-X
areas	B-X
the	B-X
exogenous	B-X
proteins	B-X
accumulated	B-X
in	B-X
a	B-X
peripheral	B-X
zone	B-X
and	B-X
associated	B-X
closely	B-X
with	B-X
the	B-X
nuclear	B-X
envelope	B-X
.	B-X
In	B-X
line	B-X
with	B-X
these	B-X
observations	B-X
,	B-X
recombinant	B-X
HP1	B-X
proteins	B-X
exhibited	B-X
saturable	B-X
binding	B-X
to	B-X
purified	B-X
nuclear	B-X
envelopes	B-X
and	B-X
stained	B-X
the	B-X
nuclei	B-X
of	B-X
detergent-permeabilized	B-X
cells	B-X
in	B-X
a	B-X
rim-like	B-X
fashion	B-X
.	B-X
Competition	B-X
experiments	B-X
with	B-X
various	B-X
M31	B-X
mutants	B-X
allowed	B-X
mapping	B-X
of	B-X
the	B-X
nuclear	B-X
envelope-binding	B-X
site	B-X
within	B-X
an	B-X
N-terminal	B-X
region	B-X
that	B-X
includes	B-X
the	B-X
chromodomain	B-X
.	B-X
A	B-X
His	B-X
(	B-X
6	B-X
)	B-X
-tagged	B-X
peptide	B-X
representing	B-X
this	B-X
region	B-X
inhibited	B-X
recruitment	B-X
of	B-X
LAP2beta	B-X
and	B-X
B-type	B-X
lamins	B-X
around	B-X
the	B-X
surfaces	B-X
of	B-X
condensed	B-X
chromosomes	B-X
,	B-X
suggesting	B-X
involvement	B-X
of	B-X
HP1	B-X
proteins	B-X
in	B-X
nuclear	B-X
envelope	B-X
reassembly	B-X
.	B-X

To	O
study	O
the	O
dynamics	O
of	O
mammalian	O
HP1	O
proteins	O
we	O
have	O
microinjected	O
recombinant	O
forms	O
of	O
mHP1alpha	B-Protein
,	O
M31	B-Protein
and	O
M32	B-Protein
into	O
the	O
cytoplasm	O
of	O
living	O
cells	O
.	O

As	O
could	O
be	O
expected	O
from	O
previous	O
studies	O
,	O
the	O
three	O
fusion	O
proteins	O
were	O
efficiently	O
transported	O
into	O
the	O
nucleus	O
and	O
targeted	O
specific	O
chromatin	O
areas	O
.	O
<EOS>	B-X
To	B-X
study	B-X
the	B-X
dynamics	B-X
of	B-X
mammalian	B-X
HP1	B-X
proteins	B-X
we	B-X
have	B-X
microinjected	B-X
recombinant	B-X
forms	B-X
of	B-X
mHP1alpha	B-X
,	B-X
M31	B-X
and	B-X
M32	B-X
into	B-X
the	B-X
cytoplasm	B-X
of	B-X
living	B-X
cells	B-X
.	B-X
As	B-X
could	B-X
be	B-X
expected	B-X
from	B-X
previous	B-X
studies	B-X
,	B-X
the	B-X
three	B-X
fusion	B-X
proteins	B-X
were	B-X
efficiently	B-X
transported	B-X
into	B-X
the	B-X
nucleus	B-X
and	B-X
targeted	B-X
specific	B-X
chromatin	B-X
areas	B-X
.	B-X
However	B-X
,	B-X
before	B-X
incorporation	B-X
into	B-X
these	B-X
areas	B-X
the	B-X
exogenous	B-X
proteins	B-X
accumulated	B-X
in	B-X
a	B-X
peripheral	B-X
zone	B-X
and	B-X
associated	B-X
closely	B-X
with	B-X
the	B-X
nuclear	B-X
envelope	B-X
.	B-X
In	B-X
line	B-X
with	B-X
these	B-X
observations	B-X
,	B-X
recombinant	B-X
HP1	B-X
proteins	B-X
exhibited	B-X
saturable	B-X
binding	B-X
to	B-X
purified	B-X
nuclear	B-X
envelopes	B-X
and	B-X
stained	B-X
the	B-X
nuclei	B-X
of	B-X
detergent-permeabilized	B-X
cells	B-X
in	B-X
a	B-X
rim-like	B-X
fashion	B-X
.	B-X
A	B-X
His	B-X
(	B-X
6	B-X
)	B-X
-tagged	B-X
peptide	B-X
representing	B-X
this	B-X
region	B-X
inhibited	B-X
recruitment	B-X
of	B-X
LAP2beta	B-X
and	B-X
B-type	B-X
lamins	B-X
around	B-X
the	B-X
surfaces	B-X
of	B-X
condensed	B-X
chromosomes	B-X
,	B-X
suggesting	B-X
involvement	B-X
of	B-X
HP1	B-X
proteins	B-X
in	B-X
nuclear	B-X
envelope	B-X
reassembly	B-X
.	B-X

However	O
,	O
before	O
incorporation	O
into	O
these	O
areas	O
the	O
exogenous	O
proteins	O
accumulated	O
in	O
a	O
peripheral	O
zone	O
and	O
associated	O
closely	O
with	O
the	O
nuclear	O
envelope	O
.	O

This	O
transient	O
association	O
did	O
not	O
occur	O
when	O
the	O
cells	O
were	O
treated	O
with	O
deacetylase	O
inhibitors	O
,	O
indicating	O
an	O
acetylation	O
-	O
inhibited	O
interaction	O
.	O
<EOS>	B-X
There	B-X
is	B-X
growing	B-X
evidence	B-X
supporting	B-X
the	B-X
association	B-X
between	B-X
migration	B-X
and	B-X
posttraumatic	B-X
stress	B-X
disorder	B-X
(	B-X
PTSD	B-X
)	B-X
.	B-X
[	B-X
Not	B-X
Available	B-X
]	B-X
.	B-X
The	B-X
Médecins	B-X
du	B-X
monde	B-X
nursing	B-X
teams	B-X
,	B-X
working	B-X
with	B-X
other	B-X
volunteer	B-X
associations	B-X
,	B-X
provide	B-X
care	B-X
and	B-X
a	B-X
listening	B-X
ear	B-X
through	B-X
outreach	B-X
interventions	B-X
or	B-X
in	B-X
temporary	B-X
housing	B-X
structures	B-X
.	B-X
Recommendations	B-X
to	B-X
policymaking	B-X
and	B-X
services	B-X
and	B-X
associations	B-X
for	B-X
advancing	B-X
the	B-X
use	B-X
of	B-X
MPs	B-X
for	B-X
the	B-X
protection	B-X
of	B-X
the	B-X
rights	B-X
of	B-X
migrants	B-X
have	B-X
been	B-X
proposed	B-X
.	B-X

In	O
line	O
with	O
these	O
observations	O
,	O
recombinant	O
HP1	O
proteins	O
exhibited	O
saturable	O
binding	O
to	O
purified	O
nuclear	O
envelopes	O
and	O
stained	O
the	O
nuclei	O
of	O
detergent	O
-	O
permeabilized	O
cells	O
in	O
a	O
rim	O
-	O
like	O
fashion	O
.	O

Competition	O
experiments	O
with	O
various	O
M31	B-Protein
mutants	O
allowed	O
mapping	O
of	O
the	O
nuclear	O
envelope	O
-	O
binding	O
site	O
within	O
an	O
N	O
-	O
terminal	O
region	O
that	O
includes	O
the	O
chromodomain	O
.	O

A	O
His	O
(	O
6	O
)	O
-	O
tagged	O
peptide	O
representing	O
this	O
region	O
inhibited	O
recruitment	O
of	O
LAP2beta	B-Protein
and	O
B	O
-	O
type	O
lamins	O
around	O
the	O
surfaces	O
of	O
condensed	O
chromosomes	O
,	O
suggesting	O
involvement	O
of	O
HP1	O
proteins	O
in	O
nuclear	O
envelope	O
reassembly	O
.	O

The	O
propeptide	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
superfamily	O
member	O
,	O
macrophage	B-Protein
inhibitory	I-Protein
cytokine	I-Protein
-	I-Protein
1	I-Protein
(	O
MIC	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
is	O
a	O
multifunctional	O
domain	O
that	O
can	O
facilitate	O
protein	O
folding	O
and	O
secretion	O
.	O
<EOS>	B-X
Macrophage	B-X
inhibitory	B-X
cytokine-1	B-X
(	B-X
MIC-1	B-X
)	B-X
is	B-X
a	B-X
divergent	B-X
member	B-X
of	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
superfamily	B-X
.	B-X
While	B-X
it	B-X
is	B-X
synthesized	B-X
in	B-X
a	B-X
pre-pro	B-X
form	B-X
,	B-X
it	B-X
is	B-X
unique	B-X
among	B-X
superfamily	B-X
members	B-X
because	B-X
it	B-X
does	B-X
not	B-X
require	B-X
its	B-X
propeptide	B-X
for	B-X
correct	B-X
folding	B-X
or	B-X
secretion	B-X
of	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
To	B-X
investigate	B-X
factors	B-X
that	B-X
enable	B-X
these	B-X
propeptide	B-X
independent	B-X
events	B-X
to	B-X
occur	B-X
,	B-X
we	B-X
constructed	B-X
MIC-1/TGF-beta1	B-X
chimeras	B-X
,	B-X
both	B-X
with	B-X
and	B-X
without	B-X
a	B-X
propeptide	B-X
.	B-X
All	B-X
chimeras	B-X
without	B-X
a	B-X
propeptide	B-X
secreted	B-X
less	B-X
efficiently	B-X
compared	B-X
with	B-X
the	B-X
corresponding	B-X
constructs	B-X
with	B-X
propeptide	B-X
.	B-X
Folding	B-X
and	B-X
secretion	B-X
were	B-X
most	B-X
affected	B-X
after	B-X
replacement	B-X
of	B-X
the	B-X
predicted	B-X
major	B-X
alpha-helix	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
,	B-X
residues	B-X
56-68	B-X
.	B-X
Exchanging	B-X
the	B-X
human	B-X
propeptide	B-X
in	B-X
this	B-X
chimera	B-X
with	B-X
either	B-X
the	B-X
murine	B-X
MIC-1	B-X
or	B-X
TGF-beta1	B-X
propeptide	B-X
resulted	B-X
in	B-X
secretion	B-X
of	B-X
the	B-X
unprocessed	B-X
,	B-X
monomeric	B-X
chimera	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
interaction	B-X
between	B-X
the	B-X
human	B-X
MIC-1	B-X
propeptide	B-X
and	B-X
mature	B-X
peptide	B-X
.	B-X
Propeptide	B-X
deletion	B-X
mutants	B-X
enabled	B-X
identification	B-X
of	B-X
a	B-X
region	B-X
between	B-X
residues	B-X
56	B-X
and	B-X
78	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
propeptide	B-X
and	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
Cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
the	B-X
propeptide	B-X
must	B-X
be	B-X
in	B-X
cis	B-X
with	B-X
the	B-X
mature	B-X
peptide	B-X
for	B-X
this	B-X
phenomenon	B-X
to	B-X
occur	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
model	B-X
for	B-X
TGF-beta	B-X
superfamily	B-X
protein	B-X
folding	B-X
.	B-X

Macrophage	B-Protein
inhibitory	I-Protein
cytokine	I-Protein
-	I-Protein
1	I-Protein
(	O
MIC	B-Protein
-	I-Protein
1	I-Protein
)	O
is	O
a	O
divergent	O
member	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
superfamily	O
.	O
<EOS>	B-X
Growth/differentiation	B-X
factor-15	B-X
(	B-X
GDF-15	B-X
)	B-X
,	B-X
also	B-X
named	B-X
macrophage	B-X
inhibitory	B-X
cytokine-1	B-X
,	B-X
is	B-X
a	B-X
divergent	B-X
member	B-X
of	B-X
the	B-X
transforming	B-X
growth	B-X
factor	B-X
β	B-X
superfamily	B-X
.	B-X
While	B-X
physiological	B-X
expression	B-X
is	B-X
barely	B-X
detectable	B-X
in	B-X
most	B-X
somatic	B-X
tissues	B-X
in	B-X
humans	B-X
,	B-X
GDF-15	B-X
is	B-X
abundant	B-X
in	B-X
placenta	B-X
.	B-X
Elsewhere	B-X
,	B-X
GDF-15	B-X
is	B-X
often	B-X
induced	B-X
under	B-X
stress	B-X
conditions	B-X
,	B-X
seemingly	B-X
to	B-X
maintain	B-X
cell	B-X
and	B-X
tissue	B-X
homeostasis	B-X
;	B-X
however	B-X
,	B-X
a	B-X
moderate	B-X
increase	B-X
in	B-X
GDF-15	B-X
blood	B-X
levels	B-X
is	B-X
observed	B-X
with	B-X
age	B-X
.	B-X
Highly	B-X
elevated	B-X
GDF-15	B-X
levels	B-X
are	B-X
mostly	B-X
linked	B-X
to	B-X
pathological	B-X
conditions	B-X
including	B-X
inflammation	B-X
,	B-X
myocardial	B-X
ischemia	B-X
,	B-X
and	B-X
notably	B-X
cancer	B-X
.	B-X
GDF-15	B-X
has	B-X
thus	B-X
been	B-X
widely	B-X
explored	B-X
as	B-X
a	B-X
biomarker	B-X
for	B-X
disease	B-X
prognosis	B-X
.	B-X
Mechanistically	B-X
,	B-X
induction	B-X
of	B-X
anorexia	B-X
via	B-X
the	B-X
brainstem-restricted	B-X
GDF-15	B-X
receptor	B-X
GFRAL	B-X
(	B-X
glial	B-X
cell-derived	B-X
neurotrophic	B-X
factor	B-X
[	B-X
GDNF	B-X
]	B-X
family	B-X
receptor	B-X
α-like	B-X
)	B-X
is	B-X
well-documented	B-X
.	B-X
GDF-15	B-X
and	B-X
GFRAL	B-X
have	B-X
thus	B-X
become	B-X
attractive	B-X
targets	B-X
for	B-X
metabolic	B-X
intervention	B-X
.	B-X
Still	B-X
,	B-X
several	B-X
GDF-15	B-X
mediated	B-X
effects	B-X
(	B-X
including	B-X
its	B-X
physiological	B-X
role	B-X
in	B-X
pregnancy	B-X
)	B-X
are	B-X
difficult	B-X
to	B-X
explain	B-X
via	B-X
the	B-X
described	B-X
pathway	B-X
.	B-X
Hence	B-X
,	B-X
there	B-X
is	B-X
a	B-X
clear	B-X
need	B-X
to	B-X
better	B-X
understand	B-X
non-metabolic	B-X
effects	B-X
of	B-X
GDF-15	B-X
.	B-X
With	B-X
particular	B-X
emphasis	B-X
on	B-X
its	B-X
immunomodulatory	B-X
potential	B-X
this	B-X
review	B-X
discusses	B-X
the	B-X
roles	B-X
of	B-X
GDF-15	B-X
in	B-X
pregnancy	B-X
and	B-X
in	B-X
pathological	B-X
conditions	B-X
including	B-X
myocardial	B-X
infarction	B-X
,	B-X
autoimmune	B-X
disease	B-X
,	B-X
and	B-X
specifically	B-X
cancer	B-X
.	B-X
Importantly	B-X
,	B-X
the	B-X
strong	B-X
predictive	B-X
value	B-X
of	B-X
GDF-15	B-X
as	B-X
biomarker	B-X
may	B-X
plausibly	B-X
be	B-X
linked	B-X
to	B-X
its	B-X
immune-regulatory	B-X
function	B-X
.	B-X
The	B-X
described	B-X
associations	B-X
and	B-X
mechanistic	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
GDF-15	B-X
acts	B-X
as	B-X
immune	B-X
checkpoint	B-X
and	B-X
is	B-X
thus	B-X
an	B-X
emerging	B-X
target	B-X
for	B-X
cancer	B-X
immunotherapy	B-X
.	B-X

While	O
it	O
is	O
synthesized	O
in	O
a	O
pre	O
-	O
pro	O
form	O
,	O
it	O
is	O
unique	O
among	O
superfamily	O
members	O
because	O
it	O
does	O
not	O
require	O
its	O
propeptide	O
for	O
correct	O
folding	O
or	O
secretion	O
of	O
the	O
mature	O
peptide	O
.	O
<EOS>	B-X
The	B-X
natriuretic	B-X
peptide	B-X
family	B-X
consists	B-X
of	B-X
three	B-X
biologically	B-X
active	B-X
peptides	B-X
:	B-X
atrial	B-X
natriuretic	B-X
peptide	B-X
(	B-X
ANP	B-X
)	B-X
,	B-X
brain	B-X
(	B-X
or	B-X
B-type	B-X
)	B-X
natriuretic	B-X
peptide	B-X
(	B-X
BNP	B-X
)	B-X
,	B-X
and	B-X
C-type	B-X
natriuretic	B-X
peptide	B-X
(	B-X
CNP	B-X
)	B-X
.	B-X
Both	B-X
ANP	B-X
and	B-X
BNP	B-X
preferentially	B-X
bind	B-X
to	B-X
natriuretic	B-X
peptide	B-X
receptor-A	B-X
(	B-X
NPR-A	B-X
or	B-X
guanylyl	B-X
cyslase-A	B-X
)	B-X
and	B-X
exert	B-X
similar	B-X
effects	B-X
through	B-X
increases	B-X
in	B-X
intracellular	B-X
cyclic	B-X
guanosine	B-X
monophosphate	B-X
(	B-X
cGMP	B-X
)	B-X
within	B-X
target	B-X
tissues	B-X
.	B-X
Expression	B-X
and	B-X
secretion	B-X
of	B-X
ANP	B-X
and	B-X
BNP	B-X
are	B-X
stimulated	B-X
by	B-X
various	B-X
factors	B-X
and	B-X
are	B-X
regulated	B-X
via	B-X
multiple	B-X
signaling	B-X
pathways	B-X
.	B-X
Human	B-X
ANP	B-X
has	B-X
three	B-X
molecular	B-X
forms	B-X
,	B-X
α-ANP	B-X
,	B-X
β-ANP	B-X
,	B-X
and	B-X
proANP	B-X
(	B-X
or	B-X
γ-ANP	B-X
)	B-X
,	B-X
with	B-X
proANP	B-X
predominating	B-X
in	B-X
healthy	B-X
atrial	B-X
tissue	B-X
.	B-X
During	B-X
secretion	B-X
proANP	B-X
is	B-X
proteolytically	B-X
processed	B-X
by	B-X
corin	B-X
,	B-X
resulting	B-X
in	B-X
secretion	B-X
of	B-X
bioactive	B-X
α-ANP	B-X
into	B-X
the	B-X
peripheral	B-X
circulation	B-X
.	B-X
ProANP	B-X
and	B-X
β-ANP	B-X
are	B-X
minor	B-X
forms	B-X
in	B-X
the	B-X
circulation	B-X
but	B-X
are	B-X
increased	B-X
in	B-X
patients	B-X
with	B-X
heart	B-X
failure	B-X
.	B-X
The	B-X
human	B-X
BNP	B-X
precursor	B-X
proBNP	B-X
is	B-X
proteolytically	B-X
processed	B-X
to	B-X
BNP	B-X

To	O
investigate	O
factors	O
that	O
enable	O
these	O
propeptide	O
independent	O
events	O
to	O
occur	O
,	O
we	O
constructed	O
MIC	B-Protein
-	I-Protein
1	I-Protein
/	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
chimeras	O
,	O
both	O
with	O
and	O
without	O
a	O
propeptide	O
.	O
<EOS>	B-X
Macrophage	B-X
inhibitory	B-X
cytokine-1	B-X
(	B-X
MIC-1	B-X
)	B-X
is	B-X
a	B-X
divergent	B-X
member	B-X
of	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
superfamily	B-X
.	B-X
While	B-X
it	B-X
is	B-X
synthesized	B-X
in	B-X
a	B-X
pre-pro	B-X
form	B-X
,	B-X
it	B-X
is	B-X
unique	B-X
among	B-X
superfamily	B-X
members	B-X
because	B-X
it	B-X
does	B-X
not	B-X
require	B-X
its	B-X
propeptide	B-X
for	B-X
correct	B-X
folding	B-X
or	B-X
secretion	B-X
of	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
To	B-X
investigate	B-X
factors	B-X
that	B-X
enable	B-X
these	B-X
propeptide	B-X
independent	B-X
events	B-X
to	B-X
occur	B-X
,	B-X
we	B-X
constructed	B-X
MIC-1/TGF-beta1	B-X
chimeras	B-X
,	B-X
both	B-X
with	B-X
and	B-X
without	B-X
a	B-X
propeptide	B-X
.	B-X
All	B-X
chimeras	B-X
without	B-X
a	B-X
propeptide	B-X
secreted	B-X
less	B-X
efficiently	B-X
compared	B-X
with	B-X
the	B-X
corresponding	B-X
constructs	B-X
with	B-X
propeptide	B-X
.	B-X
Exchanging	B-X
the	B-X
human	B-X
propeptide	B-X
in	B-X
this	B-X
chimera	B-X
with	B-X
either	B-X
the	B-X
murine	B-X
MIC-1	B-X
or	B-X
TGF-beta1	B-X
propeptide	B-X
resulted	B-X
in	B-X
secretion	B-X
of	B-X
the	B-X
unprocessed	B-X
,	B-X
monomeric	B-X
chimera	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
interaction	B-X
between	B-X
the	B-X
human	B-X
MIC-1	B-X
propeptide	B-X
and	B-X
mature	B-X
peptide	B-X
.	B-X
Propeptide	B-X
deletion	B-X
mutants	B-X
enabled	B-X
identification	B-X
of	B-X
a	B-X
region	B-X
between	B-X
residues	B-X
56	B-X
and	B-X
78	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
propeptide	B-X
and	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
Cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
the	B-X
propeptide	B-X
must	B-X
be	B-X
in	B-X
cis	B-X
with	B-X
the	B-X
mature	B-X
peptide	B-X
for	B-X
this	B-X
phenomenon	B-X
to	B-X
occur	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
model	B-X
for	B-X
TGF-beta	B-X
superfamily	B-X
protein	B-X
folding	B-X
.	B-X

All	O
chimeras	O
without	O
a	O
propeptide	O
secreted	O
less	O
efficiently	O
compared	O
with	O
the	O
corresponding	O
constructs	O
with	O
propeptide	O
.	O
<EOS>	B-X
While	B-X
it	B-X
is	B-X
synthesized	B-X
in	B-X
a	B-X
pre-pro	B-X
form	B-X
,	B-X
it	B-X
is	B-X
unique	B-X
among	B-X
superfamily	B-X
members	B-X
because	B-X
it	B-X
does	B-X
not	B-X
require	B-X
its	B-X
propeptide	B-X
for	B-X
correct	B-X
folding	B-X
or	B-X
secretion	B-X
of	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
To	B-X
investigate	B-X
factors	B-X
that	B-X
enable	B-X
these	B-X
propeptide	B-X
independent	B-X
events	B-X
to	B-X
occur	B-X
,	B-X
we	B-X
constructed	B-X
MIC-1/TGF-beta1	B-X
chimeras	B-X
,	B-X
both	B-X
with	B-X
and	B-X
without	B-X
a	B-X
propeptide	B-X
.	B-X
All	B-X
chimeras	B-X
without	B-X
a	B-X
propeptide	B-X
secreted	B-X
less	B-X
efficiently	B-X
compared	B-X
with	B-X
the	B-X
corresponding	B-X
constructs	B-X
with	B-X
propeptide	B-X
.	B-X
Exchanging	B-X
the	B-X
human	B-X
propeptide	B-X
in	B-X
this	B-X
chimera	B-X
with	B-X
either	B-X
the	B-X
murine	B-X
MIC-1	B-X
or	B-X
TGF-beta1	B-X
propeptide	B-X
resulted	B-X
in	B-X
secretion	B-X
of	B-X
the	B-X
unprocessed	B-X
,	B-X
monomeric	B-X
chimera	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
interaction	B-X
between	B-X
the	B-X
human	B-X
MIC-1	B-X
propeptide	B-X
and	B-X
mature	B-X
peptide	B-X
.	B-X
Propeptide	B-X
deletion	B-X
mutants	B-X
enabled	B-X
identification	B-X
of	B-X
a	B-X
region	B-X
between	B-X
residues	B-X
56	B-X
and	B-X
78	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
propeptide	B-X
and	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
Cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
the	B-X
propeptide	B-X
must	B-X
be	B-X
in	B-X
cis	B-X
with	B-X
the	B-X
mature	B-X
peptide	B-X
for	B-X
this	B-X
phenomenon	B-X
to	B-X
occur	B-X
.	B-X

Folding	O
and	O
secretion	O
were	O
most	O
affected	O
after	O
replacement	O
of	O
the	O
predicted	O
major	O
alpha	O
-	O
helix	O
in	O
the	O
mature	O
protein	O
,	O
residues	O
56	O
-	O
68	O
.	O
<EOS>	B-X
While	B-X
it	B-X
is	B-X
synthesized	B-X
in	B-X
a	B-X
pre-pro	B-X
form	B-X
,	B-X
it	B-X
is	B-X
unique	B-X
among	B-X
superfamily	B-X
members	B-X
because	B-X
it	B-X
does	B-X
not	B-X
require	B-X
its	B-X
propeptide	B-X
for	B-X
correct	B-X
folding	B-X
or	B-X
secretion	B-X
of	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
Folding	B-X
and	B-X
secretion	B-X
were	B-X
most	B-X
affected	B-X
after	B-X
replacement	B-X
of	B-X
the	B-X
predicted	B-X
major	B-X
alpha-helix	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
,	B-X
residues	B-X
56-68	B-X
.	B-X
Exchanging	B-X
the	B-X
human	B-X
propeptide	B-X
in	B-X
this	B-X
chimera	B-X
with	B-X
either	B-X
the	B-X
murine	B-X
MIC-1	B-X
or	B-X
TGF-beta1	B-X
propeptide	B-X
resulted	B-X
in	B-X
secretion	B-X
of	B-X
the	B-X
unprocessed	B-X
,	B-X
monomeric	B-X
chimera	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
interaction	B-X
between	B-X
the	B-X
human	B-X
MIC-1	B-X
propeptide	B-X
and	B-X
mature	B-X
peptide	B-X
.	B-X
Propeptide	B-X
deletion	B-X
mutants	B-X
enabled	B-X
identification	B-X
of	B-X
a	B-X
region	B-X
between	B-X
residues	B-X
56	B-X
and	B-X
78	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
propeptide	B-X
and	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
Cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
the	B-X
propeptide	B-X
must	B-X
be	B-X
in	B-X
cis	B-X
with	B-X
the	B-X
mature	B-X
peptide	B-X
for	B-X
this	B-X
phenomenon	B-X
to	B-X
occur	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
model	B-X
for	B-X
TGF-beta	B-X
superfamily	B-X
protein	B-X
folding	B-X
.	B-X

Exchanging	O
the	O
human	O
propeptide	O
in	O
this	O
chimera	O
with	O
either	O
the	O
murine	O
MIC	B-Protein
-	I-Protein
1	I-Protein
or	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
propeptide	O
resulted	O
in	O
secretion	O
of	O
the	O
unprocessed	O
,	O
monomeric	O
chimera	O
,	O
suggesting	O
a	O
specific	O
interaction	O
between	O
the	O
human	O
MIC	B-Protein
-	I-Protein
1	I-Protein
propeptide	O
and	O
mature	O
peptide	O
.	O
<EOS>	B-X
Macrophage	B-X
inhibitory	B-X
cytokine-1	B-X
(	B-X
MIC-1	B-X
)	B-X
is	B-X
a	B-X
divergent	B-X
member	B-X
of	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
superfamily	B-X
.	B-X
While	B-X
it	B-X
is	B-X
synthesized	B-X
in	B-X
a	B-X
pre-pro	B-X
form	B-X
,	B-X
it	B-X
is	B-X
unique	B-X
among	B-X
superfamily	B-X
members	B-X
because	B-X
it	B-X
does	B-X
not	B-X
require	B-X
its	B-X
propeptide	B-X
for	B-X
correct	B-X
folding	B-X
or	B-X
secretion	B-X
of	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
To	B-X
investigate	B-X
factors	B-X
that	B-X
enable	B-X
these	B-X
propeptide	B-X
independent	B-X
events	B-X
to	B-X
occur	B-X
,	B-X
we	B-X
constructed	B-X
MIC-1/TGF-beta1	B-X
chimeras	B-X
,	B-X
both	B-X
with	B-X
and	B-X
without	B-X
a	B-X
propeptide	B-X
.	B-X
All	B-X
chimeras	B-X
without	B-X
a	B-X
propeptide	B-X
secreted	B-X
less	B-X
efficiently	B-X
compared	B-X
with	B-X
the	B-X
corresponding	B-X
constructs	B-X
with	B-X
propeptide	B-X
.	B-X
Folding	B-X
and	B-X
secretion	B-X
were	B-X
most	B-X
affected	B-X
after	B-X
replacement	B-X
of	B-X
the	B-X
predicted	B-X
major	B-X
alpha-helix	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
,	B-X
residues	B-X
56-68	B-X
.	B-X
Exchanging	B-X
the	B-X
human	B-X
propeptide	B-X
in	B-X
this	B-X
chimera	B-X
with	B-X
either	B-X
the	B-X
murine	B-X
MIC-1	B-X
or	B-X
TGF-beta1	B-X
propeptide	B-X
resulted	B-X
in	B-X
secretion	B-X
of	B-X
the	B-X
unprocessed	B-X
,	B-X
monomeric	B-X
chimera	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
interaction	B-X
between	B-X
the	B-X
human	B-X
MIC-1	B-X
propeptide	B-X
and	B-X
mature	B-X
peptide	B-X
.	B-X
Propeptide	B-X
deletion	B-X
mutants	B-X
enabled	B-X
identification	B-X
of	B-X
a	B-X
region	B-X
between	B-X
residues	B-X
56	B-X
and	B-X
78	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
propeptide	B-X
and	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
Cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
the	B-X
propeptide	B-X
must	B-X
be	B-X
in	B-X
cis	B-X
with	B-X
the	B-X
mature	B-X
peptide	B-X
for	B-X
this	B-X
phenomenon	B-X
to	B-X
occur	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
model	B-X
for	B-X
TGF-beta	B-X
superfamily	B-X
protein	B-X
folding	B-X
.	B-X

Propeptide	O
deletion	O
mutants	O
enabled	O
identification	O
of	O
a	O
region	O
between	O
residues	O
56	O
and	O
78	O
,	O
which	O
is	O
important	O
for	O
the	O
interaction	O
between	O
the	O
propeptide	O
and	O
the	O
mature	O
peptide	O
.	O
<EOS>	B-X
While	B-X
it	B-X
is	B-X
synthesized	B-X
in	B-X
a	B-X
pre-pro	B-X
form	B-X
,	B-X
it	B-X
is	B-X
unique	B-X
among	B-X
superfamily	B-X
members	B-X
because	B-X
it	B-X
does	B-X
not	B-X
require	B-X
its	B-X
propeptide	B-X
for	B-X
correct	B-X
folding	B-X
or	B-X
secretion	B-X
of	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
To	B-X
investigate	B-X
factors	B-X
that	B-X
enable	B-X
these	B-X
propeptide	B-X
independent	B-X
events	B-X
to	B-X
occur	B-X
,	B-X
we	B-X
constructed	B-X
MIC-1/TGF-beta1	B-X
chimeras	B-X
,	B-X
both	B-X
with	B-X
and	B-X
without	B-X
a	B-X
propeptide	B-X
.	B-X
All	B-X
chimeras	B-X
without	B-X
a	B-X
propeptide	B-X
secreted	B-X
less	B-X
efficiently	B-X
compared	B-X
with	B-X
the	B-X
corresponding	B-X
constructs	B-X
with	B-X
propeptide	B-X
.	B-X
Folding	B-X
and	B-X
secretion	B-X
were	B-X
most	B-X
affected	B-X
after	B-X
replacement	B-X
of	B-X
the	B-X
predicted	B-X
major	B-X
alpha-helix	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
,	B-X
residues	B-X
56-68	B-X
.	B-X
Exchanging	B-X
the	B-X
human	B-X
propeptide	B-X
in	B-X
this	B-X
chimera	B-X
with	B-X
either	B-X
the	B-X
murine	B-X
MIC-1	B-X
or	B-X
TGF-beta1	B-X
propeptide	B-X
resulted	B-X
in	B-X
secretion	B-X
of	B-X
the	B-X
unprocessed	B-X
,	B-X
monomeric	B-X
chimera	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
interaction	B-X
between	B-X
the	B-X
human	B-X
MIC-1	B-X
propeptide	B-X
and	B-X
mature	B-X
peptide	B-X
.	B-X
Propeptide	B-X
deletion	B-X
mutants	B-X
enabled	B-X
identification	B-X
of	B-X
a	B-X
region	B-X
between	B-X
residues	B-X
56	B-X
and	B-X
78	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
propeptide	B-X
and	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
Cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
the	B-X
propeptide	B-X
must	B-X
be	B-X
in	B-X
cis	B-X
with	B-X
the	B-X
mature	B-X
peptide	B-X
for	B-X
this	B-X
phenomenon	B-X
to	B-X
occur	B-X
.	B-X

Cotransfection	O
experiments	O
demonstrated	O
that	O
the	O
propeptide	O
must	O
be	O
in	O
cis	O
with	O
the	O
mature	O
peptide	O
for	O
this	O
phenomenon	O
to	O
occur	O
.	O
<EOS>	B-X
While	B-X
it	B-X
is	B-X
synthesized	B-X
in	B-X
a	B-X
pre-pro	B-X
form	B-X
,	B-X
it	B-X
is	B-X
unique	B-X
among	B-X
superfamily	B-X
members	B-X
because	B-X
it	B-X
does	B-X
not	B-X
require	B-X
its	B-X
propeptide	B-X
for	B-X
correct	B-X
folding	B-X
or	B-X
secretion	B-X
of	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
To	B-X
investigate	B-X
factors	B-X
that	B-X
enable	B-X
these	B-X
propeptide	B-X
independent	B-X
events	B-X
to	B-X
occur	B-X
,	B-X
we	B-X
constructed	B-X
MIC-1/TGF-beta1	B-X
chimeras	B-X
,	B-X
both	B-X
with	B-X
and	B-X
without	B-X
a	B-X
propeptide	B-X
.	B-X
All	B-X
chimeras	B-X
without	B-X
a	B-X
propeptide	B-X
secreted	B-X
less	B-X
efficiently	B-X
compared	B-X
with	B-X
the	B-X
corresponding	B-X
constructs	B-X
with	B-X
propeptide	B-X
.	B-X
Folding	B-X
and	B-X
secretion	B-X
were	B-X
most	B-X
affected	B-X
after	B-X
replacement	B-X
of	B-X
the	B-X
predicted	B-X
major	B-X
alpha-helix	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
,	B-X
residues	B-X
56-68	B-X
.	B-X
Exchanging	B-X
the	B-X
human	B-X
propeptide	B-X
in	B-X
this	B-X
chimera	B-X
with	B-X
either	B-X
the	B-X
murine	B-X
MIC-1	B-X
or	B-X
TGF-beta1	B-X
propeptide	B-X
resulted	B-X
in	B-X
secretion	B-X
of	B-X
the	B-X
unprocessed	B-X
,	B-X
monomeric	B-X
chimera	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
interaction	B-X
between	B-X
the	B-X
human	B-X
MIC-1	B-X
propeptide	B-X
and	B-X
mature	B-X
peptide	B-X
.	B-X
Propeptide	B-X
deletion	B-X
mutants	B-X
enabled	B-X
identification	B-X
of	B-X
a	B-X
region	B-X
between	B-X
residues	B-X
56	B-X
and	B-X
78	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
propeptide	B-X
and	B-X
the	B-X
mature	B-X
peptide	B-X
.	B-X
Cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
the	B-X
propeptide	B-X
must	B-X
be	B-X
in	B-X
cis	B-X
with	B-X
the	B-X
mature	B-X
peptide	B-X
for	B-X
this	B-X
phenomenon	B-X
to	B-X
occur	B-X
.	B-X

These	O
results	O
suggest	O
a	O
model	O
for	O
TGF	O
-	O
beta	O
superfamily	O
protein	O
folding	O
.	O

High	O
frequency	O
of	O
promoter	O
hypermethylation	O
of	O
RASSF1A	B-Protein
in	O
nasopharyngeal	O
carcinoma	O
.	O
<EOS>	B-X
Hypermethylation	B-X
of	B-X
the	B-X
The	B-X
methylation	B-X
profile	B-X
of	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
has	B-X
been	B-X
investigated	B-X
by	B-X
a	B-X
candidate	B-X
gene	B-X
approach	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
changes	B-X
of	B-X
a	B-X
newly	B-X
isolated	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
3p21.3	B-X
,	B-X
RASSF1A	B-X
,	B-X
in	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X
Promoter	B-X
hypermethylation	B-X
of	B-X
the	B-X
5'CpG	B-X
island	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
4	B-X
of	B-X
4	B-X
(	B-X
100	B-X
%	B-X
)	B-X
xenografts	B-X
,	B-X
in	B-X
3	B-X
of	B-X
4	B-X
(	B-X
75	B-X
%	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
in	B-X
14	B-X
of	B-X
21	B-X
(	B-X
66.7	B-X
%	B-X
)	B-X
primary	B-X
tumors	B-X
but	B-X
not	B-X
in	B-X
the	B-X
normal	B-X
nasopharyngeal	B-X
epithelia	B-X
.	B-X
In	B-X
the	B-X
cell	B-X
lines	B-X
and	B-X
xenografts	B-X
with	B-X
extensive	B-X
methylation	B-X
,	B-X
no	B-X
RASSF1A	B-X
gene	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
After	B-X
treatment	B-X
with	B-X
5'-aza-2'deoxycytidine	B-X
,	B-X
reexpression	B-X
and	B-X
demethylation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
were	B-X
detected	B-X
in	B-X
a	B-X
NPC	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
transcriptional	B-X
inactivation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
in	B-X
NPC	B-X
.	B-X
The	B-X
high	B-X
incidence	B-X
of	B-X
RASSF1A	B-X
alterations	B-X
suggest	B-X
that	B-X
it	B-X
is	B-X
the	B-X
critical	B-X
target	B-X
gene	B-X
on	B-X
chromosome	B-X
3p21.3	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
NPC	B-X
.	B-X

We	O
have	O
investigated	O
the	O
genetic	O
and	O
epigenetic	O
changes	O
of	O
a	O
newly	O
isolated	O
tumor	O
suppressor	O
gene	O
on	O
3p21	O
.	O
3	O
,	O
RASSF1A	B-Protein
,	O
in	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
changes	B-X
of	B-X
a	B-X
newly	B-X
isolated	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
3p21.3	B-X
,	B-X
RASSF1A	B-X
,	B-X
in	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X
Four	B-X
xenografts	B-X
,	B-X
four	B-X
cell	B-X
lines	B-X
and	B-X
21	B-X
primary	B-X
tumors	B-X
were	B-X
examined	B-X
.	B-X
Promoter	B-X
hypermethylation	B-X
of	B-X
the	B-X
5'CpG	B-X
island	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
4	B-X
of	B-X
4	B-X
(	B-X
100	B-X
%	B-X
)	B-X
xenografts	B-X
,	B-X
in	B-X
3	B-X
of	B-X
4	B-X
(	B-X
75	B-X
%	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
in	B-X
14	B-X
of	B-X
21	B-X
(	B-X
66.7	B-X
%	B-X
)	B-X
primary	B-X
tumors	B-X
but	B-X
not	B-X
in	B-X
the	B-X
normal	B-X
nasopharyngeal	B-X
epithelia	B-X
.	B-X
Mutations	B-X
were	B-X
found	B-X
in	B-X
2	B-X
of	B-X
21	B-X
(	B-X
9.5	B-X
%	B-X
)	B-X
primary	B-X
tumors	B-X
.	B-X
In	B-X
the	B-X
cell	B-X
lines	B-X
and	B-X
xenografts	B-X
with	B-X
extensive	B-X
methylation	B-X
,	B-X
no	B-X
RASSF1A	B-X
gene	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
After	B-X
treatment	B-X
with	B-X
5'-aza-2'deoxycytidine	B-X
,	B-X
reexpression	B-X
and	B-X
demethylation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
were	B-X
detected	B-X
in	B-X
a	B-X
NPC	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
transcriptional	B-X
inactivation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
in	B-X
NPC	B-X
.	B-X
The	B-X
high	B-X
incidence	B-X
of	B-X
RASSF1A	B-X
alterations	B-X
suggest	B-X
that	B-X
it	B-X
is	B-X
the	B-X
critical	B-X
target	B-X
gene	B-X
on	B-X
chromosome	B-X
3p21.3	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
NPC	B-X
.	B-X

Four	O
xenografts	O
,	O
four	O
cell	O
lines	O
and	O
21	O
primary	O
tumors	O
were	O
examined	O
.	O
<EOS>	B-X
Glioblastoma	B-X
cell-initiated	B-X
vascularization	B-X
is	B-X
an	B-X
alternative	B-X
angiogenesis	B-X
called	B-X
vasculogenic	B-X
mimicry	B-X
.	B-X
However	B-X
,	B-X
current	B-X
knowledge	B-X
on	B-X
the	B-X
mechanism	B-X
of	B-X
de	B-X
novo	B-X
vessel	B-X
formation	B-X
from	B-X
glioblastoma	B-X
stem	B-X
cells	B-X
(	B-X
GSCs	B-X
)	B-X
is	B-X
limited	B-X
.	B-X
An	B-X
epithelial	B-X
cell	B-X
line	B-X
,	B-X
NPC-BM1	B-X
,	B-X
was	B-X
established	B-X
from	B-X
a	B-X
bone	B-X
marrow	B-X
biopsy	B-X
of	B-X
a	B-X
female	B-X
Taiwanese	B-X
patient	B-X
with	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X
Histopathology	B-X
of	B-X
the	B-X
bone	B-X
marrow	B-X
biopsy	B-X
and	B-X
xenografts	B-X
grown	B-X
in	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
mice	B-X
showed	B-X
that	B-X
the	B-X
tumor	B-X
was	B-X
a	B-X
nonkeratinizing	B-X
,	B-X
poorly	B-X
differentiated	B-X
carcinoma	B-X
.	B-X
NPC-BM1	B-X
cells	B-X
grown	B-X
as	B-X
monolayers	B-X
had	B-X
a	B-X
doubling	B-X
time	B-X
of	B-X
28.5	B-X
hours	B-X
.	B-X
;	B-X
p12	B-X
)	B-X
,	B-X
[	B-X
corrected	B-X
]	B-X
add	B-X
(	B-X
21	B-X
)	B-X
(	B-X
p11	B-X
)	B-X
,	B-X
del	B-X
(	B-X
X	B-X
)	B-X
(	B-X
q24	B-X
)	B-X
,	B-X
add	B-X
(	B-X
X	B-X
)	B-X
(	B-X
q22	B-X
)	B-X
,	B-X
and	B-X
marker	B-X
1	B-X
(	B-X
M1	B-X
)	B-X
,	B-X
in	B-X
all	B-X
metaphases	B-X
examined	B-X
,	B-X
which	B-X
were	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
two	B-X
to	B-X
five	B-X
cell	B-X
lines	B-X
from	B-X
primary	B-X
NPC	B-X
tumors	B-X
reported	B-X
previously	B-X
;	B-X
and	B-X
5	B-X
)	B-X
four	B-X
other	B-X
abnormalities	B-X
,	B-X
t	B-X
(	B-X
2	B-X
;	B-X
?	B-X
;	B-X
2	B-X
)	B-X
(	B-X
p11.2	B-X
;	B-X
?	B-X
;	B-X
q21	B-X
)	B-X
,	B-X
t	B-X
(	B-X
11	B-X
;	B-X
22	B-X
)	B-X
(	B-X
q11	B-X
;	B-X
q11	B-X
)	B-X
,	B-X
i	B-X
(	B-X
22	B-X
)	B-X
(	B-X
q10	B-X
)	B-X
,	B-X
and	B-X
marker	B-X
2	B-X
(	B-X
M2	B-X
)	B-X
,	B-X
unique	B-X
to	B-X
this	B-X
metastatic	B-X
cell	B-X
line	B-X
.	B-X
To	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
NPC-BM1	B-X
is	B-X
the	B-X
first	B-X
NPC	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
a	B-X
distant	B-X
metastatic	B-X
site	B-X
.	B-X
Further	B-X
evaluation	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
and	B-X
additional	B-X
metastatic	B-X
NPC	B-X
cell	B-X
lines	B-X
as	B-X
well	B-X
as	B-X
primary	B-X
NPC	B-X
cell	B-X
lines	B-X
with	B-X
respect	B-X
to	B-X
relations	B-X
between	B-X
the	B-X
timing	B-X
,	B-X
karyotypic	B-X
anomalies	B-X
,	B-X
and	B-X
immunobiological	B-X
characteristics	B-X
in	B-X
NPC	B-X
progression	B-X
and	B-X
metastasis	B-X
is	B-X
warranted	B-X
.	B-X

Promoter	O
hypermethylation	O
of	O
the	O
5	O
'	O
CpG	O
island	O
of	O
RASSF1A	B-Protein
was	O
detected	O
in	O
4	O
of	O
4	O
(	O
100	O
%	O
)	O
xenografts	O
,	O
in	O
3	O
of	O
4	O
(	O
75	O
%	O
)	O
cell	O
lines	O
,	O
and	O
in	O
14	O
of	O
21	O
(	O
66	O
.	O
7	O
%	O
)	O
primary	O
tumors	O
but	O
not	O
in	O
the	O
normal	O
nasopharyngeal	O
epithelia	O
.	O

Mutations	O
were	O
found	O
in	O
2	O
of	O
21	O
(	O
9	O
.	O
5	O
%	O
)	O
primary	O
tumors	O
.	O
<EOS>	B-X
In	B-X
the	B-X
primary	B-X
analysis	B-X
of	B-X
SOLO1/GOG	B-X
3004	B-X
,	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
(	B-X
PARP	B-X
)	B-X
inhibitor	B-X
olaparib	B-X
significantly	B-X
improved	B-X
progression-free	B-X
survival	B-X
versus	B-X
placebo	B-X
in	B-X
patients	B-X
with	B-X
a	B-X
BRCA	B-X
mutation	B-X
;	B-X
median	B-X
progression-free	B-X
survival	B-X
was	B-X
not	B-X
reached	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
updated	B-X
,	B-X
post-hoc	B-X
analysis	B-X
of	B-X
progression-free	B-X
survival	B-X
from	B-X
SOLO1	B-X
,	B-X
after	B-X
5	B-X
years	B-X
of	B-X
follow-up	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
isocitrate	B-X
dehydrogenase	B-X
1	B-X
(	B-X
IDH1	B-X
)	B-X
occur	B-X
in	B-X
6	B-X
to	B-X
10	B-X
%	B-X
of	B-X
patients	B-X
with	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
.	B-X
Ivosidenib	B-X
(	B-X
AG-120	B-X
)	B-X
is	B-X
an	B-X
oral	B-X
,	B-X
targeted	B-X
,	B-X
small-molecule	B-X
inhibitor	B-X
of	B-X
mutant	B-X
IDH1	B-X
.	B-X

In	O
the	O
cell	O
lines	O
and	O
xenografts	O
with	O
extensive	O
methylation	O
,	O
no	O
RASSF1A	B-Protein
gene	O
expression	O
was	O
found	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
changes	B-X
of	B-X
a	B-X
newly	B-X
isolated	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
3p21.3	B-X
,	B-X
RASSF1A	B-X
,	B-X
in	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X
Four	B-X
xenografts	B-X
,	B-X
four	B-X
cell	B-X
lines	B-X
and	B-X
21	B-X
primary	B-X
tumors	B-X
were	B-X
examined	B-X
.	B-X
Promoter	B-X
hypermethylation	B-X
of	B-X
the	B-X
5'CpG	B-X
island	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
4	B-X
of	B-X
4	B-X
(	B-X
100	B-X
%	B-X
)	B-X
xenografts	B-X
,	B-X
in	B-X
3	B-X
of	B-X
4	B-X
(	B-X
75	B-X
%	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
in	B-X
14	B-X
of	B-X
21	B-X
(	B-X
66.7	B-X
%	B-X
)	B-X
primary	B-X
tumors	B-X
but	B-X
not	B-X
in	B-X
the	B-X
normal	B-X
nasopharyngeal	B-X
epithelia	B-X
.	B-X
Mutations	B-X
were	B-X
found	B-X
in	B-X
2	B-X
of	B-X
21	B-X
(	B-X
9.5	B-X
%	B-X
)	B-X
primary	B-X
tumors	B-X
.	B-X
In	B-X
the	B-X
cell	B-X
lines	B-X
and	B-X
xenografts	B-X
with	B-X
extensive	B-X
methylation	B-X
,	B-X
no	B-X
RASSF1A	B-X
gene	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
After	B-X
treatment	B-X
with	B-X
5'-aza-2'deoxycytidine	B-X
,	B-X
reexpression	B-X
and	B-X
demethylation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
were	B-X
detected	B-X
in	B-X
a	B-X
NPC	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
transcriptional	B-X
inactivation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
in	B-X
NPC	B-X
.	B-X
The	B-X
high	B-X
incidence	B-X
of	B-X
RASSF1A	B-X
alterations	B-X
suggest	B-X
that	B-X
it	B-X
is	B-X
the	B-X
critical	B-X
target	B-X
gene	B-X
on	B-X
chromosome	B-X
3p21.3	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
NPC	B-X
.	B-X

After	O
treatment	O
with	O
5	O
'	O
-	O
aza	O
-	O
2	O
'	O
deoxycytidine	O
,	O
reexpression	O
and	O
demethylation	O
of	O
the	O
RASSF1A	B-Protein
gene	O
were	O
detected	O
in	O
a	O
NPC	O
cell	O
line	O
.	O

These	O
findings	O
suggest	O
that	O
promoter	O
hypermethylation	O
may	O
participate	O
in	O
the	O
transcriptional	O
inactivation	O
of	O
the	O
RASSF1A	B-Protein
gene	O
in	O
NPC	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
changes	B-X
of	B-X
a	B-X
newly	B-X
isolated	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
3p21.3	B-X
,	B-X
RASSF1A	B-X
,	B-X
in	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X
Promoter	B-X
hypermethylation	B-X
of	B-X
the	B-X
5'CpG	B-X
island	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
4	B-X
of	B-X
4	B-X
(	B-X
100	B-X
%	B-X
)	B-X
xenografts	B-X
,	B-X
in	B-X
3	B-X
of	B-X
4	B-X
(	B-X
75	B-X
%	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
in	B-X
14	B-X
of	B-X
21	B-X
(	B-X
66.7	B-X
%	B-X
)	B-X
primary	B-X
tumors	B-X
but	B-X
not	B-X
in	B-X
the	B-X
normal	B-X
nasopharyngeal	B-X
epithelia	B-X
.	B-X
In	B-X
the	B-X
cell	B-X
lines	B-X
and	B-X
xenografts	B-X
with	B-X
extensive	B-X
methylation	B-X
,	B-X
no	B-X
RASSF1A	B-X
gene	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
After	B-X
treatment	B-X
with	B-X
5'-aza-2'deoxycytidine	B-X
,	B-X
reexpression	B-X
and	B-X
demethylation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
were	B-X
detected	B-X
in	B-X
a	B-X
NPC	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
transcriptional	B-X
inactivation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
in	B-X
NPC	B-X
.	B-X
The	B-X
high	B-X
incidence	B-X
of	B-X
RASSF1A	B-X
alterations	B-X
suggest	B-X
that	B-X
it	B-X
is	B-X
the	B-X
critical	B-X
target	B-X
gene	B-X
on	B-X
chromosome	B-X
3p21.3	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
NPC	B-X
.	B-X

The	O
high	O
incidence	O
of	O
RASSF1A	B-Protein
alterations	O
suggest	O
that	O
it	O
is	O
the	O
critical	O
target	O
gene	O
on	O
chromosome	O
3p21	O
.	O
3	O
involved	O
in	O
the	O
development	O
of	O
NPC	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
changes	B-X
of	B-X
a	B-X
newly	B-X
isolated	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
3p21.3	B-X
,	B-X
RASSF1A	B-X
,	B-X
in	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X
Promoter	B-X
hypermethylation	B-X
of	B-X
the	B-X
5'CpG	B-X
island	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
4	B-X
of	B-X
4	B-X
(	B-X
100	B-X
%	B-X
)	B-X
xenografts	B-X
,	B-X
in	B-X
3	B-X
of	B-X
4	B-X
(	B-X
75	B-X
%	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
in	B-X
14	B-X
of	B-X
21	B-X
(	B-X
66.7	B-X
%	B-X
)	B-X
primary	B-X
tumors	B-X
but	B-X
not	B-X
in	B-X
the	B-X
normal	B-X
nasopharyngeal	B-X
epithelia	B-X
.	B-X
In	B-X
the	B-X
cell	B-X
lines	B-X
and	B-X
xenografts	B-X
with	B-X
extensive	B-X
methylation	B-X
,	B-X
no	B-X
RASSF1A	B-X
gene	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
After	B-X
treatment	B-X
with	B-X
5'-aza-2'deoxycytidine	B-X
,	B-X
reexpression	B-X
and	B-X
demethylation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
were	B-X
detected	B-X
in	B-X
a	B-X
NPC	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
transcriptional	B-X
inactivation	B-X
of	B-X
the	B-X
RASSF1A	B-X
gene	B-X
in	B-X
NPC	B-X
.	B-X
The	B-X
high	B-X
incidence	B-X
of	B-X
RASSF1A	B-X
alterations	B-X
suggest	B-X
that	B-X
it	B-X
is	B-X
the	B-X
critical	B-X
target	B-X
gene	B-X
on	B-X
chromosome	B-X
3p21.3	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
NPC	B-X
.	B-X

Cytosine	O
methylation	O
represses	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
P1	I-Protein
(	O
GSTP1	B-Protein
)	O
gene	O
expression	O
in	O
human	O
prostate	O
cancer	O
cells	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
the	B-X
glutathione	B-X
S-transferase	B-X
P1	B-X
(	B-X
GSTP1	B-X
)	B-X
gene	B-X
has	B-X
been	B-X
described	B-X
as	B-X
a	B-X
highly	B-X
specific	B-X
and	B-X
sensitive	B-X
biomarker	B-X
for	B-X
prostate	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
at	B-X
present	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
methylation	B-X
represses	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X
We	B-X
found	B-X
the	B-X
GSTP1	B-X
gene	B-X
promoter	B-X
to	B-X
be	B-X
completely	B-X
methylated	B-X
in	B-X
the	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
,	B-X
where	B-X
this	B-X
gene	B-X
is	B-X
transcriptionally	B-X
inactive	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Du145	B-X
and	B-X
PC3	B-X
prostate	B-X
cancer	B-X
cells	B-X
express	B-X
the	B-X
GSTP1	B-X
gene	B-X
and	B-X
exhibit	B-X
methylated	B-X
and	B-X
unmethylated	B-X
GSTP1	B-X
alleles	B-X
.	B-X
In	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
using	B-X
LNCaP	B-X
cells	B-X
,	B-X
methylation	B-X
of	B-X
the	B-X
GSTP1	B-X
promoter-driven	B-X
luciferase	B-X
reporter	B-X
vector	B-X
(	B-X
GSTP1-pGL3	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
>	B-X
20-fold	B-X
inhibition	B-X
of	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
not	B-X
relieved	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
LNCaP	B-X
cells	B-X
with	B-X
a	B-X
DNA	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
5-Aza-2'-deoxycytidine	B-X
,	B-X
resulted	B-X
in	B-X
demethylation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
TSA	B-X
treatment	B-X
failed	B-X
to	B-X
demethylate	B-X
or	B-X
activate	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
Fully	B-X
methylated	B-X
but	B-X
not	B-X
unmethylated	B-X
GSTP1	B-X
promoter	B-X
fragment	B-X
was	B-X
shown	B-X
to	B-X
bind	B-X
to	B-X
a	B-X
complex	B-X
similar	B-X
to	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1	B-X
that	B-X
contains	B-X
methyl-CpG-binding	B-X
domain	B-X
2	B-X
protein	B-X
(	B-X
MBD2	B-X
)	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
LNCaP	B-X
cell	B-X
nuclear	B-X
extracts	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
cytosine	B-X
methylation	B-X
can	B-X
repress	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
possibly	B-X
mediated	B-X
by	B-X
a	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1-like	B-X
complex	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
also	B-X
support	B-X
the	B-X
notion	B-X
of	B-X
the	B-X
dominance	B-X
of	B-X
methylation	B-X
over	B-X
TSA-sensitive	B-X
histone	B-X
deacetylation	B-X
in	B-X
silencing	B-X
genes	B-X
with	B-X
a	B-X
high	B-X
CpG	B-X
density	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
.	B-X

Methylation	O
of	O
the	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
P1	I-Protein
(	O
GSTP1	B-Protein
)	O
gene	O
has	O
been	O
described	O
as	O
a	O
highly	O
specific	O
and	O
sensitive	O
biomarker	O
for	O
prostate	O
cancer	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
the	B-X
glutathione	B-X
S-transferase	B-X
P1	B-X
(	B-X
GSTP1	B-X
)	B-X
gene	B-X
has	B-X
been	B-X
described	B-X
as	B-X
a	B-X
highly	B-X
specific	B-X
and	B-X
sensitive	B-X
biomarker	B-X
for	B-X
prostate	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
at	B-X
present	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
methylation	B-X
represses	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X
We	B-X
found	B-X
the	B-X
GSTP1	B-X
gene	B-X
promoter	B-X
to	B-X
be	B-X
completely	B-X
methylated	B-X
in	B-X
the	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
,	B-X
where	B-X
this	B-X
gene	B-X
is	B-X
transcriptionally	B-X
inactive	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Du145	B-X
and	B-X
PC3	B-X
prostate	B-X
cancer	B-X
cells	B-X
express	B-X
the	B-X
GSTP1	B-X
gene	B-X
and	B-X
exhibit	B-X
methylated	B-X
and	B-X
unmethylated	B-X
GSTP1	B-X
alleles	B-X
.	B-X
In	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
using	B-X
LNCaP	B-X
cells	B-X
,	B-X
methylation	B-X
of	B-X
the	B-X
GSTP1	B-X
promoter-driven	B-X
luciferase	B-X
reporter	B-X
vector	B-X
(	B-X
GSTP1-pGL3	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
>	B-X
20-fold	B-X
inhibition	B-X
of	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
not	B-X
relieved	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
LNCaP	B-X
cells	B-X
with	B-X
a	B-X
DNA	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
5-Aza-2'-deoxycytidine	B-X
,	B-X
resulted	B-X
in	B-X
demethylation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
TSA	B-X
treatment	B-X
failed	B-X
to	B-X
demethylate	B-X
or	B-X
activate	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
Fully	B-X
methylated	B-X
but	B-X
not	B-X
unmethylated	B-X
GSTP1	B-X
promoter	B-X
fragment	B-X
was	B-X
shown	B-X
to	B-X
bind	B-X
to	B-X
a	B-X
complex	B-X
similar	B-X
to	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1	B-X
that	B-X
contains	B-X
methyl-CpG-binding	B-X
domain	B-X
2	B-X
protein	B-X
(	B-X
MBD2	B-X
)	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
LNCaP	B-X
cell	B-X
nuclear	B-X
extracts	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
cytosine	B-X
methylation	B-X
can	B-X
repress	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
possibly	B-X
mediated	B-X
by	B-X
a	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1-like	B-X
complex	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
also	B-X
support	B-X
the	B-X
notion	B-X
of	B-X
the	B-X
dominance	B-X
of	B-X
methylation	B-X
over	B-X
TSA-sensitive	B-X
histone	B-X
deacetylation	B-X
in	B-X
silencing	B-X
genes	B-X
with	B-X
a	B-X
high	B-X
CpG	B-X
density	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
.	B-X

However	O
,	O
at	O
present	O
,	O
it	O
is	O
not	O
known	O
whether	O
methylation	O
represses	O
GSTP1	B-Protein
gene	O
expression	O
in	O
human	O
prostate	O
cancer	O
.	O
<EOS>	B-X
Due	B-X
to	B-X
the	B-X
difficulty	B-X
in	B-X
diagnosis	B-X
,	B-X
we	B-X
report	B-X
our	B-X
experience	B-X
of	B-X
urethral	B-X
syringocele	B-X
in	B-X
a	B-X
quaternary	B-X
paediatric	B-X
hospital	B-X
,	B-X
with	B-X
differing	B-X
presentations	B-X
,	B-X
diagnosis	B-X
and	B-X
treatment	B-X
.	B-X
In	B-X
1999	B-X
,	B-X
weekly	B-X
videoconferences	B-X
began	B-X
with	B-X
remote	B-X
laboratories	B-X
and	B-X
clinical	B-X
staff	B-X
in	B-X
four	B-X
peripheral	B-X
hospitals	B-X
and	B-X
the	B-X
Royal	B-X
Brisbane	B-X
Hospital	B-X
and	B-X
in	B-X
2000	B-X
biweekly	B-X
videoconference	B-X
pathology	B-X
grand	B-X
rounds	B-X
started	B-X
across	B-X
Queensland	B-X
with	B-X
up	B-X
to	B-X
six	B-X
sites	B-X
,	B-X
from	B-X
Cairns	B-X
to	B-X
the	B-X
Gold	B-X
Coast	B-X
,	B-X
joining	B-X
in	B-X
or	B-X
presenting	B-X
.	B-X
Problems	B-X
included	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
system	B-X
,	B-X
timing	B-X
and	B-X
need	B-X
for	B-X
bookings	B-X
,	B-X
coordination	B-X
of	B-X
presenters	B-X
and	B-X
presentations	B-X
,	B-X
and	B-X
the	B-X
time	B-X
needed	B-X
to	B-X
organize	B-X
sessions	B-X
,	B-X
set	B-X
up	B-X
linkages	B-X
,	B-X
advertise	B-X
sessions	B-X
and	B-X
attend	B-X
the	B-X
telepathology	B-X
conference	B-X
.	B-X
Future	B-X
needs	B-X
include	B-X
better	B-X
infrastructure	B-X
and	B-X
trained	B-X
staff	B-X
to	B-X
coordinate	B-X
the	B-X
linkages	B-X
and	B-X
presentations	B-X
.	B-X

We	O
found	O
the	O
GSTP1	B-Protein
gene	O
promoter	O
to	O
be	O
completely	O
methylated	O
in	O
the	O
LNCaP	O
prostate	O
cancer	O
cell	O
line	O
,	O
where	O
this	O
gene	O
is	O
transcriptionally	O
inactive	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
the	B-X
glutathione	B-X
S-transferase	B-X
P1	B-X
(	B-X
GSTP1	B-X
)	B-X
gene	B-X
has	B-X
been	B-X
described	B-X
as	B-X
a	B-X
highly	B-X
specific	B-X
and	B-X
sensitive	B-X
biomarker	B-X
for	B-X
prostate	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
at	B-X
present	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
methylation	B-X
represses	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X
We	B-X
found	B-X
the	B-X
GSTP1	B-X
gene	B-X
promoter	B-X
to	B-X
be	B-X
completely	B-X
methylated	B-X
in	B-X
the	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
,	B-X
where	B-X
this	B-X
gene	B-X
is	B-X
transcriptionally	B-X
inactive	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Du145	B-X
and	B-X
PC3	B-X
prostate	B-X
cancer	B-X
cells	B-X
express	B-X
the	B-X
GSTP1	B-X
gene	B-X
and	B-X
exhibit	B-X
methylated	B-X
and	B-X
unmethylated	B-X
GSTP1	B-X
alleles	B-X
.	B-X
In	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
using	B-X
LNCaP	B-X
cells	B-X
,	B-X
methylation	B-X
of	B-X
the	B-X
GSTP1	B-X
promoter-driven	B-X
luciferase	B-X
reporter	B-X
vector	B-X
(	B-X
GSTP1-pGL3	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
>	B-X
20-fold	B-X
inhibition	B-X
of	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
not	B-X
relieved	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
LNCaP	B-X
cells	B-X
with	B-X
a	B-X
DNA	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
5-Aza-2'-deoxycytidine	B-X
,	B-X
resulted	B-X
in	B-X
demethylation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
TSA	B-X
treatment	B-X
failed	B-X
to	B-X
demethylate	B-X
or	B-X
activate	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
Fully	B-X
methylated	B-X
but	B-X
not	B-X
unmethylated	B-X
GSTP1	B-X
promoter	B-X
fragment	B-X
was	B-X
shown	B-X
to	B-X
bind	B-X
to	B-X
a	B-X
complex	B-X
similar	B-X
to	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1	B-X
that	B-X
contains	B-X
methyl-CpG-binding	B-X
domain	B-X
2	B-X
protein	B-X
(	B-X
MBD2	B-X
)	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
LNCaP	B-X
cell	B-X
nuclear	B-X
extracts	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
cytosine	B-X
methylation	B-X
can	B-X
repress	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
possibly	B-X
mediated	B-X
by	B-X
a	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1-like	B-X
complex	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
also	B-X
support	B-X
the	B-X
notion	B-X
of	B-X
the	B-X
dominance	B-X
of	B-X
methylation	B-X
over	B-X
TSA-sensitive	B-X
histone	B-X
deacetylation	B-X
in	B-X
silencing	B-X
genes	B-X
with	B-X
a	B-X
high	B-X
CpG	B-X
density	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
.	B-X

In	O
contrast	O
,	O
Du145	O
and	O
PC3	O
prostate	O
cancer	O
cells	O
express	O
the	O
GSTP1	B-Protein
gene	O
and	O
exhibit	O
methylated	O
and	O
unmethylated	O
GSTP1	B-Protein
alleles	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
the	B-X
glutathione	B-X
S-transferase	B-X
P1	B-X
(	B-X
GSTP1	B-X
)	B-X
gene	B-X
has	B-X
been	B-X
described	B-X
as	B-X
a	B-X
highly	B-X
specific	B-X
and	B-X
sensitive	B-X
biomarker	B-X
for	B-X
prostate	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
at	B-X
present	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
methylation	B-X
represses	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X
We	B-X
found	B-X
the	B-X
GSTP1	B-X
gene	B-X
promoter	B-X
to	B-X
be	B-X
completely	B-X
methylated	B-X
in	B-X
the	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
,	B-X
where	B-X
this	B-X
gene	B-X
is	B-X
transcriptionally	B-X
inactive	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Du145	B-X
and	B-X
PC3	B-X
prostate	B-X
cancer	B-X
cells	B-X
express	B-X
the	B-X
GSTP1	B-X
gene	B-X
and	B-X
exhibit	B-X
methylated	B-X
and	B-X
unmethylated	B-X
GSTP1	B-X
alleles	B-X
.	B-X
In	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
using	B-X
LNCaP	B-X
cells	B-X
,	B-X
methylation	B-X
of	B-X
the	B-X
GSTP1	B-X
promoter-driven	B-X
luciferase	B-X
reporter	B-X
vector	B-X
(	B-X
GSTP1-pGL3	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
>	B-X
20-fold	B-X
inhibition	B-X
of	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
not	B-X
relieved	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
LNCaP	B-X
cells	B-X
with	B-X
a	B-X
DNA	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
5-Aza-2'-deoxycytidine	B-X
,	B-X
resulted	B-X
in	B-X
demethylation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
TSA	B-X
treatment	B-X
failed	B-X
to	B-X
demethylate	B-X
or	B-X
activate	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
Fully	B-X
methylated	B-X
but	B-X
not	B-X
unmethylated	B-X
GSTP1	B-X
promoter	B-X
fragment	B-X
was	B-X
shown	B-X
to	B-X
bind	B-X
to	B-X
a	B-X
complex	B-X
similar	B-X
to	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1	B-X
that	B-X
contains	B-X
methyl-CpG-binding	B-X
domain	B-X
2	B-X
protein	B-X
(	B-X
MBD2	B-X
)	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
LNCaP	B-X
cell	B-X
nuclear	B-X
extracts	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
cytosine	B-X
methylation	B-X
can	B-X
repress	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
possibly	B-X
mediated	B-X
by	B-X
a	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1-like	B-X
complex	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
also	B-X
support	B-X
the	B-X
notion	B-X
of	B-X
the	B-X
dominance	B-X
of	B-X
methylation	B-X
over	B-X
TSA-sensitive	B-X
histone	B-X
deacetylation	B-X
in	B-X
silencing	B-X
genes	B-X
with	B-X
a	B-X
high	B-X
CpG	B-X
density	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
.	B-X

In	O
a	O
transient	O
transfection	O
assay	O
using	O
LNCaP	O
cells	O
,	O
methylation	O
of	O
the	O
GSTP1	B-Protein
promoter	O
-	O
driven	O
luciferase	B-Protein
reporter	O
vector	O
(	O
GSTP1	B-Protein
-	O
pGL3	O
)	O
resulted	O
in	O
a	O
>	O
20	O
-	O
fold	O
inhibition	O
of	O
transcription	O
,	O
and	O
this	O
repression	O
was	O
not	O
relieved	O
by	O
the	O
presence	O
of	O
a	O
histone	B-Protein
deacetylase	O
inhibitor	O
,	O
trichostatin	O
A	O
(	O
TSA	O
)	O
.	O

Treatment	O
of	O
LNCaP	O
cells	O
with	O
a	O
DNA	O
methyltransferase	O
inhibitor	O
,	O
5	O
-	O
Aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
,	O
resulted	O
in	O
demethylation	O
and	O
activation	O
of	O
the	O
GSTP1	B-Protein
gene	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
the	B-X
glutathione	B-X
S-transferase	B-X
P1	B-X
(	B-X
GSTP1	B-X
)	B-X
gene	B-X
has	B-X
been	B-X
described	B-X
as	B-X
a	B-X
highly	B-X
specific	B-X
and	B-X
sensitive	B-X
biomarker	B-X
for	B-X
prostate	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
at	B-X
present	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
methylation	B-X
represses	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X
We	B-X
found	B-X
the	B-X
GSTP1	B-X
gene	B-X
promoter	B-X
to	B-X
be	B-X
completely	B-X
methylated	B-X
in	B-X
the	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
,	B-X
where	B-X
this	B-X
gene	B-X
is	B-X
transcriptionally	B-X
inactive	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Du145	B-X
and	B-X
PC3	B-X
prostate	B-X
cancer	B-X
cells	B-X
express	B-X
the	B-X
GSTP1	B-X
gene	B-X
and	B-X
exhibit	B-X
methylated	B-X
and	B-X
unmethylated	B-X
GSTP1	B-X
alleles	B-X
.	B-X
In	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
using	B-X
LNCaP	B-X
cells	B-X
,	B-X
methylation	B-X
of	B-X
the	B-X
GSTP1	B-X
promoter-driven	B-X
luciferase	B-X
reporter	B-X
vector	B-X
(	B-X
GSTP1-pGL3	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
>	B-X
20-fold	B-X
inhibition	B-X
of	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
not	B-X
relieved	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
LNCaP	B-X
cells	B-X
with	B-X
a	B-X
DNA	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
5-Aza-2'-deoxycytidine	B-X
,	B-X
resulted	B-X
in	B-X
demethylation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
TSA	B-X
treatment	B-X
failed	B-X
to	B-X
demethylate	B-X
or	B-X
activate	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
Fully	B-X
methylated	B-X
but	B-X
not	B-X
unmethylated	B-X
GSTP1	B-X
promoter	B-X
fragment	B-X
was	B-X
shown	B-X
to	B-X
bind	B-X
to	B-X
a	B-X
complex	B-X
similar	B-X
to	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1	B-X
that	B-X
contains	B-X
methyl-CpG-binding	B-X
domain	B-X
2	B-X
protein	B-X
(	B-X
MBD2	B-X
)	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
LNCaP	B-X
cell	B-X
nuclear	B-X
extracts	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
cytosine	B-X
methylation	B-X
can	B-X
repress	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
possibly	B-X
mediated	B-X
by	B-X
a	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1-like	B-X
complex	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
also	B-X
support	B-X
the	B-X
notion	B-X
of	B-X
the	B-X
dominance	B-X
of	B-X
methylation	B-X
over	B-X
TSA-sensitive	B-X
histone	B-X
deacetylation	B-X
in	B-X
silencing	B-X
genes	B-X
with	B-X
a	B-X
high	B-X
CpG	B-X
density	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
.	B-X

In	O
contrast	O
,	O
TSA	O
treatment	O
failed	O
to	O
demethylate	O
or	O
activate	O
the	O
GSTP1	B-Protein
gene	O
.	O
<EOS>	B-X
In	B-X
the	B-X
early	B-X
years	B-X
of	B-X
the	B-X
molecular	B-X
biology	B-X
revolution	B-X
,	B-X
cancer	B-X
research	B-X
mainly	B-X
focuses	B-X
on	B-X
genetic	B-X
alterations	B-X
,	B-X
including	B-X
gastric	B-X
cancer	B-X
.	B-X
Epigenetic	B-X
mechanisms	B-X
are	B-X
essential	B-X
for	B-X
normal	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
tissue-specific	B-X
gene	B-X
expression	B-X
patterns	B-X
in	B-X
mammals	B-X
.	B-X
Disruption	B-X
of	B-X
epigenetic	B-X
processes	B-X
can	B-X
lead	B-X
to	B-X
altered	B-X
gene	B-X
function	B-X
and	B-X
malignant	B-X
cellular	B-X
transformation	B-X
.	B-X
Recent	B-X
advancements	B-X
in	B-X
the	B-X
rapidly	B-X
evolving	B-X
field	B-X
of	B-X
cancer	B-X
epigenetics	B-X
have	B-X
shown	B-X
extensive	B-X
reprogramming	B-X
of	B-X
every	B-X
component	B-X
of	B-X
the	B-X
epigenetic	B-X
machinery	B-X
in	B-X
cancer	B-X
,	B-X
including	B-X
DNA	B-X
methylation	B-X
,	B-X
histone	B-X
modifications	B-X
,	B-X
nucleosome	B-X
positioning	B-X
,	B-X
noncoding	B-X
RNAs	B-X
,	B-X
and	B-X
microRNAs	B-X
.	B-X
Aberrant	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
promoter	B-X
regions	B-X
of	B-X
gene	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
inactivation	B-X
of	B-X
tumor	B-X
suppressor	B-X
and	B-X
other	B-X
cancer-related	B-X
genes	B-X
in	B-X
cancer	B-X
cells	B-X
,	B-X
is	B-X
the	B-X
most	B-X
well-defined	B-X
epigenetic	B-X
hallmark	B-X
in	B-X
gastric	B-X
cancer	B-X
.	B-X
The	B-X
advantages	B-X
of	B-X
gene	B-X
methylation	B-X
as	B-X
a	B-X
target	B-X
for	B-X
detection	B-X
and	B-X
diagnosis	B-X
of	B-X
cancer	B-X
in	B-X
biopsy	B-X
specimens	B-X
and	B-X
non-invasive	B-X
body	B-X
fluids	B-X
such	B-X
as	B-X
serum	B-X
and	B-X
gastric	B-X
washes	B-X
have	B-X
led	B-X
to	B-X
many	B-X
studies	B-X
of	B-X
application	B-X
in	B-X
gastric	B-X
cancer	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
most	B-X
common	B-X
and	B-X
important	B-X
phenomenon	B-X
of	B-X
epigenetics	B-X
,	B-X
DNA	B-X
methylation	B-X
,	B-X
in	B-X
gastric	B-X
cancer	B-X
and	B-X
illustrates	B-X
the	B-X
impact	B-X
epigenetics	B-X
has	B-X
had	B-X
on	B-X
this	B-X
field	B-X
.	B-X

Fully	O
methylated	O
but	O
not	O
unmethylated	O
GSTP1	B-Protein
promoter	O
fragment	O
was	O
shown	O
to	O
bind	O
to	O
a	O
complex	O
similar	O
to	O
methyl	O
cytosine	O
-	O
binding	O
protein	O
complex	O
1	O
that	O
contains	O
methyl	B-Protein
-	I-Protein
CpG	I-Protein
-	I-Protein
binding	I-Protein
domain	I-Protein
2	I-Protein
protein	I-Protein
(	O
MBD2	B-Protein
)	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
using	O
LNCaP	O
cell	O
nuclear	O
extracts	O
.	O
<EOS>	B-X
Ancestral	B-X
and	B-X
direct	B-X
exposures	B-X
to	B-X
environmental	B-X
toxicants	B-X
and	B-X
altered	B-X
nutrition	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
increase	B-X
susceptibility	B-X
for	B-X
obesity	B-X
and	B-X
metabolic	B-X
dysregulation	B-X
.	B-X
Psoriasis	B-X
is	B-X
a	B-X
chronic	B-X
,	B-X
systemic	B-X
,	B-X
immune-mediated	B-X
disease	B-X
with	B-X
an	B-X
incidence	B-X
of	B-X
approximately	B-X
2	B-X
%	B-X
.	B-X
The	B-X
pathogenesis	B-X
of	B-X
the	B-X
disease	B-X
is	B-X
complex	B-X
and	B-X
not	B-X
yet	B-X
fully	B-X
understood	B-X
.	B-X
Epigenetic	B-X
mechanisms	B-X
in	B-X
psoriasis	B-X
include	B-X
DNA	B-X
methylation	B-X
,	B-X
histone	B-X
modifications	B-X
and	B-X
non-coding	B-X
RNAs	B-X
.	B-X
Epigenetic	B-X
factors	B-X
can	B-X
regulate	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
transcriptional	B-X
(	B-X
via	B-X
histone	B-X
modification	B-X
,	B-X
DNA	B-X
methylation	B-X
)	B-X
and	B-X
posttranscriptional	B-X
levels	B-X
(	B-X
via	B-X
microRNAs	B-X
and	B-X
long	B-X
non-coding	B-X
RNAs	B-X
)	B-X
.	B-X

These	O
data	O
demonstrate	O
that	O
cytosine	O
methylation	O
can	O
repress	O
GSTP1	B-Protein
gene	O
expression	O
in	O
LNCaP	O
prostate	O
cancer	O
cells	O
and	O
that	O
this	O
effect	O
is	O
possibly	O
mediated	O
by	O
a	O
methyl	O
cytosine	O
-	O
binding	O
protein	O
complex	O
1	O
-	O
like	O
complex	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
the	B-X
glutathione	B-X
S-transferase	B-X
P1	B-X
(	B-X
GSTP1	B-X
)	B-X
gene	B-X
has	B-X
been	B-X
described	B-X
as	B-X
a	B-X
highly	B-X
specific	B-X
and	B-X
sensitive	B-X
biomarker	B-X
for	B-X
prostate	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
at	B-X
present	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
methylation	B-X
represses	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X
We	B-X
found	B-X
the	B-X
GSTP1	B-X
gene	B-X
promoter	B-X
to	B-X
be	B-X
completely	B-X
methylated	B-X
in	B-X
the	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
,	B-X
where	B-X
this	B-X
gene	B-X
is	B-X
transcriptionally	B-X
inactive	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Du145	B-X
and	B-X
PC3	B-X
prostate	B-X
cancer	B-X
cells	B-X
express	B-X
the	B-X
GSTP1	B-X
gene	B-X
and	B-X
exhibit	B-X
methylated	B-X
and	B-X
unmethylated	B-X
GSTP1	B-X
alleles	B-X
.	B-X
In	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
using	B-X
LNCaP	B-X
cells	B-X
,	B-X
methylation	B-X
of	B-X
the	B-X
GSTP1	B-X
promoter-driven	B-X
luciferase	B-X
reporter	B-X
vector	B-X
(	B-X
GSTP1-pGL3	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
>	B-X
20-fold	B-X
inhibition	B-X
of	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
not	B-X
relieved	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
LNCaP	B-X
cells	B-X
with	B-X
a	B-X
DNA	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
5-Aza-2'-deoxycytidine	B-X
,	B-X
resulted	B-X
in	B-X
demethylation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
TSA	B-X
treatment	B-X
failed	B-X
to	B-X
demethylate	B-X
or	B-X
activate	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
Fully	B-X
methylated	B-X
but	B-X
not	B-X
unmethylated	B-X
GSTP1	B-X
promoter	B-X
fragment	B-X
was	B-X
shown	B-X
to	B-X
bind	B-X
to	B-X
a	B-X
complex	B-X
similar	B-X
to	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1	B-X
that	B-X
contains	B-X
methyl-CpG-binding	B-X
domain	B-X
2	B-X
protein	B-X
(	B-X
MBD2	B-X
)	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
LNCaP	B-X
cell	B-X
nuclear	B-X
extracts	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
cytosine	B-X
methylation	B-X
can	B-X
repress	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
possibly	B-X
mediated	B-X
by	B-X
a	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1-like	B-X
complex	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
also	B-X
support	B-X
the	B-X
notion	B-X
of	B-X
the	B-X
dominance	B-X
of	B-X
methylation	B-X
over	B-X
TSA-sensitive	B-X
histone	B-X
deacetylation	B-X
in	B-X
silencing	B-X
genes	B-X
with	B-X
a	B-X
high	B-X
CpG	B-X
density	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
.	B-X

Furthermore	O
,	O
these	O
data	O
also	O
support	O
the	O
notion	O
of	O
the	O
dominance	O
of	O
methylation	O
over	O
TSA	O
-	O
sensitive	O
histone	B-Protein
deacetylation	O
in	O
silencing	O
genes	O
with	O
a	O
high	O
CpG	O
density	O
in	O
the	O
promoter	O
region	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
the	B-X
glutathione	B-X
S-transferase	B-X
P1	B-X
(	B-X
GSTP1	B-X
)	B-X
gene	B-X
has	B-X
been	B-X
described	B-X
as	B-X
a	B-X
highly	B-X
specific	B-X
and	B-X
sensitive	B-X
biomarker	B-X
for	B-X
prostate	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
at	B-X
present	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
methylation	B-X
represses	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X
We	B-X
found	B-X
the	B-X
GSTP1	B-X
gene	B-X
promoter	B-X
to	B-X
be	B-X
completely	B-X
methylated	B-X
in	B-X
the	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
,	B-X
where	B-X
this	B-X
gene	B-X
is	B-X
transcriptionally	B-X
inactive	B-X
.	B-X
In	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
using	B-X
LNCaP	B-X
cells	B-X
,	B-X
methylation	B-X
of	B-X
the	B-X
GSTP1	B-X
promoter-driven	B-X
luciferase	B-X
reporter	B-X
vector	B-X
(	B-X
GSTP1-pGL3	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
>	B-X
20-fold	B-X
inhibition	B-X
of	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
not	B-X
relieved	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
LNCaP	B-X
cells	B-X
with	B-X
a	B-X
DNA	B-X
methyltransferase	B-X
inhibitor	B-X
,	B-X
5-Aza-2'-deoxycytidine	B-X
,	B-X
resulted	B-X
in	B-X
demethylation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
TSA	B-X
treatment	B-X
failed	B-X
to	B-X
demethylate	B-X
or	B-X
activate	B-X
the	B-X
GSTP1	B-X
gene	B-X
.	B-X
Fully	B-X
methylated	B-X
but	B-X
not	B-X
unmethylated	B-X
GSTP1	B-X
promoter	B-X
fragment	B-X
was	B-X
shown	B-X
to	B-X
bind	B-X
to	B-X
a	B-X
complex	B-X
similar	B-X
to	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1	B-X
that	B-X
contains	B-X
methyl-CpG-binding	B-X
domain	B-X
2	B-X
protein	B-X
(	B-X
MBD2	B-X
)	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
LNCaP	B-X
cell	B-X
nuclear	B-X
extracts	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
cytosine	B-X
methylation	B-X
can	B-X
repress	B-X
GSTP1	B-X
gene	B-X
expression	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
possibly	B-X
mediated	B-X
by	B-X
a	B-X
methyl	B-X
cytosine-binding	B-X
protein	B-X
complex	B-X
1-like	B-X
complex	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
also	B-X
support	B-X
the	B-X
notion	B-X
of	B-X
the	B-X
dominance	B-X
of	B-X
methylation	B-X
over	B-X
TSA-sensitive	B-X
histone	B-X
deacetylation	B-X
in	B-X
silencing	B-X
genes	B-X
with	B-X
a	B-X
high	B-X
CpG	B-X
density	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
.	B-X

Activation	O
of	O
the	O
maternally	O
preset	O
program	O
of	O
apoptosis	O
by	O
microinjection	O
of	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
and	O
5	O
-	O
methyl	O
-	O
2	O
'	O
-	O
deoxycytidine	O
-	O
5	O
'	O
-	O
triphosphate	O
in	O
Xenopus	O
laevis	O
embryos	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
effects	B-X
on	B-X
embryogenesis	B-X
of	B-X
microinjecting	B-X
Xenopus	B-X
laevis	B-X
fertilized	B-X
eggs	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-Aza-CdR	B-X
)	B-X
,	B-X
which	B-X
induces	B-X
hypomethylation	B-X
of	B-X
DNA	B-X
,	B-X
and	B-X
5-methyl-2'-	B-X
deoxycytidine-5'-triphosphate	B-X
(	B-X
5-methyl-dCTP	B-X
)	B-X
,	B-X
which	B-X
induces	B-X
hypermethylation	B-X
of	B-X
DNA	B-X
.	B-X
Dissociated	B-X
cells	B-X
that	B-X
appeared	B-X
here	B-X
were	B-X
positive	B-X
by	B-X
terminal	B-X
deoxyribonucleotidyl	B-X
transferase-mediated	B-X
deoxyuridine	B-X
triphosphate-digoxigenin	B-X
nick	B-X
end-labeling	B-X
and	B-X
contained	B-X
fragmented	B-X
nuclei	B-X
with	B-X
condensed	B-X
chromatin	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
cell	B-X
dissociation	B-X
by	B-X
5-Aza-CdR	B-X
and	B-X
5-methyl-dCTP	B-X
was	B-X
postponed	B-X
by	B-X
2-3	B-X
h	B-X
by	B-X
co-injection	B-X
of	B-X
Bcl-2	B-X
mRNA	B-X
and	B-X
the	B-X
normal	B-X
metabolite	B-X
(	B-X
CdR	B-X
and	B-X
dCTP	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
5-methyl-cytosine	B-X
,	B-X
we	B-X
confirmed	B-X
that	B-X
5-Aza-CdR	B-X
induces	B-X
hypomethylation	B-X
,	B-X
whereas	B-X
5-methyl-dCTP	B-X
induces	B-X
hypermethylation	B-X
in	B-X
X.	B-X
laevis	B-X
embryos	B-X
before	B-X
the	B-X
onset	B-X
of	B-X
cell	B-X
dissociation	B-X
.	B-X
Incorporation	B-X
of	B-X
radioactive	B-X
precursors	B-X
revealed	B-X
that	B-X
synthesis	B-X
of	B-X
DNA	B-X
,	B-X
and	B-X
also	B-X
RNA	B-X
,	B-X
is	B-X
inhibited	B-X
significantly	B-X
in	B-X
both	B-X
5-Aza-CdR-injected	B-X
and	B-X
5-methyl-dCTP-injected	B-X
embryos	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
5-Aza-CdR	B-X
and	B-X
5-methyl-dCTP	B-X
are	B-X
incorporated	B-X
into	B-X
DNA	B-X
and	B-X
induce	B-X
apoptosis	B-X
,	B-X
probably	B-X
through	B-X
alteration	B-X
of	B-X
DNA	B-X
methylation	B-X
coupled	B-X
with	B-X
inhibition	B-X
of	B-X
DNA	B-X
replication	B-X
and/or	B-X
transcription	B-X
.	B-X

The	O
present	O
study	O
examines	O
the	O
effects	O
on	O
embryogenesis	O
of	O
microinjecting	O
Xenopus	O
laevis	O
fertilized	O
eggs	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
Aza	O
-	O
CdR	O
)	O
,	O
which	O
induces	O
hypomethylation	O
of	O
DNA	O
,	O
and	O
5	O
-	O
methyl	O
-	O
2	O
'	O
-	O
deoxycytidine	O
-	O
5	O
'	O
-	O
triphosphate	O
(	O
5	O
-	O
methyl	O
-	O
dCTP	O
)	O
,	O
which	O
induces	O
hypermethylation	O
of	O
DNA	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
effects	B-X
on	B-X
embryogenesis	B-X
of	B-X
microinjecting	B-X
Xenopus	B-X
laevis	B-X
fertilized	B-X
eggs	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-Aza-CdR	B-X
)	B-X
,	B-X
which	B-X
induces	B-X
hypomethylation	B-X
of	B-X
DNA	B-X
,	B-X
and	B-X
5-methyl-2'-	B-X
deoxycytidine-5'-triphosphate	B-X
(	B-X
5-methyl-dCTP	B-X
)	B-X
,	B-X
which	B-X
induces	B-X
hypermethylation	B-X
of	B-X
DNA	B-X
.	B-X
Dissociated	B-X
cells	B-X
that	B-X
appeared	B-X
here	B-X
were	B-X
positive	B-X
by	B-X
terminal	B-X
deoxyribonucleotidyl	B-X
transferase-mediated	B-X
deoxyuridine	B-X
triphosphate-digoxigenin	B-X
nick	B-X
end-labeling	B-X
and	B-X
contained	B-X
fragmented	B-X
nuclei	B-X
with	B-X
condensed	B-X
chromatin	B-X
.	B-X
The	B-X
DNA	B-X
from	B-X
these	B-X
cells	B-X
formed	B-X
a	B-X
``	B-X
ladder	B-X
''	B-X
on	B-X
electrophoresis	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
cell	B-X
dissociation	B-X
by	B-X
5-Aza-CdR	B-X
and	B-X
5-methyl-dCTP	B-X
was	B-X
postponed	B-X
by	B-X
2-3	B-X
h	B-X
by	B-X
co-injection	B-X
of	B-X
Bcl-2	B-X
mRNA	B-X
and	B-X
the	B-X
normal	B-X
metabolite	B-X
(	B-X
CdR	B-X
and	B-X
dCTP	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
5-methyl-cytosine	B-X
,	B-X
we	B-X
confirmed	B-X
that	B-X
5-Aza-CdR	B-X
induces	B-X
hypomethylation	B-X
,	B-X
whereas	B-X
5-methyl-dCTP	B-X
induces	B-X
hypermethylation	B-X
in	B-X
X.	B-X
laevis	B-X
embryos	B-X
before	B-X
the	B-X
onset	B-X
of	B-X
cell	B-X
dissociation	B-X
.	B-X
Incorporation	B-X
of	B-X
radioactive	B-X
precursors	B-X
revealed	B-X
that	B-X
synthesis	B-X
of	B-X
DNA	B-X
,	B-X
and	B-X
also	B-X
RNA	B-X
,	B-X
is	B-X
inhibited	B-X
significantly	B-X
in	B-X
both	B-X
5-Aza-CdR-injected	B-X
and	B-X
5-methyl-dCTP-injected	B-X
embryos	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
5-Aza-CdR	B-X
and	B-X
5-methyl-dCTP	B-X
are	B-X
incorporated	B-X
into	B-X
DNA	B-X
and	B-X
induce	B-X
apoptosis	B-X
,	B-X
probably	B-X
through	B-X
alteration	B-X
of	B-X
DNA	B-X
methylation	B-X
coupled	B-X
with	B-X
inhibition	B-X
of	B-X
DNA	B-X
replication	B-X
and/or	B-X
transcription	B-X
.	B-X

Embryos	O
injected	O
with	O
either	O
one	O
of	O
these	O
analogs	O
cleaved	O
normally	O
until	O
the	O
mid	O
-	O
blastula	O
stage	O
,	O
but	O
underwent	O
massive	O
cell	O
dissociation	O
and	O
stopped	O
development	O
at	O
the	O
early	O
gastrula	O
stage	O
.	O
<EOS>	B-X
Embryos	B-X
injected	B-X
with	B-X
either	B-X
one	B-X
of	B-X
these	B-X
analogs	B-X
cleaved	B-X
normally	B-X
until	B-X
the	B-X
mid-blastula	B-X
stage	B-X
,	B-X
but	B-X
underwent	B-X
massive	B-X
cell	B-X
dissociation	B-X
and	B-X
stopped	B-X
development	B-X
at	B-X
the	B-X
early	B-X
gastrula	B-X
stage	B-X
.	B-X
Dissociated	B-X
cells	B-X
that	B-X
appeared	B-X
here	B-X
were	B-X
positive	B-X
by	B-X
terminal	B-X
deoxyribonucleotidyl	B-X
transferase-mediated	B-X
deoxyuridine	B-X
triphosphate-digoxigenin	B-X
nick	B-X
end-labeling	B-X
and	B-X
contained	B-X
fragmented	B-X
nuclei	B-X
with	B-X
condensed	B-X
chromatin	B-X
.	B-X
The	B-X
DNA	B-X
from	B-X
these	B-X
cells	B-X
formed	B-X
a	B-X
``	B-X
ladder	B-X
''	B-X
on	B-X
electrophoresis	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
cell	B-X
dissociation	B-X
by	B-X
5-Aza-CdR	B-X
and	B-X
5-methyl-dCTP	B-X
was	B-X
postponed	B-X
by	B-X
2-3	B-X
h	B-X
by	B-X
co-injection	B-X
of	B-X
Bcl-2	B-X
mRNA	B-X
and	B-X
the	B-X
normal	B-X
metabolite	B-X
(	B-X
CdR	B-X
and	B-X
dCTP	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
5-methyl-cytosine	B-X
,	B-X
we	B-X
confirmed	B-X
that	B-X
5-Aza-CdR	B-X
induces	B-X
hypomethylation	B-X
,	B-X
whereas	B-X
5-methyl-dCTP	B-X
induces	B-X
hypermethylation	B-X
in	B-X
X.	B-X
laevis	B-X
embryos	B-X
before	B-X
the	B-X
onset	B-X
of	B-X
cell	B-X
dissociation	B-X
.	B-X
Incorporation	B-X
of	B-X
radioactive	B-X
precursors	B-X
revealed	B-X
that	B-X
synthesis	B-X
of	B-X
DNA	B-X
,	B-X
and	B-X
also	B-X
RNA	B-X
,	B-X
is	B-X
inhibited	B-X
significantly	B-X
in	B-X
both	B-X
5-Aza-CdR-injected	B-X
and	B-X
5-methyl-dCTP-injected	B-X
embryos	B-X
.	B-X

Dissociated	O
cells	O
that	O
appeared	O
here	O
were	O
positive	O
by	O
terminal	O
deoxyribonucleotidyl	O
transferase	O
-	O
mediated	O
deoxyuridine	O
triphosphate	O
-	O
digoxigenin	O
nick	O
end	O
-	O
labeling	O
and	O
contained	O
fragmented	O
nuclei	O
with	O
condensed	O
chromatin	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
effects	B-X
on	B-X
embryogenesis	B-X
of	B-X
microinjecting	B-X
Xenopus	B-X
laevis	B-X
fertilized	B-X
eggs	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-Aza-CdR	B-X
)	B-X
,	B-X
which	B-X
induces	B-X
hypomethylation	B-X
of	B-X
DNA	B-X
,	B-X
and	B-X
5-methyl-2'-	B-X
deoxycytidine-5'-triphosphate	B-X
(	B-X
5-methyl-dCTP	B-X
)	B-X
,	B-X
which	B-X
induces	B-X
hypermethylation	B-X
of	B-X
DNA	B-X
.	B-X
Dissociated	B-X
cells	B-X
that	B-X
appeared	B-X
here	B-X
were	B-X
positive	B-X
by	B-X
terminal	B-X
deoxyribonucleotidyl	B-X
transferase-mediated	B-X
deoxyuridine	B-X
triphosphate-digoxigenin	B-X
nick	B-X
end-labeling	B-X
and	B-X
contained	B-X
fragmented	B-X
nuclei	B-X
with	B-X
condensed	B-X
chromatin	B-X
.	B-X
The	B-X
DNA	B-X
from	B-X
these	B-X
cells	B-X
formed	B-X
a	B-X
``	B-X
ladder	B-X
''	B-X
on	B-X
electrophoresis	B-X
.	B-X

The	O
DNA	O
from	O
these	O
cells	O
formed	O
a	O
"	O
ladder	O
"	O
on	O
electrophoresis	O
.	O
<EOS>	B-X
Apoptosis	B-X
has	B-X
been	B-X
recognized	B-X
as	B-X
a	B-X
type	B-X
of	B-X
programmed	B-X
cell	B-X
death	B-X
connected	B-X
with	B-X
characteristic	B-X
morphological	B-X
and	B-X
biochemical	B-X
changes	B-X
in	B-X
cells	B-X
.	B-X
The	B-X
present	B-X
paper	B-X
provides	B-X
an	B-X
overview	B-X
of	B-X
methods	B-X
often	B-X
being	B-X
used	B-X
for	B-X
detecting	B-X
DNA	B-X
fragmentation	B-X
as	B-X
one	B-X
of	B-X
the	B-X
most	B-X
specific	B-X
findings	B-X
in	B-X
apoptosis	B-X
.	B-X
To	B-X
date	B-X
,	B-X
three	B-X
routine	B-X
assays	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
detecting	B-X
DNA	B-X
fragmentation	B-X
:	B-X
DNA	B-X
ladder	B-X
assay	B-X
,	B-X
TUNEL	B-X
assay	B-X
,	B-X
and	B-X
comet	B-X
assay	B-X
.	B-X
All	B-X
these	B-X
methods	B-X
differ	B-X
in	B-X
their	B-X
principles	B-X
for	B-X
detecting	B-X
DNA	B-X
fragmentation	B-X
.	B-X
DNA	B-X
ladder	B-X
assay	B-X
detects	B-X
the	B-X
characteristic	B-X
``	B-X
DNA	B-X
ladder	B-X
''	B-X
pattern	B-X
formed	B-X
during	B-X
internucleosomal	B-X
cleavage	B-X
of	B-X
DNA	B-X
.	B-X
Terminal	B-X
deoxynUcleotidyl	B-X
transferase	B-X
Nick-End	B-X
Labeling	B-X
(	B-X
TUNEL	B-X
)	B-X
assay	B-X
detects	B-X
DNA	B-X
strand	B-X
breaks	B-X
using	B-X
terminal	B-X
deoxynucleotidyl	B-X
transferase	B-X
catalyzing	B-X
attachment	B-X
of	B-X
modified	B-X
deoxynucleotides	B-X
on	B-X
the	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
Comet	B-X
assay	B-X
can	B-X
be	B-X
used	B-X
for	B-X
detecting	B-X
nucleus	B-X
breakdown	B-X
producing	B-X
single/double-strand	B-X
DNA	B-X
breaks	B-X
.	B-X

Furthermore	O
,	O
the	O
induction	O
of	O
cell	O
dissociation	O
by	O
5	O
-	O
Aza	O
-	O
CdR	O
and	O
5	O
-	O
methyl	O
-	O
dCTP	O
was	O
postponed	O
by	O
2	O
-	O
3	O
h	O
by	O
co	O
-	O
injection	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
mRNA	O
and	O
the	O
normal	O
metabolite	O
(	O
CdR	O
and	O
dCTP	O
,	O
respectively	O
)	O
.	O

Using	O
a	O
specific	O
antibody	O
against	O
5	O
-	O
methyl	O
-	O
cytosine	O
,	O
we	O
confirmed	O
that	O
5	O
-	O
Aza	O
-	O
CdR	O
induces	O
hypomethylation	O
,	O
whereas	O
5	O
-	O
methyl	O
-	O
dCTP	O
induces	O
hypermethylation	O
in	O
X	O
.	O
laevis	O
embryos	O
before	O
the	O
onset	O
of	O
cell	O
dissociation	O
.	O

Incorporation	O
of	O
radioactive	O
precursors	O
revealed	O
that	O
synthesis	O
of	O
DNA	O
,	O
and	O
also	O
RNA	O
,	O
is	O
inhibited	O
significantly	O
in	O
both	O
5	O
-	O
Aza	O
-	O
CdR	O
-	O
injected	O
and	O
5	O
-	O
methyl	O
-	O
dCTP	O
-	O
injected	O
embryos	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
effects	B-X
on	B-X
embryogenesis	B-X
of	B-X
microinjecting	B-X
Xenopus	B-X
laevis	B-X
fertilized	B-X
eggs	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-Aza-CdR	B-X
)	B-X
,	B-X
which	B-X
induces	B-X
hypomethylation	B-X
of	B-X
DNA	B-X
,	B-X
and	B-X
5-methyl-2'-	B-X
deoxycytidine-5'-triphosphate	B-X
(	B-X
5-methyl-dCTP	B-X
)	B-X
,	B-X
which	B-X
induces	B-X
hypermethylation	B-X
of	B-X
DNA	B-X
.	B-X
Embryos	B-X
injected	B-X
with	B-X
either	B-X
one	B-X
of	B-X
these	B-X
analogs	B-X
cleaved	B-X
normally	B-X
until	B-X
the	B-X
mid-blastula	B-X
stage	B-X
,	B-X
but	B-X
underwent	B-X
massive	B-X
cell	B-X
dissociation	B-X
and	B-X
stopped	B-X
development	B-X
at	B-X
the	B-X
early	B-X
gastrula	B-X
stage	B-X
.	B-X
The	B-X
DNA	B-X
from	B-X
these	B-X
cells	B-X
formed	B-X
a	B-X
``	B-X
ladder	B-X
''	B-X
on	B-X
electrophoresis	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
cell	B-X
dissociation	B-X
by	B-X
5-Aza-CdR	B-X
and	B-X
5-methyl-dCTP	B-X
was	B-X
postponed	B-X
by	B-X
2-3	B-X
h	B-X
by	B-X
co-injection	B-X
of	B-X
Bcl-2	B-X
mRNA	B-X
and	B-X
the	B-X
normal	B-X
metabolite	B-X
(	B-X
CdR	B-X
and	B-X
dCTP	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
5-methyl-cytosine	B-X
,	B-X
we	B-X
confirmed	B-X
that	B-X
5-Aza-CdR	B-X
induces	B-X
hypomethylation	B-X
,	B-X
whereas	B-X
5-methyl-dCTP	B-X
induces	B-X
hypermethylation	B-X
in	B-X
X.	B-X
laevis	B-X
embryos	B-X
before	B-X
the	B-X
onset	B-X
of	B-X
cell	B-X
dissociation	B-X
.	B-X
Incorporation	B-X
of	B-X
radioactive	B-X
precursors	B-X
revealed	B-X
that	B-X
synthesis	B-X
of	B-X
DNA	B-X
,	B-X
and	B-X
also	B-X
RNA	B-X
,	B-X
is	B-X
inhibited	B-X
significantly	B-X
in	B-X
both	B-X
5-Aza-CdR-injected	B-X
and	B-X
5-methyl-dCTP-injected	B-X
embryos	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
5-Aza-CdR	B-X
and	B-X
5-methyl-dCTP	B-X
are	B-X
incorporated	B-X
into	B-X
DNA	B-X
and	B-X
induce	B-X
apoptosis	B-X
,	B-X
probably	B-X
through	B-X
alteration	B-X
of	B-X
DNA	B-X
methylation	B-X
coupled	B-X
with	B-X
inhibition	B-X
of	B-X
DNA	B-X
replication	B-X
and/or	B-X
transcription	B-X
.	B-X

These	O
results	O
show	O
that	O
5	O
-	O
Aza	O
-	O
CdR	O
and	O
5	O
-	O
methyl	O
-	O
dCTP	O
are	O
incorporated	O
into	O
DNA	O
and	O
induce	O
apoptosis	O
,	O
probably	O
through	O
alteration	O
of	O
DNA	O
methylation	O
coupled	O
with	O
inhibition	O
of	O
DNA	O
replication	O
and	O
/	O
or	O
transcription	O
.	O
<EOS>	B-X
The	B-X
human	B-X
transcriptome	B-X
comprises	B-X
>	B-X
80,000	B-X
protein-coding	B-X
transcripts	B-X
and	B-X
the	B-X
estimated	B-X
number	B-X
of	B-X
proteins	B-X
synthesized	B-X
from	B-X
these	B-X
transcripts	B-X
is	B-X
in	B-X
the	B-X
range	B-X
of	B-X
250,000	B-X
to	B-X
1	B-X
million	B-X
.	B-X
These	B-X
transcripts	B-X
and	B-X
proteins	B-X
are	B-X
encoded	B-X
by	B-X
less	B-X
than	B-X
20,000	B-X
genes	B-X
,	B-X
suggesting	B-X
extensive	B-X
regulation	B-X
at	B-X
the	B-X
transcriptional	B-X
,	B-X
post-transcriptional	B-X
,	B-X
and	B-X
translational	B-X
level	B-X
.	B-X
We	B-X
highlight	B-X
four	B-X
different	B-X
regulatory	B-X
processes	B-X
:	B-X
alternative	B-X
transcription	B-X
initiation	B-X
,	B-X
alternative	B-X
splicing	B-X
,	B-X
alternative	B-X
polyadenylation	B-X
,	B-X
and	B-X
alternative	B-X
translation	B-X
initiation	B-X
.	B-X
The	B-X
concept	B-X
of	B-X
early	B-X
termination	B-X
as	B-X
an	B-X
important	B-X
means	B-X
of	B-X
transcriptional	B-X
control	B-X
has	B-X
long	B-X
been	B-X
established	B-X
.	B-X
Recent	B-X
technological	B-X
advances	B-X
provide	B-X
novel	B-X
insights	B-X
into	B-X
premature	B-X
transcription	B-X
termination	B-X
(	B-X
PTT	B-X
)	B-X
.	B-X
This	B-X
process	B-X
is	B-X
frequent	B-X
,	B-X
widespread	B-X
,	B-X
and	B-X
can	B-X
occur	B-X
close	B-X
to	B-X
the	B-X
transcription	B-X
start	B-X
site	B-X
(	B-X
TSS	B-X
)	B-X
,	B-X
or	B-X
within	B-X
the	B-X
gene	B-X
body	B-X
.	B-X
Independently	B-X
of	B-X
transcript	B-X
stability	B-X
and	B-X
function	B-X
,	B-X
premature	B-X
termination	B-X
opposes	B-X
the	B-X
formation	B-X
of	B-X
full-length	B-X
transcripts	B-X
,	B-X
thereby	B-X
negatively	B-X
regulating	B-X
gene	B-X
expression	B-X
,	B-X
especially	B-X
of	B-X
transcriptional	B-X
regulators	B-X
.	B-X

Impairment	O
of	O
erythrocyte	O
viscoelasticity	O
is	O
correlated	O
with	O
levels	O
of	O
glycosylated	O
haemoglobin	O
in	O
diabetic	O
patients	O
.	O
<EOS>	B-X
Erythrocytes	B-X
from	B-X
diabetic	B-X
patients	B-X
exhibit	B-X
impaired	B-X
viscoelastic	B-X
properties	B-X
when	B-X
estimated	B-X
by	B-X
various	B-X
methods	B-X
.	B-X
We	B-X
determined	B-X
erythrocyte	B-X
filterability	B-X
through	B-X
5-microm	B-X
pores	B-X
,	B-X
in	B-X
51	B-X
patients	B-X
with	B-X
non-insulin-dependent	B-X
diabetes	B-X
mellitus	B-X
,	B-X
18	B-X
healthy	B-X
controls	B-X
,	B-X
15	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
and	B-X
15	B-X
with	B-X
beta-thalassemia	B-X
traits	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
Index	B-X
of	B-X
Rigidity	B-X
(	B-X
IR	B-X
)	B-X
of	B-X
the	B-X
red	B-X
blood	B-X
cells	B-X
,	B-X
we	B-X
measured	B-X
the	B-X
passage	B-X
time	B-X
of	B-X
white	B-X
blood	B-X
cell-free	B-X
erythrocyte	B-X
suspensions	B-X
,	B-X
8	B-X
%	B-X
per	B-X
volume	B-X
,	B-X
through	B-X
the	B-X
filter	B-X
.	B-X
Diabetic	B-X
patients	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
healthy	B-X
controls	B-X
and	B-X
to	B-X
patients	B-X
with	B-X
beta-thalassemia	B-X
trait	B-X
,	B-X
but	B-X
not	B-X
at	B-X
the	B-X
level	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
.	B-X
In	B-X
diabetic	B-X
patients	B-X
,	B-X
a	B-X
strong	B-X
correlation	B-X
between	B-X
IR	B-X
and	B-X
the	B-X
percentage	B-X
of	B-X
glycosylated	B-X
haemoglobin	B-X
was	B-X
found	B-X
(	B-X
r=0.737	B-X
,	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
and	B-X
a	B-X
weaker	B-X
one	B-X
with	B-X
serum	B-X
unconjugated	B-X
bilirubin	B-X
(	B-X
r=0.363	B-X
,	B-X
P=0.0097	B-X
)	B-X
and	B-X
serum	B-X
total	B-X
lipids	B-X
(	B-X
r=0.321	B-X
,	B-X
P=0.0286	B-X
)	B-X
.	B-X
Anaemic	B-X
diabetic	B-X
patients	B-X
,	B-X
especially	B-X
those	B-X
with	B-X
the	B-X
anaemia	B-X
of	B-X
chronic	B-X
disease	B-X
,	B-X
also	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
non-anaemic	B-X
diabetics	B-X
.	B-X
No	B-X
correlation	B-X
between	B-X
IR	B-X
,	B-X
MCV	B-X
,	B-X
MCH	B-X
,	B-X
MCHC	B-X
,	B-X
RDW	B-X
,	B-X
RBC	B-X
morphology	B-X
,	B-X
serum	B-X
LDH	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
erythrocyte	B-X
inclusions	B-X
after	B-X
incubation	B-X
with	B-X
nitrous	B-X
sodium	B-X
solution	B-X
was	B-X
found	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
glycosylation	B-X
of	B-X
skeletal	B-X
proteins	B-X
probably	B-X
contributes	B-X
significantly	B-X
to	B-X
the	B-X
increased	B-X
membrane	B-X
rigidity	B-X
of	B-X
diabetic	B-X
erythrocytes	B-X
.	B-X

Erythrocytes	O
from	O
diabetic	O
patients	O
exhibit	O
impaired	O
viscoelastic	O
properties	O
when	O
estimated	O
by	O
various	O
methods	O
.	O
<EOS>	B-X
Erythrocytes	B-X
from	B-X
diabetic	B-X
patients	B-X
exhibit	B-X
impaired	B-X
viscoelastic	B-X
properties	B-X
when	B-X
estimated	B-X
by	B-X
various	B-X
methods	B-X
.	B-X
We	B-X
determined	B-X
erythrocyte	B-X
filterability	B-X
through	B-X
5-microm	B-X
pores	B-X
,	B-X
in	B-X
51	B-X
patients	B-X
with	B-X
non-insulin-dependent	B-X
diabetes	B-X
mellitus	B-X
,	B-X
18	B-X
healthy	B-X
controls	B-X
,	B-X
15	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
and	B-X
15	B-X
with	B-X
beta-thalassemia	B-X
traits	B-X
.	B-X
Diabetic	B-X
patients	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
healthy	B-X
controls	B-X
and	B-X
to	B-X
patients	B-X
with	B-X
beta-thalassemia	B-X
trait	B-X
,	B-X
but	B-X
not	B-X
at	B-X
the	B-X
level	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
.	B-X
In	B-X
diabetic	B-X
patients	B-X
,	B-X
a	B-X
strong	B-X
correlation	B-X
between	B-X
IR	B-X
and	B-X
the	B-X
percentage	B-X
of	B-X
glycosylated	B-X
haemoglobin	B-X
was	B-X
found	B-X
(	B-X
r=0.737	B-X
,	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
and	B-X
a	B-X
weaker	B-X
one	B-X
with	B-X
serum	B-X
unconjugated	B-X
bilirubin	B-X
(	B-X
r=0.363	B-X
,	B-X
P=0.0097	B-X
)	B-X
and	B-X
serum	B-X
total	B-X
lipids	B-X
(	B-X
r=0.321	B-X
,	B-X
P=0.0286	B-X
)	B-X
.	B-X
Anaemic	B-X
diabetic	B-X
patients	B-X
,	B-X
especially	B-X
those	B-X
with	B-X
the	B-X
anaemia	B-X
of	B-X
chronic	B-X
disease	B-X
,	B-X
also	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
non-anaemic	B-X
diabetics	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
glycosylation	B-X
of	B-X
skeletal	B-X
proteins	B-X
probably	B-X
contributes	B-X
significantly	B-X
to	B-X
the	B-X
increased	B-X
membrane	B-X
rigidity	B-X
of	B-X
diabetic	B-X
erythrocytes	B-X
.	B-X

We	O
determined	O
erythrocyte	O
filterability	O
through	O
5	O
-	O
microm	O
pores	O
,	O
in	O
51	O
patients	O
with	O
non	O
-	O
insulin	B-Protein
-	O
dependent	O
diabetes	O
mellitus	O
,	O
18	O
healthy	O
controls	O
,	O
15	O
patients	O
with	O
homozygous	O
beta	O
-	O
thalassemia	O
and	O
15	O
with	O
beta	O
-	O
thalassemia	O
traits	O
.	O
<EOS>	B-X
Erythrocytes	B-X
from	B-X
diabetic	B-X
patients	B-X
exhibit	B-X
impaired	B-X
viscoelastic	B-X
properties	B-X
when	B-X
estimated	B-X
by	B-X
various	B-X
methods	B-X
.	B-X
We	B-X
determined	B-X
erythrocyte	B-X
filterability	B-X
through	B-X
5-microm	B-X
pores	B-X
,	B-X
in	B-X
51	B-X
patients	B-X
with	B-X
non-insulin-dependent	B-X
diabetes	B-X
mellitus	B-X
,	B-X
18	B-X
healthy	B-X
controls	B-X
,	B-X
15	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
and	B-X
15	B-X
with	B-X
beta-thalassemia	B-X
traits	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
Index	B-X
of	B-X
Rigidity	B-X
(	B-X
IR	B-X
)	B-X
of	B-X
the	B-X
red	B-X
blood	B-X
cells	B-X
,	B-X
we	B-X
measured	B-X
the	B-X
passage	B-X
time	B-X
of	B-X
white	B-X
blood	B-X
cell-free	B-X
erythrocyte	B-X
suspensions	B-X
,	B-X
8	B-X
%	B-X
per	B-X
volume	B-X
,	B-X
through	B-X
the	B-X
filter	B-X
.	B-X
Diabetic	B-X
patients	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
healthy	B-X
controls	B-X
and	B-X
to	B-X
patients	B-X
with	B-X
beta-thalassemia	B-X
trait	B-X
,	B-X
but	B-X
not	B-X
at	B-X
the	B-X
level	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
.	B-X
In	B-X
diabetic	B-X
patients	B-X
,	B-X
a	B-X
strong	B-X
correlation	B-X
between	B-X
IR	B-X
and	B-X
the	B-X
percentage	B-X
of	B-X
glycosylated	B-X
haemoglobin	B-X
was	B-X
found	B-X
(	B-X
r=0.737	B-X
,	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
and	B-X
a	B-X
weaker	B-X
one	B-X
with	B-X
serum	B-X
unconjugated	B-X
bilirubin	B-X
(	B-X
r=0.363	B-X
,	B-X
P=0.0097	B-X
)	B-X
and	B-X
serum	B-X
total	B-X
lipids	B-X
(	B-X
r=0.321	B-X
,	B-X
P=0.0286	B-X
)	B-X
.	B-X
Anaemic	B-X
diabetic	B-X
patients	B-X
,	B-X
especially	B-X
those	B-X
with	B-X
the	B-X
anaemia	B-X
of	B-X
chronic	B-X
disease	B-X
,	B-X
also	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
non-anaemic	B-X
diabetics	B-X
.	B-X
No	B-X
correlation	B-X
between	B-X
IR	B-X
,	B-X
MCV	B-X
,	B-X
MCH	B-X
,	B-X
MCHC	B-X
,	B-X
RDW	B-X
,	B-X
RBC	B-X
morphology	B-X
,	B-X
serum	B-X
LDH	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
erythrocyte	B-X
inclusions	B-X
after	B-X
incubation	B-X
with	B-X
nitrous	B-X
sodium	B-X
solution	B-X
was	B-X
found	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
glycosylation	B-X
of	B-X
skeletal	B-X
proteins	B-X
probably	B-X
contributes	B-X
significantly	B-X
to	B-X
the	B-X
increased	B-X
membrane	B-X
rigidity	B-X
of	B-X
diabetic	B-X
erythrocytes	B-X
.	B-X

The	O
filtration	O
measurements	O
were	O
made	O
with	O
a	O
Hemorheometer	O
,	O
which	O
uses	O
the	O
"	O
initial	O
flow	O
rate	O
"	O
principle	O
.	O
<EOS>	B-X
The	B-X
filtration	B-X
measurements	B-X
were	B-X
made	B-X
with	B-X
a	B-X
Hemorheometer	B-X
,	B-X
which	B-X
uses	B-X
the	B-X
``	B-X
initial	B-X
flow	B-X
rate	B-X
''	B-X
principle	B-X
.	B-X

To	O
determine	O
the	O
Index	O
of	O
Rigidity	O
(	O
IR	O
)	O
of	O
the	O
red	O
blood	O
cells	O
,	O
we	O
measured	O
the	O
passage	O
time	O
of	O
white	O
blood	O
cell	O
-	O
free	O
erythrocyte	O
suspensions	O
,	O
8	O
%	O
per	O
volume	O
,	O
through	O
the	O
filter	O
.	O
<EOS>	B-X
Erythrocytes	B-X
from	B-X
diabetic	B-X
patients	B-X
exhibit	B-X
impaired	B-X
viscoelastic	B-X
properties	B-X
when	B-X
estimated	B-X
by	B-X
various	B-X
methods	B-X
.	B-X
We	B-X
determined	B-X
erythrocyte	B-X
filterability	B-X
through	B-X
5-microm	B-X
pores	B-X
,	B-X
in	B-X
51	B-X
patients	B-X
with	B-X
non-insulin-dependent	B-X
diabetes	B-X
mellitus	B-X
,	B-X
18	B-X
healthy	B-X
controls	B-X
,	B-X
15	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
and	B-X
15	B-X
with	B-X
beta-thalassemia	B-X
traits	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
Index	B-X
of	B-X
Rigidity	B-X
(	B-X
IR	B-X
)	B-X
of	B-X
the	B-X
red	B-X
blood	B-X
cells	B-X
,	B-X
we	B-X
measured	B-X
the	B-X
passage	B-X
time	B-X
of	B-X
white	B-X
blood	B-X
cell-free	B-X
erythrocyte	B-X
suspensions	B-X
,	B-X
8	B-X
%	B-X
per	B-X
volume	B-X
,	B-X
through	B-X
the	B-X
filter	B-X
.	B-X
Diabetic	B-X
patients	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
healthy	B-X
controls	B-X
and	B-X
to	B-X
patients	B-X
with	B-X
beta-thalassemia	B-X
trait	B-X
,	B-X
but	B-X
not	B-X
at	B-X
the	B-X
level	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
.	B-X
In	B-X
diabetic	B-X
patients	B-X
,	B-X
a	B-X
strong	B-X
correlation	B-X
between	B-X
IR	B-X
and	B-X
the	B-X
percentage	B-X
of	B-X
glycosylated	B-X
haemoglobin	B-X
was	B-X
found	B-X
(	B-X
r=0.737	B-X
,	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
and	B-X
a	B-X
weaker	B-X
one	B-X
with	B-X
serum	B-X
unconjugated	B-X
bilirubin	B-X
(	B-X
r=0.363	B-X
,	B-X
P=0.0097	B-X
)	B-X
and	B-X
serum	B-X
total	B-X
lipids	B-X
(	B-X
r=0.321	B-X
,	B-X
P=0.0286	B-X
)	B-X
.	B-X
Patients	B-X
with	B-X
severe	B-X
retinopathy	B-X
also	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
,	B-X
in	B-X
comparison	B-X
to	B-X
those	B-X
with	B-X
or	B-X
without	B-X
mild	B-X
retinopathy	B-X
.	B-X
Anaemic	B-X
diabetic	B-X
patients	B-X
,	B-X
especially	B-X
those	B-X
with	B-X
the	B-X
anaemia	B-X
of	B-X
chronic	B-X
disease	B-X
,	B-X
also	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
non-anaemic	B-X
diabetics	B-X
.	B-X
No	B-X
correlation	B-X
between	B-X
IR	B-X
,	B-X
MCV	B-X
,	B-X
MCH	B-X
,	B-X
MCHC	B-X
,	B-X
RDW	B-X
,	B-X
RBC	B-X
morphology	B-X
,	B-X
serum	B-X
LDH	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
erythrocyte	B-X
inclusions	B-X
after	B-X
incubation	B-X
with	B-X
nitrous	B-X
sodium	B-X
solution	B-X
was	B-X
found	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
glycosylation	B-X
of	B-X
skeletal	B-X
proteins	B-X
probably	B-X
contributes	B-X
significantly	B-X
to	B-X
the	B-X
increased	B-X
membrane	B-X
rigidity	B-X
of	B-X
diabetic	B-X
erythrocytes	B-X
.	B-X

Diabetic	O
patients	O
had	O
significantly	O
increased	O
IR	O
in	O
comparison	O
to	O
healthy	O
controls	O
and	O
to	O
patients	O
with	O
beta	O
-	O
thalassemia	O
trait	O
,	O
but	O
not	O
at	O
the	O
level	O
found	O
in	O
patients	O
with	O
homozygous	O
beta	O
-	O
thalassemia	O
.	O

In	O
diabetic	O
patients	O
,	O
a	O
strong	O
correlation	O
between	O
IR	O
and	O
the	O
percentage	O
of	O
glycosylated	O
haemoglobin	O
was	O
found	O
(	O
r	O
=	O
0	O
.	O
737	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
and	O
a	O
weaker	O
one	O
with	O
serum	O
unconjugated	O
bilirubin	O
(	O
r	O
=	O
0	O
.	O
363	O
,	O
P	O
=	O
0	O
.	O
0097	O
)	O
and	O
serum	O
total	O
lipids	O
(	O
r	O
=	O
0	O
.	O
321	O
,	O
P	O
=	O
0	O
.	O
0286	O
)	O
.	O

Patients	O
with	O
severe	O
retinopathy	O
also	O
had	O
significantly	O
increased	O
IR	O
,	O
in	O
comparison	O
to	O
those	O
with	O
or	O
without	O
mild	O
retinopathy	O
.	O
<EOS>	B-X
However	B-X
,	B-X
some	B-X
cautions	B-X
are	B-X
needed	B-X
to	B-X
prevent	B-X
retinopathy	B-X
,	B-X
a	B-X
rare	B-X
but	B-X
serious	B-X
complication	B-X
of	B-X
the	B-X
prolonged	B-X
use	B-X
of	B-X
HCQ	B-X
.	B-X
Expert	B-X
opinion	B-X
:	B-X
HCQ	B-X
may	B-X
offer	B-X
several	B-X
advantages	B-X
not	B-X
only	B-X
in	B-X
patients	B-X
with	B-X
mild	B-X
SLE	B-X
but	B-X
can	B-X
also	B-X
exert	B-X
important	B-X
beneficial	B-X
effects	B-X
in	B-X
lupus	B-X
patients	B-X
with	B-X
organ	B-X
involvement	B-X
and	B-X
in	B-X
pregnant	B-X
women	B-X
.	B-X
These	B-X
characteristics	B-X
should	B-X
encourage	B-X
a	B-X
larger	B-X
use	B-X
of	B-X
HCQ	B-X
,	B-X
also	B-X
in	B-X
lupus	B-X
patients	B-X
with	B-X
organ	B-X
involvement	B-X
.	B-X
Although	B-X
ERMs	B-X
are	B-X
generally	B-X
asymptomatic	B-X
or	B-X
cause	B-X
mild	B-X
metamorphopsia	B-X
and/or	B-X
a	B-X
modest	B-X
decrease	B-X
in	B-X
visual	B-X
acuity	B-X
,	B-X
some	B-X
can	B-X
cause	B-X
severe	B-X
macular	B-X
distortion	B-X
and	B-X
macular	B-X
edema	B-X
,	B-X
resulting	B-X
in	B-X
significantly	B-X
impaired	B-X
function	B-X
.	B-X

Anaemic	O
diabetic	O
patients	O
,	O
especially	O
those	O
with	O
the	O
anaemia	O
of	O
chronic	O
disease	O
,	O
also	O
had	O
significantly	O
increased	O
IR	O
in	O
comparison	O
to	O
non	O
-	O
anaemic	O
diabetics	O
.	O
<EOS>	B-X
Erythrocytes	B-X
from	B-X
diabetic	B-X
patients	B-X
exhibit	B-X
impaired	B-X
viscoelastic	B-X
properties	B-X
when	B-X
estimated	B-X
by	B-X
various	B-X
methods	B-X
.	B-X
We	B-X
determined	B-X
erythrocyte	B-X
filterability	B-X
through	B-X
5-microm	B-X
pores	B-X
,	B-X
in	B-X
51	B-X
patients	B-X
with	B-X
non-insulin-dependent	B-X
diabetes	B-X
mellitus	B-X
,	B-X
18	B-X
healthy	B-X
controls	B-X
,	B-X
15	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
and	B-X
15	B-X
with	B-X
beta-thalassemia	B-X
traits	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
Index	B-X
of	B-X
Rigidity	B-X
(	B-X
IR	B-X
)	B-X
of	B-X
the	B-X
red	B-X
blood	B-X
cells	B-X
,	B-X
we	B-X
measured	B-X
the	B-X
passage	B-X
time	B-X
of	B-X
white	B-X
blood	B-X
cell-free	B-X
erythrocyte	B-X
suspensions	B-X
,	B-X
8	B-X
%	B-X
per	B-X
volume	B-X
,	B-X
through	B-X
the	B-X
filter	B-X
.	B-X
Diabetic	B-X
patients	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
healthy	B-X
controls	B-X
and	B-X
to	B-X
patients	B-X
with	B-X
beta-thalassemia	B-X
trait	B-X
,	B-X
but	B-X
not	B-X
at	B-X
the	B-X
level	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
.	B-X
In	B-X
diabetic	B-X
patients	B-X
,	B-X
a	B-X
strong	B-X
correlation	B-X
between	B-X
IR	B-X
and	B-X
the	B-X
percentage	B-X
of	B-X
glycosylated	B-X
haemoglobin	B-X
was	B-X
found	B-X
(	B-X
r=0.737	B-X
,	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
and	B-X
a	B-X
weaker	B-X
one	B-X
with	B-X
serum	B-X
unconjugated	B-X
bilirubin	B-X
(	B-X
r=0.363	B-X
,	B-X
P=0.0097	B-X
)	B-X
and	B-X
serum	B-X
total	B-X
lipids	B-X
(	B-X
r=0.321	B-X
,	B-X
P=0.0286	B-X
)	B-X
.	B-X
Patients	B-X
with	B-X
severe	B-X
retinopathy	B-X
also	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
,	B-X
in	B-X
comparison	B-X
to	B-X
those	B-X
with	B-X
or	B-X
without	B-X
mild	B-X
retinopathy	B-X
.	B-X
Anaemic	B-X
diabetic	B-X
patients	B-X
,	B-X
especially	B-X
those	B-X
with	B-X
the	B-X
anaemia	B-X
of	B-X
chronic	B-X
disease	B-X
,	B-X
also	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
non-anaemic	B-X
diabetics	B-X
.	B-X
No	B-X
correlation	B-X
between	B-X
IR	B-X
,	B-X
MCV	B-X
,	B-X
MCH	B-X
,	B-X
MCHC	B-X
,	B-X
RDW	B-X
,	B-X
RBC	B-X
morphology	B-X
,	B-X
serum	B-X
LDH	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
erythrocyte	B-X
inclusions	B-X
after	B-X
incubation	B-X
with	B-X
nitrous	B-X
sodium	B-X
solution	B-X
was	B-X
found	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
glycosylation	B-X
of	B-X
skeletal	B-X
proteins	B-X
probably	B-X
contributes	B-X
significantly	B-X
to	B-X
the	B-X
increased	B-X
membrane	B-X
rigidity	B-X
of	B-X
diabetic	B-X
erythrocytes	B-X
.	B-X

No	O
correlation	O
between	O
IR	O
,	O
MCV	O
,	O
MCH	O
,	O
MCHC	O
,	O
RDW	O
,	O
RBC	O
morphology	O
,	O
serum	O
LDH	O
or	O
the	O
presence	O
of	O
erythrocyte	O
inclusions	O
after	O
incubation	O
with	O
nitrous	O
sodium	O
solution	O
was	O
found	O
.	O
<EOS>	B-X
We	B-X
determined	B-X
erythrocyte	B-X
filterability	B-X
through	B-X
5-microm	B-X
pores	B-X
,	B-X
in	B-X
51	B-X
patients	B-X
with	B-X
non-insulin-dependent	B-X
diabetes	B-X
mellitus	B-X
,	B-X
18	B-X
healthy	B-X
controls	B-X
,	B-X
15	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
and	B-X
15	B-X
with	B-X
beta-thalassemia	B-X
traits	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
Index	B-X
of	B-X
Rigidity	B-X
(	B-X
IR	B-X
)	B-X
of	B-X
the	B-X
red	B-X
blood	B-X
cells	B-X
,	B-X
we	B-X
measured	B-X
the	B-X
passage	B-X
time	B-X
of	B-X
white	B-X
blood	B-X
cell-free	B-X
erythrocyte	B-X
suspensions	B-X
,	B-X
8	B-X
%	B-X
per	B-X
volume	B-X
,	B-X
through	B-X
the	B-X
filter	B-X
.	B-X
Diabetic	B-X
patients	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
healthy	B-X
controls	B-X
and	B-X
to	B-X
patients	B-X
with	B-X
beta-thalassemia	B-X
trait	B-X
,	B-X
but	B-X
not	B-X
at	B-X
the	B-X
level	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
homozygous	B-X
beta-thalassemia	B-X
.	B-X
In	B-X
diabetic	B-X
patients	B-X
,	B-X
a	B-X
strong	B-X
correlation	B-X
between	B-X
IR	B-X
and	B-X
the	B-X
percentage	B-X
of	B-X
glycosylated	B-X
haemoglobin	B-X
was	B-X
found	B-X
(	B-X
r=0.737	B-X
,	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
and	B-X
a	B-X
weaker	B-X
one	B-X
with	B-X
serum	B-X
unconjugated	B-X
bilirubin	B-X
(	B-X
r=0.363	B-X
,	B-X
P=0.0097	B-X
)	B-X
and	B-X
serum	B-X
total	B-X
lipids	B-X
(	B-X
r=0.321	B-X
,	B-X
P=0.0286	B-X
)	B-X
.	B-X
Patients	B-X
with	B-X
severe	B-X
retinopathy	B-X
also	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
,	B-X
in	B-X
comparison	B-X
to	B-X
those	B-X
with	B-X
or	B-X
without	B-X
mild	B-X
retinopathy	B-X
.	B-X
Anaemic	B-X
diabetic	B-X
patients	B-X
,	B-X
especially	B-X
those	B-X
with	B-X
the	B-X
anaemia	B-X
of	B-X
chronic	B-X
disease	B-X
,	B-X
also	B-X
had	B-X
significantly	B-X
increased	B-X
IR	B-X
in	B-X
comparison	B-X
to	B-X
non-anaemic	B-X
diabetics	B-X
.	B-X
No	B-X
correlation	B-X
between	B-X
IR	B-X
,	B-X
MCV	B-X
,	B-X
MCH	B-X
,	B-X
MCHC	B-X
,	B-X
RDW	B-X
,	B-X
RBC	B-X
morphology	B-X
,	B-X
serum	B-X
LDH	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
erythrocyte	B-X
inclusions	B-X
after	B-X
incubation	B-X
with	B-X
nitrous	B-X
sodium	B-X
solution	B-X
was	B-X
found	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
glycosylation	B-X
of	B-X
skeletal	B-X
proteins	B-X
probably	B-X
contributes	B-X
significantly	B-X
to	B-X
the	B-X
increased	B-X
membrane	B-X
rigidity	B-X
of	B-X
diabetic	B-X
erythrocytes	B-X
.	B-X

Our	O
findings	O
suggest	O
that	O
glycosylation	O
of	O
skeletal	O
proteins	O
probably	O
contributes	O
significantly	O
to	O
the	O
increased	O
membrane	O
rigidity	O
of	O
diabetic	O
erythrocytes	O
.	O

Characterization	O
of	O
the	O
secretable	O
ectodomain	O
of	O
thyrotropin	B-Protein
receptor	I-Protein
produced	O
by	O
the	O
recombinant	O
baculovirus	O
system	O
.	O
<EOS>	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSHR	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
glycoprotein	B-X
hormone	B-X
receptor	B-X
family	B-X
and	B-X
an	B-X
autoantigen	B-X
of	B-X
Graves	B-X
'	B-X
disease	B-X
.	B-X
Various	B-X
attempts	B-X
have	B-X
been	B-X
made	B-X
to	B-X
obtain	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
in	B-X
insect	B-X
or	B-X
mammalian	B-X
cells	B-X
,	B-X
but	B-X
most	B-X
of	B-X
them	B-X
failed	B-X
to	B-X
secrete	B-X
the	B-X
overexpressed	B-X
ectodomain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
about	B-X
one-third	B-X
of	B-X
the	B-X
ectodomain	B-X
protein	B-X
(	B-X
sTSHR-gp	B-X
)	B-X
,	B-X
in	B-X
which	B-X
the	B-X
signal	B-X
peptide	B-X
of	B-X
TSHR	B-X
was	B-X
replaced	B-X
by	B-X
the	B-X
baculovirus-encoded	B-X
glycoprotein	B-X
67-signal	B-X
peptide	B-X
,	B-X
was	B-X
secreted	B-X
into	B-X
the	B-X
culture	B-X
medium	B-X
and	B-X
the	B-X
remainder	B-X
stayed	B-X
within	B-X
cells	B-X
in	B-X
the	B-X
recombinant	B-X
baculovirus	B-X
system	B-X
.	B-X
Microsequencing	B-X
the	B-X
N-terminal	B-X
of	B-X
the	B-X
purified	B-X
protein	B-X
confirmed	B-X
that	B-X
the	B-X
baculovirus	B-X
signal	B-X
peptide	B-X
was	B-X
cleaved	B-X
at	B-X
the	B-X
expected	B-X
site	B-X
.	B-X
Carbohydrate	B-X
studies	B-X
using	B-X
several	B-X
glycosidases	B-X
and	B-X
lectins	B-X
revealed	B-X
that	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
the	B-X
ectodomain	B-X
had	B-X
biantennary	B-X
carbohydrate	B-X
,	B-X
whereas	B-X
the	B-X
non-secreted	B-X
form	B-X
had	B-X
high-mannose	B-X
.	B-X
Regarding	B-X
the	B-X
interactions	B-X
of	B-X
TSHR	B-X
ectodomains	B-X
with	B-X
anti-TSHR	B-X
antibodies	B-X
,	B-X
both	B-X
the	B-X
secreted	B-X
and	B-X
non-secreted	B-X
forms	B-X
of	B-X
sTSHR-gp	B-X
,	B-X
almost	B-X
completely	B-X
neutralized	B-X
the	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
succeeded	B-X
in	B-X
secreting	B-X
the	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
into	B-X
culture	B-X
medium	B-X
,	B-X
which	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
TSH	B-X
and	B-X
neutralizing	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X

Thyrotropin	B-Protein
receptor	I-Protein
(	O
TSHR	B-Protein
)	O
is	O
a	O
member	O
of	O
the	O
glycoprotein	O
hormone	O
receptor	O
family	O
and	O
an	O
autoantigen	O
of	O
Graves	O
'	O
disease	O
.	O

Various	O
attempts	O
have	O
been	O
made	O
to	O
obtain	O
a	O
large	O
amount	O
of	O
soluble	O
ectodomain	O
of	O
TSHR	B-Protein
in	O
insect	O
or	O
mammalian	O
cells	O
,	O
but	O
most	O
of	O
them	O
failed	O
to	O
secrete	O
the	O
overexpressed	O
ectodomain	O
.	O
<EOS>	B-X
CD97	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
modulate	B-X
tumorigenesis	B-X
in	B-X
part	B-X
by	B-X
promoting	B-X
HUVEC	B-X
migration	B-X
,	B-X
invasion	B-X
and	B-X
angiogenesis	B-X
through	B-X
the	B-X
interaction	B-X
with	B-X
integrin	B-X
α5β1	B-X
via	B-X
its	B-X
ectodomain	B-X
RGD	B-X
motif	B-X
.	B-X
Overexpression	B-X
of	B-X
CD97	B-X
with	B-X
the	B-X
wild-type	B-X
or	B-X
mutant	B-X
RGD	B-X
motif	B-X
in	B-X
HT1080	B-X
cells	B-X
led	B-X
to	B-X
up-regulated	B-X
MMP-9	B-X
and	B-X
induced	B-X
angiogenesis	B-X
as	B-X
revealed	B-X
by	B-X
the	B-X
in	B-X
vitro	B-X
endothelial	B-X
cell	B-X
tube	B-X
formation	B-X
assay	B-X
and	B-X
in	B-X
ovo	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
assay	B-X
.	B-X
This	B-X
process	B-X
was	B-X
likely	B-X
accomplished	B-X
by	B-X
the	B-X
binding	B-X
of	B-X
Mt2	B-X
ectodomain	B-X
to	B-X
Hjv	B-X
and	B-X
Hfe	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Mt2	B-X
specifically	B-X
cleaved	B-X
the	B-X
key	B-X
components	B-X
of	B-X
the	B-X
hepcidin-induction	B-X
pathway	B-X
,	B-X
including	B-X
Hjv	B-X
,	B-X
Alk3	B-X
,	B-X
ActRIIA	B-X
,	B-X
and	B-X
Hfe	B-X
,	B-X
when	B-X
overexpressed	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
Nevertheless	B-X
,	B-X
studies	B-X
of	B-X
a	B-X
murine	B-X
iron-refractory	B-X
iron-deficiency	B-X
anemia-causing	B-X
mutant	B-X
(	B-X
Mt2I286F	B-X
)	B-X
in	B-X
the	B-X
complement	B-X
protein	B-X
subcomponents	B-X
C1r/C1s	B-X
,	B-X
urchin	B-X
embryonic	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
1	B-X
domain	B-X
indicate	B-X
that	B-X
Mt2I286F	B-X
can	B-X
be	B-X
activated	B-X
,	B-X
but	B-X
it	B-X
exhibited	B-X
a	B-X
largely	B-X
compromised	B-X
ability	B-X
to	B-X
suppress	B-X
hepcidin	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
a	B-X
serine	B-X
protease	B-X
inhibitor	B-X
,	B-X
the	B-X
hepatocyte	B-X
growth	B-X
factor	B-X
activator	B-X
inhibitor-2	B-X
,	B-X
in	B-X
the	B-X
liver	B-X
failed	B-X
to	B-X
alter	B-X
hepcidin	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
observed	O
that	O
about	O
one	O
-	O
third	O
of	O
the	O
ectodomain	O
protein	O
(	O
sTSHR	B-Protein
-	O
gp	O
)	O
,	O
in	O
which	O
the	O
signal	O
peptide	O
of	O
TSHR	B-Protein
was	O
replaced	O
by	O
the	O
baculovirus	O
-	O
encoded	O
glycoprotein	B-Protein
67	I-Protein
-	O
signal	O
peptide	O
,	O
was	O
secreted	O
into	O
the	O
culture	O
medium	O
and	O
the	O
remainder	O
stayed	O
within	O
cells	O
in	O
the	O
recombinant	O
baculovirus	O
system	O
.	O
<EOS>	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSHR	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
glycoprotein	B-X
hormone	B-X
receptor	B-X
family	B-X
and	B-X
an	B-X
autoantigen	B-X
of	B-X
Graves	B-X
'	B-X
disease	B-X
.	B-X
Various	B-X
attempts	B-X
have	B-X
been	B-X
made	B-X
to	B-X
obtain	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
in	B-X
insect	B-X
or	B-X
mammalian	B-X
cells	B-X
,	B-X
but	B-X
most	B-X
of	B-X
them	B-X
failed	B-X
to	B-X
secrete	B-X
the	B-X
overexpressed	B-X
ectodomain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
about	B-X
one-third	B-X
of	B-X
the	B-X
ectodomain	B-X
protein	B-X
(	B-X
sTSHR-gp	B-X
)	B-X
,	B-X
in	B-X
which	B-X
the	B-X
signal	B-X
peptide	B-X
of	B-X
TSHR	B-X
was	B-X
replaced	B-X
by	B-X
the	B-X
baculovirus-encoded	B-X
glycoprotein	B-X
67-signal	B-X
peptide	B-X
,	B-X
was	B-X
secreted	B-X
into	B-X
the	B-X
culture	B-X
medium	B-X
and	B-X
the	B-X
remainder	B-X
stayed	B-X
within	B-X
cells	B-X
in	B-X
the	B-X
recombinant	B-X
baculovirus	B-X
system	B-X
.	B-X
Microsequencing	B-X
the	B-X
N-terminal	B-X
of	B-X
the	B-X
purified	B-X
protein	B-X
confirmed	B-X
that	B-X
the	B-X
baculovirus	B-X
signal	B-X
peptide	B-X
was	B-X
cleaved	B-X
at	B-X
the	B-X
expected	B-X
site	B-X
.	B-X
Carbohydrate	B-X
studies	B-X
using	B-X
several	B-X
glycosidases	B-X
and	B-X
lectins	B-X
revealed	B-X
that	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
the	B-X
ectodomain	B-X
had	B-X
biantennary	B-X
carbohydrate	B-X
,	B-X
whereas	B-X
the	B-X
non-secreted	B-X
form	B-X
had	B-X
high-mannose	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
sTSHR-gp	B-X
exhibited	B-X
high-affinity	B-X
ligand	B-X
binding	B-X
,	B-X
whereas	B-X
the	B-X
non-secreted	B-X
form	B-X
did	B-X
not	B-X
show	B-X
any	B-X
significant	B-X
ligand	B-X
binding	B-X
.	B-X
Regarding	B-X
the	B-X
interactions	B-X
of	B-X
TSHR	B-X
ectodomains	B-X
with	B-X
anti-TSHR	B-X
antibodies	B-X
,	B-X
both	B-X
the	B-X
secreted	B-X
and	B-X
non-secreted	B-X
forms	B-X
of	B-X
sTSHR-gp	B-X
,	B-X
almost	B-X
completely	B-X
neutralized	B-X
the	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
succeeded	B-X
in	B-X
secreting	B-X
the	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
into	B-X
culture	B-X
medium	B-X
,	B-X
which	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
TSH	B-X
and	B-X
neutralizing	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X

Microsequencing	O
the	O
N	O
-	O
terminal	O
of	O
the	O
purified	O
protein	O
confirmed	O
that	O
the	O
baculovirus	O
signal	O
peptide	O
was	O
cleaved	O
at	O
the	O
expected	O
site	O
.	O

Carbohydrate	O
studies	O
using	O
several	O
glycosidases	O
and	O
lectins	O
revealed	O
that	O
the	O
secreted	O
form	O
of	O
the	O
ectodomain	O
had	O
biantennary	O
carbohydrate	O
,	O
whereas	O
the	O
non	O
-	O
secreted	O
form	O
had	O
high	O
-	O
mannose	O
.	O
<EOS>	B-X
Various	B-X
attempts	B-X
have	B-X
been	B-X
made	B-X
to	B-X
obtain	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
in	B-X
insect	B-X
or	B-X
mammalian	B-X
cells	B-X
,	B-X
but	B-X
most	B-X
of	B-X
them	B-X
failed	B-X
to	B-X
secrete	B-X
the	B-X
overexpressed	B-X
ectodomain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
about	B-X
one-third	B-X
of	B-X
the	B-X
ectodomain	B-X
protein	B-X
(	B-X
sTSHR-gp	B-X
)	B-X
,	B-X
in	B-X
which	B-X
the	B-X
signal	B-X
peptide	B-X
of	B-X
TSHR	B-X
was	B-X
replaced	B-X
by	B-X
the	B-X
baculovirus-encoded	B-X
glycoprotein	B-X
67-signal	B-X
peptide	B-X
,	B-X
was	B-X
secreted	B-X
into	B-X
the	B-X
culture	B-X
medium	B-X
and	B-X
the	B-X
remainder	B-X
stayed	B-X
within	B-X
cells	B-X
in	B-X
the	B-X
recombinant	B-X
baculovirus	B-X
system	B-X
.	B-X
Carbohydrate	B-X
studies	B-X
using	B-X
several	B-X
glycosidases	B-X
and	B-X
lectins	B-X
revealed	B-X
that	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
the	B-X
ectodomain	B-X
had	B-X
biantennary	B-X
carbohydrate	B-X
,	B-X
whereas	B-X
the	B-X
non-secreted	B-X
form	B-X
had	B-X
high-mannose	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
sTSHR-gp	B-X
exhibited	B-X
high-affinity	B-X
ligand	B-X
binding	B-X
,	B-X
whereas	B-X
the	B-X
non-secreted	B-X
form	B-X
did	B-X
not	B-X
show	B-X
any	B-X
significant	B-X
ligand	B-X
binding	B-X
.	B-X
Regarding	B-X
the	B-X
interactions	B-X
of	B-X
TSHR	B-X
ectodomains	B-X
with	B-X
anti-TSHR	B-X
antibodies	B-X
,	B-X
both	B-X
the	B-X
secreted	B-X
and	B-X
non-secreted	B-X
forms	B-X
of	B-X
sTSHR-gp	B-X
,	B-X
almost	B-X
completely	B-X
neutralized	B-X
the	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
succeeded	B-X
in	B-X
secreting	B-X
the	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
into	B-X
culture	B-X
medium	B-X
,	B-X
which	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
TSH	B-X
and	B-X
neutralizing	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X

Moreover	O
,	O
the	O
secreted	O
form	O
of	O
sTSHR	B-Protein
-	O
gp	O
exhibited	O
high	O
-	O
affinity	O
ligand	O
binding	O
,	O
whereas	O
the	O
non	O
-	O
secreted	O
form	O
did	O
not	O
show	O
any	O
significant	O
ligand	O
binding	O
.	O

Regarding	O
the	O
interactions	O
of	O
TSHR	B-Protein
ectodomains	O
with	O
anti	O
-	O
TSHR	B-Protein
antibodies	O
,	O
both	O
the	O
secreted	O
and	O
non	O
-	O
secreted	O
forms	O
of	O
sTSHR	B-Protein
-	O
gp	O
,	O
almost	O
completely	O
neutralized	O
the	O
stimulatory	O
and	O
inhibitory	O
anti	O
-	O
TSHR	B-Protein
antibody	O
activities	O
.	O
<EOS>	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSHR	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
glycoprotein	B-X
hormone	B-X
receptor	B-X
family	B-X
and	B-X
an	B-X
autoantigen	B-X
of	B-X
Graves	B-X
'	B-X
disease	B-X
.	B-X
Various	B-X
attempts	B-X
have	B-X
been	B-X
made	B-X
to	B-X
obtain	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
in	B-X
insect	B-X
or	B-X
mammalian	B-X
cells	B-X
,	B-X
but	B-X
most	B-X
of	B-X
them	B-X
failed	B-X
to	B-X
secrete	B-X
the	B-X
overexpressed	B-X
ectodomain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
about	B-X
one-third	B-X
of	B-X
the	B-X
ectodomain	B-X
protein	B-X
(	B-X
sTSHR-gp	B-X
)	B-X
,	B-X
in	B-X
which	B-X
the	B-X
signal	B-X
peptide	B-X
of	B-X
TSHR	B-X
was	B-X
replaced	B-X
by	B-X
the	B-X
baculovirus-encoded	B-X
glycoprotein	B-X
67-signal	B-X
peptide	B-X
,	B-X
was	B-X
secreted	B-X
into	B-X
the	B-X
culture	B-X
medium	B-X
and	B-X
the	B-X
remainder	B-X
stayed	B-X
within	B-X
cells	B-X
in	B-X
the	B-X
recombinant	B-X
baculovirus	B-X
system	B-X
.	B-X
Carbohydrate	B-X
studies	B-X
using	B-X
several	B-X
glycosidases	B-X
and	B-X
lectins	B-X
revealed	B-X
that	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
the	B-X
ectodomain	B-X
had	B-X
biantennary	B-X
carbohydrate	B-X
,	B-X
whereas	B-X
the	B-X
non-secreted	B-X
form	B-X
had	B-X
high-mannose	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
sTSHR-gp	B-X
exhibited	B-X
high-affinity	B-X
ligand	B-X
binding	B-X
,	B-X
whereas	B-X
the	B-X
non-secreted	B-X
form	B-X
did	B-X
not	B-X
show	B-X
any	B-X
significant	B-X
ligand	B-X
binding	B-X
.	B-X
Regarding	B-X
the	B-X
interactions	B-X
of	B-X
TSHR	B-X
ectodomains	B-X
with	B-X
anti-TSHR	B-X
antibodies	B-X
,	B-X
both	B-X
the	B-X
secreted	B-X
and	B-X
non-secreted	B-X
forms	B-X
of	B-X
sTSHR-gp	B-X
,	B-X
almost	B-X
completely	B-X
neutralized	B-X
the	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
succeeded	B-X
in	B-X
secreting	B-X
the	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
into	B-X
culture	B-X
medium	B-X
,	B-X
which	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
TSH	B-X
and	B-X
neutralizing	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X

In	O
conclusion	O
,	O
we	O
succeeded	O
in	O
secreting	O
the	O
ectodomain	O
of	O
TSHR	B-Protein
into	O
culture	O
medium	O
,	O
which	O
was	O
capable	O
of	O
binding	O
to	O
TSH	O
and	O
neutralizing	O
anti	O
-	O
TSHR	B-Protein
antibody	O
activities	O
.	O
<EOS>	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSHR	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
glycoprotein	B-X
hormone	B-X
receptor	B-X
family	B-X
and	B-X
an	B-X
autoantigen	B-X
of	B-X
Graves	B-X
'	B-X
disease	B-X
.	B-X
Various	B-X
attempts	B-X
have	B-X
been	B-X
made	B-X
to	B-X
obtain	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
in	B-X
insect	B-X
or	B-X
mammalian	B-X
cells	B-X
,	B-X
but	B-X
most	B-X
of	B-X
them	B-X
failed	B-X
to	B-X
secrete	B-X
the	B-X
overexpressed	B-X
ectodomain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
about	B-X
one-third	B-X
of	B-X
the	B-X
ectodomain	B-X
protein	B-X
(	B-X
sTSHR-gp	B-X
)	B-X
,	B-X
in	B-X
which	B-X
the	B-X
signal	B-X
peptide	B-X
of	B-X
TSHR	B-X
was	B-X
replaced	B-X
by	B-X
the	B-X
baculovirus-encoded	B-X
glycoprotein	B-X
67-signal	B-X
peptide	B-X
,	B-X
was	B-X
secreted	B-X
into	B-X
the	B-X
culture	B-X
medium	B-X
and	B-X
the	B-X
remainder	B-X
stayed	B-X
within	B-X
cells	B-X
in	B-X
the	B-X
recombinant	B-X
baculovirus	B-X
system	B-X
.	B-X
Carbohydrate	B-X
studies	B-X
using	B-X
several	B-X
glycosidases	B-X
and	B-X
lectins	B-X
revealed	B-X
that	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
the	B-X
ectodomain	B-X
had	B-X
biantennary	B-X
carbohydrate	B-X
,	B-X
whereas	B-X
the	B-X
non-secreted	B-X
form	B-X
had	B-X
high-mannose	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
sTSHR-gp	B-X
exhibited	B-X
high-affinity	B-X
ligand	B-X
binding	B-X
,	B-X
whereas	B-X
the	B-X
non-secreted	B-X
form	B-X
did	B-X
not	B-X
show	B-X
any	B-X
significant	B-X
ligand	B-X
binding	B-X
.	B-X
Regarding	B-X
the	B-X
interactions	B-X
of	B-X
TSHR	B-X
ectodomains	B-X
with	B-X
anti-TSHR	B-X
antibodies	B-X
,	B-X
both	B-X
the	B-X
secreted	B-X
and	B-X
non-secreted	B-X
forms	B-X
of	B-X
sTSHR-gp	B-X
,	B-X
almost	B-X
completely	B-X
neutralized	B-X
the	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
succeeded	B-X
in	B-X
secreting	B-X
the	B-X
ectodomain	B-X
of	B-X
TSHR	B-X
into	B-X
culture	B-X
medium	B-X
,	B-X
which	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
TSH	B-X
and	B-X
neutralizing	B-X
anti-TSHR	B-X
antibody	B-X
activities	B-X
.	B-X

C	O
.	O
elegans	O
EGL	B-Protein
-	I-Protein
9	I-Protein
and	O
mammalian	O
homologs	O
define	O
a	O
family	O
of	O
dioxygenases	O
that	O
regulate	O
HIF	O
by	O
prolyl	O
hydroxylation	O
.	O
<EOS>	B-X
HIF	B-X
is	B-X
a	B-X
transcriptional	B-X
complex	B-X
that	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
mammalian	B-X
oxygen	B-X
homeostasis	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
defined	B-X
posttranslational	B-X
modification	B-X
by	B-X
prolyl	B-X
hydroxylation	B-X
as	B-X
a	B-X
key	B-X
regulatory	B-X
event	B-X
that	B-X
targets	B-X
HIF-alpha	B-X
subunits	B-X
for	B-X
proteasomal	B-X
destruction	B-X
via	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
ubiquitylation	B-X
complex	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
define	B-X
a	B-X
conserved	B-X
HIF-VHL-prolyl	B-X
hydroxylase	B-X
pathway	B-X
in	B-X
C.	B-X
elegans	B-X
,	B-X
and	B-X
use	B-X
a	B-X
genetic	B-X
approach	B-X
to	B-X
identify	B-X
EGL-9	B-X
as	B-X
a	B-X
dioxygenase	B-X
that	B-X
regulates	B-X
HIF	B-X
by	B-X
prolyl	B-X
hydroxylation	B-X
.	B-X
In	B-X
mammalian	B-X
cells	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
HIF-prolyl	B-X
hydroxylases	B-X
are	B-X
represented	B-X
by	B-X
a	B-X
series	B-X
of	B-X
isoforms	B-X
bearing	B-X
a	B-X
conserved	B-X
2-histidine-1-carboxylate	B-X
iron	B-X
coordination	B-X
motif	B-X
at	B-X
the	B-X
catalytic	B-X
site	B-X
.	B-X
Direct	B-X
modulation	B-X
of	B-X
recombinant	B-X
enzyme	B-X
activity	B-X
by	B-X
graded	B-X
hypoxia	B-X
,	B-X
iron	B-X
chelation	B-X
,	B-X
and	B-X
cobaltous	B-X
ions	B-X
mirrors	B-X
the	B-X
characteristics	B-X
of	B-X
HIF	B-X
induction	B-X
in	B-X
vivo	B-X
,	B-X
fulfilling	B-X
requirements	B-X
for	B-X
these	B-X
enzymes	B-X
being	B-X
oxygen	B-X
sensors	B-X
that	B-X
regulate	B-X
HIF	B-X
.	B-X

HIF	O
is	O
a	O
transcriptional	O
complex	O
that	O
plays	O
a	O
central	O
role	O
in	O
mammalian	O
oxygen	O
homeostasis	O
.	O

Recent	O
studies	O
have	O
defined	O
posttranslational	O
modification	O
by	O
prolyl	O
hydroxylation	O
as	O
a	O
key	O
regulatory	O
event	O
that	O
targets	O
HIF	O
-	O
alpha	O
subunits	O
for	O
proteasomal	O
destruction	O
via	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
ubiquitylation	O
complex	O
.	O

Here	O
,	O
we	O
define	O
a	O
conserved	O
HIF	O
-	O
VHL	B-Protein
-	O
prolyl	O
hydroxylase	O
pathway	O
in	O
C	O
.	O
elegans	O
,	O
and	O
use	O
a	O
genetic	O
approach	O
to	O
identify	O
EGL	B-Protein
-	I-Protein
9	I-Protein
as	O
a	O
dioxygenase	O
that	O
regulates	O
HIF	O
by	O
prolyl	O
hydroxylation	O
.	O

In	O
mammalian	O
cells	O
,	O
we	O
show	O
that	O
the	O
HIF	O
-	O
prolyl	O
hydroxylases	O
are	O
represented	O
by	O
a	O
series	O
of	O
isoforms	O
bearing	O
a	O
conserved	O
2	O
-	O
histidine	O
-	O
1	O
-	O
carboxylate	O
iron	O
coordination	O
motif	O
at	O
the	O
catalytic	O
site	O
.	O
<EOS>	B-X
HIF	B-X
is	B-X
a	B-X
transcriptional	B-X
complex	B-X
that	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
mammalian	B-X
oxygen	B-X
homeostasis	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
defined	B-X
posttranslational	B-X
modification	B-X
by	B-X
prolyl	B-X
hydroxylation	B-X
as	B-X
a	B-X
key	B-X
regulatory	B-X
event	B-X
that	B-X
targets	B-X
HIF-alpha	B-X
subunits	B-X
for	B-X
proteasomal	B-X
destruction	B-X
via	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
ubiquitylation	B-X
complex	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
define	B-X
a	B-X
conserved	B-X
HIF-VHL-prolyl	B-X
hydroxylase	B-X
pathway	B-X
in	B-X
C.	B-X
elegans	B-X
,	B-X
and	B-X
use	B-X
a	B-X
genetic	B-X
approach	B-X
to	B-X
identify	B-X
EGL-9	B-X
as	B-X
a	B-X
dioxygenase	B-X
that	B-X
regulates	B-X
HIF	B-X
by	B-X
prolyl	B-X
hydroxylation	B-X
.	B-X
In	B-X
mammalian	B-X
cells	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
HIF-prolyl	B-X
hydroxylases	B-X
are	B-X
represented	B-X
by	B-X
a	B-X
series	B-X
of	B-X
isoforms	B-X
bearing	B-X
a	B-X
conserved	B-X
2-histidine-1-carboxylate	B-X
iron	B-X
coordination	B-X
motif	B-X
at	B-X
the	B-X
catalytic	B-X
site	B-X
.	B-X
Direct	B-X
modulation	B-X
of	B-X
recombinant	B-X
enzyme	B-X
activity	B-X
by	B-X
graded	B-X
hypoxia	B-X
,	B-X
iron	B-X
chelation	B-X
,	B-X
and	B-X
cobaltous	B-X
ions	B-X
mirrors	B-X
the	B-X
characteristics	B-X
of	B-X
HIF	B-X
induction	B-X
in	B-X
vivo	B-X
,	B-X
fulfilling	B-X
requirements	B-X
for	B-X
these	B-X
enzymes	B-X
being	B-X
oxygen	B-X
sensors	B-X
that	B-X
regulate	B-X
HIF	B-X
.	B-X

Direct	O
modulation	O
of	O
recombinant	O
enzyme	O
activity	O
by	O
graded	O
hypoxia	O
,	O
iron	O
chelation	O
,	O
and	O
cobaltous	O
ions	O
mirrors	O
the	O
characteristics	O
of	O
HIF	O
induction	O
in	O
vivo	O
,	O
fulfilling	O
requirements	O
for	O
these	O
enzymes	O
being	O
oxygen	O
sensors	O
that	O
regulate	O
HIF	O
.	O
<EOS>	B-X
HIF	B-X
is	B-X
a	B-X
transcriptional	B-X
complex	B-X
that	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
mammalian	B-X
oxygen	B-X
homeostasis	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
defined	B-X
posttranslational	B-X
modification	B-X
by	B-X
prolyl	B-X
hydroxylation	B-X
as	B-X
a	B-X
key	B-X
regulatory	B-X
event	B-X
that	B-X
targets	B-X
HIF-alpha	B-X
subunits	B-X
for	B-X
proteasomal	B-X
destruction	B-X
via	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
ubiquitylation	B-X
complex	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
define	B-X
a	B-X
conserved	B-X
HIF-VHL-prolyl	B-X
hydroxylase	B-X
pathway	B-X
in	B-X
C.	B-X
elegans	B-X
,	B-X
and	B-X
use	B-X
a	B-X
genetic	B-X
approach	B-X
to	B-X
identify	B-X
EGL-9	B-X
as	B-X
a	B-X
dioxygenase	B-X
that	B-X
regulates	B-X
HIF	B-X
by	B-X
prolyl	B-X
hydroxylation	B-X
.	B-X
In	B-X
mammalian	B-X
cells	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
HIF-prolyl	B-X
hydroxylases	B-X
are	B-X
represented	B-X
by	B-X
a	B-X
series	B-X
of	B-X
isoforms	B-X
bearing	B-X
a	B-X
conserved	B-X
2-histidine-1-carboxylate	B-X
iron	B-X
coordination	B-X
motif	B-X
at	B-X
the	B-X
catalytic	B-X
site	B-X
.	B-X
Direct	B-X
modulation	B-X
of	B-X
recombinant	B-X
enzyme	B-X
activity	B-X
by	B-X
graded	B-X
hypoxia	B-X
,	B-X
iron	B-X
chelation	B-X
,	B-X
and	B-X
cobaltous	B-X
ions	B-X
mirrors	B-X
the	B-X
characteristics	B-X
of	B-X
HIF	B-X
induction	B-X
in	B-X
vivo	B-X
,	B-X
fulfilling	B-X
requirements	B-X
for	B-X
these	B-X
enzymes	B-X
being	B-X
oxygen	B-X
sensors	B-X
that	B-X
regulate	B-X
HIF	B-X
.	B-X

Biochemical	O
characterization	O
of	O
the	O
vanilloid	B-Protein
receptor	I-Protein
1	I-Protein
expressed	O
in	O
a	O
dorsal	O
root	O
ganglia	O
derived	O
cell	O
line	O
.	O

The	O
vanilloid	O
receptor	O
VR1	B-Protein
is	O
an	O
ion	O
channel	O
predominantly	O
expressed	O
by	O
primary	O
sensory	O
neurons	O
involved	O
in	O
nociception	O
.	O
<EOS>	B-X
The	B-X
vanilloid	B-X
receptor	B-X
VR1	B-X
is	B-X
an	B-X
ion	B-X
channel	B-X
predominantly	B-X
expressed	B-X
by	B-X
primary	B-X
sensory	B-X
neurons	B-X
involved	B-X
in	B-X
nociception	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
its	B-X
biochemical	B-X
properties	B-X
and	B-X
assess	B-X
the	B-X
subcellular	B-X
localization	B-X
,	B-X
the	B-X
glycosylation	B-X
state	B-X
and	B-X
the	B-X
quaternary	B-X
structure	B-X
of	B-X
VR1	B-X
expressed	B-X
in	B-X
HEK293	B-X
cells	B-X
and	B-X
in	B-X
the	B-X
DRG-derived	B-X
cell	B-X
line	B-X
F-11	B-X
(	B-X
N18TG2	B-X
mouse	B-X
neuroblastoma	B-X
x	B-X
rat	B-X
dorsal	B-X
root	B-X
ganglia	B-X
,	B-X
hybridoma	B-X
)	B-X
.	B-X
VR1	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
.	B-X
Of	B-X
the	B-X
five	B-X
potential	B-X
N-glycosylation	B-X
sites	B-X
,	B-X
the	B-X
predicted	B-X
transient	B-X
receptor	B-X
potential	B-X
channel-like	B-X
transmembrane	B-X
folding	B-X
proposes	B-X
N604	B-X
is	B-X
localized	B-X
extracellularly	B-X
.	B-X
We	B-X
used	B-X
site-directed	B-X
mutagenesis	B-X
to	B-X
mutate	B-X
the	B-X
Asn	B-X
at	B-X
position	B-X
604	B-X
to	B-X
Thr	B-X
.	B-X
This	B-X
mutated	B-X
VR1	B-X
was	B-X
not	B-X
glycosylated	B-X
,	B-X
confirming	B-X
the	B-X
extracellular	B-X
location	B-X
of	B-X
N604	B-X
and	B-X
its	B-X
role	B-X
as	B-X
the	B-X
exclusive	B-X
site	B-X
of	B-X
glycosylation	B-X
of	B-X
the	B-X
VR1	B-X
protein	B-X
.	B-X
VR1	B-X
occured	B-X
in	B-X
high	B-X
molecular	B-X
mass	B-X
complexes	B-X
as	B-X
assessed	B-X
by	B-X
blue	B-X
native	B-X
PAGE	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
limited	B-X
amounts	B-X
of	B-X
SDS	B-X
dimers	B-X
,	B-X
trimers	B-X
and	B-X
tetramers	B-X
of	B-X
VR1	B-X
were	B-X
observed	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
predicted	B-X
tetrameric	B-X
quaternary	B-X
structure	B-X
of	B-X
the	B-X
receptor	B-X
.	B-X
Whereas	B-X
VR1	B-X
localized	B-X
both	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
to	B-X
intracellular	B-X
membranes	B-X
in	B-X
HEK293	B-X
cells	B-X
,	B-X
it	B-X
localized	B-X
predominantly	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
in	B-X
F-11	B-X
cells	B-X
.	B-X
Using	B-X
confocal	B-X
laserscanning	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
enrichment	B-X
of	B-X
anti-VR1	B-X
immunoreactivity	B-X
in	B-X
neurite-like	B-X
structures	B-X
of	B-X
F-11	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
light	B-X
of	B-X
conflicting	B-X
literature	B-X
data	B-X
on	B-X
biochemical	B-X
characteristics	B-X
of	B-X
VR1	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
dorsal	B-X
root	B-X
ganglion-derived	B-X
F-11	B-X
cells	B-X
provide	B-X
a	B-X
powerful	B-X
experimental	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
VR1	B-X
biochemistry	B-X
.	B-X

Here	O
we	O
describe	O
its	O
biochemical	O
properties	O
and	O
assess	O
the	O
subcellular	O
localization	O
,	O
the	O
glycosylation	O
state	O
and	O
the	O
quaternary	O
structure	O
of	O
VR1	B-Protein
expressed	O
in	O
HEK293	O
cells	O
and	O
in	O
the	O
DRG	O
-	O
derived	O
cell	O
line	O
F	O
-	O
11	O
(	O
N18TG2	O
mouse	O
neuroblastoma	O
x	O
rat	O
dorsal	O
root	O
ganglia	O
,	O
hybridoma	O
)	O
.	O
<EOS>	B-X
The	B-X
vanilloid	B-X
receptor	B-X
VR1	B-X
is	B-X
an	B-X
ion	B-X
channel	B-X
predominantly	B-X
expressed	B-X
by	B-X
primary	B-X
sensory	B-X
neurons	B-X
involved	B-X
in	B-X
nociception	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
its	B-X
biochemical	B-X
properties	B-X
and	B-X
assess	B-X
the	B-X
subcellular	B-X
localization	B-X
,	B-X
the	B-X
glycosylation	B-X
state	B-X
and	B-X
the	B-X
quaternary	B-X
structure	B-X
of	B-X
VR1	B-X
expressed	B-X
in	B-X
HEK293	B-X
cells	B-X
and	B-X
in	B-X
the	B-X
DRG-derived	B-X
cell	B-X
line	B-X
F-11	B-X
(	B-X
N18TG2	B-X
mouse	B-X
neuroblastoma	B-X
x	B-X
rat	B-X
dorsal	B-X
root	B-X
ganglia	B-X
,	B-X
hybridoma	B-X
)	B-X
.	B-X
VR1	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
.	B-X
Of	B-X
the	B-X
five	B-X
potential	B-X
N-glycosylation	B-X
sites	B-X
,	B-X
the	B-X
predicted	B-X
transient	B-X
receptor	B-X
potential	B-X
channel-like	B-X
transmembrane	B-X
folding	B-X
proposes	B-X
N604	B-X
is	B-X
localized	B-X
extracellularly	B-X
.	B-X
This	B-X
mutated	B-X
VR1	B-X
was	B-X
not	B-X
glycosylated	B-X
,	B-X
confirming	B-X
the	B-X
extracellular	B-X
location	B-X
of	B-X
N604	B-X
and	B-X
its	B-X
role	B-X
as	B-X
the	B-X
exclusive	B-X
site	B-X
of	B-X
glycosylation	B-X
of	B-X
the	B-X
VR1	B-X
protein	B-X
.	B-X
VR1	B-X
occured	B-X
in	B-X
high	B-X
molecular	B-X
mass	B-X
complexes	B-X
as	B-X
assessed	B-X
by	B-X
blue	B-X
native	B-X
PAGE	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
limited	B-X
amounts	B-X
of	B-X
SDS	B-X
dimers	B-X
,	B-X
trimers	B-X
and	B-X
tetramers	B-X
of	B-X
VR1	B-X
were	B-X
observed	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
predicted	B-X
tetrameric	B-X
quaternary	B-X
structure	B-X
of	B-X
the	B-X
receptor	B-X
.	B-X
Cross-linking	B-X
with	B-X
dimethyladipimidate	B-X
yielded	B-X
almost	B-X
exclusively	B-X
dimers	B-X
.	B-X
Whereas	B-X
VR1	B-X
localized	B-X
both	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
to	B-X
intracellular	B-X
membranes	B-X
in	B-X
HEK293	B-X
cells	B-X
,	B-X
it	B-X
localized	B-X
predominantly	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
in	B-X
F-11	B-X
cells	B-X
.	B-X
Using	B-X
confocal	B-X
laserscanning	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
enrichment	B-X
of	B-X
anti-VR1	B-X
immunoreactivity	B-X
in	B-X
neurite-like	B-X
structures	B-X
of	B-X
F-11	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
light	B-X
of	B-X
conflicting	B-X
literature	B-X
data	B-X
on	B-X
biochemical	B-X
characteristics	B-X
of	B-X
VR1	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
dorsal	B-X
root	B-X
ganglion-derived	B-X
F-11	B-X
cells	B-X
provide	B-X
a	B-X
powerful	B-X
experimental	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
VR1	B-X
biochemistry	B-X
.	B-X

VR1	B-Protein
was	O
found	O
to	O
be	O
glycosylated	O
in	O
both	O
cell	O
types	O
.	O
<EOS>	B-X
The	B-X
capsaicin	B-X
(	B-X
vanilloid	B-X
)	B-X
receptor	B-X
,	B-X
VR1	B-X
,	B-X
is	B-X
an	B-X
agonist-activated	B-X
ion	B-X
channel	B-X
expressed	B-X
by	B-X
sensory	B-X
neurons	B-X
that	B-X
serves	B-X
as	B-X
a	B-X
detector	B-X
of	B-X
chemical	B-X
and	B-X
thermal	B-X
noxious	B-X
stimuli	B-X
.	B-X
Vanilloid	B-X
receptor	B-X
subtype	B-X
1	B-X
(	B-X
VR1	B-X
)	B-X
is	B-X
a	B-X
ligand-gated	B-X
channel	B-X
that	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
capsaicin	B-X
and	B-X
other	B-X
vanilloids	B-X
as	B-X
well	B-X
as	B-X
by	B-X
protons	B-X
and	B-X
heat	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
the	B-X
oligomeric	B-X
state	B-X
of	B-X
VR1	B-X
.	B-X
Co-immunoprecipitation	B-X
of	B-X
differently	B-X
tagged	B-X
VR1	B-X
molecules	B-X
indicated	B-X
that	B-X
VR1	B-X
can	B-X
form	B-X
oligomers	B-X
.	B-X
Using	B-X
two	B-X
different	B-X
heterologous	B-X
VR1	B-X
expression	B-X
systems	B-X
as	B-X
well	B-X
as	B-X
endogenous	B-X
VR1	B-X
expressed	B-X
in	B-X
dorsal	B-X
root	B-X
ganglion	B-X
cells	B-X
,	B-X
we	B-X
analyzed	B-X
oligomer	B-X
formation	B-X
using	B-X
perfluoro-octanoic	B-X
acid	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
Our	B-X
results	B-X
clearly	B-X
show	B-X
that	B-X
VR1	B-X
forms	B-X
multimers	B-X
in	B-X
each	B-X
of	B-X
the	B-X
expression	B-X
systems	B-X
with	B-X
a	B-X
homotetramer	B-X
as	B-X
a	B-X
predominant	B-X
form	B-X
.	B-X
The	B-X
oligomeric	B-X
structure	B-X
of	B-X
VR1	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
VR1	B-X
pharmacology	B-X
.	B-X
Finally	B-X
,	B-X
differences	B-X
in	B-X
glycosylation	B-X
between	B-X
the	B-X
systems	B-X
were	B-X
observed	B-X
,	B-X
indicating	B-X
the	B-X
need	B-X
for	B-X
caution	B-X
in	B-X
the	B-X
use	B-X
of	B-X
the	B-X
heterologous	B-X
expression	B-X
systems	B-X
for	B-X
analysis	B-X
of	B-X
VR1	B-X
properties	B-X
.	B-X

Of	O
the	O
five	O
potential	O
N	O
-	O
glycosylation	O
sites	O
,	O
the	O
predicted	O
transient	O
receptor	O
potential	O
channel	O
-	O
like	O
transmembrane	O
folding	O
proposes	O
N604	O
is	O
localized	O
extracellularly	O
.	O
<EOS>	B-X
The	B-X
vanilloid	B-X
receptor	B-X
VR1	B-X
is	B-X
an	B-X
ion	B-X
channel	B-X
predominantly	B-X
expressed	B-X
by	B-X
primary	B-X
sensory	B-X
neurons	B-X
involved	B-X
in	B-X
nociception	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
its	B-X
biochemical	B-X
properties	B-X
and	B-X
assess	B-X
the	B-X
subcellular	B-X
localization	B-X
,	B-X
the	B-X
glycosylation	B-X
state	B-X
and	B-X
the	B-X
quaternary	B-X
structure	B-X
of	B-X
VR1	B-X
expressed	B-X
in	B-X
HEK293	B-X
cells	B-X
and	B-X
in	B-X
the	B-X
DRG-derived	B-X
cell	B-X
line	B-X
F-11	B-X
(	B-X
N18TG2	B-X
mouse	B-X
neuroblastoma	B-X
x	B-X
rat	B-X
dorsal	B-X
root	B-X
ganglia	B-X
,	B-X
hybridoma	B-X
)	B-X
.	B-X
Of	B-X
the	B-X
five	B-X
potential	B-X
N-glycosylation	B-X
sites	B-X
,	B-X
the	B-X
predicted	B-X
transient	B-X
receptor	B-X
potential	B-X
channel-like	B-X
transmembrane	B-X
folding	B-X
proposes	B-X
N604	B-X
is	B-X
localized	B-X
extracellularly	B-X
.	B-X
This	B-X
mutated	B-X
VR1	B-X
was	B-X
not	B-X
glycosylated	B-X
,	B-X
confirming	B-X
the	B-X
extracellular	B-X
location	B-X
of	B-X
N604	B-X
and	B-X
its	B-X
role	B-X
as	B-X
the	B-X
exclusive	B-X
site	B-X
of	B-X
glycosylation	B-X
of	B-X
the	B-X
VR1	B-X
protein	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
limited	B-X
amounts	B-X
of	B-X
SDS	B-X
dimers	B-X
,	B-X
trimers	B-X
and	B-X
tetramers	B-X
of	B-X
VR1	B-X
were	B-X
observed	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
predicted	B-X
tetrameric	B-X
quaternary	B-X
structure	B-X
of	B-X
the	B-X
receptor	B-X
.	B-X
Whereas	B-X
VR1	B-X
localized	B-X
both	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
to	B-X
intracellular	B-X
membranes	B-X
in	B-X
HEK293	B-X
cells	B-X
,	B-X
it	B-X
localized	B-X
predominantly	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
in	B-X
F-11	B-X
cells	B-X
.	B-X
Using	B-X
confocal	B-X
laserscanning	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
enrichment	B-X
of	B-X
anti-VR1	B-X
immunoreactivity	B-X
in	B-X
neurite-like	B-X
structures	B-X
of	B-X
F-11	B-X
cells	B-X
.	B-X

We	O
used	O
site	O
-	O
directed	O
mutagenesis	O
to	O
mutate	O
the	O
Asn	O
at	O
position	O
604	O
to	O
Thr	O
.	O
<EOS>	B-X
Of	B-X
the	B-X
five	B-X
potential	B-X
N-glycosylation	B-X
sites	B-X
,	B-X
the	B-X
predicted	B-X
transient	B-X
receptor	B-X
potential	B-X
channel-like	B-X
transmembrane	B-X
folding	B-X
proposes	B-X
N604	B-X
is	B-X
localized	B-X
extracellularly	B-X
.	B-X
We	B-X
used	B-X
site-directed	B-X
mutagenesis	B-X
to	B-X
mutate	B-X
the	B-X
Asn	B-X
at	B-X
position	B-X
604	B-X
to	B-X
Thr	B-X
.	B-X
This	B-X
mutated	B-X
VR1	B-X
was	B-X
not	B-X
glycosylated	B-X
,	B-X
confirming	B-X
the	B-X
extracellular	B-X
location	B-X
of	B-X
N604	B-X
and	B-X
its	B-X
role	B-X
as	B-X
the	B-X
exclusive	B-X
site	B-X
of	B-X
glycosylation	B-X
of	B-X
the	B-X
VR1	B-X
protein	B-X
.	B-X

This	O
mutated	O
VR1	B-Protein
was	O
not	O
glycosylated	O
,	O
confirming	O
the	O
extracellular	O
location	O
of	O
N604	O
and	O
its	O
role	O
as	O
the	O
exclusive	O
site	O
of	O
glycosylation	O
of	O
the	O
VR1	B-Protein
protein	O
.	O
<EOS>	B-X
The	B-X
transient	B-X
receptor	B-X
potential	B-X
(	B-X
TRP	B-X
)	B-X
protein	B-X
superfamily	B-X
consists	B-X
of	B-X
a	B-X
diverse	B-X
group	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
permeable	B-X
nonselective	B-X
cation	B-X
channels	B-X
that	B-X
bear	B-X
structural	B-X
similarities	B-X
to	B-X
Drosophila	B-X
TRP	B-X
.	B-X
TRP-related	B-X
proteins	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
nonexcitable	B-X
cells	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
recent	B-X
finding	B-X
that	B-X
a	B-X
mammalian	B-X
TRPC	B-X
protein	B-X
is	B-X
expressed	B-X
in	B-X
endothelial	B-X
cells	B-X
and	B-X
functions	B-X
in	B-X
vasorelaxation	B-X
.	B-X
However	B-X
,	B-X
an	B-X
emerging	B-X
theme	B-X
is	B-X
that	B-X
many	B-X
TRP-related	B-X
proteins	B-X
are	B-X
expressed	B-X
predominantly	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
and	B-X
function	B-X
in	B-X
sensory	B-X
physiology	B-X
.	B-X
These	B-X
proteins	B-X
all	B-X
share	B-X
the	B-X
common	B-X
features	B-X
of	B-X
three	B-X
to	B-X
four	B-X
ankryin	B-X
repeats	B-X
,	B-X
>	B-X
/=30	B-X
%	B-X
amino	B-X
acid	B-X
homology	B-X
over	B-X
>	B-X
/=750	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
a	B-X
gating	B-X
mechanism	B-X
that	B-X
operates	B-X
through	B-X
phospholipase	B-X
C.	B-X
Some	B-X
classical	B-X
TRPs	B-X
may	B-X
be	B-X
store-operated	B-X
channels	B-X
(	B-X
SOCs	B-X
)	B-X
,	B-X
which	B-X
are	B-X
activated	B-X
by	B-X
release	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
from	B-X
internal	B-X
stores	B-X
.	B-X
The	B-X
mammalian	B-X
TRPC	B-X
proteins	B-X
are	B-X
also	B-X
expressed	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
and	B-X
several	B-X
are	B-X
highly	B-X
enriched	B-X
in	B-X
the	B-X
brain	B-X
.	B-X
One	B-X
TRPC	B-X
protein	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pheromone	B-X
response	B-X
.	B-X
These	B-X
include	B-X
VR1	B-X
and	B-X
OSM-9	B-X
,	B-X
which	B-X
respond	B-X
to	B-X
heat	B-X
,	B-X
osmolarity	B-X
,	B-X
odorants	B-X
,	B-X
and	B-X
mechanical	B-X
stimuli	B-X
.	B-X
A	B-X
third	B-X
subfamily	B-X
,	B-X
TRPN	B-X
,	B-X
includes	B-X
proteins	B-X
with	B-X
many	B-X
ankyrin	B-X
repeats	B-X
,	B-X
one	B-X
of	B-X
which	B-X
,	B-X
NOMPC	B-X
,	B-X
participates	B-X
in	B-X
mechanotransduction	B-X
.	B-X
Among	B-X
the	B-X
members	B-X
of	B-X
a	B-X
fourth	B-X
subfamily	B-X
,	B-X
TRPM	B-X
,	B-X
is	B-X
a	B-X
putative	B-X
tumor	B-X
suppressor	B-X
termed	B-X
melastatin	B-X
,	B-X
and	B-X
a	B-X
bifunctional	B-X
protein	B-X
,	B-X
TRP-PLIK	B-X
,	B-X
consisting	B-X
of	B-X
a	B-X
TRPM	B-X
channel	B-X
fused	B-X
to	B-X
a	B-X
protein	B-X
kinase	B-X
.	B-X

VR1	B-Protein
occured	O
in	O
high	O
molecular	O
mass	O
complexes	O
as	O
assessed	O
by	O
blue	O
native	O
PAGE	O
.	O
<EOS>	B-X
The	B-X
vanilloid	B-X
receptor	B-X
VR1	B-X
is	B-X
an	B-X
ion	B-X
channel	B-X
predominantly	B-X
expressed	B-X
by	B-X
primary	B-X
sensory	B-X
neurons	B-X
involved	B-X
in	B-X
nociception	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
its	B-X
biochemical	B-X
properties	B-X
and	B-X
assess	B-X
the	B-X
subcellular	B-X
localization	B-X
,	B-X
the	B-X
glycosylation	B-X
state	B-X
and	B-X
the	B-X
quaternary	B-X
structure	B-X
of	B-X
VR1	B-X
expressed	B-X
in	B-X
HEK293	B-X
cells	B-X
and	B-X
in	B-X
the	B-X
DRG-derived	B-X
cell	B-X
line	B-X
F-11	B-X
(	B-X
N18TG2	B-X
mouse	B-X
neuroblastoma	B-X
x	B-X
rat	B-X
dorsal	B-X
root	B-X
ganglia	B-X
,	B-X
hybridoma	B-X
)	B-X
.	B-X
VR1	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
.	B-X
This	B-X
mutated	B-X
VR1	B-X
was	B-X
not	B-X
glycosylated	B-X
,	B-X
confirming	B-X
the	B-X
extracellular	B-X
location	B-X
of	B-X
N604	B-X
and	B-X
its	B-X
role	B-X
as	B-X
the	B-X
exclusive	B-X
site	B-X
of	B-X
glycosylation	B-X
of	B-X
the	B-X
VR1	B-X
protein	B-X
.	B-X
VR1	B-X
occured	B-X
in	B-X
high	B-X
molecular	B-X
mass	B-X
complexes	B-X
as	B-X
assessed	B-X
by	B-X
blue	B-X
native	B-X
PAGE	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
limited	B-X
amounts	B-X
of	B-X
SDS	B-X
dimers	B-X
,	B-X
trimers	B-X
and	B-X
tetramers	B-X
of	B-X
VR1	B-X
were	B-X
observed	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
predicted	B-X
tetrameric	B-X
quaternary	B-X
structure	B-X
of	B-X
the	B-X
receptor	B-X
.	B-X
Whereas	B-X
VR1	B-X
localized	B-X
both	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
to	B-X
intracellular	B-X
membranes	B-X
in	B-X
HEK293	B-X
cells	B-X
,	B-X
it	B-X
localized	B-X
predominantly	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
in	B-X
F-11	B-X
cells	B-X
.	B-X
Using	B-X
confocal	B-X
laserscanning	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
enrichment	B-X
of	B-X
anti-VR1	B-X
immunoreactivity	B-X
in	B-X
neurite-like	B-X
structures	B-X
of	B-X
F-11	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
light	B-X
of	B-X
conflicting	B-X
literature	B-X
data	B-X
on	B-X
biochemical	B-X
characteristics	B-X
of	B-X
VR1	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
dorsal	B-X
root	B-X
ganglion-derived	B-X
F-11	B-X
cells	B-X
provide	B-X
a	B-X
powerful	B-X
experimental	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
VR1	B-X
biochemistry	B-X
.	B-X

In	O
the	O
presence	O
of	O
limited	O
amounts	O
of	O
SDS	O
dimers	O
,	O
trimers	O
and	O
tetramers	O
of	O
VR1	B-Protein
were	O
observed	O
,	O
consistent	O
with	O
the	O
predicted	O
tetrameric	O
quaternary	O
structure	O
of	O
the	O
receptor	O
.	O
<EOS>	B-X
The	B-X
vanilloid	B-X
receptor	B-X
VR1	B-X
is	B-X
an	B-X
ion	B-X
channel	B-X
predominantly	B-X
expressed	B-X
by	B-X
primary	B-X
sensory	B-X
neurons	B-X
involved	B-X
in	B-X
nociception	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
its	B-X
biochemical	B-X
properties	B-X
and	B-X
assess	B-X
the	B-X
subcellular	B-X
localization	B-X
,	B-X
the	B-X
glycosylation	B-X
state	B-X
and	B-X
the	B-X
quaternary	B-X
structure	B-X
of	B-X
VR1	B-X
expressed	B-X
in	B-X
HEK293	B-X
cells	B-X
and	B-X
in	B-X
the	B-X
DRG-derived	B-X
cell	B-X
line	B-X
F-11	B-X
(	B-X
N18TG2	B-X
mouse	B-X
neuroblastoma	B-X
x	B-X
rat	B-X
dorsal	B-X
root	B-X
ganglia	B-X
,	B-X
hybridoma	B-X
)	B-X
.	B-X
VR1	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
.	B-X
Of	B-X
the	B-X
five	B-X
potential	B-X
N-glycosylation	B-X
sites	B-X
,	B-X
the	B-X
predicted	B-X
transient	B-X
receptor	B-X
potential	B-X
channel-like	B-X
transmembrane	B-X
folding	B-X
proposes	B-X
N604	B-X
is	B-X
localized	B-X
extracellularly	B-X
.	B-X
This	B-X
mutated	B-X
VR1	B-X
was	B-X
not	B-X
glycosylated	B-X
,	B-X
confirming	B-X
the	B-X
extracellular	B-X
location	B-X
of	B-X
N604	B-X
and	B-X
its	B-X
role	B-X
as	B-X
the	B-X
exclusive	B-X
site	B-X
of	B-X
glycosylation	B-X
of	B-X
the	B-X
VR1	B-X
protein	B-X
.	B-X
VR1	B-X
occured	B-X
in	B-X
high	B-X
molecular	B-X
mass	B-X
complexes	B-X
as	B-X
assessed	B-X
by	B-X
blue	B-X
native	B-X
PAGE	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
limited	B-X
amounts	B-X
of	B-X
SDS	B-X
dimers	B-X
,	B-X
trimers	B-X
and	B-X
tetramers	B-X
of	B-X
VR1	B-X
were	B-X
observed	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
predicted	B-X
tetrameric	B-X
quaternary	B-X
structure	B-X
of	B-X
the	B-X
receptor	B-X
.	B-X
Cross-linking	B-X
with	B-X
dimethyladipimidate	B-X
yielded	B-X
almost	B-X
exclusively	B-X
dimers	B-X
.	B-X
Whereas	B-X
VR1	B-X
localized	B-X
both	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
to	B-X
intracellular	B-X
membranes	B-X
in	B-X
HEK293	B-X
cells	B-X
,	B-X
it	B-X
localized	B-X
predominantly	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
in	B-X
F-11	B-X
cells	B-X
.	B-X
Using	B-X
confocal	B-X
laserscanning	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
enrichment	B-X
of	B-X
anti-VR1	B-X
immunoreactivity	B-X
in	B-X
neurite-like	B-X
structures	B-X
of	B-X
F-11	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
light	B-X
of	B-X
conflicting	B-X
literature	B-X
data	B-X
on	B-X
biochemical	B-X
characteristics	B-X
of	B-X
VR1	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
dorsal	B-X
root	B-X
ganglion-derived	B-X
F-11	B-X
cells	B-X
provide	B-X
a	B-X
powerful	B-X
experimental	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
VR1	B-X
biochemistry	B-X
.	B-X

Cross	O
-	O
linking	O
with	O
dimethyladipimidate	O
yielded	O
almost	O
exclusively	O
dimers	O
.	O
<EOS>	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
limited	B-X
amounts	B-X
of	B-X
SDS	B-X
dimers	B-X
,	B-X
trimers	B-X
and	B-X
tetramers	B-X
of	B-X
VR1	B-X
were	B-X
observed	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
predicted	B-X
tetrameric	B-X
quaternary	B-X
structure	B-X
of	B-X
the	B-X
receptor	B-X
.	B-X
Cross-linking	B-X
with	B-X
dimethyladipimidate	B-X
yielded	B-X
almost	B-X
exclusively	B-X
dimers	B-X
.	B-X

Whereas	O
VR1	B-Protein
localized	O
both	O
to	O
the	O
plasma	O
membrane	O
and	O
to	O
intracellular	O
membranes	O
in	O
HEK293	O
cells	O
,	O
it	O
localized	O
predominantly	O
to	O
the	O
plasma	O
membrane	O
in	O
F	O
-	O
11	O
cells	O
.	O

Using	O
confocal	O
laserscanning	O
microscopy	O
,	O
we	O
observed	O
an	O
enrichment	O
of	O
anti	O
-	O
VR1	B-Protein
immunoreactivity	O
in	O
neurite	O
-	O
like	O
structures	O
of	O
F	O
-	O
11	O
cells	O
.	O
<EOS>	B-X
The	B-X
vanilloid	B-X
receptor	B-X
VR1	B-X
is	B-X
an	B-X
ion	B-X
channel	B-X
predominantly	B-X
expressed	B-X
by	B-X
primary	B-X
sensory	B-X
neurons	B-X
involved	B-X
in	B-X
nociception	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
its	B-X
biochemical	B-X
properties	B-X
and	B-X
assess	B-X
the	B-X
subcellular	B-X
localization	B-X
,	B-X
the	B-X
glycosylation	B-X
state	B-X
and	B-X
the	B-X
quaternary	B-X
structure	B-X
of	B-X
VR1	B-X
expressed	B-X
in	B-X
HEK293	B-X
cells	B-X
and	B-X
in	B-X
the	B-X
DRG-derived	B-X
cell	B-X
line	B-X
F-11	B-X
(	B-X
N18TG2	B-X
mouse	B-X
neuroblastoma	B-X
x	B-X
rat	B-X
dorsal	B-X
root	B-X
ganglia	B-X
,	B-X
hybridoma	B-X
)	B-X
.	B-X
VR1	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
.	B-X
Of	B-X
the	B-X
five	B-X
potential	B-X
N-glycosylation	B-X
sites	B-X
,	B-X
the	B-X
predicted	B-X
transient	B-X
receptor	B-X
potential	B-X
channel-like	B-X
transmembrane	B-X
folding	B-X
proposes	B-X
N604	B-X
is	B-X
localized	B-X
extracellularly	B-X
.	B-X
This	B-X
mutated	B-X
VR1	B-X
was	B-X
not	B-X
glycosylated	B-X
,	B-X
confirming	B-X
the	B-X
extracellular	B-X
location	B-X
of	B-X
N604	B-X
and	B-X
its	B-X
role	B-X
as	B-X
the	B-X
exclusive	B-X
site	B-X
of	B-X
glycosylation	B-X
of	B-X
the	B-X
VR1	B-X
protein	B-X
.	B-X
VR1	B-X
occured	B-X
in	B-X
high	B-X
molecular	B-X
mass	B-X
complexes	B-X
as	B-X
assessed	B-X
by	B-X
blue	B-X
native	B-X
PAGE	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
limited	B-X
amounts	B-X
of	B-X
SDS	B-X
dimers	B-X
,	B-X
trimers	B-X
and	B-X
tetramers	B-X
of	B-X
VR1	B-X
were	B-X
observed	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
predicted	B-X
tetrameric	B-X
quaternary	B-X
structure	B-X
of	B-X
the	B-X
receptor	B-X
.	B-X
Whereas	B-X
VR1	B-X
localized	B-X
both	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
to	B-X
intracellular	B-X
membranes	B-X
in	B-X
HEK293	B-X
cells	B-X
,	B-X
it	B-X
localized	B-X
predominantly	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
in	B-X
F-11	B-X
cells	B-X
.	B-X
Using	B-X
confocal	B-X
laserscanning	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
enrichment	B-X
of	B-X
anti-VR1	B-X
immunoreactivity	B-X
in	B-X
neurite-like	B-X
structures	B-X
of	B-X
F-11	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
light	B-X
of	B-X
conflicting	B-X
literature	B-X
data	B-X
on	B-X
biochemical	B-X
characteristics	B-X
of	B-X
VR1	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
dorsal	B-X
root	B-X
ganglion-derived	B-X
F-11	B-X
cells	B-X
provide	B-X
a	B-X
powerful	B-X
experimental	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
VR1	B-X
biochemistry	B-X
.	B-X

In	O
the	O
light	O
of	O
conflicting	O
literature	O
data	O
on	O
biochemical	O
characteristics	O
of	O
VR1	B-Protein
,	O
our	O
data	O
suggest	O
that	O
dorsal	O
root	O
ganglion	O
-	O
derived	O
F	O
-	O
11	O
cells	O
provide	O
a	O
powerful	O
experimental	O
system	O
for	O
the	O
study	O
of	O
VR1	B-Protein
biochemistry	O
.	O

The	O
methylosome	O
,	O
a	O
20S	O
complex	O
containing	O
JBP1	B-Protein
and	O
pICln	B-Protein
,	O
produces	O
dimethylarginine	O
-	O
modified	O
Sm	O
proteins	O
.	O
<EOS>	B-X
snRNPs	B-X
,	B-X
integral	B-X
components	B-X
of	B-X
the	B-X
pre-mRNA	B-X
splicing	B-X
machinery	B-X
,	B-X
consist	B-X
of	B-X
seven	B-X
Sm	B-X
proteins	B-X
which	B-X
assemble	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
a	B-X
ring	B-X
structure	B-X
on	B-X
the	B-X
snRNAs	B-X
U1	B-X
,	B-X
U2	B-X
,	B-X
U4	B-X
,	B-X
and	B-X
U5	B-X
.	B-X
SMN	B-X
binds	B-X
preferentially	B-X
and	B-X
directly	B-X
to	B-X
the	B-X
symmetrical	B-X
dimethylarginine	B-X
(	B-X
sDMA	B-X
)	B-X
-modified	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
(	B-X
RG-rich	B-X
)	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
unmodified	B-X
,	B-X
but	B-X
not	B-X
the	B-X
sDMA-modified	B-X
,	B-X
RG	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
associate	B-X
with	B-X
a	B-X
20S	B-X
methyltransferase	B-X
complex	B-X
,	B-X
termed	B-X
the	B-X
methylosome	B-X
,	B-X
that	B-X
contains	B-X
the	B-X
methyltransferase	B-X
JBP1	B-X
and	B-X
a	B-X
JBP1-interacting	B-X
protein	B-X
,	B-X
pICln	B-X
.	B-X
JBP1	B-X
binds	B-X
SmD1	B-X
and	B-X
SmD3	B-X
via	B-X
their	B-X
RG	B-X
domains	B-X
,	B-X
while	B-X
pICln	B-X
binds	B-X
the	B-X
Sm	B-X
domains	B-X
.	B-X
JBP1	B-X
produces	B-X
sDMAs	B-X
in	B-X
the	B-X
RG	B-X
domain-containing	B-X
Sm	B-X
proteins	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
6S	B-X
complex	B-X
that	B-X
contains	B-X
pICln	B-X
,	B-X
SmD1	B-X
,	B-X
and	B-X
SmD3	B-X
but	B-X
not	B-X
JBP1	B-X
.	B-X
SmD3	B-X
from	B-X
the	B-X
methylosome	B-X
,	B-X
but	B-X
not	B-X
that	B-X
from	B-X
the	B-X
6S	B-X
complex	B-X
,	B-X
can	B-X
be	B-X
transferred	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
in	B-X
vitro	B-X
.	B-X
Together	B-X
with	B-X
previous	B-X
results	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
methylation	B-X
of	B-X
Sm	B-X
proteins	B-X
by	B-X
the	B-X
methylosome	B-X
directs	B-X
Sm	B-X
proteins	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
for	B-X
assembly	B-X
into	B-X
snRNP	B-X
core	B-X
particles	B-X
and	B-X
suggest	B-X
that	B-X
the	B-X
methylosome	B-X
can	B-X
regulate	B-X
snRNP	B-X
assembly	B-X
.	B-X

snRNPs	O
,	O
integral	O
components	O
of	O
the	O
pre	O
-	O
mRNA	O
splicing	O
machinery	O
,	O
consist	O
of	O
seven	O
Sm	O
proteins	O
which	O
assemble	O
in	O
the	O
cytoplasm	O
as	O
a	O
ring	O
structure	O
on	O
the	O
snRNAs	O
U1	O
,	O
U2	O
,	O
U4	O
,	O
and	O
U5	O
.	O
<EOS>	B-X
snRNPs	B-X
,	B-X
integral	B-X
components	B-X
of	B-X
the	B-X
pre-mRNA	B-X
splicing	B-X
machinery	B-X
,	B-X
consist	B-X
of	B-X
seven	B-X
Sm	B-X
proteins	B-X
which	B-X
assemble	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
a	B-X
ring	B-X
structure	B-X
on	B-X
the	B-X
snRNAs	B-X
U1	B-X
,	B-X
U2	B-X
,	B-X
U4	B-X
,	B-X
and	B-X
U5	B-X
.	B-X
SMN	B-X
binds	B-X
preferentially	B-X
and	B-X
directly	B-X
to	B-X
the	B-X
symmetrical	B-X
dimethylarginine	B-X
(	B-X
sDMA	B-X
)	B-X
-modified	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
(	B-X
RG-rich	B-X
)	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
unmodified	B-X
,	B-X
but	B-X
not	B-X
the	B-X
sDMA-modified	B-X
,	B-X
RG	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
associate	B-X
with	B-X
a	B-X
20S	B-X
methyltransferase	B-X
complex	B-X
,	B-X
termed	B-X
the	B-X
methylosome	B-X
,	B-X
that	B-X
contains	B-X
the	B-X
methyltransferase	B-X
JBP1	B-X
and	B-X
a	B-X
JBP1-interacting	B-X
protein	B-X
,	B-X
pICln	B-X
.	B-X
JBP1	B-X
binds	B-X
SmD1	B-X
and	B-X
SmD3	B-X
via	B-X
their	B-X
RG	B-X
domains	B-X
,	B-X
while	B-X
pICln	B-X
binds	B-X
the	B-X
Sm	B-X
domains	B-X
.	B-X
JBP1	B-X
produces	B-X
sDMAs	B-X
in	B-X
the	B-X
RG	B-X
domain-containing	B-X
Sm	B-X
proteins	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
6S	B-X
complex	B-X
that	B-X
contains	B-X
pICln	B-X
,	B-X
SmD1	B-X
,	B-X
and	B-X
SmD3	B-X
but	B-X
not	B-X
JBP1	B-X
.	B-X
SmD3	B-X
from	B-X
the	B-X
methylosome	B-X
,	B-X
but	B-X
not	B-X
that	B-X
from	B-X
the	B-X
6S	B-X
complex	B-X
,	B-X
can	B-X
be	B-X
transferred	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
in	B-X
vitro	B-X
.	B-X
Together	B-X
with	B-X
previous	B-X
results	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
methylation	B-X
of	B-X
Sm	B-X
proteins	B-X
by	B-X
the	B-X
methylosome	B-X
directs	B-X
Sm	B-X
proteins	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
for	B-X
assembly	B-X
into	B-X
snRNP	B-X
core	B-X
particles	B-X
and	B-X
suggest	B-X
that	B-X
the	B-X
methylosome	B-X
can	B-X
regulate	B-X
snRNP	B-X
assembly	B-X
.	B-X

The	O
survival	O
motor	O
neuron	O
(	O
SMN	O
)	O
protein	O
,	O
the	O
spinal	O
muscular	O
atrophy	O
disease	O
gene	O
product	O
,	O
is	O
crucial	O
for	O
snRNP	O
core	O
particle	O
assembly	O
in	O
vivo	O
.	O
<EOS>	B-X
snRNPs	B-X
,	B-X
integral	B-X
components	B-X
of	B-X
the	B-X
pre-mRNA	B-X
splicing	B-X
machinery	B-X
,	B-X
consist	B-X
of	B-X
seven	B-X
Sm	B-X
proteins	B-X
which	B-X
assemble	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
a	B-X
ring	B-X
structure	B-X
on	B-X
the	B-X
snRNAs	B-X
U1	B-X
,	B-X
U2	B-X
,	B-X
U4	B-X
,	B-X
and	B-X
U5	B-X
.	B-X
The	B-X
survival	B-X
motor	B-X
neuron	B-X
(	B-X
SMN	B-X
)	B-X
protein	B-X
,	B-X
the	B-X
spinal	B-X
muscular	B-X
atrophy	B-X
disease	B-X
gene	B-X
product	B-X
,	B-X
is	B-X
crucial	B-X
for	B-X
snRNP	B-X
core	B-X
particle	B-X
assembly	B-X
in	B-X
vivo	B-X
.	B-X
SMN	B-X
binds	B-X
preferentially	B-X
and	B-X
directly	B-X
to	B-X
the	B-X
symmetrical	B-X
dimethylarginine	B-X
(	B-X
sDMA	B-X
)	B-X
-modified	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
(	B-X
RG-rich	B-X
)	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
unmodified	B-X
,	B-X
but	B-X
not	B-X
the	B-X
sDMA-modified	B-X
,	B-X
RG	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
associate	B-X
with	B-X
a	B-X
20S	B-X
methyltransferase	B-X
complex	B-X
,	B-X
termed	B-X
the	B-X
methylosome	B-X
,	B-X
that	B-X
contains	B-X
the	B-X
methyltransferase	B-X
JBP1	B-X
and	B-X
a	B-X
JBP1-interacting	B-X
protein	B-X
,	B-X
pICln	B-X
.	B-X
JBP1	B-X
produces	B-X
sDMAs	B-X
in	B-X
the	B-X
RG	B-X
domain-containing	B-X
Sm	B-X
proteins	B-X
.	B-X
SmD3	B-X
from	B-X
the	B-X
methylosome	B-X
,	B-X
but	B-X
not	B-X
that	B-X
from	B-X
the	B-X
6S	B-X
complex	B-X
,	B-X
can	B-X
be	B-X
transferred	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
in	B-X
vitro	B-X
.	B-X
Together	B-X
with	B-X
previous	B-X
results	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
methylation	B-X
of	B-X
Sm	B-X
proteins	B-X
by	B-X
the	B-X
methylosome	B-X
directs	B-X
Sm	B-X
proteins	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
for	B-X
assembly	B-X
into	B-X
snRNP	B-X
core	B-X
particles	B-X
and	B-X
suggest	B-X
that	B-X
the	B-X
methylosome	B-X
can	B-X
regulate	B-X
snRNP	B-X
assembly	B-X
.	B-X

SMN	O
binds	O
preferentially	O
and	O
directly	O
to	O
the	O
symmetrical	O
dimethylarginine	O
(	O
sDMA	O
)	O
-	O
modified	O
arginine	O
-	O
and	O
glycine	O
-	O
rich	O
(	O
RG	O
-	O
rich	O
)	O
domains	O
of	O
SmD1	B-Protein
and	O
SmD3	B-Protein
.	O

We	O
found	O
that	O
the	O
unmodified	O
,	O
but	O
not	O
the	O
sDMA	O
-	O
modified	O
,	O
RG	O
domains	O
of	O
SmD1	B-Protein
and	O
SmD3	B-Protein
associate	O
with	O
a	O
20S	O
methyltransferase	O
complex	O
,	O
termed	O
the	O
methylosome	O
,	O
that	O
contains	O
the	O
methyltransferase	O
JBP1	B-Protein
and	O
a	O
JBP1	B-Protein
-	O
interacting	O
protein	O
,	O
pICln	B-Protein
.	O
<EOS>	B-X
An	B-X
mRNA	B-X
with	B-X
unmodified	B-X
nucleosides	B-X
induces	B-X
type	B-X
I	B-X
interferons	B-X
(	B-X
IFN-I	B-X
)	B-X
through	B-X
the	B-X
stimulation	B-X
of	B-X
innate	B-X
immune	B-X
sensors	B-X
.	B-X
In	B-X
B16-OVA	B-X
murine	B-X
melanoma	B-X
model	B-X
,	B-X
unmodified	B-X
OVA-LNP	B-X
significantly	B-X
reduced	B-X
tumor	B-X
growth	B-X
and	B-X
prolonged	B-X
survival	B-X
,	B-X
compared	B-X
to	B-X
OVA-LNP	B-X
with	B-X
m1Ψ	B-X
modification	B-X
.	B-X
Currently	B-X
,	B-X
developed	B-X
synthetic	B-X
approaches	B-X
have	B-X
allowed	B-X
the	B-X
design	B-X
of	B-X
diverse	B-X
modified/unmodified	B-X
semiconductor	B-X
materials	B-X
exhibiting	B-X
enhanced	B-X
performances	B-X
in	B-X
heterogeneous	B-X
photocatalysis	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
have	B-X
classified	B-X
the	B-X
so	B-X
far	B-X
reported	B-X
highly	B-X
efficient	B-X
modified/unmodified	B-X
semiconductor	B-X
photocatalysts	B-X
into	B-X
four	B-X
different	B-X
categories	B-X
based	B-X
on	B-X
the	B-X
elemental	B-X
composition	B-X
,	B-X
band	B-X
gap	B-X
engineering	B-X
and	B-X
charge	B-X
carrier	B-X
migration	B-X
mechanism	B-X
in	B-X
composite	B-X
photocatalysts	B-X
.	B-X
The	B-X
motivation	B-X
behind	B-X
the	B-X
synthetic	B-X
upgrading	B-X
of	B-X
modified/unmodified	B-X
(	B-X
pure	B-X
)	B-X
semiconductor	B-X
photocatalysts	B-X
along	B-X
with	B-X
their	B-X
particular	B-X
photochemical	B-X
applications	B-X
and	B-X
photoreactor	B-X
systems	B-X
have	B-X
been	B-X
thoroughly	B-X
reviewed	B-X
.	B-X

JBP1	B-Protein
binds	O
SmD1	B-Protein
and	O
SmD3	B-Protein
via	O
their	O
RG	O
domains	O
,	O
while	O
pICln	B-Protein
binds	O
the	O
Sm	O
domains	O
.	O

JBP1	B-Protein
produces	O
sDMAs	O
in	O
the	O
RG	O
domain	O
-	O
containing	O
Sm	O
proteins	O
.	O
<EOS>	B-X
snRNPs	B-X
,	B-X
integral	B-X
components	B-X
of	B-X
the	B-X
pre-mRNA	B-X
splicing	B-X
machinery	B-X
,	B-X
consist	B-X
of	B-X
seven	B-X
Sm	B-X
proteins	B-X
which	B-X
assemble	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
a	B-X
ring	B-X
structure	B-X
on	B-X
the	B-X
snRNAs	B-X
U1	B-X
,	B-X
U2	B-X
,	B-X
U4	B-X
,	B-X
and	B-X
U5	B-X
.	B-X
SMN	B-X
binds	B-X
preferentially	B-X
and	B-X
directly	B-X
to	B-X
the	B-X
symmetrical	B-X
dimethylarginine	B-X
(	B-X
sDMA	B-X
)	B-X
-modified	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
(	B-X
RG-rich	B-X
)	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
unmodified	B-X
,	B-X
but	B-X
not	B-X
the	B-X
sDMA-modified	B-X
,	B-X
RG	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
associate	B-X
with	B-X
a	B-X
20S	B-X
methyltransferase	B-X
complex	B-X
,	B-X
termed	B-X
the	B-X
methylosome	B-X
,	B-X
that	B-X
contains	B-X
the	B-X
methyltransferase	B-X
JBP1	B-X
and	B-X
a	B-X
JBP1-interacting	B-X
protein	B-X
,	B-X
pICln	B-X
.	B-X
JBP1	B-X
binds	B-X
SmD1	B-X
and	B-X
SmD3	B-X
via	B-X
their	B-X
RG	B-X
domains	B-X
,	B-X
while	B-X
pICln	B-X
binds	B-X
the	B-X
Sm	B-X
domains	B-X
.	B-X
JBP1	B-X
produces	B-X
sDMAs	B-X
in	B-X
the	B-X
RG	B-X
domain-containing	B-X
Sm	B-X
proteins	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
6S	B-X
complex	B-X
that	B-X
contains	B-X
pICln	B-X
,	B-X
SmD1	B-X
,	B-X
and	B-X
SmD3	B-X
but	B-X
not	B-X
JBP1	B-X
.	B-X
SmD3	B-X
from	B-X
the	B-X
methylosome	B-X
,	B-X
but	B-X
not	B-X
that	B-X
from	B-X
the	B-X
6S	B-X
complex	B-X
,	B-X
can	B-X
be	B-X
transferred	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
in	B-X
vitro	B-X
.	B-X
Together	B-X
with	B-X
previous	B-X
results	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
methylation	B-X
of	B-X
Sm	B-X
proteins	B-X
by	B-X
the	B-X
methylosome	B-X
directs	B-X
Sm	B-X
proteins	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
for	B-X
assembly	B-X
into	B-X
snRNP	B-X
core	B-X
particles	B-X
and	B-X
suggest	B-X
that	B-X
the	B-X
methylosome	B-X
can	B-X
regulate	B-X
snRNP	B-X
assembly	B-X
.	B-X

We	O
further	O
demonstrate	O
the	O
existence	O
of	O
a	O
6S	O
complex	O
that	O
contains	O
pICln	B-Protein
,	O
SmD1	B-Protein
,	O
and	O
SmD3	B-Protein
but	O
not	O
JBP1	B-Protein
.	O

SmD3	B-Protein
from	O
the	O
methylosome	O
,	O
but	O
not	O
that	O
from	O
the	O
6S	O
complex	O
,	O
can	O
be	O
transferred	O
to	O
the	O
SMN	O
complex	O
in	O
vitro	O
.	O
<EOS>	B-X
The	B-X
survival	B-X
motor	B-X
neuron	B-X
(	B-X
SMN	B-X
)	B-X
protein	B-X
,	B-X
the	B-X
spinal	B-X
muscular	B-X
atrophy	B-X
disease	B-X
gene	B-X
product	B-X
,	B-X
is	B-X
crucial	B-X
for	B-X
snRNP	B-X
core	B-X
particle	B-X
assembly	B-X
in	B-X
vivo	B-X
.	B-X
SMN	B-X
binds	B-X
preferentially	B-X
and	B-X
directly	B-X
to	B-X
the	B-X
symmetrical	B-X
dimethylarginine	B-X
(	B-X
sDMA	B-X
)	B-X
-modified	B-X
arginine-	B-X
and	B-X
glycine-rich	B-X
(	B-X
RG-rich	B-X
)	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
unmodified	B-X
,	B-X
but	B-X
not	B-X
the	B-X
sDMA-modified	B-X
,	B-X
RG	B-X
domains	B-X
of	B-X
SmD1	B-X
and	B-X
SmD3	B-X
associate	B-X
with	B-X
a	B-X
20S	B-X
methyltransferase	B-X
complex	B-X
,	B-X
termed	B-X
the	B-X
methylosome	B-X
,	B-X
that	B-X
contains	B-X
the	B-X
methyltransferase	B-X
JBP1	B-X
and	B-X
a	B-X
JBP1-interacting	B-X
protein	B-X
,	B-X
pICln	B-X
.	B-X
JBP1	B-X
binds	B-X
SmD1	B-X
and	B-X
SmD3	B-X
via	B-X
their	B-X
RG	B-X
domains	B-X
,	B-X
while	B-X
pICln	B-X
binds	B-X
the	B-X
Sm	B-X
domains	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
6S	B-X
complex	B-X
that	B-X
contains	B-X
pICln	B-X
,	B-X
SmD1	B-X
,	B-X
and	B-X
SmD3	B-X
but	B-X
not	B-X
JBP1	B-X
.	B-X
SmD3	B-X
from	B-X
the	B-X
methylosome	B-X
,	B-X
but	B-X
not	B-X
that	B-X
from	B-X
the	B-X
6S	B-X
complex	B-X
,	B-X
can	B-X
be	B-X
transferred	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
in	B-X
vitro	B-X
.	B-X
Together	B-X
with	B-X
previous	B-X
results	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
methylation	B-X
of	B-X
Sm	B-X
proteins	B-X
by	B-X
the	B-X
methylosome	B-X
directs	B-X
Sm	B-X
proteins	B-X
to	B-X
the	B-X
SMN	B-X
complex	B-X
for	B-X
assembly	B-X
into	B-X
snRNP	B-X
core	B-X
particles	B-X
and	B-X
suggest	B-X
that	B-X
the	B-X
methylosome	B-X
can	B-X
regulate	B-X
snRNP	B-X
assembly	B-X
.	B-X

Together	O
with	O
previous	O
results	O
,	O
these	O
data	O
indicate	O
that	O
methylation	O
of	O
Sm	O
proteins	O
by	O
the	O
methylosome	O
directs	O
Sm	O
proteins	O
to	O
the	O
SMN	O
complex	O
for	O
assembly	O
into	O
snRNP	O
core	O
particles	O
and	O
suggest	O
that	O
the	O
methylosome	O
can	O
regulate	O
snRNP	O
assembly	O
.	O

Methyl	O
CpG	O
-	O
binding	O
proteins	O
and	O
transcriptional	O
repression	O
.	O
<EOS>	B-X
Since	B-X
its	B-X
discovery	B-X
,	B-X
methylation	B-X
of	B-X
DNA	B-X
in	B-X
mammalian	B-X
cells	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
transcriptional	B-X
repression	B-X
and	B-X
with	B-X
specialized	B-X
chromatin	B-X
structures	B-X
.	B-X
Recently	B-X
,	B-X
considerable	B-X
progress	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
protein	B-X
factors	B-X
with	B-X
a	B-X
highly	B-X
conserved	B-X
DNA	B-X
interaction	B-X
surface	B-X
,	B-X
termed	B-X
the	B-X
methyl	B-X
CpG-binding	B-X
domain	B-X
or	B-X
MBD	B-X
.	B-X
Despite	B-X
several	B-X
obvious	B-X
attractions	B-X
,	B-X
the	B-X
connection	B-X
between	B-X
MBD	B-X
proteins	B-X
and	B-X
histone	B-X
deacetylases	B-X
fails	B-X
to	B-X
explain	B-X
all	B-X
the	B-X
existing	B-X
data	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
the	B-X
biochemistry	B-X
and	B-X
DNA-binding	B-X
properties	B-X
of	B-X
most	B-X
MBD	B-X
family	B-X
members	B-X
have	B-X
not	B-X
been	B-X
adequately	B-X
described	B-X
and	B-X
considerable	B-X
evidence	B-X
exists	B-X
for	B-X
alternative	B-X
mechanisms	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
methylated	B-X
loci	B-X
.	B-X
Here	B-X
,	B-X
I	B-X
review	B-X
the	B-X
biochemistry	B-X
,	B-X
DNA-binding	B-X
properties	B-X
,	B-X
and	B-X
genetics	B-X
of	B-X
the	B-X
MBD	B-X
proteins	B-X
that	B-X
are	B-X
linked	B-X
to	B-X
transcriptional	B-X
repression	B-X
,	B-X
namely	B-X
,	B-X
MeCP2	B-X
,	B-X
MBD1	B-X
,	B-X
MBD2	B-X
,	B-X
and	B-X
MBD3	B-X
.	B-X

Since	O
its	O
discovery	O
,	O
methylation	O
of	O
DNA	O
in	O
mammalian	O
cells	O
has	O
been	O
correlated	O
with	O
transcriptional	O
repression	O
and	O
with	O
specialized	O
chromatin	O
structures	O
.	O
<EOS>	B-X
Since	B-X
its	B-X
discovery	B-X
,	B-X
methylation	B-X
of	B-X
DNA	B-X
in	B-X
mammalian	B-X
cells	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
transcriptional	B-X
repression	B-X
and	B-X
with	B-X
specialized	B-X
chromatin	B-X
structures	B-X
.	B-X
Recently	B-X
,	B-X
considerable	B-X
progress	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
protein	B-X
factors	B-X
with	B-X
a	B-X
highly	B-X
conserved	B-X
DNA	B-X
interaction	B-X
surface	B-X
,	B-X
termed	B-X
the	B-X
methyl	B-X
CpG-binding	B-X
domain	B-X
or	B-X
MBD	B-X
.	B-X
A	B-X
subset	B-X
has	B-X
been	B-X
biochemically	B-X
linked	B-X
to	B-X
histone	B-X
deacetylases	B-X
,	B-X
suggesting	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
functional	B-X
properties	B-X
of	B-X
methylated	B-X
DNA	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
the	B-X
biochemistry	B-X
and	B-X
DNA-binding	B-X
properties	B-X
of	B-X
most	B-X
MBD	B-X
family	B-X
members	B-X
have	B-X
not	B-X
been	B-X
adequately	B-X
described	B-X
and	B-X
considerable	B-X
evidence	B-X
exists	B-X
for	B-X
alternative	B-X
mechanisms	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
methylated	B-X
loci	B-X
.	B-X
Here	B-X
,	B-X
I	B-X
review	B-X
the	B-X
biochemistry	B-X
,	B-X
DNA-binding	B-X
properties	B-X
,	B-X
and	B-X
genetics	B-X
of	B-X
the	B-X
MBD	B-X
proteins	B-X
that	B-X
are	B-X
linked	B-X
to	B-X
transcriptional	B-X
repression	B-X
,	B-X
namely	B-X
,	B-X
MeCP2	B-X
,	B-X
MBD1	B-X
,	B-X
MBD2	B-X
,	B-X
and	B-X
MBD3	B-X
.	B-X
Several	B-X
models	B-X
to	B-X
account	B-X
for	B-X
the	B-X
functional	B-X
properties	B-X
of	B-X
methylated	B-X
DNA	B-X
are	B-X
presented	B-X
.	B-X

Recently	O
,	O
considerable	O
progress	O
has	O
been	O
reported	O
in	O
the	O
identification	O
of	O
protein	O
factors	O
with	O
a	O
highly	O
conserved	O
DNA	O
interaction	O
surface	O
,	O
termed	O
the	O
methyl	O
CpG	O
-	O
binding	O
domain	O
or	O
MBD	O
.	O
<EOS>	B-X
5-Methylcytosine	B-X
binding	B-X
domain	B-X
(	B-X
MBD	B-X
)	B-X
family	B-X
proteins	B-X
are	B-X
essential	B-X
readers	B-X
of	B-X
DNA	B-X
methylation	B-X
.	B-X
Their	B-X
methylation	B-X
specific	B-X
DNA	B-X
binding	B-X
has	B-X
been	B-X
exploited	B-X
in	B-X
the	B-X
context	B-X
of	B-X
two	B-X
main	B-X
groups	B-X
of	B-X
important	B-X
biotechnological	B-X
applications	B-X
.	B-X
In	B-X
the	B-X
first	B-X
,	B-X
an	B-X
MBD	B-X
domain	B-X
is	B-X
used	B-X
to	B-X
bind	B-X
methylated	B-X
DNA	B-X
in	B-X
vitro	B-X
.	B-X
This	B-X
can	B-X
be	B-X
employed	B-X
for	B-X
global	B-X
DNA	B-X
methylation	B-X
analysis	B-X
in	B-X
MBD-seq	B-X
assays	B-X
,	B-X
where	B-X
methylated	B-X
DNA	B-X
is	B-X
purified	B-X
from	B-X
fragmented	B-X
genomic	B-X
DNA	B-X
by	B-X
MBD	B-X
pulldown	B-X
or	B-X
capture	B-X
,	B-X
followed	B-X
by	B-X
next-generation	B-X
sequencing	B-X
(	B-X
NGS	B-X
)	B-X
and	B-X
downstream	B-X
data	B-X
analysis	B-X
as	B-X
established	B-X
for	B-X
ChIP-seq	B-X
applications	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
MBD	B-X
domains	B-X
to	B-X
bind	B-X
methylated	B-X
DNA	B-X
can	B-X
be	B-X
used	B-X
for	B-X
in	B-X
vitro	B-X
DNMT	B-X
activity	B-X
and	B-X
inhibition	B-X
assays	B-X
.	B-X
In	B-X
the	B-X
second	B-X
type	B-X
of	B-X
applications	B-X
,	B-X
MBD	B-X
domains	B-X
are	B-X
used	B-X
to	B-X
bind	B-X
methylated	B-X
DNA	B-X
in	B-X
cells	B-X
.	B-X
In	B-X
MBD	B-X
imaging	B-X
,	B-X
these	B-X
domains	B-X
are	B-X
fused	B-X
to	B-X
fluorophores	B-X
and	B-X
expressed	B-X
in	B-X
cells	B-X
,	B-X
where	B-X
they	B-X
bind	B-X
to	B-X
methylated	B-X
DNA	B-X
allowing	B-X
the	B-X
readout	B-X
of	B-X
DNA	B-X
methylation	B-X
by	B-X
fluorescence	B-X
microscopy	B-X
.	B-X
This	B-X
approach	B-X
recently	B-X
has	B-X
been	B-X
further	B-X
developed	B-X
to	B-X
allow	B-X
the	B-X
locus-specific	B-X
readout	B-X
of	B-X
DNA	B-X
methylation	B-X
using	B-X
bimolecular	B-X
fluorescence	B-X
complementation-based	B-X
bimolecular	B-X
anchor	B-X
detector	B-X
sensors	B-X
.	B-X
These	B-X
tools	B-X
,	B-X
which	B-X
are	B-X
compatible	B-X
with	B-X
live	B-X
cell	B-X
imaging	B-X
,	B-X
combine	B-X
the	B-X
sequence-specific	B-X
DNA	B-X
binding	B-X
of	B-X
anchor	B-X
domains	B-X
and	B-X
the	B-X
5-methylcytosine-specific	B-X
binding	B-X
of	B-X
an	B-X
MBD	B-X
domain	B-X
to	B-X
chromatin	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
individual	B-X
assay	B-X
,	B-X
MBD-based	B-X
detection	B-X
systems	B-X
for	B-X
DNA	B-X
methylation	B-X
provide	B-X
important	B-X
advantages	B-X
,	B-X
ranging	B-X
from	B-X
cost	B-X
efficiency	B-X
and	B-X
easy	B-X
workflows	B-X
to	B-X
unique	B-X
opportunities	B-X
for	B-X
the	B-X
readout	B-X
of	B-X
methylation	B-X
levels	B-X
in	B-X
living	B-X
cells	B-X
with	B-X
locus-specific	B-X
resolution	B-X
during	B-X
organismic	B-X
development	B-X
.	B-X

A	O
subset	O
has	O
been	O
biochemically	O
linked	O
to	O
histone	B-Protein
deacetylases	O
,	O
suggesting	O
a	O
molecular	O
mechanism	O
for	O
the	O
functional	O
properties	O
of	O
methylated	O
DNA	O
.	O
<EOS>	B-X
Since	B-X
its	B-X
discovery	B-X
,	B-X
methylation	B-X
of	B-X
DNA	B-X
in	B-X
mammalian	B-X
cells	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
transcriptional	B-X
repression	B-X
and	B-X
with	B-X
specialized	B-X
chromatin	B-X
structures	B-X
.	B-X
Recently	B-X
,	B-X
considerable	B-X
progress	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
protein	B-X
factors	B-X
with	B-X
a	B-X
highly	B-X
conserved	B-X
DNA	B-X
interaction	B-X
surface	B-X
,	B-X
termed	B-X
the	B-X
methyl	B-X
CpG-binding	B-X
domain	B-X
or	B-X
MBD	B-X
.	B-X
A	B-X
subset	B-X
has	B-X
been	B-X
biochemically	B-X
linked	B-X
to	B-X
histone	B-X
deacetylases	B-X
,	B-X
suggesting	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
functional	B-X
properties	B-X
of	B-X
methylated	B-X
DNA	B-X
.	B-X
Despite	B-X
several	B-X
obvious	B-X
attractions	B-X
,	B-X
the	B-X
connection	B-X
between	B-X
MBD	B-X
proteins	B-X
and	B-X
histone	B-X
deacetylases	B-X
fails	B-X
to	B-X
explain	B-X
all	B-X
the	B-X
existing	B-X
data	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
the	B-X
biochemistry	B-X
and	B-X
DNA-binding	B-X
properties	B-X
of	B-X
most	B-X
MBD	B-X
family	B-X
members	B-X
have	B-X
not	B-X
been	B-X
adequately	B-X
described	B-X
and	B-X
considerable	B-X
evidence	B-X
exists	B-X
for	B-X
alternative	B-X
mechanisms	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
methylated	B-X
loci	B-X
.	B-X
Here	B-X
,	B-X
I	B-X
review	B-X
the	B-X
biochemistry	B-X
,	B-X
DNA-binding	B-X
properties	B-X
,	B-X
and	B-X
genetics	B-X
of	B-X
the	B-X
MBD	B-X
proteins	B-X
that	B-X
are	B-X
linked	B-X
to	B-X
transcriptional	B-X
repression	B-X
,	B-X
namely	B-X
,	B-X
MeCP2	B-X
,	B-X
MBD1	B-X
,	B-X
MBD2	B-X
,	B-X
and	B-X
MBD3	B-X
.	B-X
Several	B-X
models	B-X
to	B-X
account	B-X
for	B-X
the	B-X
functional	B-X
properties	B-X
of	B-X
methylated	B-X
DNA	B-X
are	B-X
presented	B-X
.	B-X

Despite	O
several	O
obvious	O
attractions	O
,	O
the	O
connection	O
between	O
MBD	O
proteins	O
and	O
histone	B-Protein
deacetylases	O
fails	O
to	O
explain	O
all	O
the	O
existing	O
data	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
considerable	B-X
progress	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
protein	B-X
factors	B-X
with	B-X
a	B-X
highly	B-X
conserved	B-X
DNA	B-X
interaction	B-X
surface	B-X
,	B-X
termed	B-X
the	B-X
methyl	B-X
CpG-binding	B-X
domain	B-X
or	B-X
MBD	B-X
.	B-X
A	B-X
subset	B-X
has	B-X
been	B-X
biochemically	B-X
linked	B-X
to	B-X
histone	B-X
deacetylases	B-X
,	B-X
suggesting	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
functional	B-X
properties	B-X
of	B-X
methylated	B-X
DNA	B-X
.	B-X
Despite	B-X
several	B-X
obvious	B-X
attractions	B-X
,	B-X
the	B-X
connection	B-X
between	B-X
MBD	B-X
proteins	B-X
and	B-X
histone	B-X
deacetylases	B-X
fails	B-X
to	B-X
explain	B-X
all	B-X
the	B-X
existing	B-X
data	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
the	B-X
biochemistry	B-X
and	B-X
DNA-binding	B-X
properties	B-X
of	B-X
most	B-X
MBD	B-X
family	B-X
members	B-X
have	B-X
not	B-X
been	B-X
adequately	B-X
described	B-X
and	B-X
considerable	B-X
evidence	B-X
exists	B-X
for	B-X
alternative	B-X
mechanisms	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
methylated	B-X
loci	B-X
.	B-X
Null	B-X
mutations	B-X
have	B-X
been	B-X
generated	B-X
in	B-X
mice	B-X
for	B-X
several	B-X
MBD	B-X
family	B-X
members	B-X
,	B-X
the	B-X
phenotypes	B-X
of	B-X
the	B-X
mutant	B-X
animals	B-X
raise	B-X
important	B-X
questions	B-X
regarding	B-X
the	B-X
functions	B-X
of	B-X
the	B-X
MBD	B-X
family	B-X
.	B-X
Here	B-X
,	B-X
I	B-X
review	B-X
the	B-X
biochemistry	B-X
,	B-X
DNA-binding	B-X
properties	B-X
,	B-X
and	B-X
genetics	B-X
of	B-X
the	B-X
MBD	B-X
proteins	B-X
that	B-X
are	B-X
linked	B-X
to	B-X
transcriptional	B-X
repression	B-X
,	B-X
namely	B-X
,	B-X
MeCP2	B-X
,	B-X
MBD1	B-X
,	B-X
MBD2	B-X
,	B-X
and	B-X
MBD3	B-X
.	B-X

In	O
fact	O
,	O
the	O
biochemistry	O
and	O
DNA	O
-	O
binding	O
properties	O
of	O
most	O
MBD	O
family	O
members	O
have	O
not	O
been	O
adequately	O
described	O
and	O
considerable	O
evidence	O
exists	O
for	O
alternative	O
mechanisms	O
in	O
the	O
repression	O
of	O
methylated	O
loci	O
.	O

Null	O
mutations	O
have	O
been	O
generated	O
in	O
mice	O
for	O
several	O
MBD	O
family	O
members	O
,	O
the	O
phenotypes	O
of	O
the	O
mutant	O
animals	O
raise	O
important	O
questions	O
regarding	O
the	O
functions	O
of	O
the	O
MBD	O
family	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
considerable	B-X
progress	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
protein	B-X
factors	B-X
with	B-X
a	B-X
highly	B-X
conserved	B-X
DNA	B-X
interaction	B-X
surface	B-X
,	B-X
termed	B-X
the	B-X
methyl	B-X
CpG-binding	B-X
domain	B-X
or	B-X
MBD	B-X
.	B-X
Despite	B-X
several	B-X
obvious	B-X
attractions	B-X
,	B-X
the	B-X
connection	B-X
between	B-X
MBD	B-X
proteins	B-X
and	B-X
histone	B-X
deacetylases	B-X
fails	B-X
to	B-X
explain	B-X
all	B-X
the	B-X
existing	B-X
data	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
the	B-X
biochemistry	B-X
and	B-X
DNA-binding	B-X
properties	B-X
of	B-X
most	B-X
MBD	B-X
family	B-X
members	B-X
have	B-X
not	B-X
been	B-X
adequately	B-X
described	B-X
and	B-X
considerable	B-X
evidence	B-X
exists	B-X
for	B-X
alternative	B-X
mechanisms	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
methylated	B-X
loci	B-X
.	B-X
Null	B-X
mutations	B-X
have	B-X
been	B-X
generated	B-X
in	B-X
mice	B-X
for	B-X
several	B-X
MBD	B-X
family	B-X
members	B-X
,	B-X
the	B-X
phenotypes	B-X
of	B-X
the	B-X
mutant	B-X
animals	B-X
raise	B-X
important	B-X
questions	B-X
regarding	B-X
the	B-X
functions	B-X
of	B-X
the	B-X
MBD	B-X
family	B-X
.	B-X
Here	B-X
,	B-X
I	B-X
review	B-X
the	B-X
biochemistry	B-X
,	B-X
DNA-binding	B-X
properties	B-X
,	B-X
and	B-X
genetics	B-X
of	B-X
the	B-X
MBD	B-X
proteins	B-X
that	B-X
are	B-X
linked	B-X
to	B-X
transcriptional	B-X
repression	B-X
,	B-X
namely	B-X
,	B-X
MeCP2	B-X
,	B-X
MBD1	B-X
,	B-X
MBD2	B-X
,	B-X
and	B-X
MBD3	B-X
.	B-X

Here	O
,	O
I	O
review	O
the	O
biochemistry	O
,	O
DNA	O
-	O
binding	O
properties	O
,	O
and	O
genetics	O
of	O
the	O
MBD	O
proteins	O
that	O
are	O
linked	O
to	O
transcriptional	O
repression	O
,	O
namely	O
,	O
MeCP2	B-Protein
,	O
MBD1	B-Protein
,	O
MBD2	B-Protein
,	O
and	O
MBD3	B-Protein
.	O
<EOS>	B-X
Since	B-X
its	B-X
discovery	B-X
,	B-X
methylation	B-X
of	B-X
DNA	B-X
in	B-X
mammalian	B-X
cells	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
transcriptional	B-X
repression	B-X
and	B-X
with	B-X
specialized	B-X
chromatin	B-X
structures	B-X
.	B-X
Recently	B-X
,	B-X
considerable	B-X
progress	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
protein	B-X
factors	B-X
with	B-X
a	B-X
highly	B-X
conserved	B-X
DNA	B-X
interaction	B-X
surface	B-X
,	B-X
termed	B-X
the	B-X
methyl	B-X
CpG-binding	B-X
domain	B-X
or	B-X
MBD	B-X
.	B-X
A	B-X
subset	B-X
has	B-X
been	B-X
biochemically	B-X
linked	B-X
to	B-X
histone	B-X
deacetylases	B-X
,	B-X
suggesting	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
functional	B-X
properties	B-X
of	B-X
methylated	B-X
DNA	B-X
.	B-X
Despite	B-X
several	B-X
obvious	B-X
attractions	B-X
,	B-X
the	B-X
connection	B-X
between	B-X
MBD	B-X
proteins	B-X
and	B-X
histone	B-X
deacetylases	B-X
fails	B-X
to	B-X
explain	B-X
all	B-X
the	B-X
existing	B-X
data	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
the	B-X
biochemistry	B-X
and	B-X
DNA-binding	B-X
properties	B-X
of	B-X
most	B-X
MBD	B-X
family	B-X
members	B-X
have	B-X
not	B-X
been	B-X
adequately	B-X
described	B-X
and	B-X
considerable	B-X
evidence	B-X
exists	B-X
for	B-X
alternative	B-X
mechanisms	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
methylated	B-X
loci	B-X
.	B-X
Null	B-X
mutations	B-X
have	B-X
been	B-X
generated	B-X
in	B-X
mice	B-X
for	B-X
several	B-X
MBD	B-X
family	B-X
members	B-X
,	B-X
the	B-X
phenotypes	B-X
of	B-X
the	B-X
mutant	B-X
animals	B-X
raise	B-X
important	B-X
questions	B-X
regarding	B-X
the	B-X
functions	B-X
of	B-X
the	B-X
MBD	B-X
family	B-X
.	B-X
Here	B-X
,	B-X
I	B-X
review	B-X
the	B-X
biochemistry	B-X
,	B-X
DNA-binding	B-X
properties	B-X
,	B-X
and	B-X
genetics	B-X
of	B-X
the	B-X
MBD	B-X
proteins	B-X
that	B-X
are	B-X
linked	B-X
to	B-X
transcriptional	B-X
repression	B-X
,	B-X
namely	B-X
,	B-X
MeCP2	B-X
,	B-X
MBD1	B-X
,	B-X
MBD2	B-X
,	B-X
and	B-X
MBD3	B-X
.	B-X
Several	B-X
models	B-X
to	B-X
account	B-X
for	B-X
the	B-X
functional	B-X
properties	B-X
of	B-X
methylated	B-X
DNA	B-X
are	B-X
presented	B-X
.	B-X

Several	O
models	O
to	O
account	O
for	O
the	O
functional	O
properties	O
of	O
methylated	O
DNA	O
are	O
presented	O
.	O
<EOS>	B-X
This	B-X
chapter	B-X
presents	B-X
a	B-X
personal	B-X
account	B-X
of	B-X
the	B-X
work	B-X
on	B-X
DNA	B-X
methylation	B-X
in	B-X
viral	B-X
and	B-X
mammalian	B-X
systems	B-X
performed	B-X
in	B-X
the	B-X
author	B-X
's	B-X
laboratory	B-X
in	B-X
the	B-X
course	B-X
of	B-X
the	B-X
past	B-X
thirty	B-X
years	B-X
.	B-X
The	B-X
text	B-X
does	B-X
not	B-X
attempt	B-X
to	B-X
give	B-X
a	B-X
complete	B-X
and	B-X
meticulous	B-X
account	B-X
of	B-X
the	B-X
many	B-X
relevant	B-X
and	B-X
excellent	B-X
reports	B-X
published	B-X
by	B-X
many	B-X
other	B-X
laboratories	B-X
,	B-X
so	B-X
it	B-X
is	B-X
not	B-X
a	B-X
review	B-X
of	B-X
the	B-X
field	B-X
in	B-X
a	B-X
conventional	B-X
sense	B-X
.	B-X
When	B-X
our	B-X
interest	B-X
turned	B-X
to	B-X
the	B-X
demonstration	B-X
of	B-X
genome-wide	B-X
patterns	B-X
of	B-X
DNA	B-X
methylation	B-X
,	B-X
we	B-X
focused	B-X
mainly	B-X
on	B-X
the	B-X
human	B-X
genome	B-X
.	B-X
The	B-X
following	B-X
topics	B-X
in	B-X
DNA	B-X
methylation	B-X
will	B-X
be	B-X
treated	B-X
in	B-X
detail	B-X
:	B-X
(	B-X
i	B-X
)	B-X
the	B-X
de	B-X
novo	B-X
methylation	B-X
of	B-X
integrated	B-X
foreign	B-X
genomes	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
the	B-X
long-term	B-X
gene	B-X
silencing	B-X
effect	B-X
of	B-X
sequence-specific	B-X
promoter	B-X
methylation	B-X
and	B-X
its	B-X
reversal	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
the	B-X
properties	B-X
and	B-X
specificity	B-X
of	B-X
patterns	B-X
of	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
human	B-X
genome	B-X
and	B-X
their	B-X
possible	B-X
relations	B-X
to	B-X
pathogenesis	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
the	B-X
long-range	B-X
global	B-X
effects	B-X
on	B-X
cellular	B-X
DNA	B-X
methylation	B-X
and	B-X
transcriptional	B-X
profiles	B-X
as	B-X
a	B-X
consequence	B-X
of	B-X
foreign	B-X
DNA	B-X
insertion	B-X
into	B-X
an	B-X
established	B-X
genome	B-X
;	B-X
(	B-X
v	B-X
)	B-X
the	B-X
patterns	B-X
of	B-X
DNA	B-X
methylation	B-X
can	B-X
be	B-X
considered	B-X
part	B-X
of	B-X
a	B-X
cellular	B-X
defense	B-X
mechanism	B-X
against	B-X
foreign	B-X
or	B-X
repetitive	B-X
DNA	B-X
;	B-X
what	B-X
role	B-X
has	B-X
food-ingested	B-X
DNA	B-X
played	B-X
in	B-X
the	B-X
elaboration	B-X
of	B-X
this	B-X
mechanism	B-X
?	B-X

Molecular	O
and	O
immunohistochemical	O
study	O
of	O
the	O
inactivation	O
of	O
the	O
p16	B-Protein
gene	O
in	O
primary	O
hepatocellular	O
carcinoma	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
The	B-X
molecular	B-X
status	B-X
of	B-X
the	B-X
p16	B-X
(	B-X
INK4	B-X
)	B-X
tumor-suppressor	B-X
gene	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
in	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
the	B-X
mechanism	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
inactivation	B-X
of	B-X
p16	B-X
(	B-X
INK4	B-X
)	B-X
in	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
p16	B-Protein
gene	O
is	O
involved	O
in	O
the	O
genesis	O
of	O
primary	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X

METHODS	O
:	O
Twenty	O
-	O
five	O
HCC	O
tumor	O
samples	O
with	O
corresponding	O
non	O
-	O
tumor	O
liver	O
tissue	O
specimens	O
were	O
examined	O
for	O
p16	B-Protein
gene	O
alterations	O
.	O
<EOS>	B-X
To	B-X
clarify	B-X
the	B-X
relative	B-X
role	B-X
of	B-X
hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
and	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
in	B-X
hepatocarcinogenesis	B-X
in	B-X
hepatitis	B-X
B	B-X
surface	B-X
antigen	B-X
(	B-X
HBsAg	B-X
)	B-X
-negative	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
in	B-X
Taiwan	B-X
,	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
was	B-X
used	B-X
to	B-X
detect	B-X
the	B-X
HCV-RNA	B-X
and	B-X
HBV-DNA	B-X
sequences	B-X
in	B-X
the	B-X
serum	B-X
and	B-X
liver	B-X
tissues	B-X
from	B-X
31	B-X
HBsAg-negative	B-X
HCC	B-X
patients	B-X
.	B-X
Twenty-one	B-X
were	B-X
positive	B-X
for	B-X
antibody	B-X
to	B-X
HCV	B-X
(	B-X
group	B-X
1	B-X
)	B-X
and	B-X
10	B-X
were	B-X
negative	B-X
(	B-X
group	B-X
2	B-X
)	B-X
.	B-X
Hepatitis	B-X
C	B-X
virus-RNA	B-X
was	B-X
detected	B-X
by	B-X
PCR	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
16	B-X
group	B-X
1	B-X
patients	B-X
and	B-X
in	B-X
the	B-X
liver	B-X
tissue	B-X
of	B-X
17	B-X
;	B-X
while	B-X
HBV-DNA	B-X
was	B-X
found	B-X
in	B-X
the	B-X
liver	B-X
tissue	B-X
of	B-X
only	B-X
four	B-X
,	B-X
and	B-X
no	B-X
HBV-DNA	B-X
was	B-X
found	B-X
in	B-X
the	B-X
serum	B-X
.	B-X
Hepatitis	B-X
C	B-X
virus	B-X
RNA	B-X
was	B-X
detected	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
one	B-X
group	B-X
2	B-X
patient	B-X
and	B-X
in	B-X
the	B-X
liver	B-X
tissue	B-X
of	B-X
another	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
HBV	B-X
viral	B-X
DNA	B-X
was	B-X
found	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
four	B-X
group	B-X
2	B-X
patients	B-X
and	B-X
in	B-X
the	B-X
liver	B-X
tissues	B-X
of	B-X
five	B-X
patients	B-X
.	B-X
This	B-X
indicates	B-X
that	B-X
HCV	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
hepatocarcinogenesis	B-X
in	B-X
HBsAg-negative	B-X
patients	B-X
in	B-X
Taiwan	B-X
,	B-X
especially	B-X
in	B-X
those	B-X
with	B-X
antibody	B-X
to	B-X
HCV	B-X
.	B-X
In	B-X
those	B-X
without	B-X
antibody	B-X
to	B-X
HCV	B-X
,	B-X
HBV	B-X
might	B-X
still	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
such	B-X
patients	B-X
.	B-X
In	B-X
order	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
p53	B-X
mutation	B-X
in	B-X
hepatocarcinogenesis	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
status	B-X
of	B-X
the	B-X
p53	B-X
mutation	B-X
in	B-X
61	B-X
HCC	B-X
samples	B-X
from	B-X
Taiwan	B-X
.	B-X
The	B-X
exon	B-X
5	B-X
to	B-X
8	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
in	B-X
the	B-X
tumour	B-X
tissue	B-X
of	B-X
61	B-X
HCC	B-X
were	B-X
amplified	B-X
and	B-X
sequenced	B-X
.	B-X
The	B-X
corresponding	B-X
normal	B-X
liver	B-X
showed	B-X
no	B-X
mutation	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
scattered	B-X
point	B-X
mutations	B-X
in	B-X
p53	B-X
are	B-X
not	B-X
uncommon	B-X
in	B-X
HCC	B-X
samples	B-X
from	B-X
Taiwan	B-X
and	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
this	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
the	B-X
aflatoxin-related	B-X
specific	B-X
mutation	B-X
seems	B-X
much	B-X
less	B-X
related	B-X
to	B-X
the	B-X
genesis	B-X
of	B-X
HCC	B-X
in	B-X
Taiwan	B-X
.	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
telomerase	B-X
activity	B-X
in	B-X
hepatocarcinogenesis	B-X
,	B-X
a	B-X
total	B-X
of	B-X
39	B-X
HCC	B-X
tissues	B-X
and	B-X
the	B-X
corresponding	B-X
non-tumour	B-X
liver	B-X
tissues	B-X
were	B-X
analysed	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
telomerase	B-X
activity	B-X
was	B-X
detected	B-X
in	B-X
all	B-X
the	B-X
39	B-X
tumour	B-X
tissues	B-X
,	B-X
while	B-X
it	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
six	B-X
of	B-X
the	B-X
39	B-X
non-tumour	B-X
liver	B-X
tissues	B-X
.	B-X
The	B-X
high	B-X
positive	B-X
rate	B-X
of	B-X
telomerase	B-X
activity	B-X
in	B-X
HCC	B-X
samples	B-X
suggests	B-X
that	B-X
telomerase	B-X
activity	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
development	B-X
or	B-X
progression	B-X
of	B-X
HCC	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
exon	B-X
1	B-X
and	B-X
exon	B-X
2	B-X
of	B-X
the	B-X
p16	B-X
gene	B-X
are	B-X
altered	B-X
in	B-X
HCC	B-X
,	B-X
thirty-four	B-X
tumours	B-X
from	B-X
30	B-X
HCC	B-X
patients	B-X
were	B-X
examined	B-X
by	B-X
DNA	B-X
sequencing	B-X
analysis	B-X
of	B-X
PCR-amplified	B-X
genomic	B-X
DNA	B-X
.	B-X
Homozygous	B-X
deletions	B-X
of	B-X
MTS1/p16/CDKN2	B-X
exon	B-X
1	B-X
were	B-X
identified	B-X
in	B-X
1/34	B-X
primary	B-X
tumours	B-X
(	B-X
3	B-X
%	B-X
)	B-X
,	B-X
no	B-X
mutations	B-X
or	B-X
rearrangements	B-X
were	B-X
found	B-X
in	B-X
these	B-X
specimens	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
alterations	B-X
of	B-X
MTS1/p16/CDKN2	B-X
gene	B-X
are	B-X
rarely	B-X
found	B-X
in	B-X
HCC	B-X
,	B-X
and	B-X
might	B-X
play	B-X
little	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
this	B-X
cancer	B-X
.	B-X
To	B-X
study	B-X
the	B-X
clonality	B-X
of	B-X
HCC	B-X
,	B-X
18	B-X
patients	B-X
with	B-X
multiple	B-X
HCC	B-X
,	B-X
most	B-X
of	B-X
them	B-X
small	B-X
in	B-X
size	B-X
,	B-X
were	B-X
analysed	B-X
by	B-X
DNA	B-X
fingerprinting	B-X
.	B-X
In	B-X
patients	B-X
positive	B-X
for	B-X
hepatitis	B-X
B	B-X
surface	B-X
antigen	B-X
,	B-X
the	B-X
integration	B-X
pattern	B-X
of	B-X
hepatitis	B-X
B	B-X
viral	B-X
DNA	B-X
in	B-X
liver	B-X
tissue	B-X
was	B-X
also	B-X
analysed	B-X
.	B-X
This	B-X
study	B-X
indicated	B-X
that	B-X
polyclonality	B-X
of	B-X
multiple	B-X
HCC	B-X
was	B-X
rather	B-X
frequent	B-X
and	B-X
it	B-X
highlighted	B-X
the	B-X
importance	B-X
of	B-X
eliminating	B-X
the	B-X
underlying	B-X
cause	B-X
of	B-X
liver	B-X
injury	B-X
to	B-X
improve	B-X
the	B-X
survival	B-X
of	B-X
these	B-X
patients	B-X
.	B-X
Microsatellite	B-X
markers	B-X
were	B-X
used	B-X
to	B-X
study	B-X
the	B-X
genetic	B-X
changes	B-X
of	B-X
HCC	B-X
.	B-X
Thirty	B-X
cases	B-X
of	B-X
HCC	B-X
,	B-X
most	B-X
of	B-X
them	B-X
small	B-X
in	B-X
size	B-X
,	B-X
were	B-X
studied	B-X
.	B-X

The	O
identification	O
of	O
deletion	O
of	O
exon	O
1	O
and	O
exon	O
2	O
in	O
p16	B-Protein
gene	O
was	O
performed	O
using	O
comparative	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
analysis	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
Twenty-five	B-X
primary	B-X
HCC	B-X
tumor	B-X
and	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
examined	B-X
for	B-X
P16	B-X
gene	B-X
alterations	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
deletion	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
1	B-X
and	B-X
exon	B-X
2	B-X
was	B-X
performed	B-X
using	B-X
comparative	B-X
multiplex	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
analysis	B-X
.	B-X
The	B-X
point	B-X
mutation	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
2	B-X
was	B-X
investigated	B-X
by	B-X
single	B-X
strand	B-X
conformational	B-X
polymorphism	B-X
(	B-X
SSCP	B-X
)	B-X
analysis	B-X
,	B-X
and	B-X
the	B-X
status	B-X
of	B-X
p16	B-X
gene	B-X
methylation	B-X
was	B-X
screened	B-X
using	B-X
PCR-based	B-X
methylation	B-X
analysis	B-X
.	B-X
Moreover	B-X
,	B-X
35	B-X
parafin	B-X
specimens	B-X
of	B-X
primary	B-X
HCCs	B-X
with	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissues	B-X
,	B-X
including	B-X
the	B-X
25	B-X
cases	B-X
described	B-X
above	B-X
for	B-X
screening	B-X
of	B-X
p16	B-X
gene	B-X
alterations	B-X
,	B-X
were	B-X
investigated	B-X
also	B-X
for	B-X
P16	B-X
protein	B-X
expression	B-X
by	B-X
using	B-X
immunohistochemical	B-X
analysis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
comparative	B-X
multiplex	B-X
PCR	B-X
analysis	B-X
showed	B-X
that	B-X
12	B-X
%	B-X
(	B-X
3/25	B-X
)	B-X
p16	B-X
gene	B-X
deletions	B-X
,	B-X
including	B-X
homozygous	B-X
deletions	B-X
in	B-X
2	B-X
tumors	B-X
and	B-X
hemizygous	B-X
deletion	B-X
in	B-X
1	B-X
tumor	B-X
,	B-X
were	B-X
found	B-X
in	B-X
the	B-X
primary	B-X
HCCs	B-X
samples	B-X
.	B-X
No	B-X
point	B-X
mutation	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
remaining	B-X
22	B-X
tumor	B-X
samples	B-X
without	B-X
p16	B-X
gene	B-X
deletions	B-X
by	B-X
using	B-X
SSCP	B-X
analysis	B-X
.	B-X
Hypermethylation	B-X
was	B-X
detected	B-X
in	B-X
24	B-X
%	B-X
(	B-X
6/25	B-X
)	B-X
of	B-X
tumor	B-X
samples	B-X
by	B-X
PCR-based	B-X
analysis	B-X
.	B-X
However	B-X
the	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
always	B-X
unmethylated	B-X
at	B-X
p16	B-X
locus	B-X
.	B-X
Loss	B-X
of	B-X
P16	B-X
protein	B-X
expression	B-X
,	B-X
detected	B-X
by	B-X
immunohistochemistry	B-X
,	B-X
occurred	B-X
in	B-X
16	B-X
of	B-X
35	B-X
(	B-X
45.7	B-X
%	B-X
)	B-X
tumor	B-X
samples	B-X
,	B-X
whereas	B-X
all	B-X
the	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
showed	B-X
positive	B-X
p16	B-X
staining	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
inactivation	B-X
of	B-X
p16	B-X
gene	B-X
is	B-X
relevant	B-X
to	B-X
the	B-X
genesis	B-X
of	B-X
HCC	B-X
.	B-X

The	O
point	O
mutation	O
of	O
exon	O
2	O
in	O
p16	B-Protein
gene	O
was	O
investigated	O
by	O
single	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
,	O
and	O
the	O
status	O
of	O
p16	B-Protein
gene	O
methylation	O
was	O
screened	O
using	O
a	O
PCR	O
based	O
methylation	O
analysis	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
Twenty-five	B-X
primary	B-X
HCC	B-X
tumor	B-X
and	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
examined	B-X
for	B-X
P16	B-X
gene	B-X
alterations	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
deletion	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
1	B-X
and	B-X
exon	B-X
2	B-X
was	B-X
performed	B-X
using	B-X
comparative	B-X
multiplex	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
analysis	B-X
.	B-X
The	B-X
point	B-X
mutation	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
2	B-X
was	B-X
investigated	B-X
by	B-X
single	B-X
strand	B-X
conformational	B-X
polymorphism	B-X
(	B-X
SSCP	B-X
)	B-X
analysis	B-X
,	B-X
and	B-X
the	B-X
status	B-X
of	B-X
p16	B-X
gene	B-X
methylation	B-X
was	B-X
screened	B-X
using	B-X
PCR-based	B-X
methylation	B-X
analysis	B-X
.	B-X
Moreover	B-X
,	B-X
35	B-X
parafin	B-X
specimens	B-X
of	B-X
primary	B-X
HCCs	B-X
with	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissues	B-X
,	B-X
including	B-X
the	B-X
25	B-X
cases	B-X
described	B-X
above	B-X
for	B-X
screening	B-X
of	B-X
p16	B-X
gene	B-X
alterations	B-X
,	B-X
were	B-X
investigated	B-X
also	B-X
for	B-X
P16	B-X
protein	B-X
expression	B-X
by	B-X
using	B-X
immunohistochemical	B-X
analysis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
comparative	B-X
multiplex	B-X
PCR	B-X
analysis	B-X
showed	B-X
that	B-X
12	B-X
%	B-X
(	B-X
3/25	B-X
)	B-X
p16	B-X
gene	B-X
deletions	B-X
,	B-X
including	B-X
homozygous	B-X
deletions	B-X
in	B-X
2	B-X
tumors	B-X
and	B-X
hemizygous	B-X
deletion	B-X
in	B-X
1	B-X
tumor	B-X
,	B-X
were	B-X
found	B-X
in	B-X
the	B-X
primary	B-X
HCCs	B-X
samples	B-X
.	B-X
No	B-X
point	B-X
mutation	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
remaining	B-X
22	B-X
tumor	B-X
samples	B-X
without	B-X
p16	B-X
gene	B-X
deletions	B-X
by	B-X
using	B-X
SSCP	B-X
analysis	B-X
.	B-X
Hypermethylation	B-X
was	B-X
detected	B-X
in	B-X
24	B-X
%	B-X
(	B-X
6/25	B-X
)	B-X
of	B-X
tumor	B-X
samples	B-X
by	B-X
PCR-based	B-X
analysis	B-X
.	B-X
However	B-X
the	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
always	B-X
unmethylated	B-X
at	B-X
p16	B-X
locus	B-X
.	B-X
Loss	B-X
of	B-X
P16	B-X
protein	B-X
expression	B-X
,	B-X
detected	B-X
by	B-X
immunohistochemistry	B-X
,	B-X
occurred	B-X
in	B-X
16	B-X
of	B-X
35	B-X
(	B-X
45.7	B-X
%	B-X
)	B-X
tumor	B-X
samples	B-X
,	B-X
whereas	B-X
all	B-X
the	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
showed	B-X
positive	B-X
p16	B-X
staining	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
inactivation	B-X
of	B-X
p16	B-X
gene	B-X
is	B-X
relevant	B-X
to	B-X
the	B-X
genesis	B-X
of	B-X
HCC	B-X
.	B-X

35	O
parafin	O
-	O
embedded	O
specimens	O
of	O
HCC	O
with	O
corresponding	O
non	O
-	O
tumor	O
liver	O
tissues	O
,	O
including	O
the	O
25	O
cases	O
described	O
above	O
for	O
screening	O
p16	B-Protein
gene	O
alterations	O
,	O
were	O
investigated	O
for	O
p16	B-Protein
protein	O
expression	O
using	O
immunohistochemical	O
analysis	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X

RESULTS	O
:	O
Among	O
25	O
cases	O
,	O
2	O
homozygous	O
deletions	O
and	O
1	O
hemizygous	O
deletion	O
were	O
found	O
in	O
HCC	O
samples	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
Twenty-five	B-X
primary	B-X
HCC	B-X
tumor	B-X
and	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
examined	B-X
for	B-X
P16	B-X
gene	B-X
alterations	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
deletion	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
1	B-X
and	B-X
exon	B-X
2	B-X
was	B-X
performed	B-X
using	B-X
comparative	B-X
multiplex	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
analysis	B-X
.	B-X
The	B-X
point	B-X
mutation	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
2	B-X
was	B-X
investigated	B-X
by	B-X
single	B-X
strand	B-X
conformational	B-X
polymorphism	B-X
(	B-X
SSCP	B-X
)	B-X
analysis	B-X
,	B-X
and	B-X
the	B-X
status	B-X
of	B-X
p16	B-X
gene	B-X
methylation	B-X
was	B-X
screened	B-X
using	B-X
PCR-based	B-X
methylation	B-X
analysis	B-X
.	B-X
Moreover	B-X
,	B-X
35	B-X
parafin	B-X
specimens	B-X
of	B-X
primary	B-X
HCCs	B-X
with	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissues	B-X
,	B-X
including	B-X
the	B-X
25	B-X
cases	B-X
described	B-X
above	B-X
for	B-X
screening	B-X
of	B-X
p16	B-X
gene	B-X
alterations	B-X
,	B-X
were	B-X
investigated	B-X
also	B-X
for	B-X
P16	B-X
protein	B-X
expression	B-X
by	B-X
using	B-X
immunohistochemical	B-X
analysis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
comparative	B-X
multiplex	B-X
PCR	B-X
analysis	B-X
showed	B-X
that	B-X
12	B-X
%	B-X
(	B-X
3/25	B-X
)	B-X
p16	B-X
gene	B-X
deletions	B-X
,	B-X
including	B-X
homozygous	B-X
deletions	B-X
in	B-X
2	B-X
tumors	B-X
and	B-X
hemizygous	B-X
deletion	B-X
in	B-X
1	B-X
tumor	B-X
,	B-X
were	B-X
found	B-X
in	B-X
the	B-X
primary	B-X
HCCs	B-X
samples	B-X
.	B-X
No	B-X
point	B-X
mutation	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
remaining	B-X
22	B-X
tumor	B-X
samples	B-X
without	B-X
p16	B-X
gene	B-X
deletions	B-X
by	B-X
using	B-X
SSCP	B-X
analysis	B-X
.	B-X
Hypermethylation	B-X
was	B-X
detected	B-X
in	B-X
24	B-X
%	B-X
(	B-X
6/25	B-X
)	B-X
of	B-X
tumor	B-X
samples	B-X
by	B-X
PCR-based	B-X
analysis	B-X
.	B-X
However	B-X
the	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
always	B-X
unmethylated	B-X
at	B-X
p16	B-X
locus	B-X
.	B-X
Loss	B-X
of	B-X
P16	B-X
protein	B-X
expression	B-X
,	B-X
detected	B-X
by	B-X
immunohistochemistry	B-X
,	B-X
occurred	B-X
in	B-X
16	B-X
of	B-X
35	B-X
(	B-X
45.7	B-X
%	B-X
)	B-X
tumor	B-X
samples	B-X
,	B-X
whereas	B-X
all	B-X
the	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
showed	B-X
positive	B-X
p16	B-X
staining	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
inactivation	B-X
of	B-X
p16	B-X
gene	B-X
is	B-X
relevant	B-X
to	B-X
the	B-X
genesis	B-X
of	B-X
HCC	B-X
.	B-X

No	O
point	O
mutation	O
was	O
identified	O
in	O
the	O
remaining	O
22	O
tumor	O
samples	O
without	O
p16	B-Protein
gene	O
deletions	O
.	O
<EOS>	B-X
To	B-X
clarify	B-X
the	B-X
relative	B-X
role	B-X
of	B-X
hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
and	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
in	B-X
hepatocarcinogenesis	B-X
in	B-X
hepatitis	B-X
B	B-X
surface	B-X
antigen	B-X
(	B-X
HBsAg	B-X
)	B-X
-negative	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
in	B-X
Taiwan	B-X
,	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
was	B-X
used	B-X
to	B-X
detect	B-X
the	B-X
HCV-RNA	B-X
and	B-X
HBV-DNA	B-X
sequences	B-X
in	B-X
the	B-X
serum	B-X
and	B-X
liver	B-X
tissues	B-X
from	B-X
31	B-X
HBsAg-negative	B-X
HCC	B-X
patients	B-X
.	B-X
This	B-X
indicates	B-X
that	B-X
HCV	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
hepatocarcinogenesis	B-X
in	B-X
HBsAg-negative	B-X
patients	B-X
in	B-X
Taiwan	B-X
,	B-X
especially	B-X
in	B-X
those	B-X
with	B-X
antibody	B-X
to	B-X
HCV	B-X
.	B-X
In	B-X
those	B-X
without	B-X
antibody	B-X
to	B-X
HCV	B-X
,	B-X
HBV	B-X
might	B-X
still	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
such	B-X
patients	B-X
.	B-X
In	B-X
order	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
p53	B-X
mutation	B-X
in	B-X
hepatocarcinogenesis	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
status	B-X
of	B-X
the	B-X
p53	B-X
mutation	B-X
in	B-X
61	B-X
HCC	B-X
samples	B-X
from	B-X
Taiwan	B-X
.	B-X
The	B-X
exon	B-X
5	B-X
to	B-X
8	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
in	B-X
the	B-X
tumour	B-X
tissue	B-X
of	B-X
61	B-X
HCC	B-X
were	B-X
amplified	B-X
and	B-X
sequenced	B-X
.	B-X
A	B-X
total	B-X
of	B-X
20	B-X
cases	B-X
(	B-X
32.8	B-X
%	B-X
)	B-X
were	B-X
found	B-X
to	B-X
have	B-X
mutations	B-X
:	B-X
36.6	B-X
%	B-X
(	B-X
15/41	B-X
)	B-X
from	B-X
the	B-X
HBsAg-positive	B-X
group	B-X
and	B-X
25.0	B-X
%	B-X
(	B-X
5/20	B-X
)	B-X
from	B-X
the	B-X
HBsAg-negative	B-X
group	B-X
.	B-X
The	B-X
corresponding	B-X
normal	B-X
liver	B-X
showed	B-X
no	B-X
mutation	B-X
.	B-X
The	B-X
mutation	B-X
is	B-X
widely	B-X
distributed	B-X
throughout	B-X
the	B-X
exon	B-X
5	B-X
to	B-X
8	B-X
.	B-X
Only	B-X
four	B-X
cases	B-X
(	B-X
6.6	B-X
%	B-X
)	B-X
,	B-X
all	B-X
positive	B-X
for	B-X
HBsAg	B-X
,	B-X
had	B-X
a	B-X
specific	B-X
hotspot	B-X
mutation	B-X
at	B-X
codon	B-X
249	B-X
with	B-X
G	B-X
to	B-X
T	B-X
transversion	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
scattered	B-X
point	B-X
mutations	B-X
in	B-X
p53	B-X
are	B-X
not	B-X
uncommon	B-X
in	B-X
HCC	B-X
samples	B-X
from	B-X
Taiwan	B-X
and	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
this	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
the	B-X
aflatoxin-related	B-X
specific	B-X
mutation	B-X
seems	B-X
much	B-X
less	B-X
related	B-X
to	B-X
the	B-X
genesis	B-X
of	B-X
HCC	B-X
in	B-X
Taiwan	B-X
.	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
telomerase	B-X
activity	B-X
in	B-X
hepatocarcinogenesis	B-X
,	B-X
a	B-X
total	B-X
of	B-X
39	B-X
HCC	B-X
tissues	B-X
and	B-X
the	B-X
corresponding	B-X
non-tumour	B-X
liver	B-X
tissues	B-X
were	B-X
analysed	B-X
.	B-X
The	B-X
high	B-X
positive	B-X
rate	B-X
of	B-X
telomerase	B-X
activity	B-X
in	B-X
HCC	B-X
samples	B-X
suggests	B-X
that	B-X
telomerase	B-X
activity	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
development	B-X
or	B-X
progression	B-X
of	B-X
HCC	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
exon	B-X
1	B-X
and	B-X
exon	B-X
2	B-X
of	B-X
the	B-X
p16	B-X
gene	B-X
are	B-X
altered	B-X
in	B-X
HCC	B-X
,	B-X
thirty-four	B-X
tumours	B-X
from	B-X
30	B-X
HCC	B-X
patients	B-X
were	B-X
examined	B-X
by	B-X
DNA	B-X
sequencing	B-X
analysis	B-X
of	B-X
PCR-amplified	B-X
genomic	B-X
DNA	B-X
.	B-X
Homozygous	B-X
deletions	B-X
of	B-X
MTS1/p16/CDKN2	B-X
exon	B-X
1	B-X
were	B-X
identified	B-X
in	B-X
1/34	B-X
primary	B-X
tumours	B-X
(	B-X
3	B-X
%	B-X
)	B-X
,	B-X
no	B-X
mutations	B-X
or	B-X
rearrangements	B-X
were	B-X
found	B-X
in	B-X
these	B-X
specimens	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
alterations	B-X
of	B-X
MTS1/p16/CDKN2	B-X
gene	B-X
are	B-X
rarely	B-X
found	B-X
in	B-X
HCC	B-X
,	B-X
and	B-X
might	B-X
play	B-X
little	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
this	B-X
cancer	B-X
.	B-X
In	B-X
the	B-X
remaining	B-X
nine	B-X
patients	B-X
negative	B-X
for	B-X
hepatitis	B-X
B	B-X
surface	B-X
antigen	B-X
,	B-X
four	B-X
had	B-X
different	B-X
band	B-X
patterns	B-X
in	B-X
their	B-X
tumours	B-X
by	B-X
DNA	B-X
fingerprinting	B-X
.	B-X
Microsatellite	B-X
markers	B-X
were	B-X
used	B-X
to	B-X
study	B-X
the	B-X
genetic	B-X
changes	B-X
of	B-X
HCC	B-X
.	B-X
A	B-X
total	B-X
of	B-X
242	B-X
microsatellite	B-X
markers	B-X
mapping	B-X
to	B-X
1-22	B-X
and	B-X
X	B-X
chromosomes	B-X
was	B-X
used	B-X
.	B-X

Hypermethylation	O
was	O
detected	O
in	O
24	O
%	O
(	O
6	O
/	O
25	O
)	O
of	O
tumor	O
samples	O
.	O
<EOS>	B-X
A	B-X
large	B-X
number	B-X
of	B-X
tumor-related	B-X
methylated	B-X
genes	B-X
have	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
of	B-X
diagnostic	B-X
and	B-X
prognostic	B-X
values	B-X
for	B-X
CRC	B-X
when	B-X
analyzed	B-X
in	B-X
patients	B-X
'	B-X
stool	B-X
samples	B-X
;	B-X
however	B-X
,	B-X
reported	B-X
sensitivities	B-X
and	B-X
specificities	B-X
have	B-X
been	B-X
inconsistent	B-X
and	B-X
widely	B-X
varied	B-X
.	B-X
We	B-X
searched	B-X
MEDLINE	B-X
,	B-X
Web	B-X
of	B-X
Science	B-X
,	B-X
Scopus	B-X
and	B-X
Google	B-X
Scholar	B-X
databases	B-X
until	B-X
May	B-X
1	B-X
,	B-X
2016	B-X
.	B-X
From	B-X
469	B-X
publications	B-X
obtained	B-X
in	B-X
the	B-X
initial	B-X
literature	B-X
search	B-X
,	B-X
38	B-X
studies	B-X
were	B-X
included	B-X
in	B-X
the	B-X
final	B-X
analysis	B-X
involving	B-X
4867	B-X
individuals	B-X
.	B-X
Our	B-X
results	B-X
elucidated	B-X
that	B-X
SFRP1	B-X
and	B-X
SFRP2	B-X
methylation	B-X
possessed	B-X
promising	B-X
accuracy	B-X
for	B-X
detection	B-X
of	B-X
not	B-X
only	B-X
CRC	B-X
(	B-X
DOR	B-X
:	B-X
31.67	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
12.31-81.49	B-X
and	B-X
DOR	B-X
:	B-X
35.36	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
18.71-66.84	B-X
,	B-X
respectively	B-X
)	B-X
but	B-X
also	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
cancer	B-X
,	B-X
adenoma	B-X
(	B-X
DOR	B-X
:	B-X
19.72	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
6.68-58.25	B-X
and	B-X
DOR	B-X
:	B-X
13.20	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
6.01-28.00	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Besides	B-X
,	B-X
NDRG4	B-X
could	B-X
be	B-X
also	B-X
considered	B-X
as	B-X
a	B-X
significant	B-X
diagnostic	B-X
marker	B-X
gene	B-X
in	B-X
CRC	B-X
(	B-X
DOR	B-X
:	B-X
24.37	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
10.11-58.73	B-X
)	B-X
and	B-X
VIM	B-X
in	B-X
adenoma	B-X
(	B-X
DOR	B-X
:	B-X
15.21	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
2.72-85.10	B-X
)	B-X
.	B-X

However	O
,	O
the	O
corresponding	O
non	O
-	O
tumor	O
liver	O
tissue	O
specimens	O
were	O
always	O
unmethylated	O
at	O
the	O
p16	B-Protein
locus	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
Twenty-five	B-X
primary	B-X
HCC	B-X
tumor	B-X
and	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
examined	B-X
for	B-X
P16	B-X
gene	B-X
alterations	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
deletion	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
1	B-X
and	B-X
exon	B-X
2	B-X
was	B-X
performed	B-X
using	B-X
comparative	B-X
multiplex	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
analysis	B-X
.	B-X
The	B-X
point	B-X
mutation	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
2	B-X
was	B-X
investigated	B-X
by	B-X
single	B-X
strand	B-X
conformational	B-X
polymorphism	B-X
(	B-X
SSCP	B-X
)	B-X
analysis	B-X
,	B-X
and	B-X
the	B-X
status	B-X
of	B-X
p16	B-X
gene	B-X
methylation	B-X
was	B-X
screened	B-X
using	B-X
PCR-based	B-X
methylation	B-X
analysis	B-X
.	B-X
Moreover	B-X
,	B-X
35	B-X
parafin	B-X
specimens	B-X
of	B-X
primary	B-X
HCCs	B-X
with	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissues	B-X
,	B-X
including	B-X
the	B-X
25	B-X
cases	B-X
described	B-X
above	B-X
for	B-X
screening	B-X
of	B-X
p16	B-X
gene	B-X
alterations	B-X
,	B-X
were	B-X
investigated	B-X
also	B-X
for	B-X
P16	B-X
protein	B-X
expression	B-X
by	B-X
using	B-X
immunohistochemical	B-X
analysis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
comparative	B-X
multiplex	B-X
PCR	B-X
analysis	B-X
showed	B-X
that	B-X
12	B-X
%	B-X
(	B-X
3/25	B-X
)	B-X
p16	B-X
gene	B-X
deletions	B-X
,	B-X
including	B-X
homozygous	B-X
deletions	B-X
in	B-X
2	B-X
tumors	B-X
and	B-X
hemizygous	B-X
deletion	B-X
in	B-X
1	B-X
tumor	B-X
,	B-X
were	B-X
found	B-X
in	B-X
the	B-X
primary	B-X
HCCs	B-X
samples	B-X
.	B-X
No	B-X
point	B-X
mutation	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
remaining	B-X
22	B-X
tumor	B-X
samples	B-X
without	B-X
p16	B-X
gene	B-X
deletions	B-X
by	B-X
using	B-X
SSCP	B-X
analysis	B-X
.	B-X
Hypermethylation	B-X
was	B-X
detected	B-X
in	B-X
24	B-X
%	B-X
(	B-X
6/25	B-X
)	B-X
of	B-X
tumor	B-X
samples	B-X
by	B-X
PCR-based	B-X
analysis	B-X
.	B-X
However	B-X
the	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
always	B-X
unmethylated	B-X
at	B-X
p16	B-X
locus	B-X
.	B-X
Loss	B-X
of	B-X
P16	B-X
protein	B-X
expression	B-X
,	B-X
detected	B-X
by	B-X
immunohistochemistry	B-X
,	B-X
occurred	B-X
in	B-X
16	B-X
of	B-X
35	B-X
(	B-X
45.7	B-X
%	B-X
)	B-X
tumor	B-X
samples	B-X
,	B-X
whereas	B-X
all	B-X
the	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
showed	B-X
positive	B-X
p16	B-X
staining	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
inactivation	B-X
of	B-X
p16	B-X
gene	B-X
is	B-X
relevant	B-X
to	B-X
the	B-X
genesis	B-X
of	B-X
HCC	B-X
.	B-X

Loss	O
of	O
p16	B-Protein
protein	O
expression	O
occurred	O
in	O
16	O
of	O
35	O
(	O
45	O
.	O
7	O
%	O
)	O
tumor	O
samples	O
,	O
and	O
all	O
the	O
non	O
-	O
tumor	O
liver	O
tissue	O
specimens	O
showed	O
positive	O
p16	B-Protein
staining	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
Twenty-five	B-X
primary	B-X
HCC	B-X
tumor	B-X
and	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
examined	B-X
for	B-X
P16	B-X
gene	B-X
alterations	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
deletion	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
1	B-X
and	B-X
exon	B-X
2	B-X
was	B-X
performed	B-X
using	B-X
comparative	B-X
multiplex	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
analysis	B-X
.	B-X
The	B-X
point	B-X
mutation	B-X
of	B-X
p16	B-X
gene	B-X
exon	B-X
2	B-X
was	B-X
investigated	B-X
by	B-X
single	B-X
strand	B-X
conformational	B-X
polymorphism	B-X
(	B-X
SSCP	B-X
)	B-X
analysis	B-X
,	B-X
and	B-X
the	B-X
status	B-X
of	B-X
p16	B-X
gene	B-X
methylation	B-X
was	B-X
screened	B-X
using	B-X
PCR-based	B-X
methylation	B-X
analysis	B-X
.	B-X
Moreover	B-X
,	B-X
35	B-X
parafin	B-X
specimens	B-X
of	B-X
primary	B-X
HCCs	B-X
with	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissues	B-X
,	B-X
including	B-X
the	B-X
25	B-X
cases	B-X
described	B-X
above	B-X
for	B-X
screening	B-X
of	B-X
p16	B-X
gene	B-X
alterations	B-X
,	B-X
were	B-X
investigated	B-X
also	B-X
for	B-X
P16	B-X
protein	B-X
expression	B-X
by	B-X
using	B-X
immunohistochemical	B-X
analysis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
comparative	B-X
multiplex	B-X
PCR	B-X
analysis	B-X
showed	B-X
that	B-X
12	B-X
%	B-X
(	B-X
3/25	B-X
)	B-X
p16	B-X
gene	B-X
deletions	B-X
,	B-X
including	B-X
homozygous	B-X
deletions	B-X
in	B-X
2	B-X
tumors	B-X
and	B-X
hemizygous	B-X
deletion	B-X
in	B-X
1	B-X
tumor	B-X
,	B-X
were	B-X
found	B-X
in	B-X
the	B-X
primary	B-X
HCCs	B-X
samples	B-X
.	B-X
No	B-X
point	B-X
mutation	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
remaining	B-X
22	B-X
tumor	B-X
samples	B-X
without	B-X
p16	B-X
gene	B-X
deletions	B-X
by	B-X
using	B-X
SSCP	B-X
analysis	B-X
.	B-X
Hypermethylation	B-X
was	B-X
detected	B-X
in	B-X
24	B-X
%	B-X
(	B-X
6/25	B-X
)	B-X
of	B-X
tumor	B-X
samples	B-X
by	B-X
PCR-based	B-X
analysis	B-X
.	B-X
However	B-X
the	B-X
corresponding	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
were	B-X
always	B-X
unmethylated	B-X
at	B-X
p16	B-X
locus	B-X
.	B-X
Loss	B-X
of	B-X
P16	B-X
protein	B-X
expression	B-X
,	B-X
detected	B-X
by	B-X
immunohistochemistry	B-X
,	B-X
occurred	B-X
in	B-X
16	B-X
of	B-X
35	B-X
(	B-X
45.7	B-X
%	B-X
)	B-X
tumor	B-X
samples	B-X
,	B-X
whereas	B-X
all	B-X
the	B-X
non-tumor	B-X
liver	B-X
tissue	B-X
specimens	B-X
showed	B-X
positive	B-X
p16	B-X
staining	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
inactivation	B-X
of	B-X
p16	B-X
gene	B-X
is	B-X
relevant	B-X
to	B-X
the	B-X
genesis	B-X
of	B-X
HCC	B-X
.	B-X

For	O
the	O
25	O
cases	O
examined	O
for	O
p16	B-Protein
gene	O
alterations	O
,	O
the	O
loss	O
of	O
p16	B-Protein
protein	O
expression	O
was	O
observed	O
in	O
all	O
tumors	O
with	O
p16	B-Protein
gene	O
alterations	O
and	O
also	O
in	O
3	O
tumors	O
without	O
p16	B-Protein
gene	O
alterations	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
relationship	B-X
between	B-X
alterations	B-X
of	B-X
p16INK4a	B-X
and	B-X
p14ARF	B-X
genes	B-X
and	B-X
gastric	B-X
carcinogenesis	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X

CONCLUSION	O
:	O
Inactivation	O
of	O
the	O
p16	B-Protein
gene	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
genesis	O
of	O
primary	O
hepatocellular	O
carcinoma	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
p16	B-X
gene	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X

[	O
Hypermethylation	O
of	O
DAP	O
-	O
kinase	O
gene	O
CpG	O
Island	O
in	O
malignant	O
lymphoma	O
with	O
B	O
-	O
cell	O
phenotype	O
]	O
<EOS>	B-X
Death-associated	B-X
protein-kinase	B-X
(	B-X
DAP-Kinase	B-X
)	B-X
is	B-X
a	B-X
pro-apoptotic	B-X
serine/threonine	B-X
kinase	B-X
with	B-X
a	B-X
death	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
apoptosis	B-X
induced	B-X
by	B-X
interferon-gamma	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
and	B-X
Fas	B-X
ligand	B-X
.	B-X
Epigenetic	B-X
down-regulation	B-X
of	B-X
DAP-Kinase	B-X
gene	B-X
expression	B-X
by	B-X
hypermethylation	B-X
of	B-X
its	B-X
promoter	B-X
region	B-X
was	B-X
reported	B-X
in	B-X
certain	B-X
kinds	B-X
of	B-X
malignancies	B-X
.	B-X
Previous	B-X
patho-epidemiological	B-X
studies	B-X
indicated	B-X
that	B-X
thyroid	B-X
lymphoma	B-X
(	B-X
TL	B-X
)	B-X
evolves	B-X
among	B-X
active	B-X
lymphoid	B-X
cells	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
thyroiditis	B-X
(	B-X
CLTH	B-X
)	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
methylation	B-X
status	B-X
of	B-X
DAP-Kinase	B-X
CpG	B-X
island	B-X
was	B-X
examined	B-X
in	B-X
thyroid	B-X
lesions	B-X
of	B-X
19	B-X
cases	B-X
with	B-X
TL	B-X
and	B-X
9	B-X
with	B-X
CLTH	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DAP-kinase	B-X
gene	B-X
in	B-X
16	B-X
cases	B-X
of	B-X
T-cell	B-X
malignancies	B-X
including	B-X
eight	B-X
adult	B-X
T-cell	B-X
leukemia/lymphoma	B-X
and	B-X
24	B-X
NK/T-cell	B-X
,	B-X
34	B-X
B-cell	B-X
,	B-X
and	B-X
two	B-X
immunophenotypically	B-X
undetermined	B-X
lymphomas	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
B-cell	B-X
(	B-X
27	B-X
of	B-X
34	B-X
,	B-X
79.4	B-X
%	B-X
)	B-X
than	B-X
in	B-X
T-cell	B-X
malignancies	B-X
(	B-X
eight	B-X
of	B-X
16	B-X
,	B-X
50	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Fifteen	B-X
of	B-X
24	B-X
(	B-X
62.5	B-X
%	B-X
)	B-X
NK/T-cell	B-X
lymphomas	B-X
showed	B-X
DNA	B-X
methylation	B-X
.	B-X
Hematopoietic	B-X
cell	B-X
lines	B-X
with	B-X
a	B-X
methylated	B-X
gene	B-X
were	B-X
resistant	B-X
to	B-X
apoptosis	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
a	B-X
demethylating	B-X
agent	B-X
restored	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
one	B-X
B-cell	B-X
lymphoma	B-X
cell	B-X
line	B-X
with	B-X
DNA	B-X
methylation	B-X
.	B-X
Our	B-X
results	B-X
suggested	B-X
that	B-X
suppression	B-X
of	B-X
DAP-Kinase	B-X
expression	B-X
by	B-X
DNA	B-X
methylation	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
B-cell	B-X
malignancies	B-X
.	B-X

Death	O
-	O
associated	O
protein	O
-	O
kinase	O
(	O
DAP	O
-	O
Kinase	O
)	O
is	O
a	O
pro	O
-	O
apoptotic	O
serine	O
/	O
threonine	O
kinase	O
with	O
a	O
death	O
domain	O
,	O
which	O
is	O
involved	O
in	O
apoptosis	O
induced	O
by	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
,	O
and	O
Fas	B-Protein
ligand	I-Protein
.	O
<EOS>	B-X
Death-associated	B-X
protein-kinase	B-X
(	B-X
DAP-Kinase	B-X
)	B-X
is	B-X
a	B-X
pro-apoptotic	B-X
serine/threonine	B-X
kinase	B-X
with	B-X
a	B-X
death	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
apoptosis	B-X
induced	B-X
by	B-X
interferon-gamma	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
and	B-X
Fas	B-X
ligand	B-X
.	B-X
Epigenetic	B-X
down-regulation	B-X
of	B-X
DAP-Kinase	B-X
gene	B-X
expression	B-X
by	B-X
hypermethylation	B-X
of	B-X
its	B-X
promoter	B-X
region	B-X
was	B-X
reported	B-X
in	B-X
certain	B-X
kinds	B-X
of	B-X
malignancies	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
methylation	B-X
status	B-X
of	B-X
DAP-Kinase	B-X
CpG	B-X
island	B-X
was	B-X
examined	B-X
in	B-X
thyroid	B-X
lesions	B-X
of	B-X
19	B-X
cases	B-X
with	B-X
TL	B-X
and	B-X
9	B-X
with	B-X
CLTH	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DAP-kinase	B-X
gene	B-X
in	B-X
16	B-X
cases	B-X
of	B-X
T-cell	B-X
malignancies	B-X
including	B-X
eight	B-X
adult	B-X
T-cell	B-X
leukemia/lymphoma	B-X
and	B-X
24	B-X
NK/T-cell	B-X
,	B-X
34	B-X
B-cell	B-X
,	B-X
and	B-X
two	B-X
immunophenotypically	B-X
undetermined	B-X
lymphomas	B-X
.	B-X
Hematopoietic	B-X
cell	B-X
lines	B-X
with	B-X
a	B-X
methylated	B-X
gene	B-X
were	B-X
resistant	B-X
to	B-X
apoptosis	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
a	B-X
demethylating	B-X
agent	B-X
restored	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
one	B-X
B-cell	B-X
lymphoma	B-X
cell	B-X
line	B-X
with	B-X
DNA	B-X
methylation	B-X
.	B-X
Our	B-X
results	B-X
suggested	B-X
that	B-X
suppression	B-X
of	B-X
DAP-Kinase	B-X
expression	B-X
by	B-X
DNA	B-X
methylation	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
B-cell	B-X
malignancies	B-X
.	B-X

Epigenetic	O
down	O
-	O
regulation	O
of	O
DAP	O
-	O
Kinase	O
gene	O
expression	O
by	O
hypermethylation	O
of	O
its	O
promoter	O
region	O
was	O
reported	O
in	O
certain	O
kinds	O
of	O
malignancies	O
.	O
<EOS>	B-X
Death-associated	B-X
protein-kinase	B-X
(	B-X
DAP-Kinase	B-X
)	B-X
is	B-X
a	B-X
pro-apoptotic	B-X
serine/threonine	B-X
kinase	B-X
with	B-X
a	B-X
death	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
apoptosis	B-X
induced	B-X
by	B-X
interferon-gamma	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
and	B-X
Fas	B-X
ligand	B-X
.	B-X
Epigenetic	B-X
down-regulation	B-X
of	B-X
DAP-Kinase	B-X
gene	B-X
expression	B-X
by	B-X
hypermethylation	B-X
of	B-X
its	B-X
promoter	B-X
region	B-X
was	B-X
reported	B-X
in	B-X
certain	B-X
kinds	B-X
of	B-X
malignancies	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
methylation	B-X
status	B-X
of	B-X
DAP-Kinase	B-X
CpG	B-X
island	B-X
was	B-X
examined	B-X
in	B-X
thyroid	B-X
lesions	B-X
of	B-X
19	B-X
cases	B-X
with	B-X
TL	B-X
and	B-X
9	B-X
with	B-X
CLTH	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DAP-kinase	B-X
gene	B-X
in	B-X
16	B-X
cases	B-X
of	B-X
T-cell	B-X
malignancies	B-X
including	B-X
eight	B-X
adult	B-X
T-cell	B-X
leukemia/lymphoma	B-X
and	B-X
24	B-X
NK/T-cell	B-X
,	B-X
34	B-X
B-cell	B-X
,	B-X
and	B-X
two	B-X
immunophenotypically	B-X
undetermined	B-X
lymphomas	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
B-cell	B-X
(	B-X
27	B-X
of	B-X
34	B-X
,	B-X
79.4	B-X
%	B-X
)	B-X
than	B-X
in	B-X
T-cell	B-X
malignancies	B-X
(	B-X
eight	B-X
of	B-X
16	B-X
,	B-X
50	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Hematopoietic	B-X
cell	B-X
lines	B-X
with	B-X
a	B-X
methylated	B-X
gene	B-X
were	B-X
resistant	B-X
to	B-X
apoptosis	B-X
.	B-X
Our	B-X
results	B-X
suggested	B-X
that	B-X
suppression	B-X
of	B-X
DAP-Kinase	B-X
expression	B-X
by	B-X
DNA	B-X
methylation	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
B-cell	B-X
malignancies	B-X
.	B-X

Previous	O
patho	O
-	O
epidemiological	O
studies	O
indicated	O
that	O
thyroid	O
lymphoma	O
(	O
TL	O
)	O
evolves	O
among	O
active	O
lymphoid	O
cells	O
in	O
chronic	O
lymphocytic	O
thyroiditis	O
(	O
CLTH	O
)	O
.	O
<EOS>	B-X
Previous	B-X
patho-epidemiological	B-X
studies	B-X
indicated	B-X
that	B-X
thyroid	B-X
lymphoma	B-X
(	B-X
TL	B-X
)	B-X
evolves	B-X
among	B-X
active	B-X
lymphoid	B-X
cells	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
thyroiditis	B-X
(	B-X
CLTH	B-X
)	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
methylation	B-X
status	B-X
of	B-X
DAP-Kinase	B-X
CpG	B-X
island	B-X
was	B-X
examined	B-X
in	B-X
thyroid	B-X
lesions	B-X
of	B-X
19	B-X
cases	B-X
with	B-X
TL	B-X
and	B-X
9	B-X
with	B-X
CLTH	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
TL	B-X
cases	B-X
(	B-X
16	B-X
of	B-X
19	B-X
,	B-X
84.2	B-X
%	B-X
)	B-X
than	B-X
in	B-X
CLTH	B-X
cases	B-X
(	B-X
2	B-X
of	B-X
9	B-X
,	B-X
22.2	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
DNA	B-X
extracted	B-X
from	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
from	B-X
TL	B-X
and	B-X
CLTH	B-X
cases	B-X
never	B-X
showed	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
methylation	B-X
occurred	B-X
somatically	B-X
in	B-X
lesional	B-X
lymphocytes	B-X
in	B-X
the	B-X
thyroid	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DAP-kinase	B-X
gene	B-X
in	B-X
16	B-X
cases	B-X
of	B-X
T-cell	B-X
malignancies	B-X
including	B-X
eight	B-X
adult	B-X
T-cell	B-X
leukemia/lymphoma	B-X
and	B-X
24	B-X
NK/T-cell	B-X
,	B-X
34	B-X
B-cell	B-X
,	B-X
and	B-X
two	B-X
immunophenotypically	B-X
undetermined	B-X
lymphomas	B-X
.	B-X
Fifteen	B-X
of	B-X
24	B-X
(	B-X
62.5	B-X
%	B-X
)	B-X
NK/T-cell	B-X
lymphomas	B-X
showed	B-X
DNA	B-X
methylation	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
a	B-X
demethylating	B-X
agent	B-X
restored	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
one	B-X
B-cell	B-X
lymphoma	B-X
cell	B-X
line	B-X
with	B-X
DNA	B-X
methylation	B-X
.	B-X

With	O
the	O
use	O
of	O
methylation	O
specific	O
polymerase	O
chain	O
reaction	O
,	O
methylation	O
status	O
of	O
DAP	O
-	O
Kinase	O
CpG	O
island	O
was	O
examined	O
in	O
thyroid	O
lesions	O
of	O
19	O
cases	O
with	O
TL	O
and	O
9	O
with	O
CLTH	O
.	O

Frequency	O
of	O
methylation	O
was	O
higher	O
in	O
TL	O
cases	O
(	O
16	O
of	O
19	O
,	O
84	O
.	O
2	O
%	O
)	O
than	O
in	O
CLTH	O
cases	O
(	O
2	O
of	O
9	O
,	O
22	O
.	O
2	O
%	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

DNA	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
from	O
TL	O
and	O
CLTH	O
cases	O
never	O
showed	O
methylation	O
,	O
indicating	O
that	O
the	O
methylation	O
occurred	O
somatically	O
in	O
lesional	O
lymphocytes	O
in	O
the	O
thyroid	O
.	O
<EOS>	B-X
Epigenetic	B-X
down-regulation	B-X
of	B-X
DAP-Kinase	B-X
gene	B-X
expression	B-X
by	B-X
hypermethylation	B-X
of	B-X
its	B-X
promoter	B-X
region	B-X
was	B-X
reported	B-X
in	B-X
certain	B-X
kinds	B-X
of	B-X
malignancies	B-X
.	B-X
Previous	B-X
patho-epidemiological	B-X
studies	B-X
indicated	B-X
that	B-X
thyroid	B-X
lymphoma	B-X
(	B-X
TL	B-X
)	B-X
evolves	B-X
among	B-X
active	B-X
lymphoid	B-X
cells	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
thyroiditis	B-X
(	B-X
CLTH	B-X
)	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
methylation	B-X
status	B-X
of	B-X
DAP-Kinase	B-X
CpG	B-X
island	B-X
was	B-X
examined	B-X
in	B-X
thyroid	B-X
lesions	B-X
of	B-X
19	B-X
cases	B-X
with	B-X
TL	B-X
and	B-X
9	B-X
with	B-X
CLTH	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
TL	B-X
cases	B-X
(	B-X
16	B-X
of	B-X
19	B-X
,	B-X
84.2	B-X
%	B-X
)	B-X
than	B-X
in	B-X
CLTH	B-X
cases	B-X
(	B-X
2	B-X
of	B-X
9	B-X
,	B-X
22.2	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
DNA	B-X
extracted	B-X
from	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
from	B-X
TL	B-X
and	B-X
CLTH	B-X
cases	B-X
never	B-X
showed	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
methylation	B-X
occurred	B-X
somatically	B-X
in	B-X
lesional	B-X
lymphocytes	B-X
in	B-X
the	B-X
thyroid	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DAP-kinase	B-X
gene	B-X
in	B-X
16	B-X
cases	B-X
of	B-X
T-cell	B-X
malignancies	B-X
including	B-X
eight	B-X
adult	B-X
T-cell	B-X
leukemia/lymphoma	B-X
and	B-X
24	B-X
NK/T-cell	B-X
,	B-X
34	B-X
B-cell	B-X
,	B-X
and	B-X
two	B-X
immunophenotypically	B-X
undetermined	B-X
lymphomas	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
B-cell	B-X
(	B-X
27	B-X
of	B-X
34	B-X
,	B-X
79.4	B-X
%	B-X
)	B-X
than	B-X
in	B-X
T-cell	B-X
malignancies	B-X
(	B-X
eight	B-X
of	B-X
16	B-X
,	B-X
50	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Fifteen	B-X
of	B-X
24	B-X
(	B-X
62.5	B-X
%	B-X
)	B-X
NK/T-cell	B-X
lymphomas	B-X
showed	B-X
DNA	B-X
methylation	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
a	B-X
demethylating	B-X
agent	B-X
restored	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
one	B-X
B-cell	B-X
lymphoma	B-X
cell	B-X
line	B-X
with	B-X
DNA	B-X
methylation	B-X
.	B-X
Our	B-X
results	B-X
suggested	B-X
that	B-X
suppression	B-X
of	B-X
DAP-Kinase	B-X
expression	B-X
by	B-X
DNA	B-X
methylation	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
B-cell	B-X
malignancies	B-X
.	B-X

We	O
also	O
examined	O
the	O
methylation	O
status	O
of	O
DAP	O
-	O
kinase	O
gene	O
in	O
16	O
cases	O
of	O
T	O
-	O
cell	O
malignancies	O
including	O
eight	O
adult	O
T	O
-	O
cell	O
leukemia	O
/	O
lymphoma	O
and	O
24	O
NK	O
/	O
T	O
-	O
cell	O
,	O
34	O
B	O
-	O
cell	O
,	O
and	O
two	O
immunophenotypically	O
undetermined	O
lymphomas	O
.	O
<EOS>	B-X
Death-associated	B-X
protein-kinase	B-X
(	B-X
DAP-Kinase	B-X
)	B-X
is	B-X
a	B-X
pro-apoptotic	B-X
serine/threonine	B-X
kinase	B-X
with	B-X
a	B-X
death	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
apoptosis	B-X
induced	B-X
by	B-X
interferon-gamma	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
and	B-X
Fas	B-X
ligand	B-X
.	B-X
Epigenetic	B-X
down-regulation	B-X
of	B-X
DAP-Kinase	B-X
gene	B-X
expression	B-X
by	B-X
hypermethylation	B-X
of	B-X
its	B-X
promoter	B-X
region	B-X
was	B-X
reported	B-X
in	B-X
certain	B-X
kinds	B-X
of	B-X
malignancies	B-X
.	B-X
Previous	B-X
patho-epidemiological	B-X
studies	B-X
indicated	B-X
that	B-X
thyroid	B-X
lymphoma	B-X
(	B-X
TL	B-X
)	B-X
evolves	B-X
among	B-X
active	B-X
lymphoid	B-X
cells	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
thyroiditis	B-X
(	B-X
CLTH	B-X
)	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
methylation	B-X
status	B-X
of	B-X
DAP-Kinase	B-X
CpG	B-X
island	B-X
was	B-X
examined	B-X
in	B-X
thyroid	B-X
lesions	B-X
of	B-X
19	B-X
cases	B-X
with	B-X
TL	B-X
and	B-X
9	B-X
with	B-X
CLTH	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
TL	B-X
cases	B-X
(	B-X
16	B-X
of	B-X
19	B-X
,	B-X
84.2	B-X
%	B-X
)	B-X
than	B-X
in	B-X
CLTH	B-X
cases	B-X
(	B-X
2	B-X
of	B-X
9	B-X
,	B-X
22.2	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
DNA	B-X
extracted	B-X
from	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
from	B-X
TL	B-X
and	B-X
CLTH	B-X
cases	B-X
never	B-X
showed	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
methylation	B-X
occurred	B-X
somatically	B-X
in	B-X
lesional	B-X
lymphocytes	B-X
in	B-X
the	B-X
thyroid	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DAP-kinase	B-X
gene	B-X
in	B-X
16	B-X
cases	B-X
of	B-X
T-cell	B-X
malignancies	B-X
including	B-X
eight	B-X
adult	B-X
T-cell	B-X
leukemia/lymphoma	B-X
and	B-X
24	B-X
NK/T-cell	B-X
,	B-X
34	B-X
B-cell	B-X
,	B-X
and	B-X
two	B-X
immunophenotypically	B-X
undetermined	B-X
lymphomas	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
B-cell	B-X
(	B-X
27	B-X
of	B-X
34	B-X
,	B-X
79.4	B-X
%	B-X
)	B-X
than	B-X
in	B-X
T-cell	B-X
malignancies	B-X
(	B-X
eight	B-X
of	B-X
16	B-X
,	B-X
50	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Fifteen	B-X
of	B-X
24	B-X
(	B-X
62.5	B-X
%	B-X
)	B-X
NK/T-cell	B-X
lymphomas	B-X
showed	B-X
DNA	B-X
methylation	B-X
.	B-X
Hematopoietic	B-X
cell	B-X
lines	B-X
with	B-X
a	B-X
methylated	B-X
gene	B-X
were	B-X
resistant	B-X
to	B-X
apoptosis	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
a	B-X
demethylating	B-X
agent	B-X
restored	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
one	B-X
B-cell	B-X
lymphoma	B-X
cell	B-X
line	B-X
with	B-X
DNA	B-X
methylation	B-X
.	B-X
Our	B-X
results	B-X
suggested	B-X
that	B-X
suppression	B-X
of	B-X
DAP-Kinase	B-X
expression	B-X
by	B-X
DNA	B-X
methylation	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
B-cell	B-X
malignancies	B-X
.	B-X

Frequency	O
of	O
methylation	O
was	O
higher	O
in	O
B	O
-	O
cell	O
(	O
27	O
of	O
34	O
,	O
79	O
.	O
4	O
%	O
)	O
than	O
in	O
T	O
-	O
cell	O
malignancies	O
(	O
eight	O
of	O
16	O
,	O
50	O
%	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Fifteen	O
of	O
24	O
(	O
62	O
.	O
5	O
%	O
)	O
NK	O
/	O
T	O
-	O
cell	O
lymphomas	O
showed	O
DNA	O
methylation	O
.	O
<EOS>	B-X
Epigenetic	B-X
down-regulation	B-X
of	B-X
DAP-Kinase	B-X
gene	B-X
expression	B-X
by	B-X
hypermethylation	B-X
of	B-X
its	B-X
promoter	B-X
region	B-X
was	B-X
reported	B-X
in	B-X
certain	B-X
kinds	B-X
of	B-X
malignancies	B-X
.	B-X
Previous	B-X
patho-epidemiological	B-X
studies	B-X
indicated	B-X
that	B-X
thyroid	B-X
lymphoma	B-X
(	B-X
TL	B-X
)	B-X
evolves	B-X
among	B-X
active	B-X
lymphoid	B-X
cells	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
thyroiditis	B-X
(	B-X
CLTH	B-X
)	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
methylation	B-X
status	B-X
of	B-X
DAP-Kinase	B-X
CpG	B-X
island	B-X
was	B-X
examined	B-X
in	B-X
thyroid	B-X
lesions	B-X
of	B-X
19	B-X
cases	B-X
with	B-X
TL	B-X
and	B-X
9	B-X
with	B-X
CLTH	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
TL	B-X
cases	B-X
(	B-X
16	B-X
of	B-X
19	B-X
,	B-X
84.2	B-X
%	B-X
)	B-X
than	B-X
in	B-X
CLTH	B-X
cases	B-X
(	B-X
2	B-X
of	B-X
9	B-X
,	B-X
22.2	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
DNA	B-X
extracted	B-X
from	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
from	B-X
TL	B-X
and	B-X
CLTH	B-X
cases	B-X
never	B-X
showed	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
methylation	B-X
occurred	B-X
somatically	B-X
in	B-X
lesional	B-X
lymphocytes	B-X
in	B-X
the	B-X
thyroid	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DAP-kinase	B-X
gene	B-X
in	B-X
16	B-X
cases	B-X
of	B-X
T-cell	B-X
malignancies	B-X
including	B-X
eight	B-X
adult	B-X
T-cell	B-X
leukemia/lymphoma	B-X
and	B-X
24	B-X
NK/T-cell	B-X
,	B-X
34	B-X
B-cell	B-X
,	B-X
and	B-X
two	B-X
immunophenotypically	B-X
undetermined	B-X
lymphomas	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
B-cell	B-X
(	B-X
27	B-X
of	B-X
34	B-X
,	B-X
79.4	B-X
%	B-X
)	B-X
than	B-X
in	B-X
T-cell	B-X
malignancies	B-X
(	B-X
eight	B-X
of	B-X
16	B-X
,	B-X
50	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Fifteen	B-X
of	B-X
24	B-X
(	B-X
62.5	B-X
%	B-X
)	B-X
NK/T-cell	B-X
lymphomas	B-X
showed	B-X
DNA	B-X
methylation	B-X
.	B-X
Hematopoietic	B-X
cell	B-X
lines	B-X
with	B-X
a	B-X
methylated	B-X
gene	B-X
were	B-X
resistant	B-X
to	B-X
apoptosis	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
a	B-X
demethylating	B-X
agent	B-X
restored	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
one	B-X
B-cell	B-X
lymphoma	B-X
cell	B-X
line	B-X
with	B-X
DNA	B-X
methylation	B-X
.	B-X
Our	B-X
results	B-X
suggested	B-X
that	B-X
suppression	B-X
of	B-X
DAP-Kinase	B-X
expression	B-X
by	B-X
DNA	B-X
methylation	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
B-cell	B-X
malignancies	B-X
.	B-X

Hematopoietic	O
cell	O
lines	O
with	O
a	O
methylated	O
gene	O
were	O
resistant	O
to	O
apoptosis	O
.	O
<EOS>	B-X
Asparaginase	B-X
therapy	B-X
is	B-X
a	B-X
key	B-X
component	B-X
of	B-X
chemotherapy	B-X
for	B-X
patients	B-X
with	B-X
T-cell	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
T-ALL	B-X
)	B-X
.	B-X
Normal	B-X
hematopoietic	B-X
cells	B-X
can	B-X
survive	B-X
due	B-X
to	B-X
asparagine	B-X
synthetase	B-X
(	B-X
ASNS	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
leukemia	B-X
cells	B-X
are	B-X
supposed	B-X
to	B-X
undergo	B-X
apoptosis	B-X
due	B-X
to	B-X
silencing	B-X
of	B-X
the	B-X
ASNS	B-X
gene	B-X
.	B-X
Because	B-X
the	B-X
ASNS	B-X
gene	B-X
has	B-X
a	B-X
typical	B-X
CpG	B-X
island	B-X
in	B-X
its	B-X
promoter	B-X
,	B-X
its	B-X
methylation	B-X
status	B-X
in	B-X
T-ALL	B-X
cells	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
asparaginase	B-X
sensitivity	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
significance	B-X
of	B-X
ASNS	B-X
methylation	B-X
status	B-X
in	B-X
asparaginase	B-X
sensitivity	B-X
of	B-X
T-ALL	B-X
cell	B-X
lines	B-X
and	B-X
prognosis	B-X
of	B-X
childhood	B-X
T-ALL	B-X
.	B-X
Sequencing	B-X
of	B-X
bisulfite	B-X
polymerase	B-X
chain	B-X
reaction	B-X
products	B-X
using	B-X
next-generation	B-X
sequencing	B-X
technology	B-X
in	B-X
22	B-X
T-ALL	B-X
cell	B-X
lines	B-X
revealed	B-X
a	B-X
stepwise	B-X
allele-specific	B-X
methylation	B-X
of	B-X
the	B-X
ASNS	B-X
gene	B-X
,	B-X
in	B-X
association	B-X
with	B-X
an	B-X
aberrant	B-X
methylation	B-X
of	B-X
a	B-X
7q21	B-X
imprinted	B-X
gene	B-X
cluster	B-X
.	B-X
T-ALL	B-X
cell	B-X
lines	B-X
with	B-X
ASNS	B-X
hypermethylation	B-X
status	B-X
showed	B-X
significantly	B-X
higher	B-X
in	B-X
vitro	B-X
l-asparaginase	B-X
sensitivity	B-X
in	B-X
association	B-X
with	B-X
insufficient	B-X
asparaginase-induced	B-X
upregulation	B-X
of	B-X
ASNS	B-X
gene	B-X
expression	B-X
and	B-X
lower	B-X
basal	B-X
ASNS	B-X
protein	B-X
expression	B-X
.	B-X
A	B-X
comprehensive	B-X
analysis	B-X
of	B-X
diagnostic	B-X
samples	B-X
from	B-X
pediatric	B-X
patients	B-X
with	B-X
T-ALL	B-X
in	B-X
Japanese	B-X
cohorts	B-X
(	B-X
N	B-X
=	B-X
77	B-X
)	B-X
revealed	B-X
that	B-X
methylation	B-X
of	B-X
the	B-X
ASNS	B-X
gene	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
aberrant	B-X
methylation	B-X
of	B-X
the	B-X
7q21	B-X
imprinted	B-X
gene	B-X
cluster	B-X
.	B-X

Treatment	O
of	O
the	O
cells	O
with	O
a	O
demethylating	O
agent	O
restored	O
apoptotic	O
cell	O
death	O
in	O
one	O
B	O
-	O
cell	O
lymphoma	O
cell	O
line	O
with	O
DNA	O
methylation	O
.	O

Our	O
results	O
suggested	O
that	O
suppression	O
of	O
DAP	O
-	O
Kinase	O
expression	O
by	O
DNA	O
methylation	O
might	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
B	O
-	O
cell	O
malignancies	O
.	O
<EOS>	B-X
Death-associated	B-X
protein-kinase	B-X
(	B-X
DAP-Kinase	B-X
)	B-X
is	B-X
a	B-X
pro-apoptotic	B-X
serine/threonine	B-X
kinase	B-X
with	B-X
a	B-X
death	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
apoptosis	B-X
induced	B-X
by	B-X
interferon-gamma	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
and	B-X
Fas	B-X
ligand	B-X
.	B-X
Epigenetic	B-X
down-regulation	B-X
of	B-X
DAP-Kinase	B-X
gene	B-X
expression	B-X
by	B-X
hypermethylation	B-X
of	B-X
its	B-X
promoter	B-X
region	B-X
was	B-X
reported	B-X
in	B-X
certain	B-X
kinds	B-X
of	B-X
malignancies	B-X
.	B-X
Previous	B-X
patho-epidemiological	B-X
studies	B-X
indicated	B-X
that	B-X
thyroid	B-X
lymphoma	B-X
(	B-X
TL	B-X
)	B-X
evolves	B-X
among	B-X
active	B-X
lymphoid	B-X
cells	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
thyroiditis	B-X
(	B-X
CLTH	B-X
)	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
methylation	B-X
status	B-X
of	B-X
DAP-Kinase	B-X
CpG	B-X
island	B-X
was	B-X
examined	B-X
in	B-X
thyroid	B-X
lesions	B-X
of	B-X
19	B-X
cases	B-X
with	B-X
TL	B-X
and	B-X
9	B-X
with	B-X
CLTH	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
TL	B-X
cases	B-X
(	B-X
16	B-X
of	B-X
19	B-X
,	B-X
84.2	B-X
%	B-X
)	B-X
than	B-X
in	B-X
CLTH	B-X
cases	B-X
(	B-X
2	B-X
of	B-X
9	B-X
,	B-X
22.2	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
DNA	B-X
extracted	B-X
from	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
from	B-X
TL	B-X
and	B-X
CLTH	B-X
cases	B-X
never	B-X
showed	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
methylation	B-X
occurred	B-X
somatically	B-X
in	B-X
lesional	B-X
lymphocytes	B-X
in	B-X
the	B-X
thyroid	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DAP-kinase	B-X
gene	B-X
in	B-X
16	B-X
cases	B-X
of	B-X
T-cell	B-X
malignancies	B-X
including	B-X
eight	B-X
adult	B-X
T-cell	B-X
leukemia/lymphoma	B-X
and	B-X
24	B-X
NK/T-cell	B-X
,	B-X
34	B-X
B-cell	B-X
,	B-X
and	B-X
two	B-X
immunophenotypically	B-X
undetermined	B-X
lymphomas	B-X
.	B-X
Frequency	B-X
of	B-X
methylation	B-X
was	B-X
higher	B-X
in	B-X
B-cell	B-X
(	B-X
27	B-X
of	B-X
34	B-X
,	B-X
79.4	B-X
%	B-X
)	B-X
than	B-X
in	B-X
T-cell	B-X
malignancies	B-X
(	B-X
eight	B-X
of	B-X
16	B-X
,	B-X
50	B-X
%	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Fifteen	B-X
of	B-X
24	B-X
(	B-X
62.5	B-X
%	B-X
)	B-X
NK/T-cell	B-X
lymphomas	B-X
showed	B-X
DNA	B-X
methylation	B-X
.	B-X
Hematopoietic	B-X
cell	B-X
lines	B-X
with	B-X
a	B-X
methylated	B-X
gene	B-X
were	B-X
resistant	B-X
to	B-X
apoptosis	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
a	B-X
demethylating	B-X
agent	B-X
restored	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
one	B-X
B-cell	B-X
lymphoma	B-X
cell	B-X
line	B-X
with	B-X
DNA	B-X
methylation	B-X
.	B-X
Our	B-X
results	B-X
suggested	B-X
that	B-X
suppression	B-X
of	B-X
DAP-Kinase	B-X
expression	B-X
by	B-X
DNA	B-X
methylation	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
B-cell	B-X
malignancies	B-X
.	B-X

Asparagine	O
hydroxylation	O
of	O
the	O
HIF	O
transactivation	O
domain	O
a	O
hypoxic	O
switch	O
.	O
<EOS>	B-X
The	B-X
hypoxia-inducible	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
1alpha	B-X
and	B-X
2alpha	B-X
are	B-X
key	B-X
mammalian	B-X
transcription	B-X
factors	B-X
that	B-X
exhibit	B-X
dramatic	B-X
increases	B-X
in	B-X
both	B-X
protein	B-X
stability	B-X
and	B-X
intrinsic	B-X
transcriptional	B-X
potency	B-X
during	B-X
low-oxygen	B-X
stress	B-X
.	B-X
This	B-X
increased	B-X
stability	B-X
is	B-X
due	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
proline	B-X
hydroxylation	B-X
,	B-X
which	B-X
in	B-X
normoxia	B-X
promotes	B-X
binding	B-X
of	B-X
HIF	B-X
to	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
tumor	B-X
suppressor	B-X
)	B-X
ubiquitin	B-X
ligase	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
hypoxic	B-X
induction	B-X
of	B-X
the	B-X
COOH-terminal	B-X
transactivation	B-X
domain	B-X
(	B-X
CAD	B-X
)	B-X
of	B-X
HIF	B-X
occurs	B-X
through	B-X
abrogation	B-X
of	B-X
hydroxylation	B-X
of	B-X
a	B-X
conserved	B-X
asparagine	B-X
in	B-X
the	B-X
CAD	B-X
.	B-X
Inhibitors	B-X
of	B-X
Fe	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
2-oxoglutarate-dependent	B-X
dioxygenases	B-X
prevented	B-X
hydroxylation	B-X
of	B-X
the	B-X
Asn	B-X
,	B-X
thus	B-X
allowing	B-X
the	B-X
CAD	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
p300	B-X
transcription	B-X
coactivator	B-X
.	B-X
Full	B-X
induction	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
-2alpha	B-X
,	B-X
therefore	B-X
,	B-X
relies	B-X
on	B-X
the	B-X
abrogation	B-X
of	B-X
both	B-X
Pro	B-X
and	B-X
Asn	B-X
hydroxylation	B-X
,	B-X
which	B-X
during	B-X
normoxia	B-X
occur	B-X
at	B-X
the	B-X
degradation	B-X
and	B-X
COOH-terminal	B-X
transactivation	B-X
domains	B-X
,	B-X
respectively	B-X
.	B-X

The	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factors	I-Protein
(	I-Protein
HIFs	I-Protein
)	I-Protein
1alpha	I-Protein
and	O
2alpha	B-Protein
are	O
key	O
mammalian	O
transcription	O
factors	O
that	O
exhibit	O
dramatic	O
increases	O
in	O
both	O
protein	O
stability	O
and	O
intrinsic	O
transcriptional	O
potency	O
during	O
low	O
-	O
oxygen	O
stress	O
.	O
<EOS>	B-X
The	B-X
hypoxia-inducible	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
1alpha	B-X
and	B-X
2alpha	B-X
are	B-X
key	B-X
mammalian	B-X
transcription	B-X
factors	B-X
that	B-X
exhibit	B-X
dramatic	B-X
increases	B-X
in	B-X
both	B-X
protein	B-X
stability	B-X
and	B-X
intrinsic	B-X
transcriptional	B-X
potency	B-X
during	B-X
low-oxygen	B-X
stress	B-X
.	B-X
This	B-X
increased	B-X
stability	B-X
is	B-X
due	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
proline	B-X
hydroxylation	B-X
,	B-X
which	B-X
in	B-X
normoxia	B-X
promotes	B-X
binding	B-X
of	B-X
HIF	B-X
to	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
tumor	B-X
suppressor	B-X
)	B-X
ubiquitin	B-X
ligase	B-X
.	B-X
Inhibitors	B-X
of	B-X
Fe	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
2-oxoglutarate-dependent	B-X
dioxygenases	B-X
prevented	B-X
hydroxylation	B-X
of	B-X
the	B-X
Asn	B-X
,	B-X
thus	B-X
allowing	B-X
the	B-X
CAD	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
p300	B-X
transcription	B-X
coactivator	B-X
.	B-X
Replacement	B-X
of	B-X
the	B-X
conserved	B-X
Asn	B-X
by	B-X
Ala	B-X
resulted	B-X
in	B-X
constitutive	B-X
p300	B-X
interaction	B-X
and	B-X
strong	B-X
transcriptional	B-X
activity	B-X
.	B-X
Full	B-X
induction	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
-2alpha	B-X
,	B-X
therefore	B-X
,	B-X
relies	B-X
on	B-X
the	B-X
abrogation	B-X
of	B-X
both	B-X
Pro	B-X
and	B-X
Asn	B-X
hydroxylation	B-X
,	B-X
which	B-X
during	B-X
normoxia	B-X
occur	B-X
at	B-X
the	B-X
degradation	B-X
and	B-X
COOH-terminal	B-X
transactivation	B-X
domains	B-X
,	B-X
respectively	B-X
.	B-X

This	O
increased	O
stability	O
is	O
due	O
to	O
the	O
absence	O
of	O
proline	O
hydroxylation	O
,	O
which	O
in	O
normoxia	O
promotes	O
binding	O
of	O
HIF	O
to	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	O
VHL	B-Protein
tumor	I-Protein
suppressor	I-Protein
)	O
ubiquitin	B-Protein
ligase	O
.	O

We	O
now	O
show	O
that	O
hypoxic	O
induction	O
of	O
the	O
COOH	O
-	O
terminal	O
transactivation	O
domain	O
(	O
CAD	O
)	O
of	O
HIF	O
occurs	O
through	O
abrogation	O
of	O
hydroxylation	O
of	O
a	O
conserved	O
asparagine	O
in	O
the	O
CAD	O
.	O
<EOS>	B-X
The	B-X
hypoxia-inducible	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
1alpha	B-X
and	B-X
2alpha	B-X
are	B-X
key	B-X
mammalian	B-X
transcription	B-X
factors	B-X
that	B-X
exhibit	B-X
dramatic	B-X
increases	B-X
in	B-X
both	B-X
protein	B-X
stability	B-X
and	B-X
intrinsic	B-X
transcriptional	B-X
potency	B-X
during	B-X
low-oxygen	B-X
stress	B-X
.	B-X
This	B-X
increased	B-X
stability	B-X
is	B-X
due	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
proline	B-X
hydroxylation	B-X
,	B-X
which	B-X
in	B-X
normoxia	B-X
promotes	B-X
binding	B-X
of	B-X
HIF	B-X
to	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
tumor	B-X
suppressor	B-X
)	B-X
ubiquitin	B-X
ligase	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
hypoxic	B-X
induction	B-X
of	B-X
the	B-X
COOH-terminal	B-X
transactivation	B-X
domain	B-X
(	B-X
CAD	B-X
)	B-X
of	B-X
HIF	B-X
occurs	B-X
through	B-X
abrogation	B-X
of	B-X
hydroxylation	B-X
of	B-X
a	B-X
conserved	B-X
asparagine	B-X
in	B-X
the	B-X
CAD	B-X
.	B-X
Inhibitors	B-X
of	B-X
Fe	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
2-oxoglutarate-dependent	B-X
dioxygenases	B-X
prevented	B-X
hydroxylation	B-X
of	B-X
the	B-X
Asn	B-X
,	B-X
thus	B-X
allowing	B-X
the	B-X
CAD	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
p300	B-X
transcription	B-X
coactivator	B-X
.	B-X
Replacement	B-X
of	B-X
the	B-X
conserved	B-X
Asn	B-X
by	B-X
Ala	B-X
resulted	B-X
in	B-X
constitutive	B-X
p300	B-X
interaction	B-X
and	B-X
strong	B-X
transcriptional	B-X
activity	B-X
.	B-X
Full	B-X
induction	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
-2alpha	B-X
,	B-X
therefore	B-X
,	B-X
relies	B-X
on	B-X
the	B-X
abrogation	B-X
of	B-X
both	B-X
Pro	B-X
and	B-X
Asn	B-X
hydroxylation	B-X
,	B-X
which	B-X
during	B-X
normoxia	B-X
occur	B-X
at	B-X
the	B-X
degradation	B-X
and	B-X
COOH-terminal	B-X
transactivation	B-X
domains	B-X
,	B-X
respectively	B-X
.	B-X

Inhibitors	O
of	O
Fe	O
(	O
II	O
)	O
-	O
and	O
2	O
-	O
oxoglutarate	O
-	O
dependent	O
dioxygenases	O
prevented	O
hydroxylation	O
of	O
the	O
Asn	O
,	O
thus	O
allowing	O
the	O
CAD	O
to	O
interact	O
with	O
the	O
p300	B-Protein
transcription	O
coactivator	O
.	O
<EOS>	B-X
The	B-X
hypoxia-inducible	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
1alpha	B-X
and	B-X
2alpha	B-X
are	B-X
key	B-X
mammalian	B-X
transcription	B-X
factors	B-X
that	B-X
exhibit	B-X
dramatic	B-X
increases	B-X
in	B-X
both	B-X
protein	B-X
stability	B-X
and	B-X
intrinsic	B-X
transcriptional	B-X
potency	B-X
during	B-X
low-oxygen	B-X
stress	B-X
.	B-X
This	B-X
increased	B-X
stability	B-X
is	B-X
due	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
proline	B-X
hydroxylation	B-X
,	B-X
which	B-X
in	B-X
normoxia	B-X
promotes	B-X
binding	B-X
of	B-X
HIF	B-X
to	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
tumor	B-X
suppressor	B-X
)	B-X
ubiquitin	B-X
ligase	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
hypoxic	B-X
induction	B-X
of	B-X
the	B-X
COOH-terminal	B-X
transactivation	B-X
domain	B-X
(	B-X
CAD	B-X
)	B-X
of	B-X
HIF	B-X
occurs	B-X
through	B-X
abrogation	B-X
of	B-X
hydroxylation	B-X
of	B-X
a	B-X
conserved	B-X
asparagine	B-X
in	B-X
the	B-X
CAD	B-X
.	B-X
Inhibitors	B-X
of	B-X
Fe	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
2-oxoglutarate-dependent	B-X
dioxygenases	B-X
prevented	B-X
hydroxylation	B-X
of	B-X
the	B-X
Asn	B-X
,	B-X
thus	B-X
allowing	B-X
the	B-X
CAD	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
p300	B-X
transcription	B-X
coactivator	B-X
.	B-X
Replacement	B-X
of	B-X
the	B-X
conserved	B-X
Asn	B-X
by	B-X
Ala	B-X
resulted	B-X
in	B-X
constitutive	B-X
p300	B-X
interaction	B-X
and	B-X
strong	B-X
transcriptional	B-X
activity	B-X
.	B-X
Full	B-X
induction	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
-2alpha	B-X
,	B-X
therefore	B-X
,	B-X
relies	B-X
on	B-X
the	B-X
abrogation	B-X
of	B-X
both	B-X
Pro	B-X
and	B-X
Asn	B-X
hydroxylation	B-X
,	B-X
which	B-X
during	B-X
normoxia	B-X
occur	B-X
at	B-X
the	B-X
degradation	B-X
and	B-X
COOH-terminal	B-X
transactivation	B-X
domains	B-X
,	B-X
respectively	B-X
.	B-X

Replacement	O
of	O
the	O
conserved	O
Asn	O
by	O
Ala	O
resulted	O
in	O
constitutive	O
p300	B-Protein
interaction	O
and	O
strong	O
transcriptional	O
activity	O
.	O
<EOS>	B-X
The	B-X
hypoxia-inducible	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
1alpha	B-X
and	B-X
2alpha	B-X
are	B-X
key	B-X
mammalian	B-X
transcription	B-X
factors	B-X
that	B-X
exhibit	B-X
dramatic	B-X
increases	B-X
in	B-X
both	B-X
protein	B-X
stability	B-X
and	B-X
intrinsic	B-X
transcriptional	B-X
potency	B-X
during	B-X
low-oxygen	B-X
stress	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
hypoxic	B-X
induction	B-X
of	B-X
the	B-X
COOH-terminal	B-X
transactivation	B-X
domain	B-X
(	B-X
CAD	B-X
)	B-X
of	B-X
HIF	B-X
occurs	B-X
through	B-X
abrogation	B-X
of	B-X
hydroxylation	B-X
of	B-X
a	B-X
conserved	B-X
asparagine	B-X
in	B-X
the	B-X
CAD	B-X
.	B-X
Inhibitors	B-X
of	B-X
Fe	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
2-oxoglutarate-dependent	B-X
dioxygenases	B-X
prevented	B-X
hydroxylation	B-X
of	B-X
the	B-X
Asn	B-X
,	B-X
thus	B-X
allowing	B-X
the	B-X
CAD	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
p300	B-X
transcription	B-X
coactivator	B-X
.	B-X
Replacement	B-X
of	B-X
the	B-X
conserved	B-X
Asn	B-X
by	B-X
Ala	B-X
resulted	B-X
in	B-X
constitutive	B-X
p300	B-X
interaction	B-X
and	B-X
strong	B-X
transcriptional	B-X
activity	B-X
.	B-X
Full	B-X
induction	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
-2alpha	B-X
,	B-X
therefore	B-X
,	B-X
relies	B-X
on	B-X
the	B-X
abrogation	B-X
of	B-X
both	B-X
Pro	B-X
and	B-X
Asn	B-X
hydroxylation	B-X
,	B-X
which	B-X
during	B-X
normoxia	B-X
occur	B-X
at	B-X
the	B-X
degradation	B-X
and	B-X
COOH-terminal	B-X
transactivation	B-X
domains	B-X
,	B-X
respectively	B-X
.	B-X

Full	O
induction	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
-	B-Protein
2alpha	I-Protein
,	O
therefore	O
,	O
relies	O
on	O
the	O
abrogation	O
of	O
both	O
Pro	O
and	O
Asn	O
hydroxylation	O
,	O
which	O
during	O
normoxia	O
occur	O
at	O
the	O
degradation	O
and	O
COOH	O
-	O
terminal	O
transactivation	O
domains	O
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
hypoxia-inducible	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
1alpha	B-X
and	B-X
2alpha	B-X
are	B-X
key	B-X
mammalian	B-X
transcription	B-X
factors	B-X
that	B-X
exhibit	B-X
dramatic	B-X
increases	B-X
in	B-X
both	B-X
protein	B-X
stability	B-X
and	B-X
intrinsic	B-X
transcriptional	B-X
potency	B-X
during	B-X
low-oxygen	B-X
stress	B-X
.	B-X
This	B-X
increased	B-X
stability	B-X
is	B-X
due	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
proline	B-X
hydroxylation	B-X
,	B-X
which	B-X
in	B-X
normoxia	B-X
promotes	B-X
binding	B-X
of	B-X
HIF	B-X
to	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
tumor	B-X
suppressor	B-X
)	B-X
ubiquitin	B-X
ligase	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
hypoxic	B-X
induction	B-X
of	B-X
the	B-X
COOH-terminal	B-X
transactivation	B-X
domain	B-X
(	B-X
CAD	B-X
)	B-X
of	B-X
HIF	B-X
occurs	B-X
through	B-X
abrogation	B-X
of	B-X
hydroxylation	B-X
of	B-X
a	B-X
conserved	B-X
asparagine	B-X
in	B-X
the	B-X
CAD	B-X
.	B-X
Inhibitors	B-X
of	B-X
Fe	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
2-oxoglutarate-dependent	B-X
dioxygenases	B-X
prevented	B-X
hydroxylation	B-X
of	B-X
the	B-X
Asn	B-X
,	B-X
thus	B-X
allowing	B-X
the	B-X
CAD	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
p300	B-X
transcription	B-X
coactivator	B-X
.	B-X
Replacement	B-X
of	B-X
the	B-X
conserved	B-X
Asn	B-X
by	B-X
Ala	B-X
resulted	B-X
in	B-X
constitutive	B-X
p300	B-X
interaction	B-X
and	B-X
strong	B-X
transcriptional	B-X
activity	B-X
.	B-X
Full	B-X
induction	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
-2alpha	B-X
,	B-X
therefore	B-X
,	B-X
relies	B-X
on	B-X
the	B-X
abrogation	B-X
of	B-X
both	B-X
Pro	B-X
and	B-X
Asn	B-X
hydroxylation	B-X
,	B-X
which	B-X
during	B-X
normoxia	B-X
occur	B-X
at	B-X
the	B-X
degradation	B-X
and	B-X
COOH-terminal	B-X
transactivation	B-X
domains	B-X
,	B-X
respectively	B-X
.	B-X

Polymorphism	O
of	O
the	O
N	B-Protein
-	I-Protein
acetyltransferase	I-Protein
2	I-Protein
gene	O
as	O
a	O
susceptibility	O
risk	O
factor	O
for	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
.	O

Antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
drug	O
-	O
induced	O
liver	O
injuries	O
.	O
<EOS>	B-X
Drug-induced	B-X
liver	B-X
injury	B-X
(	B-X
DILI	B-X
)	B-X
has	B-X
become	B-X
the	B-X
leading	B-X
cause	B-X
of	B-X
acute	B-X
liver	B-X
failure	B-X
in	B-X
Western	B-X
countries	B-X
,	B-X
and	B-X
pregnancy	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
risk	B-X
factor	B-X
,	B-X
but	B-X
only	B-X
few	B-X
anecdotal	B-X
reports	B-X
concerning	B-X
pregnant	B-X
women	B-X
are	B-X
found	B-X
.	B-X
Presentation	B-X
was	B-X
usually	B-X
in	B-X
the	B-X
first	B-X
20	B-X
weeks	B-X
of	B-X
gestation	B-X
following	B-X
a	B-X
latency	B-X
of	B-X
several	B-X
weeks	B-X
,	B-X
because	B-X
these	B-X
drugs	B-X
were	B-X
usually	B-X
prescribed	B-X
before	B-X
or	B-X
in	B-X
early	B-X
pregnancy	B-X
due	B-X
to	B-X
their	B-X
fetal	B-X
safety	B-X
.	B-X
The	B-X
hepatotoxicity	B-X
is	B-X
usually	B-X
of	B-X
the	B-X
idiosyncratic	B-X
form	B-X
,	B-X
and	B-X
most	B-X
would	B-X
resolve	B-X
spontaneously	B-X
although	B-X
occasional	B-X
liver	B-X
transplantation	B-X
and	B-X
maternal	B-X
death	B-X
were	B-X
reported	B-X
.	B-X
DILI	B-X
should	B-X
remain	B-X
one	B-X
of	B-X
the	B-X
differential	B-X
diagnoses	B-X
in	B-X
pregnant	B-X
women	B-X
with	B-X
hepatitis	B-X
.	B-X

Isoniazid	O
is	O
the	O
major	O
drug	O
incriminated	O
in	O
this	O
hepatotoxicity	O
.	O
<EOS>	B-X
Idiosyncratic	B-X
drug-induced	B-X
liver	B-X
injury	B-X
(	B-X
DILI	B-X
)	B-X
is	B-X
an	B-X
important	B-X
cause	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
following	B-X
drugs	B-X
taken	B-X
in	B-X
therapeutic	B-X
doses	B-X
.	B-X
Hepatotoxicity	B-X
is	B-X
a	B-X
leading	B-X
cause	B-X
of	B-X
attrition	B-X
in	B-X
drug	B-X
development	B-X
,	B-X
or	B-X
withdrawal	B-X
or	B-X
restricted	B-X
use	B-X
after	B-X
marketing	B-X
.	B-X
The	B-X
liver	B-X
specific	B-X
Roussel	B-X
Uclaf	B-X
Causality	B-X
Assessment	B-X
Method	B-X
is	B-X
the	B-X
most	B-X
validated	B-X
and	B-X
extensively	B-X
used	B-X
for	B-X
determining	B-X
the	B-X
likelihood	B-X
that	B-X
an	B-X
implicated	B-X
drug	B-X
caused	B-X
DILI	B-X
.	B-X
Antimicrobial	B-X
and	B-X
central	B-X
nervous	B-X
system	B-X
agents	B-X
including	B-X
antiepileptic	B-X
drugs	B-X
are	B-X
the	B-X
leading	B-X
causes	B-X
of	B-X
DILI	B-X
worldwide	B-X
.	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
antituberculosis	B-X
drugs	B-X
given	B-X
for	B-X
active	B-X
or	B-X
latent	B-X
disease	B-X
are	B-X
still	B-X
a	B-X
major	B-X
cause	B-X
of	B-X
drug-induced	B-X
liver	B-X
injury	B-X
in	B-X
India	B-X
and	B-X
the	B-X
West	B-X
respectively	B-X
.	B-X
The	B-X
pathogenesis	B-X
is	B-X
unclear	B-X
and	B-X
is	B-X
due	B-X
to	B-X
a	B-X
mix	B-X
of	B-X
host	B-X
,	B-X
drug	B-X
metabolite	B-X
and	B-X
environmental	B-X
factors	B-X
.	B-X
Immediate	B-X
cessation	B-X
of	B-X
the	B-X
drug	B-X
is	B-X
key	B-X
to	B-X
prevent	B-X
or	B-X
minimize	B-X
progressive	B-X
damage	B-X
.	B-X
This	B-X
article	B-X
provides	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
epidemiology	B-X
,	B-X
the	B-X
patterns	B-X
of	B-X
hepatotoxicity	B-X
,	B-X
the	B-X
pathogenesis	B-X
and	B-X
associated	B-X
risk	B-X
factors	B-X
besides	B-X
its	B-X
clinical	B-X
management	B-X
.	B-X

Isoniazid	O
is	O
mainly	O
metabolized	O
to	O
hepatotoxic	O
intermediates	O
by	O
N	O
-	O
acetyltransferase	O
(	O
NAT	O
)	O
.	O

However	O
,	O
the	O
association	O
of	O
polymorphic	O
NAT	O
acetylator	O
status	O
and	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
is	O
debatable	O
.	O
<EOS>	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
prevalent	B-X
drug-induced	B-X
liver	B-X
injuries	B-X
.	B-X
Isoniazid	B-X
is	B-X
the	B-X
major	B-X
drug	B-X
incriminated	B-X
in	B-X
this	B-X
hepatotoxicity	B-X
.	B-X
Isoniazid	B-X
is	B-X
mainly	B-X
metabolized	B-X
to	B-X
hepatotoxic	B-X
intermediates	B-X
by	B-X
N-acetyltransferase	B-X
(	B-X
NAT	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
association	B-X
of	B-X
polymorphic	B-X
NAT	B-X
acetylator	B-X
status	B-X
and	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
debatable	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
acetylator	B-X
status	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
,	B-X
we	B-X
genotyped	B-X
NAT2	B-X
in	B-X
224	B-X
incident	B-X
tuberculosis	B-X
patients	B-X
who	B-X
received	B-X
antituberculosis	B-X
treatment	B-X
.	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
was	B-X
diagnosed	B-X
based	B-X
on	B-X
a	B-X
positive	B-X
isoniazid	B-X
rechallenge	B-X
test	B-X
and	B-X
exclusion	B-X
of	B-X
viral	B-X
hepatitis	B-X
.	B-X
Acetylator	B-X
status	B-X
was	B-X
determined	B-X
by	B-X
genotyping	B-X
NAT2	B-X
in	B-X
patients	B-X
using	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
with	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
.	B-X
Univariate	B-X
analysis	B-X
and	B-X
logistic	B-X
regression	B-X
analysis	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
risk	B-X
factors	B-X
of	B-X
isoniazid-induced	B-X
hepatitis	B-X
.	B-X
Thirty-three	B-X
patients	B-X
(	B-X
14.7	B-X
%	B-X
)	B-X
were	B-X
diagnosed	B-X
with	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Slow	B-X
acetylators	B-X
had	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
(	B-X
26.4	B-X
%	B-X
vs.	B-X
11.1	B-X
%	B-X
,	B-X
P	B-X
=.013	B-X
)	B-X
.	B-X
Among	B-X
patients	B-X
with	B-X
hepatotoxicity	B-X
,	B-X
slow	B-X
acetylators	B-X
had	B-X
significantly	B-X
higher	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Additionally	B-X
,	B-X
slow	B-X
acetylators	B-X
are	B-X
prone	B-X
to	B-X
develop	B-X
more	B-X
severe	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Regular	B-X
monitoring	B-X
of	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
is	B-X
mandatory	B-X
in	B-X
patients	B-X
receiving	B-X
antituberculosis	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
slow	B-X
acetylators	B-X
.	B-X

To	O
determine	O
whether	O
acetylator	O
status	O
is	O
a	O
risk	O
factor	O
for	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
,	O
we	O
genotyped	O
NAT2	B-Protein
in	O
224	O
incident	O
tuberculosis	O
patients	O
who	O
received	O
antituberculosis	O
treatment	O
.	O
<EOS>	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
prevalent	B-X
drug-induced	B-X
liver	B-X
injuries	B-X
.	B-X
Isoniazid	B-X
is	B-X
the	B-X
major	B-X
drug	B-X
incriminated	B-X
in	B-X
this	B-X
hepatotoxicity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
association	B-X
of	B-X
polymorphic	B-X
NAT	B-X
acetylator	B-X
status	B-X
and	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
debatable	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
acetylator	B-X
status	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
,	B-X
we	B-X
genotyped	B-X
NAT2	B-X
in	B-X
224	B-X
incident	B-X
tuberculosis	B-X
patients	B-X
who	B-X
received	B-X
antituberculosis	B-X
treatment	B-X
.	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
was	B-X
diagnosed	B-X
based	B-X
on	B-X
a	B-X
positive	B-X
isoniazid	B-X
rechallenge	B-X
test	B-X
and	B-X
exclusion	B-X
of	B-X
viral	B-X
hepatitis	B-X
.	B-X
Acetylator	B-X
status	B-X
was	B-X
determined	B-X
by	B-X
genotyping	B-X
NAT2	B-X
in	B-X
patients	B-X
using	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
with	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
.	B-X
Univariate	B-X
analysis	B-X
and	B-X
logistic	B-X
regression	B-X
analysis	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
risk	B-X
factors	B-X
of	B-X
isoniazid-induced	B-X
hepatitis	B-X
.	B-X
Thirty-three	B-X
patients	B-X
(	B-X
14.7	B-X
%	B-X
)	B-X
were	B-X
diagnosed	B-X
with	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Slow	B-X
acetylators	B-X
had	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
(	B-X
26.4	B-X
%	B-X
vs.	B-X
11.1	B-X
%	B-X
,	B-X
P	B-X
=.013	B-X
)	B-X
.	B-X
Among	B-X
patients	B-X
with	B-X
hepatotoxicity	B-X
,	B-X
slow	B-X
acetylators	B-X
had	B-X
significantly	B-X
higher	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Additionally	B-X
,	B-X
slow	B-X
acetylators	B-X
are	B-X
prone	B-X
to	B-X
develop	B-X
more	B-X
severe	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Regular	B-X
monitoring	B-X
of	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
is	B-X
mandatory	B-X
in	B-X
patients	B-X
receiving	B-X
antituberculosis	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
slow	B-X
acetylators	B-X
.	B-X

Antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
was	O
diagnosed	O
based	O
on	O
a	O
positive	O
isoniazid	O
rechallenge	O
test	O
and	O
exclusion	O
of	O
viral	O
hepatitis	O
.	O
<EOS>	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
prevalent	B-X
drug-induced	B-X
liver	B-X
injuries	B-X
.	B-X
Isoniazid	B-X
is	B-X
the	B-X
major	B-X
drug	B-X
incriminated	B-X
in	B-X
this	B-X
hepatotoxicity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
association	B-X
of	B-X
polymorphic	B-X
NAT	B-X
acetylator	B-X
status	B-X
and	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
debatable	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
acetylator	B-X
status	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
,	B-X
we	B-X
genotyped	B-X
NAT2	B-X
in	B-X
224	B-X
incident	B-X
tuberculosis	B-X
patients	B-X
who	B-X
received	B-X
antituberculosis	B-X
treatment	B-X
.	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
was	B-X
diagnosed	B-X
based	B-X
on	B-X
a	B-X
positive	B-X
isoniazid	B-X
rechallenge	B-X
test	B-X
and	B-X
exclusion	B-X
of	B-X
viral	B-X
hepatitis	B-X
.	B-X
Univariate	B-X
analysis	B-X
and	B-X
logistic	B-X
regression	B-X
analysis	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
risk	B-X
factors	B-X
of	B-X
isoniazid-induced	B-X
hepatitis	B-X
.	B-X
Thirty-three	B-X
patients	B-X
(	B-X
14.7	B-X
%	B-X
)	B-X
were	B-X
diagnosed	B-X
with	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X

Acetylator	O
status	O
was	O
determined	O
by	O
genotyping	O
NAT2	B-Protein
in	O
patients	O
using	O
a	O
polymerase	O
chain	O
reaction	O
with	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
our	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
human	B-X
arylamine	B-X
N-acetyltransferase	B-X
2	B-X
(	B-X
NAT2	B-X
)	B-X
polymorphism	B-X
in	B-X
susceptibility	B-X
to	B-X
Behçet	B-X
's	B-X
disease	B-X
.	B-X
To	B-X
test	B-X
the	B-X
role	B-X
of	B-X
acetylator	B-X
status	B-X
,	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
reported	B-X
discrepancy	B-X
between	B-X
acetylator	B-X
phenotype	B-X
and	B-X
genotype	B-X
in	B-X
HIV-positive	B-X
patients	B-X
with	B-X
sulphamethoxazole	B-X
(	B-X
SMX	B-X
)	B-X
hypersensitivity	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
frequency	B-X
of	B-X
a	B-X
polymorphism	B-X
of	B-X
the	B-X
candidate	B-X
metabolic	B-X
enzyme	B-X
N-acetyltransferase-2	B-X
(	B-X
NAT2	B-X
)	B-X
in	B-X
Japanese	B-X
prostate	B-X
cancer	B-X
patients	B-X
and	B-X
Japanese	B-X
non-cancer	B-X
controls	B-X
,	B-X
in	B-X
order	B-X
to	B-X
determine	B-X
if	B-X
an	B-X
association	B-X
exists	B-X
between	B-X
NAT2	B-X
genotype	B-X
and	B-X
the	B-X
occurrence	B-X
,	B-X
clinical	B-X
stage	B-X
and	B-X
grade	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
There	B-X
are	B-X
inconsistent	B-X
reports	B-X
concerning	B-X
N-acetyltransferase	B-X
2	B-X
(	B-X
NAT2	B-X
)	B-X
genotypes	B-X
in	B-X
diabetes	B-X
mellitus	B-X
(	B-X
DM	B-X
)	B-X
.	B-X

Univariate	O
analysis	O
and	O
logistic	O
regression	O
analysis	O
were	O
used	O
to	O
evaluate	O
the	O
risk	O
factors	O
of	O
isoniazid	O
-	O
induced	O
hepatitis	O
.	O
<EOS>	B-X
Anti-TB	B-X
drugs	B-X
with	B-X
isoniazid	B-X
,	B-X
rifampicin	B-X
and	B-X
pyrazinamide	B-X
are	B-X
very	B-X
effective	B-X
but	B-X
they	B-X
can	B-X
cause	B-X
hepatotoxicity	B-X
.	B-X
Many	B-X
risk	B-X
factors	B-X
have	B-X
been	B-X
recognised	B-X
.	B-X
Data	B-X
on	B-X
prevalence	B-X
of	B-X
anti-TB	B-X
drug-induced	B-X
hepatitis	B-X
as	B-X
well	B-X
as	B-X
the	B-X
contributing	B-X
risk	B-X
factors	B-X
are	B-X
scarce	B-X
in	B-X
Malaysia	B-X
.	B-X
This	B-X
observational	B-X
case	B-X
control	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
look	B-X
at	B-X
the	B-X
prevalence	B-X
and	B-X
the	B-X
risk	B-X
factors	B-X
of	B-X
drug-induced	B-X
hepatitis	B-X
in	B-X
our	B-X
population	B-X
.	B-X

Thirty	O
-	O
three	O
patients	O
(	O
14	O
.	O
7	O
%	O
)	O
were	O
diagnosed	O
with	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
.	O
<EOS>	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
prevalent	B-X
drug-induced	B-X
liver	B-X
injuries	B-X
.	B-X
Isoniazid	B-X
is	B-X
the	B-X
major	B-X
drug	B-X
incriminated	B-X
in	B-X
this	B-X
hepatotoxicity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
association	B-X
of	B-X
polymorphic	B-X
NAT	B-X
acetylator	B-X
status	B-X
and	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
debatable	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
acetylator	B-X
status	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
,	B-X
we	B-X
genotyped	B-X
NAT2	B-X
in	B-X
224	B-X
incident	B-X
tuberculosis	B-X
patients	B-X
who	B-X
received	B-X
antituberculosis	B-X
treatment	B-X
.	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
was	B-X
diagnosed	B-X
based	B-X
on	B-X
a	B-X
positive	B-X
isoniazid	B-X
rechallenge	B-X
test	B-X
and	B-X
exclusion	B-X
of	B-X
viral	B-X
hepatitis	B-X
.	B-X
Acetylator	B-X
status	B-X
was	B-X
determined	B-X
by	B-X
genotyping	B-X
NAT2	B-X
in	B-X
patients	B-X
using	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
with	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
.	B-X
Univariate	B-X
analysis	B-X
and	B-X
logistic	B-X
regression	B-X
analysis	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
risk	B-X
factors	B-X
of	B-X
isoniazid-induced	B-X
hepatitis	B-X
.	B-X
Thirty-three	B-X
patients	B-X
(	B-X
14.7	B-X
%	B-X
)	B-X
were	B-X
diagnosed	B-X
with	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Among	B-X
patients	B-X
with	B-X
hepatotoxicity	B-X
,	B-X
slow	B-X
acetylators	B-X
had	B-X
significantly	B-X
higher	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Regular	B-X
monitoring	B-X
of	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
is	B-X
mandatory	B-X
in	B-X
patients	B-X
receiving	B-X
antituberculosis	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
slow	B-X
acetylators	B-X
.	B-X

Slow	O
acetylators	O
had	O
a	O
higher	O
risk	O
of	O
hepatotoxicity	O
than	O
rapid	O
acetylators	O
(	O
26	O
.	O
4	O
%	O
vs	O
.	O
11	O
.	O
1	O
%	O
,	O
P	O
=	O
.	O
013	O
)	O
.	O
<EOS>	B-X
Isoniazid	B-X
is	B-X
the	B-X
major	B-X
drug	B-X
incriminated	B-X
in	B-X
this	B-X
hepatotoxicity	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
acetylator	B-X
status	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
,	B-X
we	B-X
genotyped	B-X
NAT2	B-X
in	B-X
224	B-X
incident	B-X
tuberculosis	B-X
patients	B-X
who	B-X
received	B-X
antituberculosis	B-X
treatment	B-X
.	B-X
Univariate	B-X
analysis	B-X
and	B-X
logistic	B-X
regression	B-X
analysis	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
risk	B-X
factors	B-X
of	B-X
isoniazid-induced	B-X
hepatitis	B-X
.	B-X
Thirty-three	B-X
patients	B-X
(	B-X
14.7	B-X
%	B-X
)	B-X
were	B-X
diagnosed	B-X
with	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Slow	B-X
acetylators	B-X
had	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
(	B-X
26.4	B-X
%	B-X
vs.	B-X
11.1	B-X
%	B-X
,	B-X
P	B-X
=.013	B-X
)	B-X
.	B-X
Among	B-X
patients	B-X
with	B-X
hepatotoxicity	B-X
,	B-X
slow	B-X
acetylators	B-X
had	B-X
significantly	B-X
higher	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Additionally	B-X
,	B-X
slow	B-X
acetylators	B-X
are	B-X
prone	B-X
to	B-X
develop	B-X
more	B-X
severe	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Regular	B-X
monitoring	B-X
of	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
is	B-X
mandatory	B-X
in	B-X
patients	B-X
receiving	B-X
antituberculosis	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
slow	B-X
acetylators	B-X
.	B-X

Among	O
patients	O
with	O
hepatotoxicity	O
,	O
slow	O
acetylators	O
had	O
significantly	O
higher	O
serum	O
aminotransferase	O
levels	O
than	O
rapid	O
acetylators	O
.	O
<EOS>	B-X
Isoniazid	B-X
is	B-X
the	B-X
major	B-X
drug	B-X
incriminated	B-X
in	B-X
this	B-X
hepatotoxicity	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
acetylator	B-X
status	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
,	B-X
we	B-X
genotyped	B-X
NAT2	B-X
in	B-X
224	B-X
incident	B-X
tuberculosis	B-X
patients	B-X
who	B-X
received	B-X
antituberculosis	B-X
treatment	B-X
.	B-X
Acetylator	B-X
status	B-X
was	B-X
determined	B-X
by	B-X
genotyping	B-X
NAT2	B-X
in	B-X
patients	B-X
using	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
with	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
.	B-X
Thirty-three	B-X
patients	B-X
(	B-X
14.7	B-X
%	B-X
)	B-X
were	B-X
diagnosed	B-X
with	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Slow	B-X
acetylators	B-X
had	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
(	B-X
26.4	B-X
%	B-X
vs.	B-X
11.1	B-X
%	B-X
,	B-X
P	B-X
=.013	B-X
)	B-X
.	B-X
Among	B-X
patients	B-X
with	B-X
hepatotoxicity	B-X
,	B-X
slow	B-X
acetylators	B-X
had	B-X
significantly	B-X
higher	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Additionally	B-X
,	B-X
slow	B-X
acetylators	B-X
are	B-X
prone	B-X
to	B-X
develop	B-X
more	B-X
severe	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Regular	B-X
monitoring	B-X
of	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
is	B-X
mandatory	B-X
in	B-X
patients	B-X
receiving	B-X
antituberculosis	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
slow	B-X
acetylators	B-X
.	B-X

Logistic	O
regression	O
showed	O
that	O
slow	O
-	O
acetylator	O
status	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
3	O
.	O
66	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
58	O
-	O
8	O
.	O
49	O
;	O
P	O
=	O
.	O
003	O
)	O
and	O
age	O
(	O
OR	O
,	O
1	O
.	O
09	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
04	O
-	O
1	O
.	O
14	O
;	O
P	O
<	O
.	O
001	O
)	O
were	O
the	O
only	O
2	O
independent	O
risk	O
factors	O
for	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
.	O
<EOS>	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
prevalent	B-X
drug-induced	B-X
liver	B-X
injuries	B-X
.	B-X
Isoniazid	B-X
is	B-X
the	B-X
major	B-X
drug	B-X
incriminated	B-X
in	B-X
this	B-X
hepatotoxicity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
association	B-X
of	B-X
polymorphic	B-X
NAT	B-X
acetylator	B-X
status	B-X
and	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
debatable	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
acetylator	B-X
status	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
,	B-X
we	B-X
genotyped	B-X
NAT2	B-X
in	B-X
224	B-X
incident	B-X
tuberculosis	B-X
patients	B-X
who	B-X
received	B-X
antituberculosis	B-X
treatment	B-X
.	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
was	B-X
diagnosed	B-X
based	B-X
on	B-X
a	B-X
positive	B-X
isoniazid	B-X
rechallenge	B-X
test	B-X
and	B-X
exclusion	B-X
of	B-X
viral	B-X
hepatitis	B-X
.	B-X
Acetylator	B-X
status	B-X
was	B-X
determined	B-X
by	B-X
genotyping	B-X
NAT2	B-X
in	B-X
patients	B-X
using	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
with	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
.	B-X
Univariate	B-X
analysis	B-X
and	B-X
logistic	B-X
regression	B-X
analysis	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
risk	B-X
factors	B-X
of	B-X
isoniazid-induced	B-X
hepatitis	B-X
.	B-X
Thirty-three	B-X
patients	B-X
(	B-X
14.7	B-X
%	B-X
)	B-X
were	B-X
diagnosed	B-X
with	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Slow	B-X
acetylators	B-X
had	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
(	B-X
26.4	B-X
%	B-X
vs.	B-X
11.1	B-X
%	B-X
,	B-X
P	B-X
=.013	B-X
)	B-X
.	B-X
Among	B-X
patients	B-X
with	B-X
hepatotoxicity	B-X
,	B-X
slow	B-X
acetylators	B-X
had	B-X
significantly	B-X
higher	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Additionally	B-X
,	B-X
slow	B-X
acetylators	B-X
are	B-X
prone	B-X
to	B-X
develop	B-X
more	B-X
severe	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Regular	B-X
monitoring	B-X
of	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
is	B-X
mandatory	B-X
in	B-X
patients	B-X
receiving	B-X
antituberculosis	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
slow	B-X
acetylators	B-X
.	B-X

In	O
conclusion	O
,	O
slow	O
-	O
acetylator	O
status	O
of	O
NAT2	B-Protein
is	O
a	O
significant	O
susceptibility	O
risk	O
factor	O
for	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
.	O
<EOS>	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
prevalent	B-X
drug-induced	B-X
liver	B-X
injuries	B-X
.	B-X
Isoniazid	B-X
is	B-X
the	B-X
major	B-X
drug	B-X
incriminated	B-X
in	B-X
this	B-X
hepatotoxicity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
association	B-X
of	B-X
polymorphic	B-X
NAT	B-X
acetylator	B-X
status	B-X
and	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
debatable	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
acetylator	B-X
status	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
,	B-X
we	B-X
genotyped	B-X
NAT2	B-X
in	B-X
224	B-X
incident	B-X
tuberculosis	B-X
patients	B-X
who	B-X
received	B-X
antituberculosis	B-X
treatment	B-X
.	B-X
Antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
was	B-X
diagnosed	B-X
based	B-X
on	B-X
a	B-X
positive	B-X
isoniazid	B-X
rechallenge	B-X
test	B-X
and	B-X
exclusion	B-X
of	B-X
viral	B-X
hepatitis	B-X
.	B-X
Acetylator	B-X
status	B-X
was	B-X
determined	B-X
by	B-X
genotyping	B-X
NAT2	B-X
in	B-X
patients	B-X
using	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
with	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
.	B-X
Univariate	B-X
analysis	B-X
and	B-X
logistic	B-X
regression	B-X
analysis	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
risk	B-X
factors	B-X
of	B-X
isoniazid-induced	B-X
hepatitis	B-X
.	B-X
Thirty-three	B-X
patients	B-X
(	B-X
14.7	B-X
%	B-X
)	B-X
were	B-X
diagnosed	B-X
with	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Slow	B-X
acetylators	B-X
had	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
(	B-X
26.4	B-X
%	B-X
vs.	B-X
11.1	B-X
%	B-X
,	B-X
P	B-X
=.013	B-X
)	B-X
.	B-X
Among	B-X
patients	B-X
with	B-X
hepatotoxicity	B-X
,	B-X
slow	B-X
acetylators	B-X
had	B-X
significantly	B-X
higher	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Additionally	B-X
,	B-X
slow	B-X
acetylators	B-X
are	B-X
prone	B-X
to	B-X
develop	B-X
more	B-X
severe	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Regular	B-X
monitoring	B-X
of	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
is	B-X
mandatory	B-X
in	B-X
patients	B-X
receiving	B-X
antituberculosis	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
slow	B-X
acetylators	B-X
.	B-X

Additionally	O
,	O
slow	O
acetylators	O
are	O
prone	O
to	O
develop	O
more	O
severe	O
hepatotoxicity	O
than	O
rapid	O
acetylators	O
.	O
<EOS>	B-X
Isoniazid	B-X
is	B-X
the	B-X
major	B-X
drug	B-X
incriminated	B-X
in	B-X
this	B-X
hepatotoxicity	B-X
.	B-X
Slow	B-X
acetylators	B-X
had	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
(	B-X
26.4	B-X
%	B-X
vs.	B-X
11.1	B-X
%	B-X
,	B-X
P	B-X
=.013	B-X
)	B-X
.	B-X
Among	B-X
patients	B-X
with	B-X
hepatotoxicity	B-X
,	B-X
slow	B-X
acetylators	B-X
had	B-X
significantly	B-X
higher	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Additionally	B-X
,	B-X
slow	B-X
acetylators	B-X
are	B-X
prone	B-X
to	B-X
develop	B-X
more	B-X
severe	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Regular	B-X
monitoring	B-X
of	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
is	B-X
mandatory	B-X
in	B-X
patients	B-X
receiving	B-X
antituberculosis	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
slow	B-X
acetylators	B-X
.	B-X

Regular	O
monitoring	O
of	O
serum	O
aminotransferase	O
levels	O
is	O
mandatory	O
in	O
patients	O
receiving	O
antituberculosis	O
treatment	O
,	O
especially	O
in	O
slow	O
acetylators	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
association	B-X
of	B-X
polymorphic	B-X
NAT	B-X
acetylator	B-X
status	B-X
and	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
is	B-X
debatable	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
acetylator	B-X
status	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
,	B-X
we	B-X
genotyped	B-X
NAT2	B-X
in	B-X
224	B-X
incident	B-X
tuberculosis	B-X
patients	B-X
who	B-X
received	B-X
antituberculosis	B-X
treatment	B-X
.	B-X
Acetylator	B-X
status	B-X
was	B-X
determined	B-X
by	B-X
genotyping	B-X
NAT2	B-X
in	B-X
patients	B-X
using	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
with	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
.	B-X
Thirty-three	B-X
patients	B-X
(	B-X
14.7	B-X
%	B-X
)	B-X
were	B-X
diagnosed	B-X
with	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Slow	B-X
acetylators	B-X
had	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
(	B-X
26.4	B-X
%	B-X
vs.	B-X
11.1	B-X
%	B-X
,	B-X
P	B-X
=.013	B-X
)	B-X
.	B-X
Among	B-X
patients	B-X
with	B-X
hepatotoxicity	B-X
,	B-X
slow	B-X
acetylators	B-X
had	B-X
significantly	B-X
higher	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Logistic	B-X
regression	B-X
showed	B-X
that	B-X
slow-acetylator	B-X
status	B-X
(	B-X
odds	B-X
ratio	B-X
[	B-X
OR	B-X
]	B-X
,	B-X
3.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.58-8.49	B-X
;	B-X
P	B-X
=.003	B-X
)	B-X
and	B-X
age	B-X
(	B-X
OR	B-X
,	B-X
1.09	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.04-1.14	B-X
;	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
were	B-X
the	B-X
only	B-X
2	B-X
independent	B-X
risk	B-X
factors	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
slow-acetylator	B-X
status	B-X
of	B-X
NAT2	B-X
is	B-X
a	B-X
significant	B-X
susceptibility	B-X
risk	B-X
factor	B-X
for	B-X
antituberculosis	B-X
drug-induced	B-X
hepatitis	B-X
.	B-X
Additionally	B-X
,	B-X
slow	B-X
acetylators	B-X
are	B-X
prone	B-X
to	B-X
develop	B-X
more	B-X
severe	B-X
hepatotoxicity	B-X
than	B-X
rapid	B-X
acetylators	B-X
.	B-X
Regular	B-X
monitoring	B-X
of	B-X
serum	B-X
aminotransferase	B-X
levels	B-X
is	B-X
mandatory	B-X
in	B-X
patients	B-X
receiving	B-X
antituberculosis	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
slow	B-X
acetylators	B-X
.	B-X

Reversal	O
of	O
tolerance	O
induced	O
by	O
transplantation	O
of	O
skin	O
expressing	O
the	O
immunodominant	O
T	O
cell	O
epitope	O
of	O
rat	O
type	B-Protein
II	I-Protein
collagen	I-Protein
entitles	O
development	O
of	O
collagen	O
-	O
induced	O
arthritis	O
but	O
not	O
graft	O
rejection	O
.	O

Collagen	O
-	O
induced	O
arthritis	O
(	O
CIA	O
)	O
is	O
induced	O
in	O
H	O
-	O
2	O
(	O
q	O
)	O
mice	O
after	O
immunization	O
with	O
rat	O
type	B-Protein
II	I-Protein
collagen	I-Protein
(	O
CII	B-Protein
)	O
.	O

The	O
immunodominant	O
T	O
cell	O
epitope	O
on	O
heterologous	O
CII	B-Protein
has	O
been	O
located	O
to	O
CII256	B-Protein
-	O
270	O
.	O
<EOS>	B-X
Collagen-induced	B-X
arthritis	B-X
(	B-X
CIA	B-X
)	B-X
is	B-X
induced	B-X
in	B-X
H-2	B-X
(	B-X
q	B-X
)	B-X
mice	B-X
after	B-X
immunization	B-X
with	B-X
rat	B-X
type	B-X
II	B-X
collagen	B-X
(	B-X
CII	B-X
)	B-X
.	B-X
The	B-X
immunodominant	B-X
T	B-X
cell	B-X
epitope	B-X
on	B-X
heterologous	B-X
CII	B-X
has	B-X
been	B-X
located	B-X
to	B-X
CII256-270	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
TSC	B-X
transgenic	B-X
mice	B-X
,	B-X
which	B-X
express	B-X
the	B-X
heterologous	B-X
epitope	B-X
in	B-X
type	B-X
I	B-X
collagen	B-X
(	B-X
CI	B-X
)	B-X
,	B-X
e.g	B-X
.	B-X
in	B-X
skin	B-X
,	B-X
are	B-X
tolerized	B-X
against	B-X
rat	B-X
CII	B-X
and	B-X
resistant	B-X
to	B-X
CIA	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
transplanted	B-X
skin	B-X
from	B-X
TSC	B-X
transgenic	B-X
mice	B-X
onto	B-X
non-transgenic	B-X
CIA-susceptible	B-X
littermates	B-X
to	B-X
investigate	B-X
whether	B-X
introduction	B-X
of	B-X
this	B-X
epitope	B-X
to	B-X
a	B-X
naïve	B-X
immune	B-X
system	B-X
would	B-X
lead	B-X
to	B-X
T	B-X
cell	B-X
priming	B-X
and	B-X
graft	B-X
rejection	B-X
or	B-X
instead	B-X
to	B-X
tolerance	B-X
and	B-X
arthritis	B-X
protection	B-X
.	B-X
Interestingly	B-X
,	B-X
TSC	B-X
grafts	B-X
were	B-X
accepted	B-X
and	B-X
not	B-X
even	B-X
immunization	B-X
of	B-X
recipient	B-X
mice	B-X
with	B-X
CII	B-X
in	B-X
adjuvant	B-X
induced	B-X
graft	B-X
rejection	B-X
.	B-X
Instead	B-X
,	B-X
TSC	B-X
skin	B-X
recipients	B-X
displayed	B-X
a	B-X
reduced	B-X
T	B-X
and	B-X
B	B-X
cell	B-X
response	B-X
to	B-X
CII	B-X
and	B-X
were	B-X
also	B-X
protected	B-X
from	B-X
arthritis	B-X
.	B-X
However	B-X
,	B-X
additional	B-X
priming	B-X
could	B-X
break	B-X
arthritis	B-X
protection	B-X
and	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
increased	B-X
T	B-X
cell	B-X
response	B-X
to	B-X
the	B-X
grafted	B-X
epitope	B-X
.	B-X
Strikingly	B-X
,	B-X
despite	B-X
the	B-X
regained	B-X
T	B-X
cell	B-X
response	B-X
,	B-X
development	B-X
of	B-X
arthritis	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
graft	B-X
rejection	B-X
,	B-X
showing	B-X
that	B-X
these	B-X
immune-mediated	B-X
inflammatory	B-X
responses	B-X
involve	B-X
different	B-X
mechanisms	B-X
.	B-X

We	O
have	O
previously	O
shown	O
that	O
TSC	O
transgenic	O
mice	O
,	O
which	O
express	O
the	O
heterologous	O
epitope	O
in	O
type	O
I	O
collagen	O
(	O
CI	O
)	O
,	O
e	O
.	O
g	O
.	O
in	O
skin	O
,	O
are	O
tolerized	O
against	O
rat	O
CII	B-Protein
and	O
resistant	O
to	O
CIA	O
.	O

In	O
this	O
study	O
we	O
transplanted	O
skin	O
from	O
TSC	O
transgenic	O
mice	O
onto	O
non	O
-	O
transgenic	O
CIA	O
-	O
susceptible	O
littermates	O
to	O
investigate	O
whether	O
introduction	O
of	O
this	O
epitope	O
to	O
a	O
naive	O
immune	O
system	O
would	O
lead	O
to	O
T	O
cell	O
priming	O
and	O
graft	O
rejection	O
or	O
instead	O
to	O
tolerance	O
and	O
arthritis	O
protection	O
.	O
<EOS>	B-X
Rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
is	B-X
a	B-X
common	B-X
,	B-X
chronic	B-X
,	B-X
systemic	B-X
autoimmune	B-X
disease	B-X
,	B-X
and	B-X
its	B-X
clinical	B-X
features	B-X
are	B-X
the	B-X
proliferation	B-X
of	B-X
joint	B-X
synovial	B-X
tissue	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
pannus	B-X
and	B-X
the	B-X
destruction	B-X
of	B-X
cartilage	B-X
.	B-X
The	B-X
basic	B-X
feature	B-X
of	B-X
RA	B-X
is	B-X
the	B-X
body	B-X
's	B-X
immune	B-X
system	B-X
disorders	B-X
,	B-X
in	B-X
which	B-X
autoreactive	B-X
CD4	B-X
Overexpression	B-X
of	B-X
the	B-X
triggering	B-X
receptor	B-X
expressed	B-X
on	B-X
myeloid	B-X
cells	B-X
2	B-X
(	B-X
TREM2	B-X
)	B-X
reportedly	B-X
increases	B-X
adiposity	B-X
,	B-X
worsening	B-X
health	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
that	B-X
in	B-X
mice	B-X
,	B-X
TREM2	B-X
deficiency	B-X
aggravated	B-X
diet-induced	B-X
insulin	B-X
resistance	B-X
and	B-X
hepatic	B-X
steatosis	B-X
independently	B-X
of	B-X
fat	B-X
and	B-X
cholesterol	B-X
levels	B-X
.	B-X
Remarkably	B-X
,	B-X
while	B-X
inhibiting	B-X
ceramide	B-X
synthesis	B-X
exerted	B-X
no	B-X
influences	B-X
on	B-X
TREM2-dependent	B-X
ATM	B-X
remodeling	B-X
,	B-X
inflammation	B-X
,	B-X
or	B-X
lipid	B-X
load	B-X
,	B-X
it	B-X
restored	B-X
insulin	B-X
tolerance	B-X
,	B-X
reversing	B-X
adipose	B-X
hypertrophy	B-X
and	B-X
secondary	B-X
hepatic	B-X
steatosis	B-X
of	B-X
TREM2-deficient	B-X
animals	B-X
.	B-X
Bone	B-X
marrow	B-X
transplantation	B-X
experiments	B-X
revealed	B-X
unremarkable	B-X
influences	B-X
of	B-X
immune	B-X
cell-expressed	B-X
TREM2	B-X
on	B-X
health	B-X
,	B-X
instead	B-X
demonstrating	B-X
that	B-X
WAT-intrinsic	B-X
mechanisms	B-X
impinging	B-X
on	B-X
sphingolipid	B-X
metabolism	B-X
dominate	B-X
in	B-X
the	B-X
systemic	B-X
protective	B-X
effects	B-X
of	B-X
TREM2	B-X
on	B-X
metabolic	B-X
health	B-X
.	B-X

Interestingly	O
,	O
TSC	O
grafts	O
were	O
accepted	O
and	O
not	O
even	O
immunization	O
of	O
recipient	O
mice	O
with	O
CII	B-Protein
in	O
adjuvant	O
induced	O
graft	O
rejection	O
.	O

Instead	O
,	O
TSC	O
skin	O
recipients	O
displayed	O
a	O
reduced	O
T	O
and	O
B	O
cell	O
response	O
to	O
CII	B-Protein
and	O
were	O
also	O
protected	O
from	O
arthritis	O
.	O

However	O
,	O
additional	O
priming	O
could	O
break	O
arthritis	O
protection	O
and	O
was	O
accompanied	O
by	O
an	O
increased	O
T	O
cell	O
response	O
to	O
the	O
grafted	O
epitope	O
.	O

Strikingly	O
,	O
despite	O
the	O
regained	O
T	O
cell	O
response	O
,	O
development	O
of	O
arthritis	O
was	O
not	O
accompanied	O
by	O
graft	O
rejection	O
,	O
showing	O
that	O
these	O
immune	O
-	O
mediated	O
inflammatory	O
responses	O
involve	O
different	O
mechanisms	O
.	O

Glucocorticoid	O
regulation	O
and	O
glycosylation	O
of	O
mouse	O
intestinal	O
type	B-Protein
IIb	I-Protein
Na	I-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
cotransporter	I-Protein
during	O
ontogeny	O
.	O

We	O
sought	O
to	O
characterize	O
expression	O
of	O
an	O
apically	O
expressed	O
intestinal	O
Na	O
-	O
P	O
(	O
i	O
)	O
cotransporter	O
(	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	I-Protein
)	O
during	O
mouse	O
ontogeny	O
and	O
to	O
assess	O
the	O
effects	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
treatment	O
.	O

In	O
control	O
mice	O
,	O
Na	O
-	O
P	O
(	O
i	O
)	O
uptake	O
by	O
intestinal	O
brush	O
-	O
border	O
membrane	O
vesicles	O
was	O
highest	O
at	O
14	O
days	O
of	O
age	O
,	O
lower	O
at	O
21	O
days	O
,	O
and	O
further	O
reduced	O
at	O
8	O
wk	O
and	O
8	O
-	O
9	O
mo	O
of	O
age	O
.	O

Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	I-Protein
mRNA	O
and	O
immunoreactive	O
protein	O
levels	O
in	O
14	O
-	O
day	O
-	O
old	O
animals	O
were	O
markedly	O
higher	O
than	O
in	O
older	O
groups	O
.	O

MP	O
treatment	O
significantly	O
decreased	O
Na	O
-	O
P	O
(	O
i	O
)	O
uptake	O
and	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	I-Protein
mRNA	O
and	O
protein	O
expression	O
in	O
14	O
-	O
day	O
-	O
old	O
mice	O
.	O

Additionally	O
,	O
the	O
size	O
of	O
the	O
protein	O
was	O
smaller	O
in	O
14	O
-	O
day	O
-	O
old	O
mice	O
.	O
<EOS>	B-X
In	B-X
control	B-X
mice	B-X
,	B-X
Na-P	B-X
(	B-X
i	B-X
)	B-X
uptake	B-X
by	B-X
intestinal	B-X
brush-border	B-X
membrane	B-X
vesicles	B-X
was	B-X
highest	B-X
at	B-X
14	B-X
days	B-X
of	B-X
age	B-X
,	B-X
lower	B-X
at	B-X
21	B-X
days	B-X
,	B-X
and	B-X
further	B-X
reduced	B-X
at	B-X
8	B-X
wk	B-X
and	B-X
8-9	B-X
mo	B-X
of	B-X
age	B-X
.	B-X
Na-P	B-X
(	B-X
i	B-X
)	B-X
-IIb	B-X
mRNA	B-X
and	B-X
immunoreactive	B-X
protein	B-X
levels	B-X
in	B-X
14-day-old	B-X
animals	B-X
were	B-X
markedly	B-X
higher	B-X
than	B-X
in	B-X
older	B-X
groups	B-X
.	B-X
MP	B-X
treatment	B-X
significantly	B-X
decreased	B-X
Na-P	B-X
(	B-X
i	B-X
)	B-X
uptake	B-X
and	B-X
Na-P	B-X
(	B-X
i	B-X
)	B-X
-IIb	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
in	B-X
14-day-old	B-X
mice	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
size	B-X
of	B-X
the	B-X
protein	B-X
was	B-X
smaller	B-X
in	B-X
14-day-old	B-X
mice	B-X
.	B-X
Deglycosylation	B-X
of	B-X
protein	B-X
from	B-X
14-day-old	B-X
and	B-X
8-wk-old	B-X
animals	B-X
with	B-X
peptide	B-X
N-glycosidase	B-X
reduced	B-X
the	B-X
molecular	B-X
weight	B-X
to	B-X
the	B-X
predicted	B-X
size	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
intestinal	B-X
Na-P	B-X
(	B-X
i	B-X
)	B-X
uptake	B-X
and	B-X
Na-P	B-X
(	B-X
i	B-X
)	B-X
-IIb	B-X
expression	B-X
are	B-X
highest	B-X
at	B-X
14	B-X
days	B-X
and	B-X
decrease	B-X
with	B-X
age	B-X
.	B-X
Furthermore	B-X
,	B-X
MP	B-X
treatment	B-X
reduced	B-X
intestinal	B-X
Na-P	B-X
(	B-X
i	B-X
)	B-X
uptake	B-X
approximately	B-X
threefold	B-X
in	B-X
14-day-old	B-X
mice	B-X
and	B-X
this	B-X
reduction	B-X
correlates	B-X
with	B-X
reduced	B-X
Na-P	B-X
(	B-X
i	B-X
)	B-X
-IIb	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
.	B-X
We	B-X
also	B-X
demonstrate	B-X
that	B-X
Na-P	B-X
(	B-X
i	B-X
)	B-X
-IIb	B-X
is	B-X
an	B-X
N-linked	B-X
glycoprotein	B-X
and	B-X
that	B-X
glycosylation	B-X
is	B-X
age	B-X
dependent	B-X
.	B-X

Deglycosylation	O
of	O
protein	O
from	O
14	O
-	O
day	O
-	O
old	O
and	O
8	O
-	O
wk	O
-	O
old	O
animals	O
with	O
peptide	O
N	O
-	O
glycosidase	O
reduced	O
the	O
molecular	O
weight	O
to	O
the	O
predicted	O
size	O
.	O

We	O
conclude	O
that	O
intestinal	O
Na	O
-	O
P	O
(	O
i	O
)	O
uptake	O
and	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	I-Protein
expression	O
are	O
highest	O
at	O
14	O
days	O
and	O
decrease	O
with	O
age	O
.	O

Furthermore	O
,	O
MP	O
treatment	O
reduced	O
intestinal	O
Na	O
-	O
P	O
(	O
i	O
)	O
uptake	O
approximately	O
threefold	O
in	O
14	O
-	O
day	O
-	O
old	O
mice	O
and	O
this	O
reduction	O
correlates	O
with	O
reduced	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	I-Protein
mRNA	O
and	O
protein	O
expression	O
.	O

We	O
also	O
demonstrate	O
that	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	I-Protein
is	O
an	O
N	O
-	O
linked	O
glycoprotein	O
and	O
that	O
glycosylation	O
is	O
age	O
dependent	O
.	O

The	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	I-Protein
protein	O
:	O
new	O
insights	O
into	O
oxygen	O
sensing	O
and	O
cancer	O
.	O
<EOS>	B-X
The	B-X
von	B-X
Hippel-Lindau	B-X
tumor	B-X
suppressor	B-X
protein	B-X
(	B-X
pVHL	B-X
)	B-X
is	B-X
the	B-X
substrate-recognition	B-X
module	B-X
of	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
targets	B-X
the	B-X
alpha	B-X
subunits	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
for	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
HIFalpha	B-X
family	B-X
members	B-X
are	B-X
hydroxylated	B-X
on	B-X
one	B-X
of	B-X
two	B-X
conserved	B-X
prolyl	B-X
residues	B-X
by	B-X
members	B-X
of	B-X
the	B-X
egg-laying-defective	B-X
nine	B-X
(	B-X
EGLN	B-X
)	B-X
family	B-X
.	B-X
Prolyl	B-X
hydroxylation	B-X
generates	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
containing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
protein	B-X
,	B-X
which	B-X
results	B-X
in	B-X
HIFalpha	B-X
destruction	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
new	B-X
mechanistic	B-X
insights	B-X
into	B-X
oxygen	B-X
sensing	B-X
by	B-X
metazoans	B-X
and	B-X
are	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
protein	B-X
hydroxylation	B-X
being	B-X
used	B-X
in	B-X
intracellular	B-X
signaling	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
three	B-X
human	B-X
EGLN	B-X
family	B-X
members	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
putative	B-X
hydroxylases	B-X
,	B-X
raises	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
signal	B-X
is	B-X
used	B-X
in	B-X
other	B-X
contexts	B-X
by	B-X
other	B-X
proteins	B-X
.	B-X

The	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	I-Protein
protein	O
(	O
pVHL	B-Protein
)	O
is	O
the	O
substrate	O
-	O
recognition	O
module	O
of	O
an	O
E3	O
ubiquitin	O
ligase	O
that	O
targets	O
the	O
alpha	O
subunits	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
for	O
degradation	O
in	O
the	O
presence	O
of	O
oxygen	O
.	O
<EOS>	B-X
The	B-X
von	B-X
Hippel-Lindau	B-X
tumor	B-X
suppressor	B-X
protein	B-X
(	B-X
pVHL	B-X
)	B-X
is	B-X
the	B-X
substrate-recognition	B-X
module	B-X
of	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
targets	B-X
the	B-X
alpha	B-X
subunits	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
for	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
.	B-X
Recognition	B-X
of	B-X
HIF	B-X
by	B-X
pVHL	B-X
is	B-X
linked	B-X
to	B-X
enzymatic	B-X
hydroxylation	B-X
of	B-X
conserved	B-X
prolyl	B-X
residues	B-X
in	B-X
the	B-X
HIF	B-X
alpha	B-X
subunits	B-X
by	B-X
members	B-X
of	B-X
the	B-X
EGLN	B-X
family	B-X
.	B-X
Dysregulation	B-X
of	B-X
HIF-target	B-X
genes	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
alpha	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
renal	B-X
cell	B-X
carcinomas	B-X
and	B-X
of	B-X
hemangioblastomas	B-X
,	B-X
both	B-X
of	B-X
which	B-X
frequently	B-X
lack	B-X
pVHL	B-X
function	B-X
.	B-X

Recognition	O
of	O
HIF	O
by	O
pVHL	B-Protein
is	O
linked	O
to	O
enzymatic	O
hydroxylation	O
of	O
conserved	O
prolyl	O
residues	O
in	O
the	O
HIF	O
alpha	O
subunits	O
by	O
members	O
of	O
the	O
EGLN	O
family	O
.	O
<EOS>	B-X
The	B-X
von	B-X
Hippel-Lindau	B-X
tumor	B-X
suppressor	B-X
protein	B-X
(	B-X
pVHL	B-X
)	B-X
is	B-X
the	B-X
substrate-recognition	B-X
module	B-X
of	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
targets	B-X
the	B-X
alpha	B-X
subunits	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
for	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
.	B-X
Recognition	B-X
of	B-X
HIF	B-X
by	B-X
pVHL	B-X
is	B-X
linked	B-X
to	B-X
enzymatic	B-X
hydroxylation	B-X
of	B-X
conserved	B-X
prolyl	B-X
residues	B-X
in	B-X
the	B-X
HIF	B-X
alpha	B-X
subunits	B-X
by	B-X
members	B-X
of	B-X
the	B-X
EGLN	B-X
family	B-X
.	B-X
Dysregulation	B-X
of	B-X
HIF-target	B-X
genes	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
alpha	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
renal	B-X
cell	B-X
carcinomas	B-X
and	B-X
of	B-X
hemangioblastomas	B-X
,	B-X
both	B-X
of	B-X
which	B-X
frequently	B-X
lack	B-X
pVHL	B-X
function	B-X
.	B-X

Dysregulation	O
of	O
HIF	O
-	O
target	O
genes	O
such	O
as	O
vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	I-Protein
and	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
alpha	I-Protein
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
renal	O
cell	O
carcinomas	O
and	O
of	O
hemangioblastomas	O
,	O
both	O
of	O
which	O
frequently	O
lack	O
pVHL	B-Protein
function	O
.	O
<EOS>	B-X
The	B-X
von	B-X
Hippel-Lindau	B-X
tumor	B-X
suppressor	B-X
protein	B-X
(	B-X
pVHL	B-X
)	B-X
is	B-X
the	B-X
substrate-recognition	B-X
module	B-X
of	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
targets	B-X
the	B-X
alpha	B-X
subunits	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
for	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
.	B-X
Recognition	B-X
of	B-X
HIF	B-X
by	B-X
pVHL	B-X
is	B-X
linked	B-X
to	B-X
enzymatic	B-X
hydroxylation	B-X
of	B-X
conserved	B-X
prolyl	B-X
residues	B-X
in	B-X
the	B-X
HIF	B-X
alpha	B-X
subunits	B-X
by	B-X
members	B-X
of	B-X
the	B-X
EGLN	B-X
family	B-X
.	B-X
Dysregulation	B-X
of	B-X
HIF-target	B-X
genes	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
alpha	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
renal	B-X
cell	B-X
carcinomas	B-X
and	B-X
of	B-X
hemangioblastomas	B-X
,	B-X
both	B-X
of	B-X
which	B-X
frequently	B-X
lack	B-X
pVHL	B-X
function	B-X
.	B-X

The	O
roles	O
of	O
supernumerical	O
X	O
chromosomes	O
and	O
XIST	B-Protein
expression	O
in	O
testicular	O
germ	O
cell	O
tumors	O
.	O
<EOS>	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
question	B-X
whether	B-X
the	B-X
multiple	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
are	B-X
active	B-X
or	B-X
inactive	B-X
through	B-X
a	B-X
complex	B-X
mechanism	B-X
of	B-X
X	B-X
chromosomal	B-X
gain	B-X
and	B-X
XIST	B-X
expression	B-X
.	B-X

PURPOSE	O
:	O
An	O
overabundance	O
of	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumors	O
and	O
the	O
identification	O
of	O
the	O
candidate	O
testicular	O
germ	O
cell	O
tumor	O
susceptibility	O
gene	O
TGCT1	B-Protein
on	O
Xq27	O
highlight	O
the	O
potential	O
involvement	O
of	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumor	O
pathogenesis	O
.	O
<EOS>	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
question	B-X
whether	B-X
the	B-X
multiple	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
are	B-X
active	B-X
or	B-X
inactive	B-X
through	B-X
a	B-X
complex	B-X
mechanism	B-X
of	B-X
X	B-X
chromosomal	B-X
gain	B-X
and	B-X
XIST	B-X
expression	B-X
.	B-X

The	O
current	O
study	O
was	O
designed	O
to	O
shed	O
light	O
on	O
the	O
question	O
whether	O
the	O
multiple	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumor	O
are	O
active	O
or	O
inactive	O
through	O
a	O
complex	O
mechanism	O
of	O
X	O
chromosomal	O
gain	O
and	O
XIST	B-Protein
expression	O
.	O
<EOS>	B-X
Silencing	B-X
most	B-X
gene	B-X
expression	B-X
from	B-X
all	B-X
but	B-X
one	B-X
X	B-X
chromosome	B-X
in	B-X
female	B-X
mammals	B-X
provides	B-X
a	B-X
means	B-X
to	B-X
overcome	B-X
X-linked	B-X
gene	B-X
expression	B-X
imbalances	B-X
with	B-X
males	B-X
.	B-X
Central	B-X
to	B-X
establishing	B-X
gene	B-X
silencing	B-X
on	B-X
the	B-X
inactivated	B-X
X	B-X
chromosome	B-X
are	B-X
the	B-X
actions	B-X
of	B-X
the	B-X
long	B-X
non-coding	B-X
RNA	B-X
XIST	B-X
that	B-X
triggers	B-X
the	B-X
repackaging	B-X
of	B-X
the	B-X
chosen	B-X
X	B-X
into	B-X
facultative	B-X
heterochromatin	B-X
.	B-X
While	B-X
understanding	B-X
the	B-X
mechanisms	B-X
through	B-X
which	B-X
XIST	B-X
expression	B-X
is	B-X
regulated	B-X
and	B-X
mediates	B-X
its	B-X
affects	B-X
has	B-X
been	B-X
a	B-X
major	B-X
focus	B-X
of	B-X
research	B-X
since	B-X
its	B-X
discovery	B-X
,	B-X
less	B-X
is	B-X
known	B-X
about	B-X
the	B-X
role	B-X
XIST	B-X
plays	B-X
in	B-X
maintaining	B-X
chromatin	B-X
at	B-X
the	B-X
human	B-X
inactive	B-X
X	B-X
chromosome	B-X
(	B-X
Xi	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
genome	B-X
engineering	B-X
to	B-X
delete	B-X
the	B-X
promoter	B-X
of	B-X
XIST	B-X
to	B-X
knockout	B-X
expression	B-X
from	B-X
the	B-X
Xi	B-X
in	B-X
non-cancerous	B-X
diploid	B-X
human	B-X
somatic	B-X
cells	B-X
.	B-X
Although	B-X
some	B-X
heterochromatin	B-X
features	B-X
exhibit	B-X
limited	B-X
change	B-X
at	B-X
the	B-X
Xi	B-X
,	B-X
two	B-X
of	B-X
those	B-X
assessed	B-X
showed	B-X
significant	B-X
reductions	B-X
including	B-X
histone	B-X
H2A	B-X
monoubiquitylation	B-X
at	B-X
lysine	B-X
119	B-X
and	B-X
histone	B-X
H3	B-X
trimethylation	B-X
at	B-X
lysine	B-X
27	B-X
,	B-X
both	B-X
of	B-X
which	B-X
are	B-X
covalent	B-X
histone	B-X
modifications	B-X
catalyzed	B-X
by	B-X
the	B-X
polycomb	B-X
repressive	B-X
complexes	B-X
1	B-X
and	B-X
2	B-X
respectively	B-X
.	B-X
Coupled	B-X
with	B-X
these	B-X
reductions	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
occasional	B-X
gain	B-X
of	B-X
euchromatin	B-X
signatures	B-X
on	B-X
Xp	B-X
,	B-X
but	B-X
despite	B-X
these	B-X
signs	B-X
of	B-X
chromatin	B-X
instability	B-X
,	B-X
we	B-X
did	B-X
not	B-X
observe	B-X
appreciable	B-X
changes	B-X
in	B-X
the	B-X
reactivation	B-X
of	B-X
genes	B-X
from	B-X
the	B-X
Xi	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
maintenance	B-X
of	B-X
dosage	B-X
compensation	B-X
at	B-X
the	B-X
Xi	B-X
involving	B-X
multiple	B-X
redundant	B-X
layers	B-X
of	B-X
gene	B-X
silencing	B-X
.	B-X

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
analyzed	O
4	O
testicular	O
germ	O
cell	O
tumor	O
derived	O
cell	O
lines	O
and	O
20	O
primary	O
testicular	O
germ	O
cell	O
tumor	O
tissues	O
.	O
<EOS>	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
question	B-X
whether	B-X
the	B-X
multiple	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
are	B-X
active	B-X
or	B-X
inactive	B-X
through	B-X
a	B-X
complex	B-X
mechanism	B-X
of	B-X
X	B-X
chromosomal	B-X
gain	B-X
and	B-X
XIST	B-X
expression	B-X
.	B-X

The	O
number	O
of	O
X	O
chromosomes	O
was	O
determined	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
using	O
the	O
X	O
chromosome	O
specific	O
probe	O
.	O
<EOS>	B-X
Current	B-X
molecular	B-X
approaches	B-X
to	B-X
characterize	B-X
unidentified	B-X
or	B-X
misidentified	B-X
tissue	B-X
include	B-X
fluorescence	B-X
in	B-X
situ	B-X
hybridization	B-X
identification	B-X
of	B-X
sex	B-X
chromosomes	B-X
(	B-X
XY	B-X
FISH	B-X
)	B-X
and	B-X
microsatellite	B-X
analysis	B-X
.	B-X
Polymorphic	B-X
deletion	B-X
probe	B-X
(	B-X
PDP	B-X
)	B-X
FISH	B-X
,	B-X
a	B-X
novel	B-X
FISH	B-X
assay	B-X
based	B-X
on	B-X
copy	B-X
number	B-X
variants	B-X
,	B-X
can	B-X
distinguish	B-X
between	B-X
cells	B-X
and	B-X
tissues	B-X
from	B-X
2	B-X
individuals	B-X
in	B-X
situ	B-X
,	B-X
independent	B-X
of	B-X
gender	B-X
.	B-X
XY	B-X
FISH	B-X
was	B-X
added	B-X
to	B-X
increase	B-X
the	B-X
informative	B-X
potential	B-X
of	B-X
the	B-X
assay	B-X
,	B-X
and	B-X
microsatellite	B-X
analysis	B-X
was	B-X
used	B-X
as	B-X
a	B-X
gold	B-X
standard	B-X
to	B-X
confirm	B-X
PDP	B-X
FISH	B-X
results	B-X
.	B-X
The	B-X
assay	B-X
has	B-X
a	B-X
sensitivity	B-X
and	B-X
specificity	B-X
of	B-X
86	B-X
%	B-X
[	B-X
6/7	B-X
,	B-X
exact	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
(	B-X
CI	B-X
)	B-X
:	B-X
42	B-X
%	B-X
,	B-X
97	B-X
%	B-X
]	B-X
and	B-X
100	B-X
%	B-X
(	B-X
9/9	B-X
,	B-X
exact	B-X
1-sided	B-X
97.5	B-X
%	B-X
CI	B-X
:	B-X
68	B-X
%	B-X
,	B-X
100	B-X
%	B-X
)	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
a	B-X
positive	B-X
predictive	B-X
value	B-X
and	B-X
negative	B-X
predictive	B-X
value	B-X
of	B-X
100	B-X
%	B-X
(	B-X
6/6	B-X
,	B-X
exact	B-X
1-sided	B-X
97.5	B-X
%	B-X
CI	B-X
:	B-X
54	B-X
%	B-X
,	B-X
100	B-X
%	B-X
)	B-X
and	B-X
90	B-X
%	B-X
(	B-X
9/10	B-X
,	B-X
exact	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
55	B-X
%	B-X
,	B-X
98	B-X
%	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X

The	O
expression	O
patterns	O
of	O
XIST	B-Protein
and	O
the	O
3	O
X	O
-	O
linked	O
genes	O
androgen	B-Protein
receptor	I-Protein
(	O
AR	B-Protein
)	O
,	O
fragile	O
X	O
mental	O
retardation	O
(	O
FMR1	B-Protein
)	O
and	O
Glypican	B-Protein
3	I-Protein
(	O
GPC3	B-Protein
)	O
were	O
studied	O
by	O
reverse	B-Protein
transcriptase	I-Protein
-	O
polymerase	O
chain	O
reaction	O
.	O
<EOS>	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
question	B-X
whether	B-X
the	B-X
multiple	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
are	B-X
active	B-X
or	B-X
inactive	B-X
through	B-X
a	B-X
complex	B-X
mechanism	B-X
of	B-X
X	B-X
chromosomal	B-X
gain	B-X
and	B-X
XIST	B-X
expression	B-X
.	B-X

Bisulfite	O
genomic	O
sequencing	O
was	O
used	O
to	O
analyze	O
the	O
methylation	O
patterns	O
of	O
the	O
AR	B-Protein
,	O
FMR1	B-Protein
and	O
GPC3	B-Protein
genes	O
.	O
<EOS>	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X

The	O
relative	O
expression	O
levels	O
of	O
the	O
2	O
X	O
-	O
linked	O
proto	O
-	O
oncogenes	O
ARAF1	B-Protein
and	O
ELK1	B-Protein
were	O
assayed	O
by	O
quantitative	O
reverse	B-Protein
transcriptase	I-Protein
-	O
polymerase	O
chain	O
reaction	O
.	O
<EOS>	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
question	B-X
whether	B-X
the	B-X
multiple	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
are	B-X
active	B-X
or	B-X
inactive	B-X
through	B-X
a	B-X
complex	B-X
mechanism	B-X
of	B-X
X	B-X
chromosomal	B-X
gain	B-X
and	B-X
XIST	B-X
expression	B-X
.	B-X

RESULTS	O
:	O
XIST	B-Protein
expression	O
was	O
common	O
in	O
seminomatous	O
testicular	O
germ	O
cell	O
tumors	O
(	O
2	O
of	O
2	O
or	O
100	O
%	O
of	O
seminoma	O
derived	O
cell	O
lines	O
and	O
10	O
of	O
12	O
or	O
83	O
%	O
of	O
seminomatous	O
testicular	O
germ	O
cell	O
tumor	O
tissues	O
)	O
but	O
not	O
in	O
nonseminomatous	O
testicular	O
germ	O
cell	O
tumors	O
(	O
0	O
of	O
2	O
or	O
0	O
%	O
nonseminoma	O
derived	O
cell	O
lines	O
and	O
2	O
of	O
8	O
or	O
25	O
%	O
of	O
nonseminomatous	O
testicular	O
germ	O
cell	O
tumor	O
tissues	O
)	O
.	O

However	O
,	O
X	O
chromosomal	O
gain	O
was	O
consistently	O
observed	O
in	O
the	O
2	O
types	O
of	O
tumors	O
.	O
<EOS>	B-X
The	B-X
CDKN2A/B	B-X
homozygous	B-X
deletion	B-X
for	B-X
IDH-mutant	B-X
astrocytoma	B-X
and	B-X
the	B-X
following	B-X
three	B-X
criteria	B-X
for	B-X
IDH-wild-type	B-X
astrocytoma	B-X
:	B-X
the	B-X
concurrent	B-X
gain	B-X
of	B-X
whole	B-X
chromosome	B-X
7	B-X
and	B-X
loss	B-X
of	B-X
whole	B-X
chromosome	B-X
10	B-X
,	B-X
TERT	B-X
promoter	B-X
mutations	B-X
,	B-X
and	B-X
EGFR	B-X
amplification	B-X
,	B-X
were	B-X
identified	B-X
as	B-X
independent	B-X
molecular	B-X
markers	B-X
of	B-X
the	B-X
worst	B-X
clinical	B-X
outcomes	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
2021	B-X
World	B-X
Health	B-X
Organization	B-X
(	B-X
WHO	B-X
)	B-X
Classification	B-X
of	B-X
Tumors	B-X
of	B-X
the	B-X
Central	B-X
Nervous	B-X
System	B-X
adopted	B-X
these	B-X
molecular	B-X
markers	B-X
into	B-X
the	B-X
revised	B-X
grading	B-X
criteria	B-X
of	B-X
IDH-mutant	B-X
and	B-X
-wild-type	B-X
astrocytoma	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
a	B-X
grading	B-X
system	B-X
within	B-X
tumor	B-X
types	B-X
.	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
question	B-X
whether	B-X
the	B-X
multiple	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
are	B-X
active	B-X
or	B-X
inactive	B-X
through	B-X
a	B-X
complex	B-X
mechanism	B-X
of	B-X
X	B-X
chromosomal	B-X
gain	B-X
and	B-X
XIST	B-X
expression	B-X
.	B-X

XIST	B-Protein
expression	O
in	O
testicular	O
germ	O
cell	O
tumors	O
and	O
normal	O
testicular	O
parenchyma	O
was	O
not	O
associated	O
with	O
methylation	O
of	O
the	O
AR	B-Protein
,	O
FMR1	B-Protein
or	O
GPC3	B-Protein
genes	O
.	O
<EOS>	B-X
Atezolizumab	B-X
(	B-X
anti-programmed	B-X
death-ligand	B-X
1	B-X
(	B-X
PD-L1	B-X
)	B-X
)	B-X
and	B-X
bevacizumab	B-X
(	B-X
anti-vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
)	B-X
combination	B-X
therapy	B-X
has	B-X
become	B-X
the	B-X
new	B-X
standard	B-X
of	B-X
care	B-X
in	B-X
patients	B-X
with	B-X
unresectable	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
We	B-X
report	B-X
integrated	B-X
molecular	B-X
analyses	B-X
of	B-X
tumor	B-X
samples	B-X
from	B-X
358	B-X
patients	B-X
with	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
enrolled	B-X
in	B-X
the	B-X
GO30140	B-X
phase	B-X
1b	B-X
or	B-X
IMbrave150	B-X
phase	B-X
3	B-X
trial	B-X
and	B-X
treated	B-X
with	B-X
atezolizumab	B-X
combined	B-X
with	B-X
bevacizumab	B-X
,	B-X
atezolizumab	B-X
alone	B-X
or	B-X
sorafenib	B-X
(	B-X
multikinase	B-X
inhibitor	B-X
)	B-X
.	B-X
Pre-existing	B-X
immunity	B-X
(	B-X
high	B-X
expression	B-X
of	B-X
CD274	B-X
,	B-X
T-effector	B-X
signature	B-X
and	B-X
intratumoral	B-X
CD8	B-X
The	B-X
multiple	B-X
vital	B-X
functions	B-X
of	B-X
the	B-X
human	B-X
liver	B-X
are	B-X
performed	B-X
by	B-X
highly	B-X
specialised	B-X
parenchymal	B-X
and	B-X
non-parenchymal	B-X
cells	B-X
organised	B-X
in	B-X
complex	B-X
collaborative	B-X
sinusoidal	B-X
units	B-X
.	B-X
Although	B-X
crucial	B-X
for	B-X
homeostasis	B-X
,	B-X
the	B-X
cellular	B-X
make-up	B-X
of	B-X
the	B-X
human	B-X
liver	B-X
remains	B-X
to	B-X
be	B-X
fully	B-X
elucidated	B-X
.	B-X
Here	B-X
,	B-X
single-cell	B-X
RNA-sequencing	B-X
was	B-X
used	B-X
to	B-X
unravel	B-X
the	B-X
heterogeneity	B-X
of	B-X
human	B-X
liver	B-X
cells	B-X
,	B-X
in	B-X
particular	B-X
of	B-X
hepatocytes	B-X
(	B-X
HEPs	B-X
)	B-X
and	B-X
hepatic	B-X
stellate	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X

After	O
determining	O
the	O
expression	O
patterns	O
of	O
AR	B-Protein
,	O
FMR1	B-Protein
and	O
GPC3	B-Protein
in	O
testicular	O
germ	O
cell	O
tumor	O
samples	O
we	O
concluded	O
that	O
multiple	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumors	O
were	O
predominantly	O
hypomethylated	O
and	O
active	O
regardless	O
of	O
XIST	B-Protein
expression	O
.	O
<EOS>	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
question	B-X
whether	B-X
the	B-X
multiple	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
are	B-X
active	B-X
or	B-X
inactive	B-X
through	B-X
a	B-X
complex	B-X
mechanism	B-X
of	B-X
X	B-X
chromosomal	B-X
gain	B-X
and	B-X
XIST	B-X
expression	B-X
.	B-X

The	O
biological	O
significance	O
of	O
excess	O
active	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumors	O
was	O
suggested	O
by	O
enhanced	O
expression	O
of	O
the	O
2	O
X	O
-	O
linked	O
oncogenes	O
ARAF1	B-Protein
and	O
ELK1	B-Protein
in	O
the	O
testicular	O
germ	O
cell	O
tumor	O
derived	O
cell	O
lines	O
.	O
<EOS>	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
question	B-X
whether	B-X
the	B-X
multiple	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
are	B-X
active	B-X
or	B-X
inactive	B-X
through	B-X
a	B-X
complex	B-X
mechanism	B-X
of	B-X
X	B-X
chromosomal	B-X
gain	B-X
and	B-X
XIST	B-X
expression	B-X
.	B-X

CONCLUSIONS	O
:	O
The	O
current	O
data	O
may	O
suggest	O
the	O
potential	O
oncogenic	O
implications	O
of	O
X	O
chromosomal	O
gain	O
in	O
testicular	O
germ	O
cell	O
tumors	O
.	O
<EOS>	B-X
An	B-X
overabundance	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumors	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
candidate	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
susceptibility	B-X
gene	B-X
TGCT1	B-X
on	B-X
Xq27	B-X
highlight	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
pathogenesis	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
question	B-X
whether	B-X
the	B-X
multiple	B-X
X	B-X
chromosomes	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
are	B-X
active	B-X
or	B-X
inactive	B-X
through	B-X
a	B-X
complex	B-X
mechanism	B-X
of	B-X
X	B-X
chromosomal	B-X
gain	B-X
and	B-X
XIST	B-X
expression	B-X
.	B-X

Cloning	O
and	O
sequence	O
analysis	O
of	O
FSH	O
and	O
LH	O
in	O
the	O
giant	O
panda	O
(	O
Ailuropoda	O
melanoleuca	O
)	O
.	O
<EOS>	B-X
The	B-X
giant	B-X
panda	B-X
(	B-X
Ailuropoda	B-X
melanoleuca	B-X
)	B-X
is	B-X
an	B-X
endangered	B-X
species	B-X
and	B-X
indigenous	B-X
to	B-X
China	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
genes	B-X
encoding	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
follicle-stimulating	B-X
hormone	B-X
(	B-X
FSH	B-X
)	B-X
beta	B-X
and	B-X
luteinizing	B-X
hormone	B-X
(	B-X
LH	B-X
)	B-X
beta	B-X
of	B-X
the	B-X
giant	B-X
panda	B-X
were	B-X
amplified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
by	B-X
RT-PCR	B-X
from	B-X
pituitary	B-X
total	B-X
RNA	B-X
,	B-X
and	B-X
were	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
analyzed	B-X
.	B-X
The	B-X
results	B-X
revealed	B-X
that	B-X
the	B-X
open	B-X
reading	B-X
region	B-X
(	B-X
ORF	B-X
)	B-X
of	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
FSH	B-X
beta	B-X
and	B-X
LH	B-X
beta	B-X
are	B-X
363	B-X
,	B-X
390	B-X
and	B-X
426	B-X
bp	B-X
long	B-X
,	B-X
respectively	B-X
.	B-X
They	B-X
displayed	B-X
a	B-X
reasonably	B-X
high	B-X
degree	B-X
(	B-X
74-94	B-X
,	B-X
85-93	B-X
,	B-X
75-91	B-X
%	B-X
,	B-X
for	B-X
alpha	B-X
,	B-X
FSH	B-X
beta	B-X
and	B-X
LH	B-X
beta	B-X
subunits	B-X
,	B-X
respectively	B-X
)	B-X
of	B-X
identity	B-X
when	B-X
deduced	B-X
amino	B-X
acids	B-X
were	B-X
compared	B-X
with	B-X
homologous	B-X
sequences	B-X
from	B-X
partial	B-X
available	B-X
mammals	B-X
including	B-X
human	B-X
,	B-X
cattle	B-X
,	B-X
sheep	B-X
,	B-X
pig	B-X
,	B-X
rat	B-X
,	B-X
mouse	B-X
.	B-X
Three	B-X
distinct	B-X
differences	B-X
were	B-X
found	B-X
at	B-X
the	B-X
site	B-X
of	B-X
59	B-X
aa	B-X
of	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
55	B-X
aa	B-X
,	B-X
68	B-X
aa	B-X
of	B-X
FSH	B-X
beta	B-X
subunit	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
an	B-X
insight	B-X
into	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
reproduction	B-X
regulation	B-X
and	B-X
genetic	B-X
characteristics	B-X
of	B-X
giant	B-X
panda	B-X
which	B-X
will	B-X
make	B-X
an	B-X
actual	B-X
contribution	B-X
to	B-X
its	B-X
conservation	B-X
.	B-X
In	B-X
addition	B-X
they	B-X
lay	B-X
a	B-X
foundation	B-X
for	B-X
a	B-X
further	B-X
study	B-X
towards	B-X
producing	B-X
recombinant	B-X
panda	B-X
FSH	B-X
and	B-X
LH	B-X
which	B-X
can	B-X
be	B-X
used	B-X
in	B-X
artificial	B-X
breeding	B-X
aimed	B-X
to	B-X
increase	B-X
its	B-X
captive	B-X
reproductive	B-X
efficiency	B-X
.	B-X

The	O
giant	O
panda	O
(	O
Ailuropoda	O
melanoleuca	O
)	O
is	O
an	O
endangered	O
species	O
and	O
indigenous	O
to	O
China	O
.	O
<EOS>	B-X
The	B-X
giant	B-X
panda	B-X
(	B-X
Ailuropoda	B-X
melanoleuca	B-X
)	B-X
is	B-X
an	B-X
endangered	B-X
species	B-X
and	B-X
indigenous	B-X
to	B-X
China	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
genes	B-X
encoding	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
follicle-stimulating	B-X
hormone	B-X
(	B-X
FSH	B-X
)	B-X
beta	B-X
and	B-X
luteinizing	B-X
hormone	B-X
(	B-X
LH	B-X
)	B-X
beta	B-X
of	B-X
the	B-X
giant	B-X
panda	B-X
were	B-X
amplified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
by	B-X
RT-PCR	B-X
from	B-X
pituitary	B-X
total	B-X
RNA	B-X
,	B-X
and	B-X
were	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
analyzed	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
an	B-X
insight	B-X
into	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
reproduction	B-X
regulation	B-X
and	B-X
genetic	B-X
characteristics	B-X
of	B-X
giant	B-X
panda	B-X
which	B-X
will	B-X
make	B-X
an	B-X
actual	B-X
contribution	B-X
to	B-X
its	B-X
conservation	B-X
.	B-X
In	B-X
addition	B-X
they	B-X
lay	B-X
a	B-X
foundation	B-X
for	B-X
a	B-X
further	B-X
study	B-X
towards	B-X
producing	B-X
recombinant	B-X
panda	B-X
FSH	B-X
and	B-X
LH	B-X
which	B-X
can	B-X
be	B-X
used	B-X
in	B-X
artificial	B-X
breeding	B-X
aimed	B-X
to	B-X
increase	B-X
its	B-X
captive	B-X
reproductive	B-X
efficiency	B-X
.	B-X

It	O
has	O
been	O
proposed	O
that	O
it	O
has	O
a	O
highly	O
specialized	O
reproductive	O
pattern	O
with	O
low	O
fecundity	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
basic	O
reproductive	O
biology	O
at	O
the	O
molecular	O
level	O
.	O

In	O
this	O
report	O
the	O
genes	O
encoding	O
gonadotropin	B-Protein
subunits	I-Protein
alpha	I-Protein
,	O
follicle	B-Protein
-	I-Protein
stimulating	I-Protein
hormone	I-Protein
(	I-Protein
FSH	I-Protein
)	I-Protein
beta	I-Protein
and	O
luteinizing	B-Protein
hormone	I-Protein
(	I-Protein
LH	I-Protein
)	I-Protein
beta	I-Protein
of	O
the	O
giant	O
panda	O
were	O
amplified	O
for	O
the	O
first	O
time	O
by	O
RT	O
-	O
PCR	O
from	O
pituitary	O
total	O
RNA	O
,	O
and	O
were	O
cloned	O
,	O
sequenced	O
and	O
analyzed	O
.	O

The	O
results	O
revealed	O
that	O
the	O
open	O
reading	O
region	O
(	O
ORF	O
)	O
of	O
gonadotropin	B-Protein
subunits	I-Protein
alpha	I-Protein
,	O
FSH	B-Protein
beta	I-Protein
and	O
LH	B-Protein
beta	I-Protein
are	O
363	O
,	O
390	O
and	O
426	O
bp	O
long	O
,	O
respectively	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
the	B-X
genes	B-X
encoding	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
follicle-stimulating	B-X
hormone	B-X
(	B-X
FSH	B-X
)	B-X
beta	B-X
and	B-X
luteinizing	B-X
hormone	B-X
(	B-X
LH	B-X
)	B-X
beta	B-X
of	B-X
the	B-X
giant	B-X
panda	B-X
were	B-X
amplified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
by	B-X
RT-PCR	B-X
from	B-X
pituitary	B-X
total	B-X
RNA	B-X
,	B-X
and	B-X
were	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
analyzed	B-X
.	B-X
The	B-X
results	B-X
revealed	B-X
that	B-X
the	B-X
open	B-X
reading	B-X
region	B-X
(	B-X
ORF	B-X
)	B-X
of	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
FSH	B-X
beta	B-X
and	B-X
LH	B-X
beta	B-X
are	B-X
363	B-X
,	B-X
390	B-X
and	B-X
426	B-X
bp	B-X
long	B-X
,	B-X
respectively	B-X
.	B-X
They	B-X
displayed	B-X
a	B-X
reasonably	B-X
high	B-X
degree	B-X
(	B-X
74-94	B-X
,	B-X
85-93	B-X
,	B-X
75-91	B-X
%	B-X
,	B-X
for	B-X
alpha	B-X
,	B-X
FSH	B-X
beta	B-X
and	B-X
LH	B-X
beta	B-X
subunits	B-X
,	B-X
respectively	B-X
)	B-X
of	B-X
identity	B-X
when	B-X
deduced	B-X
amino	B-X
acids	B-X
were	B-X
compared	B-X
with	B-X
homologous	B-X
sequences	B-X
from	B-X
partial	B-X
available	B-X
mammals	B-X
including	B-X
human	B-X
,	B-X
cattle	B-X
,	B-X
sheep	B-X
,	B-X
pig	B-X
,	B-X
rat	B-X
,	B-X
mouse	B-X
.	B-X
Three	B-X
distinct	B-X
differences	B-X
were	B-X
found	B-X
at	B-X
the	B-X
site	B-X
of	B-X
59	B-X
aa	B-X
of	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
55	B-X
aa	B-X
,	B-X
68	B-X
aa	B-X
of	B-X
FSH	B-X
beta	B-X
subunit	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
an	B-X
insight	B-X
into	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
reproduction	B-X
regulation	B-X
and	B-X
genetic	B-X
characteristics	B-X
of	B-X
giant	B-X
panda	B-X
which	B-X
will	B-X
make	B-X
an	B-X
actual	B-X
contribution	B-X
to	B-X
its	B-X
conservation	B-X
.	B-X
In	B-X
addition	B-X
they	B-X
lay	B-X
a	B-X
foundation	B-X
for	B-X
a	B-X
further	B-X
study	B-X
towards	B-X
producing	B-X
recombinant	B-X
panda	B-X
FSH	B-X
and	B-X
LH	B-X
which	B-X
can	B-X
be	B-X
used	B-X
in	B-X
artificial	B-X
breeding	B-X
aimed	B-X
to	B-X
increase	B-X
its	B-X
captive	B-X
reproductive	B-X
efficiency	B-X
.	B-X

They	O
displayed	O
a	O
reasonably	O
high	O
degree	O
(	O
74	O
-	O
94	O
,	O
85	O
-	O
93	O
,	O
75	O
-	O
91	O
%	O
,	O
for	O
alpha	O
,	O
FSH	B-Protein
beta	I-Protein
and	O
LH	B-Protein
beta	I-Protein
subunits	O
,	O
respectively	O
)	O
of	O
identity	O
when	O
deduced	O
amino	O
acids	O
were	O
compared	O
with	O
homologous	O
sequences	O
from	O
partial	O
available	O
mammals	O
including	O
human	O
,	O
cattle	O
,	O
sheep	O
,	O
pig	O
,	O
rat	O
,	O
mouse	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
it	B-X
has	B-X
a	B-X
highly	B-X
specialized	B-X
reproductive	B-X
pattern	B-X
with	B-X
low	B-X
fecundity	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
its	B-X
basic	B-X
reproductive	B-X
biology	B-X
at	B-X
the	B-X
molecular	B-X
level	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
genes	B-X
encoding	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
follicle-stimulating	B-X
hormone	B-X
(	B-X
FSH	B-X
)	B-X
beta	B-X
and	B-X
luteinizing	B-X
hormone	B-X
(	B-X
LH	B-X
)	B-X
beta	B-X
of	B-X
the	B-X
giant	B-X
panda	B-X
were	B-X
amplified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
by	B-X
RT-PCR	B-X
from	B-X
pituitary	B-X
total	B-X
RNA	B-X
,	B-X
and	B-X
were	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
analyzed	B-X
.	B-X
The	B-X
results	B-X
revealed	B-X
that	B-X
the	B-X
open	B-X
reading	B-X
region	B-X
(	B-X
ORF	B-X
)	B-X
of	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
FSH	B-X
beta	B-X
and	B-X
LH	B-X
beta	B-X
are	B-X
363	B-X
,	B-X
390	B-X
and	B-X
426	B-X
bp	B-X
long	B-X
,	B-X
respectively	B-X
.	B-X
They	B-X
displayed	B-X
a	B-X
reasonably	B-X
high	B-X
degree	B-X
(	B-X
74-94	B-X
,	B-X
85-93	B-X
,	B-X
75-91	B-X
%	B-X
,	B-X
for	B-X
alpha	B-X
,	B-X
FSH	B-X
beta	B-X
and	B-X
LH	B-X
beta	B-X
subunits	B-X
,	B-X
respectively	B-X
)	B-X
of	B-X
identity	B-X
when	B-X
deduced	B-X
amino	B-X
acids	B-X
were	B-X
compared	B-X
with	B-X
homologous	B-X
sequences	B-X
from	B-X
partial	B-X
available	B-X
mammals	B-X
including	B-X
human	B-X
,	B-X
cattle	B-X
,	B-X
sheep	B-X
,	B-X
pig	B-X
,	B-X
rat	B-X
,	B-X
mouse	B-X
.	B-X
Three	B-X
distinct	B-X
differences	B-X
were	B-X
found	B-X
at	B-X
the	B-X
site	B-X
of	B-X
59	B-X
aa	B-X
of	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
55	B-X
aa	B-X
,	B-X
68	B-X
aa	B-X
of	B-X
FSH	B-X
beta	B-X
subunit	B-X
.	B-X
In	B-X
addition	B-X
they	B-X
lay	B-X
a	B-X
foundation	B-X
for	B-X
a	B-X
further	B-X
study	B-X
towards	B-X
producing	B-X
recombinant	B-X
panda	B-X
FSH	B-X
and	B-X
LH	B-X
which	B-X
can	B-X
be	B-X
used	B-X
in	B-X
artificial	B-X
breeding	B-X
aimed	B-X
to	B-X
increase	B-X
its	B-X
captive	B-X
reproductive	B-X
efficiency	B-X
.	B-X

Three	O
distinct	O
differences	O
were	O
found	O
at	O
the	O
site	O
of	O
59	O
aa	O
of	O
the	O
alpha	O
subunit	O
and	O
55	O
aa	O
,	O
68	O
aa	O
of	O
FSH	B-Protein
beta	I-Protein
subunit	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
the	B-X
genes	B-X
encoding	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
follicle-stimulating	B-X
hormone	B-X
(	B-X
FSH	B-X
)	B-X
beta	B-X
and	B-X
luteinizing	B-X
hormone	B-X
(	B-X
LH	B-X
)	B-X
beta	B-X
of	B-X
the	B-X
giant	B-X
panda	B-X
were	B-X
amplified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
by	B-X
RT-PCR	B-X
from	B-X
pituitary	B-X
total	B-X
RNA	B-X
,	B-X
and	B-X
were	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
analyzed	B-X
.	B-X
The	B-X
results	B-X
revealed	B-X
that	B-X
the	B-X
open	B-X
reading	B-X
region	B-X
(	B-X
ORF	B-X
)	B-X
of	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
FSH	B-X
beta	B-X
and	B-X
LH	B-X
beta	B-X
are	B-X
363	B-X
,	B-X
390	B-X
and	B-X
426	B-X
bp	B-X
long	B-X
,	B-X
respectively	B-X
.	B-X
They	B-X
displayed	B-X
a	B-X
reasonably	B-X
high	B-X
degree	B-X
(	B-X
74-94	B-X
,	B-X
85-93	B-X
,	B-X
75-91	B-X
%	B-X
,	B-X
for	B-X
alpha	B-X
,	B-X
FSH	B-X
beta	B-X
and	B-X
LH	B-X
beta	B-X
subunits	B-X
,	B-X
respectively	B-X
)	B-X
of	B-X
identity	B-X
when	B-X
deduced	B-X
amino	B-X
acids	B-X
were	B-X
compared	B-X
with	B-X
homologous	B-X
sequences	B-X
from	B-X
partial	B-X
available	B-X
mammals	B-X
including	B-X
human	B-X
,	B-X
cattle	B-X
,	B-X
sheep	B-X
,	B-X
pig	B-X
,	B-X
rat	B-X
,	B-X
mouse	B-X
.	B-X
Three	B-X
distinct	B-X
differences	B-X
were	B-X
found	B-X
at	B-X
the	B-X
site	B-X
of	B-X
59	B-X
aa	B-X
of	B-X
the	B-X
alpha	B-X
subunit	B-X
and	B-X
55	B-X
aa	B-X
,	B-X
68	B-X
aa	B-X
of	B-X
FSH	B-X
beta	B-X
subunit	B-X
.	B-X
In	B-X
addition	B-X
they	B-X
lay	B-X
a	B-X
foundation	B-X
for	B-X
a	B-X
further	B-X
study	B-X
towards	B-X
producing	B-X
recombinant	B-X
panda	B-X
FSH	B-X
and	B-X
LH	B-X
which	B-X
can	B-X
be	B-X
used	B-X
in	B-X
artificial	B-X
breeding	B-X
aimed	B-X
to	B-X
increase	B-X
its	B-X
captive	B-X
reproductive	B-X
efficiency	B-X
.	B-X

Our	O
results	O
provide	O
an	O
insight	O
into	O
understanding	O
the	O
mechanism	O
of	O
reproduction	O
regulation	O
and	O
genetic	O
characteristics	O
of	O
giant	O
panda	O
which	O
will	O
make	O
an	O
actual	O
contribution	O
to	O
its	O
conservation	O
.	O
<EOS>	B-X
The	B-X
giant	B-X
panda	B-X
(	B-X
Ailuropoda	B-X
melanoleuca	B-X
)	B-X
is	B-X
an	B-X
endangered	B-X
species	B-X
and	B-X
indigenous	B-X
to	B-X
China	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
genes	B-X
encoding	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
follicle-stimulating	B-X
hormone	B-X
(	B-X
FSH	B-X
)	B-X
beta	B-X
and	B-X
luteinizing	B-X
hormone	B-X
(	B-X
LH	B-X
)	B-X
beta	B-X
of	B-X
the	B-X
giant	B-X
panda	B-X
were	B-X
amplified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
by	B-X
RT-PCR	B-X
from	B-X
pituitary	B-X
total	B-X
RNA	B-X
,	B-X
and	B-X
were	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
analyzed	B-X
.	B-X
The	B-X
results	B-X
revealed	B-X
that	B-X
the	B-X
open	B-X
reading	B-X
region	B-X
(	B-X
ORF	B-X
)	B-X
of	B-X
gonadotropin	B-X
subunits	B-X
alpha	B-X
,	B-X
FSH	B-X
beta	B-X
and	B-X
LH	B-X
beta	B-X
are	B-X
363	B-X
,	B-X
390	B-X
and	B-X
426	B-X
bp	B-X
long	B-X
,	B-X
respectively	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
an	B-X
insight	B-X
into	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
reproduction	B-X
regulation	B-X
and	B-X
genetic	B-X
characteristics	B-X
of	B-X
giant	B-X
panda	B-X
which	B-X
will	B-X
make	B-X
an	B-X
actual	B-X
contribution	B-X
to	B-X
its	B-X
conservation	B-X
.	B-X
In	B-X
addition	B-X
they	B-X
lay	B-X
a	B-X
foundation	B-X
for	B-X
a	B-X
further	B-X
study	B-X
towards	B-X
producing	B-X
recombinant	B-X
panda	B-X
FSH	B-X
and	B-X
LH	B-X
which	B-X
can	B-X
be	B-X
used	B-X
in	B-X
artificial	B-X
breeding	B-X
aimed	B-X
to	B-X
increase	B-X
its	B-X
captive	B-X
reproductive	B-X
efficiency	B-X
.	B-X

In	O
addition	O
they	O
lay	O
a	O
foundation	O
for	O
a	O
further	O
study	O
towards	O
producing	O
recombinant	O
panda	O
FSH	O
and	O
LH	O
which	O
can	O
be	O
used	O
in	O
artificial	O
breeding	O
aimed	O
to	O
increase	O
its	O
captive	O
reproductive	O
efficiency	O
.	O

Erasure	O
of	O
methylation	O
imprinting	O
of	O
Igf2r	B-Protein
during	O
mouse	O
primordial	O
germ	O
-	O
cell	O
development	O
.	O
<EOS>	B-X
During	B-X
germ	B-X
cell	B-X
differentiation	B-X
in	B-X
mice	B-X
,	B-X
the	B-X
genome	B-X
undergoes	B-X
specific	B-X
epigenetic	B-X
modifications	B-X
.	B-X
These	B-X
include	B-X
demethylation	B-X
of	B-X
imprinted	B-X
genes	B-X
and	B-X
subsequent	B-X
establishment	B-X
of	B-X
parental	B-X
allele-specific	B-X
methylation	B-X
.	B-X
The	B-X
mouse	B-X
Igf2r	B-X
gene	B-X
is	B-X
an	B-X
imprinted	B-X
gene	B-X
that	B-X
shows	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Maternal-specific	B-X
methylation	B-X
of	B-X
differentially	B-X
methylated	B-X
region	B-X
2	B-X
(	B-X
DMR2	B-X
)	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
necessary	B-X
for	B-X
its	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Before	B-X
the	B-X
allele-specific	B-X
methylation	B-X
is	B-X
established	B-X
,	B-X
DMR2	B-X
is	B-X
demethylated	B-X
in	B-X
both	B-X
male	B-X
and	B-X
female	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
by	B-X
13.5	B-X
days	B-X
post	B-X
coitum	B-X
(	B-X
dpc	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
demethylation	B-X
of	B-X
this	B-X
region	B-X
occurs	B-X
earlier	B-X
in	B-X
PGC	B-X
development	B-X
.	B-X
The	B-X
timing	B-X
of	B-X
the	B-X
demethylation	B-X
has	B-X
been	B-X
,	B-X
however	B-X
,	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
attempted	B-X
to	B-X
determine	B-X
the	B-X
timing	B-X
of	B-X
methylation	B-X
erasure	B-X
of	B-X
Igf2r	B-X
DMR2	B-X
in	B-X
developing	B-X
PGCs	B-X
,	B-X
using	B-X
transgenic	B-X
mice	B-X
expressing	B-X
green	B-X
fluorescent	B-X
protein	B-X
specifically	B-X
in	B-X
the	B-X
germ	B-X
line	B-X
.	B-X
We	B-X
purified	B-X
migrating	B-X
PGCs	B-X
from	B-X
the	B-X
transgenic	B-X
mice	B-X
and	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DMR2	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
some	B-X
CpG	B-X
sites	B-X
within	B-X
DMR2	B-X
start	B-X
demethylation	B-X
at	B-X
9.5	B-X
dpc	B-X
in	B-X
some	B-X
migrating	B-X
PGCs	B-X
,	B-X
before	B-X
the	B-X
cells	B-X
colonize	B-X
genital	B-X
ridges	B-X
,	B-X
and	B-X
the	B-X
progression	B-X
of	B-X
demethylation	B-X
is	B-X
rapid	B-X
after	B-X
colonization	B-X
of	B-X
the	B-X
genital	B-X
ridges	B-X
.	B-X
To	B-X
examine	B-X
whether	B-X
the	B-X
gonadal	B-X
environment	B-X
is	B-X
involved	B-X
in	B-X
demethylation	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
methylation	B-X
of	B-X
DMR2	B-X
after	B-X
culturing	B-X
migrating	B-X
PGCs	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
gonadal	B-X
environment	B-X
.	B-X
These	B-X
culture	B-X
experiments	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
a	B-X
gonadal	B-X
environment	B-X
is	B-X
not	B-X
required	B-X
for	B-X
demethylation	B-X
of	B-X
the	B-X
region	B-X
in	B-X
at	B-X
least	B-X
a	B-X
fraction	B-X
of	B-X
PGCs	B-X
.	B-X

During	O
germ	O
cell	O
differentiation	O
in	O
mice	O
,	O
the	O
genome	O
undergoes	O
specific	O
epigenetic	O
modifications	O
.	O
<EOS>	B-X
Sperm	B-X
and	B-X
eggs	B-X
carry	B-X
distinctive	B-X
epigenetic	B-X
modifications	B-X
that	B-X
are	B-X
adjusted	B-X
by	B-X
reprogramming	B-X
after	B-X
fertilization	B-X
.	B-X
The	B-X
paternal	B-X
genome	B-X
in	B-X
a	B-X
zygote	B-X
undergoes	B-X
active	B-X
DNA	B-X
demethylation	B-X
before	B-X
the	B-X
first	B-X
mitosis	B-X
.	B-X
The	B-X
biological	B-X
significance	B-X
and	B-X
mechanisms	B-X
of	B-X
this	B-X
paternal	B-X
epigenome	B-X
remodelling	B-X
have	B-X
remained	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
,	B-X
within	B-X
mouse	B-X
zygotes	B-X
,	B-X
oxidation	B-X
of	B-X
5-methylcytosine	B-X
(	B-X
5mC	B-X
)	B-X
occurs	B-X
on	B-X
the	B-X
paternal	B-X
genome	B-X
,	B-X
changing	B-X
5mC	B-X
into	B-X
5-hydroxymethylcytosine	B-X
(	B-X
5hmC	B-X
)	B-X
.	B-X
5	B-X
)	B-X
is	B-X
enriched	B-X
specifically	B-X
in	B-X
the	B-X
male	B-X
pronucleus	B-X
.	B-X
In	B-X
Tet3-deficient	B-X
zygotes	B-X
from	B-X
conditional	B-X
knockout	B-X
mice	B-X
,	B-X
paternal-genome	B-X
conversion	B-X
of	B-X
5mC	B-X
into	B-X
5hmC	B-X
fails	B-X
to	B-X
occur	B-X
and	B-X
the	B-X
level	B-X
of	B-X
5mC	B-X
remains	B-X
constant	B-X
.	B-X
Female	B-X
mice	B-X
depleted	B-X
of	B-X
Tet3	B-X
in	B-X
the	B-X
germ	B-X
line	B-X
show	B-X
severely	B-X
reduced	B-X
fecundity	B-X
and	B-X
their	B-X
heterozygous	B-X
mutant	B-X
offspring	B-X
lacking	B-X
maternal	B-X
Tet3	B-X
suffer	B-X
an	B-X
increased	B-X
incidence	B-X
of	B-X
developmental	B-X
failure	B-X
.	B-X
Oocytes	B-X
lacking	B-X
Tet3	B-X
also	B-X
seem	B-X
to	B-X
have	B-X
a	B-X
reduced	B-X
ability	B-X
to	B-X
reprogram	B-X
the	B-X
injected	B-X
nuclei	B-X
from	B-X
somatic	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
Tet3-mediated	B-X
DNA	B-X
hydroxylation	B-X
is	B-X
involved	B-X
in	B-X
epigenetic	B-X
reprogramming	B-X
of	B-X
the	B-X
zygotic	B-X
paternal	B-X
DNA	B-X
following	B-X
natural	B-X
fertilization	B-X
and	B-X
may	B-X
also	B-X
contribute	B-X
to	B-X
somatic	B-X
cell	B-X
nuclear	B-X
reprogramming	B-X
during	B-X
animal	B-X
cloning	B-X
.	B-X

These	O
include	O
demethylation	O
of	O
imprinted	O
genes	O
and	O
subsequent	O
establishment	O
of	O
parental	O
allele	O
-	O
specific	O
methylation	O
.	O
<EOS>	B-X
During	B-X
germ	B-X
cell	B-X
differentiation	B-X
in	B-X
mice	B-X
,	B-X
the	B-X
genome	B-X
undergoes	B-X
specific	B-X
epigenetic	B-X
modifications	B-X
.	B-X
These	B-X
include	B-X
demethylation	B-X
of	B-X
imprinted	B-X
genes	B-X
and	B-X
subsequent	B-X
establishment	B-X
of	B-X
parental	B-X
allele-specific	B-X
methylation	B-X
.	B-X
The	B-X
mouse	B-X
Igf2r	B-X
gene	B-X
is	B-X
an	B-X
imprinted	B-X
gene	B-X
that	B-X
shows	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Maternal-specific	B-X
methylation	B-X
of	B-X
differentially	B-X
methylated	B-X
region	B-X
2	B-X
(	B-X
DMR2	B-X
)	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
necessary	B-X
for	B-X
its	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Before	B-X
the	B-X
allele-specific	B-X
methylation	B-X
is	B-X
established	B-X
,	B-X
DMR2	B-X
is	B-X
demethylated	B-X
in	B-X
both	B-X
male	B-X
and	B-X
female	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
by	B-X
13.5	B-X
days	B-X
post	B-X
coitum	B-X
(	B-X
dpc	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
demethylation	B-X
of	B-X
this	B-X
region	B-X
occurs	B-X
earlier	B-X
in	B-X
PGC	B-X
development	B-X
.	B-X
The	B-X
timing	B-X
of	B-X
the	B-X
demethylation	B-X
has	B-X
been	B-X
,	B-X
however	B-X
,	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
attempted	B-X
to	B-X
determine	B-X
the	B-X
timing	B-X
of	B-X
methylation	B-X
erasure	B-X
of	B-X
Igf2r	B-X
DMR2	B-X
in	B-X
developing	B-X
PGCs	B-X
,	B-X
using	B-X
transgenic	B-X
mice	B-X
expressing	B-X
green	B-X
fluorescent	B-X
protein	B-X
specifically	B-X
in	B-X
the	B-X
germ	B-X
line	B-X
.	B-X
We	B-X
purified	B-X
migrating	B-X
PGCs	B-X
from	B-X
the	B-X
transgenic	B-X
mice	B-X
and	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DMR2	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
some	B-X
CpG	B-X
sites	B-X
within	B-X
DMR2	B-X
start	B-X
demethylation	B-X
at	B-X
9.5	B-X
dpc	B-X
in	B-X
some	B-X
migrating	B-X
PGCs	B-X
,	B-X
before	B-X
the	B-X
cells	B-X
colonize	B-X
genital	B-X
ridges	B-X
,	B-X
and	B-X
the	B-X
progression	B-X
of	B-X
demethylation	B-X
is	B-X
rapid	B-X
after	B-X
colonization	B-X
of	B-X
the	B-X
genital	B-X
ridges	B-X
.	B-X
To	B-X
examine	B-X
whether	B-X
the	B-X
gonadal	B-X
environment	B-X
is	B-X
involved	B-X
in	B-X
demethylation	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
methylation	B-X
of	B-X
DMR2	B-X
after	B-X
culturing	B-X
migrating	B-X
PGCs	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
gonadal	B-X
environment	B-X
.	B-X
These	B-X
culture	B-X
experiments	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
a	B-X
gonadal	B-X
environment	B-X
is	B-X
not	B-X
required	B-X
for	B-X
demethylation	B-X
of	B-X
the	B-X
region	B-X
in	B-X
at	B-X
least	B-X
a	B-X
fraction	B-X
of	B-X
PGCs	B-X
.	B-X

The	O
mouse	O
Igf2r	B-Protein
gene	O
is	O
an	O
imprinted	O
gene	O
that	O
shows	O
maternal	O
-	O
specific	O
expression	O
.	O
<EOS>	B-X
Gametic	B-X
imprinting	B-X
is	B-X
a	B-X
developmental	B-X
process	B-X
that	B-X
uses	B-X
cis-acting	B-X
epigenetic	B-X
mechanisms	B-X
to	B-X
induce	B-X
parental-specific	B-X
expression	B-X
in	B-X
autosomal	B-X
and	B-X
X-linked	B-X
genes	B-X
.	B-X
From	B-X
the	B-X
limited	B-X
knowledge	B-X
we	B-X
have	B-X
of	B-X
imprinted	B-X
genes	B-X
it	B-X
seems	B-X
clear	B-X
that	B-X
they	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
growth	B-X
and	B-X
development	B-X
of	B-X
the	B-X
placenta	B-X
and	B-X
embryo	B-X
in	B-X
utero	B-X
,	B-X
and	B-X
also	B-X
in	B-X
the	B-X
early	B-X
post-natal	B-X
phase	B-X
.	B-X
The	B-X
biological	B-X
function	B-X
of	B-X
imprinting	B-X
in	B-X
mammals	B-X
is	B-X
not	B-X
yet	B-X
understood	B-X
but	B-X
it	B-X
may	B-X
act	B-X
to	B-X
regulate	B-X
the	B-X
supply	B-X
of	B-X
nutrition	B-X
to	B-X
the	B-X
embryo	B-X
in	B-X
order	B-X
to	B-X
maintain	B-X
a	B-X
balance	B-X
between	B-X
fetal	B-X
demands	B-X
and	B-X
maternal	B-X
resources	B-X
.	B-X
The	B-X
molecular	B-X
basis	B-X
of	B-X
imprinting	B-X
any	B-X
gene	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
disclosed	B-X
.	B-X
the	B-X
current	B-X
model	B-X
proposes	B-X
that	B-X
single	B-X
or	B-X
clustered	B-X
genes	B-X
should	B-X
be	B-X
associated	B-X
with	B-X
a	B-X
specific	B-X
imprinting	B-X
element	B-X
which	B-X
carries	B-X
a	B-X
reversible	B-X
epigenetic	B-X
imprinting	B-X
signal	B-X
,	B-X
inherited	B-X
from	B-X
one	B-X
parent	B-X
and	B-X
maintained	B-X
on	B-X
the	B-X
same	B-X
parental	B-X
chromosome	B-X
in	B-X
diploid	B-X
cells	B-X
.	B-X
A	B-X
common	B-X
imprinting	B-X
recognition	B-X
sequence	B-X
has	B-X
not	B-X
been	B-X
identified	B-X
amongst	B-X
the	B-X
20	B-X
known	B-X
imprinted	B-X
genes	B-X
,	B-X
but	B-X
such	B-X
an	B-X
element	B-X
is	B-X
thought	B-X
to	B-X
exist	B-X
from	B-X
observations	B-X
of	B-X
mouse	B-X
transgenes	B-X
and	B-X
transgenes	B-X
of	B-X
the	B-X
imprinted	B-X
H19	B-X
gene	B-X
,	B-X
which	B-X
have	B-X
shown	B-X
that	B-X
short	B-X
DNA	B-X
sequences	B-X
can	B-X
maintain	B-X
imprinted	B-X
expression	B-X
at	B-X
different	B-X
chromosome	B-X
locations	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
also	B-X
clear	B-X
from	B-X
gene	B-X
deletion	B-X
experiments	B-X
in	B-X
the	B-X
mouse	B-X
and	B-X
the	B-X
analysis	B-X
of	B-X
deletions	B-X
in	B-X
the	B-X
human	B-X
Prader-Willi/Angelman	B-X
syndromes	B-X
that	B-X
imprinted	B-X
genes	B-X
are	B-X
also	B-X
influenced	B-X
by	B-X
distant	B-X
DNA	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
earlier	B-X
proposed	B-X
that	B-X
CG	B-X
rich	B-X
sequences	B-X
resembling	B-X
CpG	B-X
islands	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
many	B-X
imprinted	B-X
genes	B-X
and	B-X
often	B-X
subject	B-X
to	B-X
parental-specific	B-X
methylation	B-X
,	B-X
could	B-X
act	B-X
as	B-X
a	B-X
common	B-X
imprinting	B-X
element	B-X
.	B-X
The	B-X
mouse	B-X
insulin-like	B-X
growth	B-X
factor	B-X
type	B-X
2	B-X
receptor	B-X
(	B-X
Igf2r	B-X
)	B-X
gene	B-X
contains	B-X
a	B-X
CpG	B-X
island	B-X
known	B-X
as	B-X
region2	B-X
,	B-X
in	B-X
the	B-X
second	B-X
intron	B-X
.	B-X
Region2	B-X
was	B-X
proposed	B-X
as	B-X
the	B-X
imprinting	B-X
element	B-X
of	B-X
this	B-X
gene	B-X
because	B-X
it	B-X
inherited	B-X
a	B-X
methylation	B-X
imprint	B-X
from	B-X
the	B-X
female	B-X
gamete	B-X
that	B-X
was	B-X
maintained	B-X
only	B-X
on	B-X
the	B-X
maternal	B-X
chromosome	B-X
in	B-X
diploid	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
used	B-X
YAC	B-X
(	B-X
yeast	B-X
artificial	B-X
chromosome	B-X
)	B-X
transgenes	B-X
carrying	B-X
the	B-X
complete	B-X
Igf2r	B-X
locus	B-X
,	B-X
to	B-X
test	B-X
if	B-X
imprinting	B-X
and	B-X
parental-specific	B-X
methylation	B-X
of	B-X
the	B-X
mouse	B-X
Igf2r	B-X
gene	B-X
is	B-X
maintained	B-X
when	B-X
transferred	B-X
to	B-X
other	B-X
chromosomal	B-X
locations	B-X
and	B-X
to	B-X
test	B-X
whether	B-X
imprinting	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
intronic	B-X
CpG	B-X
island	B-X
proposed	B-X
as	B-X
the	B-X
imprinting	B-X
element	B-X
for	B-X
this	B-X
gene	B-X
.	B-X
Gametic	B-X
imprints	B-X
are	B-X
epigenetic	B-X
modifications	B-X
which	B-X
are	B-X
imposed	B-X
onto	B-X
the	B-X
gametic	B-X
chromosomes	B-X
and	B-X
cause	B-X
parental-specific	B-X
differences	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
small	B-X
number	B-X
of	B-X
genes	B-X
in	B-X
the	B-X
embryo	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
,	B-X
correct	B-X
imposition	B-X
of	B-X
the	B-X
imprints	B-X
in	B-X
the	B-X
parental	B-X
germlines	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
successful	B-X
development	B-X
of	B-X
mammals	B-X
and	B-X
any	B-X
anomaly	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
imprinted	B-X
genes	B-X
is	B-X
often	B-X
accompanied	B-X
by	B-X
aberration	B-X
of	B-X
embryonic	B-X
growth	B-X
.	B-X
The	B-X
link	B-X
between	B-X
imprinting	B-X
and	B-X
growth	B-X
regulation	B-X
is	B-X
best	B-X
exemplified	B-X
by	B-X
the	B-X
Igf2	B-X
and	B-X
Igf2r	B-X
genes	B-X
.	B-X
Both	B-X
genes	B-X
show	B-X
parental-specific	B-X
expression	B-X
patterns	B-X
in	B-X
the	B-X
embryo	B-X
.	B-X
Igf2	B-X
is	B-X
a	B-X
general	B-X
embryonic	B-X
mitogen	B-X
,	B-X
and	B-X
mice	B-X
lacking	B-X
Igf2	B-X
are	B-X
markedly	B-X
reduced	B-X
in	B-X
size	B-X
(	B-X
DeChiara	B-X
,	B-X
T.M.	B-X
,	B-X
Robertson	B-X
,	B-X
E.J.	B-X
,	B-X
Efstratiadis	B-X
,	B-X
A.	B-X
,	B-X
1991	B-X
.	B-X
Parental	B-X
imprinting	B-X
of	B-X
the	B-X
mouse	B-X
insulin-like	B-X
growth	B-X
factor	B-X
II	B-X
gene	B-X
.	B-X
Igf2r	B-X
acts	B-X
to	B-X
fine	B-X
tune	B-X
the	B-X
amount	B-X
of	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
embryos	B-X
lacking	B-X
this	B-X
gene	B-X
show	B-X
overgrowth	B-X
and	B-X
die	B-X
perinatally	B-X
(	B-X
Lau	B-X
,	B-X
M.M.	B-X
,	B-X
Stewart	B-X
,	B-X
C.E.	B-X
,	B-X
Liu	B-X
,	B-X
Z.	B-X
,	B-X
Bhatt	B-X
,	B-X
H.	B-X
,	B-X
Rotwein	B-X
,	B-X
P.	B-X
,	B-X
Stewart	B-X
,	B-X
C.L.	B-X
,	B-X
1994	B-X
.	B-X
Loss	B-X
of	B-X
the	B-X
imprinted	B-X
IGF2/cation-independent	B-X
mannose	B-X
6-phosphate	B-X
receptor	B-X
results	B-X
in	B-X
fetal	B-X
overgrowth	B-X
and	B-X
perinatal	B-X
lethality	B-X
.	B-X
Regulation	B-X
of	B-X
embryonic	B-X
growth	B-X
and	B-X
lysosomal	B-X
targeting	B-X
by	B-X
the	B-X
imprinted	B-X
Igf2/Mpr	B-X
gene	B-X
.	B-X
The	B-X
phenomenon	B-X
of	B-X
gametic	B-X
imprinting	B-X
is	B-X
predicted	B-X
to	B-X
arise	B-X
by	B-X
an	B-X
unusual	B-X
regulation	B-X
of	B-X
the	B-X
imposition	B-X
and	B-X
erasure	B-X
of	B-X
epigenetic	B-X
modifications	B-X
.	B-X

Maternal	O
-	O
specific	O
methylation	O
of	O
differentially	O
methylated	O
region	O
2	O
(	O
DMR2	O
)	O
of	O
this	O
gene	O
may	O
be	O
necessary	O
for	O
its	O
maternal	O
-	O
specific	O
expression	O
.	O
<EOS>	B-X
During	B-X
germ	B-X
cell	B-X
differentiation	B-X
in	B-X
mice	B-X
,	B-X
the	B-X
genome	B-X
undergoes	B-X
specific	B-X
epigenetic	B-X
modifications	B-X
.	B-X
These	B-X
include	B-X
demethylation	B-X
of	B-X
imprinted	B-X
genes	B-X
and	B-X
subsequent	B-X
establishment	B-X
of	B-X
parental	B-X
allele-specific	B-X
methylation	B-X
.	B-X
The	B-X
mouse	B-X
Igf2r	B-X
gene	B-X
is	B-X
an	B-X
imprinted	B-X
gene	B-X
that	B-X
shows	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Maternal-specific	B-X
methylation	B-X
of	B-X
differentially	B-X
methylated	B-X
region	B-X
2	B-X
(	B-X
DMR2	B-X
)	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
necessary	B-X
for	B-X
its	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Before	B-X
the	B-X
allele-specific	B-X
methylation	B-X
is	B-X
established	B-X
,	B-X
DMR2	B-X
is	B-X
demethylated	B-X
in	B-X
both	B-X
male	B-X
and	B-X
female	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
by	B-X
13.5	B-X
days	B-X
post	B-X
coitum	B-X
(	B-X
dpc	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
demethylation	B-X
of	B-X
this	B-X
region	B-X
occurs	B-X
earlier	B-X
in	B-X
PGC	B-X
development	B-X
.	B-X
The	B-X
timing	B-X
of	B-X
the	B-X
demethylation	B-X
has	B-X
been	B-X
,	B-X
however	B-X
,	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
attempted	B-X
to	B-X
determine	B-X
the	B-X
timing	B-X
of	B-X
methylation	B-X
erasure	B-X
of	B-X
Igf2r	B-X
DMR2	B-X
in	B-X
developing	B-X
PGCs	B-X
,	B-X
using	B-X
transgenic	B-X
mice	B-X
expressing	B-X
green	B-X
fluorescent	B-X
protein	B-X
specifically	B-X
in	B-X
the	B-X
germ	B-X
line	B-X
.	B-X
We	B-X
purified	B-X
migrating	B-X
PGCs	B-X
from	B-X
the	B-X
transgenic	B-X
mice	B-X
and	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DMR2	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
some	B-X
CpG	B-X
sites	B-X
within	B-X
DMR2	B-X
start	B-X
demethylation	B-X
at	B-X
9.5	B-X
dpc	B-X
in	B-X
some	B-X
migrating	B-X
PGCs	B-X
,	B-X
before	B-X
the	B-X
cells	B-X
colonize	B-X
genital	B-X
ridges	B-X
,	B-X
and	B-X
the	B-X
progression	B-X
of	B-X
demethylation	B-X
is	B-X
rapid	B-X
after	B-X
colonization	B-X
of	B-X
the	B-X
genital	B-X
ridges	B-X
.	B-X
To	B-X
examine	B-X
whether	B-X
the	B-X
gonadal	B-X
environment	B-X
is	B-X
involved	B-X
in	B-X
demethylation	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
methylation	B-X
of	B-X
DMR2	B-X
after	B-X
culturing	B-X
migrating	B-X
PGCs	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
gonadal	B-X
environment	B-X
.	B-X
These	B-X
culture	B-X
experiments	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
a	B-X
gonadal	B-X
environment	B-X
is	B-X
not	B-X
required	B-X
for	B-X
demethylation	B-X
of	B-X
the	B-X
region	B-X
in	B-X
at	B-X
least	B-X
a	B-X
fraction	B-X
of	B-X
PGCs	B-X
.	B-X

Before	O
the	O
allele	O
-	O
specific	O
methylation	O
is	O
established	O
,	O
DMR2	O
is	O
demethylated	O
in	O
both	O
male	O
and	O
female	O
primordial	O
germ	O
cells	O
(	O
PGCs	O
)	O
by	O
13	O
.	O
5	O
days	O
post	O
coitum	O
(	O
dpc	O
)	O
,	O
indicating	O
that	O
the	O
demethylation	O
of	O
this	O
region	O
occurs	O
earlier	O
in	O
PGC	O
development	O
.	O
<EOS>	B-X
During	B-X
germ	B-X
cell	B-X
differentiation	B-X
in	B-X
mice	B-X
,	B-X
the	B-X
genome	B-X
undergoes	B-X
specific	B-X
epigenetic	B-X
modifications	B-X
.	B-X
These	B-X
include	B-X
demethylation	B-X
of	B-X
imprinted	B-X
genes	B-X
and	B-X
subsequent	B-X
establishment	B-X
of	B-X
parental	B-X
allele-specific	B-X
methylation	B-X
.	B-X
The	B-X
mouse	B-X
Igf2r	B-X
gene	B-X
is	B-X
an	B-X
imprinted	B-X
gene	B-X
that	B-X
shows	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Maternal-specific	B-X
methylation	B-X
of	B-X
differentially	B-X
methylated	B-X
region	B-X
2	B-X
(	B-X
DMR2	B-X
)	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
necessary	B-X
for	B-X
its	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Before	B-X
the	B-X
allele-specific	B-X
methylation	B-X
is	B-X
established	B-X
,	B-X
DMR2	B-X
is	B-X
demethylated	B-X
in	B-X
both	B-X
male	B-X
and	B-X
female	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
by	B-X
13.5	B-X
days	B-X
post	B-X
coitum	B-X
(	B-X
dpc	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
demethylation	B-X
of	B-X
this	B-X
region	B-X
occurs	B-X
earlier	B-X
in	B-X
PGC	B-X
development	B-X
.	B-X
The	B-X
timing	B-X
of	B-X
the	B-X
demethylation	B-X
has	B-X
been	B-X
,	B-X
however	B-X
,	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
attempted	B-X
to	B-X
determine	B-X
the	B-X
timing	B-X
of	B-X
methylation	B-X
erasure	B-X
of	B-X
Igf2r	B-X
DMR2	B-X
in	B-X
developing	B-X
PGCs	B-X
,	B-X
using	B-X
transgenic	B-X
mice	B-X
expressing	B-X
green	B-X
fluorescent	B-X
protein	B-X
specifically	B-X
in	B-X
the	B-X
germ	B-X
line	B-X
.	B-X
We	B-X
purified	B-X
migrating	B-X
PGCs	B-X
from	B-X
the	B-X
transgenic	B-X
mice	B-X
and	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DMR2	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
some	B-X
CpG	B-X
sites	B-X
within	B-X
DMR2	B-X
start	B-X
demethylation	B-X
at	B-X
9.5	B-X
dpc	B-X
in	B-X
some	B-X
migrating	B-X
PGCs	B-X
,	B-X
before	B-X
the	B-X
cells	B-X
colonize	B-X
genital	B-X
ridges	B-X
,	B-X
and	B-X
the	B-X
progression	B-X
of	B-X
demethylation	B-X
is	B-X
rapid	B-X
after	B-X
colonization	B-X
of	B-X
the	B-X
genital	B-X
ridges	B-X
.	B-X
To	B-X
examine	B-X
whether	B-X
the	B-X
gonadal	B-X
environment	B-X
is	B-X
involved	B-X
in	B-X
demethylation	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
methylation	B-X
of	B-X
DMR2	B-X
after	B-X
culturing	B-X
migrating	B-X
PGCs	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
gonadal	B-X
environment	B-X
.	B-X
These	B-X
culture	B-X
experiments	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
a	B-X
gonadal	B-X
environment	B-X
is	B-X
not	B-X
required	B-X
for	B-X
demethylation	B-X
of	B-X
the	B-X
region	B-X
in	B-X
at	B-X
least	B-X
a	B-X
fraction	B-X
of	B-X
PGCs	B-X
.	B-X

The	O
timing	O
of	O
the	O
demethylation	O
has	O
been	O
,	O
however	O
,	O
unknown	O
.	O
<EOS>	B-X
However	B-X
,	B-X
how	B-X
epigenetic	B-X
modifiers	B-X
coordinate	B-X
with	B-X
the	B-X
DNA	B-X
repair	B-X
machinery	B-X
to	B-X
modulate	B-X
cellular	B-X
radiosensitivity	B-X
is	B-X
relatively	B-X
unknown	B-X
.	B-X
Although	B-X
gametogenesis	B-X
culminates	B-X
in	B-X
transcriptional	B-X
quiescence	B-X
in	B-X
plants	B-X
and	B-X
animals	B-X
,	B-X
regulatory	B-X
mechanisms	B-X
controlling	B-X
this	B-X
are	B-X
unknown	B-X
.	B-X
Utilizing	B-X
microarray-based	B-X
techniques	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
relationships	B-X
between	B-X
DNA	B-X
methylation	B-X
,	B-X
DNA	B-X
replication	B-X
timing	B-X
and	B-X
gene	B-X
expression	B-X
levels	B-X
across	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
.	B-X
Rather	B-X
than	B-X
serving	B-X
as	B-X
a	B-X
distinctive	B-X
mark	B-X
between	B-X
active	B-X
and	B-X
inactive	B-X
genes	B-X
,	B-X
gene-body	B-X
methylation	B-X
appears	B-X
to	B-X
serve	B-X
a	B-X
vital	B-X
,	B-X
currently	B-X
unknown	B-X
function	B-X
in	B-X
active	B-X
genes	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
determine	O
the	O
timing	O
of	O
methylation	O
erasure	O
of	O
Igf2r	B-Protein
DMR2	O
in	O
developing	O
PGCs	O
,	O
using	O
transgenic	O
mice	O
expressing	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
specifically	O
in	O
the	O
germ	O
line	O
.	O
<EOS>	B-X
During	B-X
germ	B-X
cell	B-X
differentiation	B-X
in	B-X
mice	B-X
,	B-X
the	B-X
genome	B-X
undergoes	B-X
specific	B-X
epigenetic	B-X
modifications	B-X
.	B-X
These	B-X
include	B-X
demethylation	B-X
of	B-X
imprinted	B-X
genes	B-X
and	B-X
subsequent	B-X
establishment	B-X
of	B-X
parental	B-X
allele-specific	B-X
methylation	B-X
.	B-X
The	B-X
mouse	B-X
Igf2r	B-X
gene	B-X
is	B-X
an	B-X
imprinted	B-X
gene	B-X
that	B-X
shows	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Maternal-specific	B-X
methylation	B-X
of	B-X
differentially	B-X
methylated	B-X
region	B-X
2	B-X
(	B-X
DMR2	B-X
)	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
necessary	B-X
for	B-X
its	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Before	B-X
the	B-X
allele-specific	B-X
methylation	B-X
is	B-X
established	B-X
,	B-X
DMR2	B-X
is	B-X
demethylated	B-X
in	B-X
both	B-X
male	B-X
and	B-X
female	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
by	B-X
13.5	B-X
days	B-X
post	B-X
coitum	B-X
(	B-X
dpc	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
demethylation	B-X
of	B-X
this	B-X
region	B-X
occurs	B-X
earlier	B-X
in	B-X
PGC	B-X
development	B-X
.	B-X
The	B-X
timing	B-X
of	B-X
the	B-X
demethylation	B-X
has	B-X
been	B-X
,	B-X
however	B-X
,	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
attempted	B-X
to	B-X
determine	B-X
the	B-X
timing	B-X
of	B-X
methylation	B-X
erasure	B-X
of	B-X
Igf2r	B-X
DMR2	B-X
in	B-X
developing	B-X
PGCs	B-X
,	B-X
using	B-X
transgenic	B-X
mice	B-X
expressing	B-X
green	B-X
fluorescent	B-X
protein	B-X
specifically	B-X
in	B-X
the	B-X
germ	B-X
line	B-X
.	B-X
We	B-X
purified	B-X
migrating	B-X
PGCs	B-X
from	B-X
the	B-X
transgenic	B-X
mice	B-X
and	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DMR2	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
some	B-X
CpG	B-X
sites	B-X
within	B-X
DMR2	B-X
start	B-X
demethylation	B-X
at	B-X
9.5	B-X
dpc	B-X
in	B-X
some	B-X
migrating	B-X
PGCs	B-X
,	B-X
before	B-X
the	B-X
cells	B-X
colonize	B-X
genital	B-X
ridges	B-X
,	B-X
and	B-X
the	B-X
progression	B-X
of	B-X
demethylation	B-X
is	B-X
rapid	B-X
after	B-X
colonization	B-X
of	B-X
the	B-X
genital	B-X
ridges	B-X
.	B-X
To	B-X
examine	B-X
whether	B-X
the	B-X
gonadal	B-X
environment	B-X
is	B-X
involved	B-X
in	B-X
demethylation	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
methylation	B-X
of	B-X
DMR2	B-X
after	B-X
culturing	B-X
migrating	B-X
PGCs	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
gonadal	B-X
environment	B-X
.	B-X
These	B-X
culture	B-X
experiments	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
a	B-X
gonadal	B-X
environment	B-X
is	B-X
not	B-X
required	B-X
for	B-X
demethylation	B-X
of	B-X
the	B-X
region	B-X
in	B-X
at	B-X
least	B-X
a	B-X
fraction	B-X
of	B-X
PGCs	B-X
.	B-X

We	O
purified	O
migrating	O
PGCs	O
from	O
the	O
transgenic	O
mice	O
and	O
examined	O
the	O
methylation	O
status	O
of	O
DMR2	O
.	O
<EOS>	B-X
During	B-X
germ	B-X
cell	B-X
differentiation	B-X
in	B-X
mice	B-X
,	B-X
the	B-X
genome	B-X
undergoes	B-X
specific	B-X
epigenetic	B-X
modifications	B-X
.	B-X
These	B-X
include	B-X
demethylation	B-X
of	B-X
imprinted	B-X
genes	B-X
and	B-X
subsequent	B-X
establishment	B-X
of	B-X
parental	B-X
allele-specific	B-X
methylation	B-X
.	B-X
Maternal-specific	B-X
methylation	B-X
of	B-X
differentially	B-X
methylated	B-X
region	B-X
2	B-X
(	B-X
DMR2	B-X
)	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
necessary	B-X
for	B-X
its	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Before	B-X
the	B-X
allele-specific	B-X
methylation	B-X
is	B-X
established	B-X
,	B-X
DMR2	B-X
is	B-X
demethylated	B-X
in	B-X
both	B-X
male	B-X
and	B-X
female	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
by	B-X
13.5	B-X
days	B-X
post	B-X
coitum	B-X
(	B-X
dpc	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
demethylation	B-X
of	B-X
this	B-X
region	B-X
occurs	B-X
earlier	B-X
in	B-X
PGC	B-X
development	B-X
.	B-X
The	B-X
timing	B-X
of	B-X
the	B-X
demethylation	B-X
has	B-X
been	B-X
,	B-X
however	B-X
,	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
attempted	B-X
to	B-X
determine	B-X
the	B-X
timing	B-X
of	B-X
methylation	B-X
erasure	B-X
of	B-X
Igf2r	B-X
DMR2	B-X
in	B-X
developing	B-X
PGCs	B-X
,	B-X
using	B-X
transgenic	B-X
mice	B-X
expressing	B-X
green	B-X
fluorescent	B-X
protein	B-X
specifically	B-X
in	B-X
the	B-X
germ	B-X
line	B-X
.	B-X
We	B-X
purified	B-X
migrating	B-X
PGCs	B-X
from	B-X
the	B-X
transgenic	B-X
mice	B-X
and	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DMR2	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
some	B-X
CpG	B-X
sites	B-X
within	B-X
DMR2	B-X
start	B-X
demethylation	B-X
at	B-X
9.5	B-X
dpc	B-X
in	B-X
some	B-X
migrating	B-X
PGCs	B-X
,	B-X
before	B-X
the	B-X
cells	B-X
colonize	B-X
genital	B-X
ridges	B-X
,	B-X
and	B-X
the	B-X
progression	B-X
of	B-X
demethylation	B-X
is	B-X
rapid	B-X
after	B-X
colonization	B-X
of	B-X
the	B-X
genital	B-X
ridges	B-X
.	B-X
To	B-X
examine	B-X
whether	B-X
the	B-X
gonadal	B-X
environment	B-X
is	B-X
involved	B-X
in	B-X
demethylation	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
methylation	B-X
of	B-X
DMR2	B-X
after	B-X
culturing	B-X
migrating	B-X
PGCs	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
gonadal	B-X
environment	B-X
.	B-X
These	B-X
culture	B-X
experiments	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
a	B-X
gonadal	B-X
environment	B-X
is	B-X
not	B-X
required	B-X
for	B-X
demethylation	B-X
of	B-X
the	B-X
region	B-X
in	B-X
at	B-X
least	B-X
a	B-X
fraction	B-X
of	B-X
PGCs	B-X
.	B-X

The	O
results	O
show	O
that	O
some	O
CpG	O
sites	O
within	O
DMR2	O
start	O
demethylation	O
at	O
9	O
.	O
5	O
dpc	O
in	O
some	O
migrating	O
PGCs	O
,	O
before	O
the	O
cells	O
colonize	O
genital	O
ridges	O
,	O
and	O
the	O
progression	O
of	O
demethylation	O
is	O
rapid	O
after	O
colonization	O
of	O
the	O
genital	O
ridges	O
.	O
<EOS>	B-X
These	B-X
include	B-X
demethylation	B-X
of	B-X
imprinted	B-X
genes	B-X
and	B-X
subsequent	B-X
establishment	B-X
of	B-X
parental	B-X
allele-specific	B-X
methylation	B-X
.	B-X
The	B-X
mouse	B-X
Igf2r	B-X
gene	B-X
is	B-X
an	B-X
imprinted	B-X
gene	B-X
that	B-X
shows	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Maternal-specific	B-X
methylation	B-X
of	B-X
differentially	B-X
methylated	B-X
region	B-X
2	B-X
(	B-X
DMR2	B-X
)	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
necessary	B-X
for	B-X
its	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Before	B-X
the	B-X
allele-specific	B-X
methylation	B-X
is	B-X
established	B-X
,	B-X
DMR2	B-X
is	B-X
demethylated	B-X
in	B-X
both	B-X
male	B-X
and	B-X
female	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
by	B-X
13.5	B-X
days	B-X
post	B-X
coitum	B-X
(	B-X
dpc	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
demethylation	B-X
of	B-X
this	B-X
region	B-X
occurs	B-X
earlier	B-X
in	B-X
PGC	B-X
development	B-X
.	B-X
The	B-X
timing	B-X
of	B-X
the	B-X
demethylation	B-X
has	B-X
been	B-X
,	B-X
however	B-X
,	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
attempted	B-X
to	B-X
determine	B-X
the	B-X
timing	B-X
of	B-X
methylation	B-X
erasure	B-X
of	B-X
Igf2r	B-X
DMR2	B-X
in	B-X
developing	B-X
PGCs	B-X
,	B-X
using	B-X
transgenic	B-X
mice	B-X
expressing	B-X
green	B-X
fluorescent	B-X
protein	B-X
specifically	B-X
in	B-X
the	B-X
germ	B-X
line	B-X
.	B-X
We	B-X
purified	B-X
migrating	B-X
PGCs	B-X
from	B-X
the	B-X
transgenic	B-X
mice	B-X
and	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DMR2	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
some	B-X
CpG	B-X
sites	B-X
within	B-X
DMR2	B-X
start	B-X
demethylation	B-X
at	B-X
9.5	B-X
dpc	B-X
in	B-X
some	B-X
migrating	B-X
PGCs	B-X
,	B-X
before	B-X
the	B-X
cells	B-X
colonize	B-X
genital	B-X
ridges	B-X
,	B-X
and	B-X
the	B-X
progression	B-X
of	B-X
demethylation	B-X
is	B-X
rapid	B-X
after	B-X
colonization	B-X
of	B-X
the	B-X
genital	B-X
ridges	B-X
.	B-X
To	B-X
examine	B-X
whether	B-X
the	B-X
gonadal	B-X
environment	B-X
is	B-X
involved	B-X
in	B-X
demethylation	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
methylation	B-X
of	B-X
DMR2	B-X
after	B-X
culturing	B-X
migrating	B-X
PGCs	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
gonadal	B-X
environment	B-X
.	B-X
These	B-X
culture	B-X
experiments	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
a	B-X
gonadal	B-X
environment	B-X
is	B-X
not	B-X
required	B-X
for	B-X
demethylation	B-X
of	B-X
the	B-X
region	B-X
in	B-X
at	B-X
least	B-X
a	B-X
fraction	B-X
of	B-X
PGCs	B-X
.	B-X

To	O
examine	O
whether	O
the	O
gonadal	O
environment	O
is	O
involved	O
in	O
demethylation	O
,	O
we	O
analyzed	O
the	O
methylation	O
of	O
DMR2	O
after	O
culturing	O
migrating	O
PGCs	O
in	O
the	O
absence	O
of	O
a	O
gonadal	O
environment	O
.	O
<EOS>	B-X
These	B-X
include	B-X
demethylation	B-X
of	B-X
imprinted	B-X
genes	B-X
and	B-X
subsequent	B-X
establishment	B-X
of	B-X
parental	B-X
allele-specific	B-X
methylation	B-X
.	B-X
Maternal-specific	B-X
methylation	B-X
of	B-X
differentially	B-X
methylated	B-X
region	B-X
2	B-X
(	B-X
DMR2	B-X
)	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
necessary	B-X
for	B-X
its	B-X
maternal-specific	B-X
expression	B-X
.	B-X
Before	B-X
the	B-X
allele-specific	B-X
methylation	B-X
is	B-X
established	B-X
,	B-X
DMR2	B-X
is	B-X
demethylated	B-X
in	B-X
both	B-X
male	B-X
and	B-X
female	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
by	B-X
13.5	B-X
days	B-X
post	B-X
coitum	B-X
(	B-X
dpc	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
demethylation	B-X
of	B-X
this	B-X
region	B-X
occurs	B-X
earlier	B-X
in	B-X
PGC	B-X
development	B-X
.	B-X
The	B-X
timing	B-X
of	B-X
the	B-X
demethylation	B-X
has	B-X
been	B-X
,	B-X
however	B-X
,	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
attempted	B-X
to	B-X
determine	B-X
the	B-X
timing	B-X
of	B-X
methylation	B-X
erasure	B-X
of	B-X
Igf2r	B-X
DMR2	B-X
in	B-X
developing	B-X
PGCs	B-X
,	B-X
using	B-X
transgenic	B-X
mice	B-X
expressing	B-X
green	B-X
fluorescent	B-X
protein	B-X
specifically	B-X
in	B-X
the	B-X
germ	B-X
line	B-X
.	B-X
We	B-X
purified	B-X
migrating	B-X
PGCs	B-X
from	B-X
the	B-X
transgenic	B-X
mice	B-X
and	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
DMR2	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
some	B-X
CpG	B-X
sites	B-X
within	B-X
DMR2	B-X
start	B-X
demethylation	B-X
at	B-X
9.5	B-X
dpc	B-X
in	B-X
some	B-X
migrating	B-X
PGCs	B-X
,	B-X
before	B-X
the	B-X
cells	B-X
colonize	B-X
genital	B-X
ridges	B-X
,	B-X
and	B-X
the	B-X
progression	B-X
of	B-X
demethylation	B-X
is	B-X
rapid	B-X
after	B-X
colonization	B-X
of	B-X
the	B-X
genital	B-X
ridges	B-X
.	B-X
To	B-X
examine	B-X
whether	B-X
the	B-X
gonadal	B-X
environment	B-X
is	B-X
involved	B-X
in	B-X
demethylation	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
methylation	B-X
of	B-X
DMR2	B-X
after	B-X
culturing	B-X
migrating	B-X
PGCs	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
gonadal	B-X
environment	B-X
.	B-X
These	B-X
culture	B-X
experiments	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
a	B-X
gonadal	B-X
environment	B-X
is	B-X
not	B-X
required	B-X
for	B-X
demethylation	B-X
of	B-X
the	B-X
region	B-X
in	B-X
at	B-X
least	B-X
a	B-X
fraction	B-X
of	B-X
PGCs	B-X
.	B-X

These	O
culture	O
experiments	O
support	O
the	O
idea	O
that	O
a	O
gonadal	O
environment	O
is	O
not	O
required	O
for	O
demethylation	O
of	O
the	O
region	O
in	O
at	O
least	O
a	O
fraction	O
of	O
PGCs	O
.	O
<EOS>	B-X
Recent	B-X
experiments	B-X
from	B-X
our	B-X
laboratory	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
idea	B-X
that	B-X
hypothalamic	B-X
astrocytes	B-X
are	B-X
critical	B-X
components	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
mediated	B-X
estrogen	B-X
positive	B-X
feedback	B-X
mechanism	B-X
.	B-X
A	B-X
narrow	B-X
range	B-X
of	B-X
estradiol	B-X
stimulated	B-X
progesterone	B-X
production	B-X
supports	B-X
an	B-X
``	B-X
off-on-off	B-X
''	B-X
mechanism	B-X
regulating	B-X
the	B-X
transition	B-X
from	B-X
estrogen	B-X
negative	B-X
feedback	B-X
to	B-X
estrogen	B-X
positive	B-X
feedback	B-X
,	B-X
and	B-X
back	B-X
again	B-X
.	B-X
The	B-X
rapidity	B-X
of	B-X
the	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
response	B-X
and	B-X
progesterone	B-X
synthesis	B-X
support	B-X
a	B-X
non-genomic	B-X
,	B-X
membrane-initiated	B-X
signaling	B-X
mechanism	B-X
.	B-X
Hypothalamic	B-X
astrocytes	B-X
cultured	B-X
from	B-X
females	B-X
,	B-X
but	B-X
not	B-X
males	B-X
,	B-X
responded	B-X
to	B-X
estradiol	B-X
by	B-X
increasing	B-X
progesterone	B-X
synthesis	B-X
.	B-X
Indeed	B-X
,	B-X
estradiol	B-X
induced	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
release	B-X
in	B-X
male	B-X
astrocytes	B-X
,	B-X
but	B-X
not	B-X
to	B-X
levels	B-X
required	B-X
to	B-X
stimulate	B-X
progesterone	B-X
synthesis	B-X
.	B-X
In	B-X
this	B-X
model	B-X
,	B-X
genetic	B-X
sex	B-X
is	B-X
uncoupled	B-X
from	B-X
gonadal	B-X
sex	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
animals	B-X
that	B-X
developed	B-X
testes	B-X
(	B-X
XYM	B-X
and	B-X
XXM	B-X
)	B-X
lacked	B-X
estrogen	B-X
positive	B-X
feedback	B-X
,	B-X
strongly	B-X
suggesting	B-X
that	B-X
the	B-X
sexual	B-X
differentiation	B-X
of	B-X
progesterone	B-X
synthesis	B-X
is	B-X
driven	B-X
by	B-X
the	B-X
sex	B-X
steroid	B-X
environment	B-X
during	B-X
early	B-X
development	B-X
.	B-X

Inhibition	O
of	O
complex	O
glycosylation	O
increases	O
the	O
formation	O
of	O
PrPsc	B-Protein
.	O
<EOS>	B-X
N-linked	B-X
glycans	B-X
with	B-X
complex	B-X
structure	B-X
have	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cell	B-X
surface	B-X
and	B-X
secreted	B-X
glycoproteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
geldanamycin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
Hsp90	B-X
,	B-X
interferes	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
complex	B-X
glycosylated	B-X
mammalian	B-X
prion	B-X
protein	B-X
(	B-X
PrPC	B-X
)	B-X
.	B-X
Similarly	B-X
to	B-X
inhibitors	B-X
of	B-X
alpha-mannosidases	B-X
,	B-X
geldanamycin	B-X
stabilized	B-X
a	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoform	B-X
and	B-X
prevented	B-X
the	B-X
subsequent	B-X
processing	B-X
into	B-X
complex	B-X
structures	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
PrP/Grp94	B-X
complex	B-X
could	B-X
be	B-X
isolated	B-X
from	B-X
geldanamycin-treated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
Grp94	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
processing	B-X
of	B-X
PrPC	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X
Inhibition	B-X
of	B-X
complex	B-X
glycosylation	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
the	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
anchor	B-X
attachment	B-X
and	B-X
cellular	B-X
trafficking	B-X
of	B-X
high	B-X
mannose	B-X
PrPC	B-X
to	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
scrapie-infected	B-X
neuroblastoma	B-X
cells	B-X
,	B-X
however	B-X
,	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoforms	B-X
were	B-X
preferred	B-X
substrates	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PrP-scrapie	B-X
(	B-X
PrPSc	B-X
)	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
that	B-X
complex	B-X
glycosylation	B-X
is	B-X
dispensable	B-X
for	B-X
the	B-X
cellular	B-X
trafficking	B-X
of	B-X
PrPC	B-X
,	B-X
but	B-X
modulates	B-X
the	B-X
formation	B-X
of	B-X
PrPSc	B-X
.	B-X

N	O
-	O
linked	O
glycans	O
with	O
complex	O
structure	O
have	O
a	O
major	O
role	O
in	O
the	O
biological	O
activity	O
of	O
a	O
wide	O
variety	O
of	O
cell	O
surface	O
and	O
secreted	O
glycoproteins	O
.	O

Here	O
,	O
we	O
show	O
that	O
geldanamycin	O
,	O
an	O
inhibitor	O
of	O
Hsp90	O
,	O
interferes	O
with	O
the	O
formation	O
of	O
complex	O
glycosylated	O
mammalian	O
prion	B-Protein
protein	I-Protein
(	O
PrPC	B-Protein
)	O
.	O
<EOS>	B-X
N-linked	B-X
glycans	B-X
with	B-X
complex	B-X
structure	B-X
have	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cell	B-X
surface	B-X
and	B-X
secreted	B-X
glycoproteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
geldanamycin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
Hsp90	B-X
,	B-X
interferes	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
complex	B-X
glycosylated	B-X
mammalian	B-X
prion	B-X
protein	B-X
(	B-X
PrPC	B-X
)	B-X
.	B-X
Similarly	B-X
to	B-X
inhibitors	B-X
of	B-X
alpha-mannosidases	B-X
,	B-X
geldanamycin	B-X
stabilized	B-X
a	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoform	B-X
and	B-X
prevented	B-X
the	B-X
subsequent	B-X
processing	B-X
into	B-X
complex	B-X
structures	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
PrP/Grp94	B-X
complex	B-X
could	B-X
be	B-X
isolated	B-X
from	B-X
geldanamycin-treated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
Grp94	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
processing	B-X
of	B-X
PrPC	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X
Inhibition	B-X
of	B-X
complex	B-X
glycosylation	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
the	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
anchor	B-X
attachment	B-X
and	B-X
cellular	B-X
trafficking	B-X
of	B-X
high	B-X
mannose	B-X
PrPC	B-X
to	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
scrapie-infected	B-X
neuroblastoma	B-X
cells	B-X
,	B-X
however	B-X
,	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoforms	B-X
were	B-X
preferred	B-X
substrates	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PrP-scrapie	B-X
(	B-X
PrPSc	B-X
)	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
that	B-X
complex	B-X
glycosylation	B-X
is	B-X
dispensable	B-X
for	B-X
the	B-X
cellular	B-X
trafficking	B-X
of	B-X
PrPC	B-X
,	B-X
but	B-X
modulates	B-X
the	B-X
formation	B-X
of	B-X
PrPSc	B-X
.	B-X

Similarly	O
to	O
inhibitors	O
of	O
alpha	O
-	O
mannosidases	O
,	O
geldanamycin	O
stabilized	O
a	O
high	O
mannose	O
PrPC	B-Protein
glycoform	O
and	O
prevented	O
the	O
subsequent	O
processing	O
into	O
complex	O
structures	O
.	O
<EOS>	B-X
N-linked	B-X
glycans	B-X
with	B-X
complex	B-X
structure	B-X
have	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cell	B-X
surface	B-X
and	B-X
secreted	B-X
glycoproteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
geldanamycin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
Hsp90	B-X
,	B-X
interferes	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
complex	B-X
glycosylated	B-X
mammalian	B-X
prion	B-X
protein	B-X
(	B-X
PrPC	B-X
)	B-X
.	B-X
Similarly	B-X
to	B-X
inhibitors	B-X
of	B-X
alpha-mannosidases	B-X
,	B-X
geldanamycin	B-X
stabilized	B-X
a	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoform	B-X
and	B-X
prevented	B-X
the	B-X
subsequent	B-X
processing	B-X
into	B-X
complex	B-X
structures	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
PrP/Grp94	B-X
complex	B-X
could	B-X
be	B-X
isolated	B-X
from	B-X
geldanamycin-treated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
Grp94	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
processing	B-X
of	B-X
PrPC	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X
Inhibition	B-X
of	B-X
complex	B-X
glycosylation	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
the	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
anchor	B-X
attachment	B-X
and	B-X
cellular	B-X
trafficking	B-X
of	B-X
high	B-X
mannose	B-X
PrPC	B-X
to	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
scrapie-infected	B-X
neuroblastoma	B-X
cells	B-X
,	B-X
however	B-X
,	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoforms	B-X
were	B-X
preferred	B-X
substrates	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PrP-scrapie	B-X
(	B-X
PrPSc	B-X
)	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
that	B-X
complex	B-X
glycosylation	B-X
is	B-X
dispensable	B-X
for	B-X
the	B-X
cellular	B-X
trafficking	B-X
of	B-X
PrPC	B-X
,	B-X
but	B-X
modulates	B-X
the	B-X
formation	B-X
of	B-X
PrPSc	B-X
.	B-X

Moreover	O
,	O
a	O
PrP	B-Protein
/	O
Grp94	B-Protein
complex	O
could	O
be	O
isolated	O
from	O
geldanamycin	O
-	O
treated	O
cells	O
,	O
suggesting	O
that	O
Grp94	B-Protein
might	O
play	O
a	O
role	O
in	O
the	O
processing	O
of	O
PrPC	B-Protein
in	O
the	O
endoplasmic	O
reticulum	O
.	O
<EOS>	B-X
N-linked	B-X
glycans	B-X
with	B-X
complex	B-X
structure	B-X
have	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cell	B-X
surface	B-X
and	B-X
secreted	B-X
glycoproteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
geldanamycin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
Hsp90	B-X
,	B-X
interferes	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
complex	B-X
glycosylated	B-X
mammalian	B-X
prion	B-X
protein	B-X
(	B-X
PrPC	B-X
)	B-X
.	B-X
Similarly	B-X
to	B-X
inhibitors	B-X
of	B-X
alpha-mannosidases	B-X
,	B-X
geldanamycin	B-X
stabilized	B-X
a	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoform	B-X
and	B-X
prevented	B-X
the	B-X
subsequent	B-X
processing	B-X
into	B-X
complex	B-X
structures	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
PrP/Grp94	B-X
complex	B-X
could	B-X
be	B-X
isolated	B-X
from	B-X
geldanamycin-treated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
Grp94	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
processing	B-X
of	B-X
PrPC	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X
Inhibition	B-X
of	B-X
complex	B-X
glycosylation	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
the	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
anchor	B-X
attachment	B-X
and	B-X
cellular	B-X
trafficking	B-X
of	B-X
high	B-X
mannose	B-X
PrPC	B-X
to	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
scrapie-infected	B-X
neuroblastoma	B-X
cells	B-X
,	B-X
however	B-X
,	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoforms	B-X
were	B-X
preferred	B-X
substrates	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PrP-scrapie	B-X
(	B-X
PrPSc	B-X
)	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
that	B-X
complex	B-X
glycosylation	B-X
is	B-X
dispensable	B-X
for	B-X
the	B-X
cellular	B-X
trafficking	B-X
of	B-X
PrPC	B-X
,	B-X
but	B-X
modulates	B-X
the	B-X
formation	B-X
of	B-X
PrPSc	B-X
.	B-X

Inhibition	O
of	O
complex	O
glycosylation	O
did	O
not	O
interfere	O
with	O
the	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
anchor	O
attachment	O
and	O
cellular	O
trafficking	O
of	O
high	O
mannose	O
PrPC	B-Protein
to	O
the	O
outer	O
leaflet	O
of	O
the	O
plasma	O
membrane	O
.	O
<EOS>	B-X
Blocking	B-X
N-glycan	B-X
biosynthesis	B-X
at	B-X
the	B-X
oligomannose	B-X
stage	B-X
using	B-X
both	B-X
genetic	B-X
approaches	B-X
and	B-X
the	B-X
small	B-X
molecule	B-X
kifunensine	B-X
dramatically	B-X
reduced	B-X
viral	B-X
entry	B-X
into	B-X
ACE2	B-X
expressing	B-X
HEK293T	B-X
cells	B-X
.	B-X
Overall	B-X
,	B-X
chemical	B-X
inhibitors	B-X
of	B-X
glycosylation	B-X
may	B-X
be	B-X
evaluated	B-X
for	B-X
COVID-19	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
glycosyltransferase	B-X
8	B-X
domain	B-X
containing	B-X
1	B-X
(	B-X
GLT8D1	B-X
)	B-X
,	B-X
induced	B-X
by	B-X
HIF-1α	B-X
under	B-X
a	B-X
hypoxic	B-X
niche	B-X
,	B-X
significantly	B-X
correlates	B-X
with	B-X
a	B-X
higher	B-X
grade	B-X
of	B-X
glioma	B-X
,	B-X
and	B-X
a	B-X
worse	B-X
clinical	B-X
outcome	B-X
.	B-X
GLT8D1	B-X
knockdown	B-X
promotes	B-X
cell	B-X
cycle	B-X
arrest	B-X
at	B-X
G2/M	B-X
phase	B-X
and	B-X
cellular	B-X
apoptosis	B-X
with	B-X
or	B-X
without	B-X
TMZ	B-X
treatment	B-X
.	B-X
We	B-X
reveal	B-X
that	B-X
GLT8D1	B-X
impedes	B-X
CD133	B-X
degradation	B-X
through	B-X
the	B-X
endosomal-lysosomal	B-X
pathway	B-X
by	B-X
N-linked	B-X
glycosylation	B-X
and	B-X
protein-protein	B-X
interaction	B-X
.	B-X
Directly	B-X
blocking	B-X
the	B-X
GLT8D1/CD133	B-X
complex	B-X
formation	B-X
by	B-X
CD133	B-X

In	O
scrapie	O
-	O
infected	O
neuroblastoma	O
cells	O
,	O
however	O
,	O
high	O
mannose	O
PrPC	B-Protein
glycoforms	O
were	O
preferred	O
substrates	O
for	O
the	O
formation	O
of	O
PrP	B-Protein
-	O
scrapie	O
(	O
PrPSc	B-Protein
)	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
geldanamycin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
Hsp90	B-X
,	B-X
interferes	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
complex	B-X
glycosylated	B-X
mammalian	B-X
prion	B-X
protein	B-X
(	B-X
PrPC	B-X
)	B-X
.	B-X
Similarly	B-X
to	B-X
inhibitors	B-X
of	B-X
alpha-mannosidases	B-X
,	B-X
geldanamycin	B-X
stabilized	B-X
a	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoform	B-X
and	B-X
prevented	B-X
the	B-X
subsequent	B-X
processing	B-X
into	B-X
complex	B-X
structures	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
PrP/Grp94	B-X
complex	B-X
could	B-X
be	B-X
isolated	B-X
from	B-X
geldanamycin-treated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
Grp94	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
processing	B-X
of	B-X
PrPC	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X
Inhibition	B-X
of	B-X
complex	B-X
glycosylation	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
the	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
anchor	B-X
attachment	B-X
and	B-X
cellular	B-X
trafficking	B-X
of	B-X
high	B-X
mannose	B-X
PrPC	B-X
to	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
scrapie-infected	B-X
neuroblastoma	B-X
cells	B-X
,	B-X
however	B-X
,	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoforms	B-X
were	B-X
preferred	B-X
substrates	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PrP-scrapie	B-X
(	B-X
PrPSc	B-X
)	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
that	B-X
complex	B-X
glycosylation	B-X
is	B-X
dispensable	B-X
for	B-X
the	B-X
cellular	B-X
trafficking	B-X
of	B-X
PrPC	B-X
,	B-X
but	B-X
modulates	B-X
the	B-X
formation	B-X
of	B-X
PrPSc	B-X
.	B-X

Our	O
study	O
reveals	O
that	O
complex	O
glycosylation	O
is	O
dispensable	O
for	O
the	O
cellular	O
trafficking	O
of	O
PrPC	B-Protein
,	O
but	O
modulates	O
the	O
formation	O
of	O
PrPSc	B-Protein
.	O
<EOS>	B-X
N-linked	B-X
glycans	B-X
with	B-X
complex	B-X
structure	B-X
have	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cell	B-X
surface	B-X
and	B-X
secreted	B-X
glycoproteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
geldanamycin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
Hsp90	B-X
,	B-X
interferes	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
complex	B-X
glycosylated	B-X
mammalian	B-X
prion	B-X
protein	B-X
(	B-X
PrPC	B-X
)	B-X
.	B-X
Similarly	B-X
to	B-X
inhibitors	B-X
of	B-X
alpha-mannosidases	B-X
,	B-X
geldanamycin	B-X
stabilized	B-X
a	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoform	B-X
and	B-X
prevented	B-X
the	B-X
subsequent	B-X
processing	B-X
into	B-X
complex	B-X
structures	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
PrP/Grp94	B-X
complex	B-X
could	B-X
be	B-X
isolated	B-X
from	B-X
geldanamycin-treated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
Grp94	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
processing	B-X
of	B-X
PrPC	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X
Inhibition	B-X
of	B-X
complex	B-X
glycosylation	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
the	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
anchor	B-X
attachment	B-X
and	B-X
cellular	B-X
trafficking	B-X
of	B-X
high	B-X
mannose	B-X
PrPC	B-X
to	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
scrapie-infected	B-X
neuroblastoma	B-X
cells	B-X
,	B-X
however	B-X
,	B-X
high	B-X
mannose	B-X
PrPC	B-X
glycoforms	B-X
were	B-X
preferred	B-X
substrates	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PrP-scrapie	B-X
(	B-X
PrPSc	B-X
)	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
that	B-X
complex	B-X
glycosylation	B-X
is	B-X
dispensable	B-X
for	B-X
the	B-X
cellular	B-X
trafficking	B-X
of	B-X
PrPC	B-X
,	B-X
but	B-X
modulates	B-X
the	B-X
formation	B-X
of	B-X
PrPSc	B-X
.	B-X

Chromatin	O
-	O
dependent	O
regulation	O
of	O
the	O
MMTV	O
promoter	O
by	O
cAMP	O
signaling	O
is	O
mediated	O
through	O
distinct	O
pathways	O
.	O
<EOS>	B-X
The	B-X
nucleoprotein	B-X
structure	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
promoter	B-X
defines	B-X
its	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
A	B-X
stably	B-X
replicating	B-X
MMTV	B-X
template	B-X
in	B-X
highly	B-X
organized	B-X
chromatin	B-X
is	B-X
repressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cAMP	B-X
,	B-X
whereas	B-X
a	B-X
transiently	B-X
transfected	B-X
template	B-X
with	B-X
a	B-X
disorganized	B-X
structure	B-X
is	B-X
activated	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
cAMP-induced	B-X
signal	B-X
(	B-X
s	B-X
)	B-X
by	B-X
which	B-X
these	B-X
opposing	B-X
responses	B-X
occur	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
their	B-X
mechanism	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
changes	B-X
observed	B-X
at	B-X
both	B-X
templates	B-X
are	B-X
mediated	B-X
through	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
MMTV	B-X
promoter	B-X
lacks	B-X
a	B-X
consensus	B-X
cAMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
neither	B-X
template	B-X
requires	B-X
cAMP	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
to	B-X
elicit	B-X
a	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
the	B-X
responses	B-X
of	B-X
the	B-X
two	B-X
templates	B-X
differ	B-X
mechanistically	B-X
in	B-X
that	B-X
the	B-X
CREB-binding	B-X
protein	B-X
p300	B-X
potentiates	B-X
activation	B-X
from	B-X
the	B-X
transient	B-X
template	B-X
in	B-X
a	B-X
manner	B-X
dependent	B-X
on	B-X
its	B-X
Cys/His-rich	B-X
region	B-X
3	B-X
,	B-X
but	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
affect	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
replicating	B-X
chromatin	B-X
template	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
show	B-X
that	B-X
cAMP	B-X
treatment	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
acetylation	B-X
of	B-X
histone	B-X
H4	B-X
,	B-X
and	B-X
in	B-X
multiple	B-X
modifications	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
specific	B-X
nucleosomes	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
stable	B-X
MMTV	B-X
template	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
novel	B-X
CREB-independent	B-X
,	B-X
chromatin-dependent	B-X
pathways	B-X
for	B-X
transcriptional	B-X
regulation	B-X
by	B-X
cAMP	B-X
.	B-X

The	O
nucleoprotein	O
structure	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
promoter	O
defines	O
its	O
response	O
to	O
cAMP	O
signaling	O
.	O
<EOS>	B-X
The	B-X
nucleoprotein	B-X
structure	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
promoter	B-X
defines	B-X
its	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
A	B-X
stably	B-X
replicating	B-X
MMTV	B-X
template	B-X
in	B-X
highly	B-X
organized	B-X
chromatin	B-X
is	B-X
repressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cAMP	B-X
,	B-X
whereas	B-X
a	B-X
transiently	B-X
transfected	B-X
template	B-X
with	B-X
a	B-X
disorganized	B-X
structure	B-X
is	B-X
activated	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
cAMP-induced	B-X
signal	B-X
(	B-X
s	B-X
)	B-X
by	B-X
which	B-X
these	B-X
opposing	B-X
responses	B-X
occur	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
their	B-X
mechanism	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
changes	B-X
observed	B-X
at	B-X
both	B-X
templates	B-X
are	B-X
mediated	B-X
through	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
MMTV	B-X
promoter	B-X
lacks	B-X
a	B-X
consensus	B-X
cAMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
neither	B-X
template	B-X
requires	B-X
cAMP	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
to	B-X
elicit	B-X
a	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
the	B-X
responses	B-X
of	B-X
the	B-X
two	B-X
templates	B-X
differ	B-X
mechanistically	B-X
in	B-X
that	B-X
the	B-X
CREB-binding	B-X
protein	B-X
p300	B-X
potentiates	B-X
activation	B-X
from	B-X
the	B-X
transient	B-X
template	B-X
in	B-X
a	B-X
manner	B-X
dependent	B-X
on	B-X
its	B-X
Cys/His-rich	B-X
region	B-X
3	B-X
,	B-X
but	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
affect	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
replicating	B-X
chromatin	B-X
template	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
show	B-X
that	B-X
cAMP	B-X
treatment	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
acetylation	B-X
of	B-X
histone	B-X
H4	B-X
,	B-X
and	B-X
in	B-X
multiple	B-X
modifications	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
specific	B-X
nucleosomes	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
stable	B-X
MMTV	B-X
template	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
novel	B-X
CREB-independent	B-X
,	B-X
chromatin-dependent	B-X
pathways	B-X
for	B-X
transcriptional	B-X
regulation	B-X
by	B-X
cAMP	B-X
.	B-X

A	O
stably	O
replicating	O
MMTV	O
template	O
in	O
highly	O
organized	O
chromatin	O
is	O
repressed	O
in	O
the	O
presence	O
of	O
cAMP	O
,	O
whereas	O
a	O
transiently	O
transfected	O
template	O
with	O
a	O
disorganized	O
structure	O
is	O
activated	O
.	O
<EOS>	B-X
The	B-X
nucleoprotein	B-X
structure	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
promoter	B-X
defines	B-X
its	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
A	B-X
stably	B-X
replicating	B-X
MMTV	B-X
template	B-X
in	B-X
highly	B-X
organized	B-X
chromatin	B-X
is	B-X
repressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cAMP	B-X
,	B-X
whereas	B-X
a	B-X
transiently	B-X
transfected	B-X
template	B-X
with	B-X
a	B-X
disorganized	B-X
structure	B-X
is	B-X
activated	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
cAMP-induced	B-X
signal	B-X
(	B-X
s	B-X
)	B-X
by	B-X
which	B-X
these	B-X
opposing	B-X
responses	B-X
occur	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
their	B-X
mechanism	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
changes	B-X
observed	B-X
at	B-X
both	B-X
templates	B-X
are	B-X
mediated	B-X
through	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
MMTV	B-X
promoter	B-X
lacks	B-X
a	B-X
consensus	B-X
cAMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
neither	B-X
template	B-X
requires	B-X
cAMP	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
to	B-X
elicit	B-X
a	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
the	B-X
responses	B-X
of	B-X
the	B-X
two	B-X
templates	B-X
differ	B-X
mechanistically	B-X
in	B-X
that	B-X
the	B-X
CREB-binding	B-X
protein	B-X
p300	B-X
potentiates	B-X
activation	B-X
from	B-X
the	B-X
transient	B-X
template	B-X
in	B-X
a	B-X
manner	B-X
dependent	B-X
on	B-X
its	B-X
Cys/His-rich	B-X
region	B-X
3	B-X
,	B-X
but	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
affect	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
replicating	B-X
chromatin	B-X
template	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
show	B-X
that	B-X
cAMP	B-X
treatment	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
acetylation	B-X
of	B-X
histone	B-X
H4	B-X
,	B-X
and	B-X
in	B-X
multiple	B-X
modifications	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
specific	B-X
nucleosomes	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
stable	B-X
MMTV	B-X
template	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
novel	B-X
CREB-independent	B-X
,	B-X
chromatin-dependent	B-X
pathways	B-X
for	B-X
transcriptional	B-X
regulation	B-X
by	B-X
cAMP	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
nature	O
of	O
the	O
cAMP	O
-	O
induced	O
signal	O
(	O
s	O
)	O
by	O
which	O
these	O
opposing	O
responses	O
occur	O
to	O
gain	O
insight	O
into	O
their	O
mechanism	O
.	O

We	O
demonstrate	O
that	O
the	O
transcriptional	O
changes	O
observed	O
at	O
both	O
templates	O
are	O
mediated	O
through	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O
<EOS>	B-X
The	B-X
nucleoprotein	B-X
structure	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
promoter	B-X
defines	B-X
its	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
A	B-X
stably	B-X
replicating	B-X
MMTV	B-X
template	B-X
in	B-X
highly	B-X
organized	B-X
chromatin	B-X
is	B-X
repressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cAMP	B-X
,	B-X
whereas	B-X
a	B-X
transiently	B-X
transfected	B-X
template	B-X
with	B-X
a	B-X
disorganized	B-X
structure	B-X
is	B-X
activated	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
cAMP-induced	B-X
signal	B-X
(	B-X
s	B-X
)	B-X
by	B-X
which	B-X
these	B-X
opposing	B-X
responses	B-X
occur	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
their	B-X
mechanism	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
changes	B-X
observed	B-X
at	B-X
both	B-X
templates	B-X
are	B-X
mediated	B-X
through	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
MMTV	B-X
promoter	B-X
lacks	B-X
a	B-X
consensus	B-X
cAMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
neither	B-X
template	B-X
requires	B-X
cAMP	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
to	B-X
elicit	B-X
a	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
the	B-X
responses	B-X
of	B-X
the	B-X
two	B-X
templates	B-X
differ	B-X
mechanistically	B-X
in	B-X
that	B-X
the	B-X
CREB-binding	B-X
protein	B-X
p300	B-X
potentiates	B-X
activation	B-X
from	B-X
the	B-X
transient	B-X
template	B-X
in	B-X
a	B-X
manner	B-X
dependent	B-X
on	B-X
its	B-X
Cys/His-rich	B-X
region	B-X
3	B-X
,	B-X
but	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
affect	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
replicating	B-X
chromatin	B-X
template	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
show	B-X
that	B-X
cAMP	B-X
treatment	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
acetylation	B-X
of	B-X
histone	B-X
H4	B-X
,	B-X
and	B-X
in	B-X
multiple	B-X
modifications	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
specific	B-X
nucleosomes	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
stable	B-X
MMTV	B-X
template	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
novel	B-X
CREB-independent	B-X
,	B-X
chromatin-dependent	B-X
pathways	B-X
for	B-X
transcriptional	B-X
regulation	B-X
by	B-X
cAMP	B-X
.	B-X

In	O
addition	O
,	O
the	O
MMTV	O
promoter	O
lacks	O
a	O
consensus	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
and	O
neither	O
template	O
requires	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
to	O
elicit	O
a	O
response	O
to	O
cAMP	O
signaling	O
.	O
<EOS>	B-X
The	B-X
nucleoprotein	B-X
structure	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
promoter	B-X
defines	B-X
its	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
A	B-X
stably	B-X
replicating	B-X
MMTV	B-X
template	B-X
in	B-X
highly	B-X
organized	B-X
chromatin	B-X
is	B-X
repressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cAMP	B-X
,	B-X
whereas	B-X
a	B-X
transiently	B-X
transfected	B-X
template	B-X
with	B-X
a	B-X
disorganized	B-X
structure	B-X
is	B-X
activated	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
cAMP-induced	B-X
signal	B-X
(	B-X
s	B-X
)	B-X
by	B-X
which	B-X
these	B-X
opposing	B-X
responses	B-X
occur	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
their	B-X
mechanism	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
changes	B-X
observed	B-X
at	B-X
both	B-X
templates	B-X
are	B-X
mediated	B-X
through	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
MMTV	B-X
promoter	B-X
lacks	B-X
a	B-X
consensus	B-X
cAMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
neither	B-X
template	B-X
requires	B-X
cAMP	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
to	B-X
elicit	B-X
a	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
the	B-X
responses	B-X
of	B-X
the	B-X
two	B-X
templates	B-X
differ	B-X
mechanistically	B-X
in	B-X
that	B-X
the	B-X
CREB-binding	B-X
protein	B-X
p300	B-X
potentiates	B-X
activation	B-X
from	B-X
the	B-X
transient	B-X
template	B-X
in	B-X
a	B-X
manner	B-X
dependent	B-X
on	B-X
its	B-X
Cys/His-rich	B-X
region	B-X
3	B-X
,	B-X
but	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
affect	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
replicating	B-X
chromatin	B-X
template	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
show	B-X
that	B-X
cAMP	B-X
treatment	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
acetylation	B-X
of	B-X
histone	B-X
H4	B-X
,	B-X
and	B-X
in	B-X
multiple	B-X
modifications	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
specific	B-X
nucleosomes	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
stable	B-X
MMTV	B-X
template	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
novel	B-X
CREB-independent	B-X
,	B-X
chromatin-dependent	B-X
pathways	B-X
for	B-X
transcriptional	B-X
regulation	B-X
by	B-X
cAMP	B-X
.	B-X

However	O
,	O
the	O
responses	O
of	O
the	O
two	O
templates	O
differ	O
mechanistically	O
in	O
that	O
the	O
CREB	O
-	O
binding	O
protein	O
p300	B-Protein
potentiates	O
activation	O
from	O
the	O
transient	O
template	O
in	O
a	O
manner	O
dependent	O
on	O
its	O
Cys	O
/	O
His	O
-	O
rich	O
region	O
3	O
,	O
but	O
does	O
not	O
appear	O
to	O
affect	O
the	O
repression	O
of	O
the	O
replicating	O
chromatin	O
template	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
show	O
that	O
cAMP	O
treatment	O
results	O
in	O
a	O
decrease	O
in	O
acetylation	O
of	O
histone	B-Protein
H4	I-Protein
,	O
and	O
in	O
multiple	O
modifications	O
of	O
histone	B-Protein
H3	I-Protein
at	O
specific	O
nucleosomes	O
in	O
the	O
promoter	O
region	O
of	O
the	O
stable	O
MMTV	O
template	O
.	O

These	O
findings	O
suggest	O
novel	O
CREB	O
-	O
independent	O
,	O
chromatin	O
-	O
dependent	O
pathways	O
for	O
transcriptional	O
regulation	O
by	O
cAMP	O
.	O
<EOS>	B-X
The	B-X
nucleoprotein	B-X
structure	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
promoter	B-X
defines	B-X
its	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
A	B-X
stably	B-X
replicating	B-X
MMTV	B-X
template	B-X
in	B-X
highly	B-X
organized	B-X
chromatin	B-X
is	B-X
repressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cAMP	B-X
,	B-X
whereas	B-X
a	B-X
transiently	B-X
transfected	B-X
template	B-X
with	B-X
a	B-X
disorganized	B-X
structure	B-X
is	B-X
activated	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
cAMP-induced	B-X
signal	B-X
(	B-X
s	B-X
)	B-X
by	B-X
which	B-X
these	B-X
opposing	B-X
responses	B-X
occur	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
their	B-X
mechanism	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
changes	B-X
observed	B-X
at	B-X
both	B-X
templates	B-X
are	B-X
mediated	B-X
through	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
MMTV	B-X
promoter	B-X
lacks	B-X
a	B-X
consensus	B-X
cAMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
neither	B-X
template	B-X
requires	B-X
cAMP	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
to	B-X
elicit	B-X
a	B-X
response	B-X
to	B-X
cAMP	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
the	B-X
responses	B-X
of	B-X
the	B-X
two	B-X
templates	B-X
differ	B-X
mechanistically	B-X
in	B-X
that	B-X
the	B-X
CREB-binding	B-X
protein	B-X
p300	B-X
potentiates	B-X
activation	B-X
from	B-X
the	B-X
transient	B-X
template	B-X
in	B-X
a	B-X
manner	B-X
dependent	B-X
on	B-X
its	B-X
Cys/His-rich	B-X
region	B-X
3	B-X
,	B-X
but	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
affect	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
replicating	B-X
chromatin	B-X
template	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
show	B-X
that	B-X
cAMP	B-X
treatment	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
acetylation	B-X
of	B-X
histone	B-X
H4	B-X
,	B-X
and	B-X
in	B-X
multiple	B-X
modifications	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
specific	B-X
nucleosomes	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
stable	B-X
MMTV	B-X
template	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
novel	B-X
CREB-independent	B-X
,	B-X
chromatin-dependent	B-X
pathways	B-X
for	B-X
transcriptional	B-X
regulation	B-X
by	B-X
cAMP	B-X
.	B-X

Identification	O
of	O
the	O
ZPC	B-Protein
oligosaccharide	O
ligand	O
involved	O
in	O
sperm	O
binding	O
and	O
the	O
glycan	O
structures	O
of	O
Xenopus	O
laevis	O
vitelline	O
envelope	O
glycoproteins	O
.	O
<EOS>	B-X
The	B-X
Xenopus	B-X
laevis	B-X
egg	B-X
vitelline	B-X
envelope	B-X
is	B-X
composed	B-X
of	B-X
five	B-X
glycoproteins	B-X
(	B-X
ZPA	B-X
,	B-X
ZPB	B-X
,	B-X
ZPC	B-X
,	B-X
ZPD	B-X
,	B-X
and	B-X
ZPX	B-X
)	B-X
.	B-X
As	B-X
shown	B-X
previously	B-X
,	B-X
ZPC	B-X
is	B-X
the	B-X
primary	B-X
ligand	B-X
for	B-X
sperm	B-X
binding	B-X
to	B-X
the	B-X
egg	B-X
envelope	B-X
,	B-X
and	B-X
this	B-X
binding	B-X
involves	B-X
the	B-X
oligosaccharide	B-X
moieties	B-X
of	B-X
the	B-X
glycoprotein	B-X
(	B-X
Biol	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
sperm-egg	B-X
envelope	B-X
binding	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
vitelline	B-X
envelope	B-X
(	B-X
VE	B-X
)	B-X
glycoproteins	B-X
.	B-X
The	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
VE	B-X
were	B-X
composed	B-X
predominantly	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
high-mannose	B-X
(	B-X
5-9	B-X
)	B-X
and	B-X
neutral	B-X
,	B-X
complex	B-X
oligosaccharides	B-X
primarily	B-X
derived	B-X
from	B-X
ZPC	B-X
(	B-X
the	B-X
dominant	B-X
glycoprotein	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ZPA	B-X
N-linked	B-X
glycans	B-X
were	B-X
composed	B-X
of	B-X
acidic-complex	B-X
and	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
ZPX	B-X
had	B-X
only	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
and	B-X
ZPB	B-X
lacked	B-X
N-linked	B-X
oligosaccharides	B-X
.	B-X
The	B-X
consensus	B-X
sequence	B-X
for	B-X
N-linked	B-X
glycosylation	B-X
at	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
residue	B-X
N113	B-X
of	B-X
the	B-X
ZPC	B-X
protein	B-X
sequence	B-X
was	B-X
glycosylated	B-X
solely	B-X
with	B-X
high-mannose	B-X
oligosaccharides	B-X
.	B-X
This	B-X
conserved	B-X
glycosylation	B-X
site	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
the	B-X
three-dimensional	B-X
structure	B-X
of	B-X
the	B-X
ZPC	B-X
glycoproteins	B-X
.	B-X
One	B-X
of	B-X
the	B-X
complex	B-X
oligosaccharides	B-X
of	B-X
ZPC	B-X
possessed	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
The	B-X
same	B-X
ZPC	B-X
oligosaccharide	B-X
species	B-X
isolated	B-X
from	B-X
the	B-X
activated	B-X
egg	B-X
envelopes	B-X
lacked	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
an	B-X
alteration	B-X
in	B-X
the	B-X
oligosaccharide	B-X
structure	B-X
of	B-X
ZPC	B-X
by	B-X
glucosaminidase	B-X
released	B-X
from	B-X
the	B-X
cortical	B-X
granule	B-X
reaction	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
loss	B-X
of	B-X
sperm	B-X
binding	B-X
ligand	B-X
activity	B-X
at	B-X
fertilization	B-X
.	B-X

The	O
Xenopus	O
laevis	O
egg	O
vitelline	O
envelope	O
is	O
composed	O
of	O
five	O
glycoproteins	O
(	O
ZPA	B-Protein
,	O
ZPB	B-Protein
,	O
ZPC	B-Protein
,	O
ZPD	B-Protein
,	O
and	O
ZPX	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
Xenopus	B-X
laevis	B-X
egg	B-X
vitelline	B-X
envelope	B-X
is	B-X
composed	B-X
of	B-X
five	B-X
glycoproteins	B-X
(	B-X
ZPA	B-X
,	B-X
ZPB	B-X
,	B-X
ZPC	B-X
,	B-X
ZPD	B-X
,	B-X
and	B-X
ZPX	B-X
)	B-X
.	B-X
As	B-X
shown	B-X
previously	B-X
,	B-X
ZPC	B-X
is	B-X
the	B-X
primary	B-X
ligand	B-X
for	B-X
sperm	B-X
binding	B-X
to	B-X
the	B-X
egg	B-X
envelope	B-X
,	B-X
and	B-X
this	B-X
binding	B-X
involves	B-X
the	B-X
oligosaccharide	B-X
moieties	B-X
of	B-X
the	B-X
glycoprotein	B-X
(	B-X
Biol	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
sperm-egg	B-X
envelope	B-X
binding	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
vitelline	B-X
envelope	B-X
(	B-X
VE	B-X
)	B-X
glycoproteins	B-X
.	B-X
The	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
VE	B-X
were	B-X
composed	B-X
predominantly	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
high-mannose	B-X
(	B-X
5-9	B-X
)	B-X
and	B-X
neutral	B-X
,	B-X
complex	B-X
oligosaccharides	B-X
primarily	B-X
derived	B-X
from	B-X
ZPC	B-X
(	B-X
the	B-X
dominant	B-X
glycoprotein	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ZPA	B-X
N-linked	B-X
glycans	B-X
were	B-X
composed	B-X
of	B-X
acidic-complex	B-X
and	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
ZPX	B-X
had	B-X
only	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
and	B-X
ZPB	B-X
lacked	B-X
N-linked	B-X
oligosaccharides	B-X
.	B-X
The	B-X
consensus	B-X
sequence	B-X
for	B-X
N-linked	B-X
glycosylation	B-X
at	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
residue	B-X
N113	B-X
of	B-X
the	B-X
ZPC	B-X
protein	B-X
sequence	B-X
was	B-X
glycosylated	B-X
solely	B-X
with	B-X
high-mannose	B-X
oligosaccharides	B-X
.	B-X
This	B-X
conserved	B-X
glycosylation	B-X
site	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
the	B-X
three-dimensional	B-X
structure	B-X
of	B-X
the	B-X
ZPC	B-X
glycoproteins	B-X
.	B-X
One	B-X
of	B-X
the	B-X
complex	B-X
oligosaccharides	B-X
of	B-X
ZPC	B-X
possessed	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
The	B-X
same	B-X
ZPC	B-X
oligosaccharide	B-X
species	B-X
isolated	B-X
from	B-X
the	B-X
activated	B-X
egg	B-X
envelopes	B-X
lacked	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
an	B-X
alteration	B-X
in	B-X
the	B-X
oligosaccharide	B-X
structure	B-X
of	B-X
ZPC	B-X
by	B-X
glucosaminidase	B-X
released	B-X
from	B-X
the	B-X
cortical	B-X
granule	B-X
reaction	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
loss	B-X
of	B-X
sperm	B-X
binding	B-X
ligand	B-X
activity	B-X
at	B-X
fertilization	B-X
.	B-X

As	O
shown	O
previously	O
,	O
ZPC	B-Protein
is	O
the	O
primary	O
ligand	O
for	O
sperm	O
binding	O
to	O
the	O
egg	O
envelope	O
,	O
and	O
this	O
binding	O
involves	O
the	O
oligosaccharide	O
moieties	O
of	O
the	O
glycoprotein	O
(	O
Biol	O
.	O
Reprod	O
.	O
,	O
62	O
:	O
766	O
-	O
774	O
,	O
2000	O
)	O
.	O

To	O
understand	O
the	O
molecular	O
mechanism	O
of	O
sperm	O
-	O
egg	O
envelope	O
binding	O
,	O
we	O
characterized	O
the	O
N	O
-	O
linked	O
glycans	O
of	O
the	O
vitelline	O
envelope	O
(	O
VE	O
)	O
glycoproteins	O
.	O

The	O
N	O
-	O
linked	O
glycans	O
of	O
the	O
VE	O
were	O
composed	O
predominantly	O
of	O
a	O
heterogeneous	O
mixture	O
of	O
high	O
-	O
mannose	O
(	O
5	O
-	O
9	O
)	O
and	O
neutral	O
,	O
complex	O
oligosaccharides	O
primarily	O
derived	O
from	O
ZPC	B-Protein
(	O
the	O
dominant	O
glycoprotein	O
)	O
.	O

However	O
,	O
the	O
ZPA	B-Protein
N	O
-	O
linked	O
glycans	O
were	O
composed	O
of	O
acidic	O
-	O
complex	O
and	O
high	O
-	O
mannose	O
oligosaccharides	O
,	O
ZPX	B-Protein
had	O
only	O
high	O
-	O
mannose	O
oligosaccharides	O
,	O
and	O
ZPB	B-Protein
lacked	O
N	O
-	O
linked	O
oligosaccharides	O
.	O
<EOS>	B-X
The	B-X
Xenopus	B-X
laevis	B-X
egg	B-X
vitelline	B-X
envelope	B-X
is	B-X
composed	B-X
of	B-X
five	B-X
glycoproteins	B-X
(	B-X
ZPA	B-X
,	B-X
ZPB	B-X
,	B-X
ZPC	B-X
,	B-X
ZPD	B-X
,	B-X
and	B-X
ZPX	B-X
)	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
sperm-egg	B-X
envelope	B-X
binding	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
vitelline	B-X
envelope	B-X
(	B-X
VE	B-X
)	B-X
glycoproteins	B-X
.	B-X
The	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
VE	B-X
were	B-X
composed	B-X
predominantly	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
high-mannose	B-X
(	B-X
5-9	B-X
)	B-X
and	B-X
neutral	B-X
,	B-X
complex	B-X
oligosaccharides	B-X
primarily	B-X
derived	B-X
from	B-X
ZPC	B-X
(	B-X
the	B-X
dominant	B-X
glycoprotein	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ZPA	B-X
N-linked	B-X
glycans	B-X
were	B-X
composed	B-X
of	B-X
acidic-complex	B-X
and	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
ZPX	B-X
had	B-X
only	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
and	B-X
ZPB	B-X
lacked	B-X
N-linked	B-X
oligosaccharides	B-X
.	B-X
The	B-X
consensus	B-X
sequence	B-X
for	B-X
N-linked	B-X
glycosylation	B-X
at	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
residue	B-X
N113	B-X
of	B-X
the	B-X
ZPC	B-X
protein	B-X
sequence	B-X
was	B-X
glycosylated	B-X
solely	B-X
with	B-X
high-mannose	B-X
oligosaccharides	B-X
.	B-X
One	B-X
of	B-X
the	B-X
complex	B-X
oligosaccharides	B-X
of	B-X
ZPC	B-X
possessed	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
The	B-X
same	B-X
ZPC	B-X
oligosaccharide	B-X
species	B-X
isolated	B-X
from	B-X
the	B-X
activated	B-X
egg	B-X
envelopes	B-X
lacked	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
cortical	B-X
granules	B-X
contain	B-X
beta-N-acetyl-glucosaminidase	B-X
(	B-X
J.	B-X
Exp	B-X
.	B-X

The	O
consensus	O
sequence	O
for	O
N	O
-	O
linked	O
glycosylation	O
at	O
the	O
evolutionarily	O
conserved	O
residue	O
N113	O
of	O
the	O
ZPC	B-Protein
protein	O
sequence	O
was	O
glycosylated	O
solely	O
with	O
high	O
-	O
mannose	O
oligosaccharides	O
.	O
<EOS>	B-X
The	B-X
Xenopus	B-X
laevis	B-X
egg	B-X
vitelline	B-X
envelope	B-X
is	B-X
composed	B-X
of	B-X
five	B-X
glycoproteins	B-X
(	B-X
ZPA	B-X
,	B-X
ZPB	B-X
,	B-X
ZPC	B-X
,	B-X
ZPD	B-X
,	B-X
and	B-X
ZPX	B-X
)	B-X
.	B-X
As	B-X
shown	B-X
previously	B-X
,	B-X
ZPC	B-X
is	B-X
the	B-X
primary	B-X
ligand	B-X
for	B-X
sperm	B-X
binding	B-X
to	B-X
the	B-X
egg	B-X
envelope	B-X
,	B-X
and	B-X
this	B-X
binding	B-X
involves	B-X
the	B-X
oligosaccharide	B-X
moieties	B-X
of	B-X
the	B-X
glycoprotein	B-X
(	B-X
Biol	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
sperm-egg	B-X
envelope	B-X
binding	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
vitelline	B-X
envelope	B-X
(	B-X
VE	B-X
)	B-X
glycoproteins	B-X
.	B-X
The	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
VE	B-X
were	B-X
composed	B-X
predominantly	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
high-mannose	B-X
(	B-X
5-9	B-X
)	B-X
and	B-X
neutral	B-X
,	B-X
complex	B-X
oligosaccharides	B-X
primarily	B-X
derived	B-X
from	B-X
ZPC	B-X
(	B-X
the	B-X
dominant	B-X
glycoprotein	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ZPA	B-X
N-linked	B-X
glycans	B-X
were	B-X
composed	B-X
of	B-X
acidic-complex	B-X
and	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
ZPX	B-X
had	B-X
only	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
and	B-X
ZPB	B-X
lacked	B-X
N-linked	B-X
oligosaccharides	B-X
.	B-X
The	B-X
consensus	B-X
sequence	B-X
for	B-X
N-linked	B-X
glycosylation	B-X
at	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
residue	B-X
N113	B-X
of	B-X
the	B-X
ZPC	B-X
protein	B-X
sequence	B-X
was	B-X
glycosylated	B-X
solely	B-X
with	B-X
high-mannose	B-X
oligosaccharides	B-X
.	B-X
This	B-X
conserved	B-X
glycosylation	B-X
site	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
the	B-X
three-dimensional	B-X
structure	B-X
of	B-X
the	B-X
ZPC	B-X
glycoproteins	B-X
.	B-X
One	B-X
of	B-X
the	B-X
complex	B-X
oligosaccharides	B-X
of	B-X
ZPC	B-X
possessed	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
The	B-X
same	B-X
ZPC	B-X
oligosaccharide	B-X
species	B-X
isolated	B-X
from	B-X
the	B-X
activated	B-X
egg	B-X
envelopes	B-X
lacked	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
cortical	B-X
granules	B-X
contain	B-X
beta-N-acetyl-glucosaminidase	B-X
(	B-X
J.	B-X
Exp	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
an	B-X
alteration	B-X
in	B-X
the	B-X
oligosaccharide	B-X
structure	B-X
of	B-X
ZPC	B-X
by	B-X
glucosaminidase	B-X
released	B-X
from	B-X
the	B-X
cortical	B-X
granule	B-X
reaction	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
loss	B-X
of	B-X
sperm	B-X
binding	B-X
ligand	B-X
activity	B-X
at	B-X
fertilization	B-X
.	B-X

This	O
conserved	O
glycosylation	O
site	O
may	O
be	O
of	O
importance	O
to	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
ZPC	B-Protein
glycoproteins	O
.	O

One	O
of	O
the	O
complex	O
oligosaccharides	O
of	O
ZPC	B-Protein
possessed	O
terminal	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
glucosamine	O
residues	O
.	O

The	O
same	O
ZPC	B-Protein
oligosaccharide	O
species	O
isolated	O
from	O
the	O
activated	O
egg	O
envelopes	O
lacked	O
terminal	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
glucosamine	O
residues	O
.	O

We	O
previously	O
showed	O
that	O
the	O
cortical	O
granules	O
contain	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
glucosaminidase	O
(	O
J	O
.	O
Exp	O
.	O
Zool	O
.	O
,	O
235	O
:	O
335	O
-	O
340	O
,	O
1985	O
)	O
.	O

We	O
propose	O
that	O
an	O
alteration	O
in	O
the	O
oligosaccharide	O
structure	O
of	O
ZPC	B-Protein
by	O
glucosaminidase	O
released	O
from	O
the	O
cortical	O
granule	O
reaction	O
is	O
responsible	O
for	O
the	O
loss	O
of	O
sperm	O
binding	O
ligand	O
activity	O
at	O
fertilization	O
.	O
<EOS>	B-X
The	B-X
Xenopus	B-X
laevis	B-X
egg	B-X
vitelline	B-X
envelope	B-X
is	B-X
composed	B-X
of	B-X
five	B-X
glycoproteins	B-X
(	B-X
ZPA	B-X
,	B-X
ZPB	B-X
,	B-X
ZPC	B-X
,	B-X
ZPD	B-X
,	B-X
and	B-X
ZPX	B-X
)	B-X
.	B-X
As	B-X
shown	B-X
previously	B-X
,	B-X
ZPC	B-X
is	B-X
the	B-X
primary	B-X
ligand	B-X
for	B-X
sperm	B-X
binding	B-X
to	B-X
the	B-X
egg	B-X
envelope	B-X
,	B-X
and	B-X
this	B-X
binding	B-X
involves	B-X
the	B-X
oligosaccharide	B-X
moieties	B-X
of	B-X
the	B-X
glycoprotein	B-X
(	B-X
Biol	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
sperm-egg	B-X
envelope	B-X
binding	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
vitelline	B-X
envelope	B-X
(	B-X
VE	B-X
)	B-X
glycoproteins	B-X
.	B-X
The	B-X
N-linked	B-X
glycans	B-X
of	B-X
the	B-X
VE	B-X
were	B-X
composed	B-X
predominantly	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
high-mannose	B-X
(	B-X
5-9	B-X
)	B-X
and	B-X
neutral	B-X
,	B-X
complex	B-X
oligosaccharides	B-X
primarily	B-X
derived	B-X
from	B-X
ZPC	B-X
(	B-X
the	B-X
dominant	B-X
glycoprotein	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ZPA	B-X
N-linked	B-X
glycans	B-X
were	B-X
composed	B-X
of	B-X
acidic-complex	B-X
and	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
ZPX	B-X
had	B-X
only	B-X
high-mannose	B-X
oligosaccharides	B-X
,	B-X
and	B-X
ZPB	B-X
lacked	B-X
N-linked	B-X
oligosaccharides	B-X
.	B-X
The	B-X
consensus	B-X
sequence	B-X
for	B-X
N-linked	B-X
glycosylation	B-X
at	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
residue	B-X
N113	B-X
of	B-X
the	B-X
ZPC	B-X
protein	B-X
sequence	B-X
was	B-X
glycosylated	B-X
solely	B-X
with	B-X
high-mannose	B-X
oligosaccharides	B-X
.	B-X
This	B-X
conserved	B-X
glycosylation	B-X
site	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
the	B-X
three-dimensional	B-X
structure	B-X
of	B-X
the	B-X
ZPC	B-X
glycoproteins	B-X
.	B-X
One	B-X
of	B-X
the	B-X
complex	B-X
oligosaccharides	B-X
of	B-X
ZPC	B-X
possessed	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
The	B-X
same	B-X
ZPC	B-X
oligosaccharide	B-X
species	B-X
isolated	B-X
from	B-X
the	B-X
activated	B-X
egg	B-X
envelopes	B-X
lacked	B-X
terminal	B-X
beta-N-acetyl-glucosamine	B-X
residues	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
cortical	B-X
granules	B-X
contain	B-X
beta-N-acetyl-glucosaminidase	B-X
(	B-X
J.	B-X
Exp	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
an	B-X
alteration	B-X
in	B-X
the	B-X
oligosaccharide	B-X
structure	B-X
of	B-X
ZPC	B-X
by	B-X
glucosaminidase	B-X
released	B-X
from	B-X
the	B-X
cortical	B-X
granule	B-X
reaction	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
loss	B-X
of	B-X
sperm	B-X
binding	B-X
ligand	B-X
activity	B-X
at	B-X
fertilization	B-X
.	B-X

Set2	B-Protein
-	O
catalyzed	O
methylation	O
of	O
histone	B-Protein
H3	I-Protein
represses	O
basal	O
expression	O
of	O
GAL4	B-Protein
in	O
Saccharomyces	O
cerevisiae	O
.	O
<EOS>	B-X
Recent	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
histone	B-X
methylation	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
transcription	B-X
.	B-X
While	B-X
much	B-X
is	B-X
known	B-X
about	B-X
the	B-X
roles	B-X
of	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTs	B-X
)	B-X
in	B-X
the	B-X
establishment	B-X
of	B-X
heterochromatin	B-X
,	B-X
little	B-X
is	B-X
known	B-X
of	B-X
their	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
actively	B-X
transcribed	B-X
genes	B-X
.	B-X
We	B-X
describe	B-X
an	B-X
in	B-X
vivo	B-X
role	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
HMT	B-X
,	B-X
Set2	B-X
.	B-X
We	B-X
identified	B-X
SET2	B-X
as	B-X
a	B-X
gene	B-X
necessary	B-X
for	B-X
repression	B-X
of	B-X
GAL4	B-X
basal	B-X
expression	B-X
and	B-X
show	B-X
that	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
SACI	B-X
,	B-X
SACII	B-X
,	B-X
and	B-X
SET	B-X
domains	B-X
of	B-X
Set2	B-X
are	B-X
necessary	B-X
for	B-X
this	B-X
repression	B-X
.	B-X
We	B-X
confirm	B-X
that	B-X
Set2	B-X
catalyzes	B-X
methylation	B-X
of	B-X
lysine	B-X
36	B-X
on	B-X
the	B-X
N-terminal	B-X
tail	B-X
of	B-X
histone	B-X
H3	B-X
.	B-X
Conversion	B-X
of	B-X
lysine	B-X
36	B-X
to	B-X
an	B-X
unmethylatable	B-X
arginine	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
GAL4	B-X
transcription	B-X
,	B-X
as	B-X
does	B-X
a	B-X
Delta	B-X
set2	B-X
mutation	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
lysine	B-X
36	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
GAL4	B-X
is	B-X
methylated	B-X
and	B-X
that	B-X
this	B-X
methylation	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
presence	B-X
of	B-X
SET2	B-X
.	B-X

Recent	O
work	O
has	O
shown	O
that	O
histone	B-Protein
methylation	O
is	O
an	O
important	O
regulator	O
of	O
transcription	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
review	B-X
the	B-X
most	B-X
important	B-X
recent	B-X
advances	B-X
that	B-X
link	B-X
epigenetic	B-X
changes	B-X
to	B-X
the	B-X
bone	B-X
remodeling	B-X
field	B-X
.	B-X
In	B-X
eukaryotes	B-X
,	B-X
histone	B-X
H3K4	B-X
methylation	B-X
by	B-X
the	B-X
MLL/SET1	B-X
family	B-X
histone	B-X
methyltransferases	B-X
is	B-X
enriched	B-X
at	B-X
transcription	B-X
regulatory	B-X
elements	B-X
including	B-X
gene	B-X
promoters	B-X
and	B-X
enhancers	B-X
.	B-X
The	B-X
level	B-X
of	B-X
H3K4	B-X
methylation	B-X
is	B-X
highly	B-X
correlated	B-X
with	B-X
transcription	B-X
activation	B-X
and	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
frequently	B-X
used	B-X
histone	B-X
post-translational	B-X
modifications	B-X
to	B-X
predict	B-X
transcriptional	B-X
outcome	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
rearrangement	B-X
of	B-X
the	B-X
cellular	B-X
landscape	B-X
of	B-X
H3K4	B-X
mono-methylation	B-X
at	B-X
distal	B-X
enhancers	B-X
precedes	B-X
cell	B-X
fate	B-X
transition	B-X
and	B-X
is	B-X
used	B-X
for	B-X
identification	B-X
of	B-X
novel	B-X
regulatory	B-X
elements	B-X
for	B-X
development	B-X
and	B-X
disease	B-X
progression	B-X
.	B-X
Similarly	B-X
,	B-X
broad	B-X
H3K4	B-X
tri-methylation	B-X
regions	B-X
have	B-X
also	B-X
been	B-X
used	B-X
to	B-X
predict	B-X
intrinsic	B-X
tumor	B-X
suppression	B-X
properties	B-X
of	B-X
regulator	B-X
regions	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
models	B-X
.	B-X
Understanding	B-X
the	B-X
regulation	B-X
for	B-X
how	B-X
H3K4	B-X
methylation	B-X
is	B-X
deposited	B-X
and	B-X
regulated	B-X
is	B-X
of	B-X
paramount	B-X
importance	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
new	B-X
findings	B-X
on	B-X
how	B-X
the	B-X
MLL/SET1	B-X
family	B-X
enzymes	B-X
are	B-X
regulated	B-X
on	B-X
chromatin	B-X
and	B-X
their	B-X
potential	B-X
functional	B-X
and	B-X
regulatory	B-X
implications	B-X
.	B-X

While	O
much	O
is	O
known	O
about	O
the	O
roles	O
of	O
histone	O
methyltransferases	O
(	O
HMTs	O
)	O
in	O
the	O
establishment	O
of	O
heterochromatin	O
,	O
little	O
is	O
known	O
of	O
their	O
roles	O
in	O
the	O
regulation	O
of	O
actively	O
transcribed	O
genes	O
.	O
<EOS>	B-X
Recent	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
histone	B-X
methylation	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
transcription	B-X
.	B-X
While	B-X
much	B-X
is	B-X
known	B-X
about	B-X
the	B-X
roles	B-X
of	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTs	B-X
)	B-X
in	B-X
the	B-X
establishment	B-X
of	B-X
heterochromatin	B-X
,	B-X
little	B-X
is	B-X
known	B-X
of	B-X
their	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
actively	B-X
transcribed	B-X
genes	B-X
.	B-X
We	B-X
confirm	B-X
that	B-X
Set2	B-X
catalyzes	B-X
methylation	B-X
of	B-X
lysine	B-X
36	B-X
on	B-X
the	B-X
N-terminal	B-X
tail	B-X
of	B-X
histone	B-X
H3	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
lysine	B-X
36	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
GAL4	B-X
is	B-X
methylated	B-X
and	B-X
that	B-X
this	B-X
methylation	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
presence	B-X
of	B-X
SET2	B-X
.	B-X

We	O
describe	O
an	O
in	O
vivo	O
role	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
HMT	O
,	O
Set2	B-Protein
.	O

We	O
identified	O
SET2	B-Protein
as	O
a	O
gene	O
necessary	O
for	O
repression	O
of	O
GAL4	B-Protein
basal	O
expression	O
and	O
show	O
that	O
the	O
evolutionarily	O
conserved	O
SACI	O
,	O
SACII	O
,	O
and	O
SET	O
domains	O
of	O
Set2	B-Protein
are	O
necessary	O
for	O
this	O
repression	O
.	O
<EOS>	B-X
Recent	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
histone	B-X
methylation	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
transcription	B-X
.	B-X
While	B-X
much	B-X
is	B-X
known	B-X
about	B-X
the	B-X
roles	B-X
of	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTs	B-X
)	B-X
in	B-X
the	B-X
establishment	B-X
of	B-X
heterochromatin	B-X
,	B-X
little	B-X
is	B-X
known	B-X
of	B-X
their	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
actively	B-X
transcribed	B-X
genes	B-X
.	B-X
We	B-X
describe	B-X
an	B-X
in	B-X
vivo	B-X
role	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
HMT	B-X
,	B-X
Set2	B-X
.	B-X
We	B-X
identified	B-X
SET2	B-X
as	B-X
a	B-X
gene	B-X
necessary	B-X
for	B-X
repression	B-X
of	B-X
GAL4	B-X
basal	B-X
expression	B-X
and	B-X
show	B-X
that	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
SACI	B-X
,	B-X
SACII	B-X
,	B-X
and	B-X
SET	B-X
domains	B-X
of	B-X
Set2	B-X
are	B-X
necessary	B-X
for	B-X
this	B-X
repression	B-X
.	B-X
We	B-X
confirm	B-X
that	B-X
Set2	B-X
catalyzes	B-X
methylation	B-X
of	B-X
lysine	B-X
36	B-X
on	B-X
the	B-X
N-terminal	B-X
tail	B-X
of	B-X
histone	B-X
H3	B-X
.	B-X
Conversion	B-X
of	B-X
lysine	B-X
36	B-X
to	B-X
an	B-X
unmethylatable	B-X
arginine	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
GAL4	B-X
transcription	B-X
,	B-X
as	B-X
does	B-X
a	B-X
Delta	B-X
set2	B-X
mutation	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
lysine	B-X
36	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
GAL4	B-X
is	B-X
methylated	B-X
and	B-X
that	B-X
this	B-X
methylation	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
presence	B-X
of	B-X
SET2	B-X
.	B-X

We	O
confirm	O
that	O
Set2	B-Protein
catalyzes	O
methylation	O
of	O
lysine	O
36	O
on	O
the	O
N	O
-	O
terminal	O
tail	O
of	O
histone	B-Protein
H3	I-Protein
.	O

Conversion	O
of	O
lysine	O
36	O
to	O
an	O
unmethylatable	O
arginine	O
causes	O
a	O
decrease	O
in	O
the	O
repression	O
of	O
GAL4	B-Protein
transcription	O
,	O
as	O
does	O
a	O
Delta	O
set2	B-Protein
mutation	O
.	O

We	O
further	O
show	O
that	O
lysine	O
36	O
of	O
histone	B-Protein
H3	I-Protein
at	O
GAL4	B-Protein
is	O
methylated	O
and	O
that	O
this	O
methylation	O
is	O
dependent	O
upon	O
the	O
presence	O
of	O
SET2	B-Protein
.	O
<EOS>	B-X
Recent	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
histone	B-X
methylation	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
transcription	B-X
.	B-X
While	B-X
much	B-X
is	B-X
known	B-X
about	B-X
the	B-X
roles	B-X
of	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTs	B-X
)	B-X
in	B-X
the	B-X
establishment	B-X
of	B-X
heterochromatin	B-X
,	B-X
little	B-X
is	B-X
known	B-X
of	B-X
their	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
actively	B-X
transcribed	B-X
genes	B-X
.	B-X
We	B-X
identified	B-X
SET2	B-X
as	B-X
a	B-X
gene	B-X
necessary	B-X
for	B-X
repression	B-X
of	B-X
GAL4	B-X
basal	B-X
expression	B-X
and	B-X
show	B-X
that	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
SACI	B-X
,	B-X
SACII	B-X
,	B-X
and	B-X
SET	B-X
domains	B-X
of	B-X
Set2	B-X
are	B-X
necessary	B-X
for	B-X
this	B-X
repression	B-X
.	B-X
We	B-X
confirm	B-X
that	B-X
Set2	B-X
catalyzes	B-X
methylation	B-X
of	B-X
lysine	B-X
36	B-X
on	B-X
the	B-X
N-terminal	B-X
tail	B-X
of	B-X
histone	B-X
H3	B-X
.	B-X
Conversion	B-X
of	B-X
lysine	B-X
36	B-X
to	B-X
an	B-X
unmethylatable	B-X
arginine	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
GAL4	B-X
transcription	B-X
,	B-X
as	B-X
does	B-X
a	B-X
Delta	B-X
set2	B-X
mutation	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
lysine	B-X
36	B-X
of	B-X
histone	B-X
H3	B-X
at	B-X
GAL4	B-X
is	B-X
methylated	B-X
and	B-X
that	B-X
this	B-X
methylation	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
presence	B-X
of	B-X
SET2	B-X
.	B-X

A	O
possible	O
role	O
of	O
carbohydrate	O
moieties	O
in	O
prostaglandin	B-Protein
D2	I-Protein
and	O
prostaglandin	O
E2	O
receptor	O
proteins	O
from	O
the	O
porcine	O
temporal	O
cortex	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
activities	B-X
of	B-X
prostaglandins	B-X
(	B-X
PGs	B-X
)	B-X
D2	B-X
and	B-X
E2	B-X
were	B-X
measured	B-X
after	B-X
deglycosylation	B-X
of	B-X
P2	B-X
membranes	B-X
prepared	B-X
from	B-X
the	B-X
porcine	B-X
temporal	B-X
cortex	B-X
in	B-X
order	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
carbohydrate	B-X
moieties	B-X
in	B-X
the	B-X
receptor	B-X
binding	B-X
.	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
were	B-X
significantly	B-X
decreased	B-X
by	B-X
pretreatment	B-X
with	B-X
various	B-X
exoglycosidases	B-X
,	B-X
such	B-X
as	B-X
neuraminidase	B-X
for	B-X
PGE2	B-X
binding	B-X
,	B-X
alpha-mannosidase	B-X
and	B-X
beta-galactosidase	B-X
for	B-X
PGD2	B-X
binding	B-X
,	B-X
and	B-X
beta-N-acetylhexosaminidase	B-X
for	B-X
both	B-X
.	B-X
Further	B-X
,	B-X
peptide	B-X
N-glycohydrolase	B-X
F	B-X
and	B-X
endo-alpha-N-acetylgalactosaminidase	B-X
,	B-X
which	B-X
are	B-X
specific	B-X
for	B-X
the	B-X
cleavage	B-X
of	B-X
N-glycan	B-X
and	B-X
O-glycan	B-X
linkages	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
glycoproteins	B-X
were	B-X
used	B-X
.	B-X
Pretreatment	B-X
with	B-X
either	B-X
of	B-X
them	B-X
also	B-X
reduced	B-X
both	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
PG	B-X
receptor	B-X
proteins	B-X
of	B-X
the	B-X
brain	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
their	B-X
binding	B-X
activities	B-X
.	B-X

The	O
binding	O
activities	O
of	O
prostaglandins	O
(	O
PGs	O
)	O
D2	O
and	O
E2	O
were	O
measured	O
after	O
deglycosylation	O
of	O
P2	O
membranes	O
prepared	O
from	O
the	O
porcine	O
temporal	O
cortex	O
in	O
order	O
to	O
investigate	O
the	O
role	O
of	O
carbohydrate	O
moieties	O
in	O
the	O
receptor	O
binding	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
activities	B-X
of	B-X
prostaglandins	B-X
(	B-X
PGs	B-X
)	B-X
D2	B-X
and	B-X
E2	B-X
were	B-X
measured	B-X
after	B-X
deglycosylation	B-X
of	B-X
P2	B-X
membranes	B-X
prepared	B-X
from	B-X
the	B-X
porcine	B-X
temporal	B-X
cortex	B-X
in	B-X
order	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
carbohydrate	B-X
moieties	B-X
in	B-X
the	B-X
receptor	B-X
binding	B-X
.	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
were	B-X
significantly	B-X
decreased	B-X
by	B-X
pretreatment	B-X
with	B-X
various	B-X
exoglycosidases	B-X
,	B-X
such	B-X
as	B-X
neuraminidase	B-X
for	B-X
PGE2	B-X
binding	B-X
,	B-X
alpha-mannosidase	B-X
and	B-X
beta-galactosidase	B-X
for	B-X
PGD2	B-X
binding	B-X
,	B-X
and	B-X
beta-N-acetylhexosaminidase	B-X
for	B-X
both	B-X
.	B-X
Pretreatment	B-X
with	B-X
either	B-X
of	B-X
them	B-X
also	B-X
reduced	B-X
both	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
the	B-X
reduction	B-X
were	B-X
typically	B-X
characterized	B-X
by	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
the	B-X
nonspecific	B-X
bindings	B-X
.	B-X
Scatchard	B-X
plot	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
reduction	B-X
was	B-X
caused	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
affinity	B-X
rather	B-X
than	B-X
one	B-X
in	B-X
the	B-X
maximal	B-X
binding	B-X
capacity	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
thereby	B-X
shifted	B-X
to	B-X
be	B-X
more	B-X
nonspecific	B-X
without	B-X
affecting	B-X
the	B-X
order	B-X
of	B-X
the	B-X
relative	B-X
affinities	B-X
among	B-X
PGs	B-X
for	B-X
the	B-X
binding	B-X
sites	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
PG	B-X
receptor	B-X
proteins	B-X
of	B-X
the	B-X
brain	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
their	B-X
binding	B-X
activities	B-X
.	B-X

PGD2	O
and	O
PGE2	O
binding	O
activities	O
were	O
significantly	O
decreased	O
by	O
pretreatment	O
with	O
various	O
exoglycosidases	O
,	O
such	O
as	O
neuraminidase	O
for	O
PGE2	O
binding	O
,	O
alpha	O
-	O
mannosidase	O
and	O
beta	O
-	O
galactosidase	O
for	O
PGD2	O
binding	O
,	O
and	O
beta	O
-	O
N	O
-	O
acetylhexosaminidase	O
for	O
both	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
activities	B-X
of	B-X
prostaglandins	B-X
(	B-X
PGs	B-X
)	B-X
D2	B-X
and	B-X
E2	B-X
were	B-X
measured	B-X
after	B-X
deglycosylation	B-X
of	B-X
P2	B-X
membranes	B-X
prepared	B-X
from	B-X
the	B-X
porcine	B-X
temporal	B-X
cortex	B-X
in	B-X
order	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
carbohydrate	B-X
moieties	B-X
in	B-X
the	B-X
receptor	B-X
binding	B-X
.	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
were	B-X
significantly	B-X
decreased	B-X
by	B-X
pretreatment	B-X
with	B-X
various	B-X
exoglycosidases	B-X
,	B-X
such	B-X
as	B-X
neuraminidase	B-X
for	B-X
PGE2	B-X
binding	B-X
,	B-X
alpha-mannosidase	B-X
and	B-X
beta-galactosidase	B-X
for	B-X
PGD2	B-X
binding	B-X
,	B-X
and	B-X
beta-N-acetylhexosaminidase	B-X
for	B-X
both	B-X
.	B-X
Further	B-X
,	B-X
peptide	B-X
N-glycohydrolase	B-X
F	B-X
and	B-X
endo-alpha-N-acetylgalactosaminidase	B-X
,	B-X
which	B-X
are	B-X
specific	B-X
for	B-X
the	B-X
cleavage	B-X
of	B-X
N-glycan	B-X
and	B-X
O-glycan	B-X
linkages	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
glycoproteins	B-X
were	B-X
used	B-X
.	B-X
Pretreatment	B-X
with	B-X
either	B-X
of	B-X
them	B-X
also	B-X
reduced	B-X
both	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
.	B-X
The	B-X
reduction	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
pretreatment	B-X
time	B-X
and	B-X
enzyme	B-X
concentration	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
the	B-X
reduction	B-X
were	B-X
typically	B-X
characterized	B-X
by	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
the	B-X
nonspecific	B-X
bindings	B-X
.	B-X
Scatchard	B-X
plot	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
reduction	B-X
was	B-X
caused	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
affinity	B-X
rather	B-X
than	B-X
one	B-X
in	B-X
the	B-X
maximal	B-X
binding	B-X
capacity	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
thereby	B-X
shifted	B-X
to	B-X
be	B-X
more	B-X
nonspecific	B-X
without	B-X
affecting	B-X
the	B-X
order	B-X
of	B-X
the	B-X
relative	B-X
affinities	B-X
among	B-X
PGs	B-X
for	B-X
the	B-X
binding	B-X
sites	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
PG	B-X
receptor	B-X
proteins	B-X
of	B-X
the	B-X
brain	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
their	B-X
binding	B-X
activities	B-X
.	B-X

Further	O
,	O
peptide	O
N	O
-	O
glycohydrolase	O
F	O
and	O
endo	B-Protein
-	I-Protein
alpha	I-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylgalactosaminidase	I-Protein
,	O
which	O
are	O
specific	O
for	O
the	O
cleavage	O
of	O
N	O
-	O
glycan	O
and	O
O	O
-	O
glycan	O
linkages	O
,	O
respectively	O
,	O
in	O
glycoproteins	O
were	O
used	O
.	O

Pretreatment	O
with	O
either	O
of	O
them	O
also	O
reduced	O
both	O
PGD2	O
and	O
PGE2	O
binding	O
activities	O
.	O
<EOS>	B-X
Co-expression	B-X
of	B-X
EP2	B-X
and	B-X
EP3	B-X
subtypes	B-X
of	B-X
prostaglandin	B-X
E2	B-X
(	B-X
PGE2	B-X
)	B-X
receptors	B-X
(	B-X
R	B-X
)	B-X
by	B-X
U937	B-X
human	B-X
monocytic	B-X
cells	B-X
permitted	B-X
comparative	B-X
studies	B-X
of	B-X
desensitization	B-X
of	B-X
each	B-X
subtype	B-X
.	B-X
Specific	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
PGE2	B-X
to	B-X
membranes	B-X
of	B-X
U937	B-X
cells	B-X
showed	B-X
a	B-X
Kd	B-X
of	B-X
2.9	B-X
+/-	B-X
0.3	B-X
nM	B-X
(	B-X
mean	B-X
+/-	B-X
SEM	B-X
)	B-X
and	B-X
a	B-X
Bmax	B-X
of	B-X
40.5	B-X
+/-	B-X
1.0	B-X
fmol/mg	B-X
protein	B-X
,	B-X
and	B-X
was	B-X
competitively	B-X
inhibited	B-X
by	B-X
PGE2	B-X
>	B-X
or	B-X
=	B-X
PGE1	B-X
>	B-X
PGF2	B-X
alpha	B-X
>	B-X
PGD2	B-X
>	B-X
PGI2	B-X
.	B-X
EP3	B-X
R	B-X
expression	B-X
was	B-X
demonstrated	B-X
by	B-X
inhibition	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
PGE2	B-X
binding	B-X
with	B-X
the	B-X
EP1/EP3	B-X
agonist	B-X
sulprostone	B-X
[	B-X
50	B-X
%	B-X
inhibitory	B-X
concentration	B-X
(	B-X
IC50	B-X
=	B-X
3.3	B-X
+/-	B-X
0.6	B-X
nM	B-X
)	B-X
]	B-X
and	B-X
the	B-X
EP3/EP2	B-X
agonist	B-X
M	B-X
&	B-X
B	B-X
28767	B-X
(	B-X
IC50	B-X
=	B-X
2.1	B-X
+/-	B-X
0.3	B-X
nM	B-X
)	B-X
,	B-X
but	B-X
not	B-X
with	B-X
the	B-X
EP1	B-X
antagonist	B-X
SC-19220	B-X
.	B-X
EP2	B-X
R	B-X
protein	B-X
was	B-X
identified	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
using	B-X
specific	B-X
rabbit	B-X
IgG	B-X
antibodies	B-X
to	B-X
an	B-X
amino-terminal	B-X
peptide	B-X
of	B-X
the	B-X
EP2	B-X
R.	B-X
EP2	B-X
R	B-X
transduced	B-X
PGE2	B-X
stimulation	B-X
of	B-X
significant	B-X
increases	B-X
in	B-X
cellular	B-X
[	B-X
cAMP	B-X
]	B-X
i	B-X
[	B-X
50	B-X
%	B-X
effective	B-X
concentration	B-X
(	B-X
EC50	B-X
=	B-X
20	B-X
+/-	B-X
2.5	B-X
nM	B-X
)	B-X
]	B-X
,	B-X
and	B-X
EP3	B-X
R	B-X
mediated	B-X
sulprostone	B-X
inhibition	B-X
of	B-X
forskolin	B-X
elevation	B-X
of	B-X
[	B-X
cAMP	B-X
]	B-X
i	B-X
(	B-X
IC50	B-X
=	B-X
1.3	B-X
+/-	B-X
0.4	B-X
nM	B-X
)	B-X
.	B-X
Pretreatment	B-X
of	B-X
U937	B-X
cells	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
for	B-X
1	B-X
hr	B-X
reduced	B-X
the	B-X
total	B-X
number	B-X
,	B-X
but	B-X
not	B-X
the	B-X
affinity	B-X
,	B-X
of	B-X
PGE2	B-X
R	B-X
by	B-X
down-regulating	B-X
principally	B-X
EP2	B-X
R.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
24-hr	B-X
exposure	B-X
to	B-X
PMA	B-X
,	B-X
which	B-X
is	B-X
known	B-X
to	B-X
down-regulate	B-X
PKC	B-X
,	B-X
suppressed	B-X
both	B-X
the	B-X
total	B-X
number	B-X
and	B-X
affinity	B-X
of	B-X
PGE2	B-X
R	B-X
on	B-X
U937	B-X
cells	B-X
with	B-X
concurrent	B-X
reductions	B-X
in	B-X
EP2	B-X
R	B-X
and	B-X
EP3	B-X
R.	B-X
The	B-X
down-regulation	B-X
of	B-X
EP2	B-X
R	B-X
by	B-X
PMA	B-X
at	B-X
1	B-X
hr	B-X
was	B-X
blocked	B-X
by	B-X
staurosporine	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
PKC	B-X
,	B-X
whereas	B-X
the	B-X
down-regulation	B-X
of	B-X
EP3	B-X
R	B-X
by	B-X
PMA	B-X
at	B-X
24	B-X
hr	B-X
was	B-X
blocked	B-X
by	B-X
indomethacin	B-X
.	B-X
Pretreatment	B-X
of	B-X
U937	B-X
cells	B-X
with	B-X
PGE2	B-X
for	B-X
1	B-X
and	B-X
24	B-X
hr	B-X
reduced	B-X
both	B-X
the	B-X
binding	B-X
affinity	B-X
and	B-X
the	B-X
total	B-X
number	B-X
of	B-X
PGE2	B-X
R	B-X
,	B-X
by	B-X
co-ordinate	B-X
suppression	B-X
of	B-X
the	B-X
EP2	B-X
R	B-X
and	B-X
EP3	B-X
R.	B-X
Desensitization	B-X
of	B-X
EP2	B-X
R	B-X
and	B-X
EP3	B-X
R	B-X
for	B-X
1	B-X
hr	B-X
with	B-X
PGE2	B-X
suppressed	B-X
subsequent	B-X
PGE2-evoked	B-X
chemokinetic	B-X
responses	B-X
to	B-X
PGE2	B-X
,	B-X
whereas	B-X
selective	B-X
down-regulation	B-X
of	B-X
EP2	B-X
R	B-X
alone	B-X
by	B-X
PMA	B-X
for	B-X
1	B-X
hr	B-X
had	B-X
no	B-X
effects	B-X
on	B-X
U937	B-X
cell	B-X
migration	B-X
.	B-X
Thus	B-X
expression	B-X
of	B-X
each	B-X
subtype	B-X
of	B-X
PGE2	B-X
R	B-X
is	B-X
regulated	B-X
independently	B-X
and	B-X
EP3	B-X
R	B-X
,	B-X
but	B-X
not	B-X
EP2	B-X
R	B-X
,	B-X
transduces	B-X
PGE2	B-X
effects	B-X
on	B-X
migration	B-X
of	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

The	O
reduction	O
was	O
dependent	O
on	O
the	O
pretreatment	O
time	O
and	O
enzyme	O
concentration	O
.	O
<EOS>	B-X
Whereas	B-X
none	B-X
of	B-X
the	B-X
other	B-X
components	B-X
exerted	B-X
a	B-X
significant	B-X
effect	B-X
at	B-X
concentrations	B-X
lower	B-X
than	B-X
50	B-X
microM	B-X
,	B-X
myrcene	B-X
and	B-X
nerolidol	B-X
,	B-X
the	B-X
structural	B-X
analogues	B-X
of	B-X
linalool	B-X
,	B-X
were	B-X
more	B-X
potent	B-X
at	B-X
100	B-X
microM	B-X
than	B-X
the	B-X
other	B-X
components	B-X
decreasing	B-X
HepG2	B-X
viability	B-X
to	B-X
26	B-X
%	B-X
.	B-X
The	B-X
biochemical	B-X
effect	B-X
of	B-X
linalool	B-X
on	B-X
mitochondria	B-X
isolated	B-X
from	B-X
HepG2	B-X
showed	B-X
a	B-X
concentration-dependent	B-X
inhibition	B-X
in	B-X
complexes	B-X
I	B-X
and	B-X
II	B-X
activities	B-X
of	B-X
the	B-X
respiratory	B-X
chain	B-X
,	B-X
and	B-X
a	B-X
time-dependent	B-X
decrease	B-X
in	B-X
ATP	B-X
level	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
time-dependent	B-X
decrease	B-X
in	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
level	B-X
and	B-X
in	B-X
the	B-X
reduction	B-X
of	B-X
nitroblue	B-X
tetrazolium	B-X
was	B-X
obtained	B-X
,	B-X
indicating	B-X
increase	B-X
in	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
generation	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
evidence	B-X
that	B-X
skin	B-X
oxidative	B-X
stress	B-X
injury	B-X
caused	B-X
by	B-X
UVB	B-X
irradiation	B-X
is	B-X
mediated	B-X
predominantly	B-X
by	B-X
reactive	B-X
oxygen	B-X
species	B-X
immediately	B-X
after	B-X
irradiation	B-X
and	B-X
by	B-X
reactive	B-X
nitrogen	B-X
species	B-X
at	B-X
later	B-X
time	B-X
points	B-X
.	B-X
Likewise	B-X
,	B-X
the	B-X
reduction	B-X
of	B-X
antioxidant	B-X
capacity	B-X
was	B-X
not	B-X
reversed	B-X
by	B-X
NOS	B-X
inhibitors	B-X
.	B-X
Nitric	B-X
oxide	B-X
augmentation	B-X
was	B-X
not	B-X
observed	B-X
at	B-X
this	B-X
time	B-X
point	B-X
.	B-X
Low	B-X
concentrations	B-X
of	B-X
GSH	B-X
and	B-X
reduced	B-X
catalase	B-X
activity	B-X
were	B-X
also	B-X
observed	B-X
.	B-X

The	O
time	O
courses	O
of	O
the	O
reduction	O
were	O
typically	O
characterized	O
by	O
a	O
marked	O
increase	O
in	O
the	O
nonspecific	O
bindings	O
.	O
<EOS>	B-X
The	B-X
reduction	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
pretreatment	B-X
time	B-X
and	B-X
enzyme	B-X
concentration	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
the	B-X
reduction	B-X
were	B-X
typically	B-X
characterized	B-X
by	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
the	B-X
nonspecific	B-X
bindings	B-X
.	B-X
Scatchard	B-X
plot	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
reduction	B-X
was	B-X
caused	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
affinity	B-X
rather	B-X
than	B-X
one	B-X
in	B-X
the	B-X
maximal	B-X
binding	B-X
capacity	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
thereby	B-X
shifted	B-X
to	B-X
be	B-X
more	B-X
nonspecific	B-X
without	B-X
affecting	B-X
the	B-X
order	B-X
of	B-X
the	B-X
relative	B-X
affinities	B-X
among	B-X
PGs	B-X
for	B-X
the	B-X
binding	B-X
sites	B-X
.	B-X

Scatchard	O
plot	O
analysis	O
revealed	O
that	O
the	O
reduction	O
was	O
caused	O
by	O
a	O
decrease	O
in	O
the	O
affinity	O
rather	O
than	O
one	O
in	O
the	O
maximal	O
binding	O
capacity	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
activities	B-X
of	B-X
prostaglandins	B-X
(	B-X
PGs	B-X
)	B-X
D2	B-X
and	B-X
E2	B-X
were	B-X
measured	B-X
after	B-X
deglycosylation	B-X
of	B-X
P2	B-X
membranes	B-X
prepared	B-X
from	B-X
the	B-X
porcine	B-X
temporal	B-X
cortex	B-X
in	B-X
order	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
carbohydrate	B-X
moieties	B-X
in	B-X
the	B-X
receptor	B-X
binding	B-X
.	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
were	B-X
significantly	B-X
decreased	B-X
by	B-X
pretreatment	B-X
with	B-X
various	B-X
exoglycosidases	B-X
,	B-X
such	B-X
as	B-X
neuraminidase	B-X
for	B-X
PGE2	B-X
binding	B-X
,	B-X
alpha-mannosidase	B-X
and	B-X
beta-galactosidase	B-X
for	B-X
PGD2	B-X
binding	B-X
,	B-X
and	B-X
beta-N-acetylhexosaminidase	B-X
for	B-X
both	B-X
.	B-X
Pretreatment	B-X
with	B-X
either	B-X
of	B-X
them	B-X
also	B-X
reduced	B-X
both	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
.	B-X
The	B-X
reduction	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
pretreatment	B-X
time	B-X
and	B-X
enzyme	B-X
concentration	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
the	B-X
reduction	B-X
were	B-X
typically	B-X
characterized	B-X
by	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
the	B-X
nonspecific	B-X
bindings	B-X
.	B-X
Scatchard	B-X
plot	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
reduction	B-X
was	B-X
caused	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
affinity	B-X
rather	B-X
than	B-X
one	B-X
in	B-X
the	B-X
maximal	B-X
binding	B-X
capacity	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
thereby	B-X
shifted	B-X
to	B-X
be	B-X
more	B-X
nonspecific	B-X
without	B-X
affecting	B-X
the	B-X
order	B-X
of	B-X
the	B-X
relative	B-X
affinities	B-X
among	B-X
PGs	B-X
for	B-X
the	B-X
binding	B-X
sites	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
PG	B-X
receptor	B-X
proteins	B-X
of	B-X
the	B-X
brain	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
their	B-X
binding	B-X
activities	B-X
.	B-X

The	O
specificity	O
of	O
the	O
binding	O
sites	O
thereby	O
shifted	O
to	O
be	O
more	O
nonspecific	O
without	O
affecting	O
the	O
order	O
of	O
the	O
relative	O
affinities	O
among	O
PGs	O
for	O
the	O
binding	O
sites	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
activities	B-X
of	B-X
prostaglandins	B-X
(	B-X
PGs	B-X
)	B-X
D2	B-X
and	B-X
E2	B-X
were	B-X
measured	B-X
after	B-X
deglycosylation	B-X
of	B-X
P2	B-X
membranes	B-X
prepared	B-X
from	B-X
the	B-X
porcine	B-X
temporal	B-X
cortex	B-X
in	B-X
order	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
carbohydrate	B-X
moieties	B-X
in	B-X
the	B-X
receptor	B-X
binding	B-X
.	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
were	B-X
significantly	B-X
decreased	B-X
by	B-X
pretreatment	B-X
with	B-X
various	B-X
exoglycosidases	B-X
,	B-X
such	B-X
as	B-X
neuraminidase	B-X
for	B-X
PGE2	B-X
binding	B-X
,	B-X
alpha-mannosidase	B-X
and	B-X
beta-galactosidase	B-X
for	B-X
PGD2	B-X
binding	B-X
,	B-X
and	B-X
beta-N-acetylhexosaminidase	B-X
for	B-X
both	B-X
.	B-X
Pretreatment	B-X
with	B-X
either	B-X
of	B-X
them	B-X
also	B-X
reduced	B-X
both	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
the	B-X
reduction	B-X
were	B-X
typically	B-X
characterized	B-X
by	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
the	B-X
nonspecific	B-X
bindings	B-X
.	B-X
Scatchard	B-X
plot	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
reduction	B-X
was	B-X
caused	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
affinity	B-X
rather	B-X
than	B-X
one	B-X
in	B-X
the	B-X
maximal	B-X
binding	B-X
capacity	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
thereby	B-X
shifted	B-X
to	B-X
be	B-X
more	B-X
nonspecific	B-X
without	B-X
affecting	B-X
the	B-X
order	B-X
of	B-X
the	B-X
relative	B-X
affinities	B-X
among	B-X
PGs	B-X
for	B-X
the	B-X
binding	B-X
sites	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
PG	B-X
receptor	B-X
proteins	B-X
of	B-X
the	B-X
brain	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
their	B-X
binding	B-X
activities	B-X
.	B-X

These	O
results	O
suggest	O
that	O
the	O
carbohydrate	O
moieties	O
on	O
PG	O
receptor	O
proteins	O
of	O
the	O
brain	O
are	O
essential	O
for	O
the	O
expression	O
of	O
their	O
binding	O
activities	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
activities	B-X
of	B-X
prostaglandins	B-X
(	B-X
PGs	B-X
)	B-X
D2	B-X
and	B-X
E2	B-X
were	B-X
measured	B-X
after	B-X
deglycosylation	B-X
of	B-X
P2	B-X
membranes	B-X
prepared	B-X
from	B-X
the	B-X
porcine	B-X
temporal	B-X
cortex	B-X
in	B-X
order	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
carbohydrate	B-X
moieties	B-X
in	B-X
the	B-X
receptor	B-X
binding	B-X
.	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
were	B-X
significantly	B-X
decreased	B-X
by	B-X
pretreatment	B-X
with	B-X
various	B-X
exoglycosidases	B-X
,	B-X
such	B-X
as	B-X
neuraminidase	B-X
for	B-X
PGE2	B-X
binding	B-X
,	B-X
alpha-mannosidase	B-X
and	B-X
beta-galactosidase	B-X
for	B-X
PGD2	B-X
binding	B-X
,	B-X
and	B-X
beta-N-acetylhexosaminidase	B-X
for	B-X
both	B-X
.	B-X
Further	B-X
,	B-X
peptide	B-X
N-glycohydrolase	B-X
F	B-X
and	B-X
endo-alpha-N-acetylgalactosaminidase	B-X
,	B-X
which	B-X
are	B-X
specific	B-X
for	B-X
the	B-X
cleavage	B-X
of	B-X
N-glycan	B-X
and	B-X
O-glycan	B-X
linkages	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
glycoproteins	B-X
were	B-X
used	B-X
.	B-X
Pretreatment	B-X
with	B-X
either	B-X
of	B-X
them	B-X
also	B-X
reduced	B-X
both	B-X
PGD2	B-X
and	B-X
PGE2	B-X
binding	B-X
activities	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
the	B-X
reduction	B-X
were	B-X
typically	B-X
characterized	B-X
by	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
the	B-X
nonspecific	B-X
bindings	B-X
.	B-X
Scatchard	B-X
plot	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
reduction	B-X
was	B-X
caused	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
affinity	B-X
rather	B-X
than	B-X
one	B-X
in	B-X
the	B-X
maximal	B-X
binding	B-X
capacity	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
thereby	B-X
shifted	B-X
to	B-X
be	B-X
more	B-X
nonspecific	B-X
without	B-X
affecting	B-X
the	B-X
order	B-X
of	B-X
the	B-X
relative	B-X
affinities	B-X
among	B-X
PGs	B-X
for	B-X
the	B-X
binding	B-X
sites	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
PG	B-X
receptor	B-X
proteins	B-X
of	B-X
the	B-X
brain	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
their	B-X
binding	B-X
activities	B-X
.	B-X

Sequence	O
analysis	O
of	O
the	O
membrane	O
protein	O
gene	O
of	O
human	O
coronavirus	O
OC43	O
and	O
evidence	O
for	O
O	O
-	O
glycosylation	O
.	O
<EOS>	B-X
The	B-X
gene	B-X
encoding	B-X
the	B-X
membrane	B-X
(	B-X
M	B-X
)	B-X
protein	B-X
of	B-X
the	B-X
OC43	B-X
strain	B-X
of	B-X
human	B-X
coronavirus	B-X
(	B-X
HCV-OC43	B-X
)	B-X
was	B-X
amplified	B-X
by	B-X
a	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
of	B-X
viral	B-X
RNA	B-X
with	B-X
HCV-OC43-	B-X
and	B-X
bovine	B-X
coronavirus	B-X
(	B-X
BCV	B-X
)	B-X
-specific	B-X
primers	B-X
.	B-X
The	B-X
nucleotide	B-X
sequence	B-X
of	B-X
the	B-X
cloned	B-X
1.5	B-X
kb	B-X
fragment	B-X
revealed	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
(	B-X
ORF	B-X
)	B-X
of	B-X
690	B-X
nucleotides	B-X
which	B-X
was	B-X
identified	B-X
as	B-X
the	B-X
M	B-X
protein	B-X
gene	B-X
from	B-X
its	B-X
homology	B-X
to	B-X
BCV	B-X
.	B-X
This	B-X
ORF	B-X
encodes	B-X
a	B-X
protein	B-X
of	B-X
230	B-X
amino	B-X
acids	B-X
with	B-X
an	B-X
M	B-X
(	B-X
r	B-X
)	B-X
of	B-X
26416	B-X
.	B-X
The	B-X
gene	B-X
is	B-X
preceded	B-X
by	B-X
the	B-X
motif	B-X
UCCAAAC	B-X
,	B-X
analogous	B-X
to	B-X
the	B-X
consensus	B-X
coronavirus	B-X
transcription	B-X
initiation	B-X
sequence	B-X
.	B-X
The	B-X
M	B-X
protein	B-X
of	B-X
HCV-OC43	B-X
shows	B-X
features	B-X
typical	B-X
of	B-X
all	B-X
coronavirus	B-X
M	B-X
proteins	B-X
studied	B-X
:	B-X
a	B-X
hydrophilic	B-X
,	B-X
presumably	B-X
external	B-X
N	B-X
terminus	B-X
including	B-X
about	B-X
10	B-X
%	B-X
of	B-X
the	B-X
protein	B-X
,	B-X
and	B-X
a	B-X
potential	B-X
N-glycosylation	B-X
site	B-X
followed	B-X
by	B-X
three	B-X
major	B-X
hydrophobic	B-X
transmembrane	B-X
domains	B-X
.	B-X
The	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
M	B-X
protein	B-X
of	B-X
HCV-OC43	B-X
has	B-X
94	B-X
%	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
the	B-X
Mebus	B-X
strain	B-X
of	B-X
BCV	B-X
,	B-X
and	B-X
also	B-X
contains	B-X
six	B-X
potential	B-X
O-glycosylation	B-X
sites	B-X
in	B-X
the	B-X
exposed	B-X
N-terminal	B-X
domain	B-X
.	B-X
Indeed	B-X
,	B-X
the	B-X
glycosylation	B-X
of	B-X
the	B-X
M	B-X
protein	B-X
was	B-X
not	B-X
inhibited	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
tunicamycin	B-X
,	B-X
which	B-X
is	B-X
indicative	B-X
of	B-X
O-glycosylation	B-X
,	B-X
as	B-X
previously	B-X
reported	B-X
for	B-X
BCV	B-X
and	B-X
murine	B-X
hepatitis	B-X
virus	B-X
.	B-X
Virions	B-X
released	B-X
from	B-X
tunicamycin-treated	B-X
cells	B-X
contained	B-X
the	B-X
M	B-X
glycoprotein	B-X
but	B-X
were	B-X
devoid	B-X
of	B-X
both	B-X
peplomer	B-X
(	B-X
S	B-X
)	B-X
and	B-X
haemagglutinin-esterase	B-X
(	B-X
HE	B-X
)	B-X
proteins	B-X
.	B-X
Thus	B-X
,	B-X
inhibition	B-X
of	B-X
the	B-X
N-glycosylation	B-X
of	B-X
the	B-X
S	B-X
and	B-X
HE	B-X
structural	B-X
proteins	B-X
prevented	B-X
their	B-X
incorporation	B-X
into	B-X
progeny	B-X
virions	B-X
,	B-X
an	B-X
indication	B-X
that	B-X
they	B-X
are	B-X
dispensable	B-X
for	B-X
virion	B-X
morphogenesis	B-X
,	B-X
unlike	B-X
the	B-X
M	B-X
protein	B-X
.	B-X

The	O
gene	O
encoding	O
the	O
membrane	O
(	O
M	B-Protein
)	O
protein	O
of	O
the	O
OC43	O
strain	O
of	O
human	O
coronavirus	O
(	O
HCV	O
-	O
OC43	O
)	O
was	O
amplified	O
by	O
a	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
of	O
viral	O
RNA	O
with	O
HCV	O
-	O
OC43	O
-	O
and	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
-	O
specific	O
primers	O
.	O
<EOS>	B-X
The	B-X
gene	B-X
encoding	B-X
the	B-X
membrane	B-X
(	B-X
M	B-X
)	B-X
protein	B-X
of	B-X
the	B-X
OC43	B-X
strain	B-X
of	B-X
human	B-X
coronavirus	B-X
(	B-X
HCV-OC43	B-X
)	B-X
was	B-X
amplified	B-X
by	B-X
a	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
of	B-X
viral	B-X
RNA	B-X
with	B-X
HCV-OC43-	B-X
and	B-X
bovine	B-X
coronavirus	B-X
(	B-X
BCV	B-X
)	B-X
-specific	B-X
primers	B-X
.	B-X
The	B-X
nucleotide	B-X
sequence	B-X
of	B-X
the	B-X
cloned	B-X
1.5	B-X
kb	B-X
fragment	B-X
revealed	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
(	B-X
ORF	B-X
)	B-X
of	B-X
690	B-X
nucleotides	B-X
which	B-X
was	B-X
identified	B-X
as	B-X
the	B-X
M	B-X
protein	B-X
gene	B-X
from	B-X
its	B-X
homology	B-X
to	B-X
BCV	B-X
.	B-X
This	B-X
ORF	B-X
encodes	B-X
a	B-X
protein	B-X
of	B-X
230	B-X
amino	B-X
acids	B-X
with	B-X
an	B-X
M	B-X
(	B-X
r	B-X
)	B-X
of	B-X
26416	B-X
.	B-X
The	B-X
gene	B-X
is	B-X
preceded	B-X
by	B-X
the	B-X
motif	B-X
UCCAAAC	B-X
,	B-X
analogous	B-X
to	B-X
the	B-X
consensus	B-X
coronavirus	B-X
transcription	B-X
initiation	B-X
sequence	B-X
.	B-X
The	B-X
M	B-X
protein	B-X
of	B-X
HCV-OC43	B-X
shows	B-X
features	B-X
typical	B-X
of	B-X
all	B-X
coronavirus	B-X
M	B-X
proteins	B-X
studied	B-X
:	B-X
a	B-X
hydrophilic	B-X
,	B-X
presumably	B-X
external	B-X
N	B-X
terminus	B-X
including	B-X
about	B-X
10	B-X
%	B-X
of	B-X
the	B-X
protein	B-X
,	B-X
and	B-X
a	B-X
potential	B-X
N-glycosylation	B-X
site	B-X
followed	B-X
by	B-X
three	B-X
major	B-X
hydrophobic	B-X
transmembrane	B-X
domains	B-X
.	B-X
The	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
M	B-X
protein	B-X
of	B-X
HCV-OC43	B-X
has	B-X
94	B-X
%	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
the	B-X
Mebus	B-X
strain	B-X
of	B-X
BCV	B-X
,	B-X
and	B-X
also	B-X
contains	B-X
six	B-X
potential	B-X
O-glycosylation	B-X
sites	B-X
in	B-X
the	B-X
exposed	B-X
N-terminal	B-X
domain	B-X
.	B-X
Indeed	B-X
,	B-X
the	B-X
glycosylation	B-X
of	B-X
the	B-X
M	B-X
protein	B-X
was	B-X
not	B-X
inhibited	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
tunicamycin	B-X
,	B-X
which	B-X
is	B-X
indicative	B-X
of	B-X
O-glycosylation	B-X
,	B-X
as	B-X
previously	B-X
reported	B-X
for	B-X
BCV	B-X
and	B-X
murine	B-X
hepatitis	B-X
virus	B-X
.	B-X
Virions	B-X
released	B-X
from	B-X
tunicamycin-treated	B-X
cells	B-X
contained	B-X
the	B-X
M	B-X
glycoprotein	B-X
but	B-X
were	B-X
devoid	B-X
of	B-X
both	B-X
peplomer	B-X
(	B-X
S	B-X
)	B-X
and	B-X
haemagglutinin-esterase	B-X
(	B-X
HE	B-X
)	B-X
proteins	B-X
.	B-X
Thus	B-X
,	B-X
inhibition	B-X
of	B-X
the	B-X
N-glycosylation	B-X
of	B-X
the	B-X
S	B-X
and	B-X
HE	B-X
structural	B-X
proteins	B-X
prevented	B-X
their	B-X
incorporation	B-X
into	B-X
progeny	B-X
virions	B-X
,	B-X
an	B-X
indication	B-X
that	B-X
they	B-X
are	B-X
dispensable	B-X
for	B-X
virion	B-X
morphogenesis	B-X
,	B-X
unlike	B-X
the	B-X
M	B-X
protein	B-X
.	B-X

The	O
nucleotide	O
sequence	O
of	O
the	O
cloned	O
1	O
.	O
5	O
kb	O
fragment	O
revealed	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
690	O
nucleotides	O
which	O
was	O
identified	O
as	O
the	O
M	B-Protein
protein	O
gene	O
from	O
its	O
homology	O
to	O
BCV	O
.	O

This	O
ORF	O
encodes	O
a	O
protein	O
of	O
230	O
amino	O
acids	O
with	O
an	O
M	O
(	O
r	O
)	O
of	O
26416	O
.	O

The	O
gene	O
is	O
preceded	O
by	O
the	O
motif	O
UCCAAAC	O
,	O
analogous	O
to	O
the	O
consensus	O
coronavirus	O
transcription	O
initiation	O
sequence	O
.	O

The	O
M	B-Protein
protein	O
of	O
HCV	O
-	O
OC43	O
shows	O
features	O
typical	O
of	O
all	O
coronavirus	O
M	B-Protein
proteins	O
studied	O
:	O
a	O
hydrophilic	O
,	O
presumably	O
external	O
N	O
terminus	O
including	O
about	O
10	O
%	O
of	O
the	O
protein	O
,	O
and	O
a	O
potential	O
N	O
-	O
glycosylation	O
site	O
followed	O
by	O
three	O
major	O
hydrophobic	O
transmembrane	O
domains	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
M	B-Protein
protein	O
of	O
HCV	O
-	O
OC43	O
has	O
94	O
%	O
identity	O
with	O
that	O
of	O
the	O
Mebus	O
strain	O
of	O
BCV	O
,	O
and	O
also	O
contains	O
six	O
potential	O
O	O
-	O
glycosylation	O
sites	O
in	O
the	O
exposed	O
N	O
-	O
terminal	O
domain	O
.	O

Indeed	O
,	O
the	O
glycosylation	O
of	O
the	O
M	B-Protein
protein	O
was	O
not	O
inhibited	O
in	O
the	O
presence	O
of	O
tunicamycin	O
,	O
which	O
is	O
indicative	O
of	O
O	O
-	O
glycosylation	O
,	O
as	O
previously	O
reported	O
for	O
BCV	O
and	O
murine	O
hepatitis	O
virus	O
.	O

Virions	O
released	O
from	O
tunicamycin	O
-	O
treated	O
cells	O
contained	O
the	O
M	B-Protein
glycoprotein	O
but	O
were	O
devoid	O
of	O
both	O
peplomer	B-Protein
(	O
S	B-Protein
)	O
and	O
haemagglutinin	B-Protein
-	I-Protein
esterase	I-Protein
(	O
HE	B-Protein
)	O
proteins	O
.	O

Thus	O
,	O
inhibition	O
of	O
the	O
N	O
-	O
glycosylation	O
of	O
the	O
S	B-Protein
and	O
HE	B-Protein
structural	O
proteins	O
prevented	O
their	O
incorporation	O
into	O
progeny	O
virions	O
,	O
an	O
indication	O
that	O
they	O
are	O
dispensable	O
for	O
virion	O
morphogenesis	O
,	O
unlike	O
the	O
M	B-Protein
protein	O
.	O

Production	O
and	O
secretion	O
of	O
high	O
levels	O
of	O
recombinant	O
human	O
acetylcholinesterase	B-Protein
in	O
cultured	O
cell	O
lines	O
:	O
microheterogeneity	O
of	O
the	O
catalytic	O
subunit	O
.	O
<EOS>	B-X
To	B-X
allow	B-X
for	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
human	B-X
acetylcholinesterase	B-X
(	B-X
hAChE	B-X
)	B-X
subunit	B-X
,	B-X
a	B-X
series	B-X
of	B-X
eukaryotic	B-X
vectors	B-X
was	B-X
designed	B-X
for	B-X
efficient	B-X
expression	B-X
.	B-X
Several	B-X
eukaryotic	B-X
multicistronic	B-X
expression	B-X
vectors	B-X
were	B-X
tested	B-X
in	B-X
various	B-X
mammalian	B-X
cell	B-X
lines	B-X
.	B-X
Optimal	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
recombinant	B-X
hAChE	B-X
(	B-X
rehAChE	B-X
)	B-X
was	B-X
achieved	B-X
in	B-X
the	B-X
embryonal	B-X
kidney	B-X
293	B-X
cell	B-X
line	B-X
transfected	B-X
either	B-X
with	B-X
the	B-X
RSV-hAChE	B-X
or	B-X
with	B-X
CMV-hAChE	B-X
expression	B-X
vectors	B-X
.	B-X
Clones	B-X
expressing	B-X
and	B-X
secreting	B-X
as	B-X
much	B-X
as	B-X
5-25	B-X
pg	B-X
of	B-X
enzyme	B-X
per	B-X
cell	B-X
per	B-X
24	B-X
h	B-X
were	B-X
obtained	B-X
without	B-X
resorting	B-X
to	B-X
coamplification	B-X
techniques	B-X
or	B-X
continuous	B-X
maintenance	B-X
of	B-X
cells	B-X
under	B-X
selective	B-X
pressure	B-X
.	B-X
Catalytic	B-X
subunit	B-X
dimers	B-X
(	B-X
130	B-X
kDa	B-X
)	B-X
exhibit	B-X
differential	B-X
N-glycosylation	B-X
patterns	B-X
,	B-X
and	B-X
upon	B-X
reduction	B-X
resolve	B-X
into	B-X
67-	B-X
and	B-X
70-kDa	B-X
monomeric	B-X
subunits	B-X
.	B-X

To	O
allow	O
for	O
structural	O
analysis	O
of	O
the	O
human	O
acetylcholinesterase	B-Protein
(	O
hAChE	B-Protein
)	O
subunit	O
,	O
a	O
series	O
of	O
eukaryotic	O
vectors	O
was	O
designed	O
for	O
efficient	O
expression	O
.	O
<EOS>	B-X
To	B-X
allow	B-X
for	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
human	B-X
acetylcholinesterase	B-X
(	B-X
hAChE	B-X
)	B-X
subunit	B-X
,	B-X
a	B-X
series	B-X
of	B-X
eukaryotic	B-X
vectors	B-X
was	B-X
designed	B-X
for	B-X
efficient	B-X
expression	B-X
.	B-X
Several	B-X
eukaryotic	B-X
multicistronic	B-X
expression	B-X
vectors	B-X
were	B-X
tested	B-X
in	B-X
various	B-X
mammalian	B-X
cell	B-X
lines	B-X
.	B-X
All	B-X
expression	B-X
vectors	B-X
contained	B-X
the	B-X
selectable	B-X
neo	B-X
gene	B-X
under	B-X
control	B-X
of	B-X
a	B-X
weak	B-X
promoter	B-X
,	B-X
while	B-X
the	B-X
hAChE	B-X
cDNA	B-X
was	B-X
under	B-X
control	B-X
of	B-X
the	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
immediate-early	B-X
or	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
RSV	B-X
LTR	B-X
)	B-X
or	B-X
simian	B-X
virus	B-X
40	B-X
(	B-X
SV40	B-X
)	B-X
early	B-X
promoters	B-X
.	B-X
Optimal	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
recombinant	B-X
hAChE	B-X
(	B-X
rehAChE	B-X
)	B-X
was	B-X
achieved	B-X
in	B-X
the	B-X
embryonal	B-X
kidney	B-X
293	B-X
cell	B-X
line	B-X
transfected	B-X
either	B-X
with	B-X
the	B-X
RSV-hAChE	B-X
or	B-X
with	B-X
CMV-hAChE	B-X
expression	B-X
vectors	B-X
.	B-X
Catalytic	B-X
subunit	B-X
dimers	B-X
(	B-X
130	B-X
kDa	B-X
)	B-X
exhibit	B-X
differential	B-X
N-glycosylation	B-X
patterns	B-X
,	B-X
and	B-X
upon	B-X
reduction	B-X
resolve	B-X
into	B-X
67-	B-X
and	B-X
70-kDa	B-X
monomeric	B-X
subunits	B-X
.	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
the	B-X
purified	B-X
mature	B-X
enzyme	B-X
suggests	B-X
the	B-X
existence	B-X
of	B-X
two	B-X
alternative	B-X
cleavage	B-X
sites	B-X
for	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
,	B-X
in	B-X
which	B-X
the	B-X
'mature	B-X
'	B-X
position	B-X
1	B-X
is	B-X
either	B-X
Ala31	B-X
or	B-X
Gly33	B-X
.	B-X

Several	O
eukaryotic	O
multicistronic	O
expression	O
vectors	O
were	O
tested	O
in	O
various	O
mammalian	O
cell	O
lines	O
.	O
<EOS>	B-X
To	B-X
allow	B-X
for	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
human	B-X
acetylcholinesterase	B-X
(	B-X
hAChE	B-X
)	B-X
subunit	B-X
,	B-X
a	B-X
series	B-X
of	B-X
eukaryotic	B-X
vectors	B-X
was	B-X
designed	B-X
for	B-X
efficient	B-X
expression	B-X
.	B-X
Several	B-X
eukaryotic	B-X
multicistronic	B-X
expression	B-X
vectors	B-X
were	B-X
tested	B-X
in	B-X
various	B-X
mammalian	B-X
cell	B-X
lines	B-X
.	B-X
All	B-X
expression	B-X
vectors	B-X
contained	B-X
the	B-X
selectable	B-X
neo	B-X
gene	B-X
under	B-X
control	B-X
of	B-X
a	B-X
weak	B-X
promoter	B-X
,	B-X
while	B-X
the	B-X
hAChE	B-X
cDNA	B-X
was	B-X
under	B-X
control	B-X
of	B-X
the	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
immediate-early	B-X
or	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
RSV	B-X
LTR	B-X
)	B-X
or	B-X
simian	B-X
virus	B-X
40	B-X
(	B-X
SV40	B-X
)	B-X
early	B-X
promoters	B-X
.	B-X
Optimal	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
recombinant	B-X
hAChE	B-X
(	B-X
rehAChE	B-X
)	B-X
was	B-X
achieved	B-X
in	B-X
the	B-X
embryonal	B-X
kidney	B-X
293	B-X
cell	B-X
line	B-X
transfected	B-X
either	B-X
with	B-X
the	B-X
RSV-hAChE	B-X
or	B-X
with	B-X
CMV-hAChE	B-X
expression	B-X
vectors	B-X
.	B-X
Clones	B-X
expressing	B-X
and	B-X
secreting	B-X
as	B-X
much	B-X
as	B-X
5-25	B-X
pg	B-X
of	B-X
enzyme	B-X
per	B-X
cell	B-X
per	B-X
24	B-X
h	B-X
were	B-X
obtained	B-X
without	B-X
resorting	B-X
to	B-X
coamplification	B-X
techniques	B-X
or	B-X
continuous	B-X
maintenance	B-X
of	B-X
cells	B-X
under	B-X
selective	B-X
pressure	B-X
.	B-X

All	O
expression	O
vectors	O
contained	O
the	O
selectable	O
neo	O
gene	O
under	O
control	O
of	O
a	O
weak	O
promoter	O
,	O
while	O
the	O
hAChE	B-Protein
cDNA	O
was	O
under	O
control	O
of	O
the	O
cytomegalovirus	O
(	O
CMV	O
)	O
immediate	O
-	O
early	O
or	O
Rous	O
sarcoma	O
virus	O
long	O
terminal	O
repeat	O
(	O
RSV	O
LTR	O
)	O
or	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
early	O
promoters	O
.	O
<EOS>	B-X
The	B-X
early	B-X
promoter	B-X
of	B-X
the	B-X
simian	B-X
virus	B-X
40	B-X
(	B-X
SV40	B-X
)	B-X
has	B-X
been	B-X
used	B-X
as	B-X
a	B-X
model	B-X
eukaryotic	B-X
promoter	B-X
for	B-X
the	B-X
study	B-X
of	B-X
DNA	B-X
sequence	B-X
elements	B-X
and	B-X
cellular	B-X
factors	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
transcriptional	B-X
control	B-X
and	B-X
initiation	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
and	B-X
cell-free	B-X
transcription	B-X
systems	B-X
have	B-X
enabled	B-X
the	B-X
dissection	B-X
of	B-X
the	B-X
functional	B-X
domains	B-X
within	B-X
the	B-X
21	B-X
bp	B-X
upstream	B-X
sequence	B-X
element	B-X
and	B-X
the	B-X
72	B-X
bp	B-X
enhancer	B-X
,	B-X
and	B-X
a	B-X
number	B-X
of	B-X
protein	B-X
factors	B-X
that	B-X
bind	B-X
to	B-X
various	B-X
``	B-X
motifs	B-X
''	B-X
within	B-X
these	B-X
domains	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
This	B-X
article	B-X
summarizes	B-X
recent	B-X
observations	B-X
that	B-X
have	B-X
led	B-X
to	B-X
the	B-X
conclusion	B-X
that	B-X
the	B-X
SV40	B-X
promoter	B-X
,	B-X
and	B-X
particularly	B-X
,	B-X
the	B-X
enhancer	B-X
region	B-X
,	B-X
is	B-X
composed	B-X
of	B-X
multiple	B-X
sequence	B-X
elements	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
elements	B-X
are	B-X
present	B-X
in	B-X
cellular	B-X
genes	B-X
,	B-X
and	B-X
may	B-X
exhibit	B-X
tissue-specificity	B-X
in	B-X
their	B-X
action	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
proteins	B-X
that	B-X
are	B-X
being	B-X
identified	B-X
(	B-X
e.g.	B-X
,	B-X
Sp1	B-X
)	B-X
may	B-X
have	B-X
binding	B-X
sites	B-X
within	B-X
these	B-X
elements	B-X
that	B-X
are	B-X
sufficiently	B-X
specific	B-X
to	B-X
ensure	B-X
that	B-X
only	B-X
certain	B-X
sets	B-X
of	B-X
genes	B-X
will	B-X
be	B-X
selectively	B-X
expressed	B-X
.	B-X

Optimal	O
production	O
and	O
secretion	O
of	O
recombinant	O
hAChE	B-Protein
(	O
rehAChE	B-Protein
)	O
was	O
achieved	O
in	O
the	O
embryonal	O
kidney	O
293	O
cell	O
line	O
transfected	O
either	O
with	O
the	O
RSV	O
-	O
hAChE	B-Protein
or	O
with	O
CMV	O
-	O
hAChE	B-Protein
expression	O
vectors	O
.	O
<EOS>	B-X
To	B-X
allow	B-X
for	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
human	B-X
acetylcholinesterase	B-X
(	B-X
hAChE	B-X
)	B-X
subunit	B-X
,	B-X
a	B-X
series	B-X
of	B-X
eukaryotic	B-X
vectors	B-X
was	B-X
designed	B-X
for	B-X
efficient	B-X
expression	B-X
.	B-X
Several	B-X
eukaryotic	B-X
multicistronic	B-X
expression	B-X
vectors	B-X
were	B-X
tested	B-X
in	B-X
various	B-X
mammalian	B-X
cell	B-X
lines	B-X
.	B-X
All	B-X
expression	B-X
vectors	B-X
contained	B-X
the	B-X
selectable	B-X
neo	B-X
gene	B-X
under	B-X
control	B-X
of	B-X
a	B-X
weak	B-X
promoter	B-X
,	B-X
while	B-X
the	B-X
hAChE	B-X
cDNA	B-X
was	B-X
under	B-X
control	B-X
of	B-X
the	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
immediate-early	B-X
or	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
RSV	B-X
LTR	B-X
)	B-X
or	B-X
simian	B-X
virus	B-X
40	B-X
(	B-X
SV40	B-X
)	B-X
early	B-X
promoters	B-X
.	B-X
Optimal	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
recombinant	B-X
hAChE	B-X
(	B-X
rehAChE	B-X
)	B-X
was	B-X
achieved	B-X
in	B-X
the	B-X
embryonal	B-X
kidney	B-X
293	B-X
cell	B-X
line	B-X
transfected	B-X
either	B-X
with	B-X
the	B-X
RSV-hAChE	B-X
or	B-X
with	B-X
CMV-hAChE	B-X
expression	B-X
vectors	B-X
.	B-X
Clones	B-X
expressing	B-X
and	B-X
secreting	B-X
as	B-X
much	B-X
as	B-X
5-25	B-X
pg	B-X
of	B-X
enzyme	B-X
per	B-X
cell	B-X
per	B-X
24	B-X
h	B-X
were	B-X
obtained	B-X
without	B-X
resorting	B-X
to	B-X
coamplification	B-X
techniques	B-X
or	B-X
continuous	B-X
maintenance	B-X
of	B-X
cells	B-X
under	B-X
selective	B-X
pressure	B-X
.	B-X
The	B-X
purified	B-X
(	B-X
specific	B-X
activity	B-X
of	B-X
6000	B-X
units	B-X
per	B-X
mg	B-X
protein	B-X
)	B-X
homodimer	B-X
and	B-X
tetramer	B-X
enzyme	B-X
molecules	B-X
displayed	B-X
typical	B-X
AChE	B-X
biochemical	B-X
properties	B-X
:	B-X
a	B-X
Km	B-X
value	B-X
of	B-X
120	B-X
microM	B-X
for	B-X
acetylthiocholine	B-X
;	B-X
a	B-X
kcat	B-X
value	B-X
of	B-X
3.9	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
/min	B-X
,	B-X
and	B-X
selective	B-X
by	B-X
AChE-specific	B-X
inhibitors	B-X
.	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
the	B-X
purified	B-X
mature	B-X
enzyme	B-X
suggests	B-X
the	B-X
existence	B-X
of	B-X
two	B-X
alternative	B-X
cleavage	B-X
sites	B-X
for	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
,	B-X
in	B-X
which	B-X
the	B-X
'mature	B-X
'	B-X
position	B-X
1	B-X
is	B-X
either	B-X
Ala31	B-X
or	B-X
Gly33	B-X
.	B-X

Clones	O
expressing	O
and	O
secreting	O
as	O
much	O
as	O
5	O
-	O
25	O
pg	O
of	O
enzyme	O
per	O
cell	O
per	O
24	O
h	O
were	O
obtained	O
without	O
resorting	O
to	O
coamplification	O
techniques	O
or	O
continuous	O
maintenance	O
of	O
cells	O
under	O
selective	O
pressure	O
.	O
<EOS>	B-X
While	B-X
seed-propagated	B-X
crops	B-X
have	B-X
contributed	B-X
many	B-X
evolutionary	B-X
insights	B-X
,	B-X
evolutionary	B-X
biologists	B-X
have	B-X
often	B-X
neglected	B-X
clonally	B-X
propagated	B-X
crops	B-X
.	B-X
We	B-X
argue	B-X
that	B-X
widespread	B-X
notions	B-X
about	B-X
their	B-X
evolution	B-X
under	B-X
domestication	B-X
are	B-X
oversimplified	B-X
,	B-X
and	B-X
that	B-X
they	B-X
offer	B-X
rich	B-X
material	B-X
for	B-X
evolutionary	B-X
studies	B-X
.	B-X
The	B-X
diversity	B-X
of	B-X
their	B-X
wild	B-X
ancestors	B-X
,	B-X
the	B-X
diverse	B-X
ecologies	B-X
of	B-X
the	B-X
crop	B-X
populations	B-X
themselves	B-X
,	B-X
and	B-X
the	B-X
intricate	B-X
mix	B-X
of	B-X
selection	B-X
pressures	B-X
,	B-X
acting	B-X
not	B-X
only	B-X
on	B-X
the	B-X
parts	B-X
harvested	B-X
but	B-X
also	B-X
on	B-X
the	B-X
parts	B-X
used	B-X
by	B-X
humans	B-X
to	B-X
make	B-X
clonal	B-X
propagules	B-X
,	B-X
result	B-X
in	B-X
complex	B-X
and	B-X
diverse	B-X
evolutionary	B-X
trajectories	B-X
under	B-X
domestication	B-X
.	B-X
We	B-X
examine	B-X
why	B-X
farmers	B-X
propagate	B-X
some	B-X
plants	B-X
clonally	B-X
,	B-X
and	B-X
discuss	B-X
the	B-X
evolutionary	B-X
dynamics	B-X
of	B-X
sexual	B-X
reproduction	B-X
in	B-X
clonal	B-X
crops	B-X
.	B-X
We	B-X
explore	B-X
how	B-X
their	B-X
mixed	B-X
clonal/sexual	B-X
reproductive	B-X
systems	B-X
function	B-X
,	B-X
based	B-X
on	B-X
the	B-X
sole	B-X
example	B-X
studied	B-X
in	B-X
detail	B-X
,	B-X
cassava	B-X
(	B-X
Manihot	B-X
esculenta	B-X
)	B-X
.	B-X
Biotechnology	B-X
is	B-X
now	B-X
expanding	B-X
the	B-X
number	B-X
of	B-X
clonal	B-X
crops	B-X
,	B-X
continuing	B-X
the	B-X
10	B-X
000-yr-old	B-X
trend	B-X
to	B-X
increase	B-X
crop	B-X
yields	B-X
by	B-X
propagating	B-X
elite	B-X
genotypes	B-X
.	B-X
In	B-X
an	B-X
era	B-X
of	B-X
rapid	B-X
global	B-X
change	B-X
,	B-X
it	B-X
is	B-X
more	B-X
important	B-X
than	B-X
ever	B-X
to	B-X
understand	B-X
how	B-X
the	B-X
adaptive	B-X
potential	B-X
of	B-X
clonal	B-X
crops	B-X
can	B-X
be	B-X
maintained	B-X
.	B-X
A	B-X
key	B-X
component	B-X
of	B-X
strategies	B-X
for	B-X
preserving	B-X
this	B-X
adaptive	B-X
potential	B-X
is	B-X
the	B-X
maintenance	B-X
of	B-X
mixed	B-X
clonal/sexual	B-X
systems	B-X
,	B-X
which	B-X
can	B-X
be	B-X
achieved	B-X
by	B-X
encouraging	B-X
and	B-X
valuing	B-X
farmer	B-X
knowledge	B-X
about	B-X
the	B-X
sexual	B-X
reproductive	B-X
biology	B-X
of	B-X
their	B-X
clonal	B-X
crops	B-X
.	B-X

The	O
purified	O
(	O
specific	O
activity	O
of	O
6000	O
units	O
per	O
mg	O
protein	O
)	O
homodimer	O
and	O
tetramer	O
enzyme	O
molecules	O
displayed	O
typical	O
AChE	B-Protein
biochemical	O
properties	O
:	O
a	O
Km	O
value	O
of	O
120	O
microM	O
for	O
acetylthiocholine	O
;	O
a	O
kcat	O
value	O
of	O
3	O
.	O
9	O
x	O
10	O
(	O
5	O
)	O
/	O
min	O
,	O
and	O
selective	O
by	O
AChE	B-Protein
-	O
specific	O
inhibitors	O
.	O

Catalytic	O
subunit	O
dimers	O
(	O
130	O
kDa	O
)	O
exhibit	O
differential	O
N	O
-	O
glycosylation	O
patterns	O
,	O
and	O
upon	O
reduction	O
resolve	O
into	O
67	O
-	O
and	O
70	O
-	O
kDa	O
monomeric	O
subunits	O
.	O
<EOS>	B-X
To	B-X
allow	B-X
for	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
human	B-X
acetylcholinesterase	B-X
(	B-X
hAChE	B-X
)	B-X
subunit	B-X
,	B-X
a	B-X
series	B-X
of	B-X
eukaryotic	B-X
vectors	B-X
was	B-X
designed	B-X
for	B-X
efficient	B-X
expression	B-X
.	B-X
All	B-X
expression	B-X
vectors	B-X
contained	B-X
the	B-X
selectable	B-X
neo	B-X
gene	B-X
under	B-X
control	B-X
of	B-X
a	B-X
weak	B-X
promoter	B-X
,	B-X
while	B-X
the	B-X
hAChE	B-X
cDNA	B-X
was	B-X
under	B-X
control	B-X
of	B-X
the	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
immediate-early	B-X
or	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
RSV	B-X
LTR	B-X
)	B-X
or	B-X
simian	B-X
virus	B-X
40	B-X
(	B-X
SV40	B-X
)	B-X
early	B-X
promoters	B-X
.	B-X
Catalytic	B-X
subunit	B-X
dimers	B-X
(	B-X
130	B-X
kDa	B-X
)	B-X
exhibit	B-X
differential	B-X
N-glycosylation	B-X
patterns	B-X
,	B-X
and	B-X
upon	B-X
reduction	B-X
resolve	B-X
into	B-X
67-	B-X
and	B-X
70-kDa	B-X
monomeric	B-X
subunits	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
appear	B-X
as	B-X
a	B-X
single	B-X
discrete	B-X
62-kDa	B-X
band	B-X
following	B-X
deglycosylation	B-X
by	B-X
N-glycanase	B-X
.	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
the	B-X
purified	B-X
mature	B-X
enzyme	B-X
suggests	B-X
the	B-X
existence	B-X
of	B-X
two	B-X
alternative	B-X
cleavage	B-X
sites	B-X
for	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
,	B-X
in	B-X
which	B-X
the	B-X
'mature	B-X
'	B-X
position	B-X
1	B-X
is	B-X
either	B-X
Ala31	B-X
or	B-X
Gly33	B-X
.	B-X

These	O
two	O
forms	O
appear	O
as	O
a	O
single	O
discrete	O
62	O
-	O
kDa	O
band	O
following	O
deglycosylation	O
by	O
N	B-Protein
-	I-Protein
glycanase	I-Protein
.	O

The	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
analysis	O
of	O
the	O
purified	O
mature	O
enzyme	O
suggests	O
the	O
existence	O
of	O
two	O
alternative	O
cleavage	O
sites	O
for	O
the	O
removal	O
of	O
the	O
signal	O
peptide	O
,	O
in	O
which	O
the	O
'	O
mature	O
'	O
position	O
1	O
is	O
either	O
Ala31	O
or	O
Gly33	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
it	B-X
is	B-X
becoming	B-X
increasingly	B-X
evident	B-X
that	B-X
the	B-X
plasma	B-X
membrane	B-X
of	B-X
neurons	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
modulating	B-X
the	B-X
aggregation	B-X
and	B-X
toxicity	B-X
of	B-X
Alzheimer	B-X
's	B-X
amyloid-β	B-X
peptide	B-X
(	B-X
Aβ	B-X
)	B-X
.	B-X
Hamiltonian	B-X
replica	B-X
exchange	B-X
molecular	B-X
dynamics	B-X
simulations	B-X
are	B-X
utilized	B-X
to	B-X
elucidate	B-X
the	B-X
impact	B-X
of	B-X
selected	B-X
oxidized	B-X
glycine	B-X
residues	B-X
of	B-X
Aβ42	B-X
on	B-X
the	B-X
interactions	B-X
of	B-X
the	B-X
peptide	B-X
with	B-X
a	B-X
model	B-X
membrane	B-X
comprised	B-X
of	B-X
70	B-X
%	B-X
POPC	B-X
,	B-X
25	B-X
%	B-X
cholesterol	B-X
,	B-X
and	B-X
5	B-X
%	B-X
of	B-X
the	B-X
ganglioside	B-X
GM1	B-X
.	B-X
The	B-X
main	B-X
findings	B-X
are	B-X
that	B-X
,	B-X
independent	B-X
of	B-X
the	B-X
oxidation	B-X
state	B-X
,	B-X
Aβ	B-X
prefers	B-X
binding	B-X
to	B-X
GM1	B-X
over	B-X
POPC	B-X
,	B-X
which	B-X
is	B-X
further	B-X
enhanced	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Gly29	B-X
and	B-X
Gly33	B-X
and	B-X
reduced	B-X
the	B-X
formation	B-X
of	B-X
β-sheet	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
differences	B-X
observed	B-X
in	B-X
Aβ42	B-X
conformations	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
a	B-X
lipid	B-X
bilayer	B-X
upon	B-X
oxidation	B-X
originate	B-X
from	B-X
the	B-X
position	B-X
of	B-X
the	B-X
oxidized	B-X
Gly	B-X
residue	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
hydrophobic	B-X
sequence	B-X
of	B-X
Aβ42	B-X
involving	B-X
the	B-X
Gly29-XXX-Gly33-XXX-Gly37	B-X
motif	B-X
and	B-X
from	B-X
specific	B-X
interactions	B-X
between	B-X
the	B-X
peptide	B-X
and	B-X
the	B-X
terminal	B-X
sugar	B-X
groups	B-X
of	B-X
GM1	B-X
.	B-X

Both	O
of	O
these	O
positions	O
conform	O
with	O
the	O
consensus	O
signal	O
peptide	O
recognition	O
sequences	O
and	O
demonstrate	O
bidirected	O
processing	O
of	O
signal	O
peptides	O
on	O
a	O
native	O
molecule	O
.	O
<EOS>	B-X
The	B-X
purified	B-X
(	B-X
specific	B-X
activity	B-X
of	B-X
6000	B-X
units	B-X
per	B-X
mg	B-X
protein	B-X
)	B-X
homodimer	B-X
and	B-X
tetramer	B-X
enzyme	B-X
molecules	B-X
displayed	B-X
typical	B-X
AChE	B-X
biochemical	B-X
properties	B-X
:	B-X
a	B-X
Km	B-X
value	B-X
of	B-X
120	B-X
microM	B-X
for	B-X
acetylthiocholine	B-X
;	B-X
a	B-X
kcat	B-X
value	B-X
of	B-X
3.9	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
/min	B-X
,	B-X
and	B-X
selective	B-X
by	B-X
AChE-specific	B-X
inhibitors	B-X
.	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
the	B-X
purified	B-X
mature	B-X
enzyme	B-X
suggests	B-X
the	B-X
existence	B-X
of	B-X
two	B-X
alternative	B-X
cleavage	B-X
sites	B-X
for	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
,	B-X
in	B-X
which	B-X
the	B-X
'mature	B-X
'	B-X
position	B-X
1	B-X
is	B-X
either	B-X
Ala31	B-X
or	B-X
Gly33	B-X
.	B-X
Both	B-X
of	B-X
these	B-X
positions	B-X
conform	B-X
with	B-X
the	B-X
consensus	B-X
signal	B-X
peptide	B-X
recognition	B-X
sequences	B-X
and	B-X
demonstrate	B-X
bidirected	B-X
processing	B-X
of	B-X
signal	B-X
peptides	B-X
on	B-X
a	B-X
native	B-X
molecule	B-X
.	B-X

Evaluation	O
of	O
CD44	B-Protein
variant	O
6	O
expression	O
and	O
clinicopathological	O
factors	O
in	O
pulmonary	O
metastases	O
from	O
colon	O
carcinoma	O
.	O
<EOS>	B-X
Although	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
tumor	B-X
progression	B-X
,	B-X
recently	B-X
CD44	B-X
glycoproteins	B-X
and	B-X
the	B-X
c-Met	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
potentially	B-X
important	B-X
components	B-X
of	B-X
the	B-X
metastatic	B-X
cascade	B-X
.	B-X
CD44	B-X
is	B-X
a	B-X
family	B-X
of	B-X
transmembrane	B-X
receptors	B-X
generated	B-X
from	B-X
a	B-X
single	B-X
gene	B-X
by	B-X
alternative	B-X
splicing	B-X
and	B-X
differential	B-X
glycosylation	B-X
.	B-X
Important	B-X
biological	B-X
processes	B-X
involving	B-X
CD44	B-X
glycoproteins	B-X
include	B-X
cell	B-X
adhesion	B-X
,	B-X
lymphocyte	B-X
homing	B-X
,	B-X
hematopoiesis	B-X
,	B-X
tumor	B-X
progression	B-X
and	B-X
metastasis	B-X
.	B-X
The	B-X
precise	B-X
mechanism	B-X
via	B-X
which	B-X
CD44	B-X
promotes	B-X
tumorigenesis	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
elucidated	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
expression	B-X
of	B-X
adhesion	B-X
molecule	B-X
CD44	B-X
variant	B-X
6	B-X
in	B-X
pulmonary	B-X
metastases	B-X
from	B-X
colorectal	B-X
carcinomas	B-X
and	B-X
its	B-X
correlation	B-X
with	B-X
clinicopathological	B-X
parameters	B-X
.	B-X
Twenty	B-X
patients	B-X
were	B-X
randomly	B-X
selected	B-X
from	B-X
the	B-X
patients	B-X
who	B-X
had	B-X
undergone	B-X
a	B-X
resection	B-X
of	B-X
pulmonary	B-X
metastasis	B-X
from	B-X
colorectal	B-X
cancer	B-X
.	B-X
Immunoreactivity	B-X
for	B-X
CD44	B-X
was	B-X
quantified	B-X
.	B-X
CD44	B-X
v6	B-X
expression	B-X
was	B-X
related	B-X
to	B-X
the	B-X
interval	B-X
between	B-X
colon	B-X
resection	B-X
and	B-X
metastases	B-X
diagnosis	B-X
,	B-X
the	B-X
number	B-X
of	B-X
pulmonary	B-X
metastases	B-X
,	B-X
and	B-X
the	B-X
survival	B-X
after	B-X
lung	B-X
resection	B-X
.	B-X
No	B-X
statistical	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
CD44	B-X
v6	B-X
positivity	B-X
and	B-X
disease-free	B-X
interval	B-X
after	B-X
colon	B-X
resection	B-X
,	B-X
number	B-X
of	B-X
metastases	B-X
or	B-X
2-year	B-X
survival	B-X
after	B-X
lung	B-X
resection	B-X
.	B-X
Probably	B-X
CD44	B-X
v6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
confer	B-X
metastatic	B-X
potential	B-X
to	B-X
carcinoma	B-X
cells	B-X
increasing	B-X
the	B-X
migration	B-X
capacity	B-X
and	B-X
participating	B-X
in	B-X
invasion	B-X
via	B-X
changes	B-X
in	B-X
adhesion	B-X
to	B-X
the	B-X
extracellular	B-X
ligands	B-X
,	B-X
but	B-X
is	B-X
not	B-X
necessary	B-X
to	B-X
modify	B-X
the	B-X
clinical	B-X
history	B-X
of	B-X
the	B-X
metastases	B-X
.	B-X
Therefore	B-X
the	B-X
evaluation	B-X
of	B-X
CD44	B-X
v6	B-X
expression	B-X
in	B-X
lung	B-X
metastases	B-X
does	B-X
not	B-X
influence	B-X
the	B-X
therapeutic	B-X
scheme	B-X
.	B-X

Although	O
relatively	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
underlying	O
tumor	O
progression	O
,	O
recently	O
CD44	B-Protein
glycoproteins	O
and	O
the	O
c	B-Protein
-	I-Protein
Met	I-Protein
receptor	O
tyrosine	O
kinase	O
have	O
been	O
identified	O
as	O
potentially	O
important	O
components	O
of	O
the	O
metastatic	O
cascade	O
.	O

CD44	B-Protein
is	O
a	O
family	O
of	O
transmembrane	O
receptors	O
generated	O
from	O
a	O
single	O
gene	O
by	O
alternative	O
splicing	O
and	O
differential	O
glycosylation	O
.	O
<EOS>	B-X
Although	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
tumor	B-X
progression	B-X
,	B-X
recently	B-X
CD44	B-X
glycoproteins	B-X
and	B-X
the	B-X
c-Met	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
potentially	B-X
important	B-X
components	B-X
of	B-X
the	B-X
metastatic	B-X
cascade	B-X
.	B-X
CD44	B-X
is	B-X
a	B-X
family	B-X
of	B-X
transmembrane	B-X
receptors	B-X
generated	B-X
from	B-X
a	B-X
single	B-X
gene	B-X
by	B-X
alternative	B-X
splicing	B-X
and	B-X
differential	B-X
glycosylation	B-X
.	B-X
Important	B-X
biological	B-X
processes	B-X
involving	B-X
CD44	B-X
glycoproteins	B-X
include	B-X
cell	B-X
adhesion	B-X
,	B-X
lymphocyte	B-X
homing	B-X
,	B-X
hematopoiesis	B-X
,	B-X
tumor	B-X
progression	B-X
and	B-X
metastasis	B-X
.	B-X
The	B-X
precise	B-X
mechanism	B-X
via	B-X
which	B-X
CD44	B-X
promotes	B-X
tumorigenesis	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
elucidated	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
expression	B-X
of	B-X
adhesion	B-X
molecule	B-X
CD44	B-X
variant	B-X
6	B-X
in	B-X
pulmonary	B-X
metastases	B-X
from	B-X
colorectal	B-X
carcinomas	B-X
and	B-X
its	B-X
correlation	B-X
with	B-X
clinicopathological	B-X
parameters	B-X
.	B-X
Immunoreactivity	B-X
for	B-X
CD44	B-X
was	B-X
quantified	B-X
.	B-X
CD44	B-X
v6	B-X
expression	B-X
was	B-X
related	B-X
to	B-X
the	B-X
interval	B-X
between	B-X
colon	B-X
resection	B-X
and	B-X
metastases	B-X
diagnosis	B-X
,	B-X
the	B-X
number	B-X
of	B-X
pulmonary	B-X
metastases	B-X
,	B-X
and	B-X
the	B-X
survival	B-X
after	B-X
lung	B-X
resection	B-X
.	B-X
No	B-X
statistical	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
CD44	B-X
v6	B-X
positivity	B-X
and	B-X
disease-free	B-X
interval	B-X
after	B-X
colon	B-X
resection	B-X
,	B-X
number	B-X
of	B-X
metastases	B-X
or	B-X
2-year	B-X
survival	B-X
after	B-X
lung	B-X
resection	B-X
.	B-X
Probably	B-X
CD44	B-X
v6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
confer	B-X
metastatic	B-X
potential	B-X
to	B-X
carcinoma	B-X
cells	B-X
increasing	B-X
the	B-X
migration	B-X
capacity	B-X
and	B-X
participating	B-X
in	B-X
invasion	B-X
via	B-X
changes	B-X
in	B-X
adhesion	B-X
to	B-X
the	B-X
extracellular	B-X
ligands	B-X
,	B-X
but	B-X
is	B-X
not	B-X
necessary	B-X
to	B-X
modify	B-X
the	B-X
clinical	B-X
history	B-X
of	B-X
the	B-X
metastases	B-X
.	B-X
Therefore	B-X
the	B-X
evaluation	B-X
of	B-X
CD44	B-X
v6	B-X
expression	B-X
in	B-X
lung	B-X
metastases	B-X
does	B-X
not	B-X
influence	B-X
the	B-X
therapeutic	B-X
scheme	B-X
.	B-X

Important	O
biological	O
processes	O
involving	O
CD44	B-Protein
glycoproteins	O
include	O
cell	O
adhesion	O
,	O
lymphocyte	O
homing	O
,	O
hematopoiesis	O
,	O
tumor	O
progression	O
and	O
metastasis	O
.	O
<EOS>	B-X
Although	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
tumor	B-X
progression	B-X
,	B-X
recently	B-X
CD44	B-X
glycoproteins	B-X
and	B-X
the	B-X
c-Met	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
potentially	B-X
important	B-X
components	B-X
of	B-X
the	B-X
metastatic	B-X
cascade	B-X
.	B-X
CD44	B-X
is	B-X
a	B-X
family	B-X
of	B-X
transmembrane	B-X
receptors	B-X
generated	B-X
from	B-X
a	B-X
single	B-X
gene	B-X
by	B-X
alternative	B-X
splicing	B-X
and	B-X
differential	B-X
glycosylation	B-X
.	B-X
Important	B-X
biological	B-X
processes	B-X
involving	B-X
CD44	B-X
glycoproteins	B-X
include	B-X
cell	B-X
adhesion	B-X
,	B-X
lymphocyte	B-X
homing	B-X
,	B-X
hematopoiesis	B-X
,	B-X
tumor	B-X
progression	B-X
and	B-X
metastasis	B-X
.	B-X
The	B-X
precise	B-X
mechanism	B-X
via	B-X
which	B-X
CD44	B-X
promotes	B-X
tumorigenesis	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
elucidated	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
expression	B-X
of	B-X
adhesion	B-X
molecule	B-X
CD44	B-X
variant	B-X
6	B-X
in	B-X
pulmonary	B-X
metastases	B-X
from	B-X
colorectal	B-X
carcinomas	B-X
and	B-X
its	B-X
correlation	B-X
with	B-X
clinicopathological	B-X
parameters	B-X
.	B-X
Twenty	B-X
patients	B-X
were	B-X
randomly	B-X
selected	B-X
from	B-X
the	B-X
patients	B-X
who	B-X
had	B-X
undergone	B-X
a	B-X
resection	B-X
of	B-X
pulmonary	B-X
metastasis	B-X
from	B-X
colorectal	B-X
cancer	B-X
.	B-X
Formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
archival	B-X
specimens	B-X
of	B-X
tumor	B-X
tissues	B-X
and	B-X
adjacent	B-X
normal	B-X
mucosa	B-X
from	B-X
these	B-X
patients	B-X
were	B-X
the	B-X
subjects	B-X
of	B-X
the	B-X
present	B-X
study	B-X
.	B-X
Immunoreactivity	B-X
for	B-X
CD44	B-X
was	B-X
quantified	B-X
.	B-X
Specimens	B-X
were	B-X
considered	B-X
positive	B-X
if	B-X
almost	B-X
25	B-X
%	B-X
of	B-X
the	B-X
neoplastic	B-X
cells	B-X
were	B-X
stained	B-X
.	B-X
CD44	B-X
v6	B-X
expression	B-X
was	B-X
related	B-X
to	B-X
the	B-X
interval	B-X
between	B-X
colon	B-X
resection	B-X
and	B-X
metastases	B-X
diagnosis	B-X
,	B-X
the	B-X
number	B-X
of	B-X
pulmonary	B-X
metastases	B-X
,	B-X
and	B-X
the	B-X
survival	B-X
after	B-X
lung	B-X
resection	B-X
.	B-X
No	B-X
statistical	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
CD44	B-X
v6	B-X
positivity	B-X
and	B-X
disease-free	B-X
interval	B-X
after	B-X
colon	B-X
resection	B-X
,	B-X
number	B-X
of	B-X
metastases	B-X
or	B-X
2-year	B-X
survival	B-X
after	B-X
lung	B-X
resection	B-X
.	B-X
Probably	B-X
CD44	B-X
v6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
confer	B-X
metastatic	B-X
potential	B-X
to	B-X
carcinoma	B-X
cells	B-X
increasing	B-X
the	B-X
migration	B-X
capacity	B-X
and	B-X
participating	B-X
in	B-X
invasion	B-X
via	B-X
changes	B-X
in	B-X
adhesion	B-X
to	B-X
the	B-X
extracellular	B-X
ligands	B-X
,	B-X
but	B-X
is	B-X
not	B-X
necessary	B-X
to	B-X
modify	B-X
the	B-X
clinical	B-X
history	B-X
of	B-X
the	B-X
metastases	B-X
.	B-X
Therefore	B-X
the	B-X
evaluation	B-X
of	B-X
CD44	B-X
v6	B-X
expression	B-X
in	B-X
lung	B-X
metastases	B-X
does	B-X
not	B-X
influence	B-X
the	B-X
therapeutic	B-X
scheme	B-X
.	B-X

The	O
precise	O
mechanism	O
via	O
which	O
CD44	B-Protein
promotes	O
tumorigenesis	O
have	O
not	O
yet	O
been	O
elucidated	O
.	O

We	O
evaluated	O
the	O
expression	O
of	O
adhesion	O
molecule	O
CD44	B-Protein
variant	O
6	O
in	O
pulmonary	O
metastases	O
from	O
colorectal	O
carcinomas	O
and	O
its	O
correlation	O
with	O
clinicopathological	O
parameters	O
.	O
<EOS>	B-X
Although	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
tumor	B-X
progression	B-X
,	B-X
recently	B-X
CD44	B-X
glycoproteins	B-X
and	B-X
the	B-X
c-Met	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
potentially	B-X
important	B-X
components	B-X
of	B-X
the	B-X
metastatic	B-X
cascade	B-X
.	B-X
CD44	B-X
is	B-X
a	B-X
family	B-X
of	B-X
transmembrane	B-X
receptors	B-X
generated	B-X
from	B-X
a	B-X
single	B-X
gene	B-X
by	B-X
alternative	B-X
splicing	B-X
and	B-X
differential	B-X
glycosylation	B-X
.	B-X
Important	B-X
biological	B-X
processes	B-X
involving	B-X
CD44	B-X
glycoproteins	B-X
include	B-X
cell	B-X
adhesion	B-X
,	B-X
lymphocyte	B-X
homing	B-X
,	B-X
hematopoiesis	B-X
,	B-X
tumor	B-X
progression	B-X
and	B-X
metastasis	B-X
.	B-X
The	B-X
precise	B-X
mechanism	B-X
via	B-X
which	B-X
CD44	B-X
promotes	B-X
tumorigenesis	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
elucidated	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
expression	B-X
of	B-X
adhesion	B-X
molecule	B-X
CD44	B-X
variant	B-X
6	B-X
in	B-X
pulmonary	B-X
metastases	B-X
from	B-X
colorectal	B-X
carcinomas	B-X
and	B-X
its	B-X
correlation	B-X
with	B-X
clinicopathological	B-X
parameters	B-X
.	B-X
Twenty	B-X
patients	B-X
were	B-X
randomly	B-X
selected	B-X
from	B-X
the	B-X
patients	B-X
who	B-X
had	B-X
undergone	B-X
a	B-X
resection	B-X
of	B-X
pulmonary	B-X
metastasis	B-X
from	B-X
colorectal	B-X
cancer	B-X
.	B-X
Immunoreactivity	B-X
for	B-X
CD44	B-X
was	B-X
quantified	B-X
.	B-X
CD44	B-X
v6	B-X
expression	B-X
was	B-X
related	B-X
to	B-X
the	B-X
interval	B-X
between	B-X
colon	B-X
resection	B-X
and	B-X
metastases	B-X
diagnosis	B-X
,	B-X
the	B-X
number	B-X
of	B-X
pulmonary	B-X
metastases	B-X
,	B-X
and	B-X
the	B-X
survival	B-X
after	B-X
lung	B-X
resection	B-X
.	B-X
No	B-X
statistical	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
CD44	B-X
v6	B-X
positivity	B-X
and	B-X
disease-free	B-X
interval	B-X
after	B-X
colon	B-X
resection	B-X
,	B-X
number	B-X
of	B-X
metastases	B-X
or	B-X
2-year	B-X
survival	B-X
after	B-X
lung	B-X
resection	B-X
.	B-X
Probably	B-X
CD44	B-X
v6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
confer	B-X
metastatic	B-X
potential	B-X
to	B-X
carcinoma	B-X
cells	B-X
increasing	B-X
the	B-X
migration	B-X
capacity	B-X
and	B-X
participating	B-X
in	B-X
invasion	B-X
via	B-X
changes	B-X
in	B-X
adhesion	B-X
to	B-X
the	B-X
extracellular	B-X
ligands	B-X
,	B-X
but	B-X
is	B-X
not	B-X
necessary	B-X
to	B-X
modify	B-X
the	B-X
clinical	B-X
history	B-X
of	B-X
the	B-X
metastases	B-X
.	B-X
Therefore	B-X
the	B-X
evaluation	B-X
of	B-X
CD44	B-X
v6	B-X
expression	B-X
in	B-X
lung	B-X
metastases	B-X
does	B-X
not	B-X
influence	B-X
the	B-X
therapeutic	B-X
scheme	B-X
.	B-X

Twenty	O
patients	O
were	O
randomly	O
selected	O
from	O
the	O
patients	O
who	O
had	O
undergone	O
a	O
resection	O
of	O
pulmonary	O
metastasis	O
from	O
colorectal	O
cancer	O
.	O

Formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
archival	O
specimens	O
of	O
tumor	O
tissues	O
and	O
adjacent	O
normal	O
mucosa	O
from	O
these	O
patients	O
were	O
the	O
subjects	O
of	O
the	O
present	O
study	O
.	O
<EOS>	B-X
Although	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
tumor	B-X
progression	B-X
,	B-X
recently	B-X
CD44	B-X
glycoproteins	B-X
and	B-X
the	B-X
c-Met	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
potentially	B-X
important	B-X
components	B-X
of	B-X
the	B-X
metastatic	B-X
cascade	B-X
.	B-X
Important	B-X
biological	B-X
processes	B-X
involving	B-X
CD44	B-X
glycoproteins	B-X
include	B-X
cell	B-X
adhesion	B-X
,	B-X
lymphocyte	B-X
homing	B-X
,	B-X
hematopoiesis	B-X
,	B-X
tumor	B-X
progression	B-X
and	B-X
metastasis	B-X
.	B-X
The	B-X
precise	B-X
mechanism	B-X
via	B-X
which	B-X
CD44	B-X
promotes	B-X
tumorigenesis	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
elucidated	B-X
.	B-X
Twenty	B-X
patients	B-X
were	B-X
randomly	B-X
selected	B-X
from	B-X
the	B-X
patients	B-X
who	B-X
had	B-X
undergone	B-X
a	B-X
resection	B-X
of	B-X
pulmonary	B-X
metastasis	B-X
from	B-X
colorectal	B-X
cancer	B-X
.	B-X
Formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
archival	B-X
specimens	B-X
of	B-X
tumor	B-X
tissues	B-X
and	B-X
adjacent	B-X
normal	B-X
mucosa	B-X
from	B-X
these	B-X
patients	B-X
were	B-X
the	B-X
subjects	B-X
of	B-X
the	B-X
present	B-X
study	B-X
.	B-X

Immunoreactivity	O
for	O
CD44	B-Protein
was	O
quantified	O
.	O
<EOS>	B-X
Aldehyde	B-X
dehydrogenase-1A1	B-X
(	B-X
ALDH1A1	B-X
)	B-X
,	B-X
CD133	B-X
,	B-X
CD44	B-X
,	B-X
and	B-X
CD24	B-X
have	B-X
been	B-X
reported	B-X
as	B-X
cancer	B-X
stem	B-X
cell	B-X
markers	B-X
in	B-X
ovarian	B-X
cancers	B-X
.	B-X
Immunohistochemical	B-X
studies	B-X
for	B-X
ALDH1A1	B-X
,	B-X
CD133	B-X
,	B-X
CD44	B-X
,	B-X
and	B-X
CD24	B-X
were	B-X
performed	B-X
and	B-X
scored	B-X
semiquantitatively	B-X
by	B-X
2	B-X
pathologists	B-X
based	B-X
on	B-X
intensity	B-X
and	B-X
percent	B-X
of	B-X
positive	B-X
immunoreactive	B-X
cells	B-X
.	B-X
ALDH1A1	B-X
,	B-X
CD24	B-X
,	B-X
and	B-X
CD44	B-X
were	B-X
variably	B-X
detected	B-X
in	B-X
both	B-X
tumor	B-X
and	B-X
stromal	B-X
cells	B-X
,	B-X
and	B-X
immunoreactivity	B-X
in	B-X
tumor	B-X
was	B-X
stronger	B-X
than	B-X
in	B-X
stromal	B-X
cells	B-X
.	B-X
CD133	B-X
immunoreactivity	B-X
was	B-X
not	B-X
quantified	B-X
due	B-X
to	B-X
nonspecific	B-X
staining	B-X
in	B-X
tumor	B-X
and	B-X
stroma	B-X
.	B-X

Specimens	O
were	O
considered	O
positive	O
if	O
almost	O
25	O
%	O
of	O
the	O
neoplastic	O
cells	O
were	O
stained	O
.	O
<EOS>	B-X
Upper	B-X
endoscopy	B-X
showed	B-X
an	B-X
ulcer	B-X
of	B-X
25	B-X
mm	B-X
in	B-X
diameter	B-X
with	B-X
marginal	B-X
elevation	B-X
on	B-X
the	B-X
posterior	B-X
mid-gastric	B-X
body	B-X
.	B-X
Biopsy	B-X
of	B-X
the	B-X
ulcer	B-X
base	B-X
showed	B-X
monotonous	B-X
proliferation	B-X
of	B-X
small	B-X
spindle-shaped	B-X
cells	B-X
on	B-X
HE-stain	B-X
.	B-X
On	B-X
immunohistochemical	B-X
staining	B-X
,	B-X
these	B-X
cells	B-X
were	B-X
positively	B-X
stained	B-X
with	B-X
vimentin	B-X
,	B-X
cytokeratin	B-X
,	B-X
epithelial	B-X
membrane	B-X
antigen	B-X
,	B-X
and	B-X
CD99	B-X
,	B-X
but	B-X
were	B-X
negative	B-X
for	B-X
KIT	B-X
,	B-X
CD34	B-X
,	B-X
desmin	B-X
,	B-X
and	B-X
S-100	B-X
protein	B-X
.	B-X
Reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
,	B-X
using	B-X
the	B-X
RNA	B-X
from	B-X
frozen	B-X
neoplastic	B-X
tissue	B-X
of	B-X
the	B-X
resected	B-X
specimen	B-X
,	B-X
detected	B-X
a	B-X
fusion	B-X
gene	B-X
called	B-X
SYT-SSX1	B-X
,	B-X
specific	B-X
for	B-X
SS	B-X
.	B-X
Though	B-X
SS	B-X
arising	B-X
in	B-X
the	B-X
stomach	B-X
is	B-X
rare	B-X
,	B-X
it	B-X
should	B-X
be	B-X
considered	B-X
in	B-X
the	B-X
differential	B-X
diagnosis	B-X
of	B-X
KIT-negative	B-X
gastric	B-X
spindle	B-X
cell	B-X
tumor	B-X
.	B-X

CD44	B-Protein
v6	O
expression	O
was	O
related	O
to	O
the	O
interval	O
between	O
colon	O
resection	O
and	O
metastases	O
diagnosis	O
,	O
the	O
number	O
of	O
pulmonary	O
metastases	O
,	O
and	O
the	O
survival	O
after	O
lung	O
resection	O
.	O

No	O
statistical	O
correlation	O
was	O
found	O
between	O
CD44	B-Protein
v6	O
positivity	O
and	O
disease	O
-	O
free	O
interval	O
after	O
colon	O
resection	O
,	O
number	O
of	O
metastases	O
or	O
2	O
-	O
year	O
survival	O
after	O
lung	O
resection	O
.	O
<EOS>	B-X
The	B-X
liver	B-X
is	B-X
the	B-X
most	B-X
frequent	B-X
site	B-X
of	B-X
metastases	B-X
and	B-X
dominates	B-X
the	B-X
length	B-X
of	B-X
survival	B-X
for	B-X
this	B-X
disease	B-X
.	B-X
As	B-X
surgical	B-X
and	B-X
systemic	B-X
therapies	B-X
have	B-X
become	B-X
accepted	B-X
and	B-X
now	B-X
are	B-X
proven	B-X
to	B-X
be	B-X
potentially	B-X
curative	B-X
,	B-X
other	B-X
sites	B-X
of	B-X
metastases	B-X
have	B-X
become	B-X
more	B-X
clinically	B-X
relevant	B-X
in	B-X
terms	B-X
of	B-X
clinical	B-X
symptoms	B-X
and	B-X
influence	B-X
on	B-X
survival	B-X
.	B-X
Treatment	B-X
of	B-X
extrahepatic	B-X
metastases	B-X
by	B-X
surgical	B-X
and	B-X
ablative	B-X
procedures	B-X
is	B-X
increasingly	B-X
accepted	B-X
and	B-X
is	B-X
proving	B-X
to	B-X
be	B-X
effective	B-X
at	B-X
palliating	B-X
symptoms	B-X
,	B-X
as	B-X
well	B-X
as	B-X
life	B-X
prolonging	B-X
.	B-X
We	B-X
will	B-X
then	B-X
discuss	B-X
surgical	B-X
and	B-X
ablative	B-X
treatments	B-X
of	B-X
other	B-X
sites	B-X
of	B-X
disease	B-X
including	B-X
lung	B-X
,	B-X
lymph	B-X
nodes	B-X
,	B-X
peritoneum	B-X
,	B-X
bone	B-X
,	B-X
and	B-X
brain	B-X
.	B-X

Probably	O
CD44	B-Protein
v6	O
is	O
necessary	O
and	O
sufficient	O
to	O
confer	O
metastatic	O
potential	O
to	O
carcinoma	O
cells	O
increasing	O
the	O
migration	O
capacity	O
and	O
participating	O
in	O
invasion	O
via	O
changes	O
in	O
adhesion	O
to	O
the	O
extracellular	O
ligands	O
,	O
but	O
is	O
not	O
necessary	O
to	O
modify	O
the	O
clinical	O
history	O
of	O
the	O
metastases	O
.	O

Therefore	O
the	O
evaluation	O
of	O
CD44	B-Protein
v6	O
expression	O
in	O
lung	O
metastases	O
does	O
not	O
influence	O
the	O
therapeutic	O
scheme	O
.	O
<EOS>	B-X
CD44	B-X
,	B-X
belongs	B-X
to	B-X
the	B-X
cell	B-X
adhesion	B-X
molecule	B-X
family	B-X
and	B-X
is	B-X
expressed	B-X
on	B-X
cell	B-X
surfaces	B-X
in	B-X
several	B-X
isoforms	B-X
which	B-X
are	B-X
generated	B-X
by	B-X
alternative	B-X
splicing	B-X
of	B-X
messenger	B-X
RNA	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
current	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
expression	B-X
of	B-X
selected	B-X
CD44	B-X
variants	B-X
on	B-X
lung	B-X
cancer	B-X
cells	B-X
of	B-X
various	B-X
histology	B-X
and	B-X
to	B-X
compare	B-X
these	B-X
with	B-X
other	B-X
markers	B-X
of	B-X
tumor	B-X
spread	B-X
.	B-X
Surgical	B-X
samples	B-X
of	B-X
primary	B-X
lung	B-X
carcinoma	B-X
of	B-X
various	B-X
histology	B-X
were	B-X
subjected	B-X
to	B-X
alkaline	B-X
phosphatase-anti-alkaline	B-X
phosphatase	B-X
complex	B-X
immunohistochemistry	B-X
using	B-X
a	B-X
panel	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
:	B-X
anti-CD44	B-X
v5	B-X
,	B-X
v6	B-X
,	B-X
v7/8	B-X
,	B-X
v10	B-X
,	B-X
anti-Ki-67	B-X
,	B-X
anti-Bcl-2	B-X
and	B-X
anti-p53	B-X
.	B-X
The	B-X
patients	B-X
were	B-X
subdivided	B-X
into	B-X
groups	B-X
with	B-X
and	B-X
without	B-X
metastases	B-X
,	B-X
as	B-X
found	B-X
during	B-X
surgery	B-X
.	B-X
All	B-X
CD44	B-X
variants	B-X
tested	B-X
could	B-X
be	B-X
demonstrated	B-X
on	B-X
lung	B-X
cancer	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
incidence	B-X
of	B-X
particular	B-X
isoforms	B-X
varied	B-X
,	B-X
depending	B-X
on	B-X
lung	B-X
cancer	B-X
histology	B-X
.	B-X
In	B-X
general	B-X
,	B-X
CD44	B-X
expression	B-X
was	B-X
highest	B-X
in	B-X
squamous	B-X
cell	B-X
tumors	B-X
and	B-X
lowest	B-X
in	B-X
anaplastic	B-X
small	B-X
cell	B-X
carcinomas	B-X
.	B-X
Squamous	B-X
cell	B-X
cancers	B-X
had	B-X
high	B-X
expression	B-X
of	B-X
v5	B-X
and	B-X
v6	B-X
variants	B-X
,	B-X
while	B-X
in	B-X
anaplastic	B-X
large	B-X
cell	B-X
and	B-X
small	B-X
cell	B-X
carcinomas	B-X
v10	B-X
was	B-X
abundant	B-X
.	B-X
When	B-X
Ki-67	B-X
,	B-X
Bcl-2	B-X
and	B-X
p53	B-X
protein	B-X
expression	B-X
was	B-X
compared	B-X
to	B-X
the	B-X
incidence	B-X
of	B-X
CD44	B-X
variants	B-X
,	B-X
coincidence	B-X
was	B-X
found	B-X
for	B-X
v10	B-X
only	B-X
.	B-X
In	B-X
12	B-X
cases	B-X
with	B-X
metastases	B-X
,	B-X
tumor	B-X
cells	B-X
had	B-X
high	B-X
v6	B-X
and	B-X
Ki-67	B-X
expression	B-X
,	B-X
but	B-X
these	B-X
data	B-X
were	B-X
not	B-X
significant	B-X
compared	B-X
to	B-X
cases	B-X
without	B-X
metastases	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
v5	B-X
and	B-X
v6	B-X
variants	B-X
are	B-X
of	B-X
significance	B-X
in	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinoma	B-X
,	B-X
presumably	B-X
in	B-X
the	B-X
promotion	B-X
of	B-X
metastasis	B-X
,	B-X
while	B-X
in	B-X
anaplastic	B-X
small	B-X
cell	B-X
or	B-X
large	B-X
cell	B-X
cancers	B-X
only	B-X
v10	B-X
expression	B-X
seems	B-X
to	B-X
correlate	B-X
with	B-X
proteins	B-X
associated	B-X
with	B-X
tumor	B-X
growth	B-X
and	B-X
progression	B-X
.	B-X

Promoter	O
-	O
restricted	O
H3	B-Protein
Lys	O
4	O
di	O
-	O
methylation	O
is	O
an	O
epigenetic	O
mark	O
for	O
monoallelic	O
expression	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
histone	B-X
tails	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
long-term	B-X
epigenetic	B-X
memory	B-X
.	B-X
Methylated	B-X
H3	B-X
Lys	B-X
4	B-X
(	B-X
K4	B-X
)	B-X
is	B-X
a	B-X
generally	B-X
conserved	B-X
mark	B-X
for	B-X
euchromatic	B-X
,	B-X
transcriptionally	B-X
active	B-X
regions	B-X
,	B-X
although	B-X
the	B-X
effect	B-X
of	B-X
this	B-X
modification	B-X
is	B-X
likely	B-X
also	B-X
to	B-X
depend	B-X
on	B-X
its	B-X
distribution	B-X
both	B-X
within	B-X
the	B-X
euchromatic	B-X
region	B-X
and	B-X
more	B-X
specifically	B-X
within	B-X
a	B-X
given	B-X
gene	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
a	B-X
profile	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
that	B-X
is	B-X
specific	B-X
for	B-X
monoallelically	B-X
expressed	B-X
genes	B-X
.	B-X
Both	B-X
X-linked	B-X
genes	B-X
subject	B-X
to	B-X
X-inactivation	B-X
and	B-X
autosomal	B-X
imprinted	B-X
genes	B-X
have	B-X
di-methylated	B-X
H3K4	B-X
restricted	B-X
to	B-X
their	B-X
promoter	B-X
regions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
high	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
found	B-X
in	B-X
both	B-X
promoters	B-X
and	B-X
exonic	B-X
parts	B-X
of	B-X
autosomal	B-X
genes	B-X
and	B-X
of	B-X
X-linked	B-X
genes	B-X
that	B-X
escape	B-X
X-inactivation	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
this	B-X
pattern	B-X
of	B-X
promoter	B-X
restricted	B-X
H3	B-X
Lys	B-X
4	B-X
di-methylation	B-X
,	B-X
already	B-X
present	B-X
in	B-X
totipotent	B-X
cells	B-X
,	B-X
is	B-X
causally	B-X
related	B-X
to	B-X
the	B-X
long-term	B-X
programming	B-X
of	B-X
allelic	B-X
expression	B-X
and	B-X
provides	B-X
an	B-X
epigenetic	B-X
mark	B-X
for	B-X
monoallelically	B-X
expressed	B-X
genes	B-X
.	B-X

Methylation	O
of	O
histone	B-Protein
tails	O
has	O
been	O
implicated	O
in	O
long	O
-	O
term	O
epigenetic	O
memory	O
.	O
<EOS>	B-X
There	B-X
are	B-X
several	B-X
pathways	B-X
,	B-X
including	B-X
histone	B-X
tail	B-X
modifications	B-X
,	B-X
histone	B-X
variant	B-X
incorporation	B-X
,	B-X
nucleosome	B-X
remodelling	B-X
,	B-X
DNA	B-X
methylation	B-X
and	B-X
noncoding	B-X
RNAs	B-X
that	B-X
together	B-X
all	B-X
contribute	B-X
to	B-X
the	B-X
dynamic	B-X
'make-up	B-X
'	B-X
of	B-X
chromatin	B-X
under	B-X
distinct	B-X
developmental	B-X
options	B-X
.	B-X
The	B-X
histone	B-X
tail	B-X
modifications	B-X
are	B-X
most	B-X
variable	B-X
and	B-X
over	B-X
50	B-X
marks	B-X
have	B-X
by	B-X
now	B-X
been	B-X
mapped	B-X
.	B-X
While	B-X
the	B-X
majority	B-X
of	B-X
these	B-X
modifications	B-X
are	B-X
transient	B-X
,	B-X
histone	B-X
lysine	B-X
methylation	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
a	B-X
histone	B-X
lysine	B-X
tri-methyl	B-X
state	B-X
has	B-X
been	B-X
regarded	B-X
as	B-X
a	B-X
more	B-X
robust	B-X
signal	B-X
,	B-X
consistent	B-X
with	B-X
proposed	B-X
roles	B-X
to	B-X
impart	B-X
long-term	B-X
epigenetic	B-X
memory	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
paradigm	B-X
of	B-X
SET-domain	B-X
histone	B-X
lysine	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
and	B-X
chromo-domain	B-X
adaptor	B-X
proteins	B-X
,	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
Sir	B-X
Hans	B-X
Krebs	B-X
Medal	B-X
2005	B-X
,	B-X
I	B-X
describe	B-X
here	B-X
my	B-X
personal	B-X
view	B-X
on	B-X
the	B-X
discovery	B-X
of	B-X
the	B-X
first	B-X
HMTase	B-X
in	B-X
2000	B-X
,	B-X
and	B-X
the	B-X
subsequent	B-X
advances	B-X
on	B-X
the	B-X
biology	B-X
of	B-X
histone	B-X
lysine	B-X
methylation	B-X
.	B-X
This	B-X
discovery	B-X
has	B-X
changed	B-X
my	B-X
scientific	B-X
career	B-X
and	B-X
significantly	B-X
contributed	B-X
to	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
epigenetic	B-X
control	B-X
,	B-X
with	B-X
important	B-X
implications	B-X
for	B-X
heterochromatin	B-X
formation	B-X
,	B-X
X	B-X
inactivation	B-X
,	B-X
Polycomb	B-X
group	B-X
silencing	B-X
and	B-X
novel	B-X
insights	B-X
into	B-X
stem	B-X
cell	B-X
research	B-X
,	B-X
nuclear	B-X
reprogramming	B-X
and	B-X
cancer	B-X
.	B-X

Methylated	O
H3	B-Protein
Lys	O
4	O
(	O
K4	O
)	O
is	O
a	O
generally	O
conserved	O
mark	O
for	O
euchromatic	O
,	O
transcriptionally	O
active	O
regions	O
,	O
although	O
the	O
effect	O
of	O
this	O
modification	O
is	O
likely	O
also	O
to	O
depend	O
on	O
its	O
distribution	O
both	O
within	O
the	O
euchromatic	O
region	O
and	O
more	O
specifically	O
within	O
a	O
given	O
gene	O
.	O
<EOS>	B-X
Methylation	B-X
of	B-X
histone	B-X
tails	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
long-term	B-X
epigenetic	B-X
memory	B-X
.	B-X
Methylated	B-X
H3	B-X
Lys	B-X
4	B-X
(	B-X
K4	B-X
)	B-X
is	B-X
a	B-X
generally	B-X
conserved	B-X
mark	B-X
for	B-X
euchromatic	B-X
,	B-X
transcriptionally	B-X
active	B-X
regions	B-X
,	B-X
although	B-X
the	B-X
effect	B-X
of	B-X
this	B-X
modification	B-X
is	B-X
likely	B-X
also	B-X
to	B-X
depend	B-X
on	B-X
its	B-X
distribution	B-X
both	B-X
within	B-X
the	B-X
euchromatic	B-X
region	B-X
and	B-X
more	B-X
specifically	B-X
within	B-X
a	B-X
given	B-X
gene	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
a	B-X
profile	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
that	B-X
is	B-X
specific	B-X
for	B-X
monoallelically	B-X
expressed	B-X
genes	B-X
.	B-X
Both	B-X
X-linked	B-X
genes	B-X
subject	B-X
to	B-X
X-inactivation	B-X
and	B-X
autosomal	B-X
imprinted	B-X
genes	B-X
have	B-X
di-methylated	B-X
H3K4	B-X
restricted	B-X
to	B-X
their	B-X
promoter	B-X
regions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
high	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
found	B-X
in	B-X
both	B-X
promoters	B-X
and	B-X
exonic	B-X
parts	B-X
of	B-X
autosomal	B-X
genes	B-X
and	B-X
of	B-X
X-linked	B-X
genes	B-X
that	B-X
escape	B-X
X-inactivation	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
this	B-X
pattern	B-X
of	B-X
promoter	B-X
restricted	B-X
H3	B-X
Lys	B-X
4	B-X
di-methylation	B-X
,	B-X
already	B-X
present	B-X
in	B-X
totipotent	B-X
cells	B-X
,	B-X
is	B-X
causally	B-X
related	B-X
to	B-X
the	B-X
long-term	B-X
programming	B-X
of	B-X
allelic	B-X
expression	B-X
and	B-X
provides	B-X
an	B-X
epigenetic	B-X
mark	B-X
for	B-X
monoallelically	B-X
expressed	B-X
genes	B-X
.	B-X

Here	O
we	O
describe	O
a	O
profile	O
of	O
H3K4	B-Protein
di	O
-	O
methylation	O
that	O
is	O
specific	O
for	O
monoallelically	O
expressed	O
genes	O
.	O
<EOS>	B-X
Methylated	B-X
H3	B-X
Lys	B-X
4	B-X
(	B-X
K4	B-X
)	B-X
is	B-X
a	B-X
generally	B-X
conserved	B-X
mark	B-X
for	B-X
euchromatic	B-X
,	B-X
transcriptionally	B-X
active	B-X
regions	B-X
,	B-X
although	B-X
the	B-X
effect	B-X
of	B-X
this	B-X
modification	B-X
is	B-X
likely	B-X
also	B-X
to	B-X
depend	B-X
on	B-X
its	B-X
distribution	B-X
both	B-X
within	B-X
the	B-X
euchromatic	B-X
region	B-X
and	B-X
more	B-X
specifically	B-X
within	B-X
a	B-X
given	B-X
gene	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
a	B-X
profile	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
that	B-X
is	B-X
specific	B-X
for	B-X
monoallelically	B-X
expressed	B-X
genes	B-X
.	B-X
Both	B-X
X-linked	B-X
genes	B-X
subject	B-X
to	B-X
X-inactivation	B-X
and	B-X
autosomal	B-X
imprinted	B-X
genes	B-X
have	B-X
di-methylated	B-X
H3K4	B-X
restricted	B-X
to	B-X
their	B-X
promoter	B-X
regions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
high	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
found	B-X
in	B-X
both	B-X
promoters	B-X
and	B-X
exonic	B-X
parts	B-X
of	B-X
autosomal	B-X
genes	B-X
and	B-X
of	B-X
X-linked	B-X
genes	B-X
that	B-X
escape	B-X
X-inactivation	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
this	B-X
pattern	B-X
of	B-X
promoter	B-X
restricted	B-X
H3	B-X
Lys	B-X
4	B-X
di-methylation	B-X
,	B-X
already	B-X
present	B-X
in	B-X
totipotent	B-X
cells	B-X
,	B-X
is	B-X
causally	B-X
related	B-X
to	B-X
the	B-X
long-term	B-X
programming	B-X
of	B-X
allelic	B-X
expression	B-X
and	B-X
provides	B-X
an	B-X
epigenetic	B-X
mark	B-X
for	B-X
monoallelically	B-X
expressed	B-X
genes	B-X
.	B-X

Both	O
X	O
-	O
linked	O
genes	O
subject	O
to	O
X	O
-	O
inactivation	O
and	O
autosomal	O
imprinted	O
genes	O
have	O
di	O
-	O
methylated	O
H3K4	B-Protein
restricted	O
to	O
their	O
promoter	O
regions	O
.	O

In	O
contrast	O
,	O
high	O
levels	O
of	O
H3K4	B-Protein
di	O
-	O
methylation	O
are	O
found	O
in	O
both	O
promoters	O
and	O
exonic	O
parts	O
of	O
autosomal	O
genes	O
and	O
of	O
X	O
-	O
linked	O
genes	O
that	O
escape	O
X	O
-	O
inactivation	O
.	O
<EOS>	B-X
Methylated	B-X
H3	B-X
Lys	B-X
4	B-X
(	B-X
K4	B-X
)	B-X
is	B-X
a	B-X
generally	B-X
conserved	B-X
mark	B-X
for	B-X
euchromatic	B-X
,	B-X
transcriptionally	B-X
active	B-X
regions	B-X
,	B-X
although	B-X
the	B-X
effect	B-X
of	B-X
this	B-X
modification	B-X
is	B-X
likely	B-X
also	B-X
to	B-X
depend	B-X
on	B-X
its	B-X
distribution	B-X
both	B-X
within	B-X
the	B-X
euchromatic	B-X
region	B-X
and	B-X
more	B-X
specifically	B-X
within	B-X
a	B-X
given	B-X
gene	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
a	B-X
profile	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
that	B-X
is	B-X
specific	B-X
for	B-X
monoallelically	B-X
expressed	B-X
genes	B-X
.	B-X
Both	B-X
X-linked	B-X
genes	B-X
subject	B-X
to	B-X
X-inactivation	B-X
and	B-X
autosomal	B-X
imprinted	B-X
genes	B-X
have	B-X
di-methylated	B-X
H3K4	B-X
restricted	B-X
to	B-X
their	B-X
promoter	B-X
regions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
high	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
found	B-X
in	B-X
both	B-X
promoters	B-X
and	B-X
exonic	B-X
parts	B-X
of	B-X
autosomal	B-X
genes	B-X
and	B-X
of	B-X
X-linked	B-X
genes	B-X
that	B-X
escape	B-X
X-inactivation	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
this	B-X
pattern	B-X
of	B-X
promoter	B-X
restricted	B-X
H3	B-X
Lys	B-X
4	B-X
di-methylation	B-X
,	B-X
already	B-X
present	B-X
in	B-X
totipotent	B-X
cells	B-X
,	B-X
is	B-X
causally	B-X
related	B-X
to	B-X
the	B-X
long-term	B-X
programming	B-X
of	B-X
allelic	B-X
expression	B-X
and	B-X
provides	B-X
an	B-X
epigenetic	B-X
mark	B-X
for	B-X
monoallelically	B-X
expressed	B-X
genes	B-X
.	B-X

We	O
suggest	O
that	O
this	O
pattern	O
of	O
promoter	O
restricted	O
H3	B-Protein
Lys	O
4	O
di	O
-	O
methylation	O
,	O
already	O
present	O
in	O
totipotent	O
cells	O
,	O
is	O
causally	O
related	O
to	O
the	O
long	O
-	O
term	O
programming	O
of	O
allelic	O
expression	O
and	O
provides	O
an	O
epigenetic	O
mark	O
for	O
monoallelically	O
expressed	O
genes	O
.	O

Inhibition	O
of	O
histone	B-Protein
deacetylase	O
increases	O
cytotoxicity	O
to	O
anticancer	O
drugs	O
targeting	O
DNA	O
.	O
<EOS>	B-X
Several	B-X
anticancer	B-X
drugs	B-X
target	B-X
DNA	B-X
or	B-X
enzymes	B-X
acting	B-X
on	B-X
the	B-X
DNA	B-X
.	B-X
Because	B-X
chromatin	B-X
DNA	B-X
is	B-X
tightly	B-X
compacted	B-X
,	B-X
accessibility	B-X
to	B-X
the	B-X
drug	B-X
target	B-X
may	B-X
reduce	B-X
the	B-X
efficiency	B-X
of	B-X
these	B-X
anticancer	B-X
drugs	B-X
.	B-X
We	B-X
thus	B-X
treated	B-X
four	B-X
human	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
two	B-X
normal	B-X
epithelial	B-X
cell	B-X
lines	B-X
with	B-X
either	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
or	B-X
SAHA	B-X
,	B-X
two	B-X
histone	B-X
deacetylase	B-X
inhibitors	B-X
,	B-X
before	B-X
exposing	B-X
the	B-X
cells	B-X
to	B-X
VP-16	B-X
,	B-X
ellipticine	B-X
,	B-X
camptothecin	B-X
,	B-X
doxorubicin	B-X
,	B-X
cisplatin	B-X
,	B-X
5-fluorouracil	B-X
,	B-X
or	B-X
cyclophosmamide	B-X
.	B-X
Treating	B-X
the	B-X
cells	B-X
in	B-X
the	B-X
reverse	B-X
order	B-X
(	B-X
anticancer	B-X
drug	B-X
first	B-X
,	B-X
followed	B-X
by	B-X
TSA	B-X
or	B-X
SAHA	B-X
)	B-X
had	B-X
no	B-X
more	B-X
cytotoxic	B-X
effect	B-X
than	B-X
the	B-X
drug	B-X
alone	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
loosening-up	B-X
the	B-X
chromatin	B-X
structure	B-X
by	B-X
histone	B-X
acetylation	B-X
can	B-X
increase	B-X
the	B-X
efficiency	B-X
of	B-X
several	B-X
anticancer	B-X
drugs	B-X
targeting	B-X
DNA	B-X
.	B-X
This	B-X
may	B-X
be	B-X
advantageous	B-X
for	B-X
treating	B-X
tumors	B-X
intrinsically	B-X
resistant	B-X
to	B-X
these	B-X
drugs	B-X
.	B-X

Several	O
anticancer	O
drugs	O
target	O
DNA	O
or	O
enzymes	O
acting	O
on	O
the	O
DNA	O
.	O
<EOS>	B-X
Many	B-X
cancer	B-X
type-specific	B-X
anticancer	B-X
agents	B-X
have	B-X
been	B-X
developed	B-X
and	B-X
significant	B-X
advances	B-X
have	B-X
been	B-X
made	B-X
toward	B-X
precision	B-X
medicine	B-X
in	B-X
cancer	B-X
treatment	B-X
.	B-X
However	B-X
,	B-X
traditional	B-X
or	B-X
nonspecific	B-X
anticancer	B-X
drugs	B-X
are	B-X
still	B-X
important	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
many	B-X
cancer	B-X
patients	B-X
whose	B-X
cancers	B-X
either	B-X
do	B-X
not	B-X
respond	B-X
to	B-X
or	B-X
have	B-X
developed	B-X
resistance	B-X
to	B-X
cancer-specific	B-X
anticancer	B-X
agents	B-X
.	B-X
DNA	B-X
topoisomerases	B-X
,	B-X
especially	B-X
type	B-X
IIA	B-X
topoisomerases	B-X
,	B-X
are	B-X
proved	B-X
therapeutic	B-X
targets	B-X
of	B-X
anticancer	B-X
and	B-X
antibacterial	B-X
drugs	B-X
.	B-X
Clinically	B-X
successful	B-X
topoisomerase-targeting	B-X
anticancer	B-X
drugs	B-X
act	B-X
through	B-X
topoisomerase	B-X
poisoning	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
replication	B-X
fork	B-X
arrest	B-X
and	B-X
double-strand	B-X
break	B-X
formation	B-X
.	B-X
Structures	B-X
of	B-X
topoisomerase-drug-DNA	B-X
ternary	B-X
complexes	B-X
have	B-X
revealed	B-X
the	B-X
exact	B-X
binding	B-X
sites	B-X
and	B-X
mechanisms	B-X
of	B-X
topoisomerase	B-X
poisons	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
the	B-X
field	B-X
have	B-X
suggested	B-X
a	B-X
possibility	B-X
of	B-X
designing	B-X
isoform-specific	B-X
human	B-X
topoisomerase	B-X
II	B-X
poisons	B-X
,	B-X
which	B-X
may	B-X
be	B-X
developed	B-X
as	B-X
safer	B-X
anticancer	B-X
drugs	B-X
.	B-X
It	B-X
may	B-X
also	B-X
be	B-X
possible	B-X
to	B-X
design	B-X
catalytic	B-X
inhibitors	B-X
of	B-X
topoisomerases	B-X
by	B-X
targeting	B-X
certain	B-X
inactive	B-X
conformations	B-X
of	B-X
these	B-X
enzymes	B-X
.	B-X
Thus	B-X
,	B-X
topoisomerases	B-X
remain	B-X
as	B-X
important	B-X
therapeutic	B-X
targets	B-X
of	B-X
anticancer	B-X
agents	B-X
.	B-X

Because	O
chromatin	O
DNA	O
is	O
tightly	O
compacted	O
,	O
accessibility	O
to	O
the	O
drug	O
target	O
may	O
reduce	O
the	O
efficiency	O
of	O
these	O
anticancer	O
drugs	O
.	O

We	O
thus	O
treated	O
four	O
human	O
cancer	O
cell	O
lines	O
and	O
two	O
normal	O
epithelial	O
cell	O
lines	O
with	O
either	O
trichostatin	O
A	O
(	O
TSA	O
)	O
or	O
SAHA	O
,	O
two	O
histone	B-Protein
deacetylase	O
inhibitors	O
,	O
before	O
exposing	O
the	O
cells	O
to	O
VP	O
-	O
16	O
,	O
ellipticine	O
,	O
camptothecin	O
,	O
doxorubicin	O
,	O
cisplatin	O
,	O
5	O
-	O
fluorouracil	O
,	O
or	O
cyclophosmamide	O
.	O
<EOS>	B-X
Some	B-X
anticancer	B-X
drugs	B-X
,	B-X
but	B-X
not	B-X
all	B-X
,	B-X
inhibit	B-X
replication	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
and	B-X
thus	B-X
,	B-X
exhibit	B-X
a	B-X
therapeutic	B-X
potential	B-X
.	B-X
Such	B-X
drugs	B-X
,	B-X
unlike	B-X
the	B-X
traditional	B-X
HIV	B-X
enzyme	B-X
inhibitors	B-X
,	B-X
could	B-X
suppress	B-X
HIV	B-X
strains	B-X
that	B-X
are	B-X
resistant	B-X
to	B-X
inhibitors	B-X
of	B-X
viral	B-X
enzymes	B-X
,	B-X
decrease	B-X
proviral	B-X
burden	B-X
in	B-X
vivo	B-X
,	B-X
or	B-X
reduce	B-X
reservoirs	B-X
of	B-X
infection	B-X
via	B-X
killing	B-X
infected	B-X
cells	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
the	B-X
development	B-X
of	B-X
potent	B-X
anticancer	B-X
drugs	B-X
,	B-X
that	B-X
exhibit	B-X
anti-HIV	B-X
activities	B-X
.	B-X
At	B-X
least	B-X
four	B-X
chemically	B-X
and	B-X
pharmacologically	B-X
distinct	B-X
classes	B-X
of	B-X
anticancer	B-X
drugs	B-X
,	B-X
i.e	B-X
.	B-X
certain	B-X
cyclin-dependent	B-X
kinase	B-X
inhibitors	B-X
(	B-X
CDKIs	B-X
)	B-X
,	B-X
topoisomerase	B-X
1	B-X
enzyme	B-X
(	B-X
top	B-X
1	B-X
)	B-X
inhibitors	B-X
,	B-X
non-nucleoside	B-X
antimetabolites	B-X
,	B-X
and	B-X
estrogen	B-X
receptor	B-X
ligands	B-X
are	B-X
promising	B-X
candidates	B-X
.	B-X
These	B-X
drugs	B-X
,	B-X
at	B-X
high	B-X
doses	B-X
are	B-X
used	B-X
for	B-X
cancer	B-X
therapy	B-X
;	B-X
at	B-X
lower	B-X
concentrations	B-X
they	B-X
exhibit	B-X
anti-HIV	B-X
activities	B-X
in	B-X
cultured	B-X
cells	B-X
.	B-X
While	B-X
the	B-X
antiretroviral	B-X
and	B-X
the	B-X
anticancer	B-X
activities	B-X
of	B-X
the	B-X
cdk	B-X
inhibitor	B-X
flavopiridol	B-X
appear	B-X
to	B-X
be	B-X
mutually	B-X
exclusive	B-X
and	B-X
unrelated	B-X
in	B-X
cells	B-X
and	B-X
animal	B-X
model	B-X
(	B-X
s	B-X
)	B-X
of	B-X
HIV	B-X
disease	B-X
,	B-X
the	B-X
top	B-X
1	B-X
inhibitor	B-X
9-nitrocamptothecin	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
cdk-inhibitor	B-X
roscovitine	B-X
inhibit	B-X
replication	B-X
of	B-X
HIV	B-X
via	B-X
selective	B-X
sensitization	B-X
of	B-X
HIV-infected	B-X
cells	B-X
to	B-X
apoptosis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
these	B-X
compounds	B-X
are	B-X
different	B-X
from	B-X
other	B-X
cancer	B-X
therapeutics	B-X
that	B-X
,	B-X
at	B-X
toxic	B-X
concentrations	B-X
,	B-X
activate	B-X
HIV	B-X
either	B-X
in	B-X
cultured	B-X
cells	B-X
(	B-X
such	B-X
as	B-X
certain	B-X
ingenol	B-X
and	B-X
butyrate	B-X
derivatives	B-X
)	B-X
and/or	B-X
in	B-X
patients	B-X
(	B-X
such	B-X
as	B-X
the	B-X
widely	B-X
used	B-X
cyclophosmamide	B-X
and	B-X
cisplatin	B-X
)	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
relevant	B-X
available	B-X
clinical	B-X
and	B-X
in	B-X
vitro	B-X
data	B-X
that	B-X
either	B-X
support	B-X
or	B-X
discourage	B-X
using	B-X
certain	B-X
anticancer	B-X
drugs	B-X
for	B-X
treatment	B-X
of	B-X
HIV	B-X
disease	B-X
,	B-X
and	B-X
the	B-X
rationales	B-X
for	B-X
developing	B-X
novel	B-X
antiretroviral	B-X
drugs	B-X
that	B-X
may	B-X
target	B-X
infected	B-X
cells	B-X
rather	B-X
than	B-X
viral	B-X
proteins	B-X
are	B-X
discussed	B-X
.	B-X

Pretreatment	O
with	O
TSA	O
or	O
SAHA	O
increased	O
the	O
killing	O
efficiency	O
of	O
VP	O
-	O
16	O
,	O
ellipticine	O
,	O
doxorubicin	O
,	O
and	O
cisplatin	O
.	O
<EOS>	B-X
Studies	B-X
indicated	B-X
that	B-X
acetylation	B-X
of	B-X
histone	B-X
H4	B-X
at	B-X
lysine16	B-X
(	B-X
H4K16ac	B-X
)	B-X
strongly	B-X
modulated	B-X
autophagic/lysosomal	B-X
signaling	B-X
pathway	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
whether	B-X
the	B-X
autophagic	B-X
neuronal	B-X
injury	B-X
could	B-X
be	B-X
alleviated	B-X
by	B-X
amending	B-X
H4K16ac	B-X
level	B-X
after	B-X
ischemic	B-X
stroke	B-X
.	B-X
A	B-X
rat	B-X
model	B-X
of	B-X
middle	B-X
cerebral	B-X
artery	B-X
occlusion	B-X
(	B-X
MCAO	B-X
)	B-X
/reperfusion	B-X
was	B-X
prepared	B-X
to	B-X
investigate	B-X
dynamic	B-X
variations	B-X
between	B-X
H4K16ac	B-X
and	B-X
autophagy	B-X
at	B-X
the	B-X
penumbra	B-X
.	B-X
The	B-X
results	B-X
illustrated	B-X
that	B-X
the	B-X
significantly	B-X
elevated	B-X
H4K16ac	B-X
was	B-X
coupled	B-X
with	B-X
dramatically	B-X
promoted	B-X
autophagic	B-X
activity	B-X
at	B-X
4	B-X
h	B-X
after	B-X
the	B-X
insult	B-X
,	B-X
suggesting	B-X
H4K16ac	B-X
tightly	B-X
controlled	B-X
autophagic	B-X
signaling	B-X
.	B-X
After	B-X
that	B-X
,	B-X
H4K16ac	B-X
level	B-X
was	B-X
altered	B-X
by	B-X
pretreatment	B-X
with	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
,	B-X
a	B-X
H4K16ac	B-X
facilitator	B-X
)	B-X
and	B-X
MG149	B-X
(	B-X
a	B-X
H4K16ac	B-X
inhibitor	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
TSA-promoted	B-X
H4K16ac	B-X
led	B-X
to	B-X
an	B-X
excessively	B-X
up-regulated	B-X
autophagy	B-X
resulting	B-X
in	B-X
autophagic/lysosomal	B-X
dysfunction	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
the	B-X
accumulated	B-X
autophagic	B-X
substrates	B-X
and	B-X
exacerbated	B-X
lysosomal	B-X
inefficiency	B-X
in	B-X
neurons	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
MG149-depressed	B-X
H4K16ac	B-X
significantly	B-X
down-regulated	B-X
autophagic	B-X
activity	B-X
and	B-X
thereby	B-X
restored	B-X
the	B-X
impaired	B-X
autophagic	B-X
flux	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
that	B-X
the	B-X
H4K16ac	B-X
attenuation	B-X
elicits	B-X
neuroprotection	B-X
against	B-X
ischemic	B-X
stroke	B-X
by	B-X
ameliorating	B-X
autophagic/lysosomal	B-X
dysfunction	B-X
in	B-X
neurons	B-X
.	B-X

The	O
magnitude	O
of	O
sensitization	O
is	O
cell	O
type	O
specific	O
and	O
is	O
>	O
10	O
-	O
fold	O
for	O
VP	O
-	O
16	O
in	O
D54	O
,	O
a	O
brain	O
tumor	O
cell	O
line	O
intrinsically	O
resistant	O
to	O
topoisomerase	O
II	O
inhibitors	O
.	O
<EOS>	B-X
We	B-X
thus	B-X
treated	B-X
four	B-X
human	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
two	B-X
normal	B-X
epithelial	B-X
cell	B-X
lines	B-X
with	B-X
either	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
or	B-X
SAHA	B-X
,	B-X
two	B-X
histone	B-X
deacetylase	B-X
inhibitors	B-X
,	B-X
before	B-X
exposing	B-X
the	B-X
cells	B-X
to	B-X
VP-16	B-X
,	B-X
ellipticine	B-X
,	B-X
camptothecin	B-X
,	B-X
doxorubicin	B-X
,	B-X
cisplatin	B-X
,	B-X
5-fluorouracil	B-X
,	B-X
or	B-X
cyclophosmamide	B-X
.	B-X
Pretreatment	B-X
with	B-X
TSA	B-X
or	B-X
SAHA	B-X
increased	B-X
the	B-X
killing	B-X
efficiency	B-X
of	B-X
VP-16	B-X
,	B-X
ellipticine	B-X
,	B-X
doxorubicin	B-X
,	B-X
and	B-X
cisplatin	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
sensitization	B-X
is	B-X
cell	B-X
type	B-X
specific	B-X
and	B-X
is	B-X
>	B-X
10-fold	B-X
for	B-X
VP-16	B-X
in	B-X
D54	B-X
,	B-X
a	B-X
brain	B-X
tumor	B-X
cell	B-X
line	B-X
intrinsically	B-X
resistant	B-X
to	B-X
topoisomerase	B-X
II	B-X
inhibitors	B-X
.	B-X
Topoisomerase	B-X
II	B-X
levels	B-X
and	B-X
activity	B-X
were	B-X
not	B-X
affected	B-X
by	B-X
this	B-X
treatment	B-X
,	B-X
but	B-X
p53	B-X
,	B-X
p21	B-X
,	B-X
and	B-X
Gadd45	B-X
protein	B-X
levels	B-X
were	B-X
markedly	B-X
induced	B-X
.	B-X
Moreover	B-X
,	B-X
pretreatment	B-X
with	B-X
TSA	B-X
also	B-X
increased	B-X
VP-16-induced	B-X
apoptosis	B-X
in	B-X
a	B-X
p53-dependent	B-X
and	B-X
-independent	B-X
manner	B-X
.	B-X
Treating	B-X
the	B-X
cells	B-X
in	B-X
the	B-X
reverse	B-X
order	B-X
(	B-X
anticancer	B-X
drug	B-X
first	B-X
,	B-X
followed	B-X
by	B-X
TSA	B-X
or	B-X
SAHA	B-X
)	B-X
had	B-X
no	B-X
more	B-X
cytotoxic	B-X
effect	B-X
than	B-X
the	B-X
drug	B-X
alone	B-X
.	B-X
This	B-X
may	B-X
be	B-X
advantageous	B-X
for	B-X
treating	B-X
tumors	B-X
intrinsically	B-X
resistant	B-X
to	B-X
these	B-X
drugs	B-X
.	B-X

Topoisomerase	O
II	O
levels	O
and	O
activity	O
were	O
not	O
affected	O
by	O
this	O
treatment	O
,	O
but	O
p53	B-Protein
,	O
p21	B-Protein
,	O
and	O
Gadd45	B-Protein
protein	O
levels	O
were	O
markedly	O
induced	O
.	O
<EOS>	B-X
Type	B-X
II	B-X
topoisomerases	B-X
are	B-X
essential	B-X
enzymes	B-X
that	B-X
modulate	B-X
DNA	B-X
under-	B-X
and	B-X
overwinding	B-X
,	B-X
knotting	B-X
,	B-X
and	B-X
tangling	B-X
.	B-X
Beyond	B-X
their	B-X
critical	B-X
physiological	B-X
functions	B-X
,	B-X
these	B-X
enzymes	B-X
are	B-X
the	B-X
targets	B-X
for	B-X
some	B-X
of	B-X
the	B-X
most	B-X
widely	B-X
prescribed	B-X
anticancer	B-X
drugs	B-X
(	B-X
topoisomerase	B-X
II	B-X
poisons	B-X
)	B-X
in	B-X
clinical	B-X
use	B-X
.	B-X
Topoisomerase	B-X
II	B-X
poisons	B-X
kill	B-X
cells	B-X
by	B-X
increasing	B-X
levels	B-X
of	B-X
covalent	B-X
enzyme-cleaved	B-X
DNA	B-X
complexes	B-X
that	B-X
are	B-X
normal	B-X
reaction	B-X
intermediates	B-X
.	B-X
Similar	B-X
rearrangements	B-X
are	B-X
seen	B-X
in	B-X
infant	B-X
leukemias	B-X
and	B-X
are	B-X
associated	B-X
with	B-X
gestational	B-X
diets	B-X
that	B-X
are	B-X
high	B-X
in	B-X
naturally	B-X
occurring	B-X
topoisomerase	B-X
II-active	B-X
compounds	B-X
.	B-X
The	B-X
first	B-X
part	B-X
of	B-X
this	B-X
article	B-X
will	B-X
focus	B-X
on	B-X
type	B-X
II	B-X
topoisomerases	B-X
and	B-X
describe	B-X
the	B-X
mechanism	B-X
of	B-X
enzyme	B-X
and	B-X
drug	B-X
action	B-X
.	B-X
The	B-X
second	B-X
part	B-X
will	B-X
discuss	B-X
how	B-X
topoisomerase	B-X
II	B-X
poisons	B-X
trigger	B-X
chromosomal	B-X
breaks	B-X
that	B-X
lead	B-X
to	B-X
leukemia	B-X
and	B-X
potential	B-X
approaches	B-X
for	B-X
dissociating	B-X
the	B-X
actions	B-X
of	B-X
drugs	B-X
from	B-X
their	B-X
leukemogenic	B-X
potential	B-X
.	B-X

Moreover	O
,	O
pretreatment	O
with	O
TSA	O
also	O
increased	O
VP	O
-	O
16	O
-	O
induced	O
apoptosis	O
in	O
a	O
p53	B-Protein
-	O
dependent	O
and	O
-	O
independent	O
manner	O
.	O

Treating	O
the	O
cells	O
in	O
the	O
reverse	O
order	O
(	O
anticancer	O
drug	O
first	O
,	O
followed	O
by	O
TSA	O
or	O
SAHA	O
)	O
had	O
no	O
more	O
cytotoxic	O
effect	O
than	O
the	O
drug	O
alone	O
.	O

These	O
data	O
suggest	O
that	O
loosening	O
-	O
up	O
the	O
chromatin	O
structure	O
by	O
histone	B-Protein
acetylation	O
can	O
increase	O
the	O
efficiency	O
of	O
several	O
anticancer	O
drugs	O
targeting	O
DNA	O
.	O
<EOS>	B-X
Several	B-X
anticancer	B-X
drugs	B-X
target	B-X
DNA	B-X
or	B-X
enzymes	B-X
acting	B-X
on	B-X
the	B-X
DNA	B-X
.	B-X
Because	B-X
chromatin	B-X
DNA	B-X
is	B-X
tightly	B-X
compacted	B-X
,	B-X
accessibility	B-X
to	B-X
the	B-X
drug	B-X
target	B-X
may	B-X
reduce	B-X
the	B-X
efficiency	B-X
of	B-X
these	B-X
anticancer	B-X
drugs	B-X
.	B-X
We	B-X
thus	B-X
treated	B-X
four	B-X
human	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
two	B-X
normal	B-X
epithelial	B-X
cell	B-X
lines	B-X
with	B-X
either	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
or	B-X
SAHA	B-X
,	B-X
two	B-X
histone	B-X
deacetylase	B-X
inhibitors	B-X
,	B-X
before	B-X
exposing	B-X
the	B-X
cells	B-X
to	B-X
VP-16	B-X
,	B-X
ellipticine	B-X
,	B-X
camptothecin	B-X
,	B-X
doxorubicin	B-X
,	B-X
cisplatin	B-X
,	B-X
5-fluorouracil	B-X
,	B-X
or	B-X
cyclophosmamide	B-X
.	B-X
Pretreatment	B-X
with	B-X
TSA	B-X
or	B-X
SAHA	B-X
increased	B-X
the	B-X
killing	B-X
efficiency	B-X
of	B-X
VP-16	B-X
,	B-X
ellipticine	B-X
,	B-X
doxorubicin	B-X
,	B-X
and	B-X
cisplatin	B-X
.	B-X
Moreover	B-X
,	B-X
pretreatment	B-X
with	B-X
TSA	B-X
also	B-X
increased	B-X
VP-16-induced	B-X
apoptosis	B-X
in	B-X
a	B-X
p53-dependent	B-X
and	B-X
-independent	B-X
manner	B-X
.	B-X
Treating	B-X
the	B-X
cells	B-X
in	B-X
the	B-X
reverse	B-X
order	B-X
(	B-X
anticancer	B-X
drug	B-X
first	B-X
,	B-X
followed	B-X
by	B-X
TSA	B-X
or	B-X
SAHA	B-X
)	B-X
had	B-X
no	B-X
more	B-X
cytotoxic	B-X
effect	B-X
than	B-X
the	B-X
drug	B-X
alone	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
loosening-up	B-X
the	B-X
chromatin	B-X
structure	B-X
by	B-X
histone	B-X
acetylation	B-X
can	B-X
increase	B-X
the	B-X
efficiency	B-X
of	B-X
several	B-X
anticancer	B-X
drugs	B-X
targeting	B-X
DNA	B-X
.	B-X
This	B-X
may	B-X
be	B-X
advantageous	B-X
for	B-X
treating	B-X
tumors	B-X
intrinsically	B-X
resistant	B-X
to	B-X
these	B-X
drugs	B-X
.	B-X

This	O
may	O
be	O
advantageous	O
for	O
treating	O
tumors	O
intrinsically	O
resistant	O
to	O
these	O
drugs	O
.	O
<EOS>	B-X
The	B-X
transcriptional	B-X
factors	B-X
HIF-1	B-X
and	B-X
HIF-2	B-X
and	B-X
their	B-X
novel	B-X
inhibitors	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
However	B-X
,	B-X
some	B-X
unique	B-X
features	B-X
of	B-X
the	B-X
tumor	B-X
microenvironment	B-X
(	B-X
TME	B-X
)	B-X
such	B-X
as	B-X
hypoxia	B-X
,	B-X
low	B-X
pH	B-X
and	B-X
elevated	B-X
interstitial	B-X
fluid	B-X
pressure	B-X
cause	B-X
cancer	B-X
cells	B-X
resistant	B-X
to	B-X
most	B-X
therapies	B-X
.	B-X
Live	B-X
bacteria	B-X
can	B-X
be	B-X
further	B-X
integrated	B-X
with	B-X
anti-cancer	B-X
drugs	B-X
and	B-X
nanomaterials	B-X
to	B-X
increase	B-X
the	B-X
latter	B-X
's	B-X
targeted	B-X
delivery	B-X
and	B-X
accumulation	B-X
in	B-X
the	B-X
tumors	B-X
.	B-X
Pharmacological	B-X
targeting	B-X
of	B-X
mitochondrial	B-X
ion	B-X
channels	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
promising	B-X
approach	B-X
to	B-X
eliminate	B-X
cancer	B-X
cells	B-X
;	B-X
as	B-X
most	B-X
of	B-X
these	B-X
channels	B-X
are	B-X
differentially	B-X
expressed	B-X
and/or	B-X
regulated	B-X
in	B-X
cancer	B-X
cells	B-X
in	B-X
comparison	B-X
to	B-X
healthy	B-X
ones	B-X
,	B-X
this	B-X
strategy	B-X
may	B-X
selectively	B-X
eliminate	B-X
the	B-X
former	B-X
.	B-X
This	B-X
leads	B-X
to	B-X
indirect	B-X
modulation	B-X
of	B-X
oxidative	B-X
phosphorylation	B-X
,	B-X
which	B-X
is/may	B-X
be	B-X
fundamental	B-X
for	B-X
both	B-X
cancer	B-X
and	B-X
cancer	B-X
stem	B-X
cell	B-X
survival	B-X
.	B-X
Furthermore	B-X
,	B-X
given	B-X
the	B-X
crucial	B-X
contribution	B-X
of	B-X
mitochondria	B-X
to	B-X
intrinsic	B-X
apoptosis	B-X
,	B-X
modulation	B-X
of	B-X
their	B-X
ion	B-X
channels	B-X
leading	B-X
to	B-X
cytochrome	B-X
c	B-X
release	B-X
may	B-X
be	B-X
of	B-X
great	B-X
advantage	B-X
in	B-X
case	B-X
of	B-X
resistance	B-X
to	B-X
drugs	B-X
triggering	B-X
apoptotic	B-X
events	B-X
upstream	B-X
of	B-X
the	B-X
mitochondrial	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
discuss	B-X
state-of-the-art	B-X
strategies	B-X
using	B-X
mitochondriotropic	B-X
drugs	B-X
or	B-X
peptide-based	B-X
approaches	B-X
allowing	B-X
a	B-X
more	B-X
efficient	B-X
and	B-X
selective	B-X
targeting	B-X
of	B-X
mitochondrial	B-X
ion	B-X
channel-linked	B-X
events	B-X
.	B-X

Epigenetic	O
regulation	O
of	O
telomere	O
length	O
in	O
mammalian	O
cells	O
by	O
the	O
Suv39h1	B-Protein
and	O
Suv39h2	B-Protein
histone	B-Protein
methyltransferases	O
.	O
<EOS>	B-X
Yeast	B-X
and	B-X
flies	B-X
with	B-X
defects	B-X
in	B-X
activities	B-X
that	B-X
modify	B-X
the	B-X
state	B-X
of	B-X
chromatin	B-X
also	B-X
have	B-X
abnormal	B-X
telomere	B-X
function	B-X
,	B-X
but	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
chromatin-modifying	B-X
activities	B-X
in	B-X
regulating	B-X
telomeres	B-X
in	B-X
mammals	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
telomere	B-X
length	B-X
and	B-X
function	B-X
in	B-X
mice	B-X
null	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
the	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
(	B-X
called	B-X
SUV39DN	B-X
mice	B-X
)	B-X
.	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
govern	B-X
methylation	B-X
of	B-X
histone	B-X
H3	B-X
Lys9	B-X
(	B-X
H3-Lys9	B-X
)	B-X
in	B-X
heterochromatic	B-X
regions	B-X
.	B-X
We	B-X
show	B-X
that	B-X
primary	B-X
cells	B-X
derived	B-X
from	B-X
SUV39DN	B-X
mice	B-X
have	B-X
abnormally	B-X
long	B-X
telomeres	B-X
relative	B-X
to	B-X
wild-type	B-X
controls	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
telomeres	B-X
were	B-X
enriched	B-X
in	B-X
di-	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
that	B-X
telomeres	B-X
of	B-X
SUV39DN	B-X
cells	B-X
had	B-X
less	B-X
dimethylated	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
more	B-X
monomethylated	B-X
H3-Lys9	B-X
.	B-X
Concomitant	B-X
with	B-X
the	B-X
decrease	B-X
in	B-X
H3-Lys9	B-X
methylation	B-X
,	B-X
telomeres	B-X
in	B-X
SUV39DN	B-X
cells	B-X
had	B-X
reduced	B-X
binding	B-X
of	B-X
the	B-X
chromobox	B-X
proteins	B-X
Cbx1	B-X
,	B-X
Cbx3	B-X
and	B-X
Cbx5	B-X
,	B-X
homologs	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
heterochromatin	B-X
protein	B-X
1	B-X
(	B-X
HP1	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
substantial	B-X
changes	B-X
in	B-X
the	B-X
state	B-X
of	B-X
telomeric	B-X
heterochromatin	B-X
in	B-X
SUV39DN	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
abnormal	B-X
telomere	B-X
elongation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
epigenetic	B-X
regulation	B-X
of	B-X
telomere	B-X
length	B-X
in	B-X
mammals	B-X
by	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
.	B-X

Telomeres	O
are	O
capping	O
structures	O
at	O
the	O
ends	O
of	O
eukaryotic	O
chromosomes	O
composed	O
of	O
TTAGGG	O
repeats	O
bound	O
to	O
an	O
array	O
of	O
specialized	O
proteins	O
.	O

Telomeres	O
are	O
heterochromatic	O
regions	O
.	O
<EOS>	B-X
Since	B-X
its	B-X
initial	B-X
release	B-X
in	B-X
2000	B-X
,	B-X
the	B-X
human	B-X
reference	B-X
genome	B-X
has	B-X
covered	B-X
only	B-X
the	B-X
euchromatic	B-X
fraction	B-X
of	B-X
the	B-X
genome	B-X
,	B-X
leaving	B-X
important	B-X
heterochromatic	B-X
regions	B-X
unfinished	B-X
.	B-X
The	B-X
completed	B-X
regions	B-X
include	B-X
all	B-X
centromeric	B-X
satellite	B-X
arrays	B-X
,	B-X
recent	B-X
segmental	B-X
duplications	B-X
,	B-X
and	B-X
the	B-X
short	B-X
arms	B-X
of	B-X
all	B-X
five	B-X
acrocentric	B-X
chromosomes	B-X
,	B-X
unlocking	B-X
these	B-X
complex	B-X
regions	B-X
of	B-X
the	B-X
genome	B-X
to	B-X
variational	B-X
and	B-X
functional	B-X
studies	B-X
.	B-X
Telomeres	B-X
play	B-X
vital	B-X
roles	B-X
in	B-X
ensuring	B-X
chromosome	B-X
stability	B-X
and	B-X
are	B-X
thus	B-X
closely	B-X
linked	B-X
with	B-X
the	B-X
onset	B-X
of	B-X
aging	B-X
and	B-X
human	B-X
disease	B-X
.	B-X
Telomeres	B-X
undergo	B-X
extensive	B-X
lengthening	B-X
during	B-X
early	B-X
embryogenesis	B-X
.	B-X
Mechanistically	B-X
,	B-X
Dcaf11	B-X
targets	B-X
Kap1	B-X
(	B-X
KRAB-associated	B-X
protein	B-X
1	B-X
)	B-X
for	B-X
ubiquitination-mediated	B-X
degradation	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
Zscan4	B-X
downstream	B-X
enhancer	B-X
and	B-X
the	B-X
removal	B-X
of	B-X
heterochromatic	B-X
H3K9me3	B-X
at	B-X
telomere/subtelomere	B-X
regions	B-X
.	B-X

Yeast	O
and	O
flies	O
with	O
defects	O
in	O
activities	O
that	O
modify	O
the	O
state	O
of	O
chromatin	O
also	O
have	O
abnormal	O
telomere	O
function	O
,	O
but	O
the	O
putative	O
role	O
of	O
chromatin	O
-	O
modifying	O
activities	O
in	O
regulating	O
telomeres	O
in	O
mammals	O
is	O
unknown	O
.	O
<EOS>	B-X
Yeast	B-X
and	B-X
flies	B-X
with	B-X
defects	B-X
in	B-X
activities	B-X
that	B-X
modify	B-X
the	B-X
state	B-X
of	B-X
chromatin	B-X
also	B-X
have	B-X
abnormal	B-X
telomere	B-X
function	B-X
,	B-X
but	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
chromatin-modifying	B-X
activities	B-X
in	B-X
regulating	B-X
telomeres	B-X
in	B-X
mammals	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
telomere	B-X
length	B-X
and	B-X
function	B-X
in	B-X
mice	B-X
null	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
the	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
(	B-X
called	B-X
SUV39DN	B-X
mice	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
primary	B-X
cells	B-X
derived	B-X
from	B-X
SUV39DN	B-X
mice	B-X
have	B-X
abnormally	B-X
long	B-X
telomeres	B-X
relative	B-X
to	B-X
wild-type	B-X
controls	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
telomeres	B-X
were	B-X
enriched	B-X
in	B-X
di-	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
that	B-X
telomeres	B-X
of	B-X
SUV39DN	B-X
cells	B-X
had	B-X
less	B-X
dimethylated	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
more	B-X
monomethylated	B-X
H3-Lys9	B-X
.	B-X
Concomitant	B-X
with	B-X
the	B-X
decrease	B-X
in	B-X
H3-Lys9	B-X
methylation	B-X
,	B-X
telomeres	B-X
in	B-X
SUV39DN	B-X
cells	B-X
had	B-X
reduced	B-X
binding	B-X
of	B-X
the	B-X
chromobox	B-X
proteins	B-X
Cbx1	B-X
,	B-X
Cbx3	B-X
and	B-X
Cbx5	B-X
,	B-X
homologs	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
heterochromatin	B-X
protein	B-X
1	B-X
(	B-X
HP1	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
substantial	B-X
changes	B-X
in	B-X
the	B-X
state	B-X
of	B-X
telomeric	B-X
heterochromatin	B-X
in	B-X
SUV39DN	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
abnormal	B-X
telomere	B-X
elongation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
epigenetic	B-X
regulation	B-X
of	B-X
telomere	B-X
length	B-X
in	B-X
mammals	B-X
by	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
.	B-X

Here	O
we	O
report	O
on	O
telomere	O
length	O
and	O
function	O
in	O
mice	O
null	O
with	O
respect	O
to	O
both	O
the	O
histone	B-Protein
methyltransferases	O
(	O
HMTases	O
)	O
Suv39h1	B-Protein
and	O
Suv39h2	B-Protein
(	O
called	O
SUV39DN	O
mice	O
)	O
.	O
<EOS>	B-X
Yeast	B-X
and	B-X
flies	B-X
with	B-X
defects	B-X
in	B-X
activities	B-X
that	B-X
modify	B-X
the	B-X
state	B-X
of	B-X
chromatin	B-X
also	B-X
have	B-X
abnormal	B-X
telomere	B-X
function	B-X
,	B-X
but	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
chromatin-modifying	B-X
activities	B-X
in	B-X
regulating	B-X
telomeres	B-X
in	B-X
mammals	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
telomere	B-X
length	B-X
and	B-X
function	B-X
in	B-X
mice	B-X
null	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
the	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
(	B-X
called	B-X
SUV39DN	B-X
mice	B-X
)	B-X
.	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
govern	B-X
methylation	B-X
of	B-X
histone	B-X
H3	B-X
Lys9	B-X
(	B-X
H3-Lys9	B-X
)	B-X
in	B-X
heterochromatic	B-X
regions	B-X
.	B-X
We	B-X
show	B-X
that	B-X
primary	B-X
cells	B-X
derived	B-X
from	B-X
SUV39DN	B-X
mice	B-X
have	B-X
abnormally	B-X
long	B-X
telomeres	B-X
relative	B-X
to	B-X
wild-type	B-X
controls	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
telomeres	B-X
were	B-X
enriched	B-X
in	B-X
di-	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
that	B-X
telomeres	B-X
of	B-X
SUV39DN	B-X
cells	B-X
had	B-X
less	B-X
dimethylated	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
more	B-X
monomethylated	B-X
H3-Lys9	B-X
.	B-X
Concomitant	B-X
with	B-X
the	B-X
decrease	B-X
in	B-X
H3-Lys9	B-X
methylation	B-X
,	B-X
telomeres	B-X
in	B-X
SUV39DN	B-X
cells	B-X
had	B-X
reduced	B-X
binding	B-X
of	B-X
the	B-X
chromobox	B-X
proteins	B-X
Cbx1	B-X
,	B-X
Cbx3	B-X
and	B-X
Cbx5	B-X
,	B-X
homologs	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
heterochromatin	B-X
protein	B-X
1	B-X
(	B-X
HP1	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
substantial	B-X
changes	B-X
in	B-X
the	B-X
state	B-X
of	B-X
telomeric	B-X
heterochromatin	B-X
in	B-X
SUV39DN	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
abnormal	B-X
telomere	B-X
elongation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
epigenetic	B-X
regulation	B-X
of	B-X
telomere	B-X
length	B-X
in	B-X
mammals	B-X
by	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
.	B-X

Suv39h1	B-Protein
and	O
Suv39h2	B-Protein
govern	O
methylation	O
of	O
histone	B-Protein
H3	I-Protein
Lys9	O
(	O
H3	B-Protein
-	O
Lys9	O
)	O
in	O
heterochromatic	O
regions	O
.	O
<EOS>	B-X
Telomeres	B-X
are	B-X
heterochromatic	B-X
regions	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
telomere	B-X
length	B-X
and	B-X
function	B-X
in	B-X
mice	B-X
null	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
the	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
(	B-X
called	B-X
SUV39DN	B-X
mice	B-X
)	B-X
.	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
govern	B-X
methylation	B-X
of	B-X
histone	B-X
H3	B-X
Lys9	B-X
(	B-X
H3-Lys9	B-X
)	B-X
in	B-X
heterochromatic	B-X
regions	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
telomeres	B-X
were	B-X
enriched	B-X
in	B-X
di-	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
that	B-X
telomeres	B-X
of	B-X
SUV39DN	B-X
cells	B-X
had	B-X
less	B-X
dimethylated	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
more	B-X
monomethylated	B-X
H3-Lys9	B-X
.	B-X
Concomitant	B-X
with	B-X
the	B-X
decrease	B-X
in	B-X
H3-Lys9	B-X
methylation	B-X
,	B-X
telomeres	B-X
in	B-X
SUV39DN	B-X
cells	B-X
had	B-X
reduced	B-X
binding	B-X
of	B-X
the	B-X
chromobox	B-X
proteins	B-X
Cbx1	B-X
,	B-X
Cbx3	B-X
and	B-X
Cbx5	B-X
,	B-X
homologs	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
heterochromatin	B-X
protein	B-X
1	B-X
(	B-X
HP1	B-X
)	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
epigenetic	B-X
regulation	B-X
of	B-X
telomere	B-X
length	B-X
in	B-X
mammals	B-X
by	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
.	B-X

We	O
show	O
that	O
primary	O
cells	O
derived	O
from	O
SUV39DN	O
mice	O
have	O
abnormally	O
long	O
telomeres	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
.	O
<EOS>	B-X
Yeast	B-X
and	B-X
flies	B-X
with	B-X
defects	B-X
in	B-X
activities	B-X
that	B-X
modify	B-X
the	B-X
state	B-X
of	B-X
chromatin	B-X
also	B-X
have	B-X
abnormal	B-X
telomere	B-X
function	B-X
,	B-X
but	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
chromatin-modifying	B-X
activities	B-X
in	B-X
regulating	B-X
telomeres	B-X
in	B-X
mammals	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
telomere	B-X
length	B-X
and	B-X
function	B-X
in	B-X
mice	B-X
null	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
the	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
(	B-X
called	B-X
SUV39DN	B-X
mice	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
primary	B-X
cells	B-X
derived	B-X
from	B-X
SUV39DN	B-X
mice	B-X
have	B-X
abnormally	B-X
long	B-X
telomeres	B-X
relative	B-X
to	B-X
wild-type	B-X
controls	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
telomeres	B-X
were	B-X
enriched	B-X
in	B-X
di-	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
that	B-X
telomeres	B-X
of	B-X
SUV39DN	B-X
cells	B-X
had	B-X
less	B-X
dimethylated	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
more	B-X
monomethylated	B-X
H3-Lys9	B-X
.	B-X
Concomitant	B-X
with	B-X
the	B-X
decrease	B-X
in	B-X
H3-Lys9	B-X
methylation	B-X
,	B-X
telomeres	B-X
in	B-X
SUV39DN	B-X
cells	B-X
had	B-X
reduced	B-X
binding	B-X
of	B-X
the	B-X
chromobox	B-X
proteins	B-X
Cbx1	B-X
,	B-X
Cbx3	B-X
and	B-X
Cbx5	B-X
,	B-X
homologs	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
heterochromatin	B-X
protein	B-X
1	B-X
(	B-X
HP1	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
substantial	B-X
changes	B-X
in	B-X
the	B-X
state	B-X
of	B-X
telomeric	B-X
heterochromatin	B-X
in	B-X
SUV39DN	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
abnormal	B-X
telomere	B-X
elongation	B-X
.	B-X

Using	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
analysis	O
,	O
we	O
found	O
that	O
telomeres	O
were	O
enriched	O
in	O
di	O
-	O
and	O
trimethylated	O
H3	B-Protein
-	O
Lys9	O
but	O
that	O
telomeres	O
of	O
SUV39DN	O
cells	O
had	O
less	O
dimethylated	O
and	O
trimethylated	O
H3	B-Protein
-	O
Lys9	O
but	O
more	O
monomethylated	O
H3	B-Protein
-	O
Lys9	O
.	O
<EOS>	B-X
Yeast	B-X
and	B-X
flies	B-X
with	B-X
defects	B-X
in	B-X
activities	B-X
that	B-X
modify	B-X
the	B-X
state	B-X
of	B-X
chromatin	B-X
also	B-X
have	B-X
abnormal	B-X
telomere	B-X
function	B-X
,	B-X
but	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
chromatin-modifying	B-X
activities	B-X
in	B-X
regulating	B-X
telomeres	B-X
in	B-X
mammals	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
telomere	B-X
length	B-X
and	B-X
function	B-X
in	B-X
mice	B-X
null	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
the	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
(	B-X
called	B-X
SUV39DN	B-X
mice	B-X
)	B-X
.	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
govern	B-X
methylation	B-X
of	B-X
histone	B-X
H3	B-X
Lys9	B-X
(	B-X
H3-Lys9	B-X
)	B-X
in	B-X
heterochromatic	B-X
regions	B-X
.	B-X
We	B-X
show	B-X
that	B-X
primary	B-X
cells	B-X
derived	B-X
from	B-X
SUV39DN	B-X
mice	B-X
have	B-X
abnormally	B-X
long	B-X
telomeres	B-X
relative	B-X
to	B-X
wild-type	B-X
controls	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
telomeres	B-X
were	B-X
enriched	B-X
in	B-X
di-	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
that	B-X
telomeres	B-X
of	B-X
SUV39DN	B-X
cells	B-X
had	B-X
less	B-X
dimethylated	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
more	B-X
monomethylated	B-X
H3-Lys9	B-X
.	B-X
Concomitant	B-X
with	B-X
the	B-X
decrease	B-X
in	B-X
H3-Lys9	B-X
methylation	B-X
,	B-X
telomeres	B-X
in	B-X
SUV39DN	B-X
cells	B-X
had	B-X
reduced	B-X
binding	B-X
of	B-X
the	B-X
chromobox	B-X
proteins	B-X
Cbx1	B-X
,	B-X
Cbx3	B-X
and	B-X
Cbx5	B-X
,	B-X
homologs	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
heterochromatin	B-X
protein	B-X
1	B-X
(	B-X
HP1	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
substantial	B-X
changes	B-X
in	B-X
the	B-X
state	B-X
of	B-X
telomeric	B-X
heterochromatin	B-X
in	B-X
SUV39DN	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
abnormal	B-X
telomere	B-X
elongation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
epigenetic	B-X
regulation	B-X
of	B-X
telomere	B-X
length	B-X
in	B-X
mammals	B-X
by	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
.	B-X

Concomitant	O
with	O
the	O
decrease	O
in	O
H3	B-Protein
-	O
Lys9	O
methylation	O
,	O
telomeres	O
in	O
SUV39DN	O
cells	O
had	O
reduced	O
binding	O
of	O
the	O
chromobox	O
proteins	O
Cbx1	B-Protein
,	O
Cbx3	B-Protein
and	O
Cbx5	B-Protein
,	O
homologs	O
of	O
Drosophila	O
melanogaster	O
heterochromatin	B-Protein
protein	I-Protein
1	I-Protein
(	O
HP1	B-Protein
)	O
.	O
<EOS>	B-X
Telomeres	B-X
are	B-X
capping	B-X
structures	B-X
at	B-X
the	B-X
ends	B-X
of	B-X
eukaryotic	B-X
chromosomes	B-X
composed	B-X
of	B-X
TTAGGG	B-X
repeats	B-X
bound	B-X
to	B-X
an	B-X
array	B-X
of	B-X
specialized	B-X
proteins	B-X
.	B-X
Yeast	B-X
and	B-X
flies	B-X
with	B-X
defects	B-X
in	B-X
activities	B-X
that	B-X
modify	B-X
the	B-X
state	B-X
of	B-X
chromatin	B-X
also	B-X
have	B-X
abnormal	B-X
telomere	B-X
function	B-X
,	B-X
but	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
chromatin-modifying	B-X
activities	B-X
in	B-X
regulating	B-X
telomeres	B-X
in	B-X
mammals	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
telomere	B-X
length	B-X
and	B-X
function	B-X
in	B-X
mice	B-X
null	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
the	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
(	B-X
called	B-X
SUV39DN	B-X
mice	B-X
)	B-X
.	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
govern	B-X
methylation	B-X
of	B-X
histone	B-X
H3	B-X
Lys9	B-X
(	B-X
H3-Lys9	B-X
)	B-X
in	B-X
heterochromatic	B-X
regions	B-X
.	B-X
We	B-X
show	B-X
that	B-X
primary	B-X
cells	B-X
derived	B-X
from	B-X
SUV39DN	B-X
mice	B-X
have	B-X
abnormally	B-X
long	B-X
telomeres	B-X
relative	B-X
to	B-X
wild-type	B-X
controls	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
telomeres	B-X
were	B-X
enriched	B-X
in	B-X
di-	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
that	B-X
telomeres	B-X
of	B-X
SUV39DN	B-X
cells	B-X
had	B-X
less	B-X
dimethylated	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
more	B-X
monomethylated	B-X
H3-Lys9	B-X
.	B-X
Concomitant	B-X
with	B-X
the	B-X
decrease	B-X
in	B-X
H3-Lys9	B-X
methylation	B-X
,	B-X
telomeres	B-X
in	B-X
SUV39DN	B-X
cells	B-X
had	B-X
reduced	B-X
binding	B-X
of	B-X
the	B-X
chromobox	B-X
proteins	B-X
Cbx1	B-X
,	B-X
Cbx3	B-X
and	B-X
Cbx5	B-X
,	B-X
homologs	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
heterochromatin	B-X
protein	B-X
1	B-X
(	B-X
HP1	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
substantial	B-X
changes	B-X
in	B-X
the	B-X
state	B-X
of	B-X
telomeric	B-X
heterochromatin	B-X
in	B-X
SUV39DN	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
abnormal	B-X
telomere	B-X
elongation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
epigenetic	B-X
regulation	B-X
of	B-X
telomere	B-X
length	B-X
in	B-X
mammals	B-X
by	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
.	B-X

These	O
findings	O
indicate	O
substantial	O
changes	O
in	O
the	O
state	O
of	O
telomeric	O
heterochromatin	O
in	O
SUV39DN	O
cells	O
,	O
which	O
are	O
associated	O
with	O
abnormal	O
telomere	O
elongation	O
.	O
<EOS>	B-X
Yeast	B-X
and	B-X
flies	B-X
with	B-X
defects	B-X
in	B-X
activities	B-X
that	B-X
modify	B-X
the	B-X
state	B-X
of	B-X
chromatin	B-X
also	B-X
have	B-X
abnormal	B-X
telomere	B-X
function	B-X
,	B-X
but	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
chromatin-modifying	B-X
activities	B-X
in	B-X
regulating	B-X
telomeres	B-X
in	B-X
mammals	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
telomere	B-X
length	B-X
and	B-X
function	B-X
in	B-X
mice	B-X
null	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
the	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
(	B-X
called	B-X
SUV39DN	B-X
mice	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
primary	B-X
cells	B-X
derived	B-X
from	B-X
SUV39DN	B-X
mice	B-X
have	B-X
abnormally	B-X
long	B-X
telomeres	B-X
relative	B-X
to	B-X
wild-type	B-X
controls	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
telomeres	B-X
were	B-X
enriched	B-X
in	B-X
di-	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
that	B-X
telomeres	B-X
of	B-X
SUV39DN	B-X
cells	B-X
had	B-X
less	B-X
dimethylated	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
more	B-X
monomethylated	B-X
H3-Lys9	B-X
.	B-X
Concomitant	B-X
with	B-X
the	B-X
decrease	B-X
in	B-X
H3-Lys9	B-X
methylation	B-X
,	B-X
telomeres	B-X
in	B-X
SUV39DN	B-X
cells	B-X
had	B-X
reduced	B-X
binding	B-X
of	B-X
the	B-X
chromobox	B-X
proteins	B-X
Cbx1	B-X
,	B-X
Cbx3	B-X
and	B-X
Cbx5	B-X
,	B-X
homologs	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
heterochromatin	B-X
protein	B-X
1	B-X
(	B-X
HP1	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
substantial	B-X
changes	B-X
in	B-X
the	B-X
state	B-X
of	B-X
telomeric	B-X
heterochromatin	B-X
in	B-X
SUV39DN	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
abnormal	B-X
telomere	B-X
elongation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
epigenetic	B-X
regulation	B-X
of	B-X
telomere	B-X
length	B-X
in	B-X
mammals	B-X
by	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
.	B-X

Taken	O
together	O
,	O
the	O
results	O
indicate	O
epigenetic	O
regulation	O
of	O
telomere	O
length	O
in	O
mammals	O
by	O
Suv39h1	B-Protein
and	O
Suv39h2	B-Protein
.	O
<EOS>	B-X
Yeast	B-X
and	B-X
flies	B-X
with	B-X
defects	B-X
in	B-X
activities	B-X
that	B-X
modify	B-X
the	B-X
state	B-X
of	B-X
chromatin	B-X
also	B-X
have	B-X
abnormal	B-X
telomere	B-X
function	B-X
,	B-X
but	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
chromatin-modifying	B-X
activities	B-X
in	B-X
regulating	B-X
telomeres	B-X
in	B-X
mammals	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
telomere	B-X
length	B-X
and	B-X
function	B-X
in	B-X
mice	B-X
null	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
the	B-X
histone	B-X
methyltransferases	B-X
(	B-X
HMTases	B-X
)	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
(	B-X
called	B-X
SUV39DN	B-X
mice	B-X
)	B-X
.	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
govern	B-X
methylation	B-X
of	B-X
histone	B-X
H3	B-X
Lys9	B-X
(	B-X
H3-Lys9	B-X
)	B-X
in	B-X
heterochromatic	B-X
regions	B-X
.	B-X
We	B-X
show	B-X
that	B-X
primary	B-X
cells	B-X
derived	B-X
from	B-X
SUV39DN	B-X
mice	B-X
have	B-X
abnormally	B-X
long	B-X
telomeres	B-X
relative	B-X
to	B-X
wild-type	B-X
controls	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
telomeres	B-X
were	B-X
enriched	B-X
in	B-X
di-	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
that	B-X
telomeres	B-X
of	B-X
SUV39DN	B-X
cells	B-X
had	B-X
less	B-X
dimethylated	B-X
and	B-X
trimethylated	B-X
H3-Lys9	B-X
but	B-X
more	B-X
monomethylated	B-X
H3-Lys9	B-X
.	B-X
Concomitant	B-X
with	B-X
the	B-X
decrease	B-X
in	B-X
H3-Lys9	B-X
methylation	B-X
,	B-X
telomeres	B-X
in	B-X
SUV39DN	B-X
cells	B-X
had	B-X
reduced	B-X
binding	B-X
of	B-X
the	B-X
chromobox	B-X
proteins	B-X
Cbx1	B-X
,	B-X
Cbx3	B-X
and	B-X
Cbx5	B-X
,	B-X
homologs	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
heterochromatin	B-X
protein	B-X
1	B-X
(	B-X
HP1	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
substantial	B-X
changes	B-X
in	B-X
the	B-X
state	B-X
of	B-X
telomeric	B-X
heterochromatin	B-X
in	B-X
SUV39DN	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
abnormal	B-X
telomere	B-X
elongation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
epigenetic	B-X
regulation	B-X
of	B-X
telomere	B-X
length	B-X
in	B-X
mammals	B-X
by	B-X
Suv39h1	B-X
and	B-X
Suv39h2	B-X
.	B-X

Role	O
of	O
glycosylation	O
in	O
the	O
organic	O
anion	O
transporter	O
OAT1	B-Protein
.	O
<EOS>	B-X
Organic	B-X
anion	B-X
transporters	B-X
(	B-X
OAT	B-X
)	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
the	B-X
body	B-X
disposition	B-X
of	B-X
clinically	B-X
important	B-X
anionic	B-X
drugs	B-X
,	B-X
including	B-X
antiviral	B-X
drugs	B-X
,	B-X
antitumor	B-X
drugs	B-X
,	B-X
antibiotics	B-X
,	B-X
antihypertensives	B-X
,	B-X
and	B-X
anti-inflammatories	B-X
.	B-X
274	B-X
,	B-X
1519-1524	B-X
)	B-X
that	B-X
tunicamycin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
asparagine-linked	B-X
glycosylation	B-X
,	B-X
significantly	B-X
inhibited	B-X
organic	B-X
anion	B-X
transport	B-X
in	B-X
COS-7	B-X
cells	B-X
expressing	B-X
a	B-X
mouse	B-X
organic	B-X
anion	B-X
transporter	B-X
(	B-X
mOAT1	B-X
)	B-X
,	B-X
suggesting	B-X
an	B-X
important	B-X
role	B-X
of	B-X
glycosylation	B-X
in	B-X
mOAT1	B-X
function	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
disrupting	B-X
putative	B-X
glycosylation	B-X
sites	B-X
in	B-X
mOAT1	B-X
as	B-X
well	B-X
as	B-X
its	B-X
human	B-X
counterpart	B-X
,	B-X
hOAT1	B-X
,	B-X
by	B-X
mutating	B-X
asparagine	B-X
to	B-X
glutamine	B-X
and	B-X
assessing	B-X
mutant	B-X
transporters	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
the	B-X
putative	B-X
glycosylation	B-X
site	B-X
Asp-39	B-X
in	B-X
mOAT1	B-X
was	B-X
not	B-X
glycosylated	B-X
but	B-X
the	B-X
corresponding	B-X
site	B-X
(	B-X
Asp-39	B-X
)	B-X
in	B-X
hOAT1	B-X
was	B-X
glycosylated	B-X
.	B-X
Disrupting	B-X
Asp-39	B-X
resulted	B-X
in	B-X
a	B-X
complete	B-X
loss	B-X
of	B-X
transport	B-X
activity	B-X
in	B-X
both	B-X
mOAT1	B-X
and	B-X
hOAT1	B-X
without	B-X
affecting	B-X
their	B-X
cell	B-X
surface	B-X
expression	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
function	B-X
is	B-X
not	B-X
because	B-X
of	B-X
deglycosylation	B-X
of	B-X
Asp-39	B-X
per	B-X
se	B-X
but	B-X
rather	B-X
is	B-X
likely	B-X
because	B-X
of	B-X
the	B-X
change	B-X
of	B-X
this	B-X
important	B-X
amino	B-X
acid	B-X
critically	B-X
involved	B-X
in	B-X
the	B-X
substrate	B-X
binding	B-X
.	B-X
Single	B-X
replacement	B-X
of	B-X
asparagines	B-X
at	B-X
other	B-X
sites	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
transport	B-X
activity	B-X
indicating	B-X
that	B-X
glycosylation	B-X
at	B-X
individual	B-X
sites	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
OAT	B-X
function	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
simultaneous	B-X
replacement	B-X
of	B-X
all	B-X
asparagines	B-X
in	B-X
both	B-X
mOAT1	B-X
and	B-X
hOAT1	B-X
impaired	B-X
the	B-X
trafficking	B-X
of	B-X
the	B-X
transporters	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
provided	B-X
the	B-X
evidence	B-X
that	B-X
1	B-X
)	B-X
Asp-39	B-X
is	B-X
crucially	B-X
involved	B-X
in	B-X
substrate	B-X
recognition	B-X
of	B-X
OAT1	B-X
,	B-X
2	B-X
)	B-X
glycosylation	B-X
at	B-X
individual	B-X
sites	B-X
is	B-X
not	B-X
required	B-X
for	B-X
OAT1	B-X
function	B-X
,	B-X
and	B-X
3	B-X
)	B-X
glycosylation	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
targeting	B-X
of	B-X
OAT1	B-X
onto	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
molecular	B-X
identification	B-X
and	B-X
characterization	B-X
of	B-X
glycosylation	B-X
of	B-X
OAT1	B-X
and	B-X
may	B-X
provide	B-X
important	B-X
insights	B-X
into	B-X
the	B-X
structure-function	B-X
relationships	B-X
of	B-X
the	B-X
organic	B-X
anion	B-X
transporter	B-X
family	B-X
.	B-X

Organic	O
anion	O
transporters	O
(	O
OAT	O
)	O
play	O
essential	O
roles	O
in	O
the	O
body	O
disposition	O
of	O
clinically	O
important	O
anionic	O
drugs	O
,	O
including	O
antiviral	O
drugs	O
,	O
antitumor	O
drugs	O
,	O
antibiotics	O
,	O
antihypertensives	O
,	O
and	O
anti	O
-	O
inflammatories	O
.	O
<EOS>	B-X
Organic	B-X
anion	B-X
transporters	B-X
(	B-X
OAT	B-X
)	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
the	B-X
body	B-X
disposition	B-X
of	B-X
clinically	B-X
important	B-X
anionic	B-X
drugs	B-X
,	B-X
including	B-X
anti-viral	B-X
drugs	B-X
,	B-X
anti-tumor	B-X
drugs	B-X
,	B-X
antibiotics	B-X
,	B-X
anti-hypertensives	B-X
,	B-X
and	B-X
anti-inflammatories	B-X
.	B-X
The	B-X
activities	B-X
of	B-X
OATs	B-X
are	B-X
directly	B-X
linked	B-X
to	B-X
drug	B-X
toxicity	B-X
and	B-X
drug-drug	B-X
interactions	B-X
.	B-X
So	B-X
far	B-X
,	B-X
four	B-X
members	B-X
of	B-X
the	B-X
OAT	B-X
family	B-X
have	B-X
been	B-X
identified	B-X
:	B-X
OAT1	B-X
,	B-X
OAT2	B-X
,	B-X
OAT3	B-X
,	B-X
and	B-X
OAT4	B-X
.	B-X
These	B-X
transporters	B-X
share	B-X
several	B-X
common	B-X
structural	B-X
features	B-X
including	B-X
12	B-X
transmembrane	B-X
domains	B-X
,	B-X
multiple	B-X
glycosylation	B-X
sites	B-X
localized	B-X
in	B-X
the	B-X
first	B-X
extracellular	B-X
loop	B-X
between	B-X
transmembrane	B-X
domains	B-X
1	B-X
and	B-X
2	B-X
,	B-X
and	B-X
multiple	B-X
phosphorylation	B-X
sites	B-X
present	B-X
in	B-X
the	B-X
intracellular	B-X
loop	B-X
between	B-X
transmembrane	B-X
domains	B-X
6	B-X
and	B-X
7	B-X
,	B-X
and	B-X
in	B-X
the	B-X
carboxyl	B-X
terminus	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
these	B-X
structural	B-X
features	B-X
on	B-X
the	B-X
function	B-X
of	B-X
these	B-X
transporters	B-X
has	B-X
just	B-X
begun	B-X
to	B-X
be	B-X
explored	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
the	B-X
author	B-X
will	B-X
summarize	B-X
recent	B-X
progress	B-X
made	B-X
from	B-X
her	B-X
laboratory	B-X
as	B-X
well	B-X
as	B-X
from	B-X
others	B-X
,	B-X
on	B-X
the	B-X
molecular	B-X
characterization	B-X
of	B-X
the	B-X
structure-function	B-X
relationships	B-X
of	B-X
OATs	B-X
,	B-X
including	B-X
particular	B-X
amino	B-X
acid	B-X
residues/regions	B-X
of	B-X
the	B-X
transporter	B-X
protein	B-X
(	B-X
``	B-X
molecular	B-X
domains	B-X
''	B-X
)	B-X
that	B-X
potentially	B-X
determine	B-X
transport	B-X
characteristics	B-X
.	B-X

We	O
reported	O
previously	O
(	O
Kuze	O
,	O
K	O
.	O
,	O
Graves	O
,	O
P	O
.	O
,	O
Leahy	O
,	O
A	O
.	O
,	O
Wilson	O
,	O
P	O
.	O
,	O
Stuhlmann	O
,	O
H	O
.	O
,	O
and	O
You	O
,	O
G	O
.	O
(	O
1999	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
274	O
,	O
1519	O
-	O
1524	O
)	O
that	O
tunicamycin	O
,	O
an	O
inhibitor	O
of	O
asparagine	O
-	O
linked	O
glycosylation	O
,	O
significantly	O
inhibited	O
organic	O
anion	O
transport	O
in	O
COS	O
-	O
7	O
cells	O
expressing	O
a	O
mouse	O
organic	O
anion	O
transporter	O
(	O
mOAT1	B-Protein
)	O
,	O
suggesting	O
an	O
important	O
role	O
of	O
glycosylation	O
in	O
mOAT1	B-Protein
function	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
disrupting	O
putative	O
glycosylation	O
sites	O
in	O
mOAT1	B-Protein
as	O
well	O
as	O
its	O
human	O
counterpart	O
,	O
hOAT1	B-Protein
,	O
by	O
mutating	O
asparagine	O
to	O
glutamine	O
and	O
assessing	O
mutant	O
transporters	O
in	O
HeLa	O
cells	O
.	O
<EOS>	B-X
Organic	B-X
anion	B-X
transporters	B-X
(	B-X
OAT	B-X
)	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
the	B-X
body	B-X
disposition	B-X
of	B-X
clinically	B-X
important	B-X
anionic	B-X
drugs	B-X
,	B-X
including	B-X
antiviral	B-X
drugs	B-X
,	B-X
antitumor	B-X
drugs	B-X
,	B-X
antibiotics	B-X
,	B-X
antihypertensives	B-X
,	B-X
and	B-X
anti-inflammatories	B-X
.	B-X
274	B-X
,	B-X
1519-1524	B-X
)	B-X
that	B-X
tunicamycin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
asparagine-linked	B-X
glycosylation	B-X
,	B-X
significantly	B-X
inhibited	B-X
organic	B-X
anion	B-X
transport	B-X
in	B-X
COS-7	B-X
cells	B-X
expressing	B-X
a	B-X
mouse	B-X
organic	B-X
anion	B-X
transporter	B-X
(	B-X
mOAT1	B-X
)	B-X
,	B-X
suggesting	B-X
an	B-X
important	B-X
role	B-X
of	B-X
glycosylation	B-X
in	B-X
mOAT1	B-X
function	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
disrupting	B-X
putative	B-X
glycosylation	B-X
sites	B-X
in	B-X
mOAT1	B-X
as	B-X
well	B-X
as	B-X
its	B-X
human	B-X
counterpart	B-X
,	B-X
hOAT1	B-X
,	B-X
by	B-X
mutating	B-X
asparagine	B-X
to	B-X
glutamine	B-X
and	B-X
assessing	B-X
mutant	B-X
transporters	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
the	B-X
putative	B-X
glycosylation	B-X
site	B-X
Asp-39	B-X
in	B-X
mOAT1	B-X
was	B-X
not	B-X
glycosylated	B-X
but	B-X
the	B-X
corresponding	B-X
site	B-X
(	B-X
Asp-39	B-X
)	B-X
in	B-X
hOAT1	B-X
was	B-X
glycosylated	B-X
.	B-X
Disrupting	B-X
Asp-39	B-X
resulted	B-X
in	B-X
a	B-X
complete	B-X
loss	B-X
of	B-X
transport	B-X
activity	B-X
in	B-X
both	B-X
mOAT1	B-X
and	B-X
hOAT1	B-X
without	B-X
affecting	B-X
their	B-X
cell	B-X
surface	B-X
expression	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
function	B-X
is	B-X
not	B-X
because	B-X
of	B-X
deglycosylation	B-X
of	B-X
Asp-39	B-X
per	B-X
se	B-X
but	B-X
rather	B-X
is	B-X
likely	B-X
because	B-X
of	B-X
the	B-X
change	B-X
of	B-X
this	B-X
important	B-X
amino	B-X
acid	B-X
critically	B-X
involved	B-X
in	B-X
the	B-X
substrate	B-X
binding	B-X
.	B-X
Single	B-X
replacement	B-X
of	B-X
asparagines	B-X
at	B-X
other	B-X
sites	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
transport	B-X
activity	B-X
indicating	B-X
that	B-X
glycosylation	B-X
at	B-X
individual	B-X
sites	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
OAT	B-X
function	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
simultaneous	B-X
replacement	B-X
of	B-X
all	B-X
asparagines	B-X
in	B-X
both	B-X
mOAT1	B-X
and	B-X
hOAT1	B-X
impaired	B-X
the	B-X
trafficking	B-X
of	B-X
the	B-X
transporters	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
provided	B-X
the	B-X
evidence	B-X
that	B-X
1	B-X
)	B-X
Asp-39	B-X
is	B-X
crucially	B-X
involved	B-X
in	B-X
substrate	B-X
recognition	B-X
of	B-X
OAT1	B-X
,	B-X
2	B-X
)	B-X
glycosylation	B-X
at	B-X
individual	B-X
sites	B-X
is	B-X
not	B-X
required	B-X
for	B-X
OAT1	B-X
function	B-X
,	B-X
and	B-X
3	B-X
)	B-X
glycosylation	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
targeting	B-X
of	B-X
OAT1	B-X
onto	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
molecular	B-X
identification	B-X
and	B-X
characterization	B-X
of	B-X
glycosylation	B-X
of	B-X
OAT1	B-X
and	B-X
may	B-X
provide	B-X
important	B-X
insights	B-X
into	B-X
the	B-X
structure-function	B-X
relationships	B-X
of	B-X
the	B-X
organic	B-X
anion	B-X
transporter	B-X
family	B-X
.	B-X

We	O
showed	O
that	O
the	O
putative	O
glycosylation	O
site	O
Asp	O
-	O
39	O
in	O
mOAT1	B-Protein
was	O
not	O
glycosylated	O
but	O
the	O
corresponding	O
site	O
(	O
Asp	O
-	O
39	O
)	O
in	O
hOAT1	B-Protein
was	O
glycosylated	O
.	O

Disrupting	O
Asp	O
-	O
39	O
resulted	O
in	O
a	O
complete	O
loss	O
of	O
transport	O
activity	O
in	O
both	O
mOAT1	B-Protein
and	O
hOAT1	B-Protein
without	O
affecting	O
their	O
cell	O
surface	O
expression	O
,	O
suggesting	O
that	O
the	O
loss	O
of	O
function	O
is	O
not	O
because	O
of	O
deglycosylation	O
of	O
Asp	O
-	O
39	O
per	O
se	O
but	O
rather	O
is	O
likely	O
because	O
of	O
the	O
change	O
of	O
this	O
important	O
amino	O
acid	O
critically	O
involved	O
in	O
the	O
substrate	O
binding	O
.	O

Single	O
replacement	O
of	O
asparagines	O
at	O
other	O
sites	O
had	O
no	O
effect	O
on	O
transport	O
activity	O
indicating	O
that	O
glycosylation	O
at	O
individual	O
sites	O
is	O
not	O
essential	O
for	O
OAT	O
function	O
.	O

In	O
contrast	O
,	O
a	O
simultaneous	O
replacement	O
of	O
all	O
asparagines	O
in	O
both	O
mOAT1	B-Protein
and	O
hOAT1	B-Protein
impaired	O
the	O
trafficking	O
of	O
the	O
transporters	O
to	O
the	O
plasma	O
membrane	O
.	O

In	O
summary	O
,	O
we	O
provided	O
the	O
evidence	O
that	O
1	O
)	O
Asp	O
-	O
39	O
is	O
crucially	O
involved	O
in	O
substrate	O
recognition	O
of	O
OAT1	B-Protein
,	O
2	O
)	O
glycosylation	O
at	O
individual	O
sites	O
is	O
not	O
required	O
for	O
OAT1	B-Protein
function	O
,	O
and	O
3	O
)	O
glycosylation	O
plays	O
an	O
important	O
role	O
in	O
the	O
targeting	O
of	O
OAT1	B-Protein
onto	O
the	O
plasma	O
membrane	O
.	O

This	O
study	O
is	O
the	O
first	O
molecular	O
identification	O
and	O
characterization	O
of	O
glycosylation	O
of	O
OAT1	B-Protein
and	O
may	O
provide	O
important	O
insights	O
into	O
the	O
structure	O
-	O
function	O
relationships	O
of	O
the	O
organic	O
anion	O
transporter	O
family	O
.	O

Cytochrome	O
P450	O
isoenzymes	O
involved	O
in	O
rat	O
liver	O
microsomal	O
metabolism	O
of	O
californine	O
and	O
protopine	O
.	O
<EOS>	B-X
Studies	B-X
are	B-X
described	B-X
on	B-X
the	B-X
cytochrome	B-X
P450	B-X
(	B-X
CYP	B-X
)	B-X
isoenzyme	B-X
dependence	B-X
of	B-X
the	B-X
main	B-X
metabolic	B-X
steps	B-X
of	B-X
the	B-X
Eschscholtzia	B-X
californica	B-X
alkaloids	B-X
californine	B-X
and	B-X
protopine	B-X
using	B-X
rat	B-X
liver	B-X
microsomes	B-X
.	B-X
Preparations	B-X
of	B-X
E.	B-X
californica	B-X
are	B-X
in	B-X
use	B-X
as	B-X
phytopharmaceuticals	B-X
and	B-X
as	B-X
herbal	B-X
drugs	B-X
of	B-X
abuse	B-X
.	B-X
CYP2D1	B-X
and	B-X
CYP2C11	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
mainly	B-X
involved	B-X
in	B-X
demethylenation	B-X
of	B-X
both	B-X
,	B-X
californine	B-X
and	B-X
protopine	B-X
,	B-X
while	B-X
CYP1A2	B-X
and	B-X
CYP3A2	B-X
showed	B-X
only	B-X
minor	B-X
contribution	B-X
.	B-X
K	B-X
(	B-X
m	B-X
)	B-X
and	B-X
V	B-X
(	B-X
max	B-X
)	B-X
values	B-X
for	B-X
the	B-X
californine	B-X
N-demethylation	B-X
were	B-X
4.5+/-4.7	B-X
microM	B-X
and	B-X
22.9+/-13.7	B-X
min/mg	B-X
protein	B-X
(	B-X
high	B-X
affinity	B-X
)	B-X
and	B-X
161.3+/-16.7	B-X
microM	B-X
and	B-X
311.8+/-39.4	B-X
min/mg	B-X
protein	B-X
(	B-X
low	B-X
affinity	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Californine	B-X
demethylenation	B-X
and	B-X
protopine	B-X
demethylenation	B-X
showed	B-X
substrate	B-X
inhibition	B-X
and	B-X
K	B-X
(	B-X
m	B-X
)	B-X
and	B-X
V	B-X
(	B-X
max	B-X
)	B-X
values	B-X
were	B-X
5.0+/-0.5	B-X
and	B-X
7.1+/-0.6	B-X
microM	B-X
and	B-X
83.3+/-2.6	B-X
and	B-X
160.7+/-4.0	B-X
min/mg	B-X
protein	B-X
,	B-X
respectively	B-X
.	B-X

Studies	O
are	O
described	O
on	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
isoenzyme	O
dependence	O
of	O
the	O
main	O
metabolic	O
steps	O
of	O
the	O
Eschscholtzia	O
californica	O
alkaloids	O
californine	O
and	O
protopine	O
using	O
rat	O
liver	O
microsomes	O
.	O
<EOS>	B-X
Studies	B-X
are	B-X
described	B-X
on	B-X
the	B-X
cytochrome	B-X
P450	B-X
(	B-X
CYP	B-X
)	B-X
isoenzyme	B-X
dependence	B-X
of	B-X
the	B-X
main	B-X
metabolic	B-X
steps	B-X
of	B-X
the	B-X
Eschscholtzia	B-X
californica	B-X
alkaloids	B-X
californine	B-X
and	B-X
protopine	B-X
using	B-X
rat	B-X
liver	B-X
microsomes	B-X
.	B-X
Preparations	B-X
of	B-X
E.	B-X
californica	B-X
are	B-X
in	B-X
use	B-X
as	B-X
phytopharmaceuticals	B-X
and	B-X
as	B-X
herbal	B-X
drugs	B-X
of	B-X
abuse	B-X
.	B-X
CYP	B-X
isoenzyme	B-X
dependences	B-X
were	B-X
studied	B-X
using	B-X
specific	B-X
chemical	B-X
inhibitors	B-X
for	B-X
CYP1A2	B-X
,	B-X
CYP2D1	B-X
,	B-X
and	B-X
CYP3A2	B-X
(	B-X
alpha-naphthoflavone	B-X
,	B-X
quinine	B-X
,	B-X
and	B-X
ketoconazole	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
CYP2C11	B-X
was	B-X
inhibited	B-X
by	B-X
specific	B-X
antibodies	B-X
for	B-X
lack	B-X
of	B-X
specific	B-X
chemical	B-X
inhibitors	B-X
.	B-X
Californine	B-X
N-demethylation	B-X
was	B-X
mainly	B-X
catalyzed	B-X
by	B-X
CYP3A2	B-X
and	B-X
to	B-X
a	B-X
minor	B-X
extent	B-X
by	B-X
CYP1A2	B-X
and	B-X
CYP2D1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
CYP2C11	B-X
.	B-X
CYP2D1	B-X
and	B-X
CYP2C11	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
mainly	B-X
involved	B-X
in	B-X
demethylenation	B-X
of	B-X
both	B-X
,	B-X
californine	B-X
and	B-X
protopine	B-X
,	B-X
while	B-X
CYP1A2	B-X
and	B-X
CYP3A2	B-X
showed	B-X
only	B-X
minor	B-X
contribution	B-X
.	B-X
K	B-X
(	B-X
m	B-X
)	B-X
and	B-X
V	B-X
(	B-X
max	B-X
)	B-X
values	B-X
for	B-X
the	B-X
californine	B-X
N-demethylation	B-X
were	B-X
4.5+/-4.7	B-X
microM	B-X
and	B-X
22.9+/-13.7	B-X
min/mg	B-X
protein	B-X
(	B-X
high	B-X
affinity	B-X
)	B-X
and	B-X
161.3+/-16.7	B-X
microM	B-X
and	B-X
311.8+/-39.4	B-X
min/mg	B-X
protein	B-X
(	B-X
low	B-X
affinity	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Californine	B-X
demethylenation	B-X
and	B-X
protopine	B-X
demethylenation	B-X
showed	B-X
substrate	B-X
inhibition	B-X
and	B-X
K	B-X
(	B-X
m	B-X
)	B-X
and	B-X
V	B-X
(	B-X
max	B-X
)	B-X
values	B-X
were	B-X
5.0+/-0.5	B-X
and	B-X
7.1+/-0.6	B-X
microM	B-X
and	B-X
83.3+/-2.6	B-X
and	B-X
160.7+/-4.0	B-X
min/mg	B-X
protein	B-X
,	B-X
respectively	B-X
.	B-X

Preparations	O
of	O
E	O
.	O
californica	O
are	O
in	O
use	O
as	O
phytopharmaceuticals	O
and	O
as	O
herbal	O
drugs	O
of	O
abuse	O
.	O
<EOS>	B-X
Studies	B-X
are	B-X
described	B-X
on	B-X
the	B-X
cytochrome	B-X
P450	B-X
(	B-X
CYP	B-X
)	B-X
isoenzyme	B-X
dependence	B-X
of	B-X
the	B-X
main	B-X
metabolic	B-X
steps	B-X
of	B-X
the	B-X
Eschscholtzia	B-X
californica	B-X
alkaloids	B-X
californine	B-X
and	B-X
protopine	B-X
using	B-X
rat	B-X
liver	B-X
microsomes	B-X
.	B-X
Preparations	B-X
of	B-X
E.	B-X
californica	B-X
are	B-X
in	B-X
use	B-X
as	B-X
phytopharmaceuticals	B-X
and	B-X
as	B-X
herbal	B-X
drugs	B-X
of	B-X
abuse	B-X
.	B-X

CYP	O
isoenzyme	O
dependences	O
were	O
studied	O
using	O
specific	O
chemical	O
inhibitors	O
for	O
CYP1A2	B-Protein
,	O
CYP2D1	B-Protein
,	O
and	O
CYP3A2	B-Protein
(	O
alpha	O
-	O
naphthoflavone	O
,	O
quinine	O
,	O
and	O
ketoconazole	O
,	O
respectively	O
)	O
.	O
<EOS>	B-X
Studies	B-X
are	B-X
described	B-X
on	B-X
the	B-X
cytochrome	B-X
P450	B-X
(	B-X
CYP	B-X
)	B-X
isoenzyme	B-X
dependence	B-X
of	B-X
the	B-X
main	B-X
metabolic	B-X
steps	B-X
of	B-X
the	B-X
Eschscholtzia	B-X
californica	B-X
alkaloids	B-X
californine	B-X
and	B-X
protopine	B-X
using	B-X
rat	B-X
liver	B-X
microsomes	B-X
.	B-X
CYP	B-X
isoenzyme	B-X
dependences	B-X
were	B-X
studied	B-X
using	B-X
specific	B-X
chemical	B-X
inhibitors	B-X
for	B-X
CYP1A2	B-X
,	B-X
CYP2D1	B-X
,	B-X
and	B-X
CYP3A2	B-X
(	B-X
alpha-naphthoflavone	B-X
,	B-X
quinine	B-X
,	B-X
and	B-X
ketoconazole	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
CYP2C11	B-X
was	B-X
inhibited	B-X
by	B-X
specific	B-X
antibodies	B-X
for	B-X
lack	B-X
of	B-X
specific	B-X
chemical	B-X
inhibitors	B-X
.	B-X
Californine	B-X
N-demethylation	B-X
was	B-X
mainly	B-X
catalyzed	B-X
by	B-X
CYP3A2	B-X
and	B-X
to	B-X
a	B-X
minor	B-X
extent	B-X
by	B-X
CYP1A2	B-X
and	B-X
CYP2D1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
CYP2C11	B-X
.	B-X
CYP2D1	B-X
and	B-X
CYP2C11	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
mainly	B-X
involved	B-X
in	B-X
demethylenation	B-X
of	B-X
both	B-X
,	B-X
californine	B-X
and	B-X
protopine	B-X
,	B-X
while	B-X
CYP1A2	B-X
and	B-X
CYP3A2	B-X
showed	B-X
only	B-X
minor	B-X
contribution	B-X
.	B-X
K	B-X
(	B-X
m	B-X
)	B-X
and	B-X
V	B-X
(	B-X
max	B-X
)	B-X
values	B-X
for	B-X
the	B-X
californine	B-X
N-demethylation	B-X
were	B-X
4.5+/-4.7	B-X
microM	B-X
and	B-X
22.9+/-13.7	B-X
min/mg	B-X
protein	B-X
(	B-X
high	B-X
affinity	B-X
)	B-X
and	B-X
161.3+/-16.7	B-X
microM	B-X
and	B-X
311.8+/-39.4	B-X
min/mg	B-X
protein	B-X
(	B-X
low	B-X
affinity	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Californine	B-X
demethylenation	B-X
and	B-X
protopine	B-X
demethylenation	B-X
showed	B-X
substrate	B-X
inhibition	B-X
and	B-X
K	B-X
(	B-X
m	B-X
)	B-X
and	B-X
V	B-X
(	B-X
max	B-X
)	B-X
values	B-X
were	B-X
5.0+/-0.5	B-X
and	B-X
7.1+/-0.6	B-X
microM	B-X
and	B-X
83.3+/-2.6	B-X
and	B-X
160.7+/-4.0	B-X
min/mg	B-X
protein	B-X
,	B-X
respectively	B-X
.	B-X

CYP2C11	B-Protein
was	O
inhibited	O
by	O
specific	O
antibodies	O
for	O
lack	O
of	O
specific	O
chemical	O
inhibitors	O
.	O
<EOS>	B-X
CYP	B-X
isoenzyme	B-X
dependences	B-X
were	B-X
studied	B-X
using	B-X
specific	B-X
chemical	B-X
inhibitors	B-X
for	B-X
CYP1A2	B-X
,	B-X
CYP2D1	B-X
,	B-X
and	B-X
CYP3A2	B-X
(	B-X
alpha-naphthoflavone	B-X
,	B-X
quinine	B-X
,	B-X
and	B-X
ketoconazole	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
CYP2C11	B-X
was	B-X
inhibited	B-X
by	B-X
specific	B-X
antibodies	B-X
for	B-X
lack	B-X
of	B-X
specific	B-X
chemical	B-X
inhibitors	B-X
.	B-X
Californine	B-X
N-demethylation	B-X
was	B-X
mainly	B-X
catalyzed	B-X
by	B-X
CYP3A2	B-X
and	B-X
to	B-X
a	B-X
minor	B-X
extent	B-X
by	B-X
CYP1A2	B-X
and	B-X
CYP2D1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
CYP2C11	B-X
.	B-X
CYP2D1	B-X
and	B-X
CYP2C11	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
mainly	B-X
involved	B-X
in	B-X
demethylenation	B-X
of	B-X
both	B-X
,	B-X
californine	B-X
and	B-X
protopine	B-X
,	B-X
while	B-X
CYP1A2	B-X
and	B-X
CYP3A2	B-X
showed	B-X
only	B-X
minor	B-X
contribution	B-X
.	B-X

Californine	O
N	O
-	O
demethylation	O
was	O
mainly	O
catalyzed	O
by	O
CYP3A2	B-Protein
and	O
to	O
a	O
minor	O
extent	O
by	O
CYP1A2	B-Protein
and	O
CYP2D1	B-Protein
,	O
but	O
not	O
by	O
CYP2C11	B-Protein
.	O

CYP2D1	B-Protein
and	O
CYP2C11	B-Protein
were	O
shown	O
to	O
be	O
mainly	O
involved	O
in	O
demethylenation	O
of	O
both	O
,	O
californine	O
and	O
protopine	O
,	O
while	O
CYP1A2	B-Protein
and	O
CYP3A2	B-Protein
showed	O
only	O
minor	O
contribution	O
.	O
<EOS>	B-X
Studies	B-X
are	B-X
described	B-X
on	B-X
the	B-X
cytochrome	B-X
P450	B-X
(	B-X
CYP	B-X
)	B-X
isoenzyme	B-X
dependence	B-X
of	B-X
the	B-X
main	B-X
metabolic	B-X
steps	B-X
of	B-X
the	B-X
Eschscholtzia	B-X
californica	B-X
alkaloids	B-X
californine	B-X
and	B-X
protopine	B-X
using	B-X
rat	B-X
liver	B-X
microsomes	B-X
.	B-X
CYP	B-X
isoenzyme	B-X
dependences	B-X
were	B-X
studied	B-X
using	B-X
specific	B-X
chemical	B-X
inhibitors	B-X
for	B-X
CYP1A2	B-X
,	B-X
CYP2D1	B-X
,	B-X
and	B-X
CYP3A2	B-X
(	B-X
alpha-naphthoflavone	B-X
,	B-X
quinine	B-X
,	B-X
and	B-X
ketoconazole	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
CYP2C11	B-X
was	B-X
inhibited	B-X
by	B-X
specific	B-X
antibodies	B-X
for	B-X
lack	B-X
of	B-X
specific	B-X
chemical	B-X
inhibitors	B-X
.	B-X
Californine	B-X
N-demethylation	B-X
was	B-X
mainly	B-X
catalyzed	B-X
by	B-X
CYP3A2	B-X
and	B-X
to	B-X
a	B-X
minor	B-X
extent	B-X
by	B-X
CYP1A2	B-X
and	B-X
CYP2D1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
CYP2C11	B-X
.	B-X
CYP2D1	B-X
and	B-X
CYP2C11	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
mainly	B-X
involved	B-X
in	B-X
demethylenation	B-X
of	B-X
both	B-X
,	B-X
californine	B-X
and	B-X
protopine	B-X
,	B-X
while	B-X
CYP1A2	B-X
and	B-X
CYP3A2	B-X
showed	B-X
only	B-X
minor	B-X
contribution	B-X
.	B-X
K	B-X
(	B-X
m	B-X
)	B-X
and	B-X
V	B-X
(	B-X
max	B-X
)	B-X
values	B-X
for	B-X
the	B-X
californine	B-X
N-demethylation	B-X
were	B-X
4.5+/-4.7	B-X
microM	B-X
and	B-X
22.9+/-13.7	B-X
min/mg	B-X
protein	B-X
(	B-X
high	B-X
affinity	B-X
)	B-X
and	B-X
161.3+/-16.7	B-X
microM	B-X
and	B-X
311.8+/-39.4	B-X
min/mg	B-X
protein	B-X
(	B-X
low	B-X
affinity	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Californine	B-X
demethylenation	B-X
and	B-X
protopine	B-X
demethylenation	B-X
showed	B-X
substrate	B-X
inhibition	B-X
and	B-X
K	B-X
(	B-X
m	B-X
)	B-X
and	B-X
V	B-X
(	B-X
max	B-X
)	B-X
values	B-X
were	B-X
5.0+/-0.5	B-X
and	B-X
7.1+/-0.6	B-X
microM	B-X
and	B-X
83.3+/-2.6	B-X
and	B-X
160.7+/-4.0	B-X
min/mg	B-X
protein	B-X
,	B-X
respectively	B-X
.	B-X

Kinetic	O
parameters	O
of	O
the	O
reactions	O
were	O
established	O
.	O
<EOS>	B-X
The	B-X
Octet	B-X
biosensors	B-X
provide	B-X
a	B-X
high-throughput	B-X
alternative	B-X
to	B-X
the	B-X
well-established	B-X
surface	B-X
plasmon	B-X
resonance	B-X
(	B-X
SPR	B-X
)	B-X
and	B-X
SPR	B-X
imaging	B-X
(	B-X
SPRi	B-X
)	B-X
biosensors	B-X
to	B-X
characterize	B-X
antibody-antigen	B-X
interactions	B-X
.	B-X
The	B-X
titration	B-X
kinetic	B-X
and	B-X
single	B-X
cycle	B-X
kinetic	B-X
assays	B-X
performed	B-X
on	B-X
Octet	B-X
HTX	B-X
generated	B-X
reproducible	B-X
binding	B-X
kinetic	B-X
parameters	B-X
and	B-X
correlated	B-X
with	B-X
the	B-X
values	B-X
measured	B-X
on	B-X
Biacore	B-X
4000	B-X
and	B-X
MASS-1	B-X
.	B-X
Kinetic	B-X
assays	B-X
performed	B-X
on	B-X
0.1	B-X
nm	B-X
density	B-X
mAb	B-X
surfaces	B-X
significantly	B-X
reduced	B-X
MTL	B-X
and	B-X
enabled	B-X
characterization	B-X
of	B-X
picomolar	B-X
affinity	B-X
mAbs	B-X
.	B-X
The	B-X
review	B-X
highlights	B-X
the	B-X
results	B-X
of	B-X
studies	B-X
showing	B-X
how	B-X
combining	B-X
kinetic	B-X
isotope	B-X
effects	B-X
with	B-X
initial	B-X
rate	B-X
parameters	B-X
permits	B-X
the	B-X
evaluation	B-X
of	B-X
:	B-X
(	B-X
a	B-X
)	B-X
the	B-X
order	B-X
of	B-X
substrate	B-X
binding	B-X
to	B-X
multisubstrate	B-X
enzymes	B-X
;	B-X
(	B-X
b	B-X
)	B-X
the	B-X
magnitude	B-X
of	B-X
individual	B-X
rate	B-X
constants	B-X
in	B-X
complex	B-X
,	B-X
multistep	B-X
reactions	B-X
;	B-X
(	B-X
c	B-X
)	B-X
the	B-X
identification	B-X
of	B-X
chemical	B-X
intermediates	B-X
;	B-X
and	B-X
(	B-X
d	B-X
)	B-X
the	B-X
role	B-X
of	B-X
nonclassical	B-X
(	B-X
tunnelling	B-X
)	B-X
behaviour	B-X
in	B-X
C-H	B-X
activation	B-X
.	B-X

K	O
(	O
m	O
)	O
and	O
V	O
(	O
max	O
)	O
values	O
for	O
the	O
californine	O
N	O
-	O
demethylation	O
were	O
4	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
7	O
microM	O
and	O
22	O
.	O
9	O
+	O
/	O
-	O
13	O
.	O
7	O
min	O
/	O
mg	O
protein	O
(	O
high	O
affinity	O
)	O
and	O
161	O
.	O
3	O
+	O
/	O
-	O
16	O
.	O
7	O
microM	O
and	O
311	O
.	O
8	O
+	O
/	O
-	O
39	O
.	O
4	O
min	O
/	O
mg	O
protein	O
(	O
low	O
affinity	O
)	O
,	O
respectively	O
.	O

Californine	O
demethylenation	O
and	O
protopine	O
demethylenation	O
showed	O
substrate	O
inhibition	O
and	O
K	O
(	O
m	O
)	O
and	O
V	O
(	O
max	O
)	O
values	O
were	O
5	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
5	O
and	O
7	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
6	O
microM	O
and	O
83	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
6	O
and	O
160	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
0	O
min	O
/	O
mg	O
protein	O
,	O
respectively	O
.	O

Expression	O
and	O
methylation	O
status	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
gene	O
can	O
characterize	O
the	O
different	O
histological	O
features	O
of	O
ovarian	O
cancer	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
by	B-X
methylation	B-X
can	B-X
characterize	B-X
histological	B-X
types	B-X
of	B-X
primary	B-X
human	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
54	B-X
ovarian	B-X
cancer	B-X
tissue	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
expression	B-X
and	B-X
methylation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
using	B-X
methylation	B-X
specific	B-X
PCR	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
was	B-X
methylated	B-X
and	B-X
inactivated	B-X
in	B-X
ES-2	B-X
ovarian	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
clear	B-X
cell	B-X
adenocarcinoma	B-X
.	B-X
Treatment	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
with	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
restored	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
.	B-X
In	B-X
human	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
was	B-X
inactivated	B-X
in	B-X
most	B-X
of	B-X
the	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
tissues	B-X
.	B-X
Interestingly	B-X
,	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
expression	B-X
was	B-X
positive	B-X
in	B-X
significantly	B-X
higher	B-X
percentages	B-X
of	B-X
serous	B-X
(	B-X
89.5	B-X
%	B-X
)	B-X
,	B-X
endometrioid	B-X
(	B-X
90	B-X
%	B-X
)	B-X
,	B-X
and	B-X
mucinous	B-X
(	B-X
81.8	B-X
%	B-X
)	B-X
ovarian	B-X
adenocarcinoma	B-X
tissues	B-X
.	B-X
The	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
samples	B-X
with	B-X
inactivated	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
were	B-X
highly	B-X
methylated	B-X
,	B-X
suggesting	B-X
that	B-X
inactivation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
is	B-X
through	B-X
DNA	B-X
methylation	B-X
.	B-X
Using	B-X
direct	B-X
DNA	B-X
sequencing	B-X
,	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
methylation	B-X
on	B-X
all	B-X
the	B-X
17	B-X
CpG	B-X
sites	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
as	B-X
compared	B-X
to	B-X
other	B-X
histological	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
serous	B-X
,	B-X
endometrioid	B-X
,	B-X
and	B-X
mucinous	B-X
)	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
suggesting	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
methylation	B-X
status	B-X
can	B-X
characterize	B-X
histological	B-X
features	B-X
of	B-X
different	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

We	O
hypothesize	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
gene	O
expression	O
and	O
its	O
regulation	O
by	O
methylation	O
can	O
characterize	O
histological	O
types	O
of	O
primary	O
human	O
epithelial	O
ovarian	O
cancer	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
by	B-X
methylation	B-X
can	B-X
characterize	B-X
histological	B-X
types	B-X
of	B-X
primary	B-X
human	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
54	B-X
ovarian	B-X
cancer	B-X
tissue	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
expression	B-X
and	B-X
methylation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
using	B-X
methylation	B-X
specific	B-X
PCR	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
was	B-X
methylated	B-X
and	B-X
inactivated	B-X
in	B-X
ES-2	B-X
ovarian	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
clear	B-X
cell	B-X
adenocarcinoma	B-X
.	B-X
Treatment	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
with	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
restored	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
.	B-X
In	B-X
human	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
was	B-X
inactivated	B-X
in	B-X
most	B-X
of	B-X
the	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
tissues	B-X
.	B-X
Interestingly	B-X
,	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
expression	B-X
was	B-X
positive	B-X
in	B-X
significantly	B-X
higher	B-X
percentages	B-X
of	B-X
serous	B-X
(	B-X
89.5	B-X
%	B-X
)	B-X
,	B-X
endometrioid	B-X
(	B-X
90	B-X
%	B-X
)	B-X
,	B-X
and	B-X
mucinous	B-X
(	B-X
81.8	B-X
%	B-X
)	B-X
ovarian	B-X
adenocarcinoma	B-X
tissues	B-X
.	B-X
The	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
samples	B-X
with	B-X
inactivated	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
were	B-X
highly	B-X
methylated	B-X
,	B-X
suggesting	B-X
that	B-X
inactivation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
is	B-X
through	B-X
DNA	B-X
methylation	B-X
.	B-X
Using	B-X
direct	B-X
DNA	B-X
sequencing	B-X
,	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
methylation	B-X
on	B-X
all	B-X
the	B-X
17	B-X
CpG	B-X
sites	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
as	B-X
compared	B-X
to	B-X
other	B-X
histological	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
serous	B-X
,	B-X
endometrioid	B-X
,	B-X
and	B-X
mucinous	B-X
)	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
suggesting	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
methylation	B-X
status	B-X
can	B-X
characterize	B-X
histological	B-X
features	B-X
of	B-X
different	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

To	O
test	O
this	O
hypothesis	O
,	O
ovarian	O
cancer	O
cell	O
lines	O
and	O
54	O
ovarian	O
cancer	O
tissue	O
samples	O
were	O
analyzed	O
for	O
expression	O
and	O
methylation	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
gene	O
using	O
methylation	O
specific	O
PCR	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
by	B-X
methylation	B-X
can	B-X
characterize	B-X
histological	B-X
types	B-X
of	B-X
primary	B-X
human	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
54	B-X
ovarian	B-X
cancer	B-X
tissue	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
expression	B-X
and	B-X
methylation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
using	B-X
methylation	B-X
specific	B-X
PCR	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
was	B-X
methylated	B-X
and	B-X
inactivated	B-X
in	B-X
ES-2	B-X
ovarian	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
clear	B-X
cell	B-X
adenocarcinoma	B-X
.	B-X
Treatment	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
with	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
restored	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
.	B-X
In	B-X
human	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
was	B-X
inactivated	B-X
in	B-X
most	B-X
of	B-X
the	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
tissues	B-X
.	B-X
Interestingly	B-X
,	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
expression	B-X
was	B-X
positive	B-X
in	B-X
significantly	B-X
higher	B-X
percentages	B-X
of	B-X
serous	B-X
(	B-X
89.5	B-X
%	B-X
)	B-X
,	B-X
endometrioid	B-X
(	B-X
90	B-X
%	B-X
)	B-X
,	B-X
and	B-X
mucinous	B-X
(	B-X
81.8	B-X
%	B-X
)	B-X
ovarian	B-X
adenocarcinoma	B-X
tissues	B-X
.	B-X
The	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
samples	B-X
with	B-X
inactivated	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
were	B-X
highly	B-X
methylated	B-X
,	B-X
suggesting	B-X
that	B-X
inactivation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
is	B-X
through	B-X
DNA	B-X
methylation	B-X
.	B-X
Using	B-X
direct	B-X
DNA	B-X
sequencing	B-X
,	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
methylation	B-X
on	B-X
all	B-X
the	B-X
17	B-X
CpG	B-X
sites	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
as	B-X
compared	B-X
to	B-X
other	B-X
histological	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
serous	B-X
,	B-X
endometrioid	B-X
,	B-X
and	B-X
mucinous	B-X
)	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
suggesting	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
methylation	B-X
status	B-X
can	B-X
characterize	B-X
histological	B-X
features	B-X
of	B-X
different	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

The	O
results	O
of	O
our	O
experiments	O
demonstrate	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
gene	O
was	O
methylated	O
and	O
inactivated	O
in	O
ES	O
-	O
2	O
ovarian	O
cell	O
line	O
,	O
which	O
was	O
derived	O
from	O
clear	O
cell	O
adenocarcinoma	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
by	B-X
methylation	B-X
can	B-X
characterize	B-X
histological	B-X
types	B-X
of	B-X
primary	B-X
human	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
54	B-X
ovarian	B-X
cancer	B-X
tissue	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
expression	B-X
and	B-X
methylation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
using	B-X
methylation	B-X
specific	B-X
PCR	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
was	B-X
methylated	B-X
and	B-X
inactivated	B-X
in	B-X
ES-2	B-X
ovarian	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
clear	B-X
cell	B-X
adenocarcinoma	B-X
.	B-X
Treatment	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
with	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
restored	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
.	B-X
In	B-X
human	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
was	B-X
inactivated	B-X
in	B-X
most	B-X
of	B-X
the	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
tissues	B-X
.	B-X
Interestingly	B-X
,	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
expression	B-X
was	B-X
positive	B-X
in	B-X
significantly	B-X
higher	B-X
percentages	B-X
of	B-X
serous	B-X
(	B-X
89.5	B-X
%	B-X
)	B-X
,	B-X
endometrioid	B-X
(	B-X
90	B-X
%	B-X
)	B-X
,	B-X
and	B-X
mucinous	B-X
(	B-X
81.8	B-X
%	B-X
)	B-X
ovarian	B-X
adenocarcinoma	B-X
tissues	B-X
.	B-X
The	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
samples	B-X
with	B-X
inactivated	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
were	B-X
highly	B-X
methylated	B-X
,	B-X
suggesting	B-X
that	B-X
inactivation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
is	B-X
through	B-X
DNA	B-X
methylation	B-X
.	B-X
Using	B-X
direct	B-X
DNA	B-X
sequencing	B-X
,	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
methylation	B-X
on	B-X
all	B-X
the	B-X
17	B-X
CpG	B-X
sites	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
as	B-X
compared	B-X
to	B-X
other	B-X
histological	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
serous	B-X
,	B-X
endometrioid	B-X
,	B-X
and	B-X
mucinous	B-X
)	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
suggesting	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
methylation	B-X
status	B-X
can	B-X
characterize	B-X
histological	B-X
features	B-X
of	B-X
different	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

Treatment	O
of	O
this	O
cell	O
line	O
with	O
demethylating	O
agent	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
restored	O
the	O
expression	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
gene	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
by	B-X
methylation	B-X
can	B-X
characterize	B-X
histological	B-X
types	B-X
of	B-X
primary	B-X
human	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
54	B-X
ovarian	B-X
cancer	B-X
tissue	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
expression	B-X
and	B-X
methylation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
using	B-X
methylation	B-X
specific	B-X
PCR	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
was	B-X
methylated	B-X
and	B-X
inactivated	B-X
in	B-X
ES-2	B-X
ovarian	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
clear	B-X
cell	B-X
adenocarcinoma	B-X
.	B-X
Treatment	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
with	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
restored	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
.	B-X
In	B-X
human	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
was	B-X
inactivated	B-X
in	B-X
most	B-X
of	B-X
the	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
tissues	B-X
.	B-X
Interestingly	B-X
,	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
expression	B-X
was	B-X
positive	B-X
in	B-X
significantly	B-X
higher	B-X
percentages	B-X
of	B-X
serous	B-X
(	B-X
89.5	B-X
%	B-X
)	B-X
,	B-X
endometrioid	B-X
(	B-X
90	B-X
%	B-X
)	B-X
,	B-X
and	B-X
mucinous	B-X
(	B-X
81.8	B-X
%	B-X
)	B-X
ovarian	B-X
adenocarcinoma	B-X
tissues	B-X
.	B-X
The	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
samples	B-X
with	B-X
inactivated	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
were	B-X
highly	B-X
methylated	B-X
,	B-X
suggesting	B-X
that	B-X
inactivation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
is	B-X
through	B-X
DNA	B-X
methylation	B-X
.	B-X
Using	B-X
direct	B-X
DNA	B-X
sequencing	B-X
,	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
methylation	B-X
on	B-X
all	B-X
the	B-X
17	B-X
CpG	B-X
sites	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
as	B-X
compared	B-X
to	B-X
other	B-X
histological	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
serous	B-X
,	B-X
endometrioid	B-X
,	B-X
and	B-X
mucinous	B-X
)	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
suggesting	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
methylation	B-X
status	B-X
can	B-X
characterize	B-X
histological	B-X
features	B-X
of	B-X
different	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

In	O
human	O
ovarian	O
cancer	O
tissues	O
,	O
the	O
expression	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
protein	O
was	O
inactivated	O
in	O
most	O
of	O
the	O
ovarian	O
clear	O
cell	O
carcinoma	O
tissues	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
by	B-X
methylation	B-X
can	B-X
characterize	B-X
histological	B-X
types	B-X
of	B-X
primary	B-X
human	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
54	B-X
ovarian	B-X
cancer	B-X
tissue	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
expression	B-X
and	B-X
methylation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
using	B-X
methylation	B-X
specific	B-X
PCR	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
was	B-X
methylated	B-X
and	B-X
inactivated	B-X
in	B-X
ES-2	B-X
ovarian	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
clear	B-X
cell	B-X
adenocarcinoma	B-X
.	B-X
Treatment	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
with	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
restored	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
.	B-X
In	B-X
human	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
was	B-X
inactivated	B-X
in	B-X
most	B-X
of	B-X
the	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
tissues	B-X
.	B-X
Interestingly	B-X
,	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
expression	B-X
was	B-X
positive	B-X
in	B-X
significantly	B-X
higher	B-X
percentages	B-X
of	B-X
serous	B-X
(	B-X
89.5	B-X
%	B-X
)	B-X
,	B-X
endometrioid	B-X
(	B-X
90	B-X
%	B-X
)	B-X
,	B-X
and	B-X
mucinous	B-X
(	B-X
81.8	B-X
%	B-X
)	B-X
ovarian	B-X
adenocarcinoma	B-X
tissues	B-X
.	B-X
The	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
samples	B-X
with	B-X
inactivated	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
were	B-X
highly	B-X
methylated	B-X
,	B-X
suggesting	B-X
that	B-X
inactivation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
is	B-X
through	B-X
DNA	B-X
methylation	B-X
.	B-X
Using	B-X
direct	B-X
DNA	B-X
sequencing	B-X
,	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
methylation	B-X
on	B-X
all	B-X
the	B-X
17	B-X
CpG	B-X
sites	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
as	B-X
compared	B-X
to	B-X
other	B-X
histological	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
serous	B-X
,	B-X
endometrioid	B-X
,	B-X
and	B-X
mucinous	B-X
)	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
suggesting	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
methylation	B-X
status	B-X
can	B-X
characterize	B-X
histological	B-X
features	B-X
of	B-X
different	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

Interestingly	O
,	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
protein	O
expression	O
was	O
positive	O
in	O
significantly	O
higher	O
percentages	O
of	O
serous	O
(	O
89	O
.	O
5	O
%	O
)	O
,	O
endometrioid	O
(	O
90	O
%	O
)	O
,	O
and	O
mucinous	O
(	O
81	O
.	O
8	O
%	O
)	O
ovarian	O
adenocarcinoma	O
tissues	O
.	O

The	O
ovarian	O
clear	O
cell	O
carcinoma	O
samples	O
with	O
inactivated	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
protein	O
were	O
highly	O
methylated	O
,	O
suggesting	O
that	O
inactivation	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
gene	O
is	O
through	O
DNA	O
methylation	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
by	B-X
methylation	B-X
can	B-X
characterize	B-X
histological	B-X
types	B-X
of	B-X
primary	B-X
human	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
54	B-X
ovarian	B-X
cancer	B-X
tissue	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
expression	B-X
and	B-X
methylation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
using	B-X
methylation	B-X
specific	B-X
PCR	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
was	B-X
methylated	B-X
and	B-X
inactivated	B-X
in	B-X
ES-2	B-X
ovarian	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
clear	B-X
cell	B-X
adenocarcinoma	B-X
.	B-X
Treatment	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
with	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
restored	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
.	B-X
In	B-X
human	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
was	B-X
inactivated	B-X
in	B-X
most	B-X
of	B-X
the	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
tissues	B-X
.	B-X
Interestingly	B-X
,	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
expression	B-X
was	B-X
positive	B-X
in	B-X
significantly	B-X
higher	B-X
percentages	B-X
of	B-X
serous	B-X
(	B-X
89.5	B-X
%	B-X
)	B-X
,	B-X
endometrioid	B-X
(	B-X
90	B-X
%	B-X
)	B-X
,	B-X
and	B-X
mucinous	B-X
(	B-X
81.8	B-X
%	B-X
)	B-X
ovarian	B-X
adenocarcinoma	B-X
tissues	B-X
.	B-X
The	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
samples	B-X
with	B-X
inactivated	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
were	B-X
highly	B-X
methylated	B-X
,	B-X
suggesting	B-X
that	B-X
inactivation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
is	B-X
through	B-X
DNA	B-X
methylation	B-X
.	B-X
Using	B-X
direct	B-X
DNA	B-X
sequencing	B-X
,	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
methylation	B-X
on	B-X
all	B-X
the	B-X
17	B-X
CpG	B-X
sites	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
as	B-X
compared	B-X
to	B-X
other	B-X
histological	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
serous	B-X
,	B-X
endometrioid	B-X
,	B-X
and	B-X
mucinous	B-X
)	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
suggesting	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
methylation	B-X
status	B-X
can	B-X
characterize	B-X
histological	B-X
features	B-X
of	B-X
different	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

Using	O
direct	O
DNA	O
sequencing	O
,	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
gene	O
methylation	O
on	O
all	O
the	O
17	O
CpG	O
sites	O
was	O
significantly	O
higher	O
in	O
ovarian	O
clear	O
cell	O
carcinoma	O
as	O
compared	O
to	O
other	O
histological	O
types	O
of	O
ovarian	O
cancer	O
(	O
serous	O
,	O
endometrioid	O
,	O
and	O
mucinous	O
)	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
by	B-X
methylation	B-X
can	B-X
characterize	B-X
histological	B-X
types	B-X
of	B-X
primary	B-X
human	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
54	B-X
ovarian	B-X
cancer	B-X
tissue	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
expression	B-X
and	B-X
methylation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
using	B-X
methylation	B-X
specific	B-X
PCR	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
was	B-X
methylated	B-X
and	B-X
inactivated	B-X
in	B-X
ES-2	B-X
ovarian	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
clear	B-X
cell	B-X
adenocarcinoma	B-X
.	B-X
Treatment	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
with	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
restored	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
.	B-X
In	B-X
human	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
was	B-X
inactivated	B-X
in	B-X
most	B-X
of	B-X
the	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
tissues	B-X
.	B-X
Interestingly	B-X
,	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
expression	B-X
was	B-X
positive	B-X
in	B-X
significantly	B-X
higher	B-X
percentages	B-X
of	B-X
serous	B-X
(	B-X
89.5	B-X
%	B-X
)	B-X
,	B-X
endometrioid	B-X
(	B-X
90	B-X
%	B-X
)	B-X
,	B-X
and	B-X
mucinous	B-X
(	B-X
81.8	B-X
%	B-X
)	B-X
ovarian	B-X
adenocarcinoma	B-X
tissues	B-X
.	B-X
The	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
samples	B-X
with	B-X
inactivated	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
were	B-X
highly	B-X
methylated	B-X
,	B-X
suggesting	B-X
that	B-X
inactivation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
is	B-X
through	B-X
DNA	B-X
methylation	B-X
.	B-X
Using	B-X
direct	B-X
DNA	B-X
sequencing	B-X
,	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
methylation	B-X
on	B-X
all	B-X
the	B-X
17	B-X
CpG	B-X
sites	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
as	B-X
compared	B-X
to	B-X
other	B-X
histological	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
serous	B-X
,	B-X
endometrioid	B-X
,	B-X
and	B-X
mucinous	B-X
)	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
suggesting	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
methylation	B-X
status	B-X
can	B-X
characterize	B-X
histological	B-X
features	B-X
of	B-X
different	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

This	O
is	O
the	O
first	O
report	O
suggesting	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	I-Protein
gene	O
expression	O
and	O
methylation	O
status	O
can	O
characterize	O
histological	O
features	O
of	O
different	O
types	O
of	O
ovarian	O
cancer	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
by	B-X
methylation	B-X
can	B-X
characterize	B-X
histological	B-X
types	B-X
of	B-X
primary	B-X
human	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
54	B-X
ovarian	B-X
cancer	B-X
tissue	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
expression	B-X
and	B-X
methylation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
using	B-X
methylation	B-X
specific	B-X
PCR	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
was	B-X
methylated	B-X
and	B-X
inactivated	B-X
in	B-X
ES-2	B-X
ovarian	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
clear	B-X
cell	B-X
adenocarcinoma	B-X
.	B-X
Treatment	B-X
of	B-X
this	B-X
cell	B-X
line	B-X
with	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
restored	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
.	B-X
In	B-X
human	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
was	B-X
inactivated	B-X
in	B-X
most	B-X
of	B-X
the	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
tissues	B-X
.	B-X
Interestingly	B-X
,	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
expression	B-X
was	B-X
positive	B-X
in	B-X
significantly	B-X
higher	B-X
percentages	B-X
of	B-X
serous	B-X
(	B-X
89.5	B-X
%	B-X
)	B-X
,	B-X
endometrioid	B-X
(	B-X
90	B-X
%	B-X
)	B-X
,	B-X
and	B-X
mucinous	B-X
(	B-X
81.8	B-X
%	B-X
)	B-X
ovarian	B-X
adenocarcinoma	B-X
tissues	B-X
.	B-X
The	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
samples	B-X
with	B-X
inactivated	B-X
14-3-3	B-X
sigma	B-X
protein	B-X
were	B-X
highly	B-X
methylated	B-X
,	B-X
suggesting	B-X
that	B-X
inactivation	B-X
of	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
is	B-X
through	B-X
DNA	B-X
methylation	B-X
.	B-X
Using	B-X
direct	B-X
DNA	B-X
sequencing	B-X
,	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
methylation	B-X
on	B-X
all	B-X
the	B-X
17	B-X
CpG	B-X
sites	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
ovarian	B-X
clear	B-X
cell	B-X
carcinoma	B-X
as	B-X
compared	B-X
to	B-X
other	B-X
histological	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
serous	B-X
,	B-X
endometrioid	B-X
,	B-X
and	B-X
mucinous	B-X
)	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
suggesting	B-X
that	B-X
14-3-3	B-X
sigma	B-X
gene	B-X
expression	B-X
and	B-X
methylation	B-X
status	B-X
can	B-X
characterize	B-X
histological	B-X
features	B-X
of	B-X
different	B-X
types	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

Thrombophilic	O
dysfibrinogen	O
Tokyo	O
V	O
with	O
the	O
amino	O
acid	O
substitution	O
of	O
gammaAla327Thr	O
:	O
formation	O
of	O
fragile	O
but	O
fibrinolysis	O
-	O
resistant	O
fibrin	O
clots	O
and	O
its	O
relevance	O
to	O
arterial	O
thromboembolism	O
.	O
<EOS>	B-X
Thrombophilic	B-X
dysfibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
identified	B-X
in	B-X
a	B-X
43-year-old	B-X
man	B-X
with	B-X
recurrent	B-X
thromboembolism	B-X
.	B-X
Based	B-X
on	B-X
analyses	B-X
of	B-X
the	B-X
patient	B-X
fibrinogen	B-X
genes	B-X
,	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
aberrant	B-X
fibrinogen	B-X
peptide	B-X
,	B-X
and	B-X
deglycosylation	B-X
experiments	B-X
,	B-X
fibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
an	B-X
amino	B-X
acid	B-X
substitution	B-X
of	B-X
gamma	B-X
Ala327Thr	B-X
and	B-X
possibly	B-X
extra	B-X
glycosylation	B-X
at	B-X
gamma	B-X
Asn325	B-X
because	B-X
the	B-X
mutation	B-X
confers	B-X
the	B-X
N-linked	B-X
glycosylation	B-X
consensus	B-X
sequence	B-X
Asn-X-Thr	B-X
.	B-X
The	B-X
mutation	B-X
resulted	B-X
in	B-X
impaired	B-X
function	B-X
and	B-X
hypofibrinogenemia	B-X
(	B-X
hypodysfibrinogen	B-X
)	B-X
.	B-X
Polymerization	B-X
of	B-X
fibrin	B-X
monomers	B-X
derived	B-X
from	B-X
patient	B-X
fibrinogen	B-X
was	B-X
severely	B-X
impaired	B-X
with	B-X
a	B-X
partial	B-X
correction	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
,	B-X
resulting	B-X
in	B-X
very	B-X
low	B-X
clottability	B-X
.	B-X
Additionally	B-X
,	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
cross-linked	B-X
fibrin	B-X
was	B-X
formed	B-X
upon	B-X
thrombin	B-X
treatment	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
factor	B-X
XIII	B-X
and	B-X
calcium	B-X
.	B-X
However	B-X
,	B-X
Tokyo	B-X
V-derived	B-X
fibrin	B-X
was	B-X
resistant	B-X
to	B-X
degradation	B-X
by	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
-catalyzed	B-X
plasmin	B-X
digestion	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
appeared	B-X
severely	B-X
perturbed	B-X
,	B-X
since	B-X
there	B-X
are	B-X
large	B-X
pores	B-X
inside	B-X
the	B-X
tangled	B-X
fibrin	B-X
networks	B-X
and	B-X
fiber	B-X
ends	B-X
at	B-X
the	B-X
boundaries	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
clots	B-X
are	B-X
fragile	B-X
,	B-X
so	B-X
that	B-X
fibrinolysis-resistant	B-X
insoluble	B-X
fibrin	B-X
and	B-X
soluble	B-X
fibrin	B-X
polymers	B-X
may	B-X
be	B-X
released	B-X
to	B-X
the	B-X
circulation	B-X
,	B-X
partly	B-X
accounting	B-X
for	B-X
the	B-X
recurrent	B-X
embolic	B-X
episodes	B-X
in	B-X
the	B-X
patient	B-X
.	B-X

Thrombophilic	O
dysfibrinogen	O
Tokyo	O
V	O
was	O
identified	O
in	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
with	O
recurrent	O
thromboembolism	O
.	O

Based	O
on	O
analyses	O
of	O
the	O
patient	O
fibrinogen	O
genes	O
,	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
aberrant	O
fibrinogen	O
peptide	O
,	O
and	O
deglycosylation	O
experiments	O
,	O
fibrinogen	O
Tokyo	O
V	O
was	O
shown	O
to	O
have	O
an	O
amino	O
acid	O
substitution	O
of	O
gamma	O
Ala327Thr	O
and	O
possibly	O
extra	O
glycosylation	O
at	O
gamma	O
Asn325	O
because	O
the	O
mutation	O
confers	O
the	O
N	O
-	O
linked	O
glycosylation	O
consensus	O
sequence	O
Asn	O
-	O
X	O
-	O
Thr	O
.	O

The	O
mutation	O
resulted	O
in	O
impaired	O
function	O
and	O
hypofibrinogenemia	O
(	O
hypodysfibrinogen	O
)	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
analyses	B-X
of	B-X
the	B-X
patient	B-X
fibrinogen	B-X
genes	B-X
,	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
aberrant	B-X
fibrinogen	B-X
peptide	B-X
,	B-X
and	B-X
deglycosylation	B-X
experiments	B-X
,	B-X
fibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
an	B-X
amino	B-X
acid	B-X
substitution	B-X
of	B-X
gamma	B-X
Ala327Thr	B-X
and	B-X
possibly	B-X
extra	B-X
glycosylation	B-X
at	B-X
gamma	B-X
Asn325	B-X
because	B-X
the	B-X
mutation	B-X
confers	B-X
the	B-X
N-linked	B-X
glycosylation	B-X
consensus	B-X
sequence	B-X
Asn-X-Thr	B-X
.	B-X
The	B-X
mutation	B-X
resulted	B-X
in	B-X
impaired	B-X
function	B-X
and	B-X
hypofibrinogenemia	B-X
(	B-X
hypodysfibrinogen	B-X
)	B-X
.	B-X
Polymerization	B-X
of	B-X
fibrin	B-X
monomers	B-X
derived	B-X
from	B-X
patient	B-X
fibrinogen	B-X
was	B-X
severely	B-X
impaired	B-X
with	B-X
a	B-X
partial	B-X
correction	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
,	B-X
resulting	B-X
in	B-X
very	B-X
low	B-X
clottability	B-X
.	B-X

Polymerization	O
of	O
fibrin	O
monomers	O
derived	O
from	O
patient	O
fibrinogen	O
was	O
severely	O
impaired	O
with	O
a	O
partial	O
correction	O
in	O
the	O
presence	O
of	O
calcium	O
,	O
resulting	O
in	O
very	O
low	O
clottability	O
.	O
<EOS>	B-X
Emerging	B-X
lines	B-X
of	B-X
evidence	B-X
have	B-X
suggested	B-X
that	B-X
certain	B-X
dysfibrinogens	B-X
present	B-X
a	B-X
significant	B-X
risk	B-X
of	B-X
thrombosis	B-X
.	B-X
Thrombophilic	B-X
dysfibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
identified	B-X
in	B-X
a	B-X
43-year-old	B-X
man	B-X
with	B-X
recurrent	B-X
thromboembolism	B-X
.	B-X
Based	B-X
on	B-X
analyses	B-X
of	B-X
the	B-X
patient	B-X
fibrinogen	B-X
genes	B-X
,	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
aberrant	B-X
fibrinogen	B-X
peptide	B-X
,	B-X
and	B-X
deglycosylation	B-X
experiments	B-X
,	B-X
fibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
an	B-X
amino	B-X
acid	B-X
substitution	B-X
of	B-X
gamma	B-X
Ala327Thr	B-X
and	B-X
possibly	B-X
extra	B-X
glycosylation	B-X
at	B-X
gamma	B-X
Asn325	B-X
because	B-X
the	B-X
mutation	B-X
confers	B-X
the	B-X
N-linked	B-X
glycosylation	B-X
consensus	B-X
sequence	B-X
Asn-X-Thr	B-X
.	B-X
The	B-X
mutation	B-X
resulted	B-X
in	B-X
impaired	B-X
function	B-X
and	B-X
hypofibrinogenemia	B-X
(	B-X
hypodysfibrinogen	B-X
)	B-X
.	B-X
Polymerization	B-X
of	B-X
fibrin	B-X
monomers	B-X
derived	B-X
from	B-X
patient	B-X
fibrinogen	B-X
was	B-X
severely	B-X
impaired	B-X
with	B-X
a	B-X
partial	B-X
correction	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
,	B-X
resulting	B-X
in	B-X
very	B-X
low	B-X
clottability	B-X
.	B-X
Additionally	B-X
,	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
cross-linked	B-X
fibrin	B-X
was	B-X
formed	B-X
upon	B-X
thrombin	B-X
treatment	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
factor	B-X
XIII	B-X
and	B-X
calcium	B-X
.	B-X
However	B-X
,	B-X
Tokyo	B-X
V-derived	B-X
fibrin	B-X
was	B-X
resistant	B-X
to	B-X
degradation	B-X
by	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
-catalyzed	B-X
plasmin	B-X
digestion	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
appeared	B-X
severely	B-X
perturbed	B-X
,	B-X
since	B-X
there	B-X
are	B-X
large	B-X
pores	B-X
inside	B-X
the	B-X
tangled	B-X
fibrin	B-X
networks	B-X
and	B-X
fiber	B-X
ends	B-X
at	B-X
the	B-X
boundaries	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
clots	B-X
are	B-X
fragile	B-X
,	B-X
so	B-X
that	B-X
fibrinolysis-resistant	B-X
insoluble	B-X
fibrin	B-X
and	B-X
soluble	B-X
fibrin	B-X
polymers	B-X
may	B-X
be	B-X
released	B-X
to	B-X
the	B-X
circulation	B-X
,	B-X
partly	B-X
accounting	B-X
for	B-X
the	B-X
recurrent	B-X
embolic	B-X
episodes	B-X
in	B-X
the	B-X
patient	B-X
.	B-X

Additionally	O
,	O
a	O
large	O
amount	O
of	O
soluble	O
cross	O
-	O
linked	O
fibrin	O
was	O
formed	O
upon	O
thrombin	O
treatment	O
in	O
the	O
presence	O
of	O
factor	O
XIII	O
and	O
calcium	O
.	O
<EOS>	B-X
Emerging	B-X
lines	B-X
of	B-X
evidence	B-X
have	B-X
suggested	B-X
that	B-X
certain	B-X
dysfibrinogens	B-X
present	B-X
a	B-X
significant	B-X
risk	B-X
of	B-X
thrombosis	B-X
.	B-X
Thrombophilic	B-X
dysfibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
identified	B-X
in	B-X
a	B-X
43-year-old	B-X
man	B-X
with	B-X
recurrent	B-X
thromboembolism	B-X
.	B-X
Based	B-X
on	B-X
analyses	B-X
of	B-X
the	B-X
patient	B-X
fibrinogen	B-X
genes	B-X
,	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
aberrant	B-X
fibrinogen	B-X
peptide	B-X
,	B-X
and	B-X
deglycosylation	B-X
experiments	B-X
,	B-X
fibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
an	B-X
amino	B-X
acid	B-X
substitution	B-X
of	B-X
gamma	B-X
Ala327Thr	B-X
and	B-X
possibly	B-X
extra	B-X
glycosylation	B-X
at	B-X
gamma	B-X
Asn325	B-X
because	B-X
the	B-X
mutation	B-X
confers	B-X
the	B-X
N-linked	B-X
glycosylation	B-X
consensus	B-X
sequence	B-X
Asn-X-Thr	B-X
.	B-X
The	B-X
mutation	B-X
resulted	B-X
in	B-X
impaired	B-X
function	B-X
and	B-X
hypofibrinogenemia	B-X
(	B-X
hypodysfibrinogen	B-X
)	B-X
.	B-X
Polymerization	B-X
of	B-X
fibrin	B-X
monomers	B-X
derived	B-X
from	B-X
patient	B-X
fibrinogen	B-X
was	B-X
severely	B-X
impaired	B-X
with	B-X
a	B-X
partial	B-X
correction	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
,	B-X
resulting	B-X
in	B-X
very	B-X
low	B-X
clottability	B-X
.	B-X
Additionally	B-X
,	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
cross-linked	B-X
fibrin	B-X
was	B-X
formed	B-X
upon	B-X
thrombin	B-X
treatment	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
factor	B-X
XIII	B-X
and	B-X
calcium	B-X
.	B-X
However	B-X
,	B-X
Tokyo	B-X
V-derived	B-X
fibrin	B-X
was	B-X
resistant	B-X
to	B-X
degradation	B-X
by	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
-catalyzed	B-X
plasmin	B-X
digestion	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
appeared	B-X
severely	B-X
perturbed	B-X
,	B-X
since	B-X
there	B-X
are	B-X
large	B-X
pores	B-X
inside	B-X
the	B-X
tangled	B-X
fibrin	B-X
networks	B-X
and	B-X
fiber	B-X
ends	B-X
at	B-X
the	B-X
boundaries	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
clots	B-X
are	B-X
fragile	B-X
,	B-X
so	B-X
that	B-X
fibrinolysis-resistant	B-X
insoluble	B-X
fibrin	B-X
and	B-X
soluble	B-X
fibrin	B-X
polymers	B-X
may	B-X
be	B-X
released	B-X
to	B-X
the	B-X
circulation	B-X
,	B-X
partly	B-X
accounting	B-X
for	B-X
the	B-X
recurrent	B-X
embolic	B-X
episodes	B-X
in	B-X
the	B-X
patient	B-X
.	B-X

However	O
,	O
Tokyo	O
V	O
-	O
derived	O
fibrin	O
was	O
resistant	O
to	O
degradation	O
by	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
(	O
tPA	B-Protein
)	O
-	O
catalyzed	O
plasmin	B-Protein
digestion	O
.	O
<EOS>	B-X
Thrombophilic	B-X
dysfibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
identified	B-X
in	B-X
a	B-X
43-year-old	B-X
man	B-X
with	B-X
recurrent	B-X
thromboembolism	B-X
.	B-X
Based	B-X
on	B-X
analyses	B-X
of	B-X
the	B-X
patient	B-X
fibrinogen	B-X
genes	B-X
,	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
aberrant	B-X
fibrinogen	B-X
peptide	B-X
,	B-X
and	B-X
deglycosylation	B-X
experiments	B-X
,	B-X
fibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
an	B-X
amino	B-X
acid	B-X
substitution	B-X
of	B-X
gamma	B-X
Ala327Thr	B-X
and	B-X
possibly	B-X
extra	B-X
glycosylation	B-X
at	B-X
gamma	B-X
Asn325	B-X
because	B-X
the	B-X
mutation	B-X
confers	B-X
the	B-X
N-linked	B-X
glycosylation	B-X
consensus	B-X
sequence	B-X
Asn-X-Thr	B-X
.	B-X
The	B-X
mutation	B-X
resulted	B-X
in	B-X
impaired	B-X
function	B-X
and	B-X
hypofibrinogenemia	B-X
(	B-X
hypodysfibrinogen	B-X
)	B-X
.	B-X
Polymerization	B-X
of	B-X
fibrin	B-X
monomers	B-X
derived	B-X
from	B-X
patient	B-X
fibrinogen	B-X
was	B-X
severely	B-X
impaired	B-X
with	B-X
a	B-X
partial	B-X
correction	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
,	B-X
resulting	B-X
in	B-X
very	B-X
low	B-X
clottability	B-X
.	B-X
Additionally	B-X
,	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
cross-linked	B-X
fibrin	B-X
was	B-X
formed	B-X
upon	B-X
thrombin	B-X
treatment	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
factor	B-X
XIII	B-X
and	B-X
calcium	B-X
.	B-X
However	B-X
,	B-X
Tokyo	B-X
V-derived	B-X
fibrin	B-X
was	B-X
resistant	B-X
to	B-X
degradation	B-X
by	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
-catalyzed	B-X
plasmin	B-X
digestion	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
appeared	B-X
severely	B-X
perturbed	B-X
,	B-X
since	B-X
there	B-X
are	B-X
large	B-X
pores	B-X
inside	B-X
the	B-X
tangled	B-X
fibrin	B-X
networks	B-X
and	B-X
fiber	B-X
ends	B-X
at	B-X
the	B-X
boundaries	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
clots	B-X
are	B-X
fragile	B-X
,	B-X
so	B-X
that	B-X
fibrinolysis-resistant	B-X
insoluble	B-X
fibrin	B-X
and	B-X
soluble	B-X
fibrin	B-X
polymers	B-X
may	B-X
be	B-X
released	B-X
to	B-X
the	B-X
circulation	B-X
,	B-X
partly	B-X
accounting	B-X
for	B-X
the	B-X
recurrent	B-X
embolic	B-X
episodes	B-X
in	B-X
the	B-X
patient	B-X
.	B-X

The	O
structure	O
of	O
Tokyo	O
V	O
fibrin	O
appeared	O
severely	O
perturbed	O
,	O
since	O
there	O
are	O
large	O
pores	O
inside	O
the	O
tangled	O
fibrin	O
networks	O
and	O
fiber	O
ends	O
at	O
the	O
boundaries	O
.	O
<EOS>	B-X
Thrombophilic	B-X
dysfibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
identified	B-X
in	B-X
a	B-X
43-year-old	B-X
man	B-X
with	B-X
recurrent	B-X
thromboembolism	B-X
.	B-X
Based	B-X
on	B-X
analyses	B-X
of	B-X
the	B-X
patient	B-X
fibrinogen	B-X
genes	B-X
,	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
aberrant	B-X
fibrinogen	B-X
peptide	B-X
,	B-X
and	B-X
deglycosylation	B-X
experiments	B-X
,	B-X
fibrinogen	B-X
Tokyo	B-X
V	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
an	B-X
amino	B-X
acid	B-X
substitution	B-X
of	B-X
gamma	B-X
Ala327Thr	B-X
and	B-X
possibly	B-X
extra	B-X
glycosylation	B-X
at	B-X
gamma	B-X
Asn325	B-X
because	B-X
the	B-X
mutation	B-X
confers	B-X
the	B-X
N-linked	B-X
glycosylation	B-X
consensus	B-X
sequence	B-X
Asn-X-Thr	B-X
.	B-X
The	B-X
mutation	B-X
resulted	B-X
in	B-X
impaired	B-X
function	B-X
and	B-X
hypofibrinogenemia	B-X
(	B-X
hypodysfibrinogen	B-X
)	B-X
.	B-X
Polymerization	B-X
of	B-X
fibrin	B-X
monomers	B-X
derived	B-X
from	B-X
patient	B-X
fibrinogen	B-X
was	B-X
severely	B-X
impaired	B-X
with	B-X
a	B-X
partial	B-X
correction	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
,	B-X
resulting	B-X
in	B-X
very	B-X
low	B-X
clottability	B-X
.	B-X
Additionally	B-X
,	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
soluble	B-X
cross-linked	B-X
fibrin	B-X
was	B-X
formed	B-X
upon	B-X
thrombin	B-X
treatment	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
factor	B-X
XIII	B-X
and	B-X
calcium	B-X
.	B-X
However	B-X
,	B-X
Tokyo	B-X
V-derived	B-X
fibrin	B-X
was	B-X
resistant	B-X
to	B-X
degradation	B-X
by	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
-catalyzed	B-X
plasmin	B-X
digestion	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
appeared	B-X
severely	B-X
perturbed	B-X
,	B-X
since	B-X
there	B-X
are	B-X
large	B-X
pores	B-X
inside	B-X
the	B-X
tangled	B-X
fibrin	B-X
networks	B-X
and	B-X
fiber	B-X
ends	B-X
at	B-X
the	B-X
boundaries	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
Tokyo	B-X
V	B-X
fibrin	B-X
clots	B-X
are	B-X
fragile	B-X
,	B-X
so	B-X
that	B-X
fibrinolysis-resistant	B-X
insoluble	B-X
fibrin	B-X
and	B-X
soluble	B-X
fibrin	B-X
polymers	B-X
may	B-X
be	B-X
released	B-X
to	B-X
the	B-X
circulation	B-X
,	B-X
partly	B-X
accounting	B-X
for	B-X
the	B-X
recurrent	B-X
embolic	B-X
episodes	B-X
in	B-X
the	B-X
patient	B-X
.	B-X

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
Tokyo	O
V	O
fibrin	O
clots	O
are	O
fragile	O
,	O
so	O
that	O
fibrinolysis	O
-	O
resistant	O
insoluble	O
fibrin	O
and	O
soluble	O
fibrin	O
polymers	O
may	O
be	O
released	O
to	O
the	O
circulation	O
,	O
partly	O
accounting	O
for	O
the	O
recurrent	O
embolic	O
episodes	O
in	O
the	O
patient	O
.	O

Tracking	O
global	O
patterns	O
of	O
N	O
-	O
linked	O
glycosylation	O
site	O
variation	O
in	O
highly	O
variable	O
viral	O
glycoproteins	O
:	O
HIV	O
,	O
SIV	O
,	O
and	O
HCV	O
envelopes	O
and	O
influenza	O
hemagglutinin	B-Protein
.	O

Human	O
and	O
simian	O
immunodeficiency	O
viruses	O
(	O
HIV	O
and	O
SIV	O
)	O
,	O
influenza	O
virus	O
,	O
and	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
have	O
heavily	O
glycosylated	O
,	O
highly	O
variable	O
surface	O
proteins	O
.	O
<EOS>	B-X
Human	B-X
and	B-X
simian	B-X
immunodeficiency	B-X
viruses	B-X
(	B-X
HIV	B-X
and	B-X
SIV	B-X
)	B-X
,	B-X
influenza	B-X
virus	B-X
,	B-X
and	B-X
hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
have	B-X
heavily	B-X
glycosylated	B-X
,	B-X
highly	B-X
variable	B-X
surface	B-X
proteins	B-X
.	B-X
Here	B-X
we	B-X
explore	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
(	B-X
sequon	B-X
)	B-X
variation	B-X
at	B-X
the	B-X
population	B-X
level	B-X
in	B-X
these	B-X
viruses	B-X
,	B-X
using	B-X
a	B-X
new	B-X
Web-based	B-X
program	B-X
developed	B-X
to	B-X
facilitate	B-X
the	B-X
sequon	B-X
tracking	B-X
and	B-X
to	B-X
define	B-X
patterns	B-X
(	B-X
www.hiv.lanl.gov	B-X
)	B-X
.	B-X
This	B-X
tool	B-X
allowed	B-X
rapid	B-X
visualization	B-X
of	B-X
the	B-X
two	B-X
distinctive	B-X
patterns	B-X
of	B-X
sequon	B-X
variation	B-X
found	B-X
in	B-X
HIV-1	B-X
,	B-X
HIV-2	B-X
,	B-X
and	B-X
SIV	B-X
CPZ	B-X
.	B-X
HIV	B-X
,	B-X
with	B-X
its	B-X
extreme	B-X
variation	B-X
in	B-X
number	B-X
and	B-X
precise	B-X
location	B-X
of	B-X
sequons	B-X
,	B-X
does	B-X
not	B-X
have	B-X
a	B-X
net	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
sites	B-X
over	B-X
time	B-X
at	B-X
the	B-X
population	B-X
level	B-X
.	B-X
Primate	B-X
lentiviral	B-X
lineages	B-X
have	B-X
host	B-X
species-dependent	B-X
levels	B-X
of	B-X
sequon	B-X
shifting	B-X
,	B-X
with	B-X
HIV-1	B-X
in	B-X
humans	B-X
the	B-X
most	B-X
extreme	B-X
.	B-X
HCV	B-X
E1	B-X
and	B-X
E2	B-X
proteins	B-X
,	B-X
despite	B-X
evolving	B-X
extremely	B-X
rapidly	B-X
through	B-X
point	B-X
mutation	B-X
,	B-X
show	B-X
limited	B-X
sequon	B-X
variation	B-X
,	B-X
although	B-X
two	B-X
shifting	B-X
sites	B-X
were	B-X
identified	B-X
.	B-X
Human	B-X
influenza	B-X
A	B-X
hemagglutinin	B-X
H3	B-X
HA1	B-X
is	B-X
accumulating	B-X
sequons	B-X
over	B-X
time	B-X
,	B-X
but	B-X
this	B-X
trend	B-X
is	B-X
not	B-X
evident	B-X
in	B-X
any	B-X
other	B-X
avian	B-X
or	B-X
human	B-X
influenza	B-X
A	B-X
serotypes	B-X
.	B-X

Here	O
we	O
explore	O
N	O
-	O
linked	O
glycosylation	O
site	O
(	O
sequon	O
)	O
variation	O
at	O
the	O
population	O
level	O
in	O
these	O
viruses	O
,	O
using	O
a	O
new	O
Web	O
-	O
based	O
program	O
developed	O
to	O
facilitate	O
the	O
sequon	O
tracking	O
and	O
to	O
define	O
patterns	O
(	O
www	O
.	O
hiv	O
.	O
lanl	O
.	O
gov	O
)	O
.	O
<EOS>	B-X
Human	B-X
and	B-X
simian	B-X
immunodeficiency	B-X
viruses	B-X
(	B-X
HIV	B-X
and	B-X
SIV	B-X
)	B-X
,	B-X
influenza	B-X
virus	B-X
,	B-X
and	B-X
hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
have	B-X
heavily	B-X
glycosylated	B-X
,	B-X
highly	B-X
variable	B-X
surface	B-X
proteins	B-X
.	B-X
Here	B-X
we	B-X
explore	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
(	B-X
sequon	B-X
)	B-X
variation	B-X
at	B-X
the	B-X
population	B-X
level	B-X
in	B-X
these	B-X
viruses	B-X
,	B-X
using	B-X
a	B-X
new	B-X
Web-based	B-X
program	B-X
developed	B-X
to	B-X
facilitate	B-X
the	B-X
sequon	B-X
tracking	B-X
and	B-X
to	B-X
define	B-X
patterns	B-X
(	B-X
www.hiv.lanl.gov	B-X
)	B-X
.	B-X
This	B-X
tool	B-X
allowed	B-X
rapid	B-X
visualization	B-X
of	B-X
the	B-X
two	B-X
distinctive	B-X
patterns	B-X
of	B-X
sequon	B-X
variation	B-X
found	B-X
in	B-X
HIV-1	B-X
,	B-X
HIV-2	B-X
,	B-X
and	B-X
SIV	B-X
CPZ	B-X
.	B-X
The	B-X
first	B-X
pattern	B-X
(	B-X
fixed	B-X
)	B-X
describes	B-X
readily	B-X
aligned	B-X
sites	B-X
that	B-X
are	B-X
either	B-X
simply	B-X
present	B-X
or	B-X
absent	B-X
.	B-X
These	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
occupied	B-X
by	B-X
high-mannose	B-X
glycans	B-X
.	B-X
The	B-X
second	B-X
pattern	B-X
(	B-X
shifting	B-X
)	B-X
refers	B-X
to	B-X
sites	B-X
embedded	B-X
in	B-X
regions	B-X
of	B-X
extreme	B-X
local	B-X
length	B-X
variation	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
shifts	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
relative	B-X
position	B-X
and	B-X
local	B-X
density	B-X
of	B-X
sequons	B-X
;	B-X
these	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
populated	B-X
by	B-X
complex	B-X
carbohydrates	B-X
.	B-X
HIV	B-X
,	B-X
with	B-X
its	B-X
extreme	B-X
variation	B-X
in	B-X
number	B-X
and	B-X
precise	B-X
location	B-X
of	B-X
sequons	B-X
,	B-X
does	B-X
not	B-X
have	B-X
a	B-X
net	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
sites	B-X
over	B-X
time	B-X
at	B-X
the	B-X
population	B-X
level	B-X
.	B-X
Primate	B-X
lentiviral	B-X
lineages	B-X
have	B-X
host	B-X
species-dependent	B-X
levels	B-X
of	B-X
sequon	B-X
shifting	B-X
,	B-X
with	B-X
HIV-1	B-X
in	B-X
humans	B-X
the	B-X
most	B-X
extreme	B-X
.	B-X
HCV	B-X
E1	B-X
and	B-X
E2	B-X
proteins	B-X
,	B-X
despite	B-X
evolving	B-X
extremely	B-X
rapidly	B-X
through	B-X
point	B-X
mutation	B-X
,	B-X
show	B-X
limited	B-X
sequon	B-X
variation	B-X
,	B-X
although	B-X
two	B-X
shifting	B-X
sites	B-X
were	B-X
identified	B-X
.	B-X
Human	B-X
influenza	B-X
A	B-X
hemagglutinin	B-X
H3	B-X
HA1	B-X
is	B-X
accumulating	B-X
sequons	B-X
over	B-X
time	B-X
,	B-X
but	B-X
this	B-X
trend	B-X
is	B-X
not	B-X
evident	B-X
in	B-X
any	B-X
other	B-X
avian	B-X
or	B-X
human	B-X
influenza	B-X
A	B-X
serotypes	B-X
.	B-X

This	O
tool	O
allowed	O
rapid	O
visualization	O
of	O
the	O
two	O
distinctive	O
patterns	O
of	O
sequon	O
variation	O
found	O
in	O
HIV	O
-	O
1	O
,	O
HIV	O
-	O
2	O
,	O
and	O
SIV	O
CPZ	O
.	O
<EOS>	B-X
Human	B-X
and	B-X
simian	B-X
immunodeficiency	B-X
viruses	B-X
(	B-X
HIV	B-X
and	B-X
SIV	B-X
)	B-X
,	B-X
influenza	B-X
virus	B-X
,	B-X
and	B-X
hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
have	B-X
heavily	B-X
glycosylated	B-X
,	B-X
highly	B-X
variable	B-X
surface	B-X
proteins	B-X
.	B-X
Here	B-X
we	B-X
explore	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
(	B-X
sequon	B-X
)	B-X
variation	B-X
at	B-X
the	B-X
population	B-X
level	B-X
in	B-X
these	B-X
viruses	B-X
,	B-X
using	B-X
a	B-X
new	B-X
Web-based	B-X
program	B-X
developed	B-X
to	B-X
facilitate	B-X
the	B-X
sequon	B-X
tracking	B-X
and	B-X
to	B-X
define	B-X
patterns	B-X
(	B-X
www.hiv.lanl.gov	B-X
)	B-X
.	B-X
This	B-X
tool	B-X
allowed	B-X
rapid	B-X
visualization	B-X
of	B-X
the	B-X
two	B-X
distinctive	B-X
patterns	B-X
of	B-X
sequon	B-X
variation	B-X
found	B-X
in	B-X
HIV-1	B-X
,	B-X
HIV-2	B-X
,	B-X
and	B-X
SIV	B-X
CPZ	B-X
.	B-X
The	B-X
second	B-X
pattern	B-X
(	B-X
shifting	B-X
)	B-X
refers	B-X
to	B-X
sites	B-X
embedded	B-X
in	B-X
regions	B-X
of	B-X
extreme	B-X
local	B-X
length	B-X
variation	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
shifts	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
relative	B-X
position	B-X
and	B-X
local	B-X
density	B-X
of	B-X
sequons	B-X
;	B-X
these	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
populated	B-X
by	B-X
complex	B-X
carbohydrates	B-X
.	B-X
HIV	B-X
,	B-X
with	B-X
its	B-X
extreme	B-X
variation	B-X
in	B-X
number	B-X
and	B-X
precise	B-X
location	B-X
of	B-X
sequons	B-X
,	B-X
does	B-X
not	B-X
have	B-X
a	B-X
net	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
sites	B-X
over	B-X
time	B-X
at	B-X
the	B-X
population	B-X
level	B-X
.	B-X
Primate	B-X
lentiviral	B-X
lineages	B-X
have	B-X
host	B-X
species-dependent	B-X
levels	B-X
of	B-X
sequon	B-X
shifting	B-X
,	B-X
with	B-X
HIV-1	B-X
in	B-X
humans	B-X
the	B-X
most	B-X
extreme	B-X
.	B-X
HCV	B-X
E1	B-X
and	B-X
E2	B-X
proteins	B-X
,	B-X
despite	B-X
evolving	B-X
extremely	B-X
rapidly	B-X
through	B-X
point	B-X
mutation	B-X
,	B-X
show	B-X
limited	B-X
sequon	B-X
variation	B-X
,	B-X
although	B-X
two	B-X
shifting	B-X
sites	B-X
were	B-X
identified	B-X
.	B-X
Human	B-X
influenza	B-X
A	B-X
hemagglutinin	B-X
H3	B-X
HA1	B-X
is	B-X
accumulating	B-X
sequons	B-X
over	B-X
time	B-X
,	B-X
but	B-X
this	B-X
trend	B-X
is	B-X
not	B-X
evident	B-X
in	B-X
any	B-X
other	B-X
avian	B-X
or	B-X
human	B-X
influenza	B-X
A	B-X
serotypes	B-X
.	B-X

The	O
first	O
pattern	O
(	O
fixed	O
)	O
describes	O
readily	O
aligned	O
sites	O
that	O
are	O
either	O
simply	O
present	O
or	O
absent	O
.	O
<EOS>	B-X
``	B-X
Care	B-X
is	B-X
increasingly	B-X
absent	B-X
from	B-X
the	B-X
pathway	B-X
of	B-X
unaccompanied	B-X
minors	B-X
''	B-X
.	B-X
An	B-X
abnormal	B-X
or	B-X
absent	B-X
superficial	B-X
abdominal	B-X
reflex	B-X
(	B-X
SAR	B-X
)	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
underlying	B-X
spinal	B-X
cord	B-X
syrinx	B-X
.	B-X
The	B-X
sensitivity	B-X
of	B-X
an	B-X
abnormal	B-X
or	B-X
absent	B-X
SAR	B-X
and	B-X
the	B-X
relationship	B-X
to	B-X
Chiari	B-X
malformation	B-X
type	B-X
I	B-X
(	B-X
CM-I	B-X
)	B-X
or	B-X
syrinx	B-X
morphology	B-X
has	B-X
not	B-X
been	B-X
studied	B-X
.	B-X
Of	B-X
271	B-X
patients	B-X
with	B-X
spinal	B-X
cord	B-X
syrinx	B-X
,	B-X
200	B-X
had	B-X
either	B-X
CM-I-associated	B-X
or	B-X
idiopathic	B-X
syrinx	B-X
,	B-X
and	B-X
128	B-X
of	B-X
these	B-X
patients	B-X
had	B-X
SAR-evaluation	B-X
documentation	B-X
.	B-X
Forty-eight	B-X
percent	B-X
(	B-X
62/128	B-X
)	B-X
had	B-X
an	B-X
abnormal	B-X
or	B-X
absent	B-X
reflex	B-X
.	B-X
Abnormal/absent	B-X
SAR	B-X
was	B-X
more	B-X
common	B-X
in	B-X
patients	B-X
with	B-X
CM-I-associated	B-X
syrinx	B-X
(	B-X
61	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
idiopathic	B-X
syrinx	B-X
(	B-X
22	B-X
%	B-X
)	B-X
(	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
Abnormal/absent	B-X
SAR	B-X
was	B-X
associated	B-X
with	B-X
wider	B-X
syringes	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
longer	B-X
syringes	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
a	B-X
more	B-X
cranial	B-X
location	B-X
of	B-X
the	B-X
syrinx	B-X
(	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
Controlling	B-X
for	B-X
CM-I	B-X
,	B-X
scoliosis	B-X
,	B-X
age	B-X
,	B-X
sex	B-X
,	B-X
cranial	B-X
extent	B-X
of	B-X
syrinx	B-X
,	B-X
and	B-X
syrinx	B-X
dimensions	B-X
,	B-X
CM-I	B-X
was	B-X
independently	B-X
associated	B-X
with	B-X
abnormal	B-X
or	B-X
absent	B-X
SAR	B-X
(	B-X
OR	B-X
4.2	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
1.4-14	B-X
,	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
An	B-X
abnormal/absent	B-X
SAR	B-X
was	B-X
present	B-X
in	B-X
most	B-X
patients	B-X
with	B-X
CM-I-associated	B-X
syrinx	B-X
but	B-X
in	B-X
a	B-X
minority	B-X
of	B-X
patients	B-X
with	B-X
idiopathic	B-X
syrinx	B-X
.	B-X
This	B-X
has	B-X
implications	B-X
for	B-X
pathophysiology	B-X
of	B-X
CM-I-associated	B-X
syrinx	B-X
and	B-X
in	B-X
guiding	B-X
clinical	B-X
care	B-X
of	B-X
patients	B-X
presenting	B-X
with	B-X
syrinx	B-X
.	B-X

These	O
sites	O
tend	O
to	O
be	O
occupied	O
by	O
high	O
-	O
mannose	O
glycans	O
.	O
<EOS>	B-X
Human	B-X
and	B-X
simian	B-X
immunodeficiency	B-X
viruses	B-X
(	B-X
HIV	B-X
and	B-X
SIV	B-X
)	B-X
,	B-X
influenza	B-X
virus	B-X
,	B-X
and	B-X
hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
have	B-X
heavily	B-X
glycosylated	B-X
,	B-X
highly	B-X
variable	B-X
surface	B-X
proteins	B-X
.	B-X
The	B-X
first	B-X
pattern	B-X
(	B-X
fixed	B-X
)	B-X
describes	B-X
readily	B-X
aligned	B-X
sites	B-X
that	B-X
are	B-X
either	B-X
simply	B-X
present	B-X
or	B-X
absent	B-X
.	B-X
These	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
occupied	B-X
by	B-X
high-mannose	B-X
glycans	B-X
.	B-X
The	B-X
second	B-X
pattern	B-X
(	B-X
shifting	B-X
)	B-X
refers	B-X
to	B-X
sites	B-X
embedded	B-X
in	B-X
regions	B-X
of	B-X
extreme	B-X
local	B-X
length	B-X
variation	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
shifts	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
relative	B-X
position	B-X
and	B-X
local	B-X
density	B-X
of	B-X
sequons	B-X
;	B-X
these	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
populated	B-X
by	B-X
complex	B-X
carbohydrates	B-X
.	B-X
HIV	B-X
,	B-X
with	B-X
its	B-X
extreme	B-X
variation	B-X
in	B-X
number	B-X
and	B-X
precise	B-X
location	B-X
of	B-X
sequons	B-X
,	B-X
does	B-X
not	B-X
have	B-X
a	B-X
net	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
sites	B-X
over	B-X
time	B-X
at	B-X
the	B-X
population	B-X
level	B-X
.	B-X
HCV	B-X
E1	B-X
and	B-X
E2	B-X
proteins	B-X
,	B-X
despite	B-X
evolving	B-X
extremely	B-X
rapidly	B-X
through	B-X
point	B-X
mutation	B-X
,	B-X
show	B-X
limited	B-X
sequon	B-X
variation	B-X
,	B-X
although	B-X
two	B-X
shifting	B-X
sites	B-X
were	B-X
identified	B-X
.	B-X

The	O
second	O
pattern	O
(	O
shifting	O
)	O
refers	O
to	O
sites	O
embedded	O
in	O
regions	O
of	O
extreme	O
local	O
length	O
variation	O
and	O
is	O
characterized	O
by	O
shifts	O
in	O
terms	O
of	O
the	O
relative	O
position	O
and	O
local	O
density	O
of	O
sequons	O
;	O
these	O
sites	O
tend	O
to	O
be	O
populated	O
by	O
complex	O
carbohydrates	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
explore	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
(	B-X
sequon	B-X
)	B-X
variation	B-X
at	B-X
the	B-X
population	B-X
level	B-X
in	B-X
these	B-X
viruses	B-X
,	B-X
using	B-X
a	B-X
new	B-X
Web-based	B-X
program	B-X
developed	B-X
to	B-X
facilitate	B-X
the	B-X
sequon	B-X
tracking	B-X
and	B-X
to	B-X
define	B-X
patterns	B-X
(	B-X
www.hiv.lanl.gov	B-X
)	B-X
.	B-X
This	B-X
tool	B-X
allowed	B-X
rapid	B-X
visualization	B-X
of	B-X
the	B-X
two	B-X
distinctive	B-X
patterns	B-X
of	B-X
sequon	B-X
variation	B-X
found	B-X
in	B-X
HIV-1	B-X
,	B-X
HIV-2	B-X
,	B-X
and	B-X
SIV	B-X
CPZ	B-X
.	B-X
The	B-X
first	B-X
pattern	B-X
(	B-X
fixed	B-X
)	B-X
describes	B-X
readily	B-X
aligned	B-X
sites	B-X
that	B-X
are	B-X
either	B-X
simply	B-X
present	B-X
or	B-X
absent	B-X
.	B-X
These	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
occupied	B-X
by	B-X
high-mannose	B-X
glycans	B-X
.	B-X
The	B-X
second	B-X
pattern	B-X
(	B-X
shifting	B-X
)	B-X
refers	B-X
to	B-X
sites	B-X
embedded	B-X
in	B-X
regions	B-X
of	B-X
extreme	B-X
local	B-X
length	B-X
variation	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
shifts	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
relative	B-X
position	B-X
and	B-X
local	B-X
density	B-X
of	B-X
sequons	B-X
;	B-X
these	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
populated	B-X
by	B-X
complex	B-X
carbohydrates	B-X
.	B-X
HIV	B-X
,	B-X
with	B-X
its	B-X
extreme	B-X
variation	B-X
in	B-X
number	B-X
and	B-X
precise	B-X
location	B-X
of	B-X
sequons	B-X
,	B-X
does	B-X
not	B-X
have	B-X
a	B-X
net	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
sites	B-X
over	B-X
time	B-X
at	B-X
the	B-X
population	B-X
level	B-X
.	B-X
Primate	B-X
lentiviral	B-X
lineages	B-X
have	B-X
host	B-X
species-dependent	B-X
levels	B-X
of	B-X
sequon	B-X
shifting	B-X
,	B-X
with	B-X
HIV-1	B-X
in	B-X
humans	B-X
the	B-X
most	B-X
extreme	B-X
.	B-X
HCV	B-X
E1	B-X
and	B-X
E2	B-X
proteins	B-X
,	B-X
despite	B-X
evolving	B-X
extremely	B-X
rapidly	B-X
through	B-X
point	B-X
mutation	B-X
,	B-X
show	B-X
limited	B-X
sequon	B-X
variation	B-X
,	B-X
although	B-X
two	B-X
shifting	B-X
sites	B-X
were	B-X
identified	B-X
.	B-X
Human	B-X
influenza	B-X
A	B-X
hemagglutinin	B-X
H3	B-X
HA1	B-X
is	B-X
accumulating	B-X
sequons	B-X
over	B-X
time	B-X
,	B-X
but	B-X
this	B-X
trend	B-X
is	B-X
not	B-X
evident	B-X
in	B-X
any	B-X
other	B-X
avian	B-X
or	B-X
human	B-X
influenza	B-X
A	B-X
serotypes	B-X
.	B-X

HIV	O
,	O
with	O
its	O
extreme	O
variation	O
in	O
number	O
and	O
precise	O
location	O
of	O
sequons	O
,	O
does	O
not	O
have	O
a	O
net	O
increase	O
in	O
the	O
number	O
of	O
sites	O
over	O
time	O
at	O
the	O
population	O
level	O
.	O

Primate	O
lentiviral	O
lineages	O
have	O
host	O
species	O
-	O
dependent	O
levels	O
of	O
sequon	O
shifting	O
,	O
with	O
HIV	O
-	O
1	O
in	O
humans	O
the	O
most	O
extreme	O
.	O
<EOS>	B-X
Human	B-X
and	B-X
simian	B-X
immunodeficiency	B-X
viruses	B-X
(	B-X
HIV	B-X
and	B-X
SIV	B-X
)	B-X
,	B-X
influenza	B-X
virus	B-X
,	B-X
and	B-X
hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
have	B-X
heavily	B-X
glycosylated	B-X
,	B-X
highly	B-X
variable	B-X
surface	B-X
proteins	B-X
.	B-X
Here	B-X
we	B-X
explore	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
(	B-X
sequon	B-X
)	B-X
variation	B-X
at	B-X
the	B-X
population	B-X
level	B-X
in	B-X
these	B-X
viruses	B-X
,	B-X
using	B-X
a	B-X
new	B-X
Web-based	B-X
program	B-X
developed	B-X
to	B-X
facilitate	B-X
the	B-X
sequon	B-X
tracking	B-X
and	B-X
to	B-X
define	B-X
patterns	B-X
(	B-X
www.hiv.lanl.gov	B-X
)	B-X
.	B-X
This	B-X
tool	B-X
allowed	B-X
rapid	B-X
visualization	B-X
of	B-X
the	B-X
two	B-X
distinctive	B-X
patterns	B-X
of	B-X
sequon	B-X
variation	B-X
found	B-X
in	B-X
HIV-1	B-X
,	B-X
HIV-2	B-X
,	B-X
and	B-X
SIV	B-X
CPZ	B-X
.	B-X
The	B-X
second	B-X
pattern	B-X
(	B-X
shifting	B-X
)	B-X
refers	B-X
to	B-X
sites	B-X
embedded	B-X
in	B-X
regions	B-X
of	B-X
extreme	B-X
local	B-X
length	B-X
variation	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
shifts	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
relative	B-X
position	B-X
and	B-X
local	B-X
density	B-X
of	B-X
sequons	B-X
;	B-X
these	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
populated	B-X
by	B-X
complex	B-X
carbohydrates	B-X
.	B-X
HIV	B-X
,	B-X
with	B-X
its	B-X
extreme	B-X
variation	B-X
in	B-X
number	B-X
and	B-X
precise	B-X
location	B-X
of	B-X
sequons	B-X
,	B-X
does	B-X
not	B-X
have	B-X
a	B-X
net	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
sites	B-X
over	B-X
time	B-X
at	B-X
the	B-X
population	B-X
level	B-X
.	B-X
Primate	B-X
lentiviral	B-X
lineages	B-X
have	B-X
host	B-X
species-dependent	B-X
levels	B-X
of	B-X
sequon	B-X
shifting	B-X
,	B-X
with	B-X
HIV-1	B-X
in	B-X
humans	B-X
the	B-X
most	B-X
extreme	B-X
.	B-X
HCV	B-X
E1	B-X
and	B-X
E2	B-X
proteins	B-X
,	B-X
despite	B-X
evolving	B-X
extremely	B-X
rapidly	B-X
through	B-X
point	B-X
mutation	B-X
,	B-X
show	B-X
limited	B-X
sequon	B-X
variation	B-X
,	B-X
although	B-X
two	B-X
shifting	B-X
sites	B-X
were	B-X
identified	B-X
.	B-X
Human	B-X
influenza	B-X
A	B-X
hemagglutinin	B-X
H3	B-X
HA1	B-X
is	B-X
accumulating	B-X
sequons	B-X
over	B-X
time	B-X
,	B-X
but	B-X
this	B-X
trend	B-X
is	B-X
not	B-X
evident	B-X
in	B-X
any	B-X
other	B-X
avian	B-X
or	B-X
human	B-X
influenza	B-X
A	B-X
serotypes	B-X
.	B-X

HCV	O
E1	B-Protein
and	O
E2	B-Protein
proteins	O
,	O
despite	O
evolving	O
extremely	O
rapidly	O
through	O
point	O
mutation	O
,	O
show	O
limited	O
sequon	O
variation	O
,	O
although	O
two	O
shifting	O
sites	O
were	O
identified	O
.	O
<EOS>	B-X
Human	B-X
and	B-X
simian	B-X
immunodeficiency	B-X
viruses	B-X
(	B-X
HIV	B-X
and	B-X
SIV	B-X
)	B-X
,	B-X
influenza	B-X
virus	B-X
,	B-X
and	B-X
hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
have	B-X
heavily	B-X
glycosylated	B-X
,	B-X
highly	B-X
variable	B-X
surface	B-X
proteins	B-X
.	B-X
Here	B-X
we	B-X
explore	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
(	B-X
sequon	B-X
)	B-X
variation	B-X
at	B-X
the	B-X
population	B-X
level	B-X
in	B-X
these	B-X
viruses	B-X
,	B-X
using	B-X
a	B-X
new	B-X
Web-based	B-X
program	B-X
developed	B-X
to	B-X
facilitate	B-X
the	B-X
sequon	B-X
tracking	B-X
and	B-X
to	B-X
define	B-X
patterns	B-X
(	B-X
www.hiv.lanl.gov	B-X
)	B-X
.	B-X
This	B-X
tool	B-X
allowed	B-X
rapid	B-X
visualization	B-X
of	B-X
the	B-X
two	B-X
distinctive	B-X
patterns	B-X
of	B-X
sequon	B-X
variation	B-X
found	B-X
in	B-X
HIV-1	B-X
,	B-X
HIV-2	B-X
,	B-X
and	B-X
SIV	B-X
CPZ	B-X
.	B-X
The	B-X
first	B-X
pattern	B-X
(	B-X
fixed	B-X
)	B-X
describes	B-X
readily	B-X
aligned	B-X
sites	B-X
that	B-X
are	B-X
either	B-X
simply	B-X
present	B-X
or	B-X
absent	B-X
.	B-X
These	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
occupied	B-X
by	B-X
high-mannose	B-X
glycans	B-X
.	B-X
The	B-X
second	B-X
pattern	B-X
(	B-X
shifting	B-X
)	B-X
refers	B-X
to	B-X
sites	B-X
embedded	B-X
in	B-X
regions	B-X
of	B-X
extreme	B-X
local	B-X
length	B-X
variation	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
shifts	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
relative	B-X
position	B-X
and	B-X
local	B-X
density	B-X
of	B-X
sequons	B-X
;	B-X
these	B-X
sites	B-X
tend	B-X
to	B-X
be	B-X
populated	B-X
by	B-X
complex	B-X
carbohydrates	B-X
.	B-X
HIV	B-X
,	B-X
with	B-X
its	B-X
extreme	B-X
variation	B-X
in	B-X
number	B-X
and	B-X
precise	B-X
location	B-X
of	B-X
sequons	B-X
,	B-X
does	B-X
not	B-X
have	B-X
a	B-X
net	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
sites	B-X
over	B-X
time	B-X
at	B-X
the	B-X
population	B-X
level	B-X
.	B-X
Primate	B-X
lentiviral	B-X
lineages	B-X
have	B-X
host	B-X
species-dependent	B-X
levels	B-X
of	B-X
sequon	B-X
shifting	B-X
,	B-X
with	B-X
HIV-1	B-X
in	B-X
humans	B-X
the	B-X
most	B-X
extreme	B-X
.	B-X
HCV	B-X
E1	B-X
and	B-X
E2	B-X
proteins	B-X
,	B-X
despite	B-X
evolving	B-X
extremely	B-X
rapidly	B-X
through	B-X
point	B-X
mutation	B-X
,	B-X
show	B-X
limited	B-X
sequon	B-X
variation	B-X
,	B-X
although	B-X
two	B-X
shifting	B-X
sites	B-X
were	B-X
identified	B-X
.	B-X
Human	B-X
influenza	B-X
A	B-X
hemagglutinin	B-X
H3	B-X
HA1	B-X
is	B-X
accumulating	B-X
sequons	B-X
over	B-X
time	B-X
,	B-X
but	B-X
this	B-X
trend	B-X
is	B-X
not	B-X
evident	B-X
in	B-X
any	B-X
other	B-X
avian	B-X
or	B-X
human	B-X
influenza	B-X
A	B-X
serotypes	B-X
.	B-X

Human	O
influenza	O
A	O
hemagglutinin	B-Protein
H3	O
HA1	B-Protein
is	O
accumulating	O
sequons	O
over	O
time	O
,	O
but	O
this	O
trend	O
is	O
not	O
evident	O
in	O
any	O
other	O
avian	O
or	O
human	O
influenza	O
A	O
serotypes	O
.	O
<EOS>	B-X
Community	B-X
interactions	B-X
at	B-X
mucosal	B-X
surfaces	B-X
between	B-X
viruses	B-X
,	B-X
like	B-X
influenza	B-X
virus	B-X
,	B-X
and	B-X
respiratory	B-X
bacterial	B-X
pathogens	B-X
are	B-X
important	B-X
contributors	B-X
toward	B-X
pathogenesis	B-X
of	B-X
bacterial	B-X
disease	B-X
.	B-X
What	B-X
has	B-X
not	B-X
been	B-X
considered	B-X
is	B-X
the	B-X
natural	B-X
extension	B-X
of	B-X
these	B-X
interactions	B-X
to	B-X
live	B-X
attenuated	B-X
immunizations	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
live	B-X
attenuated	B-X
influenza	B-X
vaccines	B-X
(	B-X
LAIVs	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
mouse-adapted	B-X
LAIV	B-X
against	B-X
influenza	B-X
A	B-X
(	B-X
H3N2	B-X
)	B-X
virus	B-X
carrying	B-X
the	B-X
same	B-X
mutations	B-X
as	B-X
the	B-X
human	B-X
FluMist	B-X
vaccine	B-X
,	B-X
we	B-X
find	B-X
that	B-X
LAIV	B-X
vaccination	B-X
reverses	B-X
normal	B-X
bacterial	B-X
clearance	B-X
from	B-X
the	B-X
nasopharynx	B-X
and	B-X
significantly	B-X
increases	B-X
bacterial	B-X
carriage	B-X
densities	B-X
of	B-X
the	B-X
clinically	B-X
important	B-X
bacterial	B-X
pathogens	B-X
Streptococcus	B-X
pneumoniae	B-X
(	B-X
serotypes	B-X
19F	B-X
and	B-X
7F	B-X
)	B-X
and	B-X
Staphylococcus	B-X
aureus	B-X
(	B-X
strains	B-X
Newman	B-X
and	B-X
Wright	B-X
)	B-X
within	B-X
the	B-X
upper	B-X
respiratory	B-X
tract	B-X
of	B-X
mice	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
increases	B-X
in	B-X
carriage	B-X
density	B-X
and	B-X
duration	B-X
were	B-X
nearly	B-X
identical	B-X
in	B-X
all	B-X
aspects	B-X
to	B-X
changes	B-X
in	B-X
bacterial	B-X
colonizing	B-X
dynamics	B-X
following	B-X
infection	B-X
with	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
influenza	B-X
virus	B-X
.	B-X
Importantly	B-X
,	B-X
LAIV	B-X
,	B-X
unlike	B-X
WT	B-X
influenza	B-X
viruses	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
severe	B-X
bacterial	B-X
disease	B-X
or	B-X
mortality	B-X
within	B-X
the	B-X
lower	B-X
respiratory	B-X
tract	B-X
.	B-X
Our	B-X
findings	B-X
are	B-X
,	B-X
to	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
that	B-X
vaccination	B-X
with	B-X
a	B-X
live	B-X
attenuated	B-X
viral	B-X
vaccine	B-X
can	B-X
directly	B-X
modulate	B-X
colonizing	B-X
dynamics	B-X
of	B-X
important	B-X
and	B-X
unrelated	B-X
human	B-X
bacterial	B-X
pathogens	B-X
,	B-X
and	B-X
does	B-X
so	B-X
in	B-X
a	B-X
manner	B-X
highly	B-X
analogous	B-X
to	B-X
that	B-X
seen	B-X
following	B-X
wild-type	B-X
virus	B-X
infection	B-X
.	B-X

Redox	O
state	O
regulates	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
its	O
DNA	O
binding	O
and	O
phosphorylation	O
in	O
salmonid	O
cells	O
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
HIF-1alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
by	B-X
a	B-X
proteasome	B-X
under	B-X
normal	B-X
oxygen	B-X
(	B-X
21	B-X
%	B-X
O2	B-X
)	B-X
conditions	B-X
,	B-X
mainly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
prolyl	B-X
hydroxylation	B-X
needed	B-X
for	B-X
protein	B-X
destabilization	B-X
.	B-X
Although	B-X
prolyl	B-X
hydroxylation	B-X
at	B-X
conserved	B-X
proline	B-X
residues	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
,	B-X
in	B-X
addition	B-X
,	B-X
influence	B-X
the	B-X
function	B-X
of	B-X
HIF-1alpha	B-X
like	B-X
proteins	B-X
by	B-X
influencing	B-X
their	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
rainbow	B-X
trout	B-X
HIF-1alpha	B-X
contains	B-X
several	B-X
unique	B-X
cysteine	B-X
residues	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
DNA-binding	B-X
area	B-X
at	B-X
position	B-X
28	B-X
and	B-X
in	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
the	B-X
molecule	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
conserved	B-X
proline	B-X
residue	B-X
at	B-X
position	B-X
564	B-X
of	B-X
mammalian	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
we	B-X
have	B-X
investigated	B-X
if	B-X
the	B-X
redox	B-X
state	B-X
influences	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
in	B-X
two	B-X
established	B-X
salmonid	B-X
cell	B-X
lines	B-X
RTG-2	B-X
and	B-X
CHSE-214	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
redox	B-X
state	B-X
influences	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
conserved	B-X
prolyl	B-X
residues	B-X
to	B-X
oxygen-dependent	B-X
hydroxylation	B-X
and	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

Rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
is	O
a	O
heterodimeric	O
transcription	O
factor	O
structurally	O
similar	O
to	O
mammalian	O
HIF	O
-	O
1	O
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
HIF-1alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
by	B-X
a	B-X
proteasome	B-X
under	B-X
normal	B-X
oxygen	B-X
(	B-X
21	B-X
%	B-X
O2	B-X
)	B-X
conditions	B-X
,	B-X
mainly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
prolyl	B-X
hydroxylation	B-X
needed	B-X
for	B-X
protein	B-X
destabilization	B-X
.	B-X
Although	B-X
prolyl	B-X
hydroxylation	B-X
at	B-X
conserved	B-X
proline	B-X
residues	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
,	B-X
in	B-X
addition	B-X
,	B-X
influence	B-X
the	B-X
function	B-X
of	B-X
HIF-1alpha	B-X
like	B-X
proteins	B-X
by	B-X
influencing	B-X
their	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
rainbow	B-X
trout	B-X
HIF-1alpha	B-X
contains	B-X
several	B-X
unique	B-X
cysteine	B-X
residues	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
DNA-binding	B-X
area	B-X
at	B-X
position	B-X
28	B-X
and	B-X
in	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
the	B-X
molecule	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
conserved	B-X
proline	B-X
residue	B-X
at	B-X
position	B-X
564	B-X
of	B-X
mammalian	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
we	B-X
have	B-X
investigated	B-X
if	B-X
the	B-X
redox	B-X
state	B-X
influences	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
in	B-X
two	B-X
established	B-X
salmonid	B-X
cell	B-X
lines	B-X
RTG-2	B-X
and	B-X
CHSE-214	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
oxidizing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
L-buthionine	B-X
sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
dampen	B-X
the	B-X
hypoxia	B-X
response	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
hypoxia-like	B-X
effect	B-X
of	B-X
cobalt	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
reducing	B-X
agent	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
redox	B-X
state	B-X
influences	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
conserved	B-X
prolyl	B-X
residues	B-X
to	B-X
oxygen-dependent	B-X
hydroxylation	B-X
and	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

It	O
consists	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
HIF	B-Protein
-	I-Protein
1beta	I-Protein
subunits	O
,	O
of	O
which	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
subunit	O
confers	O
the	O
hypoxia	O
sensitivity	O
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
HIF-1alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
by	B-X
a	B-X
proteasome	B-X
under	B-X
normal	B-X
oxygen	B-X
(	B-X
21	B-X
%	B-X
O2	B-X
)	B-X
conditions	B-X
,	B-X
mainly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
prolyl	B-X
hydroxylation	B-X
needed	B-X
for	B-X
protein	B-X
destabilization	B-X
.	B-X
Although	B-X
prolyl	B-X
hydroxylation	B-X
at	B-X
conserved	B-X
proline	B-X
residues	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
,	B-X
in	B-X
addition	B-X
,	B-X
influence	B-X
the	B-X
function	B-X
of	B-X
HIF-1alpha	B-X
like	B-X
proteins	B-X
by	B-X
influencing	B-X
their	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
rainbow	B-X
trout	B-X
HIF-1alpha	B-X
contains	B-X
several	B-X
unique	B-X
cysteine	B-X
residues	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
DNA-binding	B-X
area	B-X
at	B-X
position	B-X
28	B-X
and	B-X
in	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
the	B-X
molecule	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
conserved	B-X
proline	B-X
residue	B-X
at	B-X
position	B-X
564	B-X
of	B-X
mammalian	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
we	B-X
have	B-X
investigated	B-X
if	B-X
the	B-X
redox	B-X
state	B-X
influences	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
in	B-X
two	B-X
established	B-X
salmonid	B-X
cell	B-X
lines	B-X
RTG-2	B-X
and	B-X
CHSE-214	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
oxidizing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
L-buthionine	B-X
sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
dampen	B-X
the	B-X
hypoxia	B-X
response	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
hypoxia-like	B-X
effect	B-X
of	B-X
cobalt	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
reducing	B-X
agent	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
redox	B-X
state	B-X
influences	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
conserved	B-X
prolyl	B-X
residues	B-X
to	B-X
oxygen-dependent	B-X
hydroxylation	B-X
and	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

HIF	B-Protein
-	I-Protein
1alpha	I-Protein
is	O
rapidly	O
degraded	O
by	O
a	O
proteasome	O
under	O
normal	O
oxygen	O
(	O
21	O
%	O
O2	O
)	O
conditions	O
,	O
mainly	O
as	O
a	O
result	O
of	O
prolyl	O
hydroxylation	O
needed	O
for	O
protein	O
destabilization	O
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
HIF-1alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
by	B-X
a	B-X
proteasome	B-X
under	B-X
normal	B-X
oxygen	B-X
(	B-X
21	B-X
%	B-X
O2	B-X
)	B-X
conditions	B-X
,	B-X
mainly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
prolyl	B-X
hydroxylation	B-X
needed	B-X
for	B-X
protein	B-X
destabilization	B-X
.	B-X
Although	B-X
prolyl	B-X
hydroxylation	B-X
at	B-X
conserved	B-X
proline	B-X
residues	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
,	B-X
in	B-X
addition	B-X
,	B-X
influence	B-X
the	B-X
function	B-X
of	B-X
HIF-1alpha	B-X
like	B-X
proteins	B-X
by	B-X
influencing	B-X
their	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
.	B-X
Sensitivity	B-X
of	B-X
the	B-X
protein	B-X
to	B-X
oxidation/reduction	B-X
may	B-X
be	B-X
due	B-X
to	B-X
cysteine	B-X
residues	B-X
at	B-X
critical	B-X
positions	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
rainbow	B-X
trout	B-X
HIF-1alpha	B-X
contains	B-X
several	B-X
unique	B-X
cysteine	B-X
residues	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
DNA-binding	B-X
area	B-X
at	B-X
position	B-X
28	B-X
and	B-X
in	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
the	B-X
molecule	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
conserved	B-X
proline	B-X
residue	B-X
at	B-X
position	B-X
564	B-X
of	B-X
mammalian	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
we	B-X
have	B-X
investigated	B-X
if	B-X
the	B-X
redox	B-X
state	B-X
influences	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
in	B-X
two	B-X
established	B-X
salmonid	B-X
cell	B-X
lines	B-X
RTG-2	B-X
and	B-X
CHSE-214	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
oxidizing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
L-buthionine	B-X
sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
dampen	B-X
the	B-X
hypoxia	B-X
response	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
redox	B-X
state	B-X
influences	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
conserved	B-X
prolyl	B-X
residues	B-X
to	B-X
oxygen-dependent	B-X
hydroxylation	B-X
and	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

Although	O
prolyl	O
hydroxylation	O
at	O
conserved	O
proline	O
residues	O
is	O
a	O
major	O
factor	O
controlling	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
stability	O
,	O
the	O
redox	O
state	O
of	O
the	O
cells	O
may	O
,	O
in	O
addition	O
,	O
influence	O
the	O
function	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
like	O
proteins	O
by	O
influencing	O
their	O
stability	O
,	O
DNA	O
binding	O
and	O
phosphorylation	O
.	O

Sensitivity	O
of	O
the	O
protein	O
to	O
oxidation	O
/	O
reduction	O
may	O
be	O
due	O
to	O
cysteine	O
residues	O
at	O
critical	O
positions	O
.	O
<EOS>	B-X
High	B-X
mobility	B-X
group	B-X
box	B-X
1	B-X
(	B-X
HMGB1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
protein	B-X
with	B-X
extracellular	B-X
inflammatory	B-X
cytokine	B-X
activity	B-X
.	B-X
HMGB1	B-X
contains	B-X
three	B-X
conserved	B-X
redox-sensitive	B-X
cysteine	B-X
residues	B-X
:	B-X
cysteines	B-X
in	B-X
position	B-X
23	B-X
and	B-X
45	B-X
(	B-X
C23	B-X
and	B-X
C45	B-X
)	B-X
can	B-X
form	B-X
an	B-X
intramolecular	B-X
disulfide	B-X
bond	B-X
,	B-X
whereas	B-X
C106	B-X
is	B-X
unpaired	B-X
and	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Toll-Like	B-X
Receptor	B-X
(	B-X
TLR	B-X
)	B-X
4	B-X
.	B-X
However	B-X
,	B-X
a	B-X
comprehensive	B-X
characterization	B-X
of	B-X
the	B-X
dynamic	B-X
redox	B-X
states	B-X
of	B-X
each	B-X
cysteine	B-X
residue	B-X
and	B-X
of	B-X
their	B-X
impacts	B-X
on	B-X
innate	B-X
immune	B-X
responses	B-X
is	B-X
lacking	B-X
.	B-X
Peroxiredoxins	B-X
(	B-X
Prx	B-X
)	B-X
are	B-X
enzymes	B-X
that	B-X
efficiently	B-X
reduce	B-X
hydroperoxides	B-X
through	B-X
active	B-X
participation	B-X
of	B-X
cysteine	B-X
residues	B-X
(	B-X
C	B-X

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
rainbow	O
trout	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
contains	O
several	O
unique	O
cysteine	O
residues	O
,	O
notably	O
in	O
the	O
DNA	O
-	O
binding	O
area	O
at	O
position	O
28	O
and	O
in	O
the	O
transactivation	O
domain	O
of	O
the	O
molecule	O
in	O
the	O
vicinity	O
of	O
the	O
conserved	O
proline	O
residue	O
at	O
position	O
564	O
of	O
mammalian	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
HIF-1alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
by	B-X
a	B-X
proteasome	B-X
under	B-X
normal	B-X
oxygen	B-X
(	B-X
21	B-X
%	B-X
O2	B-X
)	B-X
conditions	B-X
,	B-X
mainly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
prolyl	B-X
hydroxylation	B-X
needed	B-X
for	B-X
protein	B-X
destabilization	B-X
.	B-X
Although	B-X
prolyl	B-X
hydroxylation	B-X
at	B-X
conserved	B-X
proline	B-X
residues	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
,	B-X
in	B-X
addition	B-X
,	B-X
influence	B-X
the	B-X
function	B-X
of	B-X
HIF-1alpha	B-X
like	B-X
proteins	B-X
by	B-X
influencing	B-X
their	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
.	B-X
Sensitivity	B-X
of	B-X
the	B-X
protein	B-X
to	B-X
oxidation/reduction	B-X
may	B-X
be	B-X
due	B-X
to	B-X
cysteine	B-X
residues	B-X
at	B-X
critical	B-X
positions	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
rainbow	B-X
trout	B-X
HIF-1alpha	B-X
contains	B-X
several	B-X
unique	B-X
cysteine	B-X
residues	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
DNA-binding	B-X
area	B-X
at	B-X
position	B-X
28	B-X
and	B-X
in	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
the	B-X
molecule	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
conserved	B-X
proline	B-X
residue	B-X
at	B-X
position	B-X
564	B-X
of	B-X
mammalian	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
we	B-X
have	B-X
investigated	B-X
if	B-X
the	B-X
redox	B-X
state	B-X
influences	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
in	B-X
two	B-X
established	B-X
salmonid	B-X
cell	B-X
lines	B-X
RTG-2	B-X
and	B-X
CHSE-214	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
redox	B-X
state	B-X
influences	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
conserved	B-X
prolyl	B-X
residues	B-X
to	B-X
oxygen-dependent	B-X
hydroxylation	B-X
and	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

In	O
the	O
present	O
studies	O
we	O
have	O
investigated	O
if	O
the	O
redox	O
state	O
influences	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
stability	O
,	O
DNA	O
binding	O
and	O
phosphorylation	O
in	O
two	O
established	O
salmonid	O
cell	O
lines	O
RTG	O
-	O
2	O
and	O
CHSE	O
-	O
214	O
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
HIF-1alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
by	B-X
a	B-X
proteasome	B-X
under	B-X
normal	B-X
oxygen	B-X
(	B-X
21	B-X
%	B-X
O2	B-X
)	B-X
conditions	B-X
,	B-X
mainly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
prolyl	B-X
hydroxylation	B-X
needed	B-X
for	B-X
protein	B-X
destabilization	B-X
.	B-X
Although	B-X
prolyl	B-X
hydroxylation	B-X
at	B-X
conserved	B-X
proline	B-X
residues	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
,	B-X
in	B-X
addition	B-X
,	B-X
influence	B-X
the	B-X
function	B-X
of	B-X
HIF-1alpha	B-X
like	B-X
proteins	B-X
by	B-X
influencing	B-X
their	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
rainbow	B-X
trout	B-X
HIF-1alpha	B-X
contains	B-X
several	B-X
unique	B-X
cysteine	B-X
residues	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
DNA-binding	B-X
area	B-X
at	B-X
position	B-X
28	B-X
and	B-X
in	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
the	B-X
molecule	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
conserved	B-X
proline	B-X
residue	B-X
at	B-X
position	B-X
564	B-X
of	B-X
mammalian	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
we	B-X
have	B-X
investigated	B-X
if	B-X
the	B-X
redox	B-X
state	B-X
influences	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
in	B-X
two	B-X
established	B-X
salmonid	B-X
cell	B-X
lines	B-X
RTG-2	B-X
and	B-X
CHSE-214	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
redox	B-X
state	B-X
influences	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
conserved	B-X
prolyl	B-X
residues	B-X
to	B-X
oxygen-dependent	B-X
hydroxylation	B-X
and	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

The	O
results	O
indicate	O
that	O
reducing	O
conditions	O
,	O
achieved	O
using	O
N	O
-	O
propylgallate	O
(	O
nPG	O
)	O
or	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
,	O
stabilize	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
facilitate	O
its	O
DNA	O
binding	O
,	O
and	O
increase	O
its	O
phosphorylation	O
even	O
under	O
normal	O
oxygen	O
conditions	O
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
HIF-1alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
by	B-X
a	B-X
proteasome	B-X
under	B-X
normal	B-X
oxygen	B-X
(	B-X
21	B-X
%	B-X
O2	B-X
)	B-X
conditions	B-X
,	B-X
mainly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
prolyl	B-X
hydroxylation	B-X
needed	B-X
for	B-X
protein	B-X
destabilization	B-X
.	B-X
Although	B-X
prolyl	B-X
hydroxylation	B-X
at	B-X
conserved	B-X
proline	B-X
residues	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
,	B-X
in	B-X
addition	B-X
,	B-X
influence	B-X
the	B-X
function	B-X
of	B-X
HIF-1alpha	B-X
like	B-X
proteins	B-X
by	B-X
influencing	B-X
their	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
rainbow	B-X
trout	B-X
HIF-1alpha	B-X
contains	B-X
several	B-X
unique	B-X
cysteine	B-X
residues	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
DNA-binding	B-X
area	B-X
at	B-X
position	B-X
28	B-X
and	B-X
in	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
the	B-X
molecule	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
conserved	B-X
proline	B-X
residue	B-X
at	B-X
position	B-X
564	B-X
of	B-X
mammalian	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
we	B-X
have	B-X
investigated	B-X
if	B-X
the	B-X
redox	B-X
state	B-X
influences	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
in	B-X
two	B-X
established	B-X
salmonid	B-X
cell	B-X
lines	B-X
RTG-2	B-X
and	B-X
CHSE-214	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
oxidizing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
L-buthionine	B-X
sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
dampen	B-X
the	B-X
hypoxia	B-X
response	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
hypoxia-like	B-X
effect	B-X
of	B-X
cobalt	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
reducing	B-X
agent	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
redox	B-X
state	B-X
influences	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
conserved	B-X
prolyl	B-X
residues	B-X
to	B-X
oxygen-dependent	B-X
hydroxylation	B-X
and	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
oxidizing	O
conditions	O
,	O
achieved	O
using	O
L	O
-	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
dampen	O
the	O
hypoxia	O
response	O
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
HIF-1alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
by	B-X
a	B-X
proteasome	B-X
under	B-X
normal	B-X
oxygen	B-X
(	B-X
21	B-X
%	B-X
O2	B-X
)	B-X
conditions	B-X
,	B-X
mainly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
prolyl	B-X
hydroxylation	B-X
needed	B-X
for	B-X
protein	B-X
destabilization	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
oxidizing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
L-buthionine	B-X
sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
dampen	B-X
the	B-X
hypoxia	B-X
response	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
hypoxia-like	B-X
effect	B-X
of	B-X
cobalt	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
reducing	B-X
agent	B-X
.	B-X

Furthermore	O
,	O
the	O
hypoxia	O
-	O
like	O
effect	O
of	O
cobalt	O
is	O
increased	O
in	O
the	O
presence	O
of	O
the	O
reducing	O
agent	O
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
Although	B-X
prolyl	B-X
hydroxylation	B-X
at	B-X
conserved	B-X
proline	B-X
residues	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
,	B-X
in	B-X
addition	B-X
,	B-X
influence	B-X
the	B-X
function	B-X
of	B-X
HIF-1alpha	B-X
like	B-X
proteins	B-X
by	B-X
influencing	B-X
their	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
oxidizing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
L-buthionine	B-X
sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
dampen	B-X
the	B-X
hypoxia	B-X
response	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
hypoxia-like	B-X
effect	B-X
of	B-X
cobalt	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
reducing	B-X
agent	B-X
.	B-X

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
suggest	O
that	O
redox	O
state	O
influences	O
the	O
accessibility	O
of	O
the	O
conserved	O
prolyl	O
residues	O
to	O
oxygen	O
-	O
dependent	O
hydroxylation	O
and	O
the	O
accessibility	O
of	O
the	O
residues	O
involved	O
in	O
the	O
phosphorylation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O
<EOS>	B-X
Rainbow	B-X
trout	B-X
(	B-X
Oncorhynchus	B-X
mykiss	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
structurally	B-X
similar	B-X
to	B-X
mammalian	B-X
HIF-1	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
HIF-1beta	B-X
subunits	B-X
,	B-X
of	B-X
which	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
confers	B-X
the	B-X
hypoxia	B-X
sensitivity	B-X
.	B-X
HIF-1alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
by	B-X
a	B-X
proteasome	B-X
under	B-X
normal	B-X
oxygen	B-X
(	B-X
21	B-X
%	B-X
O2	B-X
)	B-X
conditions	B-X
,	B-X
mainly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
prolyl	B-X
hydroxylation	B-X
needed	B-X
for	B-X
protein	B-X
destabilization	B-X
.	B-X
Although	B-X
prolyl	B-X
hydroxylation	B-X
at	B-X
conserved	B-X
proline	B-X
residues	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
,	B-X
in	B-X
addition	B-X
,	B-X
influence	B-X
the	B-X
function	B-X
of	B-X
HIF-1alpha	B-X
like	B-X
proteins	B-X
by	B-X
influencing	B-X
their	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
.	B-X
Sensitivity	B-X
of	B-X
the	B-X
protein	B-X
to	B-X
oxidation/reduction	B-X
may	B-X
be	B-X
due	B-X
to	B-X
cysteine	B-X
residues	B-X
at	B-X
critical	B-X
positions	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
rainbow	B-X
trout	B-X
HIF-1alpha	B-X
contains	B-X
several	B-X
unique	B-X
cysteine	B-X
residues	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
DNA-binding	B-X
area	B-X
at	B-X
position	B-X
28	B-X
and	B-X
in	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
the	B-X
molecule	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
conserved	B-X
proline	B-X
residue	B-X
at	B-X
position	B-X
564	B-X
of	B-X
mammalian	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
we	B-X
have	B-X
investigated	B-X
if	B-X
the	B-X
redox	B-X
state	B-X
influences	B-X
HIF-1alpha	B-X
stability	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
phosphorylation	B-X
in	B-X
two	B-X
established	B-X
salmonid	B-X
cell	B-X
lines	B-X
RTG-2	B-X
and	B-X
CHSE-214	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
reducing	B-X
conditions	B-X
,	B-X
achieved	B-X
using	B-X
N-propylgallate	B-X
(	B-X
nPG	B-X
)	B-X
or	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
stabilize	B-X
HIF-1alpha	B-X
,	B-X
facilitate	B-X
its	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
increase	B-X
its	B-X
phosphorylation	B-X
even	B-X
under	B-X
normal	B-X
oxygen	B-X
conditions	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
redox	B-X
state	B-X
influences	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
conserved	B-X
prolyl	B-X
residues	B-X
to	B-X
oxygen-dependent	B-X
hydroxylation	B-X
and	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

Induction	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
activity	O
by	O
muscarinic	O
acetylcholine	O
receptor	O
signaling	O
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
cellular	B-X
adaptive	B-X
responses	B-X
to	B-X
hypoxia	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
increase	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Exposure	B-X
of	B-X
cells	B-X
to	B-X
growth	B-X
factors	B-X
,	B-X
prostaglandin	B-X
,	B-X
and	B-X
certain	B-X
nitric	B-X
oxide	B-X
donors	B-X
also	B-X
induces	B-X
HIF-1alpha	B-X
expression	B-X
under	B-X
non-hypoxic	B-X
conditions	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
muscarinic	B-X
acetylcholine	B-X
signals	B-X
induce	B-X
HIF-1alpha	B-X
expression	B-X
and	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
receptor	B-X
subtype-specific	B-X
manner	B-X
using	B-X
HEK293	B-X
cells	B-X
transiently	B-X
overexpressing	B-X
each	B-X
of	B-X
M1-M4	B-X
muscarinic	B-X
acetylcholine	B-X
receptors	B-X
.	B-X
The	B-X
muscarinic	B-X
signaling	B-X
pathways	B-X
inhibited	B-X
HIF-1alpha	B-X
hydroxylation	B-X
and	B-X
degradation	B-X
and	B-X
induced	B-X
HIF-1alpha	B-X
protein	B-X
synthesis	B-X
that	B-X
was	B-X
confirmed	B-X
by	B-X
pulse	B-X
labeling	B-X
studies	B-X
.	B-X
Muscarinic	B-X
signal-induced	B-X
HIF-1alpha	B-X
protein	B-X
and	B-X
HIF-1-dependent	B-X
gene	B-X
expression	B-X
were	B-X
blocked	B-X
by	B-X
treating	B-X
cells	B-X
with	B-X
inhibitors	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
,	B-X
MAP	B-X
kinase	B-X
kinase	B-X
,	B-X
or	B-X
tyrosine	B-X
kinase	B-X
signaling	B-X
pathways	B-X
.	B-X
Dominant-negative	B-X
forms	B-X
of	B-X
Ras	B-X
and/or	B-X
Rac-1	B-X
significantly	B-X
suppressed	B-X
HIF-1	B-X
activation	B-X
by	B-X
muscarinic	B-X
signaling	B-X
.	B-X
Signaling	B-X
via	B-X
M1-	B-X
and	B-X
M3-	B-X
but	B-X
not	B-X
M2-	B-X
or	B-X
M4-AchRs	B-X
promote	B-X
accumulation	B-X
and	B-X
transcriptional	B-X
activation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
muscarinic	B-X
acetylcholine	B-X
signals	B-X
activate	B-X
HIF-1	B-X
by	B-X
both	B-X
stabilization	B-X
and	B-X
synthesis	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
by	B-X
inducing	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

Hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
is	O
a	O
master	O
regulator	O
of	O
cellular	O
adaptive	O
responses	O
to	O
hypoxia	O
.	O
<EOS>	B-X
Hypoxia	B-X
occurs	B-X
frequently	B-X
in	B-X
human	B-X
cancers	B-X
and	B-X
induces	B-X
adaptive	B-X
changes	B-X
in	B-X
cell	B-X
metabolism	B-X
that	B-X
include	B-X
a	B-X
switch	B-X
from	B-X
oxidative	B-X
phosphorylation	B-X
to	B-X
glycolysis	B-X
,	B-X
increased	B-X
glycogen	B-X
synthesis	B-X
,	B-X
and	B-X
a	B-X
switch	B-X
from	B-X
glucose	B-X
to	B-X
glutamine	B-X
as	B-X
the	B-X
major	B-X
substrate	B-X
for	B-X
fatty	B-X
acid	B-X
synthesis	B-X
.	B-X
This	B-X
broad	B-X
metabolic	B-X
reprogramming	B-X
is	B-X
coordinated	B-X
at	B-X
the	B-X
transcriptional	B-X
level	B-X
by	B-X
HIF-1	B-X
,	B-X
which	B-X
functions	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
to	B-X
balance	B-X
oxygen	B-X
supply	B-X
and	B-X
demand	B-X
.	B-X
HIF-1	B-X
is	B-X
also	B-X
activated	B-X
in	B-X
cancer	B-X
cells	B-X
by	B-X
tumor	B-X
suppressor	B-X
(	B-X
e.g.	B-X
,	B-X
VHL	B-X
)	B-X
loss	B-X
of	B-X
function	B-X
and	B-X
oncogene	B-X
gain	B-X
of	B-X
function	B-X
(	B-X
leading	B-X
to	B-X
PI3K/AKT/mTOR	B-X
activity	B-X
)	B-X
and	B-X
mediates	B-X
metabolic	B-X
alterations	B-X
that	B-X
drive	B-X
cancer	B-X
progression	B-X
and	B-X
resistance	B-X
to	B-X
therapy	B-X
.	B-X
Inhibitors	B-X
of	B-X
HIF-1	B-X
or	B-X
metabolic	B-X
enzymes	B-X
may	B-X
impair	B-X
the	B-X
metabolic	B-X
flexibility	B-X
of	B-X
cancer	B-X
cells	B-X
and	B-X
make	B-X
them	B-X
more	B-X
sensitive	B-X
to	B-X
anticancer	B-X
drugs	B-X
.	B-X

Levels	O
of	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
subunit	O
increase	O
under	O
hypoxic	O
conditions	O
.	O
<EOS>	B-X
Under	B-X
conditions	B-X
of	B-X
hypoxia	B-X
,	B-X
most	B-X
eukaryotic	B-X
cells	B-X
can	B-X
shift	B-X
their	B-X
primary	B-X
metabolic	B-X
strategy	B-X
from	B-X
predominantly	B-X
mitochondrial	B-X
respiration	B-X
towards	B-X
increased	B-X
glycolysis	B-X
to	B-X
maintain	B-X
ATP	B-X
levels	B-X
.	B-X
This	B-X
hypoxia-induced	B-X
reprogramming	B-X
of	B-X
metabolism	B-X
is	B-X
key	B-X
to	B-X
satisfying	B-X
cellular	B-X
energetic	B-X
requirements	B-X
during	B-X
acute	B-X
hypoxic	B-X
stress	B-X
.	B-X
At	B-X
a	B-X
transcriptional	B-X
level	B-X
,	B-X
this	B-X
metabolic	B-X
switch	B-X
can	B-X
be	B-X
regulated	B-X
by	B-X
several	B-X
pathways	B-X
including	B-X
the	B-X
hypoxia	B-X
inducible	B-X
factor-1α	B-X
(	B-X
HIF-1α	B-X
)	B-X
which	B-X
induces	B-X
an	B-X
increased	B-X
expression	B-X
of	B-X
glycolytic	B-X
enzymes	B-X
.	B-X
While	B-X
this	B-X
increase	B-X
in	B-X
glycolytic	B-X
flux	B-X
is	B-X
beneficial	B-X
for	B-X
maintaining	B-X
bioenergetic	B-X
homeostasis	B-X
during	B-X
hypoxia	B-X
,	B-X
the	B-X
pathways	B-X
mediating	B-X
this	B-X
increase	B-X
can	B-X
also	B-X
be	B-X
exploited	B-X
by	B-X
cancer	B-X
cells	B-X
to	B-X
promote	B-X
tumour	B-X
survival	B-X
and	B-X
growth	B-X
,	B-X
an	B-X
area	B-X
which	B-X
has	B-X
been	B-X
extensively	B-X
studied	B-X
.	B-X
It	B-X
has	B-X
recently	B-X
become	B-X
appreciated	B-X
that	B-X
increased	B-X
glycolytic	B-X
metabolism	B-X
in	B-X
hypoxia	B-X
may	B-X
also	B-X
have	B-X
profound	B-X
effects	B-X
on	B-X
cellular	B-X
physiology	B-X
in	B-X
hypoxic	B-X
immune	B-X
and	B-X
endothelial	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
highlight	B-X
the	B-X
role	B-X
of	B-X
HIF-1α	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
hypoxic	B-X
glycolysis	B-X
and	B-X
its	B-X
implications	B-X
for	B-X
physiological	B-X
processes	B-X
such	B-X
as	B-X
angiogenesis	B-X
and	B-X
immune	B-X
cell	B-X
effector	B-X
function	B-X
.	B-X

Exposure	O
of	O
cells	O
to	O
growth	O
factors	O
,	O
prostaglandin	O
,	O
and	O
certain	O
nitric	O
oxide	O
donors	O
also	O
induces	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
under	O
non	O
-	O
hypoxic	O
conditions	O
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
cellular	B-X
adaptive	B-X
responses	B-X
to	B-X
hypoxia	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
increase	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Exposure	B-X
of	B-X
cells	B-X
to	B-X
growth	B-X
factors	B-X
,	B-X
prostaglandin	B-X
,	B-X
and	B-X
certain	B-X
nitric	B-X
oxide	B-X
donors	B-X
also	B-X
induces	B-X
HIF-1alpha	B-X
expression	B-X
under	B-X
non-hypoxic	B-X
conditions	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
muscarinic	B-X
acetylcholine	B-X
signals	B-X
induce	B-X
HIF-1alpha	B-X
expression	B-X
and	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
receptor	B-X
subtype-specific	B-X
manner	B-X
using	B-X
HEK293	B-X
cells	B-X
transiently	B-X
overexpressing	B-X
each	B-X
of	B-X
M1-M4	B-X
muscarinic	B-X
acetylcholine	B-X
receptors	B-X
.	B-X
The	B-X
muscarinic	B-X
signaling	B-X
pathways	B-X
inhibited	B-X
HIF-1alpha	B-X
hydroxylation	B-X
and	B-X
degradation	B-X
and	B-X
induced	B-X
HIF-1alpha	B-X
protein	B-X
synthesis	B-X
that	B-X
was	B-X
confirmed	B-X
by	B-X
pulse	B-X
labeling	B-X
studies	B-X
.	B-X
Muscarinic	B-X
signal-induced	B-X
HIF-1alpha	B-X
protein	B-X
and	B-X
HIF-1-dependent	B-X
gene	B-X
expression	B-X
were	B-X
blocked	B-X
by	B-X
treating	B-X
cells	B-X
with	B-X
inhibitors	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
,	B-X
MAP	B-X
kinase	B-X
kinase	B-X
,	B-X
or	B-X
tyrosine	B-X
kinase	B-X
signaling	B-X
pathways	B-X
.	B-X
Dominant-negative	B-X
forms	B-X
of	B-X
Ras	B-X
and/or	B-X
Rac-1	B-X
significantly	B-X
suppressed	B-X
HIF-1	B-X
activation	B-X
by	B-X
muscarinic	B-X
signaling	B-X
.	B-X
Signaling	B-X
via	B-X
M1-	B-X
and	B-X
M3-	B-X
but	B-X
not	B-X
M2-	B-X
or	B-X
M4-AchRs	B-X
promote	B-X
accumulation	B-X
and	B-X
transcriptional	B-X
activation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
muscarinic	B-X
acetylcholine	B-X
signals	B-X
activate	B-X
HIF-1	B-X
by	B-X
both	B-X
stabilization	B-X
and	B-X
synthesis	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
by	B-X
inducing	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

We	O
demonstrate	O
that	O
muscarinic	O
acetylcholine	O
signals	O
induce	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
and	O
transcriptional	O
activity	O
in	O
a	O
receptor	O
subtype	O
-	O
specific	O
manner	O
using	O
HEK293	O
cells	O
transiently	O
overexpressing	O
each	O
of	O
M1	B-Protein
-	O
M4	B-Protein
muscarinic	I-Protein
acetylcholine	I-Protein
receptors	I-Protein
.	O

The	O
muscarinic	O
signaling	O
pathways	O
inhibited	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
hydroxylation	O
and	O
degradation	O
and	O
induced	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
protein	O
synthesis	O
that	O
was	O
confirmed	O
by	O
pulse	O
labeling	O
studies	O
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
cellular	B-X
adaptive	B-X
responses	B-X
to	B-X
hypoxia	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
increase	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Exposure	B-X
of	B-X
cells	B-X
to	B-X
growth	B-X
factors	B-X
,	B-X
prostaglandin	B-X
,	B-X
and	B-X
certain	B-X
nitric	B-X
oxide	B-X
donors	B-X
also	B-X
induces	B-X
HIF-1alpha	B-X
expression	B-X
under	B-X
non-hypoxic	B-X
conditions	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
muscarinic	B-X
acetylcholine	B-X
signals	B-X
induce	B-X
HIF-1alpha	B-X
expression	B-X
and	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
receptor	B-X
subtype-specific	B-X
manner	B-X
using	B-X
HEK293	B-X
cells	B-X
transiently	B-X
overexpressing	B-X
each	B-X
of	B-X
M1-M4	B-X
muscarinic	B-X
acetylcholine	B-X
receptors	B-X
.	B-X
The	B-X
muscarinic	B-X
signaling	B-X
pathways	B-X
inhibited	B-X
HIF-1alpha	B-X
hydroxylation	B-X
and	B-X
degradation	B-X
and	B-X
induced	B-X
HIF-1alpha	B-X
protein	B-X
synthesis	B-X
that	B-X
was	B-X
confirmed	B-X
by	B-X
pulse	B-X
labeling	B-X
studies	B-X
.	B-X
Muscarinic	B-X
signal-induced	B-X
HIF-1alpha	B-X
protein	B-X
and	B-X
HIF-1-dependent	B-X
gene	B-X
expression	B-X
were	B-X
blocked	B-X
by	B-X
treating	B-X
cells	B-X
with	B-X
inhibitors	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
,	B-X
MAP	B-X
kinase	B-X
kinase	B-X
,	B-X
or	B-X
tyrosine	B-X
kinase	B-X
signaling	B-X
pathways	B-X
.	B-X
Dominant-negative	B-X
forms	B-X
of	B-X
Ras	B-X
and/or	B-X
Rac-1	B-X
significantly	B-X
suppressed	B-X
HIF-1	B-X
activation	B-X
by	B-X
muscarinic	B-X
signaling	B-X
.	B-X
Signaling	B-X
via	B-X
M1-	B-X
and	B-X
M3-	B-X
but	B-X
not	B-X
M2-	B-X
or	B-X
M4-AchRs	B-X
promote	B-X
accumulation	B-X
and	B-X
transcriptional	B-X
activation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
muscarinic	B-X
acetylcholine	B-X
signals	B-X
activate	B-X
HIF-1	B-X
by	B-X
both	B-X
stabilization	B-X
and	B-X
synthesis	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
by	B-X
inducing	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

Muscarinic	O
signal	O
-	O
induced	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
protein	O
and	O
HIF	O
-	O
1	O
-	O
dependent	O
gene	O
expression	O
were	O
blocked	O
by	O
treating	O
cells	O
with	O
inhibitors	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
,	O
MAP	O
kinase	O
kinase	O
,	O
or	O
tyrosine	O
kinase	O
signaling	O
pathways	O
.	O
<EOS>	B-X
Tyrosine	B-X
phosphorylation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
key	B-X
covalent	B-X
modifications	B-X
that	B-X
occurs	B-X
in	B-X
multicellular	B-X
organisms	B-X
as	B-X
a	B-X
result	B-X
of	B-X
intercellular	B-X
communication	B-X
during	B-X
embryogenesis	B-X
and	B-X
maintenance	B-X
of	B-X
adult	B-X
tissues	B-X
.	B-X
The	B-X
enzymes	B-X
that	B-X
carry	B-X
out	B-X
this	B-X
modification	B-X
are	B-X
the	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
(	B-X
PTKs	B-X
)	B-X
,	B-X
which	B-X
catalyze	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
phosphate	B-X
of	B-X
ATP	B-X
to	B-X
tyrosine	B-X
residues	B-X
on	B-X
protein	B-X
substrates	B-X
.	B-X
Phosphorylation	B-X
of	B-X
tyrosine	B-X
residues	B-X
modulates	B-X
enzymatic	B-X
activity	B-X
and	B-X
creates	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
recruitment	B-X
of	B-X
downstream	B-X
signaling	B-X
proteins	B-X
.	B-X
Two	B-X
classes	B-X
of	B-X
PTKs	B-X
are	B-X
present	B-X
in	B-X
cells	B-X
:	B-X
the	B-X
transmembrane	B-X
receptor	B-X
PTKs	B-X
and	B-X
the	B-X
nonreceptor	B-X
PTKs	B-X
.	B-X
Because	B-X
PTKs	B-X
are	B-X
critical	B-X
components	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
,	B-X
their	B-X
catalytic	B-X
activity	B-X
is	B-X
strictly	B-X
regulated	B-X
.	B-X

Dominant	O
-	O
negative	O
forms	O
of	O
Ras	O
and	O
/	O
or	O
Rac	B-Protein
-	I-Protein
1	I-Protein
significantly	O
suppressed	O
HIF	O
-	O
1	O
activation	O
by	O
muscarinic	O
signaling	O
.	O
<EOS>	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
first	B-X
briefly	B-X
review	B-X
CSCs	B-X
in	B-X
mammalian	B-X
systems	B-X
,	B-X
then	B-X
discuss	B-X
stem-cell	B-X
tumors	B-X
in	B-X
the	B-X
Drosophila	B-X
posterior	B-X
midgut	B-X
and	B-X
Malpighian	B-X
tubules	B-X
(	B-X
kidney	B-X
)	B-X
and	B-X
their	B-X
unique	B-X
properties	B-X
as	B-X
revealed	B-X
by	B-X
studying	B-X
oncogenic	B-X
Ras	B-X
protein	B-X
(	B-X
Ras	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
hematopoietic	B-X
cytokines	B-X
,	B-X
including	B-X
erythropoietin	B-X
(	B-X
Epo	B-X
)	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-3	B-X
,	B-X
activate	B-X
the	B-X
Ras	B-X
GTPase	B-X
and	B-X
the	B-X
downstream	B-X
Raf/Erk/Elk-1	B-X
signaling	B-X
pathway	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Epo	B-X
or	B-X
IL-3	B-X
rapidly	B-X
and	B-X
transiently	B-X
activates	B-X
Rac	B-X
,	B-X
a	B-X
Rho	B-X
family	B-X
GTPase	B-X
,	B-X
in	B-X
hematopoietic	B-X
cell	B-X
lines	B-X
,	B-X
32D/EpoR-Wt	B-X
and	B-X
UT-7	B-X
.	B-X
The	B-X
cytokine-induced	B-X
activation	B-X
of	B-X
Rac	B-X
was	B-X
augmented	B-X
in	B-X
a	B-X
32D/EpoR-Wt	B-X
clone	B-X
that	B-X
inducibly	B-X
overexpresses	B-X
the	B-X
adaptor	B-X
protein	B-X
CrkL	B-X
or	B-X
the	B-X
Ras	B-X
guanine	B-X
nucleotide	B-X
exchange	B-X
factor	B-X
C3G	B-X
,	B-X
which	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
CrkL	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Rac	B-X
activation	B-X
was	B-X
enhanced	B-X
or	B-X
inhibited	B-X
in	B-X
cells	B-X
inducibly	B-X
expressing	B-X
an	B-X
activated	B-X
Ras	B-X
mutant	B-X
,	B-X
H-Ras61L	B-X
,	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
Ras	B-X
mutant	B-X
,	B-X
H-Ras17N	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
cytokine-induced	B-X
Rac	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
a	B-X
phosphatidyl-inositol	B-X
3'-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
,	B-X
which	B-X
also	B-X
inhibited	B-X
the	B-X
Erk	B-X
activation	B-X
.	B-X
A	B-X
dominant	B-X
negative	B-X
Rac	B-X
mutant	B-X
,	B-X
Rac17N	B-X
,	B-X
also	B-X
inhibited	B-X
the	B-X
cytokine-induced	B-X
activation	B-X
of	B-X
Erk	B-X
as	B-X
well	B-X
as	B-X
Elk-1	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
activation	B-X
of	B-X
Akt	B-X
downstream	B-X
of	B-X
PI3K	B-X
was	B-X
found	B-X
to	B-X
play	B-X
an	B-X
inhibitory	B-X
role	B-X
in	B-X
cytokine	B-X
activation	B-X
of	B-X
Erk/Elk-1	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
Rac	B-X
is	B-X
activated	B-X
by	B-X
Epo	B-X
or	B-X
IL-3	B-X
at	B-X
downstream	B-X
of	B-X
the	B-X
Ras/PI3K	B-X
pathway	B-X
in	B-X
parallel	B-X
with	B-X
Akt	B-X
and	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
activation	B-X
of	B-X
the	B-X
Erk/Elk-1	B-X
signaling	B-X
pathway	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Signaling	O
via	O
M1	B-Protein
-	I-Protein
and	O
M3	B-Protein
-	I-Protein
but	O
not	O
M2	B-Protein
-	I-Protein
or	O
M4	B-Protein
-	I-Protein
AchRs	I-Protein
promote	O
accumulation	O
and	O
transcriptional	O
activation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
these	B-X
receptors	B-X
by	B-X
ACh	B-X
or	B-X
other	B-X
muscarinic	B-X
agonists	B-X
leads	B-X
to	B-X
the	B-X
augmentation	B-X
of	B-X
glucose-induced	B-X
insulin	B-X
release	B-X
via	B-X
multiple	B-X
mechanisms	B-X
.	B-X
We	B-X
observed	B-X
in	B-X
patients	B-X
who	B-X
underwent	B-X
weight	B-X
loss	B-X
surgery	B-X
,	B-X
a	B-X
decrease	B-X
in	B-X
hepatic	B-X
expression	B-X
of	B-X
M3	B-X
muscarinic	B-X
receptors	B-X
(	B-X
M3R	B-X
)	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
that	B-X
fat	B-X
loading	B-X
of	B-X
hepatocytes	B-X
,	B-X
increased	B-X
M3R	B-X
expression	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
M3R	B-X
regulate	B-X
hepatocyte	B-X
lipid	B-X
accumulation	B-X
.	B-X
Incubation	B-X
of	B-X
AML12	B-X
hepatocytes	B-X
with	B-X
1	B-X
mM	B-X
oleic	B-X
acid	B-X
resulted	B-X
in	B-X
lipid	B-X
accumulation	B-X
that	B-X
was	B-X
significantly	B-X
reduced	B-X
by	B-X
co-treatment	B-X
with	B-X
a	B-X
muscarinic	B-X
agonist	B-X
(	B-X
pilocarpine	B-X
or	B-X
carbachol	B-X
)	B-X
,	B-X
an	B-X
effect	B-X
blocked	B-X
by	B-X
atropine	B-X
(	B-X
a	B-X
muscarinic	B-X
antagonist	B-X
)	B-X
.	B-X
Compound	B-X
C	B-X
,	B-X
a	B-X
selective	B-X
and	B-X
reversible	B-X
AMPK	B-X
inhibitor	B-X
,	B-X
significantly	B-X
blunted	B-X
pilocarpine-mediated	B-X
reduction	B-X
of	B-X
lipid	B-X
accumulation	B-X
and	B-X
pilocarpine-mediated	B-X
up-regulation	B-X
of	B-X
lipolytic	B-X
genes	B-X
.	B-X
Finally	B-X
,	B-X
M3R	B-X
siRNA	B-X
attenuated	B-X
agonist-induced	B-X
AMPKα	B-X
phosphorylation	B-X
as	B-X
well	B-X
as	B-X
agonist-mediated	B-X
reduction	B-X
of	B-X
hepatocyte	B-X
steatosis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
proof-of-concept	B-X
study	B-X
demonstrates	B-X
that	B-X
M3R	B-X
has	B-X
protective	B-X
effects	B-X
against	B-X
hepatocyte	B-X
lipid	B-X
accumulation	B-X
by	B-X
activating	B-X
AMPK	B-X
pathway	B-X
and	B-X
is	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
non-alcoholic	B-X
fatty	B-X
liver	B-X
disease	B-X
.	B-X

We	O
conclude	O
that	O
muscarinic	O
acetylcholine	O
signals	O
activate	O
HIF	O
-	O
1	O
by	O
both	O
stabilization	O
and	O
synthesis	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
by	O
inducing	O
the	O
transcriptional	O
activity	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
cellular	B-X
adaptive	B-X
responses	B-X
to	B-X
hypoxia	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
increase	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Exposure	B-X
of	B-X
cells	B-X
to	B-X
growth	B-X
factors	B-X
,	B-X
prostaglandin	B-X
,	B-X
and	B-X
certain	B-X
nitric	B-X
oxide	B-X
donors	B-X
also	B-X
induces	B-X
HIF-1alpha	B-X
expression	B-X
under	B-X
non-hypoxic	B-X
conditions	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
muscarinic	B-X
acetylcholine	B-X
signals	B-X
induce	B-X
HIF-1alpha	B-X
expression	B-X
and	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
receptor	B-X
subtype-specific	B-X
manner	B-X
using	B-X
HEK293	B-X
cells	B-X
transiently	B-X
overexpressing	B-X
each	B-X
of	B-X
M1-M4	B-X
muscarinic	B-X
acetylcholine	B-X
receptors	B-X
.	B-X
The	B-X
muscarinic	B-X
signaling	B-X
pathways	B-X
inhibited	B-X
HIF-1alpha	B-X
hydroxylation	B-X
and	B-X
degradation	B-X
and	B-X
induced	B-X
HIF-1alpha	B-X
protein	B-X
synthesis	B-X
that	B-X
was	B-X
confirmed	B-X
by	B-X
pulse	B-X
labeling	B-X
studies	B-X
.	B-X
Muscarinic	B-X
signal-induced	B-X
HIF-1alpha	B-X
protein	B-X
and	B-X
HIF-1-dependent	B-X
gene	B-X
expression	B-X
were	B-X
blocked	B-X
by	B-X
treating	B-X
cells	B-X
with	B-X
inhibitors	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
,	B-X
MAP	B-X
kinase	B-X
kinase	B-X
,	B-X
or	B-X
tyrosine	B-X
kinase	B-X
signaling	B-X
pathways	B-X
.	B-X
Dominant-negative	B-X
forms	B-X
of	B-X
Ras	B-X
and/or	B-X
Rac-1	B-X
significantly	B-X
suppressed	B-X
HIF-1	B-X
activation	B-X
by	B-X
muscarinic	B-X
signaling	B-X
.	B-X
Signaling	B-X
via	B-X
M1-	B-X
and	B-X
M3-	B-X
but	B-X
not	B-X
M2-	B-X
or	B-X
M4-AchRs	B-X
promote	B-X
accumulation	B-X
and	B-X
transcriptional	B-X
activation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
muscarinic	B-X
acetylcholine	B-X
signals	B-X
activate	B-X
HIF-1	B-X
by	B-X
both	B-X
stabilization	B-X
and	B-X
synthesis	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
by	B-X
inducing	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
HIF-1alpha	B-X
.	B-X

Protein	B-Protein
C	I-Protein
inhibitor	I-Protein
as	O
an	O
anti	O
-	O
disseminated	O
intravascular	O
coagulation	O
agent	O
-	O
-	O
mechanism	O
and	O
modification	O
.	O
<EOS>	B-X
Gram-negative	B-X
sepsis	B-X
is	B-X
associated	B-X
with	B-X
disseminated	B-X
intravascular	B-X
coagulation	B-X
(	B-X
DIC	B-X
)	B-X
due	B-X
to	B-X
endothelial	B-X
damage	B-X
,	B-X
which	B-X
is	B-X
induced	B-X
by	B-X
inflammatory	B-X
mediators	B-X
released	B-X
from	B-X
phagocytes	B-X
activated	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
DIC	B-X
is	B-X
a	B-X
systemic	B-X
hemorrhagic	B-X
syndrome	B-X
,	B-X
which	B-X
results	B-X
from	B-X
the	B-X
consumption	B-X
of	B-X
coagulation	B-X
factors	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
multiple	B-X
thrombi	B-X
in	B-X
the	B-X
systemic	B-X
microvessels	B-X
;	B-X
it	B-X
is	B-X
associated	B-X
with	B-X
multiple	B-X
organ	B-X
failure	B-X
.	B-X
Therefore	B-X
,	B-X
not	B-X
only	B-X
the	B-X
systemic	B-X
activation	B-X
of	B-X
coagulation	B-X
but	B-X
also	B-X
the	B-X
inflammatory	B-X
response	B-X
has	B-X
been	B-X
perceived	B-X
as	B-X
the	B-X
therapeutic	B-X
target	B-X
for	B-X
DIC	B-X
in	B-X
sepsis	B-X
.	B-X
We	B-X
gave	B-X
attention	B-X
that	B-X
protein	B-X
C	B-X
inhibitor	B-X
(	B-X
PCI	B-X
)	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
both	B-X
plasma	B-X
kallikrein	B-X
and	B-X
thrombin	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
act	B-X
not	B-X
only	B-X
as	B-X
procoagulant	B-X
proteases	B-X
but	B-X
also	B-X
as	B-X
chemotactic	B-X
factors	B-X
toward	B-X
phagocytes	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
PCI	B-X
possibly	B-X
acts	B-X
as	B-X
an	B-X
anti-DIC	B-X
agent	B-X
rather	B-X
than	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
protein	B-X
C	B-X
anticoagulant	B-X
pathway	B-X
under	B-X
the	B-X
pathophysiology	B-X
of	B-X
DIC	B-X
,	B-X
accompanied	B-X
by	B-X
the	B-X
decrease	B-X
in	B-X
the	B-X
thrombomodulin	B-X
expression	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
Our	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
PCI	B-X
purified	B-X
from	B-X
human	B-X
urine	B-X
(	B-X
uPCI	B-X
)	B-X
improves	B-X
the	B-X
pathophysiology	B-X
of	B-X
DIC	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
activities	B-X
of	B-X
plasma	B-X
kallikrein	B-X
and	B-X
thrombin	B-X
,	B-X
and	B-X
the	B-X
activities	B-X
of	B-X
PCI	B-X
are	B-X
regulated	B-X
by	B-X
N-glycans	B-X
.	B-X
This	B-X
review	B-X
introduces	B-X
the	B-X
anti-DIC	B-X
action	B-X
of	B-X
PCI	B-X
and	B-X
about	B-X
the	B-X
modification	B-X
of	B-X
N-glycosylation	B-X
site	B-X
(	B-X
s	B-X
)	B-X
of	B-X
PCI	B-X
to	B-X
heighten	B-X
the	B-X
value	B-X
of	B-X
PCI	B-X
as	B-X
an	B-X
anti-DIC	B-X
agent	B-X
.	B-X

Gram	O
-	O
negative	O
sepsis	O
is	O
associated	O
with	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	O
)	O
due	O
to	O
endothelial	O
damage	O
,	O
which	O
is	O
induced	O
by	O
inflammatory	O
mediators	O
released	O
from	O
phagocytes	O
activated	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
<EOS>	B-X
Gram-negative	B-X
sepsis	B-X
is	B-X
associated	B-X
with	B-X
disseminated	B-X
intravascular	B-X
coagulation	B-X
(	B-X
DIC	B-X
)	B-X
due	B-X
to	B-X
endothelial	B-X
damage	B-X
,	B-X
which	B-X
is	B-X
induced	B-X
by	B-X
inflammatory	B-X
mediators	B-X
released	B-X
from	B-X
phagocytes	B-X
activated	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
DIC	B-X
is	B-X
a	B-X
systemic	B-X
hemorrhagic	B-X
syndrome	B-X
,	B-X
which	B-X
results	B-X
from	B-X
the	B-X
consumption	B-X
of	B-X
coagulation	B-X
factors	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
multiple	B-X
thrombi	B-X
in	B-X
the	B-X
systemic	B-X
microvessels	B-X
;	B-X
it	B-X
is	B-X
associated	B-X
with	B-X
multiple	B-X
organ	B-X
failure	B-X
.	B-X
Therefore	B-X
,	B-X
not	B-X
only	B-X
the	B-X
systemic	B-X
activation	B-X
of	B-X
coagulation	B-X
but	B-X
also	B-X
the	B-X
inflammatory	B-X
response	B-X
has	B-X
been	B-X
perceived	B-X
as	B-X
the	B-X
therapeutic	B-X
target	B-X
for	B-X
DIC	B-X
in	B-X
sepsis	B-X
.	B-X
We	B-X
gave	B-X
attention	B-X
that	B-X
protein	B-X
C	B-X
inhibitor	B-X
(	B-X
PCI	B-X
)	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
both	B-X
plasma	B-X
kallikrein	B-X
and	B-X
thrombin	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
act	B-X
not	B-X
only	B-X
as	B-X
procoagulant	B-X
proteases	B-X
but	B-X
also	B-X
as	B-X
chemotactic	B-X
factors	B-X
toward	B-X
phagocytes	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
PCI	B-X
possibly	B-X
acts	B-X
as	B-X
an	B-X
anti-DIC	B-X
agent	B-X
rather	B-X
than	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
protein	B-X
C	B-X
anticoagulant	B-X
pathway	B-X
under	B-X
the	B-X
pathophysiology	B-X
of	B-X
DIC	B-X
,	B-X
accompanied	B-X
by	B-X
the	B-X
decrease	B-X
in	B-X
the	B-X
thrombomodulin	B-X
expression	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
Our	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
PCI	B-X
purified	B-X
from	B-X
human	B-X
urine	B-X
(	B-X
uPCI	B-X
)	B-X
improves	B-X
the	B-X
pathophysiology	B-X
of	B-X
DIC	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
activities	B-X
of	B-X
plasma	B-X
kallikrein	B-X
and	B-X
thrombin	B-X
,	B-X
and	B-X
the	B-X
activities	B-X
of	B-X
PCI	B-X
are	B-X
regulated	B-X
by	B-X
N-glycans	B-X
.	B-X
This	B-X
review	B-X
introduces	B-X
the	B-X
anti-DIC	B-X
action	B-X
of	B-X
PCI	B-X
and	B-X
about	B-X
the	B-X
modification	B-X
of	B-X
N-glycosylation	B-X
site	B-X
(	B-X
s	B-X
)	B-X
of	B-X
PCI	B-X
to	B-X
heighten	B-X
the	B-X
value	B-X
of	B-X
PCI	B-X
as	B-X
an	B-X
anti-DIC	B-X
agent	B-X
.	B-X

DIC	O
is	O
a	O
systemic	O
hemorrhagic	O
syndrome	O
,	O
which	O
results	O
from	O
the	O
consumption	O
of	O
coagulation	O
factors	O
for	O
the	O
formation	O
of	O
multiple	O
thrombi	O
in	O
the	O
systemic	O
microvessels	O
;	O
it	O
is	O
associated	O
with	O
multiple	O
organ	O
failure	O
.	O
<EOS>	B-X
Gram-negative	B-X
sepsis	B-X
is	B-X
associated	B-X
with	B-X
disseminated	B-X
intravascular	B-X
coagulation	B-X
(	B-X
DIC	B-X
)	B-X
due	B-X
to	B-X
endothelial	B-X
damage	B-X
,	B-X
which	B-X
is	B-X
induced	B-X
by	B-X
inflammatory	B-X
mediators	B-X
released	B-X
from	B-X
phagocytes	B-X
activated	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
DIC	B-X
is	B-X
a	B-X
systemic	B-X
hemorrhagic	B-X
syndrome	B-X
,	B-X
which	B-X
results	B-X
from	B-X
the	B-X
consumption	B-X
of	B-X
coagulation	B-X
factors	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
multiple	B-X
thrombi	B-X
in	B-X
the	B-X
systemic	B-X
microvessels	B-X
;	B-X
it	B-X
is	B-X
associated	B-X
with	B-X
multiple	B-X
organ	B-X
failure	B-X
.	B-X
Therefore	B-X
,	B-X
not	B-X
only	B-X
the	B-X
systemic	B-X
activation	B-X
of	B-X
coagulation	B-X
but	B-X
also	B-X
the	B-X
inflammatory	B-X
response	B-X
has	B-X
been	B-X
perceived	B-X
as	B-X
the	B-X
therapeutic	B-X
target	B-X
for	B-X
DIC	B-X
in	B-X
sepsis	B-X
.	B-X
We	B-X
gave	B-X
attention	B-X
that	B-X
protein	B-X
C	B-X
inhibitor	B-X
(	B-X
PCI	B-X
)	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
both	B-X
plasma	B-X
kallikrein	B-X
and	B-X
thrombin	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
act	B-X
not	B-X
only	B-X
as	B-X
procoagulant	B-X
proteases	B-X
but	B-X
also	B-X
as	B-X
chemotactic	B-X
factors	B-X
toward	B-X
phagocytes	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
PCI	B-X
possibly	B-X
acts	B-X
as	B-X
an	B-X
anti-DIC	B-X
agent	B-X
rather	B-X
than	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
protein	B-X
C	B-X
anticoagulant	B-X
pathway	B-X
under	B-X
the	B-X
pathophysiology	B-X
of	B-X
DIC	B-X
,	B-X
accompanied	B-X
by	B-X
the	B-X
decrease	B-X
in	B-X
the	B-X
thrombomodulin	B-X
expression	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
Our	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
PCI	B-X
purified	B-X
from	B-X
human	B-X
urine	B-X
(	B-X
uPCI	B-X
)	B-X
improves	B-X
the	B-X
pathophysiology	B-X
of	B-X
DIC	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
activities	B-X
of	B-X
plasma	B-X
kallikrein	B-X
and	B-X
thrombin	B-X
,	B-X
and	B-X
the	B-X
activities	B-X
of	B-X
PCI	B-X
are	B-X
regulated	B-X
by	B-X
N-glycans	B-X
.	B-X
This	B-X
review	B-X
introduces	B-X
the	B-X
anti-DIC	B-X
action	B-X
of	B-X
PCI	B-X
and	B-X
about	B-X
the	B-X
modification	B-X
of	B-X
N-glycosylation	B-X
site	B-X
(	B-X
s	B-X
)	B-X
of	B-X
PCI	B-X
to	B-X
heighten	B-X
the	B-X
value	B-X
of	B-X
PCI	B-X
as	B-X
an	B-X
anti-DIC	B-X
agent	B-X
.	B-X

Therefore	O
,	O
not	O
only	O
the	O
systemic	O
activation	O
of	O
coagulation	O
but	O
also	O
the	O
inflammatory	O
response	O
has	O
been	O
perceived	O
as	O
the	O
therapeutic	O
target	O
for	O
DIC	O
in	O
sepsis	O
.	O

We	O
gave	O
attention	O
that	O
protein	B-Protein
C	I-Protein
inhibitor	I-Protein
(	O
PCI	B-Protein
)	O
acts	O
as	O
an	O
inhibitor	O
of	O
both	O
plasma	O
kallikrein	O
and	O
thrombin	B-Protein
,	O
which	O
are	O
known	O
to	O
act	O
not	O
only	O
as	O
procoagulant	O
proteases	O
but	O
also	O
as	O
chemotactic	O
factors	O
toward	O
phagocytes	O
.	O

Then	O
,	O
we	O
hypothesized	O
that	O
PCI	B-Protein
possibly	O
acts	O
as	O
an	O
anti	O
-	O
DIC	O
agent	O
rather	O
than	O
an	O
inhibitor	O
of	O
the	O
protein	B-Protein
C	I-Protein
anticoagulant	O
pathway	O
under	O
the	O
pathophysiology	O
of	O
DIC	O
,	O
accompanied	O
by	O
the	O
decrease	O
in	O
the	O
thrombomodulin	B-Protein
expression	O
on	O
endothelial	O
cells	O
.	O
<EOS>	B-X
Gram-negative	B-X
sepsis	B-X
is	B-X
associated	B-X
with	B-X
disseminated	B-X
intravascular	B-X
coagulation	B-X
(	B-X
DIC	B-X
)	B-X
due	B-X
to	B-X
endothelial	B-X
damage	B-X
,	B-X
which	B-X
is	B-X
induced	B-X
by	B-X
inflammatory	B-X
mediators	B-X
released	B-X
from	B-X
phagocytes	B-X
activated	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
DIC	B-X
is	B-X
a	B-X
systemic	B-X
hemorrhagic	B-X
syndrome	B-X
,	B-X
which	B-X
results	B-X
from	B-X
the	B-X
consumption	B-X
of	B-X
coagulation	B-X
factors	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
multiple	B-X
thrombi	B-X
in	B-X
the	B-X
systemic	B-X
microvessels	B-X
;	B-X
it	B-X
is	B-X
associated	B-X
with	B-X
multiple	B-X
organ	B-X
failure	B-X
.	B-X
Therefore	B-X
,	B-X
not	B-X
only	B-X
the	B-X
systemic	B-X
activation	B-X
of	B-X
coagulation	B-X
but	B-X
also	B-X
the	B-X
inflammatory	B-X
response	B-X
has	B-X
been	B-X
perceived	B-X
as	B-X
the	B-X
therapeutic	B-X
target	B-X
for	B-X
DIC	B-X
in	B-X
sepsis	B-X
.	B-X
We	B-X
gave	B-X
attention	B-X
that	B-X
protein	B-X
C	B-X
inhibitor	B-X
(	B-X
PCI	B-X
)	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
both	B-X
plasma	B-X
kallikrein	B-X
and	B-X
thrombin	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
act	B-X
not	B-X
only	B-X
as	B-X
procoagulant	B-X
proteases	B-X
but	B-X
also	B-X
as	B-X
chemotactic	B-X
factors	B-X
toward	B-X
phagocytes	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
PCI	B-X
possibly	B-X
acts	B-X
as	B-X
an	B-X
anti-DIC	B-X
agent	B-X
rather	B-X
than	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
protein	B-X
C	B-X
anticoagulant	B-X
pathway	B-X
under	B-X
the	B-X
pathophysiology	B-X
of	B-X
DIC	B-X
,	B-X
accompanied	B-X
by	B-X
the	B-X
decrease	B-X
in	B-X
the	B-X
thrombomodulin	B-X
expression	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
Our	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
PCI	B-X
purified	B-X
from	B-X
human	B-X
urine	B-X
(	B-X
uPCI	B-X
)	B-X
improves	B-X
the	B-X
pathophysiology	B-X
of	B-X
DIC	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
activities	B-X
of	B-X
plasma	B-X
kallikrein	B-X
and	B-X
thrombin	B-X
,	B-X
and	B-X
the	B-X
activities	B-X
of	B-X
PCI	B-X
are	B-X
regulated	B-X
by	B-X
N-glycans	B-X
.	B-X
This	B-X
review	B-X
introduces	B-X
the	B-X
anti-DIC	B-X
action	B-X
of	B-X
PCI	B-X
and	B-X
about	B-X
the	B-X
modification	B-X
of	B-X
N-glycosylation	B-X
site	B-X
(	B-X
s	B-X
)	B-X
of	B-X
PCI	B-X
to	B-X
heighten	B-X
the	B-X
value	B-X
of	B-X
PCI	B-X
as	B-X
an	B-X
anti-DIC	B-X
agent	B-X
.	B-X

Our	O
studies	O
have	O
suggested	O
that	O
PCI	B-Protein
purified	O
from	O
human	O
urine	O
(	O
uPCI	B-Protein
)	O
improves	O
the	O
pathophysiology	O
of	O
DIC	O
through	O
the	O
inhibition	O
of	O
activities	O
of	O
plasma	O
kallikrein	O
and	O
thrombin	B-Protein
,	O
and	O
the	O
activities	O
of	O
PCI	B-Protein
are	O
regulated	O
by	O
N	O
-	O
glycans	O
.	O

This	O
review	O
introduces	O
the	O
anti	O
-	O
DIC	O
action	O
of	O
PCI	B-Protein
and	O
about	O
the	O
modification	O
of	O
N	O
-	O
glycosylation	O
site	O
(	O
s	O
)	O
of	O
PCI	B-Protein
to	O
heighten	O
the	O
value	O
of	O
PCI	B-Protein
as	O
an	O
anti	O
-	O
DIC	O
agent	O
.	O

In	O
vitro	O
effects	O
of	O
high	O
glucose	O
concentrations	O
on	O
membrane	O
protein	O
oxidation	O
,	O
G	O
-	O
actin	O
and	O
deformability	O
of	O
human	O
erythrocytes	O
.	O
<EOS>	B-X
The	B-X
object	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
elevated	B-X
in	B-X
vitro	B-X
glucose	B-X
concentrations	B-X
on	B-X
protein	B-X
modification	B-X
and	B-X
functional	B-X
changes	B-X
in	B-X
human	B-X
erythrocytes	B-X
.	B-X
Groups	B-X
were	B-X
exposed	B-X
to	B-X
5-45	B-X
mM	B-X
glucose	B-X
concentrations	B-X
.	B-X
In	B-X
erythrocyte	B-X
ghosts	B-X
,	B-X
protein	B-X
glycation	B-X
and	B-X
oxidation	B-X
were	B-X
evaluated	B-X
using	B-X
spectrophotometric	B-X
methods	B-X
.	B-X
G-actin	B-X
was	B-X
measured	B-X
by	B-X
a	B-X
DNase	B-X
I	B-X
inhibition	B-X
assay	B-X
in	B-X
cell	B-X
lysates	B-X
.	B-X
Erythrocyte	B-X
deformability	B-X
was	B-X
assessed	B-X
using	B-X
a	B-X
cell	B-X
transit	B-X
analyser	B-X
.	B-X
At	B-X
24	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
protein	B-X
oxidation	B-X
(	B-X
at	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
increase	B-X
was	B-X
observed	B-X
for	B-X
all	B-X
concentrations	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
At	B-X
48	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
glycation	B-X
(	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
protein	B-X
oxidation	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
groups	B-X
.	B-X
A	B-X
significant	B-X
positive	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
glucose	B-X
/protein	B-X
oxidation	B-X
,	B-X
glucose/G-actin	B-X
and	B-X
protein	B-X
oxidation/G-actin	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
the	B-X
oxidative	B-X
effect	B-X
of	B-X
glucose	B-X
on	B-X
erythrocytes	B-X
depends	B-X
on	B-X
concentration	B-X
and	B-X
incubation	B-X
time	B-X
.	B-X
We	B-X
also	B-X
present	B-X
the	B-X
first	B-X
evidence	B-X
of	B-X
increased	B-X
G-actin	B-X
in	B-X
human	B-X
erythrocytes	B-X
exposed	B-X
to	B-X
high	B-X
glucose	B-X
concentrations	B-X
as	B-X
a	B-X
diabetes	B-X
model	B-X
.	B-X

The	O
object	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
elevated	O
in	O
vitro	O
glucose	O
concentrations	O
on	O
protein	O
modification	O
and	O
functional	O
changes	O
in	O
human	O
erythrocytes	O
.	O
<EOS>	B-X
The	B-X
object	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
elevated	B-X
in	B-X
vitro	B-X
glucose	B-X
concentrations	B-X
on	B-X
protein	B-X
modification	B-X
and	B-X
functional	B-X
changes	B-X
in	B-X
human	B-X
erythrocytes	B-X
.	B-X
Groups	B-X
were	B-X
exposed	B-X
to	B-X
5-45	B-X
mM	B-X
glucose	B-X
concentrations	B-X
.	B-X
The	B-X
time	B-X
effect	B-X
of	B-X
any	B-X
changes	B-X
was	B-X
also	B-X
evaluated	B-X
.	B-X
In	B-X
erythrocyte	B-X
ghosts	B-X
,	B-X
protein	B-X
glycation	B-X
and	B-X
oxidation	B-X
were	B-X
evaluated	B-X
using	B-X
spectrophotometric	B-X
methods	B-X
.	B-X
At	B-X
24	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
protein	B-X
oxidation	B-X
(	B-X
at	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
increase	B-X
was	B-X
observed	B-X
for	B-X
all	B-X
concentrations	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
At	B-X
48	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
glycation	B-X
(	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
protein	B-X
oxidation	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
groups	B-X
.	B-X
A	B-X
significant	B-X
positive	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
glucose	B-X
/protein	B-X
oxidation	B-X
,	B-X
glucose/G-actin	B-X
and	B-X
protein	B-X
oxidation/G-actin	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
the	B-X
oxidative	B-X
effect	B-X
of	B-X
glucose	B-X
on	B-X
erythrocytes	B-X
depends	B-X
on	B-X
concentration	B-X
and	B-X
incubation	B-X
time	B-X
.	B-X
We	B-X
also	B-X
present	B-X
the	B-X
first	B-X
evidence	B-X
of	B-X
increased	B-X
G-actin	B-X
in	B-X
human	B-X
erythrocytes	B-X
exposed	B-X
to	B-X
high	B-X
glucose	B-X
concentrations	B-X
as	B-X
a	B-X
diabetes	B-X
model	B-X
.	B-X

Groups	O
were	O
exposed	O
to	O
5	O
-	O
45	O
mM	O
glucose	O
concentrations	O
.	O
<EOS>	B-X
The	B-X
physiological	B-X
and	B-X
behavioral	B-X
responses	B-X
of	B-X
Pomacea	B-X
canaliculata	B-X
exposed	B-X
to	B-X
different	B-X
pH	B-X
values	B-X
(	B-X
4	B-X
,	B-X
5	B-X
,	B-X
6	B-X
,	B-X
7	B-X
,	B-X
8	B-X
,	B-X
9	B-X
,	B-X
and	B-X
10	B-X
)	B-X
were	B-X
evaluated	B-X
.	B-X
Chronic	B-X
exposure	B-X
to	B-X
intermittent	B-X
hypoxia	B-X
commonly	B-X
induces	B-X
the	B-X
activation	B-X
of	B-X
sympathetic	B-X
tonus	B-X
and	B-X
the	B-X
disruption	B-X
of	B-X
glucose	B-X
homoeostasis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
exposure	B-X
to	B-X
acute	B-X
intermittent	B-X
hypoxia	B-X
(	B-X
AIH	B-X
)	B-X
on	B-X
glucose	B-X
homoeostasis	B-X
are	B-X
not	B-X
yet	B-X
fully	B-X
elucidated	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
evaluated	B-X
parameters	B-X
related	B-X
to	B-X
glucose	B-X
metabolism	B-X
in	B-X
rats	B-X
exposed	B-X
to	B-X
AIH	B-X
.	B-X

The	O
time	O
effect	O
of	O
any	O
changes	O
was	O
also	O
evaluated	O
.	O
<EOS>	B-X
Many	B-X
people	B-X
use	B-X
behavioural	B-X
interventions	B-X
to	B-X
help	B-X
them	B-X
quit	B-X
smoking	B-X
;	B-X
these	B-X
interventions	B-X
can	B-X
vary	B-X
substantially	B-X
in	B-X
their	B-X
content	B-X
and	B-X
effectiveness	B-X
.	B-X
Among	B-X
lung	B-X
cancers	B-X
,	B-X
a	B-X
substantial	B-X
shift	B-X
over	B-X
time	B-X
has	B-X
occurred	B-X
in	B-X
the	B-X
recorded	B-X
frequency	B-X
of	B-X
adenocarcinoma	B-X
(	B-X
AdC	B-X
)	B-X
relative	B-X
to	B-X
that	B-X
of	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SqCC	B-X
)	B-X
.	B-X
This	B-X
is	B-X
evident	B-X
in	B-X
many	B-X
countries	B-X
,	B-X
and	B-X
also	B-X
in	B-X
those	B-X
who	B-X
have	B-X
never	B-X
smoked	B-X
.	B-X
We	B-X
also	B-X
describe	B-X
changes	B-X
to	B-X
classifications	B-X
,	B-X
and	B-X
factors	B-X
affecting	B-X
diagnostic	B-X
accuracy	B-X
and	B-X
consistency	B-X
.	B-X
The	B-X
rising	B-X
AdC/SqCC	B-X
ratio	B-X
results	B-X
at	B-X
least	B-X
partly	B-X
from	B-X
diagnostic	B-X
changes	B-X
.	B-X

In	O
erythrocyte	O
ghosts	O
,	O
protein	O
glycation	O
and	O
oxidation	O
were	O
evaluated	O
using	O
spectrophotometric	O
methods	O
.	O
<EOS>	B-X
The	B-X
object	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
elevated	B-X
in	B-X
vitro	B-X
glucose	B-X
concentrations	B-X
on	B-X
protein	B-X
modification	B-X
and	B-X
functional	B-X
changes	B-X
in	B-X
human	B-X
erythrocytes	B-X
.	B-X
The	B-X
time	B-X
effect	B-X
of	B-X
any	B-X
changes	B-X
was	B-X
also	B-X
evaluated	B-X
.	B-X
In	B-X
erythrocyte	B-X
ghosts	B-X
,	B-X
protein	B-X
glycation	B-X
and	B-X
oxidation	B-X
were	B-X
evaluated	B-X
using	B-X
spectrophotometric	B-X
methods	B-X
.	B-X
Erythrocyte	B-X
deformability	B-X
was	B-X
assessed	B-X
using	B-X
a	B-X
cell	B-X
transit	B-X
analyser	B-X
.	B-X
At	B-X
24	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
protein	B-X
oxidation	B-X
(	B-X
at	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
increase	B-X
was	B-X
observed	B-X
for	B-X
all	B-X
concentrations	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
At	B-X
48	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
glycation	B-X
(	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
protein	B-X
oxidation	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
groups	B-X
.	B-X
A	B-X
significant	B-X
positive	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
glucose	B-X
/protein	B-X
oxidation	B-X
,	B-X
glucose/G-actin	B-X
and	B-X
protein	B-X
oxidation/G-actin	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
the	B-X
oxidative	B-X
effect	B-X
of	B-X
glucose	B-X
on	B-X
erythrocytes	B-X
depends	B-X
on	B-X
concentration	B-X
and	B-X
incubation	B-X
time	B-X
.	B-X
We	B-X
also	B-X
present	B-X
the	B-X
first	B-X
evidence	B-X
of	B-X
increased	B-X
G-actin	B-X
in	B-X
human	B-X
erythrocytes	B-X
exposed	B-X
to	B-X
high	B-X
glucose	B-X
concentrations	B-X
as	B-X
a	B-X
diabetes	B-X
model	B-X
.	B-X

G	O
-	O
actin	O
was	O
measured	O
by	O
a	O
DNase	B-Protein
I	I-Protein
inhibition	O
assay	O
in	O
cell	O
lysates	O
.	O
<EOS>	B-X
Groups	B-X
were	B-X
exposed	B-X
to	B-X
5-45	B-X
mM	B-X
glucose	B-X
concentrations	B-X
.	B-X
G-actin	B-X
was	B-X
measured	B-X
by	B-X
a	B-X
DNase	B-X
I	B-X
inhibition	B-X
assay	B-X
in	B-X
cell	B-X
lysates	B-X
.	B-X
Erythrocyte	B-X
deformability	B-X
was	B-X
assessed	B-X
using	B-X
a	B-X
cell	B-X
transit	B-X
analyser	B-X
.	B-X
At	B-X
24	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
protein	B-X
oxidation	B-X
(	B-X
at	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
increase	B-X
was	B-X
observed	B-X
for	B-X
all	B-X
concentrations	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
At	B-X
48	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
glycation	B-X
(	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
protein	B-X
oxidation	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
groups	B-X
.	B-X
A	B-X
significant	B-X
positive	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
glucose	B-X
/protein	B-X
oxidation	B-X
,	B-X
glucose/G-actin	B-X
and	B-X
protein	B-X
oxidation/G-actin	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
the	B-X
oxidative	B-X
effect	B-X
of	B-X
glucose	B-X
on	B-X
erythrocytes	B-X
depends	B-X
on	B-X
concentration	B-X
and	B-X
incubation	B-X
time	B-X
.	B-X
We	B-X
also	B-X
present	B-X
the	B-X
first	B-X
evidence	B-X
of	B-X
increased	B-X
G-actin	B-X
in	B-X
human	B-X
erythrocytes	B-X
exposed	B-X
to	B-X
high	B-X
glucose	B-X
concentrations	B-X
as	B-X
a	B-X
diabetes	B-X
model	B-X
.	B-X

Erythrocyte	O
deformability	O
was	O
assessed	O
using	O
a	O
cell	O
transit	O
analyser	O
.	O
<EOS>	B-X
Cell	B-X
transit	B-X
time	B-X
analysis	B-X
(	B-X
CTTA	B-X
)	B-X
is	B-X
a	B-X
new	B-X
filtrometric	B-X
technique	B-X
for	B-X
assessing	B-X
red	B-X
blood	B-X
cell	B-X
deformability	B-X
by	B-X
measuring	B-X
the	B-X
conductivity	B-X
change	B-X
caused	B-X
by	B-X
passage	B-X
of	B-X
erythrocytes	B-X
through	B-X
a	B-X
polycarbonate	B-X
filter	B-X
.	B-X
Most	B-X
reported	B-X
studies	B-X
to	B-X
date	B-X
using	B-X
CTTA	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
transit	B-X
time	B-X
(	B-X
TT	B-X
)	B-X
,	B-X
the	B-X
duration	B-X
of	B-X
passage	B-X
of	B-X
an	B-X
individual	B-X
red	B-X
cell	B-X
through	B-X
a	B-X
micropore	B-X
.	B-X
Therefore	B-X
,	B-X
valid	B-X
measures	B-X
of	B-X
the	B-X
number	B-X
of	B-X
red	B-X
cell	B-X
transits	B-X
per	B-X
unit	B-X
time	B-X
(	B-X
counts/s	B-X
:	B-X
C/S	B-X
)	B-X
can	B-X
now	B-X
be	B-X
obtained	B-X
.	B-X
We	B-X
evaluated	B-X
both	B-X
parameters	B-X
,	B-X
TT	B-X
and	B-X
C/S	B-X
,	B-X
as	B-X
indicators	B-X
of	B-X
red	B-X
cell	B-X
filterability	B-X
.	B-X
Our	B-X
goal	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
metabolic	B-X
changes	B-X
shown	B-X
by	B-X
alternative	B-X
techniques	B-X
to	B-X
affect	B-X
red	B-X
cell	B-X
deformability	B-X
.	B-X
The	B-X
two	B-X
best	B-X
established	B-X
factors	B-X
are	B-X
changes	B-X
in	B-X
intracellular	B-X
[	B-X
ATP	B-X
]	B-X
and	B-X
[	B-X
Ca2+	B-X
]	B-X
.	B-X
The	B-X
substantial	B-X
changes	B-X
in	B-X
intracellular	B-X
calcium	B-X
induced	B-X
by	B-X
the	B-X
ionophore	B-X
A23187	B-X
result	B-X
in	B-X
a	B-X
curvilinear	B-X
pattern	B-X
of	B-X
increase	B-X
in	B-X
transit	B-X
times	B-X
and	B-X
reduction	B-X
in	B-X
counts	B-X
per	B-X
s.	B-X
Lanthanum	B-X
,	B-X
which	B-X
inhibits	B-X
egress	B-X
of	B-X
intracellular	B-X
calcium	B-X
,	B-X
causes	B-X
an	B-X
increase	B-X
in	B-X
TT	B-X
with	B-X
a	B-X
drop	B-X
in	B-X
C/S	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CTTA	B-X
demonstrates	B-X
the	B-X
same	B-X
changes	B-X
in	B-X
red	B-X
cell	B-X
deformability	B-X
measurable	B-X
by	B-X
alternative	B-X
filtrometric	B-X
techniques	B-X
;	B-X
however	B-X
,	B-X
CTTA	B-X
furnishes	B-X
two	B-X
separate	B-X
and	B-X
independent	B-X
parameters	B-X
which	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
red	B-X
cell	B-X
deformability	B-X
.	B-X

At	O
24	O
h	O
,	O
a	O
significant	O
protein	O
oxidation	O
(	O
at	O
25	O
and	O
45	O
mM	O
glucose	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
G	O
-	O
actin	O
increase	O
was	O
observed	O
for	O
all	O
concentrations	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
48	O
h	O
,	O
a	O
significant	O
increase	O
in	O
glycation	O
(	O
25	O
and	O
45	O
mM	O
glucose	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
protein	O
oxidation	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
G	O
-	O
actin	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
was	O
observed	O
in	O
all	O
groups	O
.	O

A	O
significant	O
positive	O
correlation	O
was	O
observed	O
between	O
glucose	O
/	O
protein	O
oxidation	O
,	O
glucose	O
/	O
G	O
-	O
actin	O
and	O
protein	O
oxidation	O
/	O
G	O
-	O
actin	O
at	O
24	O
and	O
48	O
h	O
.	O
<EOS>	B-X
The	B-X
object	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
elevated	B-X
in	B-X
vitro	B-X
glucose	B-X
concentrations	B-X
on	B-X
protein	B-X
modification	B-X
and	B-X
functional	B-X
changes	B-X
in	B-X
human	B-X
erythrocytes	B-X
.	B-X
Groups	B-X
were	B-X
exposed	B-X
to	B-X
5-45	B-X
mM	B-X
glucose	B-X
concentrations	B-X
.	B-X
The	B-X
time	B-X
effect	B-X
of	B-X
any	B-X
changes	B-X
was	B-X
also	B-X
evaluated	B-X
.	B-X
In	B-X
erythrocyte	B-X
ghosts	B-X
,	B-X
protein	B-X
glycation	B-X
and	B-X
oxidation	B-X
were	B-X
evaluated	B-X
using	B-X
spectrophotometric	B-X
methods	B-X
.	B-X
G-actin	B-X
was	B-X
measured	B-X
by	B-X
a	B-X
DNase	B-X
I	B-X
inhibition	B-X
assay	B-X
in	B-X
cell	B-X
lysates	B-X
.	B-X
Erythrocyte	B-X
deformability	B-X
was	B-X
assessed	B-X
using	B-X
a	B-X
cell	B-X
transit	B-X
analyser	B-X
.	B-X
At	B-X
24	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
protein	B-X
oxidation	B-X
(	B-X
at	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
increase	B-X
was	B-X
observed	B-X
for	B-X
all	B-X
concentrations	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
At	B-X
48	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
glycation	B-X
(	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
protein	B-X
oxidation	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
groups	B-X
.	B-X
A	B-X
significant	B-X
positive	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
glucose	B-X
/protein	B-X
oxidation	B-X
,	B-X
glucose/G-actin	B-X
and	B-X
protein	B-X
oxidation/G-actin	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
the	B-X
oxidative	B-X
effect	B-X
of	B-X
glucose	B-X
on	B-X
erythrocytes	B-X
depends	B-X
on	B-X
concentration	B-X
and	B-X
incubation	B-X
time	B-X
.	B-X
We	B-X
also	B-X
present	B-X
the	B-X
first	B-X
evidence	B-X
of	B-X
increased	B-X
G-actin	B-X
in	B-X
human	B-X
erythrocytes	B-X
exposed	B-X
to	B-X
high	B-X
glucose	B-X
concentrations	B-X
as	B-X
a	B-X
diabetes	B-X
model	B-X
.	B-X

Our	O
findings	O
show	O
that	O
the	O
oxidative	O
effect	O
of	O
glucose	O
on	O
erythrocytes	O
depends	O
on	O
concentration	O
and	O
incubation	O
time	O
.	O
<EOS>	B-X
Glucose-rich	B-X
plasma	B-X
is	B-X
commonly	B-X
observed	B-X
in	B-X
diabetes	B-X
mellitus	B-X
and	B-X
in-vitro	B-X
incubation	B-X
of	B-X
erythrocytes	B-X
in	B-X
glucose-rich	B-X
media	B-X
may	B-X
produce	B-X
the	B-X
non-enzymatic	B-X
glycosylation	B-X
of	B-X
erythrocyte	B-X
proteins	B-X
.	B-X
The	B-X
present	B-X
study	B-X
investigates	B-X
the	B-X
effects	B-X
of	B-X
an	B-X
increased	B-X
concentration	B-X
of	B-X
glucose	B-X
in	B-X
a	B-X
suspending	B-X
medium	B-X
on	B-X
erythrocyte	B-X
rheological	B-X
parameters	B-X
.	B-X
Erythrocytes	B-X
,	B-X
which	B-X
were	B-X
obtained	B-X
from	B-X
ten	B-X
healthy	B-X
volunteers	B-X
,	B-X
were	B-X
washed	B-X
and	B-X
incubated	B-X
in	B-X
vitro	B-X
with	B-X
glucose	B-X
solutions	B-X
at	B-X
different	B-X
concentrations	B-X
and	B-X
incubation	B-X
times	B-X
.	B-X
The	B-X
measured	B-X
hemorheological	B-X
parameters	B-X
included	B-X
deformability	B-X
and	B-X
the	B-X
aggregation	B-X
of	B-X
erythrocytes	B-X
.	B-X
Hemoglobin	B-X
concentration	B-X
in	B-X
the	B-X
erythrocyte	B-X
suspension	B-X
in	B-X
autologous	B-X
plasma	B-X
was	B-X
also	B-X
measured	B-X
after	B-X
incubation	B-X
in	B-X
order	B-X
to	B-X
assess	B-X
the	B-X
hemolysis	B-X
of	B-X
erythrocytes	B-X
.	B-X
Significant	B-X
hemorheological	B-X
changes	B-X
were	B-X
observed	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
glucose	B-X
concentration	B-X
and	B-X
incubating	B-X
time	B-X
.	B-X
Both	B-X
deformability	B-X
and	B-X
the	B-X
aggregation	B-X
of	B-X
erythrocytes	B-X
decreased	B-X
in	B-X
dose-	B-X
and	B-X
time-dependent	B-X
manner	B-X
.	B-X
A	B-X
reduction	B-X
in	B-X
hemoglobin	B-X
concentration	B-X
in	B-X
the	B-X
erythrocyte	B-X
suspensions	B-X
was	B-X
also	B-X
observed	B-X
due	B-X
to	B-X
hemolysis	B-X
of	B-X
fragile	B-X
erythrocytes	B-X
during	B-X
incubation	B-X
.	B-X
Modification	B-X
in	B-X
the	B-X
hemorheological	B-X
properties	B-X
of	B-X
cells	B-X
,	B-X
which	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
due	B-X
to	B-X
glucose-induced	B-X
(	B-X
auto	B-X
)	B-X
oxidation	B-X
and	B-X
glycation	B-X
of	B-X
erythrocyte	B-X
proteins	B-X
in	B-X
hyperglycemia	B-X
,	B-X
can	B-X
adversely	B-X
affect	B-X
the	B-X
fluidity	B-X
and	B-X
oxygen-delivery	B-X
function	B-X
of	B-X
the	B-X
erythrocytes	B-X
.	B-X

We	O
also	O
present	O
the	O
first	O
evidence	O
of	O
increased	O
G	O
-	O
actin	O
in	O
human	O
erythrocytes	O
exposed	O
to	O
high	O
glucose	O
concentrations	O
as	O
a	O
diabetes	O
model	O
.	O
<EOS>	B-X
The	B-X
object	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
elevated	B-X
in	B-X
vitro	B-X
glucose	B-X
concentrations	B-X
on	B-X
protein	B-X
modification	B-X
and	B-X
functional	B-X
changes	B-X
in	B-X
human	B-X
erythrocytes	B-X
.	B-X
Groups	B-X
were	B-X
exposed	B-X
to	B-X
5-45	B-X
mM	B-X
glucose	B-X
concentrations	B-X
.	B-X
The	B-X
time	B-X
effect	B-X
of	B-X
any	B-X
changes	B-X
was	B-X
also	B-X
evaluated	B-X
.	B-X
G-actin	B-X
was	B-X
measured	B-X
by	B-X
a	B-X
DNase	B-X
I	B-X
inhibition	B-X
assay	B-X
in	B-X
cell	B-X
lysates	B-X
.	B-X
At	B-X
24	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
protein	B-X
oxidation	B-X
(	B-X
at	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
increase	B-X
was	B-X
observed	B-X
for	B-X
all	B-X
concentrations	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
At	B-X
48	B-X
h	B-X
,	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
glycation	B-X
(	B-X
25	B-X
and	B-X
45	B-X
mM	B-X
glucose	B-X
;	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
protein	B-X
oxidation	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
and	B-X
G-actin	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
groups	B-X
.	B-X
A	B-X
significant	B-X
positive	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
glucose	B-X
/protein	B-X
oxidation	B-X
,	B-X
glucose/G-actin	B-X
and	B-X
protein	B-X
oxidation/G-actin	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
the	B-X
oxidative	B-X
effect	B-X
of	B-X
glucose	B-X
on	B-X
erythrocytes	B-X
depends	B-X
on	B-X
concentration	B-X
and	B-X
incubation	B-X
time	B-X
.	B-X
We	B-X
also	B-X
present	B-X
the	B-X
first	B-X
evidence	B-X
of	B-X
increased	B-X
G-actin	B-X
in	B-X
human	B-X
erythrocytes	B-X
exposed	B-X
to	B-X
high	B-X
glucose	B-X
concentrations	B-X
as	B-X
a	B-X
diabetes	B-X
model	B-X
.	B-X

Determination	O
and	O
comparison	O
of	O
specific	O
activity	O
of	O
the	O
HIF	O
-	O
prolyl	O
hydroxylases	O
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
is	B-X
a	B-X
transcriptional	B-X
complex	B-X
that	B-X
is	B-X
regulated	B-X
by	B-X
oxygen	B-X
sensitive	B-X
hydroxylation	B-X
of	B-X
its	B-X
alpha	B-X
subunits	B-X
by	B-X
the	B-X
prolyl	B-X
hydroxylases	B-X
PHD1	B-X
,	B-X
2	B-X
and	B-X
3	B-X
.	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
directing	B-X
cellular	B-X
responses	B-X
to	B-X
hypoxia	B-X
,	B-X
we	B-X
derived	B-X
an	B-X
assay	B-X
to	B-X
determine	B-X
their	B-X
specific	B-X
activity	B-X
in	B-X
both	B-X
native	B-X
cell	B-X
extracts	B-X
and	B-X
recombinant	B-X
sources	B-X
of	B-X
enzyme	B-X
.	B-X
We	B-X
show	B-X
that	B-X
all	B-X
three	B-X
are	B-X
capable	B-X
of	B-X
high	B-X
rates	B-X
of	B-X
catalysis	B-X
,	B-X
in	B-X
the	B-X
order	B-X
PHD2=PHD3	B-X
>	B-X
PHD1	B-X
,	B-X
using	B-X
substrate	B-X
peptides	B-X
derived	B-X
from	B-X
the	B-X
C-terminal	B-X
degradation	B-X
domain	B-X
of	B-X
HIF-alpha	B-X
subunits	B-X
,	B-X
and	B-X
that	B-X
each	B-X
demonstrates	B-X
similar	B-X
and	B-X
remarkable	B-X
sensitivity	B-X
to	B-X
oxygen	B-X
,	B-X
commensurate	B-X
with	B-X
a	B-X
common	B-X
role	B-X
in	B-X
signaling	B-X
hypoxia	B-X
.	B-X
In	B-X
animals	B-X
,	B-X
the	B-X
response	B-X
to	B-X
chronic	B-X
hypoxia	B-X
is	B-X
mediated	B-X
by	B-X
prolyl	B-X
hydroxylases	B-X
(	B-X
PHDs	B-X
)	B-X
that	B-X
regulate	B-X
the	B-X
levels	B-X
of	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
α	B-X
(	B-X
HIFα	B-X
)	B-X
.	B-X
PHD	B-X
homologues	B-X
exist	B-X
in	B-X
other	B-X
types	B-X
of	B-X
eukaryotes	B-X
and	B-X
prokaryotes	B-X
where	B-X
they	B-X
act	B-X
on	B-X
non	B-X
HIF	B-X
substrates	B-X
.	B-X

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
transcriptional	O
complex	O
that	O
is	O
regulated	O
by	O
oxygen	O
sensitive	O
hydroxylation	O
of	O
its	O
alpha	O
subunits	O
by	O
the	O
prolyl	O
hydroxylases	O
PHD1	B-Protein
,	O
2	B-Protein
and	O
3	B-Protein
.	O
<EOS>	B-X
Hypoxia	B-X
inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
is	B-X
an	B-X
alpha/beta	B-X
heterodimeric	B-X
transcriptional	B-X
complex	B-X
that	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
directing	B-X
cellular	B-X
responses	B-X
to	B-X
hypoxia	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
defined	B-X
novel	B-X
oxygen-sensitive	B-X
signal	B-X
pathways	B-X
that	B-X
regulate	B-X
the	B-X
activity	B-X
of	B-X
HIF	B-X
by	B-X
post-translational	B-X
hydroxylation	B-X
at	B-X
specific	B-X
residues	B-X
within	B-X
the	B-X
alpha	B-X
subunits	B-X
.	B-X
HIF	B-X
prolyl	B-X
hydroxylation	B-X
regulates	B-X
proteolytic	B-X
degradation	B-X
of	B-X
HIF	B-X
whereas	B-X
HIF	B-X
asparaginyl	B-X
hydroxylation	B-X
modulates	B-X
interaction	B-X
with	B-X
transcriptional	B-X
co-activators	B-X
.	B-X
These	B-X
hydroxylations	B-X
are	B-X
catalysed	B-X
by	B-X
a	B-X
set	B-X
of	B-X
non-haem	B-X
Fe	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
2-oxoglutarate	B-X
(	B-X
2-OG	B-X
)	B-X
-dependent	B-X
dioxygenases	B-X
.	B-X
During	B-X
catalysis	B-X
,	B-X
the	B-X
splitting	B-X
of	B-X
molecular	B-X
oxygen	B-X
is	B-X
coupled	B-X
to	B-X
the	B-X
hydroxylation	B-X
of	B-X
HIF	B-X
and	B-X
the	B-X
oxidative	B-X
decarboxylation	B-X
of	B-X
2-OG	B-X
to	B-X
give	B-X
succinate	B-X
and	B-X
CO2	B-X
.	B-X
Hydroxylation	B-X
at	B-X
two	B-X
prolyl	B-X
residues	B-X
within	B-X
the	B-X
central	B-X
'degradation	B-X
domain	B-X
'	B-X
of	B-X
HIF-alpha	B-X
increases	B-X
the	B-X
affinity	B-X
for	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
pVHL	B-X
)	B-X
E3	B-X
ligase	B-X
complex	B-X
by	B-X
at	B-X
least	B-X
three	B-X
orders	B-X
of	B-X
magnitude	B-X
,	B-X
thus	B-X
directing	B-X
HIF-alpha	B-X
polypeptides	B-X
for	B-X
proteolytic	B-X
destruction	B-X
by	B-X
the	B-X
ubiquitin/proteasome	B-X
pathway	B-X
.	B-X
Since	B-X
the	B-X
HIF	B-X
hydroxylases	B-X
have	B-X
an	B-X
absolute	B-X
requirement	B-X
for	B-X
molecular	B-X
oxygen	B-X
this	B-X
process	B-X
is	B-X
suppressed	B-X
in	B-X
hypoxia	B-X
allowing	B-X
the	B-X
HIF-alpha	B-X
to	B-X
escape	B-X
destruction	B-X
and	B-X
activate	B-X
transcription	B-X
.	B-X
Co-substrate	B-X
and	B-X
co-factor	B-X
requirements	B-X
for	B-X
Fe	B-X
(	B-X
II	B-X
)	B-X
,	B-X
ascorbate	B-X
,	B-X
and	B-X
the	B-X
Krebs	B-X
cycle	B-X
intermediate	B-X
2-OG	B-X
,	B-X
and	B-X
inducible	B-X
changes	B-X
in	B-X
the	B-X
cellular	B-X
abundance	B-X
of	B-X
three	B-X
closely	B-X
related	B-X
HIF	B-X
prolyl	B-X
hydroxylases	B-X
(	B-X
PHD1-3	B-X
)	B-X
provide	B-X
additional	B-X
interfaces	B-X
with	B-X
cellular	B-X
oxygen	B-X
status	B-X
that	B-X
may	B-X
be	B-X
important	B-X
in	B-X
regulating	B-X
the	B-X
oxygen-sensitive	B-X
signal	B-X
.	B-X

To	O
better	O
understand	O
the	O
role	O
of	O
these	O
enzymes	O
in	O
directing	O
cellular	O
responses	O
to	O
hypoxia	O
,	O
we	O
derived	O
an	O
assay	O
to	O
determine	O
their	O
specific	O
activity	O
in	O
both	O
native	O
cell	O
extracts	O
and	O
recombinant	O
sources	O
of	O
enzyme	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
directing	B-X
cellular	B-X
responses	B-X
to	B-X
hypoxia	B-X
,	B-X
we	B-X
derived	B-X
an	B-X
assay	B-X
to	B-X
determine	B-X
their	B-X
specific	B-X
activity	B-X
in	B-X
both	B-X
native	B-X
cell	B-X
extracts	B-X
and	B-X
recombinant	B-X
sources	B-X
of	B-X
enzyme	B-X
.	B-X
We	B-X
show	B-X
that	B-X
all	B-X
three	B-X
are	B-X
capable	B-X
of	B-X
high	B-X
rates	B-X
of	B-X
catalysis	B-X
,	B-X
in	B-X
the	B-X
order	B-X
PHD2=PHD3	B-X
>	B-X
PHD1	B-X
,	B-X
using	B-X
substrate	B-X
peptides	B-X
derived	B-X
from	B-X
the	B-X
C-terminal	B-X
degradation	B-X
domain	B-X
of	B-X
HIF-alpha	B-X
subunits	B-X
,	B-X
and	B-X
that	B-X
each	B-X
demonstrates	B-X
similar	B-X
and	B-X
remarkable	B-X
sensitivity	B-X
to	B-X
oxygen	B-X
,	B-X
commensurate	B-X
with	B-X
a	B-X
common	B-X
role	B-X
in	B-X
signaling	B-X
hypoxia	B-X
.	B-X

We	O
show	O
that	O
all	O
three	O
are	O
capable	O
of	O
high	O
rates	O
of	O
catalysis	O
,	O
in	O
the	O
order	O
PHD2	B-Protein
=	O
PHD3	B-Protein
>	O
PHD1	B-Protein
,	O
using	O
substrate	O
peptides	O
derived	O
from	O
the	O
C	O
-	O
terminal	O
degradation	O
domain	O
of	O
HIF	O
-	O
alpha	O
subunits	O
,	O
and	O
that	O
each	O
demonstrates	O
similar	O
and	O
remarkable	O
sensitivity	O
to	O
oxygen	O
,	O
commensurate	O
with	O
a	O
common	O
role	O
in	O
signaling	O
hypoxia	O
.	O

Many	O
amino	O
acid	O
substitutions	O
in	O
a	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
transcription	I-Protein
factor	I-Protein
(	I-Protein
HIF	I-Protein
)	I-Protein
-	I-Protein
1alpha	I-Protein
-	O
like	O
peptide	O
cause	O
only	O
minor	O
changes	O
in	O
its	O
hydroxylation	O
by	O
the	O
HIF	O
prolyl	O
4	O
-	O
hydroxylases	O
:	O
substitution	O
of	O
3	O
,	O
4	O
-	O
dehydroproline	O
or	O
azetidine	O
-	O
2	O
-	O
carboxylic	O
acid	O
for	O
the	O
proline	O
leads	O
to	O
a	O
high	O
rate	O
of	O
uncoupled	O
2	O
-	O
oxoglutarate	O
decarboxylation	O
.	O
<EOS>	B-X
Three	B-X
human	B-X
prolyl	B-X
4-hydroxylases	B-X
(	B-X
P4Hs	B-X
)	B-X
regulate	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
by	B-X
hydroxylating	B-X
a	B-X
Leu-Xaa-Xaa-Leu-Ala-Pro	B-X
motif	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
two	B-X
leucines	B-X
in	B-X
the	B-X
Leu-Glu-Met-Leu-Ala-Pro	B-X
core	B-X
motif	B-X
of	B-X
a	B-X
20-residue	B-X
peptide	B-X
corresponding	B-X
to	B-X
the	B-X
sequence	B-X
around	B-X
Pro	B-X
(	B-X
564	B-X
)	B-X
in	B-X
HIF-1alpha	B-X
can	B-X
be	B-X
replaced	B-X
by	B-X
many	B-X
residues	B-X
with	B-X
no	B-X
or	B-X
only	B-X
a	B-X
modest	B-X
decrease	B-X
in	B-X
its	B-X
substrate	B-X
properties	B-X
or	B-X
in	B-X
some	B-X
cases	B-X
even	B-X
a	B-X
slight	B-X
increase	B-X
.	B-X
The	B-X
glutamate	B-X
and	B-X
methionine	B-X
could	B-X
be	B-X
substituted	B-X
by	B-X
almost	B-X
any	B-X
residue	B-X
,	B-X
eight	B-X
amino	B-X
acids	B-X
in	B-X
the	B-X
former	B-X
position	B-X
and	B-X
four	B-X
in	B-X
the	B-X
latter	B-X
being	B-X
even	B-X
better	B-X
for	B-X
HIF-P4H-3	B-X
than	B-X
the	B-X
wild-type	B-X
residues	B-X
.	B-X
Alanine	B-X
was	B-X
by	B-X
far	B-X
the	B-X
strictest	B-X
requirement	B-X
,	B-X
because	B-X
no	B-X
residue	B-X
could	B-X
fully	B-X
substitute	B-X
for	B-X
it	B-X
in	B-X
the	B-X
case	B-X
of	B-X
HIF-P4H-1	B-X
,	B-X
and	B-X
only	B-X
serine	B-X
or	B-X
isoleucine	B-X
,	B-X
valine	B-X
,	B-X
and	B-X
serine	B-X
did	B-X
this	B-X
in	B-X
the	B-X
cases	B-X
of	B-X
HIF-P4Hs	B-X
2	B-X
and	B-X
3	B-X
.	B-X
Peptides	B-X
with	B-X
more	B-X
than	B-X
one	B-X
substitution	B-X
,	B-X
having	B-X
the	B-X
core	B-X
sequences	B-X
Trp-Glu-Met-Val-Ala-Pro	B-X
,	B-X
Tyr-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Ile-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Trp-Glu-Met-Val-Ser-Pro	B-X
,	B-X
and	B-X
Trp-Glu-Ala-Val-Ser-Pro	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
equally	B-X
as	B-X
good	B-X
or	B-X
almost	B-X
as	B-X
good	B-X
substrates	B-X
as	B-X
the	B-X
wild-type	B-X
peptide	B-X
.	B-X
The	B-X
acidic	B-X
residues	B-X
present	B-X
in	B-X
the	B-X
20-residue	B-X
peptide	B-X
also	B-X
played	B-X
a	B-X
distinct	B-X
role	B-X
,	B-X
but	B-X
alanine	B-X
substitution	B-X
for	B-X
any	B-X
six	B-X
of	B-X
them	B-X
,	B-X
and	B-X
in	B-X
some	B-X
combinations	B-X
even	B-X
three	B-X
of	B-X
them	B-X
,	B-X
had	B-X
no	B-X
negative	B-X
effects	B-X
.	B-X
Substitution	B-X
of	B-X
the	B-X
proline	B-X
by	B-X
3,4-dehydroproline	B-X
or	B-X
l-azetidine-2-carboxylic	B-X
acid	B-X
,	B-X
but	B-X
not	B-X
any	B-X
other	B-X
residue	B-X
,	B-X
led	B-X
to	B-X
a	B-X
high	B-X
rate	B-X
of	B-X
uncoupled	B-X
2-oxoglutarate	B-X
decarboxylation	B-X
with	B-X
no	B-X
hydroxylation	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
three	B-X
HIF-P4Hs	B-X
in	B-X
various	B-X
experiments	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
similar	B-X
,	B-X
but	B-X
in	B-X
some	B-X
cases	B-X
HIF-P4H-3	B-X
showed	B-X
distinctly	B-X
different	B-X
properties	B-X
.	B-X

Three	O
human	O
prolyl	O
4	O
-	O
hydroxylases	O
(	O
P4Hs	O
)	O
regulate	O
the	O
hypoxia	O
-	O
inducible	O
transcription	O
factors	O
(	O
HIFs	O
)	O
by	O
hydroxylating	O
a	O
Leu	O
-	O
Xaa	O
-	O
Xaa	O
-	O
Leu	O
-	O
Ala	O
-	O
Pro	O
motif	O
.	O
<EOS>	B-X
Three	B-X
human	B-X
prolyl	B-X
4-hydroxylases	B-X
(	B-X
P4Hs	B-X
)	B-X
regulate	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
by	B-X
hydroxylating	B-X
a	B-X
Leu-Xaa-Xaa-Leu-Ala-Pro	B-X
motif	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
two	B-X
leucines	B-X
in	B-X
the	B-X
Leu-Glu-Met-Leu-Ala-Pro	B-X
core	B-X
motif	B-X
of	B-X
a	B-X
20-residue	B-X
peptide	B-X
corresponding	B-X
to	B-X
the	B-X
sequence	B-X
around	B-X
Pro	B-X
(	B-X
564	B-X
)	B-X
in	B-X
HIF-1alpha	B-X
can	B-X
be	B-X
replaced	B-X
by	B-X
many	B-X
residues	B-X
with	B-X
no	B-X
or	B-X
only	B-X
a	B-X
modest	B-X
decrease	B-X
in	B-X
its	B-X
substrate	B-X
properties	B-X
or	B-X
in	B-X
some	B-X
cases	B-X
even	B-X
a	B-X
slight	B-X
increase	B-X
.	B-X
The	B-X
glutamate	B-X
and	B-X
methionine	B-X
could	B-X
be	B-X
substituted	B-X
by	B-X
almost	B-X
any	B-X
residue	B-X
,	B-X
eight	B-X
amino	B-X
acids	B-X
in	B-X
the	B-X
former	B-X
position	B-X
and	B-X
four	B-X
in	B-X
the	B-X
latter	B-X
being	B-X
even	B-X
better	B-X
for	B-X
HIF-P4H-3	B-X
than	B-X
the	B-X
wild-type	B-X
residues	B-X
.	B-X
Alanine	B-X
was	B-X
by	B-X
far	B-X
the	B-X
strictest	B-X
requirement	B-X
,	B-X
because	B-X
no	B-X
residue	B-X
could	B-X
fully	B-X
substitute	B-X
for	B-X
it	B-X
in	B-X
the	B-X
case	B-X
of	B-X
HIF-P4H-1	B-X
,	B-X
and	B-X
only	B-X
serine	B-X
or	B-X
isoleucine	B-X
,	B-X
valine	B-X
,	B-X
and	B-X
serine	B-X
did	B-X
this	B-X
in	B-X
the	B-X
cases	B-X
of	B-X
HIF-P4Hs	B-X
2	B-X
and	B-X
3	B-X
.	B-X
Peptides	B-X
with	B-X
more	B-X
than	B-X
one	B-X
substitution	B-X
,	B-X
having	B-X
the	B-X
core	B-X
sequences	B-X
Trp-Glu-Met-Val-Ala-Pro	B-X
,	B-X
Tyr-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Ile-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Trp-Glu-Met-Val-Ser-Pro	B-X
,	B-X
and	B-X
Trp-Glu-Ala-Val-Ser-Pro	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
equally	B-X
as	B-X
good	B-X
or	B-X
almost	B-X
as	B-X
good	B-X
substrates	B-X
as	B-X
the	B-X
wild-type	B-X
peptide	B-X
.	B-X
Substitution	B-X
of	B-X
the	B-X
proline	B-X
by	B-X
3,4-dehydroproline	B-X
or	B-X
l-azetidine-2-carboxylic	B-X
acid	B-X
,	B-X
but	B-X
not	B-X
any	B-X
other	B-X
residue	B-X
,	B-X
led	B-X
to	B-X
a	B-X
high	B-X
rate	B-X
of	B-X
uncoupled	B-X
2-oxoglutarate	B-X
decarboxylation	B-X
with	B-X
no	B-X
hydroxylation	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
three	B-X
HIF-P4Hs	B-X
in	B-X
various	B-X
experiments	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
similar	B-X
,	B-X
but	B-X
in	B-X
some	B-X
cases	B-X
HIF-P4H-3	B-X
showed	B-X
distinctly	B-X
different	B-X
properties	B-X
.	B-X

We	O
report	O
here	O
that	O
the	O
two	O
leucines	O
in	O
the	O
Leu	O
-	O
Glu	O
-	O
Met	O
-	O
Leu	O
-	O
Ala	O
-	O
Pro	O
core	O
motif	O
of	O
a	O
20	O
-	O
residue	O
peptide	O
corresponding	O
to	O
the	O
sequence	O
around	O
Pro	O
(	O
564	O
)	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
can	O
be	O
replaced	O
by	O
many	O
residues	O
with	O
no	O
or	O
only	O
a	O
modest	O
decrease	O
in	O
its	O
substrate	O
properties	O
or	O
in	O
some	O
cases	O
even	O
a	O
slight	O
increase	O
.	O

The	O
glutamate	O
and	O
methionine	O
could	O
be	O
substituted	O
by	O
almost	O
any	O
residue	O
,	O
eight	O
amino	O
acids	O
in	O
the	O
former	O
position	O
and	O
four	O
in	O
the	O
latter	O
being	O
even	O
better	O
for	O
HIF	B-Protein
-	I-Protein
P4H	I-Protein
-	I-Protein
3	I-Protein
than	O
the	O
wild	O
-	O
type	O
residues	O
.	O

Alanine	O
was	O
by	O
far	O
the	O
strictest	O
requirement	O
,	O
because	O
no	O
residue	O
could	O
fully	O
substitute	O
for	O
it	O
in	O
the	O
case	O
of	O
HIF	B-Protein
-	I-Protein
P4H	I-Protein
-	I-Protein
1	I-Protein
,	O
and	O
only	O
serine	O
or	O
isoleucine	O
,	O
valine	O
,	O
and	O
serine	O
did	O
this	O
in	O
the	O
cases	O
of	O
HIF	B-Protein
-	I-Protein
P4Hs	I-Protein
2	I-Protein
and	O
3	B-Protein
.	O
<EOS>	B-X
Three	B-X
human	B-X
prolyl	B-X
4-hydroxylases	B-X
(	B-X
P4Hs	B-X
)	B-X
regulate	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
by	B-X
hydroxylating	B-X
a	B-X
Leu-Xaa-Xaa-Leu-Ala-Pro	B-X
motif	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
two	B-X
leucines	B-X
in	B-X
the	B-X
Leu-Glu-Met-Leu-Ala-Pro	B-X
core	B-X
motif	B-X
of	B-X
a	B-X
20-residue	B-X
peptide	B-X
corresponding	B-X
to	B-X
the	B-X
sequence	B-X
around	B-X
Pro	B-X
(	B-X
564	B-X
)	B-X
in	B-X
HIF-1alpha	B-X
can	B-X
be	B-X
replaced	B-X
by	B-X
many	B-X
residues	B-X
with	B-X
no	B-X
or	B-X
only	B-X
a	B-X
modest	B-X
decrease	B-X
in	B-X
its	B-X
substrate	B-X
properties	B-X
or	B-X
in	B-X
some	B-X
cases	B-X
even	B-X
a	B-X
slight	B-X
increase	B-X
.	B-X
The	B-X
glutamate	B-X
and	B-X
methionine	B-X
could	B-X
be	B-X
substituted	B-X
by	B-X
almost	B-X
any	B-X
residue	B-X
,	B-X
eight	B-X
amino	B-X
acids	B-X
in	B-X
the	B-X
former	B-X
position	B-X
and	B-X
four	B-X
in	B-X
the	B-X
latter	B-X
being	B-X
even	B-X
better	B-X
for	B-X
HIF-P4H-3	B-X
than	B-X
the	B-X
wild-type	B-X
residues	B-X
.	B-X
Alanine	B-X
was	B-X
by	B-X
far	B-X
the	B-X
strictest	B-X
requirement	B-X
,	B-X
because	B-X
no	B-X
residue	B-X
could	B-X
fully	B-X
substitute	B-X
for	B-X
it	B-X
in	B-X
the	B-X
case	B-X
of	B-X
HIF-P4H-1	B-X
,	B-X
and	B-X
only	B-X
serine	B-X
or	B-X
isoleucine	B-X
,	B-X
valine	B-X
,	B-X
and	B-X
serine	B-X
did	B-X
this	B-X
in	B-X
the	B-X
cases	B-X
of	B-X
HIF-P4Hs	B-X
2	B-X
and	B-X
3	B-X
.	B-X
Peptides	B-X
with	B-X
more	B-X
than	B-X
one	B-X
substitution	B-X
,	B-X
having	B-X
the	B-X
core	B-X
sequences	B-X
Trp-Glu-Met-Val-Ala-Pro	B-X
,	B-X
Tyr-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Ile-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Trp-Glu-Met-Val-Ser-Pro	B-X
,	B-X
and	B-X
Trp-Glu-Ala-Val-Ser-Pro	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
equally	B-X
as	B-X
good	B-X
or	B-X
almost	B-X
as	B-X
good	B-X
substrates	B-X
as	B-X
the	B-X
wild-type	B-X
peptide	B-X
.	B-X
The	B-X
acidic	B-X
residues	B-X
present	B-X
in	B-X
the	B-X
20-residue	B-X
peptide	B-X
also	B-X
played	B-X
a	B-X
distinct	B-X
role	B-X
,	B-X
but	B-X
alanine	B-X
substitution	B-X
for	B-X
any	B-X
six	B-X
of	B-X
them	B-X
,	B-X
and	B-X
in	B-X
some	B-X
combinations	B-X
even	B-X
three	B-X
of	B-X
them	B-X
,	B-X
had	B-X
no	B-X
negative	B-X
effects	B-X
.	B-X
Substitution	B-X
of	B-X
the	B-X
proline	B-X
by	B-X
3,4-dehydroproline	B-X
or	B-X
l-azetidine-2-carboxylic	B-X
acid	B-X
,	B-X
but	B-X
not	B-X
any	B-X
other	B-X
residue	B-X
,	B-X
led	B-X
to	B-X
a	B-X
high	B-X
rate	B-X
of	B-X
uncoupled	B-X
2-oxoglutarate	B-X
decarboxylation	B-X
with	B-X
no	B-X
hydroxylation	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
three	B-X
HIF-P4Hs	B-X
in	B-X
various	B-X
experiments	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
similar	B-X
,	B-X
but	B-X
in	B-X
some	B-X
cases	B-X
HIF-P4H-3	B-X
showed	B-X
distinctly	B-X
different	B-X
properties	B-X
.	B-X

Peptides	O
with	O
more	O
than	O
one	O
substitution	O
,	O
having	O
the	O
core	O
sequences	O
Trp	O
-	O
Glu	O
-	O
Met	O
-	O
Val	O
-	O
Ala	O
-	O
Pro	O
,	O
Tyr	O
-	O
Glu	O
-	O
Met	O
-	O
Ile	O
-	O
Ala	O
-	O
Pro	O
,	O
Ile	O
-	O
Glu	O
-	O
Met	O
-	O
Ile	O
-	O
Ala	O
-	O
Pro	O
,	O
Trp	O
-	O
Glu	O
-	O
Met	O
-	O
Val	O
-	O
Ser	O
-	O
Pro	O
,	O
and	O
Trp	O
-	O
Glu	O
-	O
Ala	O
-	O
Val	O
-	O
Ser	O
-	O
Pro	O
were	O
in	O
most	O
cases	O
equally	O
as	O
good	O
or	O
almost	O
as	O
good	O
substrates	O
as	O
the	O
wild	O
-	O
type	O
peptide	O
.	O
<EOS>	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
the	B-X
experimental	B-X
research	B-X
within	B-X
this	B-X
field	B-X
showed	B-X
good	B-X
momentum	B-X
.	B-X
Breast	B-X
Cancer	B-X
Resistance	B-X
Protein	B-X
(	B-X
BCRP	B-X
)	B-X
,	B-X
Multidrug	B-X
Resistance	B-X
Proteins	B-X
(	B-X
MRP	B-X
)	B-X
,	B-X
P-glycoprotein	B-X
(	B-X
P-gp	B-X
)	B-X
,	B-X
Organic	B-X
Anion	B-X
Transporters	B-X
(	B-X
OATs	B-X
)	B-X
,	B-X
Organic	B-X
Anion	B-X
Transporting	B-X
Polypeptides	B-X
(	B-X
OATPs	B-X
)	B-X
,	B-X
Organic	B-X
Cation	B-X
Transporters	B-X
(	B-X
OCTs	B-X
)	B-X
,	B-X
Peptide	B-X
Transport	B-X
Proteins	B-X
(	B-X
PepTs	B-X
)	B-X
,	B-X
Human	B-X
Proton-Coupled	B-X
Folate	B-X
Transporter	B-X
(	B-X
PCFT	B-X
)	B-X
and	B-X
Multidrug	B-X
and	B-X
Toxic	B-X
Extrusion	B-X
Proteins	B-X
(	B-X
MATEs	B-X
)	B-X
,	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
exhibit	B-X
either	B-X
positive	B-X
or	B-X
negative	B-X
enantio-selective	B-X
substrate	B-X
recognition	B-X
.	B-X
Caco-2	B-X
cells	B-X
)	B-X
,	B-X
transport	B-X
study	B-X
using	B-X
drug	B-X
resistance	B-X
cell	B-X
lines	B-X
or	B-X
transgenic	B-X
cell	B-X
lines	B-X
expressing	B-X
transporters	B-X
in	B-X
wild	B-X
type	B-X
or	B-X
variant	B-X
,	B-X
the	B-X
use	B-X
of	B-X
transporter	B-X
knockout	B-X
mice	B-X
,	B-X
pharmacokinetics	B-X
association	B-X
of	B-X
single	B-X
nucleotide	B-X
polymorphism	B-X
in	B-X
transporters	B-X
,	B-X
pharmacokinetic	B-X
interaction	B-X
study	B-X
of	B-X
racemate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
specific	B-X
transporter	B-X
inhibitor	B-X
or	B-X
inducer	B-X
,	B-X
molecule	B-X
cellular	B-X
membrane	B-X
affinity	B-X
chromatography	B-X
and	B-X
pharmacophore	B-X
modeling	B-X
.	B-X
It	B-X
may	B-X
be	B-X
triggered	B-X
by	B-X
two	B-X
major	B-X
intracellular	B-X
signaling	B-X
cascades	B-X
,	B-X
the	B-X
mitochondrial	B-X
pathway	B-X
and	B-X
the	B-X
death	B-X
receptor	B-X
pathway	B-X
,	B-X
both	B-X
leading	B-X
to	B-X
caspase	B-X
activation	B-X
and	B-X
cleavage	B-X
of	B-X
specific	B-X
cellular	B-X
substrates	B-X
.	B-X
Caspase	B-X
activation	B-X
following	B-X
wild-type	B-X
p53	B-X
induction	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
release	B-X
of	B-X
the	B-X
apoptogenic	B-X
factors	B-X
cytochrome	B-X
c	B-X
and	B-X
Smac/DIABLO	B-X
from	B-X
the	B-X
mitochondria	B-X
,	B-X
that	B-X
is	B-X
in	B-X
turn	B-X
controlled	B-X
by	B-X
the	B-X
pro-apoptotic	B-X
and	B-X
anti-apoptotic	B-X
Bcl-2	B-X
family	B-X
proteins	B-X
.	B-X
Whereas	B-X
patients	B-X
with	B-X
wild-type	B-X
p53	B-X
tumors	B-X
have	B-X
a	B-X
good	B-X
chance	B-X
to	B-X
respond	B-X
to	B-X
platinum	B-X
,	B-X
patients	B-X
with	B-X
mutant	B-X
p53	B-X
tumors	B-X
may	B-X
have	B-X
a	B-X
clinical	B-X
benefit	B-X
from	B-X
the	B-X
addition	B-X
of	B-X
paclitaxel	B-X
to	B-X
platinum-based	B-X
chemotherapy	B-X
.	B-X

The	O
acidic	O
residues	O
present	O
in	O
the	O
20	O
-	O
residue	O
peptide	O
also	O
played	O
a	O
distinct	O
role	O
,	O
but	O
alanine	O
substitution	O
for	O
any	O
six	O
of	O
them	O
,	O
and	O
in	O
some	O
combinations	O
even	O
three	O
of	O
them	O
,	O
had	O
no	O
negative	O
effects	O
.	O
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
two	B-X
leucines	B-X
in	B-X
the	B-X
Leu-Glu-Met-Leu-Ala-Pro	B-X
core	B-X
motif	B-X
of	B-X
a	B-X
20-residue	B-X
peptide	B-X
corresponding	B-X
to	B-X
the	B-X
sequence	B-X
around	B-X
Pro	B-X
(	B-X
564	B-X
)	B-X
in	B-X
HIF-1alpha	B-X
can	B-X
be	B-X
replaced	B-X
by	B-X
many	B-X
residues	B-X
with	B-X
no	B-X
or	B-X
only	B-X
a	B-X
modest	B-X
decrease	B-X
in	B-X
its	B-X
substrate	B-X
properties	B-X
or	B-X
in	B-X
some	B-X
cases	B-X
even	B-X
a	B-X
slight	B-X
increase	B-X
.	B-X
The	B-X
glutamate	B-X
and	B-X
methionine	B-X
could	B-X
be	B-X
substituted	B-X
by	B-X
almost	B-X
any	B-X
residue	B-X
,	B-X
eight	B-X
amino	B-X
acids	B-X
in	B-X
the	B-X
former	B-X
position	B-X
and	B-X
four	B-X
in	B-X
the	B-X
latter	B-X
being	B-X
even	B-X
better	B-X
for	B-X
HIF-P4H-3	B-X
than	B-X
the	B-X
wild-type	B-X
residues	B-X
.	B-X
Alanine	B-X
was	B-X
by	B-X
far	B-X
the	B-X
strictest	B-X
requirement	B-X
,	B-X
because	B-X
no	B-X
residue	B-X
could	B-X
fully	B-X
substitute	B-X
for	B-X
it	B-X
in	B-X
the	B-X
case	B-X
of	B-X
HIF-P4H-1	B-X
,	B-X
and	B-X
only	B-X
serine	B-X
or	B-X
isoleucine	B-X
,	B-X
valine	B-X
,	B-X
and	B-X
serine	B-X
did	B-X
this	B-X
in	B-X
the	B-X
cases	B-X
of	B-X
HIF-P4Hs	B-X
2	B-X
and	B-X
3	B-X
.	B-X
Peptides	B-X
with	B-X
more	B-X
than	B-X
one	B-X
substitution	B-X
,	B-X
having	B-X
the	B-X
core	B-X
sequences	B-X
Trp-Glu-Met-Val-Ala-Pro	B-X
,	B-X
Tyr-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Ile-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Trp-Glu-Met-Val-Ser-Pro	B-X
,	B-X
and	B-X
Trp-Glu-Ala-Val-Ser-Pro	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
equally	B-X
as	B-X
good	B-X
or	B-X
almost	B-X
as	B-X
good	B-X
substrates	B-X
as	B-X
the	B-X
wild-type	B-X
peptide	B-X
.	B-X
The	B-X
acidic	B-X
residues	B-X
present	B-X
in	B-X
the	B-X
20-residue	B-X
peptide	B-X
also	B-X
played	B-X
a	B-X
distinct	B-X
role	B-X
,	B-X
but	B-X
alanine	B-X
substitution	B-X
for	B-X
any	B-X
six	B-X
of	B-X
them	B-X
,	B-X
and	B-X
in	B-X
some	B-X
combinations	B-X
even	B-X
three	B-X
of	B-X
them	B-X
,	B-X
had	B-X
no	B-X
negative	B-X
effects	B-X
.	B-X
Substitution	B-X
of	B-X
the	B-X
proline	B-X
by	B-X
3,4-dehydroproline	B-X
or	B-X
l-azetidine-2-carboxylic	B-X
acid	B-X
,	B-X
but	B-X
not	B-X
any	B-X
other	B-X
residue	B-X
,	B-X
led	B-X
to	B-X
a	B-X
high	B-X
rate	B-X
of	B-X
uncoupled	B-X
2-oxoglutarate	B-X
decarboxylation	B-X
with	B-X
no	B-X
hydroxylation	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
three	B-X
HIF-P4Hs	B-X
in	B-X
various	B-X
experiments	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
similar	B-X
,	B-X
but	B-X
in	B-X
some	B-X
cases	B-X
HIF-P4H-3	B-X
showed	B-X
distinctly	B-X
different	B-X
properties	B-X
.	B-X

Substitution	O
of	O
the	O
proline	O
by	O
3	O
,	O
4	O
-	O
dehydroproline	O
or	O
l	O
-	O
azetidine	O
-	O
2	O
-	O
carboxylic	O
acid	O
,	O
but	O
not	O
any	O
other	O
residue	O
,	O
led	O
to	O
a	O
high	O
rate	O
of	O
uncoupled	O
2	O
-	O
oxoglutarate	O
decarboxylation	O
with	O
no	O
hydroxylation	O
.	O
<EOS>	B-X
Azelnidipine	B-X
is	B-X
a	B-X
new	B-X
dihydropyridine	B-X
calcium	B-X
channel	B-X
antagonist	B-X
with	B-X
selectivity	B-X
for	B-X
L-type	B-X
calcium	B-X
channels	B-X
that	B-X
has	B-X
recently	B-X
been	B-X
approved	B-X
in	B-X
Japan	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
hypertension	B-X
.	B-X
Results	B-X
from	B-X
clinical	B-X
trials	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
95	B-X
patients	B-X
with	B-X
mild-to-moderate	B-X
hypertension	B-X
,	B-X
long-term	B-X
treatment	B-X
with	B-X
azelnidipine	B-X
effectively	B-X
controls	B-X
blood	B-X
pressure	B-X
(	B-X
BP	B-X
)	B-X
.	B-X
The	B-X
mean	B-X
reduction	B-X
from	B-X
baseline	B-X
in	B-X
sitting	B-X
systolic/diastolic	B-X
BP	B-X
after	B-X
1	B-X
year	B-X
of	B-X
treatment	B-X
was	B-X
27.8/16.6	B-X
mm	B-X
Hg	B-X
.	B-X
Among	B-X
172	B-X
patients	B-X
with	B-X
uncontrolled	B-X
hypertension	B-X
receiving	B-X
non-calcium	B-X
channel	B-X
antagonist	B-X
antihypertensive	B-X
agents	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
azelnidipine	B-X
therapy	B-X
significantly	B-X
reduced	B-X
mean	B-X
BP	B-X
in	B-X
a	B-X
noncomparative	B-X
,	B-X
1-year	B-X
study	B-X
(	B-X
a	B-X
reduction	B-X
from	B-X
165.7/95.4	B-X
mm	B-X
Hg	B-X
at	B-X
baseline	B-X
to	B-X
138.2/79.9	B-X
mm	B-X
Hg	B-X
at	B-X
study	B-X
end	B-X
)	B-X
.	B-X
The	B-X
antihypertensive	B-X
efficacy	B-X
of	B-X
azelnidipine	B-X
in	B-X
patients	B-X
with	B-X
mild-to-moderate	B-X
hypertension	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
amlodipine	B-X
or	B-X
nitrendipine	B-X
in	B-X
randomised	B-X
,	B-X
double-blind	B-X
studies	B-X
.	B-X
Azelnidipine	B-X
and	B-X
amlodipine	B-X
controlled	B-X
24-hour	B-X
BP	B-X
to	B-X
a	B-X
similar	B-X
extent	B-X
.	B-X
Azelnidipine	B-X
is	B-X
generally	B-X
well	B-X
tolerated	B-X
;	B-X
vasodilator	B-X
adverse	B-X
events	B-X
such	B-X
as	B-X
as	B-X
headache	B-X
and	B-X
hot	B-X
facial	B-X
flushes	B-X
account	B-X
for	B-X
most	B-X
of	B-X
the	B-X
adverse	B-X
events	B-X
.	B-X
Its	B-X
use	B-X
is	B-X
not	B-X
associated	B-X
with	B-X
reflex	B-X
tachycardia	B-X
.	B-X

The	O
data	O
obtained	O
for	O
the	O
three	O
HIF	O
-	O
P4Hs	O
in	O
various	O
experiments	O
were	O
in	O
most	O
cases	O
similar	O
,	O
but	O
in	O
some	O
cases	O
HIF	B-Protein
-	I-Protein
P4H	I-Protein
-	I-Protein
3	I-Protein
showed	O
distinctly	O
different	O
properties	O
.	O
<EOS>	B-X
Three	B-X
human	B-X
prolyl	B-X
4-hydroxylases	B-X
(	B-X
P4Hs	B-X
)	B-X
regulate	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factors	B-X
(	B-X
HIFs	B-X
)	B-X
by	B-X
hydroxylating	B-X
a	B-X
Leu-Xaa-Xaa-Leu-Ala-Pro	B-X
motif	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
two	B-X
leucines	B-X
in	B-X
the	B-X
Leu-Glu-Met-Leu-Ala-Pro	B-X
core	B-X
motif	B-X
of	B-X
a	B-X
20-residue	B-X
peptide	B-X
corresponding	B-X
to	B-X
the	B-X
sequence	B-X
around	B-X
Pro	B-X
(	B-X
564	B-X
)	B-X
in	B-X
HIF-1alpha	B-X
can	B-X
be	B-X
replaced	B-X
by	B-X
many	B-X
residues	B-X
with	B-X
no	B-X
or	B-X
only	B-X
a	B-X
modest	B-X
decrease	B-X
in	B-X
its	B-X
substrate	B-X
properties	B-X
or	B-X
in	B-X
some	B-X
cases	B-X
even	B-X
a	B-X
slight	B-X
increase	B-X
.	B-X
The	B-X
glutamate	B-X
and	B-X
methionine	B-X
could	B-X
be	B-X
substituted	B-X
by	B-X
almost	B-X
any	B-X
residue	B-X
,	B-X
eight	B-X
amino	B-X
acids	B-X
in	B-X
the	B-X
former	B-X
position	B-X
and	B-X
four	B-X
in	B-X
the	B-X
latter	B-X
being	B-X
even	B-X
better	B-X
for	B-X
HIF-P4H-3	B-X
than	B-X
the	B-X
wild-type	B-X
residues	B-X
.	B-X
Alanine	B-X
was	B-X
by	B-X
far	B-X
the	B-X
strictest	B-X
requirement	B-X
,	B-X
because	B-X
no	B-X
residue	B-X
could	B-X
fully	B-X
substitute	B-X
for	B-X
it	B-X
in	B-X
the	B-X
case	B-X
of	B-X
HIF-P4H-1	B-X
,	B-X
and	B-X
only	B-X
serine	B-X
or	B-X
isoleucine	B-X
,	B-X
valine	B-X
,	B-X
and	B-X
serine	B-X
did	B-X
this	B-X
in	B-X
the	B-X
cases	B-X
of	B-X
HIF-P4Hs	B-X
2	B-X
and	B-X
3	B-X
.	B-X
Peptides	B-X
with	B-X
more	B-X
than	B-X
one	B-X
substitution	B-X
,	B-X
having	B-X
the	B-X
core	B-X
sequences	B-X
Trp-Glu-Met-Val-Ala-Pro	B-X
,	B-X
Tyr-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Ile-Glu-Met-Ile-Ala-Pro	B-X
,	B-X
Trp-Glu-Met-Val-Ser-Pro	B-X
,	B-X
and	B-X
Trp-Glu-Ala-Val-Ser-Pro	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
equally	B-X
as	B-X
good	B-X
or	B-X
almost	B-X
as	B-X
good	B-X
substrates	B-X
as	B-X
the	B-X
wild-type	B-X
peptide	B-X
.	B-X
The	B-X
acidic	B-X
residues	B-X
present	B-X
in	B-X
the	B-X
20-residue	B-X
peptide	B-X
also	B-X
played	B-X
a	B-X
distinct	B-X
role	B-X
,	B-X
but	B-X
alanine	B-X
substitution	B-X
for	B-X
any	B-X
six	B-X
of	B-X
them	B-X
,	B-X
and	B-X
in	B-X
some	B-X
combinations	B-X
even	B-X
three	B-X
of	B-X
them	B-X
,	B-X
had	B-X
no	B-X
negative	B-X
effects	B-X
.	B-X
Substitution	B-X
of	B-X
the	B-X
proline	B-X
by	B-X
3,4-dehydroproline	B-X
or	B-X
l-azetidine-2-carboxylic	B-X
acid	B-X
,	B-X
but	B-X
not	B-X
any	B-X
other	B-X
residue	B-X
,	B-X
led	B-X
to	B-X
a	B-X
high	B-X
rate	B-X
of	B-X
uncoupled	B-X
2-oxoglutarate	B-X
decarboxylation	B-X
with	B-X
no	B-X
hydroxylation	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
three	B-X
HIF-P4Hs	B-X
in	B-X
various	B-X
experiments	B-X
were	B-X
in	B-X
most	B-X
cases	B-X
similar	B-X
,	B-X
but	B-X
in	B-X
some	B-X
cases	B-X
HIF-P4H-3	B-X
showed	B-X
distinctly	B-X
different	B-X
properties	B-X
.	B-X

Genetics	O
and	O
epigenetics	O
in	O
flower	O
pigmentation	O
associated	O
with	O
transposable	O
elements	O
in	O
morning	O
glories	O
.	O
<EOS>	B-X
Among	B-X
the	B-X
genus	B-X
Ipomoea	B-X
,	B-X
three	B-X
morning	B-X
glories	B-X
,	B-X
I.	B-X
nil	B-X
(	B-X
the	B-X
Japanese	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
I.	B-X
purpurea	B-X
(	B-X
the	B-X
common	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
and	B-X
I.	B-X
tricolor	B-X
,	B-X
were	B-X
domesticated	B-X
well	B-X
for	B-X
floricultural	B-X
plants	B-X
,	B-X
and	B-X
many	B-X
spontaneous	B-X
mutants	B-X
displaying	B-X
various	B-X
flower	B-X
pigmentation	B-X
patterns	B-X
were	B-X
isolated	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
spontaneous	B-X
mutations	B-X
were	B-X
found	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
the	B-X
insertion	B-X
of	B-X
DNA	B-X
transposable	B-X
elements	B-X
in	B-X
the	B-X
genes	B-X
for	B-X
the	B-X
anthocyanin	B-X
pigmentation	B-X
in	B-X
flowers	B-X
,	B-X
and	B-X
many	B-X
of	B-X
them	B-X
exhibited	B-X
variegated	B-X
flowers	B-X
,	B-X
such	B-X
as	B-X
white	B-X
flowers	B-X
with	B-X
pigmented	B-X
spots	B-X
and	B-X
sectors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
historical	B-X
background	B-X
of	B-X
the	B-X
mutants	B-X
displaying	B-X
variegated	B-X
flowers	B-X
and	B-X
review	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
in	B-X
flower	B-X
pigmentation	B-X
associated	B-X
with	B-X
transposable	B-X
elements	B-X
of	B-X
these	B-X
morning	B-X
glories	B-X
.	B-X
The	B-X
flecked	B-X
,	B-X
speckled	B-X
,	B-X
r-1	B-X
,	B-X
and	B-X
purple	B-X
mutations	B-X
in	B-X
I.	B-X
nil	B-X
were	B-X
caused	B-X
by	B-X
insertions	B-X
of	B-X
Tpn1	B-X
and	B-X
its	B-X
relatives	B-X
in	B-X
the	B-X
En/Spm	B-X
superfamily	B-X
,	B-X
Tpn2	B-X
,	B-X
Tpn3	B-X
,	B-X
and	B-X
Tpn4	B-X
,	B-X
into	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
coloration	B-X
in	B-X
flowers	B-X
,	B-X
i.e.	B-X
,	B-X
DFR-B	B-X
,	B-X
CHI	B-X
,	B-X
CHS-D	B-X
,	B-X
and	B-X
InNHX1	B-X
,	B-X
respectively	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
flaked	B-X
and	B-X
pink	B-X
mutants	B-X
of	B-X
I.	B-X
purpurea	B-X
have	B-X
distantly	B-X
related	B-X
elements	B-X
,	B-X
Tip100	B-X
and	B-X
Tip201	B-X
,	B-X
in	B-X
the	B-X
Ac/Ds	B-X
superfamily	B-X
inserted	B-X
into	B-X
the	B-X
CHS-D	B-X
and	B-X
F3	B-X
'	B-X
H	B-X
genes	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
flower	B-X
variegation	B-X
patterns	B-X
can	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
these	B-X
transposons	B-X
,	B-X
and	B-X
their	B-X
stable	B-X
insertions	B-X
produce	B-X
plain	B-X
color	B-X
flowers	B-X
without	B-X
generating	B-X
pigmented	B-X
spots	B-X
or	B-X
sectors	B-X
;	B-X
furthermore	B-X
,	B-X
both	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
appeared	B-X
to	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
determining	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
the	B-X
transposons	B-X
.	B-X
However	B-X
,	B-X
flower	B-X
variegation	B-X
is	B-X
not	B-X
always	B-X
associated	B-X
with	B-X
the	B-X
excision	B-X
of	B-X
an	B-X
integrated	B-X
DNA	B-X
transposon	B-X
from	B-X
one	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
pigmentation	B-X
.	B-X
The	B-X
mutant	B-X
Flying	B-X
Saucers	B-X
of	B-X
I.	B-X
tricolor	B-X
displaying	B-X
variegated	B-X
flowers	B-X
was	B-X
found	B-X
to	B-X
have	B-X
the	B-X
transposon	B-X
ItMULE1	B-X
inserted	B-X
into	B-X
the	B-X
DFR-B	B-X
promoter	B-X
region	B-X
,	B-X
but	B-X
no	B-X
excision	B-X
of	B-X
ItMULE1	B-X
from	B-X
the	B-X
DFR-B	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
the	B-X
variegated	B-X
flower	B-X
lines	B-X
.	B-X
Flying	B-X
Saucers	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
epiallele	B-X
because	B-X
the	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
DFR-B	B-X
promoter	B-X
appeared	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
flower	B-X
pigmentation	B-X
.	B-X

Among	O
the	O
genus	O
Ipomoea	O
,	O
three	O
morning	O
glories	O
,	O
I	O
.	O
nil	O
(	O
the	O
Japanese	O
morning	O
glory	O
)	O
,	O
I	O
.	O
purpurea	O
(	O
the	O
common	O
morning	O
glory	O
)	O
,	O
and	O
I	O
.	O
tricolor	O
,	O
were	O
domesticated	O
well	O
for	O
floricultural	O
plants	O
,	O
and	O
many	O
spontaneous	O
mutants	O
displaying	O
various	O
flower	O
pigmentation	O
patterns	O
were	O
isolated	O
.	O
<EOS>	B-X
Among	B-X
the	B-X
genus	B-X
Ipomoea	B-X
,	B-X
three	B-X
morning	B-X
glories	B-X
,	B-X
I.	B-X
nil	B-X
(	B-X
the	B-X
Japanese	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
I.	B-X
purpurea	B-X
(	B-X
the	B-X
common	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
and	B-X
I.	B-X
tricolor	B-X
,	B-X
were	B-X
domesticated	B-X
well	B-X
for	B-X
floricultural	B-X
plants	B-X
,	B-X
and	B-X
many	B-X
spontaneous	B-X
mutants	B-X
displaying	B-X
various	B-X
flower	B-X
pigmentation	B-X
patterns	B-X
were	B-X
isolated	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
spontaneous	B-X
mutations	B-X
were	B-X
found	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
the	B-X
insertion	B-X
of	B-X
DNA	B-X
transposable	B-X
elements	B-X
in	B-X
the	B-X
genes	B-X
for	B-X
the	B-X
anthocyanin	B-X
pigmentation	B-X
in	B-X
flowers	B-X
,	B-X
and	B-X
many	B-X
of	B-X
them	B-X
exhibited	B-X
variegated	B-X
flowers	B-X
,	B-X
such	B-X
as	B-X
white	B-X
flowers	B-X
with	B-X
pigmented	B-X
spots	B-X
and	B-X
sectors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
historical	B-X
background	B-X
of	B-X
the	B-X
mutants	B-X
displaying	B-X
variegated	B-X
flowers	B-X
and	B-X
review	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
in	B-X
flower	B-X
pigmentation	B-X
associated	B-X
with	B-X
transposable	B-X
elements	B-X
of	B-X
these	B-X
morning	B-X
glories	B-X
.	B-X
The	B-X
flecked	B-X
,	B-X
speckled	B-X
,	B-X
r-1	B-X
,	B-X
and	B-X
purple	B-X
mutations	B-X
in	B-X
I.	B-X
nil	B-X
were	B-X
caused	B-X
by	B-X
insertions	B-X
of	B-X
Tpn1	B-X
and	B-X
its	B-X
relatives	B-X
in	B-X
the	B-X
En/Spm	B-X
superfamily	B-X
,	B-X
Tpn2	B-X
,	B-X
Tpn3	B-X
,	B-X
and	B-X
Tpn4	B-X
,	B-X
into	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
coloration	B-X
in	B-X
flowers	B-X
,	B-X
i.e.	B-X
,	B-X
DFR-B	B-X
,	B-X
CHI	B-X
,	B-X
CHS-D	B-X
,	B-X
and	B-X
InNHX1	B-X
,	B-X
respectively	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
flaked	B-X
and	B-X
pink	B-X
mutants	B-X
of	B-X
I.	B-X
purpurea	B-X
have	B-X
distantly	B-X
related	B-X
elements	B-X
,	B-X
Tip100	B-X
and	B-X
Tip201	B-X
,	B-X
in	B-X
the	B-X
Ac/Ds	B-X
superfamily	B-X
inserted	B-X
into	B-X
the	B-X
CHS-D	B-X
and	B-X
F3	B-X
'	B-X
H	B-X
genes	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
flower	B-X
variegation	B-X
patterns	B-X
can	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
these	B-X
transposons	B-X
,	B-X
and	B-X
their	B-X
stable	B-X
insertions	B-X
produce	B-X
plain	B-X
color	B-X
flowers	B-X
without	B-X
generating	B-X
pigmented	B-X
spots	B-X
or	B-X
sectors	B-X
;	B-X
furthermore	B-X
,	B-X
both	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
appeared	B-X
to	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
determining	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
the	B-X
transposons	B-X
.	B-X
However	B-X
,	B-X
flower	B-X
variegation	B-X
is	B-X
not	B-X
always	B-X
associated	B-X
with	B-X
the	B-X
excision	B-X
of	B-X
an	B-X
integrated	B-X
DNA	B-X
transposon	B-X
from	B-X
one	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
pigmentation	B-X
.	B-X
The	B-X
mutant	B-X
Flying	B-X
Saucers	B-X
of	B-X
I.	B-X
tricolor	B-X
displaying	B-X
variegated	B-X
flowers	B-X
was	B-X
found	B-X
to	B-X
have	B-X
the	B-X
transposon	B-X
ItMULE1	B-X
inserted	B-X
into	B-X
the	B-X
DFR-B	B-X
promoter	B-X
region	B-X
,	B-X
but	B-X
no	B-X
excision	B-X
of	B-X
ItMULE1	B-X
from	B-X
the	B-X
DFR-B	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
the	B-X
variegated	B-X
flower	B-X
lines	B-X
.	B-X
Flying	B-X
Saucers	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
epiallele	B-X
because	B-X
the	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
DFR-B	B-X
promoter	B-X
appeared	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
flower	B-X
pigmentation	B-X
.	B-X

Most	O
of	O
these	O
spontaneous	O
mutations	O
were	O
found	O
to	O
be	O
caused	O
by	O
the	O
insertion	O
of	O
DNA	O
transposable	O
elements	O
in	O
the	O
genes	O
for	O
the	O
anthocyanin	O
pigmentation	O
in	O
flowers	O
,	O
and	O
many	O
of	O
them	O
exhibited	O
variegated	O
flowers	O
,	O
such	O
as	O
white	O
flowers	O
with	O
pigmented	O
spots	O
and	O
sectors	O
.	O
<EOS>	B-X
Among	B-X
the	B-X
genus	B-X
Ipomoea	B-X
,	B-X
three	B-X
morning	B-X
glories	B-X
,	B-X
I.	B-X
nil	B-X
(	B-X
the	B-X
Japanese	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
I.	B-X
purpurea	B-X
(	B-X
the	B-X
common	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
and	B-X
I.	B-X
tricolor	B-X
,	B-X
were	B-X
domesticated	B-X
well	B-X
for	B-X
floricultural	B-X
plants	B-X
,	B-X
and	B-X
many	B-X
spontaneous	B-X
mutants	B-X
displaying	B-X
various	B-X
flower	B-X
pigmentation	B-X
patterns	B-X
were	B-X
isolated	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
spontaneous	B-X
mutations	B-X
were	B-X
found	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
the	B-X
insertion	B-X
of	B-X
DNA	B-X
transposable	B-X
elements	B-X
in	B-X
the	B-X
genes	B-X
for	B-X
the	B-X
anthocyanin	B-X
pigmentation	B-X
in	B-X
flowers	B-X
,	B-X
and	B-X
many	B-X
of	B-X
them	B-X
exhibited	B-X
variegated	B-X
flowers	B-X
,	B-X
such	B-X
as	B-X
white	B-X
flowers	B-X
with	B-X
pigmented	B-X
spots	B-X
and	B-X
sectors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
historical	B-X
background	B-X
of	B-X
the	B-X
mutants	B-X
displaying	B-X
variegated	B-X
flowers	B-X
and	B-X
review	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
in	B-X
flower	B-X
pigmentation	B-X
associated	B-X
with	B-X
transposable	B-X
elements	B-X
of	B-X
these	B-X
morning	B-X
glories	B-X
.	B-X
The	B-X
flecked	B-X
,	B-X
speckled	B-X
,	B-X
r-1	B-X
,	B-X
and	B-X
purple	B-X
mutations	B-X
in	B-X
I.	B-X
nil	B-X
were	B-X
caused	B-X
by	B-X
insertions	B-X
of	B-X
Tpn1	B-X
and	B-X
its	B-X
relatives	B-X
in	B-X
the	B-X
En/Spm	B-X
superfamily	B-X
,	B-X
Tpn2	B-X
,	B-X
Tpn3	B-X
,	B-X
and	B-X
Tpn4	B-X
,	B-X
into	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
coloration	B-X
in	B-X
flowers	B-X
,	B-X
i.e.	B-X
,	B-X
DFR-B	B-X
,	B-X
CHI	B-X
,	B-X
CHS-D	B-X
,	B-X
and	B-X
InNHX1	B-X
,	B-X
respectively	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
flaked	B-X
and	B-X
pink	B-X
mutants	B-X
of	B-X
I.	B-X
purpurea	B-X
have	B-X
distantly	B-X
related	B-X
elements	B-X
,	B-X
Tip100	B-X
and	B-X
Tip201	B-X
,	B-X
in	B-X
the	B-X
Ac/Ds	B-X
superfamily	B-X
inserted	B-X
into	B-X
the	B-X
CHS-D	B-X
and	B-X
F3	B-X
'	B-X
H	B-X
genes	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
flower	B-X
variegation	B-X
patterns	B-X
can	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
these	B-X
transposons	B-X
,	B-X
and	B-X
their	B-X
stable	B-X
insertions	B-X
produce	B-X
plain	B-X
color	B-X
flowers	B-X
without	B-X
generating	B-X
pigmented	B-X
spots	B-X
or	B-X
sectors	B-X
;	B-X
furthermore	B-X
,	B-X
both	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
appeared	B-X
to	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
determining	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
the	B-X
transposons	B-X
.	B-X
However	B-X
,	B-X
flower	B-X
variegation	B-X
is	B-X
not	B-X
always	B-X
associated	B-X
with	B-X
the	B-X
excision	B-X
of	B-X
an	B-X
integrated	B-X
DNA	B-X
transposon	B-X
from	B-X
one	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
pigmentation	B-X
.	B-X
The	B-X
mutant	B-X
Flying	B-X
Saucers	B-X
of	B-X
I.	B-X
tricolor	B-X
displaying	B-X
variegated	B-X
flowers	B-X
was	B-X
found	B-X
to	B-X
have	B-X
the	B-X
transposon	B-X
ItMULE1	B-X
inserted	B-X
into	B-X
the	B-X
DFR-B	B-X
promoter	B-X
region	B-X
,	B-X
but	B-X
no	B-X
excision	B-X
of	B-X
ItMULE1	B-X
from	B-X
the	B-X
DFR-B	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
the	B-X
variegated	B-X
flower	B-X
lines	B-X
.	B-X
Flying	B-X
Saucers	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
epiallele	B-X
because	B-X
the	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
DFR-B	B-X
promoter	B-X
appeared	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
flower	B-X
pigmentation	B-X
.	B-X

Here	O
,	O
we	O
describe	O
the	O
historical	O
background	O
of	O
the	O
mutants	O
displaying	O
variegated	O
flowers	O
and	O
review	O
the	O
genetic	O
and	O
epigenetic	O
regulation	O
in	O
flower	O
pigmentation	O
associated	O
with	O
transposable	O
elements	O
of	O
these	O
morning	O
glories	O
.	O
<EOS>	B-X
Among	B-X
the	B-X
genus	B-X
Ipomoea	B-X
,	B-X
three	B-X
morning	B-X
glories	B-X
,	B-X
I.	B-X
nil	B-X
(	B-X
the	B-X
Japanese	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
I.	B-X
purpurea	B-X
(	B-X
the	B-X
common	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
and	B-X
I.	B-X
tricolor	B-X
,	B-X
were	B-X
domesticated	B-X
well	B-X
for	B-X
floricultural	B-X
plants	B-X
,	B-X
and	B-X
many	B-X
spontaneous	B-X
mutants	B-X
displaying	B-X
various	B-X
flower	B-X
pigmentation	B-X
patterns	B-X
were	B-X
isolated	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
spontaneous	B-X
mutations	B-X
were	B-X
found	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
the	B-X
insertion	B-X
of	B-X
DNA	B-X
transposable	B-X
elements	B-X
in	B-X
the	B-X
genes	B-X
for	B-X
the	B-X
anthocyanin	B-X
pigmentation	B-X
in	B-X
flowers	B-X
,	B-X
and	B-X
many	B-X
of	B-X
them	B-X
exhibited	B-X
variegated	B-X
flowers	B-X
,	B-X
such	B-X
as	B-X
white	B-X
flowers	B-X
with	B-X
pigmented	B-X
spots	B-X
and	B-X
sectors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
historical	B-X
background	B-X
of	B-X
the	B-X
mutants	B-X
displaying	B-X
variegated	B-X
flowers	B-X
and	B-X
review	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
in	B-X
flower	B-X
pigmentation	B-X
associated	B-X
with	B-X
transposable	B-X
elements	B-X
of	B-X
these	B-X
morning	B-X
glories	B-X
.	B-X
The	B-X
flecked	B-X
,	B-X
speckled	B-X
,	B-X
r-1	B-X
,	B-X
and	B-X
purple	B-X
mutations	B-X
in	B-X
I.	B-X
nil	B-X
were	B-X
caused	B-X
by	B-X
insertions	B-X
of	B-X
Tpn1	B-X
and	B-X
its	B-X
relatives	B-X
in	B-X
the	B-X
En/Spm	B-X
superfamily	B-X
,	B-X
Tpn2	B-X
,	B-X
Tpn3	B-X
,	B-X
and	B-X
Tpn4	B-X
,	B-X
into	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
coloration	B-X
in	B-X
flowers	B-X
,	B-X
i.e.	B-X
,	B-X
DFR-B	B-X
,	B-X
CHI	B-X
,	B-X
CHS-D	B-X
,	B-X
and	B-X
InNHX1	B-X
,	B-X
respectively	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
flaked	B-X
and	B-X
pink	B-X
mutants	B-X
of	B-X
I.	B-X
purpurea	B-X
have	B-X
distantly	B-X
related	B-X
elements	B-X
,	B-X
Tip100	B-X
and	B-X
Tip201	B-X
,	B-X
in	B-X
the	B-X
Ac/Ds	B-X
superfamily	B-X
inserted	B-X
into	B-X
the	B-X
CHS-D	B-X
and	B-X
F3	B-X
'	B-X
H	B-X
genes	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
flower	B-X
variegation	B-X
patterns	B-X
can	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
these	B-X
transposons	B-X
,	B-X
and	B-X
their	B-X
stable	B-X
insertions	B-X
produce	B-X
plain	B-X
color	B-X
flowers	B-X
without	B-X
generating	B-X
pigmented	B-X
spots	B-X
or	B-X
sectors	B-X
;	B-X
furthermore	B-X
,	B-X
both	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
appeared	B-X
to	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
determining	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
the	B-X
transposons	B-X
.	B-X
However	B-X
,	B-X
flower	B-X
variegation	B-X
is	B-X
not	B-X
always	B-X
associated	B-X
with	B-X
the	B-X
excision	B-X
of	B-X
an	B-X
integrated	B-X
DNA	B-X
transposon	B-X
from	B-X
one	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
pigmentation	B-X
.	B-X
The	B-X
mutant	B-X
Flying	B-X
Saucers	B-X
of	B-X
I.	B-X
tricolor	B-X
displaying	B-X
variegated	B-X
flowers	B-X
was	B-X
found	B-X
to	B-X
have	B-X
the	B-X
transposon	B-X
ItMULE1	B-X
inserted	B-X
into	B-X
the	B-X
DFR-B	B-X
promoter	B-X
region	B-X
,	B-X
but	B-X
no	B-X
excision	B-X
of	B-X
ItMULE1	B-X
from	B-X
the	B-X
DFR-B	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
the	B-X
variegated	B-X
flower	B-X
lines	B-X
.	B-X
Flying	B-X
Saucers	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
epiallele	B-X
because	B-X
the	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
DFR-B	B-X
promoter	B-X
appeared	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
flower	B-X
pigmentation	B-X
.	B-X

The	O
flecked	O
,	O
speckled	O
,	O
r	O
-	O
1	O
,	O
and	O
purple	O
mutations	O
in	O
I	O
.	O
nil	O
were	O
caused	O
by	O
insertions	O
of	O
Tpn1	O
and	O
its	O
relatives	O
in	O
the	O
En	O
/	O
Spm	O
superfamily	O
,	O
Tpn2	O
,	O
Tpn3	O
,	O
and	O
Tpn4	O
,	O
into	O
the	O
genes	O
for	O
anthocyanin	O
coloration	O
in	O
flowers	O
,	O
i	O
.	O
e	O
.	O
,	O
DFR	B-Protein
-	I-Protein
B	I-Protein
,	O
CHI	B-Protein
,	O
CHS	B-Protein
-	I-Protein
D	I-Protein
,	O
and	O
InNHX1	B-Protein
,	O
respectively	O
.	O

Similarly	O
,	O
the	O
flaked	O
and	O
pink	O
mutants	O
of	O
I	O
.	O
purpurea	O
have	O
distantly	O
related	O
elements	O
,	O
Tip100	O
and	O
Tip201	O
,	O
in	O
the	O
Ac	O
/	O
Ds	O
superfamily	O
inserted	O
into	O
the	O
CHS	B-Protein
-	I-Protein
D	I-Protein
and	O
F3	B-Protein
'	I-Protein
H	I-Protein
genes	O
,	O
respectively	O
.	O

The	O
flower	O
variegation	O
patterns	O
can	O
be	O
determined	O
by	O
the	O
frequency	O
and	O
timing	O
of	O
the	O
excision	O
of	O
these	O
transposons	O
,	O
and	O
their	O
stable	O
insertions	O
produce	O
plain	O
color	O
flowers	O
without	O
generating	O
pigmented	O
spots	O
or	O
sectors	O
;	O
furthermore	O
,	O
both	O
genetic	O
and	O
epigenetic	O
regulation	O
appeared	O
to	O
play	O
important	O
roles	O
in	O
determining	O
the	O
frequency	O
and	O
timing	O
of	O
the	O
excision	O
of	O
the	O
transposons	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
paper	B-X
is	B-X
to	B-X
investigate	B-X
managers	B-X
'	B-X
leadership	B-X
styles	B-X
,	B-X
from	B-X
the	B-X
perspective	B-X
of	B-X
registered	B-X
nurses	B-X
,	B-X
and	B-X
its	B-X
effects	B-X
on	B-X
the	B-X
quality	B-X
of	B-X
nursing	B-X
care	B-X
in	B-X
both	B-X
the	B-X
private	B-X
and	B-X
public	B-X
healthcare	B-X
sectors	B-X
.	B-X
We	B-X
rationalize	B-X
this	B-X
evidence	B-X
through	B-X
the	B-X
lens	B-X
of	B-X
a	B-X
general	B-X
equilibrium	B-X
model	B-X
with	B-X
two	B-X
sectors	B-X
,	B-X
matching	B-X
frictions	B-X
and	B-X
endogenous	B-X
participation	B-X
.	B-X
All	B-X
sectors	B-X
,	B-X
including	B-X
healthcare	B-X
,	B-X
must	B-X
act	B-X
to	B-X
mitigate	B-X
and	B-X
prevent	B-X
future	B-X
harms	B-X
.	B-X
Results	B-X
suggest	B-X
prevailing	B-X
positive	B-X
effects	B-X
on	B-X
national	B-X
economies	B-X
(	B-X
value-added	B-X
,	B-X
employment	B-X
and	B-X
household	B-X
income	B-X
)	B-X
when	B-X
spending	B-X
on	B-X
health-care	B-X
sector	B-X
products	B-X
and	B-X
services	B-X
increases	B-X
,	B-X
especially	B-X
in	B-X
comparison	B-X
to	B-X
the	B-X
effects	B-X
of	B-X
increases	B-X
in	B-X
spending	B-X
in	B-X
other	B-X
sectors	B-X
.	B-X
The	B-X
health-care	B-X
sector	B-X
therefore	B-X
can	B-X
play	B-X
an	B-X
important	B-X
role	B-X
as	B-X
an	B-X
instrument	B-X
of	B-X
economic	B-X
policy	B-X
.	B-X

However	O
,	O
flower	O
variegation	O
is	O
not	O
always	O
associated	O
with	O
the	O
excision	O
of	O
an	O
integrated	O
DNA	O
transposon	O
from	O
one	O
of	O
the	O
genes	O
for	O
anthocyanin	O
pigmentation	O
.	O
<EOS>	B-X
A	B-X
flowering	B-X
plant	B-X
of	B-X
variegated	B-X
ingredients	B-X
and	B-X
psychoactive	B-X
qualities	B-X
,	B-X
Cannabis	B-X
has	B-X
long	B-X
been	B-X
used	B-X
for	B-X
medicinal	B-X
and	B-X
recreational	B-X
purposes	B-X
.	B-X
A	B-X
flowering	B-X
plant	B-X
of	B-X
variegated	B-X
ingredients	B-X
and	B-X
psychoactive	B-X
qualities	B-X
,	B-X
cannabis	B-X
has	B-X
long	B-X
been	B-X
used	B-X
for	B-X
medicinal	B-X
and	B-X
recreational	B-X
purposes	B-X
.	B-X
However	B-X
,	B-X
limited	B-X
knowledge	B-X
on	B-X
the	B-X
benefits	B-X
and	B-X
risks	B-X
precludes	B-X
inclusion	B-X
of	B-X
cannabis	B-X
in	B-X
standard	B-X
treatment	B-X
guidelines	B-X
.	B-X
Primulina	B-X
pungentisepala	B-X
is	B-X
suitable	B-X
for	B-X
use	B-X
as	B-X
a	B-X
potted	B-X
plant	B-X
because	B-X
of	B-X
its	B-X
beautiful	B-X
leaf	B-X
variegation	B-X
,	B-X
which	B-X
is	B-X
significantly	B-X
different	B-X
in	B-X
its	B-X
selfed	B-X
offspring	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
P.	B-X
pungentisepala	B-X
leaf	B-X
variegation	B-X
is	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
two	B-X
types	B-X
of	B-X
offspring	B-X
showing	B-X
the	B-X
greatest	B-X
differences	B-X
were	B-X
compared	B-X
in	B-X
terms	B-X
of	B-X
leaf	B-X
structure	B-X
,	B-X
chlorophyll	B-X
contents	B-X
,	B-X
chlorophyll	B-X
fluorescence	B-X
parameters	B-X
and	B-X
transcriptomes	B-X
to	B-X
provide	B-X
a	B-X
reference	B-X
for	B-X
studying	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
structural	B-X
leaf	B-X
variegation	B-X
.	B-X

The	O
mutant	O
Flying	O
Saucers	O
of	O
I	O
.	O
tricolor	O
displaying	O
variegated	O
flowers	O
was	O
found	O
to	O
have	O
the	O
transposon	O
ItMULE1	O
inserted	O
into	O
the	O
DFR	B-Protein
-	I-Protein
B	I-Protein
promoter	O
region	O
,	O
but	O
no	O
excision	O
of	O
ItMULE1	O
from	O
the	O
DFR	B-Protein
-	I-Protein
B	I-Protein
could	O
be	O
detected	O
in	O
the	O
variegated	O
flower	O
lines	O
.	O
<EOS>	B-X
Among	B-X
the	B-X
genus	B-X
Ipomoea	B-X
,	B-X
three	B-X
morning	B-X
glories	B-X
,	B-X
I.	B-X
nil	B-X
(	B-X
the	B-X
Japanese	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
I.	B-X
purpurea	B-X
(	B-X
the	B-X
common	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
and	B-X
I.	B-X
tricolor	B-X
,	B-X
were	B-X
domesticated	B-X
well	B-X
for	B-X
floricultural	B-X
plants	B-X
,	B-X
and	B-X
many	B-X
spontaneous	B-X
mutants	B-X
displaying	B-X
various	B-X
flower	B-X
pigmentation	B-X
patterns	B-X
were	B-X
isolated	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
spontaneous	B-X
mutations	B-X
were	B-X
found	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
the	B-X
insertion	B-X
of	B-X
DNA	B-X
transposable	B-X
elements	B-X
in	B-X
the	B-X
genes	B-X
for	B-X
the	B-X
anthocyanin	B-X
pigmentation	B-X
in	B-X
flowers	B-X
,	B-X
and	B-X
many	B-X
of	B-X
them	B-X
exhibited	B-X
variegated	B-X
flowers	B-X
,	B-X
such	B-X
as	B-X
white	B-X
flowers	B-X
with	B-X
pigmented	B-X
spots	B-X
and	B-X
sectors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
historical	B-X
background	B-X
of	B-X
the	B-X
mutants	B-X
displaying	B-X
variegated	B-X
flowers	B-X
and	B-X
review	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
in	B-X
flower	B-X
pigmentation	B-X
associated	B-X
with	B-X
transposable	B-X
elements	B-X
of	B-X
these	B-X
morning	B-X
glories	B-X
.	B-X
The	B-X
flecked	B-X
,	B-X
speckled	B-X
,	B-X
r-1	B-X
,	B-X
and	B-X
purple	B-X
mutations	B-X
in	B-X
I.	B-X
nil	B-X
were	B-X
caused	B-X
by	B-X
insertions	B-X
of	B-X
Tpn1	B-X
and	B-X
its	B-X
relatives	B-X
in	B-X
the	B-X
En/Spm	B-X
superfamily	B-X
,	B-X
Tpn2	B-X
,	B-X
Tpn3	B-X
,	B-X
and	B-X
Tpn4	B-X
,	B-X
into	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
coloration	B-X
in	B-X
flowers	B-X
,	B-X
i.e.	B-X
,	B-X
DFR-B	B-X
,	B-X
CHI	B-X
,	B-X
CHS-D	B-X
,	B-X
and	B-X
InNHX1	B-X
,	B-X
respectively	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
flaked	B-X
and	B-X
pink	B-X
mutants	B-X
of	B-X
I.	B-X
purpurea	B-X
have	B-X
distantly	B-X
related	B-X
elements	B-X
,	B-X
Tip100	B-X
and	B-X
Tip201	B-X
,	B-X
in	B-X
the	B-X
Ac/Ds	B-X
superfamily	B-X
inserted	B-X
into	B-X
the	B-X
CHS-D	B-X
and	B-X
F3	B-X
'	B-X
H	B-X
genes	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
flower	B-X
variegation	B-X
patterns	B-X
can	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
these	B-X
transposons	B-X
,	B-X
and	B-X
their	B-X
stable	B-X
insertions	B-X
produce	B-X
plain	B-X
color	B-X
flowers	B-X
without	B-X
generating	B-X
pigmented	B-X
spots	B-X
or	B-X
sectors	B-X
;	B-X
furthermore	B-X
,	B-X
both	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
appeared	B-X
to	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
determining	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
the	B-X
transposons	B-X
.	B-X
However	B-X
,	B-X
flower	B-X
variegation	B-X
is	B-X
not	B-X
always	B-X
associated	B-X
with	B-X
the	B-X
excision	B-X
of	B-X
an	B-X
integrated	B-X
DNA	B-X
transposon	B-X
from	B-X
one	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
pigmentation	B-X
.	B-X
The	B-X
mutant	B-X
Flying	B-X
Saucers	B-X
of	B-X
I.	B-X
tricolor	B-X
displaying	B-X
variegated	B-X
flowers	B-X
was	B-X
found	B-X
to	B-X
have	B-X
the	B-X
transposon	B-X
ItMULE1	B-X
inserted	B-X
into	B-X
the	B-X
DFR-B	B-X
promoter	B-X
region	B-X
,	B-X
but	B-X
no	B-X
excision	B-X
of	B-X
ItMULE1	B-X
from	B-X
the	B-X
DFR-B	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
the	B-X
variegated	B-X
flower	B-X
lines	B-X
.	B-X
Flying	B-X
Saucers	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
epiallele	B-X
because	B-X
the	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
DFR-B	B-X
promoter	B-X
appeared	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
flower	B-X
pigmentation	B-X
.	B-X

The	O
instable	O
pearly	O
-	O
vrg	O
allele	O
in	O
cv	O
.	O
<EOS>	B-X
The	B-X
instable	B-X
pearly-vrg	B-X
allele	B-X
in	B-X
cv	B-X
.	B-X
Flying	B-X
Saucers	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
epiallele	B-X
because	B-X
the	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
DFR-B	B-X
promoter	B-X
appeared	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
flower	B-X
pigmentation	B-X
.	B-X
The	B-X
instable	B-X
pearly-vrg	B-X
allele	B-X
in	B-X
cv	B-X
.	B-X
Flying	B-X
Saucers	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
epiallele	B-X
because	B-X
the	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
DFR-B	B-X
promoter	B-X
appeared	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
flower	B-X
pigmentation	B-X
.	B-X

Flying	O
Saucers	O
is	O
likely	O
to	O
be	O
an	O
epiallele	O
because	O
the	O
DNA	O
methylation	O
in	O
the	O
DFR	B-Protein
-	I-Protein
B	I-Protein
promoter	O
appeared	O
to	O
be	O
associated	O
with	O
flower	O
pigmentation	O
.	O
<EOS>	B-X
Among	B-X
the	B-X
genus	B-X
Ipomoea	B-X
,	B-X
three	B-X
morning	B-X
glories	B-X
,	B-X
I.	B-X
nil	B-X
(	B-X
the	B-X
Japanese	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
I.	B-X
purpurea	B-X
(	B-X
the	B-X
common	B-X
morning	B-X
glory	B-X
)	B-X
,	B-X
and	B-X
I.	B-X
tricolor	B-X
,	B-X
were	B-X
domesticated	B-X
well	B-X
for	B-X
floricultural	B-X
plants	B-X
,	B-X
and	B-X
many	B-X
spontaneous	B-X
mutants	B-X
displaying	B-X
various	B-X
flower	B-X
pigmentation	B-X
patterns	B-X
were	B-X
isolated	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
spontaneous	B-X
mutations	B-X
were	B-X
found	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
the	B-X
insertion	B-X
of	B-X
DNA	B-X
transposable	B-X
elements	B-X
in	B-X
the	B-X
genes	B-X
for	B-X
the	B-X
anthocyanin	B-X
pigmentation	B-X
in	B-X
flowers	B-X
,	B-X
and	B-X
many	B-X
of	B-X
them	B-X
exhibited	B-X
variegated	B-X
flowers	B-X
,	B-X
such	B-X
as	B-X
white	B-X
flowers	B-X
with	B-X
pigmented	B-X
spots	B-X
and	B-X
sectors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
historical	B-X
background	B-X
of	B-X
the	B-X
mutants	B-X
displaying	B-X
variegated	B-X
flowers	B-X
and	B-X
review	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
in	B-X
flower	B-X
pigmentation	B-X
associated	B-X
with	B-X
transposable	B-X
elements	B-X
of	B-X
these	B-X
morning	B-X
glories	B-X
.	B-X
The	B-X
flecked	B-X
,	B-X
speckled	B-X
,	B-X
r-1	B-X
,	B-X
and	B-X
purple	B-X
mutations	B-X
in	B-X
I.	B-X
nil	B-X
were	B-X
caused	B-X
by	B-X
insertions	B-X
of	B-X
Tpn1	B-X
and	B-X
its	B-X
relatives	B-X
in	B-X
the	B-X
En/Spm	B-X
superfamily	B-X
,	B-X
Tpn2	B-X
,	B-X
Tpn3	B-X
,	B-X
and	B-X
Tpn4	B-X
,	B-X
into	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
coloration	B-X
in	B-X
flowers	B-X
,	B-X
i.e.	B-X
,	B-X
DFR-B	B-X
,	B-X
CHI	B-X
,	B-X
CHS-D	B-X
,	B-X
and	B-X
InNHX1	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
flower	B-X
variegation	B-X
patterns	B-X
can	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
these	B-X
transposons	B-X
,	B-X
and	B-X
their	B-X
stable	B-X
insertions	B-X
produce	B-X
plain	B-X
color	B-X
flowers	B-X
without	B-X
generating	B-X
pigmented	B-X
spots	B-X
or	B-X
sectors	B-X
;	B-X
furthermore	B-X
,	B-X
both	B-X
genetic	B-X
and	B-X
epigenetic	B-X
regulation	B-X
appeared	B-X
to	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
determining	B-X
the	B-X
frequency	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
excision	B-X
of	B-X
the	B-X
transposons	B-X
.	B-X
However	B-X
,	B-X
flower	B-X
variegation	B-X
is	B-X
not	B-X
always	B-X
associated	B-X
with	B-X
the	B-X
excision	B-X
of	B-X
an	B-X
integrated	B-X
DNA	B-X
transposon	B-X
from	B-X
one	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
anthocyanin	B-X
pigmentation	B-X
.	B-X
The	B-X
mutant	B-X
Flying	B-X
Saucers	B-X
of	B-X
I.	B-X
tricolor	B-X
displaying	B-X
variegated	B-X
flowers	B-X
was	B-X
found	B-X
to	B-X
have	B-X
the	B-X
transposon	B-X
ItMULE1	B-X
inserted	B-X
into	B-X
the	B-X
DFR-B	B-X
promoter	B-X
region	B-X
,	B-X
but	B-X
no	B-X
excision	B-X
of	B-X
ItMULE1	B-X
from	B-X
the	B-X
DFR-B	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
the	B-X
variegated	B-X
flower	B-X
lines	B-X
.	B-X
Flying	B-X
Saucers	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
epiallele	B-X
because	B-X
the	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
DFR-B	B-X
promoter	B-X
appeared	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
flower	B-X
pigmentation	B-X
.	B-X

Characterization	O
of	O
a	O
second	O
Arabidopsis	O
thaliana	O
prolyl	O
4	O
-	O
hydroxylase	O
with	O
distinct	O
substrate	O
specificity	O
.	O
<EOS>	B-X
4-Hydroxyproline	B-X
is	B-X
found	B-X
in	B-X
collagens	B-X
,	B-X
collagen-like	B-X
proteins	B-X
,	B-X
elastin	B-X
,	B-X
and	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
in	B-X
animals	B-X
and	B-X
in	B-X
many	B-X
hydroxyproline-rich	B-X
glycoproteins	B-X
in	B-X
plants	B-X
.	B-X
We	B-X
report	B-X
here	B-X
on	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
second	B-X
plant	B-X
P4H	B-X
(	B-X
prolyl	B-X
4-hydroxylase	B-X
)	B-X
,	B-X
At-P4H-2	B-X
,	B-X
from	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
299	B-X
amino	B-X
acids	B-X
and	B-X
shows	B-X
33	B-X
%	B-X
sequence	B-X
identity	B-X
to	B-X
the	B-X
first	B-X
characterized	B-X
isoenzyme	B-X
,	B-X
At-P4H-1	B-X
.	B-X
A	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
At-P4H-2	B-X
polypeptide	B-X
is	B-X
a	B-X
49-amino-acid	B-X
C-terminal	B-X
toxin	B-X
homology	B-X
domain	B-X
with	B-X
6	B-X
cysteines	B-X
that	B-X
is	B-X
not	B-X
found	B-X
in	B-X
At-P4H-1	B-X
but	B-X
is	B-X
present	B-X
in	B-X
a	B-X
putative	B-X
rice	B-X
P4H	B-X
homologue	B-X
.	B-X
At-P4H-2	B-X
differed	B-X
distinctly	B-X
from	B-X
At-P4H-1	B-X
in	B-X
its	B-X
substrate	B-X
specificity	B-X
.	B-X
Recombinant	B-X
At-P4H-2	B-X
hydroxylated	B-X
poly	B-X
(	B-X
L-proline	B-X
)	B-X
and	B-X
extensin	B-X
and	B-X
arabinogalactan-like	B-X
peptides	B-X
effectively	B-X
but	B-X
with	B-X
much	B-X
higher	B-X
Km	B-X
values	B-X
than	B-X
At-P4H-1	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
the	B-X
two	B-X
At-P4Hs	B-X
in	B-X
the	B-X
plant	B-X
cell	B-X
.	B-X
Unlike	B-X
At-P4H-1	B-X
,	B-X
At-P4H-2	B-X
hydroxylated	B-X
collagen-like	B-X
peptides	B-X
only	B-X
very	B-X
inefficiently	B-X
and	B-X
did	B-X
not	B-X
hydroxylate	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
alpha-like	B-X
peptides	B-X
at	B-X
all	B-X
.	B-X
All	B-X
the	B-X
peptides	B-X
efficiently	B-X
hydroxylated	B-X
by	B-X
At-P4H-2	B-X
had	B-X
at	B-X
least	B-X
3	B-X
consecutive	B-X
prolines	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
may	B-X
represent	B-X
a	B-X
minimum	B-X
requirement	B-X
for	B-X
efficient	B-X
hydroxylation	B-X
by	B-X
this	B-X
isoenzyme	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
an	B-X
extensin-like	B-X
peptide	B-X
SPPPVYKSPPPPVKHYSPPPV	B-X
indicated	B-X
that	B-X
At-P4H-2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
3rd	B-X
proline	B-X
in	B-X
the	B-X
C-terminal	B-X
PPP	B-X
triplet	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
of	B-X
At-P4H-2	B-X
for	B-X
the	B-X
reaction	B-X
cosubstrates	B-X
Fe2+	B-X
,	B-X
2-oxoglutarate	B-X
,	B-X
and	B-X
ascorbate	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
At-P4H-1	B-X
with	B-X
the	B-X
exception	B-X
that	B-X
the	B-X
Km	B-X
for	B-X
iron	B-X
was	B-X
about	B-X
3-fold	B-X
lower	B-X
.	B-X
Pyridine-2,4-dicarboxylate	B-X
and	B-X
pyridine-2,5-dicarboxylate	B-X
,	B-X
well	B-X
known	B-X
competitive	B-X
inhibitors	B-X
of	B-X
the	B-X
vertebrate	B-X
P4Hs	B-X
with	B-X
respect	B-X
to	B-X
2-oxoglutarate	B-X
,	B-X
were	B-X
also	B-X
competitive	B-X
inhibitors	B-X
of	B-X
At-P4H-2	B-X
but	B-X
with	B-X
Ki	B-X
values	B-X
5-100-fold	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
human	B-X
type	B-X
I	B-X
collagen	B-X
P4H	B-X
.	B-X
It	B-X
thus	B-X
seems	B-X
that	B-X
there	B-X
are	B-X
some	B-X
distinct	B-X
differences	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
2-oxoglutarate-binding	B-X
site	B-X
between	B-X
At-P4H-2	B-X
and	B-X
the	B-X
animal	B-X
collagen	B-X
P4Hs	B-X
.	B-X

4	O
-	O
Hydroxyproline	O
is	O
found	O
in	O
collagens	O
,	O
collagen	O
-	O
like	O
proteins	O
,	O
elastin	B-Protein
,	O
and	O
the	O
hypoxia	O
-	O
inducible	O
transcription	O
factor	O
in	O
animals	O
and	O
in	O
many	O
hydroxyproline	O
-	O
rich	O
glycoproteins	O
in	O
plants	O
.	O
<EOS>	B-X
4-Hydroxyproline	B-X
is	B-X
found	B-X
in	B-X
collagens	B-X
,	B-X
collagen-like	B-X
proteins	B-X
,	B-X
elastin	B-X
,	B-X
and	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
in	B-X
animals	B-X
and	B-X
in	B-X
many	B-X
hydroxyproline-rich	B-X
glycoproteins	B-X
in	B-X
plants	B-X
.	B-X
We	B-X
report	B-X
here	B-X
on	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
second	B-X
plant	B-X
P4H	B-X
(	B-X
prolyl	B-X
4-hydroxylase	B-X
)	B-X
,	B-X
At-P4H-2	B-X
,	B-X
from	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
299	B-X
amino	B-X
acids	B-X
and	B-X
shows	B-X
33	B-X
%	B-X
sequence	B-X
identity	B-X
to	B-X
the	B-X
first	B-X
characterized	B-X
isoenzyme	B-X
,	B-X
At-P4H-1	B-X
.	B-X
A	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
At-P4H-2	B-X
polypeptide	B-X
is	B-X
a	B-X
49-amino-acid	B-X
C-terminal	B-X
toxin	B-X
homology	B-X
domain	B-X
with	B-X
6	B-X
cysteines	B-X
that	B-X
is	B-X
not	B-X
found	B-X
in	B-X
At-P4H-1	B-X
but	B-X
is	B-X
present	B-X
in	B-X
a	B-X
putative	B-X
rice	B-X
P4H	B-X
homologue	B-X
.	B-X
At-P4H-2	B-X
differed	B-X
distinctly	B-X
from	B-X
At-P4H-1	B-X
in	B-X
its	B-X
substrate	B-X
specificity	B-X
.	B-X
Recombinant	B-X
At-P4H-2	B-X
hydroxylated	B-X
poly	B-X
(	B-X
L-proline	B-X
)	B-X
and	B-X
extensin	B-X
and	B-X
arabinogalactan-like	B-X
peptides	B-X
effectively	B-X
but	B-X
with	B-X
much	B-X
higher	B-X
Km	B-X
values	B-X
than	B-X
At-P4H-1	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
the	B-X
two	B-X
At-P4Hs	B-X
in	B-X
the	B-X
plant	B-X
cell	B-X
.	B-X
Unlike	B-X
At-P4H-1	B-X
,	B-X
At-P4H-2	B-X
hydroxylated	B-X
collagen-like	B-X
peptides	B-X
only	B-X
very	B-X
inefficiently	B-X
and	B-X
did	B-X
not	B-X
hydroxylate	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
alpha-like	B-X
peptides	B-X
at	B-X
all	B-X
.	B-X
All	B-X
the	B-X
peptides	B-X
efficiently	B-X
hydroxylated	B-X
by	B-X
At-P4H-2	B-X
had	B-X
at	B-X
least	B-X
3	B-X
consecutive	B-X
prolines	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
may	B-X
represent	B-X
a	B-X
minimum	B-X
requirement	B-X
for	B-X
efficient	B-X
hydroxylation	B-X
by	B-X
this	B-X
isoenzyme	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
an	B-X
extensin-like	B-X
peptide	B-X
SPPPVYKSPPPPVKHYSPPPV	B-X
indicated	B-X
that	B-X
At-P4H-2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
3rd	B-X
proline	B-X
in	B-X
the	B-X
C-terminal	B-X
PPP	B-X
triplet	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
of	B-X
At-P4H-2	B-X
for	B-X
the	B-X
reaction	B-X
cosubstrates	B-X
Fe2+	B-X
,	B-X
2-oxoglutarate	B-X
,	B-X
and	B-X
ascorbate	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
At-P4H-1	B-X
with	B-X
the	B-X
exception	B-X
that	B-X
the	B-X
Km	B-X
for	B-X
iron	B-X
was	B-X
about	B-X
3-fold	B-X
lower	B-X
.	B-X
Pyridine-2,4-dicarboxylate	B-X
and	B-X
pyridine-2,5-dicarboxylate	B-X
,	B-X
well	B-X
known	B-X
competitive	B-X
inhibitors	B-X
of	B-X
the	B-X
vertebrate	B-X
P4Hs	B-X
with	B-X
respect	B-X
to	B-X
2-oxoglutarate	B-X
,	B-X
were	B-X
also	B-X
competitive	B-X
inhibitors	B-X
of	B-X
At-P4H-2	B-X
but	B-X
with	B-X
Ki	B-X
values	B-X
5-100-fold	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
human	B-X
type	B-X
I	B-X
collagen	B-X
P4H	B-X
.	B-X
It	B-X
thus	B-X
seems	B-X
that	B-X
there	B-X
are	B-X
some	B-X
distinct	B-X
differences	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
2-oxoglutarate-binding	B-X
site	B-X
between	B-X
At-P4H-2	B-X
and	B-X
the	B-X
animal	B-X
collagen	B-X
P4Hs	B-X
.	B-X

We	O
report	O
here	O
on	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
second	O
plant	O
P4H	O
(	O
prolyl	O
4	O
-	O
hydroxylase	O
)	O
,	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
,	O
from	O
Arabidopsis	O
thaliana	O
.	O
<EOS>	B-X
4-Hydroxyproline	B-X
is	B-X
found	B-X
in	B-X
collagens	B-X
,	B-X
collagen-like	B-X
proteins	B-X
,	B-X
elastin	B-X
,	B-X
and	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
in	B-X
animals	B-X
and	B-X
in	B-X
many	B-X
hydroxyproline-rich	B-X
glycoproteins	B-X
in	B-X
plants	B-X
.	B-X
We	B-X
report	B-X
here	B-X
on	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
second	B-X
plant	B-X
P4H	B-X
(	B-X
prolyl	B-X
4-hydroxylase	B-X
)	B-X
,	B-X
At-P4H-2	B-X
,	B-X
from	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
299	B-X
amino	B-X
acids	B-X
and	B-X
shows	B-X
33	B-X
%	B-X
sequence	B-X
identity	B-X
to	B-X
the	B-X
first	B-X
characterized	B-X
isoenzyme	B-X
,	B-X
At-P4H-1	B-X
.	B-X
A	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
At-P4H-2	B-X
polypeptide	B-X
is	B-X
a	B-X
49-amino-acid	B-X
C-terminal	B-X
toxin	B-X
homology	B-X
domain	B-X
with	B-X
6	B-X
cysteines	B-X
that	B-X
is	B-X
not	B-X
found	B-X
in	B-X
At-P4H-1	B-X
but	B-X
is	B-X
present	B-X
in	B-X
a	B-X
putative	B-X
rice	B-X
P4H	B-X
homologue	B-X
.	B-X
At-P4H-2	B-X
differed	B-X
distinctly	B-X
from	B-X
At-P4H-1	B-X
in	B-X
its	B-X
substrate	B-X
specificity	B-X
.	B-X
Recombinant	B-X
At-P4H-2	B-X
hydroxylated	B-X
poly	B-X
(	B-X
L-proline	B-X
)	B-X
and	B-X
extensin	B-X
and	B-X
arabinogalactan-like	B-X
peptides	B-X
effectively	B-X
but	B-X
with	B-X
much	B-X
higher	B-X
Km	B-X
values	B-X
than	B-X
At-P4H-1	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
the	B-X
two	B-X
At-P4Hs	B-X
in	B-X
the	B-X
plant	B-X
cell	B-X
.	B-X
Unlike	B-X
At-P4H-1	B-X
,	B-X
At-P4H-2	B-X
hydroxylated	B-X
collagen-like	B-X
peptides	B-X
only	B-X
very	B-X
inefficiently	B-X
and	B-X
did	B-X
not	B-X
hydroxylate	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
alpha-like	B-X
peptides	B-X
at	B-X
all	B-X
.	B-X
All	B-X
the	B-X
peptides	B-X
efficiently	B-X
hydroxylated	B-X
by	B-X
At-P4H-2	B-X
had	B-X
at	B-X
least	B-X
3	B-X
consecutive	B-X
prolines	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
may	B-X
represent	B-X
a	B-X
minimum	B-X
requirement	B-X
for	B-X
efficient	B-X
hydroxylation	B-X
by	B-X
this	B-X
isoenzyme	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
an	B-X
extensin-like	B-X
peptide	B-X
SPPPVYKSPPPPVKHYSPPPV	B-X
indicated	B-X
that	B-X
At-P4H-2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
3rd	B-X
proline	B-X
in	B-X
the	B-X
C-terminal	B-X
PPP	B-X
triplet	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
of	B-X
At-P4H-2	B-X
for	B-X
the	B-X
reaction	B-X
cosubstrates	B-X
Fe2+	B-X
,	B-X
2-oxoglutarate	B-X
,	B-X
and	B-X
ascorbate	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
At-P4H-1	B-X
with	B-X
the	B-X
exception	B-X
that	B-X
the	B-X
Km	B-X
for	B-X
iron	B-X
was	B-X
about	B-X
3-fold	B-X
lower	B-X
.	B-X
Pyridine-2,4-dicarboxylate	B-X
and	B-X
pyridine-2,5-dicarboxylate	B-X
,	B-X
well	B-X
known	B-X
competitive	B-X
inhibitors	B-X
of	B-X
the	B-X
vertebrate	B-X
P4Hs	B-X
with	B-X
respect	B-X
to	B-X
2-oxoglutarate	B-X
,	B-X
were	B-X
also	B-X
competitive	B-X
inhibitors	B-X
of	B-X
At-P4H-2	B-X
but	B-X
with	B-X
Ki	B-X
values	B-X
5-100-fold	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
human	B-X
type	B-X
I	B-X
collagen	B-X
P4H	B-X
.	B-X
It	B-X
thus	B-X
seems	B-X
that	B-X
there	B-X
are	B-X
some	B-X
distinct	B-X
differences	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
2-oxoglutarate-binding	B-X
site	B-X
between	B-X
At-P4H-2	B-X
and	B-X
the	B-X
animal	B-X
collagen	B-X
P4Hs	B-X
.	B-X

It	O
consists	O
of	O
299	O
amino	O
acids	O
and	O
shows	O
33	O
%	O
sequence	O
identity	O
to	O
the	O
first	O
characterized	O
isoenzyme	O
,	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	I-Protein
.	O

A	O
characteristic	O
feature	O
of	O
the	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
polypeptide	O
is	O
a	O
49	O
-	O
amino	O
-	O
acid	O
C	O
-	O
terminal	O
toxin	O
homology	O
domain	O
with	O
6	O
cysteines	O
that	O
is	O
not	O
found	O
in	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	I-Protein
but	O
is	O
present	O
in	O
a	O
putative	O
rice	O
P4H	O
homologue	O
.	O
<EOS>	B-X
4-Hydroxyproline	B-X
is	B-X
found	B-X
in	B-X
collagens	B-X
,	B-X
collagen-like	B-X
proteins	B-X
,	B-X
elastin	B-X
,	B-X
and	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
in	B-X
animals	B-X
and	B-X
in	B-X
many	B-X
hydroxyproline-rich	B-X
glycoproteins	B-X
in	B-X
plants	B-X
.	B-X
We	B-X
report	B-X
here	B-X
on	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
second	B-X
plant	B-X
P4H	B-X
(	B-X
prolyl	B-X
4-hydroxylase	B-X
)	B-X
,	B-X
At-P4H-2	B-X
,	B-X
from	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
299	B-X
amino	B-X
acids	B-X
and	B-X
shows	B-X
33	B-X
%	B-X
sequence	B-X
identity	B-X
to	B-X
the	B-X
first	B-X
characterized	B-X
isoenzyme	B-X
,	B-X
At-P4H-1	B-X
.	B-X
A	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
At-P4H-2	B-X
polypeptide	B-X
is	B-X
a	B-X
49-amino-acid	B-X
C-terminal	B-X
toxin	B-X
homology	B-X
domain	B-X
with	B-X
6	B-X
cysteines	B-X
that	B-X
is	B-X
not	B-X
found	B-X
in	B-X
At-P4H-1	B-X
but	B-X
is	B-X
present	B-X
in	B-X
a	B-X
putative	B-X
rice	B-X
P4H	B-X
homologue	B-X
.	B-X
At-P4H-2	B-X
differed	B-X
distinctly	B-X
from	B-X
At-P4H-1	B-X
in	B-X
its	B-X
substrate	B-X
specificity	B-X
.	B-X
Recombinant	B-X
At-P4H-2	B-X
hydroxylated	B-X
poly	B-X
(	B-X
L-proline	B-X
)	B-X
and	B-X
extensin	B-X
and	B-X
arabinogalactan-like	B-X
peptides	B-X
effectively	B-X
but	B-X
with	B-X
much	B-X
higher	B-X
Km	B-X
values	B-X
than	B-X
At-P4H-1	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
the	B-X
two	B-X
At-P4Hs	B-X
in	B-X
the	B-X
plant	B-X
cell	B-X
.	B-X
Unlike	B-X
At-P4H-1	B-X
,	B-X
At-P4H-2	B-X
hydroxylated	B-X
collagen-like	B-X
peptides	B-X
only	B-X
very	B-X
inefficiently	B-X
and	B-X
did	B-X
not	B-X
hydroxylate	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
alpha-like	B-X
peptides	B-X
at	B-X
all	B-X
.	B-X
All	B-X
the	B-X
peptides	B-X
efficiently	B-X
hydroxylated	B-X
by	B-X
At-P4H-2	B-X
had	B-X
at	B-X
least	B-X
3	B-X
consecutive	B-X
prolines	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
may	B-X
represent	B-X
a	B-X
minimum	B-X
requirement	B-X
for	B-X
efficient	B-X
hydroxylation	B-X
by	B-X
this	B-X
isoenzyme	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
an	B-X
extensin-like	B-X
peptide	B-X
SPPPVYKSPPPPVKHYSPPPV	B-X
indicated	B-X
that	B-X
At-P4H-2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
3rd	B-X
proline	B-X
in	B-X
the	B-X
C-terminal	B-X
PPP	B-X
triplet	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
of	B-X
At-P4H-2	B-X
for	B-X
the	B-X
reaction	B-X
cosubstrates	B-X
Fe2+	B-X
,	B-X
2-oxoglutarate	B-X
,	B-X
and	B-X
ascorbate	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
At-P4H-1	B-X
with	B-X
the	B-X
exception	B-X
that	B-X
the	B-X
Km	B-X
for	B-X
iron	B-X
was	B-X
about	B-X
3-fold	B-X
lower	B-X
.	B-X
Pyridine-2,4-dicarboxylate	B-X
and	B-X
pyridine-2,5-dicarboxylate	B-X
,	B-X
well	B-X
known	B-X
competitive	B-X
inhibitors	B-X
of	B-X
the	B-X
vertebrate	B-X
P4Hs	B-X
with	B-X
respect	B-X
to	B-X
2-oxoglutarate	B-X
,	B-X
were	B-X
also	B-X
competitive	B-X
inhibitors	B-X
of	B-X
At-P4H-2	B-X
but	B-X
with	B-X
Ki	B-X
values	B-X
5-100-fold	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
human	B-X
type	B-X
I	B-X
collagen	B-X
P4H	B-X
.	B-X
It	B-X
thus	B-X
seems	B-X
that	B-X
there	B-X
are	B-X
some	B-X
distinct	B-X
differences	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
2-oxoglutarate-binding	B-X
site	B-X
between	B-X
At-P4H-2	B-X
and	B-X
the	B-X
animal	B-X
collagen	B-X
P4Hs	B-X
.	B-X

At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
differed	O
distinctly	O
from	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	I-Protein
in	O
its	O
substrate	O
specificity	O
.	O
<EOS>	B-X
We	B-X
report	B-X
here	B-X
on	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
second	B-X
plant	B-X
P4H	B-X
(	B-X
prolyl	B-X
4-hydroxylase	B-X
)	B-X
,	B-X
At-P4H-2	B-X
,	B-X
from	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
299	B-X
amino	B-X
acids	B-X
and	B-X
shows	B-X
33	B-X
%	B-X
sequence	B-X
identity	B-X
to	B-X
the	B-X
first	B-X
characterized	B-X
isoenzyme	B-X
,	B-X
At-P4H-1	B-X
.	B-X
A	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
At-P4H-2	B-X
polypeptide	B-X
is	B-X
a	B-X
49-amino-acid	B-X
C-terminal	B-X
toxin	B-X
homology	B-X
domain	B-X
with	B-X
6	B-X
cysteines	B-X
that	B-X
is	B-X
not	B-X
found	B-X
in	B-X
At-P4H-1	B-X
but	B-X
is	B-X
present	B-X
in	B-X
a	B-X
putative	B-X
rice	B-X
P4H	B-X
homologue	B-X
.	B-X
At-P4H-2	B-X
differed	B-X
distinctly	B-X
from	B-X
At-P4H-1	B-X
in	B-X
its	B-X
substrate	B-X
specificity	B-X
.	B-X
Recombinant	B-X
At-P4H-2	B-X
hydroxylated	B-X
poly	B-X
(	B-X
L-proline	B-X
)	B-X
and	B-X
extensin	B-X
and	B-X
arabinogalactan-like	B-X
peptides	B-X
effectively	B-X
but	B-X
with	B-X
much	B-X
higher	B-X
Km	B-X
values	B-X
than	B-X
At-P4H-1	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
the	B-X
two	B-X
At-P4Hs	B-X
in	B-X
the	B-X
plant	B-X
cell	B-X
.	B-X
Unlike	B-X
At-P4H-1	B-X
,	B-X
At-P4H-2	B-X
hydroxylated	B-X
collagen-like	B-X
peptides	B-X
only	B-X
very	B-X
inefficiently	B-X
and	B-X
did	B-X
not	B-X
hydroxylate	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
alpha-like	B-X
peptides	B-X
at	B-X
all	B-X
.	B-X
All	B-X
the	B-X
peptides	B-X
efficiently	B-X
hydroxylated	B-X
by	B-X
At-P4H-2	B-X
had	B-X
at	B-X
least	B-X
3	B-X
consecutive	B-X
prolines	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
may	B-X
represent	B-X
a	B-X
minimum	B-X
requirement	B-X
for	B-X
efficient	B-X
hydroxylation	B-X
by	B-X
this	B-X
isoenzyme	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
an	B-X
extensin-like	B-X
peptide	B-X
SPPPVYKSPPPPVKHYSPPPV	B-X
indicated	B-X
that	B-X
At-P4H-2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
3rd	B-X
proline	B-X
in	B-X
the	B-X
C-terminal	B-X
PPP	B-X
triplet	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
of	B-X
At-P4H-2	B-X
for	B-X
the	B-X
reaction	B-X
cosubstrates	B-X
Fe2+	B-X
,	B-X
2-oxoglutarate	B-X
,	B-X
and	B-X
ascorbate	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
At-P4H-1	B-X
with	B-X
the	B-X
exception	B-X
that	B-X
the	B-X
Km	B-X
for	B-X
iron	B-X
was	B-X
about	B-X
3-fold	B-X
lower	B-X
.	B-X
Pyridine-2,4-dicarboxylate	B-X
and	B-X
pyridine-2,5-dicarboxylate	B-X
,	B-X
well	B-X
known	B-X
competitive	B-X
inhibitors	B-X
of	B-X
the	B-X
vertebrate	B-X
P4Hs	B-X
with	B-X
respect	B-X
to	B-X
2-oxoglutarate	B-X
,	B-X
were	B-X
also	B-X
competitive	B-X
inhibitors	B-X
of	B-X
At-P4H-2	B-X
but	B-X
with	B-X
Ki	B-X
values	B-X
5-100-fold	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
human	B-X
type	B-X
I	B-X
collagen	B-X
P4H	B-X
.	B-X
It	B-X
thus	B-X
seems	B-X
that	B-X
there	B-X
are	B-X
some	B-X
distinct	B-X
differences	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
2-oxoglutarate-binding	B-X
site	B-X
between	B-X
At-P4H-2	B-X
and	B-X
the	B-X
animal	B-X
collagen	B-X
P4Hs	B-X
.	B-X

Recombinant	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
hydroxylated	O
poly	O
(	O
L	O
-	O
proline	O
)	O
and	O
extensin	O
and	O
arabinogalactan	O
-	O
like	O
peptides	O
effectively	O
but	O
with	O
much	O
higher	O
Km	O
values	O
than	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	I-Protein
,	O
suggesting	O
different	O
roles	O
for	O
the	O
two	O
At	O
-	O
P4Hs	O
in	O
the	O
plant	O
cell	O
.	O

Unlike	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	I-Protein
,	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
hydroxylated	O
collagen	O
-	O
like	O
peptides	O
only	O
very	O
inefficiently	O
and	O
did	O
not	O
hydroxylate	O
hypoxia	O
-	O
inducible	O
transcription	O
factor	O
alpha	O
-	O
like	O
peptides	O
at	O
all	O
.	O

All	O
the	O
peptides	O
efficiently	O
hydroxylated	O
by	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
had	O
at	O
least	O
3	O
consecutive	O
prolines	O
,	O
suggesting	O
that	O
these	O
may	O
represent	O
a	O
minimum	O
requirement	O
for	O
efficient	O
hydroxylation	O
by	O
this	O
isoenzyme	O
.	O
<EOS>	B-X
We	B-X
report	B-X
here	B-X
on	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
second	B-X
plant	B-X
P4H	B-X
(	B-X
prolyl	B-X
4-hydroxylase	B-X
)	B-X
,	B-X
At-P4H-2	B-X
,	B-X
from	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
299	B-X
amino	B-X
acids	B-X
and	B-X
shows	B-X
33	B-X
%	B-X
sequence	B-X
identity	B-X
to	B-X
the	B-X
first	B-X
characterized	B-X
isoenzyme	B-X
,	B-X
At-P4H-1	B-X
.	B-X
A	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
At-P4H-2	B-X
polypeptide	B-X
is	B-X
a	B-X
49-amino-acid	B-X
C-terminal	B-X
toxin	B-X
homology	B-X
domain	B-X
with	B-X
6	B-X
cysteines	B-X
that	B-X
is	B-X
not	B-X
found	B-X
in	B-X
At-P4H-1	B-X
but	B-X
is	B-X
present	B-X
in	B-X
a	B-X
putative	B-X
rice	B-X
P4H	B-X
homologue	B-X
.	B-X
At-P4H-2	B-X
differed	B-X
distinctly	B-X
from	B-X
At-P4H-1	B-X
in	B-X
its	B-X
substrate	B-X
specificity	B-X
.	B-X
Recombinant	B-X
At-P4H-2	B-X
hydroxylated	B-X
poly	B-X
(	B-X
L-proline	B-X
)	B-X
and	B-X
extensin	B-X
and	B-X
arabinogalactan-like	B-X
peptides	B-X
effectively	B-X
but	B-X
with	B-X
much	B-X
higher	B-X
Km	B-X
values	B-X
than	B-X
At-P4H-1	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
the	B-X
two	B-X
At-P4Hs	B-X
in	B-X
the	B-X
plant	B-X
cell	B-X
.	B-X
Unlike	B-X
At-P4H-1	B-X
,	B-X
At-P4H-2	B-X
hydroxylated	B-X
collagen-like	B-X
peptides	B-X
only	B-X
very	B-X
inefficiently	B-X
and	B-X
did	B-X
not	B-X
hydroxylate	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
alpha-like	B-X
peptides	B-X
at	B-X
all	B-X
.	B-X
All	B-X
the	B-X
peptides	B-X
efficiently	B-X
hydroxylated	B-X
by	B-X
At-P4H-2	B-X
had	B-X
at	B-X
least	B-X
3	B-X
consecutive	B-X
prolines	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
may	B-X
represent	B-X
a	B-X
minimum	B-X
requirement	B-X
for	B-X
efficient	B-X
hydroxylation	B-X
by	B-X
this	B-X
isoenzyme	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
an	B-X
extensin-like	B-X
peptide	B-X
SPPPVYKSPPPPVKHYSPPPV	B-X
indicated	B-X
that	B-X
At-P4H-2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
3rd	B-X
proline	B-X
in	B-X
the	B-X
C-terminal	B-X
PPP	B-X
triplet	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
of	B-X
At-P4H-2	B-X
for	B-X
the	B-X
reaction	B-X
cosubstrates	B-X
Fe2+	B-X
,	B-X
2-oxoglutarate	B-X
,	B-X
and	B-X
ascorbate	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
At-P4H-1	B-X
with	B-X
the	B-X
exception	B-X
that	B-X
the	B-X
Km	B-X
for	B-X
iron	B-X
was	B-X
about	B-X
3-fold	B-X
lower	B-X
.	B-X
Pyridine-2,4-dicarboxylate	B-X
and	B-X
pyridine-2,5-dicarboxylate	B-X
,	B-X
well	B-X
known	B-X
competitive	B-X
inhibitors	B-X
of	B-X
the	B-X
vertebrate	B-X
P4Hs	B-X
with	B-X
respect	B-X
to	B-X
2-oxoglutarate	B-X
,	B-X
were	B-X
also	B-X
competitive	B-X
inhibitors	B-X
of	B-X
At-P4H-2	B-X
but	B-X
with	B-X
Ki	B-X
values	B-X
5-100-fold	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
human	B-X
type	B-X
I	B-X
collagen	B-X
P4H	B-X
.	B-X
It	B-X
thus	B-X
seems	B-X
that	B-X
there	B-X
are	B-X
some	B-X
distinct	B-X
differences	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
2-oxoglutarate-binding	B-X
site	B-X
between	B-X
At-P4H-2	B-X
and	B-X
the	B-X
animal	B-X
collagen	B-X
P4Hs	B-X
.	B-X

N	O
-	O
terminal	O
sequencing	O
of	O
an	O
extensin	O
-	O
like	O
peptide	O
SPPPVYKSPPPPVKHYSPPPV	O
indicated	O
that	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
preferentially	O
hydroxylated	O
the	O
3rd	O
proline	O
in	O
the	O
C	O
-	O
terminal	O
PPP	O
triplet	O
.	O

The	O
Km	O
values	O
of	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
for	O
the	O
reaction	O
cosubstrates	O
Fe2	O
+	O
,	O
2	O
-	O
oxoglutarate	O
,	O
and	O
ascorbate	O
were	O
similar	O
to	O
those	O
of	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	I-Protein
with	O
the	O
exception	O
that	O
the	O
Km	O
for	O
iron	O
was	O
about	O
3	O
-	O
fold	O
lower	O
.	O
<EOS>	B-X
We	B-X
report	B-X
here	B-X
on	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
second	B-X
plant	B-X
P4H	B-X
(	B-X
prolyl	B-X
4-hydroxylase	B-X
)	B-X
,	B-X
At-P4H-2	B-X
,	B-X
from	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
299	B-X
amino	B-X
acids	B-X
and	B-X
shows	B-X
33	B-X
%	B-X
sequence	B-X
identity	B-X
to	B-X
the	B-X
first	B-X
characterized	B-X
isoenzyme	B-X
,	B-X
At-P4H-1	B-X
.	B-X
A	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
At-P4H-2	B-X
polypeptide	B-X
is	B-X
a	B-X
49-amino-acid	B-X
C-terminal	B-X
toxin	B-X
homology	B-X
domain	B-X
with	B-X
6	B-X
cysteines	B-X
that	B-X
is	B-X
not	B-X
found	B-X
in	B-X
At-P4H-1	B-X
but	B-X
is	B-X
present	B-X
in	B-X
a	B-X
putative	B-X
rice	B-X
P4H	B-X
homologue	B-X
.	B-X
At-P4H-2	B-X
differed	B-X
distinctly	B-X
from	B-X
At-P4H-1	B-X
in	B-X
its	B-X
substrate	B-X
specificity	B-X
.	B-X
Recombinant	B-X
At-P4H-2	B-X
hydroxylated	B-X
poly	B-X
(	B-X
L-proline	B-X
)	B-X
and	B-X
extensin	B-X
and	B-X
arabinogalactan-like	B-X
peptides	B-X
effectively	B-X
but	B-X
with	B-X
much	B-X
higher	B-X
Km	B-X
values	B-X
than	B-X
At-P4H-1	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
the	B-X
two	B-X
At-P4Hs	B-X
in	B-X
the	B-X
plant	B-X
cell	B-X
.	B-X
Unlike	B-X
At-P4H-1	B-X
,	B-X
At-P4H-2	B-X
hydroxylated	B-X
collagen-like	B-X
peptides	B-X
only	B-X
very	B-X
inefficiently	B-X
and	B-X
did	B-X
not	B-X
hydroxylate	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
alpha-like	B-X
peptides	B-X
at	B-X
all	B-X
.	B-X
All	B-X
the	B-X
peptides	B-X
efficiently	B-X
hydroxylated	B-X
by	B-X
At-P4H-2	B-X
had	B-X
at	B-X
least	B-X
3	B-X
consecutive	B-X
prolines	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
may	B-X
represent	B-X
a	B-X
minimum	B-X
requirement	B-X
for	B-X
efficient	B-X
hydroxylation	B-X
by	B-X
this	B-X
isoenzyme	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
an	B-X
extensin-like	B-X
peptide	B-X
SPPPVYKSPPPPVKHYSPPPV	B-X
indicated	B-X
that	B-X
At-P4H-2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
3rd	B-X
proline	B-X
in	B-X
the	B-X
C-terminal	B-X
PPP	B-X
triplet	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
of	B-X
At-P4H-2	B-X
for	B-X
the	B-X
reaction	B-X
cosubstrates	B-X
Fe2+	B-X
,	B-X
2-oxoglutarate	B-X
,	B-X
and	B-X
ascorbate	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
At-P4H-1	B-X
with	B-X
the	B-X
exception	B-X
that	B-X
the	B-X
Km	B-X
for	B-X
iron	B-X
was	B-X
about	B-X
3-fold	B-X
lower	B-X
.	B-X
Pyridine-2,4-dicarboxylate	B-X
and	B-X
pyridine-2,5-dicarboxylate	B-X
,	B-X
well	B-X
known	B-X
competitive	B-X
inhibitors	B-X
of	B-X
the	B-X
vertebrate	B-X
P4Hs	B-X
with	B-X
respect	B-X
to	B-X
2-oxoglutarate	B-X
,	B-X
were	B-X
also	B-X
competitive	B-X
inhibitors	B-X
of	B-X
At-P4H-2	B-X
but	B-X
with	B-X
Ki	B-X
values	B-X
5-100-fold	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
human	B-X
type	B-X
I	B-X
collagen	B-X
P4H	B-X
.	B-X
It	B-X
thus	B-X
seems	B-X
that	B-X
there	B-X
are	B-X
some	B-X
distinct	B-X
differences	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
2-oxoglutarate-binding	B-X
site	B-X
between	B-X
At-P4H-2	B-X
and	B-X
the	B-X
animal	B-X
collagen	B-X
P4Hs	B-X
.	B-X

Pyridine	O
-	O
2	O
,	O
4	O
-	O
dicarboxylate	O
and	O
pyridine	O
-	O
2	O
,	O
5	O
-	O
dicarboxylate	O
,	O
well	O
known	O
competitive	O
inhibitors	O
of	O
the	O
vertebrate	O
P4Hs	O
with	O
respect	O
to	O
2	O
-	O
oxoglutarate	O
,	O
were	O
also	O
competitive	O
inhibitors	O
of	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
but	O
with	O
Ki	O
values	O
5	O
-	O
100	O
-	O
fold	O
higher	O
than	O
those	O
of	O
human	O
type	O
I	O
collagen	O
P4H	O
.	O
<EOS>	B-X
4-Hydroxyproline	B-X
is	B-X
found	B-X
in	B-X
collagens	B-X
,	B-X
collagen-like	B-X
proteins	B-X
,	B-X
elastin	B-X
,	B-X
and	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
in	B-X
animals	B-X
and	B-X
in	B-X
many	B-X
hydroxyproline-rich	B-X
glycoproteins	B-X
in	B-X
plants	B-X
.	B-X
We	B-X
report	B-X
here	B-X
on	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
second	B-X
plant	B-X
P4H	B-X
(	B-X
prolyl	B-X
4-hydroxylase	B-X
)	B-X
,	B-X
At-P4H-2	B-X
,	B-X
from	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
299	B-X
amino	B-X
acids	B-X
and	B-X
shows	B-X
33	B-X
%	B-X
sequence	B-X
identity	B-X
to	B-X
the	B-X
first	B-X
characterized	B-X
isoenzyme	B-X
,	B-X
At-P4H-1	B-X
.	B-X
A	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
At-P4H-2	B-X
polypeptide	B-X
is	B-X
a	B-X
49-amino-acid	B-X
C-terminal	B-X
toxin	B-X
homology	B-X
domain	B-X
with	B-X
6	B-X
cysteines	B-X
that	B-X
is	B-X
not	B-X
found	B-X
in	B-X
At-P4H-1	B-X
but	B-X
is	B-X
present	B-X
in	B-X
a	B-X
putative	B-X
rice	B-X
P4H	B-X
homologue	B-X
.	B-X
At-P4H-2	B-X
differed	B-X
distinctly	B-X
from	B-X
At-P4H-1	B-X
in	B-X
its	B-X
substrate	B-X
specificity	B-X
.	B-X
Recombinant	B-X
At-P4H-2	B-X
hydroxylated	B-X
poly	B-X
(	B-X
L-proline	B-X
)	B-X
and	B-X
extensin	B-X
and	B-X
arabinogalactan-like	B-X
peptides	B-X
effectively	B-X
but	B-X
with	B-X
much	B-X
higher	B-X
Km	B-X
values	B-X
than	B-X
At-P4H-1	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
the	B-X
two	B-X
At-P4Hs	B-X
in	B-X
the	B-X
plant	B-X
cell	B-X
.	B-X
Unlike	B-X
At-P4H-1	B-X
,	B-X
At-P4H-2	B-X
hydroxylated	B-X
collagen-like	B-X
peptides	B-X
only	B-X
very	B-X
inefficiently	B-X
and	B-X
did	B-X
not	B-X
hydroxylate	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
alpha-like	B-X
peptides	B-X
at	B-X
all	B-X
.	B-X
All	B-X
the	B-X
peptides	B-X
efficiently	B-X
hydroxylated	B-X
by	B-X
At-P4H-2	B-X
had	B-X
at	B-X
least	B-X
3	B-X
consecutive	B-X
prolines	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
may	B-X
represent	B-X
a	B-X
minimum	B-X
requirement	B-X
for	B-X
efficient	B-X
hydroxylation	B-X
by	B-X
this	B-X
isoenzyme	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
an	B-X
extensin-like	B-X
peptide	B-X
SPPPVYKSPPPPVKHYSPPPV	B-X
indicated	B-X
that	B-X
At-P4H-2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
3rd	B-X
proline	B-X
in	B-X
the	B-X
C-terminal	B-X
PPP	B-X
triplet	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
of	B-X
At-P4H-2	B-X
for	B-X
the	B-X
reaction	B-X
cosubstrates	B-X
Fe2+	B-X
,	B-X
2-oxoglutarate	B-X
,	B-X
and	B-X
ascorbate	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
At-P4H-1	B-X
with	B-X
the	B-X
exception	B-X
that	B-X
the	B-X
Km	B-X
for	B-X
iron	B-X
was	B-X
about	B-X
3-fold	B-X
lower	B-X
.	B-X
Pyridine-2,4-dicarboxylate	B-X
and	B-X
pyridine-2,5-dicarboxylate	B-X
,	B-X
well	B-X
known	B-X
competitive	B-X
inhibitors	B-X
of	B-X
the	B-X
vertebrate	B-X
P4Hs	B-X
with	B-X
respect	B-X
to	B-X
2-oxoglutarate	B-X
,	B-X
were	B-X
also	B-X
competitive	B-X
inhibitors	B-X
of	B-X
At-P4H-2	B-X
but	B-X
with	B-X
Ki	B-X
values	B-X
5-100-fold	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
human	B-X
type	B-X
I	B-X
collagen	B-X
P4H	B-X
.	B-X
It	B-X
thus	B-X
seems	B-X
that	B-X
there	B-X
are	B-X
some	B-X
distinct	B-X
differences	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
2-oxoglutarate-binding	B-X
site	B-X
between	B-X
At-P4H-2	B-X
and	B-X
the	B-X
animal	B-X
collagen	B-X
P4Hs	B-X
.	B-X

It	O
thus	O
seems	O
that	O
there	O
are	O
some	O
distinct	O
differences	O
in	O
the	O
structure	O
of	O
the	O
2	O
-	O
oxoglutarate	O
-	O
binding	O
site	O
between	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	I-Protein
and	O
the	O
animal	O
collagen	O
P4Hs	O
.	O
<EOS>	B-X
4-Hydroxyproline	B-X
is	B-X
found	B-X
in	B-X
collagens	B-X
,	B-X
collagen-like	B-X
proteins	B-X
,	B-X
elastin	B-X
,	B-X
and	B-X
the	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
in	B-X
animals	B-X
and	B-X
in	B-X
many	B-X
hydroxyproline-rich	B-X
glycoproteins	B-X
in	B-X
plants	B-X
.	B-X
We	B-X
report	B-X
here	B-X
on	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
second	B-X
plant	B-X
P4H	B-X
(	B-X
prolyl	B-X
4-hydroxylase	B-X
)	B-X
,	B-X
At-P4H-2	B-X
,	B-X
from	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
It	B-X
consists	B-X
of	B-X
299	B-X
amino	B-X
acids	B-X
and	B-X
shows	B-X
33	B-X
%	B-X
sequence	B-X
identity	B-X
to	B-X
the	B-X
first	B-X
characterized	B-X
isoenzyme	B-X
,	B-X
At-P4H-1	B-X
.	B-X
A	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
At-P4H-2	B-X
polypeptide	B-X
is	B-X
a	B-X
49-amino-acid	B-X
C-terminal	B-X
toxin	B-X
homology	B-X
domain	B-X
with	B-X
6	B-X
cysteines	B-X
that	B-X
is	B-X
not	B-X
found	B-X
in	B-X
At-P4H-1	B-X
but	B-X
is	B-X
present	B-X
in	B-X
a	B-X
putative	B-X
rice	B-X
P4H	B-X
homologue	B-X
.	B-X
At-P4H-2	B-X
differed	B-X
distinctly	B-X
from	B-X
At-P4H-1	B-X
in	B-X
its	B-X
substrate	B-X
specificity	B-X
.	B-X
Recombinant	B-X
At-P4H-2	B-X
hydroxylated	B-X
poly	B-X
(	B-X
L-proline	B-X
)	B-X
and	B-X
extensin	B-X
and	B-X
arabinogalactan-like	B-X
peptides	B-X
effectively	B-X
but	B-X
with	B-X
much	B-X
higher	B-X
Km	B-X
values	B-X
than	B-X
At-P4H-1	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
the	B-X
two	B-X
At-P4Hs	B-X
in	B-X
the	B-X
plant	B-X
cell	B-X
.	B-X
Unlike	B-X
At-P4H-1	B-X
,	B-X
At-P4H-2	B-X
hydroxylated	B-X
collagen-like	B-X
peptides	B-X
only	B-X
very	B-X
inefficiently	B-X
and	B-X
did	B-X
not	B-X
hydroxylate	B-X
hypoxia-inducible	B-X
transcription	B-X
factor	B-X
alpha-like	B-X
peptides	B-X
at	B-X
all	B-X
.	B-X
All	B-X
the	B-X
peptides	B-X
efficiently	B-X
hydroxylated	B-X
by	B-X
At-P4H-2	B-X
had	B-X
at	B-X
least	B-X
3	B-X
consecutive	B-X
prolines	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
may	B-X
represent	B-X
a	B-X
minimum	B-X
requirement	B-X
for	B-X
efficient	B-X
hydroxylation	B-X
by	B-X
this	B-X
isoenzyme	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
an	B-X
extensin-like	B-X
peptide	B-X
SPPPVYKSPPPPVKHYSPPPV	B-X
indicated	B-X
that	B-X
At-P4H-2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
3rd	B-X
proline	B-X
in	B-X
the	B-X
C-terminal	B-X
PPP	B-X
triplet	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
of	B-X
At-P4H-2	B-X
for	B-X
the	B-X
reaction	B-X
cosubstrates	B-X
Fe2+	B-X
,	B-X
2-oxoglutarate	B-X
,	B-X
and	B-X
ascorbate	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
At-P4H-1	B-X
with	B-X
the	B-X
exception	B-X
that	B-X
the	B-X
Km	B-X
for	B-X
iron	B-X
was	B-X
about	B-X
3-fold	B-X
lower	B-X
.	B-X
Pyridine-2,4-dicarboxylate	B-X
and	B-X
pyridine-2,5-dicarboxylate	B-X
,	B-X
well	B-X
known	B-X
competitive	B-X
inhibitors	B-X
of	B-X
the	B-X
vertebrate	B-X
P4Hs	B-X
with	B-X
respect	B-X
to	B-X
2-oxoglutarate	B-X
,	B-X
were	B-X
also	B-X
competitive	B-X
inhibitors	B-X
of	B-X
At-P4H-2	B-X
but	B-X
with	B-X
Ki	B-X
values	B-X
5-100-fold	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
human	B-X
type	B-X
I	B-X
collagen	B-X
P4H	B-X
.	B-X
It	B-X
thus	B-X
seems	B-X
that	B-X
there	B-X
are	B-X
some	B-X
distinct	B-X
differences	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
2-oxoglutarate-binding	B-X
site	B-X
between	B-X
At-P4H-2	B-X
and	B-X
the	B-X
animal	B-X
collagen	B-X
P4Hs	B-X
.	B-X

The	O
role	O
of	O
protein	O
kinase	O
A	O
pathway	O
and	O
cAMP	O
responsive	O
element	O
-	O
binding	O
protein	O
in	O
androgen	B-Protein
receptor	I-Protein
-	O
mediated	O
transcription	O
at	O
the	O
prostate	B-Protein
-	I-Protein
specific	I-Protein
antigen	I-Protein
locus	O
.	O
<EOS>	B-X
Androgen-independent	B-X
prostate	B-X
cancer	B-X
is	B-X
a	B-X
lethal	B-X
form	B-X
of	B-X
the	B-X
disease	B-X
that	B-X
is	B-X
marked	B-X
by	B-X
metastasis	B-X
and	B-X
rapid	B-X
proliferation	B-X
in	B-X
its	B-X
final	B-X
stages	B-X
.	B-X
As	B-X
no	B-X
effective	B-X
therapy	B-X
for	B-X
this	B-X
aggressive	B-X
tumor	B-X
currently	B-X
exists	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
elucidate	B-X
and	B-X
target	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
progression	B-X
to	B-X
androgen	B-X
independence	B-X
.	B-X
Accumulating	B-X
evidence	B-X
indicates	B-X
that	B-X
aberrant	B-X
activation	B-X
of	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
via	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
AR	B-X
gene	B-X
mutation	B-X
and/or	B-X
amplification	B-X
,	B-X
and/or	B-X
coregulator	B-X
alterations	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
progression	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signaling	B-X
and	B-X
its	B-X
downstream	B-X
factors	B-X
on	B-X
AR	B-X
activity	B-X
at	B-X
the	B-X
prostate-specific	B-X
antigen	B-X
(	B-X
PSA	B-X
)	B-X
gene	B-X
were	B-X
tested	B-X
.	B-X
Activation	B-X
of	B-X
PKA	B-X
by	B-X
forskolin	B-X
resulted	B-X
in	B-X
enhanced	B-X
androgen-induced	B-X
expression	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
was	B-X
blocked	B-X
by	B-X
the	B-X
AR	B-X
antagonist	B-X
,	B-X
bicalutamide	B-X
.	B-X
Interestingly	B-X
,	B-X
when	B-X
either	B-X
p300	B-X
or	B-X
CBP	B-X
was	B-X
overexpressed	B-X
,	B-X
PKA	B-X
activation	B-X
was	B-X
sufficient	B-X
to	B-X
stimulate	B-X
PSA	B-X
promoter-driven	B-X
transcription	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
androgen	B-X
,	B-X
which	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
bicalutamide	B-X
.	B-X
PKA	B-X
activation	B-X
did	B-X
not	B-X
significantly	B-X
alter	B-X
AR	B-X
protein	B-X
levels	B-X
but	B-X
significantly	B-X
increased	B-X
the	B-X
phosphorylated	B-X
form	B-X
of	B-X
its	B-X
downstream	B-X
effector	B-X
,	B-X
cAMP	B-X
responsive	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
androgen	B-X
.	B-X
Furthermore	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
showed	B-X
that	B-X
the	B-X
combination	B-X
of	B-X
androgen	B-X
and	B-X
forskolin	B-X
increased	B-X
phosphorylated	B-X
CREB	B-X
occupancy	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
histone	B-X
acetylation	B-X
,	B-X
at	B-X
the	B-X
putative	B-X
cAMP	B-X
responsive	B-X
element	B-X
located	B-X
in	B-X
the	B-X
5	B-X
'	B-X
upstream	B-X
regulatory	B-X
region	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
intriguing	B-X
interplay	B-X
between	B-X
a	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
coactivator	B-X
overexpression	B-X
and	B-X
AR	B-X
signaling	B-X
as	B-X
a	B-X
possible	B-X
combined	B-X
mechanism	B-X
of	B-X
progression	B-X
to	B-X
androgen-independent	B-X
prostate	B-X
cancer	B-X
.	B-X

Androgen	O
-	O
independent	O
prostate	O
cancer	O
is	O
a	O
lethal	O
form	O
of	O
the	O
disease	O
that	O
is	O
marked	O
by	O
metastasis	O
and	O
rapid	O
proliferation	O
in	O
its	O
final	O
stages	O
.	O
<EOS>	B-X
Androgen-independent	B-X
prostate	B-X
cancer	B-X
is	B-X
a	B-X
lethal	B-X
form	B-X
of	B-X
the	B-X
disease	B-X
that	B-X
is	B-X
marked	B-X
by	B-X
metastasis	B-X
and	B-X
rapid	B-X
proliferation	B-X
in	B-X
its	B-X
final	B-X
stages	B-X
.	B-X
Accumulating	B-X
evidence	B-X
indicates	B-X
that	B-X
aberrant	B-X
activation	B-X
of	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
via	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
AR	B-X
gene	B-X
mutation	B-X
and/or	B-X
amplification	B-X
,	B-X
and/or	B-X
coregulator	B-X
alterations	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
progression	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signaling	B-X
and	B-X
its	B-X
downstream	B-X
factors	B-X
on	B-X
AR	B-X
activity	B-X
at	B-X
the	B-X
prostate-specific	B-X
antigen	B-X
(	B-X
PSA	B-X
)	B-X
gene	B-X
were	B-X
tested	B-X
.	B-X
PKA	B-X
activation	B-X
did	B-X
not	B-X
significantly	B-X
alter	B-X
AR	B-X
protein	B-X
levels	B-X
but	B-X
significantly	B-X
increased	B-X
the	B-X
phosphorylated	B-X
form	B-X
of	B-X
its	B-X
downstream	B-X
effector	B-X
,	B-X
cAMP	B-X
responsive	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
androgen	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
intriguing	B-X
interplay	B-X
between	B-X
a	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
coactivator	B-X
overexpression	B-X
and	B-X
AR	B-X
signaling	B-X
as	B-X
a	B-X
possible	B-X
combined	B-X
mechanism	B-X
of	B-X
progression	B-X
to	B-X
androgen-independent	B-X
prostate	B-X
cancer	B-X
.	B-X

As	O
no	O
effective	O
therapy	O
for	O
this	O
aggressive	O
tumor	O
currently	O
exists	O
,	O
it	O
is	O
imperative	O
to	O
elucidate	O
and	O
target	O
the	O
mechanisms	O
involved	O
in	O
the	O
progression	O
to	O
androgen	O
independence	O
.	O
<EOS>	B-X
As	B-X
no	B-X
effective	B-X
therapy	B-X
for	B-X
this	B-X
aggressive	B-X
tumor	B-X
currently	B-X
exists	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
elucidate	B-X
and	B-X
target	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
progression	B-X
to	B-X
androgen	B-X
independence	B-X
.	B-X
Accumulating	B-X
evidence	B-X
indicates	B-X
that	B-X
aberrant	B-X
activation	B-X
of	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
via	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
AR	B-X
gene	B-X
mutation	B-X
and/or	B-X
amplification	B-X
,	B-X
and/or	B-X
coregulator	B-X
alterations	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
progression	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
Activation	B-X
of	B-X
PKA	B-X
by	B-X
forskolin	B-X
resulted	B-X
in	B-X
enhanced	B-X
androgen-induced	B-X
expression	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
was	B-X
blocked	B-X
by	B-X
the	B-X
AR	B-X
antagonist	B-X
,	B-X
bicalutamide	B-X
.	B-X
Interestingly	B-X
,	B-X
when	B-X
either	B-X
p300	B-X
or	B-X
CBP	B-X
was	B-X
overexpressed	B-X
,	B-X
PKA	B-X
activation	B-X
was	B-X
sufficient	B-X
to	B-X
stimulate	B-X
PSA	B-X
promoter-driven	B-X
transcription	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
androgen	B-X
,	B-X
which	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
bicalutamide	B-X
.	B-X
PKA	B-X
activation	B-X
did	B-X
not	B-X
significantly	B-X
alter	B-X
AR	B-X
protein	B-X
levels	B-X
but	B-X
significantly	B-X
increased	B-X
the	B-X
phosphorylated	B-X
form	B-X
of	B-X
its	B-X
downstream	B-X
effector	B-X
,	B-X
cAMP	B-X
responsive	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
androgen	B-X
.	B-X
Furthermore	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
showed	B-X
that	B-X
the	B-X
combination	B-X
of	B-X
androgen	B-X
and	B-X
forskolin	B-X
increased	B-X
phosphorylated	B-X
CREB	B-X
occupancy	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
histone	B-X
acetylation	B-X
,	B-X
at	B-X
the	B-X
putative	B-X
cAMP	B-X
responsive	B-X
element	B-X
located	B-X
in	B-X
the	B-X
5	B-X
'	B-X
upstream	B-X
regulatory	B-X
region	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
intriguing	B-X
interplay	B-X
between	B-X
a	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
coactivator	B-X
overexpression	B-X
and	B-X
AR	B-X
signaling	B-X
as	B-X
a	B-X
possible	B-X
combined	B-X
mechanism	B-X
of	B-X
progression	B-X
to	B-X
androgen-independent	B-X
prostate	B-X
cancer	B-X
.	B-X

Accumulating	O
evidence	O
indicates	O
that	O
aberrant	O
activation	O
of	O
androgen	B-Protein
receptor	I-Protein
(	O
AR	B-Protein
)	O
via	O
signal	O
transduction	O
pathways	O
,	O
AR	B-Protein
gene	O
mutation	O
and	O
/	O
or	O
amplification	O
,	O
and	O
/	O
or	O
coregulator	O
alterations	O
may	O
contribute	O
to	O
the	O
progression	O
of	O
prostate	O
cancer	O
.	O
<EOS>	B-X
They	B-X
have	B-X
been	B-X
matching	B-X
forward	B-X
proudly	B-X
to	B-X
contribute	B-X
to	B-X
the	B-X
modern	B-X
analytical	B-X
science	B-X
and	B-X
life	B-X
science	B-X
.	B-X
In	B-X
order	B-X
to	B-X
improve	B-X
the	B-X
sensitivity	B-X
and	B-X
enhance	B-X
the	B-X
signal	B-X
readout	B-X
,	B-X
variable	B-X
signal	B-X
amplification	B-X
strategies	B-X
have	B-X
been	B-X
investigated	B-X
and	B-X
applied	B-X
for	B-X
PADs	B-X
.	B-X
Advances	B-X
for	B-X
improving	B-X
sensitivity	B-X
of	B-X
PADs	B-X
in	B-X
recent	B-X
five	B-X
years	B-X
are	B-X
then	B-X
summarised	B-X
according	B-X
to	B-X
three	B-X
popular	B-X
types	B-X
of	B-X
signal	B-X
amplification	B-X
strategies	B-X
(	B-X
nanomaterial	B-X
based	B-X
,	B-X
nucleic	B-X
acid	B-X
based	B-X
,	B-X
and	B-X
engineering	B-X
of	B-X
PADs	B-X
based	B-X
)	B-X
.	B-X
Pros	B-X
and	B-X
cons	B-X
of	B-X
each	B-X
signal	B-X
amplification	B-X
approach	B-X
have	B-X
been	B-X
discussed	B-X
accordingly	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signaling	O
and	O
its	O
downstream	O
factors	O
on	O
AR	B-Protein
activity	O
at	O
the	O
prostate	B-Protein
-	I-Protein
specific	I-Protein
antigen	I-Protein
(	O
PSA	B-Protein
)	O
gene	O
were	O
tested	O
.	O

Activation	O
of	O
PKA	O
by	O
forskolin	O
resulted	O
in	O
enhanced	O
androgen	O
-	O
induced	O
expression	O
of	O
the	O
PSA	B-Protein
gene	O
,	O
an	O
effect	O
that	O
was	O
blocked	O
by	O
the	O
AR	B-Protein
antagonist	O
,	O
bicalutamide	O
.	O
<EOS>	B-X
As	B-X
no	B-X
effective	B-X
therapy	B-X
for	B-X
this	B-X
aggressive	B-X
tumor	B-X
currently	B-X
exists	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
elucidate	B-X
and	B-X
target	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
progression	B-X
to	B-X
androgen	B-X
independence	B-X
.	B-X
Accumulating	B-X
evidence	B-X
indicates	B-X
that	B-X
aberrant	B-X
activation	B-X
of	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
via	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
AR	B-X
gene	B-X
mutation	B-X
and/or	B-X
amplification	B-X
,	B-X
and/or	B-X
coregulator	B-X
alterations	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
progression	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signaling	B-X
and	B-X
its	B-X
downstream	B-X
factors	B-X
on	B-X
AR	B-X
activity	B-X
at	B-X
the	B-X
prostate-specific	B-X
antigen	B-X
(	B-X
PSA	B-X
)	B-X
gene	B-X
were	B-X
tested	B-X
.	B-X
Activation	B-X
of	B-X
PKA	B-X
by	B-X
forskolin	B-X
resulted	B-X
in	B-X
enhanced	B-X
androgen-induced	B-X
expression	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
was	B-X
blocked	B-X
by	B-X
the	B-X
AR	B-X
antagonist	B-X
,	B-X
bicalutamide	B-X
.	B-X
Interestingly	B-X
,	B-X
when	B-X
either	B-X
p300	B-X
or	B-X
CBP	B-X
was	B-X
overexpressed	B-X
,	B-X
PKA	B-X
activation	B-X
was	B-X
sufficient	B-X
to	B-X
stimulate	B-X
PSA	B-X
promoter-driven	B-X
transcription	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
androgen	B-X
,	B-X
which	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
bicalutamide	B-X
.	B-X
PKA	B-X
activation	B-X
did	B-X
not	B-X
significantly	B-X
alter	B-X
AR	B-X
protein	B-X
levels	B-X
but	B-X
significantly	B-X
increased	B-X
the	B-X
phosphorylated	B-X
form	B-X
of	B-X
its	B-X
downstream	B-X
effector	B-X
,	B-X
cAMP	B-X
responsive	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
androgen	B-X
.	B-X
Furthermore	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
showed	B-X
that	B-X
the	B-X
combination	B-X
of	B-X
androgen	B-X
and	B-X
forskolin	B-X
increased	B-X
phosphorylated	B-X
CREB	B-X
occupancy	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
histone	B-X
acetylation	B-X
,	B-X
at	B-X
the	B-X
putative	B-X
cAMP	B-X
responsive	B-X
element	B-X
located	B-X
in	B-X
the	B-X
5	B-X
'	B-X
upstream	B-X
regulatory	B-X
region	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
.	B-X
Remarkably	B-X
,	B-X
mammalian	B-X
two-hybrid	B-X
assay	B-X
indicated	B-X
that	B-X
p300/CBP	B-X
may	B-X
bridge	B-X
the	B-X
interaction	B-X
between	B-X
AR	B-X
and	B-X
CREB	B-X
,	B-X
suggesting	B-X
a	B-X
novel	B-X
enhanceosomal	B-X
cooperation	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
intriguing	B-X
interplay	B-X
between	B-X
a	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
coactivator	B-X
overexpression	B-X
and	B-X
AR	B-X
signaling	B-X
as	B-X
a	B-X
possible	B-X
combined	B-X
mechanism	B-X
of	B-X
progression	B-X
to	B-X
androgen-independent	B-X
prostate	B-X
cancer	B-X
.	B-X

Interestingly	O
,	O
when	O
either	O
p300	B-Protein
or	O
CBP	B-Protein
was	O
overexpressed	O
,	O
PKA	O
activation	O
was	O
sufficient	O
to	O
stimulate	O
PSA	B-Protein
promoter	O
-	O
driven	O
transcription	O
in	O
the	O
absence	O
of	O
androgen	O
,	O
which	O
was	O
not	O
inhibited	O
by	O
bicalutamide	O
.	O
<EOS>	B-X
H3K27	B-X
acetylation	B-X
activated-COL6A1	B-X
promotes	B-X
osteosarcoma	B-X
lung	B-X
metastasis	B-X
by	B-X
repressing	B-X
STAT1	B-X
and	B-X
activating	B-X
pulmonary	B-X
cancer-associated	B-X
fibroblasts	B-X
.	B-X
Interestingly	B-X
,	B-X
p300	B-X
acetylation	B-X
of	B-X
p65	B-X
blocks	B-X
FBXW2	B-X
induced	B-X
p65	B-X
ubiquitination	B-X
.	B-X
This	B-X
provides	B-X
advantages	B-X
to	B-X
both	B-X
cell	B-X
types	B-X
:	B-X
whereas	B-X
cancer	B-X
cells	B-X
initiate	B-X
and	B-X
sustain	B-X
CAF	B-X
activation	B-X
,	B-X
CAFs	B-X
support	B-X
cancer	B-X
cell	B-X
growth	B-X
,	B-X
motility	B-X
and	B-X
invasion	B-X
.	B-X
Numerous	B-X
studies	B-X
have	B-X
detailed	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
fibroblast	B-X
activation	B-X
and	B-X
cancer	B-X
progression	B-X
,	B-X
some	B-X
of	B-X
which	B-X
are	B-X
reviewed	B-X
in	B-X
this	B-X
article	B-X
.	B-X
Graphical	B-X
Abstract	B-X
Molecular	B-X
mechanism	B-X
of	B-X
fibroblast	B-X
activation	B-X
.	B-X
Not	B-X
only	B-X
growth	B-X
factors	B-X
such	B-X
as	B-X
TGF-β	B-X
,	B-X
PDGF	B-X
,	B-X
HGF	B-X
and	B-X
FGF	B-X
but	B-X
also	B-X
interleukins	B-X
,	B-X
metalloproteinases	B-X
and	B-X
reactive	B-X
oxygen	B-X
species	B-X
can	B-X
promote	B-X
activation	B-X
.	B-X
Likewise	B-X
,	B-X
transcriptional	B-X
factors	B-X
such	B-X
as	B-X
NF-κB	B-X
and	B-X
HSF-1	B-X
play	B-X
an	B-X
important	B-X
role	B-X
,	B-X
as	B-X
do	B-X
the	B-X
gene	B-X
family	B-X
of	B-X
metalloproteinase	B-X
inhibitors	B-X
,	B-X
Timp	B-X
and	B-X
the	B-X
NF-κB	B-X
subunit	B-X
,	B-X
p62	B-X
.	B-X
Interestingly	B-X
,	B-X
fibroblasts	B-X
themselves	B-X
can	B-X
stimulate	B-X
cancer	B-X
cells	B-X
to	B-X
support	B-X
activation	B-X
further	B-X
.	B-X
c	B-X
Recently	B-X
,	B-X
the	B-X
LIF/GP130/IL6-R	B-X
pathway	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
signaling	B-X
cascade	B-X
involved	B-X
in	B-X
fibroblast	B-X
activation	B-X
.	B-X
Upon	B-X
LIF	B-X
stimulation	B-X
,	B-X
JAK	B-X
is	B-X
phosphorylated	B-X
and	B-X
further	B-X
activates	B-X
STAT3	B-X
,	B-X
a	B-X
transcriptional	B-X
factor	B-X
that	B-X
is	B-X
then	B-X
translocated	B-X
into	B-X
the	B-X
nucleus	B-X
where	B-X
it	B-X
promotes	B-X
the	B-X
transcription	B-X
of	B-X
genes	B-X
responsible	B-X
for	B-X
cell	B-X
growth	B-X
,	B-X
differentiation	B-X
,	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
.	B-X
Ruxolitinib	B-X
can	B-X
inhibit	B-X
JAK	B-X
and	B-X
prevent	B-X
STAT3	B-X
activation	B-X
.	B-X
Further	B-X
on	B-X
,	B-X
the	B-X
maintenance	B-X
of	B-X
JAK	B-X
activation	B-X
is	B-X
supported	B-X
by	B-X
epigenetical	B-X
changes	B-X
and	B-X
post-translational	B-X
modifications	B-X
.	B-X
Once	B-X
pSTAT3	B-X
is	B-X
acetylated	B-X
by	B-X
histon	B-X
acetyltransferase	B-X
,	B-X
p300	B-X
,	B-X
it	B-X
leads	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
expression	B-X
of	B-X
SHP-1	B-X
,	B-X
which	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
JAK/STAT	B-X
pathway	B-X
.	B-X
Silencing	B-X
of	B-X
SHP-1	B-X
steers	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
JAK	B-X
and	B-X
STAT3	B-X
.	B-X

PKA	O
activation	O
did	O
not	O
significantly	O
alter	O
AR	B-Protein
protein	O
levels	O
but	O
significantly	O
increased	O
the	O
phosphorylated	O
form	O
of	O
its	O
downstream	O
effector	O
,	O
cAMP	O
responsive	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
in	O
the	O
presence	O
of	O
androgen	O
.	O
<EOS>	B-X
It	B-X
is	B-X
well	B-X
recognized	B-X
that	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
(	B-X
cAMP	B-X
)	B-X
signaling	B-X
within	B-X
neurons	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
foundation	B-X
of	B-X
long-term	B-X
memories	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
cAMP	B-X
in	B-X
1958	B-X
as	B-X
the	B-X
second	B-X
messenger	B-X
also	B-X
had	B-X
a	B-X
role	B-X
in	B-X
memory	B-X
formation	B-X
and	B-X
other	B-X
neural	B-X
aspects	B-X
.	B-X
Further	B-X
,	B-X
in	B-X
1998	B-X
the	B-X
scientists	B-X
found	B-X
that	B-X
cAMP	B-X
does	B-X
not	B-X
just	B-X
activate	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
but	B-X
also	B-X
exchange	B-X
protein	B-X
directly	B-X
activated	B-X
by	B-X
cAMP	B-X
(	B-X
Epac	B-X
)	B-X
which	B-X
has	B-X
an	B-X
active	B-X
role	B-X
to	B-X
play	B-X
in	B-X
hyperalgesia	B-X
,	B-X
memory	B-X
,	B-X
and	B-X
signaling	B-X
.	B-X
The	B-X
cAMP	B-X
has	B-X
three	B-X
targets	B-X
,	B-X
hyperpolarization-activated	B-X
cyclic	B-X
nucleotide	B-X
modulated	B-X
(	B-X
HCN	B-X
)	B-X
channels	B-X
,	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
,	B-X
and	B-X
exchange	B-X
protein	B-X
activated	B-X
by	B-X
cAMP	B-X
(	B-X
Epac	B-X
)	B-X
.	B-X
Different	B-X
research	B-X
has	B-X
exposed	B-X
that	B-X
both	B-X
PKA	B-X
and	B-X
HCN	B-X
channels	B-X
are	B-X
significant	B-X
for	B-X
long-term	B-X
memory	B-X
creation	B-X
.	B-X
Epac	B-X
is	B-X
a	B-X
cAMP-dependent	B-X
guanine	B-X
nucleotide	B-X
exchange	B-X
factor	B-X
for	B-X
the	B-X
small	B-X
G	B-X
proteins	B-X
including	B-X
Rap1	B-X
.	B-X
However	B-X
,	B-X
slight	B-X
information	B-X
is	B-X
there	B-X
about	B-X
the	B-X
role	B-X
of	B-X
Epac	B-X
in	B-X
this	B-X
process	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
cAMP	B-X
are	B-X
predominantly	B-X
imparted	B-X
by	B-X
activating	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
and	B-X
the	B-X
more	B-X
newly	B-X
discovered	B-X
exchange	B-X
proteins	B-X
are	B-X
directly	B-X
activated	B-X
by	B-X
cAMP	B-X
1	B-X
and	B-X
2	B-X
(	B-X
EPAC1	B-X
and	B-X
EPAC2	B-X
)	B-X
.	B-X

Furthermore	O
,	O
chromatin	O
immunoprecipitation	O
showed	O
that	O
the	O
combination	O
of	O
androgen	O
and	O
forskolin	O
increased	O
phosphorylated	O
CREB	O
occupancy	O
,	O
which	O
was	O
accompanied	O
by	O
histone	B-Protein
acetylation	O
,	O
at	O
the	O
putative	O
cAMP	O
responsive	O
element	O
located	O
in	O
the	O
5	O
'	O
upstream	O
regulatory	O
region	O
of	O
the	O
PSA	B-Protein
gene	O
.	O
<EOS>	B-X
As	B-X
no	B-X
effective	B-X
therapy	B-X
for	B-X
this	B-X
aggressive	B-X
tumor	B-X
currently	B-X
exists	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
elucidate	B-X
and	B-X
target	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
progression	B-X
to	B-X
androgen	B-X
independence	B-X
.	B-X
Accumulating	B-X
evidence	B-X
indicates	B-X
that	B-X
aberrant	B-X
activation	B-X
of	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
via	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
AR	B-X
gene	B-X
mutation	B-X
and/or	B-X
amplification	B-X
,	B-X
and/or	B-X
coregulator	B-X
alterations	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
progression	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signaling	B-X
and	B-X
its	B-X
downstream	B-X
factors	B-X
on	B-X
AR	B-X
activity	B-X
at	B-X
the	B-X
prostate-specific	B-X
antigen	B-X
(	B-X
PSA	B-X
)	B-X
gene	B-X
were	B-X
tested	B-X
.	B-X
Activation	B-X
of	B-X
PKA	B-X
by	B-X
forskolin	B-X
resulted	B-X
in	B-X
enhanced	B-X
androgen-induced	B-X
expression	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
was	B-X
blocked	B-X
by	B-X
the	B-X
AR	B-X
antagonist	B-X
,	B-X
bicalutamide	B-X
.	B-X
Interestingly	B-X
,	B-X
when	B-X
either	B-X
p300	B-X
or	B-X
CBP	B-X
was	B-X
overexpressed	B-X
,	B-X
PKA	B-X
activation	B-X
was	B-X
sufficient	B-X
to	B-X
stimulate	B-X
PSA	B-X
promoter-driven	B-X
transcription	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
androgen	B-X
,	B-X
which	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
bicalutamide	B-X
.	B-X
PKA	B-X
activation	B-X
did	B-X
not	B-X
significantly	B-X
alter	B-X
AR	B-X
protein	B-X
levels	B-X
but	B-X
significantly	B-X
increased	B-X
the	B-X
phosphorylated	B-X
form	B-X
of	B-X
its	B-X
downstream	B-X
effector	B-X
,	B-X
cAMP	B-X
responsive	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
androgen	B-X
.	B-X
Furthermore	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
showed	B-X
that	B-X
the	B-X
combination	B-X
of	B-X
androgen	B-X
and	B-X
forskolin	B-X
increased	B-X
phosphorylated	B-X
CREB	B-X
occupancy	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
histone	B-X
acetylation	B-X
,	B-X
at	B-X
the	B-X
putative	B-X
cAMP	B-X
responsive	B-X
element	B-X
located	B-X
in	B-X
the	B-X
5	B-X
'	B-X
upstream	B-X
regulatory	B-X
region	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
.	B-X
Remarkably	B-X
,	B-X
mammalian	B-X
two-hybrid	B-X
assay	B-X
indicated	B-X
that	B-X
p300/CBP	B-X
may	B-X
bridge	B-X
the	B-X
interaction	B-X
between	B-X
AR	B-X
and	B-X
CREB	B-X
,	B-X
suggesting	B-X
a	B-X
novel	B-X
enhanceosomal	B-X
cooperation	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
intriguing	B-X
interplay	B-X
between	B-X
a	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
coactivator	B-X
overexpression	B-X
and	B-X
AR	B-X
signaling	B-X
as	B-X
a	B-X
possible	B-X
combined	B-X
mechanism	B-X
of	B-X
progression	B-X
to	B-X
androgen-independent	B-X
prostate	B-X
cancer	B-X
.	B-X

Remarkably	O
,	O
mammalian	O
two	O
-	O
hybrid	O
assay	O
indicated	O
that	O
p300	B-Protein
/	O
CBP	B-Protein
may	O
bridge	O
the	O
interaction	O
between	O
AR	B-Protein
and	O
CREB	O
,	O
suggesting	O
a	O
novel	O
enhanceosomal	O
cooperation	O
.	O
<EOS>	B-X
Accumulating	B-X
evidence	B-X
indicates	B-X
that	B-X
aberrant	B-X
activation	B-X
of	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
via	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
AR	B-X
gene	B-X
mutation	B-X
and/or	B-X
amplification	B-X
,	B-X
and/or	B-X
coregulator	B-X
alterations	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
progression	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signaling	B-X
and	B-X
its	B-X
downstream	B-X
factors	B-X
on	B-X
AR	B-X
activity	B-X
at	B-X
the	B-X
prostate-specific	B-X
antigen	B-X
(	B-X
PSA	B-X
)	B-X
gene	B-X
were	B-X
tested	B-X
.	B-X
Activation	B-X
of	B-X
PKA	B-X
by	B-X
forskolin	B-X
resulted	B-X
in	B-X
enhanced	B-X
androgen-induced	B-X
expression	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
was	B-X
blocked	B-X
by	B-X
the	B-X
AR	B-X
antagonist	B-X
,	B-X
bicalutamide	B-X
.	B-X
Interestingly	B-X
,	B-X
when	B-X
either	B-X
p300	B-X
or	B-X
CBP	B-X
was	B-X
overexpressed	B-X
,	B-X
PKA	B-X
activation	B-X
was	B-X
sufficient	B-X
to	B-X
stimulate	B-X
PSA	B-X
promoter-driven	B-X
transcription	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
androgen	B-X
,	B-X
which	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
bicalutamide	B-X
.	B-X
PKA	B-X
activation	B-X
did	B-X
not	B-X
significantly	B-X
alter	B-X
AR	B-X
protein	B-X
levels	B-X
but	B-X
significantly	B-X
increased	B-X
the	B-X
phosphorylated	B-X
form	B-X
of	B-X
its	B-X
downstream	B-X
effector	B-X
,	B-X
cAMP	B-X
responsive	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
androgen	B-X
.	B-X
Furthermore	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
showed	B-X
that	B-X
the	B-X
combination	B-X
of	B-X
androgen	B-X
and	B-X
forskolin	B-X
increased	B-X
phosphorylated	B-X
CREB	B-X
occupancy	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
histone	B-X
acetylation	B-X
,	B-X
at	B-X
the	B-X
putative	B-X
cAMP	B-X
responsive	B-X
element	B-X
located	B-X
in	B-X
the	B-X
5	B-X
'	B-X
upstream	B-X
regulatory	B-X
region	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
.	B-X
Remarkably	B-X
,	B-X
mammalian	B-X
two-hybrid	B-X
assay	B-X
indicated	B-X
that	B-X
p300/CBP	B-X
may	B-X
bridge	B-X
the	B-X
interaction	B-X
between	B-X
AR	B-X
and	B-X
CREB	B-X
,	B-X
suggesting	B-X
a	B-X
novel	B-X
enhanceosomal	B-X
cooperation	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
intriguing	B-X
interplay	B-X
between	B-X
a	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
coactivator	B-X
overexpression	B-X
and	B-X
AR	B-X
signaling	B-X
as	B-X
a	B-X
possible	B-X
combined	B-X
mechanism	B-X
of	B-X
progression	B-X
to	B-X
androgen-independent	B-X
prostate	B-X
cancer	B-X
.	B-X

These	O
results	O
demonstrate	O
an	O
intriguing	O
interplay	O
between	O
a	O
signal	O
transduction	O
pathway	O
,	O
coactivator	O
overexpression	O
and	O
AR	B-Protein
signaling	O
as	O
a	O
possible	O
combined	O
mechanism	O
of	O
progression	O
to	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
.	O
<EOS>	B-X
Androgen-independent	B-X
prostate	B-X
cancer	B-X
is	B-X
a	B-X
lethal	B-X
form	B-X
of	B-X
the	B-X
disease	B-X
that	B-X
is	B-X
marked	B-X
by	B-X
metastasis	B-X
and	B-X
rapid	B-X
proliferation	B-X
in	B-X
its	B-X
final	B-X
stages	B-X
.	B-X
As	B-X
no	B-X
effective	B-X
therapy	B-X
for	B-X
this	B-X
aggressive	B-X
tumor	B-X
currently	B-X
exists	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
elucidate	B-X
and	B-X
target	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
progression	B-X
to	B-X
androgen	B-X
independence	B-X
.	B-X
Accumulating	B-X
evidence	B-X
indicates	B-X
that	B-X
aberrant	B-X
activation	B-X
of	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
via	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
AR	B-X
gene	B-X
mutation	B-X
and/or	B-X
amplification	B-X
,	B-X
and/or	B-X
coregulator	B-X
alterations	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
progression	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signaling	B-X
and	B-X
its	B-X
downstream	B-X
factors	B-X
on	B-X
AR	B-X
activity	B-X
at	B-X
the	B-X
prostate-specific	B-X
antigen	B-X
(	B-X
PSA	B-X
)	B-X
gene	B-X
were	B-X
tested	B-X
.	B-X
Activation	B-X
of	B-X
PKA	B-X
by	B-X
forskolin	B-X
resulted	B-X
in	B-X
enhanced	B-X
androgen-induced	B-X
expression	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
was	B-X
blocked	B-X
by	B-X
the	B-X
AR	B-X
antagonist	B-X
,	B-X
bicalutamide	B-X
.	B-X
Interestingly	B-X
,	B-X
when	B-X
either	B-X
p300	B-X
or	B-X
CBP	B-X
was	B-X
overexpressed	B-X
,	B-X
PKA	B-X
activation	B-X
was	B-X
sufficient	B-X
to	B-X
stimulate	B-X
PSA	B-X
promoter-driven	B-X
transcription	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
androgen	B-X
,	B-X
which	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
bicalutamide	B-X
.	B-X
PKA	B-X
activation	B-X
did	B-X
not	B-X
significantly	B-X
alter	B-X
AR	B-X
protein	B-X
levels	B-X
but	B-X
significantly	B-X
increased	B-X
the	B-X
phosphorylated	B-X
form	B-X
of	B-X
its	B-X
downstream	B-X
effector	B-X
,	B-X
cAMP	B-X
responsive	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
androgen	B-X
.	B-X
Furthermore	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
showed	B-X
that	B-X
the	B-X
combination	B-X
of	B-X
androgen	B-X
and	B-X
forskolin	B-X
increased	B-X
phosphorylated	B-X
CREB	B-X
occupancy	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
histone	B-X
acetylation	B-X
,	B-X
at	B-X
the	B-X
putative	B-X
cAMP	B-X
responsive	B-X
element	B-X
located	B-X
in	B-X
the	B-X
5	B-X
'	B-X
upstream	B-X
regulatory	B-X
region	B-X
of	B-X
the	B-X
PSA	B-X
gene	B-X
.	B-X
Remarkably	B-X
,	B-X
mammalian	B-X
two-hybrid	B-X
assay	B-X
indicated	B-X
that	B-X
p300/CBP	B-X
may	B-X
bridge	B-X
the	B-X
interaction	B-X
between	B-X
AR	B-X
and	B-X
CREB	B-X
,	B-X
suggesting	B-X
a	B-X
novel	B-X
enhanceosomal	B-X
cooperation	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
intriguing	B-X
interplay	B-X
between	B-X
a	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
coactivator	B-X
overexpression	B-X
and	B-X
AR	B-X
signaling	B-X
as	B-X
a	B-X
possible	B-X
combined	B-X
mechanism	B-X
of	B-X
progression	B-X
to	B-X
androgen-independent	B-X
prostate	B-X
cancer	B-X
.	B-X

Oxidative	O
stress	O
is	O
involved	O
in	O
inhibition	O
of	O
copper	O
on	O
histone	B-Protein
acetylation	O
in	O
cells	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
study	B-X
demonstrates	B-X
that	B-X
copper	B-X
induces	B-X
histone	B-X
hypoacetylation	B-X
by	B-X
inhibiting	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
it	B-X
lacks	B-X
direct	B-X
evidences	B-X
whether	B-X
copper-inhibited	B-X
histone	B-X
acetylation	B-X
right	B-X
contributes	B-X
to	B-X
the	B-X
toxicity	B-X
of	B-X
copper	B-X
.	B-X
Exposure	B-X
of	B-X
human	B-X
leukemia	B-X
cells	B-X
(	B-X
HL-60	B-X
)	B-X
to	B-X
Cu2+	B-X
resulted	B-X
in	B-X
cell	B-X
proliferation	B-X
arrest	B-X
and	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
decrease	B-X
of	B-X
histone	B-X
acetylation	B-X
.	B-X
The	B-X
histone	B-X
acetylation	B-X
was	B-X
efficiently	B-X
suppressed	B-X
by	B-X
exogenous	B-X
H2O2	B-X
,	B-X
and	B-X
enhanced	B-X
by	B-X
superoxide	B-X
dismutase	B-X
(	B-X
the	B-X
scavenger	B-X
of	B-X
O2.-	B-X
)	B-X
,	B-X
catalase	B-X
(	B-X
the	B-X
scavenger	B-X
of	B-X
H2O2	B-X
)	B-X
or	B-X
the	B-X
combination	B-X
of	B-X
both	B-X
,	B-X
indicating	B-X
that	B-X
Cu2+	B-X
at	B-X
least	B-X
partially	B-X
inhibited	B-X
histone	B-X
acetylation	B-X
through	B-X
triggering	B-X
oxidative	B-X
stress	B-X
.	B-X
Further	B-X
studies	B-X
found	B-X
that	B-X
sodium	B-X
butyrate	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
,	B-X
which	B-X
had	B-X
no	B-X
obvious	B-X
effect	B-X
on	B-X
oxidative	B-X
stress	B-X
but	B-X
increased	B-X
histone	B-X
acetylation	B-X
at	B-X
the	B-X
concentration	B-X
of	B-X
50	B-X
microM	B-X
,	B-X
attenuated	B-X
Cu2+-inhibited	B-X
cell	B-X
proliferation	B-X
,	B-X
indicating	B-X
that	B-X
histone	B-X
acetylation	B-X
inhibition	B-X
is	B-X
simultaneously	B-X
involved	B-X
in	B-X
the	B-X
cytotoxicity	B-X
of	B-X
Cu2+	B-X
.	B-X
Considering	B-X
the	B-X
important	B-X
role	B-X
of	B-X
histone	B-X
acetylation	B-X
in	B-X
gene	B-X
transcription	B-X
and	B-X
regulation	B-X
of	B-X
cell	B-X
fate	B-X
,	B-X
the	B-X
present	B-X
study	B-X
may	B-X
open	B-X
a	B-X
new	B-X
door	B-X
to	B-X
further	B-X
understand	B-X
the	B-X
mechanism	B-X
of	B-X
Cu2+-induced	B-X
toxicity	B-X
.	B-X

Our	O
previous	O
study	O
demonstrates	O
that	O
copper	O
induces	O
histone	B-Protein
hypoacetylation	O
by	O
inhibiting	O
histone	B-Protein
acetyltransferase	O
(	O
HAT	O
)	O
activity	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
study	B-X
demonstrates	B-X
that	B-X
copper	B-X
induces	B-X
histone	B-X
hypoacetylation	B-X
by	B-X
inhibiting	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
it	B-X
lacks	B-X
direct	B-X
evidences	B-X
whether	B-X
copper-inhibited	B-X
histone	B-X
acetylation	B-X
right	B-X
contributes	B-X
to	B-X
the	B-X
toxicity	B-X
of	B-X
copper	B-X
.	B-X
Exposure	B-X
of	B-X
human	B-X
leukemia	B-X
cells	B-X
(	B-X
HL-60	B-X
)	B-X
to	B-X
Cu2+	B-X
resulted	B-X
in	B-X
cell	B-X
proliferation	B-X
arrest	B-X
and	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
decrease	B-X
of	B-X
histone	B-X
acetylation	B-X
.	B-X
The	B-X
histone	B-X
acetylation	B-X
was	B-X
efficiently	B-X
suppressed	B-X
by	B-X
exogenous	B-X
H2O2	B-X
,	B-X
and	B-X
enhanced	B-X
by	B-X
superoxide	B-X
dismutase	B-X
(	B-X
the	B-X
scavenger	B-X
of	B-X
O2.-	B-X
)	B-X
,	B-X
catalase	B-X
(	B-X
the	B-X
scavenger	B-X
of	B-X
H2O2	B-X
)	B-X
or	B-X
the	B-X
combination	B-X
of	B-X
both	B-X
,	B-X
indicating	B-X
that	B-X
Cu2+	B-X
at	B-X
least	B-X
partially	B-X
inhibited	B-X
histone	B-X
acetylation	B-X
through	B-X
triggering	B-X
oxidative	B-X
stress	B-X
.	B-X
Further	B-X
studies	B-X
found	B-X
that	B-X
sodium	B-X
butyrate	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
,	B-X
which	B-X
had	B-X
no	B-X
obvious	B-X
effect	B-X
on	B-X
oxidative	B-X
stress	B-X
but	B-X
increased	B-X
histone	B-X
acetylation	B-X
at	B-X
the	B-X
concentration	B-X
of	B-X
50	B-X
microM	B-X
,	B-X
attenuated	B-X
Cu2+-inhibited	B-X
cell	B-X
proliferation	B-X
,	B-X
indicating	B-X
that	B-X
histone	B-X
acetylation	B-X
inhibition	B-X
is	B-X
simultaneously	B-X
involved	B-X
in	B-X
the	B-X
cytotoxicity	B-X
of	B-X
Cu2+	B-X
.	B-X
Considering	B-X
the	B-X
important	B-X
role	B-X
of	B-X
histone	B-X
acetylation	B-X
in	B-X
gene	B-X
transcription	B-X
and	B-X
regulation	B-X
of	B-X
cell	B-X
fate	B-X
,	B-X
the	B-X
present	B-X
study	B-X
may	B-X
open	B-X
a	B-X
new	B-X
door	B-X
to	B-X
further	B-X
understand	B-X
the	B-X
mechanism	B-X
of	B-X
Cu2+-induced	B-X
toxicity	B-X
.	B-X

However	O
,	O
it	O
lacks	O
direct	O
evidences	O
whether	O
copper	O
-	O
inhibited	O
histone	B-Protein
acetylation	O
right	O
contributes	O
to	O
the	O
toxicity	O
of	O
copper	O
.	O

Exposure	O
of	O
human	O
leukemia	O
cells	O
(	O
HL	O
-	O
60	O
)	O
to	O
Cu2	O
+	O
resulted	O
in	O
cell	O
proliferation	O
arrest	O
and	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
decrease	O
of	O
histone	B-Protein
acetylation	O
.	O

At	O
the	O
same	O
time	O
,	O
Cu2	O
+	O
-	O
induced	O
significant	O
increase	O
of	O
H2O2	O
and	O
O2	O
.	O
-	O
generation	O
via	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
too	O
.	O

The	O
histone	B-Protein
acetylation	O
was	O
efficiently	O
suppressed	O
by	O
exogenous	O
H2O2	O
,	O
and	O
enhanced	O
by	O
superoxide	O
dismutase	O
(	O
the	O
scavenger	O
of	O
O2	O
.	O
-	O
)	O
,	O
catalase	B-Protein
(	O
the	O
scavenger	O
of	O
H2O2	O
)	O
or	O
the	O
combination	O
of	O
both	O
,	O
indicating	O
that	O
Cu2	O
+	O
at	O
least	O
partially	O
inhibited	O
histone	B-Protein
acetylation	O
through	O
triggering	O
oxidative	O
stress	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
study	B-X
demonstrates	B-X
that	B-X
copper	B-X
induces	B-X
histone	B-X
hypoacetylation	B-X
by	B-X
inhibiting	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
it	B-X
lacks	B-X
direct	B-X
evidences	B-X
whether	B-X
copper-inhibited	B-X
histone	B-X
acetylation	B-X
right	B-X
contributes	B-X
to	B-X
the	B-X
toxicity	B-X
of	B-X
copper	B-X
.	B-X
Exposure	B-X
of	B-X
human	B-X
leukemia	B-X
cells	B-X
(	B-X
HL-60	B-X
)	B-X
to	B-X
Cu2+	B-X
resulted	B-X
in	B-X
cell	B-X
proliferation	B-X
arrest	B-X
and	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
decrease	B-X
of	B-X
histone	B-X
acetylation	B-X
.	B-X
At	B-X
the	B-X
same	B-X
time	B-X
,	B-X
Cu2+-induced	B-X
significant	B-X
increase	B-X
of	B-X
H2O2	B-X
and	B-X
O2.-	B-X
generation	B-X
via	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manner	B-X
too	B-X
.	B-X
The	B-X
histone	B-X
acetylation	B-X
was	B-X
efficiently	B-X
suppressed	B-X
by	B-X
exogenous	B-X
H2O2	B-X
,	B-X
and	B-X
enhanced	B-X
by	B-X
superoxide	B-X
dismutase	B-X
(	B-X
the	B-X
scavenger	B-X
of	B-X
O2.-	B-X
)	B-X
,	B-X
catalase	B-X
(	B-X
the	B-X
scavenger	B-X
of	B-X
H2O2	B-X
)	B-X
or	B-X
the	B-X
combination	B-X
of	B-X
both	B-X
,	B-X
indicating	B-X
that	B-X
Cu2+	B-X
at	B-X
least	B-X
partially	B-X
inhibited	B-X
histone	B-X
acetylation	B-X
through	B-X
triggering	B-X
oxidative	B-X
stress	B-X
.	B-X
Further	B-X
studies	B-X
found	B-X
that	B-X
sodium	B-X
butyrate	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
,	B-X
which	B-X
had	B-X
no	B-X
obvious	B-X
effect	B-X
on	B-X
oxidative	B-X
stress	B-X
but	B-X
increased	B-X
histone	B-X
acetylation	B-X
at	B-X
the	B-X
concentration	B-X
of	B-X
50	B-X
microM	B-X
,	B-X
attenuated	B-X
Cu2+-inhibited	B-X
cell	B-X
proliferation	B-X
,	B-X
indicating	B-X
that	B-X
histone	B-X
acetylation	B-X
inhibition	B-X
is	B-X
simultaneously	B-X
involved	B-X
in	B-X
the	B-X
cytotoxicity	B-X
of	B-X
Cu2+	B-X
.	B-X
Considering	B-X
the	B-X
important	B-X
role	B-X
of	B-X
histone	B-X
acetylation	B-X
in	B-X
gene	B-X
transcription	B-X
and	B-X
regulation	B-X
of	B-X
cell	B-X
fate	B-X
,	B-X
the	B-X
present	B-X
study	B-X
may	B-X
open	B-X
a	B-X
new	B-X
door	B-X
to	B-X
further	B-X
understand	B-X
the	B-X
mechanism	B-X
of	B-X
Cu2+-induced	B-X
toxicity	B-X
.	B-X

Further	O
studies	O
found	O
that	O
sodium	O
butyrate	O
,	O
the	O
inhibitor	O
of	O
histone	B-Protein
deacetylase	O
(	O
HDAC	O
)	O
,	O
which	O
had	O
no	O
obvious	O
effect	O
on	O
oxidative	O
stress	O
but	O
increased	O
histone	B-Protein
acetylation	O
at	O
the	O
concentration	O
of	O
50	O
microM	O
,	O
attenuated	O
Cu2	O
+	O
-	O
inhibited	O
cell	O
proliferation	O
,	O
indicating	O
that	O
histone	B-Protein
acetylation	O
inhibition	O
is	O
simultaneously	O
involved	O
in	O
the	O
cytotoxicity	O
of	O
Cu2	O
+	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
study	B-X
demonstrates	B-X
that	B-X
copper	B-X
induces	B-X
histone	B-X
hypoacetylation	B-X
by	B-X
inhibiting	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
it	B-X
lacks	B-X
direct	B-X
evidences	B-X
whether	B-X
copper-inhibited	B-X
histone	B-X
acetylation	B-X
right	B-X
contributes	B-X
to	B-X
the	B-X
toxicity	B-X
of	B-X
copper	B-X
.	B-X
Exposure	B-X
of	B-X
human	B-X
leukemia	B-X
cells	B-X
(	B-X
HL-60	B-X
)	B-X
to	B-X
Cu2+	B-X
resulted	B-X
in	B-X
cell	B-X
proliferation	B-X
arrest	B-X
and	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
decrease	B-X
of	B-X
histone	B-X
acetylation	B-X
.	B-X
At	B-X
the	B-X
same	B-X
time	B-X
,	B-X
Cu2+-induced	B-X
significant	B-X
increase	B-X
of	B-X
H2O2	B-X
and	B-X
O2.-	B-X
generation	B-X
via	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manner	B-X
too	B-X
.	B-X
The	B-X
histone	B-X
acetylation	B-X
was	B-X
efficiently	B-X
suppressed	B-X
by	B-X
exogenous	B-X
H2O2	B-X
,	B-X
and	B-X
enhanced	B-X
by	B-X
superoxide	B-X
dismutase	B-X
(	B-X
the	B-X
scavenger	B-X
of	B-X
O2.-	B-X
)	B-X
,	B-X
catalase	B-X
(	B-X
the	B-X
scavenger	B-X
of	B-X
H2O2	B-X
)	B-X
or	B-X
the	B-X
combination	B-X
of	B-X
both	B-X
,	B-X
indicating	B-X
that	B-X
Cu2+	B-X
at	B-X
least	B-X
partially	B-X
inhibited	B-X
histone	B-X
acetylation	B-X
through	B-X
triggering	B-X
oxidative	B-X
stress	B-X
.	B-X
Further	B-X
studies	B-X
found	B-X
that	B-X
sodium	B-X
butyrate	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
,	B-X
which	B-X
had	B-X
no	B-X
obvious	B-X
effect	B-X
on	B-X
oxidative	B-X
stress	B-X
but	B-X
increased	B-X
histone	B-X
acetylation	B-X
at	B-X
the	B-X
concentration	B-X
of	B-X
50	B-X
microM	B-X
,	B-X
attenuated	B-X
Cu2+-inhibited	B-X
cell	B-X
proliferation	B-X
,	B-X
indicating	B-X
that	B-X
histone	B-X
acetylation	B-X
inhibition	B-X
is	B-X
simultaneously	B-X
involved	B-X
in	B-X
the	B-X
cytotoxicity	B-X
of	B-X
Cu2+	B-X
.	B-X
Considering	B-X
the	B-X
important	B-X
role	B-X
of	B-X
histone	B-X
acetylation	B-X
in	B-X
gene	B-X
transcription	B-X
and	B-X
regulation	B-X
of	B-X
cell	B-X
fate	B-X
,	B-X
the	B-X
present	B-X
study	B-X
may	B-X
open	B-X
a	B-X
new	B-X
door	B-X
to	B-X
further	B-X
understand	B-X
the	B-X
mechanism	B-X
of	B-X
Cu2+-induced	B-X
toxicity	B-X
.	B-X

Considering	O
the	O
important	O
role	O
of	O
histone	B-Protein
acetylation	O
in	O
gene	O
transcription	O
and	O
regulation	O
of	O
cell	O
fate	O
,	O
the	O
present	O
study	O
may	O
open	O
a	O
new	O
door	O
to	O
further	O
understand	O
the	O
mechanism	O
of	O
Cu2	O
+	O
-	O
induced	O
toxicity	O
.	O

DNA	O
methylation	O
-	O
related	O
chromatin	O
modification	O
in	O
the	O
regulation	O
of	O
mouse	O
delta	B-Protein
-	I-Protein
opioid	I-Protein
receptor	I-Protein
gene	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
gene-silencing	B-X
through	B-X
chromatin	B-X
modification	B-X
.	B-X
We	B-X
reported	B-X
previously	B-X
that	B-X
promoter-region	B-X
CpG	B-X
methylation	B-X
repressed	B-X
mouse	B-X
delta-opioid	B-X
receptor	B-X
(	B-X
mDOR	B-X
)	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
methylation	B-X
of	B-X
mDOR	B-X
gene	B-X
promoter	B-X
is	B-X
correlated	B-X
with	B-X
a	B-X
repressive	B-X
chromatin	B-X
structure	B-X
that	B-X
has	B-X
less	B-X
HaeIII	B-X
and	B-X
MspI	B-X
nuclear	B-X
accessibility	B-X
and	B-X
more	B-X
deacetylated	B-X
histone	B-X
H3	B-X
and	B-X
H4	B-X
than	B-X
that	B-X
of	B-X
unmethylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
MBD2	B-X
enhanced	B-X
the	B-X
repression	B-X
of	B-X
partially	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
partially	B-X
reversed	B-X
by	B-X
treatment	B-X
of	B-X
trichostatin	B-X
A	B-X
,	B-X
a	B-X
specific	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
indicating	B-X
that	B-X
MBD2	B-X
may	B-X
mediate	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
through	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
to	B-X
mDOR	B-X
promoter	B-X
region	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
mDOR	B-X
gene	B-X
expression	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
,	B-X
especially	B-X
histone	B-X
acetylation	B-X
and	B-X
deacetylation	B-X
.	B-X

DNA	O
methylation	O
plays	O
critical	O
roles	O
in	O
gene	O
-	O
silencing	O
through	O
chromatin	O
modification	O
.	O
<EOS>	B-X
DNA	B-X
tumor	B-X
viruses	B-X
including	B-X
members	B-X
of	B-X
the	B-X
polyomavirus	B-X
,	B-X
adenovirus	B-X
,	B-X
papillomavirus	B-X
,	B-X
and	B-X
herpes	B-X
virus	B-X
families	B-X
are	B-X
presently	B-X
the	B-X
subject	B-X
of	B-X
intense	B-X
interest	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
role	B-X
that	B-X
epigenetics	B-X
plays	B-X
in	B-X
control	B-X
of	B-X
the	B-X
virus	B-X
life	B-X
cycle	B-X
and	B-X
the	B-X
transformation	B-X
of	B-X
a	B-X
normal	B-X
cell	B-X
to	B-X
a	B-X
cancer	B-X
cell	B-X
.	B-X
To	B-X
date	B-X
,	B-X
these	B-X
studies	B-X
have	B-X
primarily	B-X
focused	B-X
on	B-X
the	B-X
role	B-X
of	B-X
histone	B-X
modification	B-X
,	B-X
nucleosome	B-X
location	B-X
,	B-X
and	B-X
DNA	B-X
methylation	B-X
in	B-X
regulating	B-X
the	B-X
biological	B-X
consequences	B-X
of	B-X
infection	B-X
.	B-X
Using	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
strategies	B-X
and	B-X
techniques	B-X
ranging	B-X
from	B-X
simple	B-X
ChIP	B-X
to	B-X
ChIP-chip	B-X
and	B-X
ChIP-seq	B-X
to	B-X
identify	B-X
histone	B-X
modifications	B-X
,	B-X
nuclease	B-X
digestion	B-X
to	B-X
genome	B-X
wide	B-X
next	B-X
generation	B-X
sequencing	B-X
to	B-X
identify	B-X
nucleosome	B-X
location	B-X
,	B-X
and	B-X
bisulfite	B-X
treatment	B-X
to	B-X
MeDIP	B-X
to	B-X
identify	B-X
DNA	B-X
methylation	B-X
sites	B-X
,	B-X
the	B-X
epigenetic	B-X
regulation	B-X
of	B-X
these	B-X
viruses	B-X
is	B-X
slowly	B-X
becoming	B-X
better	B-X
understood	B-X
.	B-X
While	B-X
the	B-X
viruses	B-X
may	B-X
differ	B-X
in	B-X
significant	B-X
ways	B-X
from	B-X
each	B-X
other	B-X
and	B-X
cellular	B-X
chromatin	B-X
,	B-X
the	B-X
role	B-X
of	B-X
epigenetics	B-X
appears	B-X
to	B-X
be	B-X
relatively	B-X
similar	B-X
.	B-X
Within	B-X
the	B-X
viral	B-X
genome	B-X
nucleosomes	B-X
are	B-X
organized	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
appropriate	B-X
genes	B-X
with	B-X
relevant	B-X
histone	B-X
modifications	B-X
particularly	B-X
histone	B-X
acetylation	B-X
.	B-X
DNA	B-X
methylation	B-X
occurs	B-X
as	B-X
part	B-X
of	B-X
the	B-X
typical	B-X
gene	B-X
silencing	B-X
during	B-X
latent	B-X
infection	B-X
by	B-X
herpesviruses	B-X
.	B-X
This	B-X
results	B-X
in	B-X
the	B-X
unregulated	B-X
expression	B-X
of	B-X
critical	B-X
viral	B-X
genes	B-X
capable	B-X
of	B-X
redirecting	B-X
cellular	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
redirected	B-X
cellular	B-X
expression	B-X
is	B-X
a	B-X
consequence	B-X
of	B-X
either	B-X
indirect	B-X
epigenetic	B-X
regulation	B-X
where	B-X
cellular	B-X
signaling	B-X
or	B-X
transcriptional	B-X
dysregulation	B-X
occurs	B-X
or	B-X
direct	B-X
epigenetic	B-X
regulation	B-X
where	B-X
epigenetic	B-X
cofactors	B-X
such	B-X
as	B-X
histone	B-X
deacetylases	B-X
are	B-X
targeted	B-X
.	B-X
In	B-X
the	B-X
more	B-X
complex	B-X
herpersviruses	B-X
transformation	B-X
is	B-X
a	B-X
consequence	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
viral	B-X
latency	B-X
proteins	B-X
and	B-X
RNAs	B-X
which	B-X
again	B-X
can	B-X
have	B-X
either	B-X
a	B-X
direct	B-X
or	B-X
indirect	B-X
effect	B-X
on	B-X
epigenetic	B-X
regulation	B-X
of	B-X
cellular	B-X
expression	B-X
.	B-X
Nevertheless	B-X
,	B-X
many	B-X
questions	B-X
still	B-X
remain	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
specific	B-X
mechanisms	B-X
underlying	B-X
epigenetic	B-X
regulation	B-X
of	B-X
the	B-X
viruses	B-X
and	B-X
transformation	B-X
.	B-X

We	O
reported	O
previously	O
that	O
promoter	O
-	O
region	O
CpG	O
methylation	O
repressed	O
mouse	O
delta	B-Protein
-	I-Protein
opioid	I-Protein
receptor	I-Protein
(	O
mDOR	B-Protein
)	O
gene	O
expression	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
gene-silencing	B-X
through	B-X
chromatin	B-X
modification	B-X
.	B-X
We	B-X
reported	B-X
previously	B-X
that	B-X
promoter-region	B-X
CpG	B-X
methylation	B-X
repressed	B-X
mouse	B-X
delta-opioid	B-X
receptor	B-X
(	B-X
mDOR	B-X
)	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
methylation	B-X
of	B-X
mDOR	B-X
gene	B-X
promoter	B-X
is	B-X
correlated	B-X
with	B-X
a	B-X
repressive	B-X
chromatin	B-X
structure	B-X
that	B-X
has	B-X
less	B-X
HaeIII	B-X
and	B-X
MspI	B-X
nuclear	B-X
accessibility	B-X
and	B-X
more	B-X
deacetylated	B-X
histone	B-X
H3	B-X
and	B-X
H4	B-X
than	B-X
that	B-X
of	B-X
unmethylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
analysis	B-X
showed	B-X
the	B-X
association	B-X
of	B-X
a	B-X
methyl-CpG-binding	B-X
domain	B-X
protein	B-X
2	B-X
(	B-X
MBD2	B-X
)	B-X
with	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
MBD2	B-X
enhanced	B-X
the	B-X
repression	B-X
of	B-X
partially	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
partially	B-X
reversed	B-X
by	B-X
treatment	B-X
of	B-X
trichostatin	B-X
A	B-X
,	B-X
a	B-X
specific	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
indicating	B-X
that	B-X
MBD2	B-X
may	B-X
mediate	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
through	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
to	B-X
mDOR	B-X
promoter	B-X
region	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
trichostatin	B-X
A	B-X
treatment	B-X
increased	B-X
both	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
and	B-X
endogenous	B-X
mDOR	B-X
mRNA	B-X
level	B-X
in	B-X
Neuro2A	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
mDOR	B-X
gene	B-X
expression	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
,	B-X
especially	B-X
histone	B-X
acetylation	B-X
and	B-X
deacetylation	B-X
.	B-X

In	O
the	O
current	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
methylation	O
of	O
mDOR	B-Protein
gene	O
promoter	O
is	O
correlated	O
with	O
a	O
repressive	O
chromatin	O
structure	O
that	O
has	O
less	O
HaeIII	B-Protein
and	O
MspI	B-Protein
nuclear	O
accessibility	O
and	O
more	O
deacetylated	O
histone	B-Protein
H3	I-Protein
and	O
H4	B-Protein
than	O
that	O
of	O
unmethylated	O
mDOR	B-Protein
promoter	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
gene-silencing	B-X
through	B-X
chromatin	B-X
modification	B-X
.	B-X
We	B-X
reported	B-X
previously	B-X
that	B-X
promoter-region	B-X
CpG	B-X
methylation	B-X
repressed	B-X
mouse	B-X
delta-opioid	B-X
receptor	B-X
(	B-X
mDOR	B-X
)	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
methylation	B-X
of	B-X
mDOR	B-X
gene	B-X
promoter	B-X
is	B-X
correlated	B-X
with	B-X
a	B-X
repressive	B-X
chromatin	B-X
structure	B-X
that	B-X
has	B-X
less	B-X
HaeIII	B-X
and	B-X
MspI	B-X
nuclear	B-X
accessibility	B-X
and	B-X
more	B-X
deacetylated	B-X
histone	B-X
H3	B-X
and	B-X
H4	B-X
than	B-X
that	B-X
of	B-X
unmethylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
analysis	B-X
showed	B-X
the	B-X
association	B-X
of	B-X
a	B-X
methyl-CpG-binding	B-X
domain	B-X
protein	B-X
2	B-X
(	B-X
MBD2	B-X
)	B-X
with	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
MBD2	B-X
enhanced	B-X
the	B-X
repression	B-X
of	B-X
partially	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
partially	B-X
reversed	B-X
by	B-X
treatment	B-X
of	B-X
trichostatin	B-X
A	B-X
,	B-X
a	B-X
specific	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
indicating	B-X
that	B-X
MBD2	B-X
may	B-X
mediate	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
through	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
to	B-X
mDOR	B-X
promoter	B-X
region	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
trichostatin	B-X
A	B-X
treatment	B-X
increased	B-X
both	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
and	B-X
endogenous	B-X
mDOR	B-X
mRNA	B-X
level	B-X
in	B-X
Neuro2A	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
mDOR	B-X
gene	B-X
expression	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
,	B-X
especially	B-X
histone	B-X
acetylation	B-X
and	B-X
deacetylation	B-X
.	B-X

Chromatin	O
immunoprecipitation	O
analysis	O
showed	O
the	O
association	O
of	O
a	O
methyl	B-Protein
-	I-Protein
CpG	I-Protein
-	I-Protein
binding	I-Protein
domain	I-Protein
protein	I-Protein
2	I-Protein
(	O
MBD2	B-Protein
)	O
with	O
methylated	O
mDOR	B-Protein
promoter	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
gene-silencing	B-X
through	B-X
chromatin	B-X
modification	B-X
.	B-X
We	B-X
reported	B-X
previously	B-X
that	B-X
promoter-region	B-X
CpG	B-X
methylation	B-X
repressed	B-X
mouse	B-X
delta-opioid	B-X
receptor	B-X
(	B-X
mDOR	B-X
)	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
methylation	B-X
of	B-X
mDOR	B-X
gene	B-X
promoter	B-X
is	B-X
correlated	B-X
with	B-X
a	B-X
repressive	B-X
chromatin	B-X
structure	B-X
that	B-X
has	B-X
less	B-X
HaeIII	B-X
and	B-X
MspI	B-X
nuclear	B-X
accessibility	B-X
and	B-X
more	B-X
deacetylated	B-X
histone	B-X
H3	B-X
and	B-X
H4	B-X
than	B-X
that	B-X
of	B-X
unmethylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
analysis	B-X
showed	B-X
the	B-X
association	B-X
of	B-X
a	B-X
methyl-CpG-binding	B-X
domain	B-X
protein	B-X
2	B-X
(	B-X
MBD2	B-X
)	B-X
with	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
MBD2	B-X
enhanced	B-X
the	B-X
repression	B-X
of	B-X
partially	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
partially	B-X
reversed	B-X
by	B-X
treatment	B-X
of	B-X
trichostatin	B-X
A	B-X
,	B-X
a	B-X
specific	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
indicating	B-X
that	B-X
MBD2	B-X
may	B-X
mediate	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
through	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
to	B-X
mDOR	B-X
promoter	B-X
region	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
trichostatin	B-X
A	B-X
treatment	B-X
increased	B-X
both	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
and	B-X
endogenous	B-X
mDOR	B-X
mRNA	B-X
level	B-X
in	B-X
Neuro2A	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
mDOR	B-X
gene	B-X
expression	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
,	B-X
especially	B-X
histone	B-X
acetylation	B-X
and	B-X
deacetylation	B-X
.	B-X

Transient	O
expression	O
of	O
MBD2	B-Protein
enhanced	O
the	O
repression	O
of	O
partially	O
methylated	O
mDOR	B-Protein
promoter	O
activity	O
,	O
and	O
this	O
repression	O
was	O
partially	O
reversed	O
by	O
treatment	O
of	O
trichostatin	O
A	O
,	O
a	O
specific	O
histone	B-Protein
deacetylase	O
inhibitor	O
,	O
indicating	O
that	O
MBD2	B-Protein
may	O
mediate	O
DNA	O
methylation	O
-	O
related	O
chromatin	O
modification	O
through	O
recruiting	O
histone	O
deacetylases	O
to	O
mDOR	B-Protein
promoter	O
region	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
gene-silencing	B-X
through	B-X
chromatin	B-X
modification	B-X
.	B-X
We	B-X
reported	B-X
previously	B-X
that	B-X
promoter-region	B-X
CpG	B-X
methylation	B-X
repressed	B-X
mouse	B-X
delta-opioid	B-X
receptor	B-X
(	B-X
mDOR	B-X
)	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
methylation	B-X
of	B-X
mDOR	B-X
gene	B-X
promoter	B-X
is	B-X
correlated	B-X
with	B-X
a	B-X
repressive	B-X
chromatin	B-X
structure	B-X
that	B-X
has	B-X
less	B-X
HaeIII	B-X
and	B-X
MspI	B-X
nuclear	B-X
accessibility	B-X
and	B-X
more	B-X
deacetylated	B-X
histone	B-X
H3	B-X
and	B-X
H4	B-X
than	B-X
that	B-X
of	B-X
unmethylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
analysis	B-X
showed	B-X
the	B-X
association	B-X
of	B-X
a	B-X
methyl-CpG-binding	B-X
domain	B-X
protein	B-X
2	B-X
(	B-X
MBD2	B-X
)	B-X
with	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
MBD2	B-X
enhanced	B-X
the	B-X
repression	B-X
of	B-X
partially	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
partially	B-X
reversed	B-X
by	B-X
treatment	B-X
of	B-X
trichostatin	B-X
A	B-X
,	B-X
a	B-X
specific	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
indicating	B-X
that	B-X
MBD2	B-X
may	B-X
mediate	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
through	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
to	B-X
mDOR	B-X
promoter	B-X
region	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
trichostatin	B-X
A	B-X
treatment	B-X
increased	B-X
both	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
and	B-X
endogenous	B-X
mDOR	B-X
mRNA	B-X
level	B-X
in	B-X
Neuro2A	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
mDOR	B-X
gene	B-X
expression	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
,	B-X
especially	B-X
histone	B-X
acetylation	B-X
and	B-X
deacetylation	B-X
.	B-X

In	O
addition	O
,	O
trichostatin	O
A	O
treatment	O
increased	O
both	O
methylated	O
mDOR	B-Protein
promoter	O
activity	O
in	O
a	O
transient	O
transfection	O
assay	O
and	O
endogenous	O
mDOR	B-Protein
mRNA	O
level	O
in	O
Neuro2A	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
mDOR	B-Protein
gene	O
expression	O
is	O
regulated	O
by	O
DNA	O
methylation	O
-	O
related	O
chromatin	O
modification	O
,	O
especially	O
histone	B-Protein
acetylation	O
and	O
deacetylation	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
gene-silencing	B-X
through	B-X
chromatin	B-X
modification	B-X
.	B-X
We	B-X
reported	B-X
previously	B-X
that	B-X
promoter-region	B-X
CpG	B-X
methylation	B-X
repressed	B-X
mouse	B-X
delta-opioid	B-X
receptor	B-X
(	B-X
mDOR	B-X
)	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
methylation	B-X
of	B-X
mDOR	B-X
gene	B-X
promoter	B-X
is	B-X
correlated	B-X
with	B-X
a	B-X
repressive	B-X
chromatin	B-X
structure	B-X
that	B-X
has	B-X
less	B-X
HaeIII	B-X
and	B-X
MspI	B-X
nuclear	B-X
accessibility	B-X
and	B-X
more	B-X
deacetylated	B-X
histone	B-X
H3	B-X
and	B-X
H4	B-X
than	B-X
that	B-X
of	B-X
unmethylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
analysis	B-X
showed	B-X
the	B-X
association	B-X
of	B-X
a	B-X
methyl-CpG-binding	B-X
domain	B-X
protein	B-X
2	B-X
(	B-X
MBD2	B-X
)	B-X
with	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
MBD2	B-X
enhanced	B-X
the	B-X
repression	B-X
of	B-X
partially	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
repression	B-X
was	B-X
partially	B-X
reversed	B-X
by	B-X
treatment	B-X
of	B-X
trichostatin	B-X
A	B-X
,	B-X
a	B-X
specific	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
indicating	B-X
that	B-X
MBD2	B-X
may	B-X
mediate	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
through	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
to	B-X
mDOR	B-X
promoter	B-X
region	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
trichostatin	B-X
A	B-X
treatment	B-X
increased	B-X
both	B-X
methylated	B-X
mDOR	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
and	B-X
endogenous	B-X
mDOR	B-X
mRNA	B-X
level	B-X
in	B-X
Neuro2A	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
mDOR	B-X
gene	B-X
expression	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation-related	B-X
chromatin	B-X
modification	B-X
,	B-X
especially	B-X
histone	B-X
acetylation	B-X
and	B-X
deacetylation	B-X
.	B-X

The	O
potential	O
of	O
Pseudozyma	O
yeastlike	O
epiphytes	O
for	O
the	O
production	O
of	O
heterologous	O
recombinant	O
proteins	O
.	O
<EOS>	B-X
Although	B-X
Basidiomycetes	B-X
represent	B-X
the	B-X
most	B-X
evolved	B-X
class	B-X
of	B-X
fungi	B-X
,	B-X
they	B-X
have	B-X
been	B-X
neglected	B-X
with	B-X
regard	B-X
to	B-X
recombinant	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
basidiomycetous	B-X
yeasts	B-X
belonging	B-X
to	B-X
Pseudozyma	B-X
spp	B-X
.	B-X
were	B-X
studied	B-X
with	B-X
respect	B-X
to	B-X
their	B-X
amenability	B-X
to	B-X
heterologous	B-X
protein	B-X
production	B-X
.	B-X
Single	B-X
plasmid	B-X
or	B-X
cotransformation	B-X
experiments	B-X
routinely	B-X
afforded	B-X
100	B-X
to	B-X
200	B-X
independent	B-X
transformants	B-X
for	B-X
the	B-X
two	B-X
tested	B-X
species	B-X
of	B-X
Pseudozyma	B-X
.	B-X
Protease	B-X
analysis	B-X
established	B-X
that	B-X
Pseudozyma	B-X
spp	B-X
.	B-X
This	B-X
proteolytic	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
over	B-X
97	B-X
%	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
PMSF	B-X
and	B-X
Pepstatin	B-X
A.	B-X
N-glycosylation	B-X
patterns	B-X
of	B-X
native	B-X
Pseudozyma	B-X
flocculosa	B-X
secreted	B-X
proteins	B-X
were	B-X
comprised	B-X
of	B-X
one	B-X
or	B-X
a	B-X
few	B-X
short	B-X
glycan	B-X
chains	B-X
that	B-X
possess	B-X
a	B-X
classic	B-X
eukaryotic	B-X
structure	B-X
typical	B-X
of	B-X
higher	B-X
fungi	B-X
and	B-X
animal	B-X
cells	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
a	B-X
Basidiomycete	B-X
that	B-X
possesses	B-X
multiple	B-X
intrinsic	B-X
characteristics	B-X
necessary	B-X
for	B-X
use	B-X
as	B-X
a	B-X
heterologous	B-X
gene	B-X
expression	B-X
system	B-X
.	B-X

Although	O
Basidiomycetes	O
represent	O
the	O
most	O
evolved	O
class	O
of	O
fungi	O
,	O
they	O
have	O
been	O
neglected	O
with	O
regard	O
to	O
recombinant	O
gene	O
expression	O
.	O
<EOS>	B-X
Although	B-X
Basidiomycetes	B-X
represent	B-X
the	B-X
most	B-X
evolved	B-X
class	B-X
of	B-X
fungi	B-X
,	B-X
they	B-X
have	B-X
been	B-X
neglected	B-X
with	B-X
regard	B-X
to	B-X
recombinant	B-X
gene	B-X
expression	B-X
.	B-X
contained	B-X
equivalent	B-X
or	B-X
less	B-X
extracellular	B-X
protease	B-X
activity	B-X
than	B-X
yeasts	B-X
and	B-X
far	B-X
less	B-X
protease	B-X
activity	B-X
than	B-X
ascomycetous	B-X
filamentous	B-X
fungi	B-X
in	B-X
similar	B-X
culture	B-X
conditions	B-X
.	B-X
This	B-X
proteolytic	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
over	B-X
97	B-X
%	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
PMSF	B-X
and	B-X
Pepstatin	B-X
A.	B-X
N-glycosylation	B-X
patterns	B-X
of	B-X
native	B-X
Pseudozyma	B-X
flocculosa	B-X
secreted	B-X
proteins	B-X
were	B-X
comprised	B-X
of	B-X
one	B-X
or	B-X
a	B-X
few	B-X
short	B-X
glycan	B-X
chains	B-X
that	B-X
possess	B-X
a	B-X
classic	B-X
eukaryotic	B-X
structure	B-X
typical	B-X
of	B-X
higher	B-X
fungi	B-X
and	B-X
animal	B-X
cells	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
a	B-X
Basidiomycete	B-X
that	B-X
possesses	B-X
multiple	B-X
intrinsic	B-X
characteristics	B-X
necessary	B-X
for	B-X
use	B-X
as	B-X
a	B-X
heterologous	B-X
gene	B-X
expression	B-X
system	B-X
.	B-X

In	O
this	O
work	O
,	O
basidiomycetous	O
yeasts	O
belonging	O
to	O
Pseudozyma	O
spp	O
.	O
were	O
studied	O
with	O
respect	O
to	O
their	O
amenability	O
to	O
heterologous	O
protein	O
production	O
.	O
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
basidiomycetous	B-X
yeasts	B-X
belonging	B-X
to	B-X
Pseudozyma	B-X
spp	B-X
.	B-X
were	B-X
studied	B-X
with	B-X
respect	B-X
to	B-X
their	B-X
amenability	B-X
to	B-X
heterologous	B-X
protein	B-X
production	B-X
.	B-X
Single	B-X
plasmid	B-X
or	B-X
cotransformation	B-X
experiments	B-X
routinely	B-X
afforded	B-X
100	B-X
to	B-X
200	B-X
independent	B-X
transformants	B-X
for	B-X
the	B-X
two	B-X
tested	B-X
species	B-X
of	B-X
Pseudozyma	B-X
.	B-X
Green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
the	B-X
correctly	B-X
folded	B-X
conformation	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
and	B-X
hen	B-X
egg	B-X
white	B-X
lysozyme	B-X
(	B-X
HEWL	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
its	B-X
active	B-X
form	B-X
,	B-X
as	B-X
revealed	B-X
by	B-X
its	B-X
lytic	B-X
activity	B-X
on	B-X
Micrococcus	B-X
lysodeikticus	B-X
cells	B-X
.	B-X
Protease	B-X
analysis	B-X
established	B-X
that	B-X
Pseudozyma	B-X
spp	B-X
.	B-X
contained	B-X
equivalent	B-X
or	B-X
less	B-X
extracellular	B-X
protease	B-X
activity	B-X
than	B-X
yeasts	B-X
and	B-X
far	B-X
less	B-X
protease	B-X
activity	B-X
than	B-X
ascomycetous	B-X
filamentous	B-X
fungi	B-X
in	B-X
similar	B-X
culture	B-X
conditions	B-X
.	B-X
This	B-X
proteolytic	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
over	B-X
97	B-X
%	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
PMSF	B-X
and	B-X
Pepstatin	B-X
A.	B-X
N-glycosylation	B-X
patterns	B-X
of	B-X
native	B-X
Pseudozyma	B-X
flocculosa	B-X
secreted	B-X
proteins	B-X
were	B-X
comprised	B-X
of	B-X
one	B-X
or	B-X
a	B-X
few	B-X
short	B-X
glycan	B-X
chains	B-X
that	B-X
possess	B-X
a	B-X
classic	B-X
eukaryotic	B-X
structure	B-X
typical	B-X
of	B-X
higher	B-X
fungi	B-X
and	B-X
animal	B-X
cells	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
a	B-X
Basidiomycete	B-X
that	B-X
possesses	B-X
multiple	B-X
intrinsic	B-X
characteristics	B-X
necessary	B-X
for	B-X
use	B-X
as	B-X
a	B-X
heterologous	B-X
gene	B-X
expression	B-X
system	B-X
.	B-X

Single	O
plasmid	O
or	O
cotransformation	O
experiments	O
routinely	O
afforded	O
100	O
to	O
200	O
independent	O
transformants	O
for	O
the	O
two	O
tested	O
species	O
of	O
Pseudozyma	O
.	O
<EOS>	B-X
Developing	B-X
for	B-X
almost	B-X
half	B-X
a	B-X
century	B-X
,	B-X
plasmid-construction	B-X
has	B-X
explored	B-X
more	B-X
than	B-X
37	B-X
methods	B-X
.	B-X
From	B-X
a	B-X
global	B-X
and	B-X
evolutionary	B-X
viewpoint	B-X
,	B-X
a	B-X
review	B-X
will	B-X
make	B-X
a	B-X
clear	B-X
understand	B-X
and	B-X
an	B-X
easy	B-X
practice	B-X
for	B-X
plasmid-construction	B-X
.	B-X
Mechanism	B-X
of	B-X
plasmid-construction	B-X
is	B-X
primer	B-X
annealing	B-X
or/and	B-X
primer	B-X
invasion	B-X
.	B-X
Scar	B-X
junction	B-X
is	B-X
a	B-X
must-be	B-X
faced	B-X
scientific	B-X
problem	B-X
in	B-X
plasmid-construction	B-X
.	B-X

Green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	B-Protein
)	O
was	O
expressed	O
in	O
the	O
correctly	O
folded	O
conformation	O
,	O
as	O
demonstrated	O
by	O
fluorescence	O
microscopy	O
,	O
and	O
hen	O
egg	O
white	O
lysozyme	B-Protein
(	O
HEWL	O
)	O
was	O
expressed	O
in	O
its	O
active	O
form	O
,	O
as	O
revealed	O
by	O
its	O
lytic	O
activity	O
on	O
Micrococcus	O
lysodeikticus	O
cells	O
.	O
<EOS>	B-X
were	B-X
studied	B-X
with	B-X
respect	B-X
to	B-X
their	B-X
amenability	B-X
to	B-X
heterologous	B-X
protein	B-X
production	B-X
.	B-X
Single	B-X
plasmid	B-X
or	B-X
cotransformation	B-X
experiments	B-X
routinely	B-X
afforded	B-X
100	B-X
to	B-X
200	B-X
independent	B-X
transformants	B-X
for	B-X
the	B-X
two	B-X
tested	B-X
species	B-X
of	B-X
Pseudozyma	B-X
.	B-X
Green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
the	B-X
correctly	B-X
folded	B-X
conformation	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
and	B-X
hen	B-X
egg	B-X
white	B-X
lysozyme	B-X
(	B-X
HEWL	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
its	B-X
active	B-X
form	B-X
,	B-X
as	B-X
revealed	B-X
by	B-X
its	B-X
lytic	B-X
activity	B-X
on	B-X
Micrococcus	B-X
lysodeikticus	B-X
cells	B-X
.	B-X
contained	B-X
equivalent	B-X
or	B-X
less	B-X
extracellular	B-X
protease	B-X
activity	B-X
than	B-X
yeasts	B-X
and	B-X
far	B-X
less	B-X
protease	B-X
activity	B-X
than	B-X
ascomycetous	B-X
filamentous	B-X
fungi	B-X
in	B-X
similar	B-X
culture	B-X
conditions	B-X
.	B-X
This	B-X
proteolytic	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
over	B-X
97	B-X
%	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
PMSF	B-X
and	B-X
Pepstatin	B-X
A.	B-X
N-glycosylation	B-X
patterns	B-X
of	B-X
native	B-X
Pseudozyma	B-X
flocculosa	B-X
secreted	B-X
proteins	B-X
were	B-X
comprised	B-X
of	B-X
one	B-X
or	B-X
a	B-X
few	B-X
short	B-X
glycan	B-X
chains	B-X
that	B-X
possess	B-X
a	B-X
classic	B-X
eukaryotic	B-X
structure	B-X
typical	B-X
of	B-X
higher	B-X
fungi	B-X
and	B-X
animal	B-X
cells	B-X
.	B-X

Protease	O
analysis	O
established	O
that	O
Pseudozyma	O
spp	O
.	O
contained	O
equivalent	O
or	O
less	O
extracellular	O
protease	O
activity	O
than	O
yeasts	O
and	O
far	O
less	O
protease	O
activity	O
than	O
ascomycetous	O
filamentous	O
fungi	O
in	O
similar	O
culture	O
conditions	O
.	O
<EOS>	B-X
Although	B-X
Basidiomycetes	B-X
represent	B-X
the	B-X
most	B-X
evolved	B-X
class	B-X
of	B-X
fungi	B-X
,	B-X
they	B-X
have	B-X
been	B-X
neglected	B-X
with	B-X
regard	B-X
to	B-X
recombinant	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
basidiomycetous	B-X
yeasts	B-X
belonging	B-X
to	B-X
Pseudozyma	B-X
spp	B-X
.	B-X
Single	B-X
plasmid	B-X
or	B-X
cotransformation	B-X
experiments	B-X
routinely	B-X
afforded	B-X
100	B-X
to	B-X
200	B-X
independent	B-X
transformants	B-X
for	B-X
the	B-X
two	B-X
tested	B-X
species	B-X
of	B-X
Pseudozyma	B-X
.	B-X
Green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
the	B-X
correctly	B-X
folded	B-X
conformation	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
and	B-X
hen	B-X
egg	B-X
white	B-X
lysozyme	B-X
(	B-X
HEWL	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
its	B-X
active	B-X
form	B-X
,	B-X
as	B-X
revealed	B-X
by	B-X
its	B-X
lytic	B-X
activity	B-X
on	B-X
Micrococcus	B-X
lysodeikticus	B-X
cells	B-X
.	B-X
Protease	B-X
analysis	B-X
established	B-X
that	B-X
Pseudozyma	B-X
spp	B-X
.	B-X
contained	B-X
equivalent	B-X
or	B-X
less	B-X
extracellular	B-X
protease	B-X
activity	B-X
than	B-X
yeasts	B-X
and	B-X
far	B-X
less	B-X
protease	B-X
activity	B-X
than	B-X
ascomycetous	B-X
filamentous	B-X
fungi	B-X
in	B-X
similar	B-X
culture	B-X
conditions	B-X
.	B-X
This	B-X
proteolytic	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
over	B-X
97	B-X
%	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
PMSF	B-X
and	B-X
Pepstatin	B-X
A.	B-X
N-glycosylation	B-X
patterns	B-X
of	B-X
native	B-X
Pseudozyma	B-X
flocculosa	B-X
secreted	B-X
proteins	B-X
were	B-X
comprised	B-X
of	B-X
one	B-X
or	B-X
a	B-X
few	B-X
short	B-X
glycan	B-X
chains	B-X
that	B-X
possess	B-X
a	B-X
classic	B-X
eukaryotic	B-X
structure	B-X
typical	B-X
of	B-X
higher	B-X
fungi	B-X
and	B-X
animal	B-X
cells	B-X
.	B-X

This	O
proteolytic	O
activity	O
was	O
inhibited	O
by	O
over	O
97	O
%	O
with	O
a	O
combination	O
of	O
PMSF	O
and	O
Pepstatin	O
A	O
.	O
<EOS>	B-X
Green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
the	B-X
correctly	B-X
folded	B-X
conformation	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
and	B-X
hen	B-X
egg	B-X
white	B-X
lysozyme	B-X
(	B-X
HEWL	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
its	B-X
active	B-X
form	B-X
,	B-X
as	B-X
revealed	B-X
by	B-X
its	B-X
lytic	B-X
activity	B-X
on	B-X
Micrococcus	B-X
lysodeikticus	B-X
cells	B-X
.	B-X
contained	B-X
equivalent	B-X
or	B-X
less	B-X
extracellular	B-X
protease	B-X
activity	B-X
than	B-X
yeasts	B-X
and	B-X
far	B-X
less	B-X
protease	B-X
activity	B-X
than	B-X
ascomycetous	B-X
filamentous	B-X
fungi	B-X
in	B-X
similar	B-X
culture	B-X
conditions	B-X
.	B-X
This	B-X
proteolytic	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
over	B-X
97	B-X
%	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
PMSF	B-X
and	B-X
Pepstatin	B-X
A.	B-X
N-glycosylation	B-X
patterns	B-X
of	B-X
native	B-X
Pseudozyma	B-X
flocculosa	B-X
secreted	B-X
proteins	B-X
were	B-X
comprised	B-X
of	B-X
one	B-X
or	B-X
a	B-X
few	B-X
short	B-X
glycan	B-X
chains	B-X
that	B-X
possess	B-X
a	B-X
classic	B-X
eukaryotic	B-X
structure	B-X
typical	B-X
of	B-X
higher	B-X
fungi	B-X
and	B-X
animal	B-X
cells	B-X
.	B-X

N	O
-	O
glycosylation	O
patterns	O
of	O
native	O
Pseudozyma	O
flocculosa	O
secreted	O
proteins	O
were	O
comprised	O
of	O
one	O
or	O
a	O
few	O
short	O
glycan	O
chains	O
that	O
possess	O
a	O
classic	O
eukaryotic	O
structure	O
typical	O
of	O
higher	O
fungi	O
and	O
animal	O
cells	O
.	O
<EOS>	B-X
Although	B-X
Basidiomycetes	B-X
represent	B-X
the	B-X
most	B-X
evolved	B-X
class	B-X
of	B-X
fungi	B-X
,	B-X
they	B-X
have	B-X
been	B-X
neglected	B-X
with	B-X
regard	B-X
to	B-X
recombinant	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
basidiomycetous	B-X
yeasts	B-X
belonging	B-X
to	B-X
Pseudozyma	B-X
spp	B-X
.	B-X
Single	B-X
plasmid	B-X
or	B-X
cotransformation	B-X
experiments	B-X
routinely	B-X
afforded	B-X
100	B-X
to	B-X
200	B-X
independent	B-X
transformants	B-X
for	B-X
the	B-X
two	B-X
tested	B-X
species	B-X
of	B-X
Pseudozyma	B-X
.	B-X
Green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
the	B-X
correctly	B-X
folded	B-X
conformation	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
and	B-X
hen	B-X
egg	B-X
white	B-X
lysozyme	B-X
(	B-X
HEWL	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
its	B-X
active	B-X
form	B-X
,	B-X
as	B-X
revealed	B-X
by	B-X
its	B-X
lytic	B-X
activity	B-X
on	B-X
Micrococcus	B-X
lysodeikticus	B-X
cells	B-X
.	B-X
Protease	B-X
analysis	B-X
established	B-X
that	B-X
Pseudozyma	B-X
spp	B-X
.	B-X
contained	B-X
equivalent	B-X
or	B-X
less	B-X
extracellular	B-X
protease	B-X
activity	B-X
than	B-X
yeasts	B-X
and	B-X
far	B-X
less	B-X
protease	B-X
activity	B-X
than	B-X
ascomycetous	B-X
filamentous	B-X
fungi	B-X
in	B-X
similar	B-X
culture	B-X
conditions	B-X
.	B-X
This	B-X
proteolytic	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
over	B-X
97	B-X
%	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
PMSF	B-X
and	B-X
Pepstatin	B-X
A.	B-X
N-glycosylation	B-X
patterns	B-X
of	B-X
native	B-X
Pseudozyma	B-X
flocculosa	B-X
secreted	B-X
proteins	B-X
were	B-X
comprised	B-X
of	B-X
one	B-X
or	B-X
a	B-X
few	B-X
short	B-X
glycan	B-X
chains	B-X
that	B-X
possess	B-X
a	B-X
classic	B-X
eukaryotic	B-X
structure	B-X
typical	B-X
of	B-X
higher	B-X
fungi	B-X
and	B-X
animal	B-X
cells	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
a	B-X
Basidiomycete	B-X
that	B-X
possesses	B-X
multiple	B-X
intrinsic	B-X
characteristics	B-X
necessary	B-X
for	B-X
use	B-X
as	B-X
a	B-X
heterologous	B-X
gene	B-X
expression	B-X
system	B-X
.	B-X

This	O
is	O
the	O
first	O
report	O
of	O
a	O
Basidiomycete	O
that	O
possesses	O
multiple	O
intrinsic	O
characteristics	O
necessary	O
for	O
use	O
as	O
a	O
heterologous	O
gene	O
expression	O
system	O
.	O
<EOS>	B-X
Although	B-X
Basidiomycetes	B-X
represent	B-X
the	B-X
most	B-X
evolved	B-X
class	B-X
of	B-X
fungi	B-X
,	B-X
they	B-X
have	B-X
been	B-X
neglected	B-X
with	B-X
regard	B-X
to	B-X
recombinant	B-X
gene	B-X
expression	B-X
.	B-X
were	B-X
studied	B-X
with	B-X
respect	B-X
to	B-X
their	B-X
amenability	B-X
to	B-X
heterologous	B-X
protein	B-X
production	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
a	B-X
Basidiomycete	B-X
that	B-X
possesses	B-X
multiple	B-X
intrinsic	B-X
characteristics	B-X
necessary	B-X
for	B-X
use	B-X
as	B-X
a	B-X
heterologous	B-X
gene	B-X
expression	B-X
system	B-X
.	B-X

Interactions	O
of	O
whey	O
proteins	O
during	O
heat	O
treatment	O
of	O
oil	O
-	O
in	O
-	O
water	O
emulsions	O
formed	O
with	O
whey	O
protein	O
isolate	O
and	O
hydroxylated	O
lecithin	O
.	O
<EOS>	B-X
The	B-X
interactions	B-X
of	B-X
proteins	B-X
during	B-X
the	B-X
heat	B-X
treatment	B-X
of	B-X
whey-protein-isolate	B-X
(	B-X
WPI	B-X
)	B-X
-based	B-X
oil-in-water	B-X
emulsions	B-X
with	B-X
and	B-X
without	B-X
added	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
studied	B-X
by	B-X
examining	B-X
the	B-X
changes	B-X
in	B-X
droplet	B-X
size	B-X
distribution	B-X
and	B-X
the	B-X
quantity	B-X
and	B-X
type	B-X
of	B-X
adsorbed	B-X
and	B-X
unadsorbed	B-X
proteins	B-X
.	B-X
Heat	B-X
treatment	B-X
at	B-X
90	B-X
degrees	B-X
C	B-X
of	B-X
WPI	B-X
emulsions	B-X
resulted	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
;	B-X
unadsorbed	B-X
beta-lactoglobulin	B-X
(	B-X
beta-lg	B-X
)	B-X
was	B-X
the	B-X
main	B-X
protein	B-X
interacting	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
the	B-X
first	B-X
10	B-X
min	B-X
of	B-X
heating	B-X
,	B-X
but	B-X
after	B-X
this	B-X
time	B-X
,	B-X
unadsorbed	B-X
alpha-lactalbumin	B-X
(	B-X
alpha-la	B-X
)	B-X
also	B-X
associated	B-X
with	B-X
the	B-X
adsorbed	B-X
protein	B-X
.	B-X
In	B-X
emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
during	B-X
heat	B-X
treatment	B-X
was	B-X
much	B-X
lower	B-X
and	B-X
the	B-X
unadsorbed	B-X
beta-lg	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
heating	B-X
.	B-X
However	B-X
,	B-X
the	B-X
behavior	B-X
of	B-X
alpha-la	B-X
during	B-X
heat	B-X
treatment	B-X
of	B-X
these	B-X
emulsions	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
in	B-X
the	B-X
emulsions	B-X
containing	B-X
no	B-X
hydroxylated	B-X
lecithin	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
NaCl	B-X
,	B-X
the	B-X
particle	B-X
size	B-X
of	B-X
the	B-X
emulsion	B-X
droplets	B-X
and	B-X
the	B-X
quantities	B-X
of	B-X
adsorbed	B-X
protein	B-X
increased	B-X
markedly	B-X
during	B-X
heating	B-X
.	B-X
Emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
less	B-X
sensitive	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
NaCl	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
hydroxylated	B-X
lecithin	B-X
to	B-X
unfolded	B-X
monomers	B-X
or	B-X
intermediate	B-X
products	B-X
of	B-X
beta-lg	B-X
reduces	B-X
the	B-X
extent	B-X
of	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
beta-lg	B-X
and	B-X
consequently	B-X
decreases	B-X
the	B-X
interactions	B-X
between	B-X
unadsorbed	B-X
beta-lg	B-X
and	B-X
adsorbed	B-X
protein	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
of	B-X
heated	B-X
whey	B-X
protein	B-X
and	B-X
hydroxylated	B-X
lecithin	B-X
solutions	B-X
.	B-X

The	O
interactions	O
of	O
proteins	O
during	O
the	O
heat	O
treatment	O
of	O
whey	O
-	O
protein	O
-	O
isolate	O
(	O
WPI	O
)	O
-	O
based	O
oil	O
-	O
in	O
-	O
water	O
emulsions	O
with	O
and	O
without	O
added	O
hydroxylated	O
lecithin	O
were	O
studied	O
by	O
examining	O
the	O
changes	O
in	O
droplet	O
size	O
distribution	O
and	O
the	O
quantity	O
and	O
type	O
of	O
adsorbed	O
and	O
unadsorbed	O
proteins	O
.	O
<EOS>	B-X
The	B-X
interactions	B-X
of	B-X
proteins	B-X
during	B-X
the	B-X
heat	B-X
treatment	B-X
of	B-X
whey-protein-isolate	B-X
(	B-X
WPI	B-X
)	B-X
-based	B-X
oil-in-water	B-X
emulsions	B-X
with	B-X
and	B-X
without	B-X
added	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
studied	B-X
by	B-X
examining	B-X
the	B-X
changes	B-X
in	B-X
droplet	B-X
size	B-X
distribution	B-X
and	B-X
the	B-X
quantity	B-X
and	B-X
type	B-X
of	B-X
adsorbed	B-X
and	B-X
unadsorbed	B-X
proteins	B-X
.	B-X
Heat	B-X
treatment	B-X
at	B-X
90	B-X
degrees	B-X
C	B-X
of	B-X
WPI	B-X
emulsions	B-X
resulted	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
;	B-X
unadsorbed	B-X
beta-lactoglobulin	B-X
(	B-X
beta-lg	B-X
)	B-X
was	B-X
the	B-X
main	B-X
protein	B-X
interacting	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
the	B-X
first	B-X
10	B-X
min	B-X
of	B-X
heating	B-X
,	B-X
but	B-X
after	B-X
this	B-X
time	B-X
,	B-X
unadsorbed	B-X
alpha-lactalbumin	B-X
(	B-X
alpha-la	B-X
)	B-X
also	B-X
associated	B-X
with	B-X
the	B-X
adsorbed	B-X
protein	B-X
.	B-X
In	B-X
emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
during	B-X
heat	B-X
treatment	B-X
was	B-X
much	B-X
lower	B-X
and	B-X
the	B-X
unadsorbed	B-X
beta-lg	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
heating	B-X
.	B-X
However	B-X
,	B-X
the	B-X
behavior	B-X
of	B-X
alpha-la	B-X
during	B-X
heat	B-X
treatment	B-X
of	B-X
these	B-X
emulsions	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
in	B-X
the	B-X
emulsions	B-X
containing	B-X
no	B-X
hydroxylated	B-X
lecithin	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
NaCl	B-X
,	B-X
the	B-X
particle	B-X
size	B-X
of	B-X
the	B-X
emulsion	B-X
droplets	B-X
and	B-X
the	B-X
quantities	B-X
of	B-X
adsorbed	B-X
protein	B-X
increased	B-X
markedly	B-X
during	B-X
heating	B-X
.	B-X
Emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
less	B-X
sensitive	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
NaCl	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
hydroxylated	B-X
lecithin	B-X
to	B-X
unfolded	B-X
monomers	B-X
or	B-X
intermediate	B-X
products	B-X
of	B-X
beta-lg	B-X
reduces	B-X
the	B-X
extent	B-X
of	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
beta-lg	B-X
and	B-X
consequently	B-X
decreases	B-X
the	B-X
interactions	B-X
between	B-X
unadsorbed	B-X
beta-lg	B-X
and	B-X
adsorbed	B-X
protein	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
of	B-X
heated	B-X
whey	B-X
protein	B-X
and	B-X
hydroxylated	B-X
lecithin	B-X
solutions	B-X
.	B-X

Heat	O
treatment	O
at	O
90	O
degrees	O
C	O
of	O
WPI	O
emulsions	O
resulted	O
in	O
an	O
increase	O
in	O
total	O
adsorbed	O
protein	O
;	O
unadsorbed	O
beta	B-Protein
-	I-Protein
lactoglobulin	I-Protein
(	O
beta	B-Protein
-	I-Protein
lg	I-Protein
)	O
was	O
the	O
main	O
protein	O
interacting	O
with	O
the	O
adsorbed	O
proteins	O
during	O
the	O
first	O
10	O
min	O
of	O
heating	O
,	O
but	O
after	O
this	O
time	O
,	O
unadsorbed	O
alpha	B-Protein
-	I-Protein
lactalbumin	I-Protein
(	O
alpha	B-Protein
-	I-Protein
la	I-Protein
)	O
also	O
associated	O
with	O
the	O
adsorbed	O
protein	O
.	O

In	O
emulsions	O
containing	O
hydroxylated	O
lecithin	O
,	O
the	O
increase	O
in	O
total	O
adsorbed	O
protein	O
during	O
heat	O
treatment	O
was	O
much	O
lower	O
and	O
the	O
unadsorbed	O
beta	B-Protein
-	I-Protein
lg	I-Protein
did	O
not	O
appear	O
to	O
interact	O
with	O
the	O
adsorbed	O
proteins	O
during	O
heating	O
.	O

However	O
,	O
the	O
behavior	O
of	O
alpha	B-Protein
-	I-Protein
la	I-Protein
during	O
heat	O
treatment	O
of	O
these	O
emulsions	O
was	O
similar	O
to	O
that	O
observed	O
in	O
the	O
emulsions	O
containing	O
no	O
hydroxylated	O
lecithin	O
.	O
<EOS>	B-X
The	B-X
interactions	B-X
of	B-X
proteins	B-X
during	B-X
the	B-X
heat	B-X
treatment	B-X
of	B-X
whey-protein-isolate	B-X
(	B-X
WPI	B-X
)	B-X
-based	B-X
oil-in-water	B-X
emulsions	B-X
with	B-X
and	B-X
without	B-X
added	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
studied	B-X
by	B-X
examining	B-X
the	B-X
changes	B-X
in	B-X
droplet	B-X
size	B-X
distribution	B-X
and	B-X
the	B-X
quantity	B-X
and	B-X
type	B-X
of	B-X
adsorbed	B-X
and	B-X
unadsorbed	B-X
proteins	B-X
.	B-X
Heat	B-X
treatment	B-X
at	B-X
90	B-X
degrees	B-X
C	B-X
of	B-X
WPI	B-X
emulsions	B-X
resulted	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
;	B-X
unadsorbed	B-X
beta-lactoglobulin	B-X
(	B-X
beta-lg	B-X
)	B-X
was	B-X
the	B-X
main	B-X
protein	B-X
interacting	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
the	B-X
first	B-X
10	B-X
min	B-X
of	B-X
heating	B-X
,	B-X
but	B-X
after	B-X
this	B-X
time	B-X
,	B-X
unadsorbed	B-X
alpha-lactalbumin	B-X
(	B-X
alpha-la	B-X
)	B-X
also	B-X
associated	B-X
with	B-X
the	B-X
adsorbed	B-X
protein	B-X
.	B-X
In	B-X
emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
during	B-X
heat	B-X
treatment	B-X
was	B-X
much	B-X
lower	B-X
and	B-X
the	B-X
unadsorbed	B-X
beta-lg	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
heating	B-X
.	B-X
However	B-X
,	B-X
the	B-X
behavior	B-X
of	B-X
alpha-la	B-X
during	B-X
heat	B-X
treatment	B-X
of	B-X
these	B-X
emulsions	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
in	B-X
the	B-X
emulsions	B-X
containing	B-X
no	B-X
hydroxylated	B-X
lecithin	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
NaCl	B-X
,	B-X
the	B-X
particle	B-X
size	B-X
of	B-X
the	B-X
emulsion	B-X
droplets	B-X
and	B-X
the	B-X
quantities	B-X
of	B-X
adsorbed	B-X
protein	B-X
increased	B-X
markedly	B-X
during	B-X
heating	B-X
.	B-X
Emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
less	B-X
sensitive	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
NaCl	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
hydroxylated	B-X
lecithin	B-X
to	B-X
unfolded	B-X
monomers	B-X
or	B-X
intermediate	B-X
products	B-X
of	B-X
beta-lg	B-X
reduces	B-X
the	B-X
extent	B-X
of	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
beta-lg	B-X
and	B-X
consequently	B-X
decreases	B-X
the	B-X
interactions	B-X
between	B-X
unadsorbed	B-X
beta-lg	B-X
and	B-X
adsorbed	B-X
protein	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
of	B-X
heated	B-X
whey	B-X
protein	B-X
and	B-X
hydroxylated	B-X
lecithin	B-X
solutions	B-X
.	B-X

In	O
the	O
presence	O
of	O
NaCl	O
,	O
the	O
particle	O
size	O
of	O
the	O
emulsion	O
droplets	O
and	O
the	O
quantities	O
of	O
adsorbed	O
protein	O
increased	O
markedly	O
during	O
heating	O
.	O
<EOS>	B-X
The	B-X
interactions	B-X
of	B-X
proteins	B-X
during	B-X
the	B-X
heat	B-X
treatment	B-X
of	B-X
whey-protein-isolate	B-X
(	B-X
WPI	B-X
)	B-X
-based	B-X
oil-in-water	B-X
emulsions	B-X
with	B-X
and	B-X
without	B-X
added	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
studied	B-X
by	B-X
examining	B-X
the	B-X
changes	B-X
in	B-X
droplet	B-X
size	B-X
distribution	B-X
and	B-X
the	B-X
quantity	B-X
and	B-X
type	B-X
of	B-X
adsorbed	B-X
and	B-X
unadsorbed	B-X
proteins	B-X
.	B-X
Heat	B-X
treatment	B-X
at	B-X
90	B-X
degrees	B-X
C	B-X
of	B-X
WPI	B-X
emulsions	B-X
resulted	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
;	B-X
unadsorbed	B-X
beta-lactoglobulin	B-X
(	B-X
beta-lg	B-X
)	B-X
was	B-X
the	B-X
main	B-X
protein	B-X
interacting	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
the	B-X
first	B-X
10	B-X
min	B-X
of	B-X
heating	B-X
,	B-X
but	B-X
after	B-X
this	B-X
time	B-X
,	B-X
unadsorbed	B-X
alpha-lactalbumin	B-X
(	B-X
alpha-la	B-X
)	B-X
also	B-X
associated	B-X
with	B-X
the	B-X
adsorbed	B-X
protein	B-X
.	B-X
In	B-X
emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
during	B-X
heat	B-X
treatment	B-X
was	B-X
much	B-X
lower	B-X
and	B-X
the	B-X
unadsorbed	B-X
beta-lg	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
heating	B-X
.	B-X
However	B-X
,	B-X
the	B-X
behavior	B-X
of	B-X
alpha-la	B-X
during	B-X
heat	B-X
treatment	B-X
of	B-X
these	B-X
emulsions	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
in	B-X
the	B-X
emulsions	B-X
containing	B-X
no	B-X
hydroxylated	B-X
lecithin	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
NaCl	B-X
,	B-X
the	B-X
particle	B-X
size	B-X
of	B-X
the	B-X
emulsion	B-X
droplets	B-X
and	B-X
the	B-X
quantities	B-X
of	B-X
adsorbed	B-X
protein	B-X
increased	B-X
markedly	B-X
during	B-X
heating	B-X
.	B-X
Emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
less	B-X
sensitive	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
NaCl	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
hydroxylated	B-X
lecithin	B-X
to	B-X
unfolded	B-X
monomers	B-X
or	B-X
intermediate	B-X
products	B-X
of	B-X
beta-lg	B-X
reduces	B-X
the	B-X
extent	B-X
of	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
beta-lg	B-X
and	B-X
consequently	B-X
decreases	B-X
the	B-X
interactions	B-X
between	B-X
unadsorbed	B-X
beta-lg	B-X
and	B-X
adsorbed	B-X
protein	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
of	B-X
heated	B-X
whey	B-X
protein	B-X
and	B-X
hydroxylated	B-X
lecithin	B-X
solutions	B-X
.	B-X

Emulsions	O
containing	O
hydroxylated	O
lecithin	O
were	O
less	O
sensitive	O
to	O
the	O
addition	O
of	O
NaCl	O
.	O

These	O
results	O
suggest	O
that	O
the	O
binding	O
of	O
hydroxylated	O
lecithin	O
to	O
unfolded	O
monomers	O
or	O
intermediate	O
products	O
of	O
beta	B-Protein
-	I-Protein
lg	I-Protein
reduces	O
the	O
extent	O
of	O
heat	O
-	O
induced	O
aggregation	O
of	O
beta	B-Protein
-	I-Protein
lg	I-Protein
and	O
consequently	O
decreases	O
the	O
interactions	O
between	O
unadsorbed	O
beta	B-Protein
-	I-Protein
lg	I-Protein
and	O
adsorbed	O
protein	O
.	O
<EOS>	B-X
The	B-X
interactions	B-X
of	B-X
proteins	B-X
during	B-X
the	B-X
heat	B-X
treatment	B-X
of	B-X
whey-protein-isolate	B-X
(	B-X
WPI	B-X
)	B-X
-based	B-X
oil-in-water	B-X
emulsions	B-X
with	B-X
and	B-X
without	B-X
added	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
studied	B-X
by	B-X
examining	B-X
the	B-X
changes	B-X
in	B-X
droplet	B-X
size	B-X
distribution	B-X
and	B-X
the	B-X
quantity	B-X
and	B-X
type	B-X
of	B-X
adsorbed	B-X
and	B-X
unadsorbed	B-X
proteins	B-X
.	B-X
Heat	B-X
treatment	B-X
at	B-X
90	B-X
degrees	B-X
C	B-X
of	B-X
WPI	B-X
emulsions	B-X
resulted	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
;	B-X
unadsorbed	B-X
beta-lactoglobulin	B-X
(	B-X
beta-lg	B-X
)	B-X
was	B-X
the	B-X
main	B-X
protein	B-X
interacting	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
the	B-X
first	B-X
10	B-X
min	B-X
of	B-X
heating	B-X
,	B-X
but	B-X
after	B-X
this	B-X
time	B-X
,	B-X
unadsorbed	B-X
alpha-lactalbumin	B-X
(	B-X
alpha-la	B-X
)	B-X
also	B-X
associated	B-X
with	B-X
the	B-X
adsorbed	B-X
protein	B-X
.	B-X
In	B-X
emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
during	B-X
heat	B-X
treatment	B-X
was	B-X
much	B-X
lower	B-X
and	B-X
the	B-X
unadsorbed	B-X
beta-lg	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
heating	B-X
.	B-X
However	B-X
,	B-X
the	B-X
behavior	B-X
of	B-X
alpha-la	B-X
during	B-X
heat	B-X
treatment	B-X
of	B-X
these	B-X
emulsions	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
in	B-X
the	B-X
emulsions	B-X
containing	B-X
no	B-X
hydroxylated	B-X
lecithin	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
NaCl	B-X
,	B-X
the	B-X
particle	B-X
size	B-X
of	B-X
the	B-X
emulsion	B-X
droplets	B-X
and	B-X
the	B-X
quantities	B-X
of	B-X
adsorbed	B-X
protein	B-X
increased	B-X
markedly	B-X
during	B-X
heating	B-X
.	B-X
Emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
less	B-X
sensitive	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
NaCl	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
hydroxylated	B-X
lecithin	B-X
to	B-X
unfolded	B-X
monomers	B-X
or	B-X
intermediate	B-X
products	B-X
of	B-X
beta-lg	B-X
reduces	B-X
the	B-X
extent	B-X
of	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
beta-lg	B-X
and	B-X
consequently	B-X
decreases	B-X
the	B-X
interactions	B-X
between	B-X
unadsorbed	B-X
beta-lg	B-X
and	B-X
adsorbed	B-X
protein	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
of	B-X
heated	B-X
whey	B-X
protein	B-X
and	B-X
hydroxylated	B-X
lecithin	B-X
solutions	B-X
.	B-X

This	O
was	O
confirmed	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
of	O
heated	O
whey	O
protein	O
and	O
hydroxylated	O
lecithin	O
solutions	O
.	O
<EOS>	B-X
The	B-X
interactions	B-X
of	B-X
proteins	B-X
during	B-X
the	B-X
heat	B-X
treatment	B-X
of	B-X
whey-protein-isolate	B-X
(	B-X
WPI	B-X
)	B-X
-based	B-X
oil-in-water	B-X
emulsions	B-X
with	B-X
and	B-X
without	B-X
added	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
studied	B-X
by	B-X
examining	B-X
the	B-X
changes	B-X
in	B-X
droplet	B-X
size	B-X
distribution	B-X
and	B-X
the	B-X
quantity	B-X
and	B-X
type	B-X
of	B-X
adsorbed	B-X
and	B-X
unadsorbed	B-X
proteins	B-X
.	B-X
Heat	B-X
treatment	B-X
at	B-X
90	B-X
degrees	B-X
C	B-X
of	B-X
WPI	B-X
emulsions	B-X
resulted	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
;	B-X
unadsorbed	B-X
beta-lactoglobulin	B-X
(	B-X
beta-lg	B-X
)	B-X
was	B-X
the	B-X
main	B-X
protein	B-X
interacting	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
the	B-X
first	B-X
10	B-X
min	B-X
of	B-X
heating	B-X
,	B-X
but	B-X
after	B-X
this	B-X
time	B-X
,	B-X
unadsorbed	B-X
alpha-lactalbumin	B-X
(	B-X
alpha-la	B-X
)	B-X
also	B-X
associated	B-X
with	B-X
the	B-X
adsorbed	B-X
protein	B-X
.	B-X
In	B-X
emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
total	B-X
adsorbed	B-X
protein	B-X
during	B-X
heat	B-X
treatment	B-X
was	B-X
much	B-X
lower	B-X
and	B-X
the	B-X
unadsorbed	B-X
beta-lg	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
adsorbed	B-X
proteins	B-X
during	B-X
heating	B-X
.	B-X
However	B-X
,	B-X
the	B-X
behavior	B-X
of	B-X
alpha-la	B-X
during	B-X
heat	B-X
treatment	B-X
of	B-X
these	B-X
emulsions	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
in	B-X
the	B-X
emulsions	B-X
containing	B-X
no	B-X
hydroxylated	B-X
lecithin	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
NaCl	B-X
,	B-X
the	B-X
particle	B-X
size	B-X
of	B-X
the	B-X
emulsion	B-X
droplets	B-X
and	B-X
the	B-X
quantities	B-X
of	B-X
adsorbed	B-X
protein	B-X
increased	B-X
markedly	B-X
during	B-X
heating	B-X
.	B-X
Emulsions	B-X
containing	B-X
hydroxylated	B-X
lecithin	B-X
were	B-X
less	B-X
sensitive	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
NaCl	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
hydroxylated	B-X
lecithin	B-X
to	B-X
unfolded	B-X
monomers	B-X
or	B-X
intermediate	B-X
products	B-X
of	B-X
beta-lg	B-X
reduces	B-X
the	B-X
extent	B-X
of	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
beta-lg	B-X
and	B-X
consequently	B-X
decreases	B-X
the	B-X
interactions	B-X
between	B-X
unadsorbed	B-X
beta-lg	B-X
and	B-X
adsorbed	B-X
protein	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
of	B-X
heated	B-X
whey	B-X
protein	B-X
and	B-X
hydroxylated	B-X
lecithin	B-X
solutions	B-X
.	B-X

Dynamic	O
lysine	O
methylation	O
on	O
histone	B-Protein
H3	I-Protein
defines	O
the	O
regulatory	O
phase	O
of	O
gene	O
transcription	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
to	B-X
histones	B-X
are	B-X
key	B-X
epigenetic	B-X
marks	B-X
that	B-X
control	B-X
gene	B-X
transcription	B-X
.	B-X
Multiple	B-X
lysine	B-X
residues	B-X
on	B-X
histone	B-X
H3	B-X
are	B-X
methylated	B-X
(	B-X
me	B-X
)	B-X
,	B-X
but	B-X
their	B-X
functions	B-X
are	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
two	B-X
phases	B-X
of	B-X
combinatorial	B-X
and	B-X
dynamic	B-X
H3	B-X
methylation	B-X
during	B-X
induction	B-X
of	B-X
transcription	B-X
at	B-X
MET16	B-X
in	B-X
yeast	B-X
.	B-X
K4me3	B-X
with	B-X
K36me2/3	B-X
define	B-X
a	B-X
postinitiation	B-X
regulatory	B-X
phase	B-X
and	B-X
precede	B-X
the	B-X
appearance	B-X
of	B-X
K4me2	B-X
with	B-X
K79me2	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
transcript	B-X
elongation	B-X
.	B-X
This	B-X
releases	B-X
RNAPII	B-X
from	B-X
Isw1	B-X
control	B-X
and	B-X
promotes	B-X
controlled	B-X
transcription	B-X
elongation	B-X
and	B-X
termination	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
newly	B-X
initiated	B-X
RNAPII	B-X
is	B-X
under	B-X
epigenetic	B-X
control	B-X
.	B-X

Covalent	O
modifications	O
to	O
histones	B-Protein
are	O
key	O
epigenetic	O
marks	O
that	O
control	O
gene	O
transcription	O
.	O
<EOS>	B-X
Epigenetics	B-X
controls	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
cellular	B-X
phenotypes	B-X
.	B-X
The	B-X
fundamental	B-X
basis	B-X
of	B-X
these	B-X
mechanisms	B-X
involves	B-X
in	B-X
part	B-X
the	B-X
post-translational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
of	B-X
DNA	B-X
and	B-X
proteins	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
the	B-X
nuclear	B-X
histones	B-X
.	B-X
Histones	B-X
are	B-X
marked	B-X
by	B-X
several	B-X
modifications	B-X
including	B-X
acetylation	B-X
and/or	B-X
methylation	B-X
,	B-X
and	B-X
of	B-X
particular	B-X
importance	B-X
are	B-X
the	B-X
covalent	B-X
modifications	B-X
of	B-X
lysine	B-X
.	B-X
There	B-X
exists	B-X
a	B-X
balance	B-X
between	B-X
addition	B-X
and	B-X
removal	B-X
of	B-X
these	B-X
PTMs	B-X
,	B-X
leading	B-X
to	B-X
three	B-X
groups	B-X
of	B-X
enzymes	B-X
involved	B-X
in	B-X
these	B-X
processes	B-X
:	B-X
the	B-X
writers	B-X
adding	B-X
marks	B-X
,	B-X
the	B-X
erasers	B-X
removing	B-X
them	B-X
,	B-X
and	B-X
the	B-X
readers	B-X
able	B-X
to	B-X
detect	B-X
these	B-X
marks	B-X
and	B-X
participating	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
The	B-X
stimulation	B-X
or	B-X
the	B-X
repression	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
is	B-X
thus	B-X
the	B-X
result	B-X
of	B-X
a	B-X
subtle	B-X
equilibrium	B-X
between	B-X
all	B-X
the	B-X
possibilities	B-X
coming	B-X
from	B-X
the	B-X
combinations	B-X
of	B-X
these	B-X
PTMs	B-X
.	B-X
Some	B-X
of	B-X
the	B-X
key	B-X
players	B-X
in	B-X
epigenetics	B-X
are	B-X
metalloenzymes	B-X
,	B-X
belonging	B-X
mostly	B-X
to	B-X
the	B-X
group	B-X
of	B-X
erasers	B-X
:	B-X
the	B-X
zinc-dependent	B-X
histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
,	B-X
the	B-X
iron-dependent	B-X
lysine	B-X
demethylases	B-X
of	B-X
the	B-X
Jumonji	B-X
family	B-X
(	B-X
JMJ	B-X
or	B-X
KDM	B-X
)	B-X
and	B-X
for	B-X
DNA	B-X
the	B-X
iron-dependent	B-X
ten-eleven-translocation	B-X
enzymes	B-X
(	B-X
TET	B-X
)	B-X
responsible	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
methylcytosine	B-X
prior	B-X
to	B-X
the	B-X
demethylation	B-X
of	B-X
DNA	B-X
.	B-X

Multiple	O
lysine	O
residues	O
on	O
histone	B-Protein
H3	I-Protein
are	O
methylated	O
(	O
me	O
)	O
,	O
but	O
their	O
functions	O
are	O
unclear	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
to	B-X
histones	B-X
are	B-X
key	B-X
epigenetic	B-X
marks	B-X
that	B-X
control	B-X
gene	B-X
transcription	B-X
.	B-X
Multiple	B-X
lysine	B-X
residues	B-X
on	B-X
histone	B-X
H3	B-X
are	B-X
methylated	B-X
(	B-X
me	B-X
)	B-X
,	B-X
but	B-X
their	B-X
functions	B-X
are	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
two	B-X
phases	B-X
of	B-X
combinatorial	B-X
and	B-X
dynamic	B-X
H3	B-X
methylation	B-X
during	B-X
induction	B-X
of	B-X
transcription	B-X
at	B-X
MET16	B-X
in	B-X
yeast	B-X
.	B-X
Post-translational	B-X
modifications	B-X
of	B-X
lysine	B-X
residues	B-X
of	B-X
histones	B-X
can	B-X
result	B-X
in	B-X
a	B-X
series	B-X
of	B-X
functional	B-X
changes	B-X
.	B-X
Lysine	B-X
79	B-X
of	B-X
histone	B-X
H3	B-X
(	B-X
H3K79	B-X
)	B-X
can	B-X
be	B-X
methylated	B-X
specifically	B-X
by	B-X
the	B-X
Dot1	B-X
family	B-X
of	B-X
histone	B-X
lysine	B-X
methyltransferases	B-X
.	B-X
Although	B-X
multiple	B-X
developmental	B-X
abnormalities	B-X
in	B-X
Dot1L-deficient	B-X
mouse	B-X
embryos	B-X
have	B-X
been	B-X
studied	B-X
,	B-X
the	B-X
biological	B-X
function	B-X
of	B-X
H3K79	B-X
methylation	B-X
in	B-X
mammal	B-X
oocytes	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
distribution	B-X
of	B-X
Dot1L	B-X
,	B-X
methyltransferase	B-X
of	B-X
residue	B-X
lys79	B-X
of	B-X
histone	B-X
H3	B-X
(	B-X
H3K79	B-X
)	B-X
in	B-X
mouse	B-X
,	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
mouse	B-X
oocytes	B-X
meiosis	B-X
were	B-X
investigated	B-X
to	B-X
examine	B-X
whether	B-X
there	B-X
are	B-X
changes	B-X
in	B-X
the	B-X
pattern	B-X
of	B-X
distribution	B-X
and	B-X
effect	B-X
of	B-X
Dot1L	B-X
on	B-X
mouse	B-X
oocytes	B-X
meiosis	B-X
.	B-X

Here	O
,	O
we	O
demonstrate	O
two	O
phases	O
of	O
combinatorial	O
and	O
dynamic	O
H3	B-Protein
methylation	O
during	O
induction	O
of	O
transcription	O
at	O
MET16	B-Protein
in	O
yeast	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
to	B-X
histones	B-X
are	B-X
key	B-X
epigenetic	B-X
marks	B-X
that	B-X
control	B-X
gene	B-X
transcription	B-X
.	B-X
Multiple	B-X
lysine	B-X
residues	B-X
on	B-X
histone	B-X
H3	B-X
are	B-X
methylated	B-X
(	B-X
me	B-X
)	B-X
,	B-X
but	B-X
their	B-X
functions	B-X
are	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
two	B-X
phases	B-X
of	B-X
combinatorial	B-X
and	B-X
dynamic	B-X
H3	B-X
methylation	B-X
during	B-X
induction	B-X
of	B-X
transcription	B-X
at	B-X
MET16	B-X
in	B-X
yeast	B-X
.	B-X
This	B-X
releases	B-X
RNAPII	B-X
from	B-X
Isw1	B-X
control	B-X
and	B-X
promotes	B-X
controlled	B-X
transcription	B-X
elongation	B-X
and	B-X
termination	B-X
.	B-X

K4me3	O
with	O
K36me2	O
/	O
3	O
define	O
a	O
postinitiation	O
regulatory	O
phase	O
and	O
precede	O
the	O
appearance	O
of	O
K4me2	O
with	O
K79me2	O
at	O
the	O
onset	O
of	O
transcript	O
elongation	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
to	B-X
histones	B-X
are	B-X
key	B-X
epigenetic	B-X
marks	B-X
that	B-X
control	B-X
gene	B-X
transcription	B-X
.	B-X
Multiple	B-X
lysine	B-X
residues	B-X
on	B-X
histone	B-X
H3	B-X
are	B-X
methylated	B-X
(	B-X
me	B-X
)	B-X
,	B-X
but	B-X
their	B-X
functions	B-X
are	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
two	B-X
phases	B-X
of	B-X
combinatorial	B-X
and	B-X
dynamic	B-X
H3	B-X
methylation	B-X
during	B-X
induction	B-X
of	B-X
transcription	B-X
at	B-X
MET16	B-X
in	B-X
yeast	B-X
.	B-X
K4me3	B-X
with	B-X
K36me2/3	B-X
define	B-X
a	B-X
postinitiation	B-X
regulatory	B-X
phase	B-X
and	B-X
precede	B-X
the	B-X
appearance	B-X
of	B-X
K4me2	B-X
with	B-X
K79me2	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
transcript	B-X
elongation	B-X
.	B-X
The	B-X
Isw1	B-X
ATPase	B-X
delays	B-X
the	B-X
release	B-X
of	B-X
initiated	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
into	B-X
elongation	B-X
to	B-X
facilitate	B-X
chromatin	B-X
modifications	B-X
.	B-X
The	B-X
Spp1	B-X
subunit	B-X
of	B-X
complex	B-X
associated	B-X
with	B-X
Set1	B-X
(	B-X
COMPASS	B-X
)	B-X
and	B-X
Set2	B-X
,	B-X
determining	B-X
K4me3	B-X
and	B-X
K36me2/3	B-X
,	B-X
respectively	B-X
,	B-X
are	B-X
required	B-X
for	B-X
transient	B-X
NuA4-dependent	B-X
H4K8ac	B-X
.	B-X
This	B-X
releases	B-X
RNAPII	B-X
from	B-X
Isw1	B-X
control	B-X
and	B-X
promotes	B-X
controlled	B-X
transcription	B-X
elongation	B-X
and	B-X
termination	B-X
.	B-X

The	O
Isw1	B-Protein
ATPase	O
delays	O
the	O
release	O
of	O
initiated	O
RNA	O
polymerase	O
II	O
(	O
RNAPII	O
)	O
into	O
elongation	O
to	O
facilitate	O
chromatin	O
modifications	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
to	B-X
histones	B-X
are	B-X
key	B-X
epigenetic	B-X
marks	B-X
that	B-X
control	B-X
gene	B-X
transcription	B-X
.	B-X
K4me3	B-X
with	B-X
K36me2/3	B-X
define	B-X
a	B-X
postinitiation	B-X
regulatory	B-X
phase	B-X
and	B-X
precede	B-X
the	B-X
appearance	B-X
of	B-X
K4me2	B-X
with	B-X
K79me2	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
transcript	B-X
elongation	B-X
.	B-X
The	B-X
Isw1	B-X
ATPase	B-X
delays	B-X
the	B-X
release	B-X
of	B-X
initiated	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
into	B-X
elongation	B-X
to	B-X
facilitate	B-X
chromatin	B-X
modifications	B-X
.	B-X
This	B-X
releases	B-X
RNAPII	B-X
from	B-X
Isw1	B-X
control	B-X
and	B-X
promotes	B-X
controlled	B-X
transcription	B-X
elongation	B-X
and	B-X
termination	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
newly	B-X
initiated	B-X
RNAPII	B-X
is	B-X
under	B-X
epigenetic	B-X
control	B-X
.	B-X

The	O
Spp1	B-Protein
subunit	O
of	O
complex	O
associated	O
with	O
Set1	B-Protein
(	O
COMPASS	O
)	O
and	O
Set2	B-Protein
,	O
determining	O
K4me3	O
and	O
K36me2	O
/	O
3	O
,	O
respectively	O
,	O
are	O
required	O
for	O
transient	O
NuA4	O
-	O
dependent	O
H4K8ac	O
.	O
<EOS>	B-X
Multiple	B-X
lysine	B-X
residues	B-X
on	B-X
histone	B-X
H3	B-X
are	B-X
methylated	B-X
(	B-X
me	B-X
)	B-X
,	B-X
but	B-X
their	B-X
functions	B-X
are	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
two	B-X
phases	B-X
of	B-X
combinatorial	B-X
and	B-X
dynamic	B-X
H3	B-X
methylation	B-X
during	B-X
induction	B-X
of	B-X
transcription	B-X
at	B-X
MET16	B-X
in	B-X
yeast	B-X
.	B-X
K4me3	B-X
with	B-X
K36me2/3	B-X
define	B-X
a	B-X
postinitiation	B-X
regulatory	B-X
phase	B-X
and	B-X
precede	B-X
the	B-X
appearance	B-X
of	B-X
K4me2	B-X
with	B-X
K79me2	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
transcript	B-X
elongation	B-X
.	B-X
The	B-X
Spp1	B-X
subunit	B-X
of	B-X
complex	B-X
associated	B-X
with	B-X
Set1	B-X
(	B-X
COMPASS	B-X
)	B-X
and	B-X
Set2	B-X
,	B-X
determining	B-X
K4me3	B-X
and	B-X
K36me2/3	B-X
,	B-X
respectively	B-X
,	B-X
are	B-X
required	B-X
for	B-X
transient	B-X
NuA4-dependent	B-X
H4K8ac	B-X
.	B-X

This	O
releases	O
RNAPII	O
from	O
Isw1	B-Protein
control	O
and	O
promotes	O
controlled	O
transcription	O
elongation	O
and	O
termination	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
to	B-X
histones	B-X
are	B-X
key	B-X
epigenetic	B-X
marks	B-X
that	B-X
control	B-X
gene	B-X
transcription	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
two	B-X
phases	B-X
of	B-X
combinatorial	B-X
and	B-X
dynamic	B-X
H3	B-X
methylation	B-X
during	B-X
induction	B-X
of	B-X
transcription	B-X
at	B-X
MET16	B-X
in	B-X
yeast	B-X
.	B-X
K4me3	B-X
with	B-X
K36me2/3	B-X
define	B-X
a	B-X
postinitiation	B-X
regulatory	B-X
phase	B-X
and	B-X
precede	B-X
the	B-X
appearance	B-X
of	B-X
K4me2	B-X
with	B-X
K79me2	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
transcript	B-X
elongation	B-X
.	B-X
The	B-X
Isw1	B-X
ATPase	B-X
delays	B-X
the	B-X
release	B-X
of	B-X
initiated	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
into	B-X
elongation	B-X
to	B-X
facilitate	B-X
chromatin	B-X
modifications	B-X
.	B-X
This	B-X
releases	B-X
RNAPII	B-X
from	B-X
Isw1	B-X
control	B-X
and	B-X
promotes	B-X
controlled	B-X
transcription	B-X
elongation	B-X
and	B-X
termination	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
newly	B-X
initiated	B-X
RNAPII	B-X
is	B-X
under	B-X
epigenetic	B-X
control	B-X
.	B-X

We	O
propose	O
that	O
newly	O
initiated	O
RNAPII	O
is	O
under	O
epigenetic	O
control	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
to	B-X
histones	B-X
are	B-X
key	B-X
epigenetic	B-X
marks	B-X
that	B-X
control	B-X
gene	B-X
transcription	B-X
.	B-X
The	B-X
Isw1	B-X
ATPase	B-X
delays	B-X
the	B-X
release	B-X
of	B-X
initiated	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
into	B-X
elongation	B-X
to	B-X
facilitate	B-X
chromatin	B-X
modifications	B-X
.	B-X
This	B-X
releases	B-X
RNAPII	B-X
from	B-X
Isw1	B-X
control	B-X
and	B-X
promotes	B-X
controlled	B-X
transcription	B-X
elongation	B-X
and	B-X
termination	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
newly	B-X
initiated	B-X
RNAPII	B-X
is	B-X
under	B-X
epigenetic	B-X
control	B-X
.	B-X

Proline	O
hydroxylation	O
and	O
gene	O
expression	O
.	O
<EOS>	B-X
Adaptation	B-X
to	B-X
low	B-X
oxygen	B-X
tension	B-X
(	B-X
hypoxia	B-X
)	B-X
in	B-X
cells	B-X
and	B-X
tissues	B-X
leads	B-X
to	B-X
the	B-X
transcriptional	B-X
induction	B-X
of	B-X
a	B-X
series	B-X
of	B-X
genes	B-X
that	B-X
participate	B-X
in	B-X
angiogenesis	B-X
,	B-X
iron	B-X
metabolism	B-X
,	B-X
glucose	B-X
metabolism	B-X
,	B-X
and	B-X
cell	B-X
proliferation/survival	B-X
.	B-X
The	B-X
stability	B-X
and	B-X
activity	B-X
of	B-X
the	B-X
alpha	B-X
subunit	B-X
of	B-X
HIF	B-X
are	B-X
regulated	B-X
by	B-X
its	B-X
post-translational	B-X
modifications	B-X
such	B-X
as	B-X
hydroxylation	B-X
,	B-X
ubiquitination	B-X
,	B-X
acetylation	B-X
,	B-X
and	B-X
phosphorylation	B-X
.	B-X
In	B-X
normoxia	B-X
,	B-X
hydroxylation	B-X
of	B-X
two	B-X
proline	B-X
residues	B-X
and	B-X
acetylation	B-X
of	B-X
a	B-X
lysine	B-X
residue	B-X
at	B-X
the	B-X
oxygen-dependent	B-X
degradation	B-X
domain	B-X
(	B-X
ODDD	B-X
)	B-X
of	B-X
HIF-1alpha	B-X
trigger	B-X
its	B-X
association	B-X
with	B-X
pVHL	B-X
E3	B-X
ligase	B-X
complex	B-X
,	B-X
leading	B-X
to	B-X
HIF-1alpha	B-X
degradation	B-X
via	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
In	B-X
hypoxia	B-X
,	B-X
the	B-X
HIF-1alpha	B-X
subunit	B-X
becomes	B-X
stable	B-X
and	B-X
interacts	B-X
with	B-X
coactivators	B-X
such	B-X
as	B-X
cAMP	B-X
response	B-X
element-binding	B-X
protein	B-X
binding	B-X
protein/p300	B-X
and	B-X
regulates	B-X
the	B-X
expression	B-X
of	B-X
target	B-X
genes	B-X
.	B-X
Overexpression	B-X
of	B-X
HIF-1	B-X
has	B-X
been	B-X
found	B-X
in	B-X
various	B-X
cancers	B-X
,	B-X
and	B-X
targeting	B-X
HIF-1	B-X
could	B-X
represent	B-X
a	B-X
novel	B-X
approach	B-X
to	B-X
cancer	B-X
therapy	B-X
.	B-X

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
master	O
transcriptional	O
regulator	O
of	O
hypoxia	O
-	O
inducible	O
genes	O
and	O
consists	O
of	O
a	O
labile	O
alpha	O
subunit	O
(	O
such	O
as	O
HIF1alpha	B-Protein
)	O
and	O
a	O
stable	O
beta	O
subunit	O
(	O
such	O
as	O
HIF1beta	B-Protein
or	O
ARNT	B-Protein
)	O
.	O

In	O
the	O
presence	O
of	O
oxygen	O
,	O
HIFalpha	O
family	O
members	O
are	O
hydroxylated	O
on	O
one	O
of	O
two	O
conserved	O
prolyl	O
residues	O
by	O
members	O
of	O
the	O
egg	O
-	O
laying	O
-	O
defective	O
nine	O
(	O
EGLN	O
)	O
family	O
.	O
<EOS>	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
HIFalpha	B-X
family	B-X
members	B-X
are	B-X
hydroxylated	B-X
on	B-X
one	B-X
of	B-X
two	B-X
conserved	B-X
prolyl	B-X
residues	B-X
by	B-X
members	B-X
of	B-X
the	B-X
egg-laying-defective	B-X
nine	B-X
(	B-X
EGLN	B-X
)	B-X
family	B-X
.	B-X
Prolyl	B-X
hydroxylation	B-X
generates	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
containing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
protein	B-X
,	B-X
which	B-X
results	B-X
in	B-X
HIFalpha	B-X
destruction	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
HIFalpha	B-X
transcriptional	B-X
activation	B-X
function	B-X
is	B-X
modulated	B-X
further	B-X
by	B-X
asparagine	B-X
hydroxylation	B-X
by	B-X
FIH	B-X
(	B-X
factor-inhibiting	B-X
HIF	B-X
)	B-X
,	B-X
which	B-X
affects	B-X
recruitment	B-X
of	B-X
the	B-X
coactivators	B-X
p300	B-X
and	B-X
CBP	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
new	B-X
mechanistic	B-X
insights	B-X
into	B-X
oxygen	B-X
sensing	B-X
by	B-X
metazoans	B-X
and	B-X
are	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
protein	B-X
hydroxylation	B-X
being	B-X
used	B-X
in	B-X
intracellular	B-X
signaling	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
three	B-X
human	B-X
EGLN	B-X
family	B-X
members	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
putative	B-X
hydroxylases	B-X
,	B-X
raises	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
signal	B-X
is	B-X
used	B-X
in	B-X
other	B-X
contexts	B-X
by	B-X
other	B-X
proteins	B-X
.	B-X

Prolyl	O
hydroxylation	O
generates	O
a	O
binding	O
site	O
for	O
a	O
ubiquitin	B-Protein
ligase	O
complex	O
containing	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	I-Protein
VHL	I-Protein
)	I-Protein
tumor	I-Protein
suppressor	I-Protein
protein	O
,	O
which	O
results	O
in	O
HIFalpha	O
destruction	O
.	O

In	O
addition	O
,	O
the	O
HIFalpha	O
transcriptional	O
activation	O
function	O
is	O
modulated	O
further	O
by	O
asparagine	O
hydroxylation	O
by	O
FIH	B-Protein
(	O
factor	B-Protein
-	I-Protein
inhibiting	I-Protein
HIF	I-Protein
)	O
,	O
which	O
affects	O
recruitment	O
of	O
the	O
coactivators	O
p300	B-Protein
and	O
CBP	B-Protein
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
is	B-X
a	B-X
master	B-X
transcriptional	B-X
regulator	B-X
of	B-X
hypoxia-inducible	B-X
genes	B-X
and	B-X
consists	B-X
of	B-X
a	B-X
labile	B-X
alpha	B-X
subunit	B-X
(	B-X
such	B-X
as	B-X
HIF1alpha	B-X
)	B-X
and	B-X
a	B-X
stable	B-X
beta	B-X
subunit	B-X
(	B-X
such	B-X
as	B-X
HIF1beta	B-X
or	B-X
ARNT	B-X
)	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
HIFalpha	B-X
family	B-X
members	B-X
are	B-X
hydroxylated	B-X
on	B-X
one	B-X
of	B-X
two	B-X
conserved	B-X
prolyl	B-X
residues	B-X
by	B-X
members	B-X
of	B-X
the	B-X
egg-laying-defective	B-X
nine	B-X
(	B-X
EGLN	B-X
)	B-X
family	B-X
.	B-X
Prolyl	B-X
hydroxylation	B-X
generates	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
containing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
protein	B-X
,	B-X
which	B-X
results	B-X
in	B-X
HIFalpha	B-X
destruction	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
HIFalpha	B-X
transcriptional	B-X
activation	B-X
function	B-X
is	B-X
modulated	B-X
further	B-X
by	B-X
asparagine	B-X
hydroxylation	B-X
by	B-X
FIH	B-X
(	B-X
factor-inhibiting	B-X
HIF	B-X
)	B-X
,	B-X
which	B-X
affects	B-X
recruitment	B-X
of	B-X
the	B-X
coactivators	B-X
p300	B-X
and	B-X
CBP	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
new	B-X
mechanistic	B-X
insights	B-X
into	B-X
oxygen	B-X
sensing	B-X
by	B-X
metazoans	B-X
and	B-X
are	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
protein	B-X
hydroxylation	B-X
being	B-X
used	B-X
in	B-X
intracellular	B-X
signaling	B-X
.	B-X

These	O
findings	O
provide	O
new	O
mechanistic	O
insights	O
into	O
oxygen	O
sensing	O
by	O
metazoans	O
and	O
are	O
the	O
first	O
examples	O
of	O
protein	O
hydroxylation	O
being	O
used	O
in	O
intracellular	O
signaling	O
.	O
<EOS>	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
HIFalpha	B-X
family	B-X
members	B-X
are	B-X
hydroxylated	B-X
on	B-X
one	B-X
of	B-X
two	B-X
conserved	B-X
prolyl	B-X
residues	B-X
by	B-X
members	B-X
of	B-X
the	B-X
egg-laying-defective	B-X
nine	B-X
(	B-X
EGLN	B-X
)	B-X
family	B-X
.	B-X
Prolyl	B-X
hydroxylation	B-X
generates	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
containing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
protein	B-X
,	B-X
which	B-X
results	B-X
in	B-X
HIFalpha	B-X
destruction	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
HIFalpha	B-X
transcriptional	B-X
activation	B-X
function	B-X
is	B-X
modulated	B-X
further	B-X
by	B-X
asparagine	B-X
hydroxylation	B-X
by	B-X
FIH	B-X
(	B-X
factor-inhibiting	B-X
HIF	B-X
)	B-X
,	B-X
which	B-X
affects	B-X
recruitment	B-X
of	B-X
the	B-X
coactivators	B-X
p300	B-X
and	B-X
CBP	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
new	B-X
mechanistic	B-X
insights	B-X
into	B-X
oxygen	B-X
sensing	B-X
by	B-X
metazoans	B-X
and	B-X
are	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
protein	B-X
hydroxylation	B-X
being	B-X
used	B-X
in	B-X
intracellular	B-X
signaling	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
three	B-X
human	B-X
EGLN	B-X
family	B-X
members	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
putative	B-X
hydroxylases	B-X
,	B-X
raises	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
signal	B-X
is	B-X
used	B-X
in	B-X
other	B-X
contexts	B-X
by	B-X
other	B-X
proteins	B-X
.	B-X

The	O
existence	O
of	O
three	O
human	O
EGLN	O
family	O
members	O
,	O
as	O
well	O
as	O
other	O
putative	O
hydroxylases	O
,	O
raises	O
the	O
possibility	O
that	O
this	O
signal	O
is	O
used	O
in	O
other	O
contexts	O
by	O
other	O
proteins	O
.	O
<EOS>	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
HIFalpha	B-X
family	B-X
members	B-X
are	B-X
hydroxylated	B-X
on	B-X
one	B-X
of	B-X
two	B-X
conserved	B-X
prolyl	B-X
residues	B-X
by	B-X
members	B-X
of	B-X
the	B-X
egg-laying-defective	B-X
nine	B-X
(	B-X
EGLN	B-X
)	B-X
family	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
new	B-X
mechanistic	B-X
insights	B-X
into	B-X
oxygen	B-X
sensing	B-X
by	B-X
metazoans	B-X
and	B-X
are	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
protein	B-X
hydroxylation	B-X
being	B-X
used	B-X
in	B-X
intracellular	B-X
signaling	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
three	B-X
human	B-X
EGLN	B-X
family	B-X
members	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
putative	B-X
hydroxylases	B-X
,	B-X
raises	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
signal	B-X
is	B-X
used	B-X
in	B-X
other	B-X
contexts	B-X
by	B-X
other	B-X
proteins	B-X
.	B-X

Histone	B-Protein
acetyltransferase	O
activity	O
of	O
p300	B-Protein
is	O
required	O
for	O
transcriptional	O
repression	O
by	O
the	O
promyelocytic	O
leukemia	O
zinc	O
finger	O
protein	O
.	O
<EOS>	B-X
Histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
activities	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
p300	B-X
,	B-X
CBP	B-X
,	B-X
and	B-X
P/CAF	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
activation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
the	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
can	B-X
also	B-X
be	B-X
required	B-X
for	B-X
down-regulation	B-X
of	B-X
transcription	B-X
by	B-X
a	B-X
DNA	B-X
binding	B-X
repressor	B-X
protein	B-X
.	B-X
Promyelocytic	B-X
leukemia	B-X
zinc	B-X
finger	B-X
(	B-X
PLZF	B-X
)	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
fusion	B-X
with	B-X
retinoic	B-X
acid	B-X
receptor	B-X
alpha	B-X
in	B-X
rare	B-X
cases	B-X
of	B-X
all-trans-retinoic	B-X
acid-resistant	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
,	B-X
is	B-X
a	B-X
transcriptional	B-X
repressor	B-X
that	B-X
recruits	B-X
histone	B-X
deacetylase-containing	B-X
corepressor	B-X
complexes	B-X
to	B-X
specific	B-X
DNA	B-X
binding	B-X
sites	B-X
.	B-X
PLZF	B-X
associates	B-X
with	B-X
p300	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
repress	B-X
transcription	B-X
is	B-X
specifically	B-X
dependent	B-X
on	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
and	B-X
acetylation	B-X
of	B-X
lysines	B-X
in	B-X
its	B-X
C-terminal	B-X
C2-H2	B-X
zinc	B-X
finger	B-X
motif	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
histone	B-X
deacetylase-dependent	B-X
transcriptional	B-X
repressor	B-X
can	B-X
be	B-X
positively	B-X
regulated	B-X
through	B-X
acetylation	B-X
and	B-X
point	B-X
to	B-X
an	B-X
unexpected	B-X
role	B-X
of	B-X
a	B-X
coactivator	B-X
protein	B-X
in	B-X
transcriptional	B-X
repression	B-X
.	B-X

Histone	B-Protein
acetyltransferase	O
(	O
HAT	O
)	O
activities	O
of	O
proteins	O
such	O
as	O
p300	B-Protein
,	O
CBP	B-Protein
,	O
and	O
P	B-Protein
/	I-Protein
CAF	I-Protein
play	O
important	O
roles	O
in	O
activation	O
of	O
gene	O
expression	O
.	O
<EOS>	B-X
Histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
activities	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
p300	B-X
,	B-X
CBP	B-X
,	B-X
and	B-X
P/CAF	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
activation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
the	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
can	B-X
also	B-X
be	B-X
required	B-X
for	B-X
down-regulation	B-X
of	B-X
transcription	B-X
by	B-X
a	B-X
DNA	B-X
binding	B-X
repressor	B-X
protein	B-X
.	B-X
Promyelocytic	B-X
leukemia	B-X
zinc	B-X
finger	B-X
(	B-X
PLZF	B-X
)	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
fusion	B-X
with	B-X
retinoic	B-X
acid	B-X
receptor	B-X
alpha	B-X
in	B-X
rare	B-X
cases	B-X
of	B-X
all-trans-retinoic	B-X
acid-resistant	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
,	B-X
is	B-X
a	B-X
transcriptional	B-X
repressor	B-X
that	B-X
recruits	B-X
histone	B-X
deacetylase-containing	B-X
corepressor	B-X
complexes	B-X
to	B-X
specific	B-X
DNA	B-X
binding	B-X
sites	B-X
.	B-X
PLZF	B-X
associates	B-X
with	B-X
p300	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
repress	B-X
transcription	B-X
is	B-X
specifically	B-X
dependent	B-X
on	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
and	B-X
acetylation	B-X
of	B-X
lysines	B-X
in	B-X
its	B-X
C-terminal	B-X
C2-H2	B-X
zinc	B-X
finger	B-X
motif	B-X
.	B-X
An	B-X
acetylation	B-X
site	B-X
mutant	B-X
of	B-X
PLZF	B-X
does	B-X
not	B-X
repress	B-X
transcription	B-X
and	B-X
is	B-X
functionally	B-X
deficient	B-X
in	B-X
a	B-X
colony	B-X
suppression	B-X
assay	B-X
despite	B-X
retaining	B-X
its	B-X
abilities	B-X
to	B-X
interact	B-X
with	B-X
corepressor/histone	B-X
deacetylase	B-X
complexes	B-X
.	B-X
This	B-X
is	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
acetylation	B-X
of	B-X
PLZF	B-X
activates	B-X
its	B-X
ability	B-X
to	B-X
bind	B-X
specific	B-X
DNA	B-X
sequences	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

We	O
now	O
show	O
that	O
the	O
HAT	O
activity	O
of	O
p300	B-Protein
can	O
also	O
be	O
required	O
for	O
down	O
-	O
regulation	O
of	O
transcription	O
by	O
a	O
DNA	O
binding	O
repressor	O
protein	O
.	O
<EOS>	B-X
Histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
activities	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
p300	B-X
,	B-X
CBP	B-X
,	B-X
and	B-X
P/CAF	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
activation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
the	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
can	B-X
also	B-X
be	B-X
required	B-X
for	B-X
down-regulation	B-X
of	B-X
transcription	B-X
by	B-X
a	B-X
DNA	B-X
binding	B-X
repressor	B-X
protein	B-X
.	B-X
Promyelocytic	B-X
leukemia	B-X
zinc	B-X
finger	B-X
(	B-X
PLZF	B-X
)	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
fusion	B-X
with	B-X
retinoic	B-X
acid	B-X
receptor	B-X
alpha	B-X
in	B-X
rare	B-X
cases	B-X
of	B-X
all-trans-retinoic	B-X
acid-resistant	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
,	B-X
is	B-X
a	B-X
transcriptional	B-X
repressor	B-X
that	B-X
recruits	B-X
histone	B-X
deacetylase-containing	B-X
corepressor	B-X
complexes	B-X
to	B-X
specific	B-X
DNA	B-X
binding	B-X
sites	B-X
.	B-X
PLZF	B-X
associates	B-X
with	B-X
p300	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
repress	B-X
transcription	B-X
is	B-X
specifically	B-X
dependent	B-X
on	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
and	B-X
acetylation	B-X
of	B-X
lysines	B-X
in	B-X
its	B-X
C-terminal	B-X
C2-H2	B-X
zinc	B-X
finger	B-X
motif	B-X
.	B-X
An	B-X
acetylation	B-X
site	B-X
mutant	B-X
of	B-X
PLZF	B-X
does	B-X
not	B-X
repress	B-X
transcription	B-X
and	B-X
is	B-X
functionally	B-X
deficient	B-X
in	B-X
a	B-X
colony	B-X
suppression	B-X
assay	B-X
despite	B-X
retaining	B-X
its	B-X
abilities	B-X
to	B-X
interact	B-X
with	B-X
corepressor/histone	B-X
deacetylase	B-X
complexes	B-X
.	B-X
This	B-X
is	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
acetylation	B-X
of	B-X
PLZF	B-X
activates	B-X
its	B-X
ability	B-X
to	B-X
bind	B-X
specific	B-X
DNA	B-X
sequences	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
histone	B-X
deacetylase-dependent	B-X
transcriptional	B-X
repressor	B-X
can	B-X
be	B-X
positively	B-X
regulated	B-X
through	B-X
acetylation	B-X
and	B-X
point	B-X
to	B-X
an	B-X
unexpected	B-X
role	B-X
of	B-X
a	B-X
coactivator	B-X
protein	B-X
in	B-X
transcriptional	B-X
repression	B-X
.	B-X

Promyelocytic	B-Protein
leukemia	I-Protein
zinc	I-Protein
finger	I-Protein
(	O
PLZF	B-Protein
)	O
,	O
originally	O
identified	O
as	O
a	O
fusion	O
with	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
alpha	I-Protein
in	O
rare	O
cases	O
of	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
-	O
resistant	O
acute	O
promyelocytic	O
leukemia	O
,	O
is	O
a	O
transcriptional	O
repressor	O
that	O
recruits	O
histone	B-Protein
deacetylase	O
-	O
containing	O
corepressor	O
complexes	O
to	O
specific	O
DNA	O
binding	O
sites	O
.	O
<EOS>	B-X
Histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
activities	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
p300	B-X
,	B-X
CBP	B-X
,	B-X
and	B-X
P/CAF	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
activation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
the	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
can	B-X
also	B-X
be	B-X
required	B-X
for	B-X
down-regulation	B-X
of	B-X
transcription	B-X
by	B-X
a	B-X
DNA	B-X
binding	B-X
repressor	B-X
protein	B-X
.	B-X
Promyelocytic	B-X
leukemia	B-X
zinc	B-X
finger	B-X
(	B-X
PLZF	B-X
)	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
fusion	B-X
with	B-X
retinoic	B-X
acid	B-X
receptor	B-X
alpha	B-X
in	B-X
rare	B-X
cases	B-X
of	B-X
all-trans-retinoic	B-X
acid-resistant	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
,	B-X
is	B-X
a	B-X
transcriptional	B-X
repressor	B-X
that	B-X
recruits	B-X
histone	B-X
deacetylase-containing	B-X
corepressor	B-X
complexes	B-X
to	B-X
specific	B-X
DNA	B-X
binding	B-X
sites	B-X
.	B-X
PLZF	B-X
associates	B-X
with	B-X
p300	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
repress	B-X
transcription	B-X
is	B-X
specifically	B-X
dependent	B-X
on	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
and	B-X
acetylation	B-X
of	B-X
lysines	B-X
in	B-X
its	B-X
C-terminal	B-X
C2-H2	B-X
zinc	B-X
finger	B-X
motif	B-X
.	B-X
An	B-X
acetylation	B-X
site	B-X
mutant	B-X
of	B-X
PLZF	B-X
does	B-X
not	B-X
repress	B-X
transcription	B-X
and	B-X
is	B-X
functionally	B-X
deficient	B-X
in	B-X
a	B-X
colony	B-X
suppression	B-X
assay	B-X
despite	B-X
retaining	B-X
its	B-X
abilities	B-X
to	B-X
interact	B-X
with	B-X
corepressor/histone	B-X
deacetylase	B-X
complexes	B-X
.	B-X
This	B-X
is	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
acetylation	B-X
of	B-X
PLZF	B-X
activates	B-X
its	B-X
ability	B-X
to	B-X
bind	B-X
specific	B-X
DNA	B-X
sequences	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
histone	B-X
deacetylase-dependent	B-X
transcriptional	B-X
repressor	B-X
can	B-X
be	B-X
positively	B-X
regulated	B-X
through	B-X
acetylation	B-X
and	B-X
point	B-X
to	B-X
an	B-X
unexpected	B-X
role	B-X
of	B-X
a	B-X
coactivator	B-X
protein	B-X
in	B-X
transcriptional	B-X
repression	B-X
.	B-X

PLZF	B-Protein
associates	O
with	O
p300	B-Protein
in	O
vivo	O
,	O
and	O
its	O
ability	O
to	O
repress	O
transcription	O
is	O
specifically	O
dependent	O
on	O
HAT	O
activity	O
of	O
p300	B-Protein
and	O
acetylation	O
of	O
lysines	O
in	O
its	O
C	O
-	O
terminal	O
C2	O
-	O
H2	O
zinc	O
finger	O
motif	O
.	O
<EOS>	B-X
Histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
activities	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
p300	B-X
,	B-X
CBP	B-X
,	B-X
and	B-X
P/CAF	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
activation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
the	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
can	B-X
also	B-X
be	B-X
required	B-X
for	B-X
down-regulation	B-X
of	B-X
transcription	B-X
by	B-X
a	B-X
DNA	B-X
binding	B-X
repressor	B-X
protein	B-X
.	B-X
Promyelocytic	B-X
leukemia	B-X
zinc	B-X
finger	B-X
(	B-X
PLZF	B-X
)	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
fusion	B-X
with	B-X
retinoic	B-X
acid	B-X
receptor	B-X
alpha	B-X
in	B-X
rare	B-X
cases	B-X
of	B-X
all-trans-retinoic	B-X
acid-resistant	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
,	B-X
is	B-X
a	B-X
transcriptional	B-X
repressor	B-X
that	B-X
recruits	B-X
histone	B-X
deacetylase-containing	B-X
corepressor	B-X
complexes	B-X
to	B-X
specific	B-X
DNA	B-X
binding	B-X
sites	B-X
.	B-X
PLZF	B-X
associates	B-X
with	B-X
p300	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
repress	B-X
transcription	B-X
is	B-X
specifically	B-X
dependent	B-X
on	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
and	B-X
acetylation	B-X
of	B-X
lysines	B-X
in	B-X
its	B-X
C-terminal	B-X
C2-H2	B-X
zinc	B-X
finger	B-X
motif	B-X
.	B-X
An	B-X
acetylation	B-X
site	B-X
mutant	B-X
of	B-X
PLZF	B-X
does	B-X
not	B-X
repress	B-X
transcription	B-X
and	B-X
is	B-X
functionally	B-X
deficient	B-X
in	B-X
a	B-X
colony	B-X
suppression	B-X
assay	B-X
despite	B-X
retaining	B-X
its	B-X
abilities	B-X
to	B-X
interact	B-X
with	B-X
corepressor/histone	B-X
deacetylase	B-X
complexes	B-X
.	B-X
This	B-X
is	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
acetylation	B-X
of	B-X
PLZF	B-X
activates	B-X
its	B-X
ability	B-X
to	B-X
bind	B-X
specific	B-X
DNA	B-X
sequences	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
histone	B-X
deacetylase-dependent	B-X
transcriptional	B-X
repressor	B-X
can	B-X
be	B-X
positively	B-X
regulated	B-X
through	B-X
acetylation	B-X
and	B-X
point	B-X
to	B-X
an	B-X
unexpected	B-X
role	B-X
of	B-X
a	B-X
coactivator	B-X
protein	B-X
in	B-X
transcriptional	B-X
repression	B-X
.	B-X

An	O
acetylation	O
site	O
mutant	O
of	O
PLZF	B-Protein
does	O
not	O
repress	O
transcription	O
and	O
is	O
functionally	O
deficient	O
in	O
a	O
colony	O
suppression	O
assay	O
despite	O
retaining	O
its	O
abilities	O
to	O
interact	O
with	O
corepressor	O
/	O
histone	B-Protein
deacetylase	O
complexes	O
.	O
<EOS>	B-X
We	B-X
now	B-X
show	B-X
that	B-X
the	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
can	B-X
also	B-X
be	B-X
required	B-X
for	B-X
down-regulation	B-X
of	B-X
transcription	B-X
by	B-X
a	B-X
DNA	B-X
binding	B-X
repressor	B-X
protein	B-X
.	B-X
Promyelocytic	B-X
leukemia	B-X
zinc	B-X
finger	B-X
(	B-X
PLZF	B-X
)	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
fusion	B-X
with	B-X
retinoic	B-X
acid	B-X
receptor	B-X
alpha	B-X
in	B-X
rare	B-X
cases	B-X
of	B-X
all-trans-retinoic	B-X
acid-resistant	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
,	B-X
is	B-X
a	B-X
transcriptional	B-X
repressor	B-X
that	B-X
recruits	B-X
histone	B-X
deacetylase-containing	B-X
corepressor	B-X
complexes	B-X
to	B-X
specific	B-X
DNA	B-X
binding	B-X
sites	B-X
.	B-X
PLZF	B-X
associates	B-X
with	B-X
p300	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
repress	B-X
transcription	B-X
is	B-X
specifically	B-X
dependent	B-X
on	B-X
HAT	B-X
activity	B-X
of	B-X
p300	B-X
and	B-X
acetylation	B-X
of	B-X
lysines	B-X
in	B-X
its	B-X
C-terminal	B-X
C2-H2	B-X
zinc	B-X
finger	B-X
motif	B-X
.	B-X
An	B-X
acetylation	B-X
site	B-X
mutant	B-X
of	B-X
PLZF	B-X
does	B-X
not	B-X
repress	B-X
transcription	B-X
and	B-X
is	B-X
functionally	B-X
deficient	B-X
in	B-X
a	B-X
colony	B-X
suppression	B-X
assay	B-X
despite	B-X
retaining	B-X
its	B-X
abilities	B-X
to	B-X
interact	B-X
with	B-X
corepressor/histone	B-X
deacetylase	B-X
complexes	B-X
.	B-X
This	B-X
is	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
acetylation	B-X
of	B-X
PLZF	B-X
activates	B-X
its	B-X
ability	B-X
to	B-X
bind	B-X
specific	B-X
DNA	B-X
sequences	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
histone	B-X
deacetylase-dependent	B-X
transcriptional	B-X
repressor	B-X
can	B-X
be	B-X
positively	B-X
regulated	B-X
through	B-X
acetylation	B-X
and	B-X
point	B-X
to	B-X
an	B-X
unexpected	B-X
role	B-X
of	B-X
a	B-X
coactivator	B-X
protein	B-X
in	B-X
transcriptional	B-X
repression	B-X
.	B-X

This	O
is	O
due	O
to	O
the	O
fact	O
that	O
acetylation	O
of	O
PLZF	B-Protein
activates	O
its	O
ability	O
to	O
bind	O
specific	O
DNA	O
sequences	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
a	O
histone	B-Protein
deacetylase	O
-	O
dependent	O
transcriptional	O
repressor	O
can	O
be	O
positively	O
regulated	O
through	O
acetylation	O
and	O
point	O
to	O
an	O
unexpected	O
role	O
of	O
a	O
coactivator	O
protein	O
in	O
transcriptional	O
repression	O
.	O

Coordinate	O
regulation	O
of	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
domains	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
Oxygen-dependent	B-X
proteolysis	B-X
is	B-X
the	B-X
primary	B-X
means	B-X
of	B-X
regulating	B-X
the	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
The	B-X
alpha-subunit	B-X
of	B-X
HIF	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
contains	B-X
two	B-X
highly	B-X
conserved	B-X
oxygen-dependent	B-X
degradation	B-X
domains	B-X
(	B-X
402	B-X
ODD	B-X
and	B-X
564	B-X
ODD	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
includes	B-X
a	B-X
proline	B-X
that	B-X
is	B-X
hydroxylated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
allowing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
interact	B-X
and	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Mutation	B-X
of	B-X
either	B-X
proline	B-X
is	B-X
sufficient	B-X
to	B-X
partially	B-X
stabilize	B-X
HIF-1alpha	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
,	B-X
but	B-X
the	B-X
specific	B-X
contributions	B-X
of	B-X
each	B-X
hydroxylation	B-X
event	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
are	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
two	B-X
ODDs	B-X
of	B-X
HIF-1alpha	B-X
have	B-X
independent	B-X
yet	B-X
interactive	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
turnover	B-X
,	B-X
with	B-X
the	B-X
relative	B-X
involvement	B-X
of	B-X
each	B-X
ODD	B-X
depending	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
oxygen	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
the	B-X
more	B-X
rapid	B-X
hydroxylation	B-X
of	B-X
the	B-X
proline	B-X
564	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
is	B-X
due	B-X
to	B-X
a	B-X
preference	B-X
for	B-X
the	B-X
particular	B-X
sequence	B-X
surrounding	B-X
proline	B-X
564	B-X
or	B-X
for	B-X
that	B-X
site	B-X
within	B-X
the	B-X
protein	B-X
,	B-X
we	B-X
exchanged	B-X
the	B-X
degradation	B-X
domains	B-X
within	B-X
the	B-X
full-length	B-X
HIF-1alpha	B-X
protein	B-X
.	B-X
In	B-X
these	B-X
domain-swapping	B-X
experiments	B-X
,	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
1	B-X
(	B-X
PHD1	B-X
)	B-X
and	B-X
PHD2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
proline	B-X
located	B-X
in	B-X
the	B-X
site	B-X
of	B-X
the	B-X
original	B-X
564	B-X
ODD	B-X
,	B-X
while	B-X
PHD3	B-X
preferred	B-X
the	B-X
proline	B-X
564	B-X
sequence	B-X
,	B-X
regardless	B-X
of	B-X
its	B-X
location	B-X
.	B-X
At	B-X
limiting	B-X
oxygen	B-X
tensions	B-X
,	B-X
we	B-X
found	B-X
that	B-X
proline	B-X
402	B-X
exhibits	B-X
an	B-X
oxygen-dependent	B-X
decrease	B-X
in	B-X
hydroxylation	B-X
at	B-X
higher	B-X
oxygen	B-X
tensions	B-X
relative	B-X
to	B-X
proline	B-X
564	B-X
hydroxylation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
is	B-X
highly	B-X
responsive	B-X
to	B-X
physiologic	B-X
changes	B-X
in	B-X
oxygen	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
plays	B-X
a	B-X
more	B-X
important	B-X
role	B-X
in	B-X
HIF-1alpha	B-X
regulation	B-X
under	B-X
conditions	B-X
of	B-X
hypoxia	B-X
than	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
each	B-X
hydroxylated	B-X
proline	B-X
of	B-X
HIF-1alpha	B-X
has	B-X
a	B-X
distinct	B-X
activity	B-X
in	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
in	B-X
response	B-X
to	B-X
different	B-X
levels	B-X
of	B-X
oxygenation	B-X
.	B-X

Oxygen	O
-	O
dependent	O
proteolysis	O
is	O
the	O
primary	O
means	O
of	O
regulating	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
family	O
of	O
transcription	O
factors	O
.	O
<EOS>	B-X
Oxygen-dependent	B-X
proteolysis	B-X
is	B-X
the	B-X
primary	B-X
means	B-X
of	B-X
regulating	B-X
the	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
The	B-X
alpha-subunit	B-X
of	B-X
HIF	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
contains	B-X
two	B-X
highly	B-X
conserved	B-X
oxygen-dependent	B-X
degradation	B-X
domains	B-X
(	B-X
402	B-X
ODD	B-X
and	B-X
564	B-X
ODD	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
includes	B-X
a	B-X
proline	B-X
that	B-X
is	B-X
hydroxylated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
allowing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
interact	B-X
and	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Mutation	B-X
of	B-X
either	B-X
proline	B-X
is	B-X
sufficient	B-X
to	B-X
partially	B-X
stabilize	B-X
HIF-1alpha	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
,	B-X
but	B-X
the	B-X
specific	B-X
contributions	B-X
of	B-X
each	B-X
hydroxylation	B-X
event	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
are	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
two	B-X
ODDs	B-X
of	B-X
HIF-1alpha	B-X
have	B-X
independent	B-X
yet	B-X
interactive	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
turnover	B-X
,	B-X
with	B-X
the	B-X
relative	B-X
involvement	B-X
of	B-X
each	B-X
ODD	B-X
depending	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
oxygen	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
the	B-X
more	B-X
rapid	B-X
hydroxylation	B-X
of	B-X
the	B-X
proline	B-X
564	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
is	B-X
due	B-X
to	B-X
a	B-X
preference	B-X
for	B-X
the	B-X
particular	B-X
sequence	B-X
surrounding	B-X
proline	B-X
564	B-X
or	B-X
for	B-X
that	B-X
site	B-X
within	B-X
the	B-X
protein	B-X
,	B-X
we	B-X
exchanged	B-X
the	B-X
degradation	B-X
domains	B-X
within	B-X
the	B-X
full-length	B-X
HIF-1alpha	B-X
protein	B-X
.	B-X
At	B-X
limiting	B-X
oxygen	B-X
tensions	B-X
,	B-X
we	B-X
found	B-X
that	B-X
proline	B-X
402	B-X
exhibits	B-X
an	B-X
oxygen-dependent	B-X
decrease	B-X
in	B-X
hydroxylation	B-X
at	B-X
higher	B-X
oxygen	B-X
tensions	B-X
relative	B-X
to	B-X
proline	B-X
564	B-X
hydroxylation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
is	B-X
highly	B-X
responsive	B-X
to	B-X
physiologic	B-X
changes	B-X
in	B-X
oxygen	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
plays	B-X
a	B-X
more	B-X
important	B-X
role	B-X
in	B-X
HIF-1alpha	B-X
regulation	B-X
under	B-X
conditions	B-X
of	B-X
hypoxia	B-X
than	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
each	B-X
hydroxylated	B-X
proline	B-X
of	B-X
HIF-1alpha	B-X
has	B-X
a	B-X
distinct	B-X
activity	B-X
in	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
in	B-X
response	B-X
to	B-X
different	B-X
levels	B-X
of	B-X
oxygenation	B-X
.	B-X

The	O
alpha	O
-	O
subunit	O
of	O
HIF	O
factor	O
1	O
(	O
HIF	O
-	O
1	O
)	O
contains	O
two	O
highly	O
conserved	O
oxygen	O
-	O
dependent	O
degradation	O
domains	O
(	O
402	O
ODD	O
and	O
564	O
ODD	O
)	O
,	O
each	O
of	O
which	O
includes	O
a	O
proline	O
that	O
is	O
hydroxylated	O
in	O
the	O
presence	O
of	O
oxygen	O
,	O
allowing	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	O
VHL	B-Protein
)	O
E3	O
ubiquitin	B-Protein
ligase	O
to	O
interact	O
and	O
target	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
to	O
the	O
proteasome	O
for	O
degradation	O
.	O

Mutation	O
of	O
either	O
proline	O
is	O
sufficient	O
to	O
partially	O
stabilize	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
under	O
conditions	O
of	O
normoxia	O
,	O
but	O
the	O
specific	O
contributions	O
of	O
each	O
hydroxylation	O
event	O
to	O
the	O
regulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
are	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
the	O
two	O
ODDs	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
have	O
independent	O
yet	O
interactive	O
roles	O
in	O
the	O
regulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
protein	O
turnover	O
,	O
with	O
the	O
relative	O
involvement	O
of	O
each	O
ODD	O
depending	O
on	O
the	O
levels	O
of	O
oxygen	O
.	O
<EOS>	B-X
Oxygen-dependent	B-X
proteolysis	B-X
is	B-X
the	B-X
primary	B-X
means	B-X
of	B-X
regulating	B-X
the	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
The	B-X
alpha-subunit	B-X
of	B-X
HIF	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
contains	B-X
two	B-X
highly	B-X
conserved	B-X
oxygen-dependent	B-X
degradation	B-X
domains	B-X
(	B-X
402	B-X
ODD	B-X
and	B-X
564	B-X
ODD	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
includes	B-X
a	B-X
proline	B-X
that	B-X
is	B-X
hydroxylated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
allowing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
interact	B-X
and	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Mutation	B-X
of	B-X
either	B-X
proline	B-X
is	B-X
sufficient	B-X
to	B-X
partially	B-X
stabilize	B-X
HIF-1alpha	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
,	B-X
but	B-X
the	B-X
specific	B-X
contributions	B-X
of	B-X
each	B-X
hydroxylation	B-X
event	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
are	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
two	B-X
ODDs	B-X
of	B-X
HIF-1alpha	B-X
have	B-X
independent	B-X
yet	B-X
interactive	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
turnover	B-X
,	B-X
with	B-X
the	B-X
relative	B-X
involvement	B-X
of	B-X
each	B-X
ODD	B-X
depending	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
oxygen	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
the	B-X
more	B-X
rapid	B-X
hydroxylation	B-X
of	B-X
the	B-X
proline	B-X
564	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
is	B-X
due	B-X
to	B-X
a	B-X
preference	B-X
for	B-X
the	B-X
particular	B-X
sequence	B-X
surrounding	B-X
proline	B-X
564	B-X
or	B-X
for	B-X
that	B-X
site	B-X
within	B-X
the	B-X
protein	B-X
,	B-X
we	B-X
exchanged	B-X
the	B-X
degradation	B-X
domains	B-X
within	B-X
the	B-X
full-length	B-X
HIF-1alpha	B-X
protein	B-X
.	B-X
In	B-X
these	B-X
domain-swapping	B-X
experiments	B-X
,	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
1	B-X
(	B-X
PHD1	B-X
)	B-X
and	B-X
PHD2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
proline	B-X
located	B-X
in	B-X
the	B-X
site	B-X
of	B-X
the	B-X
original	B-X
564	B-X
ODD	B-X
,	B-X
while	B-X
PHD3	B-X
preferred	B-X
the	B-X
proline	B-X
564	B-X
sequence	B-X
,	B-X
regardless	B-X
of	B-X
its	B-X
location	B-X
.	B-X
At	B-X
limiting	B-X
oxygen	B-X
tensions	B-X
,	B-X
we	B-X
found	B-X
that	B-X
proline	B-X
402	B-X
exhibits	B-X
an	B-X
oxygen-dependent	B-X
decrease	B-X
in	B-X
hydroxylation	B-X
at	B-X
higher	B-X
oxygen	B-X
tensions	B-X
relative	B-X
to	B-X
proline	B-X
564	B-X
hydroxylation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
is	B-X
highly	B-X
responsive	B-X
to	B-X
physiologic	B-X
changes	B-X
in	B-X
oxygen	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
plays	B-X
a	B-X
more	B-X
important	B-X
role	B-X
in	B-X
HIF-1alpha	B-X
regulation	B-X
under	B-X
conditions	B-X
of	B-X
hypoxia	B-X
than	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
each	B-X
hydroxylated	B-X
proline	B-X
of	B-X
HIF-1alpha	B-X
has	B-X
a	B-X
distinct	B-X
activity	B-X
in	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
in	B-X
response	B-X
to	B-X
different	B-X
levels	B-X
of	B-X
oxygenation	B-X
.	B-X

Using	O
hydroxylation	O
-	O
specific	O
antibodies	O
,	O
we	O
found	O
that	O
under	O
conditions	O
of	O
normoxia	O
proline	O
564	O
is	O
hydroxylated	O
prior	O
to	O
proline	O
402	O
,	O
and	O
mutation	O
of	O
proline	O
564	O
results	O
in	O
a	O
significant	O
reduction	O
in	O
the	O
hydroxylation	O
of	O
proline	O
402	O
.	O

Mutation	O
of	O
proline	O
402	O
,	O
however	O
,	O
has	O
little	O
effect	O
on	O
the	O
hydroxylation	O
of	O
proline	O
564	O
.	O
<EOS>	B-X
The	B-X
alpha-subunit	B-X
of	B-X
HIF	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
contains	B-X
two	B-X
highly	B-X
conserved	B-X
oxygen-dependent	B-X
degradation	B-X
domains	B-X
(	B-X
402	B-X
ODD	B-X
and	B-X
564	B-X
ODD	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
includes	B-X
a	B-X
proline	B-X
that	B-X
is	B-X
hydroxylated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
allowing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
interact	B-X
and	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Mutation	B-X
of	B-X
either	B-X
proline	B-X
is	B-X
sufficient	B-X
to	B-X
partially	B-X
stabilize	B-X
HIF-1alpha	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
,	B-X
but	B-X
the	B-X
specific	B-X
contributions	B-X
of	B-X
each	B-X
hydroxylation	B-X
event	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
are	B-X
unknown	B-X
.	B-X
Using	B-X
hydroxylation-specific	B-X
antibodies	B-X
,	B-X
we	B-X
found	B-X
that	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
proline	B-X
564	B-X
is	B-X
hydroxylated	B-X
prior	B-X
to	B-X
proline	B-X
402	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
proline	B-X
564	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
.	B-X
Mutation	B-X
of	B-X
proline	B-X
402	B-X
,	B-X
however	B-X
,	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
hydroxylation	B-X
of	B-X
proline	B-X
564	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
the	B-X
more	B-X
rapid	B-X
hydroxylation	B-X
of	B-X
the	B-X
proline	B-X
564	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
is	B-X
due	B-X
to	B-X
a	B-X
preference	B-X
for	B-X
the	B-X
particular	B-X
sequence	B-X
surrounding	B-X
proline	B-X
564	B-X
or	B-X
for	B-X
that	B-X
site	B-X
within	B-X
the	B-X
protein	B-X
,	B-X
we	B-X
exchanged	B-X
the	B-X
degradation	B-X
domains	B-X
within	B-X
the	B-X
full-length	B-X
HIF-1alpha	B-X
protein	B-X
.	B-X
In	B-X
these	B-X
domain-swapping	B-X
experiments	B-X
,	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
1	B-X
(	B-X
PHD1	B-X
)	B-X
and	B-X
PHD2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
proline	B-X
located	B-X
in	B-X
the	B-X
site	B-X
of	B-X
the	B-X
original	B-X
564	B-X
ODD	B-X
,	B-X
while	B-X
PHD3	B-X
preferred	B-X
the	B-X
proline	B-X
564	B-X
sequence	B-X
,	B-X
regardless	B-X
of	B-X
its	B-X
location	B-X
.	B-X
At	B-X
limiting	B-X
oxygen	B-X
tensions	B-X
,	B-X
we	B-X
found	B-X
that	B-X
proline	B-X
402	B-X
exhibits	B-X
an	B-X
oxygen-dependent	B-X
decrease	B-X
in	B-X
hydroxylation	B-X
at	B-X
higher	B-X
oxygen	B-X
tensions	B-X
relative	B-X
to	B-X
proline	B-X
564	B-X
hydroxylation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
is	B-X
highly	B-X
responsive	B-X
to	B-X
physiologic	B-X
changes	B-X
in	B-X
oxygen	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
plays	B-X
a	B-X
more	B-X
important	B-X
role	B-X
in	B-X
HIF-1alpha	B-X
regulation	B-X
under	B-X
conditions	B-X
of	B-X
hypoxia	B-X
than	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
each	B-X
hydroxylated	B-X
proline	B-X
of	B-X
HIF-1alpha	B-X
has	B-X
a	B-X
distinct	B-X
activity	B-X
in	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
in	B-X
response	B-X
to	B-X
different	B-X
levels	B-X
of	B-X
oxygenation	B-X
.	B-X

To	O
determine	O
whether	O
the	O
more	O
rapid	O
hydroxylation	O
of	O
the	O
proline	O
564	O
under	O
conditions	O
of	O
normoxia	O
is	O
due	O
to	O
a	O
preference	O
for	O
the	O
particular	O
sequence	O
surrounding	O
proline	O
564	O
or	O
for	O
that	O
site	O
within	O
the	O
protein	O
,	O
we	O
exchanged	O
the	O
degradation	O
domains	O
within	O
the	O
full	O
-	O
length	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
protein	O
.	O
<EOS>	B-X
Oxygen-dependent	B-X
proteolysis	B-X
is	B-X
the	B-X
primary	B-X
means	B-X
of	B-X
regulating	B-X
the	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
The	B-X
alpha-subunit	B-X
of	B-X
HIF	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
contains	B-X
two	B-X
highly	B-X
conserved	B-X
oxygen-dependent	B-X
degradation	B-X
domains	B-X
(	B-X
402	B-X
ODD	B-X
and	B-X
564	B-X
ODD	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
includes	B-X
a	B-X
proline	B-X
that	B-X
is	B-X
hydroxylated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
allowing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
interact	B-X
and	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Mutation	B-X
of	B-X
either	B-X
proline	B-X
is	B-X
sufficient	B-X
to	B-X
partially	B-X
stabilize	B-X
HIF-1alpha	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
,	B-X
but	B-X
the	B-X
specific	B-X
contributions	B-X
of	B-X
each	B-X
hydroxylation	B-X
event	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
are	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
two	B-X
ODDs	B-X
of	B-X
HIF-1alpha	B-X
have	B-X
independent	B-X
yet	B-X
interactive	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
turnover	B-X
,	B-X
with	B-X
the	B-X
relative	B-X
involvement	B-X
of	B-X
each	B-X
ODD	B-X
depending	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
oxygen	B-X
.	B-X
Using	B-X
hydroxylation-specific	B-X
antibodies	B-X
,	B-X
we	B-X
found	B-X
that	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
proline	B-X
564	B-X
is	B-X
hydroxylated	B-X
prior	B-X
to	B-X
proline	B-X
402	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
proline	B-X
564	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
.	B-X
Mutation	B-X
of	B-X
proline	B-X
402	B-X
,	B-X
however	B-X
,	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
hydroxylation	B-X
of	B-X
proline	B-X
564	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
the	B-X
more	B-X
rapid	B-X
hydroxylation	B-X
of	B-X
the	B-X
proline	B-X
564	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
is	B-X
due	B-X
to	B-X
a	B-X
preference	B-X
for	B-X
the	B-X
particular	B-X
sequence	B-X
surrounding	B-X
proline	B-X
564	B-X
or	B-X
for	B-X
that	B-X
site	B-X
within	B-X
the	B-X
protein	B-X
,	B-X
we	B-X
exchanged	B-X
the	B-X
degradation	B-X
domains	B-X
within	B-X
the	B-X
full-length	B-X
HIF-1alpha	B-X
protein	B-X
.	B-X
In	B-X
these	B-X
domain-swapping	B-X
experiments	B-X
,	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
1	B-X
(	B-X
PHD1	B-X
)	B-X
and	B-X
PHD2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
proline	B-X
located	B-X
in	B-X
the	B-X
site	B-X
of	B-X
the	B-X
original	B-X
564	B-X
ODD	B-X
,	B-X
while	B-X
PHD3	B-X
preferred	B-X
the	B-X
proline	B-X
564	B-X
sequence	B-X
,	B-X
regardless	B-X
of	B-X
its	B-X
location	B-X
.	B-X
At	B-X
limiting	B-X
oxygen	B-X
tensions	B-X
,	B-X
we	B-X
found	B-X
that	B-X
proline	B-X
402	B-X
exhibits	B-X
an	B-X
oxygen-dependent	B-X
decrease	B-X
in	B-X
hydroxylation	B-X
at	B-X
higher	B-X
oxygen	B-X
tensions	B-X
relative	B-X
to	B-X
proline	B-X
564	B-X
hydroxylation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
is	B-X
highly	B-X
responsive	B-X
to	B-X
physiologic	B-X
changes	B-X
in	B-X
oxygen	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
plays	B-X
a	B-X
more	B-X
important	B-X
role	B-X
in	B-X
HIF-1alpha	B-X
regulation	B-X
under	B-X
conditions	B-X
of	B-X
hypoxia	B-X
than	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
each	B-X
hydroxylated	B-X
proline	B-X
of	B-X
HIF-1alpha	B-X
has	B-X
a	B-X
distinct	B-X
activity	B-X
in	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
in	B-X
response	B-X
to	B-X
different	B-X
levels	B-X
of	B-X
oxygenation	B-X
.	B-X

In	O
these	O
domain	O
-	O
swapping	O
experiments	O
,	O
prolyl	O
hydroxylase	O
domain	O
1	O
(	O
PHD1	O
)	O
and	O
PHD2	O
preferentially	O
hydroxylated	O
the	O
proline	O
located	O
in	O
the	O
site	O
of	O
the	O
original	O
564	O
ODD	O
,	O
while	O
PHD3	O
preferred	O
the	O
proline	O
564	O
sequence	O
,	O
regardless	O
of	O
its	O
location	O
.	O
<EOS>	B-X
The	B-X
alpha-subunit	B-X
of	B-X
HIF	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
contains	B-X
two	B-X
highly	B-X
conserved	B-X
oxygen-dependent	B-X
degradation	B-X
domains	B-X
(	B-X
402	B-X
ODD	B-X
and	B-X
564	B-X
ODD	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
includes	B-X
a	B-X
proline	B-X
that	B-X
is	B-X
hydroxylated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
allowing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
interact	B-X
and	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Mutation	B-X
of	B-X
either	B-X
proline	B-X
is	B-X
sufficient	B-X
to	B-X
partially	B-X
stabilize	B-X
HIF-1alpha	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
,	B-X
but	B-X
the	B-X
specific	B-X
contributions	B-X
of	B-X
each	B-X
hydroxylation	B-X
event	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
are	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
two	B-X
ODDs	B-X
of	B-X
HIF-1alpha	B-X
have	B-X
independent	B-X
yet	B-X
interactive	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
turnover	B-X
,	B-X
with	B-X
the	B-X
relative	B-X
involvement	B-X
of	B-X
each	B-X
ODD	B-X
depending	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
oxygen	B-X
.	B-X
Using	B-X
hydroxylation-specific	B-X
antibodies	B-X
,	B-X
we	B-X
found	B-X
that	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
proline	B-X
564	B-X
is	B-X
hydroxylated	B-X
prior	B-X
to	B-X
proline	B-X
402	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
proline	B-X
564	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
.	B-X
Mutation	B-X
of	B-X
proline	B-X
402	B-X
,	B-X
however	B-X
,	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
hydroxylation	B-X
of	B-X
proline	B-X
564	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
the	B-X
more	B-X
rapid	B-X
hydroxylation	B-X
of	B-X
the	B-X
proline	B-X
564	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
is	B-X
due	B-X
to	B-X
a	B-X
preference	B-X
for	B-X
the	B-X
particular	B-X
sequence	B-X
surrounding	B-X
proline	B-X
564	B-X
or	B-X
for	B-X
that	B-X
site	B-X
within	B-X
the	B-X
protein	B-X
,	B-X
we	B-X
exchanged	B-X
the	B-X
degradation	B-X
domains	B-X
within	B-X
the	B-X
full-length	B-X
HIF-1alpha	B-X
protein	B-X
.	B-X
In	B-X
these	B-X
domain-swapping	B-X
experiments	B-X
,	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
1	B-X
(	B-X
PHD1	B-X
)	B-X
and	B-X
PHD2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
proline	B-X
located	B-X
in	B-X
the	B-X
site	B-X
of	B-X
the	B-X
original	B-X
564	B-X
ODD	B-X
,	B-X
while	B-X
PHD3	B-X
preferred	B-X
the	B-X
proline	B-X
564	B-X
sequence	B-X
,	B-X
regardless	B-X
of	B-X
its	B-X
location	B-X
.	B-X
At	B-X
limiting	B-X
oxygen	B-X
tensions	B-X
,	B-X
we	B-X
found	B-X
that	B-X
proline	B-X
402	B-X
exhibits	B-X
an	B-X
oxygen-dependent	B-X
decrease	B-X
in	B-X
hydroxylation	B-X
at	B-X
higher	B-X
oxygen	B-X
tensions	B-X
relative	B-X
to	B-X
proline	B-X
564	B-X
hydroxylation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
is	B-X
highly	B-X
responsive	B-X
to	B-X
physiologic	B-X
changes	B-X
in	B-X
oxygen	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
plays	B-X
a	B-X
more	B-X
important	B-X
role	B-X
in	B-X
HIF-1alpha	B-X
regulation	B-X
under	B-X
conditions	B-X
of	B-X
hypoxia	B-X
than	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
each	B-X
hydroxylated	B-X
proline	B-X
of	B-X
HIF-1alpha	B-X
has	B-X
a	B-X
distinct	B-X
activity	B-X
in	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
in	B-X
response	B-X
to	B-X
different	B-X
levels	B-X
of	B-X
oxygenation	B-X
.	B-X

At	O
limiting	O
oxygen	O
tensions	O
,	O
we	O
found	O
that	O
proline	O
402	O
exhibits	O
an	O
oxygen	O
-	O
dependent	O
decrease	O
in	O
hydroxylation	O
at	O
higher	O
oxygen	O
tensions	O
relative	O
to	O
proline	O
564	O
hydroxylation	O
.	O
<EOS>	B-X
Oxygen-dependent	B-X
proteolysis	B-X
is	B-X
the	B-X
primary	B-X
means	B-X
of	B-X
regulating	B-X
the	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
The	B-X
alpha-subunit	B-X
of	B-X
HIF	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
contains	B-X
two	B-X
highly	B-X
conserved	B-X
oxygen-dependent	B-X
degradation	B-X
domains	B-X
(	B-X
402	B-X
ODD	B-X
and	B-X
564	B-X
ODD	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
includes	B-X
a	B-X
proline	B-X
that	B-X
is	B-X
hydroxylated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
allowing	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
interact	B-X
and	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Mutation	B-X
of	B-X
either	B-X
proline	B-X
is	B-X
sufficient	B-X
to	B-X
partially	B-X
stabilize	B-X
HIF-1alpha	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
,	B-X
but	B-X
the	B-X
specific	B-X
contributions	B-X
of	B-X
each	B-X
hydroxylation	B-X
event	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
are	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
two	B-X
ODDs	B-X
of	B-X
HIF-1alpha	B-X
have	B-X
independent	B-X
yet	B-X
interactive	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
turnover	B-X
,	B-X
with	B-X
the	B-X
relative	B-X
involvement	B-X
of	B-X
each	B-X
ODD	B-X
depending	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
oxygen	B-X
.	B-X
Using	B-X
hydroxylation-specific	B-X
antibodies	B-X
,	B-X
we	B-X
found	B-X
that	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
proline	B-X
564	B-X
is	B-X
hydroxylated	B-X
prior	B-X
to	B-X
proline	B-X
402	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
proline	B-X
564	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
.	B-X
Mutation	B-X
of	B-X
proline	B-X
402	B-X
,	B-X
however	B-X
,	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
hydroxylation	B-X
of	B-X
proline	B-X
564	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
the	B-X
more	B-X
rapid	B-X
hydroxylation	B-X
of	B-X
the	B-X
proline	B-X
564	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
is	B-X
due	B-X
to	B-X
a	B-X
preference	B-X
for	B-X
the	B-X
particular	B-X
sequence	B-X
surrounding	B-X
proline	B-X
564	B-X
or	B-X
for	B-X
that	B-X
site	B-X
within	B-X
the	B-X
protein	B-X
,	B-X
we	B-X
exchanged	B-X
the	B-X
degradation	B-X
domains	B-X
within	B-X
the	B-X
full-length	B-X
HIF-1alpha	B-X
protein	B-X
.	B-X
In	B-X
these	B-X
domain-swapping	B-X
experiments	B-X
,	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
1	B-X
(	B-X
PHD1	B-X
)	B-X
and	B-X
PHD2	B-X
preferentially	B-X
hydroxylated	B-X
the	B-X
proline	B-X
located	B-X
in	B-X
the	B-X
site	B-X
of	B-X
the	B-X
original	B-X
564	B-X
ODD	B-X
,	B-X
while	B-X
PHD3	B-X
preferred	B-X
the	B-X
proline	B-X
564	B-X
sequence	B-X
,	B-X
regardless	B-X
of	B-X
its	B-X
location	B-X
.	B-X
At	B-X
limiting	B-X
oxygen	B-X
tensions	B-X
,	B-X
we	B-X
found	B-X
that	B-X
proline	B-X
402	B-X
exhibits	B-X
an	B-X
oxygen-dependent	B-X
decrease	B-X
in	B-X
hydroxylation	B-X
at	B-X
higher	B-X
oxygen	B-X
tensions	B-X
relative	B-X
to	B-X
proline	B-X
564	B-X
hydroxylation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
hydroxylation	B-X
of	B-X
proline	B-X
402	B-X
is	B-X
highly	B-X
responsive	B-X
to	B-X
physiologic	B-X
changes	B-X
in	B-X
oxygen	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
plays	B-X
a	B-X
more	B-X
important	B-X
role	B-X
in	B-X
HIF-1alpha	B-X
regulation	B-X
under	B-X
conditions	B-X
of	B-X
hypoxia	B-X
than	B-X
under	B-X
conditions	B-X
of	B-X
normoxia	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
each	B-X
hydroxylated	B-X
proline	B-X
of	B-X
HIF-1alpha	B-X
has	B-X
a	B-X
distinct	B-X
activity	B-X
in	B-X
controlling	B-X
HIF-1alpha	B-X
stability	B-X
in	B-X
response	B-X
to	B-X
different	B-X
levels	B-X
of	B-X
oxygenation	B-X
.	B-X

These	O
results	O
indicate	O
that	O
hydroxylation	O
of	O
proline	O
402	O
is	O
highly	O
responsive	O
to	O
physiologic	O
changes	O
in	O
oxygen	O
and	O
,	O
therefore	O
,	O
plays	O
a	O
more	O
important	O
role	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
regulation	O
under	O
conditions	O
of	O
hypoxia	O
than	O
under	O
conditions	O
of	O
normoxia	O
.	O

Together	O
,	O
these	O
findings	O
demonstrate	O
that	O
each	O
hydroxylated	O
proline	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
has	O
a	O
distinct	O
activity	O
in	O
controlling	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
stability	O
in	O
response	O
to	O
different	O
levels	O
of	O
oxygenation	O
.	O

Carboxyl	O
-	O
terminal	O
extensions	O
beyond	O
the	O
conserved	O
pentapeptide	O
reduce	O
rates	O
of	O
chemoreceptor	O
adaptational	O
modification	O
.	O
<EOS>	B-X
Sensory	B-X
adaptation	B-X
in	B-X
bacterial	B-X
chemotaxis	B-X
is	B-X
mediated	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
chemoreceptors	B-X
.	B-X
In	B-X
the	B-X
well-characterized	B-X
chemosensory	B-X
systems	B-X
of	B-X
Escherichia	B-X
coli	B-X
and	B-X
Salmonella	B-X
spp.	B-X
,	B-X
efficient	B-X
modification	B-X
by	B-X
either	B-X
enzyme	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
conserved	B-X
pentapeptide	B-X
sequence	B-X
,	B-X
NWETF	B-X
or	B-X
NWESF	B-X
,	B-X
present	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
of	B-X
high-abundance	B-X
chemoreceptors	B-X
.	B-X
To	B-X
what	B-X
extent	B-X
is	B-X
position	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
important	B-X
for	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
adaptational	B-X
modification	B-X
?	B-X
To	B-X
address	B-X
these	B-X
questions	B-X
,	B-X
we	B-X
created	B-X
forms	B-X
of	B-X
high-abundance	B-X
receptor	B-X
Tsr	B-X
or	B-X
Tar	B-X
carrying	B-X
one	B-X
,	B-X
six	B-X
,	B-X
or	B-X
eight	B-X
additional	B-X
amino	B-X
acids	B-X
extending	B-X
beyond	B-X
the	B-X
pentapeptide	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
and	B-X
assayed	B-X
methylation	B-X
,	B-X
demethylation	B-X
,	B-X
deamidation	B-X
,	B-X
and	B-X
ability	B-X
to	B-X
mediate	B-X
chemotaxis	B-X
.	B-X
In	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
all	B-X
three	B-X
carboxyl-terminal	B-X
extensions	B-X
reduced	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
rates	B-X
of	B-X
adaptational	B-X
modification	B-X
.	B-X
Effects	B-X
were	B-X
less	B-X
severe	B-X
for	B-X
the	B-X
complete	B-X
sensory	B-X
system	B-X
in	B-X
vivo	B-X
than	B-X
for	B-X
the	B-X
minimal	B-X
system	B-X
of	B-X
receptor	B-X
and	B-X
modification	B-X
enzymes	B-X
in	B-X
vitro	B-X
.	B-X
This	B-X
could	B-X
reflect	B-X
compensatory	B-X
reductions	B-X
of	B-X
rates	B-X
for	B-X
both	B-X
modification	B-X
reactions	B-X
,	B-X
mitigation	B-X
of	B-X
effects	B-X
of	B-X
slower	B-X
reactions	B-X
by	B-X
the	B-X
intertwined	B-X
circuitry	B-X
of	B-X
signaling	B-X
and	B-X
adaptation	B-X
,	B-X
or	B-X
tolerance	B-X
of	B-X
a	B-X
range	B-X
of	B-X
reactions	B-X
rates	B-X
for	B-X
adaptational	B-X
modification	B-X
.	B-X

Sensory	O
adaptation	O
in	O
bacterial	O
chemotaxis	O
is	O
mediated	O
by	O
covalent	O
modification	O
of	O
chemoreceptors	O
.	O
<EOS>	B-X
However	B-X
,	B-X
this	B-X
organization	B-X
likely	B-X
also	B-X
affects	B-X
the	B-X
kinetics	B-X
of	B-X
signaling	B-X
since	B-X
the	B-X
cytoplasmic	B-X
enzymes	B-X
that	B-X
modulate	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
receptors	B-X
must	B-X
localize	B-X
to	B-X
the	B-X
cluster	B-X
prior	B-X
to	B-X
receptor	B-X
modification	B-X
.	B-X
As	B-X
a	B-X
model	B-X
system	B-X
,	B-X
we	B-X
use	B-X
the	B-X
chemotaxis	B-X
pathway	B-X
of	B-X
Escherichia	B-X
coli	B-X
,	B-X
a	B-X
canonical	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
how	B-X
organisms	B-X
sense	B-X
,	B-X
respond	B-X
,	B-X
and	B-X
adapt	B-X
to	B-X
environmental	B-X
stimuli	B-X
.	B-X
In	B-X
bacterial	B-X
chemotaxis	B-X
,	B-X
adaptation	B-X
is	B-X
mediated	B-X
by	B-X
two	B-X
enzymes	B-X
that	B-X
localize	B-X
to	B-X
the	B-X
clustered	B-X
receptors	B-X
and	B-X
modulate	B-X
their	B-X
activity	B-X
through	B-X
methylation-demethylation	B-X
.	B-X
Using	B-X
a	B-X
novel	B-X
stochastic	B-X
simulation	B-X
,	B-X
we	B-X
show	B-X
that	B-X
distributive	B-X
receptor	B-X
methylation	B-X
is	B-X
necessary	B-X
for	B-X
successful	B-X
adaptation	B-X
to	B-X
stimulus	B-X
and	B-X
also	B-X
leads	B-X
to	B-X
large	B-X
fluctuations	B-X
in	B-X
receptor	B-X
activity	B-X
in	B-X
the	B-X
steady	B-X
state	B-X
.	B-X
These	B-X
fluctuations	B-X
arise	B-X
from	B-X
noise	B-X
in	B-X
the	B-X
number	B-X
of	B-X
localized	B-X
enzymes	B-X
combined	B-X
with	B-X
saturated	B-X
modification	B-X
kinetics	B-X
between	B-X
the	B-X
localized	B-X
enzymes	B-X
and	B-X
the	B-X
receptor	B-X
substrate	B-X
.	B-X
This	B-X
contrasts	B-X
with	B-X
the	B-X
well-mixed	B-X
covalent	B-X
modification	B-X
system	B-X
studied	B-X
by	B-X
Goldbeter	B-X
and	B-X
Koshland	B-X
in	B-X
which	B-X
mean	B-X
activity	B-X
becomes	B-X
ultrasensitive	B-X
to	B-X
protein	B-X
abundances	B-X
when	B-X
the	B-X
enzymes	B-X
operate	B-X
at	B-X
saturation	B-X
.	B-X
Here	B-X
we	B-X
clarify	B-X
the	B-X
mechanistic	B-X
relationship	B-X
of	B-X
these	B-X
large	B-X
fluctuations	B-X
to	B-X
well-studied	B-X
aspects	B-X
of	B-X
the	B-X
chemotaxis	B-X
system	B-X
,	B-X
precise	B-X
adaptation	B-X
and	B-X
functional	B-X
robustness	B-X
.	B-X

Specific	O
glutamyl	O
residues	O
are	O
methylated	O
and	O
demethylated	O
in	O
reactions	O
catalyzed	O
by	O
methyltransferase	O
CheR	B-Protein
and	O
methylesterase	O
CheB	B-Protein
.	O
<EOS>	B-X
Specific	B-X
glutamyl	B-X
residues	B-X
are	B-X
methylated	B-X
and	B-X
demethylated	B-X
in	B-X
reactions	B-X
catalyzed	B-X
by	B-X
methyltransferase	B-X
CheR	B-X
and	B-X
methylesterase	B-X
CheB	B-X
.	B-X
CheB-catalyzed	B-X
reactions	B-X
were	B-X
more	B-X
affected	B-X
than	B-X
CheR-catalyzed	B-X
reactions	B-X
.	B-X
This	B-X
could	B-X
reflect	B-X
compensatory	B-X
reductions	B-X
of	B-X
rates	B-X
for	B-X
both	B-X
modification	B-X
reactions	B-X
,	B-X
mitigation	B-X
of	B-X
effects	B-X
of	B-X
slower	B-X
reactions	B-X
by	B-X
the	B-X
intertwined	B-X
circuitry	B-X
of	B-X
signaling	B-X
and	B-X
adaptation	B-X
,	B-X
or	B-X
tolerance	B-X
of	B-X
a	B-X
range	B-X
of	B-X
reactions	B-X
rates	B-X
for	B-X
adaptational	B-X
modification	B-X
.	B-X
Specific	B-X
glutamyl	B-X
residues	B-X
are	B-X
methylated	B-X
and	B-X
demethylated	B-X
in	B-X
reactions	B-X
catalyzed	B-X
by	B-X
methyltransferase	B-X
CheR	B-X
and	B-X
methylesterase	B-X
CheB	B-X
.	B-X
For	B-X
CheR-catalyzed	B-X
methylation	B-X
,	B-X
previous	B-X
work	B-X
demonstrated	B-X
that	B-X
this	B-X
sequence	B-X
acts	B-X
as	B-X
a	B-X
high	B-X
affinity	B-X
docking	B-X
site	B-X
,	B-X
enhancing	B-X
methylation	B-X
by	B-X
increasing	B-X
enzyme	B-X
concentration	B-X
near	B-X
methyl-accepting	B-X
glutamates	B-X
.	B-X
We	B-X
investigated	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
CheB-catalyzed	B-X
demethylation	B-X
and	B-X
found	B-X
it	B-X
occurred	B-X
by	B-X
a	B-X
distinctly	B-X
different	B-X
mechanism	B-X
.	B-X
Assays	B-X
of	B-X
binding	B-X
between	B-X
CheB	B-X
and	B-X
the	B-X
pentapeptide	B-X
sequence	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
too	B-X
weak	B-X
to	B-X
have	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
local	B-X
enzyme	B-X
concentration	B-X
.	B-X
Kinetic	B-X
analyses	B-X
revealed	B-X
that	B-X
interaction	B-X
of	B-X
the	B-X
sequence	B-X
and	B-X
the	B-X
methylesterase	B-X
enhanced	B-X
the	B-X
rate	B-X
constant	B-X
of	B-X
demethylation	B-X
not	B-X
the	B-X
Michaelis	B-X
constant	B-X
.	B-X

In	O
the	O
well	O
-	O
characterized	O
chemosensory	O
systems	O
of	O
Escherichia	O
coli	O
and	O
Salmonella	O
spp	O
.	O
,	O
efficient	O
modification	O
by	O
either	O
enzyme	O
is	O
dependent	O
on	O
a	O
conserved	O
pentapeptide	O
sequence	O
,	O
NWETF	O
or	O
NWESF	O
,	O
present	O
at	O
the	O
extreme	O
carboxyl	O
terminus	O
of	O
high	O
-	O
abundance	O
chemoreceptors	O
.	O
<EOS>	B-X
Sensory	B-X
adaptation	B-X
in	B-X
bacterial	B-X
chemotaxis	B-X
is	B-X
mediated	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
chemoreceptors	B-X
.	B-X
In	B-X
the	B-X
well-characterized	B-X
chemosensory	B-X
systems	B-X
of	B-X
Escherichia	B-X
coli	B-X
and	B-X
Salmonella	B-X
spp.	B-X
,	B-X
efficient	B-X
modification	B-X
by	B-X
either	B-X
enzyme	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
conserved	B-X
pentapeptide	B-X
sequence	B-X
,	B-X
NWETF	B-X
or	B-X
NWESF	B-X
,	B-X
present	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
of	B-X
high-abundance	B-X
chemoreceptors	B-X
.	B-X
To	B-X
what	B-X
extent	B-X
is	B-X
position	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
important	B-X
for	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
adaptational	B-X
modification	B-X
?	B-X
Is	B-X
this	B-X
position	B-X
equally	B-X
important	B-X
for	B-X
enhancement	B-X
of	B-X
both	B-X
enzyme	B-X
activities	B-X
?	B-X
To	B-X
address	B-X
these	B-X
questions	B-X
,	B-X
we	B-X
created	B-X
forms	B-X
of	B-X
high-abundance	B-X
receptor	B-X
Tsr	B-X
or	B-X
Tar	B-X
carrying	B-X
one	B-X
,	B-X
six	B-X
,	B-X
or	B-X
eight	B-X
additional	B-X
amino	B-X
acids	B-X
extending	B-X
beyond	B-X
the	B-X
pentapeptide	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
and	B-X
assayed	B-X
methylation	B-X
,	B-X
demethylation	B-X
,	B-X
deamidation	B-X
,	B-X
and	B-X
ability	B-X
to	B-X
mediate	B-X
chemotaxis	B-X
.	B-X
In	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
all	B-X
three	B-X
carboxyl-terminal	B-X
extensions	B-X
reduced	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
rates	B-X
of	B-X
adaptational	B-X
modification	B-X
.	B-X
Effects	B-X
were	B-X
less	B-X
severe	B-X
for	B-X
the	B-X
complete	B-X
sensory	B-X
system	B-X
in	B-X
vivo	B-X
than	B-X
for	B-X
the	B-X
minimal	B-X
system	B-X
of	B-X
receptor	B-X
and	B-X
modification	B-X
enzymes	B-X
in	B-X
vitro	B-X
.	B-X
Notably	B-X
,	B-X
extended	B-X
receptors	B-X
mediated	B-X
chemotaxis	B-X
as	B-X
efficiently	B-X
as	B-X
wild-type	B-X
receptors	B-X
,	B-X
providing	B-X
a	B-X
striking	B-X
example	B-X
of	B-X
robustness	B-X
in	B-X
chemotactic	B-X
systems	B-X
.	B-X
This	B-X
could	B-X
reflect	B-X
compensatory	B-X
reductions	B-X
of	B-X
rates	B-X
for	B-X
both	B-X
modification	B-X
reactions	B-X
,	B-X
mitigation	B-X
of	B-X
effects	B-X
of	B-X
slower	B-X
reactions	B-X
by	B-X
the	B-X
intertwined	B-X
circuitry	B-X
of	B-X
signaling	B-X
and	B-X
adaptation	B-X
,	B-X
or	B-X
tolerance	B-X
of	B-X
a	B-X
range	B-X
of	B-X
reactions	B-X
rates	B-X
for	B-X
adaptational	B-X
modification	B-X
.	B-X

To	O
what	O
extent	O
is	O
position	O
at	O
the	O
extreme	O
carboxyl	O
terminus	O
important	O
for	O
pentapeptide	O
-	O
mediated	O
enhancement	O
of	O
adaptational	O
modification	O
?	O
<EOS>	B-X
Sensory	B-X
adaptation	B-X
in	B-X
bacterial	B-X
chemotaxis	B-X
is	B-X
mediated	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
chemoreceptors	B-X
.	B-X
In	B-X
the	B-X
well-characterized	B-X
chemosensory	B-X
systems	B-X
of	B-X
Escherichia	B-X
coli	B-X
and	B-X
Salmonella	B-X
spp.	B-X
,	B-X
efficient	B-X
modification	B-X
by	B-X
either	B-X
enzyme	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
conserved	B-X
pentapeptide	B-X
sequence	B-X
,	B-X
NWETF	B-X
or	B-X
NWESF	B-X
,	B-X
present	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
of	B-X
high-abundance	B-X
chemoreceptors	B-X
.	B-X
To	B-X
what	B-X
extent	B-X
is	B-X
position	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
important	B-X
for	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
adaptational	B-X
modification	B-X
?	B-X
Is	B-X
this	B-X
position	B-X
equally	B-X
important	B-X
for	B-X
enhancement	B-X
of	B-X
both	B-X
enzyme	B-X
activities	B-X
?	B-X
To	B-X
address	B-X
these	B-X
questions	B-X
,	B-X
we	B-X
created	B-X
forms	B-X
of	B-X
high-abundance	B-X
receptor	B-X
Tsr	B-X
or	B-X
Tar	B-X
carrying	B-X
one	B-X
,	B-X
six	B-X
,	B-X
or	B-X
eight	B-X
additional	B-X
amino	B-X
acids	B-X
extending	B-X
beyond	B-X
the	B-X
pentapeptide	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
and	B-X
assayed	B-X
methylation	B-X
,	B-X
demethylation	B-X
,	B-X
deamidation	B-X
,	B-X
and	B-X
ability	B-X
to	B-X
mediate	B-X
chemotaxis	B-X
.	B-X
In	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
all	B-X
three	B-X
carboxyl-terminal	B-X
extensions	B-X
reduced	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
rates	B-X
of	B-X
adaptational	B-X
modification	B-X
.	B-X
Effects	B-X
were	B-X
less	B-X
severe	B-X
for	B-X
the	B-X
complete	B-X
sensory	B-X
system	B-X
in	B-X
vivo	B-X
than	B-X
for	B-X
the	B-X
minimal	B-X
system	B-X
of	B-X
receptor	B-X
and	B-X
modification	B-X
enzymes	B-X
in	B-X
vitro	B-X
.	B-X
Notably	B-X
,	B-X
extended	B-X
receptors	B-X
mediated	B-X
chemotaxis	B-X
as	B-X
efficiently	B-X
as	B-X
wild-type	B-X
receptors	B-X
,	B-X
providing	B-X
a	B-X
striking	B-X
example	B-X
of	B-X
robustness	B-X
in	B-X
chemotactic	B-X
systems	B-X
.	B-X
This	B-X
could	B-X
reflect	B-X
compensatory	B-X
reductions	B-X
of	B-X
rates	B-X
for	B-X
both	B-X
modification	B-X
reactions	B-X
,	B-X
mitigation	B-X
of	B-X
effects	B-X
of	B-X
slower	B-X
reactions	B-X
by	B-X
the	B-X
intertwined	B-X
circuitry	B-X
of	B-X
signaling	B-X
and	B-X
adaptation	B-X
,	B-X
or	B-X
tolerance	B-X
of	B-X
a	B-X
range	B-X
of	B-X
reactions	B-X
rates	B-X
for	B-X
adaptational	B-X
modification	B-X
.	B-X

Is	O
this	O
position	O
equally	O
important	O
for	O
enhancement	O
of	O
both	O
enzyme	O
activities	O
?	O
<EOS>	B-X
Norfloxacin	B-X
is	B-X
an	B-X
orally	B-X
absorbed	B-X
fluoroquinolone	B-X
antibacterial	B-X
with	B-X
a	B-X
fluorine	B-X
at	B-X
position	B-X
6	B-X
and	B-X
a	B-X
piperazine	B-X
ring	B-X
at	B-X
position	B-X
7	B-X
.	B-X
These	B-X
changes	B-X
have	B-X
resulted	B-X
in	B-X
a	B-X
marked	B-X
enhancement	B-X
(	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
the	B-X
older	B-X
quinolones	B-X
)	B-X
of	B-X
in	B-X
vitro	B-X
antibacterial	B-X
activity	B-X
.	B-X
The	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
norfloxacin	B-X
involves	B-X
inhibition	B-X
of	B-X
the	B-X
A	B-X
subunit	B-X
of	B-X
the	B-X
important	B-X
bacterial	B-X
enzyme	B-X
DNA	B-X
gyrase	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
DNA	B-X
replication	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
regular	B-X
exercise	B-X
enhances	B-X
antioxidative	B-X
enzymes	B-X
in	B-X
pregnant	B-X
women	B-X
,	B-X
which	B-X
reduce	B-X
oxidative	B-X
stress	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
the	B-X
incidence	B-X
of	B-X
preeclampsia	B-X
.	B-X
In	B-X
humans	B-X
,	B-X
training	B-X
effects	B-X
have	B-X
been	B-X
identified	B-X
with	B-X
an	B-X
enhanced	B-X
activity	B-X
of	B-X
antioxidative	B-X
enzymes	B-X
.	B-X
Equally	B-X
important	B-X
is	B-X
a	B-X
training	B-X
effect	B-X
that	B-X
decreases	B-X
susceptibility	B-X
to	B-X
lipid	B-X
peroxidation	B-X
.	B-X
In	B-X
theory	B-X
,	B-X
intracellular	B-X
and	B-X
extracellular	B-X
conditions	B-X
resulting	B-X
from	B-X
regular	B-X
exercise	B-X
should	B-X
counteract	B-X
the	B-X
enhancement	B-X
of	B-X
oxidative	B-X
stress	B-X
,	B-X
thus	B-X
interfering	B-X
with	B-X
the	B-X
process	B-X
leading	B-X
to	B-X
endothelial	B-X
dysfunction	B-X
.	B-X
This	B-X
position	B-X
paper	B-X
describes	B-X
a	B-X
hypothesis	B-X
and	B-X
includes	B-X
a	B-X
brief	B-X
review	B-X
of	B-X
exercise	B-X
physiology	B-X
and	B-X
biochemical	B-X
research	B-X
in	B-X
preeclampsia	B-X
.	B-X

To	O
address	O
these	O
questions	O
,	O
we	O
created	O
forms	O
of	O
high	O
-	O
abundance	O
receptor	O
Tsr	B-Protein
or	O
Tar	B-Protein
carrying	O
one	O
,	O
six	O
,	O
or	O
eight	O
additional	O
amino	O
acids	O
extending	O
beyond	O
the	O
pentapeptide	O
at	O
their	O
carboxyl	O
termini	O
and	O
assayed	O
methylation	O
,	O
demethylation	O
,	O
deamidation	O
,	O
and	O
ability	O
to	O
mediate	O
chemotaxis	O
.	O
<EOS>	B-X
Seborrhea	B-X
dermatitis	B-X
is	B-X
a	B-X
skin	B-X
disorder	B-X
that	B-X
usually	B-X
appears	B-X
on	B-X
parts	B-X
of	B-X
the	B-X
body	B-X
that	B-X
have	B-X
high	B-X
density	B-X
of	B-X
sebaceous	B-X
glands	B-X
,	B-X
such	B-X
as	B-X
the	B-X
face	B-X
,	B-X
chest	B-X
,	B-X
and	B-X
scalp	B-X
.	B-X
Seborrhea	B-X
dermatitis	B-X
is	B-X
also	B-X
known	B-X
as	B-X
one	B-X
of	B-X
the	B-X
causes	B-X
of	B-X
alopecia	B-X
.	B-X
Of	B-X
the	B-X
25	B-X
articles	B-X
,	B-X
six	B-X
were	B-X
clinical	B-X
trials	B-X
,	B-X
while	B-X
19	B-X
were	B-X
in	B-X
vitro	B-X
studies	B-X
of	B-X
Malassezia	B-X
.	B-X
Sensory	B-X
adaptation	B-X
in	B-X
bacterial	B-X
chemotaxis	B-X
is	B-X
mediated	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
chemoreceptors	B-X
.	B-X
In	B-X
the	B-X
well-characterized	B-X
chemosensory	B-X
systems	B-X
of	B-X
Escherichia	B-X
coli	B-X
and	B-X
Salmonella	B-X
spp.	B-X
,	B-X
efficient	B-X
modification	B-X
by	B-X
either	B-X
enzyme	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
conserved	B-X
pentapeptide	B-X
sequence	B-X
,	B-X
NWETF	B-X
or	B-X
NWESF	B-X
,	B-X
present	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
of	B-X
high-abundance	B-X
chemoreceptors	B-X
.	B-X
To	B-X
what	B-X
extent	B-X
is	B-X
position	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
important	B-X
for	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
adaptational	B-X
modification	B-X
?	B-X
To	B-X
address	B-X
these	B-X
questions	B-X
,	B-X
we	B-X
created	B-X
forms	B-X
of	B-X
high-abundance	B-X
receptor	B-X
Tsr	B-X
or	B-X
Tar	B-X
carrying	B-X
one	B-X
,	B-X
six	B-X
,	B-X
or	B-X
eight	B-X
additional	B-X
amino	B-X
acids	B-X
extending	B-X
beyond	B-X
the	B-X
pentapeptide	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
and	B-X
assayed	B-X
methylation	B-X
,	B-X
demethylation	B-X
,	B-X
deamidation	B-X
,	B-X
and	B-X
ability	B-X
to	B-X
mediate	B-X
chemotaxis	B-X
.	B-X
In	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
all	B-X
three	B-X
carboxyl-terminal	B-X
extensions	B-X
reduced	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
rates	B-X
of	B-X
adaptational	B-X
modification	B-X
.	B-X
Effects	B-X
were	B-X
less	B-X
severe	B-X
for	B-X
the	B-X
complete	B-X
sensory	B-X
system	B-X
in	B-X
vivo	B-X
than	B-X
for	B-X
the	B-X
minimal	B-X
system	B-X
of	B-X
receptor	B-X
and	B-X
modification	B-X
enzymes	B-X
in	B-X
vitro	B-X
.	B-X
Notably	B-X
,	B-X
extended	B-X
receptors	B-X
mediated	B-X
chemotaxis	B-X
as	B-X
efficiently	B-X
as	B-X
wild-type	B-X
receptors	B-X
,	B-X
providing	B-X
a	B-X
striking	B-X
example	B-X
of	B-X
robustness	B-X
in	B-X
chemotactic	B-X
systems	B-X
.	B-X
No	B-X
matter	B-X
what	B-X
the	B-X
mechanism	B-X
,	B-X
the	B-X
observations	B-X
provide	B-X
a	B-X
challenging	B-X
test	B-X
for	B-X
mathematical	B-X
models	B-X
of	B-X
chemotaxis	B-X
.	B-X

In	O
vitro	O
and	O
in	O
vivo	O
,	O
all	O
three	O
carboxyl	O
-	O
terminal	O
extensions	O
reduced	O
pentapeptide	O
-	O
mediated	O
enhancement	O
of	O
rates	O
of	O
adaptational	O
modification	O
.	O
<EOS>	B-X
Sensory	B-X
adaptation	B-X
in	B-X
bacterial	B-X
chemotaxis	B-X
is	B-X
mediated	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
chemoreceptors	B-X
.	B-X
In	B-X
the	B-X
well-characterized	B-X
chemosensory	B-X
systems	B-X
of	B-X
Escherichia	B-X
coli	B-X
and	B-X
Salmonella	B-X
spp.	B-X
,	B-X
efficient	B-X
modification	B-X
by	B-X
either	B-X
enzyme	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
conserved	B-X
pentapeptide	B-X
sequence	B-X
,	B-X
NWETF	B-X
or	B-X
NWESF	B-X
,	B-X
present	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
of	B-X
high-abundance	B-X
chemoreceptors	B-X
.	B-X
To	B-X
what	B-X
extent	B-X
is	B-X
position	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
important	B-X
for	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
adaptational	B-X
modification	B-X
?	B-X
Is	B-X
this	B-X
position	B-X
equally	B-X
important	B-X
for	B-X
enhancement	B-X
of	B-X
both	B-X
enzyme	B-X
activities	B-X
?	B-X
To	B-X
address	B-X
these	B-X
questions	B-X
,	B-X
we	B-X
created	B-X
forms	B-X
of	B-X
high-abundance	B-X
receptor	B-X
Tsr	B-X
or	B-X
Tar	B-X
carrying	B-X
one	B-X
,	B-X
six	B-X
,	B-X
or	B-X
eight	B-X
additional	B-X
amino	B-X
acids	B-X
extending	B-X
beyond	B-X
the	B-X
pentapeptide	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
and	B-X
assayed	B-X
methylation	B-X
,	B-X
demethylation	B-X
,	B-X
deamidation	B-X
,	B-X
and	B-X
ability	B-X
to	B-X
mediate	B-X
chemotaxis	B-X
.	B-X
In	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
all	B-X
three	B-X
carboxyl-terminal	B-X
extensions	B-X
reduced	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
rates	B-X
of	B-X
adaptational	B-X
modification	B-X
.	B-X
Effects	B-X
were	B-X
less	B-X
severe	B-X
for	B-X
the	B-X
complete	B-X
sensory	B-X
system	B-X
in	B-X
vivo	B-X
than	B-X
for	B-X
the	B-X
minimal	B-X
system	B-X
of	B-X
receptor	B-X
and	B-X
modification	B-X
enzymes	B-X
in	B-X
vitro	B-X
.	B-X
Notably	B-X
,	B-X
extended	B-X
receptors	B-X
mediated	B-X
chemotaxis	B-X
as	B-X
efficiently	B-X
as	B-X
wild-type	B-X
receptors	B-X
,	B-X
providing	B-X
a	B-X
striking	B-X
example	B-X
of	B-X
robustness	B-X
in	B-X
chemotactic	B-X
systems	B-X
.	B-X
This	B-X
could	B-X
reflect	B-X
compensatory	B-X
reductions	B-X
of	B-X
rates	B-X
for	B-X
both	B-X
modification	B-X
reactions	B-X
,	B-X
mitigation	B-X
of	B-X
effects	B-X
of	B-X
slower	B-X
reactions	B-X
by	B-X
the	B-X
intertwined	B-X
circuitry	B-X
of	B-X
signaling	B-X
and	B-X
adaptation	B-X
,	B-X
or	B-X
tolerance	B-X
of	B-X
a	B-X
range	B-X
of	B-X
reactions	B-X
rates	B-X
for	B-X
adaptational	B-X
modification	B-X
.	B-X

CheB	B-Protein
-	O
catalyzed	O
reactions	O
were	O
more	O
affected	O
than	O
CheR	B-Protein
-	O
catalyzed	O
reactions	O
.	O
<EOS>	B-X
Specific	B-X
glutamyl	B-X
residues	B-X
are	B-X
methylated	B-X
and	B-X
demethylated	B-X
in	B-X
reactions	B-X
catalyzed	B-X
by	B-X
methyltransferase	B-X
CheR	B-X
and	B-X
methylesterase	B-X
CheB	B-X
.	B-X
CheB-catalyzed	B-X
reactions	B-X
were	B-X
more	B-X
affected	B-X
than	B-X
CheR-catalyzed	B-X
reactions	B-X
.	B-X
This	B-X
could	B-X
reflect	B-X
compensatory	B-X
reductions	B-X
of	B-X
rates	B-X
for	B-X
both	B-X
modification	B-X
reactions	B-X
,	B-X
mitigation	B-X
of	B-X
effects	B-X
of	B-X
slower	B-X
reactions	B-X
by	B-X
the	B-X
intertwined	B-X
circuitry	B-X
of	B-X
signaling	B-X
and	B-X
adaptation	B-X
,	B-X
or	B-X
tolerance	B-X
of	B-X
a	B-X
range	B-X
of	B-X
reactions	B-X
rates	B-X
for	B-X
adaptational	B-X
modification	B-X
.	B-X

Effects	O
were	O
less	O
severe	O
for	O
the	O
complete	O
sensory	O
system	O
in	O
vivo	O
than	O
for	O
the	O
minimal	O
system	O
of	O
receptor	O
and	O
modification	O
enzymes	O
in	O
vitro	O
.	O
<EOS>	B-X
Sensory	B-X
adaptation	B-X
in	B-X
bacterial	B-X
chemotaxis	B-X
is	B-X
mediated	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
chemoreceptors	B-X
.	B-X
In	B-X
the	B-X
well-characterized	B-X
chemosensory	B-X
systems	B-X
of	B-X
Escherichia	B-X
coli	B-X
and	B-X
Salmonella	B-X
spp.	B-X
,	B-X
efficient	B-X
modification	B-X
by	B-X
either	B-X
enzyme	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
conserved	B-X
pentapeptide	B-X
sequence	B-X
,	B-X
NWETF	B-X
or	B-X
NWESF	B-X
,	B-X
present	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
of	B-X
high-abundance	B-X
chemoreceptors	B-X
.	B-X
To	B-X
what	B-X
extent	B-X
is	B-X
position	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
important	B-X
for	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
adaptational	B-X
modification	B-X
?	B-X
To	B-X
address	B-X
these	B-X
questions	B-X
,	B-X
we	B-X
created	B-X
forms	B-X
of	B-X
high-abundance	B-X
receptor	B-X
Tsr	B-X
or	B-X
Tar	B-X
carrying	B-X
one	B-X
,	B-X
six	B-X
,	B-X
or	B-X
eight	B-X
additional	B-X
amino	B-X
acids	B-X
extending	B-X
beyond	B-X
the	B-X
pentapeptide	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
and	B-X
assayed	B-X
methylation	B-X
,	B-X
demethylation	B-X
,	B-X
deamidation	B-X
,	B-X
and	B-X
ability	B-X
to	B-X
mediate	B-X
chemotaxis	B-X
.	B-X
In	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
all	B-X
three	B-X
carboxyl-terminal	B-X
extensions	B-X
reduced	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
rates	B-X
of	B-X
adaptational	B-X
modification	B-X
.	B-X
Effects	B-X
were	B-X
less	B-X
severe	B-X
for	B-X
the	B-X
complete	B-X
sensory	B-X
system	B-X
in	B-X
vivo	B-X
than	B-X
for	B-X
the	B-X
minimal	B-X
system	B-X
of	B-X
receptor	B-X
and	B-X
modification	B-X
enzymes	B-X
in	B-X
vitro	B-X
.	B-X
Notably	B-X
,	B-X
extended	B-X
receptors	B-X
mediated	B-X
chemotaxis	B-X
as	B-X
efficiently	B-X
as	B-X
wild-type	B-X
receptors	B-X
,	B-X
providing	B-X
a	B-X
striking	B-X
example	B-X
of	B-X
robustness	B-X
in	B-X
chemotactic	B-X
systems	B-X
.	B-X
This	B-X
could	B-X
reflect	B-X
compensatory	B-X
reductions	B-X
of	B-X
rates	B-X
for	B-X
both	B-X
modification	B-X
reactions	B-X
,	B-X
mitigation	B-X
of	B-X
effects	B-X
of	B-X
slower	B-X
reactions	B-X
by	B-X
the	B-X
intertwined	B-X
circuitry	B-X
of	B-X
signaling	B-X
and	B-X
adaptation	B-X
,	B-X
or	B-X
tolerance	B-X
of	B-X
a	B-X
range	B-X
of	B-X
reactions	B-X
rates	B-X
for	B-X
adaptational	B-X
modification	B-X
.	B-X

Notably	O
,	O
extended	O
receptors	O
mediated	O
chemotaxis	O
as	O
efficiently	O
as	O
wild	O
-	O
type	O
receptors	O
,	O
providing	O
a	O
striking	O
example	O
of	O
robustness	O
in	O
chemotactic	O
systems	O
.	O
<EOS>	B-X
Sensory	B-X
adaptation	B-X
in	B-X
bacterial	B-X
chemotaxis	B-X
is	B-X
mediated	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
chemoreceptors	B-X
.	B-X
In	B-X
the	B-X
well-characterized	B-X
chemosensory	B-X
systems	B-X
of	B-X
Escherichia	B-X
coli	B-X
and	B-X
Salmonella	B-X
spp.	B-X
,	B-X
efficient	B-X
modification	B-X
by	B-X
either	B-X
enzyme	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
conserved	B-X
pentapeptide	B-X
sequence	B-X
,	B-X
NWETF	B-X
or	B-X
NWESF	B-X
,	B-X
present	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
of	B-X
high-abundance	B-X
chemoreceptors	B-X
.	B-X
To	B-X
what	B-X
extent	B-X
is	B-X
position	B-X
at	B-X
the	B-X
extreme	B-X
carboxyl	B-X
terminus	B-X
important	B-X
for	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
adaptational	B-X
modification	B-X
?	B-X
To	B-X
address	B-X
these	B-X
questions	B-X
,	B-X
we	B-X
created	B-X
forms	B-X
of	B-X
high-abundance	B-X
receptor	B-X
Tsr	B-X
or	B-X
Tar	B-X
carrying	B-X
one	B-X
,	B-X
six	B-X
,	B-X
or	B-X
eight	B-X
additional	B-X
amino	B-X
acids	B-X
extending	B-X
beyond	B-X
the	B-X
pentapeptide	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
and	B-X
assayed	B-X
methylation	B-X
,	B-X
demethylation	B-X
,	B-X
deamidation	B-X
,	B-X
and	B-X
ability	B-X
to	B-X
mediate	B-X
chemotaxis	B-X
.	B-X
In	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
all	B-X
three	B-X
carboxyl-terminal	B-X
extensions	B-X
reduced	B-X
pentapeptide-mediated	B-X
enhancement	B-X
of	B-X
rates	B-X
of	B-X
adaptational	B-X
modification	B-X
.	B-X
Notably	B-X
,	B-X
extended	B-X
receptors	B-X
mediated	B-X
chemotaxis	B-X
as	B-X
efficiently	B-X
as	B-X
wild-type	B-X
receptors	B-X
,	B-X
providing	B-X
a	B-X
striking	B-X
example	B-X
of	B-X
robustness	B-X
in	B-X
chemotactic	B-X
systems	B-X
.	B-X
No	B-X
matter	B-X
what	B-X
the	B-X
mechanism	B-X
,	B-X
the	B-X
observations	B-X
provide	B-X
a	B-X
challenging	B-X
test	B-X
for	B-X
mathematical	B-X
models	B-X
of	B-X
chemotaxis	B-X
.	B-X

This	O
could	O
reflect	O
compensatory	O
reductions	O
of	O
rates	O
for	O
both	O
modification	O
reactions	O
,	O
mitigation	O
of	O
effects	O
of	O
slower	O
reactions	O
by	O
the	O
intertwined	O
circuitry	O
of	O
signaling	O
and	O
adaptation	O
,	O
or	O
tolerance	O
of	O
a	O
range	O
of	O
reactions	O
rates	O
for	O
adaptational	O
modification	O
.	O
<EOS>	B-X
Enzymes	B-X
,	B-X
in	B-X
general	B-X
,	B-X
get	B-X
inactivated	B-X
or	B-X
give	B-X
very	B-X
low	B-X
rates	B-X
of	B-X
reaction	B-X
in	B-X
non-aqueous	B-X
media	B-X
.	B-X
Thus	B-X
,	B-X
early	B-X
efforts	B-X
,	B-X
and	B-X
even	B-X
some	B-X
recent	B-X
ones	B-X
,	B-X
have	B-X
aimed	B-X
at	B-X
stabilization	B-X
of	B-X
enzymes	B-X
in	B-X
organic	B-X
media	B-X
by	B-X
immobilization	B-X
,	B-X
surface	B-X
modifications	B-X
,	B-X
mutagenesis	B-X
,	B-X
and	B-X
protein	B-X
engineering	B-X
.	B-X
Enzymes	B-X
from	B-X
solvent-tolerant	B-X
microbes	B-X
appear	B-X
to	B-X
be	B-X
the	B-X
choicest	B-X
source	B-X
for	B-X
studying	B-X
solvent-stable	B-X
enzymes	B-X
because	B-X
of	B-X
their	B-X
unique	B-X
ability	B-X
to	B-X
survive	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
range	B-X
of	B-X
organic	B-X
solvents	B-X
.	B-X
These	B-X
bacteria	B-X
circumvent	B-X
the	B-X
solvent	B-X
's	B-X
toxic	B-X
effects	B-X
by	B-X
virtue	B-X
of	B-X
various	B-X
adaptations	B-X
,	B-X
e.g	B-X
.	B-X
The	B-X
unique	B-X
properties	B-X
of	B-X
these	B-X
novel	B-X
biocatalysts	B-X
have	B-X
great	B-X
potential	B-X
for	B-X
applications	B-X
in	B-X
non-aqueous	B-X
enzymology	B-X
for	B-X
a	B-X
range	B-X
of	B-X
industrial	B-X
processes	B-X
.	B-X

No	O
matter	O
what	O
the	O
mechanism	O
,	O
the	O
observations	O
provide	O
a	O
challenging	O
test	O
for	O
mathematical	O
models	O
of	O
chemotaxis	O
.	O
<EOS>	B-X
Sensory	B-X
adaptation	B-X
in	B-X
bacterial	B-X
chemotaxis	B-X
is	B-X
mediated	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
chemoreceptors	B-X
.	B-X
To	B-X
address	B-X
these	B-X
questions	B-X
,	B-X
we	B-X
created	B-X
forms	B-X
of	B-X
high-abundance	B-X
receptor	B-X
Tsr	B-X
or	B-X
Tar	B-X
carrying	B-X
one	B-X
,	B-X
six	B-X
,	B-X
or	B-X
eight	B-X
additional	B-X
amino	B-X
acids	B-X
extending	B-X
beyond	B-X
the	B-X
pentapeptide	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
and	B-X
assayed	B-X
methylation	B-X
,	B-X
demethylation	B-X
,	B-X
deamidation	B-X
,	B-X
and	B-X
ability	B-X
to	B-X
mediate	B-X
chemotaxis	B-X
.	B-X
Notably	B-X
,	B-X
extended	B-X
receptors	B-X
mediated	B-X
chemotaxis	B-X
as	B-X
efficiently	B-X
as	B-X
wild-type	B-X
receptors	B-X
,	B-X
providing	B-X
a	B-X
striking	B-X
example	B-X
of	B-X
robustness	B-X
in	B-X
chemotactic	B-X
systems	B-X
.	B-X
No	B-X
matter	B-X
what	B-X
the	B-X
mechanism	B-X
,	B-X
the	B-X
observations	B-X
provide	B-X
a	B-X
challenging	B-X
test	B-X
for	B-X
mathematical	B-X
models	B-X
of	B-X
chemotaxis	B-X
.	B-X

Dimethylation	O
of	O
histone	B-Protein
H3	I-Protein
at	O
lysine	O
36	O
demarcates	O
regulatory	O
and	O
nonregulatory	O
chromatin	O
genome	O
-	O
wide	O
.	O
<EOS>	B-X
Set2p	B-X
,	B-X
which	B-X
mediates	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
dimethylation	B-X
(	B-X
H3K36me2	B-X
)	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
associate	B-X
with	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAP	B-X
II	B-X
)	B-X
at	B-X
individual	B-X
loci	B-X
.	B-X
Here	B-X
,	B-X
chromatin	B-X
immunoprecipitation-microarray	B-X
experiments	B-X
normalized	B-X
to	B-X
general	B-X
nucleosome	B-X
occupancy	B-X
reveal	B-X
that	B-X
nucleosomes	B-X
within	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
and	B-X
downstream	B-X
noncoding	B-X
chromatin	B-X
were	B-X
highly	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
and	B-X
that	B-X
Set2p	B-X
activity	B-X
begins	B-X
at	B-X
a	B-X
stereotypic	B-X
distance	B-X
from	B-X
the	B-X
initiation	B-X
of	B-X
transcription	B-X
genome-wide	B-X
.	B-X
H3K36me2	B-X
is	B-X
scarce	B-X
in	B-X
regions	B-X
upstream	B-X
of	B-X
divergently	B-X
transcribed	B-X
genes	B-X
,	B-X
telomeres	B-X
,	B-X
silenced	B-X
mating	B-X
loci	B-X
,	B-X
and	B-X
regions	B-X
transcribed	B-X
by	B-X
RNA	B-X
polymerase	B-X
III	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
Set2p	B-X
is	B-X
restricted	B-X
to	B-X
its	B-X
association	B-X
with	B-X
RNAP	B-X
II	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
H3K36me2	B-X
within	B-X
ORFs	B-X
correlated	B-X
with	B-X
the	B-X
``	B-X
on	B-X
''	B-X
or	B-X
``	B-X
off	B-X
''	B-X
state	B-X
of	B-X
transcription	B-X
,	B-X
but	B-X
the	B-X
degree	B-X
of	B-X
H3K36	B-X
dimethylation	B-X
within	B-X
ORFs	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
transcription	B-X
frequency	B-X
.	B-X
This	B-X
provides	B-X
evidence	B-X
that	B-X
H3K36me2	B-X
is	B-X
established	B-X
during	B-X
the	B-X
initial	B-X
instances	B-X
of	B-X
gene	B-X
transcription	B-X
,	B-X
with	B-X
subsequent	B-X
transcription	B-X
having	B-X
at	B-X
most	B-X
a	B-X
maintenance	B-X
role	B-X
.	B-X
Accordingly	B-X
,	B-X
newly	B-X
activated	B-X
genes	B-X
acquire	B-X
H3K36me2	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
gene	B-X
transcript	B-X
levels	B-X
.	B-X
Finally	B-X
,	B-X
nucleosomes	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
appear	B-X
to	B-X
be	B-X
refractory	B-X
to	B-X
loss	B-X
from	B-X
highly	B-X
transcribed	B-X
chromatin	B-X
.	B-X
Thus	B-X
,	B-X
H3K36me2	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
conserved	B-X
throughout	B-X
eukaryotic	B-X
evolution	B-X
,	B-X
provides	B-X
a	B-X
stable	B-X
molecular	B-X
mechanism	B-X
for	B-X
establishing	B-X
chromatin	B-X
context	B-X
throughout	B-X
the	B-X
genome	B-X
by	B-X
distinguishing	B-X
potential	B-X
regulatory	B-X
regions	B-X
from	B-X
transcribed	B-X
chromatin	B-X
.	B-X

Set2p	B-Protein
,	O
which	O
mediates	O
histone	B-Protein
H3	I-Protein
lysine	O
36	O
dimethylation	O
(	O
H3K36me2	B-Protein
)	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
has	O
been	O
shown	O
to	O
associate	O
with	O
RNA	O
polymerase	O
II	O
(	O
RNAP	O
II	O
)	O
at	O
individual	O
loci	O
.	O
<EOS>	B-X
Set2p	B-X
,	B-X
which	B-X
mediates	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
dimethylation	B-X
(	B-X
H3K36me2	B-X
)	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
associate	B-X
with	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAP	B-X
II	B-X
)	B-X
at	B-X
individual	B-X
loci	B-X
.	B-X
Here	B-X
,	B-X
chromatin	B-X
immunoprecipitation-microarray	B-X
experiments	B-X
normalized	B-X
to	B-X
general	B-X
nucleosome	B-X
occupancy	B-X
reveal	B-X
that	B-X
nucleosomes	B-X
within	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
and	B-X
downstream	B-X
noncoding	B-X
chromatin	B-X
were	B-X
highly	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
and	B-X
that	B-X
Set2p	B-X
activity	B-X
begins	B-X
at	B-X
a	B-X
stereotypic	B-X
distance	B-X
from	B-X
the	B-X
initiation	B-X
of	B-X
transcription	B-X
genome-wide	B-X
.	B-X
H3K36me2	B-X
is	B-X
scarce	B-X
in	B-X
regions	B-X
upstream	B-X
of	B-X
divergently	B-X
transcribed	B-X
genes	B-X
,	B-X
telomeres	B-X
,	B-X
silenced	B-X
mating	B-X
loci	B-X
,	B-X
and	B-X
regions	B-X
transcribed	B-X
by	B-X
RNA	B-X
polymerase	B-X
III	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
Set2p	B-X
is	B-X
restricted	B-X
to	B-X
its	B-X
association	B-X
with	B-X
RNAP	B-X
II	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
H3K36me2	B-X
within	B-X
ORFs	B-X
correlated	B-X
with	B-X
the	B-X
``	B-X
on	B-X
''	B-X
or	B-X
``	B-X
off	B-X
''	B-X
state	B-X
of	B-X
transcription	B-X
,	B-X
but	B-X
the	B-X
degree	B-X
of	B-X
H3K36	B-X
dimethylation	B-X
within	B-X
ORFs	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
transcription	B-X
frequency	B-X
.	B-X
This	B-X
provides	B-X
evidence	B-X
that	B-X
H3K36me2	B-X
is	B-X
established	B-X
during	B-X
the	B-X
initial	B-X
instances	B-X
of	B-X
gene	B-X
transcription	B-X
,	B-X
with	B-X
subsequent	B-X
transcription	B-X
having	B-X
at	B-X
most	B-X
a	B-X
maintenance	B-X
role	B-X
.	B-X
Accordingly	B-X
,	B-X
newly	B-X
activated	B-X
genes	B-X
acquire	B-X
H3K36me2	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
gene	B-X
transcript	B-X
levels	B-X
.	B-X
Finally	B-X
,	B-X
nucleosomes	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
appear	B-X
to	B-X
be	B-X
refractory	B-X
to	B-X
loss	B-X
from	B-X
highly	B-X
transcribed	B-X
chromatin	B-X
.	B-X
Thus	B-X
,	B-X
H3K36me2	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
conserved	B-X
throughout	B-X
eukaryotic	B-X
evolution	B-X
,	B-X
provides	B-X
a	B-X
stable	B-X
molecular	B-X
mechanism	B-X
for	B-X
establishing	B-X
chromatin	B-X
context	B-X
throughout	B-X
the	B-X
genome	B-X
by	B-X
distinguishing	B-X
potential	B-X
regulatory	B-X
regions	B-X
from	B-X
transcribed	B-X
chromatin	B-X
.	B-X

Here	O
,	O
chromatin	O
immunoprecipitation	O
-	O
microarray	O
experiments	O
normalized	O
to	O
general	O
nucleosome	O
occupancy	O
reveal	O
that	O
nucleosomes	O
within	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
and	O
downstream	O
noncoding	O
chromatin	O
were	O
highly	O
dimethylated	O
at	O
H3K36	B-Protein
and	O
that	O
Set2p	B-Protein
activity	O
begins	O
at	O
a	O
stereotypic	O
distance	O
from	O
the	O
initiation	O
of	O
transcription	O
genome	O
-	O
wide	O
.	O

H3K36me2	B-Protein
is	O
scarce	O
in	O
regions	O
upstream	O
of	O
divergently	O
transcribed	O
genes	O
,	O
telomeres	O
,	O
silenced	O
mating	O
loci	O
,	O
and	O
regions	O
transcribed	O
by	O
RNA	O
polymerase	O
III	O
,	O
providing	O
evidence	O
that	O
the	O
enzymatic	O
activity	O
of	O
Set2p	B-Protein
is	O
restricted	O
to	O
its	O
association	O
with	O
RNAP	O
II	O
.	O
<EOS>	B-X
Set2p	B-X
,	B-X
which	B-X
mediates	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
dimethylation	B-X
(	B-X
H3K36me2	B-X
)	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
associate	B-X
with	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAP	B-X
II	B-X
)	B-X
at	B-X
individual	B-X
loci	B-X
.	B-X
Here	B-X
,	B-X
chromatin	B-X
immunoprecipitation-microarray	B-X
experiments	B-X
normalized	B-X
to	B-X
general	B-X
nucleosome	B-X
occupancy	B-X
reveal	B-X
that	B-X
nucleosomes	B-X
within	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
and	B-X
downstream	B-X
noncoding	B-X
chromatin	B-X
were	B-X
highly	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
and	B-X
that	B-X
Set2p	B-X
activity	B-X
begins	B-X
at	B-X
a	B-X
stereotypic	B-X
distance	B-X
from	B-X
the	B-X
initiation	B-X
of	B-X
transcription	B-X
genome-wide	B-X
.	B-X
H3K36me2	B-X
is	B-X
scarce	B-X
in	B-X
regions	B-X
upstream	B-X
of	B-X
divergently	B-X
transcribed	B-X
genes	B-X
,	B-X
telomeres	B-X
,	B-X
silenced	B-X
mating	B-X
loci	B-X
,	B-X
and	B-X
regions	B-X
transcribed	B-X
by	B-X
RNA	B-X
polymerase	B-X
III	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
Set2p	B-X
is	B-X
restricted	B-X
to	B-X
its	B-X
association	B-X
with	B-X
RNAP	B-X
II	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
H3K36me2	B-X
within	B-X
ORFs	B-X
correlated	B-X
with	B-X
the	B-X
``	B-X
on	B-X
''	B-X
or	B-X
``	B-X
off	B-X
''	B-X
state	B-X
of	B-X
transcription	B-X
,	B-X
but	B-X
the	B-X
degree	B-X
of	B-X
H3K36	B-X
dimethylation	B-X
within	B-X
ORFs	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
transcription	B-X
frequency	B-X
.	B-X
This	B-X
provides	B-X
evidence	B-X
that	B-X
H3K36me2	B-X
is	B-X
established	B-X
during	B-X
the	B-X
initial	B-X
instances	B-X
of	B-X
gene	B-X
transcription	B-X
,	B-X
with	B-X
subsequent	B-X
transcription	B-X
having	B-X
at	B-X
most	B-X
a	B-X
maintenance	B-X
role	B-X
.	B-X
Accordingly	B-X
,	B-X
newly	B-X
activated	B-X
genes	B-X
acquire	B-X
H3K36me2	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
gene	B-X
transcript	B-X
levels	B-X
.	B-X
Finally	B-X
,	B-X
nucleosomes	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
appear	B-X
to	B-X
be	B-X
refractory	B-X
to	B-X
loss	B-X
from	B-X
highly	B-X
transcribed	B-X
chromatin	B-X
.	B-X
Thus	B-X
,	B-X
H3K36me2	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
conserved	B-X
throughout	B-X
eukaryotic	B-X
evolution	B-X
,	B-X
provides	B-X
a	B-X
stable	B-X
molecular	B-X
mechanism	B-X
for	B-X
establishing	B-X
chromatin	B-X
context	B-X
throughout	B-X
the	B-X
genome	B-X
by	B-X
distinguishing	B-X
potential	B-X
regulatory	B-X
regions	B-X
from	B-X
transcribed	B-X
chromatin	B-X
.	B-X

The	O
presence	O
of	O
H3K36me2	B-Protein
within	O
ORFs	O
correlated	O
with	O
the	O
"	O
on	O
"	O
or	O
"	O
off	O
"	O
state	O
of	O
transcription	O
,	O
but	O
the	O
degree	O
of	O
H3K36	B-Protein
dimethylation	O
within	O
ORFs	O
did	O
not	O
correlate	O
with	O
transcription	O
frequency	O
.	O

This	O
provides	O
evidence	O
that	O
H3K36me2	B-Protein
is	O
established	O
during	O
the	O
initial	O
instances	O
of	O
gene	O
transcription	O
,	O
with	O
subsequent	O
transcription	O
having	O
at	O
most	O
a	O
maintenance	O
role	O
.	O
<EOS>	B-X
Set2p	B-X
,	B-X
which	B-X
mediates	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
dimethylation	B-X
(	B-X
H3K36me2	B-X
)	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
associate	B-X
with	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAP	B-X
II	B-X
)	B-X
at	B-X
individual	B-X
loci	B-X
.	B-X
Here	B-X
,	B-X
chromatin	B-X
immunoprecipitation-microarray	B-X
experiments	B-X
normalized	B-X
to	B-X
general	B-X
nucleosome	B-X
occupancy	B-X
reveal	B-X
that	B-X
nucleosomes	B-X
within	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
and	B-X
downstream	B-X
noncoding	B-X
chromatin	B-X
were	B-X
highly	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
and	B-X
that	B-X
Set2p	B-X
activity	B-X
begins	B-X
at	B-X
a	B-X
stereotypic	B-X
distance	B-X
from	B-X
the	B-X
initiation	B-X
of	B-X
transcription	B-X
genome-wide	B-X
.	B-X
H3K36me2	B-X
is	B-X
scarce	B-X
in	B-X
regions	B-X
upstream	B-X
of	B-X
divergently	B-X
transcribed	B-X
genes	B-X
,	B-X
telomeres	B-X
,	B-X
silenced	B-X
mating	B-X
loci	B-X
,	B-X
and	B-X
regions	B-X
transcribed	B-X
by	B-X
RNA	B-X
polymerase	B-X
III	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
Set2p	B-X
is	B-X
restricted	B-X
to	B-X
its	B-X
association	B-X
with	B-X
RNAP	B-X
II	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
H3K36me2	B-X
within	B-X
ORFs	B-X
correlated	B-X
with	B-X
the	B-X
``	B-X
on	B-X
''	B-X
or	B-X
``	B-X
off	B-X
''	B-X
state	B-X
of	B-X
transcription	B-X
,	B-X
but	B-X
the	B-X
degree	B-X
of	B-X
H3K36	B-X
dimethylation	B-X
within	B-X
ORFs	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
transcription	B-X
frequency	B-X
.	B-X
This	B-X
provides	B-X
evidence	B-X
that	B-X
H3K36me2	B-X
is	B-X
established	B-X
during	B-X
the	B-X
initial	B-X
instances	B-X
of	B-X
gene	B-X
transcription	B-X
,	B-X
with	B-X
subsequent	B-X
transcription	B-X
having	B-X
at	B-X
most	B-X
a	B-X
maintenance	B-X
role	B-X
.	B-X
Accordingly	B-X
,	B-X
newly	B-X
activated	B-X
genes	B-X
acquire	B-X
H3K36me2	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
gene	B-X
transcript	B-X
levels	B-X
.	B-X
Thus	B-X
,	B-X
H3K36me2	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
conserved	B-X
throughout	B-X
eukaryotic	B-X
evolution	B-X
,	B-X
provides	B-X
a	B-X
stable	B-X
molecular	B-X
mechanism	B-X
for	B-X
establishing	B-X
chromatin	B-X
context	B-X
throughout	B-X
the	B-X
genome	B-X
by	B-X
distinguishing	B-X
potential	B-X
regulatory	B-X
regions	B-X
from	B-X
transcribed	B-X
chromatin	B-X
.	B-X

Accordingly	O
,	O
newly	O
activated	O
genes	O
acquire	O
H3K36me2	B-Protein
in	O
a	O
manner	O
that	O
does	O
not	O
correlate	O
with	O
gene	O
transcript	O
levels	O
.	O

Finally	O
,	O
nucleosomes	O
dimethylated	O
at	O
H3K36	B-Protein
appear	O
to	O
be	O
refractory	O
to	O
loss	O
from	O
highly	O
transcribed	O
chromatin	O
.	O
<EOS>	B-X
Set2p	B-X
,	B-X
which	B-X
mediates	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
dimethylation	B-X
(	B-X
H3K36me2	B-X
)	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
associate	B-X
with	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAP	B-X
II	B-X
)	B-X
at	B-X
individual	B-X
loci	B-X
.	B-X
Here	B-X
,	B-X
chromatin	B-X
immunoprecipitation-microarray	B-X
experiments	B-X
normalized	B-X
to	B-X
general	B-X
nucleosome	B-X
occupancy	B-X
reveal	B-X
that	B-X
nucleosomes	B-X
within	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
and	B-X
downstream	B-X
noncoding	B-X
chromatin	B-X
were	B-X
highly	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
and	B-X
that	B-X
Set2p	B-X
activity	B-X
begins	B-X
at	B-X
a	B-X
stereotypic	B-X
distance	B-X
from	B-X
the	B-X
initiation	B-X
of	B-X
transcription	B-X
genome-wide	B-X
.	B-X
H3K36me2	B-X
is	B-X
scarce	B-X
in	B-X
regions	B-X
upstream	B-X
of	B-X
divergently	B-X
transcribed	B-X
genes	B-X
,	B-X
telomeres	B-X
,	B-X
silenced	B-X
mating	B-X
loci	B-X
,	B-X
and	B-X
regions	B-X
transcribed	B-X
by	B-X
RNA	B-X
polymerase	B-X
III	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
Set2p	B-X
is	B-X
restricted	B-X
to	B-X
its	B-X
association	B-X
with	B-X
RNAP	B-X
II	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
H3K36me2	B-X
within	B-X
ORFs	B-X
correlated	B-X
with	B-X
the	B-X
``	B-X
on	B-X
''	B-X
or	B-X
``	B-X
off	B-X
''	B-X
state	B-X
of	B-X
transcription	B-X
,	B-X
but	B-X
the	B-X
degree	B-X
of	B-X
H3K36	B-X
dimethylation	B-X
within	B-X
ORFs	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
transcription	B-X
frequency	B-X
.	B-X
This	B-X
provides	B-X
evidence	B-X
that	B-X
H3K36me2	B-X
is	B-X
established	B-X
during	B-X
the	B-X
initial	B-X
instances	B-X
of	B-X
gene	B-X
transcription	B-X
,	B-X
with	B-X
subsequent	B-X
transcription	B-X
having	B-X
at	B-X
most	B-X
a	B-X
maintenance	B-X
role	B-X
.	B-X
Accordingly	B-X
,	B-X
newly	B-X
activated	B-X
genes	B-X
acquire	B-X
H3K36me2	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
gene	B-X
transcript	B-X
levels	B-X
.	B-X
Finally	B-X
,	B-X
nucleosomes	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
appear	B-X
to	B-X
be	B-X
refractory	B-X
to	B-X
loss	B-X
from	B-X
highly	B-X
transcribed	B-X
chromatin	B-X
.	B-X
Thus	B-X
,	B-X
H3K36me2	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
conserved	B-X
throughout	B-X
eukaryotic	B-X
evolution	B-X
,	B-X
provides	B-X
a	B-X
stable	B-X
molecular	B-X
mechanism	B-X
for	B-X
establishing	B-X
chromatin	B-X
context	B-X
throughout	B-X
the	B-X
genome	B-X
by	B-X
distinguishing	B-X
potential	B-X
regulatory	B-X
regions	B-X
from	B-X
transcribed	B-X
chromatin	B-X
.	B-X

Thus	O
,	O
H3K36me2	B-Protein
,	O
which	O
is	O
highly	O
conserved	O
throughout	O
eukaryotic	O
evolution	O
,	O
provides	O
a	O
stable	O
molecular	O
mechanism	O
for	O
establishing	O
chromatin	O
context	O
throughout	O
the	O
genome	O
by	O
distinguishing	O
potential	O
regulatory	O
regions	O
from	O
transcribed	O
chromatin	O
.	O
<EOS>	B-X
Set2p	B-X
,	B-X
which	B-X
mediates	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
dimethylation	B-X
(	B-X
H3K36me2	B-X
)	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
associate	B-X
with	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAP	B-X
II	B-X
)	B-X
at	B-X
individual	B-X
loci	B-X
.	B-X
Here	B-X
,	B-X
chromatin	B-X
immunoprecipitation-microarray	B-X
experiments	B-X
normalized	B-X
to	B-X
general	B-X
nucleosome	B-X
occupancy	B-X
reveal	B-X
that	B-X
nucleosomes	B-X
within	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
and	B-X
downstream	B-X
noncoding	B-X
chromatin	B-X
were	B-X
highly	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
and	B-X
that	B-X
Set2p	B-X
activity	B-X
begins	B-X
at	B-X
a	B-X
stereotypic	B-X
distance	B-X
from	B-X
the	B-X
initiation	B-X
of	B-X
transcription	B-X
genome-wide	B-X
.	B-X
H3K36me2	B-X
is	B-X
scarce	B-X
in	B-X
regions	B-X
upstream	B-X
of	B-X
divergently	B-X
transcribed	B-X
genes	B-X
,	B-X
telomeres	B-X
,	B-X
silenced	B-X
mating	B-X
loci	B-X
,	B-X
and	B-X
regions	B-X
transcribed	B-X
by	B-X
RNA	B-X
polymerase	B-X
III	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
Set2p	B-X
is	B-X
restricted	B-X
to	B-X
its	B-X
association	B-X
with	B-X
RNAP	B-X
II	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
H3K36me2	B-X
within	B-X
ORFs	B-X
correlated	B-X
with	B-X
the	B-X
``	B-X
on	B-X
''	B-X
or	B-X
``	B-X
off	B-X
''	B-X
state	B-X
of	B-X
transcription	B-X
,	B-X
but	B-X
the	B-X
degree	B-X
of	B-X
H3K36	B-X
dimethylation	B-X
within	B-X
ORFs	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
transcription	B-X
frequency	B-X
.	B-X
This	B-X
provides	B-X
evidence	B-X
that	B-X
H3K36me2	B-X
is	B-X
established	B-X
during	B-X
the	B-X
initial	B-X
instances	B-X
of	B-X
gene	B-X
transcription	B-X
,	B-X
with	B-X
subsequent	B-X
transcription	B-X
having	B-X
at	B-X
most	B-X
a	B-X
maintenance	B-X
role	B-X
.	B-X
Accordingly	B-X
,	B-X
newly	B-X
activated	B-X
genes	B-X
acquire	B-X
H3K36me2	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
gene	B-X
transcript	B-X
levels	B-X
.	B-X
Finally	B-X
,	B-X
nucleosomes	B-X
dimethylated	B-X
at	B-X
H3K36	B-X
appear	B-X
to	B-X
be	B-X
refractory	B-X
to	B-X
loss	B-X
from	B-X
highly	B-X
transcribed	B-X
chromatin	B-X
.	B-X
Thus	B-X
,	B-X
H3K36me2	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
conserved	B-X
throughout	B-X
eukaryotic	B-X
evolution	B-X
,	B-X
provides	B-X
a	B-X
stable	B-X
molecular	B-X
mechanism	B-X
for	B-X
establishing	B-X
chromatin	B-X
context	B-X
throughout	B-X
the	B-X
genome	B-X
by	B-X
distinguishing	B-X
potential	B-X
regulatory	B-X
regions	B-X
from	B-X
transcribed	B-X
chromatin	B-X
.	B-X

Versatile	O
peroxidase	O
oxidation	O
of	O
high	O
redox	O
potential	O
aromatic	O
compounds	O
:	O
site	O
-	O
directed	O
mutagenesis	O
,	O
spectroscopic	O
and	O
crystallographic	O
investigation	O
of	O
three	O
long	O
-	O
range	O
electron	O
transfer	O
pathways	O
.	O
<EOS>	B-X
Versatile	B-X
peroxidases	B-X
(	B-X
VP	B-X
)	B-X
,	B-X
a	B-X
recently	B-X
described	B-X
family	B-X
of	B-X
ligninolytic	B-X
peroxidases	B-X
,	B-X
show	B-X
a	B-X
hybrid	B-X
molecular	B-X
architecture	B-X
combining	B-X
different	B-X
oxidation	B-X
sites	B-X
connected	B-X
to	B-X
the	B-X
heme	B-X
cofactor	B-X
.	B-X
High-resolution	B-X
crystal	B-X
structures	B-X
as	B-X
well	B-X
as	B-X
homology	B-X
models	B-X
of	B-X
VP	B-X
isoenzymes	B-X
from	B-X
the	B-X
fungus	B-X
Pleurotus	B-X
eryngii	B-X
revealed	B-X
three	B-X
possibilities	B-X
for	B-X
long-range	B-X
electron	B-X
transfer	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
compounds	B-X
.	B-X
The	B-X
possible	B-X
pathways	B-X
would	B-X
start	B-X
either	B-X
at	B-X
Trp164	B-X
or	B-X
His232	B-X
of	B-X
isoenzyme	B-X
VPL	B-X
,	B-X
and	B-X
at	B-X
His82	B-X
or	B-X
Trp170	B-X
of	B-X
isoenzyme	B-X
VPS1	B-X
.	B-X
With	B-X
the	B-X
purpose	B-X
of	B-X
investigating	B-X
their	B-X
functionality	B-X
,	B-X
two	B-X
single	B-X
mutations	B-X
(	B-X
W164S	B-X
and	B-X
H232F	B-X
)	B-X
and	B-X
one	B-X
double	B-X
mutation	B-X
(	B-X
W164S/P76H	B-X
)	B-X
were	B-X
introduced	B-X
in	B-X
VPL	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
removed	B-X
the	B-X
two	B-X
pathways	B-X
in	B-X
this	B-X
isoenzyme	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
incorporated	B-X
the	B-X
absent	B-X
putative	B-X
pathway	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
variants	B-X
showed	B-X
that	B-X
Trp164	B-X
is	B-X
required	B-X
for	B-X
oxidation	B-X
of	B-X
two	B-X
high	B-X
redox	B-X
potential	B-X
model	B-X
substrates	B-X
(	B-X
veratryl	B-X
alcohol	B-X
and	B-X
Reactive	B-X
Black	B-X
5	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
two	B-X
other	B-X
pathways	B-X
(	B-X
starting	B-X
at	B-X
His232	B-X
and	B-X
His82	B-X
)	B-X
are	B-X
not	B-X
involved	B-X
in	B-X
long-range	B-X
electron	B-X
transfer	B-X
(	B-X
LRET	B-X
)	B-X
.	B-X
None	B-X
of	B-X
the	B-X
mutations	B-X
affected	B-X
Mn2+	B-X
oxidation	B-X
,	B-X
which	B-X
would	B-X
take	B-X
place	B-X
at	B-X
the	B-X
opposite	B-X
side	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
It	B-X
is	B-X
proposed	B-X
that	B-X
substrate	B-X
oxidation	B-X
occurs	B-X
via	B-X
a	B-X
protein-based	B-X
radical	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
in	B-X
a	B-X
ligninolytic	B-X
peroxidase	B-X
such	B-X
an	B-X
intermediate	B-X
species	B-X
could	B-X
be	B-X
detected	B-X
by	B-X
low-temperature	B-X
electron	B-X
paramagnetic	B-X
resonance	B-X
of	B-X
H2O2-activated	B-X
VP	B-X
,	B-X
and	B-X
was	B-X
found	B-X
to	B-X
exist	B-X
at	B-X
Trp164	B-X
as	B-X
a	B-X
neutral	B-X
radical	B-X
.	B-X
This	B-X
is	B-X
in	B-X
contrast	B-X
to	B-X
lignin	B-X
peroxidase	B-X
Trp171	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
both	B-X
peroxidases	B-X
showed	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
radical-forming	B-X
residue	B-X
that	B-X
could	B-X
affect	B-X
its	B-X
reactivity	B-X
.	B-X
These	B-X
variations	B-X
would	B-X
also	B-X
explain	B-X
differences	B-X
found	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
some	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
substrates	B-X
.	B-X

Versatile	O
peroxidases	O
(	O
VP	O
)	O
,	O
a	O
recently	O
described	O
family	O
of	O
ligninolytic	O
peroxidases	O
,	O
show	O
a	O
hybrid	O
molecular	O
architecture	O
combining	O
different	O
oxidation	O
sites	O
connected	O
to	O
the	O
heme	O
cofactor	O
.	O

High	O
-	O
resolution	O
crystal	O
structures	O
as	O
well	O
as	O
homology	O
models	O
of	O
VP	O
isoenzymes	O
from	O
the	O
fungus	O
Pleurotus	O
eryngii	O
revealed	O
three	O
possibilities	O
for	O
long	O
-	O
range	O
electron	O
transfer	O
for	O
the	O
oxidation	O
of	O
high	O
redox	O
potential	O
aromatic	O
compounds	O
.	O
<EOS>	B-X
Versatile	B-X
peroxidases	B-X
(	B-X
VP	B-X
)	B-X
,	B-X
a	B-X
recently	B-X
described	B-X
family	B-X
of	B-X
ligninolytic	B-X
peroxidases	B-X
,	B-X
show	B-X
a	B-X
hybrid	B-X
molecular	B-X
architecture	B-X
combining	B-X
different	B-X
oxidation	B-X
sites	B-X
connected	B-X
to	B-X
the	B-X
heme	B-X
cofactor	B-X
.	B-X
High-resolution	B-X
crystal	B-X
structures	B-X
as	B-X
well	B-X
as	B-X
homology	B-X
models	B-X
of	B-X
VP	B-X
isoenzymes	B-X
from	B-X
the	B-X
fungus	B-X
Pleurotus	B-X
eryngii	B-X
revealed	B-X
three	B-X
possibilities	B-X
for	B-X
long-range	B-X
electron	B-X
transfer	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
compounds	B-X
.	B-X
The	B-X
possible	B-X
pathways	B-X
would	B-X
start	B-X
either	B-X
at	B-X
Trp164	B-X
or	B-X
His232	B-X
of	B-X
isoenzyme	B-X
VPL	B-X
,	B-X
and	B-X
at	B-X
His82	B-X
or	B-X
Trp170	B-X
of	B-X
isoenzyme	B-X
VPS1	B-X
.	B-X
With	B-X
the	B-X
purpose	B-X
of	B-X
investigating	B-X
their	B-X
functionality	B-X
,	B-X
two	B-X
single	B-X
mutations	B-X
(	B-X
W164S	B-X
and	B-X
H232F	B-X
)	B-X
and	B-X
one	B-X
double	B-X
mutation	B-X
(	B-X
W164S/P76H	B-X
)	B-X
were	B-X
introduced	B-X
in	B-X
VPL	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
removed	B-X
the	B-X
two	B-X
pathways	B-X
in	B-X
this	B-X
isoenzyme	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
incorporated	B-X
the	B-X
absent	B-X
putative	B-X
pathway	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
variants	B-X
showed	B-X
that	B-X
Trp164	B-X
is	B-X
required	B-X
for	B-X
oxidation	B-X
of	B-X
two	B-X
high	B-X
redox	B-X
potential	B-X
model	B-X
substrates	B-X
(	B-X
veratryl	B-X
alcohol	B-X
and	B-X
Reactive	B-X
Black	B-X
5	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
two	B-X
other	B-X
pathways	B-X
(	B-X
starting	B-X
at	B-X
His232	B-X
and	B-X
His82	B-X
)	B-X
are	B-X
not	B-X
involved	B-X
in	B-X
long-range	B-X
electron	B-X
transfer	B-X
(	B-X
LRET	B-X
)	B-X
.	B-X
None	B-X
of	B-X
the	B-X
mutations	B-X
affected	B-X
Mn2+	B-X
oxidation	B-X
,	B-X
which	B-X
would	B-X
take	B-X
place	B-X
at	B-X
the	B-X
opposite	B-X
side	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
It	B-X
is	B-X
proposed	B-X
that	B-X
substrate	B-X
oxidation	B-X
occurs	B-X
via	B-X
a	B-X
protein-based	B-X
radical	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
in	B-X
a	B-X
ligninolytic	B-X
peroxidase	B-X
such	B-X
an	B-X
intermediate	B-X
species	B-X
could	B-X
be	B-X
detected	B-X
by	B-X
low-temperature	B-X
electron	B-X
paramagnetic	B-X
resonance	B-X
of	B-X
H2O2-activated	B-X
VP	B-X
,	B-X
and	B-X
was	B-X
found	B-X
to	B-X
exist	B-X
at	B-X
Trp164	B-X
as	B-X
a	B-X
neutral	B-X
radical	B-X
.	B-X
The	B-X
H2O2-activated	B-X
VP	B-X
was	B-X
self-reduced	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
reducing	B-X
substrates	B-X
.	B-X
When	B-X
analyzing	B-X
VP	B-X
crystal	B-X
structures	B-X
close	B-X
to	B-X
atomic	B-X
resolution	B-X
,	B-X
no	B-X
hydroxylation	B-X
of	B-X
the	B-X
Trp164	B-X
Cbeta	B-X
atom	B-X
was	B-X
observed	B-X
(	B-X
even	B-X
after	B-X
addition	B-X
of	B-X
several	B-X
equivalents	B-X
of	B-X
H2O2	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
both	B-X
peroxidases	B-X
showed	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
radical-forming	B-X
residue	B-X
that	B-X
could	B-X
affect	B-X
its	B-X
reactivity	B-X
.	B-X
These	B-X
variations	B-X
would	B-X
also	B-X
explain	B-X
differences	B-X
found	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
some	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
substrates	B-X
.	B-X

The	O
possible	O
pathways	O
would	O
start	O
either	O
at	O
Trp164	O
or	O
His232	O
of	O
isoenzyme	O
VPL	O
,	O
and	O
at	O
His82	O
or	O
Trp170	O
of	O
isoenzyme	O
VPS1	B-Protein
.	O
<EOS>	B-X
High-resolution	B-X
crystal	B-X
structures	B-X
as	B-X
well	B-X
as	B-X
homology	B-X
models	B-X
of	B-X
VP	B-X
isoenzymes	B-X
from	B-X
the	B-X
fungus	B-X
Pleurotus	B-X
eryngii	B-X
revealed	B-X
three	B-X
possibilities	B-X
for	B-X
long-range	B-X
electron	B-X
transfer	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
compounds	B-X
.	B-X
The	B-X
possible	B-X
pathways	B-X
would	B-X
start	B-X
either	B-X
at	B-X
Trp164	B-X
or	B-X
His232	B-X
of	B-X
isoenzyme	B-X
VPL	B-X
,	B-X
and	B-X
at	B-X
His82	B-X
or	B-X
Trp170	B-X
of	B-X
isoenzyme	B-X
VPS1	B-X
.	B-X
With	B-X
the	B-X
purpose	B-X
of	B-X
investigating	B-X
their	B-X
functionality	B-X
,	B-X
two	B-X
single	B-X
mutations	B-X
(	B-X
W164S	B-X
and	B-X
H232F	B-X
)	B-X
and	B-X
one	B-X
double	B-X
mutation	B-X
(	B-X
W164S/P76H	B-X
)	B-X
were	B-X
introduced	B-X
in	B-X
VPL	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
removed	B-X
the	B-X
two	B-X
pathways	B-X
in	B-X
this	B-X
isoenzyme	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
incorporated	B-X
the	B-X
absent	B-X
putative	B-X
pathway	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
variants	B-X
showed	B-X
that	B-X
Trp164	B-X
is	B-X
required	B-X
for	B-X
oxidation	B-X
of	B-X
two	B-X
high	B-X
redox	B-X
potential	B-X
model	B-X
substrates	B-X
(	B-X
veratryl	B-X
alcohol	B-X
and	B-X
Reactive	B-X
Black	B-X
5	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
two	B-X
other	B-X
pathways	B-X
(	B-X
starting	B-X
at	B-X
His232	B-X
and	B-X
His82	B-X
)	B-X
are	B-X
not	B-X
involved	B-X
in	B-X
long-range	B-X
electron	B-X
transfer	B-X
(	B-X
LRET	B-X
)	B-X
.	B-X
None	B-X
of	B-X
the	B-X
mutations	B-X
affected	B-X
Mn2+	B-X
oxidation	B-X
,	B-X
which	B-X
would	B-X
take	B-X
place	B-X
at	B-X
the	B-X
opposite	B-X
side	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
Substitution	B-X
of	B-X
Trp164	B-X
by	B-X
His	B-X
also	B-X
resulted	B-X
in	B-X
an	B-X
inactive	B-X
variant	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
indole	B-X
side-chain	B-X
is	B-X
required	B-X
for	B-X
activity	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
in	B-X
a	B-X
ligninolytic	B-X
peroxidase	B-X
such	B-X
an	B-X
intermediate	B-X
species	B-X
could	B-X
be	B-X
detected	B-X
by	B-X
low-temperature	B-X
electron	B-X
paramagnetic	B-X
resonance	B-X
of	B-X
H2O2-activated	B-X
VP	B-X
,	B-X
and	B-X
was	B-X
found	B-X
to	B-X
exist	B-X
at	B-X
Trp164	B-X
as	B-X
a	B-X
neutral	B-X
radical	B-X
.	B-X
Trp164	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
this	B-X
reaction	B-X
,	B-X
which	B-X
in	B-X
the	B-X
W164S	B-X
variant	B-X
was	B-X
blocked	B-X
at	B-X
the	B-X
level	B-X
of	B-X
compound	B-X
II	B-X
.	B-X
When	B-X
analyzing	B-X
VP	B-X
crystal	B-X
structures	B-X
close	B-X
to	B-X
atomic	B-X
resolution	B-X
,	B-X
no	B-X
hydroxylation	B-X
of	B-X
the	B-X
Trp164	B-X
Cbeta	B-X
atom	B-X
was	B-X
observed	B-X
(	B-X
even	B-X
after	B-X
addition	B-X
of	B-X
several	B-X
equivalents	B-X
of	B-X
H2O2	B-X
)	B-X
.	B-X
These	B-X
variations	B-X
would	B-X
also	B-X
explain	B-X
differences	B-X
found	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
some	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
substrates	B-X
.	B-X

These	O
residues	O
are	O
exposed	O
,	O
and	O
less	O
than	O
11	O
A	O
apart	O
from	O
the	O
heme	O
.	O
<EOS>	B-X
Versatile	B-X
peroxidases	B-X
(	B-X
VP	B-X
)	B-X
,	B-X
a	B-X
recently	B-X
described	B-X
family	B-X
of	B-X
ligninolytic	B-X
peroxidases	B-X
,	B-X
show	B-X
a	B-X
hybrid	B-X
molecular	B-X
architecture	B-X
combining	B-X
different	B-X
oxidation	B-X
sites	B-X
connected	B-X
to	B-X
the	B-X
heme	B-X
cofactor	B-X
.	B-X
These	B-X
residues	B-X
are	B-X
exposed	B-X
,	B-X
and	B-X
less	B-X
than	B-X
11	B-X
A	B-X
apart	B-X
from	B-X
the	B-X
heme	B-X
.	B-X

With	O
the	O
purpose	O
of	O
investigating	O
their	O
functionality	O
,	O
two	O
single	O
mutations	O
(	O
W164S	O
and	O
H232F	O
)	O
and	O
one	O
double	O
mutation	O
(	O
W164S	O
/	O
P76H	O
)	O
were	O
introduced	O
in	O
VPL	O
that	O
:	O
(	O
i	O
)	O
removed	O
the	O
two	O
pathways	O
in	O
this	O
isoenzyme	O
;	O
and	O
(	O
ii	O
)	O
incorporated	O
the	O
absent	O
putative	O
pathway	O
.	O

Analysis	O
of	O
the	O
variants	O
showed	O
that	O
Trp164	O
is	O
required	O
for	O
oxidation	O
of	O
two	O
high	O
redox	O
potential	O
model	O
substrates	O
(	O
veratryl	O
alcohol	O
and	O
Reactive	O
Black	O
5	O
)	O
,	O
whereas	O
the	O
two	O
other	O
pathways	O
(	O
starting	O
at	O
His232	O
and	O
His82	O
)	O
are	O
not	O
involved	O
in	O
long	O
-	O
range	O
electron	O
transfer	O
(	O
LRET	O
)	O
.	O

None	O
of	O
the	O
mutations	O
affected	O
Mn2	O
+	O
oxidation	O
,	O
which	O
would	O
take	O
place	O
at	O
the	O
opposite	O
side	O
of	O
the	O
enzyme	O
.	O

Substitution	O
of	O
Trp164	O
by	O
His	O
also	O
resulted	O
in	O
an	O
inactive	O
variant	O
,	O
indicating	O
that	O
an	O
indole	O
side	O
-	O
chain	O
is	O
required	O
for	O
activity	O
.	O

It	O
is	O
proposed	O
that	O
substrate	O
oxidation	O
occurs	O
via	O
a	O
protein	O
-	O
based	O
radical	O
.	O

For	O
the	O
first	O
time	O
in	O
a	O
ligninolytic	O
peroxidase	O
such	O
an	O
intermediate	O
species	O
could	O
be	O
detected	O
by	O
low	O
-	O
temperature	O
electron	O
paramagnetic	O
resonance	O
of	O
H2O2	O
-	O
activated	O
VP	O
,	O
and	O
was	O
found	O
to	O
exist	O
at	O
Trp164	O
as	O
a	O
neutral	O
radical	O
.	O

The	O
H2O2	O
-	O
activated	O
VP	O
was	O
self	O
-	O
reduced	O
in	O
the	O
absence	O
of	O
reducing	O
substrates	O
.	O
<EOS>	B-X
Versatile	B-X
peroxidases	B-X
(	B-X
VP	B-X
)	B-X
,	B-X
a	B-X
recently	B-X
described	B-X
family	B-X
of	B-X
ligninolytic	B-X
peroxidases	B-X
,	B-X
show	B-X
a	B-X
hybrid	B-X
molecular	B-X
architecture	B-X
combining	B-X
different	B-X
oxidation	B-X
sites	B-X
connected	B-X
to	B-X
the	B-X
heme	B-X
cofactor	B-X
.	B-X
High-resolution	B-X
crystal	B-X
structures	B-X
as	B-X
well	B-X
as	B-X
homology	B-X
models	B-X
of	B-X
VP	B-X
isoenzymes	B-X
from	B-X
the	B-X
fungus	B-X
Pleurotus	B-X
eryngii	B-X
revealed	B-X
three	B-X
possibilities	B-X
for	B-X
long-range	B-X
electron	B-X
transfer	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
compounds	B-X
.	B-X
The	B-X
possible	B-X
pathways	B-X
would	B-X
start	B-X
either	B-X
at	B-X
Trp164	B-X
or	B-X
His232	B-X
of	B-X
isoenzyme	B-X
VPL	B-X
,	B-X
and	B-X
at	B-X
His82	B-X
or	B-X
Trp170	B-X
of	B-X
isoenzyme	B-X
VPS1	B-X
.	B-X
With	B-X
the	B-X
purpose	B-X
of	B-X
investigating	B-X
their	B-X
functionality	B-X
,	B-X
two	B-X
single	B-X
mutations	B-X
(	B-X
W164S	B-X
and	B-X
H232F	B-X
)	B-X
and	B-X
one	B-X
double	B-X
mutation	B-X
(	B-X
W164S/P76H	B-X
)	B-X
were	B-X
introduced	B-X
in	B-X
VPL	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
removed	B-X
the	B-X
two	B-X
pathways	B-X
in	B-X
this	B-X
isoenzyme	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
incorporated	B-X
the	B-X
absent	B-X
putative	B-X
pathway	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
variants	B-X
showed	B-X
that	B-X
Trp164	B-X
is	B-X
required	B-X
for	B-X
oxidation	B-X
of	B-X
two	B-X
high	B-X
redox	B-X
potential	B-X
model	B-X
substrates	B-X
(	B-X
veratryl	B-X
alcohol	B-X
and	B-X
Reactive	B-X
Black	B-X
5	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
two	B-X
other	B-X
pathways	B-X
(	B-X
starting	B-X
at	B-X
His232	B-X
and	B-X
His82	B-X
)	B-X
are	B-X
not	B-X
involved	B-X
in	B-X
long-range	B-X
electron	B-X
transfer	B-X
(	B-X
LRET	B-X
)	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
in	B-X
a	B-X
ligninolytic	B-X
peroxidase	B-X
such	B-X
an	B-X
intermediate	B-X
species	B-X
could	B-X
be	B-X
detected	B-X
by	B-X
low-temperature	B-X
electron	B-X
paramagnetic	B-X
resonance	B-X
of	B-X
H2O2-activated	B-X
VP	B-X
,	B-X
and	B-X
was	B-X
found	B-X
to	B-X
exist	B-X
at	B-X
Trp164	B-X
as	B-X
a	B-X
neutral	B-X
radical	B-X
.	B-X
The	B-X
H2O2-activated	B-X
VP	B-X
was	B-X
self-reduced	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
reducing	B-X
substrates	B-X
.	B-X
When	B-X
analyzing	B-X
VP	B-X
crystal	B-X
structures	B-X
close	B-X
to	B-X
atomic	B-X
resolution	B-X
,	B-X
no	B-X
hydroxylation	B-X
of	B-X
the	B-X
Trp164	B-X
Cbeta	B-X
atom	B-X
was	B-X
observed	B-X
(	B-X
even	B-X
after	B-X
addition	B-X
of	B-X
several	B-X
equivalents	B-X
of	B-X
H2O2	B-X
)	B-X
.	B-X
These	B-X
variations	B-X
would	B-X
also	B-X
explain	B-X
differences	B-X
found	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
some	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
substrates	B-X
.	B-X

Trp164	O
is	O
also	O
involved	O
in	O
this	O
reaction	O
,	O
which	O
in	O
the	O
W164S	O
variant	O
was	O
blocked	O
at	O
the	O
level	O
of	O
compound	O
II	O
.	O
<EOS>	B-X
High-resolution	B-X
crystal	B-X
structures	B-X
as	B-X
well	B-X
as	B-X
homology	B-X
models	B-X
of	B-X
VP	B-X
isoenzymes	B-X
from	B-X
the	B-X
fungus	B-X
Pleurotus	B-X
eryngii	B-X
revealed	B-X
three	B-X
possibilities	B-X
for	B-X
long-range	B-X
electron	B-X
transfer	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
compounds	B-X
.	B-X
The	B-X
possible	B-X
pathways	B-X
would	B-X
start	B-X
either	B-X
at	B-X
Trp164	B-X
or	B-X
His232	B-X
of	B-X
isoenzyme	B-X
VPL	B-X
,	B-X
and	B-X
at	B-X
His82	B-X
or	B-X
Trp170	B-X
of	B-X
isoenzyme	B-X
VPS1	B-X
.	B-X
With	B-X
the	B-X
purpose	B-X
of	B-X
investigating	B-X
their	B-X
functionality	B-X
,	B-X
two	B-X
single	B-X
mutations	B-X
(	B-X
W164S	B-X
and	B-X
H232F	B-X
)	B-X
and	B-X
one	B-X
double	B-X
mutation	B-X
(	B-X
W164S/P76H	B-X
)	B-X
were	B-X
introduced	B-X
in	B-X
VPL	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
removed	B-X
the	B-X
two	B-X
pathways	B-X
in	B-X
this	B-X
isoenzyme	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
incorporated	B-X
the	B-X
absent	B-X
putative	B-X
pathway	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
variants	B-X
showed	B-X
that	B-X
Trp164	B-X
is	B-X
required	B-X
for	B-X
oxidation	B-X
of	B-X
two	B-X
high	B-X
redox	B-X
potential	B-X
model	B-X
substrates	B-X
(	B-X
veratryl	B-X
alcohol	B-X
and	B-X
Reactive	B-X
Black	B-X
5	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
two	B-X
other	B-X
pathways	B-X
(	B-X
starting	B-X
at	B-X
His232	B-X
and	B-X
His82	B-X
)	B-X
are	B-X
not	B-X
involved	B-X
in	B-X
long-range	B-X
electron	B-X
transfer	B-X
(	B-X
LRET	B-X
)	B-X
.	B-X
Substitution	B-X
of	B-X
Trp164	B-X
by	B-X
His	B-X
also	B-X
resulted	B-X
in	B-X
an	B-X
inactive	B-X
variant	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
indole	B-X
side-chain	B-X
is	B-X
required	B-X
for	B-X
activity	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
in	B-X
a	B-X
ligninolytic	B-X
peroxidase	B-X
such	B-X
an	B-X
intermediate	B-X
species	B-X
could	B-X
be	B-X
detected	B-X
by	B-X
low-temperature	B-X
electron	B-X
paramagnetic	B-X
resonance	B-X
of	B-X
H2O2-activated	B-X
VP	B-X
,	B-X
and	B-X
was	B-X
found	B-X
to	B-X
exist	B-X
at	B-X
Trp164	B-X
as	B-X
a	B-X
neutral	B-X
radical	B-X
.	B-X
Trp164	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
this	B-X
reaction	B-X
,	B-X
which	B-X
in	B-X
the	B-X
W164S	B-X
variant	B-X
was	B-X
blocked	B-X
at	B-X
the	B-X
level	B-X
of	B-X
compound	B-X
II	B-X
.	B-X
When	B-X
analyzing	B-X
VP	B-X
crystal	B-X
structures	B-X
close	B-X
to	B-X
atomic	B-X
resolution	B-X
,	B-X
no	B-X
hydroxylation	B-X
of	B-X
the	B-X
Trp164	B-X
Cbeta	B-X
atom	B-X
was	B-X
observed	B-X
(	B-X
even	B-X
after	B-X
addition	B-X
of	B-X
several	B-X
equivalents	B-X
of	B-X
H2O2	B-X
)	B-X
.	B-X
These	B-X
variations	B-X
would	B-X
also	B-X
explain	B-X
differences	B-X
found	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
some	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
substrates	B-X
.	B-X

When	O
analyzing	O
VP	O
crystal	O
structures	O
close	O
to	O
atomic	O
resolution	O
,	O
no	O
hydroxylation	O
of	O
the	O
Trp164	O
Cbeta	O
atom	O
was	O
observed	O
(	O
even	O
after	O
addition	O
of	O
several	O
equivalents	O
of	O
H2O2	O
)	O
.	O
<EOS>	B-X
Versatile	B-X
peroxidases	B-X
(	B-X
VP	B-X
)	B-X
,	B-X
a	B-X
recently	B-X
described	B-X
family	B-X
of	B-X
ligninolytic	B-X
peroxidases	B-X
,	B-X
show	B-X
a	B-X
hybrid	B-X
molecular	B-X
architecture	B-X
combining	B-X
different	B-X
oxidation	B-X
sites	B-X
connected	B-X
to	B-X
the	B-X
heme	B-X
cofactor	B-X
.	B-X
High-resolution	B-X
crystal	B-X
structures	B-X
as	B-X
well	B-X
as	B-X
homology	B-X
models	B-X
of	B-X
VP	B-X
isoenzymes	B-X
from	B-X
the	B-X
fungus	B-X
Pleurotus	B-X
eryngii	B-X
revealed	B-X
three	B-X
possibilities	B-X
for	B-X
long-range	B-X
electron	B-X
transfer	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
compounds	B-X
.	B-X
The	B-X
possible	B-X
pathways	B-X
would	B-X
start	B-X
either	B-X
at	B-X
Trp164	B-X
or	B-X
His232	B-X
of	B-X
isoenzyme	B-X
VPL	B-X
,	B-X
and	B-X
at	B-X
His82	B-X
or	B-X
Trp170	B-X
of	B-X
isoenzyme	B-X
VPS1	B-X
.	B-X
With	B-X
the	B-X
purpose	B-X
of	B-X
investigating	B-X
their	B-X
functionality	B-X
,	B-X
two	B-X
single	B-X
mutations	B-X
(	B-X
W164S	B-X
and	B-X
H232F	B-X
)	B-X
and	B-X
one	B-X
double	B-X
mutation	B-X
(	B-X
W164S/P76H	B-X
)	B-X
were	B-X
introduced	B-X
in	B-X
VPL	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
removed	B-X
the	B-X
two	B-X
pathways	B-X
in	B-X
this	B-X
isoenzyme	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
incorporated	B-X
the	B-X
absent	B-X
putative	B-X
pathway	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
variants	B-X
showed	B-X
that	B-X
Trp164	B-X
is	B-X
required	B-X
for	B-X
oxidation	B-X
of	B-X
two	B-X
high	B-X
redox	B-X
potential	B-X
model	B-X
substrates	B-X
(	B-X
veratryl	B-X
alcohol	B-X
and	B-X
Reactive	B-X
Black	B-X
5	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
two	B-X
other	B-X
pathways	B-X
(	B-X
starting	B-X
at	B-X
His232	B-X
and	B-X
His82	B-X
)	B-X
are	B-X
not	B-X
involved	B-X
in	B-X
long-range	B-X
electron	B-X
transfer	B-X
(	B-X
LRET	B-X
)	B-X
.	B-X
Substitution	B-X
of	B-X
Trp164	B-X
by	B-X
His	B-X
also	B-X
resulted	B-X
in	B-X
an	B-X
inactive	B-X
variant	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
indole	B-X
side-chain	B-X
is	B-X
required	B-X
for	B-X
activity	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
in	B-X
a	B-X
ligninolytic	B-X
peroxidase	B-X
such	B-X
an	B-X
intermediate	B-X
species	B-X
could	B-X
be	B-X
detected	B-X
by	B-X
low-temperature	B-X
electron	B-X
paramagnetic	B-X
resonance	B-X
of	B-X
H2O2-activated	B-X
VP	B-X
,	B-X
and	B-X
was	B-X
found	B-X
to	B-X
exist	B-X
at	B-X
Trp164	B-X
as	B-X
a	B-X
neutral	B-X
radical	B-X
.	B-X
The	B-X
H2O2-activated	B-X
VP	B-X
was	B-X
self-reduced	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
reducing	B-X
substrates	B-X
.	B-X
Trp164	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
this	B-X
reaction	B-X
,	B-X
which	B-X
in	B-X
the	B-X
W164S	B-X
variant	B-X
was	B-X
blocked	B-X
at	B-X
the	B-X
level	B-X
of	B-X
compound	B-X
II	B-X
.	B-X
When	B-X
analyzing	B-X
VP	B-X
crystal	B-X
structures	B-X
close	B-X
to	B-X
atomic	B-X
resolution	B-X
,	B-X
no	B-X
hydroxylation	B-X
of	B-X
the	B-X
Trp164	B-X
Cbeta	B-X
atom	B-X
was	B-X
observed	B-X
(	B-X
even	B-X
after	B-X
addition	B-X
of	B-X
several	B-X
equivalents	B-X
of	B-X
H2O2	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
both	B-X
peroxidases	B-X
showed	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
radical-forming	B-X
residue	B-X
that	B-X
could	B-X
affect	B-X
its	B-X
reactivity	B-X
.	B-X

This	O
is	O
in	O
contrast	O
to	O
lignin	O
peroxidase	O
Trp171	O
.	O
<EOS>	B-X
The	B-X
site-directed	B-X
mutations	B-X
H82A	B-X
and	B-X
Q222A	B-X
(	B-X
residues	B-X
near	B-X
the	B-X
heme	B-X
access	B-X
channel	B-X
)	B-X
,	B-X
and	B-X
W171A	B-X
and	B-X
F267L	B-X
(	B-X
residues	B-X
near	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
protein	B-X
)	B-X
were	B-X
introduced	B-X
into	B-X
the	B-X
gene	B-X
encoding	B-X
lignin	B-X
peroxidase	B-X
(	B-X
LiP	B-X
)	B-X
isozyme	B-X
H8	B-X
from	B-X
Phanerochaete	B-X
chrysosporium	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
W171A	B-X
variant	B-X
was	B-X
unable	B-X
to	B-X
oxidize	B-X
VA	B-X
,	B-X
confirming	B-X
the	B-X
apparent	B-X
essentiality	B-X
of	B-X
Trp171	B-X
in	B-X
VA	B-X
oxidation	B-X
by	B-X
LiP	B-X
.	B-X
The	B-X
kinetic	B-X
rates	B-X
of	B-X
spontaneous	B-X
LiP	B-X
compound	B-X
I	B-X
reduction	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
VA	B-X
were	B-X
similar	B-X
for	B-X
W171A	B-X
and	B-X
wild-type	B-X
LiP	B-X
,	B-X
suggesting	B-X
that	B-X
there	B-X
may	B-X
not	B-X
be	B-X
a	B-X
radical	B-X
formed	B-X
on	B-X
the	B-X
Trp171	B-X
residue	B-X
of	B-X
LiP	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
VA.	B-X
For	B-X
the	B-X
F267L	B-X
variant	B-X
,	B-X
both	B-X
the	B-X
K	B-X
(	B-X
m	B-X
app	B-X
)	B-X
value	B-X
in	B-X
the	B-X
steady	B-X
state	B-X
and	B-X
the	B-X
apparent	B-X
dissociation	B-X
constant	B-X
(	B-X
K	B-X
(	B-X
D	B-X
)	B-X
)	B-X
for	B-X
compound	B-X
II	B-X
reduction	B-X
were	B-X
greater	B-X
than	B-X
those	B-X
for	B-X
wtLiP	B-X
.	B-X
Whereas	B-X
Trp171	B-X
appears	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
VA	B-X
oxidation	B-X
,	B-X
it	B-X
apparently	B-X
is	B-X
not	B-X
independently	B-X
responsible	B-X
for	B-X
the	B-X
spontaneous	B-X
decomposition	B-X
of	B-X
oxidized	B-X
intermediates	B-X
.	B-X

Analysis	O
of	O
the	O
crystal	O
structures	O
of	O
both	O
peroxidases	O
showed	O
differences	O
in	O
the	O
environment	O
of	O
the	O
protein	O
radical	O
-	O
forming	O
residue	O
that	O
could	O
affect	O
its	O
reactivity	O
.	O
<EOS>	B-X
Versatile	B-X
peroxidases	B-X
(	B-X
VP	B-X
)	B-X
,	B-X
a	B-X
recently	B-X
described	B-X
family	B-X
of	B-X
ligninolytic	B-X
peroxidases	B-X
,	B-X
show	B-X
a	B-X
hybrid	B-X
molecular	B-X
architecture	B-X
combining	B-X
different	B-X
oxidation	B-X
sites	B-X
connected	B-X
to	B-X
the	B-X
heme	B-X
cofactor	B-X
.	B-X
High-resolution	B-X
crystal	B-X
structures	B-X
as	B-X
well	B-X
as	B-X
homology	B-X
models	B-X
of	B-X
VP	B-X
isoenzymes	B-X
from	B-X
the	B-X
fungus	B-X
Pleurotus	B-X
eryngii	B-X
revealed	B-X
three	B-X
possibilities	B-X
for	B-X
long-range	B-X
electron	B-X
transfer	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
compounds	B-X
.	B-X
These	B-X
residues	B-X
are	B-X
exposed	B-X
,	B-X
and	B-X
less	B-X
than	B-X
11	B-X
A	B-X
apart	B-X
from	B-X
the	B-X
heme	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
variants	B-X
showed	B-X
that	B-X
Trp164	B-X
is	B-X
required	B-X
for	B-X
oxidation	B-X
of	B-X
two	B-X
high	B-X
redox	B-X
potential	B-X
model	B-X
substrates	B-X
(	B-X
veratryl	B-X
alcohol	B-X
and	B-X
Reactive	B-X
Black	B-X
5	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
two	B-X
other	B-X
pathways	B-X
(	B-X
starting	B-X
at	B-X
His232	B-X
and	B-X
His82	B-X
)	B-X
are	B-X
not	B-X
involved	B-X
in	B-X
long-range	B-X
electron	B-X
transfer	B-X
(	B-X
LRET	B-X
)	B-X
.	B-X
None	B-X
of	B-X
the	B-X
mutations	B-X
affected	B-X
Mn2+	B-X
oxidation	B-X
,	B-X
which	B-X
would	B-X
take	B-X
place	B-X
at	B-X
the	B-X
opposite	B-X
side	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
It	B-X
is	B-X
proposed	B-X
that	B-X
substrate	B-X
oxidation	B-X
occurs	B-X
via	B-X
a	B-X
protein-based	B-X
radical	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
in	B-X
a	B-X
ligninolytic	B-X
peroxidase	B-X
such	B-X
an	B-X
intermediate	B-X
species	B-X
could	B-X
be	B-X
detected	B-X
by	B-X
low-temperature	B-X
electron	B-X
paramagnetic	B-X
resonance	B-X
of	B-X
H2O2-activated	B-X
VP	B-X
,	B-X
and	B-X
was	B-X
found	B-X
to	B-X
exist	B-X
at	B-X
Trp164	B-X
as	B-X
a	B-X
neutral	B-X
radical	B-X
.	B-X
When	B-X
analyzing	B-X
VP	B-X
crystal	B-X
structures	B-X
close	B-X
to	B-X
atomic	B-X
resolution	B-X
,	B-X
no	B-X
hydroxylation	B-X
of	B-X
the	B-X
Trp164	B-X
Cbeta	B-X
atom	B-X
was	B-X
observed	B-X
(	B-X
even	B-X
after	B-X
addition	B-X
of	B-X
several	B-X
equivalents	B-X
of	B-X
H2O2	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
both	B-X
peroxidases	B-X
showed	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
radical-forming	B-X
residue	B-X
that	B-X
could	B-X
affect	B-X
its	B-X
reactivity	B-X
.	B-X
These	B-X
variations	B-X
would	B-X
also	B-X
explain	B-X
differences	B-X
found	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
some	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
substrates	B-X
.	B-X

These	O
variations	O
would	O
also	O
explain	O
differences	O
found	O
for	O
the	O
oxidation	O
of	O
some	O
high	O
redox	O
potential	O
aromatic	O
substrates	O
.	O
<EOS>	B-X
Versatile	B-X
peroxidases	B-X
(	B-X
VP	B-X
)	B-X
,	B-X
a	B-X
recently	B-X
described	B-X
family	B-X
of	B-X
ligninolytic	B-X
peroxidases	B-X
,	B-X
show	B-X
a	B-X
hybrid	B-X
molecular	B-X
architecture	B-X
combining	B-X
different	B-X
oxidation	B-X
sites	B-X
connected	B-X
to	B-X
the	B-X
heme	B-X
cofactor	B-X
.	B-X
High-resolution	B-X
crystal	B-X
structures	B-X
as	B-X
well	B-X
as	B-X
homology	B-X
models	B-X
of	B-X
VP	B-X
isoenzymes	B-X
from	B-X
the	B-X
fungus	B-X
Pleurotus	B-X
eryngii	B-X
revealed	B-X
three	B-X
possibilities	B-X
for	B-X
long-range	B-X
electron	B-X
transfer	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
compounds	B-X
.	B-X
The	B-X
possible	B-X
pathways	B-X
would	B-X
start	B-X
either	B-X
at	B-X
Trp164	B-X
or	B-X
His232	B-X
of	B-X
isoenzyme	B-X
VPL	B-X
,	B-X
and	B-X
at	B-X
His82	B-X
or	B-X
Trp170	B-X
of	B-X
isoenzyme	B-X
VPS1	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
variants	B-X
showed	B-X
that	B-X
Trp164	B-X
is	B-X
required	B-X
for	B-X
oxidation	B-X
of	B-X
two	B-X
high	B-X
redox	B-X
potential	B-X
model	B-X
substrates	B-X
(	B-X
veratryl	B-X
alcohol	B-X
and	B-X
Reactive	B-X
Black	B-X
5	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
two	B-X
other	B-X
pathways	B-X
(	B-X
starting	B-X
at	B-X
His232	B-X
and	B-X
His82	B-X
)	B-X
are	B-X
not	B-X
involved	B-X
in	B-X
long-range	B-X
electron	B-X
transfer	B-X
(	B-X
LRET	B-X
)	B-X
.	B-X
None	B-X
of	B-X
the	B-X
mutations	B-X
affected	B-X
Mn2+	B-X
oxidation	B-X
,	B-X
which	B-X
would	B-X
take	B-X
place	B-X
at	B-X
the	B-X
opposite	B-X
side	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
Substitution	B-X
of	B-X
Trp164	B-X
by	B-X
His	B-X
also	B-X
resulted	B-X
in	B-X
an	B-X
inactive	B-X
variant	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
indole	B-X
side-chain	B-X
is	B-X
required	B-X
for	B-X
activity	B-X
.	B-X
It	B-X
is	B-X
proposed	B-X
that	B-X
substrate	B-X
oxidation	B-X
occurs	B-X
via	B-X
a	B-X
protein-based	B-X
radical	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
in	B-X
a	B-X
ligninolytic	B-X
peroxidase	B-X
such	B-X
an	B-X
intermediate	B-X
species	B-X
could	B-X
be	B-X
detected	B-X
by	B-X
low-temperature	B-X
electron	B-X
paramagnetic	B-X
resonance	B-X
of	B-X
H2O2-activated	B-X
VP	B-X
,	B-X
and	B-X
was	B-X
found	B-X
to	B-X
exist	B-X
at	B-X
Trp164	B-X
as	B-X
a	B-X
neutral	B-X
radical	B-X
.	B-X
The	B-X
H2O2-activated	B-X
VP	B-X
was	B-X
self-reduced	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
reducing	B-X
substrates	B-X
.	B-X
Trp164	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
this	B-X
reaction	B-X
,	B-X
which	B-X
in	B-X
the	B-X
W164S	B-X
variant	B-X
was	B-X
blocked	B-X
at	B-X
the	B-X
level	B-X
of	B-X
compound	B-X
II	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
both	B-X
peroxidases	B-X
showed	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
radical-forming	B-X
residue	B-X
that	B-X
could	B-X
affect	B-X
its	B-X
reactivity	B-X
.	B-X
These	B-X
variations	B-X
would	B-X
also	B-X
explain	B-X
differences	B-X
found	B-X
for	B-X
the	B-X
oxidation	B-X
of	B-X
some	B-X
high	B-X
redox	B-X
potential	B-X
aromatic	B-X
substrates	B-X
.	B-X

Promoter	O
hypermethylation	O
profile	O
of	O
RASSF1A	B-Protein
,	O
FHIT	B-Protein
,	O
and	O
sFRP1	B-Protein
in	O
intracranial	O
primitive	O
neuroectodermal	O
tumors	O
.	O
<EOS>	B-X
Medulloblastomas	B-X
(	B-X
MBs	B-X
)	B-X
and	B-X
supratentorial	B-X
primitive	B-X
neuroectodermal	B-X
tumors	B-X
(	B-X
SPNETs	B-X
)	B-X
are	B-X
histologically	B-X
alike	B-X
intracranial	B-X
PNETs	B-X
found	B-X
in	B-X
different	B-X
anatomical	B-X
locations	B-X
of	B-X
the	B-X
brain	B-X
.	B-X
Current	B-X
evidence	B-X
suggests	B-X
that	B-X
hypermethylation	B-X
of	B-X
promoter	B-X
CpG	B-X
islands	B-X
is	B-X
a	B-X
common	B-X
epigenetic	B-X
event	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
whether	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
putative	B-X
tumor	B-X
suppressor	B-X
genes	B-X
was	B-X
involved	B-X
in	B-X
both	B-X
types	B-X
of	B-X
intracranial	B-X
PNETs	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
at	B-X
promoter	B-X
regions	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
by	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
in	B-X
a	B-X
cohort	B-X
of	B-X
25	B-X
primary	B-X
MBs	B-X
,	B-X
9	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
3	B-X
MB	B-X
and	B-X
2	B-X
SPNET	B-X
cell	B-X
lines	B-X
.	B-X
Our	B-X
results	B-X
revealed	B-X
no	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
in	B-X
2	B-X
normal	B-X
cerebellar	B-X
and	B-X
5	B-X
normal	B-X
cerebral	B-X
tissue	B-X
specimens	B-X
examined	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
100	B-X
%	B-X
of	B-X
primary	B-X
MBs	B-X
,	B-X
67	B-X
%	B-X
(	B-X
6/9	B-X
)	B-X
of	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
all	B-X
PNET	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
SPNETs	B-X
than	B-X
in	B-X
MBs	B-X
(	B-X
Fisher	B-X
exact	B-X
test	B-X
,	B-X
P	B-X
=	B-X
.014	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
RASSF1A-deficient	B-X
PNET	B-X
cell	B-X
lines	B-X
with	B-X
5-aza-2'deoxycytidine	B-X
,	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
restored	B-X
RASSF1A	B-X
expression	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
contributes	B-X
to	B-X
transcriptional	B-X
silencing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
was	B-X
detected	B-X
in	B-X
22	B-X
%	B-X
(	B-X
2/9	B-X
)	B-X
and	B-X
11	B-X
%	B-X
(	B-X
1/9	B-X
)	B-X
of	B-X
SPNETs	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
not	B-X
in	B-X
any	B-X
MBs	B-X
studied	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
demonstrates	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
is	B-X
a	B-X
common	B-X
event	B-X
in	B-X
intracranial	B-X
PNETs	B-X
,	B-X
whereas	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
are	B-X
epigenetically	B-X
affected	B-X
in	B-X
a	B-X
fraction	B-X
of	B-X
SPNETs	B-X
.	B-X

Medulloblastomas	O
(	O
MBs	O
)	O
and	O
supratentorial	O
primitive	O
neuroectodermal	O
tumors	O
(	O
SPNETs	O
)	O
are	O
histologically	O
alike	O
intracranial	O
PNETs	O
found	O
in	O
different	O
anatomical	O
locations	O
of	O
the	O
brain	O
.	O
<EOS>	B-X
Medulloblastomas	B-X
(	B-X
MBs	B-X
)	B-X
and	B-X
supratentorial	B-X
primitive	B-X
neuroectodermal	B-X
tumors	B-X
(	B-X
SPNETs	B-X
)	B-X
are	B-X
histologically	B-X
alike	B-X
intracranial	B-X
PNETs	B-X
found	B-X
in	B-X
different	B-X
anatomical	B-X
locations	B-X
of	B-X
the	B-X
brain	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
whether	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
putative	B-X
tumor	B-X
suppressor	B-X
genes	B-X
was	B-X
involved	B-X
in	B-X
both	B-X
types	B-X
of	B-X
intracranial	B-X
PNETs	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
at	B-X
promoter	B-X
regions	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
by	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
in	B-X
a	B-X
cohort	B-X
of	B-X
25	B-X
primary	B-X
MBs	B-X
,	B-X
9	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
3	B-X
MB	B-X
and	B-X
2	B-X
SPNET	B-X
cell	B-X
lines	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
100	B-X
%	B-X
of	B-X
primary	B-X
MBs	B-X
,	B-X
67	B-X
%	B-X
(	B-X
6/9	B-X
)	B-X
of	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
all	B-X
PNET	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
SPNETs	B-X
than	B-X
in	B-X
MBs	B-X
(	B-X
Fisher	B-X
exact	B-X
test	B-X
,	B-X
P	B-X
=	B-X
.014	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
was	B-X
detected	B-X
in	B-X
22	B-X
%	B-X
(	B-X
2/9	B-X
)	B-X
and	B-X
11	B-X
%	B-X
(	B-X
1/9	B-X
)	B-X
of	B-X
SPNETs	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
not	B-X
in	B-X
any	B-X
MBs	B-X
studied	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
demonstrates	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
is	B-X
a	B-X
common	B-X
event	B-X
in	B-X
intracranial	B-X
PNETs	B-X
,	B-X
whereas	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
are	B-X
epigenetically	B-X
affected	B-X
in	B-X
a	B-X
fraction	B-X
of	B-X
SPNETs	B-X
.	B-X

Current	O
evidence	O
suggests	O
that	O
hypermethylation	O
of	O
promoter	O
CpG	O
islands	O
is	O
a	O
common	O
epigenetic	O
event	O
in	O
a	O
variety	O
of	O
human	O
cancers	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
promoter	O
hypermethylation	O
of	O
putative	O
tumor	O
suppressor	O
genes	O
was	O
involved	O
in	O
both	O
types	O
of	O
intracranial	O
PNETs	O
.	O
<EOS>	B-X
Medulloblastomas	B-X
(	B-X
MBs	B-X
)	B-X
and	B-X
supratentorial	B-X
primitive	B-X
neuroectodermal	B-X
tumors	B-X
(	B-X
SPNETs	B-X
)	B-X
are	B-X
histologically	B-X
alike	B-X
intracranial	B-X
PNETs	B-X
found	B-X
in	B-X
different	B-X
anatomical	B-X
locations	B-X
of	B-X
the	B-X
brain	B-X
.	B-X
Current	B-X
evidence	B-X
suggests	B-X
that	B-X
hypermethylation	B-X
of	B-X
promoter	B-X
CpG	B-X
islands	B-X
is	B-X
a	B-X
common	B-X
epigenetic	B-X
event	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
whether	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
putative	B-X
tumor	B-X
suppressor	B-X
genes	B-X
was	B-X
involved	B-X
in	B-X
both	B-X
types	B-X
of	B-X
intracranial	B-X
PNETs	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
at	B-X
promoter	B-X
regions	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
by	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
in	B-X
a	B-X
cohort	B-X
of	B-X
25	B-X
primary	B-X
MBs	B-X
,	B-X
9	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
3	B-X
MB	B-X
and	B-X
2	B-X
SPNET	B-X
cell	B-X
lines	B-X
.	B-X
Our	B-X
results	B-X
revealed	B-X
no	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
in	B-X
2	B-X
normal	B-X
cerebellar	B-X
and	B-X
5	B-X
normal	B-X
cerebral	B-X
tissue	B-X
specimens	B-X
examined	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
100	B-X
%	B-X
of	B-X
primary	B-X
MBs	B-X
,	B-X
67	B-X
%	B-X
(	B-X
6/9	B-X
)	B-X
of	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
all	B-X
PNET	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
SPNETs	B-X
than	B-X
in	B-X
MBs	B-X
(	B-X
Fisher	B-X
exact	B-X
test	B-X
,	B-X
P	B-X
=	B-X
.014	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
RASSF1A-deficient	B-X
PNET	B-X
cell	B-X
lines	B-X
with	B-X
5-aza-2'deoxycytidine	B-X
,	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
restored	B-X
RASSF1A	B-X
expression	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
contributes	B-X
to	B-X
transcriptional	B-X
silencing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
was	B-X
detected	B-X
in	B-X
22	B-X
%	B-X
(	B-X
2/9	B-X
)	B-X
and	B-X
11	B-X
%	B-X
(	B-X
1/9	B-X
)	B-X
of	B-X
SPNETs	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
not	B-X
in	B-X
any	B-X
MBs	B-X
studied	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
demonstrates	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
is	B-X
a	B-X
common	B-X
event	B-X
in	B-X
intracranial	B-X
PNETs	B-X
,	B-X
whereas	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
are	B-X
epigenetically	B-X
affected	B-X
in	B-X
a	B-X
fraction	B-X
of	B-X
SPNETs	B-X
.	B-X

We	O
examined	O
the	O
methylation	O
status	O
at	O
promoter	O
regions	O
of	O
RASSF1A	B-Protein
,	O
FHIT	B-Protein
,	O
and	O
sFRP1	B-Protein
by	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
in	O
a	O
cohort	O
of	O
25	O
primary	O
MBs	O
,	O
9	O
primary	O
SPNETs	O
,	O
and	O
3	O
MB	O
and	O
2	O
SPNET	O
cell	O
lines	O
.	O

Our	O
results	O
revealed	O
no	O
promoter	O
hypermethylation	O
of	O
RASSF1A	B-Protein
,	O
FHIT	B-Protein
,	O
and	O
sFRP1	B-Protein
in	O
2	O
normal	O
cerebellar	O
and	O
5	O
normal	O
cerebral	O
tissue	O
specimens	O
examined	O
.	O
<EOS>	B-X
Current	B-X
evidence	B-X
suggests	B-X
that	B-X
hypermethylation	B-X
of	B-X
promoter	B-X
CpG	B-X
islands	B-X
is	B-X
a	B-X
common	B-X
epigenetic	B-X
event	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
whether	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
putative	B-X
tumor	B-X
suppressor	B-X
genes	B-X
was	B-X
involved	B-X
in	B-X
both	B-X
types	B-X
of	B-X
intracranial	B-X
PNETs	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
at	B-X
promoter	B-X
regions	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
by	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
in	B-X
a	B-X
cohort	B-X
of	B-X
25	B-X
primary	B-X
MBs	B-X
,	B-X
9	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
3	B-X
MB	B-X
and	B-X
2	B-X
SPNET	B-X
cell	B-X
lines	B-X
.	B-X
Our	B-X
results	B-X
revealed	B-X
no	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
in	B-X
2	B-X
normal	B-X
cerebellar	B-X
and	B-X
5	B-X
normal	B-X
cerebral	B-X
tissue	B-X
specimens	B-X
examined	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
100	B-X
%	B-X
of	B-X
primary	B-X
MBs	B-X
,	B-X
67	B-X
%	B-X
(	B-X
6/9	B-X
)	B-X
of	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
all	B-X
PNET	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
SPNETs	B-X
than	B-X
in	B-X
MBs	B-X
(	B-X
Fisher	B-X
exact	B-X
test	B-X
,	B-X
P	B-X
=	B-X
.014	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
RASSF1A-deficient	B-X
PNET	B-X
cell	B-X
lines	B-X
with	B-X
5-aza-2'deoxycytidine	B-X
,	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
restored	B-X
RASSF1A	B-X
expression	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
contributes	B-X
to	B-X
transcriptional	B-X
silencing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
was	B-X
detected	B-X
in	B-X
22	B-X
%	B-X
(	B-X
2/9	B-X
)	B-X
and	B-X
11	B-X
%	B-X
(	B-X
1/9	B-X
)	B-X
of	B-X
SPNETs	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
not	B-X
in	B-X
any	B-X
MBs	B-X
studied	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
demonstrates	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
is	B-X
a	B-X
common	B-X
event	B-X
in	B-X
intracranial	B-X
PNETs	B-X
,	B-X
whereas	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
are	B-X
epigenetically	B-X
affected	B-X
in	B-X
a	B-X
fraction	B-X
of	B-X
SPNETs	B-X
.	B-X

In	O
contrast	O
,	O
promoter	O
hypermethylation	O
of	O
RASSF1A	B-Protein
was	O
detected	O
in	O
100	O
%	O
of	O
primary	O
MBs	O
,	O
67	O
%	O
(	O
6	O
/	O
9	O
)	O
of	O
primary	O
SPNETs	O
,	O
and	O
all	O
PNET	O
cell	O
lines	O
.	O
<EOS>	B-X
Medulloblastomas	B-X
(	B-X
MBs	B-X
)	B-X
and	B-X
supratentorial	B-X
primitive	B-X
neuroectodermal	B-X
tumors	B-X
(	B-X
SPNETs	B-X
)	B-X
are	B-X
histologically	B-X
alike	B-X
intracranial	B-X
PNETs	B-X
found	B-X
in	B-X
different	B-X
anatomical	B-X
locations	B-X
of	B-X
the	B-X
brain	B-X
.	B-X
Current	B-X
evidence	B-X
suggests	B-X
that	B-X
hypermethylation	B-X
of	B-X
promoter	B-X
CpG	B-X
islands	B-X
is	B-X
a	B-X
common	B-X
epigenetic	B-X
event	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
whether	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
putative	B-X
tumor	B-X
suppressor	B-X
genes	B-X
was	B-X
involved	B-X
in	B-X
both	B-X
types	B-X
of	B-X
intracranial	B-X
PNETs	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
at	B-X
promoter	B-X
regions	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
by	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
in	B-X
a	B-X
cohort	B-X
of	B-X
25	B-X
primary	B-X
MBs	B-X
,	B-X
9	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
3	B-X
MB	B-X
and	B-X
2	B-X
SPNET	B-X
cell	B-X
lines	B-X
.	B-X
Our	B-X
results	B-X
revealed	B-X
no	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
in	B-X
2	B-X
normal	B-X
cerebellar	B-X
and	B-X
5	B-X
normal	B-X
cerebral	B-X
tissue	B-X
specimens	B-X
examined	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
100	B-X
%	B-X
of	B-X
primary	B-X
MBs	B-X
,	B-X
67	B-X
%	B-X
(	B-X
6/9	B-X
)	B-X
of	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
all	B-X
PNET	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
SPNETs	B-X
than	B-X
in	B-X
MBs	B-X
(	B-X
Fisher	B-X
exact	B-X
test	B-X
,	B-X
P	B-X
=	B-X
.014	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
RASSF1A-deficient	B-X
PNET	B-X
cell	B-X
lines	B-X
with	B-X
5-aza-2'deoxycytidine	B-X
,	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
restored	B-X
RASSF1A	B-X
expression	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
contributes	B-X
to	B-X
transcriptional	B-X
silencing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
was	B-X
detected	B-X
in	B-X
22	B-X
%	B-X
(	B-X
2/9	B-X
)	B-X
and	B-X
11	B-X
%	B-X
(	B-X
1/9	B-X
)	B-X
of	B-X
SPNETs	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
not	B-X
in	B-X
any	B-X
MBs	B-X
studied	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
demonstrates	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
is	B-X
a	B-X
common	B-X
event	B-X
in	B-X
intracranial	B-X
PNETs	B-X
,	B-X
whereas	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
are	B-X
epigenetically	B-X
affected	B-X
in	B-X
a	B-X
fraction	B-X
of	B-X
SPNETs	B-X
.	B-X

The	O
frequency	O
of	O
promoter	O
hypermethylation	O
of	O
RASSF1A	B-Protein
was	O
significantly	O
lower	O
in	O
SPNETs	O
than	O
in	O
MBs	O
(	O
Fisher	O
exact	O
test	O
,	O
P	O
=	O
.	O
014	O
)	O
.	O

Treatment	O
of	O
RASSF1A	B-Protein
-	O
deficient	O
PNET	O
cell	O
lines	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
deoxycytidine	O
,	O
a	O
demethylating	O
agent	O
,	O
restored	O
RASSF1A	B-Protein
expression	O
,	O
providing	O
evidence	O
that	O
promoter	O
hypermethylation	O
contributes	O
to	O
transcriptional	O
silencing	O
.	O
<EOS>	B-X
Medulloblastomas	B-X
(	B-X
MBs	B-X
)	B-X
and	B-X
supratentorial	B-X
primitive	B-X
neuroectodermal	B-X
tumors	B-X
(	B-X
SPNETs	B-X
)	B-X
are	B-X
histologically	B-X
alike	B-X
intracranial	B-X
PNETs	B-X
found	B-X
in	B-X
different	B-X
anatomical	B-X
locations	B-X
of	B-X
the	B-X
brain	B-X
.	B-X
Current	B-X
evidence	B-X
suggests	B-X
that	B-X
hypermethylation	B-X
of	B-X
promoter	B-X
CpG	B-X
islands	B-X
is	B-X
a	B-X
common	B-X
epigenetic	B-X
event	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
whether	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
putative	B-X
tumor	B-X
suppressor	B-X
genes	B-X
was	B-X
involved	B-X
in	B-X
both	B-X
types	B-X
of	B-X
intracranial	B-X
PNETs	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
at	B-X
promoter	B-X
regions	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
by	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
in	B-X
a	B-X
cohort	B-X
of	B-X
25	B-X
primary	B-X
MBs	B-X
,	B-X
9	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
3	B-X
MB	B-X
and	B-X
2	B-X
SPNET	B-X
cell	B-X
lines	B-X
.	B-X
Our	B-X
results	B-X
revealed	B-X
no	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
,	B-X
FHIT	B-X
,	B-X
and	B-X
sFRP1	B-X
in	B-X
2	B-X
normal	B-X
cerebellar	B-X
and	B-X
5	B-X
normal	B-X
cerebral	B-X
tissue	B-X
specimens	B-X
examined	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
detected	B-X
in	B-X
100	B-X
%	B-X
of	B-X
primary	B-X
MBs	B-X
,	B-X
67	B-X
%	B-X
(	B-X
6/9	B-X
)	B-X
of	B-X
primary	B-X
SPNETs	B-X
,	B-X
and	B-X
all	B-X
PNET	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
SPNETs	B-X
than	B-X
in	B-X
MBs	B-X
(	B-X
Fisher	B-X
exact	B-X
test	B-X
,	B-X
P	B-X
=	B-X
.014	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
RASSF1A-deficient	B-X
PNET	B-X
cell	B-X
lines	B-X
with	B-X
5-aza-2'deoxycytidine	B-X
,	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
restored	B-X
RASSF1A	B-X
expression	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
contributes	B-X
to	B-X
transcriptional	B-X
silencing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
was	B-X
detected	B-X
in	B-X
22	B-X
%	B-X
(	B-X
2/9	B-X
)	B-X
and	B-X
11	B-X
%	B-X
(	B-X
1/9	B-X
)	B-X
of	B-X
SPNETs	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
not	B-X
in	B-X
any	B-X
MBs	B-X
studied	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
demonstrates	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
RASSF1A	B-X
is	B-X
a	B-X
common	B-X
event	B-X
in	B-X
intracranial	B-X
PNETs	B-X
,	B-X
whereas	B-X
FHIT	B-X
and	B-X
sFRP1	B-X
are	B-X
epigenetically	B-X
affected	B-X
in	B-X
a	B-X
fraction	B-X
of	B-X
SPNETs	B-X
.	B-X

In	O
addition	O
,	O
promoter	O
hypermethylation	O
of	O
FHIT	B-Protein
and	O
sFRP1	B-Protein
was	O
detected	O
in	O
22	O
%	O
(	O
2	O
/	O
9	O
)	O
and	O
11	O
%	O
(	O
1	O
/	O
9	O
)	O
of	O
SPNETs	O
,	O
respectively	O
,	O
but	O
not	O
in	O
any	O
MBs	O
studied	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
demonstrates	O
that	O
promoter	O
hypermethylation	O
of	O
RASSF1A	B-Protein
is	O
a	O
common	O
event	O
in	O
intracranial	O
PNETs	O
,	O
whereas	O
FHIT	B-Protein
and	O
sFRP1	B-Protein
are	O
epigenetically	O
affected	O
in	O
a	O
fraction	O
of	O
SPNETs	O
.	O

Macroprolactin	B-Protein
(	O
s	O
)	O
:	O
composition	O
and	O
reactivity	O
in	O
immunoassays	O
and	O
laboratory	O
interpretation	O
of	O
results	O
of	O
an	O
unusual	O
patient	O
serum	O
.	O
<EOS>	B-X
Macroprolactin	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
complex	B-X
of	B-X
prolactin	B-X
that	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
elevated	B-X
serum	B-X
prolactin	B-X
as	B-X
determined	B-X
by	B-X
immunoassay	B-X
.	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X

BACKGROUND	O
:	O
Macroprolactin	B-Protein
is	O
a	O
high	O
molecular	O
mass	O
complex	O
of	O
prolactin	B-Protein
that	O
may	O
be	O
the	O
cause	O
of	O
elevated	O
serum	O
prolactin	B-Protein
as	O
determined	O
by	O
immunoassay	O
.	O
<EOS>	B-X
Macroprolactin	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
complex	B-X
of	B-X
prolactin	B-X
that	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
elevated	B-X
serum	B-X
prolactin	B-X
as	B-X
determined	B-X
by	B-X
immunoassay	B-X
.	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

The	O
composition	O
of	O
macroprolactin	B-Protein
and	O
its	O
reactivity	O
in	O
immunoassays	O
are	O
variable	O
but	O
the	O
complex	O
has	O
minimal	O
bioactivity	O
in	O
vivo	O
.	O
<EOS>	B-X
Two	B-X
high	B-X
molecular	B-X
mass	B-X
forms	B-X
of	B-X
prolactin	B-X
(	B-X
PRL	B-X
)	B-X
in	B-X
serum	B-X
have	B-X
been	B-X
identified	B-X
by	B-X
gel	B-X
filtration	B-X
chromatography	B-X
(	B-X
GFC	B-X
)	B-X
:	B-X
macroprolactin	B-X
(	B-X
big-big	B-X
PRL	B-X
,	B-X
>	B-X
100	B-X
kDa	B-X
)	B-X
and	B-X
big	B-X
PRL	B-X
(	B-X
40-60	B-X
kDa	B-X
)	B-X
.	B-X
Macroprolactin	B-X
has	B-X
a	B-X
variable	B-X
composition	B-X
and	B-X
structure	B-X
,	B-X
but	B-X
is	B-X
most	B-X
frequently	B-X
a	B-X
complex	B-X
of	B-X
PRL	B-X
and	B-X
IgG	B-X
,	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
150-170	B-X
kDa	B-X
.	B-X
It	B-X
is	B-X
formed	B-X
in	B-X
the	B-X
circulation	B-X
following	B-X
pituitary	B-X
secretion	B-X
of	B-X
monomeric	B-X
PRL	B-X
but	B-X
has	B-X
a	B-X
longer	B-X
half-life	B-X
,	B-X
and	B-X
the	B-X
PRL	B-X
in	B-X
the	B-X
complex	B-X
remains	B-X
reactive	B-X
to	B-X
a	B-X
variable	B-X
extent	B-X
in	B-X
immunoassays	B-X
.	B-X
In	B-X
the	B-X
majority	B-X
of	B-X
subjects	B-X
little	B-X
or	B-X
no	B-X
macroprolactin	B-X
can	B-X
be	B-X
detected	B-X
in	B-X
serum	B-X
,	B-X
but	B-X
in	B-X
some	B-X
individuals	B-X
it	B-X
may	B-X
be	B-X
the	B-X
predominant	B-X
immunoreactive	B-X
component	B-X
of	B-X
circulating	B-X
PRL	B-X
and	B-X
the	B-X
cause	B-X
of	B-X
apparent	B-X
hyperprolactinaemia	B-X
.	B-X
Owing	B-X
to	B-X
its	B-X
high	B-X
molecular	B-X
mass	B-X
,	B-X
macroprolactin	B-X
appears	B-X
to	B-X
be	B-X
confined	B-X
to	B-X
the	B-X
intravascular	B-X
compartment	B-X
and	B-X
much	B-X
evidence	B-X
indicates	B-X
that	B-X
it	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
and	B-X
is	B-X
not	B-X
of	B-X
pathological	B-X
significance	B-X
.	B-X
Nevertheless	B-X
,	B-X
hyperprolactinaemia	B-X
due	B-X
to	B-X
macroprolactin	B-X
can	B-X
lead	B-X
to	B-X
diagnostic	B-X
confusion	B-X
and	B-X
unnecessary	B-X
further	B-X
investigation	B-X
and	B-X
treatment	B-X
if	B-X
it	B-X
is	B-X
not	B-X
recognized	B-X
as	B-X
such	B-X
.	B-X
Macroprolactin	B-X
is	B-X
a	B-X
common	B-X
cause	B-X
of	B-X
apparent	B-X
hyperprolactinaemia	B-X
with	B-X
some	B-X
assays	B-X
and	B-X
it	B-X
is	B-X
essential	B-X
that	B-X
laboratories	B-X
introduce	B-X
screening	B-X
programmes	B-X
to	B-X
examine	B-X
samples	B-X
with	B-X
elevated	B-X
total	B-X
immunoreactive	B-X
PRL	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
macroprolactin	B-X
and	B-X
determine	B-X
the	B-X
monomeric	B-X
PRL	B-X
component	B-X
which	B-X
is	B-X
known	B-X
to	B-X
be	B-X
bioactive	B-X
in	B-X
vivo	B-X
.	B-X
A	B-X
number	B-X
of	B-X
screening	B-X
tests	B-X
have	B-X
been	B-X
described	B-X
;	B-X
that	B-X
based	B-X
on	B-X
the	B-X
precipitation	B-X
of	B-X
macroprolactin	B-X
with	B-X
polyethylene	B-X
glycol	B-X
has	B-X
been	B-X
the	B-X
most	B-X
widely	B-X
validated	B-X
and	B-X
applied	B-X
.	B-X
In	B-X
comparison	B-X
with	B-X
macroprolactin	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
big	B-X
PRL	B-X
.	B-X
Further	B-X
research	B-X
is	B-X
required	B-X
into	B-X
the	B-X
nature	B-X
of	B-X
macroprolactin	B-X
and	B-X
big	B-X
PRL	B-X
,	B-X
the	B-X
relationships	B-X
between	B-X
high	B-X
molecular	B-X
mass	B-X
forms	B-X
of	B-X
PRL	B-X
,	B-X
and	B-X
their	B-X
clinical	B-X
significance	B-X
.	B-X

Hyperprolactinaemia	O
due	O
to	O
unrecognized	O
macroprolactinaemia	O
can	O
lead	O
to	O
misdiagnosis	O
and	O
mistreatment	O
.	O
<EOS>	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

METHODS	O
:	O
Serum	O
from	O
a	O
patient	O
with	O
an	O
unusual	O
pattern	O
of	O
immunoreactivity	O
was	O
distributed	O
to	O
three	O
users	O
of	O
each	O
of	O
the	O
most	O
popular	O
immunoassays	O
represented	O
in	O
the	O
UK	O
National	O
External	O
Quality	O
Assessment	O
Scheme	O
(	O
NEQAS	O
)	O
for	O
prolactin	B-Protein
.	O
<EOS>	B-X
Macroprolactin	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
complex	B-X
of	B-X
prolactin	B-X
that	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
elevated	B-X
serum	B-X
prolactin	B-X
as	B-X
determined	B-X
by	B-X
immunoassay	B-X
.	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

Clinical	O
details	O
were	O
provided	O
and	O
participating	O
centres	O
were	O
invited	O
to	O
investigate	O
the	O
prolactin	B-Protein
content	O
of	O
the	O
specimen	O
according	O
to	O
their	O
local	O
protocol	O
,	O
and	O
to	O
comment	O
on	O
their	O
results	O
.	O
<EOS>	B-X
Macroprolactin	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
complex	B-X
of	B-X
prolactin	B-X
that	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
elevated	B-X
serum	B-X
prolactin	B-X
as	B-X
determined	B-X
by	B-X
immunoassay	B-X
.	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

The	O
nature	O
of	O
the	O
macroprolactin	B-Protein
in	O
the	O
specimen	O
was	O
investigated	O
in	O
detail	O
by	O
gel	O
filtration	O
chromatography	O
of	O
the	O
native	O
serum	O
and	O
of	O
the	O
serum	O
after	O
adsorption	O
of	O
IgG	O
with	O
protein	O
A	O
,	O
and	O
by	O
affinity	O
chromatography	O
with	O
concanavalin	B-Protein
A	I-Protein
.	O
<EOS>	B-X
Macroprolactin	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
complex	B-X
of	B-X
prolactin	B-X
that	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
elevated	B-X
serum	B-X
prolactin	B-X
as	B-X
determined	B-X
by	B-X
immunoassay	B-X
.	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

RESULTS	O
:	O
Gel	O
filtration	O
studies	O
revealed	O
two	O
peaks	O
of	O
macroprolactin	B-Protein
in	O
this	O
serum	O
.	O
<EOS>	B-X
Macroprolactin	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
complex	B-X
of	B-X
prolactin	B-X
that	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
elevated	B-X
serum	B-X
prolactin	B-X
as	B-X
determined	B-X
by	B-X
immunoassay	B-X
.	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

These	O
macroprolactins	B-Protein
were	O
shown	O
to	O
be	O
different	O
in	O
their	O
IgG	O
content	O
and	O
degree	O
of	O
glycosylation	O
.	O

All	O
eight	O
immunoassays	O
reacted	O
strongly	O
with	O
the	O
macroprolactin	B-Protein
present	O
.	O
<EOS>	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

The	O
majority	O
(	O
78	O
%	O
)	O
of	O
centres	O
that	O
interpreted	O
their	O
results	O
either	O
demonstrated	O
the	O
presence	O
of	O
macroprolactin	B-Protein
in	O
the	O
specimen	O
,	O
or	O
suggested	O
it	O
as	O
a	O
likely	O
cause	O
of	O
the	O
hyperprolactinaemia	O
.	O
<EOS>	B-X
Nonalcoholic	B-X
fatty	B-X
liver	B-X
disease	B-X
(	B-X
NAFLD	B-X
)	B-X
is	B-X
the	B-X
leading	B-X
cause	B-X
of	B-X
chronic	B-X
liver	B-X
disease	B-X
.	B-X
For	B-X
instance	B-X
,	B-X
our	B-X
results	B-X
show	B-X
that	B-X
hyperprolactinemia	B-X
,	B-X
hypercortisolemia	B-X
,	B-X
and	B-X
polycystic	B-X
ovary	B-X
syndrome	B-X
seem	B-X
to	B-X
worsen	B-X
NAFLD	B-X
's	B-X
pathway	B-X
.	B-X
Hypothyroidism	B-X
and	B-X
low	B-X
growth	B-X
hormone	B-X
levels	B-X
also	B-X
may	B-X
contribute	B-X
to	B-X
NAFLD	B-X
's	B-X
progression	B-X
,	B-X
and	B-X
a	B-X
bidirectional	B-X
association	B-X
between	B-X
hypercortisolism	B-X
and	B-X
hypogonadism	B-X
and	B-X
the	B-X
NAFLD	B-X
pathway	B-X
looks	B-X
likely	B-X
,	B-X
given	B-X
the	B-X
current	B-X
evidence	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
concluded	B-X
that	B-X
it	B-X
appears	B-X
likely	B-X
that	B-X
there	B-X
is	B-X
a	B-X
link	B-X
between	B-X
several	B-X
endocrine	B-X
disorders	B-X
and	B-X
NAFLD	B-X
other	B-X
than	B-X
the	B-X
typically	B-X
known	B-X
type	B-X
2	B-X
diabetes	B-X
mellitus	B-X
and	B-X
metabolic	B-X
syndrome	B-X
(	B-X
MS	B-X
)	B-X
.	B-X

However	O
,	O
two	O
centres	O
inappropriately	O
excluded	O
macroprolactinaemia	O
as	O
the	O
cause	O
of	O
the	O
elevated	O
prolactin	B-Protein
,	O
and	O
a	O
further	O
two	O
did	O
not	O
consider	O
it	O
at	O
all	O
.	O

Data	O
from	O
previous	O
UK	O
NEQAS	O
distributions	O
(	O
between	O
1996	O
and	O
2003	O
)	O
of	O
macroprolactin	B-Protein
containing	O
sera	O
are	O
presented	O
which	O
suggest	O
that	O
the	O
frequency	O
of	O
recognition	O
of	O
macroprolactin	B-Protein
as	O
a	O
possible	O
cause	O
of	O
hyperprolactinaemia	O
has	O
increased	O
over	O
time	O
.	O
<EOS>	B-X
Macroprolactin	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
complex	B-X
of	B-X
prolactin	B-X
that	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
elevated	B-X
serum	B-X
prolactin	B-X
as	B-X
determined	B-X
by	B-X
immunoassay	B-X
.	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

CONCLUSIONS	O
:	O
Very	O
high	O
molecular	O
mass	O
forms	O
of	O
prolactin	B-Protein
and	O
the	O
presence	O
of	O
multiple	O
molecular	O
mass	O
forms	O
,	O
as	O
detected	O
in	O
the	O
case	O
presented	O
here	O
,	O
are	O
uncommon	O
.	O
<EOS>	B-X
Macroprolactin	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
complex	B-X
of	B-X
prolactin	B-X
that	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
elevated	B-X
serum	B-X
prolactin	B-X
as	B-X
determined	B-X
by	B-X
immunoassay	B-X
.	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

Also	O
,	O
the	O
pattern	O
of	O
immunoreactivity	O
reported	O
in	O
this	O
specimen	O
was	O
unusual	O
as	O
most	O
macroprolactins	B-Protein
studied	O
previously	O
react	O
less	O
strongly	O
in	O
,	O
for	O
example	O
,	O
the	O
Bayer	O
ADVIA	O
Centaur	O
assay	O
compared	O
to	O
the	O
Roche	O
E170	O
assay	O
.	O

Both	O
peaks	O
of	O
macroprolactin	B-Protein
in	O
this	O
serum	O
reacted	O
in	O
all	O
assays	O
tested	O
.	O
<EOS>	B-X
Macroprolactin	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
complex	B-X
of	B-X
prolactin	B-X
that	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
elevated	B-X
serum	B-X
prolactin	B-X
as	B-X
determined	B-X
by	B-X
immunoassay	B-X
.	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

This	O
case	O
highlights	O
the	O
variable	O
nature	O
and	O
immunoreactive	O
behaviour	O
of	O
macroprolactin	B-Protein
species	O
.	O
<EOS>	B-X
The	B-X
composition	B-X
of	B-X
macroprolactin	B-X
and	B-X
its	B-X
reactivity	B-X
in	B-X
immunoassays	B-X
are	B-X
variable	B-X
but	B-X
the	B-X
complex	B-X
has	B-X
minimal	B-X
bioactivity	B-X
in	B-X
vivo	B-X
.	B-X
Hyperprolactinaemia	B-X
due	B-X
to	B-X
unrecognized	B-X
macroprolactinaemia	B-X
can	B-X
lead	B-X
to	B-X
misdiagnosis	B-X
and	B-X
mistreatment	B-X
.	B-X

Sodium	O
butyrate	O
ameliorates	O
histone	B-Protein
hypoacetylation	O
and	O
neurodegenerative	O
phenotypes	O
in	O
a	O
mouse	O
model	O
for	O
DRPLA	O
.	O

Dentatorubral	O
-	O
pallidoluysian	O
atrophy	O
(	O
DRPLA	O
)	O
is	O
a	O
progressive	O
neurodegenerative	O
disease	O
caused	O
by	O
polyglutamine	O
expansion	O
within	O
the	O
Atrophin	B-Protein
-	I-Protein
1	I-Protein
protein	O
.	O
<EOS>	B-X
Dentatorubral-pallidoluysian	B-X
atrophy	B-X
(	B-X
DRPLA	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
,	B-X
incurable	B-X
genetic	B-X
disease	B-X
that	B-X
belongs	B-X
to	B-X
the	B-X
group	B-X
of	B-X
polyglutamine	B-X
(	B-X
polyQ	B-X
)	B-X
diseases	B-X
.	B-X
DRPLA	B-X
is	B-X
the	B-X
most	B-X
common	B-X
in	B-X
the	B-X
Japanese	B-X
population	B-X
;	B-X
however	B-X
,	B-X
its	B-X
global	B-X
prevalence	B-X
is	B-X
also	B-X
increasing	B-X
due	B-X
to	B-X
better	B-X
clinical	B-X
recognition	B-X
.	B-X
DRPLA	B-X
is	B-X
caused	B-X
by	B-X
dynamic	B-X
mutation	B-X
of	B-X
CAG	B-X
repeat	B-X
expansion	B-X
in	B-X
ATN1	B-X
gene	B-X
encoding	B-X
the	B-X
atrophin-1	B-X
protein	B-X
.	B-X
In	B-X
the	B-X
cascade	B-X
of	B-X
molecular	B-X
disturbances	B-X
,	B-X
the	B-X
pathological	B-X
form	B-X
of	B-X
atrophin-1	B-X
is	B-X
the	B-X
initial	B-X
factor	B-X
,	B-X
which	B-X
has	B-X
not	B-X
been	B-X
precisely	B-X
characterized	B-X
so	B-X
far	B-X
.	B-X
Reports	B-X
indicate	B-X
that	B-X
DRPLA	B-X
is	B-X
associated	B-X
with	B-X
disrupted	B-X
protein-protein	B-X
interactions	B-X
(	B-X
in	B-X
which	B-X
an	B-X
expanded	B-X
polyQ	B-X
tract	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
gene	B-X
expression	B-X
deregulation	B-X
.	B-X
There	B-X
is	B-X
a	B-X
great	B-X
need	B-X
to	B-X
design	B-X
efficient	B-X
therapy	B-X
that	B-X
would	B-X
address	B-X
the	B-X
underlying	B-X
neurodegenerative	B-X
process	B-X
and	B-X
thus	B-X
prevent	B-X
or	B-X
alleviate	B-X
DRPLA	B-X
symptoms	B-X
.	B-X
An	B-X
in-depth	B-X
understanding	B-X
of	B-X
the	B-X
normal	B-X
atrophin-1	B-X
function	B-X
and	B-X
mutant	B-X
atrophin-1	B-X
dysfunction	B-X
is	B-X
crucial	B-X
for	B-X
this	B-X
purpose	B-X
.	B-X

To	O
study	O
the	O
mechanism	O
of	O
this	O
disease	O
and	O
to	O
test	O
potential	O
therapeutic	O
methods	O
,	O
we	O
established	O
Atro	O
-	O
118Q	O
transgenic	O
mice	O
,	O
which	O
express	O
in	O
neurons	O
a	O
mutant	O
human	O
Atrophin	B-Protein
-	I-Protein
1	I-Protein
protein	O
that	O
contains	O
an	O
expanded	O
stretch	O
of	O
118	O
glutamines	O
.	O

Consistent	O
with	O
the	O
results	O
from	O
previous	O
studies	O
on	O
transgenic	O
mice	O
that	O
expressed	O
mutant	O
Atrophin	B-Protein
-	I-Protein
1	I-Protein
with	O
65	O
glutamines	O
,	O
Atro	O
-	O
118Q	O
mice	O
exhibited	O
several	O
neurodegenerative	O
phenotypes	O
that	O
are	O
commonly	O
seen	O
in	O
DRPLA	O
patients	O
,	O
including	O
ataxia	O
,	O
tremors	O
,	O
and	O
other	O
motor	O
defects	O
.	O
<EOS>	B-X
Dentatorubral-pallidoluysian	B-X
atrophy	B-X
(	B-X
DRPLA	B-X
)	B-X
is	B-X
a	B-X
progressive	B-X
neurodegenerative	B-X
disease	B-X
caused	B-X
by	B-X
polyglutamine	B-X
expansion	B-X
within	B-X
the	B-X
Atrophin-1	B-X
protein	B-X
.	B-X
To	B-X
study	B-X
the	B-X
mechanism	B-X
of	B-X
this	B-X
disease	B-X
and	B-X
to	B-X
test	B-X
potential	B-X
therapeutic	B-X
methods	B-X
,	B-X
we	B-X
established	B-X
Atro-118Q	B-X
transgenic	B-X
mice	B-X
,	B-X
which	B-X
express	B-X
in	B-X
neurons	B-X
a	B-X
mutant	B-X
human	B-X
Atrophin-1	B-X
protein	B-X
that	B-X
contains	B-X
an	B-X
expanded	B-X
stretch	B-X
of	B-X
118	B-X
glutamines	B-X
.	B-X
Consistent	B-X
with	B-X
the	B-X
results	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transgenic	B-X
mice	B-X
that	B-X
expressed	B-X
mutant	B-X
Atrophin-1	B-X
with	B-X
65	B-X
glutamines	B-X
,	B-X
Atro-118Q	B-X
mice	B-X
exhibited	B-X
several	B-X
neurodegenerative	B-X
phenotypes	B-X
that	B-X
are	B-X
commonly	B-X
seen	B-X
in	B-X
DRPLA	B-X
patients	B-X
,	B-X
including	B-X
ataxia	B-X
,	B-X
tremors	B-X
,	B-X
and	B-X
other	B-X
motor	B-X
defects	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
human	B-X
Atrophin-1	B-X
could	B-X
not	B-X
rescue	B-X
the	B-X
motor	B-X
and	B-X
survival	B-X
defects	B-X
in	B-X
Atro-118Q	B-X
mice	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
mutant	B-X
protein	B-X
with	B-X
polyglutamine	B-X
expansion	B-X
does	B-X
not	B-X
simply	B-X
function	B-X
in	B-X
a	B-X
dominant	B-X
negative	B-X
manner	B-X
.	B-X
Biochemical	B-X
analysis	B-X
of	B-X
Atro-118Q	B-X
mice	B-X
revealed	B-X
hypoacetylation	B-X
of	B-X
histone	B-X
H3	B-X
in	B-X
brain	B-X
tissues	B-X
and	B-X
thus	B-X
suggested	B-X
that	B-X
global	B-X
gene	B-X
repression	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
neurodegeneration	B-X
in	B-X
this	B-X
mouse	B-X
model	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
intraperitoneal	B-X
administration	B-X
of	B-X
sodium	B-X
butyrate	B-X
,	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
ameliorated	B-X
the	B-X
histone	B-X
acetylation	B-X
defects	B-X
,	B-X
significantly	B-X
improved	B-X
motor	B-X
performance	B-X
,	B-X
and	B-X
extended	B-X
the	B-X
average	B-X
life	B-X
span	B-X
of	B-X
Atro-118Q	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
transcription	B-X
deregulation	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
polyglutamine	B-X
expansion	B-X
diseases	B-X
and	B-X
suggest	B-X
that	B-X
reversion	B-X
of	B-X
transcription	B-X
repression	B-X
with	B-X
small	B-X
molecules	B-X
such	B-X
as	B-X
sodium	B-X
butyrate	B-X
is	B-X
a	B-X
feasible	B-X
approach	B-X
to	B-X
treating	B-X
DRPLA	B-X
symptoms	B-X
.	B-X

Overexpression	O
of	O
wild	O
-	O
type	O
human	O
Atrophin	B-Protein
-	I-Protein
1	I-Protein
could	O
not	O
rescue	O
the	O
motor	O
and	O
survival	O
defects	O
in	O
Atro	O
-	O
118Q	O
mice	O
,	O
indicating	O
that	O
the	O
mutant	O
protein	O
with	O
polyglutamine	O
expansion	O
does	O
not	O
simply	O
function	O
in	O
a	O
dominant	O
negative	O
manner	O
.	O

Biochemical	O
analysis	O
of	O
Atro	O
-	O
118Q	O
mice	O
revealed	O
hypoacetylation	O
of	O
histone	B-Protein
H3	I-Protein
in	O
brain	O
tissues	O
and	O
thus	O
suggested	O
that	O
global	O
gene	O
repression	O
is	O
an	O
underlying	O
mechanism	O
for	O
neurodegeneration	O
in	O
this	O
mouse	O
model	O
.	O
<EOS>	B-X
Dentatorubral-pallidoluysian	B-X
atrophy	B-X
(	B-X
DRPLA	B-X
)	B-X
is	B-X
a	B-X
progressive	B-X
neurodegenerative	B-X
disease	B-X
caused	B-X
by	B-X
polyglutamine	B-X
expansion	B-X
within	B-X
the	B-X
Atrophin-1	B-X
protein	B-X
.	B-X
To	B-X
study	B-X
the	B-X
mechanism	B-X
of	B-X
this	B-X
disease	B-X
and	B-X
to	B-X
test	B-X
potential	B-X
therapeutic	B-X
methods	B-X
,	B-X
we	B-X
established	B-X
Atro-118Q	B-X
transgenic	B-X
mice	B-X
,	B-X
which	B-X
express	B-X
in	B-X
neurons	B-X
a	B-X
mutant	B-X
human	B-X
Atrophin-1	B-X
protein	B-X
that	B-X
contains	B-X
an	B-X
expanded	B-X
stretch	B-X
of	B-X
118	B-X
glutamines	B-X
.	B-X
Consistent	B-X
with	B-X
the	B-X
results	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transgenic	B-X
mice	B-X
that	B-X
expressed	B-X
mutant	B-X
Atrophin-1	B-X
with	B-X
65	B-X
glutamines	B-X
,	B-X
Atro-118Q	B-X
mice	B-X
exhibited	B-X
several	B-X
neurodegenerative	B-X
phenotypes	B-X
that	B-X
are	B-X
commonly	B-X
seen	B-X
in	B-X
DRPLA	B-X
patients	B-X
,	B-X
including	B-X
ataxia	B-X
,	B-X
tremors	B-X
,	B-X
and	B-X
other	B-X
motor	B-X
defects	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
human	B-X
Atrophin-1	B-X
could	B-X
not	B-X
rescue	B-X
the	B-X
motor	B-X
and	B-X
survival	B-X
defects	B-X
in	B-X
Atro-118Q	B-X
mice	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
mutant	B-X
protein	B-X
with	B-X
polyglutamine	B-X
expansion	B-X
does	B-X
not	B-X
simply	B-X
function	B-X
in	B-X
a	B-X
dominant	B-X
negative	B-X
manner	B-X
.	B-X
Biochemical	B-X
analysis	B-X
of	B-X
Atro-118Q	B-X
mice	B-X
revealed	B-X
hypoacetylation	B-X
of	B-X
histone	B-X
H3	B-X
in	B-X
brain	B-X
tissues	B-X
and	B-X
thus	B-X
suggested	B-X
that	B-X
global	B-X
gene	B-X
repression	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
neurodegeneration	B-X
in	B-X
this	B-X
mouse	B-X
model	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
intraperitoneal	B-X
administration	B-X
of	B-X
sodium	B-X
butyrate	B-X
,	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
ameliorated	B-X
the	B-X
histone	B-X
acetylation	B-X
defects	B-X
,	B-X
significantly	B-X
improved	B-X
motor	B-X
performance	B-X
,	B-X
and	B-X
extended	B-X
the	B-X
average	B-X
life	B-X
span	B-X
of	B-X
Atro-118Q	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
transcription	B-X
deregulation	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
polyglutamine	B-X
expansion	B-X
diseases	B-X
and	B-X
suggest	B-X
that	B-X
reversion	B-X
of	B-X
transcription	B-X
repression	B-X
with	B-X
small	B-X
molecules	B-X
such	B-X
as	B-X
sodium	B-X
butyrate	B-X
is	B-X
a	B-X
feasible	B-X
approach	B-X
to	B-X
treating	B-X
DRPLA	B-X
symptoms	B-X
.	B-X

We	O
further	O
show	O
that	O
intraperitoneal	O
administration	O
of	O
sodium	O
butyrate	O
,	O
a	O
histone	B-Protein
deacetylase	O
inhibitor	O
,	O
ameliorated	O
the	O
histone	B-Protein
acetylation	O
defects	O
,	O
significantly	O
improved	O
motor	O
performance	O
,	O
and	O
extended	O
the	O
average	O
life	O
span	O
of	O
Atro	O
-	O
118Q	O
mice	O
.	O
<EOS>	B-X
Dentatorubral-pallidoluysian	B-X
atrophy	B-X
(	B-X
DRPLA	B-X
)	B-X
is	B-X
a	B-X
progressive	B-X
neurodegenerative	B-X
disease	B-X
caused	B-X
by	B-X
polyglutamine	B-X
expansion	B-X
within	B-X
the	B-X
Atrophin-1	B-X
protein	B-X
.	B-X
To	B-X
study	B-X
the	B-X
mechanism	B-X
of	B-X
this	B-X
disease	B-X
and	B-X
to	B-X
test	B-X
potential	B-X
therapeutic	B-X
methods	B-X
,	B-X
we	B-X
established	B-X
Atro-118Q	B-X
transgenic	B-X
mice	B-X
,	B-X
which	B-X
express	B-X
in	B-X
neurons	B-X
a	B-X
mutant	B-X
human	B-X
Atrophin-1	B-X
protein	B-X
that	B-X
contains	B-X
an	B-X
expanded	B-X
stretch	B-X
of	B-X
118	B-X
glutamines	B-X
.	B-X
Consistent	B-X
with	B-X
the	B-X
results	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transgenic	B-X
mice	B-X
that	B-X
expressed	B-X
mutant	B-X
Atrophin-1	B-X
with	B-X
65	B-X
glutamines	B-X
,	B-X
Atro-118Q	B-X
mice	B-X
exhibited	B-X
several	B-X
neurodegenerative	B-X
phenotypes	B-X
that	B-X
are	B-X
commonly	B-X
seen	B-X
in	B-X
DRPLA	B-X
patients	B-X
,	B-X
including	B-X
ataxia	B-X
,	B-X
tremors	B-X
,	B-X
and	B-X
other	B-X
motor	B-X
defects	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
human	B-X
Atrophin-1	B-X
could	B-X
not	B-X
rescue	B-X
the	B-X
motor	B-X
and	B-X
survival	B-X
defects	B-X
in	B-X
Atro-118Q	B-X
mice	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
mutant	B-X
protein	B-X
with	B-X
polyglutamine	B-X
expansion	B-X
does	B-X
not	B-X
simply	B-X
function	B-X
in	B-X
a	B-X
dominant	B-X
negative	B-X
manner	B-X
.	B-X
Biochemical	B-X
analysis	B-X
of	B-X
Atro-118Q	B-X
mice	B-X
revealed	B-X
hypoacetylation	B-X
of	B-X
histone	B-X
H3	B-X
in	B-X
brain	B-X
tissues	B-X
and	B-X
thus	B-X
suggested	B-X
that	B-X
global	B-X
gene	B-X
repression	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
neurodegeneration	B-X
in	B-X
this	B-X
mouse	B-X
model	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
intraperitoneal	B-X
administration	B-X
of	B-X
sodium	B-X
butyrate	B-X
,	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
ameliorated	B-X
the	B-X
histone	B-X
acetylation	B-X
defects	B-X
,	B-X
significantly	B-X
improved	B-X
motor	B-X
performance	B-X
,	B-X
and	B-X
extended	B-X
the	B-X
average	B-X
life	B-X
span	B-X
of	B-X
Atro-118Q	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
transcription	B-X
deregulation	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
polyglutamine	B-X
expansion	B-X
diseases	B-X
and	B-X
suggest	B-X
that	B-X
reversion	B-X
of	B-X
transcription	B-X
repression	B-X
with	B-X
small	B-X
molecules	B-X
such	B-X
as	B-X
sodium	B-X
butyrate	B-X
is	B-X
a	B-X
feasible	B-X
approach	B-X
to	B-X
treating	B-X
DRPLA	B-X
symptoms	B-X
.	B-X

These	O
results	O
support	O
the	O
hypothesis	O
that	O
transcription	O
deregulation	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
polyglutamine	O
expansion	O
diseases	O
and	O
suggest	O
that	O
reversion	O
of	O
transcription	O
repression	O
with	O
small	O
molecules	O
such	O
as	O
sodium	O
butyrate	O
is	O
a	O
feasible	O
approach	O
to	O
treating	O
DRPLA	O
symptoms	O
.	O
<EOS>	B-X
Dentatorubral-pallidoluysian	B-X
atrophy	B-X
(	B-X
DRPLA	B-X
)	B-X
is	B-X
a	B-X
progressive	B-X
neurodegenerative	B-X
disease	B-X
caused	B-X
by	B-X
polyglutamine	B-X
expansion	B-X
within	B-X
the	B-X
Atrophin-1	B-X
protein	B-X
.	B-X
Consistent	B-X
with	B-X
the	B-X
results	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transgenic	B-X
mice	B-X
that	B-X
expressed	B-X
mutant	B-X
Atrophin-1	B-X
with	B-X
65	B-X
glutamines	B-X
,	B-X
Atro-118Q	B-X
mice	B-X
exhibited	B-X
several	B-X
neurodegenerative	B-X
phenotypes	B-X
that	B-X
are	B-X
commonly	B-X
seen	B-X
in	B-X
DRPLA	B-X
patients	B-X
,	B-X
including	B-X
ataxia	B-X
,	B-X
tremors	B-X
,	B-X
and	B-X
other	B-X
motor	B-X
defects	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
human	B-X
Atrophin-1	B-X
could	B-X
not	B-X
rescue	B-X
the	B-X
motor	B-X
and	B-X
survival	B-X
defects	B-X
in	B-X
Atro-118Q	B-X
mice	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
mutant	B-X
protein	B-X
with	B-X
polyglutamine	B-X
expansion	B-X
does	B-X
not	B-X
simply	B-X
function	B-X
in	B-X
a	B-X
dominant	B-X
negative	B-X
manner	B-X
.	B-X
Biochemical	B-X
analysis	B-X
of	B-X
Atro-118Q	B-X
mice	B-X
revealed	B-X
hypoacetylation	B-X
of	B-X
histone	B-X
H3	B-X
in	B-X
brain	B-X
tissues	B-X
and	B-X
thus	B-X
suggested	B-X
that	B-X
global	B-X
gene	B-X
repression	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
neurodegeneration	B-X
in	B-X
this	B-X
mouse	B-X
model	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
intraperitoneal	B-X
administration	B-X
of	B-X
sodium	B-X
butyrate	B-X
,	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
ameliorated	B-X
the	B-X
histone	B-X
acetylation	B-X
defects	B-X
,	B-X
significantly	B-X
improved	B-X
motor	B-X
performance	B-X
,	B-X
and	B-X
extended	B-X
the	B-X
average	B-X
life	B-X
span	B-X
of	B-X
Atro-118Q	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
transcription	B-X
deregulation	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
polyglutamine	B-X
expansion	B-X
diseases	B-X
and	B-X
suggest	B-X
that	B-X
reversion	B-X
of	B-X
transcription	B-X
repression	B-X
with	B-X
small	B-X
molecules	B-X
such	B-X
as	B-X
sodium	B-X
butyrate	B-X
is	B-X
a	B-X
feasible	B-X
approach	B-X
to	B-X
treating	B-X
DRPLA	B-X
symptoms	B-X
.	B-X

Changes	O
in	O
liver	O
and	O
plasma	O
acetylcholinesterase	B-Protein
in	O
rats	O
with	O
cirrhosis	O
induced	O
by	O
bile	O
duct	O
ligation	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

Classical	O
studies	O
of	O
cholinesterase	O
activity	O
during	O
liver	O
dysfunction	O
have	O
focused	O
on	O
butyrylcholinesterase	B-Protein
(	O
BuChE	B-Protein
)	O
,	O
whereas	O
acetylcholinesterase	B-Protein
(	O
AChE	B-Protein
)	O
has	O
not	O
received	O
much	O
attention	O
.	O

In	O
the	O
current	O
study	O
,	O
liver	O
and	O
plasma	O
AChE	B-Protein
levels	O
were	O
investigated	O
in	O
rats	O
with	O
cirrhosis	O
induced	O
after	O
3	O
weeks	O
of	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
SDS-PAGE	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
major	B-X
55-kd	B-X
immunoreactive	B-X
AChE	B-X
band	B-X
was	B-X
decreased	B-X
in	B-X
BDL	B-X
as	B-X
compared	B-X
with	B-X
NL	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
BDL	B-X
affects	B-X
AChE	B-X
levels	B-X
in	B-X
both	B-X
hepatocytes	B-X
and	B-X
Kupffer	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
altered	B-X
AChE	B-X
expression	B-X
was	B-X
mainly	B-X
reflected	B-X
in	B-X
an	B-X
alteration	B-X
in	B-X
hepatocyte	B-X
AChE	B-X
pattern	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

BDL	O
rats	O
showed	O
a	O
pronounced	O
decrease	O
in	O
liver	O
AChE	B-Protein
levels	O
(	O
approximately	O
50	O
%	O
)	O
compared	O
with	O
sham	O
-	O
operated	O
(	O
non	O
-	O
ligated	O
,	O
NL	O
)	O
controls	O
;	O
whereas	O
liver	O
BuChE	B-Protein
appeared	O
unaffected	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
SDS-PAGE	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
major	B-X
55-kd	B-X
immunoreactive	B-X
AChE	B-X
band	B-X
was	B-X
decreased	B-X
in	B-X
BDL	B-X
as	B-X
compared	B-X
with	B-X
NL	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
BDL	B-X
affects	B-X
AChE	B-X
levels	B-X
in	B-X
both	B-X
hepatocytes	B-X
and	B-X
Kupffer	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
altered	B-X
AChE	B-X
expression	B-X
was	B-X
mainly	B-X
reflected	B-X
in	B-X
an	B-X
alteration	B-X
in	B-X
hepatocyte	B-X
AChE	B-X
pattern	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

A	O
selective	O
loss	O
of	O
tetrameric	O
(	O
G4	O
)	O
AChE	B-Protein
was	O
detected	O
in	O
BDL	O
rats	O
,	O
an	O
effect	O
also	O
observed	O
in	O
rats	O
with	O
carbon	O
tetrachloride	O
-	O
induced	O
cirrhosis	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
SDS-PAGE	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
major	B-X
55-kd	B-X
immunoreactive	B-X
AChE	B-X
band	B-X
was	B-X
decreased	B-X
in	B-X
BDL	B-X
as	B-X
compared	B-X
with	B-X
NL	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
BDL	B-X
affects	B-X
AChE	B-X
levels	B-X
in	B-X
both	B-X
hepatocytes	B-X
and	B-X
Kupffer	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
altered	B-X
AChE	B-X
expression	B-X
was	B-X
mainly	B-X
reflected	B-X
in	B-X
an	B-X
alteration	B-X
in	B-X
hepatocyte	B-X
AChE	B-X
pattern	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

In	O
accordance	O
,	O
SDS	O
-	O
PAGE	O
analysis	O
showed	O
that	O
the	O
major	O
55	O
-	O
kd	O
immunoreactive	O
AChE	B-Protein
band	O
was	O
decreased	O
in	O
BDL	O
as	O
compared	O
with	O
NL	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
SDS-PAGE	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
major	B-X
55-kd	B-X
immunoreactive	B-X
AChE	B-X
band	B-X
was	B-X
decreased	B-X
in	B-X
BDL	B-X
as	B-X
compared	B-X
with	B-X
NL	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
BDL	B-X
affects	B-X
AChE	B-X
levels	B-X
in	B-X
both	B-X
hepatocytes	B-X
and	B-X
Kupffer	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
altered	B-X
AChE	B-X
expression	B-X
was	B-X
mainly	B-X
reflected	B-X
in	B-X
an	B-X
alteration	B-X
in	B-X
hepatocyte	B-X
AChE	B-X
pattern	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

A	O
65	O
-	O
kd	O
band	O
,	O
attributed	O
in	O
part	O
to	O
inactive	O
AChE	B-Protein
,	O
was	O
increased	O
as	O
became	O
the	O
most	O
abundant	O
AChE	B-Protein
subunit	O
in	O
BDL	O
liver	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
SDS-PAGE	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
major	B-X
55-kd	B-X
immunoreactive	B-X
AChE	B-X
band	B-X
was	B-X
decreased	B-X
in	B-X
BDL	B-X
as	B-X
compared	B-X
with	B-X
NL	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
BDL	B-X
affects	B-X
AChE	B-X
levels	B-X
in	B-X
both	B-X
hepatocytes	B-X
and	B-X
Kupffer	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
altered	B-X
AChE	B-X
expression	B-X
was	B-X
mainly	B-X
reflected	B-X
in	B-X
an	B-X
alteration	B-X
in	B-X
hepatocyte	B-X
AChE	B-X
pattern	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

The	O
overall	O
decrease	O
in	O
AChE	B-Protein
activity	O
in	O
BDL	O
liver	O
was	O
not	O
accompanied	O
by	O
a	O
reduction	O
of	O
AChE	B-Protein
transcripts	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
examined	B-X
potential	B-X
alterations	B-X
in	B-X
the	B-X
brain	B-X
levels	B-X
of	B-X
key	B-X
cholinergic	B-X
enzymes	B-X
in	B-X
cirrhotic	B-X
patients	B-X
and	B-X
animal	B-X
models	B-X
with	B-X
liver	B-X
failure	B-X
.	B-X
An	B-X
increase	B-X
(	B-X
~30	B-X
%	B-X
)	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
acetylcholine-hydrolyzing	B-X
enzyme	B-X
,	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
is	B-X
observed	B-X
in	B-X
the	B-X
brain	B-X
cortex	B-X
from	B-X
patients	B-X
deceased	B-X
from	B-X
hepatic	B-X
coma	B-X
,	B-X
while	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
acetylcholine-synthesizing	B-X
enzyme	B-X
,	B-X
choline	B-X
acetyltransferase	B-X
,	B-X
remains	B-X
unaffected	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
the	B-X
human	B-X
data	B-X
,	B-X
AChE	B-X
activity	B-X
in	B-X
brain	B-X
cortical	B-X
extracts	B-X
of	B-X
bile	B-X
duct	B-X
ligated	B-X
(	B-X
BDL	B-X
)	B-X
rats	B-X
was	B-X
increased	B-X
(	B-X
~20	B-X
%	B-X
)	B-X
compared	B-X
to	B-X
controls	B-X
.	B-X
A	B-X
hyperammonemic	B-X
diet	B-X
did	B-X
not	B-X
result	B-X
in	B-X
any	B-X
further	B-X
increase	B-X
of	B-X
AChE	B-X
levels	B-X
in	B-X
the	B-X
BDL	B-X
model	B-X
,	B-X
and	B-X
no	B-X
change	B-X
was	B-X
observed	B-X
in	B-X
hyperammonemic	B-X
diet	B-X
rats	B-X
without	B-X
liver	B-X
disease	B-X
.	B-X
Portacaval	B-X
shunted	B-X
rats	B-X
which	B-X
display	B-X
increased	B-X
levels	B-X
of	B-X
cerebral	B-X
ammonia	B-X
did	B-X
not	B-X
show	B-X
any	B-X
brain	B-X
cholinergic	B-X
abnormalities	B-X
,	B-X
confirming	B-X
that	B-X
high	B-X
ammonia	B-X
levels	B-X
do	B-X
not	B-X
play	B-X
a	B-X
role	B-X
in	B-X
brain	B-X
AChE	B-X
changes	B-X
.	B-X
A	B-X
selective	B-X
increase	B-X
of	B-X
tetrameric	B-X
AChE	B-X
,	B-X
the	B-X
major	B-X
AChE	B-X
species	B-X
involved	B-X
in	B-X
hydrolysis	B-X
of	B-X
acetylcholine	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
both	B-X
cirrhotic	B-X
humans	B-X
and	B-X
BDL	B-X
rats	B-X
.	B-X
Histological	B-X
examination	B-X
of	B-X
BDL	B-X
and	B-X
non-ligated	B-X
rat	B-X
brains	B-X
shows	B-X
that	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
both	B-X
AChE	B-X
and	B-X
choline	B-X
acetyltransferase	B-X
,	B-X
and	B-X
thus	B-X
the	B-X
accessibility	B-X
to	B-X
their	B-X
substrates	B-X
,	B-X
appears	B-X
unaltered	B-X
by	B-X
the	B-X
pathological	B-X
condition	B-X
.	B-X
The	B-X
BDL-induced	B-X
increase	B-X
in	B-X
AChE	B-X
activity	B-X
was	B-X
not	B-X
parallelled	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
mRNA	B-X
levels	B-X
.	B-X
Increased	B-X
AChE	B-X
in	B-X
BDL	B-X
cirrhotic	B-X
rats	B-X
leads	B-X
to	B-X
a	B-X
pronounced	B-X
decrease	B-X
(	B-X
~50-60	B-X
%	B-X
)	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
acetylcholine	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
AChE	B-X
inhibitor	B-X
rivastigmine	B-X
is	B-X
able	B-X
to	B-X
improve	B-X
memory	B-X
deficits	B-X
in	B-X
BDL	B-X
rats	B-X
.	B-X
One	B-X
week	B-X
treatment	B-X
with	B-X
rivastigmine	B-X
(	B-X
0.6	B-X
mg/kg	B-X
;	B-X
once	B-X
a	B-X
day	B-X
,	B-X
orally	B-X
,	B-X
for	B-X
a	B-X
week	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
25	B-X
%	B-X
of	B-X
inhibition	B-X
in	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
AChE	B-X
with	B-X
no	B-X
change	B-X
in	B-X
protein	B-X
composition	B-X
,	B-X
as	B-X
assessed	B-X
by	B-X
sucrose	B-X
density	B-X
gradient	B-X
fractionation	B-X
and	B-X
western	B-X
blotting	B-X
analysis	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
is	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
of	B-X
a	B-X
cholinergic	B-X
imbalance	B-X
in	B-X
the	B-X
brain	B-X
as	B-X
a	B-X
consequence	B-X
of	B-X
liver	B-X
failure	B-X
and	B-X
points	B-X
to	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
the	B-X
cholinergic	B-X
system	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
hepatic	B-X
encephalopathy	B-X
.	B-X

The	O
loss	O
of	O
G4	O
was	O
also	O
reflected	O
by	O
changes	O
observed	O
in	O
AChE	B-Protein
glycosylation	O
pattern	O
attributable	O
to	O
different	O
liver	O
AChE	B-Protein
forms	O
being	O
differentially	O
glycosylated	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
SDS-PAGE	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
major	B-X
55-kd	B-X
immunoreactive	B-X
AChE	B-X
band	B-X
was	B-X
decreased	B-X
in	B-X
BDL	B-X
as	B-X
compared	B-X
with	B-X
NL	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
BDL	B-X
affects	B-X
AChE	B-X
levels	B-X
in	B-X
both	B-X
hepatocytes	B-X
and	B-X
Kupffer	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
altered	B-X
AChE	B-X
expression	B-X
was	B-X
mainly	B-X
reflected	B-X
in	B-X
an	B-X
alteration	B-X
in	B-X
hepatocyte	B-X
AChE	B-X
pattern	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

BDL	O
affects	O
AChE	B-Protein
levels	O
in	O
both	O
hepatocytes	O
and	O
Kupffer	O
cells	O
;	O
however	O
,	O
altered	O
AChE	B-Protein
expression	O
was	O
mainly	O
reflected	O
in	O
an	O
alteration	O
in	O
hepatocyte	O
AChE	B-Protein
pattern	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
SDS-PAGE	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
major	B-X
55-kd	B-X
immunoreactive	B-X
AChE	B-X
band	B-X
was	B-X
decreased	B-X
in	B-X
BDL	B-X
as	B-X
compared	B-X
with	B-X
NL	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
BDL	B-X
affects	B-X
AChE	B-X
levels	B-X
in	B-X
both	B-X
hepatocytes	B-X
and	B-X
Kupffer	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
altered	B-X
AChE	B-X
expression	B-X
was	B-X
mainly	B-X
reflected	B-X
in	B-X
an	B-X
alteration	B-X
in	B-X
hepatocyte	B-X
AChE	B-X
pattern	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

Plasma	O
from	O
BDL	O
rats	O
had	O
approximately	O
45	O
%	O
lower	O
AChE	B-Protein
activity	O
than	O
controls	O
,	O
displaying	O
decreased	O
G4	O
levels	O
and	O
altered	O
lectin	O
-	O
binding	O
patterns	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
SDS-PAGE	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
major	B-X
55-kd	B-X
immunoreactive	B-X
AChE	B-X
band	B-X
was	B-X
decreased	B-X
in	B-X
BDL	B-X
as	B-X
compared	B-X
with	B-X
NL	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
BDL	B-X
affects	B-X
AChE	B-X
levels	B-X
in	B-X
both	B-X
hepatocytes	B-X
and	B-X
Kupffer	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
altered	B-X
AChE	B-X
expression	B-X
was	B-X
mainly	B-X
reflected	B-X
in	B-X
an	B-X
alteration	B-X
in	B-X
hepatocyte	B-X
AChE	B-X
pattern	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

In	O
conclusion	O
,	O
the	O
liver	O
is	O
an	O
important	O
source	O
of	O
serum	O
AChE	B-Protein
;	O
altered	O
AChE	B-Protein
levels	O
may	O
be	O
a	O
useful	O
biomarker	O
for	O
liver	O
cirrhosis	O
.	O
<EOS>	B-X
Classical	B-X
studies	B-X
of	B-X
cholinesterase	B-X
activity	B-X
during	B-X
liver	B-X
dysfunction	B-X
have	B-X
focused	B-X
on	B-X
butyrylcholinesterase	B-X
(	B-X
BuChE	B-X
)	B-X
,	B-X
whereas	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
liver	B-X
and	B-X
plasma	B-X
AChE	B-X
levels	B-X
were	B-X
investigated	B-X
in	B-X
rats	B-X
with	B-X
cirrhosis	B-X
induced	B-X
after	B-X
3	B-X
weeks	B-X
of	B-X
bile	B-X
duct	B-X
ligation	B-X
(	B-X
BDL	B-X
)	B-X
.	B-X
BDL	B-X
rats	B-X
showed	B-X
a	B-X
pronounced	B-X
decrease	B-X
in	B-X
liver	B-X
AChE	B-X
levels	B-X
(	B-X
approximately	B-X
50	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
sham-operated	B-X
(	B-X
non-ligated	B-X
,	B-X
NL	B-X
)	B-X
controls	B-X
;	B-X
whereas	B-X
liver	B-X
BuChE	B-X
appeared	B-X
unaffected	B-X
.	B-X
A	B-X
selective	B-X
loss	B-X
of	B-X
tetrameric	B-X
(	B-X
G4	B-X
)	B-X
AChE	B-X
was	B-X
detected	B-X
in	B-X
BDL	B-X
rats	B-X
,	B-X
an	B-X
effect	B-X
also	B-X
observed	B-X
in	B-X
rats	B-X
with	B-X
carbon	B-X
tetrachloride-induced	B-X
cirrhosis	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
SDS-PAGE	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
major	B-X
55-kd	B-X
immunoreactive	B-X
AChE	B-X
band	B-X
was	B-X
decreased	B-X
in	B-X
BDL	B-X
as	B-X
compared	B-X
with	B-X
NL	B-X
.	B-X
A	B-X
65-kd	B-X
band	B-X
,	B-X
attributed	B-X
in	B-X
part	B-X
to	B-X
inactive	B-X
AChE	B-X
,	B-X
was	B-X
increased	B-X
as	B-X
became	B-X
the	B-X
most	B-X
abundant	B-X
AChE	B-X
subunit	B-X
in	B-X
BDL	B-X
liver	B-X
.	B-X
The	B-X
overall	B-X
decrease	B-X
in	B-X
AChE	B-X
activity	B-X
in	B-X
BDL	B-X
liver	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
of	B-X
AChE	B-X
transcripts	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
G4	B-X
was	B-X
also	B-X
reflected	B-X
by	B-X
changes	B-X
observed	B-X
in	B-X
AChE	B-X
glycosylation	B-X
pattern	B-X
attributable	B-X
to	B-X
different	B-X
liver	B-X
AChE	B-X
forms	B-X
being	B-X
differentially	B-X
glycosylated	B-X
.	B-X
BDL	B-X
affects	B-X
AChE	B-X
levels	B-X
in	B-X
both	B-X
hepatocytes	B-X
and	B-X
Kupffer	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
altered	B-X
AChE	B-X
expression	B-X
was	B-X
mainly	B-X
reflected	B-X
in	B-X
an	B-X
alteration	B-X
in	B-X
hepatocyte	B-X
AChE	B-X
pattern	B-X
.	B-X
Plasma	B-X
from	B-X
BDL	B-X
rats	B-X
had	B-X
approximately	B-X
45	B-X
%	B-X
lower	B-X
AChE	B-X
activity	B-X
than	B-X
controls	B-X
,	B-X
displaying	B-X
decreased	B-X
G4	B-X
levels	B-X
and	B-X
altered	B-X
lectin-binding	B-X
patterns	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
liver	B-X
is	B-X
an	B-X
important	B-X
source	B-X
of	B-X
serum	B-X
AChE	B-X
;	B-X
altered	B-X
AChE	B-X
levels	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
liver	B-X
cirrhosis	B-X
.	B-X

NF	O
-	O
kappaB	O
activation	O
upregulates	O
fibroblast	B-Protein
growth	I-Protein
factor	I-Protein
8	I-Protein
expression	O
in	O
prostate	O
cancer	O
cells	O
.	O
<EOS>	B-X
Fibroblast	B-X
growth	B-X
factor	B-X
8	B-X
(	B-X
FGF8	B-X
)	B-X
is	B-X
over-expressed	B-X
in	B-X
prostate	B-X
cancer	B-X
(	B-X
CaP	B-X
)	B-X
correlating	B-X
with	B-X
high-grade	B-X
disease	B-X
and	B-X
reduced	B-X
survival	B-X
.	B-X
The	B-X
role	B-X
of	B-X
acetylation	B-X
in	B-X
transcriptional	B-X
regulation	B-X
of	B-X
FGF8	B-X
was	B-X
investigated	B-X
using	B-X
the	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitor	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X

BACKGROUND	O
:	O
Fibroblast	B-Protein
growth	I-Protein
factor	I-Protein
8	I-Protein
(	O
FGF8	B-Protein
)	O
is	O
over	O
-	O
expressed	O
in	O
prostate	O
cancer	O
(	O
CaP	O
)	O
correlating	O
with	O
high	O
-	O
grade	O
disease	O
and	O
reduced	O
survival	O
.	O
<EOS>	B-X
Fibroblast	B-X
growth	B-X
factor	B-X
8	B-X
(	B-X
FGF8	B-X
)	B-X
is	B-X
over-expressed	B-X
in	B-X
prostate	B-X
cancer	B-X
(	B-X
CaP	B-X
)	B-X
correlating	B-X
with	B-X
high-grade	B-X
disease	B-X
and	B-X
reduced	B-X
survival	B-X
.	B-X
The	B-X
role	B-X
of	B-X
acetylation	B-X
in	B-X
transcriptional	B-X
regulation	B-X
of	B-X
FGF8	B-X
was	B-X
investigated	B-X
using	B-X
the	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitor	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X

The	O
role	O
of	O
acetylation	O
in	O
transcriptional	O
regulation	O
of	O
FGF8	B-Protein
was	O
investigated	O
using	O
the	O
histone	B-Protein
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
Trichostatin	O
A	O
(	O
TSA	O
)	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
number	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
embryonic	B-X
development	B-X
after	B-X
treatment	B-X
with	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
,	B-X
a	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitor	B-X
,	B-X
in	B-X
the	B-X
limbs	B-X
of	B-X
chicken	B-X
embryos	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
that	B-X
TSA	B-X
affects	B-X
the	B-X
expression	B-X
profiles	B-X
of	B-X
some	B-X
genes	B-X
that	B-X
play	B-X
important	B-X
roles	B-X
during	B-X
limb	B-X
development	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
BMP4	B-X
,	B-X
SF/HGF	B-X
and	B-X
Twist1	B-X
increased	B-X
,	B-X
whereas	B-X
the	B-X
expression	B-X
of	B-X
BMP2	B-X
,	B-X
FGF8	B-X
,	B-X
Shh	B-X
,	B-X
Scleraxis	B-X
,	B-X
Myf5	B-X
and	B-X
MyoD	B-X
was	B-X
decreased	B-X
or	B-X
even	B-X
inhibited	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
chicken	B-X
embryo	B-X
can	B-X
serve	B-X
as	B-X
an	B-X
effective	B-X
in	B-X
vivo	B-X
model	B-X
for	B-X
studying	B-X
the	B-X
effect	B-X
of	B-X
HDAC	B-X
inhibitors	B-X
on	B-X
gene	B-X
expression	B-X
and	B-X
can	B-X
be	B-X
helpful	B-X
for	B-X
understanding	B-X
the	B-X
role	B-X
of	B-X
chromatin	B-X
remodeling	B-X
and	B-X
epigenetic	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

METHODS	O
:	O
FGF8	B-Protein
transcriptional	O
response	O
to	O
TSA	O
was	O
investigated	O
by	O
gene	O
reporter	O
assays	O
,	O
RT	O
-	O
PCR	O
,	O
and	O
Western	O
blotting	O
.	O
<EOS>	B-X
Fibroblast	B-X
growth	B-X
factor	B-X
8	B-X
(	B-X
FGF8	B-X
)	B-X
is	B-X
over-expressed	B-X
in	B-X
prostate	B-X
cancer	B-X
(	B-X
CaP	B-X
)	B-X
correlating	B-X
with	B-X
high-grade	B-X
disease	B-X
and	B-X
reduced	B-X
survival	B-X
.	B-X
The	B-X
role	B-X
of	B-X
acetylation	B-X
in	B-X
transcriptional	B-X
regulation	B-X
of	B-X
FGF8	B-X
was	B-X
investigated	B-X
using	B-X
the	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitor	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
were	O
also	O
performed	O
.	O
<EOS>	B-X
The	B-X
RNA	B-X
immunoprecipitation	B-X
(	B-X
RIP	B-X
)	B-X
is	B-X
a	B-X
powerful	B-X
method	B-X
to	B-X
study	B-X
the	B-X
physical	B-X
association	B-X
between	B-X
individual	B-X
proteins	B-X
and	B-X
RNA	B-X
molecules	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
basic	B-X
principles	B-X
of	B-X
RIP	B-X
are	B-X
very	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
,	B-X
a	B-X
largely	B-X
used	B-X
tool	B-X
in	B-X
the	B-X
epigenetic	B-X
field	B-X
,	B-X
but	B-X
with	B-X
some	B-X
important	B-X
caveats	B-X
.	B-X
Any	B-X
RNA	B-X
that	B-X
is	B-X
associated	B-X
with	B-X
this	B-X
protein	B-X
complex	B-X
will	B-X
also	B-X
be	B-X
isolated	B-X
and	B-X
can	B-X
be	B-X
further	B-X
analyzed	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction-based	B-X
methods	B-X
,	B-X
hybridization	B-X
,	B-X
or	B-X
sequencing.Several	B-X
variants	B-X
of	B-X
this	B-X
technique	B-X
exist	B-X
and	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
two	B-X
main	B-X
classes	B-X
:	B-X
native	B-X
and	B-X
cross-linked	B-X
RNA	B-X
immunoprecipitation	B-X
.	B-X
Enrichments	B-X
of	B-X
these	B-X
histone	B-X
modifications	B-X
on	B-X
specific	B-X
loci	B-X
,	B-X
or	B-X
in	B-X
genome	B-X
wide	B-X
,	B-X
in	B-X
given	B-X
cells	B-X
can	B-X
be	B-X
analyzed	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
-based	B-X
methods	B-X
using	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
the	B-X
site-specific	B-X
modification	B-X
.	B-X
When	B-X
performing	B-X
ChIP	B-X
experiments	B-X
,	B-X
one	B-X
should	B-X
be	B-X
careful	B-X
about	B-X
the	B-X
specificity	B-X
of	B-X
antibody	B-X
,	B-X
as	B-X
this	B-X
affects	B-X
the	B-X
data	B-X
interpretation	B-X
.	B-X

RESULTS	O
:	O
FGF8	B-Protein
is	O
upregulated	O
in	O
response	O
to	O
TSA	O
treatment	O
along	O
with	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
.	O
<EOS>	B-X
Fibroblast	B-X
growth	B-X
factor	B-X
8	B-X
(	B-X
FGF8	B-X
)	B-X
is	B-X
over-expressed	B-X
in	B-X
prostate	B-X
cancer	B-X
(	B-X
CaP	B-X
)	B-X
correlating	B-X
with	B-X
high-grade	B-X
disease	B-X
and	B-X
reduced	B-X
survival	B-X
.	B-X
The	B-X
role	B-X
of	B-X
acetylation	B-X
in	B-X
transcriptional	B-X
regulation	B-X
of	B-X
FGF8	B-X
was	B-X
investigated	B-X
using	B-X
the	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitor	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X

Over	O
-	O
expression	O
of	O
p65	B-Protein
activated	O
FGF8	B-Protein
transcription	O
.	O
<EOS>	B-X
Fibroblast	B-X
growth	B-X
factor	B-X
8	B-X
(	B-X
FGF8	B-X
)	B-X
is	B-X
over-expressed	B-X
in	B-X
prostate	B-X
cancer	B-X
(	B-X
CaP	B-X
)	B-X
correlating	B-X
with	B-X
high-grade	B-X
disease	B-X
and	B-X
reduced	B-X
survival	B-X
.	B-X
The	B-X
role	B-X
of	B-X
acetylation	B-X
in	B-X
transcriptional	B-X
regulation	B-X
of	B-X
FGF8	B-X
was	B-X
investigated	B-X
using	B-X
the	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitor	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X

ChIP	O
assays	O
revealed	O
p65	B-Protein
recruitment	O
to	O
the	O
fgf8	B-Protein
promoter	O
,	O
containing	O
putative	O
NF	O
-	O
kappaB	O
binding	O
sites	O
,	O
post	O
TSA	O
stimulation	O
.	O

PI	O
-	O
3K	O
activity	O
is	O
required	O
for	O
TSA	O
mediated	O
FGF8	B-Protein
upregulation	O
.	O
<EOS>	B-X
Fibroblast	B-X
growth	B-X
factor	B-X
8	B-X
(	B-X
FGF8	B-X
)	B-X
is	B-X
over-expressed	B-X
in	B-X
prostate	B-X
cancer	B-X
(	B-X
CaP	B-X
)	B-X
correlating	B-X
with	B-X
high-grade	B-X
disease	B-X
and	B-X
reduced	B-X
survival	B-X
.	B-X
The	B-X
role	B-X
of	B-X
acetylation	B-X
in	B-X
transcriptional	B-X
regulation	B-X
of	B-X
FGF8	B-X
was	B-X
investigated	B-X
using	B-X
the	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitor	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
.	B-X

CONCLUSION	O
:	O
Using	O
TSA	O
treatment	O
in	O
prostate	O
cancer	O
cells	O
,	O
a	O
requirement	O
of	O
PI	O
-	O
3K	O
activity	O
in	O
mediating	O
TSA	O
function	O
is	O
demonstrated	O
and	O
a	O
novel	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
the	O
regulation	O
of	O
FGF8	B-Protein
expression	O
is	O
uncovered	O
.	O

Epigenetics	O
of	O
gene	O
expression	O
in	O
human	O
hepatoma	O
cells	O
:	O
expression	O
profiling	O
the	O
response	O
to	O
inhibition	O
of	O
DNA	O
methylation	O
and	O
histone	B-Protein
deacetylation	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
are	B-X
epigenetic	B-X
mechanisms	B-X
that	B-X
play	B-X
major	B-X
roles	B-X
in	B-X
eukaryotic	B-X
gene	B-X
regulation	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
many	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
HepG2	B-X
are	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
.	B-X
Treatment	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-aza-dC	B-X
)	B-X
to	B-X
inhibit	B-X
DNA	B-X
methylation	B-X
with	B-X
and/or	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
to	B-X
inhibit	B-X
histone	B-X
deacetylation	B-X
should	B-X
allow	B-X
us	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
are	B-X
regulated	B-X
epigenetically	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X

BACKGROUND	O
:	O
DNA	O
methylation	O
and	O
histone	B-Protein
deacetylation	O
are	O
epigenetic	O
mechanisms	O
that	O
play	O
major	O
roles	O
in	O
eukaryotic	O
gene	O
regulation	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
are	B-X
epigenetic	B-X
mechanisms	B-X
that	B-X
play	B-X
major	B-X
roles	B-X
in	B-X
eukaryotic	B-X
gene	B-X
regulation	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
many	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
HepG2	B-X
are	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
.	B-X
Treatment	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-aza-dC	B-X
)	B-X
to	B-X
inhibit	B-X
DNA	B-X
methylation	B-X
with	B-X
and/or	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
to	B-X
inhibit	B-X
histone	B-X
deacetylation	B-X
should	B-X
allow	B-X
us	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
are	B-X
regulated	B-X
epigenetically	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
Klotho	B-X
was	B-X
originally	B-X
characterized	B-X
as	B-X
an	B-X
anti-aging	B-X
gene	B-X
that	B-X
predisposed	B-X
Klotho-deficient	B-X
mice	B-X
to	B-X
a	B-X
premature	B-X
aging-like	B-X
syndrome	B-X
.	B-X
Epigenetic	B-X
gene	B-X
silencing	B-X
of	B-X
secreted	B-X
Wnt	B-X
antagonists	B-X
is	B-X
considered	B-X
a	B-X
common	B-X
event	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
human	B-X
malignancies	B-X
.	B-X
Abnormal	B-X
activation	B-X
of	B-X
the	B-X
canonical	B-X
Wnt	B-X
pathway	B-X
due	B-X
to	B-X
epigenetic	B-X
deregulation	B-X
of	B-X
Wnt	B-X
antagonists	B-X
is	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
cervical	B-X
tumorigenesis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
epigenetic	B-X
silencing	B-X
of	B-X
KLOTHO	B-X
in	B-X
human	B-X
cervical	B-X
carcinoma	B-X
.	B-X

We	O
hypothesize	O
that	O
many	O
genes	O
in	O
the	O
human	O
hepatoma	O
cell	O
line	O
HepG2	O
are	O
regulated	O
by	O
DNA	O
methylation	O
and	O
histone	B-Protein
deacetylation	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
are	B-X
epigenetic	B-X
mechanisms	B-X
that	B-X
play	B-X
major	B-X
roles	B-X
in	B-X
eukaryotic	B-X
gene	B-X
regulation	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
many	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
HepG2	B-X
are	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
.	B-X
Treatment	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-aza-dC	B-X
)	B-X
to	B-X
inhibit	B-X
DNA	B-X
methylation	B-X
with	B-X
and/or	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
to	B-X
inhibit	B-X
histone	B-X
deacetylation	B-X
should	B-X
allow	B-X
us	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
are	B-X
regulated	B-X
epigenetically	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X

Treatment	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
aza	O
-	O
dC	O
)	O
to	O
inhibit	O
DNA	O
methylation	O
with	O
and	O
/	O
or	O
Trichostatin	O
A	O
(	O
TSA	O
)	O
to	O
inhibit	O
histone	B-Protein
deacetylation	O
should	O
allow	O
us	O
to	O
identify	O
genes	O
that	O
are	O
regulated	O
epigenetically	O
in	O
hepatoma	O
cells	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
are	B-X
epigenetic	B-X
mechanisms	B-X
that	B-X
play	B-X
major	B-X
roles	B-X
in	B-X
eukaryotic	B-X
gene	B-X
regulation	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
many	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
HepG2	B-X
are	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
.	B-X
Treatment	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-aza-dC	B-X
)	B-X
to	B-X
inhibit	B-X
DNA	B-X
methylation	B-X
with	B-X
and/or	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
to	B-X
inhibit	B-X
histone	B-X
deacetylation	B-X
should	B-X
allow	B-X
us	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
are	B-X
regulated	B-X
epigenetically	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X

RESULTS	O
:	O
5	O
-	O
aza	O
-	O
dC	O
had	O
a	O
much	O
larger	O
effect	O
on	O
gene	O
expression	O
in	O
HepG2	O
cells	O
than	O
did	O
TSA	O
,	O
as	O
measured	O
using	O
Affymetrix	O
HG	O
-	O
U133	O
Plus	O
2	O
.	O
0	O
microarrays	O
.	O

The	O
expression	O
of	O
1504	O
probe	O
sets	O
was	O
affected	O
by	O
5	O
-	O
aza	O
-	O
dC	O
(	O
at	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
535	O
probe	O
sets	O
by	O
TSA	O
,	O
and	O
1929	O
probe	O
sets	O
by	O
the	O
combination	O
of	O
5	O
-	O
aza	O
-	O
dC	O
and	O
TSA	O
.	O

5	O
-	O
aza	O
-	O
dC	O
treatment	O
turned	O
on	O
the	O
expression	O
of	O
211	O
probe	O
sets	O
that	O
were	O
not	O
detectably	O
expressed	O
in	O
its	O
absence	O
.	O

Expression	O
of	O
imprinted	O
genes	O
regulated	O
by	O
DNA	O
methylation	O
,	O
such	O
as	O
H19	B-Protein
and	O
NNAT	B-Protein
,	O
was	O
turned	O
on	O
or	O
greatly	O
increased	O
in	O
response	O
to	O
5	O
-	O
aza	O
-	O
dC	O
.	O
<EOS>	B-X
SPF	B-X
chickens	B-X
injected	B-X
with	B-X
S.	B-X
enteritidis	B-X
were	B-X
partitioned	B-X
into	B-X
two	B-X
groups	B-X
,	B-X
one	B-X
consisted	B-X
of	B-X
those	B-X
from	B-X
Salmonella-susceptible	B-X
chickens	B-X
(	B-X
died	B-X
within	B-X
5	B-X
d	B-X
after	B-X
injection	B-X
,	B-X
n	B-X
=	B-X
6	B-X
)	B-X
,	B-X
the	B-X
other	B-X
consisted	B-X
of	B-X
six	B-X
Salmonella-resistant	B-X
chickens	B-X
that	B-X
survived	B-X
for	B-X
15	B-X
d	B-X
after	B-X
injection	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
expression	B-X
of	B-X
pro-inflammatory	B-X
cytokine	B-X
genes	B-X
,	B-X
IL-6	B-X
and	B-X
IFN-β	B-X
,	B-X
was	B-X
greatly	B-X
enhanced	B-X
in	B-X
the	B-X
resistant	B-X
but	B-X
not	B-X
in	B-X
susceptible	B-X
chickens	B-X
.	B-X
Contrasting	B-X
with	B-X
the	B-X
reduced	B-X
expression	B-X
of	B-X
TLR	B-X
genes	B-X
,	B-X
those	B-X
of	B-X
the	B-X
zinc	B-X
finger	B-X
protein	B-X
493	B-X
(	B-X
ZNF493	B-X
)	B-X
gene	B-X
and	B-X
Toll-interacting	B-X
protein	B-X
(	B-X
TOLLIP	B-X
)	B-X
gene	B-X
were	B-X
enhanced	B-X
in	B-X
the	B-X
susceptible	B-X
chickens	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
TLR4	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
infected	B-X
in	B-X
vitro	B-X
with	B-X
S.	B-X
enteritidis	B-X
increased	B-X
significantly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
treatment	B-X
with	B-X
5-Aza-2-deoxycytidine	B-X
(	B-X
5-Aza-dc	B-X
)	B-X
while	B-X
either	B-X
5-Aza-dc	B-X
or	B-X
trichostatin	B-X
A	B-X
was	B-X
effective	B-X
in	B-X
up-regulating	B-X
the	B-X
expression	B-X
of	B-X
TLR21	B-X
and	B-X
TLR2-1	B-X
.	B-X
DNA	B-X
methylation	B-X
,	B-X
in	B-X
the	B-X
predicted	B-X
promoter	B-X
region	B-X
of	B-X
TLR4	B-X
and	B-X
TLR21	B-X
genes	B-X
,	B-X
and	B-X
an	B-X
exonic	B-X
CpG	B-X
island	B-X
of	B-X
the	B-X
TLR2-1	B-X
gene	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
the	B-X
susceptible	B-X
chickens	B-X
than	B-X
in	B-X
resistant	B-X
chickens	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
demonstrate	B-X
that	B-X
ZNF493-related	B-X
epigenetic	B-X
modification	B-X
in	B-X
leukocytes	B-X
probably	B-X
accounts	B-X
for	B-X
increased	B-X
susceptibility	B-X
to	B-X
S.	B-X
enteritidis	B-X
in	B-X
chickens	B-X
by	B-X
diminishing	B-X
the	B-X
expression	B-X
and	B-X
response	B-X
of	B-X
TLR4	B-X
,	B-X
TLR21	B-X
and	B-X
TLR2-1	B-X
.	B-X

Genes	O
involved	O
in	O
liver	O
processes	O
such	O
as	O
xenobiotic	O
metabolism	O
(	O
CYP3A4	B-Protein
,	O
CYP3A5	B-Protein
,	O
and	O
CYP3A7	B-Protein
)	O
and	O
steroid	O
biosynthesis	O
(	O
CYP17A1	B-Protein
and	O
CYP19A1	B-Protein
)	O
,	O
and	O
genes	O
encoding	O
CCAAT	O
element	O
-	O
binding	O
proteins	O
(	O
C	B-Protein
/	I-Protein
EBPalpha	I-Protein
,	O
C	B-Protein
/	I-Protein
EBPbeta	I-Protein
,	O
and	O
C	B-Protein
/	I-Protein
EBPgamma	I-Protein
)	O
were	O
affected	O
by	O
5	O
-	O
aza	O
-	O
dC	O
or	O
the	O
combination	O
.	O
<EOS>	B-X
Combinative	B-X
treatment	B-X
of	B-X
β-elemene	B-X
and	B-X
cetuximab	B-X
is	B-X
sensitive	B-X
to	B-X
KRAS	B-X
mutant	B-X
colorectal	B-X
cancer	B-X
cells	B-X
by	B-X
inducing	B-X
ferroptosis	B-X
and	B-X
inhibiting	B-X
epithelial-mesenchymal	B-X
transformation	B-X
.	B-X
The	B-X
systemic	B-X
treatment	B-X
landscape	B-X
for	B-X
advanced	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
has	B-X
experienced	B-X
tremendous	B-X
paradigm	B-X
shift	B-X
towards	B-X
targeting	B-X
tumor	B-X
microenvironment	B-X
(	B-X
TME	B-X
)	B-X
following	B-X
recent	B-X
trials	B-X
utilizing	B-X
immune	B-X
checkpoint	B-X
blockade	B-X
(	B-X
ICB	B-X
)	B-X
.	B-X
However	B-X
,	B-X
limited	B-X
success	B-X
of	B-X
ICB	B-X
as	B-X
monotherapy	B-X
mandates	B-X
the	B-X
evaluation	B-X
of	B-X
combination	B-X
strategies	B-X
incorporating	B-X
immunotherapy	B-X
for	B-X
improved	B-X
clinical	B-X
efficacy	B-X
.	B-X
Radiotherapy	B-X
(	B-X
RT	B-X
)	B-X
is	B-X
an	B-X
integral	B-X
component	B-X
in	B-X
treatment	B-X
of	B-X
solid	B-X
cancers	B-X
,	B-X
including	B-X
HCC	B-X
.	B-X
Radiation	B-X
mediates	B-X
localized	B-X
tumor	B-X
killing	B-X
and	B-X
TME	B-X
modification	B-X
,	B-X
thereby	B-X
potentiating	B-X
the	B-X
action	B-X
of	B-X
ICB	B-X
.	B-X
Several	B-X
preclinical	B-X
and	B-X
clinical	B-X
studies	B-X
have	B-X
explored	B-X
the	B-X
efficacy	B-X
of	B-X
combining	B-X
RT	B-X
and	B-X
ICB	B-X
in	B-X
HCC	B-X
with	B-X
promising	B-X
outcomes	B-X
.	B-X
Greater	B-X
efforts	B-X
are	B-X
required	B-X
in	B-X
discovery	B-X
and	B-X
understanding	B-X
of	B-X
novel	B-X
combination	B-X
strategies	B-X
to	B-X
maximize	B-X
clinical	B-X
benefit	B-X
with	B-X
tolerable	B-X
adverse	B-X
effects	B-X
.	B-X
This	B-X
current	B-X
review	B-X
provides	B-X
a	B-X
comprehensive	B-X
assessment	B-X
of	B-X
RT	B-X
and	B-X
ICB	B-X
in	B-X
HCC	B-X
,	B-X
their	B-X
respective	B-X
impact	B-X
on	B-X
TME	B-X
,	B-X
the	B-X
rationale	B-X
for	B-X
their	B-X
synergistic	B-X
combination	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
current	B-X
potential	B-X
biomarkers	B-X
available	B-X
to	B-X
predict	B-X
clinical	B-X
response	B-X
.	B-X
We	B-X
also	B-X
speculate	B-X
on	B-X
novel	B-X
future	B-X
strategies	B-X
to	B-X
further	B-X
enhance	B-X
the	B-X
efficacy	B-X
of	B-X
this	B-X
combination	B-X
.	B-X

Many	O
of	O
the	O
genes	O
that	O
fall	O
within	O
these	O
groups	O
are	O
also	O
expressed	O
in	O
the	O
developing	O
fetal	O
liver	O
and	O
adult	O
liver	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
many	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
HepG2	B-X
are	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
.	B-X
Treatment	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-aza-dC	B-X
)	B-X
to	B-X
inhibit	B-X
DNA	B-X
methylation	B-X
with	B-X
and/or	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
to	B-X
inhibit	B-X
histone	B-X
deacetylation	B-X
should	B-X
allow	B-X
us	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
are	B-X
regulated	B-X
epigenetically	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
To	B-X
identify	B-X
new	B-X
and	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
rat	B-X
fetal	B-X
liver	B-X
epithelial	B-X
stem/progenitor	B-X
cells	B-X
during	B-X
their	B-X
proliferation	B-X
,	B-X
lineage	B-X
commitment	B-X
,	B-X
and	B-X
differentiation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
high	B-X
throughput	B-X
method-mouse	B-X
complementary	B-X
DNA	B-X
(	B-X
cDNA	B-X
)	B-X
microarrays-for	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
gene	B-X
expression	B-X
pattern	B-X
of	B-X
rat	B-X
hepatic	B-X
cells	B-X
was	B-X
studied	B-X
during	B-X
their	B-X
differentiation	B-X
in	B-X
vivo	B-X
:	B-X
from	B-X
embryonic	B-X
day	B-X
(	B-X
ED	B-X
)	B-X
13	B-X
until	B-X
adulthood	B-X
.	B-X
The	B-X
differentially	B-X
regulated	B-X
genes	B-X
were	B-X
grouped	B-X
into	B-X
two	B-X
clusters	B-X
:	B-X
a	B-X
cluster	B-X
of	B-X
up-regulated	B-X
genes	B-X
comprised	B-X
of	B-X
281	B-X
clones	B-X
and	B-X
a	B-X
cluster	B-X
of	B-X
down-regulated	B-X
genes	B-X
comprised	B-X
of	B-X
230	B-X
members	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
overexpressed	B-X
genes	B-X
from	B-X
the	B-X
first	B-X
cluster	B-X
fall	B-X
into	B-X
distinct	B-X
,	B-X
differentially	B-X
expressed	B-X
functional	B-X
groups	B-X
:	B-X
genes	B-X
related	B-X
to	B-X
development	B-X
,	B-X
morphogenesis	B-X
,	B-X
and	B-X
differentiation	B-X
;	B-X
calcium-	B-X
and	B-X
phospholipid-binding	B-X
proteins	B-X
and	B-X
signal	B-X
transducers	B-X
;	B-X
and	B-X
cell	B-X
adhesion	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
matrix	B-X
proteins	B-X
.	B-X
Several	B-X
other	B-X
functional	B-X
groups	B-X
of	B-X
genes	B-X
that	B-X
are	B-X
initially	B-X
down-regulated	B-X
,	B-X
then	B-X
increase	B-X
during	B-X
development	B-X
,	B-X
also	B-X
emerged	B-X
:	B-X
genes	B-X
related	B-X
to	B-X
inflammation	B-X
,	B-X
blood	B-X
coagulation	B-X
,	B-X
detoxification	B-X
,	B-X
serum	B-X
proteins	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
lipids	B-X
,	B-X
and	B-X
carbohydrate	B-X
metabolism	B-X
.	B-X
Twenty-eight	B-X
genes	B-X
overexpressed	B-X
in	B-X
fetal	B-X
liver	B-X
that	B-X
were	B-X
not	B-X
detected	B-X
in	B-X
adult	B-X
liver	B-X
are	B-X
suggested	B-X
as	B-X
potential	B-X
markers	B-X
for	B-X
identification	B-X
of	B-X
liver	B-X
progenitor	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
data	B-X
show	B-X
that	B-X
the	B-X
gene	B-X
expression	B-X
program	B-X
of	B-X
fetal	B-X
hepatoblasts	B-X
differs	B-X
profoundly	B-X
from	B-X
that	B-X
of	B-X
adult	B-X
hepatocytes	B-X
and	B-X
that	B-X
it	B-X
is	B-X
regulated	B-X
in	B-X
a	B-X
specific	B-X
manner	B-X
with	B-X
a	B-X
major	B-X
switch	B-X
at	B-X
ED	B-X
16	B-X
to	B-X
17	B-X
,	B-X
marking	B-X
a	B-X
dramatic	B-X
change	B-X
in	B-X
the	B-X
gene	B-X
expression	B-X
program	B-X
during	B-X
the	B-X
transition	B-X
of	B-X
fetal	B-X
liver	B-X
progenitor	B-X
cells	B-X
from	B-X
an	B-X
undifferentiated	B-X
to	B-X
a	B-X
differentiated	B-X
state	B-X
.	B-X

Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
confirmed	O
selected	O
gene	O
expression	O
changes	O
seen	O
in	O
microarray	O
analyses	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
analyse	B-X
transcriptomes	B-X
and	B-X
mRNA	B-X
expression	B-X
levels	B-X
for	B-X
specific	B-X
genes	B-X
in	B-X
calcium-channel	B-X
blocker-induced	B-X
gingival	B-X
overgrowth	B-X
(	B-X
GO	B-X
)	B-X
tissues	B-X
.	B-X
Estradiol	B-X
and	B-X
progesterone	B-X
are	B-X
crucial	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
receptivity	B-X
and	B-X
the	B-X
change	B-X
in	B-X
transcriptional	B-X
activity	B-X
of	B-X
target	B-X
genes	B-X
in	B-X
the	B-X
implantation	B-X
window	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
differentiate	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
in	B-X
the	B-X
endometrium	B-X
of	B-X
patients	B-X
with	B-X
recurrent	B-X
implantation	B-X
failure	B-X
(	B-X
IF	B-X
)	B-X
versus	B-X
those	B-X
who	B-X
became	B-X
pregnant	B-X
after	B-X
in	B-X
vitro	B-X
fertilization	B-X
(	B-X
IVF	B-X
)	B-X
treatment	B-X
.	B-X
Differential	B-X
expression	B-X
of	B-X
selected	B-X
genes	B-X
was	B-X
re-analysed	B-X
by	B-X
quantitative	B-X
PCR	B-X
,	B-X
in	B-X
which	B-X
the	B-X
results	B-X
were	B-X
calculated	B-X
as	B-X
threshold	B-X
cycle	B-X
differences	B-X
between	B-X
the	B-X
groups	B-X
and	B-X
normalized	B-X
to	B-X
Glyceraldehyde	B-X
phosphate	B-X
dehydrogenase	B-X
and	B-X
beta-actin	B-X
.	B-X
Differences	B-X
were	B-X
seen	B-X
for	B-X
several	B-X
genes	B-X
from	B-X
endometrial	B-X
tissue	B-X
between	B-X
the	B-X
IF	B-X
and	B-X
the	B-X
pregnancy	B-X
groups	B-X
,	B-X
and	B-X
when	B-X
comparing	B-X
OP	B-X
with	B-X
M	B-X
,	B-X
1875	B-X
up-	B-X
and	B-X
1807	B-X
down-regulated	B-X
genes	B-X
were	B-X
returned	B-X
.	B-X
Real-time	B-X
PCR	B-X
analysis	B-X
confirmed	B-X
up-regulation	B-X
for	B-X
somatostatin	B-X
,	B-X
PLAP-2	B-X
,	B-X
mucin	B-X
4	B-X
and	B-X
CD163	B-X
,	B-X
and	B-X
down-regulation	B-X
of	B-X
glycodelin	B-X
,	B-X
IL-24	B-X
,	B-X
CD69	B-X
,	B-X
leukaemia	B-X
inhibitory	B-X
factor	B-X
and	B-X
prolactin	B-X
receptor	B-X
between	B-X
Op	B-X
and	B-X
M.	B-X
When	B-X
the	B-X
different	B-X
embryo-conditioned	B-X
media	B-X
were	B-X
compared	B-X
,	B-X
no	B-X
significant	B-X
differential	B-X
regulation	B-X
could	B-X
be	B-X
demonstrated	B-X
.	B-X
Although	B-X
microarray	B-X
profiling	B-X
may	B-X
currently	B-X
not	B-X
be	B-X
sensitive	B-X
enough	B-X
for	B-X
studying	B-X
the	B-X
effects	B-X
of	B-X
embryo-derived	B-X
factors	B-X
on	B-X
the	B-X
endometrium	B-X
,	B-X
the	B-X
observed	B-X
differences	B-X
in	B-X
gene	B-X
expression	B-X
between	B-X
M	B-X
and	B-X
OP	B-X
suggest	B-X
that	B-X
it	B-X
will	B-X
become	B-X
an	B-X
interesting	B-X
tool	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
fertility-relevant	B-X
markers	B-X
produced	B-X
by	B-X
the	B-X
endometrium	B-X
.	B-X

CONCLUSION	O
:	O
Epigenetics	O
play	O
a	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
several	O
genes	O
involved	O
in	O
essential	O
liver	O
processes	O
such	O
as	O
xenobiotic	O
metabolism	O
and	O
steroid	O
biosynthesis	O
in	O
HepG2	O
cells	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
are	B-X
epigenetic	B-X
mechanisms	B-X
that	B-X
play	B-X
major	B-X
roles	B-X
in	B-X
eukaryotic	B-X
gene	B-X
regulation	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
many	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
HepG2	B-X
are	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
.	B-X
Treatment	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-aza-dC	B-X
)	B-X
to	B-X
inhibit	B-X
DNA	B-X
methylation	B-X
with	B-X
and/or	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
to	B-X
inhibit	B-X
histone	B-X
deacetylation	B-X
should	B-X
allow	B-X
us	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
are	B-X
regulated	B-X
epigenetically	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X

Many	O
genes	O
whose	O
expression	O
is	O
normally	O
silenced	O
in	O
these	O
hepatoma	O
cells	O
were	O
re	O
-	O
expressed	O
by	O
5	O
-	O
aza	O
-	O
dC	O
treatment	O
.	O
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
many	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
HepG2	B-X
are	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
.	B-X
Treatment	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-aza-dC	B-X
)	B-X
to	B-X
inhibit	B-X
DNA	B-X
methylation	B-X
with	B-X
and/or	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
to	B-X
inhibit	B-X
histone	B-X
deacetylation	B-X
should	B-X
allow	B-X
us	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
are	B-X
regulated	B-X
epigenetically	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X

DNA	O
methylation	O
may	O
be	O
a	O
factor	O
in	O
restricting	O
the	O
expression	O
of	O
fetal	O
genes	O
during	O
liver	O
development	O
and	O
in	O
shutting	O
down	O
expression	O
in	O
hepatoma	O
cells	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
are	B-X
epigenetic	B-X
mechanisms	B-X
that	B-X
play	B-X
major	B-X
roles	B-X
in	B-X
eukaryotic	B-X
gene	B-X
regulation	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
many	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
HepG2	B-X
are	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
deacetylation	B-X
.	B-X
Treatment	B-X
with	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-aza-dC	B-X
)	B-X
to	B-X
inhibit	B-X
DNA	B-X
methylation	B-X
with	B-X
and/or	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
to	B-X
inhibit	B-X
histone	B-X
deacetylation	B-X
should	B-X
allow	B-X
us	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
are	B-X
regulated	B-X
epigenetically	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X

Epigenetic	O
regulation	O
of	O
the	O
imprinted	O
U2af1	B-Protein
-	I-Protein
rs1	I-Protein
gene	O
during	O
retinoic	O
acid	O
-	O
induced	O
differentiation	O
of	O
embryonic	O
stem	O
cells	O
.	O
<EOS>	B-X
Epigenetic	B-X
modifications	B-X
such	B-X
as	B-X
DNA	B-X
methylation	B-X
and	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
are	B-X
changes	B-X
in	B-X
the	B-X
chemical	B-X
composition	B-X
or	B-X
structure	B-X
of	B-X
DNA	B-X
that	B-X
work	B-X
by	B-X
regulating	B-X
gene	B-X
expression	B-X
.	B-X
Their	B-X
mechanisms	B-X
of	B-X
action	B-X
have	B-X
been	B-X
generally	B-X
studied	B-X
in	B-X
imprinted	B-X
genes	B-X
.	B-X
The	B-X
present	B-X
work	B-X
analyzes	B-X
the	B-X
involvement	B-X
of	B-X
these	B-X
mechanisms	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
imprinted	B-X
gene	B-X
during	B-X
the	B-X
differentiation	B-X
process	B-X
of	B-X
embryonic	B-X
stem	B-X
(	B-X
ES	B-X
)	B-X
cells	B-X
induced	B-X
by	B-X
retinoic	B-X
acid	B-X
.	B-X
By	B-X
DNA	B-X
digestion	B-X
with	B-X
methylation-dependent	B-X
or	B-X
independent	B-X
restriction	B-X
enzymes	B-X
and	B-X
consecutive	B-X
Southern	B-X
blot	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
methylation	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
increases	B-X
in	B-X
differentiated	B-X
ES	B-X
cells	B-X
and	B-X
in	B-X
embryoid	B-X
bodies	B-X
.	B-X
However	B-X
,	B-X
northern	B-X
blot	B-X
and	B-X
real-time	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
showed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
in	B-X
differentiated	B-X
ES	B-X
cells	B-X
and	B-X
in	B-X
embryoid	B-X
bodies	B-X
than	B-X
in	B-X
undifferentiated	B-X
ones	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
sensitivity	B-X
to	B-X
DNase-I	B-X
assay	B-X
demonstrated	B-X
an	B-X
open	B-X
chromatin	B-X
conformation	B-X
for	B-X
differentiated	B-X
cells	B-X
with	B-X
regard	B-X
to	B-X
undifferentiated	B-X
ES	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
would	B-X
be	B-X
regulated	B-X
by	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
rather	B-X
than	B-X
by	B-X
DNA	B-X
methylation	B-X
during	B-X
the	B-X
RA-induced	B-X
process	B-X
of	B-X
differentiation	B-X
of	B-X
ES	B-X
cells	B-X
.	B-X

Epigenetic	O
modifications	O
such	O
as	O
DNA	O
methylation	O
and	O
changes	O
in	O
chromatin	O
structure	O
are	O
changes	O
in	O
the	O
chemical	O
composition	O
or	O
structure	O
of	O
DNA	O
that	O
work	O
by	O
regulating	O
gene	O
expression	O
.	O
<EOS>	B-X
Long	B-X
noncoding	B-X
RNAs	B-X
(	B-X
lncRNAs	B-X
)	B-X
have	B-X
emerged	B-X
as	B-X
significant	B-X
players	B-X
in	B-X
almost	B-X
every	B-X
level	B-X
of	B-X
gene	B-X
function	B-X
and	B-X
regulation	B-X
.	B-X
Thus	B-X
,	B-X
characterizing	B-X
the	B-X
structures	B-X
and	B-X
interactions	B-X
of	B-X
lncRNAs	B-X
is	B-X
essential	B-X
for	B-X
understanding	B-X
their	B-X
mechanistic	B-X
roles	B-X
in	B-X
cells	B-X
.	B-X
Through	B-X
a	B-X
combination	B-X
of	B-X
(	B-X
bio	B-X
)	B-X
chemical	B-X
approaches	B-X
and	B-X
automated	B-X
capillary	B-X
and	B-X
high-throughput	B-X
sequencing	B-X
(	B-X
HTS	B-X
)	B-X
,	B-X
the	B-X
complexity	B-X
and	B-X
diversity	B-X
of	B-X
RNA	B-X
structures	B-X
and	B-X
interactions	B-X
has	B-X
been	B-X
revealed	B-X
in	B-X
the	B-X
transcriptomes	B-X
of	B-X
multiple	B-X
species	B-X
.	B-X
These	B-X
methods	B-X
have	B-X
uncovered	B-X
important	B-X
biological	B-X
insights	B-X
into	B-X
the	B-X
mechanistic	B-X
and	B-X
functional	B-X
roles	B-X
of	B-X
lncRNA	B-X
in	B-X
gene	B-X
expression	B-X
and	B-X
RNA	B-X
metabolism	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
development	B-X
and	B-X
disease	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
latest	B-X
sequencing	B-X
strategies	B-X
to	B-X
reveal	B-X
RNA	B-X
structure	B-X
,	B-X
RNA-RNA	B-X
,	B-X
RNA-DNA	B-X
,	B-X
and	B-X
RNA-protein	B-X
interactions	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
recent	B-X
applications	B-X
of	B-X
these	B-X
approaches	B-X
to	B-X
map	B-X
functional	B-X
lncRNAs	B-X
.	B-X
We	B-X
discuss	B-X
the	B-X
advantages	B-X
and	B-X
limitations	B-X
of	B-X
these	B-X
strategies	B-X
,	B-X
and	B-X
provide	B-X
recommendations	B-X
to	B-X
further	B-X
advance	B-X
methodologies	B-X
capable	B-X
of	B-X
mapping	B-X
RNA	B-X
structure	B-X
and	B-X
interactions	B-X
in	B-X
order	B-X
to	B-X
discover	B-X
new	B-X
biology	B-X
of	B-X
lncRNAs	B-X
and	B-X
decipher	B-X
their	B-X
molecular	B-X
mechanisms	B-X
and	B-X
implication	B-X
in	B-X
diseases	B-X
.	B-X

Their	O
mechanisms	O
of	O
action	O
have	O
been	O
generally	O
studied	O
in	O
imprinted	O
genes	O
.	O
<EOS>	B-X
Multifactorial	B-X
disorders	B-X
are	B-X
quantitative	B-X
traits	B-X
where	B-X
the	B-X
action	B-X
of	B-X
more	B-X
than	B-X
one	B-X
gene	B-X
together	B-X
with	B-X
environmental	B-X
factors	B-X
contributes	B-X
to	B-X
the	B-X
disease	B-X
phenotype	B-X
.	B-X
The	B-X
EL	B-X
(	B-X
epilepsy	B-X
)	B-X
mouse	B-X
has	B-X
been	B-X
studied	B-X
extensively	B-X
as	B-X
a	B-X
genetic	B-X
model	B-X
for	B-X
idiopathic	B-X
complex	B-X
partial	B-X
seizures	B-X
in	B-X
humans	B-X
.	B-X
AGS	B-X
susceptibility	B-X
and	B-X
long-term	B-X
potentiation	B-X
(	B-X
LTP	B-X
)	B-X
may	B-X
also	B-X
share	B-X
common	B-X
mechanisms	B-X
.	B-X
Several	B-X
Asp	B-X
genes	B-X
have	B-X
been	B-X
mapped	B-X
that	B-X
influence	B-X
AGS	B-X
susceptibility	B-X
.	B-X
The	B-X
genetic	B-X
dissection	B-X
of	B-X
convulsive	B-X
behavior	B-X
in	B-X
EL	B-X
and	B-X
AGS	B-X
susceptible	B-X
mice	B-X
could	B-X
help	B-X
identify	B-X
candidate	B-X
genes	B-X
for	B-X
human	B-X
multifactorial	B-X
epilepsies	B-X
.	B-X

The	O
present	O
work	O
analyzes	O
the	O
involvement	O
of	O
these	O
mechanisms	O
in	O
the	O
expression	O
of	O
the	O
U2af1	B-Protein
-	I-Protein
rs1	I-Protein
imprinted	O
gene	O
during	O
the	O
differentiation	O
process	O
of	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
induced	O
by	O
retinoic	O
acid	O
.	O

By	O
DNA	O
digestion	O
with	O
methylation	O
-	O
dependent	O
or	O
independent	O
restriction	O
enzymes	O
and	O
consecutive	O
Southern	O
blot	O
,	O
we	O
have	O
found	O
that	O
methylation	O
of	O
the	O
U2af1	B-Protein
-	I-Protein
rs1	I-Protein
gene	O
increases	O
in	O
differentiated	O
ES	O
cells	O
and	O
in	O
embryoid	O
bodies	O
.	O
<EOS>	B-X
GC	B-X
is	B-X
a	B-X
pathologically	B-X
and	B-X
molecularly	B-X
heterogeneous	B-X
disease	B-X
.	B-X
DNA	B-X
hypermethylation	B-X
in	B-X
promoter	B-X
CpG	B-X
islands	B-X
causes	B-X
silencing	B-X
of	B-X
tumor-suppressor	B-X
genes	B-X
and	B-X
thus	B-X
contributes	B-X
to	B-X
gastric	B-X
carcinogenesis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
various	B-X
molecular	B-X
aberrations	B-X
,	B-X
including	B-X
aberrant	B-X
chromatin	B-X
structures	B-X
,	B-X
gene	B-X
mutations	B-X
,	B-X
structural	B-X
variants	B-X
,	B-X
and	B-X
somatic	B-X
copy	B-X
number	B-X
alterations	B-X
,	B-X
are	B-X
involved	B-X
in	B-X
gastric	B-X
carcinogenesis	B-X
.	B-X
Epigenetic	B-X
mechanisms	B-X
have	B-X
recently	B-X
been	B-X
suggested	B-X
to	B-X
operate	B-X
at	B-X
the	B-X
interface	B-X
between	B-X
the	B-X
microbiota	B-X
and	B-X
the	B-X
intestinal	B-X
epithelium	B-X
.	B-X
We	B-X
performed	B-X
whole-genome	B-X
bisulfite	B-X
sequencing	B-X
on	B-X
conventionally	B-X
raised	B-X
and	B-X
germ-free	B-X
mice	B-X
,	B-X
and	B-X
discovered	B-X
that	B-X
exposure	B-X
to	B-X
commensal	B-X
microbiota	B-X
induced	B-X
localized	B-X
DNA	B-X
methylation	B-X
changes	B-X
at	B-X
regulatory	B-X
elements	B-X
,	B-X
which	B-X
are	B-X
TET2/3-dependent	B-X
.	B-X
This	B-X
culminated	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
set	B-X
of	B-X
'early	B-X
sentinel	B-X
'	B-X
response	B-X
genes	B-X
to	B-X
maintain	B-X
intestinal	B-X
homeostasis	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
exposure	B-X
to	B-X
the	B-X
microbiota	B-X
in	B-X
dextran	B-X
sodium	B-X
sulfate-induced	B-X
acute	B-X
inflammation	B-X
results	B-X
in	B-X
profound	B-X
DNA	B-X
methylation	B-X
and	B-X
chromatin	B-X
accessibility	B-X
changes	B-X
at	B-X
regulatory	B-X
elements	B-X
,	B-X
leading	B-X
to	B-X
alterations	B-X
in	B-X
gene	B-X
expression	B-X
programs	B-X
enriched	B-X
in	B-X
colitis-	B-X
and	B-X
colon-cancer-associated	B-X
functions	B-X
.	B-X
Finally	B-X
,	B-X
by	B-X
employing	B-X
genetic	B-X
interventions	B-X
,	B-X
we	B-X
show	B-X
that	B-X
microbiota-induced	B-X
epigenetic	B-X
programming	B-X
is	B-X
necessary	B-X
for	B-X
proper	B-X
intestinal	B-X
homeostasis	B-X
in	B-X
vivo	B-X
.	B-X

However	O
,	O
northern	O
blot	O
and	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
showed	O
a	O
higher	O
expression	O
of	O
the	O
U2af1	B-Protein
-	I-Protein
rs1	I-Protein
gene	O
in	O
differentiated	O
ES	O
cells	O
and	O
in	O
embryoid	O
bodies	O
than	O
in	O
undifferentiated	O
ones	O
.	O
<EOS>	B-X
Epigenetic	B-X
modifications	B-X
such	B-X
as	B-X
DNA	B-X
methylation	B-X
and	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
are	B-X
changes	B-X
in	B-X
the	B-X
chemical	B-X
composition	B-X
or	B-X
structure	B-X
of	B-X
DNA	B-X
that	B-X
work	B-X
by	B-X
regulating	B-X
gene	B-X
expression	B-X
.	B-X
Their	B-X
mechanisms	B-X
of	B-X
action	B-X
have	B-X
been	B-X
generally	B-X
studied	B-X
in	B-X
imprinted	B-X
genes	B-X
.	B-X
The	B-X
present	B-X
work	B-X
analyzes	B-X
the	B-X
involvement	B-X
of	B-X
these	B-X
mechanisms	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
imprinted	B-X
gene	B-X
during	B-X
the	B-X
differentiation	B-X
process	B-X
of	B-X
embryonic	B-X
stem	B-X
(	B-X
ES	B-X
)	B-X
cells	B-X
induced	B-X
by	B-X
retinoic	B-X
acid	B-X
.	B-X
By	B-X
DNA	B-X
digestion	B-X
with	B-X
methylation-dependent	B-X
or	B-X
independent	B-X
restriction	B-X
enzymes	B-X
and	B-X
consecutive	B-X
Southern	B-X
blot	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
methylation	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
increases	B-X
in	B-X
differentiated	B-X
ES	B-X
cells	B-X
and	B-X
in	B-X
embryoid	B-X
bodies	B-X
.	B-X
However	B-X
,	B-X
northern	B-X
blot	B-X
and	B-X
real-time	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
showed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
in	B-X
differentiated	B-X
ES	B-X
cells	B-X
and	B-X
in	B-X
embryoid	B-X
bodies	B-X
than	B-X
in	B-X
undifferentiated	B-X
ones	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
sensitivity	B-X
to	B-X
DNase-I	B-X
assay	B-X
demonstrated	B-X
an	B-X
open	B-X
chromatin	B-X
conformation	B-X
for	B-X
differentiated	B-X
cells	B-X
with	B-X
regard	B-X
to	B-X
undifferentiated	B-X
ES	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
would	B-X
be	B-X
regulated	B-X
by	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
rather	B-X
than	B-X
by	B-X
DNA	B-X
methylation	B-X
during	B-X
the	B-X
RA-induced	B-X
process	B-X
of	B-X
differentiation	B-X
of	B-X
ES	B-X
cells	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
the	O
sensitivity	O
to	O
DNase	B-Protein
-	I-Protein
I	I-Protein
assay	O
demonstrated	O
an	O
open	O
chromatin	O
conformation	O
for	O
differentiated	O
cells	O
with	O
regard	O
to	O
undifferentiated	O
ES	O
cells	O
.	O
<EOS>	B-X
Epigenetic	B-X
modifications	B-X
such	B-X
as	B-X
DNA	B-X
methylation	B-X
and	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
are	B-X
changes	B-X
in	B-X
the	B-X
chemical	B-X
composition	B-X
or	B-X
structure	B-X
of	B-X
DNA	B-X
that	B-X
work	B-X
by	B-X
regulating	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
present	B-X
work	B-X
analyzes	B-X
the	B-X
involvement	B-X
of	B-X
these	B-X
mechanisms	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
imprinted	B-X
gene	B-X
during	B-X
the	B-X
differentiation	B-X
process	B-X
of	B-X
embryonic	B-X
stem	B-X
(	B-X
ES	B-X
)	B-X
cells	B-X
induced	B-X
by	B-X
retinoic	B-X
acid	B-X
.	B-X
By	B-X
DNA	B-X
digestion	B-X
with	B-X
methylation-dependent	B-X
or	B-X
independent	B-X
restriction	B-X
enzymes	B-X
and	B-X
consecutive	B-X
Southern	B-X
blot	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
methylation	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
increases	B-X
in	B-X
differentiated	B-X
ES	B-X
cells	B-X
and	B-X
in	B-X
embryoid	B-X
bodies	B-X
.	B-X
However	B-X
,	B-X
northern	B-X
blot	B-X
and	B-X
real-time	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
showed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
in	B-X
differentiated	B-X
ES	B-X
cells	B-X
and	B-X
in	B-X
embryoid	B-X
bodies	B-X
than	B-X
in	B-X
undifferentiated	B-X
ones	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
sensitivity	B-X
to	B-X
DNase-I	B-X
assay	B-X
demonstrated	B-X
an	B-X
open	B-X
chromatin	B-X
conformation	B-X
for	B-X
differentiated	B-X
cells	B-X
with	B-X
regard	B-X
to	B-X
undifferentiated	B-X
ES	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
would	B-X
be	B-X
regulated	B-X
by	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
rather	B-X
than	B-X
by	B-X
DNA	B-X
methylation	B-X
during	B-X
the	B-X
RA-induced	B-X
process	B-X
of	B-X
differentiation	B-X
of	B-X
ES	B-X
cells	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
the	O
U2af1	B-Protein
-	I-Protein
rs1	I-Protein
gene	O
would	O
be	O
regulated	O
by	O
changes	O
in	O
chromatin	O
structure	O
rather	O
than	O
by	O
DNA	O
methylation	O
during	O
the	O
RA	O
-	O
induced	O
process	O
of	O
differentiation	O
of	O
ES	O
cells	O
.	O
<EOS>	B-X
Epigenetic	B-X
modifications	B-X
such	B-X
as	B-X
DNA	B-X
methylation	B-X
and	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
are	B-X
changes	B-X
in	B-X
the	B-X
chemical	B-X
composition	B-X
or	B-X
structure	B-X
of	B-X
DNA	B-X
that	B-X
work	B-X
by	B-X
regulating	B-X
gene	B-X
expression	B-X
.	B-X
Their	B-X
mechanisms	B-X
of	B-X
action	B-X
have	B-X
been	B-X
generally	B-X
studied	B-X
in	B-X
imprinted	B-X
genes	B-X
.	B-X
The	B-X
present	B-X
work	B-X
analyzes	B-X
the	B-X
involvement	B-X
of	B-X
these	B-X
mechanisms	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
imprinted	B-X
gene	B-X
during	B-X
the	B-X
differentiation	B-X
process	B-X
of	B-X
embryonic	B-X
stem	B-X
(	B-X
ES	B-X
)	B-X
cells	B-X
induced	B-X
by	B-X
retinoic	B-X
acid	B-X
.	B-X
By	B-X
DNA	B-X
digestion	B-X
with	B-X
methylation-dependent	B-X
or	B-X
independent	B-X
restriction	B-X
enzymes	B-X
and	B-X
consecutive	B-X
Southern	B-X
blot	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
methylation	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
increases	B-X
in	B-X
differentiated	B-X
ES	B-X
cells	B-X
and	B-X
in	B-X
embryoid	B-X
bodies	B-X
.	B-X
However	B-X
,	B-X
northern	B-X
blot	B-X
and	B-X
real-time	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
showed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
in	B-X
differentiated	B-X
ES	B-X
cells	B-X
and	B-X
in	B-X
embryoid	B-X
bodies	B-X
than	B-X
in	B-X
undifferentiated	B-X
ones	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
sensitivity	B-X
to	B-X
DNase-I	B-X
assay	B-X
demonstrated	B-X
an	B-X
open	B-X
chromatin	B-X
conformation	B-X
for	B-X
differentiated	B-X
cells	B-X
with	B-X
regard	B-X
to	B-X
undifferentiated	B-X
ES	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
U2af1-rs1	B-X
gene	B-X
would	B-X
be	B-X
regulated	B-X
by	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
rather	B-X
than	B-X
by	B-X
DNA	B-X
methylation	B-X
during	B-X
the	B-X
RA-induced	B-X
process	B-X
of	B-X
differentiation	B-X
of	B-X
ES	B-X
cells	B-X
.	B-X

The	O
Yng1p	B-Protein
plant	O
homeodomain	O
finger	O
is	O
a	O
methyl	O
-	O
histone	B-Protein
binding	O
module	O
that	O
recognizes	O
lysine	O
4	O
-	O
methylated	O
histone	B-Protein
H3	I-Protein
.	O

The	O
ING	O
(	O
inhibitor	O
of	O
growth	O
)	O
protein	O
family	O
includes	O
a	O
group	O
of	O
homologous	O
nuclear	O
proteins	O
that	O
share	O
a	O
highly	O
conserved	O
plant	O
homeodomain	O
(	O
PHD	O
)	O
finger	O
domain	O
at	O
their	O
carboxyl	O
termini	O
.	O

Members	O
of	O
this	O
family	O
are	O
found	O
in	O
multiprotein	O
complexes	O
that	O
posttranslationally	O
modify	O
histones	B-Protein
,	O
suggesting	O
that	O
these	O
proteins	O
serve	O
a	O
general	O
role	O
in	O
permitting	O
various	O
enzymatic	O
activities	O
to	O
interact	O
with	O
nucleosomes	O
.	O

There	O
are	O
three	O
members	O
of	O
the	O
ING	O
family	O
in	O
Saccharomyces	O
cerevisiae	O
:	O
Yng1p	B-Protein
,	O
Yng2p	B-Protein
,	O
and	O
Pho23p	B-Protein
.	O
<EOS>	B-X
The	B-X
ING	B-X
(	B-X
inhibitor	B-X
of	B-X
growth	B-X
)	B-X
protein	B-X
family	B-X
includes	B-X
a	B-X
group	B-X
of	B-X
homologous	B-X
nuclear	B-X
proteins	B-X
that	B-X
share	B-X
a	B-X
highly	B-X
conserved	B-X
plant	B-X
homeodomain	B-X
(	B-X
PHD	B-X
)	B-X
finger	B-X
domain	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
.	B-X
Members	B-X
of	B-X
this	B-X
family	B-X
are	B-X
found	B-X
in	B-X
multiprotein	B-X
complexes	B-X
that	B-X
posttranslationally	B-X
modify	B-X
histones	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
serve	B-X
a	B-X
general	B-X
role	B-X
in	B-X
permitting	B-X
various	B-X
enzymatic	B-X
activities	B-X
to	B-X
interact	B-X
with	B-X
nucleosomes	B-X
.	B-X
There	B-X
are	B-X
three	B-X
members	B-X
of	B-X
the	B-X
ING	B-X
family	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
:	B-X
Yng1p	B-X
,	B-X
Yng2p	B-X
,	B-X
and	B-X
Pho23p	B-X
.	B-X
Yng1p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
NuA3	B-X
histone	B-X
acetyltransferase	B-X
complex	B-X
and	B-X
is	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
of	B-X
NuA3	B-X
with	B-X
chromatin	B-X
.	B-X
To	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
function	B-X
of	B-X
the	B-X
ING	B-X
proteins	B-X
,	B-X
we	B-X
made	B-X
use	B-X
of	B-X
a	B-X
genetic	B-X
strategy	B-X
to	B-X
identify	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
Yng1p	B-X
to	B-X
histones	B-X
.	B-X
Using	B-X
the	B-X
toxicity	B-X
of	B-X
YNG1	B-X
overexpression	B-X
as	B-X
a	B-X
tool	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
Yng1p	B-X
interacts	B-X
with	B-X
the	B-X
amino-terminal	B-X
tail	B-X
of	B-X
histone	B-X
H3	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
can	B-X
be	B-X
disrupted	B-X
by	B-X
loss	B-X
of	B-X
lysine	B-X
4	B-X
methylation	B-X
within	B-X
this	B-X
tail	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
region	B-X
of	B-X
Yng1p	B-X
required	B-X
for	B-X
overexpression	B-X
of	B-X
toxicity	B-X
to	B-X
the	B-X
PHD	B-X
finger	B-X
,	B-X
showed	B-X
that	B-X
this	B-X
region	B-X
capable	B-X
of	B-X
binding	B-X
lysine	B-X
4-methylated	B-X
histone	B-X
H3	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
demonstrated	B-X
that	B-X
mutations	B-X
of	B-X
the	B-X
PHD	B-X
finger	B-X
that	B-X
abolish	B-X
binding	B-X
in	B-X
vitro	B-X
are	B-X
no	B-X
longer	B-X
toxic	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
function	B-X
for	B-X
the	B-X
Yng1p	B-X
PHD	B-X
finger	B-X
in	B-X
promoting	B-X
stabilization	B-X
of	B-X
the	B-X
NuA3	B-X
complex	B-X
at	B-X
chromatin	B-X
through	B-X
recognition	B-X
of	B-X
histone	B-X
H3	B-X
lysine	B-X
4	B-X
methylation	B-X
.	B-X

Yng1p	B-Protein
is	O
a	O
component	O
of	O
the	O
NuA3	O
histone	B-Protein
acetyltransferase	O
complex	O
and	O
is	O
required	O
for	O
the	O
interaction	O
of	O
NuA3	O
with	O
chromatin	O
.	O
<EOS>	B-X
The	B-X
mammalian	B-X
ING1	B-X
gene	B-X
encodes	B-X
a	B-X
tumor	B-X
suppressor	B-X
required	B-X
for	B-X
the	B-X
function	B-X
of	B-X
p53	B-X
.	B-X
Yng1p	B-X
is	B-X
a	B-X
stable	B-X
component	B-X
of	B-X
the	B-X
NuA3	B-X
histone	B-X
acetyltransferase	B-X
complex	B-X
,	B-X
which	B-X
contains	B-X
Sas3p	B-X
,	B-X
the	B-X
yeast	B-X
homolog	B-X
of	B-X
the	B-X
mammalian	B-X
MOZ	B-X
proto-oncogene	B-X
product	B-X
,	B-X
as	B-X
its	B-X
catalytic	B-X
subunit	B-X
.	B-X
Yng1p	B-X
is	B-X
required	B-X
for	B-X
NuA3	B-X
function	B-X
in	B-X
vivo	B-X
but	B-X
surprisingly	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
complex	B-X
.	B-X
Instead	B-X
,	B-X
we	B-X
find	B-X
that	B-X
Yng1p	B-X
mediates	B-X
the	B-X
interaction	B-X
of	B-X
Sas3p	B-X
with	B-X
nucleosomes	B-X
and	B-X
is	B-X
thus	B-X
required	B-X
for	B-X
the	B-X
ability	B-X
of	B-X
NuA3	B-X
to	B-X
modify	B-X
histone	B-X
tails	B-X
.	B-X
These	B-X
data	B-X
,	B-X
and	B-X
the	B-X
observations	B-X
that	B-X
other	B-X
ING1	B-X
homologs	B-X
are	B-X
found	B-X
in	B-X
additional	B-X
yeast	B-X
complexes	B-X
that	B-X
posttranslationally	B-X
modify	B-X
histones	B-X
,	B-X
suggest	B-X
that	B-X
members	B-X
of	B-X
the	B-X
ING1	B-X
class	B-X
of	B-X
proteins	B-X
may	B-X
have	B-X
broad	B-X
roles	B-X
in	B-X
enhancing	B-X
or	B-X
modifying	B-X
the	B-X
activities	B-X
of	B-X
chromatin-modifying	B-X
complexes	B-X
,	B-X
thereby	B-X
regulating	B-X
their	B-X
activities	B-X
in	B-X
transcription	B-X
control	B-X
.	B-X

To	O
gain	O
insight	O
into	O
the	O
function	O
of	O
the	O
ING	O
proteins	O
,	O
we	O
made	O
use	O
of	O
a	O
genetic	O
strategy	O
to	O
identify	O
genes	O
required	O
for	O
the	O
binding	O
of	O
Yng1p	B-Protein
to	O
histones	B-Protein
.	O
<EOS>	B-X
The	B-X
ING	B-X
(	B-X
inhibitor	B-X
of	B-X
growth	B-X
)	B-X
protein	B-X
family	B-X
includes	B-X
a	B-X
group	B-X
of	B-X
homologous	B-X
nuclear	B-X
proteins	B-X
that	B-X
share	B-X
a	B-X
highly	B-X
conserved	B-X
plant	B-X
homeodomain	B-X
(	B-X
PHD	B-X
)	B-X
finger	B-X
domain	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
.	B-X
Members	B-X
of	B-X
this	B-X
family	B-X
are	B-X
found	B-X
in	B-X
multiprotein	B-X
complexes	B-X
that	B-X
posttranslationally	B-X
modify	B-X
histones	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
serve	B-X
a	B-X
general	B-X
role	B-X
in	B-X
permitting	B-X
various	B-X
enzymatic	B-X
activities	B-X
to	B-X
interact	B-X
with	B-X
nucleosomes	B-X
.	B-X
There	B-X
are	B-X
three	B-X
members	B-X
of	B-X
the	B-X
ING	B-X
family	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
:	B-X
Yng1p	B-X
,	B-X
Yng2p	B-X
,	B-X
and	B-X
Pho23p	B-X
.	B-X
Yng1p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
NuA3	B-X
histone	B-X
acetyltransferase	B-X
complex	B-X
and	B-X
is	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
of	B-X
NuA3	B-X
with	B-X
chromatin	B-X
.	B-X
To	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
function	B-X
of	B-X
the	B-X
ING	B-X
proteins	B-X
,	B-X
we	B-X
made	B-X
use	B-X
of	B-X
a	B-X
genetic	B-X
strategy	B-X
to	B-X
identify	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
Yng1p	B-X
to	B-X
histones	B-X
.	B-X
Using	B-X
the	B-X
toxicity	B-X
of	B-X
YNG1	B-X
overexpression	B-X
as	B-X
a	B-X
tool	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
Yng1p	B-X
interacts	B-X
with	B-X
the	B-X
amino-terminal	B-X
tail	B-X
of	B-X
histone	B-X
H3	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
can	B-X
be	B-X
disrupted	B-X
by	B-X
loss	B-X
of	B-X
lysine	B-X
4	B-X
methylation	B-X
within	B-X
this	B-X
tail	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
region	B-X
of	B-X
Yng1p	B-X
required	B-X
for	B-X
overexpression	B-X
of	B-X
toxicity	B-X
to	B-X
the	B-X
PHD	B-X
finger	B-X
,	B-X
showed	B-X
that	B-X
this	B-X
region	B-X
capable	B-X
of	B-X
binding	B-X
lysine	B-X
4-methylated	B-X
histone	B-X
H3	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
demonstrated	B-X
that	B-X
mutations	B-X
of	B-X
the	B-X
PHD	B-X
finger	B-X
that	B-X
abolish	B-X
binding	B-X
in	B-X
vitro	B-X
are	B-X
no	B-X
longer	B-X
toxic	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
function	B-X
for	B-X
the	B-X
Yng1p	B-X
PHD	B-X
finger	B-X
in	B-X
promoting	B-X
stabilization	B-X
of	B-X
the	B-X
NuA3	B-X
complex	B-X
at	B-X
chromatin	B-X
through	B-X
recognition	B-X
of	B-X
histone	B-X
H3	B-X
lysine	B-X
4	B-X
methylation	B-X
.	B-X

Using	O
the	O
toxicity	O
of	O
YNG1	B-Protein
overexpression	O
as	O
a	O
tool	O
,	O
we	O
showed	O
that	O
Yng1p	B-Protein
interacts	O
with	O
the	O
amino	O
-	O
terminal	O
tail	O
of	O
histone	B-Protein
H3	I-Protein
and	O
that	O
this	O
interaction	O
can	O
be	O
disrupted	O
by	O
loss	O
of	O
lysine	O
4	O
methylation	O
within	O
this	O
tail	O
.	O
<EOS>	B-X
Members	B-X
of	B-X
this	B-X
family	B-X
are	B-X
found	B-X
in	B-X
multiprotein	B-X
complexes	B-X
that	B-X
posttranslationally	B-X
modify	B-X
histones	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
serve	B-X
a	B-X
general	B-X
role	B-X
in	B-X
permitting	B-X
various	B-X
enzymatic	B-X
activities	B-X
to	B-X
interact	B-X
with	B-X
nucleosomes	B-X
.	B-X
There	B-X
are	B-X
three	B-X
members	B-X
of	B-X
the	B-X
ING	B-X
family	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
:	B-X
Yng1p	B-X
,	B-X
Yng2p	B-X
,	B-X
and	B-X
Pho23p	B-X
.	B-X
Yng1p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
NuA3	B-X
histone	B-X
acetyltransferase	B-X
complex	B-X
and	B-X
is	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
of	B-X
NuA3	B-X
with	B-X
chromatin	B-X
.	B-X
To	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
function	B-X
of	B-X
the	B-X
ING	B-X
proteins	B-X
,	B-X
we	B-X
made	B-X
use	B-X
of	B-X
a	B-X
genetic	B-X
strategy	B-X
to	B-X
identify	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
Yng1p	B-X
to	B-X
histones	B-X
.	B-X
Using	B-X
the	B-X
toxicity	B-X
of	B-X
YNG1	B-X
overexpression	B-X
as	B-X
a	B-X
tool	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
Yng1p	B-X
interacts	B-X
with	B-X
the	B-X
amino-terminal	B-X
tail	B-X
of	B-X
histone	B-X
H3	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
can	B-X
be	B-X
disrupted	B-X
by	B-X
loss	B-X
of	B-X
lysine	B-X
4	B-X
methylation	B-X
within	B-X
this	B-X
tail	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
region	B-X
of	B-X
Yng1p	B-X
required	B-X
for	B-X
overexpression	B-X
of	B-X
toxicity	B-X
to	B-X
the	B-X
PHD	B-X
finger	B-X
,	B-X
showed	B-X
that	B-X
this	B-X
region	B-X
capable	B-X
of	B-X
binding	B-X
lysine	B-X
4-methylated	B-X
histone	B-X
H3	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
demonstrated	B-X
that	B-X
mutations	B-X
of	B-X
the	B-X
PHD	B-X
finger	B-X
that	B-X
abolish	B-X
binding	B-X
in	B-X
vitro	B-X
are	B-X
no	B-X
longer	B-X
toxic	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
function	B-X
for	B-X
the	B-X
Yng1p	B-X
PHD	B-X
finger	B-X
in	B-X
promoting	B-X
stabilization	B-X
of	B-X
the	B-X
NuA3	B-X
complex	B-X
at	B-X
chromatin	B-X
through	B-X
recognition	B-X
of	B-X
histone	B-X
H3	B-X
lysine	B-X
4	B-X
methylation	B-X
.	B-X

Additionally	O
,	O
we	O
mapped	O
the	O
region	O
of	O
Yng1p	B-Protein
required	O
for	O
overexpression	O
of	O
toxicity	O
to	O
the	O
PHD	O
finger	O
,	O
showed	O
that	O
this	O
region	O
capable	O
of	O
binding	O
lysine	O
4	O
-	O
methylated	O
histone	B-Protein
H3	I-Protein
in	O
vitro	O
,	O
and	O
demonstrated	O
that	O
mutations	O
of	O
the	O
PHD	O
finger	O
that	O
abolish	O
binding	O
in	O
vitro	O
are	O
no	O
longer	O
toxic	O
in	O
vivo	O
.	O

These	O
results	O
identify	O
a	O
novel	O
function	O
for	O
the	O
Yng1p	B-Protein
PHD	O
finger	O
in	O
promoting	O
stabilization	O
of	O
the	O
NuA3	O
complex	O
at	O
chromatin	O
through	O
recognition	O
of	O
histone	B-Protein
H3	I-Protein
lysine	O
4	O
methylation	O
.	O
<EOS>	B-X
The	B-X
ING	B-X
(	B-X
inhibitor	B-X
of	B-X
growth	B-X
)	B-X
protein	B-X
family	B-X
includes	B-X
a	B-X
group	B-X
of	B-X
homologous	B-X
nuclear	B-X
proteins	B-X
that	B-X
share	B-X
a	B-X
highly	B-X
conserved	B-X
plant	B-X
homeodomain	B-X
(	B-X
PHD	B-X
)	B-X
finger	B-X
domain	B-X
at	B-X
their	B-X
carboxyl	B-X
termini	B-X
.	B-X
Members	B-X
of	B-X
this	B-X
family	B-X
are	B-X
found	B-X
in	B-X
multiprotein	B-X
complexes	B-X
that	B-X
posttranslationally	B-X
modify	B-X
histones	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
serve	B-X
a	B-X
general	B-X
role	B-X
in	B-X
permitting	B-X
various	B-X
enzymatic	B-X
activities	B-X
to	B-X
interact	B-X
with	B-X
nucleosomes	B-X
.	B-X
There	B-X
are	B-X
three	B-X
members	B-X
of	B-X
the	B-X
ING	B-X
family	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
:	B-X
Yng1p	B-X
,	B-X
Yng2p	B-X
,	B-X
and	B-X
Pho23p	B-X
.	B-X
Yng1p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
NuA3	B-X
histone	B-X
acetyltransferase	B-X
complex	B-X
and	B-X
is	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
of	B-X
NuA3	B-X
with	B-X
chromatin	B-X
.	B-X
To	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
function	B-X
of	B-X
the	B-X
ING	B-X
proteins	B-X
,	B-X
we	B-X
made	B-X
use	B-X
of	B-X
a	B-X
genetic	B-X
strategy	B-X
to	B-X
identify	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
Yng1p	B-X
to	B-X
histones	B-X
.	B-X
Using	B-X
the	B-X
toxicity	B-X
of	B-X
YNG1	B-X
overexpression	B-X
as	B-X
a	B-X
tool	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
Yng1p	B-X
interacts	B-X
with	B-X
the	B-X
amino-terminal	B-X
tail	B-X
of	B-X
histone	B-X
H3	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
can	B-X
be	B-X
disrupted	B-X
by	B-X
loss	B-X
of	B-X
lysine	B-X
4	B-X
methylation	B-X
within	B-X
this	B-X
tail	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
region	B-X
of	B-X
Yng1p	B-X
required	B-X
for	B-X
overexpression	B-X
of	B-X
toxicity	B-X
to	B-X
the	B-X
PHD	B-X
finger	B-X
,	B-X
showed	B-X
that	B-X
this	B-X
region	B-X
capable	B-X
of	B-X
binding	B-X
lysine	B-X
4-methylated	B-X
histone	B-X
H3	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
demonstrated	B-X
that	B-X
mutations	B-X
of	B-X
the	B-X
PHD	B-X
finger	B-X
that	B-X
abolish	B-X
binding	B-X
in	B-X
vitro	B-X
are	B-X
no	B-X
longer	B-X
toxic	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
function	B-X
for	B-X
the	B-X
Yng1p	B-X
PHD	B-X
finger	B-X
in	B-X
promoting	B-X
stabilization	B-X
of	B-X
the	B-X
NuA3	B-X
complex	B-X
at	B-X
chromatin	B-X
through	B-X
recognition	B-X
of	B-X
histone	B-X
H3	B-X
lysine	B-X
4	B-X
methylation	B-X
.	B-X

Clioquinol	O
,	O
a	O
Cu	O
(	O
II	O
)	O
/	O
Zn	O
(	O
II	O
)	O
chelator	O
,	O
inhibits	O
both	O
ubiquitination	O
and	O
asparagine	O
hydroxylation	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
,	O
leading	O
to	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
erythropoietin	B-Protein
in	O
normoxic	O
cells	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
Cu	B-X
(	B-X
II	B-X
)	B-X
and	B-X
Zn	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
chelator	B-X
Clioquinol	B-X
(	B-X
10-50	B-X
microM	B-X
)	B-X
increased	B-X
functional	B-X
hypoxia-inducible	B-X
factor	B-X
1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
protein	B-X
,	B-X
leading	B-X
to	B-X
increased	B-X
expression	B-X
of	B-X
its	B-X
target	B-X
genes	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
and	B-X
erythropoietin	B-X
,	B-X
in	B-X
SH-SY5Y	B-X
cells	B-X
and	B-X
HepG2	B-X
cells	B-X
.	B-X
Clioquinol	B-X
inhibited	B-X
ubiquitination	B-X
of	B-X
HIF-1alpha	B-X
in	B-X
a	B-X
Cu	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
Zn	B-X
(	B-X
II	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
It	B-X
prevents	B-X
FIH-1	B-X
from	B-X
hydroxylating	B-X
the	B-X
asparagine	B-X
residue	B-X
(	B-X
803	B-X
)	B-X
of	B-X
HIF-1alpha	B-X
in	B-X
a	B-X
Cu	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
Zn	B-X
(	B-X
II	B-X
)	B-X
-independent	B-X
fashion	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
leads	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
HIF-1alpha	B-X
that	B-X
is	B-X
prolyl	B-X
but	B-X
not	B-X
asparaginyl	B-X
hydroxylated	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
co-immunoprecipitation	B-X
assays	B-X
showed	B-X
that	B-X
Clioquinol-induced	B-X
HIF-1alpha	B-X
interacted	B-X
with	B-X
cAMP-responsive	B-X
element-binding	B-X
protein	B-X
in	B-X
normoxic	B-X
cells	B-X
,	B-X
implying	B-X
that	B-X
Clioquinol	B-X
stabilizes	B-X
the	B-X
trans-active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
Clioquinol	B-X
could	B-X
be	B-X
useful	B-X
as	B-X
an	B-X
inducer	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
its	B-X
target	B-X
genes	B-X
in	B-X
ischemic	B-X
diseases	B-X
.	B-X

We	O
found	O
that	O
the	O
Cu	O
(	O
II	O
)	O
and	O
Zn	O
(	O
II	O
)	O
-	O
specific	O
chelator	O
Clioquinol	O
(	O
10	O
-	O
50	O
microM	O
)	O
increased	O
functional	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
protein	O
,	O
leading	O
to	O
increased	O
expression	O
of	O
its	O
target	O
genes	O
,	O
vascular	O
endothelial	O
growth	O
factors	O
and	O
erythropoietin	B-Protein
,	O
in	O
SH	O
-	O
SY5Y	O
cells	O
and	O
HepG2	O
cells	O
.	O

Clioquinol	O
inhibited	O
ubiquitination	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
in	O
a	O
Cu	O
(	O
II	O
)	O
-	O
and	O
Zn	O
(	O
II	O
)	O
-	O
dependent	O
manner	O
.	O

It	O
prevents	O
FIH	B-Protein
-	I-Protein
1	I-Protein
from	O
hydroxylating	O
the	O
asparagine	O
residue	O
(	O
803	O
)	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
in	O
a	O
Cu	O
(	O
II	O
)	O
-	O
and	O
Zn	O
(	O
II	O
)	O
-	O
independent	O
fashion	O
.	O

Therefore	O
,	O
it	O
leads	O
to	O
the	O
accumulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
that	O
is	O
prolyl	O
but	O
not	O
asparaginyl	O
hydroxylated	O
.	O

Consistent	O
with	O
this	O
,	O
co	O
-	O
immunoprecipitation	O
assays	O
showed	O
that	O
Clioquinol	O
-	O
induced	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
interacted	O
with	O
cAMP	O
-	O
responsive	O
element	O
-	O
binding	O
protein	O
in	O
normoxic	O
cells	O
,	O
implying	O
that	O
Clioquinol	O
stabilizes	O
the	O
trans	O
-	O
active	O
form	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
Cu	B-X
(	B-X
II	B-X
)	B-X
and	B-X
Zn	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
chelator	B-X
Clioquinol	B-X
(	B-X
10-50	B-X
microM	B-X
)	B-X
increased	B-X
functional	B-X
hypoxia-inducible	B-X
factor	B-X
1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
protein	B-X
,	B-X
leading	B-X
to	B-X
increased	B-X
expression	B-X
of	B-X
its	B-X
target	B-X
genes	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
and	B-X
erythropoietin	B-X
,	B-X
in	B-X
SH-SY5Y	B-X
cells	B-X
and	B-X
HepG2	B-X
cells	B-X
.	B-X
Clioquinol	B-X
inhibited	B-X
ubiquitination	B-X
of	B-X
HIF-1alpha	B-X
in	B-X
a	B-X
Cu	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
Zn	B-X
(	B-X
II	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
It	B-X
prevents	B-X
FIH-1	B-X
from	B-X
hydroxylating	B-X
the	B-X
asparagine	B-X
residue	B-X
(	B-X
803	B-X
)	B-X
of	B-X
HIF-1alpha	B-X
in	B-X
a	B-X
Cu	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
Zn	B-X
(	B-X
II	B-X
)	B-X
-independent	B-X
fashion	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
leads	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
HIF-1alpha	B-X
that	B-X
is	B-X
prolyl	B-X
but	B-X
not	B-X
asparaginyl	B-X
hydroxylated	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
co-immunoprecipitation	B-X
assays	B-X
showed	B-X
that	B-X
Clioquinol-induced	B-X
HIF-1alpha	B-X
interacted	B-X
with	B-X
cAMP-responsive	B-X
element-binding	B-X
protein	B-X
in	B-X
normoxic	B-X
cells	B-X
,	B-X
implying	B-X
that	B-X
Clioquinol	B-X
stabilizes	B-X
the	B-X
trans-active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
Clioquinol	B-X
could	B-X
be	B-X
useful	B-X
as	B-X
an	B-X
inducer	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
its	B-X
target	B-X
genes	B-X
in	B-X
ischemic	B-X
diseases	B-X
.	B-X

Our	O
results	O
indicate	O
that	O
Clioquinol	O
could	O
be	O
useful	O
as	O
an	O
inducer	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
its	O
target	O
genes	O
in	O
ischemic	O
diseases	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
Cu	B-X
(	B-X
II	B-X
)	B-X
and	B-X
Zn	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
chelator	B-X
Clioquinol	B-X
(	B-X
10-50	B-X
microM	B-X
)	B-X
increased	B-X
functional	B-X
hypoxia-inducible	B-X
factor	B-X
1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
protein	B-X
,	B-X
leading	B-X
to	B-X
increased	B-X
expression	B-X
of	B-X
its	B-X
target	B-X
genes	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
and	B-X
erythropoietin	B-X
,	B-X
in	B-X
SH-SY5Y	B-X
cells	B-X
and	B-X
HepG2	B-X
cells	B-X
.	B-X
Clioquinol	B-X
inhibited	B-X
ubiquitination	B-X
of	B-X
HIF-1alpha	B-X
in	B-X
a	B-X
Cu	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
Zn	B-X
(	B-X
II	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
It	B-X
prevents	B-X
FIH-1	B-X
from	B-X
hydroxylating	B-X
the	B-X
asparagine	B-X
residue	B-X
(	B-X
803	B-X
)	B-X
of	B-X
HIF-1alpha	B-X
in	B-X
a	B-X
Cu	B-X
(	B-X
II	B-X
)	B-X
-	B-X
and	B-X
Zn	B-X
(	B-X
II	B-X
)	B-X
-independent	B-X
fashion	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
leads	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
HIF-1alpha	B-X
that	B-X
is	B-X
prolyl	B-X
but	B-X
not	B-X
asparaginyl	B-X
hydroxylated	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
co-immunoprecipitation	B-X
assays	B-X
showed	B-X
that	B-X
Clioquinol-induced	B-X
HIF-1alpha	B-X
interacted	B-X
with	B-X
cAMP-responsive	B-X
element-binding	B-X
protein	B-X
in	B-X
normoxic	B-X
cells	B-X
,	B-X
implying	B-X
that	B-X
Clioquinol	B-X
stabilizes	B-X
the	B-X
trans-active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
Clioquinol	B-X
could	B-X
be	B-X
useful	B-X
as	B-X
an	B-X
inducer	B-X
of	B-X
HIF-1alpha	B-X
and	B-X
its	B-X
target	B-X
genes	B-X
in	B-X
ischemic	B-X
diseases	B-X
.	B-X

Interaction	O
of	O
HIV	O
-	O
1	O
with	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	I-Protein
-	O
expressing	O
cells	O
is	O
influenced	O
by	O
gp120	B-Protein
envelope	O
modifications	O
associated	O
with	O
disease	O
progression	O
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
can	B-X
enhance	B-X
the	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
through	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
gp120	B-X
envelope	B-X
protein	B-X
with	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
.	B-X
The	B-X
variable	B-X
loops	B-X
of	B-X
gp120	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
modulate	B-X
the	B-X
interaction	B-X
of	B-X
HIV-1	B-X
with	B-X
its	B-X
principal	B-X
receptor	B-X
CD4	B-X
and	B-X
its	B-X
various	B-X
coreceptors	B-X
,	B-X
namely	B-X
CCR5	B-X
and	B-X
CXCR4	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
molecular	B-X
cloned	B-X
viruses	B-X
to	B-X
identify	B-X
whether	B-X
gp120	B-X
modifications	B-X
can	B-X
influence	B-X
the	B-X
virus	B-X
interaction	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
or	B-X
a	B-X
cell	B-X
line	B-X
expressing	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
(	B-X
Raji-DC-SIGN	B-X
)	B-X
.	B-X
The	B-X
viruses	B-X
encompass	B-X
the	B-X
R5	B-X
,	B-X
R5X4	B-X
and	B-X
X4	B-X
phenotypes	B-X
,	B-X
and	B-X
are	B-X
based	B-X
upon	B-X
V1V2	B-X
and	B-X
V3	B-X
sequences	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
disease	B-X
progression	B-X
.	B-X
We	B-X
found	B-X
that	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
enhancement	B-X
of	B-X
virus	B-X
replication	B-X
can	B-X
be	B-X
modulated	B-X
by	B-X
the	B-X
V1V2	B-X
length	B-X
,	B-X
the	B-X
overall	B-X
V3	B-X
charge	B-X
and	B-X
N-linked	B-X
glycosylation	B-X
patterns	B-X
;	B-X
similar	B-X
results	B-X
were	B-X
observed	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
.	B-X
Viruses	B-X
with	B-X
higher	B-X
V3	B-X
charges	B-X
are	B-X
more	B-X
readily	B-X
transferred	B-X
to	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
longer	B-X
and	B-X
contains	B-X
an	B-X
additional	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
whereas	B-X
transfer	B-X
of	B-X
viruses	B-X
with	B-X
lower	B-X
V3	B-X
charges	B-X
is	B-X
greater	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
shorter	B-X
.	B-X
Viruses	B-X
differing	B-X
in	B-X
the	B-X
V1V2	B-X
and	B-X
V3	B-X
regions	B-X
also	B-X
demonstrated	B-X
differential	B-X
capture	B-X
by	B-X
Raji-DC-SIGN	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
mannan	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
interaction	B-X
between	B-X
HIV-1	B-X
and	B-X
immature	B-X
dendritic	B-X
cells	B-X
via	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
selecting	B-X
viruses	B-X
undergoing	B-X
transmission	B-X
and	B-X
evolution	B-X
during	B-X
disease	B-X
progression	B-X
.	B-X

Dendritic	O
cells	O
can	O
enhance	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
CD4	B-Protein
(	O
+	O
)	O
lymphocytes	O
through	O
the	O
interaction	O
of	O
the	O
gp120	B-Protein
envelope	O
protein	O
with	O
such	O
molecules	O
as	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	I-Protein
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
can	B-X
enhance	B-X
the	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
through	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
gp120	B-X
envelope	B-X
protein	B-X
with	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
.	B-X
The	B-X
variable	B-X
loops	B-X
of	B-X
gp120	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
modulate	B-X
the	B-X
interaction	B-X
of	B-X
HIV-1	B-X
with	B-X
its	B-X
principal	B-X
receptor	B-X
CD4	B-X
and	B-X
its	B-X
various	B-X
coreceptors	B-X
,	B-X
namely	B-X
CCR5	B-X
and	B-X
CXCR4	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
molecular	B-X
cloned	B-X
viruses	B-X
to	B-X
identify	B-X
whether	B-X
gp120	B-X
modifications	B-X
can	B-X
influence	B-X
the	B-X
virus	B-X
interaction	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
or	B-X
a	B-X
cell	B-X
line	B-X
expressing	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
(	B-X
Raji-DC-SIGN	B-X
)	B-X
.	B-X
The	B-X
viruses	B-X
encompass	B-X
the	B-X
R5	B-X
,	B-X
R5X4	B-X
and	B-X
X4	B-X
phenotypes	B-X
,	B-X
and	B-X
are	B-X
based	B-X
upon	B-X
V1V2	B-X
and	B-X
V3	B-X
sequences	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
disease	B-X
progression	B-X
.	B-X
We	B-X
found	B-X
that	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
enhancement	B-X
of	B-X
virus	B-X
replication	B-X
can	B-X
be	B-X
modulated	B-X
by	B-X
the	B-X
V1V2	B-X
length	B-X
,	B-X
the	B-X
overall	B-X
V3	B-X
charge	B-X
and	B-X
N-linked	B-X
glycosylation	B-X
patterns	B-X
;	B-X
similar	B-X
results	B-X
were	B-X
observed	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
.	B-X
Viruses	B-X
with	B-X
higher	B-X
V3	B-X
charges	B-X
are	B-X
more	B-X
readily	B-X
transferred	B-X
to	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
longer	B-X
and	B-X
contains	B-X
an	B-X
additional	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
whereas	B-X
transfer	B-X
of	B-X
viruses	B-X
with	B-X
lower	B-X
V3	B-X
charges	B-X
is	B-X
greater	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
shorter	B-X
.	B-X
Viruses	B-X
differing	B-X
in	B-X
the	B-X
V1V2	B-X
and	B-X
V3	B-X
regions	B-X
also	B-X
demonstrated	B-X
differential	B-X
capture	B-X
by	B-X
Raji-DC-SIGN	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
mannan	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
interaction	B-X
between	B-X
HIV-1	B-X
and	B-X
immature	B-X
dendritic	B-X
cells	B-X
via	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
selecting	B-X
viruses	B-X
undergoing	B-X
transmission	B-X
and	B-X
evolution	B-X
during	B-X
disease	B-X
progression	B-X
.	B-X

The	O
variable	O
loops	O
of	O
gp120	B-Protein
have	O
previously	O
been	O
shown	O
to	O
modulate	O
the	O
interaction	O
of	O
HIV	O
-	O
1	O
with	O
its	O
principal	O
receptor	O
CD4	B-Protein
and	O
its	O
various	O
coreceptors	O
,	O
namely	O
CCR5	B-Protein
and	O
CXCR4	B-Protein
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
can	B-X
enhance	B-X
the	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
through	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
gp120	B-X
envelope	B-X
protein	B-X
with	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
.	B-X
The	B-X
variable	B-X
loops	B-X
of	B-X
gp120	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
modulate	B-X
the	B-X
interaction	B-X
of	B-X
HIV-1	B-X
with	B-X
its	B-X
principal	B-X
receptor	B-X
CD4	B-X
and	B-X
its	B-X
various	B-X
coreceptors	B-X
,	B-X
namely	B-X
CCR5	B-X
and	B-X
CXCR4	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
molecular	B-X
cloned	B-X
viruses	B-X
to	B-X
identify	B-X
whether	B-X
gp120	B-X
modifications	B-X
can	B-X
influence	B-X
the	B-X
virus	B-X
interaction	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
or	B-X
a	B-X
cell	B-X
line	B-X
expressing	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
(	B-X
Raji-DC-SIGN	B-X
)	B-X
.	B-X
The	B-X
viruses	B-X
encompass	B-X
the	B-X
R5	B-X
,	B-X
R5X4	B-X
and	B-X
X4	B-X
phenotypes	B-X
,	B-X
and	B-X
are	B-X
based	B-X
upon	B-X
V1V2	B-X
and	B-X
V3	B-X
sequences	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
disease	B-X
progression	B-X
.	B-X
We	B-X
found	B-X
that	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
enhancement	B-X
of	B-X
virus	B-X
replication	B-X
can	B-X
be	B-X
modulated	B-X
by	B-X
the	B-X
V1V2	B-X
length	B-X
,	B-X
the	B-X
overall	B-X
V3	B-X
charge	B-X
and	B-X
N-linked	B-X
glycosylation	B-X
patterns	B-X
;	B-X
similar	B-X
results	B-X
were	B-X
observed	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
.	B-X
Viruses	B-X
with	B-X
higher	B-X
V3	B-X
charges	B-X
are	B-X
more	B-X
readily	B-X
transferred	B-X
to	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
longer	B-X
and	B-X
contains	B-X
an	B-X
additional	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
whereas	B-X
transfer	B-X
of	B-X
viruses	B-X
with	B-X
lower	B-X
V3	B-X
charges	B-X
is	B-X
greater	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
shorter	B-X
.	B-X
Viruses	B-X
differing	B-X
in	B-X
the	B-X
V1V2	B-X
and	B-X
V3	B-X
regions	B-X
also	B-X
demonstrated	B-X
differential	B-X
capture	B-X
by	B-X
Raji-DC-SIGN	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
mannan	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
interaction	B-X
between	B-X
HIV-1	B-X
and	B-X
immature	B-X
dendritic	B-X
cells	B-X
via	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
selecting	B-X
viruses	B-X
undergoing	B-X
transmission	B-X
and	B-X
evolution	B-X
during	B-X
disease	B-X
progression	B-X
.	B-X

Here	O
,	O
we	O
utilized	O
a	O
panel	O
of	O
molecular	O
cloned	O
viruses	O
to	O
identify	O
whether	O
gp120	B-Protein
modifications	O
can	O
influence	O
the	O
virus	O
interaction	O
with	O
immature	O
dendritic	O
cells	O
or	O
a	O
cell	O
line	O
expressing	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	I-Protein
(	O
Raji	O
-	O
DC	B-Protein
-	I-Protein
SIGN	I-Protein
)	O
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
can	B-X
enhance	B-X
the	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
through	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
gp120	B-X
envelope	B-X
protein	B-X
with	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
.	B-X
The	B-X
variable	B-X
loops	B-X
of	B-X
gp120	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
modulate	B-X
the	B-X
interaction	B-X
of	B-X
HIV-1	B-X
with	B-X
its	B-X
principal	B-X
receptor	B-X
CD4	B-X
and	B-X
its	B-X
various	B-X
coreceptors	B-X
,	B-X
namely	B-X
CCR5	B-X
and	B-X
CXCR4	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
molecular	B-X
cloned	B-X
viruses	B-X
to	B-X
identify	B-X
whether	B-X
gp120	B-X
modifications	B-X
can	B-X
influence	B-X
the	B-X
virus	B-X
interaction	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
or	B-X
a	B-X
cell	B-X
line	B-X
expressing	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
(	B-X
Raji-DC-SIGN	B-X
)	B-X
.	B-X
The	B-X
viruses	B-X
encompass	B-X
the	B-X
R5	B-X
,	B-X
R5X4	B-X
and	B-X
X4	B-X
phenotypes	B-X
,	B-X
and	B-X
are	B-X
based	B-X
upon	B-X
V1V2	B-X
and	B-X
V3	B-X
sequences	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
disease	B-X
progression	B-X
.	B-X
We	B-X
found	B-X
that	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
enhancement	B-X
of	B-X
virus	B-X
replication	B-X
can	B-X
be	B-X
modulated	B-X
by	B-X
the	B-X
V1V2	B-X
length	B-X
,	B-X
the	B-X
overall	B-X
V3	B-X
charge	B-X
and	B-X
N-linked	B-X
glycosylation	B-X
patterns	B-X
;	B-X
similar	B-X
results	B-X
were	B-X
observed	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
.	B-X
Viruses	B-X
with	B-X
higher	B-X
V3	B-X
charges	B-X
are	B-X
more	B-X
readily	B-X
transferred	B-X
to	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
longer	B-X
and	B-X
contains	B-X
an	B-X
additional	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
whereas	B-X
transfer	B-X
of	B-X
viruses	B-X
with	B-X
lower	B-X
V3	B-X
charges	B-X
is	B-X
greater	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
shorter	B-X
.	B-X
Viruses	B-X
differing	B-X
in	B-X
the	B-X
V1V2	B-X
and	B-X
V3	B-X
regions	B-X
also	B-X
demonstrated	B-X
differential	B-X
capture	B-X
by	B-X
Raji-DC-SIGN	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
mannan	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
interaction	B-X
between	B-X
HIV-1	B-X
and	B-X
immature	B-X
dendritic	B-X
cells	B-X
via	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
selecting	B-X
viruses	B-X
undergoing	B-X
transmission	B-X
and	B-X
evolution	B-X
during	B-X
disease	B-X
progression	B-X
.	B-X

The	O
viruses	O
encompass	O
the	O
R5	O
,	O
R5X4	O
and	O
X4	O
phenotypes	O
,	O
and	O
are	O
based	O
upon	O
V1V2	O
and	O
V3	O
sequences	O
from	O
a	O
patient	O
with	O
disease	O
progression	O
.	O
<EOS>	B-X
The	B-X
variable	B-X
loops	B-X
of	B-X
gp120	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
modulate	B-X
the	B-X
interaction	B-X
of	B-X
HIV-1	B-X
with	B-X
its	B-X
principal	B-X
receptor	B-X
CD4	B-X
and	B-X
its	B-X
various	B-X
coreceptors	B-X
,	B-X
namely	B-X
CCR5	B-X
and	B-X
CXCR4	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
molecular	B-X
cloned	B-X
viruses	B-X
to	B-X
identify	B-X
whether	B-X
gp120	B-X
modifications	B-X
can	B-X
influence	B-X
the	B-X
virus	B-X
interaction	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
or	B-X
a	B-X
cell	B-X
line	B-X
expressing	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
(	B-X
Raji-DC-SIGN	B-X
)	B-X
.	B-X
The	B-X
viruses	B-X
encompass	B-X
the	B-X
R5	B-X
,	B-X
R5X4	B-X
and	B-X
X4	B-X
phenotypes	B-X
,	B-X
and	B-X
are	B-X
based	B-X
upon	B-X
V1V2	B-X
and	B-X
V3	B-X
sequences	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
disease	B-X
progression	B-X
.	B-X
We	B-X
found	B-X
that	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
enhancement	B-X
of	B-X
virus	B-X
replication	B-X
can	B-X
be	B-X
modulated	B-X
by	B-X
the	B-X
V1V2	B-X
length	B-X
,	B-X
the	B-X
overall	B-X
V3	B-X
charge	B-X
and	B-X
N-linked	B-X
glycosylation	B-X
patterns	B-X
;	B-X
similar	B-X
results	B-X
were	B-X
observed	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
.	B-X
Viruses	B-X
with	B-X
higher	B-X
V3	B-X
charges	B-X
are	B-X
more	B-X
readily	B-X
transferred	B-X
to	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
longer	B-X
and	B-X
contains	B-X
an	B-X
additional	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
whereas	B-X
transfer	B-X
of	B-X
viruses	B-X
with	B-X
lower	B-X
V3	B-X
charges	B-X
is	B-X
greater	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
shorter	B-X
.	B-X
Viruses	B-X
differing	B-X
in	B-X
the	B-X
V1V2	B-X
and	B-X
V3	B-X
regions	B-X
also	B-X
demonstrated	B-X
differential	B-X
capture	B-X
by	B-X
Raji-DC-SIGN	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
mannan	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
interaction	B-X
between	B-X
HIV-1	B-X
and	B-X
immature	B-X
dendritic	B-X
cells	B-X
via	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
selecting	B-X
viruses	B-X
undergoing	B-X
transmission	B-X
and	B-X
evolution	B-X
during	B-X
disease	B-X
progression	B-X
.	B-X

We	O
found	O
that	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	I-Protein
enhancement	O
of	O
virus	O
replication	O
can	O
be	O
modulated	O
by	O
the	O
V1V2	O
length	O
,	O
the	O
overall	O
V3	O
charge	O
and	O
N	O
-	O
linked	O
glycosylation	O
patterns	O
;	O
similar	O
results	O
were	O
observed	O
with	O
immature	O
dendritic	O
cells	O
.	O

Viruses	O
with	O
higher	O
V3	O
charges	O
are	O
more	O
readily	O
transferred	O
to	O
CD4	B-Protein
(	O
+	O
)	O
lymphocytes	O
when	O
the	O
V1V2	O
region	O
is	O
longer	O
and	O
contains	O
an	O
additional	O
N	O
-	O
linked	O
glycosylation	O
site	O
,	O
whereas	O
transfer	O
of	O
viruses	O
with	O
lower	O
V3	O
charges	O
is	O
greater	O
when	O
the	O
V1V2	O
region	O
is	O
shorter	O
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
can	B-X
enhance	B-X
the	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
through	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
gp120	B-X
envelope	B-X
protein	B-X
with	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
.	B-X
The	B-X
variable	B-X
loops	B-X
of	B-X
gp120	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
modulate	B-X
the	B-X
interaction	B-X
of	B-X
HIV-1	B-X
with	B-X
its	B-X
principal	B-X
receptor	B-X
CD4	B-X
and	B-X
its	B-X
various	B-X
coreceptors	B-X
,	B-X
namely	B-X
CCR5	B-X
and	B-X
CXCR4	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
molecular	B-X
cloned	B-X
viruses	B-X
to	B-X
identify	B-X
whether	B-X
gp120	B-X
modifications	B-X
can	B-X
influence	B-X
the	B-X
virus	B-X
interaction	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
or	B-X
a	B-X
cell	B-X
line	B-X
expressing	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
(	B-X
Raji-DC-SIGN	B-X
)	B-X
.	B-X
The	B-X
viruses	B-X
encompass	B-X
the	B-X
R5	B-X
,	B-X
R5X4	B-X
and	B-X
X4	B-X
phenotypes	B-X
,	B-X
and	B-X
are	B-X
based	B-X
upon	B-X
V1V2	B-X
and	B-X
V3	B-X
sequences	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
disease	B-X
progression	B-X
.	B-X
We	B-X
found	B-X
that	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
enhancement	B-X
of	B-X
virus	B-X
replication	B-X
can	B-X
be	B-X
modulated	B-X
by	B-X
the	B-X
V1V2	B-X
length	B-X
,	B-X
the	B-X
overall	B-X
V3	B-X
charge	B-X
and	B-X
N-linked	B-X
glycosylation	B-X
patterns	B-X
;	B-X
similar	B-X
results	B-X
were	B-X
observed	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
.	B-X
Viruses	B-X
with	B-X
higher	B-X
V3	B-X
charges	B-X
are	B-X
more	B-X
readily	B-X
transferred	B-X
to	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
longer	B-X
and	B-X
contains	B-X
an	B-X
additional	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
whereas	B-X
transfer	B-X
of	B-X
viruses	B-X
with	B-X
lower	B-X
V3	B-X
charges	B-X
is	B-X
greater	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
shorter	B-X
.	B-X
Viruses	B-X
differing	B-X
in	B-X
the	B-X
V1V2	B-X
and	B-X
V3	B-X
regions	B-X
also	B-X
demonstrated	B-X
differential	B-X
capture	B-X
by	B-X
Raji-DC-SIGN	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
mannan	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
interaction	B-X
between	B-X
HIV-1	B-X
and	B-X
immature	B-X
dendritic	B-X
cells	B-X
via	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
selecting	B-X
viruses	B-X
undergoing	B-X
transmission	B-X
and	B-X
evolution	B-X
during	B-X
disease	B-X
progression	B-X
.	B-X

Viruses	O
differing	O
in	O
the	O
V1V2	O
and	O
V3	O
regions	O
also	O
demonstrated	O
differential	O
capture	O
by	O
Raji	O
-	O
DC	B-Protein
-	I-Protein
SIGN	I-Protein
cells	O
in	O
the	O
presence	O
of	O
mannan	O
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
can	B-X
enhance	B-X
the	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
through	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
gp120	B-X
envelope	B-X
protein	B-X
with	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
molecular	B-X
cloned	B-X
viruses	B-X
to	B-X
identify	B-X
whether	B-X
gp120	B-X
modifications	B-X
can	B-X
influence	B-X
the	B-X
virus	B-X
interaction	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
or	B-X
a	B-X
cell	B-X
line	B-X
expressing	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
(	B-X
Raji-DC-SIGN	B-X
)	B-X
.	B-X
The	B-X
viruses	B-X
encompass	B-X
the	B-X
R5	B-X
,	B-X
R5X4	B-X
and	B-X
X4	B-X
phenotypes	B-X
,	B-X
and	B-X
are	B-X
based	B-X
upon	B-X
V1V2	B-X
and	B-X
V3	B-X
sequences	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
disease	B-X
progression	B-X
.	B-X
We	B-X
found	B-X
that	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
enhancement	B-X
of	B-X
virus	B-X
replication	B-X
can	B-X
be	B-X
modulated	B-X
by	B-X
the	B-X
V1V2	B-X
length	B-X
,	B-X
the	B-X
overall	B-X
V3	B-X
charge	B-X
and	B-X
N-linked	B-X
glycosylation	B-X
patterns	B-X
;	B-X
similar	B-X
results	B-X
were	B-X
observed	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
.	B-X
Viruses	B-X
with	B-X
higher	B-X
V3	B-X
charges	B-X
are	B-X
more	B-X
readily	B-X
transferred	B-X
to	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
longer	B-X
and	B-X
contains	B-X
an	B-X
additional	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
whereas	B-X
transfer	B-X
of	B-X
viruses	B-X
with	B-X
lower	B-X
V3	B-X
charges	B-X
is	B-X
greater	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
shorter	B-X
.	B-X
Viruses	B-X
differing	B-X
in	B-X
the	B-X
V1V2	B-X
and	B-X
V3	B-X
regions	B-X
also	B-X
demonstrated	B-X
differential	B-X
capture	B-X
by	B-X
Raji-DC-SIGN	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
mannan	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
interaction	B-X
between	B-X
HIV-1	B-X
and	B-X
immature	B-X
dendritic	B-X
cells	B-X
via	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
selecting	B-X
viruses	B-X
undergoing	B-X
transmission	B-X
and	B-X
evolution	B-X
during	B-X
disease	B-X
progression	B-X
.	B-X

These	O
results	O
indicate	O
that	O
the	O
interaction	O
between	O
HIV	O
-	O
1	O
and	O
immature	O
dendritic	O
cells	O
via	O
such	O
molecules	O
as	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	I-Protein
may	O
have	O
a	O
role	O
in	O
selecting	O
viruses	O
undergoing	O
transmission	O
and	O
evolution	O
during	O
disease	O
progression	O
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
can	B-X
enhance	B-X
the	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
through	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
gp120	B-X
envelope	B-X
protein	B-X
with	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
.	B-X
The	B-X
variable	B-X
loops	B-X
of	B-X
gp120	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
modulate	B-X
the	B-X
interaction	B-X
of	B-X
HIV-1	B-X
with	B-X
its	B-X
principal	B-X
receptor	B-X
CD4	B-X
and	B-X
its	B-X
various	B-X
coreceptors	B-X
,	B-X
namely	B-X
CCR5	B-X
and	B-X
CXCR4	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
molecular	B-X
cloned	B-X
viruses	B-X
to	B-X
identify	B-X
whether	B-X
gp120	B-X
modifications	B-X
can	B-X
influence	B-X
the	B-X
virus	B-X
interaction	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
or	B-X
a	B-X
cell	B-X
line	B-X
expressing	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
(	B-X
Raji-DC-SIGN	B-X
)	B-X
.	B-X
The	B-X
viruses	B-X
encompass	B-X
the	B-X
R5	B-X
,	B-X
R5X4	B-X
and	B-X
X4	B-X
phenotypes	B-X
,	B-X
and	B-X
are	B-X
based	B-X
upon	B-X
V1V2	B-X
and	B-X
V3	B-X
sequences	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
disease	B-X
progression	B-X
.	B-X
We	B-X
found	B-X
that	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
enhancement	B-X
of	B-X
virus	B-X
replication	B-X
can	B-X
be	B-X
modulated	B-X
by	B-X
the	B-X
V1V2	B-X
length	B-X
,	B-X
the	B-X
overall	B-X
V3	B-X
charge	B-X
and	B-X
N-linked	B-X
glycosylation	B-X
patterns	B-X
;	B-X
similar	B-X
results	B-X
were	B-X
observed	B-X
with	B-X
immature	B-X
dendritic	B-X
cells	B-X
.	B-X
Viruses	B-X
with	B-X
higher	B-X
V3	B-X
charges	B-X
are	B-X
more	B-X
readily	B-X
transferred	B-X
to	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
longer	B-X
and	B-X
contains	B-X
an	B-X
additional	B-X
N-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
whereas	B-X
transfer	B-X
of	B-X
viruses	B-X
with	B-X
lower	B-X
V3	B-X
charges	B-X
is	B-X
greater	B-X
when	B-X
the	B-X
V1V2	B-X
region	B-X
is	B-X
shorter	B-X
.	B-X
Viruses	B-X
differing	B-X
in	B-X
the	B-X
V1V2	B-X
and	B-X
V3	B-X
regions	B-X
also	B-X
demonstrated	B-X
differential	B-X
capture	B-X
by	B-X
Raji-DC-SIGN	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
mannan	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
interaction	B-X
between	B-X
HIV-1	B-X
and	B-X
immature	B-X
dendritic	B-X
cells	B-X
via	B-X
such	B-X
molecules	B-X
as	B-X
dendritic	B-X
cell-specific	B-X
intercellular	B-X
adhesion	B-X
molecule-3-grabbing	B-X
nonintegrin	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
selecting	B-X
viruses	B-X
undergoing	B-X
transmission	B-X
and	B-X
evolution	B-X
during	B-X
disease	B-X
progression	B-X
.	B-X

Knockdown	O
of	O
ALR	B-Protein
(	O
MLL2	B-Protein
)	O
reveals	O
ALR	B-Protein
target	O
genes	O
and	O
leads	O
to	O
alterations	O
in	O
cell	O
adhesion	O
and	O
growth	O
.	O
<EOS>	B-X
ALR	B-X
(	B-X
MLL2	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
human	B-X
MLL	B-X
family	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
a	B-X
larger	B-X
SET1	B-X
family	B-X
of	B-X
histone	B-X
methyltransferases	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALR	B-X
is	B-X
present	B-X
within	B-X
a	B-X
stable	B-X
multiprotein	B-X
complex	B-X
containing	B-X
a	B-X
cohort	B-X
of	B-X
proteins	B-X
shared	B-X
with	B-X
other	B-X
SET1	B-X
family	B-X
complexes	B-X
and	B-X
several	B-X
unique	B-X
components	B-X
,	B-X
such	B-X
as	B-X
PTIP	B-X
and	B-X
the	B-X
jumonji	B-X
family	B-X
member	B-X
UTX	B-X
.	B-X
Like	B-X
other	B-X
complexes	B-X
formed	B-X
by	B-X
SET1	B-X
family	B-X
members	B-X
,	B-X
the	B-X
ALR	B-X
complex	B-X
exhibited	B-X
strong	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
,	B-X
conferred	B-X
by	B-X
the	B-X
ALR	B-X
SET	B-X
domain	B-X
.	B-X
By	B-X
generating	B-X
ALR	B-X
knockdown	B-X
cell	B-X
lines	B-X
and	B-X
comparing	B-X
their	B-X
expression	B-X
profiles	B-X
to	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
set	B-X
of	B-X
genes	B-X
whose	B-X
expression	B-X
is	B-X
activated	B-X
by	B-X
ALR	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
genes	B-X
were	B-X
identified	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
as	B-X
direct	B-X
ALR	B-X
targets	B-X
.	B-X
The	B-X
ALR	B-X
complex	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
in	B-X
an	B-X
ALR-dependent	B-X
fashion	B-X
with	B-X
promoters	B-X
and	B-X
transcription	B-X
initiation	B-X
sites	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
induce	B-X
H3K4	B-X
trimethylation	B-X
.	B-X
The	B-X
most	B-X
characteristic	B-X
features	B-X
of	B-X
the	B-X
ALR	B-X
knockdown	B-X
cells	B-X
were	B-X
changes	B-X
in	B-X
the	B-X
dynamics	B-X
and	B-X
mode	B-X
of	B-X
cell	B-X
spreading/polarization	B-X
,	B-X
reduced	B-X
migration	B-X
capacity	B-X
,	B-X
impaired	B-X
anchorage-dependent	B-X
and	B-X
-independent	B-X
growth	B-X
,	B-X
and	B-X
decreased	B-X
tumorigenicity	B-X
in	B-X
mice	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
ALR	B-X
is	B-X
a	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
by	B-X
covalent	B-X
histone	B-X
modification	B-X
.	B-X
ALR	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion-related	B-X
cytoskeletal	B-X
events	B-X
,	B-X
which	B-X
might	B-X
affect	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
.	B-X

ALR	B-Protein
(	O
MLL2	B-Protein
)	O
is	O
a	O
member	O
of	O
the	O
human	O
MLL	O
family	O
,	O
which	O
belongs	O
to	O
a	O
larger	O
SET1	O
family	O
of	O
histone	B-Protein
methyltransferases	O
.	O
<EOS>	B-X
ALR	B-X
(	B-X
MLL2	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
human	B-X
MLL	B-X
family	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
a	B-X
larger	B-X
SET1	B-X
family	B-X
of	B-X
histone	B-X
methyltransferases	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALR	B-X
is	B-X
present	B-X
within	B-X
a	B-X
stable	B-X
multiprotein	B-X
complex	B-X
containing	B-X
a	B-X
cohort	B-X
of	B-X
proteins	B-X
shared	B-X
with	B-X
other	B-X
SET1	B-X
family	B-X
complexes	B-X
and	B-X
several	B-X
unique	B-X
components	B-X
,	B-X
such	B-X
as	B-X
PTIP	B-X
and	B-X
the	B-X
jumonji	B-X
family	B-X
member	B-X
UTX	B-X
.	B-X
Like	B-X
other	B-X
complexes	B-X
formed	B-X
by	B-X
SET1	B-X
family	B-X
members	B-X
,	B-X
the	B-X
ALR	B-X
complex	B-X
exhibited	B-X
strong	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
,	B-X
conferred	B-X
by	B-X
the	B-X
ALR	B-X
SET	B-X
domain	B-X
.	B-X
By	B-X
generating	B-X
ALR	B-X
knockdown	B-X
cell	B-X
lines	B-X
and	B-X
comparing	B-X
their	B-X
expression	B-X
profiles	B-X
to	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
set	B-X
of	B-X
genes	B-X
whose	B-X
expression	B-X
is	B-X
activated	B-X
by	B-X
ALR	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
genes	B-X
were	B-X
identified	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
as	B-X
direct	B-X
ALR	B-X
targets	B-X
.	B-X
The	B-X
ALR	B-X
complex	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
in	B-X
an	B-X
ALR-dependent	B-X
fashion	B-X
with	B-X
promoters	B-X
and	B-X
transcription	B-X
initiation	B-X
sites	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
induce	B-X
H3K4	B-X
trimethylation	B-X
.	B-X
The	B-X
most	B-X
characteristic	B-X
features	B-X
of	B-X
the	B-X
ALR	B-X
knockdown	B-X
cells	B-X
were	B-X
changes	B-X
in	B-X
the	B-X
dynamics	B-X
and	B-X
mode	B-X
of	B-X
cell	B-X
spreading/polarization	B-X
,	B-X
reduced	B-X
migration	B-X
capacity	B-X
,	B-X
impaired	B-X
anchorage-dependent	B-X
and	B-X
-independent	B-X
growth	B-X
,	B-X
and	B-X
decreased	B-X
tumorigenicity	B-X
in	B-X
mice	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
ALR	B-X
is	B-X
a	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
by	B-X
covalent	B-X
histone	B-X
modification	B-X
.	B-X
ALR	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion-related	B-X
cytoskeletal	B-X
events	B-X
,	B-X
which	B-X
might	B-X
affect	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
.	B-X

We	O
found	O
that	O
ALR	B-Protein
is	O
present	O
within	O
a	O
stable	O
multiprotein	O
complex	O
containing	O
a	O
cohort	O
of	O
proteins	O
shared	O
with	O
other	O
SET1	O
family	O
complexes	O
and	O
several	O
unique	O
components	O
,	O
such	O
as	O
PTIP	B-Protein
and	O
the	O
jumonji	O
family	O
member	O
UTX	B-Protein
.	O
<EOS>	B-X
ALR	B-X
(	B-X
MLL2	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
human	B-X
MLL	B-X
family	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
a	B-X
larger	B-X
SET1	B-X
family	B-X
of	B-X
histone	B-X
methyltransferases	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALR	B-X
is	B-X
present	B-X
within	B-X
a	B-X
stable	B-X
multiprotein	B-X
complex	B-X
containing	B-X
a	B-X
cohort	B-X
of	B-X
proteins	B-X
shared	B-X
with	B-X
other	B-X
SET1	B-X
family	B-X
complexes	B-X
and	B-X
several	B-X
unique	B-X
components	B-X
,	B-X
such	B-X
as	B-X
PTIP	B-X
and	B-X
the	B-X
jumonji	B-X
family	B-X
member	B-X
UTX	B-X
.	B-X
Like	B-X
other	B-X
complexes	B-X
formed	B-X
by	B-X
SET1	B-X
family	B-X
members	B-X
,	B-X
the	B-X
ALR	B-X
complex	B-X
exhibited	B-X
strong	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
,	B-X
conferred	B-X
by	B-X
the	B-X
ALR	B-X
SET	B-X
domain	B-X
.	B-X
By	B-X
generating	B-X
ALR	B-X
knockdown	B-X
cell	B-X
lines	B-X
and	B-X
comparing	B-X
their	B-X
expression	B-X
profiles	B-X
to	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
set	B-X
of	B-X
genes	B-X
whose	B-X
expression	B-X
is	B-X
activated	B-X
by	B-X
ALR	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
genes	B-X
were	B-X
identified	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
as	B-X
direct	B-X
ALR	B-X
targets	B-X
.	B-X
The	B-X
ALR	B-X
complex	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
in	B-X
an	B-X
ALR-dependent	B-X
fashion	B-X
with	B-X
promoters	B-X
and	B-X
transcription	B-X
initiation	B-X
sites	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
induce	B-X
H3K4	B-X
trimethylation	B-X
.	B-X
The	B-X
most	B-X
characteristic	B-X
features	B-X
of	B-X
the	B-X
ALR	B-X
knockdown	B-X
cells	B-X
were	B-X
changes	B-X
in	B-X
the	B-X
dynamics	B-X
and	B-X
mode	B-X
of	B-X
cell	B-X
spreading/polarization	B-X
,	B-X
reduced	B-X
migration	B-X
capacity	B-X
,	B-X
impaired	B-X
anchorage-dependent	B-X
and	B-X
-independent	B-X
growth	B-X
,	B-X
and	B-X
decreased	B-X
tumorigenicity	B-X
in	B-X
mice	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
ALR	B-X
is	B-X
a	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
by	B-X
covalent	B-X
histone	B-X
modification	B-X
.	B-X
ALR	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion-related	B-X
cytoskeletal	B-X
events	B-X
,	B-X
which	B-X
might	B-X
affect	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
.	B-X

Like	O
other	O
complexes	O
formed	O
by	O
SET1	O
family	O
members	O
,	O
the	O
ALR	B-Protein
complex	O
exhibited	O
strong	O
H3K4	B-Protein
methyltransferase	O
activity	O
,	O
conferred	O
by	O
the	O
ALR	B-Protein
SET	O
domain	O
.	O
<EOS>	B-X
ALR	B-X
(	B-X
MLL2	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
human	B-X
MLL	B-X
family	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
a	B-X
larger	B-X
SET1	B-X
family	B-X
of	B-X
histone	B-X
methyltransferases	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALR	B-X
is	B-X
present	B-X
within	B-X
a	B-X
stable	B-X
multiprotein	B-X
complex	B-X
containing	B-X
a	B-X
cohort	B-X
of	B-X
proteins	B-X
shared	B-X
with	B-X
other	B-X
SET1	B-X
family	B-X
complexes	B-X
and	B-X
several	B-X
unique	B-X
components	B-X
,	B-X
such	B-X
as	B-X
PTIP	B-X
and	B-X
the	B-X
jumonji	B-X
family	B-X
member	B-X
UTX	B-X
.	B-X
Like	B-X
other	B-X
complexes	B-X
formed	B-X
by	B-X
SET1	B-X
family	B-X
members	B-X
,	B-X
the	B-X
ALR	B-X
complex	B-X
exhibited	B-X
strong	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
,	B-X
conferred	B-X
by	B-X
the	B-X
ALR	B-X
SET	B-X
domain	B-X
.	B-X
By	B-X
generating	B-X
ALR	B-X
knockdown	B-X
cell	B-X
lines	B-X
and	B-X
comparing	B-X
their	B-X
expression	B-X
profiles	B-X
to	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
set	B-X
of	B-X
genes	B-X
whose	B-X
expression	B-X
is	B-X
activated	B-X
by	B-X
ALR	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
genes	B-X
were	B-X
identified	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
as	B-X
direct	B-X
ALR	B-X
targets	B-X
.	B-X
The	B-X
ALR	B-X
complex	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
in	B-X
an	B-X
ALR-dependent	B-X
fashion	B-X
with	B-X
promoters	B-X
and	B-X
transcription	B-X
initiation	B-X
sites	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
induce	B-X
H3K4	B-X
trimethylation	B-X
.	B-X
The	B-X
most	B-X
characteristic	B-X
features	B-X
of	B-X
the	B-X
ALR	B-X
knockdown	B-X
cells	B-X
were	B-X
changes	B-X
in	B-X
the	B-X
dynamics	B-X
and	B-X
mode	B-X
of	B-X
cell	B-X
spreading/polarization	B-X
,	B-X
reduced	B-X
migration	B-X
capacity	B-X
,	B-X
impaired	B-X
anchorage-dependent	B-X
and	B-X
-independent	B-X
growth	B-X
,	B-X
and	B-X
decreased	B-X
tumorigenicity	B-X
in	B-X
mice	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
ALR	B-X
is	B-X
a	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
by	B-X
covalent	B-X
histone	B-X
modification	B-X
.	B-X
ALR	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion-related	B-X
cytoskeletal	B-X
events	B-X
,	B-X
which	B-X
might	B-X
affect	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
.	B-X

By	O
generating	O
ALR	B-Protein
knockdown	O
cell	O
lines	O
and	O
comparing	O
their	O
expression	O
profiles	O
to	O
that	O
of	O
control	O
cells	O
,	O
we	O
identified	O
a	O
set	O
of	O
genes	O
whose	O
expression	O
is	O
activated	O
by	O
ALR	B-Protein
.	O
<EOS>	B-X
ALR	B-X
(	B-X
MLL2	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
human	B-X
MLL	B-X
family	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
a	B-X
larger	B-X
SET1	B-X
family	B-X
of	B-X
histone	B-X
methyltransferases	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALR	B-X
is	B-X
present	B-X
within	B-X
a	B-X
stable	B-X
multiprotein	B-X
complex	B-X
containing	B-X
a	B-X
cohort	B-X
of	B-X
proteins	B-X
shared	B-X
with	B-X
other	B-X
SET1	B-X
family	B-X
complexes	B-X
and	B-X
several	B-X
unique	B-X
components	B-X
,	B-X
such	B-X
as	B-X
PTIP	B-X
and	B-X
the	B-X
jumonji	B-X
family	B-X
member	B-X
UTX	B-X
.	B-X
Like	B-X
other	B-X
complexes	B-X
formed	B-X
by	B-X
SET1	B-X
family	B-X
members	B-X
,	B-X
the	B-X
ALR	B-X
complex	B-X
exhibited	B-X
strong	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
,	B-X
conferred	B-X
by	B-X
the	B-X
ALR	B-X
SET	B-X
domain	B-X
.	B-X
By	B-X
generating	B-X
ALR	B-X
knockdown	B-X
cell	B-X
lines	B-X
and	B-X
comparing	B-X
their	B-X
expression	B-X
profiles	B-X
to	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
set	B-X
of	B-X
genes	B-X
whose	B-X
expression	B-X
is	B-X
activated	B-X
by	B-X
ALR	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
genes	B-X
were	B-X
identified	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
as	B-X
direct	B-X
ALR	B-X
targets	B-X
.	B-X
The	B-X
ALR	B-X
complex	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
in	B-X
an	B-X
ALR-dependent	B-X
fashion	B-X
with	B-X
promoters	B-X
and	B-X
transcription	B-X
initiation	B-X
sites	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
induce	B-X
H3K4	B-X
trimethylation	B-X
.	B-X
The	B-X
most	B-X
characteristic	B-X
features	B-X
of	B-X
the	B-X
ALR	B-X
knockdown	B-X
cells	B-X
were	B-X
changes	B-X
in	B-X
the	B-X
dynamics	B-X
and	B-X
mode	B-X
of	B-X
cell	B-X
spreading/polarization	B-X
,	B-X
reduced	B-X
migration	B-X
capacity	B-X
,	B-X
impaired	B-X
anchorage-dependent	B-X
and	B-X
-independent	B-X
growth	B-X
,	B-X
and	B-X
decreased	B-X
tumorigenicity	B-X
in	B-X
mice	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
ALR	B-X
is	B-X
a	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
by	B-X
covalent	B-X
histone	B-X
modification	B-X
.	B-X
ALR	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion-related	B-X
cytoskeletal	B-X
events	B-X
,	B-X
which	B-X
might	B-X
affect	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
.	B-X

Some	O
of	O
these	O
genes	O
were	O
identified	O
by	O
chromatin	O
immunoprecipitation	O
as	O
direct	O
ALR	B-Protein
targets	O
.	O
<EOS>	B-X
ALR	B-X
(	B-X
MLL2	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
human	B-X
MLL	B-X
family	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
a	B-X
larger	B-X
SET1	B-X
family	B-X
of	B-X
histone	B-X
methyltransferases	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALR	B-X
is	B-X
present	B-X
within	B-X
a	B-X
stable	B-X
multiprotein	B-X
complex	B-X
containing	B-X
a	B-X
cohort	B-X
of	B-X
proteins	B-X
shared	B-X
with	B-X
other	B-X
SET1	B-X
family	B-X
complexes	B-X
and	B-X
several	B-X
unique	B-X
components	B-X
,	B-X
such	B-X
as	B-X
PTIP	B-X
and	B-X
the	B-X
jumonji	B-X
family	B-X
member	B-X
UTX	B-X
.	B-X
Like	B-X
other	B-X
complexes	B-X
formed	B-X
by	B-X
SET1	B-X
family	B-X
members	B-X
,	B-X
the	B-X
ALR	B-X
complex	B-X
exhibited	B-X
strong	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
,	B-X
conferred	B-X
by	B-X
the	B-X
ALR	B-X
SET	B-X
domain	B-X
.	B-X
By	B-X
generating	B-X
ALR	B-X
knockdown	B-X
cell	B-X
lines	B-X
and	B-X
comparing	B-X
their	B-X
expression	B-X
profiles	B-X
to	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
set	B-X
of	B-X
genes	B-X
whose	B-X
expression	B-X
is	B-X
activated	B-X
by	B-X
ALR	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
genes	B-X
were	B-X
identified	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
as	B-X
direct	B-X
ALR	B-X
targets	B-X
.	B-X
The	B-X
ALR	B-X
complex	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
in	B-X
an	B-X
ALR-dependent	B-X
fashion	B-X
with	B-X
promoters	B-X
and	B-X
transcription	B-X
initiation	B-X
sites	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
induce	B-X
H3K4	B-X
trimethylation	B-X
.	B-X
The	B-X
most	B-X
characteristic	B-X
features	B-X
of	B-X
the	B-X
ALR	B-X
knockdown	B-X
cells	B-X
were	B-X
changes	B-X
in	B-X
the	B-X
dynamics	B-X
and	B-X
mode	B-X
of	B-X
cell	B-X
spreading/polarization	B-X
,	B-X
reduced	B-X
migration	B-X
capacity	B-X
,	B-X
impaired	B-X
anchorage-dependent	B-X
and	B-X
-independent	B-X
growth	B-X
,	B-X
and	B-X
decreased	B-X
tumorigenicity	B-X
in	B-X
mice	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
ALR	B-X
is	B-X
a	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
by	B-X
covalent	B-X
histone	B-X
modification	B-X
.	B-X
ALR	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion-related	B-X
cytoskeletal	B-X
events	B-X
,	B-X
which	B-X
might	B-X
affect	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
.	B-X

The	O
ALR	B-Protein
complex	O
was	O
found	O
to	O
associate	O
in	O
an	O
ALR	B-Protein
-	O
dependent	O
fashion	O
with	O
promoters	O
and	O
transcription	O
initiation	O
sites	O
of	O
target	O
genes	O
and	O
to	O
induce	O
H3K4	B-Protein
trimethylation	O
.	O

The	O
most	O
characteristic	O
features	O
of	O
the	O
ALR	B-Protein
knockdown	O
cells	O
were	O
changes	O
in	O
the	O
dynamics	O
and	O
mode	O
of	O
cell	O
spreading	O
/	O
polarization	O
,	O
reduced	O
migration	O
capacity	O
,	O
impaired	O
anchorage	O
-	O
dependent	O
and	O
-	O
independent	O
growth	O
,	O
and	O
decreased	O
tumorigenicity	O
in	O
mice	O
.	O
<EOS>	B-X
ALR	B-X
(	B-X
MLL2	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
human	B-X
MLL	B-X
family	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
a	B-X
larger	B-X
SET1	B-X
family	B-X
of	B-X
histone	B-X
methyltransferases	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALR	B-X
is	B-X
present	B-X
within	B-X
a	B-X
stable	B-X
multiprotein	B-X
complex	B-X
containing	B-X
a	B-X
cohort	B-X
of	B-X
proteins	B-X
shared	B-X
with	B-X
other	B-X
SET1	B-X
family	B-X
complexes	B-X
and	B-X
several	B-X
unique	B-X
components	B-X
,	B-X
such	B-X
as	B-X
PTIP	B-X
and	B-X
the	B-X
jumonji	B-X
family	B-X
member	B-X
UTX	B-X
.	B-X
Like	B-X
other	B-X
complexes	B-X
formed	B-X
by	B-X
SET1	B-X
family	B-X
members	B-X
,	B-X
the	B-X
ALR	B-X
complex	B-X
exhibited	B-X
strong	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
,	B-X
conferred	B-X
by	B-X
the	B-X
ALR	B-X
SET	B-X
domain	B-X
.	B-X
By	B-X
generating	B-X
ALR	B-X
knockdown	B-X
cell	B-X
lines	B-X
and	B-X
comparing	B-X
their	B-X
expression	B-X
profiles	B-X
to	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
set	B-X
of	B-X
genes	B-X
whose	B-X
expression	B-X
is	B-X
activated	B-X
by	B-X
ALR	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
genes	B-X
were	B-X
identified	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
as	B-X
direct	B-X
ALR	B-X
targets	B-X
.	B-X
The	B-X
ALR	B-X
complex	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
in	B-X
an	B-X
ALR-dependent	B-X
fashion	B-X
with	B-X
promoters	B-X
and	B-X
transcription	B-X
initiation	B-X
sites	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
induce	B-X
H3K4	B-X
trimethylation	B-X
.	B-X
The	B-X
most	B-X
characteristic	B-X
features	B-X
of	B-X
the	B-X
ALR	B-X
knockdown	B-X
cells	B-X
were	B-X
changes	B-X
in	B-X
the	B-X
dynamics	B-X
and	B-X
mode	B-X
of	B-X
cell	B-X
spreading/polarization	B-X
,	B-X
reduced	B-X
migration	B-X
capacity	B-X
,	B-X
impaired	B-X
anchorage-dependent	B-X
and	B-X
-independent	B-X
growth	B-X
,	B-X
and	B-X
decreased	B-X
tumorigenicity	B-X
in	B-X
mice	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
ALR	B-X
is	B-X
a	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
by	B-X
covalent	B-X
histone	B-X
modification	B-X
.	B-X
ALR	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion-related	B-X
cytoskeletal	B-X
events	B-X
,	B-X
which	B-X
might	B-X
affect	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
.	B-X

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
ALR	B-Protein
is	O
a	O
transcriptional	O
activator	O
that	O
induces	O
the	O
transcription	O
of	O
target	O
genes	O
by	O
covalent	O
histone	O
modification	O
.	O
<EOS>	B-X
ALR	B-X
(	B-X
MLL2	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
human	B-X
MLL	B-X
family	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
a	B-X
larger	B-X
SET1	B-X
family	B-X
of	B-X
histone	B-X
methyltransferases	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALR	B-X
is	B-X
present	B-X
within	B-X
a	B-X
stable	B-X
multiprotein	B-X
complex	B-X
containing	B-X
a	B-X
cohort	B-X
of	B-X
proteins	B-X
shared	B-X
with	B-X
other	B-X
SET1	B-X
family	B-X
complexes	B-X
and	B-X
several	B-X
unique	B-X
components	B-X
,	B-X
such	B-X
as	B-X
PTIP	B-X
and	B-X
the	B-X
jumonji	B-X
family	B-X
member	B-X
UTX	B-X
.	B-X
Like	B-X
other	B-X
complexes	B-X
formed	B-X
by	B-X
SET1	B-X
family	B-X
members	B-X
,	B-X
the	B-X
ALR	B-X
complex	B-X
exhibited	B-X
strong	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
,	B-X
conferred	B-X
by	B-X
the	B-X
ALR	B-X
SET	B-X
domain	B-X
.	B-X
By	B-X
generating	B-X
ALR	B-X
knockdown	B-X
cell	B-X
lines	B-X
and	B-X
comparing	B-X
their	B-X
expression	B-X
profiles	B-X
to	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
set	B-X
of	B-X
genes	B-X
whose	B-X
expression	B-X
is	B-X
activated	B-X
by	B-X
ALR	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
genes	B-X
were	B-X
identified	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
as	B-X
direct	B-X
ALR	B-X
targets	B-X
.	B-X
The	B-X
ALR	B-X
complex	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
in	B-X
an	B-X
ALR-dependent	B-X
fashion	B-X
with	B-X
promoters	B-X
and	B-X
transcription	B-X
initiation	B-X
sites	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
induce	B-X
H3K4	B-X
trimethylation	B-X
.	B-X
The	B-X
most	B-X
characteristic	B-X
features	B-X
of	B-X
the	B-X
ALR	B-X
knockdown	B-X
cells	B-X
were	B-X
changes	B-X
in	B-X
the	B-X
dynamics	B-X
and	B-X
mode	B-X
of	B-X
cell	B-X
spreading/polarization	B-X
,	B-X
reduced	B-X
migration	B-X
capacity	B-X
,	B-X
impaired	B-X
anchorage-dependent	B-X
and	B-X
-independent	B-X
growth	B-X
,	B-X
and	B-X
decreased	B-X
tumorigenicity	B-X
in	B-X
mice	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
ALR	B-X
is	B-X
a	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
by	B-X
covalent	B-X
histone	B-X
modification	B-X
.	B-X
ALR	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion-related	B-X
cytoskeletal	B-X
events	B-X
,	B-X
which	B-X
might	B-X
affect	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
.	B-X

ALR	B-Protein
appears	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
adhesion	O
-	O
related	O
cytoskeletal	O
events	O
,	O
which	O
might	O
affect	O
cell	O
growth	O
and	O
survival	O
.	O
<EOS>	B-X
ALR	B-X
(	B-X
MLL2	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
human	B-X
MLL	B-X
family	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
a	B-X
larger	B-X
SET1	B-X
family	B-X
of	B-X
histone	B-X
methyltransferases	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALR	B-X
is	B-X
present	B-X
within	B-X
a	B-X
stable	B-X
multiprotein	B-X
complex	B-X
containing	B-X
a	B-X
cohort	B-X
of	B-X
proteins	B-X
shared	B-X
with	B-X
other	B-X
SET1	B-X
family	B-X
complexes	B-X
and	B-X
several	B-X
unique	B-X
components	B-X
,	B-X
such	B-X
as	B-X
PTIP	B-X
and	B-X
the	B-X
jumonji	B-X
family	B-X
member	B-X
UTX	B-X
.	B-X
Like	B-X
other	B-X
complexes	B-X
formed	B-X
by	B-X
SET1	B-X
family	B-X
members	B-X
,	B-X
the	B-X
ALR	B-X
complex	B-X
exhibited	B-X
strong	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
,	B-X
conferred	B-X
by	B-X
the	B-X
ALR	B-X
SET	B-X
domain	B-X
.	B-X
By	B-X
generating	B-X
ALR	B-X
knockdown	B-X
cell	B-X
lines	B-X
and	B-X
comparing	B-X
their	B-X
expression	B-X
profiles	B-X
to	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
set	B-X
of	B-X
genes	B-X
whose	B-X
expression	B-X
is	B-X
activated	B-X
by	B-X
ALR	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
genes	B-X
were	B-X
identified	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
as	B-X
direct	B-X
ALR	B-X
targets	B-X
.	B-X
The	B-X
ALR	B-X
complex	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
in	B-X
an	B-X
ALR-dependent	B-X
fashion	B-X
with	B-X
promoters	B-X
and	B-X
transcription	B-X
initiation	B-X
sites	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
induce	B-X
H3K4	B-X
trimethylation	B-X
.	B-X
The	B-X
most	B-X
characteristic	B-X
features	B-X
of	B-X
the	B-X
ALR	B-X
knockdown	B-X
cells	B-X
were	B-X
changes	B-X
in	B-X
the	B-X
dynamics	B-X
and	B-X
mode	B-X
of	B-X
cell	B-X
spreading/polarization	B-X
,	B-X
reduced	B-X
migration	B-X
capacity	B-X
,	B-X
impaired	B-X
anchorage-dependent	B-X
and	B-X
-independent	B-X
growth	B-X
,	B-X
and	B-X
decreased	B-X
tumorigenicity	B-X
in	B-X
mice	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
ALR	B-X
is	B-X
a	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
by	B-X
covalent	B-X
histone	B-X
modification	B-X
.	B-X
ALR	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion-related	B-X
cytoskeletal	B-X
events	B-X
,	B-X
which	B-X
might	B-X
affect	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
.	B-X

Glycogen	O
synthase	O
kinase	O
3	O
phosphorylates	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1alpha	I-Protein
and	O
mediates	O
its	O
destabilization	O
in	O
a	O
VHL	O
-	O
independent	O
manner	O
.	O

Hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
transcription	I-Protein
factor	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
is	O
a	O
key	O
player	O
in	O
the	O
response	O
to	O
hypoxia	O
.	O
<EOS>	B-X
Impaired	B-X
Neovascularization	B-X
in	B-X
Aging	B-X
.	B-X
Focussed	B-X
research	B-X
are	B-X
being	B-X
carried	B-X
out	B-X
to	B-X
identify	B-X
key	B-X
molecular	B-X
agents	B-X
defining	B-X
gut	B-X
homeostasis	B-X
.	B-X
Of	B-X
these	B-X
,	B-X
Hypoxia-inducible	B-X
factor-1α	B-X
(	B-X
HIF-1α	B-X
)	B-X
is	B-X
a	B-X
central	B-X
player	B-X
in	B-X
host-microbial	B-X
crosstalk	B-X
to	B-X
maintain	B-X
gut	B-X
homeostasis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
an	B-X
effort	B-X
has	B-X
been	B-X
made	B-X
to	B-X
summarize	B-X
the	B-X
key	B-X
role	B-X
of	B-X
HIF-1α	B-X
to	B-X
maintain	B-X
gut	B-X
homeostasis	B-X
.	B-X

Additionally	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
responds	O
to	O
growth	O
factors	O
and	O
hormones	O
which	O
can	O
act	O
via	O
protein	B-Protein
kinase	I-Protein
B	I-Protein
(	O
Akt	B-Protein
)	O
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
transcription	B-X
factor	B-X
1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
is	B-X
a	B-X
key	B-X
player	B-X
in	B-X
the	B-X
response	B-X
to	B-X
hypoxia	B-X
.	B-X
Additionally	B-X
,	B-X
HIF-1alpha	B-X
responds	B-X
to	B-X
growth	B-X
factors	B-X
and	B-X
hormones	B-X
which	B-X
can	B-X
act	B-X
via	B-X
protein	B-X
kinase	B-X
B	B-X
(	B-X
Akt	B-X
)	B-X
.	B-X
However	B-X
,	B-X
HIF-1alpha	B-X
is	B-X
not	B-X
a	B-X
direct	B-X
substrate	B-X
for	B-X
this	B-X
kinase	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
the	B-X
protein	B-X
kinase	B-X
B	B-X
target	B-X
glycogen	B-X
synthase	B-X
kinase	B-X
3	B-X
(	B-X
GSK-3	B-X
)	B-X
may	B-X
have	B-X
an	B-X
impact	B-X
on	B-X
HIF-1alpha	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
inhibition	B-X
or	B-X
depletion	B-X
of	B-X
GSK-3	B-X
induced	B-X
HIF-1alpha	B-X
whereas	B-X
the	B-X
overexpression	B-X
of	B-X
GSK-3beta	B-X
reduced	B-X
HIF-1alpha	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
mediated	B-X
via	B-X
three	B-X
amino	B-X
acid	B-X
residues	B-X
in	B-X
the	B-X
oxygen-dependent	B-X
degradation	B-X
domain	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
analyses	B-X
and	B-X
experiments	B-X
with	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
-defective	B-X
cells	B-X
indicated	B-X
that	B-X
GSK-3	B-X
mediates	B-X
HIF-1alpha	B-X
degradation	B-X
in	B-X
a	B-X
VHL-independent	B-X
manner	B-X
.	B-X
In	B-X
line	B-X
with	B-X
these	B-X
observations	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
the	B-X
proteasome	B-X
reversed	B-X
the	B-X
GSK-3	B-X
effects	B-X
,	B-X
indicating	B-X
that	B-X
GSK-3	B-X
may	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
by	B-X
phosphorylation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
direct	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
stability	B-X
by	B-X
GSK-3	B-X
may	B-X
influence	B-X
physiological	B-X
processes	B-X
or	B-X
pathophysiological	B-X
situations	B-X
such	B-X
as	B-X
metabolic	B-X
diseases	B-X
or	B-X
tumors	B-X
.	B-X

However	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
is	O
not	O
a	O
direct	O
substrate	O
for	O
this	O
kinase	O
.	O
<EOS>	B-X
Hypoxia	B-X
induicible	B-X
factor-1	B-X
alpha	B-X
(	B-X
HIF-1α	B-X
)	B-X
is	B-X
a	B-X
key	B-X
transcription	B-X
factor	B-X
in	B-X
cancer	B-X
progression	B-X
and	B-X
target	B-X
therapy	B-X
in	B-X
cancer	B-X
.	B-X
HIF-1α	B-X
acts	B-X
differently	B-X
depending	B-X
on	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
Oxygen	B-X
.	B-X
In	B-X
an	B-X
oxygen-immersed	B-X
environment	B-X
,	B-X
HIF-1α	B-X
completely	B-X
deactivated	B-X
and	B-X
destroyed	B-X
by	B-X
the	B-X
ubiquitin	B-X
proteasome	B-X
pathway	B-X
(	B-X
UPP	B-X
)	B-X
.	B-X
Overexpressed	B-X
HIF-1α	B-X
and	B-X
downstream	B-X
genes	B-X
support	B-X
cancer	B-X
progression	B-X
through	B-X
various	B-X
mechanisms	B-X
including	B-X
angiogenesis	B-X
,	B-X
proliferation	B-X
and	B-X
survival	B-X
of	B-X
cells	B-X
,	B-X
metabolism	B-X
reprogramming	B-X
,	B-X
invasion	B-X
and	B-X
metastasis	B-X
,	B-X
cancer	B-X
stem	B-X
cell	B-X
maintenance	B-X
,	B-X
induction	B-X
of	B-X
genetic	B-X
instability	B-X
,	B-X
and	B-X
treatment	B-X
resistance	B-X
.	B-X
HIF-1α	B-X
can	B-X
be	B-X
provoked	B-X
by	B-X
signaling	B-X
pathways	B-X
unrelated	B-X
to	B-X
hypoxia	B-X
during	B-X
cancer	B-X
progression	B-X
.	B-X
Therefore	B-X
,	B-X
cancer	B-X
development	B-X
and	B-X
progression	B-X
can	B-X
be	B-X
modulated	B-X
by	B-X
targeting	B-X
HIF-1α	B-X
and	B-X
its	B-X
downstream	B-X
signaling	B-X
molecules	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
HIF-1α	B-X
inhibitors	B-X
which	B-X
are	B-X
categorized	B-X
into	B-X
the	B-X
agents	B-X
that	B-X
regulate	B-X
HIF-1α	B-X
in	B-X
gene	B-X
,	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
used	B-X
as	B-X
an	B-X
efficient	B-X
way	B-X
in	B-X
cancer	B-X
treatment	B-X
.	B-X
Also	B-X
,	B-X
HIF-1α	B-X
expression	B-X
can	B-X
be	B-X
negatively	B-X
affected	B-X
by	B-X
the	B-X
agents	B-X
suppressing	B-X
the	B-X
activation	B-X
of	B-X
mTOR	B-X
,	B-X
PI3k/Akt	B-X
and	B-X
MAPK	B-X
pathways	B-X
.	B-X

Therefore	O
,	O
we	O
investigated	O
whether	O
the	O
protein	B-Protein
kinase	I-Protein
B	I-Protein
target	O
glycogen	O
synthase	O
kinase	O
3	O
(	O
GSK	O
-	O
3	O
)	O
may	O
have	O
an	O
impact	O
on	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
transcription	B-X
factor	B-X
1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
is	B-X
a	B-X
key	B-X
player	B-X
in	B-X
the	B-X
response	B-X
to	B-X
hypoxia	B-X
.	B-X
Additionally	B-X
,	B-X
HIF-1alpha	B-X
responds	B-X
to	B-X
growth	B-X
factors	B-X
and	B-X
hormones	B-X
which	B-X
can	B-X
act	B-X
via	B-X
protein	B-X
kinase	B-X
B	B-X
(	B-X
Akt	B-X
)	B-X
.	B-X
However	B-X
,	B-X
HIF-1alpha	B-X
is	B-X
not	B-X
a	B-X
direct	B-X
substrate	B-X
for	B-X
this	B-X
kinase	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
the	B-X
protein	B-X
kinase	B-X
B	B-X
target	B-X
glycogen	B-X
synthase	B-X
kinase	B-X
3	B-X
(	B-X
GSK-3	B-X
)	B-X
may	B-X
have	B-X
an	B-X
impact	B-X
on	B-X
HIF-1alpha	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
inhibition	B-X
or	B-X
depletion	B-X
of	B-X
GSK-3	B-X
induced	B-X
HIF-1alpha	B-X
whereas	B-X
the	B-X
overexpression	B-X
of	B-X
GSK-3beta	B-X
reduced	B-X
HIF-1alpha	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
mediated	B-X
via	B-X
three	B-X
amino	B-X
acid	B-X
residues	B-X
in	B-X
the	B-X
oxygen-dependent	B-X
degradation	B-X
domain	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
analyses	B-X
and	B-X
experiments	B-X
with	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
-defective	B-X
cells	B-X
indicated	B-X
that	B-X
GSK-3	B-X
mediates	B-X
HIF-1alpha	B-X
degradation	B-X
in	B-X
a	B-X
VHL-independent	B-X
manner	B-X
.	B-X
In	B-X
line	B-X
with	B-X
these	B-X
observations	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
the	B-X
proteasome	B-X
reversed	B-X
the	B-X
GSK-3	B-X
effects	B-X
,	B-X
indicating	B-X
that	B-X
GSK-3	B-X
may	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
by	B-X
phosphorylation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
direct	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
stability	B-X
by	B-X
GSK-3	B-X
may	B-X
influence	B-X
physiological	B-X
processes	B-X
or	B-X
pathophysiological	B-X
situations	B-X
such	B-X
as	B-X
metabolic	B-X
diseases	B-X
or	B-X
tumors	B-X
.	B-X

We	O
found	O
that	O
the	O
inhibition	O
or	O
depletion	O
of	O
GSK	O
-	O
3	O
induced	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
whereas	O
the	O
overexpression	O
of	O
GSK	B-Protein
-	I-Protein
3beta	I-Protein
reduced	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O
<EOS>	B-X
Over	B-X
low-conflict	B-X
tests	B-X
,	B-X
intoxicated	B-X
subjects	B-X
behaved	B-X
only	B-X
a	B-X
tenth	B-X
of	B-X
a	B-X
standard	B-X
deviation	B-X
more	B-X
extremely	B-X
than	B-X
their	B-X
sober	B-X
controls	B-X
,	B-X
whereas	B-X
over	B-X
high-conflict	B-X
tests	B-X
they	B-X
were	B-X
a	B-X
full	B-X
standard	B-X
deviation	B-X
more	B-X
extreme	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
conflict	B-X
increased	B-X
with	B-X
alcohol	B-X
dosage	B-X
,	B-X
was	B-X
shown	B-X
not	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
drinking	B-X
expectancies	B-X
,	B-X
and	B-X
generalized	B-X
with	B-X
few	B-X
exceptions	B-X
across	B-X
the	B-X
34	B-X
studies	B-X
and	B-X
12	B-X
social	B-X
behaviors	B-X
included	B-X
in	B-X
this	B-X
analysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
responding	B-X
that	B-X
develops	B-X
in	B-X
feature-negative	B-X
learning	B-X
,	B-X
where	B-X
the	B-X
response	B-X
is	B-X
reinforced	B-X
during	B-X
one	B-X
discriminative	B-X
stimulus	B-X
(	B-X
A	B-X
)	B-X
but	B-X
not	B-X
in	B-X
a	B-X
compound	B-X
of	B-X
A	B-X
and	B-X
stimulus	B-X
B	B-X
,	B-X
is	B-X
less	B-X
response-specific	B-X
:	B-X
The	B-X
inhibition	B-X
of	B-X
responding	B-X
by	B-X
stimulus	B-X
B	B-X
transfers	B-X
and	B-X
inhibits	B-X
a	B-X
second	B-X
response	B-X
,	B-X
especially	B-X
if	B-X
the	B-X
second	B-X
response	B-X
has	B-X
itself	B-X
been	B-X
inhibited	B-X
before	B-X
.	B-X
The	B-X
results	B-X
thus	B-X
indicate	B-X
both	B-X
response-specific	B-X
and	B-X
response-general	B-X
forms	B-X
of	B-X
behavioral	B-X
inhibition	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
response-specific	B-X
inhibition	B-X
is	B-X
learned	B-X
when	B-X
the	B-X
circumstances	B-X
encourage	B-X
the	B-X
organism	B-X
to	B-X
pay	B-X
attention	B-X
to	B-X
the	B-X
response-to	B-X
what	B-X
it	B-X
is	B-X
actually	B-X
doing-as	B-X
behavioral	B-X
suppression	B-X
is	B-X
learned	B-X
.	B-X

These	O
effects	O
were	O
mediated	O
via	O
three	O
amino	O
acid	O
residues	O
in	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
domain	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
transcription	B-X
factor	B-X
1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
is	B-X
a	B-X
key	B-X
player	B-X
in	B-X
the	B-X
response	B-X
to	B-X
hypoxia	B-X
.	B-X
Additionally	B-X
,	B-X
HIF-1alpha	B-X
responds	B-X
to	B-X
growth	B-X
factors	B-X
and	B-X
hormones	B-X
which	B-X
can	B-X
act	B-X
via	B-X
protein	B-X
kinase	B-X
B	B-X
(	B-X
Akt	B-X
)	B-X
.	B-X
However	B-X
,	B-X
HIF-1alpha	B-X
is	B-X
not	B-X
a	B-X
direct	B-X
substrate	B-X
for	B-X
this	B-X
kinase	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
the	B-X
protein	B-X
kinase	B-X
B	B-X
target	B-X
glycogen	B-X
synthase	B-X
kinase	B-X
3	B-X
(	B-X
GSK-3	B-X
)	B-X
may	B-X
have	B-X
an	B-X
impact	B-X
on	B-X
HIF-1alpha	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
inhibition	B-X
or	B-X
depletion	B-X
of	B-X
GSK-3	B-X
induced	B-X
HIF-1alpha	B-X
whereas	B-X
the	B-X
overexpression	B-X
of	B-X
GSK-3beta	B-X
reduced	B-X
HIF-1alpha	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
mediated	B-X
via	B-X
three	B-X
amino	B-X
acid	B-X
residues	B-X
in	B-X
the	B-X
oxygen-dependent	B-X
degradation	B-X
domain	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
analyses	B-X
and	B-X
experiments	B-X
with	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
-defective	B-X
cells	B-X
indicated	B-X
that	B-X
GSK-3	B-X
mediates	B-X
HIF-1alpha	B-X
degradation	B-X
in	B-X
a	B-X
VHL-independent	B-X
manner	B-X
.	B-X
In	B-X
line	B-X
with	B-X
these	B-X
observations	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
the	B-X
proteasome	B-X
reversed	B-X
the	B-X
GSK-3	B-X
effects	B-X
,	B-X
indicating	B-X
that	B-X
GSK-3	B-X
may	B-X
target	B-X
HIF-1alpha	B-X
to	B-X
the	B-X
proteasome	B-X
by	B-X
phosphorylation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
direct	B-X
regulation	B-X
of	B-X
HIF-1alpha	B-X
stability	B-X
by	B-X
GSK-3	B-X
may	B-X
influence	B-X
physiological	B-X
processes	B-X
or	B-X
pathophysiological	B-X
situations	B-X
such	B-X
as	B-X
metabolic	B-X
diseases	B-X
or	B-X
tumors	B-X
.	B-X

In	O
addition	O
,	O
mutation	O
analyses	O
and	O
experiments	O
with	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	O
VHL	B-Protein
)	O
-	O
defective	O
cells	O
indicated	O
that	O
GSK	O
-	O
3	O
mediates	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
degradation	O
in	O
a	O
VHL	B-Protein
-	O
independent	O
manner	O
.	O

In	O
line	O
with	O
these	O
observations	O
,	O
the	O
inhibition	O
of	O
the	O
proteasome	O
reversed	O
the	O
GSK	O
-	O
3	O
effects	O
,	O
indicating	O
that	O
GSK	O
-	O
3	O
may	O
target	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
to	O
the	O
proteasome	O
by	O
phosphorylation	O
.	O

Thus	O
,	O
the	O
direct	O
regulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
stability	O
by	O
GSK	O
-	O
3	O
may	O
influence	O
physiological	O
processes	O
or	O
pathophysiological	O
situations	O
such	O
as	O
metabolic	O
diseases	O
or	O
tumors	O
.	O
<EOS>	B-X
Nerve	B-X
sheath	B-X
tumors	B-X
of	B-X
the	B-X
upper	B-X
extremity	B-X
are	B-X
among	B-X
the	B-X
common	B-X
neoplastic	B-X
pathologies	B-X
encountered	B-X
by	B-X
hand	B-X
surgeons	B-X
.	B-X
A	B-X
majority	B-X
of	B-X
these	B-X
tumors	B-X
are	B-X
benign	B-X
schwannomas	B-X
or	B-X
neurofibromas	B-X
and	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
neurofibromatosis	B-X
.	B-X
Imaging	B-X
characteristics	B-X
,	B-X
such	B-X
as	B-X
standardized	B-X
uptake	B-X
value	B-X
greater	B-X
than	B-X
4.0	B-X
on	B-X
PET	B-X
scan	B-X
,	B-X
may	B-X
aid	B-X
in	B-X
the	B-X
diagnosis	B-X
of	B-X
a	B-X
malignant	B-X
tumor	B-X
.	B-X
Neurofibromatosis	B-X
type	B-X
1	B-X
(	B-X
NF1	B-X
)	B-X
is	B-X
a	B-X
common	B-X
tumor	B-X
predisposition	B-X
syndrome	B-X
caused	B-X
by	B-X
NF1	B-X
gene	B-X
mutation	B-X
,	B-X
in	B-X
which	B-X
affected	B-X
patients	B-X
develop	B-X
Schwann	B-X
cell	B-X
lineage	B-X
peripheral	B-X
nerve	B-X
sheath	B-X
tumors	B-X
(	B-X
neurofibromas	B-X
)	B-X
.	B-X
We	B-X
found	B-X
that	B-X
,	B-X
although	B-X
WT	B-X
and	B-X
heterozygous	B-X
NF1-mutant	B-X
hiPSCs-SLCs	B-X
did	B-X
not	B-X
form	B-X
tumors	B-X
following	B-X
mouse	B-X
sciatic	B-X
nerve	B-X
implantation	B-X
,	B-X
NF1-null	B-X
SLCs	B-X
formed	B-X
bona	B-X
fide	B-X
neurofibromas	B-X
with	B-X
high	B-X
levels	B-X
of	B-X
SOX10	B-X
expression	B-X
.	B-X

Kinetic	O
manifestation	O
of	O
processivity	O
during	O
multiple	O
methylations	O
catalyzed	O
by	O
SET	O
domain	O
protein	O
methyltransferases	O
.	O
<EOS>	B-X
Processive	B-X
versus	B-X
distributive	B-X
methyl	B-X
group	B-X
transfer	B-X
was	B-X
assessed	B-X
for	B-X
pea	B-X
Rubisco	B-X
large	B-X
subunit	B-X
methyltransferase	B-X
,	B-X
a	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferase	B-X
catalyzing	B-X
the	B-X
formation	B-X
of	B-X
trimethyllysine-14	B-X
in	B-X
the	B-X
large	B-X
subunit	B-X
of	B-X
Rubisco	B-X
.	B-X
These	B-X
results	B-X
were	B-X
compared	B-X
with	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
and	B-X
product	B-X
analyses	B-X
obtained	B-X
for	B-X
HsSET7/9	B-X
(	B-X
a	B-X
monomethyltransferase	B-X
)	B-X
and	B-X
SpCLR4	B-X
(	B-X
a	B-X
dimethyltransferase	B-X
)	B-X
and	B-X
suggest	B-X
a	B-X
predictive	B-X
ability	B-X
of	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
for	B-X
single	B-X
versus	B-X
multiple	B-X
methyl	B-X
group	B-X
transfers	B-X
by	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
.	B-X
A	B-X
model	B-X
is	B-X
proposed	B-X
for	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
in	B-X
which	B-X
initial	B-X
binding	B-X
of	B-X
polypeptide	B-X
substrate	B-X
and	B-X
S-adenosylmethionine	B-X
is	B-X
random	B-X
,	B-X
with	B-X
polypeptide	B-X
binding	B-X
followed	B-X
by	B-X
deprotonation	B-X
of	B-X
the	B-X
epsilon-amine	B-X
of	B-X
the	B-X
target	B-X
lysyl	B-X
residue	B-X
and	B-X
subsequent	B-X
methylation	B-X
.	B-X
Following	B-X
methyl	B-X
group	B-X
transfer	B-X
,	B-X
S-adenosylhomocysteine	B-X
and	B-X
monomethylated	B-X
polypeptide	B-X
dissociate	B-X
from	B-X
monomethyltransferases	B-X
,	B-X
but	B-X
di-	B-X
and	B-X
trimethyltransferases	B-X
begin	B-X
a	B-X
successive	B-X
and	B-X
catalytically	B-X
obligatory	B-X
deprotonation	B-X
of	B-X
enzyme-bound	B-X
methylated	B-X
lysyl	B-X
intermediates	B-X
,	B-X
which	B-X
along	B-X
with	B-X
binding	B-X
and	B-X
release	B-X
of	B-X
S-adenosylmethionine	B-X
and	B-X
S-adenosylhomocysteine	B-X
is	B-X
manifested	B-X
as	B-X
a	B-X
hybrid	B-X
ping-pong-like	B-X
reaction	B-X
mechanism	B-X
.	B-X

Processive	O
versus	O
distributive	O
methyl	O
group	O
transfer	O
was	O
assessed	O
for	O
pea	O
Rubisco	B-Protein
large	I-Protein
subunit	I-Protein
methyltransferase	I-Protein
,	O
a	O
SET	O
domain	O
protein	O
lysine	O
methyltransferase	O
catalyzing	O
the	O
formation	O
of	O
trimethyllysine	O
-	O
14	O
in	O
the	O
large	O
subunit	O
of	O
Rubisco	O
.	O
<EOS>	B-X
Processive	B-X
versus	B-X
distributive	B-X
methyl	B-X
group	B-X
transfer	B-X
was	B-X
assessed	B-X
for	B-X
pea	B-X
Rubisco	B-X
large	B-X
subunit	B-X
methyltransferase	B-X
,	B-X
a	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferase	B-X
catalyzing	B-X
the	B-X
formation	B-X
of	B-X
trimethyllysine-14	B-X
in	B-X
the	B-X
large	B-X
subunit	B-X
of	B-X
Rubisco	B-X
.	B-X
Catalytically	B-X
competent	B-X
complexes	B-X
between	B-X
an	B-X
immobilized	B-X
form	B-X
of	B-X
des	B-X
(	B-X
methyl	B-X
)	B-X
Rubisco	B-X
and	B-X
Rubisco	B-X
large	B-X
subunit	B-X
methyltransferase	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
enzyme	B-X
release	B-X
that	B-X
was	B-X
co-incident	B-X
with	B-X
and	B-X
dependent	B-X
on	B-X
formation	B-X
of	B-X
trimethyllysine	B-X
.	B-X
Catalytic	B-X
rate	B-X
constants	B-X
determined	B-X
for	B-X
formation	B-X
of	B-X
trimethyllysine	B-X
were	B-X
considerably	B-X
lower	B-X
(	B-X
approximately	B-X
10-fold	B-X
)	B-X
than	B-X
rate	B-X
constants	B-X
determined	B-X
for	B-X
total	B-X
radiolabel	B-X
incorporation	B-X
from	B-X
[	B-X
3H-methyl	B-X
]	B-X
-S-adenosylmethionine	B-X
.	B-X
Double-reciprocal	B-X
velocity	B-X
plots	B-X
under	B-X
catalytic	B-X
conditions	B-X
favoring	B-X
monomethyllysine	B-X
indicated	B-X
a	B-X
random	B-X
or	B-X
ordered	B-X
reaction	B-X
mechanism	B-X
,	B-X
while	B-X
conditions	B-X
favoring	B-X
trimethyllysine	B-X
suggested	B-X
a	B-X
hybrid	B-X
ping-pong	B-X
mechanism	B-X
.	B-X
These	B-X
results	B-X
were	B-X
compared	B-X
with	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
and	B-X
product	B-X
analyses	B-X
obtained	B-X
for	B-X
HsSET7/9	B-X
(	B-X
a	B-X
monomethyltransferase	B-X
)	B-X
and	B-X
SpCLR4	B-X
(	B-X
a	B-X
dimethyltransferase	B-X
)	B-X
and	B-X
suggest	B-X
a	B-X
predictive	B-X
ability	B-X
of	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
for	B-X
single	B-X
versus	B-X
multiple	B-X
methyl	B-X
group	B-X
transfers	B-X
by	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
.	B-X
A	B-X
model	B-X
is	B-X
proposed	B-X
for	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
in	B-X
which	B-X
initial	B-X
binding	B-X
of	B-X
polypeptide	B-X
substrate	B-X
and	B-X
S-adenosylmethionine	B-X
is	B-X
random	B-X
,	B-X
with	B-X
polypeptide	B-X
binding	B-X
followed	B-X
by	B-X
deprotonation	B-X
of	B-X
the	B-X
epsilon-amine	B-X
of	B-X
the	B-X
target	B-X
lysyl	B-X
residue	B-X
and	B-X
subsequent	B-X
methylation	B-X
.	B-X
Following	B-X
methyl	B-X
group	B-X
transfer	B-X
,	B-X
S-adenosylhomocysteine	B-X
and	B-X
monomethylated	B-X
polypeptide	B-X
dissociate	B-X
from	B-X
monomethyltransferases	B-X
,	B-X
but	B-X
di-	B-X
and	B-X
trimethyltransferases	B-X
begin	B-X
a	B-X
successive	B-X
and	B-X
catalytically	B-X
obligatory	B-X
deprotonation	B-X
of	B-X
enzyme-bound	B-X
methylated	B-X
lysyl	B-X
intermediates	B-X
,	B-X
which	B-X
along	B-X
with	B-X
binding	B-X
and	B-X
release	B-X
of	B-X
S-adenosylmethionine	B-X
and	B-X
S-adenosylhomocysteine	B-X
is	B-X
manifested	B-X
as	B-X
a	B-X
hybrid	B-X
ping-pong-like	B-X
reaction	B-X
mechanism	B-X
.	B-X

Catalytically	O
competent	O
complexes	O
between	O
an	O
immobilized	O
form	O
of	O
des	O
(	O
methyl	O
)	O
Rubisco	O
and	O
Rubisco	B-Protein
large	I-Protein
subunit	I-Protein
methyltransferase	I-Protein
were	O
used	O
to	O
demonstrate	O
enzyme	O
release	O
that	O
was	O
co	O
-	O
incident	O
with	O
and	O
dependent	O
on	O
formation	O
of	O
trimethyllysine	O
.	O
<EOS>	B-X
Processive	B-X
versus	B-X
distributive	B-X
methyl	B-X
group	B-X
transfer	B-X
was	B-X
assessed	B-X
for	B-X
pea	B-X
Rubisco	B-X
large	B-X
subunit	B-X
methyltransferase	B-X
,	B-X
a	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferase	B-X
catalyzing	B-X
the	B-X
formation	B-X
of	B-X
trimethyllysine-14	B-X
in	B-X
the	B-X
large	B-X
subunit	B-X
of	B-X
Rubisco	B-X
.	B-X
Catalytically	B-X
competent	B-X
complexes	B-X
between	B-X
an	B-X
immobilized	B-X
form	B-X
of	B-X
des	B-X
(	B-X
methyl	B-X
)	B-X
Rubisco	B-X
and	B-X
Rubisco	B-X
large	B-X
subunit	B-X
methyltransferase	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
enzyme	B-X
release	B-X
that	B-X
was	B-X
co-incident	B-X
with	B-X
and	B-X
dependent	B-X
on	B-X
formation	B-X
of	B-X
trimethyllysine	B-X
.	B-X
Catalytic	B-X
rate	B-X
constants	B-X
determined	B-X
for	B-X
formation	B-X
of	B-X
trimethyllysine	B-X
were	B-X
considerably	B-X
lower	B-X
(	B-X
approximately	B-X
10-fold	B-X
)	B-X
than	B-X
rate	B-X
constants	B-X
determined	B-X
for	B-X
total	B-X
radiolabel	B-X
incorporation	B-X
from	B-X
[	B-X
3H-methyl	B-X
]	B-X
-S-adenosylmethionine	B-X
.	B-X
Double-reciprocal	B-X
velocity	B-X
plots	B-X
under	B-X
catalytic	B-X
conditions	B-X
favoring	B-X
monomethyllysine	B-X
indicated	B-X
a	B-X
random	B-X
or	B-X
ordered	B-X
reaction	B-X
mechanism	B-X
,	B-X
while	B-X
conditions	B-X
favoring	B-X
trimethyllysine	B-X
suggested	B-X
a	B-X
hybrid	B-X
ping-pong	B-X
mechanism	B-X
.	B-X
These	B-X
results	B-X
were	B-X
compared	B-X
with	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
and	B-X
product	B-X
analyses	B-X
obtained	B-X
for	B-X
HsSET7/9	B-X
(	B-X
a	B-X
monomethyltransferase	B-X
)	B-X
and	B-X
SpCLR4	B-X
(	B-X
a	B-X
dimethyltransferase	B-X
)	B-X
and	B-X
suggest	B-X
a	B-X
predictive	B-X
ability	B-X
of	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
for	B-X
single	B-X
versus	B-X
multiple	B-X
methyl	B-X
group	B-X
transfers	B-X
by	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
.	B-X
A	B-X
model	B-X
is	B-X
proposed	B-X
for	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
in	B-X
which	B-X
initial	B-X
binding	B-X
of	B-X
polypeptide	B-X
substrate	B-X
and	B-X
S-adenosylmethionine	B-X
is	B-X
random	B-X
,	B-X
with	B-X
polypeptide	B-X
binding	B-X
followed	B-X
by	B-X
deprotonation	B-X
of	B-X
the	B-X
epsilon-amine	B-X
of	B-X
the	B-X
target	B-X
lysyl	B-X
residue	B-X
and	B-X
subsequent	B-X
methylation	B-X
.	B-X
Following	B-X
methyl	B-X
group	B-X
transfer	B-X
,	B-X
S-adenosylhomocysteine	B-X
and	B-X
monomethylated	B-X
polypeptide	B-X
dissociate	B-X
from	B-X
monomethyltransferases	B-X
,	B-X
but	B-X
di-	B-X
and	B-X
trimethyltransferases	B-X
begin	B-X
a	B-X
successive	B-X
and	B-X
catalytically	B-X
obligatory	B-X
deprotonation	B-X
of	B-X
enzyme-bound	B-X
methylated	B-X
lysyl	B-X
intermediates	B-X
,	B-X
which	B-X
along	B-X
with	B-X
binding	B-X
and	B-X
release	B-X
of	B-X
S-adenosylmethionine	B-X
and	B-X
S-adenosylhomocysteine	B-X
is	B-X
manifested	B-X
as	B-X
a	B-X
hybrid	B-X
ping-pong-like	B-X
reaction	B-X
mechanism	B-X
.	B-X

Catalytic	O
rate	O
constants	O
determined	O
for	O
formation	O
of	O
trimethyllysine	O
were	O
considerably	O
lower	O
(	O
approximately	O
10	O
-	O
fold	O
)	O
than	O
rate	O
constants	O
determined	O
for	O
total	O
radiolabel	O
incorporation	O
from	O
[	O
3H	O
-	O
methyl	O
]	O
-	O
S	O
-	O
adenosylmethionine	O
.	O

Double	O
-	O
reciprocal	O
velocity	O
plots	O
under	O
catalytic	O
conditions	O
favoring	O
monomethyllysine	O
indicated	O
a	O
random	O
or	O
ordered	O
reaction	O
mechanism	O
,	O
while	O
conditions	O
favoring	O
trimethyllysine	O
suggested	O
a	O
hybrid	O
ping	O
-	O
pong	O
mechanism	O
.	O
<EOS>	B-X
Processive	B-X
versus	B-X
distributive	B-X
methyl	B-X
group	B-X
transfer	B-X
was	B-X
assessed	B-X
for	B-X
pea	B-X
Rubisco	B-X
large	B-X
subunit	B-X
methyltransferase	B-X
,	B-X
a	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferase	B-X
catalyzing	B-X
the	B-X
formation	B-X
of	B-X
trimethyllysine-14	B-X
in	B-X
the	B-X
large	B-X
subunit	B-X
of	B-X
Rubisco	B-X
.	B-X
Catalytically	B-X
competent	B-X
complexes	B-X
between	B-X
an	B-X
immobilized	B-X
form	B-X
of	B-X
des	B-X
(	B-X
methyl	B-X
)	B-X
Rubisco	B-X
and	B-X
Rubisco	B-X
large	B-X
subunit	B-X
methyltransferase	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
enzyme	B-X
release	B-X
that	B-X
was	B-X
co-incident	B-X
with	B-X
and	B-X
dependent	B-X
on	B-X
formation	B-X
of	B-X
trimethyllysine	B-X
.	B-X
Catalytic	B-X
rate	B-X
constants	B-X
determined	B-X
for	B-X
formation	B-X
of	B-X
trimethyllysine	B-X
were	B-X
considerably	B-X
lower	B-X
(	B-X
approximately	B-X
10-fold	B-X
)	B-X
than	B-X
rate	B-X
constants	B-X
determined	B-X
for	B-X
total	B-X
radiolabel	B-X
incorporation	B-X
from	B-X
[	B-X
3H-methyl	B-X
]	B-X
-S-adenosylmethionine	B-X
.	B-X
Double-reciprocal	B-X
velocity	B-X
plots	B-X
under	B-X
catalytic	B-X
conditions	B-X
favoring	B-X
monomethyllysine	B-X
indicated	B-X
a	B-X
random	B-X
or	B-X
ordered	B-X
reaction	B-X
mechanism	B-X
,	B-X
while	B-X
conditions	B-X
favoring	B-X
trimethyllysine	B-X
suggested	B-X
a	B-X
hybrid	B-X
ping-pong	B-X
mechanism	B-X
.	B-X
These	B-X
results	B-X
were	B-X
compared	B-X
with	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
and	B-X
product	B-X
analyses	B-X
obtained	B-X
for	B-X
HsSET7/9	B-X
(	B-X
a	B-X
monomethyltransferase	B-X
)	B-X
and	B-X
SpCLR4	B-X
(	B-X
a	B-X
dimethyltransferase	B-X
)	B-X
and	B-X
suggest	B-X
a	B-X
predictive	B-X
ability	B-X
of	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
for	B-X
single	B-X
versus	B-X
multiple	B-X
methyl	B-X
group	B-X
transfers	B-X
by	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
.	B-X
A	B-X
model	B-X
is	B-X
proposed	B-X
for	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
in	B-X
which	B-X
initial	B-X
binding	B-X
of	B-X
polypeptide	B-X
substrate	B-X
and	B-X
S-adenosylmethionine	B-X
is	B-X
random	B-X
,	B-X
with	B-X
polypeptide	B-X
binding	B-X
followed	B-X
by	B-X
deprotonation	B-X
of	B-X
the	B-X
epsilon-amine	B-X
of	B-X
the	B-X
target	B-X
lysyl	B-X
residue	B-X
and	B-X
subsequent	B-X
methylation	B-X
.	B-X
Following	B-X
methyl	B-X
group	B-X
transfer	B-X
,	B-X
S-adenosylhomocysteine	B-X
and	B-X
monomethylated	B-X
polypeptide	B-X
dissociate	B-X
from	B-X
monomethyltransferases	B-X
,	B-X
but	B-X
di-	B-X
and	B-X
trimethyltransferases	B-X
begin	B-X
a	B-X
successive	B-X
and	B-X
catalytically	B-X
obligatory	B-X
deprotonation	B-X
of	B-X
enzyme-bound	B-X
methylated	B-X
lysyl	B-X
intermediates	B-X
,	B-X
which	B-X
along	B-X
with	B-X
binding	B-X
and	B-X
release	B-X
of	B-X
S-adenosylmethionine	B-X
and	B-X
S-adenosylhomocysteine	B-X
is	B-X
manifested	B-X
as	B-X
a	B-X
hybrid	B-X
ping-pong-like	B-X
reaction	B-X
mechanism	B-X
.	B-X

These	O
results	O
were	O
compared	O
with	O
double	O
-	O
reciprocal	O
velocity	O
plots	O
and	O
product	O
analyses	O
obtained	O
for	O
HsSET7	B-Protein
/	I-Protein
9	I-Protein
(	O
a	O
monomethyltransferase	O
)	O
and	O
SpCLR4	B-Protein
(	O
a	O
dimethyltransferase	O
)	O
and	O
suggest	O
a	O
predictive	O
ability	O
of	O
double	O
-	O
reciprocal	O
velocity	O
plots	O
for	O
single	O
versus	O
multiple	O
methyl	O
group	O
transfers	O
by	O
SET	O
domain	O
protein	O
lysine	O
methyltransferases	O
.	O
<EOS>	B-X
Processive	B-X
versus	B-X
distributive	B-X
methyl	B-X
group	B-X
transfer	B-X
was	B-X
assessed	B-X
for	B-X
pea	B-X
Rubisco	B-X
large	B-X
subunit	B-X
methyltransferase	B-X
,	B-X
a	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferase	B-X
catalyzing	B-X
the	B-X
formation	B-X
of	B-X
trimethyllysine-14	B-X
in	B-X
the	B-X
large	B-X
subunit	B-X
of	B-X
Rubisco	B-X
.	B-X
Catalytically	B-X
competent	B-X
complexes	B-X
between	B-X
an	B-X
immobilized	B-X
form	B-X
of	B-X
des	B-X
(	B-X
methyl	B-X
)	B-X
Rubisco	B-X
and	B-X
Rubisco	B-X
large	B-X
subunit	B-X
methyltransferase	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
enzyme	B-X
release	B-X
that	B-X
was	B-X
co-incident	B-X
with	B-X
and	B-X
dependent	B-X
on	B-X
formation	B-X
of	B-X
trimethyllysine	B-X
.	B-X
Catalytic	B-X
rate	B-X
constants	B-X
determined	B-X
for	B-X
formation	B-X
of	B-X
trimethyllysine	B-X
were	B-X
considerably	B-X
lower	B-X
(	B-X
approximately	B-X
10-fold	B-X
)	B-X
than	B-X
rate	B-X
constants	B-X
determined	B-X
for	B-X
total	B-X
radiolabel	B-X
incorporation	B-X
from	B-X
[	B-X
3H-methyl	B-X
]	B-X
-S-adenosylmethionine	B-X
.	B-X
Double-reciprocal	B-X
velocity	B-X
plots	B-X
under	B-X
catalytic	B-X
conditions	B-X
favoring	B-X
monomethyllysine	B-X
indicated	B-X
a	B-X
random	B-X
or	B-X
ordered	B-X
reaction	B-X
mechanism	B-X
,	B-X
while	B-X
conditions	B-X
favoring	B-X
trimethyllysine	B-X
suggested	B-X
a	B-X
hybrid	B-X
ping-pong	B-X
mechanism	B-X
.	B-X
These	B-X
results	B-X
were	B-X
compared	B-X
with	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
and	B-X
product	B-X
analyses	B-X
obtained	B-X
for	B-X
HsSET7/9	B-X
(	B-X
a	B-X
monomethyltransferase	B-X
)	B-X
and	B-X
SpCLR4	B-X
(	B-X
a	B-X
dimethyltransferase	B-X
)	B-X
and	B-X
suggest	B-X
a	B-X
predictive	B-X
ability	B-X
of	B-X
double-reciprocal	B-X
velocity	B-X
plots	B-X
for	B-X
single	B-X
versus	B-X
multiple	B-X
methyl	B-X
group	B-X
transfers	B-X
by	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
.	B-X
A	B-X
model	B-X
is	B-X
proposed	B-X
for	B-X
SET	B-X
domain	B-X
protein	B-X
lysine	B-X
methyltransferases	B-X
in	B-X
which	B-X
initial	B-X
binding	B-X
of	B-X
polypeptide	B-X
substrate	B-X
and	B-X
S-adenosylmethionine	B-X
is	B-X
random	B-X
,	B-X
with	B-X
polypeptide	B-X
binding	B-X
followed	B-X
by	B-X
deprotonation	B-X
of	B-X
the	B-X
epsilon-amine	B-X
of	B-X
the	B-X
target	B-X
lysyl	B-X
residue	B-X
and	B-X
subsequent	B-X
methylation	B-X
.	B-X
Following	B-X
methyl	B-X
group	B-X
transfer	B-X
,	B-X
S-adenosylhomocysteine	B-X
and	B-X
monomethylated	B-X
polypeptide	B-X
dissociate	B-X
from	B-X
monomethyltransferases	B-X
,	B-X
but	B-X
di-	B-X
and	B-X
trimethyltransferases	B-X
begin	B-X
a	B-X
successive	B-X
and	B-X
catalytically	B-X
obligatory	B-X
deprotonation	B-X
of	B-X
enzyme-bound	B-X
methylated	B-X
lysyl	B-X
intermediates	B-X
,	B-X
which	B-X
along	B-X
with	B-X
binding	B-X
and	B-X
release	B-X
of	B-X
S-adenosylmethionine	B-X
and	B-X
S-adenosylhomocysteine	B-X
is	B-X
manifested	B-X
as	B-X
a	B-X
hybrid	B-X
ping-pong-like	B-X
reaction	B-X
mechanism	B-X
.	B-X

A	O
model	O
is	O
proposed	O
for	O
SET	O
domain	O
protein	O
lysine	O
methyltransferases	O
in	O
which	O
initial	O
binding	O
of	O
polypeptide	O
substrate	O
and	O
S	O
-	O
adenosylmethionine	O
is	O
random	O
,	O
with	O
polypeptide	O
binding	O
followed	O
by	O
deprotonation	O
of	O
the	O
epsilon	O
-	O
amine	O
of	O
the	O
target	O
lysyl	O
residue	O
and	O
subsequent	O
methylation	O
.	O

Following	O
methyl	O
group	O
transfer	O
,	O
S	O
-	O
adenosylhomocysteine	O
and	O
monomethylated	O
polypeptide	O
dissociate	O
from	O
monomethyltransferases	O
,	O
but	O
di	O
-	O
and	O
trimethyltransferases	O
begin	O
a	O
successive	O
and	O
catalytically	O
obligatory	O
deprotonation	O
of	O
enzyme	O
-	O
bound	O
methylated	O
lysyl	O
intermediates	O
,	O
which	O
along	O
with	O
binding	O
and	O
release	O
of	O
S	O
-	O
adenosylmethionine	O
and	O
S	O
-	O
adenosylhomocysteine	O
is	O
manifested	O
as	O
a	O
hybrid	O
ping	O
-	O
pong	O
-	O
like	O
reaction	O
mechanism	O
.	O

Aberrant	O
hypermethylation	O
of	O
p14ARF	B-Protein
and	O
O6	B-Protein
-	I-Protein
methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
methyltransferase	I-Protein
genes	O
in	O
astrocytoma	O
progression	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
genetic	B-X
alterations	B-X
that	B-X
are	B-X
critically	B-X
involved	B-X
in	B-X
astrocytoma	B-X
progression	B-X
.	B-X
We	B-X
characterized	B-X
27	B-X
World	B-X
Health	B-X
Organization	B-X
grade	B-X
II	B-X
fibrillary	B-X
astrocytomas	B-X
which	B-X
later	B-X
underwent	B-X
recurrence	B-X
or	B-X
progression	B-X
,	B-X
paying	B-X
specific	B-X
attention	B-X
to	B-X
the	B-X
CpG	B-X
island	B-X
methylation	B-X
status	B-X
of	B-X
critical	B-X
growth	B-X
regulatory	B-X
genes	B-X
.	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
and	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-methylguanine-DNA	B-X
methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
hypermethylation	B-X
represented	B-X
frequent	B-X
events	B-X
(	B-X
26	B-X
%	B-X
and	B-X
63	B-X
%	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
which	B-X
were	B-X
mutually	B-X
exclusive	B-X
except	B-X
in	B-X
one	B-X
case	B-X
,	B-X
with	B-X
alternate	B-X
or	B-X
simultaneous	B-X
methylation	B-X
of	B-X
these	B-X
two	B-X
genes	B-X
occurring	B-X
in	B-X
85	B-X
%	B-X
of	B-X
our	B-X
tumor	B-X
series	B-X
.	B-X
Methylation	B-X
of	B-X
the	B-X
p21	B-X
(	B-X
Waf1/Cip1	B-X
)	B-X
,	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
and	B-X
p73	B-X
genes	B-X
and	B-X
homozygous	B-X
deletion	B-X
of	B-X
the	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
genes	B-X
were	B-X
not	B-X
detected	B-X
in	B-X
any	B-X
of	B-X
the	B-X
primary	B-X
low-grade	B-X
tumors	B-X
.	B-X
Examination	B-X
of	B-X
20	B-X
cases	B-X
whose	B-X
histological	B-X
data	B-X
for	B-X
recurrent	B-X
tumors	B-X
were	B-X
available	B-X
revealed	B-X
that	B-X
malignant	B-X
progression	B-X
occurred	B-X
in	B-X
all	B-X
of	B-X
the	B-X
tumors	B-X
with	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
but	B-X
less	B-X
frequently	B-X
(	B-X
50	B-X
%	B-X
)	B-X
in	B-X
the	B-X
lesions	B-X
with	B-X
MGMT	B-X
methylation	B-X
.	B-X
On	B-X
analysis	B-X
of	B-X
their	B-X
respective	B-X
recurrent	B-X
tumors	B-X
,	B-X
five	B-X
of	B-X
six	B-X
patients	B-X
whose	B-X
primary	B-X
low-grade	B-X
tumors	B-X
carried	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
exhibited	B-X
homozygous	B-X
co-deletions	B-X
of	B-X
the	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
genes	B-X
,	B-X
which	B-X
were	B-X
restricted	B-X
to	B-X
glioblastoma	B-X
as	B-X
the	B-X
most	B-X
malignant	B-X
end	B-X
point	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
hypermethylation	B-X
and	B-X
MGMT	B-X
hypermethylation	B-X
constitute	B-X
distinct	B-X
molecular	B-X
pathways	B-X
of	B-X
astrocytoma	B-X
progression	B-X
,	B-X
which	B-X
could	B-X
differ	B-X
in	B-X
biological	B-X
behavior	B-X
and	B-X
clinical	B-X
outcome	B-X
.	B-X

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
elucidate	O
genetic	O
alterations	O
that	O
are	O
critically	O
involved	O
in	O
astrocytoma	O
progression	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
genetic	B-X
alterations	B-X
that	B-X
are	B-X
critically	B-X
involved	B-X
in	B-X
astrocytoma	B-X
progression	B-X
.	B-X
We	B-X
characterized	B-X
27	B-X
World	B-X
Health	B-X
Organization	B-X
grade	B-X
II	B-X
fibrillary	B-X
astrocytomas	B-X
which	B-X
later	B-X
underwent	B-X
recurrence	B-X
or	B-X
progression	B-X
,	B-X
paying	B-X
specific	B-X
attention	B-X
to	B-X
the	B-X
CpG	B-X
island	B-X
methylation	B-X
status	B-X
of	B-X
critical	B-X
growth	B-X
regulatory	B-X
genes	B-X
.	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
and	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-methylguanine-DNA	B-X
methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
hypermethylation	B-X
represented	B-X
frequent	B-X
events	B-X
(	B-X
26	B-X
%	B-X
and	B-X
63	B-X
%	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
which	B-X
were	B-X
mutually	B-X
exclusive	B-X
except	B-X
in	B-X
one	B-X
case	B-X
,	B-X
with	B-X
alternate	B-X
or	B-X
simultaneous	B-X
methylation	B-X
of	B-X
these	B-X
two	B-X
genes	B-X
occurring	B-X
in	B-X
85	B-X
%	B-X
of	B-X
our	B-X
tumor	B-X
series	B-X
.	B-X
Examination	B-X
of	B-X
20	B-X
cases	B-X
whose	B-X
histological	B-X
data	B-X
for	B-X
recurrent	B-X
tumors	B-X
were	B-X
available	B-X
revealed	B-X
that	B-X
malignant	B-X
progression	B-X
occurred	B-X
in	B-X
all	B-X
of	B-X
the	B-X
tumors	B-X
with	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
but	B-X
less	B-X
frequently	B-X
(	B-X
50	B-X
%	B-X
)	B-X
in	B-X
the	B-X
lesions	B-X
with	B-X
MGMT	B-X
methylation	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
hypermethylation	B-X
and	B-X
MGMT	B-X
hypermethylation	B-X
constitute	B-X
distinct	B-X
molecular	B-X
pathways	B-X
of	B-X
astrocytoma	B-X
progression	B-X
,	B-X
which	B-X
could	B-X
differ	B-X
in	B-X
biological	B-X
behavior	B-X
and	B-X
clinical	B-X
outcome	B-X
.	B-X

We	O
characterized	O
27	O
World	O
Health	O
Organization	O
grade	O
II	O
fibrillary	O
astrocytomas	O
which	O
later	O
underwent	O
recurrence	O
or	O
progression	O
,	O
paying	O
specific	O
attention	O
to	O
the	O
CpG	O
island	O
methylation	O
status	O
of	O
critical	O
growth	O
regulatory	O
genes	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
genetic	B-X
alterations	B-X
that	B-X
are	B-X
critically	B-X
involved	B-X
in	B-X
astrocytoma	B-X
progression	B-X
.	B-X
We	B-X
characterized	B-X
27	B-X
World	B-X
Health	B-X
Organization	B-X
grade	B-X
II	B-X
fibrillary	B-X
astrocytomas	B-X
which	B-X
later	B-X
underwent	B-X
recurrence	B-X
or	B-X
progression	B-X
,	B-X
paying	B-X
specific	B-X
attention	B-X
to	B-X
the	B-X
CpG	B-X
island	B-X
methylation	B-X
status	B-X
of	B-X
critical	B-X
growth	B-X
regulatory	B-X
genes	B-X
.	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
and	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-methylguanine-DNA	B-X
methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
hypermethylation	B-X
represented	B-X
frequent	B-X
events	B-X
(	B-X
26	B-X
%	B-X
and	B-X
63	B-X
%	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
which	B-X
were	B-X
mutually	B-X
exclusive	B-X
except	B-X
in	B-X
one	B-X
case	B-X
,	B-X
with	B-X
alternate	B-X
or	B-X
simultaneous	B-X
methylation	B-X
of	B-X
these	B-X
two	B-X
genes	B-X
occurring	B-X
in	B-X
85	B-X
%	B-X
of	B-X
our	B-X
tumor	B-X
series	B-X
.	B-X
Seventeen	B-X
tumors	B-X
(	B-X
63	B-X
%	B-X
)	B-X
contained	B-X
TP53	B-X
mutations	B-X
,	B-X
which	B-X
were	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
.	B-X
Methylation	B-X
of	B-X
the	B-X
p21	B-X
(	B-X
Waf1/Cip1	B-X
)	B-X
,	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
and	B-X
p73	B-X
genes	B-X
and	B-X
homozygous	B-X
deletion	B-X
of	B-X
the	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
genes	B-X
were	B-X
not	B-X
detected	B-X
in	B-X
any	B-X
of	B-X
the	B-X
primary	B-X
low-grade	B-X
tumors	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
at	B-X
first	B-X
biopsy	B-X
was	B-X
associated	B-X
with	B-X
shorter	B-X
patient	B-X
survival	B-X
,	B-X
whereas	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
carried	B-X
a	B-X
better	B-X
clinical	B-X
outcome	B-X
after	B-X
salvage	B-X
therapy	B-X
.	B-X
Examination	B-X
of	B-X
20	B-X
cases	B-X
whose	B-X
histological	B-X
data	B-X
for	B-X
recurrent	B-X
tumors	B-X
were	B-X
available	B-X
revealed	B-X
that	B-X
malignant	B-X
progression	B-X
occurred	B-X
in	B-X
all	B-X
of	B-X
the	B-X
tumors	B-X
with	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
but	B-X
less	B-X
frequently	B-X
(	B-X
50	B-X
%	B-X
)	B-X
in	B-X
the	B-X
lesions	B-X
with	B-X
MGMT	B-X
methylation	B-X
.	B-X
On	B-X
analysis	B-X
of	B-X
their	B-X
respective	B-X
recurrent	B-X
tumors	B-X
,	B-X
five	B-X
of	B-X
six	B-X
patients	B-X
whose	B-X
primary	B-X
low-grade	B-X
tumors	B-X
carried	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
exhibited	B-X
homozygous	B-X
co-deletions	B-X
of	B-X
the	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
genes	B-X
,	B-X
which	B-X
were	B-X
restricted	B-X
to	B-X
glioblastoma	B-X
as	B-X
the	B-X
most	B-X
malignant	B-X
end	B-X
point	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
hypermethylation	B-X
and	B-X
MGMT	B-X
hypermethylation	B-X
constitute	B-X
distinct	B-X
molecular	B-X
pathways	B-X
of	B-X
astrocytoma	B-X
progression	B-X
,	B-X
which	B-X
could	B-X
differ	B-X
in	B-X
biological	B-X
behavior	B-X
and	B-X
clinical	B-X
outcome	B-X
.	B-X

p14	B-Protein
(	O
ARF	B-Protein
)	O
and	O
O	B-Protein
(	I-Protein
6	I-Protein
)	I-Protein
-	I-Protein
methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
methyltransferase	I-Protein
(	O
MGMT	B-Protein
)	O
hypermethylation	O
represented	O
frequent	O
events	O
(	O
26	O
%	O
and	O
63	O
%	O
,	O
respectively	O
)	O
,	O
which	O
were	O
mutually	O
exclusive	O
except	O
in	O
one	O
case	O
,	O
with	O
alternate	O
or	O
simultaneous	O
methylation	O
of	O
these	O
two	O
genes	O
occurring	O
in	O
85	O
%	O
of	O
our	O
tumor	O
series	O
.	O
<EOS>	B-X
We	B-X
characterized	B-X
27	B-X
World	B-X
Health	B-X
Organization	B-X
grade	B-X
II	B-X
fibrillary	B-X
astrocytomas	B-X
which	B-X
later	B-X
underwent	B-X
recurrence	B-X
or	B-X
progression	B-X
,	B-X
paying	B-X
specific	B-X
attention	B-X
to	B-X
the	B-X
CpG	B-X
island	B-X
methylation	B-X
status	B-X
of	B-X
critical	B-X
growth	B-X
regulatory	B-X
genes	B-X
.	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
and	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-methylguanine-DNA	B-X
methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
hypermethylation	B-X
represented	B-X
frequent	B-X
events	B-X
(	B-X
26	B-X
%	B-X
and	B-X
63	B-X
%	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
which	B-X
were	B-X
mutually	B-X
exclusive	B-X
except	B-X
in	B-X
one	B-X
case	B-X
,	B-X
with	B-X
alternate	B-X
or	B-X
simultaneous	B-X
methylation	B-X
of	B-X
these	B-X
two	B-X
genes	B-X
occurring	B-X
in	B-X
85	B-X
%	B-X
of	B-X
our	B-X
tumor	B-X
series	B-X
.	B-X
Seventeen	B-X
tumors	B-X
(	B-X
63	B-X
%	B-X
)	B-X
contained	B-X
TP53	B-X
mutations	B-X
,	B-X
which	B-X
were	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
.	B-X
Methylation	B-X
of	B-X
the	B-X
p21	B-X
(	B-X
Waf1/Cip1	B-X
)	B-X
,	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
and	B-X
p73	B-X
genes	B-X
and	B-X
homozygous	B-X
deletion	B-X
of	B-X
the	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
genes	B-X
were	B-X
not	B-X
detected	B-X
in	B-X
any	B-X
of	B-X
the	B-X
primary	B-X
low-grade	B-X
tumors	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
at	B-X
first	B-X
biopsy	B-X
was	B-X
associated	B-X
with	B-X
shorter	B-X
patient	B-X
survival	B-X
,	B-X
whereas	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
carried	B-X
a	B-X
better	B-X
clinical	B-X
outcome	B-X
after	B-X
salvage	B-X
therapy	B-X
.	B-X
Examination	B-X
of	B-X
20	B-X
cases	B-X
whose	B-X
histological	B-X
data	B-X
for	B-X
recurrent	B-X
tumors	B-X
were	B-X
available	B-X
revealed	B-X
that	B-X
malignant	B-X
progression	B-X
occurred	B-X
in	B-X
all	B-X
of	B-X
the	B-X
tumors	B-X
with	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
but	B-X
less	B-X
frequently	B-X
(	B-X
50	B-X
%	B-X
)	B-X
in	B-X
the	B-X
lesions	B-X
with	B-X
MGMT	B-X
methylation	B-X
.	B-X
On	B-X
analysis	B-X
of	B-X
their	B-X
respective	B-X
recurrent	B-X
tumors	B-X
,	B-X
five	B-X
of	B-X
six	B-X
patients	B-X
whose	B-X
primary	B-X
low-grade	B-X
tumors	B-X
carried	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
exhibited	B-X
homozygous	B-X
co-deletions	B-X
of	B-X
the	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
genes	B-X
,	B-X
which	B-X
were	B-X
restricted	B-X
to	B-X
glioblastoma	B-X
as	B-X
the	B-X
most	B-X
malignant	B-X
end	B-X
point	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
hypermethylation	B-X
and	B-X
MGMT	B-X
hypermethylation	B-X
constitute	B-X
distinct	B-X
molecular	B-X
pathways	B-X
of	B-X
astrocytoma	B-X
progression	B-X
,	B-X
which	B-X
could	B-X
differ	B-X
in	B-X
biological	B-X
behavior	B-X
and	B-X
clinical	B-X
outcome	B-X
.	B-X

Seventeen	O
tumors	O
(	O
63	O
%	O
)	O
contained	O
TP53	B-Protein
mutations	O
,	O
which	O
were	O
closely	O
related	O
to	O
the	O
presence	O
of	O
MGMT	B-Protein
methylation	O
.	O

Methylation	O
of	O
the	O
p21	B-Protein
(	O
Waf1	B-Protein
/	O
Cip1	B-Protein
)	O
,	O
p27	B-Protein
(	O
Kip1	B-Protein
)	O
and	O
p73	B-Protein
genes	O
and	O
homozygous	O
deletion	O
of	O
the	O
p16	B-Protein
(	O
INK4a	B-Protein
)	O
,	O
p15	B-Protein
(	O
INK4b	B-Protein
)	O
and	O
p14	B-Protein
(	O
ARF	B-Protein
)	O
genes	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
primary	O
low	O
-	O
grade	O
tumors	O
.	O

The	O
presence	O
of	O
p14	B-Protein
(	O
ARF	B-Protein
)	O
methylation	O
at	O
first	O
biopsy	O
was	O
associated	O
with	O
shorter	O
patient	O
survival	O
,	O
whereas	O
the	O
presence	O
of	O
MGMT	B-Protein
methylation	O
carried	O
a	O
better	O
clinical	O
outcome	O
after	O
salvage	O
therapy	O
.	O
<EOS>	B-X
We	B-X
characterized	B-X
27	B-X
World	B-X
Health	B-X
Organization	B-X
grade	B-X
II	B-X
fibrillary	B-X
astrocytomas	B-X
which	B-X
later	B-X
underwent	B-X
recurrence	B-X
or	B-X
progression	B-X
,	B-X
paying	B-X
specific	B-X
attention	B-X
to	B-X
the	B-X
CpG	B-X
island	B-X
methylation	B-X
status	B-X
of	B-X
critical	B-X
growth	B-X
regulatory	B-X
genes	B-X
.	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
and	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-methylguanine-DNA	B-X
methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
hypermethylation	B-X
represented	B-X
frequent	B-X
events	B-X
(	B-X
26	B-X
%	B-X
and	B-X
63	B-X
%	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
which	B-X
were	B-X
mutually	B-X
exclusive	B-X
except	B-X
in	B-X
one	B-X
case	B-X
,	B-X
with	B-X
alternate	B-X
or	B-X
simultaneous	B-X
methylation	B-X
of	B-X
these	B-X
two	B-X
genes	B-X
occurring	B-X
in	B-X
85	B-X
%	B-X
of	B-X
our	B-X
tumor	B-X
series	B-X
.	B-X
Seventeen	B-X
tumors	B-X
(	B-X
63	B-X
%	B-X
)	B-X
contained	B-X
TP53	B-X
mutations	B-X
,	B-X
which	B-X
were	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
.	B-X
Methylation	B-X
of	B-X
the	B-X
p21	B-X
(	B-X
Waf1/Cip1	B-X
)	B-X
,	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
and	B-X
p73	B-X
genes	B-X
and	B-X
homozygous	B-X
deletion	B-X
of	B-X
the	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
genes	B-X
were	B-X
not	B-X
detected	B-X
in	B-X
any	B-X
of	B-X
the	B-X
primary	B-X
low-grade	B-X
tumors	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
at	B-X
first	B-X
biopsy	B-X
was	B-X
associated	B-X
with	B-X
shorter	B-X
patient	B-X
survival	B-X
,	B-X
whereas	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
carried	B-X
a	B-X
better	B-X
clinical	B-X
outcome	B-X
after	B-X
salvage	B-X
therapy	B-X
.	B-X
Examination	B-X
of	B-X
20	B-X
cases	B-X
whose	B-X
histological	B-X
data	B-X
for	B-X
recurrent	B-X
tumors	B-X
were	B-X
available	B-X
revealed	B-X
that	B-X
malignant	B-X
progression	B-X
occurred	B-X
in	B-X
all	B-X
of	B-X
the	B-X
tumors	B-X
with	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
but	B-X
less	B-X
frequently	B-X
(	B-X
50	B-X
%	B-X
)	B-X
in	B-X
the	B-X
lesions	B-X
with	B-X
MGMT	B-X
methylation	B-X
.	B-X
On	B-X
analysis	B-X
of	B-X
their	B-X
respective	B-X
recurrent	B-X
tumors	B-X
,	B-X
five	B-X
of	B-X
six	B-X
patients	B-X
whose	B-X
primary	B-X
low-grade	B-X
tumors	B-X
carried	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
exhibited	B-X
homozygous	B-X
co-deletions	B-X
of	B-X
the	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
genes	B-X
,	B-X
which	B-X
were	B-X
restricted	B-X
to	B-X
glioblastoma	B-X
as	B-X
the	B-X
most	B-X
malignant	B-X
end	B-X
point	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
hypermethylation	B-X
and	B-X
MGMT	B-X
hypermethylation	B-X
constitute	B-X
distinct	B-X
molecular	B-X
pathways	B-X
of	B-X
astrocytoma	B-X
progression	B-X
,	B-X
which	B-X
could	B-X
differ	B-X
in	B-X
biological	B-X
behavior	B-X
and	B-X
clinical	B-X
outcome	B-X
.	B-X

Examination	O
of	O
20	O
cases	O
whose	O
histological	O
data	O
for	O
recurrent	O
tumors	O
were	O
available	O
revealed	O
that	O
malignant	O
progression	O
occurred	O
in	O
all	O
of	O
the	O
tumors	O
with	O
p14	B-Protein
(	O
ARF	B-Protein
)	O
methylation	O
but	O
less	O
frequently	O
(	O
50	O
%	O
)	O
in	O
the	O
lesions	O
with	O
MGMT	B-Protein
methylation	O
.	O

On	O
analysis	O
of	O
their	O
respective	O
recurrent	O
tumors	O
,	O
five	O
of	O
six	O
patients	O
whose	O
primary	O
low	O
-	O
grade	O
tumors	O
carried	O
p14	B-Protein
(	O
ARF	B-Protein
)	O
methylation	O
exhibited	O
homozygous	O
co	O
-	O
deletions	O
of	O
the	O
p14	B-Protein
(	O
ARF	B-Protein
)	O
,	O
p15	B-Protein
(	O
INK4b	B-Protein
)	O
and	O
p16	B-Protein
(	O
INK4a	B-Protein
)	O
genes	O
,	O
which	O
were	O
restricted	O
to	O
glioblastoma	O
as	O
the	O
most	O
malignant	O
end	O
point	O
.	O
<EOS>	B-X
We	B-X
characterized	B-X
27	B-X
World	B-X
Health	B-X
Organization	B-X
grade	B-X
II	B-X
fibrillary	B-X
astrocytomas	B-X
which	B-X
later	B-X
underwent	B-X
recurrence	B-X
or	B-X
progression	B-X
,	B-X
paying	B-X
specific	B-X
attention	B-X
to	B-X
the	B-X
CpG	B-X
island	B-X
methylation	B-X
status	B-X
of	B-X
critical	B-X
growth	B-X
regulatory	B-X
genes	B-X
.	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
and	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-methylguanine-DNA	B-X
methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
hypermethylation	B-X
represented	B-X
frequent	B-X
events	B-X
(	B-X
26	B-X
%	B-X
and	B-X
63	B-X
%	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
which	B-X
were	B-X
mutually	B-X
exclusive	B-X
except	B-X
in	B-X
one	B-X
case	B-X
,	B-X
with	B-X
alternate	B-X
or	B-X
simultaneous	B-X
methylation	B-X
of	B-X
these	B-X
two	B-X
genes	B-X
occurring	B-X
in	B-X
85	B-X
%	B-X
of	B-X
our	B-X
tumor	B-X
series	B-X
.	B-X
Seventeen	B-X
tumors	B-X
(	B-X
63	B-X
%	B-X
)	B-X
contained	B-X
TP53	B-X
mutations	B-X
,	B-X
which	B-X
were	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
.	B-X
Methylation	B-X
of	B-X
the	B-X
p21	B-X
(	B-X
Waf1/Cip1	B-X
)	B-X
,	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
and	B-X
p73	B-X
genes	B-X
and	B-X
homozygous	B-X
deletion	B-X
of	B-X
the	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
genes	B-X
were	B-X
not	B-X
detected	B-X
in	B-X
any	B-X
of	B-X
the	B-X
primary	B-X
low-grade	B-X
tumors	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
at	B-X
first	B-X
biopsy	B-X
was	B-X
associated	B-X
with	B-X
shorter	B-X
patient	B-X
survival	B-X
,	B-X
whereas	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
carried	B-X
a	B-X
better	B-X
clinical	B-X
outcome	B-X
after	B-X
salvage	B-X
therapy	B-X
.	B-X
Examination	B-X
of	B-X
20	B-X
cases	B-X
whose	B-X
histological	B-X
data	B-X
for	B-X
recurrent	B-X
tumors	B-X
were	B-X
available	B-X
revealed	B-X
that	B-X
malignant	B-X
progression	B-X
occurred	B-X
in	B-X
all	B-X
of	B-X
the	B-X
tumors	B-X
with	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
but	B-X
less	B-X
frequently	B-X
(	B-X
50	B-X
%	B-X
)	B-X
in	B-X
the	B-X
lesions	B-X
with	B-X
MGMT	B-X
methylation	B-X
.	B-X
On	B-X
analysis	B-X
of	B-X
their	B-X
respective	B-X
recurrent	B-X
tumors	B-X
,	B-X
five	B-X
of	B-X
six	B-X
patients	B-X
whose	B-X
primary	B-X
low-grade	B-X
tumors	B-X
carried	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
exhibited	B-X
homozygous	B-X
co-deletions	B-X
of	B-X
the	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
genes	B-X
,	B-X
which	B-X
were	B-X
restricted	B-X
to	B-X
glioblastoma	B-X
as	B-X
the	B-X
most	B-X
malignant	B-X
end	B-X
point	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
hypermethylation	B-X
and	B-X
MGMT	B-X
hypermethylation	B-X
constitute	B-X
distinct	B-X
molecular	B-X
pathways	B-X
of	B-X
astrocytoma	B-X
progression	B-X
,	B-X
which	B-X
could	B-X
differ	B-X
in	B-X
biological	B-X
behavior	B-X
and	B-X
clinical	B-X
outcome	B-X
.	B-X

Our	O
findings	O
suggest	O
that	O
p14	B-Protein
(	O
ARF	B-Protein
)	O
hypermethylation	O
and	O
MGMT	B-Protein
hypermethylation	O
constitute	O
distinct	O
molecular	O
pathways	O
of	O
astrocytoma	O
progression	O
,	O
which	O
could	O
differ	O
in	O
biological	O
behavior	O
and	O
clinical	O
outcome	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
genetic	B-X
alterations	B-X
that	B-X
are	B-X
critically	B-X
involved	B-X
in	B-X
astrocytoma	B-X
progression	B-X
.	B-X
We	B-X
characterized	B-X
27	B-X
World	B-X
Health	B-X
Organization	B-X
grade	B-X
II	B-X
fibrillary	B-X
astrocytomas	B-X
which	B-X
later	B-X
underwent	B-X
recurrence	B-X
or	B-X
progression	B-X
,	B-X
paying	B-X
specific	B-X
attention	B-X
to	B-X
the	B-X
CpG	B-X
island	B-X
methylation	B-X
status	B-X
of	B-X
critical	B-X
growth	B-X
regulatory	B-X
genes	B-X
.	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
and	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-methylguanine-DNA	B-X
methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
hypermethylation	B-X
represented	B-X
frequent	B-X
events	B-X
(	B-X
26	B-X
%	B-X
and	B-X
63	B-X
%	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
which	B-X
were	B-X
mutually	B-X
exclusive	B-X
except	B-X
in	B-X
one	B-X
case	B-X
,	B-X
with	B-X
alternate	B-X
or	B-X
simultaneous	B-X
methylation	B-X
of	B-X
these	B-X
two	B-X
genes	B-X
occurring	B-X
in	B-X
85	B-X
%	B-X
of	B-X
our	B-X
tumor	B-X
series	B-X
.	B-X
Seventeen	B-X
tumors	B-X
(	B-X
63	B-X
%	B-X
)	B-X
contained	B-X
TP53	B-X
mutations	B-X
,	B-X
which	B-X
were	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
.	B-X
Methylation	B-X
of	B-X
the	B-X
p21	B-X
(	B-X
Waf1/Cip1	B-X
)	B-X
,	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
and	B-X
p73	B-X
genes	B-X
and	B-X
homozygous	B-X
deletion	B-X
of	B-X
the	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
genes	B-X
were	B-X
not	B-X
detected	B-X
in	B-X
any	B-X
of	B-X
the	B-X
primary	B-X
low-grade	B-X
tumors	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
at	B-X
first	B-X
biopsy	B-X
was	B-X
associated	B-X
with	B-X
shorter	B-X
patient	B-X
survival	B-X
,	B-X
whereas	B-X
the	B-X
presence	B-X
of	B-X
MGMT	B-X
methylation	B-X
carried	B-X
a	B-X
better	B-X
clinical	B-X
outcome	B-X
after	B-X
salvage	B-X
therapy	B-X
.	B-X
Examination	B-X
of	B-X
20	B-X
cases	B-X
whose	B-X
histological	B-X
data	B-X
for	B-X
recurrent	B-X
tumors	B-X
were	B-X
available	B-X
revealed	B-X
that	B-X
malignant	B-X
progression	B-X
occurred	B-X
in	B-X
all	B-X
of	B-X
the	B-X
tumors	B-X
with	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
but	B-X
less	B-X
frequently	B-X
(	B-X
50	B-X
%	B-X
)	B-X
in	B-X
the	B-X
lesions	B-X
with	B-X
MGMT	B-X
methylation	B-X
.	B-X
On	B-X
analysis	B-X
of	B-X
their	B-X
respective	B-X
recurrent	B-X
tumors	B-X
,	B-X
five	B-X
of	B-X
six	B-X
patients	B-X
whose	B-X
primary	B-X
low-grade	B-X
tumors	B-X
carried	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
methylation	B-X
exhibited	B-X
homozygous	B-X
co-deletions	B-X
of	B-X
the	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
p15	B-X
(	B-X
INK4b	B-X
)	B-X
and	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
genes	B-X
,	B-X
which	B-X
were	B-X
restricted	B-X
to	B-X
glioblastoma	B-X
as	B-X
the	B-X
most	B-X
malignant	B-X
end	B-X
point	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
hypermethylation	B-X
and	B-X
MGMT	B-X
hypermethylation	B-X
constitute	B-X
distinct	B-X
molecular	B-X
pathways	B-X
of	B-X
astrocytoma	B-X
progression	B-X
,	B-X
which	B-X
could	B-X
differ	B-X
in	B-X
biological	B-X
behavior	B-X
and	B-X
clinical	B-X
outcome	B-X
.	B-X

Mechanisms	O
of	O
ceramide	O
-	O
mediated	O
repression	O
of	O
the	O
human	O
telomerase	B-Protein
reverse	I-Protein
transcriptase	I-Protein
promoter	O
via	O
deacetylation	O
of	O
Sp3	B-Protein
by	O
histone	B-Protein
deacetylase	I-Protein
1	I-Protein
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
distinct	B-X
roles	B-X
of	B-X
de	B-X
novo-generated	B-X
endogenous	B-X
ceramides	B-X
and	B-X
mechanisms	B-X
by	B-X
which	B-X
deacetylated	B-X
Sp3	B-X
regulates	B-X
the	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
ceramide	B-X
signaling	B-X
were	B-X
explored	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
ceramide	B-X
synthase	B-X
1	B-X
(	B-X
CerS1	B-X
)	B-X
,	B-X
and	B-X
not	B-X
C16-ceramide	B-X
by	B-X
CerS5	B-X
or	B-X
CerS6	B-X
expression	B-X
,	B-X
resulted	B-X
in	B-X
repression	B-X
of	B-X
the	B-X
hTERT	B-X
promoter	B-X
via	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
by	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
in	B-X
A549	B-X
human	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Then	B-X
roles	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
ceramide-mediated	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
in	B-X
inhibiting	B-X
the	B-X
hTERT	B-X
promoter	B-X
were	B-X
determined	B-X
using	B-X
constitutively	B-X
deacetylated	B-X
or	B-X
acetylated	B-X
Sp3	B-X
mutants	B-X
at	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
551	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3	B-X
mutant	B-X
resulted	B-X
in	B-X
repression	B-X
,	B-X
whereas	B-X
its	B-X
acetylated	B-X
mutant	B-X
induced	B-X
basal	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
Drosophila	B-X
S2	B-X
cells	B-X
,	B-X
which	B-X
do	B-X
not	B-X
express	B-X
any	B-X
endogenous	B-X
Sp3	B-X
,	B-X
and	B-X
in	B-X
A549	B-X
cells	B-X
.	B-X
Remarkably	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
data	B-X
revealed	B-X
that	B-X
acetylated	B-X
Sp3	B-X
mutant	B-X
(	B-X
K551Q-Sp3	B-X
)	B-X
did	B-X
not	B-X
bind	B-X
whereas	B-X
deacetylated	B-X
Sp3	B-X
(	B-X
K551R-Sp3	B-X
)	B-X
mutant	B-X
bound	B-X
strongly	B-X
to	B-X
the	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
association	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
with	B-X
the	B-X
promoter	B-X
.	B-X
Mechanistically	B-X
,	B-X
increased	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
by	B-X
hCerS1	B-X
expression	B-X
,	B-X
but	B-X
not	B-X
by	B-X
its	B-X
catalytically	B-X
inactive	B-X
mutant	B-X
,	B-X
mediated	B-X
the	B-X
association	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3/HDAC1	B-X
complex	B-X
to	B-X
the	B-X
hTERT	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
local	B-X
histone	B-X
H3	B-X
deacetylation	B-X
and	B-X
repression	B-X
of	B-X
the	B-X
promoter	B-X
.	B-X

In	O
this	O
study	O
,	O
distinct	O
roles	O
of	O
de	O
novo	O
-	O
generated	O
endogenous	O
ceramides	O
and	O
mechanisms	O
by	O
which	O
deacetylated	O
Sp3	B-Protein
regulates	O
the	O
hTERT	B-Protein
promoter	O
activity	O
in	O
response	O
to	O
ceramide	O
signaling	O
were	O
explored	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
distinct	B-X
roles	B-X
of	B-X
de	B-X
novo-generated	B-X
endogenous	B-X
ceramides	B-X
and	B-X
mechanisms	B-X
by	B-X
which	B-X
deacetylated	B-X
Sp3	B-X
regulates	B-X
the	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
ceramide	B-X
signaling	B-X
were	B-X
explored	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
ceramide	B-X
synthase	B-X
1	B-X
(	B-X
CerS1	B-X
)	B-X
,	B-X
and	B-X
not	B-X
C16-ceramide	B-X
by	B-X
CerS5	B-X
or	B-X
CerS6	B-X
expression	B-X
,	B-X
resulted	B-X
in	B-X
repression	B-X
of	B-X
the	B-X
hTERT	B-X
promoter	B-X
via	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
by	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
in	B-X
A549	B-X
human	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Then	B-X
roles	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
ceramide-mediated	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
in	B-X
inhibiting	B-X
the	B-X
hTERT	B-X
promoter	B-X
were	B-X
determined	B-X
using	B-X
constitutively	B-X
deacetylated	B-X
or	B-X
acetylated	B-X
Sp3	B-X
mutants	B-X
at	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
551	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3	B-X
mutant	B-X
resulted	B-X
in	B-X
repression	B-X
,	B-X
whereas	B-X
its	B-X
acetylated	B-X
mutant	B-X
induced	B-X
basal	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
Drosophila	B-X
S2	B-X
cells	B-X
,	B-X
which	B-X
do	B-X
not	B-X
express	B-X
any	B-X
endogenous	B-X
Sp3	B-X
,	B-X
and	B-X
in	B-X
A549	B-X
cells	B-X
.	B-X
Remarkably	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
data	B-X
revealed	B-X
that	B-X
acetylated	B-X
Sp3	B-X
mutant	B-X
(	B-X
K551Q-Sp3	B-X
)	B-X
did	B-X
not	B-X
bind	B-X
whereas	B-X
deacetylated	B-X
Sp3	B-X
(	B-X
K551R-Sp3	B-X
)	B-X
mutant	B-X
bound	B-X
strongly	B-X
to	B-X
the	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
association	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
with	B-X
the	B-X
promoter	B-X
.	B-X
Mechanistically	B-X
,	B-X
increased	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
by	B-X
hCerS1	B-X
expression	B-X
,	B-X
but	B-X
not	B-X
by	B-X
its	B-X
catalytically	B-X
inactive	B-X
mutant	B-X
,	B-X
mediated	B-X
the	B-X
association	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3/HDAC1	B-X
complex	B-X
to	B-X
the	B-X
hTERT	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
local	B-X
histone	B-X
H3	B-X
deacetylation	B-X
and	B-X
repression	B-X
of	B-X
the	B-X
promoter	B-X
.	B-X

The	O
generation	O
of	O
C18	O
-	O
ceramide	O
via	O
the	O
expression	O
of	O
ceramide	B-Protein
synthase	I-Protein
1	I-Protein
(	O
CerS1	B-Protein
)	O
,	O
and	O
not	O
C16	O
-	O
ceramide	O
by	O
CerS5	B-Protein
or	O
CerS6	B-Protein
expression	O
,	O
resulted	O
in	O
repression	O
of	O
the	O
hTERT	B-Protein
promoter	O
via	O
deacetylation	O
of	O
Sp3	B-Protein
by	O
histone	B-Protein
deacetylase	I-Protein
1	I-Protein
(	O
HDAC1	B-Protein
)	O
in	O
A549	O
human	O
lung	O
adenocarcinoma	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
distinct	B-X
roles	B-X
of	B-X
de	B-X
novo-generated	B-X
endogenous	B-X
ceramides	B-X
and	B-X
mechanisms	B-X
by	B-X
which	B-X
deacetylated	B-X
Sp3	B-X
regulates	B-X
the	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
ceramide	B-X
signaling	B-X
were	B-X
explored	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
ceramide	B-X
synthase	B-X
1	B-X
(	B-X
CerS1	B-X
)	B-X
,	B-X
and	B-X
not	B-X
C16-ceramide	B-X
by	B-X
CerS5	B-X
or	B-X
CerS6	B-X
expression	B-X
,	B-X
resulted	B-X
in	B-X
repression	B-X
of	B-X
the	B-X
hTERT	B-X
promoter	B-X
via	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
by	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
in	B-X
A549	B-X
human	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Then	B-X
roles	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
ceramide-mediated	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
in	B-X
inhibiting	B-X
the	B-X
hTERT	B-X
promoter	B-X
were	B-X
determined	B-X
using	B-X
constitutively	B-X
deacetylated	B-X
or	B-X
acetylated	B-X
Sp3	B-X
mutants	B-X
at	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
551	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3	B-X
mutant	B-X
resulted	B-X
in	B-X
repression	B-X
,	B-X
whereas	B-X
its	B-X
acetylated	B-X
mutant	B-X
induced	B-X
basal	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
Drosophila	B-X
S2	B-X
cells	B-X
,	B-X
which	B-X
do	B-X
not	B-X
express	B-X
any	B-X
endogenous	B-X
Sp3	B-X
,	B-X
and	B-X
in	B-X
A549	B-X
cells	B-X
.	B-X
Remarkably	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
data	B-X
revealed	B-X
that	B-X
acetylated	B-X
Sp3	B-X
mutant	B-X
(	B-X
K551Q-Sp3	B-X
)	B-X
did	B-X
not	B-X
bind	B-X
whereas	B-X
deacetylated	B-X
Sp3	B-X
(	B-X
K551R-Sp3	B-X
)	B-X
mutant	B-X
bound	B-X
strongly	B-X
to	B-X
the	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
association	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
with	B-X
the	B-X
promoter	B-X
.	B-X
Mechanistically	B-X
,	B-X
increased	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
by	B-X
hCerS1	B-X
expression	B-X
,	B-X
but	B-X
not	B-X
by	B-X
its	B-X
catalytically	B-X
inactive	B-X
mutant	B-X
,	B-X
mediated	B-X
the	B-X
association	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3/HDAC1	B-X
complex	B-X
to	B-X
the	B-X
hTERT	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
local	B-X
histone	B-X
H3	B-X
deacetylation	B-X
and	B-X
repression	B-X
of	B-X
the	B-X
promoter	B-X
.	B-X

Then	O
roles	O
and	O
mechanisms	O
of	O
action	O
of	O
ceramide	O
-	O
mediated	O
deacetylation	O
of	O
Sp3	B-Protein
in	O
inhibiting	O
the	O
hTERT	B-Protein
promoter	O
were	O
determined	O
using	O
constitutively	O
deacetylated	O
or	O
acetylated	O
Sp3	B-Protein
mutants	O
at	O
lysine	O
(	O
K	O
)	O
551	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
distinct	B-X
roles	B-X
of	B-X
de	B-X
novo-generated	B-X
endogenous	B-X
ceramides	B-X
and	B-X
mechanisms	B-X
by	B-X
which	B-X
deacetylated	B-X
Sp3	B-X
regulates	B-X
the	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
ceramide	B-X
signaling	B-X
were	B-X
explored	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
ceramide	B-X
synthase	B-X
1	B-X
(	B-X
CerS1	B-X
)	B-X
,	B-X
and	B-X
not	B-X
C16-ceramide	B-X
by	B-X
CerS5	B-X
or	B-X
CerS6	B-X
expression	B-X
,	B-X
resulted	B-X
in	B-X
repression	B-X
of	B-X
the	B-X
hTERT	B-X
promoter	B-X
via	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
by	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
in	B-X
A549	B-X
human	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Then	B-X
roles	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
ceramide-mediated	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
in	B-X
inhibiting	B-X
the	B-X
hTERT	B-X
promoter	B-X
were	B-X
determined	B-X
using	B-X
constitutively	B-X
deacetylated	B-X
or	B-X
acetylated	B-X
Sp3	B-X
mutants	B-X
at	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
551	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3	B-X
mutant	B-X
resulted	B-X
in	B-X
repression	B-X
,	B-X
whereas	B-X
its	B-X
acetylated	B-X
mutant	B-X
induced	B-X
basal	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
Drosophila	B-X
S2	B-X
cells	B-X
,	B-X
which	B-X
do	B-X
not	B-X
express	B-X
any	B-X
endogenous	B-X
Sp3	B-X
,	B-X
and	B-X
in	B-X
A549	B-X
cells	B-X
.	B-X
Remarkably	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
data	B-X
revealed	B-X
that	B-X
acetylated	B-X
Sp3	B-X
mutant	B-X
(	B-X
K551Q-Sp3	B-X
)	B-X
did	B-X
not	B-X
bind	B-X
whereas	B-X
deacetylated	B-X
Sp3	B-X
(	B-X
K551R-Sp3	B-X
)	B-X
mutant	B-X
bound	B-X
strongly	B-X
to	B-X
the	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
association	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
with	B-X
the	B-X
promoter	B-X
.	B-X
Mechanistically	B-X
,	B-X
increased	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
by	B-X
hCerS1	B-X
expression	B-X
,	B-X
but	B-X
not	B-X
by	B-X
its	B-X
catalytically	B-X
inactive	B-X
mutant	B-X
,	B-X
mediated	B-X
the	B-X
association	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3/HDAC1	B-X
complex	B-X
to	B-X
the	B-X
hTERT	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
local	B-X
histone	B-X
H3	B-X
deacetylation	B-X
and	B-X
repression	B-X
of	B-X
the	B-X
promoter	B-X
.	B-X

Expression	O
of	O
the	O
deacetylated	O
Sp3	B-Protein
mutant	O
resulted	O
in	O
repression	O
,	O
whereas	O
its	O
acetylated	O
mutant	O
induced	O
basal	O
hTERT	B-Protein
promoter	O
activity	O
in	O
Drosophila	O
S2	O
cells	O
,	O
which	O
do	O
not	O
express	O
any	O
endogenous	O
Sp3	B-Protein
,	O
and	O
in	O
A549	O
cells	O
.	O

Remarkably	O
,	O
chromatin	O
immunoprecipitation	O
data	O
revealed	O
that	O
acetylated	O
Sp3	B-Protein
mutant	O
(	O
K551Q	O
-	O
Sp3	B-Protein
)	O
did	O
not	O
bind	O
whereas	O
deacetylated	O
Sp3	B-Protein
(	O
K551R	O
-	O
Sp3	B-Protein
)	O
mutant	O
bound	O
strongly	O
to	O
the	O
promoter	O
DNA	O
,	O
resulting	O
in	O
the	O
recruitment	O
of	O
histone	B-Protein
deacetylase	I-Protein
1	I-Protein
(	O
HDAC1	B-Protein
)	O
and	O
inhibition	O
of	O
the	O
association	O
of	O
RNA	O
polymerase	O
II	O
with	O
the	O
promoter	O
.	O

Mechanistically	O
,	O
increased	O
generation	O
of	O
C18	O
-	O
ceramide	O
by	O
hCerS1	B-Protein
expression	O
,	O
but	O
not	O
by	O
its	O
catalytically	O
inactive	O
mutant	O
,	O
mediated	O
the	O
association	O
and	O
recruitment	O
of	O
the	O
deacetylated	O
Sp3	B-Protein
/	O
HDAC1	B-Protein
complex	O
to	O
the	O
hTERT	B-Protein
promoter	O
DNA	O
,	O
resulting	O
in	O
the	O
local	O
histone	B-Protein
H3	I-Protein
deacetylation	O
and	O
repression	O
of	O
the	O
promoter	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
distinct	B-X
roles	B-X
of	B-X
de	B-X
novo-generated	B-X
endogenous	B-X
ceramides	B-X
and	B-X
mechanisms	B-X
by	B-X
which	B-X
deacetylated	B-X
Sp3	B-X
regulates	B-X
the	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
ceramide	B-X
signaling	B-X
were	B-X
explored	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
ceramide	B-X
synthase	B-X
1	B-X
(	B-X
CerS1	B-X
)	B-X
,	B-X
and	B-X
not	B-X
C16-ceramide	B-X
by	B-X
CerS5	B-X
or	B-X
CerS6	B-X
expression	B-X
,	B-X
resulted	B-X
in	B-X
repression	B-X
of	B-X
the	B-X
hTERT	B-X
promoter	B-X
via	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
by	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
in	B-X
A549	B-X
human	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Then	B-X
roles	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
ceramide-mediated	B-X
deacetylation	B-X
of	B-X
Sp3	B-X
in	B-X
inhibiting	B-X
the	B-X
hTERT	B-X
promoter	B-X
were	B-X
determined	B-X
using	B-X
constitutively	B-X
deacetylated	B-X
or	B-X
acetylated	B-X
Sp3	B-X
mutants	B-X
at	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
551	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3	B-X
mutant	B-X
resulted	B-X
in	B-X
repression	B-X
,	B-X
whereas	B-X
its	B-X
acetylated	B-X
mutant	B-X
induced	B-X
basal	B-X
hTERT	B-X
promoter	B-X
activity	B-X
in	B-X
Drosophila	B-X
S2	B-X
cells	B-X
,	B-X
which	B-X
do	B-X
not	B-X
express	B-X
any	B-X
endogenous	B-X
Sp3	B-X
,	B-X
and	B-X
in	B-X
A549	B-X
cells	B-X
.	B-X
Remarkably	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
data	B-X
revealed	B-X
that	B-X
acetylated	B-X
Sp3	B-X
mutant	B-X
(	B-X
K551Q-Sp3	B-X
)	B-X
did	B-X
not	B-X
bind	B-X
whereas	B-X
deacetylated	B-X
Sp3	B-X
(	B-X
K551R-Sp3	B-X
)	B-X
mutant	B-X
bound	B-X
strongly	B-X
to	B-X
the	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
histone	B-X
deacetylase	B-X
1	B-X
(	B-X
HDAC1	B-X
)	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
association	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
with	B-X
the	B-X
promoter	B-X
.	B-X
Mechanistically	B-X
,	B-X
increased	B-X
generation	B-X
of	B-X
C18-ceramide	B-X
by	B-X
hCerS1	B-X
expression	B-X
,	B-X
but	B-X
not	B-X
by	B-X
its	B-X
catalytically	B-X
inactive	B-X
mutant	B-X
,	B-X
mediated	B-X
the	B-X
association	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
deacetylated	B-X
Sp3/HDAC1	B-X
complex	B-X
to	B-X
the	B-X
hTERT	B-X
promoter	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
local	B-X
histone	B-X
H3	B-X
deacetylation	B-X
and	B-X
repression	B-X
of	B-X
the	B-X
promoter	B-X
.	B-X

Drosophila	O
dSet2	B-Protein
functions	O
in	O
H3	B-Protein
-	O
K36	O
methylation	O
and	O
is	O
required	O
for	O
development	O
.	O
<EOS>	B-X
Lysine	B-X
methylation	B-X
has	B-X
important	B-X
functions	B-X
in	B-X
biological	B-X
processes	B-X
that	B-X
range	B-X
from	B-X
heterochromatin	B-X
formation	B-X
to	B-X
transcription	B-X
regulation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
Drosophila	B-X
dSet2	B-X
encodes	B-X
a	B-X
developmentally	B-X
essential	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
(	B-X
K36	B-X
)	B-X
methyltransferase	B-X
.	B-X
Larvae	B-X
subjected	B-X
to	B-X
RNA	B-X
interference-mediated	B-X
(	B-X
RNAi	B-X
)	B-X
suppression	B-X
of	B-X
dSet2	B-X
lack	B-X
dSet2	B-X
expression	B-X
and	B-X
H3-K36	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
dSet2	B-X
is	B-X
the	B-X
sole	B-X
enzyme	B-X
responsible	B-X
for	B-X
this	B-X
modification	B-X
in	B-X
Drosophila	B-X
melanogaster	B-X
.	B-X
dSet2	B-X
RNAi	B-X
blocks	B-X
puparium	B-X
formation	B-X
and	B-X
adult	B-X
development	B-X
,	B-X
and	B-X
causes	B-X
partial	B-X
(	B-X
blister	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
dorsal	B-X
and	B-X
ventral	B-X
wing	B-X
epithelia	B-X
,	B-X
defects	B-X
suggesting	B-X
a	B-X
failure	B-X
of	B-X
the	B-X
ecdysone-controlled	B-X
genetic	B-X
program	B-X
.	B-X
A	B-X
transheterozygous	B-X
EcR	B-X
null	B-X
mutation/dSet2	B-X
RNAi	B-X
combination	B-X
produces	B-X
a	B-X
complete	B-X
(	B-X
balloon	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
wing	B-X
surfaces	B-X
,	B-X
revealing	B-X
a	B-X
genetic	B-X
interaction	B-X
between	B-X
EcR	B-X
and	B-X
dSet2	B-X
.	B-X
Using	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
dSet2	B-X
associates	B-X
with	B-X
the	B-X
hyperphosphorylated	B-X
form	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
.	B-X

Lysine	O
methylation	O
has	O
important	O
functions	O
in	O
biological	O
processes	O
that	O
range	O
from	O
heterochromatin	O
formation	O
to	O
transcription	O
regulation	O
.	O
<EOS>	B-X
Lysine	B-X
methylation	B-X
has	B-X
important	B-X
functions	B-X
in	B-X
biological	B-X
processes	B-X
that	B-X
range	B-X
from	B-X
heterochromatin	B-X
formation	B-X
to	B-X
transcription	B-X
regulation	B-X
.	B-X
Larvae	B-X
subjected	B-X
to	B-X
RNA	B-X
interference-mediated	B-X
(	B-X
RNAi	B-X
)	B-X
suppression	B-X
of	B-X
dSet2	B-X
lack	B-X
dSet2	B-X
expression	B-X
and	B-X
H3-K36	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
dSet2	B-X
is	B-X
the	B-X
sole	B-X
enzyme	B-X
responsible	B-X
for	B-X
this	B-X
modification	B-X
in	B-X
Drosophila	B-X
melanogaster	B-X
.	B-X
dSet2	B-X
RNAi	B-X
blocks	B-X
puparium	B-X
formation	B-X
and	B-X
adult	B-X
development	B-X
,	B-X
and	B-X
causes	B-X
partial	B-X
(	B-X
blister	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
dorsal	B-X
and	B-X
ventral	B-X
wing	B-X
epithelia	B-X
,	B-X
defects	B-X
suggesting	B-X
a	B-X
failure	B-X
of	B-X
the	B-X
ecdysone-controlled	B-X
genetic	B-X
program	B-X
.	B-X
Posttranslational	B-X
histone	B-X
modifications	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
chromatin	B-X
dynamics	B-X
and	B-X
function	B-X
.	B-X
One	B-X
of	B-X
the	B-X
modifications	B-X
,	B-X
methylation	B-X
,	B-X
occurs	B-X
on	B-X
both	B-X
lysine	B-X
and	B-X
arginine	B-X
residues	B-X
and	B-X
participates	B-X
in	B-X
diverse	B-X
range	B-X
of	B-X
biological	B-X
processes	B-X
including	B-X
heterochromatin	B-X
formation	B-X
,	B-X
X-chromosome	B-X
inactivation	B-X
,	B-X
and	B-X
transcriptional	B-X
regulation	B-X
.	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
these	B-X
histone	B-X
demethylases	B-X
is	B-X
an	B-X
important	B-X
step	B-X
towards	B-X
understanding	B-X
both	B-X
the	B-X
function	B-X
and	B-X
regulation	B-X
of	B-X
histone	B-X
methylation	B-X
.	B-X

Here	O
,	O
we	O
demonstrate	O
that	O
Drosophila	O
dSet2	B-Protein
encodes	O
a	O
developmentally	O
essential	O
histone	B-Protein
H3	I-Protein
lysine	O
36	O
(	O
K36	O
)	O
methyltransferase	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
Drosophila	B-X
dSet2	B-X
encodes	B-X
a	B-X
developmentally	B-X
essential	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
(	B-X
K36	B-X
)	B-X
methyltransferase	B-X
.	B-X
Larvae	B-X
subjected	B-X
to	B-X
RNA	B-X
interference-mediated	B-X
(	B-X
RNAi	B-X
)	B-X
suppression	B-X
of	B-X
dSet2	B-X
lack	B-X
dSet2	B-X
expression	B-X
and	B-X
H3-K36	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
dSet2	B-X
is	B-X
the	B-X
sole	B-X
enzyme	B-X
responsible	B-X
for	B-X
this	B-X
modification	B-X
in	B-X
Drosophila	B-X
melanogaster	B-X
.	B-X
dSet2	B-X
RNAi	B-X
blocks	B-X
puparium	B-X
formation	B-X
and	B-X
adult	B-X
development	B-X
,	B-X
and	B-X
causes	B-X
partial	B-X
(	B-X
blister	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
dorsal	B-X
and	B-X
ventral	B-X
wing	B-X
epithelia	B-X
,	B-X
defects	B-X
suggesting	B-X
a	B-X
failure	B-X
of	B-X
the	B-X
ecdysone-controlled	B-X
genetic	B-X
program	B-X
.	B-X
A	B-X
transheterozygous	B-X
EcR	B-X
null	B-X
mutation/dSet2	B-X
RNAi	B-X
combination	B-X
produces	B-X
a	B-X
complete	B-X
(	B-X
balloon	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
wing	B-X
surfaces	B-X
,	B-X
revealing	B-X
a	B-X
genetic	B-X
interaction	B-X
between	B-X
EcR	B-X
and	B-X
dSet2	B-X
.	B-X
Using	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
dSet2	B-X
associates	B-X
with	B-X
the	B-X
hyperphosphorylated	B-X
form	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
.	B-X

Larvae	O
subjected	O
to	O
RNA	O
interference	O
-	O
mediated	O
(	O
RNAi	O
)	O
suppression	O
of	O
dSet2	B-Protein
lack	O
dSet2	B-Protein
expression	O
and	O
H3	B-Protein
-	O
K36	O
methylation	O
,	O
indicating	O
that	O
dSet2	B-Protein
is	O
the	O
sole	O
enzyme	O
responsible	O
for	O
this	O
modification	O
in	O
Drosophila	O
melanogaster	O
.	O
<EOS>	B-X
Lysine	B-X
methylation	B-X
has	B-X
important	B-X
functions	B-X
in	B-X
biological	B-X
processes	B-X
that	B-X
range	B-X
from	B-X
heterochromatin	B-X
formation	B-X
to	B-X
transcription	B-X
regulation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
Drosophila	B-X
dSet2	B-X
encodes	B-X
a	B-X
developmentally	B-X
essential	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
(	B-X
K36	B-X
)	B-X
methyltransferase	B-X
.	B-X
Larvae	B-X
subjected	B-X
to	B-X
RNA	B-X
interference-mediated	B-X
(	B-X
RNAi	B-X
)	B-X
suppression	B-X
of	B-X
dSet2	B-X
lack	B-X
dSet2	B-X
expression	B-X
and	B-X
H3-K36	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
dSet2	B-X
is	B-X
the	B-X
sole	B-X
enzyme	B-X
responsible	B-X
for	B-X
this	B-X
modification	B-X
in	B-X
Drosophila	B-X
melanogaster	B-X
.	B-X
dSet2	B-X
RNAi	B-X
blocks	B-X
puparium	B-X
formation	B-X
and	B-X
adult	B-X
development	B-X
,	B-X
and	B-X
causes	B-X
partial	B-X
(	B-X
blister	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
dorsal	B-X
and	B-X
ventral	B-X
wing	B-X
epithelia	B-X
,	B-X
defects	B-X
suggesting	B-X
a	B-X
failure	B-X
of	B-X
the	B-X
ecdysone-controlled	B-X
genetic	B-X
program	B-X
.	B-X
A	B-X
transheterozygous	B-X
EcR	B-X
null	B-X
mutation/dSet2	B-X
RNAi	B-X
combination	B-X
produces	B-X
a	B-X
complete	B-X
(	B-X
balloon	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
wing	B-X
surfaces	B-X
,	B-X
revealing	B-X
a	B-X
genetic	B-X
interaction	B-X
between	B-X
EcR	B-X
and	B-X
dSet2	B-X
.	B-X
Using	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
dSet2	B-X
associates	B-X
with	B-X
the	B-X
hyperphosphorylated	B-X
form	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
.	B-X

dSet2	B-Protein
RNAi	O
blocks	O
puparium	O
formation	O
and	O
adult	O
development	O
,	O
and	O
causes	O
partial	O
(	O
blister	O
)	O
separation	O
of	O
the	O
dorsal	O
and	O
ventral	O
wing	O
epithelia	O
,	O
defects	O
suggesting	O
a	O
failure	O
of	O
the	O
ecdysone	O
-	O
controlled	O
genetic	O
program	O
.	O
<EOS>	B-X
Lysine	B-X
methylation	B-X
has	B-X
important	B-X
functions	B-X
in	B-X
biological	B-X
processes	B-X
that	B-X
range	B-X
from	B-X
heterochromatin	B-X
formation	B-X
to	B-X
transcription	B-X
regulation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
Drosophila	B-X
dSet2	B-X
encodes	B-X
a	B-X
developmentally	B-X
essential	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
(	B-X
K36	B-X
)	B-X
methyltransferase	B-X
.	B-X
Larvae	B-X
subjected	B-X
to	B-X
RNA	B-X
interference-mediated	B-X
(	B-X
RNAi	B-X
)	B-X
suppression	B-X
of	B-X
dSet2	B-X
lack	B-X
dSet2	B-X
expression	B-X
and	B-X
H3-K36	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
dSet2	B-X
is	B-X
the	B-X
sole	B-X
enzyme	B-X
responsible	B-X
for	B-X
this	B-X
modification	B-X
in	B-X
Drosophila	B-X
melanogaster	B-X
.	B-X
dSet2	B-X
RNAi	B-X
blocks	B-X
puparium	B-X
formation	B-X
and	B-X
adult	B-X
development	B-X
,	B-X
and	B-X
causes	B-X
partial	B-X
(	B-X
blister	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
dorsal	B-X
and	B-X
ventral	B-X
wing	B-X
epithelia	B-X
,	B-X
defects	B-X
suggesting	B-X
a	B-X
failure	B-X
of	B-X
the	B-X
ecdysone-controlled	B-X
genetic	B-X
program	B-X
.	B-X
A	B-X
transheterozygous	B-X
EcR	B-X
null	B-X
mutation/dSet2	B-X
RNAi	B-X
combination	B-X
produces	B-X
a	B-X
complete	B-X
(	B-X
balloon	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
wing	B-X
surfaces	B-X
,	B-X
revealing	B-X
a	B-X
genetic	B-X
interaction	B-X
between	B-X
EcR	B-X
and	B-X
dSet2	B-X
.	B-X
Using	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
dSet2	B-X
associates	B-X
with	B-X
the	B-X
hyperphosphorylated	B-X
form	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
.	B-X

A	O
transheterozygous	O
EcR	B-Protein
null	O
mutation	O
/	O
dSet2	B-Protein
RNAi	O
combination	O
produces	O
a	O
complete	O
(	O
balloon	O
)	O
separation	O
of	O
the	O
wing	O
surfaces	O
,	O
revealing	O
a	O
genetic	O
interaction	O
between	O
EcR	B-Protein
and	O
dSet2	B-Protein
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
Drosophila	B-X
dSet2	B-X
encodes	B-X
a	B-X
developmentally	B-X
essential	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
(	B-X
K36	B-X
)	B-X
methyltransferase	B-X
.	B-X
Larvae	B-X
subjected	B-X
to	B-X
RNA	B-X
interference-mediated	B-X
(	B-X
RNAi	B-X
)	B-X
suppression	B-X
of	B-X
dSet2	B-X
lack	B-X
dSet2	B-X
expression	B-X
and	B-X
H3-K36	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
dSet2	B-X
is	B-X
the	B-X
sole	B-X
enzyme	B-X
responsible	B-X
for	B-X
this	B-X
modification	B-X
in	B-X
Drosophila	B-X
melanogaster	B-X
.	B-X
dSet2	B-X
RNAi	B-X
blocks	B-X
puparium	B-X
formation	B-X
and	B-X
adult	B-X
development	B-X
,	B-X
and	B-X
causes	B-X
partial	B-X
(	B-X
blister	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
dorsal	B-X
and	B-X
ventral	B-X
wing	B-X
epithelia	B-X
,	B-X
defects	B-X
suggesting	B-X
a	B-X
failure	B-X
of	B-X
the	B-X
ecdysone-controlled	B-X
genetic	B-X
program	B-X
.	B-X
A	B-X
transheterozygous	B-X
EcR	B-X
null	B-X
mutation/dSet2	B-X
RNAi	B-X
combination	B-X
produces	B-X
a	B-X
complete	B-X
(	B-X
balloon	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
wing	B-X
surfaces	B-X
,	B-X
revealing	B-X
a	B-X
genetic	B-X
interaction	B-X
between	B-X
EcR	B-X
and	B-X
dSet2	B-X
.	B-X
Using	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
dSet2	B-X
associates	B-X
with	B-X
the	B-X
hyperphosphorylated	B-X
form	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
.	B-X

Using	O
immunoprecipitation	O
,	O
we	O
demonstrate	O
that	O
dSet2	B-Protein
associates	O
with	O
the	O
hyperphosphorylated	O
form	O
of	O
RNA	O
polymerase	O
II	O
(	O
RNAPII	O
)	O
.	O
<EOS>	B-X
Lysine	B-X
methylation	B-X
has	B-X
important	B-X
functions	B-X
in	B-X
biological	B-X
processes	B-X
that	B-X
range	B-X
from	B-X
heterochromatin	B-X
formation	B-X
to	B-X
transcription	B-X
regulation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
Drosophila	B-X
dSet2	B-X
encodes	B-X
a	B-X
developmentally	B-X
essential	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
(	B-X
K36	B-X
)	B-X
methyltransferase	B-X
.	B-X
Larvae	B-X
subjected	B-X
to	B-X
RNA	B-X
interference-mediated	B-X
(	B-X
RNAi	B-X
)	B-X
suppression	B-X
of	B-X
dSet2	B-X
lack	B-X
dSet2	B-X
expression	B-X
and	B-X
H3-K36	B-X
methylation	B-X
,	B-X
indicating	B-X
that	B-X
dSet2	B-X
is	B-X
the	B-X
sole	B-X
enzyme	B-X
responsible	B-X
for	B-X
this	B-X
modification	B-X
in	B-X
Drosophila	B-X
melanogaster	B-X
.	B-X
dSet2	B-X
RNAi	B-X
blocks	B-X
puparium	B-X
formation	B-X
and	B-X
adult	B-X
development	B-X
,	B-X
and	B-X
causes	B-X
partial	B-X
(	B-X
blister	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
dorsal	B-X
and	B-X
ventral	B-X
wing	B-X
epithelia	B-X
,	B-X
defects	B-X
suggesting	B-X
a	B-X
failure	B-X
of	B-X
the	B-X
ecdysone-controlled	B-X
genetic	B-X
program	B-X
.	B-X
A	B-X
transheterozygous	B-X
EcR	B-X
null	B-X
mutation/dSet2	B-X
RNAi	B-X
combination	B-X
produces	B-X
a	B-X
complete	B-X
(	B-X
balloon	B-X
)	B-X
separation	B-X
of	B-X
the	B-X
wing	B-X
surfaces	B-X
,	B-X
revealing	B-X
a	B-X
genetic	B-X
interaction	B-X
between	B-X
EcR	B-X
and	B-X
dSet2	B-X
.	B-X
Using	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
dSet2	B-X
associates	B-X
with	B-X
the	B-X
hyperphosphorylated	B-X
form	B-X
of	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
RNAPII	B-X
)	B-X
.	B-X

VIPL	B-Protein
has	O
sugar	O
-	O
binding	O
activity	O
specific	O
for	O
high	O
-	O
mannose	O
-	O
type	O
N	O
-	O
glycans	O
,	O
and	O
glucosylation	O
of	O
the	O
alpha1	O
,	O
2	O
mannotriosyl	O
branch	O
blocks	O
its	O
binding	O
.	O

VIP36	B-Protein
-	I-Protein
like	I-Protein
protein	I-Protein
(	O
VIPL	B-Protein
)	O
was	O
identified	O
as	O
an	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
resident	O
protein	O
with	O
homology	O
to	O
VIP36	B-Protein
,	O
a	O
cargo	O
receptor	O
involved	O
in	O
the	O
transport	O
of	O
glycoproteins	O
within	O
cells	O
.	O
<EOS>	B-X
VIP36-like	B-X
protein	B-X
(	B-X
VIPL	B-X
)	B-X
was	B-X
identified	B-X
as	B-X
an	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
resident	B-X
protein	B-X
with	B-X
homology	B-X
to	B-X
VIP36	B-X
,	B-X
a	B-X
cargo	B-X
receptor	B-X
involved	B-X
in	B-X
the	B-X
transport	B-X
of	B-X
glycoproteins	B-X
within	B-X
cells	B-X
.	B-X
Although	B-X
VIPL	B-X
is	B-X
structurally	B-X
similar	B-X
to	B-X
VIP36	B-X
,	B-X
VIPL	B-X
is	B-X
thought	B-X
not	B-X
to	B-X
be	B-X
a	B-X
lectin	B-X
,	B-X
because	B-X
its	B-X
sugar-binding	B-X
activity	B-X
has	B-X
not	B-X
been	B-X
detected	B-X
in	B-X
several	B-X
experiments	B-X
.	B-X
Here	B-X
,	B-X
recombinant	B-X
soluble	B-X
VIPL	B-X
proteins	B-X
(	B-X
sVIPL	B-X
)	B-X
were	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
,	B-X
biotinylated	B-X
with	B-X
biotin	B-X
ligase	B-X
and	B-X
oligomerized	B-X
with	B-X
R-phycoerythrin	B-X
(	B-X
PE	B-X
)	B-X
-labeled	B-X
streptavidin	B-X
(	B-X
SA	B-X
)	B-X
.	B-X
As	B-X
measured	B-X
with	B-X
flow	B-X
cytometry	B-X
,	B-X
PE-labeled	B-X
sVIPL-SA	B-X
bound	B-X
to	B-X
deoxymannojirimycin	B-X
(	B-X
DMJ	B-X
)	B-X
-	B-X
or	B-X
kifunensine	B-X
(	B-X
KIF	B-X
)	B-X
-	B-X
but	B-X
not	B-X
to	B-X
swainsonine	B-X
(	B-X
SW	B-X
)	B-X
-treated	B-X
HeLaS3	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
.	B-X
A	B-X
surface	B-X
plasmon	B-X
resonance	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
avidity	B-X
of	B-X
sVIPL	B-X
was	B-X
enhanced	B-X
after	B-X
it	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
SA	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
PE-labeled	B-X
sVIPL-SA	B-X
was	B-X
abrogated	B-X
by	B-X
endo	B-X
beta-N-acetylglucosaminidase	B-X
H	B-X
treatment	B-X
of	B-X
the	B-X
DMJ-	B-X
or	B-X
KIF-treated	B-X
cells	B-X
.	B-X
Competition	B-X
with	B-X
several	B-X
high-mannose-type	B-X
N-glycans	B-X
inhibited	B-X
VIPL	B-X
binding	B-X
,	B-X
and	B-X
indicated	B-X
that	B-X
VIPL	B-X
recognizes	B-X
the	B-X
Manalpha1-2Manalpha1-2Man	B-X
sequence	B-X
.	B-X
Although	B-X
the	B-X
biochemical	B-X
characteristics	B-X
of	B-X
VIPL	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
VIP36	B-X
,	B-X
the	B-X
sugar-binding	B-X
activity	B-X
of	B-X
VIPL	B-X
was	B-X
stronger	B-X
at	B-X
neutral	B-X
pH	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
pH	B-X
in	B-X
the	B-X
lumen	B-X
of	B-X
the	B-X
ER	B-X
,	B-X
than	B-X
under	B-X
acidic	B-X
conditions	B-X
.	B-X

Although	O
VIPL	B-Protein
is	O
structurally	O
similar	O
to	O
VIP36	B-Protein
,	O
VIPL	B-Protein
is	O
thought	O
not	O
to	O
be	O
a	O
lectin	O
,	O
because	O
its	O
sugar	O
-	O
binding	O
activity	O
has	O
not	O
been	O
detected	O
in	O
several	O
experiments	O
.	O

Here	O
,	O
recombinant	O
soluble	O
VIPL	B-Protein
proteins	O
(	O
sVIPL	B-Protein
)	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
biotinylated	O
with	O
biotin	B-Protein
ligase	I-Protein
and	O
oligomerized	O
with	O
R	O
-	O
phycoerythrin	O
(	O
PE	O
)	O
-	O
labeled	O
streptavidin	B-Protein
(	O
SA	B-Protein
)	O
.	O

As	O
measured	O
with	O
flow	O
cytometry	O
,	O
PE	O
-	O
labeled	O
sVIPL	B-Protein
-	O
SA	B-Protein
bound	O
to	O
deoxymannojirimycin	O
(	O
DMJ	O
)	O
-	O
or	O
kifunensine	O
(	O
KIF	O
)	O
-	O
but	O
not	O
to	O
swainsonine	O
(	O
SW	O
)	O
-	O
treated	O
HeLaS3	O
cells	O
in	O
the	O
presence	O
of	O
calcium	O
.	O

A	O
surface	O
plasmon	O
resonance	O
analysis	O
showed	O
that	O
the	O
avidity	O
of	O
sVIPL	B-Protein
was	O
enhanced	O
after	O
it	O
formed	O
a	O
complex	O
with	O
SA	B-Protein
.	O

The	O
binding	O
of	O
PE	O
-	O
labeled	O
sVIPL	B-Protein
-	O
SA	B-Protein
was	O
abrogated	O
by	O
endo	B-Protein
beta	I-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylglucosaminidase	I-Protein
H	I-Protein
treatment	O
of	O
the	O
DMJ	O
-	O
or	O
KIF	O
-	O
treated	O
cells	O
.	O
<EOS>	B-X
ROT	B-X
exposure	B-X
on	B-X
female	B-X
Drosophila	B-X
melanogaster	B-X
resulted	B-X
in	B-X
developmental	B-X
inhibition	B-X
and	B-X
ovarian	B-X
abnormality	B-X
,	B-X
which	B-X
were	B-X
evident	B-X
from	B-X
the	B-X
disruptive	B-X
growth	B-X
of	B-X
border	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
morphological	B-X
changes	B-X
in	B-X
the	B-X
orientation	B-X
of	B-X
nurse	B-X
cells	B-X
during	B-X
the	B-X
9th-10th	B-X
stage	B-X
of	B-X
developing	B-X
egg	B-X
chamber	B-X
of	B-X
in	B-X
the	B-X
Drosophila	B-X
ovary	B-X
.	B-X
Other	B-X
abnormalities	B-X
,	B-X
such	B-X
as	B-X
,	B-X
altered	B-X
developmental	B-X
gene	B-X
expression	B-X
(	B-X
Osk	B-X
,	B-X
Grk	B-X
,	B-X
Nos	B-X
,	B-X
Bic-d	B-X
)	B-X
,	B-X
inhibition	B-X
in	B-X
the	B-X
kinesin	B-X
motor	B-X
protein	B-X
level	B-X
(	B-X
KIF-5B	B-X
)	B-X
,	B-X
increased	B-X
caspases	B-X
activities	B-X
(	B-X
Caspase	B-X
3	B-X
,	B-X
8	B-X
,	B-X
&	B-X
9	B-X
)	B-X
and	B-X
apoptosis	B-X
were	B-X
also	B-X
observed	B-X
.	B-X
Subsequently	B-X
,	B-X
ROT	B-X
treated	B-X
larvae	B-X
exhibited	B-X
behavioral	B-X
deficits	B-X
and	B-X
delay	B-X
in	B-X
developmental	B-X
time	B-X
.	B-X
Breast	B-X
cancer	B-X
pathobiology	B-X
is	B-X
known	B-X
to	B-X
be	B-X
influenced	B-X
by	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
a	B-X
group	B-X
of	B-X
proteins	B-X
called	B-X
the	B-X
kinesin	B-X
superfamily	B-X
(	B-X
KIFs	B-X
)	B-X
,	B-X
which	B-X
is	B-X
instrumental	B-X
in	B-X
the	B-X
intracellular	B-X
transport	B-X
of	B-X
chromosomes	B-X
along	B-X
microtubules	B-X
during	B-X
mitosis	B-X
.	B-X
However	B-X
,	B-X
their	B-X
misregulation	B-X
may	B-X
contribute	B-X
to	B-X
uncontrolled	B-X
cell	B-X
growth	B-X
owing	B-X
to	B-X
premature	B-X
sister	B-X
chromatid	B-X
separation	B-X
,	B-X
highlighting	B-X
their	B-X
importance	B-X
in	B-X
cancer	B-X
.	B-X
This	B-X
review	B-X
covers	B-X
the	B-X
functions	B-X
of	B-X
kinesins	B-X
in	B-X
normal	B-X
and	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
the	B-X
use	B-X
of	B-X
kinesins	B-X
for	B-X
breast	B-X
cancer	B-X
patient	B-X
prognosis	B-X
,	B-X
and	B-X
the	B-X
targeting	B-X
of	B-X
these	B-X
molecules	B-X
for	B-X
therapeutics	B-X
.	B-X
A	B-X
better	B-X
understanding	B-X
of	B-X
KIF	B-X
proteins	B-X
may	B-X
be	B-X
pivotal	B-X
to	B-X
improved	B-X
disease	B-X
outcomes	B-X
for	B-X
breast	B-X
cancer	B-X
patients	B-X
.	B-X

Competition	O
with	O
several	O
high	O
-	O
mannose	O
-	O
type	O
N	O
-	O
glycans	O
inhibited	O
VIPL	B-Protein
binding	O
,	O
and	O
indicated	O
that	O
VIPL	B-Protein
recognizes	O
the	O
Manalpha1	O
-	O
2Manalpha1	O
-	O
2Man	O
sequence	O
.	O

Glucosylation	O
of	O
the	O
outer	O
mannose	O
residue	O
of	O
this	O
portion	O
decreased	O
the	O
binding	O
.	O
<EOS>	B-X
Although	B-X
VIPL	B-X
is	B-X
structurally	B-X
similar	B-X
to	B-X
VIP36	B-X
,	B-X
VIPL	B-X
is	B-X
thought	B-X
not	B-X
to	B-X
be	B-X
a	B-X
lectin	B-X
,	B-X
because	B-X
its	B-X
sugar-binding	B-X
activity	B-X
has	B-X
not	B-X
been	B-X
detected	B-X
in	B-X
several	B-X
experiments	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
PE-labeled	B-X
sVIPL-SA	B-X
was	B-X
abrogated	B-X
by	B-X
endo	B-X
beta-N-acetylglucosaminidase	B-X
H	B-X
treatment	B-X
of	B-X
the	B-X
DMJ-	B-X
or	B-X
KIF-treated	B-X
cells	B-X
.	B-X
Competition	B-X
with	B-X
several	B-X
high-mannose-type	B-X
N-glycans	B-X
inhibited	B-X
VIPL	B-X
binding	B-X
,	B-X
and	B-X
indicated	B-X
that	B-X
VIPL	B-X
recognizes	B-X
the	B-X
Manalpha1-2Manalpha1-2Man	B-X
sequence	B-X
.	B-X
Glucosylation	B-X
of	B-X
the	B-X
outer	B-X
mannose	B-X
residue	B-X
of	B-X
this	B-X
portion	B-X
decreased	B-X
the	B-X
binding	B-X
.	B-X
Although	B-X
the	B-X
biochemical	B-X
characteristics	B-X
of	B-X
VIPL	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
VIP36	B-X
,	B-X
the	B-X
sugar-binding	B-X
activity	B-X
of	B-X
VIPL	B-X
was	B-X
stronger	B-X
at	B-X
neutral	B-X
pH	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
pH	B-X
in	B-X
the	B-X
lumen	B-X
of	B-X
the	B-X
ER	B-X
,	B-X
than	B-X
under	B-X
acidic	B-X
conditions	B-X
.	B-X

Although	O
the	O
biochemical	O
characteristics	O
of	O
VIPL	B-Protein
are	O
similar	O
to	O
those	O
of	O
VIP36	B-Protein
,	O
the	O
sugar	O
-	O
binding	O
activity	O
of	O
VIPL	B-Protein
was	O
stronger	O
at	O
neutral	O
pH	O
,	O
corresponding	O
to	O
the	O
pH	O
in	O
the	O
lumen	O
of	O
the	O
ER	O
,	O
than	O
under	O
acidic	O
conditions	O
.	O

The	O
transcription	O
factor	O
snail	O
mediates	O
epithelial	O
to	O
mesenchymal	O
transitions	O
by	O
repression	O
of	O
estrogen	B-Protein
receptor	I-Protein
-	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
The	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
-alpha	B-X
(	B-X
ESR1	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
molecule	B-X
in	B-X
mammary	B-X
epithelial	B-X
cell	B-X
development	B-X
.	B-X
Loss	B-X
of	B-X
ER-alpha	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
,	B-X
increased	B-X
recurrence	B-X
after	B-X
treatment	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
incidence	B-X
of	B-X
metastasis	B-X
.	B-X
A	B-X
proposed	B-X
molecular	B-X
pathway	B-X
by	B-X
which	B-X
ER-alpha	B-X
acts	B-X
to	B-X
constrain	B-X
invasive	B-X
growth	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
involves	B-X
direct	B-X
,	B-X
ER-alpha-dependent	B-X
expression	B-X
of	B-X
metastasis-associated	B-X
protein	B-X
3	B-X
,	B-X
a	B-X
cell-type-specific	B-X
component	B-X
of	B-X
the	B-X
Mi-2/NuRD	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
.	B-X
MTA3	B-X
in	B-X
turn	B-X
represses	B-X
expression	B-X
of	B-X
Snail	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
linked	B-X
to	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
and	B-X
cancer	B-X
metastasis	B-X
.	B-X
To	B-X
elucidate	B-X
its	B-X
role	B-X
(	B-X
s	B-X
)	B-X
in	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
we	B-X
expressed	B-X
Snail	B-X
in	B-X
the	B-X
noninvasive	B-X
,	B-X
ER-alpha-positive	B-X
MCF-7	B-X
cell	B-X
line	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
loss	B-X
of	B-X
ER-alpha	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
RNA	B-X
and	B-X
protein	B-X
level	B-X
that	B-X
was	B-X
accompanied	B-X
by	B-X
direct	B-X
interaction	B-X
of	B-X
Snail	B-X
with	B-X
regulatory	B-X
DNA	B-X
sequences	B-X
at	B-X
the	B-X
ESR1	B-X
locus	B-X
.	B-X
A	B-X
consequence	B-X
of	B-X
loss	B-X
of	B-X
ER-alpha	B-X
function	B-X
in	B-X
this	B-X
system	B-X
was	B-X
the	B-X
increased	B-X
abundance	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TGF-beta	B-X
signaling	B-X
pathway	B-X
.	B-X
Thus	B-X
,	B-X
cross-talk	B-X
among	B-X
ER-alpha	B-X
,	B-X
Snail	B-X
,	B-X
and	B-X
the	B-X
TGF-beta	B-X
pathway	B-X
appears	B-X
to	B-X
control	B-X
critical	B-X
phenotypic	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

The	O
estrogen	B-Protein
receptor	I-Protein
(	I-Protein
ER	I-Protein
)	I-Protein
-	I-Protein
alpha	I-Protein
(	O
ESR1	B-Protein
)	O
is	O
a	O
key	O
regulatory	O
molecule	O
in	O
mammary	O
epithelial	O
cell	O
development	O
.	O
<EOS>	B-X
The	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
-alpha	B-X
(	B-X
ESR1	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
molecule	B-X
in	B-X
mammary	B-X
epithelial	B-X
cell	B-X
development	B-X
.	B-X
Loss	B-X
of	B-X
ER-alpha	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
,	B-X
increased	B-X
recurrence	B-X
after	B-X
treatment	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
incidence	B-X
of	B-X
metastasis	B-X
.	B-X
A	B-X
proposed	B-X
molecular	B-X
pathway	B-X
by	B-X
which	B-X
ER-alpha	B-X
acts	B-X
to	B-X
constrain	B-X
invasive	B-X
growth	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
involves	B-X
direct	B-X
,	B-X
ER-alpha-dependent	B-X
expression	B-X
of	B-X
metastasis-associated	B-X
protein	B-X
3	B-X
,	B-X
a	B-X
cell-type-specific	B-X
component	B-X
of	B-X
the	B-X
Mi-2/NuRD	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
.	B-X
MTA3	B-X
in	B-X
turn	B-X
represses	B-X
expression	B-X
of	B-X
Snail	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
linked	B-X
to	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
and	B-X
cancer	B-X
metastasis	B-X
.	B-X
To	B-X
elucidate	B-X
its	B-X
role	B-X
(	B-X
s	B-X
)	B-X
in	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
we	B-X
expressed	B-X
Snail	B-X
in	B-X
the	B-X
noninvasive	B-X
,	B-X
ER-alpha-positive	B-X
MCF-7	B-X
cell	B-X
line	B-X
.	B-X
Snail	B-X
expression	B-X
led	B-X
to	B-X
decreased	B-X
cell-cell	B-X
adhesion	B-X
and	B-X
increased	B-X
cell	B-X
invasiveness	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
loss	B-X
of	B-X
ER-alpha	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
RNA	B-X
and	B-X
protein	B-X
level	B-X
that	B-X
was	B-X
accompanied	B-X
by	B-X
direct	B-X
interaction	B-X
of	B-X
Snail	B-X
with	B-X
regulatory	B-X
DNA	B-X
sequences	B-X
at	B-X
the	B-X
ESR1	B-X
locus	B-X
.	B-X
A	B-X
consequence	B-X
of	B-X
loss	B-X
of	B-X
ER-alpha	B-X
function	B-X
in	B-X
this	B-X
system	B-X
was	B-X
the	B-X
increased	B-X
abundance	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TGF-beta	B-X
signaling	B-X
pathway	B-X
.	B-X
Thus	B-X
,	B-X
cross-talk	B-X
among	B-X
ER-alpha	B-X
,	B-X
Snail	B-X
,	B-X
and	B-X
the	B-X
TGF-beta	B-X
pathway	B-X
appears	B-X
to	B-X
control	B-X
critical	B-X
phenotypic	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

Loss	O
of	O
ER	B-Protein
-	I-Protein
alpha	I-Protein
in	O
breast	O
cancer	O
is	O
correlated	O
with	O
poor	O
prognosis	O
,	O
increased	O
recurrence	O
after	O
treatment	O
,	O
and	O
an	O
elevated	O
incidence	O
of	O
metastasis	O
.	O

A	O
proposed	O
molecular	O
pathway	O
by	O
which	O
ER	B-Protein
-	I-Protein
alpha	I-Protein
acts	O
to	O
constrain	O
invasive	O
growth	O
in	O
breast	O
cancer	O
cells	O
involves	O
direct	O
,	O
ER	B-Protein
-	I-Protein
alpha	I-Protein
-	O
dependent	O
expression	O
of	O
metastasis	O
-	O
associated	O
protein	O
3	O
,	O
a	O
cell	O
-	O
type	O
-	O
specific	O
component	O
of	O
the	O
Mi	O
-	O
2	O
/	O
NuRD	O
chromatin	O
remodeling	O
complex	O
.	O
<EOS>	B-X
The	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
-alpha	B-X
(	B-X
ESR1	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
molecule	B-X
in	B-X
mammary	B-X
epithelial	B-X
cell	B-X
development	B-X
.	B-X
Loss	B-X
of	B-X
ER-alpha	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
,	B-X
increased	B-X
recurrence	B-X
after	B-X
treatment	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
incidence	B-X
of	B-X
metastasis	B-X
.	B-X
A	B-X
proposed	B-X
molecular	B-X
pathway	B-X
by	B-X
which	B-X
ER-alpha	B-X
acts	B-X
to	B-X
constrain	B-X
invasive	B-X
growth	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
involves	B-X
direct	B-X
,	B-X
ER-alpha-dependent	B-X
expression	B-X
of	B-X
metastasis-associated	B-X
protein	B-X
3	B-X
,	B-X
a	B-X
cell-type-specific	B-X
component	B-X
of	B-X
the	B-X
Mi-2/NuRD	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
.	B-X
MTA3	B-X
in	B-X
turn	B-X
represses	B-X
expression	B-X
of	B-X
Snail	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
linked	B-X
to	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
and	B-X
cancer	B-X
metastasis	B-X
.	B-X
To	B-X
elucidate	B-X
its	B-X
role	B-X
(	B-X
s	B-X
)	B-X
in	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
we	B-X
expressed	B-X
Snail	B-X
in	B-X
the	B-X
noninvasive	B-X
,	B-X
ER-alpha-positive	B-X
MCF-7	B-X
cell	B-X
line	B-X
.	B-X
Snail	B-X
expression	B-X
led	B-X
to	B-X
decreased	B-X
cell-cell	B-X
adhesion	B-X
and	B-X
increased	B-X
cell	B-X
invasiveness	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
loss	B-X
of	B-X
ER-alpha	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
RNA	B-X
and	B-X
protein	B-X
level	B-X
that	B-X
was	B-X
accompanied	B-X
by	B-X
direct	B-X
interaction	B-X
of	B-X
Snail	B-X
with	B-X
regulatory	B-X
DNA	B-X
sequences	B-X
at	B-X
the	B-X
ESR1	B-X
locus	B-X
.	B-X
A	B-X
consequence	B-X
of	B-X
loss	B-X
of	B-X
ER-alpha	B-X
function	B-X
in	B-X
this	B-X
system	B-X
was	B-X
the	B-X
increased	B-X
abundance	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TGF-beta	B-X
signaling	B-X
pathway	B-X
.	B-X
Thus	B-X
,	B-X
cross-talk	B-X
among	B-X
ER-alpha	B-X
,	B-X
Snail	B-X
,	B-X
and	B-X
the	B-X
TGF-beta	B-X
pathway	B-X
appears	B-X
to	B-X
control	B-X
critical	B-X
phenotypic	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

MTA3	B-Protein
in	O
turn	O
represses	O
expression	O
of	O
Snail	O
,	O
a	O
transcription	O
factor	O
linked	O
to	O
epithelial	O
to	O
mesenchymal	O
transition	O
and	O
cancer	O
metastasis	O
.	O
<EOS>	B-X
The	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
-alpha	B-X
(	B-X
ESR1	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
molecule	B-X
in	B-X
mammary	B-X
epithelial	B-X
cell	B-X
development	B-X
.	B-X
Loss	B-X
of	B-X
ER-alpha	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
,	B-X
increased	B-X
recurrence	B-X
after	B-X
treatment	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
incidence	B-X
of	B-X
metastasis	B-X
.	B-X
A	B-X
proposed	B-X
molecular	B-X
pathway	B-X
by	B-X
which	B-X
ER-alpha	B-X
acts	B-X
to	B-X
constrain	B-X
invasive	B-X
growth	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
involves	B-X
direct	B-X
,	B-X
ER-alpha-dependent	B-X
expression	B-X
of	B-X
metastasis-associated	B-X
protein	B-X
3	B-X
,	B-X
a	B-X
cell-type-specific	B-X
component	B-X
of	B-X
the	B-X
Mi-2/NuRD	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
.	B-X
MTA3	B-X
in	B-X
turn	B-X
represses	B-X
expression	B-X
of	B-X
Snail	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
linked	B-X
to	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
and	B-X
cancer	B-X
metastasis	B-X
.	B-X
To	B-X
elucidate	B-X
its	B-X
role	B-X
(	B-X
s	B-X
)	B-X
in	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
we	B-X
expressed	B-X
Snail	B-X
in	B-X
the	B-X
noninvasive	B-X
,	B-X
ER-alpha-positive	B-X
MCF-7	B-X
cell	B-X
line	B-X
.	B-X
Snail	B-X
expression	B-X
led	B-X
to	B-X
decreased	B-X
cell-cell	B-X
adhesion	B-X
and	B-X
increased	B-X
cell	B-X
invasiveness	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
loss	B-X
of	B-X
ER-alpha	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
RNA	B-X
and	B-X
protein	B-X
level	B-X
that	B-X
was	B-X
accompanied	B-X
by	B-X
direct	B-X
interaction	B-X
of	B-X
Snail	B-X
with	B-X
regulatory	B-X
DNA	B-X
sequences	B-X
at	B-X
the	B-X
ESR1	B-X
locus	B-X
.	B-X
Thus	B-X
,	B-X
cross-talk	B-X
among	B-X
ER-alpha	B-X
,	B-X
Snail	B-X
,	B-X
and	B-X
the	B-X
TGF-beta	B-X
pathway	B-X
appears	B-X
to	B-X
control	B-X
critical	B-X
phenotypic	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

To	O
elucidate	O
its	O
role	O
(	O
s	O
)	O
in	O
epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
we	O
expressed	O
Snail	O
in	O
the	O
noninvasive	O
,	O
ER	B-Protein
-	I-Protein
alpha	I-Protein
-	O
positive	O
MCF	O
-	O
7	O
cell	O
line	O
.	O
<EOS>	B-X
The	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
-alpha	B-X
(	B-X
ESR1	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
molecule	B-X
in	B-X
mammary	B-X
epithelial	B-X
cell	B-X
development	B-X
.	B-X
Loss	B-X
of	B-X
ER-alpha	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
,	B-X
increased	B-X
recurrence	B-X
after	B-X
treatment	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
incidence	B-X
of	B-X
metastasis	B-X
.	B-X
A	B-X
proposed	B-X
molecular	B-X
pathway	B-X
by	B-X
which	B-X
ER-alpha	B-X
acts	B-X
to	B-X
constrain	B-X
invasive	B-X
growth	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
involves	B-X
direct	B-X
,	B-X
ER-alpha-dependent	B-X
expression	B-X
of	B-X
metastasis-associated	B-X
protein	B-X
3	B-X
,	B-X
a	B-X
cell-type-specific	B-X
component	B-X
of	B-X
the	B-X
Mi-2/NuRD	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
.	B-X
MTA3	B-X
in	B-X
turn	B-X
represses	B-X
expression	B-X
of	B-X
Snail	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
linked	B-X
to	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
and	B-X
cancer	B-X
metastasis	B-X
.	B-X
To	B-X
elucidate	B-X
its	B-X
role	B-X
(	B-X
s	B-X
)	B-X
in	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
we	B-X
expressed	B-X
Snail	B-X
in	B-X
the	B-X
noninvasive	B-X
,	B-X
ER-alpha-positive	B-X
MCF-7	B-X
cell	B-X
line	B-X
.	B-X
Snail	B-X
expression	B-X
led	B-X
to	B-X
decreased	B-X
cell-cell	B-X
adhesion	B-X
and	B-X
increased	B-X
cell	B-X
invasiveness	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
loss	B-X
of	B-X
ER-alpha	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
RNA	B-X
and	B-X
protein	B-X
level	B-X
that	B-X
was	B-X
accompanied	B-X
by	B-X
direct	B-X
interaction	B-X
of	B-X
Snail	B-X
with	B-X
regulatory	B-X
DNA	B-X
sequences	B-X
at	B-X
the	B-X
ESR1	B-X
locus	B-X
.	B-X
A	B-X
consequence	B-X
of	B-X
loss	B-X
of	B-X
ER-alpha	B-X
function	B-X
in	B-X
this	B-X
system	B-X
was	B-X
the	B-X
increased	B-X
abundance	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TGF-beta	B-X
signaling	B-X
pathway	B-X
.	B-X
Thus	B-X
,	B-X
cross-talk	B-X
among	B-X
ER-alpha	B-X
,	B-X
Snail	B-X
,	B-X
and	B-X
the	B-X
TGF-beta	B-X
pathway	B-X
appears	B-X
to	B-X
control	B-X
critical	B-X
phenotypic	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

Snail	O
expression	O
led	O
to	O
decreased	O
cell	O
-	O
cell	O
adhesion	O
and	O
increased	O
cell	O
invasiveness	O
.	O
<EOS>	B-X
Adhesion	B-X
of	B-X
epithelial	B-X
cell	B-X
to	B-X
each	B-X
other	B-X
and	B-X
to	B-X
extracellular	B-X
matrix	B-X
,	B-X
as	B-X
well	B-X
as	B-X
cell	B-X
migration	B-X
ability	B-X
and	B-X
cytoskeleton	B-X
organization	B-X
undergo	B-X
significant	B-X
alterations	B-X
in	B-X
the	B-X
course	B-X
of	B-X
neoplastic	B-X
transformation	B-X
,	B-X
but	B-X
regulatory	B-X
mechanisms	B-X
involved	B-X
in	B-X
these	B-X
processes	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
role	B-X
of	B-X
a	B-X
Rho	B-X
GAP	B-X
protein	B-X
GRAF1	B-X
(	B-X
GTPase	B-X
Regulator	B-X
Associated	B-X
with	B-X
Focal	B-X
adhesion	B-X
kinase-1	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
epithelial	B-X
phenotype	B-X
in	B-X
cells	B-X
of	B-X
breast	B-X
derived	B-X
,	B-X
non-malignant	B-X
,	B-X
MCF10A	B-X
cell	B-X
line	B-X
.	B-X
GRAF1	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
localized	B-X
to	B-X
cell-cell	B-X
junctions	B-X
,	B-X
and	B-X
its	B-X
depletion	B-X
resulted	B-X
in	B-X
accelerated	B-X
cell	B-X
migration	B-X
velocity	B-X
,	B-X
elongation	B-X
of	B-X
the	B-X
cells	B-X
and	B-X
cell	B-X
colonies	B-X
,	B-X
impaired	B-X
monolayer	B-X
integrity	B-X
and	B-X
significant	B-X
disruption	B-X
of	B-X
desmosomes	B-X
with	B-X
a	B-X
loss	B-X
of	B-X
associated	B-X
keratin	B-X
filaments	B-X
.	B-X
These	B-X
processes	B-X
were	B-X
accompanied	B-X
by	B-X
formation	B-X
of	B-X
larger	B-X
focal	B-X
adhesions	B-X
,	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
contractile	B-X
actin	B-X
stress	B-X
fibers	B-X
,	B-X
reduction	B-X
in	B-X
epithelial	B-X
markers	B-X
and	B-X
increase	B-X
in	B-X
mesenchymal	B-X
markers	B-X
such	B-X
as	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
-specific	B-X
transcription	B-X
factors	B-X
Snail-1	B-X
and	B-X
Snail-2	B-X
,	B-X
as	B-X
well	B-X
as	B-X
N-cadherin	B-X
,	B-X
and	B-X
vimentin	B-X
.	B-X
Moreover	B-X
,	B-X
unlike	B-X
control	B-X
cells	B-X
,	B-X
GRAF1	B-X
knocked-down	B-X
cells	B-X
demonstrated	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
GRAF1	B-X
expression	B-X
in	B-X
several	B-X
highly	B-X
invasive	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
was	B-X
low	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
non-malignant	B-X
MCF10A	B-X
cells	B-X
,	B-X
while	B-X
overexpressing	B-X
of	B-X
GRAF1	B-X
in	B-X
the	B-X
malignant	B-X
BT-549	B-X
cell	B-X
line	B-X
led	B-X
to	B-X
a	B-X
decrease	B-X
of	B-X
mesenchymal	B-X
markers	B-X
,	B-X
especially	B-X
the	B-X
Snail-1	B-X
and	B-X
2	B-X
.	B-X

Furthermore	O
,	O
we	O
observed	O
loss	O
of	O
ER	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
at	O
both	O
the	O
RNA	O
and	O
protein	O
level	O
that	O
was	O
accompanied	O
by	O
direct	O
interaction	O
of	O
Snail	O
with	O
regulatory	O
DNA	O
sequences	O
at	O
the	O
ESR1	B-Protein
locus	O
.	O
<EOS>	B-X
The	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
-alpha	B-X
(	B-X
ESR1	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
molecule	B-X
in	B-X
mammary	B-X
epithelial	B-X
cell	B-X
development	B-X
.	B-X
Loss	B-X
of	B-X
ER-alpha	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
,	B-X
increased	B-X
recurrence	B-X
after	B-X
treatment	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
incidence	B-X
of	B-X
metastasis	B-X
.	B-X
A	B-X
proposed	B-X
molecular	B-X
pathway	B-X
by	B-X
which	B-X
ER-alpha	B-X
acts	B-X
to	B-X
constrain	B-X
invasive	B-X
growth	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
involves	B-X
direct	B-X
,	B-X
ER-alpha-dependent	B-X
expression	B-X
of	B-X
metastasis-associated	B-X
protein	B-X
3	B-X
,	B-X
a	B-X
cell-type-specific	B-X
component	B-X
of	B-X
the	B-X
Mi-2/NuRD	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
.	B-X
MTA3	B-X
in	B-X
turn	B-X
represses	B-X
expression	B-X
of	B-X
Snail	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
linked	B-X
to	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
and	B-X
cancer	B-X
metastasis	B-X
.	B-X
To	B-X
elucidate	B-X
its	B-X
role	B-X
(	B-X
s	B-X
)	B-X
in	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
we	B-X
expressed	B-X
Snail	B-X
in	B-X
the	B-X
noninvasive	B-X
,	B-X
ER-alpha-positive	B-X
MCF-7	B-X
cell	B-X
line	B-X
.	B-X
Snail	B-X
expression	B-X
led	B-X
to	B-X
decreased	B-X
cell-cell	B-X
adhesion	B-X
and	B-X
increased	B-X
cell	B-X
invasiveness	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
loss	B-X
of	B-X
ER-alpha	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
RNA	B-X
and	B-X
protein	B-X
level	B-X
that	B-X
was	B-X
accompanied	B-X
by	B-X
direct	B-X
interaction	B-X
of	B-X
Snail	B-X
with	B-X
regulatory	B-X
DNA	B-X
sequences	B-X
at	B-X
the	B-X
ESR1	B-X
locus	B-X
.	B-X
A	B-X
consequence	B-X
of	B-X
loss	B-X
of	B-X
ER-alpha	B-X
function	B-X
in	B-X
this	B-X
system	B-X
was	B-X
the	B-X
increased	B-X
abundance	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TGF-beta	B-X
signaling	B-X
pathway	B-X
.	B-X
Thus	B-X
,	B-X
cross-talk	B-X
among	B-X
ER-alpha	B-X
,	B-X
Snail	B-X
,	B-X
and	B-X
the	B-X
TGF-beta	B-X
pathway	B-X
appears	B-X
to	B-X
control	B-X
critical	B-X
phenotypic	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

A	O
consequence	O
of	O
loss	O
of	O
ER	B-Protein
-	I-Protein
alpha	I-Protein
function	O
in	O
this	O
system	O
was	O
the	O
increased	O
abundance	O
of	O
key	O
components	O
of	O
the	O
TGF	O
-	O
beta	O
signaling	O
pathway	O
.	O
<EOS>	B-X
The	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
-alpha	B-X
(	B-X
ESR1	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
molecule	B-X
in	B-X
mammary	B-X
epithelial	B-X
cell	B-X
development	B-X
.	B-X
Loss	B-X
of	B-X
ER-alpha	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
,	B-X
increased	B-X
recurrence	B-X
after	B-X
treatment	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
incidence	B-X
of	B-X
metastasis	B-X
.	B-X
A	B-X
proposed	B-X
molecular	B-X
pathway	B-X
by	B-X
which	B-X
ER-alpha	B-X
acts	B-X
to	B-X
constrain	B-X
invasive	B-X
growth	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
involves	B-X
direct	B-X
,	B-X
ER-alpha-dependent	B-X
expression	B-X
of	B-X
metastasis-associated	B-X
protein	B-X
3	B-X
,	B-X
a	B-X
cell-type-specific	B-X
component	B-X
of	B-X
the	B-X
Mi-2/NuRD	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
.	B-X
To	B-X
elucidate	B-X
its	B-X
role	B-X
(	B-X
s	B-X
)	B-X
in	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
we	B-X
expressed	B-X
Snail	B-X
in	B-X
the	B-X
noninvasive	B-X
,	B-X
ER-alpha-positive	B-X
MCF-7	B-X
cell	B-X
line	B-X
.	B-X
Snail	B-X
expression	B-X
led	B-X
to	B-X
decreased	B-X
cell-cell	B-X
adhesion	B-X
and	B-X
increased	B-X
cell	B-X
invasiveness	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
loss	B-X
of	B-X
ER-alpha	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
RNA	B-X
and	B-X
protein	B-X
level	B-X
that	B-X
was	B-X
accompanied	B-X
by	B-X
direct	B-X
interaction	B-X
of	B-X
Snail	B-X
with	B-X
regulatory	B-X
DNA	B-X
sequences	B-X
at	B-X
the	B-X
ESR1	B-X
locus	B-X
.	B-X
A	B-X
consequence	B-X
of	B-X
loss	B-X
of	B-X
ER-alpha	B-X
function	B-X
in	B-X
this	B-X
system	B-X
was	B-X
the	B-X
increased	B-X
abundance	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TGF-beta	B-X
signaling	B-X
pathway	B-X
.	B-X
Thus	B-X
,	B-X
cross-talk	B-X
among	B-X
ER-alpha	B-X
,	B-X
Snail	B-X
,	B-X
and	B-X
the	B-X
TGF-beta	B-X
pathway	B-X
appears	B-X
to	B-X
control	B-X
critical	B-X
phenotypic	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

Thus	O
,	O
cross	O
-	O
talk	O
among	O
ER	B-Protein
-	I-Protein
alpha	I-Protein
,	O
Snail	O
,	O
and	O
the	O
TGF	O
-	O
beta	O
pathway	O
appears	O
to	O
control	O
critical	O
phenotypic	O
properties	O
of	O
breast	O
cancer	O
cells	O
.	O
<EOS>	B-X
The	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
-alpha	B-X
(	B-X
ESR1	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
molecule	B-X
in	B-X
mammary	B-X
epithelial	B-X
cell	B-X
development	B-X
.	B-X
Loss	B-X
of	B-X
ER-alpha	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
,	B-X
increased	B-X
recurrence	B-X
after	B-X
treatment	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
incidence	B-X
of	B-X
metastasis	B-X
.	B-X
A	B-X
proposed	B-X
molecular	B-X
pathway	B-X
by	B-X
which	B-X
ER-alpha	B-X
acts	B-X
to	B-X
constrain	B-X
invasive	B-X
growth	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
involves	B-X
direct	B-X
,	B-X
ER-alpha-dependent	B-X
expression	B-X
of	B-X
metastasis-associated	B-X
protein	B-X
3	B-X
,	B-X
a	B-X
cell-type-specific	B-X
component	B-X
of	B-X
the	B-X
Mi-2/NuRD	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
.	B-X
MTA3	B-X
in	B-X
turn	B-X
represses	B-X
expression	B-X
of	B-X
Snail	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
linked	B-X
to	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
and	B-X
cancer	B-X
metastasis	B-X
.	B-X
To	B-X
elucidate	B-X
its	B-X
role	B-X
(	B-X
s	B-X
)	B-X
in	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
we	B-X
expressed	B-X
Snail	B-X
in	B-X
the	B-X
noninvasive	B-X
,	B-X
ER-alpha-positive	B-X
MCF-7	B-X
cell	B-X
line	B-X
.	B-X
Snail	B-X
expression	B-X
led	B-X
to	B-X
decreased	B-X
cell-cell	B-X
adhesion	B-X
and	B-X
increased	B-X
cell	B-X
invasiveness	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
loss	B-X
of	B-X
ER-alpha	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
RNA	B-X
and	B-X
protein	B-X
level	B-X
that	B-X
was	B-X
accompanied	B-X
by	B-X
direct	B-X
interaction	B-X
of	B-X
Snail	B-X
with	B-X
regulatory	B-X
DNA	B-X
sequences	B-X
at	B-X
the	B-X
ESR1	B-X
locus	B-X
.	B-X
A	B-X
consequence	B-X
of	B-X
loss	B-X
of	B-X
ER-alpha	B-X
function	B-X
in	B-X
this	B-X
system	B-X
was	B-X
the	B-X
increased	B-X
abundance	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TGF-beta	B-X
signaling	B-X
pathway	B-X
.	B-X
Thus	B-X
,	B-X
cross-talk	B-X
among	B-X
ER-alpha	B-X
,	B-X
Snail	B-X
,	B-X
and	B-X
the	B-X
TGF-beta	B-X
pathway	B-X
appears	B-X
to	B-X
control	B-X
critical	B-X
phenotypic	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

DNA	O
stool	O
test	O
for	O
colorectal	O
cancer	O
:	O
hypermethylation	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
gene	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
a	B-X
potential	B-X
mode	B-X
of	B-X
noninvasive	B-X
screening	B-X
for	B-X
colorectal	B-X
cancer	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
hypermethylation	B-X
of	B-X
the	B-X
secreted	B-X
frizzled-related	B-X
protein-1	B-X
gene	B-X
promoter	B-X
in	B-X
human	B-X
stool	B-X
DNA	B-X
.	B-X

PURPOSE	O
:	O
To	O
investigate	O
a	O
potential	O
mode	O
of	O
noninvasive	O
screening	O
for	O
colorectal	O
cancer	O
,	O
we	O
evaluated	O
the	O
hypermethylation	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
gene	O
promoter	O
in	O
human	O
stool	O
DNA	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
a	B-X
potential	B-X
mode	B-X
of	B-X
noninvasive	B-X
screening	B-X
for	B-X
colorectal	B-X
cancer	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
hypermethylation	B-X
of	B-X
the	B-X
secreted	B-X
frizzled-related	B-X
protein-1	B-X
gene	B-X
promoter	B-X
in	B-X
human	B-X
stool	B-X
DNA	B-X
.	B-X

METHODS	O
:	O
In	O
stool	O
samples	O
from	O
36	O
patients	O
with	O
colorectal	O
neoplasia	O
(	O
7	O
adenoma	O
,	O
29	O
colorectal	O
cancer	O
)	O
and	O
17	O
healthy	O
control	O
subjects	O
,	O
isolated	O
DNA	O
was	O
treated	O
with	O
sodium	O
bisulfite	O
and	O
analyzed	O
by	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
with	O
primers	O
specific	O
for	O
methylated	O
or	O
unmethylated	O
promoter	O
sequences	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
gene	O
.	O
<EOS>	B-X
Background	B-X
:	B-X
The	B-X
development	B-X
of	B-X
colorectal	B-X
carcinoma	B-X
(	B-X
CRC	B-X
)	B-X
involves	B-X
many	B-X
genetic	B-X
and	B-X
epigenetic	B-X
alterations	B-X
and	B-X
methylation	B-X
being	B-X
an	B-X
important	B-X
epigenetic	B-X
event	B-X
has	B-X
been	B-X
described	B-X
as	B-X
a	B-X
diagnostic	B-X
and	B-X
prognostic	B-X
biomarker	B-X
.	B-X
Secreted	B-X
Frizzled-	B-X
Related	B-X
Protein	B-X
1	B-X
(	B-X
SFRP1	B-X
)	B-X
gene	B-X
regulates	B-X
diverse	B-X
physiological	B-X
processes	B-X
via	B-X
the	B-X
Wnt	B-X
signaling	B-X
.	B-X
Promoter	B-X
hypermethylation	B-X
of	B-X
SFRP1	B-X
gene	B-X
is	B-X
an	B-X
epigenetic	B-X
regulation	B-X
mechanism	B-X
that	B-X
downregulates	B-X
SFRP1	B-X
protein	B-X
level	B-X
in	B-X
the	B-X
tumor	B-X
,	B-X
and	B-X
happens	B-X
to	B-X
be	B-X
one	B-X
of	B-X
the	B-X
significant	B-X
events	B-X
in	B-X
colorectal	B-X
carcinogenesis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
clinicopathological	B-X
relationship	B-X
of	B-X
CRC	B-X
including	B-X
survival	B-X
outcomes	B-X
with	B-X
SFRP1	B-X
gene	B-X
promoter	B-X
methylation	B-X
.	B-X
Methods	B-X
:	B-X
We	B-X
evaluated	B-X
promoter	B-X
methylation	B-X
status	B-X
of	B-X
SFRP1	B-X
gene	B-X
by	B-X
methylation-specific	B-X
PCR	B-X
(	B-X
MS-PCR	B-X
)	B-X
in	B-X
the	B-X
tumor	B-X
tissue	B-X
in	B-X
54	B-X
cases	B-X
of	B-X
stage	B-X
II-III	B-X
CRC	B-X
patients	B-X
in	B-X
north	B-X
India	B-X
.	B-X
The	B-X
MS-PCR	B-X
result	B-X
was	B-X
further	B-X
validated	B-X
by	B-X
bisulfite	B-X
sequencing	B-X
.	B-X
Results	B-X
:	B-X
SFRP1	B-X
gene	B-X
was	B-X
methylated	B-X
in	B-X
72.2	B-X
%	B-X
cases	B-X
and	B-X
un-methylated	B-X
in	B-X
27.8	B-X
%	B-X
.	B-X
We	B-X
found	B-X
,	B-X
that	B-X
SFRP1	B-X
gene	B-X
methylation	B-X
in	B-X
tumor	B-X
was	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
invasion	B-X
(	B-X
p=0.05	B-X
)	B-X
.	B-X
The	B-X
mean	B-X
overall	B-X
survival	B-X
was	B-X
22.318	B-X
months	B-X
and	B-X
45.173	B-X
months	B-X
respectively	B-X
for	B-X
patients	B-X
with	B-X
methylated	B-X
and	B-X
unmethylated	B-X
SFRP1	B-X
gene	B-X
(	B-X
p=	B-X
0.010	B-X
,	B-X
log	B-X
rank	B-X
test	B-X
)	B-X
,	B-X
(	B-X
HR	B-X
=	B-X
17.313	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
2.021-148.290	B-X
P=0.009	B-X
)	B-X
.	B-X
Conclusion	B-X
:	B-X
Study	B-X
indicates	B-X
that	B-X
promoter	B-X
methylation	B-X
of	B-X
SFRP1	B-X
gene	B-X
is	B-X
associated	B-X
with	B-X
lymph-node	B-X
metastasis	B-X
and	B-X
poor	B-X
mean	B-X
overall	B-X
survival	B-X
and	B-X
it	B-X
can	B-X
be	B-X
a	B-X
prognostic	B-X
marker	B-X
in	B-X
CRC	B-X
.	B-X

RESULTS	O
:	O
Hypermethylation	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
promoter	O
was	O
present	O
in	O
the	O
stool	O
DNA	O
of	O
patients	O
with	O
adenoma	O
and	O
colorectal	O
cancer	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
a	B-X
potential	B-X
mode	B-X
of	B-X
noninvasive	B-X
screening	B-X
for	B-X
colorectal	B-X
cancer	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
hypermethylation	B-X
of	B-X
the	B-X
secreted	B-X
frizzled-related	B-X
protein-1	B-X
gene	B-X
promoter	B-X
in	B-X
human	B-X
stool	B-X
DNA	B-X
.	B-X

A	O
sensitivity	O
of	O
89	O
percent	O
and	O
specificity	O
of	O
86	O
percent	O
were	O
achieved	O
in	O
the	O
detection	O
of	O
colorectal	O
neoplasia	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
a	B-X
potential	B-X
mode	B-X
of	B-X
noninvasive	B-X
screening	B-X
for	B-X
colorectal	B-X
cancer	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
hypermethylation	B-X
of	B-X
the	B-X
secreted	B-X
frizzled-related	B-X
protein-1	B-X
gene	B-X
promoter	B-X
in	B-X
human	B-X
stool	B-X
DNA	B-X
.	B-X

The	O
difference	O
in	O
hypermethylation	O
status	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
promoter	O
between	O
the	O
patients	O
with	O
colorectal	O
neoplasia	O
and	O
the	O
control	O
group	O
was	O
statistically	O
highly	O
significant	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Adenoma	O
and	O
early	O
tumor	O
Stage	O
I	O
(	O
International	O
Union	O
Against	O
Cancer	O
)	O
displayed	O
both	O
unmethylated	O
and	O
methylated	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
promoter	O
sequences	O
,	O
whereas	O
advanced	O
tumor	O
stages	O
showed	O
only	O
methylated	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
indicate	O
that	O
this	O
DNA	O
stool	O
test	O
of	O
hypermethylation	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
promoter	O
is	O
a	O
sensitive	O
and	O
specific	O
method	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
a	B-X
potential	B-X
mode	B-X
of	B-X
noninvasive	B-X
screening	B-X
for	B-X
colorectal	B-X
cancer	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
hypermethylation	B-X
of	B-X
the	B-X
secreted	B-X
frizzled-related	B-X
protein-1	B-X
gene	B-X
promoter	B-X
in	B-X
human	B-X
stool	B-X
DNA	B-X
.	B-X

It	O
has	O
the	O
potential	O
of	O
a	O
clinically	O
useful	O
test	O
for	O
the	O
early	O
detection	O
of	O
colorectal	O
cancer	O
.	O
<EOS>	B-X
Colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
incidence	B-X
and	B-X
mortality	B-X
can	B-X
be	B-X
significantly	B-X
reduced	B-X
by	B-X
population	B-X
screening	B-X
.	B-X
The	B-X
challenges	B-X
and	B-X
logistics	B-X
of	B-X
CTC	B-X
screening	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
importance	B-X
of	B-X
test	B-X
accuracy	B-X
,	B-X
uptake	B-X
,	B-X
quality	B-X
assurance	B-X
and	B-X
cost-effectiveness	B-X
will	B-X
be	B-X
discussed	B-X
.	B-X
With	B-X
comparable	B-X
advanced	B-X
adenoma	B-X
detection	B-X
rates	B-X
to	B-X
colonoscopy	B-X
(	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
whole-colon	B-X
investigation	B-X
)	B-X
,	B-X
CTC	B-X
is	B-X
a	B-X
less-invasive	B-X
alternative	B-X
,	B-X
requiring	B-X
less	B-X
laxative	B-X
,	B-X
and	B-X
with	B-X
the	B-X
potential	B-X
benefit	B-X
that	B-X
it	B-X
permits	B-X
assessment	B-X
of	B-X
extra	B-X
colonic	B-X
structures	B-X
.	B-X
Future	B-X
research	B-X
into	B-X
CTC-screening	B-X
will	B-X
likely	B-X
focus	B-X
on	B-X
radiologist	B-X
training	B-X
and	B-X
CTC	B-X
quality	B-X
assurance	B-X
,	B-X
with	B-X
identification	B-X
of	B-X
evidence-based	B-X
key	B-X
performance	B-X
indicators	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
clinically-relevant	B-X
outcomes	B-X
such	B-X
as	B-X
the	B-X
incidence	B-X
of	B-X
post-test	B-X
interval	B-X
cancers	B-X
(	B-X
CRC	B-X
occurring	B-X
after	B-X
a	B-X
presumed	B-X
negative	B-X
CTC	B-X
)	B-X
.	B-X
In	B-X
comparison	B-X
to	B-X
other	B-X
CRC	B-X
screening	B-X
techniques	B-X
,	B-X
CTC	B-X
offers	B-X
a	B-X
safe	B-X
and	B-X
accurate	B-X
option	B-X
that	B-X
is	B-X
particularly	B-X
useful	B-X
when	B-X
colonoscopy	B-X
is	B-X
contraindicated	B-X
.	B-X
Forthcoming	B-X
cost-effectiveness	B-X
analyses	B-X
which	B-X
evaluate	B-X
referral	B-X
thresholds	B-X
,	B-X
the	B-X
impact	B-X
of	B-X
extra-colonic	B-X
findings	B-X
and	B-X
real-world	B-X
uptake	B-X
will	B-X
provide	B-X
useful	B-X
information	B-X
regarding	B-X
the	B-X
feasibility	B-X
of	B-X
future	B-X
CTC	B-X
population	B-X
screening	B-X
.	B-X

Characterization	O
of	O
a	O
novel	O
Cullin5	B-Protein
binding	O
domain	O
in	O
HIV	O
-	O
1	O
Vif	B-Protein
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
tyoe	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
Vif	B-X
counteracts	B-X
host	B-X
restriction	B-X
cytidine	B-X
deaminase	B-X
(	B-X
APOBEC3G	B-X
)	B-X
A3G	B-X
by	B-X
co-opting	B-X
the	B-X
cellular	B-X
ubiquitin-proteasome	B-X
machinery	B-X
.	B-X
Vif	B-X
utilizes	B-X
a	B-X
viral-specific	B-X
BC-box	B-X
to	B-X
recruit	B-X
ElonginB-ElonginC	B-X
and	B-X
a	B-X
novel	B-X
zinc-binding	B-X
HCCH	B-X
motif	B-X
to	B-X
recruit	B-X
Cullin5	B-X
(	B-X
Cul5	B-X
)	B-X
to	B-X
form	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
targeting	B-X
A3G	B-X
for	B-X
polyubiquitination	B-X
and	B-X
subsequently	B-X
proteasomal	B-X
degradation	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
structural	B-X
requirements	B-X
in	B-X
HIV-1	B-X
Vif	B-X
HCCH	B-X
motif	B-X
for	B-X
Cul5	B-X
binding	B-X
and	B-X
Vif	B-X
function	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
arrangement	B-X
of	B-X
the	B-X
His	B-X
and	B-X
Cys	B-X
residues	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
spacing	B-X
between	B-X
them	B-X
,	B-X
and	B-X
the	B-X
requirement	B-X
for	B-X
the	B-X
conserved	B-X
residues	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
exchanging	B-X
Cys	B-X
for	B-X
His	B-X
and	B-X
vice	B-X
versa	B-X
in	B-X
the	B-X
highly	B-X
conserved	B-X
Zn-coordinating	B-X
HCCH	B-X
motif	B-X
disrupted	B-X
Vif	B-X
function	B-X
and	B-X
interaction	B-X
with	B-X
Cul5	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
maintenance	B-X
of	B-X
both	B-X
conserved	B-X
residues	B-X
and	B-X
spacing	B-X
within	B-X
the	B-X
HCCH	B-X
motif	B-X
is	B-X
critical	B-X
for	B-X
Vif	B-X
function	B-X
.	B-X
This	B-X
novel	B-X
motif	B-X
may	B-X
represent	B-X
a	B-X
potential	B-X
new	B-X
target	B-X
for	B-X
anti-viral	B-X
drug	B-X
development	B-X
.	B-X

Human	O
immunodeficiency	O
virus	O
tyoe	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Vif	O
counteracts	O
host	O
restriction	O
cytidine	O
deaminase	O
(	O
APOBEC3G	B-Protein
)	O
A3G	B-Protein
by	O
co	O
-	O
opting	O
the	O
cellular	O
ubiquitin	B-Protein
-	O
proteasome	O
machinery	O
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
tyoe	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
Vif	B-X
counteracts	B-X
host	B-X
restriction	B-X
cytidine	B-X
deaminase	B-X
(	B-X
APOBEC3G	B-X
)	B-X
A3G	B-X
by	B-X
co-opting	B-X
the	B-X
cellular	B-X
ubiquitin-proteasome	B-X
machinery	B-X
.	B-X
Vif	B-X
utilizes	B-X
a	B-X
viral-specific	B-X
BC-box	B-X
to	B-X
recruit	B-X
ElonginB-ElonginC	B-X
and	B-X
a	B-X
novel	B-X
zinc-binding	B-X
HCCH	B-X
motif	B-X
to	B-X
recruit	B-X
Cullin5	B-X
(	B-X
Cul5	B-X
)	B-X
to	B-X
form	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
targeting	B-X
A3G	B-X
for	B-X
polyubiquitination	B-X
and	B-X
subsequently	B-X
proteasomal	B-X
degradation	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
structural	B-X
requirements	B-X
in	B-X
HIV-1	B-X
Vif	B-X
HCCH	B-X
motif	B-X
for	B-X
Cul5	B-X
binding	B-X
and	B-X
Vif	B-X
function	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
arrangement	B-X
of	B-X
the	B-X
His	B-X
and	B-X
Cys	B-X
residues	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
spacing	B-X
between	B-X
them	B-X
,	B-X
and	B-X
the	B-X
requirement	B-X
for	B-X
the	B-X
conserved	B-X
residues	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
exchanging	B-X
Cys	B-X
for	B-X
His	B-X
and	B-X
vice	B-X
versa	B-X
in	B-X
the	B-X
highly	B-X
conserved	B-X
Zn-coordinating	B-X
HCCH	B-X
motif	B-X
disrupted	B-X
Vif	B-X
function	B-X
and	B-X
interaction	B-X
with	B-X
Cul5	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
maintenance	B-X
of	B-X
both	B-X
conserved	B-X
residues	B-X
and	B-X
spacing	B-X
within	B-X
the	B-X
HCCH	B-X
motif	B-X
is	B-X
critical	B-X
for	B-X
Vif	B-X
function	B-X
.	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
``	B-X
viral	B-X
Cul5	B-X
box	B-X
''	B-X
with	B-X
consensus	B-X
Hx2YFxCFx4Phix2APhix7-8Cx5H	B-X
that	B-X
is	B-X
required	B-X
for	B-X
Cul5	B-X
selection	B-X
and	B-X
subsequent	B-X
A3G	B-X
degradation	B-X
.	B-X

Vif	B-Protein
utilizes	O
a	O
viral	O
-	O
specific	O
BC	O
-	O
box	O
to	O
recruit	O
ElonginB	B-Protein
-	O
ElonginC	B-Protein
and	O
a	O
novel	O
zinc	O
-	O
binding	O
HCCH	O
motif	O
to	O
recruit	O
Cullin5	B-Protein
(	O
Cul5	B-Protein
)	O
to	O
form	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
targeting	O
A3G	B-Protein
for	O
polyubiquitination	O
and	O
subsequently	O
proteasomal	O
degradation	O
.	O

To	O
determine	O
the	O
structural	O
requirements	O
in	O
HIV	O
-	O
1	O
Vif	O
HCCH	O
motif	O
for	O
Cul5	B-Protein
binding	O
and	O
Vif	B-Protein
function	O
,	O
we	O
investigated	O
the	O
arrangement	O
of	O
the	O
His	O
and	O
Cys	O
residues	O
,	O
the	O
role	O
of	O
the	O
spacing	O
between	O
them	O
,	O
and	O
the	O
requirement	O
for	O
the	O
conserved	O
residues	O
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
tyoe	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
Vif	B-X
counteracts	B-X
host	B-X
restriction	B-X
cytidine	B-X
deaminase	B-X
(	B-X
APOBEC3G	B-X
)	B-X
A3G	B-X
by	B-X
co-opting	B-X
the	B-X
cellular	B-X
ubiquitin-proteasome	B-X
machinery	B-X
.	B-X
Vif	B-X
utilizes	B-X
a	B-X
viral-specific	B-X
BC-box	B-X
to	B-X
recruit	B-X
ElonginB-ElonginC	B-X
and	B-X
a	B-X
novel	B-X
zinc-binding	B-X
HCCH	B-X
motif	B-X
to	B-X
recruit	B-X
Cullin5	B-X
(	B-X
Cul5	B-X
)	B-X
to	B-X
form	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
targeting	B-X
A3G	B-X
for	B-X
polyubiquitination	B-X
and	B-X
subsequently	B-X
proteasomal	B-X
degradation	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
structural	B-X
requirements	B-X
in	B-X
HIV-1	B-X
Vif	B-X
HCCH	B-X
motif	B-X
for	B-X
Cul5	B-X
binding	B-X
and	B-X
Vif	B-X
function	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
arrangement	B-X
of	B-X
the	B-X
His	B-X
and	B-X
Cys	B-X
residues	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
spacing	B-X
between	B-X
them	B-X
,	B-X
and	B-X
the	B-X
requirement	B-X
for	B-X
the	B-X
conserved	B-X
residues	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
exchanging	B-X
Cys	B-X
for	B-X
His	B-X
and	B-X
vice	B-X
versa	B-X
in	B-X
the	B-X
highly	B-X
conserved	B-X
Zn-coordinating	B-X
HCCH	B-X
motif	B-X
disrupted	B-X
Vif	B-X
function	B-X
and	B-X
interaction	B-X
with	B-X
Cul5	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
maintenance	B-X
of	B-X
both	B-X
conserved	B-X
residues	B-X
and	B-X
spacing	B-X
within	B-X
the	B-X
HCCH	B-X
motif	B-X
is	B-X
critical	B-X
for	B-X
Vif	B-X
function	B-X
.	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
``	B-X
viral	B-X
Cul5	B-X
box	B-X
''	B-X
with	B-X
consensus	B-X
Hx2YFxCFx4Phix2APhix7-8Cx5H	B-X
that	B-X
is	B-X
required	B-X
for	B-X
Cul5	B-X
selection	B-X
and	B-X
subsequent	B-X
A3G	B-X
degradation	B-X
.	B-X
This	B-X
novel	B-X
motif	B-X
may	B-X
represent	B-X
a	B-X
potential	B-X
new	B-X
target	B-X
for	B-X
anti-viral	B-X
drug	B-X
development	B-X
.	B-X

Our	O
data	O
demonstrate	O
that	O
exchanging	O
Cys	O
for	O
His	O
and	O
vice	O
versa	O
in	O
the	O
highly	O
conserved	O
Zn	O
-	O
coordinating	O
HCCH	O
motif	O
disrupted	O
Vif	B-Protein
function	O
and	O
interaction	O
with	O
Cul5	B-Protein
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
tyoe	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
Vif	B-X
counteracts	B-X
host	B-X
restriction	B-X
cytidine	B-X
deaminase	B-X
(	B-X
APOBEC3G	B-X
)	B-X
A3G	B-X
by	B-X
co-opting	B-X
the	B-X
cellular	B-X
ubiquitin-proteasome	B-X
machinery	B-X
.	B-X
Vif	B-X
utilizes	B-X
a	B-X
viral-specific	B-X
BC-box	B-X
to	B-X
recruit	B-X
ElonginB-ElonginC	B-X
and	B-X
a	B-X
novel	B-X
zinc-binding	B-X
HCCH	B-X
motif	B-X
to	B-X
recruit	B-X
Cullin5	B-X
(	B-X
Cul5	B-X
)	B-X
to	B-X
form	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
targeting	B-X
A3G	B-X
for	B-X
polyubiquitination	B-X
and	B-X
subsequently	B-X
proteasomal	B-X
degradation	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
structural	B-X
requirements	B-X
in	B-X
HIV-1	B-X
Vif	B-X
HCCH	B-X
motif	B-X
for	B-X
Cul5	B-X
binding	B-X
and	B-X
Vif	B-X
function	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
arrangement	B-X
of	B-X
the	B-X
His	B-X
and	B-X
Cys	B-X
residues	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
spacing	B-X
between	B-X
them	B-X
,	B-X
and	B-X
the	B-X
requirement	B-X
for	B-X
the	B-X
conserved	B-X
residues	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
exchanging	B-X
Cys	B-X
for	B-X
His	B-X
and	B-X
vice	B-X
versa	B-X
in	B-X
the	B-X
highly	B-X
conserved	B-X
Zn-coordinating	B-X
HCCH	B-X
motif	B-X
disrupted	B-X
Vif	B-X
function	B-X
and	B-X
interaction	B-X
with	B-X
Cul5	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
maintenance	B-X
of	B-X
both	B-X
conserved	B-X
residues	B-X
and	B-X
spacing	B-X
within	B-X
the	B-X
HCCH	B-X
motif	B-X
is	B-X
critical	B-X
for	B-X
Vif	B-X
function	B-X
.	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
``	B-X
viral	B-X
Cul5	B-X
box	B-X
''	B-X
with	B-X
consensus	B-X
Hx2YFxCFx4Phix2APhix7-8Cx5H	B-X
that	B-X
is	B-X
required	B-X
for	B-X
Cul5	B-X
selection	B-X
and	B-X
subsequent	B-X
A3G	B-X
degradation	B-X
.	B-X
This	B-X
novel	B-X
motif	B-X
may	B-X
represent	B-X
a	B-X
potential	B-X
new	B-X
target	B-X
for	B-X
anti-viral	B-X
drug	B-X
development	B-X
.	B-X

Moreover	O
,	O
the	O
maintenance	O
of	O
both	O
conserved	O
residues	O
and	O
spacing	O
within	O
the	O
HCCH	O
motif	O
is	O
critical	O
for	O
Vif	B-Protein
function	O
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
tyoe	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
Vif	B-X
counteracts	B-X
host	B-X
restriction	B-X
cytidine	B-X
deaminase	B-X
(	B-X
APOBEC3G	B-X
)	B-X
A3G	B-X
by	B-X
co-opting	B-X
the	B-X
cellular	B-X
ubiquitin-proteasome	B-X
machinery	B-X
.	B-X
Vif	B-X
utilizes	B-X
a	B-X
viral-specific	B-X
BC-box	B-X
to	B-X
recruit	B-X
ElonginB-ElonginC	B-X
and	B-X
a	B-X
novel	B-X
zinc-binding	B-X
HCCH	B-X
motif	B-X
to	B-X
recruit	B-X
Cullin5	B-X
(	B-X
Cul5	B-X
)	B-X
to	B-X
form	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
targeting	B-X
A3G	B-X
for	B-X
polyubiquitination	B-X
and	B-X
subsequently	B-X
proteasomal	B-X
degradation	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
structural	B-X
requirements	B-X
in	B-X
HIV-1	B-X
Vif	B-X
HCCH	B-X
motif	B-X
for	B-X
Cul5	B-X
binding	B-X
and	B-X
Vif	B-X
function	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
arrangement	B-X
of	B-X
the	B-X
His	B-X
and	B-X
Cys	B-X
residues	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
spacing	B-X
between	B-X
them	B-X
,	B-X
and	B-X
the	B-X
requirement	B-X
for	B-X
the	B-X
conserved	B-X
residues	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
exchanging	B-X
Cys	B-X
for	B-X
His	B-X
and	B-X
vice	B-X
versa	B-X
in	B-X
the	B-X
highly	B-X
conserved	B-X
Zn-coordinating	B-X
HCCH	B-X
motif	B-X
disrupted	B-X
Vif	B-X
function	B-X
and	B-X
interaction	B-X
with	B-X
Cul5	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
maintenance	B-X
of	B-X
both	B-X
conserved	B-X
residues	B-X
and	B-X
spacing	B-X
within	B-X
the	B-X
HCCH	B-X
motif	B-X
is	B-X
critical	B-X
for	B-X
Vif	B-X
function	B-X
.	B-X
This	B-X
novel	B-X
motif	B-X
may	B-X
represent	B-X
a	B-X
potential	B-X
new	B-X
target	B-X
for	B-X
anti-viral	B-X
drug	B-X
development	B-X
.	B-X

We	O
have	O
identified	O
a	O
"	O
viral	O
Cul5	B-Protein
box	O
"	O
with	O
consensus	O
Hx2YFxCFx4Phix2APhix7	O
-	O
8Cx5H	O
that	O
is	O
required	O
for	O
Cul5	B-Protein
selection	O
and	O
subsequent	O
A3G	B-Protein
degradation	O
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
tyoe	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
Vif	B-X
counteracts	B-X
host	B-X
restriction	B-X
cytidine	B-X
deaminase	B-X
(	B-X
APOBEC3G	B-X
)	B-X
A3G	B-X
by	B-X
co-opting	B-X
the	B-X
cellular	B-X
ubiquitin-proteasome	B-X
machinery	B-X
.	B-X
Vif	B-X
utilizes	B-X
a	B-X
viral-specific	B-X
BC-box	B-X
to	B-X
recruit	B-X
ElonginB-ElonginC	B-X
and	B-X
a	B-X
novel	B-X
zinc-binding	B-X
HCCH	B-X
motif	B-X
to	B-X
recruit	B-X
Cullin5	B-X
(	B-X
Cul5	B-X
)	B-X
to	B-X
form	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
targeting	B-X
A3G	B-X
for	B-X
polyubiquitination	B-X
and	B-X
subsequently	B-X
proteasomal	B-X
degradation	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
structural	B-X
requirements	B-X
in	B-X
HIV-1	B-X
Vif	B-X
HCCH	B-X
motif	B-X
for	B-X
Cul5	B-X
binding	B-X
and	B-X
Vif	B-X
function	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
arrangement	B-X
of	B-X
the	B-X
His	B-X
and	B-X
Cys	B-X
residues	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
spacing	B-X
between	B-X
them	B-X
,	B-X
and	B-X
the	B-X
requirement	B-X
for	B-X
the	B-X
conserved	B-X
residues	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
exchanging	B-X
Cys	B-X
for	B-X
His	B-X
and	B-X
vice	B-X
versa	B-X
in	B-X
the	B-X
highly	B-X
conserved	B-X
Zn-coordinating	B-X
HCCH	B-X
motif	B-X
disrupted	B-X
Vif	B-X
function	B-X
and	B-X
interaction	B-X
with	B-X
Cul5	B-X
.	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
``	B-X
viral	B-X
Cul5	B-X
box	B-X
''	B-X
with	B-X
consensus	B-X
Hx2YFxCFx4Phix2APhix7-8Cx5H	B-X
that	B-X
is	B-X
required	B-X
for	B-X
Cul5	B-X
selection	B-X
and	B-X
subsequent	B-X
A3G	B-X
degradation	B-X
.	B-X
This	B-X
novel	B-X
motif	B-X
may	B-X
represent	B-X
a	B-X
potential	B-X
new	B-X
target	B-X
for	B-X
anti-viral	B-X
drug	B-X
development	B-X
.	B-X

This	O
novel	O
motif	O
may	O
represent	O
a	O
potential	O
new	O
target	O
for	O
anti	O
-	O
viral	O
drug	O
development	O
.	O
<EOS>	B-X
They	B-X
control	B-X
essential	B-X
genes	B-X
in	B-X
many	B-X
pathogenic	B-X
bacteria	B-X
,	B-X
thus	B-X
representing	B-X
an	B-X
inviting	B-X
new	B-X
class	B-X
of	B-X
biomolecular	B-X
target	B-X
for	B-X
the	B-X
development	B-X
of	B-X
antibiotics	B-X
and	B-X
chemical-biological	B-X
tools	B-X
.	B-X
We	B-X
then	B-X
discuss	B-X
the	B-X
progress	B-X
achieved	B-X
so	B-X
far	B-X
in	B-X
using	B-X
riboswitches	B-X
as	B-X
a	B-X
focus	B-X
for	B-X
drug	B-X
discovery	B-X
,	B-X
considering	B-X
both	B-X
the	B-X
value	B-X
of	B-X
past	B-X
serendipity	B-X
and	B-X
the	B-X
particular	B-X
challenges	B-X
that	B-X
confront	B-X
current	B-X
researchers	B-X
.	B-X
Three-dimensional	B-X
structures	B-X
have	B-X
been	B-X
determined	B-X
for	B-X
representatives	B-X
of	B-X
13	B-X
structurally	B-X
distinct	B-X
riboswitch	B-X
classes	B-X
,	B-X
providing	B-X
atomic-level	B-X
insight	B-X
into	B-X
their	B-X
mechanisms	B-X
of	B-X
ligand	B-X
recognition	B-X
.	B-X
While	B-X
cellular	B-X
and	B-X
viral	B-X
RNAs	B-X
have	B-X
attracted	B-X
widespread	B-X
interest	B-X
as	B-X
potential	B-X
drug	B-X
targets	B-X
,	B-X
riboswitches	B-X
show	B-X
special	B-X
promise	B-X
due	B-X
to	B-X
the	B-X
diversity	B-X
of	B-X
small-molecule	B-X
recognition	B-X
strategies	B-X
that	B-X
are	B-X
on	B-X
display	B-X
in	B-X
their	B-X
ligand-binding	B-X
pockets	B-X
.	B-X
Structural	B-X
and	B-X
biochemical	B-X
advances	B-X
in	B-X
the	B-X
study	B-X
of	B-X
riboswitches	B-X
provide	B-X
an	B-X
impetus	B-X
for	B-X
the	B-X
development	B-X
of	B-X
methods	B-X
for	B-X
the	B-X
discovery	B-X
of	B-X
novel	B-X
riboswitch	B-X
activators	B-X
and	B-X
inhibitors	B-X
.	B-X
Recent	B-X
rational	B-X
drug	B-X
design	B-X
efforts	B-X
focused	B-X
on	B-X
select	B-X
riboswitch	B-X
classes	B-X
have	B-X
yielded	B-X
a	B-X
small	B-X
number	B-X
of	B-X
candidate	B-X
antibiotic	B-X
compounds	B-X
,	B-X
including	B-X
one	B-X
active	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
Staphylococcus	B-X
aureus	B-X
infection	B-X
.	B-X
The	B-X
development	B-X
of	B-X
high-throughput	B-X
methods	B-X
suitable	B-X
for	B-X
riboswitch-specific	B-X
drug	B-X
discovery	B-X
is	B-X
ongoing	B-X
.	B-X
A	B-X
fragment-based	B-X
screening	B-X
approach	B-X
employing	B-X
equilibrium	B-X
dialysis	B-X
that	B-X
may	B-X
be	B-X
generically	B-X
useful	B-X
has	B-X
demonstrated	B-X
early	B-X
success	B-X
.	B-X
Thus	B-X
,	B-X
riboswitches	B-X
are	B-X
particularly	B-X
attractive	B-X
as	B-X
targets	B-X
for	B-X
antibacterials	B-X
.	B-X
Indeed	B-X
,	B-X
antimicrobials	B-X
with	B-X
previously	B-X
unknown	B-X
mechanisms	B-X
have	B-X
been	B-X
found	B-X
to	B-X
function	B-X
by	B-X
binding	B-X
riboswitches	B-X
and	B-X
causing	B-X
aberrant	B-X
gene	B-X
expression	B-X
.	B-X

Splicing	O
determines	O
the	O
glycosylation	O
state	O
of	O
ameloblastin	B-Protein
.	O
<EOS>	B-X
In	B-X
developing	B-X
porcine	B-X
enamel	B-X
,	B-X
the	B-X
space	B-X
between	B-X
enamel	B-X
rods	B-X
selectively	B-X
binds	B-X
lectins	B-X
and	B-X
ameloblastin	B-X
(	B-X
Ambn	B-X
)	B-X
N-terminal	B-X
antibodies	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
ameloblastin	B-X
N-terminal	B-X
cleavage	B-X
products	B-X
are	B-X
glycosylated	B-X
.	B-X
Assorted	B-X
Ambn	B-X
cleavage	B-X
products	B-X
showed	B-X
positive	B-X
lectin	B-X
staining	B-X
by	B-X
peanut	B-X
agglutinin	B-X
(	B-X
PNA	B-X
)	B-X
,	B-X
Maclura	B-X
pomifera	B-X
agglutinin	B-X
(	B-X
MPA	B-X
)	B-X
,	B-X
and	B-X
Limulus	B-X
polyphemus	B-X
agglutinin	B-X
(	B-X
LPA	B-X
)	B-X
,	B-X
suggesting	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
containing	B-X
galactose	B-X
(	B-X
Gal	B-X
)	B-X
,	B-X
N-acetylgalactosamine	B-X
(	B-X
GalNAc	B-X
)	B-X
,	B-X
and	B-X
sialic	B-X
acid	B-X
.	B-X
The	B-X
O-glycosylation	B-X
site	B-X
was	B-X
determined	B-X
by	B-X
Edman	B-X
sequencing	B-X
of	B-X
pronase-digested	B-X
Ambn	B-X
,	B-X
which	B-X
gave	B-X
HPPPLPXQPS	B-X
,	B-X
indicating	B-X
that	B-X
Ser	B-X
(	B-X
86	B-X
)	B-X
is	B-X
the	B-X
site	B-X
of	B-X
the	B-X
O-linked	B-X
glycosylation	B-X
.	B-X

In	O
developing	O
porcine	O
enamel	O
,	O
the	O
space	O
between	O
enamel	O
rods	O
selectively	O
binds	O
lectins	O
and	O
ameloblastin	B-Protein
(	O
Ambn	B-Protein
)	O
N	O
-	O
terminal	O
antibodies	O
.	O
<EOS>	B-X
In	B-X
developing	B-X
porcine	B-X
enamel	B-X
,	B-X
the	B-X
space	B-X
between	B-X
enamel	B-X
rods	B-X
selectively	B-X
binds	B-X
lectins	B-X
and	B-X
ameloblastin	B-X
(	B-X
Ambn	B-X
)	B-X
N-terminal	B-X
antibodies	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
ameloblastin	B-X
N-terminal	B-X
cleavage	B-X
products	B-X
are	B-X
glycosylated	B-X
.	B-X
Assorted	B-X
Ambn	B-X
cleavage	B-X
products	B-X
showed	B-X
positive	B-X
lectin	B-X
staining	B-X
by	B-X
peanut	B-X
agglutinin	B-X
(	B-X
PNA	B-X
)	B-X
,	B-X
Maclura	B-X
pomifera	B-X
agglutinin	B-X
(	B-X
MPA	B-X
)	B-X
,	B-X
and	B-X
Limulus	B-X
polyphemus	B-X
agglutinin	B-X
(	B-X
LPA	B-X
)	B-X
,	B-X
suggesting	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
containing	B-X
galactose	B-X
(	B-X
Gal	B-X
)	B-X
,	B-X
N-acetylgalactosamine	B-X
(	B-X
GalNAc	B-X
)	B-X
,	B-X
and	B-X
sialic	B-X
acid	B-X
.	B-X
Edman	B-X
sequencing	B-X
of	B-X
the	B-X
lectin-positive	B-X
bands	B-X
gave	B-X
the	B-X
Ambn	B-X
N-terminal	B-X
sequence	B-X
:	B-X
VPAFPRQPGTXGVASLXLE	B-X
.	B-X
The	B-X
O-glycosylation	B-X
site	B-X
was	B-X
determined	B-X
by	B-X
Edman	B-X
sequencing	B-X
of	B-X
pronase-digested	B-X
Ambn	B-X
,	B-X
which	B-X
gave	B-X
HPPPLPXQPS	B-X
,	B-X
indicating	B-X
that	B-X
Ser	B-X
(	B-X
86	B-X
)	B-X
is	B-X
the	B-X
site	B-X
of	B-X
the	B-X
O-linked	B-X
glycosylation	B-X
.	B-X
This	B-X
modification	B-X
is	B-X
within	B-X
the	B-X
15-amino-acid	B-X
segment	B-X
(	B-X
73-YEYSLPVHPPPLPSQ-87	B-X
)	B-X
deleted	B-X
by	B-X
splicing	B-X
in	B-X
the	B-X
mRNA	B-X
encoding	B-X
the	B-X
380-amino-acid	B-X
Ambn	B-X
isoform	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
only	B-X
the	B-X
N-terminal	B-X
Ambn	B-X
products	B-X
derived	B-X
from	B-X
the	B-X
395-Ambn	B-X
isoform	B-X
are	B-X
glycosylated	B-X
.	B-X

We	O
tested	O
the	O
hypothesis	O
that	O
ameloblastin	B-Protein
N	O
-	O
terminal	O
cleavage	O
products	O
are	O
glycosylated	O
.	O
<EOS>	B-X
Ameloblastin	B-X
(	B-X
AMBN	B-X
)	B-X
cleavage	B-X
products	B-X
are	B-X
the	B-X
most	B-X
abundant	B-X
non-amelogenin	B-X
proteins	B-X
in	B-X
the	B-X
enamel	B-X
matrix	B-X
of	B-X
developing	B-X
teeth	B-X
.	B-X
AMBN	B-X
N-terminal	B-X
cleavage	B-X
products	B-X
accumulate	B-X
in	B-X
the	B-X
sheath	B-X
space	B-X
between	B-X
enamel	B-X
rods	B-X
,	B-X
while	B-X
AMBN	B-X
C-terminal	B-X
products	B-X
localize	B-X
within	B-X
rods	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
MMP-20	B-X
is	B-X
the	B-X
protease	B-X
that	B-X
cleaves	B-X
AMBN	B-X
.	B-X
Glycosylated	B-X
recombinant	B-X
porcine	B-X
AMBN	B-X
(	B-X
rpAMBN	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
human	B-X
kidney	B-X
293F	B-X
cells	B-X
,	B-X
and	B-X
recombinant	B-X
porcine	B-X
enamelysin	B-X
(	B-X
rpMMP-20	B-X
)	B-X
was	B-X
expressed	B-X
in	B-X
bacteria	B-X
.	B-X
N-terminal	B-X
sequencing	B-X
of	B-X
AMBN	B-X
digestion	B-X
products	B-X
determined	B-X
that	B-X
rpMMP-20	B-X
cleaved	B-X
rpAMBN	B-X
after	B-X
Pro	B-X
(	B-X
2	B-X
)	B-X
,	B-X
Gln	B-X
(	B-X
130	B-X
)	B-X
,	B-X
Gln	B-X
(	B-X
139	B-X
)	B-X
,	B-X
Arg	B-X
(	B-X
170	B-X
)	B-X
,	B-X
and	B-X
Ala	B-X
(	B-X
222	B-X
)	B-X
.	B-X
This	B-X
shows	B-X
that	B-X
MMP-20	B-X
generates	B-X
the	B-X
23-kDa	B-X
AMBN	B-X
starting	B-X
at	B-X
Tyr	B-X
(	B-X
223	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
17-kDa	B-X
(	B-X
Val	B-X
(	B-X
1	B-X
)	B-X
-Arg	B-X
(	B-X
170	B-X
)	B-X
)	B-X
and	B-X
15-kDa	B-X
(	B-X
Val	B-X
(	B-X
1	B-X
)	B-X
-Gln	B-X
(	B-X
130	B-X
)	B-X
)	B-X
AMBN	B-X
cleavage	B-X
products	B-X
that	B-X
concentrate	B-X
in	B-X
the	B-X
sheath	B-X
space	B-X
during	B-X
the	B-X
secretory	B-X
stage	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
MMP-20	B-X
processes	B-X
ameloblastin	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

Assorted	O
Ambn	B-Protein
cleavage	O
products	O
showed	O
positive	O
lectin	O
staining	O
by	O
peanut	O
agglutinin	B-Protein
(	O
PNA	B-Protein
)	O
,	O
Maclura	O
pomifera	O
agglutinin	O
(	O
MPA	O
)	O
,	O
and	O
Limulus	O
polyphemus	O
agglutinin	O
(	O
LPA	O
)	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
O	O
-	O
linked	O
glycosylation	O
containing	O
galactose	O
(	O
Gal	O
)	O
,	O
N	O
-	O
acetylgalactosamine	O
(	O
GalNAc	O
)	O
,	O
and	O
sialic	O
acid	O
.	O

Edman	O
sequencing	O
of	O
the	O
lectin	O
-	O
positive	O
bands	O
gave	O
the	O
Ambn	B-Protein
N	O
-	O
terminal	O
sequence	O
:	O
VPAFPRQPGTXGVASLXLE	O
.	O
<EOS>	B-X
In	B-X
developing	B-X
porcine	B-X
enamel	B-X
,	B-X
the	B-X
space	B-X
between	B-X
enamel	B-X
rods	B-X
selectively	B-X
binds	B-X
lectins	B-X
and	B-X
ameloblastin	B-X
(	B-X
Ambn	B-X
)	B-X
N-terminal	B-X
antibodies	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
ameloblastin	B-X
N-terminal	B-X
cleavage	B-X
products	B-X
are	B-X
glycosylated	B-X
.	B-X
Assorted	B-X
Ambn	B-X
cleavage	B-X
products	B-X
showed	B-X
positive	B-X
lectin	B-X
staining	B-X
by	B-X
peanut	B-X
agglutinin	B-X
(	B-X
PNA	B-X
)	B-X
,	B-X
Maclura	B-X
pomifera	B-X
agglutinin	B-X
(	B-X
MPA	B-X
)	B-X
,	B-X
and	B-X
Limulus	B-X
polyphemus	B-X
agglutinin	B-X
(	B-X
LPA	B-X
)	B-X
,	B-X
suggesting	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
containing	B-X
galactose	B-X
(	B-X
Gal	B-X
)	B-X
,	B-X
N-acetylgalactosamine	B-X
(	B-X
GalNAc	B-X
)	B-X
,	B-X
and	B-X
sialic	B-X
acid	B-X
.	B-X
Edman	B-X
sequencing	B-X
of	B-X
the	B-X
lectin-positive	B-X
bands	B-X
gave	B-X
the	B-X
Ambn	B-X
N-terminal	B-X
sequence	B-X
:	B-X
VPAFPRQPGTXGVASLXLE	B-X
.	B-X
The	B-X
O-glycosylation	B-X
site	B-X
was	B-X
determined	B-X
by	B-X
Edman	B-X
sequencing	B-X
of	B-X
pronase-digested	B-X
Ambn	B-X
,	B-X
which	B-X
gave	B-X
HPPPLPXQPS	B-X
,	B-X
indicating	B-X
that	B-X
Ser	B-X
(	B-X
86	B-X
)	B-X
is	B-X
the	B-X
site	B-X
of	B-X
the	B-X
O-linked	B-X
glycosylation	B-X
.	B-X
This	B-X
modification	B-X
is	B-X
within	B-X
the	B-X
15-amino-acid	B-X
segment	B-X
(	B-X
73-YEYSLPVHPPPLPSQ-87	B-X
)	B-X
deleted	B-X
by	B-X
splicing	B-X
in	B-X
the	B-X
mRNA	B-X
encoding	B-X
the	B-X
380-amino-acid	B-X
Ambn	B-X
isoform	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
only	B-X
the	B-X
N-terminal	B-X
Ambn	B-X
products	B-X
derived	B-X
from	B-X
the	B-X
395-Ambn	B-X
isoform	B-X
are	B-X
glycosylated	B-X
.	B-X

The	O
blank	O
cycles	O
for	O
Pro	O
(	O
11	O
)	O
and	O
Ser	O
(	O
17	O
)	O
confirmed	O
that	O
these	O
residues	O
are	O
hydroxylated	O
and	O
phosphorylated	O
,	O
respectively	O
.	O

The	O
O	O
-	O
glycosylation	O
site	O
was	O
determined	O
by	O
Edman	O
sequencing	O
of	O
pronase	O
-	O
digested	O
Ambn	B-Protein
,	O
which	O
gave	O
HPPPLPXQPS	O
,	O
indicating	O
that	O
Ser	O
(	O
86	O
)	O
is	O
the	O
site	O
of	O
the	O
O	O
-	O
linked	O
glycosylation	O
.	O
<EOS>	B-X
In	B-X
developing	B-X
porcine	B-X
enamel	B-X
,	B-X
the	B-X
space	B-X
between	B-X
enamel	B-X
rods	B-X
selectively	B-X
binds	B-X
lectins	B-X
and	B-X
ameloblastin	B-X
(	B-X
Ambn	B-X
)	B-X
N-terminal	B-X
antibodies	B-X
.	B-X
Assorted	B-X
Ambn	B-X
cleavage	B-X
products	B-X
showed	B-X
positive	B-X
lectin	B-X
staining	B-X
by	B-X
peanut	B-X
agglutinin	B-X
(	B-X
PNA	B-X
)	B-X
,	B-X
Maclura	B-X
pomifera	B-X
agglutinin	B-X
(	B-X
MPA	B-X
)	B-X
,	B-X
and	B-X
Limulus	B-X
polyphemus	B-X
agglutinin	B-X
(	B-X
LPA	B-X
)	B-X
,	B-X
suggesting	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
containing	B-X
galactose	B-X
(	B-X
Gal	B-X
)	B-X
,	B-X
N-acetylgalactosamine	B-X
(	B-X
GalNAc	B-X
)	B-X
,	B-X
and	B-X
sialic	B-X
acid	B-X
.	B-X
Edman	B-X
sequencing	B-X
of	B-X
the	B-X
lectin-positive	B-X
bands	B-X
gave	B-X
the	B-X
Ambn	B-X
N-terminal	B-X
sequence	B-X
:	B-X
VPAFPRQPGTXGVASLXLE	B-X
.	B-X
The	B-X
blank	B-X
cycles	B-X
for	B-X
Pro	B-X
(	B-X
11	B-X
)	B-X
and	B-X
Ser	B-X
(	B-X
17	B-X
)	B-X
confirmed	B-X
that	B-X
these	B-X
residues	B-X
are	B-X
hydroxylated	B-X
and	B-X
phosphorylated	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
O-glycosylation	B-X
site	B-X
was	B-X
determined	B-X
by	B-X
Edman	B-X
sequencing	B-X
of	B-X
pronase-digested	B-X
Ambn	B-X
,	B-X
which	B-X
gave	B-X
HPPPLPXQPS	B-X
,	B-X
indicating	B-X
that	B-X
Ser	B-X
(	B-X
86	B-X
)	B-X
is	B-X
the	B-X
site	B-X
of	B-X
the	B-X
O-linked	B-X
glycosylation	B-X
.	B-X
This	B-X
modification	B-X
is	B-X
within	B-X
the	B-X
15-amino-acid	B-X
segment	B-X
(	B-X
73-YEYSLPVHPPPLPSQ-87	B-X
)	B-X
deleted	B-X
by	B-X
splicing	B-X
in	B-X
the	B-X
mRNA	B-X
encoding	B-X
the	B-X
380-amino-acid	B-X
Ambn	B-X
isoform	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
only	B-X
the	B-X
N-terminal	B-X
Ambn	B-X
products	B-X
derived	B-X
from	B-X
the	B-X
395-Ambn	B-X
isoform	B-X
are	B-X
glycosylated	B-X
.	B-X

This	O
modification	O
is	O
within	O
the	O
15	O
-	O
amino	O
-	O
acid	O
segment	O
(	O
73	O
-	O
YEYSLPVHPPPLPSQ	O
-	O
87	O
)	O
deleted	O
by	O
splicing	O
in	O
the	O
mRNA	O
encoding	O
the	O
380	O
-	O
amino	O
-	O
acid	O
Ambn	B-Protein
isoform	O
.	O
<EOS>	B-X
In	B-X
developing	B-X
porcine	B-X
enamel	B-X
,	B-X
the	B-X
space	B-X
between	B-X
enamel	B-X
rods	B-X
selectively	B-X
binds	B-X
lectins	B-X
and	B-X
ameloblastin	B-X
(	B-X
Ambn	B-X
)	B-X
N-terminal	B-X
antibodies	B-X
.	B-X
Assorted	B-X
Ambn	B-X
cleavage	B-X
products	B-X
showed	B-X
positive	B-X
lectin	B-X
staining	B-X
by	B-X
peanut	B-X
agglutinin	B-X
(	B-X
PNA	B-X
)	B-X
,	B-X
Maclura	B-X
pomifera	B-X
agglutinin	B-X
(	B-X
MPA	B-X
)	B-X
,	B-X
and	B-X
Limulus	B-X
polyphemus	B-X
agglutinin	B-X
(	B-X
LPA	B-X
)	B-X
,	B-X
suggesting	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
containing	B-X
galactose	B-X
(	B-X
Gal	B-X
)	B-X
,	B-X
N-acetylgalactosamine	B-X
(	B-X
GalNAc	B-X
)	B-X
,	B-X
and	B-X
sialic	B-X
acid	B-X
.	B-X
Edman	B-X
sequencing	B-X
of	B-X
the	B-X
lectin-positive	B-X
bands	B-X
gave	B-X
the	B-X
Ambn	B-X
N-terminal	B-X
sequence	B-X
:	B-X
VPAFPRQPGTXGVASLXLE	B-X
.	B-X
The	B-X
O-glycosylation	B-X
site	B-X
was	B-X
determined	B-X
by	B-X
Edman	B-X
sequencing	B-X
of	B-X
pronase-digested	B-X
Ambn	B-X
,	B-X
which	B-X
gave	B-X
HPPPLPXQPS	B-X
,	B-X
indicating	B-X
that	B-X
Ser	B-X
(	B-X
86	B-X
)	B-X
is	B-X
the	B-X
site	B-X
of	B-X
the	B-X
O-linked	B-X
glycosylation	B-X
.	B-X
This	B-X
modification	B-X
is	B-X
within	B-X
the	B-X
15-amino-acid	B-X
segment	B-X
(	B-X
73-YEYSLPVHPPPLPSQ-87	B-X
)	B-X
deleted	B-X
by	B-X
splicing	B-X
in	B-X
the	B-X
mRNA	B-X
encoding	B-X
the	B-X
380-amino-acid	B-X
Ambn	B-X
isoform	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
only	B-X
the	B-X
N-terminal	B-X
Ambn	B-X
products	B-X
derived	B-X
from	B-X
the	B-X
395-Ambn	B-X
isoform	B-X
are	B-X
glycosylated	B-X
.	B-X

We	O
conclude	O
that	O
only	O
the	O
N	O
-	O
terminal	O
Ambn	B-Protein
products	O
derived	O
from	O
the	O
395	O
-	O
Ambn	B-Protein
isoform	O
are	O
glycosylated	O
.	O

Chemical	O
genetic	O
interrogation	O
of	O
natural	O
variation	O
uncovers	O
a	O
molecule	O
that	O
is	O
glycoactivated	O
.	O
<EOS>	B-X
Natural	B-X
variation	B-X
in	B-X
human	B-X
drug	B-X
metabolism	B-X
and	B-X
target	B-X
genes	B-X
can	B-X
cause	B-X
pharmacogenetic	B-X
or	B-X
interindividual	B-X
variation	B-X
in	B-X
drug	B-X
sensitivity	B-X
.	B-X
We	B-X
reasoned	B-X
that	B-X
natural	B-X
pharmacogenetic	B-X
variation	B-X
in	B-X
model	B-X
organisms	B-X
could	B-X
be	B-X
systematically	B-X
exploited	B-X
to	B-X
facilitate	B-X
the	B-X
characterization	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
.	B-X
To	B-X
test	B-X
this	B-X
,	B-X
we	B-X
subjected	B-X
multiple	B-X
Arabidopsis	B-X
thaliana	B-X
accessions	B-X
to	B-X
chemical	B-X
genetic	B-X
screens	B-X
and	B-X
discovered	B-X
12	B-X
accession-selective	B-X
hit	B-X
molecules	B-X
.	B-X
As	B-X
a	B-X
model	B-X
for	B-X
understanding	B-X
this	B-X
variation	B-X
,	B-X
we	B-X
characterized	B-X
natural	B-X
resistance	B-X
to	B-X
hypostatin	B-X
,	B-X
a	B-X
new	B-X
inhibitor	B-X
of	B-X
cell	B-X
expansion	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
delineated	B-X
a	B-X
HYR1	B-X
substrate	B-X
motif	B-X
and	B-X
used	B-X
it	B-X
to	B-X
identify	B-X
another	B-X
molecule	B-X
modulated	B-X
by	B-X
glucosylation	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
natural	B-X
variation	B-X
can	B-X
be	B-X
exploited	B-X
to	B-X
inform	B-X
the	B-X
biology	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
,	B-X
and	B-X
that	B-X
UGT	B-X
sequence	B-X
variation	B-X
affects	B-X
xenobiotic	B-X
sensitivity	B-X
across	B-X
biological	B-X
kingdoms	B-X
.	B-X

Natural	O
variation	O
in	O
human	O
drug	O
metabolism	O
and	O
target	O
genes	O
can	O
cause	O
pharmacogenetic	O
or	O
interindividual	O
variation	O
in	O
drug	O
sensitivity	O
.	O
<EOS>	B-X
Data	B-X
on	B-X
the	B-X
detection	B-X
times	B-X
of	B-X
drugs	B-X
of	B-X
abuse	B-X
are	B-X
based	B-X
on	B-X
studies	B-X
of	B-X
controlled	B-X
administration	B-X
to	B-X
volunteers	B-X
or	B-X
on	B-X
the	B-X
analysis	B-X
of	B-X
biologic	B-X
samples	B-X
of	B-X
subjects	B-X
who	B-X
are	B-X
forced	B-X
to	B-X
stop	B-X
their	B-X
(	B-X
often	B-X
chronic	B-X
)	B-X
use	B-X
of	B-X
drugs	B-X
of	B-X
abuse	B-X
,	B-X
eg	B-X
,	B-X
because	B-X
of	B-X
imprisonment	B-X
or	B-X
detoxification	B-X
.	B-X
The	B-X
detection	B-X
times	B-X
depend	B-X
mainly	B-X
on	B-X
the	B-X
dose	B-X
and	B-X
sensitivity	B-X
of	B-X
the	B-X
method	B-X
used	B-X
and	B-X
also	B-X
on	B-X
the	B-X
preparation	B-X
and	B-X
route	B-X
of	B-X
administration	B-X
,	B-X
the	B-X
duration	B-X
of	B-X
use	B-X
(	B-X
acute	B-X
or	B-X
chronic	B-X
)	B-X
,	B-X
the	B-X
matrix	B-X
that	B-X
is	B-X
analyzed	B-X
,	B-X
the	B-X
molecule	B-X
or	B-X
metabolite	B-X
that	B-X
is	B-X
looked	B-X
for	B-X
,	B-X
the	B-X
pH	B-X
and	B-X
concentration	B-X
of	B-X
the	B-X
matrix	B-X
(	B-X
urine	B-X
,	B-X
oral	B-X
fluid	B-X
)	B-X
,	B-X
and	B-X
the	B-X
interindividual	B-X
variation	B-X
in	B-X
metabolic	B-X
and	B-X
renal	B-X
clearance	B-X
.	B-X
In	B-X
blood	B-X
or	B-X
plasma	B-X
,	B-X
most	B-X
drugs	B-X
of	B-X
abuse	B-X
can	B-X
be	B-X
detected	B-X
at	B-X
the	B-X
low	B-X
nanogram	B-X
per	B-X
milliliter	B-X
level	B-X
for	B-X
1	B-X
or	B-X
2	B-X
days	B-X
.	B-X
In	B-X
chronic	B-X
users	B-X
,	B-X
drugs	B-X
of	B-X
abuse	B-X
can	B-X
be	B-X
detected	B-X
in	B-X
urine	B-X
for	B-X
approximately	B-X
1	B-X
week	B-X
after	B-X
last	B-X
use	B-X
,	B-X
and	B-X
in	B-X
extreme	B-X
cases	B-X
even	B-X
longer	B-X
in	B-X
cocaine	B-X
and	B-X
cannabis	B-X
users	B-X
.	B-X
In	B-X
oral	B-X
fluid	B-X
,	B-X
drugs	B-X
of	B-X
abuse	B-X
can	B-X
be	B-X
detected	B-X
for	B-X
5-48	B-X
hours	B-X
at	B-X
a	B-X
low	B-X
nanogram	B-X
per	B-X
milliliter	B-X
level	B-X
.	B-X

We	O
reasoned	O
that	O
natural	O
pharmacogenetic	O
variation	O
in	O
model	O
organisms	O
could	O
be	O
systematically	O
exploited	O
to	O
facilitate	O
the	O
characterization	O
of	O
new	O
small	O
molecules	O
.	O
<EOS>	B-X
Natural	B-X
variation	B-X
in	B-X
human	B-X
drug	B-X
metabolism	B-X
and	B-X
target	B-X
genes	B-X
can	B-X
cause	B-X
pharmacogenetic	B-X
or	B-X
interindividual	B-X
variation	B-X
in	B-X
drug	B-X
sensitivity	B-X
.	B-X
We	B-X
reasoned	B-X
that	B-X
natural	B-X
pharmacogenetic	B-X
variation	B-X
in	B-X
model	B-X
organisms	B-X
could	B-X
be	B-X
systematically	B-X
exploited	B-X
to	B-X
facilitate	B-X
the	B-X
characterization	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
.	B-X
To	B-X
test	B-X
this	B-X
,	B-X
we	B-X
subjected	B-X
multiple	B-X
Arabidopsis	B-X
thaliana	B-X
accessions	B-X
to	B-X
chemical	B-X
genetic	B-X
screens	B-X
and	B-X
discovered	B-X
12	B-X
accession-selective	B-X
hit	B-X
molecules	B-X
.	B-X
As	B-X
a	B-X
model	B-X
for	B-X
understanding	B-X
this	B-X
variation	B-X
,	B-X
we	B-X
characterized	B-X
natural	B-X
resistance	B-X
to	B-X
hypostatin	B-X
,	B-X
a	B-X
new	B-X
inhibitor	B-X
of	B-X
cell	B-X
expansion	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
natural	B-X
variation	B-X
can	B-X
be	B-X
exploited	B-X
to	B-X
inform	B-X
the	B-X
biology	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
,	B-X
and	B-X
that	B-X
UGT	B-X
sequence	B-X
variation	B-X
affects	B-X
xenobiotic	B-X
sensitivity	B-X
across	B-X
biological	B-X
kingdoms	B-X
.	B-X

To	O
test	O
this	O
,	O
we	O
subjected	O
multiple	O
Arabidopsis	O
thaliana	O
accessions	O
to	O
chemical	O
genetic	O
screens	O
and	O
discovered	O
12	O
accession	O
-	O
selective	O
hit	O
molecules	O
.	O
<EOS>	B-X
Natural	B-X
variation	B-X
in	B-X
human	B-X
drug	B-X
metabolism	B-X
and	B-X
target	B-X
genes	B-X
can	B-X
cause	B-X
pharmacogenetic	B-X
or	B-X
interindividual	B-X
variation	B-X
in	B-X
drug	B-X
sensitivity	B-X
.	B-X
We	B-X
reasoned	B-X
that	B-X
natural	B-X
pharmacogenetic	B-X
variation	B-X
in	B-X
model	B-X
organisms	B-X
could	B-X
be	B-X
systematically	B-X
exploited	B-X
to	B-X
facilitate	B-X
the	B-X
characterization	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
.	B-X
To	B-X
test	B-X
this	B-X
,	B-X
we	B-X
subjected	B-X
multiple	B-X
Arabidopsis	B-X
thaliana	B-X
accessions	B-X
to	B-X
chemical	B-X
genetic	B-X
screens	B-X
and	B-X
discovered	B-X
12	B-X
accession-selective	B-X
hit	B-X
molecules	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
natural	B-X
variation	B-X
can	B-X
be	B-X
exploited	B-X
to	B-X
inform	B-X
the	B-X
biology	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
,	B-X
and	B-X
that	B-X
UGT	B-X
sequence	B-X
variation	B-X
affects	B-X
xenobiotic	B-X
sensitivity	B-X
across	B-X
biological	B-X
kingdoms	B-X
.	B-X

As	O
a	O
model	O
for	O
understanding	O
this	O
variation	O
,	O
we	O
characterized	O
natural	O
resistance	O
to	O
hypostatin	O
,	O
a	O
new	O
inhibitor	O
of	O
cell	O
expansion	O
.	O

Map	O
-	O
based	O
cloning	O
identified	O
HYR1	B-Protein
,	O
a	O
UDP	O
glycosyltransferase	O
(	O
UGT	O
)	O
,	O
as	O
causative	O
for	O
hypostatin	O
resistance	O
.	O
<EOS>	B-X
As	B-X
a	B-X
model	B-X
for	B-X
understanding	B-X
this	B-X
variation	B-X
,	B-X
we	B-X
characterized	B-X
natural	B-X
resistance	B-X
to	B-X
hypostatin	B-X
,	B-X
a	B-X
new	B-X
inhibitor	B-X
of	B-X
cell	B-X
expansion	B-X
.	B-X
Map-based	B-X
cloning	B-X
identified	B-X
HYR1	B-X
,	B-X
a	B-X
UDP	B-X
glycosyltransferase	B-X
(	B-X
UGT	B-X
)	B-X
,	B-X
as	B-X
causative	B-X
for	B-X
hypostatin	B-X
resistance	B-X
.	B-X
Multiple	B-X
lines	B-X
of	B-X
evidence	B-X
demonstrate	B-X
that	B-X
HYR1	B-X
glucosylates	B-X
hypostatin	B-X
in	B-X
vivo	B-X
to	B-X
form	B-X
a	B-X
bioactive	B-X
glucoside	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
delineated	B-X
a	B-X
HYR1	B-X
substrate	B-X
motif	B-X
and	B-X
used	B-X
it	B-X
to	B-X
identify	B-X
another	B-X
molecule	B-X
modulated	B-X
by	B-X
glucosylation	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
natural	B-X
variation	B-X
can	B-X
be	B-X
exploited	B-X
to	B-X
inform	B-X
the	B-X
biology	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
,	B-X
and	B-X
that	B-X
UGT	B-X
sequence	B-X
variation	B-X
affects	B-X
xenobiotic	B-X
sensitivity	B-X
across	B-X
biological	B-X
kingdoms	B-X
.	B-X

Multiple	O
lines	O
of	O
evidence	O
demonstrate	O
that	O
HYR1	B-Protein
glucosylates	O
hypostatin	O
in	O
vivo	O
to	O
form	O
a	O
bioactive	O
glucoside	O
.	O

Additionally	O
,	O
we	O
delineated	O
a	O
HYR1	B-Protein
substrate	O
motif	O
and	O
used	O
it	O
to	O
identify	O
another	O
molecule	O
modulated	O
by	O
glucosylation	O
.	O
<EOS>	B-X
We	B-X
reasoned	B-X
that	B-X
natural	B-X
pharmacogenetic	B-X
variation	B-X
in	B-X
model	B-X
organisms	B-X
could	B-X
be	B-X
systematically	B-X
exploited	B-X
to	B-X
facilitate	B-X
the	B-X
characterization	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
.	B-X
To	B-X
test	B-X
this	B-X
,	B-X
we	B-X
subjected	B-X
multiple	B-X
Arabidopsis	B-X
thaliana	B-X
accessions	B-X
to	B-X
chemical	B-X
genetic	B-X
screens	B-X
and	B-X
discovered	B-X
12	B-X
accession-selective	B-X
hit	B-X
molecules	B-X
.	B-X
Map-based	B-X
cloning	B-X
identified	B-X
HYR1	B-X
,	B-X
a	B-X
UDP	B-X
glycosyltransferase	B-X
(	B-X
UGT	B-X
)	B-X
,	B-X
as	B-X
causative	B-X
for	B-X
hypostatin	B-X
resistance	B-X
.	B-X
Multiple	B-X
lines	B-X
of	B-X
evidence	B-X
demonstrate	B-X
that	B-X
HYR1	B-X
glucosylates	B-X
hypostatin	B-X
in	B-X
vivo	B-X
to	B-X
form	B-X
a	B-X
bioactive	B-X
glucoside	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
delineated	B-X
a	B-X
HYR1	B-X
substrate	B-X
motif	B-X
and	B-X
used	B-X
it	B-X
to	B-X
identify	B-X
another	B-X
molecule	B-X
modulated	B-X
by	B-X
glucosylation	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
natural	B-X
variation	B-X
can	B-X
be	B-X
exploited	B-X
to	B-X
inform	B-X
the	B-X
biology	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
,	B-X
and	B-X
that	B-X
UGT	B-X
sequence	B-X
variation	B-X
affects	B-X
xenobiotic	B-X
sensitivity	B-X
across	B-X
biological	B-X
kingdoms	B-X
.	B-X

Our	O
results	O
demonstrate	O
that	O
natural	O
variation	O
can	O
be	O
exploited	O
to	O
inform	O
the	O
biology	O
of	O
new	O
small	O
molecules	O
,	O
and	O
that	O
UGT	O
sequence	O
variation	O
affects	O
xenobiotic	O
sensitivity	O
across	O
biological	O
kingdoms	O
.	O
<EOS>	B-X
Natural	B-X
variation	B-X
in	B-X
human	B-X
drug	B-X
metabolism	B-X
and	B-X
target	B-X
genes	B-X
can	B-X
cause	B-X
pharmacogenetic	B-X
or	B-X
interindividual	B-X
variation	B-X
in	B-X
drug	B-X
sensitivity	B-X
.	B-X
We	B-X
reasoned	B-X
that	B-X
natural	B-X
pharmacogenetic	B-X
variation	B-X
in	B-X
model	B-X
organisms	B-X
could	B-X
be	B-X
systematically	B-X
exploited	B-X
to	B-X
facilitate	B-X
the	B-X
characterization	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
.	B-X
To	B-X
test	B-X
this	B-X
,	B-X
we	B-X
subjected	B-X
multiple	B-X
Arabidopsis	B-X
thaliana	B-X
accessions	B-X
to	B-X
chemical	B-X
genetic	B-X
screens	B-X
and	B-X
discovered	B-X
12	B-X
accession-selective	B-X
hit	B-X
molecules	B-X
.	B-X
As	B-X
a	B-X
model	B-X
for	B-X
understanding	B-X
this	B-X
variation	B-X
,	B-X
we	B-X
characterized	B-X
natural	B-X
resistance	B-X
to	B-X
hypostatin	B-X
,	B-X
a	B-X
new	B-X
inhibitor	B-X
of	B-X
cell	B-X
expansion	B-X
.	B-X
Map-based	B-X
cloning	B-X
identified	B-X
HYR1	B-X
,	B-X
a	B-X
UDP	B-X
glycosyltransferase	B-X
(	B-X
UGT	B-X
)	B-X
,	B-X
as	B-X
causative	B-X
for	B-X
hypostatin	B-X
resistance	B-X
.	B-X
Multiple	B-X
lines	B-X
of	B-X
evidence	B-X
demonstrate	B-X
that	B-X
HYR1	B-X
glucosylates	B-X
hypostatin	B-X
in	B-X
vivo	B-X
to	B-X
form	B-X
a	B-X
bioactive	B-X
glucoside	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
natural	B-X
variation	B-X
can	B-X
be	B-X
exploited	B-X
to	B-X
inform	B-X
the	B-X
biology	B-X
of	B-X
new	B-X
small	B-X
molecules	B-X
,	B-X
and	B-X
that	B-X
UGT	B-X
sequence	B-X
variation	B-X
affects	B-X
xenobiotic	B-X
sensitivity	B-X
across	B-X
biological	B-X
kingdoms	B-X
.	B-X

Kaposi	O
'	O
s	O
sarcoma	O
herpesvirus	O
-	O
encoded	O
latency	B-Protein
-	I-Protein
associated	I-Protein
nuclear	I-Protein
antigen	I-Protein
stabilizes	O
intracellular	O
activated	O
Notch	O
by	O
targeting	O
the	O
Sel10	B-Protein
protein	O
.	O
<EOS>	B-X
Deregulation	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
Notch	B-X
signaling	B-X
is	B-X
highly	B-X
correlated	B-X
with	B-X
oncogenesis	B-X
.	B-X
Intracellular	B-X
activated	B-X
Notch	B-X
(	B-X
ICN	B-X
)	B-X
is	B-X
a	B-X
protooncogene	B-X
linked	B-X
to	B-X
the	B-X
transcription	B-X
activation	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
cell	B-X
cycle	B-X
regulation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
proliferation	B-X
.	B-X
Stability	B-X
of	B-X
ICN	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
the	B-X
Sel10-mediated	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Sel10	B-X
can	B-X
function	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
Notch	B-X
and	B-X
exhibits	B-X
activities	B-X
of	B-X
a	B-X
tumor-suppressor	B-X
protein	B-X
.	B-X
This	B-X
article	B-X
shows	B-X
that	B-X
the	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
latency-associated	B-X
nuclear	B-X
antigen	B-X
(	B-X
LANA	B-X
)	B-X
directly	B-X
interacts	B-X
with	B-X
Sel10	B-X
and	B-X
forms	B-X
a	B-X
complex	B-X
in	B-X
KSHV-infected	B-X
cells	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
LANA	B-X
interacts	B-X
with	B-X
the	B-X
F-box	B-X
and	B-X
WD40	B-X
domains	B-X
of	B-X
Sel10	B-X
and	B-X
competes	B-X
with	B-X
ICN	B-X
for	B-X
binding	B-X
to	B-X
Sel10	B-X
.	B-X
These	B-X
findings	B-X
describe	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
KSHV-encoded	B-X
LANA	B-X
protein	B-X
regulates	B-X
ubiquitination	B-X
of	B-X
ICN	B-X
mediated	B-X
by	B-X
the	B-X
F-box	B-X
component	B-X
of	B-X
the	B-X
E3	B-X
ligase	B-X
Sel10	B-X
,	B-X
leading	B-X
to	B-X
proliferation	B-X
of	B-X
the	B-X
virus-infected	B-X
cells	B-X
.	B-X

Deregulation	O
of	O
the	O
evolutionarily	O
conserved	O
Notch	O
signaling	O
is	O
highly	O
correlated	O
with	O
oncogenesis	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
KSHV	B-X
mediates	B-X
oncogenesis	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
Notch	B-X
signaling	B-X
is	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
pathway	B-X
controlling	B-X
diverse	B-X
events	B-X
related	B-X
to	B-X
development	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
tissue	B-X
homeostasis	B-X
.	B-X
Deregulation	B-X
of	B-X
Notch	B-X
signaling	B-X
has	B-X
also	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
highly	B-X
correlated	B-X
with	B-X
oncogenesis	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
activated	B-X
intracellular	B-X
domain	B-X
of	B-X
Notch1	B-X
(	B-X
ICN	B-X
)	B-X
is	B-X
aberrantly	B-X
accumulated	B-X
in	B-X
latently	B-X
KSHV-infected	B-X
pleural	B-X
effusion	B-X
lymphoma	B-X
cells	B-X
and	B-X
results	B-X
in	B-X
increased	B-X
proliferation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
studies	B-X
define	B-X
an	B-X
important	B-X
mechanism	B-X
directly	B-X
linking	B-X
latent	B-X
KSHV	B-X
infection	B-X
to	B-X
induction	B-X
of	B-X
oncogenesis	B-X
through	B-X
dysregulation	B-X
of	B-X
the	B-X
conserved	B-X
Notch	B-X
signaling	B-X
pathway	B-X
.	B-X

Intracellular	O
activated	O
Notch	O
(	O
ICN	O
)	O
is	O
a	O
protooncogene	O
linked	O
to	O
the	O
transcription	O
activation	O
of	O
a	O
number	O
of	O
cellular	O
genes	O
involved	O
in	O
cell	O
cycle	O
regulation	O
,	O
differentiation	O
,	O
and	O
proliferation	O
.	O

Stability	O
of	O
ICN	O
is	O
tightly	O
regulated	O
by	O
the	O
Sel10	B-Protein
-	O
mediated	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O
<EOS>	B-X
Intracellular	B-X
activated	B-X
Notch	B-X
(	B-X
ICN	B-X
)	B-X
is	B-X
a	B-X
protooncogene	B-X
linked	B-X
to	B-X
the	B-X
transcription	B-X
activation	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
cell	B-X
cycle	B-X
regulation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
proliferation	B-X
.	B-X
Stability	B-X
of	B-X
ICN	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
the	B-X
Sel10-mediated	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Sel10	B-X
can	B-X
function	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
Notch	B-X
and	B-X
exhibits	B-X
activities	B-X
of	B-X
a	B-X
tumor-suppressor	B-X
protein	B-X
.	B-X
This	B-X
article	B-X
shows	B-X
that	B-X
the	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
latency-associated	B-X
nuclear	B-X
antigen	B-X
(	B-X
LANA	B-X
)	B-X
directly	B-X
interacts	B-X
with	B-X
Sel10	B-X
and	B-X
forms	B-X
a	B-X
complex	B-X
in	B-X
KSHV-infected	B-X
cells	B-X
.	B-X
This	B-X
results	B-X
in	B-X
suppression	B-X
of	B-X
ICN	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
LANA	B-X
interacts	B-X
with	B-X
the	B-X
F-box	B-X
and	B-X
WD40	B-X
domains	B-X
of	B-X
Sel10	B-X
and	B-X
competes	B-X
with	B-X
ICN	B-X
for	B-X
binding	B-X
to	B-X
Sel10	B-X
.	B-X
This	B-X
elevated	B-X
level	B-X
of	B-X
ICN	B-X
is	B-X
also	B-X
critical	B-X
for	B-X
maintaining	B-X
the	B-X
enhanced	B-X
proliferation	B-X
of	B-X
KSHV-infected	B-X
tumor	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
describe	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
KSHV-encoded	B-X
LANA	B-X
protein	B-X
regulates	B-X
ubiquitination	B-X
of	B-X
ICN	B-X
mediated	B-X
by	B-X
the	B-X
F-box	B-X
component	B-X
of	B-X
the	B-X
E3	B-X
ligase	B-X
Sel10	B-X
,	B-X
leading	B-X
to	B-X
proliferation	B-X
of	B-X
the	B-X
virus-infected	B-X
cells	B-X
.	B-X

Sel10	B-Protein
can	O
function	O
as	O
a	O
negative	O
regulator	O
of	O
Notch	O
and	O
exhibits	O
activities	O
of	O
a	O
tumor	O
-	O
suppressor	O
protein	O
.	O
<EOS>	B-X
Deregulation	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
Notch	B-X
signaling	B-X
is	B-X
highly	B-X
correlated	B-X
with	B-X
oncogenesis	B-X
.	B-X
Intracellular	B-X
activated	B-X
Notch	B-X
(	B-X
ICN	B-X
)	B-X
is	B-X
a	B-X
protooncogene	B-X
linked	B-X
to	B-X
the	B-X
transcription	B-X
activation	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
cell	B-X
cycle	B-X
regulation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
proliferation	B-X
.	B-X
Stability	B-X
of	B-X
ICN	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
the	B-X
Sel10-mediated	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Sel10	B-X
can	B-X
function	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
Notch	B-X
and	B-X
exhibits	B-X
activities	B-X
of	B-X
a	B-X
tumor-suppressor	B-X
protein	B-X
.	B-X
This	B-X
article	B-X
shows	B-X
that	B-X
the	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
latency-associated	B-X
nuclear	B-X
antigen	B-X
(	B-X
LANA	B-X
)	B-X
directly	B-X
interacts	B-X
with	B-X
Sel10	B-X
and	B-X
forms	B-X
a	B-X
complex	B-X
in	B-X
KSHV-infected	B-X
cells	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
LANA	B-X
interacts	B-X
with	B-X
the	B-X
F-box	B-X
and	B-X
WD40	B-X
domains	B-X
of	B-X
Sel10	B-X
and	B-X
competes	B-X
with	B-X
ICN	B-X
for	B-X
binding	B-X
to	B-X
Sel10	B-X
.	B-X
This	B-X
elevated	B-X
level	B-X
of	B-X
ICN	B-X
is	B-X
also	B-X
critical	B-X
for	B-X
maintaining	B-X
the	B-X
enhanced	B-X
proliferation	B-X
of	B-X
KSHV-infected	B-X
tumor	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
describe	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
KSHV-encoded	B-X
LANA	B-X
protein	B-X
regulates	B-X
ubiquitination	B-X
of	B-X
ICN	B-X
mediated	B-X
by	B-X
the	B-X
F-box	B-X
component	B-X
of	B-X
the	B-X
E3	B-X
ligase	B-X
Sel10	B-X
,	B-X
leading	B-X
to	B-X
proliferation	B-X
of	B-X
the	B-X
virus-infected	B-X
cells	B-X
.	B-X

This	O
article	O
shows	O
that	O
the	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
latency	B-Protein
-	I-Protein
associated	I-Protein
nuclear	I-Protein
antigen	I-Protein
(	O
LANA	B-Protein
)	O
directly	O
interacts	O
with	O
Sel10	B-Protein
and	O
forms	O
a	O
complex	O
in	O
KSHV	O
-	O
infected	O
cells	O
.	O
<EOS>	B-X
Stability	B-X
of	B-X
ICN	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
the	B-X
Sel10-mediated	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Sel10	B-X
can	B-X
function	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
Notch	B-X
and	B-X
exhibits	B-X
activities	B-X
of	B-X
a	B-X
tumor-suppressor	B-X
protein	B-X
.	B-X
This	B-X
article	B-X
shows	B-X
that	B-X
the	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
latency-associated	B-X
nuclear	B-X
antigen	B-X
(	B-X
LANA	B-X
)	B-X
directly	B-X
interacts	B-X
with	B-X
Sel10	B-X
and	B-X
forms	B-X
a	B-X
complex	B-X
in	B-X
KSHV-infected	B-X
cells	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
LANA	B-X
interacts	B-X
with	B-X
the	B-X
F-box	B-X
and	B-X
WD40	B-X
domains	B-X
of	B-X
Sel10	B-X
and	B-X
competes	B-X
with	B-X
ICN	B-X
for	B-X
binding	B-X
to	B-X
Sel10	B-X
.	B-X
This	B-X
elevated	B-X
level	B-X
of	B-X
ICN	B-X
is	B-X
also	B-X
critical	B-X
for	B-X
maintaining	B-X
the	B-X
enhanced	B-X
proliferation	B-X
of	B-X
KSHV-infected	B-X
tumor	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
describe	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
KSHV-encoded	B-X
LANA	B-X
protein	B-X
regulates	B-X
ubiquitination	B-X
of	B-X
ICN	B-X
mediated	B-X
by	B-X
the	B-X
F-box	B-X
component	B-X
of	B-X
the	B-X
E3	B-X
ligase	B-X
Sel10	B-X
,	B-X
leading	B-X
to	B-X
proliferation	B-X
of	B-X
the	B-X
virus-infected	B-X
cells	B-X
.	B-X

This	O
results	O
in	O
suppression	O
of	O
ICN	O
ubiquitination	O
and	O
degradation	O
.	O
<EOS>	B-X
Intracellular	B-X
activated	B-X
Notch	B-X
(	B-X
ICN	B-X
)	B-X
is	B-X
a	B-X
protooncogene	B-X
linked	B-X
to	B-X
the	B-X
transcription	B-X
activation	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
cell	B-X
cycle	B-X
regulation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
proliferation	B-X
.	B-X
Stability	B-X
of	B-X
ICN	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
the	B-X
Sel10-mediated	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
This	B-X
results	B-X
in	B-X
suppression	B-X
of	B-X
ICN	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
LANA	B-X
interacts	B-X
with	B-X
the	B-X
F-box	B-X
and	B-X
WD40	B-X
domains	B-X
of	B-X
Sel10	B-X
and	B-X
competes	B-X
with	B-X
ICN	B-X
for	B-X
binding	B-X
to	B-X
Sel10	B-X
.	B-X
This	B-X
elevated	B-X
level	B-X
of	B-X
ICN	B-X
is	B-X
also	B-X
critical	B-X
for	B-X
maintaining	B-X
the	B-X
enhanced	B-X
proliferation	B-X
of	B-X
KSHV-infected	B-X
tumor	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
describe	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
KSHV-encoded	B-X
LANA	B-X
protein	B-X
regulates	B-X
ubiquitination	B-X
of	B-X
ICN	B-X
mediated	B-X
by	B-X
the	B-X
F-box	B-X
component	B-X
of	B-X
the	B-X
E3	B-X
ligase	B-X
Sel10	B-X
,	B-X
leading	B-X
to	B-X
proliferation	B-X
of	B-X
the	B-X
virus-infected	B-X
cells	B-X
.	B-X

The	O
carboxyl	O
terminus	O
of	O
LANA	B-Protein
interacts	O
with	O
the	O
F	O
-	O
box	O
and	O
WD40	O
domains	O
of	O
Sel10	B-Protein
and	O
competes	O
with	O
ICN	O
for	O
binding	O
to	O
Sel10	B-Protein
.	O

This	O
elevated	O
level	O
of	O
ICN	O
is	O
also	O
critical	O
for	O
maintaining	O
the	O
enhanced	O
proliferation	O
of	O
KSHV	O
-	O
infected	O
tumor	O
cells	O
.	O
<EOS>	B-X
Intracellular	B-X
activated	B-X
Notch	B-X
(	B-X
ICN	B-X
)	B-X
is	B-X
a	B-X
protooncogene	B-X
linked	B-X
to	B-X
the	B-X
transcription	B-X
activation	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
cell	B-X
cycle	B-X
regulation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
proliferation	B-X
.	B-X
Stability	B-X
of	B-X
ICN	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
the	B-X
Sel10-mediated	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Sel10	B-X
can	B-X
function	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
Notch	B-X
and	B-X
exhibits	B-X
activities	B-X
of	B-X
a	B-X
tumor-suppressor	B-X
protein	B-X
.	B-X
This	B-X
article	B-X
shows	B-X
that	B-X
the	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
latency-associated	B-X
nuclear	B-X
antigen	B-X
(	B-X
LANA	B-X
)	B-X
directly	B-X
interacts	B-X
with	B-X
Sel10	B-X
and	B-X
forms	B-X
a	B-X
complex	B-X
in	B-X
KSHV-infected	B-X
cells	B-X
.	B-X
This	B-X
results	B-X
in	B-X
suppression	B-X
of	B-X
ICN	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
LANA	B-X
interacts	B-X
with	B-X
the	B-X
F-box	B-X
and	B-X
WD40	B-X
domains	B-X
of	B-X
Sel10	B-X
and	B-X
competes	B-X
with	B-X
ICN	B-X
for	B-X
binding	B-X
to	B-X
Sel10	B-X
.	B-X
This	B-X
elevated	B-X
level	B-X
of	B-X
ICN	B-X
is	B-X
also	B-X
critical	B-X
for	B-X
maintaining	B-X
the	B-X
enhanced	B-X
proliferation	B-X
of	B-X
KSHV-infected	B-X
tumor	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
describe	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
KSHV-encoded	B-X
LANA	B-X
protein	B-X
regulates	B-X
ubiquitination	B-X
of	B-X
ICN	B-X
mediated	B-X
by	B-X
the	B-X
F-box	B-X
component	B-X
of	B-X
the	B-X
E3	B-X
ligase	B-X
Sel10	B-X
,	B-X
leading	B-X
to	B-X
proliferation	B-X
of	B-X
the	B-X
virus-infected	B-X
cells	B-X
.	B-X

These	O
findings	O
describe	O
a	O
mechanism	O
by	O
which	O
the	O
KSHV	O
-	O
encoded	O
LANA	B-Protein
protein	O
regulates	O
ubiquitination	O
of	O
ICN	O
mediated	O
by	O
the	O
F	O
-	O
box	O
component	O
of	O
the	O
E3	O
ligase	O
Sel10	B-Protein
,	O
leading	O
to	O
proliferation	O
of	O
the	O
virus	O
-	O
infected	O
cells	O
.	O

The	O
initiation	O
and	O
pattern	O
of	O
spread	O
of	O
histone	B-Protein
H4	I-Protein
acetylation	O
parallel	O
the	O
order	O
of	O
transcriptional	O
activation	O
of	O
genes	O
in	O
the	O
aflatoxin	O
cluster	O
.	O
<EOS>	B-X
The	B-X
27	B-X
genes	B-X
involved	B-X
in	B-X
aflatoxin	B-X
biosynthesis	B-X
are	B-X
clustered	B-X
within	B-X
a	B-X
70	B-X
kb	B-X
region	B-X
in	B-X
the	B-X
Aspergillus	B-X
parasiticus	B-X
genome	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrated	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
the	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
in	B-X
aflatoxin	B-X
promoters	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
accumulation	B-X
of	B-X
aflatoxin	B-X
proteins	B-X
and	B-X
aflatoxin	B-X
.	B-X
Histone	B-X
H4	B-X
acetylation	B-X
in	B-X
the	B-X
pksA	B-X
(	B-X
encodes	B-X
an	B-X
'early	B-X
'	B-X
biosynthetic	B-X
pathway	B-X
enzyme	B-X
)	B-X
promoter	B-X
peaked	B-X
at	B-X
30	B-X
h	B-X
,	B-X
prior	B-X
to	B-X
the	B-X
increased	B-X
acetylation	B-X
in	B-X
the	B-X
omtA	B-X
and	B-X
ordA	B-X
(	B-X
encode	B-X
'late	B-X
'	B-X
enzymes	B-X
)	B-X
promoters	B-X
detected	B-X
at	B-X
40	B-X
h.	B-X
The	B-X
specific	B-X
order	B-X
in	B-X
which	B-X
pksA	B-X
,	B-X
ver-1	B-X
(	B-X
encodes	B-X
a	B-X
'middle	B-X
'	B-X
enzyme	B-X
)	B-X
and	B-X
omtA	B-X
transcripts	B-X
accumulated	B-X
in	B-X
cells	B-X
paralleled	B-X
the	B-X
pattern	B-X
of	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
Binding	B-X
of	B-X
AflR	B-X
,	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
aflatoxin	B-X
biosynthesis	B-X
,	B-X
to	B-X
the	B-X
ordA	B-X
promoter	B-X
showed	B-X
a	B-X
positive	B-X
correlation	B-X
with	B-X
the	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
order	B-X
of	B-X
genes	B-X
within	B-X
the	B-X
aflatoxin	B-X
cluster	B-X
determines	B-X
the	B-X
timing	B-X
and	B-X
order	B-X
of	B-X
transcriptional	B-X
activation	B-X
,	B-X
and	B-X
that	B-X
the	B-X
site	B-X
of	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
mediate	B-X
this	B-X
process	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
aflatoxin	B-X
and	B-X
adjacent	B-X
sugar	B-X
utilization	B-X
clusters	B-X
are	B-X
part	B-X
of	B-X
a	B-X
larger	B-X
'regulatory	B-X
unit	B-X
'	B-X
.	B-X

The	O
27	O
genes	O
involved	O
in	O
aflatoxin	O
biosynthesis	O
are	O
clustered	O
within	O
a	O
70	O
kb	O
region	O
in	O
the	O
Aspergillus	O
parasiticus	O
genome	O
.	O
<EOS>	B-X
The	B-X
27	B-X
genes	B-X
involved	B-X
in	B-X
aflatoxin	B-X
biosynthesis	B-X
are	B-X
clustered	B-X
within	B-X
a	B-X
70	B-X
kb	B-X
region	B-X
in	B-X
the	B-X
Aspergillus	B-X
parasiticus	B-X
genome	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrated	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
the	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
in	B-X
aflatoxin	B-X
promoters	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
accumulation	B-X
of	B-X
aflatoxin	B-X
proteins	B-X
and	B-X
aflatoxin	B-X
.	B-X
Binding	B-X
of	B-X
AflR	B-X
,	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
aflatoxin	B-X
biosynthesis	B-X
,	B-X
to	B-X
the	B-X
ordA	B-X
promoter	B-X
showed	B-X
a	B-X
positive	B-X
correlation	B-X
with	B-X
the	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
order	B-X
of	B-X
genes	B-X
within	B-X
the	B-X
aflatoxin	B-X
cluster	B-X
determines	B-X
the	B-X
timing	B-X
and	B-X
order	B-X
of	B-X
transcriptional	B-X
activation	B-X
,	B-X
and	B-X
that	B-X
the	B-X
site	B-X
of	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
mediate	B-X
this	B-X
process	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
aflatoxin	B-X
and	B-X
adjacent	B-X
sugar	B-X
utilization	B-X
clusters	B-X
are	B-X
part	B-X
of	B-X
a	B-X
larger	B-X
'regulatory	B-X
unit	B-X
'	B-X
.	B-X

Using	O
chromatin	O
immunoprecipitation	O
,	O
we	O
demonstrated	O
a	O
positive	O
correlation	O
between	O
the	O
initiation	O
and	O
spread	O
of	O
histone	B-Protein
H4	I-Protein
acetylation	O
in	O
aflatoxin	O
promoters	O
and	O
the	O
onset	O
of	O
accumulation	O
of	O
aflatoxin	O
proteins	O
and	O
aflatoxin	O
.	O
<EOS>	B-X
The	B-X
27	B-X
genes	B-X
involved	B-X
in	B-X
aflatoxin	B-X
biosynthesis	B-X
are	B-X
clustered	B-X
within	B-X
a	B-X
70	B-X
kb	B-X
region	B-X
in	B-X
the	B-X
Aspergillus	B-X
parasiticus	B-X
genome	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrated	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
the	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
in	B-X
aflatoxin	B-X
promoters	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
accumulation	B-X
of	B-X
aflatoxin	B-X
proteins	B-X
and	B-X
aflatoxin	B-X
.	B-X
Histone	B-X
H4	B-X
acetylation	B-X
in	B-X
the	B-X
pksA	B-X
(	B-X
encodes	B-X
an	B-X
'early	B-X
'	B-X
biosynthetic	B-X
pathway	B-X
enzyme	B-X
)	B-X
promoter	B-X
peaked	B-X
at	B-X
30	B-X
h	B-X
,	B-X
prior	B-X
to	B-X
the	B-X
increased	B-X
acetylation	B-X
in	B-X
the	B-X
omtA	B-X
and	B-X
ordA	B-X
(	B-X
encode	B-X
'late	B-X
'	B-X
enzymes	B-X
)	B-X
promoters	B-X
detected	B-X
at	B-X
40	B-X
h.	B-X
The	B-X
specific	B-X
order	B-X
in	B-X
which	B-X
pksA	B-X
,	B-X
ver-1	B-X
(	B-X
encodes	B-X
a	B-X
'middle	B-X
'	B-X
enzyme	B-X
)	B-X
and	B-X
omtA	B-X
transcripts	B-X
accumulated	B-X
in	B-X
cells	B-X
paralleled	B-X
the	B-X
pattern	B-X
of	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
Binding	B-X
of	B-X
AflR	B-X
,	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
aflatoxin	B-X
biosynthesis	B-X
,	B-X
to	B-X
the	B-X
ordA	B-X
promoter	B-X
showed	B-X
a	B-X
positive	B-X
correlation	B-X
with	B-X
the	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
order	B-X
of	B-X
genes	B-X
within	B-X
the	B-X
aflatoxin	B-X
cluster	B-X
determines	B-X
the	B-X
timing	B-X
and	B-X
order	B-X
of	B-X
transcriptional	B-X
activation	B-X
,	B-X
and	B-X
that	B-X
the	B-X
site	B-X
of	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
mediate	B-X
this	B-X
process	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
aflatoxin	B-X
and	B-X
adjacent	B-X
sugar	B-X
utilization	B-X
clusters	B-X
are	B-X
part	B-X
of	B-X
a	B-X
larger	B-X
'regulatory	B-X
unit	B-X
'	B-X
.	B-X

Histone	B-Protein
H4	I-Protein
acetylation	O
in	O
the	O
pksA	B-Protein
(	O
encodes	O
an	O
'	O
early	O
'	O
biosynthetic	O
pathway	O
enzyme	O
)	O
promoter	O
peaked	O
at	O
30	O
h	O
,	O
prior	O
to	O
the	O
increased	O
acetylation	O
in	O
the	O
omtA	B-Protein
and	O
ordA	B-Protein
(	O
encode	O
'	O
late	O
'	O
enzymes	O
)	O
promoters	O
detected	O
at	O
40	O
h	O
.	O

The	O
specific	O
order	O
in	O
which	O
pksA	B-Protein
,	O
ver	B-Protein
-	I-Protein
1	I-Protein
(	O
encodes	O
a	O
'	O
middle	O
'	O
enzyme	O
)	O
and	O
omtA	B-Protein
transcripts	O
accumulated	O
in	O
cells	O
paralleled	O
the	O
pattern	O
of	O
spread	O
of	O
histone	B-Protein
H4	I-Protein
acetylation	O
.	O
<EOS>	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrated	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
the	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
in	B-X
aflatoxin	B-X
promoters	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
accumulation	B-X
of	B-X
aflatoxin	B-X
proteins	B-X
and	B-X
aflatoxin	B-X
.	B-X
Histone	B-X
H4	B-X
acetylation	B-X
in	B-X
the	B-X
pksA	B-X
(	B-X
encodes	B-X
an	B-X
'early	B-X
'	B-X
biosynthetic	B-X
pathway	B-X
enzyme	B-X
)	B-X
promoter	B-X
peaked	B-X
at	B-X
30	B-X
h	B-X
,	B-X
prior	B-X
to	B-X
the	B-X
increased	B-X
acetylation	B-X
in	B-X
the	B-X
omtA	B-X
and	B-X
ordA	B-X
(	B-X
encode	B-X
'late	B-X
'	B-X
enzymes	B-X
)	B-X
promoters	B-X
detected	B-X
at	B-X
40	B-X
h.	B-X
The	B-X
specific	B-X
order	B-X
in	B-X
which	B-X
pksA	B-X
,	B-X
ver-1	B-X
(	B-X
encodes	B-X
a	B-X
'middle	B-X
'	B-X
enzyme	B-X
)	B-X
and	B-X
omtA	B-X
transcripts	B-X
accumulated	B-X
in	B-X
cells	B-X
paralleled	B-X
the	B-X
pattern	B-X
of	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
Binding	B-X
of	B-X
AflR	B-X
,	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
aflatoxin	B-X
biosynthesis	B-X
,	B-X
to	B-X
the	B-X
ordA	B-X
promoter	B-X
showed	B-X
a	B-X
positive	B-X
correlation	B-X
with	B-X
the	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
order	B-X
of	B-X
genes	B-X
within	B-X
the	B-X
aflatoxin	B-X
cluster	B-X
determines	B-X
the	B-X
timing	B-X
and	B-X
order	B-X
of	B-X
transcriptional	B-X
activation	B-X
,	B-X
and	B-X
that	B-X
the	B-X
site	B-X
of	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
mediate	B-X
this	B-X
process	B-X
.	B-X

Binding	O
of	O
AflR	B-Protein
,	O
a	O
positive	O
regulator	O
of	O
aflatoxin	O
biosynthesis	O
,	O
to	O
the	O
ordA	B-Protein
promoter	O
showed	O
a	O
positive	O
correlation	O
with	O
the	O
spread	O
of	O
histone	B-Protein
H4	I-Protein
acetylation	O
.	O

The	O
data	O
suggest	O
that	O
the	O
order	O
of	O
genes	O
within	O
the	O
aflatoxin	O
cluster	O
determines	O
the	O
timing	O
and	O
order	O
of	O
transcriptional	O
activation	O
,	O
and	O
that	O
the	O
site	O
of	O
initiation	O
and	O
spread	O
of	O
histone	B-Protein
H4	I-Protein
acetylation	O
mediate	O
this	O
process	O
.	O
<EOS>	B-X
The	B-X
27	B-X
genes	B-X
involved	B-X
in	B-X
aflatoxin	B-X
biosynthesis	B-X
are	B-X
clustered	B-X
within	B-X
a	B-X
70	B-X
kb	B-X
region	B-X
in	B-X
the	B-X
Aspergillus	B-X
parasiticus	B-X
genome	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrated	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
the	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
in	B-X
aflatoxin	B-X
promoters	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
accumulation	B-X
of	B-X
aflatoxin	B-X
proteins	B-X
and	B-X
aflatoxin	B-X
.	B-X
Histone	B-X
H4	B-X
acetylation	B-X
in	B-X
the	B-X
pksA	B-X
(	B-X
encodes	B-X
an	B-X
'early	B-X
'	B-X
biosynthetic	B-X
pathway	B-X
enzyme	B-X
)	B-X
promoter	B-X
peaked	B-X
at	B-X
30	B-X
h	B-X
,	B-X
prior	B-X
to	B-X
the	B-X
increased	B-X
acetylation	B-X
in	B-X
the	B-X
omtA	B-X
and	B-X
ordA	B-X
(	B-X
encode	B-X
'late	B-X
'	B-X
enzymes	B-X
)	B-X
promoters	B-X
detected	B-X
at	B-X
40	B-X
h.	B-X
The	B-X
specific	B-X
order	B-X
in	B-X
which	B-X
pksA	B-X
,	B-X
ver-1	B-X
(	B-X
encodes	B-X
a	B-X
'middle	B-X
'	B-X
enzyme	B-X
)	B-X
and	B-X
omtA	B-X
transcripts	B-X
accumulated	B-X
in	B-X
cells	B-X
paralleled	B-X
the	B-X
pattern	B-X
of	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
Binding	B-X
of	B-X
AflR	B-X
,	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
aflatoxin	B-X
biosynthesis	B-X
,	B-X
to	B-X
the	B-X
ordA	B-X
promoter	B-X
showed	B-X
a	B-X
positive	B-X
correlation	B-X
with	B-X
the	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
order	B-X
of	B-X
genes	B-X
within	B-X
the	B-X
aflatoxin	B-X
cluster	B-X
determines	B-X
the	B-X
timing	B-X
and	B-X
order	B-X
of	B-X
transcriptional	B-X
activation	B-X
,	B-X
and	B-X
that	B-X
the	B-X
site	B-X
of	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
mediate	B-X
this	B-X
process	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
aflatoxin	B-X
and	B-X
adjacent	B-X
sugar	B-X
utilization	B-X
clusters	B-X
are	B-X
part	B-X
of	B-X
a	B-X
larger	B-X
'regulatory	B-X
unit	B-X
'	B-X
.	B-X

Our	O
data	O
indicate	O
that	O
the	O
aflatoxin	O
and	O
adjacent	O
sugar	O
utilization	O
clusters	O
are	O
part	O
of	O
a	O
larger	O
'	O
regulatory	O
unit	O
'	O
.	O
<EOS>	B-X
The	B-X
27	B-X
genes	B-X
involved	B-X
in	B-X
aflatoxin	B-X
biosynthesis	B-X
are	B-X
clustered	B-X
within	B-X
a	B-X
70	B-X
kb	B-X
region	B-X
in	B-X
the	B-X
Aspergillus	B-X
parasiticus	B-X
genome	B-X
.	B-X
Using	B-X
chromatin	B-X
immunoprecipitation	B-X
,	B-X
we	B-X
demonstrated	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
the	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
in	B-X
aflatoxin	B-X
promoters	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
accumulation	B-X
of	B-X
aflatoxin	B-X
proteins	B-X
and	B-X
aflatoxin	B-X
.	B-X
Binding	B-X
of	B-X
AflR	B-X
,	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
aflatoxin	B-X
biosynthesis	B-X
,	B-X
to	B-X
the	B-X
ordA	B-X
promoter	B-X
showed	B-X
a	B-X
positive	B-X
correlation	B-X
with	B-X
the	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
order	B-X
of	B-X
genes	B-X
within	B-X
the	B-X
aflatoxin	B-X
cluster	B-X
determines	B-X
the	B-X
timing	B-X
and	B-X
order	B-X
of	B-X
transcriptional	B-X
activation	B-X
,	B-X
and	B-X
that	B-X
the	B-X
site	B-X
of	B-X
initiation	B-X
and	B-X
spread	B-X
of	B-X
histone	B-X
H4	B-X
acetylation	B-X
mediate	B-X
this	B-X
process	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
aflatoxin	B-X
and	B-X
adjacent	B-X
sugar	B-X
utilization	B-X
clusters	B-X
are	B-X
part	B-X
of	B-X
a	B-X
larger	B-X
'regulatory	B-X
unit	B-X
'	B-X
.	B-X

Correlation	O
of	O
DNA	O
methylation	O
with	O
histone	B-Protein
modifications	O
across	O
the	O
HNRPA2B1	B-Protein
-	O
CBX3	B-Protein
ubiquitously	O
-	O
acting	O
chromatin	O
open	O
element	O
(	O
UCOE	O
)	O
.	O
<EOS>	B-X
The	B-X
methylation-free	B-X
CpG	B-X
island	B-X
encompassing	B-X
the	B-X
divergently	B-X
transcribed	B-X
promoters	B-X
of	B-X
the	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
housekeeping	B-X
genes	B-X
possesses	B-X
a	B-X
dominant	B-X
ubiquitously-acting	B-X
chromatin	B-X
opening	B-X
element	B-X
(	B-X
UCOE	B-X
)	B-X
capability	B-X
.	B-X
This	B-X
element	B-X
allows	B-X
reproducible	B-X
and	B-X
stable	B-X
transgene	B-X
expression	B-X
including	B-X
from	B-X
within	B-X
centromeric	B-X
heterochromatin	B-X
.	B-X
We	B-X
present	B-X
an	B-X
investigation	B-X
of	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
modification	B-X
marks	B-X
across	B-X
the	B-X
HNRPA2B1-CBX3	B-X
locus	B-X
in	B-X
primary	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
to	B-X
characterise	B-X
the	B-X
chromatin	B-X
structure	B-X
that	B-X
underlies	B-X
UCOE	B-X
activity	B-X
.	B-X
The	B-X
CpG	B-X
methylation-free	B-X
region	B-X
associated	B-X
with	B-X
the	B-X
UCOE	B-X
extends	B-X
into	B-X
the	B-X
central	B-X
areas	B-X
of	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
,	B-X
with	B-X
a	B-X
total	B-X
length	B-X
of	B-X
approximately	B-X
5	B-X
kb	B-X
.	B-X
However	B-X
,	B-X
the	B-X
DNA	B-X
in	B-X
the	B-X
3	B-X
'	B-X
half	B-X
of	B-X
both	B-X
genes	B-X
is	B-X
methylated	B-X
.	B-X
Histone	B-X
H4	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
acetylation	B-X
shows	B-X
a	B-X
broad	B-X
distribution	B-X
across	B-X
both	B-X
genes	B-X
,	B-X
whilst	B-X
histone	B-X
H3	B-X
lysine	B-X
acetylation	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
and	B-X
drops	B-X
to	B-X
background	B-X
levels	B-X
at	B-X
the	B-X
3	B-X
'	B-X
ends	B-X
.	B-X
Higher	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
present	B-X
at	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
genes	B-X
in	B-X
contrast	B-X
to	B-X
H3K4	B-X
tri-methylation	B-X
which	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
.	B-X
Therefore	B-X
,	B-X
methylated	B-X
DNA	B-X
in	B-X
transcribed	B-X
regions	B-X
of	B-X
these	B-X
genes	B-X
has	B-X
been	B-X
shown	B-X
here	B-X
to	B-X
co-exist	B-X
with	B-X
active	B-X
histone	B-X
modification	B-X
marks	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
functionally	B-X
opposing	B-X
epigenetic	B-X
signatures	B-X
can	B-X
overlap	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
an	B-X
extended	B-X
large	B-X
region	B-X
of	B-X
unmethylated	B-X
DNA	B-X
in	B-X
combination	B-X
with	B-X
distinct	B-X
histone	B-X
modification	B-X
patterns	B-X
are	B-X
at	B-X
the	B-X
basis	B-X
of	B-X
UCOE	B-X
function	B-X
.	B-X

The	O
methylation	O
-	O
free	O
CpG	O
island	O
encompassing	O
the	O
divergently	O
transcribed	O
promoters	O
of	O
the	O
HNRPA2B1	B-Protein
and	O
CBX3	B-Protein
housekeeping	O
genes	O
possesses	O
a	O
dominant	O
ubiquitously	O
-	O
acting	O
chromatin	O
opening	O
element	O
(	O
UCOE	O
)	O
capability	O
.	O
<EOS>	B-X
The	B-X
methylation-free	B-X
CpG	B-X
island	B-X
encompassing	B-X
the	B-X
divergently	B-X
transcribed	B-X
promoters	B-X
of	B-X
the	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
housekeeping	B-X
genes	B-X
possesses	B-X
a	B-X
dominant	B-X
ubiquitously-acting	B-X
chromatin	B-X
opening	B-X
element	B-X
(	B-X
UCOE	B-X
)	B-X
capability	B-X
.	B-X
This	B-X
element	B-X
allows	B-X
reproducible	B-X
and	B-X
stable	B-X
transgene	B-X
expression	B-X
including	B-X
from	B-X
within	B-X
centromeric	B-X
heterochromatin	B-X
.	B-X
We	B-X
present	B-X
an	B-X
investigation	B-X
of	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
modification	B-X
marks	B-X
across	B-X
the	B-X
HNRPA2B1-CBX3	B-X
locus	B-X
in	B-X
primary	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
to	B-X
characterise	B-X
the	B-X
chromatin	B-X
structure	B-X
that	B-X
underlies	B-X
UCOE	B-X
activity	B-X
.	B-X
The	B-X
CpG	B-X
methylation-free	B-X
region	B-X
associated	B-X
with	B-X
the	B-X
UCOE	B-X
extends	B-X
into	B-X
the	B-X
central	B-X
areas	B-X
of	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
,	B-X
with	B-X
a	B-X
total	B-X
length	B-X
of	B-X
approximately	B-X
5	B-X
kb	B-X
.	B-X
However	B-X
,	B-X
the	B-X
DNA	B-X
in	B-X
the	B-X
3	B-X
'	B-X
half	B-X
of	B-X
both	B-X
genes	B-X
is	B-X
methylated	B-X
.	B-X
Histone	B-X
H4	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
acetylation	B-X
shows	B-X
a	B-X
broad	B-X
distribution	B-X
across	B-X
both	B-X
genes	B-X
,	B-X
whilst	B-X
histone	B-X
H3	B-X
lysine	B-X
acetylation	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
and	B-X
drops	B-X
to	B-X
background	B-X
levels	B-X
at	B-X
the	B-X
3	B-X
'	B-X
ends	B-X
.	B-X
Higher	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
present	B-X
at	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
genes	B-X
in	B-X
contrast	B-X
to	B-X
H3K4	B-X
tri-methylation	B-X
which	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
.	B-X
Therefore	B-X
,	B-X
methylated	B-X
DNA	B-X
in	B-X
transcribed	B-X
regions	B-X
of	B-X
these	B-X
genes	B-X
has	B-X
been	B-X
shown	B-X
here	B-X
to	B-X
co-exist	B-X
with	B-X
active	B-X
histone	B-X
modification	B-X
marks	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
functionally	B-X
opposing	B-X
epigenetic	B-X
signatures	B-X
can	B-X
overlap	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
an	B-X
extended	B-X
large	B-X
region	B-X
of	B-X
unmethylated	B-X
DNA	B-X
in	B-X
combination	B-X
with	B-X
distinct	B-X
histone	B-X
modification	B-X
patterns	B-X
are	B-X
at	B-X
the	B-X
basis	B-X
of	B-X
UCOE	B-X
function	B-X
.	B-X

This	O
element	O
allows	O
reproducible	O
and	O
stable	O
transgene	O
expression	O
including	O
from	O
within	O
centromeric	O
heterochromatin	O
.	O
<EOS>	B-X
The	B-X
methylation-free	B-X
CpG	B-X
island	B-X
encompassing	B-X
the	B-X
divergently	B-X
transcribed	B-X
promoters	B-X
of	B-X
the	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
housekeeping	B-X
genes	B-X
possesses	B-X
a	B-X
dominant	B-X
ubiquitously-acting	B-X
chromatin	B-X
opening	B-X
element	B-X
(	B-X
UCOE	B-X
)	B-X
capability	B-X
.	B-X
This	B-X
element	B-X
allows	B-X
reproducible	B-X
and	B-X
stable	B-X
transgene	B-X
expression	B-X
including	B-X
from	B-X
within	B-X
centromeric	B-X
heterochromatin	B-X
.	B-X

We	O
present	O
an	O
investigation	O
of	O
DNA	O
methylation	O
and	O
histone	B-Protein
modification	O
marks	O
across	O
the	O
HNRPA2B1	B-Protein
-	O
CBX3	B-Protein
locus	O
in	O
primary	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
to	O
characterise	O
the	O
chromatin	O
structure	O
that	O
underlies	O
UCOE	O
activity	O
.	O
<EOS>	B-X
The	B-X
methylation-free	B-X
CpG	B-X
island	B-X
encompassing	B-X
the	B-X
divergently	B-X
transcribed	B-X
promoters	B-X
of	B-X
the	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
housekeeping	B-X
genes	B-X
possesses	B-X
a	B-X
dominant	B-X
ubiquitously-acting	B-X
chromatin	B-X
opening	B-X
element	B-X
(	B-X
UCOE	B-X
)	B-X
capability	B-X
.	B-X
This	B-X
element	B-X
allows	B-X
reproducible	B-X
and	B-X
stable	B-X
transgene	B-X
expression	B-X
including	B-X
from	B-X
within	B-X
centromeric	B-X
heterochromatin	B-X
.	B-X
We	B-X
present	B-X
an	B-X
investigation	B-X
of	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
modification	B-X
marks	B-X
across	B-X
the	B-X
HNRPA2B1-CBX3	B-X
locus	B-X
in	B-X
primary	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
to	B-X
characterise	B-X
the	B-X
chromatin	B-X
structure	B-X
that	B-X
underlies	B-X
UCOE	B-X
activity	B-X
.	B-X
The	B-X
CpG	B-X
methylation-free	B-X
region	B-X
associated	B-X
with	B-X
the	B-X
UCOE	B-X
extends	B-X
into	B-X
the	B-X
central	B-X
areas	B-X
of	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
,	B-X
with	B-X
a	B-X
total	B-X
length	B-X
of	B-X
approximately	B-X
5	B-X
kb	B-X
.	B-X
However	B-X
,	B-X
the	B-X
DNA	B-X
in	B-X
the	B-X
3	B-X
'	B-X
half	B-X
of	B-X
both	B-X
genes	B-X
is	B-X
methylated	B-X
.	B-X
Histone	B-X
H4	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
acetylation	B-X
shows	B-X
a	B-X
broad	B-X
distribution	B-X
across	B-X
both	B-X
genes	B-X
,	B-X
whilst	B-X
histone	B-X
H3	B-X
lysine	B-X
acetylation	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
and	B-X
drops	B-X
to	B-X
background	B-X
levels	B-X
at	B-X
the	B-X
3	B-X
'	B-X
ends	B-X
.	B-X
Higher	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
present	B-X
at	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
genes	B-X
in	B-X
contrast	B-X
to	B-X
H3K4	B-X
tri-methylation	B-X
which	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
.	B-X
Therefore	B-X
,	B-X
methylated	B-X
DNA	B-X
in	B-X
transcribed	B-X
regions	B-X
of	B-X
these	B-X
genes	B-X
has	B-X
been	B-X
shown	B-X
here	B-X
to	B-X
co-exist	B-X
with	B-X
active	B-X
histone	B-X
modification	B-X
marks	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
functionally	B-X
opposing	B-X
epigenetic	B-X
signatures	B-X
can	B-X
overlap	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
an	B-X
extended	B-X
large	B-X
region	B-X
of	B-X
unmethylated	B-X
DNA	B-X
in	B-X
combination	B-X
with	B-X
distinct	B-X
histone	B-X
modification	B-X
patterns	B-X
are	B-X
at	B-X
the	B-X
basis	B-X
of	B-X
UCOE	B-X
function	B-X
.	B-X

The	O
CpG	O
methylation	O
-	O
free	O
region	O
associated	O
with	O
the	O
UCOE	O
extends	O
into	O
the	O
central	O
areas	O
of	O
HNRPA2B1	B-Protein
and	O
CBX3	B-Protein
,	O
with	O
a	O
total	O
length	O
of	O
approximately	O
5	O
kb	O
.	O
<EOS>	B-X
The	B-X
methylation-free	B-X
CpG	B-X
island	B-X
encompassing	B-X
the	B-X
divergently	B-X
transcribed	B-X
promoters	B-X
of	B-X
the	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
housekeeping	B-X
genes	B-X
possesses	B-X
a	B-X
dominant	B-X
ubiquitously-acting	B-X
chromatin	B-X
opening	B-X
element	B-X
(	B-X
UCOE	B-X
)	B-X
capability	B-X
.	B-X
We	B-X
present	B-X
an	B-X
investigation	B-X
of	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
modification	B-X
marks	B-X
across	B-X
the	B-X
HNRPA2B1-CBX3	B-X
locus	B-X
in	B-X
primary	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
to	B-X
characterise	B-X
the	B-X
chromatin	B-X
structure	B-X
that	B-X
underlies	B-X
UCOE	B-X
activity	B-X
.	B-X
The	B-X
CpG	B-X
methylation-free	B-X
region	B-X
associated	B-X
with	B-X
the	B-X
UCOE	B-X
extends	B-X
into	B-X
the	B-X
central	B-X
areas	B-X
of	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
,	B-X
with	B-X
a	B-X
total	B-X
length	B-X
of	B-X
approximately	B-X
5	B-X
kb	B-X
.	B-X
Higher	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
present	B-X
at	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
genes	B-X
in	B-X
contrast	B-X
to	B-X
H3K4	B-X
tri-methylation	B-X
which	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
.	B-X
Therefore	B-X
,	B-X
methylated	B-X
DNA	B-X
in	B-X
transcribed	B-X
regions	B-X
of	B-X
these	B-X
genes	B-X
has	B-X
been	B-X
shown	B-X
here	B-X
to	B-X
co-exist	B-X
with	B-X
active	B-X
histone	B-X
modification	B-X
marks	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
functionally	B-X
opposing	B-X
epigenetic	B-X
signatures	B-X
can	B-X
overlap	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
an	B-X
extended	B-X
large	B-X
region	B-X
of	B-X
unmethylated	B-X
DNA	B-X
in	B-X
combination	B-X
with	B-X
distinct	B-X
histone	B-X
modification	B-X
patterns	B-X
are	B-X
at	B-X
the	B-X
basis	B-X
of	B-X
UCOE	B-X
function	B-X
.	B-X

However	O
,	O
the	O
DNA	O
in	O
the	O
3	O
'	O
half	O
of	O
both	O
genes	O
is	O
methylated	O
.	O

Histone	B-Protein
H4	I-Protein
lysine	O
(	O
K	O
)	O
acetylation	O
shows	O
a	O
broad	O
distribution	O
across	O
both	O
genes	O
,	O
whilst	O
histone	B-Protein
H3	I-Protein
lysine	O
acetylation	O
peaks	O
around	O
the	O
transcriptional	O
start	O
sites	O
and	O
drops	O
to	O
background	O
levels	O
at	O
the	O
3	O
'	O
ends	O
.	O

Higher	O
levels	O
of	O
H3K4	B-Protein
di	O
-	O
methylation	O
are	O
present	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
genes	O
in	O
contrast	O
to	O
H3K4	B-Protein
tri	O
-	O
methylation	O
which	O
peaks	O
around	O
the	O
transcriptional	O
start	O
sites	O
.	O
<EOS>	B-X
The	B-X
methylation-free	B-X
CpG	B-X
island	B-X
encompassing	B-X
the	B-X
divergently	B-X
transcribed	B-X
promoters	B-X
of	B-X
the	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
housekeeping	B-X
genes	B-X
possesses	B-X
a	B-X
dominant	B-X
ubiquitously-acting	B-X
chromatin	B-X
opening	B-X
element	B-X
(	B-X
UCOE	B-X
)	B-X
capability	B-X
.	B-X
This	B-X
element	B-X
allows	B-X
reproducible	B-X
and	B-X
stable	B-X
transgene	B-X
expression	B-X
including	B-X
from	B-X
within	B-X
centromeric	B-X
heterochromatin	B-X
.	B-X
We	B-X
present	B-X
an	B-X
investigation	B-X
of	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
modification	B-X
marks	B-X
across	B-X
the	B-X
HNRPA2B1-CBX3	B-X
locus	B-X
in	B-X
primary	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
to	B-X
characterise	B-X
the	B-X
chromatin	B-X
structure	B-X
that	B-X
underlies	B-X
UCOE	B-X
activity	B-X
.	B-X
The	B-X
CpG	B-X
methylation-free	B-X
region	B-X
associated	B-X
with	B-X
the	B-X
UCOE	B-X
extends	B-X
into	B-X
the	B-X
central	B-X
areas	B-X
of	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
,	B-X
with	B-X
a	B-X
total	B-X
length	B-X
of	B-X
approximately	B-X
5	B-X
kb	B-X
.	B-X
However	B-X
,	B-X
the	B-X
DNA	B-X
in	B-X
the	B-X
3	B-X
'	B-X
half	B-X
of	B-X
both	B-X
genes	B-X
is	B-X
methylated	B-X
.	B-X
Histone	B-X
H4	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
acetylation	B-X
shows	B-X
a	B-X
broad	B-X
distribution	B-X
across	B-X
both	B-X
genes	B-X
,	B-X
whilst	B-X
histone	B-X
H3	B-X
lysine	B-X
acetylation	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
and	B-X
drops	B-X
to	B-X
background	B-X
levels	B-X
at	B-X
the	B-X
3	B-X
'	B-X
ends	B-X
.	B-X
Higher	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
present	B-X
at	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
genes	B-X
in	B-X
contrast	B-X
to	B-X
H3K4	B-X
tri-methylation	B-X
which	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
.	B-X
Therefore	B-X
,	B-X
methylated	B-X
DNA	B-X
in	B-X
transcribed	B-X
regions	B-X
of	B-X
these	B-X
genes	B-X
has	B-X
been	B-X
shown	B-X
here	B-X
to	B-X
co-exist	B-X
with	B-X
active	B-X
histone	B-X
modification	B-X
marks	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
functionally	B-X
opposing	B-X
epigenetic	B-X
signatures	B-X
can	B-X
overlap	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
an	B-X
extended	B-X
large	B-X
region	B-X
of	B-X
unmethylated	B-X
DNA	B-X
in	B-X
combination	B-X
with	B-X
distinct	B-X
histone	B-X
modification	B-X
patterns	B-X
are	B-X
at	B-X
the	B-X
basis	B-X
of	B-X
UCOE	B-X
function	B-X
.	B-X

Therefore	O
,	O
methylated	O
DNA	O
in	O
transcribed	O
regions	O
of	O
these	O
genes	O
has	O
been	O
shown	O
here	O
to	O
co	O
-	O
exist	O
with	O
active	O
histone	B-Protein
modification	O
marks	O
,	O
indicating	O
that	O
these	O
functionally	O
opposing	O
epigenetic	O
signatures	O
can	O
overlap	O
.	O
<EOS>	B-X
The	B-X
methylation-free	B-X
CpG	B-X
island	B-X
encompassing	B-X
the	B-X
divergently	B-X
transcribed	B-X
promoters	B-X
of	B-X
the	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
housekeeping	B-X
genes	B-X
possesses	B-X
a	B-X
dominant	B-X
ubiquitously-acting	B-X
chromatin	B-X
opening	B-X
element	B-X
(	B-X
UCOE	B-X
)	B-X
capability	B-X
.	B-X
We	B-X
present	B-X
an	B-X
investigation	B-X
of	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
modification	B-X
marks	B-X
across	B-X
the	B-X
HNRPA2B1-CBX3	B-X
locus	B-X
in	B-X
primary	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
to	B-X
characterise	B-X
the	B-X
chromatin	B-X
structure	B-X
that	B-X
underlies	B-X
UCOE	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
DNA	B-X
in	B-X
the	B-X
3	B-X
'	B-X
half	B-X
of	B-X
both	B-X
genes	B-X
is	B-X
methylated	B-X
.	B-X
Histone	B-X
H4	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
acetylation	B-X
shows	B-X
a	B-X
broad	B-X
distribution	B-X
across	B-X
both	B-X
genes	B-X
,	B-X
whilst	B-X
histone	B-X
H3	B-X
lysine	B-X
acetylation	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
and	B-X
drops	B-X
to	B-X
background	B-X
levels	B-X
at	B-X
the	B-X
3	B-X
'	B-X
ends	B-X
.	B-X
Higher	B-X
levels	B-X
of	B-X
H3K4	B-X
di-methylation	B-X
are	B-X
present	B-X
at	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
genes	B-X
in	B-X
contrast	B-X
to	B-X
H3K4	B-X
tri-methylation	B-X
which	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
.	B-X
Therefore	B-X
,	B-X
methylated	B-X
DNA	B-X
in	B-X
transcribed	B-X
regions	B-X
of	B-X
these	B-X
genes	B-X
has	B-X
been	B-X
shown	B-X
here	B-X
to	B-X
co-exist	B-X
with	B-X
active	B-X
histone	B-X
modification	B-X
marks	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
functionally	B-X
opposing	B-X
epigenetic	B-X
signatures	B-X
can	B-X
overlap	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
an	B-X
extended	B-X
large	B-X
region	B-X
of	B-X
unmethylated	B-X
DNA	B-X
in	B-X
combination	B-X
with	B-X
distinct	B-X
histone	B-X
modification	B-X
patterns	B-X
are	B-X
at	B-X
the	B-X
basis	B-X
of	B-X
UCOE	B-X
function	B-X
.	B-X

This	O
suggests	O
that	O
an	O
extended	O
large	O
region	O
of	O
unmethylated	O
DNA	O
in	O
combination	O
with	O
distinct	O
histone	B-Protein
modification	O
patterns	O
are	O
at	O
the	O
basis	O
of	O
UCOE	O
function	O
.	O
<EOS>	B-X
The	B-X
methylation-free	B-X
CpG	B-X
island	B-X
encompassing	B-X
the	B-X
divergently	B-X
transcribed	B-X
promoters	B-X
of	B-X
the	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
housekeeping	B-X
genes	B-X
possesses	B-X
a	B-X
dominant	B-X
ubiquitously-acting	B-X
chromatin	B-X
opening	B-X
element	B-X
(	B-X
UCOE	B-X
)	B-X
capability	B-X
.	B-X
We	B-X
present	B-X
an	B-X
investigation	B-X
of	B-X
DNA	B-X
methylation	B-X
and	B-X
histone	B-X
modification	B-X
marks	B-X
across	B-X
the	B-X
HNRPA2B1-CBX3	B-X
locus	B-X
in	B-X
primary	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
to	B-X
characterise	B-X
the	B-X
chromatin	B-X
structure	B-X
that	B-X
underlies	B-X
UCOE	B-X
activity	B-X
.	B-X
The	B-X
CpG	B-X
methylation-free	B-X
region	B-X
associated	B-X
with	B-X
the	B-X
UCOE	B-X
extends	B-X
into	B-X
the	B-X
central	B-X
areas	B-X
of	B-X
HNRPA2B1	B-X
and	B-X
CBX3	B-X
,	B-X
with	B-X
a	B-X
total	B-X
length	B-X
of	B-X
approximately	B-X
5	B-X
kb	B-X
.	B-X
However	B-X
,	B-X
the	B-X
DNA	B-X
in	B-X
the	B-X
3	B-X
'	B-X
half	B-X
of	B-X
both	B-X
genes	B-X
is	B-X
methylated	B-X
.	B-X
Histone	B-X
H4	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
acetylation	B-X
shows	B-X
a	B-X
broad	B-X
distribution	B-X
across	B-X
both	B-X
genes	B-X
,	B-X
whilst	B-X
histone	B-X
H3	B-X
lysine	B-X
acetylation	B-X
peaks	B-X
around	B-X
the	B-X
transcriptional	B-X
start	B-X
sites	B-X
and	B-X
drops	B-X
to	B-X
background	B-X
levels	B-X
at	B-X
the	B-X
3	B-X
'	B-X
ends	B-X
.	B-X
Therefore	B-X
,	B-X
methylated	B-X
DNA	B-X
in	B-X
transcribed	B-X
regions	B-X
of	B-X
these	B-X
genes	B-X
has	B-X
been	B-X
shown	B-X
here	B-X
to	B-X
co-exist	B-X
with	B-X
active	B-X
histone	B-X
modification	B-X
marks	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
functionally	B-X
opposing	B-X
epigenetic	B-X
signatures	B-X
can	B-X
overlap	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
an	B-X
extended	B-X
large	B-X
region	B-X
of	B-X
unmethylated	B-X
DNA	B-X
in	B-X
combination	B-X
with	B-X
distinct	B-X
histone	B-X
modification	B-X
patterns	B-X
are	B-X
at	B-X
the	B-X
basis	B-X
of	B-X
UCOE	B-X
function	B-X
.	B-X

Cdc42	B-Protein
regulates	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
ubiquitination	O
and	O
degradation	O
through	O
an	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
to	O
Src	B-Protein
-	O
mediated	O
pathway	O
.	O
<EOS>	B-X
E-cadherins	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
maintaining	B-X
epithelial	B-X
polarity	B-X
by	B-X
forming	B-X
Ca2+-dependent	B-X
adherens	B-X
junctions	B-X
between	B-X
epithelial	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
and	B-X
that	B-X
Cdc42	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
this	B-X
process	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
activation	B-X
of	B-X
Cdc42	B-X
.	B-X
This	B-X
in	B-X
turn	B-X
up-regulates	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
signaling	B-X
to	B-X
mediate	B-X
Src	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Silencing	B-X
Cdc42	B-X
blocks	B-X
activation	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
induced	B-X
by	B-X
Ca2+	B-X
depletion	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
E-cadherin	B-X
degradation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
Cdc42	B-X
in	B-X
regulating	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
is	B-X
underscored	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
constitutively	B-X
active	B-X
Cdc42	B-X
(	B-X
F28L	B-X
)	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
and	B-X
significantly	B-X
enhances	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
GTP-dependent	B-X
binding	B-X
of	B-X
Cdc42	B-X
to	B-X
E-cadherin	B-X
is	B-X
critical	B-X
for	B-X
Cdc42	B-X
to	B-X
induce	B-X
the	B-X
dissolution	B-X
of	B-X
adherens	B-X
junctions	B-X
.	B-X
Our	B-X
data	B-X
support	B-X
a	B-X
model	B-X
that	B-X
activation	B-X
of	B-X
Cdc42	B-X
contributes	B-X
to	B-X
mesenchyme-like	B-X
phenotype	B-X
by	B-X
targeting	B-X
of	B-X
E-cadherin	B-X
for	B-X
lysosomal	B-X
degradation	B-X
.	B-X

E	B-Protein
-	I-Protein
cadherins	I-Protein
play	O
an	O
essential	O
role	O
in	O
maintaining	O
epithelial	O
polarity	O
by	O
forming	O
Ca2	O
+	O
-	O
dependent	O
adherens	O
junctions	O
between	O
epithelial	O
cells	O
.	O
<EOS>	B-X
E-cadherins	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
maintaining	B-X
epithelial	B-X
polarity	B-X
by	B-X
forming	B-X
Ca2+-dependent	B-X
adherens	B-X
junctions	B-X
between	B-X
epithelial	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
and	B-X
that	B-X
Cdc42	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
this	B-X
process	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
activation	B-X
of	B-X
Cdc42	B-X
.	B-X
This	B-X
in	B-X
turn	B-X
up-regulates	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
signaling	B-X
to	B-X
mediate	B-X
Src	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Silencing	B-X
Cdc42	B-X
blocks	B-X
activation	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
induced	B-X
by	B-X
Ca2+	B-X
depletion	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
E-cadherin	B-X
degradation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
Cdc42	B-X
in	B-X
regulating	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
is	B-X
underscored	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
constitutively	B-X
active	B-X
Cdc42	B-X
(	B-X
F28L	B-X
)	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
and	B-X
significantly	B-X
enhances	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
GTP-dependent	B-X
binding	B-X
of	B-X
Cdc42	B-X
to	B-X
E-cadherin	B-X
is	B-X
critical	B-X
for	B-X
Cdc42	B-X
to	B-X
induce	B-X
the	B-X
dissolution	B-X
of	B-X
adherens	B-X
junctions	B-X
.	B-X
Our	B-X
data	B-X
support	B-X
a	B-X
model	B-X
that	B-X
activation	B-X
of	B-X
Cdc42	B-X
contributes	B-X
to	B-X
mesenchyme-like	B-X
phenotype	B-X
by	B-X
targeting	B-X
of	B-X
E-cadherin	B-X
for	B-X
lysosomal	B-X
degradation	B-X
.	B-X

Here	O
,	O
we	O
report	O
that	O
Ca2	O
+	O
depletion	O
induces	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
ubiquitination	O
and	O
lysosomal	O
degradation	O
and	O
that	O
Cdc42	B-Protein
plays	O
an	O
important	O
role	O
in	O
regulating	O
this	O
process	O
.	O
<EOS>	B-X
E-cadherins	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
maintaining	B-X
epithelial	B-X
polarity	B-X
by	B-X
forming	B-X
Ca2+-dependent	B-X
adherens	B-X
junctions	B-X
between	B-X
epithelial	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
and	B-X
that	B-X
Cdc42	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
this	B-X
process	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
activation	B-X
of	B-X
Cdc42	B-X
.	B-X
This	B-X
in	B-X
turn	B-X
up-regulates	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
signaling	B-X
to	B-X
mediate	B-X
Src	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Silencing	B-X
Cdc42	B-X
blocks	B-X
activation	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
induced	B-X
by	B-X
Ca2+	B-X
depletion	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
E-cadherin	B-X
degradation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
Cdc42	B-X
in	B-X
regulating	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
is	B-X
underscored	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
constitutively	B-X
active	B-X
Cdc42	B-X
(	B-X
F28L	B-X
)	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
and	B-X
significantly	B-X
enhances	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
GTP-dependent	B-X
binding	B-X
of	B-X
Cdc42	B-X
to	B-X
E-cadherin	B-X
is	B-X
critical	B-X
for	B-X
Cdc42	B-X
to	B-X
induce	B-X
the	B-X
dissolution	B-X
of	B-X
adherens	B-X
junctions	B-X
.	B-X
Our	B-X
data	B-X
support	B-X
a	B-X
model	B-X
that	B-X
activation	B-X
of	B-X
Cdc42	B-X
contributes	B-X
to	B-X
mesenchyme-like	B-X
phenotype	B-X
by	B-X
targeting	B-X
of	B-X
E-cadherin	B-X
for	B-X
lysosomal	B-X
degradation	B-X
.	B-X

We	O
demonstrate	O
that	O
Ca2	O
+	O
depletion	O
induces	O
activation	O
of	O
Cdc42	B-Protein
.	O
<EOS>	B-X
E-cadherins	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
maintaining	B-X
epithelial	B-X
polarity	B-X
by	B-X
forming	B-X
Ca2+-dependent	B-X
adherens	B-X
junctions	B-X
between	B-X
epithelial	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
and	B-X
that	B-X
Cdc42	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
this	B-X
process	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
activation	B-X
of	B-X
Cdc42	B-X
.	B-X
This	B-X
in	B-X
turn	B-X
up-regulates	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
signaling	B-X
to	B-X
mediate	B-X
Src	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Silencing	B-X
Cdc42	B-X
blocks	B-X
activation	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
induced	B-X
by	B-X
Ca2+	B-X
depletion	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
E-cadherin	B-X
degradation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
Cdc42	B-X
in	B-X
regulating	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
is	B-X
underscored	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
constitutively	B-X
active	B-X
Cdc42	B-X
(	B-X
F28L	B-X
)	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
and	B-X
significantly	B-X
enhances	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
GTP-dependent	B-X
binding	B-X
of	B-X
Cdc42	B-X
to	B-X
E-cadherin	B-X
is	B-X
critical	B-X
for	B-X
Cdc42	B-X
to	B-X
induce	B-X
the	B-X
dissolution	B-X
of	B-X
adherens	B-X
junctions	B-X
.	B-X
Our	B-X
data	B-X
support	B-X
a	B-X
model	B-X
that	B-X
activation	B-X
of	B-X
Cdc42	B-X
contributes	B-X
to	B-X
mesenchyme-like	B-X
phenotype	B-X
by	B-X
targeting	B-X
of	B-X
E-cadherin	B-X
for	B-X
lysosomal	B-X
degradation	B-X
.	B-X

This	O
in	O
turn	O
up	O
-	O
regulates	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
(	O
EGFR	B-Protein
)	O
signaling	O
to	O
mediate	O
Src	B-Protein
activation	O
,	O
leading	O
to	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
ubiquitination	O
and	O
lysosomal	O
degradation	O
.	O

Silencing	O
Cdc42	B-Protein
blocks	O
activation	O
of	O
EGFR	B-Protein
and	O
Src	B-Protein
induced	O
by	O
Ca2	O
+	O
depletion	O
,	O
resulting	O
in	O
a	O
reduction	O
in	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
degradation	O
.	O

The	O
role	O
of	O
Cdc42	B-Protein
in	O
regulating	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
ubiquitination	O
and	O
degradation	O
is	O
underscored	O
by	O
the	O
fact	O
that	O
constitutively	O
active	O
Cdc42	B-Protein
(	O
F28L	B-Protein
)	O
increases	O
the	O
activity	O
of	O
EGFR	B-Protein
and	O
Src	B-Protein
and	O
significantly	O
enhances	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
ubiquitination	O
and	O
lysosomal	O
degradation	O
.	O
<EOS>	B-X
E-cadherins	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
maintaining	B-X
epithelial	B-X
polarity	B-X
by	B-X
forming	B-X
Ca2+-dependent	B-X
adherens	B-X
junctions	B-X
between	B-X
epithelial	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
and	B-X
that	B-X
Cdc42	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
this	B-X
process	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
Ca2+	B-X
depletion	B-X
induces	B-X
activation	B-X
of	B-X
Cdc42	B-X
.	B-X
This	B-X
in	B-X
turn	B-X
up-regulates	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
signaling	B-X
to	B-X
mediate	B-X
Src	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Silencing	B-X
Cdc42	B-X
blocks	B-X
activation	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
induced	B-X
by	B-X
Ca2+	B-X
depletion	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
E-cadherin	B-X
degradation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
Cdc42	B-X
in	B-X
regulating	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
is	B-X
underscored	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
constitutively	B-X
active	B-X
Cdc42	B-X
(	B-X
F28L	B-X
)	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
EGFR	B-X
and	B-X
Src	B-X
and	B-X
significantly	B-X
enhances	B-X
E-cadherin	B-X
ubiquitination	B-X
and	B-X
lysosomal	B-X
degradation	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
GTP-dependent	B-X
binding	B-X
of	B-X
Cdc42	B-X
to	B-X
E-cadherin	B-X
is	B-X
critical	B-X
for	B-X
Cdc42	B-X
to	B-X
induce	B-X
the	B-X
dissolution	B-X
of	B-X
adherens	B-X
junctions	B-X
.	B-X
Our	B-X
data	B-X
support	B-X
a	B-X
model	B-X
that	B-X
activation	B-X
of	B-X
Cdc42	B-X
contributes	B-X
to	B-X
mesenchyme-like	B-X
phenotype	B-X
by	B-X
targeting	B-X
of	B-X
E-cadherin	B-X
for	B-X
lysosomal	B-X
degradation	B-X
.	B-X

Furthermore	O
,	O
we	O
found	O
that	O
GTP	O
-	O
dependent	O
binding	O
of	O
Cdc42	B-Protein
to	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
is	O
critical	O
for	O
Cdc42	B-Protein
to	O
induce	O
the	O
dissolution	O
of	O
adherens	O
junctions	O
.	O

Our	O
data	O
support	O
a	O
model	O
that	O
activation	O
of	O
Cdc42	B-Protein
contributes	O
to	O
mesenchyme	O
-	O
like	O
phenotype	O
by	O
targeting	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
for	O
lysosomal	O
degradation	O
.	O

A	O
conserved	O
SET	O
domain	O
methyltransferase	O
,	O
Set11	B-Protein
,	O
modifies	O
ribosomal	O
protein	O
Rpl12	B-Protein
in	O
fission	O
yeast	O
.	O
<EOS>	B-X
SET	B-X
domain-containing	B-X
methyltransferases	B-X
post-translationally	B-X
modify	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
histones	B-X
,	B-X
cytochrome	B-X
c	B-X
,	B-X
ribulose-bisphosphate	B-X
carboxylase/oxygenase	B-X
,	B-X
and	B-X
ribosomal	B-X
proteins	B-X
.	B-X
In	B-X
the	B-X
fission	B-X
yeast	B-X
Schizosaccharomyces	B-X
pombe	B-X
,	B-X
at	B-X
least	B-X
13	B-X
SET	B-X
domain-containing	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
,	B-X
four	B-X
of	B-X
which	B-X
are	B-X
involved	B-X
in	B-X
transcriptional	B-X
regulation	B-X
through	B-X
their	B-X
modification	B-X
of	B-X
histone	B-X
tails	B-X
.	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
played	B-X
by	B-X
the	B-X
other	B-X
SET	B-X
domain	B-X
proteins	B-X
in	B-X
cellular	B-X
processes	B-X
and	B-X
their	B-X
physiological	B-X
substrates	B-X
remain	B-X
unresolved	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
S.	B-X
pombe	B-X
Set11	B-X
,	B-X
a	B-X
SET	B-X
domain-containing	B-X
protein	B-X
encoded	B-X
by	B-X
SPCC1223.04c	B-X
,	B-X
specifically	B-X
modifies	B-X
Rpl12	B-X
(	B-X
ribosomal	B-X
protein	B-X
L12	B-X
)	B-X
.	B-X
Recombinant	B-X
Set11	B-X
prepared	B-X
from	B-X
Escherichia	B-X
coli	B-X
had	B-X
catalytic	B-X
activity	B-X
and	B-X
methylated	B-X
a	B-X
17-kDa	B-X
polypeptide	B-X
in	B-X
cellular	B-X
extracts	B-X
of	B-X
set11	B-X
mutant	B-X
cells	B-X
.	B-X
The	B-X
methylated	B-X
protein	B-X
was	B-X
isolated	B-X
by	B-X
two-dimensional	B-X
gel	B-X
electrophoresis	B-X
or	B-X
by	B-X
reverse-phase	B-X
chromatography	B-X
and	B-X
was	B-X
identified	B-X
as	B-X
Rpl12	B-X
by	B-X
mass	B-X
spectrometry	B-X
.	B-X
In	B-X
vitro	B-X
methylation	B-X
experiments	B-X
using	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rpl12	B-X
proteins	B-X
verified	B-X
that	B-X
Set11	B-X
modified	B-X
recombinant	B-X
Rpl12	B-X
and	B-X
suggested	B-X
that	B-X
its	B-X
potential	B-X
target	B-X
site	B-X
was	B-X
lysine	B-X
3	B-X
.	B-X
The	B-X
methylation	B-X
site	B-X
modified	B-X
by	B-X
Set11	B-X
was	B-X
also	B-X
confirmed	B-X
by	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
,	B-X
which	B-X
also	B-X
revealed	B-X
other	B-X
unique	B-X
methylation	B-X
sites	B-X
of	B-X
Rpl12	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Set11	B-X
predominantly	B-X
localized	B-X
to	B-X
the	B-X
nucleolus	B-X
and	B-X
that	B-X
the	B-X
overproduction	B-X
of	B-X
Set11	B-X
caused	B-X
a	B-X
severe	B-X
growth	B-X
defect	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Rpl12	B-X
methylation	B-X
occurs	B-X
during	B-X
the	B-X
ribosomal	B-X
assembly	B-X
processes	B-X
and	B-X
that	B-X
control	B-X
of	B-X
the	B-X
Set11	B-X
expression	B-X
level	B-X
is	B-X
important	B-X
for	B-X
its	B-X
cellular	B-X
function	B-X
.	B-X

SET	O
domain	O
-	O
containing	O
methyltransferases	O
post	O
-	O
translationally	O
modify	O
a	O
variety	O
of	O
cellular	O
proteins	O
,	O
such	O
as	O
histones	B-Protein
,	O
cytochrome	B-Protein
c	I-Protein
,	O
ribulose	O
-	O
bisphosphate	O
carboxylase	O
/	O
oxygenase	O
,	O
and	O
ribosomal	O
proteins	O
.	O
<EOS>	B-X
SET	B-X
domain-containing	B-X
methyltransferases	B-X
post-translationally	B-X
modify	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
histones	B-X
,	B-X
cytochrome	B-X
c	B-X
,	B-X
ribulose-bisphosphate	B-X
carboxylase/oxygenase	B-X
,	B-X
and	B-X
ribosomal	B-X
proteins	B-X
.	B-X
In	B-X
the	B-X
fission	B-X
yeast	B-X
Schizosaccharomyces	B-X
pombe	B-X
,	B-X
at	B-X
least	B-X
13	B-X
SET	B-X
domain-containing	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
,	B-X
four	B-X
of	B-X
which	B-X
are	B-X
involved	B-X
in	B-X
transcriptional	B-X
regulation	B-X
through	B-X
their	B-X
modification	B-X
of	B-X
histone	B-X
tails	B-X
.	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
played	B-X
by	B-X
the	B-X
other	B-X
SET	B-X
domain	B-X
proteins	B-X
in	B-X
cellular	B-X
processes	B-X
and	B-X
their	B-X
physiological	B-X
substrates	B-X
remain	B-X
unresolved	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
S.	B-X
pombe	B-X
Set11	B-X
,	B-X
a	B-X
SET	B-X
domain-containing	B-X
protein	B-X
encoded	B-X
by	B-X
SPCC1223.04c	B-X
,	B-X
specifically	B-X
modifies	B-X
Rpl12	B-X
(	B-X
ribosomal	B-X
protein	B-X
L12	B-X
)	B-X
.	B-X
Recombinant	B-X
Set11	B-X
prepared	B-X
from	B-X
Escherichia	B-X
coli	B-X
had	B-X
catalytic	B-X
activity	B-X
and	B-X
methylated	B-X
a	B-X
17-kDa	B-X
polypeptide	B-X
in	B-X
cellular	B-X
extracts	B-X
of	B-X
set11	B-X
mutant	B-X
cells	B-X
.	B-X
The	B-X
methylated	B-X
protein	B-X
was	B-X
isolated	B-X
by	B-X
two-dimensional	B-X
gel	B-X
electrophoresis	B-X
or	B-X
by	B-X
reverse-phase	B-X
chromatography	B-X
and	B-X
was	B-X
identified	B-X
as	B-X
Rpl12	B-X
by	B-X
mass	B-X
spectrometry	B-X
.	B-X
In	B-X
vitro	B-X
methylation	B-X
experiments	B-X
using	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rpl12	B-X
proteins	B-X
verified	B-X
that	B-X
Set11	B-X
modified	B-X
recombinant	B-X
Rpl12	B-X
and	B-X
suggested	B-X
that	B-X
its	B-X
potential	B-X
target	B-X
site	B-X
was	B-X
lysine	B-X
3	B-X
.	B-X
The	B-X
methylation	B-X
site	B-X
modified	B-X
by	B-X
Set11	B-X
was	B-X
also	B-X
confirmed	B-X
by	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
,	B-X
which	B-X
also	B-X
revealed	B-X
other	B-X
unique	B-X
methylation	B-X
sites	B-X
of	B-X
Rpl12	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Set11	B-X
predominantly	B-X
localized	B-X
to	B-X
the	B-X
nucleolus	B-X
and	B-X
that	B-X
the	B-X
overproduction	B-X
of	B-X
Set11	B-X
caused	B-X
a	B-X
severe	B-X
growth	B-X
defect	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Rpl12	B-X
methylation	B-X
occurs	B-X
during	B-X
the	B-X
ribosomal	B-X
assembly	B-X
processes	B-X
and	B-X
that	B-X
control	B-X
of	B-X
the	B-X
Set11	B-X
expression	B-X
level	B-X
is	B-X
important	B-X
for	B-X
its	B-X
cellular	B-X
function	B-X
.	B-X

In	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
,	O
at	O
least	O
13	O
SET	O
domain	O
-	O
containing	O
proteins	O
have	O
been	O
identified	O
in	O
the	O
genome	O
,	O
four	O
of	O
which	O
are	O
involved	O
in	O
transcriptional	O
regulation	O
through	O
their	O
modification	O
of	O
histone	B-Protein
tails	O
.	O
<EOS>	B-X
SET	B-X
domain-containing	B-X
methyltransferases	B-X
post-translationally	B-X
modify	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
histones	B-X
,	B-X
cytochrome	B-X
c	B-X
,	B-X
ribulose-bisphosphate	B-X
carboxylase/oxygenase	B-X
,	B-X
and	B-X
ribosomal	B-X
proteins	B-X
.	B-X
In	B-X
the	B-X
fission	B-X
yeast	B-X
Schizosaccharomyces	B-X
pombe	B-X
,	B-X
at	B-X
least	B-X
13	B-X
SET	B-X
domain-containing	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
,	B-X
four	B-X
of	B-X
which	B-X
are	B-X
involved	B-X
in	B-X
transcriptional	B-X
regulation	B-X
through	B-X
their	B-X
modification	B-X
of	B-X
histone	B-X
tails	B-X
.	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
played	B-X
by	B-X
the	B-X
other	B-X
SET	B-X
domain	B-X
proteins	B-X
in	B-X
cellular	B-X
processes	B-X
and	B-X
their	B-X
physiological	B-X
substrates	B-X
remain	B-X
unresolved	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
S.	B-X
pombe	B-X
Set11	B-X
,	B-X
a	B-X
SET	B-X
domain-containing	B-X
protein	B-X
encoded	B-X
by	B-X
SPCC1223.04c	B-X
,	B-X
specifically	B-X
modifies	B-X
Rpl12	B-X
(	B-X
ribosomal	B-X
protein	B-X
L12	B-X
)	B-X
.	B-X
The	B-X
methylated	B-X
protein	B-X
was	B-X
isolated	B-X
by	B-X
two-dimensional	B-X
gel	B-X
electrophoresis	B-X
or	B-X
by	B-X
reverse-phase	B-X
chromatography	B-X
and	B-X
was	B-X
identified	B-X
as	B-X
Rpl12	B-X
by	B-X
mass	B-X
spectrometry	B-X
.	B-X
In	B-X
vitro	B-X
methylation	B-X
experiments	B-X
using	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rpl12	B-X
proteins	B-X
verified	B-X
that	B-X
Set11	B-X
modified	B-X
recombinant	B-X
Rpl12	B-X
and	B-X
suggested	B-X
that	B-X
its	B-X
potential	B-X
target	B-X
site	B-X
was	B-X
lysine	B-X
3	B-X
.	B-X

However	O
,	O
the	O
roles	O
played	O
by	O
the	O
other	O
SET	O
domain	O
proteins	O
in	O
cellular	O
processes	O
and	O
their	O
physiological	O
substrates	O
remain	O
unresolved	O
.	O
<EOS>	B-X
SET	B-X
domain-containing	B-X
methyltransferases	B-X
post-translationally	B-X
modify	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
histones	B-X
,	B-X
cytochrome	B-X
c	B-X
,	B-X
ribulose-bisphosphate	B-X
carboxylase/oxygenase	B-X
,	B-X
and	B-X
ribosomal	B-X
proteins	B-X
.	B-X
In	B-X
the	B-X
fission	B-X
yeast	B-X
Schizosaccharomyces	B-X
pombe	B-X
,	B-X
at	B-X
least	B-X
13	B-X
SET	B-X
domain-containing	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
,	B-X
four	B-X
of	B-X
which	B-X
are	B-X
involved	B-X
in	B-X
transcriptional	B-X
regulation	B-X
through	B-X
their	B-X
modification	B-X
of	B-X
histone	B-X
tails	B-X
.	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
played	B-X
by	B-X
the	B-X
other	B-X
SET	B-X
domain	B-X
proteins	B-X
in	B-X
cellular	B-X
processes	B-X
and	B-X
their	B-X
physiological	B-X
substrates	B-X
remain	B-X
unresolved	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
S.	B-X
pombe	B-X
Set11	B-X
,	B-X
a	B-X
SET	B-X
domain-containing	B-X
protein	B-X
encoded	B-X
by	B-X
SPCC1223.04c	B-X
,	B-X
specifically	B-X
modifies	B-X
Rpl12	B-X
(	B-X
ribosomal	B-X
protein	B-X
L12	B-X
)	B-X
.	B-X
Recombinant	B-X
Set11	B-X
prepared	B-X
from	B-X
Escherichia	B-X
coli	B-X
had	B-X
catalytic	B-X
activity	B-X
and	B-X
methylated	B-X
a	B-X
17-kDa	B-X
polypeptide	B-X
in	B-X
cellular	B-X
extracts	B-X
of	B-X
set11	B-X
mutant	B-X
cells	B-X
.	B-X
In	B-X
vitro	B-X
methylation	B-X
experiments	B-X
using	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rpl12	B-X
proteins	B-X
verified	B-X
that	B-X
Set11	B-X
modified	B-X
recombinant	B-X
Rpl12	B-X
and	B-X
suggested	B-X
that	B-X
its	B-X
potential	B-X
target	B-X
site	B-X
was	B-X
lysine	B-X
3	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Rpl12	B-X
methylation	B-X
occurs	B-X
during	B-X
the	B-X
ribosomal	B-X
assembly	B-X
processes	B-X
and	B-X
that	B-X
control	B-X
of	B-X
the	B-X
Set11	B-X
expression	B-X
level	B-X
is	B-X
important	B-X
for	B-X
its	B-X
cellular	B-X
function	B-X
.	B-X

We	O
show	O
here	O
that	O
S	O
.	O
pombe	O
Set11	B-Protein
,	O
a	O
SET	O
domain	O
-	O
containing	O
protein	O
encoded	O
by	O
SPCC1223	O
.	O
04c	O
,	O
specifically	O
modifies	O
Rpl12	B-Protein
(	O
ribosomal	B-Protein
protein	I-Protein
L12	I-Protein
)	O
.	O
<EOS>	B-X
SET	B-X
domain-containing	B-X
methyltransferases	B-X
post-translationally	B-X
modify	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
histones	B-X
,	B-X
cytochrome	B-X
c	B-X
,	B-X
ribulose-bisphosphate	B-X
carboxylase/oxygenase	B-X
,	B-X
and	B-X
ribosomal	B-X
proteins	B-X
.	B-X
In	B-X
the	B-X
fission	B-X
yeast	B-X
Schizosaccharomyces	B-X
pombe	B-X
,	B-X
at	B-X
least	B-X
13	B-X
SET	B-X
domain-containing	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
,	B-X
four	B-X
of	B-X
which	B-X
are	B-X
involved	B-X
in	B-X
transcriptional	B-X
regulation	B-X
through	B-X
their	B-X
modification	B-X
of	B-X
histone	B-X
tails	B-X
.	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
played	B-X
by	B-X
the	B-X
other	B-X
SET	B-X
domain	B-X
proteins	B-X
in	B-X
cellular	B-X
processes	B-X
and	B-X
their	B-X
physiological	B-X
substrates	B-X
remain	B-X
unresolved	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
S.	B-X
pombe	B-X
Set11	B-X
,	B-X
a	B-X
SET	B-X
domain-containing	B-X
protein	B-X
encoded	B-X
by	B-X
SPCC1223.04c	B-X
,	B-X
specifically	B-X
modifies	B-X
Rpl12	B-X
(	B-X
ribosomal	B-X
protein	B-X
L12	B-X
)	B-X
.	B-X
Recombinant	B-X
Set11	B-X
prepared	B-X
from	B-X
Escherichia	B-X
coli	B-X
had	B-X
catalytic	B-X
activity	B-X
and	B-X
methylated	B-X
a	B-X
17-kDa	B-X
polypeptide	B-X
in	B-X
cellular	B-X
extracts	B-X
of	B-X
set11	B-X
mutant	B-X
cells	B-X
.	B-X
The	B-X
methylated	B-X
protein	B-X
was	B-X
isolated	B-X
by	B-X
two-dimensional	B-X
gel	B-X
electrophoresis	B-X
or	B-X
by	B-X
reverse-phase	B-X
chromatography	B-X
and	B-X
was	B-X
identified	B-X
as	B-X
Rpl12	B-X
by	B-X
mass	B-X
spectrometry	B-X
.	B-X
In	B-X
vitro	B-X
methylation	B-X
experiments	B-X
using	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rpl12	B-X
proteins	B-X
verified	B-X
that	B-X
Set11	B-X
modified	B-X
recombinant	B-X
Rpl12	B-X
and	B-X
suggested	B-X
that	B-X
its	B-X
potential	B-X
target	B-X
site	B-X
was	B-X
lysine	B-X
3	B-X
.	B-X
The	B-X
methylation	B-X
site	B-X
modified	B-X
by	B-X
Set11	B-X
was	B-X
also	B-X
confirmed	B-X
by	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
,	B-X
which	B-X
also	B-X
revealed	B-X
other	B-X
unique	B-X
methylation	B-X
sites	B-X
of	B-X
Rpl12	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Set11	B-X
predominantly	B-X
localized	B-X
to	B-X
the	B-X
nucleolus	B-X
and	B-X
that	B-X
the	B-X
overproduction	B-X
of	B-X
Set11	B-X
caused	B-X
a	B-X
severe	B-X
growth	B-X
defect	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Rpl12	B-X
methylation	B-X
occurs	B-X
during	B-X
the	B-X
ribosomal	B-X
assembly	B-X
processes	B-X
and	B-X
that	B-X
control	B-X
of	B-X
the	B-X
Set11	B-X
expression	B-X
level	B-X
is	B-X
important	B-X
for	B-X
its	B-X
cellular	B-X
function	B-X
.	B-X

Recombinant	O
Set11	B-Protein
prepared	O
from	O
Escherichia	O
coli	O
had	O
catalytic	O
activity	O
and	O
methylated	O
a	O
17	O
-	O
kDa	O
polypeptide	O
in	O
cellular	O
extracts	O
of	O
set11	B-Protein
mutant	O
cells	O
.	O
<EOS>	B-X
SET	B-X
domain-containing	B-X
methyltransferases	B-X
post-translationally	B-X
modify	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
histones	B-X
,	B-X
cytochrome	B-X
c	B-X
,	B-X
ribulose-bisphosphate	B-X
carboxylase/oxygenase	B-X
,	B-X
and	B-X
ribosomal	B-X
proteins	B-X
.	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
played	B-X
by	B-X
the	B-X
other	B-X
SET	B-X
domain	B-X
proteins	B-X
in	B-X
cellular	B-X
processes	B-X
and	B-X
their	B-X
physiological	B-X
substrates	B-X
remain	B-X
unresolved	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
S.	B-X
pombe	B-X
Set11	B-X
,	B-X
a	B-X
SET	B-X
domain-containing	B-X
protein	B-X
encoded	B-X
by	B-X
SPCC1223.04c	B-X
,	B-X
specifically	B-X
modifies	B-X
Rpl12	B-X
(	B-X
ribosomal	B-X
protein	B-X
L12	B-X
)	B-X
.	B-X
Recombinant	B-X
Set11	B-X
prepared	B-X
from	B-X
Escherichia	B-X
coli	B-X
had	B-X
catalytic	B-X
activity	B-X
and	B-X
methylated	B-X
a	B-X
17-kDa	B-X
polypeptide	B-X
in	B-X
cellular	B-X
extracts	B-X
of	B-X
set11	B-X
mutant	B-X
cells	B-X
.	B-X
The	B-X
methylated	B-X
protein	B-X
was	B-X
isolated	B-X
by	B-X
two-dimensional	B-X
gel	B-X
electrophoresis	B-X
or	B-X
by	B-X
reverse-phase	B-X
chromatography	B-X
and	B-X
was	B-X
identified	B-X
as	B-X
Rpl12	B-X
by	B-X
mass	B-X
spectrometry	B-X
.	B-X
In	B-X
vitro	B-X
methylation	B-X
experiments	B-X
using	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rpl12	B-X
proteins	B-X
verified	B-X
that	B-X
Set11	B-X
modified	B-X
recombinant	B-X
Rpl12	B-X
and	B-X
suggested	B-X
that	B-X
its	B-X
potential	B-X
target	B-X
site	B-X
was	B-X
lysine	B-X
3	B-X
.	B-X
The	B-X
methylation	B-X
site	B-X
modified	B-X
by	B-X
Set11	B-X
was	B-X
also	B-X
confirmed	B-X
by	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
,	B-X
which	B-X
also	B-X
revealed	B-X
other	B-X
unique	B-X
methylation	B-X
sites	B-X
of	B-X
Rpl12	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Set11	B-X
predominantly	B-X
localized	B-X
to	B-X
the	B-X
nucleolus	B-X
and	B-X
that	B-X
the	B-X
overproduction	B-X
of	B-X
Set11	B-X
caused	B-X
a	B-X
severe	B-X
growth	B-X
defect	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Rpl12	B-X
methylation	B-X
occurs	B-X
during	B-X
the	B-X
ribosomal	B-X
assembly	B-X
processes	B-X
and	B-X
that	B-X
control	B-X
of	B-X
the	B-X
Set11	B-X
expression	B-X
level	B-X
is	B-X
important	B-X
for	B-X
its	B-X
cellular	B-X
function	B-X
.	B-X

The	O
methylated	O
protein	O
was	O
isolated	O
by	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
or	O
by	O
reverse	O
-	O
phase	O
chromatography	O
and	O
was	O
identified	O
as	O
Rpl12	B-Protein
by	O
mass	O
spectrometry	O
.	O
<EOS>	B-X
The	B-X
genome	B-X
information	B-X
combined	B-X
with	B-X
data	B-X
derived	B-X
from	B-X
modern	B-X
mass	B-X
spectrometry	B-X
enables	B-X
us	B-X
to	B-X
determine	B-X
the	B-X
identity	B-X
of	B-X
a	B-X
protein	B-X
once	B-X
it	B-X
is	B-X
isolated	B-X
from	B-X
a	B-X
complex	B-X
mixture	B-X
.	B-X
Two-dimensional	B-X
gel	B-X
electrophoresis	B-X
established	B-X
more	B-X
than	B-X
four	B-X
decades	B-X
ago	B-X
serves	B-X
as	B-X
a	B-X
powerful	B-X
protocol	B-X
to	B-X
isolate	B-X
many	B-X
proteins	B-X
at	B-X
once	B-X
for	B-X
such	B-X
protein	B-X
analysis	B-X
.	B-X
In	B-X
the	B-X
first	B-X
two	B-X
decades	B-X
,	B-X
the	B-X
original	B-X
procedure	B-X
to	B-X
use	B-X
a	B-X
glass	B-X
tube-based	B-X
IEF	B-X
had	B-X
been	B-X
commonly	B-X
used	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
protocol	B-X
that	B-X
uses	B-X
a	B-X
glass	B-X
tube-based	B-X
IEF	B-X
because	B-X
the	B-X
capacity	B-X
of	B-X
protein	B-X
loading	B-X
and	B-X
resolving	B-X
power	B-X
of	B-X
this	B-X
type	B-X
of	B-X
classic	B-X
two-dimensional	B-X
gel	B-X
is	B-X
still	B-X
indispensable	B-X
for	B-X
many	B-X
applications	B-X
,	B-X
not	B-X
only	B-X
for	B-X
protein	B-X
identification	B-X
but	B-X
also	B-X
for	B-X
protocols	B-X
that	B-X
are	B-X
benefited	B-X
by	B-X
larger	B-X
amounts	B-X
of	B-X
materials	B-X
,	B-X
i.e.	B-X
,	B-X
analysis	B-X
of	B-X
posttranslational	B-X
modification	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
phosphorylation	B-X
,	B-X
methylation	B-X
,	B-X
glycosylation	B-X
,	B-X
and	B-X
others	B-X
.	B-X

In	O
vitro	O
methylation	O
experiments	O
using	O
wild	O
-	O
type	O
and	O
mutant	O
Rpl12	B-Protein
proteins	O
verified	O
that	O
Set11	B-Protein
modified	O
recombinant	O
Rpl12	B-Protein
and	O
suggested	O
that	O
its	O
potential	O
target	O
site	O
was	O
lysine	O
3	O
.	O
<EOS>	B-X
SET	B-X
domain-containing	B-X
methyltransferases	B-X
post-translationally	B-X
modify	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
histones	B-X
,	B-X
cytochrome	B-X
c	B-X
,	B-X
ribulose-bisphosphate	B-X
carboxylase/oxygenase	B-X
,	B-X
and	B-X
ribosomal	B-X
proteins	B-X
.	B-X
In	B-X
the	B-X
fission	B-X
yeast	B-X
Schizosaccharomyces	B-X
pombe	B-X
,	B-X
at	B-X
least	B-X
13	B-X
SET	B-X
domain-containing	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
,	B-X
four	B-X
of	B-X
which	B-X
are	B-X
involved	B-X
in	B-X
transcriptional	B-X
regulation	B-X
through	B-X
their	B-X
modification	B-X
of	B-X
histone	B-X
tails	B-X
.	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
played	B-X
by	B-X
the	B-X
other	B-X
SET	B-X
domain	B-X
proteins	B-X
in	B-X
cellular	B-X
processes	B-X
and	B-X
their	B-X
physiological	B-X
substrates	B-X
remain	B-X
unresolved	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
S.	B-X
pombe	B-X
Set11	B-X
,	B-X
a	B-X
SET	B-X
domain-containing	B-X
protein	B-X
encoded	B-X
by	B-X
SPCC1223.04c	B-X
,	B-X
specifically	B-X
modifies	B-X
Rpl12	B-X
(	B-X
ribosomal	B-X
protein	B-X
L12	B-X
)	B-X
.	B-X
Recombinant	B-X
Set11	B-X
prepared	B-X
from	B-X
Escherichia	B-X
coli	B-X
had	B-X
catalytic	B-X
activity	B-X
and	B-X
methylated	B-X
a	B-X
17-kDa	B-X
polypeptide	B-X
in	B-X
cellular	B-X
extracts	B-X
of	B-X
set11	B-X
mutant	B-X
cells	B-X
.	B-X
The	B-X
methylated	B-X
protein	B-X
was	B-X
isolated	B-X
by	B-X
two-dimensional	B-X
gel	B-X
electrophoresis	B-X
or	B-X
by	B-X
reverse-phase	B-X
chromatography	B-X
and	B-X
was	B-X
identified	B-X
as	B-X
Rpl12	B-X
by	B-X
mass	B-X
spectrometry	B-X
.	B-X
In	B-X
vitro	B-X
methylation	B-X
experiments	B-X
using	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rpl12	B-X
proteins	B-X
verified	B-X
that	B-X
Set11	B-X
modified	B-X
recombinant	B-X
Rpl12	B-X
and	B-X
suggested	B-X
that	B-X
its	B-X
potential	B-X
target	B-X
site	B-X
was	B-X
lysine	B-X
3	B-X
.	B-X
The	B-X
methylation	B-X
site	B-X
modified	B-X
by	B-X
Set11	B-X
was	B-X
also	B-X
confirmed	B-X
by	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
,	B-X
which	B-X
also	B-X
revealed	B-X
other	B-X
unique	B-X
methylation	B-X
sites	B-X
of	B-X
Rpl12	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Set11	B-X
predominantly	B-X
localized	B-X
to	B-X
the	B-X
nucleolus	B-X
and	B-X
that	B-X
the	B-X
overproduction	B-X
of	B-X
Set11	B-X
caused	B-X
a	B-X
severe	B-X
growth	B-X
defect	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Rpl12	B-X
methylation	B-X
occurs	B-X
during	B-X
the	B-X
ribosomal	B-X
assembly	B-X
processes	B-X
and	B-X
that	B-X
control	B-X
of	B-X
the	B-X
Set11	B-X
expression	B-X
level	B-X
is	B-X
important	B-X
for	B-X
its	B-X
cellular	B-X
function	B-X
.	B-X

The	O
methylation	O
site	O
modified	O
by	O
Set11	B-Protein
was	O
also	O
confirmed	O
by	O
mass	O
spectrometric	O
analysis	O
,	O
which	O
also	O
revealed	O
other	O
unique	O
methylation	O
sites	O
of	O
Rpl12	B-Protein
.	O
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
S.	B-X
pombe	B-X
Set11	B-X
,	B-X
a	B-X
SET	B-X
domain-containing	B-X
protein	B-X
encoded	B-X
by	B-X
SPCC1223.04c	B-X
,	B-X
specifically	B-X
modifies	B-X
Rpl12	B-X
(	B-X
ribosomal	B-X
protein	B-X
L12	B-X
)	B-X
.	B-X
Recombinant	B-X
Set11	B-X
prepared	B-X
from	B-X
Escherichia	B-X
coli	B-X
had	B-X
catalytic	B-X
activity	B-X
and	B-X
methylated	B-X
a	B-X
17-kDa	B-X
polypeptide	B-X
in	B-X
cellular	B-X
extracts	B-X
of	B-X
set11	B-X
mutant	B-X
cells	B-X
.	B-X
The	B-X
methylated	B-X
protein	B-X
was	B-X
isolated	B-X
by	B-X
two-dimensional	B-X
gel	B-X
electrophoresis	B-X
or	B-X
by	B-X
reverse-phase	B-X
chromatography	B-X
and	B-X
was	B-X
identified	B-X
as	B-X
Rpl12	B-X
by	B-X
mass	B-X
spectrometry	B-X
.	B-X
In	B-X
vitro	B-X
methylation	B-X
experiments	B-X
using	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rpl12	B-X
proteins	B-X
verified	B-X
that	B-X
Set11	B-X
modified	B-X
recombinant	B-X
Rpl12	B-X
and	B-X
suggested	B-X
that	B-X
its	B-X
potential	B-X
target	B-X
site	B-X
was	B-X
lysine	B-X
3	B-X
.	B-X
The	B-X
methylation	B-X
site	B-X
modified	B-X
by	B-X
Set11	B-X
was	B-X
also	B-X
confirmed	B-X
by	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
,	B-X
which	B-X
also	B-X
revealed	B-X
other	B-X
unique	B-X
methylation	B-X
sites	B-X
of	B-X
Rpl12	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Set11	B-X
predominantly	B-X
localized	B-X
to	B-X
the	B-X
nucleolus	B-X
and	B-X
that	B-X
the	B-X
overproduction	B-X
of	B-X
Set11	B-X
caused	B-X
a	B-X
severe	B-X
growth	B-X
defect	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Rpl12	B-X
methylation	B-X
occurs	B-X
during	B-X
the	B-X
ribosomal	B-X
assembly	B-X
processes	B-X
and	B-X
that	B-X
control	B-X
of	B-X
the	B-X
Set11	B-X
expression	B-X
level	B-X
is	B-X
important	B-X
for	B-X
its	B-X
cellular	B-X
function	B-X
.	B-X

Finally	O
,	O
we	O
found	O
that	O
Set11	B-Protein
predominantly	O
localized	O
to	O
the	O
nucleolus	O
and	O
that	O
the	O
overproduction	O
of	O
Set11	B-Protein
caused	O
a	O
severe	O
growth	O
defect	O
.	O

These	O
results	O
suggest	O
that	O
Rpl12	B-Protein
methylation	O
occurs	O
during	O
the	O
ribosomal	O
assembly	O
processes	O
and	O
that	O
control	O
of	O
the	O
Set11	B-Protein
expression	O
level	O
is	O
important	O
for	O
its	O
cellular	O
function	O
.	O
<EOS>	B-X
SET	B-X
domain-containing	B-X
methyltransferases	B-X
post-translationally	B-X
modify	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
histones	B-X
,	B-X
cytochrome	B-X
c	B-X
,	B-X
ribulose-bisphosphate	B-X
carboxylase/oxygenase	B-X
,	B-X
and	B-X
ribosomal	B-X
proteins	B-X
.	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
played	B-X
by	B-X
the	B-X
other	B-X
SET	B-X
domain	B-X
proteins	B-X
in	B-X
cellular	B-X
processes	B-X
and	B-X
their	B-X
physiological	B-X
substrates	B-X
remain	B-X
unresolved	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
S.	B-X
pombe	B-X
Set11	B-X
,	B-X
a	B-X
SET	B-X
domain-containing	B-X
protein	B-X
encoded	B-X
by	B-X
SPCC1223.04c	B-X
,	B-X
specifically	B-X
modifies	B-X
Rpl12	B-X
(	B-X
ribosomal	B-X
protein	B-X
L12	B-X
)	B-X
.	B-X
Recombinant	B-X
Set11	B-X
prepared	B-X
from	B-X
Escherichia	B-X
coli	B-X
had	B-X
catalytic	B-X
activity	B-X
and	B-X
methylated	B-X
a	B-X
17-kDa	B-X
polypeptide	B-X
in	B-X
cellular	B-X
extracts	B-X
of	B-X
set11	B-X
mutant	B-X
cells	B-X
.	B-X
The	B-X
methylated	B-X
protein	B-X
was	B-X
isolated	B-X
by	B-X
two-dimensional	B-X
gel	B-X
electrophoresis	B-X
or	B-X
by	B-X
reverse-phase	B-X
chromatography	B-X
and	B-X
was	B-X
identified	B-X
as	B-X
Rpl12	B-X
by	B-X
mass	B-X
spectrometry	B-X
.	B-X
In	B-X
vitro	B-X
methylation	B-X
experiments	B-X
using	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rpl12	B-X
proteins	B-X
verified	B-X
that	B-X
Set11	B-X
modified	B-X
recombinant	B-X
Rpl12	B-X
and	B-X
suggested	B-X
that	B-X
its	B-X
potential	B-X
target	B-X
site	B-X
was	B-X
lysine	B-X
3	B-X
.	B-X
The	B-X
methylation	B-X
site	B-X
modified	B-X
by	B-X
Set11	B-X
was	B-X
also	B-X
confirmed	B-X
by	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
,	B-X
which	B-X
also	B-X
revealed	B-X
other	B-X
unique	B-X
methylation	B-X
sites	B-X
of	B-X
Rpl12	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Set11	B-X
predominantly	B-X
localized	B-X
to	B-X
the	B-X
nucleolus	B-X
and	B-X
that	B-X
the	B-X
overproduction	B-X
of	B-X
Set11	B-X
caused	B-X
a	B-X
severe	B-X
growth	B-X
defect	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Rpl12	B-X
methylation	B-X
occurs	B-X
during	B-X
the	B-X
ribosomal	B-X
assembly	B-X
processes	B-X
and	B-X
that	B-X
control	B-X
of	B-X
the	B-X
Set11	B-X
expression	B-X
level	B-X
is	B-X
important	B-X
for	B-X
its	B-X
cellular	B-X
function	B-X
.	B-X

Yeast	O
Chfr	B-Protein
homologs	O
retard	O
cell	O
cycle	O
at	O
G1	O
and	O
G2	O
/	O
M	O
via	O
Ubc4	B-Protein
and	O
Ubc13	B-Protein
/	O
Mms2	B-Protein
-	O
dependent	O
ubiquitination	O
.	O
<EOS>	B-X
Checkpoint	B-X
with	B-X
forkhead-associated	B-X
and	B-X
RING	B-X
(	B-X
Chfr	B-X
)	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
that	B-X
establishes	B-X
an	B-X
antephase	B-X
or	B-X
prometaphase	B-X
checkpoint	B-X
in	B-X
response	B-X
to	B-X
mitotic	B-X
stress	B-X
.	B-X
Though	B-X
ubiquitination	B-X
is	B-X
essential	B-X
for	B-X
checkpoint	B-X
function	B-X
,	B-X
the	B-X
sites	B-X
,	B-X
linkages	B-X
and	B-X
ubiquitin	B-X
conjugating	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
specificity	B-X
are	B-X
controversial	B-X
.	B-X
Here	B-X
we	B-X
dissect	B-X
the	B-X
function	B-X
of	B-X
the	B-X
two	B-X
Chfr	B-X
homologs	B-X
in	B-X
S.	B-X
cerevisiae	B-X
,	B-X
Chf1	B-X
and	B-X
Chf2	B-X
,	B-X
overexpression	B-X
of	B-X
which	B-X
retard	B-X
cell	B-X
cycle	B-X
at	B-X
both	B-X
G	B-X
(	B-X
1	B-X
)	B-X
and	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
genetic	B-X
assay	B-X
,	B-X
we	B-X
establish	B-X
that	B-X
Ubc4	B-X
is	B-X
required	B-X
for	B-X
Chf2-dependent	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
delay	B-X
and	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Ubc13/Mms2	B-X
is	B-X
required	B-X
for	B-X
G	B-X
(	B-X
2	B-X
)	B-X
delay	B-X
and	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
By	B-X
reconstituting	B-X
cis	B-X
and	B-X
trans-ubiquitination	B-X
activities	B-X
of	B-X
Chf	B-X
proteins	B-X
in	B-X
purified	B-X
systems	B-X
and	B-X
characterizing	B-X
sites	B-X
modified	B-X
and	B-X
linkages	B-X
formed	B-X
by	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
Ubc13/Mms2-	B-X
dependent	B-X
modifications	B-X
are	B-X
a	B-X
distinct	B-X
subset	B-X
of	B-X
those	B-X
catalyzed	B-X
by	B-X
Ubc4	B-X
.	B-X
Mutagenesis	B-X
of	B-X
Lys	B-X
residues	B-X
identified	B-X
in	B-X
vitro	B-X
indicates	B-X
that	B-X
site-specific	B-X
Ubc4-dependent	B-X
Chf	B-X
protein	B-X
autoubiquitination	B-X
is	B-X
responsible	B-X
for	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
Thus	B-X
,	B-X
combined	B-X
genetic	B-X
and	B-X
biochemical	B-X
analyses	B-X
indicate	B-X
that	B-X
Chf	B-X
proteins	B-X
have	B-X
dual	B-X
E2	B-X
specificity	B-X
accounting	B-X
for	B-X
different	B-X
functions	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

Checkpoint	B-Protein
with	I-Protein
forkhead	I-Protein
-	I-Protein
associated	I-Protein
and	I-Protein
RING	I-Protein
(	O
Chfr	B-Protein
)	O
is	O
a	O
ubiquitin	B-Protein
ligase	O
(	O
E3	O
)	O
that	O
establishes	O
an	O
antephase	O
or	O
prometaphase	O
checkpoint	O
in	O
response	O
to	O
mitotic	O
stress	O
.	O
<EOS>	B-X
Checkpoint	B-X
with	B-X
forkhead-associated	B-X
and	B-X
RING	B-X
(	B-X
Chfr	B-X
)	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
that	B-X
establishes	B-X
an	B-X
antephase	B-X
or	B-X
prometaphase	B-X
checkpoint	B-X
in	B-X
response	B-X
to	B-X
mitotic	B-X
stress	B-X
.	B-X
Though	B-X
ubiquitination	B-X
is	B-X
essential	B-X
for	B-X
checkpoint	B-X
function	B-X
,	B-X
the	B-X
sites	B-X
,	B-X
linkages	B-X
and	B-X
ubiquitin	B-X
conjugating	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
specificity	B-X
are	B-X
controversial	B-X
.	B-X
Here	B-X
we	B-X
dissect	B-X
the	B-X
function	B-X
of	B-X
the	B-X
two	B-X
Chfr	B-X
homologs	B-X
in	B-X
S.	B-X
cerevisiae	B-X
,	B-X
Chf1	B-X
and	B-X
Chf2	B-X
,	B-X
overexpression	B-X
of	B-X
which	B-X
retard	B-X
cell	B-X
cycle	B-X
at	B-X
both	B-X
G	B-X
(	B-X
1	B-X
)	B-X
and	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
By	B-X
reconstituting	B-X
cis	B-X
and	B-X
trans-ubiquitination	B-X
activities	B-X
of	B-X
Chf	B-X
proteins	B-X
in	B-X
purified	B-X
systems	B-X
and	B-X
characterizing	B-X
sites	B-X
modified	B-X
and	B-X
linkages	B-X
formed	B-X
by	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
Ubc13/Mms2-	B-X
dependent	B-X
modifications	B-X
are	B-X
a	B-X
distinct	B-X
subset	B-X
of	B-X
those	B-X
catalyzed	B-X
by	B-X
Ubc4	B-X
.	B-X
Mutagenesis	B-X
of	B-X
Lys	B-X
residues	B-X
identified	B-X
in	B-X
vitro	B-X
indicates	B-X
that	B-X
site-specific	B-X
Ubc4-dependent	B-X
Chf	B-X
protein	B-X
autoubiquitination	B-X
is	B-X
responsible	B-X
for	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X

Though	O
ubiquitination	O
is	O
essential	O
for	O
checkpoint	O
function	O
,	O
the	O
sites	O
,	O
linkages	O
and	O
ubiquitin	B-Protein
conjugating	O
enzyme	O
(	O
E2	O
)	O
specificity	O
are	O
controversial	O
.	O
<EOS>	B-X
Checkpoint	B-X
with	B-X
forkhead-associated	B-X
and	B-X
RING	B-X
(	B-X
Chfr	B-X
)	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
that	B-X
establishes	B-X
an	B-X
antephase	B-X
or	B-X
prometaphase	B-X
checkpoint	B-X
in	B-X
response	B-X
to	B-X
mitotic	B-X
stress	B-X
.	B-X
Though	B-X
ubiquitination	B-X
is	B-X
essential	B-X
for	B-X
checkpoint	B-X
function	B-X
,	B-X
the	B-X
sites	B-X
,	B-X
linkages	B-X
and	B-X
ubiquitin	B-X
conjugating	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
specificity	B-X
are	B-X
controversial	B-X
.	B-X
Here	B-X
we	B-X
dissect	B-X
the	B-X
function	B-X
of	B-X
the	B-X
two	B-X
Chfr	B-X
homologs	B-X
in	B-X
S.	B-X
cerevisiae	B-X
,	B-X
Chf1	B-X
and	B-X
Chf2	B-X
,	B-X
overexpression	B-X
of	B-X
which	B-X
retard	B-X
cell	B-X
cycle	B-X
at	B-X
both	B-X
G	B-X
(	B-X
1	B-X
)	B-X
and	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
By	B-X
reconstituting	B-X
cis	B-X
and	B-X
trans-ubiquitination	B-X
activities	B-X
of	B-X
Chf	B-X
proteins	B-X
in	B-X
purified	B-X
systems	B-X
and	B-X
characterizing	B-X
sites	B-X
modified	B-X
and	B-X
linkages	B-X
formed	B-X
by	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
Ubc13/Mms2-	B-X
dependent	B-X
modifications	B-X
are	B-X
a	B-X
distinct	B-X
subset	B-X
of	B-X
those	B-X
catalyzed	B-X
by	B-X
Ubc4	B-X
.	B-X
Mutagenesis	B-X
of	B-X
Lys	B-X
residues	B-X
identified	B-X
in	B-X
vitro	B-X
indicates	B-X
that	B-X
site-specific	B-X
Ubc4-dependent	B-X
Chf	B-X
protein	B-X
autoubiquitination	B-X
is	B-X
responsible	B-X
for	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
Thus	B-X
,	B-X
combined	B-X
genetic	B-X
and	B-X
biochemical	B-X
analyses	B-X
indicate	B-X
that	B-X
Chf	B-X
proteins	B-X
have	B-X
dual	B-X
E2	B-X
specificity	B-X
accounting	B-X
for	B-X
different	B-X
functions	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

Here	O
we	O
dissect	O
the	O
function	O
of	O
the	O
two	O
Chfr	B-Protein
homologs	O
in	O
S	O
.	O
cerevisiae	O
,	O
Chf1	B-Protein
and	O
Chf2	B-Protein
,	O
overexpression	O
of	O
which	O
retard	O
cell	O
cycle	O
at	O
both	O
G	O
(	O
1	O
)	O
and	O
G	O
(	O
2	O
)	O
.	O

Using	O
a	O
genetic	O
assay	O
,	O
we	O
establish	O
that	O
Ubc4	B-Protein
is	O
required	O
for	O
Chf2	B-Protein
-	O
dependent	O
G	O
(	O
1	O
)	O
cell	O
cycle	O
delay	O
and	O
Chf	O
protein	O
turnover	O
.	O
<EOS>	B-X
Checkpoint	B-X
with	B-X
forkhead-associated	B-X
and	B-X
RING	B-X
(	B-X
Chfr	B-X
)	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
that	B-X
establishes	B-X
an	B-X
antephase	B-X
or	B-X
prometaphase	B-X
checkpoint	B-X
in	B-X
response	B-X
to	B-X
mitotic	B-X
stress	B-X
.	B-X
Here	B-X
we	B-X
dissect	B-X
the	B-X
function	B-X
of	B-X
the	B-X
two	B-X
Chfr	B-X
homologs	B-X
in	B-X
S.	B-X
cerevisiae	B-X
,	B-X
Chf1	B-X
and	B-X
Chf2	B-X
,	B-X
overexpression	B-X
of	B-X
which	B-X
retard	B-X
cell	B-X
cycle	B-X
at	B-X
both	B-X
G	B-X
(	B-X
1	B-X
)	B-X
and	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
genetic	B-X
assay	B-X
,	B-X
we	B-X
establish	B-X
that	B-X
Ubc4	B-X
is	B-X
required	B-X
for	B-X
Chf2-dependent	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
delay	B-X
and	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Ubc13/Mms2	B-X
is	B-X
required	B-X
for	B-X
G	B-X
(	B-X
2	B-X
)	B-X
delay	B-X
and	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
By	B-X
reconstituting	B-X
cis	B-X
and	B-X
trans-ubiquitination	B-X
activities	B-X
of	B-X
Chf	B-X
proteins	B-X
in	B-X
purified	B-X
systems	B-X
and	B-X
characterizing	B-X
sites	B-X
modified	B-X
and	B-X
linkages	B-X
formed	B-X
by	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
Ubc13/Mms2-	B-X
dependent	B-X
modifications	B-X
are	B-X
a	B-X
distinct	B-X
subset	B-X
of	B-X
those	B-X
catalyzed	B-X
by	B-X
Ubc4	B-X
.	B-X
Mutagenesis	B-X
of	B-X
Lys	B-X
residues	B-X
identified	B-X
in	B-X
vitro	B-X
indicates	B-X
that	B-X
site-specific	B-X
Ubc4-dependent	B-X
Chf	B-X
protein	B-X
autoubiquitination	B-X
is	B-X
responsible	B-X
for	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
Thus	B-X
,	B-X
combined	B-X
genetic	B-X
and	B-X
biochemical	B-X
analyses	B-X
indicate	B-X
that	B-X
Chf	B-X
proteins	B-X
have	B-X
dual	B-X
E2	B-X
specificity	B-X
accounting	B-X
for	B-X
different	B-X
functions	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

In	O
contrast	O
,	O
Ubc13	B-Protein
/	O
Mms2	B-Protein
is	O
required	O
for	O
G	O
(	O
2	O
)	O
delay	O
and	O
does	O
not	O
contribute	O
to	O
Chf	O
protein	O
turnover	O
.	O

By	O
reconstituting	O
cis	O
and	O
trans	O
-	O
ubiquitination	O
activities	O
of	O
Chf	O
proteins	O
in	O
purified	O
systems	O
and	O
characterizing	O
sites	O
modified	O
and	O
linkages	O
formed	O
by	O
tandem	O
mass	O
spectrometry	O
,	O
we	O
discovered	O
that	O
Ubc13	B-Protein
/	O
Mms2	B-Protein
-	O
dependent	O
modifications	O
are	O
a	O
distinct	O
subset	O
of	O
those	O
catalyzed	O
by	O
Ubc4	B-Protein
.	O
<EOS>	B-X
Checkpoint	B-X
with	B-X
forkhead-associated	B-X
and	B-X
RING	B-X
(	B-X
Chfr	B-X
)	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
that	B-X
establishes	B-X
an	B-X
antephase	B-X
or	B-X
prometaphase	B-X
checkpoint	B-X
in	B-X
response	B-X
to	B-X
mitotic	B-X
stress	B-X
.	B-X
Though	B-X
ubiquitination	B-X
is	B-X
essential	B-X
for	B-X
checkpoint	B-X
function	B-X
,	B-X
the	B-X
sites	B-X
,	B-X
linkages	B-X
and	B-X
ubiquitin	B-X
conjugating	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
specificity	B-X
are	B-X
controversial	B-X
.	B-X
Here	B-X
we	B-X
dissect	B-X
the	B-X
function	B-X
of	B-X
the	B-X
two	B-X
Chfr	B-X
homologs	B-X
in	B-X
S.	B-X
cerevisiae	B-X
,	B-X
Chf1	B-X
and	B-X
Chf2	B-X
,	B-X
overexpression	B-X
of	B-X
which	B-X
retard	B-X
cell	B-X
cycle	B-X
at	B-X
both	B-X
G	B-X
(	B-X
1	B-X
)	B-X
and	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
genetic	B-X
assay	B-X
,	B-X
we	B-X
establish	B-X
that	B-X
Ubc4	B-X
is	B-X
required	B-X
for	B-X
Chf2-dependent	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
delay	B-X
and	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Ubc13/Mms2	B-X
is	B-X
required	B-X
for	B-X
G	B-X
(	B-X
2	B-X
)	B-X
delay	B-X
and	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
By	B-X
reconstituting	B-X
cis	B-X
and	B-X
trans-ubiquitination	B-X
activities	B-X
of	B-X
Chf	B-X
proteins	B-X
in	B-X
purified	B-X
systems	B-X
and	B-X
characterizing	B-X
sites	B-X
modified	B-X
and	B-X
linkages	B-X
formed	B-X
by	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
Ubc13/Mms2-	B-X
dependent	B-X
modifications	B-X
are	B-X
a	B-X
distinct	B-X
subset	B-X
of	B-X
those	B-X
catalyzed	B-X
by	B-X
Ubc4	B-X
.	B-X
Mutagenesis	B-X
of	B-X
Lys	B-X
residues	B-X
identified	B-X
in	B-X
vitro	B-X
indicates	B-X
that	B-X
site-specific	B-X
Ubc4-dependent	B-X
Chf	B-X
protein	B-X
autoubiquitination	B-X
is	B-X
responsible	B-X
for	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
Thus	B-X
,	B-X
combined	B-X
genetic	B-X
and	B-X
biochemical	B-X
analyses	B-X
indicate	B-X
that	B-X
Chf	B-X
proteins	B-X
have	B-X
dual	B-X
E2	B-X
specificity	B-X
accounting	B-X
for	B-X
different	B-X
functions	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

Mutagenesis	O
of	O
Lys	O
residues	O
identified	O
in	O
vitro	O
indicates	O
that	O
site	O
-	O
specific	O
Ubc4	B-Protein
-	O
dependent	O
Chf	O
protein	O
autoubiquitination	O
is	O
responsible	O
for	O
Chf	O
protein	O
turnover	O
.	O
<EOS>	B-X
Checkpoint	B-X
with	B-X
forkhead-associated	B-X
and	B-X
RING	B-X
(	B-X
Chfr	B-X
)	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
that	B-X
establishes	B-X
an	B-X
antephase	B-X
or	B-X
prometaphase	B-X
checkpoint	B-X
in	B-X
response	B-X
to	B-X
mitotic	B-X
stress	B-X
.	B-X
Though	B-X
ubiquitination	B-X
is	B-X
essential	B-X
for	B-X
checkpoint	B-X
function	B-X
,	B-X
the	B-X
sites	B-X
,	B-X
linkages	B-X
and	B-X
ubiquitin	B-X
conjugating	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
specificity	B-X
are	B-X
controversial	B-X
.	B-X
Here	B-X
we	B-X
dissect	B-X
the	B-X
function	B-X
of	B-X
the	B-X
two	B-X
Chfr	B-X
homologs	B-X
in	B-X
S.	B-X
cerevisiae	B-X
,	B-X
Chf1	B-X
and	B-X
Chf2	B-X
,	B-X
overexpression	B-X
of	B-X
which	B-X
retard	B-X
cell	B-X
cycle	B-X
at	B-X
both	B-X
G	B-X
(	B-X
1	B-X
)	B-X
and	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
genetic	B-X
assay	B-X
,	B-X
we	B-X
establish	B-X
that	B-X
Ubc4	B-X
is	B-X
required	B-X
for	B-X
Chf2-dependent	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
delay	B-X
and	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Ubc13/Mms2	B-X
is	B-X
required	B-X
for	B-X
G	B-X
(	B-X
2	B-X
)	B-X
delay	B-X
and	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
By	B-X
reconstituting	B-X
cis	B-X
and	B-X
trans-ubiquitination	B-X
activities	B-X
of	B-X
Chf	B-X
proteins	B-X
in	B-X
purified	B-X
systems	B-X
and	B-X
characterizing	B-X
sites	B-X
modified	B-X
and	B-X
linkages	B-X
formed	B-X
by	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
Ubc13/Mms2-	B-X
dependent	B-X
modifications	B-X
are	B-X
a	B-X
distinct	B-X
subset	B-X
of	B-X
those	B-X
catalyzed	B-X
by	B-X
Ubc4	B-X
.	B-X
Mutagenesis	B-X
of	B-X
Lys	B-X
residues	B-X
identified	B-X
in	B-X
vitro	B-X
indicates	B-X
that	B-X
site-specific	B-X
Ubc4-dependent	B-X
Chf	B-X
protein	B-X
autoubiquitination	B-X
is	B-X
responsible	B-X
for	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
Thus	B-X
,	B-X
combined	B-X
genetic	B-X
and	B-X
biochemical	B-X
analyses	B-X
indicate	B-X
that	B-X
Chf	B-X
proteins	B-X
have	B-X
dual	B-X
E2	B-X
specificity	B-X
accounting	B-X
for	B-X
different	B-X
functions	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

Thus	O
,	O
combined	O
genetic	O
and	O
biochemical	O
analyses	O
indicate	O
that	O
Chf	O
proteins	O
have	O
dual	O
E2	O
specificity	O
accounting	O
for	O
different	O
functions	O
in	O
the	O
cell	O
cycle	O
.	O
<EOS>	B-X
Checkpoint	B-X
with	B-X
forkhead-associated	B-X
and	B-X
RING	B-X
(	B-X
Chfr	B-X
)	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
that	B-X
establishes	B-X
an	B-X
antephase	B-X
or	B-X
prometaphase	B-X
checkpoint	B-X
in	B-X
response	B-X
to	B-X
mitotic	B-X
stress	B-X
.	B-X
Though	B-X
ubiquitination	B-X
is	B-X
essential	B-X
for	B-X
checkpoint	B-X
function	B-X
,	B-X
the	B-X
sites	B-X
,	B-X
linkages	B-X
and	B-X
ubiquitin	B-X
conjugating	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
specificity	B-X
are	B-X
controversial	B-X
.	B-X
Here	B-X
we	B-X
dissect	B-X
the	B-X
function	B-X
of	B-X
the	B-X
two	B-X
Chfr	B-X
homologs	B-X
in	B-X
S.	B-X
cerevisiae	B-X
,	B-X
Chf1	B-X
and	B-X
Chf2	B-X
,	B-X
overexpression	B-X
of	B-X
which	B-X
retard	B-X
cell	B-X
cycle	B-X
at	B-X
both	B-X
G	B-X
(	B-X
1	B-X
)	B-X
and	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Using	B-X
a	B-X
genetic	B-X
assay	B-X
,	B-X
we	B-X
establish	B-X
that	B-X
Ubc4	B-X
is	B-X
required	B-X
for	B-X
Chf2-dependent	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
delay	B-X
and	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Ubc13/Mms2	B-X
is	B-X
required	B-X
for	B-X
G	B-X
(	B-X
2	B-X
)	B-X
delay	B-X
and	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
By	B-X
reconstituting	B-X
cis	B-X
and	B-X
trans-ubiquitination	B-X
activities	B-X
of	B-X
Chf	B-X
proteins	B-X
in	B-X
purified	B-X
systems	B-X
and	B-X
characterizing	B-X
sites	B-X
modified	B-X
and	B-X
linkages	B-X
formed	B-X
by	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
Ubc13/Mms2-	B-X
dependent	B-X
modifications	B-X
are	B-X
a	B-X
distinct	B-X
subset	B-X
of	B-X
those	B-X
catalyzed	B-X
by	B-X
Ubc4	B-X
.	B-X
Mutagenesis	B-X
of	B-X
Lys	B-X
residues	B-X
identified	B-X
in	B-X
vitro	B-X
indicates	B-X
that	B-X
site-specific	B-X
Ubc4-dependent	B-X
Chf	B-X
protein	B-X
autoubiquitination	B-X
is	B-X
responsible	B-X
for	B-X
Chf	B-X
protein	B-X
turnover	B-X
.	B-X
Thus	B-X
,	B-X
combined	B-X
genetic	B-X
and	B-X
biochemical	B-X
analyses	B-X
indicate	B-X
that	B-X
Chf	B-X
proteins	B-X
have	B-X
dual	B-X
E2	B-X
specificity	B-X
accounting	B-X
for	B-X
different	B-X
functions	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

The	O
histone	B-Protein
-	O
like	O
NF	O
-	O
Y	O
is	O
a	O
bifunctional	O
transcription	O
factor	O
.	O
<EOS>	B-X
NF-Y	B-X
is	B-X
a	B-X
trimeric	B-X
transcription	B-X
factor	B-X
containing	B-X
H2A/H2B-like	B-X
subunits	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
the	B-X
CCAAT	B-X
box	B-X
,	B-X
a	B-X
common	B-X
eukaryotic	B-X
promoter	B-X
element	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
NF-Y-dependent	B-X
transcriptional	B-X
regulation	B-X
,	B-X
we	B-X
assessed	B-X
its	B-X
relationships	B-X
with	B-X
positive	B-X
histone	B-X
marks	B-X
by	B-X
chromatin	B-X
immunoprecipitation-on-chip	B-X
and	B-X
correlative-profiling	B-X
studies	B-X
.	B-X
Unbiased	B-X
identification	B-X
of	B-X
binding	B-X
sites	B-X
shows	B-X
that	B-X
the	B-X
majority	B-X
of	B-X
genes	B-X
are	B-X
bound	B-X
by	B-X
NF-Y	B-X
in	B-X
the	B-X
promoter	B-X
and/or	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
.	B-X
Parallel	B-X
analysis	B-X
of	B-X
H3K9-14ac	B-X
and	B-X
H3K4me3	B-X
sites	B-X
indicates	B-X
that	B-X
NF-Y	B-X
loci	B-X
can	B-X
be	B-X
divided	B-X
in	B-X
two	B-X
distinct	B-X
clusters	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
large	B-X
cohort	B-X
contains	B-X
H3K9-14ac	B-X
and	B-X
H3K4me3	B-X
marks	B-X
and	B-X
correlates	B-X
with	B-X
expression	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
sizeable	B-X
group	B-X
is	B-X
devoid	B-X
of	B-X
these	B-X
marks	B-X
and	B-X
is	B-X
found	B-X
on	B-X
transcriptionally	B-X
silent	B-X
genes	B-X
.	B-X
Within	B-X
this	B-X
class	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-Y	B-X
binding	B-X
is	B-X
associated	B-X
with	B-X
negative	B-X
histone	B-X
marks	B-X
,	B-X
such	B-X
as	B-X
H4K20me3	B-X
and	B-X
H3K27me3	B-X
.	B-X
NF-Y	B-X
removal	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
NF-YA	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
expressed	B-X
genes	B-X
associated	B-X
with	B-X
H3K4me3	B-X
and	B-X
H3K9-14ac	B-X
,	B-X
while	B-X
increasing	B-X
the	B-X
levels	B-X
of	B-X
many	B-X
inactive	B-X
genes	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
NF-Y	B-X
is	B-X
embedded	B-X
in	B-X
positive	B-X
as	B-X
well	B-X
as	B-X
in	B-X
negative	B-X
methyl	B-X
histone	B-X
marks	B-X
,	B-X
serving	B-X
a	B-X
dual	B-X
function	B-X
in	B-X
transcriptional	B-X
regulation	B-X
,	B-X
as	B-X
an	B-X
activator	B-X
or	B-X
as	B-X
a	B-X
repressor	B-X
.	B-X

NF	O
-	O
Y	O
is	O
a	O
trimeric	O
transcription	O
factor	O
containing	O
H2A	B-Protein
/	O
H2B	B-Protein
-	O
like	O
subunits	O
,	O
which	O
specifically	O
binds	O
to	O
the	O
CCAAT	O
box	O
,	O
a	O
common	O
eukaryotic	O
promoter	O
element	O
.	O

To	O
gain	O
insights	O
into	O
NF	O
-	O
Y	O
-	O
dependent	O
transcriptional	O
regulation	O
,	O
we	O
assessed	O
its	O
relationships	O
with	O
positive	O
histone	B-Protein
marks	O
by	O
chromatin	O
immunoprecipitation	O
-	O
on	O
-	O
chip	O
and	O
correlative	O
-	O
profiling	O
studies	O
.	O
<EOS>	B-X
NF-Y	B-X
is	B-X
a	B-X
trimeric	B-X
transcription	B-X
factor	B-X
containing	B-X
H2A/H2B-like	B-X
subunits	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
the	B-X
CCAAT	B-X
box	B-X
,	B-X
a	B-X
common	B-X
eukaryotic	B-X
promoter	B-X
element	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
NF-Y-dependent	B-X
transcriptional	B-X
regulation	B-X
,	B-X
we	B-X
assessed	B-X
its	B-X
relationships	B-X
with	B-X
positive	B-X
histone	B-X
marks	B-X
by	B-X
chromatin	B-X
immunoprecipitation-on-chip	B-X
and	B-X
correlative-profiling	B-X
studies	B-X
.	B-X
Unbiased	B-X
identification	B-X
of	B-X
binding	B-X
sites	B-X
shows	B-X
that	B-X
the	B-X
majority	B-X
of	B-X
genes	B-X
are	B-X
bound	B-X
by	B-X
NF-Y	B-X
in	B-X
the	B-X
promoter	B-X
and/or	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
.	B-X
Parallel	B-X
analysis	B-X
of	B-X
H3K9-14ac	B-X
and	B-X
H3K4me3	B-X
sites	B-X
indicates	B-X
that	B-X
NF-Y	B-X
loci	B-X
can	B-X
be	B-X
divided	B-X
in	B-X
two	B-X
distinct	B-X
clusters	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
large	B-X
cohort	B-X
contains	B-X
H3K9-14ac	B-X
and	B-X
H3K4me3	B-X
marks	B-X
and	B-X
correlates	B-X
with	B-X
expression	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
sizeable	B-X
group	B-X
is	B-X
devoid	B-X
of	B-X
these	B-X
marks	B-X
and	B-X
is	B-X
found	B-X
on	B-X
transcriptionally	B-X
silent	B-X
genes	B-X
.	B-X
Within	B-X
this	B-X
class	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-Y	B-X
binding	B-X
is	B-X
associated	B-X
with	B-X
negative	B-X
histone	B-X
marks	B-X
,	B-X
such	B-X
as	B-X
H4K20me3	B-X
and	B-X
H3K27me3	B-X
.	B-X
NF-Y	B-X
removal	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
NF-YA	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
expressed	B-X
genes	B-X
associated	B-X
with	B-X
H3K4me3	B-X
and	B-X
H3K9-14ac	B-X
,	B-X
while	B-X
increasing	B-X
the	B-X
levels	B-X
of	B-X
many	B-X
inactive	B-X
genes	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
NF-Y	B-X
is	B-X
embedded	B-X
in	B-X
positive	B-X
as	B-X
well	B-X
as	B-X
in	B-X
negative	B-X
methyl	B-X
histone	B-X
marks	B-X
,	B-X
serving	B-X
a	B-X
dual	B-X
function	B-X
in	B-X
transcriptional	B-X
regulation	B-X
,	B-X
as	B-X
an	B-X
activator	B-X
or	B-X
as	B-X
a	B-X
repressor	B-X
.	B-X

Unbiased	O
identification	O
of	O
binding	O
sites	O
shows	O
that	O
the	O
majority	O
of	O
genes	O
are	O
bound	O
by	O
NF	O
-	O
Y	O
in	O
the	O
promoter	O
and	O
/	O
or	O
within	O
the	O
coding	O
region	O
.	O
<EOS>	B-X
Current	B-X
clinical	B-X
next-generation	B-X
sequencing	B-X
is	B-X
done	B-X
by	B-X
using	B-X
gene	B-X
panels	B-X
and	B-X
exome	B-X
analysis	B-X
,	B-X
both	B-X
of	B-X
which	B-X
involve	B-X
selective	B-X
capturing	B-X
of	B-X
target	B-X
regions	B-X
.	B-X
However	B-X
,	B-X
capturing	B-X
has	B-X
limitations	B-X
in	B-X
sufficiently	B-X
covering	B-X
coding	B-X
exons	B-X
,	B-X
especially	B-X
GC-rich	B-X
regions	B-X
.	B-X
We	B-X
compared	B-X
whole	B-X
exome	B-X
sequencing	B-X
(	B-X
WES	B-X
)	B-X
with	B-X
the	B-X
most	B-X
recent	B-X
PCR-free	B-X
whole	B-X
genome	B-X
sequencing	B-X
(	B-X
WGS	B-X
)	B-X
,	B-X
showing	B-X
that	B-X
only	B-X
the	B-X
latter	B-X
is	B-X
able	B-X
to	B-X
provide	B-X
hitherto	B-X
unprecedented	B-X
complete	B-X
coverage	B-X
of	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
genome	B-X
.	B-X
The	B-X
hidden	B-X
world	B-X
of	B-X
non-canonical	B-X
ORFs	B-X
.	B-X

Parallel	O
analysis	O
of	O
H3K9	B-Protein
-	O
14ac	O
and	O
H3K4me3	B-Protein
sites	O
indicates	O
that	O
NF	O
-	O
Y	O
loci	O
can	O
be	O
divided	O
in	O
two	O
distinct	O
clusters	O
:	O
(	O
i	O
)	O
a	O
large	O
cohort	O
contains	O
H3K9	B-Protein
-	O
14ac	O
and	O
H3K4me3	B-Protein
marks	O
and	O
correlates	O
with	O
expression	O
and	O
(	O
ii	O
)	O
a	O
sizeable	O
group	O
is	O
devoid	O
of	O
these	O
marks	O
and	O
is	O
found	O
on	O
transcriptionally	O
silent	O
genes	O
.	O

Within	O
this	O
class	O
,	O
we	O
find	O
that	O
NF	O
-	O
Y	O
binding	O
is	O
associated	O
with	O
negative	O
histone	O
marks	O
,	O
such	O
as	O
H4K20me3	B-Protein
and	O
H3K27me3	B-Protein
.	O
<EOS>	B-X
NF-Y	B-X
is	B-X
a	B-X
trimeric	B-X
transcription	B-X
factor	B-X
containing	B-X
H2A/H2B-like	B-X
subunits	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
the	B-X
CCAAT	B-X
box	B-X
,	B-X
a	B-X
common	B-X
eukaryotic	B-X
promoter	B-X
element	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
NF-Y-dependent	B-X
transcriptional	B-X
regulation	B-X
,	B-X
we	B-X
assessed	B-X
its	B-X
relationships	B-X
with	B-X
positive	B-X
histone	B-X
marks	B-X
by	B-X
chromatin	B-X
immunoprecipitation-on-chip	B-X
and	B-X
correlative-profiling	B-X
studies	B-X
.	B-X
Unbiased	B-X
identification	B-X
of	B-X
binding	B-X
sites	B-X
shows	B-X
that	B-X
the	B-X
majority	B-X
of	B-X
genes	B-X
are	B-X
bound	B-X
by	B-X
NF-Y	B-X
in	B-X
the	B-X
promoter	B-X
and/or	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
.	B-X
Parallel	B-X
analysis	B-X
of	B-X
H3K9-14ac	B-X
and	B-X
H3K4me3	B-X
sites	B-X
indicates	B-X
that	B-X
NF-Y	B-X
loci	B-X
can	B-X
be	B-X
divided	B-X
in	B-X
two	B-X
distinct	B-X
clusters	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
large	B-X
cohort	B-X
contains	B-X
H3K9-14ac	B-X
and	B-X
H3K4me3	B-X
marks	B-X
and	B-X
correlates	B-X
with	B-X
expression	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
sizeable	B-X
group	B-X
is	B-X
devoid	B-X
of	B-X
these	B-X
marks	B-X
and	B-X
is	B-X
found	B-X
on	B-X
transcriptionally	B-X
silent	B-X
genes	B-X
.	B-X
Within	B-X
this	B-X
class	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-Y	B-X
binding	B-X
is	B-X
associated	B-X
with	B-X
negative	B-X
histone	B-X
marks	B-X
,	B-X
such	B-X
as	B-X
H4K20me3	B-X
and	B-X
H3K27me3	B-X
.	B-X
NF-Y	B-X
removal	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
NF-YA	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
expressed	B-X
genes	B-X
associated	B-X
with	B-X
H3K4me3	B-X
and	B-X
H3K9-14ac	B-X
,	B-X
while	B-X
increasing	B-X
the	B-X
levels	B-X
of	B-X
many	B-X
inactive	B-X
genes	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
NF-Y	B-X
is	B-X
embedded	B-X
in	B-X
positive	B-X
as	B-X
well	B-X
as	B-X
in	B-X
negative	B-X
methyl	B-X
histone	B-X
marks	B-X
,	B-X
serving	B-X
a	B-X
dual	B-X
function	B-X
in	B-X
transcriptional	B-X
regulation	B-X
,	B-X
as	B-X
an	B-X
activator	B-X
or	B-X
as	B-X
a	B-X
repressor	B-X
.	B-X

NF	O
-	O
Y	O
removal	O
by	O
a	O
dominant	O
negative	O
NF	B-Protein
-	I-Protein
YA	I-Protein
leads	O
to	O
a	O
decrease	O
in	O
the	O
transcription	O
of	O
expressed	O
genes	O
associated	O
with	O
H3K4me3	B-Protein
and	O
H3K9	B-Protein
-	O
14ac	O
,	O
while	O
increasing	O
the	O
levels	O
of	O
many	O
inactive	O
genes	O
.	O
<EOS>	B-X
NF-Y	B-X
is	B-X
a	B-X
trimeric	B-X
transcription	B-X
factor	B-X
containing	B-X
H2A/H2B-like	B-X
subunits	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
the	B-X
CCAAT	B-X
box	B-X
,	B-X
a	B-X
common	B-X
eukaryotic	B-X
promoter	B-X
element	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
NF-Y-dependent	B-X
transcriptional	B-X
regulation	B-X
,	B-X
we	B-X
assessed	B-X
its	B-X
relationships	B-X
with	B-X
positive	B-X
histone	B-X
marks	B-X
by	B-X
chromatin	B-X
immunoprecipitation-on-chip	B-X
and	B-X
correlative-profiling	B-X
studies	B-X
.	B-X
Unbiased	B-X
identification	B-X
of	B-X
binding	B-X
sites	B-X
shows	B-X
that	B-X
the	B-X
majority	B-X
of	B-X
genes	B-X
are	B-X
bound	B-X
by	B-X
NF-Y	B-X
in	B-X
the	B-X
promoter	B-X
and/or	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
.	B-X
Parallel	B-X
analysis	B-X
of	B-X
H3K9-14ac	B-X
and	B-X
H3K4me3	B-X
sites	B-X
indicates	B-X
that	B-X
NF-Y	B-X
loci	B-X
can	B-X
be	B-X
divided	B-X
in	B-X
two	B-X
distinct	B-X
clusters	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
large	B-X
cohort	B-X
contains	B-X
H3K9-14ac	B-X
and	B-X
H3K4me3	B-X
marks	B-X
and	B-X
correlates	B-X
with	B-X
expression	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
sizeable	B-X
group	B-X
is	B-X
devoid	B-X
of	B-X
these	B-X
marks	B-X
and	B-X
is	B-X
found	B-X
on	B-X
transcriptionally	B-X
silent	B-X
genes	B-X
.	B-X
Within	B-X
this	B-X
class	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-Y	B-X
binding	B-X
is	B-X
associated	B-X
with	B-X
negative	B-X
histone	B-X
marks	B-X
,	B-X
such	B-X
as	B-X
H4K20me3	B-X
and	B-X
H3K27me3	B-X
.	B-X
NF-Y	B-X
removal	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
NF-YA	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
expressed	B-X
genes	B-X
associated	B-X
with	B-X
H3K4me3	B-X
and	B-X
H3K9-14ac	B-X
,	B-X
while	B-X
increasing	B-X
the	B-X
levels	B-X
of	B-X
many	B-X
inactive	B-X
genes	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
NF-Y	B-X
is	B-X
embedded	B-X
in	B-X
positive	B-X
as	B-X
well	B-X
as	B-X
in	B-X
negative	B-X
methyl	B-X
histone	B-X
marks	B-X
,	B-X
serving	B-X
a	B-X
dual	B-X
function	B-X
in	B-X
transcriptional	B-X
regulation	B-X
,	B-X
as	B-X
an	B-X
activator	B-X
or	B-X
as	B-X
a	B-X
repressor	B-X
.	B-X

These	O
data	O
indicate	O
that	O
NF	O
-	O
Y	O
is	O
embedded	O
in	O
positive	O
as	O
well	O
as	O
in	O
negative	O
methyl	O
histone	B-Protein
marks	O
,	O
serving	O
a	O
dual	O
function	O
in	O
transcriptional	O
regulation	O
,	O
as	O
an	O
activator	O
or	O
as	O
a	O
repressor	O
.	O
<EOS>	B-X
Many	B-X
R2R3-MYB	B-X
transcriptional	B-X
activators	B-X
are	B-X
known	B-X
,	B-X
but	B-X
the	B-X
prevalence	B-X
of	B-X
MYB	B-X
repressors	B-X
has	B-X
only	B-X
recently	B-X
become	B-X
recognized	B-X
.	B-X
This	B-X
review	B-X
article	B-X
summarizes	B-X
recent	B-X
progress	B-X
on	B-X
function	B-X
and	B-X
mechanism	B-X
of	B-X
these	B-X
MYB	B-X
repressors	B-X
.	B-X
The	B-X
characterized	B-X
phenylpropanoid	B-X
R2R3-MYB	B-X
repressors	B-X
comprise	B-X
two	B-X
phylogenetic	B-X
clades	B-X
that	B-X
act	B-X
on	B-X
the	B-X
lignin	B-X
and	B-X
general	B-X
phenylpropanoid	B-X
genes	B-X
,	B-X
or	B-X
the	B-X
flavonoid	B-X
genes	B-X
,	B-X
respectively	B-X
;	B-X
anthocyanin	B-X
R3-MYB	B-X
repressors	B-X
form	B-X
a	B-X
separate	B-X
clade	B-X
.	B-X
While	B-X
some	B-X
flavonoid	B-X
MYBs	B-X
repressors	B-X
can	B-X
bind	B-X
basic-helix-loop-helix	B-X
factors	B-X
and	B-X
disrupt	B-X
the	B-X
MBW	B-X
complex	B-X
,	B-X
for	B-X
the	B-X
lignin	B-X
repressor	B-X
MYBs	B-X
interactions	B-X
with	B-X
promoter	B-X
cis-elements	B-X
have	B-X
been	B-X
demonstrated	B-X
.	B-X
The	B-X
role	B-X
of	B-X
the	B-X
conserved	B-X
repression	B-X
motifs	B-X
that	B-X
define	B-X
the	B-X
MYB	B-X
repressors	B-X
is	B-X
not	B-X
yet	B-X
known	B-X
,	B-X
however	B-X
.	B-X

Role	O
of	O
S3	O
and	O
S4	O
transmembrane	O
domain	O
charged	O
amino	O
acids	O
in	O
channel	O
biogenesis	O
and	O
gating	O
of	O
KCa2	B-Protein
.	I-Protein
3	I-Protein
and	O
KCa3	B-Protein
.	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
positively	B-X
charged	B-X
arginines	B-X
in	B-X
the	B-X
fourth	B-X
transmembrane	B-X
domain	B-X
(	B-X
S4	B-X
)	B-X
and	B-X
a	B-X
single	B-X
negatively	B-X
charged	B-X
amino	B-X
acid	B-X
in	B-X
the	B-X
third	B-X
transmembrane	B-X
domain	B-X
(	B-X
S3	B-X
)	B-X
on	B-X
channel	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
voltage-gated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
(	B-X
Kv	B-X
)	B-X
has	B-X
been	B-X
well	B-X
established	B-X
.	B-X
Both	B-X
intermediate	B-X
(	B-X
KCa3.1	B-X
)	B-X
and	B-X
small	B-X
(	B-X
KCa2.x	B-X
)	B-X
conductance	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-activated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
have	B-X
two	B-X
conserved	B-X
arginines	B-X
in	B-X
S4	B-X
and	B-X
a	B-X
single	B-X
conserved	B-X
glutamic	B-X
acid	B-X
in	B-X
S3	B-X
,	B-X
although	B-X
these	B-X
channels	B-X
are	B-X
voltage-independent	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
mutation	B-X
of	B-X
any	B-X
of	B-X
these	B-X
charged	B-X
amino	B-X
acids	B-X
in	B-X
KCa3.1	B-X
or	B-X
KCa2.3	B-X
to	B-X
alanine	B-X
,	B-X
glutamine	B-X
,	B-X
or	B-X
charge	B-X
reversal	B-X
mutations	B-X
results	B-X
in	B-X
a	B-X
rapid	B-X
degradation	B-X
(	B-X
<	B-X
30	B-X
min	B-X
)	B-X
of	B-X
total	B-X
protein	B-X
,	B-X
confirming	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
these	B-X
amino	B-X
acids	B-X
in	B-X
channel	B-X
biogenesis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
S4	B-X
arginine	B-X
closest	B-X
to	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
KCa3.1	B-X
to	B-X
histidine	B-X
resulted	B-X
in	B-X
expression	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Excised	B-X
patch	B-X
clamp	B-X
experiments	B-X
revealed	B-X
that	B-X
this	B-X
Arg/His	B-X
mutation	B-X
had	B-X
a	B-X
dramatically	B-X
reduced	B-X
open	B-X
probability	B-X
(	B-X
P	B-X
(	B-X
o	B-X
)	B-X
)	B-X
,	B-X
relative	B-X
to	B-X
wild	B-X
type	B-X
channels	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
demonstrate	B-X
,	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
short	B-X
hairpin	B-X
RNA	B-X
,	B-X
dominant	B-X
negative	B-X
,	B-X
and	B-X
co-immunoprecipitation	B-X
studies	B-X
,	B-X
that	B-X
both	B-X
KCa3.1	B-X
and	B-X
KCa2.3	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
associated	B-X
with	B-X
Derlin-1	B-X
.	B-X
These	B-X
misfolded	B-X
channels	B-X
are	B-X
poly-ubiquitylated	B-X
,	B-X
recognized	B-X
by	B-X
p97	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
S3	B-X
and	B-X
S4	B-X
charged	B-X
amino	B-X
acids	B-X
play	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
role	B-X
in	B-X
the	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
KCa	B-X
channels	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
improperly	B-X
folded	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
in	B-X
a	B-X
Derlin-1-	B-X
and	B-X
p97-dependent	B-X
fashion	B-X
,	B-X
poly-ubiquitylated	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X

The	O
role	O
of	O
positively	O
charged	O
arginines	O
in	O
the	O
fourth	O
transmembrane	O
domain	O
(	O
S4	O
)	O
and	O
a	O
single	O
negatively	O
charged	O
amino	O
acid	O
in	O
the	O
third	O
transmembrane	O
domain	O
(	O
S3	O
)	O
on	O
channel	O
biogenesis	O
and	O
gating	O
of	O
voltage	O
-	O
gated	O
K	O
(	O
+	O
)	O
channels	O
(	O
Kv	O
)	O
has	O
been	O
well	O
established	O
.	O

Both	O
intermediate	O
(	O
KCa3	B-Protein
.	I-Protein
1	I-Protein
)	O
and	O
small	O
(	O
KCa2	O
.	O
x	O
)	O
conductance	O
,	O
Ca	O
(	O
2	O
+	O
)	O
-	O
activated	O
K	O
(	O
+	O
)	O
channels	O
have	O
two	O
conserved	O
arginines	O
in	O
S4	O
and	O
a	O
single	O
conserved	O
glutamic	O
acid	O
in	O
S3	O
,	O
although	O
these	O
channels	O
are	O
voltage	O
-	O
independent	O
.	O

We	O
demonstrate	O
that	O
mutation	O
of	O
any	O
of	O
these	O
charged	O
amino	O
acids	O
in	O
KCa3	B-Protein
.	I-Protein
1	I-Protein
or	O
KCa2	B-Protein
.	I-Protein
3	I-Protein
to	O
alanine	O
,	O
glutamine	O
,	O
or	O
charge	O
reversal	O
mutations	O
results	O
in	O
a	O
rapid	O
degradation	O
(	O
<	O
30	O
min	O
)	O
of	O
total	O
protein	O
,	O
confirming	O
the	O
critical	O
role	O
of	O
these	O
amino	O
acids	O
in	O
channel	O
biogenesis	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
positively	B-X
charged	B-X
arginines	B-X
in	B-X
the	B-X
fourth	B-X
transmembrane	B-X
domain	B-X
(	B-X
S4	B-X
)	B-X
and	B-X
a	B-X
single	B-X
negatively	B-X
charged	B-X
amino	B-X
acid	B-X
in	B-X
the	B-X
third	B-X
transmembrane	B-X
domain	B-X
(	B-X
S3	B-X
)	B-X
on	B-X
channel	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
voltage-gated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
(	B-X
Kv	B-X
)	B-X
has	B-X
been	B-X
well	B-X
established	B-X
.	B-X
Both	B-X
intermediate	B-X
(	B-X
KCa3.1	B-X
)	B-X
and	B-X
small	B-X
(	B-X
KCa2.x	B-X
)	B-X
conductance	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-activated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
have	B-X
two	B-X
conserved	B-X
arginines	B-X
in	B-X
S4	B-X
and	B-X
a	B-X
single	B-X
conserved	B-X
glutamic	B-X
acid	B-X
in	B-X
S3	B-X
,	B-X
although	B-X
these	B-X
channels	B-X
are	B-X
voltage-independent	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
mutation	B-X
of	B-X
any	B-X
of	B-X
these	B-X
charged	B-X
amino	B-X
acids	B-X
in	B-X
KCa3.1	B-X
or	B-X
KCa2.3	B-X
to	B-X
alanine	B-X
,	B-X
glutamine	B-X
,	B-X
or	B-X
charge	B-X
reversal	B-X
mutations	B-X
results	B-X
in	B-X
a	B-X
rapid	B-X
degradation	B-X
(	B-X
<	B-X
30	B-X
min	B-X
)	B-X
of	B-X
total	B-X
protein	B-X
,	B-X
confirming	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
these	B-X
amino	B-X
acids	B-X
in	B-X
channel	B-X
biogenesis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
S4	B-X
arginine	B-X
closest	B-X
to	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
KCa3.1	B-X
to	B-X
histidine	B-X
resulted	B-X
in	B-X
expression	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Excised	B-X
patch	B-X
clamp	B-X
experiments	B-X
revealed	B-X
that	B-X
this	B-X
Arg/His	B-X
mutation	B-X
had	B-X
a	B-X
dramatically	B-X
reduced	B-X
open	B-X
probability	B-X
(	B-X
P	B-X
(	B-X
o	B-X
)	B-X
)	B-X
,	B-X
relative	B-X
to	B-X
wild	B-X
type	B-X
channels	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
demonstrate	B-X
,	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
short	B-X
hairpin	B-X
RNA	B-X
,	B-X
dominant	B-X
negative	B-X
,	B-X
and	B-X
co-immunoprecipitation	B-X
studies	B-X
,	B-X
that	B-X
both	B-X
KCa3.1	B-X
and	B-X
KCa2.3	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
associated	B-X
with	B-X
Derlin-1	B-X
.	B-X
These	B-X
misfolded	B-X
channels	B-X
are	B-X
poly-ubiquitylated	B-X
,	B-X
recognized	B-X
by	B-X
p97	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
S3	B-X
and	B-X
S4	B-X
charged	B-X
amino	B-X
acids	B-X
play	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
role	B-X
in	B-X
the	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
KCa	B-X
channels	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
improperly	B-X
folded	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
in	B-X
a	B-X
Derlin-1-	B-X
and	B-X
p97-dependent	B-X
fashion	B-X
,	B-X
poly-ubiquitylated	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X

Mutation	O
of	O
the	O
S4	O
arginine	O
closest	O
to	O
the	O
cytosolic	O
side	O
of	O
KCa3	B-Protein
.	I-Protein
1	I-Protein
to	O
histidine	O
resulted	O
in	O
expression	O
at	O
the	O
cell	O
surface	O
.	O

Excised	O
patch	O
clamp	O
experiments	O
revealed	O
that	O
this	O
Arg	O
/	O
His	O
mutation	O
had	O
a	O
dramatically	O
reduced	O
open	O
probability	O
(	O
P	O
(	O
o	O
)	O
)	O
,	O
relative	O
to	O
wild	O
type	O
channels	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
positively	B-X
charged	B-X
arginines	B-X
in	B-X
the	B-X
fourth	B-X
transmembrane	B-X
domain	B-X
(	B-X
S4	B-X
)	B-X
and	B-X
a	B-X
single	B-X
negatively	B-X
charged	B-X
amino	B-X
acid	B-X
in	B-X
the	B-X
third	B-X
transmembrane	B-X
domain	B-X
(	B-X
S3	B-X
)	B-X
on	B-X
channel	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
voltage-gated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
(	B-X
Kv	B-X
)	B-X
has	B-X
been	B-X
well	B-X
established	B-X
.	B-X
Both	B-X
intermediate	B-X
(	B-X
KCa3.1	B-X
)	B-X
and	B-X
small	B-X
(	B-X
KCa2.x	B-X
)	B-X
conductance	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-activated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
have	B-X
two	B-X
conserved	B-X
arginines	B-X
in	B-X
S4	B-X
and	B-X
a	B-X
single	B-X
conserved	B-X
glutamic	B-X
acid	B-X
in	B-X
S3	B-X
,	B-X
although	B-X
these	B-X
channels	B-X
are	B-X
voltage-independent	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
mutation	B-X
of	B-X
any	B-X
of	B-X
these	B-X
charged	B-X
amino	B-X
acids	B-X
in	B-X
KCa3.1	B-X
or	B-X
KCa2.3	B-X
to	B-X
alanine	B-X
,	B-X
glutamine	B-X
,	B-X
or	B-X
charge	B-X
reversal	B-X
mutations	B-X
results	B-X
in	B-X
a	B-X
rapid	B-X
degradation	B-X
(	B-X
<	B-X
30	B-X
min	B-X
)	B-X
of	B-X
total	B-X
protein	B-X
,	B-X
confirming	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
these	B-X
amino	B-X
acids	B-X
in	B-X
channel	B-X
biogenesis	B-X
.	B-X
Excised	B-X
patch	B-X
clamp	B-X
experiments	B-X
revealed	B-X
that	B-X
this	B-X
Arg/His	B-X
mutation	B-X
had	B-X
a	B-X
dramatically	B-X
reduced	B-X
open	B-X
probability	B-X
(	B-X
P	B-X
(	B-X
o	B-X
)	B-X
)	B-X
,	B-X
relative	B-X
to	B-X
wild	B-X
type	B-X
channels	B-X
.	B-X
These	B-X
misfolded	B-X
channels	B-X
are	B-X
poly-ubiquitylated	B-X
,	B-X
recognized	B-X
by	B-X
p97	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
S3	B-X
and	B-X
S4	B-X
charged	B-X
amino	B-X
acids	B-X
play	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
role	B-X
in	B-X
the	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
KCa	B-X
channels	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
improperly	B-X
folded	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
in	B-X
a	B-X
Derlin-1-	B-X
and	B-X
p97-dependent	B-X
fashion	B-X
,	B-X
poly-ubiquitylated	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X

Additionally	O
,	O
we	O
demonstrate	O
,	O
using	O
a	O
combination	O
of	O
short	O
hairpin	O
RNA	O
,	O
dominant	O
negative	O
,	O
and	O
co	O
-	O
immunoprecipitation	O
studies	O
,	O
that	O
both	O
KCa3	B-Protein
.	I-Protein
1	I-Protein
and	O
KCa2	B-Protein
.	I-Protein
3	I-Protein
are	O
translocated	O
out	O
of	O
the	O
endoplasmic	O
reticulum	O
associated	O
with	O
Derlin	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
positively	B-X
charged	B-X
arginines	B-X
in	B-X
the	B-X
fourth	B-X
transmembrane	B-X
domain	B-X
(	B-X
S4	B-X
)	B-X
and	B-X
a	B-X
single	B-X
negatively	B-X
charged	B-X
amino	B-X
acid	B-X
in	B-X
the	B-X
third	B-X
transmembrane	B-X
domain	B-X
(	B-X
S3	B-X
)	B-X
on	B-X
channel	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
voltage-gated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
(	B-X
Kv	B-X
)	B-X
has	B-X
been	B-X
well	B-X
established	B-X
.	B-X
Both	B-X
intermediate	B-X
(	B-X
KCa3.1	B-X
)	B-X
and	B-X
small	B-X
(	B-X
KCa2.x	B-X
)	B-X
conductance	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-activated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
have	B-X
two	B-X
conserved	B-X
arginines	B-X
in	B-X
S4	B-X
and	B-X
a	B-X
single	B-X
conserved	B-X
glutamic	B-X
acid	B-X
in	B-X
S3	B-X
,	B-X
although	B-X
these	B-X
channels	B-X
are	B-X
voltage-independent	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
mutation	B-X
of	B-X
any	B-X
of	B-X
these	B-X
charged	B-X
amino	B-X
acids	B-X
in	B-X
KCa3.1	B-X
or	B-X
KCa2.3	B-X
to	B-X
alanine	B-X
,	B-X
glutamine	B-X
,	B-X
or	B-X
charge	B-X
reversal	B-X
mutations	B-X
results	B-X
in	B-X
a	B-X
rapid	B-X
degradation	B-X
(	B-X
<	B-X
30	B-X
min	B-X
)	B-X
of	B-X
total	B-X
protein	B-X
,	B-X
confirming	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
these	B-X
amino	B-X
acids	B-X
in	B-X
channel	B-X
biogenesis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
S4	B-X
arginine	B-X
closest	B-X
to	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
KCa3.1	B-X
to	B-X
histidine	B-X
resulted	B-X
in	B-X
expression	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
demonstrate	B-X
,	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
short	B-X
hairpin	B-X
RNA	B-X
,	B-X
dominant	B-X
negative	B-X
,	B-X
and	B-X
co-immunoprecipitation	B-X
studies	B-X
,	B-X
that	B-X
both	B-X
KCa3.1	B-X
and	B-X
KCa2.3	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
associated	B-X
with	B-X
Derlin-1	B-X
.	B-X
These	B-X
misfolded	B-X
channels	B-X
are	B-X
poly-ubiquitylated	B-X
,	B-X
recognized	B-X
by	B-X
p97	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
S3	B-X
and	B-X
S4	B-X
charged	B-X
amino	B-X
acids	B-X
play	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
role	B-X
in	B-X
the	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
KCa	B-X
channels	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
improperly	B-X
folded	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
in	B-X
a	B-X
Derlin-1-	B-X
and	B-X
p97-dependent	B-X
fashion	B-X
,	B-X
poly-ubiquitylated	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X

These	O
misfolded	O
channels	O
are	O
poly	O
-	O
ubiquitylated	O
,	O
recognized	O
by	O
p97	B-Protein
,	O
and	O
targeted	O
for	O
proteasomal	O
degradation	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
positively	B-X
charged	B-X
arginines	B-X
in	B-X
the	B-X
fourth	B-X
transmembrane	B-X
domain	B-X
(	B-X
S4	B-X
)	B-X
and	B-X
a	B-X
single	B-X
negatively	B-X
charged	B-X
amino	B-X
acid	B-X
in	B-X
the	B-X
third	B-X
transmembrane	B-X
domain	B-X
(	B-X
S3	B-X
)	B-X
on	B-X
channel	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
voltage-gated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
(	B-X
Kv	B-X
)	B-X
has	B-X
been	B-X
well	B-X
established	B-X
.	B-X
Both	B-X
intermediate	B-X
(	B-X
KCa3.1	B-X
)	B-X
and	B-X
small	B-X
(	B-X
KCa2.x	B-X
)	B-X
conductance	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-activated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
have	B-X
two	B-X
conserved	B-X
arginines	B-X
in	B-X
S4	B-X
and	B-X
a	B-X
single	B-X
conserved	B-X
glutamic	B-X
acid	B-X
in	B-X
S3	B-X
,	B-X
although	B-X
these	B-X
channels	B-X
are	B-X
voltage-independent	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
mutation	B-X
of	B-X
any	B-X
of	B-X
these	B-X
charged	B-X
amino	B-X
acids	B-X
in	B-X
KCa3.1	B-X
or	B-X
KCa2.3	B-X
to	B-X
alanine	B-X
,	B-X
glutamine	B-X
,	B-X
or	B-X
charge	B-X
reversal	B-X
mutations	B-X
results	B-X
in	B-X
a	B-X
rapid	B-X
degradation	B-X
(	B-X
<	B-X
30	B-X
min	B-X
)	B-X
of	B-X
total	B-X
protein	B-X
,	B-X
confirming	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
these	B-X
amino	B-X
acids	B-X
in	B-X
channel	B-X
biogenesis	B-X
.	B-X
Excised	B-X
patch	B-X
clamp	B-X
experiments	B-X
revealed	B-X
that	B-X
this	B-X
Arg/His	B-X
mutation	B-X
had	B-X
a	B-X
dramatically	B-X
reduced	B-X
open	B-X
probability	B-X
(	B-X
P	B-X
(	B-X
o	B-X
)	B-X
)	B-X
,	B-X
relative	B-X
to	B-X
wild	B-X
type	B-X
channels	B-X
.	B-X
These	B-X
misfolded	B-X
channels	B-X
are	B-X
poly-ubiquitylated	B-X
,	B-X
recognized	B-X
by	B-X
p97	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
S3	B-X
and	B-X
S4	B-X
charged	B-X
amino	B-X
acids	B-X
play	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
role	B-X
in	B-X
the	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
KCa	B-X
channels	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
improperly	B-X
folded	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
in	B-X
a	B-X
Derlin-1-	B-X
and	B-X
p97-dependent	B-X
fashion	B-X
,	B-X
poly-ubiquitylated	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
S3	O
and	O
S4	O
charged	O
amino	O
acids	O
play	O
an	O
evolutionarily	O
conserved	O
role	O
in	O
the	O
biogenesis	O
and	O
gating	O
of	O
KCa	O
channels	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
positively	B-X
charged	B-X
arginines	B-X
in	B-X
the	B-X
fourth	B-X
transmembrane	B-X
domain	B-X
(	B-X
S4	B-X
)	B-X
and	B-X
a	B-X
single	B-X
negatively	B-X
charged	B-X
amino	B-X
acid	B-X
in	B-X
the	B-X
third	B-X
transmembrane	B-X
domain	B-X
(	B-X
S3	B-X
)	B-X
on	B-X
channel	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
voltage-gated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
(	B-X
Kv	B-X
)	B-X
has	B-X
been	B-X
well	B-X
established	B-X
.	B-X
Both	B-X
intermediate	B-X
(	B-X
KCa3.1	B-X
)	B-X
and	B-X
small	B-X
(	B-X
KCa2.x	B-X
)	B-X
conductance	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-activated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
have	B-X
two	B-X
conserved	B-X
arginines	B-X
in	B-X
S4	B-X
and	B-X
a	B-X
single	B-X
conserved	B-X
glutamic	B-X
acid	B-X
in	B-X
S3	B-X
,	B-X
although	B-X
these	B-X
channels	B-X
are	B-X
voltage-independent	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
mutation	B-X
of	B-X
any	B-X
of	B-X
these	B-X
charged	B-X
amino	B-X
acids	B-X
in	B-X
KCa3.1	B-X
or	B-X
KCa2.3	B-X
to	B-X
alanine	B-X
,	B-X
glutamine	B-X
,	B-X
or	B-X
charge	B-X
reversal	B-X
mutations	B-X
results	B-X
in	B-X
a	B-X
rapid	B-X
degradation	B-X
(	B-X
<	B-X
30	B-X
min	B-X
)	B-X
of	B-X
total	B-X
protein	B-X
,	B-X
confirming	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
these	B-X
amino	B-X
acids	B-X
in	B-X
channel	B-X
biogenesis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
S4	B-X
arginine	B-X
closest	B-X
to	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
KCa3.1	B-X
to	B-X
histidine	B-X
resulted	B-X
in	B-X
expression	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Excised	B-X
patch	B-X
clamp	B-X
experiments	B-X
revealed	B-X
that	B-X
this	B-X
Arg/His	B-X
mutation	B-X
had	B-X
a	B-X
dramatically	B-X
reduced	B-X
open	B-X
probability	B-X
(	B-X
P	B-X
(	B-X
o	B-X
)	B-X
)	B-X
,	B-X
relative	B-X
to	B-X
wild	B-X
type	B-X
channels	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
demonstrate	B-X
,	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
short	B-X
hairpin	B-X
RNA	B-X
,	B-X
dominant	B-X
negative	B-X
,	B-X
and	B-X
co-immunoprecipitation	B-X
studies	B-X
,	B-X
that	B-X
both	B-X
KCa3.1	B-X
and	B-X
KCa2.3	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
associated	B-X
with	B-X
Derlin-1	B-X
.	B-X
These	B-X
misfolded	B-X
channels	B-X
are	B-X
poly-ubiquitylated	B-X
,	B-X
recognized	B-X
by	B-X
p97	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
S3	B-X
and	B-X
S4	B-X
charged	B-X
amino	B-X
acids	B-X
play	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
role	B-X
in	B-X
the	B-X
biogenesis	B-X
and	B-X
gating	B-X
of	B-X
KCa	B-X
channels	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
improperly	B-X
folded	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channels	B-X
are	B-X
translocated	B-X
out	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
in	B-X
a	B-X
Derlin-1-	B-X
and	B-X
p97-dependent	B-X
fashion	B-X
,	B-X
poly-ubiquitylated	B-X
,	B-X
and	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X

Furthermore	O
,	O
these	O
improperly	O
folded	O
K	O
(	O
+	O
)	O
channels	O
are	O
translocated	O
out	O
of	O
the	O
endoplasmic	O
reticulum	O
in	O
a	O
Derlin	B-Protein
-	I-Protein
1	I-Protein
-	O
and	O
p97	B-Protein
-	O
dependent	O
fashion	O
,	O
poly	O
-	O
ubiquitylated	O
,	O
and	O
targeted	O
for	O
proteasomal	O
degradation	O
.	O

Role	O
and	O
regulation	O
of	O
prolyl	O
hydroxylase	O
domain	O
proteins	O
.	O
<EOS>	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
role	B-X
and	B-X
regulation	B-X
of	B-X
the	B-X
HIF-1α	B-X
in	B-X
cancer	B-X
,	B-X
and	B-X
recent	B-X
therapeutic	B-X
approaches	B-X
targeting	B-X
this	B-X
important	B-X
pathway	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
indicated	B-X
that	B-X
the	B-X
regulation	B-X
of	B-X
innate	B-X
immunity	B-X
and	B-X
energy	B-X
metabolism	B-X
are	B-X
connected	B-X
together	B-X
through	B-X
an	B-X
antagonistic	B-X
crosstalk	B-X
between	B-X
NF-κB	B-X
and	B-X
SIRT1	B-X
signaling	B-X
pathways	B-X
.	B-X
In	B-X
particular	B-X
HIF-2	B-X
has	B-X
emerged	B-X
as	B-X
the	B-X
transcription	B-X
factor	B-X
that	B-X
regulates	B-X
EPO	B-X
synthesis	B-X
in	B-X
the	B-X
kidney	B-X
and	B-X
liver	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
intestinal	B-X
iron	B-X
uptake	B-X
.	B-X
Its	B-X
key	B-X
function	B-X
in	B-X
the	B-X
hypoxic	B-X
regulation	B-X
of	B-X
erythropoiesis	B-X
is	B-X
underscored	B-X
by	B-X
genetic	B-X
studies	B-X
in	B-X
human	B-X
populations	B-X
that	B-X
live	B-X
at	B-X
high-altitude	B-X
and	B-X
by	B-X
mutational	B-X
analysis	B-X
of	B-X
patients	B-X
with	B-X
familial	B-X
erythrocytosis	B-X
.	B-X

Oxygen	O
-	O
dependent	O
hydroxylation	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
alpha	O
subunits	O
by	O
prolyl	O
hydroxylase	O
domain	O
(	O
PHD	O
)	O
proteins	O
signals	O
their	O
polyubiquitination	O
and	O
proteasomal	O
degradation	O
,	O
and	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
HIF	O
abundance	O
and	O
oxygen	O
homeostasis	O
.	O

While	O
oxygen	O
concentration	O
plays	O
a	O
major	O
role	O
in	O
determining	O
the	O
efficiency	O
of	O
PHD	O
-	O
catalyzed	O
hydroxylation	O
reactions	O
,	O
many	O
other	O
environmental	O
and	O
intracellular	O
factors	O
also	O
significantly	O
modulate	O
PHD	O
activities	O
.	O

In	O
addition	O
,	O
PHDs	O
may	O
also	O
employ	O
hydroxylase	O
-	O
independent	O
mechanisms	O
to	O
modify	O
HIF	O
activity	O
.	O
<EOS>	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
-alpha	B-X
subunits	B-X
by	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
(	B-X
PHD	B-X
)	B-X
proteins	B-X
signals	B-X
their	B-X
polyubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
,	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
HIF	B-X
abundance	B-X
and	B-X
oxygen	B-X
homeostasis	B-X
.	B-X
While	B-X
oxygen	B-X
concentration	B-X
plays	B-X
a	B-X
major	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
efficiency	B-X
of	B-X
PHD-catalyzed	B-X
hydroxylation	B-X
reactions	B-X
,	B-X
many	B-X
other	B-X
environmental	B-X
and	B-X
intracellular	B-X
factors	B-X
also	B-X
significantly	B-X
modulate	B-X
PHD	B-X
activities	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PHDs	B-X
may	B-X
also	B-X
employ	B-X
hydroxylase-independent	B-X
mechanisms	B-X
to	B-X
modify	B-X
HIF	B-X
activity	B-X
.	B-X
Interestingly	B-X
,	B-X
while	B-X
PHDs	B-X
regulate	B-X
HIF-alpha	B-X
protein	B-X
stability	B-X
,	B-X
PHD2	B-X
and	B-X
PHD3	B-X
themselves	B-X
are	B-X
subject	B-X
to	B-X
feedback	B-X
upregulation	B-X
by	B-X
HIFs	B-X
.	B-X
Functionally	B-X
,	B-X
different	B-X
PHD	B-X
isoforms	B-X
may	B-X
differentially	B-X
contribute	B-X
to	B-X
specific	B-X
pathophysiological	B-X
processes	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
erythropoiesis	B-X
,	B-X
tumorigenesis	B-X
,	B-X
and	B-X
cell	B-X
growth	B-X
,	B-X
differentiation	B-X
and	B-X
survival	B-X
.	B-X
Because	B-X
of	B-X
diverse	B-X
roles	B-X
of	B-X
PHDs	B-X
in	B-X
many	B-X
different	B-X
processes	B-X
,	B-X
loss	B-X
of	B-X
PHD	B-X
expression	B-X
or	B-X
function	B-X
triggers	B-X
multi-faceted	B-X
pathophysiological	B-X
changes	B-X
as	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
mice	B-X
lacking	B-X
different	B-X
PHD	B-X
isoforms	B-X
.	B-X
Future	B-X
investigations	B-X
are	B-X
needed	B-X
to	B-X
explore	B-X
in	B-X
vivo	B-X
specificity	B-X
of	B-X
PHDs	B-X
over	B-X
different	B-X
HIF-alpha	B-X
subunits	B-X
and	B-X
differential	B-X
roles	B-X
of	B-X
PHD	B-X
isoforms	B-X
in	B-X
different	B-X
biological	B-X
processes	B-X
.	B-X

Interestingly	O
,	O
while	O
PHDs	O
regulate	O
HIF	O
-	O
alpha	O
protein	O
stability	O
,	O
PHD2	B-Protein
and	O
PHD3	B-Protein
themselves	O
are	O
subject	O
to	O
feedback	O
upregulation	O
by	O
HIFs	O
.	O
<EOS>	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
-alpha	B-X
subunits	B-X
by	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
(	B-X
PHD	B-X
)	B-X
proteins	B-X
signals	B-X
their	B-X
polyubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
,	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
HIF	B-X
abundance	B-X
and	B-X
oxygen	B-X
homeostasis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PHDs	B-X
may	B-X
also	B-X
employ	B-X
hydroxylase-independent	B-X
mechanisms	B-X
to	B-X
modify	B-X
HIF	B-X
activity	B-X
.	B-X
Interestingly	B-X
,	B-X
while	B-X
PHDs	B-X
regulate	B-X
HIF-alpha	B-X
protein	B-X
stability	B-X
,	B-X
PHD2	B-X
and	B-X
PHD3	B-X
themselves	B-X
are	B-X
subject	B-X
to	B-X
feedback	B-X
upregulation	B-X
by	B-X
HIFs	B-X
.	B-X
Because	B-X
of	B-X
diverse	B-X
roles	B-X
of	B-X
PHDs	B-X
in	B-X
many	B-X
different	B-X
processes	B-X
,	B-X
loss	B-X
of	B-X
PHD	B-X
expression	B-X
or	B-X
function	B-X
triggers	B-X
multi-faceted	B-X
pathophysiological	B-X
changes	B-X
as	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
mice	B-X
lacking	B-X
different	B-X
PHD	B-X
isoforms	B-X
.	B-X
Future	B-X
investigations	B-X
are	B-X
needed	B-X
to	B-X
explore	B-X
in	B-X
vivo	B-X
specificity	B-X
of	B-X
PHDs	B-X
over	B-X
different	B-X
HIF-alpha	B-X
subunits	B-X
and	B-X
differential	B-X
roles	B-X
of	B-X
PHD	B-X
isoforms	B-X
in	B-X
different	B-X
biological	B-X
processes	B-X
.	B-X

Functionally	O
,	O
different	O
PHD	O
isoforms	O
may	O
differentially	O
contribute	O
to	O
specific	O
pathophysiological	O
processes	O
,	O
including	O
angiogenesis	O
,	O
erythropoiesis	O
,	O
tumorigenesis	O
,	O
and	O
cell	O
growth	O
,	O
differentiation	O
and	O
survival	O
.	O
<EOS>	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
-alpha	B-X
subunits	B-X
by	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
(	B-X
PHD	B-X
)	B-X
proteins	B-X
signals	B-X
their	B-X
polyubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
,	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
HIF	B-X
abundance	B-X
and	B-X
oxygen	B-X
homeostasis	B-X
.	B-X
While	B-X
oxygen	B-X
concentration	B-X
plays	B-X
a	B-X
major	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
efficiency	B-X
of	B-X
PHD-catalyzed	B-X
hydroxylation	B-X
reactions	B-X
,	B-X
many	B-X
other	B-X
environmental	B-X
and	B-X
intracellular	B-X
factors	B-X
also	B-X
significantly	B-X
modulate	B-X
PHD	B-X
activities	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PHDs	B-X
may	B-X
also	B-X
employ	B-X
hydroxylase-independent	B-X
mechanisms	B-X
to	B-X
modify	B-X
HIF	B-X
activity	B-X
.	B-X
Interestingly	B-X
,	B-X
while	B-X
PHDs	B-X
regulate	B-X
HIF-alpha	B-X
protein	B-X
stability	B-X
,	B-X
PHD2	B-X
and	B-X
PHD3	B-X
themselves	B-X
are	B-X
subject	B-X
to	B-X
feedback	B-X
upregulation	B-X
by	B-X
HIFs	B-X
.	B-X
Functionally	B-X
,	B-X
different	B-X
PHD	B-X
isoforms	B-X
may	B-X
differentially	B-X
contribute	B-X
to	B-X
specific	B-X
pathophysiological	B-X
processes	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
erythropoiesis	B-X
,	B-X
tumorigenesis	B-X
,	B-X
and	B-X
cell	B-X
growth	B-X
,	B-X
differentiation	B-X
and	B-X
survival	B-X
.	B-X
Because	B-X
of	B-X
diverse	B-X
roles	B-X
of	B-X
PHDs	B-X
in	B-X
many	B-X
different	B-X
processes	B-X
,	B-X
loss	B-X
of	B-X
PHD	B-X
expression	B-X
or	B-X
function	B-X
triggers	B-X
multi-faceted	B-X
pathophysiological	B-X
changes	B-X
as	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
mice	B-X
lacking	B-X
different	B-X
PHD	B-X
isoforms	B-X
.	B-X
Future	B-X
investigations	B-X
are	B-X
needed	B-X
to	B-X
explore	B-X
in	B-X
vivo	B-X
specificity	B-X
of	B-X
PHDs	B-X
over	B-X
different	B-X
HIF-alpha	B-X
subunits	B-X
and	B-X
differential	B-X
roles	B-X
of	B-X
PHD	B-X
isoforms	B-X
in	B-X
different	B-X
biological	B-X
processes	B-X
.	B-X

Because	O
of	O
diverse	O
roles	O
of	O
PHDs	O
in	O
many	O
different	O
processes	O
,	O
loss	O
of	O
PHD	O
expression	O
or	O
function	O
triggers	O
multi	O
-	O
faceted	O
pathophysiological	O
changes	O
as	O
has	O
been	O
shown	O
in	O
mice	O
lacking	O
different	O
PHD	O
isoforms	O
.	O
<EOS>	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
-alpha	B-X
subunits	B-X
by	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
(	B-X
PHD	B-X
)	B-X
proteins	B-X
signals	B-X
their	B-X
polyubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
,	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
HIF	B-X
abundance	B-X
and	B-X
oxygen	B-X
homeostasis	B-X
.	B-X
While	B-X
oxygen	B-X
concentration	B-X
plays	B-X
a	B-X
major	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
efficiency	B-X
of	B-X
PHD-catalyzed	B-X
hydroxylation	B-X
reactions	B-X
,	B-X
many	B-X
other	B-X
environmental	B-X
and	B-X
intracellular	B-X
factors	B-X
also	B-X
significantly	B-X
modulate	B-X
PHD	B-X
activities	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PHDs	B-X
may	B-X
also	B-X
employ	B-X
hydroxylase-independent	B-X
mechanisms	B-X
to	B-X
modify	B-X
HIF	B-X
activity	B-X
.	B-X
Interestingly	B-X
,	B-X
while	B-X
PHDs	B-X
regulate	B-X
HIF-alpha	B-X
protein	B-X
stability	B-X
,	B-X
PHD2	B-X
and	B-X
PHD3	B-X
themselves	B-X
are	B-X
subject	B-X
to	B-X
feedback	B-X
upregulation	B-X
by	B-X
HIFs	B-X
.	B-X
Functionally	B-X
,	B-X
different	B-X
PHD	B-X
isoforms	B-X
may	B-X
differentially	B-X
contribute	B-X
to	B-X
specific	B-X
pathophysiological	B-X
processes	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
erythropoiesis	B-X
,	B-X
tumorigenesis	B-X
,	B-X
and	B-X
cell	B-X
growth	B-X
,	B-X
differentiation	B-X
and	B-X
survival	B-X
.	B-X
Because	B-X
of	B-X
diverse	B-X
roles	B-X
of	B-X
PHDs	B-X
in	B-X
many	B-X
different	B-X
processes	B-X
,	B-X
loss	B-X
of	B-X
PHD	B-X
expression	B-X
or	B-X
function	B-X
triggers	B-X
multi-faceted	B-X
pathophysiological	B-X
changes	B-X
as	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
mice	B-X
lacking	B-X
different	B-X
PHD	B-X
isoforms	B-X
.	B-X
Future	B-X
investigations	B-X
are	B-X
needed	B-X
to	B-X
explore	B-X
in	B-X
vivo	B-X
specificity	B-X
of	B-X
PHDs	B-X
over	B-X
different	B-X
HIF-alpha	B-X
subunits	B-X
and	B-X
differential	B-X
roles	B-X
of	B-X
PHD	B-X
isoforms	B-X
in	B-X
different	B-X
biological	B-X
processes	B-X
.	B-X

Future	O
investigations	O
are	O
needed	O
to	O
explore	O
in	O
vivo	O
specificity	O
of	O
PHDs	O
over	O
different	O
HIF	O
-	O
alpha	O
subunits	O
and	O
differential	O
roles	O
of	O
PHD	O
isoforms	O
in	O
different	O
biological	O
processes	O
.	O
<EOS>	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
-alpha	B-X
subunits	B-X
by	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
(	B-X
PHD	B-X
)	B-X
proteins	B-X
signals	B-X
their	B-X
polyubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
,	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
HIF	B-X
abundance	B-X
and	B-X
oxygen	B-X
homeostasis	B-X
.	B-X
While	B-X
oxygen	B-X
concentration	B-X
plays	B-X
a	B-X
major	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
efficiency	B-X
of	B-X
PHD-catalyzed	B-X
hydroxylation	B-X
reactions	B-X
,	B-X
many	B-X
other	B-X
environmental	B-X
and	B-X
intracellular	B-X
factors	B-X
also	B-X
significantly	B-X
modulate	B-X
PHD	B-X
activities	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PHDs	B-X
may	B-X
also	B-X
employ	B-X
hydroxylase-independent	B-X
mechanisms	B-X
to	B-X
modify	B-X
HIF	B-X
activity	B-X
.	B-X
Interestingly	B-X
,	B-X
while	B-X
PHDs	B-X
regulate	B-X
HIF-alpha	B-X
protein	B-X
stability	B-X
,	B-X
PHD2	B-X
and	B-X
PHD3	B-X
themselves	B-X
are	B-X
subject	B-X
to	B-X
feedback	B-X
upregulation	B-X
by	B-X
HIFs	B-X
.	B-X
Functionally	B-X
,	B-X
different	B-X
PHD	B-X
isoforms	B-X
may	B-X
differentially	B-X
contribute	B-X
to	B-X
specific	B-X
pathophysiological	B-X
processes	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
erythropoiesis	B-X
,	B-X
tumorigenesis	B-X
,	B-X
and	B-X
cell	B-X
growth	B-X
,	B-X
differentiation	B-X
and	B-X
survival	B-X
.	B-X
Because	B-X
of	B-X
diverse	B-X
roles	B-X
of	B-X
PHDs	B-X
in	B-X
many	B-X
different	B-X
processes	B-X
,	B-X
loss	B-X
of	B-X
PHD	B-X
expression	B-X
or	B-X
function	B-X
triggers	B-X
multi-faceted	B-X
pathophysiological	B-X
changes	B-X
as	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
mice	B-X
lacking	B-X
different	B-X
PHD	B-X
isoforms	B-X
.	B-X
Future	B-X
investigations	B-X
are	B-X
needed	B-X
to	B-X
explore	B-X
in	B-X
vivo	B-X
specificity	B-X
of	B-X
PHDs	B-X
over	B-X
different	B-X
HIF-alpha	B-X
subunits	B-X
and	B-X
differential	B-X
roles	B-X
of	B-X
PHD	B-X
isoforms	B-X
in	B-X
different	B-X
biological	B-X
processes	B-X
.	B-X

Characterization	O
of	O
the	O
molecular	O
interaction	O
between	O
tropoelastin	B-Protein
and	O
DANCE	B-Protein
/	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

Fibulin	B-Protein
-	I-Protein
5	I-Protein
is	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
elastic	O
fiber	O
formation	O
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

The	O
present	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
molecular	O
interaction	O
between	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
and	O
tropoelastin	B-Protein
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

Our	O
data	O
showed	O
that	O
the	O
divalent	O
cations	O
of	O
Ca	O
(	O
2	O
+	O
)	O
,	O
Ba	O
(	O
2	O
+	O
)	O
and	O
Mg	O
(	O
2	O
+	O
)	O
significantly	O
enhanced	O
the	O
binding	O
of	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
to	O
tropoelastin	B-Protein
.	O

In	O
addition	O
,	O
N	O
-	O
linked	O
glycosylation	O
of	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
does	O
not	O
require	O
for	O
the	O
binding	O
to	O
tropoelastin	B-Protein
.	O

To	O
address	O
the	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
binding	O
site	O
on	O
tropoelastin	B-Protein
constructs	O
containing	O
,	O
exons	O
2	O
-	O
15	O
and	O
exons	O
16	O
-	O
36	O
,	O
of	O
tropoelastin	B-Protein
were	O
used	O
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

Fibulin	B-Protein
-	I-Protein
5	I-Protein
binding	O
was	O
significantly	O
reduced	O
to	O
either	O
fragment	O
and	O
also	O
to	O
a	O
mixture	O
of	O
the	O
two	O
fragments	O
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

These	O
results	O
suggested	O
that	O
the	O
whole	O
molecule	O
of	O
tropoelastin	B-Protein
was	O
required	O
for	O
the	O
interaction	O
with	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

In	O
co	O
-	O
immunoprecipitation	O
experiments	O
,	O
tropoelastin	B-Protein
binding	O
to	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
was	O
enhanced	O
by	O
an	O
increase	O
of	O
temperature	O
and	O
sodium	O
chloride	O
concentration	O
,	O
conditions	O
that	O
enhance	O
the	O
coacervation	O
of	O
tropoelastin	B-Protein
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

The	O
binding	O
of	O
tropoelastin	B-Protein
fragments	O
to	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
was	O
directly	O
proportional	O
to	O
their	O
propensity	O
to	O
coacervate	O
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

Furthermore	O
,	O
the	O
addition	O
of	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
to	O
tropoelastin	B-Protein
facilitated	O
coacervation	O
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

Taken	O
together	O
,	O
the	O
present	O
study	O
shows	O
that	O
fibulin	B-Protein
-	I-Protein
5	I-Protein
enhances	O
elastic	O
fiber	O
formation	O
in	O
part	O
by	O
improving	O
the	O
self	O
-	O
association	O
properties	O
of	O
tropoelastin	B-Protein
.	O
<EOS>	B-X
Fibulin-5	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
elastic	B-X
fiber	B-X
formation	B-X
.	B-X
The	B-X
present	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
interaction	B-X
between	B-X
fibulin-5	B-X
and	B-X
tropoelastin	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
divalent	B-X
cations	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ba	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
enhanced	B-X
the	B-X
binding	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
fibulin-5	B-X
does	B-X
not	B-X
require	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
tropoelastin	B-X
.	B-X
To	B-X
address	B-X
the	B-X
fibulin-5	B-X
binding	B-X
site	B-X
on	B-X
tropoelastin	B-X
constructs	B-X
containing	B-X
,	B-X
exons	B-X
2-15	B-X
and	B-X
exons	B-X
16-36	B-X
,	B-X
of	B-X
tropoelastin	B-X
were	B-X
used	B-X
.	B-X
Fibulin-5	B-X
binding	B-X
was	B-X
significantly	B-X
reduced	B-X
to	B-X
either	B-X
fragment	B-X
and	B-X
also	B-X
to	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
two	B-X
fragments	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
whole	B-X
molecule	B-X
of	B-X
tropoelastin	B-X
was	B-X
required	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
fibulin-5	B-X
.	B-X
In	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
tropoelastin	B-X
binding	B-X
to	B-X
fibulin-5	B-X
was	B-X
enhanced	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
temperature	B-X
and	B-X
sodium	B-X
chloride	B-X
concentration	B-X
,	B-X
conditions	B-X
that	B-X
enhance	B-X
the	B-X
coacervation	B-X
of	B-X
tropoelastin	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
tropoelastin	B-X
fragments	B-X
to	B-X
fibulin-5	B-X
was	B-X
directly	B-X
proportional	B-X
to	B-X
their	B-X
propensity	B-X
to	B-X
coacervate	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
fibulin-5	B-X
to	B-X
tropoelastin	B-X
facilitated	B-X
coacervation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
fibulin-5	B-X
enhances	B-X
elastic	B-X
fiber	B-X
formation	B-X
in	B-X
part	B-X
by	B-X
improving	B-X
the	B-X
self-association	B-X
properties	B-X
of	B-X
tropoelastin	B-X
.	B-X

E3	O
ubiquitin	B-Protein
ligase	O
SIAH1	B-Protein
mediates	O
ubiquitination	O
and	O
degradation	O
of	O
TRB3	B-Protein
.	O
<EOS>	B-X
Tribbles	B-X
3	B-X
homolog	B-X
(	B-X
TRB3	B-X
)	B-X
is	B-X
recently	B-X
identified	B-X
as	B-X
a	B-X
scaffold-like	B-X
regulator	B-X
of	B-X
various	B-X
signal	B-X
transducers	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
several	B-X
processes	B-X
including	B-X
insulin	B-X
signaling	B-X
,	B-X
NF-kappaB	B-X
signaling	B-X
,	B-X
lipid	B-X
metabolism	B-X
and	B-X
BMP	B-X
signaling	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
cellular	B-X
mechanisms	B-X
of	B-X
TRB3	B-X
regulation	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
to	B-X
identify	B-X
novel	B-X
TRB3	B-X
interacting	B-X
proteins	B-X
and	B-X
totally	B-X
obtained	B-X
ten	B-X
in-frame	B-X
fused	B-X
preys	B-X
.	B-X
Its	B-X
interaction	B-X
with	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SIAH1	B-X
was	B-X
further	B-X
investigated	B-X
.	B-X
SIAH1	B-X
could	B-X
interact	B-X
with	B-X
TRB3	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Importantly	B-X
,	B-X
SIAH1	B-X
targeted	B-X
TRB3	B-X
for	B-X
proteasome-dependent	B-X
degradation	B-X
.	B-X
Cotransfection	B-X
of	B-X
SIAH1	B-X
could	B-X
withdraw	B-X
up-regulation	B-X
of	B-X
TGF-beta	B-X
signaling	B-X
by	B-X
TRB3	B-X
,	B-X
suggesting	B-X
SIAH1-induced	B-X
degradation	B-X
of	B-X
TRB3	B-X
represents	B-X
a	B-X
potential	B-X
regulatory	B-X
mechanism	B-X
for	B-X
TGF-beta	B-X
signaling	B-X
.	B-X

Tribbles	B-Protein
3	I-Protein
homolog	I-Protein
(	O
TRB3	B-Protein
)	O
is	O
recently	O
identified	O
as	O
a	O
scaffold	O
-	O
like	O
regulator	O
of	O
various	O
signal	O
transducers	O
and	O
has	O
been	O
implicated	O
in	O
several	O
processes	O
including	O
insulin	B-Protein
signaling	O
,	O
NF	O
-	O
kappaB	O
signaling	O
,	O
lipid	O
metabolism	O
and	O
BMP	O
signaling	O
.	O
<EOS>	B-X
Tribbles	B-X
3	B-X
homolog	B-X
(	B-X
TRB3	B-X
)	B-X
is	B-X
recently	B-X
identified	B-X
as	B-X
a	B-X
scaffold-like	B-X
regulator	B-X
of	B-X
various	B-X
signal	B-X
transducers	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
several	B-X
processes	B-X
including	B-X
insulin	B-X
signaling	B-X
,	B-X
NF-kappaB	B-X
signaling	B-X
,	B-X
lipid	B-X
metabolism	B-X
and	B-X
BMP	B-X
signaling	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
cellular	B-X
mechanisms	B-X
of	B-X
TRB3	B-X
regulation	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
to	B-X
identify	B-X
novel	B-X
TRB3	B-X
interacting	B-X
proteins	B-X
and	B-X
totally	B-X
obtained	B-X
ten	B-X
in-frame	B-X
fused	B-X
preys	B-X
.	B-X
We	B-X
further	B-X
characterized	B-X
the	B-X
identified	B-X
proteins	B-X
sorted	B-X
by	B-X
Gene	B-X
Ontology	B-X
Annotation	B-X
.	B-X
Its	B-X
interaction	B-X
with	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SIAH1	B-X
was	B-X
further	B-X
investigated	B-X
.	B-X
SIAH1	B-X
could	B-X
interact	B-X
with	B-X
TRB3	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Importantly	B-X
,	B-X
SIAH1	B-X
targeted	B-X
TRB3	B-X
for	B-X
proteasome-dependent	B-X
degradation	B-X
.	B-X
Cotransfection	B-X
of	B-X
SIAH1	B-X
could	B-X
withdraw	B-X
up-regulation	B-X
of	B-X
TGF-beta	B-X
signaling	B-X
by	B-X
TRB3	B-X
,	B-X
suggesting	B-X
SIAH1-induced	B-X
degradation	B-X
of	B-X
TRB3	B-X
represents	B-X
a	B-X
potential	B-X
regulatory	B-X
mechanism	B-X
for	B-X
TGF-beta	B-X
signaling	B-X
.	B-X

To	O
further	O
understand	O
cellular	O
mechanisms	O
of	O
TRB3	B-Protein
regulation	O
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
to	O
identify	O
novel	O
TRB3	O
interacting	O
proteins	O
and	O
totally	O
obtained	O
ten	O
in	O
-	O
frame	O
fused	O
preys	O
.	O
<EOS>	B-X
Tribbles	B-X
3	B-X
homolog	B-X
(	B-X
TRB3	B-X
)	B-X
is	B-X
recently	B-X
identified	B-X
as	B-X
a	B-X
scaffold-like	B-X
regulator	B-X
of	B-X
various	B-X
signal	B-X
transducers	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
several	B-X
processes	B-X
including	B-X
insulin	B-X
signaling	B-X
,	B-X
NF-kappaB	B-X
signaling	B-X
,	B-X
lipid	B-X
metabolism	B-X
and	B-X
BMP	B-X
signaling	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
cellular	B-X
mechanisms	B-X
of	B-X
TRB3	B-X
regulation	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
to	B-X
identify	B-X
novel	B-X
TRB3	B-X
interacting	B-X
proteins	B-X
and	B-X
totally	B-X
obtained	B-X
ten	B-X
in-frame	B-X
fused	B-X
preys	B-X
.	B-X
We	B-X
further	B-X
characterized	B-X
the	B-X
identified	B-X
proteins	B-X
sorted	B-X
by	B-X
Gene	B-X
Ontology	B-X
Annotation	B-X
.	B-X
SIAH1	B-X
could	B-X
interact	B-X
with	B-X
TRB3	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Importantly	B-X
,	B-X
SIAH1	B-X
targeted	B-X
TRB3	B-X
for	B-X
proteasome-dependent	B-X
degradation	B-X
.	B-X
Cotransfection	B-X
of	B-X
SIAH1	B-X
could	B-X
withdraw	B-X
up-regulation	B-X
of	B-X
TGF-beta	B-X
signaling	B-X
by	B-X
TRB3	B-X
,	B-X
suggesting	B-X
SIAH1-induced	B-X
degradation	B-X
of	B-X
TRB3	B-X
represents	B-X
a	B-X
potential	B-X
regulatory	B-X
mechanism	B-X
for	B-X
TGF-beta	B-X
signaling	B-X
.	B-X

Candidate	O
interactions	O
were	O
validated	O
by	O
co	O
-	O
immunoprecipitation	O
assays	O
in	O
mammalian	O
cells	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
potential	B-X
mechanisms	B-X
of	B-X
the	B-X
immune-metabolism	B-X
interaction	B-X
between	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
cells	B-X
and	B-X
TAMs	B-X
remain	B-X
unclear	B-X
.	B-X
This	B-X
research	B-X
aims	B-X
to	B-X
reveal	B-X
regulatory	B-X
mechanism	B-X
of	B-X
STOML2	B-X
and	B-X
to	B-X
provide	B-X
evidence	B-X
for	B-X
clinical	B-X
therapeutics	B-X
,	B-X
via	B-X
exploration	B-X
of	B-X
its	B-X
role	B-X
in	B-X
colorectal	B-X
cancer	B-X
,	B-X
and	B-X
identification	B-X
of	B-X
its	B-X
interacting	B-X
protein	B-X
.	B-X
Extensive	B-X
changes	B-X
of	B-X
circRNA	B-X
expression	B-X
underscore	B-X
their	B-X
essential	B-X
contributions	B-X
to	B-X
multiple	B-X
hallmarks	B-X
of	B-X
cancers	B-X
;	B-X
however	B-X
,	B-X
their	B-X
functions	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
ESCC	B-X
)	B-X
remain	B-X
undetermined	B-X
.	B-X
Target	B-X
transcripts	B-X
were	B-X
predicted	B-X
using	B-X
online	B-X
tools	B-X
and	B-X
verified	B-X
by	B-X
dual-luciferase	B-X
,	B-X
RNA	B-X
immunoprecipitation	B-X
,	B-X
qRT-PCR	B-X
,	B-X
and	B-X
western	B-X
blot	B-X
.	B-X
Biotin-labeled	B-X
RNA-protein	B-X
pull-down	B-X
,	B-X
mass	B-X
spectrometry	B-X
,	B-X
and	B-X
RNA	B-X
immunoprecipitation	B-X
were	B-X
employed	B-X
to	B-X
identify	B-X
proteins	B-X
interacting	B-X
with	B-X
circRNAs	B-X
.	B-X
Gain-	B-X
and	B-X
loss-of-function	B-X
experiments	B-X
were	B-X
performed	B-X
to	B-X
uncover	B-X
the	B-X
roles	B-X
of	B-X
circRNAs	B-X
,	B-X
their	B-X
target	B-X
genes	B-X
,	B-X
and	B-X
binding	B-X
proteins	B-X
in	B-X
the	B-X
proliferation	B-X
,	B-X
metastasis	B-X
,	B-X
and	B-X
invasion	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
circFAM120B	B-X
could	B-X
reduce	B-X
the	B-X
stability	B-X
of	B-X
RNA-dependent	B-X
protein	B-X
kinase	B-X
(	B-X
PKR	B-X
)	B-X
by	B-X
promoting	B-X
its	B-X
ubiquitination-dependent	B-X
degradation	B-X
and	B-X
subsequently	B-X
regulating	B-X
the	B-X
p38	B-X
MAPK	B-X
signaling	B-X
pathway	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
repression	B-X
of	B-X
EMTs	B-X
in	B-X
ESCC	B-X
cells	B-X
.	B-X

We	O
further	O
characterized	O
the	O
identified	O
proteins	O
sorted	O
by	O
Gene	O
Ontology	O
Annotation	O
.	O
<EOS>	B-X
Although	B-X
these	B-X
phase	B-X
transitions	B-X
have	B-X
been	B-X
reconstituted	B-X
in	B-X
vitro	B-X
,	B-X
for	B-X
endogenous	B-X
bodies	B-X
the	B-X
diversity	B-X
of	B-X
the	B-X
components	B-X
,	B-X
the	B-X
specificity	B-X
of	B-X
the	B-X
interaction	B-X
networks	B-X
,	B-X
and	B-X
the	B-X
function	B-X
of	B-X
the	B-X
coassemblies	B-X
remain	B-X
to	B-X
be	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
by	B-X
developing	B-X
a	B-X
fluorescence-activated	B-X
particle	B-X
sorting	B-X
(	B-X
FAPS	B-X
)	B-X
method	B-X
to	B-X
purify	B-X
cytosolic	B-X
processing	B-X
bodies	B-X
(	B-X
P-bodies	B-X
)	B-X
from	B-X
human	B-X
epithelial	B-X
cells	B-X
,	B-X
we	B-X
identified	B-X
hundreds	B-X
of	B-X
proteins	B-X
and	B-X
thousands	B-X
of	B-X
mRNAs	B-X
that	B-X
structure	B-X
a	B-X
dense	B-X
network	B-X
of	B-X
interactions	B-X
,	B-X
separating	B-X
P-body	B-X
from	B-X
non-P-body	B-X
RNPs	B-X
.	B-X
Tribbles	B-X
3	B-X
homolog	B-X
(	B-X
TRB3	B-X
)	B-X
is	B-X
recently	B-X
identified	B-X
as	B-X
a	B-X
scaffold-like	B-X
regulator	B-X
of	B-X
various	B-X
signal	B-X
transducers	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
several	B-X
processes	B-X
including	B-X
insulin	B-X
signaling	B-X
,	B-X
NF-kappaB	B-X
signaling	B-X
,	B-X
lipid	B-X
metabolism	B-X
and	B-X
BMP	B-X
signaling	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
cellular	B-X
mechanisms	B-X
of	B-X
TRB3	B-X
regulation	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
to	B-X
identify	B-X
novel	B-X
TRB3	B-X
interacting	B-X
proteins	B-X
and	B-X
totally	B-X
obtained	B-X
ten	B-X
in-frame	B-X
fused	B-X
preys	B-X
.	B-X
We	B-X
further	B-X
characterized	B-X
the	B-X
identified	B-X
proteins	B-X
sorted	B-X
by	B-X
Gene	B-X
Ontology	B-X
Annotation	B-X
.	B-X

Its	O
interaction	O
with	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
SIAH1	B-Protein
was	O
further	O
investigated	O
.	O
<EOS>	B-X
Siah1	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
contributes	B-X
to	B-X
proteasome-mediated	B-X
degradation	B-X
of	B-X
multiple	B-X
targets	B-X
in	B-X
key	B-X
cellular	B-X
processes	B-X
and	B-X
which	B-X
shows	B-X
promise	B-X
as	B-X
a	B-X
therapeutic	B-X
target	B-X
in	B-X
oncology	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
HIF-1α	B-X
in	B-X
trans‑activating	B-X
the	B-X
seven	B-X
in	B-X
absentia	B-X
homolog	B-X
1	B-X
(	B-X
SIAH1	B-X
)	B-X
gene	B-X
and	B-X
the	B-X
underlying	B-X
mechanism	B-X
.	B-X
We	B-X
report	B-X
that	B-X
in	B-X
response	B-X
to	B-X
nutritional	B-X
stress	B-X
,	B-X
SIAH1	B-X
expression	B-X
was	B-X
up-regulated	B-X
in	B-X
the	B-X
liver	B-X
in	B-X
mice	B-X
and	B-X
in	B-X
cultured	B-X
hepatocytes	B-X
.	B-X
In	B-X
the	B-X
meantime	B-X
,	B-X
HIF-1α	B-X
started	B-X
to	B-X
occupy	B-X
the	B-X
SIAH1	B-X
promoter	B-X
.	B-X
Depletion	B-X
of	B-X
HIF-1α	B-X
with	B-X
siRNA	B-X
or	B-X
inhibition	B-X
of	B-X
HIF-1α	B-X
with	B-X
chetomin	B-X
abrogated	B-X
the	B-X
induction	B-X
of	B-X
SIAH1	B-X
expression	B-X
.	B-X
HIF-1α	B-X
knockdown	B-X
or	B-X
inhibition	B-X
paralleled	B-X
epigenetic	B-X
alterations	B-X
surrounding	B-X
the	B-X
SIAH1	B-X
promoter	B-X
characterized	B-X
by	B-X
the	B-X
loss	B-X
of	B-X
acetylated	B-X
histone	B-X
H3	B-X
and	B-X
trimethylated	B-X
H3K4	B-X
as	B-X
well	B-X
as	B-X
the	B-X
acquisition	B-X
of	B-X
dimethylated	B-X
H3K9	B-X
.	B-X
Further	B-X
analyses	B-X
revealed	B-X
that	B-X
HIF-1α	B-X
interacted	B-X
with	B-X
and	B-X
recruited	B-X
the	B-X
histone	B-X
demethylase	B-X
KDM3A	B-X
to	B-X
the	B-X
SIAH1	B-X
promoter	B-X
to	B-X
activate	B-X
transcription	B-X
.	B-X
Depletion	B-X
of	B-X
KDM3A	B-X
coincided	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
SIAH1	B-X
induction	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
dimethylated	B-X
H3K9	B-X
surrounding	B-X
the	B-X
SIAH1	B-X
promoter	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
uncover	B-X
a	B-X
novel	B-X
epigenetic	B-X
pathway	B-X
that	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
SIAH1	B-X
expression	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
steatosis	B-X
.	B-X

SIAH1	B-Protein
could	O
interact	O
with	O
TRB3	B-Protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
Tribbles	B-X
3	B-X
homolog	B-X
(	B-X
TRB3	B-X
)	B-X
is	B-X
recently	B-X
identified	B-X
as	B-X
a	B-X
scaffold-like	B-X
regulator	B-X
of	B-X
various	B-X
signal	B-X
transducers	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
several	B-X
processes	B-X
including	B-X
insulin	B-X
signaling	B-X
,	B-X
NF-kappaB	B-X
signaling	B-X
,	B-X
lipid	B-X
metabolism	B-X
and	B-X
BMP	B-X
signaling	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
cellular	B-X
mechanisms	B-X
of	B-X
TRB3	B-X
regulation	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
to	B-X
identify	B-X
novel	B-X
TRB3	B-X
interacting	B-X
proteins	B-X
and	B-X
totally	B-X
obtained	B-X
ten	B-X
in-frame	B-X
fused	B-X
preys	B-X
.	B-X
Candidate	B-X
interactions	B-X
were	B-X
validated	B-X
by	B-X
co-immunoprecipitation	B-X
assays	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
Its	B-X
interaction	B-X
with	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SIAH1	B-X
was	B-X
further	B-X
investigated	B-X
.	B-X
SIAH1	B-X
could	B-X
interact	B-X
with	B-X
TRB3	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Importantly	B-X
,	B-X
SIAH1	B-X
targeted	B-X
TRB3	B-X
for	B-X
proteasome-dependent	B-X
degradation	B-X
.	B-X
Cotransfection	B-X
of	B-X
SIAH1	B-X
could	B-X
withdraw	B-X
up-regulation	B-X
of	B-X
TGF-beta	B-X
signaling	B-X
by	B-X
TRB3	B-X
,	B-X
suggesting	B-X
SIAH1-induced	B-X
degradation	B-X
of	B-X
TRB3	B-X
represents	B-X
a	B-X
potential	B-X
regulatory	B-X
mechanism	B-X
for	B-X
TGF-beta	B-X
signaling	B-X
.	B-X

Importantly	O
,	O
SIAH1	B-Protein
targeted	O
TRB3	B-Protein
for	O
proteasome	O
-	O
dependent	O
degradation	O
.	O
<EOS>	B-X
Tribbles	B-X
3	B-X
homolog	B-X
(	B-X
TRB3	B-X
)	B-X
is	B-X
recently	B-X
identified	B-X
as	B-X
a	B-X
scaffold-like	B-X
regulator	B-X
of	B-X
various	B-X
signal	B-X
transducers	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
several	B-X
processes	B-X
including	B-X
insulin	B-X
signaling	B-X
,	B-X
NF-kappaB	B-X
signaling	B-X
,	B-X
lipid	B-X
metabolism	B-X
and	B-X
BMP	B-X
signaling	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
cellular	B-X
mechanisms	B-X
of	B-X
TRB3	B-X
regulation	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
to	B-X
identify	B-X
novel	B-X
TRB3	B-X
interacting	B-X
proteins	B-X
and	B-X
totally	B-X
obtained	B-X
ten	B-X
in-frame	B-X
fused	B-X
preys	B-X
.	B-X
Its	B-X
interaction	B-X
with	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SIAH1	B-X
was	B-X
further	B-X
investigated	B-X
.	B-X
SIAH1	B-X
could	B-X
interact	B-X
with	B-X
TRB3	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Importantly	B-X
,	B-X
SIAH1	B-X
targeted	B-X
TRB3	B-X
for	B-X
proteasome-dependent	B-X
degradation	B-X
.	B-X
Cotransfection	B-X
of	B-X
SIAH1	B-X
could	B-X
withdraw	B-X
up-regulation	B-X
of	B-X
TGF-beta	B-X
signaling	B-X
by	B-X
TRB3	B-X
,	B-X
suggesting	B-X
SIAH1-induced	B-X
degradation	B-X
of	B-X
TRB3	B-X
represents	B-X
a	B-X
potential	B-X
regulatory	B-X
mechanism	B-X
for	B-X
TGF-beta	B-X
signaling	B-X
.	B-X

Cotransfection	O
of	O
SIAH1	B-Protein
could	O
withdraw	O
up	O
-	O
regulation	O
of	O
TGF	O
-	O
beta	O
signaling	O
by	O
TRB3	B-Protein
,	O
suggesting	O
SIAH1	B-Protein
-	O
induced	O
degradation	O
of	O
TRB3	B-Protein
represents	O
a	O
potential	O
regulatory	O
mechanism	O
for	O
TGF	O
-	O
beta	O
signaling	O
.	O
<EOS>	B-X
Tribbles	B-X
3	B-X
homolog	B-X
(	B-X
TRB3	B-X
)	B-X
is	B-X
recently	B-X
identified	B-X
as	B-X
a	B-X
scaffold-like	B-X
regulator	B-X
of	B-X
various	B-X
signal	B-X
transducers	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
several	B-X
processes	B-X
including	B-X
insulin	B-X
signaling	B-X
,	B-X
NF-kappaB	B-X
signaling	B-X
,	B-X
lipid	B-X
metabolism	B-X
and	B-X
BMP	B-X
signaling	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
cellular	B-X
mechanisms	B-X
of	B-X
TRB3	B-X
regulation	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
to	B-X
identify	B-X
novel	B-X
TRB3	B-X
interacting	B-X
proteins	B-X
and	B-X
totally	B-X
obtained	B-X
ten	B-X
in-frame	B-X
fused	B-X
preys	B-X
.	B-X
Its	B-X
interaction	B-X
with	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SIAH1	B-X
was	B-X
further	B-X
investigated	B-X
.	B-X
SIAH1	B-X
could	B-X
interact	B-X
with	B-X
TRB3	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Importantly	B-X
,	B-X
SIAH1	B-X
targeted	B-X
TRB3	B-X
for	B-X
proteasome-dependent	B-X
degradation	B-X
.	B-X
Cotransfection	B-X
of	B-X
SIAH1	B-X
could	B-X
withdraw	B-X
up-regulation	B-X
of	B-X
TGF-beta	B-X
signaling	B-X
by	B-X
TRB3	B-X
,	B-X
suggesting	B-X
SIAH1-induced	B-X
degradation	B-X
of	B-X
TRB3	B-X
represents	B-X
a	B-X
potential	B-X
regulatory	B-X
mechanism	B-X
for	B-X
TGF-beta	B-X
signaling	B-X
.	B-X

Histone	B-Protein
deacetylase	I-Protein
3	I-Protein
localizes	O
to	O
the	O
mitotic	O
spindle	O
and	O
is	O
required	O
for	O
kinetochore	O
-	O
microtubule	O
attachment	O
.	O

Protein	O
acetylation	O
and	O
deacetylation	O
play	O
key	O
roles	O
in	O
multiple	O
physiological	O
functions	O
.	O
<EOS>	B-X
Many	B-X
transcription	B-X
factors	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
cellular	B-X
differentiation	B-X
and	B-X
the	B-X
delineation	B-X
of	B-X
cell	B-X
phenotype	B-X
.	B-X
Transcription	B-X
factors	B-X
are	B-X
regulated	B-X
by	B-X
phosphorylation	B-X
,	B-X
ubiquitination	B-X
,	B-X
acetylation/deacetylation	B-X
and	B-X
interactions	B-X
between	B-X
two	B-X
or	B-X
more	B-X
proteins	B-X
controlling	B-X
multiple	B-X
signaling	B-X
pathways	B-X
.	B-X
These	B-X
pathways	B-X
regulate	B-X
different	B-X
physiological	B-X
processes	B-X
and	B-X
pathological	B-X
events	B-X
,	B-X
such	B-X
as	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
.	B-X
The	B-X
Forkhead	B-X
box	B-X
O	B-X
(	B-X
FOXO	B-X
)	B-X
is	B-X
one	B-X
subfamily	B-X
of	B-X
the	B-X
fork	B-X
head	B-X
transcription	B-X
factor	B-X
family	B-X
with	B-X
important	B-X
roles	B-X
in	B-X
cell	B-X
fate	B-X
decisions	B-X
and	B-X
this	B-X
subfamily	B-X
is	B-X
also	B-X
suggested	B-X
to	B-X
play	B-X
a	B-X
pivotal	B-X
functional	B-X
role	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
cancers	B-X
.	B-X

Histone	B-Protein
deacetylase	I-Protein
3	I-Protein
(	O
HDAC3	B-Protein
)	O
is	O
a	O
highly	O
conserved	O
,	O
ubiquitously	O
expressed	O
protein	O
that	O
forms	O
multiprotein	O
corepressor	O
complexes	O
to	O
repress	O
gene	O
transcription	O
.	O
<EOS>	B-X
Histone	B-X
deacetylase	B-X
3	B-X
(	B-X
HDAC3	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
,	B-X
ubiquitously	B-X
expressed	B-X
protein	B-X
that	B-X
forms	B-X
multiprotein	B-X
corepressor	B-X
complexes	B-X
to	B-X
repress	B-X
gene	B-X
transcription	B-X
.	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
HDAC3	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Altered	B-X
HDAC3	B-X
level	B-X
increases	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
,	B-X
including	B-X
nuclear	B-X
receptor	B-X
corepressor	B-X
(	B-X
N-CoR	B-X
)	B-X
,	B-X
transducin-beta-like	B-X
protein	B-X
1	B-X
(	B-X
TBL1	B-X
)	B-X
,	B-X
and	B-X
TBL1-related	B-X
protein	B-X
1	B-X
(	B-X
TBLR1	B-X
)	B-X
,	B-X
is	B-X
localized	B-X
on	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X
Knockdown	B-X
of	B-X
HDAC3	B-X
or	B-X
N-CoR	B-X
resulted	B-X
in	B-X
a	B-X
collapsed	B-X
mitotic	B-X
spindle	B-X
that	B-X
was	B-X
surrounded	B-X
by	B-X
chromosomes	B-X
arranged	B-X
in	B-X
a	B-X
dome-like	B-X
configuration	B-X
.	B-X
Treatment	B-X
of	B-X
mitotic	B-X
cells	B-X
with	B-X
Trichostatin	B-X
A	B-X
,	B-X
an	B-X
HDAC	B-X
inhibitor	B-X
,	B-X
resulted	B-X
in	B-X
similar	B-X
spindle	B-X
defects	B-X
independent	B-X
of	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
wild-type	B-X
HDAC3	B-X
but	B-X
not	B-X
a	B-X
deacetylase-dead	B-X
mutant	B-X
HDAC3	B-X
rescued	B-X
the	B-X
phenotypes	B-X
of	B-X
HDAC3-depleted	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
HDAC3	B-X
is	B-X
important	B-X
for	B-X
proper	B-X
spindle	B-X
function	B-X
.	B-X
Whereas	B-X
the	B-X
kinetochores	B-X
and	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
appeared	B-X
intact	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
,	B-X
kinetochore-microtubule	B-X
attachments	B-X
were	B-X
impaired	B-X
because	B-X
spindle	B-X
microtubules	B-X
were	B-X
unstable	B-X
in	B-X
response	B-X
to	B-X
cold	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
functional	B-X
mitotic	B-X
spindles	B-X
and	B-X
proper	B-X
kinetochore-microtubule	B-X
attachment	B-X
.	B-X
The	B-X
level	B-X
or	B-X
distribution	B-X
of	B-X
acetylated	B-X
alpha-tubulin	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
.	B-X

Recent	O
studies	O
show	O
that	O
HDAC3	B-Protein
may	O
play	O
a	O
role	O
in	O
cell	O
proliferation	O
.	O
<EOS>	B-X
Protein	B-X
acetylation	B-X
and	B-X
deacetylation	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
multiple	B-X
physiological	B-X
functions	B-X
.	B-X
Histone	B-X
deacetylase	B-X
3	B-X
(	B-X
HDAC3	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
,	B-X
ubiquitously	B-X
expressed	B-X
protein	B-X
that	B-X
forms	B-X
multiprotein	B-X
corepressor	B-X
complexes	B-X
to	B-X
repress	B-X
gene	B-X
transcription	B-X
.	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
HDAC3	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Altered	B-X
HDAC3	B-X
level	B-X
increases	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
,	B-X
including	B-X
nuclear	B-X
receptor	B-X
corepressor	B-X
(	B-X
N-CoR	B-X
)	B-X
,	B-X
transducin-beta-like	B-X
protein	B-X
1	B-X
(	B-X
TBL1	B-X
)	B-X
,	B-X
and	B-X
TBL1-related	B-X
protein	B-X
1	B-X
(	B-X
TBLR1	B-X
)	B-X
,	B-X
is	B-X
localized	B-X
on	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X
Knockdown	B-X
of	B-X
HDAC3	B-X
or	B-X
N-CoR	B-X
resulted	B-X
in	B-X
a	B-X
collapsed	B-X
mitotic	B-X
spindle	B-X
that	B-X
was	B-X
surrounded	B-X
by	B-X
chromosomes	B-X
arranged	B-X
in	B-X
a	B-X
dome-like	B-X
configuration	B-X
.	B-X
Treatment	B-X
of	B-X
mitotic	B-X
cells	B-X
with	B-X
Trichostatin	B-X
A	B-X
,	B-X
an	B-X
HDAC	B-X
inhibitor	B-X
,	B-X
resulted	B-X
in	B-X
similar	B-X
spindle	B-X
defects	B-X
independent	B-X
of	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
wild-type	B-X
HDAC3	B-X
but	B-X
not	B-X
a	B-X
deacetylase-dead	B-X
mutant	B-X
HDAC3	B-X
rescued	B-X
the	B-X
phenotypes	B-X
of	B-X
HDAC3-depleted	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
HDAC3	B-X
is	B-X
important	B-X
for	B-X
proper	B-X
spindle	B-X
function	B-X
.	B-X
Whereas	B-X
the	B-X
kinetochores	B-X
and	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
appeared	B-X
intact	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
,	B-X
kinetochore-microtubule	B-X
attachments	B-X
were	B-X
impaired	B-X
because	B-X
spindle	B-X
microtubules	B-X
were	B-X
unstable	B-X
in	B-X
response	B-X
to	B-X
cold	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
functional	B-X
mitotic	B-X
spindles	B-X
and	B-X
proper	B-X
kinetochore-microtubule	B-X
attachment	B-X
.	B-X
The	B-X
level	B-X
or	B-X
distribution	B-X
of	B-X
acetylated	B-X
alpha-tubulin	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
studies	B-X
raise	B-X
the	B-X
interesting	B-X
possibility	B-X
that	B-X
acetylation-deacetylation	B-X
of	B-X
mitotic	B-X
spindle	B-X
components	B-X
may	B-X
be	B-X
essential	B-X
for	B-X
mitotic	B-X
spindle	B-X
function	B-X
.	B-X

Altered	O
HDAC3	B-Protein
level	O
increases	O
G	O
(	O
2	O
)	O
/	O
M	O
cells	O
,	O
but	O
the	O
mechanism	O
remains	O
unknown	O
.	O
<EOS>	B-X
Histone	B-X
deacetylase	B-X
3	B-X
(	B-X
HDAC3	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
,	B-X
ubiquitously	B-X
expressed	B-X
protein	B-X
that	B-X
forms	B-X
multiprotein	B-X
corepressor	B-X
complexes	B-X
to	B-X
repress	B-X
gene	B-X
transcription	B-X
.	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
HDAC3	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Altered	B-X
HDAC3	B-X
level	B-X
increases	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
,	B-X
including	B-X
nuclear	B-X
receptor	B-X
corepressor	B-X
(	B-X
N-CoR	B-X
)	B-X
,	B-X
transducin-beta-like	B-X
protein	B-X
1	B-X
(	B-X
TBL1	B-X
)	B-X
,	B-X
and	B-X
TBL1-related	B-X
protein	B-X
1	B-X
(	B-X
TBLR1	B-X
)	B-X
,	B-X
is	B-X
localized	B-X
on	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X
Knockdown	B-X
of	B-X
HDAC3	B-X
or	B-X
N-CoR	B-X
resulted	B-X
in	B-X
a	B-X
collapsed	B-X
mitotic	B-X
spindle	B-X
that	B-X
was	B-X
surrounded	B-X
by	B-X
chromosomes	B-X
arranged	B-X
in	B-X
a	B-X
dome-like	B-X
configuration	B-X
.	B-X
Treatment	B-X
of	B-X
mitotic	B-X
cells	B-X
with	B-X
Trichostatin	B-X
A	B-X
,	B-X
an	B-X
HDAC	B-X
inhibitor	B-X
,	B-X
resulted	B-X
in	B-X
similar	B-X
spindle	B-X
defects	B-X
independent	B-X
of	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
wild-type	B-X
HDAC3	B-X
but	B-X
not	B-X
a	B-X
deacetylase-dead	B-X
mutant	B-X
HDAC3	B-X
rescued	B-X
the	B-X
phenotypes	B-X
of	B-X
HDAC3-depleted	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
HDAC3	B-X
is	B-X
important	B-X
for	B-X
proper	B-X
spindle	B-X
function	B-X
.	B-X
Whereas	B-X
the	B-X
kinetochores	B-X
and	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
appeared	B-X
intact	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
,	B-X
kinetochore-microtubule	B-X
attachments	B-X
were	B-X
impaired	B-X
because	B-X
spindle	B-X
microtubules	B-X
were	B-X
unstable	B-X
in	B-X
response	B-X
to	B-X
cold	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
functional	B-X
mitotic	B-X
spindles	B-X
and	B-X
proper	B-X
kinetochore-microtubule	B-X
attachment	B-X
.	B-X
The	B-X
level	B-X
or	B-X
distribution	B-X
of	B-X
acetylated	B-X
alpha-tubulin	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
.	B-X

Here	O
we	O
show	O
for	O
the	O
first	O
time	O
,	O
to	O
our	O
knowledge	O
,	O
that	O
the	O
HDAC3	B-Protein
complex	O
,	O
including	O
nuclear	O
receptor	O
corepressor	O
(	O
N	O
-	O
CoR	O
)	O
,	O
transducin	O
-	O
beta	O
-	O
like	O
protein	O
1	O
(	O
TBL1	O
)	O
,	O
and	O
TBL1	B-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
1	I-Protein
(	O
TBLR1	B-Protein
)	O
,	O
is	O
localized	O
on	O
the	O
mitotic	O
spindle	O
.	O
<EOS>	B-X
Histone	B-X
deacetylase	B-X
3	B-X
(	B-X
HDAC3	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
,	B-X
ubiquitously	B-X
expressed	B-X
protein	B-X
that	B-X
forms	B-X
multiprotein	B-X
corepressor	B-X
complexes	B-X
to	B-X
repress	B-X
gene	B-X
transcription	B-X
.	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
HDAC3	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Altered	B-X
HDAC3	B-X
level	B-X
increases	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
,	B-X
including	B-X
nuclear	B-X
receptor	B-X
corepressor	B-X
(	B-X
N-CoR	B-X
)	B-X
,	B-X
transducin-beta-like	B-X
protein	B-X
1	B-X
(	B-X
TBL1	B-X
)	B-X
,	B-X
and	B-X
TBL1-related	B-X
protein	B-X
1	B-X
(	B-X
TBLR1	B-X
)	B-X
,	B-X
is	B-X
localized	B-X
on	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X
Knockdown	B-X
of	B-X
HDAC3	B-X
or	B-X
N-CoR	B-X
resulted	B-X
in	B-X
a	B-X
collapsed	B-X
mitotic	B-X
spindle	B-X
that	B-X
was	B-X
surrounded	B-X
by	B-X
chromosomes	B-X
arranged	B-X
in	B-X
a	B-X
dome-like	B-X
configuration	B-X
.	B-X
Treatment	B-X
of	B-X
mitotic	B-X
cells	B-X
with	B-X
Trichostatin	B-X
A	B-X
,	B-X
an	B-X
HDAC	B-X
inhibitor	B-X
,	B-X
resulted	B-X
in	B-X
similar	B-X
spindle	B-X
defects	B-X
independent	B-X
of	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
wild-type	B-X
HDAC3	B-X
but	B-X
not	B-X
a	B-X
deacetylase-dead	B-X
mutant	B-X
HDAC3	B-X
rescued	B-X
the	B-X
phenotypes	B-X
of	B-X
HDAC3-depleted	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
HDAC3	B-X
is	B-X
important	B-X
for	B-X
proper	B-X
spindle	B-X
function	B-X
.	B-X
Whereas	B-X
the	B-X
kinetochores	B-X
and	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
appeared	B-X
intact	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
,	B-X
kinetochore-microtubule	B-X
attachments	B-X
were	B-X
impaired	B-X
because	B-X
spindle	B-X
microtubules	B-X
were	B-X
unstable	B-X
in	B-X
response	B-X
to	B-X
cold	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
functional	B-X
mitotic	B-X
spindles	B-X
and	B-X
proper	B-X
kinetochore-microtubule	B-X
attachment	B-X
.	B-X
The	B-X
level	B-X
or	B-X
distribution	B-X
of	B-X
acetylated	B-X
alpha-tubulin	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
studies	B-X
raise	B-X
the	B-X
interesting	B-X
possibility	B-X
that	B-X
acetylation-deacetylation	B-X
of	B-X
mitotic	B-X
spindle	B-X
components	B-X
may	B-X
be	B-X
essential	B-X
for	B-X
mitotic	B-X
spindle	B-X
function	B-X
.	B-X

Knockdown	O
of	O
HDAC3	B-Protein
or	O
N	O
-	O
CoR	O
resulted	O
in	O
a	O
collapsed	O
mitotic	O
spindle	O
that	O
was	O
surrounded	O
by	O
chromosomes	O
arranged	O
in	O
a	O
dome	O
-	O
like	O
configuration	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
aberrant	B-X
HDAC3	B-X
induction	B-X
and	B-X
its	B-X
inhibition	B-X
of	B-X
Klotho	B-X
,	B-X
a	B-X
renal	B-X
epithelium-enriched	B-X
aging	B-X
suppressor	B-X
,	B-X
contribute	B-X
significantly	B-X
to	B-X
renal	B-X
fibrogenesis	B-X
.	B-X
HDAC3	B-X
was	B-X
preferentially	B-X
elevated	B-X
with	B-X
concomitant	B-X
Klotho	B-X
suppression	B-X
in	B-X
fibrotic	B-X
kidneys	B-X
incurred	B-X
by	B-X
unilateral	B-X
ureter	B-X
obstruction	B-X
(	B-X
UUO	B-X
)	B-X
and	B-X
aristolochic	B-X
acid	B-X
nephropathy	B-X
(	B-X
AAN	B-X
)	B-X
,	B-X
whereas	B-X
Hdac3	B-X
knockout	B-X
resisted	B-X
the	B-X
fibrotic	B-X
pathologies	B-X
.	B-X
The	B-X
HDAC3	B-X
elevation	B-X
is	B-X
substantially	B-X
blocked	B-X
by	B-X
the	B-X
inhibitors	B-X
of	B-X
TGFβ	B-X
receptor	B-X
and	B-X
Smad3	B-X
phosphorylation	B-X
,	B-X
suggesting	B-X
that	B-X
TGFβ/Smad	B-X
signal	B-X
activates	B-X
Hdac3	B-X
transcription	B-X
.	B-X
Consistently	B-X
,	B-X
an	B-X
HDAC3-selective	B-X
inhibitor	B-X
RGFP966	B-X
derepressed	B-X
Klotho	B-X
and	B-X
mitigated	B-X
the	B-X
renal	B-X
fibrotic	B-X
injuries	B-X
in	B-X
both	B-X
UUO	B-X
and	B-X
AAN	B-X
mice	B-X
.	B-X
Further	B-X
,	B-X
HDAC3	B-X
overexpression	B-X
or	B-X
inhibition	B-X
in	B-X
renal	B-X
epithelia	B-X
inversely	B-X
affected	B-X
Klotho	B-X
abundances	B-X
and	B-X
HDAC3	B-X
was	B-X
inducibly	B-X
associated	B-X
with	B-X
transcription	B-X
regulators	B-X
NCoR	B-X
and	B-X
NF-kB	B-X
and	B-X
bound	B-X
to	B-X
Klotho	B-X
promoter	B-X
in	B-X
fibrotic	B-X
kidney	B-X
,	B-X
supporting	B-X
that	B-X
aberrant	B-X
HDAC3	B-X
targets	B-X
and	B-X
transcriptionally	B-X
inhibits	B-X
Klotho	B-X
under	B-X
renal	B-X
fibrotic	B-X
conditions	B-X
.	B-X
More	B-X
importantly	B-X
,	B-X
the	B-X
antirenal	B-X
fibrosis	B-X
effects	B-X
of	B-X
RGFP966	B-X
were	B-X
largely	B-X
compromised	B-X
in	B-X
mice	B-X
with	B-X
siRNA-mediated	B-X
Klotho	B-X
knockdown	B-X
.	B-X
Hence	B-X
,	B-X
HDAC3	B-X
aberration	B-X
and	B-X
the	B-X
subsequent	B-X
Klotho	B-X
suppression	B-X
constitute	B-X
an	B-X
important	B-X
regulatory	B-X
loop	B-X
that	B-X
promotes	B-X
MTD	B-X
and	B-X
renal	B-X
fibrosis	B-X
and	B-X
uses	B-X
of	B-X
HDAC3-selective	B-X
inhibitors	B-X
are	B-X
potentially	B-X
effective	B-X
in	B-X
treating	B-X
renal	B-X
fibrotic	B-X
disorders	B-X
.	B-X

Treatment	O
of	O
mitotic	O
cells	O
with	O
Trichostatin	O
A	O
,	O
an	O
HDAC	O
inhibitor	O
,	O
resulted	O
in	O
similar	O
spindle	O
defects	O
independent	O
of	O
transcriptional	O
regulation	O
.	O
<EOS>	B-X
Histone	B-X
deacetylase	B-X
3	B-X
(	B-X
HDAC3	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
,	B-X
ubiquitously	B-X
expressed	B-X
protein	B-X
that	B-X
forms	B-X
multiprotein	B-X
corepressor	B-X
complexes	B-X
to	B-X
repress	B-X
gene	B-X
transcription	B-X
.	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
HDAC3	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Altered	B-X
HDAC3	B-X
level	B-X
increases	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
,	B-X
including	B-X
nuclear	B-X
receptor	B-X
corepressor	B-X
(	B-X
N-CoR	B-X
)	B-X
,	B-X
transducin-beta-like	B-X
protein	B-X
1	B-X
(	B-X
TBL1	B-X
)	B-X
,	B-X
and	B-X
TBL1-related	B-X
protein	B-X
1	B-X
(	B-X
TBLR1	B-X
)	B-X
,	B-X
is	B-X
localized	B-X
on	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X
Knockdown	B-X
of	B-X
HDAC3	B-X
or	B-X
N-CoR	B-X
resulted	B-X
in	B-X
a	B-X
collapsed	B-X
mitotic	B-X
spindle	B-X
that	B-X
was	B-X
surrounded	B-X
by	B-X
chromosomes	B-X
arranged	B-X
in	B-X
a	B-X
dome-like	B-X
configuration	B-X
.	B-X
Treatment	B-X
of	B-X
mitotic	B-X
cells	B-X
with	B-X
Trichostatin	B-X
A	B-X
,	B-X
an	B-X
HDAC	B-X
inhibitor	B-X
,	B-X
resulted	B-X
in	B-X
similar	B-X
spindle	B-X
defects	B-X
independent	B-X
of	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
wild-type	B-X
HDAC3	B-X
but	B-X
not	B-X
a	B-X
deacetylase-dead	B-X
mutant	B-X
HDAC3	B-X
rescued	B-X
the	B-X
phenotypes	B-X
of	B-X
HDAC3-depleted	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
HDAC3	B-X
is	B-X
important	B-X
for	B-X
proper	B-X
spindle	B-X
function	B-X
.	B-X
Whereas	B-X
the	B-X
kinetochores	B-X
and	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
appeared	B-X
intact	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
,	B-X
kinetochore-microtubule	B-X
attachments	B-X
were	B-X
impaired	B-X
because	B-X
spindle	B-X
microtubules	B-X
were	B-X
unstable	B-X
in	B-X
response	B-X
to	B-X
cold	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
functional	B-X
mitotic	B-X
spindles	B-X
and	B-X
proper	B-X
kinetochore-microtubule	B-X
attachment	B-X
.	B-X
The	B-X
level	B-X
or	B-X
distribution	B-X
of	B-X
acetylated	B-X
alpha-tubulin	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
studies	B-X
raise	B-X
the	B-X
interesting	B-X
possibility	B-X
that	B-X
acetylation-deacetylation	B-X
of	B-X
mitotic	B-X
spindle	B-X
components	B-X
may	B-X
be	B-X
essential	B-X
for	B-X
mitotic	B-X
spindle	B-X
function	B-X
.	B-X

In	O
addition	O
,	O
wild	O
-	O
type	O
HDAC3	B-Protein
but	O
not	O
a	O
deacetylase	O
-	O
dead	O
mutant	O
HDAC3	B-Protein
rescued	O
the	O
phenotypes	O
of	O
HDAC3	B-Protein
-	O
depleted	O
cells	O
,	O
suggesting	O
that	O
the	O
enzymatic	O
activity	O
of	O
HDAC3	B-Protein
is	O
important	O
for	O
proper	O
spindle	O
function	O
.	O
<EOS>	B-X
HDAC3	B-X
,	B-X
one	B-X
of	B-X
the	B-X
class	B-X
I	B-X
histone	B-X
deacetylase	B-X
modulates	B-X
epigenetic	B-X
landscape	B-X
through	B-X
histone	B-X
modification	B-X
.	B-X
HDAC3	B-X
also	B-X
interacts	B-X
with	B-X
non-histone	B-X
proteins	B-X
including	B-X
p53	B-X
for	B-X
deacetylation	B-X
.	B-X
Moreover	B-X
,	B-X
HDAC3	B-X
serves	B-X
as	B-X
a	B-X
transcriptional	B-X
repressor	B-X
,	B-X
interacting	B-X
with	B-X
NCor1/SMRT	B-X
complex	B-X
.	B-X
Although	B-X
HDAC3	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
cellular	B-X
homeostasis	B-X
,	B-X
regulatory	B-X
mechanism	B-X
of	B-X
HDAC3	B-X
have	B-X
been	B-X
poorly	B-X
understood	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
a	B-X
novel	B-X
regulatory	B-X
mechanism	B-X
of	B-X
HDAC3	B-X
about	B-X
its	B-X
monoubiquitination	B-X
and	B-X
stabilization	B-X
by	B-X
Mdm2	B-X
.	B-X
HDAC3	B-X
levels	B-X
were	B-X
increased	B-X
by	B-X
ectopic	B-X
expression	B-X
of	B-X
Mdm2	B-X
and	B-X
decreased	B-X
by	B-X
Mdm2	B-X
ablation	B-X
in	B-X
various	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Mdm2	B-X
directly	B-X
interacts	B-X
with	B-X
HDAC3	B-X
and	B-X
induces	B-X
HDAC3	B-X
protein	B-X
levels	B-X
without	B-X
alteration	B-X
of	B-X
mRNA	B-X
levels	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
but	B-X
not	B-X
RING	B-X
mutant	B-X
of	B-X
Mdm2	B-X
increased	B-X
HDAC3	B-X
monoubiquitination	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
MdmX	B-X
is	B-X
beneficial	B-X
for	B-X
mdm2-mediated	B-X
HDAC3	B-X
regulation	B-X
.	B-X
Ablation	B-X
of	B-X
Mdm2	B-X
and	B-X
Mdm2/MdmX	B-X
decreased	B-X
cell	B-X
migration	B-X
along	B-X
with	B-X
the	B-X
decrease	B-X
of	B-X
HDAC3	B-X
levels	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
an	B-X
evidence	B-X
that	B-X
Mdm2	B-X
positively	B-X
regulates	B-X
HDAC3	B-X
monoubiquitination	B-X
and	B-X
stability	B-X
.	B-X

Whereas	O
the	O
kinetochores	O
and	O
the	O
spindle	O
assembly	O
checkpoint	O
appeared	O
intact	O
in	O
HDAC3	B-Protein
-	O
deficient	O
cells	O
,	O
kinetochore	O
-	O
microtubule	O
attachments	O
were	O
impaired	O
because	O
spindle	O
microtubules	O
were	O
unstable	O
in	O
response	O
to	O
cold	O
treatment	O
.	O
<EOS>	B-X
Histone	B-X
deacetylase	B-X
3	B-X
(	B-X
HDAC3	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
,	B-X
ubiquitously	B-X
expressed	B-X
protein	B-X
that	B-X
forms	B-X
multiprotein	B-X
corepressor	B-X
complexes	B-X
to	B-X
repress	B-X
gene	B-X
transcription	B-X
.	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
HDAC3	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Altered	B-X
HDAC3	B-X
level	B-X
increases	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
,	B-X
including	B-X
nuclear	B-X
receptor	B-X
corepressor	B-X
(	B-X
N-CoR	B-X
)	B-X
,	B-X
transducin-beta-like	B-X
protein	B-X
1	B-X
(	B-X
TBL1	B-X
)	B-X
,	B-X
and	B-X
TBL1-related	B-X
protein	B-X
1	B-X
(	B-X
TBLR1	B-X
)	B-X
,	B-X
is	B-X
localized	B-X
on	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X
Knockdown	B-X
of	B-X
HDAC3	B-X
or	B-X
N-CoR	B-X
resulted	B-X
in	B-X
a	B-X
collapsed	B-X
mitotic	B-X
spindle	B-X
that	B-X
was	B-X
surrounded	B-X
by	B-X
chromosomes	B-X
arranged	B-X
in	B-X
a	B-X
dome-like	B-X
configuration	B-X
.	B-X
Treatment	B-X
of	B-X
mitotic	B-X
cells	B-X
with	B-X
Trichostatin	B-X
A	B-X
,	B-X
an	B-X
HDAC	B-X
inhibitor	B-X
,	B-X
resulted	B-X
in	B-X
similar	B-X
spindle	B-X
defects	B-X
independent	B-X
of	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
wild-type	B-X
HDAC3	B-X
but	B-X
not	B-X
a	B-X
deacetylase-dead	B-X
mutant	B-X
HDAC3	B-X
rescued	B-X
the	B-X
phenotypes	B-X
of	B-X
HDAC3-depleted	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
HDAC3	B-X
is	B-X
important	B-X
for	B-X
proper	B-X
spindle	B-X
function	B-X
.	B-X
Whereas	B-X
the	B-X
kinetochores	B-X
and	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
appeared	B-X
intact	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
,	B-X
kinetochore-microtubule	B-X
attachments	B-X
were	B-X
impaired	B-X
because	B-X
spindle	B-X
microtubules	B-X
were	B-X
unstable	B-X
in	B-X
response	B-X
to	B-X
cold	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
functional	B-X
mitotic	B-X
spindles	B-X
and	B-X
proper	B-X
kinetochore-microtubule	B-X
attachment	B-X
.	B-X
The	B-X
level	B-X
or	B-X
distribution	B-X
of	B-X
acetylated	B-X
alpha-tubulin	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
studies	B-X
raise	B-X
the	B-X
interesting	B-X
possibility	B-X
that	B-X
acetylation-deacetylation	B-X
of	B-X
mitotic	B-X
spindle	B-X
components	B-X
may	B-X
be	B-X
essential	B-X
for	B-X
mitotic	B-X
spindle	B-X
function	B-X
.	B-X

These	O
data	O
suggest	O
that	O
the	O
HDAC3	B-Protein
complex	O
is	O
involved	O
in	O
the	O
formation	O
of	O
functional	O
mitotic	O
spindles	O
and	O
proper	O
kinetochore	O
-	O
microtubule	O
attachment	O
.	O
<EOS>	B-X
Histone	B-X
deacetylase	B-X
3	B-X
(	B-X
HDAC3	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
,	B-X
ubiquitously	B-X
expressed	B-X
protein	B-X
that	B-X
forms	B-X
multiprotein	B-X
corepressor	B-X
complexes	B-X
to	B-X
repress	B-X
gene	B-X
transcription	B-X
.	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
HDAC3	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Altered	B-X
HDAC3	B-X
level	B-X
increases	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
,	B-X
including	B-X
nuclear	B-X
receptor	B-X
corepressor	B-X
(	B-X
N-CoR	B-X
)	B-X
,	B-X
transducin-beta-like	B-X
protein	B-X
1	B-X
(	B-X
TBL1	B-X
)	B-X
,	B-X
and	B-X
TBL1-related	B-X
protein	B-X
1	B-X
(	B-X
TBLR1	B-X
)	B-X
,	B-X
is	B-X
localized	B-X
on	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X
Knockdown	B-X
of	B-X
HDAC3	B-X
or	B-X
N-CoR	B-X
resulted	B-X
in	B-X
a	B-X
collapsed	B-X
mitotic	B-X
spindle	B-X
that	B-X
was	B-X
surrounded	B-X
by	B-X
chromosomes	B-X
arranged	B-X
in	B-X
a	B-X
dome-like	B-X
configuration	B-X
.	B-X
Treatment	B-X
of	B-X
mitotic	B-X
cells	B-X
with	B-X
Trichostatin	B-X
A	B-X
,	B-X
an	B-X
HDAC	B-X
inhibitor	B-X
,	B-X
resulted	B-X
in	B-X
similar	B-X
spindle	B-X
defects	B-X
independent	B-X
of	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
wild-type	B-X
HDAC3	B-X
but	B-X
not	B-X
a	B-X
deacetylase-dead	B-X
mutant	B-X
HDAC3	B-X
rescued	B-X
the	B-X
phenotypes	B-X
of	B-X
HDAC3-depleted	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
HDAC3	B-X
is	B-X
important	B-X
for	B-X
proper	B-X
spindle	B-X
function	B-X
.	B-X
Whereas	B-X
the	B-X
kinetochores	B-X
and	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
appeared	B-X
intact	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
,	B-X
kinetochore-microtubule	B-X
attachments	B-X
were	B-X
impaired	B-X
because	B-X
spindle	B-X
microtubules	B-X
were	B-X
unstable	B-X
in	B-X
response	B-X
to	B-X
cold	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
functional	B-X
mitotic	B-X
spindles	B-X
and	B-X
proper	B-X
kinetochore-microtubule	B-X
attachment	B-X
.	B-X
The	B-X
level	B-X
or	B-X
distribution	B-X
of	B-X
acetylated	B-X
alpha-tubulin	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
studies	B-X
raise	B-X
the	B-X
interesting	B-X
possibility	B-X
that	B-X
acetylation-deacetylation	B-X
of	B-X
mitotic	B-X
spindle	B-X
components	B-X
may	B-X
be	B-X
essential	B-X
for	B-X
mitotic	B-X
spindle	B-X
function	B-X
.	B-X

The	O
level	O
or	O
distribution	O
of	O
acetylated	O
alpha	O
-	O
tubulin	O
was	O
not	O
altered	O
in	O
HDAC3	B-Protein
-	O
deficient	O
cells	O
.	O
<EOS>	B-X
This	B-X
might	B-X
be	B-X
because	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
KIFC1	B-X
on	B-X
HDAC6	B-X
and	B-X
NAT10-based	B-X
tubulin	B-X
acetylation	B-X
,	B-X
which	B-X
further	B-X
affected	B-X
microtubule	B-X
stability	B-X
.	B-X
Mass	B-X
spectroscopy	B-X
analysis	B-X
revealed	B-X
that	B-X
KIFC1	B-X
also	B-X
associated	B-X
with	B-X
several	B-X
actin	B-X
nucleation	B-X
factors	B-X
and	B-X
we	B-X
found	B-X
that	B-X
KIFC1	B-X
was	B-X
essential	B-X
for	B-X
the	B-X
distribution	B-X
of	B-X
actin	B-X
filaments	B-X
,	B-X
which	B-X
further	B-X
affected	B-X
spindle	B-X
migration	B-X
.	B-X
Depletion	B-X
of	B-X
KIFC1	B-X
leaded	B-X
to	B-X
aberrant	B-X
expression	B-X
of	B-X
formin	B-X
2	B-X
and	B-X
the	B-X
ARP2/3	B-X
complex	B-X
,	B-X
and	B-X
endoplasmic	B-X
reticulum	B-X
distribution	B-X
was	B-X
also	B-X
disturbed	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
as	B-X
well	B-X
as	B-X
its	B-X
roles	B-X
in	B-X
tubulin	B-X
acetylation	B-X
,	B-X
our	B-X
study	B-X
reported	B-X
a	B-X
previously	B-X
undescribed	B-X
role	B-X
of	B-X
kinesin	B-X
KIFC1	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
actin	B-X
dynamics	B-X
for	B-X
spindle	B-X
migration	B-X
in	B-X
mouse	B-X
oocytes	B-X
.	B-X

Taken	O
together	O
,	O
our	O
studies	O
raise	O
the	O
interesting	O
possibility	O
that	O
acetylation	O
-	O
deacetylation	O
of	O
mitotic	O
spindle	O
components	O
may	O
be	O
essential	O
for	O
mitotic	O
spindle	O
function	O
.	O
<EOS>	B-X
Protein	B-X
acetylation	B-X
and	B-X
deacetylation	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
multiple	B-X
physiological	B-X
functions	B-X
.	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
HDAC3	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
,	B-X
including	B-X
nuclear	B-X
receptor	B-X
corepressor	B-X
(	B-X
N-CoR	B-X
)	B-X
,	B-X
transducin-beta-like	B-X
protein	B-X
1	B-X
(	B-X
TBL1	B-X
)	B-X
,	B-X
and	B-X
TBL1-related	B-X
protein	B-X
1	B-X
(	B-X
TBLR1	B-X
)	B-X
,	B-X
is	B-X
localized	B-X
on	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X
Knockdown	B-X
of	B-X
HDAC3	B-X
or	B-X
N-CoR	B-X
resulted	B-X
in	B-X
a	B-X
collapsed	B-X
mitotic	B-X
spindle	B-X
that	B-X
was	B-X
surrounded	B-X
by	B-X
chromosomes	B-X
arranged	B-X
in	B-X
a	B-X
dome-like	B-X
configuration	B-X
.	B-X
Treatment	B-X
of	B-X
mitotic	B-X
cells	B-X
with	B-X
Trichostatin	B-X
A	B-X
,	B-X
an	B-X
HDAC	B-X
inhibitor	B-X
,	B-X
resulted	B-X
in	B-X
similar	B-X
spindle	B-X
defects	B-X
independent	B-X
of	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
wild-type	B-X
HDAC3	B-X
but	B-X
not	B-X
a	B-X
deacetylase-dead	B-X
mutant	B-X
HDAC3	B-X
rescued	B-X
the	B-X
phenotypes	B-X
of	B-X
HDAC3-depleted	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzymatic	B-X
activity	B-X
of	B-X
HDAC3	B-X
is	B-X
important	B-X
for	B-X
proper	B-X
spindle	B-X
function	B-X
.	B-X
Whereas	B-X
the	B-X
kinetochores	B-X
and	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
appeared	B-X
intact	B-X
in	B-X
HDAC3-deficient	B-X
cells	B-X
,	B-X
kinetochore-microtubule	B-X
attachments	B-X
were	B-X
impaired	B-X
because	B-X
spindle	B-X
microtubules	B-X
were	B-X
unstable	B-X
in	B-X
response	B-X
to	B-X
cold	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
HDAC3	B-X
complex	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
functional	B-X
mitotic	B-X
spindles	B-X
and	B-X
proper	B-X
kinetochore-microtubule	B-X
attachment	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
studies	B-X
raise	B-X
the	B-X
interesting	B-X
possibility	B-X
that	B-X
acetylation-deacetylation	B-X
of	B-X
mitotic	B-X
spindle	B-X
components	B-X
may	B-X
be	B-X
essential	B-X
for	B-X
mitotic	B-X
spindle	B-X
function	B-X
.	B-X

VprBP	B-Protein
targets	O
Merlin	B-Protein
to	O
the	O
Roc1	B-Protein
-	O
Cul4A	B-Protein
-	O
DDB1	B-Protein
E3	O
ligase	O
complex	O
for	O
degradation	O
.	O

Inactivation	O
of	O
the	O
neurofibromatosis	B-Protein
type	I-Protein
2	I-Protein
(	O
NF2	B-Protein
)	O
tumor	O
suppressor	O
gene	O
function	O
has	O
been	O
observed	O
not	O
only	O
in	O
familial	O
schwannomas	O
and	O
other	O
central	O
nervous	O
system	O
tumors	O
,	O
but	O
also	O
in	O
malignant	O
tumors	O
unrelated	O
to	O
the	O
NF2	B-Protein
syndrome	O
,	O
indicating	O
a	O
broader	O
role	O
of	O
NF2	B-Protein
in	O
human	O
tumorigenesis	O
.	O
<EOS>	B-X
Malignant	B-X
mesothelioma	B-X
(	B-X
MM	B-X
)	B-X
is	B-X
a	B-X
tumor	B-X
with	B-X
poor	B-X
prognosis	B-X
associated	B-X
with	B-X
asbestos	B-X
exposure	B-X
.	B-X
While	B-X
it	B-X
remains	B-X
to	B-X
be	B-X
clarified	B-X
how	B-X
asbestos	B-X
fibers	B-X
confer	B-X
genetic/epigenetic	B-X
alterations	B-X
and	B-X
induce	B-X
cellular	B-X
transformation	B-X
in	B-X
normal	B-X
mesothelial	B-X
cells	B-X
,	B-X
the	B-X
understanding	B-X
of	B-X
key	B-X
molecular	B-X
mechanisms	B-X
of	B-X
MM	B-X
cell	B-X
development	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
invasion	B-X
has	B-X
progressed	B-X
.	B-X
MM	B-X
shows	B-X
frequent	B-X
genetic	B-X
inactivation	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
of	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
/p14	B-X
(	B-X
ARF	B-X
)	B-X
and	B-X
neurofibromatosis	B-X
type	B-X
2	B-X
(	B-X
NF2	B-X
)	B-X
which	B-X
encodes	B-X
Merlin	B-X
,	B-X
and	B-X
epigenetic	B-X
inactivation	B-X
of	B-X
RASSF1A	B-X
.	B-X
However	B-X
,	B-X
no	B-X
frequent	B-X
mutations	B-X
of	B-X
well-known	B-X
oncogenes	B-X
such	B-X
as	B-X
K-RAS	B-X
and	B-X
PIK3CA	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
Activation	B-X
of	B-X
multiple	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
including	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
family	B-X
and	B-X
MET	B-X
,	B-X
and	B-X
subsequent	B-X
deregulations	B-X
of	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
and	B-X
phosphatidylinositol-3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
-AKT	B-X
signaling	B-X
cascades	B-X
are	B-X
frequently	B-X
observed	B-X
in	B-X
most	B-X
MM	B-X
cells	B-X
.	B-X
The	B-X
tumor	B-X
suppressive	B-X
function	B-X
of	B-X
Merlin	B-X
in	B-X
MM	B-X
cells	B-X
is	B-X
also	B-X
being	B-X
investigated	B-X
by	B-X
dissecting	B-X
its	B-X
possible	B-X
downstream	B-X
signaling	B-X
cascade	B-X
called	B-X
the	B-X
Hippo	B-X
pathway	B-X
.	B-X

The	O
NF2	B-Protein
-	O
encoded	O
protein	O
Merlin	B-Protein
is	O
closely	O
related	O
to	O
the	O
Ezrin	B-Protein
-	O
Radixin	B-Protein
-	O
Moesin	B-Protein
family	O
of	O
membrane	O
/	O
cytoskeleton	O
linker	O
proteins	O
,	O
and	O
has	O
been	O
demonstrated	O
to	O
suppress	O
tumor	O
growth	O
by	O
inhibiting	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
and	O
Rac1	B-Protein
activation	O
.	O

Interestingly	O
,	O
serum	O
deprivation	O
has	O
been	O
shown	O
to	O
regulate	O
Merlin	B-Protein
at	O
the	O
protein	O
level	O
,	O
however	O
,	O
exactly	O
how	O
such	O
condition	O
affects	O
Merlin	B-Protein
remains	O
elusive	O
.	O
<EOS>	B-X
The	B-X
NF2-encoded	B-X
protein	B-X
Merlin	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
Ezrin-Radixin-Moesin	B-X
family	B-X
of	B-X
membrane/cytoskeleton	B-X
linker	B-X
proteins	B-X
,	B-X
and	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
suppress	B-X
tumor	B-X
growth	B-X
by	B-X
inhibiting	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
and	B-X
Rac1	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
serum	B-X
deprivation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
Merlin	B-X
at	B-X
the	B-X
protein	B-X
level	B-X
,	B-X
however	B-X
,	B-X
exactly	B-X
how	B-X
such	B-X
condition	B-X
affects	B-X
Merlin	B-X
remains	B-X
elusive	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
to	B-X
show	B-X
that	B-X
Merlin	B-X
is	B-X
regulated	B-X
in	B-X
a	B-X
Roc1-Cullin4A-DDB1-dependent	B-X
manner	B-X
.	B-X
Following	B-X
serum	B-X
stimulation	B-X
,	B-X
Merlin	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
E3	B-X
ligase	B-X
complex	B-X
through	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
WD40-containing	B-X
adaptor	B-X
protein	B-X
VprBP	B-X
.	B-X
Loading	B-X
of	B-X
Merlin	B-X
to	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
resulted	B-X
in	B-X
its	B-X
polyubiquitination	B-X
,	B-X
and	B-X
consequently	B-X
its	B-X
proteasome-mediated	B-X
degradation	B-X
.	B-X
Consistently	B-X
,	B-X
VprBP	B-X
depletion	B-X
abolished	B-X
the	B-X
in	B-X
vivo	B-X
interaction	B-X
of	B-X
Merlin	B-X
and	B-X
Roc1-Cullin4A-DDB1	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
Merlin	B-X
stabilization	B-X
and	B-X
inhibited	B-X
ERK	B-X
and	B-X
Rac	B-X
activation	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
revealed	B-X
a	B-X
novel	B-X
regulatory	B-X
mechanism	B-X
for	B-X
the	B-X
tumor	B-X
suppressor	B-X
function	B-X
of	B-X
Merlin	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
provide	O
evidence	O
to	O
show	O
that	O
Merlin	B-Protein
is	O
regulated	O
in	O
a	O
Roc1	B-Protein
-	O
Cullin4A	B-Protein
-	O
DDB1	B-Protein
-	O
dependent	O
manner	O
.	O

Following	O
serum	O
stimulation	O
,	O
Merlin	B-Protein
is	O
recruited	O
to	O
the	O
E3	O
ligase	O
complex	O
through	O
a	O
direct	O
interaction	O
with	O
the	O
WD40	O
-	O
containing	O
adaptor	O
protein	O
VprBP	B-Protein
.	O

Loading	O
of	O
Merlin	B-Protein
to	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
complex	O
resulted	O
in	O
its	O
polyubiquitination	O
,	O
and	O
consequently	O
its	O
proteasome	O
-	O
mediated	O
degradation	O
.	O

Consistently	O
,	O
VprBP	B-Protein
depletion	O
abolished	O
the	O
in	O
vivo	O
interaction	O
of	O
Merlin	B-Protein
and	O
Roc1	B-Protein
-	O
Cullin4A	B-Protein
-	O
DDB1	B-Protein
,	O
which	O
resulted	O
in	O
Merlin	B-Protein
stabilization	O
and	O
inhibited	O
ERK	O
and	O
Rac	O
activation	O
.	O
<EOS>	B-X
Inactivation	B-X
of	B-X
the	B-X
neurofibromatosis	B-X
type	B-X
2	B-X
(	B-X
NF2	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
function	B-X
has	B-X
been	B-X
observed	B-X
not	B-X
only	B-X
in	B-X
familial	B-X
schwannomas	B-X
and	B-X
other	B-X
central	B-X
nervous	B-X
system	B-X
tumors	B-X
,	B-X
but	B-X
also	B-X
in	B-X
malignant	B-X
tumors	B-X
unrelated	B-X
to	B-X
the	B-X
NF2	B-X
syndrome	B-X
,	B-X
indicating	B-X
a	B-X
broader	B-X
role	B-X
of	B-X
NF2	B-X
in	B-X
human	B-X
tumorigenesis	B-X
.	B-X
The	B-X
NF2-encoded	B-X
protein	B-X
Merlin	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
Ezrin-Radixin-Moesin	B-X
family	B-X
of	B-X
membrane/cytoskeleton	B-X
linker	B-X
proteins	B-X
,	B-X
and	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
suppress	B-X
tumor	B-X
growth	B-X
by	B-X
inhibiting	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
and	B-X
Rac1	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
serum	B-X
deprivation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
Merlin	B-X
at	B-X
the	B-X
protein	B-X
level	B-X
,	B-X
however	B-X
,	B-X
exactly	B-X
how	B-X
such	B-X
condition	B-X
affects	B-X
Merlin	B-X
remains	B-X
elusive	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
to	B-X
show	B-X
that	B-X
Merlin	B-X
is	B-X
regulated	B-X
in	B-X
a	B-X
Roc1-Cullin4A-DDB1-dependent	B-X
manner	B-X
.	B-X
Following	B-X
serum	B-X
stimulation	B-X
,	B-X
Merlin	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
E3	B-X
ligase	B-X
complex	B-X
through	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
WD40-containing	B-X
adaptor	B-X
protein	B-X
VprBP	B-X
.	B-X
Loading	B-X
of	B-X
Merlin	B-X
to	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
resulted	B-X
in	B-X
its	B-X
polyubiquitination	B-X
,	B-X
and	B-X
consequently	B-X
its	B-X
proteasome-mediated	B-X
degradation	B-X
.	B-X
Consistently	B-X
,	B-X
VprBP	B-X
depletion	B-X
abolished	B-X
the	B-X
in	B-X
vivo	B-X
interaction	B-X
of	B-X
Merlin	B-X
and	B-X
Roc1-Cullin4A-DDB1	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
Merlin	B-X
stabilization	B-X
and	B-X
inhibited	B-X
ERK	B-X
and	B-X
Rac	B-X
activation	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
revealed	B-X
a	B-X
novel	B-X
regulatory	B-X
mechanism	B-X
for	B-X
the	B-X
tumor	B-X
suppressor	B-X
function	B-X
of	B-X
Merlin	B-X
.	B-X

Together	O
,	O
our	O
data	O
revealed	O
a	O
novel	O
regulatory	O
mechanism	O
for	O
the	O
tumor	O
suppressor	O
function	O
of	O
Merlin	B-Protein
.	O
<EOS>	B-X
Inactivation	B-X
of	B-X
the	B-X
neurofibromatosis	B-X
type	B-X
2	B-X
(	B-X
NF2	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
function	B-X
has	B-X
been	B-X
observed	B-X
not	B-X
only	B-X
in	B-X
familial	B-X
schwannomas	B-X
and	B-X
other	B-X
central	B-X
nervous	B-X
system	B-X
tumors	B-X
,	B-X
but	B-X
also	B-X
in	B-X
malignant	B-X
tumors	B-X
unrelated	B-X
to	B-X
the	B-X
NF2	B-X
syndrome	B-X
,	B-X
indicating	B-X
a	B-X
broader	B-X
role	B-X
of	B-X
NF2	B-X
in	B-X
human	B-X
tumorigenesis	B-X
.	B-X
The	B-X
NF2-encoded	B-X
protein	B-X
Merlin	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
Ezrin-Radixin-Moesin	B-X
family	B-X
of	B-X
membrane/cytoskeleton	B-X
linker	B-X
proteins	B-X
,	B-X
and	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
suppress	B-X
tumor	B-X
growth	B-X
by	B-X
inhibiting	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
and	B-X
Rac1	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
serum	B-X
deprivation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
Merlin	B-X
at	B-X
the	B-X
protein	B-X
level	B-X
,	B-X
however	B-X
,	B-X
exactly	B-X
how	B-X
such	B-X
condition	B-X
affects	B-X
Merlin	B-X
remains	B-X
elusive	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
to	B-X
show	B-X
that	B-X
Merlin	B-X
is	B-X
regulated	B-X
in	B-X
a	B-X
Roc1-Cullin4A-DDB1-dependent	B-X
manner	B-X
.	B-X
Following	B-X
serum	B-X
stimulation	B-X
,	B-X
Merlin	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
E3	B-X
ligase	B-X
complex	B-X
through	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
WD40-containing	B-X
adaptor	B-X
protein	B-X
VprBP	B-X
.	B-X
Loading	B-X
of	B-X
Merlin	B-X
to	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
resulted	B-X
in	B-X
its	B-X
polyubiquitination	B-X
,	B-X
and	B-X
consequently	B-X
its	B-X
proteasome-mediated	B-X
degradation	B-X
.	B-X
Consistently	B-X
,	B-X
VprBP	B-X
depletion	B-X
abolished	B-X
the	B-X
in	B-X
vivo	B-X
interaction	B-X
of	B-X
Merlin	B-X
and	B-X
Roc1-Cullin4A-DDB1	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
Merlin	B-X
stabilization	B-X
and	B-X
inhibited	B-X
ERK	B-X
and	B-X
Rac	B-X
activation	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
revealed	B-X
a	B-X
novel	B-X
regulatory	B-X
mechanism	B-X
for	B-X
the	B-X
tumor	B-X
suppressor	B-X
function	B-X
of	B-X
Merlin	B-X
.	B-X

The	O
novel	O
gene	O
LRP15	B-Protein
is	O
regulated	O
by	O
DNA	O
methylation	O
and	O
confers	O
increased	O
efficiency	O
of	O
DNA	O
repair	O
of	O
ultraviolet	O
-	O
induced	O
DNA	O
damage	O
.	O
<EOS>	B-X
LRP15	B-X
is	B-X
a	B-X
novel	B-X
gene	B-X
cloned	B-X
from	B-X
lymphocytic	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
function	B-X
is	B-X
still	B-X
unknown	B-X
.	B-X
Bioinformatic	B-X
data	B-X
showed	B-X
that	B-X
LRP15	B-X
might	B-X
be	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
had	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
whether	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
,	B-X
and	B-X
whether	B-X
overexpression	B-X
of	B-X
LRP15	B-X
increases	B-X
efficiency	B-X
of	B-X
DNA	B-X
repair	B-X
of	B-X
UV-induced	B-X
DNA	B-X
damage	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
(	B-X
1	B-X
)	B-X
the	B-X
promoter	B-X
of	B-X
LRP15	B-X
was	B-X
hypermethylated	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
resulting	B-X
a	B-X
silence	B-X
of	B-X
its	B-X
expression	B-X
.	B-X
Gene	B-X
expression	B-X
was	B-X
restored	B-X
by	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
5-aza-2'-deoxycytidine	B-X
,	B-X
but	B-X
not	B-X
by	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
;	B-X
(	B-X
2	B-X
)	B-X
overexpression	B-X
of	B-X
LRP15	B-X
inhibited	B-X
HeLa	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
numbers	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
G2/M	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
LRP15	B-X
increased	B-X
about	B-X
10	B-X
%	B-X
compared	B-X
with	B-X
controls	B-X
;	B-X
(	B-X
3	B-X
)	B-X
cyclin	B-X
B1	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
in	B-X
cells	B-X
overexpressing	B-X
LRP15	B-X
than	B-X
in	B-X
control	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
after	B-X
exposure	B-X
to	B-X
UV	B-X
radiation	B-X
,	B-X
the	B-X
LRP15-positive	B-X
cells	B-X
showed	B-X
shorter	B-X
comet	B-X
tails	B-X
compared	B-X
with	B-X
the	B-X
LRP15-negative	B-X
cells	B-X
.	B-X
From	B-X
these	B-X
results	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
controlled	B-X
by	B-X
methylation	B-X
in	B-X
its	B-X
promoter	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
and	B-X
LRP15	B-X
confers	B-X
resistance	B-X
to	B-X
UV	B-X
damage	B-X
and	B-X
accelerates	B-X
the	B-X
DNA	B-X
repair	B-X
rate	B-X
.	B-X

LRP15	B-Protein
is	O
a	O
novel	O
gene	O
cloned	O
from	O
lymphocytic	O
cells	O
,	O
and	O
its	O
function	O
is	O
still	O
unknown	O
.	O
<EOS>	B-X
LRP15	B-X
is	B-X
a	B-X
novel	B-X
gene	B-X
cloned	B-X
from	B-X
lymphocytic	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
function	B-X
is	B-X
still	B-X
unknown	B-X
.	B-X
Bioinformatic	B-X
data	B-X
showed	B-X
that	B-X
LRP15	B-X
might	B-X
be	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
had	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
whether	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
,	B-X
and	B-X
whether	B-X
overexpression	B-X
of	B-X
LRP15	B-X
increases	B-X
efficiency	B-X
of	B-X
DNA	B-X
repair	B-X
of	B-X
UV-induced	B-X
DNA	B-X
damage	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
(	B-X
1	B-X
)	B-X
the	B-X
promoter	B-X
of	B-X
LRP15	B-X
was	B-X
hypermethylated	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
resulting	B-X
a	B-X
silence	B-X
of	B-X
its	B-X
expression	B-X
.	B-X
Gene	B-X
expression	B-X
was	B-X
restored	B-X
by	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
5-aza-2'-deoxycytidine	B-X
,	B-X
but	B-X
not	B-X
by	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
;	B-X
(	B-X
2	B-X
)	B-X
overexpression	B-X
of	B-X
LRP15	B-X
inhibited	B-X
HeLa	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
numbers	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
G2/M	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
LRP15	B-X
increased	B-X
about	B-X
10	B-X
%	B-X
compared	B-X
with	B-X
controls	B-X
;	B-X
(	B-X
3	B-X
)	B-X
cyclin	B-X
B1	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
in	B-X
cells	B-X
overexpressing	B-X
LRP15	B-X
than	B-X
in	B-X
control	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
after	B-X
exposure	B-X
to	B-X
UV	B-X
radiation	B-X
,	B-X
the	B-X
LRP15-positive	B-X
cells	B-X
showed	B-X
shorter	B-X
comet	B-X
tails	B-X
compared	B-X
with	B-X
the	B-X
LRP15-negative	B-X
cells	B-X
.	B-X
From	B-X
these	B-X
results	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
controlled	B-X
by	B-X
methylation	B-X
in	B-X
its	B-X
promoter	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
and	B-X
LRP15	B-X
confers	B-X
resistance	B-X
to	B-X
UV	B-X
damage	B-X
and	B-X
accelerates	B-X
the	B-X
DNA	B-X
repair	B-X
rate	B-X
.	B-X

Bioinformatic	O
data	O
showed	O
that	O
LRP15	B-Protein
might	O
be	O
regulated	O
by	O
DNA	O
methylation	O
and	O
had	O
an	O
important	O
role	O
in	O
DNA	O
repair	O
.	O
<EOS>	B-X
LRP15	B-X
is	B-X
a	B-X
novel	B-X
gene	B-X
cloned	B-X
from	B-X
lymphocytic	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
function	B-X
is	B-X
still	B-X
unknown	B-X
.	B-X
Bioinformatic	B-X
data	B-X
showed	B-X
that	B-X
LRP15	B-X
might	B-X
be	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
had	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
whether	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
,	B-X
and	B-X
whether	B-X
overexpression	B-X
of	B-X
LRP15	B-X
increases	B-X
efficiency	B-X
of	B-X
DNA	B-X
repair	B-X
of	B-X
UV-induced	B-X
DNA	B-X
damage	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
(	B-X
1	B-X
)	B-X
the	B-X
promoter	B-X
of	B-X
LRP15	B-X
was	B-X
hypermethylated	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
resulting	B-X
a	B-X
silence	B-X
of	B-X
its	B-X
expression	B-X
.	B-X
Gene	B-X
expression	B-X
was	B-X
restored	B-X
by	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
5-aza-2'-deoxycytidine	B-X
,	B-X
but	B-X
not	B-X
by	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
;	B-X
(	B-X
2	B-X
)	B-X
overexpression	B-X
of	B-X
LRP15	B-X
inhibited	B-X
HeLa	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
numbers	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
G2/M	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
LRP15	B-X
increased	B-X
about	B-X
10	B-X
%	B-X
compared	B-X
with	B-X
controls	B-X
;	B-X
(	B-X
3	B-X
)	B-X
cyclin	B-X
B1	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
in	B-X
cells	B-X
overexpressing	B-X
LRP15	B-X
than	B-X
in	B-X
control	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
after	B-X
exposure	B-X
to	B-X
UV	B-X
radiation	B-X
,	B-X
the	B-X
LRP15-positive	B-X
cells	B-X
showed	B-X
shorter	B-X
comet	B-X
tails	B-X
compared	B-X
with	B-X
the	B-X
LRP15-negative	B-X
cells	B-X
.	B-X
From	B-X
these	B-X
results	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
controlled	B-X
by	B-X
methylation	B-X
in	B-X
its	B-X
promoter	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
and	B-X
LRP15	B-X
confers	B-X
resistance	B-X
to	B-X
UV	B-X
damage	B-X
and	B-X
accelerates	B-X
the	B-X
DNA	B-X
repair	B-X
rate	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
investigate	O
whether	O
the	O
expression	O
of	O
LRP15	B-Protein
is	O
regulated	O
by	O
DNA	O
methylation	O
,	O
and	O
whether	O
overexpression	O
of	O
LRP15	B-Protein
increases	O
efficiency	O
of	O
DNA	O
repair	O
of	O
UV	O
-	O
induced	O
DNA	O
damage	O
in	O
HeLa	O
cells	O
.	O
<EOS>	B-X
LRP15	B-X
is	B-X
a	B-X
novel	B-X
gene	B-X
cloned	B-X
from	B-X
lymphocytic	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
function	B-X
is	B-X
still	B-X
unknown	B-X
.	B-X
Bioinformatic	B-X
data	B-X
showed	B-X
that	B-X
LRP15	B-X
might	B-X
be	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
had	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
whether	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
,	B-X
and	B-X
whether	B-X
overexpression	B-X
of	B-X
LRP15	B-X
increases	B-X
efficiency	B-X
of	B-X
DNA	B-X
repair	B-X
of	B-X
UV-induced	B-X
DNA	B-X
damage	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
(	B-X
1	B-X
)	B-X
the	B-X
promoter	B-X
of	B-X
LRP15	B-X
was	B-X
hypermethylated	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
resulting	B-X
a	B-X
silence	B-X
of	B-X
its	B-X
expression	B-X
.	B-X
Gene	B-X
expression	B-X
was	B-X
restored	B-X
by	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
5-aza-2'-deoxycytidine	B-X
,	B-X
but	B-X
not	B-X
by	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
;	B-X
(	B-X
2	B-X
)	B-X
overexpression	B-X
of	B-X
LRP15	B-X
inhibited	B-X
HeLa	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
numbers	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
G2/M	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
LRP15	B-X
increased	B-X
about	B-X
10	B-X
%	B-X
compared	B-X
with	B-X
controls	B-X
;	B-X
(	B-X
3	B-X
)	B-X
cyclin	B-X
B1	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
in	B-X
cells	B-X
overexpressing	B-X
LRP15	B-X
than	B-X
in	B-X
control	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
after	B-X
exposure	B-X
to	B-X
UV	B-X
radiation	B-X
,	B-X
the	B-X
LRP15-positive	B-X
cells	B-X
showed	B-X
shorter	B-X
comet	B-X
tails	B-X
compared	B-X
with	B-X
the	B-X
LRP15-negative	B-X
cells	B-X
.	B-X
From	B-X
these	B-X
results	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
controlled	B-X
by	B-X
methylation	B-X
in	B-X
its	B-X
promoter	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
and	B-X
LRP15	B-X
confers	B-X
resistance	B-X
to	B-X
UV	B-X
damage	B-X
and	B-X
accelerates	B-X
the	B-X
DNA	B-X
repair	B-X
rate	B-X
.	B-X

The	O
results	O
showed	O
(	O
1	O
)	O
the	O
promoter	O
of	O
LRP15	B-Protein
was	O
hypermethylated	O
in	O
HeLa	O
cells	O
,	O
resulting	O
a	O
silence	O
of	O
its	O
expression	O
.	O
<EOS>	B-X
LRP15	B-X
is	B-X
a	B-X
novel	B-X
gene	B-X
cloned	B-X
from	B-X
lymphocytic	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
function	B-X
is	B-X
still	B-X
unknown	B-X
.	B-X
Bioinformatic	B-X
data	B-X
showed	B-X
that	B-X
LRP15	B-X
might	B-X
be	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
had	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
whether	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
,	B-X
and	B-X
whether	B-X
overexpression	B-X
of	B-X
LRP15	B-X
increases	B-X
efficiency	B-X
of	B-X
DNA	B-X
repair	B-X
of	B-X
UV-induced	B-X
DNA	B-X
damage	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
(	B-X
1	B-X
)	B-X
the	B-X
promoter	B-X
of	B-X
LRP15	B-X
was	B-X
hypermethylated	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
resulting	B-X
a	B-X
silence	B-X
of	B-X
its	B-X
expression	B-X
.	B-X
Gene	B-X
expression	B-X
was	B-X
restored	B-X
by	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
5-aza-2'-deoxycytidine	B-X
,	B-X
but	B-X
not	B-X
by	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
;	B-X
(	B-X
2	B-X
)	B-X
overexpression	B-X
of	B-X
LRP15	B-X
inhibited	B-X
HeLa	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
numbers	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
G2/M	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
LRP15	B-X
increased	B-X
about	B-X
10	B-X
%	B-X
compared	B-X
with	B-X
controls	B-X
;	B-X
(	B-X
3	B-X
)	B-X
cyclin	B-X
B1	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
in	B-X
cells	B-X
overexpressing	B-X
LRP15	B-X
than	B-X
in	B-X
control	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
after	B-X
exposure	B-X
to	B-X
UV	B-X
radiation	B-X
,	B-X
the	B-X
LRP15-positive	B-X
cells	B-X
showed	B-X
shorter	B-X
comet	B-X
tails	B-X
compared	B-X
with	B-X
the	B-X
LRP15-negative	B-X
cells	B-X
.	B-X
From	B-X
these	B-X
results	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
controlled	B-X
by	B-X
methylation	B-X
in	B-X
its	B-X
promoter	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
and	B-X
LRP15	B-X
confers	B-X
resistance	B-X
to	B-X
UV	B-X
damage	B-X
and	B-X
accelerates	B-X
the	B-X
DNA	B-X
repair	B-X
rate	B-X
.	B-X

Gene	O
expression	O
was	O
restored	O
by	O
a	O
demethylating	O
agent	O
,	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
,	O
but	O
not	O
by	O
a	O
histone	B-Protein
deacetylase	O
inhibitor	O
,	O
trichostatin	O
A	O
;	O
(	O
2	O
)	O
overexpression	O
of	O
LRP15	B-Protein
inhibited	O
HeLa	O
cell	O
proliferation	O
,	O
and	O
the	O
numbers	O
of	O
cells	O
in	O
the	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
in	O
cells	O
transfected	O
with	O
LRP15	B-Protein
increased	O
about	O
10	O
%	O
compared	O
with	O
controls	O
;	O
(	O
3	O
)	O
cyclin	O
B1	O
level	O
was	O
much	O
lower	O
in	O
cells	O
overexpressing	O
LRP15	B-Protein
than	O
in	O
control	O
cells	O
;	O
and	O
(	O
4	O
)	O
after	O
exposure	O
to	O
UV	O
radiation	O
,	O
the	O
LRP15	B-Protein
-	O
positive	O
cells	O
showed	O
shorter	O
comet	O
tails	O
compared	O
with	O
the	O
LRP15	B-Protein
-	O
negative	O
cells	O
.	O
<EOS>	B-X
Development	B-X
of	B-X
pulmonary	B-X
fibrosis	B-X
is	B-X
associated	B-X
with	B-X
altered	B-X
DNA	B-X
methylation	B-X
modifications	B-X
of	B-X
fibrogenic	B-X
gene	B-X
expression	B-X
.	B-X
Kank1	B-X
,	B-X
which	B-X
was	B-X
first	B-X
described	B-X
as	B-X
a	B-X
potential	B-X
tumor	B-X
suppressor	B-X
for	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
,	B-X
mapped	B-X
to	B-X
9p24.3	B-X
and	B-X
encoded	B-X
an	B-X
ankyrin-repeat	B-X
domain-containing	B-X
protein	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Kank1	B-X
expression	B-X
was	B-X
down-regulated	B-X
in	B-X
NPC	B-X
cells	B-X
than	B-X
in	B-X
human	B-X
nasopharyngeal	B-X
epithelial	B-X
cell	B-X
line	B-X
NP69	B-X
and	B-X
demethylating	B-X
agent	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
5-aza-CdR	B-X
)	B-X
could	B-X
improve	B-X
its	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
level	B-X
.	B-X
Further	B-X
studies	B-X
demonstrated	B-X
that	B-X
DNA	B-X
methylation	B-X
might	B-X
be	B-X
the	B-X
mainly	B-X
cause	B-X
for	B-X
Kank1	B-X
decreased	B-X
expression	B-X
and	B-X
restored	B-X
Kank1	B-X
expression	B-X
mediated	B-X
by	B-X
5-aza-CdR	B-X
played	B-X
a	B-X
key	B-X
role	B-X
in	B-X
suppressing	B-X
NPC	B-X
cells	B-X
growth	B-X
and	B-X
inducing	B-X
its	B-X
apoptosis	B-X
.	B-X

From	O
these	O
results	O
we	O
conclude	O
that	O
the	O
expression	O
of	O
LRP15	B-Protein
is	O
controlled	O
by	O
methylation	O
in	O
its	O
promoter	O
in	O
HeLa	O
cells	O
,	O
and	O
LRP15	B-Protein
confers	O
resistance	O
to	O
UV	O
damage	O
and	O
accelerates	O
the	O
DNA	O
repair	O
rate	O
.	O
<EOS>	B-X
LRP15	B-X
is	B-X
a	B-X
novel	B-X
gene	B-X
cloned	B-X
from	B-X
lymphocytic	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
function	B-X
is	B-X
still	B-X
unknown	B-X
.	B-X
Bioinformatic	B-X
data	B-X
showed	B-X
that	B-X
LRP15	B-X
might	B-X
be	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
had	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
whether	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
regulated	B-X
by	B-X
DNA	B-X
methylation	B-X
,	B-X
and	B-X
whether	B-X
overexpression	B-X
of	B-X
LRP15	B-X
increases	B-X
efficiency	B-X
of	B-X
DNA	B-X
repair	B-X
of	B-X
UV-induced	B-X
DNA	B-X
damage	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
(	B-X
1	B-X
)	B-X
the	B-X
promoter	B-X
of	B-X
LRP15	B-X
was	B-X
hypermethylated	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
resulting	B-X
a	B-X
silence	B-X
of	B-X
its	B-X
expression	B-X
.	B-X
Gene	B-X
expression	B-X
was	B-X
restored	B-X
by	B-X
a	B-X
demethylating	B-X
agent	B-X
,	B-X
5-aza-2'-deoxycytidine	B-X
,	B-X
but	B-X
not	B-X
by	B-X
a	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
,	B-X
trichostatin	B-X
A	B-X
;	B-X
(	B-X
2	B-X
)	B-X
overexpression	B-X
of	B-X
LRP15	B-X
inhibited	B-X
HeLa	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
numbers	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
G2/M	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
LRP15	B-X
increased	B-X
about	B-X
10	B-X
%	B-X
compared	B-X
with	B-X
controls	B-X
;	B-X
(	B-X
3	B-X
)	B-X
cyclin	B-X
B1	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
in	B-X
cells	B-X
overexpressing	B-X
LRP15	B-X
than	B-X
in	B-X
control	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
after	B-X
exposure	B-X
to	B-X
UV	B-X
radiation	B-X
,	B-X
the	B-X
LRP15-positive	B-X
cells	B-X
showed	B-X
shorter	B-X
comet	B-X
tails	B-X
compared	B-X
with	B-X
the	B-X
LRP15-negative	B-X
cells	B-X
.	B-X
From	B-X
these	B-X
results	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
LRP15	B-X
is	B-X
controlled	B-X
by	B-X
methylation	B-X
in	B-X
its	B-X
promoter	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
and	B-X
LRP15	B-X
confers	B-X
resistance	B-X
to	B-X
UV	B-X
damage	B-X
and	B-X
accelerates	B-X
the	B-X
DNA	B-X
repair	B-X
rate	B-X
.	B-X

Enzymatic	O
mechanism	O
and	O
product	O
specificity	O
of	O
SET	O
-	O
domain	O
protein	O
lysine	O
methyltransferases	O
.	O
<EOS>	B-X
Molecular	B-X
dynamics	B-X
and	B-X
hybrid	B-X
quantum	B-X
mechanics/molecular	B-X
mechanics	B-X
have	B-X
been	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
mechanisms	B-X
of	B-X
(	B-X
+	B-X
)	B-X
AdoMet	B-X
methylation	B-X
of	B-X
protein-Lys-NH	B-X
(	B-X
2	B-X
)	B-X
catalyzed	B-X
by	B-X
the	B-X
lysine	B-X
methyltransferase	B-X
enzymes	B-X
:	B-X
histone	B-X
lysine	B-X
monomethyltransferase	B-X
SET7/9	B-X
,	B-X
Rubisco	B-X
large-subunit	B-X
dimethyltransferase	B-X
,	B-X
viral	B-X
histone	B-X
lysine	B-X
trimethyltransferase	B-X
,	B-X
and	B-X
the	B-X
Tyr245Phe	B-X
mutation	B-X
of	B-X
SET7/9	B-X
.	B-X
Repeat	B-X
of	B-X
the	B-X
sequence	B-X
provides	B-X
dimethylated	B-X
lysine	B-X
,	B-X
and	B-X
another	B-X
repeat	B-X
yields	B-X
a	B-X
trimethylated	B-X
lysine	B-X
.	B-X
SET	B-X
and	B-X
MYND	B-X
domain-containing	B-X
protein	B-X
2	B-X
(	B-X
SMYD2	B-X
)	B-X
is	B-X
a	B-X
protein	B-X
lysine	B-X
methyltransferase	B-X
that	B-X
catalyzes	B-X
the	B-X
transfer	B-X
of	B-X
methyl	B-X
groups	B-X
from	B-X
S-adenosylmethionine	B-X
(	B-X
AdoMet	B-X
)	B-X
to	B-X
acceptor	B-X
lysine	B-X
residues	B-X
on	B-X
histones	B-X
and	B-X
other	B-X
proteins	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
kinetic	B-X
mechanism	B-X
and	B-X
the	B-X
function	B-X
of	B-X
individual	B-X
domains	B-X
,	B-X
human	B-X
SMYD2	B-X
was	B-X
overexpressed	B-X
,	B-X
purified	B-X
,	B-X
and	B-X
characterized	B-X
.	B-X
Substrate	B-X
specificity	B-X
and	B-X
product	B-X
analysis	B-X
studies	B-X
established	B-X
SMYD2	B-X
as	B-X
a	B-X
monomethyltransferase	B-X
that	B-X
prefers	B-X
nonmethylated	B-X
p53	B-X
peptide	B-X
substrate	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
and	B-X
product	B-X
inhibition	B-X
studies	B-X
showed	B-X
that	B-X
SMYD2	B-X
operates	B-X
via	B-X
a	B-X
rapid	B-X
equilibrium	B-X
random	B-X
Bi	B-X
Bi	B-X
mechanism	B-X
at	B-X
a	B-X
rate	B-X
of	B-X
0.048	B-X
±	B-X
0.001	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
,	B-X
with	B-X
K	B-X
(	B-X
M	B-X
)	B-X
s	B-X
for	B-X
AdoMet	B-X
and	B-X
the	B-X
p53	B-X
peptide	B-X
of	B-X
0.031	B-X
±	B-X
0.01	B-X
μM	B-X
and	B-X
0.68	B-X
±	B-X
0.22	B-X
μM	B-X
,	B-X
respectively	B-X
.	B-X
Catalytic	B-X
activity	B-X
was	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
dependent	B-X
on	B-X
the	B-X
GxG	B-X
motif	B-X
in	B-X
the	B-X
S-sequence	B-X
of	B-X
the	B-X
split	B-X
SET	B-X
domain	B-X
,	B-X
as	B-X
a	B-X
G18A/G20A	B-X
double	B-X
mutant	B-X
and	B-X
a	B-X
sequence	B-X
deletion	B-X
within	B-X
the	B-X
conserved	B-X
motif	B-X
impaired	B-X
AdoMet	B-X
binding	B-X
and	B-X
significantly	B-X
decreased	B-X
enzymatic	B-X
activity	B-X
.	B-X
The	B-X
functional	B-X
importance	B-X
of	B-X
other	B-X
SMYD2	B-X
domains	B-X
including	B-X
the	B-X
MYND	B-X
domain	B-X
,	B-X
the	B-X
cysteine-rich	B-X
post-SET	B-X
domain	B-X
,	B-X
and	B-X
the	B-X
C-terminal	B-X
domain	B-X
(	B-X
CTD	B-X
)	B-X
,	B-X
were	B-X
also	B-X
investigated	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrated	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
distinct	B-X
domains	B-X
in	B-X
the	B-X
SMYD	B-X
family	B-X
of	B-X
proteins	B-X
and	B-X
further	B-X
advanced	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
catalytic	B-X
mechanism	B-X
of	B-X
this	B-X
family	B-X
.	B-X

Molecular	O
dynamics	O
and	O
hybrid	O
quantum	O
mechanics	O
/	O
molecular	O
mechanics	O
have	O
been	O
used	O
to	O
investigate	O
the	O
mechanisms	O
of	O
(	O
+	O
)	O
AdoMet	O
methylation	O
of	O
protein	O
-	O
Lys	O
-	O
NH	O
(	O
2	O
)	O
catalyzed	O
by	O
the	O
lysine	O
methyltransferase	O
enzymes	O
:	O
histone	O
lysine	O
monomethyltransferase	O
SET7	B-Protein
/	I-Protein
9	I-Protein
,	O
Rubisco	O
large	O
-	O
subunit	O
dimethyltransferase	O
,	O
viral	O
histone	O
lysine	O
trimethyltransferase	O
,	O
and	O
the	O
Tyr245Phe	O
mutation	O
of	O
SET7	B-Protein
/	I-Protein
9	I-Protein
.	O

At	O
neutrality	O
in	O
aqueous	O
solution	O
,	O
primary	O
amines	O
are	O
protonated	O
.	O
<EOS>	B-X
At	B-X
neutrality	B-X
in	B-X
aqueous	B-X
solution	B-X
,	B-X
primary	B-X
amines	B-X
are	B-X
protonated	B-X
.	B-X
The	B-X
close	B-X
positioning	B-X
of	B-X
two	B-X
positive	B-X
charges	B-X
lowers	B-X
the	B-X
pK	B-X
(	B-X
a	B-X
)	B-X
of	B-X
the	B-X
Lys-NH	B-X
(	B-X
3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
entity	B-X
,	B-X
a	B-X
water	B-X
channel	B-X
appears	B-X
,	B-X
and	B-X
the	B-X
proton	B-X
escapes	B-X
to	B-X
the	B-X
aqueous	B-X
solvent	B-X
;	B-X
then	B-X
the	B-X
reaction	B-X
Enz.Lys-NH	B-X
(	B-X
2	B-X
)	B-X
.	B-X

The	O
enzyme	O
reacts	O
with	O
Lys	O
-	O
NH	O
(	O
3	O
)	O
(	O
+	O
)	O
and	O
(	O
+	O
)	O
AdoMet	O
species	O
to	O
provide	O
an	O
Enz	O
.	O
Lys	O
-	O
NH	O
(	O
3	O
)	O
(	O
+	O
)	O
.	O
(	O
+	O
)	O
AdoMet	O
complex	O
.	O

The	O
close	O
positioning	O
of	O
two	O
positive	O
charges	O
lowers	O
the	O
pK	O
(	O
a	O
)	O
of	O
the	O
Lys	O
-	O
NH	O
(	O
3	O
)	O
(	O
+	O
)	O
entity	O
,	O
a	O
water	O
channel	O
appears	O
,	O
and	O
the	O
proton	O
escapes	O
to	O
the	O
aqueous	O
solvent	O
;	O
then	O
the	O
reaction	O
Enz	O
.	O
Lys	O
-	O
NH	O
(	O
2	O
)	O
.	O
(	O
+	O
)	O
AdoMet	O
-	O
-	O
>	O
Enz	O
.	O
Lys	O
-	O
N	O
(	O
Me	O
)	O
H	O
(	O
2	O
)	O
(	O
+	O
)	O
.	O
AdoHcy	O
occurs	O
.	O

Repeat	O
of	O
the	O
sequence	O
provides	O
dimethylated	O
lysine	O
,	O
and	O
another	O
repeat	O
yields	O
a	O
trimethylated	O
lysine	O
.	O
<EOS>	B-X
Molecular	B-X
dynamics	B-X
and	B-X
hybrid	B-X
quantum	B-X
mechanics/molecular	B-X
mechanics	B-X
have	B-X
been	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
mechanisms	B-X
of	B-X
(	B-X
+	B-X
)	B-X
AdoMet	B-X
methylation	B-X
of	B-X
protein-Lys-NH	B-X
(	B-X
2	B-X
)	B-X
catalyzed	B-X
by	B-X
the	B-X
lysine	B-X
methyltransferase	B-X
enzymes	B-X
:	B-X
histone	B-X
lysine	B-X
monomethyltransferase	B-X
SET7/9	B-X
,	B-X
Rubisco	B-X
large-subunit	B-X
dimethyltransferase	B-X
,	B-X
viral	B-X
histone	B-X
lysine	B-X
trimethyltransferase	B-X
,	B-X
and	B-X
the	B-X
Tyr245Phe	B-X
mutation	B-X
of	B-X
SET7/9	B-X
.	B-X
Repeat	B-X
of	B-X
the	B-X
sequence	B-X
provides	B-X
dimethylated	B-X
lysine	B-X
,	B-X
and	B-X
another	B-X
repeat	B-X
yields	B-X
a	B-X
trimethylated	B-X
lysine	B-X
.	B-X
The	B-X
sequence	B-X
is	B-X
halted	B-X
at	B-X
monomethylation	B-X
when	B-X
the	B-X
conformation	B-X
of	B-X
the	B-X
Enz.Lys-N	B-X
(	B-X
Me	B-X
)	B-X
H	B-X
(	B-X
2	B-X
)	B-X
(	B-X
+	B-X
)	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
reactions	B-X
stops	B-X
at	B-X
dimethylation	B-X
if	B-X
the	B-X
conformation	B-X
of	B-X
Enz.Lys-N	B-X
(	B-X
Me	B-X
)	B-X
(	B-X
2	B-X
)	B-X
H	B-X
(	B-X
+	B-X
)	B-X
.	B-X

The	O
sequence	O
is	O
halted	O
at	O
monomethylation	O
when	O
the	O
conformation	O
of	O
the	O
Enz	O
.	O
Lys	O
-	O
N	O
(	O
Me	O
)	O
H	O
(	O
2	O
)	O
(	O
+	O
)	O
.	O
(	O
+	O
)	O
AdoMet	O
has	O
the	O
methyl	O
positioned	O
to	O
block	O
formation	O
of	O
a	O
water	O
channel	O
.	O

The	O
sequence	O
of	O
reactions	O
stops	O
at	O
dimethylation	O
if	O
the	O
conformation	O
of	O
Enz	O
.	O
Lys	O
-	O
N	O
(	O
Me	O
)	O
(	O
2	O
)	O
H	O
(	O
+	O
)	O
.	O
(	O
+	O
)	O
AdoMet	O
has	O
a	O
methyl	O
in	O
position	O
,	O
which	O
forbids	O
the	O
formation	O
of	O
the	O
water	O
channel	O
.	O

Cdc34p	B-Protein
ubiquitin	B-Protein
-	O
conjugating	O
enzyme	O
is	O
a	O
component	O
of	O
the	O
tombusvirus	O
replicase	O
complex	O
and	O
ubiquitinates	O
p33	B-Protein
replication	O
protein	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
Tomato	B-X
bushy	B-X
stunt	B-X
virus	B-X
(	B-X
TBSV	B-X
)	B-X
replication	B-X
proteins	B-X
in	B-X
a	B-X
genome-wide	B-X
scale	B-X
,	B-X
we	B-X
have	B-X
used	B-X
a	B-X
yeast	B-X
(	B-X
Saccharomyces	B-X
cerevisiae	B-X
)	B-X
proteome	B-X
microarray	B-X
carrying	B-X
4,088	B-X
purified	B-X
proteins	B-X
.	B-X
This	B-X
approach	B-X
led	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
58	B-X
yeast	B-X
proteins	B-X
that	B-X
interacted	B-X
with	B-X
p33	B-X
replication	B-X
protein	B-X
.	B-X
The	B-X
identified	B-X
host	B-X
proteins	B-X
included	B-X
protein	B-X
chaperones	B-X
,	B-X
ubiquitin-associated	B-X
proteins	B-X
,	B-X
translation	B-X
factors	B-X
,	B-X
RNA-modifying	B-X
enzymes	B-X
,	B-X
and	B-X
other	B-X
proteins	B-X
with	B-X
yet-unknown	B-X
functions	B-X
.	B-X
We	B-X
confirmed	B-X
that	B-X
19	B-X
of	B-X
the	B-X
identified	B-X
host	B-X
proteins	B-X
bound	B-X
to	B-X
p33	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
a	B-X
split-ubiquitin-based	B-X
two-hybrid	B-X
assay	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
Cdc34p	B-X
E2	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
one	B-X
of	B-X
the	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
p33	B-X
,	B-X
revealed	B-X
that	B-X
Cdc34p	B-X
is	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
purified	B-X
viral	B-X
replicase	B-X
.	B-X
Downregulation	B-X
of	B-X
Cdc34p	B-X
expression	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
supports	B-X
replication	B-X
of	B-X
a	B-X
TBSV	B-X
replicon	B-X
RNA	B-X
(	B-X
repRNA	B-X
)	B-X
,	B-X
reduced	B-X
repRNA	B-X
accumulation	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
tombusvirus	B-X
replicase	B-X
by	B-X
up	B-X
to	B-X
fivefold	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
Cdc34p	B-X
,	B-X
but	B-X
not	B-X
that	B-X
of	B-X
an	B-X
E2-defective	B-X
mutant	B-X
of	B-X
Cdc34p	B-X
,	B-X
increased	B-X
repRNA	B-X
accumulation	B-X
,	B-X
suggesting	B-X
a	B-X
significant	B-X
role	B-X
for	B-X
the	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
function	B-X
of	B-X
Cdc34p	B-X
in	B-X
TBSV	B-X
replication	B-X
.	B-X
Also	B-X
,	B-X
Cdc34p	B-X
was	B-X
able	B-X
to	B-X
ubiquitinate	B-X
p33	B-X
in	B-X
vitro	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
p33	B-X
becomes	B-X
ubiquitinated	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ubiquitination	B-X
of	B-X
p33	B-X
likely	B-X
alters	B-X
its	B-X
function	B-X
or	B-X
affects	B-X
the	B-X
recruitment	B-X
of	B-X
host	B-X
factors	B-X
during	B-X
TBSV	B-X
replication	B-X
.	B-X

To	O
identify	O
host	O
proteins	O
interacting	O
with	O
Tomato	O
bushy	O
stunt	O
virus	O
(	O
TBSV	O
)	O
replication	O
proteins	O
in	O
a	O
genome	O
-	O
wide	O
scale	O
,	O
we	O
have	O
used	O
a	O
yeast	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
proteome	O
microarray	O
carrying	O
4	O
,	O
088	O
purified	O
proteins	O
.	O

This	O
approach	O
led	O
to	O
the	O
identification	O
of	O
58	O
yeast	O
proteins	O
that	O
interacted	O
with	O
p33	B-Protein
replication	O
protein	O
.	O

The	O
identified	O
host	O
proteins	O
included	O
protein	O
chaperones	O
,	O
ubiquitin	B-Protein
-	O
associated	O
proteins	O
,	O
translation	O
factors	O
,	O
RNA	O
-	O
modifying	O
enzymes	O
,	O
and	O
other	O
proteins	O
with	O
yet	O
-	O
unknown	O
functions	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
Tomato	B-X
bushy	B-X
stunt	B-X
virus	B-X
(	B-X
TBSV	B-X
)	B-X
replication	B-X
proteins	B-X
in	B-X
a	B-X
genome-wide	B-X
scale	B-X
,	B-X
we	B-X
have	B-X
used	B-X
a	B-X
yeast	B-X
(	B-X
Saccharomyces	B-X
cerevisiae	B-X
)	B-X
proteome	B-X
microarray	B-X
carrying	B-X
4,088	B-X
purified	B-X
proteins	B-X
.	B-X
This	B-X
approach	B-X
led	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
58	B-X
yeast	B-X
proteins	B-X
that	B-X
interacted	B-X
with	B-X
p33	B-X
replication	B-X
protein	B-X
.	B-X
The	B-X
identified	B-X
host	B-X
proteins	B-X
included	B-X
protein	B-X
chaperones	B-X
,	B-X
ubiquitin-associated	B-X
proteins	B-X
,	B-X
translation	B-X
factors	B-X
,	B-X
RNA-modifying	B-X
enzymes	B-X
,	B-X
and	B-X
other	B-X
proteins	B-X
with	B-X
yet-unknown	B-X
functions	B-X
.	B-X
We	B-X
confirmed	B-X
that	B-X
19	B-X
of	B-X
the	B-X
identified	B-X
host	B-X
proteins	B-X
bound	B-X
to	B-X
p33	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
a	B-X
split-ubiquitin-based	B-X
two-hybrid	B-X
assay	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
Cdc34p	B-X
E2	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
one	B-X
of	B-X
the	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
p33	B-X
,	B-X
revealed	B-X
that	B-X
Cdc34p	B-X
is	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
purified	B-X
viral	B-X
replicase	B-X
.	B-X
Downregulation	B-X
of	B-X
Cdc34p	B-X
expression	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
supports	B-X
replication	B-X
of	B-X
a	B-X
TBSV	B-X
replicon	B-X
RNA	B-X
(	B-X
repRNA	B-X
)	B-X
,	B-X
reduced	B-X
repRNA	B-X
accumulation	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
tombusvirus	B-X
replicase	B-X
by	B-X
up	B-X
to	B-X
fivefold	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
Cdc34p	B-X
,	B-X
but	B-X
not	B-X
that	B-X
of	B-X
an	B-X
E2-defective	B-X
mutant	B-X
of	B-X
Cdc34p	B-X
,	B-X
increased	B-X
repRNA	B-X
accumulation	B-X
,	B-X
suggesting	B-X
a	B-X
significant	B-X
role	B-X
for	B-X
the	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
function	B-X
of	B-X
Cdc34p	B-X
in	B-X
TBSV	B-X
replication	B-X
.	B-X
Also	B-X
,	B-X
Cdc34p	B-X
was	B-X
able	B-X
to	B-X
ubiquitinate	B-X
p33	B-X
in	B-X
vitro	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
p33	B-X
becomes	B-X
ubiquitinated	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ubiquitination	B-X
of	B-X
p33	B-X
likely	B-X
alters	B-X
its	B-X
function	B-X
or	B-X
affects	B-X
the	B-X
recruitment	B-X
of	B-X
host	B-X
factors	B-X
during	B-X
TBSV	B-X
replication	B-X
.	B-X

We	O
confirmed	O
that	O
19	O
of	O
the	O
identified	O
host	O
proteins	O
bound	O
to	O
p33	B-Protein
in	O
vitro	O
or	O
in	O
a	O
split	O
-	O
ubiquitin	B-Protein
-	O
based	O
two	O
-	O
hybrid	O
assay	O
.	O

Further	O
analysis	O
of	O
Cdc34p	B-Protein
E2	O
ubiquitin	B-Protein
-	O
conjugating	O
enzyme	O
,	O
which	O
is	O
one	O
of	O
the	O
host	O
proteins	O
interacting	O
with	O
p33	B-Protein
,	O
revealed	O
that	O
Cdc34p	B-Protein
is	O
a	O
novel	O
component	O
of	O
the	O
purified	O
viral	O
replicase	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
Tomato	B-X
bushy	B-X
stunt	B-X
virus	B-X
(	B-X
TBSV	B-X
)	B-X
replication	B-X
proteins	B-X
in	B-X
a	B-X
genome-wide	B-X
scale	B-X
,	B-X
we	B-X
have	B-X
used	B-X
a	B-X
yeast	B-X
(	B-X
Saccharomyces	B-X
cerevisiae	B-X
)	B-X
proteome	B-X
microarray	B-X
carrying	B-X
4,088	B-X
purified	B-X
proteins	B-X
.	B-X
This	B-X
approach	B-X
led	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
58	B-X
yeast	B-X
proteins	B-X
that	B-X
interacted	B-X
with	B-X
p33	B-X
replication	B-X
protein	B-X
.	B-X
The	B-X
identified	B-X
host	B-X
proteins	B-X
included	B-X
protein	B-X
chaperones	B-X
,	B-X
ubiquitin-associated	B-X
proteins	B-X
,	B-X
translation	B-X
factors	B-X
,	B-X
RNA-modifying	B-X
enzymes	B-X
,	B-X
and	B-X
other	B-X
proteins	B-X
with	B-X
yet-unknown	B-X
functions	B-X
.	B-X
We	B-X
confirmed	B-X
that	B-X
19	B-X
of	B-X
the	B-X
identified	B-X
host	B-X
proteins	B-X
bound	B-X
to	B-X
p33	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
a	B-X
split-ubiquitin-based	B-X
two-hybrid	B-X
assay	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
Cdc34p	B-X
E2	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
one	B-X
of	B-X
the	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
p33	B-X
,	B-X
revealed	B-X
that	B-X
Cdc34p	B-X
is	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
purified	B-X
viral	B-X
replicase	B-X
.	B-X
Downregulation	B-X
of	B-X
Cdc34p	B-X
expression	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
supports	B-X
replication	B-X
of	B-X
a	B-X
TBSV	B-X
replicon	B-X
RNA	B-X
(	B-X
repRNA	B-X
)	B-X
,	B-X
reduced	B-X
repRNA	B-X
accumulation	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
tombusvirus	B-X
replicase	B-X
by	B-X
up	B-X
to	B-X
fivefold	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
Cdc34p	B-X
,	B-X
but	B-X
not	B-X
that	B-X
of	B-X
an	B-X
E2-defective	B-X
mutant	B-X
of	B-X
Cdc34p	B-X
,	B-X
increased	B-X
repRNA	B-X
accumulation	B-X
,	B-X
suggesting	B-X
a	B-X
significant	B-X
role	B-X
for	B-X
the	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
function	B-X
of	B-X
Cdc34p	B-X
in	B-X
TBSV	B-X
replication	B-X
.	B-X
Also	B-X
,	B-X
Cdc34p	B-X
was	B-X
able	B-X
to	B-X
ubiquitinate	B-X
p33	B-X
in	B-X
vitro	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
p33	B-X
becomes	B-X
ubiquitinated	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ubiquitination	B-X
of	B-X
p33	B-X
likely	B-X
alters	B-X
its	B-X
function	B-X
or	B-X
affects	B-X
the	B-X
recruitment	B-X
of	B-X
host	B-X
factors	B-X
during	B-X
TBSV	B-X
replication	B-X
.	B-X

Downregulation	O
of	O
Cdc34p	B-Protein
expression	O
in	O
yeast	O
,	O
which	O
supports	O
replication	O
of	O
a	O
TBSV	O
replicon	O
RNA	O
(	O
repRNA	O
)	O
,	O
reduced	O
repRNA	O
accumulation	O
and	O
the	O
activity	O
of	O
the	O
tombusvirus	O
replicase	O
by	O
up	O
to	O
fivefold	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
Tomato	B-X
bushy	B-X
stunt	B-X
virus	B-X
(	B-X
TBSV	B-X
)	B-X
replication	B-X
proteins	B-X
in	B-X
a	B-X
genome-wide	B-X
scale	B-X
,	B-X
we	B-X
have	B-X
used	B-X
a	B-X
yeast	B-X
(	B-X
Saccharomyces	B-X
cerevisiae	B-X
)	B-X
proteome	B-X
microarray	B-X
carrying	B-X
4,088	B-X
purified	B-X
proteins	B-X
.	B-X
This	B-X
approach	B-X
led	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
58	B-X
yeast	B-X
proteins	B-X
that	B-X
interacted	B-X
with	B-X
p33	B-X
replication	B-X
protein	B-X
.	B-X
The	B-X
identified	B-X
host	B-X
proteins	B-X
included	B-X
protein	B-X
chaperones	B-X
,	B-X
ubiquitin-associated	B-X
proteins	B-X
,	B-X
translation	B-X
factors	B-X
,	B-X
RNA-modifying	B-X
enzymes	B-X
,	B-X
and	B-X
other	B-X
proteins	B-X
with	B-X
yet-unknown	B-X
functions	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
Cdc34p	B-X
E2	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
one	B-X
of	B-X
the	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
p33	B-X
,	B-X
revealed	B-X
that	B-X
Cdc34p	B-X
is	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
purified	B-X
viral	B-X
replicase	B-X
.	B-X
Downregulation	B-X
of	B-X
Cdc34p	B-X
expression	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
supports	B-X
replication	B-X
of	B-X
a	B-X
TBSV	B-X
replicon	B-X
RNA	B-X
(	B-X
repRNA	B-X
)	B-X
,	B-X
reduced	B-X
repRNA	B-X
accumulation	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
tombusvirus	B-X
replicase	B-X
by	B-X
up	B-X
to	B-X
fivefold	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
Cdc34p	B-X
,	B-X
but	B-X
not	B-X
that	B-X
of	B-X
an	B-X
E2-defective	B-X
mutant	B-X
of	B-X
Cdc34p	B-X
,	B-X
increased	B-X
repRNA	B-X
accumulation	B-X
,	B-X
suggesting	B-X
a	B-X
significant	B-X
role	B-X
for	B-X
the	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
function	B-X
of	B-X
Cdc34p	B-X
in	B-X
TBSV	B-X
replication	B-X
.	B-X
Also	B-X
,	B-X
Cdc34p	B-X
was	B-X
able	B-X
to	B-X
ubiquitinate	B-X
p33	B-X
in	B-X
vitro	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ubiquitination	B-X
of	B-X
p33	B-X
likely	B-X
alters	B-X
its	B-X
function	B-X
or	B-X
affects	B-X
the	B-X
recruitment	B-X
of	B-X
host	B-X
factors	B-X
during	B-X
TBSV	B-X
replication	B-X
.	B-X

Overexpression	O
of	O
wild	O
-	O
type	O
Cdc34p	B-Protein
,	O
but	O
not	O
that	O
of	O
an	O
E2	O
-	O
defective	O
mutant	O
of	O
Cdc34p	B-Protein
,	O
increased	O
repRNA	O
accumulation	O
,	O
suggesting	O
a	O
significant	O
role	O
for	O
the	O
ubiquitin	B-Protein
-	O
conjugating	O
enzyme	O
function	O
of	O
Cdc34p	B-Protein
in	O
TBSV	O
replication	O
.	O
<EOS>	B-X
Cyclin-dependent	B-X
kinase	B-X
inhibitors	B-X
(	B-X
CKIs	B-X
)	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
controlling	B-X
the	B-X
eukaryotic	B-X
cell	B-X
cycle	B-X
by	B-X
coordinating	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
Understanding	B-X
the	B-X
roles	B-X
of	B-X
CKIs	B-X
requires	B-X
knowledge	B-X
of	B-X
how	B-X
they	B-X
are	B-X
regulated	B-X
both	B-X
through	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
in	B-X
response	B-X
to	B-X
extracellular	B-X
signals	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
yeast	B-X
CKI	B-X
,	B-X
Far1p	B-X
,	B-X
is	B-X
controlled	B-X
by	B-X
ubiquitin-dependent	B-X
proteolysis	B-X
.	B-X
Wild-type	B-X
Far1p	B-X
was	B-X
stable	B-X
only	B-X
in	B-X
the	B-X
G1	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X
Biochemical	B-X
and	B-X
genetic	B-X
evidence	B-X
indicate	B-X
that	B-X
its	B-X
degradation	B-X
required	B-X
the	B-X
components	B-X
of	B-X
the	B-X
G1-S	B-X
ubiquitination	B-X
system	B-X
,	B-X
Cdc34p	B-X
,	B-X
Cdc4p	B-X
,	B-X
Cdc53p	B-X
,	B-X
and	B-X
Skp1p	B-X
.	B-X
We	B-X
isolated	B-X
a	B-X
mutant	B-X
form	B-X
of	B-X
Far1p	B-X
(	B-X
Far1p-22	B-X
)	B-X
that	B-X
was	B-X
able	B-X
to	B-X
induce	B-X
cell	B-X
cycle	B-X
arrest	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
alpha-factor	B-X
.	B-X
Wild-type	B-X
Far1p	B-X
,	B-X
but	B-X
not	B-X
Far1-22p	B-X
,	B-X
was	B-X
readily	B-X
ubiquitinated	B-X
in	B-X
vitro	B-X
in	B-X
a	B-X
CDC34-	B-X
and	B-X
CDC4-dependent	B-X
manner	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
that	B-X
Far1p	B-X
is	B-X
regulated	B-X
by	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
and	B-X
suggest	B-X
that	B-X
phosphorylation	B-X
of	B-X
Far1p	B-X
by	B-X
the	B-X
Cdc28p-Clnp	B-X
kinase	B-X
is	B-X
part	B-X
of	B-X
the	B-X
recognition	B-X
signal	B-X
for	B-X
ubiquitination	B-X
.	B-X

Also	O
,	O
Cdc34p	B-Protein
was	O
able	O
to	O
ubiquitinate	O
p33	B-Protein
in	O
vitro	O
.	O
<EOS>	B-X
This	B-X
approach	B-X
led	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
58	B-X
yeast	B-X
proteins	B-X
that	B-X
interacted	B-X
with	B-X
p33	B-X
replication	B-X
protein	B-X
.	B-X
We	B-X
confirmed	B-X
that	B-X
19	B-X
of	B-X
the	B-X
identified	B-X
host	B-X
proteins	B-X
bound	B-X
to	B-X
p33	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
a	B-X
split-ubiquitin-based	B-X
two-hybrid	B-X
assay	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
Cdc34p	B-X
E2	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
one	B-X
of	B-X
the	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
p33	B-X
,	B-X
revealed	B-X
that	B-X
Cdc34p	B-X
is	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
purified	B-X
viral	B-X
replicase	B-X
.	B-X
Downregulation	B-X
of	B-X
Cdc34p	B-X
expression	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
supports	B-X
replication	B-X
of	B-X
a	B-X
TBSV	B-X
replicon	B-X
RNA	B-X
(	B-X
repRNA	B-X
)	B-X
,	B-X
reduced	B-X
repRNA	B-X
accumulation	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
tombusvirus	B-X
replicase	B-X
by	B-X
up	B-X
to	B-X
fivefold	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
Cdc34p	B-X
,	B-X
but	B-X
not	B-X
that	B-X
of	B-X
an	B-X
E2-defective	B-X
mutant	B-X
of	B-X
Cdc34p	B-X
,	B-X
increased	B-X
repRNA	B-X
accumulation	B-X
,	B-X
suggesting	B-X
a	B-X
significant	B-X
role	B-X
for	B-X
the	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
function	B-X
of	B-X
Cdc34p	B-X
in	B-X
TBSV	B-X
replication	B-X
.	B-X
Also	B-X
,	B-X
Cdc34p	B-X
was	B-X
able	B-X
to	B-X
ubiquitinate	B-X
p33	B-X
in	B-X
vitro	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
p33	B-X
becomes	B-X
ubiquitinated	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ubiquitination	B-X
of	B-X
p33	B-X
likely	B-X
alters	B-X
its	B-X
function	B-X
or	B-X
affects	B-X
the	B-X
recruitment	B-X
of	B-X
host	B-X
factors	B-X
during	B-X
TBSV	B-X
replication	B-X
.	B-X

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
p33	B-Protein
becomes	O
ubiquitinated	O
in	O
vivo	O
.	O
<EOS>	B-X
This	B-X
approach	B-X
led	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
58	B-X
yeast	B-X
proteins	B-X
that	B-X
interacted	B-X
with	B-X
p33	B-X
replication	B-X
protein	B-X
.	B-X
We	B-X
confirmed	B-X
that	B-X
19	B-X
of	B-X
the	B-X
identified	B-X
host	B-X
proteins	B-X
bound	B-X
to	B-X
p33	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
a	B-X
split-ubiquitin-based	B-X
two-hybrid	B-X
assay	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
Cdc34p	B-X
E2	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
one	B-X
of	B-X
the	B-X
host	B-X
proteins	B-X
interacting	B-X
with	B-X
p33	B-X
,	B-X
revealed	B-X
that	B-X
Cdc34p	B-X
is	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
purified	B-X
viral	B-X
replicase	B-X
.	B-X
Also	B-X
,	B-X
Cdc34p	B-X
was	B-X
able	B-X
to	B-X
ubiquitinate	B-X
p33	B-X
in	B-X
vitro	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
p33	B-X
becomes	B-X
ubiquitinated	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ubiquitination	B-X
of	B-X
p33	B-X
likely	B-X
alters	B-X
its	B-X
function	B-X
or	B-X
affects	B-X
the	B-X
recruitment	B-X
of	B-X
host	B-X
factors	B-X
during	B-X
TBSV	B-X
replication	B-X
.	B-X

We	O
propose	O
that	O
ubiquitination	O
of	O
p33	B-Protein
likely	O
alters	O
its	O
function	O
or	O
affects	O
the	O
recruitment	O
of	O
host	O
factors	O
during	O
TBSV	O
replication	O
.	O
<EOS>	B-X
Positive-strand	B-X
RNA	B-X
viruses	B-X
build	B-X
large	B-X
viral	B-X
replication	B-X
organelles	B-X
(	B-X
VROs	B-X
)	B-X
with	B-X
the	B-X
help	B-X
of	B-X
coopted	B-X
host	B-X
factors	B-X
.	B-X
Previous	B-X
works	B-X
on	B-X
tomato	B-X
bushy	B-X
stunt	B-X
virus	B-X
(	B-X
TBSV	B-X
)	B-X
showed	B-X
that	B-X
the	B-X
p33	B-X
replication	B-X
protein	B-X
subverts	B-X
the	B-X
actin	B-X
cytoskeleton	B-X
by	B-X
sequestering	B-X
the	B-X
actin	B-X
depolymerization	B-X
factor	B-X
,	B-X
cofilin	B-X
,	B-X
to	B-X
reduce	B-X
actin	B-X
filament	B-X
disassembly	B-X
and	B-X
stabilize	B-X
the	B-X
actin	B-X
filaments	B-X
.	B-X
Then	B-X
,	B-X
TBSV	B-X
utilizes	B-X
the	B-X
stable	B-X
actin	B-X
filaments	B-X
as	B-X
``	B-X
trafficking	B-X
highways	B-X
''	B-X
to	B-X
deliver	B-X
proviral	B-X
host	B-X
factors	B-X
into	B-X
the	B-X
protective	B-X
VROs	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
cellular	B-X
intrinsic	B-X
restriction	B-X
factors	B-X
(	B-X
CIRFs	B-X
)	B-X
also	B-X
use	B-X
the	B-X
actin	B-X
network	B-X
to	B-X
reach	B-X
VROs	B-X
and	B-X
inhibit	B-X
viral	B-X
replication	B-X
.	B-X

O6	B-Protein
-	I-Protein
Methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
-	I-Protein
methyltransferase	I-Protein
in	O
recurring	O
anaplastic	O
ependymomas	O
:	O
PCR	O
and	O
immunohistochemistry	O
.	O
<EOS>	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-Methylguanine-DNA-Methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
is	B-X
a	B-X
DNA	B-X
repair	B-X
protein	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
chemosensitivity	B-X
predictor	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
MGMT	B-X
gene	B-X
promoter	B-X
methylation	B-X
and	B-X
the	B-X
immunohistochemical	B-X
MGMT	B-X
protein	B-X
expression	B-X
in	B-X
12	B-X
recurrent	B-X
anaplastic	B-X
ependymomas	B-X
affecting	B-X
children	B-X
.	B-X
Our	B-X
purpose	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
rationale	B-X
of	B-X
the	B-X
administration	B-X
of	B-X
alkylating	B-X
agents	B-X
to	B-X
children	B-X
affected	B-X
by	B-X
recurrent	B-X
anaplastic	B-X
ependymomas	B-X
.	B-X
All	B-X
ependymomas	B-X
lacked	B-X
MGMT	B-X
promoter	B-X
hypermethylation	B-X
and	B-X
9	B-X
(	B-X
75	B-X
%	B-X
)	B-X
showed	B-X
high	B-X
MGMT	B-X
protein	B-X
expression	B-X
(	B-X
>	B-X
50	B-X
%	B-X
tumoral	B-X
cells	B-X
)	B-X
.	B-X
These	B-X
results	B-X
may	B-X
indicate	B-X
MGMT	B-X
as	B-X
a	B-X
factor	B-X
of	B-X
chemoresistance	B-X
to	B-X
alkylating	B-X
drugs	B-X
in	B-X
anaplastic	B-X
ependymomas	B-X
and	B-X
support	B-X
the	B-X
uncertainties	B-X
regarding	B-X
the	B-X
actual	B-X
benefit	B-X
of	B-X
chemotherapy	B-X
for	B-X
patients	B-X
with	B-X
anaplastic	B-X
ependymomas	B-X
.	B-X

Ependymomas	O
are	O
the	O
third	O
most	O
common	O
brain	O
tumor	O
in	O
children	O
.	O
<EOS>	B-X
Ependymomas	B-X
are	B-X
chemotherapy-resistant	B-X
brain	B-X
tumours	B-X
,	B-X
which	B-X
,	B-X
despite	B-X
genomic	B-X
sequencing	B-X
,	B-X
lack	B-X
effective	B-X
molecular	B-X
targets	B-X
.	B-X
The	B-X
most	B-X
common	B-X
and	B-X
aggressive	B-X
subgroup	B-X
,	B-X
posterior	B-X
fossa	B-X
ependymoma	B-X
group	B-X
A	B-X
(	B-X
PF-EPN-A	B-X
)	B-X
,	B-X
occurs	B-X
in	B-X
young	B-X
children	B-X
and	B-X
appears	B-X
to	B-X
lack	B-X
recurrent	B-X
somatic	B-X
mutations	B-X
.	B-X
Brain	B-X
tumors	B-X
are	B-X
the	B-X
leading	B-X
cause	B-X
of	B-X
cancer	B-X
death	B-X
in	B-X
children	B-X
,	B-X
with	B-X
ependymoma	B-X
being	B-X
the	B-X
third	B-X
most	B-X
common	B-X
and	B-X
posing	B-X
a	B-X
significant	B-X
clinical	B-X
burden	B-X
.	B-X
Until	B-X
recently	B-X
,	B-X
ependymoma	B-X
research	B-X
was	B-X
hindered	B-X
by	B-X
the	B-X
small	B-X
number	B-X
of	B-X
tumors	B-X
available	B-X
for	B-X
study	B-X
,	B-X
low	B-X
resolution	B-X
of	B-X
cytogenetic	B-X
techniques	B-X
,	B-X
and	B-X
lack	B-X
of	B-X
cell	B-X
lines	B-X
and	B-X
animal	B-X
models	B-X
.	B-X
Ependymoma	B-X
heterogeneity	B-X
,	B-X
which	B-X
manifests	B-X
as	B-X
variations	B-X
in	B-X
tumor	B-X
location	B-X
,	B-X
patient	B-X
age	B-X
,	B-X
histological	B-X
grade	B-X
,	B-X
and	B-X
clinical	B-X
behavior	B-X
,	B-X
together	B-X
with	B-X
the	B-X
observation	B-X
of	B-X
a	B-X
balanced	B-X
genomic	B-X
profile	B-X
in	B-X
up	B-X
to	B-X
50	B-X
%	B-X
of	B-X
cases	B-X
,	B-X
presents	B-X
additional	B-X
challenges	B-X
in	B-X
understanding	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
this	B-X
disease	B-X
.	B-X
Despite	B-X
these	B-X
difficulties	B-X
,	B-X
we	B-X
have	B-X
made	B-X
significant	B-X
headway	B-X
in	B-X
the	B-X
past	B-X
decade	B-X
in	B-X
identifying	B-X
the	B-X
genetic	B-X
alterations	B-X
and	B-X
pathways	B-X
involved	B-X
in	B-X
ependymoma	B-X
tumorigenesis	B-X
through	B-X
collaborative	B-X
efforts	B-X
and	B-X
the	B-X
application	B-X
of	B-X
microarray-based	B-X
genetic	B-X
(	B-X
copy	B-X
number	B-X
)	B-X
and	B-X
transcriptome	B-X
profiling	B-X
platforms	B-X
.	B-X

The	O
post	O
surgical	O
management	O
is	O
controversial	O
.	O
<EOS>	B-X
The	B-X
optimal	B-X
management	B-X
of	B-X
external	B-X
ventricular	B-X
drains	B-X
(	B-X
EVD	B-X
)	B-X
in	B-X
the	B-X
setting	B-X
of	B-X
acute	B-X
brain	B-X
injury	B-X
remains	B-X
controversial	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
determine	B-X
whether	B-X
there	B-X
are	B-X
optimal	B-X
management	B-X
approaches	B-X
based	B-X
on	B-X
the	B-X
current	B-X
evidence	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
review	B-X
the	B-X
current	B-X
knowledge	B-X
on	B-X
the	B-X
nomenclature	B-X
,	B-X
etiology	B-X
,	B-X
pathophysiology	B-X
,	B-X
clinical	B-X
presentation	B-X
,	B-X
diagnostic	B-X
workup	B-X
,	B-X
and	B-X
risk	B-X
stratification	B-X
of	B-X
post-ERCP	B-X
pancreatitis	B-X
(	B-X
PEP	B-X
)	B-X
.	B-X
A	B-X
structured	B-X
search	B-X
in	B-X
PubMed	B-X
and	B-X
Scopus	B-X
databases	B-X
was	B-X
performed	B-X
using	B-X
search	B-X
terms	B-X
related	B-X
to	B-X
the	B-X
subject	B-X
of	B-X
diagnosis	B-X
,	B-X
pathophysiology	B-X
,	B-X
risk	B-X
stratification	B-X
of	B-X
post-ERCP	B-X
pancreatitis	B-X
,	B-X
including	B-X
full	B-X
text	B-X
articles	B-X
and	B-X
abstracts	B-X
in	B-X
the	B-X
English	B-X
language	B-X
.	B-X
Different	B-X
patient-related	B-X
risk	B-X
factors	B-X
can	B-X
help	B-X
predict	B-X
post-ERCP	B-X
pancreatitis	B-X
;	B-X
diagnosis	B-X
depends	B-X
on	B-X
clinical	B-X
presentation	B-X
,	B-X
imaging	B-X
and	B-X
laboratory	B-X
investigations	B-X
.	B-X
As	B-X
an	B-X
outpatient	B-X
procedure	B-X
,	B-X
post-ERCP	B-X
pancreatitis	B-X
may	B-X
be	B-X
safe	B-X
in	B-X
a	B-X
selected	B-X
group	B-X
of	B-X
low-risk	B-X
patients	B-X
.	B-X
Further	B-X
investigation	B-X
of	B-X
the	B-X
etio-pathogenesis	B-X
of	B-X
post-ERCP	B-X
pancreatitis	B-X
is	B-X
required	B-X
in	B-X
order	B-X
to	B-X
improve	B-X
diagnosis	B-X
and	B-X
treatment	B-X
.	B-X
Early	B-X
identification	B-X
and	B-X
severity	B-X
stratification	B-X
of	B-X
post-ERCP	B-X
pancreatitis	B-X
greatly	B-X
affects	B-X
the	B-X
patient	B-X
's	B-X
outcome	B-X
.	B-X
More	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
clarify	B-X
early	B-X
and	B-X
definite	B-X
diagnosis	B-X
,	B-X
risk	B-X
and	B-X
severity	B-X
stratification	B-X
,	B-X
as	B-X
well	B-X
as	B-X
treatment	B-X
of	B-X
post-ERCP	B-X
pancreatitis	B-X
.	B-X

There	O
are	O
no	O
convincing	O
data	O
on	O
an	O
effective	O
role	O
for	O
chemotherapy	O
.	O

O	B-Protein
(	I-Protein
6	I-Protein
)	I-Protein
-	I-Protein
Methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
-	I-Protein
Methyltransferase	I-Protein
(	O
MGMT	B-Protein
)	O
is	O
a	O
DNA	O
repair	O
protein	O
considered	O
to	O
be	O
a	O
chemosensitivity	O
predictor	O
.	O

Hypermethylation	O
of	O
the	O
MGMT	B-Protein
gene	O
promoter	O
is	O
an	O
important	O
cause	O
of	O
MGMT	B-Protein
inactivation	O
.	O
<EOS>	B-X
GBMs	B-X
are	B-X
characterized	B-X
by	B-X
large	B-X
and	B-X
small	B-X
alterations	B-X
in	B-X
genes	B-X
that	B-X
control	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
invasion	B-X
.	B-X
Epigenetic	B-X
alterations	B-X
also	B-X
affect	B-X
the	B-X
expression	B-X
of	B-X
cancer	B-X
genes	B-X
,	B-X
either	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
genetic	B-X
mechanisms	B-X
.	B-X
The	B-X
current	B-X
evidence	B-X
suggests	B-X
that	B-X
hypermethylation	B-X
of	B-X
promoter	B-X
CpG	B-X
islands	B-X
is	B-X
a	B-X
common	B-X
epigenetic	B-X
event	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
Epigenetic	B-X
alterations	B-X
are	B-X
important	B-X
in	B-X
the	B-X
molecular	B-X
pathology	B-X
of	B-X
GBM	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
very	B-X
limited	B-X
data	B-X
about	B-X
these	B-X
epigenetic	B-X
alterations	B-X
in	B-X
GBM	B-X
.	B-X
Alterations	B-X
in	B-X
promoter	B-X
methylations	B-X
are	B-X
important	B-X
to	B-X
understand	B-X
because	B-X
histone	B-X
deacetylases	B-X
are	B-X
targets	B-X
for	B-X
drugs	B-X
that	B-X
are	B-X
in	B-X
clinical	B-X
trial	B-X
for	B-X
GBMs	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
current	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
whether	B-X
the	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
putative	B-X
tumor	B-X
suppressor	B-X
genes	B-X
was	B-X
involved	B-X
in	B-X
GBM	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
methylation	B-X
status	B-X
at	B-X
the	B-X
promoter	B-X
regions	B-X
of	B-X
GATA6	B-X
,	B-X
MGMT	B-X
,	B-X
and	B-X
FHIT	B-X
using	B-X
the	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
in	B-X
61	B-X
primary	B-X
GBMs	B-X
.	B-X
Our	B-X
results	B-X
reveal	B-X
that	B-X
there	B-X
is	B-X
no	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
FHIT	B-X
in	B-X
the	B-X
examined	B-X
GBM	B-X
tissue	B-X
specimens	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
GATA6	B-X
and	B-X
MGMT	B-X
was	B-X
detected	B-X
in	B-X
42.8	B-X
and	B-X
11.11	B-X
%	B-X
of	B-X
GBMs	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
MGMT	B-X
promoter	B-X
hypermethylation	B-X
was	B-X
low	B-X
in	B-X
the	B-X
group	B-X
of	B-X
patients	B-X
we	B-X
evaluated	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
demonstrates	B-X
that	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
MGMT	B-X
is	B-X
a	B-X
common	B-X
event	B-X
in	B-X
GBMs	B-X
,	B-X
whereas	B-X
GATA6	B-X
is	B-X
epigenetically	B-X
affected	B-X
in	B-X
GBMs	B-X
.	B-X
Furthermore	B-X
,	B-X
inactivation	B-X
of	B-X
FHIT	B-X
by	B-X
epigenetic	B-X
mechanisms	B-X
in	B-X
GBM	B-X
may	B-X
not	B-X
be	B-X
associated	B-X
with	B-X
brain	B-X
tumorigenesis	B-X
.	B-X

We	O
evaluated	O
the	O
MGMT	B-Protein
gene	O
promoter	O
methylation	O
and	O
the	O
immunohistochemical	O
MGMT	B-Protein
protein	O
expression	O
in	O
12	O
recurrent	O
anaplastic	O
ependymomas	O
affecting	O
children	O
.	O
<EOS>	B-X
Ependymomas	B-X
are	B-X
the	B-X
third	B-X
most	B-X
common	B-X
brain	B-X
tumor	B-X
in	B-X
children	B-X
.	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-Methylguanine-DNA-Methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
is	B-X
a	B-X
DNA	B-X
repair	B-X
protein	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
chemosensitivity	B-X
predictor	B-X
.	B-X
Hypermethylation	B-X
of	B-X
the	B-X
MGMT	B-X
gene	B-X
promoter	B-X
is	B-X
an	B-X
important	B-X
cause	B-X
of	B-X
MGMT	B-X
inactivation	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
MGMT	B-X
gene	B-X
promoter	B-X
methylation	B-X
and	B-X
the	B-X
immunohistochemical	B-X
MGMT	B-X
protein	B-X
expression	B-X
in	B-X
12	B-X
recurrent	B-X
anaplastic	B-X
ependymomas	B-X
affecting	B-X
children	B-X
.	B-X
Our	B-X
purpose	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
rationale	B-X
of	B-X
the	B-X
administration	B-X
of	B-X
alkylating	B-X
agents	B-X
to	B-X
children	B-X
affected	B-X
by	B-X
recurrent	B-X
anaplastic	B-X
ependymomas	B-X
.	B-X
All	B-X
ependymomas	B-X
lacked	B-X
MGMT	B-X
promoter	B-X
hypermethylation	B-X
and	B-X
9	B-X
(	B-X
75	B-X
%	B-X
)	B-X
showed	B-X
high	B-X
MGMT	B-X
protein	B-X
expression	B-X
(	B-X
>	B-X
50	B-X
%	B-X
tumoral	B-X
cells	B-X
)	B-X
.	B-X
These	B-X
results	B-X
may	B-X
indicate	B-X
MGMT	B-X
as	B-X
a	B-X
factor	B-X
of	B-X
chemoresistance	B-X
to	B-X
alkylating	B-X
drugs	B-X
in	B-X
anaplastic	B-X
ependymomas	B-X
and	B-X
support	B-X
the	B-X
uncertainties	B-X
regarding	B-X
the	B-X
actual	B-X
benefit	B-X
of	B-X
chemotherapy	B-X
for	B-X
patients	B-X
with	B-X
anaplastic	B-X
ependymomas	B-X
.	B-X

Our	O
purpose	O
was	O
to	O
investigate	O
the	O
molecular	O
rationale	O
of	O
the	O
administration	O
of	O
alkylating	O
agents	O
to	O
children	O
affected	O
by	O
recurrent	O
anaplastic	O
ependymomas	O
.	O
<EOS>	B-X
Ependymomas	B-X
are	B-X
the	B-X
third	B-X
most	B-X
common	B-X
brain	B-X
tumor	B-X
in	B-X
children	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
MGMT	B-X
gene	B-X
promoter	B-X
methylation	B-X
and	B-X
the	B-X
immunohistochemical	B-X
MGMT	B-X
protein	B-X
expression	B-X
in	B-X
12	B-X
recurrent	B-X
anaplastic	B-X
ependymomas	B-X
affecting	B-X
children	B-X
.	B-X
Our	B-X
purpose	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
rationale	B-X
of	B-X
the	B-X
administration	B-X
of	B-X
alkylating	B-X
agents	B-X
to	B-X
children	B-X
affected	B-X
by	B-X
recurrent	B-X
anaplastic	B-X
ependymomas	B-X
.	B-X
All	B-X
ependymomas	B-X
lacked	B-X
MGMT	B-X
promoter	B-X
hypermethylation	B-X
and	B-X
9	B-X
(	B-X
75	B-X
%	B-X
)	B-X
showed	B-X
high	B-X
MGMT	B-X
protein	B-X
expression	B-X
(	B-X
>	B-X
50	B-X
%	B-X
tumoral	B-X
cells	B-X
)	B-X
.	B-X
These	B-X
results	B-X
may	B-X
indicate	B-X
MGMT	B-X
as	B-X
a	B-X
factor	B-X
of	B-X
chemoresistance	B-X
to	B-X
alkylating	B-X
drugs	B-X
in	B-X
anaplastic	B-X
ependymomas	B-X
and	B-X
support	B-X
the	B-X
uncertainties	B-X
regarding	B-X
the	B-X
actual	B-X
benefit	B-X
of	B-X
chemotherapy	B-X
for	B-X
patients	B-X
with	B-X
anaplastic	B-X
ependymomas	B-X
.	B-X

All	O
ependymomas	O
lacked	O
MGMT	B-Protein
promoter	O
hypermethylation	O
and	O
9	O
(	O
75	O
%	O
)	O
showed	O
high	O
MGMT	B-Protein
protein	O
expression	O
(	O
>	O
50	O
%	O
tumoral	O
cells	O
)	O
.	O

Differences	O
between	O
different	O
recurrences	O
in	O
the	O
same	O
patient	O
were	O
not	O
observed	O
.	O
<EOS>	B-X
Patellar	B-X
instability	B-X
has	B-X
a	B-X
high	B-X
incidence	B-X
and	B-X
occurs	B-X
particularly	B-X
in	B-X
young	B-X
and	B-X
female	B-X
patients	B-X
.	B-X
A	B-X
retrospective	B-X
analysis	B-X
of	B-X
patients	B-X
affected	B-X
by	B-X
BP	B-X
and	B-X
RBP	B-X
were	B-X
performed	B-X
to	B-X
define	B-X
the	B-X
signs	B-X
and	B-X
symptoms	B-X
associated	B-X
with	B-X
recurrence	B-X
and	B-X
the	B-X
outcomes	B-X
.	B-X
Clinical	B-X
and	B-X
subjective	B-X
characteristics	B-X
of	B-X
341	B-X
patients	B-X
affected	B-X
by	B-X
facial	B-X
palsy	B-X
were	B-X
analysed	B-X
.	B-X
Characteristics	B-X
of	B-X
the	B-X
palsy	B-X
and	B-X
systemic	B-X
comorbidities	B-X
(	B-X
diabetes	B-X
,	B-X
hypertension	B-X
,	B-X
herpetic	B-X
infections	B-X
,	B-X
autoimmunity	B-X
disorders	B-X
,	B-X
audio-vestibular	B-X
symptoms	B-X
)	B-X
were	B-X
analysed	B-X
in	B-X
BP	B-X
and	B-X
RBP	B-X
patients	B-X
applying	B-X
Fisher	B-X
exact	B-X
and	B-X
the	B-X
Mann-Whitney	B-X
U	B-X
tests	B-X
,	B-X
while	B-X
time	B-X
to	B-X
recovery	B-X
was	B-X
explored	B-X
with	B-X
univariate	B-X
and	B-X
multivariate	B-X
analysis	B-X
.	B-X
Twenty-four	B-X
patients	B-X
presented	B-X
two	B-X
or	B-X
more	B-X
episodes	B-X
of	B-X
facial	B-X
palsy	B-X
,	B-X
representing	B-X
a	B-X
recurrence	B-X
rate	B-X
of	B-X
7	B-X
%	B-X
.	B-X
were	B-X
similar	B-X
between	B-X
BP	B-X
and	B-X
RBP	B-X
patients	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
no	B-X
significant	B-X
differences	B-X
were	B-X
found	B-X
between	B-X
primary	B-X
BP	B-X
patients	B-X
and	B-X
RBP	B-X
patients	B-X
in	B-X
terms	B-X
of	B-X
symptoms	B-X
,	B-X
palsy	B-X
severity	B-X
and	B-X
presence	B-X
of	B-X
comorbidities	B-X
.	B-X
Treatment	B-X
of	B-X
facial	B-X
nerve	B-X
recurrences	B-X
must	B-X
be	B-X
the	B-X
same	B-X
of	B-X
the	B-X
primary	B-X
episode	B-X
,	B-X
although	B-X
the	B-X
presence	B-X
of	B-X
prodromal	B-X
symptoms	B-X
may	B-X
alert	B-X
the	B-X
patient	B-X
and	B-X
early	B-X
corticosteroid	B-X
treatment	B-X
may	B-X
be	B-X
commenced	B-X
even	B-X
before	B-X
the	B-X
onset	B-X
of	B-X
paresis	B-X
.	B-X

These	O
results	O
may	O
indicate	O
MGMT	B-Protein
as	O
a	O
factor	O
of	O
chemoresistance	O
to	O
alkylating	O
drugs	O
in	O
anaplastic	O
ependymomas	O
and	O
support	O
the	O
uncertainties	O
regarding	O
the	O
actual	O
benefit	O
of	O
chemotherapy	O
for	O
patients	O
with	O
anaplastic	O
ependymomas	O
.	O
<EOS>	B-X
There	B-X
are	B-X
no	B-X
convincing	B-X
data	B-X
on	B-X
an	B-X
effective	B-X
role	B-X
for	B-X
chemotherapy	B-X
.	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-Methylguanine-DNA-Methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
is	B-X
a	B-X
DNA	B-X
repair	B-X
protein	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
chemosensitivity	B-X
predictor	B-X
.	B-X
Hypermethylation	B-X
of	B-X
the	B-X
MGMT	B-X
gene	B-X
promoter	B-X
is	B-X
an	B-X
important	B-X
cause	B-X
of	B-X
MGMT	B-X
inactivation	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
MGMT	B-X
gene	B-X
promoter	B-X
methylation	B-X
and	B-X
the	B-X
immunohistochemical	B-X
MGMT	B-X
protein	B-X
expression	B-X
in	B-X
12	B-X
recurrent	B-X
anaplastic	B-X
ependymomas	B-X
affecting	B-X
children	B-X
.	B-X
Our	B-X
purpose	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
rationale	B-X
of	B-X
the	B-X
administration	B-X
of	B-X
alkylating	B-X
agents	B-X
to	B-X
children	B-X
affected	B-X
by	B-X
recurrent	B-X
anaplastic	B-X
ependymomas	B-X
.	B-X
All	B-X
ependymomas	B-X
lacked	B-X
MGMT	B-X
promoter	B-X
hypermethylation	B-X
and	B-X
9	B-X
(	B-X
75	B-X
%	B-X
)	B-X
showed	B-X
high	B-X
MGMT	B-X
protein	B-X
expression	B-X
(	B-X
>	B-X
50	B-X
%	B-X
tumoral	B-X
cells	B-X
)	B-X
.	B-X
These	B-X
results	B-X
may	B-X
indicate	B-X
MGMT	B-X
as	B-X
a	B-X
factor	B-X
of	B-X
chemoresistance	B-X
to	B-X
alkylating	B-X
drugs	B-X
in	B-X
anaplastic	B-X
ependymomas	B-X
and	B-X
support	B-X
the	B-X
uncertainties	B-X
regarding	B-X
the	B-X
actual	B-X
benefit	B-X
of	B-X
chemotherapy	B-X
for	B-X
patients	B-X
with	B-X
anaplastic	B-X
ependymomas	B-X
.	B-X

The	O
aggresome	O
pathway	O
as	O
a	O
target	O
for	O
therapy	O
in	O
hematologic	O
malignancies	O
.	O
<EOS>	B-X
An	B-X
alternative	B-X
fate	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X
Recently	B-X
,	B-X
two	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
have	B-X
been	B-X
described	B-X
.	B-X
Tubacin	B-X
acts	B-X
synergistically	B-X
with	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
bortezomib	B-X
,	B-X
to	B-X
induce	B-X
cytotoxicity	B-X
in	B-X
one	B-X
type	B-X
of	B-X
hematologic	B-X
malignancy	B-X
,	B-X
multiple	B-X
myeloma	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
reports	B-X
on	B-X
targeting	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
in	B-X
hematologic	B-X
malignancies	B-X
.	B-X

Misfolded	O
or	O
unfolded	O
proteins	O
are	O
often	O
refolded	O
with	O
the	O
help	O
of	O
chaperones	O
or	O
degraded	O
by	O
the	O
26S	O
proteasome	O
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
proteasome	B-X
pathway	B-X
is	B-X
responsible	B-X
for	B-X
most	B-X
of	B-X
the	B-X
protein	B-X
degradation	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
studies	B-X
indicate	B-X
that	B-X
proteasome	B-X
function	B-X
is	B-X
also	B-X
tightly	B-X
regulated	B-X
and	B-X
determines	B-X
whether	B-X
a	B-X
ubiquitylated	B-X
protein	B-X
is	B-X
destroyed	B-X
or	B-X
deubiquitylated	B-X
and	B-X
survives	B-X
longer	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
proteasome	B-X
's	B-X
multistep	B-X
ATP-dependent	B-X
mechanism	B-X
,	B-X
its	B-X
biochemical	B-X
and	B-X
structural	B-X
features	B-X
that	B-X
ensure	B-X
efficient	B-X
proteolysis	B-X
and	B-X
ubiquitin	B-X
recycling	B-X
while	B-X
preventing	B-X
nonselective	B-X
proteolysis	B-X
,	B-X
and	B-X
the	B-X
regulation	B-X
of	B-X
proteasome	B-X
activity	B-X
by	B-X
interacting	B-X
proteins	B-X
and	B-X
subunit	B-X
modifications	B-X
,	B-X
especially	B-X
phosphorylation	B-X
.	B-X
Ubiquitin	B-X
can	B-X
be	B-X
attached	B-X
to	B-X
other	B-X
proteins	B-X
at	B-X
either	B-X
a	B-X
lysine	B-X
residue	B-X
or	B-X
to	B-X
the	B-X
N-terminus	B-X
by	B-X
the	B-X
consecutive	B-X
actions	B-X
of	B-X
E1	B-X
,	B-X
E2	B-X
,	B-X
and	B-X
E3	B-X
enzymes	B-X
.	B-X
Ubiquitination	B-X
affects	B-X
substrate	B-X
proteins	B-X
in	B-X
different	B-X
ways	B-X
,	B-X
for	B-X
example	B-X
by	B-X
resulting	B-X
in	B-X
degradation	B-X
of	B-X
the	B-X
substrate	B-X
protein	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Ubiquitination	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
deubiquitinating	B-X
enzymes	B-X
,	B-X
which	B-X
either	B-X
trim	B-X
or	B-X
remove	B-X
ubiquitin	B-X
chains	B-X
from	B-X
proteins	B-X
.	B-X
Many	B-X
proteins	B-X
involved	B-X
in	B-X
either	B-X
the	B-X
ubiquitination	B-X
,	B-X
deubiquitination	B-X
or	B-X
degradation	B-X
of	B-X
proteins	B-X
are	B-X
implicated	B-X
in	B-X
human	B-X
diseases	B-X
and	B-X
are	B-X
currently	B-X
under	B-X
investigation	B-X
as	B-X
potential	B-X
drug	B-X
targets	B-X
.	B-X

An	O
alternative	O
fate	O
of	O
these	O
proteins	O
is	O
the	O
aggresome	O
pathway	O
.	O
<EOS>	B-X
Misfolded	B-X
or	B-X
unfolded	B-X
proteins	B-X
are	B-X
often	B-X
refolded	B-X
with	B-X
the	B-X
help	B-X
of	B-X
chaperones	B-X
or	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
An	B-X
alternative	B-X
fate	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X
The	B-X
microtubule-organizing	B-X
center	B-X
(	B-X
MTOC	B-X
)	B-X
transports	B-X
unfolded	B-X
proteins	B-X
to	B-X
lysosomes	B-X
and	B-X
are	B-X
degraded	B-X
through	B-X
autophagy	B-X
.	B-X
Recently	B-X
,	B-X
two	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
have	B-X
been	B-X
described	B-X
.	B-X
One	B-X
inhibitor	B-X
,	B-X
tubacin	B-X
,	B-X
prevents	B-X
deacetylation	B-X
of	B-X
alpha-tubulin	B-X
and	B-X
produces	B-X
accumulation	B-X
of	B-X
polyubiquitinated	B-X
proteins	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
reports	B-X
on	B-X
targeting	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
in	B-X
hematologic	B-X
malignancies	B-X
.	B-X

The	O
microtubule	O
-	O
organizing	O
center	O
(	O
MTOC	O
)	O
transports	O
unfolded	O
proteins	O
to	O
lysosomes	O
and	O
are	O
degraded	O
through	O
autophagy	O
.	O
<EOS>	B-X
Misfolded	B-X
or	B-X
unfolded	B-X
proteins	B-X
are	B-X
often	B-X
refolded	B-X
with	B-X
the	B-X
help	B-X
of	B-X
chaperones	B-X
or	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
An	B-X
alternative	B-X
fate	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X
The	B-X
microtubule-organizing	B-X
center	B-X
(	B-X
MTOC	B-X
)	B-X
transports	B-X
unfolded	B-X
proteins	B-X
to	B-X
lysosomes	B-X
and	B-X
are	B-X
degraded	B-X
through	B-X
autophagy	B-X
.	B-X
Histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
deacetylates	B-X
alpha-tubulin	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
component	B-X
of	B-X
the	B-X
MTOC	B-X
.	B-X
One	B-X
inhibitor	B-X
,	B-X
tubacin	B-X
,	B-X
prevents	B-X
deacetylation	B-X
of	B-X
alpha-tubulin	B-X
and	B-X
produces	B-X
accumulation	B-X
of	B-X
polyubiquitinated	B-X
proteins	B-X
and	B-X
apoptosis	B-X
.	B-X

Histone	B-Protein
deacetylase	I-Protein
6	I-Protein
(	O
HDAC6	B-Protein
)	O
deacetylates	O
alpha	O
-	O
tubulin	O
,	O
which	O
is	O
thought	O
to	O
be	O
a	O
component	O
of	O
the	O
MTOC	O
.	O
<EOS>	B-X
Misfolded	B-X
or	B-X
unfolded	B-X
proteins	B-X
are	B-X
often	B-X
refolded	B-X
with	B-X
the	B-X
help	B-X
of	B-X
chaperones	B-X
or	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
The	B-X
microtubule-organizing	B-X
center	B-X
(	B-X
MTOC	B-X
)	B-X
transports	B-X
unfolded	B-X
proteins	B-X
to	B-X
lysosomes	B-X
and	B-X
are	B-X
degraded	B-X
through	B-X
autophagy	B-X
.	B-X
Histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
deacetylates	B-X
alpha-tubulin	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
component	B-X
of	B-X
the	B-X
MTOC	B-X
.	B-X
Recently	B-X
,	B-X
two	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
have	B-X
been	B-X
described	B-X
.	B-X
One	B-X
inhibitor	B-X
,	B-X
tubacin	B-X
,	B-X
prevents	B-X
deacetylation	B-X
of	B-X
alpha-tubulin	B-X
and	B-X
produces	B-X
accumulation	B-X
of	B-X
polyubiquitinated	B-X
proteins	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
reports	B-X
on	B-X
targeting	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
in	B-X
hematologic	B-X
malignancies	B-X
.	B-X

Recently	O
,	O
two	O
small	O
molecule	O
inhibitors	O
of	O
the	O
aggresome	O
pathway	O
and	O
HDAC6	B-Protein
have	O
been	O
described	O
.	O
<EOS>	B-X
An	B-X
alternative	B-X
fate	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X
Histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
deacetylates	B-X
alpha-tubulin	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
component	B-X
of	B-X
the	B-X
MTOC	B-X
.	B-X
Recently	B-X
,	B-X
two	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
have	B-X
been	B-X
described	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
reports	B-X
on	B-X
targeting	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
in	B-X
hematologic	B-X
malignancies	B-X
.	B-X

One	O
inhibitor	O
,	O
tubacin	O
,	O
prevents	O
deacetylation	O
of	O
alpha	O
-	O
tubulin	O
and	O
produces	O
accumulation	O
of	O
polyubiquitinated	O
proteins	O
and	O
apoptosis	O
.	O
<EOS>	B-X
Misfolded	B-X
or	B-X
unfolded	B-X
proteins	B-X
are	B-X
often	B-X
refolded	B-X
with	B-X
the	B-X
help	B-X
of	B-X
chaperones	B-X
or	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
An	B-X
alternative	B-X
fate	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X
The	B-X
microtubule-organizing	B-X
center	B-X
(	B-X
MTOC	B-X
)	B-X
transports	B-X
unfolded	B-X
proteins	B-X
to	B-X
lysosomes	B-X
and	B-X
are	B-X
degraded	B-X
through	B-X
autophagy	B-X
.	B-X
Histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
deacetylates	B-X
alpha-tubulin	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
component	B-X
of	B-X
the	B-X
MTOC	B-X
.	B-X
Recently	B-X
,	B-X
two	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
have	B-X
been	B-X
described	B-X
.	B-X
One	B-X
inhibitor	B-X
,	B-X
tubacin	B-X
,	B-X
prevents	B-X
deacetylation	B-X
of	B-X
alpha-tubulin	B-X
and	B-X
produces	B-X
accumulation	B-X
of	B-X
polyubiquitinated	B-X
proteins	B-X
and	B-X
apoptosis	B-X
.	B-X
Tubacin	B-X
acts	B-X
synergistically	B-X
with	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
bortezomib	B-X
,	B-X
to	B-X
induce	B-X
cytotoxicity	B-X
in	B-X
one	B-X
type	B-X
of	B-X
hematologic	B-X
malignancy	B-X
,	B-X
multiple	B-X
myeloma	B-X
.	B-X
The	B-X
other	B-X
,	B-X
LBH589	B-X
,	B-X
is	B-X
a	B-X
pan	B-X
HDAC	B-X
inhibitor	B-X
and	B-X
hydroxamic	B-X
acid	B-X
derivative	B-X
that	B-X
induces	B-X
apoptosis	B-X
of	B-X
multiple	B-X
myeloma	B-X
cells	B-X
resistant	B-X
to	B-X
conventional	B-X
therapies	B-X
.	B-X

Tubacin	O
acts	O
synergistically	O
with	O
the	O
proteasome	O
inhibitor	O
,	O
bortezomib	O
,	O
to	O
induce	O
cytotoxicity	O
in	O
one	O
type	O
of	O
hematologic	O
malignancy	O
,	O
multiple	O
myeloma	O
.	O
<EOS>	B-X
Misfolded	B-X
or	B-X
unfolded	B-X
proteins	B-X
are	B-X
often	B-X
refolded	B-X
with	B-X
the	B-X
help	B-X
of	B-X
chaperones	B-X
or	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
deacetylates	B-X
alpha-tubulin	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
component	B-X
of	B-X
the	B-X
MTOC	B-X
.	B-X
Recently	B-X
,	B-X
two	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
have	B-X
been	B-X
described	B-X
.	B-X
One	B-X
inhibitor	B-X
,	B-X
tubacin	B-X
,	B-X
prevents	B-X
deacetylation	B-X
of	B-X
alpha-tubulin	B-X
and	B-X
produces	B-X
accumulation	B-X
of	B-X
polyubiquitinated	B-X
proteins	B-X
and	B-X
apoptosis	B-X
.	B-X
Tubacin	B-X
acts	B-X
synergistically	B-X
with	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
bortezomib	B-X
,	B-X
to	B-X
induce	B-X
cytotoxicity	B-X
in	B-X
one	B-X
type	B-X
of	B-X
hematologic	B-X
malignancy	B-X
,	B-X
multiple	B-X
myeloma	B-X
.	B-X
The	B-X
other	B-X
,	B-X
LBH589	B-X
,	B-X
is	B-X
a	B-X
pan	B-X
HDAC	B-X
inhibitor	B-X
and	B-X
hydroxamic	B-X
acid	B-X
derivative	B-X
that	B-X
induces	B-X
apoptosis	B-X
of	B-X
multiple	B-X
myeloma	B-X
cells	B-X
resistant	B-X
to	B-X
conventional	B-X
therapies	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
reports	B-X
on	B-X
targeting	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
in	B-X
hematologic	B-X
malignancies	B-X
.	B-X

The	O
other	O
,	O
LBH589	O
,	O
is	O
a	O
pan	O
HDAC	O
inhibitor	O
and	O
hydroxamic	O
acid	O
derivative	O
that	O
induces	O
apoptosis	O
of	O
multiple	O
myeloma	O
cells	O
resistant	O
to	O
conventional	O
therapies	O
.	O
<EOS>	B-X
Histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
deacetylates	B-X
alpha-tubulin	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
component	B-X
of	B-X
the	B-X
MTOC	B-X
.	B-X
Recently	B-X
,	B-X
two	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
have	B-X
been	B-X
described	B-X
.	B-X
One	B-X
inhibitor	B-X
,	B-X
tubacin	B-X
,	B-X
prevents	B-X
deacetylation	B-X
of	B-X
alpha-tubulin	B-X
and	B-X
produces	B-X
accumulation	B-X
of	B-X
polyubiquitinated	B-X
proteins	B-X
and	B-X
apoptosis	B-X
.	B-X
Tubacin	B-X
acts	B-X
synergistically	B-X
with	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
bortezomib	B-X
,	B-X
to	B-X
induce	B-X
cytotoxicity	B-X
in	B-X
one	B-X
type	B-X
of	B-X
hematologic	B-X
malignancy	B-X
,	B-X
multiple	B-X
myeloma	B-X
.	B-X
The	B-X
other	B-X
,	B-X
LBH589	B-X
,	B-X
is	B-X
a	B-X
pan	B-X
HDAC	B-X
inhibitor	B-X
and	B-X
hydroxamic	B-X
acid	B-X
derivative	B-X
that	B-X
induces	B-X
apoptosis	B-X
of	B-X
multiple	B-X
myeloma	B-X
cells	B-X
resistant	B-X
to	B-X
conventional	B-X
therapies	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
reports	B-X
on	B-X
targeting	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
in	B-X
hematologic	B-X
malignancies	B-X
.	B-X

In	O
this	O
review	O
,	O
we	O
summarize	O
recent	O
reports	O
on	O
targeting	O
the	O
aggresome	O
pathway	O
and	O
HDAC6	B-Protein
in	O
hematologic	O
malignancies	O
.	O
<EOS>	B-X
An	B-X
alternative	B-X
fate	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X
Histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
deacetylates	B-X
alpha-tubulin	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
component	B-X
of	B-X
the	B-X
MTOC	B-X
.	B-X
Recently	B-X
,	B-X
two	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
have	B-X
been	B-X
described	B-X
.	B-X
Tubacin	B-X
acts	B-X
synergistically	B-X
with	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
bortezomib	B-X
,	B-X
to	B-X
induce	B-X
cytotoxicity	B-X
in	B-X
one	B-X
type	B-X
of	B-X
hematologic	B-X
malignancy	B-X
,	B-X
multiple	B-X
myeloma	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
reports	B-X
on	B-X
targeting	B-X
the	B-X
aggresome	B-X
pathway	B-X
and	B-X
HDAC6	B-X
in	B-X
hematologic	B-X
malignancies	B-X
.	B-X

Interactions	O
between	O
the	O
quality	O
control	O
ubiquitin	B-Protein
ligase	O
CHIP	B-Protein
and	O
ubiquitin	B-Protein
conjugating	O
enzymes	O
.	O
<EOS>	B-X
Ubiquitin	B-X
(	B-X
E3	B-X
)	B-X
ligases	B-X
interact	B-X
with	B-X
specific	B-X
ubiquitin	B-X
conjugating	B-X
(	B-X
E2	B-X
)	B-X
enzymes	B-X
to	B-X
ubiquitinate	B-X
particular	B-X
substrate	B-X
proteins	B-X
.	B-X
As	B-X
the	B-X
combination	B-X
of	B-X
E2	B-X
and	B-X
E3	B-X
dictates	B-X
the	B-X
type	B-X
and	B-X
biological	B-X
consequence	B-X
of	B-X
ubiquitination	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
basis	B-X
of	B-X
specificity	B-X
in	B-X
E2	B-X
:	B-X
E3	B-X
interactions	B-X
.	B-X
The	B-X
E3	B-X
ligase	B-X
CHIP	B-X
interacts	B-X
with	B-X
Hsp70	B-X
and	B-X
Hsp90	B-X
and	B-X
ubiquitinates	B-X
client	B-X
proteins	B-X
that	B-X
are	B-X
chaperoned	B-X
by	B-X
these	B-X
heat	B-X
shock	B-X
proteins	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
two	B-X
types	B-X
of	B-X
E2	B-X
enzymes	B-X
,	B-X
UbcH5	B-X
and	B-X
Ubc13-Uev1a	B-X
.	B-X
It	B-X
is	B-X
unclear	B-X
,	B-X
however	B-X
,	B-X
why	B-X
CHIP	B-X
binds	B-X
these	B-X
E2	B-X
enzymes	B-X
rather	B-X
than	B-X
others	B-X
,	B-X
and	B-X
whether	B-X
CHIP	B-X
interacts	B-X
preferentially	B-X
with	B-X
UbcH5	B-X
or	B-X
Ubc13-Uev1a	B-X
,	B-X
which	B-X
form	B-X
different	B-X
types	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
.	B-X

BACKGROUND	O
:	O
Ubiquitin	B-Protein
(	O
E3	O
)	O
ligases	O
interact	O
with	O
specific	O
ubiquitin	B-Protein
conjugating	O
(	O
E2	O
)	O
enzymes	O
to	O
ubiquitinate	O
particular	O
substrate	O
proteins	O
.	O
<EOS>	B-X
Ubiquitin	B-X
(	B-X
E3	B-X
)	B-X
ligases	B-X
interact	B-X
with	B-X
specific	B-X
ubiquitin	B-X
conjugating	B-X
(	B-X
E2	B-X
)	B-X
enzymes	B-X
to	B-X
ubiquitinate	B-X
particular	B-X
substrate	B-X
proteins	B-X
.	B-X
As	B-X
the	B-X
combination	B-X
of	B-X
E2	B-X
and	B-X
E3	B-X
dictates	B-X
the	B-X
type	B-X
and	B-X
biological	B-X
consequence	B-X
of	B-X
ubiquitination	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
basis	B-X
of	B-X
specificity	B-X
in	B-X
E2	B-X
:	B-X
E3	B-X
interactions	B-X
.	B-X
The	B-X
E3	B-X
ligase	B-X
CHIP	B-X
interacts	B-X
with	B-X
Hsp70	B-X
and	B-X
Hsp90	B-X
and	B-X
ubiquitinates	B-X
client	B-X
proteins	B-X
that	B-X
are	B-X
chaperoned	B-X
by	B-X
these	B-X
heat	B-X
shock	B-X
proteins	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
two	B-X
types	B-X
of	B-X
E2	B-X
enzymes	B-X
,	B-X
UbcH5	B-X
and	B-X
Ubc13-Uev1a	B-X
.	B-X
It	B-X
is	B-X
unclear	B-X
,	B-X
however	B-X
,	B-X
why	B-X
CHIP	B-X
binds	B-X
these	B-X
E2	B-X
enzymes	B-X
rather	B-X
than	B-X
others	B-X
,	B-X
and	B-X
whether	B-X
CHIP	B-X
interacts	B-X
preferentially	B-X
with	B-X
UbcH5	B-X
or	B-X
Ubc13-Uev1a	B-X
,	B-X
which	B-X
form	B-X
different	B-X
types	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
.	B-X

As	O
the	O
combination	O
of	O
E2	O
and	O
E3	O
dictates	O
the	O
type	O
and	O
biological	O
consequence	O
of	O
ubiquitination	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
basis	O
of	O
specificity	O
in	O
E2	O
:	O
E3	O
interactions	O
.	O
<EOS>	B-X
Ubiquitin	B-X
(	B-X
E3	B-X
)	B-X
ligases	B-X
interact	B-X
with	B-X
specific	B-X
ubiquitin	B-X
conjugating	B-X
(	B-X
E2	B-X
)	B-X
enzymes	B-X
to	B-X
ubiquitinate	B-X
particular	B-X
substrate	B-X
proteins	B-X
.	B-X
As	B-X
the	B-X
combination	B-X
of	B-X
E2	B-X
and	B-X
E3	B-X
dictates	B-X
the	B-X
type	B-X
and	B-X
biological	B-X
consequence	B-X
of	B-X
ubiquitination	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
basis	B-X
of	B-X
specificity	B-X
in	B-X
E2	B-X
:	B-X
E3	B-X
interactions	B-X
.	B-X
The	B-X
E3	B-X
ligase	B-X
CHIP	B-X
interacts	B-X
with	B-X
Hsp70	B-X
and	B-X
Hsp90	B-X
and	B-X
ubiquitinates	B-X
client	B-X
proteins	B-X
that	B-X
are	B-X
chaperoned	B-X
by	B-X
these	B-X
heat	B-X
shock	B-X
proteins	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
two	B-X
types	B-X
of	B-X
E2	B-X
enzymes	B-X
,	B-X
UbcH5	B-X
and	B-X
Ubc13-Uev1a	B-X
.	B-X
It	B-X
is	B-X
unclear	B-X
,	B-X
however	B-X
,	B-X
why	B-X
CHIP	B-X
binds	B-X
these	B-X
E2	B-X
enzymes	B-X
rather	B-X
than	B-X
others	B-X
,	B-X
and	B-X
whether	B-X
CHIP	B-X
interacts	B-X
preferentially	B-X
with	B-X
UbcH5	B-X
or	B-X
Ubc13-Uev1a	B-X
,	B-X
which	B-X
form	B-X
different	B-X
types	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
.	B-X

The	O
E3	O
ligase	O
CHIP	B-Protein
interacts	O
with	O
Hsp70	O
and	O
Hsp90	O
and	O
ubiquitinates	O
client	O
proteins	O
that	O
are	O
chaperoned	O
by	O
these	O
heat	O
shock	O
proteins	O
.	O
<EOS>	B-X
Critical	B-X
target	B-X
proteins	B-X
that	B-X
unfold	B-X
and	B-X
aggregate	B-X
in	B-X
these	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
the	B-X
polyglutamine	B-X
androgen	B-X
receptor	B-X
in	B-X
spinal	B-X
and	B-X
bulbar	B-X
muscular	B-X
atrophy	B-X
,	B-X
huntingtin	B-X
in	B-X
Huntington	B-X
's	B-X
disease	B-X
,	B-X
α-synuclein	B-X
in	B-X
Parkinson	B-X
's	B-X
disease	B-X
,	B-X
and	B-X
tau	B-X
in	B-X
Alzheimer	B-X
's	B-X
disease	B-X
,	B-X
are	B-X
client	B-X
proteins	B-X
of	B-X
heat	B-X
shock	B-X
protein	B-X
90	B-X
(	B-X
Hsp90	B-X
)	B-X
,	B-X
and	B-X
their	B-X
turnover	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
protein	B-X
quality	B-X
control	B-X
function	B-X
of	B-X
the	B-X
Hsp90/Hsp70-based	B-X
chaperone	B-X
machinery	B-X
.	B-X
Hsp90	B-X
and	B-X
Hsp70	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
client	B-X
protein	B-X
stability	B-X
in	B-X
protein	B-X
quality	B-X
control	B-X
;	B-X
Hsp90	B-X
stabilizes	B-X
the	B-X
clients	B-X
and	B-X
inhibits	B-X
their	B-X
ubiquitination	B-X
,	B-X
whereas	B-X
Hsp70	B-X
promotes	B-X
ubiquitination	B-X
dependent	B-X
on	B-X
CHIP	B-X
(	B-X
C	B-X
terminus	B-X
of	B-X
Hsc70-interacting	B-X
protein	B-X
)	B-X
and	B-X
proteasomal	B-X
degradation	B-X
.	B-X
We	B-X
discuss	B-X
how	B-X
drugs	B-X
that	B-X
modulate	B-X
proteostasis	B-X
by	B-X
inhibiting	B-X
Hsp90	B-X
function	B-X
or	B-X
promoting	B-X
Hsp70	B-X
function	B-X
enhance	B-X
the	B-X
degradation	B-X
of	B-X
the	B-X
critical	B-X
aggregating	B-X
proteins	B-X
and	B-X
ameliorate	B-X
toxic	B-X
symptoms	B-X
in	B-X
cell	B-X
and	B-X
animal	B-X
disease	B-X
models	B-X
.	B-X
CHIP	B-X
,	B-X
carboxy	B-X
terminus	B-X
of	B-X
Hsc70	B-X
interacting	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
cytoplasmic	B-X
protein	B-X
whose	B-X
amino	B-X
acid	B-X
sequence	B-X
is	B-X
highly	B-X
conserved	B-X
across	B-X
species	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
the	B-X
molecular	B-X
chaperones	B-X
Hsc70-Hsp70	B-X
and	B-X
Hsp90	B-X
through	B-X
its	B-X
TPR	B-X
domain	B-X
,	B-X
whereas	B-X
its	B-X
U-box	B-X
domain	B-X
contains	B-X
its	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X
Its	B-X
interaction	B-X
with	B-X
these	B-X
molecular	B-X
chaperones	B-X
results	B-X
in	B-X
client	B-X
substrate	B-X
ubiquitylation	B-X
and	B-X
degradation	B-X
by	B-X
the	B-X
proteasome	B-X
.	B-X
Thus	B-X
,	B-X
CHIP	B-X
acts	B-X
to	B-X
tilt	B-X
the	B-X
folding-refolding	B-X
machinery	B-X
toward	B-X
the	B-X
degradative	B-X
pathway	B-X
,	B-X
and	B-X
it	B-X
serves	B-X
as	B-X
a	B-X
link	B-X
between	B-X
the	B-X
two	B-X
.	B-X
Because	B-X
protein	B-X
degradation	B-X
is	B-X
required	B-X
for	B-X
healthy	B-X
cellular	B-X
function	B-X
,	B-X
CHIP	B-X
's	B-X
ability	B-X
to	B-X
degrade	B-X
proteins	B-X
that	B-X
are	B-X
the	B-X
signature	B-X
of	B-X
disease	B-X
,	B-X
eg	B-X
,	B-X
ErbB2	B-X
in	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
,	B-X
could	B-X
prove	B-X
to	B-X
be	B-X
a	B-X
point	B-X
of	B-X
therapeutic	B-X
intervention	B-X
.	B-X

CHIP	B-Protein
interacts	O
with	O
two	O
types	O
of	O
E2	O
enzymes	O
,	O
UbcH5	B-Protein
and	O
Ubc13	B-Protein
-	O
Uev1a	B-Protein
.	O
<EOS>	B-X
Ubiquitin	B-X
(	B-X
E3	B-X
)	B-X
ligases	B-X
interact	B-X
with	B-X
specific	B-X
ubiquitin	B-X
conjugating	B-X
(	B-X
E2	B-X
)	B-X
enzymes	B-X
to	B-X
ubiquitinate	B-X
particular	B-X
substrate	B-X
proteins	B-X
.	B-X
As	B-X
the	B-X
combination	B-X
of	B-X
E2	B-X
and	B-X
E3	B-X
dictates	B-X
the	B-X
type	B-X
and	B-X
biological	B-X
consequence	B-X
of	B-X
ubiquitination	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
basis	B-X
of	B-X
specificity	B-X
in	B-X
E2	B-X
:	B-X
E3	B-X
interactions	B-X
.	B-X
The	B-X
E3	B-X
ligase	B-X
CHIP	B-X
interacts	B-X
with	B-X
Hsp70	B-X
and	B-X
Hsp90	B-X
and	B-X
ubiquitinates	B-X
client	B-X
proteins	B-X
that	B-X
are	B-X
chaperoned	B-X
by	B-X
these	B-X
heat	B-X
shock	B-X
proteins	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
two	B-X
types	B-X
of	B-X
E2	B-X
enzymes	B-X
,	B-X
UbcH5	B-X
and	B-X
Ubc13-Uev1a	B-X
.	B-X
It	B-X
is	B-X
unclear	B-X
,	B-X
however	B-X
,	B-X
why	B-X
CHIP	B-X
binds	B-X
these	B-X
E2	B-X
enzymes	B-X
rather	B-X
than	B-X
others	B-X
,	B-X
and	B-X
whether	B-X
CHIP	B-X
interacts	B-X
preferentially	B-X
with	B-X
UbcH5	B-X
or	B-X
Ubc13-Uev1a	B-X
,	B-X
which	B-X
form	B-X
different	B-X
types	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
.	B-X

It	O
is	O
unclear	O
,	O
however	O
,	O
why	O
CHIP	B-Protein
binds	O
these	O
E2	O
enzymes	O
rather	O
than	O
others	O
,	O
and	O
whether	O
CHIP	B-Protein
interacts	O
preferentially	O
with	O
UbcH5	B-Protein
or	O
Ubc13	B-Protein
-	O
Uev1a	B-Protein
,	O
which	O
form	O
different	O
types	O
of	O
polyubiquitin	B-Protein
chains	O
.	O
<EOS>	B-X
Ubiquitin	B-X
(	B-X
E3	B-X
)	B-X
ligases	B-X
interact	B-X
with	B-X
specific	B-X
ubiquitin	B-X
conjugating	B-X
(	B-X
E2	B-X
)	B-X
enzymes	B-X
to	B-X
ubiquitinate	B-X
particular	B-X
substrate	B-X
proteins	B-X
.	B-X
As	B-X
the	B-X
combination	B-X
of	B-X
E2	B-X
and	B-X
E3	B-X
dictates	B-X
the	B-X
type	B-X
and	B-X
biological	B-X
consequence	B-X
of	B-X
ubiquitination	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
basis	B-X
of	B-X
specificity	B-X
in	B-X
E2	B-X
:	B-X
E3	B-X
interactions	B-X
.	B-X
The	B-X
E3	B-X
ligase	B-X
CHIP	B-X
interacts	B-X
with	B-X
Hsp70	B-X
and	B-X
Hsp90	B-X
and	B-X
ubiquitinates	B-X
client	B-X
proteins	B-X
that	B-X
are	B-X
chaperoned	B-X
by	B-X
these	B-X
heat	B-X
shock	B-X
proteins	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
two	B-X
types	B-X
of	B-X
E2	B-X
enzymes	B-X
,	B-X
UbcH5	B-X
and	B-X
Ubc13-Uev1a	B-X
.	B-X
It	B-X
is	B-X
unclear	B-X
,	B-X
however	B-X
,	B-X
why	B-X
CHIP	B-X
binds	B-X
these	B-X
E2	B-X
enzymes	B-X
rather	B-X
than	B-X
others	B-X
,	B-X
and	B-X
whether	B-X
CHIP	B-X
interacts	B-X
preferentially	B-X
with	B-X
UbcH5	B-X
or	B-X
Ubc13-Uev1a	B-X
,	B-X
which	B-X
form	B-X
different	B-X
types	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
.	B-X

RESULTS	O
:	O
The	O
2	O
.	O
9	O
A	O
crystal	O
structure	O
of	O
the	O
CHIP	B-Protein
U	O
-	O
box	O
domain	O
complexed	O
with	O
UbcH5a	B-Protein
shows	O
that	O
CHIP	B-Protein
binds	O
to	O
UbcH5	B-Protein
and	O
Ubc13	B-Protein
through	O
similar	O
specificity	O
determinants	O
,	O
including	O
a	O
key	O
S	O
-	O
P	O
-	O
A	O
motif	O
on	O
the	O
E2	O
enzymes	O
.	O

The	O
determinants	O
make	O
different	O
relative	O
contributions	O
to	O
the	O
overall	O
interactions	O
between	O
CHIP	B-Protein
and	O
the	O
two	O
E2	O
enzymes	O
.	O

CHIP	B-Protein
undergoes	O
auto	O
-	O
ubiquitination	O
by	O
UbcH5	B-Protein
but	O
not	O
by	O
Ubc13	B-Protein
-	O
Uev1a	B-Protein
.	O

Instead	O
,	O
CHIP	B-Protein
drives	O
the	O
formation	O
of	O
unanchored	O
polyubiquitin	B-Protein
by	O
Ubc13	B-Protein
-	O
Uev1a	B-Protein
.	O
<EOS>	B-X
The	B-X
E3	B-X
ligase	B-X
CHIP	B-X
interacts	B-X
with	B-X
Hsp70	B-X
and	B-X
Hsp90	B-X
and	B-X
ubiquitinates	B-X
client	B-X
proteins	B-X
that	B-X
are	B-X
chaperoned	B-X
by	B-X
these	B-X
heat	B-X
shock	B-X
proteins	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
two	B-X
types	B-X
of	B-X
E2	B-X
enzymes	B-X
,	B-X
UbcH5	B-X
and	B-X
Ubc13-Uev1a	B-X
.	B-X
It	B-X
is	B-X
unclear	B-X
,	B-X
however	B-X
,	B-X
why	B-X
CHIP	B-X
binds	B-X
these	B-X
E2	B-X
enzymes	B-X
rather	B-X
than	B-X
others	B-X
,	B-X
and	B-X
whether	B-X
CHIP	B-X
interacts	B-X
preferentially	B-X
with	B-X
UbcH5	B-X
or	B-X
Ubc13-Uev1a	B-X
,	B-X
which	B-X
form	B-X
different	B-X
types	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
.	B-X

CHIP	B-Protein
also	O
interacts	O
productively	O
with	O
the	O
class	O
III	O
E2	O
enzyme	O
Ube2e2	B-Protein
,	O
in	O
which	O
the	O
UbcH5	B-Protein
-	O
and	O
Ubc13	B-Protein
-	O
binding	O
specificity	O
determinants	O
are	O
highly	O
conserved	O
.	O
<EOS>	B-X
Ubiquitin	B-X
(	B-X
E3	B-X
)	B-X
ligases	B-X
interact	B-X
with	B-X
specific	B-X
ubiquitin	B-X
conjugating	B-X
(	B-X
E2	B-X
)	B-X
enzymes	B-X
to	B-X
ubiquitinate	B-X
particular	B-X
substrate	B-X
proteins	B-X
.	B-X
As	B-X
the	B-X
combination	B-X
of	B-X
E2	B-X
and	B-X
E3	B-X
dictates	B-X
the	B-X
type	B-X
and	B-X
biological	B-X
consequence	B-X
of	B-X
ubiquitination	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
basis	B-X
of	B-X
specificity	B-X
in	B-X
E2	B-X
:	B-X
E3	B-X
interactions	B-X
.	B-X
The	B-X
E3	B-X
ligase	B-X
CHIP	B-X
interacts	B-X
with	B-X
Hsp70	B-X
and	B-X
Hsp90	B-X
and	B-X
ubiquitinates	B-X
client	B-X
proteins	B-X
that	B-X
are	B-X
chaperoned	B-X
by	B-X
these	B-X
heat	B-X
shock	B-X
proteins	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
two	B-X
types	B-X
of	B-X
E2	B-X
enzymes	B-X
,	B-X
UbcH5	B-X
and	B-X
Ubc13-Uev1a	B-X
.	B-X
It	B-X
is	B-X
unclear	B-X
,	B-X
however	B-X
,	B-X
why	B-X
CHIP	B-X
binds	B-X
these	B-X
E2	B-X
enzymes	B-X
rather	B-X
than	B-X
others	B-X
,	B-X
and	B-X
whether	B-X
CHIP	B-X
interacts	B-X
preferentially	B-X
with	B-X
UbcH5	B-X
or	B-X
Ubc13-Uev1a	B-X
,	B-X
which	B-X
form	B-X
different	B-X
types	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
.	B-X

CONCLUSION	O
:	O
The	O
CHIP	B-Protein
:	O
UbcH5a	B-Protein
structure	O
emphasizes	O
the	O
importance	O
of	O
specificity	O
determinants	O
located	O
on	O
the	O
long	O
loops	O
and	O
central	O
helix	O
of	O
the	O
CHIP	B-Protein
U	O
-	O
box	O
,	O
and	O
on	O
the	O
N	O
-	O
terminal	O
helix	O
and	O
loops	O
L4	O
and	O
L7	O
of	O
its	O
cognate	O
E2	O
enzymes	O
.	O

The	O
S	O
-	O
P	O
-	O
A	O
motif	O
and	O
other	O
specificity	O
determinants	O
define	O
the	O
set	O
of	O
cognate	O
E2	O
enzymes	O
for	O
CHIP	B-Protein
,	O
which	O
likely	O
includes	O
several	O
Class	O
III	O
E2	O
enzymes	O
.	O

CHIP	B-Protein
'	O
s	O
interactions	O
with	O
UbcH5	B-Protein
,	O
Ube2e2	B-Protein
and	O
Ubc13	B-Protein
-	O
Uev1a	B-Protein
are	O
consistent	O
with	O
the	O
notion	O
that	O
Ubc13	B-Protein
-	O
Uev1a	B-Protein
may	O
work	O
sequentially	O
with	O
other	O
E2	O
enzymes	O
to	O
carry	O
out	O
K63	O
-	O
linked	O
polyubiquitination	O
of	O
CHIP	B-Protein
substrates	O
.	O

Regulation	O
of	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
self	O
-	O
ubiquitination	O
and	O
stability	O
by	O
a	O
PY	O
motif	O
located	O
within	O
its	O
HECT	O
-	O
domain	O
.	O
<EOS>	B-X
Nedd4	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
4	B-X
)	B-X
-2	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
composed	B-X
of	B-X
a	B-X
C2	B-X
domain	B-X
,	B-X
four	B-X
WW	B-X
domains	B-X
(	B-X
protein-protein	B-X
interaction	B-X
domains	B-X
containing	B-X
two	B-X
conserved	B-X
tryptophan	B-X
residues	B-X
)	B-X
that	B-X
bind	B-X
PY	B-X
motifs	B-X
(	B-X
L/PPXY	B-X
)	B-X
and	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
HECT	B-X
(	B-X
homologous	B-X
with	B-X
E6-associated	B-X
protein	B-X
C-terminus	B-X
)	B-X
domain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
we	B-X
show	B-X
that	B-X
the	B-X
WW	B-X
domains	B-X
of	B-X
Nedd4-2	B-X
bind	B-X
(	B-X
weakly	B-X
)	B-X
to	B-X
a	B-X
PY	B-X
motif	B-X
(	B-X
LPXY	B-X
)	B-X
located	B-X
within	B-X
its	B-X
own	B-X
HECT	B-X
domain	B-X
and	B-X
inhibit	B-X
auto-ubiquitination	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
demonstrated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
HECT	B-X
PY-motif	B-X
decreases	B-X
the	B-X
stability	B-X
of	B-X
Nedd4-2	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
stabilization	B-X
of	B-X
this	B-X
E3	B-X
ligase	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
HECT	B-X
PY-motif	B-X
mutation	B-X
does	B-X
not	B-X
affect	B-X
ubiquitination	B-X
or	B-X
down-regulation	B-X
of	B-X
a	B-X
known	B-X
Nedd4-2	B-X
substrate	B-X
,	B-X
ENaC	B-X
(	B-X
epithelial	B-X
sodium	B-X
channel	B-X
)	B-X
.	B-X
ENaC	B-X
ubiquitination	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
appears	B-X
to	B-X
promote	B-X
Nedd4-2	B-X
self-ubiquitination	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
the	B-X
inter-	B-X
or	B-X
intra-molecular	B-X
WW-domain-HECT	B-X
PY-motif	B-X
interaction	B-X
stabilizes	B-X
Nedd4-2	B-X
by	B-X
preventing	B-X
self-ubiquitination	B-X
.	B-X
Substrate	B-X
binding	B-X
disrupts	B-X
this	B-X
interaction	B-X
,	B-X
allowing	B-X
self-ubiquitination	B-X
of	B-X
Nedd4-2	B-X
and	B-X
subsequent	B-X
degradation	B-X
,	B-X
resulting	B-X
in	B-X
down-regulation	B-X
of	B-X
Nedd4-2	B-X
once	B-X
it	B-X
has	B-X
ubiquitinated	B-X
its	B-X
target	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
employed	B-X
by	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
regulate	B-X
itself	B-X
differentially	B-X
compared	B-X
with	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
stability	B-X
.	B-X

Ubiquitin	B-Protein
ligases	O
play	O
a	O
pivotal	O
role	O
in	O
substrate	O
recognition	O
and	O
ubiquitin	B-Protein
transfer	O
,	O
yet	O
little	O
is	O
known	O
about	O
the	O
regulation	O
of	O
their	O
catalytic	O
activity	O
.	O
<EOS>	B-X
Ubiquitin	B-X
ligases	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
substrate	B-X
recognition	B-X
and	B-X
ubiquitin	B-X
transfer	B-X
,	B-X
yet	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
regulation	B-X
of	B-X
their	B-X
catalytic	B-X
activity	B-X
.	B-X
Nedd4	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
4	B-X
)	B-X
-2	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
composed	B-X
of	B-X
a	B-X
C2	B-X
domain	B-X
,	B-X
four	B-X
WW	B-X
domains	B-X
(	B-X
protein-protein	B-X
interaction	B-X
domains	B-X
containing	B-X
two	B-X
conserved	B-X
tryptophan	B-X
residues	B-X
)	B-X
that	B-X
bind	B-X
PY	B-X
motifs	B-X
(	B-X
L/PPXY	B-X
)	B-X
and	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
HECT	B-X
(	B-X
homologous	B-X
with	B-X
E6-associated	B-X
protein	B-X
C-terminus	B-X
)	B-X
domain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
we	B-X
show	B-X
that	B-X
the	B-X
WW	B-X
domains	B-X
of	B-X
Nedd4-2	B-X
bind	B-X
(	B-X
weakly	B-X
)	B-X
to	B-X
a	B-X
PY	B-X
motif	B-X
(	B-X
LPXY	B-X
)	B-X
located	B-X
within	B-X
its	B-X
own	B-X
HECT	B-X
domain	B-X
and	B-X
inhibit	B-X
auto-ubiquitination	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
HECT	B-X
PY-motif	B-X
mutation	B-X
does	B-X
not	B-X
affect	B-X
ubiquitination	B-X
or	B-X
down-regulation	B-X
of	B-X
a	B-X
known	B-X
Nedd4-2	B-X
substrate	B-X
,	B-X
ENaC	B-X
(	B-X
epithelial	B-X
sodium	B-X
channel	B-X
)	B-X
.	B-X
ENaC	B-X
ubiquitination	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
appears	B-X
to	B-X
promote	B-X
Nedd4-2	B-X
self-ubiquitination	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
the	B-X
inter-	B-X
or	B-X
intra-molecular	B-X
WW-domain-HECT	B-X
PY-motif	B-X
interaction	B-X
stabilizes	B-X
Nedd4-2	B-X
by	B-X
preventing	B-X
self-ubiquitination	B-X
.	B-X
Substrate	B-X
binding	B-X
disrupts	B-X
this	B-X
interaction	B-X
,	B-X
allowing	B-X
self-ubiquitination	B-X
of	B-X
Nedd4-2	B-X
and	B-X
subsequent	B-X
degradation	B-X
,	B-X
resulting	B-X
in	B-X
down-regulation	B-X
of	B-X
Nedd4-2	B-X
once	B-X
it	B-X
has	B-X
ubiquitinated	B-X
its	B-X
target	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
employed	B-X
by	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
regulate	B-X
itself	B-X
differentially	B-X
compared	B-X
with	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
stability	B-X
.	B-X

Nedd4	B-Protein
(	I-Protein
neural	I-Protein
-	I-Protein
precursor	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
expressed	I-Protein
,	I-Protein
developmentally	I-Protein
down	I-Protein
-	I-Protein
regulated	I-Protein
4	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
is	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
composed	O
of	O
a	O
C2	O
domain	O
,	O
four	O
WW	O
domains	O
(	O
protein	O
-	O
protein	O
interaction	O
domains	O
containing	O
two	O
conserved	O
tryptophan	O
residues	O
)	O
that	O
bind	O
PY	O
motifs	O
(	O
L	O
/	O
PPXY	O
)	O
and	O
a	O
ubiquitin	B-Protein
ligase	O
HECT	O
(	O
homologous	O
with	O
E6	O
-	O
associated	O
protein	O
C	O
-	O
terminus	O
)	O
domain	O
.	O

In	O
the	O
present	O
paper	O
we	O
show	O
that	O
the	O
WW	O
domains	O
of	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
bind	O
(	O
weakly	O
)	O
to	O
a	O
PY	O
motif	O
(	O
LPXY	O
)	O
located	O
within	O
its	O
own	O
HECT	O
domain	O
and	O
inhibit	O
auto	O
-	O
ubiquitination	O
.	O
<EOS>	B-X
Nedd4	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
4	B-X
)	B-X
-2	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
composed	B-X
of	B-X
a	B-X
C2	B-X
domain	B-X
,	B-X
four	B-X
WW	B-X
domains	B-X
(	B-X
protein-protein	B-X
interaction	B-X
domains	B-X
containing	B-X
two	B-X
conserved	B-X
tryptophan	B-X
residues	B-X
)	B-X
that	B-X
bind	B-X
PY	B-X
motifs	B-X
(	B-X
L/PPXY	B-X
)	B-X
and	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
HECT	B-X
(	B-X
homologous	B-X
with	B-X
E6-associated	B-X
protein	B-X
C-terminus	B-X
)	B-X
domain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
we	B-X
show	B-X
that	B-X
the	B-X
WW	B-X
domains	B-X
of	B-X
Nedd4-2	B-X
bind	B-X
(	B-X
weakly	B-X
)	B-X
to	B-X
a	B-X
PY	B-X
motif	B-X
(	B-X
LPXY	B-X
)	B-X
located	B-X
within	B-X
its	B-X
own	B-X
HECT	B-X
domain	B-X
and	B-X
inhibit	B-X
auto-ubiquitination	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
demonstrated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
HECT	B-X
PY-motif	B-X
decreases	B-X
the	B-X
stability	B-X
of	B-X
Nedd4-2	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
stabilization	B-X
of	B-X
this	B-X
E3	B-X
ligase	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
HECT	B-X
PY-motif	B-X
mutation	B-X
does	B-X
not	B-X
affect	B-X
ubiquitination	B-X
or	B-X
down-regulation	B-X
of	B-X
a	B-X
known	B-X
Nedd4-2	B-X
substrate	B-X
,	B-X
ENaC	B-X
(	B-X
epithelial	B-X
sodium	B-X
channel	B-X
)	B-X
.	B-X
ENaC	B-X
ubiquitination	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
appears	B-X
to	B-X
promote	B-X
Nedd4-2	B-X
self-ubiquitination	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
the	B-X
inter-	B-X
or	B-X
intra-molecular	B-X
WW-domain-HECT	B-X
PY-motif	B-X
interaction	B-X
stabilizes	B-X
Nedd4-2	B-X
by	B-X
preventing	B-X
self-ubiquitination	B-X
.	B-X
Substrate	B-X
binding	B-X
disrupts	B-X
this	B-X
interaction	B-X
,	B-X
allowing	B-X
self-ubiquitination	B-X
of	B-X
Nedd4-2	B-X
and	B-X
subsequent	B-X
degradation	B-X
,	B-X
resulting	B-X
in	B-X
down-regulation	B-X
of	B-X
Nedd4-2	B-X
once	B-X
it	B-X
has	B-X
ubiquitinated	B-X
its	B-X
target	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
employed	B-X
by	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
regulate	B-X
itself	B-X
differentially	B-X
compared	B-X
with	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
stability	B-X
.	B-X

Pulse	O
-	O
chase	O
experiments	O
demonstrated	O
that	O
mutation	O
of	O
the	O
HECT	O
PY	O
-	O
motif	O
decreases	O
the	O
stability	O
of	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
,	O
suggesting	O
that	O
it	O
is	O
involved	O
in	O
stabilization	O
of	O
this	O
E3	O
ligase	O
.	O
<EOS>	B-X
Ubiquitin	B-X
ligases	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
substrate	B-X
recognition	B-X
and	B-X
ubiquitin	B-X
transfer	B-X
,	B-X
yet	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
regulation	B-X
of	B-X
their	B-X
catalytic	B-X
activity	B-X
.	B-X
Nedd4	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
4	B-X
)	B-X
-2	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
composed	B-X
of	B-X
a	B-X
C2	B-X
domain	B-X
,	B-X
four	B-X
WW	B-X
domains	B-X
(	B-X
protein-protein	B-X
interaction	B-X
domains	B-X
containing	B-X
two	B-X
conserved	B-X
tryptophan	B-X
residues	B-X
)	B-X
that	B-X
bind	B-X
PY	B-X
motifs	B-X
(	B-X
L/PPXY	B-X
)	B-X
and	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
HECT	B-X
(	B-X
homologous	B-X
with	B-X
E6-associated	B-X
protein	B-X
C-terminus	B-X
)	B-X
domain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
we	B-X
show	B-X
that	B-X
the	B-X
WW	B-X
domains	B-X
of	B-X
Nedd4-2	B-X
bind	B-X
(	B-X
weakly	B-X
)	B-X
to	B-X
a	B-X
PY	B-X
motif	B-X
(	B-X
LPXY	B-X
)	B-X
located	B-X
within	B-X
its	B-X
own	B-X
HECT	B-X
domain	B-X
and	B-X
inhibit	B-X
auto-ubiquitination	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
demonstrated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
HECT	B-X
PY-motif	B-X
decreases	B-X
the	B-X
stability	B-X
of	B-X
Nedd4-2	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
stabilization	B-X
of	B-X
this	B-X
E3	B-X
ligase	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
HECT	B-X
PY-motif	B-X
mutation	B-X
does	B-X
not	B-X
affect	B-X
ubiquitination	B-X
or	B-X
down-regulation	B-X
of	B-X
a	B-X
known	B-X
Nedd4-2	B-X
substrate	B-X
,	B-X
ENaC	B-X
(	B-X
epithelial	B-X
sodium	B-X
channel	B-X
)	B-X
.	B-X
ENaC	B-X
ubiquitination	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
appears	B-X
to	B-X
promote	B-X
Nedd4-2	B-X
self-ubiquitination	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
the	B-X
inter-	B-X
or	B-X
intra-molecular	B-X
WW-domain-HECT	B-X
PY-motif	B-X
interaction	B-X
stabilizes	B-X
Nedd4-2	B-X
by	B-X
preventing	B-X
self-ubiquitination	B-X
.	B-X
Substrate	B-X
binding	B-X
disrupts	B-X
this	B-X
interaction	B-X
,	B-X
allowing	B-X
self-ubiquitination	B-X
of	B-X
Nedd4-2	B-X
and	B-X
subsequent	B-X
degradation	B-X
,	B-X
resulting	B-X
in	B-X
down-regulation	B-X
of	B-X
Nedd4-2	B-X
once	B-X
it	B-X
has	B-X
ubiquitinated	B-X
its	B-X
target	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
employed	B-X
by	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
regulate	B-X
itself	B-X
differentially	B-X
compared	B-X
with	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
stability	B-X
.	B-X

Interestingly	O
,	O
the	O
HECT	O
PY	O
-	O
motif	O
mutation	O
does	O
not	O
affect	O
ubiquitination	O
or	O
down	O
-	O
regulation	O
of	O
a	O
known	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
substrate	O
,	O
ENaC	O
(	O
epithelial	O
sodium	O
channel	O
)	O
.	O
<EOS>	B-X
Ubiquitin	B-X
ligases	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
substrate	B-X
recognition	B-X
and	B-X
ubiquitin	B-X
transfer	B-X
,	B-X
yet	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
regulation	B-X
of	B-X
their	B-X
catalytic	B-X
activity	B-X
.	B-X
Nedd4	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
4	B-X
)	B-X
-2	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
composed	B-X
of	B-X
a	B-X
C2	B-X
domain	B-X
,	B-X
four	B-X
WW	B-X
domains	B-X
(	B-X
protein-protein	B-X
interaction	B-X
domains	B-X
containing	B-X
two	B-X
conserved	B-X
tryptophan	B-X
residues	B-X
)	B-X
that	B-X
bind	B-X
PY	B-X
motifs	B-X
(	B-X
L/PPXY	B-X
)	B-X
and	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
HECT	B-X
(	B-X
homologous	B-X
with	B-X
E6-associated	B-X
protein	B-X
C-terminus	B-X
)	B-X
domain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
we	B-X
show	B-X
that	B-X
the	B-X
WW	B-X
domains	B-X
of	B-X
Nedd4-2	B-X
bind	B-X
(	B-X
weakly	B-X
)	B-X
to	B-X
a	B-X
PY	B-X
motif	B-X
(	B-X
LPXY	B-X
)	B-X
located	B-X
within	B-X
its	B-X
own	B-X
HECT	B-X
domain	B-X
and	B-X
inhibit	B-X
auto-ubiquitination	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
demonstrated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
HECT	B-X
PY-motif	B-X
decreases	B-X
the	B-X
stability	B-X
of	B-X
Nedd4-2	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
stabilization	B-X
of	B-X
this	B-X
E3	B-X
ligase	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
HECT	B-X
PY-motif	B-X
mutation	B-X
does	B-X
not	B-X
affect	B-X
ubiquitination	B-X
or	B-X
down-regulation	B-X
of	B-X
a	B-X
known	B-X
Nedd4-2	B-X
substrate	B-X
,	B-X
ENaC	B-X
(	B-X
epithelial	B-X
sodium	B-X
channel	B-X
)	B-X
.	B-X
ENaC	B-X
ubiquitination	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
appears	B-X
to	B-X
promote	B-X
Nedd4-2	B-X
self-ubiquitination	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
the	B-X
inter-	B-X
or	B-X
intra-molecular	B-X
WW-domain-HECT	B-X
PY-motif	B-X
interaction	B-X
stabilizes	B-X
Nedd4-2	B-X
by	B-X
preventing	B-X
self-ubiquitination	B-X
.	B-X
Substrate	B-X
binding	B-X
disrupts	B-X
this	B-X
interaction	B-X
,	B-X
allowing	B-X
self-ubiquitination	B-X
of	B-X
Nedd4-2	B-X
and	B-X
subsequent	B-X
degradation	B-X
,	B-X
resulting	B-X
in	B-X
down-regulation	B-X
of	B-X
Nedd4-2	B-X
once	B-X
it	B-X
has	B-X
ubiquitinated	B-X
its	B-X
target	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
employed	B-X
by	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
regulate	B-X
itself	B-X
differentially	B-X
compared	B-X
with	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
stability	B-X
.	B-X

ENaC	O
ubiquitination	O
,	O
in	O
turn	O
,	O
appears	O
to	O
promote	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
self	O
-	O
ubiquitination	O
.	O
<EOS>	B-X
Nedd4	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
4	B-X
)	B-X
-2	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
composed	B-X
of	B-X
a	B-X
C2	B-X
domain	B-X
,	B-X
four	B-X
WW	B-X
domains	B-X
(	B-X
protein-protein	B-X
interaction	B-X
domains	B-X
containing	B-X
two	B-X
conserved	B-X
tryptophan	B-X
residues	B-X
)	B-X
that	B-X
bind	B-X
PY	B-X
motifs	B-X
(	B-X
L/PPXY	B-X
)	B-X
and	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
HECT	B-X
(	B-X
homologous	B-X
with	B-X
E6-associated	B-X
protein	B-X
C-terminus	B-X
)	B-X
domain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
we	B-X
show	B-X
that	B-X
the	B-X
WW	B-X
domains	B-X
of	B-X
Nedd4-2	B-X
bind	B-X
(	B-X
weakly	B-X
)	B-X
to	B-X
a	B-X
PY	B-X
motif	B-X
(	B-X
LPXY	B-X
)	B-X
located	B-X
within	B-X
its	B-X
own	B-X
HECT	B-X
domain	B-X
and	B-X
inhibit	B-X
auto-ubiquitination	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
demonstrated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
HECT	B-X
PY-motif	B-X
decreases	B-X
the	B-X
stability	B-X
of	B-X
Nedd4-2	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
stabilization	B-X
of	B-X
this	B-X
E3	B-X
ligase	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
HECT	B-X
PY-motif	B-X
mutation	B-X
does	B-X
not	B-X
affect	B-X
ubiquitination	B-X
or	B-X
down-regulation	B-X
of	B-X
a	B-X
known	B-X
Nedd4-2	B-X
substrate	B-X
,	B-X
ENaC	B-X
(	B-X
epithelial	B-X
sodium	B-X
channel	B-X
)	B-X
.	B-X
ENaC	B-X
ubiquitination	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
appears	B-X
to	B-X
promote	B-X
Nedd4-2	B-X
self-ubiquitination	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
the	B-X
inter-	B-X
or	B-X
intra-molecular	B-X
WW-domain-HECT	B-X
PY-motif	B-X
interaction	B-X
stabilizes	B-X
Nedd4-2	B-X
by	B-X
preventing	B-X
self-ubiquitination	B-X
.	B-X
Substrate	B-X
binding	B-X
disrupts	B-X
this	B-X
interaction	B-X
,	B-X
allowing	B-X
self-ubiquitination	B-X
of	B-X
Nedd4-2	B-X
and	B-X
subsequent	B-X
degradation	B-X
,	B-X
resulting	B-X
in	B-X
down-regulation	B-X
of	B-X
Nedd4-2	B-X
once	B-X
it	B-X
has	B-X
ubiquitinated	B-X
its	B-X
target	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
employed	B-X
by	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
regulate	B-X
itself	B-X
differentially	B-X
compared	B-X
with	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
stability	B-X
.	B-X

These	O
results	O
support	O
a	O
model	O
in	O
which	O
the	O
inter	O
-	O
or	O
intra	O
-	O
molecular	O
WW	O
-	O
domain	O
-	O
HECT	O
PY	O
-	O
motif	O
interaction	O
stabilizes	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
by	O
preventing	O
self	O
-	O
ubiquitination	O
.	O
<EOS>	B-X
Nedd4	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
4	B-X
)	B-X
-2	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
composed	B-X
of	B-X
a	B-X
C2	B-X
domain	B-X
,	B-X
four	B-X
WW	B-X
domains	B-X
(	B-X
protein-protein	B-X
interaction	B-X
domains	B-X
containing	B-X
two	B-X
conserved	B-X
tryptophan	B-X
residues	B-X
)	B-X
that	B-X
bind	B-X
PY	B-X
motifs	B-X
(	B-X
L/PPXY	B-X
)	B-X
and	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
HECT	B-X
(	B-X
homologous	B-X
with	B-X
E6-associated	B-X
protein	B-X
C-terminus	B-X
)	B-X
domain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
we	B-X
show	B-X
that	B-X
the	B-X
WW	B-X
domains	B-X
of	B-X
Nedd4-2	B-X
bind	B-X
(	B-X
weakly	B-X
)	B-X
to	B-X
a	B-X
PY	B-X
motif	B-X
(	B-X
LPXY	B-X
)	B-X
located	B-X
within	B-X
its	B-X
own	B-X
HECT	B-X
domain	B-X
and	B-X
inhibit	B-X
auto-ubiquitination	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
demonstrated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
HECT	B-X
PY-motif	B-X
decreases	B-X
the	B-X
stability	B-X
of	B-X
Nedd4-2	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
stabilization	B-X
of	B-X
this	B-X
E3	B-X
ligase	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
HECT	B-X
PY-motif	B-X
mutation	B-X
does	B-X
not	B-X
affect	B-X
ubiquitination	B-X
or	B-X
down-regulation	B-X
of	B-X
a	B-X
known	B-X
Nedd4-2	B-X
substrate	B-X
,	B-X
ENaC	B-X
(	B-X
epithelial	B-X
sodium	B-X
channel	B-X
)	B-X
.	B-X
ENaC	B-X
ubiquitination	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
appears	B-X
to	B-X
promote	B-X
Nedd4-2	B-X
self-ubiquitination	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
the	B-X
inter-	B-X
or	B-X
intra-molecular	B-X
WW-domain-HECT	B-X
PY-motif	B-X
interaction	B-X
stabilizes	B-X
Nedd4-2	B-X
by	B-X
preventing	B-X
self-ubiquitination	B-X
.	B-X
Substrate	B-X
binding	B-X
disrupts	B-X
this	B-X
interaction	B-X
,	B-X
allowing	B-X
self-ubiquitination	B-X
of	B-X
Nedd4-2	B-X
and	B-X
subsequent	B-X
degradation	B-X
,	B-X
resulting	B-X
in	B-X
down-regulation	B-X
of	B-X
Nedd4-2	B-X
once	B-X
it	B-X
has	B-X
ubiquitinated	B-X
its	B-X
target	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
employed	B-X
by	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
regulate	B-X
itself	B-X
differentially	B-X
compared	B-X
with	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
stability	B-X
.	B-X

Substrate	O
binding	O
disrupts	O
this	O
interaction	O
,	O
allowing	O
self	O
-	O
ubiquitination	O
of	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
and	O
subsequent	O
degradation	O
,	O
resulting	O
in	O
down	O
-	O
regulation	O
of	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
once	O
it	O
has	O
ubiquitinated	O
its	O
target	O
.	O
<EOS>	B-X
Ubiquitin	B-X
ligases	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
substrate	B-X
recognition	B-X
and	B-X
ubiquitin	B-X
transfer	B-X
,	B-X
yet	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
regulation	B-X
of	B-X
their	B-X
catalytic	B-X
activity	B-X
.	B-X
Nedd4	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
4	B-X
)	B-X
-2	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
composed	B-X
of	B-X
a	B-X
C2	B-X
domain	B-X
,	B-X
four	B-X
WW	B-X
domains	B-X
(	B-X
protein-protein	B-X
interaction	B-X
domains	B-X
containing	B-X
two	B-X
conserved	B-X
tryptophan	B-X
residues	B-X
)	B-X
that	B-X
bind	B-X
PY	B-X
motifs	B-X
(	B-X
L/PPXY	B-X
)	B-X
and	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
HECT	B-X
(	B-X
homologous	B-X
with	B-X
E6-associated	B-X
protein	B-X
C-terminus	B-X
)	B-X
domain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
we	B-X
show	B-X
that	B-X
the	B-X
WW	B-X
domains	B-X
of	B-X
Nedd4-2	B-X
bind	B-X
(	B-X
weakly	B-X
)	B-X
to	B-X
a	B-X
PY	B-X
motif	B-X
(	B-X
LPXY	B-X
)	B-X
located	B-X
within	B-X
its	B-X
own	B-X
HECT	B-X
domain	B-X
and	B-X
inhibit	B-X
auto-ubiquitination	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
demonstrated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
HECT	B-X
PY-motif	B-X
decreases	B-X
the	B-X
stability	B-X
of	B-X
Nedd4-2	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
stabilization	B-X
of	B-X
this	B-X
E3	B-X
ligase	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
HECT	B-X
PY-motif	B-X
mutation	B-X
does	B-X
not	B-X
affect	B-X
ubiquitination	B-X
or	B-X
down-regulation	B-X
of	B-X
a	B-X
known	B-X
Nedd4-2	B-X
substrate	B-X
,	B-X
ENaC	B-X
(	B-X
epithelial	B-X
sodium	B-X
channel	B-X
)	B-X
.	B-X
ENaC	B-X
ubiquitination	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
appears	B-X
to	B-X
promote	B-X
Nedd4-2	B-X
self-ubiquitination	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
the	B-X
inter-	B-X
or	B-X
intra-molecular	B-X
WW-domain-HECT	B-X
PY-motif	B-X
interaction	B-X
stabilizes	B-X
Nedd4-2	B-X
by	B-X
preventing	B-X
self-ubiquitination	B-X
.	B-X
Substrate	B-X
binding	B-X
disrupts	B-X
this	B-X
interaction	B-X
,	B-X
allowing	B-X
self-ubiquitination	B-X
of	B-X
Nedd4-2	B-X
and	B-X
subsequent	B-X
degradation	B-X
,	B-X
resulting	B-X
in	B-X
down-regulation	B-X
of	B-X
Nedd4-2	B-X
once	B-X
it	B-X
has	B-X
ubiquitinated	B-X
its	B-X
target	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
employed	B-X
by	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
regulate	B-X
itself	B-X
differentially	B-X
compared	B-X
with	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
stability	B-X
.	B-X

These	O
findings	O
also	O
point	O
to	O
a	O
novel	O
mechanism	O
employed	O
by	O
a	O
ubiquitin	B-Protein
ligase	O
to	O
regulate	O
itself	O
differentially	O
compared	O
with	O
substrate	O
ubiquitination	O
and	O
stability	O
.	O
<EOS>	B-X
Ubiquitin	B-X
ligases	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
substrate	B-X
recognition	B-X
and	B-X
ubiquitin	B-X
transfer	B-X
,	B-X
yet	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
regulation	B-X
of	B-X
their	B-X
catalytic	B-X
activity	B-X
.	B-X
Nedd4	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
4	B-X
)	B-X
-2	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
composed	B-X
of	B-X
a	B-X
C2	B-X
domain	B-X
,	B-X
four	B-X
WW	B-X
domains	B-X
(	B-X
protein-protein	B-X
interaction	B-X
domains	B-X
containing	B-X
two	B-X
conserved	B-X
tryptophan	B-X
residues	B-X
)	B-X
that	B-X
bind	B-X
PY	B-X
motifs	B-X
(	B-X
L/PPXY	B-X
)	B-X
and	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
HECT	B-X
(	B-X
homologous	B-X
with	B-X
E6-associated	B-X
protein	B-X
C-terminus	B-X
)	B-X
domain	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
we	B-X
show	B-X
that	B-X
the	B-X
WW	B-X
domains	B-X
of	B-X
Nedd4-2	B-X
bind	B-X
(	B-X
weakly	B-X
)	B-X
to	B-X
a	B-X
PY	B-X
motif	B-X
(	B-X
LPXY	B-X
)	B-X
located	B-X
within	B-X
its	B-X
own	B-X
HECT	B-X
domain	B-X
and	B-X
inhibit	B-X
auto-ubiquitination	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
demonstrated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
HECT	B-X
PY-motif	B-X
decreases	B-X
the	B-X
stability	B-X
of	B-X
Nedd4-2	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
stabilization	B-X
of	B-X
this	B-X
E3	B-X
ligase	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
HECT	B-X
PY-motif	B-X
mutation	B-X
does	B-X
not	B-X
affect	B-X
ubiquitination	B-X
or	B-X
down-regulation	B-X
of	B-X
a	B-X
known	B-X
Nedd4-2	B-X
substrate	B-X
,	B-X
ENaC	B-X
(	B-X
epithelial	B-X
sodium	B-X
channel	B-X
)	B-X
.	B-X
ENaC	B-X
ubiquitination	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
appears	B-X
to	B-X
promote	B-X
Nedd4-2	B-X
self-ubiquitination	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
the	B-X
inter-	B-X
or	B-X
intra-molecular	B-X
WW-domain-HECT	B-X
PY-motif	B-X
interaction	B-X
stabilizes	B-X
Nedd4-2	B-X
by	B-X
preventing	B-X
self-ubiquitination	B-X
.	B-X
Substrate	B-X
binding	B-X
disrupts	B-X
this	B-X
interaction	B-X
,	B-X
allowing	B-X
self-ubiquitination	B-X
of	B-X
Nedd4-2	B-X
and	B-X
subsequent	B-X
degradation	B-X
,	B-X
resulting	B-X
in	B-X
down-regulation	B-X
of	B-X
Nedd4-2	B-X
once	B-X
it	B-X
has	B-X
ubiquitinated	B-X
its	B-X
target	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
employed	B-X
by	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
to	B-X
regulate	B-X
itself	B-X
differentially	B-X
compared	B-X
with	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
stability	B-X
.	B-X

Polyubiquitination	O
of	O
prolactin	B-Protein
receptor	I-Protein
stimulates	O
its	O
internalization	O
,	O
postinternalization	O
sorting	O
,	O
and	O
degradation	O
via	O
the	O
lysosomal	O
pathway	O
.	O
<EOS>	B-X
The	B-X
ubiquitination	B-X
of	B-X
the	B-X
receptor	B-X
that	B-X
mediates	B-X
signaling	B-X
induced	B-X
by	B-X
the	B-X
polypeptide	B-X
pituitary	B-X
hormone	B-X
prolactin	B-X
(	B-X
PRL	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
lead	B-X
to	B-X
the	B-X
degradation	B-X
of	B-X
this	B-X
receptor	B-X
and	B-X
to	B-X
the	B-X
ensuing	B-X
negative	B-X
regulation	B-X
of	B-X
cellular	B-X
responses	B-X
to	B-X
PRL	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
of	B-X
PRL	B-X
receptor	B-X
(	B-X
PRLr	B-X
)	B-X
proteolysis	B-X
remain	B-X
largely	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Here	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
PRLr	B-X
is	B-X
internalized	B-X
and	B-X
primarily	B-X
degraded	B-X
via	B-X
the	B-X
lysosomal	B-X
pathway	B-X
.	B-X
Ubiquitination	B-X
of	B-X
PRLr	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
rapid	B-X
internalization	B-X
of	B-X
PRLr	B-X
,	B-X
which	B-X
proceeds	B-X
through	B-X
a	B-X
pathway	B-X
dependent	B-X
on	B-X
clathrin	B-X
and	B-X
the	B-X
assembly	B-X
polypeptide	B-X
2	B-X
(	B-X
AP2	B-X
)	B-X
adaptor	B-X
complexes	B-X
.	B-X
Recruitment	B-X
of	B-X
AP2	B-X
to	B-X
PRLr	B-X
is	B-X
stimulated	B-X
by	B-X
PRLr	B-X
ubiquitination	B-X
,	B-X
which	B-X
also	B-X
is	B-X
required	B-X
for	B-X
the	B-X
targeting	B-X
of	B-X
already	B-X
internalized	B-X
PRLr	B-X
to	B-X
the	B-X
lysosomal	B-X
compartment	B-X
.	B-X
While	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
both	B-X
monoubiquitination	B-X
and	B-X
polyubiquitination	B-X
(	B-X
via	B-X
both	B-X
K48-	B-X
and	B-X
K63-linked	B-X
chains	B-X
)	B-X
occur	B-X
on	B-X
PRLr	B-X
,	B-X
the	B-X
results	B-X
of	B-X
experiments	B-X
using	B-X
forced	B-X
expression	B-X
of	B-X
ubiquitin	B-X
mutants	B-X
indicate	B-X
that	B-X
PRLr	B-X
polyubiquitination	B-X
via	B-X
K63-linked	B-X
chains	B-X
is	B-X
important	B-X
for	B-X
efficient	B-X
interaction	B-X
of	B-X
PRLr	B-X
with	B-X
AP2	B-X
as	B-X
well	B-X
as	B-X
for	B-X
efficient	B-X
internalization	B-X
,	B-X
postinternalization	B-X
sorting	B-X
,	B-X
and	B-X
proteolytic	B-X
turnover	B-X
of	B-X
PRLr	B-X
.	B-X
We	B-X
discuss	B-X
how	B-X
specific	B-X
ubiquitination	B-X
may	B-X
regulate	B-X
early	B-X
and	B-X
late	B-X
stages	B-X
of	B-X
endocytosis	B-X
of	B-X
PRLr	B-X
and	B-X
of	B-X
related	B-X
receptors	B-X
to	B-X
contribute	B-X
to	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
magnitude	B-X
and	B-X
duration	B-X
of	B-X
downstream	B-X
signaling	B-X
.	B-X

The	O
ubiquitination	O
of	O
the	O
receptor	O
that	O
mediates	O
signaling	O
induced	O
by	O
the	O
polypeptide	O
pituitary	O
hormone	O
prolactin	B-Protein
(	O
PRL	B-Protein
)	O
has	O
been	O
shown	O
to	O
lead	O
to	O
the	O
degradation	O
of	O
this	O
receptor	O
and	O
to	O
the	O
ensuing	O
negative	O
regulation	O
of	O
cellular	O
responses	O
to	O
PRL	B-Protein
.	O

However	O
,	O
the	O
mechanisms	O
of	O
PRL	B-Protein
receptor	I-Protein
(	O
PRLr	B-Protein
)	O
proteolysis	O
remain	O
largely	O
to	O
be	O
determined	O
.	O
<EOS>	B-X
The	B-X
ubiquitination	B-X
of	B-X
the	B-X
receptor	B-X
that	B-X
mediates	B-X
signaling	B-X
induced	B-X
by	B-X
the	B-X
polypeptide	B-X
pituitary	B-X
hormone	B-X
prolactin	B-X
(	B-X
PRL	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
lead	B-X
to	B-X
the	B-X
degradation	B-X
of	B-X
this	B-X
receptor	B-X
and	B-X
to	B-X
the	B-X
ensuing	B-X
negative	B-X
regulation	B-X
of	B-X
cellular	B-X
responses	B-X
to	B-X
PRL	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
of	B-X
PRL	B-X
receptor	B-X
(	B-X
PRLr	B-X
)	B-X
proteolysis	B-X
remain	B-X
largely	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Here	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
PRLr	B-X
is	B-X
internalized	B-X
and	B-X
primarily	B-X
degraded	B-X
via	B-X
the	B-X
lysosomal	B-X
pathway	B-X
.	B-X
Ubiquitination	B-X
of	B-X
PRLr	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
rapid	B-X
internalization	B-X
of	B-X
PRLr	B-X
,	B-X
which	B-X
proceeds	B-X
through	B-X
a	B-X
pathway	B-X
dependent	B-X
on	B-X
clathrin	B-X
and	B-X
the	B-X
assembly	B-X
polypeptide	B-X
2	B-X
(	B-X
AP2	B-X
)	B-X
adaptor	B-X
complexes	B-X
.	B-X
Recruitment	B-X
of	B-X
AP2	B-X
to	B-X
PRLr	B-X
is	B-X
stimulated	B-X
by	B-X
PRLr	B-X
ubiquitination	B-X
,	B-X
which	B-X
also	B-X
is	B-X
required	B-X
for	B-X
the	B-X
targeting	B-X
of	B-X
already	B-X
internalized	B-X
PRLr	B-X
to	B-X
the	B-X
lysosomal	B-X
compartment	B-X
.	B-X
While	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
both	B-X
monoubiquitination	B-X
and	B-X
polyubiquitination	B-X
(	B-X
via	B-X
both	B-X
K48-	B-X
and	B-X
K63-linked	B-X
chains	B-X
)	B-X
occur	B-X
on	B-X
PRLr	B-X
,	B-X
the	B-X
results	B-X
of	B-X
experiments	B-X
using	B-X
forced	B-X
expression	B-X
of	B-X
ubiquitin	B-X
mutants	B-X
indicate	B-X
that	B-X
PRLr	B-X
polyubiquitination	B-X
via	B-X
K63-linked	B-X
chains	B-X
is	B-X
important	B-X
for	B-X
efficient	B-X
interaction	B-X
of	B-X
PRLr	B-X
with	B-X
AP2	B-X
as	B-X
well	B-X
as	B-X
for	B-X
efficient	B-X
internalization	B-X
,	B-X
postinternalization	B-X
sorting	B-X
,	B-X
and	B-X
proteolytic	B-X
turnover	B-X
of	B-X
PRLr	B-X
.	B-X
We	B-X
discuss	B-X
how	B-X
specific	B-X
ubiquitination	B-X
may	B-X
regulate	B-X
early	B-X
and	B-X
late	B-X
stages	B-X
of	B-X
endocytosis	B-X
of	B-X
PRLr	B-X
and	B-X
of	B-X
related	B-X
receptors	B-X
to	B-X
contribute	B-X
to	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
magnitude	B-X
and	B-X
duration	B-X
of	B-X
downstream	B-X
signaling	B-X
.	B-X

Here	O
we	O
provide	O
evidence	O
that	O
PRLr	B-Protein
is	O
internalized	O
and	O
primarily	O
degraded	O
via	O
the	O
lysosomal	O
pathway	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
of	B-X
PRL	B-X
receptor	B-X
(	B-X
PRLr	B-X
)	B-X
proteolysis	B-X
remain	B-X
largely	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Here	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
PRLr	B-X
is	B-X
internalized	B-X
and	B-X
primarily	B-X
degraded	B-X
via	B-X
the	B-X
lysosomal	B-X
pathway	B-X
.	B-X
Ubiquitination	B-X
of	B-X
PRLr	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
rapid	B-X
internalization	B-X
of	B-X
PRLr	B-X
,	B-X
which	B-X
proceeds	B-X
through	B-X
a	B-X
pathway	B-X
dependent	B-X
on	B-X
clathrin	B-X
and	B-X
the	B-X
assembly	B-X
polypeptide	B-X
2	B-X
(	B-X
AP2	B-X
)	B-X
adaptor	B-X
complexes	B-X
.	B-X
Recruitment	B-X
of	B-X
AP2	B-X
to	B-X
PRLr	B-X
is	B-X
stimulated	B-X
by	B-X
PRLr	B-X
ubiquitination	B-X
,	B-X
which	B-X
also	B-X
is	B-X
required	B-X
for	B-X
the	B-X
targeting	B-X
of	B-X
already	B-X
internalized	B-X
PRLr	B-X
to	B-X
the	B-X
lysosomal	B-X
compartment	B-X
.	B-X
While	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
both	B-X
monoubiquitination	B-X
and	B-X
polyubiquitination	B-X
(	B-X
via	B-X
both	B-X
K48-	B-X
and	B-X
K63-linked	B-X
chains	B-X
)	B-X
occur	B-X
on	B-X
PRLr	B-X
,	B-X
the	B-X
results	B-X
of	B-X
experiments	B-X
using	B-X
forced	B-X
expression	B-X
of	B-X
ubiquitin	B-X
mutants	B-X
indicate	B-X
that	B-X
PRLr	B-X
polyubiquitination	B-X
via	B-X
K63-linked	B-X
chains	B-X
is	B-X
important	B-X
for	B-X
efficient	B-X
interaction	B-X
of	B-X
PRLr	B-X
with	B-X
AP2	B-X
as	B-X
well	B-X
as	B-X
for	B-X
efficient	B-X
internalization	B-X
,	B-X
postinternalization	B-X
sorting	B-X
,	B-X
and	B-X
proteolytic	B-X
turnover	B-X
of	B-X
PRLr	B-X
.	B-X
We	B-X
discuss	B-X
how	B-X
specific	B-X
ubiquitination	B-X
may	B-X
regulate	B-X
early	B-X
and	B-X
late	B-X
stages	B-X
of	B-X
endocytosis	B-X
of	B-X
PRLr	B-X
and	B-X
of	B-X
related	B-X
receptors	B-X
to	B-X
contribute	B-X
to	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
magnitude	B-X
and	B-X
duration	B-X
of	B-X
downstream	B-X
signaling	B-X
.	B-X

Ubiquitination	O
of	O
PRLr	B-Protein
is	O
essential	O
for	O
the	O
rapid	O
internalization	O
of	O
PRLr	B-Protein
,	O
which	O
proceeds	O
through	O
a	O
pathway	O
dependent	O
on	O
clathrin	O
and	O
the	O
assembly	O
polypeptide	O
2	O
(	O
AP2	O
)	O
adaptor	O
complexes	O
.	O
<EOS>	B-X
The	B-X
ubiquitination	B-X
of	B-X
the	B-X
receptor	B-X
that	B-X
mediates	B-X
signaling	B-X
induced	B-X
by	B-X
the	B-X
polypeptide	B-X
pituitary	B-X
hormone	B-X
prolactin	B-X
(	B-X
PRL	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
lead	B-X
to	B-X
the	B-X
degradation	B-X
of	B-X
this	B-X
receptor	B-X
and	B-X
to	B-X
the	B-X
ensuing	B-X
negative	B-X
regulation	B-X
of	B-X
cellular	B-X
responses	B-X
to	B-X
PRL	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
of	B-X
PRL	B-X
receptor	B-X
(	B-X
PRLr	B-X
)	B-X
proteolysis	B-X
remain	B-X
largely	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Here	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
PRLr	B-X
is	B-X
internalized	B-X
and	B-X
primarily	B-X
degraded	B-X
via	B-X
the	B-X
lysosomal	B-X
pathway	B-X
.	B-X
Ubiquitination	B-X
of	B-X
PRLr	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
rapid	B-X
internalization	B-X
of	B-X
PRLr	B-X
,	B-X
which	B-X
proceeds	B-X
through	B-X
a	B-X
pathway	B-X
dependent	B-X
on	B-X
clathrin	B-X
and	B-X
the	B-X
assembly	B-X
polypeptide	B-X
2	B-X
(	B-X
AP2	B-X
)	B-X
adaptor	B-X
complexes	B-X
.	B-X
Recruitment	B-X
of	B-X
AP2	B-X
to	B-X
PRLr	B-X
is	B-X
stimulated	B-X
by	B-X
PRLr	B-X
ubiquitination	B-X
,	B-X
which	B-X
also	B-X
is	B-X
required	B-X
for	B-X
the	B-X
targeting	B-X
of	B-X
already	B-X
internalized	B-X
PRLr	B-X
to	B-X
the	B-X
lysosomal	B-X
compartment	B-X
.	B-X
While	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
both	B-X
monoubiquitination	B-X
and	B-X
polyubiquitination	B-X
(	B-X
via	B-X
both	B-X
K48-	B-X
and	B-X
K63-linked	B-X
chains	B-X
)	B-X
occur	B-X
on	B-X
PRLr	B-X
,	B-X
the	B-X
results	B-X
of	B-X
experiments	B-X
using	B-X
forced	B-X
expression	B-X
of	B-X
ubiquitin	B-X
mutants	B-X
indicate	B-X
that	B-X
PRLr	B-X
polyubiquitination	B-X
via	B-X
K63-linked	B-X
chains	B-X
is	B-X
important	B-X
for	B-X
efficient	B-X
interaction	B-X
of	B-X
PRLr	B-X
with	B-X
AP2	B-X
as	B-X
well	B-X
as	B-X
for	B-X
efficient	B-X
internalization	B-X
,	B-X
postinternalization	B-X
sorting	B-X
,	B-X
and	B-X
proteolytic	B-X
turnover	B-X
of	B-X
PRLr	B-X
.	B-X
We	B-X
discuss	B-X
how	B-X
specific	B-X
ubiquitination	B-X
may	B-X
regulate	B-X
early	B-X
and	B-X
late	B-X
stages	B-X
of	B-X
endocytosis	B-X
of	B-X
PRLr	B-X
and	B-X
of	B-X
related	B-X
receptors	B-X
to	B-X
contribute	B-X
to	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
magnitude	B-X
and	B-X
duration	B-X
of	B-X
downstream	B-X
signaling	B-X
.	B-X

Recruitment	O
of	O
AP2	O
to	O
PRLr	B-Protein
is	O
stimulated	O
by	O
PRLr	B-Protein
ubiquitination	O
,	O
which	O
also	O
is	O
required	O
for	O
the	O
targeting	O
of	O
already	O
internalized	O
PRLr	O
to	O
the	O
lysosomal	O
compartment	O
.	O

While	O
mass	O
spectrometry	O
analysis	O
revealed	O
that	O
both	O
monoubiquitination	O
and	O
polyubiquitination	O
(	O
via	O
both	O
K48	O
-	O
and	O
K63	O
-	O
linked	O
chains	O
)	O
occur	O
on	O
PRLr	B-Protein
,	O
the	O
results	O
of	O
experiments	O
using	O
forced	O
expression	O
of	O
ubiquitin	B-Protein
mutants	O
indicate	O
that	O
PRLr	B-Protein
polyubiquitination	O
via	O
K63	O
-	O
linked	O
chains	O
is	O
important	O
for	O
efficient	O
interaction	O
of	O
PRLr	B-Protein
with	O
AP2	O
as	O
well	O
as	O
for	O
efficient	O
internalization	O
,	O
postinternalization	O
sorting	O
,	O
and	O
proteolytic	O
turnover	O
of	O
PRLr	B-Protein
.	O
<EOS>	B-X
The	B-X
ubiquitination	B-X
of	B-X
the	B-X
receptor	B-X
that	B-X
mediates	B-X
signaling	B-X
induced	B-X
by	B-X
the	B-X
polypeptide	B-X
pituitary	B-X
hormone	B-X
prolactin	B-X
(	B-X
PRL	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
lead	B-X
to	B-X
the	B-X
degradation	B-X
of	B-X
this	B-X
receptor	B-X
and	B-X
to	B-X
the	B-X
ensuing	B-X
negative	B-X
regulation	B-X
of	B-X
cellular	B-X
responses	B-X
to	B-X
PRL	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
of	B-X
PRL	B-X
receptor	B-X
(	B-X
PRLr	B-X
)	B-X
proteolysis	B-X
remain	B-X
largely	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Here	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
PRLr	B-X
is	B-X
internalized	B-X
and	B-X
primarily	B-X
degraded	B-X
via	B-X
the	B-X
lysosomal	B-X
pathway	B-X
.	B-X
Ubiquitination	B-X
of	B-X
PRLr	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
rapid	B-X
internalization	B-X
of	B-X
PRLr	B-X
,	B-X
which	B-X
proceeds	B-X
through	B-X
a	B-X
pathway	B-X
dependent	B-X
on	B-X
clathrin	B-X
and	B-X
the	B-X
assembly	B-X
polypeptide	B-X
2	B-X
(	B-X
AP2	B-X
)	B-X
adaptor	B-X
complexes	B-X
.	B-X
Recruitment	B-X
of	B-X
AP2	B-X
to	B-X
PRLr	B-X
is	B-X
stimulated	B-X
by	B-X
PRLr	B-X
ubiquitination	B-X
,	B-X
which	B-X
also	B-X
is	B-X
required	B-X
for	B-X
the	B-X
targeting	B-X
of	B-X
already	B-X
internalized	B-X
PRLr	B-X
to	B-X
the	B-X
lysosomal	B-X
compartment	B-X
.	B-X
While	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
both	B-X
monoubiquitination	B-X
and	B-X
polyubiquitination	B-X
(	B-X
via	B-X
both	B-X
K48-	B-X
and	B-X
K63-linked	B-X
chains	B-X
)	B-X
occur	B-X
on	B-X
PRLr	B-X
,	B-X
the	B-X
results	B-X
of	B-X
experiments	B-X
using	B-X
forced	B-X
expression	B-X
of	B-X
ubiquitin	B-X
mutants	B-X
indicate	B-X
that	B-X
PRLr	B-X
polyubiquitination	B-X
via	B-X
K63-linked	B-X
chains	B-X
is	B-X
important	B-X
for	B-X
efficient	B-X
interaction	B-X
of	B-X
PRLr	B-X
with	B-X
AP2	B-X
as	B-X
well	B-X
as	B-X
for	B-X
efficient	B-X
internalization	B-X
,	B-X
postinternalization	B-X
sorting	B-X
,	B-X
and	B-X
proteolytic	B-X
turnover	B-X
of	B-X
PRLr	B-X
.	B-X
We	B-X
discuss	B-X
how	B-X
specific	B-X
ubiquitination	B-X
may	B-X
regulate	B-X
early	B-X
and	B-X
late	B-X
stages	B-X
of	B-X
endocytosis	B-X
of	B-X
PRLr	B-X
and	B-X
of	B-X
related	B-X
receptors	B-X
to	B-X
contribute	B-X
to	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
magnitude	B-X
and	B-X
duration	B-X
of	B-X
downstream	B-X
signaling	B-X
.	B-X

We	O
discuss	O
how	O
specific	O
ubiquitination	O
may	O
regulate	O
early	O
and	O
late	O
stages	O
of	O
endocytosis	O
of	O
PRLr	B-Protein
and	O
of	O
related	O
receptors	O
to	O
contribute	O
to	O
the	O
negative	O
regulation	O
of	O
the	O
magnitude	O
and	O
duration	O
of	O
downstream	O
signaling	O
.	O

The	O
glycosylation	O
status	O
of	O
murine	O
[	O
corrected	O
]	O
postnatal	O
thymus	O
:	O
a	O
study	O
by	O
histochemistry	O
and	O
lectin	O
blotting	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
changes	B-X
of	B-X
cell	B-X
surface	B-X
glycosylation	B-X
status	B-X
also	B-X
affect	B-X
the	B-X
thymocyte	B-X
maturation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
the	B-X
glycosylation	B-X
alterations	B-X
in	B-X
thymic	B-X
tissues	B-X
from	B-X
1	B-X
,	B-X
9	B-X
,	B-X
13	B-X
and	B-X
16	B-X
days	B-X
old	B-X
mice	B-X
were	B-X
evaluated	B-X
by	B-X
histochemical	B-X
and	B-X
lectin	B-X
blotting	B-X
techniques	B-X
.	B-X
With	B-X
lectin	B-X
blotting	B-X
studies	B-X
,	B-X
five	B-X
glycoprotein	B-X
bands	B-X
of	B-X
molecular	B-X
weights	B-X
approximately	B-X
39	B-X
,	B-X
approximately	B-X
54	B-X
,	B-X
100	B-X
,	B-X
approximately	B-X
110	B-X
and	B-X
approximately	B-X
212	B-X
were	B-X
found	B-X
which	B-X
reacted	B-X
with	B-X
MAL	B-X
,	B-X
PNA	B-X
and	B-X
DSA	B-X
as	B-X
well	B-X
as	B-X
GNA	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
glycosylation	B-X
patterns	B-X
of	B-X
cell	B-X
surface	B-X
glycoconjugates	B-X
are	B-X
modified	B-X
during	B-X
thymocyte	B-X
selection	B-X
processes	B-X
of	B-X
postnatal	B-X
days	B-X
.	B-X

During	O
the	O
intrathymic	O
development	O
,	O
the	O
fate	O
of	O
the	O
thymocytes	O
depends	O
largely	O
on	O
variable	O
expression	O
of	O
CD4	B-Protein
/	O
CD8	O
markers	O
and	O
T	O
cell	O
receptor	O
protein	O
expressions	O
.	O

In	O
addition	O
,	O
changes	O
of	O
cell	O
surface	O
glycosylation	O
status	O
also	O
affect	O
the	O
thymocyte	O
maturation	O
.	O
<EOS>	B-X
In	B-X
the	B-X
thymus	B-X
,	B-X
glycosylation	B-X
status	B-X
of	B-X
many	B-X
cell	B-X
surface	B-X
molecules	B-X
changes	B-X
during	B-X
the	B-X
thymocyte	B-X
maturation	B-X
and	B-X
selection	B-X
processes	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
glycosylation	B-X
changes	B-X
and	B-X
possible	B-X
relationships	B-X
with	B-X
programmed	B-X
cell	B-X
death	B-X
in	B-X
the	B-X
thymic	B-X
tissues	B-X
from	B-X
mouse	B-X
embryos	B-X
at	B-X
the	B-X
days	B-X
14	B-X
(	B-X
E14	B-X
)	B-X
,	B-X
15	B-X
(	B-X
E15	B-X
)	B-X
,	B-X
16	B-X
(	B-X
E16	B-X
)	B-X
,	B-X
17	B-X
(	B-X
E17	B-X
)	B-X
and	B-X
18	B-X
(	B-X
E18	B-X
)	B-X
of	B-X
embryonic	B-X
development	B-X
.	B-X
In	B-X
order	B-X
to	B-X
determine	B-X
glycosylation	B-X
changes	B-X
we	B-X
used	B-X
three	B-X
different	B-X
plant	B-X
lectins	B-X
:	B-X
peanut	B-X
agglutinin	B-X
(	B-X
PNA	B-X
)	B-X
,	B-X
Maackia	B-X
amurensis	B-X
leucoagglutinin	B-X
(	B-X
MAL	B-X
or	B-X
MAAI	B-X
)	B-X
and	B-X
Sambucus	B-X
nigra	B-X
agglutinin	B-X
(	B-X
SNA	B-X
)	B-X
,	B-X
which	B-X
recognize	B-X
core	B-X
disaccharide	B-X
galactose	B-X
(	B-X
1-3	B-X
)	B-X
N-acetylgalactosamine	B-X
[	B-X
Galbeta	B-X
(	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
GalNAc	B-X
]	B-X
,	B-X
sialic	B-X
acid	B-X
linked	B-X
(	B-X
2	B-X
--	B-X
>	B-X
3	B-X
)	B-X
to	B-X
galactose	B-X
[	B-X
SAalpha	B-X
(	B-X
2	B-X
--	B-X
>	B-X
3	B-X
)	B-X
Gal	B-X
]	B-X
and	B-X
sialic	B-X
acid	B-X
linked	B-X
to	B-X
galactose	B-X
[	B-X
SAalpha	B-X
(	B-X
2	B-X
--	B-X
>	B-X
6	B-X
)	B-X
Gal	B-X
]	B-X
structures	B-X
,	B-X
respectively	B-X
.	B-X
Our	B-X
lectin	B-X
histochemistry	B-X
and	B-X
lectin	B-X
blotting	B-X
studies	B-X
indicated	B-X
that	B-X
glycosylation	B-X
pattern	B-X
was	B-X
modified	B-X
in	B-X
thymocytes	B-X
at	B-X
the	B-X
embryonic	B-X
developmental	B-X
stages	B-X
analyzed	B-X
.	B-X
The	B-X
immature	B-X
cortical	B-X
thymocytes	B-X
were	B-X
labeled	B-X
by	B-X
PNA	B-X
,	B-X
whereas	B-X
medullary	B-X
thymocytes	B-X
were	B-X
positive	B-X
for	B-X
MAL	B-X
and	B-X
SNA	B-X
binding	B-X
.	B-X
Many	B-X
medullary	B-X
thymocytes	B-X
exhibited	B-X
alpha	B-X
(	B-X
2	B-X
--	B-X
>	B-X
6	B-X
)	B-X
-linked	B-X
sialic	B-X
acid	B-X
on	B-X
their	B-X
surface	B-X
and	B-X
this	B-X
increased	B-X
throughout	B-X
the	B-X
gestational	B-X
stages	B-X
.	B-X
In	B-X
the	B-X
lectin	B-X
blotting	B-X
studies	B-X
,	B-X
different	B-X
protein	B-X
bands	B-X
of	B-X
various	B-X
molecular	B-X
weights	B-X
were	B-X
identified	B-X
in	B-X
thymocytes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
TUNEL	B-X
(	B-X
deoxynucleotdyltransferase-mediated	B-X
dUDP	B-X
nick	B-X
end	B-X
labeling	B-X
)	B-X
indicated	B-X
that	B-X
only	B-X
PNA-positive	B-X
cortical	B-X
thymocytes	B-X
were	B-X
deleted	B-X
in	B-X
all	B-X
embryonic	B-X
stages	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
glycosylation	B-X
pattern	B-X
was	B-X
modified	B-X
in	B-X
thymocytes	B-X
at	B-X
all	B-X
embryonic	B-X
developmental	B-X
stages	B-X
,	B-X
and	B-X
these	B-X
modifications	B-X
can	B-X
affect	B-X
the	B-X
T	B-X
cell	B-X
deletion	B-X
,	B-X
probably	B-X
via	B-X
the	B-X
galectin-1	B-X
molecule	B-X
in	B-X
the	B-X
embryonic	B-X
thymus	B-X
.	B-X

In	O
this	O
study	O
the	O
glycosylation	O
alterations	O
in	O
thymic	O
tissues	O
from	O
1	O
,	O
9	O
,	O
13	O
and	O
16	O
days	O
old	O
mice	O
were	O
evaluated	O
by	O
histochemical	O
and	O
lectin	O
blotting	O
techniques	O
.	O

With	O
alcian	O
blue	O
(	O
AB	O
)	O
at	O
pH	O
5	O
.	O
7	O
/	O
periodic	O
acid	O
-	O
Schiff	O
(	O
PAS	O
)	O
stainings	O
,	O
it	O
was	O
shown	O
that	O
thymic	O
microenvironments	O
contained	O
carboxlylated	O
and	O
sulfated	O
glycosaminoglycans	O
(	O
GAGs	O
)	O
.	O
<EOS>	B-X
During	B-X
the	B-X
intrathymic	B-X
development	B-X
,	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
thymocytes	B-X
depends	B-X
largely	B-X
on	B-X
variable	B-X
expression	B-X
of	B-X
CD4/CD8	B-X
markers	B-X
and	B-X
T	B-X
cell	B-X
receptor	B-X
protein	B-X
expressions	B-X
.	B-X
In	B-X
this	B-X
study	B-X
the	B-X
glycosylation	B-X
alterations	B-X
in	B-X
thymic	B-X
tissues	B-X
from	B-X
1	B-X
,	B-X
9	B-X
,	B-X
13	B-X
and	B-X
16	B-X
days	B-X
old	B-X
mice	B-X
were	B-X
evaluated	B-X
by	B-X
histochemical	B-X
and	B-X
lectin	B-X
blotting	B-X
techniques	B-X
.	B-X
With	B-X
alcian	B-X
blue	B-X
(	B-X
AB	B-X
)	B-X
at	B-X
pH	B-X
5.7/periodic	B-X
acid-Schiff	B-X
(	B-X
PAS	B-X
)	B-X
stainings	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
thymic	B-X
microenvironments	B-X
contained	B-X
carboxlylated	B-X
and	B-X
sulfated	B-X
glycosaminoglycans	B-X
(	B-X
GAGs	B-X
)	B-X
.	B-X
Strong	B-X
positivity	B-X
to	B-X
AB	B-X
at	B-X
pH	B-X
2.5	B-X
,	B-X
which	B-X
specific	B-X
for	B-X
sialomucins	B-X
,	B-X
was	B-X
seen	B-X
in	B-X
some	B-X
medullary	B-X
thymocytes	B-X
.	B-X
Similarly	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
with	B-X
Maackia	B-X
amurensis	B-X
agglutinin	B-X
(	B-X
MAL	B-X
)	B-X
medullary	B-X
thymocytes	B-X
,	B-X
but	B-X
not	B-X
cortical	B-X
ones	B-X
,	B-X
contained	B-X
alpha	B-X
(	B-X
2	B-X
--	B-X
>	B-X
3	B-X
)	B-X
linked	B-X
sialic	B-X
acid	B-X
structures	B-X
.	B-X
However	B-X
,	B-X
Datura	B-X
stramonium	B-X
agglutinin	B-X
(	B-X
DSA	B-X
)	B-X
,	B-X
which	B-X
recognizes	B-X
galactose	B-X
beta	B-X
(	B-X
1	B-X
--	B-X
>	B-X
4	B-X
)	B-X
N-acetylglucosamine	B-X
,	B-X
was	B-X
not	B-X
only	B-X
cell-specific	B-X
,	B-X
but	B-X
it	B-X
was	B-X
bound	B-X
some	B-X
thymic	B-X
vessels	B-X
.	B-X
With	B-X
lectin	B-X
blotting	B-X
studies	B-X
,	B-X
five	B-X
glycoprotein	B-X
bands	B-X
of	B-X
molecular	B-X
weights	B-X
approximately	B-X
39	B-X
,	B-X
approximately	B-X
54	B-X
,	B-X
100	B-X
,	B-X
approximately	B-X
110	B-X
and	B-X
approximately	B-X
212	B-X
were	B-X
found	B-X
which	B-X
reacted	B-X
with	B-X
MAL	B-X
,	B-X
PNA	B-X
and	B-X
DSA	B-X
as	B-X
well	B-X
as	B-X
GNA	B-X
.	B-X

Strong	O
positivity	O
to	O
AB	O
at	O
pH	O
2	O
.	O
5	O
,	O
which	O
specific	O
for	O
sialomucins	O
,	O
was	O
seen	O
in	O
some	O
medullary	O
thymocytes	O
.	O
<EOS>	B-X
During	B-X
the	B-X
intrathymic	B-X
development	B-X
,	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
thymocytes	B-X
depends	B-X
largely	B-X
on	B-X
variable	B-X
expression	B-X
of	B-X
CD4/CD8	B-X
markers	B-X
and	B-X
T	B-X
cell	B-X
receptor	B-X
protein	B-X
expressions	B-X
.	B-X
With	B-X
alcian	B-X
blue	B-X
(	B-X
AB	B-X
)	B-X
at	B-X
pH	B-X
5.7/periodic	B-X
acid-Schiff	B-X
(	B-X
PAS	B-X
)	B-X
stainings	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
thymic	B-X
microenvironments	B-X
contained	B-X
carboxlylated	B-X
and	B-X
sulfated	B-X
glycosaminoglycans	B-X
(	B-X
GAGs	B-X
)	B-X
.	B-X
Strong	B-X
positivity	B-X
to	B-X
AB	B-X
at	B-X
pH	B-X
2.5	B-X
,	B-X
which	B-X
specific	B-X
for	B-X
sialomucins	B-X
,	B-X
was	B-X
seen	B-X
in	B-X
some	B-X
medullary	B-X
thymocytes	B-X
.	B-X
Similarly	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
with	B-X
Maackia	B-X
amurensis	B-X
agglutinin	B-X
(	B-X
MAL	B-X
)	B-X
medullary	B-X
thymocytes	B-X
,	B-X
but	B-X
not	B-X
cortical	B-X
ones	B-X
,	B-X
contained	B-X
alpha	B-X
(	B-X
2	B-X
--	B-X
>	B-X
3	B-X
)	B-X
linked	B-X
sialic	B-X
acid	B-X
structures	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
while	B-X
reaction	B-X
with	B-X
peanut	B-X
agglutinin	B-X
(	B-X
PNA	B-X
)	B-X
,	B-X
which	B-X
specific	B-X
for	B-X
core	B-X
disaccharide	B-X
galactose	B-X
beta	B-X
(	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
N-acetylgalactosamine	B-X
,	B-X
was	B-X
only	B-X
seen	B-X
in	B-X
cortical	B-X
thymocytes	B-X
,	B-X
reaction	B-X
with	B-X
Galanthus	B-X
nivalis	B-X
agglutinin	B-X
(	B-X
GNA	B-X
)	B-X
,	B-X
which	B-X
specific	B-X
for	B-X
terminal	B-X
mannose	B-X
residues	B-X
,	B-X
was	B-X
seen	B-X
in	B-X
both	B-X
cortex	B-X
and	B-X
medulla	B-X
.	B-X
However	B-X
,	B-X
Datura	B-X
stramonium	B-X
agglutinin	B-X
(	B-X
DSA	B-X
)	B-X
,	B-X
which	B-X
recognizes	B-X
galactose	B-X
beta	B-X
(	B-X
1	B-X
--	B-X
>	B-X
4	B-X
)	B-X
N-acetylglucosamine	B-X
,	B-X
was	B-X
not	B-X
only	B-X
cell-specific	B-X
,	B-X
but	B-X
it	B-X
was	B-X
bound	B-X
some	B-X
thymic	B-X
vessels	B-X
.	B-X
With	B-X
lectin	B-X
blotting	B-X
studies	B-X
,	B-X
five	B-X
glycoprotein	B-X
bands	B-X
of	B-X
molecular	B-X
weights	B-X
approximately	B-X
39	B-X
,	B-X
approximately	B-X
54	B-X
,	B-X
100	B-X
,	B-X
approximately	B-X
110	B-X
and	B-X
approximately	B-X
212	B-X
were	B-X
found	B-X
which	B-X
reacted	B-X
with	B-X
MAL	B-X
,	B-X
PNA	B-X
and	B-X
DSA	B-X
as	B-X
well	B-X
as	B-X
GNA	B-X
.	B-X

Similarly	O
,	O
it	O
was	O
shown	O
that	O
with	O
Maackia	O
amurensis	O
agglutinin	O
(	O
MAL	O
)	O
medullary	O
thymocytes	O
,	O
but	O
not	O
cortical	O
ones	O
,	O
contained	O
alpha	O
(	O
2	O
-	O
-	O
>	O
3	O
)	O
linked	O
sialic	O
acid	O
structures	O
.	O

On	O
the	O
other	O
hand	O
,	O
while	O
reaction	O
with	O
peanut	O
agglutinin	B-Protein
(	O
PNA	B-Protein
)	O
,	O
which	O
specific	O
for	O
core	O
disaccharide	O
galactose	O
beta	O
(	O
1	O
-	O
-	O
>	O
3	O
)	O
N	O
-	O
acetylgalactosamine	O
,	O
was	O
only	O
seen	O
in	O
cortical	O
thymocytes	O
,	O
reaction	O
with	O
Galanthus	O
nivalis	O
agglutinin	B-Protein
(	O
GNA	B-Protein
)	O
,	O
which	O
specific	O
for	O
terminal	O
mannose	O
residues	O
,	O
was	O
seen	O
in	O
both	O
cortex	O
and	O
medulla	O
.	O

However	O
,	O
Datura	O
stramonium	O
agglutinin	O
(	O
DSA	O
)	O
,	O
which	O
recognizes	O
galactose	O
beta	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
N	O
-	O
acetylglucosamine	O
,	O
was	O
not	O
only	O
cell	O
-	O
specific	O
,	O
but	O
it	O
was	O
bound	O
some	O
thymic	O
vessels	O
.	O

With	O
lectin	O
blotting	O
studies	O
,	O
five	O
glycoprotein	O
bands	O
of	O
molecular	O
weights	O
approximately	O
39	O
,	O
approximately	O
54	O
,	O
100	O
,	O
approximately	O
110	O
and	O
approximately	O
212	O
were	O
found	O
which	O
reacted	O
with	O
MAL	O
,	O
PNA	B-Protein
and	O
DSA	O
as	O
well	O
as	O
GNA	B-Protein
.	O

These	O
results	O
suggest	O
that	O
glycosylation	O
patterns	O
of	O
cell	O
surface	O
glycoconjugates	O
are	O
modified	O
during	O
thymocyte	O
selection	O
processes	O
of	O
postnatal	O
days	O
.	O
<EOS>	B-X
During	B-X
the	B-X
intrathymic	B-X
development	B-X
,	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
thymocytes	B-X
depends	B-X
largely	B-X
on	B-X
variable	B-X
expression	B-X
of	B-X
CD4/CD8	B-X
markers	B-X
and	B-X
T	B-X
cell	B-X
receptor	B-X
protein	B-X
expressions	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
changes	B-X
of	B-X
cell	B-X
surface	B-X
glycosylation	B-X
status	B-X
also	B-X
affect	B-X
the	B-X
thymocyte	B-X
maturation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
the	B-X
glycosylation	B-X
alterations	B-X
in	B-X
thymic	B-X
tissues	B-X
from	B-X
1	B-X
,	B-X
9	B-X
,	B-X
13	B-X
and	B-X
16	B-X
days	B-X
old	B-X
mice	B-X
were	B-X
evaluated	B-X
by	B-X
histochemical	B-X
and	B-X
lectin	B-X
blotting	B-X
techniques	B-X
.	B-X
Strong	B-X
positivity	B-X
to	B-X
AB	B-X
at	B-X
pH	B-X
2.5	B-X
,	B-X
which	B-X
specific	B-X
for	B-X
sialomucins	B-X
,	B-X
was	B-X
seen	B-X
in	B-X
some	B-X
medullary	B-X
thymocytes	B-X
.	B-X
Similarly	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
with	B-X
Maackia	B-X
amurensis	B-X
agglutinin	B-X
(	B-X
MAL	B-X
)	B-X
medullary	B-X
thymocytes	B-X
,	B-X
but	B-X
not	B-X
cortical	B-X
ones	B-X
,	B-X
contained	B-X
alpha	B-X
(	B-X
2	B-X
--	B-X
>	B-X
3	B-X
)	B-X
linked	B-X
sialic	B-X
acid	B-X
structures	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
while	B-X
reaction	B-X
with	B-X
peanut	B-X
agglutinin	B-X
(	B-X
PNA	B-X
)	B-X
,	B-X
which	B-X
specific	B-X
for	B-X
core	B-X
disaccharide	B-X
galactose	B-X
beta	B-X
(	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
N-acetylgalactosamine	B-X
,	B-X
was	B-X
only	B-X
seen	B-X
in	B-X
cortical	B-X
thymocytes	B-X
,	B-X
reaction	B-X
with	B-X
Galanthus	B-X
nivalis	B-X
agglutinin	B-X
(	B-X
GNA	B-X
)	B-X
,	B-X
which	B-X
specific	B-X
for	B-X
terminal	B-X
mannose	B-X
residues	B-X
,	B-X
was	B-X
seen	B-X
in	B-X
both	B-X
cortex	B-X
and	B-X
medulla	B-X
.	B-X
However	B-X
,	B-X
Datura	B-X
stramonium	B-X
agglutinin	B-X
(	B-X
DSA	B-X
)	B-X
,	B-X
which	B-X
recognizes	B-X
galactose	B-X
beta	B-X
(	B-X
1	B-X
--	B-X
>	B-X
4	B-X
)	B-X
N-acetylglucosamine	B-X
,	B-X
was	B-X
not	B-X
only	B-X
cell-specific	B-X
,	B-X
but	B-X
it	B-X
was	B-X
bound	B-X
some	B-X
thymic	B-X
vessels	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
glycosylation	B-X
patterns	B-X
of	B-X
cell	B-X
surface	B-X
glycoconjugates	B-X
are	B-X
modified	B-X
during	B-X
thymocyte	B-X
selection	B-X
processes	B-X
of	B-X
postnatal	B-X
days	B-X
.	B-X

Chemical	O
and	O
structural	O
probing	O
of	O
the	O
N	O
-	O
terminal	O
residues	O
encoded	O
by	O
FMR1	B-Protein
exon	O
15	O
and	O
their	O
effect	O
on	O
downstream	O
arginine	O
methylation	O
.	O

Exon	O
15	O
of	O
the	O
fragile	O
X	O
mental	O
retardation	O
protein	O
gene	O
(	O
FMR1	B-Protein
)	O
is	O
alternatively	O
spliced	O
into	O
three	O
variants	O
.	O
<EOS>	B-X
Exon	B-X
15	B-X
of	B-X
the	B-X
fragile	B-X
X	B-X
mental	B-X
retardation	B-X
protein	B-X
gene	B-X
(	B-X
FMR1	B-X
)	B-X
is	B-X
alternatively	B-X
spliced	B-X
into	B-X
three	B-X
variants	B-X
.	B-X
Previous	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
exon	B-X
15-encoded	B-X
N-terminal	B-X
residues	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
arginine	B-X
methylation	B-X
,	B-X
independent	B-X
of	B-X
S	B-X
500	B-X
phosphorylation	B-X
.	B-X
Chemical	B-X
and	B-X
structural	B-X
probing	B-X
of	B-X
Ex15	B-X
alternatively	B-X
spliced	B-X
variant	B-X
proteins	B-X
and	B-X
several	B-X
mutants	B-X
leads	B-X
to	B-X
the	B-X
following	B-X
conclusions	B-X
:	B-X
Ex15c	B-X
resides	B-X
largely	B-X
in	B-X
a	B-X
conformation	B-X
that	B-X
is	B-X
refractory	B-X
toward	B-X
methylation	B-X
;	B-X
however	B-X
,	B-X
it	B-X
can	B-X
be	B-X
methylated	B-X
by	B-X
supplementing	B-X
extracts	B-X
with	B-X
recombinant	B-X
PRMT1	B-X
or	B-X
PRMT3	B-X
.	B-X
Protein	B-X
modeling	B-X
studies	B-X
reveal	B-X
that	B-X
the	B-X
RG-rich	B-X
region	B-X
is	B-X
part	B-X
of	B-X
a	B-X
three	B-X
to	B-X
four	B-X
strand	B-X
antiparallel	B-X
beta-sheet	B-X
,	B-X
which	B-X
in	B-X
other	B-X
RNA	B-X
binding	B-X
proteins	B-X
functions	B-X
as	B-X
a	B-X
platform	B-X
for	B-X
nucleic	B-X
acid	B-X
interactions	B-X
.	B-X
In	B-X
the	B-X
Ex15c	B-X
variant	B-X
the	B-X
first	B-X
strand	B-X
of	B-X
this	B-X
sheet	B-X
is	B-X
truncated	B-X
,	B-X
and	B-X
this	B-X
significantly	B-X
perturbs	B-X
the	B-X
side-chain	B-X
conformations	B-X
of	B-X
the	B-X
arginine	B-X
residues	B-X
in	B-X
the	B-X
RG-rich	B-X
region	B-X
.	B-X

The	O
amino	O
acids	O
encoded	O
by	O
the	O
5	O
'	O
end	O
of	O
the	O
exon	O
contain	O
several	O
regulatory	O
determinants	O
including	O
phosphorylation	O
sites	O
and	O
a	O
potential	O
conformational	O
switch	O
.	O

Residues	O
encoded	O
by	O
the	O
3	O
'	O
end	O
of	O
the	O
exon	O
specify	O
FMRP	O
'	O
s	O
RGG	O
box	O
,	O
an	O
RNA	O
binding	O
domain	O
that	O
interacts	O
with	O
G	O
-	O
quartet	O
motifs	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
exon	O
15	O
-	O
encoded	O
N	O
-	O
terminal	O
residues	O
influence	O
the	O
extent	O
of	O
arginine	O
methylation	O
,	O
independent	O
of	O
S	O
500	O
phosphorylation	O
.	O
<EOS>	B-X
Exon	B-X
15	B-X
of	B-X
the	B-X
fragile	B-X
X	B-X
mental	B-X
retardation	B-X
protein	B-X
gene	B-X
(	B-X
FMR1	B-X
)	B-X
is	B-X
alternatively	B-X
spliced	B-X
into	B-X
three	B-X
variants	B-X
.	B-X
The	B-X
amino	B-X
acids	B-X
encoded	B-X
by	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
exon	B-X
contain	B-X
several	B-X
regulatory	B-X
determinants	B-X
including	B-X
phosphorylation	B-X
sites	B-X
and	B-X
a	B-X
potential	B-X
conformational	B-X
switch	B-X
.	B-X
Residues	B-X
encoded	B-X
by	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
exon	B-X
specify	B-X
FMRP	B-X
's	B-X
RGG	B-X
box	B-X
,	B-X
an	B-X
RNA	B-X
binding	B-X
domain	B-X
that	B-X
interacts	B-X
with	B-X
G-quartet	B-X
motifs	B-X
.	B-X
Previous	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
exon	B-X
15-encoded	B-X
N-terminal	B-X
residues	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
arginine	B-X
methylation	B-X
,	B-X
independent	B-X
of	B-X
S	B-X
500	B-X
phosphorylation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
role	B-X
the	B-X
putative	B-X
conformational	B-X
switch	B-X
plays	B-X
in	B-X
arginine	B-X
methylation	B-X
.	B-X
Chemical	B-X
and	B-X
structural	B-X
probing	B-X
of	B-X
Ex15	B-X
alternatively	B-X
spliced	B-X
variant	B-X
proteins	B-X
and	B-X
several	B-X
mutants	B-X
leads	B-X
to	B-X
the	B-X
following	B-X
conclusions	B-X
:	B-X
Ex15c	B-X
resides	B-X
largely	B-X
in	B-X
a	B-X
conformation	B-X
that	B-X
is	B-X
refractory	B-X
toward	B-X
methylation	B-X
;	B-X
however	B-X
,	B-X
it	B-X
can	B-X
be	B-X
methylated	B-X
by	B-X
supplementing	B-X
extracts	B-X
with	B-X
recombinant	B-X
PRMT1	B-X
or	B-X
PRMT3	B-X
.	B-X
Protein	B-X
modeling	B-X
studies	B-X
reveal	B-X
that	B-X
the	B-X
RG-rich	B-X
region	B-X
is	B-X
part	B-X
of	B-X
a	B-X
three	B-X
to	B-X
four	B-X
strand	B-X
antiparallel	B-X
beta-sheet	B-X
,	B-X
which	B-X
in	B-X
other	B-X
RNA	B-X
binding	B-X
proteins	B-X
functions	B-X
as	B-X
a	B-X
platform	B-X
for	B-X
nucleic	B-X
acid	B-X
interactions	B-X
.	B-X
In	B-X
the	B-X
Ex15c	B-X
variant	B-X
the	B-X
first	B-X
strand	B-X
of	B-X
this	B-X
sheet	B-X
is	B-X
truncated	B-X
,	B-X
and	B-X
this	B-X
significantly	B-X
perturbs	B-X
the	B-X
side-chain	B-X
conformations	B-X
of	B-X
the	B-X
arginine	B-X
residues	B-X
in	B-X
the	B-X
RG-rich	B-X
region	B-X
.	B-X
Mutating	B-X
R	B-X
507	B-X
in	B-X
the	B-X
conformational	B-X
switch	B-X
to	B-X
K	B-X
also	B-X
truncates	B-X
the	B-X
first	B-X
strand	B-X
of	B-X
the	B-X
beta-sheet	B-X
,	B-X
and	B-X
corresponding	B-X
decreases	B-X
in	B-X
in	B-X
vitro	B-X
methylation	B-X
were	B-X
found	B-X
for	B-X
this	B-X
and	B-X
R	B-X
507/R	B-X
544	B-X
and	B-X
R	B-X
507/R	B-X
546	B-X
double	B-X
mutants	B-X
.	B-X
These	B-X
effects	B-X
are	B-X
not	B-X
due	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
R	B-X
507	B-X
methylation	B-X
as	B-X
a	B-X
conformational	B-X
switch-containing	B-X
peptide	B-X
reacted	B-X
under	B-X
substrate	B-X
excess	B-X
and	B-X
in	B-X
methyl	B-X
donor	B-X
excess	B-X
was	B-X
not	B-X
significantly	B-X
methylated	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
similar	B-X
changes	B-X
in	B-X
beta-sheet	B-X
structure	B-X
and	B-X
decreases	B-X
in	B-X
in	B-X
vitro	B-X
methylation	B-X
were	B-X
observed	B-X
with	B-X
a	B-X
W	B-X
513-K	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
novel	B-X
model	B-X
for	B-X
FMRP	B-X
arginine	B-X
methylation	B-X
and	B-X
a	B-X
role	B-X
for	B-X
conformational	B-X
switch	B-X
residues	B-X
in	B-X
arginine	B-X
modification	B-X
.	B-X

In	O
the	O
present	O
study	O
we	O
focus	O
on	O
the	O
role	O
the	O
putative	O
conformational	O
switch	O
plays	O
in	O
arginine	O
methylation	O
.	O
<EOS>	B-X
The	B-X
amino	B-X
acids	B-X
encoded	B-X
by	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
exon	B-X
contain	B-X
several	B-X
regulatory	B-X
determinants	B-X
including	B-X
phosphorylation	B-X
sites	B-X
and	B-X
a	B-X
potential	B-X
conformational	B-X
switch	B-X
.	B-X
Previous	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
exon	B-X
15-encoded	B-X
N-terminal	B-X
residues	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
arginine	B-X
methylation	B-X
,	B-X
independent	B-X
of	B-X
S	B-X
500	B-X
phosphorylation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
role	B-X
the	B-X
putative	B-X
conformational	B-X
switch	B-X
plays	B-X
in	B-X
arginine	B-X
methylation	B-X
.	B-X
Chemical	B-X
and	B-X
structural	B-X
probing	B-X
of	B-X
Ex15	B-X
alternatively	B-X
spliced	B-X
variant	B-X
proteins	B-X
and	B-X
several	B-X
mutants	B-X
leads	B-X
to	B-X
the	B-X
following	B-X
conclusions	B-X
:	B-X
Ex15c	B-X
resides	B-X
largely	B-X
in	B-X
a	B-X
conformation	B-X
that	B-X
is	B-X
refractory	B-X
toward	B-X
methylation	B-X
;	B-X
however	B-X
,	B-X
it	B-X
can	B-X
be	B-X
methylated	B-X
by	B-X
supplementing	B-X
extracts	B-X
with	B-X
recombinant	B-X
PRMT1	B-X
or	B-X
PRMT3	B-X
.	B-X
In	B-X
the	B-X
Ex15c	B-X
variant	B-X
the	B-X
first	B-X
strand	B-X
of	B-X
this	B-X
sheet	B-X
is	B-X
truncated	B-X
,	B-X
and	B-X
this	B-X
significantly	B-X
perturbs	B-X
the	B-X
side-chain	B-X
conformations	B-X
of	B-X
the	B-X
arginine	B-X
residues	B-X
in	B-X
the	B-X
RG-rich	B-X
region	B-X
.	B-X
Mutating	B-X
R	B-X
507	B-X
in	B-X
the	B-X
conformational	B-X
switch	B-X
to	B-X
K	B-X
also	B-X
truncates	B-X
the	B-X
first	B-X
strand	B-X
of	B-X
the	B-X
beta-sheet	B-X
,	B-X
and	B-X
corresponding	B-X
decreases	B-X
in	B-X
in	B-X
vitro	B-X
methylation	B-X
were	B-X
found	B-X
for	B-X
this	B-X
and	B-X
R	B-X
507/R	B-X
544	B-X
and	B-X
R	B-X
507/R	B-X
546	B-X
double	B-X
mutants	B-X
.	B-X
These	B-X
effects	B-X
are	B-X
not	B-X
due	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
R	B-X
507	B-X
methylation	B-X
as	B-X
a	B-X
conformational	B-X
switch-containing	B-X
peptide	B-X
reacted	B-X
under	B-X
substrate	B-X
excess	B-X
and	B-X
in	B-X
methyl	B-X
donor	B-X
excess	B-X
was	B-X
not	B-X
significantly	B-X
methylated	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
similar	B-X
changes	B-X
in	B-X
beta-sheet	B-X
structure	B-X
and	B-X
decreases	B-X
in	B-X
in	B-X
vitro	B-X
methylation	B-X
were	B-X
observed	B-X
with	B-X
a	B-X
W	B-X
513-K	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
novel	B-X
model	B-X
for	B-X
FMRP	B-X
arginine	B-X
methylation	B-X
and	B-X
a	B-X
role	B-X
for	B-X
conformational	B-X
switch	B-X
residues	B-X
in	B-X
arginine	B-X
modification	B-X
.	B-X

Chemical	O
and	O
structural	O
probing	O
of	O
Ex15	O
alternatively	O
spliced	O
variant	O
proteins	O
and	O
several	O
mutants	O
leads	O
to	O
the	O
following	O
conclusions	O
:	O
Ex15c	O
resides	O
largely	O
in	O
a	O
conformation	O
that	O
is	O
refractory	O
toward	O
methylation	O
;	O
however	O
,	O
it	O
can	O
be	O
methylated	O
by	O
supplementing	O
extracts	O
with	O
recombinant	O
PRMT1	B-Protein
or	O
PRMT3	B-Protein
.	O

Protein	O
modeling	O
studies	O
reveal	O
that	O
the	O
RG	O
-	O
rich	O
region	O
is	O
part	O
of	O
a	O
three	O
to	O
four	O
strand	O
antiparallel	O
beta	O
-	O
sheet	O
,	O
which	O
in	O
other	O
RNA	O
binding	O
proteins	O
functions	O
as	O
a	O
platform	O
for	O
nucleic	O
acid	O
interactions	O
.	O
<EOS>	B-X
Exon	B-X
15	B-X
of	B-X
the	B-X
fragile	B-X
X	B-X
mental	B-X
retardation	B-X
protein	B-X
gene	B-X
(	B-X
FMR1	B-X
)	B-X
is	B-X
alternatively	B-X
spliced	B-X
into	B-X
three	B-X
variants	B-X
.	B-X
The	B-X
amino	B-X
acids	B-X
encoded	B-X
by	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
exon	B-X
contain	B-X
several	B-X
regulatory	B-X
determinants	B-X
including	B-X
phosphorylation	B-X
sites	B-X
and	B-X
a	B-X
potential	B-X
conformational	B-X
switch	B-X
.	B-X
Residues	B-X
encoded	B-X
by	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
exon	B-X
specify	B-X
FMRP	B-X
's	B-X
RGG	B-X
box	B-X
,	B-X
an	B-X
RNA	B-X
binding	B-X
domain	B-X
that	B-X
interacts	B-X
with	B-X
G-quartet	B-X
motifs	B-X
.	B-X
Previous	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
exon	B-X
15-encoded	B-X
N-terminal	B-X
residues	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
arginine	B-X
methylation	B-X
,	B-X
independent	B-X
of	B-X
S	B-X
500	B-X
phosphorylation	B-X
.	B-X
Chemical	B-X
and	B-X
structural	B-X
probing	B-X
of	B-X
Ex15	B-X
alternatively	B-X
spliced	B-X
variant	B-X
proteins	B-X
and	B-X
several	B-X
mutants	B-X
leads	B-X
to	B-X
the	B-X
following	B-X
conclusions	B-X
:	B-X
Ex15c	B-X
resides	B-X
largely	B-X
in	B-X
a	B-X
conformation	B-X
that	B-X
is	B-X
refractory	B-X
toward	B-X
methylation	B-X
;	B-X
however	B-X
,	B-X
it	B-X
can	B-X
be	B-X
methylated	B-X
by	B-X
supplementing	B-X
extracts	B-X
with	B-X
recombinant	B-X
PRMT1	B-X
or	B-X
PRMT3	B-X
.	B-X
Protein	B-X
modeling	B-X
studies	B-X
reveal	B-X
that	B-X
the	B-X
RG-rich	B-X
region	B-X
is	B-X
part	B-X
of	B-X
a	B-X
three	B-X
to	B-X
four	B-X
strand	B-X
antiparallel	B-X
beta-sheet	B-X
,	B-X
which	B-X
in	B-X
other	B-X
RNA	B-X
binding	B-X
proteins	B-X
functions	B-X
as	B-X
a	B-X
platform	B-X
for	B-X
nucleic	B-X
acid	B-X
interactions	B-X
.	B-X
In	B-X
the	B-X
Ex15c	B-X
variant	B-X
the	B-X
first	B-X
strand	B-X
of	B-X
this	B-X
sheet	B-X
is	B-X
truncated	B-X
,	B-X
and	B-X
this	B-X
significantly	B-X
perturbs	B-X
the	B-X
side-chain	B-X
conformations	B-X
of	B-X
the	B-X
arginine	B-X
residues	B-X
in	B-X
the	B-X
RG-rich	B-X
region	B-X
.	B-X
Mutating	B-X
R	B-X
507	B-X
in	B-X
the	B-X
conformational	B-X
switch	B-X
to	B-X
K	B-X
also	B-X
truncates	B-X
the	B-X
first	B-X
strand	B-X
of	B-X
the	B-X
beta-sheet	B-X
,	B-X
and	B-X
corresponding	B-X
decreases	B-X
in	B-X
in	B-X
vitro	B-X
methylation	B-X
were	B-X
found	B-X
for	B-X
this	B-X
and	B-X
R	B-X
507/R	B-X
544	B-X
and	B-X
R	B-X
507/R	B-X
546	B-X
double	B-X
mutants	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
similar	B-X
changes	B-X
in	B-X
beta-sheet	B-X
structure	B-X
and	B-X
decreases	B-X
in	B-X
in	B-X
vitro	B-X
methylation	B-X
were	B-X
observed	B-X
with	B-X
a	B-X
W	B-X
513-K	B-X
mutant	B-X
.	B-X

In	O
the	O
Ex15c	O
variant	O
the	O
first	O
strand	O
of	O
this	O
sheet	O
is	O
truncated	O
,	O
and	O
this	O
significantly	O
perturbs	O
the	O
side	O
-	O
chain	O
conformations	O
of	O
the	O
arginine	O
residues	O
in	O
the	O
RG	O
-	O
rich	O
region	O
.	O
<EOS>	B-X
Exon	B-X
15	B-X
of	B-X
the	B-X
fragile	B-X
X	B-X
mental	B-X
retardation	B-X
protein	B-X
gene	B-X
(	B-X
FMR1	B-X
)	B-X
is	B-X
alternatively	B-X
spliced	B-X
into	B-X
three	B-X
variants	B-X
.	B-X
Residues	B-X
encoded	B-X
by	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
exon	B-X
specify	B-X
FMRP	B-X
's	B-X
RGG	B-X
box	B-X
,	B-X
an	B-X
RNA	B-X
binding	B-X
domain	B-X
that	B-X
interacts	B-X
with	B-X
G-quartet	B-X
motifs	B-X
.	B-X
Previous	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
exon	B-X
15-encoded	B-X
N-terminal	B-X
residues	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
arginine	B-X
methylation	B-X
,	B-X
independent	B-X
of	B-X
S	B-X
500	B-X
phosphorylation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
role	B-X
the	B-X
putative	B-X
conformational	B-X
switch	B-X
plays	B-X
in	B-X
arginine	B-X
methylation	B-X
.	B-X
Chemical	B-X
and	B-X
structural	B-X
probing	B-X
of	B-X
Ex15	B-X
alternatively	B-X
spliced	B-X
variant	B-X
proteins	B-X
and	B-X
several	B-X
mutants	B-X
leads	B-X
to	B-X
the	B-X
following	B-X
conclusions	B-X
:	B-X
Ex15c	B-X
resides	B-X
largely	B-X
in	B-X
a	B-X
conformation	B-X
that	B-X
is	B-X
refractory	B-X
toward	B-X
methylation	B-X
;	B-X
however	B-X
,	B-X
it	B-X
can	B-X
be	B-X
methylated	B-X
by	B-X
supplementing	B-X
extracts	B-X
with	B-X
recombinant	B-X
PRMT1	B-X
or	B-X
PRMT3	B-X
.	B-X
Protein	B-X
modeling	B-X
studies	B-X
reveal	B-X
that	B-X
the	B-X
RG-rich	B-X
region	B-X
is	B-X
part	B-X
of	B-X
a	B-X
three	B-X
to	B-X
four	B-X
strand	B-X
antiparallel	B-X
beta-sheet	B-X
,	B-X
which	B-X
in	B-X
other	B-X
RNA	B-X
binding	B-X
proteins	B-X
functions	B-X
as	B-X
a	B-X
platform	B-X
for	B-X
nucleic	B-X
acid	B-X
interactions	B-X
.	B-X
In	B-X
the	B-X
Ex15c	B-X
variant	B-X
the	B-X
first	B-X
strand	B-X
of	B-X
this	B-X
sheet	B-X
is	B-X
truncated	B-X
,	B-X
and	B-X
this	B-X
significantly	B-X
perturbs	B-X
the	B-X
side-chain	B-X
conformations	B-X
of	B-X
the	B-X
arginine	B-X
residues	B-X
in	B-X
the	B-X
RG-rich	B-X
region	B-X
.	B-X
Mutating	B-X
R	B-X
507	B-X
in	B-X
the	B-X
conformational	B-X
switch	B-X
to	B-X
K	B-X
also	B-X
truncates	B-X
the	B-X
first	B-X
strand	B-X
of	B-X
the	B-X
beta-sheet	B-X
,	B-X
and	B-X
corresponding	B-X
decreases	B-X
in	B-X
in	B-X
vitro	B-X
methylation	B-X
were	B-X
found	B-X
for	B-X
this	B-X
and	B-X
R	B-X
507/R	B-X
544	B-X
and	B-X
R	B-X
507/R	B-X
546	B-X
double	B-X
mutants	B-X
.	B-X
These	B-X
effects	B-X
are	B-X
not	B-X
due	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
R	B-X
507	B-X
methylation	B-X
as	B-X
a	B-X
conformational	B-X
switch-containing	B-X
peptide	B-X
reacted	B-X
under	B-X
substrate	B-X
excess	B-X
and	B-X
in	B-X
methyl	B-X
donor	B-X
excess	B-X
was	B-X
not	B-X
significantly	B-X
methylated	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
similar	B-X
changes	B-X
in	B-X
beta-sheet	B-X
structure	B-X
and	B-X
decreases	B-X
in	B-X
in	B-X
vitro	B-X
methylation	B-X
were	B-X
observed	B-X
with	B-X
a	B-X
W	B-X
513-K	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
novel	B-X
model	B-X
for	B-X
FMRP	B-X
arginine	B-X
methylation	B-X
and	B-X
a	B-X
role	B-X
for	B-X
conformational	B-X
switch	B-X
residues	B-X
in	B-X
arginine	B-X
modification	B-X
.	B-X

Mutating	O
R	O
507	O
in	O
the	O
conformational	O
switch	O
to	O
K	O
also	O
truncates	O
the	O
first	O
strand	O
of	O
the	O
beta	O
-	O
sheet	O
,	O
and	O
corresponding	O
decreases	O
in	O
in	O
vitro	O
methylation	O
were	O
found	O
for	O
this	O
and	O
R	O
507	O
/	O
R	O
544	O
and	O
R	O
507	O
/	O
R	O
546	O
double	O
mutants	O
.	O

These	O
effects	O
are	O
not	O
due	O
to	O
the	O
loss	O
of	O
R	O
507	O
methylation	O
as	O
a	O
conformational	O
switch	O
-	O
containing	O
peptide	O
reacted	O
under	O
substrate	O
excess	O
and	O
in	O
methyl	O
donor	O
excess	O
was	O
not	O
significantly	O
methylated	O
.	O
<EOS>	B-X
Mindfulness-based	B-X
approaches	B-X
are	B-X
growing	B-X
in	B-X
popularity	B-X
as	B-X
interventions	B-X
for	B-X
disordered	B-X
eating	B-X
and	B-X
weight	B-X
loss	B-X
.	B-X
Using	B-X
the	B-X
PRISMA	B-X
method	B-X
for	B-X
systematic	B-X
reviews	B-X
,	B-X
we	B-X
reviewed	B-X
14	B-X
studies	B-X
that	B-X
investigated	B-X
mindfulness	B-X
meditation	B-X
as	B-X
the	B-X
primary	B-X
intervention	B-X
and	B-X
assessed	B-X
binge	B-X
eating	B-X
,	B-X
emotional	B-X
eating	B-X
,	B-X
and/or	B-X
weight	B-X
change	B-X
.	B-X
Results	B-X
suggest	B-X
that	B-X
mindfulness	B-X
meditation	B-X
effectively	B-X
decreases	B-X
binge	B-X
eating	B-X
and	B-X
emotional	B-X
eating	B-X
in	B-X
populations	B-X
engaging	B-X
in	B-X
this	B-X
behavior	B-X
;	B-X
evidence	B-X
for	B-X
its	B-X
effect	B-X
on	B-X
weight	B-X
is	B-X
mixed	B-X
.	B-X
Additional	B-X
research	B-X
is	B-X
warranted	B-X
to	B-X
determine	B-X
comparative	B-X
effectiveness	B-X
and	B-X
long-term	B-X
effects	B-X
of	B-X
mindfulness	B-X
training	B-X
.	B-X

Consistent	O
with	O
this	O
,	O
similar	O
changes	O
in	O
beta	O
-	O
sheet	O
structure	O
and	O
decreases	O
in	O
in	O
vitro	O
methylation	O
were	O
observed	O
with	O
a	O
W	O
513	O
-	O
K	O
mutant	O
.	O

These	O
data	O
support	O
a	O
novel	O
model	O
for	O
FMRP	O
arginine	O
methylation	O
and	O
a	O
role	O
for	O
conformational	O
switch	O
residues	O
in	O
arginine	O
modification	O
.	O

Oridonin	O
confers	O
protection	O
against	O
arsenic	O
-	O
induced	O
toxicity	O
through	O
activation	O
of	O
the	O
Nrf2	B-Protein
-	O
mediated	O
defensive	O
response	O
.	O
<EOS>	B-X
Groundwater	B-X
contaminated	B-X
with	B-X
arsenic	B-X
imposes	B-X
a	B-X
big	B-X
challenge	B-X
to	B-X
human	B-X
health	B-X
worldwide	B-X
.	B-X
Using	B-X
natural	B-X
compounds	B-X
to	B-X
subvert	B-X
the	B-X
detrimental	B-X
effects	B-X
of	B-X
arsenic	B-X
represents	B-X
an	B-X
attractive	B-X
strategy	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
the	B-X
cellular	B-X
antioxidant	B-X
response	B-X
and	B-X
xenobiotic	B-X
metabolism	B-X
.	B-X
Recently	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
Nrf2	B-X
signaling	B-X
pathway	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
confer	B-X
protection	B-X
against	B-X
arsenic-induced	B-X
toxicity	B-X
in	B-X
a	B-X
cell	B-X
culture	B-X
model	B-X
.	B-X

BACKGROUND	O
:	O
Groundwater	O
contaminated	O
with	O
arsenic	O
imposes	O
a	O
big	O
challenge	O
to	O
human	O
health	O
worldwide	O
.	O
<EOS>	B-X
Groundwater	B-X
contaminated	B-X
with	B-X
arsenic	B-X
imposes	B-X
a	B-X
big	B-X
challenge	B-X
to	B-X
human	B-X
health	B-X
worldwide	B-X
.	B-X
Using	B-X
natural	B-X
compounds	B-X
to	B-X
subvert	B-X
the	B-X
detrimental	B-X
effects	B-X
of	B-X
arsenic	B-X
represents	B-X
an	B-X
attractive	B-X
strategy	B-X
.	B-X
Recently	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
Nrf2	B-X
signaling	B-X
pathway	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
confer	B-X
protection	B-X
against	B-X
arsenic-induced	B-X
toxicity	B-X
in	B-X
a	B-X
cell	B-X
culture	B-X
model	B-X
.	B-X

Using	O
natural	O
compounds	O
to	O
subvert	O
the	O
detrimental	O
effects	O
of	O
arsenic	O
represents	O
an	O
attractive	O
strategy	O
.	O
<EOS>	B-X
Groundwater	B-X
contaminated	B-X
with	B-X
arsenic	B-X
imposes	B-X
a	B-X
big	B-X
challenge	B-X
to	B-X
human	B-X
health	B-X
worldwide	B-X
.	B-X
Using	B-X
natural	B-X
compounds	B-X
to	B-X
subvert	B-X
the	B-X
detrimental	B-X
effects	B-X
of	B-X
arsenic	B-X
represents	B-X
an	B-X
attractive	B-X
strategy	B-X
.	B-X
Recently	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
Nrf2	B-X
signaling	B-X
pathway	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
confer	B-X
protection	B-X
against	B-X
arsenic-induced	B-X
toxicity	B-X
in	B-X
a	B-X
cell	B-X
culture	B-X
model	B-X
.	B-X

The	O
transcription	O
factor	O
nuclear	B-Protein
factor	I-Protein
erythroid	I-Protein
2	I-Protein
-	I-Protein
related	I-Protein
factor	I-Protein
2	I-Protein
(	O
Nrf2	B-Protein
)	O
is	O
a	O
critical	O
regulator	O
of	O
the	O
cellular	O
antioxidant	O
response	O
and	O
xenobiotic	O
metabolism	O
.	O
<EOS>	B-X
The	B-X
human	B-X
body	B-X
is	B-X
continuously	B-X
exposed	B-X
to	B-X
xenobiotics	B-X
and	B-X
internal	B-X
or	B-X
external	B-X
oxidants	B-X
.	B-X
As	B-X
a	B-X
core	B-X
regulator	B-X
of	B-X
constitutive	B-X
and	B-X
inducible	B-X
expression	B-X
of	B-X
antioxidant	B-X
response	B-X
element	B-X
(	B-X
ARE	B-X
)	B-X
-dependent	B-X
genes	B-X
,	B-X
nuclear	B-X
factor	B-X
erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
maintaining	B-X
cellular	B-X
redox	B-X
homeostasis	B-X
.	B-X
Consistent	B-X
with	B-X
the	B-X
properties	B-X
of	B-X
Nrf2-mediated	B-X
antioxidant	B-X
response	B-X
,	B-X
Nrf2-ARE	B-X
activity	B-X
is	B-X
a	B-X
direct	B-X
indicator	B-X
of	B-X
oxidative	B-X
stress	B-X
and	B-X
thus	B-X
has	B-X
been	B-X
used	B-X
to	B-X
identify	B-X
and	B-X
characterize	B-X
oxidative	B-X
stressors	B-X
and	B-X
redox	B-X
modulators	B-X
.	B-X
To	B-X
screen	B-X
and	B-X
distinguish	B-X
chemicals	B-X
or	B-X
environmental	B-X
insults	B-X
that	B-X
affect	B-X
the	B-X
cellular	B-X
antioxidant	B-X
activity	B-X
and/or	B-X
induce	B-X
oxidative	B-X
stress	B-X
,	B-X
various	B-X
in	B-X
vitro	B-X
cell	B-X
models	B-X
expressing	B-X
distinct	B-X
ARE	B-X
reporters	B-X
with	B-X
high-throughput	B-X
and	B-X
high-content	B-X
properties	B-X
have	B-X
been	B-X
developed	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
basic	B-X
structures	B-X
and	B-X
applications	B-X
of	B-X
various	B-X
ARE-reporter	B-X
systems	B-X
employed	B-X
for	B-X
discovering	B-X
Nrf2-ARE	B-X
modulators	B-X
and	B-X
characterizing	B-X
oxidative	B-X
stressors	B-X
.	B-X

Recently	O
,	O
activation	O
of	O
the	O
Nrf2	B-Protein
signaling	O
pathway	O
has	O
been	O
reported	O
to	O
confer	O
protection	O
against	O
arsenic	O
-	O
induced	O
toxicity	O
in	O
a	O
cell	O
culture	O
model	O
.	O

OBJECTIVES	O
:	O
The	O
goal	O
of	O
the	O
present	O
work	O
was	O
to	O
identify	O
a	O
potent	O
Nrf2	B-Protein
activator	O
from	O
plants	O
as	O
a	O
chemopreventive	O
compound	O
and	O
to	O
demonstrate	O
the	O
efficacy	O
of	O
the	O
compound	O
in	O
battling	O
arsenic	O
-	O
induced	O
toxicity	O
.	O
<EOS>	B-X
Groundwater	B-X
contaminated	B-X
with	B-X
arsenic	B-X
imposes	B-X
a	B-X
big	B-X
challenge	B-X
to	B-X
human	B-X
health	B-X
worldwide	B-X
.	B-X
Using	B-X
natural	B-X
compounds	B-X
to	B-X
subvert	B-X
the	B-X
detrimental	B-X
effects	B-X
of	B-X
arsenic	B-X
represents	B-X
an	B-X
attractive	B-X
strategy	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
the	B-X
cellular	B-X
antioxidant	B-X
response	B-X
and	B-X
xenobiotic	B-X
metabolism	B-X
.	B-X
Recently	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
Nrf2	B-X
signaling	B-X
pathway	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
confer	B-X
protection	B-X
against	B-X
arsenic-induced	B-X
toxicity	B-X
in	B-X
a	B-X
cell	B-X
culture	B-X
model	B-X
.	B-X

RESULTS	O
:	O
Oridonin	O
activated	O
the	O
Nrf2	B-Protein
signaling	O
pathway	O
at	O
a	O
low	O
subtoxic	O
dose	O
and	O
was	O
able	O
to	O
stabilize	O
Nrf2	B-Protein
by	O
blocking	O
Nrf2	B-Protein
ubiquitination	O
and	O
degradation	O
,	O
leading	O
to	O
accumulation	O
of	O
the	O
Nrf2	B-Protein
protein	O
and	O
activation	O
of	O
the	O
Nrf2	B-Protein
-	O
dependent	O
cytoprotective	O
response	O
.	O

Pretreatment	O
of	O
UROtsa	O
cells	O
with	O
1	O
.	O
4	O
muM	O
oridonin	O
significantly	O
enhanced	O
the	O
cellular	O
redox	O
capacity	O
,	O
reduced	O
formation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
and	O
improved	O
cell	O
survival	O
after	O
arsenic	O
challenge	O
.	O
<EOS>	B-X
Groundwater	B-X
contaminated	B-X
with	B-X
arsenic	B-X
imposes	B-X
a	B-X
big	B-X
challenge	B-X
to	B-X
human	B-X
health	B-X
worldwide	B-X
.	B-X
Using	B-X
natural	B-X
compounds	B-X
to	B-X
subvert	B-X
the	B-X
detrimental	B-X
effects	B-X
of	B-X
arsenic	B-X
represents	B-X
an	B-X
attractive	B-X
strategy	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
the	B-X
cellular	B-X
antioxidant	B-X
response	B-X
and	B-X
xenobiotic	B-X
metabolism	B-X
.	B-X
Recently	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
Nrf2	B-X
signaling	B-X
pathway	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
confer	B-X
protection	B-X
against	B-X
arsenic-induced	B-X
toxicity	B-X
in	B-X
a	B-X
cell	B-X
culture	B-X
model	B-X
.	B-X

CONCLUSIONS	O
:	O
We	O
identified	O
oridonin	O
as	O
representing	O
a	O
novel	O
class	O
of	O
Nrf2	B-Protein
activators	O
and	O
illustrated	O
the	O
mechanism	O
by	O
which	O
the	O
Nrf2	B-Protein
pathway	O
is	O
activated	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
the	B-X
cellular	B-X
antioxidant	B-X
response	B-X
and	B-X
xenobiotic	B-X
metabolism	B-X
.	B-X
Recently	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
Nrf2	B-X
signaling	B-X
pathway	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
confer	B-X
protection	B-X
against	B-X
arsenic-induced	B-X
toxicity	B-X
in	B-X
a	B-X
cell	B-X
culture	B-X
model	B-X
.	B-X

Furthermore	O
,	O
we	O
demonstrated	O
the	O
feasibility	O
of	O
using	O
natural	O
compounds	O
targeting	O
Nrf2	B-Protein
as	O
a	O
therapeutic	O
approach	O
to	O
protect	O
humans	O
from	O
various	O
environmental	O
insults	O
that	O
may	O
occur	O
daily	O
.	O
<EOS>	B-X
Using	B-X
natural	B-X
compounds	B-X
to	B-X
subvert	B-X
the	B-X
detrimental	B-X
effects	B-X
of	B-X
arsenic	B-X
represents	B-X
an	B-X
attractive	B-X
strategy	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
the	B-X
cellular	B-X
antioxidant	B-X
response	B-X
and	B-X
xenobiotic	B-X
metabolism	B-X
.	B-X
Recently	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
Nrf2	B-X
signaling	B-X
pathway	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
confer	B-X
protection	B-X
against	B-X
arsenic-induced	B-X
toxicity	B-X
in	B-X
a	B-X
cell	B-X
culture	B-X
model	B-X
.	B-X

beta	O
-	O
Hydroxylation	O
of	O
the	O
aspartyl	O
residue	O
in	O
the	O
phytotoxin	O
syringomycin	O
E	O
:	O
characterization	O
of	O
two	O
candidate	O
hydroxylases	O
AspH	B-Protein
and	O
SyrP	B-Protein
in	O
Pseudomonas	O
syringae	O
.	O
<EOS>	B-X
The	B-X
pseudomonal	B-X
phytotoxin	B-X
syringomycin	B-X
E	B-X
and	B-X
related	B-X
nonribosomal	B-X
peptides	B-X
contain	B-X
an	B-X
L-	B-X
threo-beta-hydroxyaspartyl	B-X
residue	B-X
at	B-X
the	B-X
eighth	B-X
position	B-X
of	B-X
the	B-X
lipodepsipeptide	B-X
backbone	B-X
as	B-X
part	B-X
of	B-X
a	B-X
conserved	B-X
nonproteinogenic	B-X
tripeptide	B-X
motif	B-X
.	B-X
Informatic	B-X
analysis	B-X
of	B-X
the	B-X
P.	B-X
syringae	B-X
genome	B-X
suggests	B-X
only	B-X
one	B-X
putative	B-X
non-heme	B-X
iron	B-X
hydroxylase	B-X
,	B-X
AspH	B-X
.	B-X
On	B-X
heterologous	B-X
expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
AspH	B-X
shows	B-X
robust	B-X
catalytic	B-X
activity	B-X
with	B-X
free	B-X
L-Asp	B-X
and	B-X
L-Asp	B-X
thioesters	B-X
to	B-X
make	B-X
beta-OH-Asp	B-X
but	B-X
yields	B-X
the	B-X
erythro	B-X
diastereomer	B-X
rather	B-X
than	B-X
the	B-X
threo	B-X
configuration	B-X
that	B-X
is	B-X
found	B-X
in	B-X
syringomycin	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
the	B-X
Syr	B-X
gene	B-X
cluster	B-X
indicated	B-X
that	B-X
SyrP	B-X
,	B-X
previously	B-X
annotated	B-X
as	B-X
the	B-X
gene	B-X
regulatory	B-X
protein	B-X
for	B-X
the	B-X
five-gene	B-X
Syr	B-X
cluster	B-X
,	B-X
is	B-X
actually	B-X
homologous	B-X
to	B-X
the	B-X
known	B-X
non-heme	B-X
mononuclear	B-X
iron	B-X
hydroxylase	B-X
TauD	B-X
.	B-X
Indeed	B-X
,	B-X
purified	B-X
SyrP	B-X
acts	B-X
on	B-X
Asp	B-X
tethered	B-X
as	B-X
the	B-X
protein-bound	B-X
S-pantetheinyl	B-X
thioester	B-X
on	B-X
the	B-X
eighth	B-X
module	B-X
of	B-X
the	B-X
SyrE	B-X
megasynthetase	B-X
.	B-X
The	B-X
hydroxylation	B-X
gives	B-X
the	B-X
anticipated	B-X
L-	B-X
threo-3-OH-Asp	B-X
diastereomer	B-X
found	B-X
in	B-X
syringomycin	B-X
.	B-X
The	B-X
knockout	B-X
of	B-X
syrP	B-X
abolishes	B-X
the	B-X
production	B-X
of	B-X
the	B-X
mature	B-X
syringomycin	B-X
E	B-X
,	B-X
while	B-X
knockout	B-X
of	B-X
aspH	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
syringomycin	B-X
production	B-X
.	B-X

The	O
pseudomonal	O
phytotoxin	O
syringomycin	O
E	O
and	O
related	O
nonribosomal	O
peptides	O
contain	O
an	O
L	O
-	O
threo	O
-	O
beta	O
-	O
hydroxyaspartyl	O
residue	O
at	O
the	O
eighth	O
position	O
of	O
the	O
lipodepsipeptide	O
backbone	O
as	O
part	O
of	O
a	O
conserved	O
nonproteinogenic	O
tripeptide	O
motif	O
.	O

Informatic	O
analysis	O
of	O
the	O
P	O
.	O
syringae	O
genome	O
suggests	O
only	O
one	O
putative	O
non	O
-	O
heme	O
iron	O
hydroxylase	O
,	O
AspH	B-Protein
.	O

On	O
heterologous	O
expression	O
in	O
Escherichia	O
coli	O
AspH	B-Protein
shows	O
robust	O
catalytic	O
activity	O
with	O
free	O
L	O
-	O
Asp	O
and	O
L	O
-	O
Asp	O
thioesters	O
to	O
make	O
beta	O
-	O
OH	O
-	O
Asp	O
but	O
yields	O
the	O
erythro	O
diastereomer	O
rather	O
than	O
the	O
threo	O
configuration	O
that	O
is	O
found	O
in	O
syringomycin	O
.	O

Further	O
analysis	O
of	O
the	O
Syr	O
gene	O
cluster	O
indicated	O
that	O
SyrP	B-Protein
,	O
previously	O
annotated	O
as	O
the	O
gene	O
regulatory	O
protein	O
for	O
the	O
five	O
-	O
gene	O
Syr	O
cluster	O
,	O
is	O
actually	O
homologous	O
to	O
the	O
known	O
non	O
-	O
heme	O
mononuclear	O
iron	O
hydroxylase	O
TauD	B-Protein
.	O

Indeed	O
,	O
purified	O
SyrP	B-Protein
acts	O
on	O
Asp	O
tethered	O
as	O
the	O
protein	O
-	O
bound	O
S	O
-	O
pantetheinyl	O
thioester	O
on	O
the	O
eighth	O
module	O
of	O
the	O
SyrE	B-Protein
megasynthetase	O
.	O

The	O
hydroxylation	O
gives	O
the	O
anticipated	O
L	O
-	O
threo	O
-	O
3	O
-	O
OH	O
-	O
Asp	O
diastereomer	O
found	O
in	O
syringomycin	O
.	O
<EOS>	B-X
The	B-X
pseudomonal	B-X
phytotoxin	B-X
syringomycin	B-X
E	B-X
and	B-X
related	B-X
nonribosomal	B-X
peptides	B-X
contain	B-X
an	B-X
L-	B-X
threo-beta-hydroxyaspartyl	B-X
residue	B-X
at	B-X
the	B-X
eighth	B-X
position	B-X
of	B-X
the	B-X
lipodepsipeptide	B-X
backbone	B-X
as	B-X
part	B-X
of	B-X
a	B-X
conserved	B-X
nonproteinogenic	B-X
tripeptide	B-X
motif	B-X
.	B-X
Informatic	B-X
analysis	B-X
of	B-X
the	B-X
P.	B-X
syringae	B-X
genome	B-X
suggests	B-X
only	B-X
one	B-X
putative	B-X
non-heme	B-X
iron	B-X
hydroxylase	B-X
,	B-X
AspH	B-X
.	B-X
On	B-X
heterologous	B-X
expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
AspH	B-X
shows	B-X
robust	B-X
catalytic	B-X
activity	B-X
with	B-X
free	B-X
L-Asp	B-X
and	B-X
L-Asp	B-X
thioesters	B-X
to	B-X
make	B-X
beta-OH-Asp	B-X
but	B-X
yields	B-X
the	B-X
erythro	B-X
diastereomer	B-X
rather	B-X
than	B-X
the	B-X
threo	B-X
configuration	B-X
that	B-X
is	B-X
found	B-X
in	B-X
syringomycin	B-X
.	B-X
Indeed	B-X
,	B-X
purified	B-X
SyrP	B-X
acts	B-X
on	B-X
Asp	B-X
tethered	B-X
as	B-X
the	B-X
protein-bound	B-X
S-pantetheinyl	B-X
thioester	B-X
on	B-X
the	B-X
eighth	B-X
module	B-X
of	B-X
the	B-X
SyrE	B-X
megasynthetase	B-X
.	B-X
The	B-X
hydroxylation	B-X
gives	B-X
the	B-X
anticipated	B-X
L-	B-X
threo-3-OH-Asp	B-X
diastereomer	B-X
found	B-X
in	B-X
syringomycin	B-X
.	B-X
The	B-X
knockout	B-X
of	B-X
syrP	B-X
abolishes	B-X
the	B-X
production	B-X
of	B-X
the	B-X
mature	B-X
syringomycin	B-X
E	B-X
,	B-X
while	B-X
knockout	B-X
of	B-X
aspH	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
syringomycin	B-X
production	B-X
.	B-X

The	O
knockout	O
of	O
syrP	B-Protein
abolishes	O
the	O
production	O
of	O
the	O
mature	O
syringomycin	O
E	O
,	O
while	O
knockout	O
of	O
aspH	B-Protein
has	O
no	O
effect	O
on	O
syringomycin	O
production	O
.	O
<EOS>	B-X
The	B-X
pseudomonal	B-X
phytotoxin	B-X
syringomycin	B-X
E	B-X
and	B-X
related	B-X
nonribosomal	B-X
peptides	B-X
contain	B-X
an	B-X
L-	B-X
threo-beta-hydroxyaspartyl	B-X
residue	B-X
at	B-X
the	B-X
eighth	B-X
position	B-X
of	B-X
the	B-X
lipodepsipeptide	B-X
backbone	B-X
as	B-X
part	B-X
of	B-X
a	B-X
conserved	B-X
nonproteinogenic	B-X
tripeptide	B-X
motif	B-X
.	B-X
On	B-X
heterologous	B-X
expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
AspH	B-X
shows	B-X
robust	B-X
catalytic	B-X
activity	B-X
with	B-X
free	B-X
L-Asp	B-X
and	B-X
L-Asp	B-X
thioesters	B-X
to	B-X
make	B-X
beta-OH-Asp	B-X
but	B-X
yields	B-X
the	B-X
erythro	B-X
diastereomer	B-X
rather	B-X
than	B-X
the	B-X
threo	B-X
configuration	B-X
that	B-X
is	B-X
found	B-X
in	B-X
syringomycin	B-X
.	B-X
Indeed	B-X
,	B-X
purified	B-X
SyrP	B-X
acts	B-X
on	B-X
Asp	B-X
tethered	B-X
as	B-X
the	B-X
protein-bound	B-X
S-pantetheinyl	B-X
thioester	B-X
on	B-X
the	B-X
eighth	B-X
module	B-X
of	B-X
the	B-X
SyrE	B-X
megasynthetase	B-X
.	B-X
The	B-X
hydroxylation	B-X
gives	B-X
the	B-X
anticipated	B-X
L-	B-X
threo-3-OH-Asp	B-X
diastereomer	B-X
found	B-X
in	B-X
syringomycin	B-X
.	B-X
The	B-X
knockout	B-X
of	B-X
syrP	B-X
abolishes	B-X
the	B-X
production	B-X
of	B-X
the	B-X
mature	B-X
syringomycin	B-X
E	B-X
,	B-X
while	B-X
knockout	B-X
of	B-X
aspH	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
syringomycin	B-X
production	B-X
.	B-X

A	O
critical	O
role	O
for	O
CHIP	B-Protein
in	O
the	O
aggresome	O
pathway	O
.	O
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
aggresome	B-X
formation	B-X
is	B-X
a	B-X
physiologic	B-X
stress	B-X
response	B-X
not	B-X
limited	B-X
to	B-X
misfolded	B-X
proteins	B-X
.	B-X
That	B-X
stress	B-X
response	B-X
,	B-X
termed	B-X
``	B-X
physiologic	B-X
aggresome	B-X
,	B-X
''	B-X
is	B-X
exemplified	B-X
by	B-X
aggresome	B-X
formation	B-X
of	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
,	B-X
an	B-X
important	B-X
host	B-X
defense	B-X
protein	B-X
.	B-X
CHIP	B-X
(	B-X
carboxy	B-X
terminus	B-X
of	B-X
Hsp70-interacting	B-X
protein	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
protein	B-X
that	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
mediate	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
by	B-X
the	B-X
proteasome	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
CHIP	B-X
has	B-X
a	B-X
previously	B-X
unexpected	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
iNOS	B-X
and	B-X
promotes	B-X
its	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
by	B-X
the	B-X
proteasome	B-X
as	B-X
well	B-X
as	B-X
its	B-X
sequestration	B-X
to	B-X
the	B-X
aggresome	B-X
.	B-X
CHIP-mediated	B-X
iNOS	B-X
targeting	B-X
to	B-X
the	B-X
proteasome	B-X
sequentially	B-X
precedes	B-X
CHIP-mediated	B-X
iNOS	B-X
sequestration	B-X
to	B-X
the	B-X
aggresome	B-X
.	B-X
CHIP	B-X
is	B-X
required	B-X
for	B-X
iNOS	B-X
preaggresome	B-X
structures	B-X
to	B-X
form	B-X
a	B-X
mature	B-X
aggresome	B-X
.	B-X
Furthermore	B-X
,	B-X
CHIP	B-X
is	B-X
required	B-X
for	B-X
targeting	B-X
the	B-X
mutant	B-X
form	B-X
of	B-X
cystic	B-X
fibrosis	B-X
transconductance	B-X
regulator	B-X
(	B-X
CFTRDeltaF508	B-X
)	B-X
to	B-X
the	B-X
aggresome	B-X
.	B-X
Importantly	B-X
,	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
function	B-X
of	B-X
CHIP	B-X
is	B-X
required	B-X
in	B-X
targeting	B-X
preaggresomal	B-X
structures	B-X
to	B-X
the	B-X
aggresome	B-X
by	B-X
promoting	B-X
an	B-X
iNOS	B-X
interaction	B-X
with	B-X
histone	B-X
deacetylase	B-X
6	B-X
,	B-X
which	B-X
serves	B-X
as	B-X
an	B-X
adaptor	B-X
between	B-X
ubiquitinated	B-X
proteins	B-X
and	B-X
the	B-X
dynein	B-X
motor	B-X
.	B-X
This	B-X
study	B-X
reveals	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
CHIP	B-X
in	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X

Recent	O
evidence	O
suggests	O
that	O
aggresome	O
formation	O
is	O
a	O
physiologic	O
stress	O
response	O
not	O
limited	O
to	O
misfolded	O
proteins	O
.	O

That	O
stress	O
response	O
,	O
termed	O
"	O
physiologic	O
aggresome	O
,	O
"	O
is	O
exemplified	O
by	O
aggresome	O
formation	O
of	O
inducible	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	I-Protein
(	O
iNOS	B-Protein
)	O
,	O
an	O
important	O
host	O
defense	O
protein	O
.	O
<EOS>	B-X
Nitric	B-X
Oxide	B-X
(	B-X
NO	B-X
)	B-X
,	B-X
produced	B-X
by	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
,	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
biological	B-X
and	B-X
inflammatory	B-X
disorders	B-X
.	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
aggresome	B-X
formation	B-X
is	B-X
a	B-X
physiologic	B-X
stress	B-X
response	B-X
not	B-X
limited	B-X
to	B-X
misfolded	B-X
proteins	B-X
.	B-X
That	B-X
stress	B-X
response	B-X
,	B-X
termed	B-X
``	B-X
physiologic	B-X
aggresome	B-X
,	B-X
''	B-X
is	B-X
exemplified	B-X
by	B-X
aggresome	B-X
formation	B-X
of	B-X
iNOS	B-X
,	B-X
an	B-X
important	B-X
host	B-X
defense	B-X
protein	B-X
.	B-X
The	B-X
functional	B-X
significance	B-X
of	B-X
cellular	B-X
formation	B-X
of	B-X
the	B-X
iNOS	B-X
aggresome	B-X
is	B-X
hitherto	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
live	B-X
cell	B-X
imaging	B-X
,	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
and	B-X
intracellular	B-X
fluorescence	B-X
NO	B-X
probes	B-X
to	B-X
map	B-X
the	B-X
subcellular	B-X
location	B-X
of	B-X
iNOS	B-X
and	B-X
NO	B-X
under	B-X
various	B-X
conditions	B-X
.	B-X
We	B-X
found	B-X
that	B-X
NO	B-X
production	B-X
colocalized	B-X
with	B-X
cytosolic	B-X
iNOS	B-X
but	B-X
aggresomes	B-X
containing	B-X
iNOS	B-X
were	B-X
distinctly	B-X
devoid	B-X
of	B-X
NO	B-X
production	B-X
.	B-X
Further	B-X
,	B-X
cells	B-X
expressing	B-X
iNOS	B-X
aggresomes	B-X
produced	B-X
significantly	B-X
less	B-X
NO	B-X
as	B-X
compared	B-X
with	B-X
cells	B-X
not	B-X
expressing	B-X
aggresomes	B-X
.	B-X
Importantly	B-X
,	B-X
primary	B-X
normal	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
,	B-X
stimulated	B-X
by	B-X
cytokines	B-X
to	B-X
express	B-X
iNOS	B-X
,	B-X
progressively	B-X
sequestered	B-X
iNOS	B-X
to	B-X
the	B-X
aggresome	B-X
,	B-X
a	B-X
process	B-X
that	B-X
correlated	B-X
with	B-X
marked	B-X
reduction	B-X
of	B-X
NO	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
used	B-X
the	B-X
physiologic	B-X
aggresome	B-X
mechanism	B-X
for	B-X
iNOS	B-X
inactivation	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
a	B-X
novel	B-X
cellular	B-X
strategy	B-X
to	B-X
terminate	B-X
NO	B-X
production	B-X
via	B-X
formation	B-X
of	B-X
the	B-X
iNOS	B-X
aggresome	B-X
.	B-X

CHIP	B-Protein
(	O
carboxy	B-Protein
terminus	I-Protein
of	I-Protein
Hsp70	I-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
)	O
is	O
a	O
highly	O
conserved	O
protein	O
that	O
has	O
been	O
shown	O
to	O
mediate	O
substrate	O
ubiquitination	O
and	O
degradation	O
by	O
the	O
proteasome	O
.	O
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
aggresome	B-X
formation	B-X
is	B-X
a	B-X
physiologic	B-X
stress	B-X
response	B-X
not	B-X
limited	B-X
to	B-X
misfolded	B-X
proteins	B-X
.	B-X
That	B-X
stress	B-X
response	B-X
,	B-X
termed	B-X
``	B-X
physiologic	B-X
aggresome	B-X
,	B-X
''	B-X
is	B-X
exemplified	B-X
by	B-X
aggresome	B-X
formation	B-X
of	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
,	B-X
an	B-X
important	B-X
host	B-X
defense	B-X
protein	B-X
.	B-X
CHIP	B-X
(	B-X
carboxy	B-X
terminus	B-X
of	B-X
Hsp70-interacting	B-X
protein	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
protein	B-X
that	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
mediate	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
by	B-X
the	B-X
proteasome	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
CHIP	B-X
has	B-X
a	B-X
previously	B-X
unexpected	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
iNOS	B-X
and	B-X
promotes	B-X
its	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
by	B-X
the	B-X
proteasome	B-X
as	B-X
well	B-X
as	B-X
its	B-X
sequestration	B-X
to	B-X
the	B-X
aggresome	B-X
.	B-X
CHIP-mediated	B-X
iNOS	B-X
targeting	B-X
to	B-X
the	B-X
proteasome	B-X
sequentially	B-X
precedes	B-X
CHIP-mediated	B-X
iNOS	B-X
sequestration	B-X
to	B-X
the	B-X
aggresome	B-X
.	B-X
CHIP	B-X
is	B-X
required	B-X
for	B-X
iNOS	B-X
preaggresome	B-X
structures	B-X
to	B-X
form	B-X
a	B-X
mature	B-X
aggresome	B-X
.	B-X
Furthermore	B-X
,	B-X
CHIP	B-X
is	B-X
required	B-X
for	B-X
targeting	B-X
the	B-X
mutant	B-X
form	B-X
of	B-X
cystic	B-X
fibrosis	B-X
transconductance	B-X
regulator	B-X
(	B-X
CFTRDeltaF508	B-X
)	B-X
to	B-X
the	B-X
aggresome	B-X
.	B-X
Importantly	B-X
,	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
function	B-X
of	B-X
CHIP	B-X
is	B-X
required	B-X
in	B-X
targeting	B-X
preaggresomal	B-X
structures	B-X
to	B-X
the	B-X
aggresome	B-X
by	B-X
promoting	B-X
an	B-X
iNOS	B-X
interaction	B-X
with	B-X
histone	B-X
deacetylase	B-X
6	B-X
,	B-X
which	B-X
serves	B-X
as	B-X
an	B-X
adaptor	B-X
between	B-X
ubiquitinated	B-X
proteins	B-X
and	B-X
the	B-X
dynein	B-X
motor	B-X
.	B-X
This	B-X
study	B-X
reveals	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
CHIP	B-X
in	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
show	O
that	O
CHIP	B-Protein
has	O
a	O
previously	O
unexpected	O
critical	O
role	O
in	O
the	O
aggresome	O
pathway	O
.	O

CHIP	B-Protein
interacts	O
with	O
iNOS	B-Protein
and	O
promotes	O
its	O
ubiquitination	O
and	O
degradation	O
by	O
the	O
proteasome	O
as	O
well	O
as	O
its	O
sequestration	O
to	O
the	O
aggresome	O
.	O

CHIP	B-Protein
-	O
mediated	O
iNOS	B-Protein
targeting	O
to	O
the	O
proteasome	O
sequentially	O
precedes	O
CHIP	B-Protein
-	O
mediated	O
iNOS	B-Protein
sequestration	O
to	O
the	O
aggresome	O
.	O

CHIP	B-Protein
is	O
required	O
for	O
iNOS	B-Protein
preaggresome	O
structures	O
to	O
form	O
a	O
mature	O
aggresome	O
.	O

Furthermore	O
,	O
CHIP	B-Protein
is	O
required	O
for	O
targeting	O
the	O
mutant	O
form	O
of	O
cystic	B-Protein
fibrosis	I-Protein
transconductance	I-Protein
regulator	I-Protein
(	O
CFTRDeltaF508	B-Protein
)	O
to	O
the	O
aggresome	O
.	O

Importantly	O
,	O
the	O
ubiquitin	B-Protein
ligase	O
function	O
of	O
CHIP	B-Protein
is	O
required	O
in	O
targeting	O
preaggresomal	O
structures	O
to	O
the	O
aggresome	O
by	O
promoting	O
an	O
iNOS	B-Protein
interaction	O
with	O
histone	B-Protein
deacetylase	I-Protein
6	I-Protein
,	O
which	O
serves	O
as	O
an	O
adaptor	O
between	O
ubiquitinated	O
proteins	O
and	O
the	O
dynein	O
motor	O
.	O

This	O
study	O
reveals	O
a	O
critical	O
role	O
for	O
CHIP	B-Protein
in	O
the	O
aggresome	O
pathway	O
.	O
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
aggresome	B-X
formation	B-X
is	B-X
a	B-X
physiologic	B-X
stress	B-X
response	B-X
not	B-X
limited	B-X
to	B-X
misfolded	B-X
proteins	B-X
.	B-X
That	B-X
stress	B-X
response	B-X
,	B-X
termed	B-X
``	B-X
physiologic	B-X
aggresome	B-X
,	B-X
''	B-X
is	B-X
exemplified	B-X
by	B-X
aggresome	B-X
formation	B-X
of	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
,	B-X
an	B-X
important	B-X
host	B-X
defense	B-X
protein	B-X
.	B-X
CHIP	B-X
(	B-X
carboxy	B-X
terminus	B-X
of	B-X
Hsp70-interacting	B-X
protein	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
protein	B-X
that	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
mediate	B-X
substrate	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
by	B-X
the	B-X
proteasome	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
CHIP	B-X
has	B-X
a	B-X
previously	B-X
unexpected	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X
CHIP	B-X
interacts	B-X
with	B-X
iNOS	B-X
and	B-X
promotes	B-X
its	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
by	B-X
the	B-X
proteasome	B-X
as	B-X
well	B-X
as	B-X
its	B-X
sequestration	B-X
to	B-X
the	B-X
aggresome	B-X
.	B-X
CHIP-mediated	B-X
iNOS	B-X
targeting	B-X
to	B-X
the	B-X
proteasome	B-X
sequentially	B-X
precedes	B-X
CHIP-mediated	B-X
iNOS	B-X
sequestration	B-X
to	B-X
the	B-X
aggresome	B-X
.	B-X
CHIP	B-X
is	B-X
required	B-X
for	B-X
iNOS	B-X
preaggresome	B-X
structures	B-X
to	B-X
form	B-X
a	B-X
mature	B-X
aggresome	B-X
.	B-X
Furthermore	B-X
,	B-X
CHIP	B-X
is	B-X
required	B-X
for	B-X
targeting	B-X
the	B-X
mutant	B-X
form	B-X
of	B-X
cystic	B-X
fibrosis	B-X
transconductance	B-X
regulator	B-X
(	B-X
CFTRDeltaF508	B-X
)	B-X
to	B-X
the	B-X
aggresome	B-X
.	B-X
Importantly	B-X
,	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
function	B-X
of	B-X
CHIP	B-X
is	B-X
required	B-X
in	B-X
targeting	B-X
preaggresomal	B-X
structures	B-X
to	B-X
the	B-X
aggresome	B-X
by	B-X
promoting	B-X
an	B-X
iNOS	B-X
interaction	B-X
with	B-X
histone	B-X
deacetylase	B-X
6	B-X
,	B-X
which	B-X
serves	B-X
as	B-X
an	B-X
adaptor	B-X
between	B-X
ubiquitinated	B-X
proteins	B-X
and	B-X
the	B-X
dynein	B-X
motor	B-X
.	B-X
This	B-X
study	B-X
reveals	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
CHIP	B-X
in	B-X
the	B-X
aggresome	B-X
pathway	B-X
.	B-X

AZGP1	B-Protein
autoantibody	O
predicts	O
survival	O
and	O
histone	B-Protein
deacetylase	O
inhibitors	O
increase	O
expression	O
in	O
lung	O
adenocarcinoma	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

INTRODUCTION	O
:	O
The	O
importance	O
of	O
alpha	B-Protein
-	I-Protein
2	I-Protein
-	I-Protein
glycoprotein	I-Protein
1	I-Protein
,	I-Protein
zinc	I-Protein
(	O
AZGP1	B-Protein
)	O
in	O
lung	O
adenocarcinoma	O
(	O
AD	O
)	O
remains	O
largely	O
unknown	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

Analysis	O
of	O
serum	O
autoantibodies	O
to	O
tumor	O
antigens	O
combined	O
with	O
gene	O
expression	O
profiling	O
of	O
primary	O
tumors	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
lung	O
carcinogenesis	O
and	O
identify	O
new	O
AD	O
biomarkers	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

METHODS	O
:	O
T7	O
phage	O
cDNA	O
libraries	O
were	O
used	O
to	O
identify	O
AZGP1	B-Protein
autoantibodies	O
in	O
the	O
serum	O
of	O
473	O
patients	O
(	O
192	O
ADs	O
,	O
192	O
matched	O
controls	O
,	O
and	O
89	O
additional	O
ADs	O
for	O
confirmation	O
of	O
findings	O
)	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

AZGP1	B-Protein
mRNA	O
expression	O
was	O
examined	O
in	O
86	O
ADs	O
and	O
10	O
control	O
lung	O
tissue	O
samples	O
using	O
oligonucleotide	O
microarrays	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

AZGP1	B-Protein
protein	O
expression	O
was	O
studied	O
in	O
230	O
tissue	O
samples	O
(	O
222	O
ADs	O
;	O
8	O
controls	O
)	O
with	O
immunohistochemistry	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

Kaplan	O
-	O
Meier	O
analyses	O
were	O
used	O
to	O
correlate	O
circulating	O
autoantibody	O
and	O
tissue	O
mRNA	O
production	O
with	O
survival	O
.	O

AD	O
cell	O
lines	O
A549	O
and	O
SKLU1	O
were	O
treated	O
with	O
5	O
-	O
aza	O
-	O
2	O
;	O
-	O
deoxycytidine	O
(	O
5	O
-	O
AZA	O
)	O
and	O
trichostatin	O
A	O
(	O
TSA	O
)	O
to	O
examine	O
the	O
role	O
of	O
promoter	O
methylation	O
and	O
histone	B-Protein
deacetylation	O
in	O
the	O
expression	O
of	O
AZGP1	B-Protein
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
quantify	O
the	O
effects	O
of	O
treatment	O
.	O
<EOS>	B-X
Medicines	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
2019-novel	B-X
coronavirus	B-X
(	B-X
2019-nCoV	B-X
)	B-X
infections	B-X
are	B-X
urgently	B-X
needed	B-X
.	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
repurpose	B-X
the	B-X
clinically	B-X
approved	B-X
drugs	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
in	B-X
a	B-X
2019-nCoV-related	B-X
coronavirus	B-X
model	B-X
.	B-X
The	B-X
quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qPCR	B-X
)	B-X
method	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
tool	B-X
to	B-X
detect	B-X
and	B-X
quantify	B-X
microorganisms	B-X
in	B-X
water	B-X
within	B-X
a	B-X
few	B-X
hours	B-X
.	B-X
Quantitative	B-X
PCR	B-X
can	B-X
be	B-X
applied	B-X
for	B-X
microbial	B-X
source	B-X
tracking	B-X
in	B-X
water	B-X
sources	B-X
,	B-X
to	B-X
determine	B-X
the	B-X
efficiency	B-X
of	B-X
water	B-X
and	B-X
wastewater	B-X
treatment	B-X
plants	B-X
and	B-X
act	B-X
as	B-X
a	B-X
tool	B-X
for	B-X
risk	B-X
assessment	B-X
.	B-X
Different	B-X
qPCR	B-X
assays	B-X
exist	B-X
depending	B-X
on	B-X
whether	B-X
an	B-X
internal	B-X
control	B-X
is	B-X
used	B-X
or	B-X
whether	B-X
measurements	B-X
are	B-X
taken	B-X
at	B-X
the	B-X
end	B-X
of	B-X
the	B-X
PCR	B-X
reaction	B-X
(	B-X
end-point	B-X
qPCR	B-X
)	B-X
or	B-X
in	B-X
the	B-X
exponential	B-X
phase	B-X
(	B-X
real-time	B-X
qPCR	B-X
)	B-X
.	B-X
Fluorescent	B-X
probes	B-X
are	B-X
used	B-X
in	B-X
the	B-X
PCR	B-X
reaction	B-X
to	B-X
hybridise	B-X
within	B-X
the	B-X
target	B-X
sequence	B-X
to	B-X
generate	B-X
a	B-X
signal	B-X
and	B-X
,	B-X
together	B-X
with	B-X
specialised	B-X
systems	B-X
,	B-X
quantify	B-X
the	B-X
amount	B-X
of	B-X
PCR	B-X
product	B-X
.	B-X
Quantitative	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
q-RT-PCR	B-X
)	B-X
is	B-X
a	B-X
more	B-X
sensitive	B-X
technique	B-X
that	B-X
detects	B-X
low	B-X
copy	B-X
number	B-X
RNA	B-X
and	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
detect	B-X
,	B-X
e.g	B-X
.	B-X
There	B-X
is	B-X
,	B-X
however	B-X
,	B-X
a	B-X
need	B-X
to	B-X
standardise	B-X
qPCR	B-X
protocols	B-X
if	B-X
this	B-X
technique	B-X
is	B-X
to	B-X
be	B-X
used	B-X
as	B-X
an	B-X
analytical	B-X
diagnostic	B-X
tool	B-X
for	B-X
routine	B-X
monitoring	B-X
.	B-X

RESULTS	O
:	O
In	O
patients	O
with	O
AD	O
,	O
AZGP1	B-Protein
autoantibodies	O
were	O
observed	O
in	O
40	O
%	O
of	O
serum	O
samples	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

Autoantibody	O
production	O
correlated	O
with	O
improved	O
overall	O
5	O
-	O
year	O
survival	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
and	O
improved	O
survival	O
in	O
those	O
with	O
stage	O
I	O
to	O
II	O
disease	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

A	O
verification	O
analysis	O
was	O
performed	O
for	O
the	O
survival	O
benefit	O
and	O
found	O
similar	O
results	O
with	O
p	O
values	O
of	O
0	O
.	O
02	O
and	O
0	O
.	O
036	O
,	O
respectively	O
.	O

Although	O
abundant	O
mRNA	O
expression	O
was	O
found	O
in	O
a	O
subset	O
of	O
tumors	O
,	O
mRNA	O
expression	O
did	O
not	O
correlate	O
with	O
prognosis	O
.	O

In	O
normal	O
lung	O
,	O
AZGP1	B-Protein
mRNA	O
and	O
protein	O
expression	O
were	O
low	O
or	O
absent	O
,	O
whereas	O
in	O
AD	O
they	O
were	O
highly	O
expressed	O
in	O
31	O
.	O
3	O
%	O
and	O
42	O
.	O
8	O
%	O
of	O
samples	O
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

To	O
determine	O
whether	O
AZGP1	B-Protein
expression	O
in	O
this	O
subset	O
of	O
tumors	O
might	O
be	O
affected	O
by	O
epigenetic	O
mechanisms	O
,	O
low	O
AZGP1	B-Protein
-	O
expressing	O
A549	O
and	O
SKLU1	O
AD	O
cell	O
lines	O
were	O
treated	O
with	O
TSA	O
and	O
5	O
-	O
AZA	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

A	O
713	O
-	O
fold	O
and	O
169	O
-	O
fold	O
increase	O
in	O
mRNA	O
expression	O
were	O
noted	O
on	O
treatment	O
with	O
TSA	O
,	O
respectively	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

Treatment	O
with	O
5	O
-	O
AZA	O
had	O
minimal	O
effect	O
on	O
AZGP1	B-Protein
mRNA	O
expression	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

CONCLUSIONS	O
:	O
The	O
presence	O
of	O
AZGP1	B-Protein
serum	O
autoantibody	O
may	O
be	O
used	O
as	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
AD	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

Furthermore	O
,	O
up	O
-	O
regulation	O
of	O
AZGP1	B-Protein
mRNA	O
in	O
AD	O
may	O
be	O
affected	O
by	O
chromatin	O
remodeling	O
by	O
means	O
of	O
histone	B-Protein
acetylation	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
alpha-2-glycoprotein	B-X
1	B-X
,	B-X
zinc	B-X
(	B-X
AZGP1	B-X
)	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
(	B-X
AD	B-X
)	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Analysis	B-X
of	B-X
serum	B-X
autoantibodies	B-X
to	B-X
tumor	B-X
antigens	B-X
combined	B-X
with	B-X
gene	B-X
expression	B-X
profiling	B-X
of	B-X
primary	B-X
tumors	B-X
may	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lung	B-X
carcinogenesis	B-X
and	B-X
identify	B-X
new	B-X
AD	B-X
biomarkers	B-X
.	B-X

A	O
phosphorylation	O
-	O
acetylation	O
switch	O
regulates	O
STAT1	B-Protein
signaling	O
.	O
<EOS>	B-X
The	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
histone	B-X
deacetylase	B-X
inhibitors	B-X
(	B-X
HDACi	B-X
)	B-X
was	B-X
reported	B-X
to	B-X
reveal	B-X
the	B-X
acetylation	B-X
of	B-X
STAT1	B-X
at	B-X
lysine	B-X
410	B-X
and	B-X
lysine	B-X
413	B-X
(	B-X
O.	B-X
H.	B-X
Krämer	B-X
et	B-X
al.	B-X
,	B-X
Genes	B-X
Dev	B-X
.	B-X
STAT1	B-X
acetylation	B-X
was	B-X
proposed	B-X
to	B-X
regulate	B-X
apoptosis	B-X
by	B-X
facilitating	B-X
binding	B-X
to	B-X
NF-κB	B-X
and	B-X
to	B-X
control	B-X
immune	B-X
responses	B-X
by	B-X
suppressing	B-X
STAT1	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
suggesting	B-X
that	B-X
STAT1	B-X
acetylation	B-X
is	B-X
a	B-X
central	B-X
mechanism	B-X
by	B-X
which	B-X
histone	B-X
deacetylase	B-X
inhibitors	B-X
ameliorate	B-X
inflammatory	B-X
diseases	B-X
(	B-X
O.	B-X
H.	B-X
Krämer	B-X
et	B-X
al.	B-X
,	B-X
Genes	B-X
Dev	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
inhibition	B-X
of	B-X
deacetylases	B-X
had	B-X
no	B-X
bearing	B-X
on	B-X
STAT1	B-X
acetylation	B-X
and	B-X
did	B-X
not	B-X
diminish	B-X
STAT1	B-X
tyrosine	B-X
phosphorylation	B-X
.	B-X
The	B-X
glutamine	B-X
mutation	B-X
of	B-X
the	B-X
alleged	B-X
acetylation	B-X
sites	B-X
,	B-X
claimed	B-X
to	B-X
mimic	B-X
acetylated	B-X
STAT1	B-X
,	B-X
similarly	B-X
did	B-X
not	B-X
diminish	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
STAT1	B-X
but	B-X
precluded	B-X
its	B-X
DNA	B-X
binding	B-X
and	B-X
nuclear	B-X
import	B-X
.	B-X
The	B-X
defective	B-X
transcription	B-X
activity	B-X
of	B-X
this	B-X
mutant	B-X
therefore	B-X
can	B-X
not	B-X
be	B-X
attributed	B-X
to	B-X
STAT1	B-X
acetylation	B-X
but	B-X
rather	B-X
to	B-X
the	B-X
inactivation	B-X
of	B-X
the	B-X
STAT1	B-X
DNA	B-X
binding	B-X
domain	B-X
and	B-X
its	B-X
nuclear	B-X
import	B-X
signal	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
effects	B-X
and	B-X
potential	B-X
clinical	B-X
benefits	B-X
associated	B-X
with	B-X
histone	B-X
deacetylase	B-X
inhibition	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
promoting	B-X
the	B-X
acetylation	B-X
of	B-X
STAT1	B-X
at	B-X
lysines	B-X
410	B-X
and	B-X
413	B-X
.	B-X

Cytokines	O
such	O
as	O
interferons	O
(	O
IFNs	O
)	O
activate	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
via	O
phosphorylation	O
.	O
<EOS>	B-X
Interferons	B-X
(	B-X
IFNs	B-X
)	B-X
encode	B-X
a	B-X
large	B-X
family	B-X
of	B-X
multifonctional	B-X
secreted	B-X
proteins	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
antiviral	B-X
defense	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
growth	B-X
and	B-X
modulation	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
.	B-X
They	B-X
are	B-X
subdivided	B-X
into	B-X
two	B-X
types	B-X
that	B-X
activate	B-X
transduction	B-X
pathways	B-X
via	B-X
different	B-X
cell	B-X
surface	B-X
receptors	B-X
.	B-X
Binding	B-X
of	B-X
both	B-X
IFN	B-X
type	B-X
I	B-X
and	B-X
II	B-X
results	B-X
in	B-X
the	B-X
differential	B-X
activation	B-X
of	B-X
JAK	B-X
(	B-X
Janus	B-X
kinases	B-X
)	B-X
that	B-X
phosphorylate	B-X
latent	B-X
cytoplasmic	B-X
transcription	B-X
factors	B-X
termed	B-X
STATs	B-X
(	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
)	B-X
.	B-X
Phosphorylated	B-X
STATs	B-X
translocate	B-X
to	B-X
the	B-X
nucleus	B-X
,	B-X
bind	B-X
specific	B-X
DNA	B-X
elements	B-X
and	B-X
direct	B-X
transcription	B-X
.	B-X
Type	B-X
I	B-X
IFN	B-X
induces	B-X
the	B-X
phosphorylation	B-X
of	B-X
STAT1	B-X
and	B-X
STAT2	B-X
proteins	B-X
by	B-X
tyrosine	B-X
phosphorylation	B-X
involving	B-X
the	B-X
type	B-X
I	B-X
IFN	B-X
receptor-associated	B-X
tyrosine	B-X
kinases	B-X
TYK2	B-X
and	B-X
JAK1	B-X
.	B-X
Following	B-X
phosphorylation	B-X
,	B-X
STAT1	B-X
and	B-X
STAT2	B-X
form	B-X
the	B-X
transcriptionally	B-X
active	B-X
IFN-stimulated	B-X
gene	B-X
factor	B-X
3	B-X
(	B-X
ISGF3	B-X
)	B-X
by	B-X
association	B-X
with	B-X
a	B-X
protein	B-X
of	B-X
the	B-X
IFN	B-X
regulatory	B-X
factor	B-X
(	B-X
IRF	B-X
)	B-X
family	B-X
,	B-X
p48	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
the	B-X
transcriptional	B-X
activation	B-X
by	B-X
ISGF3	B-X
is	B-X
mediated	B-X
by	B-X
specific	B-X
elements	B-X
termed	B-X
IFN-stimulatory	B-X
response	B-X
element	B-X
(	B-X
ISRE	B-X
)	B-X
located	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
IFN-inducible	B-X
genes	B-X
.	B-X
Gene	B-X
induction	B-X
by	B-X
type	B-X
II	B-X
IFN	B-X
involves	B-X
the	B-X
phosphorylation	B-X
of	B-X
only	B-X
STAT1	B-X
by	B-X
JAK1	B-X
and	B-X
Jak2	B-X
kinases	B-X
.	B-X
This	B-X
phosphorylation	B-X
generates	B-X
a	B-X
homodimer	B-X
of	B-X
STAT1	B-X
which	B-X
is	B-X
able	B-X
to	B-X
bind	B-X
the	B-X
IFNgamma-activated	B-X
site	B-X
(	B-X
GAS	B-X
)	B-X
to	B-X
activate	B-X
transcription	B-X
.	B-X
This	B-X
signaling	B-X
is	B-X
rapid	B-X
and	B-X
direct	B-X
.	B-X
Molecules	B-X
involved	B-X
in	B-X
the	B-X
IFN	B-X
signaling	B-X
pathways	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
used	B-X
by	B-X
other	B-X
polypeptide	B-X
ligands	B-X
in	B-X
their	B-X
own	B-X
signal	B-X
transduction	B-X
pathways	B-X
.	B-X
Pathways	B-X
other	B-X
than	B-X
JAK/STAT	B-X
are	B-X
also	B-X
involved	B-X
in	B-X
IFN	B-X
signaling	B-X
,	B-X
but	B-X
their	B-X
mechanisms	B-X
are	B-X
less	B-X
clear	B-X
.	B-X
The	B-X
best	B-X
documented	B-X
are	B-X
the	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
cascade	B-X
,	B-X
the	B-X
components	B-X
of	B-X
the	B-X
TCR	B-X
(	B-X
T	B-X
cell	B-X
receptor	B-X
)	B-X
signaling	B-X
cascade	B-X
and	B-X
the	B-X
Pi3	B-X
kinase	B-X
pathway	B-X
.	B-X

Histone	B-Protein
deacetylases	O
(	O
HDACs	O
)	O
and	O
the	O
histone	B-Protein
acetyltransferase	O
(	O
HAT	O
)	O
CBP	B-Protein
dynamically	O
regulate	O
STAT1	B-Protein
acetylation	O
.	O
<EOS>	B-X
Histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
and	B-X
the	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
CBP	B-X
dynamically	B-X
regulate	B-X
STAT1	B-X
acetylation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
acetylation	B-X
of	B-X
STAT1	B-X
counteracts	B-X
IFN-induced	B-X
STAT1	B-X
phosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
target	B-X
gene	B-X
expression	B-X
.	B-X
Biochemical	B-X
and	B-X
genetic	B-X
experiments	B-X
altering	B-X
the	B-X
HAT/HDAC	B-X
activity	B-X
ratio	B-X
and	B-X
STAT1	B-X
mutants	B-X
reveal	B-X
that	B-X
a	B-X
phospho-acetyl	B-X
switch	B-X
regulates	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP	B-X
,	B-X
HDAC3	B-X
,	B-X
and	B-X
the	B-X
T-cell	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
TCP45	B-X
)	B-X
.	B-X
Strikingly	B-X
,	B-X
inhibition	B-X
of	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP-mediated	B-X
acetylation	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
functions	B-X
of	B-X
this	B-X
HAT	B-X
in	B-X
transcriptional	B-X
activation	B-X
.	B-X
STAT1	B-X
acetylation	B-X
induces	B-X
binding	B-X
of	B-X
TCP45	B-X
,	B-X
which	B-X
catalyzes	B-X
dephosphorylation	B-X
and	B-X
latency	B-X
of	B-X
STAT1	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
a	B-X
deeper	B-X
understanding	B-X
of	B-X
the	B-X
modulation	B-X
of	B-X
STAT1	B-X
activity	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
new	B-X
layer	B-X
of	B-X
physiologically	B-X
relevant	B-X
STAT1	B-X
regulation	B-X
and	B-X
suggest	B-X
that	B-X
a	B-X
previously	B-X
unidentified	B-X
balance	B-X
between	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
affects	B-X
cytokine	B-X
signaling	B-X
.	B-X

Here	O
we	O
show	O
that	O
acetylation	O
of	O
STAT1	B-Protein
counteracts	O
IFN	O
-	O
induced	O
STAT1	B-Protein
phosphorylation	O
,	O
nuclear	O
translocation	O
,	O
DNA	O
binding	O
,	O
and	O
target	O
gene	O
expression	O
.	O
<EOS>	B-X
Cytokines	B-X
such	B-X
as	B-X
interferons	B-X
(	B-X
IFNs	B-X
)	B-X
activate	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
(	B-X
STATs	B-X
)	B-X
via	B-X
phosphorylation	B-X
.	B-X
Histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
and	B-X
the	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
CBP	B-X
dynamically	B-X
regulate	B-X
STAT1	B-X
acetylation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
acetylation	B-X
of	B-X
STAT1	B-X
counteracts	B-X
IFN-induced	B-X
STAT1	B-X
phosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
target	B-X
gene	B-X
expression	B-X
.	B-X
Biochemical	B-X
and	B-X
genetic	B-X
experiments	B-X
altering	B-X
the	B-X
HAT/HDAC	B-X
activity	B-X
ratio	B-X
and	B-X
STAT1	B-X
mutants	B-X
reveal	B-X
that	B-X
a	B-X
phospho-acetyl	B-X
switch	B-X
regulates	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP	B-X
,	B-X
HDAC3	B-X
,	B-X
and	B-X
the	B-X
T-cell	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
TCP45	B-X
)	B-X
.	B-X
Strikingly	B-X
,	B-X
inhibition	B-X
of	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP-mediated	B-X
acetylation	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
functions	B-X
of	B-X
this	B-X
HAT	B-X
in	B-X
transcriptional	B-X
activation	B-X
.	B-X
STAT1	B-X
acetylation	B-X
induces	B-X
binding	B-X
of	B-X
TCP45	B-X
,	B-X
which	B-X
catalyzes	B-X
dephosphorylation	B-X
and	B-X
latency	B-X
of	B-X
STAT1	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
a	B-X
deeper	B-X
understanding	B-X
of	B-X
the	B-X
modulation	B-X
of	B-X
STAT1	B-X
activity	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
new	B-X
layer	B-X
of	B-X
physiologically	B-X
relevant	B-X
STAT1	B-X
regulation	B-X
and	B-X
suggest	B-X
that	B-X
a	B-X
previously	B-X
unidentified	B-X
balance	B-X
between	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
affects	B-X
cytokine	B-X
signaling	B-X
.	B-X

Biochemical	O
and	O
genetic	O
experiments	O
altering	O
the	O
HAT	O
/	O
HDAC	O
activity	O
ratio	O
and	O
STAT1	B-Protein
mutants	O
reveal	O
that	O
a	O
phospho	O
-	O
acetyl	O
switch	O
regulates	O
STAT1	B-Protein
signaling	O
via	O
CBP	B-Protein
,	O
HDAC3	B-Protein
,	O
and	O
the	O
T	B-Protein
-	I-Protein
cell	I-Protein
protein	I-Protein
tyrosine	I-Protein
phosphatase	I-Protein
(	O
TCP45	B-Protein
)	O
.	O

Strikingly	O
,	O
inhibition	O
of	O
STAT1	B-Protein
signaling	O
via	O
CBP	B-Protein
-	O
mediated	O
acetylation	O
is	O
distinct	O
from	O
the	O
functions	O
of	O
this	O
HAT	O
in	O
transcriptional	O
activation	O
.	O
<EOS>	B-X
Cytokines	B-X
such	B-X
as	B-X
interferons	B-X
(	B-X
IFNs	B-X
)	B-X
activate	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
(	B-X
STATs	B-X
)	B-X
via	B-X
phosphorylation	B-X
.	B-X
Histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
and	B-X
the	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
CBP	B-X
dynamically	B-X
regulate	B-X
STAT1	B-X
acetylation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
acetylation	B-X
of	B-X
STAT1	B-X
counteracts	B-X
IFN-induced	B-X
STAT1	B-X
phosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
target	B-X
gene	B-X
expression	B-X
.	B-X
Biochemical	B-X
and	B-X
genetic	B-X
experiments	B-X
altering	B-X
the	B-X
HAT/HDAC	B-X
activity	B-X
ratio	B-X
and	B-X
STAT1	B-X
mutants	B-X
reveal	B-X
that	B-X
a	B-X
phospho-acetyl	B-X
switch	B-X
regulates	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP	B-X
,	B-X
HDAC3	B-X
,	B-X
and	B-X
the	B-X
T-cell	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
TCP45	B-X
)	B-X
.	B-X
Strikingly	B-X
,	B-X
inhibition	B-X
of	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP-mediated	B-X
acetylation	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
functions	B-X
of	B-X
this	B-X
HAT	B-X
in	B-X
transcriptional	B-X
activation	B-X
.	B-X
STAT1	B-X
acetylation	B-X
induces	B-X
binding	B-X
of	B-X
TCP45	B-X
,	B-X
which	B-X
catalyzes	B-X
dephosphorylation	B-X
and	B-X
latency	B-X
of	B-X
STAT1	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
a	B-X
deeper	B-X
understanding	B-X
of	B-X
the	B-X
modulation	B-X
of	B-X
STAT1	B-X
activity	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
new	B-X
layer	B-X
of	B-X
physiologically	B-X
relevant	B-X
STAT1	B-X
regulation	B-X
and	B-X
suggest	B-X
that	B-X
a	B-X
previously	B-X
unidentified	B-X
balance	B-X
between	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
affects	B-X
cytokine	B-X
signaling	B-X
.	B-X

STAT1	B-Protein
acetylation	O
induces	O
binding	O
of	O
TCP45	B-Protein
,	O
which	O
catalyzes	O
dephosphorylation	O
and	O
latency	O
of	O
STAT1	B-Protein
.	O
<EOS>	B-X
Histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
and	B-X
the	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
CBP	B-X
dynamically	B-X
regulate	B-X
STAT1	B-X
acetylation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
acetylation	B-X
of	B-X
STAT1	B-X
counteracts	B-X
IFN-induced	B-X
STAT1	B-X
phosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
target	B-X
gene	B-X
expression	B-X
.	B-X
Biochemical	B-X
and	B-X
genetic	B-X
experiments	B-X
altering	B-X
the	B-X
HAT/HDAC	B-X
activity	B-X
ratio	B-X
and	B-X
STAT1	B-X
mutants	B-X
reveal	B-X
that	B-X
a	B-X
phospho-acetyl	B-X
switch	B-X
regulates	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP	B-X
,	B-X
HDAC3	B-X
,	B-X
and	B-X
the	B-X
T-cell	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
TCP45	B-X
)	B-X
.	B-X
Strikingly	B-X
,	B-X
inhibition	B-X
of	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP-mediated	B-X
acetylation	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
functions	B-X
of	B-X
this	B-X
HAT	B-X
in	B-X
transcriptional	B-X
activation	B-X
.	B-X
STAT1	B-X
acetylation	B-X
induces	B-X
binding	B-X
of	B-X
TCP45	B-X
,	B-X
which	B-X
catalyzes	B-X
dephosphorylation	B-X
and	B-X
latency	B-X
of	B-X
STAT1	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
a	B-X
deeper	B-X
understanding	B-X
of	B-X
the	B-X
modulation	B-X
of	B-X
STAT1	B-X
activity	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
new	B-X
layer	B-X
of	B-X
physiologically	B-X
relevant	B-X
STAT1	B-X
regulation	B-X
and	B-X
suggest	B-X
that	B-X
a	B-X
previously	B-X
unidentified	B-X
balance	B-X
between	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
affects	B-X
cytokine	B-X
signaling	B-X
.	B-X

Our	O
results	O
provide	O
a	O
deeper	O
understanding	O
of	O
the	O
modulation	O
of	O
STAT1	B-Protein
activity	O
.	O
<EOS>	B-X
The	B-X
accessory	B-X
proteins	B-X
of	B-X
coronaviruses	B-X
are	B-X
essential	B-X
for	B-X
virus-host	B-X
interactions	B-X
and	B-X
the	B-X
modulation	B-X
of	B-X
host	B-X
immune	B-X
responses	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
apoptosis-inducing	B-X
activity	B-X
of	B-X
ORF7b	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
could	B-X
provide	B-X
deeper	B-X
understanding	B-X
about	B-X
the	B-X
pathogenicity	B-X
of	B-X
SARS-CoV-2	B-X
as	B-X
well	B-X
as	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
accessory	B-X
protein	B-X
ORF7b	B-X
with	B-X
host	B-X
immune	B-X
responses	B-X
.	B-X
Histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
and	B-X
the	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
CBP	B-X
dynamically	B-X
regulate	B-X
STAT1	B-X
acetylation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
acetylation	B-X
of	B-X
STAT1	B-X
counteracts	B-X
IFN-induced	B-X
STAT1	B-X
phosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
target	B-X
gene	B-X
expression	B-X
.	B-X
Biochemical	B-X
and	B-X
genetic	B-X
experiments	B-X
altering	B-X
the	B-X
HAT/HDAC	B-X
activity	B-X
ratio	B-X
and	B-X
STAT1	B-X
mutants	B-X
reveal	B-X
that	B-X
a	B-X
phospho-acetyl	B-X
switch	B-X
regulates	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP	B-X
,	B-X
HDAC3	B-X
,	B-X
and	B-X
the	B-X
T-cell	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
TCP45	B-X
)	B-X
.	B-X
Strikingly	B-X
,	B-X
inhibition	B-X
of	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP-mediated	B-X
acetylation	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
functions	B-X
of	B-X
this	B-X
HAT	B-X
in	B-X
transcriptional	B-X
activation	B-X
.	B-X
STAT1	B-X
acetylation	B-X
induces	B-X
binding	B-X
of	B-X
TCP45	B-X
,	B-X
which	B-X
catalyzes	B-X
dephosphorylation	B-X
and	B-X
latency	B-X
of	B-X
STAT1	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
a	B-X
deeper	B-X
understanding	B-X
of	B-X
the	B-X
modulation	B-X
of	B-X
STAT1	B-X
activity	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
new	B-X
layer	B-X
of	B-X
physiologically	B-X
relevant	B-X
STAT1	B-X
regulation	B-X
and	B-X
suggest	B-X
that	B-X
a	B-X
previously	B-X
unidentified	B-X
balance	B-X
between	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
affects	B-X
cytokine	B-X
signaling	B-X
.	B-X

These	O
findings	O
reveal	O
a	O
new	O
layer	O
of	O
physiologically	O
relevant	O
STAT1	B-Protein
regulation	O
and	O
suggest	O
that	O
a	O
previously	O
unidentified	O
balance	O
between	O
phosphorylation	O
and	O
acetylation	O
affects	O
cytokine	O
signaling	O
.	O
<EOS>	B-X
Cytokines	B-X
such	B-X
as	B-X
interferons	B-X
(	B-X
IFNs	B-X
)	B-X
activate	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
(	B-X
STATs	B-X
)	B-X
via	B-X
phosphorylation	B-X
.	B-X
Histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
and	B-X
the	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
CBP	B-X
dynamically	B-X
regulate	B-X
STAT1	B-X
acetylation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
acetylation	B-X
of	B-X
STAT1	B-X
counteracts	B-X
IFN-induced	B-X
STAT1	B-X
phosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
target	B-X
gene	B-X
expression	B-X
.	B-X
Biochemical	B-X
and	B-X
genetic	B-X
experiments	B-X
altering	B-X
the	B-X
HAT/HDAC	B-X
activity	B-X
ratio	B-X
and	B-X
STAT1	B-X
mutants	B-X
reveal	B-X
that	B-X
a	B-X
phospho-acetyl	B-X
switch	B-X
regulates	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP	B-X
,	B-X
HDAC3	B-X
,	B-X
and	B-X
the	B-X
T-cell	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
TCP45	B-X
)	B-X
.	B-X
Strikingly	B-X
,	B-X
inhibition	B-X
of	B-X
STAT1	B-X
signaling	B-X
via	B-X
CBP-mediated	B-X
acetylation	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
functions	B-X
of	B-X
this	B-X
HAT	B-X
in	B-X
transcriptional	B-X
activation	B-X
.	B-X
STAT1	B-X
acetylation	B-X
induces	B-X
binding	B-X
of	B-X
TCP45	B-X
,	B-X
which	B-X
catalyzes	B-X
dephosphorylation	B-X
and	B-X
latency	B-X
of	B-X
STAT1	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
a	B-X
deeper	B-X
understanding	B-X
of	B-X
the	B-X
modulation	B-X
of	B-X
STAT1	B-X
activity	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
new	B-X
layer	B-X
of	B-X
physiologically	B-X
relevant	B-X
STAT1	B-X
regulation	B-X
and	B-X
suggest	B-X
that	B-X
a	B-X
previously	B-X
unidentified	B-X
balance	B-X
between	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
affects	B-X
cytokine	B-X
signaling	B-X
.	B-X

Sem1p	B-Protein
and	O
Ubp6p	B-Protein
orchestrate	O
telomeric	O
silencing	O
by	O
modulating	O
histone	B-Protein
H2B	I-Protein
ubiquitination	O
and	O
H3	B-Protein
acetylation	O
.	O
<EOS>	B-X
In	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
heterochromatin	B-X
mediates	B-X
transcriptional	B-X
silencing	B-X
at	B-X
telomeres	B-X
,	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
proteasome-associated	B-X
Sem1p	B-X
and	B-X
its	B-X
interacting	B-X
partner	B-X
,	B-X
Ubp6p	B-X
(	B-X
a	B-X
deubiquitinating	B-X
enzyme	B-X
)	B-X
,	B-X
are	B-X
essential	B-X
to	B-X
maintain	B-X
telomeric	B-X
silencing	B-X
.	B-X
Simultaneous	B-X
deletion	B-X
of	B-X
SEM1	B-X
and	B-X
UBP6	B-X
induces	B-X
dramatic	B-X
silencing	B-X
defect	B-X
accompanied	B-X
by	B-X
significantly	B-X
increased	B-X
level	B-X
of	B-X
ubiquitinated-histone	B-X
H2B	B-X
and	B-X
markedly	B-X
reduced	B-X
levels	B-X
of	B-X
acetylated-lysine	B-X
14	B-X
and	B-X
23	B-X
on	B-X
histone	B-X
H3	B-X
at	B-X
the	B-X
telomeres	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
triggers	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
(	B-X
e.g	B-X
.	B-X
Such	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
enhances	B-X
gene	B-X
silencing	B-X
at	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
,	B-X
but	B-X
diminishes	B-X
telomeric	B-X
silencing	B-X
.	B-X
Interestingly	B-X
,	B-X
both	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
participate	B-X
in	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
.	B-X
However	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
telomeric	B-X
silencing	B-X
is	B-X
not	B-X
influenced	B-X
by	B-X
proteolysis	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
maintain	B-X
telomeric	B-X
heterochromatin	B-X
structure	B-X
(	B-X
and	B-X
hence	B-X
silencing	B-X
)	B-X
through	B-X
modulation	B-X
of	B-X
histone	B-X
covalent	B-X
modifications	B-X
and	B-X
association	B-X
of	B-X
silencing	B-X
factors	B-X
independently	B-X
of	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
,	B-X
thus	B-X
offering	B-X
a	B-X
new	B-X
regulatory	B-X
mechanism	B-X
of	B-X
telomeric	B-X
silencing	B-X
.	B-X

Histone	B-Protein
covalent	O
modifications	O
and	O
26S	O
proteasome	O
-	O
mediated	O
proteolysis	O
modulate	O
many	O
regulatory	O
events	O
in	O
eukaryotes	O
.	O
<EOS>	B-X
Histone	B-X
covalent	B-X
modifications	B-X
and	B-X
26S	B-X
proteasome-mediated	B-X
proteolysis	B-X
modulate	B-X
many	B-X
regulatory	B-X
events	B-X
in	B-X
eukaryotes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
proteasome-associated	B-X
Sem1p	B-X
and	B-X
its	B-X
interacting	B-X
partner	B-X
,	B-X
Ubp6p	B-X
(	B-X
a	B-X
deubiquitinating	B-X
enzyme	B-X
)	B-X
,	B-X
are	B-X
essential	B-X
to	B-X
maintain	B-X
telomeric	B-X
silencing	B-X
.	B-X
Interestingly	B-X
,	B-X
both	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
participate	B-X
in	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
.	B-X
However	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
telomeric	B-X
silencing	B-X
is	B-X
not	B-X
influenced	B-X
by	B-X
proteolysis	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
maintain	B-X
telomeric	B-X
heterochromatin	B-X
structure	B-X
(	B-X
and	B-X
hence	B-X
silencing	B-X
)	B-X
through	B-X
modulation	B-X
of	B-X
histone	B-X
covalent	B-X
modifications	B-X
and	B-X
association	B-X
of	B-X
silencing	B-X
factors	B-X
independently	B-X
of	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
,	B-X
thus	B-X
offering	B-X
a	B-X
new	B-X
regulatory	B-X
mechanism	B-X
of	B-X
telomeric	B-X
silencing	B-X
.	B-X

In	O
Saccharomyces	O
cerevisiae	O
,	O
heterochromatin	O
mediates	O
transcriptional	O
silencing	O
at	O
telomeres	O
,	O
HM	O
loci	O
and	O
rDNA	O
array	O
.	O
<EOS>	B-X
In	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
heterochromatin	B-X
mediates	B-X
transcriptional	B-X
silencing	B-X
at	B-X
telomeres	B-X
,	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
proteasome-associated	B-X
Sem1p	B-X
and	B-X
its	B-X
interacting	B-X
partner	B-X
,	B-X
Ubp6p	B-X
(	B-X
a	B-X
deubiquitinating	B-X
enzyme	B-X
)	B-X
,	B-X
are	B-X
essential	B-X
to	B-X
maintain	B-X
telomeric	B-X
silencing	B-X
.	B-X
Simultaneous	B-X
deletion	B-X
of	B-X
SEM1	B-X
and	B-X
UBP6	B-X
induces	B-X
dramatic	B-X
silencing	B-X
defect	B-X
accompanied	B-X
by	B-X
significantly	B-X
increased	B-X
level	B-X
of	B-X
ubiquitinated-histone	B-X
H2B	B-X
and	B-X
markedly	B-X
reduced	B-X
levels	B-X
of	B-X
acetylated-lysine	B-X
14	B-X
and	B-X
23	B-X
on	B-X
histone	B-X
H3	B-X
at	B-X
the	B-X
telomeres	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
triggers	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
(	B-X
e.g	B-X
.	B-X
Sir	B-X
proteins	B-X
)	B-X
from	B-X
telomere	B-X
to	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
.	B-X
Such	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
enhances	B-X
gene	B-X
silencing	B-X
at	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
,	B-X
but	B-X
diminishes	B-X
telomeric	B-X
silencing	B-X
.	B-X
However	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
telomeric	B-X
silencing	B-X
is	B-X
not	B-X
influenced	B-X
by	B-X
proteolysis	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
maintain	B-X
telomeric	B-X
heterochromatin	B-X
structure	B-X
(	B-X
and	B-X
hence	B-X
silencing	B-X
)	B-X
through	B-X
modulation	B-X
of	B-X
histone	B-X
covalent	B-X
modifications	B-X
and	B-X
association	B-X
of	B-X
silencing	B-X
factors	B-X
independently	B-X
of	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
,	B-X
thus	B-X
offering	B-X
a	B-X
new	B-X
regulatory	B-X
mechanism	B-X
of	B-X
telomeric	B-X
silencing	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
proteasome	O
-	O
associated	O
Sem1p	B-Protein
and	O
its	O
interacting	O
partner	O
,	O
Ubp6p	B-Protein
(	O
a	O
deubiquitinating	O
enzyme	O
)	O
,	O
are	O
essential	O
to	O
maintain	O
telomeric	O
silencing	O
.	O
<EOS>	B-X
Histone	B-X
covalent	B-X
modifications	B-X
and	B-X
26S	B-X
proteasome-mediated	B-X
proteolysis	B-X
modulate	B-X
many	B-X
regulatory	B-X
events	B-X
in	B-X
eukaryotes	B-X
.	B-X
In	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
heterochromatin	B-X
mediates	B-X
transcriptional	B-X
silencing	B-X
at	B-X
telomeres	B-X
,	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
proteasome-associated	B-X
Sem1p	B-X
and	B-X
its	B-X
interacting	B-X
partner	B-X
,	B-X
Ubp6p	B-X
(	B-X
a	B-X
deubiquitinating	B-X
enzyme	B-X
)	B-X
,	B-X
are	B-X
essential	B-X
to	B-X
maintain	B-X
telomeric	B-X
silencing	B-X
.	B-X
Simultaneous	B-X
deletion	B-X
of	B-X
SEM1	B-X
and	B-X
UBP6	B-X
induces	B-X
dramatic	B-X
silencing	B-X
defect	B-X
accompanied	B-X
by	B-X
significantly	B-X
increased	B-X
level	B-X
of	B-X
ubiquitinated-histone	B-X
H2B	B-X
and	B-X
markedly	B-X
reduced	B-X
levels	B-X
of	B-X
acetylated-lysine	B-X
14	B-X
and	B-X
23	B-X
on	B-X
histone	B-X
H3	B-X
at	B-X
the	B-X
telomeres	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
triggers	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
(	B-X
e.g	B-X
.	B-X
Such	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
enhances	B-X
gene	B-X
silencing	B-X
at	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
,	B-X
but	B-X
diminishes	B-X
telomeric	B-X
silencing	B-X
.	B-X
Interestingly	B-X
,	B-X
both	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
participate	B-X
in	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
.	B-X
However	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
telomeric	B-X
silencing	B-X
is	B-X
not	B-X
influenced	B-X
by	B-X
proteolysis	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
maintain	B-X
telomeric	B-X
heterochromatin	B-X
structure	B-X
(	B-X
and	B-X
hence	B-X
silencing	B-X
)	B-X
through	B-X
modulation	B-X
of	B-X
histone	B-X
covalent	B-X
modifications	B-X
and	B-X
association	B-X
of	B-X
silencing	B-X
factors	B-X
independently	B-X
of	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
,	B-X
thus	B-X
offering	B-X
a	B-X
new	B-X
regulatory	B-X
mechanism	B-X
of	B-X
telomeric	B-X
silencing	B-X
.	B-X

Simultaneous	O
deletion	O
of	O
SEM1	B-Protein
and	O
UBP6	B-Protein
induces	O
dramatic	O
silencing	O
defect	O
accompanied	O
by	O
significantly	O
increased	O
level	O
of	O
ubiquitinated	O
-	O
histone	B-Protein
H2B	I-Protein
and	O
markedly	O
reduced	O
levels	O
of	O
acetylated	O
-	O
lysine	O
14	O
and	O
23	O
on	O
histone	B-Protein
H3	I-Protein
at	O
the	O
telomeres	O
.	O
<EOS>	B-X
In	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
heterochromatin	B-X
mediates	B-X
transcriptional	B-X
silencing	B-X
at	B-X
telomeres	B-X
,	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
proteasome-associated	B-X
Sem1p	B-X
and	B-X
its	B-X
interacting	B-X
partner	B-X
,	B-X
Ubp6p	B-X
(	B-X
a	B-X
deubiquitinating	B-X
enzyme	B-X
)	B-X
,	B-X
are	B-X
essential	B-X
to	B-X
maintain	B-X
telomeric	B-X
silencing	B-X
.	B-X
Simultaneous	B-X
deletion	B-X
of	B-X
SEM1	B-X
and	B-X
UBP6	B-X
induces	B-X
dramatic	B-X
silencing	B-X
defect	B-X
accompanied	B-X
by	B-X
significantly	B-X
increased	B-X
level	B-X
of	B-X
ubiquitinated-histone	B-X
H2B	B-X
and	B-X
markedly	B-X
reduced	B-X
levels	B-X
of	B-X
acetylated-lysine	B-X
14	B-X
and	B-X
23	B-X
on	B-X
histone	B-X
H3	B-X
at	B-X
the	B-X
telomeres	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
triggers	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
(	B-X
e.g	B-X
.	B-X
Such	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
enhances	B-X
gene	B-X
silencing	B-X
at	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
,	B-X
but	B-X
diminishes	B-X
telomeric	B-X
silencing	B-X
.	B-X
However	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
telomeric	B-X
silencing	B-X
is	B-X
not	B-X
influenced	B-X
by	B-X
proteolysis	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
maintain	B-X
telomeric	B-X
heterochromatin	B-X
structure	B-X
(	B-X
and	B-X
hence	B-X
silencing	B-X
)	B-X
through	B-X
modulation	B-X
of	B-X
histone	B-X
covalent	B-X
modifications	B-X
and	B-X
association	B-X
of	B-X
silencing	B-X
factors	B-X
independently	B-X
of	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
,	B-X
thus	B-X
offering	B-X
a	B-X
new	B-X
regulatory	B-X
mechanism	B-X
of	B-X
telomeric	B-X
silencing	B-X
.	B-X

Further	O
,	O
the	O
loss	O
of	O
Sem1p	B-Protein
and	O
Ubp6p	B-Protein
triggers	O
relocation	O
of	O
silencing	O
factors	O
(	O
e	O
.	O
g	O
.	O
Sir	O
proteins	O
)	O
from	O
telomere	O
to	O
HM	O
loci	O
and	O
rDNA	O
array	O
.	O

Such	O
relocation	O
of	O
silencing	O
factors	O
enhances	O
gene	O
silencing	O
at	O
HM	O
loci	O
and	O
rDNA	O
array	O
,	O
but	O
diminishes	O
telomeric	O
silencing	O
.	O
<EOS>	B-X
In	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
heterochromatin	B-X
mediates	B-X
transcriptional	B-X
silencing	B-X
at	B-X
telomeres	B-X
,	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
proteasome-associated	B-X
Sem1p	B-X
and	B-X
its	B-X
interacting	B-X
partner	B-X
,	B-X
Ubp6p	B-X
(	B-X
a	B-X
deubiquitinating	B-X
enzyme	B-X
)	B-X
,	B-X
are	B-X
essential	B-X
to	B-X
maintain	B-X
telomeric	B-X
silencing	B-X
.	B-X
Simultaneous	B-X
deletion	B-X
of	B-X
SEM1	B-X
and	B-X
UBP6	B-X
induces	B-X
dramatic	B-X
silencing	B-X
defect	B-X
accompanied	B-X
by	B-X
significantly	B-X
increased	B-X
level	B-X
of	B-X
ubiquitinated-histone	B-X
H2B	B-X
and	B-X
markedly	B-X
reduced	B-X
levels	B-X
of	B-X
acetylated-lysine	B-X
14	B-X
and	B-X
23	B-X
on	B-X
histone	B-X
H3	B-X
at	B-X
the	B-X
telomeres	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
triggers	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
(	B-X
e.g	B-X
.	B-X
Sir	B-X
proteins	B-X
)	B-X
from	B-X
telomere	B-X
to	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
.	B-X
Such	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
enhances	B-X
gene	B-X
silencing	B-X
at	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
,	B-X
but	B-X
diminishes	B-X
telomeric	B-X
silencing	B-X
.	B-X
However	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
telomeric	B-X
silencing	B-X
is	B-X
not	B-X
influenced	B-X
by	B-X
proteolysis	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
maintain	B-X
telomeric	B-X
heterochromatin	B-X
structure	B-X
(	B-X
and	B-X
hence	B-X
silencing	B-X
)	B-X
through	B-X
modulation	B-X
of	B-X
histone	B-X
covalent	B-X
modifications	B-X
and	B-X
association	B-X
of	B-X
silencing	B-X
factors	B-X
independently	B-X
of	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
,	B-X
thus	B-X
offering	B-X
a	B-X
new	B-X
regulatory	B-X
mechanism	B-X
of	B-X
telomeric	B-X
silencing	B-X
.	B-X

Interestingly	O
,	O
both	O
Sem1p	B-Protein
and	O
Ubp6p	B-Protein
participate	O
in	O
the	O
proteolytic	O
function	O
of	O
the	O
proteasome	O
.	O
<EOS>	B-X
Histone	B-X
covalent	B-X
modifications	B-X
and	B-X
26S	B-X
proteasome-mediated	B-X
proteolysis	B-X
modulate	B-X
many	B-X
regulatory	B-X
events	B-X
in	B-X
eukaryotes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
proteasome-associated	B-X
Sem1p	B-X
and	B-X
its	B-X
interacting	B-X
partner	B-X
,	B-X
Ubp6p	B-X
(	B-X
a	B-X
deubiquitinating	B-X
enzyme	B-X
)	B-X
,	B-X
are	B-X
essential	B-X
to	B-X
maintain	B-X
telomeric	B-X
silencing	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
triggers	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
(	B-X
e.g	B-X
.	B-X
Interestingly	B-X
,	B-X
both	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
participate	B-X
in	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
maintain	B-X
telomeric	B-X
heterochromatin	B-X
structure	B-X
(	B-X
and	B-X
hence	B-X
silencing	B-X
)	B-X
through	B-X
modulation	B-X
of	B-X
histone	B-X
covalent	B-X
modifications	B-X
and	B-X
association	B-X
of	B-X
silencing	B-X
factors	B-X
independently	B-X
of	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
,	B-X
thus	B-X
offering	B-X
a	B-X
new	B-X
regulatory	B-X
mechanism	B-X
of	B-X
telomeric	B-X
silencing	B-X
.	B-X

However	O
,	O
we	O
find	O
that	O
the	O
telomeric	O
silencing	O
is	O
not	O
influenced	O
by	O
proteolysis	O
.	O
<EOS>	B-X
Parallel	B-X
research	B-X
on	B-X
multiple	B-X
model	B-X
organisms	B-X
shows	B-X
that	B-X
while	B-X
some	B-X
principles	B-X
of	B-X
telomere	B-X
biology	B-X
are	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotic	B-X
kingdoms	B-X
,	B-X
we	B-X
also	B-X
find	B-X
some	B-X
deviations	B-X
that	B-X
reflect	B-X
different	B-X
evolutionary	B-X
paths	B-X
and	B-X
life	B-X
strategies	B-X
,	B-X
which	B-X
may	B-X
have	B-X
diversified	B-X
after	B-X
the	B-X
establishment	B-X
of	B-X
telomerase	B-X
as	B-X
a	B-X
primary	B-X
mechanism	B-X
for	B-X
telomere	B-X
maintenance	B-X
.	B-X
Furthermore	B-X
,	B-X
plant	B-X
ontogenesis	B-X
differs	B-X
from	B-X
that	B-X
of	B-X
animals	B-X
in	B-X
which	B-X
tissue	B-X
differentiation	B-X
and	B-X
telomerase	B-X
silencing	B-X
occur	B-X
during	B-X
early	B-X
embryonic	B-X
development	B-X
,	B-X
and	B-X
the	B-X
``	B-X
telomere	B-X
clock	B-X
''	B-X
in	B-X
somatic	B-X
cells	B-X
may	B-X
act	B-X
as	B-X
a	B-X
preventive	B-X
measure	B-X
against	B-X
carcinogenesis	B-X
.	B-X
Telomeres	B-X
also	B-X
recruit	B-X
histone	B-X
deacetylase	B-X
complexes	B-X
that	B-X
can	B-X
then	B-X
spread	B-X
along	B-X
chromosome	B-X
arms	B-X
and	B-X
repress	B-X
the	B-X
expression	B-X
of	B-X
subtelomeric	B-X
genes	B-X
in	B-X
a	B-X
process	B-X
known	B-X
as	B-X
telomere	B-X
position	B-X
effect	B-X
(	B-X
TPE	B-X
)	B-X
.	B-X
Recent	B-X
findings	B-X
suggested	B-X
that	B-X
decreased	B-X
growth	B-X
on	B-X
5FOA-containing	B-X
media	B-X
may	B-X
not	B-X
always	B-X
indicate	B-X
increased	B-X
expression	B-X
of	B-X
a	B-X
telomeric	B-X
URA3	B-X
reporter	B-X
,	B-X
but	B-X
can	B-X
rather	B-X
reflect	B-X
an	B-X
increase	B-X
in	B-X
ribonucleotide	B-X
reductase	B-X
(	B-X
RNR	B-X
)	B-X
function	B-X
and	B-X
nucleotide	B-X
metabolism	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
set	B-X
out	B-X
to	B-X
test	B-X
if	B-X
the	B-X
5FOA	B-X
sensitivity	B-X
of	B-X
subtelomeric	B-X
URA3-harboring	B-X
cells	B-X
in	B-X
which	B-X
we	B-X
deleted	B-X
various	B-X
factors	B-X
implicated	B-X
in	B-X
perinuclear	B-X
telomere	B-X
tethering	B-X
reflects	B-X
changes	B-X
to	B-X
TPE	B-X
and/or	B-X
RNR	B-X
.	B-X
We	B-X
report	B-X
that	B-X
RNR	B-X
inhibition	B-X
restores	B-X
5FOA	B-X
resistance	B-X
to	B-X
cells	B-X
lacking	B-X
RNR	B-X
regulatory	B-X
factors	B-X
but	B-X
not	B-X
any	B-X
of	B-X
the	B-X
major	B-X
telomere	B-X
tethering	B-X
and	B-X
silencing	B-X
factors	B-X
,	B-X
including	B-X
Sir2	B-X
,	B-X
cohibin	B-X
,	B-X
Mps3	B-X
,	B-X
Heh1	B-X
,	B-X
and	B-X
Esc1	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
disruption	B-X
of	B-X
tethering	B-X
pathways	B-X
in	B-X
which	B-X
these	B-X
factors	B-X
participate	B-X
increases	B-X
the	B-X
level	B-X
of	B-X
URA3	B-X
transcripts	B-X
originating	B-X
from	B-X
the	B-X
telomeric	B-X
reporter	B-X
gene	B-X
and	B-X
abrogates	B-X
silencing	B-X
of	B-X
subtelomeric	B-X
HIS3	B-X
reporter	B-X
genes	B-X
without	B-X
altering	B-X
RNR	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
increased	B-X
5FOA	B-X
sensitivity	B-X
of	B-X
telomeric	B-X
URA3-harboring	B-X
cells	B-X
deficient	B-X
in	B-X
telomere	B-X
tethers	B-X
reflects	B-X
the	B-X
dysregulation	B-X
of	B-X
TPE	B-X
but	B-X
not	B-X
RNR	B-X
.	B-X
This	B-X
is	B-X
key	B-X
to	B-X
understanding	B-X
relationships	B-X
between	B-X
telomere	B-X
positioning	B-X
,	B-X
chromatin	B-X
silencing	B-X
,	B-X
and	B-X
lifespan	B-X
.	B-X

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
Sem1p	B-Protein
and	O
Ubp6p	B-Protein
maintain	O
telomeric	O
heterochromatin	O
structure	O
(	O
and	O
hence	O
silencing	O
)	O
through	O
modulation	O
of	O
histone	B-Protein
covalent	O
modifications	O
and	O
association	O
of	O
silencing	O
factors	O
independently	O
of	O
the	O
proteolytic	O
function	O
of	O
the	O
proteasome	O
,	O
thus	O
offering	O
a	O
new	O
regulatory	O
mechanism	O
of	O
telomeric	O
silencing	O
.	O
<EOS>	B-X
Histone	B-X
covalent	B-X
modifications	B-X
and	B-X
26S	B-X
proteasome-mediated	B-X
proteolysis	B-X
modulate	B-X
many	B-X
regulatory	B-X
events	B-X
in	B-X
eukaryotes	B-X
.	B-X
In	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
heterochromatin	B-X
mediates	B-X
transcriptional	B-X
silencing	B-X
at	B-X
telomeres	B-X
,	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
proteasome-associated	B-X
Sem1p	B-X
and	B-X
its	B-X
interacting	B-X
partner	B-X
,	B-X
Ubp6p	B-X
(	B-X
a	B-X
deubiquitinating	B-X
enzyme	B-X
)	B-X
,	B-X
are	B-X
essential	B-X
to	B-X
maintain	B-X
telomeric	B-X
silencing	B-X
.	B-X
Simultaneous	B-X
deletion	B-X
of	B-X
SEM1	B-X
and	B-X
UBP6	B-X
induces	B-X
dramatic	B-X
silencing	B-X
defect	B-X
accompanied	B-X
by	B-X
significantly	B-X
increased	B-X
level	B-X
of	B-X
ubiquitinated-histone	B-X
H2B	B-X
and	B-X
markedly	B-X
reduced	B-X
levels	B-X
of	B-X
acetylated-lysine	B-X
14	B-X
and	B-X
23	B-X
on	B-X
histone	B-X
H3	B-X
at	B-X
the	B-X
telomeres	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
triggers	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
(	B-X
e.g	B-X
.	B-X
Such	B-X
relocation	B-X
of	B-X
silencing	B-X
factors	B-X
enhances	B-X
gene	B-X
silencing	B-X
at	B-X
HM	B-X
loci	B-X
and	B-X
rDNA	B-X
array	B-X
,	B-X
but	B-X
diminishes	B-X
telomeric	B-X
silencing	B-X
.	B-X
Interestingly	B-X
,	B-X
both	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
participate	B-X
in	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
.	B-X
However	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
telomeric	B-X
silencing	B-X
is	B-X
not	B-X
influenced	B-X
by	B-X
proteolysis	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
Sem1p	B-X
and	B-X
Ubp6p	B-X
maintain	B-X
telomeric	B-X
heterochromatin	B-X
structure	B-X
(	B-X
and	B-X
hence	B-X
silencing	B-X
)	B-X
through	B-X
modulation	B-X
of	B-X
histone	B-X
covalent	B-X
modifications	B-X
and	B-X
association	B-X
of	B-X
silencing	B-X
factors	B-X
independently	B-X
of	B-X
the	B-X
proteolytic	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
,	B-X
thus	B-X
offering	B-X
a	B-X
new	B-X
regulatory	B-X
mechanism	B-X
of	B-X
telomeric	B-X
silencing	B-X
.	B-X

Ubiquitination	O
of	O
mammalian	O
AP	O
endonuclease	O
(	O
APE1	B-Protein
)	O
regulated	O
by	O
the	O
p53	B-Protein
-	O
MDM2	B-Protein
signaling	O
pathway	O
.	O
<EOS>	B-X
APE1/Ref-1	B-X
is	B-X
an	B-X
essential	B-X
DNA	B-X
repair/gene	B-X
regulatory	B-X
protein	B-X
in	B-X
mammals	B-X
of	B-X
which	B-X
intracellular	B-X
level	B-X
significantly	B-X
affects	B-X
cellular	B-X
sensitivity	B-X
to	B-X
genotoxicants	B-X
.	B-X
The	B-X
apurinic/apyrimidinic	B-X
endonuclease	B-X
1	B-X
(	B-X
APE1	B-X
)	B-X
functions	B-X
are	B-X
altered	B-X
by	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
.	B-X
We	B-X
here	B-X
report	B-X
that	B-X
APE1	B-X
is	B-X
also	B-X
modified	B-X
by	B-X
ubiquitination	B-X
.	B-X
APE1	B-X
ubiquitination	B-X
occurred	B-X
specifically	B-X
at	B-X
Lys	B-X
residues	B-X
near	B-X
the	B-X
N-terminus	B-X
,	B-X
and	B-X
was	B-X
markedly	B-X
enhanced	B-X
by	B-X
mouse	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
,	B-X
the	B-X
major	B-X
intracellular	B-X
p53	B-X
inhibitor	B-X
.	B-X
Moreover	B-X
,	B-X
DNA-damaging	B-X
reagents	B-X
and	B-X
nutlin-3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
MDM2-p53	B-X
interaction	B-X
,	B-X
increased	B-X
APE1	B-X
ubiquitination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
p53	B-X
.	B-X
Downmodulation	B-X
of	B-X
MDM2	B-X
increased	B-X
APE1	B-X
level	B-X
,	B-X
suggesting	B-X
that	B-X
MDM2-mediated	B-X
ubiquitination	B-X
can	B-X
be	B-X
a	B-X
signal	B-X
for	B-X
APE1	B-X
degradation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
unlike	B-X
the	B-X
wild-type	B-X
APE1	B-X
,	B-X
ubiquitin-APE1	B-X
fusion	B-X
proteins	B-X
were	B-X
predominantly	B-X
present	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Therefore	B-X
,	B-X
monoubiquitination	B-X
not	B-X
only	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
degradation	B-X
,	B-X
but	B-X
may	B-X
also	B-X
alter	B-X
the	B-X
APE1	B-X
activities	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
APE1	B-X
through	B-X
ubiquitination	B-X
.	B-X

APE1	B-Protein
/	O
Ref	B-Protein
-	I-Protein
1	I-Protein
is	O
an	O
essential	O
DNA	O
repair	O
/	O
gene	O
regulatory	O
protein	O
in	O
mammals	O
of	O
which	O
intracellular	O
level	O
significantly	O
affects	O
cellular	O
sensitivity	O
to	O
genotoxicants	O
.	O
<EOS>	B-X
APE1/Ref-1	B-X
is	B-X
an	B-X
essential	B-X
DNA	B-X
repair/gene	B-X
regulatory	B-X
protein	B-X
in	B-X
mammals	B-X
of	B-X
which	B-X
intracellular	B-X
level	B-X
significantly	B-X
affects	B-X
cellular	B-X
sensitivity	B-X
to	B-X
genotoxicants	B-X
.	B-X
The	B-X
apurinic/apyrimidinic	B-X
endonuclease	B-X
1	B-X
(	B-X
APE1	B-X
)	B-X
functions	B-X
are	B-X
altered	B-X
by	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
.	B-X
We	B-X
here	B-X
report	B-X
that	B-X
APE1	B-X
is	B-X
also	B-X
modified	B-X
by	B-X
ubiquitination	B-X
.	B-X
APE1	B-X
ubiquitination	B-X
occurred	B-X
specifically	B-X
at	B-X
Lys	B-X
residues	B-X
near	B-X
the	B-X
N-terminus	B-X
,	B-X
and	B-X
was	B-X
markedly	B-X
enhanced	B-X
by	B-X
mouse	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
,	B-X
the	B-X
major	B-X
intracellular	B-X
p53	B-X
inhibitor	B-X
.	B-X
Moreover	B-X
,	B-X
DNA-damaging	B-X
reagents	B-X
and	B-X
nutlin-3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
MDM2-p53	B-X
interaction	B-X
,	B-X
increased	B-X
APE1	B-X
ubiquitination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
p53	B-X
.	B-X
Downmodulation	B-X
of	B-X
MDM2	B-X
increased	B-X
APE1	B-X
level	B-X
,	B-X
suggesting	B-X
that	B-X
MDM2-mediated	B-X
ubiquitination	B-X
can	B-X
be	B-X
a	B-X
signal	B-X
for	B-X
APE1	B-X
degradation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
unlike	B-X
the	B-X
wild-type	B-X
APE1	B-X
,	B-X
ubiquitin-APE1	B-X
fusion	B-X
proteins	B-X
were	B-X
predominantly	B-X
present	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Therefore	B-X
,	B-X
monoubiquitination	B-X
not	B-X
only	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
degradation	B-X
,	B-X
but	B-X
may	B-X
also	B-X
alter	B-X
the	B-X
APE1	B-X
activities	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
APE1	B-X
through	B-X
ubiquitination	B-X
.	B-X

The	O
apurinic	B-Protein
/	I-Protein
apyrimidinic	I-Protein
endonuclease	I-Protein
1	I-Protein
(	O
APE1	B-Protein
)	O
functions	O
are	O
altered	O
by	O
phosphorylation	O
and	O
acetylation	O
.	O
<EOS>	B-X
APE1/Ref-1	B-X
is	B-X
an	B-X
essential	B-X
DNA	B-X
repair/gene	B-X
regulatory	B-X
protein	B-X
in	B-X
mammals	B-X
of	B-X
which	B-X
intracellular	B-X
level	B-X
significantly	B-X
affects	B-X
cellular	B-X
sensitivity	B-X
to	B-X
genotoxicants	B-X
.	B-X
The	B-X
apurinic/apyrimidinic	B-X
endonuclease	B-X
1	B-X
(	B-X
APE1	B-X
)	B-X
functions	B-X
are	B-X
altered	B-X
by	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
.	B-X
We	B-X
here	B-X
report	B-X
that	B-X
APE1	B-X
is	B-X
also	B-X
modified	B-X
by	B-X
ubiquitination	B-X
.	B-X
APE1	B-X
ubiquitination	B-X
occurred	B-X
specifically	B-X
at	B-X
Lys	B-X
residues	B-X
near	B-X
the	B-X
N-terminus	B-X
,	B-X
and	B-X
was	B-X
markedly	B-X
enhanced	B-X
by	B-X
mouse	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
,	B-X
the	B-X
major	B-X
intracellular	B-X
p53	B-X
inhibitor	B-X
.	B-X
Moreover	B-X
,	B-X
DNA-damaging	B-X
reagents	B-X
and	B-X
nutlin-3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
MDM2-p53	B-X
interaction	B-X
,	B-X
increased	B-X
APE1	B-X
ubiquitination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
p53	B-X
.	B-X
Downmodulation	B-X
of	B-X
MDM2	B-X
increased	B-X
APE1	B-X
level	B-X
,	B-X
suggesting	B-X
that	B-X
MDM2-mediated	B-X
ubiquitination	B-X
can	B-X
be	B-X
a	B-X
signal	B-X
for	B-X
APE1	B-X
degradation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
unlike	B-X
the	B-X
wild-type	B-X
APE1	B-X
,	B-X
ubiquitin-APE1	B-X
fusion	B-X
proteins	B-X
were	B-X
predominantly	B-X
present	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Therefore	B-X
,	B-X
monoubiquitination	B-X
not	B-X
only	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
degradation	B-X
,	B-X
but	B-X
may	B-X
also	B-X
alter	B-X
the	B-X
APE1	B-X
activities	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
APE1	B-X
through	B-X
ubiquitination	B-X
.	B-X

We	O
here	O
report	O
that	O
APE1	B-Protein
is	O
also	O
modified	O
by	O
ubiquitination	O
.	O
<EOS>	B-X
APE1/Ref-1	B-X
is	B-X
an	B-X
essential	B-X
DNA	B-X
repair/gene	B-X
regulatory	B-X
protein	B-X
in	B-X
mammals	B-X
of	B-X
which	B-X
intracellular	B-X
level	B-X
significantly	B-X
affects	B-X
cellular	B-X
sensitivity	B-X
to	B-X
genotoxicants	B-X
.	B-X
The	B-X
apurinic/apyrimidinic	B-X
endonuclease	B-X
1	B-X
(	B-X
APE1	B-X
)	B-X
functions	B-X
are	B-X
altered	B-X
by	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
.	B-X
We	B-X
here	B-X
report	B-X
that	B-X
APE1	B-X
is	B-X
also	B-X
modified	B-X
by	B-X
ubiquitination	B-X
.	B-X
APE1	B-X
ubiquitination	B-X
occurred	B-X
specifically	B-X
at	B-X
Lys	B-X
residues	B-X
near	B-X
the	B-X
N-terminus	B-X
,	B-X
and	B-X
was	B-X
markedly	B-X
enhanced	B-X
by	B-X
mouse	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
,	B-X
the	B-X
major	B-X
intracellular	B-X
p53	B-X
inhibitor	B-X
.	B-X
Moreover	B-X
,	B-X
DNA-damaging	B-X
reagents	B-X
and	B-X
nutlin-3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
MDM2-p53	B-X
interaction	B-X
,	B-X
increased	B-X
APE1	B-X
ubiquitination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
p53	B-X
.	B-X
Downmodulation	B-X
of	B-X
MDM2	B-X
increased	B-X
APE1	B-X
level	B-X
,	B-X
suggesting	B-X
that	B-X
MDM2-mediated	B-X
ubiquitination	B-X
can	B-X
be	B-X
a	B-X
signal	B-X
for	B-X
APE1	B-X
degradation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
unlike	B-X
the	B-X
wild-type	B-X
APE1	B-X
,	B-X
ubiquitin-APE1	B-X
fusion	B-X
proteins	B-X
were	B-X
predominantly	B-X
present	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Therefore	B-X
,	B-X
monoubiquitination	B-X
not	B-X
only	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
degradation	B-X
,	B-X
but	B-X
may	B-X
also	B-X
alter	B-X
the	B-X
APE1	B-X
activities	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
APE1	B-X
through	B-X
ubiquitination	B-X
.	B-X

APE1	B-Protein
ubiquitination	O
occurred	O
specifically	O
at	O
Lys	O
residues	O
near	O
the	O
N	O
-	O
terminus	O
,	O
and	O
was	O
markedly	O
enhanced	O
by	O
mouse	B-Protein
double	I-Protein
minute	I-Protein
2	I-Protein
(	O
MDM2	B-Protein
)	O
,	O
the	O
major	O
intracellular	O
p53	B-Protein
inhibitor	O
.	O

Moreover	O
,	O
DNA	O
-	O
damaging	O
reagents	O
and	O
nutlin	O
-	O
3	O
,	O
an	O
inhibitor	O
of	O
MDM2	B-Protein
-	O
p53	B-Protein
interaction	O
,	O
increased	O
APE1	B-Protein
ubiquitination	O
in	O
the	O
presence	O
of	O
p53	B-Protein
.	O
<EOS>	B-X
APE1/Ref-1	B-X
is	B-X
an	B-X
essential	B-X
DNA	B-X
repair/gene	B-X
regulatory	B-X
protein	B-X
in	B-X
mammals	B-X
of	B-X
which	B-X
intracellular	B-X
level	B-X
significantly	B-X
affects	B-X
cellular	B-X
sensitivity	B-X
to	B-X
genotoxicants	B-X
.	B-X
The	B-X
apurinic/apyrimidinic	B-X
endonuclease	B-X
1	B-X
(	B-X
APE1	B-X
)	B-X
functions	B-X
are	B-X
altered	B-X
by	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
.	B-X
We	B-X
here	B-X
report	B-X
that	B-X
APE1	B-X
is	B-X
also	B-X
modified	B-X
by	B-X
ubiquitination	B-X
.	B-X
APE1	B-X
ubiquitination	B-X
occurred	B-X
specifically	B-X
at	B-X
Lys	B-X
residues	B-X
near	B-X
the	B-X
N-terminus	B-X
,	B-X
and	B-X
was	B-X
markedly	B-X
enhanced	B-X
by	B-X
mouse	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
,	B-X
the	B-X
major	B-X
intracellular	B-X
p53	B-X
inhibitor	B-X
.	B-X
Moreover	B-X
,	B-X
DNA-damaging	B-X
reagents	B-X
and	B-X
nutlin-3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
MDM2-p53	B-X
interaction	B-X
,	B-X
increased	B-X
APE1	B-X
ubiquitination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
p53	B-X
.	B-X
Downmodulation	B-X
of	B-X
MDM2	B-X
increased	B-X
APE1	B-X
level	B-X
,	B-X
suggesting	B-X
that	B-X
MDM2-mediated	B-X
ubiquitination	B-X
can	B-X
be	B-X
a	B-X
signal	B-X
for	B-X
APE1	B-X
degradation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
unlike	B-X
the	B-X
wild-type	B-X
APE1	B-X
,	B-X
ubiquitin-APE1	B-X
fusion	B-X
proteins	B-X
were	B-X
predominantly	B-X
present	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Therefore	B-X
,	B-X
monoubiquitination	B-X
not	B-X
only	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
degradation	B-X
,	B-X
but	B-X
may	B-X
also	B-X
alter	B-X
the	B-X
APE1	B-X
activities	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
APE1	B-X
through	B-X
ubiquitination	B-X
.	B-X

Downmodulation	O
of	O
MDM2	B-Protein
increased	O
APE1	B-Protein
level	O
,	O
suggesting	O
that	O
MDM2	B-Protein
-	O
mediated	O
ubiquitination	O
can	O
be	O
a	O
signal	O
for	O
APE1	B-Protein
degradation	O
.	O
<EOS>	B-X
APE1/Ref-1	B-X
is	B-X
an	B-X
essential	B-X
DNA	B-X
repair/gene	B-X
regulatory	B-X
protein	B-X
in	B-X
mammals	B-X
of	B-X
which	B-X
intracellular	B-X
level	B-X
significantly	B-X
affects	B-X
cellular	B-X
sensitivity	B-X
to	B-X
genotoxicants	B-X
.	B-X
The	B-X
apurinic/apyrimidinic	B-X
endonuclease	B-X
1	B-X
(	B-X
APE1	B-X
)	B-X
functions	B-X
are	B-X
altered	B-X
by	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
.	B-X
We	B-X
here	B-X
report	B-X
that	B-X
APE1	B-X
is	B-X
also	B-X
modified	B-X
by	B-X
ubiquitination	B-X
.	B-X
APE1	B-X
ubiquitination	B-X
occurred	B-X
specifically	B-X
at	B-X
Lys	B-X
residues	B-X
near	B-X
the	B-X
N-terminus	B-X
,	B-X
and	B-X
was	B-X
markedly	B-X
enhanced	B-X
by	B-X
mouse	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
,	B-X
the	B-X
major	B-X
intracellular	B-X
p53	B-X
inhibitor	B-X
.	B-X
Moreover	B-X
,	B-X
DNA-damaging	B-X
reagents	B-X
and	B-X
nutlin-3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
MDM2-p53	B-X
interaction	B-X
,	B-X
increased	B-X
APE1	B-X
ubiquitination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
p53	B-X
.	B-X
Downmodulation	B-X
of	B-X
MDM2	B-X
increased	B-X
APE1	B-X
level	B-X
,	B-X
suggesting	B-X
that	B-X
MDM2-mediated	B-X
ubiquitination	B-X
can	B-X
be	B-X
a	B-X
signal	B-X
for	B-X
APE1	B-X
degradation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
unlike	B-X
the	B-X
wild-type	B-X
APE1	B-X
,	B-X
ubiquitin-APE1	B-X
fusion	B-X
proteins	B-X
were	B-X
predominantly	B-X
present	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Therefore	B-X
,	B-X
monoubiquitination	B-X
not	B-X
only	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
degradation	B-X
,	B-X
but	B-X
may	B-X
also	B-X
alter	B-X
the	B-X
APE1	B-X
activities	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
APE1	B-X
through	B-X
ubiquitination	B-X
.	B-X

In	O
addition	O
,	O
unlike	O
the	O
wild	O
-	O
type	O
APE1	B-Protein
,	O
ubiquitin	B-Protein
-	O
APE1	B-Protein
fusion	O
proteins	O
were	O
predominantly	O
present	O
in	O
the	O
cytoplasm	O
.	O
<EOS>	B-X
APE1/Ref-1	B-X
is	B-X
an	B-X
essential	B-X
DNA	B-X
repair/gene	B-X
regulatory	B-X
protein	B-X
in	B-X
mammals	B-X
of	B-X
which	B-X
intracellular	B-X
level	B-X
significantly	B-X
affects	B-X
cellular	B-X
sensitivity	B-X
to	B-X
genotoxicants	B-X
.	B-X
The	B-X
apurinic/apyrimidinic	B-X
endonuclease	B-X
1	B-X
(	B-X
APE1	B-X
)	B-X
functions	B-X
are	B-X
altered	B-X
by	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
.	B-X
We	B-X
here	B-X
report	B-X
that	B-X
APE1	B-X
is	B-X
also	B-X
modified	B-X
by	B-X
ubiquitination	B-X
.	B-X
APE1	B-X
ubiquitination	B-X
occurred	B-X
specifically	B-X
at	B-X
Lys	B-X
residues	B-X
near	B-X
the	B-X
N-terminus	B-X
,	B-X
and	B-X
was	B-X
markedly	B-X
enhanced	B-X
by	B-X
mouse	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
,	B-X
the	B-X
major	B-X
intracellular	B-X
p53	B-X
inhibitor	B-X
.	B-X
Moreover	B-X
,	B-X
DNA-damaging	B-X
reagents	B-X
and	B-X
nutlin-3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
MDM2-p53	B-X
interaction	B-X
,	B-X
increased	B-X
APE1	B-X
ubiquitination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
p53	B-X
.	B-X
Downmodulation	B-X
of	B-X
MDM2	B-X
increased	B-X
APE1	B-X
level	B-X
,	B-X
suggesting	B-X
that	B-X
MDM2-mediated	B-X
ubiquitination	B-X
can	B-X
be	B-X
a	B-X
signal	B-X
for	B-X
APE1	B-X
degradation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
unlike	B-X
the	B-X
wild-type	B-X
APE1	B-X
,	B-X
ubiquitin-APE1	B-X
fusion	B-X
proteins	B-X
were	B-X
predominantly	B-X
present	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Therefore	B-X
,	B-X
monoubiquitination	B-X
not	B-X
only	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
degradation	B-X
,	B-X
but	B-X
may	B-X
also	B-X
alter	B-X
the	B-X
APE1	B-X
activities	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
APE1	B-X
through	B-X
ubiquitination	B-X
.	B-X

Therefore	O
,	O
monoubiquitination	O
not	O
only	O
is	O
a	O
prerequisite	O
for	O
degradation	O
,	O
but	O
may	O
also	O
alter	O
the	O
APE1	B-Protein
activities	O
in	O
cells	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
p53	B-X
protein	B-X
protects	B-X
the	B-X
organism	B-X
against	B-X
the	B-X
propagation	B-X
of	B-X
cells	B-X
that	B-X
carry	B-X
damaged	B-X
DNA	B-X
with	B-X
potentially	B-X
oncogenic	B-X
mutations	B-X
.	B-X
MDM2	B-X
,	B-X
a	B-X
p53-specific	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
is	B-X
the	B-X
principal	B-X
cellular	B-X
antagonist	B-X
of	B-X
p53	B-X
,	B-X
acting	B-X
to	B-X
limit	B-X
the	B-X
p53	B-X
growth-suppressive	B-X
function	B-X
in	B-X
unstressed	B-X
cells	B-X
.	B-X
In	B-X
unstressed	B-X
cells	B-X
,	B-X
MDM2	B-X
constantly	B-X
monoubiquitinates	B-X
p53	B-X
and	B-X
thus	B-X
is	B-X
the	B-X
critical	B-X
step	B-X
in	B-X
mediating	B-X
its	B-X
degradation	B-X
by	B-X
nuclear	B-X
and	B-X
cytoplasmic	B-X
proteasomes	B-X
.	B-X
Although	B-X
serine	B-X
metabolism	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
proliferation	B-X
and	B-X
survival	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
how	B-X
it	B-X
supports	B-X
tumor	B-X
cell	B-X
migration	B-X
remains	B-X
poorly	B-X
understood	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
PHGDH	B-X
was	B-X
monoubiquitinated	B-X
by	B-X
cullin	B-X
4A-based	B-X
E3	B-X
ligase	B-X
complex	B-X
at	B-X
lysine	B-X
146	B-X
in	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
cells	B-X
,	B-X
which	B-X
enhanced	B-X
PHGDH	B-X
activity	B-X
by	B-X
recruiting	B-X
a	B-X
chaperone	B-X
protein	B-X
,	B-X
DnaJ	B-X
homolog	B-X
subfamily	B-X
A	B-X
member	B-X
1	B-X
,	B-X
to	B-X
promote	B-X
its	B-X
tetrameric	B-X
formation	B-X
,	B-X
thereby	B-X
increasing	B-X
the	B-X
levels	B-X
of	B-X
serine	B-X
,	B-X
glycine	B-X
,	B-X
and	B-X
S-adenosylmethionine	B-X
(	B-X
SAM	B-X
)	B-X
.	B-X
Our	B-X
finding	B-X
not	B-X
only	B-X
reveals	B-X
a	B-X
potentially	B-X
new	B-X
role	B-X
and	B-X
mechanism	B-X
of	B-X
SAM-promoted	B-X
tumor	B-X
metastasis	B-X
but	B-X
also	B-X
demonstrates	B-X
a	B-X
regulatory	B-X
mechanism	B-X
of	B-X
PHGDH	B-X
activity	B-X
by	B-X
monoubiquitination	B-X
.	B-X

These	O
results	O
reveal	O
a	O
novel	O
regulation	O
of	O
APE1	B-Protein
through	O
ubiquitination	O
.	O
<EOS>	B-X
APE1/Ref-1	B-X
is	B-X
an	B-X
essential	B-X
DNA	B-X
repair/gene	B-X
regulatory	B-X
protein	B-X
in	B-X
mammals	B-X
of	B-X
which	B-X
intracellular	B-X
level	B-X
significantly	B-X
affects	B-X
cellular	B-X
sensitivity	B-X
to	B-X
genotoxicants	B-X
.	B-X
The	B-X
apurinic/apyrimidinic	B-X
endonuclease	B-X
1	B-X
(	B-X
APE1	B-X
)	B-X
functions	B-X
are	B-X
altered	B-X
by	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
.	B-X
We	B-X
here	B-X
report	B-X
that	B-X
APE1	B-X
is	B-X
also	B-X
modified	B-X
by	B-X
ubiquitination	B-X
.	B-X
APE1	B-X
ubiquitination	B-X
occurred	B-X
specifically	B-X
at	B-X
Lys	B-X
residues	B-X
near	B-X
the	B-X
N-terminus	B-X
,	B-X
and	B-X
was	B-X
markedly	B-X
enhanced	B-X
by	B-X
mouse	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
,	B-X
the	B-X
major	B-X
intracellular	B-X
p53	B-X
inhibitor	B-X
.	B-X
Moreover	B-X
,	B-X
DNA-damaging	B-X
reagents	B-X
and	B-X
nutlin-3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
MDM2-p53	B-X
interaction	B-X
,	B-X
increased	B-X
APE1	B-X
ubiquitination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
p53	B-X
.	B-X
Downmodulation	B-X
of	B-X
MDM2	B-X
increased	B-X
APE1	B-X
level	B-X
,	B-X
suggesting	B-X
that	B-X
MDM2-mediated	B-X
ubiquitination	B-X
can	B-X
be	B-X
a	B-X
signal	B-X
for	B-X
APE1	B-X
degradation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
unlike	B-X
the	B-X
wild-type	B-X
APE1	B-X
,	B-X
ubiquitin-APE1	B-X
fusion	B-X
proteins	B-X
were	B-X
predominantly	B-X
present	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Therefore	B-X
,	B-X
monoubiquitination	B-X
not	B-X
only	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
degradation	B-X
,	B-X
but	B-X
may	B-X
also	B-X
alter	B-X
the	B-X
APE1	B-X
activities	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
APE1	B-X
through	B-X
ubiquitination	B-X
.	B-X

A	O
histone	B-Protein
map	O
of	O
human	O
chromosome	O
20q13	O
.	O
12	O
.	O
<EOS>	B-X
We	B-X
present	B-X
a	B-X
systematic	B-X
search	B-X
for	B-X
regulatory	B-X
elements	B-X
in	B-X
a	B-X
3.5	B-X
Mb	B-X
region	B-X
on	B-X
human	B-X
chromosome	B-X
20q13.12	B-X
,	B-X
a	B-X
region	B-X
associated	B-X
with	B-X
a	B-X
number	B-X
of	B-X
medical	B-X
conditions	B-X
such	B-X
as	B-X
type	B-X
II	B-X
diabetes	B-X
and	B-X
obesity	B-X
.	B-X

BACKGROUND	O
:	O
We	O
present	O
a	O
systematic	O
search	O
for	O
regulatory	O
elements	O
in	O
a	O
3	O
.	O
5	O
Mb	O
region	O
on	O
human	O
chromosome	O
20q13	O
.	O
12	O
,	O
a	O
region	O
associated	O
with	O
a	O
number	O
of	O
medical	O
conditions	O
such	O
as	O
type	O
II	O
diabetes	O
and	O
obesity	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
profiled	O
six	O
histone	B-Protein
modifications	O
alongside	O
RNA	O
polymerase	O
II	O
(	O
PolII	O
)	O
and	O
CTCF	B-Protein
in	O
two	O
cell	O
lines	O
,	O
HeLa	O
S3	O
and	O
NTERA	O
-	O
2	O
clone	O
D1	O
(	O
NT2	O
/	O
D1	O
)	O
,	O
by	O
chromatin	O
immunoprecipitation	O
using	O
an	O
in	O
-	O
house	O
spotted	O
DNA	O
array	O
,	O
constructed	O
with	O
1	O
.	O
8	O
kb	O
overlapping	O
plasmid	O
clones	O
.	O

In	O
both	O
cells	O
,	O
more	O
than	O
90	O
%	O
of	O
transcription	O
start	O
sites	O
(	O
TSSs	O
)	O
of	O
expressed	O
genes	O
showed	O
enrichments	O
with	O
PolII	O
,	O
di	O
-	O
methylated	O
lysine	O
4	O
of	O
histone	B-Protein
H3	I-Protein
(	O
H3K4me2	B-Protein
)	O
,	O
tri	O
-	O
methylated	O
lysine	O
4	O
of	O
histone	B-Protein
H3	I-Protein
(	O
H3K4me3	B-Protein
)	O
or	O
acetylated	O
H3	B-Protein
(	O
H3Ac	B-Protein
)	O
,	O
whereas	O
mono	O
-	O
methylated	O
lysine	O
4	O
of	O
histone	B-Protein
H3	I-Protein
(	O
H3K4me1	B-Protein
)	O
signals	O
did	O
not	O
correlate	O
with	O
expression	O
.	O

No	O
TSSs	O
were	O
enriched	O
with	O
tri	O
-	O
methylated	O
lysine	O
27	O
of	O
histone	B-Protein
H3	I-Protein
(	O
H3K27me3	B-Protein
)	O
in	O
HeLa	O
S3	O
,	O
while	O
eight	O
TSSs	O
(	O
4	O
expressed	O
)	O
showed	O
enrichments	O
in	O
NT2	O
/	O
D1	O
.	O

We	O
have	O
also	O
located	O
several	O
CTCF	B-Protein
binding	O
sites	O
that	O
are	O
potential	O
insulator	O
elements	O
.	O
<EOS>	B-X
Often	B-X
,	B-X
developmental	B-X
genes	B-X
can	B-X
be	B-X
associated	B-X
with	B-X
dozens	B-X
of	B-X
enhancers	B-X
,	B-X
some	B-X
of	B-X
which	B-X
are	B-X
located	B-X
at	B-X
large	B-X
distances	B-X
from	B-X
the	B-X
promoters	B-X
that	B-X
they	B-X
regulate	B-X
.	B-X
This	B-X
review	B-X
briefly	B-X
describes	B-X
the	B-X
properties	B-X
of	B-X
enhancers	B-X
and	B-X
discusses	B-X
the	B-X
mechanisms	B-X
of	B-X
distance	B-X
interactions	B-X
and	B-X
potential	B-X
proteins	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
.	B-X
Many	B-X
investigators	B-X
,	B-X
ourselves	B-X
included	B-X
,	B-X
have	B-X
sought	B-X
to	B-X
understand	B-X
how	B-X
these	B-X
processes	B-X
specifically	B-X
target	B-X
the	B-X
Igh	B-X
locus	B-X
and	B-X
avoid	B-X
other	B-X
loci	B-X
and	B-X
potential	B-X
deleterious	B-X
consequences	B-X
of	B-X
malignant	B-X
transformation	B-X
.	B-X
Our	B-X
laboratory	B-X
has	B-X
concentrated	B-X
on	B-X
a	B-X
complex	B-X
regulatory	B-X
region	B-X
(	B-X
RR	B-X
)	B-X
that	B-X
is	B-X
located	B-X
downstream	B-X
of	B-X
Cα	B-X
,	B-X
the	B-X
most	B-X
3	B-X
'	B-X
of	B-X
the	B-X
Igh	B-X
constant	B-X
region	B-X
genes	B-X
.	B-X
The	B-X
~40	B-X
kb	B-X
3	B-X
'	B-X
RR	B-X
,	B-X
which	B-X
is	B-X
predicted	B-X
to	B-X
serve	B-X
as	B-X
a	B-X
downstream	B-X
major	B-X
regulator	B-X
of	B-X
the	B-X
Igh	B-X
locus	B-X
,	B-X
contains	B-X
two	B-X
distinct	B-X
segments	B-X
:	B-X
an	B-X
~28	B-X
kb	B-X
region	B-X
comprising	B-X
four	B-X
enhancers	B-X
,	B-X
and	B-X
an	B-X
adjacent	B-X
~12	B-X
kb	B-X
region	B-X
containing	B-X
multiple	B-X
CTCF	B-X
and	B-X
Pax5	B-X
binding	B-X
sites	B-X
.	B-X
The	B-X
CTCF/Pax5	B-X
binding	B-X
region	B-X
is	B-X
a	B-X
candidate	B-X
for	B-X
influencing	B-X
VDJ	B-X
joining	B-X
early	B-X
in	B-X
B	B-X
cell	B-X
development	B-X
and	B-X
serving	B-X
as	B-X
a	B-X
potential	B-X
insulator	B-X
of	B-X
the	B-X
Igh	B-X
locus	B-X
.	B-X
Components	B-X
of	B-X
the	B-X
3	B-X
'	B-X
RR	B-X
are	B-X
subject	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
epigenetic	B-X
changes	B-X
during	B-X
B	B-X
cell	B-X
development	B-X
,	B-X
i.e.	B-X
,	B-X
DNAse	B-X
I	B-X
hypersensitivity	B-X
,	B-X
histone	B-X
modifications	B-X
,	B-X
and	B-X
DNA	B-X
methylation	B-X
,	B-X
in	B-X
association	B-X
with	B-X
transcription	B-X
factor	B-X
binding	B-X
.	B-X
I	B-X
propose	B-X
that	B-X
these	B-X
changes	B-X
provide	B-X
a	B-X
foundation	B-X
by	B-X
which	B-X
regulatory	B-X
elements	B-X
in	B-X
modules	B-X
of	B-X
the	B-X
3	B-X
'	B-X
RR	B-X
function	B-X
by	B-X
interacting	B-X
with	B-X
each	B-X
other	B-X
and	B-X
with	B-X
target	B-X
sequences	B-X
of	B-X
the	B-X
Igh	B-X
locus	B-X
.	B-X

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
In	O
summary	O
,	O
we	O
annotated	O
a	O
number	O
of	O
putative	O
regulatory	O
elements	O
in	O
20q13	O
.	O
12	O
and	O
went	O
on	O
to	O
verify	O
experimentally	O
a	O
subset	O
of	O
them	O
using	O
dual	O
luciferase	B-Protein
reporter	O
assays	O
.	O
<EOS>	B-X
We	B-X
present	B-X
a	B-X
systematic	B-X
search	B-X
for	B-X
regulatory	B-X
elements	B-X
in	B-X
a	B-X
3.5	B-X
Mb	B-X
region	B-X
on	B-X
human	B-X
chromosome	B-X
20q13.12	B-X
,	B-X
a	B-X
region	B-X
associated	B-X
with	B-X
a	B-X
number	B-X
of	B-X
medical	B-X
conditions	B-X
such	B-X
as	B-X
type	B-X
II	B-X
diabetes	B-X
and	B-X
obesity	B-X
.	B-X

Correlating	O
this	O
data	O
to	O
sequence	O
variation	O
can	O
aid	O
identification	O
of	O
disease	O
causing	O
variants	O
.	O
<EOS>	B-X
Ebolavirus	B-X
(	B-X
EBOV	B-X
)	B-X
is	B-X
responsible	B-X
for	B-X
one	B-X
of	B-X
the	B-X
most	B-X
fatal	B-X
diseases	B-X
encountered	B-X
by	B-X
mankind	B-X
.	B-X
Antigenic	B-X
variation	B-X
can	B-X
result	B-X
in	B-X
viral	B-X
escape	B-X
from	B-X
immune	B-X
recognition	B-X
.	B-X
Mapping	B-X
targets	B-X
of	B-X
immune	B-X
responses	B-X
among	B-X
the	B-X
sequence	B-X
of	B-X
viral	B-X
proteins	B-X
is	B-X
,	B-X
thus	B-X
,	B-X
an	B-X
important	B-X
first	B-X
step	B-X
towards	B-X
understanding	B-X
the	B-X
immune	B-X
responses	B-X
to	B-X
viral	B-X
variants	B-X
and	B-X
can	B-X
aid	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
vaccine	B-X
targets	B-X
.	B-X
DECIPHER	B-X
(	B-X
https	B-X
:	B-X
//decipher.sanger.ac.uk	B-X
)	B-X
is	B-X
a	B-X
web-based	B-X
platform	B-X
for	B-X
secure	B-X
deposition	B-X
,	B-X
analysis	B-X
,	B-X
and	B-X
sharing	B-X
of	B-X
plausibly	B-X
pathogenic	B-X
genomic	B-X
variants	B-X
from	B-X
well-phenotyped	B-X
patients	B-X
suffering	B-X
from	B-X
genetic	B-X
disorders	B-X
.	B-X
DECIPHER	B-X
aids	B-X
clinical	B-X
interpretation	B-X
of	B-X
these	B-X
rare	B-X
sequence	B-X
and	B-X
copy-number	B-X
variants	B-X
by	B-X
providing	B-X
tools	B-X
for	B-X
variant	B-X
analysis	B-X
and	B-X
identification	B-X
of	B-X
other	B-X
patients	B-X
exhibiting	B-X
similar	B-X
genotype-phenotype	B-X
characteristics	B-X
.	B-X
DECIPHER	B-X
has	B-X
contributed	B-X
to	B-X
matchmaking	B-X
efforts	B-X
by	B-X
enabling	B-X
the	B-X
global	B-X
clinical	B-X
genetics	B-X
community	B-X
to	B-X
identify	B-X
many	B-X
previously	B-X
undiagnosed	B-X
syndromes	B-X
and	B-X
new	B-X
disease	B-X
genes	B-X
,	B-X
and	B-X
has	B-X
facilitated	B-X
the	B-X
publication	B-X
of	B-X
over	B-X
700	B-X
peer-reviewed	B-X
scientific	B-X
publications	B-X
since	B-X
2004	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
writing	B-X
,	B-X
DECIPHER	B-X
contains	B-X
anonymized	B-X
data	B-X
from	B-X
∼250	B-X
registered	B-X
centers	B-X
on	B-X
more	B-X
than	B-X
51,500	B-X
patients	B-X
(	B-X
∼18000	B-X
patients	B-X
with	B-X
consent	B-X
for	B-X
data	B-X
sharing	B-X
and	B-X
∼25000	B-X
anonymized	B-X
records	B-X
shared	B-X
privately	B-X
)	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
describe	B-X
salient	B-X
features	B-X
of	B-X
the	B-X
platform	B-X
,	B-X
with	B-X
special	B-X
emphasis	B-X
on	B-X
the	B-X
tools	B-X
and	B-X
processes	B-X
that	B-X
aid	B-X
interpretation	B-X
,	B-X
sharing	B-X
,	B-X
and	B-X
effective	B-X
matchmaking	B-X
with	B-X
other	B-X
data	B-X
held	B-X
in	B-X
the	B-X
database	B-X
and	B-X
that	B-X
make	B-X
DECIPHER	B-X
an	B-X
invaluable	B-X
clinical	B-X
and	B-X
research	B-X
resource	B-X
.	B-X

Untargeted	O
tail	O
acetylation	O
of	O
histones	B-Protein
in	O
chromatin	O
:	O
lessons	O
from	O
yeast	O
.	O
<EOS>	B-X
Dynamic	B-X
acetylation	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
the	B-X
amino-terminal	B-X
tails	B-X
of	B-X
the	B-X
core	B-X
histones	B-X
is	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
diverse	B-X
DNA-dependent	B-X
processes	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
including	B-X
replication	B-X
,	B-X
transcription	B-X
,	B-X
and	B-X
DNA	B-X
repair	B-X
.	B-X
The	B-X
targeted	B-X
and	B-X
untargeted	B-X
activities	B-X
of	B-X
histone	B-X
lysine	B-X
acetylases	B-X
(	B-X
KATs	B-X
)	B-X
and	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
both	B-X
contribute	B-X
to	B-X
the	B-X
dynamics	B-X
of	B-X
chromatin	B-X
acetylation	B-X
.	B-X
While	B-X
the	B-X
mechanisms	B-X
and	B-X
functional	B-X
consequences	B-X
of	B-X
targeted	B-X
on	B-X
histone	B-X
acetylation	B-X
are	B-X
well	B-X
understood	B-X
,	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
untargeted	B-X
histone	B-X
acetylation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
untargeted	B-X
KAT	B-X
and	B-X
HDAC	B-X
activities	B-X
modulate	B-X
the	B-X
acetylation	B-X
state	B-X
of	B-X
nucleosomal	B-X
histones	B-X
,	B-X
focusing	B-X
on	B-X
results	B-X
obtained	B-X
for	B-X
H3	B-X
and	B-X
H4	B-X
in	B-X
budding	B-X
yeast	B-X
.	B-X
We	B-X
also	B-X
highlight	B-X
unresolved	B-X
problems	B-X
in	B-X
this	B-X
area	B-X
,	B-X
including	B-X
the	B-X
question	B-X
of	B-X
how	B-X
a	B-X
particular	B-X
steady-state	B-X
level	B-X
of	B-X
untargeted	B-X
acetylation	B-X
is	B-X
set	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cis-dependent	B-X
mechanisms	B-X
that	B-X
instruct	B-X
the	B-X
activity	B-X
of	B-X
KATs	B-X
and	B-X
HDACs	B-X
.	B-X

Dynamic	O
acetylation	O
of	O
lysine	O
residues	O
in	O
the	O
amino	O
-	O
terminal	O
tails	O
of	O
the	O
core	O
histones	B-Protein
is	O
functionally	O
important	O
for	O
the	O
regulation	O
of	O
diverse	O
DNA	O
-	O
dependent	O
processes	O
in	O
the	O
nucleus	O
,	O
including	O
replication	O
,	O
transcription	O
,	O
and	O
DNA	O
repair	O
.	O
<EOS>	B-X
Dynamic	B-X
acetylation	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
the	B-X
amino-terminal	B-X
tails	B-X
of	B-X
the	B-X
core	B-X
histones	B-X
is	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
diverse	B-X
DNA-dependent	B-X
processes	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
including	B-X
replication	B-X
,	B-X
transcription	B-X
,	B-X
and	B-X
DNA	B-X
repair	B-X
.	B-X
The	B-X
targeted	B-X
and	B-X
untargeted	B-X
activities	B-X
of	B-X
histone	B-X
lysine	B-X
acetylases	B-X
(	B-X
KATs	B-X
)	B-X
and	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
both	B-X
contribute	B-X
to	B-X
the	B-X
dynamics	B-X
of	B-X
chromatin	B-X
acetylation	B-X
.	B-X
While	B-X
the	B-X
mechanisms	B-X
and	B-X
functional	B-X
consequences	B-X
of	B-X
targeted	B-X
on	B-X
histone	B-X
acetylation	B-X
are	B-X
well	B-X
understood	B-X
,	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
untargeted	B-X
histone	B-X
acetylation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
untargeted	B-X
KAT	B-X
and	B-X
HDAC	B-X
activities	B-X
modulate	B-X
the	B-X
acetylation	B-X
state	B-X
of	B-X
nucleosomal	B-X
histones	B-X
,	B-X
focusing	B-X
on	B-X
results	B-X
obtained	B-X
for	B-X
H3	B-X
and	B-X
H4	B-X
in	B-X
budding	B-X
yeast	B-X
.	B-X
We	B-X
also	B-X
highlight	B-X
unresolved	B-X
problems	B-X
in	B-X
this	B-X
area	B-X
,	B-X
including	B-X
the	B-X
question	B-X
of	B-X
how	B-X
a	B-X
particular	B-X
steady-state	B-X
level	B-X
of	B-X
untargeted	B-X
acetylation	B-X
is	B-X
set	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cis-dependent	B-X
mechanisms	B-X
that	B-X
instruct	B-X
the	B-X
activity	B-X
of	B-X
KATs	B-X
and	B-X
HDACs	B-X
.	B-X

The	O
targeted	O
and	O
untargeted	O
activities	O
of	O
histone	B-Protein
lysine	O
acetylases	O
(	O
KATs	O
)	O
and	O
deacetylases	O
(	O
HDACs	O
)	O
both	O
contribute	O
to	O
the	O
dynamics	O
of	O
chromatin	O
acetylation	O
.	O

While	O
the	O
mechanisms	O
and	O
functional	O
consequences	O
of	O
targeted	O
on	O
histone	B-Protein
acetylation	O
are	O
well	O
understood	O
,	O
relatively	O
little	O
is	O
known	O
about	O
untargeted	O
histone	B-Protein
acetylation	O
.	O
<EOS>	B-X
Dynamic	B-X
acetylation	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
the	B-X
amino-terminal	B-X
tails	B-X
of	B-X
the	B-X
core	B-X
histones	B-X
is	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
diverse	B-X
DNA-dependent	B-X
processes	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
including	B-X
replication	B-X
,	B-X
transcription	B-X
,	B-X
and	B-X
DNA	B-X
repair	B-X
.	B-X
The	B-X
targeted	B-X
and	B-X
untargeted	B-X
activities	B-X
of	B-X
histone	B-X
lysine	B-X
acetylases	B-X
(	B-X
KATs	B-X
)	B-X
and	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
both	B-X
contribute	B-X
to	B-X
the	B-X
dynamics	B-X
of	B-X
chromatin	B-X
acetylation	B-X
.	B-X
While	B-X
the	B-X
mechanisms	B-X
and	B-X
functional	B-X
consequences	B-X
of	B-X
targeted	B-X
on	B-X
histone	B-X
acetylation	B-X
are	B-X
well	B-X
understood	B-X
,	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
untargeted	B-X
histone	B-X
acetylation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
untargeted	B-X
KAT	B-X
and	B-X
HDAC	B-X
activities	B-X
modulate	B-X
the	B-X
acetylation	B-X
state	B-X
of	B-X
nucleosomal	B-X
histones	B-X
,	B-X
focusing	B-X
on	B-X
results	B-X
obtained	B-X
for	B-X
H3	B-X
and	B-X
H4	B-X
in	B-X
budding	B-X
yeast	B-X
.	B-X
We	B-X
also	B-X
highlight	B-X
unresolved	B-X
problems	B-X
in	B-X
this	B-X
area	B-X
,	B-X
including	B-X
the	B-X
question	B-X
of	B-X
how	B-X
a	B-X
particular	B-X
steady-state	B-X
level	B-X
of	B-X
untargeted	B-X
acetylation	B-X
is	B-X
set	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cis-dependent	B-X
mechanisms	B-X
that	B-X
instruct	B-X
the	B-X
activity	B-X
of	B-X
KATs	B-X
and	B-X
HDACs	B-X
.	B-X

Here	O
,	O
we	O
review	O
the	O
current	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
untargeted	O
KAT	O
and	O
HDAC	O
activities	O
modulate	O
the	O
acetylation	O
state	O
of	O
nucleosomal	O
histones	B-Protein
,	O
focusing	O
on	O
results	O
obtained	O
for	O
H3	B-Protein
and	O
H4	B-Protein
in	O
budding	O
yeast	O
.	O
<EOS>	B-X
Dynamic	B-X
acetylation	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
the	B-X
amino-terminal	B-X
tails	B-X
of	B-X
the	B-X
core	B-X
histones	B-X
is	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
diverse	B-X
DNA-dependent	B-X
processes	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
including	B-X
replication	B-X
,	B-X
transcription	B-X
,	B-X
and	B-X
DNA	B-X
repair	B-X
.	B-X
The	B-X
targeted	B-X
and	B-X
untargeted	B-X
activities	B-X
of	B-X
histone	B-X
lysine	B-X
acetylases	B-X
(	B-X
KATs	B-X
)	B-X
and	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
both	B-X
contribute	B-X
to	B-X
the	B-X
dynamics	B-X
of	B-X
chromatin	B-X
acetylation	B-X
.	B-X
While	B-X
the	B-X
mechanisms	B-X
and	B-X
functional	B-X
consequences	B-X
of	B-X
targeted	B-X
on	B-X
histone	B-X
acetylation	B-X
are	B-X
well	B-X
understood	B-X
,	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
untargeted	B-X
histone	B-X
acetylation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
untargeted	B-X
KAT	B-X
and	B-X
HDAC	B-X
activities	B-X
modulate	B-X
the	B-X
acetylation	B-X
state	B-X
of	B-X
nucleosomal	B-X
histones	B-X
,	B-X
focusing	B-X
on	B-X
results	B-X
obtained	B-X
for	B-X
H3	B-X
and	B-X
H4	B-X
in	B-X
budding	B-X
yeast	B-X
.	B-X
We	B-X
also	B-X
highlight	B-X
unresolved	B-X
problems	B-X
in	B-X
this	B-X
area	B-X
,	B-X
including	B-X
the	B-X
question	B-X
of	B-X
how	B-X
a	B-X
particular	B-X
steady-state	B-X
level	B-X
of	B-X
untargeted	B-X
acetylation	B-X
is	B-X
set	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cis-dependent	B-X
mechanisms	B-X
that	B-X
instruct	B-X
the	B-X
activity	B-X
of	B-X
KATs	B-X
and	B-X
HDACs	B-X
.	B-X

We	O
also	O
highlight	O
unresolved	O
problems	O
in	O
this	O
area	O
,	O
including	O
the	O
question	O
of	O
how	O
a	O
particular	O
steady	O
-	O
state	O
level	O
of	O
untargeted	O
acetylation	O
is	O
set	O
in	O
the	O
absence	O
of	O
cis	O
-	O
dependent	O
mechanisms	O
that	O
instruct	O
the	O
activity	O
of	O
KATs	O
and	O
HDACs	O
.	O
<EOS>	B-X
Dynamic	B-X
acetylation	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
the	B-X
amino-terminal	B-X
tails	B-X
of	B-X
the	B-X
core	B-X
histones	B-X
is	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
diverse	B-X
DNA-dependent	B-X
processes	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
including	B-X
replication	B-X
,	B-X
transcription	B-X
,	B-X
and	B-X
DNA	B-X
repair	B-X
.	B-X
The	B-X
targeted	B-X
and	B-X
untargeted	B-X
activities	B-X
of	B-X
histone	B-X
lysine	B-X
acetylases	B-X
(	B-X
KATs	B-X
)	B-X
and	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
both	B-X
contribute	B-X
to	B-X
the	B-X
dynamics	B-X
of	B-X
chromatin	B-X
acetylation	B-X
.	B-X
While	B-X
the	B-X
mechanisms	B-X
and	B-X
functional	B-X
consequences	B-X
of	B-X
targeted	B-X
on	B-X
histone	B-X
acetylation	B-X
are	B-X
well	B-X
understood	B-X
,	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
untargeted	B-X
histone	B-X
acetylation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
untargeted	B-X
KAT	B-X
and	B-X
HDAC	B-X
activities	B-X
modulate	B-X
the	B-X
acetylation	B-X
state	B-X
of	B-X
nucleosomal	B-X
histones	B-X
,	B-X
focusing	B-X
on	B-X
results	B-X
obtained	B-X
for	B-X
H3	B-X
and	B-X
H4	B-X
in	B-X
budding	B-X
yeast	B-X
.	B-X
We	B-X
also	B-X
highlight	B-X
unresolved	B-X
problems	B-X
in	B-X
this	B-X
area	B-X
,	B-X
including	B-X
the	B-X
question	B-X
of	B-X
how	B-X
a	B-X
particular	B-X
steady-state	B-X
level	B-X
of	B-X
untargeted	B-X
acetylation	B-X
is	B-X
set	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cis-dependent	B-X
mechanisms	B-X
that	B-X
instruct	B-X
the	B-X
activity	B-X
of	B-X
KATs	B-X
and	B-X
HDACs	B-X
.	B-X

Hdm2	B-Protein
is	O
a	O
ubiquitin	B-Protein
ligase	O
of	O
Ku70	B-Protein
-	O
Akt	B-Protein
promotes	O
cell	O
survival	O
by	O
inhibiting	O
Hdm2	B-Protein
-	O
dependent	O
Ku70	B-Protein
destabilization	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
An	B-X
interaction	B-X
between	B-X
Ku70	B-X
and	B-X
Hdm2	B-X
was	B-X
shown	B-X
by	B-X
means	B-X
of	B-X
immunoprecipitation	B-X
,	B-X
whereas	B-X
none	B-X
could	B-X
be	B-X
shown	B-X
between	B-X
80	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
and	B-X
Hdm2	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
apoptosis	B-X
through	B-X
an	B-X
Akt-mediated	B-X
survival	B-X
kinase	B-X
signal	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
this	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
inhibited	B-X
cytosolic	B-X
Ku70	B-X
degradation	B-X
induced	B-X
by	B-X
apoptotic	B-X
stress	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
Akt-dependent	B-X
phosphorylation	B-X
of	B-X
Hdm2	B-X
causes	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
followed	B-X
by	B-X
Hdm2-mediated	B-X
inactivation	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

Earlier	O
,	O
we	O
have	O
reported	O
that	O
70	O
kDa	O
subunit	O
of	O
Ku	O
protein	O
heterodimer	O
(	O
Ku70	B-Protein
)	O
binds	O
and	O
inhibits	O
Bax	B-Protein
activity	O
in	O
the	O
cytosol	O
and	O
that	O
ubiquitin	B-Protein
(	O
Ub	B-Protein
)	O
-	O
dependent	O
proteolysis	O
of	O
cytosolic	O
Ku70	B-Protein
facilitates	O
Bax	B-Protein
-	O
mediated	O
apoptosis	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
An	B-X
interaction	B-X
between	B-X
Ku70	B-X
and	B-X
Hdm2	B-X
was	B-X
shown	B-X
by	B-X
means	B-X
of	B-X
immunoprecipitation	B-X
,	B-X
whereas	B-X
none	B-X
could	B-X
be	B-X
shown	B-X
between	B-X
80	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
and	B-X
Hdm2	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
apoptosis	B-X
through	B-X
an	B-X
Akt-mediated	B-X
survival	B-X
kinase	B-X
signal	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
this	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
inhibited	B-X
cytosolic	B-X
Ku70	B-X
degradation	B-X
induced	B-X
by	B-X
apoptotic	B-X
stress	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
Akt-dependent	B-X
phosphorylation	B-X
of	B-X
Hdm2	B-X
causes	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
followed	B-X
by	B-X
Hdm2-mediated	B-X
inactivation	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

We	O
found	O
that	O
Hdm2	B-Protein
(	O
human	O
homolog	O
of	O
murine	O
double	O
minute	O
)	O
has	O
an	O
ability	O
to	O
ubiquitinate	O
Ku70	B-Protein
and	O
that	O
Hdm2	B-Protein
overexpression	O
in	O
cultured	O
cells	O
causes	O
a	O
decrease	O
in	O
Ku70	B-Protein
expression	O
levels	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
An	B-X
interaction	B-X
between	B-X
Ku70	B-X
and	B-X
Hdm2	B-X
was	B-X
shown	B-X
by	B-X
means	B-X
of	B-X
immunoprecipitation	B-X
,	B-X
whereas	B-X
none	B-X
could	B-X
be	B-X
shown	B-X
between	B-X
80	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
and	B-X
Hdm2	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
inhibited	B-X
cytosolic	B-X
Ku70	B-X
degradation	B-X
induced	B-X
by	B-X
apoptotic	B-X
stress	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
Akt-dependent	B-X
phosphorylation	B-X
of	B-X
Hdm2	B-X
causes	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
followed	B-X
by	B-X
Hdm2-mediated	B-X
inactivation	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

An	O
interaction	O
between	O
Ku70	B-Protein
and	O
Hdm2	B-Protein
was	O
shown	O
by	O
means	O
of	O
immunoprecipitation	O
,	O
whereas	O
none	O
could	O
be	O
shown	O
between	O
80	O
kDa	O
subunit	O
of	O
Ku	O
protein	O
heterodimer	O
and	O
Hdm2	B-Protein
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
An	B-X
interaction	B-X
between	B-X
Ku70	B-X
and	B-X
Hdm2	B-X
was	B-X
shown	B-X
by	B-X
means	B-X
of	B-X
immunoprecipitation	B-X
,	B-X
whereas	B-X
none	B-X
could	B-X
be	B-X
shown	B-X
between	B-X
80	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
and	B-X
Hdm2	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
inhibited	B-X
cytosolic	B-X
Ku70	B-X
degradation	B-X
induced	B-X
by	B-X
apoptotic	B-X
stress	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
Akt-dependent	B-X
phosphorylation	B-X
of	B-X
Hdm2	B-X
causes	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
followed	B-X
by	B-X
Hdm2-mediated	B-X
inactivation	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

Vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	I-Protein
(	O
VEGF	B-Protein
)	O
is	O
known	O
to	O
inhibit	O
endothelial	O
cell	O
(	O
EC	O
)	O
apoptosis	O
through	O
an	O
Akt	O
-	O
mediated	O
survival	O
kinase	O
signal	O
;	O
however	O
,	O
the	O
mechanism	O
underlying	O
this	O
inhibition	O
of	O
apoptosis	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
apoptosis	B-X
through	B-X
an	B-X
Akt-mediated	B-X
survival	B-X
kinase	B-X
signal	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
this	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
inhibited	B-X
cytosolic	B-X
Ku70	B-X
degradation	B-X
induced	B-X
by	B-X
apoptotic	B-X
stress	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
Akt-dependent	B-X
phosphorylation	B-X
of	B-X
Hdm2	B-X
causes	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
followed	B-X
by	B-X
Hdm2-mediated	B-X
inactivation	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

We	O
found	O
that	O
VEGF	B-Protein
inhibited	O
cytosolic	O
Ku70	B-Protein
degradation	O
induced	O
by	O
apoptotic	O
stress	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
An	B-X
interaction	B-X
between	B-X
Ku70	B-X
and	B-X
Hdm2	B-X
was	B-X
shown	B-X
by	B-X
means	B-X
of	B-X
immunoprecipitation	B-X
,	B-X
whereas	B-X
none	B-X
could	B-X
be	B-X
shown	B-X
between	B-X
80	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
and	B-X
Hdm2	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
apoptosis	B-X
through	B-X
an	B-X
Akt-mediated	B-X
survival	B-X
kinase	B-X
signal	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
this	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
inhibited	B-X
cytosolic	B-X
Ku70	B-X
degradation	B-X
induced	B-X
by	B-X
apoptotic	B-X
stress	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

It	O
is	O
known	O
that	O
Akt	O
-	O
dependent	O
phosphorylation	O
of	O
Hdm2	B-Protein
causes	O
nuclear	O
translocation	O
of	O
Hdm2	B-Protein
followed	O
by	O
Hdm2	O
-	O
mediated	O
inactivation	O
of	O
p53	B-Protein
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
An	B-X
interaction	B-X
between	B-X
Ku70	B-X
and	B-X
Hdm2	B-X
was	B-X
shown	B-X
by	B-X
means	B-X
of	B-X
immunoprecipitation	B-X
,	B-X
whereas	B-X
none	B-X
could	B-X
be	B-X
shown	B-X
between	B-X
80	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
and	B-X
Hdm2	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
apoptosis	B-X
through	B-X
an	B-X
Akt-mediated	B-X
survival	B-X
kinase	B-X
signal	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
this	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
Akt-dependent	B-X
phosphorylation	B-X
of	B-X
Hdm2	B-X
causes	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
followed	B-X
by	B-X
Hdm2-mediated	B-X
inactivation	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

We	O
found	O
that	O
VEGF	B-Protein
stimulated	O
nuclear	O
translocation	O
of	O
Hdm2	B-Protein
in	O
EC	O
and	O
efficiently	O
inhibited	O
Ku70	B-Protein
degradation	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
An	B-X
interaction	B-X
between	B-X
Ku70	B-X
and	B-X
Hdm2	B-X
was	B-X
shown	B-X
by	B-X
means	B-X
of	B-X
immunoprecipitation	B-X
,	B-X
whereas	B-X
none	B-X
could	B-X
be	B-X
shown	B-X
between	B-X
80	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
and	B-X
Hdm2	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
apoptosis	B-X
through	B-X
an	B-X
Akt-mediated	B-X
survival	B-X
kinase	B-X
signal	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
this	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
inhibited	B-X
cytosolic	B-X
Ku70	B-X
degradation	B-X
induced	B-X
by	B-X
apoptotic	B-X
stress	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
Akt-dependent	B-X
phosphorylation	B-X
of	B-X
Hdm2	B-X
causes	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
followed	B-X
by	B-X
Hdm2-mediated	B-X
inactivation	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

We	O
also	O
found	O
that	O
constitutively	O
active	O
Akt	O
,	O
but	O
not	O
kinase	O
-	O
dead	O
Akt	O
,	O
inhibited	O
Ku70	B-Protein
degradation	O
in	O
the	O
cytosol	O
.	O
<EOS>	B-X
Mitogen-activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPKs	B-X
)	B-X
and	B-X
AMP-activated	B-X
protein	B-X
kinase	B-X
α	B-X
(	B-X
AMPKα	B-X
)	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
process	B-X
of	B-X
cardiac	B-X
hypertrophy	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
piperine	B-X
activates	B-X
AMPKα	B-X
and	B-X
reduces	B-X
the	B-X
phosphorylation	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
.	B-X
Piperine	B-X
inhibited	B-X
the	B-X
transformation	B-X
of	B-X
cardiac	B-X
fibroblasts	B-X
to	B-X
myofibroblasts	B-X
induced	B-X
by	B-X
transforming	B-X
growth	B-X
factor-β	B-X
(	B-X
TGF-β	B-X
)	B-X
or	B-X
angiotensin	B-X
II	B-X
(	B-X
Ang	B-X
II	B-X
)	B-X
in	B-X
vitro	B-X
.	B-X
Piperine	B-X
blocked	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
B	B-X
(	B-X
AKT	B-X
)	B-X
and	B-X
,	B-X
downstream	B-X
,	B-X
glycogen	B-X
synthase	B-X
kinase	B-X
3β	B-X
(	B-X
GSK3β	B-X
)	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
constitutively	B-X
active	B-X
AKT	B-X
or	B-X
the	B-X
knockdown	B-X
of	B-X
GSK3β	B-X
completely	B-X
abolished	B-X
the	B-X
piperine-mediated	B-X
protection	B-X
of	B-X
cardiac	B-X
fibroblasts	B-X
.	B-X
The	B-X
cardioprotective	B-X
effects	B-X
of	B-X
piperine	B-X
were	B-X
blocked	B-X
in	B-X
mice	B-X
with	B-X
constitutively	B-X
active	B-X
AKT	B-X
.	B-X

Furthermore	O
,	O
Ku70	B-Protein
knockdown	O
diminished	O
antiapoptotic	O
activity	O
of	O
Akt	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
An	B-X
interaction	B-X
between	B-X
Ku70	B-X
and	B-X
Hdm2	B-X
was	B-X
shown	B-X
by	B-X
means	B-X
of	B-X
immunoprecipitation	B-X
,	B-X
whereas	B-X
none	B-X
could	B-X
be	B-X
shown	B-X
between	B-X
80	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
and	B-X
Hdm2	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
apoptosis	B-X
through	B-X
an	B-X
Akt-mediated	B-X
survival	B-X
kinase	B-X
signal	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
this	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
inhibited	B-X
cytosolic	B-X
Ku70	B-X
degradation	B-X
induced	B-X
by	B-X
apoptotic	B-X
stress	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
Akt-dependent	B-X
phosphorylation	B-X
of	B-X
Hdm2	B-X
causes	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
followed	B-X
by	B-X
Hdm2-mediated	B-X
inactivation	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

Taken	O
together	O
,	O
we	O
propose	O
that	O
Hdm2	B-Protein
is	O
a	O
Ku70	B-Protein
Ub	B-Protein
ligase	O
and	O
that	O
Akt	O
inhibits	O
Bax	B-Protein
-	O
mediated	O
apoptosis	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
maintaining	O
Ku70	B-Protein
levels	O
through	O
the	O
promotion	O
of	O
Hdm2	B-Protein
nuclear	O
translocation	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
70	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
(	B-X
Ku70	B-X
)	B-X
binds	B-X
and	B-X
inhibits	B-X
Bax	B-X
activity	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
that	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
-dependent	B-X
proteolysis	B-X
of	B-X
cytosolic	B-X
Ku70	B-X
facilitates	B-X
Bax-mediated	B-X
apoptosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Hdm2	B-X
(	B-X
human	B-X
homolog	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
)	B-X
has	B-X
an	B-X
ability	B-X
to	B-X
ubiquitinate	B-X
Ku70	B-X
and	B-X
that	B-X
Hdm2	B-X
overexpression	B-X
in	B-X
cultured	B-X
cells	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
Ku70	B-X
expression	B-X
levels	B-X
.	B-X
An	B-X
interaction	B-X
between	B-X
Ku70	B-X
and	B-X
Hdm2	B-X
was	B-X
shown	B-X
by	B-X
means	B-X
of	B-X
immunoprecipitation	B-X
,	B-X
whereas	B-X
none	B-X
could	B-X
be	B-X
shown	B-X
between	B-X
80	B-X
kDa	B-X
subunit	B-X
of	B-X
Ku	B-X
protein	B-X
heterodimer	B-X
and	B-X
Hdm2	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
apoptosis	B-X
through	B-X
an	B-X
Akt-mediated	B-X
survival	B-X
kinase	B-X
signal	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
this	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
inhibited	B-X
cytosolic	B-X
Ku70	B-X
degradation	B-X
induced	B-X
by	B-X
apoptotic	B-X
stress	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
Akt-dependent	B-X
phosphorylation	B-X
of	B-X
Hdm2	B-X
causes	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
followed	B-X
by	B-X
Hdm2-mediated	B-X
inactivation	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
found	B-X
that	B-X
VEGF	B-X
stimulated	B-X
nuclear	B-X
translocation	B-X
of	B-X
Hdm2	B-X
in	B-X
EC	B-X
and	B-X
efficiently	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
constitutively	B-X
active	B-X
Akt	B-X
,	B-X
but	B-X
not	B-X
kinase-dead	B-X
Akt	B-X
,	B-X
inhibited	B-X
Ku70	B-X
degradation	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Furthermore	B-X
,	B-X
Ku70	B-X
knockdown	B-X
diminished	B-X
antiapoptotic	B-X
activity	B-X
of	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Hdm2	B-X
is	B-X
a	B-X
Ku70	B-X
Ub	B-X
ligase	B-X
and	B-X
that	B-X
Akt	B-X
inhibits	B-X
Bax-mediated	B-X
apoptosis	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
maintaining	B-X
Ku70	B-X
levels	B-X
through	B-X
the	B-X
promotion	B-X
of	B-X
Hdm2	B-X
nuclear	B-X
translocation	B-X
.	B-X

TRIM21	B-Protein
is	O
essential	O
to	O
sustain	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
3	I-Protein
activation	O
during	O
antiviral	O
response	O
.	O
<EOS>	B-X
Virus	B-X
infection	B-X
induces	B-X
host	B-X
antiviral	B-X
responses	B-X
including	B-X
induction	B-X
of	B-X
type	B-X
I	B-X
IFNs	B-X
.	B-X
Transcription	B-X
factor	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF3	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
and	B-X
is	B-X
tightly	B-X
regulated	B-X
in	B-X
this	B-X
process	B-X
.	B-X
Herein	B-X
we	B-X
report	B-X
that	B-X
TRIM21	B-X
(	B-X
tripartite	B-X
motif-containing	B-X
21	B-X
)	B-X
is	B-X
significantly	B-X
induced	B-X
and	B-X
interacts	B-X
with	B-X
IRF3	B-X
upon	B-X
RNA	B-X
virus	B-X
infection	B-X
.	B-X
Ectopic	B-X
expression	B-X
or	B-X
knockdown	B-X
of	B-X
TRIM21	B-X
could	B-X
respectively	B-X
enhance	B-X
or	B-X
impair	B-X
IRF3-mediated	B-X
gene	B-X
expression	B-X
.	B-X
Mechanistically	B-X
,	B-X
TRIM21	B-X
interferes	B-X
with	B-X
the	B-X
interaction	B-X
between	B-X
Pin1	B-X
(	B-X
peptidyl-prolyl	B-X
cis/trans	B-X
isomerase	B-X
,	B-X
NIMA-interacting	B-X
1	B-X
)	B-X
and	B-X
IRF3	B-X
,	B-X
thus	B-X
preventing	B-X
IRF3	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
A	B-X
conserved	B-X
motif	B-X
in	B-X
the	B-X
B	B-X
30.2	B-X
domain	B-X
of	B-X
TRIM21	B-X
is	B-X
critical	B-X
for	B-X
its	B-X
modulation	B-X
of	B-X
IRF3	B-X
function	B-X
,	B-X
while	B-X
the	B-X
RING	B-X
finger	B-X
is	B-X
dispensable	B-X
.	B-X
Host	B-X
antiviral	B-X
responses	B-X
are	B-X
significantly	B-X
boosted	B-X
or	B-X
crippled	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
TRIM21	B-X
.	B-X
Our	B-X
results	B-X
identify	B-X
TRIM21	B-X
as	B-X
an	B-X
essential	B-X
modulator	B-X
of	B-X
IRF3	B-X
stability	B-X
and	B-X
demonstrate	B-X
that	B-X
it	B-X
positively	B-X
regulates	B-X
the	B-X
strength	B-X
and	B-X
duration	B-X
of	B-X
primary	B-X
antiviral	B-X
response	B-X
,	B-X
thus	B-X
further	B-X
strengthening	B-X
the	B-X
notion	B-X
that	B-X
the	B-X
TRIM	B-X
family	B-X
is	B-X
evolutionarily	B-X
integrated	B-X
with	B-X
innate	B-X
immunity	B-X
.	B-X

Virus	O
infection	O
induces	O
host	O
antiviral	O
responses	O
including	O
induction	O
of	O
type	O
I	O
IFNs	O
.	O
<EOS>	B-X
Inflammatory	B-X
factors	B-X
and	B-X
type	B-X
I	B-X
interferons	B-X
(	B-X
IFNs	B-X
)	B-X
are	B-X
key	B-X
components	B-X
of	B-X
host	B-X
antiviral	B-X
innate	B-X
immune	B-X
responses	B-X
,	B-X
which	B-X
can	B-X
be	B-X
released	B-X
from	B-X
the	B-X
pathogen-infected	B-X
macrophages	B-X
.	B-X
African	B-X
swine	B-X
fever	B-X
virus	B-X
(	B-X
ASFV	B-X
)	B-X
has	B-X
developed	B-X
various	B-X
strategies	B-X
to	B-X
evade	B-X
host	B-X
antiviral	B-X
innate	B-X
immune	B-X
responses	B-X
,	B-X
including	B-X
alteration	B-X
of	B-X
inflammatory	B-X
responses	B-X
and	B-X
IFNs	B-X
production	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
inhibition	B-X
of	B-X
inflammatory	B-X
responses	B-X
and	B-X
IFNs	B-X
production	B-X
by	B-X
ASFV-encoded	B-X
proteins	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
understood	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
ASFV	B-X
infection	B-X
only	B-X
induced	B-X
low	B-X
levels	B-X
of	B-X
IL-1β	B-X
and	B-X
type	B-X
I	B-X
IFNs	B-X
in	B-X
porcine	B-X
alveolar	B-X
macrophages	B-X
(	B-X
PAMs	B-X
)	B-X
,	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
strong	B-X
inducers	B-X
such	B-X
as	B-X
LPS	B-X
and	B-X
poly	B-X
(	B-X
dA	B-X
:	B-X
dT	B-X
)	B-X
.	B-X
As	B-X
we	B-X
expected	B-X
,	B-X
ASFV-Δ7R	B-X
infection	B-X
induced	B-X
higher	B-X
levels	B-X
of	B-X
IL-1β	B-X
and	B-X
IFN-β	B-X
compared	B-X
with	B-X
its	B-X
parental	B-X
ASFV	B-X
HLJ/18	B-X
strain	B-X
.	B-X
ASFV	B-X
infection-induced	B-X
IL-1β	B-X
production	B-X
was	B-X
then	B-X
found	B-X
to	B-X
be	B-X
dependent	B-X
on	B-X
TLRs/NF-κB	B-X
signaling	B-X
pathway	B-X
and	B-X
NLRP3	B-X
inflammasome	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
found	B-X
that	B-X
pMGF505-7R	B-X
interacted	B-X
with	B-X
and	B-X
inhibited	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
IRF3	B-X
to	B-X
block	B-X
type	B-X
I	B-X
IFN	B-X
production	B-X
.	B-X
Importantly	B-X
,	B-X
the	B-X
virulence	B-X
of	B-X
ASFV-Δ7R	B-X
is	B-X
reduced	B-X
in	B-X
piglets	B-X
compared	B-X
with	B-X
its	B-X
parental	B-X
ASFV	B-X
HLJ/18	B-X
strain	B-X
,	B-X
which	B-X
may	B-X
due	B-X
to	B-X
induction	B-X
of	B-X
higher	B-X
IL-1β	B-X
and	B-X
type	B-X
I	B-X
IFN	B-X
production	B-X
in	B-X
vivo	B-X
.	B-X
Our	B-X
findings	B-X
provide	B-X
a	B-X
new	B-X
clue	B-X
to	B-X
understand	B-X
the	B-X
functions	B-X
of	B-X
ASFV-encoded	B-X
pMGF505-7R	B-X
and	B-X
its	B-X
role	B-X
in	B-X
viral	B-X
infection-induced	B-X
pathogenesis	B-X
,	B-X
which	B-X
might	B-X
help	B-X
design	B-X
antiviral	B-X
agents	B-X
or	B-X
live	B-X
attenuated	B-X
vaccines	B-X
to	B-X
control	B-X
ASF	B-X
.	B-X

Transcription	O
factor	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
3	I-Protein
(	O
IRF3	B-Protein
)	O
plays	O
an	O
essential	O
role	O
and	O
is	O
tightly	O
regulated	O
in	O
this	O
process	O
.	O
<EOS>	B-X
Virus	B-X
infection	B-X
induces	B-X
host	B-X
antiviral	B-X
responses	B-X
including	B-X
induction	B-X
of	B-X
type	B-X
I	B-X
IFNs	B-X
.	B-X
Transcription	B-X
factor	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF3	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
and	B-X
is	B-X
tightly	B-X
regulated	B-X
in	B-X
this	B-X
process	B-X
.	B-X
Herein	B-X
we	B-X
report	B-X
that	B-X
TRIM21	B-X
(	B-X
tripartite	B-X
motif-containing	B-X
21	B-X
)	B-X
is	B-X
significantly	B-X
induced	B-X
and	B-X
interacts	B-X
with	B-X
IRF3	B-X
upon	B-X
RNA	B-X
virus	B-X
infection	B-X
.	B-X
Ectopic	B-X
expression	B-X
or	B-X
knockdown	B-X
of	B-X
TRIM21	B-X
could	B-X
respectively	B-X
enhance	B-X
or	B-X
impair	B-X
IRF3-mediated	B-X
gene	B-X
expression	B-X
.	B-X
Mechanistically	B-X
,	B-X
TRIM21	B-X
interferes	B-X
with	B-X
the	B-X
interaction	B-X
between	B-X
Pin1	B-X
(	B-X
peptidyl-prolyl	B-X
cis/trans	B-X
isomerase	B-X
,	B-X
NIMA-interacting	B-X
1	B-X
)	B-X
and	B-X
IRF3	B-X
,	B-X
thus	B-X
preventing	B-X
IRF3	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
A	B-X
conserved	B-X
motif	B-X
in	B-X
the	B-X
B	B-X
30.2	B-X
domain	B-X
of	B-X
TRIM21	B-X
is	B-X
critical	B-X
for	B-X
its	B-X
modulation	B-X
of	B-X
IRF3	B-X
function	B-X
,	B-X
while	B-X
the	B-X
RING	B-X
finger	B-X
is	B-X
dispensable	B-X
.	B-X
Our	B-X
results	B-X
identify	B-X
TRIM21	B-X
as	B-X
an	B-X
essential	B-X
modulator	B-X
of	B-X
IRF3	B-X
stability	B-X
and	B-X
demonstrate	B-X
that	B-X
it	B-X
positively	B-X
regulates	B-X
the	B-X
strength	B-X
and	B-X
duration	B-X
of	B-X
primary	B-X
antiviral	B-X
response	B-X
,	B-X
thus	B-X
further	B-X
strengthening	B-X
the	B-X
notion	B-X
that	B-X
the	B-X
TRIM	B-X
family	B-X
is	B-X
evolutionarily	B-X
integrated	B-X
with	B-X
innate	B-X
immunity	B-X
.	B-X

Herein	O
we	O
report	O
that	O
TRIM21	B-Protein
(	O
tripartite	B-Protein
motif	I-Protein
-	I-Protein
containing	I-Protein
21	I-Protein
)	O
is	O
significantly	O
induced	O
and	O
interacts	O
with	O
IRF3	B-Protein
upon	O
RNA	O
virus	O
infection	O
.	O
<EOS>	B-X
Virus	B-X
infection	B-X
induces	B-X
host	B-X
antiviral	B-X
responses	B-X
including	B-X
induction	B-X
of	B-X
type	B-X
I	B-X
IFNs	B-X
.	B-X
Transcription	B-X
factor	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF3	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
and	B-X
is	B-X
tightly	B-X
regulated	B-X
in	B-X
this	B-X
process	B-X
.	B-X
Herein	B-X
we	B-X
report	B-X
that	B-X
TRIM21	B-X
(	B-X
tripartite	B-X
motif-containing	B-X
21	B-X
)	B-X
is	B-X
significantly	B-X
induced	B-X
and	B-X
interacts	B-X
with	B-X
IRF3	B-X
upon	B-X
RNA	B-X
virus	B-X
infection	B-X
.	B-X
Ectopic	B-X
expression	B-X
or	B-X
knockdown	B-X
of	B-X
TRIM21	B-X
could	B-X
respectively	B-X
enhance	B-X
or	B-X
impair	B-X
IRF3-mediated	B-X
gene	B-X
expression	B-X
.	B-X
Mechanistically	B-X
,	B-X
TRIM21	B-X
interferes	B-X
with	B-X
the	B-X
interaction	B-X
between	B-X
Pin1	B-X
(	B-X
peptidyl-prolyl	B-X
cis/trans	B-X
isomerase	B-X
,	B-X
NIMA-interacting	B-X
1	B-X
)	B-X
and	B-X
IRF3	B-X
,	B-X
thus	B-X
preventing	B-X
IRF3	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
A	B-X
conserved	B-X
motif	B-X
in	B-X
the	B-X
B	B-X
30.2	B-X
domain	B-X
of	B-X
TRIM21	B-X
is	B-X
critical	B-X
for	B-X
its	B-X
modulation	B-X
of	B-X
IRF3	B-X
function	B-X
,	B-X
while	B-X
the	B-X
RING	B-X
finger	B-X
is	B-X
dispensable	B-X
.	B-X
Host	B-X
antiviral	B-X
responses	B-X
are	B-X
significantly	B-X
boosted	B-X
or	B-X
crippled	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
TRIM21	B-X
.	B-X
Our	B-X
results	B-X
identify	B-X
TRIM21	B-X
as	B-X
an	B-X
essential	B-X
modulator	B-X
of	B-X
IRF3	B-X
stability	B-X
and	B-X
demonstrate	B-X
that	B-X
it	B-X
positively	B-X
regulates	B-X
the	B-X
strength	B-X
and	B-X
duration	B-X
of	B-X
primary	B-X
antiviral	B-X
response	B-X
,	B-X
thus	B-X
further	B-X
strengthening	B-X
the	B-X
notion	B-X
that	B-X
the	B-X
TRIM	B-X
family	B-X
is	B-X
evolutionarily	B-X
integrated	B-X
with	B-X
innate	B-X
immunity	B-X
.	B-X

Ectopic	O
expression	O
or	O
knockdown	O
of	O
TRIM21	B-Protein
could	O
respectively	O
enhance	O
or	O
impair	O
IRF3	B-Protein
-	O
mediated	O
gene	O
expression	O
.	O
<EOS>	B-X
Suppression	B-X
of	B-X
STING	B-X
Associated	B-X
with	B-X
LKB1	B-X
Loss	B-X
in	B-X
KRAS-Driven	B-X
Lung	B-X
Cancer	B-X
.	B-X
Many	B-X
tumors	B-X
express	B-X
meiotic	B-X
genes	B-X
that	B-X
could	B-X
potentially	B-X
drive	B-X
somatic	B-X
chromosome	B-X
instability	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
potential	B-X
of	B-X
meiotic	B-X
cohesins	B-X
to	B-X
contribute	B-X
to	B-X
genome	B-X
instability	B-X
,	B-X
their	B-X
expression	B-X
was	B-X
investigated	B-X
in	B-X
human	B-X
cell	B-X
lines	B-X
,	B-X
predominately	B-X
in	B-X
DLD-1	B-X
.	B-X
While	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
REC8	B-X
complex	B-X
resulted	B-X
in	B-X
a	B-X
mild	B-X
mitotic	B-X
phenotype	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
RAD21L	B-X
complex	B-X
produced	B-X
an	B-X
arrested	B-X
but	B-X
viable	B-X
cell	B-X
pool	B-X
,	B-X
thus	B-X
providing	B-X
a	B-X
source	B-X
of	B-X
DNA	B-X
damage	B-X
,	B-X
mitotic	B-X
chromosome	B-X
missegregation	B-X
,	B-X
sporadic	B-X
polyteny	B-X
,	B-X
and	B-X
altered	B-X
gene	B-X
expression	B-X
.	B-X
These	B-X
findings	B-X
highlight	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
germline	B-X
epigenomic	B-X
memory	B-X
that	B-X
is	B-X
conserved	B-X
in	B-X
cells	B-X
that	B-X
normally	B-X
do	B-X
not	B-X
express	B-X
meiotic	B-X
genes	B-X
.	B-X

Mechanistically	O
,	O
TRIM21	B-Protein
interferes	O
with	O
the	O
interaction	O
between	O
Pin1	B-Protein
(	O
peptidyl	B-Protein
-	I-Protein
prolyl	I-Protein
cis	I-Protein
/	I-Protein
trans	I-Protein
isomerase	I-Protein
,	I-Protein
NIMA	I-Protein
-	I-Protein
interacting	I-Protein
1	I-Protein
)	O
and	O
IRF3	B-Protein
,	O
thus	O
preventing	O
IRF3	B-Protein
ubiquitination	O
and	O
degradation	O
.	O
<EOS>	B-X
Transcription	B-X
factor	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF3	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
and	B-X
is	B-X
tightly	B-X
regulated	B-X
in	B-X
this	B-X
process	B-X
.	B-X
Herein	B-X
we	B-X
report	B-X
that	B-X
TRIM21	B-X
(	B-X
tripartite	B-X
motif-containing	B-X
21	B-X
)	B-X
is	B-X
significantly	B-X
induced	B-X
and	B-X
interacts	B-X
with	B-X
IRF3	B-X
upon	B-X
RNA	B-X
virus	B-X
infection	B-X
.	B-X
Ectopic	B-X
expression	B-X
or	B-X
knockdown	B-X
of	B-X
TRIM21	B-X
could	B-X
respectively	B-X
enhance	B-X
or	B-X
impair	B-X
IRF3-mediated	B-X
gene	B-X
expression	B-X
.	B-X
Mechanistically	B-X
,	B-X
TRIM21	B-X
interferes	B-X
with	B-X
the	B-X
interaction	B-X
between	B-X
Pin1	B-X
(	B-X
peptidyl-prolyl	B-X
cis/trans	B-X
isomerase	B-X
,	B-X
NIMA-interacting	B-X
1	B-X
)	B-X
and	B-X
IRF3	B-X
,	B-X
thus	B-X
preventing	B-X
IRF3	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
A	B-X
conserved	B-X
motif	B-X
in	B-X
the	B-X
B	B-X
30.2	B-X
domain	B-X
of	B-X
TRIM21	B-X
is	B-X
critical	B-X
for	B-X
its	B-X
modulation	B-X
of	B-X
IRF3	B-X
function	B-X
,	B-X
while	B-X
the	B-X
RING	B-X
finger	B-X
is	B-X
dispensable	B-X
.	B-X
Host	B-X
antiviral	B-X
responses	B-X
are	B-X
significantly	B-X
boosted	B-X
or	B-X
crippled	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
TRIM21	B-X
.	B-X
Our	B-X
results	B-X
identify	B-X
TRIM21	B-X
as	B-X
an	B-X
essential	B-X
modulator	B-X
of	B-X
IRF3	B-X
stability	B-X
and	B-X
demonstrate	B-X
that	B-X
it	B-X
positively	B-X
regulates	B-X
the	B-X
strength	B-X
and	B-X
duration	B-X
of	B-X
primary	B-X
antiviral	B-X
response	B-X
,	B-X
thus	B-X
further	B-X
strengthening	B-X
the	B-X
notion	B-X
that	B-X
the	B-X
TRIM	B-X
family	B-X
is	B-X
evolutionarily	B-X
integrated	B-X
with	B-X
innate	B-X
immunity	B-X
.	B-X

A	O
conserved	O
motif	O
in	O
the	O
B	O
30	O
.	O
2	O
domain	O
of	O
TRIM21	B-Protein
is	O
critical	O
for	O
its	O
modulation	O
of	O
IRF3	B-Protein
function	O
,	O
while	O
the	O
RING	O
finger	O
is	O
dispensable	O
.	O

Host	O
antiviral	O
responses	O
are	O
significantly	O
boosted	O
or	O
crippled	O
in	O
the	O
presence	O
or	O
absence	O
of	O
TRIM21	B-Protein
.	O
<EOS>	B-X
A	B-X
key	B-X
player	B-X
in	B-X
driving	B-X
cellular	B-X
immunity	B-X
,	B-X
IFN-γ	B-X
is	B-X
capable	B-X
of	B-X
orchestrating	B-X
numerous	B-X
protective	B-X
functions	B-X
to	B-X
heighten	B-X
immune	B-X
responses	B-X
in	B-X
infections	B-X
and	B-X
cancers	B-X
.	B-X
leads	B-X
to	B-X
initiation	B-X
of	B-X
a	B-X
cascade	B-X
of	B-X
pro-inflammatory	B-X
responses	B-X
.	B-X
In	B-X
the	B-X
current	B-X
review	B-X
,	B-X
we	B-X
emphasized	B-X
the	B-X
GSDMD	B-X
protein	B-X
expression	B-X
,	B-X
stabilization	B-X
,	B-X
modification	B-X
,	B-X
activation	B-X
,	B-X
pore	B-X
formation	B-X
,	B-X
and	B-X
repair	B-X
during	B-X
pyroptosis	B-X
,	B-X
especially	B-X
the	B-X
regulation	B-X
and	B-X
modification	B-X
of	B-X
GSDMD	B-X
signaling	B-X
,	B-X
such	B-X
as	B-X
GSDMD	B-X
complex	B-X
in	B-X
polyubiquitination	B-X
and	B-X
non-pyroptosis	B-X
release	B-X
of	B-X
IL-1β	B-X
,	B-X
ADP-riboxanation	B-X
,	B-X
NINJ1	B-X
in	B-X
pore	B-X
forming	B-X
,	B-X
GSDMD	B-X
binding	B-X
protein	B-X
TRIM21	B-X
,	B-X
GSDMD	B-X
succination	B-X
,	B-X
and	B-X
Regulator-Rag-mTOR-ROS	B-X
regulation	B-X
of	B-X
GSDMD	B-X
.	B-X
TRIM21	B-X
(	B-X
Ro52/SSA1	B-X
)	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
with	B-X
key	B-X
roles	B-X
in	B-X
immune	B-X
host	B-X
defence	B-X
,	B-X
signal	B-X
transduction	B-X
,	B-X
and	B-X
possibly	B-X
cell	B-X
cycle	B-X
regulation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarise	B-X
the	B-X
structure	B-X
and	B-X
function	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
its	B-X
roles	B-X
in	B-X
innate	B-X
immunity	B-X
,	B-X
adaptive	B-X
immunity	B-X
and	B-X
cellular	B-X
homeostasis	B-X
,	B-X
the	B-X
pathogenesis	B-X
of	B-X
autoimmunity	B-X
against	B-X
TRIM21	B-X
,	B-X
and	B-X
the	B-X
potential	B-X
impacts	B-X
of	B-X
autoantibodies	B-X
to	B-X
this	B-X
intracellular	B-X
protein	B-X
.	B-X

Our	O
results	O
identify	O
TRIM21	B-Protein
as	O
an	O
essential	O
modulator	O
of	O
IRF3	B-Protein
stability	O
and	O
demonstrate	O
that	O
it	O
positively	O
regulates	O
the	O
strength	O
and	O
duration	O
of	O
primary	O
antiviral	O
response	O
,	O
thus	O
further	O
strengthening	O
the	O
notion	O
that	O
the	O
TRIM	O
family	O
is	O
evolutionarily	O
integrated	O
with	O
innate	O
immunity	O
.	O
<EOS>	B-X
Virus	B-X
infection	B-X
induces	B-X
host	B-X
antiviral	B-X
responses	B-X
including	B-X
induction	B-X
of	B-X
type	B-X
I	B-X
IFNs	B-X
.	B-X
Transcription	B-X
factor	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF3	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
and	B-X
is	B-X
tightly	B-X
regulated	B-X
in	B-X
this	B-X
process	B-X
.	B-X
Herein	B-X
we	B-X
report	B-X
that	B-X
TRIM21	B-X
(	B-X
tripartite	B-X
motif-containing	B-X
21	B-X
)	B-X
is	B-X
significantly	B-X
induced	B-X
and	B-X
interacts	B-X
with	B-X
IRF3	B-X
upon	B-X
RNA	B-X
virus	B-X
infection	B-X
.	B-X
Ectopic	B-X
expression	B-X
or	B-X
knockdown	B-X
of	B-X
TRIM21	B-X
could	B-X
respectively	B-X
enhance	B-X
or	B-X
impair	B-X
IRF3-mediated	B-X
gene	B-X
expression	B-X
.	B-X
Mechanistically	B-X
,	B-X
TRIM21	B-X
interferes	B-X
with	B-X
the	B-X
interaction	B-X
between	B-X
Pin1	B-X
(	B-X
peptidyl-prolyl	B-X
cis/trans	B-X
isomerase	B-X
,	B-X
NIMA-interacting	B-X
1	B-X
)	B-X
and	B-X
IRF3	B-X
,	B-X
thus	B-X
preventing	B-X
IRF3	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
A	B-X
conserved	B-X
motif	B-X
in	B-X
the	B-X
B	B-X
30.2	B-X
domain	B-X
of	B-X
TRIM21	B-X
is	B-X
critical	B-X
for	B-X
its	B-X
modulation	B-X
of	B-X
IRF3	B-X
function	B-X
,	B-X
while	B-X
the	B-X
RING	B-X
finger	B-X
is	B-X
dispensable	B-X
.	B-X
Host	B-X
antiviral	B-X
responses	B-X
are	B-X
significantly	B-X
boosted	B-X
or	B-X
crippled	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
TRIM21	B-X
.	B-X
Our	B-X
results	B-X
identify	B-X
TRIM21	B-X
as	B-X
an	B-X
essential	B-X
modulator	B-X
of	B-X
IRF3	B-X
stability	B-X
and	B-X
demonstrate	B-X
that	B-X
it	B-X
positively	B-X
regulates	B-X
the	B-X
strength	B-X
and	B-X
duration	B-X
of	B-X
primary	B-X
antiviral	B-X
response	B-X
,	B-X
thus	B-X
further	B-X
strengthening	B-X
the	B-X
notion	B-X
that	B-X
the	B-X
TRIM	B-X
family	B-X
is	B-X
evolutionarily	B-X
integrated	B-X
with	B-X
innate	B-X
immunity	B-X
.	B-X

Phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser468	O
controls	O
its	O
COMMD1	B-Protein
-	O
dependent	O
ubiquitination	O
and	O
target	O
gene	O
-	O
specific	O
proteasomal	O
elimination	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
transcription	B-X
factor	B-X
system	B-X
is	B-X
a	B-X
crucial	B-X
component	B-X
that	B-X
controls	B-X
several	B-X
important	B-X
biological	B-X
functions	B-X
,	B-X
thus	B-X
raising	B-X
the	B-X
need	B-X
for	B-X
mechanisms	B-X
that	B-X
ensure	B-X
the	B-X
correct	B-X
termination	B-X
of	B-X
its	B-X
activity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
a	B-X
new	B-X
phosphorylation/ubiquitination	B-X
switch	B-X
in	B-X
the	B-X
NF-kappaB	B-X
network	B-X
that	B-X
controls	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
transactivating	B-X
p65	B-X
subunit	B-X
.	B-X
Tumour	B-X
necrosis	B-X
factor-induced	B-X
phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
allows	B-X
binding	B-X
of	B-X
COMMD1	B-X
and	B-X
cullin	B-X
2	B-X
,	B-X
components	B-X
of	B-X
a	B-X
multimeric	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
mediating	B-X
p65	B-X
ubiquitination	B-X
.	B-X
Mutation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
largely	B-X
prevents	B-X
p65	B-X
ubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Inducible	B-X
p65	B-X
elimination	B-X
is	B-X
restricted	B-X
to	B-X
a	B-X
subset	B-X
of	B-X
NF-kappaB	B-X
target	B-X
genes	B-X
such	B-X
as	B-X
Icam1	B-X
.	B-X
Accordingly	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
reveal	B-X
the	B-X
selective	B-X
recruitment	B-X
of	B-X
Ser468-phosphorylated	B-X
p65	B-X
and	B-X
COMMD1	B-X
to	B-X
the	B-X
Icam1	B-X
promoter	B-X
.	B-X
Phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
leads	B-X
to	B-X
ubiquitin/proteasome-dependent	B-X
removal	B-X
of	B-X
chromatin-bound	B-X
p65	B-X
,	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
selective	B-X
termination	B-X
of	B-X
NF-kappaB-dependent	B-X
gene	B-X
expression	B-X
.	B-X

The	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
transcription	O
factor	O
system	O
is	O
a	O
crucial	O
component	O
that	O
controls	O
several	O
important	O
biological	O
functions	O
,	O
thus	O
raising	O
the	O
need	O
for	O
mechanisms	O
that	O
ensure	O
the	O
correct	O
termination	O
of	O
its	O
activity	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
transcription	B-X
factor	B-X
system	B-X
is	B-X
a	B-X
crucial	B-X
component	B-X
that	B-X
controls	B-X
several	B-X
important	B-X
biological	B-X
functions	B-X
,	B-X
thus	B-X
raising	B-X
the	B-X
need	B-X
for	B-X
mechanisms	B-X
that	B-X
ensure	B-X
the	B-X
correct	B-X
termination	B-X
of	B-X
its	B-X
activity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
a	B-X
new	B-X
phosphorylation/ubiquitination	B-X
switch	B-X
in	B-X
the	B-X
NF-kappaB	B-X
network	B-X
that	B-X
controls	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
transactivating	B-X
p65	B-X
subunit	B-X
.	B-X
Tumour	B-X
necrosis	B-X
factor-induced	B-X
phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
allows	B-X
binding	B-X
of	B-X
COMMD1	B-X
and	B-X
cullin	B-X
2	B-X
,	B-X
components	B-X
of	B-X
a	B-X
multimeric	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
mediating	B-X
p65	B-X
ubiquitination	B-X
.	B-X
Inducible	B-X
p65	B-X
elimination	B-X
is	B-X
restricted	B-X
to	B-X
a	B-X
subset	B-X
of	B-X
NF-kappaB	B-X
target	B-X
genes	B-X
such	B-X
as	B-X
Icam1	B-X
.	B-X
Phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
leads	B-X
to	B-X
ubiquitin/proteasome-dependent	B-X
removal	B-X
of	B-X
chromatin-bound	B-X
p65	B-X
,	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
selective	B-X
termination	B-X
of	B-X
NF-kappaB-dependent	B-X
gene	B-X
expression	B-X
.	B-X

Here	O
,	O
we	O
identify	O
a	O
new	O
phosphorylation	O
/	O
ubiquitination	O
switch	O
in	O
the	O
NF	O
-	O
kappaB	O
network	O
that	O
controls	O
the	O
stability	O
of	O
the	O
transactivating	O
p65	B-Protein
subunit	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
transcription	B-X
factor	B-X
system	B-X
is	B-X
a	B-X
crucial	B-X
component	B-X
that	B-X
controls	B-X
several	B-X
important	B-X
biological	B-X
functions	B-X
,	B-X
thus	B-X
raising	B-X
the	B-X
need	B-X
for	B-X
mechanisms	B-X
that	B-X
ensure	B-X
the	B-X
correct	B-X
termination	B-X
of	B-X
its	B-X
activity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
a	B-X
new	B-X
phosphorylation/ubiquitination	B-X
switch	B-X
in	B-X
the	B-X
NF-kappaB	B-X
network	B-X
that	B-X
controls	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
transactivating	B-X
p65	B-X
subunit	B-X
.	B-X
Tumour	B-X
necrosis	B-X
factor-induced	B-X
phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
allows	B-X
binding	B-X
of	B-X
COMMD1	B-X
and	B-X
cullin	B-X
2	B-X
,	B-X
components	B-X
of	B-X
a	B-X
multimeric	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
mediating	B-X
p65	B-X
ubiquitination	B-X
.	B-X
Mutation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
largely	B-X
prevents	B-X
p65	B-X
ubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Inducible	B-X
p65	B-X
elimination	B-X
is	B-X
restricted	B-X
to	B-X
a	B-X
subset	B-X
of	B-X
NF-kappaB	B-X
target	B-X
genes	B-X
such	B-X
as	B-X
Icam1	B-X
.	B-X
Accordingly	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
reveal	B-X
the	B-X
selective	B-X
recruitment	B-X
of	B-X
Ser468-phosphorylated	B-X
p65	B-X
and	B-X
COMMD1	B-X
to	B-X
the	B-X
Icam1	B-X
promoter	B-X
.	B-X
Phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
leads	B-X
to	B-X
ubiquitin/proteasome-dependent	B-X
removal	B-X
of	B-X
chromatin-bound	B-X
p65	B-X
,	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
selective	B-X
termination	B-X
of	B-X
NF-kappaB-dependent	B-X
gene	B-X
expression	B-X
.	B-X

Tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
-	O
induced	O
phosphorylation	O
of	O
p65	B-Protein
at	O
Ser468	O
allows	O
binding	O
of	O
COMMD1	B-Protein
and	O
cullin	B-Protein
2	I-Protein
,	O
components	O
of	O
a	O
multimeric	O
ubiquitin	B-Protein
ligase	O
complex	O
mediating	O
p65	B-Protein
ubiquitination	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
transcription	B-X
factor	B-X
system	B-X
is	B-X
a	B-X
crucial	B-X
component	B-X
that	B-X
controls	B-X
several	B-X
important	B-X
biological	B-X
functions	B-X
,	B-X
thus	B-X
raising	B-X
the	B-X
need	B-X
for	B-X
mechanisms	B-X
that	B-X
ensure	B-X
the	B-X
correct	B-X
termination	B-X
of	B-X
its	B-X
activity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
a	B-X
new	B-X
phosphorylation/ubiquitination	B-X
switch	B-X
in	B-X
the	B-X
NF-kappaB	B-X
network	B-X
that	B-X
controls	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
transactivating	B-X
p65	B-X
subunit	B-X
.	B-X
Tumour	B-X
necrosis	B-X
factor-induced	B-X
phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
allows	B-X
binding	B-X
of	B-X
COMMD1	B-X
and	B-X
cullin	B-X
2	B-X
,	B-X
components	B-X
of	B-X
a	B-X
multimeric	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
mediating	B-X
p65	B-X
ubiquitination	B-X
.	B-X
Mutation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
largely	B-X
prevents	B-X
p65	B-X
ubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Inducible	B-X
p65	B-X
elimination	B-X
is	B-X
restricted	B-X
to	B-X
a	B-X
subset	B-X
of	B-X
NF-kappaB	B-X
target	B-X
genes	B-X
such	B-X
as	B-X
Icam1	B-X
.	B-X
Accordingly	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
reveal	B-X
the	B-X
selective	B-X
recruitment	B-X
of	B-X
Ser468-phosphorylated	B-X
p65	B-X
and	B-X
COMMD1	B-X
to	B-X
the	B-X
Icam1	B-X
promoter	B-X
.	B-X
Phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
leads	B-X
to	B-X
ubiquitin/proteasome-dependent	B-X
removal	B-X
of	B-X
chromatin-bound	B-X
p65	B-X
,	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
selective	B-X
termination	B-X
of	B-X
NF-kappaB-dependent	B-X
gene	B-X
expression	B-X
.	B-X

Mutation	O
of	O
p65	B-Protein
at	O
Ser468	O
largely	O
prevents	O
p65	B-Protein
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
a	B-X
new	B-X
phosphorylation/ubiquitination	B-X
switch	B-X
in	B-X
the	B-X
NF-kappaB	B-X
network	B-X
that	B-X
controls	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
transactivating	B-X
p65	B-X
subunit	B-X
.	B-X
Tumour	B-X
necrosis	B-X
factor-induced	B-X
phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
allows	B-X
binding	B-X
of	B-X
COMMD1	B-X
and	B-X
cullin	B-X
2	B-X
,	B-X
components	B-X
of	B-X
a	B-X
multimeric	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
mediating	B-X
p65	B-X
ubiquitination	B-X
.	B-X
Mutation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
largely	B-X
prevents	B-X
p65	B-X
ubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Inducible	B-X
p65	B-X
elimination	B-X
is	B-X
restricted	B-X
to	B-X
a	B-X
subset	B-X
of	B-X
NF-kappaB	B-X
target	B-X
genes	B-X
such	B-X
as	B-X
Icam1	B-X
.	B-X
Accordingly	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
reveal	B-X
the	B-X
selective	B-X
recruitment	B-X
of	B-X
Ser468-phosphorylated	B-X
p65	B-X
and	B-X
COMMD1	B-X
to	B-X
the	B-X
Icam1	B-X
promoter	B-X
.	B-X
Phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
leads	B-X
to	B-X
ubiquitin/proteasome-dependent	B-X
removal	B-X
of	B-X
chromatin-bound	B-X
p65	B-X
,	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
selective	B-X
termination	B-X
of	B-X
NF-kappaB-dependent	B-X
gene	B-X
expression	B-X
.	B-X

Inducible	O
p65	B-Protein
elimination	O
is	O
restricted	O
to	O
a	O
subset	O
of	O
NF	O
-	O
kappaB	O
target	O
genes	O
such	O
as	O
Icam1	B-Protein
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
transcription	B-X
factor	B-X
system	B-X
is	B-X
a	B-X
crucial	B-X
component	B-X
that	B-X
controls	B-X
several	B-X
important	B-X
biological	B-X
functions	B-X
,	B-X
thus	B-X
raising	B-X
the	B-X
need	B-X
for	B-X
mechanisms	B-X
that	B-X
ensure	B-X
the	B-X
correct	B-X
termination	B-X
of	B-X
its	B-X
activity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
a	B-X
new	B-X
phosphorylation/ubiquitination	B-X
switch	B-X
in	B-X
the	B-X
NF-kappaB	B-X
network	B-X
that	B-X
controls	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
transactivating	B-X
p65	B-X
subunit	B-X
.	B-X
Tumour	B-X
necrosis	B-X
factor-induced	B-X
phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
allows	B-X
binding	B-X
of	B-X
COMMD1	B-X
and	B-X
cullin	B-X
2	B-X
,	B-X
components	B-X
of	B-X
a	B-X
multimeric	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
mediating	B-X
p65	B-X
ubiquitination	B-X
.	B-X
Mutation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
largely	B-X
prevents	B-X
p65	B-X
ubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Inducible	B-X
p65	B-X
elimination	B-X
is	B-X
restricted	B-X
to	B-X
a	B-X
subset	B-X
of	B-X
NF-kappaB	B-X
target	B-X
genes	B-X
such	B-X
as	B-X
Icam1	B-X
.	B-X
Accordingly	B-X
,	B-X
chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
reveal	B-X
the	B-X
selective	B-X
recruitment	B-X
of	B-X
Ser468-phosphorylated	B-X
p65	B-X
and	B-X
COMMD1	B-X
to	B-X
the	B-X
Icam1	B-X
promoter	B-X
.	B-X
Phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
Ser468	B-X
leads	B-X
to	B-X
ubiquitin/proteasome-dependent	B-X
removal	B-X
of	B-X
chromatin-bound	B-X
p65	B-X
,	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
selective	B-X
termination	B-X
of	B-X
NF-kappaB-dependent	B-X
gene	B-X
expression	B-X
.	B-X

Accordingly	O
,	O
chromatin	O
immunoprecipitation	O
experiments	O
reveal	O
the	O
selective	O
recruitment	O
of	O
Ser468	O
-	O
phosphorylated	O
p65	B-Protein
and	O
COMMD1	B-Protein
to	O
the	O
Icam1	B-Protein
promoter	O
.	O

Phosphorylation	O
of	O
p65	B-Protein
at	O
Ser468	O
leads	O
to	O
ubiquitin	B-Protein
/	O
proteasome	O
-	O
dependent	O
removal	O
of	O
chromatin	O
-	O
bound	O
p65	B-Protein
,	O
thus	O
contributing	O
to	O
the	O
selective	O
termination	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
.	O

PDCD5	B-Protein
interacts	O
with	O
Tip60	B-Protein
and	O
functions	O
as	O
a	O
cooperator	O
in	O
acetyltransferase	O
activity	O
and	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

Tip60	B-Protein
is	O
a	O
histone	B-Protein
acetyltransferase	O
(	O
HAT	O
)	O
involved	O
in	O
the	O
acetyltransferase	O
activity	O
and	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
.	O
<EOS>	B-X
The	B-X
ataxia	B-X
telangiectasia	B-X
mutant	B-X
(	B-X
ATM	B-X
)	B-X
protein	B-X
kinase	B-X
regulates	B-X
the	B-X
cell	B-X
's	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
through	B-X
the	B-X
phosphorylation	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
cell-cycle	B-X
checkpoints	B-X
and	B-X
DNA	B-X
repair	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signal-transduction	B-X
pathway	B-X
linking	B-X
DNA	B-X
strand	B-X
breaks	B-X
to	B-X
activation	B-X
of	B-X
ATM	B-X
's	B-X
kinase	B-X
activity	B-X
is	B-X
not	B-X
clearly	B-X
defined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
DNA	B-X
damage	B-X
induces	B-X
the	B-X
rapid	B-X
acetylation	B-X
of	B-X
ATM	B-X
.	B-X
This	B-X
acetylation	B-X
depends	B-X
on	B-X
the	B-X
Tip60	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
.	B-X
Suppression	B-X
of	B-X
Tip60	B-X
blocks	B-X
the	B-X
activation	B-X
of	B-X
ATM	B-X
's	B-X
kinase	B-X
activity	B-X
and	B-X
prevents	B-X
the	B-X
ATM-dependent	B-X
phosphorylation	B-X
of	B-X
p53	B-X
and	B-X
chk2	B-X
.	B-X
Further	B-X
,	B-X
inactivation	B-X
of	B-X
Tip60	B-X
sensitizes	B-X
cells	B-X
to	B-X
ionizing	B-X
radiation	B-X
.	B-X
ATM	B-X
forms	B-X
a	B-X
stable	B-X
complex	B-X
with	B-X
Tip60	B-X
through	B-X
the	B-X
conserved	B-X
FATC	B-X
domain	B-X
of	B-X
ATM	B-X
.	B-X
The	B-X
interaction	B-X
between	B-X
ATM	B-X
and	B-X
Tip60	B-X
is	B-X
not	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
HAT	B-X
activity	B-X
of	B-X
the	B-X
ATM-Tip60	B-X
complex	B-X
is	B-X
specifically	B-X
activated	B-X
by	B-X
DNA	B-X
damage	B-X
.	B-X
Furthermore	B-X
,	B-X
this	B-X
activation	B-X
of	B-X
Tip60	B-X
by	B-X
DNA	B-X
damage	B-X
and	B-X
the	B-X
recruitment	B-X
of	B-X
the	B-X
ATM-Tip60	B-X
complex	B-X
to	B-X
sites	B-X
of	B-X
DNA	B-X
damage	B-X
is	B-X
independent	B-X
of	B-X
ATM	B-X
's	B-X
kinase	B-X
activity	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
Tip60	B-X
HAT	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
ATM	B-X
's	B-X
kinase	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
programmed	B-Protein
cell	I-Protein
death	I-Protein
5	I-Protein
(	O
PDCD5	B-Protein
)	O
,	O
a	O
human	O
apoptosis	O
-	O
related	O
protein	O
,	O
binds	O
to	O
Tip60	B-Protein
and	O
enhances	O
the	O
stability	O
of	O
Tip60	B-Protein
protein	O
in	O
unstressed	O
conditions	O
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

The	O
binding	O
amount	O
of	O
PDCD5	B-Protein
and	O
Tip60	B-Protein
is	O
significantly	O
increased	O
after	O
UV	O
irradiation	O
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

Further	O
,	O
PDCD5	B-Protein
enhances	O
HAT	O
activity	O
of	O
Tip60	B-Protein
and	O
Tip60	B-Protein
-	O
dependent	O
histone	B-Protein
acetylation	O
in	O
both	O
basal	O
and	O
UV	O
-	O
induced	O
levels	O
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

We	O
also	O
find	O
that	O
PDCD5	B-Protein
increases	O
Tip60	B-Protein
-	O
dependent	O
K120	O
acetylation	O
of	O
p53	B-Protein
and	O
participates	O
in	O
the	O
p53	B-Protein
-	O
dependent	O
expression	O
of	O
apoptosis	O
-	O
related	O
genes	O
,	O
such	O
as	O
Bax	B-Protein
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

Moreover	O
,	O
we	O
demonstrate	O
the	O
biological	O
significance	O
of	O
the	O
PDCD5	B-Protein
-	O
Tip60	B-Protein
interaction	O
;	O
that	O
is	O
,	O
they	O
function	O
in	O
cooperation	O
to	O
accelerate	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
and	O
knockdown	O
of	O
PDCD5	B-Protein
or	O
Tip60	B-Protein
impairs	O
their	O
apoptosis	O
-	O
accelerating	O
activity	O
,	O
mutually	O
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

Consistent	O
with	O
this	O
,	O
PDCD5	B-Protein
levels	O
increase	O
significantly	O
on	O
DNA	O
damage	O
in	O
U2OS	O
cells	O
,	O
as	O
does	O
Tip60	B-Protein
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

Together	O
,	O
our	O
findings	O
indicate	O
that	O
PDCD5	B-Protein
may	O
play	O
a	O
dual	O
role	O
in	O
the	O
Tip60	B-Protein
pathway	O
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

Specifically	O
,	O
under	O
normal	O
growth	O
conditions	O
,	O
PDCD5	B-Protein
contributes	O
to	O
maintaining	O
a	O
basal	O
pool	O
of	O
Tip60	B-Protein
and	O
its	O
HAT	O
activity	O
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

After	O
DNA	O
damage	O
,	O
PDCD5	B-Protein
functions	O
as	O
a	O
Tip60	B-Protein
coactivator	O
to	O
promote	O
apoptosis	O
.	O
<EOS>	B-X
Tip60	B-X
is	B-X
a	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
acetyltransferase	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
programmed	B-X
cell	B-X
death	B-X
5	B-X
(	B-X
PDCD5	B-X
)	B-X
,	B-X
a	B-X
human	B-X
apoptosis-related	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
Tip60	B-X
and	B-X
enhances	B-X
the	B-X
stability	B-X
of	B-X
Tip60	B-X
protein	B-X
in	B-X
unstressed	B-X
conditions	B-X
.	B-X
The	B-X
binding	B-X
amount	B-X
of	B-X
PDCD5	B-X
and	B-X
Tip60	B-X
is	B-X
significantly	B-X
increased	B-X
after	B-X
UV	B-X
irradiation	B-X
.	B-X
Further	B-X
,	B-X
PDCD5	B-X
enhances	B-X
HAT	B-X
activity	B-X
of	B-X
Tip60	B-X
and	B-X
Tip60-dependent	B-X
histone	B-X
acetylation	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
UV-induced	B-X
levels	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
PDCD5	B-X
increases	B-X
Tip60-dependent	B-X
K120	B-X
acetylation	B-X
of	B-X
p53	B-X
and	B-X
participates	B-X
in	B-X
the	B-X
p53-dependent	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
Bax	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
PDCD5-Tip60	B-X
interaction	B-X
;	B-X
that	B-X
is	B-X
,	B-X
they	B-X
function	B-X
in	B-X
cooperation	B-X
to	B-X
accelerate	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
and	B-X
knockdown	B-X
of	B-X
PDCD5	B-X
or	B-X
Tip60	B-X
impairs	B-X
their	B-X
apoptosis-accelerating	B-X
activity	B-X
,	B-X
mutually	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
PDCD5	B-X
levels	B-X
increase	B-X
significantly	B-X
on	B-X
DNA	B-X
damage	B-X
in	B-X
U2OS	B-X
cells	B-X
,	B-X
as	B-X
does	B-X
Tip60	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
PDCD5	B-X
may	B-X
play	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
the	B-X
Tip60	B-X
pathway	B-X
.	B-X
Specifically	B-X
,	B-X
under	B-X
normal	B-X
growth	B-X
conditions	B-X
,	B-X
PDCD5	B-X
contributes	B-X
to	B-X
maintaining	B-X
a	B-X
basal	B-X
pool	B-X
of	B-X
Tip60	B-X
and	B-X
its	B-X
HAT	B-X
activity	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
PDCD5	B-X
functions	B-X
as	B-X
a	B-X
Tip60	B-X
coactivator	B-X
to	B-X
promote	B-X
apoptosis	B-X
.	B-X

MDM2	B-Protein
acts	O
downstream	O
of	O
p53	B-Protein
as	O
an	O
E3	O
ligase	O
to	O
promote	O
FOXO	O
ubiquitination	O
and	O
degradation	O
.	O
<EOS>	B-X
Members	B-X
of	B-X
the	B-X
FOXO	B-X
(	B-X
forkhead	B-X
O	B-X
)	B-X
class	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
tumor	B-X
suppressors	B-X
that	B-X
also	B-X
control	B-X
aging	B-X
and	B-X
organismal	B-X
life	B-X
span	B-X
.	B-X
Mammalian	B-X
FOXO	B-X
degradation	B-X
is	B-X
proteasome-mediated	B-X
,	B-X
although	B-X
the	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
for	B-X
FOXO	B-X
factors	B-X
remains	B-X
to	B-X
be	B-X
defined	B-X
.	B-X
We	B-X
show	B-X
that	B-X
MDM2	B-X
binds	B-X
to	B-X
FOXO1	B-X
and	B-X
FOXO3A	B-X
and	B-X
promotes	B-X
their	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
,	B-X
a	B-X
process	B-X
apparently	B-X
dependent	B-X
on	B-X
FOXO	B-X
phosphorylation	B-X
at	B-X
AKT	B-X
sites	B-X
and	B-X
the	B-X
E3	B-X
ligase	B-X
activity	B-X
of	B-X
MDM2	B-X
.	B-X
Binding	B-X
of	B-X
MDM2	B-X
to	B-X
FOXO	B-X
occurs	B-X
through	B-X
the	B-X
region	B-X
of	B-X
MDM2	B-X
that	B-X
directs	B-X
its	B-X
cellular	B-X
trafficking	B-X
and	B-X
the	B-X
forkhead	B-X
box	B-X
of	B-X
FOXO1	B-X
.	B-X
MDM2	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
of	B-X
FOXO1	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
,	B-X
and	B-X
its	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
causes	B-X
accumulation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
protein	B-X
in	B-X
cells	B-X
and	B-X
enhances	B-X
the	B-X
expression	B-X
of	B-X
FOXO	B-X
target	B-X
genes	B-X
.	B-X
In	B-X
cells	B-X
stably	B-X
expressing	B-X
a	B-X
temperature-sensitive	B-X
p53	B-X
mutant	B-X
,	B-X
activation	B-X
of	B-X
p53	B-X
by	B-X
shifting	B-X
to	B-X
permissive	B-X
temperatures	B-X
leads	B-X
to	B-X
MDM2	B-X
induction	B-X
and	B-X
degradation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
MDM2	B-X
acts	B-X
as	B-X
an	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
,	B-X
downstream	B-X
of	B-X
p53	B-X
,	B-X
to	B-X
regulate	B-X
the	B-X
degradation	B-X
of	B-X
mammalian	B-X
FOXO	B-X
factors	B-X
.	B-X

Members	O
of	O
the	O
FOXO	O
(	O
forkhead	O
O	O
)	O
class	O
of	O
transcription	O
factors	O
are	O
tumor	O
suppressors	O
that	O
also	O
control	O
aging	O
and	O
organismal	O
life	O
span	O
.	O
<EOS>	B-X
Members	B-X
of	B-X
the	B-X
FOXO	B-X
(	B-X
forkhead	B-X
O	B-X
)	B-X
class	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
tumor	B-X
suppressors	B-X
that	B-X
also	B-X
control	B-X
aging	B-X
and	B-X
organismal	B-X
life	B-X
span	B-X
.	B-X
Mammalian	B-X
FOXO	B-X
degradation	B-X
is	B-X
proteasome-mediated	B-X
,	B-X
although	B-X
the	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
for	B-X
FOXO	B-X
factors	B-X
remains	B-X
to	B-X
be	B-X
defined	B-X
.	B-X
We	B-X
show	B-X
that	B-X
MDM2	B-X
binds	B-X
to	B-X
FOXO1	B-X
and	B-X
FOXO3A	B-X
and	B-X
promotes	B-X
their	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
,	B-X
a	B-X
process	B-X
apparently	B-X
dependent	B-X
on	B-X
FOXO	B-X
phosphorylation	B-X
at	B-X
AKT	B-X
sites	B-X
and	B-X
the	B-X
E3	B-X
ligase	B-X
activity	B-X
of	B-X
MDM2	B-X
.	B-X
Binding	B-X
of	B-X
MDM2	B-X
to	B-X
FOXO	B-X
occurs	B-X
through	B-X
the	B-X
region	B-X
of	B-X
MDM2	B-X
that	B-X
directs	B-X
its	B-X
cellular	B-X
trafficking	B-X
and	B-X
the	B-X
forkhead	B-X
box	B-X
of	B-X
FOXO1	B-X
.	B-X
MDM2	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
of	B-X
FOXO1	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
,	B-X
and	B-X
its	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
causes	B-X
accumulation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
protein	B-X
in	B-X
cells	B-X
and	B-X
enhances	B-X
the	B-X
expression	B-X
of	B-X
FOXO	B-X
target	B-X
genes	B-X
.	B-X
In	B-X
cells	B-X
stably	B-X
expressing	B-X
a	B-X
temperature-sensitive	B-X
p53	B-X
mutant	B-X
,	B-X
activation	B-X
of	B-X
p53	B-X
by	B-X
shifting	B-X
to	B-X
permissive	B-X
temperatures	B-X
leads	B-X
to	B-X
MDM2	B-X
induction	B-X
and	B-X
degradation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
MDM2	B-X
acts	B-X
as	B-X
an	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
,	B-X
downstream	B-X
of	B-X
p53	B-X
,	B-X
to	B-X
regulate	B-X
the	B-X
degradation	B-X
of	B-X
mammalian	B-X
FOXO	B-X
factors	B-X
.	B-X

Mammalian	O
FOXO	O
degradation	O
is	O
proteasome	O
-	O
mediated	O
,	O
although	O
the	O
ubiquitin	B-Protein
E3	O
ligase	O
for	O
FOXO	O
factors	O
remains	O
to	O
be	O
defined	O
.	O
<EOS>	B-X
Members	B-X
of	B-X
the	B-X
FOXO	B-X
(	B-X
forkhead	B-X
O	B-X
)	B-X
class	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
tumor	B-X
suppressors	B-X
that	B-X
also	B-X
control	B-X
aging	B-X
and	B-X
organismal	B-X
life	B-X
span	B-X
.	B-X
Mammalian	B-X
FOXO	B-X
degradation	B-X
is	B-X
proteasome-mediated	B-X
,	B-X
although	B-X
the	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
for	B-X
FOXO	B-X
factors	B-X
remains	B-X
to	B-X
be	B-X
defined	B-X
.	B-X
We	B-X
show	B-X
that	B-X
MDM2	B-X
binds	B-X
to	B-X
FOXO1	B-X
and	B-X
FOXO3A	B-X
and	B-X
promotes	B-X
their	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
,	B-X
a	B-X
process	B-X
apparently	B-X
dependent	B-X
on	B-X
FOXO	B-X
phosphorylation	B-X
at	B-X
AKT	B-X
sites	B-X
and	B-X
the	B-X
E3	B-X
ligase	B-X
activity	B-X
of	B-X
MDM2	B-X
.	B-X
Binding	B-X
of	B-X
MDM2	B-X
to	B-X
FOXO	B-X
occurs	B-X
through	B-X
the	B-X
region	B-X
of	B-X
MDM2	B-X
that	B-X
directs	B-X
its	B-X
cellular	B-X
trafficking	B-X
and	B-X
the	B-X
forkhead	B-X
box	B-X
of	B-X
FOXO1	B-X
.	B-X
MDM2	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
of	B-X
FOXO1	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
,	B-X
and	B-X
its	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
causes	B-X
accumulation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
protein	B-X
in	B-X
cells	B-X
and	B-X
enhances	B-X
the	B-X
expression	B-X
of	B-X
FOXO	B-X
target	B-X
genes	B-X
.	B-X
In	B-X
cells	B-X
stably	B-X
expressing	B-X
a	B-X
temperature-sensitive	B-X
p53	B-X
mutant	B-X
,	B-X
activation	B-X
of	B-X
p53	B-X
by	B-X
shifting	B-X
to	B-X
permissive	B-X
temperatures	B-X
leads	B-X
to	B-X
MDM2	B-X
induction	B-X
and	B-X
degradation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
MDM2	B-X
acts	B-X
as	B-X
an	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
,	B-X
downstream	B-X
of	B-X
p53	B-X
,	B-X
to	B-X
regulate	B-X
the	B-X
degradation	B-X
of	B-X
mammalian	B-X
FOXO	B-X
factors	B-X
.	B-X

We	O
show	O
that	O
MDM2	B-Protein
binds	O
to	O
FOXO1	B-Protein
and	O
FOXO3A	B-Protein
and	O
promotes	O
their	O
ubiquitination	O
and	O
degradation	O
,	O
a	O
process	O
apparently	O
dependent	O
on	O
FOXO	O
phosphorylation	O
at	O
AKT	B-Protein
sites	O
and	O
the	O
E3	O
ligase	O
activity	O
of	O
MDM2	B-Protein
.	O
<EOS>	B-X
Members	B-X
of	B-X
the	B-X
FOXO	B-X
(	B-X
forkhead	B-X
O	B-X
)	B-X
class	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
tumor	B-X
suppressors	B-X
that	B-X
also	B-X
control	B-X
aging	B-X
and	B-X
organismal	B-X
life	B-X
span	B-X
.	B-X
Mammalian	B-X
FOXO	B-X
degradation	B-X
is	B-X
proteasome-mediated	B-X
,	B-X
although	B-X
the	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
for	B-X
FOXO	B-X
factors	B-X
remains	B-X
to	B-X
be	B-X
defined	B-X
.	B-X
We	B-X
show	B-X
that	B-X
MDM2	B-X
binds	B-X
to	B-X
FOXO1	B-X
and	B-X
FOXO3A	B-X
and	B-X
promotes	B-X
their	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
,	B-X
a	B-X
process	B-X
apparently	B-X
dependent	B-X
on	B-X
FOXO	B-X
phosphorylation	B-X
at	B-X
AKT	B-X
sites	B-X
and	B-X
the	B-X
E3	B-X
ligase	B-X
activity	B-X
of	B-X
MDM2	B-X
.	B-X
Binding	B-X
of	B-X
MDM2	B-X
to	B-X
FOXO	B-X
occurs	B-X
through	B-X
the	B-X
region	B-X
of	B-X
MDM2	B-X
that	B-X
directs	B-X
its	B-X
cellular	B-X
trafficking	B-X
and	B-X
the	B-X
forkhead	B-X
box	B-X
of	B-X
FOXO1	B-X
.	B-X
MDM2	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
of	B-X
FOXO1	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
,	B-X
and	B-X
its	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
causes	B-X
accumulation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
protein	B-X
in	B-X
cells	B-X
and	B-X
enhances	B-X
the	B-X
expression	B-X
of	B-X
FOXO	B-X
target	B-X
genes	B-X
.	B-X
In	B-X
cells	B-X
stably	B-X
expressing	B-X
a	B-X
temperature-sensitive	B-X
p53	B-X
mutant	B-X
,	B-X
activation	B-X
of	B-X
p53	B-X
by	B-X
shifting	B-X
to	B-X
permissive	B-X
temperatures	B-X
leads	B-X
to	B-X
MDM2	B-X
induction	B-X
and	B-X
degradation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
MDM2	B-X
acts	B-X
as	B-X
an	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
,	B-X
downstream	B-X
of	B-X
p53	B-X
,	B-X
to	B-X
regulate	B-X
the	B-X
degradation	B-X
of	B-X
mammalian	B-X
FOXO	B-X
factors	B-X
.	B-X

Binding	O
of	O
MDM2	B-Protein
to	O
FOXO	O
occurs	O
through	O
the	O
region	O
of	O
MDM2	B-Protein
that	O
directs	O
its	O
cellular	O
trafficking	O
and	O
the	O
forkhead	O
box	O
of	O
FOXO1	B-Protein
.	O
<EOS>	B-X
Members	B-X
of	B-X
the	B-X
FOXO	B-X
(	B-X
forkhead	B-X
O	B-X
)	B-X
class	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
tumor	B-X
suppressors	B-X
that	B-X
also	B-X
control	B-X
aging	B-X
and	B-X
organismal	B-X
life	B-X
span	B-X
.	B-X
Mammalian	B-X
FOXO	B-X
degradation	B-X
is	B-X
proteasome-mediated	B-X
,	B-X
although	B-X
the	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
for	B-X
FOXO	B-X
factors	B-X
remains	B-X
to	B-X
be	B-X
defined	B-X
.	B-X
We	B-X
show	B-X
that	B-X
MDM2	B-X
binds	B-X
to	B-X
FOXO1	B-X
and	B-X
FOXO3A	B-X
and	B-X
promotes	B-X
their	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
,	B-X
a	B-X
process	B-X
apparently	B-X
dependent	B-X
on	B-X
FOXO	B-X
phosphorylation	B-X
at	B-X
AKT	B-X
sites	B-X
and	B-X
the	B-X
E3	B-X
ligase	B-X
activity	B-X
of	B-X
MDM2	B-X
.	B-X
Binding	B-X
of	B-X
MDM2	B-X
to	B-X
FOXO	B-X
occurs	B-X
through	B-X
the	B-X
region	B-X
of	B-X
MDM2	B-X
that	B-X
directs	B-X
its	B-X
cellular	B-X
trafficking	B-X
and	B-X
the	B-X
forkhead	B-X
box	B-X
of	B-X
FOXO1	B-X
.	B-X
MDM2	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
of	B-X
FOXO1	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
,	B-X
and	B-X
its	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
causes	B-X
accumulation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
protein	B-X
in	B-X
cells	B-X
and	B-X
enhances	B-X
the	B-X
expression	B-X
of	B-X
FOXO	B-X
target	B-X
genes	B-X
.	B-X
In	B-X
cells	B-X
stably	B-X
expressing	B-X
a	B-X
temperature-sensitive	B-X
p53	B-X
mutant	B-X
,	B-X
activation	B-X
of	B-X
p53	B-X
by	B-X
shifting	B-X
to	B-X
permissive	B-X
temperatures	B-X
leads	B-X
to	B-X
MDM2	B-X
induction	B-X
and	B-X
degradation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
MDM2	B-X
acts	B-X
as	B-X
an	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
,	B-X
downstream	B-X
of	B-X
p53	B-X
,	B-X
to	B-X
regulate	B-X
the	B-X
degradation	B-X
of	B-X
mammalian	B-X
FOXO	B-X
factors	B-X
.	B-X

MDM2	B-Protein
promotes	O
the	O
ubiquitination	O
of	O
FOXO1	B-Protein
in	O
a	O
cell	O
-	O
free	O
system	O
,	O
and	O
its	O
knockdown	O
by	O
small	O
interfering	O
RNA	O
causes	O
accumulation	O
of	O
endogenous	O
FOXO3A	B-Protein
protein	O
in	O
cells	O
and	O
enhances	O
the	O
expression	O
of	O
FOXO	O
target	O
genes	O
.	O

In	O
cells	O
stably	O
expressing	O
a	O
temperature	O
-	O
sensitive	O
p53	B-Protein
mutant	O
,	O
activation	O
of	O
p53	B-Protein
by	O
shifting	O
to	O
permissive	O
temperatures	O
leads	O
to	O
MDM2	B-Protein
induction	O
and	O
degradation	O
of	O
endogenous	O
FOXO3A	B-Protein
.	O
<EOS>	B-X
Mammalian	B-X
FOXO	B-X
degradation	B-X
is	B-X
proteasome-mediated	B-X
,	B-X
although	B-X
the	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
for	B-X
FOXO	B-X
factors	B-X
remains	B-X
to	B-X
be	B-X
defined	B-X
.	B-X
We	B-X
show	B-X
that	B-X
MDM2	B-X
binds	B-X
to	B-X
FOXO1	B-X
and	B-X
FOXO3A	B-X
and	B-X
promotes	B-X
their	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
,	B-X
a	B-X
process	B-X
apparently	B-X
dependent	B-X
on	B-X
FOXO	B-X
phosphorylation	B-X
at	B-X
AKT	B-X
sites	B-X
and	B-X
the	B-X
E3	B-X
ligase	B-X
activity	B-X
of	B-X
MDM2	B-X
.	B-X
Binding	B-X
of	B-X
MDM2	B-X
to	B-X
FOXO	B-X
occurs	B-X
through	B-X
the	B-X
region	B-X
of	B-X
MDM2	B-X
that	B-X
directs	B-X
its	B-X
cellular	B-X
trafficking	B-X
and	B-X
the	B-X
forkhead	B-X
box	B-X
of	B-X
FOXO1	B-X
.	B-X
MDM2	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
of	B-X
FOXO1	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
,	B-X
and	B-X
its	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
causes	B-X
accumulation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
protein	B-X
in	B-X
cells	B-X
and	B-X
enhances	B-X
the	B-X
expression	B-X
of	B-X
FOXO	B-X
target	B-X
genes	B-X
.	B-X
In	B-X
cells	B-X
stably	B-X
expressing	B-X
a	B-X
temperature-sensitive	B-X
p53	B-X
mutant	B-X
,	B-X
activation	B-X
of	B-X
p53	B-X
by	B-X
shifting	B-X
to	B-X
permissive	B-X
temperatures	B-X
leads	B-X
to	B-X
MDM2	B-X
induction	B-X
and	B-X
degradation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
MDM2	B-X
acts	B-X
as	B-X
an	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
,	B-X
downstream	B-X
of	B-X
p53	B-X
,	B-X
to	B-X
regulate	B-X
the	B-X
degradation	B-X
of	B-X
mammalian	B-X
FOXO	B-X
factors	B-X
.	B-X

These	O
data	O
suggest	O
that	O
MDM2	B-Protein
acts	O
as	O
an	O
ubiquitin	B-Protein
E3	O
ligase	O
,	O
downstream	O
of	O
p53	B-Protein
,	O
to	O
regulate	O
the	O
degradation	O
of	O
mammalian	O
FOXO	O
factors	O
.	O
<EOS>	B-X
Members	B-X
of	B-X
the	B-X
FOXO	B-X
(	B-X
forkhead	B-X
O	B-X
)	B-X
class	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
tumor	B-X
suppressors	B-X
that	B-X
also	B-X
control	B-X
aging	B-X
and	B-X
organismal	B-X
life	B-X
span	B-X
.	B-X
Mammalian	B-X
FOXO	B-X
degradation	B-X
is	B-X
proteasome-mediated	B-X
,	B-X
although	B-X
the	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
for	B-X
FOXO	B-X
factors	B-X
remains	B-X
to	B-X
be	B-X
defined	B-X
.	B-X
We	B-X
show	B-X
that	B-X
MDM2	B-X
binds	B-X
to	B-X
FOXO1	B-X
and	B-X
FOXO3A	B-X
and	B-X
promotes	B-X
their	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
,	B-X
a	B-X
process	B-X
apparently	B-X
dependent	B-X
on	B-X
FOXO	B-X
phosphorylation	B-X
at	B-X
AKT	B-X
sites	B-X
and	B-X
the	B-X
E3	B-X
ligase	B-X
activity	B-X
of	B-X
MDM2	B-X
.	B-X
Binding	B-X
of	B-X
MDM2	B-X
to	B-X
FOXO	B-X
occurs	B-X
through	B-X
the	B-X
region	B-X
of	B-X
MDM2	B-X
that	B-X
directs	B-X
its	B-X
cellular	B-X
trafficking	B-X
and	B-X
the	B-X
forkhead	B-X
box	B-X
of	B-X
FOXO1	B-X
.	B-X
MDM2	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
of	B-X
FOXO1	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
,	B-X
and	B-X
its	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
causes	B-X
accumulation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
protein	B-X
in	B-X
cells	B-X
and	B-X
enhances	B-X
the	B-X
expression	B-X
of	B-X
FOXO	B-X
target	B-X
genes	B-X
.	B-X
In	B-X
cells	B-X
stably	B-X
expressing	B-X
a	B-X
temperature-sensitive	B-X
p53	B-X
mutant	B-X
,	B-X
activation	B-X
of	B-X
p53	B-X
by	B-X
shifting	B-X
to	B-X
permissive	B-X
temperatures	B-X
leads	B-X
to	B-X
MDM2	B-X
induction	B-X
and	B-X
degradation	B-X
of	B-X
endogenous	B-X
FOXO3A	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
MDM2	B-X
acts	B-X
as	B-X
an	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
,	B-X
downstream	B-X
of	B-X
p53	B-X
,	B-X
to	B-X
regulate	B-X
the	B-X
degradation	B-X
of	B-X
mammalian	B-X
FOXO	B-X
factors	B-X
.	B-X

Properties	O
of	O
Nat4	B-Protein
,	O
an	O
N	O
(	O
alpha	O
)	O
-	O
acetyltransferase	O
of	O
Saccharomyces	O
cerevisiae	O
that	O
modifies	O
N	O
termini	O
of	O
histones	B-Protein
H2A	I-Protein
and	O
H4	B-Protein
.	O

Nat4	B-Protein
,	O
also	O
designated	O
NatD	B-Protein
,	O
was	O
previously	O
shown	O
to	O
acetylate	O
the	O
N	O
termini	O
of	O
histones	B-Protein
H2A	I-Protein
and	O
H4	B-Protein
,	O
which	O
have	O
SGGKG	O
and	O
SGRGK	O
N	O
termini	O
(	O
O	O
.	O
K	O
.	O
Song	O
,	O
X	O
.	O
Wang	O
,	O
J	O
.	O
H	O
.	O
Waterborg	O
,	O
and	O
R	O
.	O
Sternglanz	O
,	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
278	O
:	O
38109	O
-	O
38112	O
,	O
2003	O
)	O
.	O

The	O
analysis	O
of	O
chimeric	O
proteins	O
with	O
various	O
N	O
-	O
terminal	O
segments	O
of	O
histone	B-Protein
H4	I-Protein
fused	O
to	O
iso	B-Protein
-	I-Protein
1	I-Protein
-	I-Protein
cytochrome	I-Protein
c	I-Protein
revealed	O
that	O
efficient	O
acetylation	O
by	O
NatD	B-Protein
required	O
at	O
least	O
30	O
to	O
50	O
amino	O
acid	O
residues	O
of	O
the	O
N	O
terminus	O
of	O
histone	B-Protein
H4	I-Protein
.	O

This	O
requirement	O
for	O
an	O
extended	O
N	O
terminus	O
is	O
in	O
marked	O
contrast	O
with	O
the	O
major	O
N	O
-	O
terminal	O
acetyl	O
transferases	O
(	O
NATs	O
)	O
,	O
i	O
.	O
e	O
.	O
,	O
NatA	B-Protein
,	O
NatB	B-Protein
,	O
and	O
NatC	B-Protein
,	O
which	O
require	O
as	O
few	O
as	O
two	O
specific	O
residues	O
and	O
usually	O
no	O
more	O
than	O
four	O
or	O
five	O
.	O
<EOS>	B-X
This	B-X
article	B-X
examines	B-X
some	B-X
aspects	B-X
of	B-X
the	B-X
enduring	B-X
influence	B-X
of	B-X
the	B-X
work	B-X
of	B-X
Dr.	B-X
Elisabeth	B-X
Kübler-Ross	B-X
and	B-X
especially	B-X
of	B-X
her	B-X
``	B-X
five	B-X
stages	B-X
''	B-X
model	B-X
through	B-X
a	B-X
sampling	B-X
of	B-X
recent	B-X
textbooks	B-X
published	B-X
in	B-X
the	B-X
United	B-X
States	B-X
in	B-X
selected	B-X
academic	B-X
disciplines	B-X
and	B-X
professional	B-X
fields	B-X
.	B-X
The	B-X
following	B-X
are	B-X
the	B-X
questions	B-X
to	B-X
be	B-X
asked:1	B-X
.	B-X
Does	B-X
the	B-X
``	B-X
five	B-X
stages	B-X
''	B-X
model	B-X
appear	B-X
without	B-X
significant	B-X
change	B-X
in	B-X
the	B-X
textbooks	B-X
described	B-X
here	B-X
?	B-X
2	B-X
.	B-X
Is	B-X
the	B-X
``	B-X
five	B-X
stages	B-X
''	B-X
model	B-X
applied	B-X
in	B-X
these	B-X
textbooks	B-X
to	B-X
issues	B-X
involving	B-X
loss	B-X
,	B-X
grief	B-X
,	B-X
and	B-X
bereavement	B-X
,	B-X
as	B-X
well	B-X
as	B-X
to	B-X
those	B-X
involving	B-X
terminal	B-X
illness	B-X
and	B-X
dying	B-X
?	B-X
3	B-X
.	B-X
Is	B-X
the	B-X
``	B-X
five	B-X
stages	B-X
''	B-X
model	B-X
criticized	B-X
in	B-X
some	B-X
or	B-X
all	B-X
of	B-X
these	B-X
textbooks	B-X
?	B-X
4	B-X
.	B-X
If	B-X
so	B-X
,	B-X
is	B-X
the	B-X
criticism	B-X
sufficient	B-X
to	B-X
argue	B-X
that	B-X
,	B-X
while	B-X
the	B-X
``	B-X
five	B-X
stages	B-X
''	B-X
model	B-X
might	B-X
be	B-X
presented	B-X
as	B-X
an	B-X
important	B-X
historical	B-X
framework	B-X
,	B-X
it	B-X
should	B-X
no	B-X
longer	B-X
be	B-X
regarded	B-X
as	B-X
a	B-X
sound	B-X
theory	B-X
to	B-X
guide	B-X
contemporary	B-X
education	B-X
and	B-X
practice	B-X
?	B-X

However	O
,	O
similar	O
to	O
the	O
other	O
NATs	O
,	O
NatD	B-Protein
is	O
associated	O
with	O
ribosomes	O
.	O

The	O
nat4	B-Protein
-	O
Delta	O
strain	O
showed	O
several	O
minor	O
phenotypes	O
,	O
including	O
sensitivity	O
to	O
3	O
-	O
aminotriazole	O
,	O
benomyl	O
,	O
and	O
thiabendazole	O
.	O
<EOS>	B-X
278:38109-38112	B-X
,	B-X
2003	B-X
)	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
chimeric	B-X
proteins	B-X
with	B-X
various	B-X
N-terminal	B-X
segments	B-X
of	B-X
histone	B-X
H4	B-X
fused	B-X
to	B-X
iso-1-cytochrome	B-X
c	B-X
revealed	B-X
that	B-X
efficient	B-X
acetylation	B-X
by	B-X
NatD	B-X
required	B-X
at	B-X
least	B-X
30	B-X
to	B-X
50	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
N	B-X
terminus	B-X
of	B-X
histone	B-X
H4	B-X
.	B-X
The	B-X
nat4-Delta	B-X
strain	B-X
showed	B-X
several	B-X
minor	B-X
phenotypes	B-X
,	B-X
including	B-X
sensitivity	B-X
to	B-X
3-aminotriazole	B-X
,	B-X
benomyl	B-X
,	B-X
and	B-X
thiabendazole	B-X
.	B-X
Moreover	B-X
,	B-X
these	B-X
nat4-Delta	B-X
phenotypes	B-X
were	B-X
enhanced	B-X
in	B-X
the	B-X
strain	B-X
containing	B-X
K5R	B-X
K8R	B-X
K12R	B-X
replacements	B-X
in	B-X
the	B-X
N-tail	B-X
of	B-X
histone	B-X
H4	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
lack	B-X
of	B-X
N-terminal	B-X
serine	B-X
acetylation	B-X
is	B-X
synergistic	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
acetylation	B-X
of	B-X
the	B-X
H4	B-X
N-tail	B-X
lysines	B-X
.	B-X

Moreover	O
,	O
these	O
nat4	B-Protein
-	O
Delta	O
phenotypes	O
were	O
enhanced	O
in	O
the	O
strain	O
containing	O
K5R	O
K8R	O
K12R	O
replacements	O
in	O
the	O
N	O
-	O
tail	O
of	O
histone	B-Protein
H4	I-Protein
,	O
suggesting	O
that	O
the	O
lack	O
of	O
N	O
-	O
terminal	O
serine	O
acetylation	O
is	O
synergistic	O
to	O
the	O
lack	O
of	O
acetylation	O
of	O
the	O
H4	B-Protein
N	O
-	O
tail	O
lysines	O
.	O

Thus	O
,	O
N	O
-	O
terminal	O
serine	O
acetylation	O
of	O
histone	B-Protein
H4	I-Protein
may	O
be	O
a	O
part	O
of	O
an	O
essential	O
charge	O
patch	O
first	O
described	O
for	O
the	O
histone	B-Protein
H2A	I-Protein
.	I-Protein
Z	I-Protein
variant	O
in	O
Tetrahymena	O
species	O
.	O
<EOS>	B-X
Nat4	B-X
,	B-X
also	B-X
designated	B-X
NatD	B-X
,	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
acetylate	B-X
the	B-X
N	B-X
termini	B-X
of	B-X
histones	B-X
H2A	B-X
and	B-X
H4	B-X
,	B-X
which	B-X
have	B-X
SGGKG	B-X
and	B-X
SGRGK	B-X
N	B-X
termini	B-X
(	B-X
O.	B-X
K.	B-X
Song	B-X
,	B-X
X.	B-X
Wang	B-X
,	B-X
J.	B-X
H.	B-X
Waterborg	B-X
,	B-X
and	B-X
R.	B-X
Sternglanz	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
chimeric	B-X
proteins	B-X
with	B-X
various	B-X
N-terminal	B-X
segments	B-X
of	B-X
histone	B-X
H4	B-X
fused	B-X
to	B-X
iso-1-cytochrome	B-X
c	B-X
revealed	B-X
that	B-X
efficient	B-X
acetylation	B-X
by	B-X
NatD	B-X
required	B-X
at	B-X
least	B-X
30	B-X
to	B-X
50	B-X
amino	B-X
acid	B-X
residues	B-X
of	B-X
the	B-X
N	B-X
terminus	B-X
of	B-X
histone	B-X
H4	B-X
.	B-X
This	B-X
requirement	B-X
for	B-X
an	B-X
extended	B-X
N	B-X
terminus	B-X
is	B-X
in	B-X
marked	B-X
contrast	B-X
with	B-X
the	B-X
major	B-X
N-terminal	B-X
acetyl	B-X
transferases	B-X
(	B-X
NATs	B-X
)	B-X
,	B-X
i.e.	B-X
,	B-X
NatA	B-X
,	B-X
NatB	B-X
,	B-X
and	B-X
NatC	B-X
,	B-X
which	B-X
require	B-X
as	B-X
few	B-X
as	B-X
two	B-X
specific	B-X
residues	B-X
and	B-X
usually	B-X
no	B-X
more	B-X
than	B-X
four	B-X
or	B-X
five	B-X
.	B-X
However	B-X
,	B-X
similar	B-X
to	B-X
the	B-X
other	B-X
NATs	B-X
,	B-X
NatD	B-X
is	B-X
associated	B-X
with	B-X
ribosomes	B-X
.	B-X
Moreover	B-X
,	B-X
these	B-X
nat4-Delta	B-X
phenotypes	B-X
were	B-X
enhanced	B-X
in	B-X
the	B-X
strain	B-X
containing	B-X
K5R	B-X
K8R	B-X
K12R	B-X
replacements	B-X
in	B-X
the	B-X
N-tail	B-X
of	B-X
histone	B-X
H4	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
lack	B-X
of	B-X
N-terminal	B-X
serine	B-X
acetylation	B-X
is	B-X
synergistic	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
acetylation	B-X
of	B-X
the	B-X
H4	B-X
N-tail	B-X
lysines	B-X
.	B-X
Thus	B-X
,	B-X
N-terminal	B-X
serine	B-X
acetylation	B-X
of	B-X
histone	B-X
H4	B-X
may	B-X
be	B-X
a	B-X
part	B-X
of	B-X
an	B-X
essential	B-X
charge	B-X
patch	B-X
first	B-X
described	B-X
for	B-X
the	B-X
histone	B-X
H2A.Z	B-X
variant	B-X
in	B-X
Tetrahymena	B-X
species	B-X
.	B-X

Ah	B-Protein
receptor	I-Protein
represses	O
acute	O
-	O
phase	O
response	O
gene	O
expression	O
without	O
binding	O
to	O
its	O
cognate	O
response	O
element	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
the	B-X
aryl	B-X
hydrocarbon	B-X
receptor	B-X
(	B-X
AHR	B-X
)	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
regulated-gene	B-X
expression	B-X
,	B-X
especially	B-X
acute-phase	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
serum	B-X
amyloid	B-X
A	B-X
(	B-X
Saa	B-X
)	B-X
.	B-X
Using	B-X
AHR	B-X
mutants	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
nuclear	B-X
translocation	B-X
and	B-X
heterodimerization	B-X
with	B-X
AHR-nuclear	B-X
translocator	B-X
are	B-X
essential	B-X
,	B-X
but	B-X
DNA	B-X
binding	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
AHR-mediated	B-X
Saa	B-X
repression	B-X
.	B-X
A	B-X
number	B-X
of	B-X
AHR	B-X
ligands	B-X
were	B-X
capable	B-X
of	B-X
repressing	B-X
Saa3	B-X
expression	B-X
.	B-X
AHR	B-X
activation	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
RELA	B-X
and	B-X
C/EBP/beta	B-X
recruitment	B-X
to	B-X
and	B-X
histone	B-X
acetylation	B-X
at	B-X
Saa3	B-X
gene	B-X
promoter	B-X
.	B-X
A	B-X
battery	B-X
of	B-X
acute-phase	B-X
genes	B-X
(	B-X
eg	B-X
C-reactive	B-X
protein	B-X
and	B-X
haptoglobin	B-X
)	B-X
induced	B-X
by	B-X
cytokine	B-X
exposure	B-X
was	B-X
repressed	B-X
by	B-X
AHR	B-X
activation	B-X
in	B-X
mouse	B-X
hepatocytes	B-X
.	B-X
Dietary	B-X
exposure	B-X
to	B-X
an	B-X
AHR	B-X
ligand	B-X
represses	B-X
cytokine-induced	B-X
acute-phase	B-X
response	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
Repression	B-X
of	B-X
AHR	B-X
expression	B-X
also	B-X
enhanced	B-X
Saa	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
cytokines	B-X
,	B-X
suggesting	B-X
that	B-X
AHR	B-X
is	B-X
capable	B-X
of	B-X
constitutively	B-X
repressing	B-X
Saa	B-X
gene	B-X
expression	B-X
.	B-X

Repression	O
of	O
the	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
pathway	O
has	O
been	O
extensively	O
researched	O
because	O
of	O
its	O
pivotal	O
role	O
in	O
inflammation	O
.	O
<EOS>	B-X
Repression	B-X
of	B-X
the	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
pathway	B-X
has	B-X
been	B-X
extensively	B-X
researched	B-X
because	B-X
of	B-X
its	B-X
pivotal	B-X
role	B-X
in	B-X
inflammation	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
the	B-X
aryl	B-X
hydrocarbon	B-X
receptor	B-X
(	B-X
AHR	B-X
)	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
regulated-gene	B-X
expression	B-X
,	B-X
especially	B-X
acute-phase	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
serum	B-X
amyloid	B-X
A	B-X
(	B-X
Saa	B-X
)	B-X
.	B-X
Using	B-X
AHR	B-X
mutants	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
nuclear	B-X
translocation	B-X
and	B-X
heterodimerization	B-X
with	B-X
AHR-nuclear	B-X
translocator	B-X
are	B-X
essential	B-X
,	B-X
but	B-X
DNA	B-X
binding	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
AHR-mediated	B-X
Saa	B-X
repression	B-X
.	B-X
Repression	B-X
of	B-X
AHR	B-X
expression	B-X
also	B-X
enhanced	B-X
Saa	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
cytokines	B-X
,	B-X
suggesting	B-X
that	B-X
AHR	B-X
is	B-X
capable	B-X
of	B-X
constitutively	B-X
repressing	B-X
Saa	B-X
gene	B-X
expression	B-X
.	B-X
These	B-X
results	B-X
establish	B-X
a	B-X
role	B-X
for	B-X
AHR	B-X
in	B-X
inflammatory	B-X
signaling	B-X
within	B-X
the	B-X
liver	B-X
,	B-X
presenting	B-X
a	B-X
new	B-X
therapeutic	B-X
opportunity	B-X
,	B-X
and	B-X
signify	B-X
AHR	B-X
's	B-X
ability	B-X
to	B-X
function	B-X
in	B-X
a	B-X
DNA-independent	B-X
manner	B-X
.	B-X

We	O
investigated	O
the	O
potential	O
of	O
the	O
aryl	B-Protein
hydrocarbon	I-Protein
receptor	I-Protein
(	O
AHR	B-Protein
)	O
to	O
suppress	O
NF	O
-	O
kappaB	O
regulated	O
-	O
gene	O
expression	O
,	O
especially	O
acute	O
-	O
phase	O
genes	O
,	O
such	O
as	O
serum	B-Protein
amyloid	I-Protein
A	I-Protein
(	O
Saa	B-Protein
)	O
.	O
<EOS>	B-X
Repression	B-X
of	B-X
the	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
pathway	B-X
has	B-X
been	B-X
extensively	B-X
researched	B-X
because	B-X
of	B-X
its	B-X
pivotal	B-X
role	B-X
in	B-X
inflammation	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
the	B-X
aryl	B-X
hydrocarbon	B-X
receptor	B-X
(	B-X
AHR	B-X
)	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
regulated-gene	B-X
expression	B-X
,	B-X
especially	B-X
acute-phase	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
serum	B-X
amyloid	B-X
A	B-X
(	B-X
Saa	B-X
)	B-X
.	B-X
Using	B-X
AHR	B-X
mutants	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
nuclear	B-X
translocation	B-X
and	B-X
heterodimerization	B-X
with	B-X
AHR-nuclear	B-X
translocator	B-X
are	B-X
essential	B-X
,	B-X
but	B-X
DNA	B-X
binding	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
AHR-mediated	B-X
Saa	B-X
repression	B-X
.	B-X
A	B-X
number	B-X
of	B-X
AHR	B-X
ligands	B-X
were	B-X
capable	B-X
of	B-X
repressing	B-X
Saa3	B-X
expression	B-X
.	B-X
AHR	B-X
activation	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
RELA	B-X
and	B-X
C/EBP/beta	B-X
recruitment	B-X
to	B-X
and	B-X
histone	B-X
acetylation	B-X
at	B-X
Saa3	B-X
gene	B-X
promoter	B-X
.	B-X
A	B-X
battery	B-X
of	B-X
acute-phase	B-X
genes	B-X
(	B-X
eg	B-X
C-reactive	B-X
protein	B-X
and	B-X
haptoglobin	B-X
)	B-X
induced	B-X
by	B-X
cytokine	B-X
exposure	B-X
was	B-X
repressed	B-X
by	B-X
AHR	B-X
activation	B-X
in	B-X
mouse	B-X
hepatocytes	B-X
.	B-X
Dietary	B-X
exposure	B-X
to	B-X
an	B-X
AHR	B-X
ligand	B-X
represses	B-X
cytokine-induced	B-X
acute-phase	B-X
response	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
Use	B-X
of	B-X
a	B-X
human	B-X
liver-derived	B-X
cell	B-X
line	B-X
revealed	B-X
similar	B-X
repression	B-X
of	B-X
Saa	B-X
mRNA	B-X
levels	B-X
and	B-X
secreted	B-X
protein	B-X
.	B-X
Repression	B-X
of	B-X
AHR	B-X
expression	B-X
also	B-X
enhanced	B-X
Saa	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
cytokines	B-X
,	B-X
suggesting	B-X
that	B-X
AHR	B-X
is	B-X
capable	B-X
of	B-X
constitutively	B-X
repressing	B-X
Saa	B-X
gene	B-X
expression	B-X
.	B-X
These	B-X
results	B-X
establish	B-X
a	B-X
role	B-X
for	B-X
AHR	B-X
in	B-X
inflammatory	B-X
signaling	B-X
within	B-X
the	B-X
liver	B-X
,	B-X
presenting	B-X
a	B-X
new	B-X
therapeutic	B-X
opportunity	B-X
,	B-X
and	B-X
signify	B-X
AHR	B-X
's	B-X
ability	B-X
to	B-X
function	B-X
in	B-X
a	B-X
DNA-independent	B-X
manner	B-X
.	B-X

Using	O
AHR	B-Protein
mutants	O
,	O
it	O
was	O
determined	O
that	O
nuclear	O
translocation	O
and	O
heterodimerization	O
with	O
AHR	B-Protein
-	O
nuclear	O
translocator	O
are	O
essential	O
,	O
but	O
DNA	O
binding	O
is	O
not	O
involved	O
in	O
AHR	B-Protein
-	O
mediated	O
Saa	B-Protein
repression	O
.	O

A	O
number	O
of	O
AHR	B-Protein
ligands	O
were	O
capable	O
of	O
repressing	O
Saa3	B-Protein
expression	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
the	B-X
aryl	B-X
hydrocarbon	B-X
receptor	B-X
(	B-X
AHR	B-X
)	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
regulated-gene	B-X
expression	B-X
,	B-X
especially	B-X
acute-phase	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
serum	B-X
amyloid	B-X
A	B-X
(	B-X
Saa	B-X
)	B-X
.	B-X
Using	B-X
AHR	B-X
mutants	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
nuclear	B-X
translocation	B-X
and	B-X
heterodimerization	B-X
with	B-X
AHR-nuclear	B-X
translocator	B-X
are	B-X
essential	B-X
,	B-X
but	B-X
DNA	B-X
binding	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
AHR-mediated	B-X
Saa	B-X
repression	B-X
.	B-X
A	B-X
number	B-X
of	B-X
AHR	B-X
ligands	B-X
were	B-X
capable	B-X
of	B-X
repressing	B-X
Saa3	B-X
expression	B-X
.	B-X
AHR	B-X
activation	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
RELA	B-X
and	B-X
C/EBP/beta	B-X
recruitment	B-X
to	B-X
and	B-X
histone	B-X
acetylation	B-X
at	B-X
Saa3	B-X
gene	B-X
promoter	B-X
.	B-X
A	B-X
battery	B-X
of	B-X
acute-phase	B-X
genes	B-X
(	B-X
eg	B-X
C-reactive	B-X
protein	B-X
and	B-X
haptoglobin	B-X
)	B-X
induced	B-X
by	B-X
cytokine	B-X
exposure	B-X
was	B-X
repressed	B-X
by	B-X
AHR	B-X
activation	B-X
in	B-X
mouse	B-X
hepatocytes	B-X
.	B-X
Dietary	B-X
exposure	B-X
to	B-X
an	B-X
AHR	B-X
ligand	B-X
represses	B-X
cytokine-induced	B-X
acute-phase	B-X
response	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
Repression	B-X
of	B-X
AHR	B-X
expression	B-X
also	B-X
enhanced	B-X
Saa	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
cytokines	B-X
,	B-X
suggesting	B-X
that	B-X
AHR	B-X
is	B-X
capable	B-X
of	B-X
constitutively	B-X
repressing	B-X
Saa	B-X
gene	B-X
expression	B-X
.	B-X
These	B-X
results	B-X
establish	B-X
a	B-X
role	B-X
for	B-X
AHR	B-X
in	B-X
inflammatory	B-X
signaling	B-X
within	B-X
the	B-X
liver	B-X
,	B-X
presenting	B-X
a	B-X
new	B-X
therapeutic	B-X
opportunity	B-X
,	B-X
and	B-X
signify	B-X
AHR	B-X
's	B-X
ability	B-X
to	B-X
function	B-X
in	B-X
a	B-X
DNA-independent	B-X
manner	B-X
.	B-X

AHR	B-Protein
activation	O
leads	O
to	O
a	O
decrease	O
in	O
RELA	B-Protein
and	O
C	B-Protein
/	I-Protein
EBP	I-Protein
/	I-Protein
beta	I-Protein
recruitment	O
to	O
and	O
histone	B-Protein
acetylation	O
at	O
Saa3	B-Protein
gene	O
promoter	O
.	O

A	O
battery	O
of	O
acute	O
-	O
phase	O
genes	O
(	O
eg	O
C	B-Protein
-	I-Protein
reactive	I-Protein
protein	I-Protein
and	O
haptoglobin	B-Protein
)	O
induced	O
by	O
cytokine	O
exposure	O
was	O
repressed	O
by	O
AHR	B-Protein
activation	O
in	O
mouse	O
hepatocytes	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
the	B-X
aryl	B-X
hydrocarbon	B-X
receptor	B-X
(	B-X
AHR	B-X
)	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
regulated-gene	B-X
expression	B-X
,	B-X
especially	B-X
acute-phase	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
serum	B-X
amyloid	B-X
A	B-X
(	B-X
Saa	B-X
)	B-X
.	B-X
Using	B-X
AHR	B-X
mutants	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
nuclear	B-X
translocation	B-X
and	B-X
heterodimerization	B-X
with	B-X
AHR-nuclear	B-X
translocator	B-X
are	B-X
essential	B-X
,	B-X
but	B-X
DNA	B-X
binding	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
AHR-mediated	B-X
Saa	B-X
repression	B-X
.	B-X
A	B-X
number	B-X
of	B-X
AHR	B-X
ligands	B-X
were	B-X
capable	B-X
of	B-X
repressing	B-X
Saa3	B-X
expression	B-X
.	B-X
AHR	B-X
activation	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
RELA	B-X
and	B-X
C/EBP/beta	B-X
recruitment	B-X
to	B-X
and	B-X
histone	B-X
acetylation	B-X
at	B-X
Saa3	B-X
gene	B-X
promoter	B-X
.	B-X
A	B-X
battery	B-X
of	B-X
acute-phase	B-X
genes	B-X
(	B-X
eg	B-X
C-reactive	B-X
protein	B-X
and	B-X
haptoglobin	B-X
)	B-X
induced	B-X
by	B-X
cytokine	B-X
exposure	B-X
was	B-X
repressed	B-X
by	B-X
AHR	B-X
activation	B-X
in	B-X
mouse	B-X
hepatocytes	B-X
.	B-X
Dietary	B-X
exposure	B-X
to	B-X
an	B-X
AHR	B-X
ligand	B-X
represses	B-X
cytokine-induced	B-X
acute-phase	B-X
response	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
Use	B-X
of	B-X
a	B-X
human	B-X
liver-derived	B-X
cell	B-X
line	B-X
revealed	B-X
similar	B-X
repression	B-X
of	B-X
Saa	B-X
mRNA	B-X
levels	B-X
and	B-X
secreted	B-X
protein	B-X
.	B-X
Repression	B-X
of	B-X
AHR	B-X
expression	B-X
also	B-X
enhanced	B-X
Saa	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
cytokines	B-X
,	B-X
suggesting	B-X
that	B-X
AHR	B-X
is	B-X
capable	B-X
of	B-X
constitutively	B-X
repressing	B-X
Saa	B-X
gene	B-X
expression	B-X
.	B-X
These	B-X
results	B-X
establish	B-X
a	B-X
role	B-X
for	B-X
AHR	B-X
in	B-X
inflammatory	B-X
signaling	B-X
within	B-X
the	B-X
liver	B-X
,	B-X
presenting	B-X
a	B-X
new	B-X
therapeutic	B-X
opportunity	B-X
,	B-X
and	B-X
signify	B-X
AHR	B-X
's	B-X
ability	B-X
to	B-X
function	B-X
in	B-X
a	B-X
DNA-independent	B-X
manner	B-X
.	B-X

Dietary	O
exposure	O
to	O
an	O
AHR	B-Protein
ligand	O
represses	O
cytokine	O
-	O
induced	O
acute	O
-	O
phase	O
response	O
in	O
the	O
liver	O
.	O

Use	O
of	O
a	O
human	O
liver	O
-	O
derived	O
cell	O
line	O
revealed	O
similar	O
repression	O
of	O
Saa	B-Protein
mRNA	O
levels	O
and	O
secreted	O
protein	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
the	B-X
aryl	B-X
hydrocarbon	B-X
receptor	B-X
(	B-X
AHR	B-X
)	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
regulated-gene	B-X
expression	B-X
,	B-X
especially	B-X
acute-phase	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
serum	B-X
amyloid	B-X
A	B-X
(	B-X
Saa	B-X
)	B-X
.	B-X
Using	B-X
AHR	B-X
mutants	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
nuclear	B-X
translocation	B-X
and	B-X
heterodimerization	B-X
with	B-X
AHR-nuclear	B-X
translocator	B-X
are	B-X
essential	B-X
,	B-X
but	B-X
DNA	B-X
binding	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
AHR-mediated	B-X
Saa	B-X
repression	B-X
.	B-X
A	B-X
number	B-X
of	B-X
AHR	B-X
ligands	B-X
were	B-X
capable	B-X
of	B-X
repressing	B-X
Saa3	B-X
expression	B-X
.	B-X
AHR	B-X
activation	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
RELA	B-X
and	B-X
C/EBP/beta	B-X
recruitment	B-X
to	B-X
and	B-X
histone	B-X
acetylation	B-X
at	B-X
Saa3	B-X
gene	B-X
promoter	B-X
.	B-X
A	B-X
battery	B-X
of	B-X
acute-phase	B-X
genes	B-X
(	B-X
eg	B-X
C-reactive	B-X
protein	B-X
and	B-X
haptoglobin	B-X
)	B-X
induced	B-X
by	B-X
cytokine	B-X
exposure	B-X
was	B-X
repressed	B-X
by	B-X
AHR	B-X
activation	B-X
in	B-X
mouse	B-X
hepatocytes	B-X
.	B-X
Dietary	B-X
exposure	B-X
to	B-X
an	B-X
AHR	B-X
ligand	B-X
represses	B-X
cytokine-induced	B-X
acute-phase	B-X
response	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
Use	B-X
of	B-X
a	B-X
human	B-X
liver-derived	B-X
cell	B-X
line	B-X
revealed	B-X
similar	B-X
repression	B-X
of	B-X
Saa	B-X
mRNA	B-X
levels	B-X
and	B-X
secreted	B-X
protein	B-X
.	B-X
Repression	B-X
of	B-X
AHR	B-X
expression	B-X
also	B-X
enhanced	B-X
Saa	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
cytokines	B-X
,	B-X
suggesting	B-X
that	B-X
AHR	B-X
is	B-X
capable	B-X
of	B-X
constitutively	B-X
repressing	B-X
Saa	B-X
gene	B-X
expression	B-X
.	B-X
These	B-X
results	B-X
establish	B-X
a	B-X
role	B-X
for	B-X
AHR	B-X
in	B-X
inflammatory	B-X
signaling	B-X
within	B-X
the	B-X
liver	B-X
,	B-X
presenting	B-X
a	B-X
new	B-X
therapeutic	B-X
opportunity	B-X
,	B-X
and	B-X
signify	B-X
AHR	B-X
's	B-X
ability	B-X
to	B-X
function	B-X
in	B-X
a	B-X
DNA-independent	B-X
manner	B-X
.	B-X

Repression	O
of	O
AHR	B-Protein
expression	O
also	O
enhanced	O
Saa	O
induction	O
in	O
response	O
to	O
cytokines	O
,	O
suggesting	O
that	O
AHR	B-Protein
is	O
capable	O
of	O
constitutively	O
repressing	O
Saa	B-Protein
gene	O
expression	O
.	O
<EOS>	B-X
Repression	B-X
of	B-X
the	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
pathway	B-X
has	B-X
been	B-X
extensively	B-X
researched	B-X
because	B-X
of	B-X
its	B-X
pivotal	B-X
role	B-X
in	B-X
inflammation	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
the	B-X
aryl	B-X
hydrocarbon	B-X
receptor	B-X
(	B-X
AHR	B-X
)	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
regulated-gene	B-X
expression	B-X
,	B-X
especially	B-X
acute-phase	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
serum	B-X
amyloid	B-X
A	B-X
(	B-X
Saa	B-X
)	B-X
.	B-X
Using	B-X
AHR	B-X
mutants	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
nuclear	B-X
translocation	B-X
and	B-X
heterodimerization	B-X
with	B-X
AHR-nuclear	B-X
translocator	B-X
are	B-X
essential	B-X
,	B-X
but	B-X
DNA	B-X
binding	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
AHR-mediated	B-X
Saa	B-X
repression	B-X
.	B-X
A	B-X
number	B-X
of	B-X
AHR	B-X
ligands	B-X
were	B-X
capable	B-X
of	B-X
repressing	B-X
Saa3	B-X
expression	B-X
.	B-X
AHR	B-X
activation	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
RELA	B-X
and	B-X
C/EBP/beta	B-X
recruitment	B-X
to	B-X
and	B-X
histone	B-X
acetylation	B-X
at	B-X
Saa3	B-X
gene	B-X
promoter	B-X
.	B-X
A	B-X
battery	B-X
of	B-X
acute-phase	B-X
genes	B-X
(	B-X
eg	B-X
C-reactive	B-X
protein	B-X
and	B-X
haptoglobin	B-X
)	B-X
induced	B-X
by	B-X
cytokine	B-X
exposure	B-X
was	B-X
repressed	B-X
by	B-X
AHR	B-X
activation	B-X
in	B-X
mouse	B-X
hepatocytes	B-X
.	B-X
Dietary	B-X
exposure	B-X
to	B-X
an	B-X
AHR	B-X
ligand	B-X
represses	B-X
cytokine-induced	B-X
acute-phase	B-X
response	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
Use	B-X
of	B-X
a	B-X
human	B-X
liver-derived	B-X
cell	B-X
line	B-X
revealed	B-X
similar	B-X
repression	B-X
of	B-X
Saa	B-X
mRNA	B-X
levels	B-X
and	B-X
secreted	B-X
protein	B-X
.	B-X
Repression	B-X
of	B-X
AHR	B-X
expression	B-X
also	B-X
enhanced	B-X
Saa	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
cytokines	B-X
,	B-X
suggesting	B-X
that	B-X
AHR	B-X
is	B-X
capable	B-X
of	B-X
constitutively	B-X
repressing	B-X
Saa	B-X
gene	B-X
expression	B-X
.	B-X
These	B-X
results	B-X
establish	B-X
a	B-X
role	B-X
for	B-X
AHR	B-X
in	B-X
inflammatory	B-X
signaling	B-X
within	B-X
the	B-X
liver	B-X
,	B-X
presenting	B-X
a	B-X
new	B-X
therapeutic	B-X
opportunity	B-X
,	B-X
and	B-X
signify	B-X
AHR	B-X
's	B-X
ability	B-X
to	B-X
function	B-X
in	B-X
a	B-X
DNA-independent	B-X
manner	B-X
.	B-X

These	O
results	O
establish	O
a	O
role	O
for	O
AHR	B-Protein
in	O
inflammatory	O
signaling	O
within	O
the	O
liver	O
,	O
presenting	O
a	O
new	O
therapeutic	O
opportunity	O
,	O
and	O
signify	O
AHR	B-Protein
'	O
s	O
ability	O
to	O
function	O
in	O
a	O
DNA	O
-	O
independent	O
manner	O
.	O

Ubiquitin	B-Protein
-	O
like	O
protein	O
activation	O
by	O
E1	O
enzymes	O
:	O
the	O
apex	O
for	O
downstream	O
signalling	O
pathways	O
.	O
<EOS>	B-X
Attachment	B-X
of	B-X
ubiquitin	B-X
or	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
known	B-X
as	B-X
UBLs	B-X
)	B-X
to	B-X
their	B-X
targets	B-X
through	B-X
multienzyme	B-X
cascades	B-X
is	B-X
a	B-X
central	B-X
mechanism	B-X
to	B-X
modulate	B-X
protein	B-X
functions	B-X
.	B-X
This	B-X
process	B-X
is	B-X
initiated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
mechanistically	B-X
and	B-X
structurally	B-X
related	B-X
E1	B-X
(	B-X
or	B-X
activating	B-X
)	B-X
enzymes	B-X
.	B-X
These	B-X
activate	B-X
UBLs	B-X
through	B-X
carboxy-terminal	B-X
adenylation	B-X
and	B-X
thiol	B-X
transfer	B-X
,	B-X
and	B-X
coordinate	B-X
the	B-X
use	B-X
of	B-X
UBLs	B-X
in	B-X
specific	B-X
downstream	B-X
pathways	B-X
by	B-X
charging	B-X
cognate	B-X
E2	B-X
(	B-X
or	B-X
conjugating	B-X
)	B-X
enzymes	B-X
,	B-X
which	B-X
then	B-X
interact	B-X
with	B-X
the	B-X
downstream	B-X
ubiquitylation	B-X
machinery	B-X
to	B-X
coordinate	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
target	B-X
.	B-X
A	B-X
broad	B-X
understanding	B-X
of	B-X
how	B-X
E1	B-X
enzymes	B-X
activate	B-X
UBLs	B-X
and	B-X
how	B-X
they	B-X
selectively	B-X
coordinate	B-X
UBLs	B-X
with	B-X
downstream	B-X
function	B-X
has	B-X
come	B-X
from	B-X
enzymatic	B-X
,	B-X
structural	B-X
and	B-X
genetic	B-X
studies	B-X
.	B-X

Attachment	O
of	O
ubiquitin	B-Protein
or	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
(	O
known	O
as	O
UBLs	O
)	O
to	O
their	O
targets	O
through	O
multienzyme	O
cascades	O
is	O
a	O
central	O
mechanism	O
to	O
modulate	O
protein	O
functions	O
.	O
<EOS>	B-X
Protein	B-X
ubiquitination	B-X
is	B-X
a	B-X
dynamic	B-X
multifaceted	B-X
post-translational	B-X
modification	B-X
involved	B-X
in	B-X
nearly	B-X
all	B-X
aspects	B-X
of	B-X
eukaryotic	B-X
biology	B-X
.	B-X
Once	B-X
attached	B-X
to	B-X
a	B-X
substrate	B-X
,	B-X
the	B-X
76-amino	B-X
acid	B-X
protein	B-X
ubiquitin	B-X
is	B-X
subjected	B-X
to	B-X
further	B-X
modifications	B-X
,	B-X
creating	B-X
a	B-X
multitude	B-X
of	B-X
distinct	B-X
signals	B-X
with	B-X
distinct	B-X
cellular	B-X
outcomes	B-X
,	B-X
referred	B-X
to	B-X
as	B-X
the	B-X
'ubiquitin	B-X
code	B-X
'	B-X
.	B-X
Ubiquitin	B-X
can	B-X
be	B-X
ubiquitinated	B-X
on	B-X
seven	B-X
lysine	B-X
(	B-X
Lys	B-X
)	B-X
residues	B-X
or	B-X
on	B-X
the	B-X
N-terminus	B-X
,	B-X
leading	B-X
to	B-X
polyubiquitin	B-X
chains	B-X
that	B-X
can	B-X
encompass	B-X
complex	B-X
topologies	B-X
.	B-X
Alternatively	B-X
or	B-X
in	B-X
addition	B-X
,	B-X
ubiquitin	B-X
Lys	B-X
residues	B-X
can	B-X
be	B-X
modified	B-X
by	B-X
ubiquitin-like	B-X
molecules	B-X
(	B-X
such	B-X
as	B-X
SUMO	B-X
or	B-X
NEDD8	B-X
)	B-X
.	B-X
Finally	B-X
,	B-X
ubiquitin	B-X
can	B-X
also	B-X
be	B-X
acetylated	B-X
on	B-X
Lys	B-X
,	B-X
or	B-X
phosphorylated	B-X
on	B-X
Ser	B-X
,	B-X
Thr	B-X
or	B-X
Tyr	B-X
residues	B-X
,	B-X
and	B-X
each	B-X
modification	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
dramatically	B-X
alter	B-X
the	B-X
signaling	B-X
outcome	B-X
.	B-X
While	B-X
the	B-X
number	B-X
of	B-X
distinctly	B-X
modified	B-X
ubiquitin	B-X
species	B-X
in	B-X
cells	B-X
is	B-X
mind-boggling	B-X
,	B-X
much	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
to	B-X
characterize	B-X
the	B-X
roles	B-X
of	B-X
distinct	B-X
ubiquitin	B-X
modifications	B-X
,	B-X
and	B-X
many	B-X
enzymes	B-X
and	B-X
receptors	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
create	B-X
,	B-X
recognize	B-X
or	B-X
remove	B-X
these	B-X
ubiquitin	B-X
modifications	B-X
.	B-X
We	B-X
here	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
various	B-X
ubiquitin	B-X
modifications	B-X
present	B-X
in	B-X
cells	B-X
,	B-X
and	B-X
highlight	B-X
recent	B-X
progress	B-X
on	B-X
ubiquitin	B-X
chain	B-X
biology	B-X
.	B-X
We	B-X
then	B-X
discuss	B-X
the	B-X
recent	B-X
findings	B-X
in	B-X
the	B-X
field	B-X
of	B-X
ubiquitin	B-X
acetylation	B-X
and	B-X
phosphorylation	B-X
,	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
Ser65-phosphorylation	B-X
and	B-X
its	B-X
role	B-X
in	B-X
mitophagy	B-X
and	B-X
Parkin	B-X
activation	B-X
.	B-X

This	O
process	O
is	O
initiated	O
by	O
a	O
family	O
of	O
mechanistically	O
and	O
structurally	O
related	O
E1	O
(	O
or	O
activating	O
)	O
enzymes	O
.	O
<EOS>	B-X
This	B-X
process	B-X
is	B-X
initiated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
mechanistically	B-X
and	B-X
structurally	B-X
related	B-X
E1	B-X
(	B-X
or	B-X
activating	B-X
)	B-X
enzymes	B-X
.	B-X
These	B-X
activate	B-X
UBLs	B-X
through	B-X
carboxy-terminal	B-X
adenylation	B-X
and	B-X
thiol	B-X
transfer	B-X
,	B-X
and	B-X
coordinate	B-X
the	B-X
use	B-X
of	B-X
UBLs	B-X
in	B-X
specific	B-X
downstream	B-X
pathways	B-X
by	B-X
charging	B-X
cognate	B-X
E2	B-X
(	B-X
or	B-X
conjugating	B-X
)	B-X
enzymes	B-X
,	B-X
which	B-X
then	B-X
interact	B-X
with	B-X
the	B-X
downstream	B-X
ubiquitylation	B-X
machinery	B-X
to	B-X
coordinate	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
target	B-X
.	B-X
A	B-X
broad	B-X
understanding	B-X
of	B-X
how	B-X
E1	B-X
enzymes	B-X
activate	B-X
UBLs	B-X
and	B-X
how	B-X
they	B-X
selectively	B-X
coordinate	B-X
UBLs	B-X
with	B-X
downstream	B-X
function	B-X
has	B-X
come	B-X
from	B-X
enzymatic	B-X
,	B-X
structural	B-X
and	B-X
genetic	B-X
studies	B-X
.	B-X
Attachment	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
requires	B-X
the	B-X
activities	B-X
of	B-X
an	B-X
E1	B-X
activating	B-X
enzyme	B-X
,	B-X
an	B-X
E2	B-X
carrier	B-X
protein	B-X
,	B-X
and	B-X
an	B-X
E3	B-X
ligase	B-X
.	B-X
The	B-X
tripartite	B-X
motif	B-X
(	B-X
TRIM	B-X
)	B-X
superfamily	B-X
of	B-X
ligases	B-X
functions	B-X
in	B-X
many	B-X
cellular	B-X
processes	B-X
including	B-X
innate	B-X
immunity	B-X
,	B-X
cellular	B-X
localization	B-X
,	B-X
development	B-X
and	B-X
differentiation	B-X
,	B-X
signaling	B-X
,	B-X
and	B-X
cancer	B-X
progression	B-X
.	B-X
Initial	B-X
rate	B-X
studies	B-X
under	B-X
biochemically	B-X
defined	B-X
conditions	B-X
show	B-X
that	B-X
TRIM32	B-X
and	B-X
TRIM25	B-X
are	B-X
specific	B-X
for	B-X
the	B-X
Ubc5	B-X
family	B-X
of	B-X
E2-conjugating	B-X
proteins	B-X
and	B-X
,	B-X
along	B-X
with	B-X
TRIM5α	B-X
,	B-X
exhibit	B-X
cooperative	B-X
kinetics	B-X
with	B-X
respect	B-X
to	B-X
Ubc5	B-X
concentration	B-X
,	B-X
with	B-X
submicromolar	B-X
[	B-X
S	B-X
]	B-X
0.5	B-X
and	B-X
Hill	B-X
coefficients	B-X
of	B-X
3-5	B-X
,	B-X
suggesting	B-X
they	B-X
possess	B-X
multiple	B-X
binding	B-X
sites	B-X
for	B-X
their	B-X
cognate	B-X
E2-ubiquitin	B-X
thioester	B-X
.	B-X
These	B-X
results	B-X
represent	B-X
the	B-X
first	B-X
detailed	B-X
mechanistic	B-X
study	B-X
of	B-X
TRIM	B-X
ligase	B-X
activity	B-X
and	B-X
provide	B-X
a	B-X
functional	B-X
context	B-X
for	B-X
oligomerization	B-X
observed	B-X
in	B-X
the	B-X
superfamily	B-X
.	B-X

These	O
activate	O
UBLs	O
through	O
carboxy	O
-	O
terminal	O
adenylation	O
and	O
thiol	O
transfer	O
,	O
and	O
coordinate	O
the	O
use	O
of	O
UBLs	O
in	O
specific	O
downstream	O
pathways	O
by	O
charging	O
cognate	O
E2	O
(	O
or	O
conjugating	O
)	O
enzymes	O
,	O
which	O
then	O
interact	O
with	O
the	O
downstream	O
ubiquitylation	O
machinery	O
to	O
coordinate	O
the	O
modification	O
of	O
the	O
target	O
.	O
<EOS>	B-X
Attachment	B-X
of	B-X
ubiquitin	B-X
or	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
known	B-X
as	B-X
UBLs	B-X
)	B-X
to	B-X
their	B-X
targets	B-X
through	B-X
multienzyme	B-X
cascades	B-X
is	B-X
a	B-X
central	B-X
mechanism	B-X
to	B-X
modulate	B-X
protein	B-X
functions	B-X
.	B-X
This	B-X
process	B-X
is	B-X
initiated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
mechanistically	B-X
and	B-X
structurally	B-X
related	B-X
E1	B-X
(	B-X
or	B-X
activating	B-X
)	B-X
enzymes	B-X
.	B-X
These	B-X
activate	B-X
UBLs	B-X
through	B-X
carboxy-terminal	B-X
adenylation	B-X
and	B-X
thiol	B-X
transfer	B-X
,	B-X
and	B-X
coordinate	B-X
the	B-X
use	B-X
of	B-X
UBLs	B-X
in	B-X
specific	B-X
downstream	B-X
pathways	B-X
by	B-X
charging	B-X
cognate	B-X
E2	B-X
(	B-X
or	B-X
conjugating	B-X
)	B-X
enzymes	B-X
,	B-X
which	B-X
then	B-X
interact	B-X
with	B-X
the	B-X
downstream	B-X
ubiquitylation	B-X
machinery	B-X
to	B-X
coordinate	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
target	B-X
.	B-X
A	B-X
broad	B-X
understanding	B-X
of	B-X
how	B-X
E1	B-X
enzymes	B-X
activate	B-X
UBLs	B-X
and	B-X
how	B-X
they	B-X
selectively	B-X
coordinate	B-X
UBLs	B-X
with	B-X
downstream	B-X
function	B-X
has	B-X
come	B-X
from	B-X
enzymatic	B-X
,	B-X
structural	B-X
and	B-X
genetic	B-X
studies	B-X
.	B-X

A	O
broad	O
understanding	O
of	O
how	O
E1	O
enzymes	O
activate	O
UBLs	O
and	O
how	O
they	O
selectively	O
coordinate	O
UBLs	O
with	O
downstream	O
function	O
has	O
come	O
from	O
enzymatic	O
,	O
structural	O
and	O
genetic	O
studies	O
.	O
<EOS>	B-X
Attachment	B-X
of	B-X
ubiquitin	B-X
or	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
known	B-X
as	B-X
UBLs	B-X
)	B-X
to	B-X
their	B-X
targets	B-X
through	B-X
multienzyme	B-X
cascades	B-X
is	B-X
a	B-X
central	B-X
mechanism	B-X
to	B-X
modulate	B-X
protein	B-X
functions	B-X
.	B-X
This	B-X
process	B-X
is	B-X
initiated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
mechanistically	B-X
and	B-X
structurally	B-X
related	B-X
E1	B-X
(	B-X
or	B-X
activating	B-X
)	B-X
enzymes	B-X
.	B-X
These	B-X
activate	B-X
UBLs	B-X
through	B-X
carboxy-terminal	B-X
adenylation	B-X
and	B-X
thiol	B-X
transfer	B-X
,	B-X
and	B-X
coordinate	B-X
the	B-X
use	B-X
of	B-X
UBLs	B-X
in	B-X
specific	B-X
downstream	B-X
pathways	B-X
by	B-X
charging	B-X
cognate	B-X
E2	B-X
(	B-X
or	B-X
conjugating	B-X
)	B-X
enzymes	B-X
,	B-X
which	B-X
then	B-X
interact	B-X
with	B-X
the	B-X
downstream	B-X
ubiquitylation	B-X
machinery	B-X
to	B-X
coordinate	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
target	B-X
.	B-X
A	B-X
broad	B-X
understanding	B-X
of	B-X
how	B-X
E1	B-X
enzymes	B-X
activate	B-X
UBLs	B-X
and	B-X
how	B-X
they	B-X
selectively	B-X
coordinate	B-X
UBLs	B-X
with	B-X
downstream	B-X
function	B-X
has	B-X
come	B-X
from	B-X
enzymatic	B-X
,	B-X
structural	B-X
and	B-X
genetic	B-X
studies	B-X
.	B-X

Histone	B-Protein
acetylations	O
mark	O
origins	O
of	O
polycistronic	O
transcription	O
in	O
Leishmania	O
major	O
.	O
<EOS>	B-X
Many	B-X
components	B-X
of	B-X
the	B-X
RNA	B-X
polymerase	B-X
II	B-X
transcription	B-X
machinery	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
kinetoplastid	B-X
protozoa	B-X
,	B-X
but	B-X
they	B-X
diverge	B-X
substantially	B-X
from	B-X
other	B-X
eukaryotes	B-X
.	B-X
Furthermore	B-X
,	B-X
protein-coding	B-X
genes	B-X
in	B-X
these	B-X
organisms	B-X
lack	B-X
individual	B-X
transcriptional	B-X
regulation	B-X
,	B-X
since	B-X
they	B-X
are	B-X
transcribed	B-X
as	B-X
long	B-X
polycistronic	B-X
units	B-X
.	B-X
The	B-X
transcription	B-X
initiation	B-X
sites	B-X
are	B-X
assumed	B-X
to	B-X
lie	B-X
within	B-X
the	B-X
'divergent	B-X
strand-switch	B-X
'	B-X
regions	B-X
at	B-X
the	B-X
junction	B-X
between	B-X
opposing	B-X
polycistronic	B-X
gene	B-X
clusters	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
Kinetoplastidae	B-X
initiate	B-X
transcription	B-X
is	B-X
unclear	B-X
,	B-X
and	B-X
promoter	B-X
sequences	B-X
are	B-X
undefined	B-X
.	B-X

BACKGROUND	O
:	O
Many	O
components	O
of	O
the	O
RNA	O
polymerase	O
II	O
transcription	O
machinery	O
have	O
been	O
identified	O
in	O
kinetoplastid	O
protozoa	O
,	O
but	O
they	O
diverge	O
substantially	O
from	O
other	O
eukaryotes	O
.	O
<EOS>	B-X
Many	B-X
components	B-X
of	B-X
the	B-X
RNA	B-X
polymerase	B-X
II	B-X
transcription	B-X
machinery	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
kinetoplastid	B-X
protozoa	B-X
,	B-X
but	B-X
they	B-X
diverge	B-X
substantially	B-X
from	B-X
other	B-X
eukaryotes	B-X
.	B-X
Furthermore	B-X
,	B-X
protein-coding	B-X
genes	B-X
in	B-X
these	B-X
organisms	B-X
lack	B-X
individual	B-X
transcriptional	B-X
regulation	B-X
,	B-X
since	B-X
they	B-X
are	B-X
transcribed	B-X
as	B-X
long	B-X
polycistronic	B-X
units	B-X
.	B-X
The	B-X
transcription	B-X
initiation	B-X
sites	B-X
are	B-X
assumed	B-X
to	B-X
lie	B-X
within	B-X
the	B-X
'divergent	B-X
strand-switch	B-X
'	B-X
regions	B-X
at	B-X
the	B-X
junction	B-X
between	B-X
opposing	B-X
polycistronic	B-X
gene	B-X
clusters	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
Kinetoplastidae	B-X
initiate	B-X
transcription	B-X
is	B-X
unclear	B-X
,	B-X
and	B-X
promoter	B-X
sequences	B-X
are	B-X
undefined	B-X
.	B-X

Furthermore	O
,	O
protein	O
-	O
coding	O
genes	O
in	O
these	O
organisms	O
lack	O
individual	O
transcriptional	O
regulation	O
,	O
since	O
they	O
are	O
transcribed	O
as	O
long	O
polycistronic	O
units	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
protein-coding	B-X
genes	B-X
in	B-X
these	B-X
organisms	B-X
lack	B-X
individual	B-X
transcriptional	B-X
regulation	B-X
,	B-X
since	B-X
they	B-X
are	B-X
transcribed	B-X
as	B-X
long	B-X
polycistronic	B-X
units	B-X
.	B-X
The	B-X
transcription	B-X
initiation	B-X
sites	B-X
are	B-X
assumed	B-X
to	B-X
lie	B-X
within	B-X
the	B-X
'divergent	B-X
strand-switch	B-X
'	B-X
regions	B-X
at	B-X
the	B-X
junction	B-X
between	B-X
opposing	B-X
polycistronic	B-X
gene	B-X
clusters	B-X
.	B-X

The	O
transcription	O
initiation	O
sites	O
are	O
assumed	O
to	O
lie	O
within	O
the	O
'	O
divergent	O
strand	O
-	O
switch	O
'	O
regions	O
at	O
the	O
junction	O
between	O
opposing	O
polycistronic	O
gene	O
clusters	O
.	O
<EOS>	B-X
Many	B-X
components	B-X
of	B-X
the	B-X
RNA	B-X
polymerase	B-X
II	B-X
transcription	B-X
machinery	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
kinetoplastid	B-X
protozoa	B-X
,	B-X
but	B-X
they	B-X
diverge	B-X
substantially	B-X
from	B-X
other	B-X
eukaryotes	B-X
.	B-X
Furthermore	B-X
,	B-X
protein-coding	B-X
genes	B-X
in	B-X
these	B-X
organisms	B-X
lack	B-X
individual	B-X
transcriptional	B-X
regulation	B-X
,	B-X
since	B-X
they	B-X
are	B-X
transcribed	B-X
as	B-X
long	B-X
polycistronic	B-X
units	B-X
.	B-X
The	B-X
transcription	B-X
initiation	B-X
sites	B-X
are	B-X
assumed	B-X
to	B-X
lie	B-X
within	B-X
the	B-X
'divergent	B-X
strand-switch	B-X
'	B-X
regions	B-X
at	B-X
the	B-X
junction	B-X
between	B-X
opposing	B-X
polycistronic	B-X
gene	B-X
clusters	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
Kinetoplastidae	B-X
initiate	B-X
transcription	B-X
is	B-X
unclear	B-X
,	B-X
and	B-X
promoter	B-X
sequences	B-X
are	B-X
undefined	B-X
.	B-X

However	O
,	O
the	O
mechanism	O
by	O
which	O
Kinetoplastidae	O
initiate	O
transcription	O
is	O
unclear	O
,	O
and	O
promoter	O
sequences	O
are	O
undefined	O
.	O
<EOS>	B-X
Many	B-X
components	B-X
of	B-X
the	B-X
RNA	B-X
polymerase	B-X
II	B-X
transcription	B-X
machinery	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
kinetoplastid	B-X
protozoa	B-X
,	B-X
but	B-X
they	B-X
diverge	B-X
substantially	B-X
from	B-X
other	B-X
eukaryotes	B-X
.	B-X
Furthermore	B-X
,	B-X
protein-coding	B-X
genes	B-X
in	B-X
these	B-X
organisms	B-X
lack	B-X
individual	B-X
transcriptional	B-X
regulation	B-X
,	B-X
since	B-X
they	B-X
are	B-X
transcribed	B-X
as	B-X
long	B-X
polycistronic	B-X
units	B-X
.	B-X
The	B-X
transcription	B-X
initiation	B-X
sites	B-X
are	B-X
assumed	B-X
to	B-X
lie	B-X
within	B-X
the	B-X
'divergent	B-X
strand-switch	B-X
'	B-X
regions	B-X
at	B-X
the	B-X
junction	B-X
between	B-X
opposing	B-X
polycistronic	B-X
gene	B-X
clusters	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
Kinetoplastidae	B-X
initiate	B-X
transcription	B-X
is	B-X
unclear	B-X
,	B-X
and	B-X
promoter	B-X
sequences	B-X
are	B-X
undefined	B-X
.	B-X

RESULTS	O
:	O
The	O
chromosomal	O
location	O
of	O
TATA	O
-	O
binding	O
protein	O
(	O
TBP	O
or	O
TRF4	B-Protein
)	O
,	O
Small	O
Nuclear	O
Activating	O
Protein	O
complex	O
(	O
SNAP50	B-Protein
)	O
,	O
and	O
H3	B-Protein
histones	I-Protein
were	O
assessed	O
in	O
Leishmania	O
major	O
using	O
microarrays	O
hybridized	O
with	O
DNA	O
obtained	O
through	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
-	O
chip	O
)	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
protein-coding	B-X
genes	B-X
in	B-X
these	B-X
organisms	B-X
lack	B-X
individual	B-X
transcriptional	B-X
regulation	B-X
,	B-X
since	B-X
they	B-X
are	B-X
transcribed	B-X
as	B-X
long	B-X
polycistronic	B-X
units	B-X
.	B-X

The	O
TBP	O
and	O
SNAP50	B-Protein
binding	O
patterns	O
were	O
almost	O
identical	O
and	O
high	O
intensity	O
peaks	O
were	O
associated	O
with	O
tRNAs	O
and	O
snRNAs	O
.	O

Only	O
184	O
peaks	O
of	O
acetylated	O
H3	B-Protein
histone	I-Protein
were	O
found	O
in	O
the	O
entire	O
genome	O
,	O
with	O
substantially	O
higher	O
intensity	O
in	O
rapidly	O
-	O
dividing	O
cells	O
than	O
stationary	O
-	O
phase	O
.	O
<EOS>	B-X
Many	B-X
components	B-X
of	B-X
the	B-X
RNA	B-X
polymerase	B-X
II	B-X
transcription	B-X
machinery	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
kinetoplastid	B-X
protozoa	B-X
,	B-X
but	B-X
they	B-X
diverge	B-X
substantially	B-X
from	B-X
other	B-X
eukaryotes	B-X
.	B-X

The	O
majority	O
of	O
the	O
acetylated	O
H3	B-Protein
peaks	O
were	O
found	O
at	O
divergent	O
strand	O
-	O
switch	O
regions	O
,	O
but	O
some	O
occurred	O
at	O
chromosome	O
ends	O
and	O
within	O
polycistronic	O
gene	O
clusters	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
protein-coding	B-X
genes	B-X
in	B-X
these	B-X
organisms	B-X
lack	B-X
individual	B-X
transcriptional	B-X
regulation	B-X
,	B-X
since	B-X
they	B-X
are	B-X
transcribed	B-X
as	B-X
long	B-X
polycistronic	B-X
units	B-X
.	B-X
The	B-X
transcription	B-X
initiation	B-X
sites	B-X
are	B-X
assumed	B-X
to	B-X
lie	B-X
within	B-X
the	B-X
'divergent	B-X
strand-switch	B-X
'	B-X
regions	B-X
at	B-X
the	B-X
junction	B-X
between	B-X
opposing	B-X
polycistronic	B-X
gene	B-X
clusters	B-X
.	B-X

Almost	O
all	O
these	O
peaks	O
were	O
associated	O
with	O
lower	O
intensity	O
peaks	O
of	O
TBP	O
/	O
SNAP50	B-Protein
binding	O
a	O
few	O
kilobases	O
upstream	O
,	O
evidence	O
that	O
they	O
represent	O
transcription	O
initiation	O
sites	O
.	O

CONCLUSION	O
:	O
The	O
first	O
genome	O
-	O
wide	O
maps	O
of	O
DNA	O
-	O
binding	O
protein	O
occupancy	O
in	O
a	O
kinetoplastid	O
organism	O
suggest	O
that	O
H3	B-Protein
histones	I-Protein
at	O
the	O
origins	O
of	O
polycistronic	O
transcription	O
of	O
protein	O
-	O
coding	O
genes	O
are	O
acetylated	O
.	O

Global	O
regulation	O
of	O
transcription	O
initiation	O
may	O
be	O
achieved	O
by	O
modifying	O
the	O
acetylation	O
state	O
of	O
these	O
origins	O
.	O
<EOS>	B-X
Many	B-X
components	B-X
of	B-X
the	B-X
RNA	B-X
polymerase	B-X
II	B-X
transcription	B-X
machinery	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
kinetoplastid	B-X
protozoa	B-X
,	B-X
but	B-X
they	B-X
diverge	B-X
substantially	B-X
from	B-X
other	B-X
eukaryotes	B-X
.	B-X
Furthermore	B-X
,	B-X
protein-coding	B-X
genes	B-X
in	B-X
these	B-X
organisms	B-X
lack	B-X
individual	B-X
transcriptional	B-X
regulation	B-X
,	B-X
since	B-X
they	B-X
are	B-X
transcribed	B-X
as	B-X
long	B-X
polycistronic	B-X
units	B-X
.	B-X
The	B-X
transcription	B-X
initiation	B-X
sites	B-X
are	B-X
assumed	B-X
to	B-X
lie	B-X
within	B-X
the	B-X
'divergent	B-X
strand-switch	B-X
'	B-X
regions	B-X
at	B-X
the	B-X
junction	B-X
between	B-X
opposing	B-X
polycistronic	B-X
gene	B-X
clusters	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
Kinetoplastidae	B-X
initiate	B-X
transcription	B-X
is	B-X
unclear	B-X
,	B-X
and	B-X
promoter	B-X
sequences	B-X
are	B-X
undefined	B-X
.	B-X

Secretion	O
of	O
human	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
from	O
Saccharomyces	O
cerevisiae	O
using	O
synthetic	O
leader	O
sequences	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
different	B-X
leader	B-X
sequences	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
direct	B-X
the	B-X
efficient	B-X
secretion	B-X
of	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
hEGF	B-X
)	B-X
from	B-X
Saccharomyces	B-X
cerevisiae	B-X
.	B-X
However	B-X
,	B-X
secretion	B-X
is	B-X
increased	B-X
over	B-X
fivefold	B-X
by	B-X
the	B-X
introduction	B-X
,	B-X
after	B-X
the	B-X
signal	B-X
sequence	B-X
,	B-X
of	B-X
a	B-X
synthetic	B-X
19-amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
pro-sequence	B-X
containing	B-X
a	B-X
cleavage	B-X
recognition	B-X
site	B-X
for	B-X
the	B-X
KEX2	B-X
protease	B-X
.	B-X
Even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
Asn-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
secretion	B-X
of	B-X
hEGF	B-X
using	B-X
the	B-X
synthetic	B-X
prepro-leader	B-X
was	B-X
as	B-X
efficient	B-X
as	B-X
that	B-X
directed	B-X
by	B-X
the	B-X
alpha-factor	B-X
leader	B-X
.	B-X
The	B-X
role	B-X
of	B-X
the	B-X
KEX2	B-X
protease	B-X
cleavage	B-X
site	B-X
was	B-X
investigated	B-X
by	B-X
mutation	B-X
of	B-X
the	B-X
yeast	B-X
alpha-factor	B-X
KEX2	B-X
site	B-X
(	B-X
cleavage	B-X
after	B-X
Lys-Arg	B-X
)	B-X
.	B-X

We	O
have	O
investigated	O
different	O
leader	O
sequences	O
for	O
their	O
ability	O
to	O
direct	O
the	O
efficient	O
secretion	O
of	O
human	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
(	O
hEGF	B-Protein
)	O
from	O
Saccharomyces	O
cerevisiae	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
different	B-X
leader	B-X
sequences	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
direct	B-X
the	B-X
efficient	B-X
secretion	B-X
of	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
hEGF	B-X
)	B-X
from	B-X
Saccharomyces	B-X
cerevisiae	B-X
.	B-X
We	B-X
designed	B-X
a	B-X
consensus	B-X
signal	B-X
sequence	B-X
which	B-X
directs	B-X
secretion	B-X
of	B-X
hEGF	B-X
from	B-X
yeast	B-X
as	B-X
efficiently	B-X
as	B-X
the	B-X
yeast	B-X
invertase	B-X
signal	B-X
sequence	B-X
.	B-X
However	B-X
,	B-X
secretion	B-X
is	B-X
increased	B-X
over	B-X
fivefold	B-X
by	B-X
the	B-X
introduction	B-X
,	B-X
after	B-X
the	B-X
signal	B-X
sequence	B-X
,	B-X
of	B-X
a	B-X
synthetic	B-X
19-amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
pro-sequence	B-X
containing	B-X
a	B-X
cleavage	B-X
recognition	B-X
site	B-X
for	B-X
the	B-X
KEX2	B-X
protease	B-X
.	B-X
Even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
Asn-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
secretion	B-X
of	B-X
hEGF	B-X
using	B-X
the	B-X
synthetic	B-X
prepro-leader	B-X
was	B-X
as	B-X
efficient	B-X
as	B-X
that	B-X
directed	B-X
by	B-X
the	B-X
alpha-factor	B-X
leader	B-X
.	B-X
The	B-X
role	B-X
of	B-X
the	B-X
KEX2	B-X
protease	B-X
cleavage	B-X
site	B-X
was	B-X
investigated	B-X
by	B-X
mutation	B-X
of	B-X
the	B-X
yeast	B-X
alpha-factor	B-X
KEX2	B-X
site	B-X
(	B-X
cleavage	B-X
after	B-X
Lys-Arg	B-X
)	B-X
.	B-X

We	O
designed	O
a	O
consensus	O
signal	O
sequence	O
which	O
directs	O
secretion	O
of	O
hEGF	B-Protein
from	O
yeast	O
as	O
efficiently	O
as	O
the	O
yeast	O
invertase	O
signal	O
sequence	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
different	B-X
leader	B-X
sequences	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
direct	B-X
the	B-X
efficient	B-X
secretion	B-X
of	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
hEGF	B-X
)	B-X
from	B-X
Saccharomyces	B-X
cerevisiae	B-X
.	B-X
We	B-X
designed	B-X
a	B-X
consensus	B-X
signal	B-X
sequence	B-X
which	B-X
directs	B-X
secretion	B-X
of	B-X
hEGF	B-X
from	B-X
yeast	B-X
as	B-X
efficiently	B-X
as	B-X
the	B-X
yeast	B-X
invertase	B-X
signal	B-X
sequence	B-X
.	B-X
However	B-X
,	B-X
secretion	B-X
is	B-X
increased	B-X
over	B-X
fivefold	B-X
by	B-X
the	B-X
introduction	B-X
,	B-X
after	B-X
the	B-X
signal	B-X
sequence	B-X
,	B-X
of	B-X
a	B-X
synthetic	B-X
19-amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
pro-sequence	B-X
containing	B-X
a	B-X
cleavage	B-X
recognition	B-X
site	B-X
for	B-X
the	B-X
KEX2	B-X
protease	B-X
.	B-X
Even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
Asn-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
secretion	B-X
of	B-X
hEGF	B-X
using	B-X
the	B-X
synthetic	B-X
prepro-leader	B-X
was	B-X
as	B-X
efficient	B-X
as	B-X
that	B-X
directed	B-X
by	B-X
the	B-X
alpha-factor	B-X
leader	B-X
.	B-X
The	B-X
role	B-X
of	B-X
the	B-X
KEX2	B-X
protease	B-X
cleavage	B-X
site	B-X
was	B-X
investigated	B-X
by	B-X
mutation	B-X
of	B-X
the	B-X
yeast	B-X
alpha-factor	B-X
KEX2	B-X
site	B-X
(	B-X
cleavage	B-X
after	B-X
Lys-Arg	B-X
)	B-X
.	B-X
Cleavage	B-X
was	B-X
obtained	B-X
with	B-X
the	B-X
following	B-X
order	B-X
of	B-X
efficiency	B-X
,	B-X
Lys-Arg	B-X
greater	B-X
than	B-X
Pro-Arg	B-X
greater	B-X
than	B-X
Asp-Arg	B-X
,	B-X
although	B-X
the	B-X
sequence	B-X
context	B-X
was	B-X
also	B-X
found	B-X
to	B-X
affect	B-X
efficiency	B-X
.	B-X

However	O
,	O
secretion	O
is	O
increased	O
over	O
fivefold	O
by	O
the	O
introduction	O
,	O
after	O
the	O
signal	O
sequence	O
,	O
of	O
a	O
synthetic	O
19	O
-	O
amino	O
acid	O
(	O
aa	O
)	O
pro	O
-	O
sequence	O
containing	O
a	O
cleavage	O
recognition	O
site	O
for	O
the	O
KEX2	B-Protein
protease	O
.	O

Even	O
in	O
the	O
absence	O
of	O
an	O
Asn	O
-	O
linked	O
glycosylation	O
site	O
,	O
secretion	O
of	O
hEGF	B-Protein
using	O
the	O
synthetic	O
prepro	O
-	O
leader	O
was	O
as	O
efficient	O
as	O
that	O
directed	O
by	O
the	O
alpha	O
-	O
factor	O
leader	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
different	B-X
leader	B-X
sequences	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
direct	B-X
the	B-X
efficient	B-X
secretion	B-X
of	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
hEGF	B-X
)	B-X
from	B-X
Saccharomyces	B-X
cerevisiae	B-X
.	B-X
We	B-X
designed	B-X
a	B-X
consensus	B-X
signal	B-X
sequence	B-X
which	B-X
directs	B-X
secretion	B-X
of	B-X
hEGF	B-X
from	B-X
yeast	B-X
as	B-X
efficiently	B-X
as	B-X
the	B-X
yeast	B-X
invertase	B-X
signal	B-X
sequence	B-X
.	B-X
However	B-X
,	B-X
secretion	B-X
is	B-X
increased	B-X
over	B-X
fivefold	B-X
by	B-X
the	B-X
introduction	B-X
,	B-X
after	B-X
the	B-X
signal	B-X
sequence	B-X
,	B-X
of	B-X
a	B-X
synthetic	B-X
19-amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
pro-sequence	B-X
containing	B-X
a	B-X
cleavage	B-X
recognition	B-X
site	B-X
for	B-X
the	B-X
KEX2	B-X
protease	B-X
.	B-X
Even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
Asn-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
secretion	B-X
of	B-X
hEGF	B-X
using	B-X
the	B-X
synthetic	B-X
prepro-leader	B-X
was	B-X
as	B-X
efficient	B-X
as	B-X
that	B-X
directed	B-X
by	B-X
the	B-X
alpha-factor	B-X
leader	B-X
.	B-X
The	B-X
role	B-X
of	B-X
the	B-X
KEX2	B-X
protease	B-X
cleavage	B-X
site	B-X
was	B-X
investigated	B-X
by	B-X
mutation	B-X
of	B-X
the	B-X
yeast	B-X
alpha-factor	B-X
KEX2	B-X
site	B-X
(	B-X
cleavage	B-X
after	B-X
Lys-Arg	B-X
)	B-X
.	B-X

The	O
role	O
of	O
the	O
KEX2	B-Protein
protease	O
cleavage	O
site	O
was	O
investigated	O
by	O
mutation	O
of	O
the	O
yeast	O
alpha	O
-	O
factor	O
KEX2	B-Protein
site	O
(	O
cleavage	O
after	O
Lys	O
-	O
Arg	O
)	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
different	B-X
leader	B-X
sequences	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
direct	B-X
the	B-X
efficient	B-X
secretion	B-X
of	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
hEGF	B-X
)	B-X
from	B-X
Saccharomyces	B-X
cerevisiae	B-X
.	B-X
We	B-X
designed	B-X
a	B-X
consensus	B-X
signal	B-X
sequence	B-X
which	B-X
directs	B-X
secretion	B-X
of	B-X
hEGF	B-X
from	B-X
yeast	B-X
as	B-X
efficiently	B-X
as	B-X
the	B-X
yeast	B-X
invertase	B-X
signal	B-X
sequence	B-X
.	B-X
However	B-X
,	B-X
secretion	B-X
is	B-X
increased	B-X
over	B-X
fivefold	B-X
by	B-X
the	B-X
introduction	B-X
,	B-X
after	B-X
the	B-X
signal	B-X
sequence	B-X
,	B-X
of	B-X
a	B-X
synthetic	B-X
19-amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
pro-sequence	B-X
containing	B-X
a	B-X
cleavage	B-X
recognition	B-X
site	B-X
for	B-X
the	B-X
KEX2	B-X
protease	B-X
.	B-X
Even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
Asn-linked	B-X
glycosylation	B-X
site	B-X
,	B-X
secretion	B-X
of	B-X
hEGF	B-X
using	B-X
the	B-X
synthetic	B-X
prepro-leader	B-X
was	B-X
as	B-X
efficient	B-X
as	B-X
that	B-X
directed	B-X
by	B-X
the	B-X
alpha-factor	B-X
leader	B-X
.	B-X
The	B-X
role	B-X
of	B-X
the	B-X
KEX2	B-X
protease	B-X
cleavage	B-X
site	B-X
was	B-X
investigated	B-X
by	B-X
mutation	B-X
of	B-X
the	B-X
yeast	B-X
alpha-factor	B-X
KEX2	B-X
site	B-X
(	B-X
cleavage	B-X
after	B-X
Lys-Arg	B-X
)	B-X
.	B-X
Cleavage	B-X
was	B-X
obtained	B-X
with	B-X
the	B-X
following	B-X
order	B-X
of	B-X
efficiency	B-X
,	B-X
Lys-Arg	B-X
greater	B-X
than	B-X
Pro-Arg	B-X
greater	B-X
than	B-X
Asp-Arg	B-X
,	B-X
although	B-X
the	B-X
sequence	B-X
context	B-X
was	B-X
also	B-X
found	B-X
to	B-X
affect	B-X
efficiency	B-X
.	B-X

Cleavage	O
was	O
obtained	O
with	O
the	O
following	O
order	O
of	O
efficiency	O
,	O
Lys	O
-	O
Arg	O
greater	O
than	O
Pro	O
-	O
Arg	O
greater	O
than	O
Asp	O
-	O
Arg	O
,	O
although	O
the	O
sequence	O
context	O
was	O
also	O
found	O
to	O
affect	O
efficiency	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
different	B-X
leader	B-X
sequences	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
direct	B-X
the	B-X
efficient	B-X
secretion	B-X
of	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
hEGF	B-X
)	B-X
from	B-X
Saccharomyces	B-X
cerevisiae	B-X
.	B-X
We	B-X
designed	B-X
a	B-X
consensus	B-X
signal	B-X
sequence	B-X
which	B-X
directs	B-X
secretion	B-X
of	B-X
hEGF	B-X
from	B-X
yeast	B-X
as	B-X
efficiently	B-X
as	B-X
the	B-X
yeast	B-X
invertase	B-X
signal	B-X
sequence	B-X
.	B-X
However	B-X
,	B-X
secretion	B-X
is	B-X
increased	B-X
over	B-X
fivefold	B-X
by	B-X
the	B-X
introduction	B-X
,	B-X
after	B-X
the	B-X
signal	B-X
sequence	B-X
,	B-X
of	B-X
a	B-X
synthetic	B-X
19-amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
pro-sequence	B-X
containing	B-X
a	B-X
cleavage	B-X
recognition	B-X
site	B-X
for	B-X
the	B-X
KEX2	B-X
protease	B-X
.	B-X
The	B-X
role	B-X
of	B-X
the	B-X
KEX2	B-X
protease	B-X
cleavage	B-X
site	B-X
was	B-X
investigated	B-X
by	B-X
mutation	B-X
of	B-X
the	B-X
yeast	B-X
alpha-factor	B-X
KEX2	B-X
site	B-X
(	B-X
cleavage	B-X
after	B-X
Lys-Arg	B-X
)	B-X
.	B-X
Cleavage	B-X
was	B-X
obtained	B-X
with	B-X
the	B-X
following	B-X
order	B-X
of	B-X
efficiency	B-X
,	B-X
Lys-Arg	B-X
greater	B-X
than	B-X
Pro-Arg	B-X
greater	B-X
than	B-X
Asp-Arg	B-X
,	B-X
although	B-X
the	B-X
sequence	B-X
context	B-X
was	B-X
also	B-X
found	B-X
to	B-X
affect	B-X
efficiency	B-X
.	B-X

CYLD	B-Protein
:	O
a	O
tumor	O
suppressor	O
deubiquitinase	O
regulating	O
NF	O
-	O
kappaB	O
activation	O
and	O
diverse	O
biological	O
processes	O
.	O
<EOS>	B-X
Protein	B-X
ubiquitination	B-X
is	B-X
a	B-X
reversible	B-X
reaction	B-X
,	B-X
in	B-X
which	B-X
the	B-X
ubiquitin	B-X
chains	B-X
are	B-X
deconjugated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
deubiquitinases	B-X
(	B-X
DUBs	B-X
)	B-X
.	B-X
Indeed	B-X
,	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
a	B-X
tumor	B-X
suppressor	B-X
DUB	B-X
,	B-X
cylindromatosis	B-X
(	B-X
CYLD	B-X
)	B-X
,	B-X
has	B-X
a	B-X
predominant	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
promotes	B-X
cell	B-X
survival	B-X
and	B-X
oncogenesis	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
involves	B-X
attachment	B-X
of	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
to	B-X
its	B-X
upstream	B-X
signaling	B-X
factors	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
facilitate	B-X
protein-protein	B-X
interactions	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
signaling	B-X
complexes	B-X
.	B-X
By	B-X
deconjugating	B-X
these	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
,	B-X
CYLD	B-X
negatively	B-X
regulates	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
tumor	B-X
suppressor	B-X
function	B-X
.	B-X
CYLD	B-X
also	B-X
regulates	B-X
diverse	B-X
physiological	B-X
processes	B-X
,	B-X
ranging	B-X
from	B-X
immune	B-X
response	B-X
and	B-X
inflammation	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
spermatogenesis	B-X
,	B-X
and	B-X
osteoclastogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
CYLD	B-X
itself	B-X
is	B-X
subject	B-X
to	B-X
different	B-X
mechanisms	B-X
of	B-X
regulation	B-X
.	B-X

Protein	O
ubiquitination	O
is	O
a	O
reversible	O
reaction	O
,	O
in	O
which	O
the	O
ubiquitin	B-Protein
chains	O
are	O
deconjugated	O
by	O
a	O
family	O
of	O
deubiquitinases	O
(	O
DUBs	O
)	O
.	O
<EOS>	B-X
Protein	B-X
ubiquitination	B-X
is	B-X
a	B-X
reversible	B-X
reaction	B-X
,	B-X
in	B-X
which	B-X
the	B-X
ubiquitin	B-X
chains	B-X
are	B-X
deconjugated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
deubiquitinases	B-X
(	B-X
DUBs	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
large	B-X
number	B-X
of	B-X
DUBs	B-X
suggests	B-X
that	B-X
they	B-X
likely	B-X
possess	B-X
certain	B-X
levels	B-X
of	B-X
substrate	B-X
selectivity	B-X
and	B-X
functional	B-X
specificity	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
involves	B-X
attachment	B-X
of	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
to	B-X
its	B-X
upstream	B-X
signaling	B-X
factors	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
facilitate	B-X
protein-protein	B-X
interactions	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
signaling	B-X
complexes	B-X
.	B-X
By	B-X
deconjugating	B-X
these	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
,	B-X
CYLD	B-X
negatively	B-X
regulates	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
tumor	B-X
suppressor	B-X
function	B-X
.	B-X

The	O
presence	O
of	O
a	O
large	O
number	O
of	O
DUBs	O
suggests	O
that	O
they	O
likely	O
possess	O
certain	O
levels	O
of	O
substrate	O
selectivity	O
and	O
functional	O
specificity	O
.	O
<EOS>	B-X
Protein	B-X
ubiquitination	B-X
is	B-X
a	B-X
reversible	B-X
reaction	B-X
,	B-X
in	B-X
which	B-X
the	B-X
ubiquitin	B-X
chains	B-X
are	B-X
deconjugated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
deubiquitinases	B-X
(	B-X
DUBs	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
large	B-X
number	B-X
of	B-X
DUBs	B-X
suggests	B-X
that	B-X
they	B-X
likely	B-X
possess	B-X
certain	B-X
levels	B-X
of	B-X
substrate	B-X
selectivity	B-X
and	B-X
functional	B-X
specificity	B-X
.	B-X

Indeed	O
,	O
recent	O
studies	O
show	O
that	O
a	O
tumor	O
suppressor	O
DUB	O
,	O
cylindromatosis	B-Protein
(	O
CYLD	B-Protein
)	O
,	O
has	O
a	O
predominant	O
role	O
in	O
the	O
regulation	O
of	O
NF	O
-	O
kappaB	O
,	O
a	O
transcription	O
factor	O
that	O
promotes	O
cell	O
survival	O
and	O
oncogenesis	O
.	O

NF	O
-	O
kappaB	O
activation	O
involves	O
attachment	O
of	O
K63	O
-	O
linked	O
ubiquitin	B-Protein
chains	O
to	O
its	O
upstream	O
signaling	O
factors	O
,	O
which	O
is	O
thought	O
to	O
facilitate	O
protein	O
-	O
protein	O
interactions	O
in	O
the	O
assembly	O
of	O
signaling	O
complexes	O
.	O
<EOS>	B-X
Protein	B-X
ubiquitination	B-X
is	B-X
a	B-X
reversible	B-X
reaction	B-X
,	B-X
in	B-X
which	B-X
the	B-X
ubiquitin	B-X
chains	B-X
are	B-X
deconjugated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
deubiquitinases	B-X
(	B-X
DUBs	B-X
)	B-X
.	B-X
Indeed	B-X
,	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
a	B-X
tumor	B-X
suppressor	B-X
DUB	B-X
,	B-X
cylindromatosis	B-X
(	B-X
CYLD	B-X
)	B-X
,	B-X
has	B-X
a	B-X
predominant	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
promotes	B-X
cell	B-X
survival	B-X
and	B-X
oncogenesis	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
involves	B-X
attachment	B-X
of	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
to	B-X
its	B-X
upstream	B-X
signaling	B-X
factors	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
facilitate	B-X
protein-protein	B-X
interactions	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
signaling	B-X
complexes	B-X
.	B-X
By	B-X
deconjugating	B-X
these	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
,	B-X
CYLD	B-X
negatively	B-X
regulates	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
tumor	B-X
suppressor	B-X
function	B-X
.	B-X

By	O
deconjugating	O
these	O
K63	O
-	O
linked	O
ubiquitin	B-Protein
chains	O
,	O
CYLD	B-Protein
negatively	O
regulates	O
NF	O
-	O
kappaB	O
activation	O
,	O
which	O
may	O
contribute	O
to	O
its	O
tumor	O
suppressor	O
function	O
.	O
<EOS>	B-X
Protein	B-X
ubiquitination	B-X
is	B-X
a	B-X
reversible	B-X
reaction	B-X
,	B-X
in	B-X
which	B-X
the	B-X
ubiquitin	B-X
chains	B-X
are	B-X
deconjugated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
deubiquitinases	B-X
(	B-X
DUBs	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
large	B-X
number	B-X
of	B-X
DUBs	B-X
suggests	B-X
that	B-X
they	B-X
likely	B-X
possess	B-X
certain	B-X
levels	B-X
of	B-X
substrate	B-X
selectivity	B-X
and	B-X
functional	B-X
specificity	B-X
.	B-X
Indeed	B-X
,	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
a	B-X
tumor	B-X
suppressor	B-X
DUB	B-X
,	B-X
cylindromatosis	B-X
(	B-X
CYLD	B-X
)	B-X
,	B-X
has	B-X
a	B-X
predominant	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
promotes	B-X
cell	B-X
survival	B-X
and	B-X
oncogenesis	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
involves	B-X
attachment	B-X
of	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
to	B-X
its	B-X
upstream	B-X
signaling	B-X
factors	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
facilitate	B-X
protein-protein	B-X
interactions	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
signaling	B-X
complexes	B-X
.	B-X
By	B-X
deconjugating	B-X
these	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
,	B-X
CYLD	B-X
negatively	B-X
regulates	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
tumor	B-X
suppressor	B-X
function	B-X
.	B-X
CYLD	B-X
also	B-X
regulates	B-X
diverse	B-X
physiological	B-X
processes	B-X
,	B-X
ranging	B-X
from	B-X
immune	B-X
response	B-X
and	B-X
inflammation	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
spermatogenesis	B-X
,	B-X
and	B-X
osteoclastogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
CYLD	B-X
itself	B-X
is	B-X
subject	B-X
to	B-X
different	B-X
mechanisms	B-X
of	B-X
regulation	B-X
.	B-X

CYLD	B-Protein
also	O
regulates	O
diverse	O
physiological	O
processes	O
,	O
ranging	O
from	O
immune	O
response	O
and	O
inflammation	O
to	O
cell	O
cycle	O
progression	O
,	O
spermatogenesis	O
,	O
and	O
osteoclastogenesis	O
.	O
<EOS>	B-X
Indeed	B-X
,	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
a	B-X
tumor	B-X
suppressor	B-X
DUB	B-X
,	B-X
cylindromatosis	B-X
(	B-X
CYLD	B-X
)	B-X
,	B-X
has	B-X
a	B-X
predominant	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
promotes	B-X
cell	B-X
survival	B-X
and	B-X
oncogenesis	B-X
.	B-X
By	B-X
deconjugating	B-X
these	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
,	B-X
CYLD	B-X
negatively	B-X
regulates	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
tumor	B-X
suppressor	B-X
function	B-X
.	B-X
CYLD	B-X
also	B-X
regulates	B-X
diverse	B-X
physiological	B-X
processes	B-X
,	B-X
ranging	B-X
from	B-X
immune	B-X
response	B-X
and	B-X
inflammation	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
spermatogenesis	B-X
,	B-X
and	B-X
osteoclastogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
CYLD	B-X
itself	B-X
is	B-X
subject	B-X
to	B-X
different	B-X
mechanisms	B-X
of	B-X
regulation	B-X
.	B-X

Interestingly	O
,	O
CYLD	B-Protein
itself	O
is	O
subject	O
to	O
different	O
mechanisms	O
of	O
regulation	O
.	O
<EOS>	B-X
Indeed	B-X
,	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
a	B-X
tumor	B-X
suppressor	B-X
DUB	B-X
,	B-X
cylindromatosis	B-X
(	B-X
CYLD	B-X
)	B-X
,	B-X
has	B-X
a	B-X
predominant	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
promotes	B-X
cell	B-X
survival	B-X
and	B-X
oncogenesis	B-X
.	B-X
By	B-X
deconjugating	B-X
these	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
,	B-X
CYLD	B-X
negatively	B-X
regulates	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
tumor	B-X
suppressor	B-X
function	B-X
.	B-X
CYLD	B-X
also	B-X
regulates	B-X
diverse	B-X
physiological	B-X
processes	B-X
,	B-X
ranging	B-X
from	B-X
immune	B-X
response	B-X
and	B-X
inflammation	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
spermatogenesis	B-X
,	B-X
and	B-X
osteoclastogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
CYLD	B-X
itself	B-X
is	B-X
subject	B-X
to	B-X
different	B-X
mechanisms	B-X
of	B-X
regulation	B-X
.	B-X

LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
is	O
targeted	O
to	O
different	O
subcellular	O
compartments	O
by	O
ubiquitinylation	O
and	O
intrinsic	O
nuclear	O
localization	O
signals	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

PURPOSE	O
:	O
LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
reported	O
to	O
influence	O
breast	O
cancer	O
survival	O
and	O
metastases	O
,	O
and	O
its	O
altered	O
expression	O
has	O
been	O
found	O
in	O
a	O
number	O
of	O
cancers	O
.	O

The	O
cellular	O
function	O
of	O
LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
has	O
previously	O
been	O
related	O
to	O
its	O
subcellular	O
distribution	O
in	O
cell	O
lines	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
contains	O
three	O
uncharacterized	O
nuclear	O
localization	O
signals	O
(	O
NLS	O
)	O
,	O
which	O
may	O
regulate	O
its	O
distribution	O
and	O
,	O
ultimately	O
,	O
function	O
in	O
cells	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

EXPERIMENTAL	O
DESIGN	O
:	O
Immunohistochemistry	O
of	O
a	O
human	O
prostate	O
tissue	O
microarray	O
composed	O
of	O
179	O
prostate	O
cancer	O
and	O
24	O
benign	O
samples	O
was	O
used	O
to	O
assess	O
LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
distribution	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

Green	B-Protein
fluorescent	I-Protein
protein	I-Protein
-	O
NLS	O
fusion	O
proteins	O
and	O
deletion	O
constructs	O
were	O
used	O
to	O
show	O
the	O
ability	O
of	O
LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
NLS	O
to	O
target	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O

Immunoprecipitation	O
and	O
Western	O
blotting	O
were	O
used	O
to	O
show	O
posttranslational	O
modification	O
of	O
LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
NLS	O
regions	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

RESULTS	O
:	O
Using	O
a	O
prostate	O
tissue	O
microarray	O
,	O
significant	O
changes	O
in	O
the	O
distribution	O
of	O
LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
were	O
observed	O
in	O
prostate	O
cancer	O
as	O
an	O
increased	O
cytoplasmic	O
distribution	O
in	O
tumors	O
compared	O
with	O
benign	O
tissue	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

These	O
differences	O
were	O
most	O
marked	O
in	O
high	O
grade	O
and	O
aggressive	O
prostate	O
cancers	O
and	O
were	O
associated	O
with	O
decreased	O
survival	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X

The	O
COOH	O
-	O
terminal	O
extended	O
NLS	O
-	O
3	O
(	O
amino	O
acids	O
546	O
-	O
582	O
)	O
is	O
the	O
predominant	O
regulator	O
of	O
nuclear	O
localization	O
,	O
whereas	O
extended	O
NLS	O
-	O
1	O
(	O
amino	O
acids	O
78	O
-	O
130	O
)	O
regulates	O
its	O
nucleolar	O
localization	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

Within	O
the	O
extended	O
NLS	O
-	O
2	O
region	O
(	O
amino	O
acids	O
415	O
-	O
486	O
)	O
,	O
LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
can	O
be	O
modified	O
by	O
ubiquitin	B-Protein
almost	O
exclusively	O
within	O
the	O
cytoplasm	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

CONCLUSIONS	O
:	O
Changes	O
in	O
LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
subcellular	O
distribution	O
can	O
predict	O
Gleason	O
grade	O
and	O
survival	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

Two	O
lysine	O
-	O
rich	O
regions	O
(	O
NLS	O
-	O
1	O
and	O
NLS	O
-	O
3	O
)	O
can	O
target	O
LYRIC	B-Protein
/	O
AEG	B-Protein
-	I-Protein
1	I-Protein
to	O
subcellular	O
compartments	O
whereas	O
NLS	O
-	O
2	O
is	O
modified	O
by	O
ubiquitin	B-Protein
in	O
the	O
cytoplasm	O
.	O
<EOS>	B-X
LYRIC/AEG-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
influence	B-X
breast	B-X
cancer	B-X
survival	B-X
and	B-X
metastases	B-X
,	B-X
and	B-X
its	B-X
altered	B-X
expression	B-X
has	B-X
been	B-X
found	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
cellular	B-X
function	B-X
of	B-X
LYRIC/AEG-1	B-X
has	B-X
previously	B-X
been	B-X
related	B-X
to	B-X
its	B-X
subcellular	B-X
distribution	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
LYRIC/AEG-1	B-X
contains	B-X
three	B-X
uncharacterized	B-X
nuclear	B-X
localization	B-X
signals	B-X
(	B-X
NLS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
regulate	B-X
its	B-X
distribution	B-X
and	B-X
,	B-X
ultimately	B-X
,	B-X
function	B-X
in	B-X
cells	B-X
.	B-X

Bile	O
acid	O
signaling	O
pathways	O
increase	O
stability	O
of	O
Small	B-Protein
Heterodimer	I-Protein
Partner	I-Protein
(	O
SHP	B-Protein
)	O
by	O
inhibiting	O
ubiquitin	B-Protein
-	O
proteasomal	O
degradation	O
.	O
<EOS>	B-X
Small	B-X
Heterodimer	B-X
Partner	B-X
(	B-X
SHP	B-X
)	B-X
inhibits	B-X
activities	B-X
of	B-X
numerous	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
pathways	B-X
.	B-X
As	B-X
an	B-X
important	B-X
metabolic	B-X
regulator	B-X
,	B-X
SHP	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
maintaining	B-X
cholesterol	B-X
and	B-X
bile	B-X
acid	B-X
homeostasis	B-X
by	B-X
inhibiting	B-X
cholesterol	B-X
conversion	B-X
to	B-X
bile	B-X
acids	B-X
.	B-X
While	B-X
SHP	B-X
gene	B-X
induction	B-X
by	B-X
increased	B-X
bile	B-X
acids	B-X
is	B-X
well	B-X
established	B-X
,	B-X
whether	B-X
SHP	B-X
activity	B-X
is	B-X
also	B-X
modulated	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
surprising	B-X
findings	B-X
that	B-X
SHP	B-X
is	B-X
a	B-X
rapidly	B-X
degraded	B-X
protein	B-X
via	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
and	B-X
that	B-X
bile	B-X
acids	B-X
or	B-X
bile	B-X
acid-induced	B-X
intestinal	B-X
fibroblast	B-X
growth	B-X
factor	B-X
19	B-X
(	B-X
FGF19	B-X
)	B-X
increases	B-X
stability	B-X
of	B-X
hepatic	B-X
SHP	B-X
by	B-X
inhibiting	B-X
proteasomal	B-X
degradation	B-X
in	B-X
an	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
SHP	B-X
was	B-X
ubiquitinated	B-X
at	B-X
Lys122	B-X
and	B-X
Lys123	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
these	B-X
sites	B-X
altered	B-X
its	B-X
stability	B-X
and	B-X
repression	B-X
activity	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
upon	B-X
bile	B-X
acid	B-X
treatment	B-X
,	B-X
SHP	B-X
was	B-X
phosphorylated	B-X
at	B-X
Ser26	B-X
,	B-X
within	B-X
an	B-X
ERK	B-X
motif	B-X
in	B-X
SHP	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
dramatically	B-X
abolished	B-X
SHP	B-X
stability	B-X
.	B-X
Surprisingly	B-X
,	B-X
SHP	B-X
stability	B-X
was	B-X
abnormally	B-X
elevated	B-X
in	B-X
ob/ob	B-X
mice	B-X
and	B-X
diet-induced	B-X
obese	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
important	B-X
role	B-X
for	B-X
regulation	B-X
of	B-X
SHP	B-X
stability	B-X
in	B-X
bile	B-X
acid	B-X
signaling	B-X
in	B-X
normal	B-X
conditions	B-X
,	B-X
and	B-X
that	B-X
abnormal	B-X
stabilization	B-X
of	B-X
SHP	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
metabolic	B-X
disorders	B-X
,	B-X
including	B-X
obesity	B-X
and	B-X
diabetes	B-X
.	B-X

Small	B-Protein
Heterodimer	I-Protein
Partner	I-Protein
(	O
SHP	B-Protein
)	O
inhibits	O
activities	O
of	O
numerous	O
transcription	O
factors	O
involved	O
in	O
diverse	O
biological	O
pathways	O
.	O
<EOS>	B-X
Small	B-X
Heterodimer	B-X
Partner	B-X
(	B-X
SHP	B-X
)	B-X
inhibits	B-X
activities	B-X
of	B-X
numerous	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
pathways	B-X
.	B-X
As	B-X
an	B-X
important	B-X
metabolic	B-X
regulator	B-X
,	B-X
SHP	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
maintaining	B-X
cholesterol	B-X
and	B-X
bile	B-X
acid	B-X
homeostasis	B-X
by	B-X
inhibiting	B-X
cholesterol	B-X
conversion	B-X
to	B-X
bile	B-X
acids	B-X
.	B-X
While	B-X
SHP	B-X
gene	B-X
induction	B-X
by	B-X
increased	B-X
bile	B-X
acids	B-X
is	B-X
well	B-X
established	B-X
,	B-X
whether	B-X
SHP	B-X
activity	B-X
is	B-X
also	B-X
modulated	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
surprising	B-X
findings	B-X
that	B-X
SHP	B-X
is	B-X
a	B-X
rapidly	B-X
degraded	B-X
protein	B-X
via	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
and	B-X
that	B-X
bile	B-X
acids	B-X
or	B-X
bile	B-X
acid-induced	B-X
intestinal	B-X
fibroblast	B-X
growth	B-X
factor	B-X
19	B-X
(	B-X
FGF19	B-X
)	B-X
increases	B-X
stability	B-X
of	B-X
hepatic	B-X
SHP	B-X
by	B-X
inhibiting	B-X
proteasomal	B-X
degradation	B-X
in	B-X
an	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
SHP	B-X
was	B-X
ubiquitinated	B-X
at	B-X
Lys122	B-X
and	B-X
Lys123	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
these	B-X
sites	B-X
altered	B-X
its	B-X
stability	B-X
and	B-X
repression	B-X
activity	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
upon	B-X
bile	B-X
acid	B-X
treatment	B-X
,	B-X
SHP	B-X
was	B-X
phosphorylated	B-X
at	B-X
Ser26	B-X
,	B-X
within	B-X
an	B-X
ERK	B-X
motif	B-X
in	B-X
SHP	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
dramatically	B-X
abolished	B-X
SHP	B-X
stability	B-X
.	B-X
Surprisingly	B-X
,	B-X
SHP	B-X
stability	B-X
was	B-X
abnormally	B-X
elevated	B-X
in	B-X
ob/ob	B-X
mice	B-X
and	B-X
diet-induced	B-X
obese	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
important	B-X
role	B-X
for	B-X
regulation	B-X
of	B-X
SHP	B-X
stability	B-X
in	B-X
bile	B-X
acid	B-X
signaling	B-X
in	B-X
normal	B-X
conditions	B-X
,	B-X
and	B-X
that	B-X
abnormal	B-X
stabilization	B-X
of	B-X
SHP	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
metabolic	B-X
disorders	B-X
,	B-X
including	B-X
obesity	B-X
and	B-X
diabetes	B-X
.	B-X

As	O
an	O
important	O
metabolic	O
regulator	O
,	O
SHP	B-Protein
plays	O
a	O
key	O
role	O
in	O
maintaining	O
cholesterol	O
and	O
bile	O
acid	O
homeostasis	O
by	O
inhibiting	O
cholesterol	O
conversion	O
to	O
bile	O
acids	O
.	O

While	O
SHP	B-Protein
gene	O
induction	O
by	O
increased	O
bile	O
acids	O
is	O
well	O
established	O
,	O
whether	O
SHP	B-Protein
activity	O
is	O
also	O
modulated	O
remains	O
unknown	O
.	O
<EOS>	B-X
Small	B-X
Heterodimer	B-X
Partner	B-X
(	B-X
SHP	B-X
)	B-X
inhibits	B-X
activities	B-X
of	B-X
numerous	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
pathways	B-X
.	B-X
As	B-X
an	B-X
important	B-X
metabolic	B-X
regulator	B-X
,	B-X
SHP	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
maintaining	B-X
cholesterol	B-X
and	B-X
bile	B-X
acid	B-X
homeostasis	B-X
by	B-X
inhibiting	B-X
cholesterol	B-X
conversion	B-X
to	B-X
bile	B-X
acids	B-X
.	B-X
While	B-X
SHP	B-X
gene	B-X
induction	B-X
by	B-X
increased	B-X
bile	B-X
acids	B-X
is	B-X
well	B-X
established	B-X
,	B-X
whether	B-X
SHP	B-X
activity	B-X
is	B-X
also	B-X
modulated	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
surprising	B-X
findings	B-X
that	B-X
SHP	B-X
is	B-X
a	B-X
rapidly	B-X
degraded	B-X
protein	B-X
via	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
and	B-X
that	B-X
bile	B-X
acids	B-X
or	B-X
bile	B-X
acid-induced	B-X
intestinal	B-X
fibroblast	B-X
growth	B-X
factor	B-X
19	B-X
(	B-X
FGF19	B-X
)	B-X
increases	B-X
stability	B-X
of	B-X
hepatic	B-X
SHP	B-X
by	B-X
inhibiting	B-X
proteasomal	B-X
degradation	B-X
in	B-X
an	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
SHP	B-X
was	B-X
ubiquitinated	B-X
at	B-X
Lys122	B-X
and	B-X
Lys123	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
these	B-X
sites	B-X
altered	B-X
its	B-X
stability	B-X
and	B-X
repression	B-X
activity	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
upon	B-X
bile	B-X
acid	B-X
treatment	B-X
,	B-X
SHP	B-X
was	B-X
phosphorylated	B-X
at	B-X
Ser26	B-X
,	B-X
within	B-X
an	B-X
ERK	B-X
motif	B-X
in	B-X
SHP	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
dramatically	B-X
abolished	B-X
SHP	B-X
stability	B-X
.	B-X
Surprisingly	B-X
,	B-X
SHP	B-X
stability	B-X
was	B-X
abnormally	B-X
elevated	B-X
in	B-X
ob/ob	B-X
mice	B-X
and	B-X
diet-induced	B-X
obese	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
important	B-X
role	B-X
for	B-X
regulation	B-X
of	B-X
SHP	B-X
stability	B-X
in	B-X
bile	B-X
acid	B-X
signaling	B-X
in	B-X
normal	B-X
conditions	B-X
,	B-X
and	B-X
that	B-X
abnormal	B-X
stabilization	B-X
of	B-X
SHP	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
metabolic	B-X
disorders	B-X
,	B-X
including	B-X
obesity	B-X
and	B-X
diabetes	B-X
.	B-X

Here	O
,	O
we	O
report	O
surprising	O
findings	O
that	O
SHP	B-Protein
is	O
a	O
rapidly	O
degraded	O
protein	O
via	O
the	O
ubiquitin	B-Protein
-	O
proteasomal	O
pathway	O
and	O
that	O
bile	O
acids	O
or	O
bile	O
acid	O
-	O
induced	O
intestinal	O
fibroblast	B-Protein
growth	I-Protein
factor	I-Protein
19	I-Protein
(	O
FGF19	B-Protein
)	O
increases	O
stability	O
of	O
hepatic	O
SHP	B-Protein
by	O
inhibiting	O
proteasomal	O
degradation	O
in	O
an	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
-	O
dependent	O
manner	O
.	O

SHP	B-Protein
was	O
ubiquitinated	O
at	O
Lys122	O
and	O
Lys123	O
,	O
and	O
mutation	O
of	O
these	O
sites	O
altered	O
its	O
stability	O
and	O
repression	O
activity	O
.	O
<EOS>	B-X
Small	B-X
Heterodimer	B-X
Partner	B-X
(	B-X
SHP	B-X
)	B-X
inhibits	B-X
activities	B-X
of	B-X
numerous	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
pathways	B-X
.	B-X
As	B-X
an	B-X
important	B-X
metabolic	B-X
regulator	B-X
,	B-X
SHP	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
maintaining	B-X
cholesterol	B-X
and	B-X
bile	B-X
acid	B-X
homeostasis	B-X
by	B-X
inhibiting	B-X
cholesterol	B-X
conversion	B-X
to	B-X
bile	B-X
acids	B-X
.	B-X
While	B-X
SHP	B-X
gene	B-X
induction	B-X
by	B-X
increased	B-X
bile	B-X
acids	B-X
is	B-X
well	B-X
established	B-X
,	B-X
whether	B-X
SHP	B-X
activity	B-X
is	B-X
also	B-X
modulated	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
surprising	B-X
findings	B-X
that	B-X
SHP	B-X
is	B-X
a	B-X
rapidly	B-X
degraded	B-X
protein	B-X
via	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
and	B-X
that	B-X
bile	B-X
acids	B-X
or	B-X
bile	B-X
acid-induced	B-X
intestinal	B-X
fibroblast	B-X
growth	B-X
factor	B-X
19	B-X
(	B-X
FGF19	B-X
)	B-X
increases	B-X
stability	B-X
of	B-X
hepatic	B-X
SHP	B-X
by	B-X
inhibiting	B-X
proteasomal	B-X
degradation	B-X
in	B-X
an	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
SHP	B-X
was	B-X
ubiquitinated	B-X
at	B-X
Lys122	B-X
and	B-X
Lys123	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
these	B-X
sites	B-X
altered	B-X
its	B-X
stability	B-X
and	B-X
repression	B-X
activity	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
upon	B-X
bile	B-X
acid	B-X
treatment	B-X
,	B-X
SHP	B-X
was	B-X
phosphorylated	B-X
at	B-X
Ser26	B-X
,	B-X
within	B-X
an	B-X
ERK	B-X
motif	B-X
in	B-X
SHP	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
dramatically	B-X
abolished	B-X
SHP	B-X
stability	B-X
.	B-X
Surprisingly	B-X
,	B-X
SHP	B-X
stability	B-X
was	B-X
abnormally	B-X
elevated	B-X
in	B-X
ob/ob	B-X
mice	B-X
and	B-X
diet-induced	B-X
obese	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
important	B-X
role	B-X
for	B-X
regulation	B-X
of	B-X
SHP	B-X
stability	B-X
in	B-X
bile	B-X
acid	B-X
signaling	B-X
in	B-X
normal	B-X
conditions	B-X
,	B-X
and	B-X
that	B-X
abnormal	B-X
stabilization	B-X
of	B-X
SHP	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
metabolic	B-X
disorders	B-X
,	B-X
including	B-X
obesity	B-X
and	B-X
diabetes	B-X
.	B-X

Tandem	O
mass	O
spectrometry	O
revealed	O
that	O
upon	O
bile	O
acid	O
treatment	O
,	O
SHP	B-Protein
was	O
phosphorylated	O
at	O
Ser26	O
,	O
within	O
an	O
ERK	O
motif	O
in	O
SHP	B-Protein
,	O
and	O
mutation	O
of	O
this	O
site	O
dramatically	O
abolished	O
SHP	B-Protein
stability	O
.	O
<EOS>	B-X
Small	B-X
Heterodimer	B-X
Partner	B-X
(	B-X
SHP	B-X
)	B-X
inhibits	B-X
activities	B-X
of	B-X
numerous	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
pathways	B-X
.	B-X
As	B-X
an	B-X
important	B-X
metabolic	B-X
regulator	B-X
,	B-X
SHP	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
maintaining	B-X
cholesterol	B-X
and	B-X
bile	B-X
acid	B-X
homeostasis	B-X
by	B-X
inhibiting	B-X
cholesterol	B-X
conversion	B-X
to	B-X
bile	B-X
acids	B-X
.	B-X
While	B-X
SHP	B-X
gene	B-X
induction	B-X
by	B-X
increased	B-X
bile	B-X
acids	B-X
is	B-X
well	B-X
established	B-X
,	B-X
whether	B-X
SHP	B-X
activity	B-X
is	B-X
also	B-X
modulated	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
surprising	B-X
findings	B-X
that	B-X
SHP	B-X
is	B-X
a	B-X
rapidly	B-X
degraded	B-X
protein	B-X
via	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
and	B-X
that	B-X
bile	B-X
acids	B-X
or	B-X
bile	B-X
acid-induced	B-X
intestinal	B-X
fibroblast	B-X
growth	B-X
factor	B-X
19	B-X
(	B-X
FGF19	B-X
)	B-X
increases	B-X
stability	B-X
of	B-X
hepatic	B-X
SHP	B-X
by	B-X
inhibiting	B-X
proteasomal	B-X
degradation	B-X
in	B-X
an	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
SHP	B-X
was	B-X
ubiquitinated	B-X
at	B-X
Lys122	B-X
and	B-X
Lys123	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
these	B-X
sites	B-X
altered	B-X
its	B-X
stability	B-X
and	B-X
repression	B-X
activity	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
upon	B-X
bile	B-X
acid	B-X
treatment	B-X
,	B-X
SHP	B-X
was	B-X
phosphorylated	B-X
at	B-X
Ser26	B-X
,	B-X
within	B-X
an	B-X
ERK	B-X
motif	B-X
in	B-X
SHP	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
dramatically	B-X
abolished	B-X
SHP	B-X
stability	B-X
.	B-X
Surprisingly	B-X
,	B-X
SHP	B-X
stability	B-X
was	B-X
abnormally	B-X
elevated	B-X
in	B-X
ob/ob	B-X
mice	B-X
and	B-X
diet-induced	B-X
obese	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
important	B-X
role	B-X
for	B-X
regulation	B-X
of	B-X
SHP	B-X
stability	B-X
in	B-X
bile	B-X
acid	B-X
signaling	B-X
in	B-X
normal	B-X
conditions	B-X
,	B-X
and	B-X
that	B-X
abnormal	B-X
stabilization	B-X
of	B-X
SHP	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
metabolic	B-X
disorders	B-X
,	B-X
including	B-X
obesity	B-X
and	B-X
diabetes	B-X
.	B-X

Surprisingly	O
,	O
SHP	B-Protein
stability	O
was	O
abnormally	O
elevated	O
in	O
ob	O
/	O
ob	O
mice	O
and	O
diet	O
-	O
induced	O
obese	O
mice	O
.	O
<EOS>	B-X
Small	B-X
Heterodimer	B-X
Partner	B-X
(	B-X
SHP	B-X
)	B-X
inhibits	B-X
activities	B-X
of	B-X
numerous	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
pathways	B-X
.	B-X
As	B-X
an	B-X
important	B-X
metabolic	B-X
regulator	B-X
,	B-X
SHP	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
maintaining	B-X
cholesterol	B-X
and	B-X
bile	B-X
acid	B-X
homeostasis	B-X
by	B-X
inhibiting	B-X
cholesterol	B-X
conversion	B-X
to	B-X
bile	B-X
acids	B-X
.	B-X
While	B-X
SHP	B-X
gene	B-X
induction	B-X
by	B-X
increased	B-X
bile	B-X
acids	B-X
is	B-X
well	B-X
established	B-X
,	B-X
whether	B-X
SHP	B-X
activity	B-X
is	B-X
also	B-X
modulated	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
surprising	B-X
findings	B-X
that	B-X
SHP	B-X
is	B-X
a	B-X
rapidly	B-X
degraded	B-X
protein	B-X
via	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
and	B-X
that	B-X
bile	B-X
acids	B-X
or	B-X
bile	B-X
acid-induced	B-X
intestinal	B-X
fibroblast	B-X
growth	B-X
factor	B-X
19	B-X
(	B-X
FGF19	B-X
)	B-X
increases	B-X
stability	B-X
of	B-X
hepatic	B-X
SHP	B-X
by	B-X
inhibiting	B-X
proteasomal	B-X
degradation	B-X
in	B-X
an	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
SHP	B-X
was	B-X
ubiquitinated	B-X
at	B-X
Lys122	B-X
and	B-X
Lys123	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
these	B-X
sites	B-X
altered	B-X
its	B-X
stability	B-X
and	B-X
repression	B-X
activity	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
upon	B-X
bile	B-X
acid	B-X
treatment	B-X
,	B-X
SHP	B-X
was	B-X
phosphorylated	B-X
at	B-X
Ser26	B-X
,	B-X
within	B-X
an	B-X
ERK	B-X
motif	B-X
in	B-X
SHP	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
dramatically	B-X
abolished	B-X
SHP	B-X
stability	B-X
.	B-X
Surprisingly	B-X
,	B-X
SHP	B-X
stability	B-X
was	B-X
abnormally	B-X
elevated	B-X
in	B-X
ob/ob	B-X
mice	B-X
and	B-X
diet-induced	B-X
obese	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
important	B-X
role	B-X
for	B-X
regulation	B-X
of	B-X
SHP	B-X
stability	B-X
in	B-X
bile	B-X
acid	B-X
signaling	B-X
in	B-X
normal	B-X
conditions	B-X
,	B-X
and	B-X
that	B-X
abnormal	B-X
stabilization	B-X
of	B-X
SHP	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
metabolic	B-X
disorders	B-X
,	B-X
including	B-X
obesity	B-X
and	B-X
diabetes	B-X
.	B-X

These	O
results	O
demonstrate	O
an	O
important	O
role	O
for	O
regulation	O
of	O
SHP	B-Protein
stability	O
in	O
bile	O
acid	O
signaling	O
in	O
normal	O
conditions	O
,	O
and	O
that	O
abnormal	O
stabilization	O
of	O
SHP	B-Protein
may	O
be	O
associated	O
with	O
metabolic	O
disorders	O
,	O
including	O
obesity	O
and	O
diabetes	O
.	O
<EOS>	B-X
Small	B-X
Heterodimer	B-X
Partner	B-X
(	B-X
SHP	B-X
)	B-X
inhibits	B-X
activities	B-X
of	B-X
numerous	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
pathways	B-X
.	B-X
As	B-X
an	B-X
important	B-X
metabolic	B-X
regulator	B-X
,	B-X
SHP	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
maintaining	B-X
cholesterol	B-X
and	B-X
bile	B-X
acid	B-X
homeostasis	B-X
by	B-X
inhibiting	B-X
cholesterol	B-X
conversion	B-X
to	B-X
bile	B-X
acids	B-X
.	B-X
While	B-X
SHP	B-X
gene	B-X
induction	B-X
by	B-X
increased	B-X
bile	B-X
acids	B-X
is	B-X
well	B-X
established	B-X
,	B-X
whether	B-X
SHP	B-X
activity	B-X
is	B-X
also	B-X
modulated	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
surprising	B-X
findings	B-X
that	B-X
SHP	B-X
is	B-X
a	B-X
rapidly	B-X
degraded	B-X
protein	B-X
via	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
and	B-X
that	B-X
bile	B-X
acids	B-X
or	B-X
bile	B-X
acid-induced	B-X
intestinal	B-X
fibroblast	B-X
growth	B-X
factor	B-X
19	B-X
(	B-X
FGF19	B-X
)	B-X
increases	B-X
stability	B-X
of	B-X
hepatic	B-X
SHP	B-X
by	B-X
inhibiting	B-X
proteasomal	B-X
degradation	B-X
in	B-X
an	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
SHP	B-X
was	B-X
ubiquitinated	B-X
at	B-X
Lys122	B-X
and	B-X
Lys123	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
these	B-X
sites	B-X
altered	B-X
its	B-X
stability	B-X
and	B-X
repression	B-X
activity	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
upon	B-X
bile	B-X
acid	B-X
treatment	B-X
,	B-X
SHP	B-X
was	B-X
phosphorylated	B-X
at	B-X
Ser26	B-X
,	B-X
within	B-X
an	B-X
ERK	B-X
motif	B-X
in	B-X
SHP	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
dramatically	B-X
abolished	B-X
SHP	B-X
stability	B-X
.	B-X
Surprisingly	B-X
,	B-X
SHP	B-X
stability	B-X
was	B-X
abnormally	B-X
elevated	B-X
in	B-X
ob/ob	B-X
mice	B-X
and	B-X
diet-induced	B-X
obese	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
an	B-X
important	B-X
role	B-X
for	B-X
regulation	B-X
of	B-X
SHP	B-X
stability	B-X
in	B-X
bile	B-X
acid	B-X
signaling	B-X
in	B-X
normal	B-X
conditions	B-X
,	B-X
and	B-X
that	B-X
abnormal	B-X
stabilization	B-X
of	B-X
SHP	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
metabolic	B-X
disorders	B-X
,	B-X
including	B-X
obesity	B-X
and	B-X
diabetes	B-X
.	B-X

Rapid	O
proteasomal	O
degradation	O
of	O
transcription	B-Protein
factor	I-Protein
IIB	I-Protein
in	O
accordance	O
with	O
F9	O
cell	O
differentiation	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
all	B-X
general	B-X
transcription	B-X
factors	B-X
(	B-X
GTFs	B-X
)	B-X
for	B-X
RNA	B-X
polymerase	B-X
II	B-X
decreased	B-X
in	B-X
F9	B-X
cells	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
a	B-X
differentiation	B-X
procedure	B-X
.	B-X
Different	B-X
from	B-X
other	B-X
GTFs	B-X
,	B-X
decrease	B-X
of	B-X
TFIIB	B-X
during	B-X
the	B-X
differentiation	B-X
was	B-X
suppressed	B-X
by	B-X
addition	B-X
of	B-X
a	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
MG132	B-X
.	B-X
The	B-X
half-life	B-X
of	B-X
TFIIB	B-X
in	B-X
the	B-X
differentiated	B-X
cells	B-X
was	B-X
remarkably	B-X
reduced	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
TFIIB	B-X
is	B-X
a	B-X
poly-ubiquitinated	B-X
protein	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
components	B-X
of	B-X
the	B-X
transcription	B-X
machinery	B-X
decreased	B-X
in	B-X
accordance	B-X
with	B-X
cell	B-X
differentiation	B-X
and	B-X
that	B-X
TFIIB	B-X
is	B-X
specifically	B-X
and	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X

We	O
found	O
that	O
the	O
levels	O
of	O
all	O
general	O
transcription	O
factors	O
(	O
GTFs	O
)	O
for	O
RNA	O
polymerase	O
II	O
decreased	O
in	O
F9	O
cells	O
when	O
the	O
cells	O
were	O
subjected	O
to	O
a	O
differentiation	O
procedure	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
all	B-X
general	B-X
transcription	B-X
factors	B-X
(	B-X
GTFs	B-X
)	B-X
for	B-X
RNA	B-X
polymerase	B-X
II	B-X
decreased	B-X
in	B-X
F9	B-X
cells	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
a	B-X
differentiation	B-X
procedure	B-X
.	B-X
Different	B-X
from	B-X
other	B-X
GTFs	B-X
,	B-X
decrease	B-X
of	B-X
TFIIB	B-X
during	B-X
the	B-X
differentiation	B-X
was	B-X
suppressed	B-X
by	B-X
addition	B-X
of	B-X
a	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
MG132	B-X
.	B-X
The	B-X
half-life	B-X
of	B-X
TFIIB	B-X
in	B-X
the	B-X
differentiated	B-X
cells	B-X
was	B-X
remarkably	B-X
reduced	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
TFIIB	B-X
is	B-X
a	B-X
poly-ubiquitinated	B-X
protein	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
components	B-X
of	B-X
the	B-X
transcription	B-X
machinery	B-X
decreased	B-X
in	B-X
accordance	B-X
with	B-X
cell	B-X
differentiation	B-X
and	B-X
that	B-X
TFIIB	B-X
is	B-X
specifically	B-X
and	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X

Different	O
from	O
other	O
GTFs	O
,	O
decrease	O
of	O
TFIIB	B-Protein
during	O
the	O
differentiation	O
was	O
suppressed	O
by	O
addition	O
of	O
a	O
proteasome	O
inhibitor	O
,	O
MG132	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
all	B-X
general	B-X
transcription	B-X
factors	B-X
(	B-X
GTFs	B-X
)	B-X
for	B-X
RNA	B-X
polymerase	B-X
II	B-X
decreased	B-X
in	B-X
F9	B-X
cells	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
a	B-X
differentiation	B-X
procedure	B-X
.	B-X
Different	B-X
from	B-X
other	B-X
GTFs	B-X
,	B-X
decrease	B-X
of	B-X
TFIIB	B-X
during	B-X
the	B-X
differentiation	B-X
was	B-X
suppressed	B-X
by	B-X
addition	B-X
of	B-X
a	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
MG132	B-X
.	B-X
The	B-X
half-life	B-X
of	B-X
TFIIB	B-X
in	B-X
the	B-X
differentiated	B-X
cells	B-X
was	B-X
remarkably	B-X
reduced	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
TFIIB	B-X
is	B-X
a	B-X
poly-ubiquitinated	B-X
protein	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
components	B-X
of	B-X
the	B-X
transcription	B-X
machinery	B-X
decreased	B-X
in	B-X
accordance	B-X
with	B-X
cell	B-X
differentiation	B-X
and	B-X
that	B-X
TFIIB	B-X
is	B-X
specifically	B-X
and	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X

The	O
half	O
-	O
life	O
of	O
TFIIB	B-Protein
in	O
the	O
differentiated	O
cells	O
was	O
remarkably	O
reduced	O
compared	O
with	O
that	O
in	O
the	O
undifferentiated	O
cells	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
all	B-X
general	B-X
transcription	B-X
factors	B-X
(	B-X
GTFs	B-X
)	B-X
for	B-X
RNA	B-X
polymerase	B-X
II	B-X
decreased	B-X
in	B-X
F9	B-X
cells	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
a	B-X
differentiation	B-X
procedure	B-X
.	B-X
Different	B-X
from	B-X
other	B-X
GTFs	B-X
,	B-X
decrease	B-X
of	B-X
TFIIB	B-X
during	B-X
the	B-X
differentiation	B-X
was	B-X
suppressed	B-X
by	B-X
addition	B-X
of	B-X
a	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
MG132	B-X
.	B-X
The	B-X
half-life	B-X
of	B-X
TFIIB	B-X
in	B-X
the	B-X
differentiated	B-X
cells	B-X
was	B-X
remarkably	B-X
reduced	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
TFIIB	B-X
is	B-X
a	B-X
poly-ubiquitinated	B-X
protein	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
components	B-X
of	B-X
the	B-X
transcription	B-X
machinery	B-X
decreased	B-X
in	B-X
accordance	B-X
with	B-X
cell	B-X
differentiation	B-X
and	B-X
that	B-X
TFIIB	B-X
is	B-X
specifically	B-X
and	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X

Moreover	O
,	O
it	O
was	O
demonstrated	O
that	O
TFIIB	B-Protein
is	O
a	O
poly	O
-	O
ubiquitinated	O
protein	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
all	B-X
general	B-X
transcription	B-X
factors	B-X
(	B-X
GTFs	B-X
)	B-X
for	B-X
RNA	B-X
polymerase	B-X
II	B-X
decreased	B-X
in	B-X
F9	B-X
cells	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
a	B-X
differentiation	B-X
procedure	B-X
.	B-X
Different	B-X
from	B-X
other	B-X
GTFs	B-X
,	B-X
decrease	B-X
of	B-X
TFIIB	B-X
during	B-X
the	B-X
differentiation	B-X
was	B-X
suppressed	B-X
by	B-X
addition	B-X
of	B-X
a	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
MG132	B-X
.	B-X
The	B-X
half-life	B-X
of	B-X
TFIIB	B-X
in	B-X
the	B-X
differentiated	B-X
cells	B-X
was	B-X
remarkably	B-X
reduced	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
TFIIB	B-X
is	B-X
a	B-X
poly-ubiquitinated	B-X
protein	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
components	B-X
of	B-X
the	B-X
transcription	B-X
machinery	B-X
decreased	B-X
in	B-X
accordance	B-X
with	B-X
cell	B-X
differentiation	B-X
and	B-X
that	B-X
TFIIB	B-X
is	B-X
specifically	B-X
and	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X

Results	O
of	O
this	O
study	O
suggest	O
that	O
components	O
of	O
the	O
transcription	O
machinery	O
decreased	O
in	O
accordance	O
with	O
cell	O
differentiation	O
and	O
that	O
TFIIB	B-Protein
is	O
specifically	O
and	O
rapidly	O
degraded	O
by	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
all	B-X
general	B-X
transcription	B-X
factors	B-X
(	B-X
GTFs	B-X
)	B-X
for	B-X
RNA	B-X
polymerase	B-X
II	B-X
decreased	B-X
in	B-X
F9	B-X
cells	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
a	B-X
differentiation	B-X
procedure	B-X
.	B-X
Different	B-X
from	B-X
other	B-X
GTFs	B-X
,	B-X
decrease	B-X
of	B-X
TFIIB	B-X
during	B-X
the	B-X
differentiation	B-X
was	B-X
suppressed	B-X
by	B-X
addition	B-X
of	B-X
a	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
MG132	B-X
.	B-X
The	B-X
half-life	B-X
of	B-X
TFIIB	B-X
in	B-X
the	B-X
differentiated	B-X
cells	B-X
was	B-X
remarkably	B-X
reduced	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
TFIIB	B-X
is	B-X
a	B-X
poly-ubiquitinated	B-X
protein	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
components	B-X
of	B-X
the	B-X
transcription	B-X
machinery	B-X
decreased	B-X
in	B-X
accordance	B-X
with	B-X
cell	B-X
differentiation	B-X
and	B-X
that	B-X
TFIIB	B-X
is	B-X
specifically	B-X
and	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X

Acetaldehyde	O
stimulates	O
FANCD2	B-Protein
monoubiquitination	O
,	O
H2AX	B-Protein
phosphorylation	O
,	O
and	O
BRCA1	B-Protein
phosphorylation	O
in	O
human	O
cells	O
in	O
vitro	O
:	O
implications	O
for	O
alcohol	O
-	O
related	O
carcinogenesis	O
.	O
<EOS>	B-X
According	B-X
to	B-X
a	B-X
recent	B-X
IARC	B-X
Working	B-X
Group	B-X
report	B-X
,	B-X
alcohol	B-X
consumption	B-X
is	B-X
causally	B-X
related	B-X
to	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
cancer	B-X
of	B-X
the	B-X
upper	B-X
aerodigestive	B-X
tract	B-X
,	B-X
liver	B-X
,	B-X
colorectum	B-X
,	B-X
and	B-X
female	B-X
breast	B-X
[	B-X
R.	B-X
Baan	B-X
,	B-X
K.	B-X
Straif	B-X
,	B-X
Y.	B-X
Grosse	B-X
,	B-X
B.	B-X
Secretan	B-X
,	B-X
F.	B-X
El	B-X
Ghissassi	B-X
,	B-X
V.	B-X
Bouvard	B-X
,	B-X
A.	B-X
Altieri	B-X
,	B-X
V.	B-X
Cogliano	B-X
,	B-X
Carcinogenicity	B-X
of	B-X
alcoholic	B-X
beverages	B-X
,	B-X
Lancet	B-X
Oncol	B-X
.	B-X
Several	B-X
lines	B-X
of	B-X
evidence	B-X
indicate	B-X
that	B-X
acetaldehyde	B-X
(	B-X
AA	B-X
)	B-X
,	B-X
the	B-X
first	B-X
product	B-X
of	B-X
alcohol	B-X
metabolism	B-X
,	B-X
plays	B-X
a	B-X
very	B-X
important	B-X
role	B-X
in	B-X
alcohol-related	B-X
carcinogenesis	B-X
,	B-X
particularly	B-X
in	B-X
the	B-X
esophagus	B-X
.	B-X
We	B-X
previously	B-X
proposed	B-X
a	B-X
model	B-X
for	B-X
alcohol-related	B-X
carcinogenesis	B-X
in	B-X
which	B-X
AA	B-X
,	B-X
generated	B-X
from	B-X
alcohol	B-X
metabolism	B-X
,	B-X
reacts	B-X
in	B-X
cells	B-X
to	B-X
generate	B-X
DNA	B-X
lesions	B-X
that	B-X
form	B-X
interstrand	B-X
crosslinks	B-X
(	B-X
ICLs	B-X
)	B-X
[	B-X
J.A	B-X
.	B-X
Since	B-X
the	B-X
Fanconi	B-X
anemia-breast	B-X
cancer	B-X
associated	B-X
(	B-X
FANC-BRCA	B-X
)	B-X
DNA	B-X
damage	B-X
response	B-X
network	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
against	B-X
ICLs	B-X
,	B-X
in	B-X
the	B-X
present	B-X
work	B-X
we	B-X
tested	B-X
this	B-X
hypothesis	B-X
by	B-X
exposing	B-X
cells	B-X
to	B-X
AA	B-X
and	B-X
monitoring	B-X
activation	B-X
of	B-X
this	B-X
network	B-X
.	B-X
We	B-X
found	B-X
that	B-X
AA	B-X
exposure	B-X
results	B-X
in	B-X
a	B-X
concentration-dependent	B-X
increase	B-X
in	B-X
FANCD2	B-X
monoubiquitination	B-X
,	B-X
which	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
FANC	B-X
core	B-X
complex	B-X
.	B-X
AA	B-X
also	B-X
stimulated	B-X
BRCA1	B-X
phosphorylation	B-X
at	B-X
Ser1524	B-X
and	B-X
increased	B-X
the	B-X
level	B-X
of	B-X
gammaH2AX	B-X
,	B-X
with	B-X
both	B-X
modifications	B-X
occurring	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
We	B-X
discuss	B-X
the	B-X
mechanistic	B-X
implications	B-X
of	B-X
these	B-X
results	B-X
,	B-X
as	B-X
well	B-X
as	B-X
their	B-X
possible	B-X
relationship	B-X
to	B-X
alcohol-related	B-X
carcinogenesis	B-X
in	B-X
different	B-X
human	B-X
tissues	B-X
.	B-X

According	O
to	O
a	O
recent	O
IARC	O
Working	O
Group	O
report	O
,	O
alcohol	O
consumption	O
is	O
causally	O
related	O
to	O
an	O
increased	O
risk	O
of	O
cancer	O
of	O
the	O
upper	O
aerodigestive	O
tract	O
,	O
liver	O
,	O
colorectum	O
,	O
and	O
female	O
breast	O
[	O
R	O
.	O
Baan	O
,	O
K	O
.	O
Straif	O
,	O
Y	O
.	O
Grosse	O
,	O
B	O
.	O
Secretan	O
,	O
F	O
.	O
El	O
Ghissassi	O
,	O
V	O
.	O
Bouvard	O
,	O
A	O
.	O
Altieri	O
,	O
V	O
.	O
Cogliano	O
,	O
Carcinogenicity	O
of	O
alcoholic	O
beverages	O
,	O
Lancet	O
Oncol	O
.	O
8	O
(	O
2007	O
)	O
292	O
-	O
293	O
]	O
.	O

Several	O
lines	O
of	O
evidence	O
indicate	O
that	O
acetaldehyde	O
(	O
AA	O
)	O
,	O
the	O
first	O
product	O
of	O
alcohol	O
metabolism	O
,	O
plays	O
a	O
very	O
important	O
role	O
in	O
alcohol	O
-	O
related	O
carcinogenesis	O
,	O
particularly	O
in	O
the	O
esophagus	O
.	O

We	O
previously	O
proposed	O
a	O
model	O
for	O
alcohol	O
-	O
related	O
carcinogenesis	O
in	O
which	O
AA	O
,	O
generated	O
from	O
alcohol	O
metabolism	O
,	O
reacts	O
in	O
cells	O
to	O
generate	O
DNA	O
lesions	O
that	O
form	O
interstrand	O
crosslinks	O
(	O
ICLs	O
)	O
[	O
J	O
.	O
A	O
.	O
Theruvathu	O
,	O
P	O
.	O
Jaruga	O
,	O
R	O
.	O
G	O
.	O
Nath	O
,	O
M	O
.	O
Dizdaroglu	O
,	O
P	O
.	O
J	O
.	O
Brooks	O
,	O
Polyamines	O
stimulate	O
the	O
formation	O
of	O
mutagenic	O
1	O
,	O
N2	O
-	O
propanodeoxyguanosine	O
adducts	O
from	O
acetaldehyde	O
,	O
Nucleic	O
Acids	O
Res	O
.	O
33	O
(	O
2005	O
)	O
3513	O
-	O
3520	O
]	O
.	O

Since	O
the	O
Fanconi	O
anemia	O
-	O
breast	O
cancer	O
associated	O
(	O
FANC	O
-	O
BRCA	O
)	O
DNA	O
damage	O
response	O
network	O
plays	O
a	O
crucial	O
role	O
in	O
protecting	O
cells	O
against	O
ICLs	O
,	O
in	O
the	O
present	O
work	O
we	O
tested	O
this	O
hypothesis	O
by	O
exposing	O
cells	O
to	O
AA	O
and	O
monitoring	O
activation	O
of	O
this	O
network	O
.	O

We	O
found	O
that	O
AA	O
exposure	O
results	O
in	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
FANCD2	B-Protein
monoubiquitination	O
,	O
which	O
is	O
dependent	O
upon	O
the	O
FANC	O
core	O
complex	O
.	O

AA	O
also	O
stimulated	O
BRCA1	B-Protein
phosphorylation	O
at	O
Ser1524	O
and	O
increased	O
the	O
level	O
of	O
gammaH2AX	B-Protein
,	O
with	O
both	O
modifications	O
occurring	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

However	O
,	O
AA	O
did	O
not	O
detectably	O
increase	O
the	O
levels	O
of	O
hyperphosphorylated	O
RPA34	B-Protein
,	O
a	O
marker	O
of	O
single	O
-	O
stranded	O
DNA	O
exposure	O
at	O
replication	O
forks	O
.	O
<EOS>	B-X
AA	B-X
cardiomyopathy	B-X
.	B-X
The	B-X
use	B-X
of	B-X
phosphodiesterase	B-X
inhibitors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
alopecia	B-X
.	B-X
Acrylamide	B-X
(	B-X
AA	B-X
)	B-X
formation	B-X
in	B-X
starch-based	B-X
processed	B-X
foods	B-X
at	B-X
elevated	B-X
temperatures	B-X
is	B-X
a	B-X
serious	B-X
health	B-X
issue	B-X
as	B-X
it	B-X
is	B-X
a	B-X
toxic	B-X
and	B-X
carcinogenic	B-X
substance	B-X
.	B-X
However	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
more	B-X
AA	B-X
entangles	B-X
with	B-X
modern-day	B-X
fast	B-X
food	B-X
industries	B-X
,	B-X
and	B-X
a	B-X
considerable	B-X
amount	B-X
of	B-X
this	B-X
ingredient	B-X
is	B-X
being	B-X
consumed	B-X
by	B-X
fast	B-X
food	B-X
eaters	B-X
inadvertently	B-X
throughout	B-X
the	B-X
world	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
the	B-X
factors	B-X
responsible	B-X
for	B-X
AA	B-X
formation	B-X
pathways	B-X
,	B-X
investigation	B-X
techniques	B-X
of	B-X
AA	B-X
,	B-X
toxicity	B-X
,	B-X
and	B-X
health-related	B-X
issues	B-X
followed	B-X
by	B-X
mitigation	B-X
methods	B-X
that	B-X
have	B-X
been	B-X
studied	B-X
in	B-X
the	B-X
past	B-X
few	B-X
decades	B-X
comprehensively	B-X
.	B-X
Predominantly	B-X
,	B-X
AA	B-X
and	B-X
hydroxymethylfurfural	B-X
(	B-X
HMF	B-X
)	B-X
are	B-X
produced	B-X
via	B-X
the	B-X
Maillard	B-X
reaction	B-X
and	B-X
can	B-X
be	B-X
highlighted	B-X
as	B-X
the	B-X
major	B-X
heat-induced	B-X
toxins	B-X
formulated	B-X
in	B-X
bread	B-X
and	B-X
bakery	B-X
products	B-X
.	B-X
Epidemiological	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
there	B-X
is	B-X
a	B-X
strong	B-X
relationship	B-X
between	B-X
AA	B-X
accumulation	B-X
in	B-X
the	B-X
body	B-X
and	B-X
the	B-X
increased	B-X
risk	B-X
of	B-X
cancers	B-X
.	B-X
The	B-X
scientific	B-X
community	B-X
is	B-X
still	B-X
in	B-X
a	B-X
dearth	B-X
of	B-X
technology	B-X
in	B-X
producing	B-X
AA-free	B-X
starch-protein-fat-based	B-X
thermally	B-X
processed	B-X
food	B-X
products	B-X
.	B-X
Therefore	B-X
,	B-X
this	B-X
paper	B-X
may	B-X
facilitate	B-X
the	B-X
food	B-X
scientists	B-X
to	B-X
their	B-X
endeavor	B-X
in	B-X
developing	B-X
mitigation	B-X
techniques	B-X
pertaining	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
AA	B-X
and	B-X
HMF	B-X
in	B-X
baked	B-X
foods	B-X
in	B-X
the	B-X
future	B-X
.	B-X

These	O
results	O
provide	O
the	O
initial	O
description	O
of	O
the	O
AA	O
-	O
DNA	O
damage	O
response	O
,	O
which	O
is	O
qualitatively	O
similar	O
to	O
the	O
cellular	O
response	O
to	O
mitomycin	O
C	O
,	O
a	O
known	O
DNA	O
crosslinking	O
agent	O
.	O

We	O
discuss	O
the	O
mechanistic	O
implications	O
of	O
these	O
results	O
,	O
as	O
well	O
as	O
their	O
possible	O
relationship	O
to	O
alcohol	O
-	O
related	O
carcinogenesis	O
in	O
different	O
human	O
tissues	O
.	O
<EOS>	B-X
According	B-X
to	B-X
a	B-X
recent	B-X
IARC	B-X
Working	B-X
Group	B-X
report	B-X
,	B-X
alcohol	B-X
consumption	B-X
is	B-X
causally	B-X
related	B-X
to	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
cancer	B-X
of	B-X
the	B-X
upper	B-X
aerodigestive	B-X
tract	B-X
,	B-X
liver	B-X
,	B-X
colorectum	B-X
,	B-X
and	B-X
female	B-X
breast	B-X
[	B-X
R.	B-X
Baan	B-X
,	B-X
K.	B-X
Straif	B-X
,	B-X
Y.	B-X
Grosse	B-X
,	B-X
B.	B-X
Secretan	B-X
,	B-X
F.	B-X
El	B-X
Ghissassi	B-X
,	B-X
V.	B-X
Bouvard	B-X
,	B-X
A.	B-X
Altieri	B-X
,	B-X
V.	B-X
Cogliano	B-X
,	B-X
Carcinogenicity	B-X
of	B-X
alcoholic	B-X
beverages	B-X
,	B-X
Lancet	B-X
Oncol	B-X
.	B-X
Several	B-X
lines	B-X
of	B-X
evidence	B-X
indicate	B-X
that	B-X
acetaldehyde	B-X
(	B-X
AA	B-X
)	B-X
,	B-X
the	B-X
first	B-X
product	B-X
of	B-X
alcohol	B-X
metabolism	B-X
,	B-X
plays	B-X
a	B-X
very	B-X
important	B-X
role	B-X
in	B-X
alcohol-related	B-X
carcinogenesis	B-X
,	B-X
particularly	B-X
in	B-X
the	B-X
esophagus	B-X
.	B-X
We	B-X
previously	B-X
proposed	B-X
a	B-X
model	B-X
for	B-X
alcohol-related	B-X
carcinogenesis	B-X
in	B-X
which	B-X
AA	B-X
,	B-X
generated	B-X
from	B-X
alcohol	B-X
metabolism	B-X
,	B-X
reacts	B-X
in	B-X
cells	B-X
to	B-X
generate	B-X
DNA	B-X
lesions	B-X
that	B-X
form	B-X
interstrand	B-X
crosslinks	B-X
(	B-X
ICLs	B-X
)	B-X
[	B-X
J.A	B-X
.	B-X
We	B-X
found	B-X
that	B-X
AA	B-X
exposure	B-X
results	B-X
in	B-X
a	B-X
concentration-dependent	B-X
increase	B-X
in	B-X
FANCD2	B-X
monoubiquitination	B-X
,	B-X
which	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
FANC	B-X
core	B-X
complex	B-X
.	B-X
These	B-X
results	B-X
provide	B-X
the	B-X
initial	B-X
description	B-X
of	B-X
the	B-X
AA-DNA	B-X
damage	B-X
response	B-X
,	B-X
which	B-X
is	B-X
qualitatively	B-X
similar	B-X
to	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
mitomycin	B-X
C	B-X
,	B-X
a	B-X
known	B-X
DNA	B-X
crosslinking	B-X
agent	B-X
.	B-X
We	B-X
discuss	B-X
the	B-X
mechanistic	B-X
implications	B-X
of	B-X
these	B-X
results	B-X
,	B-X
as	B-X
well	B-X
as	B-X
their	B-X
possible	B-X
relationship	B-X
to	B-X
alcohol-related	B-X
carcinogenesis	B-X
in	B-X
different	B-X
human	B-X
tissues	B-X
.	B-X

Atg5	B-Protein
-	O
independent	O
sequestration	O
of	O
ubiquitinated	O
mycobacteria	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
cytosolic	B-X
access	B-X
results	B-X
in	B-X
a	B-X
new	B-X
and	B-X
intricate	B-X
host	B-X
pathogen	B-X
interaction	B-X
:	B-X
host	B-X
macrophages	B-X
ubiquitinate	B-X
Mm	B-X
,	B-X
while	B-X
Mm	B-X
shed	B-X
their	B-X
ubiquitinated	B-X
cell	B-X
walls	B-X
.	B-X
Phagosomal	B-X
escape	B-X
and	B-X
ubiquitination	B-X
of	B-X
Mm	B-X
occurred	B-X
rapidly	B-X
,	B-X
prior	B-X
to	B-X
3.5	B-X
hours	B-X
post	B-X
infection	B-X
;	B-X
at	B-X
the	B-X
same	B-X
time	B-X
,	B-X
ubiquitinated	B-X
Mm	B-X
cell	B-X
wall	B-X
material	B-X
mixed	B-X
with	B-X
host-derived	B-X
dense	B-X
membrane	B-X
networks	B-X
appeared	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
cytosolic	B-X
bacteria	B-X
,	B-X
suggesting	B-X
cell	B-X
wall	B-X
shedding	B-X
and	B-X
association	B-X
with	B-X
remnants	B-X
of	B-X
the	B-X
lysed	B-X
phagosome	B-X
.	B-X
At	B-X
24	B-X
hours	B-X
post-infection	B-X
,	B-X
Mm	B-X
that	B-X
polymerized	B-X
actin	B-X
were	B-X
not	B-X
ubiquitinated	B-X
,	B-X
whereas	B-X
ubiquitinated	B-X
Mm	B-X
were	B-X
found	B-X
within	B-X
LAMP-1-positive	B-X
vacuoles	B-X
resembling	B-X
lysosomes	B-X
.	B-X
Though	B-X
double	B-X
membranes	B-X
were	B-X
observed	B-X
which	B-X
sequestered	B-X
Mm	B-X
away	B-X
from	B-X
the	B-X
cytosol	B-X
,	B-X
targeting	B-X
of	B-X
Mm	B-X
to	B-X
the	B-X
LAMP-1-positive	B-X
vacuoles	B-X
was	B-X
independent	B-X
of	B-X
classical	B-X
autophagy	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
absence	B-X
of	B-X
LC3	B-X
association	B-X
and	B-X
by	B-X
Atg5-independence	B-X
of	B-X
their	B-X
formation	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
virulent	B-X
Mm	B-X
follow	B-X
two	B-X
distinct	B-X
paths	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
infected	B-X
host	B-X
cells	B-X
:	B-X
bacterial	B-X
ubiquitination	B-X
is	B-X
followed	B-X
by	B-X
sequestration	B-X
into	B-X
lysosome-like	B-X
organelles	B-X
via	B-X
an	B-X
autophagy-independent	B-X
pathway	B-X
,	B-X
while	B-X
cell	B-X
wall	B-X
shedding	B-X
may	B-X
allow	B-X
escape	B-X
from	B-X
this	B-X
fate	B-X
to	B-X
permit	B-X
continued	B-X
residence	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
formation	B-X
of	B-X
actin	B-X
tails	B-X
.	B-X

Like	O
several	O
other	O
intracellular	O
pathogens	O
,	O
Mycobacterium	O
marinum	O
(	O
Mm	O
)	O
escapes	O
from	O
phagosomes	O
into	O
the	O
host	O
cytosol	O
where	O
it	O
can	O
polymerize	O
actin	O
,	O
leading	O
to	O
motility	O
that	O
promotes	O
spread	O
to	O
neighboring	O
cells	O
.	O
<EOS>	B-X
Like	B-X
several	B-X
other	B-X
intracellular	B-X
pathogens	B-X
,	B-X
Mycobacterium	B-X
marinum	B-X
(	B-X
Mm	B-X
)	B-X
escapes	B-X
from	B-X
phagosomes	B-X
into	B-X
the	B-X
host	B-X
cytosol	B-X
where	B-X
it	B-X
can	B-X
polymerize	B-X
actin	B-X
,	B-X
leading	B-X
to	B-X
motility	B-X
that	B-X
promotes	B-X
spread	B-X
to	B-X
neighboring	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
only	B-X
approximately	B-X
25	B-X
%	B-X
of	B-X
internalized	B-X
Mm	B-X
form	B-X
actin	B-X
tails	B-X
,	B-X
and	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
remaining	B-X
bacteria	B-X
has	B-X
been	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
cytosolic	B-X
access	B-X
results	B-X
in	B-X
a	B-X
new	B-X
and	B-X
intricate	B-X
host	B-X
pathogen	B-X
interaction	B-X
:	B-X
host	B-X
macrophages	B-X
ubiquitinate	B-X
Mm	B-X
,	B-X
while	B-X
Mm	B-X
shed	B-X
their	B-X
ubiquitinated	B-X
cell	B-X
walls	B-X
.	B-X
Phagosomal	B-X
escape	B-X
and	B-X
ubiquitination	B-X
of	B-X
Mm	B-X
occurred	B-X
rapidly	B-X
,	B-X
prior	B-X
to	B-X
3.5	B-X
hours	B-X
post	B-X
infection	B-X
;	B-X
at	B-X
the	B-X
same	B-X
time	B-X
,	B-X
ubiquitinated	B-X
Mm	B-X
cell	B-X
wall	B-X
material	B-X
mixed	B-X
with	B-X
host-derived	B-X
dense	B-X
membrane	B-X
networks	B-X
appeared	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
cytosolic	B-X
bacteria	B-X
,	B-X
suggesting	B-X
cell	B-X
wall	B-X
shedding	B-X
and	B-X
association	B-X
with	B-X
remnants	B-X
of	B-X
the	B-X
lysed	B-X
phagosome	B-X
.	B-X
At	B-X
24	B-X
hours	B-X
post-infection	B-X
,	B-X
Mm	B-X
that	B-X
polymerized	B-X
actin	B-X
were	B-X
not	B-X
ubiquitinated	B-X
,	B-X
whereas	B-X
ubiquitinated	B-X
Mm	B-X
were	B-X
found	B-X
within	B-X
LAMP-1-positive	B-X
vacuoles	B-X
resembling	B-X
lysosomes	B-X
.	B-X
Though	B-X
double	B-X
membranes	B-X
were	B-X
observed	B-X
which	B-X
sequestered	B-X
Mm	B-X
away	B-X
from	B-X
the	B-X
cytosol	B-X
,	B-X
targeting	B-X
of	B-X
Mm	B-X
to	B-X
the	B-X
LAMP-1-positive	B-X
vacuoles	B-X
was	B-X
independent	B-X
of	B-X
classical	B-X
autophagy	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
absence	B-X
of	B-X
LC3	B-X
association	B-X
and	B-X
by	B-X
Atg5-independence	B-X
of	B-X
their	B-X
formation	B-X
.	B-X
Further	B-X
,	B-X
ubiquitination	B-X
and	B-X
LAMP-1	B-X
association	B-X
did	B-X
not	B-X
occur	B-X
with	B-X
mutant	B-X
avirulent	B-X
Mm	B-X
lacking	B-X
ESX-1	B-X
(	B-X
type	B-X
VII	B-X
)	B-X
secretion	B-X
,	B-X
which	B-X
fail	B-X
to	B-X
escape	B-X
the	B-X
primary	B-X
phagosome	B-X
;	B-X
apart	B-X
from	B-X
its	B-X
function	B-X
in	B-X
phagosome	B-X
escape	B-X
,	B-X
ESX-1	B-X
was	B-X
not	B-X
directly	B-X
required	B-X
for	B-X
Mm	B-X
ubiquitination	B-X
in	B-X
macrophages	B-X
or	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
virulent	B-X
Mm	B-X
follow	B-X
two	B-X
distinct	B-X
paths	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
infected	B-X
host	B-X
cells	B-X
:	B-X
bacterial	B-X
ubiquitination	B-X
is	B-X
followed	B-X
by	B-X
sequestration	B-X
into	B-X
lysosome-like	B-X
organelles	B-X
via	B-X
an	B-X
autophagy-independent	B-X
pathway	B-X
,	B-X
while	B-X
cell	B-X
wall	B-X
shedding	B-X
may	B-X
allow	B-X
escape	B-X
from	B-X
this	B-X
fate	B-X
to	B-X
permit	B-X
continued	B-X
residence	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
formation	B-X
of	B-X
actin	B-X
tails	B-X
.	B-X

However	O
,	O
only	O
approximately	O
25	O
%	O
of	O
internalized	O
Mm	O
form	O
actin	O
tails	O
,	O
and	O
the	O
fate	O
of	O
the	O
remaining	O
bacteria	O
has	O
been	O
unknown	O
.	O
<EOS>	B-X
Like	B-X
several	B-X
other	B-X
intracellular	B-X
pathogens	B-X
,	B-X
Mycobacterium	B-X
marinum	B-X
(	B-X
Mm	B-X
)	B-X
escapes	B-X
from	B-X
phagosomes	B-X
into	B-X
the	B-X
host	B-X
cytosol	B-X
where	B-X
it	B-X
can	B-X
polymerize	B-X
actin	B-X
,	B-X
leading	B-X
to	B-X
motility	B-X
that	B-X
promotes	B-X
spread	B-X
to	B-X
neighboring	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
only	B-X
approximately	B-X
25	B-X
%	B-X
of	B-X
internalized	B-X
Mm	B-X
form	B-X
actin	B-X
tails	B-X
,	B-X
and	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
remaining	B-X
bacteria	B-X
has	B-X
been	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
cytosolic	B-X
access	B-X
results	B-X
in	B-X
a	B-X
new	B-X
and	B-X
intricate	B-X
host	B-X
pathogen	B-X
interaction	B-X
:	B-X
host	B-X
macrophages	B-X
ubiquitinate	B-X
Mm	B-X
,	B-X
while	B-X
Mm	B-X
shed	B-X
their	B-X
ubiquitinated	B-X
cell	B-X
walls	B-X
.	B-X
Phagosomal	B-X
escape	B-X
and	B-X
ubiquitination	B-X
of	B-X
Mm	B-X
occurred	B-X
rapidly	B-X
,	B-X
prior	B-X
to	B-X
3.5	B-X
hours	B-X
post	B-X
infection	B-X
;	B-X
at	B-X
the	B-X
same	B-X
time	B-X
,	B-X
ubiquitinated	B-X
Mm	B-X
cell	B-X
wall	B-X
material	B-X
mixed	B-X
with	B-X
host-derived	B-X
dense	B-X
membrane	B-X
networks	B-X
appeared	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
cytosolic	B-X
bacteria	B-X
,	B-X
suggesting	B-X
cell	B-X
wall	B-X
shedding	B-X
and	B-X
association	B-X
with	B-X
remnants	B-X
of	B-X
the	B-X
lysed	B-X
phagosome	B-X
.	B-X
At	B-X
24	B-X
hours	B-X
post-infection	B-X
,	B-X
Mm	B-X
that	B-X
polymerized	B-X
actin	B-X
were	B-X
not	B-X
ubiquitinated	B-X
,	B-X
whereas	B-X
ubiquitinated	B-X
Mm	B-X
were	B-X
found	B-X
within	B-X
LAMP-1-positive	B-X
vacuoles	B-X
resembling	B-X
lysosomes	B-X
.	B-X
Though	B-X
double	B-X
membranes	B-X
were	B-X
observed	B-X
which	B-X
sequestered	B-X
Mm	B-X
away	B-X
from	B-X
the	B-X
cytosol	B-X
,	B-X
targeting	B-X
of	B-X
Mm	B-X
to	B-X
the	B-X
LAMP-1-positive	B-X
vacuoles	B-X
was	B-X
independent	B-X
of	B-X
classical	B-X
autophagy	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
absence	B-X
of	B-X
LC3	B-X
association	B-X
and	B-X
by	B-X
Atg5-independence	B-X
of	B-X
their	B-X
formation	B-X
.	B-X
Further	B-X
,	B-X
ubiquitination	B-X
and	B-X
LAMP-1	B-X
association	B-X
did	B-X
not	B-X
occur	B-X
with	B-X
mutant	B-X
avirulent	B-X
Mm	B-X
lacking	B-X
ESX-1	B-X
(	B-X
type	B-X
VII	B-X
)	B-X
secretion	B-X
,	B-X
which	B-X
fail	B-X
to	B-X
escape	B-X
the	B-X
primary	B-X
phagosome	B-X
;	B-X
apart	B-X
from	B-X
its	B-X
function	B-X
in	B-X
phagosome	B-X
escape	B-X
,	B-X
ESX-1	B-X
was	B-X
not	B-X
directly	B-X
required	B-X
for	B-X
Mm	B-X
ubiquitination	B-X
in	B-X
macrophages	B-X
or	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
virulent	B-X
Mm	B-X
follow	B-X
two	B-X
distinct	B-X
paths	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
infected	B-X
host	B-X
cells	B-X
:	B-X
bacterial	B-X
ubiquitination	B-X
is	B-X
followed	B-X
by	B-X
sequestration	B-X
into	B-X
lysosome-like	B-X
organelles	B-X
via	B-X
an	B-X
autophagy-independent	B-X
pathway	B-X
,	B-X
while	B-X
cell	B-X
wall	B-X
shedding	B-X
may	B-X
allow	B-X
escape	B-X
from	B-X
this	B-X
fate	B-X
to	B-X
permit	B-X
continued	B-X
residence	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
formation	B-X
of	B-X
actin	B-X
tails	B-X
.	B-X

Here	O
we	O
show	O
that	O
cytosolic	O
access	O
results	O
in	O
a	O
new	O
and	O
intricate	O
host	O
pathogen	O
interaction	O
:	O
host	O
macrophages	O
ubiquitinate	O
Mm	O
,	O
while	O
Mm	O
shed	O
their	O
ubiquitinated	O
cell	O
walls	O
.	O

Phagosomal	O
escape	O
and	O
ubiquitination	O
of	O
Mm	O
occurred	O
rapidly	O
,	O
prior	O
to	O
3	O
.	O
5	O
hours	O
post	O
infection	O
;	O
at	O
the	O
same	O
time	O
,	O
ubiquitinated	O
Mm	O
cell	O
wall	O
material	O
mixed	O
with	O
host	O
-	O
derived	O
dense	O
membrane	O
networks	O
appeared	O
in	O
close	O
proximity	O
to	O
cytosolic	O
bacteria	O
,	O
suggesting	O
cell	O
wall	O
shedding	O
and	O
association	O
with	O
remnants	O
of	O
the	O
lysed	O
phagosome	O
.	O
<EOS>	B-X
Like	B-X
several	B-X
other	B-X
intracellular	B-X
pathogens	B-X
,	B-X
Mycobacterium	B-X
marinum	B-X
(	B-X
Mm	B-X
)	B-X
escapes	B-X
from	B-X
phagosomes	B-X
into	B-X
the	B-X
host	B-X
cytosol	B-X
where	B-X
it	B-X
can	B-X
polymerize	B-X
actin	B-X
,	B-X
leading	B-X
to	B-X
motility	B-X
that	B-X
promotes	B-X
spread	B-X
to	B-X
neighboring	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
only	B-X
approximately	B-X
25	B-X
%	B-X
of	B-X
internalized	B-X
Mm	B-X
form	B-X
actin	B-X
tails	B-X
,	B-X
and	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
remaining	B-X
bacteria	B-X
has	B-X
been	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
cytosolic	B-X
access	B-X
results	B-X
in	B-X
a	B-X
new	B-X
and	B-X
intricate	B-X
host	B-X
pathogen	B-X
interaction	B-X
:	B-X
host	B-X
macrophages	B-X
ubiquitinate	B-X
Mm	B-X
,	B-X
while	B-X
Mm	B-X
shed	B-X
their	B-X
ubiquitinated	B-X
cell	B-X
walls	B-X
.	B-X
Phagosomal	B-X
escape	B-X
and	B-X
ubiquitination	B-X
of	B-X
Mm	B-X
occurred	B-X
rapidly	B-X
,	B-X
prior	B-X
to	B-X
3.5	B-X
hours	B-X
post	B-X
infection	B-X
;	B-X
at	B-X
the	B-X
same	B-X
time	B-X
,	B-X
ubiquitinated	B-X
Mm	B-X
cell	B-X
wall	B-X
material	B-X
mixed	B-X
with	B-X
host-derived	B-X
dense	B-X
membrane	B-X
networks	B-X
appeared	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
cytosolic	B-X
bacteria	B-X
,	B-X
suggesting	B-X
cell	B-X
wall	B-X
shedding	B-X
and	B-X
association	B-X
with	B-X
remnants	B-X
of	B-X
the	B-X
lysed	B-X
phagosome	B-X
.	B-X
At	B-X
24	B-X
hours	B-X
post-infection	B-X
,	B-X
Mm	B-X
that	B-X
polymerized	B-X
actin	B-X
were	B-X
not	B-X
ubiquitinated	B-X
,	B-X
whereas	B-X
ubiquitinated	B-X
Mm	B-X
were	B-X
found	B-X
within	B-X
LAMP-1-positive	B-X
vacuoles	B-X
resembling	B-X
lysosomes	B-X
.	B-X
Though	B-X
double	B-X
membranes	B-X
were	B-X
observed	B-X
which	B-X
sequestered	B-X
Mm	B-X
away	B-X
from	B-X
the	B-X
cytosol	B-X
,	B-X
targeting	B-X
of	B-X
Mm	B-X
to	B-X
the	B-X
LAMP-1-positive	B-X
vacuoles	B-X
was	B-X
independent	B-X
of	B-X
classical	B-X
autophagy	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
absence	B-X
of	B-X
LC3	B-X
association	B-X
and	B-X
by	B-X
Atg5-independence	B-X
of	B-X
their	B-X
formation	B-X
.	B-X
Further	B-X
,	B-X
ubiquitination	B-X
and	B-X
LAMP-1	B-X
association	B-X
did	B-X
not	B-X
occur	B-X
with	B-X
mutant	B-X
avirulent	B-X
Mm	B-X
lacking	B-X
ESX-1	B-X
(	B-X
type	B-X
VII	B-X
)	B-X
secretion	B-X
,	B-X
which	B-X
fail	B-X
to	B-X
escape	B-X
the	B-X
primary	B-X
phagosome	B-X
;	B-X
apart	B-X
from	B-X
its	B-X
function	B-X
in	B-X
phagosome	B-X
escape	B-X
,	B-X
ESX-1	B-X
was	B-X
not	B-X
directly	B-X
required	B-X
for	B-X
Mm	B-X
ubiquitination	B-X
in	B-X
macrophages	B-X
or	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
virulent	B-X
Mm	B-X
follow	B-X
two	B-X
distinct	B-X
paths	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
infected	B-X
host	B-X
cells	B-X
:	B-X
bacterial	B-X
ubiquitination	B-X
is	B-X
followed	B-X
by	B-X
sequestration	B-X
into	B-X
lysosome-like	B-X
organelles	B-X
via	B-X
an	B-X
autophagy-independent	B-X
pathway	B-X
,	B-X
while	B-X
cell	B-X
wall	B-X
shedding	B-X
may	B-X
allow	B-X
escape	B-X
from	B-X
this	B-X
fate	B-X
to	B-X
permit	B-X
continued	B-X
residence	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
formation	B-X
of	B-X
actin	B-X
tails	B-X
.	B-X

At	O
24	O
hours	O
post	O
-	O
infection	O
,	O
Mm	O
that	O
polymerized	O
actin	O
were	O
not	O
ubiquitinated	O
,	O
whereas	O
ubiquitinated	O
Mm	O
were	O
found	O
within	O
LAMP	B-Protein
-	I-Protein
1	I-Protein
-	O
positive	O
vacuoles	O
resembling	O
lysosomes	O
.	O
<EOS>	B-X
Chicken	B-X
embryo	B-X
fibroblasts	B-X
(	B-X
CEFs	B-X
)	B-X
are	B-X
among	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
cells	B-X
for	B-X
the	B-X
study	B-X
of	B-X
interactions	B-X
between	B-X
chicken	B-X
hosts	B-X
and	B-X
H5N1	B-X
avian	B-X
influenza	B-X
virus	B-X
(	B-X
AIV	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
eleven	B-X
housekeeping	B-X
genes	B-X
typically	B-X
used	B-X
for	B-X
the	B-X
normalization	B-X
of	B-X
quantitative	B-X
real-time	B-X
PCR	B-X
(	B-X
QPCR	B-X
)	B-X
analysis	B-X
in	B-X
mammals	B-X
were	B-X
compared	B-X
in	B-X
CEFs	B-X
infected	B-X
with	B-X
H5N1	B-X
AIV	B-X
to	B-X
determine	B-X
the	B-X
most	B-X
reliable	B-X
reference	B-X
genes	B-X
in	B-X
this	B-X
system	B-X
.	B-X
CEFs	B-X
cultured	B-X
from	B-X
10-day-old	B-X
SPF	B-X
chicken	B-X
embryos	B-X
were	B-X
infected	B-X
with	B-X
100	B-X
TCID	B-X
(	B-X
50	B-X
)	B-X
of	B-X
H5N1	B-X
AIV	B-X
and	B-X
harvested	B-X
at	B-X
3	B-X
,	B-X
12	B-X
,	B-X
24	B-X
and	B-X
30	B-X
hours	B-X
post-infection	B-X
.	B-X
Based	B-X
on	B-X
expression	B-X
stability	B-X
and	B-X
expression	B-X
levels	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
ribosomal	B-X
protein	B-X
L4	B-X
(	B-X
RPL4	B-X
)	B-X
and	B-X
tyrosine	B-X
3-monooxygenase	B-X
tryptophan	B-X
5-monooxygenase	B-X
activation	B-X
protein	B-X
zeta	B-X
polypeptide	B-X
(	B-X
YWHAZ	B-X
)	B-X
are	B-X
the	B-X
best	B-X
reference	B-X
genes	B-X
to	B-X
use	B-X
in	B-X
the	B-X
study	B-X
of	B-X
host	B-X
cell	B-X
response	B-X
to	B-X
H5N1	B-X
AIV	B-X
infection	B-X
.	B-X
However	B-X
,	B-X
for	B-X
the	B-X
study	B-X
of	B-X
replication	B-X
levels	B-X
of	B-X
H5N1	B-X
AIV	B-X
in	B-X
CEFs	B-X
,	B-X
the	B-X
β-actin	B-X
gene	B-X
(	B-X
ACTB	B-X
)	B-X
and	B-X
the	B-X
ribosomal	B-X
protein	B-X
L4	B-X
(	B-X
RPL4	B-X
)	B-X
gene	B-X
are	B-X
the	B-X
best	B-X
references	B-X
.	B-X

Though	O
double	O
membranes	O
were	O
observed	O
which	O
sequestered	O
Mm	O
away	O
from	O
the	O
cytosol	O
,	O
targeting	O
of	O
Mm	O
to	O
the	O
LAMP	B-Protein
-	I-Protein
1	I-Protein
-	O
positive	O
vacuoles	O
was	O
independent	O
of	O
classical	O
autophagy	O
,	O
as	O
demonstrated	O
by	O
absence	O
of	O
LC3	O
association	O
and	O
by	O
Atg5	B-Protein
-	O
independence	O
of	O
their	O
formation	O
.	O

Further	O
,	O
ubiquitination	O
and	O
LAMP	B-Protein
-	I-Protein
1	I-Protein
association	O
did	O
not	O
occur	O
with	O
mutant	O
avirulent	O
Mm	O
lacking	O
ESX	B-Protein
-	I-Protein
1	I-Protein
(	O
type	O
VII	O
)	O
secretion	O
,	O
which	O
fail	O
to	O
escape	O
the	O
primary	O
phagosome	O
;	O
apart	O
from	O
its	O
function	O
in	O
phagosome	O
escape	O
,	O
ESX	B-Protein
-	I-Protein
1	I-Protein
was	O
not	O
directly	O
required	O
for	O
Mm	O
ubiquitination	O
in	O
macrophages	O
or	O
in	O
vitro	O
.	O
<EOS>	B-X
It	B-X
is	B-X
characterized	B-X
by	B-X
cell	B-X
rounding	B-X
,	B-X
membrane	B-X
blebbing	B-X
,	B-X
cytoskeletal	B-X
collapse	B-X
,	B-X
cytoplasmic	B-X
condensation	B-X
,	B-X
and	B-X
fragmentation	B-X
,	B-X
nuclear	B-X
pyknosis	B-X
,	B-X
chromatin	B-X
condensation/fragmentation	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
membrane-enveloped	B-X
apoptotic	B-X
bodies	B-X
,	B-X
that	B-X
are	B-X
rapidly	B-X
phagocytosed	B-X
by	B-X
macrophages	B-X
or	B-X
neighboring	B-X
cells	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
describe	B-X
functions	B-X
of	B-X
autophagy	B-X
and	B-X
apoptosis	B-X
in	B-X
brain	B-X
homeostasis	B-X
,	B-X
especially	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
aforementioned	B-X
disorders	B-X
.	B-X
Sarcopenia	B-X
,	B-X
the	B-X
age-related	B-X
loss	B-X
of	B-X
muscle	B-X
mass	B-X
and	B-X
function	B-X
,	B-X
imposes	B-X
a	B-X
dramatic	B-X
burden	B-X
on	B-X
individuals	B-X
and	B-X
society	B-X
.	B-X
The	B-X
pathogenesis	B-X
of	B-X
sarcopenia	B-X
is	B-X
multifaceted	B-X
and	B-X
encompasses	B-X
lifestyle	B-X
habits	B-X
,	B-X
systemic	B-X
factors	B-X
(	B-X
e.g.	B-X
,	B-X
chronic	B-X
inflammation	B-X
and	B-X
hormonal	B-X
alterations	B-X
)	B-X
,	B-X
local	B-X
environment	B-X
perturbations	B-X
(	B-X
e.g.	B-X
,	B-X
vascular	B-X
dysfunction	B-X
)	B-X
,	B-X
and	B-X
intramuscular	B-X
specific	B-X
processes	B-X
.	B-X
In	B-X
this	B-X
scenario	B-X
,	B-X
derangements	B-X
in	B-X
skeletal	B-X
myocyte	B-X
mitochondrial	B-X
function	B-X
are	B-X
recognized	B-X
as	B-X
major	B-X
factors	B-X
contributing	B-X
to	B-X
the	B-X
age-dependent	B-X
muscle	B-X
degeneration	B-X
.	B-X
Extramuscular	B-X
alterations	B-X
accompanying	B-X
the	B-X
aging	B-X
process	B-X
with	B-X
a	B-X
potential	B-X
impact	B-X
on	B-X
myocyte	B-X
mitochondrial	B-X
function	B-X
are	B-X
also	B-X
discussed	B-X
.	B-X
We	B-X
conclude	B-X
with	B-X
presenting	B-X
methodological	B-X
and	B-X
safety	B-X
considerations	B-X
for	B-X
the	B-X
design	B-X
of	B-X
clinical	B-X
trials	B-X
targeting	B-X
mitochondrial	B-X
dysfunction	B-X
to	B-X
treat	B-X
sarcopenia	B-X
.	B-X
Special	B-X
emphasis	B-X
is	B-X
placed	B-X
on	B-X
the	B-X
importance	B-X
of	B-X
monitoring	B-X
the	B-X
effects	B-X
of	B-X
an	B-X
intervention	B-X
on	B-X
muscle	B-X
mitochondrial	B-X
function	B-X
and	B-X
identifying	B-X
the	B-X
optimal	B-X
target	B-X
population	B-X
for	B-X
the	B-X
trial	B-X
.	B-X

These	O
data	O
suggest	O
that	O
virulent	O
Mm	O
follow	O
two	O
distinct	O
paths	O
in	O
the	O
cytosol	O
of	O
infected	O
host	O
cells	O
:	O
bacterial	O
ubiquitination	O
is	O
followed	O
by	O
sequestration	O
into	O
lysosome	O
-	O
like	O
organelles	O
via	O
an	O
autophagy	O
-	O
independent	O
pathway	O
,	O
while	O
cell	O
wall	O
shedding	O
may	O
allow	O
escape	O
from	O
this	O
fate	O
to	O
permit	O
continued	O
residence	O
in	O
the	O
cytosol	O
and	O
formation	O
of	O
actin	O
tails	O
.	O
<EOS>	B-X
Like	B-X
several	B-X
other	B-X
intracellular	B-X
pathogens	B-X
,	B-X
Mycobacterium	B-X
marinum	B-X
(	B-X
Mm	B-X
)	B-X
escapes	B-X
from	B-X
phagosomes	B-X
into	B-X
the	B-X
host	B-X
cytosol	B-X
where	B-X
it	B-X
can	B-X
polymerize	B-X
actin	B-X
,	B-X
leading	B-X
to	B-X
motility	B-X
that	B-X
promotes	B-X
spread	B-X
to	B-X
neighboring	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
only	B-X
approximately	B-X
25	B-X
%	B-X
of	B-X
internalized	B-X
Mm	B-X
form	B-X
actin	B-X
tails	B-X
,	B-X
and	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
remaining	B-X
bacteria	B-X
has	B-X
been	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
cytosolic	B-X
access	B-X
results	B-X
in	B-X
a	B-X
new	B-X
and	B-X
intricate	B-X
host	B-X
pathogen	B-X
interaction	B-X
:	B-X
host	B-X
macrophages	B-X
ubiquitinate	B-X
Mm	B-X
,	B-X
while	B-X
Mm	B-X
shed	B-X
their	B-X
ubiquitinated	B-X
cell	B-X
walls	B-X
.	B-X
Phagosomal	B-X
escape	B-X
and	B-X
ubiquitination	B-X
of	B-X
Mm	B-X
occurred	B-X
rapidly	B-X
,	B-X
prior	B-X
to	B-X
3.5	B-X
hours	B-X
post	B-X
infection	B-X
;	B-X
at	B-X
the	B-X
same	B-X
time	B-X
,	B-X
ubiquitinated	B-X
Mm	B-X
cell	B-X
wall	B-X
material	B-X
mixed	B-X
with	B-X
host-derived	B-X
dense	B-X
membrane	B-X
networks	B-X
appeared	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
cytosolic	B-X
bacteria	B-X
,	B-X
suggesting	B-X
cell	B-X
wall	B-X
shedding	B-X
and	B-X
association	B-X
with	B-X
remnants	B-X
of	B-X
the	B-X
lysed	B-X
phagosome	B-X
.	B-X
At	B-X
24	B-X
hours	B-X
post-infection	B-X
,	B-X
Mm	B-X
that	B-X
polymerized	B-X
actin	B-X
were	B-X
not	B-X
ubiquitinated	B-X
,	B-X
whereas	B-X
ubiquitinated	B-X
Mm	B-X
were	B-X
found	B-X
within	B-X
LAMP-1-positive	B-X
vacuoles	B-X
resembling	B-X
lysosomes	B-X
.	B-X
Though	B-X
double	B-X
membranes	B-X
were	B-X
observed	B-X
which	B-X
sequestered	B-X
Mm	B-X
away	B-X
from	B-X
the	B-X
cytosol	B-X
,	B-X
targeting	B-X
of	B-X
Mm	B-X
to	B-X
the	B-X
LAMP-1-positive	B-X
vacuoles	B-X
was	B-X
independent	B-X
of	B-X
classical	B-X
autophagy	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
absence	B-X
of	B-X
LC3	B-X
association	B-X
and	B-X
by	B-X
Atg5-independence	B-X
of	B-X
their	B-X
formation	B-X
.	B-X
Further	B-X
,	B-X
ubiquitination	B-X
and	B-X
LAMP-1	B-X
association	B-X
did	B-X
not	B-X
occur	B-X
with	B-X
mutant	B-X
avirulent	B-X
Mm	B-X
lacking	B-X
ESX-1	B-X
(	B-X
type	B-X
VII	B-X
)	B-X
secretion	B-X
,	B-X
which	B-X
fail	B-X
to	B-X
escape	B-X
the	B-X
primary	B-X
phagosome	B-X
;	B-X
apart	B-X
from	B-X
its	B-X
function	B-X
in	B-X
phagosome	B-X
escape	B-X
,	B-X
ESX-1	B-X
was	B-X
not	B-X
directly	B-X
required	B-X
for	B-X
Mm	B-X
ubiquitination	B-X
in	B-X
macrophages	B-X
or	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
virulent	B-X
Mm	B-X
follow	B-X
two	B-X
distinct	B-X
paths	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
infected	B-X
host	B-X
cells	B-X
:	B-X
bacterial	B-X
ubiquitination	B-X
is	B-X
followed	B-X
by	B-X
sequestration	B-X
into	B-X
lysosome-like	B-X
organelles	B-X
via	B-X
an	B-X
autophagy-independent	B-X
pathway	B-X
,	B-X
while	B-X
cell	B-X
wall	B-X
shedding	B-X
may	B-X
allow	B-X
escape	B-X
from	B-X
this	B-X
fate	B-X
to	B-X
permit	B-X
continued	B-X
residence	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
formation	B-X
of	B-X
actin	B-X
tails	B-X
.	B-X

CHIP	B-Protein
functions	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
of	O
Runx1	B-Protein
.	O
<EOS>	B-X
Runx1	B-X
is	B-X
a	B-X
key	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
Improper	B-X
expression	B-X
and	B-X
mutations	B-X
in	B-X
Runx1	B-X
are	B-X
frequently	B-X
implicated	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
CHIP	B-X
,	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Hsc70-interacting	B-X
protein	B-X
,	B-X
also	B-X
named	B-X
Stub1	B-X
,	B-X
physically	B-X
interacts	B-X
with	B-X
Runx1	B-X
through	B-X
the	B-X
TPR	B-X
and	B-X
Charged	B-X
domains	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
Over-expression	B-X
of	B-X
CHIP	B-X
directly	B-X
induced	B-X
Runx1	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
through	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CHIP-mediated	B-X
degradation	B-X
of	B-X
Runx1	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
chaperone	B-X
Hsp70/90	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
CHIP	B-X
serves	B-X
as	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
regulates	B-X
Runx1	B-X
protein	B-X
stability	B-X
via	B-X
an	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
Hsp70/90	B-X
.	B-X

Runx1	B-Protein
is	O
a	O
key	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
hematopoietic	O
stem	O
cells	O
.	O
<EOS>	B-X
RUNX1/AML1	B-X
,	B-X
located	B-X
on	B-X
chromosome	B-X
21	B-X
,	B-X
is	B-X
a	B-X
key	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
and	B-X
the	B-X
gene	B-X
most	B-X
frequently	B-X
implicated	B-X
in	B-X
human	B-X
leukemias	B-X
.	B-X
Targeting	B-X
leukemia-initiating	B-X
cells	B-X
(	B-X
LICs	B-X
)	B-X
is	B-X
the	B-X
key	B-X
to	B-X
eradicating	B-X
leukemia	B-X
and	B-X
preventing	B-X
its	B-X
relapse	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
indicated	B-X
that	B-X
metabolic	B-X
regulation	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
maintenance	B-X
of	B-X
stemness	B-X
in	B-X
LICs	B-X
,	B-X
although	B-X
the	B-X
detailed	B-X
mechanisms	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
provide	B-X
intriguing	B-X
evidence	B-X
showing	B-X
that	B-X
a	B-X
glucose-responsive	B-X
transcription	B-X
factor	B-X
,	B-X
carbohydrate	B-X
responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
ChREBP	B-X
)	B-X
,	B-X
served	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
rather	B-X
than	B-X
an	B-X
oncogene	B-X
,	B-X
as	B-X
previously	B-X
described	B-X
,	B-X
to	B-X
inhibit	B-X
the	B-X
development	B-X
of	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
by	B-X
promoting	B-X
the	B-X
differentiation	B-X
of	B-X
LICs	B-X
.	B-X
However	B-X
,	B-X
ChREBP	B-X
was	B-X
not	B-X
required	B-X
for	B-X
the	B-X
normal	B-X
repopulation	B-X
abilities	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
ChREBP	B-X
promoted	B-X
leukemia	B-X
cell	B-X
differentiation	B-X
through	B-X
the	B-X
direct	B-X
inhibition	B-X
of	B-X
RUNX1	B-X
or	B-X
the	B-X
transactivation	B-X
of	B-X
TXNIP	B-X
to	B-X
downregulate	B-X
the	B-X
RUNX1	B-X
level	B-X
and	B-X
ROS	B-X
generation	B-X
.	B-X
Moreover	B-X
,	B-X
knockdown	B-X
of	B-X
ChREBP	B-X
in	B-X
human	B-X
leukemia	B-X
THP1	B-X
cells	B-X
led	B-X
to	B-X
markedly	B-X
enhanced	B-X
proliferation	B-X
and	B-X
decreased	B-X
differentiation	B-X
upon	B-X
PMA	B-X
treatment	B-X
.	B-X

Improper	O
expression	O
and	O
mutations	O
in	O
Runx1	B-Protein
are	O
frequently	O
implicated	O
in	O
human	O
leukemia	O
.	O
<EOS>	B-X
Runx1	B-X
is	B-X
a	B-X
key	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
Improper	B-X
expression	B-X
and	B-X
mutations	B-X
in	B-X
Runx1	B-X
are	B-X
frequently	B-X
implicated	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
CHIP	B-X
,	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Hsc70-interacting	B-X
protein	B-X
,	B-X
also	B-X
named	B-X
Stub1	B-X
,	B-X
physically	B-X
interacts	B-X
with	B-X
Runx1	B-X
through	B-X
the	B-X
TPR	B-X
and	B-X
Charged	B-X
domains	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
Over-expression	B-X
of	B-X
CHIP	B-X
directly	B-X
induced	B-X
Runx1	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
through	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CHIP-mediated	B-X
degradation	B-X
of	B-X
Runx1	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
chaperone	B-X
Hsp70/90	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
CHIP	B-X
serves	B-X
as	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
regulates	B-X
Runx1	B-X
protein	B-X
stability	B-X
via	B-X
an	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
Hsp70/90	B-X
.	B-X

Here	O
,	O
we	O
report	O
that	O
CHIP	B-Protein
,	O
the	O
carboxyl	O
terminus	O
of	O
Hsc70	O
-	O
interacting	O
protein	O
,	O
also	O
named	O
Stub1	B-Protein
,	O
physically	O
interacts	O
with	O
Runx1	B-Protein
through	O
the	O
TPR	O
and	O
Charged	O
domains	O
in	O
the	O
nucleus	O
.	O
<EOS>	B-X
Runx1	B-X
is	B-X
a	B-X
key	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
Improper	B-X
expression	B-X
and	B-X
mutations	B-X
in	B-X
Runx1	B-X
are	B-X
frequently	B-X
implicated	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
CHIP	B-X
,	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Hsc70-interacting	B-X
protein	B-X
,	B-X
also	B-X
named	B-X
Stub1	B-X
,	B-X
physically	B-X
interacts	B-X
with	B-X
Runx1	B-X
through	B-X
the	B-X
TPR	B-X
and	B-X
Charged	B-X
domains	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
Over-expression	B-X
of	B-X
CHIP	B-X
directly	B-X
induced	B-X
Runx1	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
through	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CHIP-mediated	B-X
degradation	B-X
of	B-X
Runx1	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
chaperone	B-X
Hsp70/90	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
CHIP	B-X
serves	B-X
as	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
regulates	B-X
Runx1	B-X
protein	B-X
stability	B-X
via	B-X
an	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
Hsp70/90	B-X
.	B-X

Over	O
-	O
expression	O
of	O
CHIP	B-Protein
directly	O
induced	O
Runx1	B-Protein
ubiquitination	O
and	O
degradation	O
through	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O
<EOS>	B-X
Runx1	B-X
is	B-X
a	B-X
key	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
Improper	B-X
expression	B-X
and	B-X
mutations	B-X
in	B-X
Runx1	B-X
are	B-X
frequently	B-X
implicated	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
CHIP	B-X
,	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Hsc70-interacting	B-X
protein	B-X
,	B-X
also	B-X
named	B-X
Stub1	B-X
,	B-X
physically	B-X
interacts	B-X
with	B-X
Runx1	B-X
through	B-X
the	B-X
TPR	B-X
and	B-X
Charged	B-X
domains	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
Over-expression	B-X
of	B-X
CHIP	B-X
directly	B-X
induced	B-X
Runx1	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
through	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CHIP-mediated	B-X
degradation	B-X
of	B-X
Runx1	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
chaperone	B-X
Hsp70/90	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
CHIP	B-X
serves	B-X
as	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
regulates	B-X
Runx1	B-X
protein	B-X
stability	B-X
via	B-X
an	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
Hsp70/90	B-X
.	B-X

Interestingly	O
,	O
we	O
found	O
that	O
CHIP	B-Protein
-	O
mediated	O
degradation	O
of	O
Runx1	B-Protein
is	O
independent	O
of	O
the	O
molecular	O
chaperone	O
Hsp70	O
/	O
90	O
.	O
<EOS>	B-X
Runx1	B-X
is	B-X
a	B-X
key	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
Improper	B-X
expression	B-X
and	B-X
mutations	B-X
in	B-X
Runx1	B-X
are	B-X
frequently	B-X
implicated	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
CHIP	B-X
,	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Hsc70-interacting	B-X
protein	B-X
,	B-X
also	B-X
named	B-X
Stub1	B-X
,	B-X
physically	B-X
interacts	B-X
with	B-X
Runx1	B-X
through	B-X
the	B-X
TPR	B-X
and	B-X
Charged	B-X
domains	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
Over-expression	B-X
of	B-X
CHIP	B-X
directly	B-X
induced	B-X
Runx1	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
through	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CHIP-mediated	B-X
degradation	B-X
of	B-X
Runx1	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
chaperone	B-X
Hsp70/90	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
CHIP	B-X
serves	B-X
as	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
regulates	B-X
Runx1	B-X
protein	B-X
stability	B-X
via	B-X
an	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
Hsp70/90	B-X
.	B-X

Taken	O
together	O
,	O
we	O
propose	O
that	O
CHIP	B-Protein
serves	O
as	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
that	O
regulates	O
Runx1	B-Protein
protein	O
stability	O
via	O
an	O
ubiquitination	O
and	O
degradation	O
mechanism	O
that	O
is	O
independent	O
of	O
Hsp70	O
/	O
90	O
.	O
<EOS>	B-X
Runx1	B-X
is	B-X
a	B-X
key	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
Improper	B-X
expression	B-X
and	B-X
mutations	B-X
in	B-X
Runx1	B-X
are	B-X
frequently	B-X
implicated	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
CHIP	B-X
,	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Hsc70-interacting	B-X
protein	B-X
,	B-X
also	B-X
named	B-X
Stub1	B-X
,	B-X
physically	B-X
interacts	B-X
with	B-X
Runx1	B-X
through	B-X
the	B-X
TPR	B-X
and	B-X
Charged	B-X
domains	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
Over-expression	B-X
of	B-X
CHIP	B-X
directly	B-X
induced	B-X
Runx1	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
through	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CHIP-mediated	B-X
degradation	B-X
of	B-X
Runx1	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
chaperone	B-X
Hsp70/90	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
CHIP	B-X
serves	B-X
as	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
that	B-X
regulates	B-X
Runx1	B-X
protein	B-X
stability	B-X
via	B-X
an	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
Hsp70/90	B-X
.	B-X

RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
like	O
receptors	O
:	O
sensing	O
and	O
responding	O
to	O
RNA	O
virus	O
infection	O
.	O
<EOS>	B-X
Viral	B-X
and	B-X
microbial	B-X
pathogens	B-X
contain	B-X
specific	B-X
motifs	B-X
or	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
(	B-X
PAMPs	B-X
)	B-X
that	B-X
are	B-X
recognized	B-X
by	B-X
cell	B-X
surface-	B-X
and	B-X
endosome-associated	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
.	B-X
RNA	B-X
virus	B-X
infection	B-X
is	B-X
also	B-X
detected	B-X
through	B-X
TLR-independent	B-X
mechanisms	B-X
.	B-X
Early	B-X
viral	B-X
replicative	B-X
intermediates	B-X
are	B-X
detected	B-X
by	B-X
two	B-X
recently	B-X
characterized	B-X
cystolic	B-X
viral	B-X
RNA	B-X
receptors-RIG-I	B-X
and	B-X
MDA-5	B-X
.	B-X
Both	B-X
are	B-X
DExDH/box	B-X
RNA	B-X
helicases	B-X
,	B-X
and	B-X
RIG-I	B-X
specifically	B-X
recognizes	B-X
5'-triphosphate	B-X
containing	B-X
viral	B-X
RNA	B-X
and	B-X
transmits	B-X
signals	B-X
that	B-X
induce	B-X
type	B-X
I	B-X
interferon-mediated	B-X
host	B-X
immunity	B-X
against	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
RIG-I-like	B-X
receptor	B-X
(	B-X
RLR	B-X
)	B-X
signal	B-X
transduction	B-X
and	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
-	B-X
ubiquitination	B-X
,	B-X
deubiquitination	B-X
,	B-X
ISGylation	B-X
-	B-X
underlying	B-X
this	B-X
important	B-X
host	B-X
response	B-X
.	B-X

Viral	O
and	O
microbial	O
pathogens	O
contain	O
specific	O
motifs	O
or	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
(	O
PAMPs	O
)	O
that	O
are	O
recognized	O
by	O
cell	O
surface	O
-	O
and	O
endosome	O
-	O
associated	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
.	O
<EOS>	B-X
Innate	B-X
immunity	B-X
represents	B-X
the	B-X
first	B-X
barrier	B-X
for	B-X
host	B-X
defense	B-X
against	B-X
microbial	B-X
infection	B-X
.	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
are	B-X
the	B-X
most	B-X
well-defined	B-X
PRRs	B-X
with	B-X
respect	B-X
to	B-X
PAMP	B-X
recognition	B-X
and	B-X
induction	B-X
of	B-X
innate	B-X
immune	B-X
responses	B-X
.	B-X
They	B-X
recognize	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
(	B-X
PAMPs	B-X
)	B-X
and	B-X
trigger	B-X
innate	B-X
immune	B-X
responses	B-X
by	B-X
inducing	B-X
inflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
,	B-X
antigen-presenting	B-X
molecules	B-X
,	B-X
and	B-X
costimulatory	B-X
molecules	B-X
.	B-X
TLRs	B-X
are	B-X
expressed	B-X
either	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
or	B-X
within	B-X
endosomes	B-X
of	B-X
innate	B-X
immune	B-X
cells	B-X
.	B-X
NK	B-X
cells	B-X
are	B-X
one	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
cells	B-X
and	B-X
also	B-X
express	B-X
TLRs	B-X
to	B-X
recognize	B-X
or	B-X
respond	B-X
to	B-X
PAMPs	B-X
.	B-X
TLRs	B-X
in	B-X
NK	B-X
cells	B-X
induce	B-X
the	B-X
innate	B-X
immune	B-X
responses	B-X
against	B-X
bacterial	B-X
and	B-X
viral	B-X
infections	B-X
via	B-X
inducing	B-X
NK	B-X
cytotoxicity	B-X
and	B-X
cytokine	B-X
production	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
the	B-X
expression	B-X
and	B-X
cellular	B-X
function	B-X
of	B-X
TLRs	B-X
in	B-X
NK	B-X
cells	B-X
and	B-X
also	B-X
introduce	B-X
some	B-X
therapeutic	B-X
applications	B-X
of	B-X
TLR	B-X
agonists	B-X
for	B-X
NK	B-X
cell-mediated	B-X
immunotherapy	B-X
.	B-X

RNA	O
virus	O
infection	O
is	O
also	O
detected	O
through	O
TLR	O
-	O
independent	O
mechanisms	O
.	O
<EOS>	B-X
Viral	B-X
and	B-X
microbial	B-X
pathogens	B-X
contain	B-X
specific	B-X
motifs	B-X
or	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
(	B-X
PAMPs	B-X
)	B-X
that	B-X
are	B-X
recognized	B-X
by	B-X
cell	B-X
surface-	B-X
and	B-X
endosome-associated	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
.	B-X
RNA	B-X
virus	B-X
infection	B-X
is	B-X
also	B-X
detected	B-X
through	B-X
TLR-independent	B-X
mechanisms	B-X
.	B-X
Early	B-X
viral	B-X
replicative	B-X
intermediates	B-X
are	B-X
detected	B-X
by	B-X
two	B-X
recently	B-X
characterized	B-X
cystolic	B-X
viral	B-X
RNA	B-X
receptors-RIG-I	B-X
and	B-X
MDA-5	B-X
.	B-X
Both	B-X
are	B-X
DExDH/box	B-X
RNA	B-X
helicases	B-X
,	B-X
and	B-X
RIG-I	B-X
specifically	B-X
recognizes	B-X
5'-triphosphate	B-X
containing	B-X
viral	B-X
RNA	B-X
and	B-X
transmits	B-X
signals	B-X
that	B-X
induce	B-X
type	B-X
I	B-X
interferon-mediated	B-X
host	B-X
immunity	B-X
against	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
RIG-I-like	B-X
receptor	B-X
(	B-X
RLR	B-X
)	B-X
signal	B-X
transduction	B-X
and	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
-	B-X
ubiquitination	B-X
,	B-X
deubiquitination	B-X
,	B-X
ISGylation	B-X
-	B-X
underlying	B-X
this	B-X
important	B-X
host	B-X
response	B-X
.	B-X

Early	O
viral	O
replicative	O
intermediates	O
are	O
detected	O
by	O
two	O
recently	O
characterized	O
cystolic	O
viral	O
RNA	O
receptors	O
-	O
RIG	B-Protein
-	I-Protein
I	I-Protein
and	O
MDA	B-Protein
-	I-Protein
5	I-Protein
.	O
<EOS>	B-X
Viral	B-X
and	B-X
microbial	B-X
pathogens	B-X
contain	B-X
specific	B-X
motifs	B-X
or	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
(	B-X
PAMPs	B-X
)	B-X
that	B-X
are	B-X
recognized	B-X
by	B-X
cell	B-X
surface-	B-X
and	B-X
endosome-associated	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
.	B-X
RNA	B-X
virus	B-X
infection	B-X
is	B-X
also	B-X
detected	B-X
through	B-X
TLR-independent	B-X
mechanisms	B-X
.	B-X
Early	B-X
viral	B-X
replicative	B-X
intermediates	B-X
are	B-X
detected	B-X
by	B-X
two	B-X
recently	B-X
characterized	B-X
cystolic	B-X
viral	B-X
RNA	B-X
receptors-RIG-I	B-X
and	B-X
MDA-5	B-X
.	B-X
Both	B-X
are	B-X
DExDH/box	B-X
RNA	B-X
helicases	B-X
,	B-X
and	B-X
RIG-I	B-X
specifically	B-X
recognizes	B-X
5'-triphosphate	B-X
containing	B-X
viral	B-X
RNA	B-X
and	B-X
transmits	B-X
signals	B-X
that	B-X
induce	B-X
type	B-X
I	B-X
interferon-mediated	B-X
host	B-X
immunity	B-X
against	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
RIG-I-like	B-X
receptor	B-X
(	B-X
RLR	B-X
)	B-X
signal	B-X
transduction	B-X
and	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
-	B-X
ubiquitination	B-X
,	B-X
deubiquitination	B-X
,	B-X
ISGylation	B-X
-	B-X
underlying	B-X
this	B-X
important	B-X
host	B-X
response	B-X
.	B-X

Both	O
are	O
DExDH	O
/	O
box	O
RNA	O
helicases	O
,	O
and	O
RIG	B-Protein
-	I-Protein
I	I-Protein
specifically	O
recognizes	O
5	O
'	O
-	O
triphosphate	O
containing	O
viral	O
RNA	O
and	O
transmits	O
signals	O
that	O
induce	O
type	O
I	O
interferon	O
-	O
mediated	O
host	O
immunity	O
against	O
virus	O
infection	O
.	O
<EOS>	B-X
RNA	B-X
virus	B-X
infection	B-X
is	B-X
also	B-X
detected	B-X
through	B-X
TLR-independent	B-X
mechanisms	B-X
.	B-X
Early	B-X
viral	B-X
replicative	B-X
intermediates	B-X
are	B-X
detected	B-X
by	B-X
two	B-X
recently	B-X
characterized	B-X
cystolic	B-X
viral	B-X
RNA	B-X
receptors-RIG-I	B-X
and	B-X
MDA-5	B-X
.	B-X
Both	B-X
are	B-X
DExDH/box	B-X
RNA	B-X
helicases	B-X
,	B-X
and	B-X
RIG-I	B-X
specifically	B-X
recognizes	B-X
5'-triphosphate	B-X
containing	B-X
viral	B-X
RNA	B-X
and	B-X
transmits	B-X
signals	B-X
that	B-X
induce	B-X
type	B-X
I	B-X
interferon-mediated	B-X
host	B-X
immunity	B-X
against	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
RIG-I-like	B-X
receptor	B-X
(	B-X
RLR	B-X
)	B-X
signal	B-X
transduction	B-X
and	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
-	B-X
ubiquitination	B-X
,	B-X
deubiquitination	B-X
,	B-X
ISGylation	B-X
-	B-X
underlying	B-X
this	B-X
important	B-X
host	B-X
response	B-X
.	B-X

In	O
this	O
review	O
,	O
we	O
will	O
focus	O
on	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
like	O
receptor	O
(	O
RLR	O
)	O
signal	O
transduction	O
and	O
the	O
regulatory	O
mechanisms	O
-	O
ubiquitination	O
,	O
deubiquitination	O
,	O
ISGylation	O
-	O
underlying	O
this	O
important	O
host	O
response	O
.	O
<EOS>	B-X
Viral	B-X
and	B-X
microbial	B-X
pathogens	B-X
contain	B-X
specific	B-X
motifs	B-X
or	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
(	B-X
PAMPs	B-X
)	B-X
that	B-X
are	B-X
recognized	B-X
by	B-X
cell	B-X
surface-	B-X
and	B-X
endosome-associated	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
.	B-X
RNA	B-X
virus	B-X
infection	B-X
is	B-X
also	B-X
detected	B-X
through	B-X
TLR-independent	B-X
mechanisms	B-X
.	B-X
Early	B-X
viral	B-X
replicative	B-X
intermediates	B-X
are	B-X
detected	B-X
by	B-X
two	B-X
recently	B-X
characterized	B-X
cystolic	B-X
viral	B-X
RNA	B-X
receptors-RIG-I	B-X
and	B-X
MDA-5	B-X
.	B-X
Both	B-X
are	B-X
DExDH/box	B-X
RNA	B-X
helicases	B-X
,	B-X
and	B-X
RIG-I	B-X
specifically	B-X
recognizes	B-X
5'-triphosphate	B-X
containing	B-X
viral	B-X
RNA	B-X
and	B-X
transmits	B-X
signals	B-X
that	B-X
induce	B-X
type	B-X
I	B-X
interferon-mediated	B-X
host	B-X
immunity	B-X
against	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
RIG-I-like	B-X
receptor	B-X
(	B-X
RLR	B-X
)	B-X
signal	B-X
transduction	B-X
and	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
-	B-X
ubiquitination	B-X
,	B-X
deubiquitination	B-X
,	B-X
ISGylation	B-X
-	B-X
underlying	B-X
this	B-X
important	B-X
host	B-X
response	B-X
.	B-X

Arginine	O
methylation	O
analysis	O
of	O
the	O
splicing	O
-	O
associated	O
SR	O
protein	O
SFRS9	B-Protein
/	O
SRP30C	B-Protein
.	O
<EOS>	B-X
The	B-X
human	B-X
SFRS9/SRp30c	B-X
belongs	B-X
to	B-X
the	B-X
SR	B-X
family	B-X
of	B-X
splicing	B-X
regulators	B-X
.	B-X
Despite	B-X
evidence	B-X
that	B-X
members	B-X
of	B-X
this	B-X
protein	B-X
family	B-X
may	B-X
be	B-X
targeted	B-X
by	B-X
arginine	B-X
methylation	B-X
,	B-X
this	B-X
has	B-X
yet	B-X
to	B-X
be	B-X
experimentally	B-X
addressed	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
SFRS9	B-X
is	B-X
a	B-X
target	B-X
for	B-X
PRMT1-mediated	B-X
arginine	B-X
methylation	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
that	B-X
it	B-X
is	B-X
immunoprecipitated	B-X
from	B-X
HEK-293	B-X
lysates	B-X
by	B-X
antibodies	B-X
that	B-X
recognize	B-X
both	B-X
mono-	B-X
and	B-X
dimethylated	B-X
arginines	B-X
.	B-X
We	B-X
further	B-X
observed	B-X
that	B-X
upon	B-X
treatment	B-X
with	B-X
the	B-X
methylation	B-X
inhibitor	B-X
Adox	B-X
,	B-X
the	B-X
fluorescent	B-X
EGFP-SFRS9	B-X
re-localizes	B-X
to	B-X
dot-like	B-X
structures	B-X
in	B-X
the	B-X
cell	B-X
nucleus	B-X
.	B-X
In	B-X
subsequent	B-X
confocal	B-X
analyses	B-X
,	B-X
we	B-X
found	B-X
that	B-X
EGFP-SFRS9	B-X
localizes	B-X
to	B-X
nucleoli	B-X
in	B-X
Adox-treated	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
the	B-X
importance	B-X
of	B-X
arginine	B-X
methylation	B-X
for	B-X
the	B-X
subnuclear	B-X
localization	B-X
of	B-X
SFRS9	B-X
.	B-X

The	O
human	O
SFRS9	B-Protein
/	O
SRp30c	B-Protein
belongs	O
to	O
the	O
SR	O
family	O
of	O
splicing	O
regulators	O
.	O

Despite	O
evidence	O
that	O
members	O
of	O
this	O
protein	O
family	O
may	O
be	O
targeted	O
by	O
arginine	O
methylation	O
,	O
this	O
has	O
yet	O
to	O
be	O
experimentally	O
addressed	O
.	O
<EOS>	B-X
The	B-X
human	B-X
SFRS9/SRp30c	B-X
belongs	B-X
to	B-X
the	B-X
SR	B-X
family	B-X
of	B-X
splicing	B-X
regulators	B-X
.	B-X
Despite	B-X
evidence	B-X
that	B-X
members	B-X
of	B-X
this	B-X
protein	B-X
family	B-X
may	B-X
be	B-X
targeted	B-X
by	B-X
arginine	B-X
methylation	B-X
,	B-X
this	B-X
has	B-X
yet	B-X
to	B-X
be	B-X
experimentally	B-X
addressed	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
SFRS9	B-X
is	B-X
a	B-X
target	B-X
for	B-X
PRMT1-mediated	B-X
arginine	B-X
methylation	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
that	B-X
it	B-X
is	B-X
immunoprecipitated	B-X
from	B-X
HEK-293	B-X
lysates	B-X
by	B-X
antibodies	B-X
that	B-X
recognize	B-X
both	B-X
mono-	B-X
and	B-X
dimethylated	B-X
arginines	B-X
.	B-X
We	B-X
further	B-X
observed	B-X
that	B-X
upon	B-X
treatment	B-X
with	B-X
the	B-X
methylation	B-X
inhibitor	B-X
Adox	B-X
,	B-X
the	B-X
fluorescent	B-X
EGFP-SFRS9	B-X
re-localizes	B-X
to	B-X
dot-like	B-X
structures	B-X
in	B-X
the	B-X
cell	B-X
nucleus	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
the	B-X
importance	B-X
of	B-X
arginine	B-X
methylation	B-X
for	B-X
the	B-X
subnuclear	B-X
localization	B-X
of	B-X
SFRS9	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
found	O
that	O
SFRS9	B-Protein
is	O
a	O
target	O
for	O
PRMT1	B-Protein
-	O
mediated	O
arginine	O
methylation	O
in	O
vitro	O
,	O
and	O
that	O
it	O
is	O
immunoprecipitated	O
from	O
HEK	O
-	O
293	O
lysates	O
by	O
antibodies	O
that	O
recognize	O
both	O
mono	O
-	O
and	O
dimethylated	O
arginines	O
.	O
<EOS>	B-X
The	B-X
human	B-X
SFRS9/SRp30c	B-X
belongs	B-X
to	B-X
the	B-X
SR	B-X
family	B-X
of	B-X
splicing	B-X
regulators	B-X
.	B-X
Despite	B-X
evidence	B-X
that	B-X
members	B-X
of	B-X
this	B-X
protein	B-X
family	B-X
may	B-X
be	B-X
targeted	B-X
by	B-X
arginine	B-X
methylation	B-X
,	B-X
this	B-X
has	B-X
yet	B-X
to	B-X
be	B-X
experimentally	B-X
addressed	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
SFRS9	B-X
is	B-X
a	B-X
target	B-X
for	B-X
PRMT1-mediated	B-X
arginine	B-X
methylation	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
that	B-X
it	B-X
is	B-X
immunoprecipitated	B-X
from	B-X
HEK-293	B-X
lysates	B-X
by	B-X
antibodies	B-X
that	B-X
recognize	B-X
both	B-X
mono-	B-X
and	B-X
dimethylated	B-X
arginines	B-X
.	B-X
We	B-X
further	B-X
observed	B-X
that	B-X
upon	B-X
treatment	B-X
with	B-X
the	B-X
methylation	B-X
inhibitor	B-X
Adox	B-X
,	B-X
the	B-X
fluorescent	B-X
EGFP-SFRS9	B-X
re-localizes	B-X
to	B-X
dot-like	B-X
structures	B-X
in	B-X
the	B-X
cell	B-X
nucleus	B-X
.	B-X
In	B-X
subsequent	B-X
confocal	B-X
analyses	B-X
,	B-X
we	B-X
found	B-X
that	B-X
EGFP-SFRS9	B-X
localizes	B-X
to	B-X
nucleoli	B-X
in	B-X
Adox-treated	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
the	B-X
importance	B-X
of	B-X
arginine	B-X
methylation	B-X
for	B-X
the	B-X
subnuclear	B-X
localization	B-X
of	B-X
SFRS9	B-X
.	B-X

We	O
further	O
observed	O
that	O
upon	O
treatment	O
with	O
the	O
methylation	O
inhibitor	O
Adox	O
,	O
the	O
fluorescent	O
EGFP	B-Protein
-	O
SFRS9	B-Protein
re	O
-	O
localizes	O
to	O
dot	O
-	O
like	O
structures	O
in	O
the	O
cell	O
nucleus	O
.	O
<EOS>	B-X
The	B-X
human	B-X
SFRS9/SRp30c	B-X
belongs	B-X
to	B-X
the	B-X
SR	B-X
family	B-X
of	B-X
splicing	B-X
regulators	B-X
.	B-X
Despite	B-X
evidence	B-X
that	B-X
members	B-X
of	B-X
this	B-X
protein	B-X
family	B-X
may	B-X
be	B-X
targeted	B-X
by	B-X
arginine	B-X
methylation	B-X
,	B-X
this	B-X
has	B-X
yet	B-X
to	B-X
be	B-X
experimentally	B-X
addressed	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
SFRS9	B-X
is	B-X
a	B-X
target	B-X
for	B-X
PRMT1-mediated	B-X
arginine	B-X
methylation	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
that	B-X
it	B-X
is	B-X
immunoprecipitated	B-X
from	B-X
HEK-293	B-X
lysates	B-X
by	B-X
antibodies	B-X
that	B-X
recognize	B-X
both	B-X
mono-	B-X
and	B-X
dimethylated	B-X
arginines	B-X
.	B-X
We	B-X
further	B-X
observed	B-X
that	B-X
upon	B-X
treatment	B-X
with	B-X
the	B-X
methylation	B-X
inhibitor	B-X
Adox	B-X
,	B-X
the	B-X
fluorescent	B-X
EGFP-SFRS9	B-X
re-localizes	B-X
to	B-X
dot-like	B-X
structures	B-X
in	B-X
the	B-X
cell	B-X
nucleus	B-X
.	B-X
In	B-X
subsequent	B-X
confocal	B-X
analyses	B-X
,	B-X
we	B-X
found	B-X
that	B-X
EGFP-SFRS9	B-X
localizes	B-X
to	B-X
nucleoli	B-X
in	B-X
Adox-treated	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
the	B-X
importance	B-X
of	B-X
arginine	B-X
methylation	B-X
for	B-X
the	B-X
subnuclear	B-X
localization	B-X
of	B-X
SFRS9	B-X
.	B-X

In	O
subsequent	O
confocal	O
analyses	O
,	O
we	O
found	O
that	O
EGFP	B-Protein
-	O
SFRS9	B-Protein
localizes	O
to	O
nucleoli	O
in	O
Adox	O
-	O
treated	O
cells	O
.	O
<EOS>	B-X
The	B-X
human	B-X
SFRS9/SRp30c	B-X
belongs	B-X
to	B-X
the	B-X
SR	B-X
family	B-X
of	B-X
splicing	B-X
regulators	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
SFRS9	B-X
is	B-X
a	B-X
target	B-X
for	B-X
PRMT1-mediated	B-X
arginine	B-X
methylation	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
that	B-X
it	B-X
is	B-X
immunoprecipitated	B-X
from	B-X
HEK-293	B-X
lysates	B-X
by	B-X
antibodies	B-X
that	B-X
recognize	B-X
both	B-X
mono-	B-X
and	B-X
dimethylated	B-X
arginines	B-X
.	B-X
We	B-X
further	B-X
observed	B-X
that	B-X
upon	B-X
treatment	B-X
with	B-X
the	B-X
methylation	B-X
inhibitor	B-X
Adox	B-X
,	B-X
the	B-X
fluorescent	B-X
EGFP-SFRS9	B-X
re-localizes	B-X
to	B-X
dot-like	B-X
structures	B-X
in	B-X
the	B-X
cell	B-X
nucleus	B-X
.	B-X
In	B-X
subsequent	B-X
confocal	B-X
analyses	B-X
,	B-X
we	B-X
found	B-X
that	B-X
EGFP-SFRS9	B-X
localizes	B-X
to	B-X
nucleoli	B-X
in	B-X
Adox-treated	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
the	B-X
importance	B-X
of	B-X
arginine	B-X
methylation	B-X
for	B-X
the	B-X
subnuclear	B-X
localization	B-X
of	B-X
SFRS9	B-X
.	B-X

Our	O
findings	O
indicate	O
the	O
importance	O
of	O
arginine	O
methylation	O
for	O
the	O
subnuclear	O
localization	O
of	O
SFRS9	B-Protein
.	O
<EOS>	B-X
The	B-X
human	B-X
SFRS9/SRp30c	B-X
belongs	B-X
to	B-X
the	B-X
SR	B-X
family	B-X
of	B-X
splicing	B-X
regulators	B-X
.	B-X
Despite	B-X
evidence	B-X
that	B-X
members	B-X
of	B-X
this	B-X
protein	B-X
family	B-X
may	B-X
be	B-X
targeted	B-X
by	B-X
arginine	B-X
methylation	B-X
,	B-X
this	B-X
has	B-X
yet	B-X
to	B-X
be	B-X
experimentally	B-X
addressed	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
SFRS9	B-X
is	B-X
a	B-X
target	B-X
for	B-X
PRMT1-mediated	B-X
arginine	B-X
methylation	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
that	B-X
it	B-X
is	B-X
immunoprecipitated	B-X
from	B-X
HEK-293	B-X
lysates	B-X
by	B-X
antibodies	B-X
that	B-X
recognize	B-X
both	B-X
mono-	B-X
and	B-X
dimethylated	B-X
arginines	B-X
.	B-X
We	B-X
further	B-X
observed	B-X
that	B-X
upon	B-X
treatment	B-X
with	B-X
the	B-X
methylation	B-X
inhibitor	B-X
Adox	B-X
,	B-X
the	B-X
fluorescent	B-X
EGFP-SFRS9	B-X
re-localizes	B-X
to	B-X
dot-like	B-X
structures	B-X
in	B-X
the	B-X
cell	B-X
nucleus	B-X
.	B-X
In	B-X
subsequent	B-X
confocal	B-X
analyses	B-X
,	B-X
we	B-X
found	B-X
that	B-X
EGFP-SFRS9	B-X
localizes	B-X
to	B-X
nucleoli	B-X
in	B-X
Adox-treated	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
the	B-X
importance	B-X
of	B-X
arginine	B-X
methylation	B-X
for	B-X
the	B-X
subnuclear	B-X
localization	B-X
of	B-X
SFRS9	B-X
.	B-X

Multicenter	O
evaluation	O
of	O
an	O
investigational	O
prostate	O
cancer	O
methylation	O
assay	O
.	O
<EOS>	B-X
Prostate	B-X
specific	B-X
antigen	B-X
tests	B-X
have	B-X
low	B-X
specificity	B-X
,	B-X
which	B-X
frequently	B-X
results	B-X
in	B-X
unnecessary	B-X
biopsy	B-X
and	B-X
typically	B-X
limits	B-X
screening	B-X
to	B-X
patients	B-X
with	B-X
prostate	B-X
specific	B-X
antigen	B-X
greater	B-X
than	B-X
4.0	B-X
ng/ml	B-X
.	B-X
We	B-X
evaluated	B-X
an	B-X
investigational	B-X
prostate	B-X
cancer	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
assay	B-X
that	B-X
detects	B-X
aberrant	B-X
methylation	B-X
in	B-X
3	B-X
markers	B-X
(	B-X
GSTP1	B-X
,	B-X
RARbeta2	B-X
and	B-X
APC	B-X
)	B-X
that	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
The	B-X
inadequacies	B-X
of	B-X
prostate	B-X
specific	B-X
antigen	B-X
testing	B-X
have	B-X
created	B-X
a	B-X
need	B-X
for	B-X
novel	B-X
markers	B-X
for	B-X
prostate	B-X
cancer	B-X
screening	B-X
.	B-X
The	B-X
investigational	B-X
ProCaM™	B-X
prostate	B-X
cancer	B-X
methylation	B-X
assay	B-X
detects	B-X
aberrant	B-X
methylation	B-X
of	B-X
DNA	B-X
in	B-X
cells	B-X
associated	B-X
with	B-X
prostate	B-X
cancer	B-X
.	B-X
We	B-X
describe	B-X
a	B-X
large	B-X
,	B-X
prospective	B-X
,	B-X
multicenter	B-X
study	B-X
done	B-X
to	B-X
verify	B-X
the	B-X
performance	B-X
of	B-X
this	B-X
assay	B-X
.	B-X

PURPOSE	O
:	O
Prostate	B-Protein
specific	I-Protein
antigen	I-Protein
tests	O
have	O
low	O
specificity	O
,	O
which	O
frequently	O
results	O
in	O
unnecessary	O
biopsy	O
and	O
typically	O
limits	O
screening	O
to	O
patients	O
with	O
prostate	B-Protein
specific	I-Protein
antigen	I-Protein
greater	O
than	O
4	O
.	O
0	O
ng	O
/	O
ml	O
.	O

We	O
evaluated	O
an	O
investigational	O
prostate	O
cancer	O
methylation	O
specific	O
polymerase	O
chain	O
reaction	O
assay	O
that	O
detects	O
aberrant	O
methylation	O
in	O
3	O
markers	O
(	O
GSTP1	B-Protein
,	O
RARbeta2	B-Protein
and	O
APC	B-Protein
)	O
that	O
indicate	O
the	O
presence	O
of	O
prostate	O
cancer	O
.	O
<EOS>	B-X
Prostate	B-X
specific	B-X
antigen	B-X
tests	B-X
have	B-X
low	B-X
specificity	B-X
,	B-X
which	B-X
frequently	B-X
results	B-X
in	B-X
unnecessary	B-X
biopsy	B-X
and	B-X
typically	B-X
limits	B-X
screening	B-X
to	B-X
patients	B-X
with	B-X
prostate	B-X
specific	B-X
antigen	B-X
greater	B-X
than	B-X
4.0	B-X
ng/ml	B-X
.	B-X
We	B-X
evaluated	B-X
an	B-X
investigational	B-X
prostate	B-X
cancer	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
assay	B-X
that	B-X
detects	B-X
aberrant	B-X
methylation	B-X
in	B-X
3	B-X
markers	B-X
(	B-X
GSTP1	B-X
,	B-X
RARbeta2	B-X
and	B-X
APC	B-X
)	B-X
that	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
assay	O
was	O
evaluated	O
in	O
337	O
post	O
-	O
digital	O
rectal	O
examination	O
urine	O
samples	O
(	O
178	O
cancer	O
and	O
159	O
noncancer	O
)	O
collected	O
prospectively	O
at	O
a	O
total	O
of	O
9	O
clinical	O
sites	O
.	O

Samples	O
were	O
processed	O
wholly	O
or	O
after	O
division	O
into	O
equal	O
portions	O
.	O
<EOS>	B-X
In	B-X
younger	B-X
populations	B-X
,	B-X
partial	B-X
meniscectomy	B-X
may	B-X
provide	B-X
equal	B-X
long-term	B-X
symptom	B-X
relief	B-X
,	B-X
earlier	B-X
return	B-X
to	B-X
play	B-X
,	B-X
and	B-X
lower	B-X
revision	B-X
surgery	B-X
rate	B-X
compared	B-X
with	B-X
meniscal	B-X
repair	B-X
.	B-X
Considering	B-X
that	B-X
the	B-X
composition	B-X
of	B-X
our	B-X
current	B-X
diet	B-X
is	B-X
characterized	B-X
by	B-X
a	B-X
high	B-X
sodium	B-X
and	B-X
low	B-X
potassium	B-X
content	B-X
,	B-X
increasing	B-X
dietary	B-X
potassium	B-X
may	B-X
be	B-X
equally	B-X
important	B-X
as	B-X
reducing	B-X
sodium	B-X
.	B-X
Data	B-X
collection	B-X
was	B-X
undertaken	B-X
partly	B-X
or	B-X
wholly	B-X
by	B-X
volunteers	B-X
in	B-X
37	B-X
%	B-X
of	B-X
schemes	B-X
,	B-X
and	B-X
such	B-X
schemes	B-X
covered	B-X
significantly	B-X
more	B-X
sites	B-X
and	B-X
species	B-X
than	B-X
those	B-X
undertaken	B-X
by	B-X
professionals	B-X
alone	B-X
.	B-X
This	B-X
would	B-X
stop	B-X
the	B-X
dissection	B-X
of	B-X
the	B-X
dural	B-X
border	B-X
cell	B-X
layer	B-X
,	B-X
and	B-X
pressure	B-X
within	B-X
the	B-X
hematoma	B-X
cavity	B-X
would	B-X
equalize	B-X
with	B-X
that	B-X
in	B-X
the	B-X
torn	B-X
bridging	B-X
vein	B-X
or	B-X
veins	B-X
.	B-X

Subject	O
prostate	B-Protein
specific	I-Protein
antigen	I-Protein
was	O
2	O
.	O
0	O
to	O
10	O
.	O
0	O
ng	O
/	O
ml	O
.	O

All	O
subjects	O
underwent	O
transrectal	O
ultrasound	O
guided	O
needle	O
biopsy	O
with	O
6	O
or	O
greater	O
cores	O
sampled	O
.	O
<EOS>	B-X
Ultrasound	B-X
(	B-X
US	B-X
)	B-X
-guided	B-X
biopsy	B-X
is	B-X
widely	B-X
used	B-X
for	B-X
the	B-X
diagnostic	B-X
confirmation	B-X
of	B-X
focal	B-X
lesions	B-X
.	B-X
For	B-X
sampling	B-X
of	B-X
prostate	B-X
tissue	B-X
,	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
/US	B-X
fusion-guided	B-X
biopsy	B-X
has	B-X
already	B-X
been	B-X
implemented	B-X
in	B-X
routine	B-X
clinical	B-X
practice	B-X
and	B-X
has	B-X
shown	B-X
a	B-X
superior	B-X
detection	B-X
rate	B-X
of	B-X
significant	B-X
prostate	B-X
cancer	B-X
in	B-X
risk	B-X
assessment	B-X
compared	B-X
with	B-X
standard	B-X
systematic	B-X
biopsy	B-X
.	B-X
Newer	B-X
three-dimensional	B-X
software	B-X
tools	B-X
with	B-X
volumetric	B-X
mapping	B-X
of	B-X
the	B-X
prostate	B-X
and	B-X
biopsy	B-X
core	B-X
channels	B-X
provide	B-X
a	B-X
better	B-X
overview	B-X
of	B-X
systematic	B-X
biopsy	B-X
and	B-X
thus	B-X
contribute	B-X
to	B-X
more	B-X
accurate	B-X
treatment	B-X
planning	B-X
.	B-X
Automatic	B-X
fusion	B-X
is	B-X
a	B-X
time-saver	B-X
and	B-X
can	B-X
reduce	B-X
potential	B-X
examiner	B-X
errors	B-X
through	B-X
greater	B-X
standardization	B-X
of	B-X
the	B-X
fusion	B-X
process	B-X
itself	B-X
.	B-X

Detection	O
of	O
1	O
or	O
greater	O
markers	O
indicated	O
positivity	O
.	O
<EOS>	B-X
Our	B-X
aim	B-X
of	B-X
was	B-X
to	B-X
compare	B-X
importance	B-X
of	B-X
the	B-X
tumor	B-X
markers	B-X
(	B-X
TMs	B-X
)	B-X
serum	B-X
carcinoembryonic	B-X
antigen	B-X
(	B-X
CEA	B-X
)	B-X
and	B-X
carbohydrate	B-X
antigen	B-X
(	B-X
CA	B-X
)	B-X
19-9	B-X
in	B-X
prediction	B-X
of	B-X
recurrence	B-X
after	B-X
curative	B-X
gastrectomy	B-X
for	B-X
gastric	B-X
cancer	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
authors	B-X
conducted	B-X
a	B-X
comparative	B-X
quantitative	B-X
evaluation	B-X
of	B-X
the	B-X
proliferation	B-X
markers	B-X
ProEx	B-X
C	B-X
(	B-X
an	B-X
aberrant	B-X
S-phase	B-X
induction	B-X
marker	B-X
,	B-X
human	B-X
papillomavirus	B-X
E6-E7	B-X
correlated	B-X
)	B-X
and	B-X
MIB-1	B-X
in	B-X
squamous	B-X
intraepithelial	B-X
lesions	B-X
(	B-X
SIL	B-X
)	B-X
to	B-X
identify	B-X
a	B-X
biomolecular	B-X
profile	B-X
informative	B-X
for	B-X
the	B-X
diagnosis	B-X
of	B-X
high-grade	B-X
SIL/cervical	B-X
intraepithelial	B-X
neoplasia	B-X
3	B-X
or	B-X
greater	B-X
that	B-X
was	B-X
complementary	B-X
to	B-X
the	B-X
morphologic	B-X
Papanicolaou	B-X
(	B-X
Pap	B-X
)	B-X
test	B-X
(	B-X
``	B-X
biomolecular	B-X
Pap	B-X
test	B-X
''	B-X
)	B-X
.	B-X
Other	B-X
PET	B-X
tracers	B-X
which	B-X
are	B-X
considered	B-X
as	B-X
proliferation	B-X
markers	B-X
may	B-X
allow	B-X
an	B-X
improved	B-X
differential	B-X
diagnosis	B-X
of	B-X
tumor	B-X
and	B-X
inflammation	B-X
.	B-X
2-	B-X
(	B-X
11	B-X
)	B-X
C-thymidine	B-X
,	B-X
(	B-X
76	B-X
)	B-X
Br-bromofluorodeoxyuridine	B-X
,	B-X
(	B-X
11	B-X
)	B-X
C-FMAU	B-X
)	B-X
are	B-X
true	B-X
proliferation	B-X
markers	B-X
,	B-X
but	B-X
the	B-X
tissue	B-X
kinetics	B-X
of	B-X
radiopharmaceuticals	B-X
tracing	B-X
amino	B-X
acid	B-X
transport	B-X
,	B-X
membrane	B-X
metabolism	B-X
,	B-X
enzyme	B-X
activity	B-X
or	B-X
receptor	B-X
expression	B-X
can	B-X
be	B-X
a	B-X
surrogate	B-X
marker	B-X
of	B-X
cellular	B-X
proliferation	B-X
if	B-X
the	B-X
activity	B-X
of	B-X
such	B-X
processes	B-X
is	B-X
increased	B-X
in	B-X
rapidly	B-X
dividing	B-X
cells	B-X
.	B-X
Well-known	B-X
imaging	B-X
targets	B-X
for	B-X
oncology	B-X
are	B-X
:	B-X
(	B-X
i	B-X
)	B-X
glucose	B-X
transport	B-X
(	B-X
(	B-X
18	B-X
)	B-X
F-FDG	B-X
)	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
choline	B-X
kinase	B-X
activity	B-X
(	B-X
(	B-X
11	B-X
)	B-X
C-choline	B-X
)	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
amino	B-X
acid	B-X
transport	B-X
(	B-X
(	B-X
11	B-X
)	B-X
C-methionine	B-X
)	B-X
;	B-X
and	B-X
(	B-X
iv	B-X
)	B-X
activity	B-X
of	B-X
thymidine	B-X
kinase	B-X
1	B-X
(	B-X
(	B-X
18	B-X
)	B-X
F-FLT	B-X
)	B-X
.	B-X
Radiolabeled	B-X
choline	B-X
,	B-X
amino	B-X
acids	B-X
and	B-X
nucleosides	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
show	B-X
greater	B-X
tumor-specificity	B-X
than	B-X
(	B-X
18	B-X
)	B-X
F-FDG	B-X
,	B-X
both	B-X
in	B-X
experimental	B-X
animals	B-X
and	B-X
in	B-X
humans	B-X
.	B-X
(	B-X
11	B-X
)	B-X
C-choline	B-X
is	B-X
strongly	B-X
accumulated	B-X
in	B-X
bacterial	B-X
infections	B-X
and	B-X
sterile	B-X
inflammation	B-X
.	B-X
(	B-X
11	B-X
)	B-X
C-Methionine	B-X
can	B-X
show	B-X
high	B-X
uptake	B-X
in	B-X
brain	B-X
abscesses	B-X
.	B-X
(	B-X
18	B-X
)	B-X
F-FLT	B-X
is	B-X
taken	B-X
up	B-X
in	B-X
non-metastatic	B-X
reactive	B-X
lymph	B-X
nodes	B-X
because	B-X
of	B-X
reactive	B-X
B-lymphocyte	B-X
proliferation	B-X
.	B-X
Because	B-X
of	B-X
such	B-X
limitations	B-X
,	B-X
the	B-X
tumor	B-X
specificity	B-X
of	B-X
PET	B-X
will	B-X
never	B-X
reach	B-X
100	B-X
%	B-X
.	B-X
Proliferation	B-X
markers	B-X
should	B-X
therefore	B-X
not	B-X
be	B-X
considered	B-X
as	B-X
replacements	B-X
of	B-X
FDG	B-X
,	B-X
but	B-X
rather	B-X
as	B-X
useful	B-X
additions	B-X
to	B-X
the	B-X
imaging	B-X
arsenal	B-X
which	B-X
can	B-X
provide	B-X
additional	B-X
diagnostic	B-X
specificity	B-X
and	B-X
biological	B-X
information	B-X
for	B-X
treatment	B-X
planning	B-X
and	B-X
response	B-X
monitoring	B-X
.	B-X

RESULTS	O
:	O
Methylation	O
specific	O
polymerase	O
chain	O
reaction	O
assay	O
performance	O
was	O
better	O
in	O
whole	O
than	O
in	O
divided	O
urine	O
cohorts	O
(	O
p	O
=	O
0	O
.	O
035	O
)	O
.	O

Assay	O
AUC	O
was	O
0	O
.	O
72	O
in	O
the	O
whole	O
urine	O
cohort	O
and	O
0	O
.	O
67	O
in	O
the	O
combined	O
population	O
.	O

These	O
values	O
were	O
higher	O
than	O
those	O
of	O
prostate	B-Protein
specific	I-Protein
antigen	I-Protein
alone	O
using	O
4	O
.	O
0	O
ng	O
/	O
ml	O
as	O
the	O
cutoff	O
(	O
p	O
=	O
0	O
.	O
00	O
and	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

Moreover	O
,	O
the	O
assay	O
together	O
with	O
the	O
Prostate	O
Cancer	O
Prevention	O
Trial	O
risk	O
calculator	O
or	O
a	O
standard	O
nomogram	O
significantly	O
improved	O
AUC	O
in	O
the	O
whole	O
urine	O
cohort	O
and	O
the	O
combined	O
population	O
vs	O
predictive	O
algorithms	O
alone	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
<EOS>	B-X
Prostate	B-X
specific	B-X
antigen	B-X
tests	B-X
have	B-X
low	B-X
specificity	B-X
,	B-X
which	B-X
frequently	B-X
results	B-X
in	B-X
unnecessary	B-X
biopsy	B-X
and	B-X
typically	B-X
limits	B-X
screening	B-X
to	B-X
patients	B-X
with	B-X
prostate	B-X
specific	B-X
antigen	B-X
greater	B-X
than	B-X
4.0	B-X
ng/ml	B-X
.	B-X
We	B-X
evaluated	B-X
an	B-X
investigational	B-X
prostate	B-X
cancer	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
assay	B-X
that	B-X
detects	B-X
aberrant	B-X
methylation	B-X
in	B-X
3	B-X
markers	B-X
(	B-X
GSTP1	B-X
,	B-X
RARbeta2	B-X
and	B-X
APC	B-X
)	B-X
that	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X

Assay	O
positive	O
predictive	O
value	O
was	O
54	O
%	O
in	O
whole	O
urine	O
cohort	O
with	O
prostate	B-Protein
specific	I-Protein
antigen	I-Protein
2	O
.	O
0	O
to	O
4	O
.	O
0	O
ng	O
/	O
ml	O
and	O
negative	O
predictive	O
value	O
was	O
87	O
%	O
with	O
prostate	B-Protein
specific	I-Protein
antigen	I-Protein
4	O
.	O
1	O
to	O
10	O
.	O
0	O
ng	O
/	O
ml	O
.	O

Assay	O
positive	O
predictive	O
value	O
was	O
higher	O
in	O
subjects	O
with	O
all	O
3	O
methylation	O
markers	O
positive	O
.	O
<EOS>	B-X
We	B-X
evaluated	B-X
an	B-X
investigational	B-X
prostate	B-X
cancer	B-X
methylation	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
assay	B-X
that	B-X
detects	B-X
aberrant	B-X
methylation	B-X
in	B-X
3	B-X
markers	B-X
(	B-X
GSTP1	B-X
,	B-X
RARbeta2	B-X
and	B-X
APC	B-X
)	B-X
that	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
mismatch	B-X
of	B-X
thallium-201	B-X
(	B-X
Tl	B-X
)	B-X
and	B-X
iodine-123-beta-methyl-iodophenyl-pentadecanoic	B-X
acid	B-X
(	B-X
BMIPP	B-X
)	B-X
myocardial	B-X
single-photon	B-X
emission	B-X
computed	B-X
tomography	B-X
(	B-X
SPECT	B-X
)	B-X
and	B-X
autonomic	B-X
nervous	B-X
system	B-X
activity	B-X
in	B-X
myocardial	B-X
infarction	B-X
(	B-X
MI	B-X
)	B-X
patients	B-X
.	B-X
The	B-X
subjects	B-X
were	B-X
40	B-X
patients	B-X
(	B-X
34	B-X
males	B-X
,	B-X
6	B-X
females	B-X
)	B-X
who	B-X
underwent	B-X
examinations	B-X
by	B-X
123I-BMIPP	B-X
and	B-X
201Tl	B-X
myocardial	B-X
SPECT	B-X
imaging	B-X
and	B-X
24-hour	B-X
Holter	B-X
monitoring	B-X
within	B-X
a	B-X
3-day	B-X
period	B-X
3	B-X
weeks	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
their	B-X
first	B-X
MI	B-X
.	B-X
High	B-X
frequency	B-X
(	B-X
HF	B-X
)	B-X
and	B-X
low	B-X
frequency	B-X
(	B-X
LF	B-X
)	B-X
were	B-X
defined	B-X
as	B-X
markers	B-X
of	B-X
cardiac	B-X
vagal	B-X
activity	B-X
in	B-X
the	B-X
former	B-X
and	B-X
the	B-X
LF/HF	B-X
ratio	B-X
as	B-X
sympathetic	B-X
activity	B-X
.	B-X
Greater	B-X
or	B-X
more	B-X
extensive	B-X
decreases	B-X
in	B-X
the	B-X
BMIPP	B-X
image	B-X
than	B-X
that	B-X
in	B-X
the	B-X
Tl	B-X
image	B-X
were	B-X
defined	B-X
as	B-X
a	B-X
positive	B-X
mismatch	B-X
.	B-X
Patients	B-X
were	B-X
divided	B-X
into	B-X
positive	B-X
and	B-X
negative	B-X
mismatch	B-X
groups	B-X
of	B-X
20	B-X
patients	B-X
each	B-X
.	B-X
The	B-X
incidences	B-X
of	B-X
clinical	B-X
signs	B-X
suggesting	B-X
residual	B-X
myocardial	B-X
ischemia	B-X
were	B-X
significantly	B-X
greater	B-X
in	B-X
the	B-X
positive	B-X
than	B-X
in	B-X
the	B-X
negative	B-X
mismatch	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
The	B-X
mean	B-X
values	B-X
for	B-X
HF	B-X
over	B-X
the	B-X
entire	B-X
24-hour	B-X
period	B-X
and	B-X
over	B-X
the	B-X
5-hour	B-X
nocturnal	B-X
period	B-X
(	B-X
0-5	B-X
AM	B-X
)	B-X
in	B-X
the	B-X
positive	B-X
mismatch	B-X
group	B-X
were	B-X
both	B-X
significantly	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
the	B-X
negative	B-X
mismatch	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
in	B-X
both	B-X
groups	B-X
)	B-X
.	B-X
The	B-X
24-hour	B-X
mean	B-X
HF	B-X
and	B-X
mean	B-X
nighttime	B-X
HF	B-X
in	B-X
patients	B-X
with	B-X
signs	B-X
of	B-X
residual	B-X
ischemia	B-X
were	B-X
both	B-X
significantly	B-X
lower	B-X
than	B-X
in	B-X
those	B-X
without	B-X
signs	B-X
of	B-X
residual	B-X
ischemia	B-X
in	B-X
the	B-X
positive	B-X
mismatch	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
in	B-X
both	B-X
groups	B-X
)	B-X
.	B-X
The	B-X
mean	B-X
LF/HF	B-X
ratio	B-X
for	B-X
both	B-X
the	B-X
entire	B-X
24-hour	B-X
and	B-X
the	B-X
nocturnal	B-X
period	B-X
in	B-X
the	B-X
positive	B-X
mismatch	B-X
group	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
those	B-X
in	B-X
the	B-X
negative	B-X
mismatch	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
,	B-X
P	B-X
<	B-X
0.05	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
The	B-X
daily	B-X
profile	B-X
of	B-X
hourly	B-X
HF	B-X
measurements	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
the	B-X
positive	B-X
mismatch	B-X
group	B-X
than	B-X
in	B-X
the	B-X
negative	B-X
mismatch	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0.02	B-X
)	B-X
.	B-X
The	B-X
mean	B-X
values	B-X
of	B-X
HF	B-X
for	B-X
24-hour	B-X
and	B-X
5-hour	B-X
periods	B-X
were	B-X
significantly	B-X
lower	B-X
in	B-X
patients	B-X
with	B-X
signs	B-X
of	B-X
residual	B-X
ischemia	B-X
in	B-X
the	B-X
positive	B-X
mismatch	B-X
group	B-X
than	B-X
in	B-X
those	B-X
with	B-X
signs	B-X
of	B-X
residual	B-X
ischemia	B-X
in	B-X
the	B-X
negative	B-X
mismatch	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
,	B-X
P	B-X
<	B-X
0.02	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
There	B-X
were	B-X
no	B-X
significant	B-X
differences	B-X
between	B-X
the	B-X
patients	B-X
with	B-X
signs	B-X
of	B-X
residual	B-X
ischemia	B-X
in	B-X
the	B-X
negative	B-X
mismatch	B-X
group	B-X
and	B-X
those	B-X
without	B-X
signs	B-X
of	B-X
residual	B-X
ischemia	B-X
in	B-X
the	B-X
positive	B-X
and	B-X
negative	B-X
mismatch	B-X
group	B-X
with	B-X
regard	B-X
to	B-X
the	B-X
mean	B-X
values	B-X
of	B-X
HF	B-X
and	B-X
the	B-X
LF/HF	B-X
ratio	B-X
measured	B-X
every	B-X
hour	B-X
for	B-X
24	B-X
hours	B-X
and	B-X
5	B-X
hours	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
from	B-X
the	B-X
present	B-X
study	B-X
that	B-X
the	B-X
findings	B-X
of	B-X
a	B-X
mismatch	B-X
on	B-X
123I-BMIPP	B-X
and	B-X
201Tl	B-X
myocardial	B-X
SPECT	B-X
3	B-X
weeks	B-X
after	B-X
a	B-X
first	B-X
acute	B-X
myocardial	B-X
infarction	B-X
with	B-X
uncomplicated	B-X
moderate	B-X
or	B-X
severe	B-X
heart	B-X
failure	B-X
and	B-X
decreased	B-X
heart	B-X
rate	B-X
variability	B-X
are	B-X
related	B-X
to	B-X
residual	B-X
myocardial	B-X
ischemia	B-X
.	B-X
A	B-X
combined	B-X
assessment	B-X
of	B-X
heart	B-X
rate	B-X
variability	B-X
in	B-X
24-hour	B-X
Holter	B-X
ECG	B-X
monitoring	B-X
and	B-X
perfusion-metabolism	B-X
mismatch	B-X
in	B-X
123I-BMIPP	B-X
and	B-X
201Tl	B-X
myocardial	B-X
SPECT	B-X
is	B-X
useful	B-X
for	B-X
determining	B-X
residual	B-X
myocardial	B-X
ischemia	B-X
in	B-X
the	B-X
follow-up	B-X
of	B-X
those	B-X
with	B-X
acute	B-X
myocardial	B-X
infarction	B-X
.	B-X

CONCLUSIONS	O
:	O
These	O
data	O
demonstrate	O
that	O
this	O
investigational	O
assay	O
used	O
in	O
conjunction	O
with	O
current	O
screening	O
algorithms	O
may	O
potentially	O
add	O
value	O
to	O
the	O
biopsy	O
decision	O
making	O
process	O
.	O

The	O
HECT	O
-	O
type	O
E3	O
ubiquitin	B-Protein
ligase	O
AIP2	B-Protein
inhibits	O
activation	O
-	O
induced	O
T	O
-	O
cell	O
death	O
by	O
catalyzing	O
EGR2	B-Protein
ubiquitination	O
.	O
<EOS>	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
which	B-X
target	B-X
specific	B-X
molecules	B-X
for	B-X
proteolytic	B-X
destruction	B-X
,	B-X
have	B-X
emerged	B-X
as	B-X
key	B-X
regulators	B-X
of	B-X
immune	B-X
functions	B-X
.	B-X
Several	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
including	B-X
c-Cbl	B-X
,	B-X
Cbl-b	B-X
,	B-X
GRAIL	B-X
,	B-X
Itch	B-X
,	B-X
and	B-X
Nedd4	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
negatively	B-X
regulate	B-X
T-cell	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
HECT-type	B-X
E3	B-X
ligase	B-X
AIP2	B-X
positively	B-X
regulates	B-X
T-cell	B-X
activation	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
AIP2	B-X
in	B-X
mouse	B-X
primary	B-X
T	B-X
cells	B-X
enhances	B-X
their	B-X
proliferation	B-X
and	B-X
interleukin-2	B-X
production	B-X
by	B-X
suppressing	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
AIP2	B-X
interacts	B-X
with	B-X
and	B-X
promotes	B-X
ubiquitin-mediated	B-X
degradation	B-X
of	B-X
EGR2	B-X
,	B-X
a	B-X
zinc	B-X
finger	B-X
transcription	B-X
factor	B-X
that	B-X
has	B-X
been	B-X
found	B-X
to	B-X
regulate	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
expression	B-X
during	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
.	B-X
Suppression	B-X
of	B-X
AIP2	B-X
expression	B-X
by	B-X
small	B-X
RNA	B-X
interference	B-X
upregulates	B-X
EGR2	B-X
,	B-X
inhibits	B-X
EGR2	B-X
ubiquitination	B-X
and	B-X
FasL	B-X
expression	B-X
,	B-X
and	B-X
enhances	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
AIP2	B-X
regulates	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
by	B-X
suppressing	B-X
EGR2-mediated	B-X
FasL	B-X
expression	B-X
via	B-X
the	B-X
ubiquitin	B-X
pathway	B-X
.	B-X

E3	O
ubiquitin	B-Protein
ligases	O
,	O
which	O
target	O
specific	O
molecules	O
for	O
proteolytic	O
destruction	O
,	O
have	O
emerged	O
as	O
key	O
regulators	O
of	O
immune	O
functions	O
.	O
<EOS>	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
have	B-X
emerged	B-X
as	B-X
key	B-X
molecular	B-X
regulators	B-X
of	B-X
immune	B-X
cell	B-X
function	B-X
.	B-X
Three	B-X
families	B-X
of	B-X
proteins	B-X
with	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
have	B-X
been	B-X
described	B-X
(	B-X
the	B-X
HECT	B-X
,	B-X
RING	B-X
and	B-X
U-box	B-X
proteins	B-X
)	B-X
,	B-X
and	B-X
each	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
immune	B-X
responses	B-X
during	B-X
infection	B-X
by	B-X
targeting	B-X
specific	B-X
inhibitory	B-X
molecules	B-X
for	B-X
proteolytic	B-X
destruction	B-X
.	B-X
Several	B-X
HECT	B-X
and	B-X
RING	B-X
E3	B-X
proteins	B-X
have	B-X
now	B-X
also	B-X
been	B-X
linked	B-X
to	B-X
the	B-X
induction	B-X
and	B-X
maintenance	B-X
of	B-X
immune	B-X
self-tolerance	B-X
:	B-X
c-Cbl	B-X
,	B-X
Cbl-b	B-X
,	B-X
GRAIL	B-X
,	B-X
Itch	B-X
and	B-X
Nedd4	B-X
each	B-X
negatively	B-X
regulate	B-X
T	B-X
cell	B-X
growth	B-X
factor	B-X
production	B-X
and	B-X
proliferation	B-X
.	B-X
This	B-X
review	B-X
will	B-X
discuss	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
ubiquitination	B-X
of	B-X
select	B-X
components	B-X
of	B-X
the	B-X
antigen-sensing	B-X
signaling	B-X
apparatus	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
the	B-X
clonal	B-X
anergy	B-X
state	B-X
.	B-X

Several	O
E3	O
ubiquitin	B-Protein
ligases	O
,	O
including	O
c	B-Protein
-	I-Protein
Cbl	I-Protein
,	O
Cbl	B-Protein
-	I-Protein
b	I-Protein
,	O
GRAIL	B-Protein
,	O
Itch	B-Protein
,	O
and	O
Nedd4	B-Protein
,	O
have	O
been	O
shown	O
to	O
negatively	O
regulate	O
T	O
-	O
cell	O
activation	O
.	O
<EOS>	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
which	B-X
target	B-X
specific	B-X
molecules	B-X
for	B-X
proteolytic	B-X
destruction	B-X
,	B-X
have	B-X
emerged	B-X
as	B-X
key	B-X
regulators	B-X
of	B-X
immune	B-X
functions	B-X
.	B-X
Several	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
including	B-X
c-Cbl	B-X
,	B-X
Cbl-b	B-X
,	B-X
GRAIL	B-X
,	B-X
Itch	B-X
,	B-X
and	B-X
Nedd4	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
negatively	B-X
regulate	B-X
T-cell	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
HECT-type	B-X
E3	B-X
ligase	B-X
AIP2	B-X
positively	B-X
regulates	B-X
T-cell	B-X
activation	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
AIP2	B-X
in	B-X
mouse	B-X
primary	B-X
T	B-X
cells	B-X
enhances	B-X
their	B-X
proliferation	B-X
and	B-X
interleukin-2	B-X
production	B-X
by	B-X
suppressing	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
AIP2	B-X
interacts	B-X
with	B-X
and	B-X
promotes	B-X
ubiquitin-mediated	B-X
degradation	B-X
of	B-X
EGR2	B-X
,	B-X
a	B-X
zinc	B-X
finger	B-X
transcription	B-X
factor	B-X
that	B-X
has	B-X
been	B-X
found	B-X
to	B-X
regulate	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
expression	B-X
during	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
.	B-X
Suppression	B-X
of	B-X
AIP2	B-X
expression	B-X
by	B-X
small	B-X
RNA	B-X
interference	B-X
upregulates	B-X
EGR2	B-X
,	B-X
inhibits	B-X
EGR2	B-X
ubiquitination	B-X
and	B-X
FasL	B-X
expression	B-X
,	B-X
and	B-X
enhances	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
AIP2	B-X
regulates	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
by	B-X
suppressing	B-X
EGR2-mediated	B-X
FasL	B-X
expression	B-X
via	B-X
the	B-X
ubiquitin	B-X
pathway	B-X
.	B-X

Here	O
,	O
we	O
report	O
that	O
the	O
HECT	O
-	O
type	O
E3	O
ligase	O
AIP2	B-Protein
positively	O
regulates	O
T	O
-	O
cell	O
activation	O
.	O
<EOS>	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
which	B-X
target	B-X
specific	B-X
molecules	B-X
for	B-X
proteolytic	B-X
destruction	B-X
,	B-X
have	B-X
emerged	B-X
as	B-X
key	B-X
regulators	B-X
of	B-X
immune	B-X
functions	B-X
.	B-X
Several	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
including	B-X
c-Cbl	B-X
,	B-X
Cbl-b	B-X
,	B-X
GRAIL	B-X
,	B-X
Itch	B-X
,	B-X
and	B-X
Nedd4	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
negatively	B-X
regulate	B-X
T-cell	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
HECT-type	B-X
E3	B-X
ligase	B-X
AIP2	B-X
positively	B-X
regulates	B-X
T-cell	B-X
activation	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
AIP2	B-X
in	B-X
mouse	B-X
primary	B-X
T	B-X
cells	B-X
enhances	B-X
their	B-X
proliferation	B-X
and	B-X
interleukin-2	B-X
production	B-X
by	B-X
suppressing	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
AIP2	B-X
interacts	B-X
with	B-X
and	B-X
promotes	B-X
ubiquitin-mediated	B-X
degradation	B-X
of	B-X
EGR2	B-X
,	B-X
a	B-X
zinc	B-X
finger	B-X
transcription	B-X
factor	B-X
that	B-X
has	B-X
been	B-X
found	B-X
to	B-X
regulate	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
expression	B-X
during	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
.	B-X
Suppression	B-X
of	B-X
AIP2	B-X
expression	B-X
by	B-X
small	B-X
RNA	B-X
interference	B-X
upregulates	B-X
EGR2	B-X
,	B-X
inhibits	B-X
EGR2	B-X
ubiquitination	B-X
and	B-X
FasL	B-X
expression	B-X
,	B-X
and	B-X
enhances	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
AIP2	B-X
regulates	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
by	B-X
suppressing	B-X
EGR2-mediated	B-X
FasL	B-X
expression	B-X
via	B-X
the	B-X
ubiquitin	B-X
pathway	B-X
.	B-X

Ectopic	O
expression	O
of	O
AIP2	B-Protein
in	O
mouse	O
primary	O
T	O
cells	O
enhances	O
their	O
proliferation	O
and	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
production	O
by	O
suppressing	O
the	O
apoptosis	O
of	O
T	O
cells	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
HECT-type	B-X
E3	B-X
ligase	B-X
AIP2	B-X
positively	B-X
regulates	B-X
T-cell	B-X
activation	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
AIP2	B-X
in	B-X
mouse	B-X
primary	B-X
T	B-X
cells	B-X
enhances	B-X
their	B-X
proliferation	B-X
and	B-X
interleukin-2	B-X
production	B-X
by	B-X
suppressing	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
AIP2	B-X
interacts	B-X
with	B-X
and	B-X
promotes	B-X
ubiquitin-mediated	B-X
degradation	B-X
of	B-X
EGR2	B-X
,	B-X
a	B-X
zinc	B-X
finger	B-X
transcription	B-X
factor	B-X
that	B-X
has	B-X
been	B-X
found	B-X
to	B-X
regulate	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
expression	B-X
during	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
.	B-X
Suppression	B-X
of	B-X
AIP2	B-X
expression	B-X
by	B-X
small	B-X
RNA	B-X
interference	B-X
upregulates	B-X
EGR2	B-X
,	B-X
inhibits	B-X
EGR2	B-X
ubiquitination	B-X
and	B-X
FasL	B-X
expression	B-X
,	B-X
and	B-X
enhances	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
AIP2	B-X
regulates	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
by	B-X
suppressing	B-X
EGR2-mediated	B-X
FasL	B-X
expression	B-X
via	B-X
the	B-X
ubiquitin	B-X
pathway	B-X
.	B-X

AIP2	B-Protein
interacts	O
with	O
and	O
promotes	O
ubiquitin	B-Protein
-	O
mediated	O
degradation	O
of	O
EGR2	B-Protein
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
that	O
has	O
been	O
found	O
to	O
regulate	O
Fas	B-Protein
ligand	I-Protein
(	O
FasL	B-Protein
)	O
expression	O
during	O
activation	O
-	O
induced	O
T	O
-	O
cell	O
death	O
.	O
<EOS>	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
which	B-X
target	B-X
specific	B-X
molecules	B-X
for	B-X
proteolytic	B-X
destruction	B-X
,	B-X
have	B-X
emerged	B-X
as	B-X
key	B-X
regulators	B-X
of	B-X
immune	B-X
functions	B-X
.	B-X
Several	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
including	B-X
c-Cbl	B-X
,	B-X
Cbl-b	B-X
,	B-X
GRAIL	B-X
,	B-X
Itch	B-X
,	B-X
and	B-X
Nedd4	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
negatively	B-X
regulate	B-X
T-cell	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
HECT-type	B-X
E3	B-X
ligase	B-X
AIP2	B-X
positively	B-X
regulates	B-X
T-cell	B-X
activation	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
AIP2	B-X
in	B-X
mouse	B-X
primary	B-X
T	B-X
cells	B-X
enhances	B-X
their	B-X
proliferation	B-X
and	B-X
interleukin-2	B-X
production	B-X
by	B-X
suppressing	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
AIP2	B-X
interacts	B-X
with	B-X
and	B-X
promotes	B-X
ubiquitin-mediated	B-X
degradation	B-X
of	B-X
EGR2	B-X
,	B-X
a	B-X
zinc	B-X
finger	B-X
transcription	B-X
factor	B-X
that	B-X
has	B-X
been	B-X
found	B-X
to	B-X
regulate	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
expression	B-X
during	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
.	B-X
Suppression	B-X
of	B-X
AIP2	B-X
expression	B-X
by	B-X
small	B-X
RNA	B-X
interference	B-X
upregulates	B-X
EGR2	B-X
,	B-X
inhibits	B-X
EGR2	B-X
ubiquitination	B-X
and	B-X
FasL	B-X
expression	B-X
,	B-X
and	B-X
enhances	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
AIP2	B-X
regulates	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
by	B-X
suppressing	B-X
EGR2-mediated	B-X
FasL	B-X
expression	B-X
via	B-X
the	B-X
ubiquitin	B-X
pathway	B-X
.	B-X

Suppression	O
of	O
AIP2	B-Protein
expression	O
by	O
small	O
RNA	O
interference	O
upregulates	O
EGR2	B-Protein
,	O
inhibits	O
EGR2	B-Protein
ubiquitination	O
and	O
FasL	B-Protein
expression	O
,	O
and	O
enhances	O
the	O
apoptosis	O
of	O
T	O
cells	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
HECT-type	B-X
E3	B-X
ligase	B-X
AIP2	B-X
positively	B-X
regulates	B-X
T-cell	B-X
activation	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
AIP2	B-X
in	B-X
mouse	B-X
primary	B-X
T	B-X
cells	B-X
enhances	B-X
their	B-X
proliferation	B-X
and	B-X
interleukin-2	B-X
production	B-X
by	B-X
suppressing	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
AIP2	B-X
interacts	B-X
with	B-X
and	B-X
promotes	B-X
ubiquitin-mediated	B-X
degradation	B-X
of	B-X
EGR2	B-X
,	B-X
a	B-X
zinc	B-X
finger	B-X
transcription	B-X
factor	B-X
that	B-X
has	B-X
been	B-X
found	B-X
to	B-X
regulate	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
expression	B-X
during	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
.	B-X
Suppression	B-X
of	B-X
AIP2	B-X
expression	B-X
by	B-X
small	B-X
RNA	B-X
interference	B-X
upregulates	B-X
EGR2	B-X
,	B-X
inhibits	B-X
EGR2	B-X
ubiquitination	B-X
and	B-X
FasL	B-X
expression	B-X
,	B-X
and	B-X
enhances	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
AIP2	B-X
regulates	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
by	B-X
suppressing	B-X
EGR2-mediated	B-X
FasL	B-X
expression	B-X
via	B-X
the	B-X
ubiquitin	B-X
pathway	B-X
.	B-X

Therefore	O
,	O
AIP2	B-Protein
regulates	O
activation	O
-	O
induced	O
T	O
-	O
cell	O
death	O
by	O
suppressing	O
EGR2	B-Protein
-	O
mediated	O
FasL	B-Protein
expression	O
via	O
the	O
ubiquitin	B-Protein
pathway	O
.	O
<EOS>	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
which	B-X
target	B-X
specific	B-X
molecules	B-X
for	B-X
proteolytic	B-X
destruction	B-X
,	B-X
have	B-X
emerged	B-X
as	B-X
key	B-X
regulators	B-X
of	B-X
immune	B-X
functions	B-X
.	B-X
Several	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
including	B-X
c-Cbl	B-X
,	B-X
Cbl-b	B-X
,	B-X
GRAIL	B-X
,	B-X
Itch	B-X
,	B-X
and	B-X
Nedd4	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
negatively	B-X
regulate	B-X
T-cell	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
HECT-type	B-X
E3	B-X
ligase	B-X
AIP2	B-X
positively	B-X
regulates	B-X
T-cell	B-X
activation	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
AIP2	B-X
in	B-X
mouse	B-X
primary	B-X
T	B-X
cells	B-X
enhances	B-X
their	B-X
proliferation	B-X
and	B-X
interleukin-2	B-X
production	B-X
by	B-X
suppressing	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
AIP2	B-X
interacts	B-X
with	B-X
and	B-X
promotes	B-X
ubiquitin-mediated	B-X
degradation	B-X
of	B-X
EGR2	B-X
,	B-X
a	B-X
zinc	B-X
finger	B-X
transcription	B-X
factor	B-X
that	B-X
has	B-X
been	B-X
found	B-X
to	B-X
regulate	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
expression	B-X
during	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
.	B-X
Suppression	B-X
of	B-X
AIP2	B-X
expression	B-X
by	B-X
small	B-X
RNA	B-X
interference	B-X
upregulates	B-X
EGR2	B-X
,	B-X
inhibits	B-X
EGR2	B-X
ubiquitination	B-X
and	B-X
FasL	B-X
expression	B-X
,	B-X
and	B-X
enhances	B-X
the	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
AIP2	B-X
regulates	B-X
activation-induced	B-X
T-cell	B-X
death	B-X
by	B-X
suppressing	B-X
EGR2-mediated	B-X
FasL	B-X
expression	B-X
via	B-X
the	B-X
ubiquitin	B-X
pathway	B-X
.	B-X

Linking	O
cell	O
cycle	O
to	O
histone	B-Protein
modifications	O
:	O
SBF	O
and	O
H2B	B-Protein
monoubiquitination	O
machinery	O
and	O
cell	O
-	O
cycle	O
regulation	O
of	O
H3K79	B-Protein
dimethylation	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
regulators	B-X
involved	B-X
in	B-X
determining	B-X
the	B-X
differential	B-X
pattern	B-X
of	B-X
H3K79	B-X
methylation	B-X
by	B-X
Dot1	B-X
,	B-X
we	B-X
screened	B-X
the	B-X
entire	B-X
yeast	B-X
gene	B-X
deletion	B-X
collection	B-X
by	B-X
GPS	B-X
for	B-X
genes	B-X
required	B-X
for	B-X
normal	B-X
levels	B-X
of	B-X
H3K79	B-X
di-	B-X
but	B-X
not	B-X
trimethylation	B-X
.	B-X
We	B-X
identified	B-X
the	B-X
cell	B-X
cycle-regulated	B-X
SBF	B-X
protein	B-X
complex	B-X
required	B-X
for	B-X
H3K79	B-X
dimethylation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
H3K79	B-X
di-	B-X
and	B-X
trimethylation	B-X
are	B-X
mutually	B-X
exclusive	B-X
,	B-X
with	B-X
M/G1	B-X
cell	B-X
cycle-regulated	B-X
genes	B-X
significantly	B-X
enriched	B-X
for	B-X
H3K79	B-X
dimethylation	B-X
.	B-X
Since	B-X
H3K79	B-X
trimethylation	B-X
requires	B-X
prior	B-X
monoubiquitination	B-X
of	B-X
H2B	B-X
,	B-X
we	B-X
performed	B-X
genome-wide	B-X
profiling	B-X
of	B-X
H2BK123	B-X
monoubiquitination	B-X
and	B-X
showed	B-X
that	B-X
H2BK123	B-X
monoubiquitination	B-X
is	B-X
not	B-X
detected	B-X
on	B-X
cell	B-X
cycle-regulated	B-X
genes	B-X
and	B-X
sites	B-X
containing	B-X
H3K79me2	B-X
,	B-X
but	B-X
is	B-X
found	B-X
on	B-X
H3K79me3-containing	B-X
regions	B-X
.	B-X
A	B-X
screen	B-X
for	B-X
genes	B-X
responsible	B-X
for	B-X
the	B-X
establishment/removal	B-X
of	B-X
H3K79	B-X
dimethylation	B-X
resulted	B-X
in	B-X
identification	B-X
of	B-X
NRM1	B-X
and	B-X
WHI3	B-X
,	B-X
both	B-X
of	B-X
which	B-X
impact	B-X
the	B-X
transcription	B-X
by	B-X
the	B-X
SBF	B-X
and	B-X
MBF	B-X
protein	B-X
complexes	B-X
,	B-X
further	B-X
linking	B-X
the	B-X
regulation	B-X
of	B-X
methylation	B-X
status	B-X
of	B-X
H3K79	B-X
to	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

To	O
identify	O
regulators	O
involved	O
in	O
determining	O
the	O
differential	O
pattern	O
of	O
H3K79	B-Protein
methylation	O
by	O
Dot1	B-Protein
,	O
we	O
screened	O
the	O
entire	O
yeast	O
gene	O
deletion	O
collection	O
by	O
GPS	O
for	O
genes	O
required	O
for	O
normal	O
levels	O
of	O
H3K79	B-Protein
di	O
-	O
but	O
not	O
trimethylation	O
.	O

We	O
identified	O
the	O
cell	O
cycle	O
-	O
regulated	O
SBF	O
protein	O
complex	O
required	O
for	O
H3K79	B-Protein
dimethylation	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
regulators	B-X
involved	B-X
in	B-X
determining	B-X
the	B-X
differential	B-X
pattern	B-X
of	B-X
H3K79	B-X
methylation	B-X
by	B-X
Dot1	B-X
,	B-X
we	B-X
screened	B-X
the	B-X
entire	B-X
yeast	B-X
gene	B-X
deletion	B-X
collection	B-X
by	B-X
GPS	B-X
for	B-X
genes	B-X
required	B-X
for	B-X
normal	B-X
levels	B-X
of	B-X
H3K79	B-X
di-	B-X
but	B-X
not	B-X
trimethylation	B-X
.	B-X
We	B-X
identified	B-X
the	B-X
cell	B-X
cycle-regulated	B-X
SBF	B-X
protein	B-X
complex	B-X
required	B-X
for	B-X
H3K79	B-X
dimethylation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
H3K79	B-X
di-	B-X
and	B-X
trimethylation	B-X
are	B-X
mutually	B-X
exclusive	B-X
,	B-X
with	B-X
M/G1	B-X
cell	B-X
cycle-regulated	B-X
genes	B-X
significantly	B-X
enriched	B-X
for	B-X
H3K79	B-X
dimethylation	B-X
.	B-X
Since	B-X
H3K79	B-X
trimethylation	B-X
requires	B-X
prior	B-X
monoubiquitination	B-X
of	B-X
H2B	B-X
,	B-X
we	B-X
performed	B-X
genome-wide	B-X
profiling	B-X
of	B-X
H2BK123	B-X
monoubiquitination	B-X
and	B-X
showed	B-X
that	B-X
H2BK123	B-X
monoubiquitination	B-X
is	B-X
not	B-X
detected	B-X
on	B-X
cell	B-X
cycle-regulated	B-X
genes	B-X
and	B-X
sites	B-X
containing	B-X
H3K79me2	B-X
,	B-X
but	B-X
is	B-X
found	B-X
on	B-X
H3K79me3-containing	B-X
regions	B-X
.	B-X
A	B-X
screen	B-X
for	B-X
genes	B-X
responsible	B-X
for	B-X
the	B-X
establishment/removal	B-X
of	B-X
H3K79	B-X
dimethylation	B-X
resulted	B-X
in	B-X
identification	B-X
of	B-X
NRM1	B-X
and	B-X
WHI3	B-X
,	B-X
both	B-X
of	B-X
which	B-X
impact	B-X
the	B-X
transcription	B-X
by	B-X
the	B-X
SBF	B-X
and	B-X
MBF	B-X
protein	B-X
complexes	B-X
,	B-X
further	B-X
linking	B-X
the	B-X
regulation	B-X
of	B-X
methylation	B-X
status	B-X
of	B-X
H3K79	B-X
to	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

We	O
also	O
found	O
that	O
H3K79	B-Protein
di	O
-	O
and	O
trimethylation	O
are	O
mutually	O
exclusive	O
,	O
with	O
M	O
/	O
G1	O
cell	O
cycle	O
-	O
regulated	O
genes	O
significantly	O
enriched	O
for	O
H3K79	B-Protein
dimethylation	O
.	O

Since	O
H3K79	B-Protein
trimethylation	O
requires	O
prior	O
monoubiquitination	O
of	O
H2B	B-Protein
,	O
we	O
performed	O
genome	O
-	O
wide	O
profiling	O
of	O
H2BK123	B-Protein
monoubiquitination	O
and	O
showed	O
that	O
H2BK123	B-Protein
monoubiquitination	O
is	O
not	O
detected	O
on	O
cell	O
cycle	O
-	O
regulated	O
genes	O
and	O
sites	O
containing	O
H3K79me2	B-Protein
,	O
but	O
is	O
found	O
on	O
H3K79me3	B-Protein
-	O
containing	O
regions	O
.	O

A	O
screen	O
for	O
genes	O
responsible	O
for	O
the	O
establishment	O
/	O
removal	O
of	O
H3K79	B-Protein
dimethylation	O
resulted	O
in	O
identification	O
of	O
NRM1	B-Protein
and	O
WHI3	B-Protein
,	O
both	O
of	O
which	O
impact	O
the	O
transcription	O
by	O
the	O
SBF	O
and	O
MBF	O
protein	O
complexes	O
,	O
further	O
linking	O
the	O
regulation	O
of	O
methylation	O
status	O
of	O
H3K79	B-Protein
to	O
the	O
cell	O
cycle	O
.	O

Absence	O
of	O
ubiquitinated	O
inclusions	O
in	O
hypocretin	B-Protein
neurons	O
of	O
patients	O
with	O
narcolepsy	O
.	O
<EOS>	B-X
The	B-X
cause	B-X
of	B-X
hypocretin	B-X
cell	B-X
loss	B-X
in	B-X
human	B-X
narcolepsy-cataplexy	B-X
is	B-X
unknown	B-X
but	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
neurodegenerative	B-X
in	B-X
nature	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
remaining	B-X
hypocretin	B-X
cells	B-X
in	B-X
human	B-X
narcolepsy	B-X
brains	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
aggregated	B-X
protein	B-X
inclusions	B-X
,	B-X
gliosis	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X

OBJECTIVES	O
:	O
The	O
cause	O
of	O
hypocretin	B-Protein
cell	O
loss	O
in	O
human	O
narcolepsy	O
-	O
cataplexy	O
is	O
unknown	O
but	O
has	O
been	O
suggested	O
to	O
be	O
neurodegenerative	O
in	O
nature	O
.	O
<EOS>	B-X
The	B-X
cause	B-X
of	B-X
hypocretin	B-X
cell	B-X
loss	B-X
in	B-X
human	B-X
narcolepsy-cataplexy	B-X
is	B-X
unknown	B-X
but	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
neurodegenerative	B-X
in	B-X
nature	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
remaining	B-X
hypocretin	B-X
cells	B-X
in	B-X
human	B-X
narcolepsy	B-X
brains	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
aggregated	B-X
protein	B-X
inclusions	B-X
,	B-X
gliosis	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X

To	O
test	O
this	O
hypothesis	O
,	O
we	O
evaluated	O
the	O
remaining	O
hypocretin	B-Protein
cells	O
in	O
human	O
narcolepsy	O
brains	O
for	O
the	O
presence	O
of	O
aggregated	O
protein	O
inclusions	O
,	O
gliosis	O
,	O
and	O
inflammation	O
.	O
<EOS>	B-X
The	B-X
cause	B-X
of	B-X
hypocretin	B-X
cell	B-X
loss	B-X
in	B-X
human	B-X
narcolepsy-cataplexy	B-X
is	B-X
unknown	B-X
but	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
neurodegenerative	B-X
in	B-X
nature	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
remaining	B-X
hypocretin	B-X
cells	B-X
in	B-X
human	B-X
narcolepsy	B-X
brains	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
aggregated	B-X
protein	B-X
inclusions	B-X
,	B-X
gliosis	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X

METHODS	O
:	O
Brains	O
were	O
examined	O
by	O
routine	O
histologic	O
methods	O
for	O
potential	O
comorbid	O
neurodegenerative	O
diseases	O
and	O
through	O
immunohistochemical	O
screening	O
for	O
protein	O
inclusions	O
in	O
the	O
hypothalamus	O
.	O
<EOS>	B-X
The	B-X
cause	B-X
of	B-X
hypocretin	B-X
cell	B-X
loss	B-X
in	B-X
human	B-X
narcolepsy-cataplexy	B-X
is	B-X
unknown	B-X
but	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
neurodegenerative	B-X
in	B-X
nature	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
remaining	B-X
hypocretin	B-X
cells	B-X
in	B-X
human	B-X
narcolepsy	B-X
brains	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
aggregated	B-X
protein	B-X
inclusions	B-X
,	B-X
gliosis	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X

Hypothalamic	O
sections	O
of	O
4	O
subjects	O
with	O
narcolepsy	O
and	O
5	O
nonneurologic	O
controls	O
were	O
examined	O
immunohistochemically	O
with	O
antibodies	O
against	O
ubiquitin	B-Protein
(	O
a	O
marker	O
of	O
aggregated	O
protein	O
)	O
,	O
allograft	B-Protein
inflammatory	I-Protein
factor	I-Protein
1	I-Protein
(	O
AIF1	B-Protein
,	O
a	O
microglial	O
activation	O
marker	O
)	O
,	O
glial	B-Protein
fibrillary	I-Protein
acidic	I-Protein
protein	I-Protein
(	O
GFAP	B-Protein
,	O
a	O
reactive	O
astrocytic	O
marker	O
)	O
,	O
and	O
hypocretin	B-Protein
.	O
<EOS>	B-X
The	B-X
cause	B-X
of	B-X
hypocretin	B-X
cell	B-X
loss	B-X
in	B-X
human	B-X
narcolepsy-cataplexy	B-X
is	B-X
unknown	B-X
but	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
neurodegenerative	B-X
in	B-X
nature	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
remaining	B-X
hypocretin	B-X
cells	B-X
in	B-X
human	B-X
narcolepsy	B-X
brains	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
aggregated	B-X
protein	B-X
inclusions	B-X
,	B-X
gliosis	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X

Hypothalami	O
of	O
subjects	O
with	O
narcolepsy	O
were	O
additionally	O
examined	O
for	O
the	O
presence	O
of	O
known	O
components	O
of	O
protein	O
aggregates	O
(	O
tau	B-Protein
,	O
alpha	B-Protein
-	I-Protein
synuclein	I-Protein
,	O
amyloid	B-Protein
beta	I-Protein
,	O
and	O
TDP	B-Protein
-	I-Protein
43	I-Protein
)	O
.	O
<EOS>	B-X
The	B-X
cause	B-X
of	B-X
hypocretin	B-X
cell	B-X
loss	B-X
in	B-X
human	B-X
narcolepsy-cataplexy	B-X
is	B-X
unknown	B-X
but	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
neurodegenerative	B-X
in	B-X
nature	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
remaining	B-X
hypocretin	B-X
cells	B-X
in	B-X
human	B-X
narcolepsy	B-X
brains	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
aggregated	B-X
protein	B-X
inclusions	B-X
,	B-X
gliosis	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X

RESULTS	O
:	O
Hypocretin	B-Protein
cells	O
were	O
markedly	O
decreased	O
in	O
all	O
4	O
subjects	O
with	O
narcolepsy	O
.	O
<EOS>	B-X
The	B-X
cause	B-X
of	B-X
hypocretin	B-X
cell	B-X
loss	B-X
in	B-X
human	B-X
narcolepsy-cataplexy	B-X
is	B-X
unknown	B-X
but	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
neurodegenerative	B-X
in	B-X
nature	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
remaining	B-X
hypocretin	B-X
cells	B-X
in	B-X
human	B-X
narcolepsy	B-X
brains	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
aggregated	B-X
protein	B-X
inclusions	B-X
,	B-X
gliosis	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X

Ubiquitinated	O
inclusions	O
were	O
not	O
observed	O
in	O
the	O
total	O
of	O
96	O
remaining	O
hypocretin	B-Protein
cells	O
in	O
these	O
subjects	O
.	O
<EOS>	B-X
There	B-X
is	B-X
partial	B-X
but	B-X
not	B-X
perfect	B-X
overlap	B-X
among	B-X
the	B-X
cells	B-X
in	B-X
which	B-X
abnormal	B-X
proteins	B-X
are	B-X
deposited	B-X
and	B-X
the	B-X
cells	B-X
that	B-X
degenerate	B-X
.	B-X
The	B-X
most	B-X
likely	B-X
explanation	B-X
is	B-X
that	B-X
inclusions	B-X
and	B-X
other	B-X
visible	B-X
protein	B-X
aggregates	B-X
represent	B-X
an	B-X
end	B-X
stage	B-X
of	B-X
a	B-X
molecular	B-X
cascade	B-X
of	B-X
several	B-X
steps	B-X
,	B-X
and	B-X
that	B-X
earlier	B-X
steps	B-X
in	B-X
the	B-X
cascade	B-X
may	B-X
be	B-X
more	B-X
directly	B-X
tied	B-X
to	B-X
pathogenesis	B-X
than	B-X
the	B-X
inclusions	B-X
themselves	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
either	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
or	B-X
infection	B-X
of	B-X
the	B-X
cells	B-X
by	B-X
influenza	B-X
A	B-X
viruses	B-X
triggers	B-X
the	B-X
phosphorylation	B-X
of	B-X
TRIM28	B-X
at	B-X
S473	B-X
in	B-X
a	B-X
way	B-X
that	B-X
depends	B-X
on	B-X
double-stranded	B-X
RNA-activated	B-X
protein	B-X
kinase	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
the	B-X
important	B-X
role	B-X
of	B-X
autophagy	B-X
in	B-X
starvation	B-X
response	B-X
and	B-X
the	B-X
quality	B-X
control	B-X
of	B-X
proteins	B-X
and	B-X
organelles	B-X
in	B-X
quiescent	B-X
cells	B-X
.	B-X

Further	O
,	O
we	O
noted	O
that	O
even	O
in	O
patients	O
with	O
dementia	O
neuropathology	O
,	O
the	O
lateral	O
hypothalamic	O
hypocretin	B-Protein
area	O
was	O
spared	O
from	O
ubiquitinated	O
inclusions	O
.	O
<EOS>	B-X
The	B-X
cause	B-X
of	B-X
hypocretin	B-X
cell	B-X
loss	B-X
in	B-X
human	B-X
narcolepsy-cataplexy	B-X
is	B-X
unknown	B-X
but	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
neurodegenerative	B-X
in	B-X
nature	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
remaining	B-X
hypocretin	B-X
cells	B-X
in	B-X
human	B-X
narcolepsy	B-X
brains	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
aggregated	B-X
protein	B-X
inclusions	B-X
,	B-X
gliosis	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X

AIF1	B-Protein
and	O
GFAP	B-Protein
staining	O
in	O
the	O
perifornical	O
area	O
was	O
unremarkable	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
hypocretin	B-Protein
cell	O
loss	O
does	O
not	O
involve	O
ubiquitinated	O
inclusions	O
,	O
the	O
hallmark	O
of	O
most	O
neurodegenerative	O
diseases	O
.	O
<EOS>	B-X
The	B-X
hypocretins	B-X
(	B-X
HCRTs	B-X
)	B-X
are	B-X
two	B-X
hypothalamic	B-X
peptides	B-X
predominantly	B-X
localized	B-X
to	B-X
neurons	B-X
in	B-X
the	B-X
perifornical	B-X
,	B-X
dorsomedial	B-X
,	B-X
and	B-X
lateral	B-X
hypothalamic	B-X
area	B-X
(	B-X
PF-LHA	B-X
)	B-X
.	B-X
Evidence	B-X
suggests	B-X
that	B-X
HCRT	B-X
signaling	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
promotion	B-X
and	B-X
stabilization	B-X
of	B-X
active-arousal	B-X
and	B-X
its	B-X
loss	B-X
or	B-X
malfunction	B-X
leads	B-X
to	B-X
symptoms	B-X
of	B-X
narcolepsy	B-X
.	B-X
Evidence	B-X
suggests	B-X
that	B-X
HCRT-glutamate	B-X
interactions	B-X
within	B-X
the	B-X
PF-LHA	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
maintaining	B-X
behavioral	B-X
arousal	B-X
.	B-X
Narcoleptic	B-X
patients	B-X
with	B-X
cataplexy	B-X
have	B-X
a	B-X
general	B-X
loss	B-X
of	B-X
hypocretin	B-X
(	B-X
orexin	B-X
)	B-X
in	B-X
the	B-X
lateral	B-X
hypothalamus	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
an	B-X
autoimmune-mediated	B-X
degeneration	B-X
of	B-X
the	B-X
hypocretin	B-X
neurons	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
excessive	B-X
daytime	B-X
sleepiness	B-X
,	B-X
Prader-Willi	B-X
syndrome	B-X
(	B-X
PWS	B-X
)	B-X
patients	B-X
may	B-X
show	B-X
narcolepsy-like	B-X
symptoms	B-X
,	B-X
such	B-X
as	B-X
sleep-onset	B-X
rapid	B-X
eye	B-X
movement	B-X
sleep	B-X
and	B-X
cataplexy	B-X
,	B-X
independent	B-X
of	B-X
obesity-related	B-X
sleep	B-X
disturbances	B-X
,	B-X
which	B-X
suggests	B-X
a	B-X
disorder	B-X
of	B-X
the	B-X
hypocretin	B-X
neurons	B-X
.	B-X

The	O
lack	O
of	O
increased	O
markers	O
of	O
inflammation	O
also	O
argues	O
against	O
a	O
progressive	O
and	O
continuous	O
neurodegenerative	O
process	O
.	O

Structural	O
basis	O
for	O
the	O
lack	O
of	O
E2	O
interaction	O
in	O
the	O
RING	O
domain	O
of	O
TRAF2	B-Protein
.	O
<EOS>	B-X
Specifically	B-X
,	B-X
TRAF2	B-X
interacts	B-X
with	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
and	B-X
connects	B-X
the	B-X
receptors	B-X
to	B-X
downstream	B-X
signaling	B-X
proteins	B-X
.	B-X
It	B-X
has	B-X
been	B-X
assumed	B-X
that	B-X
TRAF2	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
like	B-X
TRAF6	B-X
and	B-X
mediates	B-X
K63-linked	B-X
polyubiquitination	B-X
of	B-X
RIP1	B-X
,	B-X
a	B-X
kinase	B-X
pivotal	B-X
in	B-X
TNFalpha-induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
RING	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
domains	B-X
of	B-X
TRAF2	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
TRAF2	B-X
RING	B-X
structure	B-X
is	B-X
very	B-X
different	B-X
from	B-X
the	B-X
known	B-X
TRAF6	B-X
RING	B-X
structure	B-X
.	B-X
The	B-X
differences	B-X
are	B-X
multifaceted	B-X
,	B-X
including	B-X
amino	B-X
acid	B-X
differences	B-X
at	B-X
the	B-X
critical	B-X
Ubc13-interacting	B-X
site	B-X
,	B-X
local	B-X
conformational	B-X
differences	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
nine-residue	B-X
insertion	B-X
between	B-X
the	B-X
RING	B-X
domain	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
in	B-X
TRAF2	B-X
.	B-X
These	B-X
structural	B-X
differences	B-X
prevent	B-X
TRAF2	B-X
from	B-X
interacting	B-X
with	B-X
Ubc13	B-X
and	B-X
other	B-X
related	B-X
E2s	B-X
via	B-X
steric	B-X
clash	B-X
and	B-X
unfavorable	B-X
interfaces	B-X
.	B-X
Our	B-X
structural	B-X
observation	B-X
should	B-X
prompt	B-X
a	B-X
re-evaluation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
TRAF2	B-X
in	B-X
TNFalpha	B-X
signaling	B-X
and	B-X
may	B-X
indicate	B-X
that	B-X
TRAF2-associated	B-X
proteins	B-X
such	B-X
as	B-X
cIAPs	B-X
may	B-X
be	B-X
the	B-X
ubiquitin	B-X
ligases	B-X
for	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X

TRAF	O
proteins	O
are	O
intracellular	O
signal	O
transducers	O
for	O
a	O
number	O
of	O
immune	O
receptor	O
superfamilies	O
.	O
<EOS>	B-X
TRAF	B-X
proteins	B-X
are	B-X
intracellular	B-X
signal	B-X
transducers	B-X
for	B-X
a	B-X
number	B-X
of	B-X
immune	B-X
receptor	B-X
superfamilies	B-X
.	B-X
Specifically	B-X
,	B-X
TRAF2	B-X
interacts	B-X
with	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
and	B-X
connects	B-X
the	B-X
receptors	B-X
to	B-X
downstream	B-X
signaling	B-X
proteins	B-X
.	B-X
It	B-X
has	B-X
been	B-X
assumed	B-X
that	B-X
TRAF2	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
like	B-X
TRAF6	B-X
and	B-X
mediates	B-X
K63-linked	B-X
polyubiquitination	B-X
of	B-X
RIP1	B-X
,	B-X
a	B-X
kinase	B-X
pivotal	B-X
in	B-X
TNFalpha-induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
RING	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
domains	B-X
of	B-X
TRAF2	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
TRAF2	B-X
RING	B-X
structure	B-X
is	B-X
very	B-X
different	B-X
from	B-X
the	B-X
known	B-X
TRAF6	B-X
RING	B-X
structure	B-X
.	B-X
The	B-X
differences	B-X
are	B-X
multifaceted	B-X
,	B-X
including	B-X
amino	B-X
acid	B-X
differences	B-X
at	B-X
the	B-X
critical	B-X
Ubc13-interacting	B-X
site	B-X
,	B-X
local	B-X
conformational	B-X
differences	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
nine-residue	B-X
insertion	B-X
between	B-X
the	B-X
RING	B-X
domain	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
in	B-X
TRAF2	B-X
.	B-X
These	B-X
structural	B-X
differences	B-X
prevent	B-X
TRAF2	B-X
from	B-X
interacting	B-X
with	B-X
Ubc13	B-X
and	B-X
other	B-X
related	B-X
E2s	B-X
via	B-X
steric	B-X
clash	B-X
and	B-X
unfavorable	B-X
interfaces	B-X
.	B-X
Our	B-X
structural	B-X
observation	B-X
should	B-X
prompt	B-X
a	B-X
re-evaluation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
TRAF2	B-X
in	B-X
TNFalpha	B-X
signaling	B-X
and	B-X
may	B-X
indicate	B-X
that	B-X
TRAF2-associated	B-X
proteins	B-X
such	B-X
as	B-X
cIAPs	B-X
may	B-X
be	B-X
the	B-X
ubiquitin	B-X
ligases	B-X
for	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X

Specifically	O
,	O
TRAF2	B-Protein
interacts	O
with	O
members	O
of	O
the	O
TNF	O
receptor	O
superfamily	O
and	O
connects	O
the	O
receptors	O
to	O
downstream	O
signaling	O
proteins	O
.	O
<EOS>	B-X
TRAF	B-X
proteins	B-X
are	B-X
intracellular	B-X
signal	B-X
transducers	B-X
for	B-X
a	B-X
number	B-X
of	B-X
immune	B-X
receptor	B-X
superfamilies	B-X
.	B-X
Specifically	B-X
,	B-X
TRAF2	B-X
interacts	B-X
with	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
and	B-X
connects	B-X
the	B-X
receptors	B-X
to	B-X
downstream	B-X
signaling	B-X
proteins	B-X
.	B-X
It	B-X
has	B-X
been	B-X
assumed	B-X
that	B-X
TRAF2	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
like	B-X
TRAF6	B-X
and	B-X
mediates	B-X
K63-linked	B-X
polyubiquitination	B-X
of	B-X
RIP1	B-X
,	B-X
a	B-X
kinase	B-X
pivotal	B-X
in	B-X
TNFalpha-induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
RING	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
domains	B-X
of	B-X
TRAF2	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
TRAF2	B-X
RING	B-X
structure	B-X
is	B-X
very	B-X
different	B-X
from	B-X
the	B-X
known	B-X
TRAF6	B-X
RING	B-X
structure	B-X
.	B-X
The	B-X
differences	B-X
are	B-X
multifaceted	B-X
,	B-X
including	B-X
amino	B-X
acid	B-X
differences	B-X
at	B-X
the	B-X
critical	B-X
Ubc13-interacting	B-X
site	B-X
,	B-X
local	B-X
conformational	B-X
differences	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
nine-residue	B-X
insertion	B-X
between	B-X
the	B-X
RING	B-X
domain	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
in	B-X
TRAF2	B-X
.	B-X
These	B-X
structural	B-X
differences	B-X
prevent	B-X
TRAF2	B-X
from	B-X
interacting	B-X
with	B-X
Ubc13	B-X
and	B-X
other	B-X
related	B-X
E2s	B-X
via	B-X
steric	B-X
clash	B-X
and	B-X
unfavorable	B-X
interfaces	B-X
.	B-X
Our	B-X
structural	B-X
observation	B-X
should	B-X
prompt	B-X
a	B-X
re-evaluation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
TRAF2	B-X
in	B-X
TNFalpha	B-X
signaling	B-X
and	B-X
may	B-X
indicate	B-X
that	B-X
TRAF2-associated	B-X
proteins	B-X
such	B-X
as	B-X
cIAPs	B-X
may	B-X
be	B-X
the	B-X
ubiquitin	B-X
ligases	B-X
for	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X

It	O
has	O
been	O
assumed	O
that	O
TRAF2	B-Protein
is	O
a	O
ubiquitin	B-Protein
ligase	O
like	O
TRAF6	B-Protein
and	O
mediates	O
K63	O
-	O
linked	O
polyubiquitination	O
of	O
RIP1	B-Protein
,	O
a	O
kinase	O
pivotal	O
in	O
TNFalpha	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Specifically	B-X
,	B-X
TRAF2	B-X
interacts	B-X
with	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
and	B-X
connects	B-X
the	B-X
receptors	B-X
to	B-X
downstream	B-X
signaling	B-X
proteins	B-X
.	B-X
It	B-X
has	B-X
been	B-X
assumed	B-X
that	B-X
TRAF2	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
like	B-X
TRAF6	B-X
and	B-X
mediates	B-X
K63-linked	B-X
polyubiquitination	B-X
of	B-X
RIP1	B-X
,	B-X
a	B-X
kinase	B-X
pivotal	B-X
in	B-X
TNFalpha-induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
RING	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
domains	B-X
of	B-X
TRAF2	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
TRAF2	B-X
RING	B-X
structure	B-X
is	B-X
very	B-X
different	B-X
from	B-X
the	B-X
known	B-X
TRAF6	B-X
RING	B-X
structure	B-X
.	B-X
The	B-X
differences	B-X
are	B-X
multifaceted	B-X
,	B-X
including	B-X
amino	B-X
acid	B-X
differences	B-X
at	B-X
the	B-X
critical	B-X
Ubc13-interacting	B-X
site	B-X
,	B-X
local	B-X
conformational	B-X
differences	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
nine-residue	B-X
insertion	B-X
between	B-X
the	B-X
RING	B-X
domain	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
in	B-X
TRAF2	B-X
.	B-X
These	B-X
structural	B-X
differences	B-X
prevent	B-X
TRAF2	B-X
from	B-X
interacting	B-X
with	B-X
Ubc13	B-X
and	B-X
other	B-X
related	B-X
E2s	B-X
via	B-X
steric	B-X
clash	B-X
and	B-X
unfavorable	B-X
interfaces	B-X
.	B-X
Our	B-X
structural	B-X
observation	B-X
should	B-X
prompt	B-X
a	B-X
re-evaluation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
TRAF2	B-X
in	B-X
TNFalpha	B-X
signaling	B-X
and	B-X
may	B-X
indicate	B-X
that	B-X
TRAF2-associated	B-X
proteins	B-X
such	B-X
as	B-X
cIAPs	B-X
may	B-X
be	B-X
the	B-X
ubiquitin	B-X
ligases	B-X
for	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
RING	O
and	O
the	O
first	O
zinc	O
finger	O
domains	O
of	O
TRAF2	B-Protein
.	O
<EOS>	B-X
Specifically	B-X
,	B-X
TRAF2	B-X
interacts	B-X
with	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
and	B-X
connects	B-X
the	B-X
receptors	B-X
to	B-X
downstream	B-X
signaling	B-X
proteins	B-X
.	B-X
It	B-X
has	B-X
been	B-X
assumed	B-X
that	B-X
TRAF2	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
like	B-X
TRAF6	B-X
and	B-X
mediates	B-X
K63-linked	B-X
polyubiquitination	B-X
of	B-X
RIP1	B-X
,	B-X
a	B-X
kinase	B-X
pivotal	B-X
in	B-X
TNFalpha-induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
RING	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
domains	B-X
of	B-X
TRAF2	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
TRAF2	B-X
RING	B-X
structure	B-X
is	B-X
very	B-X
different	B-X
from	B-X
the	B-X
known	B-X
TRAF6	B-X
RING	B-X
structure	B-X
.	B-X
The	B-X
differences	B-X
are	B-X
multifaceted	B-X
,	B-X
including	B-X
amino	B-X
acid	B-X
differences	B-X
at	B-X
the	B-X
critical	B-X
Ubc13-interacting	B-X
site	B-X
,	B-X
local	B-X
conformational	B-X
differences	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
nine-residue	B-X
insertion	B-X
between	B-X
the	B-X
RING	B-X
domain	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
in	B-X
TRAF2	B-X
.	B-X
These	B-X
structural	B-X
differences	B-X
prevent	B-X
TRAF2	B-X
from	B-X
interacting	B-X
with	B-X
Ubc13	B-X
and	B-X
other	B-X
related	B-X
E2s	B-X
via	B-X
steric	B-X
clash	B-X
and	B-X
unfavorable	B-X
interfaces	B-X
.	B-X
Our	B-X
structural	B-X
observation	B-X
should	B-X
prompt	B-X
a	B-X
re-evaluation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
TRAF2	B-X
in	B-X
TNFalpha	B-X
signaling	B-X
and	B-X
may	B-X
indicate	B-X
that	B-X
TRAF2-associated	B-X
proteins	B-X
such	B-X
as	B-X
cIAPs	B-X
may	B-X
be	B-X
the	B-X
ubiquitin	B-X
ligases	B-X
for	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X

We	O
show	O
that	O
the	O
TRAF2	B-Protein
RING	O
structure	O
is	O
very	O
different	O
from	O
the	O
known	O
TRAF6	B-Protein
RING	O
structure	O
.	O
<EOS>	B-X
Specifically	B-X
,	B-X
TRAF2	B-X
interacts	B-X
with	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
and	B-X
connects	B-X
the	B-X
receptors	B-X
to	B-X
downstream	B-X
signaling	B-X
proteins	B-X
.	B-X
It	B-X
has	B-X
been	B-X
assumed	B-X
that	B-X
TRAF2	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
like	B-X
TRAF6	B-X
and	B-X
mediates	B-X
K63-linked	B-X
polyubiquitination	B-X
of	B-X
RIP1	B-X
,	B-X
a	B-X
kinase	B-X
pivotal	B-X
in	B-X
TNFalpha-induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
RING	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
domains	B-X
of	B-X
TRAF2	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
TRAF2	B-X
RING	B-X
structure	B-X
is	B-X
very	B-X
different	B-X
from	B-X
the	B-X
known	B-X
TRAF6	B-X
RING	B-X
structure	B-X
.	B-X
The	B-X
differences	B-X
are	B-X
multifaceted	B-X
,	B-X
including	B-X
amino	B-X
acid	B-X
differences	B-X
at	B-X
the	B-X
critical	B-X
Ubc13-interacting	B-X
site	B-X
,	B-X
local	B-X
conformational	B-X
differences	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
nine-residue	B-X
insertion	B-X
between	B-X
the	B-X
RING	B-X
domain	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
in	B-X
TRAF2	B-X
.	B-X
These	B-X
structural	B-X
differences	B-X
prevent	B-X
TRAF2	B-X
from	B-X
interacting	B-X
with	B-X
Ubc13	B-X
and	B-X
other	B-X
related	B-X
E2s	B-X
via	B-X
steric	B-X
clash	B-X
and	B-X
unfavorable	B-X
interfaces	B-X
.	B-X
Our	B-X
structural	B-X
observation	B-X
should	B-X
prompt	B-X
a	B-X
re-evaluation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
TRAF2	B-X
in	B-X
TNFalpha	B-X
signaling	B-X
and	B-X
may	B-X
indicate	B-X
that	B-X
TRAF2-associated	B-X
proteins	B-X
such	B-X
as	B-X
cIAPs	B-X
may	B-X
be	B-X
the	B-X
ubiquitin	B-X
ligases	B-X
for	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X

The	O
differences	O
are	O
multifaceted	O
,	O
including	O
amino	O
acid	O
differences	O
at	O
the	O
critical	O
Ubc13	B-Protein
-	O
interacting	O
site	O
,	O
local	O
conformational	O
differences	O
,	O
and	O
a	O
unique	O
nine	O
-	O
residue	O
insertion	O
between	O
the	O
RING	O
domain	O
and	O
the	O
first	O
zinc	O
finger	O
in	O
TRAF2	B-Protein
.	O

These	O
structural	O
differences	O
prevent	O
TRAF2	B-Protein
from	O
interacting	O
with	O
Ubc13	B-Protein
and	O
other	O
related	O
E2s	O
via	O
steric	O
clash	O
and	O
unfavorable	O
interfaces	O
.	O
<EOS>	B-X
Specifically	B-X
,	B-X
TRAF2	B-X
interacts	B-X
with	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
and	B-X
connects	B-X
the	B-X
receptors	B-X
to	B-X
downstream	B-X
signaling	B-X
proteins	B-X
.	B-X
It	B-X
has	B-X
been	B-X
assumed	B-X
that	B-X
TRAF2	B-X
is	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
like	B-X
TRAF6	B-X
and	B-X
mediates	B-X
K63-linked	B-X
polyubiquitination	B-X
of	B-X
RIP1	B-X
,	B-X
a	B-X
kinase	B-X
pivotal	B-X
in	B-X
TNFalpha-induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
RING	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
domains	B-X
of	B-X
TRAF2	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
TRAF2	B-X
RING	B-X
structure	B-X
is	B-X
very	B-X
different	B-X
from	B-X
the	B-X
known	B-X
TRAF6	B-X
RING	B-X
structure	B-X
.	B-X
The	B-X
differences	B-X
are	B-X
multifaceted	B-X
,	B-X
including	B-X
amino	B-X
acid	B-X
differences	B-X
at	B-X
the	B-X
critical	B-X
Ubc13-interacting	B-X
site	B-X
,	B-X
local	B-X
conformational	B-X
differences	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
nine-residue	B-X
insertion	B-X
between	B-X
the	B-X
RING	B-X
domain	B-X
and	B-X
the	B-X
first	B-X
zinc	B-X
finger	B-X
in	B-X
TRAF2	B-X
.	B-X
These	B-X
structural	B-X
differences	B-X
prevent	B-X
TRAF2	B-X
from	B-X
interacting	B-X
with	B-X
Ubc13	B-X
and	B-X
other	B-X
related	B-X
E2s	B-X
via	B-X
steric	B-X
clash	B-X
and	B-X
unfavorable	B-X
interfaces	B-X
.	B-X
Our	B-X
structural	B-X
observation	B-X
should	B-X
prompt	B-X
a	B-X
re-evaluation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
TRAF2	B-X
in	B-X
TNFalpha	B-X
signaling	B-X
and	B-X
may	B-X
indicate	B-X
that	B-X
TRAF2-associated	B-X
proteins	B-X
such	B-X
as	B-X
cIAPs	B-X
may	B-X
be	B-X
the	B-X
ubiquitin	B-X
ligases	B-X
for	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X

Our	O
structural	O
observation	O
should	O
prompt	O
a	O
re	O
-	O
evaluation	O
of	O
the	O
role	O
of	O
TRAF2	B-Protein
in	O
TNFalpha	B-Protein
signaling	O
and	O
may	O
indicate	O
that	O
TRAF2	B-Protein
-	O
associated	O
proteins	O
such	O
as	O
cIAPs	O
may	O
be	O
the	O
ubiquitin	B-Protein
ligases	O
for	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Changes	O
in	O
the	O
allelic	O
methylation	O
patterns	O
of	O
c	B-Protein
-	I-Protein
H	I-Protein
-	I-Protein
ras	I-Protein
-	I-Protein
1	I-Protein
,	O
insulin	B-Protein
and	O
retinoblastoma	B-Protein
genes	O
in	O
human	O
development	O
.	O

The	O
methylation	O
status	O
of	O
the	O
c	B-Protein
-	I-Protein
H	I-Protein
-	I-Protein
ras	I-Protein
-	I-Protein
1	I-Protein
,	O
insulin	B-Protein
and	O
retinoblastoma	B-Protein
genes	O
was	O
determined	O
in	O
human	O
sperm	O
,	O
hydatidiform	O
mole	O
,	O
fetal	O
tissues	O
,	O
adult	O
lymphocytes	O
and	O
adult	O
kidney	O
.	O

Individual	O
alleles	O
of	O
c	B-Protein
-	I-Protein
H	I-Protein
-	I-Protein
ras	I-Protein
-	I-Protein
1	I-Protein
and	O
insulin	B-Protein
were	O
distinguishable	O
due	O
to	O
presence	O
of	O
endogenous	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
)	O
polymorphisms	O
.	O

Both	O
alleles	O
of	O
the	O
latter	O
two	O
genes	O
were	O
extensively	O
methylated	O
in	O
sperm	O
compared	O
to	O
the	O
other	O
tissues	O
.	O

Several	O
sites	O
within	O
these	O
genes	O
were	O
less	O
methylated	O
in	O
fetal	O
tissues	O
and	O
the	O
two	O
alleles	O
were	O
differentially	O
methylated	O
in	O
some	O
cases	O
.	O
<EOS>	B-X
The	B-X
methylation	B-X
status	B-X
of	B-X
the	B-X
c-H-ras-1	B-X
,	B-X
insulin	B-X
and	B-X
retinoblastoma	B-X
genes	B-X
was	B-X
determined	B-X
in	B-X
human	B-X
sperm	B-X
,	B-X
hydatidiform	B-X
mole	B-X
,	B-X
fetal	B-X
tissues	B-X
,	B-X
adult	B-X
lymphocytes	B-X
and	B-X
adult	B-X
kidney	B-X
.	B-X
Individual	B-X
alleles	B-X
of	B-X
c-H-ras-1	B-X
and	B-X
insulin	B-X
were	B-X
distinguishable	B-X
due	B-X
to	B-X
presence	B-X
of	B-X
endogenous	B-X
variable	B-X
number	B-X
of	B-X
tandem	B-X
repeat	B-X
(	B-X
VNTR	B-X
)	B-X
polymorphisms	B-X
.	B-X
Both	B-X
alleles	B-X
of	B-X
the	B-X
latter	B-X
two	B-X
genes	B-X
were	B-X
extensively	B-X
methylated	B-X
in	B-X
sperm	B-X
compared	B-X
to	B-X
the	B-X
other	B-X
tissues	B-X
.	B-X
Several	B-X
sites	B-X
within	B-X
these	B-X
genes	B-X
were	B-X
less	B-X
methylated	B-X
in	B-X
fetal	B-X
tissues	B-X
and	B-X
the	B-X
two	B-X
alleles	B-X
were	B-X
differentially	B-X
methylated	B-X
in	B-X
some	B-X
cases	B-X
.	B-X
The	B-X
retinoblastoma	B-X
gene	B-X
was	B-X
highly	B-X
methylated	B-X
in	B-X
all	B-X
tissues	B-X
examined	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
a	B-X
single	B-X
site	B-X
that	B-X
was	B-X
under-methylated	B-X
in	B-X
sperm	B-X
only	B-X
.	B-X
The	B-X
sperm-specific	B-X
methylation	B-X
patterns	B-X
in	B-X
all	B-X
three	B-X
genes	B-X
could	B-X
represent	B-X
imprinting	B-X
of	B-X
the	B-X
parental	B-X
chromosomes	B-X
.	B-X
Since	B-X
5-methylcytosine	B-X
is	B-X
inherently	B-X
mutagenic	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
methylation	B-X
imprinting	B-X
could	B-X
alter	B-X
the	B-X
susceptibilities	B-X
of	B-X
human	B-X
genes	B-X
to	B-X
point	B-X
mutations	B-X
.	B-X

The	O
retinoblastoma	B-Protein
gene	O
was	O
highly	O
methylated	O
in	O
all	O
tissues	O
examined	O
,	O
with	O
the	O
exception	O
of	O
a	O
single	O
site	O
that	O
was	O
under	O
-	O
methylated	O
in	O
sperm	O
only	O
.	O
<EOS>	B-X
The	B-X
methylation	B-X
status	B-X
of	B-X
the	B-X
c-H-ras-1	B-X
,	B-X
insulin	B-X
and	B-X
retinoblastoma	B-X
genes	B-X
was	B-X
determined	B-X
in	B-X
human	B-X
sperm	B-X
,	B-X
hydatidiform	B-X
mole	B-X
,	B-X
fetal	B-X
tissues	B-X
,	B-X
adult	B-X
lymphocytes	B-X
and	B-X
adult	B-X
kidney	B-X
.	B-X
Both	B-X
alleles	B-X
of	B-X
the	B-X
latter	B-X
two	B-X
genes	B-X
were	B-X
extensively	B-X
methylated	B-X
in	B-X
sperm	B-X
compared	B-X
to	B-X
the	B-X
other	B-X
tissues	B-X
.	B-X
Several	B-X
sites	B-X
within	B-X
these	B-X
genes	B-X
were	B-X
less	B-X
methylated	B-X
in	B-X
fetal	B-X
tissues	B-X
and	B-X
the	B-X
two	B-X
alleles	B-X
were	B-X
differentially	B-X
methylated	B-X
in	B-X
some	B-X
cases	B-X
.	B-X
The	B-X
retinoblastoma	B-X
gene	B-X
was	B-X
highly	B-X
methylated	B-X
in	B-X
all	B-X
tissues	B-X
examined	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
a	B-X
single	B-X
site	B-X
that	B-X
was	B-X
under-methylated	B-X
in	B-X
sperm	B-X
only	B-X
.	B-X
The	B-X
sperm-specific	B-X
methylation	B-X
patterns	B-X
in	B-X
all	B-X
three	B-X
genes	B-X
could	B-X
represent	B-X
imprinting	B-X
of	B-X
the	B-X
parental	B-X
chromosomes	B-X
.	B-X
Since	B-X
5-methylcytosine	B-X
is	B-X
inherently	B-X
mutagenic	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
methylation	B-X
imprinting	B-X
could	B-X
alter	B-X
the	B-X
susceptibilities	B-X
of	B-X
human	B-X
genes	B-X
to	B-X
point	B-X
mutations	B-X
.	B-X

The	O
sperm	O
-	O
specific	O
methylation	O
patterns	O
in	O
all	O
three	O
genes	O
could	O
represent	O
imprinting	O
of	O
the	O
parental	O
chromosomes	O
.	O
<EOS>	B-X
The	B-X
methylation	B-X
status	B-X
of	B-X
the	B-X
c-H-ras-1	B-X
,	B-X
insulin	B-X
and	B-X
retinoblastoma	B-X
genes	B-X
was	B-X
determined	B-X
in	B-X
human	B-X
sperm	B-X
,	B-X
hydatidiform	B-X
mole	B-X
,	B-X
fetal	B-X
tissues	B-X
,	B-X
adult	B-X
lymphocytes	B-X
and	B-X
adult	B-X
kidney	B-X
.	B-X
Both	B-X
alleles	B-X
of	B-X
the	B-X
latter	B-X
two	B-X
genes	B-X
were	B-X
extensively	B-X
methylated	B-X
in	B-X
sperm	B-X
compared	B-X
to	B-X
the	B-X
other	B-X
tissues	B-X
.	B-X
Several	B-X
sites	B-X
within	B-X
these	B-X
genes	B-X
were	B-X
less	B-X
methylated	B-X
in	B-X
fetal	B-X
tissues	B-X
and	B-X
the	B-X
two	B-X
alleles	B-X
were	B-X
differentially	B-X
methylated	B-X
in	B-X
some	B-X
cases	B-X
.	B-X
The	B-X
retinoblastoma	B-X
gene	B-X
was	B-X
highly	B-X
methylated	B-X
in	B-X
all	B-X
tissues	B-X
examined	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
a	B-X
single	B-X
site	B-X
that	B-X
was	B-X
under-methylated	B-X
in	B-X
sperm	B-X
only	B-X
.	B-X
The	B-X
sperm-specific	B-X
methylation	B-X
patterns	B-X
in	B-X
all	B-X
three	B-X
genes	B-X
could	B-X
represent	B-X
imprinting	B-X
of	B-X
the	B-X
parental	B-X
chromosomes	B-X
.	B-X
Since	B-X
5-methylcytosine	B-X
is	B-X
inherently	B-X
mutagenic	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
methylation	B-X
imprinting	B-X
could	B-X
alter	B-X
the	B-X
susceptibilities	B-X
of	B-X
human	B-X
genes	B-X
to	B-X
point	B-X
mutations	B-X
.	B-X

Since	O
5	O
-	O
methylcytosine	O
is	O
inherently	O
mutagenic	O
,	O
it	O
is	O
possible	O
that	O
methylation	O
imprinting	O
could	O
alter	O
the	O
susceptibilities	O
of	O
human	O
genes	O
to	O
point	O
mutations	O
.	O
<EOS>	B-X
The	B-X
methylation	B-X
status	B-X
of	B-X
the	B-X
c-H-ras-1	B-X
,	B-X
insulin	B-X
and	B-X
retinoblastoma	B-X
genes	B-X
was	B-X
determined	B-X
in	B-X
human	B-X
sperm	B-X
,	B-X
hydatidiform	B-X
mole	B-X
,	B-X
fetal	B-X
tissues	B-X
,	B-X
adult	B-X
lymphocytes	B-X
and	B-X
adult	B-X
kidney	B-X
.	B-X
Both	B-X
alleles	B-X
of	B-X
the	B-X
latter	B-X
two	B-X
genes	B-X
were	B-X
extensively	B-X
methylated	B-X
in	B-X
sperm	B-X
compared	B-X
to	B-X
the	B-X
other	B-X
tissues	B-X
.	B-X
Several	B-X
sites	B-X
within	B-X
these	B-X
genes	B-X
were	B-X
less	B-X
methylated	B-X
in	B-X
fetal	B-X
tissues	B-X
and	B-X
the	B-X
two	B-X
alleles	B-X
were	B-X
differentially	B-X
methylated	B-X
in	B-X
some	B-X
cases	B-X
.	B-X
The	B-X
sperm-specific	B-X
methylation	B-X
patterns	B-X
in	B-X
all	B-X
three	B-X
genes	B-X
could	B-X
represent	B-X
imprinting	B-X
of	B-X
the	B-X
parental	B-X
chromosomes	B-X
.	B-X
Since	B-X
5-methylcytosine	B-X
is	B-X
inherently	B-X
mutagenic	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
methylation	B-X
imprinting	B-X
could	B-X
alter	B-X
the	B-X
susceptibilities	B-X
of	B-X
human	B-X
genes	B-X
to	B-X
point	B-X
mutations	B-X
.	B-X

Screening	O
for	O
OST	O
deficiencies	O
in	O
unsolved	O
CDG	O
-	O
I	O
patients	O
.	O
<EOS>	B-X
Congenital	B-X
Disorders	B-X
of	B-X
Glycosylation	B-X
(	B-X
CDG	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
inherited	B-X
disorders	B-X
caused	B-X
by	B-X
deficiencies	B-X
in	B-X
glycosylation	B-X
.	B-X
Since	B-X
1980	B-X
,	B-X
14	B-X
CDG	B-X
type	B-X
I	B-X
(	B-X
CDG-I	B-X
)	B-X
defects	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
all	B-X
affecting	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
number	B-X
of	B-X
unsolved	B-X
CDG-I	B-X
(	B-X
CDG-Ix	B-X
)	B-X
patients	B-X
displaying	B-X
protein	B-X
hypoglycosylation	B-X
in	B-X
combination	B-X
with	B-X
an	B-X
apparently	B-X
normal	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
is	B-X
currently	B-X
expanding	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hypoglycosylation	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
these	B-X
patients	B-X
could	B-X
be	B-X
caused	B-X
by	B-X
a	B-X
deficiency	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
onto	B-X
protein	B-X
,	B-X
a	B-X
reaction	B-X
catalyzed	B-X
by	B-X
the	B-X
oligosaccharyltransferase	B-X
(	B-X
OST	B-X
)	B-X
complex	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
different	B-X
subunits	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
were	B-X
screened	B-X
in	B-X
27	B-X
CDG-Ix	B-X
patients	B-X
for	B-X
whom	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
lipid-linked	B-X
oligosaccharides	B-X
revealed	B-X
a	B-X
normal	B-X
level	B-X
and	B-X
intact	B-X
structure	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
Among	B-X
these	B-X
27	B-X
patients	B-X
,	B-X
one	B-X
was	B-X
identified	B-X
with	B-X
a	B-X
homozygous	B-X
missense	B-X
mutation	B-X
(	B-X
c.1121G	B-X
>	B-X
A	B-X
;	B-X
p.G374D	B-X
)	B-X
in	B-X
the	B-X
ribophorin	B-X
2	B-X
(	B-X
RPN2	B-X
)	B-X
subunit	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
.	B-X
The	B-X
pathogenic	B-X
nature	B-X
of	B-X
this	B-X
mutation	B-X
remains	B-X
unproven	B-X
due	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
tackling	B-X
a	B-X
possible	B-X
OST	B-X
defect	B-X
.	B-X

Congenital	O
Disorders	O
of	O
Glycosylation	O
(	O
CDG	O
)	O
are	O
a	O
group	O
of	O
inherited	O
disorders	O
caused	O
by	O
deficiencies	O
in	O
glycosylation	O
.	O
<EOS>	B-X
Phosphomannomutase	B-X
2	B-X
(	B-X
PMM2-CDG	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
congenital	B-X
disorder	B-X
of	B-X
N-glycosylation	B-X
and	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
deficient	B-X
PMM2	B-X
activity	B-X
.	B-X
The	B-X
clinical	B-X
presentation	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
PMM2-CDG	B-X
vary	B-X
among	B-X
affected	B-X
individuals	B-X
ranging	B-X
from	B-X
a	B-X
severe	B-X
antenatal	B-X
presentation	B-X
with	B-X
multisystem	B-X
involvement	B-X
to	B-X
mild	B-X
adulthood	B-X
presentation	B-X
limited	B-X
to	B-X
minor	B-X
neurological	B-X
involvement	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
on	B-X
PMM2-CDG	B-X
was	B-X
conducted	B-X
by	B-X
a	B-X
group	B-X
of	B-X
international	B-X
experts	B-X
in	B-X
different	B-X
aspects	B-X
of	B-X
CDG	B-X
.	B-X
This	B-X
guideline	B-X
mainly	B-X
addresses	B-X
the	B-X
clinical	B-X
evaluation	B-X
of	B-X
each	B-X
system/organ	B-X
involved	B-X
in	B-X
PMM2-CDG	B-X
,	B-X
and	B-X
the	B-X
recommended	B-X
management	B-X
approach	B-X
.	B-X
It	B-X
is	B-X
the	B-X
first	B-X
systematic	B-X
review	B-X
of	B-X
current	B-X
practices	B-X
in	B-X
PMM2-CDG	B-X
and	B-X
the	B-X
first	B-X
guidelines	B-X
aiming	B-X
at	B-X
establishing	B-X
a	B-X
practical	B-X
approach	B-X
to	B-X
the	B-X
recognition	B-X
,	B-X
diagnosis	B-X
and	B-X
management	B-X
of	B-X
PMM2-CDG	B-X
patients	B-X
.	B-X

Since	O
1980	O
,	O
14	O
CDG	O
type	O
I	O
(	O
CDG	O
-	O
I	O
)	O
defects	O
have	O
been	O
identified	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
all	O
affecting	O
the	O
assembly	O
of	O
the	O
oligosaccharide	O
precursor	O
.	O
<EOS>	B-X
Congenital	B-X
Disorders	B-X
of	B-X
Glycosylation	B-X
(	B-X
CDG	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
inherited	B-X
disorders	B-X
caused	B-X
by	B-X
deficiencies	B-X
in	B-X
glycosylation	B-X
.	B-X
Since	B-X
1980	B-X
,	B-X
14	B-X
CDG	B-X
type	B-X
I	B-X
(	B-X
CDG-I	B-X
)	B-X
defects	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
all	B-X
affecting	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
number	B-X
of	B-X
unsolved	B-X
CDG-I	B-X
(	B-X
CDG-Ix	B-X
)	B-X
patients	B-X
displaying	B-X
protein	B-X
hypoglycosylation	B-X
in	B-X
combination	B-X
with	B-X
an	B-X
apparently	B-X
normal	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
is	B-X
currently	B-X
expanding	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hypoglycosylation	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
these	B-X
patients	B-X
could	B-X
be	B-X
caused	B-X
by	B-X
a	B-X
deficiency	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
onto	B-X
protein	B-X
,	B-X
a	B-X
reaction	B-X
catalyzed	B-X
by	B-X
the	B-X
oligosaccharyltransferase	B-X
(	B-X
OST	B-X
)	B-X
complex	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
different	B-X
subunits	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
were	B-X
screened	B-X
in	B-X
27	B-X
CDG-Ix	B-X
patients	B-X
for	B-X
whom	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
lipid-linked	B-X
oligosaccharides	B-X
revealed	B-X
a	B-X
normal	B-X
level	B-X
and	B-X
intact	B-X
structure	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
Among	B-X
these	B-X
27	B-X
patients	B-X
,	B-X
one	B-X
was	B-X
identified	B-X
with	B-X
a	B-X
homozygous	B-X
missense	B-X
mutation	B-X
(	B-X
c.1121G	B-X
>	B-X
A	B-X
;	B-X
p.G374D	B-X
)	B-X
in	B-X
the	B-X
ribophorin	B-X
2	B-X
(	B-X
RPN2	B-X
)	B-X
subunit	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
.	B-X

However	O
,	O
the	O
number	O
of	O
unsolved	O
CDG	O
-	O
I	O
(	O
CDG	O
-	O
Ix	O
)	O
patients	O
displaying	O
protein	O
hypoglycosylation	O
in	O
combination	O
with	O
an	O
apparently	O
normal	O
assembly	O
of	O
the	O
oligosaccharide	O
precursor	O
is	O
currently	O
expanding	O
.	O
<EOS>	B-X
Congenital	B-X
Disorders	B-X
of	B-X
Glycosylation	B-X
(	B-X
CDG	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
inherited	B-X
disorders	B-X
caused	B-X
by	B-X
deficiencies	B-X
in	B-X
glycosylation	B-X
.	B-X
Since	B-X
1980	B-X
,	B-X
14	B-X
CDG	B-X
type	B-X
I	B-X
(	B-X
CDG-I	B-X
)	B-X
defects	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
all	B-X
affecting	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
number	B-X
of	B-X
unsolved	B-X
CDG-I	B-X
(	B-X
CDG-Ix	B-X
)	B-X
patients	B-X
displaying	B-X
protein	B-X
hypoglycosylation	B-X
in	B-X
combination	B-X
with	B-X
an	B-X
apparently	B-X
normal	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
is	B-X
currently	B-X
expanding	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hypoglycosylation	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
these	B-X
patients	B-X
could	B-X
be	B-X
caused	B-X
by	B-X
a	B-X
deficiency	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
onto	B-X
protein	B-X
,	B-X
a	B-X
reaction	B-X
catalyzed	B-X
by	B-X
the	B-X
oligosaccharyltransferase	B-X
(	B-X
OST	B-X
)	B-X
complex	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
different	B-X
subunits	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
were	B-X
screened	B-X
in	B-X
27	B-X
CDG-Ix	B-X
patients	B-X
for	B-X
whom	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
lipid-linked	B-X
oligosaccharides	B-X
revealed	B-X
a	B-X
normal	B-X
level	B-X
and	B-X
intact	B-X
structure	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
Among	B-X
these	B-X
27	B-X
patients	B-X
,	B-X
one	B-X
was	B-X
identified	B-X
with	B-X
a	B-X
homozygous	B-X
missense	B-X
mutation	B-X
(	B-X
c.1121G	B-X
>	B-X
A	B-X
;	B-X
p.G374D	B-X
)	B-X
in	B-X
the	B-X
ribophorin	B-X
2	B-X
(	B-X
RPN2	B-X
)	B-X
subunit	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
.	B-X

We	O
hypothesized	O
that	O
the	O
hypoglycosylation	O
observed	O
in	O
some	O
of	O
these	O
patients	O
could	O
be	O
caused	O
by	O
a	O
deficiency	O
in	O
the	O
transfer	O
of	O
the	O
oligosaccharide	O
precursor	O
onto	O
protein	O
,	O
a	O
reaction	O
catalyzed	O
by	O
the	O
oligosaccharyltransferase	O
(	O
OST	O
)	O
complex	O
.	O
<EOS>	B-X
Congenital	B-X
Disorders	B-X
of	B-X
Glycosylation	B-X
(	B-X
CDG	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
inherited	B-X
disorders	B-X
caused	B-X
by	B-X
deficiencies	B-X
in	B-X
glycosylation	B-X
.	B-X
Since	B-X
1980	B-X
,	B-X
14	B-X
CDG	B-X
type	B-X
I	B-X
(	B-X
CDG-I	B-X
)	B-X
defects	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
all	B-X
affecting	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
number	B-X
of	B-X
unsolved	B-X
CDG-I	B-X
(	B-X
CDG-Ix	B-X
)	B-X
patients	B-X
displaying	B-X
protein	B-X
hypoglycosylation	B-X
in	B-X
combination	B-X
with	B-X
an	B-X
apparently	B-X
normal	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
is	B-X
currently	B-X
expanding	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hypoglycosylation	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
these	B-X
patients	B-X
could	B-X
be	B-X
caused	B-X
by	B-X
a	B-X
deficiency	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
onto	B-X
protein	B-X
,	B-X
a	B-X
reaction	B-X
catalyzed	B-X
by	B-X
the	B-X
oligosaccharyltransferase	B-X
(	B-X
OST	B-X
)	B-X
complex	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
different	B-X
subunits	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
were	B-X
screened	B-X
in	B-X
27	B-X
CDG-Ix	B-X
patients	B-X
for	B-X
whom	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
lipid-linked	B-X
oligosaccharides	B-X
revealed	B-X
a	B-X
normal	B-X
level	B-X
and	B-X
intact	B-X
structure	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
Among	B-X
these	B-X
27	B-X
patients	B-X
,	B-X
one	B-X
was	B-X
identified	B-X
with	B-X
a	B-X
homozygous	B-X
missense	B-X
mutation	B-X
(	B-X
c.1121G	B-X
>	B-X
A	B-X
;	B-X
p.G374D	B-X
)	B-X
in	B-X
the	B-X
ribophorin	B-X
2	B-X
(	B-X
RPN2	B-X
)	B-X
subunit	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
.	B-X
The	B-X
pathogenic	B-X
nature	B-X
of	B-X
this	B-X
mutation	B-X
remains	B-X
unproven	B-X
due	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
tackling	B-X
a	B-X
possible	B-X
OST	B-X
defect	B-X
.	B-X

For	O
this	O
purpose	O
,	O
the	O
different	O
subunits	O
of	O
the	O
OST	O
complex	O
were	O
screened	O
in	O
27	O
CDG	O
-	O
Ix	O
patients	O
for	O
whom	O
structural	O
analysis	O
of	O
the	O
lipid	O
-	O
linked	O
oligosaccharides	O
revealed	O
a	O
normal	O
level	O
and	O
intact	O
structure	O
of	O
the	O
oligosaccharide	O
precursor	O
.	O
<EOS>	B-X
Congenital	B-X
Disorders	B-X
of	B-X
Glycosylation	B-X
(	B-X
CDG	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
inherited	B-X
disorders	B-X
caused	B-X
by	B-X
deficiencies	B-X
in	B-X
glycosylation	B-X
.	B-X
Since	B-X
1980	B-X
,	B-X
14	B-X
CDG	B-X
type	B-X
I	B-X
(	B-X
CDG-I	B-X
)	B-X
defects	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
all	B-X
affecting	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
number	B-X
of	B-X
unsolved	B-X
CDG-I	B-X
(	B-X
CDG-Ix	B-X
)	B-X
patients	B-X
displaying	B-X
protein	B-X
hypoglycosylation	B-X
in	B-X
combination	B-X
with	B-X
an	B-X
apparently	B-X
normal	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
is	B-X
currently	B-X
expanding	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hypoglycosylation	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
these	B-X
patients	B-X
could	B-X
be	B-X
caused	B-X
by	B-X
a	B-X
deficiency	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
onto	B-X
protein	B-X
,	B-X
a	B-X
reaction	B-X
catalyzed	B-X
by	B-X
the	B-X
oligosaccharyltransferase	B-X
(	B-X
OST	B-X
)	B-X
complex	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
different	B-X
subunits	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
were	B-X
screened	B-X
in	B-X
27	B-X
CDG-Ix	B-X
patients	B-X
for	B-X
whom	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
lipid-linked	B-X
oligosaccharides	B-X
revealed	B-X
a	B-X
normal	B-X
level	B-X
and	B-X
intact	B-X
structure	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
Among	B-X
these	B-X
27	B-X
patients	B-X
,	B-X
one	B-X
was	B-X
identified	B-X
with	B-X
a	B-X
homozygous	B-X
missense	B-X
mutation	B-X
(	B-X
c.1121G	B-X
>	B-X
A	B-X
;	B-X
p.G374D	B-X
)	B-X
in	B-X
the	B-X
ribophorin	B-X
2	B-X
(	B-X
RPN2	B-X
)	B-X
subunit	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
.	B-X
The	B-X
pathogenic	B-X
nature	B-X
of	B-X
this	B-X
mutation	B-X
remains	B-X
unproven	B-X
due	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
tackling	B-X
a	B-X
possible	B-X
OST	B-X
defect	B-X
.	B-X

Among	O
these	O
27	O
patients	O
,	O
one	O
was	O
identified	O
with	O
a	O
homozygous	O
missense	O
mutation	O
(	O
c	O
.	O
1121G	O
>	O
A	O
;	O
p	O
.	O
G374D	O
)	O
in	O
the	O
ribophorin	B-Protein
2	I-Protein
(	O
RPN2	B-Protein
)	O
subunit	O
of	O
the	O
OST	O
complex	O
.	O
<EOS>	B-X
Congenital	B-X
Disorders	B-X
of	B-X
Glycosylation	B-X
(	B-X
CDG	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
inherited	B-X
disorders	B-X
caused	B-X
by	B-X
deficiencies	B-X
in	B-X
glycosylation	B-X
.	B-X
Since	B-X
1980	B-X
,	B-X
14	B-X
CDG	B-X
type	B-X
I	B-X
(	B-X
CDG-I	B-X
)	B-X
defects	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
all	B-X
affecting	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
number	B-X
of	B-X
unsolved	B-X
CDG-I	B-X
(	B-X
CDG-Ix	B-X
)	B-X
patients	B-X
displaying	B-X
protein	B-X
hypoglycosylation	B-X
in	B-X
combination	B-X
with	B-X
an	B-X
apparently	B-X
normal	B-X
assembly	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
is	B-X
currently	B-X
expanding	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hypoglycosylation	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
these	B-X
patients	B-X
could	B-X
be	B-X
caused	B-X
by	B-X
a	B-X
deficiency	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
onto	B-X
protein	B-X
,	B-X
a	B-X
reaction	B-X
catalyzed	B-X
by	B-X
the	B-X
oligosaccharyltransferase	B-X
(	B-X
OST	B-X
)	B-X
complex	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
different	B-X
subunits	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
were	B-X
screened	B-X
in	B-X
27	B-X
CDG-Ix	B-X
patients	B-X
for	B-X
whom	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
lipid-linked	B-X
oligosaccharides	B-X
revealed	B-X
a	B-X
normal	B-X
level	B-X
and	B-X
intact	B-X
structure	B-X
of	B-X
the	B-X
oligosaccharide	B-X
precursor	B-X
.	B-X
Among	B-X
these	B-X
27	B-X
patients	B-X
,	B-X
one	B-X
was	B-X
identified	B-X
with	B-X
a	B-X
homozygous	B-X
missense	B-X
mutation	B-X
(	B-X
c.1121G	B-X
>	B-X
A	B-X
;	B-X
p.G374D	B-X
)	B-X
in	B-X
the	B-X
ribophorin	B-X
2	B-X
(	B-X
RPN2	B-X
)	B-X
subunit	B-X
of	B-X
the	B-X
OST	B-X
complex	B-X
.	B-X
The	B-X
pathogenic	B-X
nature	B-X
of	B-X
this	B-X
mutation	B-X
remains	B-X
unproven	B-X
due	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
tackling	B-X
a	B-X
possible	B-X
OST	B-X
defect	B-X
.	B-X

The	O
pathogenic	O
nature	O
of	O
this	O
mutation	O
remains	O
unproven	O
due	O
to	O
the	O
complexity	O
of	O
tackling	O
a	O
possible	O
OST	O
defect	O
.	O

MdmX	B-Protein
is	O
a	O
substrate	O
for	O
the	O
deubiquitinating	O
enzyme	O
USP2a	B-Protein
.	O
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
ubiquitin-specific	B-X
protease	B-X
2a	B-X
(	B-X
USP2a	B-X
)	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
the	B-X
Mdm2/p53	B-X
pathway	B-X
.	B-X
USP2a	B-X
binds	B-X
to	B-X
Mdm2	B-X
and	B-X
can	B-X
deubiquitinate	B-X
Mdm2	B-X
without	B-X
reversing	B-X
Mdm2-mediated	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
The	B-X
therapeutic	B-X
drug	B-X
,	B-X
cisplatin	B-X
decreases	B-X
MdmX	B-X
protein	B-X
expression	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

It	O
has	O
previously	O
been	O
shown	O
that	O
ubiquitin	B-Protein
-	I-Protein
specific	I-Protein
protease	I-Protein
2a	I-Protein
(	O
USP2a	B-Protein
)	O
is	O
a	O
regulator	O
of	O
the	O
Mdm2	B-Protein
/	O
p53	B-Protein
pathway	O
.	O
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
ubiquitin-specific	B-X
protease	B-X
2a	B-X
(	B-X
USP2a	B-X
)	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
the	B-X
Mdm2/p53	B-X
pathway	B-X
.	B-X
USP2a	B-X
binds	B-X
to	B-X
Mdm2	B-X
and	B-X
can	B-X
deubiquitinate	B-X
Mdm2	B-X
without	B-X
reversing	B-X
Mdm2-mediated	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

USP2a	B-Protein
binds	O
to	O
Mdm2	B-Protein
and	O
can	O
deubiquitinate	O
Mdm2	B-Protein
without	O
reversing	O
Mdm2	B-Protein
-	O
mediated	O
p53	B-Protein
ubiquitination	O
.	O
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
ubiquitin-specific	B-X
protease	B-X
2a	B-X
(	B-X
USP2a	B-X
)	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
the	B-X
Mdm2/p53	B-X
pathway	B-X
.	B-X
USP2a	B-X
binds	B-X
to	B-X
Mdm2	B-X
and	B-X
can	B-X
deubiquitinate	B-X
Mdm2	B-X
without	B-X
reversing	B-X
Mdm2-mediated	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

Overexpression	O
of	O
USP2a	B-Protein
causes	O
accumulation	O
of	O
Mdm2	B-Protein
and	O
promotes	O
p53	B-Protein
degradation	O
.	O
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
ubiquitin-specific	B-X
protease	B-X
2a	B-X
(	B-X
USP2a	B-X
)	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
the	B-X
Mdm2/p53	B-X
pathway	B-X
.	B-X
USP2a	B-X
binds	B-X
to	B-X
Mdm2	B-X
and	B-X
can	B-X
deubiquitinate	B-X
Mdm2	B-X
without	B-X
reversing	B-X
Mdm2-mediated	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

We	O
now	O
show	O
that	O
MdmX	B-Protein
is	O
also	O
a	O
substrate	O
for	O
USP2a	B-Protein
.	O
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
ubiquitin-specific	B-X
protease	B-X
2a	B-X
(	B-X
USP2a	B-X
)	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
the	B-X
Mdm2/p53	B-X
pathway	B-X
.	B-X
USP2a	B-X
binds	B-X
to	B-X
Mdm2	B-X
and	B-X
can	B-X
deubiquitinate	B-X
Mdm2	B-X
without	B-X
reversing	B-X
Mdm2-mediated	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
The	B-X
therapeutic	B-X
drug	B-X
,	B-X
cisplatin	B-X
decreases	B-X
MdmX	B-X
protein	B-X
expression	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

MdmX	O
associates	O
with	O
USP2a	B-Protein
independently	O
of	O
Mdm2	B-Protein
.	O
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
ubiquitin-specific	B-X
protease	B-X
2a	B-X
(	B-X
USP2a	B-X
)	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
the	B-X
Mdm2/p53	B-X
pathway	B-X
.	B-X
USP2a	B-X
binds	B-X
to	B-X
Mdm2	B-X
and	B-X
can	B-X
deubiquitinate	B-X
Mdm2	B-X
without	B-X
reversing	B-X
Mdm2-mediated	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
The	B-X
therapeutic	B-X
drug	B-X
,	B-X
cisplatin	B-X
decreases	B-X
MdmX	B-X
protein	B-X
expression	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

Ectopic	O
expression	O
of	O
wild	O
-	O
type	O
USP2a	B-Protein
but	O
not	O
a	O
catalytic	O
mutant	O
prevents	O
Mdm2	B-Protein
-	O
mediated	O
degradation	O
of	O
MdmX	B-Protein
.	O

This	O
correlates	O
with	O
the	O
ability	O
of	O
wild	O
-	O
type	O
USP2a	B-Protein
to	O
deubiquitinate	O
MdmX	B-Protein
.	O
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
ubiquitin-specific	B-X
protease	B-X
2a	B-X
(	B-X
USP2a	B-X
)	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
the	B-X
Mdm2/p53	B-X
pathway	B-X
.	B-X
USP2a	B-X
binds	B-X
to	B-X
Mdm2	B-X
and	B-X
can	B-X
deubiquitinate	B-X
Mdm2	B-X
without	B-X
reversing	B-X
Mdm2-mediated	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
The	B-X
therapeutic	B-X
drug	B-X
,	B-X
cisplatin	B-X
decreases	B-X
MdmX	B-X
protein	B-X
expression	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

siRNA	O
-	O
mediated	O
knockdown	O
of	O
USP2a	B-Protein
in	O
NTERA	O
-	O
2	O
testicular	O
embryonal	O
carcinoma	O
cells	O
and	O
MCF7	O
breast	O
cancer	O
cells	O
causes	O
destabilization	O
of	O
MdmX	B-Protein
and	O
results	O
in	O
a	O
decrease	O
in	O
MdmX	B-Protein
protein	O
levels	O
,	O
showing	O
that	O
endogenous	O
USP2a	B-Protein
participates	O
in	O
the	O
regulation	O
of	O
MdmX	B-Protein
stability	O
.	O

The	O
therapeutic	O
drug	O
,	O
cisplatin	O
decreases	O
MdmX	B-Protein
protein	O
expression	O
.	O
<EOS>	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
The	B-X
therapeutic	B-X
drug	B-X
,	B-X
cisplatin	B-X
decreases	B-X
MdmX	B-X
protein	B-X
expression	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

USP2a	B-Protein
mRNA	O
and	O
protein	O
levels	O
were	O
also	O
reduced	O
after	O
cisplatin	O
exposure	O
.	O
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
ubiquitin-specific	B-X
protease	B-X
2a	B-X
(	B-X
USP2a	B-X
)	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
the	B-X
Mdm2/p53	B-X
pathway	B-X
.	B-X
USP2a	B-X
binds	B-X
to	B-X
Mdm2	B-X
and	B-X
can	B-X
deubiquitinate	B-X
Mdm2	B-X
without	B-X
reversing	B-X
Mdm2-mediated	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
The	B-X
therapeutic	B-X
drug	B-X
,	B-X
cisplatin	B-X
decreases	B-X
MdmX	B-X
protein	B-X
expression	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

The	O
magnitude	O
and	O
time	O
course	O
of	O
USP2a	B-Protein
downregulation	O
suggests	O
that	O
the	O
reduction	O
in	O
USP2a	B-Protein
levels	O
could	O
contribute	O
to	O
the	O
decrease	O
in	O
MdmX	B-Protein
expression	O
following	O
treatment	O
with	O
cisplatin	O
.	O

Knockdown	O
of	O
USP2a	B-Protein
increases	O
the	O
sensitivity	O
of	O
NTERA	O
-	O
2	O
cells	O
to	O
cisplatin	O
,	O
raising	O
the	O
possibility	O
that	O
suppression	O
of	O
USP2a	B-Protein
in	O
combination	O
with	O
cisplatin	O
may	O
be	O
an	O
approach	O
for	O
cancer	O
therapy	O
.	O
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
ubiquitin-specific	B-X
protease	B-X
2a	B-X
(	B-X
USP2a	B-X
)	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
the	B-X
Mdm2/p53	B-X
pathway	B-X
.	B-X
USP2a	B-X
binds	B-X
to	B-X
Mdm2	B-X
and	B-X
can	B-X
deubiquitinate	B-X
Mdm2	B-X
without	B-X
reversing	B-X
Mdm2-mediated	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Overexpression	B-X
of	B-X
USP2a	B-X
causes	B-X
accumulation	B-X
of	B-X
Mdm2	B-X
and	B-X
promotes	B-X
p53	B-X
degradation	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
MdmX	B-X
is	B-X
also	B-X
a	B-X
substrate	B-X
for	B-X
USP2a	B-X
.	B-X
MdmX	B-X
associates	B-X
with	B-X
USP2a	B-X
independently	B-X
of	B-X
Mdm2	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
USP2a	B-X
but	B-X
not	B-X
a	B-X
catalytic	B-X
mutant	B-X
prevents	B-X
Mdm2-mediated	B-X
degradation	B-X
of	B-X
MdmX	B-X
.	B-X
This	B-X
correlates	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
wild-type	B-X
USP2a	B-X
to	B-X
deubiquitinate	B-X
MdmX	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
USP2a	B-X
in	B-X
NTERA-2	B-X
testicular	B-X
embryonal	B-X
carcinoma	B-X
cells	B-X
and	B-X
MCF7	B-X
breast	B-X
cancer	B-X
cells	B-X
causes	B-X
destabilization	B-X
of	B-X
MdmX	B-X
and	B-X
results	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
levels	B-X
,	B-X
showing	B-X
that	B-X
endogenous	B-X
USP2a	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
MdmX	B-X
stability	B-X
.	B-X
The	B-X
therapeutic	B-X
drug	B-X
,	B-X
cisplatin	B-X
decreases	B-X
MdmX	B-X
protein	B-X
expression	B-X
.	B-X
USP2a	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
also	B-X
reduced	B-X
after	B-X
cisplatin	B-X
exposure	B-X
.	B-X
The	B-X
magnitude	B-X
and	B-X
time	B-X
course	B-X
of	B-X
USP2a	B-X
downregulation	B-X
suggests	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
USP2a	B-X
levels	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
MdmX	B-X
expression	B-X
following	B-X
treatment	B-X
with	B-X
cisplatin	B-X
.	B-X
Knockdown	B-X
of	B-X
USP2a	B-X
increases	B-X
the	B-X
sensitivity	B-X
of	B-X
NTERA-2	B-X
cells	B-X
to	B-X
cisplatin	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
suppression	B-X
of	B-X
USP2a	B-X
in	B-X
combination	B-X
with	B-X
cisplatin	B-X
may	B-X
be	B-X
an	B-X
approach	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

Prolyl	B-Protein
3	I-Protein
-	I-Protein
hydroxylase	I-Protein
1	I-Protein
and	O
CRTAP	B-Protein
are	O
mutually	O
stabilizing	O
in	O
the	O
endoplasmic	O
reticulum	O
collagen	O
prolyl	O
3	O
-	O
hydroxylation	O
complex	O
.	O
<EOS>	B-X
Null	B-X
mutations	B-X
in	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
and	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
cause	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
,	B-X
respectively	B-X
,	B-X
two	B-X
novel	B-X
recessive	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
with	B-X
severe	B-X
to	B-X
lethal	B-X
bone	B-X
dysplasia	B-X
and	B-X
overmodification	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
helical	B-X
region	B-X
.	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
CyPB	B-X
)	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
which	B-X
3-hydroxylates	B-X
the	B-X
Pro986	B-X
residue	B-X
of	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
and	B-X
alpha1	B-X
(	B-X
II	B-X
)	B-X
collagen	B-X
chains	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
interaction	B-X
of	B-X
complex	B-X
components	B-X
in	B-X
fibroblasts	B-X
from	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
patients	B-X
.	B-X
Both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
absent	B-X
or	B-X
reduced	B-X
on	B-X
western	B-X
blots	B-X
and	B-X
by	B-X
immunofluorescence	B-X
microscopy	B-X
in	B-X
cells	B-X
containing	B-X
null	B-X
mutations	B-X
in	B-X
either	B-X
gene	B-X
.	B-X
Levels	B-X
of	B-X
LEPRE1	B-X
or	B-X
CRTAP	B-X
transcripts	B-X
,	B-X
however	B-X
,	B-X
are	B-X
normal	B-X
in	B-X
CRTAP-	B-X
or	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Stable	B-X
transfection	B-X
of	B-X
a	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
expression	B-X
construct	B-X
into	B-X
cells	B-X
with	B-X
null	B-X
mutations	B-X
for	B-X
the	B-X
transfected	B-X
cDNA	B-X
restored	B-X
both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
protein	B-X
levels	B-X
.	B-X
Normalization	B-X
of	B-X
collagen	B-X
helical	B-X
modification	B-X
in	B-X
transfected	B-X
CRTAP-null	B-X
cells	B-X
demonstrated	B-X
that	B-X
the	B-X
restored	B-X
proteins	B-X
functioned	B-X
effectively	B-X
as	B-X
a	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
mutually	B-X
stabilized	B-X
in	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
.	B-X
CyPB	B-X
levels	B-X
were	B-X
unaffected	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
.	B-X
Proteasomal	B-X
inhibitors	B-X
partially	B-X
rescue	B-X
P3H1	B-X
protein	B-X
in	B-X
CRTAP-null	B-X
cells	B-X
.	B-X
In	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
secretion	B-X
of	B-X
CRTAP	B-X
is	B-X
increased	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
and	B-X
accounts	B-X
for	B-X
15-20	B-X
%	B-X
of	B-X
the	B-X
decreased	B-X
CRTAP	B-X
detected	B-X
in	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
mutual	B-X
stabilization	B-X
of	B-X
P3H1	B-X
and	B-X
CRTAP	B-X
in	B-X
the	B-X
ER	B-X
collagen	B-X
modification	B-X
complex	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
overlapping	B-X
phenotype	B-X
of	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
.	B-X

Null	O
mutations	O
in	O
cartilage	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
(	O
CRTAP	B-Protein
)	O
and	O
prolyl	B-Protein
3	I-Protein
-	I-Protein
hydroxylase	I-Protein
1	I-Protein
(	O
P3H1	B-Protein
/	O
LEPRE1	B-Protein
)	O
cause	O
types	O
VII	O
and	O
VIII	O
OI	O
,	O
respectively	O
,	O
two	O
novel	O
recessive	O
forms	O
of	O
osteogenesis	O
imperfecta	O
(	O
OI	O
)	O
with	O
severe	O
to	O
lethal	O
bone	O
dysplasia	O
and	O
overmodification	O
of	O
the	O
type	O
I	O
collagen	O
helical	O
region	O
.	O
<EOS>	B-X
Null	B-X
mutations	B-X
in	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
and	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
cause	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
,	B-X
respectively	B-X
,	B-X
two	B-X
novel	B-X
recessive	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
with	B-X
severe	B-X
to	B-X
lethal	B-X
bone	B-X
dysplasia	B-X
and	B-X
overmodification	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
helical	B-X
region	B-X
.	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
CyPB	B-X
)	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
which	B-X
3-hydroxylates	B-X
the	B-X
Pro986	B-X
residue	B-X
of	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
and	B-X
alpha1	B-X
(	B-X
II	B-X
)	B-X
collagen	B-X
chains	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
interaction	B-X
of	B-X
complex	B-X
components	B-X
in	B-X
fibroblasts	B-X
from	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
patients	B-X
.	B-X
Both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
absent	B-X
or	B-X
reduced	B-X
on	B-X
western	B-X
blots	B-X
and	B-X
by	B-X
immunofluorescence	B-X
microscopy	B-X
in	B-X
cells	B-X
containing	B-X
null	B-X
mutations	B-X
in	B-X
either	B-X
gene	B-X
.	B-X
Levels	B-X
of	B-X
LEPRE1	B-X
or	B-X
CRTAP	B-X
transcripts	B-X
,	B-X
however	B-X
,	B-X
are	B-X
normal	B-X
in	B-X
CRTAP-	B-X
or	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Stable	B-X
transfection	B-X
of	B-X
a	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
expression	B-X
construct	B-X
into	B-X
cells	B-X
with	B-X
null	B-X
mutations	B-X
for	B-X
the	B-X
transfected	B-X
cDNA	B-X
restored	B-X
both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
protein	B-X
levels	B-X
.	B-X
Normalization	B-X
of	B-X
collagen	B-X
helical	B-X
modification	B-X
in	B-X
transfected	B-X
CRTAP-null	B-X
cells	B-X
demonstrated	B-X
that	B-X
the	B-X
restored	B-X
proteins	B-X
functioned	B-X
effectively	B-X
as	B-X
a	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
mutually	B-X
stabilized	B-X
in	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
.	B-X
CyPB	B-X
levels	B-X
were	B-X
unaffected	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
.	B-X
Proteasomal	B-X
inhibitors	B-X
partially	B-X
rescue	B-X
P3H1	B-X
protein	B-X
in	B-X
CRTAP-null	B-X
cells	B-X
.	B-X
In	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
secretion	B-X
of	B-X
CRTAP	B-X
is	B-X
increased	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
and	B-X
accounts	B-X
for	B-X
15-20	B-X
%	B-X
of	B-X
the	B-X
decreased	B-X
CRTAP	B-X
detected	B-X
in	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
mutual	B-X
stabilization	B-X
of	B-X
P3H1	B-X
and	B-X
CRTAP	B-X
in	B-X
the	B-X
ER	B-X
collagen	B-X
modification	B-X
complex	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
overlapping	B-X
phenotype	B-X
of	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
.	B-X

CRTAP	B-Protein
and	O
P3H1	B-Protein
form	O
a	O
complex	O
with	O
cyclophilin	B-Protein
B	I-Protein
(	O
CyPB	B-Protein
)	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
which	O
3	O
-	O
hydroxylates	O
the	O
Pro986	O
residue	O
of	O
alpha1	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
and	O
alpha1	B-Protein
(	I-Protein
II	I-Protein
)	I-Protein
collagen	I-Protein
chains	O
.	O

We	O
investigated	O
the	O
interaction	O
of	O
complex	O
components	O
in	O
fibroblasts	O
from	O
types	O
VII	O
and	O
VIII	O
OI	O
patients	O
.	O
<EOS>	B-X
Null	B-X
mutations	B-X
in	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
and	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
cause	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
,	B-X
respectively	B-X
,	B-X
two	B-X
novel	B-X
recessive	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
with	B-X
severe	B-X
to	B-X
lethal	B-X
bone	B-X
dysplasia	B-X
and	B-X
overmodification	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
helical	B-X
region	B-X
.	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
CyPB	B-X
)	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
which	B-X
3-hydroxylates	B-X
the	B-X
Pro986	B-X
residue	B-X
of	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
and	B-X
alpha1	B-X
(	B-X
II	B-X
)	B-X
collagen	B-X
chains	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
interaction	B-X
of	B-X
complex	B-X
components	B-X
in	B-X
fibroblasts	B-X
from	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
patients	B-X
.	B-X
Normalization	B-X
of	B-X
collagen	B-X
helical	B-X
modification	B-X
in	B-X
transfected	B-X
CRTAP-null	B-X
cells	B-X
demonstrated	B-X
that	B-X
the	B-X
restored	B-X
proteins	B-X
functioned	B-X
effectively	B-X
as	B-X
a	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
mutually	B-X
stabilized	B-X
in	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
.	B-X
Thus	B-X
,	B-X
mutual	B-X
stabilization	B-X
of	B-X
P3H1	B-X
and	B-X
CRTAP	B-X
in	B-X
the	B-X
ER	B-X
collagen	B-X
modification	B-X
complex	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
overlapping	B-X
phenotype	B-X
of	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
.	B-X

Both	O
CRTAP	B-Protein
and	O
P3H1	B-Protein
are	O
absent	O
or	O
reduced	O
on	O
western	O
blots	O
and	O
by	O
immunofluorescence	O
microscopy	O
in	O
cells	O
containing	O
null	O
mutations	O
in	O
either	O
gene	O
.	O
<EOS>	B-X
Classical	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
is	B-X
a	B-X
dominant	B-X
genetic	B-X
disorder	B-X
of	B-X
connective	B-X
tissue	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
of	B-X
the	B-X
two	B-X
genes	B-X
encoding	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
COL1A1	B-X
and	B-X
COL1A2	B-X
.	B-X
Recent	B-X
investigations	B-X
,	B-X
however	B-X
,	B-X
have	B-X
generated	B-X
a	B-X
new	B-X
paradigm	B-X
for	B-X
OI	B-X
incorporating	B-X
many	B-X
of	B-X
the	B-X
prototypical	B-X
features	B-X
that	B-X
distinguish	B-X
dominant	B-X
and	B-X
recessive	B-X
conditions	B-X
,	B-X
within	B-X
a	B-X
type	B-X
I	B-X
collagen	B-X
framework	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
long-sought	B-X
cause	B-X
of	B-X
the	B-X
recessive	B-X
form	B-X
of	B-X
OI	B-X
,	B-X
first	B-X
postulated	B-X
in	B-X
the	B-X
Sillence	B-X
classification	B-X
,	B-X
lies	B-X
in	B-X
defects	B-X
in	B-X
the	B-X
genes	B-X
encoding	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
or	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
.	B-X
Together	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
PPIB	B-X
)	B-X
,	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
comprise	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
,	B-X
which	B-X
catalyzes	B-X
a	B-X
specific	B-X
posttranslational	B-X
modification	B-X
of	B-X
types	B-X
I	B-X
,	B-X
II	B-X
,	B-X
and	B-X
V	B-X
collagen	B-X
,	B-X
and	B-X
may	B-X
act	B-X
as	B-X
a	B-X
general	B-X
chaperone	B-X
.	B-X
Patients	B-X
with	B-X
mutations	B-X
in	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
have	B-X
a	B-X
lethal	B-X
to	B-X
severe	B-X
osteochondrodystrophy	B-X
that	B-X
overlaps	B-X
with	B-X
Sillence	B-X
types	B-X
II	B-X
and	B-X
III	B-X
OI	B-X
but	B-X
has	B-X
distinctive	B-X
features	B-X
.	B-X
Most	B-X
causative	B-X
mutations	B-X
result	B-X
in	B-X
null	B-X
alleles	B-X
,	B-X
with	B-X
the	B-X
absence	B-X
or	B-X
severe	B-X
reduction	B-X
of	B-X
gene	B-X
transcripts	B-X
and	B-X
proteins	B-X
.	B-X
As	B-X
expected	B-X
,	B-X
3-hydroxylation	B-X
of	B-X
the	B-X
Pro986	B-X
residue	B-X
is	B-X
absent	B-X
or	B-X
severly	B-X
reduced	B-X
,	B-X
but	B-X
bone	B-X
severity	B-X
and	B-X
survival	B-X
length	B-X
do	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
residual	B-X
hydroxylation	B-X
.	B-X
Surprisingly	B-X
,	B-X
the	B-X
collagen	B-X
produced	B-X
by	B-X
cells	B-X
with	B-X
an	B-X
absence	B-X
of	B-X
Pro986	B-X
hydroxylation	B-X
has	B-X
helical	B-X
overmodification	B-X
by	B-X
lysyl	B-X
hydroxylase	B-X
and	B-X
prolyl	B-X
4-hydroxylase	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
folding	B-X
of	B-X
the	B-X
collagen	B-X
helix	B-X
has	B-X
been	B-X
substantially	B-X
delayed	B-X
.	B-X

Levels	O
of	O
LEPRE1	B-Protein
or	O
CRTAP	B-Protein
transcripts	O
,	O
however	O
,	O
are	O
normal	O
in	O
CRTAP	B-Protein
-	O
or	O
LEPRE1	B-Protein
-	O
null	O
cells	O
,	O
respectively	O
.	O
<EOS>	B-X
Recent	B-X
investigations	B-X
,	B-X
however	B-X
,	B-X
have	B-X
generated	B-X
a	B-X
new	B-X
paradigm	B-X
for	B-X
OI	B-X
incorporating	B-X
many	B-X
of	B-X
the	B-X
prototypical	B-X
features	B-X
that	B-X
distinguish	B-X
dominant	B-X
and	B-X
recessive	B-X
conditions	B-X
,	B-X
within	B-X
a	B-X
type	B-X
I	B-X
collagen	B-X
framework	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
long-sought	B-X
cause	B-X
of	B-X
the	B-X
recessive	B-X
form	B-X
of	B-X
OI	B-X
,	B-X
first	B-X
postulated	B-X
in	B-X
the	B-X
Sillence	B-X
classification	B-X
,	B-X
lies	B-X
in	B-X
defects	B-X
in	B-X
the	B-X
genes	B-X
encoding	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
or	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
.	B-X
Together	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
PPIB	B-X
)	B-X
,	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
comprise	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
,	B-X
which	B-X
catalyzes	B-X
a	B-X
specific	B-X
posttranslational	B-X
modification	B-X
of	B-X
types	B-X
I	B-X
,	B-X
II	B-X
,	B-X
and	B-X
V	B-X
collagen	B-X
,	B-X
and	B-X
may	B-X
act	B-X
as	B-X
a	B-X
general	B-X
chaperone	B-X
.	B-X
Patients	B-X
with	B-X
mutations	B-X
in	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
have	B-X
a	B-X
lethal	B-X
to	B-X
severe	B-X
osteochondrodystrophy	B-X
that	B-X
overlaps	B-X
with	B-X
Sillence	B-X
types	B-X
II	B-X
and	B-X
III	B-X
OI	B-X
but	B-X
has	B-X
distinctive	B-X
features	B-X
.	B-X
Infants	B-X
with	B-X
recessive	B-X
OI	B-X
have	B-X
white	B-X
sclerae	B-X
,	B-X
undertubulation	B-X
of	B-X
the	B-X
long	B-X
bones	B-X
,	B-X
gracile	B-X
ribs	B-X
without	B-X
beading	B-X
,	B-X
and	B-X
a	B-X
small	B-X
to	B-X
normal	B-X
head	B-X
circumference	B-X
.	B-X
Most	B-X
causative	B-X
mutations	B-X
result	B-X
in	B-X
null	B-X
alleles	B-X
,	B-X
with	B-X
the	B-X
absence	B-X
or	B-X
severe	B-X
reduction	B-X
of	B-X
gene	B-X
transcripts	B-X
and	B-X
proteins	B-X
.	B-X
Surprisingly	B-X
,	B-X
the	B-X
collagen	B-X
produced	B-X
by	B-X
cells	B-X
with	B-X
an	B-X
absence	B-X
of	B-X
Pro986	B-X
hydroxylation	B-X
has	B-X
helical	B-X
overmodification	B-X
by	B-X
lysyl	B-X
hydroxylase	B-X
and	B-X
prolyl	B-X
4-hydroxylase	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
folding	B-X
of	B-X
the	B-X
collagen	B-X
helix	B-X
has	B-X
been	B-X
substantially	B-X
delayed	B-X
.	B-X

Stable	O
transfection	O
of	O
a	O
CRTAP	B-Protein
or	O
LEPRE1	B-Protein
expression	O
construct	O
into	O
cells	O
with	O
null	O
mutations	O
for	O
the	O
transfected	O
cDNA	O
restored	O
both	O
CRTAP	B-Protein
and	O
P3H1	B-Protein
protein	O
levels	O
.	O
<EOS>	B-X
Null	B-X
mutations	B-X
in	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
and	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
cause	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
,	B-X
respectively	B-X
,	B-X
two	B-X
novel	B-X
recessive	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
with	B-X
severe	B-X
to	B-X
lethal	B-X
bone	B-X
dysplasia	B-X
and	B-X
overmodification	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
helical	B-X
region	B-X
.	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
CyPB	B-X
)	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
which	B-X
3-hydroxylates	B-X
the	B-X
Pro986	B-X
residue	B-X
of	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
and	B-X
alpha1	B-X
(	B-X
II	B-X
)	B-X
collagen	B-X
chains	B-X
.	B-X
Both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
absent	B-X
or	B-X
reduced	B-X
on	B-X
western	B-X
blots	B-X
and	B-X
by	B-X
immunofluorescence	B-X
microscopy	B-X
in	B-X
cells	B-X
containing	B-X
null	B-X
mutations	B-X
in	B-X
either	B-X
gene	B-X
.	B-X
Levels	B-X
of	B-X
LEPRE1	B-X
or	B-X
CRTAP	B-X
transcripts	B-X
,	B-X
however	B-X
,	B-X
are	B-X
normal	B-X
in	B-X
CRTAP-	B-X
or	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Stable	B-X
transfection	B-X
of	B-X
a	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
expression	B-X
construct	B-X
into	B-X
cells	B-X
with	B-X
null	B-X
mutations	B-X
for	B-X
the	B-X
transfected	B-X
cDNA	B-X
restored	B-X
both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
protein	B-X
levels	B-X
.	B-X
Normalization	B-X
of	B-X
collagen	B-X
helical	B-X
modification	B-X
in	B-X
transfected	B-X
CRTAP-null	B-X
cells	B-X
demonstrated	B-X
that	B-X
the	B-X
restored	B-X
proteins	B-X
functioned	B-X
effectively	B-X
as	B-X
a	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
mutually	B-X
stabilized	B-X
in	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
.	B-X
CyPB	B-X
levels	B-X
were	B-X
unaffected	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
.	B-X
Proteasomal	B-X
inhibitors	B-X
partially	B-X
rescue	B-X
P3H1	B-X
protein	B-X
in	B-X
CRTAP-null	B-X
cells	B-X
.	B-X
In	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
secretion	B-X
of	B-X
CRTAP	B-X
is	B-X
increased	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
and	B-X
accounts	B-X
for	B-X
15-20	B-X
%	B-X
of	B-X
the	B-X
decreased	B-X
CRTAP	B-X
detected	B-X
in	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
mutual	B-X
stabilization	B-X
of	B-X
P3H1	B-X
and	B-X
CRTAP	B-X
in	B-X
the	B-X
ER	B-X
collagen	B-X
modification	B-X
complex	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
overlapping	B-X
phenotype	B-X
of	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
.	B-X

Normalization	O
of	O
collagen	O
helical	O
modification	O
in	O
transfected	O
CRTAP	B-Protein
-	O
null	O
cells	O
demonstrated	O
that	O
the	O
restored	O
proteins	O
functioned	O
effectively	O
as	O
a	O
complex	O
.	O
<EOS>	B-X
Null	B-X
mutations	B-X
in	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
and	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
cause	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
,	B-X
respectively	B-X
,	B-X
two	B-X
novel	B-X
recessive	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
with	B-X
severe	B-X
to	B-X
lethal	B-X
bone	B-X
dysplasia	B-X
and	B-X
overmodification	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
helical	B-X
region	B-X
.	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
CyPB	B-X
)	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
which	B-X
3-hydroxylates	B-X
the	B-X
Pro986	B-X
residue	B-X
of	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
and	B-X
alpha1	B-X
(	B-X
II	B-X
)	B-X
collagen	B-X
chains	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
interaction	B-X
of	B-X
complex	B-X
components	B-X
in	B-X
fibroblasts	B-X
from	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
patients	B-X
.	B-X
Both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
absent	B-X
or	B-X
reduced	B-X
on	B-X
western	B-X
blots	B-X
and	B-X
by	B-X
immunofluorescence	B-X
microscopy	B-X
in	B-X
cells	B-X
containing	B-X
null	B-X
mutations	B-X
in	B-X
either	B-X
gene	B-X
.	B-X
Levels	B-X
of	B-X
LEPRE1	B-X
or	B-X
CRTAP	B-X
transcripts	B-X
,	B-X
however	B-X
,	B-X
are	B-X
normal	B-X
in	B-X
CRTAP-	B-X
or	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Stable	B-X
transfection	B-X
of	B-X
a	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
expression	B-X
construct	B-X
into	B-X
cells	B-X
with	B-X
null	B-X
mutations	B-X
for	B-X
the	B-X
transfected	B-X
cDNA	B-X
restored	B-X
both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
protein	B-X
levels	B-X
.	B-X
Normalization	B-X
of	B-X
collagen	B-X
helical	B-X
modification	B-X
in	B-X
transfected	B-X
CRTAP-null	B-X
cells	B-X
demonstrated	B-X
that	B-X
the	B-X
restored	B-X
proteins	B-X
functioned	B-X
effectively	B-X
as	B-X
a	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
mutually	B-X
stabilized	B-X
in	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
.	B-X
CyPB	B-X
levels	B-X
were	B-X
unaffected	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
.	B-X
Proteasomal	B-X
inhibitors	B-X
partially	B-X
rescue	B-X
P3H1	B-X
protein	B-X
in	B-X
CRTAP-null	B-X
cells	B-X
.	B-X
In	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
secretion	B-X
of	B-X
CRTAP	B-X
is	B-X
increased	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
and	B-X
accounts	B-X
for	B-X
15-20	B-X
%	B-X
of	B-X
the	B-X
decreased	B-X
CRTAP	B-X
detected	B-X
in	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
mutual	B-X
stabilization	B-X
of	B-X
P3H1	B-X
and	B-X
CRTAP	B-X
in	B-X
the	B-X
ER	B-X
collagen	B-X
modification	B-X
complex	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
overlapping	B-X
phenotype	B-X
of	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
.	B-X

These	O
data	O
indicate	O
that	O
CRTAP	B-Protein
and	O
P3H1	B-Protein
are	O
mutually	O
stabilized	O
in	O
the	O
collagen	O
prolyl	O
3	O
-	O
hydroxylation	O
complex	O
.	O
<EOS>	B-X
Null	B-X
mutations	B-X
in	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
and	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
cause	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
,	B-X
respectively	B-X
,	B-X
two	B-X
novel	B-X
recessive	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
with	B-X
severe	B-X
to	B-X
lethal	B-X
bone	B-X
dysplasia	B-X
and	B-X
overmodification	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
helical	B-X
region	B-X
.	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
CyPB	B-X
)	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
which	B-X
3-hydroxylates	B-X
the	B-X
Pro986	B-X
residue	B-X
of	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
and	B-X
alpha1	B-X
(	B-X
II	B-X
)	B-X
collagen	B-X
chains	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
interaction	B-X
of	B-X
complex	B-X
components	B-X
in	B-X
fibroblasts	B-X
from	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
patients	B-X
.	B-X
Both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
absent	B-X
or	B-X
reduced	B-X
on	B-X
western	B-X
blots	B-X
and	B-X
by	B-X
immunofluorescence	B-X
microscopy	B-X
in	B-X
cells	B-X
containing	B-X
null	B-X
mutations	B-X
in	B-X
either	B-X
gene	B-X
.	B-X
Levels	B-X
of	B-X
LEPRE1	B-X
or	B-X
CRTAP	B-X
transcripts	B-X
,	B-X
however	B-X
,	B-X
are	B-X
normal	B-X
in	B-X
CRTAP-	B-X
or	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Stable	B-X
transfection	B-X
of	B-X
a	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
expression	B-X
construct	B-X
into	B-X
cells	B-X
with	B-X
null	B-X
mutations	B-X
for	B-X
the	B-X
transfected	B-X
cDNA	B-X
restored	B-X
both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
protein	B-X
levels	B-X
.	B-X
Normalization	B-X
of	B-X
collagen	B-X
helical	B-X
modification	B-X
in	B-X
transfected	B-X
CRTAP-null	B-X
cells	B-X
demonstrated	B-X
that	B-X
the	B-X
restored	B-X
proteins	B-X
functioned	B-X
effectively	B-X
as	B-X
a	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
mutually	B-X
stabilized	B-X
in	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
.	B-X
CyPB	B-X
levels	B-X
were	B-X
unaffected	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
.	B-X
Proteasomal	B-X
inhibitors	B-X
partially	B-X
rescue	B-X
P3H1	B-X
protein	B-X
in	B-X
CRTAP-null	B-X
cells	B-X
.	B-X
In	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
secretion	B-X
of	B-X
CRTAP	B-X
is	B-X
increased	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
and	B-X
accounts	B-X
for	B-X
15-20	B-X
%	B-X
of	B-X
the	B-X
decreased	B-X
CRTAP	B-X
detected	B-X
in	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
mutual	B-X
stabilization	B-X
of	B-X
P3H1	B-X
and	B-X
CRTAP	B-X
in	B-X
the	B-X
ER	B-X
collagen	B-X
modification	B-X
complex	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
overlapping	B-X
phenotype	B-X
of	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
.	B-X

CyPB	B-Protein
levels	O
were	O
unaffected	O
by	O
mutations	O
in	O
either	O
CRTAP	B-Protein
or	O
LEPRE1	B-Protein
.	O
<EOS>	B-X
Classical	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
is	B-X
a	B-X
dominant	B-X
genetic	B-X
disorder	B-X
of	B-X
connective	B-X
tissue	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
of	B-X
the	B-X
two	B-X
genes	B-X
encoding	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
COL1A1	B-X
and	B-X
COL1A2	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
long-sought	B-X
cause	B-X
of	B-X
the	B-X
recessive	B-X
form	B-X
of	B-X
OI	B-X
,	B-X
first	B-X
postulated	B-X
in	B-X
the	B-X
Sillence	B-X
classification	B-X
,	B-X
lies	B-X
in	B-X
defects	B-X
in	B-X
the	B-X
genes	B-X
encoding	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
or	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
.	B-X
Together	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
PPIB	B-X
)	B-X
,	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
comprise	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
,	B-X
which	B-X
catalyzes	B-X
a	B-X
specific	B-X
posttranslational	B-X
modification	B-X
of	B-X
types	B-X
I	B-X
,	B-X
II	B-X
,	B-X
and	B-X
V	B-X
collagen	B-X
,	B-X
and	B-X
may	B-X
act	B-X
as	B-X
a	B-X
general	B-X
chaperone	B-X
.	B-X
Patients	B-X
with	B-X
mutations	B-X
in	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
have	B-X
a	B-X
lethal	B-X
to	B-X
severe	B-X
osteochondrodystrophy	B-X
that	B-X
overlaps	B-X
with	B-X
Sillence	B-X
types	B-X
II	B-X
and	B-X
III	B-X
OI	B-X
but	B-X
has	B-X
distinctive	B-X
features	B-X
.	B-X
Most	B-X
causative	B-X
mutations	B-X
result	B-X
in	B-X
null	B-X
alleles	B-X
,	B-X
with	B-X
the	B-X
absence	B-X
or	B-X
severe	B-X
reduction	B-X
of	B-X
gene	B-X
transcripts	B-X
and	B-X
proteins	B-X
.	B-X

Proteasomal	O
inhibitors	O
partially	O
rescue	O
P3H1	B-Protein
protein	O
in	O
CRTAP	B-Protein
-	O
null	O
cells	O
.	O
<EOS>	B-X
Null	B-X
mutations	B-X
in	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
and	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
cause	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
,	B-X
respectively	B-X
,	B-X
two	B-X
novel	B-X
recessive	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
with	B-X
severe	B-X
to	B-X
lethal	B-X
bone	B-X
dysplasia	B-X
and	B-X
overmodification	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
helical	B-X
region	B-X
.	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
CyPB	B-X
)	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
which	B-X
3-hydroxylates	B-X
the	B-X
Pro986	B-X
residue	B-X
of	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
and	B-X
alpha1	B-X
(	B-X
II	B-X
)	B-X
collagen	B-X
chains	B-X
.	B-X
Both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
absent	B-X
or	B-X
reduced	B-X
on	B-X
western	B-X
blots	B-X
and	B-X
by	B-X
immunofluorescence	B-X
microscopy	B-X
in	B-X
cells	B-X
containing	B-X
null	B-X
mutations	B-X
in	B-X
either	B-X
gene	B-X
.	B-X
Levels	B-X
of	B-X
LEPRE1	B-X
or	B-X
CRTAP	B-X
transcripts	B-X
,	B-X
however	B-X
,	B-X
are	B-X
normal	B-X
in	B-X
CRTAP-	B-X
or	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Stable	B-X
transfection	B-X
of	B-X
a	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
expression	B-X
construct	B-X
into	B-X
cells	B-X
with	B-X
null	B-X
mutations	B-X
for	B-X
the	B-X
transfected	B-X
cDNA	B-X
restored	B-X
both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
protein	B-X
levels	B-X
.	B-X
Normalization	B-X
of	B-X
collagen	B-X
helical	B-X
modification	B-X
in	B-X
transfected	B-X
CRTAP-null	B-X
cells	B-X
demonstrated	B-X
that	B-X
the	B-X
restored	B-X
proteins	B-X
functioned	B-X
effectively	B-X
as	B-X
a	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
mutually	B-X
stabilized	B-X
in	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
.	B-X
CyPB	B-X
levels	B-X
were	B-X
unaffected	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
.	B-X
Proteasomal	B-X
inhibitors	B-X
partially	B-X
rescue	B-X
P3H1	B-X
protein	B-X
in	B-X
CRTAP-null	B-X
cells	B-X
.	B-X
In	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
secretion	B-X
of	B-X
CRTAP	B-X
is	B-X
increased	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
and	B-X
accounts	B-X
for	B-X
15-20	B-X
%	B-X
of	B-X
the	B-X
decreased	B-X
CRTAP	B-X
detected	B-X
in	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
mutual	B-X
stabilization	B-X
of	B-X
P3H1	B-X
and	B-X
CRTAP	B-X
in	B-X
the	B-X
ER	B-X
collagen	B-X
modification	B-X
complex	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
overlapping	B-X
phenotype	B-X
of	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
.	B-X

In	O
LEPRE1	B-Protein
-	O
null	O
cells	O
,	O
secretion	O
of	O
CRTAP	B-Protein
is	O
increased	O
compared	O
with	O
control	O
cells	O
and	O
accounts	O
for	O
15	O
-	O
20	O
%	O
of	O
the	O
decreased	O
CRTAP	B-Protein
detected	O
in	O
cells	O
.	O
<EOS>	B-X
Null	B-X
mutations	B-X
in	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
and	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
cause	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
,	B-X
respectively	B-X
,	B-X
two	B-X
novel	B-X
recessive	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
with	B-X
severe	B-X
to	B-X
lethal	B-X
bone	B-X
dysplasia	B-X
and	B-X
overmodification	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
helical	B-X
region	B-X
.	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
CyPB	B-X
)	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
which	B-X
3-hydroxylates	B-X
the	B-X
Pro986	B-X
residue	B-X
of	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
and	B-X
alpha1	B-X
(	B-X
II	B-X
)	B-X
collagen	B-X
chains	B-X
.	B-X
Both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
absent	B-X
or	B-X
reduced	B-X
on	B-X
western	B-X
blots	B-X
and	B-X
by	B-X
immunofluorescence	B-X
microscopy	B-X
in	B-X
cells	B-X
containing	B-X
null	B-X
mutations	B-X
in	B-X
either	B-X
gene	B-X
.	B-X
Levels	B-X
of	B-X
LEPRE1	B-X
or	B-X
CRTAP	B-X
transcripts	B-X
,	B-X
however	B-X
,	B-X
are	B-X
normal	B-X
in	B-X
CRTAP-	B-X
or	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Stable	B-X
transfection	B-X
of	B-X
a	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
expression	B-X
construct	B-X
into	B-X
cells	B-X
with	B-X
null	B-X
mutations	B-X
for	B-X
the	B-X
transfected	B-X
cDNA	B-X
restored	B-X
both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
protein	B-X
levels	B-X
.	B-X
Normalization	B-X
of	B-X
collagen	B-X
helical	B-X
modification	B-X
in	B-X
transfected	B-X
CRTAP-null	B-X
cells	B-X
demonstrated	B-X
that	B-X
the	B-X
restored	B-X
proteins	B-X
functioned	B-X
effectively	B-X
as	B-X
a	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
mutually	B-X
stabilized	B-X
in	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
.	B-X
CyPB	B-X
levels	B-X
were	B-X
unaffected	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
.	B-X
Proteasomal	B-X
inhibitors	B-X
partially	B-X
rescue	B-X
P3H1	B-X
protein	B-X
in	B-X
CRTAP-null	B-X
cells	B-X
.	B-X
In	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
secretion	B-X
of	B-X
CRTAP	B-X
is	B-X
increased	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
and	B-X
accounts	B-X
for	B-X
15-20	B-X
%	B-X
of	B-X
the	B-X
decreased	B-X
CRTAP	B-X
detected	B-X
in	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
mutual	B-X
stabilization	B-X
of	B-X
P3H1	B-X
and	B-X
CRTAP	B-X
in	B-X
the	B-X
ER	B-X
collagen	B-X
modification	B-X
complex	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
overlapping	B-X
phenotype	B-X
of	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
.	B-X

Thus	O
,	O
mutual	O
stabilization	O
of	O
P3H1	B-Protein
and	O
CRTAP	B-Protein
in	O
the	O
ER	O
collagen	O
modification	O
complex	O
is	O
an	O
underlying	O
mechanism	O
for	O
the	O
overlapping	O
phenotype	O
of	O
types	O
VII	O
and	O
VIII	O
OI	O
.	O
<EOS>	B-X
Null	B-X
mutations	B-X
in	B-X
cartilage-associated	B-X
protein	B-X
(	B-X
CRTAP	B-X
)	B-X
and	B-X
prolyl	B-X
3-hydroxylase	B-X
1	B-X
(	B-X
P3H1/LEPRE1	B-X
)	B-X
cause	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
,	B-X
respectively	B-X
,	B-X
two	B-X
novel	B-X
recessive	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
with	B-X
severe	B-X
to	B-X
lethal	B-X
bone	B-X
dysplasia	B-X
and	B-X
overmodification	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
helical	B-X
region	B-X
.	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
cyclophilin	B-X
B	B-X
(	B-X
CyPB	B-X
)	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
which	B-X
3-hydroxylates	B-X
the	B-X
Pro986	B-X
residue	B-X
of	B-X
alpha1	B-X
(	B-X
I	B-X
)	B-X
and	B-X
alpha1	B-X
(	B-X
II	B-X
)	B-X
collagen	B-X
chains	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
interaction	B-X
of	B-X
complex	B-X
components	B-X
in	B-X
fibroblasts	B-X
from	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
patients	B-X
.	B-X
Both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
absent	B-X
or	B-X
reduced	B-X
on	B-X
western	B-X
blots	B-X
and	B-X
by	B-X
immunofluorescence	B-X
microscopy	B-X
in	B-X
cells	B-X
containing	B-X
null	B-X
mutations	B-X
in	B-X
either	B-X
gene	B-X
.	B-X
Levels	B-X
of	B-X
LEPRE1	B-X
or	B-X
CRTAP	B-X
transcripts	B-X
,	B-X
however	B-X
,	B-X
are	B-X
normal	B-X
in	B-X
CRTAP-	B-X
or	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Stable	B-X
transfection	B-X
of	B-X
a	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
expression	B-X
construct	B-X
into	B-X
cells	B-X
with	B-X
null	B-X
mutations	B-X
for	B-X
the	B-X
transfected	B-X
cDNA	B-X
restored	B-X
both	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
protein	B-X
levels	B-X
.	B-X
Normalization	B-X
of	B-X
collagen	B-X
helical	B-X
modification	B-X
in	B-X
transfected	B-X
CRTAP-null	B-X
cells	B-X
demonstrated	B-X
that	B-X
the	B-X
restored	B-X
proteins	B-X
functioned	B-X
effectively	B-X
as	B-X
a	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CRTAP	B-X
and	B-X
P3H1	B-X
are	B-X
mutually	B-X
stabilized	B-X
in	B-X
the	B-X
collagen	B-X
prolyl	B-X
3-hydroxylation	B-X
complex	B-X
.	B-X
CyPB	B-X
levels	B-X
were	B-X
unaffected	B-X
by	B-X
mutations	B-X
in	B-X
either	B-X
CRTAP	B-X
or	B-X
LEPRE1	B-X
.	B-X
Proteasomal	B-X
inhibitors	B-X
partially	B-X
rescue	B-X
P3H1	B-X
protein	B-X
in	B-X
CRTAP-null	B-X
cells	B-X
.	B-X
In	B-X
LEPRE1-null	B-X
cells	B-X
,	B-X
secretion	B-X
of	B-X
CRTAP	B-X
is	B-X
increased	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
and	B-X
accounts	B-X
for	B-X
15-20	B-X
%	B-X
of	B-X
the	B-X
decreased	B-X
CRTAP	B-X
detected	B-X
in	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
mutual	B-X
stabilization	B-X
of	B-X
P3H1	B-X
and	B-X
CRTAP	B-X
in	B-X
the	B-X
ER	B-X
collagen	B-X
modification	B-X
complex	B-X
is	B-X
an	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
overlapping	B-X
phenotype	B-X
of	B-X
types	B-X
VII	B-X
and	B-X
VIII	B-X
OI	B-X
.	B-X

GDP	B-Protein
-	I-Protein
mannose	I-Protein
pyrophosphorylase	I-Protein
is	O
essential	O
in	O
the	O
bloodstream	O
form	O
of	O
Trypanosoma	O
brucei	O
.	O
<EOS>	B-X
A	B-X
putative	B-X
GDP-Man	B-X
PP	B-X
(	B-X
guanidine	B-X
diphosphomannose	B-X
pyrophosphorylase	B-X
)	B-X
gene	B-X
from	B-X
Trypanosoma	B-X
brucei	B-X
(	B-X
TbGDP-Man	B-X
PP	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
and	B-X
subsequently	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
recombinantly	B-X
expressed	B-X
,	B-X
and	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
catalytically	B-X
active	B-X
dimer	B-X
.	B-X
Kinetic	B-X
analysis	B-X
revealed	B-X
a	B-X
Vmax	B-X
of	B-X
0.34	B-X
mumol/min	B-X
per	B-X
mg	B-X
of	B-X
protein	B-X
and	B-X
Km	B-X
values	B-X
of	B-X
67	B-X
muM	B-X
and	B-X
12	B-X
muM	B-X
for	B-X
GTP	B-X
and	B-X
mannose	B-X
1-phosphate	B-X
respectively	B-X
.	B-X
Further	B-X
kinetic	B-X
studies	B-X
showed	B-X
GDP-Man	B-X
was	B-X
a	B-X
potent	B-X
product	B-X
feedback	B-X
inhibitor	B-X
.	B-X
RNAi	B-X
(	B-X
RNA	B-X
interference	B-X
)	B-X
of	B-X
the	B-X
cytosolic	B-X
TbGDP-Man	B-X
PP	B-X
showed	B-X
that	B-X
mRNA	B-X
levels	B-X
were	B-X
reduced	B-X
to	B-X
~20	B-X
%	B-X
of	B-X
wild-type	B-X
levels	B-X
,	B-X
causing	B-X
the	B-X
cells	B-X
to	B-X
die	B-X
after	B-X
3-4	B-X
days	B-X
,	B-X
demonstrating	B-X
that	B-X
TbGDP-Man	B-X
PP	B-X
is	B-X
essential	B-X
in	B-X
the	B-X
bloodstream	B-X
form	B-X
of	B-X
T.	B-X
brucei	B-X
and	B-X
thus	B-X
a	B-X
potential	B-X
drug	B-X
target	B-X
.	B-X
The	B-X
RNAi-induced	B-X
parasites	B-X
have	B-X
a	B-X
greatly	B-X
reduced	B-X
capability	B-X
to	B-X
form	B-X
GDP-Man	B-X
,	B-X
leading	B-X
ultimately	B-X
to	B-X
a	B-X
reduction	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
synthesize	B-X
their	B-X
essential	B-X
GPI	B-X
(	B-X
glycosylphosphatidylinositol	B-X
)	B-X
anchors	B-X
.	B-X
The	B-X
RNAi-induced	B-X
parasites	B-X
also	B-X
showed	B-X
aberrant	B-X
N-glycosylation	B-X
of	B-X
their	B-X
major	B-X
cell-surface	B-X
glycoprotein	B-X
,	B-X
variant	B-X
surface	B-X
glycoprotein	B-X
,	B-X
with	B-X
loss	B-X
of	B-X
the	B-X
high-mannose	B-X
Man9GlcNAc2	B-X
N-glycosylation	B-X
at	B-X
Asn428	B-X
and	B-X
formation	B-X
of	B-X
complex	B-X
N-glycans	B-X
at	B-X
Asn263	B-X
.	B-X

A	O
putative	O
GDP	B-Protein
-	I-Protein
Man	I-Protein
PP	I-Protein
(	O
guanidine	B-Protein
diphosphomannose	I-Protein
pyrophosphorylase	I-Protein
)	O
gene	O
from	O
Trypanosoma	O
brucei	O
(	O
TbGDP	B-Protein
-	I-Protein
Man	I-Protein
PP	I-Protein
)	O
was	O
identified	O
in	O
the	O
genome	O
and	O
subsequently	O
cloned	O
,	O
sequenced	O
and	O
recombinantly	O
expressed	O
,	O
and	O
shown	O
to	O
be	O
a	O
catalytically	O
active	O
dimer	O
.	O

Kinetic	O
analysis	O
revealed	O
a	O
Vmax	O
of	O
0	O
.	O
34	O
mumol	O
/	O
min	O
per	O
mg	O
of	O
protein	O
and	O
Km	O
values	O
of	O
67	O
muM	O
and	O
12	O
muM	O
for	O
GTP	O
and	O
mannose	O
1	O
-	O
phosphate	O
respectively	O
.	O

Further	O
kinetic	O
studies	O
showed	O
GDP	O
-	O
Man	O
was	O
a	O
potent	O
product	O
feedback	O
inhibitor	O
.	O
<EOS>	B-X
A	B-X
putative	B-X
GDP-Man	B-X
PP	B-X
(	B-X
guanidine	B-X
diphosphomannose	B-X
pyrophosphorylase	B-X
)	B-X
gene	B-X
from	B-X
Trypanosoma	B-X
brucei	B-X
(	B-X
TbGDP-Man	B-X
PP	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
and	B-X
subsequently	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
recombinantly	B-X
expressed	B-X
,	B-X
and	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
catalytically	B-X
active	B-X
dimer	B-X
.	B-X
Further	B-X
kinetic	B-X
studies	B-X
showed	B-X
GDP-Man	B-X
was	B-X
a	B-X
potent	B-X
product	B-X
feedback	B-X
inhibitor	B-X
.	B-X
RNAi	B-X
(	B-X
RNA	B-X
interference	B-X
)	B-X
of	B-X
the	B-X
cytosolic	B-X
TbGDP-Man	B-X
PP	B-X
showed	B-X
that	B-X
mRNA	B-X
levels	B-X
were	B-X
reduced	B-X
to	B-X
~20	B-X
%	B-X
of	B-X
wild-type	B-X
levels	B-X
,	B-X
causing	B-X
the	B-X
cells	B-X
to	B-X
die	B-X
after	B-X
3-4	B-X
days	B-X
,	B-X
demonstrating	B-X
that	B-X
TbGDP-Man	B-X
PP	B-X
is	B-X
essential	B-X
in	B-X
the	B-X
bloodstream	B-X
form	B-X
of	B-X
T.	B-X
brucei	B-X
and	B-X
thus	B-X
a	B-X
potential	B-X
drug	B-X
target	B-X
.	B-X
The	B-X
RNAi-induced	B-X
parasites	B-X
have	B-X
a	B-X
greatly	B-X
reduced	B-X
capability	B-X
to	B-X
form	B-X
GDP-Man	B-X
,	B-X
leading	B-X
ultimately	B-X
to	B-X
a	B-X
reduction	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
synthesize	B-X
their	B-X
essential	B-X
GPI	B-X
(	B-X
glycosylphosphatidylinositol	B-X
)	B-X
anchors	B-X
.	B-X
The	B-X
RNAi-induced	B-X
parasites	B-X
also	B-X
showed	B-X
aberrant	B-X
N-glycosylation	B-X
of	B-X
their	B-X
major	B-X
cell-surface	B-X
glycoprotein	B-X
,	B-X
variant	B-X
surface	B-X
glycoprotein	B-X
,	B-X
with	B-X
loss	B-X
of	B-X
the	B-X
high-mannose	B-X
Man9GlcNAc2	B-X
N-glycosylation	B-X
at	B-X
Asn428	B-X
and	B-X
formation	B-X
of	B-X
complex	B-X
N-glycans	B-X
at	B-X
Asn263	B-X
.	B-X

RNAi	O
(	O
RNA	O
interference	O
)	O
of	O
the	O
cytosolic	O
TbGDP	B-Protein
-	I-Protein
Man	I-Protein
PP	I-Protein
showed	O
that	O
mRNA	O
levels	O
were	O
reduced	O
to	O
~	O
20	O
%	O
of	O
wild	O
-	O
type	O
levels	O
,	O
causing	O
the	O
cells	O
to	O
die	O
after	O
3	O
-	O
4	O
days	O
,	O
demonstrating	O
that	O
TbGDP	B-Protein
-	I-Protein
Man	I-Protein
PP	I-Protein
is	O
essential	O
in	O
the	O
bloodstream	O
form	O
of	O
T	O
.	O
brucei	O
and	O
thus	O
a	O
potential	O
drug	O
target	O
.	O

The	O
RNAi	O
-	O
induced	O
parasites	O
have	O
a	O
greatly	O
reduced	O
capability	O
to	O
form	O
GDP	O
-	O
Man	O
,	O
leading	O
ultimately	O
to	O
a	O
reduction	O
in	O
their	O
ability	O
to	O
synthesize	O
their	O
essential	O
GPI	O
(	O
glycosylphosphatidylinositol	O
)	O
anchors	O
.	O
<EOS>	B-X
A	B-X
putative	B-X
GDP-Man	B-X
PP	B-X
(	B-X
guanidine	B-X
diphosphomannose	B-X
pyrophosphorylase	B-X
)	B-X
gene	B-X
from	B-X
Trypanosoma	B-X
brucei	B-X
(	B-X
TbGDP-Man	B-X
PP	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
and	B-X
subsequently	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
recombinantly	B-X
expressed	B-X
,	B-X
and	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
catalytically	B-X
active	B-X
dimer	B-X
.	B-X
Further	B-X
kinetic	B-X
studies	B-X
showed	B-X
GDP-Man	B-X
was	B-X
a	B-X
potent	B-X
product	B-X
feedback	B-X
inhibitor	B-X
.	B-X
RNAi	B-X
(	B-X
RNA	B-X
interference	B-X
)	B-X
of	B-X
the	B-X
cytosolic	B-X
TbGDP-Man	B-X
PP	B-X
showed	B-X
that	B-X
mRNA	B-X
levels	B-X
were	B-X
reduced	B-X
to	B-X
~20	B-X
%	B-X
of	B-X
wild-type	B-X
levels	B-X
,	B-X
causing	B-X
the	B-X
cells	B-X
to	B-X
die	B-X
after	B-X
3-4	B-X
days	B-X
,	B-X
demonstrating	B-X
that	B-X
TbGDP-Man	B-X
PP	B-X
is	B-X
essential	B-X
in	B-X
the	B-X
bloodstream	B-X
form	B-X
of	B-X
T.	B-X
brucei	B-X
and	B-X
thus	B-X
a	B-X
potential	B-X
drug	B-X
target	B-X
.	B-X
The	B-X
RNAi-induced	B-X
parasites	B-X
have	B-X
a	B-X
greatly	B-X
reduced	B-X
capability	B-X
to	B-X
form	B-X
GDP-Man	B-X
,	B-X
leading	B-X
ultimately	B-X
to	B-X
a	B-X
reduction	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
synthesize	B-X
their	B-X
essential	B-X
GPI	B-X
(	B-X
glycosylphosphatidylinositol	B-X
)	B-X
anchors	B-X
.	B-X
The	B-X
RNAi-induced	B-X
parasites	B-X
also	B-X
showed	B-X
aberrant	B-X
N-glycosylation	B-X
of	B-X
their	B-X
major	B-X
cell-surface	B-X
glycoprotein	B-X
,	B-X
variant	B-X
surface	B-X
glycoprotein	B-X
,	B-X
with	B-X
loss	B-X
of	B-X
the	B-X
high-mannose	B-X
Man9GlcNAc2	B-X
N-glycosylation	B-X
at	B-X
Asn428	B-X
and	B-X
formation	B-X
of	B-X
complex	B-X
N-glycans	B-X
at	B-X
Asn263	B-X
.	B-X

The	O
RNAi	O
-	O
induced	O
parasites	O
also	O
showed	O
aberrant	O
N	O
-	O
glycosylation	O
of	O
their	O
major	O
cell	O
-	O
surface	O
glycoprotein	O
,	O
variant	O
surface	O
glycoprotein	O
,	O
with	O
loss	O
of	O
the	O
high	O
-	O
mannose	O
Man9GlcNAc2	O
N	O
-	O
glycosylation	O
at	O
Asn428	O
and	O
formation	O
of	O
complex	O
N	O
-	O
glycans	O
at	O
Asn263	O
.	O
<EOS>	B-X
A	B-X
putative	B-X
GDP-Man	B-X
PP	B-X
(	B-X
guanidine	B-X
diphosphomannose	B-X
pyrophosphorylase	B-X
)	B-X
gene	B-X
from	B-X
Trypanosoma	B-X
brucei	B-X
(	B-X
TbGDP-Man	B-X
PP	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
genome	B-X
and	B-X
subsequently	B-X
cloned	B-X
,	B-X
sequenced	B-X
and	B-X
recombinantly	B-X
expressed	B-X
,	B-X
and	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
catalytically	B-X
active	B-X
dimer	B-X
.	B-X
Kinetic	B-X
analysis	B-X
revealed	B-X
a	B-X
Vmax	B-X
of	B-X
0.34	B-X
mumol/min	B-X
per	B-X
mg	B-X
of	B-X
protein	B-X
and	B-X
Km	B-X
values	B-X
of	B-X
67	B-X
muM	B-X
and	B-X
12	B-X
muM	B-X
for	B-X
GTP	B-X
and	B-X
mannose	B-X
1-phosphate	B-X
respectively	B-X
.	B-X
Further	B-X
kinetic	B-X
studies	B-X
showed	B-X
GDP-Man	B-X
was	B-X
a	B-X
potent	B-X
product	B-X
feedback	B-X
inhibitor	B-X
.	B-X
RNAi	B-X
(	B-X
RNA	B-X
interference	B-X
)	B-X
of	B-X
the	B-X
cytosolic	B-X
TbGDP-Man	B-X
PP	B-X
showed	B-X
that	B-X
mRNA	B-X
levels	B-X
were	B-X
reduced	B-X
to	B-X
~20	B-X
%	B-X
of	B-X
wild-type	B-X
levels	B-X
,	B-X
causing	B-X
the	B-X
cells	B-X
to	B-X
die	B-X
after	B-X
3-4	B-X
days	B-X
,	B-X
demonstrating	B-X
that	B-X
TbGDP-Man	B-X
PP	B-X
is	B-X
essential	B-X
in	B-X
the	B-X
bloodstream	B-X
form	B-X
of	B-X
T.	B-X
brucei	B-X
and	B-X
thus	B-X
a	B-X
potential	B-X
drug	B-X
target	B-X
.	B-X
The	B-X
RNAi-induced	B-X
parasites	B-X
have	B-X
a	B-X
greatly	B-X
reduced	B-X
capability	B-X
to	B-X
form	B-X
GDP-Man	B-X
,	B-X
leading	B-X
ultimately	B-X
to	B-X
a	B-X
reduction	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
synthesize	B-X
their	B-X
essential	B-X
GPI	B-X
(	B-X
glycosylphosphatidylinositol	B-X
)	B-X
anchors	B-X
.	B-X
The	B-X
RNAi-induced	B-X
parasites	B-X
also	B-X
showed	B-X
aberrant	B-X
N-glycosylation	B-X
of	B-X
their	B-X
major	B-X
cell-surface	B-X
glycoprotein	B-X
,	B-X
variant	B-X
surface	B-X
glycoprotein	B-X
,	B-X
with	B-X
loss	B-X
of	B-X
the	B-X
high-mannose	B-X
Man9GlcNAc2	B-X
N-glycosylation	B-X
at	B-X
Asn428	B-X
and	B-X
formation	B-X
of	B-X
complex	B-X
N-glycans	B-X
at	B-X
Asn263	B-X
.	B-X

Regulation	O
of	O
virus	O
-	O
triggered	O
signaling	O
by	O
OTUB1	B-Protein
-	O
and	O
OTUB2	B-Protein
-	O
mediated	O
deubiquitination	O
of	O
TRAF3	B-Protein
and	O
TRAF6	B-Protein
.	O
<EOS>	B-X
Ubiquitination	B-X
and	B-X
deubiquitination	B-X
have	B-X
emerged	B-X
as	B-X
critical	B-X
post-translational	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
activation	B-X
or	B-X
attenuation	B-X
of	B-X
the	B-X
virus-triggered	B-X
type	B-X
I	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
(	B-X
2	B-X
)	B-X
induction	B-X
pathways	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
two	B-X
deubiquitinating	B-X
enzymes	B-X
,	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
,	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
inhibited	B-X
virus-induced	B-X
activation	B-X
of	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
,	B-X
transcription	B-X
of	B-X
the	B-X
IFNB1	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
cellular	B-X
antiviral	B-X
response	B-X
,	B-X
whereas	B-X
knockdown	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
had	B-X
opposite	B-X
effects	B-X
.	B-X
Coimmunoprecipitations	B-X
indicated	B-X
OTUB1	B-X
and	B-X
-2	B-X
interacted	B-X
with	B-X
TRAF3	B-X
and	B-X
TRAF6	B-X
,	B-X
two	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
required	B-X
for	B-X
virus-triggered	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
respectively	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
mediated	B-X
virus-triggered	B-X
deubiquitination	B-X
of	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
negatively	B-X
regulate	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
and	B-X
cellular	B-X
antiviral	B-X
response	B-X
by	B-X
deubiquitinating	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X

Ubiquitination	O
and	O
deubiquitination	O
have	O
emerged	O
as	O
critical	O
post	O
-	O
translational	O
regulatory	O
mechanisms	O
for	O
activation	O
or	O
attenuation	O
of	O
the	O
virus	O
-	O
triggered	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
(	O
2	O
)	O
induction	O
pathways	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
two	O
deubiquitinating	O
enzymes	O
,	O
OTUB1	B-Protein
and	O
OTUB2	B-Protein
,	O
as	O
negative	O
regulators	O
of	O
virus	O
-	O
triggered	O
type	O
I	O
IFN	O
induction	O
.	O
<EOS>	B-X
Ubiquitination	B-X
and	B-X
deubiquitination	B-X
have	B-X
emerged	B-X
as	B-X
critical	B-X
post-translational	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
activation	B-X
or	B-X
attenuation	B-X
of	B-X
the	B-X
virus-triggered	B-X
type	B-X
I	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
(	B-X
2	B-X
)	B-X
induction	B-X
pathways	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
two	B-X
deubiquitinating	B-X
enzymes	B-X
,	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
,	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
inhibited	B-X
virus-induced	B-X
activation	B-X
of	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
,	B-X
transcription	B-X
of	B-X
the	B-X
IFNB1	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
cellular	B-X
antiviral	B-X
response	B-X
,	B-X
whereas	B-X
knockdown	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
had	B-X
opposite	B-X
effects	B-X
.	B-X
Coimmunoprecipitations	B-X
indicated	B-X
OTUB1	B-X
and	B-X
-2	B-X
interacted	B-X
with	B-X
TRAF3	B-X
and	B-X
TRAF6	B-X
,	B-X
two	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
required	B-X
for	B-X
virus-triggered	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
respectively	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
mediated	B-X
virus-triggered	B-X
deubiquitination	B-X
of	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
negatively	B-X
regulate	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
and	B-X
cellular	B-X
antiviral	B-X
response	B-X
by	B-X
deubiquitinating	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X

Overexpression	O
of	O
OTUB1	B-Protein
and	O
OTUB2	B-Protein
inhibited	O
virus	O
-	O
induced	O
activation	O
of	O
IRF3	B-Protein
and	O
NF	O
-	O
kappaB	O
,	O
transcription	O
of	O
the	O
IFNB1	B-Protein
gene	O
as	O
well	O
as	O
cellular	O
antiviral	O
response	O
,	O
whereas	O
knockdown	O
of	O
OTUB1	B-Protein
and	O
OTUB2	B-Protein
had	O
opposite	O
effects	O
.	O
<EOS>	B-X
Ubiquitination	B-X
and	B-X
deubiquitination	B-X
have	B-X
emerged	B-X
as	B-X
critical	B-X
post-translational	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
activation	B-X
or	B-X
attenuation	B-X
of	B-X
the	B-X
virus-triggered	B-X
type	B-X
I	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
(	B-X
2	B-X
)	B-X
induction	B-X
pathways	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
two	B-X
deubiquitinating	B-X
enzymes	B-X
,	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
,	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
inhibited	B-X
virus-induced	B-X
activation	B-X
of	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
,	B-X
transcription	B-X
of	B-X
the	B-X
IFNB1	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
cellular	B-X
antiviral	B-X
response	B-X
,	B-X
whereas	B-X
knockdown	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
had	B-X
opposite	B-X
effects	B-X
.	B-X
Coimmunoprecipitations	B-X
indicated	B-X
OTUB1	B-X
and	B-X
-2	B-X
interacted	B-X
with	B-X
TRAF3	B-X
and	B-X
TRAF6	B-X
,	B-X
two	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
required	B-X
for	B-X
virus-triggered	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
respectively	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
mediated	B-X
virus-triggered	B-X
deubiquitination	B-X
of	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
negatively	B-X
regulate	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
and	B-X
cellular	B-X
antiviral	B-X
response	B-X
by	B-X
deubiquitinating	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X

Coimmunoprecipitations	O
indicated	O
OTUB1	B-Protein
and	O
-	B-Protein
2	I-Protein
interacted	O
with	O
TRAF3	B-Protein
and	O
TRAF6	B-Protein
,	O
two	O
E3	O
ubiquitin	B-Protein
ligases	O
required	O
for	O
virus	O
-	O
triggered	O
IRF3	B-Protein
and	O
NF	O
-	O
kappaB	O
activation	O
,	O
respectively	O
.	O
<EOS>	B-X
Ubiquitination	B-X
and	B-X
deubiquitination	B-X
have	B-X
emerged	B-X
as	B-X
critical	B-X
post-translational	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
activation	B-X
or	B-X
attenuation	B-X
of	B-X
the	B-X
virus-triggered	B-X
type	B-X
I	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
(	B-X
2	B-X
)	B-X
induction	B-X
pathways	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
two	B-X
deubiquitinating	B-X
enzymes	B-X
,	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
,	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
inhibited	B-X
virus-induced	B-X
activation	B-X
of	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
,	B-X
transcription	B-X
of	B-X
the	B-X
IFNB1	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
cellular	B-X
antiviral	B-X
response	B-X
,	B-X
whereas	B-X
knockdown	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
had	B-X
opposite	B-X
effects	B-X
.	B-X
Coimmunoprecipitations	B-X
indicated	B-X
OTUB1	B-X
and	B-X
-2	B-X
interacted	B-X
with	B-X
TRAF3	B-X
and	B-X
TRAF6	B-X
,	B-X
two	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
required	B-X
for	B-X
virus-triggered	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
respectively	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
mediated	B-X
virus-triggered	B-X
deubiquitination	B-X
of	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
negatively	B-X
regulate	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
and	B-X
cellular	B-X
antiviral	B-X
response	B-X
by	B-X
deubiquitinating	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X

Furthermore	O
,	O
we	O
found	O
that	O
OTUB1	B-Protein
and	O
OTUB2	B-Protein
mediated	O
virus	O
-	O
triggered	O
deubiquitination	O
of	O
TRAF3	B-Protein
and	O
-	B-Protein
6	I-Protein
.	O
<EOS>	B-X
Ubiquitination	B-X
and	B-X
deubiquitination	B-X
have	B-X
emerged	B-X
as	B-X
critical	B-X
post-translational	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
activation	B-X
or	B-X
attenuation	B-X
of	B-X
the	B-X
virus-triggered	B-X
type	B-X
I	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
(	B-X
2	B-X
)	B-X
induction	B-X
pathways	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
two	B-X
deubiquitinating	B-X
enzymes	B-X
,	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
,	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
inhibited	B-X
virus-induced	B-X
activation	B-X
of	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
,	B-X
transcription	B-X
of	B-X
the	B-X
IFNB1	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
cellular	B-X
antiviral	B-X
response	B-X
,	B-X
whereas	B-X
knockdown	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
had	B-X
opposite	B-X
effects	B-X
.	B-X
Coimmunoprecipitations	B-X
indicated	B-X
OTUB1	B-X
and	B-X
-2	B-X
interacted	B-X
with	B-X
TRAF3	B-X
and	B-X
TRAF6	B-X
,	B-X
two	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
required	B-X
for	B-X
virus-triggered	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
respectively	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
mediated	B-X
virus-triggered	B-X
deubiquitination	B-X
of	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
negatively	B-X
regulate	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
and	B-X
cellular	B-X
antiviral	B-X
response	B-X
by	B-X
deubiquitinating	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X

These	O
findings	O
suggest	O
that	O
OTUB1	B-Protein
and	O
OTUB2	B-Protein
negatively	O
regulate	O
virus	O
-	O
triggered	O
type	O
I	O
IFN	O
induction	O
and	O
cellular	O
antiviral	O
response	O
by	O
deubiquitinating	O
TRAF3	B-Protein
and	O
-	B-Protein
6	I-Protein
.	O
<EOS>	B-X
Ubiquitination	B-X
and	B-X
deubiquitination	B-X
have	B-X
emerged	B-X
as	B-X
critical	B-X
post-translational	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
activation	B-X
or	B-X
attenuation	B-X
of	B-X
the	B-X
virus-triggered	B-X
type	B-X
I	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
(	B-X
2	B-X
)	B-X
induction	B-X
pathways	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
two	B-X
deubiquitinating	B-X
enzymes	B-X
,	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
,	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
inhibited	B-X
virus-induced	B-X
activation	B-X
of	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
,	B-X
transcription	B-X
of	B-X
the	B-X
IFNB1	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
cellular	B-X
antiviral	B-X
response	B-X
,	B-X
whereas	B-X
knockdown	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
had	B-X
opposite	B-X
effects	B-X
.	B-X
Coimmunoprecipitations	B-X
indicated	B-X
OTUB1	B-X
and	B-X
-2	B-X
interacted	B-X
with	B-X
TRAF3	B-X
and	B-X
TRAF6	B-X
,	B-X
two	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
required	B-X
for	B-X
virus-triggered	B-X
IRF3	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
respectively	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
mediated	B-X
virus-triggered	B-X
deubiquitination	B-X
of	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
negatively	B-X
regulate	B-X
virus-triggered	B-X
type	B-X
I	B-X
IFN	B-X
induction	B-X
and	B-X
cellular	B-X
antiviral	B-X
response	B-X
by	B-X
deubiquitinating	B-X
TRAF3	B-X
and	B-X
-6	B-X
.	B-X

Fbxo45	B-Protein
,	O
a	O
novel	O
ubiquitin	B-Protein
ligase	O
,	O
regulates	O
synaptic	O
activity	O
.	O
<EOS>	B-X
To	B-X
establish	B-X
the	B-X
precise	B-X
yet	B-X
flexible	B-X
connections	B-X
that	B-X
make	B-X
up	B-X
neural	B-X
networks	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
continuous	B-X
synaptic	B-X
modulation	B-X
is	B-X
required	B-X
.	B-X
The	B-X
ubiquitin-proteasome	B-X
system	B-X
of	B-X
protein	B-X
degradation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
mechanisms	B-X
that	B-X
underlie	B-X
this	B-X
process	B-X
,	B-X
playing	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
novel	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
Fbxo45	B-X
,	B-X
that	B-X
functions	B-X
at	B-X
synapses	B-X
.	B-X
Fbxo45	B-X
is	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
the	B-X
knockdown	B-X
of	B-X
Fbxo45	B-X
in	B-X
primary	B-X
cultured	B-X
hippocampal	B-X
neurons	B-X
resulted	B-X
in	B-X
a	B-X
greater	B-X
frequency	B-X
of	B-X
miniature	B-X
excitatory	B-X
postsynaptic	B-X
currents	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
Fbxo45	B-X
induces	B-X
the	B-X
degradation	B-X
of	B-X
a	B-X
synaptic	B-X
vesicle-priming	B-X
factor	B-X
,	B-X
Munc13-1	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Fbxo45	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
neurotransmission	B-X
by	B-X
modulating	B-X
Munc13-1	B-X
at	B-X
the	B-X
synapse	B-X
.	B-X

Neurons	O
communicate	O
with	O
each	O
other	O
through	O
synapses	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
GABA-receptive	B-X
microglia	B-X
selectively	B-X
interact	B-X
with	B-X
inhibitory	B-X
cortical	B-X
synapses	B-X
during	B-X
a	B-X
critical	B-X
window	B-X
of	B-X
mouse	B-X
postnatal	B-X
development	B-X
.	B-X
GABA	B-X
initiates	B-X
a	B-X
transcriptional	B-X
synapse	B-X
remodeling	B-X
program	B-X
within	B-X
these	B-X
specialized	B-X
microglia	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
sculpt	B-X
inhibitory	B-X
connectivity	B-X
without	B-X
impacting	B-X
excitatory	B-X
synapses	B-X
.	B-X
Nerve	B-X
cells	B-X
(	B-X
i.e.	B-X
,	B-X
neurons	B-X
)	B-X
communicate	B-X
via	B-X
a	B-X
combination	B-X
of	B-X
electrical	B-X
and	B-X
chemical	B-X
signals	B-X
.	B-X
Communication	B-X
between	B-X
neurons	B-X
occurs	B-X
at	B-X
tiny	B-X
gaps	B-X
called	B-X
synapses	B-X
,	B-X
where	B-X
specialized	B-X
parts	B-X
of	B-X
the	B-X
two	B-X
cells	B-X
(	B-X
i.e.	B-X
,	B-X
the	B-X
presynaptic	B-X
and	B-X
postsynaptic	B-X
neurons	B-X
)	B-X
come	B-X
within	B-X
nanometers	B-X
of	B-X
one	B-X
another	B-X
to	B-X
allow	B-X
for	B-X
chemical	B-X
transmission	B-X
.	B-X

To	O
establish	O
the	O
precise	O
yet	O
flexible	O
connections	O
that	O
make	O
up	O
neural	O
networks	O
in	O
the	O
brain	O
,	O
continuous	O
synaptic	O
modulation	O
is	O
required	O
.	O
<EOS>	B-X
To	B-X
establish	B-X
the	B-X
precise	B-X
yet	B-X
flexible	B-X
connections	B-X
that	B-X
make	B-X
up	B-X
neural	B-X
networks	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
continuous	B-X
synaptic	B-X
modulation	B-X
is	B-X
required	B-X
.	B-X
The	B-X
ubiquitin-proteasome	B-X
system	B-X
of	B-X
protein	B-X
degradation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
mechanisms	B-X
that	B-X
underlie	B-X
this	B-X
process	B-X
,	B-X
playing	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
the	B-X
knockdown	B-X
of	B-X
Fbxo45	B-X
in	B-X
primary	B-X
cultured	B-X
hippocampal	B-X
neurons	B-X
resulted	B-X
in	B-X
a	B-X
greater	B-X
frequency	B-X
of	B-X
miniature	B-X
excitatory	B-X
postsynaptic	B-X
currents	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
Fbxo45	B-X
induces	B-X
the	B-X
degradation	B-X
of	B-X
a	B-X
synaptic	B-X
vesicle-priming	B-X
factor	B-X
,	B-X
Munc13-1	B-X
.	B-X

The	O
ubiquitin	B-Protein
-	O
proteasome	O
system	O
of	O
protein	O
degradation	O
is	O
one	O
of	O
the	O
critical	O
mechanisms	O
that	O
underlie	O
this	O
process	O
,	O
playing	O
crucial	O
roles	O
in	O
the	O
regulation	O
of	O
synaptic	O
structure	O
and	O
function	O
.	O
<EOS>	B-X
To	B-X
establish	B-X
the	B-X
precise	B-X
yet	B-X
flexible	B-X
connections	B-X
that	B-X
make	B-X
up	B-X
neural	B-X
networks	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
continuous	B-X
synaptic	B-X
modulation	B-X
is	B-X
required	B-X
.	B-X
The	B-X
ubiquitin-proteasome	B-X
system	B-X
of	B-X
protein	B-X
degradation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
mechanisms	B-X
that	B-X
underlie	B-X
this	B-X
process	B-X
,	B-X
playing	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
novel	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
Fbxo45	B-X
,	B-X
that	B-X
functions	B-X
at	B-X
synapses	B-X
.	B-X
Fbxo45	B-X
is	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
the	B-X
knockdown	B-X
of	B-X
Fbxo45	B-X
in	B-X
primary	B-X
cultured	B-X
hippocampal	B-X
neurons	B-X
resulted	B-X
in	B-X
a	B-X
greater	B-X
frequency	B-X
of	B-X
miniature	B-X
excitatory	B-X
postsynaptic	B-X
currents	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
Fbxo45	B-X
induces	B-X
the	B-X
degradation	B-X
of	B-X
a	B-X
synaptic	B-X
vesicle-priming	B-X
factor	B-X
,	B-X
Munc13-1	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Fbxo45	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
neurotransmission	B-X
by	B-X
modulating	B-X
Munc13-1	B-X
at	B-X
the	B-X
synapse	B-X
.	B-X

We	O
identified	O
a	O
novel	O
ubiquitin	B-Protein
ligase	O
,	O
Fbxo45	B-Protein
,	O
that	O
functions	O
at	O
synapses	O
.	O
<EOS>	B-X
Neurons	B-X
communicate	B-X
with	B-X
each	B-X
other	B-X
through	B-X
synapses	B-X
.	B-X
The	B-X
ubiquitin-proteasome	B-X
system	B-X
of	B-X
protein	B-X
degradation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
mechanisms	B-X
that	B-X
underlie	B-X
this	B-X
process	B-X
,	B-X
playing	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
novel	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
Fbxo45	B-X
,	B-X
that	B-X
functions	B-X
at	B-X
synapses	B-X
.	B-X
Fbxo45	B-X
is	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
the	B-X
knockdown	B-X
of	B-X
Fbxo45	B-X
in	B-X
primary	B-X
cultured	B-X
hippocampal	B-X
neurons	B-X
resulted	B-X
in	B-X
a	B-X
greater	B-X
frequency	B-X
of	B-X
miniature	B-X
excitatory	B-X
postsynaptic	B-X
currents	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
Fbxo45	B-X
induces	B-X
the	B-X
degradation	B-X
of	B-X
a	B-X
synaptic	B-X
vesicle-priming	B-X
factor	B-X
,	B-X
Munc13-1	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Fbxo45	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
neurotransmission	B-X
by	B-X
modulating	B-X
Munc13-1	B-X
at	B-X
the	B-X
synapse	B-X
.	B-X

Fbxo45	B-Protein
is	O
evolutionarily	O
conserved	O
and	O
selectively	O
expressed	O
in	O
the	O
nervous	O
system	O
.	O
<EOS>	B-X
The	B-X
ubiquitin-proteasome	B-X
system	B-X
of	B-X
protein	B-X
degradation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
mechanisms	B-X
that	B-X
underlie	B-X
this	B-X
process	B-X
,	B-X
playing	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
novel	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
Fbxo45	B-X
,	B-X
that	B-X
functions	B-X
at	B-X
synapses	B-X
.	B-X
Fbxo45	B-X
is	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
the	B-X
knockdown	B-X
of	B-X
Fbxo45	B-X
in	B-X
primary	B-X
cultured	B-X
hippocampal	B-X
neurons	B-X
resulted	B-X
in	B-X
a	B-X
greater	B-X
frequency	B-X
of	B-X
miniature	B-X
excitatory	B-X
postsynaptic	B-X
currents	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
Fbxo45	B-X
induces	B-X
the	B-X
degradation	B-X
of	B-X
a	B-X
synaptic	B-X
vesicle-priming	B-X
factor	B-X
,	B-X
Munc13-1	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Fbxo45	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
neurotransmission	B-X
by	B-X
modulating	B-X
Munc13-1	B-X
at	B-X
the	B-X
synapse	B-X
.	B-X

We	O
demonstrated	O
that	O
the	O
knockdown	O
of	O
Fbxo45	B-Protein
in	O
primary	O
cultured	O
hippocampal	O
neurons	O
resulted	O
in	O
a	O
greater	O
frequency	O
of	O
miniature	O
excitatory	O
postsynaptic	O
currents	O
.	O

We	O
also	O
found	O
that	O
Fbxo45	B-Protein
induces	O
the	O
degradation	O
of	O
a	O
synaptic	O
vesicle	O
-	O
priming	O
factor	O
,	O
Munc13	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
To	B-X
establish	B-X
the	B-X
precise	B-X
yet	B-X
flexible	B-X
connections	B-X
that	B-X
make	B-X
up	B-X
neural	B-X
networks	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
continuous	B-X
synaptic	B-X
modulation	B-X
is	B-X
required	B-X
.	B-X
The	B-X
ubiquitin-proteasome	B-X
system	B-X
of	B-X
protein	B-X
degradation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
mechanisms	B-X
that	B-X
underlie	B-X
this	B-X
process	B-X
,	B-X
playing	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
novel	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
Fbxo45	B-X
,	B-X
that	B-X
functions	B-X
at	B-X
synapses	B-X
.	B-X
Fbxo45	B-X
is	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
the	B-X
knockdown	B-X
of	B-X
Fbxo45	B-X
in	B-X
primary	B-X
cultured	B-X
hippocampal	B-X
neurons	B-X
resulted	B-X
in	B-X
a	B-X
greater	B-X
frequency	B-X
of	B-X
miniature	B-X
excitatory	B-X
postsynaptic	B-X
currents	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
Fbxo45	B-X
induces	B-X
the	B-X
degradation	B-X
of	B-X
a	B-X
synaptic	B-X
vesicle-priming	B-X
factor	B-X
,	B-X
Munc13-1	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Fbxo45	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
neurotransmission	B-X
by	B-X
modulating	B-X
Munc13-1	B-X
at	B-X
the	B-X
synapse	B-X
.	B-X

We	O
propose	O
that	O
Fbxo45	B-Protein
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
neurotransmission	O
by	O
modulating	O
Munc13	B-Protein
-	I-Protein
1	I-Protein
at	O
the	O
synapse	O
.	O
<EOS>	B-X
Neurons	B-X
communicate	B-X
with	B-X
each	B-X
other	B-X
through	B-X
synapses	B-X
.	B-X
The	B-X
ubiquitin-proteasome	B-X
system	B-X
of	B-X
protein	B-X
degradation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
mechanisms	B-X
that	B-X
underlie	B-X
this	B-X
process	B-X
,	B-X
playing	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
novel	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
Fbxo45	B-X
,	B-X
that	B-X
functions	B-X
at	B-X
synapses	B-X
.	B-X
Fbxo45	B-X
is	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
the	B-X
knockdown	B-X
of	B-X
Fbxo45	B-X
in	B-X
primary	B-X
cultured	B-X
hippocampal	B-X
neurons	B-X
resulted	B-X
in	B-X
a	B-X
greater	B-X
frequency	B-X
of	B-X
miniature	B-X
excitatory	B-X
postsynaptic	B-X
currents	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
Fbxo45	B-X
induces	B-X
the	B-X
degradation	B-X
of	B-X
a	B-X
synaptic	B-X
vesicle-priming	B-X
factor	B-X
,	B-X
Munc13-1	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Fbxo45	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
neurotransmission	B-X
by	B-X
modulating	B-X
Munc13-1	B-X
at	B-X
the	B-X
synapse	B-X
.	B-X

The	O
19S	O
proteasomal	O
lid	O
subunit	O
POH1	B-Protein
enhances	O
the	O
transcriptional	O
activation	O
by	O
Mitf	B-Protein
in	O
osteoclasts	O
.	O
<EOS>	B-X
The	B-X
microphthalmia-associated	B-X
transcription	B-X
factor	B-X
(	B-X
Mitf	B-X
)	B-X
regulates	B-X
gene	B-X
expression	B-X
required	B-X
for	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
Genes	B-X
regulated	B-X
by	B-X
Mitf	B-X
have	B-X
been	B-X
previously	B-X
identified	B-X
.	B-X
However	B-X
,	B-X
proteins	B-X
that	B-X
interact	B-X
and	B-X
regulate	B-X
Mitf	B-X
's	B-X
activity	B-X
in	B-X
osteoclasts	B-X
are	B-X
not	B-X
well	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
POH1	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
19S	B-X
proteasome	B-X
lid	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
Mitf	B-X
.	B-X
We	B-X
show	B-X
that	B-X
POH1	B-X
and	B-X
Mitf	B-X
interact	B-X
in	B-X
osteoclasts	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
is	B-X
dependent	B-X
on	B-X
RANKL	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
POH1	B-X
increased	B-X
Mitf	B-X
's	B-X
activation	B-X
of	B-X
5XGal4-TK	B-X
and	B-X
Acp5	B-X
promoters	B-X
.	B-X
The	B-X
amino	B-X
terminus	B-X
of	B-X
POH1	B-X
mediates	B-X
the	B-X
binding	B-X
to	B-X
Mitf	B-X
and	B-X
is	B-X
sufficient	B-X
to	B-X
increase	B-X
Mitf	B-X
's	B-X
transcriptional	B-X
activity	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
JAMM	B-X
motif	B-X
of	B-X
POH1	B-X
reduced	B-X
Mitf	B-X
activation	B-X
of	B-X
promoters	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
Mitf	B-X
regulation	B-X
in	B-X
osteoclasts	B-X
by	B-X
POH1	B-X
.	B-X

The	O
microphthalmia	B-Protein
-	I-Protein
associated	I-Protein
transcription	I-Protein
factor	I-Protein
(	O
Mitf	B-Protein
)	O
regulates	O
gene	O
expression	O
required	O
for	O
osteoclast	O
differentiation	O
.	O
<EOS>	B-X
Haematopoiesis	B-X
,	B-X
the	B-X
process	B-X
by	B-X
which	B-X
a	B-X
restrained	B-X
population	B-X
of	B-X
stem	B-X
cells	B-X
terminally	B-X
differentiates	B-X
into	B-X
specific	B-X
types	B-X
of	B-X
blood	B-X
cells	B-X
,	B-X
depends	B-X
on	B-X
the	B-X
tightly	B-X
regulated	B-X
temporospatial	B-X
activity	B-X
of	B-X
several	B-X
transcription	B-X
factors	B-X
(	B-X
TFs	B-X
)	B-X
.	B-X
The	B-X
deregulation	B-X
of	B-X
their	B-X
activity	B-X
or	B-X
expression	B-X
is	B-X
a	B-X
main	B-X
cause	B-X
of	B-X
pathological	B-X
haematopoiesis	B-X
,	B-X
leading	B-X
to	B-X
bone	B-X
marrow	B-X
failure	B-X
(	B-X
BMF	B-X
)	B-X
,	B-X
anaemia	B-X
and	B-X
leukaemia	B-X
.	B-X
TFs	B-X
can	B-X
be	B-X
induced	B-X
and/or	B-X
activated	B-X
by	B-X
different	B-X
stimuli	B-X
,	B-X
to	B-X
which	B-X
they	B-X
respond	B-X
by	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
and	B-X
gene	B-X
networks	B-X
.	B-X
The	B-X
microphthalmia-associated	B-X
TF	B-X
(	B-X
MiTF	B-X
)	B-X
is	B-X
a	B-X
prototype	B-X
TF	B-X
in	B-X
multiple	B-X
situations	B-X
.	B-X
MiTF	B-X
has	B-X
been	B-X
described	B-X
extensively	B-X
as	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
melanocyte	B-X
and	B-X
melanoma	B-X
development	B-X
because	B-X
it	B-X
acts	B-X
mainly	B-X
as	B-X
an	B-X
oncogene	B-X
.	B-X
Mitf-mutated	B-X
mice	B-X
show	B-X
a	B-X
plethora	B-X
of	B-X
pleiotropic	B-X
phenotypes	B-X
,	B-X
such	B-X
as	B-X
microphthalmia	B-X
,	B-X
deafness	B-X
,	B-X
abnormal	B-X
pigmentation	B-X
,	B-X
retinal	B-X
degeneration	B-X
,	B-X
reduced	B-X
mast	B-X
cell	B-X
numbers	B-X
and	B-X
osteopetrosis	B-X
,	B-X
revealing	B-X
a	B-X
greater	B-X
requirement	B-X
for	B-X
MiTF	B-X
activity	B-X
in	B-X
cells	B-X
and	B-X
tissue	B-X
.	B-X
A	B-X
growing	B-X
amount	B-X
of	B-X
evidence	B-X
has	B-X
led	B-X
to	B-X
the	B-X
delineation	B-X
of	B-X
key	B-X
roles	B-X
for	B-X
MiTF	B-X
in	B-X
haematopoiesis	B-X
and/or	B-X
in	B-X
cells	B-X
of	B-X
haematopoietic	B-X
origin	B-X
,	B-X
including	B-X
haematopoietic	B-X
stem	B-X
cells	B-X
,	B-X
mast	B-X
cells	B-X
,	B-X
NK	B-X
cells	B-X
,	B-X
basophiles	B-X
,	B-X
B	B-X
cells	B-X
and	B-X
osteoclasts	B-X
.	B-X

Genes	O
regulated	O
by	O
Mitf	B-Protein
have	O
been	O
previously	O
identified	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
find	B-X
that	B-X
MITF	B-X
binding	B-X
to	B-X
genes	B-X
associated	B-X
with	B-X
high	B-X
MITF	B-X
is	B-X
via	B-X
classical	B-X
E/M-box	B-X
motifs	B-X
,	B-X
but	B-X
genes	B-X
downregulated	B-X
when	B-X
MITF	B-X
is	B-X
high	B-X
contain	B-X
FOS/JUN/AP1/ATF3	B-X
sites	B-X
.	B-X
Significantly	B-X
,	B-X
the	B-X
repertoire	B-X
of	B-X
MITF-interacting	B-X
factors	B-X
identified	B-X
here	B-X
includes	B-X
JUN	B-X
and	B-X
ATF3	B-X
as	B-X
well	B-X
as	B-X
many	B-X
previously	B-X
unidentified	B-X
interactors	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
knockdown	B-X
of	B-X
znf503	B-X
(	B-X
the	B-X
ortholog	B-X
of	B-X
mouse	B-X
Zfp503	B-X
)	B-X
in	B-X
zebrafish	B-X
causes	B-X
coloboma	B-X
.	B-X
Both	B-X
MITF	B-X
and	B-X
USF1	B-X
were	B-X
activated	B-X
by	B-X
glycogen	B-X
synthase	B-X
kinase	B-X
(	B-X
GSK	B-X
)	B-X
3	B-X
,	B-X
with	B-X
GSK3	B-X
phosphorylation	B-X
sites	B-X
on	B-X
USF1	B-X
identified	B-X
as	B-X
the	B-X
previously	B-X
described	B-X
activating	B-X
site	B-X
threonine	B-X
153	B-X
as	B-X
well	B-X
as	B-X
serine	B-X
186.	B-X
siRNA	B-X
against	B-X
MITF	B-X
as	B-X
well	B-X
as	B-X
against	B-X
FoxO3a	B-X
protected	B-X
cells	B-X
from	B-X
apoptosis	B-X
following	B-X
PI	B-X
3-kinase	B-X
inhibition	B-X
.	B-X
These	B-X
results	B-X
define	B-X
a	B-X
novel	B-X
E-box-regulated	B-X
network	B-X
that	B-X
functions	B-X
coordinately	B-X
with	B-X
FoxO	B-X
to	B-X
regulate	B-X
transcription	B-X
of	B-X
apoptotic	B-X
and	B-X
cell	B-X
cycle	B-X
regulatory	B-X
genes	B-X
downstream	B-X
of	B-X
PI	B-X
3-kinase/Akt/GSK3	B-X
signaling	B-X
.	B-X

However	O
,	O
proteins	O
that	O
interact	O
and	O
regulate	O
Mitf	B-Protein
'	O
s	O
activity	O
in	O
osteoclasts	O
are	O
not	O
well	O
known	O
.	O
<EOS>	B-X
The	B-X
Microphthalmia-associated	B-X
transcription	B-X
factor	B-X
(	B-X
Mitf	B-X
)	B-X
is	B-X
required	B-X
for	B-X
the	B-X
proper	B-X
development	B-X
of	B-X
several	B-X
cell	B-X
lineages	B-X
including	B-X
osteoclasts	B-X
,	B-X
melanocytes	B-X
,	B-X
retinal	B-X
pigment	B-X
epithelial	B-X
cells	B-X
,	B-X
mast	B-X
cells	B-X
and	B-X
natural	B-X
killer	B-X
cells	B-X
.	B-X
Mutations	B-X
in	B-X
Mitf	B-X
in	B-X
multiple	B-X
organisms	B-X
result	B-X
in	B-X
osteopetrosis	B-X
due	B-X
to	B-X
defective	B-X
osteoclast	B-X
development	B-X
.	B-X
Mitf	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
basic/helix-loop-helix/leucine	B-X
zipper	B-X
(	B-X
b-HLH-ZIP	B-X
)	B-X
transcription	B-X
factor	B-X
subfamily	B-X
named	B-X
MiT	B-X
,	B-X
which	B-X
also	B-X
includes	B-X
Tfe3	B-X
.	B-X
Genetic	B-X
evidence	B-X
indicates	B-X
that	B-X
Mitf	B-X
and	B-X
Tfe3	B-X
carry	B-X
out	B-X
essential	B-X
functions	B-X
in	B-X
osteoclast	B-X
development	B-X
.	B-X
Mitf	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
reside	B-X
downstream	B-X
of	B-X
the	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
and	B-X
receptor	B-X
activator	B-X
of	B-X
NF-kappaB	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
signaling	B-X
pathways	B-X
that	B-X
are	B-X
critical	B-X
for	B-X
osteoclast	B-X
proliferation	B-X
,	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X
Mitf	B-X
and	B-X
Tfe3	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
several	B-X
target	B-X
genes	B-X
necessary	B-X
for	B-X
bone	B-X
degradation	B-X
by	B-X
mature	B-X
osteoclasts	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
bone	B-X
and	B-X
osteoclast	B-X
phenotypes	B-X
of	B-X
animals	B-X
with	B-X
mutations	B-X
in	B-X
Mitf	B-X
and	B-X
Tfe3	B-X
,	B-X
Mitf	B-X
's	B-X
interaction	B-X
partners	B-X
and	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
known	B-X
target	B-X
genes	B-X
which	B-X
,	B-X
together	B-X
with	B-X
others	B-X
yet	B-X
to	B-X
be	B-X
identified	B-X
,	B-X
likely	B-X
represent	B-X
key	B-X
effectors	B-X
of	B-X
bone	B-X
resorption	B-X
.	B-X

Here	O
,	O
we	O
report	O
that	O
POH1	B-Protein
,	O
a	O
subunit	O
of	O
the	O
19S	O
proteasome	O
lid	O
is	O
a	O
regulator	O
of	O
Mitf	B-Protein
.	O
<EOS>	B-X
The	B-X
microphthalmia-associated	B-X
transcription	B-X
factor	B-X
(	B-X
Mitf	B-X
)	B-X
regulates	B-X
gene	B-X
expression	B-X
required	B-X
for	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
Genes	B-X
regulated	B-X
by	B-X
Mitf	B-X
have	B-X
been	B-X
previously	B-X
identified	B-X
.	B-X
However	B-X
,	B-X
proteins	B-X
that	B-X
interact	B-X
and	B-X
regulate	B-X
Mitf	B-X
's	B-X
activity	B-X
in	B-X
osteoclasts	B-X
are	B-X
not	B-X
well	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
POH1	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
19S	B-X
proteasome	B-X
lid	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
Mitf	B-X
.	B-X
We	B-X
show	B-X
that	B-X
POH1	B-X
and	B-X
Mitf	B-X
interact	B-X
in	B-X
osteoclasts	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
is	B-X
dependent	B-X
on	B-X
RANKL	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
POH1	B-X
increased	B-X
Mitf	B-X
's	B-X
activation	B-X
of	B-X
5XGal4-TK	B-X
and	B-X
Acp5	B-X
promoters	B-X
.	B-X
The	B-X
amino	B-X
terminus	B-X
of	B-X
POH1	B-X
mediates	B-X
the	B-X
binding	B-X
to	B-X
Mitf	B-X
and	B-X
is	B-X
sufficient	B-X
to	B-X
increase	B-X
Mitf	B-X
's	B-X
transcriptional	B-X
activity	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
JAMM	B-X
motif	B-X
of	B-X
POH1	B-X
reduced	B-X
Mitf	B-X
activation	B-X
of	B-X
promoters	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
Mitf	B-X
regulation	B-X
in	B-X
osteoclasts	B-X
by	B-X
POH1	B-X
.	B-X

We	O
show	O
that	O
POH1	B-Protein
and	O
Mitf	B-Protein
interact	O
in	O
osteoclasts	O
and	O
that	O
this	O
interaction	O
is	O
dependent	O
on	O
RANKL	B-Protein
signaling	O
.	O
<EOS>	B-X
The	B-X
microphthalmia-associated	B-X
transcription	B-X
factor	B-X
(	B-X
Mitf	B-X
)	B-X
regulates	B-X
gene	B-X
expression	B-X
required	B-X
for	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
Genes	B-X
regulated	B-X
by	B-X
Mitf	B-X
have	B-X
been	B-X
previously	B-X
identified	B-X
.	B-X
However	B-X
,	B-X
proteins	B-X
that	B-X
interact	B-X
and	B-X
regulate	B-X
Mitf	B-X
's	B-X
activity	B-X
in	B-X
osteoclasts	B-X
are	B-X
not	B-X
well	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
POH1	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
19S	B-X
proteasome	B-X
lid	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
Mitf	B-X
.	B-X
We	B-X
show	B-X
that	B-X
POH1	B-X
and	B-X
Mitf	B-X
interact	B-X
in	B-X
osteoclasts	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
is	B-X
dependent	B-X
on	B-X
RANKL	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
POH1	B-X
increased	B-X
Mitf	B-X
's	B-X
activation	B-X
of	B-X
5XGal4-TK	B-X
and	B-X
Acp5	B-X
promoters	B-X
.	B-X
The	B-X
amino	B-X
terminus	B-X
of	B-X
POH1	B-X
mediates	B-X
the	B-X
binding	B-X
to	B-X
Mitf	B-X
and	B-X
is	B-X
sufficient	B-X
to	B-X
increase	B-X
Mitf	B-X
's	B-X
transcriptional	B-X
activity	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
JAMM	B-X
motif	B-X
of	B-X
POH1	B-X
reduced	B-X
Mitf	B-X
activation	B-X
of	B-X
promoters	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
Mitf	B-X
regulation	B-X
in	B-X
osteoclasts	B-X
by	B-X
POH1	B-X
.	B-X

Overexpression	O
of	O
POH1	B-Protein
increased	O
Mitf	B-Protein
'	O
s	O
activation	O
of	O
5XGal4	O
-	O
TK	O
and	O
Acp5	B-Protein
promoters	O
.	O
<EOS>	B-X
The	B-X
microphthalmia-associated	B-X
transcription	B-X
factor	B-X
(	B-X
Mitf	B-X
)	B-X
regulates	B-X
gene	B-X
expression	B-X
required	B-X
for	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
Genes	B-X
regulated	B-X
by	B-X
Mitf	B-X
have	B-X
been	B-X
previously	B-X
identified	B-X
.	B-X
However	B-X
,	B-X
proteins	B-X
that	B-X
interact	B-X
and	B-X
regulate	B-X
Mitf	B-X
's	B-X
activity	B-X
in	B-X
osteoclasts	B-X
are	B-X
not	B-X
well	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
POH1	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
19S	B-X
proteasome	B-X
lid	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
Mitf	B-X
.	B-X
We	B-X
show	B-X
that	B-X
POH1	B-X
and	B-X
Mitf	B-X
interact	B-X
in	B-X
osteoclasts	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
is	B-X
dependent	B-X
on	B-X
RANKL	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
POH1	B-X
increased	B-X
Mitf	B-X
's	B-X
activation	B-X
of	B-X
5XGal4-TK	B-X
and	B-X
Acp5	B-X
promoters	B-X
.	B-X
The	B-X
amino	B-X
terminus	B-X
of	B-X
POH1	B-X
mediates	B-X
the	B-X
binding	B-X
to	B-X
Mitf	B-X
and	B-X
is	B-X
sufficient	B-X
to	B-X
increase	B-X
Mitf	B-X
's	B-X
transcriptional	B-X
activity	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
JAMM	B-X
motif	B-X
of	B-X
POH1	B-X
reduced	B-X
Mitf	B-X
activation	B-X
of	B-X
promoters	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
Mitf	B-X
regulation	B-X
in	B-X
osteoclasts	B-X
by	B-X
POH1	B-X
.	B-X

The	O
amino	O
terminus	O
of	O
POH1	B-Protein
mediates	O
the	O
binding	O
to	O
Mitf	B-Protein
and	O
is	O
sufficient	O
to	O
increase	O
Mitf	B-Protein
'	O
s	O
transcriptional	O
activity	O
.	O
<EOS>	B-X
The	B-X
microphthalmia-associated	B-X
transcription	B-X
factor	B-X
(	B-X
Mitf	B-X
)	B-X
regulates	B-X
gene	B-X
expression	B-X
required	B-X
for	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
Genes	B-X
regulated	B-X
by	B-X
Mitf	B-X
have	B-X
been	B-X
previously	B-X
identified	B-X
.	B-X
However	B-X
,	B-X
proteins	B-X
that	B-X
interact	B-X
and	B-X
regulate	B-X
Mitf	B-X
's	B-X
activity	B-X
in	B-X
osteoclasts	B-X
are	B-X
not	B-X
well	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
POH1	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
19S	B-X
proteasome	B-X
lid	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
Mitf	B-X
.	B-X
We	B-X
show	B-X
that	B-X
POH1	B-X
and	B-X
Mitf	B-X
interact	B-X
in	B-X
osteoclasts	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
is	B-X
dependent	B-X
on	B-X
RANKL	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
POH1	B-X
increased	B-X
Mitf	B-X
's	B-X
activation	B-X
of	B-X
5XGal4-TK	B-X
and	B-X
Acp5	B-X
promoters	B-X
.	B-X
The	B-X
amino	B-X
terminus	B-X
of	B-X
POH1	B-X
mediates	B-X
the	B-X
binding	B-X
to	B-X
Mitf	B-X
and	B-X
is	B-X
sufficient	B-X
to	B-X
increase	B-X
Mitf	B-X
's	B-X
transcriptional	B-X
activity	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
JAMM	B-X
motif	B-X
of	B-X
POH1	B-X
reduced	B-X
Mitf	B-X
activation	B-X
of	B-X
promoters	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
Mitf	B-X
regulation	B-X
in	B-X
osteoclasts	B-X
by	B-X
POH1	B-X
.	B-X

Finally	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
JAMM	O
motif	O
of	O
POH1	B-Protein
reduced	O
Mitf	B-Protein
activation	O
of	O
promoters	O
.	O
<EOS>	B-X
The	B-X
microphthalmia-associated	B-X
transcription	B-X
factor	B-X
(	B-X
Mitf	B-X
)	B-X
regulates	B-X
gene	B-X
expression	B-X
required	B-X
for	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
Genes	B-X
regulated	B-X
by	B-X
Mitf	B-X
have	B-X
been	B-X
previously	B-X
identified	B-X
.	B-X
However	B-X
,	B-X
proteins	B-X
that	B-X
interact	B-X
and	B-X
regulate	B-X
Mitf	B-X
's	B-X
activity	B-X
in	B-X
osteoclasts	B-X
are	B-X
not	B-X
well	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
POH1	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
19S	B-X
proteasome	B-X
lid	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
Mitf	B-X
.	B-X
We	B-X
show	B-X
that	B-X
POH1	B-X
and	B-X
Mitf	B-X
interact	B-X
in	B-X
osteoclasts	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
is	B-X
dependent	B-X
on	B-X
RANKL	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
POH1	B-X
increased	B-X
Mitf	B-X
's	B-X
activation	B-X
of	B-X
5XGal4-TK	B-X
and	B-X
Acp5	B-X
promoters	B-X
.	B-X
The	B-X
amino	B-X
terminus	B-X
of	B-X
POH1	B-X
mediates	B-X
the	B-X
binding	B-X
to	B-X
Mitf	B-X
and	B-X
is	B-X
sufficient	B-X
to	B-X
increase	B-X
Mitf	B-X
's	B-X
transcriptional	B-X
activity	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
JAMM	B-X
motif	B-X
of	B-X
POH1	B-X
reduced	B-X
Mitf	B-X
activation	B-X
of	B-X
promoters	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
Mitf	B-X
regulation	B-X
in	B-X
osteoclasts	B-X
by	B-X
POH1	B-X
.	B-X

In	O
summary	O
,	O
our	O
results	O
identify	O
a	O
novel	O
mechanism	O
of	O
Mitf	B-Protein
regulation	O
in	O
osteoclasts	O
by	O
POH1	B-Protein
.	O
<EOS>	B-X
The	B-X
microphthalmia-associated	B-X
transcription	B-X
factor	B-X
(	B-X
Mitf	B-X
)	B-X
regulates	B-X
gene	B-X
expression	B-X
required	B-X
for	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
Genes	B-X
regulated	B-X
by	B-X
Mitf	B-X
have	B-X
been	B-X
previously	B-X
identified	B-X
.	B-X
However	B-X
,	B-X
proteins	B-X
that	B-X
interact	B-X
and	B-X
regulate	B-X
Mitf	B-X
's	B-X
activity	B-X
in	B-X
osteoclasts	B-X
are	B-X
not	B-X
well	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
POH1	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
19S	B-X
proteasome	B-X
lid	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
Mitf	B-X
.	B-X
We	B-X
show	B-X
that	B-X
POH1	B-X
and	B-X
Mitf	B-X
interact	B-X
in	B-X
osteoclasts	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
is	B-X
dependent	B-X
on	B-X
RANKL	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
POH1	B-X
increased	B-X
Mitf	B-X
's	B-X
activation	B-X
of	B-X
5XGal4-TK	B-X
and	B-X
Acp5	B-X
promoters	B-X
.	B-X
The	B-X
amino	B-X
terminus	B-X
of	B-X
POH1	B-X
mediates	B-X
the	B-X
binding	B-X
to	B-X
Mitf	B-X
and	B-X
is	B-X
sufficient	B-X
to	B-X
increase	B-X
Mitf	B-X
's	B-X
transcriptional	B-X
activity	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
JAMM	B-X
motif	B-X
of	B-X
POH1	B-X
reduced	B-X
Mitf	B-X
activation	B-X
of	B-X
promoters	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
identify	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
Mitf	B-X
regulation	B-X
in	B-X
osteoclasts	B-X
by	B-X
POH1	B-X
.	B-X

Mutations	O
in	O
Cullin	B-Protein
4B	I-Protein
result	O
in	O
a	O
human	O
syndrome	O
associated	O
with	O
increased	O
camptothecin	O
-	O
induced	O
topoisomerase	B-Protein
I	I-Protein
-	O
dependent	O
DNA	O
breaks	O
.	O

CUL4A	B-Protein
and	O
B	B-Protein
encode	O
subunits	O
of	O
E3	O
-	O
ubiquitin	B-Protein
ligases	O
implicated	O
in	O
diverse	O
processes	O
including	O
nucleotide	O
excision	O
repair	O
,	O
regulating	O
gene	O
expression	O
and	O
controlling	O
DNA	O
replication	O
fork	O
licensing	O
.	O

But	O
,	O
the	O
functional	O
distinction	O
between	O
CUL4A	B-Protein
and	O
CUL4B	B-Protein
,	O
if	O
any	O
,	O
is	O
unclear	O
.	O
<EOS>	B-X
UV-DDB	B-X
consists	B-X
of	B-X
DDB1	B-X
and	B-X
DDB2	B-X
,	B-X
and	B-X
it	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
cullin	B-X
4A	B-X
(	B-X
CUL4A	B-X
)	B-X
-based	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
DDB1-CUL4A	B-X
(	B-X
DDB2	B-X
)	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
DDB1-CUL4A	B-X
(	B-X
DDB2	B-X
)	B-X
ubiquitinates	B-X
histone	B-X
H2A	B-X
at	B-X
the	B-X
sites	B-X
of	B-X
UV	B-X
lesions	B-X
in	B-X
a	B-X
DDB2-dependent	B-X
manner	B-X
.	B-X
CUL4A	B-X
and	B-X
its	B-X
paralog	B-X
,	B-X
cullin	B-X
4B	B-X
(	B-X
CUL4B	B-X
)	B-X
,	B-X
copurify	B-X
with	B-X
the	B-X
UV-DDB	B-X
complex	B-X
,	B-X
but	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
CUL4B	B-X
has	B-X
a	B-X
role	B-X
in	B-X
NER	B-X
as	B-X
a	B-X
separate	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
evidence	B-X
that	B-X
CUL4A	B-X
and	B-X
CUL4B	B-X
form	B-X
two	B-X
individual	B-X
E3	B-X
ligases	B-X
,	B-X
DDB1-CUL4A	B-X
(	B-X
DDB2	B-X
)	B-X
and	B-X
DDB1-CUL4B	B-X
(	B-X
DDB2	B-X
)	B-X
.	B-X
To	B-X
investigate	B-X
CUL4B	B-X
's	B-X
possible	B-X
role	B-X
in	B-X
NER	B-X
,	B-X
we	B-X
examined	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
unirradiated	B-X
and	B-X
irradiated	B-X
cells	B-X
.	B-X
CUL4B	B-X
colocalizes	B-X
with	B-X
DDB2	B-X
at	B-X
UV-damaged	B-X
DNA	B-X
sites	B-X
.	B-X
Furthermore	B-X
,	B-X
CUL4B	B-X
binds	B-X
to	B-X
UV-damaged	B-X
chromatin	B-X
as	B-X
a	B-X
part	B-X
of	B-X
the	B-X
DDB1-CUL4B	B-X
(	B-X
DDB2	B-X
)	B-X
E3	B-X
ligase	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
functional	B-X
DDB2	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
CUL4A	B-X
,	B-X
CUL4B	B-X
is	B-X
localized	B-X
in	B-X
the	B-X
nucleus	B-X
and	B-X
facilitates	B-X
the	B-X
transfer	B-X
of	B-X
DDB1	B-X
into	B-X
the	B-X
nucleus	B-X
independently	B-X
of	B-X
DDB2	B-X
.	B-X
Importantly	B-X
,	B-X
DDB1-CUL4B	B-X
(	B-X
DDB2	B-X
)	B-X
is	B-X
more	B-X
efficient	B-X
than	B-X
DDB1-CUL4A	B-X
(	B-X
DDB2	B-X
)	B-X
in	B-X
monoubiquitinating	B-X
histone	B-X
H2A	B-X
in	B-X
vitro	B-X
.	B-X
Overall	B-X
,	B-X
this	B-X
study	B-X
suggests	B-X
that	B-X
DDB1-CUL4B	B-X
(	B-X
DDB2	B-X
)	B-X
E3	B-X
ligase	B-X
may	B-X
have	B-X
a	B-X
distinctive	B-X
function	B-X
in	B-X
modifying	B-X
the	B-X
chromatin	B-X
structure	B-X
at	B-X
the	B-X
site	B-X
of	B-X
UV	B-X
lesions	B-X
to	B-X
promote	B-X
efficient	B-X
NER	B-X
.	B-X

Recently	O
,	O
mutations	O
in	O
CUL4B	B-Protein
were	O
identified	O
in	O
humans	O
associated	O
with	O
mental	O
retardation	O
,	O
relative	O
macrocephaly	O
,	O
tremor	O
and	O
a	O
peripheral	O
neuropathy	O
.	O

Cells	O
from	O
these	O
patients	O
offer	O
a	O
unique	O
system	O
to	O
help	O
define	O
at	O
the	O
molecular	O
level	O
the	O
consequences	O
of	O
defective	O
CUL4B	B-Protein
specifically	O
.	O

We	O
show	O
that	O
these	O
patient	O
-	O
derived	O
cells	O
exhibit	O
sensitivity	O
to	O
camptothecin	O
(	O
CPT	O
)	O
,	O
impaired	O
CPT	O
-	O
induced	O
topoisomerase	B-Protein
I	I-Protein
(	O
Topo	B-Protein
I	I-Protein
)	O
degradation	O
and	O
ubiquitination	O
,	O
thereby	O
suggesting	O
Topo	B-Protein
I	I-Protein
to	O
be	O
a	O
novel	O
Cul4	O
-	O
dependent	O
substrate	O
.	O
<EOS>	B-X
Cells	B-X
from	B-X
these	B-X
patients	B-X
offer	B-X
a	B-X
unique	B-X
system	B-X
to	B-X
help	B-X
define	B-X
at	B-X
the	B-X
molecular	B-X
level	B-X
the	B-X
consequences	B-X
of	B-X
defective	B-X
CUL4B	B-X
specifically	B-X
.	B-X
We	B-X
show	B-X
that	B-X
these	B-X
patient-derived	B-X
cells	B-X
exhibit	B-X
sensitivity	B-X
to	B-X
camptothecin	B-X
(	B-X
CPT	B-X
)	B-X
,	B-X
impaired	B-X
CPT-induced	B-X
topoisomerase	B-X
I	B-X
(	B-X
Topo	B-X
I	B-X
)	B-X
degradation	B-X
and	B-X
ubiquitination	B-X
,	B-X
thereby	B-X
suggesting	B-X
Topo	B-X
I	B-X
to	B-X
be	B-X
a	B-X
novel	B-X
Cul4-dependent	B-X
substrate	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
we	B-X
also	B-X
find	B-X
that	B-X
these	B-X
cells	B-X
exhibit	B-X
increased	B-X
levels	B-X
of	B-X
CPT-induced	B-X
DNA	B-X
breaks	B-X
.	B-X
Furthermore	B-X
,	B-X
over-expression	B-X
of	B-X
known	B-X
CUL4-dependent	B-X
substrates	B-X
including	B-X
Cdt1	B-X
and	B-X
p21	B-X
appear	B-X
to	B-X
be	B-X
a	B-X
feature	B-X
of	B-X
these	B-X
patient-derived	B-X
cells	B-X
.	B-X

Consistent	O
with	O
this	O
,	O
we	O
also	O
find	O
that	O
these	O
cells	O
exhibit	O
increased	O
levels	O
of	O
CPT	O
-	O
induced	O
DNA	O
breaks	O
.	O
<EOS>	B-X
CUL4A	B-X
and	B-X
B	B-X
encode	B-X
subunits	B-X
of	B-X
E3-ubiquitin	B-X
ligases	B-X
implicated	B-X
in	B-X
diverse	B-X
processes	B-X
including	B-X
nucleotide	B-X
excision	B-X
repair	B-X
,	B-X
regulating	B-X
gene	B-X
expression	B-X
and	B-X
controlling	B-X
DNA	B-X
replication	B-X
fork	B-X
licensing	B-X
.	B-X
We	B-X
show	B-X
that	B-X
these	B-X
patient-derived	B-X
cells	B-X
exhibit	B-X
sensitivity	B-X
to	B-X
camptothecin	B-X
(	B-X
CPT	B-X
)	B-X
,	B-X
impaired	B-X
CPT-induced	B-X
topoisomerase	B-X
I	B-X
(	B-X
Topo	B-X
I	B-X
)	B-X
degradation	B-X
and	B-X
ubiquitination	B-X
,	B-X
thereby	B-X
suggesting	B-X
Topo	B-X
I	B-X
to	B-X
be	B-X
a	B-X
novel	B-X
Cul4-dependent	B-X
substrate	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
we	B-X
also	B-X
find	B-X
that	B-X
these	B-X
cells	B-X
exhibit	B-X
increased	B-X
levels	B-X
of	B-X
CPT-induced	B-X
DNA	B-X
breaks	B-X
.	B-X
Furthermore	B-X
,	B-X
over-expression	B-X
of	B-X
known	B-X
CUL4-dependent	B-X
substrates	B-X
including	B-X
Cdt1	B-X
and	B-X
p21	B-X
appear	B-X
to	B-X
be	B-X
a	B-X
feature	B-X
of	B-X
these	B-X
patient-derived	B-X
cells	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
findings	B-X
highlight	B-X
the	B-X
interplay	B-X
between	B-X
CUL4A	B-X
and	B-X
CUL4B	B-X
and	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
pathogenesis	B-X
of	B-X
CUL4B-deficiency	B-X
in	B-X
humans	B-X
.	B-X

Furthermore	O
,	O
over	O
-	O
expression	O
of	O
known	O
CUL4	O
-	O
dependent	O
substrates	O
including	O
Cdt1	B-Protein
and	O
p21	B-Protein
appear	O
to	O
be	O
a	O
feature	O
of	O
these	O
patient	O
-	O
derived	O
cells	O
.	O
<EOS>	B-X
CUL4A	B-X
and	B-X
B	B-X
encode	B-X
subunits	B-X
of	B-X
E3-ubiquitin	B-X
ligases	B-X
implicated	B-X
in	B-X
diverse	B-X
processes	B-X
including	B-X
nucleotide	B-X
excision	B-X
repair	B-X
,	B-X
regulating	B-X
gene	B-X
expression	B-X
and	B-X
controlling	B-X
DNA	B-X
replication	B-X
fork	B-X
licensing	B-X
.	B-X
But	B-X
,	B-X
the	B-X
functional	B-X
distinction	B-X
between	B-X
CUL4A	B-X
and	B-X
CUL4B	B-X
,	B-X
if	B-X
any	B-X
,	B-X
is	B-X
unclear	B-X
.	B-X
Recently	B-X
,	B-X
mutations	B-X
in	B-X
CUL4B	B-X
were	B-X
identified	B-X
in	B-X
humans	B-X
associated	B-X
with	B-X
mental	B-X
retardation	B-X
,	B-X
relative	B-X
macrocephaly	B-X
,	B-X
tremor	B-X
and	B-X
a	B-X
peripheral	B-X
neuropathy	B-X
.	B-X
Cells	B-X
from	B-X
these	B-X
patients	B-X
offer	B-X
a	B-X
unique	B-X
system	B-X
to	B-X
help	B-X
define	B-X
at	B-X
the	B-X
molecular	B-X
level	B-X
the	B-X
consequences	B-X
of	B-X
defective	B-X
CUL4B	B-X
specifically	B-X
.	B-X
We	B-X
show	B-X
that	B-X
these	B-X
patient-derived	B-X
cells	B-X
exhibit	B-X
sensitivity	B-X
to	B-X
camptothecin	B-X
(	B-X
CPT	B-X
)	B-X
,	B-X
impaired	B-X
CPT-induced	B-X
topoisomerase	B-X
I	B-X
(	B-X
Topo	B-X
I	B-X
)	B-X
degradation	B-X
and	B-X
ubiquitination	B-X
,	B-X
thereby	B-X
suggesting	B-X
Topo	B-X
I	B-X
to	B-X
be	B-X
a	B-X
novel	B-X
Cul4-dependent	B-X
substrate	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
we	B-X
also	B-X
find	B-X
that	B-X
these	B-X
cells	B-X
exhibit	B-X
increased	B-X
levels	B-X
of	B-X
CPT-induced	B-X
DNA	B-X
breaks	B-X
.	B-X
Furthermore	B-X
,	B-X
over-expression	B-X
of	B-X
known	B-X
CUL4-dependent	B-X
substrates	B-X
including	B-X
Cdt1	B-X
and	B-X
p21	B-X
appear	B-X
to	B-X
be	B-X
a	B-X
feature	B-X
of	B-X
these	B-X
patient-derived	B-X
cells	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
findings	B-X
highlight	B-X
the	B-X
interplay	B-X
between	B-X
CUL4A	B-X
and	B-X
CUL4B	B-X
and	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
pathogenesis	B-X
of	B-X
CUL4B-deficiency	B-X
in	B-X
humans	B-X
.	B-X

Collectively	O
,	O
our	O
findings	O
highlight	O
the	O
interplay	O
between	O
CUL4A	B-Protein
and	O
CUL4B	B-Protein
and	O
provide	O
insight	O
into	O
the	O
pathogenesis	O
of	O
CUL4B	B-Protein
-	O
deficiency	O
in	O
humans	O
.	O
<EOS>	B-X
CUL4A	B-X
and	B-X
B	B-X
encode	B-X
subunits	B-X
of	B-X
E3-ubiquitin	B-X
ligases	B-X
implicated	B-X
in	B-X
diverse	B-X
processes	B-X
including	B-X
nucleotide	B-X
excision	B-X
repair	B-X
,	B-X
regulating	B-X
gene	B-X
expression	B-X
and	B-X
controlling	B-X
DNA	B-X
replication	B-X
fork	B-X
licensing	B-X
.	B-X
But	B-X
,	B-X
the	B-X
functional	B-X
distinction	B-X
between	B-X
CUL4A	B-X
and	B-X
CUL4B	B-X
,	B-X
if	B-X
any	B-X
,	B-X
is	B-X
unclear	B-X
.	B-X
Recently	B-X
,	B-X
mutations	B-X
in	B-X
CUL4B	B-X
were	B-X
identified	B-X
in	B-X
humans	B-X
associated	B-X
with	B-X
mental	B-X
retardation	B-X
,	B-X
relative	B-X
macrocephaly	B-X
,	B-X
tremor	B-X
and	B-X
a	B-X
peripheral	B-X
neuropathy	B-X
.	B-X
Cells	B-X
from	B-X
these	B-X
patients	B-X
offer	B-X
a	B-X
unique	B-X
system	B-X
to	B-X
help	B-X
define	B-X
at	B-X
the	B-X
molecular	B-X
level	B-X
the	B-X
consequences	B-X
of	B-X
defective	B-X
CUL4B	B-X
specifically	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
findings	B-X
highlight	B-X
the	B-X
interplay	B-X
between	B-X
CUL4A	B-X
and	B-X
CUL4B	B-X
and	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
pathogenesis	B-X
of	B-X
CUL4B-deficiency	B-X
in	B-X
humans	B-X
.	B-X

Normal	O
shear	O
stress	O
and	O
vascular	O
smooth	O
muscle	O
cells	O
modulate	O
migration	O
of	O
endothelial	O
cells	O
through	O
histone	B-Protein
deacetylase	I-Protein
6	I-Protein
activation	O
and	O
tubulin	O
acetylation	O
.	O
<EOS>	B-X
Endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
line	B-X
the	B-X
innermost	B-X
of	B-X
the	B-X
blood	B-X
vessel	B-X
wall	B-X
and	B-X
are	B-X
constantly	B-X
subjected	B-X
to	B-X
shear	B-X
stress	B-X
imposed	B-X
by	B-X
blood	B-X
flow	B-X
.	B-X
ECs	B-X
were	B-X
also	B-X
influenced	B-X
by	B-X
the	B-X
neighboring	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
.	B-X
The	B-X
bidirectional	B-X
communication	B-X
between	B-X
ECs	B-X
and	B-X
VSMCs	B-X
modulates	B-X
vascular	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
in	B-X
modulating	B-X
migration	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
by	B-X
the	B-X
normal	B-X
level	B-X
of	B-X
laminar	B-X
shear	B-X
stress	B-X
(	B-X
NSS	B-X
)	B-X
was	B-X
investigated	B-X
.	B-X
It	B-X
was	B-X
demonstrated	B-X
that	B-X
both	B-X
NSS	B-X
and	B-X
VSMCs	B-X
could	B-X
increase	B-X
EC	B-X
migration	B-X
.	B-X
The	B-X
migration	B-X
level	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
NSS	B-X
was	B-X
not	B-X
higher	B-X
than	B-X
that	B-X
under	B-X
the	B-X
static	B-X
condition	B-X
.	B-X
The	B-X
process	B-X
of	B-X
EC	B-X
migration	B-X
regulated	B-X
by	B-X
VSMCs	B-X
and	B-X
NSS	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
HDAC6	B-X
and	B-X
low	B-X
level	B-X
of	B-X
acetylated	B-X
tubulin	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
HDAC6	B-X
expression	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
time-dependent	B-X
decrease	B-X
in	B-X
the	B-X
acetylation	B-X
of	B-X
tubulin	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
HDAC6	B-X
by	B-X
siRNA	B-X
or	B-X
tributyrin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HDACs	B-X
,	B-X
induced	B-X
a	B-X
parallel	B-X
alteration	B-X
in	B-X
the	B-X
migration	B-X
and	B-X
the	B-X
acetylated	B-X
tubulin	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
It	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
that	B-X
the	B-X
acetylated	B-X
tubulin	B-X
was	B-X
distributed	B-X
mostly	B-X
around	B-X
the	B-X
cell	B-X
nucleus	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
NSS	B-X
may	B-X
display	B-X
a	B-X
protective	B-X
function	B-X
on	B-X
the	B-X
vascular	B-X
homeostasis	B-X
by	B-X
modulating	B-X
EC	B-X
migration	B-X
to	B-X
a	B-X
normal	B-X
level	B-X
in	B-X
a	B-X
VSMC-dependent	B-X
manner	B-X
.	B-X
This	B-X
modulation	B-X
process	B-X
involves	B-X
the	B-X
down-regulation	B-X
of	B-X
acetylated	B-X
tubulin	B-X
which	B-X
results	B-X
from	B-X
increased	B-X
HDAC6	B-X
activity	B-X
in	B-X
ECs	B-X
.	B-X

Endothelial	O
cells	O
(	O
ECs	O
)	O
line	O
the	O
innermost	O
of	O
the	O
blood	O
vessel	O
wall	O
and	O
are	O
constantly	O
subjected	O
to	O
shear	O
stress	O
imposed	O
by	O
blood	O
flow	O
.	O

ECs	O
were	O
also	O
influenced	O
by	O
the	O
neighboring	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
.	O
<EOS>	B-X
The	B-X
evolutionarily	B-X
conserved	B-X
Notch	B-X
signaling	B-X
pathway	B-X
is	B-X
required	B-X
for	B-X
normal	B-X
vascular	B-X
development	B-X
and	B-X
function	B-X
,	B-X
and	B-X
genetic	B-X
associations	B-X
link	B-X
select	B-X
Notch	B-X
receptors	B-X
and	B-X
ligands	B-X
to	B-X
human	B-X
clinical	B-X
syndromes	B-X
featuring	B-X
blood	B-X
vessel	B-X
abnormalities	B-X
and	B-X
stroke	B-X
susceptibility	B-X
.	B-X
A	B-X
previously	B-X
described	B-X
mouse	B-X
model	B-X
engineered	B-X
to	B-X
suppress	B-X
canonical	B-X
Notch	B-X
signaling	B-X
in	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
vSMCs	B-X
)	B-X
revealed	B-X
surprising	B-X
anatomical	B-X
defects	B-X
in	B-X
arterial	B-X
patterning	B-X
and	B-X
vessel	B-X
maturation	B-X
,	B-X
suggesting	B-X
that	B-X
vSMCs	B-X
have	B-X
the	B-X
functional	B-X
capacity	B-X
to	B-X
influence	B-X
blood	B-X
vessel	B-X
formation	B-X
in	B-X
a	B-X
Notch	B-X
signaling-dependent	B-X
manner	B-X
.	B-X
In	B-X
further	B-X
analyses	B-X
using	B-X
this	B-X
model	B-X
system	B-X
,	B-X
we	B-X
now	B-X
show	B-X
that	B-X
explanted	B-X
aortic	B-X
ring	B-X
tissue	B-X
and	B-X
Matrigel	B-X
implants	B-X
from	B-X
the	B-X
smooth	B-X
muscle	B-X
Notch	B-X
signaling-deficient	B-X
mice	B-X
yield	B-X
markedly	B-X
diminished	B-X
responses	B-X
to	B-X
angiogenic	B-X
stimuli	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
studies	B-X
suggest	B-X
a	B-X
heterotypic	B-X
model	B-X
wherein	B-X
Notch	B-X
signaling	B-X
in	B-X
vSMCs	B-X
provides	B-X
early	B-X
instructive	B-X
cues	B-X
to	B-X
neighboring	B-X
ECs	B-X
important	B-X
for	B-X
optimal	B-X
postnatal	B-X
angiogenesis	B-X
.	B-X

The	O
bidirectional	O
communication	O
between	O
ECs	O
and	O
VSMCs	O
modulates	O
vascular	O
homeostasis	O
.	O
<EOS>	B-X
Endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
line	B-X
the	B-X
innermost	B-X
of	B-X
the	B-X
blood	B-X
vessel	B-X
wall	B-X
and	B-X
are	B-X
constantly	B-X
subjected	B-X
to	B-X
shear	B-X
stress	B-X
imposed	B-X
by	B-X
blood	B-X
flow	B-X
.	B-X
ECs	B-X
were	B-X
also	B-X
influenced	B-X
by	B-X
the	B-X
neighboring	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
.	B-X
The	B-X
bidirectional	B-X
communication	B-X
between	B-X
ECs	B-X
and	B-X
VSMCs	B-X
modulates	B-X
vascular	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
in	B-X
modulating	B-X
migration	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
by	B-X
the	B-X
normal	B-X
level	B-X
of	B-X
laminar	B-X
shear	B-X
stress	B-X
(	B-X
NSS	B-X
)	B-X
was	B-X
investigated	B-X
.	B-X
ECs	B-X
was	B-X
either	B-X
cultured	B-X
alone	B-X
or	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
static	B-X
conditions	B-X
or	B-X
subjected	B-X
to	B-X
NSS	B-X
of	B-X
15	B-X
dyne/cm2	B-X
by	B-X
using	B-X
a	B-X
parallel-plate	B-X
co-culture	B-X
flow	B-X
chamber	B-X
system	B-X
.	B-X
It	B-X
was	B-X
demonstrated	B-X
that	B-X
both	B-X
NSS	B-X
and	B-X
VSMCs	B-X
could	B-X
increase	B-X
EC	B-X
migration	B-X
.	B-X
The	B-X
migration	B-X
level	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
NSS	B-X
was	B-X
not	B-X
higher	B-X
than	B-X
that	B-X
under	B-X
the	B-X
static	B-X
condition	B-X
.	B-X
The	B-X
process	B-X
of	B-X
EC	B-X
migration	B-X
regulated	B-X
by	B-X
VSMCs	B-X
and	B-X
NSS	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
HDAC6	B-X
and	B-X
low	B-X
level	B-X
of	B-X
acetylated	B-X
tubulin	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
HDAC6	B-X
expression	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
time-dependent	B-X
decrease	B-X
in	B-X
the	B-X
acetylation	B-X
of	B-X
tubulin	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
HDAC6	B-X
by	B-X
siRNA	B-X
or	B-X
tributyrin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HDACs	B-X
,	B-X
induced	B-X
a	B-X
parallel	B-X
alteration	B-X
in	B-X
the	B-X
migration	B-X
and	B-X
the	B-X
acetylated	B-X
tubulin	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
It	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
that	B-X
the	B-X
acetylated	B-X
tubulin	B-X
was	B-X
distributed	B-X
mostly	B-X
around	B-X
the	B-X
cell	B-X
nucleus	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
NSS	B-X
may	B-X
display	B-X
a	B-X
protective	B-X
function	B-X
on	B-X
the	B-X
vascular	B-X
homeostasis	B-X
by	B-X
modulating	B-X
EC	B-X
migration	B-X
to	B-X
a	B-X
normal	B-X
level	B-X
in	B-X
a	B-X
VSMC-dependent	B-X
manner	B-X
.	B-X
This	B-X
modulation	B-X
process	B-X
involves	B-X
the	B-X
down-regulation	B-X
of	B-X
acetylated	B-X
tubulin	B-X
which	B-X
results	B-X
from	B-X
increased	B-X
HDAC6	B-X
activity	B-X
in	B-X
ECs	B-X
.	B-X

In	O
this	O
study	O
,	O
the	O
involvement	O
of	O
histone	B-Protein
deacetylase	I-Protein
6	I-Protein
(	O
HDAC6	B-Protein
)	O
in	O
modulating	O
migration	O
of	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
by	O
the	O
normal	O
level	O
of	O
laminar	O
shear	O
stress	O
(	O
NSS	O
)	O
was	O
investigated	O
.	O

ECs	O
was	O
either	O
cultured	O
alone	O
or	O
co	O
-	O
cultured	O
with	O
VSMCs	O
under	O
static	O
conditions	O
or	O
subjected	O
to	O
NSS	O
of	O
15	O
dyne	O
/	O
cm2	O
by	O
using	O
a	O
parallel	O
-	O
plate	O
co	O
-	O
culture	O
flow	O
chamber	O
system	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
identify	B-X
the	B-X
molecular	B-X
mechanism	B-X
for	B-X
hyperglycaemia-induced	B-X
metabolic	B-X
memory	B-X
in	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
,	B-X
and	B-X
to	B-X
show	B-X
its	B-X
critical	B-X
importance	B-X
to	B-X
development	B-X
of	B-X
cardiovascular	B-X
dysfunction	B-X
in	B-X
diabetes	B-X
.	B-X
Hypoxia	B-X
plays	B-X
an	B-X
important	B-X
regulatory	B-X
role	B-X
in	B-X
the	B-X
vasculature	B-X
to	B-X
adjust	B-X
blood	B-X
flow	B-X
to	B-X
meet	B-X
metabolic	B-X
requirements	B-X
.	B-X
At	B-X
the	B-X
level	B-X
of	B-X
gene	B-X
transcription	B-X
,	B-X
the	B-X
responses	B-X
are	B-X
mediated	B-X
by	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
the	B-X
stability	B-X
of	B-X
which	B-X
is	B-X
controlled	B-X
by	B-X
the	B-X
HIF	B-X
prolyl	B-X
4-hydroxylase-2	B-X
(	B-X
PHD2	B-X
)	B-X
.	B-X
In	B-X
the	B-X
lungs	B-X
hypoxia	B-X
results	B-X
in	B-X
vasoconstriction	B-X
,	B-X
however	B-X
,	B-X
the	B-X
pathophysiological	B-X
relevance	B-X
of	B-X
PHD2	B-X
in	B-X
the	B-X
major	B-X
arterial	B-X
cell	B-X
types	B-X
;	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
and	B-X
arterial	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
aSMCs	B-X
)	B-X
in	B-X
the	B-X
adult	B-X
vasculature	B-X
is	B-X
incompletely	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
PHD2-dependent	B-X
vascular	B-X
homeostasis	B-X
utilizing	B-X
inducible	B-X
deletions	B-X
of	B-X
PHD2	B-X
either	B-X
in	B-X
ECs	B-X
(	B-X
Phd2	B-X

It	O
was	O
demonstrated	O
that	O
both	O
NSS	O
and	O
VSMCs	O
could	O
increase	O
EC	O
migration	O
.	O
<EOS>	B-X
Endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
line	B-X
the	B-X
innermost	B-X
of	B-X
the	B-X
blood	B-X
vessel	B-X
wall	B-X
and	B-X
are	B-X
constantly	B-X
subjected	B-X
to	B-X
shear	B-X
stress	B-X
imposed	B-X
by	B-X
blood	B-X
flow	B-X
.	B-X
ECs	B-X
were	B-X
also	B-X
influenced	B-X
by	B-X
the	B-X
neighboring	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
.	B-X
The	B-X
bidirectional	B-X
communication	B-X
between	B-X
ECs	B-X
and	B-X
VSMCs	B-X
modulates	B-X
vascular	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
in	B-X
modulating	B-X
migration	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
by	B-X
the	B-X
normal	B-X
level	B-X
of	B-X
laminar	B-X
shear	B-X
stress	B-X
(	B-X
NSS	B-X
)	B-X
was	B-X
investigated	B-X
.	B-X
ECs	B-X
was	B-X
either	B-X
cultured	B-X
alone	B-X
or	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
static	B-X
conditions	B-X
or	B-X
subjected	B-X
to	B-X
NSS	B-X
of	B-X
15	B-X
dyne/cm2	B-X
by	B-X
using	B-X
a	B-X
parallel-plate	B-X
co-culture	B-X
flow	B-X
chamber	B-X
system	B-X
.	B-X
It	B-X
was	B-X
demonstrated	B-X
that	B-X
both	B-X
NSS	B-X
and	B-X
VSMCs	B-X
could	B-X
increase	B-X
EC	B-X
migration	B-X
.	B-X
The	B-X
migration	B-X
level	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
NSS	B-X
was	B-X
not	B-X
higher	B-X
than	B-X
that	B-X
under	B-X
the	B-X
static	B-X
condition	B-X
.	B-X
The	B-X
process	B-X
of	B-X
EC	B-X
migration	B-X
regulated	B-X
by	B-X
VSMCs	B-X
and	B-X
NSS	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
HDAC6	B-X
and	B-X
low	B-X
level	B-X
of	B-X
acetylated	B-X
tubulin	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
HDAC6	B-X
expression	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
time-dependent	B-X
decrease	B-X
in	B-X
the	B-X
acetylation	B-X
of	B-X
tubulin	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
HDAC6	B-X
by	B-X
siRNA	B-X
or	B-X
tributyrin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HDACs	B-X
,	B-X
induced	B-X
a	B-X
parallel	B-X
alteration	B-X
in	B-X
the	B-X
migration	B-X
and	B-X
the	B-X
acetylated	B-X
tubulin	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
It	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
that	B-X
the	B-X
acetylated	B-X
tubulin	B-X
was	B-X
distributed	B-X
mostly	B-X
around	B-X
the	B-X
cell	B-X
nucleus	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
NSS	B-X
may	B-X
display	B-X
a	B-X
protective	B-X
function	B-X
on	B-X
the	B-X
vascular	B-X
homeostasis	B-X
by	B-X
modulating	B-X
EC	B-X
migration	B-X
to	B-X
a	B-X
normal	B-X
level	B-X
in	B-X
a	B-X
VSMC-dependent	B-X
manner	B-X
.	B-X
This	B-X
modulation	B-X
process	B-X
involves	B-X
the	B-X
down-regulation	B-X
of	B-X
acetylated	B-X
tubulin	B-X
which	B-X
results	B-X
from	B-X
increased	B-X
HDAC6	B-X
activity	B-X
in	B-X
ECs	B-X
.	B-X

The	O
migration	O
level	O
of	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
under	O
NSS	O
was	O
not	O
higher	O
than	O
that	O
under	O
the	O
static	O
condition	O
.	O

The	O
process	O
of	O
EC	O
migration	O
regulated	O
by	O
VSMCs	O
and	O
NSS	O
was	O
associated	O
with	O
the	O
increased	O
expression	O
of	O
HDAC6	B-Protein
and	O
low	O
level	O
of	O
acetylated	O
tubulin	O
.	O
<EOS>	B-X
Endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
line	B-X
the	B-X
innermost	B-X
of	B-X
the	B-X
blood	B-X
vessel	B-X
wall	B-X
and	B-X
are	B-X
constantly	B-X
subjected	B-X
to	B-X
shear	B-X
stress	B-X
imposed	B-X
by	B-X
blood	B-X
flow	B-X
.	B-X
ECs	B-X
were	B-X
also	B-X
influenced	B-X
by	B-X
the	B-X
neighboring	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
.	B-X
The	B-X
bidirectional	B-X
communication	B-X
between	B-X
ECs	B-X
and	B-X
VSMCs	B-X
modulates	B-X
vascular	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
in	B-X
modulating	B-X
migration	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
by	B-X
the	B-X
normal	B-X
level	B-X
of	B-X
laminar	B-X
shear	B-X
stress	B-X
(	B-X
NSS	B-X
)	B-X
was	B-X
investigated	B-X
.	B-X
ECs	B-X
was	B-X
either	B-X
cultured	B-X
alone	B-X
or	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
static	B-X
conditions	B-X
or	B-X
subjected	B-X
to	B-X
NSS	B-X
of	B-X
15	B-X
dyne/cm2	B-X
by	B-X
using	B-X
a	B-X
parallel-plate	B-X
co-culture	B-X
flow	B-X
chamber	B-X
system	B-X
.	B-X
It	B-X
was	B-X
demonstrated	B-X
that	B-X
both	B-X
NSS	B-X
and	B-X
VSMCs	B-X
could	B-X
increase	B-X
EC	B-X
migration	B-X
.	B-X
The	B-X
migration	B-X
level	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
NSS	B-X
was	B-X
not	B-X
higher	B-X
than	B-X
that	B-X
under	B-X
the	B-X
static	B-X
condition	B-X
.	B-X
The	B-X
process	B-X
of	B-X
EC	B-X
migration	B-X
regulated	B-X
by	B-X
VSMCs	B-X
and	B-X
NSS	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
HDAC6	B-X
and	B-X
low	B-X
level	B-X
of	B-X
acetylated	B-X
tubulin	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
HDAC6	B-X
expression	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
time-dependent	B-X
decrease	B-X
in	B-X
the	B-X
acetylation	B-X
of	B-X
tubulin	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
HDAC6	B-X
by	B-X
siRNA	B-X
or	B-X
tributyrin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HDACs	B-X
,	B-X
induced	B-X
a	B-X
parallel	B-X
alteration	B-X
in	B-X
the	B-X
migration	B-X
and	B-X
the	B-X
acetylated	B-X
tubulin	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
It	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
that	B-X
the	B-X
acetylated	B-X
tubulin	B-X
was	B-X
distributed	B-X
mostly	B-X
around	B-X
the	B-X
cell	B-X
nucleus	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
NSS	B-X
may	B-X
display	B-X
a	B-X
protective	B-X
function	B-X
on	B-X
the	B-X
vascular	B-X
homeostasis	B-X
by	B-X
modulating	B-X
EC	B-X
migration	B-X
to	B-X
a	B-X
normal	B-X
level	B-X
in	B-X
a	B-X
VSMC-dependent	B-X
manner	B-X
.	B-X
This	B-X
modulation	B-X
process	B-X
involves	B-X
the	B-X
down-regulation	B-X
of	B-X
acetylated	B-X
tubulin	B-X
which	B-X
results	B-X
from	B-X
increased	B-X
HDAC6	B-X
activity	B-X
in	B-X
ECs	B-X
.	B-X

The	O
increase	O
in	O
HDAC6	B-Protein
expression	O
was	O
accompanied	O
by	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
the	O
acetylation	O
of	O
tubulin	O
in	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
.	O
<EOS>	B-X
Endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
line	B-X
the	B-X
innermost	B-X
of	B-X
the	B-X
blood	B-X
vessel	B-X
wall	B-X
and	B-X
are	B-X
constantly	B-X
subjected	B-X
to	B-X
shear	B-X
stress	B-X
imposed	B-X
by	B-X
blood	B-X
flow	B-X
.	B-X
ECs	B-X
were	B-X
also	B-X
influenced	B-X
by	B-X
the	B-X
neighboring	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
.	B-X
The	B-X
bidirectional	B-X
communication	B-X
between	B-X
ECs	B-X
and	B-X
VSMCs	B-X
modulates	B-X
vascular	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
in	B-X
modulating	B-X
migration	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
by	B-X
the	B-X
normal	B-X
level	B-X
of	B-X
laminar	B-X
shear	B-X
stress	B-X
(	B-X
NSS	B-X
)	B-X
was	B-X
investigated	B-X
.	B-X
ECs	B-X
was	B-X
either	B-X
cultured	B-X
alone	B-X
or	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
static	B-X
conditions	B-X
or	B-X
subjected	B-X
to	B-X
NSS	B-X
of	B-X
15	B-X
dyne/cm2	B-X
by	B-X
using	B-X
a	B-X
parallel-plate	B-X
co-culture	B-X
flow	B-X
chamber	B-X
system	B-X
.	B-X
It	B-X
was	B-X
demonstrated	B-X
that	B-X
both	B-X
NSS	B-X
and	B-X
VSMCs	B-X
could	B-X
increase	B-X
EC	B-X
migration	B-X
.	B-X
The	B-X
migration	B-X
level	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
NSS	B-X
was	B-X
not	B-X
higher	B-X
than	B-X
that	B-X
under	B-X
the	B-X
static	B-X
condition	B-X
.	B-X
The	B-X
process	B-X
of	B-X
EC	B-X
migration	B-X
regulated	B-X
by	B-X
VSMCs	B-X
and	B-X
NSS	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
HDAC6	B-X
and	B-X
low	B-X
level	B-X
of	B-X
acetylated	B-X
tubulin	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
HDAC6	B-X
expression	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
time-dependent	B-X
decrease	B-X
in	B-X
the	B-X
acetylation	B-X
of	B-X
tubulin	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
HDAC6	B-X
by	B-X
siRNA	B-X
or	B-X
tributyrin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HDACs	B-X
,	B-X
induced	B-X
a	B-X
parallel	B-X
alteration	B-X
in	B-X
the	B-X
migration	B-X
and	B-X
the	B-X
acetylated	B-X
tubulin	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
It	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
that	B-X
the	B-X
acetylated	B-X
tubulin	B-X
was	B-X
distributed	B-X
mostly	B-X
around	B-X
the	B-X
cell	B-X
nucleus	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
NSS	B-X
may	B-X
display	B-X
a	B-X
protective	B-X
function	B-X
on	B-X
the	B-X
vascular	B-X
homeostasis	B-X
by	B-X
modulating	B-X
EC	B-X
migration	B-X
to	B-X
a	B-X
normal	B-X
level	B-X
in	B-X
a	B-X
VSMC-dependent	B-X
manner	B-X
.	B-X
This	B-X
modulation	B-X
process	B-X
involves	B-X
the	B-X
down-regulation	B-X
of	B-X
acetylated	B-X
tubulin	B-X
which	B-X
results	B-X
from	B-X
increased	B-X
HDAC6	B-X
activity	B-X
in	B-X
ECs	B-X
.	B-X

Inhibition	O
of	O
the	O
HDAC6	B-Protein
by	O
siRNA	O
or	O
tributyrin	O
,	O
an	O
inhibitor	O
of	O
HDACs	O
,	O
induced	O
a	O
parallel	O
alteration	O
in	O
the	O
migration	O
and	O
the	O
acetylated	O
tubulin	O
of	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
candidate	B-X
therapeutics	B-X
,	B-X
we	B-X
developed	B-X
an	B-X
in	B-X
vitro	B-X
DCM	B-X
model	B-X
using	B-X
induced	B-X
pluripotent	B-X
stem	B-X
cell-derived	B-X
cardiomyocytes	B-X
(	B-X
iPSC-CMs	B-X
)	B-X
deficient	B-X
in	B-X
B-cell	B-X
lymphoma	B-X
2	B-X
(	B-X
BCL2	B-X
)	B-X
-associated	B-X
athanogene	B-X
3	B-X
(	B-X
BAG3	B-X
)	B-X
.	B-X
From	B-X
a	B-X
library	B-X
of	B-X
5500	B-X
bioactive	B-X
compounds	B-X
and	B-X
siRNA	B-X
validation	B-X
,	B-X
we	B-X
found	B-X
that	B-X
inhibiting	B-X
histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
was	B-X
cardioprotective	B-X
at	B-X
the	B-X
sarcomere	B-X
level	B-X
.	B-X
Selective	B-X
recognition	B-X
and	B-X
elimination	B-X
of	B-X
misfolded	B-X
polypeptides	B-X
are	B-X
crucial	B-X
for	B-X
protein	B-X
homeostasis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
TRIM28/TIF1β/KAP1	B-X
(	B-X
tripartite	B-X
motif	B-X
containing	B-X
28	B-X
)	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
aggresome	B-X
formation	B-X
.	B-X
Direct	B-X
interaction	B-X
between	B-X
TRIM28	B-X
and	B-X
CTIF	B-X
(	B-X
cap	B-X
binding	B-X
complex	B-X
dependent	B-X
translation	B-X
initiation	B-X
factor	B-X
)	B-X
leads	B-X
to	B-X
inefficient	B-X
aggresomal	B-X
targeting	B-X
of	B-X
misfolded	B-X
polypeptides	B-X
.	B-X
The	B-X
phosphorylation	B-X
promotes	B-X
association	B-X
of	B-X
TRIM28	B-X
with	B-X
CTIF	B-X
,	B-X
inhibits	B-X
aggresome	B-X
formation	B-X
,	B-X
and	B-X
consequently	B-X
suppresses	B-X
viral	B-X
proliferation	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
data	B-X
provide	B-X
compelling	B-X
evidence	B-X
that	B-X
TRIM28	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
aggresome	B-X
formation	B-X
.	B-X

It	O
was	O
observed	O
by	O
immunofluorescence	O
staining	O
that	O
the	O
acetylated	O
tubulin	O
was	O
distributed	O
mostly	O
around	O
the	O
cell	O
nucleus	O
in	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
.	O
<EOS>	B-X
Endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
line	B-X
the	B-X
innermost	B-X
of	B-X
the	B-X
blood	B-X
vessel	B-X
wall	B-X
and	B-X
are	B-X
constantly	B-X
subjected	B-X
to	B-X
shear	B-X
stress	B-X
imposed	B-X
by	B-X
blood	B-X
flow	B-X
.	B-X
ECs	B-X
were	B-X
also	B-X
influenced	B-X
by	B-X
the	B-X
neighboring	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
.	B-X
The	B-X
bidirectional	B-X
communication	B-X
between	B-X
ECs	B-X
and	B-X
VSMCs	B-X
modulates	B-X
vascular	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
in	B-X
modulating	B-X
migration	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
by	B-X
the	B-X
normal	B-X
level	B-X
of	B-X
laminar	B-X
shear	B-X
stress	B-X
(	B-X
NSS	B-X
)	B-X
was	B-X
investigated	B-X
.	B-X
ECs	B-X
was	B-X
either	B-X
cultured	B-X
alone	B-X
or	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
static	B-X
conditions	B-X
or	B-X
subjected	B-X
to	B-X
NSS	B-X
of	B-X
15	B-X
dyne/cm2	B-X
by	B-X
using	B-X
a	B-X
parallel-plate	B-X
co-culture	B-X
flow	B-X
chamber	B-X
system	B-X
.	B-X
It	B-X
was	B-X
demonstrated	B-X
that	B-X
both	B-X
NSS	B-X
and	B-X
VSMCs	B-X
could	B-X
increase	B-X
EC	B-X
migration	B-X
.	B-X
The	B-X
migration	B-X
level	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
NSS	B-X
was	B-X
not	B-X
higher	B-X
than	B-X
that	B-X
under	B-X
the	B-X
static	B-X
condition	B-X
.	B-X
The	B-X
process	B-X
of	B-X
EC	B-X
migration	B-X
regulated	B-X
by	B-X
VSMCs	B-X
and	B-X
NSS	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
HDAC6	B-X
and	B-X
low	B-X
level	B-X
of	B-X
acetylated	B-X
tubulin	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
HDAC6	B-X
expression	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
time-dependent	B-X
decrease	B-X
in	B-X
the	B-X
acetylation	B-X
of	B-X
tubulin	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
HDAC6	B-X
by	B-X
siRNA	B-X
or	B-X
tributyrin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HDACs	B-X
,	B-X
induced	B-X
a	B-X
parallel	B-X
alteration	B-X
in	B-X
the	B-X
migration	B-X
and	B-X
the	B-X
acetylated	B-X
tubulin	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
It	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
that	B-X
the	B-X
acetylated	B-X
tubulin	B-X
was	B-X
distributed	B-X
mostly	B-X
around	B-X
the	B-X
cell	B-X
nucleus	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
This	B-X
modulation	B-X
process	B-X
involves	B-X
the	B-X
down-regulation	B-X
of	B-X
acetylated	B-X
tubulin	B-X
which	B-X
results	B-X
from	B-X
increased	B-X
HDAC6	B-X
activity	B-X
in	B-X
ECs	B-X
.	B-X

The	O
results	O
suggest	O
that	O
the	O
NSS	O
may	O
display	O
a	O
protective	O
function	O
on	O
the	O
vascular	O
homeostasis	O
by	O
modulating	O
EC	O
migration	O
to	O
a	O
normal	O
level	O
in	O
a	O
VSMC	O
-	O
dependent	O
manner	O
.	O

This	O
modulation	O
process	O
involves	O
the	O
down	O
-	O
regulation	O
of	O
acetylated	O
tubulin	O
which	O
results	O
from	O
increased	O
HDAC6	B-Protein
activity	O
in	O
ECs	O
.	O
<EOS>	B-X
Endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
line	B-X
the	B-X
innermost	B-X
of	B-X
the	B-X
blood	B-X
vessel	B-X
wall	B-X
and	B-X
are	B-X
constantly	B-X
subjected	B-X
to	B-X
shear	B-X
stress	B-X
imposed	B-X
by	B-X
blood	B-X
flow	B-X
.	B-X
ECs	B-X
were	B-X
also	B-X
influenced	B-X
by	B-X
the	B-X
neighboring	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
.	B-X
The	B-X
bidirectional	B-X
communication	B-X
between	B-X
ECs	B-X
and	B-X
VSMCs	B-X
modulates	B-X
vascular	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
histone	B-X
deacetylase	B-X
6	B-X
(	B-X
HDAC6	B-X
)	B-X
in	B-X
modulating	B-X
migration	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
by	B-X
the	B-X
normal	B-X
level	B-X
of	B-X
laminar	B-X
shear	B-X
stress	B-X
(	B-X
NSS	B-X
)	B-X
was	B-X
investigated	B-X
.	B-X
ECs	B-X
was	B-X
either	B-X
cultured	B-X
alone	B-X
or	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
static	B-X
conditions	B-X
or	B-X
subjected	B-X
to	B-X
NSS	B-X
of	B-X
15	B-X
dyne/cm2	B-X
by	B-X
using	B-X
a	B-X
parallel-plate	B-X
co-culture	B-X
flow	B-X
chamber	B-X
system	B-X
.	B-X
The	B-X
migration	B-X
level	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
under	B-X
NSS	B-X
was	B-X
not	B-X
higher	B-X
than	B-X
that	B-X
under	B-X
the	B-X
static	B-X
condition	B-X
.	B-X
The	B-X
process	B-X
of	B-X
EC	B-X
migration	B-X
regulated	B-X
by	B-X
VSMCs	B-X
and	B-X
NSS	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
HDAC6	B-X
and	B-X
low	B-X
level	B-X
of	B-X
acetylated	B-X
tubulin	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
HDAC6	B-X
expression	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
time-dependent	B-X
decrease	B-X
in	B-X
the	B-X
acetylation	B-X
of	B-X
tubulin	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
HDAC6	B-X
by	B-X
siRNA	B-X
or	B-X
tributyrin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HDACs	B-X
,	B-X
induced	B-X
a	B-X
parallel	B-X
alteration	B-X
in	B-X
the	B-X
migration	B-X
and	B-X
the	B-X
acetylated	B-X
tubulin	B-X
of	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
It	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
that	B-X
the	B-X
acetylated	B-X
tubulin	B-X
was	B-X
distributed	B-X
mostly	B-X
around	B-X
the	B-X
cell	B-X
nucleus	B-X
in	B-X
ECs	B-X
co-cultured	B-X
with	B-X
VSMCs	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
NSS	B-X
may	B-X
display	B-X
a	B-X
protective	B-X
function	B-X
on	B-X
the	B-X
vascular	B-X
homeostasis	B-X
by	B-X
modulating	B-X
EC	B-X
migration	B-X
to	B-X
a	B-X
normal	B-X
level	B-X
in	B-X
a	B-X
VSMC-dependent	B-X
manner	B-X
.	B-X
This	B-X
modulation	B-X
process	B-X
involves	B-X
the	B-X
down-regulation	B-X
of	B-X
acetylated	B-X
tubulin	B-X
which	B-X
results	B-X
from	B-X
increased	B-X
HDAC6	B-X
activity	B-X
in	B-X
ECs	B-X
.	B-X

Tonic	O
ubiquitylation	O
controls	O
T	O
-	O
cell	O
receptor	O
:	O
CD3	O
complex	O
expression	O
during	O
T	O
-	O
cell	O
development	O
.	O

Expression	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
:	O
CD3	O
complex	O
is	O
tightly	O
regulated	O
during	O
T	O
-	O
cell	O
development	O
.	O

The	O
mechanism	O
and	O
physiological	O
role	O
of	O
this	O
regulation	O
are	O
unclear	O
.	O
<EOS>	B-X
Tight	B-X
junctions	B-X
(	B-X
TJs	B-X
)	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
intestinal	B-X
barrier	B-X
function	B-X
.	B-X
One	B-X
of	B-X
the	B-X
most	B-X
important	B-X
roles	B-X
of	B-X
the	B-X
TJ	B-X
structure	B-X
is	B-X
to	B-X
provide	B-X
a	B-X
physical	B-X
barrier	B-X
to	B-X
luminal	B-X
inflammatory	B-X
molecules	B-X
.	B-X
According	B-X
to	B-X
recent	B-X
studies	B-X
,	B-X
the	B-X
intestinal	B-X
TJ	B-X
barrier	B-X
could	B-X
be	B-X
regulated	B-X
,	B-X
as	B-X
a	B-X
potential	B-X
target	B-X
,	B-X
by	B-X
dietary	B-X
factors	B-X
to	B-X
prevent	B-X
and	B-X
reduce	B-X
different	B-X
inflammatory	B-X
disorders	B-X
,	B-X
although	B-X
the	B-X
precise	B-X
mechanisms	B-X
underlying	B-X
the	B-X
dietary	B-X
regulation	B-X
remain	B-X
unclear	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
currently	B-X
available	B-X
information	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
intestinal	B-X
TJ	B-X
barrier	B-X
by	B-X
food	B-X
components	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
the	O
TCR	O
:	O
CD3	O
complex	O
is	O
constitutively	O
ubiquitylated	O
in	O
immature	O
double	O
positive	O
(	O
DP	O
)	O
thymocytes	O
,	O
but	O
not	O
mature	O
single	O
positive	O
(	O
SP	O
)	O
thymocytes	O
or	O
splenic	O
T	O
cells	O
.	O
<EOS>	B-X
The	B-X
enzyme-linked	B-X
immune	B-X
absorbent	B-X
spot	B-X
(	B-X
ELISpot	B-X
)	B-X
assay	B-X
allows	B-X
for	B-X
the	B-X
quantification	B-X
of	B-X
the	B-X
number	B-X
of	B-X
cells	B-X
producing	B-X
a	B-X
particular	B-X
secreted	B-X
analyte	B-X
.	B-X
As	B-X
T	B-X
lymphocytes	B-X
secrete	B-X
cytokines	B-X
such	B-X
as	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-γ	B-X
upon	B-X
binding	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
with	B-X
its	B-X
cognate	B-X
antigen	B-X
epitope	B-X
,	B-X
IFN-γ	B-X
ELISpot	B-X
allows	B-X
for	B-X
the	B-X
measurement	B-X
of	B-X
antigen-specific	B-X
T	B-X
cells	B-X
in	B-X
an	B-X
immune	B-X
sample	B-X
.	B-X
Immune	B-X
cells	B-X
are	B-X
isolated	B-X
from	B-X
the	B-X
vaccinated	B-X
subject	B-X
and	B-X
incubated	B-X
with	B-X
the	B-X
epitope/antigen	B-X
of	B-X
interest	B-X
on	B-X
polyvinylidene	B-X
difluoride	B-X
(	B-X
PVDF	B-X
)	B-X
-lined	B-X
microplates	B-X
precoated	B-X
with	B-X
a	B-X
capture	B-X
antibody	B-X
to	B-X
IFN-γ	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
quantification	B-X
of	B-X
OVA-specific	B-X
CD8	B-X
and	B-X
CD4	B-X
T	B-X
cells	B-X
from	B-X
mouse	B-X
splenocytes	B-X
to	B-X
measure	B-X
vaccine-induced	B-X
cellular	B-X
responses	B-X
.	B-X

This	O
steady	O
state	O
,	O
tonic	O
CD3	O
monoubiquitylation	O
is	O
mediated	O
by	O
the	O
CD3varepsilon	O
proline	O
-	O
rich	O
sequence	O
,	O
Lck	B-Protein
,	O
c	B-Protein
-	I-Protein
Cbl	I-Protein
,	O
and	O
SLAP	B-Protein
,	O
which	O
collectively	O
trigger	O
the	O
dynamin	O
-	O
dependent	O
downmodulation	O
,	O
lysosomal	O
sequestration	O
and	O
degradation	O
of	O
surface	O
TCR	O
:	O
CD3	O
complexes	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
tightly	B-X
regulated	B-X
during	B-X
T-cell	B-X
development	B-X
.	B-X
The	B-X
mechanism	B-X
and	B-X
physiological	B-X
role	B-X
of	B-X
this	B-X
regulation	B-X
are	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
TCR	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
constitutively	B-X
ubiquitylated	B-X
in	B-X
immature	B-X
double	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
thymocytes	B-X
,	B-X
but	B-X
not	B-X
mature	B-X
single	B-X
positive	B-X
(	B-X
SP	B-X
)	B-X
thymocytes	B-X
or	B-X
splenic	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
steady	B-X
state	B-X
,	B-X
tonic	B-X
CD3	B-X
monoubiquitylation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
CD3varepsilon	B-X
proline-rich	B-X
sequence	B-X
,	B-X
Lck	B-X
,	B-X
c-Cbl	B-X
,	B-X
and	B-X
SLAP	B-X
,	B-X
which	B-X
collectively	B-X
trigger	B-X
the	B-X
dynamin-dependent	B-X
downmodulation	B-X
,	B-X
lysosomal	B-X
sequestration	B-X
and	B-X
degradation	B-X
of	B-X
surface	B-X
TCR	B-X
:	B-X
CD3	B-X
complexes	B-X
.	B-X
Blocking	B-X
this	B-X
tonic	B-X
ubiquitylation	B-X
by	B-X
mutating	B-X
all	B-X
the	B-X
lysines	B-X
in	B-X
the	B-X
CD3	B-X
cytoplasmic	B-X
tails	B-X
significantly	B-X
upregulates	B-X
TCR	B-X
levels	B-X
on	B-X
DP	B-X
thymocytes	B-X
.	B-X
Mimicking	B-X
monoubiquitylation	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
CD3zeta-monoubiquitin	B-X
(	B-X
monoUb	B-X
)	B-X
fusion	B-X
molecule	B-X
significantly	B-X
reduces	B-X
TCR	B-X
levels	B-X
on	B-X
immature	B-X
thymocytes	B-X
.	B-X
Moreover	B-X
,	B-X
modulating	B-X
CD3	B-X
ubiquitylation	B-X
alters	B-X
immunological	B-X
synapse	B-X
(	B-X
IS	B-X
)	B-X
formation	B-X
and	B-X
Erk	B-X
phosphorylation	B-X
,	B-X
thereby	B-X
shifting	B-X
the	B-X
signalling	B-X
threshold	B-X
for	B-X
positive	B-X
and	B-X
negative	B-X
selection	B-X
,	B-X
and	B-X
regulatory	B-X
T-cell	B-X
development	B-X
.	B-X
Thus	B-X
,	B-X
tonic	B-X
TCR	B-X
:	B-X
CD3	B-X
ubiquitylation	B-X
results	B-X
in	B-X
precise	B-X
regulation	B-X
of	B-X
TCR	B-X
expression	B-X
on	B-X
immature	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
is	B-X
required	B-X
to	B-X
maintain	B-X
the	B-X
fidelity	B-X
of	B-X
T-cell	B-X
development	B-X
.	B-X

Blocking	O
this	O
tonic	O
ubiquitylation	O
by	O
mutating	O
all	O
the	O
lysines	O
in	O
the	O
CD3	O
cytoplasmic	O
tails	O
significantly	O
upregulates	O
TCR	O
levels	O
on	O
DP	O
thymocytes	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
tightly	B-X
regulated	B-X
during	B-X
T-cell	B-X
development	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
TCR	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
constitutively	B-X
ubiquitylated	B-X
in	B-X
immature	B-X
double	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
thymocytes	B-X
,	B-X
but	B-X
not	B-X
mature	B-X
single	B-X
positive	B-X
(	B-X
SP	B-X
)	B-X
thymocytes	B-X
or	B-X
splenic	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
steady	B-X
state	B-X
,	B-X
tonic	B-X
CD3	B-X
monoubiquitylation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
CD3varepsilon	B-X
proline-rich	B-X
sequence	B-X
,	B-X
Lck	B-X
,	B-X
c-Cbl	B-X
,	B-X
and	B-X
SLAP	B-X
,	B-X
which	B-X
collectively	B-X
trigger	B-X
the	B-X
dynamin-dependent	B-X
downmodulation	B-X
,	B-X
lysosomal	B-X
sequestration	B-X
and	B-X
degradation	B-X
of	B-X
surface	B-X
TCR	B-X
:	B-X
CD3	B-X
complexes	B-X
.	B-X
Blocking	B-X
this	B-X
tonic	B-X
ubiquitylation	B-X
by	B-X
mutating	B-X
all	B-X
the	B-X
lysines	B-X
in	B-X
the	B-X
CD3	B-X
cytoplasmic	B-X
tails	B-X
significantly	B-X
upregulates	B-X
TCR	B-X
levels	B-X
on	B-X
DP	B-X
thymocytes	B-X
.	B-X
Mimicking	B-X
monoubiquitylation	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
CD3zeta-monoubiquitin	B-X
(	B-X
monoUb	B-X
)	B-X
fusion	B-X
molecule	B-X
significantly	B-X
reduces	B-X
TCR	B-X
levels	B-X
on	B-X
immature	B-X
thymocytes	B-X
.	B-X
Moreover	B-X
,	B-X
modulating	B-X
CD3	B-X
ubiquitylation	B-X
alters	B-X
immunological	B-X
synapse	B-X
(	B-X
IS	B-X
)	B-X
formation	B-X
and	B-X
Erk	B-X
phosphorylation	B-X
,	B-X
thereby	B-X
shifting	B-X
the	B-X
signalling	B-X
threshold	B-X
for	B-X
positive	B-X
and	B-X
negative	B-X
selection	B-X
,	B-X
and	B-X
regulatory	B-X
T-cell	B-X
development	B-X
.	B-X
Thus	B-X
,	B-X
tonic	B-X
TCR	B-X
:	B-X
CD3	B-X
ubiquitylation	B-X
results	B-X
in	B-X
precise	B-X
regulation	B-X
of	B-X
TCR	B-X
expression	B-X
on	B-X
immature	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
is	B-X
required	B-X
to	B-X
maintain	B-X
the	B-X
fidelity	B-X
of	B-X
T-cell	B-X
development	B-X
.	B-X

Mimicking	O
monoubiquitylation	O
by	O
expression	O
of	O
a	O
CD3zeta	B-Protein
-	O
monoubiquitin	B-Protein
(	O
monoUb	B-Protein
)	O
fusion	O
molecule	O
significantly	O
reduces	O
TCR	O
levels	O
on	O
immature	O
thymocytes	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
tightly	B-X
regulated	B-X
during	B-X
T-cell	B-X
development	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
TCR	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
constitutively	B-X
ubiquitylated	B-X
in	B-X
immature	B-X
double	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
thymocytes	B-X
,	B-X
but	B-X
not	B-X
mature	B-X
single	B-X
positive	B-X
(	B-X
SP	B-X
)	B-X
thymocytes	B-X
or	B-X
splenic	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
steady	B-X
state	B-X
,	B-X
tonic	B-X
CD3	B-X
monoubiquitylation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
CD3varepsilon	B-X
proline-rich	B-X
sequence	B-X
,	B-X
Lck	B-X
,	B-X
c-Cbl	B-X
,	B-X
and	B-X
SLAP	B-X
,	B-X
which	B-X
collectively	B-X
trigger	B-X
the	B-X
dynamin-dependent	B-X
downmodulation	B-X
,	B-X
lysosomal	B-X
sequestration	B-X
and	B-X
degradation	B-X
of	B-X
surface	B-X
TCR	B-X
:	B-X
CD3	B-X
complexes	B-X
.	B-X
Blocking	B-X
this	B-X
tonic	B-X
ubiquitylation	B-X
by	B-X
mutating	B-X
all	B-X
the	B-X
lysines	B-X
in	B-X
the	B-X
CD3	B-X
cytoplasmic	B-X
tails	B-X
significantly	B-X
upregulates	B-X
TCR	B-X
levels	B-X
on	B-X
DP	B-X
thymocytes	B-X
.	B-X
Mimicking	B-X
monoubiquitylation	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
CD3zeta-monoubiquitin	B-X
(	B-X
monoUb	B-X
)	B-X
fusion	B-X
molecule	B-X
significantly	B-X
reduces	B-X
TCR	B-X
levels	B-X
on	B-X
immature	B-X
thymocytes	B-X
.	B-X
Thus	B-X
,	B-X
tonic	B-X
TCR	B-X
:	B-X
CD3	B-X
ubiquitylation	B-X
results	B-X
in	B-X
precise	B-X
regulation	B-X
of	B-X
TCR	B-X
expression	B-X
on	B-X
immature	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
is	B-X
required	B-X
to	B-X
maintain	B-X
the	B-X
fidelity	B-X
of	B-X
T-cell	B-X
development	B-X
.	B-X

Moreover	O
,	O
modulating	O
CD3	O
ubiquitylation	O
alters	O
immunological	O
synapse	O
(	O
IS	O
)	O
formation	O
and	O
Erk	O
phosphorylation	O
,	O
thereby	O
shifting	O
the	O
signalling	O
threshold	O
for	O
positive	O
and	O
negative	O
selection	O
,	O
and	O
regulatory	O
T	O
-	O
cell	O
development	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
tightly	B-X
regulated	B-X
during	B-X
T-cell	B-X
development	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
TCR	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
constitutively	B-X
ubiquitylated	B-X
in	B-X
immature	B-X
double	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
thymocytes	B-X
,	B-X
but	B-X
not	B-X
mature	B-X
single	B-X
positive	B-X
(	B-X
SP	B-X
)	B-X
thymocytes	B-X
or	B-X
splenic	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
steady	B-X
state	B-X
,	B-X
tonic	B-X
CD3	B-X
monoubiquitylation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
CD3varepsilon	B-X
proline-rich	B-X
sequence	B-X
,	B-X
Lck	B-X
,	B-X
c-Cbl	B-X
,	B-X
and	B-X
SLAP	B-X
,	B-X
which	B-X
collectively	B-X
trigger	B-X
the	B-X
dynamin-dependent	B-X
downmodulation	B-X
,	B-X
lysosomal	B-X
sequestration	B-X
and	B-X
degradation	B-X
of	B-X
surface	B-X
TCR	B-X
:	B-X
CD3	B-X
complexes	B-X
.	B-X
Blocking	B-X
this	B-X
tonic	B-X
ubiquitylation	B-X
by	B-X
mutating	B-X
all	B-X
the	B-X
lysines	B-X
in	B-X
the	B-X
CD3	B-X
cytoplasmic	B-X
tails	B-X
significantly	B-X
upregulates	B-X
TCR	B-X
levels	B-X
on	B-X
DP	B-X
thymocytes	B-X
.	B-X
Mimicking	B-X
monoubiquitylation	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
CD3zeta-monoubiquitin	B-X
(	B-X
monoUb	B-X
)	B-X
fusion	B-X
molecule	B-X
significantly	B-X
reduces	B-X
TCR	B-X
levels	B-X
on	B-X
immature	B-X
thymocytes	B-X
.	B-X
Moreover	B-X
,	B-X
modulating	B-X
CD3	B-X
ubiquitylation	B-X
alters	B-X
immunological	B-X
synapse	B-X
(	B-X
IS	B-X
)	B-X
formation	B-X
and	B-X
Erk	B-X
phosphorylation	B-X
,	B-X
thereby	B-X
shifting	B-X
the	B-X
signalling	B-X
threshold	B-X
for	B-X
positive	B-X
and	B-X
negative	B-X
selection	B-X
,	B-X
and	B-X
regulatory	B-X
T-cell	B-X
development	B-X
.	B-X
Thus	B-X
,	B-X
tonic	B-X
TCR	B-X
:	B-X
CD3	B-X
ubiquitylation	B-X
results	B-X
in	B-X
precise	B-X
regulation	B-X
of	B-X
TCR	B-X
expression	B-X
on	B-X
immature	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
is	B-X
required	B-X
to	B-X
maintain	B-X
the	B-X
fidelity	B-X
of	B-X
T-cell	B-X
development	B-X
.	B-X

Thus	O
,	O
tonic	O
TCR	O
:	O
CD3	O
ubiquitylation	O
results	O
in	O
precise	O
regulation	O
of	O
TCR	O
expression	O
on	O
immature	O
T	O
cells	O
,	O
which	O
is	O
required	O
to	O
maintain	O
the	O
fidelity	O
of	O
T	O
-	O
cell	O
development	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
tightly	B-X
regulated	B-X
during	B-X
T-cell	B-X
development	B-X
.	B-X
The	B-X
mechanism	B-X
and	B-X
physiological	B-X
role	B-X
of	B-X
this	B-X
regulation	B-X
are	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
TCR	B-X
:	B-X
CD3	B-X
complex	B-X
is	B-X
constitutively	B-X
ubiquitylated	B-X
in	B-X
immature	B-X
double	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
thymocytes	B-X
,	B-X
but	B-X
not	B-X
mature	B-X
single	B-X
positive	B-X
(	B-X
SP	B-X
)	B-X
thymocytes	B-X
or	B-X
splenic	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
steady	B-X
state	B-X
,	B-X
tonic	B-X
CD3	B-X
monoubiquitylation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
CD3varepsilon	B-X
proline-rich	B-X
sequence	B-X
,	B-X
Lck	B-X
,	B-X
c-Cbl	B-X
,	B-X
and	B-X
SLAP	B-X
,	B-X
which	B-X
collectively	B-X
trigger	B-X
the	B-X
dynamin-dependent	B-X
downmodulation	B-X
,	B-X
lysosomal	B-X
sequestration	B-X
and	B-X
degradation	B-X
of	B-X
surface	B-X
TCR	B-X
:	B-X
CD3	B-X
complexes	B-X
.	B-X
Blocking	B-X
this	B-X
tonic	B-X
ubiquitylation	B-X
by	B-X
mutating	B-X
all	B-X
the	B-X
lysines	B-X
in	B-X
the	B-X
CD3	B-X
cytoplasmic	B-X
tails	B-X
significantly	B-X
upregulates	B-X
TCR	B-X
levels	B-X
on	B-X
DP	B-X
thymocytes	B-X
.	B-X
Mimicking	B-X
monoubiquitylation	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
CD3zeta-monoubiquitin	B-X
(	B-X
monoUb	B-X
)	B-X
fusion	B-X
molecule	B-X
significantly	B-X
reduces	B-X
TCR	B-X
levels	B-X
on	B-X
immature	B-X
thymocytes	B-X
.	B-X
Moreover	B-X
,	B-X
modulating	B-X
CD3	B-X
ubiquitylation	B-X
alters	B-X
immunological	B-X
synapse	B-X
(	B-X
IS	B-X
)	B-X
formation	B-X
and	B-X
Erk	B-X
phosphorylation	B-X
,	B-X
thereby	B-X
shifting	B-X
the	B-X
signalling	B-X
threshold	B-X
for	B-X
positive	B-X
and	B-X
negative	B-X
selection	B-X
,	B-X
and	B-X
regulatory	B-X
T-cell	B-X
development	B-X
.	B-X
Thus	B-X
,	B-X
tonic	B-X
TCR	B-X
:	B-X
CD3	B-X
ubiquitylation	B-X
results	B-X
in	B-X
precise	B-X
regulation	B-X
of	B-X
TCR	B-X
expression	B-X
on	B-X
immature	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
is	B-X
required	B-X
to	B-X
maintain	B-X
the	B-X
fidelity	B-X
of	B-X
T-cell	B-X
development	B-X
.	B-X

RNF8	B-Protein
-	O
dependent	O
histone	B-Protein
modifications	O
regulate	O
nucleosome	O
removal	O
during	O
spermatogenesis	O
.	O
<EOS>	B-X
During	B-X
spermatogenesis	B-X
,	B-X
global	B-X
nucleosome	B-X
removal	B-X
occurs	B-X
where	B-X
histones	B-X
are	B-X
initially	B-X
replaced	B-X
by	B-X
transition	B-X
proteins	B-X
and	B-X
subsequently	B-X
by	B-X
protamines	B-X
.	B-X
Histone	B-X
ubiquitination	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
important	B-X
for	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
during	B-X
meiotic	B-X
prophase	B-X
and	B-X
nucleosome	B-X
removal	B-X
at	B-X
postmeiotic	B-X
stages	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
RNF8	B-X
during	B-X
spermatogenesis	B-X
and	B-X
find	B-X
that	B-X
RNF8-deficient	B-X
mice	B-X
are	B-X
proficient	B-X
in	B-X
meiotic	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
(	B-X
MSCI	B-X
)	B-X
but	B-X
deficient	B-X
in	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
RNF8-dependent	B-X
histone	B-X
ubiquitination	B-X
induces	B-X
H4K16	B-X
acetylation	B-X
,	B-X
which	B-X
may	B-X
be	B-X
an	B-X
initial	B-X
step	B-X
in	B-X
nucleosome	B-X
removal	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
results	B-X
show	B-X
that	B-X
RNF8	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
spermatogenesis	B-X
through	B-X
histone	B-X
ubiquitination	B-X
,	B-X
resulting	B-X
in	B-X
trans-histone	B-X
acetylation	B-X
and	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X

During	O
spermatogenesis	O
,	O
global	O
nucleosome	O
removal	O
occurs	O
where	O
histones	B-Protein
are	O
initially	O
replaced	O
by	O
transition	O
proteins	O
and	O
subsequently	O
by	O
protamines	O
.	O
<EOS>	B-X
During	B-X
spermatogenesis	B-X
,	B-X
global	B-X
nucleosome	B-X
removal	B-X
occurs	B-X
where	B-X
histones	B-X
are	B-X
initially	B-X
replaced	B-X
by	B-X
transition	B-X
proteins	B-X
and	B-X
subsequently	B-X
by	B-X
protamines	B-X
.	B-X
Histone	B-X
ubiquitination	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
important	B-X
for	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
during	B-X
meiotic	B-X
prophase	B-X
and	B-X
nucleosome	B-X
removal	B-X
at	B-X
postmeiotic	B-X
stages	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
RNF8	B-X
during	B-X
spermatogenesis	B-X
and	B-X
find	B-X
that	B-X
RNF8-deficient	B-X
mice	B-X
are	B-X
proficient	B-X
in	B-X
meiotic	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
(	B-X
MSCI	B-X
)	B-X
but	B-X
deficient	B-X
in	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
RNF8-dependent	B-X
histone	B-X
ubiquitination	B-X
induces	B-X
H4K16	B-X
acetylation	B-X
,	B-X
which	B-X
may	B-X
be	B-X
an	B-X
initial	B-X
step	B-X
in	B-X
nucleosome	B-X
removal	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
results	B-X
show	B-X
that	B-X
RNF8	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
spermatogenesis	B-X
through	B-X
histone	B-X
ubiquitination	B-X
,	B-X
resulting	B-X
in	B-X
trans-histone	B-X
acetylation	B-X
and	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X

This	O
chromatin	O
reorganization	O
is	O
thought	O
to	O
facilitate	O
the	O
compaction	O
of	O
the	O
paternal	O
genome	O
into	O
the	O
sperm	O
head	O
and	O
to	O
protect	O
the	O
DNA	O
from	O
damaging	O
agents	O
.	O
<EOS>	B-X
During	B-X
spermatogenesis	B-X
,	B-X
global	B-X
nucleosome	B-X
removal	B-X
occurs	B-X
where	B-X
histones	B-X
are	B-X
initially	B-X
replaced	B-X
by	B-X
transition	B-X
proteins	B-X
and	B-X
subsequently	B-X
by	B-X
protamines	B-X
.	B-X
This	B-X
chromatin	B-X
reorganization	B-X
is	B-X
thought	B-X
to	B-X
facilitate	B-X
the	B-X
compaction	B-X
of	B-X
the	B-X
paternal	B-X
genome	B-X
into	B-X
the	B-X
sperm	B-X
head	B-X
and	B-X
to	B-X
protect	B-X
the	B-X
DNA	B-X
from	B-X
damaging	B-X
agents	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
RNF8	B-X
during	B-X
spermatogenesis	B-X
and	B-X
find	B-X
that	B-X
RNF8-deficient	B-X
mice	B-X
are	B-X
proficient	B-X
in	B-X
meiotic	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
(	B-X
MSCI	B-X
)	B-X
but	B-X
deficient	B-X
in	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
results	B-X
show	B-X
that	B-X
RNF8	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
spermatogenesis	B-X
through	B-X
histone	B-X
ubiquitination	B-X
,	B-X
resulting	B-X
in	B-X
trans-histone	B-X
acetylation	B-X
and	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X

Histone	B-Protein
ubiquitination	O
has	O
been	O
suggested	O
to	O
be	O
important	O
for	O
sex	O
chromosome	O
inactivation	O
during	O
meiotic	O
prophase	O
and	O
nucleosome	O
removal	O
at	O
postmeiotic	O
stages	O
.	O
<EOS>	B-X
During	B-X
spermatogenesis	B-X
,	B-X
global	B-X
nucleosome	B-X
removal	B-X
occurs	B-X
where	B-X
histones	B-X
are	B-X
initially	B-X
replaced	B-X
by	B-X
transition	B-X
proteins	B-X
and	B-X
subsequently	B-X
by	B-X
protamines	B-X
.	B-X
Histone	B-X
ubiquitination	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
important	B-X
for	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
during	B-X
meiotic	B-X
prophase	B-X
and	B-X
nucleosome	B-X
removal	B-X
at	B-X
postmeiotic	B-X
stages	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
RNF8	B-X
during	B-X
spermatogenesis	B-X
and	B-X
find	B-X
that	B-X
RNF8-deficient	B-X
mice	B-X
are	B-X
proficient	B-X
in	B-X
meiotic	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
(	B-X
MSCI	B-X
)	B-X
but	B-X
deficient	B-X
in	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
RNF8-dependent	B-X
histone	B-X
ubiquitination	B-X
induces	B-X
H4K16	B-X
acetylation	B-X
,	B-X
which	B-X
may	B-X
be	B-X
an	B-X
initial	B-X
step	B-X
in	B-X
nucleosome	B-X
removal	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
results	B-X
show	B-X
that	B-X
RNF8	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
spermatogenesis	B-X
through	B-X
histone	B-X
ubiquitination	B-X
,	B-X
resulting	B-X
in	B-X
trans-histone	B-X
acetylation	B-X
and	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X

However	O
,	O
the	O
mechanisms	O
regulating	O
these	O
ubiquitin	B-Protein
-	O
mediated	O
processes	O
are	O
unknown	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
regulation	B-X
of	B-X
PARP1	B-X
require	B-X
further	B-X
study	B-X
.	B-X
WWP2	B-X
,	B-X
a	B-X
HECT-type	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
the	B-X
heart	B-X
,	B-X
but	B-X
its	B-X
function	B-X
there	B-X
is	B-X
largely	B-X
unknown	B-X
.	B-X
We	B-X
determined	B-X
that	B-X
the	B-X
knockout	B-X
of	B-X
WWP2	B-X
specifically	B-X
in	B-X
myocardium	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
PARP1	B-X
ubiquitination	B-X
and	B-X
increased	B-X
the	B-X
effects	B-X
of	B-X
isoproterenol	B-X
(	B-X
ISO	B-X
)	B-X
-induced	B-X
PARP1	B-X
and	B-X
PARylation	B-X
,	B-X
in	B-X
turn	B-X
aggravating	B-X
ISO-induced	B-X
myocardial	B-X
hypertrophy	B-X
,	B-X
heart	B-X
failure	B-X
,	B-X
and	B-X
myocardial	B-X
fibrosis	B-X
.	B-X
Similar	B-X
findings	B-X
were	B-X
obtained	B-X
in	B-X
a	B-X
model	B-X
of	B-X
ISO-induced	B-X
H9c2	B-X
cells	B-X
with	B-X
WWP2	B-X
knockdown	B-X
,	B-X
while	B-X
the	B-X
reexpression	B-X
of	B-X
WWP2	B-X
significantly	B-X
increased	B-X
PARP1	B-X
ubiquitination	B-X
and	B-X
decreased	B-X
PAPR1	B-X
and	B-X
PARylation	B-X
levels	B-X
.	B-X
Mechanistically	B-X
,	B-X
coimmunoprecipitation	B-X
results	B-X
identified	B-X
that	B-X
WWP2	B-X
is	B-X
a	B-X
novel	B-X
interacting	B-X
protein	B-X
of	B-X
PARP1	B-X
and	B-X
mainly	B-X
interacts	B-X
with	B-X
its	B-X
BRCT	B-X
domain	B-X
,	B-X
thus	B-X
mediating	B-X
the	B-X
degradation	B-X
of	B-X
PARP1	B-X
through	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
lysine	B-X
418	B-X
(	B-X
K418	B-X
)	B-X
and	B-X
lysine	B-X
249	B-X
(	B-X
K249	B-X
)	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
of	B-X
critical	B-X
importance	B-X
in	B-X
regulating	B-X
PARP1	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
by	B-X
WWP2	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
role	O
of	O
the	O
ubiquitin	B-Protein
ligase	O
RNF8	B-Protein
during	O
spermatogenesis	O
and	O
find	O
that	O
RNF8	B-Protein
-	O
deficient	O
mice	O
are	O
proficient	O
in	O
meiotic	O
sex	O
chromosome	O
inactivation	O
(	O
MSCI	O
)	O
but	O
deficient	O
in	O
global	O
nucleosome	O
removal	O
.	O
<EOS>	B-X
During	B-X
spermatogenesis	B-X
,	B-X
global	B-X
nucleosome	B-X
removal	B-X
occurs	B-X
where	B-X
histones	B-X
are	B-X
initially	B-X
replaced	B-X
by	B-X
transition	B-X
proteins	B-X
and	B-X
subsequently	B-X
by	B-X
protamines	B-X
.	B-X
Histone	B-X
ubiquitination	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
important	B-X
for	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
during	B-X
meiotic	B-X
prophase	B-X
and	B-X
nucleosome	B-X
removal	B-X
at	B-X
postmeiotic	B-X
stages	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
these	B-X
ubiquitin-mediated	B-X
processes	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
RNF8	B-X
during	B-X
spermatogenesis	B-X
and	B-X
find	B-X
that	B-X
RNF8-deficient	B-X
mice	B-X
are	B-X
proficient	B-X
in	B-X
meiotic	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
(	B-X
MSCI	B-X
)	B-X
but	B-X
deficient	B-X
in	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
RNF8-dependent	B-X
histone	B-X
ubiquitination	B-X
induces	B-X
H4K16	B-X
acetylation	B-X
,	B-X
which	B-X
may	B-X
be	B-X
an	B-X
initial	B-X
step	B-X
in	B-X
nucleosome	B-X
removal	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
results	B-X
show	B-X
that	B-X
RNF8	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
spermatogenesis	B-X
through	B-X
histone	B-X
ubiquitination	B-X
,	B-X
resulting	B-X
in	B-X
trans-histone	B-X
acetylation	B-X
and	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X

Moreover	O
,	O
we	O
show	O
that	O
RNF8	B-Protein
-	O
dependent	O
histone	B-Protein
ubiquitination	O
induces	O
H4K16	B-Protein
acetylation	O
,	O
which	O
may	O
be	O
an	O
initial	O
step	O
in	O
nucleosome	O
removal	O
.	O
<EOS>	B-X
During	B-X
spermatogenesis	B-X
,	B-X
global	B-X
nucleosome	B-X
removal	B-X
occurs	B-X
where	B-X
histones	B-X
are	B-X
initially	B-X
replaced	B-X
by	B-X
transition	B-X
proteins	B-X
and	B-X
subsequently	B-X
by	B-X
protamines	B-X
.	B-X
Histone	B-X
ubiquitination	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
important	B-X
for	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
during	B-X
meiotic	B-X
prophase	B-X
and	B-X
nucleosome	B-X
removal	B-X
at	B-X
postmeiotic	B-X
stages	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
RNF8	B-X
during	B-X
spermatogenesis	B-X
and	B-X
find	B-X
that	B-X
RNF8-deficient	B-X
mice	B-X
are	B-X
proficient	B-X
in	B-X
meiotic	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
(	B-X
MSCI	B-X
)	B-X
but	B-X
deficient	B-X
in	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
RNF8-dependent	B-X
histone	B-X
ubiquitination	B-X
induces	B-X
H4K16	B-X
acetylation	B-X
,	B-X
which	B-X
may	B-X
be	B-X
an	B-X
initial	B-X
step	B-X
in	B-X
nucleosome	B-X
removal	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
results	B-X
show	B-X
that	B-X
RNF8	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
spermatogenesis	B-X
through	B-X
histone	B-X
ubiquitination	B-X
,	B-X
resulting	B-X
in	B-X
trans-histone	B-X
acetylation	B-X
and	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X

Thus	O
,	O
our	O
results	O
show	O
that	O
RNF8	B-Protein
plays	O
an	O
important	O
role	O
during	O
spermatogenesis	O
through	O
histone	B-Protein
ubiquitination	O
,	O
resulting	O
in	O
trans	O
-	O
histone	B-Protein
acetylation	O
and	O
global	O
nucleosome	O
removal	O
.	O
<EOS>	B-X
During	B-X
spermatogenesis	B-X
,	B-X
global	B-X
nucleosome	B-X
removal	B-X
occurs	B-X
where	B-X
histones	B-X
are	B-X
initially	B-X
replaced	B-X
by	B-X
transition	B-X
proteins	B-X
and	B-X
subsequently	B-X
by	B-X
protamines	B-X
.	B-X
Histone	B-X
ubiquitination	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
important	B-X
for	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
during	B-X
meiotic	B-X
prophase	B-X
and	B-X
nucleosome	B-X
removal	B-X
at	B-X
postmeiotic	B-X
stages	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
RNF8	B-X
during	B-X
spermatogenesis	B-X
and	B-X
find	B-X
that	B-X
RNF8-deficient	B-X
mice	B-X
are	B-X
proficient	B-X
in	B-X
meiotic	B-X
sex	B-X
chromosome	B-X
inactivation	B-X
(	B-X
MSCI	B-X
)	B-X
but	B-X
deficient	B-X
in	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
RNF8-dependent	B-X
histone	B-X
ubiquitination	B-X
induces	B-X
H4K16	B-X
acetylation	B-X
,	B-X
which	B-X
may	B-X
be	B-X
an	B-X
initial	B-X
step	B-X
in	B-X
nucleosome	B-X
removal	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
results	B-X
show	B-X
that	B-X
RNF8	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
spermatogenesis	B-X
through	B-X
histone	B-X
ubiquitination	B-X
,	B-X
resulting	B-X
in	B-X
trans-histone	B-X
acetylation	B-X
and	B-X
global	B-X
nucleosome	B-X
removal	B-X
.	B-X

Predicted	O
functions	O
of	O
MdmX	B-Protein
in	O
fine	O
-	O
tuning	O
the	O
response	O
of	O
p53	B-Protein
to	O
DNA	O
damage	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
protein	B-X
p53	B-X
is	B-X
regulated	B-X
by	B-X
two	B-X
structurally	B-X
homologous	B-X
proteins	B-X
,	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
Mdm2	B-X
,	B-X
MdmX	B-X
lacks	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X
Although	B-X
the	B-X
essential	B-X
interactions	B-X
of	B-X
MdmX	B-X
are	B-X
known	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
how	B-X
they	B-X
function	B-X
to	B-X
regulate	B-X
p53	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
p53	B-X
by	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
was	B-X
investigated	B-X
by	B-X
mathematical	B-X
modeling	B-X
of	B-X
a	B-X
simplified	B-X
network	B-X
.	B-X
The	B-X
simplified	B-X
network	B-X
model	B-X
was	B-X
derived	B-X
from	B-X
a	B-X
detailed	B-X
molecular	B-X
interaction	B-X
map	B-X
(	B-X
MIM	B-X
)	B-X
that	B-X
exhibited	B-X
four	B-X
coherent	B-X
DNA	B-X
damage	B-X
response	B-X
pathways	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
MdmX	B-X
may	B-X
amplify	B-X
or	B-X
stabilize	B-X
DNA	B-X
damage-induced	B-X
p53	B-X
responses	B-X
via	B-X
non-enzymatic	B-X
interactions	B-X
.	B-X
Transient	B-X
effects	B-X
of	B-X
MdmX	B-X
are	B-X
mediated	B-X
by	B-X
reservoirs	B-X
of	B-X
p53ratioMdmX	B-X
and	B-X
Mdm2ratioMdmX	B-X
heterodimers	B-X
,	B-X
with	B-X
MdmX	B-X
buffering	B-X
the	B-X
concentrations	B-X
of	B-X
p53	B-X
and/or	B-X
Mdm2	B-X
.	B-X
During	B-X
an	B-X
early	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
positively	B-X
or	B-X
negatively	B-X
regulated	B-X
p53	B-X
activity	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
level	B-X
of	B-X
Mdm2	B-X
;	B-X
this	B-X
led	B-X
to	B-X
amplification	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
switch-like	B-X
response	B-X
.	B-X
During	B-X
a	B-X
late	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
could	B-X
dampen	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
.	B-X
A	B-X
possible	B-X
role	B-X
of	B-X
MdmX	B-X
may	B-X
be	B-X
to	B-X
dampen	B-X
such	B-X
oscillations	B-X
that	B-X
otherwise	B-X
could	B-X
produce	B-X
erratic	B-X
cell	B-X
behavior	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
how	B-X
MdmX	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
response	B-X
of	B-X
p53	B-X
to	B-X
DNA	B-X
damage	B-X
either	B-X
by	B-X
increasing	B-X
dependency	B-X
of	B-X
p53	B-X
on	B-X
Mdm2	B-X
or	B-X
by	B-X
dampening	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
presents	B-X
a	B-X
model	B-X
for	B-X
experimental	B-X
investigation	B-X
.	B-X

Tumor	O
suppressor	O
protein	O
p53	B-Protein
is	O
regulated	O
by	O
two	O
structurally	O
homologous	O
proteins	O
,	O
Mdm2	B-Protein
and	O
MdmX	B-Protein
.	O
<EOS>	B-X
The	B-X
negative	B-X
regulation	B-X
of	B-X
p53	B-X
,	B-X
a	B-X
major	B-X
human	B-X
tumor	B-X
suppressor	B-X
,	B-X
by	B-X
Mdm2	B-X
and	B-X
Mdmx	B-X
is	B-X
crucial	B-X
for	B-X
the	B-X
survival	B-X
of	B-X
a	B-X
cell	B-X
,	B-X
whereas	B-X
its	B-X
aberrant	B-X
function	B-X
is	B-X
a	B-X
common	B-X
feature	B-X
of	B-X
cancer	B-X
.	B-X
Both	B-X
Mdm	B-X
proteins	B-X
act	B-X
through	B-X
the	B-X
spatial	B-X
occlusion	B-X
of	B-X
the	B-X
p53	B-X
transactivation	B-X
(	B-X
TA	B-X
)	B-X
domain	B-X
and	B-X
by	B-X
the	B-X
ubiquitination	B-X
of	B-X
p53	B-X
,	B-X
resulting	B-X
in	B-X
its	B-X
degradation	B-X
.	B-X
Two	B-X
p53	B-X
homologues	B-X
,	B-X
p63	B-X
and	B-X
p73	B-X
,	B-X
have	B-X
been	B-X
described	B-X
in	B-X
humans	B-X
.	B-X
Unlike	B-X
p53	B-X
,	B-X
these	B-X
proteins	B-X
regulate	B-X
developmental	B-X
processes	B-X
rather	B-X
than	B-X
genome	B-X
stability	B-X
.	B-X
Both	B-X
p63	B-X
and	B-X
p73	B-X
contain	B-X
TA	B-X
domains	B-X
homologous	B-X
to	B-X
that	B-X
of	B-X
p53	B-X
,	B-X
but	B-X
relatively	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
regulation	B-X
by	B-X
Mdm2	B-X
or	B-X
Mdmx	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
a	B-X
detailed	B-X
characterization	B-X
of	B-X
the	B-X
interaction	B-X
of	B-X
Mdm2	B-X
and	B-X
Mdmx	B-X
with	B-X
the	B-X
TA	B-X
domains	B-X
of	B-X
p63	B-X
and	B-X
p73	B-X
.	B-X
Earlier	B-X
reports	B-X
of	B-X
Mdm2	B-X
and	B-X
Mdmx	B-X
interactions	B-X
with	B-X
p73	B-X
are	B-X
substantiated	B-X
by	B-X
the	B-X
detailed	B-X
quantitative	B-X
characterization	B-X
reported	B-X
in	B-X
this	B-X
study	B-X
.	B-X
Most	B-X
importantly	B-X
,	B-X
earlier	B-X
contradictions	B-X
concerning	B-X
the	B-X
presumed	B-X
interaction	B-X
of	B-X
the	B-X
Mdm	B-X
proteins	B-X
with	B-X
p63	B-X
are	B-X
convincingly	B-X
resolved	B-X
and	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
the	B-X
affinities	B-X
of	B-X
these	B-X
interactions	B-X
are	B-X
determined	B-X
.	B-X

In	O
contrast	O
to	O
Mdm2	B-Protein
,	O
MdmX	B-Protein
lacks	O
ubiquitin	B-Protein
ligase	O
activity	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
protein	B-X
p53	B-X
is	B-X
regulated	B-X
by	B-X
two	B-X
structurally	B-X
homologous	B-X
proteins	B-X
,	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
Mdm2	B-X
,	B-X
MdmX	B-X
lacks	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X
Although	B-X
the	B-X
essential	B-X
interactions	B-X
of	B-X
MdmX	B-X
are	B-X
known	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
how	B-X
they	B-X
function	B-X
to	B-X
regulate	B-X
p53	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
p53	B-X
by	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
was	B-X
investigated	B-X
by	B-X
mathematical	B-X
modeling	B-X
of	B-X
a	B-X
simplified	B-X
network	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
MdmX	B-X
may	B-X
amplify	B-X
or	B-X
stabilize	B-X
DNA	B-X
damage-induced	B-X
p53	B-X
responses	B-X
via	B-X
non-enzymatic	B-X
interactions	B-X
.	B-X
Transient	B-X
effects	B-X
of	B-X
MdmX	B-X
are	B-X
mediated	B-X
by	B-X
reservoirs	B-X
of	B-X
p53ratioMdmX	B-X
and	B-X
Mdm2ratioMdmX	B-X
heterodimers	B-X
,	B-X
with	B-X
MdmX	B-X
buffering	B-X
the	B-X
concentrations	B-X
of	B-X
p53	B-X
and/or	B-X
Mdm2	B-X
.	B-X
During	B-X
an	B-X
early	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
positively	B-X
or	B-X
negatively	B-X
regulated	B-X
p53	B-X
activity	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
level	B-X
of	B-X
Mdm2	B-X
;	B-X
this	B-X
led	B-X
to	B-X
amplification	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
switch-like	B-X
response	B-X
.	B-X
During	B-X
a	B-X
late	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
could	B-X
dampen	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
.	B-X
A	B-X
possible	B-X
role	B-X
of	B-X
MdmX	B-X
may	B-X
be	B-X
to	B-X
dampen	B-X
such	B-X
oscillations	B-X
that	B-X
otherwise	B-X
could	B-X
produce	B-X
erratic	B-X
cell	B-X
behavior	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
how	B-X
MdmX	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
response	B-X
of	B-X
p53	B-X
to	B-X
DNA	B-X
damage	B-X
either	B-X
by	B-X
increasing	B-X
dependency	B-X
of	B-X
p53	B-X
on	B-X
Mdm2	B-X
or	B-X
by	B-X
dampening	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
presents	B-X
a	B-X
model	B-X
for	B-X
experimental	B-X
investigation	B-X
.	B-X

Although	O
the	O
essential	O
interactions	O
of	O
MdmX	B-Protein
are	O
known	O
,	O
it	O
is	O
not	O
clear	O
how	O
they	O
function	O
to	O
regulate	O
p53	B-Protein
.	O
<EOS>	B-X
The	B-X
eukaryotic	B-X
rp	B-X
uS19	B-X
(	B-X
previously	B-X
known	B-X
as	B-X
S15	B-X
)	B-X
comprises	B-X
a	B-X
C-terminal	B-X
extension	B-X
that	B-X
has	B-X
no	B-X
homology	B-X
in	B-X
the	B-X
bacterial	B-X
counterparts	B-X
.	B-X
Another	B-X
eukaryote-specific	B-X
feature	B-X
of	B-X
rp	B-X
uS19	B-X
is	B-X
its	B-X
essential	B-X
participance	B-X
in	B-X
the	B-X
40S	B-X
subunit	B-X
maturation	B-X
due	B-X
to	B-X
the	B-X
interactions	B-X
with	B-X
the	B-X
subunit	B-X
assembly	B-X
factors	B-X
required	B-X
for	B-X
the	B-X
nuclear	B-X
exit	B-X
of	B-X
pre-40S	B-X
particles	B-X
.	B-X
Beyond	B-X
properties	B-X
related	B-X
to	B-X
the	B-X
translation	B-X
machinery	B-X
,	B-X
eukaryotic	B-X
rp	B-X
uS19	B-X
has	B-X
an	B-X
extra-ribosomal	B-X
function	B-X
concerned	B-X
with	B-X
its	B-X
direct	B-X
involvement	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
an	B-X
important	B-X
tumor	B-X
suppressor	B-X
p53	B-X
in	B-X
the	B-X
Mdm2/Mdmx-p53	B-X
pathway	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
RPS15	B-X
gene	B-X
encoding	B-X
rp	B-X
uS19	B-X
are	B-X
linked	B-X
to	B-X
diseases	B-X
(	B-X
Diamond	B-X
Blackfan	B-X
anemia	B-X
,	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
and	B-X
Parkinson	B-X
's	B-X
disease	B-X
)	B-X
caused	B-X
either	B-X
by	B-X
defects	B-X
in	B-X
the	B-X
ribosome	B-X
biogenesis	B-X
or	B-X
disturbances	B-X
in	B-X
the	B-X
functioning	B-X
of	B-X
ribosomes	B-X
containing	B-X
mutant	B-X
rp	B-X
uS19	B-X
,	B-X
likely	B-X
due	B-X
to	B-X
the	B-X
changed	B-X
translational	B-X
fidelity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
currently	B-X
available	B-X
data	B-X
on	B-X
the	B-X
involvement	B-X
of	B-X
rp	B-X
uS19	B-X
in	B-X
the	B-X
operation	B-X
of	B-X
the	B-X
translational	B-X
machinery	B-X
and	B-X
in	B-X
the	B-X
maturation	B-X
of	B-X
40S	B-X
subunits	B-X
,	B-X
on	B-X
its	B-X
extra-ribosomal	B-X
function	B-X
,	B-X
and	B-X
on	B-X
relationships	B-X
between	B-X
mutations	B-X
in	B-X
the	B-X
RPS15	B-X
gene	B-X
and	B-X
certain	B-X
human	B-X
diseases	B-X
.	B-X

The	O
regulation	O
of	O
tumor	O
suppressor	O
p53	B-Protein
by	O
Mdm2	B-Protein
and	O
MdmX	B-Protein
in	O
response	O
to	O
DNA	O
damage	O
was	O
investigated	O
by	O
mathematical	O
modeling	O
of	O
a	O
simplified	O
network	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
protein	B-X
p53	B-X
is	B-X
regulated	B-X
by	B-X
two	B-X
structurally	B-X
homologous	B-X
proteins	B-X
,	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
Mdm2	B-X
,	B-X
MdmX	B-X
lacks	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X
Although	B-X
the	B-X
essential	B-X
interactions	B-X
of	B-X
MdmX	B-X
are	B-X
known	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
how	B-X
they	B-X
function	B-X
to	B-X
regulate	B-X
p53	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
p53	B-X
by	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
was	B-X
investigated	B-X
by	B-X
mathematical	B-X
modeling	B-X
of	B-X
a	B-X
simplified	B-X
network	B-X
.	B-X
The	B-X
simplified	B-X
network	B-X
model	B-X
was	B-X
derived	B-X
from	B-X
a	B-X
detailed	B-X
molecular	B-X
interaction	B-X
map	B-X
(	B-X
MIM	B-X
)	B-X
that	B-X
exhibited	B-X
four	B-X
coherent	B-X
DNA	B-X
damage	B-X
response	B-X
pathways	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
MdmX	B-X
may	B-X
amplify	B-X
or	B-X
stabilize	B-X
DNA	B-X
damage-induced	B-X
p53	B-X
responses	B-X
via	B-X
non-enzymatic	B-X
interactions	B-X
.	B-X
Transient	B-X
effects	B-X
of	B-X
MdmX	B-X
are	B-X
mediated	B-X
by	B-X
reservoirs	B-X
of	B-X
p53ratioMdmX	B-X
and	B-X
Mdm2ratioMdmX	B-X
heterodimers	B-X
,	B-X
with	B-X
MdmX	B-X
buffering	B-X
the	B-X
concentrations	B-X
of	B-X
p53	B-X
and/or	B-X
Mdm2	B-X
.	B-X
During	B-X
an	B-X
early	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
positively	B-X
or	B-X
negatively	B-X
regulated	B-X
p53	B-X
activity	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
level	B-X
of	B-X
Mdm2	B-X
;	B-X
this	B-X
led	B-X
to	B-X
amplification	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
switch-like	B-X
response	B-X
.	B-X
During	B-X
a	B-X
late	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
could	B-X
dampen	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
.	B-X
A	B-X
possible	B-X
role	B-X
of	B-X
MdmX	B-X
may	B-X
be	B-X
to	B-X
dampen	B-X
such	B-X
oscillations	B-X
that	B-X
otherwise	B-X
could	B-X
produce	B-X
erratic	B-X
cell	B-X
behavior	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
how	B-X
MdmX	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
response	B-X
of	B-X
p53	B-X
to	B-X
DNA	B-X
damage	B-X
either	B-X
by	B-X
increasing	B-X
dependency	B-X
of	B-X
p53	B-X
on	B-X
Mdm2	B-X
or	B-X
by	B-X
dampening	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
presents	B-X
a	B-X
model	B-X
for	B-X
experimental	B-X
investigation	B-X
.	B-X

The	O
simplified	O
network	O
model	O
was	O
derived	O
from	O
a	O
detailed	O
molecular	O
interaction	O
map	O
(	O
MIM	O
)	O
that	O
exhibited	O
four	O
coherent	O
DNA	O
damage	O
response	O
pathways	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
essential	B-X
interactions	B-X
of	B-X
MdmX	B-X
are	B-X
known	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
how	B-X
they	B-X
function	B-X
to	B-X
regulate	B-X
p53	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
p53	B-X
by	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
was	B-X
investigated	B-X
by	B-X
mathematical	B-X
modeling	B-X
of	B-X
a	B-X
simplified	B-X
network	B-X
.	B-X
The	B-X
simplified	B-X
network	B-X
model	B-X
was	B-X
derived	B-X
from	B-X
a	B-X
detailed	B-X
molecular	B-X
interaction	B-X
map	B-X
(	B-X
MIM	B-X
)	B-X
that	B-X
exhibited	B-X
four	B-X
coherent	B-X
DNA	B-X
damage	B-X
response	B-X
pathways	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
MdmX	B-X
may	B-X
amplify	B-X
or	B-X
stabilize	B-X
DNA	B-X
damage-induced	B-X
p53	B-X
responses	B-X
via	B-X
non-enzymatic	B-X
interactions	B-X
.	B-X
During	B-X
an	B-X
early	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
positively	B-X
or	B-X
negatively	B-X
regulated	B-X
p53	B-X
activity	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
level	B-X
of	B-X
Mdm2	B-X
;	B-X
this	B-X
led	B-X
to	B-X
amplification	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
switch-like	B-X
response	B-X
.	B-X
During	B-X
a	B-X
late	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
could	B-X
dampen	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
how	B-X
MdmX	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
response	B-X
of	B-X
p53	B-X
to	B-X
DNA	B-X
damage	B-X
either	B-X
by	B-X
increasing	B-X
dependency	B-X
of	B-X
p53	B-X
on	B-X
Mdm2	B-X
or	B-X
by	B-X
dampening	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
presents	B-X
a	B-X
model	B-X
for	B-X
experimental	B-X
investigation	B-X
.	B-X

The	O
results	O
suggest	O
that	O
MdmX	B-Protein
may	O
amplify	O
or	O
stabilize	O
DNA	O
damage	O
-	O
induced	O
p53	B-Protein
responses	O
via	O
non	O
-	O
enzymatic	O
interactions	O
.	O
<EOS>	B-X
MDM2	B-X
is	B-X
the	B-X
principal	B-X
antagonist	B-X
of	B-X
the	B-X
tumor	B-X
suppressor	B-X
p53	B-X
.	B-X
p53	B-X
binds	B-X
to	B-X
its	B-X
cognate	B-X
DNA	B-X
element	B-X
within	B-X
promoters	B-X
and	B-X
activates	B-X
the	B-X
transcription	B-X
of	B-X
adjacent	B-X
genes	B-X
.	B-X
Upon	B-X
induction	B-X
by	B-X
p53	B-X
,	B-X
the	B-X
MDM2	B-X
protein	B-X
binds	B-X
and	B-X
ubiquitinates	B-X
p53	B-X
,	B-X
triggering	B-X
its	B-X
proteasomal	B-X
degradation	B-X
and	B-X
providing	B-X
negative	B-X
feedback	B-X
.	B-X
This	B-X
raises	B-X
the	B-X
question	B-X
whether	B-X
MDM2	B-X
can	B-X
also	B-X
remove	B-X
p53	B-X
from	B-X
its	B-X
target	B-X
promoters	B-X
,	B-X
and	B-X
whether	B-X
this	B-X
also	B-X
involves	B-X
ubiquitination	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
,	B-X
we	B-X
employ	B-X
the	B-X
MDM2-targeted	B-X
small	B-X
molecule	B-X
Nutlin-3a	B-X
(	B-X
Nutlin	B-X
)	B-X
to	B-X
disrupt	B-X
the	B-X
interaction	B-X
of	B-X
MDM2	B-X
and	B-X
p53	B-X
in	B-X
three	B-X
different	B-X
cancer	B-X
cell	B-X
lines	B-X
:	B-X
SJSA-1	B-X
(	B-X
osteosarcoma	B-X
)	B-X
,	B-X
93T449	B-X
(	B-X
liposarcoma	B-X
;	B-X
both	B-X
carrying	B-X
amplified	B-X
MDM2	B-X
)	B-X
,	B-X
and	B-X
MCF7	B-X
(	B-X
breast	B-X
adenocarcinoma	B-X
)	B-X
.	B-X
Remarkably	B-X
,	B-X
removing	B-X
Nutlin	B-X
from	B-X
the	B-X
culture	B-X
medium	B-X
for	B-X
less	B-X
than	B-X
five	B-X
minutes	B-X
not	B-X
only	B-X
triggered	B-X
p53	B-X
ubiquitination	B-X
,	B-X
but	B-X
also	B-X
dissociated	B-X
most	B-X
p53	B-X
from	B-X
its	B-X
chromatin	B-X
binding	B-X
sites	B-X
,	B-X
as	B-X
revealed	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
.	B-X
This	B-X
also	B-X
resulted	B-X
in	B-X
reduced	B-X
p53-responsive	B-X
transcription	B-X
,	B-X
and	B-X
it	B-X
occurred	B-X
much	B-X
earlier	B-X
than	B-X
the	B-X
degradation	B-X
of	B-X
p53	B-X
by	B-X
the	B-X
proteasome	B-X
,	B-X
arguing	B-X
that	B-X
MDM2	B-X
removes	B-X
p53	B-X
from	B-X
promoters	B-X
prior	B-X
to	B-X
and	B-X
thus	B-X
independent	B-X
of	B-X
degradation	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
short-term	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
the	B-X
proteasome	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
removal	B-X
of	B-X
p53	B-X
from	B-X
promoters	B-X
by	B-X
Nutlin	B-X
washout	B-X
.	B-X
However	B-X
,	B-X
when	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
was	B-X
applied	B-X
for	B-X
several	B-X
hours	B-X
,	B-X
depleting	B-X
non-conjugated	B-X
ubiquitin	B-X
prior	B-X
to	B-X
eliminating	B-X
Nutlin	B-X
,	B-X
this	B-X
compromised	B-X
the	B-X
removal	B-X
of	B-X
DNA-bound	B-X
p53	B-X
,	B-X
as	B-X
did	B-X
an	B-X
E1	B-X
ubiquitin	B-X
ligase	B-X
inhibitor	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
the	B-X
ubiquitination	B-X
of	B-X
p53	B-X
by	B-X
MDM2	B-X
is	B-X
necessary	B-X
for	B-X
its	B-X
clearance	B-X
from	B-X
promoters	B-X
.	B-X
Depleting	B-X
the	B-X
MDM2	B-X
cofactor	B-X
MDM4	B-X
in	B-X
SJSA	B-X
cells	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
velocity	B-X
by	B-X
that	B-X
p53	B-X
was	B-X
removed	B-X
from	B-X
promoters	B-X
upon	B-X
Nutlin	B-X
washout	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
MDM2	B-X
antagonizes	B-X
p53	B-X
not	B-X
only	B-X
by	B-X
covering	B-X
its	B-X
transactivation	B-X
domain	B-X
and	B-X
by	B-X
destabilization	B-X
,	B-X
but	B-X
also	B-X
by	B-X
the	B-X
rapid	B-X
,	B-X
ubiquitin-dependent	B-X
termination	B-X
of	B-X
p53-chromatin	B-X
interactions	B-X
.	B-X

Transient	O
effects	O
of	O
MdmX	B-Protein
are	O
mediated	O
by	O
reservoirs	O
of	O
p53ratioMdmX	B-Protein
and	O
Mdm2ratioMdmX	B-Protein
heterodimers	O
,	O
with	O
MdmX	B-Protein
buffering	O
the	O
concentrations	O
of	O
p53	B-Protein
and	O
/	O
or	O
Mdm2	B-Protein
.	O
<EOS>	B-X
Mouse	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
tumor	B-X
suppressor	B-X
p53	B-X
,	B-X
playing	B-X
a	B-X
key	B-X
role	B-X
in	B-X
controlling	B-X
its	B-X
transcriptional	B-X
activity	B-X
,	B-X
protein	B-X
stability	B-X
,	B-X
and	B-X
nuclear	B-X
localization	B-X
.	B-X
MDM2	B-X
expression	B-X
is	B-X
up-regulated	B-X
in	B-X
numerous	B-X
cancers	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
loss	B-X
of	B-X
p53-dependent	B-X
activities	B-X
,	B-X
such	B-X
as	B-X
apoptosis	B-X
and	B-X
cell-cycle	B-X
arrest	B-X
.	B-X
The	B-X
p53	B-X
tumour-suppressor	B-X
protein	B-X
exerts	B-X
antiproliferative	B-X
effects	B-X
,	B-X
including	B-X
growth	B-X
arrest	B-X
and	B-X
apoptosis	B-X
,	B-X
in	B-X
response	B-X
to	B-X
various	B-X
types	B-X
of	B-X
stress	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
p53	B-X
is	B-X
abrogated	B-X
by	B-X
mutations	B-X
that	B-X
occur	B-X
frequently	B-X
in	B-X
tumours	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
several	B-X
viral	B-X
and	B-X
cellular	B-X
proteins	B-X
.	B-X
The	B-X
Mdm2	B-X
oncoprotein	B-X
is	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
p53	B-X
.	B-X
Mdm2	B-X
binds	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
p53	B-X
and	B-X
blocks	B-X
its	B-X
ability	B-X
to	B-X
regulate	B-X
target	B-X
genes	B-X
and	B-X
to	B-X
exert	B-X
antiproliferative	B-X
effects	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
p53	B-X
activates	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
mdm2	B-X
gene	B-X
in	B-X
an	B-X
autoregulatory	B-X
feedback	B-X
loop	B-X
.	B-X
The	B-X
interval	B-X
between	B-X
p53	B-X
activation	B-X
and	B-X
consequent	B-X
Mdm2	B-X
accumulation	B-X
defines	B-X
a	B-X
time	B-X
window	B-X
during	B-X
which	B-X
p53	B-X
exerts	B-X
its	B-X
effects	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
Mdm2	B-X
also	B-X
promotes	B-X
the	B-X
rapid	B-X
degradation	B-X
of	B-X
p53	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
p53	B-X
is	B-X
otherwise	B-X
stabilized	B-X
.	B-X
This	B-X
effect	B-X
of	B-X
Mdm2	B-X
requires	B-X
binding	B-X
of	B-X
p53	B-X
;	B-X
moreover	B-X
,	B-X
a	B-X
small	B-X
domain	B-X
of	B-X
p53	B-X
,	B-X
encompassing	B-X
the	B-X
Mdm2-binding	B-X
site	B-X
,	B-X
confers	B-X
Mdm2-dependent	B-X
detstabilization	B-X
upon	B-X
heterologous	B-X
proteins	B-X
.	B-X
Raised	B-X
amounts	B-X
of	B-X
Mdm2	B-X
strongly	B-X
repress	B-X
mutant	B-X
p53	B-X
accumulation	B-X
in	B-X
tumour-derived	B-X
cells	B-X
.	B-X
During	B-X
recovery	B-X
from	B-X
DNA	B-X
damage	B-X
,	B-X
maximal	B-X
Mdm2	B-X
induction	B-X
coincides	B-X
with	B-X
rapid	B-X
p53	B-X
loss	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
Mdm2-promoted	B-X
degradation	B-X
of	B-X
p53	B-X
provides	B-X
a	B-X
new	B-X
mechanism	B-X
to	B-X
ensure	B-X
effective	B-X
termination	B-X
of	B-X
the	B-X
p53	B-X
signal	B-X
.	B-X

A	O
survey	O
of	O
kinetic	O
parameter	O
space	O
disclosed	O
regions	O
of	O
switch	O
-	O
like	O
behavior	O
stemming	O
from	O
such	O
reservoir	O
-	O
based	O
transients	O
.	O
<EOS>	B-X
Transient	B-X
effects	B-X
of	B-X
MdmX	B-X
are	B-X
mediated	B-X
by	B-X
reservoirs	B-X
of	B-X
p53ratioMdmX	B-X
and	B-X
Mdm2ratioMdmX	B-X
heterodimers	B-X
,	B-X
with	B-X
MdmX	B-X
buffering	B-X
the	B-X
concentrations	B-X
of	B-X
p53	B-X
and/or	B-X
Mdm2	B-X
.	B-X
A	B-X
survey	B-X
of	B-X
kinetic	B-X
parameter	B-X
space	B-X
disclosed	B-X
regions	B-X
of	B-X
switch-like	B-X
behavior	B-X
stemming	B-X
from	B-X
such	B-X
reservoir-based	B-X
transients	B-X
.	B-X
During	B-X
an	B-X
early	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
positively	B-X
or	B-X
negatively	B-X
regulated	B-X
p53	B-X
activity	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
level	B-X
of	B-X
Mdm2	B-X
;	B-X
this	B-X
led	B-X
to	B-X
amplification	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
switch-like	B-X
response	B-X
.	B-X
A	B-X
possible	B-X
role	B-X
of	B-X
MdmX	B-X
may	B-X
be	B-X
to	B-X
dampen	B-X
such	B-X
oscillations	B-X
that	B-X
otherwise	B-X
could	B-X
produce	B-X
erratic	B-X
cell	B-X
behavior	B-X
.	B-X

During	O
an	O
early	O
response	O
to	O
DNA	O
damage	O
,	O
MdmX	B-Protein
positively	O
or	O
negatively	O
regulated	O
p53	B-Protein
activity	O
,	O
depending	O
on	O
the	O
level	O
of	O
Mdm2	B-Protein
;	O
this	O
led	O
to	O
amplification	O
of	O
p53	B-Protein
activity	O
and	O
switch	O
-	O
like	O
response	O
.	O
<EOS>	B-X
Plasminogen	B-X
activator	B-X
inhibitor-1	B-X
(	B-X
PAI-1	B-X
)	B-X
,	B-X
a	B-X
major	B-X
TGF-β1/p53	B-X
target	B-X
gene	B-X
and	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
plasmin-based	B-X
pericellular	B-X
proteolytic	B-X
cascade	B-X
,	B-X
is	B-X
elevated	B-X
in	B-X
arterial	B-X
plaques	B-X
,	B-X
vessel	B-X
fibrosis	B-X
,	B-X
arteriosclerosis	B-X
,	B-X
and	B-X
thrombosis	B-X
,	B-X
correlating	B-X
with	B-X
increased	B-X
tissue	B-X
TGF-β1	B-X
levels	B-X
.	B-X
Additionally	B-X
,	B-X
PAI-1	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
p53-dependent	B-X
replicative	B-X
senescence	B-X
.	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
preventing	B-X
tumor	B-X
formation	B-X
.	B-X
The	B-X
levels	B-X
and	B-X
activity	B-X
of	B-X
p53	B-X
is	B-X
under	B-X
tight	B-X
regulation	B-X
to	B-X
ensure	B-X
its	B-X
proper	B-X
function	B-X
.	B-X
Murine	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
MDM2	B-X
)	B-X
,	B-X
a	B-X
p53	B-X
target	B-X
gene	B-X
,	B-X
is	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
.	B-X
MDM2	B-X
is	B-X
a	B-X
key	B-X
negative	B-X
regulator	B-X
of	B-X
p53	B-X
protein	B-X
,	B-X
and	B-X
forms	B-X
an	B-X
auto-regulatory	B-X
feedback	B-X
loop	B-X
with	B-X
p53	B-X
.	B-X
MDM2	B-X
is	B-X
an	B-X
oncogene	B-X
with	B-X
both	B-X
p53-dependent	B-X
and	B-X
p53-independent	B-X
oncogenic	B-X
activities	B-X
,	B-X
and	B-X
often	B-X
has	B-X
increased	B-X
expression	B-X
levels	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
MDM2	B-X
is	B-X
highly	B-X
regulated	B-X
;	B-X
the	B-X
levels	B-X
and	B-X
function	B-X
of	B-X
MDM2	B-X
are	B-X
regulated	B-X
at	B-X
the	B-X
transcriptional	B-X
,	B-X
translational	B-X
and	B-X
post-translational	B-X
levels	B-X
.	B-X
Dysregulation	B-X
of	B-X
MDM2	B-X
impacts	B-X
significantly	B-X
upon	B-X
the	B-X
p53	B-X
functions	B-X
,	B-X
and	B-X
in	B-X
turn	B-X
the	B-X
tumorigenesis	B-X
.	B-X
Considering	B-X
the	B-X
key	B-X
role	B-X
that	B-X
MDM2	B-X
plays	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
MDM2	B-X
will	B-X
help	B-X
us	B-X
to	B-X
develop	B-X
novel	B-X
and	B-X
more	B-X
effective	B-X
cancer	B-X
therapeutic	B-X
strategies	B-X
to	B-X
target	B-X
MDM2	B-X
and	B-X
activate	B-X
p53	B-X
in	B-X
cells	B-X
.	B-X

During	O
a	O
late	O
response	O
to	O
DNA	O
damage	O
,	O
MdmX	B-Protein
could	O
dampen	O
oscillations	O
of	O
p53	B-Protein
activity	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
protein	B-X
p53	B-X
is	B-X
regulated	B-X
by	B-X
two	B-X
structurally	B-X
homologous	B-X
proteins	B-X
,	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
Mdm2	B-X
,	B-X
MdmX	B-X
lacks	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X
Although	B-X
the	B-X
essential	B-X
interactions	B-X
of	B-X
MdmX	B-X
are	B-X
known	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
how	B-X
they	B-X
function	B-X
to	B-X
regulate	B-X
p53	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
p53	B-X
by	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
was	B-X
investigated	B-X
by	B-X
mathematical	B-X
modeling	B-X
of	B-X
a	B-X
simplified	B-X
network	B-X
.	B-X
The	B-X
simplified	B-X
network	B-X
model	B-X
was	B-X
derived	B-X
from	B-X
a	B-X
detailed	B-X
molecular	B-X
interaction	B-X
map	B-X
(	B-X
MIM	B-X
)	B-X
that	B-X
exhibited	B-X
four	B-X
coherent	B-X
DNA	B-X
damage	B-X
response	B-X
pathways	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
MdmX	B-X
may	B-X
amplify	B-X
or	B-X
stabilize	B-X
DNA	B-X
damage-induced	B-X
p53	B-X
responses	B-X
via	B-X
non-enzymatic	B-X
interactions	B-X
.	B-X
Transient	B-X
effects	B-X
of	B-X
MdmX	B-X
are	B-X
mediated	B-X
by	B-X
reservoirs	B-X
of	B-X
p53ratioMdmX	B-X
and	B-X
Mdm2ratioMdmX	B-X
heterodimers	B-X
,	B-X
with	B-X
MdmX	B-X
buffering	B-X
the	B-X
concentrations	B-X
of	B-X
p53	B-X
and/or	B-X
Mdm2	B-X
.	B-X
During	B-X
an	B-X
early	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
positively	B-X
or	B-X
negatively	B-X
regulated	B-X
p53	B-X
activity	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
level	B-X
of	B-X
Mdm2	B-X
;	B-X
this	B-X
led	B-X
to	B-X
amplification	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
switch-like	B-X
response	B-X
.	B-X
During	B-X
a	B-X
late	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
could	B-X
dampen	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
.	B-X
A	B-X
possible	B-X
role	B-X
of	B-X
MdmX	B-X
may	B-X
be	B-X
to	B-X
dampen	B-X
such	B-X
oscillations	B-X
that	B-X
otherwise	B-X
could	B-X
produce	B-X
erratic	B-X
cell	B-X
behavior	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
how	B-X
MdmX	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
response	B-X
of	B-X
p53	B-X
to	B-X
DNA	B-X
damage	B-X
either	B-X
by	B-X
increasing	B-X
dependency	B-X
of	B-X
p53	B-X
on	B-X
Mdm2	B-X
or	B-X
by	B-X
dampening	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
presents	B-X
a	B-X
model	B-X
for	B-X
experimental	B-X
investigation	B-X
.	B-X

A	O
possible	O
role	O
of	O
MdmX	B-Protein
may	O
be	O
to	O
dampen	O
such	O
oscillations	O
that	O
otherwise	O
could	O
produce	O
erratic	O
cell	O
behavior	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
protein	B-X
p53	B-X
is	B-X
regulated	B-X
by	B-X
two	B-X
structurally	B-X
homologous	B-X
proteins	B-X
,	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
Mdm2	B-X
,	B-X
MdmX	B-X
lacks	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X
Although	B-X
the	B-X
essential	B-X
interactions	B-X
of	B-X
MdmX	B-X
are	B-X
known	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
how	B-X
they	B-X
function	B-X
to	B-X
regulate	B-X
p53	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
p53	B-X
by	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
was	B-X
investigated	B-X
by	B-X
mathematical	B-X
modeling	B-X
of	B-X
a	B-X
simplified	B-X
network	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
MdmX	B-X
may	B-X
amplify	B-X
or	B-X
stabilize	B-X
DNA	B-X
damage-induced	B-X
p53	B-X
responses	B-X
via	B-X
non-enzymatic	B-X
interactions	B-X
.	B-X
Transient	B-X
effects	B-X
of	B-X
MdmX	B-X
are	B-X
mediated	B-X
by	B-X
reservoirs	B-X
of	B-X
p53ratioMdmX	B-X
and	B-X
Mdm2ratioMdmX	B-X
heterodimers	B-X
,	B-X
with	B-X
MdmX	B-X
buffering	B-X
the	B-X
concentrations	B-X
of	B-X
p53	B-X
and/or	B-X
Mdm2	B-X
.	B-X
A	B-X
survey	B-X
of	B-X
kinetic	B-X
parameter	B-X
space	B-X
disclosed	B-X
regions	B-X
of	B-X
switch-like	B-X
behavior	B-X
stemming	B-X
from	B-X
such	B-X
reservoir-based	B-X
transients	B-X
.	B-X
During	B-X
an	B-X
early	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
positively	B-X
or	B-X
negatively	B-X
regulated	B-X
p53	B-X
activity	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
level	B-X
of	B-X
Mdm2	B-X
;	B-X
this	B-X
led	B-X
to	B-X
amplification	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
switch-like	B-X
response	B-X
.	B-X
During	B-X
a	B-X
late	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
MdmX	B-X
could	B-X
dampen	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
.	B-X
A	B-X
possible	B-X
role	B-X
of	B-X
MdmX	B-X
may	B-X
be	B-X
to	B-X
dampen	B-X
such	B-X
oscillations	B-X
that	B-X
otherwise	B-X
could	B-X
produce	B-X
erratic	B-X
cell	B-X
behavior	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
how	B-X
MdmX	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
response	B-X
of	B-X
p53	B-X
to	B-X
DNA	B-X
damage	B-X
either	B-X
by	B-X
increasing	B-X
dependency	B-X
of	B-X
p53	B-X
on	B-X
Mdm2	B-X
or	B-X
by	B-X
dampening	B-X
oscillations	B-X
of	B-X
p53	B-X
activity	B-X
and	B-X
presents	B-X
a	B-X
model	B-X
for	B-X
experimental	B-X
investigation	B-X
.	B-X

Our	O
study	O
suggests	O
how	O
MdmX	B-Protein
may	O
participate	O
in	O
the	O
response	O
of	O
p53	B-Protein
to	O
DNA	O
damage	O
either	O
by	O
increasing	O
dependency	O
of	O
p53	B-Protein
on	O
Mdm2	B-Protein
or	O
by	O
dampening	O
oscillations	O
of	O
p53	B-Protein
activity	O
and	O
presents	O
a	O
model	O
for	O
experimental	O
investigation	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
interfering	B-X
with	B-X
the	B-X
splicing	B-X
machinery	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
the	B-X
tumour-suppressor	B-X
p53	B-X
.	B-X
These	B-X
interventions	B-X
cause	B-X
:	B-X
the	B-X
accumulation	B-X
of	B-X
p53	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
p53	B-X
transcriptional	B-X
activity	B-X
and	B-X
can	B-X
result	B-X
in	B-X
p53-dependent	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
arrest	B-X
.	B-X
Mdm2	B-X
and	B-X
MdmX	B-X
are	B-X
two	B-X
key	B-X
repressors	B-X
of	B-X
p53	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
decrease	B-X
in	B-X
MdmX	B-X
protein	B-X
level	B-X
contributes	B-X
to	B-X
p53	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
targeting	B-X
the	B-X
spliceosome	B-X
.	B-X
Interfering	B-X
with	B-X
the	B-X
spliceosome	B-X
also	B-X
causes	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
degradation	B-X
of	B-X
Mdm2	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
that	B-X
p53	B-X
activation	B-X
could	B-X
participate	B-X
in	B-X
protection	B-X
against	B-X
potential	B-X
tumour-promoting	B-X
defects	B-X
in	B-X
the	B-X
spliceosome	B-X
.	B-X
A	B-X
number	B-X
of	B-X
known	B-X
p53-activating	B-X
agents	B-X
affect	B-X
the	B-X
splicing	B-X
machinery	B-X
and	B-X
this	B-X
could	B-X
contribute	B-X
to	B-X
their	B-X
ability	B-X
to	B-X
upregulate	B-X
p53	B-X
.	B-X
Activation	B-X
of	B-X
p53	B-X
could	B-X
influence	B-X
the	B-X
selective	B-X
anti-tumour	B-X
activity	B-X
of	B-X
this	B-X
therapeutic	B-X
approach	B-X
.	B-X

Glioma	B-Protein
pathogenesis	I-Protein
-	I-Protein
related	I-Protein
1	I-Protein
-	I-Protein
like	I-Protein
1	I-Protein
is	O
testis	O
enriched	O
,	O
dynamically	O
modified	O
,	O
and	O
redistributed	O
during	O
male	O
germ	O
cell	O
maturation	O
and	O
has	O
a	O
potential	O
role	O
in	O
sperm	O
-	O
oocyte	O
binding	O
.	O

The	O
glioma	B-Protein
pathogenesis	I-Protein
-	I-Protein
related	I-Protein
1	I-Protein
(	O
GLIPR1	B-Protein
)	O
family	O
consists	O
of	O
three	O
genes	O
[	O
GLIPR1	B-Protein
,	O
GLIPR1	B-Protein
-	I-Protein
like	I-Protein
1	I-Protein
(	O
GLIPR1L1	B-Protein
)	O
,	O
and	O
GLIPR1	B-Protein
-	I-Protein
like	I-Protein
2	I-Protein
(	O
GLIPR1L2	B-Protein
)	O
]	O
and	O
forms	O
a	O
distinct	O
subgroup	O
within	O
the	O
cysteine	O
-	O
rich	O
secretory	O
protein	O
(	O
CRISP	O
)	O
,	O
antigen	O
5	O
,	O
and	O
pathogenesis	O
-	O
related	O
1	O
(	O
CAP	O
)	O
superfamily	O
.	O
<EOS>	B-X
The	B-X
glioma	B-X
pathogenesis-related	B-X
1	B-X
(	B-X
GLIPR1	B-X
)	B-X
family	B-X
consists	B-X
of	B-X
three	B-X
genes	B-X
[	B-X
GLIPR1	B-X
,	B-X
GLIPR1-like	B-X
1	B-X
(	B-X
GLIPR1L1	B-X
)	B-X
,	B-X
and	B-X
GLIPR1-like	B-X
2	B-X
(	B-X
GLIPR1L2	B-X
)	B-X
]	B-X
and	B-X
forms	B-X
a	B-X
distinct	B-X
subgroup	B-X
within	B-X
the	B-X
cysteine-rich	B-X
secretory	B-X
protein	B-X
(	B-X
CRISP	B-X
)	B-X
,	B-X
antigen	B-X
5	B-X
,	B-X
and	B-X
pathogenesis-related	B-X
1	B-X
(	B-X
CAP	B-X
)	B-X
superfamily	B-X
.	B-X
CAP	B-X
superfamily	B-X
proteins	B-X
are	B-X
found	B-X
in	B-X
phyla	B-X
ranging	B-X
from	B-X
plants	B-X
to	B-X
humans	B-X
and	B-X
,	B-X
based	B-X
largely	B-X
on	B-X
expression	B-X
and	B-X
limited	B-X
functional	B-X
studies	B-X
,	B-X
are	B-X
hypothesized	B-X
to	B-X
have	B-X
roles	B-X
in	B-X
carcinogenesis	B-X
,	B-X
immunity	B-X
,	B-X
cell	B-X
adhesion	B-X
,	B-X
and	B-X
male	B-X
fertility	B-X
.	B-X
Specifically	B-X
data	B-X
from	B-X
a	B-X
number	B-X
of	B-X
systems	B-X
suggests	B-X
that	B-X
sequences	B-X
within	B-X
the	B-X
C-terminal	B-X
CAP	B-X
domain	B-X
of	B-X
CAP	B-X
proteins	B-X
have	B-X
the	B-X
ability	B-X
to	B-X
promote	B-X
cell-cell	B-X
adhesion	B-X
.	B-X
Herein	B-X
we	B-X
cloned	B-X
mouse	B-X
Glipr1l1	B-X
and	B-X
have	B-X
shown	B-X
it	B-X
has	B-X
a	B-X
testis-enriched	B-X
expression	B-X
profile	B-X
.	B-X
GLIPR1L1	B-X
is	B-X
posttranslationally	B-X
modified	B-X
by	B-X
N-linked	B-X
glycosylation	B-X
during	B-X
spermatogenesis	B-X
and	B-X
ultimately	B-X
becomes	B-X
localized	B-X
to	B-X
the	B-X
connecting	B-X
piece	B-X
of	B-X
elongated	B-X
spermatids	B-X
and	B-X
sperm	B-X
.	B-X
After	B-X
sperm	B-X
capacitation	B-X
,	B-X
however	B-X
,	B-X
GLIPR1L1	B-X
is	B-X
also	B-X
localized	B-X
to	B-X
the	B-X
anterior	B-X
regions	B-X
of	B-X
the	B-X
sperm	B-X
head	B-X
.	B-X
Zona	B-X
pellucida	B-X
binding	B-X
assays	B-X
indicate	B-X
that	B-X
GLIPR1L1	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
sperm	B-X
to	B-X
the	B-X
zona	B-X
pellucida	B-X
surrounding	B-X
the	B-X
oocyte	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
along	B-X
with	B-X
other	B-X
members	B-X
of	B-X
the	B-X
CAP	B-X
superfamily	B-X
and	B-X
several	B-X
other	B-X
proteins	B-X
,	B-X
GLIPR1L1	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
sperm	B-X
to	B-X
the	B-X
oocyte	B-X
complex	B-X
.	B-X
Collectively	B-X
these	B-X
data	B-X
further	B-X
strengthen	B-X
the	B-X
role	B-X
of	B-X
CAP	B-X
domain-containing	B-X
proteins	B-X
in	B-X
cellular	B-X
adhesion	B-X
and	B-X
propose	B-X
a	B-X
mechanism	B-X
whereby	B-X
CAP	B-X
proteins	B-X
show	B-X
overlapping	B-X
functional	B-X
significance	B-X
during	B-X
fertilization	B-X
.	B-X

CAP	O
superfamily	O
proteins	O
are	O
found	O
in	O
phyla	O
ranging	O
from	O
plants	O
to	O
humans	O
and	O
,	O
based	O
largely	O
on	O
expression	O
and	O
limited	O
functional	O
studies	O
,	O
are	O
hypothesized	O
to	O
have	O
roles	O
in	O
carcinogenesis	O
,	O
immunity	O
,	O
cell	O
adhesion	O
,	O
and	O
male	O
fertility	O
.	O
<EOS>	B-X
The	B-X
glioma	B-X
pathogenesis-related	B-X
1	B-X
(	B-X
GLIPR1	B-X
)	B-X
family	B-X
consists	B-X
of	B-X
three	B-X
genes	B-X
[	B-X
GLIPR1	B-X
,	B-X
GLIPR1-like	B-X
1	B-X
(	B-X
GLIPR1L1	B-X
)	B-X
,	B-X
and	B-X
GLIPR1-like	B-X
2	B-X
(	B-X
GLIPR1L2	B-X
)	B-X
]	B-X
and	B-X
forms	B-X
a	B-X
distinct	B-X
subgroup	B-X
within	B-X
the	B-X
cysteine-rich	B-X
secretory	B-X
protein	B-X
(	B-X
CRISP	B-X
)	B-X
,	B-X
antigen	B-X
5	B-X
,	B-X
and	B-X
pathogenesis-related	B-X
1	B-X
(	B-X
CAP	B-X
)	B-X
superfamily	B-X
.	B-X
CAP	B-X
superfamily	B-X
proteins	B-X
are	B-X
found	B-X
in	B-X
phyla	B-X
ranging	B-X
from	B-X
plants	B-X
to	B-X
humans	B-X
and	B-X
,	B-X
based	B-X
largely	B-X
on	B-X
expression	B-X
and	B-X
limited	B-X
functional	B-X
studies	B-X
,	B-X
are	B-X
hypothesized	B-X
to	B-X
have	B-X
roles	B-X
in	B-X
carcinogenesis	B-X
,	B-X
immunity	B-X
,	B-X
cell	B-X
adhesion	B-X
,	B-X
and	B-X
male	B-X
fertility	B-X
.	B-X
Specifically	B-X
data	B-X
from	B-X
a	B-X
number	B-X
of	B-X
systems	B-X
suggests	B-X
that	B-X
sequences	B-X
within	B-X
the	B-X
C-terminal	B-X
CAP	B-X
domain	B-X
of	B-X
CAP	B-X
proteins	B-X
have	B-X
the	B-X
ability	B-X
to	B-X
promote	B-X
cell-cell	B-X
adhesion	B-X
.	B-X
Herein	B-X
we	B-X
cloned	B-X
mouse	B-X
Glipr1l1	B-X
and	B-X
have	B-X
shown	B-X
it	B-X
has	B-X
a	B-X
testis-enriched	B-X
expression	B-X
profile	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
along	B-X
with	B-X
other	B-X
members	B-X
of	B-X
the	B-X
CAP	B-X
superfamily	B-X
and	B-X
several	B-X
other	B-X
proteins	B-X
,	B-X
GLIPR1L1	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
sperm	B-X
to	B-X
the	B-X
oocyte	B-X
complex	B-X
.	B-X
Collectively	B-X
these	B-X
data	B-X
further	B-X
strengthen	B-X
the	B-X
role	B-X
of	B-X
CAP	B-X
domain-containing	B-X
proteins	B-X
in	B-X
cellular	B-X
adhesion	B-X
and	B-X
propose	B-X
a	B-X
mechanism	B-X
whereby	B-X
CAP	B-X
proteins	B-X
show	B-X
overlapping	B-X
functional	B-X
significance	B-X
during	B-X
fertilization	B-X
.	B-X

Specifically	O
data	O
from	O
a	O
number	O
of	O
systems	O
suggests	O
that	O
sequences	O
within	O
the	O
C	O
-	O
terminal	O
CAP	O
domain	O
of	O
CAP	O
proteins	O
have	O
the	O
ability	O
to	O
promote	O
cell	O
-	O
cell	O
adhesion	O
.	O

Herein	O
we	O
cloned	O
mouse	O
Glipr1l1	B-Protein
and	O
have	O
shown	O
it	O
has	O
a	O
testis	O
-	O
enriched	O
expression	O
profile	O
.	O

GLIPR1L1	B-Protein
is	O
posttranslationally	O
modified	O
by	O
N	O
-	O
linked	O
glycosylation	O
during	O
spermatogenesis	O
and	O
ultimately	O
becomes	O
localized	O
to	O
the	O
connecting	O
piece	O
of	O
elongated	O
spermatids	O
and	O
sperm	O
.	O

After	O
sperm	O
capacitation	O
,	O
however	O
,	O
GLIPR1L1	B-Protein
is	O
also	O
localized	O
to	O
the	O
anterior	O
regions	O
of	O
the	O
sperm	O
head	O
.	O

Zona	O
pellucida	O
binding	O
assays	O
indicate	O
that	O
GLIPR1L1	B-Protein
has	O
a	O
role	O
in	O
the	O
binding	O
of	O
sperm	O
to	O
the	O
zona	O
pellucida	O
surrounding	O
the	O
oocyte	O
.	O

These	O
data	O
suggest	O
that	O
,	O
along	O
with	O
other	O
members	O
of	O
the	O
CAP	O
superfamily	O
and	O
several	O
other	O
proteins	O
,	O
GLIPR1L1	B-Protein
is	O
involved	O
in	O
the	O
binding	O
of	O
sperm	O
to	O
the	O
oocyte	O
complex	O
.	O

Collectively	O
these	O
data	O
further	O
strengthen	O
the	O
role	O
of	O
CAP	O
domain	O
-	O
containing	O
proteins	O
in	O
cellular	O
adhesion	O
and	O
propose	O
a	O
mechanism	O
whereby	O
CAP	O
proteins	O
show	O
overlapping	O
functional	O
significance	O
during	O
fertilization	O
.	O
<EOS>	B-X
The	B-X
glioma	B-X
pathogenesis-related	B-X
1	B-X
(	B-X
GLIPR1	B-X
)	B-X
family	B-X
consists	B-X
of	B-X
three	B-X
genes	B-X
[	B-X
GLIPR1	B-X
,	B-X
GLIPR1-like	B-X
1	B-X
(	B-X
GLIPR1L1	B-X
)	B-X
,	B-X
and	B-X
GLIPR1-like	B-X
2	B-X
(	B-X
GLIPR1L2	B-X
)	B-X
]	B-X
and	B-X
forms	B-X
a	B-X
distinct	B-X
subgroup	B-X
within	B-X
the	B-X
cysteine-rich	B-X
secretory	B-X
protein	B-X
(	B-X
CRISP	B-X
)	B-X
,	B-X
antigen	B-X
5	B-X
,	B-X
and	B-X
pathogenesis-related	B-X
1	B-X
(	B-X
CAP	B-X
)	B-X
superfamily	B-X
.	B-X
CAP	B-X
superfamily	B-X
proteins	B-X
are	B-X
found	B-X
in	B-X
phyla	B-X
ranging	B-X
from	B-X
plants	B-X
to	B-X
humans	B-X
and	B-X
,	B-X
based	B-X
largely	B-X
on	B-X
expression	B-X
and	B-X
limited	B-X
functional	B-X
studies	B-X
,	B-X
are	B-X
hypothesized	B-X
to	B-X
have	B-X
roles	B-X
in	B-X
carcinogenesis	B-X
,	B-X
immunity	B-X
,	B-X
cell	B-X
adhesion	B-X
,	B-X
and	B-X
male	B-X
fertility	B-X
.	B-X
Specifically	B-X
data	B-X
from	B-X
a	B-X
number	B-X
of	B-X
systems	B-X
suggests	B-X
that	B-X
sequences	B-X
within	B-X
the	B-X
C-terminal	B-X
CAP	B-X
domain	B-X
of	B-X
CAP	B-X
proteins	B-X
have	B-X
the	B-X
ability	B-X
to	B-X
promote	B-X
cell-cell	B-X
adhesion	B-X
.	B-X
Herein	B-X
we	B-X
cloned	B-X
mouse	B-X
Glipr1l1	B-X
and	B-X
have	B-X
shown	B-X
it	B-X
has	B-X
a	B-X
testis-enriched	B-X
expression	B-X
profile	B-X
.	B-X
Zona	B-X
pellucida	B-X
binding	B-X
assays	B-X
indicate	B-X
that	B-X
GLIPR1L1	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
sperm	B-X
to	B-X
the	B-X
zona	B-X
pellucida	B-X
surrounding	B-X
the	B-X
oocyte	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
along	B-X
with	B-X
other	B-X
members	B-X
of	B-X
the	B-X
CAP	B-X
superfamily	B-X
and	B-X
several	B-X
other	B-X
proteins	B-X
,	B-X
GLIPR1L1	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
sperm	B-X
to	B-X
the	B-X
oocyte	B-X
complex	B-X
.	B-X
Collectively	B-X
these	B-X
data	B-X
further	B-X
strengthen	B-X
the	B-X
role	B-X
of	B-X
CAP	B-X
domain-containing	B-X
proteins	B-X
in	B-X
cellular	B-X
adhesion	B-X
and	B-X
propose	B-X
a	B-X
mechanism	B-X
whereby	B-X
CAP	B-X
proteins	B-X
show	B-X
overlapping	B-X
functional	B-X
significance	B-X
during	B-X
fertilization	B-X
.	B-X

UTX	B-Protein
mediates	O
demethylation	O
of	O
H3K27me3	B-Protein
at	O
muscle	O
-	O
specific	O
genes	O
during	O
myogenesis	O
.	O
<EOS>	B-X
Polycomb	B-X
(	B-X
PcG	B-X
)	B-X
and	B-X
Trithorax	B-X
(	B-X
TrxG	B-X
)	B-X
group	B-X
proteins	B-X
act	B-X
antagonistically	B-X
to	B-X
establish	B-X
tissue-specific	B-X
patterns	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
PcG	B-X
protein	B-X
Ezh2	B-X
facilitates	B-X
repression	B-X
by	B-X
catalysing	B-X
histone	B-X
H3-Lys27	B-X
trimethylation	B-X
(	B-X
H3K27me3	B-X
)	B-X
.	B-X
For	B-X
expression	B-X
,	B-X
H3K27me3	B-X
marks	B-X
are	B-X
removed	B-X
and	B-X
replaced	B-X
by	B-X
TrxG	B-X
protein	B-X
catalysed	B-X
histone	B-X
H3-Lys4	B-X
trimethylation	B-X
(	B-X
H3K4me3	B-X
)	B-X
.	B-X
Although	B-X
H3K27	B-X
demethylases	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
these	B-X
enzymes	B-X
are	B-X
targeted	B-X
to	B-X
specific	B-X
genomic	B-X
regions	B-X
to	B-X
remove	B-X
H3K27me3	B-X
marks	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
two-step	B-X
mechanism	B-X
for	B-X
UTX-mediated	B-X
demethylation	B-X
at	B-X
muscle-specific	B-X
genes	B-X
during	B-X
myogenesis	B-X
.	B-X
Although	B-X
the	B-X
transactivator	B-X
Six4	B-X
initially	B-X
recruits	B-X
UTX	B-X
to	B-X
the	B-X
regulatory	B-X
region	B-X
of	B-X
muscle	B-X
genes	B-X
,	B-X
the	B-X
resulting	B-X
loss	B-X
of	B-X
H3K27me3	B-X
marks	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Removal	B-X
of	B-X
the	B-X
repressive	B-X
H3K27me3	B-X
mark	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
then	B-X
requires	B-X
RNA	B-X
Polymerase	B-X
II	B-X
(	B-X
Pol	B-X
II	B-X
)	B-X
elongation	B-X
.	B-X
Interestingly	B-X
,	B-X
blocking	B-X
Pol	B-X
II	B-X
elongation	B-X
on	B-X
transcribed	B-X
genes	B-X
leads	B-X
to	B-X
increased	B-X
H3K27me3	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
bivalent	B-X
(	B-X
H3K27me3/H3K4me3	B-X
)	B-X
chromatin	B-X
domains	B-X
.	B-X
Thus	B-X
,	B-X
removal	B-X
of	B-X
repressive	B-X
H3K27me3	B-X
marks	B-X
by	B-X
UTX	B-X
occurs	B-X
through	B-X
targeted	B-X
recruitment	B-X
followed	B-X
by	B-X
spreading	B-X
across	B-X
the	B-X
gene	B-X
.	B-X

Polycomb	O
(	O
PcG	O
)	O
and	O
Trithorax	O
(	O
TrxG	O
)	O
group	O
proteins	O
act	O
antagonistically	O
to	O
establish	O
tissue	O
-	O
specific	O
patterns	O
of	O
gene	O
expression	O
.	O
<EOS>	B-X
Polycomb	B-X
(	B-X
PcG	B-X
)	B-X
and	B-X
Trithorax	B-X
(	B-X
TrxG	B-X
)	B-X
group	B-X
proteins	B-X
act	B-X
antagonistically	B-X
to	B-X
establish	B-X
tissue-specific	B-X
patterns	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
PcG	B-X
protein	B-X
Ezh2	B-X
facilitates	B-X
repression	B-X
by	B-X
catalysing	B-X
histone	B-X
H3-Lys27	B-X
trimethylation	B-X
(	B-X
H3K27me3	B-X
)	B-X
.	B-X
For	B-X
expression	B-X
,	B-X
H3K27me3	B-X
marks	B-X
are	B-X
removed	B-X
and	B-X
replaced	B-X
by	B-X
TrxG	B-X
protein	B-X
catalysed	B-X
histone	B-X
H3-Lys4	B-X
trimethylation	B-X
(	B-X
H3K4me3	B-X
)	B-X
.	B-X
Although	B-X
H3K27	B-X
demethylases	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
these	B-X
enzymes	B-X
are	B-X
targeted	B-X
to	B-X
specific	B-X
genomic	B-X
regions	B-X
to	B-X
remove	B-X
H3K27me3	B-X
marks	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
two-step	B-X
mechanism	B-X
for	B-X
UTX-mediated	B-X
demethylation	B-X
at	B-X
muscle-specific	B-X
genes	B-X
during	B-X
myogenesis	B-X
.	B-X
Although	B-X
the	B-X
transactivator	B-X
Six4	B-X
initially	B-X
recruits	B-X
UTX	B-X
to	B-X
the	B-X
regulatory	B-X
region	B-X
of	B-X
muscle	B-X
genes	B-X
,	B-X
the	B-X
resulting	B-X
loss	B-X
of	B-X
H3K27me3	B-X
marks	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Interestingly	B-X
,	B-X
blocking	B-X
Pol	B-X
II	B-X
elongation	B-X
on	B-X
transcribed	B-X
genes	B-X
leads	B-X
to	B-X
increased	B-X
H3K27me3	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
bivalent	B-X
(	B-X
H3K27me3/H3K4me3	B-X
)	B-X
chromatin	B-X
domains	B-X
.	B-X
Thus	B-X
,	B-X
removal	B-X
of	B-X
repressive	B-X
H3K27me3	B-X
marks	B-X
by	B-X
UTX	B-X
occurs	B-X
through	B-X
targeted	B-X
recruitment	B-X
followed	B-X
by	B-X
spreading	B-X
across	B-X
the	B-X
gene	B-X
.	B-X

The	O
PcG	O
protein	O
Ezh2	B-Protein
facilitates	O
repression	O
by	O
catalysing	O
histone	B-Protein
H3	I-Protein
-	O
Lys27	O
trimethylation	O
(	O
H3K27me3	B-Protein
)	O
.	O
<EOS>	B-X
Polycomb	B-X
(	B-X
PcG	B-X
)	B-X
and	B-X
Trithorax	B-X
(	B-X
TrxG	B-X
)	B-X
group	B-X
proteins	B-X
act	B-X
antagonistically	B-X
to	B-X
establish	B-X
tissue-specific	B-X
patterns	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
PcG	B-X
protein	B-X
Ezh2	B-X
facilitates	B-X
repression	B-X
by	B-X
catalysing	B-X
histone	B-X
H3-Lys27	B-X
trimethylation	B-X
(	B-X
H3K27me3	B-X
)	B-X
.	B-X
For	B-X
expression	B-X
,	B-X
H3K27me3	B-X
marks	B-X
are	B-X
removed	B-X
and	B-X
replaced	B-X
by	B-X
TrxG	B-X
protein	B-X
catalysed	B-X
histone	B-X
H3-Lys4	B-X
trimethylation	B-X
(	B-X
H3K4me3	B-X
)	B-X
.	B-X
Although	B-X
H3K27	B-X
demethylases	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
these	B-X
enzymes	B-X
are	B-X
targeted	B-X
to	B-X
specific	B-X
genomic	B-X
regions	B-X
to	B-X
remove	B-X
H3K27me3	B-X
marks	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X
Although	B-X
the	B-X
transactivator	B-X
Six4	B-X
initially	B-X
recruits	B-X
UTX	B-X
to	B-X
the	B-X
regulatory	B-X
region	B-X
of	B-X
muscle	B-X
genes	B-X
,	B-X
the	B-X
resulting	B-X
loss	B-X
of	B-X
H3K27me3	B-X
marks	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Removal	B-X
of	B-X
the	B-X
repressive	B-X
H3K27me3	B-X
mark	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
then	B-X
requires	B-X
RNA	B-X
Polymerase	B-X
II	B-X
(	B-X
Pol	B-X
II	B-X
)	B-X
elongation	B-X
.	B-X
Interestingly	B-X
,	B-X
blocking	B-X
Pol	B-X
II	B-X
elongation	B-X
on	B-X
transcribed	B-X
genes	B-X
leads	B-X
to	B-X
increased	B-X
H3K27me3	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
bivalent	B-X
(	B-X
H3K27me3/H3K4me3	B-X
)	B-X
chromatin	B-X
domains	B-X
.	B-X
Thus	B-X
,	B-X
removal	B-X
of	B-X
repressive	B-X
H3K27me3	B-X
marks	B-X
by	B-X
UTX	B-X
occurs	B-X
through	B-X
targeted	B-X
recruitment	B-X
followed	B-X
by	B-X
spreading	B-X
across	B-X
the	B-X
gene	B-X
.	B-X

For	O
expression	O
,	O
H3K27me3	B-Protein
marks	O
are	O
removed	O
and	O
replaced	O
by	O
TrxG	O
protein	O
catalysed	O
histone	O
H3	B-Protein
-	O
Lys4	O
trimethylation	O
(	O
H3K4me3	B-Protein
)	O
.	O
<EOS>	B-X
Polycomb	B-X
(	B-X
PcG	B-X
)	B-X
and	B-X
Trithorax	B-X
(	B-X
TrxG	B-X
)	B-X
group	B-X
proteins	B-X
act	B-X
antagonistically	B-X
to	B-X
establish	B-X
tissue-specific	B-X
patterns	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
PcG	B-X
protein	B-X
Ezh2	B-X
facilitates	B-X
repression	B-X
by	B-X
catalysing	B-X
histone	B-X
H3-Lys27	B-X
trimethylation	B-X
(	B-X
H3K27me3	B-X
)	B-X
.	B-X
For	B-X
expression	B-X
,	B-X
H3K27me3	B-X
marks	B-X
are	B-X
removed	B-X
and	B-X
replaced	B-X
by	B-X
TrxG	B-X
protein	B-X
catalysed	B-X
histone	B-X
H3-Lys4	B-X
trimethylation	B-X
(	B-X
H3K4me3	B-X
)	B-X
.	B-X
Although	B-X
H3K27	B-X
demethylases	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
these	B-X
enzymes	B-X
are	B-X
targeted	B-X
to	B-X
specific	B-X
genomic	B-X
regions	B-X
to	B-X
remove	B-X
H3K27me3	B-X
marks	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X
Although	B-X
the	B-X
transactivator	B-X
Six4	B-X
initially	B-X
recruits	B-X
UTX	B-X
to	B-X
the	B-X
regulatory	B-X
region	B-X
of	B-X
muscle	B-X
genes	B-X
,	B-X
the	B-X
resulting	B-X
loss	B-X
of	B-X
H3K27me3	B-X
marks	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Removal	B-X
of	B-X
the	B-X
repressive	B-X
H3K27me3	B-X
mark	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
then	B-X
requires	B-X
RNA	B-X
Polymerase	B-X
II	B-X
(	B-X
Pol	B-X
II	B-X
)	B-X
elongation	B-X
.	B-X
Interestingly	B-X
,	B-X
blocking	B-X
Pol	B-X
II	B-X
elongation	B-X
on	B-X
transcribed	B-X
genes	B-X
leads	B-X
to	B-X
increased	B-X
H3K27me3	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
bivalent	B-X
(	B-X
H3K27me3/H3K4me3	B-X
)	B-X
chromatin	B-X
domains	B-X
.	B-X
Thus	B-X
,	B-X
removal	B-X
of	B-X
repressive	B-X
H3K27me3	B-X
marks	B-X
by	B-X
UTX	B-X
occurs	B-X
through	B-X
targeted	B-X
recruitment	B-X
followed	B-X
by	B-X
spreading	B-X
across	B-X
the	B-X
gene	B-X
.	B-X

Although	O
H3K27	B-Protein
demethylases	O
have	O
been	O
identified	O
,	O
the	O
mechanism	O
by	O
which	O
these	O
enzymes	O
are	O
targeted	O
to	O
specific	O
genomic	O
regions	O
to	O
remove	O
H3K27me3	B-Protein
marks	O
has	O
not	O
been	O
established	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
two	O
-	O
step	O
mechanism	O
for	O
UTX	B-Protein
-	O
mediated	O
demethylation	O
at	O
muscle	O
-	O
specific	O
genes	O
during	O
myogenesis	O
.	O
<EOS>	B-X
Polycomb	B-X
(	B-X
PcG	B-X
)	B-X
and	B-X
Trithorax	B-X
(	B-X
TrxG	B-X
)	B-X
group	B-X
proteins	B-X
act	B-X
antagonistically	B-X
to	B-X
establish	B-X
tissue-specific	B-X
patterns	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
Although	B-X
H3K27	B-X
demethylases	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
these	B-X
enzymes	B-X
are	B-X
targeted	B-X
to	B-X
specific	B-X
genomic	B-X
regions	B-X
to	B-X
remove	B-X
H3K27me3	B-X
marks	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
two-step	B-X
mechanism	B-X
for	B-X
UTX-mediated	B-X
demethylation	B-X
at	B-X
muscle-specific	B-X
genes	B-X
during	B-X
myogenesis	B-X
.	B-X
Although	B-X
the	B-X
transactivator	B-X
Six4	B-X
initially	B-X
recruits	B-X
UTX	B-X
to	B-X
the	B-X
regulatory	B-X
region	B-X
of	B-X
muscle	B-X
genes	B-X
,	B-X
the	B-X
resulting	B-X
loss	B-X
of	B-X
H3K27me3	B-X
marks	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Interestingly	B-X
,	B-X
blocking	B-X
Pol	B-X
II	B-X
elongation	B-X
on	B-X
transcribed	B-X
genes	B-X
leads	B-X
to	B-X
increased	B-X
H3K27me3	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
bivalent	B-X
(	B-X
H3K27me3/H3K4me3	B-X
)	B-X
chromatin	B-X
domains	B-X
.	B-X
Thus	B-X
,	B-X
removal	B-X
of	B-X
repressive	B-X
H3K27me3	B-X
marks	B-X
by	B-X
UTX	B-X
occurs	B-X
through	B-X
targeted	B-X
recruitment	B-X
followed	B-X
by	B-X
spreading	B-X
across	B-X
the	B-X
gene	B-X
.	B-X

Although	O
the	O
transactivator	O
Six4	B-Protein
initially	O
recruits	O
UTX	B-Protein
to	O
the	O
regulatory	O
region	O
of	O
muscle	O
genes	O
,	O
the	O
resulting	O
loss	O
of	O
H3K27me3	B-Protein
marks	O
is	O
limited	O
to	O
the	O
region	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

Removal	O
of	O
the	O
repressive	O
H3K27me3	B-Protein
mark	O
within	O
the	O
coding	O
region	O
then	O
requires	O
RNA	O
Polymerase	O
II	O
(	O
Pol	O
II	O
)	O
elongation	O
.	O
<EOS>	B-X
Polycomb	B-X
(	B-X
PcG	B-X
)	B-X
and	B-X
Trithorax	B-X
(	B-X
TrxG	B-X
)	B-X
group	B-X
proteins	B-X
act	B-X
antagonistically	B-X
to	B-X
establish	B-X
tissue-specific	B-X
patterns	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
PcG	B-X
protein	B-X
Ezh2	B-X
facilitates	B-X
repression	B-X
by	B-X
catalysing	B-X
histone	B-X
H3-Lys27	B-X
trimethylation	B-X
(	B-X
H3K27me3	B-X
)	B-X
.	B-X
For	B-X
expression	B-X
,	B-X
H3K27me3	B-X
marks	B-X
are	B-X
removed	B-X
and	B-X
replaced	B-X
by	B-X
TrxG	B-X
protein	B-X
catalysed	B-X
histone	B-X
H3-Lys4	B-X
trimethylation	B-X
(	B-X
H3K4me3	B-X
)	B-X
.	B-X
Although	B-X
H3K27	B-X
demethylases	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
these	B-X
enzymes	B-X
are	B-X
targeted	B-X
to	B-X
specific	B-X
genomic	B-X
regions	B-X
to	B-X
remove	B-X
H3K27me3	B-X
marks	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X
Although	B-X
the	B-X
transactivator	B-X
Six4	B-X
initially	B-X
recruits	B-X
UTX	B-X
to	B-X
the	B-X
regulatory	B-X
region	B-X
of	B-X
muscle	B-X
genes	B-X
,	B-X
the	B-X
resulting	B-X
loss	B-X
of	B-X
H3K27me3	B-X
marks	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Removal	B-X
of	B-X
the	B-X
repressive	B-X
H3K27me3	B-X
mark	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
then	B-X
requires	B-X
RNA	B-X
Polymerase	B-X
II	B-X
(	B-X
Pol	B-X
II	B-X
)	B-X
elongation	B-X
.	B-X
Interestingly	B-X
,	B-X
blocking	B-X
Pol	B-X
II	B-X
elongation	B-X
on	B-X
transcribed	B-X
genes	B-X
leads	B-X
to	B-X
increased	B-X
H3K27me3	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
bivalent	B-X
(	B-X
H3K27me3/H3K4me3	B-X
)	B-X
chromatin	B-X
domains	B-X
.	B-X
Thus	B-X
,	B-X
removal	B-X
of	B-X
repressive	B-X
H3K27me3	B-X
marks	B-X
by	B-X
UTX	B-X
occurs	B-X
through	B-X
targeted	B-X
recruitment	B-X
followed	B-X
by	B-X
spreading	B-X
across	B-X
the	B-X
gene	B-X
.	B-X

Interestingly	O
,	O
blocking	O
Pol	O
II	O
elongation	O
on	O
transcribed	O
genes	O
leads	O
to	O
increased	O
H3K27me3	B-Protein
within	O
the	O
coding	O
region	O
,	O
and	O
formation	O
of	O
bivalent	O
(	O
H3K27me3	B-Protein
/	O
H3K4me3	B-Protein
)	O
chromatin	O
domains	O
.	O
<EOS>	B-X
Polycomb	B-X
(	B-X
PcG	B-X
)	B-X
and	B-X
Trithorax	B-X
(	B-X
TrxG	B-X
)	B-X
group	B-X
proteins	B-X
act	B-X
antagonistically	B-X
to	B-X
establish	B-X
tissue-specific	B-X
patterns	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
PcG	B-X
protein	B-X
Ezh2	B-X
facilitates	B-X
repression	B-X
by	B-X
catalysing	B-X
histone	B-X
H3-Lys27	B-X
trimethylation	B-X
(	B-X
H3K27me3	B-X
)	B-X
.	B-X
For	B-X
expression	B-X
,	B-X
H3K27me3	B-X
marks	B-X
are	B-X
removed	B-X
and	B-X
replaced	B-X
by	B-X
TrxG	B-X
protein	B-X
catalysed	B-X
histone	B-X
H3-Lys4	B-X
trimethylation	B-X
(	B-X
H3K4me3	B-X
)	B-X
.	B-X
Although	B-X
H3K27	B-X
demethylases	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
these	B-X
enzymes	B-X
are	B-X
targeted	B-X
to	B-X
specific	B-X
genomic	B-X
regions	B-X
to	B-X
remove	B-X
H3K27me3	B-X
marks	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
two-step	B-X
mechanism	B-X
for	B-X
UTX-mediated	B-X
demethylation	B-X
at	B-X
muscle-specific	B-X
genes	B-X
during	B-X
myogenesis	B-X
.	B-X
Although	B-X
the	B-X
transactivator	B-X
Six4	B-X
initially	B-X
recruits	B-X
UTX	B-X
to	B-X
the	B-X
regulatory	B-X
region	B-X
of	B-X
muscle	B-X
genes	B-X
,	B-X
the	B-X
resulting	B-X
loss	B-X
of	B-X
H3K27me3	B-X
marks	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Removal	B-X
of	B-X
the	B-X
repressive	B-X
H3K27me3	B-X
mark	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
then	B-X
requires	B-X
RNA	B-X
Polymerase	B-X
II	B-X
(	B-X
Pol	B-X
II	B-X
)	B-X
elongation	B-X
.	B-X
Interestingly	B-X
,	B-X
blocking	B-X
Pol	B-X
II	B-X
elongation	B-X
on	B-X
transcribed	B-X
genes	B-X
leads	B-X
to	B-X
increased	B-X
H3K27me3	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
bivalent	B-X
(	B-X
H3K27me3/H3K4me3	B-X
)	B-X
chromatin	B-X
domains	B-X
.	B-X
Thus	B-X
,	B-X
removal	B-X
of	B-X
repressive	B-X
H3K27me3	B-X
marks	B-X
by	B-X
UTX	B-X
occurs	B-X
through	B-X
targeted	B-X
recruitment	B-X
followed	B-X
by	B-X
spreading	B-X
across	B-X
the	B-X
gene	B-X
.	B-X

Thus	O
,	O
removal	O
of	O
repressive	O
H3K27me3	B-Protein
marks	O
by	O
UTX	B-Protein
occurs	O
through	O
targeted	O
recruitment	O
followed	O
by	O
spreading	O
across	O
the	O
gene	O
.	O
<EOS>	B-X
Polycomb	B-X
(	B-X
PcG	B-X
)	B-X
and	B-X
Trithorax	B-X
(	B-X
TrxG	B-X
)	B-X
group	B-X
proteins	B-X
act	B-X
antagonistically	B-X
to	B-X
establish	B-X
tissue-specific	B-X
patterns	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
PcG	B-X
protein	B-X
Ezh2	B-X
facilitates	B-X
repression	B-X
by	B-X
catalysing	B-X
histone	B-X
H3-Lys27	B-X
trimethylation	B-X
(	B-X
H3K27me3	B-X
)	B-X
.	B-X
For	B-X
expression	B-X
,	B-X
H3K27me3	B-X
marks	B-X
are	B-X
removed	B-X
and	B-X
replaced	B-X
by	B-X
TrxG	B-X
protein	B-X
catalysed	B-X
histone	B-X
H3-Lys4	B-X
trimethylation	B-X
(	B-X
H3K4me3	B-X
)	B-X
.	B-X
Although	B-X
H3K27	B-X
demethylases	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
these	B-X
enzymes	B-X
are	B-X
targeted	B-X
to	B-X
specific	B-X
genomic	B-X
regions	B-X
to	B-X
remove	B-X
H3K27me3	B-X
marks	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
two-step	B-X
mechanism	B-X
for	B-X
UTX-mediated	B-X
demethylation	B-X
at	B-X
muscle-specific	B-X
genes	B-X
during	B-X
myogenesis	B-X
.	B-X
Although	B-X
the	B-X
transactivator	B-X
Six4	B-X
initially	B-X
recruits	B-X
UTX	B-X
to	B-X
the	B-X
regulatory	B-X
region	B-X
of	B-X
muscle	B-X
genes	B-X
,	B-X
the	B-X
resulting	B-X
loss	B-X
of	B-X
H3K27me3	B-X
marks	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Removal	B-X
of	B-X
the	B-X
repressive	B-X
H3K27me3	B-X
mark	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
then	B-X
requires	B-X
RNA	B-X
Polymerase	B-X
II	B-X
(	B-X
Pol	B-X
II	B-X
)	B-X
elongation	B-X
.	B-X
Interestingly	B-X
,	B-X
blocking	B-X
Pol	B-X
II	B-X
elongation	B-X
on	B-X
transcribed	B-X
genes	B-X
leads	B-X
to	B-X
increased	B-X
H3K27me3	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
bivalent	B-X
(	B-X
H3K27me3/H3K4me3	B-X
)	B-X
chromatin	B-X
domains	B-X
.	B-X
Thus	B-X
,	B-X
removal	B-X
of	B-X
repressive	B-X
H3K27me3	B-X
marks	B-X
by	B-X
UTX	B-X
occurs	B-X
through	B-X
targeted	B-X
recruitment	B-X
followed	B-X
by	B-X
spreading	B-X
across	B-X
the	B-X
gene	B-X
.	B-X

Protein	O
-	O
protein	O
interactions	O
involving	O
IKKgamma	B-Protein
(	O
NEMO	B-Protein
)	O
that	O
promote	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
Inhibitor	B-X
of	B-X
kappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
gamma	B-X
(	B-X
IKKgamma	B-X
)	B-X
,	B-X
also	B-X
referred	B-X
to	B-X
as	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
essential	B-X
modulator	B-X
(	B-X
NEMO	B-X
)	B-X
,	B-X
is	B-X
an	B-X
important	B-X
regulatory	B-X
component	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
.	B-X
The	B-X
IKK	B-X
complex	B-X
is	B-X
a	B-X
signalosome	B-X
that	B-X
catalyzes	B-X
the	B-X
inducible	B-X
phosphorylation	B-X
of	B-X
IkappaB	B-X
proteins	B-X
,	B-X
which	B-X
is	B-X
a	B-X
key	B-X
step	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
exact	B-X
functions	B-X
of	B-X
IKKgamma	B-X
(	B-X
NEMO	B-X
)	B-X
as	B-X
part	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
This	B-X
mini-review	B-X
covers	B-X
16	B-X
proteins	B-X
that	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
bind	B-X
to	B-X
IKKgamma	B-X
and	B-X
lead	B-X
to	B-X
the	B-X
enhancement	B-X
of	B-X
the	B-X
activities	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
,	B-X
thus	B-X
resulting	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
The	B-X
major	B-X
mechanisms	B-X
by	B-X
which	B-X
these	B-X
interactions	B-X
are	B-X
mediated	B-X
involve	B-X
the	B-X
recognition	B-X
of	B-X
ubiquitinated	B-X
upstream	B-X
signaling	B-X
components	B-X
by	B-X
IKKgamma	B-X
or	B-X
the	B-X
modification	B-X
of	B-X
IKKgamma	B-X
itself	B-X
by	B-X
ubiquitination	B-X
.	B-X
Additional	B-X
mechanisms	B-X
include	B-X
the	B-X
sumoylation	B-X
or	B-X
phosphorylation	B-X
of	B-X
IKKgamma	B-X
and	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
tertiary	B-X
or	B-X
quaternary	B-X
structure	B-X
of	B-X
IKKgamma	B-X
.	B-X

Inhibitor	B-Protein
of	I-Protein
kappaB	I-Protein
kinase	I-Protein
(	I-Protein
IKK	I-Protein
)	I-Protein
gamma	I-Protein
(	O
IKKgamma	B-Protein
)	O
,	O
also	O
referred	O
to	O
as	O
nuclear	B-Protein
factor	I-Protein
kappaB	I-Protein
(	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
)	I-Protein
essential	I-Protein
modulator	I-Protein
(	O
NEMO	B-Protein
)	O
,	O
is	O
an	O
important	O
regulatory	O
component	O
of	O
the	O
IKK	O
complex	O
.	O

The	O
IKK	O
complex	O
is	O
a	O
signalosome	O
that	O
catalyzes	O
the	O
inducible	O
phosphorylation	O
of	O
IkappaB	O
proteins	O
,	O
which	O
is	O
a	O
key	O
step	O
that	O
leads	O
to	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
exact	O
functions	O
of	O
IKKgamma	B-Protein
(	O
NEMO	B-Protein
)	O
as	O
part	O
of	O
the	O
IKK	O
complex	O
have	O
not	O
yet	O
been	O
fully	O
elucidated	O
.	O
<EOS>	B-X
Inhibitor	B-X
of	B-X
kappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
gamma	B-X
(	B-X
IKKgamma	B-X
)	B-X
,	B-X
also	B-X
referred	B-X
to	B-X
as	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
essential	B-X
modulator	B-X
(	B-X
NEMO	B-X
)	B-X
,	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
.	B-X
Following	B-X
the	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
NF-kappaB-inducing	B-X
stimuli	B-X
,	B-X
the	B-X
IKK	B-X
complex	B-X
catalyzes	B-X
the	B-X
phosphorylation	B-X
of	B-X
inhibitor	B-X
of	B-X
kappaB	B-X
(	B-X
IkappaB	B-X
)	B-X
proteins	B-X
,	B-X
which	B-X
is	B-X
a	B-X
critical	B-X
step	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
via	B-X
the	B-X
canonical	B-X
pathway	B-X
.	B-X
The	B-X
exact	B-X
functions	B-X
of	B-X
IKKgamma	B-X
as	B-X
part	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
have	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
A	B-X
number	B-X
of	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
directly	B-X
interacting	B-X
with	B-X
IKKgamma	B-X
and	B-X
modulating	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
.	B-X
This	B-X
mini	B-X
review	B-X
covers	B-X
eight	B-X
proteins	B-X
that	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
bind	B-X
to	B-X
IKKgamma	B-X
and	B-X
lead	B-X
to	B-X
the	B-X
suppression	B-X
of	B-X
the	B-X
activities	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
and	B-X
hence	B-X
result	B-X
in	B-X
the	B-X
down-regulation	B-X
of	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
reported	B-X
mechanisms	B-X
by	B-X
which	B-X
these	B-X
interactions	B-X
suppress	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
include	B-X
the	B-X
deubiquitination	B-X
of	B-X
IKKgamma	B-X
and	B-X
competition	B-X
with	B-X
upstream	B-X
activators	B-X
for	B-X
binding	B-X
to	B-X
IKKgamma	B-X
.	B-X

This	O
mini	O
-	O
review	O
covers	O
16	O
proteins	O
that	O
have	O
been	O
reported	O
to	O
bind	O
to	O
IKKgamma	B-Protein
and	O
lead	O
to	O
the	O
enhancement	O
of	O
the	O
activities	O
of	O
the	O
IKK	O
complex	O
,	O
thus	O
resulting	O
in	O
NF	O
-	O
kappaB	O
activation	O
.	O

The	O
major	O
mechanisms	O
by	O
which	O
these	O
interactions	O
are	O
mediated	O
involve	O
the	O
recognition	O
of	O
ubiquitinated	O
upstream	O
signaling	O
components	O
by	O
IKKgamma	B-Protein
or	O
the	O
modification	O
of	O
IKKgamma	B-Protein
itself	O
by	O
ubiquitination	O
.	O
<EOS>	B-X
NF-κB	B-X
signaling	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
tumor	B-X
growth	B-X
and	B-X
treatment	B-X
resistance	B-X
in	B-X
GBM	B-X
as	B-X
in	B-X
many	B-X
other	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
high	B-X
,	B-X
constitutive	B-X
NF-κB	B-X
activity	B-X
in	B-X
GBM	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
Co-immunoprecipitations	B-X
demonstrated	B-X
that	B-X
TRIM22	B-X
bound	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
NF-κB	B-X
,	B-X
NF-κB	B-X
inhibitor	B-X
alpha	B-X
(	B-X
IκBα	B-X
)	B-X
,	B-X
and	B-X
accelerated	B-X
its	B-X
degradation	B-X
by	B-X
inducing	B-X
K48-linked	B-X
ubiquitination	B-X
.	B-X
TRIM22	B-X
also	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
NF-κB	B-X
upstream	B-X
regulator	B-X
IKKγ	B-X
and	B-X
promoted	B-X
K63-linked	B-X
ubiquitination	B-X
,	B-X
which	B-X
led	B-X
to	B-X
the	B-X
phosphorylation	B-X
of	B-X
both	B-X
IKKα/β	B-X
and	B-X
IκBα	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
study	B-X
revealed	B-X
that	B-X
TRIM22	B-X
activated	B-X
NF-κB	B-X
signaling	B-X
through	B-X
posttranslational	B-X
modification	B-X
of	B-X
two	B-X
critical	B-X
regulators	B-X
of	B-X
NF-κB	B-X
signaling	B-X
in	B-X
GBM	B-X
cells	B-X
.	B-X

Additional	O
mechanisms	O
include	O
the	O
sumoylation	O
or	O
phosphorylation	O
of	O
IKKgamma	B-Protein
and	O
the	O
modification	O
of	O
the	O
tertiary	O
or	O
quaternary	O
structure	O
of	O
IKKgamma	B-Protein
.	O
<EOS>	B-X
This	B-X
initial	B-X
description	B-X
of	B-X
the	B-X
JAK-STAT	B-X
pathway	B-X
led	B-X
quickly	B-X
to	B-X
additional	B-X
discoveries	B-X
that	B-X
type	B-X
II	B-X
interferons	B-X
and	B-X
many	B-X
other	B-X
cytokines	B-X
signal	B-X
through	B-X
similar	B-X
mechanisms	B-X
.	B-X
We	B-X
also	B-X
review	B-X
recent	B-X
work	B-X
on	B-X
the	B-X
STAT	B-X
proteins	B-X
showing	B-X
the	B-X
importance	B-X
of	B-X
several	B-X
different	B-X
posttranslational	B-X
modifications	B-X
,	B-X
including	B-X
serine	B-X
phosphorylation	B-X
,	B-X
acetylation	B-X
,	B-X
methylation	B-X
,	B-X
and	B-X
sumoylation	B-X
.	B-X
The	B-X
Expression	B-X
and	B-X
Prognostic	B-X
Value	B-X
of	B-X
SUMO1-Activating	B-X
Enzyme	B-X
Subunit	B-X
1	B-X
and	B-X
Its	B-X
Potential	B-X
Mechanism	B-X
in	B-X
Triple-Negative	B-X
Breast	B-X
Cancer	B-X
.	B-X
In	B-X
response	B-X
to	B-X
the	B-X
pathogens	B-X
,	B-X
the	B-X
host	B-X
immune	B-X
system	B-X
mounts	B-X
orchestrated	B-X
defense	B-X
responses	B-X
initiating	B-X
various	B-X
mechanisms	B-X
both	B-X
at	B-X
the	B-X
cellular	B-X
and	B-X
molecular	B-X
levels	B-X
,	B-X
including	B-X
multiple	B-X
post-translational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
leading	B-X
to	B-X
the	B-X
initiation	B-X
of	B-X
signaling	B-X
pathways	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
discuss	B-X
in	B-X
detail	B-X
the	B-X
regulation	B-X
exerted	B-X
by	B-X
covalent	B-X
SUMO	B-X
modifications	B-X
of	B-X
target	B-X
proteins	B-X
,	B-X
and	B-X
SIM	B-X
mediated	B-X
non-covalent	B-X
interactions	B-X
with	B-X
several	B-X
effector	B-X
proteins	B-X
.	B-X

Extended	O
ischemia	O
prevents	O
HIF1alpha	B-Protein
degradation	O
at	O
reoxygenation	O
by	O
impairing	O
prolyl	O
-	O
hydroxylation	O
:	O
role	O
of	O
Krebs	O
cycle	O
metabolites	O
.	O
<EOS>	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
Brain	B-X
ischemia	B-X
limits	B-X
the	B-X
availability	B-X
not	B-X
only	B-X
of	B-X
oxygen	B-X
but	B-X
also	B-X
of	B-X
glucose	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
fumarate	B-X
and	B-X
succinate	B-X
are	B-X
known	B-X
inhibitors	B-X
of	B-X
PHD	B-X
,	B-X
while	B-X
alpha-ketoglutarate	B-X
is	B-X
a	B-X
co-substrate	B-X
of	B-X
the	B-X
reaction	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
heterodimeric	O
transcription	O
factor	O
that	O
activates	O
the	O
cellular	O
response	O
to	O
hypoxia	O
.	O
<EOS>	B-X
Hypoxia	B-X
inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
protein	B-X
,	B-X
part	B-X
of	B-X
the	B-X
basic	B-X
helix-loop-helix	B-X
family	B-X
and	B-X
one	B-X
of	B-X
the	B-X
main	B-X
regulators	B-X
of	B-X
cellular	B-X
responses	B-X
in	B-X
a	B-X
low‑oxygen	B-X
environment	B-X
.	B-X
It	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
atherosclerosis	B-X
through	B-X
cell-specific	B-X
responses	B-X
,	B-X
acting	B-X
on	B-X
endothelial	B-X
cells	B-X
,	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
SMCs	B-X
)	B-X
and	B-X
macrophages	B-X
.	B-X
Through	B-X
the	B-X
upregulation	B-X
of	B-X
VEGF	B-X
,	B-X
NO	B-X
,	B-X
ROS	B-X
and	B-X
PDGF	B-X
,	B-X
HIF-1	B-X
is	B-X
able	B-X
to	B-X
cause	B-X
endothelial	B-X
cell	B-X
dysfunction	B-X
,	B-X
proliferation	B-X
,	B-X
angiogenesis	B-X
and	B-X
inflammation	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
NF-kB	B-X
pathway	B-X
in	B-X
endothelial	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
contributor	B-X
to	B-X
inflammation	B-X
and	B-X
positively	B-X
feedbacks	B-X
to	B-X
HIF-1	B-X
.	B-X
HIF-1	B-X
also	B-X
plays	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
both	B-X
the	B-X
proliferation	B-X
and	B-X
migration	B-X
of	B-X
smooth	B-X
muscle	B-X
cells	B-X
-	B-X
two	B-X
important	B-X
features	B-X
of	B-X
atherosclerosis	B-X
,	B-X
while	B-X
the	B-X
formation	B-X
of	B-X
foam	B-X
cells	B-X
(	B-X
lipid-laden	B-X
macrophages	B-X
)	B-X
is	B-X
also	B-X
a	B-X
critical	B-X
step	B-X
in	B-X
atherosclerosis	B-X
and	B-X
mediated	B-X
by	B-X
HIF-1	B-X
through	B-X
various	B-X
mechanisms	B-X
such	B-X
as	B-X
dysfunctional	B-X
efflux	B-X
pathways	B-X
in	B-X
macrophages	B-X
.	B-X
Overall	B-X
,	B-X
HIF-1	B-X
exerts	B-X
its	B-X
effect	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
atherosclerosis	B-X
via	B-X
a	B-X
variety	B-X
of	B-X
molecular	B-X
and	B-X
cellular	B-X
events	B-X
in	B-X
the	B-X
process	B-X
.	B-X
In	B-X
this	B-X
review	B-X
article	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
effects	B-X
HIF-1	B-X
on	B-X
vascular	B-X
cells	B-X
and	B-X
macrophages	B-X
in	B-X
the	B-X
development	B-X
of	B-X
atherosclerosis	B-X
,	B-X
highlighting	B-X
the	B-X
environmental	B-X
cues	B-X
and	B-X
signalling	B-X
pathways	B-X
that	B-X
control	B-X
HIF-1	B-X
expression/activation	B-X
within	B-X
the	B-X
vasculature	B-X
.	B-X
We	B-X
will	B-X
highlight	B-X
the	B-X
potential	B-X
of	B-X
HIF-1	B-X
as	B-X
a	B-X
therapeutic	B-X
target	B-X
on	B-X
the	B-X
disease	B-X
development	B-X
.	B-X

The	O
HIF1alpha	B-Protein
subunit	O
is	O
constantly	O
synthesized	O
and	O
degraded	O
under	O
normoxia	O
,	O
but	O
degradation	O
is	O
rapidly	O
inhibited	O
when	O
oxygen	O
levels	O
drop	O
.	O
<EOS>	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
Brain	B-X
ischemia	B-X
limits	B-X
the	B-X
availability	B-X
not	B-X
only	B-X
of	B-X
oxygen	B-X
but	B-X
also	B-X
of	B-X
glucose	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

Oxygen	O
-	O
dependent	O
hydroxylation	O
by	O
prolyl	O
-	O
4	O
-	O
hydroxylases	O
(	O
PHD	O
)	O
mediates	O
HIF1alpha	B-Protein
proteasome	O
degradation	O
.	O
<EOS>	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
fumarate	B-X
and	B-X
succinate	B-X
are	B-X
known	B-X
inhibitors	B-X
of	B-X
PHD	B-X
,	B-X
while	B-X
alpha-ketoglutarate	B-X
is	B-X
a	B-X
co-substrate	B-X
of	B-X
the	B-X
reaction	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

Brain	O
ischemia	O
limits	O
the	O
availability	O
not	O
only	O
of	O
oxygen	O
but	O
also	O
of	O
glucose	O
.	O
<EOS>	B-X
The	B-X
evaluation	B-X
of	B-X
the	B-X
severity	B-X
of	B-X
ischemia/hypoxia	B-X
after	B-X
birth	B-X
is	B-X
crucial	B-X
to	B-X
the	B-X
choice	B-X
of	B-X
treatment	B-X
,	B-X
and	B-X
with	B-X
accurate	B-X
long-term	B-X
prognosis	B-X
,	B-X
appropriate	B-X
further	B-X
patient	B-X
care	B-X
can	B-X
be	B-X
planned	B-X
.	B-X
New	B-X
methods	B-X
are	B-X
also	B-X
noted	B-X
,	B-X
which	B-X
are	B-X
at	B-X
the	B-X
stage	B-X
of	B-X
clinical	B-X
trials	B-X
.	B-X
The	B-X
availability	B-X
of	B-X
fast	B-X
,	B-X
relatively	B-X
inexpensive	B-X
CT	B-X
imaging	B-X
has	B-X
fundamentally	B-X
changed	B-X
the	B-X
clinician	B-X
's	B-X
ability	B-X
to	B-X
noninvasively	B-X
visualize	B-X
neuroanatomy	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
authors	B-X
review	B-X
emerging	B-X
advanced	B-X
imaging	B-X
for	B-X
evaluation	B-X
of	B-X
both	B-X
acute	B-X
and	B-X
chronic	B-X
TBI	B-X
and	B-X
include	B-X
QuickBrain	B-X
MRI	B-X
as	B-X
an	B-X
initial	B-X
imaging	B-X
modality	B-X
.	B-X

We	O
hypothesized	O
that	O
this	O
circumstance	O
could	O
have	O
a	O
modulating	O
effect	O
on	O
HIF	O
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
is	B-X
a	B-X
heterodimeric	B-X
transcription	B-X
factor	B-X
that	B-X
activates	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
hypoxia	B-X
.	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
this	B-X
circumstance	B-X
could	B-X
have	B-X
a	B-X
modulating	B-X
effect	B-X
on	B-X
HIF	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

We	O
assessed	O
the	O
separate	O
involvement	O
of	O
oxygen	O
and	O
glucose	O
in	O
HIF1alpha	B-Protein
regulation	O
in	O
differentiated	O
neuroblastoma	O
cells	O
subjected	O
to	O
ischemia	O
.	O
<EOS>	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
Brain	B-X
ischemia	B-X
limits	B-X
the	B-X
availability	B-X
not	B-X
only	B-X
of	B-X
oxygen	B-X
but	B-X
also	B-X
of	B-X
glucose	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

We	O
report	O
higher	O
transcriptional	O
activity	O
and	O
HIF1alpha	B-Protein
expression	O
under	O
oxygen	O
deprivation	O
in	O
the	O
presence	O
of	O
glucose	O
(	O
OD	O
)	O
,	O
than	O
in	O
its	O
absence	O
(	O
oxygen	O
and	O
glucose	O
deprivation	O
,	O
OGD	O
)	O
.	O
<EOS>	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
Brain	B-X
ischemia	B-X
limits	B-X
the	B-X
availability	B-X
not	B-X
only	B-X
of	B-X
oxygen	B-X
but	B-X
also	B-X
of	B-X
glucose	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

Unexpectedly	O
,	O
HIF1alpha	B-Protein
was	O
not	O
degraded	O
at	O
reoxygenation	O
after	O
an	O
episode	O
of	O
OGD	O
.	O
<EOS>	B-X
Unexpectedly	B-X
,	B-X
combinatorial	B-X
loss	B-X
of	B-X
both	B-X
myeloid	B-X
HIF-1α	B-X
and	B-X
HIF-2α	B-X
was	B-X
catastrophic	B-X
and	B-X
led	B-X
to	B-X
macrophage	B-X
necroptosis	B-X
,	B-X
impaired	B-X
fibrogenesis	B-X
,	B-X
and	B-X
cardiac	B-X
rupture	B-X
.	B-X
Unexpectedly	B-X
,	B-X
the	B-X
responsible	B-X
mutation	B-X
(	B-X
s	B-X
)	B-X
reducing	B-X
red	B-X
blood	B-X
cell	B-X
production	B-X
do	B-X
not	B-X
involve	B-X
either	B-X
the	B-X
gene	B-X
encoding	B-X
the	B-X
blood	B-X
hormone	B-X
erythropoietin	B-X
(	B-X
Epo	B-X
)	B-X
,	B-X
or	B-X
the	B-X
corresponding	B-X
regulatory	B-X
sequences	B-X
flanking	B-X
the	B-X
Epo	B-X
gene	B-X
.	B-X
Unexpectedly	B-X
,	B-X
reticulocytes	B-X
from	B-X
hypoxic	B-X
mice	B-X
show	B-X
decreased	B-X
levels	B-X
of	B-X
the	B-X
hypoxia-inducible	B-X
factor	B-X
HIF-1α	B-X
and	B-X
decreased	B-X
activity	B-X
of	B-X
the	B-X
BCL2/adenovirus	B-X
E1B	B-X
19	B-X
kDa	B-X
protein-interacting	B-X
protein	B-X
3	B-X
(	B-X
BNIP3	B-X
)	B-X
,	B-X
which	B-X
results	B-X
in	B-X
elevated	B-X
mitochondrial	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
``	B-X
cardiac-specific	B-X
''	B-X
MYBPC3	B-X
gene	B-X
was	B-X
actually	B-X
expressed	B-X
in	B-X
cardiac	B-X
fibroblasts	B-X
from	B-X
different	B-X
species	B-X
as	B-X
well	B-X
as	B-X
NIH3T3	B-X
fibroblasts	B-X
at	B-X
the	B-X
transcription	B-X
and	B-X
protein	B-X
levels	B-X
.	B-X

This	O
was	O
not	O
due	O
to	O
impairment	O
of	O
proteasome	O
function	O
,	O
but	O
was	O
associated	O
with	O
lower	O
HIF1alpha	B-Protein
hydroxylation	O
.	O

Krebs	O
cycle	O
metabolites	O
fumarate	O
and	O
succinate	O
are	O
known	O
inhibitors	O
of	O
PHD	O
,	O
while	O
alpha	O
-	O
ketoglutarate	O
is	O
a	O
co	O
-	O
substrate	O
of	O
the	O
reaction	O
.	O
<EOS>	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
Brain	B-X
ischemia	B-X
limits	B-X
the	B-X
availability	B-X
not	B-X
only	B-X
of	B-X
oxygen	B-X
but	B-X
also	B-X
of	B-X
glucose	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
this	B-X
circumstance	B-X
could	B-X
have	B-X
a	B-X
modulating	B-X
effect	B-X
on	B-X
HIF	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
fumarate	B-X
and	B-X
succinate	B-X
are	B-X
known	B-X
inhibitors	B-X
of	B-X
PHD	B-X
,	B-X
while	B-X
alpha-ketoglutarate	B-X
is	B-X
a	B-X
co-substrate	B-X
of	B-X
the	B-X
reaction	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

Lack	O
of	O
HIF1alpha	B-Protein
degradation	O
in	O
the	O
presence	O
of	O
oxygen	O
was	O
accompanied	O
by	O
a	O
very	O
low	O
alpha	O
-	O
ketoglutarate	O
/	O
fumarate	O
ratio	O
.	O
<EOS>	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
Brain	B-X
ischemia	B-X
limits	B-X
the	B-X
availability	B-X
not	B-X
only	B-X
of	B-X
oxygen	B-X
but	B-X
also	B-X
of	B-X
glucose	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
fumarate	B-X
and	B-X
succinate	B-X
are	B-X
known	B-X
inhibitors	B-X
of	B-X
PHD	B-X
,	B-X
while	B-X
alpha-ketoglutarate	B-X
is	B-X
a	B-X
co-substrate	B-X
of	B-X
the	B-X
reaction	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

Furthermore	O
,	O
treatment	O
with	O
a	O
fumarate	O
analogue	O
prevented	O
HIF1alpha	O
degradation	O
under	O
normoxia	O
.	O
<EOS>	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
fumarate	B-X
and	B-X
succinate	B-X
are	B-X
known	B-X
inhibitors	B-X
of	B-X
PHD	B-X
,	B-X
while	B-X
alpha-ketoglutarate	B-X
is	B-X
a	B-X
co-substrate	B-X
of	B-X
the	B-X
reaction	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

In	O
all	O
,	O
our	O
data	O
suggest	O
that	O
postischemic	O
metabolic	O
alterations	O
in	O
Krebs	O
cycle	O
metabolites	O
impair	O
HIF1alpha	O
degradation	O
in	O
the	O
presence	O
of	O
oxygen	O
by	O
decreasing	O
its	O
hydroxylation	O
,	O
and	O
highlight	O
the	O
involvement	O
of	O
metabolic	O
pathways	O
in	O
HIF1alpha	B-Protein
regulation	O
besides	O
the	O
well	O
known	O
effects	O
of	O
oxygen	O
.	O
<EOS>	B-X
The	B-X
HIF1alpha	B-X
subunit	B-X
is	B-X
constantly	B-X
synthesized	B-X
and	B-X
degraded	B-X
under	B-X
normoxia	B-X
,	B-X
but	B-X
degradation	B-X
is	B-X
rapidly	B-X
inhibited	B-X
when	B-X
oxygen	B-X
levels	B-X
drop	B-X
.	B-X
Oxygen-dependent	B-X
hydroxylation	B-X
by	B-X
prolyl-4-hydroxylases	B-X
(	B-X
PHD	B-X
)	B-X
mediates	B-X
HIF1alpha	B-X
proteasome	B-X
degradation	B-X
.	B-X
Brain	B-X
ischemia	B-X
limits	B-X
the	B-X
availability	B-X
not	B-X
only	B-X
of	B-X
oxygen	B-X
but	B-X
also	B-X
of	B-X
glucose	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
separate	B-X
involvement	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
in	B-X
differentiated	B-X
neuroblastoma	B-X
cells	B-X
subjected	B-X
to	B-X
ischemia	B-X
.	B-X
We	B-X
report	B-X
higher	B-X
transcriptional	B-X
activity	B-X
and	B-X
HIF1alpha	B-X
expression	B-X
under	B-X
oxygen	B-X
deprivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
(	B-X
OD	B-X
)	B-X
,	B-X
than	B-X
in	B-X
its	B-X
absence	B-X
(	B-X
oxygen	B-X
and	B-X
glucose	B-X
deprivation	B-X
,	B-X
OGD	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
HIF1alpha	B-X
was	B-X
not	B-X
degraded	B-X
at	B-X
reoxygenation	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
OGD	B-X
.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
proteasome	B-X
function	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
lower	B-X
HIF1alpha	B-X
hydroxylation	B-X
.	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
fumarate	B-X
and	B-X
succinate	B-X
are	B-X
known	B-X
inhibitors	B-X
of	B-X
PHD	B-X
,	B-X
while	B-X
alpha-ketoglutarate	B-X
is	B-X
a	B-X
co-substrate	B-X
of	B-X
the	B-X
reaction	B-X
.	B-X
Lack	B-X
of	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
very	B-X
low	B-X
alpha-ketoglutarate/fumarate	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
a	B-X
fumarate	B-X
analogue	B-X
prevented	B-X
HIF1alpha	B-X
degradation	B-X
under	B-X
normoxia	B-X
.	B-X
In	B-X
all	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
postischemic	B-X
metabolic	B-X
alterations	B-X
in	B-X
Krebs	B-X
cycle	B-X
metabolites	B-X
impair	B-X
HIF1alpha	B-X
degradation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
by	B-X
decreasing	B-X
its	B-X
hydroxylation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
involvement	B-X
of	B-X
metabolic	B-X
pathways	B-X
in	B-X
HIF1alpha	B-X
regulation	B-X
besides	B-X
the	B-X
well	B-X
known	B-X
effects	B-X
of	B-X
oxygen	B-X
.	B-X

Regulated	O
degradation	O
of	O
spindle	O
assembly	O
factors	O
by	O
the	O
anaphase	O
-	O
promoting	O
complex	O
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
anaphase-promoting	B-X
complex	B-X
(	B-X
APC/C	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
cell	B-X
division	B-X
in	B-X
all	B-X
eukaryotes	B-X
.	B-X
Loss	B-X
of	B-X
APC/C	B-X
activity	B-X
arrests	B-X
cells	B-X
at	B-X
metaphase	B-X
and	B-X
results	B-X
in	B-X
severe	B-X
aberrations	B-X
of	B-X
the	B-X
mitotic	B-X
spindle	B-X
,	B-X
but	B-X
how	B-X
the	B-X
APC/C	B-X
regulates	B-X
spindle	B-X
formation	B-X
is	B-X
not	B-X
understood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
APC/C	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
four	B-X
proteins	B-X
required	B-X
for	B-X
Ran-dependent	B-X
spindle	B-X
assembly	B-X
:	B-X
Bard1	B-X
,	B-X
Hmmr	B-X
,	B-X
HURP	B-X
,	B-X
and	B-X
NuSAP	B-X
.	B-X
Among	B-X
these	B-X
substrates	B-X
,	B-X
HURP	B-X
and	B-X
NuSAP	B-X
can	B-X
be	B-X
degraded	B-X
during	B-X
spindle	B-X
formation	B-X
when	B-X
the	B-X
spindle	B-X
checkpoint	B-X
is	B-X
active	B-X
.	B-X
Their	B-X
degradation	B-X
requires	B-X
additional	B-X
layers	B-X
of	B-X
regulation	B-X
,	B-X
and	B-X
both	B-X
SAFs	B-X
are	B-X
only	B-X
degraded	B-X
after	B-X
being	B-X
released	B-X
from	B-X
their	B-X
inhibitor	B-X
importin	B-X
beta	B-X
by	B-X
Ran	B-X
(	B-X
GTP	B-X
)	B-X
.	B-X
Our	B-X
findings	B-X
reveal	B-X
a	B-X
tightly	B-X
regulated	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
APC/C	B-X
and	B-X
the	B-X
GTPase	B-X
Ran	B-X
control	B-X
the	B-X
abundance	B-X
of	B-X
active	B-X
spindle	B-X
assembly	B-X
factors	B-X
to	B-X
achieve	B-X
the	B-X
accurate	B-X
formation	B-X
of	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X

The	O
ubiquitin	B-Protein
ligase	O
anaphase	O
-	O
promoting	O
complex	O
(	O
APC	O
/	O
C	O
)	O
is	O
essential	O
for	O
cell	O
division	O
in	O
all	O
eukaryotes	O
.	O
<EOS>	B-X
The	B-X
Anaphase-Promoting	B-X
Complex/Cyclosome	B-X
(	B-X
APC/C	B-X
)	B-X
,	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
and	B-X
two	B-X
co-activators	B-X
,	B-X
Cdc20	B-X
and	B-X
Cdh1	B-X
,	B-X
enable	B-X
the	B-X
ubiquitin-dependent	B-X
proteasomal	B-X
degradation	B-X
of	B-X
various	B-X
critical	B-X
cell	B-X
cycle	B-X
regulators	B-X
and	B-X
govern	B-X
cell	B-X
division	B-X
in	B-X
a	B-X
timely	B-X
and	B-X
precise	B-X
manner	B-X
.	B-X
Dysregulated	B-X
cell	B-X
cycle	B-X
events	B-X
cause	B-X
uncontrolled	B-X
cell	B-X
proliferation	B-X
,	B-X
leading	B-X
to	B-X
tumorigenesis	B-X
.	B-X
Studies	B-X
have	B-X
shown	B-X
that	B-X
Cdh1	B-X
has	B-X
tumor	B-X
suppressive	B-X
activities	B-X
while	B-X
Cdc20	B-X
has	B-X
an	B-X
oncogenic	B-X
property	B-X
,	B-X
suggesting	B-X
that	B-X
Cdc20	B-X
is	B-X
an	B-X
emerging	B-X
therapeutic	B-X
target	B-X
for	B-X
cancer	B-X
treatment	B-X
.	B-X
Therefore	B-X
,	B-X
in	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discussed	B-X
recent	B-X
findings	B-X
about	B-X
the	B-X
essential	B-X
roles	B-X
of	B-X
APC/C-Cdc20	B-X
in	B-X
cell	B-X
cycle	B-X
regulation	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
briefly	B-X
summarized	B-X
that	B-X
the	B-X
regulation	B-X
of	B-X
Cdc20	B-X
expression	B-X
levels	B-X
is	B-X
strictly	B-X
controlled	B-X
to	B-X
order	B-X
cell	B-X
cycle	B-X
events	B-X
appropriately	B-X
.	B-X
Finally	B-X
,	B-X
given	B-X
the	B-X
function	B-X
of	B-X
Cdc20	B-X
as	B-X
an	B-X
oncogene	B-X
,	B-X
therapeutic	B-X
interventions	B-X
targeting	B-X
Cdc20	B-X
activity	B-X
may	B-X
be	B-X
beneficial	B-X
in	B-X
cancer	B-X
treatment	B-X
.	B-X

Loss	O
of	O
APC	O
/	O
C	O
activity	O
arrests	O
cells	O
at	O
metaphase	O
and	O
results	O
in	O
severe	O
aberrations	O
of	O
the	O
mitotic	O
spindle	O
,	O
but	O
how	O
the	O
APC	O
/	O
C	O
regulates	O
spindle	O
formation	O
is	O
not	O
understood	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
APC	O
/	O
C	O
promotes	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
four	O
proteins	O
required	O
for	O
Ran	B-Protein
-	O
dependent	O
spindle	O
assembly	O
:	O
Bard1	B-Protein
,	O
Hmmr	B-Protein
,	O
HURP	B-Protein
,	O
and	O
NuSAP	B-Protein
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
anaphase-promoting	B-X
complex	B-X
(	B-X
APC/C	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
cell	B-X
division	B-X
in	B-X
all	B-X
eukaryotes	B-X
.	B-X
Loss	B-X
of	B-X
APC/C	B-X
activity	B-X
arrests	B-X
cells	B-X
at	B-X
metaphase	B-X
and	B-X
results	B-X
in	B-X
severe	B-X
aberrations	B-X
of	B-X
the	B-X
mitotic	B-X
spindle	B-X
,	B-X
but	B-X
how	B-X
the	B-X
APC/C	B-X
regulates	B-X
spindle	B-X
formation	B-X
is	B-X
not	B-X
understood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
APC/C	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
four	B-X
proteins	B-X
required	B-X
for	B-X
Ran-dependent	B-X
spindle	B-X
assembly	B-X
:	B-X
Bard1	B-X
,	B-X
Hmmr	B-X
,	B-X
HURP	B-X
,	B-X
and	B-X
NuSAP	B-X
.	B-X
Among	B-X
these	B-X
substrates	B-X
,	B-X
HURP	B-X
and	B-X
NuSAP	B-X
can	B-X
be	B-X
degraded	B-X
during	B-X
spindle	B-X
formation	B-X
when	B-X
the	B-X
spindle	B-X
checkpoint	B-X
is	B-X
active	B-X
.	B-X
Their	B-X
degradation	B-X
requires	B-X
additional	B-X
layers	B-X
of	B-X
regulation	B-X
,	B-X
and	B-X
both	B-X
SAFs	B-X
are	B-X
only	B-X
degraded	B-X
after	B-X
being	B-X
released	B-X
from	B-X
their	B-X
inhibitor	B-X
importin	B-X
beta	B-X
by	B-X
Ran	B-X
(	B-X
GTP	B-X
)	B-X
.	B-X
Our	B-X
findings	B-X
reveal	B-X
a	B-X
tightly	B-X
regulated	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
APC/C	B-X
and	B-X
the	B-X
GTPase	B-X
Ran	B-X
control	B-X
the	B-X
abundance	B-X
of	B-X
active	B-X
spindle	B-X
assembly	B-X
factors	B-X
to	B-X
achieve	B-X
the	B-X
accurate	B-X
formation	B-X
of	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X

Among	O
these	O
substrates	O
,	O
HURP	B-Protein
and	O
NuSAP	B-Protein
can	O
be	O
degraded	O
during	O
spindle	O
formation	O
when	O
the	O
spindle	O
checkpoint	O
is	O
active	O
.	O
<EOS>	B-X
Loss	B-X
of	B-X
APC/C	B-X
activity	B-X
arrests	B-X
cells	B-X
at	B-X
metaphase	B-X
and	B-X
results	B-X
in	B-X
severe	B-X
aberrations	B-X
of	B-X
the	B-X
mitotic	B-X
spindle	B-X
,	B-X
but	B-X
how	B-X
the	B-X
APC/C	B-X
regulates	B-X
spindle	B-X
formation	B-X
is	B-X
not	B-X
understood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
APC/C	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
four	B-X
proteins	B-X
required	B-X
for	B-X
Ran-dependent	B-X
spindle	B-X
assembly	B-X
:	B-X
Bard1	B-X
,	B-X
Hmmr	B-X
,	B-X
HURP	B-X
,	B-X
and	B-X
NuSAP	B-X
.	B-X
Among	B-X
these	B-X
substrates	B-X
,	B-X
HURP	B-X
and	B-X
NuSAP	B-X
can	B-X
be	B-X
degraded	B-X
during	B-X
spindle	B-X
formation	B-X
when	B-X
the	B-X
spindle	B-X
checkpoint	B-X
is	B-X
active	B-X
.	B-X
Their	B-X
degradation	B-X
requires	B-X
additional	B-X
layers	B-X
of	B-X
regulation	B-X
,	B-X
and	B-X
both	B-X
SAFs	B-X
are	B-X
only	B-X
degraded	B-X
after	B-X
being	B-X
released	B-X
from	B-X
their	B-X
inhibitor	B-X
importin	B-X
beta	B-X
by	B-X
Ran	B-X
(	B-X
GTP	B-X
)	B-X
.	B-X
Our	B-X
findings	B-X
reveal	B-X
a	B-X
tightly	B-X
regulated	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
APC/C	B-X
and	B-X
the	B-X
GTPase	B-X
Ran	B-X
control	B-X
the	B-X
abundance	B-X
of	B-X
active	B-X
spindle	B-X
assembly	B-X
factors	B-X
to	B-X
achieve	B-X
the	B-X
accurate	B-X
formation	B-X
of	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X

Their	O
degradation	O
requires	O
additional	O
layers	O
of	O
regulation	O
,	O
and	O
both	O
SAFs	O
are	O
only	O
degraded	O
after	O
being	O
released	O
from	O
their	O
inhibitor	O
importin	O
beta	O
by	O
Ran	B-Protein
(	O
GTP	O
)	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
APC/C	B-X
promotes	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
four	B-X
proteins	B-X
required	B-X
for	B-X
Ran-dependent	B-X
spindle	B-X
assembly	B-X
:	B-X
Bard1	B-X
,	B-X
Hmmr	B-X
,	B-X
HURP	B-X
,	B-X
and	B-X
NuSAP	B-X
.	B-X
Among	B-X
these	B-X
substrates	B-X
,	B-X
HURP	B-X
and	B-X
NuSAP	B-X
can	B-X
be	B-X
degraded	B-X
during	B-X
spindle	B-X
formation	B-X
when	B-X
the	B-X
spindle	B-X
checkpoint	B-X
is	B-X
active	B-X
.	B-X
Their	B-X
degradation	B-X
requires	B-X
additional	B-X
layers	B-X
of	B-X
regulation	B-X
,	B-X
and	B-X
both	B-X
SAFs	B-X
are	B-X
only	B-X
degraded	B-X
after	B-X
being	B-X
released	B-X
from	B-X
their	B-X
inhibitor	B-X
importin	B-X
beta	B-X
by	B-X
Ran	B-X
(	B-X
GTP	B-X
)	B-X
.	B-X
Our	B-X
findings	B-X
reveal	B-X
a	B-X
tightly	B-X
regulated	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
APC/C	B-X
and	B-X
the	B-X
GTPase	B-X
Ran	B-X
control	B-X
the	B-X
abundance	B-X
of	B-X
active	B-X
spindle	B-X
assembly	B-X
factors	B-X
to	B-X
achieve	B-X
the	B-X
accurate	B-X
formation	B-X
of	B-X
the	B-X
mitotic	B-X
spindle	B-X
.	B-X

Our	O
findings	O
reveal	O
a	O
tightly	O
regulated	O
mechanism	O
by	O
which	O
the	O
APC	O
/	O
C	O
and	O
the	O
GTPase	O
Ran	B-Protein
control	O
the	O
abundance	O
of	O
active	O
spindle	O
assembly	O
factors	O
to	O
achieve	O
the	O
accurate	O
formation	O
of	O
the	O
mitotic	O
spindle	O
.	O

A	O
novel	O
antioxidant	O
role	O
for	O
hemoglobin	O
.	O
<EOS>	B-X
Ferrylhemoglobin	B-X
(	B-X
X-FeIV-OH	B-X
,	B-X
where	B-X
X	B-X
denotes	B-X
an	B-X
amino	B-X
acid	B-X
residue	B-X
in	B-X
the	B-X
globin	B-X
moiety	B-X
)	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
as	B-X
a	B-X
cytotoxic	B-X
agent	B-X
produced	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
oxyhemoglobin	B-X
(	B-X
X-FeIIO2	B-X
)	B-X
or	B-X
methemoglobin	B-X
(	B-X
X-FeIII	B-X
)	B-X
with	B-X
H2O2	B-X
in	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
Oxyhemoglobin	B-X
exposed	B-X
to	B-X
a	B-X
continuous	B-X
flux	B-X
of	B-X
H2O2	B-X
(	B-X
generated	B-X
at	B-X
a	B-X
rate	B-X
of	B-X
120	B-X
microM/min	B-X
during	B-X
the	B-X
glucose	B-X
oxidase-catalyzed	B-X
oxidation	B-X
of	B-X
glucose	B-X
)	B-X
was	B-X
oxidized	B-X
to	B-X
(	B-X
a	B-X
)	B-X
X-FeIV-OH	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
less	B-X
than	B-X
75	B-X
microM	B-X
and	B-X
(	B-X
b	B-X
)	B-X
X-FeIII	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
greater	B-X
than	B-X
75	B-X
microM	B-X
(	B-X
the	B-X
production	B-X
of	B-X
X-FeIII	B-X
proceeded	B-X
with	B-X
intermediate	B-X
formation	B-X
of	B-X
X-FeIV-OH	B-X
)	B-X
.	B-X
The	B-X
efficient	B-X
sequestration	B-X
of	B-X
hemoglobin	B-X
by	B-X
the	B-X
red	B-X
blood	B-X
cell	B-X
membrane	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
multiple	B-X
hemoglobin	B-X
clearance	B-X
mechanisms	B-X
suggest	B-X
a	B-X
critical	B-X
need	B-X
to	B-X
prevent	B-X
the	B-X
buildup	B-X
of	B-X
this	B-X
molecule	B-X
in	B-X
the	B-X
plasma	B-X
.	B-X
A	B-X
growing	B-X
list	B-X
of	B-X
clinical	B-X
manifestations	B-X
attributed	B-X
to	B-X
hemoglobin	B-X
release	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
acquired	B-X
and	B-X
iatrogenic	B-X
hemolytic	B-X
disorders	B-X
suggests	B-X
that	B-X
hemolysis	B-X
and	B-X
hemoglobinemia	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
human	B-X
disease	B-X
.	B-X

The	O
comproportionation	O
of	O
ferrylhemoglobin	O
with	O
oxyhemoglobin	O
.	O
<EOS>	B-X
Ferrylhemoglobin	B-X
(	B-X
X-FeIV-OH	B-X
,	B-X
where	B-X
X	B-X
denotes	B-X
an	B-X
amino	B-X
acid	B-X
residue	B-X
in	B-X
the	B-X
globin	B-X
moiety	B-X
)	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
as	B-X
a	B-X
cytotoxic	B-X
agent	B-X
produced	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
oxyhemoglobin	B-X
(	B-X
X-FeIIO2	B-X
)	B-X
or	B-X
methemoglobin	B-X
(	B-X
X-FeIII	B-X
)	B-X
with	B-X
H2O2	B-X
in	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
X-FeIV-OH	B-X
to	B-X
X-FeIII	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
either	B-X
of	B-X
two	B-X
alternative	B-X
mechanisms	B-X
:	B-X
a	B-X
O2	B-X
(	B-X
-	B-X
)	B-X
-mediated	B-X
X-FeIV-OH	B-X
--	B-X
-X-FeIII	B-X
transition	B-X
or	B-X
a	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
to	B-X
yield	B-X
X-FeIII	B-X
(	B-X
a	B-X
process	B-X
mediated	B-X
by	B-X
a	B-X
tyrosine	B-X
moiety	B-X
in	B-X
the	B-X
hemoprotein	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
dependence	B-X
of	B-X
X-FeIII	B-X
formation	B-X
on	B-X
X-FeIIO2	B-X
concentration	B-X
,	B-X
together	B-X
with	B-X
the	B-X
results	B-X
of	B-X
O2	B-X
uptake	B-X
and	B-X
H2O2	B-X
consumption	B-X
measurements	B-X
,	B-X
provide	B-X
experimental	B-X
evidence	B-X
to	B-X
support	B-X
the	B-X
comproportionation	B-X
reaction	B-X
.	B-X
Measurements	B-X
of	B-X
concentrations	B-X
and	B-X
relative	B-X
rate	B-X
constants	B-X
for	B-X
the	B-X
reaction	B-X
of	B-X
various	B-X
intracellular	B-X
reductants	B-X
(	B-X
glutathione	B-X
,	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
,	B-X
uric	B-X
acid	B-X
,	B-X
ascorbic	B-X
acid	B-X
)	B-X
with	B-X
X-FeIV-OH	B-X
revealed	B-X
that	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
with	B-X
X-FeIIO2	B-X
is	B-X
the	B-X
favored	B-X
reaction	B-X
.	B-X
The	B-X
rapid	B-X
comproportionation	B-X
reaction	B-X
between	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
(	B-X
to	B-X
produce	B-X
X-FeIII	B-X
)	B-X
explains	B-X
why	B-X
X-FeIV-OH	B-X
has	B-X
been	B-X
elusive	B-X
to	B-X
date	B-X
.	B-X

Ferrylhemoglobin	O
(	O
X	O
-	O
FeIV	O
-	O
OH	O
,	O
where	O
X	O
denotes	O
an	O
amino	O
acid	O
residue	O
in	O
the	O
globin	O
moiety	O
)	O
has	O
long	O
been	O
suspected	O
as	O
a	O
cytotoxic	O
agent	O
produced	O
by	O
the	O
interaction	O
of	O
oxyhemoglobin	O
(	O
X	O
-	O
FeIIO2	O
)	O
or	O
methemoglobin	O
(	O
X	O
-	O
FeIII	O
)	O
with	O
H2O2	O
in	O
red	O
blood	O
cells	O
.	O
<EOS>	B-X
Ferrylhemoglobin	B-X
(	B-X
X-FeIV-OH	B-X
,	B-X
where	B-X
X	B-X
denotes	B-X
an	B-X
amino	B-X
acid	B-X
residue	B-X
in	B-X
the	B-X
globin	B-X
moiety	B-X
)	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
as	B-X
a	B-X
cytotoxic	B-X
agent	B-X
produced	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
oxyhemoglobin	B-X
(	B-X
X-FeIIO2	B-X
)	B-X
or	B-X
methemoglobin	B-X
(	B-X
X-FeIII	B-X
)	B-X
with	B-X
H2O2	B-X
in	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
technical	B-X
difficulties	B-X
have	B-X
prevented	B-X
the	B-X
identification	B-X
and	B-X
quantification	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Oxyhemoglobin	B-X
exposed	B-X
to	B-X
a	B-X
continuous	B-X
flux	B-X
of	B-X
H2O2	B-X
(	B-X
generated	B-X
at	B-X
a	B-X
rate	B-X
of	B-X
120	B-X
microM/min	B-X
during	B-X
the	B-X
glucose	B-X
oxidase-catalyzed	B-X
oxidation	B-X
of	B-X
glucose	B-X
)	B-X
was	B-X
oxidized	B-X
to	B-X
(	B-X
a	B-X
)	B-X
X-FeIV-OH	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
less	B-X
than	B-X
75	B-X
microM	B-X
and	B-X
(	B-X
b	B-X
)	B-X
X-FeIII	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
greater	B-X
than	B-X
75	B-X
microM	B-X
(	B-X
the	B-X
production	B-X
of	B-X
X-FeIII	B-X
proceeded	B-X
with	B-X
intermediate	B-X
formation	B-X
of	B-X
X-FeIV-OH	B-X
)	B-X
.	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
X-FeIV-OH	B-X
to	B-X
X-FeIII	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
either	B-X
of	B-X
two	B-X
alternative	B-X
mechanisms	B-X
:	B-X
a	B-X
O2	B-X
(	B-X
-	B-X
)	B-X
-mediated	B-X
X-FeIV-OH	B-X
--	B-X
-X-FeIII	B-X
transition	B-X
or	B-X
a	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
to	B-X
yield	B-X
X-FeIII	B-X
(	B-X
a	B-X
process	B-X
mediated	B-X
by	B-X
a	B-X
tyrosine	B-X
moiety	B-X
in	B-X
the	B-X
hemoprotein	B-X
)	B-X
.	B-X
The	B-X
low	B-X
rate	B-X
of	B-X
X-FeIIO2	B-X
autoxidation	B-X
plus	B-X
the	B-X
negligible	B-X
decrease	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
X-FeIII	B-X
formation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
native	B-X
or	B-X
heat-denatured	B-X
superoxide	B-X
dismutase	B-X
or	B-X
apoenzyme	B-X
(	B-X
1	B-X
microM	B-X
)	B-X
suggested	B-X
that	B-X
O2-	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
the	B-X
reduction	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
dependence	B-X
of	B-X
X-FeIII	B-X
formation	B-X
on	B-X
X-FeIIO2	B-X
concentration	B-X
,	B-X
together	B-X
with	B-X
the	B-X
results	B-X
of	B-X
O2	B-X
uptake	B-X
and	B-X
H2O2	B-X
consumption	B-X
measurements	B-X
,	B-X
provide	B-X
experimental	B-X
evidence	B-X
to	B-X
support	B-X
the	B-X
comproportionation	B-X
reaction	B-X
.	B-X
Comproportionation	B-X
is	B-X
apparently	B-X
catalyzed	B-X
by	B-X
intermolecular	B-X
electron	B-X
transfer	B-X
between	B-X
tyrosine	B-X
residues	B-X
,	B-X
since	B-X
the	B-X
reaction	B-X
did	B-X
not	B-X
occur	B-X
when	B-X
tyrosine	B-X
residues	B-X
were	B-X
blocked	B-X
by	B-X
acetylation	B-X
.	B-X
Intact	B-X
red	B-X
blood	B-X
cells	B-X
exposed	B-X
to	B-X
the	B-X
same	B-X
flow	B-X
rate	B-X
of	B-X
H2O2	B-X
presented	B-X
a	B-X
spectral	B-X
profile	B-X
which	B-X
could	B-X
be	B-X
explained	B-X
as	B-X
a	B-X
transition	B-X
from	B-X
X-FeIIO2	B-X
to	B-X
X-FeIII	B-X
.	B-X
The	B-X
intermediate	B-X
production	B-X
of	B-X
X-FeIV-OH	B-X
was	B-X
detected	B-X
by	B-X
adding	B-X
Na2S	B-X
(	B-X
2	B-X
mM	B-X
)	B-X
,	B-X
which	B-X
revealed	B-X
a	B-X
spectral	B-X
profile	B-X
identical	B-X
with	B-X
that	B-X
obtained	B-X
with	B-X
purified	B-X
X-FeIV-OH	B-X
.	B-X
Measurements	B-X
of	B-X
concentrations	B-X
and	B-X
relative	B-X
rate	B-X
constants	B-X
for	B-X
the	B-X
reaction	B-X
of	B-X
various	B-X
intracellular	B-X
reductants	B-X
(	B-X
glutathione	B-X
,	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
,	B-X
uric	B-X
acid	B-X
,	B-X
ascorbic	B-X
acid	B-X
)	B-X
with	B-X
X-FeIV-OH	B-X
revealed	B-X
that	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
with	B-X
X-FeIIO2	B-X
is	B-X
the	B-X
favored	B-X
reaction	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
(	B-X
to	B-X
our	B-X
knowledge	B-X
)	B-X
the	B-X
first	B-X
definitive	B-X
evidence	B-X
for	B-X
X-FeIV-OH	B-X
in	B-X
intact	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
The	B-X
rapid	B-X
comproportionation	B-X
reaction	B-X
between	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
(	B-X
to	B-X
produce	B-X
X-FeIII	B-X
)	B-X
explains	B-X
why	B-X
X-FeIV-OH	B-X
has	B-X
been	B-X
elusive	B-X
to	B-X
date	B-X
.	B-X

To	O
date	O
,	O
however	O
,	O
technical	O
difficulties	O
have	O
prevented	O
the	O
identification	O
and	O
quantification	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
.	O
<EOS>	B-X
Ferrylhemoglobin	B-X
(	B-X
X-FeIV-OH	B-X
,	B-X
where	B-X
X	B-X
denotes	B-X
an	B-X
amino	B-X
acid	B-X
residue	B-X
in	B-X
the	B-X
globin	B-X
moiety	B-X
)	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
as	B-X
a	B-X
cytotoxic	B-X
agent	B-X
produced	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
oxyhemoglobin	B-X
(	B-X
X-FeIIO2	B-X
)	B-X
or	B-X
methemoglobin	B-X
(	B-X
X-FeIII	B-X
)	B-X
with	B-X
H2O2	B-X
in	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
technical	B-X
difficulties	B-X
have	B-X
prevented	B-X
the	B-X
identification	B-X
and	B-X
quantification	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Oxyhemoglobin	B-X
exposed	B-X
to	B-X
a	B-X
continuous	B-X
flux	B-X
of	B-X
H2O2	B-X
(	B-X
generated	B-X
at	B-X
a	B-X
rate	B-X
of	B-X
120	B-X
microM/min	B-X
during	B-X
the	B-X
glucose	B-X
oxidase-catalyzed	B-X
oxidation	B-X
of	B-X
glucose	B-X
)	B-X
was	B-X
oxidized	B-X
to	B-X
(	B-X
a	B-X
)	B-X
X-FeIV-OH	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
less	B-X
than	B-X
75	B-X
microM	B-X
and	B-X
(	B-X
b	B-X
)	B-X
X-FeIII	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
greater	B-X
than	B-X
75	B-X
microM	B-X
(	B-X
the	B-X
production	B-X
of	B-X
X-FeIII	B-X
proceeded	B-X
with	B-X
intermediate	B-X
formation	B-X
of	B-X
X-FeIV-OH	B-X
)	B-X
.	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
X-FeIV-OH	B-X
to	B-X
X-FeIII	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
either	B-X
of	B-X
two	B-X
alternative	B-X
mechanisms	B-X
:	B-X
a	B-X
O2	B-X
(	B-X
-	B-X
)	B-X
-mediated	B-X
X-FeIV-OH	B-X
--	B-X
-X-FeIII	B-X
transition	B-X
or	B-X
a	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
to	B-X
yield	B-X
X-FeIII	B-X
(	B-X
a	B-X
process	B-X
mediated	B-X
by	B-X
a	B-X
tyrosine	B-X
moiety	B-X
in	B-X
the	B-X
hemoprotein	B-X
)	B-X
.	B-X
The	B-X
low	B-X
rate	B-X
of	B-X
X-FeIIO2	B-X
autoxidation	B-X
plus	B-X
the	B-X
negligible	B-X
decrease	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
X-FeIII	B-X
formation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
native	B-X
or	B-X
heat-denatured	B-X
superoxide	B-X
dismutase	B-X
or	B-X
apoenzyme	B-X
(	B-X
1	B-X
microM	B-X
)	B-X
suggested	B-X
that	B-X
O2-	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
the	B-X
reduction	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
dependence	B-X
of	B-X
X-FeIII	B-X
formation	B-X
on	B-X
X-FeIIO2	B-X
concentration	B-X
,	B-X
together	B-X
with	B-X
the	B-X
results	B-X
of	B-X
O2	B-X
uptake	B-X
and	B-X
H2O2	B-X
consumption	B-X
measurements	B-X
,	B-X
provide	B-X
experimental	B-X
evidence	B-X
to	B-X
support	B-X
the	B-X
comproportionation	B-X
reaction	B-X
.	B-X
Intact	B-X
red	B-X
blood	B-X
cells	B-X
exposed	B-X
to	B-X
the	B-X
same	B-X
flow	B-X
rate	B-X
of	B-X
H2O2	B-X
presented	B-X
a	B-X
spectral	B-X
profile	B-X
which	B-X
could	B-X
be	B-X
explained	B-X
as	B-X
a	B-X
transition	B-X
from	B-X
X-FeIIO2	B-X
to	B-X
X-FeIII	B-X
.	B-X
The	B-X
intermediate	B-X
production	B-X
of	B-X
X-FeIV-OH	B-X
was	B-X
detected	B-X
by	B-X
adding	B-X
Na2S	B-X
(	B-X
2	B-X
mM	B-X
)	B-X
,	B-X
which	B-X
revealed	B-X
a	B-X
spectral	B-X
profile	B-X
identical	B-X
with	B-X
that	B-X
obtained	B-X
with	B-X
purified	B-X
X-FeIV-OH	B-X
.	B-X
Measurements	B-X
of	B-X
concentrations	B-X
and	B-X
relative	B-X
rate	B-X
constants	B-X
for	B-X
the	B-X
reaction	B-X
of	B-X
various	B-X
intracellular	B-X
reductants	B-X
(	B-X
glutathione	B-X
,	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
,	B-X
uric	B-X
acid	B-X
,	B-X
ascorbic	B-X
acid	B-X
)	B-X
with	B-X
X-FeIV-OH	B-X
revealed	B-X
that	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
with	B-X
X-FeIIO2	B-X
is	B-X
the	B-X
favored	B-X
reaction	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
(	B-X
to	B-X
our	B-X
knowledge	B-X
)	B-X
the	B-X
first	B-X
definitive	B-X
evidence	B-X
for	B-X
X-FeIV-OH	B-X
in	B-X
intact	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
The	B-X
rapid	B-X
comproportionation	B-X
reaction	B-X
between	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
(	B-X
to	B-X
produce	B-X
X-FeIII	B-X
)	B-X
explains	B-X
why	B-X
X-FeIV-OH	B-X
has	B-X
been	B-X
elusive	B-X
to	B-X
date	B-X
.	B-X

Oxyhemoglobin	O
exposed	O
to	O
a	O
continuous	O
flux	O
of	O
H2O2	O
(	O
generated	O
at	O
a	O
rate	O
of	O
120	O
microM	O
/	O
min	O
during	O
the	O
glucose	B-Protein
oxidase	I-Protein
-	O
catalyzed	O
oxidation	O
of	O
glucose	O
)	O
was	O
oxidized	O
to	O
(	O
a	O
)	O
X	O
-	O
FeIV	O
-	O
OH	O
when	O
[	O
X	O
-	O
FeIIO2	O
]	O
less	O
than	O
75	O
microM	O
and	O
(	O
b	O
)	O
X	O
-	O
FeIII	O
when	O
[	O
X	O
-	O
FeIIO2	O
]	O
greater	O
than	O
75	O
microM	O
(	O
the	O
production	O
of	O
X	O
-	O
FeIII	O
proceeded	O
with	O
intermediate	O
formation	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
)	O
.	O

The	O
reduction	O
of	O
the	O
X	O
-	O
FeIV	O
-	O
OH	O
to	O
X	O
-	O
FeIII	O
could	O
be	O
explained	O
by	O
either	O
of	O
two	O
alternative	O
mechanisms	O
:	O
a	O
O2	O
(	O
-	O
)	O
-	O
mediated	O
X	O
-	O
FeIV	O
-	O
OH	O
-	O
-	O
-	O
X	O
-	O
FeIII	O
transition	O
or	O
a	O
comproportionation	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
and	O
X	O
-	O
FeIIO2	O
to	O
yield	O
X	O
-	O
FeIII	O
(	O
a	O
process	O
mediated	O
by	O
a	O
tyrosine	O
moiety	O
in	O
the	O
hemoprotein	O
)	O
.	O

The	O
low	O
rate	O
of	O
X	O
-	O
FeIIO2	O
autoxidation	O
plus	O
the	O
negligible	O
decrease	O
in	O
the	O
rate	O
of	O
X	O
-	O
FeIII	O
formation	O
in	O
the	O
presence	O
of	O
either	O
native	O
or	O
heat	O
-	O
denatured	O
superoxide	O
dismutase	O
or	O
apoenzyme	O
(	O
1	O
microM	O
)	O
suggested	O
that	O
O2	O
-	O
does	O
not	O
contribute	O
to	O
the	O
reduction	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
.	O
<EOS>	B-X
Thermostability	B-X
of	B-X
a	B-X
protein	B-X
is	B-X
a	B-X
property	B-X
which	B-X
can	B-X
not	B-X
be	B-X
attributed	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
particular	B-X
amino	B-X
acid	B-X
or	B-X
to	B-X
a	B-X
post	B-X
synthetic	B-X
modification	B-X
.	B-X
Proteins	B-X
produced	B-X
by	B-X
thermo	B-X
and	B-X
hyperthermophilic	B-X
microorganisms	B-X
,	B-X
growing	B-X
between	B-X
45	B-X
and	B-X
110	B-X
degrees	B-X
C	B-X
are	B-X
in	B-X
general	B-X
more	B-X
resistant	B-X
to	B-X
thermal	B-X
and	B-X
chemical	B-X
denaturation	B-X
than	B-X
their	B-X
mesophilic	B-X
counterparts	B-X
.	B-X
The	B-X
observed	B-X
structural	B-X
resistance	B-X
may	B-X
reflect	B-X
a	B-X
restriction	B-X
on	B-X
the	B-X
flexibility	B-X
of	B-X
these	B-X
proteins	B-X
,	B-X
which	B-X
,	B-X
while	B-X
allowing	B-X
them	B-X
to	B-X
be	B-X
functionally	B-X
competent	B-X
at	B-X
elevated	B-X
temperatures	B-X
,	B-X
renders	B-X
them	B-X
unusually	B-X
rigid	B-X
at	B-X
mesophilic	B-X
temperatures	B-X
(	B-X
10-45	B-X
degrees	B-X
C	B-X
)	B-X
.	B-X
These	B-X
exchanges	B-X
with	B-X
some	B-X
strategic	B-X
placement	B-X
of	B-X
proline	B-X
in	B-X
beta-turns	B-X
give	B-X
rise	B-X
to	B-X
a	B-X
stabilization	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
From	B-X
the	B-X
comparative	B-X
analysis	B-X
of	B-X
the	B-X
X-ray	B-X
structures	B-X
available	B-X
for	B-X
several	B-X
families	B-X
of	B-X
proteins	B-X
,	B-X
including	B-X
at	B-X
least	B-X
one	B-X
thermophilic	B-X
structure	B-X
in	B-X
each	B-X
case	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
thermal	B-X
stabilization	B-X
is	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
hydrogen	B-X
bonds	B-X
and	B-X
salt	B-X
bridges	B-X
.	B-X

Moreover	O
,	O
the	O
dependence	O
of	O
X	O
-	O
FeIII	O
formation	O
on	O
X	O
-	O
FeIIO2	O
concentration	O
,	O
together	O
with	O
the	O
results	O
of	O
O2	O
uptake	O
and	O
H2O2	O
consumption	O
measurements	O
,	O
provide	O
experimental	O
evidence	O
to	O
support	O
the	O
comproportionation	O
reaction	O
.	O
<EOS>	B-X
Ferrylhemoglobin	B-X
(	B-X
X-FeIV-OH	B-X
,	B-X
where	B-X
X	B-X
denotes	B-X
an	B-X
amino	B-X
acid	B-X
residue	B-X
in	B-X
the	B-X
globin	B-X
moiety	B-X
)	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
as	B-X
a	B-X
cytotoxic	B-X
agent	B-X
produced	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
oxyhemoglobin	B-X
(	B-X
X-FeIIO2	B-X
)	B-X
or	B-X
methemoglobin	B-X
(	B-X
X-FeIII	B-X
)	B-X
with	B-X
H2O2	B-X
in	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
technical	B-X
difficulties	B-X
have	B-X
prevented	B-X
the	B-X
identification	B-X
and	B-X
quantification	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Oxyhemoglobin	B-X
exposed	B-X
to	B-X
a	B-X
continuous	B-X
flux	B-X
of	B-X
H2O2	B-X
(	B-X
generated	B-X
at	B-X
a	B-X
rate	B-X
of	B-X
120	B-X
microM/min	B-X
during	B-X
the	B-X
glucose	B-X
oxidase-catalyzed	B-X
oxidation	B-X
of	B-X
glucose	B-X
)	B-X
was	B-X
oxidized	B-X
to	B-X
(	B-X
a	B-X
)	B-X
X-FeIV-OH	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
less	B-X
than	B-X
75	B-X
microM	B-X
and	B-X
(	B-X
b	B-X
)	B-X
X-FeIII	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
greater	B-X
than	B-X
75	B-X
microM	B-X
(	B-X
the	B-X
production	B-X
of	B-X
X-FeIII	B-X
proceeded	B-X
with	B-X
intermediate	B-X
formation	B-X
of	B-X
X-FeIV-OH	B-X
)	B-X
.	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
X-FeIV-OH	B-X
to	B-X
X-FeIII	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
either	B-X
of	B-X
two	B-X
alternative	B-X
mechanisms	B-X
:	B-X
a	B-X
O2	B-X
(	B-X
-	B-X
)	B-X
-mediated	B-X
X-FeIV-OH	B-X
--	B-X
-X-FeIII	B-X
transition	B-X
or	B-X
a	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
to	B-X
yield	B-X
X-FeIII	B-X
(	B-X
a	B-X
process	B-X
mediated	B-X
by	B-X
a	B-X
tyrosine	B-X
moiety	B-X
in	B-X
the	B-X
hemoprotein	B-X
)	B-X
.	B-X
The	B-X
low	B-X
rate	B-X
of	B-X
X-FeIIO2	B-X
autoxidation	B-X
plus	B-X
the	B-X
negligible	B-X
decrease	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
X-FeIII	B-X
formation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
native	B-X
or	B-X
heat-denatured	B-X
superoxide	B-X
dismutase	B-X
or	B-X
apoenzyme	B-X
(	B-X
1	B-X
microM	B-X
)	B-X
suggested	B-X
that	B-X
O2-	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
the	B-X
reduction	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
dependence	B-X
of	B-X
X-FeIII	B-X
formation	B-X
on	B-X
X-FeIIO2	B-X
concentration	B-X
,	B-X
together	B-X
with	B-X
the	B-X
results	B-X
of	B-X
O2	B-X
uptake	B-X
and	B-X
H2O2	B-X
consumption	B-X
measurements	B-X
,	B-X
provide	B-X
experimental	B-X
evidence	B-X
to	B-X
support	B-X
the	B-X
comproportionation	B-X
reaction	B-X
.	B-X
Comproportionation	B-X
is	B-X
apparently	B-X
catalyzed	B-X
by	B-X
intermolecular	B-X
electron	B-X
transfer	B-X
between	B-X
tyrosine	B-X
residues	B-X
,	B-X
since	B-X
the	B-X
reaction	B-X
did	B-X
not	B-X
occur	B-X
when	B-X
tyrosine	B-X
residues	B-X
were	B-X
blocked	B-X
by	B-X
acetylation	B-X
.	B-X
Intact	B-X
red	B-X
blood	B-X
cells	B-X
exposed	B-X
to	B-X
the	B-X
same	B-X
flow	B-X
rate	B-X
of	B-X
H2O2	B-X
presented	B-X
a	B-X
spectral	B-X
profile	B-X
which	B-X
could	B-X
be	B-X
explained	B-X
as	B-X
a	B-X
transition	B-X
from	B-X
X-FeIIO2	B-X
to	B-X
X-FeIII	B-X
.	B-X
The	B-X
intermediate	B-X
production	B-X
of	B-X
X-FeIV-OH	B-X
was	B-X
detected	B-X
by	B-X
adding	B-X
Na2S	B-X
(	B-X
2	B-X
mM	B-X
)	B-X
,	B-X
which	B-X
revealed	B-X
a	B-X
spectral	B-X
profile	B-X
identical	B-X
with	B-X
that	B-X
obtained	B-X
with	B-X
purified	B-X
X-FeIV-OH	B-X
.	B-X
Measurements	B-X
of	B-X
concentrations	B-X
and	B-X
relative	B-X
rate	B-X
constants	B-X
for	B-X
the	B-X
reaction	B-X
of	B-X
various	B-X
intracellular	B-X
reductants	B-X
(	B-X
glutathione	B-X
,	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
,	B-X
uric	B-X
acid	B-X
,	B-X
ascorbic	B-X
acid	B-X
)	B-X
with	B-X
X-FeIV-OH	B-X
revealed	B-X
that	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
with	B-X
X-FeIIO2	B-X
is	B-X
the	B-X
favored	B-X
reaction	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
(	B-X
to	B-X
our	B-X
knowledge	B-X
)	B-X
the	B-X
first	B-X
definitive	B-X
evidence	B-X
for	B-X
X-FeIV-OH	B-X
in	B-X
intact	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
The	B-X
rapid	B-X
comproportionation	B-X
reaction	B-X
between	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
(	B-X
to	B-X
produce	B-X
X-FeIII	B-X
)	B-X
explains	B-X
why	B-X
X-FeIV-OH	B-X
has	B-X
been	B-X
elusive	B-X
to	B-X
date	B-X
.	B-X

Comproportionation	O
is	O
apparently	O
catalyzed	O
by	O
intermolecular	O
electron	O
transfer	O
between	O
tyrosine	O
residues	O
,	O
since	O
the	O
reaction	O
did	O
not	O
occur	O
when	O
tyrosine	O
residues	O
were	O
blocked	O
by	O
acetylation	O
.	O

Intact	O
red	O
blood	O
cells	O
exposed	O
to	O
the	O
same	O
flow	O
rate	O
of	O
H2O2	O
presented	O
a	O
spectral	O
profile	O
which	O
could	O
be	O
explained	O
as	O
a	O
transition	O
from	O
X	O
-	O
FeIIO2	O
to	O
X	O
-	O
FeIII	O
.	O

The	O
intermediate	O
production	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
was	O
detected	O
by	O
adding	O
Na2S	O
(	O
2	O
mM	O
)	O
,	O
which	O
revealed	O
a	O
spectral	O
profile	O
identical	O
with	O
that	O
obtained	O
with	O
purified	O
X	O
-	O
FeIV	O
-	O
OH	O
.	O
<EOS>	B-X
Ferrylhemoglobin	B-X
(	B-X
X-FeIV-OH	B-X
,	B-X
where	B-X
X	B-X
denotes	B-X
an	B-X
amino	B-X
acid	B-X
residue	B-X
in	B-X
the	B-X
globin	B-X
moiety	B-X
)	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
as	B-X
a	B-X
cytotoxic	B-X
agent	B-X
produced	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
oxyhemoglobin	B-X
(	B-X
X-FeIIO2	B-X
)	B-X
or	B-X
methemoglobin	B-X
(	B-X
X-FeIII	B-X
)	B-X
with	B-X
H2O2	B-X
in	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
technical	B-X
difficulties	B-X
have	B-X
prevented	B-X
the	B-X
identification	B-X
and	B-X
quantification	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Oxyhemoglobin	B-X
exposed	B-X
to	B-X
a	B-X
continuous	B-X
flux	B-X
of	B-X
H2O2	B-X
(	B-X
generated	B-X
at	B-X
a	B-X
rate	B-X
of	B-X
120	B-X
microM/min	B-X
during	B-X
the	B-X
glucose	B-X
oxidase-catalyzed	B-X
oxidation	B-X
of	B-X
glucose	B-X
)	B-X
was	B-X
oxidized	B-X
to	B-X
(	B-X
a	B-X
)	B-X
X-FeIV-OH	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
less	B-X
than	B-X
75	B-X
microM	B-X
and	B-X
(	B-X
b	B-X
)	B-X
X-FeIII	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
greater	B-X
than	B-X
75	B-X
microM	B-X
(	B-X
the	B-X
production	B-X
of	B-X
X-FeIII	B-X
proceeded	B-X
with	B-X
intermediate	B-X
formation	B-X
of	B-X
X-FeIV-OH	B-X
)	B-X
.	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
X-FeIV-OH	B-X
to	B-X
X-FeIII	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
either	B-X
of	B-X
two	B-X
alternative	B-X
mechanisms	B-X
:	B-X
a	B-X
O2	B-X
(	B-X
-	B-X
)	B-X
-mediated	B-X
X-FeIV-OH	B-X
--	B-X
-X-FeIII	B-X
transition	B-X
or	B-X
a	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
to	B-X
yield	B-X
X-FeIII	B-X
(	B-X
a	B-X
process	B-X
mediated	B-X
by	B-X
a	B-X
tyrosine	B-X
moiety	B-X
in	B-X
the	B-X
hemoprotein	B-X
)	B-X
.	B-X
The	B-X
low	B-X
rate	B-X
of	B-X
X-FeIIO2	B-X
autoxidation	B-X
plus	B-X
the	B-X
negligible	B-X
decrease	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
X-FeIII	B-X
formation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
native	B-X
or	B-X
heat-denatured	B-X
superoxide	B-X
dismutase	B-X
or	B-X
apoenzyme	B-X
(	B-X
1	B-X
microM	B-X
)	B-X
suggested	B-X
that	B-X
O2-	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
the	B-X
reduction	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
dependence	B-X
of	B-X
X-FeIII	B-X
formation	B-X
on	B-X
X-FeIIO2	B-X
concentration	B-X
,	B-X
together	B-X
with	B-X
the	B-X
results	B-X
of	B-X
O2	B-X
uptake	B-X
and	B-X
H2O2	B-X
consumption	B-X
measurements	B-X
,	B-X
provide	B-X
experimental	B-X
evidence	B-X
to	B-X
support	B-X
the	B-X
comproportionation	B-X
reaction	B-X
.	B-X
Intact	B-X
red	B-X
blood	B-X
cells	B-X
exposed	B-X
to	B-X
the	B-X
same	B-X
flow	B-X
rate	B-X
of	B-X
H2O2	B-X
presented	B-X
a	B-X
spectral	B-X
profile	B-X
which	B-X
could	B-X
be	B-X
explained	B-X
as	B-X
a	B-X
transition	B-X
from	B-X
X-FeIIO2	B-X
to	B-X
X-FeIII	B-X
.	B-X
The	B-X
intermediate	B-X
production	B-X
of	B-X
X-FeIV-OH	B-X
was	B-X
detected	B-X
by	B-X
adding	B-X
Na2S	B-X
(	B-X
2	B-X
mM	B-X
)	B-X
,	B-X
which	B-X
revealed	B-X
a	B-X
spectral	B-X
profile	B-X
identical	B-X
with	B-X
that	B-X
obtained	B-X
with	B-X
purified	B-X
X-FeIV-OH	B-X
.	B-X
Measurements	B-X
of	B-X
concentrations	B-X
and	B-X
relative	B-X
rate	B-X
constants	B-X
for	B-X
the	B-X
reaction	B-X
of	B-X
various	B-X
intracellular	B-X
reductants	B-X
(	B-X
glutathione	B-X
,	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
,	B-X
uric	B-X
acid	B-X
,	B-X
ascorbic	B-X
acid	B-X
)	B-X
with	B-X
X-FeIV-OH	B-X
revealed	B-X
that	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
with	B-X
X-FeIIO2	B-X
is	B-X
the	B-X
favored	B-X
reaction	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
(	B-X
to	B-X
our	B-X
knowledge	B-X
)	B-X
the	B-X
first	B-X
definitive	B-X
evidence	B-X
for	B-X
X-FeIV-OH	B-X
in	B-X
intact	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
The	B-X
rapid	B-X
comproportionation	B-X
reaction	B-X
between	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
(	B-X
to	B-X
produce	B-X
X-FeIII	B-X
)	B-X
explains	B-X
why	B-X
X-FeIV-OH	B-X
has	B-X
been	B-X
elusive	B-X
to	B-X
date	B-X
.	B-X

Measurements	O
of	O
concentrations	O
and	O
relative	O
rate	O
constants	O
for	O
the	O
reaction	O
of	O
various	O
intracellular	O
reductants	O
(	O
glutathione	O
,	O
NAD	O
(	O
P	O
)	O
H	O
,	O
uric	O
acid	O
,	O
ascorbic	O
acid	O
)	O
with	O
X	O
-	O
FeIV	O
-	O
OH	O
revealed	O
that	O
comproportionation	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
with	O
X	O
-	O
FeIIO2	O
is	O
the	O
favored	O
reaction	O
.	O
<EOS>	B-X
Ferrylhemoglobin	B-X
(	B-X
X-FeIV-OH	B-X
,	B-X
where	B-X
X	B-X
denotes	B-X
an	B-X
amino	B-X
acid	B-X
residue	B-X
in	B-X
the	B-X
globin	B-X
moiety	B-X
)	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
as	B-X
a	B-X
cytotoxic	B-X
agent	B-X
produced	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
oxyhemoglobin	B-X
(	B-X
X-FeIIO2	B-X
)	B-X
or	B-X
methemoglobin	B-X
(	B-X
X-FeIII	B-X
)	B-X
with	B-X
H2O2	B-X
in	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
technical	B-X
difficulties	B-X
have	B-X
prevented	B-X
the	B-X
identification	B-X
and	B-X
quantification	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Oxyhemoglobin	B-X
exposed	B-X
to	B-X
a	B-X
continuous	B-X
flux	B-X
of	B-X
H2O2	B-X
(	B-X
generated	B-X
at	B-X
a	B-X
rate	B-X
of	B-X
120	B-X
microM/min	B-X
during	B-X
the	B-X
glucose	B-X
oxidase-catalyzed	B-X
oxidation	B-X
of	B-X
glucose	B-X
)	B-X
was	B-X
oxidized	B-X
to	B-X
(	B-X
a	B-X
)	B-X
X-FeIV-OH	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
less	B-X
than	B-X
75	B-X
microM	B-X
and	B-X
(	B-X
b	B-X
)	B-X
X-FeIII	B-X
when	B-X
[	B-X
X-FeIIO2	B-X
]	B-X
greater	B-X
than	B-X
75	B-X
microM	B-X
(	B-X
the	B-X
production	B-X
of	B-X
X-FeIII	B-X
proceeded	B-X
with	B-X
intermediate	B-X
formation	B-X
of	B-X
X-FeIV-OH	B-X
)	B-X
.	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
X-FeIV-OH	B-X
to	B-X
X-FeIII	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
either	B-X
of	B-X
two	B-X
alternative	B-X
mechanisms	B-X
:	B-X
a	B-X
O2	B-X
(	B-X
-	B-X
)	B-X
-mediated	B-X
X-FeIV-OH	B-X
--	B-X
-X-FeIII	B-X
transition	B-X
or	B-X
a	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
to	B-X
yield	B-X
X-FeIII	B-X
(	B-X
a	B-X
process	B-X
mediated	B-X
by	B-X
a	B-X
tyrosine	B-X
moiety	B-X
in	B-X
the	B-X
hemoprotein	B-X
)	B-X
.	B-X
The	B-X
low	B-X
rate	B-X
of	B-X
X-FeIIO2	B-X
autoxidation	B-X
plus	B-X
the	B-X
negligible	B-X
decrease	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
X-FeIII	B-X
formation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
native	B-X
or	B-X
heat-denatured	B-X
superoxide	B-X
dismutase	B-X
or	B-X
apoenzyme	B-X
(	B-X
1	B-X
microM	B-X
)	B-X
suggested	B-X
that	B-X
O2-	B-X
does	B-X
not	B-X
contribute	B-X
to	B-X
the	B-X
reduction	B-X
of	B-X
X-FeIV-OH	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
dependence	B-X
of	B-X
X-FeIII	B-X
formation	B-X
on	B-X
X-FeIIO2	B-X
concentration	B-X
,	B-X
together	B-X
with	B-X
the	B-X
results	B-X
of	B-X
O2	B-X
uptake	B-X
and	B-X
H2O2	B-X
consumption	B-X
measurements	B-X
,	B-X
provide	B-X
experimental	B-X
evidence	B-X
to	B-X
support	B-X
the	B-X
comproportionation	B-X
reaction	B-X
.	B-X
Comproportionation	B-X
is	B-X
apparently	B-X
catalyzed	B-X
by	B-X
intermolecular	B-X
electron	B-X
transfer	B-X
between	B-X
tyrosine	B-X
residues	B-X
,	B-X
since	B-X
the	B-X
reaction	B-X
did	B-X
not	B-X
occur	B-X
when	B-X
tyrosine	B-X
residues	B-X
were	B-X
blocked	B-X
by	B-X
acetylation	B-X
.	B-X
Intact	B-X
red	B-X
blood	B-X
cells	B-X
exposed	B-X
to	B-X
the	B-X
same	B-X
flow	B-X
rate	B-X
of	B-X
H2O2	B-X
presented	B-X
a	B-X
spectral	B-X
profile	B-X
which	B-X
could	B-X
be	B-X
explained	B-X
as	B-X
a	B-X
transition	B-X
from	B-X
X-FeIIO2	B-X
to	B-X
X-FeIII	B-X
.	B-X
The	B-X
intermediate	B-X
production	B-X
of	B-X
X-FeIV-OH	B-X
was	B-X
detected	B-X
by	B-X
adding	B-X
Na2S	B-X
(	B-X
2	B-X
mM	B-X
)	B-X
,	B-X
which	B-X
revealed	B-X
a	B-X
spectral	B-X
profile	B-X
identical	B-X
with	B-X
that	B-X
obtained	B-X
with	B-X
purified	B-X
X-FeIV-OH	B-X
.	B-X
Measurements	B-X
of	B-X
concentrations	B-X
and	B-X
relative	B-X
rate	B-X
constants	B-X
for	B-X
the	B-X
reaction	B-X
of	B-X
various	B-X
intracellular	B-X
reductants	B-X
(	B-X
glutathione	B-X
,	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
,	B-X
uric	B-X
acid	B-X
,	B-X
ascorbic	B-X
acid	B-X
)	B-X
with	B-X
X-FeIV-OH	B-X
revealed	B-X
that	B-X
comproportionation	B-X
of	B-X
X-FeIV-OH	B-X
with	B-X
X-FeIIO2	B-X
is	B-X
the	B-X
favored	B-X
reaction	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
(	B-X
to	B-X
our	B-X
knowledge	B-X
)	B-X
the	B-X
first	B-X
definitive	B-X
evidence	B-X
for	B-X
X-FeIV-OH	B-X
in	B-X
intact	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
The	B-X
rapid	B-X
comproportionation	B-X
reaction	B-X
between	B-X
X-FeIV-OH	B-X
and	B-X
X-FeIIO2	B-X
(	B-X
to	B-X
produce	B-X
X-FeIII	B-X
)	B-X
explains	B-X
why	B-X
X-FeIV-OH	B-X
has	B-X
been	B-X
elusive	B-X
to	B-X
date	B-X
.	B-X

Our	O
results	O
provide	O
(	O
to	O
our	O
knowledge	O
)	O
the	O
first	O
definitive	O
evidence	O
for	O
X	O
-	O
FeIV	O
-	O
OH	O
in	O
intact	O
red	O
blood	O
cells	O
.	O

The	O
rapid	O
comproportionation	O
reaction	O
between	O
X	O
-	O
FeIV	O
-	O
OH	O
and	O
X	O
-	O
FeIIO2	O
(	O
to	O
produce	O
X	O
-	O
FeIII	O
)	O
explains	O
why	O
X	O
-	O
FeIV	O
-	O
OH	O
has	O
been	O
elusive	O
to	O
date	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Expression	O
and	O
characterization	O
of	O
human	O
factor	B-Protein
IX	I-Protein
and	O
factor	B-Protein
IX	I-Protein
-	O
factor	B-Protein
X	I-Protein
chimeras	O
in	O
mouse	O
C127	O
cells	O
.	O
<EOS>	B-X
Human	B-X
blood	B-X
clotting	B-X
factor	B-X
IX	B-X
,	B-X
and	B-X
two	B-X
chimeric	B-X
molecules	B-X
of	B-X
factor	B-X
IX	B-X
,	B-X
in	B-X
which	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
or	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
have	B-X
been	B-X
replaced	B-X
by	B-X
that	B-X
of	B-X
human	B-X
factor	B-X
X	B-X
,	B-X
have	B-X
been	B-X
expressed	B-X
in	B-X
mouse	B-X
C127	B-X
cells	B-X
.	B-X
The	B-X
recombinants	B-X
have	B-X
been	B-X
purified	B-X
using	B-X
a	B-X
metal	B-X
ion-dependent	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
residues	B-X
1-42	B-X
of	B-X
human	B-X
factor	B-X
IX	B-X
.	B-X
All	B-X
recombinant	B-X
molecules	B-X
are	B-X
activated	B-X
normally	B-X
by	B-X
human	B-X
factor	B-X
XIa	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
ion	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
factor	B-X
IX	B-X
recombinants	B-X
by	B-X
factor	B-X
VIIa-tissue	B-X
factor	B-X
appears	B-X
to	B-X
be	B-X
normal	B-X
for	B-X
the	B-X
epidermal	B-X
growth	B-X
factor-1	B-X
exchange	B-X
but	B-X
considerably	B-X
reduced	B-X
for	B-X
the	B-X
construction	B-X
containing	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
of	B-X
factor	B-X
X	B-X
.	B-X
The	B-X
chimeric	B-X
molecule	B-X
with	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
from	B-X
factor	B-X
X	B-X
has	B-X
about	B-X
4	B-X
%	B-X
normal	B-X
activity	B-X
in	B-X
the	B-X
activated	B-X
partial	B-X
thromboplastin	B-X
time	B-X
assay	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
construct	B-X
containing	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
of	B-X
factor	B-X
X	B-X
shows	B-X
essentially	B-X
normal	B-X
clotting	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
unlikely	B-X
that	B-X
this	B-X
domain	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
unique	B-X
interaction	B-X
with	B-X
factor	B-X
VIII	B-X
.	B-X

Human	O
blood	O
clotting	O
factor	B-Protein
IX	I-Protein
,	O
and	O
two	O
chimeric	O
molecules	O
of	O
factor	B-Protein
IX	I-Protein
,	O
in	O
which	O
the	O
first	O
epidermal	O
growth	O
factor	O
-	O
like	O
domain	O
or	O
both	O
epidermal	O
growth	O
factor	O
-	O
like	O
domains	O
have	O
been	O
replaced	O
by	O
that	O
of	O
human	O
factor	B-Protein
X	I-Protein
,	O
have	O
been	O
expressed	O
in	O
mouse	O
C127	O
cells	O
.	O
<EOS>	B-X
Human	B-X
blood	B-X
clotting	B-X
factor	B-X
IX	B-X
,	B-X
and	B-X
two	B-X
chimeric	B-X
molecules	B-X
of	B-X
factor	B-X
IX	B-X
,	B-X
in	B-X
which	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
or	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
have	B-X
been	B-X
replaced	B-X
by	B-X
that	B-X
of	B-X
human	B-X
factor	B-X
X	B-X
,	B-X
have	B-X
been	B-X
expressed	B-X
in	B-X
mouse	B-X
C127	B-X
cells	B-X
.	B-X
The	B-X
recombinants	B-X
have	B-X
been	B-X
purified	B-X
using	B-X
a	B-X
metal	B-X
ion-dependent	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
residues	B-X
1-42	B-X
of	B-X
human	B-X
factor	B-X
IX	B-X
.	B-X
All	B-X
recombinant	B-X
molecules	B-X
are	B-X
activated	B-X
normally	B-X
by	B-X
human	B-X
factor	B-X
XIa	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
ion	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
factor	B-X
IX	B-X
recombinants	B-X
by	B-X
factor	B-X
VIIa-tissue	B-X
factor	B-X
appears	B-X
to	B-X
be	B-X
normal	B-X
for	B-X
the	B-X
epidermal	B-X
growth	B-X
factor-1	B-X
exchange	B-X
but	B-X
considerably	B-X
reduced	B-X
for	B-X
the	B-X
construction	B-X
containing	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
of	B-X
factor	B-X
X	B-X
.	B-X
The	B-X
chimeric	B-X
molecule	B-X
with	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
from	B-X
factor	B-X
X	B-X
has	B-X
about	B-X
4	B-X
%	B-X
normal	B-X
activity	B-X
in	B-X
the	B-X
activated	B-X
partial	B-X
thromboplastin	B-X
time	B-X
assay	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
construct	B-X
containing	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
of	B-X
factor	B-X
X	B-X
shows	B-X
essentially	B-X
normal	B-X
clotting	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
unlikely	B-X
that	B-X
this	B-X
domain	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
unique	B-X
interaction	B-X
with	B-X
factor	B-X
VIII	B-X
.	B-X

The	O
recombinants	O
have	O
been	O
purified	O
using	O
a	O
metal	O
ion	O
-	O
dependent	O
monoclonal	O
antibody	O
specific	O
for	O
residues	O
1	O
-	O
42	O
of	O
human	O
factor	B-Protein
IX	I-Protein
.	O
<EOS>	B-X
Human	B-X
blood	B-X
clotting	B-X
factor	B-X
IX	B-X
,	B-X
and	B-X
two	B-X
chimeric	B-X
molecules	B-X
of	B-X
factor	B-X
IX	B-X
,	B-X
in	B-X
which	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
or	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
have	B-X
been	B-X
replaced	B-X
by	B-X
that	B-X
of	B-X
human	B-X
factor	B-X
X	B-X
,	B-X
have	B-X
been	B-X
expressed	B-X
in	B-X
mouse	B-X
C127	B-X
cells	B-X
.	B-X
The	B-X
recombinants	B-X
have	B-X
been	B-X
purified	B-X
using	B-X
a	B-X
metal	B-X
ion-dependent	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
residues	B-X
1-42	B-X
of	B-X
human	B-X
factor	B-X
IX	B-X
.	B-X
All	B-X
recombinant	B-X
molecules	B-X
are	B-X
activated	B-X
normally	B-X
by	B-X
human	B-X
factor	B-X
XIa	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
ion	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
factor	B-X
IX	B-X
recombinants	B-X
by	B-X
factor	B-X
VIIa-tissue	B-X
factor	B-X
appears	B-X
to	B-X
be	B-X
normal	B-X
for	B-X
the	B-X
epidermal	B-X
growth	B-X
factor-1	B-X
exchange	B-X
but	B-X
considerably	B-X
reduced	B-X
for	B-X
the	B-X
construction	B-X
containing	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
of	B-X
factor	B-X
X	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
reveals	B-X
that	B-X
all	B-X
of	B-X
the	B-X
purified	B-X
recombinants	B-X
are	B-X
almost	B-X
fully	B-X
carboxylated	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
aspartic	B-X
acid	B-X
hydroxylation	B-X
at	B-X
residue	B-X
64	B-X
is	B-X
60	B-X
%	B-X
for	B-X
all	B-X
recombinants	B-X
.	B-X
The	B-X
chimeric	B-X
molecule	B-X
with	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
from	B-X
factor	B-X
X	B-X
has	B-X
about	B-X
4	B-X
%	B-X
normal	B-X
activity	B-X
in	B-X
the	B-X
activated	B-X
partial	B-X
thromboplastin	B-X
time	B-X
assay	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
construct	B-X
containing	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
of	B-X
factor	B-X
X	B-X
shows	B-X
essentially	B-X
normal	B-X
clotting	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
unlikely	B-X
that	B-X
this	B-X
domain	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
unique	B-X
interaction	B-X
with	B-X
factor	B-X
VIII	B-X
.	B-X

All	O
recombinant	O
molecules	O
are	O
activated	O
normally	O
by	O
human	O
factor	B-Protein
XIa	I-Protein
in	O
the	O
presence	O
of	O
calcium	O
ion	O
.	O
<EOS>	B-X
Human	B-X
blood	B-X
clotting	B-X
factor	B-X
IX	B-X
,	B-X
and	B-X
two	B-X
chimeric	B-X
molecules	B-X
of	B-X
factor	B-X
IX	B-X
,	B-X
in	B-X
which	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
or	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
have	B-X
been	B-X
replaced	B-X
by	B-X
that	B-X
of	B-X
human	B-X
factor	B-X
X	B-X
,	B-X
have	B-X
been	B-X
expressed	B-X
in	B-X
mouse	B-X
C127	B-X
cells	B-X
.	B-X
The	B-X
recombinants	B-X
have	B-X
been	B-X
purified	B-X
using	B-X
a	B-X
metal	B-X
ion-dependent	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
residues	B-X
1-42	B-X
of	B-X
human	B-X
factor	B-X
IX	B-X
.	B-X
All	B-X
recombinant	B-X
molecules	B-X
are	B-X
activated	B-X
normally	B-X
by	B-X
human	B-X
factor	B-X
XIa	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
ion	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
factor	B-X
IX	B-X
recombinants	B-X
by	B-X
factor	B-X
VIIa-tissue	B-X
factor	B-X
appears	B-X
to	B-X
be	B-X
normal	B-X
for	B-X
the	B-X
epidermal	B-X
growth	B-X
factor-1	B-X
exchange	B-X
but	B-X
considerably	B-X
reduced	B-X
for	B-X
the	B-X
construction	B-X
containing	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
of	B-X
factor	B-X
X	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
reveals	B-X
that	B-X
all	B-X
of	B-X
the	B-X
purified	B-X
recombinants	B-X
are	B-X
almost	B-X
fully	B-X
carboxylated	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
aspartic	B-X
acid	B-X
hydroxylation	B-X
at	B-X
residue	B-X
64	B-X
is	B-X
60	B-X
%	B-X
for	B-X
all	B-X
recombinants	B-X
.	B-X
The	B-X
chimeric	B-X
molecule	B-X
with	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
from	B-X
factor	B-X
X	B-X
has	B-X
about	B-X
4	B-X
%	B-X
normal	B-X
activity	B-X
in	B-X
the	B-X
activated	B-X
partial	B-X
thromboplastin	B-X
time	B-X
assay	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
construct	B-X
containing	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
of	B-X
factor	B-X
X	B-X
shows	B-X
essentially	B-X
normal	B-X
clotting	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
unlikely	B-X
that	B-X
this	B-X
domain	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
unique	B-X
interaction	B-X
with	B-X
factor	B-X
VIII	B-X
.	B-X

Activation	O
of	O
the	O
factor	B-Protein
IX	I-Protein
recombinants	O
by	O
factor	B-Protein
VIIa	I-Protein
-	O
tissue	B-Protein
factor	I-Protein
appears	O
to	O
be	O
normal	O
for	O
the	O
epidermal	O
growth	O
factor	O
-	O
1	O
exchange	O
but	O
considerably	O
reduced	O
for	O
the	O
construction	O
containing	O
both	O
epidermal	O
growth	O
factor	O
-	O
like	O
domains	O
of	O
factor	B-Protein
X	I-Protein
.	O
<EOS>	B-X
Human	B-X
blood	B-X
clotting	B-X
factor	B-X
IX	B-X
,	B-X
and	B-X
two	B-X
chimeric	B-X
molecules	B-X
of	B-X
factor	B-X
IX	B-X
,	B-X
in	B-X
which	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
or	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
have	B-X
been	B-X
replaced	B-X
by	B-X
that	B-X
of	B-X
human	B-X
factor	B-X
X	B-X
,	B-X
have	B-X
been	B-X
expressed	B-X
in	B-X
mouse	B-X
C127	B-X
cells	B-X
.	B-X
The	B-X
recombinants	B-X
have	B-X
been	B-X
purified	B-X
using	B-X
a	B-X
metal	B-X
ion-dependent	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
residues	B-X
1-42	B-X
of	B-X
human	B-X
factor	B-X
IX	B-X
.	B-X
All	B-X
recombinant	B-X
molecules	B-X
are	B-X
activated	B-X
normally	B-X
by	B-X
human	B-X
factor	B-X
XIa	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
ion	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
factor	B-X
IX	B-X
recombinants	B-X
by	B-X
factor	B-X
VIIa-tissue	B-X
factor	B-X
appears	B-X
to	B-X
be	B-X
normal	B-X
for	B-X
the	B-X
epidermal	B-X
growth	B-X
factor-1	B-X
exchange	B-X
but	B-X
considerably	B-X
reduced	B-X
for	B-X
the	B-X
construction	B-X
containing	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
of	B-X
factor	B-X
X	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
reveals	B-X
that	B-X
all	B-X
of	B-X
the	B-X
purified	B-X
recombinants	B-X
are	B-X
almost	B-X
fully	B-X
carboxylated	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
aspartic	B-X
acid	B-X
hydroxylation	B-X
at	B-X
residue	B-X
64	B-X
is	B-X
60	B-X
%	B-X
for	B-X
all	B-X
recombinants	B-X
.	B-X
The	B-X
chimeric	B-X
molecule	B-X
with	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
from	B-X
factor	B-X
X	B-X
has	B-X
about	B-X
4	B-X
%	B-X
normal	B-X
activity	B-X
in	B-X
the	B-X
activated	B-X
partial	B-X
thromboplastin	B-X
time	B-X
assay	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
construct	B-X
containing	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
of	B-X
factor	B-X
X	B-X
shows	B-X
essentially	B-X
normal	B-X
clotting	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
unlikely	B-X
that	B-X
this	B-X
domain	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
unique	B-X
interaction	B-X
with	B-X
factor	B-X
VIII	B-X
.	B-X

The	O
analysis	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
residues	O
reveals	O
that	O
all	O
of	O
the	O
purified	O
recombinants	O
are	O
almost	O
fully	O
carboxylated	O
.	O
<EOS>	B-X
The	B-X
recombinants	B-X
have	B-X
been	B-X
purified	B-X
using	B-X
a	B-X
metal	B-X
ion-dependent	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
residues	B-X
1-42	B-X
of	B-X
human	B-X
factor	B-X
IX	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
factor	B-X
IX	B-X
recombinants	B-X
by	B-X
factor	B-X
VIIa-tissue	B-X
factor	B-X
appears	B-X
to	B-X
be	B-X
normal	B-X
for	B-X
the	B-X
epidermal	B-X
growth	B-X
factor-1	B-X
exchange	B-X
but	B-X
considerably	B-X
reduced	B-X
for	B-X
the	B-X
construction	B-X
containing	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
of	B-X
factor	B-X
X	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
reveals	B-X
that	B-X
all	B-X
of	B-X
the	B-X
purified	B-X
recombinants	B-X
are	B-X
almost	B-X
fully	B-X
carboxylated	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
aspartic	B-X
acid	B-X
hydroxylation	B-X
at	B-X
residue	B-X
64	B-X
is	B-X
60	B-X
%	B-X
for	B-X
all	B-X
recombinants	B-X
.	B-X

The	O
extent	O
of	O
aspartic	O
acid	O
hydroxylation	O
at	O
residue	O
64	O
is	O
60	O
%	O
for	O
all	O
recombinants	O
.	O
<EOS>	B-X
The	B-X
recombinants	B-X
have	B-X
been	B-X
purified	B-X
using	B-X
a	B-X
metal	B-X
ion-dependent	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
residues	B-X
1-42	B-X
of	B-X
human	B-X
factor	B-X
IX	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
factor	B-X
IX	B-X
recombinants	B-X
by	B-X
factor	B-X
VIIa-tissue	B-X
factor	B-X
appears	B-X
to	B-X
be	B-X
normal	B-X
for	B-X
the	B-X
epidermal	B-X
growth	B-X
factor-1	B-X
exchange	B-X
but	B-X
considerably	B-X
reduced	B-X
for	B-X
the	B-X
construction	B-X
containing	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
of	B-X
factor	B-X
X	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
reveals	B-X
that	B-X
all	B-X
of	B-X
the	B-X
purified	B-X
recombinants	B-X
are	B-X
almost	B-X
fully	B-X
carboxylated	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
aspartic	B-X
acid	B-X
hydroxylation	B-X
at	B-X
residue	B-X
64	B-X
is	B-X
60	B-X
%	B-X
for	B-X
all	B-X
recombinants	B-X
.	B-X

The	O
chimeric	O
molecule	O
with	O
both	O
epidermal	O
growth	O
factor	O
-	O
like	O
domains	O
from	O
factor	B-Protein
X	I-Protein
has	O
about	O
4	O
%	O
normal	O
activity	O
in	O
the	O
activated	O
partial	O
thromboplastin	B-Protein
time	O
assay	O
.	O
<EOS>	B-X
Human	B-X
blood	B-X
clotting	B-X
factor	B-X
IX	B-X
,	B-X
and	B-X
two	B-X
chimeric	B-X
molecules	B-X
of	B-X
factor	B-X
IX	B-X
,	B-X
in	B-X
which	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
or	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
have	B-X
been	B-X
replaced	B-X
by	B-X
that	B-X
of	B-X
human	B-X
factor	B-X
X	B-X
,	B-X
have	B-X
been	B-X
expressed	B-X
in	B-X
mouse	B-X
C127	B-X
cells	B-X
.	B-X
The	B-X
recombinants	B-X
have	B-X
been	B-X
purified	B-X
using	B-X
a	B-X
metal	B-X
ion-dependent	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
residues	B-X
1-42	B-X
of	B-X
human	B-X
factor	B-X
IX	B-X
.	B-X
All	B-X
recombinant	B-X
molecules	B-X
are	B-X
activated	B-X
normally	B-X
by	B-X
human	B-X
factor	B-X
XIa	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
ion	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
factor	B-X
IX	B-X
recombinants	B-X
by	B-X
factor	B-X
VIIa-tissue	B-X
factor	B-X
appears	B-X
to	B-X
be	B-X
normal	B-X
for	B-X
the	B-X
epidermal	B-X
growth	B-X
factor-1	B-X
exchange	B-X
but	B-X
considerably	B-X
reduced	B-X
for	B-X
the	B-X
construction	B-X
containing	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
of	B-X
factor	B-X
X	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
aspartic	B-X
acid	B-X
hydroxylation	B-X
at	B-X
residue	B-X
64	B-X
is	B-X
60	B-X
%	B-X
for	B-X
all	B-X
recombinants	B-X
.	B-X
The	B-X
chimeric	B-X
molecule	B-X
with	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
from	B-X
factor	B-X
X	B-X
has	B-X
about	B-X
4	B-X
%	B-X
normal	B-X
activity	B-X
in	B-X
the	B-X
activated	B-X
partial	B-X
thromboplastin	B-X
time	B-X
assay	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
construct	B-X
containing	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
of	B-X
factor	B-X
X	B-X
shows	B-X
essentially	B-X
normal	B-X
clotting	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
unlikely	B-X
that	B-X
this	B-X
domain	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
unique	B-X
interaction	B-X
with	B-X
factor	B-X
VIII	B-X
.	B-X

In	O
contrast	O
,	O
the	O
construct	O
containing	O
the	O
first	O
epidermal	O
growth	O
factor	O
-	O
like	O
domain	O
of	O
factor	B-Protein
X	I-Protein
shows	O
essentially	O
normal	O
clotting	O
activity	O
.	O
<EOS>	B-X
Human	B-X
blood	B-X
clotting	B-X
factor	B-X
IX	B-X
,	B-X
and	B-X
two	B-X
chimeric	B-X
molecules	B-X
of	B-X
factor	B-X
IX	B-X
,	B-X
in	B-X
which	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
or	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
have	B-X
been	B-X
replaced	B-X
by	B-X
that	B-X
of	B-X
human	B-X
factor	B-X
X	B-X
,	B-X
have	B-X
been	B-X
expressed	B-X
in	B-X
mouse	B-X
C127	B-X
cells	B-X
.	B-X
The	B-X
recombinants	B-X
have	B-X
been	B-X
purified	B-X
using	B-X
a	B-X
metal	B-X
ion-dependent	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
residues	B-X
1-42	B-X
of	B-X
human	B-X
factor	B-X
IX	B-X
.	B-X
All	B-X
recombinant	B-X
molecules	B-X
are	B-X
activated	B-X
normally	B-X
by	B-X
human	B-X
factor	B-X
XIa	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
calcium	B-X
ion	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
factor	B-X
IX	B-X
recombinants	B-X
by	B-X
factor	B-X
VIIa-tissue	B-X
factor	B-X
appears	B-X
to	B-X
be	B-X
normal	B-X
for	B-X
the	B-X
epidermal	B-X
growth	B-X
factor-1	B-X
exchange	B-X
but	B-X
considerably	B-X
reduced	B-X
for	B-X
the	B-X
construction	B-X
containing	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
of	B-X
factor	B-X
X	B-X
.	B-X
The	B-X
chimeric	B-X
molecule	B-X
with	B-X
both	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domains	B-X
from	B-X
factor	B-X
X	B-X
has	B-X
about	B-X
4	B-X
%	B-X
normal	B-X
activity	B-X
in	B-X
the	B-X
activated	B-X
partial	B-X
thromboplastin	B-X
time	B-X
assay	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
construct	B-X
containing	B-X
the	B-X
first	B-X
epidermal	B-X
growth	B-X
factor-like	B-X
domain	B-X
of	B-X
factor	B-X
X	B-X
shows	B-X
essentially	B-X
normal	B-X
clotting	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
unlikely	B-X
that	B-X
this	B-X
domain	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
unique	B-X
interaction	B-X
with	B-X
factor	B-X
VIII	B-X
.	B-X

Thus	O
,	O
it	O
is	O
unlikely	O
that	O
this	O
domain	O
is	O
involved	O
in	O
a	O
unique	O
interaction	O
with	O
factor	B-Protein
VIII	I-Protein
.	O

Release	O
of	O
[	O
hydroxyproline3	O
]	O
-	O
kinins	B-Protein
by	O
tissue	O
kallikreins	O
of	O
pig	O
,	O
rat	O
and	O
man	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
susceptibility	B-X
of	B-X
kininogens	B-X
containing	B-X
the	B-X
recently	B-X
described	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
moiety	B-X
to	B-X
cleavage	B-X
by	B-X
tissue	B-X
kallikreins	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
release	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-kinins	B-X
from	B-X
heat	B-X
inactivated	B-X
human	B-X
plasma	B-X
by	B-X
purified	B-X
tissue	B-X
kallikreins	B-X
.	B-X
Kallikreins	B-X
from	B-X
man	B-X
and	B-X
pig	B-X
were	B-X
employed	B-X
and	B-X
compared	B-X
with	B-X
purified	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
which	B-X
is	B-X
known	B-X
to	B-X
have	B-X
a	B-X
different	B-X
cleavage	B-X
specificity	B-X
.	B-X
Kinins	B-X
released	B-X
were	B-X
separated	B-X
by	B-X
a	B-X
modified	B-X
reversed	B-X
phase	B-X
HPLC	B-X
method	B-X
and	B-X
quantitated	B-X
by	B-X
bioassay	B-X
and	B-X
radioimmunoassay	B-X
.	B-X
Human	B-X
urinary	B-X
kallikrein	B-X
and	B-X
hog	B-X
tissue	B-X
kallikreins	B-X
released	B-X
85-90	B-X
%	B-X
of	B-X
the	B-X
total	B-X
kinins	B-X
as	B-X
Lys-bradykinin	B-X
and	B-X
10-15	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
released	B-X
77	B-X
%	B-X
as	B-X
bradykinin	B-X
,	B-X
22	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
and	B-X
negligible	B-X
amounts	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
from	B-X
the	B-X
identical	B-X
substrate	B-X
source	B-X
indicating	B-X
that	B-X
rat	B-X
tissue	B-X
kallikreins	B-X
prefer	B-X
the	B-X
Lys-Arg-bond	B-X
within	B-X
both	B-X
unhydroxylated	B-X
and	B-X
hydroxylated	B-X
kininogens	B-X
.	B-X
Therefore	B-X
,	B-X
hydroxylation	B-X
of	B-X
human	B-X
kininogens	B-X
apparently	B-X
does	B-X
not	B-X
affect	B-X
their	B-X
ability	B-X
to	B-X
serve	B-X
as	B-X
substrates	B-X
for	B-X
tissue	B-X
kallikreins	B-X
with	B-X
different	B-X
cleavage	B-X
specificities	B-X
.	B-X

To	O
determine	O
the	O
susceptibility	O
of	O
kininogens	B-Protein
containing	O
the	O
recently	O
described	O
[	O
Hyp3	O
]	O
-	O
bradykinin	B-Protein
moiety	O
to	O
cleavage	O
by	O
tissue	O
kallikreins	O
,	O
we	O
have	O
studied	O
the	O
release	O
of	O
[	O
Hyp3	O
]	O
-	O
kinins	B-Protein
from	O
heat	O
inactivated	O
human	O
plasma	O
by	O
purified	O
tissue	O
kallikreins	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
susceptibility	B-X
of	B-X
kininogens	B-X
containing	B-X
the	B-X
recently	B-X
described	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
moiety	B-X
to	B-X
cleavage	B-X
by	B-X
tissue	B-X
kallikreins	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
release	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-kinins	B-X
from	B-X
heat	B-X
inactivated	B-X
human	B-X
plasma	B-X
by	B-X
purified	B-X
tissue	B-X
kallikreins	B-X
.	B-X
Kallikreins	B-X
from	B-X
man	B-X
and	B-X
pig	B-X
were	B-X
employed	B-X
and	B-X
compared	B-X
with	B-X
purified	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
which	B-X
is	B-X
known	B-X
to	B-X
have	B-X
a	B-X
different	B-X
cleavage	B-X
specificity	B-X
.	B-X
Kinins	B-X
released	B-X
were	B-X
separated	B-X
by	B-X
a	B-X
modified	B-X
reversed	B-X
phase	B-X
HPLC	B-X
method	B-X
and	B-X
quantitated	B-X
by	B-X
bioassay	B-X
and	B-X
radioimmunoassay	B-X
.	B-X
Human	B-X
urinary	B-X
kallikrein	B-X
and	B-X
hog	B-X
tissue	B-X
kallikreins	B-X
released	B-X
85-90	B-X
%	B-X
of	B-X
the	B-X
total	B-X
kinins	B-X
as	B-X
Lys-bradykinin	B-X
and	B-X
10-15	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
released	B-X
77	B-X
%	B-X
as	B-X
bradykinin	B-X
,	B-X
22	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
and	B-X
negligible	B-X
amounts	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
from	B-X
the	B-X
identical	B-X
substrate	B-X
source	B-X
indicating	B-X
that	B-X
rat	B-X
tissue	B-X
kallikreins	B-X
prefer	B-X
the	B-X
Lys-Arg-bond	B-X
within	B-X
both	B-X
unhydroxylated	B-X
and	B-X
hydroxylated	B-X
kininogens	B-X
.	B-X
Therefore	B-X
,	B-X
hydroxylation	B-X
of	B-X
human	B-X
kininogens	B-X
apparently	B-X
does	B-X
not	B-X
affect	B-X
their	B-X
ability	B-X
to	B-X
serve	B-X
as	B-X
substrates	B-X
for	B-X
tissue	B-X
kallikreins	B-X
with	B-X
different	B-X
cleavage	B-X
specificities	B-X
.	B-X

Kallikreins	O
from	O
man	O
and	O
pig	O
were	O
employed	O
and	O
compared	O
with	O
purified	O
rat	O
urinary	O
kallikrein	O
which	O
is	O
known	O
to	O
have	O
a	O
different	O
cleavage	O
specificity	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
susceptibility	B-X
of	B-X
kininogens	B-X
containing	B-X
the	B-X
recently	B-X
described	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
moiety	B-X
to	B-X
cleavage	B-X
by	B-X
tissue	B-X
kallikreins	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
release	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-kinins	B-X
from	B-X
heat	B-X
inactivated	B-X
human	B-X
plasma	B-X
by	B-X
purified	B-X
tissue	B-X
kallikreins	B-X
.	B-X
Kallikreins	B-X
from	B-X
man	B-X
and	B-X
pig	B-X
were	B-X
employed	B-X
and	B-X
compared	B-X
with	B-X
purified	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
which	B-X
is	B-X
known	B-X
to	B-X
have	B-X
a	B-X
different	B-X
cleavage	B-X
specificity	B-X
.	B-X
Kinins	B-X
released	B-X
were	B-X
separated	B-X
by	B-X
a	B-X
modified	B-X
reversed	B-X
phase	B-X
HPLC	B-X
method	B-X
and	B-X
quantitated	B-X
by	B-X
bioassay	B-X
and	B-X
radioimmunoassay	B-X
.	B-X
Human	B-X
urinary	B-X
kallikrein	B-X
and	B-X
hog	B-X
tissue	B-X
kallikreins	B-X
released	B-X
85-90	B-X
%	B-X
of	B-X
the	B-X
total	B-X
kinins	B-X
as	B-X
Lys-bradykinin	B-X
and	B-X
10-15	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
released	B-X
77	B-X
%	B-X
as	B-X
bradykinin	B-X
,	B-X
22	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
and	B-X
negligible	B-X
amounts	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
from	B-X
the	B-X
identical	B-X
substrate	B-X
source	B-X
indicating	B-X
that	B-X
rat	B-X
tissue	B-X
kallikreins	B-X
prefer	B-X
the	B-X
Lys-Arg-bond	B-X
within	B-X
both	B-X
unhydroxylated	B-X
and	B-X
hydroxylated	B-X
kininogens	B-X
.	B-X
Therefore	B-X
,	B-X
hydroxylation	B-X
of	B-X
human	B-X
kininogens	B-X
apparently	B-X
does	B-X
not	B-X
affect	B-X
their	B-X
ability	B-X
to	B-X
serve	B-X
as	B-X
substrates	B-X
for	B-X
tissue	B-X
kallikreins	B-X
with	B-X
different	B-X
cleavage	B-X
specificities	B-X
.	B-X

Kinins	O
released	O
were	O
separated	O
by	O
a	O
modified	O
reversed	O
phase	O
HPLC	O
method	O
and	O
quantitated	O
by	O
bioassay	O
and	O
radioimmunoassay	O
.	O
<EOS>	B-X
Kinins	B-X
released	B-X
were	B-X
separated	B-X
by	B-X
a	B-X
modified	B-X
reversed	B-X
phase	B-X
HPLC	B-X
method	B-X
and	B-X
quantitated	B-X
by	B-X
bioassay	B-X
and	B-X
radioimmunoassay	B-X
.	B-X
Human	B-X
urinary	B-X
kallikrein	B-X
and	B-X
hog	B-X
tissue	B-X
kallikreins	B-X
released	B-X
85-90	B-X
%	B-X
of	B-X
the	B-X
total	B-X
kinins	B-X
as	B-X
Lys-bradykinin	B-X
and	B-X
10-15	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
released	B-X
77	B-X
%	B-X
as	B-X
bradykinin	B-X
,	B-X
22	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
and	B-X
negligible	B-X
amounts	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
from	B-X
the	B-X
identical	B-X
substrate	B-X
source	B-X
indicating	B-X
that	B-X
rat	B-X
tissue	B-X
kallikreins	B-X
prefer	B-X
the	B-X
Lys-Arg-bond	B-X
within	B-X
both	B-X
unhydroxylated	B-X
and	B-X
hydroxylated	B-X
kininogens	B-X
.	B-X

Human	O
urinary	O
kallikrein	O
and	O
hog	O
tissue	O
kallikreins	O
released	O
85	O
-	O
90	O
%	O
of	O
the	O
total	O
kinins	B-Protein
as	O
Lys	O
-	O
bradykinin	B-Protein
and	O
10	O
-	O
15	O
%	O
as	O
[	O
Hyp3	O
]	O
-	O
Lys	O
-	O
bradykinin	B-Protein
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
susceptibility	B-X
of	B-X
kininogens	B-X
containing	B-X
the	B-X
recently	B-X
described	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
moiety	B-X
to	B-X
cleavage	B-X
by	B-X
tissue	B-X
kallikreins	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
release	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-kinins	B-X
from	B-X
heat	B-X
inactivated	B-X
human	B-X
plasma	B-X
by	B-X
purified	B-X
tissue	B-X
kallikreins	B-X
.	B-X
Kallikreins	B-X
from	B-X
man	B-X
and	B-X
pig	B-X
were	B-X
employed	B-X
and	B-X
compared	B-X
with	B-X
purified	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
which	B-X
is	B-X
known	B-X
to	B-X
have	B-X
a	B-X
different	B-X
cleavage	B-X
specificity	B-X
.	B-X
Kinins	B-X
released	B-X
were	B-X
separated	B-X
by	B-X
a	B-X
modified	B-X
reversed	B-X
phase	B-X
HPLC	B-X
method	B-X
and	B-X
quantitated	B-X
by	B-X
bioassay	B-X
and	B-X
radioimmunoassay	B-X
.	B-X
Human	B-X
urinary	B-X
kallikrein	B-X
and	B-X
hog	B-X
tissue	B-X
kallikreins	B-X
released	B-X
85-90	B-X
%	B-X
of	B-X
the	B-X
total	B-X
kinins	B-X
as	B-X
Lys-bradykinin	B-X
and	B-X
10-15	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
released	B-X
77	B-X
%	B-X
as	B-X
bradykinin	B-X
,	B-X
22	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
and	B-X
negligible	B-X
amounts	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
from	B-X
the	B-X
identical	B-X
substrate	B-X
source	B-X
indicating	B-X
that	B-X
rat	B-X
tissue	B-X
kallikreins	B-X
prefer	B-X
the	B-X
Lys-Arg-bond	B-X
within	B-X
both	B-X
unhydroxylated	B-X
and	B-X
hydroxylated	B-X
kininogens	B-X
.	B-X
Therefore	B-X
,	B-X
hydroxylation	B-X
of	B-X
human	B-X
kininogens	B-X
apparently	B-X
does	B-X
not	B-X
affect	B-X
their	B-X
ability	B-X
to	B-X
serve	B-X
as	B-X
substrates	B-X
for	B-X
tissue	B-X
kallikreins	B-X
with	B-X
different	B-X
cleavage	B-X
specificities	B-X
.	B-X

In	O
contrast	O
,	O
rat	O
urinary	O
kallikrein	O
released	O
77	O
%	O
as	O
bradykinin	B-Protein
,	O
22	O
%	O
as	O
[	O
Hyp3	O
]	O
-	O
bradykinin	B-Protein
and	O
negligible	O
amounts	O
of	O
[	O
Hyp3	O
]	O
-	O
Lys	O
-	O
bradykinin	B-Protein
from	O
the	O
identical	O
substrate	O
source	O
indicating	O
that	O
rat	O
tissue	O
kallikreins	O
prefer	O
the	O
Lys	O
-	O
Arg	O
-	O
bond	O
within	O
both	O
unhydroxylated	O
and	O
hydroxylated	O
kininogens	B-Protein
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
susceptibility	B-X
of	B-X
kininogens	B-X
containing	B-X
the	B-X
recently	B-X
described	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
moiety	B-X
to	B-X
cleavage	B-X
by	B-X
tissue	B-X
kallikreins	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
release	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-kinins	B-X
from	B-X
heat	B-X
inactivated	B-X
human	B-X
plasma	B-X
by	B-X
purified	B-X
tissue	B-X
kallikreins	B-X
.	B-X
Kallikreins	B-X
from	B-X
man	B-X
and	B-X
pig	B-X
were	B-X
employed	B-X
and	B-X
compared	B-X
with	B-X
purified	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
which	B-X
is	B-X
known	B-X
to	B-X
have	B-X
a	B-X
different	B-X
cleavage	B-X
specificity	B-X
.	B-X
Kinins	B-X
released	B-X
were	B-X
separated	B-X
by	B-X
a	B-X
modified	B-X
reversed	B-X
phase	B-X
HPLC	B-X
method	B-X
and	B-X
quantitated	B-X
by	B-X
bioassay	B-X
and	B-X
radioimmunoassay	B-X
.	B-X
Human	B-X
urinary	B-X
kallikrein	B-X
and	B-X
hog	B-X
tissue	B-X
kallikreins	B-X
released	B-X
85-90	B-X
%	B-X
of	B-X
the	B-X
total	B-X
kinins	B-X
as	B-X
Lys-bradykinin	B-X
and	B-X
10-15	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
rat	B-X
urinary	B-X
kallikrein	B-X
released	B-X
77	B-X
%	B-X
as	B-X
bradykinin	B-X
,	B-X
22	B-X
%	B-X
as	B-X
[	B-X
Hyp3	B-X
]	B-X
-bradykinin	B-X
and	B-X
negligible	B-X
amounts	B-X
of	B-X
[	B-X
Hyp3	B-X
]	B-X
-Lys-bradykinin	B-X
from	B-X
the	B-X
identical	B-X
substrate	B-X
source	B-X
indicating	B-X
that	B-X
rat	B-X
tissue	B-X
kallikreins	B-X
prefer	B-X
the	B-X
Lys-Arg-bond	B-X
within	B-X
both	B-X
unhydroxylated	B-X
and	B-X
hydroxylated	B-X
kininogens	B-X
.	B-X
Therefore	B-X
,	B-X
hydroxylation	B-X
of	B-X
human	B-X
kininogens	B-X
apparently	B-X
does	B-X
not	B-X
affect	B-X
their	B-X
ability	B-X
to	B-X
serve	B-X
as	B-X
substrates	B-X
for	B-X
tissue	B-X
kallikreins	B-X
with	B-X
different	B-X
cleavage	B-X
specificities	B-X
.	B-X

Therefore	O
,	O
hydroxylation	O
of	O
human	O
kininogens	B-Protein
apparently	O
does	O
not	O
affect	O
their	O
ability	O
to	O
serve	O
as	O
substrates	O
for	O
tissue	O
kallikreins	O
with	O
different	O
cleavage	O
specificities	O
.	O

Processing	O
of	O
the	O
gp55	B-Protein
-	O
116	B-Protein
envelope	O
glycoprotein	O
complex	O
(	O
gB	B-Protein
)	O
of	O
human	O
cytomegalovirus	O
.	O
<EOS>	B-X
The	B-X
processing	B-X
pathway	B-X
of	B-X
the	B-X
major	B-X
envelope	B-X
glycoprotein	B-X
complex	B-X
,	B-X
gp55-116	B-X
(	B-X
gB	B-X
)	B-X
,	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
was	B-X
studied	B-X
using	B-X
inhibitors	B-X
of	B-X
glycosylation	B-X
and	B-X
endoglycosidases	B-X
.	B-X
The	B-X
results	B-X
of	B-X
these	B-X
studies	B-X
indicated	B-X
that	B-X
the	B-X
mature	B-X
gp55-116	B-X
is	B-X
synthesized	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
both	B-X
simple	B-X
and	B-X
complex	B-X
N-linked	B-X
sugars	B-X
to	B-X
a	B-X
nonglycosylated	B-X
precursor	B-X
of	B-X
estimated	B-X
Mr	B-X
105,000	B-X
.	B-X
The	B-X
gp150	B-X
is	B-X
then	B-X
processed	B-X
relatively	B-X
slowly	B-X
to	B-X
a	B-X
Mr	B-X
165,000	B-X
to	B-X
170,000	B-X
species	B-X
(	B-X
gp165-170	B-X
)	B-X
,	B-X
which	B-X
is	B-X
then	B-X
cleaved	B-X
to	B-X
yield	B-X
the	B-X
mature	B-X
gp55-116	B-X
.	B-X
Digestion	B-X
of	B-X
the	B-X
intracellular	B-X
forms	B-X
of	B-X
this	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
the	B-X
virion	B-X
forms	B-X
confirmed	B-X
the	B-X
above	B-X
findings	B-X
and	B-X
indicated	B-X
that	B-X
the	B-X
mature	B-X
virion	B-X
form	B-X
of	B-X
gp55	B-X
contains	B-X
8,000	B-X
daltons	B-X
of	B-X
N-linked	B-X
sugars	B-X
.	B-X
The	B-X
virion	B-X
gp116	B-X
contains	B-X
some	B-X
52,000	B-X
to	B-X
57,000	B-X
daltons	B-X
of	B-X
N-linked	B-X
carbohydrates	B-X
and	B-X
approximately	B-X
5,000	B-X
daltons	B-X
of	B-X
O-linked	B-X
sugars	B-X
.	B-X

The	O
processing	O
pathway	O
of	O
the	O
major	O
envelope	O
glycoprotein	O
complex	O
,	O
gp55	B-Protein
-	O
116	B-Protein
(	O
gB	B-Protein
)	O
,	O
of	O
human	O
cytomegalovirus	O
was	O
studied	O
using	O
inhibitors	O
of	O
glycosylation	O
and	O
endoglycosidases	O
.	O
<EOS>	B-X
The	B-X
processing	B-X
pathway	B-X
of	B-X
the	B-X
major	B-X
envelope	B-X
glycoprotein	B-X
complex	B-X
,	B-X
gp55-116	B-X
(	B-X
gB	B-X
)	B-X
,	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
was	B-X
studied	B-X
using	B-X
inhibitors	B-X
of	B-X
glycosylation	B-X
and	B-X
endoglycosidases	B-X
.	B-X
The	B-X
results	B-X
of	B-X
these	B-X
studies	B-X
indicated	B-X
that	B-X
the	B-X
mature	B-X
gp55-116	B-X
is	B-X
synthesized	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
both	B-X
simple	B-X
and	B-X
complex	B-X
N-linked	B-X
sugars	B-X
to	B-X
a	B-X
nonglycosylated	B-X
precursor	B-X
of	B-X
estimated	B-X
Mr	B-X
105,000	B-X
.	B-X
In	B-X
a	B-X
rapid	B-X
processing	B-X
step	B-X
,	B-X
the	B-X
Mr	B-X
105,000	B-X
precursor	B-X
is	B-X
glycosylated	B-X
to	B-X
a	B-X
protein	B-X
of	B-X
Mr	B-X
150,000	B-X
(	B-X
gp150	B-X
)	B-X
which	B-X
contains	B-X
only	B-X
endoglycosidase	B-X
H-sensitive	B-X
sugar	B-X
linkages	B-X
.	B-X
The	B-X
gp150	B-X
is	B-X
then	B-X
processed	B-X
relatively	B-X
slowly	B-X
to	B-X
a	B-X
Mr	B-X
165,000	B-X
to	B-X
170,000	B-X
species	B-X
(	B-X
gp165-170	B-X
)	B-X
,	B-X
which	B-X
is	B-X
then	B-X
cleaved	B-X
to	B-X
yield	B-X
the	B-X
mature	B-X
gp55-116	B-X
.	B-X
Monensin	B-X
prevented	B-X
the	B-X
final	B-X
processing	B-X
steps	B-X
of	B-X
the	B-X
gp150	B-X
,	B-X
including	B-X
cleavage	B-X
,	B-X
suggesting	B-X
that	B-X
transport	B-X
through	B-X
the	B-X
Golgi	B-X
apparatus	B-X
is	B-X
required	B-X
for	B-X
complete	B-X
processing	B-X
.	B-X
Digestion	B-X
of	B-X
the	B-X
intracellular	B-X
forms	B-X
of	B-X
this	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
the	B-X
virion	B-X
forms	B-X
confirmed	B-X
the	B-X
above	B-X
findings	B-X
and	B-X
indicated	B-X
that	B-X
the	B-X
mature	B-X
virion	B-X
form	B-X
of	B-X
gp55	B-X
contains	B-X
8,000	B-X
daltons	B-X
of	B-X
N-linked	B-X
sugars	B-X
.	B-X
The	B-X
virion	B-X
gp116	B-X
contains	B-X
some	B-X
52,000	B-X
to	B-X
57,000	B-X
daltons	B-X
of	B-X
N-linked	B-X
carbohydrates	B-X
and	B-X
approximately	B-X
5,000	B-X
daltons	B-X
of	B-X
O-linked	B-X
sugars	B-X
.	B-X

The	O
results	O
of	O
these	O
studies	O
indicated	O
that	O
the	O
mature	O
gp55	B-Protein
-	O
116	B-Protein
is	O
synthesized	O
by	O
the	O
addition	O
of	O
both	O
simple	O
and	O
complex	O
N	O
-	O
linked	O
sugars	O
to	O
a	O
nonglycosylated	O
precursor	O
of	O
estimated	O
Mr	O
105	O
,	O
000	O
.	O
<EOS>	B-X
The	B-X
processing	B-X
pathway	B-X
of	B-X
the	B-X
major	B-X
envelope	B-X
glycoprotein	B-X
complex	B-X
,	B-X
gp55-116	B-X
(	B-X
gB	B-X
)	B-X
,	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
was	B-X
studied	B-X
using	B-X
inhibitors	B-X
of	B-X
glycosylation	B-X
and	B-X
endoglycosidases	B-X
.	B-X
The	B-X
results	B-X
of	B-X
these	B-X
studies	B-X
indicated	B-X
that	B-X
the	B-X
mature	B-X
gp55-116	B-X
is	B-X
synthesized	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
both	B-X
simple	B-X
and	B-X
complex	B-X
N-linked	B-X
sugars	B-X
to	B-X
a	B-X
nonglycosylated	B-X
precursor	B-X
of	B-X
estimated	B-X
Mr	B-X
105,000	B-X
.	B-X
In	B-X
a	B-X
rapid	B-X
processing	B-X
step	B-X
,	B-X
the	B-X
Mr	B-X
105,000	B-X
precursor	B-X
is	B-X
glycosylated	B-X
to	B-X
a	B-X
protein	B-X
of	B-X
Mr	B-X
150,000	B-X
(	B-X
gp150	B-X
)	B-X
which	B-X
contains	B-X
only	B-X
endoglycosidase	B-X
H-sensitive	B-X
sugar	B-X
linkages	B-X
.	B-X
The	B-X
gp150	B-X
is	B-X
then	B-X
processed	B-X
relatively	B-X
slowly	B-X
to	B-X
a	B-X
Mr	B-X
165,000	B-X
to	B-X
170,000	B-X
species	B-X
(	B-X
gp165-170	B-X
)	B-X
,	B-X
which	B-X
is	B-X
then	B-X
cleaved	B-X
to	B-X
yield	B-X
the	B-X
mature	B-X
gp55-116	B-X
.	B-X
Digestion	B-X
of	B-X
the	B-X
intracellular	B-X
forms	B-X
of	B-X
this	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
the	B-X
virion	B-X
forms	B-X
confirmed	B-X
the	B-X
above	B-X
findings	B-X
and	B-X
indicated	B-X
that	B-X
the	B-X
mature	B-X
virion	B-X
form	B-X
of	B-X
gp55	B-X
contains	B-X
8,000	B-X
daltons	B-X
of	B-X
N-linked	B-X
sugars	B-X
.	B-X
The	B-X
virion	B-X
gp116	B-X
contains	B-X
some	B-X
52,000	B-X
to	B-X
57,000	B-X
daltons	B-X
of	B-X
N-linked	B-X
carbohydrates	B-X
and	B-X
approximately	B-X
5,000	B-X
daltons	B-X
of	B-X
O-linked	B-X
sugars	B-X
.	B-X

In	O
a	O
rapid	O
processing	O
step	O
,	O
the	O
Mr	O
105	O
,	O
000	O
precursor	O
is	O
glycosylated	O
to	O
a	O
protein	O
of	O
Mr	O
150	O
,	O
000	O
(	O
gp150	B-Protein
)	O
which	O
contains	O
only	O
endoglycosidase	B-Protein
H	I-Protein
-	O
sensitive	O
sugar	O
linkages	O
.	O

The	O
gp150	B-Protein
is	O
then	O
processed	O
relatively	O
slowly	O
to	O
a	O
Mr	O
165	O
,	O
000	O
to	O
170	O
,	O
000	O
species	O
(	O
gp165	B-Protein
-	I-Protein
170	I-Protein
)	O
,	O
which	O
is	O
then	O
cleaved	O
to	O
yield	O
the	O
mature	O
gp55	B-Protein
-	O
116	B-Protein
.	O
<EOS>	B-X
The	B-X
processing	B-X
pathway	B-X
of	B-X
the	B-X
major	B-X
envelope	B-X
glycoprotein	B-X
complex	B-X
,	B-X
gp55-116	B-X
(	B-X
gB	B-X
)	B-X
,	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
was	B-X
studied	B-X
using	B-X
inhibitors	B-X
of	B-X
glycosylation	B-X
and	B-X
endoglycosidases	B-X
.	B-X
The	B-X
results	B-X
of	B-X
these	B-X
studies	B-X
indicated	B-X
that	B-X
the	B-X
mature	B-X
gp55-116	B-X
is	B-X
synthesized	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
both	B-X
simple	B-X
and	B-X
complex	B-X
N-linked	B-X
sugars	B-X
to	B-X
a	B-X
nonglycosylated	B-X
precursor	B-X
of	B-X
estimated	B-X
Mr	B-X
105,000	B-X
.	B-X
In	B-X
a	B-X
rapid	B-X
processing	B-X
step	B-X
,	B-X
the	B-X
Mr	B-X
105,000	B-X
precursor	B-X
is	B-X
glycosylated	B-X
to	B-X
a	B-X
protein	B-X
of	B-X
Mr	B-X
150,000	B-X
(	B-X
gp150	B-X
)	B-X
which	B-X
contains	B-X
only	B-X
endoglycosidase	B-X
H-sensitive	B-X
sugar	B-X
linkages	B-X
.	B-X
The	B-X
gp150	B-X
is	B-X
then	B-X
processed	B-X
relatively	B-X
slowly	B-X
to	B-X
a	B-X
Mr	B-X
165,000	B-X
to	B-X
170,000	B-X
species	B-X
(	B-X
gp165-170	B-X
)	B-X
,	B-X
which	B-X
is	B-X
then	B-X
cleaved	B-X
to	B-X
yield	B-X
the	B-X
mature	B-X
gp55-116	B-X
.	B-X
Monensin	B-X
prevented	B-X
the	B-X
final	B-X
processing	B-X
steps	B-X
of	B-X
the	B-X
gp150	B-X
,	B-X
including	B-X
cleavage	B-X
,	B-X
suggesting	B-X
that	B-X
transport	B-X
through	B-X
the	B-X
Golgi	B-X
apparatus	B-X
is	B-X
required	B-X
for	B-X
complete	B-X
processing	B-X
.	B-X
Digestion	B-X
of	B-X
the	B-X
intracellular	B-X
forms	B-X
of	B-X
this	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
the	B-X
virion	B-X
forms	B-X
confirmed	B-X
the	B-X
above	B-X
findings	B-X
and	B-X
indicated	B-X
that	B-X
the	B-X
mature	B-X
virion	B-X
form	B-X
of	B-X
gp55	B-X
contains	B-X
8,000	B-X
daltons	B-X
of	B-X
N-linked	B-X
sugars	B-X
.	B-X
The	B-X
virion	B-X
gp116	B-X
contains	B-X
some	B-X
52,000	B-X
to	B-X
57,000	B-X
daltons	B-X
of	B-X
N-linked	B-X
carbohydrates	B-X
and	B-X
approximately	B-X
5,000	B-X
daltons	B-X
of	B-X
O-linked	B-X
sugars	B-X
.	B-X

Monensin	O
prevented	O
the	O
final	O
processing	O
steps	O
of	O
the	O
gp150	B-Protein
,	O
including	O
cleavage	O
,	O
suggesting	O
that	O
transport	O
through	O
the	O
Golgi	O
apparatus	O
is	O
required	O
for	O
complete	O
processing	O
.	O
<EOS>	B-X
The	B-X
processing	B-X
pathway	B-X
of	B-X
the	B-X
major	B-X
envelope	B-X
glycoprotein	B-X
complex	B-X
,	B-X
gp55-116	B-X
(	B-X
gB	B-X
)	B-X
,	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
was	B-X
studied	B-X
using	B-X
inhibitors	B-X
of	B-X
glycosylation	B-X
and	B-X
endoglycosidases	B-X
.	B-X
In	B-X
a	B-X
rapid	B-X
processing	B-X
step	B-X
,	B-X
the	B-X
Mr	B-X
105,000	B-X
precursor	B-X
is	B-X
glycosylated	B-X
to	B-X
a	B-X
protein	B-X
of	B-X
Mr	B-X
150,000	B-X
(	B-X
gp150	B-X
)	B-X
which	B-X
contains	B-X
only	B-X
endoglycosidase	B-X
H-sensitive	B-X
sugar	B-X
linkages	B-X
.	B-X
The	B-X
gp150	B-X
is	B-X
then	B-X
processed	B-X
relatively	B-X
slowly	B-X
to	B-X
a	B-X
Mr	B-X
165,000	B-X
to	B-X
170,000	B-X
species	B-X
(	B-X
gp165-170	B-X
)	B-X
,	B-X
which	B-X
is	B-X
then	B-X
cleaved	B-X
to	B-X
yield	B-X
the	B-X
mature	B-X
gp55-116	B-X
.	B-X
Monensin	B-X
prevented	B-X
the	B-X
final	B-X
processing	B-X
steps	B-X
of	B-X
the	B-X
gp150	B-X
,	B-X
including	B-X
cleavage	B-X
,	B-X
suggesting	B-X
that	B-X
transport	B-X
through	B-X
the	B-X
Golgi	B-X
apparatus	B-X
is	B-X
required	B-X
for	B-X
complete	B-X
processing	B-X
.	B-X

Digestion	O
of	O
the	O
intracellular	O
forms	O
of	O
this	O
complex	O
as	O
well	O
as	O
the	O
virion	O
forms	O
confirmed	O
the	O
above	O
findings	O
and	O
indicated	O
that	O
the	O
mature	O
virion	O
form	O
of	O
gp55	B-Protein
contains	O
8	O
,	O
000	O
daltons	O
of	O
N	O
-	O
linked	O
sugars	O
.	O

The	O
virion	O
gp116	B-Protein
contains	O
some	O
52	O
,	O
000	O
to	O
57	O
,	O
000	O
daltons	O
of	O
N	O
-	O
linked	O
carbohydrates	O
and	O
approximately	O
5	O
,	O
000	O
daltons	O
of	O
O	O
-	O
linked	O
sugars	O
.	O

Microthrombomodulin	B-Protein
.	O

Residues	O
310	O
-	O
486	O
from	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
precursor	O
homology	O
domain	O
of	O
thrombomodulin	B-Protein
will	O
accelerate	O
protein	O
C	O
activation	O
.	O
<EOS>	B-X
Thrombomodulin	B-X
is	B-X
the	B-X
endothelial	B-X
cell	B-X
cofactor	B-X
for	B-X
thrombin-catalyzed	B-X
activation	B-X
of	B-X
protein	B-X
C.	B-X
Recently	B-X
,	B-X
we	B-X
isolated	B-X
a	B-X
10-kDa	B-X
thrombin	B-X
binding	B-X
fragment	B-X
,	B-X
CB3	B-X
,	B-X
from	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
precursor	B-X
homology	B-X
domain	B-X
(	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
regions	B-X
)	B-X
of	B-X
thrombomodulin	B-X
(	B-X
Kurasawa	B-X
,	B-X
S.	B-X
,	B-X
Stearns	B-X
,	B-X
D.	B-X
J.	B-X
,	B-X
Jackson	B-X
,	B-X
K.W.	B-X
,	B-X
and	B-X
Esmon	B-X
,	B-X
C.T	B-X
.	B-X
Chem	B-X
.	B-X
The	B-X
CB3	B-X
fragment	B-X
did	B-X
not	B-X
,	B-X
however	B-X
,	B-X
support	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
A	B-X
29-kDa	B-X
fragment	B-X
,	B-X
called	B-X
CB23	B-X
,	B-X
has	B-X
now	B-X
been	B-X
isolated	B-X
and	B-X
corresponds	B-X
to	B-X
residues	B-X
310-486	B-X
in	B-X
the	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
The	B-X
CB23	B-X
fragment	B-X
bound	B-X
thrombin	B-X
and	B-X
accelerated	B-X
thrombin-catalyzed	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
With	B-X
two	B-X
separate	B-X
preparations	B-X
of	B-X
CB23	B-X
,	B-X
the	B-X
Km	B-X
for	B-X
protein	B-X
C	B-X
was	B-X
1.6	B-X
and	B-X
1.9	B-X
microM	B-X
and	B-X
the	B-X
Kd	B-X
for	B-X
thrombin	B-X
was	B-X
8.9	B-X
and	B-X
13.2	B-X
nM	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
CB23	B-X
and	B-X
CB3	B-X
was	B-X
identified	B-X
by	B-X
isolation	B-X
and	B-X
sequence	B-X
analysis	B-X
of	B-X
a	B-X
tryptic	B-X
peptide	B-X
from	B-X
CB3	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
this	B-X
peptide	B-X
corresponded	B-X
to	B-X
Asn457-Ser486	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
these	B-X
fragments	B-X
is	B-X
6	B-X
residues	B-X
beyond	B-X
the	B-X
sixth	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
CB3	B-X
can	B-X
not	B-X
accelerate	B-X
protein	B-X
C	B-X
activation	B-X
,	B-X
CB3	B-X
did	B-X
inhibit	B-X
the	B-X
rate	B-X
of	B-X
thrombin-catalyzed	B-X
fibrinopeptide	B-X
release	B-X
from	B-X
fibrinogen	B-X
.	B-X
Thus	B-X
,	B-X
like	B-X
native	B-X
thrombomodulin	B-X
,	B-X
CB3	B-X
will	B-X
alter	B-X
thrombin	B-X
's	B-X
substrate	B-X
specificity	B-X
,	B-X
but	B-X
protein	B-X
C	B-X
activation	B-X
requires	B-X
additional	B-X
information	B-X
all	B-X
of	B-X
which	B-X
can	B-X
be	B-X
provided	B-X
by	B-X
other	B-X
regions	B-X
of	B-X
the	B-X
EGF-like	B-X
domain	B-X
.	B-X

Thrombomodulin	B-Protein
is	O
the	O
endothelial	O
cell	O
cofactor	O
for	O
thrombin	O
-	O
catalyzed	O
activation	O
of	O
protein	B-Protein
C	I-Protein
.	O
<EOS>	B-X
The	B-X
process	B-X
of	B-X
blood	B-X
coagulation	B-X
is	B-X
mediated	B-X
by	B-X
activation	B-X
of	B-X
a	B-X
series	B-X
of	B-X
serine-protease	B-X
zymogens	B-X
.	B-X
The	B-X
protein	B-X
C	B-X
(	B-X
PC	B-X
)	B-X
anticoagulant	B-X
pathway	B-X
,	B-X
one	B-X
of	B-X
the	B-X
important	B-X
pathways	B-X
related	B-X
to	B-X
physiological	B-X
thrombosis	B-X
formation	B-X
,	B-X
includes	B-X
PC	B-X
,	B-X
thrombomodulin	B-X
(	B-X
TM	B-X
)	B-X
,	B-X
endothelial	B-X
PC	B-X
receptor	B-X
(	B-X
EPCR	B-X
)	B-X
,	B-X
protein	B-X
S	B-X
(	B-X
PS	B-X
)	B-X
and	B-X
C4b-binding	B-X
protein	B-X
(	B-X
C4BP	B-X
)	B-X
.	B-X
TM	B-X
,	B-X
mainly	B-X
present	B-X
in	B-X
endothelial	B-X
cells	B-X
,	B-X
is	B-X
a	B-X
cofactor	B-X
for	B-X
thrombin-catalyzed	B-X
activation	B-X
of	B-X
PC	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
activated	B-X
PC	B-X
(	B-X
aPC	B-X
)	B-X
inactivates	B-X
the	B-X
blood	B-X
coagulation	B-X
cofactors	B-X
factor	B-X
Va	B-X
and	B-X
factor	B-X
VIIIa	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PS	B-X
.	B-X
PS	B-X
,	B-X
mainly	B-X
synthesized	B-X
in	B-X
hepatocytes	B-X
and	B-X
endothelial	B-X
cells	B-X
,	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
as	B-X
a	B-X
cofactor	B-X
of	B-X
anticoagulant	B-X
aPC	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
blood	B-X
coagulation	B-X
.	B-X
The	B-X
cofactor	B-X
activity	B-X
of	B-X
PS	B-X
for	B-X
aPC	B-X
is	B-X
regulated	B-X
by	B-X
C4BP	B-X
,	B-X
a	B-X
multimeric	B-X
protein	B-X
whose	B-X
structure	B-X
consists	B-X
of	B-X
seven	B-X
α-chains	B-X
(	B-X
C4BPα	B-X
)	B-X
and	B-X
a	B-X
β-chain	B-X
(	B-X
C4BPβ	B-X
)	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
based	B-X
primarily	B-X
on	B-X
our	B-X
previous	B-X
studies	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
LPS-	B-X
and	B-X
cytokine-induced	B-X
changes	B-X
in	B-X
various	B-X
proteins	B-X
in	B-X
the	B-X
PC	B-X
anticoagulant	B-X
pathway	B-X
that	B-X
are	B-X
related	B-X
to	B-X
the	B-X
increased	B-X
risk	B-X
of	B-X
thrombosis	B-X
under	B-X
sepsis	B-X
.	B-X

Recently	O
,	O
we	O
isolated	O
a	O
10	O
-	O
kDa	O
thrombin	B-Protein
binding	O
fragment	O
,	O
CB3	O
,	O
from	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
precursor	O
homology	O
domain	O
(	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
(	O
EGF	B-Protein
)	O
-	O
like	O
regions	O
)	O
of	O
thrombomodulin	B-Protein
(	O
Kurasawa	O
,	O
S	O
.	O
,	O
Stearns	O
,	O
D	O
.	O
J	O
.	O
,	O
Jackson	O
,	O
K	O
.	O
W	O
.	O
,	O
and	O
Esmon	O
,	O
C	O
.	O
T	O
.	O
(	O
1988	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
263	O
,	O
5993	O
-	O
5996	O
)	O
.	O

The	O
CB3	O
fragment	O
did	O
not	O
,	O
however	O
,	O
support	O
protein	B-Protein
C	I-Protein
activation	O
.	O
<EOS>	B-X
An	B-X
interesting	B-X
example	B-X
for	B-X
complex	B-X
collagens	B-X
is	B-X
collagen	B-X
type	B-X
VI	B-X
for	B-X
it	B-X
shares	B-X
non-collagenous	B-X
domains	B-X
with	B-X
the	B-X
von	B-X
Willebrand	B-X
factor	B-X
A	B-X
domain	B-X
,	B-X
the	B-X
platelet	B-X
glycoprotein	B-X
Ib	B-X
,	B-X
fibronectin	B-X
type	B-X
III	B-X
repeats	B-X
,	B-X
and	B-X
Kunitz	B-X
type	B-X
protease	B-X
inhibitor	B-X
.	B-X
Monomeric	B-X
and	B-X
fibrillar	B-X
collagens	B-X
effectively	B-X
support	B-X
platelet	B-X
adhesion	B-X
,	B-X
whereas	B-X
for	B-X
collagen-induced	B-X
platelet	B-X
aggregation	B-X
and	B-X
secretion	B-X
,	B-X
the	B-X
native	B-X
,	B-X
triple-helical	B-X
structure	B-X
of	B-X
collagen	B-X
is	B-X
required	B-X
.	B-X
Using	B-X
CNBr-peptides	B-X
three	B-X
aggregatory	B-X
sites	B-X
in	B-X
the	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
chain	B-X
and	B-X
one	B-X
in	B-X
the	B-X
alpha	B-X
1	B-X
(	B-X
III	B-X
)	B-X
chain	B-X
have	B-X
been	B-X
found	B-X
.	B-X
Cyanogen	B-X
bromide	B-X
fragments	B-X
of	B-X
collagen	B-X
type	B-X
I	B-X
were	B-X
also	B-X
used	B-X
to	B-X
measure	B-X
platelet	B-X
adhesion	B-X
under	B-X
flow	B-X
conditions	B-X
.	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
CB3	B-X
strongly	B-X
supports	B-X
platelet	B-X
adhesion	B-X
.	B-X
The	B-X
two	B-X
peptides	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
CB3	B-X
and	B-X
alpha	B-X
1	B-X
(	B-X
III	B-X
)	B-X
CB4	B-X
are	B-X
highly	B-X
homologous	B-X
.	B-X
alpha	B-X
1	B-X
(	B-X
III	B-X
)	B-X
CB4	B-X
is	B-X
highly	B-X
aggregatory	B-X
.	B-X
Among	B-X
them	B-X
are	B-X
the	B-X
``	B-X
leech	B-X
anti-platelet	B-X
protein	B-X
''	B-X
(	B-X
LAPP	B-X
)	B-X
,	B-X
calin	B-X
,	B-X
moubatin	B-X
,	B-X
and	B-X
pallidipin	B-X
.	B-X

A	O
29	O
-	O
kDa	O
fragment	O
,	O
called	O
CB23	O
,	O
has	O
now	O
been	O
isolated	O
and	O
corresponds	O
to	O
residues	O
310	O
-	O
486	O
in	O
the	O
EGF	B-Protein
-	O
like	O
region	O
of	O
thrombomodulin	B-Protein
.	O
<EOS>	B-X
Thrombomodulin	B-X
is	B-X
the	B-X
endothelial	B-X
cell	B-X
cofactor	B-X
for	B-X
thrombin-catalyzed	B-X
activation	B-X
of	B-X
protein	B-X
C.	B-X
Recently	B-X
,	B-X
we	B-X
isolated	B-X
a	B-X
10-kDa	B-X
thrombin	B-X
binding	B-X
fragment	B-X
,	B-X
CB3	B-X
,	B-X
from	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
precursor	B-X
homology	B-X
domain	B-X
(	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
regions	B-X
)	B-X
of	B-X
thrombomodulin	B-X
(	B-X
Kurasawa	B-X
,	B-X
S.	B-X
,	B-X
Stearns	B-X
,	B-X
D.	B-X
J.	B-X
,	B-X
Jackson	B-X
,	B-X
K.W.	B-X
,	B-X
and	B-X
Esmon	B-X
,	B-X
C.T	B-X
.	B-X
The	B-X
CB3	B-X
fragment	B-X
did	B-X
not	B-X
,	B-X
however	B-X
,	B-X
support	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
A	B-X
29-kDa	B-X
fragment	B-X
,	B-X
called	B-X
CB23	B-X
,	B-X
has	B-X
now	B-X
been	B-X
isolated	B-X
and	B-X
corresponds	B-X
to	B-X
residues	B-X
310-486	B-X
in	B-X
the	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
The	B-X
CB23	B-X
fragment	B-X
bound	B-X
thrombin	B-X
and	B-X
accelerated	B-X
thrombin-catalyzed	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
With	B-X
two	B-X
separate	B-X
preparations	B-X
of	B-X
CB23	B-X
,	B-X
the	B-X
Km	B-X
for	B-X
protein	B-X
C	B-X
was	B-X
1.6	B-X
and	B-X
1.9	B-X
microM	B-X
and	B-X
the	B-X
Kd	B-X
for	B-X
thrombin	B-X
was	B-X
8.9	B-X
and	B-X
13.2	B-X
nM	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
CB23	B-X
and	B-X
CB3	B-X
was	B-X
identified	B-X
by	B-X
isolation	B-X
and	B-X
sequence	B-X
analysis	B-X
of	B-X
a	B-X
tryptic	B-X
peptide	B-X
from	B-X
CB3	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
this	B-X
peptide	B-X
corresponded	B-X
to	B-X
Asn457-Ser486	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
these	B-X
fragments	B-X
is	B-X
6	B-X
residues	B-X
beyond	B-X
the	B-X
sixth	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
Thus	B-X
,	B-X
like	B-X
native	B-X
thrombomodulin	B-X
,	B-X
CB3	B-X
will	B-X
alter	B-X
thrombin	B-X
's	B-X
substrate	B-X
specificity	B-X
,	B-X
but	B-X
protein	B-X
C	B-X
activation	B-X
requires	B-X
additional	B-X
information	B-X
all	B-X
of	B-X
which	B-X
can	B-X
be	B-X
provided	B-X
by	B-X
other	B-X
regions	B-X
of	B-X
the	B-X
EGF-like	B-X
domain	B-X
.	B-X

The	O
CB23	O
fragment	O
bound	O
thrombin	B-Protein
and	O
accelerated	O
thrombin	B-Protein
-	O
catalyzed	O
protein	B-Protein
C	I-Protein
activation	O
.	O
<EOS>	B-X
Thrombomodulin	B-X
is	B-X
the	B-X
endothelial	B-X
cell	B-X
cofactor	B-X
for	B-X
thrombin-catalyzed	B-X
activation	B-X
of	B-X
protein	B-X
C.	B-X
Recently	B-X
,	B-X
we	B-X
isolated	B-X
a	B-X
10-kDa	B-X
thrombin	B-X
binding	B-X
fragment	B-X
,	B-X
CB3	B-X
,	B-X
from	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
precursor	B-X
homology	B-X
domain	B-X
(	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
regions	B-X
)	B-X
of	B-X
thrombomodulin	B-X
(	B-X
Kurasawa	B-X
,	B-X
S.	B-X
,	B-X
Stearns	B-X
,	B-X
D.	B-X
J.	B-X
,	B-X
Jackson	B-X
,	B-X
K.W.	B-X
,	B-X
and	B-X
Esmon	B-X
,	B-X
C.T	B-X
.	B-X
Chem	B-X
.	B-X
The	B-X
CB3	B-X
fragment	B-X
did	B-X
not	B-X
,	B-X
however	B-X
,	B-X
support	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
A	B-X
29-kDa	B-X
fragment	B-X
,	B-X
called	B-X
CB23	B-X
,	B-X
has	B-X
now	B-X
been	B-X
isolated	B-X
and	B-X
corresponds	B-X
to	B-X
residues	B-X
310-486	B-X
in	B-X
the	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
The	B-X
CB23	B-X
fragment	B-X
bound	B-X
thrombin	B-X
and	B-X
accelerated	B-X
thrombin-catalyzed	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
With	B-X
two	B-X
separate	B-X
preparations	B-X
of	B-X
CB23	B-X
,	B-X
the	B-X
Km	B-X
for	B-X
protein	B-X
C	B-X
was	B-X
1.6	B-X
and	B-X
1.9	B-X
microM	B-X
and	B-X
the	B-X
Kd	B-X
for	B-X
thrombin	B-X
was	B-X
8.9	B-X
and	B-X
13.2	B-X
nM	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
CB23	B-X
and	B-X
CB3	B-X
was	B-X
identified	B-X
by	B-X
isolation	B-X
and	B-X
sequence	B-X
analysis	B-X
of	B-X
a	B-X
tryptic	B-X
peptide	B-X
from	B-X
CB3	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
this	B-X
peptide	B-X
corresponded	B-X
to	B-X
Asn457-Ser486	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
these	B-X
fragments	B-X
is	B-X
6	B-X
residues	B-X
beyond	B-X
the	B-X
sixth	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
CB3	B-X
can	B-X
not	B-X
accelerate	B-X
protein	B-X
C	B-X
activation	B-X
,	B-X
CB3	B-X
did	B-X
inhibit	B-X
the	B-X
rate	B-X
of	B-X
thrombin-catalyzed	B-X
fibrinopeptide	B-X
release	B-X
from	B-X
fibrinogen	B-X
.	B-X
Thus	B-X
,	B-X
like	B-X
native	B-X
thrombomodulin	B-X
,	B-X
CB3	B-X
will	B-X
alter	B-X
thrombin	B-X
's	B-X
substrate	B-X
specificity	B-X
,	B-X
but	B-X
protein	B-X
C	B-X
activation	B-X
requires	B-X
additional	B-X
information	B-X
all	B-X
of	B-X
which	B-X
can	B-X
be	B-X
provided	B-X
by	B-X
other	B-X
regions	B-X
of	B-X
the	B-X
EGF-like	B-X
domain	B-X
.	B-X

With	O
two	O
separate	O
preparations	O
of	O
CB23	O
,	O
the	O
Km	O
for	O
protein	B-Protein
C	I-Protein
was	O
1	O
.	O
6	O
and	O
1	O
.	O
9	O
microM	O
and	O
the	O
Kd	O
for	O
thrombin	B-Protein
was	O
8	O
.	O
9	O
and	O
13	O
.	O
2	O
nM	O
.	O
<EOS>	B-X
Thrombomodulin	B-X
is	B-X
the	B-X
endothelial	B-X
cell	B-X
cofactor	B-X
for	B-X
thrombin-catalyzed	B-X
activation	B-X
of	B-X
protein	B-X
C.	B-X
Recently	B-X
,	B-X
we	B-X
isolated	B-X
a	B-X
10-kDa	B-X
thrombin	B-X
binding	B-X
fragment	B-X
,	B-X
CB3	B-X
,	B-X
from	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
precursor	B-X
homology	B-X
domain	B-X
(	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
regions	B-X
)	B-X
of	B-X
thrombomodulin	B-X
(	B-X
Kurasawa	B-X
,	B-X
S.	B-X
,	B-X
Stearns	B-X
,	B-X
D.	B-X
J.	B-X
,	B-X
Jackson	B-X
,	B-X
K.W.	B-X
,	B-X
and	B-X
Esmon	B-X
,	B-X
C.T	B-X
.	B-X
(	B-X
1988	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
Chem	B-X
.	B-X
263	B-X
,	B-X
5993-5996	B-X
)	B-X
.	B-X
The	B-X
CB3	B-X
fragment	B-X
did	B-X
not	B-X
,	B-X
however	B-X
,	B-X
support	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
A	B-X
29-kDa	B-X
fragment	B-X
,	B-X
called	B-X
CB23	B-X
,	B-X
has	B-X
now	B-X
been	B-X
isolated	B-X
and	B-X
corresponds	B-X
to	B-X
residues	B-X
310-486	B-X
in	B-X
the	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
The	B-X
CB23	B-X
fragment	B-X
bound	B-X
thrombin	B-X
and	B-X
accelerated	B-X
thrombin-catalyzed	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
With	B-X
two	B-X
separate	B-X
preparations	B-X
of	B-X
CB23	B-X
,	B-X
the	B-X
Km	B-X
for	B-X
protein	B-X
C	B-X
was	B-X
1.6	B-X
and	B-X
1.9	B-X
microM	B-X
and	B-X
the	B-X
Kd	B-X
for	B-X
thrombin	B-X
was	B-X
8.9	B-X
and	B-X
13.2	B-X
nM	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
CB23	B-X
and	B-X
CB3	B-X
was	B-X
identified	B-X
by	B-X
isolation	B-X
and	B-X
sequence	B-X
analysis	B-X
of	B-X
a	B-X
tryptic	B-X
peptide	B-X
from	B-X
CB3	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
this	B-X
peptide	B-X
corresponded	B-X
to	B-X
Asn457-Ser486	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
these	B-X
fragments	B-X
is	B-X
6	B-X
residues	B-X
beyond	B-X
the	B-X
sixth	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
CB3	B-X
can	B-X
not	B-X
accelerate	B-X
protein	B-X
C	B-X
activation	B-X
,	B-X
CB3	B-X
did	B-X
inhibit	B-X
the	B-X
rate	B-X
of	B-X
thrombin-catalyzed	B-X
fibrinopeptide	B-X
release	B-X
from	B-X
fibrinogen	B-X
.	B-X
Thus	B-X
,	B-X
like	B-X
native	B-X
thrombomodulin	B-X
,	B-X
CB3	B-X
will	B-X
alter	B-X
thrombin	B-X
's	B-X
substrate	B-X
specificity	B-X
,	B-X
but	B-X
protein	B-X
C	B-X
activation	B-X
requires	B-X
additional	B-X
information	B-X
all	B-X
of	B-X
which	B-X
can	B-X
be	B-X
provided	B-X
by	B-X
other	B-X
regions	B-X
of	B-X
the	B-X
EGF-like	B-X
domain	B-X
.	B-X

The	O
carboxyl	O
terminus	O
of	O
CB23	O
and	O
CB3	O
was	O
identified	O
by	O
isolation	O
and	O
sequence	O
analysis	O
of	O
a	O
tryptic	O
peptide	O
from	O
CB3	O
.	O
<EOS>	B-X
Thrombomodulin	B-X
is	B-X
the	B-X
endothelial	B-X
cell	B-X
cofactor	B-X
for	B-X
thrombin-catalyzed	B-X
activation	B-X
of	B-X
protein	B-X
C.	B-X
Recently	B-X
,	B-X
we	B-X
isolated	B-X
a	B-X
10-kDa	B-X
thrombin	B-X
binding	B-X
fragment	B-X
,	B-X
CB3	B-X
,	B-X
from	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
precursor	B-X
homology	B-X
domain	B-X
(	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
regions	B-X
)	B-X
of	B-X
thrombomodulin	B-X
(	B-X
Kurasawa	B-X
,	B-X
S.	B-X
,	B-X
Stearns	B-X
,	B-X
D.	B-X
J.	B-X
,	B-X
Jackson	B-X
,	B-X
K.W.	B-X
,	B-X
and	B-X
Esmon	B-X
,	B-X
C.T	B-X
.	B-X
The	B-X
CB3	B-X
fragment	B-X
did	B-X
not	B-X
,	B-X
however	B-X
,	B-X
support	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
A	B-X
29-kDa	B-X
fragment	B-X
,	B-X
called	B-X
CB23	B-X
,	B-X
has	B-X
now	B-X
been	B-X
isolated	B-X
and	B-X
corresponds	B-X
to	B-X
residues	B-X
310-486	B-X
in	B-X
the	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
The	B-X
CB23	B-X
fragment	B-X
bound	B-X
thrombin	B-X
and	B-X
accelerated	B-X
thrombin-catalyzed	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
With	B-X
two	B-X
separate	B-X
preparations	B-X
of	B-X
CB23	B-X
,	B-X
the	B-X
Km	B-X
for	B-X
protein	B-X
C	B-X
was	B-X
1.6	B-X
and	B-X
1.9	B-X
microM	B-X
and	B-X
the	B-X
Kd	B-X
for	B-X
thrombin	B-X
was	B-X
8.9	B-X
and	B-X
13.2	B-X
nM	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
CB23	B-X
and	B-X
CB3	B-X
was	B-X
identified	B-X
by	B-X
isolation	B-X
and	B-X
sequence	B-X
analysis	B-X
of	B-X
a	B-X
tryptic	B-X
peptide	B-X
from	B-X
CB3	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
this	B-X
peptide	B-X
corresponded	B-X
to	B-X
Asn457-Ser486	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
these	B-X
fragments	B-X
is	B-X
6	B-X
residues	B-X
beyond	B-X
the	B-X
sixth	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
CB3	B-X
can	B-X
not	B-X
accelerate	B-X
protein	B-X
C	B-X
activation	B-X
,	B-X
CB3	B-X
did	B-X
inhibit	B-X
the	B-X
rate	B-X
of	B-X
thrombin-catalyzed	B-X
fibrinopeptide	B-X
release	B-X
from	B-X
fibrinogen	B-X
.	B-X
Thus	B-X
,	B-X
like	B-X
native	B-X
thrombomodulin	B-X
,	B-X
CB3	B-X
will	B-X
alter	B-X
thrombin	B-X
's	B-X
substrate	B-X
specificity	B-X
,	B-X
but	B-X
protein	B-X
C	B-X
activation	B-X
requires	B-X
additional	B-X
information	B-X
all	B-X
of	B-X
which	B-X
can	B-X
be	B-X
provided	B-X
by	B-X
other	B-X
regions	B-X
of	B-X
the	B-X
EGF-like	B-X
domain	B-X
.	B-X

The	O
sequence	O
of	O
this	O
peptide	O
corresponded	O
to	O
Asn457	O
-	O
Ser486	O
,	O
indicating	O
that	O
the	O
carboxyl	O
terminus	O
of	O
these	O
fragments	O
is	O
6	O
residues	O
beyond	O
the	O
sixth	O
EGF	B-Protein
-	O
like	O
region	O
of	O
thrombomodulin	B-Protein
.	O
<EOS>	B-X
Thrombomodulin	B-X
is	B-X
the	B-X
endothelial	B-X
cell	B-X
cofactor	B-X
for	B-X
thrombin-catalyzed	B-X
activation	B-X
of	B-X
protein	B-X
C.	B-X
Recently	B-X
,	B-X
we	B-X
isolated	B-X
a	B-X
10-kDa	B-X
thrombin	B-X
binding	B-X
fragment	B-X
,	B-X
CB3	B-X
,	B-X
from	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
precursor	B-X
homology	B-X
domain	B-X
(	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
regions	B-X
)	B-X
of	B-X
thrombomodulin	B-X
(	B-X
Kurasawa	B-X
,	B-X
S.	B-X
,	B-X
Stearns	B-X
,	B-X
D.	B-X
J.	B-X
,	B-X
Jackson	B-X
,	B-X
K.W.	B-X
,	B-X
and	B-X
Esmon	B-X
,	B-X
C.T	B-X
.	B-X
263	B-X
,	B-X
5993-5996	B-X
)	B-X
.	B-X
A	B-X
29-kDa	B-X
fragment	B-X
,	B-X
called	B-X
CB23	B-X
,	B-X
has	B-X
now	B-X
been	B-X
isolated	B-X
and	B-X
corresponds	B-X
to	B-X
residues	B-X
310-486	B-X
in	B-X
the	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
With	B-X
two	B-X
separate	B-X
preparations	B-X
of	B-X
CB23	B-X
,	B-X
the	B-X
Km	B-X
for	B-X
protein	B-X
C	B-X
was	B-X
1.6	B-X
and	B-X
1.9	B-X
microM	B-X
and	B-X
the	B-X
Kd	B-X
for	B-X
thrombin	B-X
was	B-X
8.9	B-X
and	B-X
13.2	B-X
nM	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
CB23	B-X
and	B-X
CB3	B-X
was	B-X
identified	B-X
by	B-X
isolation	B-X
and	B-X
sequence	B-X
analysis	B-X
of	B-X
a	B-X
tryptic	B-X
peptide	B-X
from	B-X
CB3	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
this	B-X
peptide	B-X
corresponded	B-X
to	B-X
Asn457-Ser486	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
these	B-X
fragments	B-X
is	B-X
6	B-X
residues	B-X
beyond	B-X
the	B-X
sixth	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
CB3	B-X
can	B-X
not	B-X
accelerate	B-X
protein	B-X
C	B-X
activation	B-X
,	B-X
CB3	B-X
did	B-X
inhibit	B-X
the	B-X
rate	B-X
of	B-X
thrombin-catalyzed	B-X
fibrinopeptide	B-X
release	B-X
from	B-X
fibrinogen	B-X
.	B-X
Thus	B-X
,	B-X
like	B-X
native	B-X
thrombomodulin	B-X
,	B-X
CB3	B-X
will	B-X
alter	B-X
thrombin	B-X
's	B-X
substrate	B-X
specificity	B-X
,	B-X
but	B-X
protein	B-X
C	B-X
activation	B-X
requires	B-X
additional	B-X
information	B-X
all	B-X
of	B-X
which	B-X
can	B-X
be	B-X
provided	B-X
by	B-X
other	B-X
regions	B-X
of	B-X
the	B-X
EGF-like	B-X
domain	B-X
.	B-X

In	O
addition	O
,	O
although	O
CB3	O
cannot	O
accelerate	O
protein	B-Protein
C	I-Protein
activation	O
,	O
CB3	O
did	O
inhibit	O
the	O
rate	O
of	O
thrombin	B-Protein
-	O
catalyzed	O
fibrinopeptide	O
release	O
from	O
fibrinogen	O
.	O
<EOS>	B-X
Thrombomodulin	B-X
is	B-X
the	B-X
endothelial	B-X
cell	B-X
cofactor	B-X
for	B-X
thrombin-catalyzed	B-X
activation	B-X
of	B-X
protein	B-X
C.	B-X
Recently	B-X
,	B-X
we	B-X
isolated	B-X
a	B-X
10-kDa	B-X
thrombin	B-X
binding	B-X
fragment	B-X
,	B-X
CB3	B-X
,	B-X
from	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
precursor	B-X
homology	B-X
domain	B-X
(	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
regions	B-X
)	B-X
of	B-X
thrombomodulin	B-X
(	B-X
Kurasawa	B-X
,	B-X
S.	B-X
,	B-X
Stearns	B-X
,	B-X
D.	B-X
J.	B-X
,	B-X
Jackson	B-X
,	B-X
K.W.	B-X
,	B-X
and	B-X
Esmon	B-X
,	B-X
C.T	B-X
.	B-X
Chem	B-X
.	B-X
The	B-X
CB3	B-X
fragment	B-X
did	B-X
not	B-X
,	B-X
however	B-X
,	B-X
support	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
A	B-X
29-kDa	B-X
fragment	B-X
,	B-X
called	B-X
CB23	B-X
,	B-X
has	B-X
now	B-X
been	B-X
isolated	B-X
and	B-X
corresponds	B-X
to	B-X
residues	B-X
310-486	B-X
in	B-X
the	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
The	B-X
CB23	B-X
fragment	B-X
bound	B-X
thrombin	B-X
and	B-X
accelerated	B-X
thrombin-catalyzed	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
With	B-X
two	B-X
separate	B-X
preparations	B-X
of	B-X
CB23	B-X
,	B-X
the	B-X
Km	B-X
for	B-X
protein	B-X
C	B-X
was	B-X
1.6	B-X
and	B-X
1.9	B-X
microM	B-X
and	B-X
the	B-X
Kd	B-X
for	B-X
thrombin	B-X
was	B-X
8.9	B-X
and	B-X
13.2	B-X
nM	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
CB23	B-X
and	B-X
CB3	B-X
was	B-X
identified	B-X
by	B-X
isolation	B-X
and	B-X
sequence	B-X
analysis	B-X
of	B-X
a	B-X
tryptic	B-X
peptide	B-X
from	B-X
CB3	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
CB3	B-X
can	B-X
not	B-X
accelerate	B-X
protein	B-X
C	B-X
activation	B-X
,	B-X
CB3	B-X
did	B-X
inhibit	B-X
the	B-X
rate	B-X
of	B-X
thrombin-catalyzed	B-X
fibrinopeptide	B-X
release	B-X
from	B-X
fibrinogen	B-X
.	B-X
Thus	B-X
,	B-X
like	B-X
native	B-X
thrombomodulin	B-X
,	B-X
CB3	B-X
will	B-X
alter	B-X
thrombin	B-X
's	B-X
substrate	B-X
specificity	B-X
,	B-X
but	B-X
protein	B-X
C	B-X
activation	B-X
requires	B-X
additional	B-X
information	B-X
all	B-X
of	B-X
which	B-X
can	B-X
be	B-X
provided	B-X
by	B-X
other	B-X
regions	B-X
of	B-X
the	B-X
EGF-like	B-X
domain	B-X
.	B-X

Thus	O
,	O
like	O
native	O
thrombomodulin	B-Protein
,	O
CB3	O
will	O
alter	O
thrombin	B-Protein
'	O
s	O
substrate	O
specificity	O
,	O
but	O
protein	B-Protein
C	I-Protein
activation	O
requires	O
additional	O
information	O
all	O
of	O
which	O
can	O
be	O
provided	O
by	O
other	O
regions	O
of	O
the	O
EGF	B-Protein
-	O
like	O
domain	O
.	O
<EOS>	B-X
Thrombomodulin	B-X
is	B-X
the	B-X
endothelial	B-X
cell	B-X
cofactor	B-X
for	B-X
thrombin-catalyzed	B-X
activation	B-X
of	B-X
protein	B-X
C.	B-X
Recently	B-X
,	B-X
we	B-X
isolated	B-X
a	B-X
10-kDa	B-X
thrombin	B-X
binding	B-X
fragment	B-X
,	B-X
CB3	B-X
,	B-X
from	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
precursor	B-X
homology	B-X
domain	B-X
(	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
regions	B-X
)	B-X
of	B-X
thrombomodulin	B-X
(	B-X
Kurasawa	B-X
,	B-X
S.	B-X
,	B-X
Stearns	B-X
,	B-X
D.	B-X
J.	B-X
,	B-X
Jackson	B-X
,	B-X
K.W.	B-X
,	B-X
and	B-X
Esmon	B-X
,	B-X
C.T	B-X
.	B-X
Chem	B-X
.	B-X
The	B-X
CB3	B-X
fragment	B-X
did	B-X
not	B-X
,	B-X
however	B-X
,	B-X
support	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
A	B-X
29-kDa	B-X
fragment	B-X
,	B-X
called	B-X
CB23	B-X
,	B-X
has	B-X
now	B-X
been	B-X
isolated	B-X
and	B-X
corresponds	B-X
to	B-X
residues	B-X
310-486	B-X
in	B-X
the	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
The	B-X
CB23	B-X
fragment	B-X
bound	B-X
thrombin	B-X
and	B-X
accelerated	B-X
thrombin-catalyzed	B-X
protein	B-X
C	B-X
activation	B-X
.	B-X
With	B-X
two	B-X
separate	B-X
preparations	B-X
of	B-X
CB23	B-X
,	B-X
the	B-X
Km	B-X
for	B-X
protein	B-X
C	B-X
was	B-X
1.6	B-X
and	B-X
1.9	B-X
microM	B-X
and	B-X
the	B-X
Kd	B-X
for	B-X
thrombin	B-X
was	B-X
8.9	B-X
and	B-X
13.2	B-X
nM	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
CB23	B-X
and	B-X
CB3	B-X
was	B-X
identified	B-X
by	B-X
isolation	B-X
and	B-X
sequence	B-X
analysis	B-X
of	B-X
a	B-X
tryptic	B-X
peptide	B-X
from	B-X
CB3	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
this	B-X
peptide	B-X
corresponded	B-X
to	B-X
Asn457-Ser486	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
these	B-X
fragments	B-X
is	B-X
6	B-X
residues	B-X
beyond	B-X
the	B-X
sixth	B-X
EGF-like	B-X
region	B-X
of	B-X
thrombomodulin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
CB3	B-X
can	B-X
not	B-X
accelerate	B-X
protein	B-X
C	B-X
activation	B-X
,	B-X
CB3	B-X
did	B-X
inhibit	B-X
the	B-X
rate	B-X
of	B-X
thrombin-catalyzed	B-X
fibrinopeptide	B-X
release	B-X
from	B-X
fibrinogen	B-X
.	B-X
Thus	B-X
,	B-X
like	B-X
native	B-X
thrombomodulin	B-X
,	B-X
CB3	B-X
will	B-X
alter	B-X
thrombin	B-X
's	B-X
substrate	B-X
specificity	B-X
,	B-X
but	B-X
protein	B-X
C	B-X
activation	B-X
requires	B-X
additional	B-X
information	B-X
all	B-X
of	B-X
which	B-X
can	B-X
be	B-X
provided	B-X
by	B-X
other	B-X
regions	B-X
of	B-X
the	B-X
EGF-like	B-X
domain	B-X
.	B-X

Clonal	O
analysis	O
of	O
the	O
glycosylation	O
of	O
immunoglobulin	O
G	O
secreted	O
by	O
murine	O
hybridomas	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
10	B-X
hybridomas	B-X
was	B-X
assembled	B-X
to	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
various	B-X
genetic	B-X
and	B-X
biological	B-X
factors	B-X
upon	B-X
glycosylation	B-X
of	B-X
secreted	B-X
monoclonal	B-X
IgG	B-X
.	B-X
After	B-X
exhaustive	B-X
Pronase	B-X
digestion	B-X
of	B-X
IgG	B-X
,	B-X
glycopeptides	B-X
were	B-X
characterized	B-X
chromatographically	B-X
by	B-X
apparent	B-X
size	B-X
,	B-X
charge	B-X
,	B-X
and	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
-Sepharose	B-X
and	B-X
Lens	B-X
culinaris	B-X
(	B-X
LcH	B-X
)	B-X
-agarose	B-X
affinity	B-X
.	B-X
Six	B-X
glycosylation	B-X
phenotypes	B-X
were	B-X
found	B-X
to	B-X
be	B-X
common	B-X
among	B-X
all	B-X
clones	B-X
studied	B-X
.	B-X
Despite	B-X
this	B-X
phenotypic	B-X
heterogeneity	B-X
in	B-X
glycosylation	B-X
of	B-X
IgG	B-X
,	B-X
considerable	B-X
similarity	B-X
exists	B-X
between	B-X
different	B-X
clones	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
virtually	B-X
all	B-X
IgG	B-X
glycopeptides	B-X
bear	B-X
a	B-X
core	B-X
fucose	B-X
residue	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
glycosylation	B-X
repertoire	B-X
is	B-X
comprised	B-X
of	B-X
two	B-X
phenotypes	B-X
,	B-X
characterized	B-X
by	B-X
glycopeptides	B-X
which	B-X
differ	B-X
in	B-X
affinity	B-X
for	B-X
Con	B-X
A-Sepharose	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
no	B-X
apparent	B-X
correlation	B-X
of	B-X
phenotype	B-X
with	B-X
either	B-X
the	B-X
hybridoma	B-X
's	B-X
parentage	B-X
or	B-X
the	B-X
serologically	B-X
defined	B-X
polypeptide	B-X
structure	B-X
of	B-X
the	B-X
IgG	B-X
which	B-X
it	B-X
secretes	B-X
.	B-X
Also	B-X
,	B-X
differences	B-X
in	B-X
culture	B-X
medium	B-X
pH	B-X
or	B-X
proliferative	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
have	B-X
a	B-X
modest	B-X
influence	B-X
upon	B-X
the	B-X
glycosylation	B-X
phenotype	B-X
.	B-X

A	O
panel	O
of	O
10	O
hybridomas	O
was	O
assembled	O
to	O
assess	O
the	O
influence	O
of	O
various	O
genetic	O
and	O
biological	O
factors	O
upon	O
glycosylation	O
of	O
secreted	O
monoclonal	O
IgG	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
10	B-X
hybridomas	B-X
was	B-X
assembled	B-X
to	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
various	B-X
genetic	B-X
and	B-X
biological	B-X
factors	B-X
upon	B-X
glycosylation	B-X
of	B-X
secreted	B-X
monoclonal	B-X
IgG	B-X
.	B-X
After	B-X
exhaustive	B-X
Pronase	B-X
digestion	B-X
of	B-X
IgG	B-X
,	B-X
glycopeptides	B-X
were	B-X
characterized	B-X
chromatographically	B-X
by	B-X
apparent	B-X
size	B-X
,	B-X
charge	B-X
,	B-X
and	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
-Sepharose	B-X
and	B-X
Lens	B-X
culinaris	B-X
(	B-X
LcH	B-X
)	B-X
-agarose	B-X
affinity	B-X
.	B-X
Six	B-X
glycosylation	B-X
phenotypes	B-X
were	B-X
found	B-X
to	B-X
be	B-X
common	B-X
among	B-X
all	B-X
clones	B-X
studied	B-X
.	B-X
Despite	B-X
this	B-X
phenotypic	B-X
heterogeneity	B-X
in	B-X
glycosylation	B-X
of	B-X
IgG	B-X
,	B-X
considerable	B-X
similarity	B-X
exists	B-X
between	B-X
different	B-X
clones	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
virtually	B-X
all	B-X
IgG	B-X
glycopeptides	B-X
bear	B-X
a	B-X
core	B-X
fucose	B-X
residue	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
glycosylation	B-X
repertoire	B-X
is	B-X
comprised	B-X
of	B-X
two	B-X
phenotypes	B-X
,	B-X
characterized	B-X
by	B-X
glycopeptides	B-X
which	B-X
differ	B-X
in	B-X
affinity	B-X
for	B-X
Con	B-X
A-Sepharose	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
no	B-X
apparent	B-X
correlation	B-X
of	B-X
phenotype	B-X
with	B-X
either	B-X
the	B-X
hybridoma	B-X
's	B-X
parentage	B-X
or	B-X
the	B-X
serologically	B-X
defined	B-X
polypeptide	B-X
structure	B-X
of	B-X
the	B-X
IgG	B-X
which	B-X
it	B-X
secretes	B-X
.	B-X
A	B-X
generational	B-X
variability	B-X
is	B-X
apparent	B-X
upon	B-X
continuous	B-X
culturing	B-X
of	B-X
the	B-X
same	B-X
hybridoma	B-X
.	B-X
Also	B-X
,	B-X
differences	B-X
in	B-X
culture	B-X
medium	B-X
pH	B-X
or	B-X
proliferative	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
have	B-X
a	B-X
modest	B-X
influence	B-X
upon	B-X
the	B-X
glycosylation	B-X
phenotype	B-X
.	B-X

After	O
exhaustive	O
Pronase	O
digestion	O
of	O
IgG	O
,	O
glycopeptides	O
were	O
characterized	O
chromatographically	O
by	O
apparent	O
size	O
,	O
charge	O
,	O
and	O
concanavalin	B-Protein
A	I-Protein
(	O
Con	B-Protein
A	I-Protein
)	O
-	O
Sepharose	O
and	O
Lens	O
culinaris	O
(	O
LcH	O
)	O
-	O
agarose	O
affinity	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
10	B-X
hybridomas	B-X
was	B-X
assembled	B-X
to	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
various	B-X
genetic	B-X
and	B-X
biological	B-X
factors	B-X
upon	B-X
glycosylation	B-X
of	B-X
secreted	B-X
monoclonal	B-X
IgG	B-X
.	B-X
After	B-X
exhaustive	B-X
Pronase	B-X
digestion	B-X
of	B-X
IgG	B-X
,	B-X
glycopeptides	B-X
were	B-X
characterized	B-X
chromatographically	B-X
by	B-X
apparent	B-X
size	B-X
,	B-X
charge	B-X
,	B-X
and	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
-Sepharose	B-X
and	B-X
Lens	B-X
culinaris	B-X
(	B-X
LcH	B-X
)	B-X
-agarose	B-X
affinity	B-X
.	B-X
Despite	B-X
this	B-X
phenotypic	B-X
heterogeneity	B-X
in	B-X
glycosylation	B-X
of	B-X
IgG	B-X
,	B-X
considerable	B-X
similarity	B-X
exists	B-X
between	B-X
different	B-X
clones	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
virtually	B-X
all	B-X
IgG	B-X
glycopeptides	B-X
bear	B-X
a	B-X
core	B-X
fucose	B-X
residue	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
glycosylation	B-X
repertoire	B-X
is	B-X
comprised	B-X
of	B-X
two	B-X
phenotypes	B-X
,	B-X
characterized	B-X
by	B-X
glycopeptides	B-X
which	B-X
differ	B-X
in	B-X
affinity	B-X
for	B-X
Con	B-X
A-Sepharose	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
no	B-X
apparent	B-X
correlation	B-X
of	B-X
phenotype	B-X
with	B-X
either	B-X
the	B-X
hybridoma	B-X
's	B-X
parentage	B-X
or	B-X
the	B-X
serologically	B-X
defined	B-X
polypeptide	B-X
structure	B-X
of	B-X
the	B-X
IgG	B-X
which	B-X
it	B-X
secretes	B-X
.	B-X
A	B-X
generational	B-X
variability	B-X
is	B-X
apparent	B-X
upon	B-X
continuous	B-X
culturing	B-X
of	B-X
the	B-X
same	B-X
hybridoma	B-X
.	B-X

Six	O
glycosylation	O
phenotypes	O
were	O
found	O
to	O
be	O
common	O
among	O
all	O
clones	O
studied	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
10	B-X
hybridomas	B-X
was	B-X
assembled	B-X
to	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
various	B-X
genetic	B-X
and	B-X
biological	B-X
factors	B-X
upon	B-X
glycosylation	B-X
of	B-X
secreted	B-X
monoclonal	B-X
IgG	B-X
.	B-X
Six	B-X
glycosylation	B-X
phenotypes	B-X
were	B-X
found	B-X
to	B-X
be	B-X
common	B-X
among	B-X
all	B-X
clones	B-X
studied	B-X
.	B-X
Despite	B-X
this	B-X
phenotypic	B-X
heterogeneity	B-X
in	B-X
glycosylation	B-X
of	B-X
IgG	B-X
,	B-X
considerable	B-X
similarity	B-X
exists	B-X
between	B-X
different	B-X
clones	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
glycosylation	B-X
repertoire	B-X
is	B-X
comprised	B-X
of	B-X
two	B-X
phenotypes	B-X
,	B-X
characterized	B-X
by	B-X
glycopeptides	B-X
which	B-X
differ	B-X
in	B-X
affinity	B-X
for	B-X
Con	B-X
A-Sepharose	B-X
.	B-X
Of	B-X
these	B-X
,	B-X
the	B-X
predominantly	B-X
expressed	B-X
phenotype	B-X
is	B-X
the	B-X
same	B-X
for	B-X
all	B-X
clones	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
Other	B-X
differences	B-X
between	B-X
clones	B-X
may	B-X
reflect	B-X
the	B-X
expression	B-X
of	B-X
an	B-X
additional	B-X
site	B-X
which	B-X
is	B-X
glycosylated	B-X
differently	B-X
.	B-X
Also	B-X
,	B-X
differences	B-X
in	B-X
culture	B-X
medium	B-X
pH	B-X
or	B-X
proliferative	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
have	B-X
a	B-X
modest	B-X
influence	B-X
upon	B-X
the	B-X
glycosylation	B-X
phenotype	B-X
.	B-X

Despite	O
this	O
phenotypic	O
heterogeneity	O
in	O
glycosylation	O
of	O
IgG	O
,	O
considerable	O
similarity	O
exists	O
between	O
different	O
clones	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
10	B-X
hybridomas	B-X
was	B-X
assembled	B-X
to	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
various	B-X
genetic	B-X
and	B-X
biological	B-X
factors	B-X
upon	B-X
glycosylation	B-X
of	B-X
secreted	B-X
monoclonal	B-X
IgG	B-X
.	B-X
After	B-X
exhaustive	B-X
Pronase	B-X
digestion	B-X
of	B-X
IgG	B-X
,	B-X
glycopeptides	B-X
were	B-X
characterized	B-X
chromatographically	B-X
by	B-X
apparent	B-X
size	B-X
,	B-X
charge	B-X
,	B-X
and	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
-Sepharose	B-X
and	B-X
Lens	B-X
culinaris	B-X
(	B-X
LcH	B-X
)	B-X
-agarose	B-X
affinity	B-X
.	B-X
Six	B-X
glycosylation	B-X
phenotypes	B-X
were	B-X
found	B-X
to	B-X
be	B-X
common	B-X
among	B-X
all	B-X
clones	B-X
studied	B-X
.	B-X
Despite	B-X
this	B-X
phenotypic	B-X
heterogeneity	B-X
in	B-X
glycosylation	B-X
of	B-X
IgG	B-X
,	B-X
considerable	B-X
similarity	B-X
exists	B-X
between	B-X
different	B-X
clones	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
virtually	B-X
all	B-X
IgG	B-X
glycopeptides	B-X
bear	B-X
a	B-X
core	B-X
fucose	B-X
residue	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
glycosylation	B-X
repertoire	B-X
is	B-X
comprised	B-X
of	B-X
two	B-X
phenotypes	B-X
,	B-X
characterized	B-X
by	B-X
glycopeptides	B-X
which	B-X
differ	B-X
in	B-X
affinity	B-X
for	B-X
Con	B-X
A-Sepharose	B-X
.	B-X
Of	B-X
these	B-X
,	B-X
the	B-X
predominantly	B-X
expressed	B-X
phenotype	B-X
is	B-X
the	B-X
same	B-X
for	B-X
all	B-X
clones	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
Other	B-X
differences	B-X
between	B-X
clones	B-X
may	B-X
reflect	B-X
the	B-X
expression	B-X
of	B-X
an	B-X
additional	B-X
site	B-X
which	B-X
is	B-X
glycosylated	B-X
differently	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
no	B-X
apparent	B-X
correlation	B-X
of	B-X
phenotype	B-X
with	B-X
either	B-X
the	B-X
hybridoma	B-X
's	B-X
parentage	B-X
or	B-X
the	B-X
serologically	B-X
defined	B-X
polypeptide	B-X
structure	B-X
of	B-X
the	B-X
IgG	B-X
which	B-X
it	B-X
secretes	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
clonal	B-X
variability	B-X
,	B-X
other	B-X
sources	B-X
of	B-X
variability	B-X
in	B-X
phenotypic	B-X
expression	B-X
were	B-X
identified	B-X
.	B-X
Also	B-X
,	B-X
differences	B-X
in	B-X
culture	B-X
medium	B-X
pH	B-X
or	B-X
proliferative	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
have	B-X
a	B-X
modest	B-X
influence	B-X
upon	B-X
the	B-X
glycosylation	B-X
phenotype	B-X
.	B-X

In	O
particular	O
,	O
virtually	O
all	O
IgG	O
glycopeptides	O
bear	O
a	O
core	O
fucose	O
residue	O
.	O

Second	O
,	O
the	O
majority	O
of	O
the	O
glycosylation	O
repertoire	O
is	O
comprised	O
of	O
two	O
phenotypes	O
,	O
characterized	O
by	O
glycopeptides	O
which	O
differ	O
in	O
affinity	O
for	O
Con	B-Protein
A	I-Protein
-	O
Sepharose	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
10	B-X
hybridomas	B-X
was	B-X
assembled	B-X
to	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
various	B-X
genetic	B-X
and	B-X
biological	B-X
factors	B-X
upon	B-X
glycosylation	B-X
of	B-X
secreted	B-X
monoclonal	B-X
IgG	B-X
.	B-X
After	B-X
exhaustive	B-X
Pronase	B-X
digestion	B-X
of	B-X
IgG	B-X
,	B-X
glycopeptides	B-X
were	B-X
characterized	B-X
chromatographically	B-X
by	B-X
apparent	B-X
size	B-X
,	B-X
charge	B-X
,	B-X
and	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
-Sepharose	B-X
and	B-X
Lens	B-X
culinaris	B-X
(	B-X
LcH	B-X
)	B-X
-agarose	B-X
affinity	B-X
.	B-X
Six	B-X
glycosylation	B-X
phenotypes	B-X
were	B-X
found	B-X
to	B-X
be	B-X
common	B-X
among	B-X
all	B-X
clones	B-X
studied	B-X
.	B-X
Despite	B-X
this	B-X
phenotypic	B-X
heterogeneity	B-X
in	B-X
glycosylation	B-X
of	B-X
IgG	B-X
,	B-X
considerable	B-X
similarity	B-X
exists	B-X
between	B-X
different	B-X
clones	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
virtually	B-X
all	B-X
IgG	B-X
glycopeptides	B-X
bear	B-X
a	B-X
core	B-X
fucose	B-X
residue	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
glycosylation	B-X
repertoire	B-X
is	B-X
comprised	B-X
of	B-X
two	B-X
phenotypes	B-X
,	B-X
characterized	B-X
by	B-X
glycopeptides	B-X
which	B-X
differ	B-X
in	B-X
affinity	B-X
for	B-X
Con	B-X
A-Sepharose	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
Other	B-X
differences	B-X
between	B-X
clones	B-X
may	B-X
reflect	B-X
the	B-X
expression	B-X
of	B-X
an	B-X
additional	B-X
site	B-X
which	B-X
is	B-X
glycosylated	B-X
differently	B-X
.	B-X
Also	B-X
,	B-X
differences	B-X
in	B-X
culture	B-X
medium	B-X
pH	B-X
or	B-X
proliferative	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
have	B-X
a	B-X
modest	B-X
influence	B-X
upon	B-X
the	B-X
glycosylation	B-X
phenotype	B-X
.	B-X

Of	O
these	O
,	O
the	O
predominantly	O
expressed	O
phenotype	O
is	O
the	O
same	O
for	O
all	O
clones	O
.	O
<EOS>	B-X
NAT2	B-X
codes	B-X
for	B-X
a	B-X
protein	B-X
predominantly	B-X
expressed	B-X
in	B-X
liver	B-X
with	B-X
a	B-X
high	B-X
affinity	B-X
for	B-X
sulfamethazine	B-X
and	B-X
other	B-X
polymorphically	B-X
metabolized	B-X
drugs	B-X
.	B-X
NAT2	B-X
was	B-X
analyzed	B-X
at	B-X
the	B-X
level	B-X
of	B-X
protein	B-X
,	B-X
RNA	B-X
and	B-X
DNA	B-X
derived	B-X
from	B-X
phenotyped	B-X
slow	B-X
and	B-X
rapid	B-X
acetylators	B-X
.	B-X
A	B-X
simple	B-X
polymerase	B-X
chain	B-X
reaction-based	B-X
DNA	B-X
test	B-X
can	B-X
identify	B-X
>	B-X
95	B-X
%	B-X
of	B-X
mutant	B-X
alleles	B-X
and	B-X
predict	B-X
the	B-X
phenotype	B-X
.	B-X
With	B-X
the	B-X
aim	B-X
to	B-X
identify	B-X
genetic	B-X
determinants	B-X
that	B-X
modulate	B-X
the	B-X
development	B-X
of	B-X
bunch	B-X
architecture	B-X
,	B-X
we	B-X
have	B-X
compared	B-X
loose	B-X
and	B-X
compact	B-X
'Pinot	B-X
noir	B-X
'	B-X
clones	B-X
.	B-X
Using	B-X
transcriptome	B-X
analysis	B-X
in	B-X
combination	B-X
with	B-X
whole	B-X
genome	B-X
sequencing	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
growth-regulating	B-X
factor	B-X
gene	B-X
,	B-X
VvGRF4	B-X
,	B-X
upregulated	B-X
and	B-X
harbours	B-X
heterozygous	B-X
mutations	B-X
in	B-X
the	B-X
loose	B-X
cluster	B-X
clones	B-X
.	B-X
At	B-X
late	B-X
stages	B-X
of	B-X
inflorescence	B-X
development	B-X
,	B-X
the	B-X
mRNA	B-X
pools	B-X
of	B-X
loose	B-X
cluster	B-X
clones	B-X
contain	B-X
predominantly	B-X
mRNAs	B-X
derived	B-X
from	B-X
the	B-X
mutated	B-X
alleles	B-X
,	B-X
which	B-X
are	B-X
resistant	B-X
to	B-X
miR396	B-X
degradation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
VvGRF4	B-X
modulates	B-X
bunch	B-X
architecture	B-X
in	B-X
grapevine	B-X
'Pinot	B-X
noir	B-X
'	B-X
clones	B-X
.	B-X

The	O
carbohydrate	O
structure	O
derived	O
from	O
this	O
phenotype	O
,	O
elucidated	O
by	O
500	O
-	O
MHz	O
1H	O
NMR	O
spectroscopy	O
,	O
is	O
(	O
Formula	O
:	O
see	O
text	O
)	O
.	O
<EOS>	B-X
Six	B-X
glycosylation	B-X
phenotypes	B-X
were	B-X
found	B-X
to	B-X
be	B-X
common	B-X
among	B-X
all	B-X
clones	B-X
studied	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
glycosylation	B-X
repertoire	B-X
is	B-X
comprised	B-X
of	B-X
two	B-X
phenotypes	B-X
,	B-X
characterized	B-X
by	B-X
glycopeptides	B-X
which	B-X
differ	B-X
in	B-X
affinity	B-X
for	B-X
Con	B-X
A-Sepharose	B-X
.	B-X
Of	B-X
these	B-X
,	B-X
the	B-X
predominantly	B-X
expressed	B-X
phenotype	B-X
is	B-X
the	B-X
same	B-X
for	B-X
all	B-X
clones	B-X
.	B-X
The	B-X
carbohydrate	B-X
structure	B-X
derived	B-X
from	B-X
this	B-X
phenotype	B-X
,	B-X
elucidated	B-X
by	B-X
500-MHz	B-X
1H	B-X
NMR	B-X
spectroscopy	B-X
,	B-X
is	B-X
(	B-X
Formula	B-X
:	B-X
see	B-X
text	B-X
)	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
no	B-X
apparent	B-X
correlation	B-X
of	B-X
phenotype	B-X
with	B-X
either	B-X
the	B-X
hybridoma	B-X
's	B-X
parentage	B-X
or	B-X
the	B-X
serologically	B-X
defined	B-X
polypeptide	B-X
structure	B-X
of	B-X
the	B-X
IgG	B-X
which	B-X
it	B-X
secretes	B-X
.	B-X
Also	B-X
,	B-X
differences	B-X
in	B-X
culture	B-X
medium	B-X
pH	B-X
or	B-X
proliferative	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
have	B-X
a	B-X
modest	B-X
influence	B-X
upon	B-X
the	B-X
glycosylation	B-X
phenotype	B-X
.	B-X

Significant	O
variability	O
between	O
different	O
hybridomas	O
exists	O
in	O
the	O
relative	O
expression	O
of	O
the	O
two	O
major	O
phenotypes	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
10	B-X
hybridomas	B-X
was	B-X
assembled	B-X
to	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
various	B-X
genetic	B-X
and	B-X
biological	B-X
factors	B-X
upon	B-X
glycosylation	B-X
of	B-X
secreted	B-X
monoclonal	B-X
IgG	B-X
.	B-X
Six	B-X
glycosylation	B-X
phenotypes	B-X
were	B-X
found	B-X
to	B-X
be	B-X
common	B-X
among	B-X
all	B-X
clones	B-X
studied	B-X
.	B-X
Despite	B-X
this	B-X
phenotypic	B-X
heterogeneity	B-X
in	B-X
glycosylation	B-X
of	B-X
IgG	B-X
,	B-X
considerable	B-X
similarity	B-X
exists	B-X
between	B-X
different	B-X
clones	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
glycosylation	B-X
repertoire	B-X
is	B-X
comprised	B-X
of	B-X
two	B-X
phenotypes	B-X
,	B-X
characterized	B-X
by	B-X
glycopeptides	B-X
which	B-X
differ	B-X
in	B-X
affinity	B-X
for	B-X
Con	B-X
A-Sepharose	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
Other	B-X
differences	B-X
between	B-X
clones	B-X
may	B-X
reflect	B-X
the	B-X
expression	B-X
of	B-X
an	B-X
additional	B-X
site	B-X
which	B-X
is	B-X
glycosylated	B-X
differently	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
clonal	B-X
variability	B-X
,	B-X
other	B-X
sources	B-X
of	B-X
variability	B-X
in	B-X
phenotypic	B-X
expression	B-X
were	B-X
identified	B-X
.	B-X
A	B-X
generational	B-X
variability	B-X
is	B-X
apparent	B-X
upon	B-X
continuous	B-X
culturing	B-X
of	B-X
the	B-X
same	B-X
hybridoma	B-X
.	B-X

Other	O
differences	O
between	O
clones	O
may	O
reflect	O
the	O
expression	O
of	O
an	O
additional	O
site	O
which	O
is	O
glycosylated	O
differently	O
.	O
<EOS>	B-X
Six	B-X
glycosylation	B-X
phenotypes	B-X
were	B-X
found	B-X
to	B-X
be	B-X
common	B-X
among	B-X
all	B-X
clones	B-X
studied	B-X
.	B-X
Despite	B-X
this	B-X
phenotypic	B-X
heterogeneity	B-X
in	B-X
glycosylation	B-X
of	B-X
IgG	B-X
,	B-X
considerable	B-X
similarity	B-X
exists	B-X
between	B-X
different	B-X
clones	B-X
.	B-X
Of	B-X
these	B-X
,	B-X
the	B-X
predominantly	B-X
expressed	B-X
phenotype	B-X
is	B-X
the	B-X
same	B-X
for	B-X
all	B-X
clones	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
Other	B-X
differences	B-X
between	B-X
clones	B-X
may	B-X
reflect	B-X
the	B-X
expression	B-X
of	B-X
an	B-X
additional	B-X
site	B-X
which	B-X
is	B-X
glycosylated	B-X
differently	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
clonal	B-X
variability	B-X
,	B-X
other	B-X
sources	B-X
of	B-X
variability	B-X
in	B-X
phenotypic	B-X
expression	B-X
were	B-X
identified	B-X
.	B-X
Also	B-X
,	B-X
differences	B-X
in	B-X
culture	B-X
medium	B-X
pH	B-X
or	B-X
proliferative	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
have	B-X
a	B-X
modest	B-X
influence	B-X
upon	B-X
the	B-X
glycosylation	B-X
phenotype	B-X
.	B-X

However	O
,	O
there	O
is	O
no	O
apparent	O
correlation	O
of	O
phenotype	O
with	O
either	O
the	O
hybridoma	O
'	O
s	O
parentage	O
or	O
the	O
serologically	O
defined	O
polypeptide	O
structure	O
of	O
the	O
IgG	O
which	O
it	O
secretes	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
10	B-X
hybridomas	B-X
was	B-X
assembled	B-X
to	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
various	B-X
genetic	B-X
and	B-X
biological	B-X
factors	B-X
upon	B-X
glycosylation	B-X
of	B-X
secreted	B-X
monoclonal	B-X
IgG	B-X
.	B-X
After	B-X
exhaustive	B-X
Pronase	B-X
digestion	B-X
of	B-X
IgG	B-X
,	B-X
glycopeptides	B-X
were	B-X
characterized	B-X
chromatographically	B-X
by	B-X
apparent	B-X
size	B-X
,	B-X
charge	B-X
,	B-X
and	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
-Sepharose	B-X
and	B-X
Lens	B-X
culinaris	B-X
(	B-X
LcH	B-X
)	B-X
-agarose	B-X
affinity	B-X
.	B-X
Six	B-X
glycosylation	B-X
phenotypes	B-X
were	B-X
found	B-X
to	B-X
be	B-X
common	B-X
among	B-X
all	B-X
clones	B-X
studied	B-X
.	B-X
Despite	B-X
this	B-X
phenotypic	B-X
heterogeneity	B-X
in	B-X
glycosylation	B-X
of	B-X
IgG	B-X
,	B-X
considerable	B-X
similarity	B-X
exists	B-X
between	B-X
different	B-X
clones	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
virtually	B-X
all	B-X
IgG	B-X
glycopeptides	B-X
bear	B-X
a	B-X
core	B-X
fucose	B-X
residue	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
glycosylation	B-X
repertoire	B-X
is	B-X
comprised	B-X
of	B-X
two	B-X
phenotypes	B-X
,	B-X
characterized	B-X
by	B-X
glycopeptides	B-X
which	B-X
differ	B-X
in	B-X
affinity	B-X
for	B-X
Con	B-X
A-Sepharose	B-X
.	B-X
Of	B-X
these	B-X
,	B-X
the	B-X
predominantly	B-X
expressed	B-X
phenotype	B-X
is	B-X
the	B-X
same	B-X
for	B-X
all	B-X
clones	B-X
.	B-X
The	B-X
carbohydrate	B-X
structure	B-X
derived	B-X
from	B-X
this	B-X
phenotype	B-X
,	B-X
elucidated	B-X
by	B-X
500-MHz	B-X
1H	B-X
NMR	B-X
spectroscopy	B-X
,	B-X
is	B-X
(	B-X
Formula	B-X
:	B-X
see	B-X
text	B-X
)	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
no	B-X
apparent	B-X
correlation	B-X
of	B-X
phenotype	B-X
with	B-X
either	B-X
the	B-X
hybridoma	B-X
's	B-X
parentage	B-X
or	B-X
the	B-X
serologically	B-X
defined	B-X
polypeptide	B-X
structure	B-X
of	B-X
the	B-X
IgG	B-X
which	B-X
it	B-X
secretes	B-X
.	B-X
A	B-X
generational	B-X
variability	B-X
is	B-X
apparent	B-X
upon	B-X
continuous	B-X
culturing	B-X
of	B-X
the	B-X
same	B-X
hybridoma	B-X
.	B-X
Also	B-X
,	B-X
differences	B-X
in	B-X
culture	B-X
medium	B-X
pH	B-X
or	B-X
proliferative	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
have	B-X
a	B-X
modest	B-X
influence	B-X
upon	B-X
the	B-X
glycosylation	B-X
phenotype	B-X
.	B-X

In	O
addition	O
to	O
clonal	O
variability	O
,	O
other	O
sources	O
of	O
variability	O
in	O
phenotypic	O
expression	O
were	O
identified	O
.	O
<EOS>	B-X
An	B-X
indirect	B-X
phenotyping	B-X
method	B-X
was	B-X
developed	B-X
in	B-X
order	B-X
to	B-X
estimate	B-X
the	B-X
susceptibility	B-X
of	B-X
rubber	B-X
tree	B-X
clonal	B-X
varieties	B-X
to	B-X
Corynespora	B-X
Leaf	B-X
Fall	B-X
(	B-X
CLF	B-X
)	B-X
disease	B-X
caused	B-X
by	B-X
the	B-X
ascomycete	B-X
Corynespora	B-X
cassiicola	B-X
.	B-X
The	B-X
toxicity	B-X
test	B-X
applied	B-X
to	B-X
18	B-X
clones	B-X
using	B-X
13	B-X
toxinic	B-X
treatments	B-X
evidenced	B-X
an	B-X
important	B-X
variability	B-X
among	B-X
clones	B-X
and	B-X
treatments	B-X
,	B-X
with	B-X
a	B-X
significant	B-X
additional	B-X
clone	B-X
x	B-X
treatment	B-X
interaction	B-X
effect	B-X
.	B-X
Phenotyping	B-X
of	B-X
the	B-X
population	B-X
for	B-X
sensitivity	B-X
to	B-X
the	B-X
purified	B-X
Cas1	B-X
effector	B-X
and	B-X
to	B-X
culture	B-X
filtrates	B-X
from	B-X
seven	B-X
C.	B-X
cassiicola	B-X
isolates	B-X
revealed	B-X
a	B-X
polygenic	B-X
determinism	B-X
,	B-X
with	B-X
six	B-X
QTL	B-X
detected	B-X
on	B-X
five	B-X
chromosomes	B-X
and	B-X
percentages	B-X
of	B-X
explained	B-X
phenotypic	B-X
variance	B-X
varying	B-X
from	B-X
11	B-X
to	B-X
17	B-X
%	B-X
.	B-X
Two	B-X
common	B-X
QTL	B-X
were	B-X
identified	B-X
for	B-X
the	B-X
CCP	B-X
filtrate	B-X
and	B-X
the	B-X
purified	B-X
cassiicolin	B-X
,	B-X
suggesting	B-X
that	B-X
Cas1	B-X
may	B-X
be	B-X
the	B-X
main	B-X
effector	B-X
of	B-X
CCP	B-X
filtrate	B-X
toxicity	B-X
.	B-X

A	O
generational	O
variability	O
is	O
apparent	O
upon	O
continuous	O
culturing	O
of	O
the	O
same	O
hybridoma	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
10	B-X
hybridomas	B-X
was	B-X
assembled	B-X
to	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
various	B-X
genetic	B-X
and	B-X
biological	B-X
factors	B-X
upon	B-X
glycosylation	B-X
of	B-X
secreted	B-X
monoclonal	B-X
IgG	B-X
.	B-X
After	B-X
exhaustive	B-X
Pronase	B-X
digestion	B-X
of	B-X
IgG	B-X
,	B-X
glycopeptides	B-X
were	B-X
characterized	B-X
chromatographically	B-X
by	B-X
apparent	B-X
size	B-X
,	B-X
charge	B-X
,	B-X
and	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
-Sepharose	B-X
and	B-X
Lens	B-X
culinaris	B-X
(	B-X
LcH	B-X
)	B-X
-agarose	B-X
affinity	B-X
.	B-X
Significant	B-X
variability	B-X
between	B-X
different	B-X
hybridomas	B-X
exists	B-X
in	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
major	B-X
phenotypes	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
no	B-X
apparent	B-X
correlation	B-X
of	B-X
phenotype	B-X
with	B-X
either	B-X
the	B-X
hybridoma	B-X
's	B-X
parentage	B-X
or	B-X
the	B-X
serologically	B-X
defined	B-X
polypeptide	B-X
structure	B-X
of	B-X
the	B-X
IgG	B-X
which	B-X
it	B-X
secretes	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
clonal	B-X
variability	B-X
,	B-X
other	B-X
sources	B-X
of	B-X
variability	B-X
in	B-X
phenotypic	B-X
expression	B-X
were	B-X
identified	B-X
.	B-X
A	B-X
generational	B-X
variability	B-X
is	B-X
apparent	B-X
upon	B-X
continuous	B-X
culturing	B-X
of	B-X
the	B-X
same	B-X
hybridoma	B-X
.	B-X
Also	B-X
,	B-X
differences	B-X
in	B-X
culture	B-X
medium	B-X
pH	B-X
or	B-X
proliferative	B-X
state	B-X
of	B-X
the	B-X
cells	B-X
may	B-X
have	B-X
a	B-X
modest	B-X
influence	B-X
upon	B-X
the	B-X
glycosylation	B-X
phenotype	B-X
.	B-X

Also	O
,	O
differences	O
in	O
culture	O
medium	O
pH	O
or	O
proliferative	O
state	O
of	O
the	O
cells	O
may	O
have	O
a	O
modest	O
influence	O
upon	O
the	O
glycosylation	O
phenotype	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
eight	B-X
commercially	B-X
available	B-X
,	B-X
chemically	B-X
defined	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cell	B-X
culture	B-X
media	B-X
from	B-X
different	B-X
vendors	B-X
were	B-X
evaluated	B-X
in	B-X
batch	B-X
culture	B-X
using	B-X
an	B-X
IgG-producing	B-X
CHO	B-X
DG44	B-X
cell	B-X
line	B-X
as	B-X
a	B-X
model	B-X
.	B-X
Medium	B-X
adaptation	B-X
revealed	B-X
that	B-X
the	B-X
occurrence	B-X
of	B-X
even	B-X
small	B-X
aggregates	B-X
might	B-X
be	B-X
a	B-X
good	B-X
indicator	B-X
of	B-X
cell	B-X
growth	B-X
performance	B-X
in	B-X
subsequent	B-X
high	B-X
cell	B-X
density	B-X
cultures	B-X
.	B-X
Batch	B-X
experiments	B-X
confirmed	B-X
that	B-X
the	B-X
culture	B-X
medium	B-X
has	B-X
a	B-X
significant	B-X
impact	B-X
on	B-X
bioprocess	B-X
performance	B-X
,	B-X
but	B-X
high	B-X
amino	B-X
acid	B-X
concentrations	B-X
alone	B-X
were	B-X
not	B-X
sufficient	B-X
to	B-X
ensure	B-X
superior	B-X
cell	B-X
growth	B-X
and	B-X
high	B-X
antibody	B-X
production	B-X
.	B-X
Further	B-X
analysis	B-X
revealed	B-X
that	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
feed	B-X
additives	B-X
,	B-X
the	B-X
basal	B-X
medium	B-X
can	B-X
make	B-X
a	B-X
considerable	B-X
contribution	B-X
to	B-X
the	B-X
ammonium	B-X
metabolism	B-X
of	B-X
the	B-X
cells	B-X
.	B-X
The	B-X
glycosylation	B-X
of	B-X
the	B-X
recombinant	B-X
antibody	B-X
was	B-X
influenced	B-X
by	B-X
the	B-X
selection	B-X
of	B-X
basal	B-X
medium	B-X
and	B-X
feeds	B-X
.	B-X

Specific	O
immune	O
responses	O
restored	O
by	O
alteration	O
in	O
carbohydrate	O
chains	O
of	O
surface	O
molecules	O
on	O
antigen	O
-	O
presenting	O
cells	O
.	O
<EOS>	B-X
The	B-X
bm14	B-X
Db	B-X
mutation	B-X
results	B-X
in	B-X
specific	B-X
failure	B-X
of	B-X
female	B-X
bm14	B-X
mice	B-X
to	B-X
generate	B-X
a	B-X
cytotoxic	B-X
T	B-X
lymphocyte	B-X
(	B-X
Tc	B-X
)	B-X
response	B-X
to	B-X
the	B-X
male-specific	B-X
antigen	B-X
H-Y	B-X
.	B-X
The	B-X
allospecific	B-X
Tc	B-X
response	B-X
of	B-X
CD8+	B-X
B6T	B-X
cells	B-X
against	B-X
bm6	B-X
Kb	B-X
mutant	B-X
spleen	B-X
cells	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
against	B-X
other	B-X
Kb	B-X
mutants	B-X
,	B-X
is	B-X
absolutely	B-X
CD4+	B-X
T	B-X
helper	B-X
cell	B-X
dependent	B-X
.	B-X
Purified	B-X
CD8+	B-X
T	B-X
cells	B-X
completely	B-X
fail	B-X
to	B-X
respond	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
the	B-X
inability	B-X
to	B-X
mount	B-X
these	B-X
specific	B-X
immune	B-X
responses	B-X
is	B-X
restored	B-X
by	B-X
the	B-X
use	B-X
of	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
as	B-X
antigen-presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
.	B-X
Comparison	B-X
of	B-X
MHC	B-X
expression	B-X
on	B-X
various	B-X
types	B-X
of	B-X
APC	B-X
by	B-X
cytofluorimetry	B-X
and	B-X
quantitative	B-X
immunoprecipitation	B-X
showed	B-X
very	B-X
high	B-X
expression	B-X
of	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
MHC	B-X
molecules	B-X
on	B-X
DC	B-X
.	B-X
Strikingly	B-X
,	B-X
examination	B-X
of	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
molecules	B-X
by	B-X
isoelectric	B-X
focusing	B-X
revealed	B-X
qualitative	B-X
differences	B-X
as	B-X
well	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
surface	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
of	B-X
DC	B-X
are	B-X
present	B-X
in	B-X
greater	B-X
quantity	B-X
and	B-X
carry	B-X
on	B-X
average	B-X
fewer	B-X
sialic	B-X
acids	B-X
than	B-X
the	B-X
same	B-X
molecules	B-X
isolated	B-X
from	B-X
other	B-X
APC	B-X
types	B-X
such	B-X
as	B-X
spleen	B-X
cells	B-X
,	B-X
lipopolysaccharide	B-X
blasts	B-X
or	B-X
concanavalin	B-X
A	B-X
blasts	B-X
.	B-X
That	B-X
sialic	B-X
acids	B-X
on	B-X
cell	B-X
surface	B-X
molecules	B-X
,	B-X
including	B-X
MHC	B-X
,	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
antigen	B-X
presentation	B-X
is	B-X
suggested	B-X
by	B-X
our	B-X
finding	B-X
that	B-X
removal	B-X
of	B-X
sialic	B-X
acids	B-X
,	B-X
by	B-X
neuraminidase	B-X
,	B-X
can	B-X
restore	B-X
specific	B-X
responses	B-X
to	B-X
nonresponder	B-X
APC	B-X
as	B-X
well	B-X
.	B-X

Two	O
class	O
I	O
major	O
histocompatibility	O
(	O
MHC	O
)	O
mutant	O
mouse	O
strains	O
,	O
H	O
-	O
2bm14	O
and	O
H	O
-	O
2bm6	O
,	O
differ	O
from	O
the	O
strain	O
of	O
origin	O
C57BL	O
/	O
6	O
(	O
B6	O
,	O
H	O
-	O
2b	O
)	O
in	O
one	O
and	O
two	O
amino	O
acids	O
of	O
the	O
H	B-Protein
-	I-Protein
2Db	I-Protein
and	O
H	B-Protein
-	I-Protein
2Kb	I-Protein
molecule	O
,	O
respectively	O
.	O

The	O
bm14	O
Db	O
mutation	O
results	O
in	O
specific	O
failure	O
of	O
female	O
bm14	O
mice	O
to	O
generate	O
a	O
cytotoxic	O
T	O
lymphocyte	O
(	O
Tc	O
)	O
response	O
to	O
the	O
male	O
-	O
specific	O
antigen	O
H	B-Protein
-	I-Protein
Y	I-Protein
.	O

The	O
allospecific	O
Tc	O
response	O
of	O
CD8	B-Protein
+	O
B6T	O
cells	O
against	O
bm6	O
Kb	O
mutant	O
spleen	O
cells	O
,	O
in	O
contrast	O
to	O
that	O
against	O
other	O
Kb	O
mutants	O
,	O
is	O
absolutely	O
CD4	B-Protein
+	O
T	O
helper	O
cell	O
dependent	O
.	O
<EOS>	B-X
Two	B-X
class	B-X
I	B-X
major	B-X
histocompatibility	B-X
(	B-X
MHC	B-X
)	B-X
mutant	B-X
mouse	B-X
strains	B-X
,	B-X
H-2bm14	B-X
and	B-X
H-2bm6	B-X
,	B-X
differ	B-X
from	B-X
the	B-X
strain	B-X
of	B-X
origin	B-X
C57BL/6	B-X
(	B-X
B6	B-X
,	B-X
H-2b	B-X
)	B-X
in	B-X
one	B-X
and	B-X
two	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
H-2Db	B-X
and	B-X
H-2Kb	B-X
molecule	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
bm14	B-X
Db	B-X
mutation	B-X
results	B-X
in	B-X
specific	B-X
failure	B-X
of	B-X
female	B-X
bm14	B-X
mice	B-X
to	B-X
generate	B-X
a	B-X
cytotoxic	B-X
T	B-X
lymphocyte	B-X
(	B-X
Tc	B-X
)	B-X
response	B-X
to	B-X
the	B-X
male-specific	B-X
antigen	B-X
H-Y	B-X
.	B-X
The	B-X
allospecific	B-X
Tc	B-X
response	B-X
of	B-X
CD8+	B-X
B6T	B-X
cells	B-X
against	B-X
bm6	B-X
Kb	B-X
mutant	B-X
spleen	B-X
cells	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
against	B-X
other	B-X
Kb	B-X
mutants	B-X
,	B-X
is	B-X
absolutely	B-X
CD4+	B-X
T	B-X
helper	B-X
cell	B-X
dependent	B-X
.	B-X
Purified	B-X
CD8+	B-X
T	B-X
cells	B-X
completely	B-X
fail	B-X
to	B-X
respond	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
the	B-X
inability	B-X
to	B-X
mount	B-X
these	B-X
specific	B-X
immune	B-X
responses	B-X
is	B-X
restored	B-X
by	B-X
the	B-X
use	B-X
of	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
as	B-X
antigen-presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
surface	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
of	B-X
DC	B-X
are	B-X
present	B-X
in	B-X
greater	B-X
quantity	B-X
and	B-X
carry	B-X
on	B-X
average	B-X
fewer	B-X
sialic	B-X
acids	B-X
than	B-X
the	B-X
same	B-X
molecules	B-X
isolated	B-X
from	B-X
other	B-X
APC	B-X
types	B-X
such	B-X
as	B-X
spleen	B-X
cells	B-X
,	B-X
lipopolysaccharide	B-X
blasts	B-X
or	B-X
concanavalin	B-X
A	B-X
blasts	B-X
.	B-X
That	B-X
sialic	B-X
acids	B-X
on	B-X
cell	B-X
surface	B-X
molecules	B-X
,	B-X
including	B-X
MHC	B-X
,	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
antigen	B-X
presentation	B-X
is	B-X
suggested	B-X
by	B-X
our	B-X
finding	B-X
that	B-X
removal	B-X
of	B-X
sialic	B-X
acids	B-X
,	B-X
by	B-X
neuraminidase	B-X
,	B-X
can	B-X
restore	B-X
specific	B-X
responses	B-X
to	B-X
nonresponder	B-X
APC	B-X
as	B-X
well	B-X
.	B-X

Purified	O
CD8	B-Protein
+	O
T	O
cells	O
completely	O
fail	O
to	O
respond	O
.	O
<EOS>	B-X
The	B-X
bm14	B-X
Db	B-X
mutation	B-X
results	B-X
in	B-X
specific	B-X
failure	B-X
of	B-X
female	B-X
bm14	B-X
mice	B-X
to	B-X
generate	B-X
a	B-X
cytotoxic	B-X
T	B-X
lymphocyte	B-X
(	B-X
Tc	B-X
)	B-X
response	B-X
to	B-X
the	B-X
male-specific	B-X
antigen	B-X
H-Y	B-X
.	B-X
The	B-X
allospecific	B-X
Tc	B-X
response	B-X
of	B-X
CD8+	B-X
B6T	B-X
cells	B-X
against	B-X
bm6	B-X
Kb	B-X
mutant	B-X
spleen	B-X
cells	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
against	B-X
other	B-X
Kb	B-X
mutants	B-X
,	B-X
is	B-X
absolutely	B-X
CD4+	B-X
T	B-X
helper	B-X
cell	B-X
dependent	B-X
.	B-X
Purified	B-X
CD8+	B-X
T	B-X
cells	B-X
completely	B-X
fail	B-X
to	B-X
respond	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
the	B-X
inability	B-X
to	B-X
mount	B-X
these	B-X
specific	B-X
immune	B-X
responses	B-X
is	B-X
restored	B-X
by	B-X
the	B-X
use	B-X
of	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
as	B-X
antigen-presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
surface	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
of	B-X
DC	B-X
are	B-X
present	B-X
in	B-X
greater	B-X
quantity	B-X
and	B-X
carry	B-X
on	B-X
average	B-X
fewer	B-X
sialic	B-X
acids	B-X
than	B-X
the	B-X
same	B-X
molecules	B-X
isolated	B-X
from	B-X
other	B-X
APC	B-X
types	B-X
such	B-X
as	B-X
spleen	B-X
cells	B-X
,	B-X
lipopolysaccharide	B-X
blasts	B-X
or	B-X
concanavalin	B-X
A	B-X
blasts	B-X
.	B-X
That	B-X
sialic	B-X
acids	B-X
on	B-X
cell	B-X
surface	B-X
molecules	B-X
,	B-X
including	B-X
MHC	B-X
,	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
antigen	B-X
presentation	B-X
is	B-X
suggested	B-X
by	B-X
our	B-X
finding	B-X
that	B-X
removal	B-X
of	B-X
sialic	B-X
acids	B-X
,	B-X
by	B-X
neuraminidase	B-X
,	B-X
can	B-X
restore	B-X
specific	B-X
responses	B-X
to	B-X
nonresponder	B-X
APC	B-X
as	B-X
well	B-X
.	B-X

We	O
now	O
report	O
that	O
the	O
inability	O
to	O
mount	O
these	O
specific	O
immune	O
responses	O
is	O
restored	O
by	O
the	O
use	O
of	O
dendritic	O
cells	O
(	O
DC	O
)	O
as	O
antigen	O
-	O
presenting	O
cells	O
(	O
APC	O
)	O
.	O
<EOS>	B-X
Two	B-X
class	B-X
I	B-X
major	B-X
histocompatibility	B-X
(	B-X
MHC	B-X
)	B-X
mutant	B-X
mouse	B-X
strains	B-X
,	B-X
H-2bm14	B-X
and	B-X
H-2bm6	B-X
,	B-X
differ	B-X
from	B-X
the	B-X
strain	B-X
of	B-X
origin	B-X
C57BL/6	B-X
(	B-X
B6	B-X
,	B-X
H-2b	B-X
)	B-X
in	B-X
one	B-X
and	B-X
two	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
H-2Db	B-X
and	B-X
H-2Kb	B-X
molecule	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
bm14	B-X
Db	B-X
mutation	B-X
results	B-X
in	B-X
specific	B-X
failure	B-X
of	B-X
female	B-X
bm14	B-X
mice	B-X
to	B-X
generate	B-X
a	B-X
cytotoxic	B-X
T	B-X
lymphocyte	B-X
(	B-X
Tc	B-X
)	B-X
response	B-X
to	B-X
the	B-X
male-specific	B-X
antigen	B-X
H-Y	B-X
.	B-X
The	B-X
allospecific	B-X
Tc	B-X
response	B-X
of	B-X
CD8+	B-X
B6T	B-X
cells	B-X
against	B-X
bm6	B-X
Kb	B-X
mutant	B-X
spleen	B-X
cells	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
against	B-X
other	B-X
Kb	B-X
mutants	B-X
,	B-X
is	B-X
absolutely	B-X
CD4+	B-X
T	B-X
helper	B-X
cell	B-X
dependent	B-X
.	B-X
Purified	B-X
CD8+	B-X
T	B-X
cells	B-X
completely	B-X
fail	B-X
to	B-X
respond	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
the	B-X
inability	B-X
to	B-X
mount	B-X
these	B-X
specific	B-X
immune	B-X
responses	B-X
is	B-X
restored	B-X
by	B-X
the	B-X
use	B-X
of	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
as	B-X
antigen-presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
.	B-X
Comparison	B-X
of	B-X
MHC	B-X
expression	B-X
on	B-X
various	B-X
types	B-X
of	B-X
APC	B-X
by	B-X
cytofluorimetry	B-X
and	B-X
quantitative	B-X
immunoprecipitation	B-X
showed	B-X
very	B-X
high	B-X
expression	B-X
of	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
MHC	B-X
molecules	B-X
on	B-X
DC	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
surface	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
of	B-X
DC	B-X
are	B-X
present	B-X
in	B-X
greater	B-X
quantity	B-X
and	B-X
carry	B-X
on	B-X
average	B-X
fewer	B-X
sialic	B-X
acids	B-X
than	B-X
the	B-X
same	B-X
molecules	B-X
isolated	B-X
from	B-X
other	B-X
APC	B-X
types	B-X
such	B-X
as	B-X
spleen	B-X
cells	B-X
,	B-X
lipopolysaccharide	B-X
blasts	B-X
or	B-X
concanavalin	B-X
A	B-X
blasts	B-X
.	B-X
That	B-X
sialic	B-X
acids	B-X
on	B-X
cell	B-X
surface	B-X
molecules	B-X
,	B-X
including	B-X
MHC	B-X
,	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
antigen	B-X
presentation	B-X
is	B-X
suggested	B-X
by	B-X
our	B-X
finding	B-X
that	B-X
removal	B-X
of	B-X
sialic	B-X
acids	B-X
,	B-X
by	B-X
neuraminidase	B-X
,	B-X
can	B-X
restore	B-X
specific	B-X
responses	B-X
to	B-X
nonresponder	B-X
APC	B-X
as	B-X
well	B-X
.	B-X

Comparison	O
of	O
MHC	O
expression	O
on	O
various	O
types	O
of	O
APC	O
by	O
cytofluorimetry	O
and	O
quantitative	O
immunoprecipitation	O
showed	O
very	O
high	O
expression	O
of	O
class	O
I	O
and	O
class	O
II	O
MHC	O
molecules	O
on	O
DC	O
.	O

Strikingly	O
,	O
examination	O
of	O
class	O
I	O
and	O
class	O
II	O
molecules	O
by	O
isoelectric	O
focusing	O
revealed	O
qualitative	O
differences	O
as	O
well	O
.	O

We	O
show	O
that	O
the	O
surface	O
MHC	O
class	O
I	O
molecules	O
of	O
DC	O
are	O
present	O
in	O
greater	O
quantity	O
and	O
carry	O
on	O
average	O
fewer	O
sialic	O
acids	O
than	O
the	O
same	O
molecules	O
isolated	O
from	O
other	O
APC	O
types	O
such	O
as	O
spleen	O
cells	O
,	O
lipopolysaccharide	O
blasts	O
or	O
concanavalin	B-Protein
A	I-Protein
blasts	O
.	O
<EOS>	B-X
A	B-X
low	B-X
proportion	B-X
of	B-X
cells	B-X
from	B-X
rosettes	B-X
with	B-X
sheep	B-X
erythrocytes	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
which	B-X
is	B-X
considerably	B-X
increased	B-X
after	B-X
neuraminidase	B-X
treatment	B-X
.	B-X
Unlike	B-X
B	B-X
lines	B-X
but	B-X
like	B-X
T	B-X
lines	B-X
,	B-X
K562	B-X
cells	B-X
are	B-X
lysed	B-X
rapidly	B-X
by	B-X
C'/Fc	B-X
receptor-positive	B-X
human	B-X
blood	B-X
leukocytes	B-X
and	B-X
do	B-X
not	B-X
stimulate	B-X
MLC	B-X
reactions	B-X
.	B-X
The	B-X
cells	B-X
do	B-X
not	B-X
contain	B-X
N-APase	B-X
,	B-X
an	B-X
enzyme	B-X
found	B-X
in	B-X
all	B-X
lines	B-X
derived	B-X
from	B-X
lymphoid	B-X
cells	B-X
and	B-X
in	B-X
lymphoproliferative	B-X
diseases	B-X
.	B-X
By	B-X
scanning	B-X
electron	B-X
microscopy	B-X
,	B-X
K562	B-X
cells	B-X
were	B-X
seen	B-X
to	B-X
be	B-X
rounded	B-X
and	B-X
relatively	B-X
smooth	B-X
,	B-X
with	B-X
small	B-X
numbers	B-X
of	B-X
short	B-X
microvilli	B-X
resembling	B-X
undifferentiated	B-X
leukemic	B-X
cells	B-X
.	B-X
A	B-X
few	B-X
cells	B-X
had	B-X
narrow	B-X
ridge-like	B-X
profiles	B-X
and	B-X
small	B-X
ruffles	B-X
similar	B-X
to	B-X
granulocytic	B-X
leukemic	B-X
cells	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
possible	B-X
presence	B-X
of	B-X
the	B-X
cellular	B-X
marker	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
,	B-X
the	B-X
Ph	B-X
chromosome	B-X
,	B-X
it	B-X
may	B-X
be	B-X
regarded	B-X
as	B-X
belonging	B-X
to	B-X
the	B-X
granulocytic	B-X
series	B-X
of	B-X
cells	B-X
.	B-X

That	O
sialic	O
acids	O
on	O
cell	O
surface	O
molecules	O
,	O
including	O
MHC	O
,	O
may	O
play	O
a	O
role	O
in	O
antigen	O
presentation	O
is	O
suggested	O
by	O
our	O
finding	O
that	O
removal	O
of	O
sialic	O
acids	O
,	O
by	O
neuraminidase	O
,	O
can	O
restore	O
specific	O
responses	O
to	O
nonresponder	O
APC	O
as	O
well	O
.	O
<EOS>	B-X
Two	B-X
class	B-X
I	B-X
major	B-X
histocompatibility	B-X
(	B-X
MHC	B-X
)	B-X
mutant	B-X
mouse	B-X
strains	B-X
,	B-X
H-2bm14	B-X
and	B-X
H-2bm6	B-X
,	B-X
differ	B-X
from	B-X
the	B-X
strain	B-X
of	B-X
origin	B-X
C57BL/6	B-X
(	B-X
B6	B-X
,	B-X
H-2b	B-X
)	B-X
in	B-X
one	B-X
and	B-X
two	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
H-2Db	B-X
and	B-X
H-2Kb	B-X
molecule	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
bm14	B-X
Db	B-X
mutation	B-X
results	B-X
in	B-X
specific	B-X
failure	B-X
of	B-X
female	B-X
bm14	B-X
mice	B-X
to	B-X
generate	B-X
a	B-X
cytotoxic	B-X
T	B-X
lymphocyte	B-X
(	B-X
Tc	B-X
)	B-X
response	B-X
to	B-X
the	B-X
male-specific	B-X
antigen	B-X
H-Y	B-X
.	B-X
The	B-X
allospecific	B-X
Tc	B-X
response	B-X
of	B-X
CD8+	B-X
B6T	B-X
cells	B-X
against	B-X
bm6	B-X
Kb	B-X
mutant	B-X
spleen	B-X
cells	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
against	B-X
other	B-X
Kb	B-X
mutants	B-X
,	B-X
is	B-X
absolutely	B-X
CD4+	B-X
T	B-X
helper	B-X
cell	B-X
dependent	B-X
.	B-X
Purified	B-X
CD8+	B-X
T	B-X
cells	B-X
completely	B-X
fail	B-X
to	B-X
respond	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
the	B-X
inability	B-X
to	B-X
mount	B-X
these	B-X
specific	B-X
immune	B-X
responses	B-X
is	B-X
restored	B-X
by	B-X
the	B-X
use	B-X
of	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
as	B-X
antigen-presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
.	B-X
Comparison	B-X
of	B-X
MHC	B-X
expression	B-X
on	B-X
various	B-X
types	B-X
of	B-X
APC	B-X
by	B-X
cytofluorimetry	B-X
and	B-X
quantitative	B-X
immunoprecipitation	B-X
showed	B-X
very	B-X
high	B-X
expression	B-X
of	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
MHC	B-X
molecules	B-X
on	B-X
DC	B-X
.	B-X
Strikingly	B-X
,	B-X
examination	B-X
of	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
molecules	B-X
by	B-X
isoelectric	B-X
focusing	B-X
revealed	B-X
qualitative	B-X
differences	B-X
as	B-X
well	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
surface	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
of	B-X
DC	B-X
are	B-X
present	B-X
in	B-X
greater	B-X
quantity	B-X
and	B-X
carry	B-X
on	B-X
average	B-X
fewer	B-X
sialic	B-X
acids	B-X
than	B-X
the	B-X
same	B-X
molecules	B-X
isolated	B-X
from	B-X
other	B-X
APC	B-X
types	B-X
such	B-X
as	B-X
spleen	B-X
cells	B-X
,	B-X
lipopolysaccharide	B-X
blasts	B-X
or	B-X
concanavalin	B-X
A	B-X
blasts	B-X
.	B-X
That	B-X
sialic	B-X
acids	B-X
on	B-X
cell	B-X
surface	B-X
molecules	B-X
,	B-X
including	B-X
MHC	B-X
,	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
antigen	B-X
presentation	B-X
is	B-X
suggested	B-X
by	B-X
our	B-X
finding	B-X
that	B-X
removal	B-X
of	B-X
sialic	B-X
acids	B-X
,	B-X
by	B-X
neuraminidase	B-X
,	B-X
can	B-X
restore	B-X
specific	B-X
responses	B-X
to	B-X
nonresponder	B-X
APC	B-X
as	B-X
well	B-X
.	B-X

Effects	O
of	O
histone	B-Protein
acetylation	O
on	O
nucleosome	O
properties	O
as	O
evaluated	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
hydroxylapatite	O
dissociation	O
chromatography	O
.	O
<EOS>	B-X
The	B-X
release	B-X
of	B-X
acetylated	B-X
histones	B-X
from	B-X
chick	B-X
oviduct	B-X
chromatin	B-X
was	B-X
analyzed	B-X
by	B-X
hydroxylapatite	B-X
column	B-X
chromatography	B-X
.	B-X
By	B-X
raising	B-X
of	B-X
the	B-X
NaCl	B-X
concentration	B-X
,	B-X
acetylated	B-X
histones	B-X
were	B-X
eluted	B-X
from	B-X
hydroxylapatite-bound	B-X
chromatin	B-X
depending	B-X
on	B-X
their	B-X
release	B-X
from	B-X
nucleosomal	B-X
DNA	B-X
.	B-X
Electrophoresis	B-X
on	B-X
acid-urea	B-X
gel	B-X
showed	B-X
that	B-X
hyperacetylated	B-X
forms	B-X
of	B-X
histone	B-X
H4	B-X
were	B-X
eluted	B-X
at	B-X
a	B-X
lower	B-X
NaCl	B-X
concentration	B-X
than	B-X
non-acetylated	B-X
or	B-X
hypoacetylated	B-X
H4	B-X
,	B-X
suggesting	B-X
that	B-X
hyperacetylated	B-X
H4	B-X
has	B-X
decreased	B-X
stability	B-X
in	B-X
nucleosomes	B-X
.	B-X
However	B-X
,	B-X
under	B-X
milder	B-X
ionic	B-X
conditions	B-X
which	B-X
do	B-X
not	B-X
induce	B-X
dissociation	B-X
between	B-X
histones	B-X
and	B-X
DNA	B-X
,	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
of	B-X
purified	B-X
nucleosome	B-X
cores	B-X
showed	B-X
no	B-X
evidence	B-X
for	B-X
their	B-X
unfolding	B-X
or	B-X
for	B-X
increased	B-X
accessibility	B-X
by	B-X
high	B-X
mobility	B-X
group	B-X
protein-17	B-X
.	B-X

The	O
release	O
of	O
acetylated	O
histones	B-Protein
from	O
chick	O
oviduct	O
chromatin	O
was	O
analyzed	O
by	O
hydroxylapatite	O
column	O
chromatography	O
.	O
<EOS>	B-X
The	B-X
release	B-X
of	B-X
acetylated	B-X
histones	B-X
from	B-X
chick	B-X
oviduct	B-X
chromatin	B-X
was	B-X
analyzed	B-X
by	B-X
hydroxylapatite	B-X
column	B-X
chromatography	B-X
.	B-X
By	B-X
raising	B-X
of	B-X
the	B-X
NaCl	B-X
concentration	B-X
,	B-X
acetylated	B-X
histones	B-X
were	B-X
eluted	B-X
from	B-X
hydroxylapatite-bound	B-X
chromatin	B-X
depending	B-X
on	B-X
their	B-X
release	B-X
from	B-X
nucleosomal	B-X
DNA	B-X
.	B-X
Electrophoresis	B-X
on	B-X
acid-urea	B-X
gel	B-X
showed	B-X
that	B-X
hyperacetylated	B-X
forms	B-X
of	B-X
histone	B-X
H4	B-X
were	B-X
eluted	B-X
at	B-X
a	B-X
lower	B-X
NaCl	B-X
concentration	B-X
than	B-X
non-acetylated	B-X
or	B-X
hypoacetylated	B-X
H4	B-X
,	B-X
suggesting	B-X
that	B-X
hyperacetylated	B-X
H4	B-X
has	B-X
decreased	B-X
stability	B-X
in	B-X
nucleosomes	B-X
.	B-X
However	B-X
,	B-X
under	B-X
milder	B-X
ionic	B-X
conditions	B-X
which	B-X
do	B-X
not	B-X
induce	B-X
dissociation	B-X
between	B-X
histones	B-X
and	B-X
DNA	B-X
,	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
of	B-X
purified	B-X
nucleosome	B-X
cores	B-X
showed	B-X
no	B-X
evidence	B-X
for	B-X
their	B-X
unfolding	B-X
or	B-X
for	B-X
increased	B-X
accessibility	B-X
by	B-X
high	B-X
mobility	B-X
group	B-X
protein-17	B-X
.	B-X

By	O
raising	O
of	O
the	O
NaCl	O
concentration	O
,	O
acetylated	O
histones	B-Protein
were	O
eluted	O
from	O
hydroxylapatite	O
-	O
bound	O
chromatin	O
depending	O
on	O
their	O
release	O
from	O
nucleosomal	O
DNA	O
.	O
<EOS>	B-X
The	B-X
release	B-X
of	B-X
acetylated	B-X
histones	B-X
from	B-X
chick	B-X
oviduct	B-X
chromatin	B-X
was	B-X
analyzed	B-X
by	B-X
hydroxylapatite	B-X
column	B-X
chromatography	B-X
.	B-X
By	B-X
raising	B-X
of	B-X
the	B-X
NaCl	B-X
concentration	B-X
,	B-X
acetylated	B-X
histones	B-X
were	B-X
eluted	B-X
from	B-X
hydroxylapatite-bound	B-X
chromatin	B-X
depending	B-X
on	B-X
their	B-X
release	B-X
from	B-X
nucleosomal	B-X
DNA	B-X
.	B-X
Electrophoresis	B-X
on	B-X
acid-urea	B-X
gel	B-X
showed	B-X
that	B-X
hyperacetylated	B-X
forms	B-X
of	B-X
histone	B-X
H4	B-X
were	B-X
eluted	B-X
at	B-X
a	B-X
lower	B-X
NaCl	B-X
concentration	B-X
than	B-X
non-acetylated	B-X
or	B-X
hypoacetylated	B-X
H4	B-X
,	B-X
suggesting	B-X
that	B-X
hyperacetylated	B-X
H4	B-X
has	B-X
decreased	B-X
stability	B-X
in	B-X
nucleosomes	B-X
.	B-X
However	B-X
,	B-X
under	B-X
milder	B-X
ionic	B-X
conditions	B-X
which	B-X
do	B-X
not	B-X
induce	B-X
dissociation	B-X
between	B-X
histones	B-X
and	B-X
DNA	B-X
,	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
of	B-X
purified	B-X
nucleosome	B-X
cores	B-X
showed	B-X
no	B-X
evidence	B-X
for	B-X
their	B-X
unfolding	B-X
or	B-X
for	B-X
increased	B-X
accessibility	B-X
by	B-X
high	B-X
mobility	B-X
group	B-X
protein-17	B-X
.	B-X

Electrophoresis	O
on	O
acid	O
-	O
urea	O
gel	O
showed	O
that	O
hyperacetylated	O
forms	O
of	O
histone	B-Protein
H4	I-Protein
were	O
eluted	O
at	O
a	O
lower	O
NaCl	O
concentration	O
than	O
non	O
-	O
acetylated	O
or	O
hypoacetylated	O
H4	B-Protein
,	O
suggesting	O
that	O
hyperacetylated	O
H4	B-Protein
has	O
decreased	O
stability	O
in	O
nucleosomes	O
.	O
<EOS>	B-X
The	B-X
release	B-X
of	B-X
acetylated	B-X
histones	B-X
from	B-X
chick	B-X
oviduct	B-X
chromatin	B-X
was	B-X
analyzed	B-X
by	B-X
hydroxylapatite	B-X
column	B-X
chromatography	B-X
.	B-X
By	B-X
raising	B-X
of	B-X
the	B-X
NaCl	B-X
concentration	B-X
,	B-X
acetylated	B-X
histones	B-X
were	B-X
eluted	B-X
from	B-X
hydroxylapatite-bound	B-X
chromatin	B-X
depending	B-X
on	B-X
their	B-X
release	B-X
from	B-X
nucleosomal	B-X
DNA	B-X
.	B-X
Electrophoresis	B-X
on	B-X
acid-urea	B-X
gel	B-X
showed	B-X
that	B-X
hyperacetylated	B-X
forms	B-X
of	B-X
histone	B-X
H4	B-X
were	B-X
eluted	B-X
at	B-X
a	B-X
lower	B-X
NaCl	B-X
concentration	B-X
than	B-X
non-acetylated	B-X
or	B-X
hypoacetylated	B-X
H4	B-X
,	B-X
suggesting	B-X
that	B-X
hyperacetylated	B-X
H4	B-X
has	B-X
decreased	B-X
stability	B-X
in	B-X
nucleosomes	B-X
.	B-X
However	B-X
,	B-X
under	B-X
milder	B-X
ionic	B-X
conditions	B-X
which	B-X
do	B-X
not	B-X
induce	B-X
dissociation	B-X
between	B-X
histones	B-X
and	B-X
DNA	B-X
,	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
of	B-X
purified	B-X
nucleosome	B-X
cores	B-X
showed	B-X
no	B-X
evidence	B-X
for	B-X
their	B-X
unfolding	B-X
or	B-X
for	B-X
increased	B-X
accessibility	B-X
by	B-X
high	B-X
mobility	B-X
group	B-X
protein-17	B-X
.	B-X

However	O
,	O
under	O
milder	O
ionic	O
conditions	O
which	O
do	O
not	O
induce	O
dissociation	O
between	O
histones	B-Protein
and	O
DNA	O
,	O
polyacrylamide	O
gel	O
electrophoresis	O
of	O
purified	O
nucleosome	O
cores	O
showed	O
no	O
evidence	O
for	O
their	O
unfolding	O
or	O
for	O
increased	O
accessibility	O
by	O
high	B-Protein
mobility	I-Protein
group	I-Protein
protein	I-Protein
-	I-Protein
17	I-Protein
.	O
<EOS>	B-X
Chalcogenides	B-X
are	B-X
one	B-X
of	B-X
the	B-X
most	B-X
versatile	B-X
inorganic	B-X
materials	B-X
families	B-X
,	B-X
further	B-X
subdivided	B-X
into	B-X
a	B-X
large	B-X
variety	B-X
of	B-X
specific	B-X
groups	B-X
of	B-X
compounds	B-X
,	B-X
ranging	B-X
from	B-X
neat	B-X
binary	B-X
or	B-X
multinary	B-X
solids	B-X
and	B-X
nanoparticles	B-X
of	B-X
the	B-X
same	B-X
formal	B-X
compositions	B-X
,	B-X
both	B-X
in	B-X
crystalline	B-X
or	B-X
non-crystalline	B-X
form	B-X
,	B-X
to	B-X
complicated	B-X
open-framework	B-X
structures	B-X
and	B-X
cluster	B-X
compounds	B-X
,	B-X
also	B-X
including	B-X
organ	B-X
(	B-X
ometall	B-X
)	B-X
ic	B-X
derivates	B-X
of	B-X
the	B-X
latter	B-X
.	B-X
The	B-X
large	B-X
variety	B-X
regarding	B-X
both	B-X
the	B-X
compositions	B-X
and	B-X
the	B-X
structures	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
enormous	B-X
variety	B-X
of	B-X
properties	B-X
,	B-X
ranging	B-X
from	B-X
simple	B-X
or	B-X
high-tech	B-X
pigments	B-X
through	B-X
a	B-X
multitude	B-X
of	B-X
opto-electronic	B-X
devices	B-X
and	B-X
electrolytes	B-X
to	B-X
materials	B-X
for	B-X
ion	B-X
separation	B-X
or	B-X
high-sophisticated	B-X
catalysts	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
the	B-X
cyclocarbonylation	B-X
of	B-X
2-methyl-3-buten-2-ol	B-X
was	B-X
studied	B-X
for	B-X
the	B-X
first	B-X
time	B-X
using	B-X
a	B-X
very	B-X
active	B-X
Pd-DPEphos	B-X
(	B-X
bis	B-X
[	B-X
(	B-X
2-diphenylphosphino	B-X
)	B-X
phenyl	B-X
]	B-X
ether	B-X
)	B-X
catalyst	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ionic	B-X
liquid	B-X
(	B-X
IL	B-X
)	B-X
[	B-X
BMIM	B-X
]	B-X
Cl	B-X
(	B-X
1-butyl-3-methylimidazolium	B-X
chloride	B-X
)	B-X
in	B-X
dichloromethane	B-X
to	B-X
selectively	B-X
produce	B-X
4,4-dimethyl-γ-butyrolactone	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
different	B-X
parameters	B-X
such	B-X
as	B-X
temperature	B-X
,	B-X
gas	B-X
partial	B-X
pressures	B-X
,	B-X
time	B-X
of	B-X
reaction	B-X
,	B-X
substrate	B-X
and	B-X
ligand	B-X
concentrations	B-X
were	B-X
investigated	B-X
and	B-X
found	B-X
to	B-X
provide	B-X
optimal	B-X
conditions	B-X
for	B-X
lactonization	B-X
(	B-X
95	B-X
°C	B-X
,	B-X
28	B-X
bar	B-X
(	B-X
CO/H	B-X

beta	O
-	O
Hydroxyasparagine	O
in	O
domains	O
homologous	O
to	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
precursor	O
in	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
S	I-Protein
.	O

Vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
S	I-Protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
blood	O
coagulation	O
.	O
<EOS>	B-X
Protein	B-X
S	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
coagulation	B-X
that	B-X
functions	B-X
as	B-X
a	B-X
cofactor	B-X
for	B-X
the	B-X
activated	B-X
protein	B-X
C	B-X
(	B-X
APC	B-X
)	B-X
and	B-X
tissue	B-X
factor	B-X
pathway	B-X
inhibitor	B-X
(	B-X
TFPI	B-X
)	B-X
pathways	B-X
.	B-X
Through	B-X
these	B-X
functions	B-X
,	B-X
protein	B-X
S	B-X
regulates	B-X
coagulation	B-X
during	B-X
both	B-X
its	B-X
initiation	B-X
and	B-X
its	B-X
propagation	B-X
phases	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
protein	B-X
S	B-X
in	B-X
hemostatic	B-X
regulation	B-X
is	B-X
apparent	B-X
from	B-X
the	B-X
strong	B-X
association	B-X
between	B-X
protein	B-X
S	B-X
deficiencies	B-X
and	B-X
increased	B-X
risk	B-X
for	B-X
venous	B-X
thrombosis	B-X
.	B-X
The	B-X
detailed	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
protein	B-X
S	B-X
cofactor	B-X
functions	B-X
remain	B-X
to	B-X
be	B-X
fully	B-X
clarified	B-X
.	B-X
Evidence	B-X
suggests	B-X
that	B-X
protein	B-X
S	B-X
anticoagulant	B-X
properties	B-X
often	B-X
depend	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
synergistic	B-X
cofactors	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
multicomponent	B-X
complexes	B-X
on	B-X
negatively	B-X
charged	B-X
phospholipid	B-X
surfaces	B-X
.	B-X
Their	B-X
high	B-X
affinity	B-X
binding	B-X
to	B-X
negatively	B-X
charged	B-X
phospholipids	B-X
helps	B-X
bring	B-X
the	B-X
anticoagulant	B-X
proteins	B-X
to	B-X
the	B-X
membranes	B-X
,	B-X
resulting	B-X
in	B-X
efficient	B-X
and	B-X
targeted	B-X
regulation	B-X
of	B-X
coagulation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
update	B-X
on	B-X
protein	B-X
S	B-X
and	B-X
how	B-X
it	B-X
functions	B-X
as	B-X
a	B-X
critical	B-X
hemostatic	B-X
regulator	B-X
.	B-X

It	O
is	O
a	O
75	O
-	O
kDa	O
single	O
chain	O
protein	O
with	O
an	O
NH2	O
-	O
terminal	O
gamma	O
-	O
carboxyglutamic	O
acid	O
-	O
containing	O
domain	O
followed	O
by	O
a	O
thrombin	B-Protein
-	O
sensitive	O
region	O
and	O
four	O
domains	O
arranged	O
in	O
tandem	O
,	O
each	O
of	O
which	O
is	O
homologous	O
to	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
(	O
EGF	B-Protein
)	O
precursor	O
.	O

The	O
NH2	O
-	O
terminal	O
EGF	O
-	O
like	O
domain	O
contains	O
beta	O
-	O
hydroxyaspartic	O
acid	O
,	O
which	O
has	O
been	O
identified	O
in	O
vitamin	O
K	O
-	O
dependent	O
proteins	O
.	O
<EOS>	B-X
Vitamin	B-X
K-dependent	B-X
protein	B-X
S	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
blood	B-X
coagulation	B-X
.	B-X
It	B-X
is	B-X
a	B-X
75-kDa	B-X
single	B-X
chain	B-X
protein	B-X
with	B-X
an	B-X
NH2-terminal	B-X
gamma-carboxyglutamic	B-X
acid-containing	B-X
domain	B-X
followed	B-X
by	B-X
a	B-X
thrombin-sensitive	B-X
region	B-X
and	B-X
four	B-X
domains	B-X
arranged	B-X
in	B-X
tandem	B-X
,	B-X
each	B-X
of	B-X
which	B-X
is	B-X
homologous	B-X
to	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
precursor	B-X
.	B-X
The	B-X
NH2-terminal	B-X
EGF-like	B-X
domain	B-X
contains	B-X
beta-hydroxyaspartic	B-X
acid	B-X
,	B-X
which	B-X
has	B-X
been	B-X
identified	B-X
in	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X
The	B-X
following	B-X
EGF-like	B-X
repeat	B-X
has	B-X
a	B-X
very	B-X
pronounced	B-X
sequence	B-X
homology	B-X
(	B-X
10	B-X
consecutive	B-X
residues	B-X
identical	B-X
)	B-X
to	B-X
one	B-X
of	B-X
the	B-X
EGF-like	B-X
units	B-X
in	B-X
the	B-X
EGF	B-X
precursor	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
,	B-X
in	B-X
protein	B-X
S	B-X
,	B-X
this	B-X
EGF-like	B-X
repeat	B-X
has	B-X
one	B-X
beta-hydroxyasparagine	B-X
residue	B-X
formed	B-X
by	B-X
hydroxylation	B-X
of	B-X
asparagine	B-X
.	B-X
The	B-X
two	B-X
COOH-terminal	B-X
EGF-like	B-X
repeats	B-X
also	B-X
contain	B-X
beta-hydroxyasparagine	B-X
,	B-X
an	B-X
amino	B-X
acid	B-X
not	B-X
previously	B-X
found	B-X
in	B-X
proteins	B-X
.	B-X

The	O
following	O
EGF	O
-	O
like	O
repeat	O
has	O
a	O
very	O
pronounced	O
sequence	O
homology	O
(	O
10	O
consecutive	O
residues	O
identical	O
)	O
to	O
one	O
of	O
the	O
EGF	O
-	O
like	O
units	O
in	O
the	O
EGF	B-Protein
precursor	O
.	O

We	O
now	O
show	O
that	O
,	O
in	O
protein	B-Protein
S	I-Protein
,	O
this	O
EGF	O
-	O
like	O
repeat	O
has	O
one	O
beta	O
-	O
hydroxyasparagine	O
residue	O
formed	O
by	O
hydroxylation	O
of	O
asparagine	O
.	O
<EOS>	B-X
Vitamin	B-X
K-dependent	B-X
protein	B-X
S	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
blood	B-X
coagulation	B-X
.	B-X
It	B-X
is	B-X
a	B-X
75-kDa	B-X
single	B-X
chain	B-X
protein	B-X
with	B-X
an	B-X
NH2-terminal	B-X
gamma-carboxyglutamic	B-X
acid-containing	B-X
domain	B-X
followed	B-X
by	B-X
a	B-X
thrombin-sensitive	B-X
region	B-X
and	B-X
four	B-X
domains	B-X
arranged	B-X
in	B-X
tandem	B-X
,	B-X
each	B-X
of	B-X
which	B-X
is	B-X
homologous	B-X
to	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
precursor	B-X
.	B-X
The	B-X
NH2-terminal	B-X
EGF-like	B-X
domain	B-X
contains	B-X
beta-hydroxyaspartic	B-X
acid	B-X
,	B-X
which	B-X
has	B-X
been	B-X
identified	B-X
in	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X
The	B-X
following	B-X
EGF-like	B-X
repeat	B-X
has	B-X
a	B-X
very	B-X
pronounced	B-X
sequence	B-X
homology	B-X
(	B-X
10	B-X
consecutive	B-X
residues	B-X
identical	B-X
)	B-X
to	B-X
one	B-X
of	B-X
the	B-X
EGF-like	B-X
units	B-X
in	B-X
the	B-X
EGF	B-X
precursor	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
,	B-X
in	B-X
protein	B-X
S	B-X
,	B-X
this	B-X
EGF-like	B-X
repeat	B-X
has	B-X
one	B-X
beta-hydroxyasparagine	B-X
residue	B-X
formed	B-X
by	B-X
hydroxylation	B-X
of	B-X
asparagine	B-X
.	B-X
The	B-X
two	B-X
COOH-terminal	B-X
EGF-like	B-X
repeats	B-X
also	B-X
contain	B-X
beta-hydroxyasparagine	B-X
,	B-X
an	B-X
amino	B-X
acid	B-X
not	B-X
previously	B-X
found	B-X
in	B-X
proteins	B-X
.	B-X

The	O
two	O
COOH	O
-	O
terminal	O
EGF	O
-	O
like	O
repeats	O
also	O
contain	O
beta	O
-	O
hydroxyasparagine	O
,	O
an	O
amino	O
acid	O
not	O
previously	O
found	O
in	O
proteins	O
.	O

Sequence	O
comparisons	O
have	O
enabled	O
us	O
to	O
identify	O
a	O
consensus	O
sequence	O
that	O
seems	O
to	O
be	O
required	O
by	O
the	O
hydroxylase	O
(	O
s	O
)	O
.	O
<EOS>	B-X
It	B-X
is	B-X
a	B-X
75-kDa	B-X
single	B-X
chain	B-X
protein	B-X
with	B-X
an	B-X
NH2-terminal	B-X
gamma-carboxyglutamic	B-X
acid-containing	B-X
domain	B-X
followed	B-X
by	B-X
a	B-X
thrombin-sensitive	B-X
region	B-X
and	B-X
four	B-X
domains	B-X
arranged	B-X
in	B-X
tandem	B-X
,	B-X
each	B-X
of	B-X
which	B-X
is	B-X
homologous	B-X
to	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
precursor	B-X
.	B-X
The	B-X
following	B-X
EGF-like	B-X
repeat	B-X
has	B-X
a	B-X
very	B-X
pronounced	B-X
sequence	B-X
homology	B-X
(	B-X
10	B-X
consecutive	B-X
residues	B-X
identical	B-X
)	B-X
to	B-X
one	B-X
of	B-X
the	B-X
EGF-like	B-X
units	B-X
in	B-X
the	B-X
EGF	B-X
precursor	B-X
.	B-X
The	B-X
two	B-X
COOH-terminal	B-X
EGF-like	B-X
repeats	B-X
also	B-X
contain	B-X
beta-hydroxyasparagine	B-X
,	B-X
an	B-X
amino	B-X
acid	B-X
not	B-X
previously	B-X
found	B-X
in	B-X
proteins	B-X
.	B-X
Sequence	B-X
comparisons	B-X
have	B-X
enabled	B-X
us	B-X
to	B-X
identify	B-X
a	B-X
consensus	B-X
sequence	B-X
that	B-X
seems	B-X
to	B-X
be	B-X
required	B-X
by	B-X
the	B-X
hydroxylase	B-X
(	B-X
s	B-X
)	B-X
.	B-X

Comparison	O
of	O
the	O
immune	O
response	O
to	O
variant	O
influenza	O
type	O
B	O
hemagglutinins	B-Protein
expressed	O
in	O
vaccinia	O
virus	O
.	O
<EOS>	B-X
To	B-X
compare	B-X
the	B-X
immune	B-X
response	B-X
induced	B-X
by	B-X
influenza	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
variants	B-X
differing	B-X
by	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
,	B-X
the	B-X
genes	B-X
for	B-X
each	B-X
HA	B-X
variant	B-X
were	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
vaccinia	B-X
virus	B-X
.	B-X
These	B-X
variant	B-X
HA	B-X
genes	B-X
have	B-X
been	B-X
previously	B-X
described	B-X
as	B-X
being	B-X
present	B-X
exclusively	B-X
in	B-X
either	B-X
egg-derived	B-X
or	B-X
MDCK	B-X
cell-derived	B-X
subpopulations	B-X
of	B-X
influenza	B-X
B/England/222/82	B-X
virus	B-X
.	B-X
By	B-X
using	B-X
this	B-X
approach	B-X
we	B-X
were	B-X
able	B-X
to	B-X
vaccinate	B-X
animals	B-X
with	B-X
homogeneous	B-X
preparations	B-X
of	B-X
these	B-X
viral	B-X
antigens	B-X
and	B-X
thus	B-X
circumvent	B-X
the	B-X
problem	B-X
of	B-X
heterogeneity	B-X
within	B-X
RNA	B-X
virus	B-X
stocks	B-X
.	B-X
Immunization	B-X
and	B-X
challenge	B-X
experiments	B-X
in	B-X
mice	B-X
indicated	B-X
that	B-X
even	B-X
though	B-X
vaccination	B-X
with	B-X
the	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
induced	B-X
different	B-X
levels	B-X
of	B-X
cross-reactive	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
mice	B-X
vaccinated	B-X
with	B-X
either	B-X
recombinant	B-X
vaccinia	B-X
virus	B-X
were	B-X
protected	B-X
from	B-X
infection	B-X
with	B-X
either	B-X
subpopulation	B-X
of	B-X
influenza	B-X
virus	B-X
.	B-X
Results	B-X
with	B-X
this	B-X
model	B-X
system	B-X
support	B-X
the	B-X
view	B-X
that	B-X
influenza	B-X
vaccines	B-X
prepared	B-X
with	B-X
egg-derived	B-X
virus	B-X
should	B-X
be	B-X
protective	B-X
against	B-X
microvariants	B-X
of	B-X
virus	B-X
that	B-X
grow	B-X
preferentially	B-X
in	B-X
MDCK	B-X
and	B-X
possibly	B-X
other	B-X
mammalian	B-X
cells	B-X
.	B-X

To	O
compare	O
the	O
immune	O
response	O
induced	O
by	O
influenza	O
hemagglutinin	B-Protein
(	O
HA	B-Protein
)	O
variants	O
differing	O
by	O
a	O
single	O
amino	O
acid	O
,	O
the	O
genes	O
for	O
each	O
HA	B-Protein
variant	O
were	O
cloned	O
and	O
expressed	O
in	O
vaccinia	O
virus	O
.	O
<EOS>	B-X
To	B-X
compare	B-X
the	B-X
immune	B-X
response	B-X
induced	B-X
by	B-X
influenza	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
variants	B-X
differing	B-X
by	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
,	B-X
the	B-X
genes	B-X
for	B-X
each	B-X
HA	B-X
variant	B-X
were	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
vaccinia	B-X
virus	B-X
.	B-X
These	B-X
variant	B-X
HA	B-X
genes	B-X
have	B-X
been	B-X
previously	B-X
described	B-X
as	B-X
being	B-X
present	B-X
exclusively	B-X
in	B-X
either	B-X
egg-derived	B-X
or	B-X
MDCK	B-X
cell-derived	B-X
subpopulations	B-X
of	B-X
influenza	B-X
B/England/222/82	B-X
virus	B-X
.	B-X
By	B-X
using	B-X
this	B-X
approach	B-X
we	B-X
were	B-X
able	B-X
to	B-X
vaccinate	B-X
animals	B-X
with	B-X
homogeneous	B-X
preparations	B-X
of	B-X
these	B-X
viral	B-X
antigens	B-X
and	B-X
thus	B-X
circumvent	B-X
the	B-X
problem	B-X
of	B-X
heterogeneity	B-X
within	B-X
RNA	B-X
virus	B-X
stocks	B-X
.	B-X
Immunization	B-X
and	B-X
challenge	B-X
experiments	B-X
in	B-X
mice	B-X
indicated	B-X
that	B-X
even	B-X
though	B-X
vaccination	B-X
with	B-X
the	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
induced	B-X
different	B-X
levels	B-X
of	B-X
cross-reactive	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
mice	B-X
vaccinated	B-X
with	B-X
either	B-X
recombinant	B-X
vaccinia	B-X
virus	B-X
were	B-X
protected	B-X
from	B-X
infection	B-X
with	B-X
either	B-X
subpopulation	B-X
of	B-X
influenza	B-X
virus	B-X
.	B-X
Results	B-X
with	B-X
this	B-X
model	B-X
system	B-X
support	B-X
the	B-X
view	B-X
that	B-X
influenza	B-X
vaccines	B-X
prepared	B-X
with	B-X
egg-derived	B-X
virus	B-X
should	B-X
be	B-X
protective	B-X
against	B-X
microvariants	B-X
of	B-X
virus	B-X
that	B-X
grow	B-X
preferentially	B-X
in	B-X
MDCK	B-X
and	B-X
possibly	B-X
other	B-X
mammalian	B-X
cells	B-X
.	B-X

These	O
variant	O
HA	B-Protein
genes	O
have	O
been	O
previously	O
described	O
as	O
being	O
present	O
exclusively	O
in	O
either	O
egg	O
-	O
derived	O
or	O
MDCK	O
cell	O
-	O
derived	O
subpopulations	O
of	O
influenza	O
B	O
/	O
England	O
/	O
222	O
/	O
82	O
virus	O
.	O
<EOS>	B-X
B/Singapore/222/79-like	B-X
influenza	B-X
viruses	B-X
isolated	B-X
from	B-X
three	B-X
patients	B-X
during	B-X
the	B-X
winter	B-X
of	B-X
1981	B-X
to	B-X
1982	B-X
and	B-X
cultured	B-X
in	B-X
either	B-X
embryonated	B-X
hens	B-X
'	B-X
eggs	B-X
or	B-X
MDCK	B-X
cells	B-X
were	B-X
studied	B-X
.	B-X
Sequence	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
haemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
genes	B-X
of	B-X
the	B-X
six	B-X
virus	B-X
preparations	B-X
contained	B-X
at	B-X
least	B-X
four	B-X
distinct	B-X
HA1	B-X
sequences	B-X
which	B-X
differed	B-X
by	B-X
up	B-X
to	B-X
six	B-X
amino	B-X
acids	B-X
.	B-X
Only	B-X
one	B-X
pair	B-X
of	B-X
viruses	B-X
had	B-X
amino	B-X
acid	B-X
differences	B-X
between	B-X
the	B-X
egg-	B-X
and	B-X
MDCK	B-X
cell-derived	B-X
viral	B-X
subpopulations	B-X
and	B-X
this	B-X
change	B-X
did	B-X
not	B-X
affect	B-X
a	B-X
glycosylation	B-X
site	B-X
.	B-X
Mice	B-X
infected	B-X
with	B-X
previously	B-X
described	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
expressing	B-X
either	B-X
the	B-X
egg-	B-X
or	B-X
MDCK	B-X
cell-derived	B-X
HA	B-X
of	B-X
B/England/222/82	B-X
developed	B-X
neutralizing	B-X
antibodies	B-X
against	B-X
all	B-X
of	B-X
the	B-X
1982	B-X
type	B-X
B	B-X
viruses	B-X
and	B-X
were	B-X
protected	B-X
against	B-X
intranasal	B-X
challenge	B-X
with	B-X
these	B-X
viruses	B-X
.	B-X
Therefore	B-X
,	B-X
in	B-X
this	B-X
model	B-X
system	B-X
,	B-X
the	B-X
minor	B-X
sequence	B-X
variation	B-X
between	B-X
the	B-X
HAs	B-X
of	B-X
egg-	B-X
and	B-X
MDCK	B-X
cell-derived	B-X
influenza	B-X
B/England/222/82	B-X
virus	B-X
had	B-X
no	B-X
detectable	B-X
effect	B-X
on	B-X
the	B-X
induction	B-X
of	B-X
cross-protection	B-X
.	B-X

By	O
using	O
this	O
approach	O
we	O
were	O
able	O
to	O
vaccinate	O
animals	O
with	O
homogeneous	O
preparations	O
of	O
these	O
viral	O
antigens	O
and	O
thus	O
circumvent	O
the	O
problem	O
of	O
heterogeneity	O
within	O
RNA	O
virus	O
stocks	O
.	O
<EOS>	B-X
To	B-X
compare	B-X
the	B-X
immune	B-X
response	B-X
induced	B-X
by	B-X
influenza	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
variants	B-X
differing	B-X
by	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
,	B-X
the	B-X
genes	B-X
for	B-X
each	B-X
HA	B-X
variant	B-X
were	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
vaccinia	B-X
virus	B-X
.	B-X
These	B-X
variant	B-X
HA	B-X
genes	B-X
have	B-X
been	B-X
previously	B-X
described	B-X
as	B-X
being	B-X
present	B-X
exclusively	B-X
in	B-X
either	B-X
egg-derived	B-X
or	B-X
MDCK	B-X
cell-derived	B-X
subpopulations	B-X
of	B-X
influenza	B-X
B/England/222/82	B-X
virus	B-X
.	B-X
By	B-X
using	B-X
this	B-X
approach	B-X
we	B-X
were	B-X
able	B-X
to	B-X
vaccinate	B-X
animals	B-X
with	B-X
homogeneous	B-X
preparations	B-X
of	B-X
these	B-X
viral	B-X
antigens	B-X
and	B-X
thus	B-X
circumvent	B-X
the	B-X
problem	B-X
of	B-X
heterogeneity	B-X
within	B-X
RNA	B-X
virus	B-X
stocks	B-X
.	B-X
Immunization	B-X
and	B-X
challenge	B-X
experiments	B-X
in	B-X
mice	B-X
indicated	B-X
that	B-X
even	B-X
though	B-X
vaccination	B-X
with	B-X
the	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
induced	B-X
different	B-X
levels	B-X
of	B-X
cross-reactive	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
mice	B-X
vaccinated	B-X
with	B-X
either	B-X
recombinant	B-X
vaccinia	B-X
virus	B-X
were	B-X
protected	B-X
from	B-X
infection	B-X
with	B-X
either	B-X
subpopulation	B-X
of	B-X
influenza	B-X
virus	B-X
.	B-X
Results	B-X
with	B-X
this	B-X
model	B-X
system	B-X
support	B-X
the	B-X
view	B-X
that	B-X
influenza	B-X
vaccines	B-X
prepared	B-X
with	B-X
egg-derived	B-X
virus	B-X
should	B-X
be	B-X
protective	B-X
against	B-X
microvariants	B-X
of	B-X
virus	B-X
that	B-X
grow	B-X
preferentially	B-X
in	B-X
MDCK	B-X
and	B-X
possibly	B-X
other	B-X
mammalian	B-X
cells	B-X
.	B-X

Immunization	O
and	O
challenge	O
experiments	O
in	O
mice	O
indicated	O
that	O
even	O
though	O
vaccination	O
with	O
the	O
recombinant	O
vaccinia	O
viruses	O
induced	O
different	O
levels	O
of	O
cross	O
-	O
reactive	O
neutralizing	O
antibodies	O
,	O
mice	O
vaccinated	O
with	O
either	O
recombinant	O
vaccinia	O
virus	O
were	O
protected	O
from	O
infection	O
with	O
either	O
subpopulation	O
of	O
influenza	O
virus	O
.	O
<EOS>	B-X
To	B-X
compare	B-X
the	B-X
immune	B-X
response	B-X
induced	B-X
by	B-X
influenza	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
variants	B-X
differing	B-X
by	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
,	B-X
the	B-X
genes	B-X
for	B-X
each	B-X
HA	B-X
variant	B-X
were	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
vaccinia	B-X
virus	B-X
.	B-X
These	B-X
variant	B-X
HA	B-X
genes	B-X
have	B-X
been	B-X
previously	B-X
described	B-X
as	B-X
being	B-X
present	B-X
exclusively	B-X
in	B-X
either	B-X
egg-derived	B-X
or	B-X
MDCK	B-X
cell-derived	B-X
subpopulations	B-X
of	B-X
influenza	B-X
B/England/222/82	B-X
virus	B-X
.	B-X
By	B-X
using	B-X
this	B-X
approach	B-X
we	B-X
were	B-X
able	B-X
to	B-X
vaccinate	B-X
animals	B-X
with	B-X
homogeneous	B-X
preparations	B-X
of	B-X
these	B-X
viral	B-X
antigens	B-X
and	B-X
thus	B-X
circumvent	B-X
the	B-X
problem	B-X
of	B-X
heterogeneity	B-X
within	B-X
RNA	B-X
virus	B-X
stocks	B-X
.	B-X
Immunization	B-X
and	B-X
challenge	B-X
experiments	B-X
in	B-X
mice	B-X
indicated	B-X
that	B-X
even	B-X
though	B-X
vaccination	B-X
with	B-X
the	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
induced	B-X
different	B-X
levels	B-X
of	B-X
cross-reactive	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
mice	B-X
vaccinated	B-X
with	B-X
either	B-X
recombinant	B-X
vaccinia	B-X
virus	B-X
were	B-X
protected	B-X
from	B-X
infection	B-X
with	B-X
either	B-X
subpopulation	B-X
of	B-X
influenza	B-X
virus	B-X
.	B-X
Results	B-X
with	B-X
this	B-X
model	B-X
system	B-X
support	B-X
the	B-X
view	B-X
that	B-X
influenza	B-X
vaccines	B-X
prepared	B-X
with	B-X
egg-derived	B-X
virus	B-X
should	B-X
be	B-X
protective	B-X
against	B-X
microvariants	B-X
of	B-X
virus	B-X
that	B-X
grow	B-X
preferentially	B-X
in	B-X
MDCK	B-X
and	B-X
possibly	B-X
other	B-X
mammalian	B-X
cells	B-X
.	B-X

Results	O
with	O
this	O
model	O
system	O
support	O
the	O
view	O
that	O
influenza	O
vaccines	O
prepared	O
with	O
egg	O
-	O
derived	O
virus	O
should	O
be	O
protective	O
against	O
microvariants	O
of	O
virus	O
that	O
grow	O
preferentially	O
in	O
MDCK	O
and	O
possibly	O
other	O
mammalian	O
cells	O
.	O
<EOS>	B-X
To	B-X
compare	B-X
the	B-X
immune	B-X
response	B-X
induced	B-X
by	B-X
influenza	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
variants	B-X
differing	B-X
by	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
,	B-X
the	B-X
genes	B-X
for	B-X
each	B-X
HA	B-X
variant	B-X
were	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
vaccinia	B-X
virus	B-X
.	B-X
These	B-X
variant	B-X
HA	B-X
genes	B-X
have	B-X
been	B-X
previously	B-X
described	B-X
as	B-X
being	B-X
present	B-X
exclusively	B-X
in	B-X
either	B-X
egg-derived	B-X
or	B-X
MDCK	B-X
cell-derived	B-X
subpopulations	B-X
of	B-X
influenza	B-X
B/England/222/82	B-X
virus	B-X
.	B-X
By	B-X
using	B-X
this	B-X
approach	B-X
we	B-X
were	B-X
able	B-X
to	B-X
vaccinate	B-X
animals	B-X
with	B-X
homogeneous	B-X
preparations	B-X
of	B-X
these	B-X
viral	B-X
antigens	B-X
and	B-X
thus	B-X
circumvent	B-X
the	B-X
problem	B-X
of	B-X
heterogeneity	B-X
within	B-X
RNA	B-X
virus	B-X
stocks	B-X
.	B-X
Immunization	B-X
and	B-X
challenge	B-X
experiments	B-X
in	B-X
mice	B-X
indicated	B-X
that	B-X
even	B-X
though	B-X
vaccination	B-X
with	B-X
the	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
induced	B-X
different	B-X
levels	B-X
of	B-X
cross-reactive	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
mice	B-X
vaccinated	B-X
with	B-X
either	B-X
recombinant	B-X
vaccinia	B-X
virus	B-X
were	B-X
protected	B-X
from	B-X
infection	B-X
with	B-X
either	B-X
subpopulation	B-X
of	B-X
influenza	B-X
virus	B-X
.	B-X
Results	B-X
with	B-X
this	B-X
model	B-X
system	B-X
support	B-X
the	B-X
view	B-X
that	B-X
influenza	B-X
vaccines	B-X
prepared	B-X
with	B-X
egg-derived	B-X
virus	B-X
should	B-X
be	B-X
protective	B-X
against	B-X
microvariants	B-X
of	B-X
virus	B-X
that	B-X
grow	B-X
preferentially	B-X
in	B-X
MDCK	B-X
and	B-X
possibly	B-X
other	B-X
mammalian	B-X
cells	B-X
.	B-X

Biosynthesis	O
of	O
type	O
I	O
procollagen	O
.	O
<EOS>	B-X
The	B-X
more	B-X
prevalent	B-X
autosomal	B-X
dominant	B-X
forms	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
are	B-X
caused	B-X
by	B-X
primary	B-X
defects	B-X
in	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
whereas	B-X
autosomal	B-X
recessive	B-X
forms	B-X
are	B-X
caused	B-X
by	B-X
deficiency	B-X
of	B-X
proteins	B-X
which	B-X
interact	B-X
with	B-X
type	B-X
I	B-X
procollagen	B-X
for	B-X
post-translational	B-X
modification	B-X
and/or	B-X
folding	B-X
.	B-X
The	B-X
aminoterminal	B-X
propeptide	B-X
of	B-X
type	B-X
I	B-X
procollagen	B-X
(	B-X
PINP	B-X
)	B-X
in	B-X
serum	B-X
is	B-X
a	B-X
sensitive	B-X
indicator	B-X
of	B-X
the	B-X
synthesis	B-X
of	B-X
type	B-X
I	B-X
collagen	B-X
.	B-X
All	B-X
of	B-X
the	B-X
type	B-X
I	B-X
collagen	B-X
in	B-X
connective	B-X
tissue	B-X
is	B-X
the	B-X
product	B-X
of	B-X
one	B-X
structural	B-X
gene	B-X
for	B-X
the	B-X
pro	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
chain	B-X
and	B-X
another	B-X
for	B-X
the	B-X
pro	B-X
alpha	B-X
2	B-X
(	B-X
I	B-X
)	B-X
chain	B-X
of	B-X
type	B-X
I	B-X
procollagen	B-X
.	B-X
One	B-X
approach	B-X
that	B-X
our	B-X
laboratory	B-X
has	B-X
pursued	B-X
to	B-X
answer	B-X
this	B-X
and	B-X
related	B-X
questions	B-X
is	B-X
to	B-X
develop	B-X
a	B-X
new	B-X
system	B-X
whereby	B-X
one	B-X
can	B-X
examine	B-X
the	B-X
self-assembly	B-X
of	B-X
collagen	B-X
fibrils	B-X
de	B-X
novo	B-X
by	B-X
controlled	B-X
enzymic	B-X
cleavage	B-X
of	B-X
procollagen	B-X
to	B-X
collagen	B-X
under	B-X
physiological	B-X
conditions	B-X
.	B-X
A	B-X
second	B-X
approach	B-X
has	B-X
been	B-X
to	B-X
define	B-X
mutations	B-X
in	B-X
type	B-X
I	B-X
procollagen	B-X
genes	B-X
that	B-X
cause	B-X
increased	B-X
brittleness	B-X
of	B-X
bone	B-X
.	B-X
Over	B-X
a	B-X
dozen	B-X
mutations	B-X
in	B-X
type	B-X
I	B-X
procollagen	B-X
genes	B-X
have	B-X
been	B-X
found	B-X
in	B-X
probands	B-X
with	B-X
osteogenesis	B-X
imperfecta	B-X
.	B-X
One	B-X
of	B-X
the	B-X
surprises	B-X
has	B-X
been	B-X
that	B-X
at	B-X
least	B-X
25	B-X
%	B-X
of	B-X
the	B-X
probands	B-X
with	B-X
lethal	B-X
variants	B-X
of	B-X
osteogenesis	B-X
imperfecta	B-X
have	B-X
mutations	B-X
in	B-X
type	B-X
I	B-X
procollagen	B-X
genes	B-X
.	B-X

Characterization	O
of	O
the	O
distribution	O
of	O
chain	O
sizes	O
and	O
extent	O
of	O
hydroxylation	O
of	O
polysome	O
-	O
associated	O
pro	O
-	O
alpha	O
-	O
chains	O
.	O
<EOS>	B-X
[	B-X
3H	B-X
]	B-X
Proline-labeled	B-X
nascent	B-X
procollagen	B-X
chains	B-X
were	B-X
isolated	B-X
from	B-X
chick	B-X
tendon	B-X
polysome	B-X
preparations	B-X
as	B-X
peptidyl-tRNA	B-X
complexes	B-X
by	B-X
ion	B-X
exchange	B-X
chromatography	B-X
.	B-X
Proline	B-X
hydroxylation	B-X
of	B-X
the	B-X
nascent	B-X
chains	B-X
was	B-X
at	B-X
least	B-X
40	B-X
%	B-X
complete	B-X
,	B-X
based	B-X
on	B-X
radioactive	B-X
hydroxyproline/proline	B-X
ratios	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
that	B-X
hydroxylation	B-X
of	B-X
procollagen	B-X
proline	B-X
residues	B-X
does	B-X
occur	B-X
on	B-X
nascent	B-X
chains	B-X
.	B-X
The	B-X
electrophoretic	B-X
profiles	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
nascent	B-X
chains	B-X
and	B-X
of	B-X
unlabeled	B-X
nascent	B-X
chains	B-X
visualized	B-X
by	B-X
Western	B-X
blotting	B-X
with	B-X
35S-labeled	B-X
monoclonal	B-X
antibodies	B-X
to	B-X
the	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
N-propeptide	B-X
or	B-X
the	B-X
C-propeptides	B-X
indicate	B-X
that	B-X
there	B-X
are	B-X
pauses	B-X
in	B-X
the	B-X
translation	B-X
of	B-X
procollagen	B-X
alpha-chains	B-X
in	B-X
the	B-X
intact	B-X
cells	B-X
.	B-X
Approximately	B-X
25	B-X
%	B-X
of	B-X
the	B-X
radioactivity	B-X
associated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
polysomes	B-X
was	B-X
in	B-X
fully	B-X
elongated	B-X
but	B-X
underhydroxylated	B-X
(	B-X
relative	B-X
to	B-X
secreted	B-X
procollagen	B-X
)	B-X
pro-alpha-chains	B-X
.	B-X
The	B-X
association	B-X
of	B-X
these	B-X
completely	B-X
elongated	B-X
but	B-X
only	B-X
partially	B-X
modified	B-X
procollagen	B-X
chains	B-X
with	B-X
the	B-X
polysome	B-X
complex	B-X
may	B-X
facilitate	B-X
the	B-X
carboxyl-terminal	B-X
interactions	B-X
which	B-X
lead	B-X
to	B-X
triple	B-X
helix	B-X
formation	B-X
.	B-X

[	O
3H	O
]	O
Proline	O
-	O
labeled	O
nascent	O
procollagen	O
chains	O
were	O
isolated	O
from	O
chick	O
tendon	O
polysome	O
preparations	O
as	O
peptidyl	O
-	O
tRNA	O
complexes	O
by	O
ion	O
exchange	O
chromatography	O
.	O
<EOS>	B-X
[	B-X
3H	B-X
]	B-X
Proline-labeled	B-X
nascent	B-X
procollagen	B-X
chains	B-X
were	B-X
isolated	B-X
from	B-X
chick	B-X
tendon	B-X
polysome	B-X
preparations	B-X
as	B-X
peptidyl-tRNA	B-X
complexes	B-X
by	B-X
ion	B-X
exchange	B-X
chromatography	B-X
.	B-X
Proline	B-X
hydroxylation	B-X
of	B-X
the	B-X
nascent	B-X
chains	B-X
was	B-X
at	B-X
least	B-X
40	B-X
%	B-X
complete	B-X
,	B-X
based	B-X
on	B-X
radioactive	B-X
hydroxyproline/proline	B-X
ratios	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
that	B-X
hydroxylation	B-X
of	B-X
procollagen	B-X
proline	B-X
residues	B-X
does	B-X
occur	B-X
on	B-X
nascent	B-X
chains	B-X
.	B-X
The	B-X
electrophoretic	B-X
profiles	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
nascent	B-X
chains	B-X
and	B-X
of	B-X
unlabeled	B-X
nascent	B-X
chains	B-X
visualized	B-X
by	B-X
Western	B-X
blotting	B-X
with	B-X
35S-labeled	B-X
monoclonal	B-X
antibodies	B-X
to	B-X
the	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
N-propeptide	B-X
or	B-X
the	B-X
C-propeptides	B-X
indicate	B-X
that	B-X
there	B-X
are	B-X
pauses	B-X
in	B-X
the	B-X
translation	B-X
of	B-X
procollagen	B-X
alpha-chains	B-X
in	B-X
the	B-X
intact	B-X
cells	B-X
.	B-X
Approximately	B-X
25	B-X
%	B-X
of	B-X
the	B-X
radioactivity	B-X
associated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
polysomes	B-X
was	B-X
in	B-X
fully	B-X
elongated	B-X
but	B-X
underhydroxylated	B-X
(	B-X
relative	B-X
to	B-X
secreted	B-X
procollagen	B-X
)	B-X
pro-alpha-chains	B-X
.	B-X
The	B-X
association	B-X
of	B-X
these	B-X
completely	B-X
elongated	B-X
but	B-X
only	B-X
partially	B-X
modified	B-X
procollagen	B-X
chains	B-X
with	B-X
the	B-X
polysome	B-X
complex	B-X
may	B-X
facilitate	B-X
the	B-X
carboxyl-terminal	B-X
interactions	B-X
which	B-X
lead	B-X
to	B-X
triple	B-X
helix	B-X
formation	B-X
.	B-X

Proline	O
hydroxylation	O
of	O
the	O
nascent	O
chains	O
was	O
at	O
least	O
40	O
%	O
complete	O
,	O
based	O
on	O
radioactive	O
hydroxyproline	O
/	O
proline	O
ratios	O
.	O
<EOS>	B-X
[	B-X
3H	B-X
]	B-X
Proline-labeled	B-X
nascent	B-X
procollagen	B-X
chains	B-X
were	B-X
isolated	B-X
from	B-X
chick	B-X
tendon	B-X
polysome	B-X
preparations	B-X
as	B-X
peptidyl-tRNA	B-X
complexes	B-X
by	B-X
ion	B-X
exchange	B-X
chromatography	B-X
.	B-X
Proline	B-X
hydroxylation	B-X
of	B-X
the	B-X
nascent	B-X
chains	B-X
was	B-X
at	B-X
least	B-X
40	B-X
%	B-X
complete	B-X
,	B-X
based	B-X
on	B-X
radioactive	B-X
hydroxyproline/proline	B-X
ratios	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
that	B-X
hydroxylation	B-X
of	B-X
procollagen	B-X
proline	B-X
residues	B-X
does	B-X
occur	B-X
on	B-X
nascent	B-X
chains	B-X
.	B-X
The	B-X
electrophoretic	B-X
profiles	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
nascent	B-X
chains	B-X
and	B-X
of	B-X
unlabeled	B-X
nascent	B-X
chains	B-X
visualized	B-X
by	B-X
Western	B-X
blotting	B-X
with	B-X
35S-labeled	B-X
monoclonal	B-X
antibodies	B-X
to	B-X
the	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
N-propeptide	B-X
or	B-X
the	B-X
C-propeptides	B-X
indicate	B-X
that	B-X
there	B-X
are	B-X
pauses	B-X
in	B-X
the	B-X
translation	B-X
of	B-X
procollagen	B-X
alpha-chains	B-X
in	B-X
the	B-X
intact	B-X
cells	B-X
.	B-X
Approximately	B-X
25	B-X
%	B-X
of	B-X
the	B-X
radioactivity	B-X
associated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
polysomes	B-X
was	B-X
in	B-X
fully	B-X
elongated	B-X
but	B-X
underhydroxylated	B-X
(	B-X
relative	B-X
to	B-X
secreted	B-X
procollagen	B-X
)	B-X
pro-alpha-chains	B-X
.	B-X
The	B-X
association	B-X
of	B-X
these	B-X
completely	B-X
elongated	B-X
but	B-X
only	B-X
partially	B-X
modified	B-X
procollagen	B-X
chains	B-X
with	B-X
the	B-X
polysome	B-X
complex	B-X
may	B-X
facilitate	B-X
the	B-X
carboxyl-terminal	B-X
interactions	B-X
which	B-X
lead	B-X
to	B-X
triple	B-X
helix	B-X
formation	B-X
.	B-X

These	O
data	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
hydroxylation	O
of	O
procollagen	O
proline	O
residues	O
does	O
occur	O
on	O
nascent	O
chains	O
.	O
<EOS>	B-X
[	B-X
3H	B-X
]	B-X
Proline-labeled	B-X
nascent	B-X
procollagen	B-X
chains	B-X
were	B-X
isolated	B-X
from	B-X
chick	B-X
tendon	B-X
polysome	B-X
preparations	B-X
as	B-X
peptidyl-tRNA	B-X
complexes	B-X
by	B-X
ion	B-X
exchange	B-X
chromatography	B-X
.	B-X
Proline	B-X
hydroxylation	B-X
of	B-X
the	B-X
nascent	B-X
chains	B-X
was	B-X
at	B-X
least	B-X
40	B-X
%	B-X
complete	B-X
,	B-X
based	B-X
on	B-X
radioactive	B-X
hydroxyproline/proline	B-X
ratios	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
that	B-X
hydroxylation	B-X
of	B-X
procollagen	B-X
proline	B-X
residues	B-X
does	B-X
occur	B-X
on	B-X
nascent	B-X
chains	B-X
.	B-X
The	B-X
electrophoretic	B-X
profiles	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
nascent	B-X
chains	B-X
and	B-X
of	B-X
unlabeled	B-X
nascent	B-X
chains	B-X
visualized	B-X
by	B-X
Western	B-X
blotting	B-X
with	B-X
35S-labeled	B-X
monoclonal	B-X
antibodies	B-X
to	B-X
the	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
N-propeptide	B-X
or	B-X
the	B-X
C-propeptides	B-X
indicate	B-X
that	B-X
there	B-X
are	B-X
pauses	B-X
in	B-X
the	B-X
translation	B-X
of	B-X
procollagen	B-X
alpha-chains	B-X
in	B-X
the	B-X
intact	B-X
cells	B-X
.	B-X
Approximately	B-X
25	B-X
%	B-X
of	B-X
the	B-X
radioactivity	B-X
associated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
polysomes	B-X
was	B-X
in	B-X
fully	B-X
elongated	B-X
but	B-X
underhydroxylated	B-X
(	B-X
relative	B-X
to	B-X
secreted	B-X
procollagen	B-X
)	B-X
pro-alpha-chains	B-X
.	B-X
The	B-X
association	B-X
of	B-X
these	B-X
completely	B-X
elongated	B-X
but	B-X
only	B-X
partially	B-X
modified	B-X
procollagen	B-X
chains	B-X
with	B-X
the	B-X
polysome	B-X
complex	B-X
may	B-X
facilitate	B-X
the	B-X
carboxyl-terminal	B-X
interactions	B-X
which	B-X
lead	B-X
to	B-X
triple	B-X
helix	B-X
formation	B-X
.	B-X

The	O
electrophoretic	O
profiles	O
of	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
nascent	O
chains	O
and	O
of	O
unlabeled	O
nascent	O
chains	O
visualized	O
by	O
Western	O
blotting	O
with	O
35S	O
-	O
labeled	O
monoclonal	O
antibodies	O
to	O
the	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
N	O
-	O
propeptide	O
or	O
the	O
C	O
-	O
propeptides	O
indicate	O
that	O
there	O
are	O
pauses	O
in	O
the	O
translation	O
of	O
procollagen	O
alpha	O
-	O
chains	O
in	O
the	O
intact	O
cells	O
.	O

Approximately	O
25	O
%	O
of	O
the	O
radioactivity	O
associated	O
with	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
polysomes	O
was	O
in	O
fully	O
elongated	O
but	O
underhydroxylated	O
(	O
relative	O
to	O
secreted	O
procollagen	O
)	O
pro	O
-	O
alpha	O
-	O
chains	O
.	O
<EOS>	B-X
[	B-X
3H	B-X
]	B-X
Proline-labeled	B-X
nascent	B-X
procollagen	B-X
chains	B-X
were	B-X
isolated	B-X
from	B-X
chick	B-X
tendon	B-X
polysome	B-X
preparations	B-X
as	B-X
peptidyl-tRNA	B-X
complexes	B-X
by	B-X
ion	B-X
exchange	B-X
chromatography	B-X
.	B-X
Proline	B-X
hydroxylation	B-X
of	B-X
the	B-X
nascent	B-X
chains	B-X
was	B-X
at	B-X
least	B-X
40	B-X
%	B-X
complete	B-X
,	B-X
based	B-X
on	B-X
radioactive	B-X
hydroxyproline/proline	B-X
ratios	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
that	B-X
hydroxylation	B-X
of	B-X
procollagen	B-X
proline	B-X
residues	B-X
does	B-X
occur	B-X
on	B-X
nascent	B-X
chains	B-X
.	B-X
The	B-X
electrophoretic	B-X
profiles	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
nascent	B-X
chains	B-X
and	B-X
of	B-X
unlabeled	B-X
nascent	B-X
chains	B-X
visualized	B-X
by	B-X
Western	B-X
blotting	B-X
with	B-X
35S-labeled	B-X
monoclonal	B-X
antibodies	B-X
to	B-X
the	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
N-propeptide	B-X
or	B-X
the	B-X
C-propeptides	B-X
indicate	B-X
that	B-X
there	B-X
are	B-X
pauses	B-X
in	B-X
the	B-X
translation	B-X
of	B-X
procollagen	B-X
alpha-chains	B-X
in	B-X
the	B-X
intact	B-X
cells	B-X
.	B-X
Approximately	B-X
25	B-X
%	B-X
of	B-X
the	B-X
radioactivity	B-X
associated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
polysomes	B-X
was	B-X
in	B-X
fully	B-X
elongated	B-X
but	B-X
underhydroxylated	B-X
(	B-X
relative	B-X
to	B-X
secreted	B-X
procollagen	B-X
)	B-X
pro-alpha-chains	B-X
.	B-X
The	B-X
association	B-X
of	B-X
these	B-X
completely	B-X
elongated	B-X
but	B-X
only	B-X
partially	B-X
modified	B-X
procollagen	B-X
chains	B-X
with	B-X
the	B-X
polysome	B-X
complex	B-X
may	B-X
facilitate	B-X
the	B-X
carboxyl-terminal	B-X
interactions	B-X
which	B-X
lead	B-X
to	B-X
triple	B-X
helix	B-X
formation	B-X
.	B-X

The	O
association	O
of	O
these	O
completely	O
elongated	O
but	O
only	O
partially	O
modified	O
procollagen	O
chains	O
with	O
the	O
polysome	O
complex	O
may	O
facilitate	O
the	O
carboxyl	O
-	O
terminal	O
interactions	O
which	O
lead	O
to	O
triple	O
helix	O
formation	O
.	O
<EOS>	B-X
[	B-X
3H	B-X
]	B-X
Proline-labeled	B-X
nascent	B-X
procollagen	B-X
chains	B-X
were	B-X
isolated	B-X
from	B-X
chick	B-X
tendon	B-X
polysome	B-X
preparations	B-X
as	B-X
peptidyl-tRNA	B-X
complexes	B-X
by	B-X
ion	B-X
exchange	B-X
chromatography	B-X
.	B-X
Proline	B-X
hydroxylation	B-X
of	B-X
the	B-X
nascent	B-X
chains	B-X
was	B-X
at	B-X
least	B-X
40	B-X
%	B-X
complete	B-X
,	B-X
based	B-X
on	B-X
radioactive	B-X
hydroxyproline/proline	B-X
ratios	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
that	B-X
hydroxylation	B-X
of	B-X
procollagen	B-X
proline	B-X
residues	B-X
does	B-X
occur	B-X
on	B-X
nascent	B-X
chains	B-X
.	B-X
The	B-X
electrophoretic	B-X
profiles	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
nascent	B-X
chains	B-X
and	B-X
of	B-X
unlabeled	B-X
nascent	B-X
chains	B-X
visualized	B-X
by	B-X
Western	B-X
blotting	B-X
with	B-X
35S-labeled	B-X
monoclonal	B-X
antibodies	B-X
to	B-X
the	B-X
alpha	B-X
1	B-X
(	B-X
I	B-X
)	B-X
N-propeptide	B-X
or	B-X
the	B-X
C-propeptides	B-X
indicate	B-X
that	B-X
there	B-X
are	B-X
pauses	B-X
in	B-X
the	B-X
translation	B-X
of	B-X
procollagen	B-X
alpha-chains	B-X
in	B-X
the	B-X
intact	B-X
cells	B-X
.	B-X
Approximately	B-X
25	B-X
%	B-X
of	B-X
the	B-X
radioactivity	B-X
associated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
polysomes	B-X
was	B-X
in	B-X
fully	B-X
elongated	B-X
but	B-X
underhydroxylated	B-X
(	B-X
relative	B-X
to	B-X
secreted	B-X
procollagen	B-X
)	B-X
pro-alpha-chains	B-X
.	B-X
The	B-X
association	B-X
of	B-X
these	B-X
completely	B-X
elongated	B-X
but	B-X
only	B-X
partially	B-X
modified	B-X
procollagen	B-X
chains	B-X
with	B-X
the	B-X
polysome	B-X
complex	B-X
may	B-X
facilitate	B-X
the	B-X
carboxyl-terminal	B-X
interactions	B-X
which	B-X
lead	B-X
to	B-X
triple	B-X
helix	B-X
formation	B-X
.	B-X

A	O
comparison	O
of	O
accessibility	O
of	O
ribosomal	O
proteins	O
on	O
free	O
and	O
membrane	O
-	O
bound	O
ribosomes	O
:	O
the	O
ribosomal	O
proteins	O
potentially	O
involved	O
in	O
ribosome	O
-	O
membrane	O
binding	O
.	O
<EOS>	B-X
The	B-X
relative	B-X
accessibility	B-X
of	B-X
rat	B-X
liver	B-X
ribosomal	B-X
proteins	B-X
to	B-X
reductive	B-X
methylation	B-X
was	B-X
examined	B-X
using	B-X
membrane-bound	B-X
and	B-X
free	B-X
ribosomes	B-X
.	B-X
Comparisons	B-X
indicated	B-X
that	B-X
12-13	B-X
large	B-X
ribosomal	B-X
proteins	B-X
are	B-X
masked	B-X
by	B-X
ribosomal	B-X
association	B-X
with	B-X
membranes	B-X
.	B-X
These	B-X
proteins	B-X
seem	B-X
to	B-X
surround	B-X
a	B-X
region	B-X
centered	B-X
about	B-X
L3	B-X
and	B-X
may	B-X
partly	B-X
define	B-X
a	B-X
ribosomal	B-X
channel	B-X
through	B-X
which	B-X
the	B-X
nascent	B-X
peptide	B-X
emerges	B-X
.	B-X
10-20	B-X
%	B-X
of	B-X
the	B-X
large	B-X
ribosomal	B-X
subunit	B-X
surface	B-X
area	B-X
is	B-X
shielded	B-X
by	B-X
the	B-X
membrane	B-X
.	B-X

The	O
relative	O
accessibility	O
of	O
rat	O
liver	O
ribosomal	O
proteins	O
to	O
reductive	O
methylation	O
was	O
examined	O
using	O
membrane	O
-	O
bound	O
and	O
free	O
ribosomes	O
.	O
<EOS>	B-X
The	B-X
relative	B-X
accessibility	B-X
of	B-X
rat	B-X
liver	B-X
ribosomal	B-X
proteins	B-X
to	B-X
reductive	B-X
methylation	B-X
was	B-X
examined	B-X
using	B-X
membrane-bound	B-X
and	B-X
free	B-X
ribosomes	B-X
.	B-X
Comparisons	B-X
indicated	B-X
that	B-X
12-13	B-X
large	B-X
ribosomal	B-X
proteins	B-X
are	B-X
masked	B-X
by	B-X
ribosomal	B-X
association	B-X
with	B-X
membranes	B-X
.	B-X
These	B-X
proteins	B-X
seem	B-X
to	B-X
surround	B-X
a	B-X
region	B-X
centered	B-X
about	B-X
L3	B-X
and	B-X
may	B-X
partly	B-X
define	B-X
a	B-X
ribosomal	B-X
channel	B-X
through	B-X
which	B-X
the	B-X
nascent	B-X
peptide	B-X
emerges	B-X
.	B-X
10-20	B-X
%	B-X
of	B-X
the	B-X
large	B-X
ribosomal	B-X
subunit	B-X
surface	B-X
area	B-X
is	B-X
shielded	B-X
by	B-X
the	B-X
membrane	B-X
.	B-X

Comparisons	O
indicated	O
that	O
12	O
-	O
13	O
large	O
ribosomal	O
proteins	O
are	O
masked	O
by	O
ribosomal	O
association	O
with	O
membranes	O
.	O
<EOS>	B-X
The	B-X
relative	B-X
accessibility	B-X
of	B-X
rat	B-X
liver	B-X
ribosomal	B-X
proteins	B-X
to	B-X
reductive	B-X
methylation	B-X
was	B-X
examined	B-X
using	B-X
membrane-bound	B-X
and	B-X
free	B-X
ribosomes	B-X
.	B-X
Comparisons	B-X
indicated	B-X
that	B-X
12-13	B-X
large	B-X
ribosomal	B-X
proteins	B-X
are	B-X
masked	B-X
by	B-X
ribosomal	B-X
association	B-X
with	B-X
membranes	B-X
.	B-X
These	B-X
proteins	B-X
seem	B-X
to	B-X
surround	B-X
a	B-X
region	B-X
centered	B-X
about	B-X
L3	B-X
and	B-X
may	B-X
partly	B-X
define	B-X
a	B-X
ribosomal	B-X
channel	B-X
through	B-X
which	B-X
the	B-X
nascent	B-X
peptide	B-X
emerges	B-X
.	B-X
10-20	B-X
%	B-X
of	B-X
the	B-X
large	B-X
ribosomal	B-X
subunit	B-X
surface	B-X
area	B-X
is	B-X
shielded	B-X
by	B-X
the	B-X
membrane	B-X
.	B-X

These	O
consisted	O
of	O
L8	B-Protein
,	O
L10	B-Protein
,	O
L17	B-Protein
,	O
L26	B-Protein
-	O
28	B-Protein
,	O
L31	B-Protein
and	O
L36	B-Protein
,	O
and	O
probably	O
also	O
include	O
L4	B-Protein
,	O
L5	B-Protein
,	O
L7	B-Protein
and	O
L29	B-Protein
.	O
<EOS>	B-X
These	B-X
consisted	B-X
of	B-X
L8	B-X
,	B-X
L10	B-X
,	B-X
L17	B-X
,	B-X
L26-28	B-X
,	B-X
L31	B-X
and	B-X
L36	B-X
,	B-X
and	B-X
probably	B-X
also	B-X
include	B-X
L4	B-X
,	B-X
L5	B-X
,	B-X
L7	B-X
and	B-X
L29	B-X
.	B-X

These	O
proteins	O
seem	O
to	O
surround	O
a	O
region	O
centered	O
about	O
L3	B-Protein
and	O
may	O
partly	O
define	O
a	O
ribosomal	O
channel	O
through	O
which	O
the	O
nascent	O
peptide	O
emerges	O
.	O
<EOS>	B-X
The	B-X
relative	B-X
accessibility	B-X
of	B-X
rat	B-X
liver	B-X
ribosomal	B-X
proteins	B-X
to	B-X
reductive	B-X
methylation	B-X
was	B-X
examined	B-X
using	B-X
membrane-bound	B-X
and	B-X
free	B-X
ribosomes	B-X
.	B-X
Comparisons	B-X
indicated	B-X
that	B-X
12-13	B-X
large	B-X
ribosomal	B-X
proteins	B-X
are	B-X
masked	B-X
by	B-X
ribosomal	B-X
association	B-X
with	B-X
membranes	B-X
.	B-X
These	B-X
consisted	B-X
of	B-X
L8	B-X
,	B-X
L10	B-X
,	B-X
L17	B-X
,	B-X
L26-28	B-X
,	B-X
L31	B-X
and	B-X
L36	B-X
,	B-X
and	B-X
probably	B-X
also	B-X
include	B-X
L4	B-X
,	B-X
L5	B-X
,	B-X
L7	B-X
and	B-X
L29	B-X
.	B-X
These	B-X
proteins	B-X
seem	B-X
to	B-X
surround	B-X
a	B-X
region	B-X
centered	B-X
about	B-X
L3	B-X
and	B-X
may	B-X
partly	B-X
define	B-X
a	B-X
ribosomal	B-X
channel	B-X
through	B-X
which	B-X
the	B-X
nascent	B-X
peptide	B-X
emerges	B-X
.	B-X
10-20	B-X
%	B-X
of	B-X
the	B-X
large	B-X
ribosomal	B-X
subunit	B-X
surface	B-X
area	B-X
is	B-X
shielded	B-X
by	B-X
the	B-X
membrane	B-X
.	B-X

Approx	O
.	O
10	O
-	O
20	O
%	O
of	O
the	O
large	O
ribosomal	O
subunit	O
surface	O
area	O
is	O
shielded	O
by	O
the	O
membrane	O
.	O
<EOS>	B-X
The	B-X
relative	B-X
accessibility	B-X
of	B-X
rat	B-X
liver	B-X
ribosomal	B-X
proteins	B-X
to	B-X
reductive	B-X
methylation	B-X
was	B-X
examined	B-X
using	B-X
membrane-bound	B-X
and	B-X
free	B-X
ribosomes	B-X
.	B-X
Comparisons	B-X
indicated	B-X
that	B-X
12-13	B-X
large	B-X
ribosomal	B-X
proteins	B-X
are	B-X
masked	B-X
by	B-X
ribosomal	B-X
association	B-X
with	B-X
membranes	B-X
.	B-X
These	B-X
consisted	B-X
of	B-X
L8	B-X
,	B-X
L10	B-X
,	B-X
L17	B-X
,	B-X
L26-28	B-X
,	B-X
L31	B-X
and	B-X
L36	B-X
,	B-X
and	B-X
probably	B-X
also	B-X
include	B-X
L4	B-X
,	B-X
L5	B-X
,	B-X
L7	B-X
and	B-X
L29	B-X
.	B-X
These	B-X
proteins	B-X
seem	B-X
to	B-X
surround	B-X
a	B-X
region	B-X
centered	B-X
about	B-X
L3	B-X
and	B-X
may	B-X
partly	B-X
define	B-X
a	B-X
ribosomal	B-X
channel	B-X
through	B-X
which	B-X
the	B-X
nascent	B-X
peptide	B-X
emerges	B-X
.	B-X
Approx	B-X
.	B-X
10-20	B-X
%	B-X
of	B-X
the	B-X
large	B-X
ribosomal	B-X
subunit	B-X
surface	B-X
area	B-X
is	B-X
shielded	B-X
by	B-X
the	B-X
membrane	B-X
.	B-X

The	O
prolonged	O
stimulatory	O
effect	O
of	O
ACTH	B-Protein
on	O
11	O
beta	O
-	O
hydroxylation	O
,	O
and	O
its	O
contribution	O
to	O
the	O
steroidogenic	O
potency	O
of	O
adrenocortical	O
cells	O
.	O

The	O
mechanism	O
of	O
the	O
prolonged	O
stimulatory	O
influence	O
of	O
corticotropin	B-Protein
(	O
ACTH	B-Protein
)	O
on	O
the	O
capacity	O
of	O
adrenocortical	O
cells	O
to	O
produce	O
cortisol	O
in	O
response	O
to	O
ACTH	B-Protein
and	O
more	O
specifically	O
the	O
role	O
of	O
11	O
beta	O
-	O
hydroxylation	O
,	O
was	O
studied	O
on	O
guinea	O
-	O
pig	O
adrenocortical	O
cells	O
dispersed	O
from	O
control	O
and	O
ACTH	B-Protein
-	O
treated	O
animals	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
of	B-X
the	B-X
prolonged	B-X
stimulatory	B-X
influence	B-X
of	B-X
corticotropin	B-X
(	B-X
ACTH	B-X
)	B-X
on	B-X
the	B-X
capacity	B-X
of	B-X
adrenocortical	B-X
cells	B-X
to	B-X
produce	B-X
cortisol	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
and	B-X
more	B-X
specifically	B-X
the	B-X
role	B-X
of	B-X
11	B-X
beta-hydroxylation	B-X
,	B-X
was	B-X
studied	B-X
on	B-X
guinea-pig	B-X
adrenocortical	B-X
cells	B-X
dispersed	B-X
from	B-X
control	B-X
and	B-X
ACTH-treated	B-X
animals	B-X
.	B-X
As	B-X
a	B-X
result	B-X
of	B-X
the	B-X
previous	B-X
in	B-X
vivo	B-X
exposure	B-X
to	B-X
ACTH	B-X
,	B-X
the	B-X
net	B-X
maximal	B-X
production	B-X
of	B-X
glucocorticoids	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
(	B-X
by	B-X
10	B-X
(	B-X
5	B-X
)	B-X
cells	B-X
and	B-X
2	B-X
h	B-X
incubation	B-X
)	B-X
increased	B-X
from	B-X
660	B-X
+/-	B-X
33.9	B-X
ng	B-X
(	B-X
control	B-X
group	B-X
)	B-X
to	B-X
1105	B-X
+/-	B-X
117.9	B-X
ng	B-X
for	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
apparent	B-X
affinity	B-X
of	B-X
the	B-X
steroidogenic	B-X
response	B-X
remained	B-X
unchanged	B-X
.	B-X
In	B-X
addition	B-X
there	B-X
occurred	B-X
an	B-X
increased	B-X
conversion	B-X
of	B-X
exogenous	B-X
pregnenolone	B-X
into	B-X
cortisol	B-X
by	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
,	B-X
indicating	B-X
a	B-X
prolonged	B-X
stimulatory	B-X
influence	B-X
of	B-X
ACTH	B-X
on	B-X
the	B-X
post-pregnenolone	B-X
pathway	B-X
of	B-X
cortisol	B-X
biosynthesis	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
11	B-X
beta-hydroxylation	B-X
step	B-X
was	B-X
therefore	B-X
examined	B-X
by	B-X
incubating	B-X
the	B-X
adrenocortical	B-X
cells	B-X
from	B-X
control	B-X
and	B-X
ACTH-treated	B-X
animals	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
increasing	B-X
amounts	B-X
of	B-X
11-deoxycortisol	B-X
.	B-X
The	B-X
maximal	B-X
capacity	B-X
of	B-X
11-deoxycortisol	B-X
conversion	B-X
into	B-X
cortisol	B-X
was	B-X
increased	B-X
as	B-X
a	B-X
result	B-X
of	B-X
the	B-X
in	B-X
vivo	B-X
exposure	B-X
to	B-X
ACTH	B-X
,	B-X
averaging	B-X
3423	B-X
+/-	B-X
211	B-X
ng	B-X
cortisol	B-X
formed	B-X
from	B-X
5	B-X
micrograms	B-X
11-deoxycortisol	B-X
by	B-X
10	B-X
(	B-X
5	B-X
)	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
vs	B-X
2074	B-X
+/-	B-X
185	B-X
ng	B-X
for	B-X
cells	B-X
from	B-X
control	B-X
guinea-pigs	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
conversion	B-X
of	B-X
lower	B-X
amounts	B-X
of	B-X
11-deoxycortisol	B-X
into	B-X
cortisol	B-X
,	B-X
reproducing	B-X
quantitatively	B-X
the	B-X
maximal	B-X
effect	B-X
of	B-X
ACTH	B-X
on	B-X
cortisol	B-X
biosynthesis	B-X
,	B-X
was	B-X
only	B-X
barely	B-X
increased	B-X
in	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
(	B-X
P	B-X
greater	B-X
than	B-X
0.05	B-X
)	B-X
.	B-X
Therefore	B-X
it	B-X
was	B-X
concluded	B-X
that	B-X
ACTH	B-X
increases	B-X
in	B-X
a	B-X
lasting	B-X
way	B-X
not	B-X
only	B-X
the	B-X
overall	B-X
steroidogenic	B-X
capacity	B-X
of	B-X
adrenocortical	B-X
cells	B-X
but	B-X
also	B-X
the	B-X
maximal	B-X
efficiency	B-X
of	B-X
11	B-X
beta-hydroxylation	B-X
.	B-X
Since	B-X
the	B-X
latter	B-X
effect	B-X
can	B-X
not	B-X
account	B-X
quantitatively	B-X
for	B-X
the	B-X
magnitude	B-X
of	B-X
the	B-X
lasting	B-X
effect	B-X
of	B-X
ACTH	B-X
on	B-X
the	B-X
maximal	B-X
capacity	B-X
of	B-X
adrenocortical	B-X
cells	B-X
to	B-X
produce	B-X
cortisol	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
the	B-X
prolonged	B-X
influence	B-X
of	B-X
ACTH	B-X
on	B-X
cortisol	B-X
biosynthesis	B-X
should	B-X
also	B-X
involve	B-X
a	B-X
stimulatory	B-X
influence	B-X
of	B-X
the	B-X
peptide	B-X
on	B-X
earlier	B-X
step	B-X
(	B-X
s	B-X
)	B-X
of	B-X
steroidogenesis	B-X
.	B-X

As	O
a	O
result	O
of	O
the	O
previous	O
in	O
vivo	O
exposure	O
to	O
ACTH	B-Protein
,	O
the	O
net	O
maximal	O
production	O
of	O
glucocorticoids	O
in	O
response	O
to	O
ACTH	B-Protein
(	O
by	O
10	O
(	O
5	O
)	O
cells	O
and	O
2	O
h	O
incubation	O
)	O
increased	O
from	O
660	O
+	O
/	O
-	O
33	O
.	O
9	O
ng	O
(	O
control	O
group	O
)	O
to	O
1105	O
+	O
/	O
-	O
117	O
.	O
9	O
ng	O
for	O
cells	O
from	O
ACTH	B-Protein
-	O
treated	O
animals	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
whereas	O
the	O
apparent	O
affinity	O
of	O
the	O
steroidogenic	O
response	O
remained	O
unchanged	O
.	O

In	O
addition	O
there	O
occurred	O
an	O
increased	O
conversion	O
of	O
exogenous	O
pregnenolone	O
into	O
cortisol	O
by	O
cells	O
from	O
ACTH	B-Protein
-	O
treated	O
animals	O
,	O
indicating	O
a	O
prolonged	O
stimulatory	O
influence	O
of	O
ACTH	B-Protein
on	O
the	O
post	O
-	O
pregnenolone	O
pathway	O
of	O
cortisol	O
biosynthesis	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
of	B-X
the	B-X
prolonged	B-X
stimulatory	B-X
influence	B-X
of	B-X
corticotropin	B-X
(	B-X
ACTH	B-X
)	B-X
on	B-X
the	B-X
capacity	B-X
of	B-X
adrenocortical	B-X
cells	B-X
to	B-X
produce	B-X
cortisol	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
and	B-X
more	B-X
specifically	B-X
the	B-X
role	B-X
of	B-X
11	B-X
beta-hydroxylation	B-X
,	B-X
was	B-X
studied	B-X
on	B-X
guinea-pig	B-X
adrenocortical	B-X
cells	B-X
dispersed	B-X
from	B-X
control	B-X
and	B-X
ACTH-treated	B-X
animals	B-X
.	B-X
As	B-X
a	B-X
result	B-X
of	B-X
the	B-X
previous	B-X
in	B-X
vivo	B-X
exposure	B-X
to	B-X
ACTH	B-X
,	B-X
the	B-X
net	B-X
maximal	B-X
production	B-X
of	B-X
glucocorticoids	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
(	B-X
by	B-X
10	B-X
(	B-X
5	B-X
)	B-X
cells	B-X
and	B-X
2	B-X
h	B-X
incubation	B-X
)	B-X
increased	B-X
from	B-X
660	B-X
+/-	B-X
33.9	B-X
ng	B-X
(	B-X
control	B-X
group	B-X
)	B-X
to	B-X
1105	B-X
+/-	B-X
117.9	B-X
ng	B-X
for	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
apparent	B-X
affinity	B-X
of	B-X
the	B-X
steroidogenic	B-X
response	B-X
remained	B-X
unchanged	B-X
.	B-X
In	B-X
addition	B-X
there	B-X
occurred	B-X
an	B-X
increased	B-X
conversion	B-X
of	B-X
exogenous	B-X
pregnenolone	B-X
into	B-X
cortisol	B-X
by	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
,	B-X
indicating	B-X
a	B-X
prolonged	B-X
stimulatory	B-X
influence	B-X
of	B-X
ACTH	B-X
on	B-X
the	B-X
post-pregnenolone	B-X
pathway	B-X
of	B-X
cortisol	B-X
biosynthesis	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
11	B-X
beta-hydroxylation	B-X
step	B-X
was	B-X
therefore	B-X
examined	B-X
by	B-X
incubating	B-X
the	B-X
adrenocortical	B-X
cells	B-X
from	B-X
control	B-X
and	B-X
ACTH-treated	B-X
animals	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
increasing	B-X
amounts	B-X
of	B-X
11-deoxycortisol	B-X
.	B-X
The	B-X
maximal	B-X
capacity	B-X
of	B-X
11-deoxycortisol	B-X
conversion	B-X
into	B-X
cortisol	B-X
was	B-X
increased	B-X
as	B-X
a	B-X
result	B-X
of	B-X
the	B-X
in	B-X
vivo	B-X
exposure	B-X
to	B-X
ACTH	B-X
,	B-X
averaging	B-X
3423	B-X
+/-	B-X
211	B-X
ng	B-X
cortisol	B-X
formed	B-X
from	B-X
5	B-X
micrograms	B-X
11-deoxycortisol	B-X
by	B-X
10	B-X
(	B-X
5	B-X
)	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
vs	B-X
2074	B-X
+/-	B-X
185	B-X
ng	B-X
for	B-X
cells	B-X
from	B-X
control	B-X
guinea-pigs	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
conversion	B-X
of	B-X
lower	B-X
amounts	B-X
of	B-X
11-deoxycortisol	B-X
into	B-X
cortisol	B-X
,	B-X
reproducing	B-X
quantitatively	B-X
the	B-X
maximal	B-X
effect	B-X
of	B-X
ACTH	B-X
on	B-X
cortisol	B-X
biosynthesis	B-X
,	B-X
was	B-X
only	B-X
barely	B-X
increased	B-X
in	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
(	B-X
P	B-X
greater	B-X
than	B-X
0.05	B-X
)	B-X
.	B-X
Therefore	B-X
it	B-X
was	B-X
concluded	B-X
that	B-X
ACTH	B-X
increases	B-X
in	B-X
a	B-X
lasting	B-X
way	B-X
not	B-X
only	B-X
the	B-X
overall	B-X
steroidogenic	B-X
capacity	B-X
of	B-X
adrenocortical	B-X
cells	B-X
but	B-X
also	B-X
the	B-X
maximal	B-X
efficiency	B-X
of	B-X
11	B-X
beta-hydroxylation	B-X
.	B-X
Since	B-X
the	B-X
latter	B-X
effect	B-X
can	B-X
not	B-X
account	B-X
quantitatively	B-X
for	B-X
the	B-X
magnitude	B-X
of	B-X
the	B-X
lasting	B-X
effect	B-X
of	B-X
ACTH	B-X
on	B-X
the	B-X
maximal	B-X
capacity	B-X
of	B-X
adrenocortical	B-X
cells	B-X
to	B-X
produce	B-X
cortisol	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
the	B-X
prolonged	B-X
influence	B-X
of	B-X
ACTH	B-X
on	B-X
cortisol	B-X
biosynthesis	B-X
should	B-X
also	B-X
involve	B-X
a	B-X
stimulatory	B-X
influence	B-X
of	B-X
the	B-X
peptide	B-X
on	B-X
earlier	B-X
step	B-X
(	B-X
s	B-X
)	B-X
of	B-X
steroidogenesis	B-X
.	B-X

The	O
activity	O
of	O
11	O
beta	O
-	O
hydroxylation	O
step	O
was	O
therefore	O
examined	O
by	O
incubating	O
the	O
adrenocortical	O
cells	O
from	O
control	O
and	O
ACTH	B-Protein
-	O
treated	O
animals	O
in	O
the	O
presence	O
of	O
increasing	O
amounts	O
of	O
11	O
-	O
deoxycortisol	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
of	B-X
the	B-X
prolonged	B-X
stimulatory	B-X
influence	B-X
of	B-X
corticotropin	B-X
(	B-X
ACTH	B-X
)	B-X
on	B-X
the	B-X
capacity	B-X
of	B-X
adrenocortical	B-X
cells	B-X
to	B-X
produce	B-X
cortisol	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
and	B-X
more	B-X
specifically	B-X
the	B-X
role	B-X
of	B-X
11	B-X
beta-hydroxylation	B-X
,	B-X
was	B-X
studied	B-X
on	B-X
guinea-pig	B-X
adrenocortical	B-X
cells	B-X
dispersed	B-X
from	B-X
control	B-X
and	B-X
ACTH-treated	B-X
animals	B-X
.	B-X
As	B-X
a	B-X
result	B-X
of	B-X
the	B-X
previous	B-X
in	B-X
vivo	B-X
exposure	B-X
to	B-X
ACTH	B-X
,	B-X
the	B-X
net	B-X
maximal	B-X
production	B-X
of	B-X
glucocorticoids	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
(	B-X
by	B-X
10	B-X
(	B-X
5	B-X
)	B-X
cells	B-X
and	B-X
2	B-X
h	B-X
incubation	B-X
)	B-X
increased	B-X
from	B-X
660	B-X
+/-	B-X
33.9	B-X
ng	B-X
(	B-X
control	B-X
group	B-X
)	B-X
to	B-X
1105	B-X
+/-	B-X
117.9	B-X
ng	B-X
for	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
apparent	B-X
affinity	B-X
of	B-X
the	B-X
steroidogenic	B-X
response	B-X
remained	B-X
unchanged	B-X
.	B-X
In	B-X
addition	B-X
there	B-X
occurred	B-X
an	B-X
increased	B-X
conversion	B-X
of	B-X
exogenous	B-X
pregnenolone	B-X
into	B-X
cortisol	B-X
by	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
,	B-X
indicating	B-X
a	B-X
prolonged	B-X
stimulatory	B-X
influence	B-X
of	B-X
ACTH	B-X
on	B-X
the	B-X
post-pregnenolone	B-X
pathway	B-X
of	B-X
cortisol	B-X
biosynthesis	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
11	B-X
beta-hydroxylation	B-X
step	B-X
was	B-X
therefore	B-X
examined	B-X
by	B-X
incubating	B-X
the	B-X
adrenocortical	B-X
cells	B-X
from	B-X
control	B-X
and	B-X
ACTH-treated	B-X
animals	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
increasing	B-X
amounts	B-X
of	B-X
11-deoxycortisol	B-X
.	B-X
The	B-X
maximal	B-X
capacity	B-X
of	B-X
11-deoxycortisol	B-X
conversion	B-X
into	B-X
cortisol	B-X
was	B-X
increased	B-X
as	B-X
a	B-X
result	B-X
of	B-X
the	B-X
in	B-X
vivo	B-X
exposure	B-X
to	B-X
ACTH	B-X
,	B-X
averaging	B-X
3423	B-X
+/-	B-X
211	B-X
ng	B-X
cortisol	B-X
formed	B-X
from	B-X
5	B-X
micrograms	B-X
11-deoxycortisol	B-X
by	B-X
10	B-X
(	B-X
5	B-X
)	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
vs	B-X
2074	B-X
+/-	B-X
185	B-X
ng	B-X
for	B-X
cells	B-X
from	B-X
control	B-X
guinea-pigs	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
conversion	B-X
of	B-X
lower	B-X
amounts	B-X
of	B-X
11-deoxycortisol	B-X
into	B-X
cortisol	B-X
,	B-X
reproducing	B-X
quantitatively	B-X
the	B-X
maximal	B-X
effect	B-X
of	B-X
ACTH	B-X
on	B-X
cortisol	B-X
biosynthesis	B-X
,	B-X
was	B-X
only	B-X
barely	B-X
increased	B-X
in	B-X
cells	B-X
from	B-X
ACTH-treated	B-X
animals	B-X
(	B-X
P	B-X
greater	B-X
than	B-X
0.05	B-X
)	B-X
.	B-X
Therefore	B-X
it	B-X
was	B-X
concluded	B-X
that	B-X
ACTH	B-X
increases	B-X
in	B-X
a	B-X
lasting	B-X
way	B-X
not	B-X
only	B-X
the	B-X
overall	B-X
steroidogenic	B-X
capacity	B-X
of	B-X
adrenocortical	B-X
cells	B-X
but	B-X
also	B-X
the	B-X
maximal	B-X
efficiency	B-X
of	B-X
11	B-X
beta-hydroxylation	B-X
.	B-X
Since	B-X
the	B-X
latter	B-X
effect	B-X
can	B-X
not	B-X
account	B-X
quantitatively	B-X
for	B-X
the	B-X
magnitude	B-X
of	B-X
the	B-X
lasting	B-X
effect	B-X
of	B-X
ACTH	B-X
on	B-X
the	B-X
maximal	B-X
capacity	B-X
of	B-X
adrenocortical	B-X
cells	B-X
to	B-X
produce	B-X
cortisol	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
the	B-X
prolonged	B-X
influence	B-X
of	B-X
ACTH	B-X
on	B-X
cortisol	B-X
biosynthesis	B-X
should	B-X
also	B-X
involve	B-X
a	B-X
stimulatory	B-X
influence	B-X
of	B-X
the	B-X
peptide	B-X
on	B-X
earlier	B-X
step	B-X
(	B-X
s	B-X
)	B-X
of	B-X
steroidogenesis	B-X
.	B-X

The	O
maximal	O
capacity	O
of	O
11	O
-	O
deoxycortisol	O
conversion	O
into	O
cortisol	O
was	O
increased	O
as	O
a	O
result	O
of	O
the	O
in	O
vivo	O
exposure	O
to	O
ACTH	B-Protein
,	O
averaging	O
3423	O
+	O
/	O
-	O
211	O
ng	O
cortisol	O
formed	O
from	O
5	O
micrograms	O
11	O
-	O
deoxycortisol	O
by	O
10	O
(	O
5	O
)	O
cells	O
from	O
ACTH	B-Protein
-	O
treated	O
animals	O
vs	O
2074	O
+	O
/	O
-	O
185	O
ng	O
for	O
cells	O
from	O
control	O
guinea	O
-	O
pigs	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
the	O
conversion	O
of	O
lower	O
amounts	O
of	O
11	O
-	O
deoxycortisol	O
into	O
cortisol	O
,	O
reproducing	O
quantitatively	O
the	O
maximal	O
effect	O
of	O
ACTH	B-Protein
on	O
cortisol	O
biosynthesis	O
,	O
was	O
only	O
barely	O
increased	O
in	O
cells	O
from	O
ACTH	B-Protein
-	O
treated	O
animals	O
(	O
P	O
greater	O
than	O
0	O
.	O
05	O
)	O
.	O

Therefore	O
it	O
was	O
concluded	O
that	O
ACTH	B-Protein
increases	O
in	O
a	O
lasting	O
way	O
not	O
only	O
the	O
overall	O
steroidogenic	O
capacity	O
of	O
adrenocortical	O
cells	O
but	O
also	O
the	O
maximal	O
efficiency	O
of	O
11	O
beta	O
-	O
hydroxylation	O
.	O

Since	O
the	O
latter	O
effect	O
cannot	O
account	O
quantitatively	O
for	O
the	O
magnitude	O
of	O
the	O
lasting	O
effect	O
of	O
ACTH	B-Protein
on	O
the	O
maximal	O
capacity	O
of	O
adrenocortical	O
cells	O
to	O
produce	O
cortisol	O
in	O
response	O
to	O
ACTH	B-Protein
,	O
it	O
appears	O
that	O
the	O
prolonged	O
influence	O
of	O
ACTH	B-Protein
on	O
cortisol	O
biosynthesis	O
should	O
also	O
involve	O
a	O
stimulatory	O
influence	O
of	O
the	O
peptide	O
on	O
earlier	O
step	O
(	O
s	O
)	O
of	O
steroidogenesis	O
.	O

Pyridine	O
borane	O
as	O
a	O
reducing	O
agent	O
for	O
proteins	O
.	O
<EOS>	B-X
PEGylation	B-X
is	B-X
a	B-X
reductive	B-X
alkylation	B-X
of	B-X
a	B-X
protein	B-X
N-terminal/α-amine	B-X
of	B-X
protein	B-X
with	B-X
mPEG	B-X
chain	B-X
by	B-X
reducing	B-X
agent	B-X
.	B-X
To	B-X
obtain	B-X
quantitative	B-X
and	B-X
site-specific	B-X
PEGylation	B-X
,	B-X
sodium	B-X
cyanoborohydride	B-X
is	B-X
commonly	B-X
used	B-X
as	B-X
a	B-X
reducing	B-X
agent	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
various	B-X
reducing	B-X
agents	B-X
such	B-X
as	B-X
dimethylamine	B-X
borane	B-X
,	B-X
triethylamine	B-X
borane	B-X
,	B-X
trimethylamine	B-X
borane	B-X
,	B-X
pyridine	B-X
borane	B-X
,	B-X
morpholine	B-X
borane	B-X
,	B-X
2-picoline	B-X
borane	B-X
,	B-X
and	B-X
5-ethyl-2-methyl-pyridine	B-X
borane	B-X
were	B-X
tested	B-X
as	B-X
alternatives	B-X
to	B-X
sodium	B-X
cyanoborohydride	B-X
for	B-X
the	B-X
PEGylation	B-X
of	B-X
L-asparaginase	B-X
.	B-X
Pyridine	B-X
borane	B-X
was	B-X
determined	B-X
to	B-X
be	B-X
the	B-X
best	B-X
acceptable	B-X
reducing	B-X
agent	B-X
for	B-X
PEGylation	B-X
in	B-X
terms	B-X
of	B-X
purity	B-X
and	B-X
activity	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
instead	B-X
of	B-X
sodium	B-X
cyanoborohydride	B-X
,	B-X
pyridine	B-X
borane	B-X
can	B-X
be	B-X
employed	B-X
.	B-X

Pyridine	O
borane	O
has	O
been	O
reported	O
as	O
a	O
superior	O
reagent	O
over	O
a	O
wide	O
pH	O
range	O
,	O
5	O
-	O
9	O
,	O
for	O
the	O
reductive	O
methylation	O
of	O
amino	O
groups	O
of	O
proteins	O
with	O
formaldehyde	O
[	O
J	O
.	O
C	O
.	O
Cabacungan	O
,	O
A	O
.	O
I	O
.	O
Ahmed	O
,	O
and	O
R	O
.	O
E	O
.	O
Feeney	O
(	O
1982	O
)	O
Anal	O
.	O
Biochem	O
.	O
124	O
,	O
272	O
-	O
278	O
]	O
.	O

It	O
has	O
also	O
been	O
reported	O
to	O
reduce	O
tryptophan	O
to	O
dihydrotryptophan	O
and	O
to	O
inactivate	O
lysozyme	B-Protein
in	O
trifluoroacetic	O
acid	O
[	O
M	O
.	O
Kurata	O
,	O
Y	O
.	O
Kikugawa	O
,	O
T	O
.	O
Kuwae	O
,	O
I	O
.	O
Koyama	O
,	O
and	O
T	O
.	O
Takagi	O
(	O
1980	O
)	O
Chem	O
.	O
Pharm	O
.	O
Bull	O
28	O
,	O
2274	O
-	O
2275	O
]	O
.	O
<EOS>	B-X
Pyridine	B-X
borane	B-X
has	B-X
been	B-X
reported	B-X
as	B-X
a	B-X
superior	B-X
reagent	B-X
over	B-X
a	B-X
wide	B-X
pH	B-X
range	B-X
,	B-X
5-9	B-X
,	B-X
for	B-X
the	B-X
reductive	B-X
methylation	B-X
of	B-X
amino	B-X
groups	B-X
of	B-X
proteins	B-X
with	B-X
formaldehyde	B-X
[	B-X
J.	B-X
C.	B-X
Cabacungan	B-X
,	B-X
A.	B-X
I.	B-X
Ahmed	B-X
,	B-X
and	B-X
R.	B-X
E.	B-X
Feeney	B-X
(	B-X
1982	B-X
)	B-X
Anal	B-X
.	B-X
It	B-X
has	B-X
also	B-X
been	B-X
reported	B-X
to	B-X
reduce	B-X
tryptophan	B-X
to	B-X
dihydrotryptophan	B-X
and	B-X
to	B-X
inactivate	B-X
lysozyme	B-X
in	B-X
trifluoroacetic	B-X
acid	B-X
[	B-X
M.	B-X
Kurata	B-X
,	B-X
Y.	B-X
Kikugawa	B-X
,	B-X
T.	B-X
Kuwae	B-X
,	B-X
I.	B-X
Koyama	B-X
,	B-X
and	B-X
T.	B-X
Takagi	B-X
(	B-X
1980	B-X
)	B-X
Chem	B-X
.	B-X
Pharm	B-X
.	B-X
Bull	B-X
28	B-X
,	B-X
2274-2275	B-X
]	B-X
.	B-X
In	B-X
the	B-X
acid	B-X
reduction	B-X
,	B-X
pyridine	B-X
borane	B-X
selectively	B-X
reduced	B-X
all	B-X
six	B-X
tryptophans	B-X
in	B-X
lysozyme	B-X
to	B-X
dihydrotryptophan	B-X
while	B-X
all	B-X
other	B-X
amino	B-X
acids	B-X
remained	B-X
intact	B-X
.	B-X
On	B-X
similar	B-X
treatment	B-X
no	B-X
cleavage	B-X
of	B-X
the	B-X
carbohydrate	B-X
moiety	B-X
from	B-X
chicken	B-X
ovomucoid	B-X
,	B-X
and	B-X
no	B-X
losses	B-X
of	B-X
activity	B-X
of	B-X
ovomucoid	B-X
or	B-X
ribonuclease	B-X
,	B-X
two	B-X
proteins	B-X
devoid	B-X
of	B-X
tryptophan	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
Nearly	B-X
complete	B-X
methylation	B-X
of	B-X
the	B-X
lysines	B-X
of	B-X
lysozyme	B-X
,	B-X
chicken	B-X
ovomucoid	B-X
,	B-X
and	B-X
ribonuclease	B-X
was	B-X
achieved	B-X
with	B-X
formaldehyde	B-X
at	B-X
pH	B-X
7.0	B-X
after	B-X
2	B-X
h	B-X
at	B-X
room	B-X
temperature	B-X
,	B-X
with	B-X
the	B-X
retention	B-X
of	B-X
full	B-X
activity	B-X
of	B-X
the	B-X
protein	B-X
without	B-X
any	B-X
destruction	B-X
of	B-X
tryptophan	B-X
.	B-X
The	B-X
covalent	B-X
attachment	B-X
of	B-X
sugar	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
lysine	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
synthesis	B-X
of	B-X
N-alpha-	B-X
acetylglucitollysine	B-X
and	B-X
comparison	B-X
with	B-X
acid	B-X
hydrolysates	B-X
of	B-X
the	B-X
bovine	B-X
serum	B-X
albumin-sugar	B-X
derivatives	B-X
.	B-X

In	O
the	O
present	O
study	O
the	O
specificity	O
of	O
pyridine	O
borane	O
for	O
the	O
two	O
different	O
modifications	O
under	O
different	O
reaction	O
conditions	O
has	O
been	O
demonstrated	O
,	O
and	O
extended	O
to	O
the	O
application	O
to	O
the	O
synthesis	O
of	O
protein	O
containing	O
reductively	O
attached	O
carbohydrates	O
.	O

In	O
the	O
acid	O
reduction	O
,	O
pyridine	O
borane	O
selectively	O
reduced	O
all	O
six	O
tryptophans	O
in	O
lysozyme	B-Protein
to	O
dihydrotryptophan	O
while	O
all	O
other	O
amino	O
acids	O
remained	O
intact	O
.	O
<EOS>	B-X
Pyridine	B-X
borane	B-X
has	B-X
been	B-X
reported	B-X
as	B-X
a	B-X
superior	B-X
reagent	B-X
over	B-X
a	B-X
wide	B-X
pH	B-X
range	B-X
,	B-X
5-9	B-X
,	B-X
for	B-X
the	B-X
reductive	B-X
methylation	B-X
of	B-X
amino	B-X
groups	B-X
of	B-X
proteins	B-X
with	B-X
formaldehyde	B-X
[	B-X
J.	B-X
C.	B-X
Cabacungan	B-X
,	B-X
A.	B-X
I.	B-X
Ahmed	B-X
,	B-X
and	B-X
R.	B-X
E.	B-X
Feeney	B-X
(	B-X
1982	B-X
)	B-X
Anal	B-X
.	B-X
It	B-X
has	B-X
also	B-X
been	B-X
reported	B-X
to	B-X
reduce	B-X
tryptophan	B-X
to	B-X
dihydrotryptophan	B-X
and	B-X
to	B-X
inactivate	B-X
lysozyme	B-X
in	B-X
trifluoroacetic	B-X
acid	B-X
[	B-X
M.	B-X
Kurata	B-X
,	B-X
Y.	B-X
Kikugawa	B-X
,	B-X
T.	B-X
Kuwae	B-X
,	B-X
I.	B-X
Koyama	B-X
,	B-X
and	B-X
T.	B-X
Takagi	B-X
(	B-X
1980	B-X
)	B-X
Chem	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
specificity	B-X
of	B-X
pyridine	B-X
borane	B-X
for	B-X
the	B-X
two	B-X
different	B-X
modifications	B-X
under	B-X
different	B-X
reaction	B-X
conditions	B-X
has	B-X
been	B-X
demonstrated	B-X
,	B-X
and	B-X
extended	B-X
to	B-X
the	B-X
application	B-X
to	B-X
the	B-X
synthesis	B-X
of	B-X
protein	B-X
containing	B-X
reductively	B-X
attached	B-X
carbohydrates	B-X
.	B-X
In	B-X
the	B-X
acid	B-X
reduction	B-X
,	B-X
pyridine	B-X
borane	B-X
selectively	B-X
reduced	B-X
all	B-X
six	B-X
tryptophans	B-X
in	B-X
lysozyme	B-X
to	B-X
dihydrotryptophan	B-X
while	B-X
all	B-X
other	B-X
amino	B-X
acids	B-X
remained	B-X
intact	B-X
.	B-X
Nearly	B-X
complete	B-X
methylation	B-X
of	B-X
the	B-X
lysines	B-X
of	B-X
lysozyme	B-X
,	B-X
chicken	B-X
ovomucoid	B-X
,	B-X
and	B-X
ribonuclease	B-X
was	B-X
achieved	B-X
with	B-X
formaldehyde	B-X
at	B-X
pH	B-X
7.0	B-X
after	B-X
2	B-X
h	B-X
at	B-X
room	B-X
temperature	B-X
,	B-X
with	B-X
the	B-X
retention	B-X
of	B-X
full	B-X
activity	B-X
of	B-X
the	B-X
protein	B-X
without	B-X
any	B-X
destruction	B-X
of	B-X
tryptophan	B-X
.	B-X
Incremental	B-X
additions	B-X
of	B-X
pyridine	B-X
borane	B-X
during	B-X
the	B-X
course	B-X
of	B-X
the	B-X
reactions	B-X
increased	B-X
the	B-X
rate	B-X
of	B-X
modification	B-X
.	B-X
The	B-X
covalent	B-X
attachment	B-X
of	B-X
sugar	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
lysine	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
synthesis	B-X
of	B-X
N-alpha-	B-X
acetylglucitollysine	B-X
and	B-X
comparison	B-X
with	B-X
acid	B-X
hydrolysates	B-X
of	B-X
the	B-X
bovine	B-X
serum	B-X
albumin-sugar	B-X
derivatives	B-X
.	B-X

On	O
similar	O
treatment	O
no	O
cleavage	O
of	O
the	O
carbohydrate	O
moiety	O
from	O
chicken	O
ovomucoid	B-Protein
,	O
and	O
no	O
losses	O
of	O
activity	O
of	O
ovomucoid	B-Protein
or	O
ribonuclease	O
,	O
two	O
proteins	O
devoid	O
of	O
tryptophan	O
,	O
were	O
observed	O
.	O
<EOS>	B-X
Pyridine	B-X
borane	B-X
has	B-X
been	B-X
reported	B-X
as	B-X
a	B-X
superior	B-X
reagent	B-X
over	B-X
a	B-X
wide	B-X
pH	B-X
range	B-X
,	B-X
5-9	B-X
,	B-X
for	B-X
the	B-X
reductive	B-X
methylation	B-X
of	B-X
amino	B-X
groups	B-X
of	B-X
proteins	B-X
with	B-X
formaldehyde	B-X
[	B-X
J.	B-X
C.	B-X
Cabacungan	B-X
,	B-X
A.	B-X
I.	B-X
Ahmed	B-X
,	B-X
and	B-X
R.	B-X
E.	B-X
Feeney	B-X
(	B-X
1982	B-X
)	B-X
Anal	B-X
.	B-X
It	B-X
has	B-X
also	B-X
been	B-X
reported	B-X
to	B-X
reduce	B-X
tryptophan	B-X
to	B-X
dihydrotryptophan	B-X
and	B-X
to	B-X
inactivate	B-X
lysozyme	B-X
in	B-X
trifluoroacetic	B-X
acid	B-X
[	B-X
M.	B-X
Kurata	B-X
,	B-X
Y.	B-X
Kikugawa	B-X
,	B-X
T.	B-X
Kuwae	B-X
,	B-X
I.	B-X
Koyama	B-X
,	B-X
and	B-X
T.	B-X
Takagi	B-X
(	B-X
1980	B-X
)	B-X
Chem	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
specificity	B-X
of	B-X
pyridine	B-X
borane	B-X
for	B-X
the	B-X
two	B-X
different	B-X
modifications	B-X
under	B-X
different	B-X
reaction	B-X
conditions	B-X
has	B-X
been	B-X
demonstrated	B-X
,	B-X
and	B-X
extended	B-X
to	B-X
the	B-X
application	B-X
to	B-X
the	B-X
synthesis	B-X
of	B-X
protein	B-X
containing	B-X
reductively	B-X
attached	B-X
carbohydrates	B-X
.	B-X
In	B-X
the	B-X
acid	B-X
reduction	B-X
,	B-X
pyridine	B-X
borane	B-X
selectively	B-X
reduced	B-X
all	B-X
six	B-X
tryptophans	B-X
in	B-X
lysozyme	B-X
to	B-X
dihydrotryptophan	B-X
while	B-X
all	B-X
other	B-X
amino	B-X
acids	B-X
remained	B-X
intact	B-X
.	B-X
On	B-X
similar	B-X
treatment	B-X
no	B-X
cleavage	B-X
of	B-X
the	B-X
carbohydrate	B-X
moiety	B-X
from	B-X
chicken	B-X
ovomucoid	B-X
,	B-X
and	B-X
no	B-X
losses	B-X
of	B-X
activity	B-X
of	B-X
ovomucoid	B-X
or	B-X
ribonuclease	B-X
,	B-X
two	B-X
proteins	B-X
devoid	B-X
of	B-X
tryptophan	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
Nearly	B-X
complete	B-X
methylation	B-X
of	B-X
the	B-X
lysines	B-X
of	B-X
lysozyme	B-X
,	B-X
chicken	B-X
ovomucoid	B-X
,	B-X
and	B-X
ribonuclease	B-X
was	B-X
achieved	B-X
with	B-X
formaldehyde	B-X
at	B-X
pH	B-X
7.0	B-X
after	B-X
2	B-X
h	B-X
at	B-X
room	B-X
temperature	B-X
,	B-X
with	B-X
the	B-X
retention	B-X
of	B-X
full	B-X
activity	B-X
of	B-X
the	B-X
protein	B-X
without	B-X
any	B-X
destruction	B-X
of	B-X
tryptophan	B-X
.	B-X

Nearly	O
complete	O
methylation	O
of	O
the	O
lysines	O
of	O
lysozyme	B-Protein
,	O
chicken	O
ovomucoid	B-Protein
,	O
and	O
ribonuclease	O
was	O
achieved	O
with	O
formaldehyde	O
at	O
pH	O
7	O
.	O
0	O
after	O
2	O
h	O
at	O
room	O
temperature	O
,	O
with	O
the	O
retention	O
of	O
full	O
activity	O
of	O
the	O
protein	O
without	O
any	O
destruction	O
of	O
tryptophan	O
.	O

The	O
same	O
chemistry	O
was	O
applied	O
to	O
covalently	O
attach	O
glucose	O
and	O
lactose	O
to	O
bovine	O
serum	B-Protein
albumin	I-Protein
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
specificity	B-X
of	B-X
pyridine	B-X
borane	B-X
for	B-X
the	B-X
two	B-X
different	B-X
modifications	B-X
under	B-X
different	B-X
reaction	B-X
conditions	B-X
has	B-X
been	B-X
demonstrated	B-X
,	B-X
and	B-X
extended	B-X
to	B-X
the	B-X
application	B-X
to	B-X
the	B-X
synthesis	B-X
of	B-X
protein	B-X
containing	B-X
reductively	B-X
attached	B-X
carbohydrates	B-X
.	B-X
The	B-X
same	B-X
chemistry	B-X
was	B-X
applied	B-X
to	B-X
covalently	B-X
attach	B-X
glucose	B-X
and	B-X
lactose	B-X
to	B-X
bovine	B-X
serum	B-X
albumin	B-X
.	B-X
The	B-X
covalent	B-X
attachment	B-X
of	B-X
sugar	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
lysine	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
synthesis	B-X
of	B-X
N-alpha-	B-X
acetylglucitollysine	B-X
and	B-X
comparison	B-X
with	B-X
acid	B-X
hydrolysates	B-X
of	B-X
the	B-X
bovine	B-X
serum	B-X
albumin-sugar	B-X
derivatives	B-X
.	B-X

Parameters	O
,	O
including	O
pH	O
,	O
temperature	O
,	O
and	O
methanol	O
,	O
that	O
affect	O
the	O
reactions	O
were	O
investigated	O
.	O
<EOS>	B-X
Pyridine	B-X
borane	B-X
has	B-X
been	B-X
reported	B-X
as	B-X
a	B-X
superior	B-X
reagent	B-X
over	B-X
a	B-X
wide	B-X
pH	B-X
range	B-X
,	B-X
5-9	B-X
,	B-X
for	B-X
the	B-X
reductive	B-X
methylation	B-X
of	B-X
amino	B-X
groups	B-X
of	B-X
proteins	B-X
with	B-X
formaldehyde	B-X
[	B-X
J.	B-X
C.	B-X
Cabacungan	B-X
,	B-X
A.	B-X
I.	B-X
Ahmed	B-X
,	B-X
and	B-X
R.	B-X
E.	B-X
Feeney	B-X
(	B-X
1982	B-X
)	B-X
Anal	B-X
.	B-X
Nearly	B-X
complete	B-X
methylation	B-X
of	B-X
the	B-X
lysines	B-X
of	B-X
lysozyme	B-X
,	B-X
chicken	B-X
ovomucoid	B-X
,	B-X
and	B-X
ribonuclease	B-X
was	B-X
achieved	B-X
with	B-X
formaldehyde	B-X
at	B-X
pH	B-X
7.0	B-X
after	B-X
2	B-X
h	B-X
at	B-X
room	B-X
temperature	B-X
,	B-X
with	B-X
the	B-X
retention	B-X
of	B-X
full	B-X
activity	B-X
of	B-X
the	B-X
protein	B-X
without	B-X
any	B-X
destruction	B-X
of	B-X
tryptophan	B-X
.	B-X
Parameters	B-X
,	B-X
including	B-X
pH	B-X
,	B-X
temperature	B-X
,	B-X
and	B-X
methanol	B-X
,	B-X
that	B-X
affect	B-X
the	B-X
reactions	B-X
were	B-X
investigated	B-X
.	B-X
Incremental	B-X
additions	B-X
of	B-X
pyridine	B-X
borane	B-X
during	B-X
the	B-X
course	B-X
of	B-X
the	B-X
reactions	B-X
increased	B-X
the	B-X
rate	B-X
of	B-X
modification	B-X
.	B-X

Incremental	O
additions	O
of	O
pyridine	O
borane	O
during	O
the	O
course	O
of	O
the	O
reactions	O
increased	O
the	O
rate	O
of	O
modification	O
.	O
<EOS>	B-X
Pyridine	B-X
borane	B-X
has	B-X
been	B-X
reported	B-X
as	B-X
a	B-X
superior	B-X
reagent	B-X
over	B-X
a	B-X
wide	B-X
pH	B-X
range	B-X
,	B-X
5-9	B-X
,	B-X
for	B-X
the	B-X
reductive	B-X
methylation	B-X
of	B-X
amino	B-X
groups	B-X
of	B-X
proteins	B-X
with	B-X
formaldehyde	B-X
[	B-X
J.	B-X
C.	B-X
Cabacungan	B-X
,	B-X
A.	B-X
I.	B-X
Ahmed	B-X
,	B-X
and	B-X
R.	B-X
E.	B-X
Feeney	B-X
(	B-X
1982	B-X
)	B-X
Anal	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
specificity	B-X
of	B-X
pyridine	B-X
borane	B-X
for	B-X
the	B-X
two	B-X
different	B-X
modifications	B-X
under	B-X
different	B-X
reaction	B-X
conditions	B-X
has	B-X
been	B-X
demonstrated	B-X
,	B-X
and	B-X
extended	B-X
to	B-X
the	B-X
application	B-X
to	B-X
the	B-X
synthesis	B-X
of	B-X
protein	B-X
containing	B-X
reductively	B-X
attached	B-X
carbohydrates	B-X
.	B-X
In	B-X
the	B-X
acid	B-X
reduction	B-X
,	B-X
pyridine	B-X
borane	B-X
selectively	B-X
reduced	B-X
all	B-X
six	B-X
tryptophans	B-X
in	B-X
lysozyme	B-X
to	B-X
dihydrotryptophan	B-X
while	B-X
all	B-X
other	B-X
amino	B-X
acids	B-X
remained	B-X
intact	B-X
.	B-X
On	B-X
similar	B-X
treatment	B-X
no	B-X
cleavage	B-X
of	B-X
the	B-X
carbohydrate	B-X
moiety	B-X
from	B-X
chicken	B-X
ovomucoid	B-X
,	B-X
and	B-X
no	B-X
losses	B-X
of	B-X
activity	B-X
of	B-X
ovomucoid	B-X
or	B-X
ribonuclease	B-X
,	B-X
two	B-X
proteins	B-X
devoid	B-X
of	B-X
tryptophan	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
Parameters	B-X
,	B-X
including	B-X
pH	B-X
,	B-X
temperature	B-X
,	B-X
and	B-X
methanol	B-X
,	B-X
that	B-X
affect	B-X
the	B-X
reactions	B-X
were	B-X
investigated	B-X
.	B-X
Incremental	B-X
additions	B-X
of	B-X
pyridine	B-X
borane	B-X
during	B-X
the	B-X
course	B-X
of	B-X
the	B-X
reactions	B-X
increased	B-X
the	B-X
rate	B-X
of	B-X
modification	B-X
.	B-X
The	B-X
covalent	B-X
attachment	B-X
of	B-X
sugar	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
lysine	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
synthesis	B-X
of	B-X
N-alpha-	B-X
acetylglucitollysine	B-X
and	B-X
comparison	B-X
with	B-X
acid	B-X
hydrolysates	B-X
of	B-X
the	B-X
bovine	B-X
serum	B-X
albumin-sugar	B-X
derivatives	B-X
.	B-X

The	O
covalent	O
attachment	O
of	O
sugar	O
to	O
the	O
epsilon	O
-	O
amino	O
group	O
of	O
lysine	O
was	O
demonstrated	O
by	O
the	O
synthesis	O
of	O
N	O
-	O
alpha	O
-	O
acetylglucitollysine	O
and	O
comparison	O
with	O
acid	O
hydrolysates	O
of	O
the	O
bovine	O
serum	B-Protein
albumin	I-Protein
-	O
sugar	O
derivatives	O
.	O

Arylamine	O
N	O
-	O
acetyltransferase	O
and	O
arylalkylamine	B-Protein
N	I-Protein
-	I-Protein
acetyltransferase	I-Protein
in	O
the	O
mammalian	O
pineal	O
gland	O
.	O
<EOS>	B-X
Amine	B-X
N-acetylation	B-X
in	B-X
the	B-X
pineal	B-X
gland	B-X
is	B-X
of	B-X
special	B-X
importance	B-X
because	B-X
it	B-X
is	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
melatonin	B-X
from	B-X
serotonin	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
N-acetylation	B-X
of	B-X
arylamines	B-X
and	B-X
arylalkylamines	B-X
by	B-X
homogenates	B-X
of	B-X
rat	B-X
and	B-X
sheep	B-X
pineal	B-X
glands	B-X
was	B-X
investigated	B-X
.	B-X
The	B-X
arylamines	B-X
studied	B-X
were	B-X
p-phenetidine	B-X
and	B-X
aniline	B-X
;	B-X
the	B-X
arylalkylamines	B-X
studied	B-X
were	B-X
tryptamine	B-X
,	B-X
serotonin	B-X
,	B-X
5-methoxytryptamine	B-X
,	B-X
6-fluorotryptamine	B-X
,	B-X
and	B-X
phenylethylamine	B-X
.	B-X
These	B-X
amines	B-X
were	B-X
acetylated	B-X
by	B-X
pineal	B-X
homogenates	B-X
of	B-X
both	B-X
species	B-X
,	B-X
although	B-X
marked	B-X
interspecies	B-X
differences	B-X
in	B-X
apparent	B-X
Km	B-X
and	B-X
Vmax	B-X
values	B-X
were	B-X
found	B-X
.	B-X
A	B-X
series	B-X
of	B-X
observations	B-X
in	B-X
both	B-X
species	B-X
indicate	B-X
that	B-X
aromatic	B-X
amine	B-X
N-acetylation	B-X
is	B-X
catalyzed	B-X
by	B-X
two	B-X
distinct	B-X
enzymes	B-X
;	B-X
one	B-X
preferentially	B-X
acetylates	B-X
arylamines	B-X
and	B-X
the	B-X
other	B-X
preferentially	B-X
acetylates	B-X
arylalkylamines	B-X
.	B-X
First	B-X
,	B-X
isoproterenol	B-X
treatment	B-X
of	B-X
the	B-X
rat	B-X
increased	B-X
arylalkylamine	B-X
N-acetylation	B-X
100-fold	B-X
without	B-X
increasing	B-X
arylamine	B-X
N-acetylation	B-X
.	B-X
Second	B-X
,	B-X
cycloheximide	B-X
treatment	B-X
in	B-X
sheep	B-X
reduced	B-X
arylalkylamine	B-X
N-acetylation	B-X
at	B-X
night	B-X
to	B-X
one-tenth	B-X
control	B-X
values	B-X
,	B-X
without	B-X
altering	B-X
arylamine	B-X
N-acetylation	B-X
.	B-X
Third	B-X
,	B-X
arylamine	B-X
N-acetyltransferase	B-X
and	B-X
arylalkylamine	B-X
N-acetyltransferase	B-X
inactivated	B-X
at	B-X
different	B-X
rates	B-X
at	B-X
4	B-X
degrees	B-X
C.	B-X
Fourth	B-X
,	B-X
the	B-X
two	B-X
enzymes	B-X
were	B-X
resolved	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
.	B-X
These	B-X
results	B-X
clearly	B-X
establish	B-X
that	B-X
the	B-X
pineal	B-X
gland	B-X
contains	B-X
an	B-X
arylamine	B-X
N-acetyltransferase	B-X
and	B-X
a	B-X
second	B-X
,	B-X
independently	B-X
regulated	B-X
arylalkylamine	B-X
N-acetyltransferase	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
primarily	B-X
responsible	B-X
for	B-X
the	B-X
physiological	B-X
conversion	B-X
of	B-X
serotonin	B-X
to	B-X
melatonin	B-X
via	B-X
the	B-X
intermediate	B-X
N-acetylserotonin	B-X
.	B-X

Amine	O
N	O
-	O
acetylation	O
in	O
the	O
pineal	O
gland	O
is	O
of	O
special	O
importance	O
because	O
it	O
is	O
the	O
first	O
step	O
in	O
the	O
synthesis	O
of	O
melatonin	O
from	O
serotonin	O
.	O

In	O
the	O
present	O
study	O
the	O
N	O
-	O
acetylation	O
of	O
arylamines	O
and	O
arylalkylamines	O
by	O
homogenates	O
of	O
rat	O
and	O
sheep	O
pineal	O
glands	O
was	O
investigated	O
.	O

The	O
arylamines	O
studied	O
were	O
p	O
-	O
phenetidine	O
and	O
aniline	O
;	O
the	O
arylalkylamines	O
studied	O
were	O
tryptamine	O
,	O
serotonin	O
,	O
5	O
-	O
methoxytryptamine	O
,	O
6	O
-	O
fluorotryptamine	O
,	O
and	O
phenylethylamine	O
.	O

These	O
amines	O
were	O
acetylated	O
by	O
pineal	O
homogenates	O
of	O
both	O
species	O
,	O
although	O
marked	O
interspecies	O
differences	O
in	O
apparent	O
Km	O
and	O
Vmax	O
values	O
were	O
found	O
.	O
<EOS>	B-X
Amine	B-X
N-acetylation	B-X
in	B-X
the	B-X
pineal	B-X
gland	B-X
is	B-X
of	B-X
special	B-X
importance	B-X
because	B-X
it	B-X
is	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
melatonin	B-X
from	B-X
serotonin	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
N-acetylation	B-X
of	B-X
arylamines	B-X
and	B-X
arylalkylamines	B-X
by	B-X
homogenates	B-X
of	B-X
rat	B-X
and	B-X
sheep	B-X
pineal	B-X
glands	B-X
was	B-X
investigated	B-X
.	B-X
The	B-X
arylamines	B-X
studied	B-X
were	B-X
p-phenetidine	B-X
and	B-X
aniline	B-X
;	B-X
the	B-X
arylalkylamines	B-X
studied	B-X
were	B-X
tryptamine	B-X
,	B-X
serotonin	B-X
,	B-X
5-methoxytryptamine	B-X
,	B-X
6-fluorotryptamine	B-X
,	B-X
and	B-X
phenylethylamine	B-X
.	B-X
These	B-X
amines	B-X
were	B-X
acetylated	B-X
by	B-X
pineal	B-X
homogenates	B-X
of	B-X
both	B-X
species	B-X
,	B-X
although	B-X
marked	B-X
interspecies	B-X
differences	B-X
in	B-X
apparent	B-X
Km	B-X
and	B-X
Vmax	B-X
values	B-X
were	B-X
found	B-X
.	B-X
A	B-X
series	B-X
of	B-X
observations	B-X
in	B-X
both	B-X
species	B-X
indicate	B-X
that	B-X
aromatic	B-X
amine	B-X
N-acetylation	B-X
is	B-X
catalyzed	B-X
by	B-X
two	B-X
distinct	B-X
enzymes	B-X
;	B-X
one	B-X
preferentially	B-X
acetylates	B-X
arylamines	B-X
and	B-X
the	B-X
other	B-X
preferentially	B-X
acetylates	B-X
arylalkylamines	B-X
.	B-X
Second	B-X
,	B-X
cycloheximide	B-X
treatment	B-X
in	B-X
sheep	B-X
reduced	B-X
arylalkylamine	B-X
N-acetylation	B-X
at	B-X
night	B-X
to	B-X
one-tenth	B-X
control	B-X
values	B-X
,	B-X
without	B-X
altering	B-X
arylamine	B-X
N-acetylation	B-X
.	B-X
These	B-X
results	B-X
clearly	B-X
establish	B-X
that	B-X
the	B-X
pineal	B-X
gland	B-X
contains	B-X
an	B-X
arylamine	B-X
N-acetyltransferase	B-X
and	B-X
a	B-X
second	B-X
,	B-X
independently	B-X
regulated	B-X
arylalkylamine	B-X
N-acetyltransferase	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
primarily	B-X
responsible	B-X
for	B-X
the	B-X
physiological	B-X
conversion	B-X
of	B-X
serotonin	B-X
to	B-X
melatonin	B-X
via	B-X
the	B-X
intermediate	B-X
N-acetylserotonin	B-X
.	B-X

A	O
series	O
of	O
observations	O
in	O
both	O
species	O
indicate	O
that	O
aromatic	O
amine	O
N	O
-	O
acetylation	O
is	O
catalyzed	O
by	O
two	O
distinct	O
enzymes	O
;	O
one	O
preferentially	O
acetylates	O
arylamines	O
and	O
the	O
other	O
preferentially	O
acetylates	O
arylalkylamines	O
.	O

First	O
,	O
isoproterenol	O
treatment	O
of	O
the	O
rat	O
increased	O
arylalkylamine	O
N	O
-	O
acetylation	O
100	O
-	O
fold	O
without	O
increasing	O
arylamine	O
N	O
-	O
acetylation	O
.	O
<EOS>	B-X
Amine	B-X
N-acetylation	B-X
in	B-X
the	B-X
pineal	B-X
gland	B-X
is	B-X
of	B-X
special	B-X
importance	B-X
because	B-X
it	B-X
is	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
melatonin	B-X
from	B-X
serotonin	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
N-acetylation	B-X
of	B-X
arylamines	B-X
and	B-X
arylalkylamines	B-X
by	B-X
homogenates	B-X
of	B-X
rat	B-X
and	B-X
sheep	B-X
pineal	B-X
glands	B-X
was	B-X
investigated	B-X
.	B-X
The	B-X
arylamines	B-X
studied	B-X
were	B-X
p-phenetidine	B-X
and	B-X
aniline	B-X
;	B-X
the	B-X
arylalkylamines	B-X
studied	B-X
were	B-X
tryptamine	B-X
,	B-X
serotonin	B-X
,	B-X
5-methoxytryptamine	B-X
,	B-X
6-fluorotryptamine	B-X
,	B-X
and	B-X
phenylethylamine	B-X
.	B-X
A	B-X
series	B-X
of	B-X
observations	B-X
in	B-X
both	B-X
species	B-X
indicate	B-X
that	B-X
aromatic	B-X
amine	B-X
N-acetylation	B-X
is	B-X
catalyzed	B-X
by	B-X
two	B-X
distinct	B-X
enzymes	B-X
;	B-X
one	B-X
preferentially	B-X
acetylates	B-X
arylamines	B-X
and	B-X
the	B-X
other	B-X
preferentially	B-X
acetylates	B-X
arylalkylamines	B-X
.	B-X
First	B-X
,	B-X
isoproterenol	B-X
treatment	B-X
of	B-X
the	B-X
rat	B-X
increased	B-X
arylalkylamine	B-X
N-acetylation	B-X
100-fold	B-X
without	B-X
increasing	B-X
arylamine	B-X
N-acetylation	B-X
.	B-X
Second	B-X
,	B-X
cycloheximide	B-X
treatment	B-X
in	B-X
sheep	B-X
reduced	B-X
arylalkylamine	B-X
N-acetylation	B-X
at	B-X
night	B-X
to	B-X
one-tenth	B-X
control	B-X
values	B-X
,	B-X
without	B-X
altering	B-X
arylamine	B-X
N-acetylation	B-X
.	B-X
Third	B-X
,	B-X
arylamine	B-X
N-acetyltransferase	B-X
and	B-X
arylalkylamine	B-X
N-acetyltransferase	B-X
inactivated	B-X
at	B-X
different	B-X
rates	B-X
at	B-X
4	B-X
degrees	B-X
C.	B-X
Fourth	B-X
,	B-X
the	B-X
two	B-X
enzymes	B-X
were	B-X
resolved	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
.	B-X
These	B-X
results	B-X
clearly	B-X
establish	B-X
that	B-X
the	B-X
pineal	B-X
gland	B-X
contains	B-X
an	B-X
arylamine	B-X
N-acetyltransferase	B-X
and	B-X
a	B-X
second	B-X
,	B-X
independently	B-X
regulated	B-X
arylalkylamine	B-X
N-acetyltransferase	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
primarily	B-X
responsible	B-X
for	B-X
the	B-X
physiological	B-X
conversion	B-X
of	B-X
serotonin	B-X
to	B-X
melatonin	B-X
via	B-X
the	B-X
intermediate	B-X
N-acetylserotonin	B-X
.	B-X

Second	O
,	O
cycloheximide	O
treatment	O
in	O
sheep	O
reduced	O
arylalkylamine	O
N	O
-	O
acetylation	O
at	O
night	O
to	O
one	O
-	O
tenth	O
control	O
values	O
,	O
without	O
altering	O
arylamine	O
N	O
-	O
acetylation	O
.	O
<EOS>	B-X
Amine	B-X
N-acetylation	B-X
in	B-X
the	B-X
pineal	B-X
gland	B-X
is	B-X
of	B-X
special	B-X
importance	B-X
because	B-X
it	B-X
is	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
melatonin	B-X
from	B-X
serotonin	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
N-acetylation	B-X
of	B-X
arylamines	B-X
and	B-X
arylalkylamines	B-X
by	B-X
homogenates	B-X
of	B-X
rat	B-X
and	B-X
sheep	B-X
pineal	B-X
glands	B-X
was	B-X
investigated	B-X
.	B-X
The	B-X
arylamines	B-X
studied	B-X
were	B-X
p-phenetidine	B-X
and	B-X
aniline	B-X
;	B-X
the	B-X
arylalkylamines	B-X
studied	B-X
were	B-X
tryptamine	B-X
,	B-X
serotonin	B-X
,	B-X
5-methoxytryptamine	B-X
,	B-X
6-fluorotryptamine	B-X
,	B-X
and	B-X
phenylethylamine	B-X
.	B-X
These	B-X
amines	B-X
were	B-X
acetylated	B-X
by	B-X
pineal	B-X
homogenates	B-X
of	B-X
both	B-X
species	B-X
,	B-X
although	B-X
marked	B-X
interspecies	B-X
differences	B-X
in	B-X
apparent	B-X
Km	B-X
and	B-X
Vmax	B-X
values	B-X
were	B-X
found	B-X
.	B-X
A	B-X
series	B-X
of	B-X
observations	B-X
in	B-X
both	B-X
species	B-X
indicate	B-X
that	B-X
aromatic	B-X
amine	B-X
N-acetylation	B-X
is	B-X
catalyzed	B-X
by	B-X
two	B-X
distinct	B-X
enzymes	B-X
;	B-X
one	B-X
preferentially	B-X
acetylates	B-X
arylamines	B-X
and	B-X
the	B-X
other	B-X
preferentially	B-X
acetylates	B-X
arylalkylamines	B-X
.	B-X
First	B-X
,	B-X
isoproterenol	B-X
treatment	B-X
of	B-X
the	B-X
rat	B-X
increased	B-X
arylalkylamine	B-X
N-acetylation	B-X
100-fold	B-X
without	B-X
increasing	B-X
arylamine	B-X
N-acetylation	B-X
.	B-X
Second	B-X
,	B-X
cycloheximide	B-X
treatment	B-X
in	B-X
sheep	B-X
reduced	B-X
arylalkylamine	B-X
N-acetylation	B-X
at	B-X
night	B-X
to	B-X
one-tenth	B-X
control	B-X
values	B-X
,	B-X
without	B-X
altering	B-X
arylamine	B-X
N-acetylation	B-X
.	B-X
Third	B-X
,	B-X
arylamine	B-X
N-acetyltransferase	B-X
and	B-X
arylalkylamine	B-X
N-acetyltransferase	B-X
inactivated	B-X
at	B-X
different	B-X
rates	B-X
at	B-X
4	B-X
degrees	B-X
C.	B-X
Fourth	B-X
,	B-X
the	B-X
two	B-X
enzymes	B-X
were	B-X
resolved	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
.	B-X
These	B-X
results	B-X
clearly	B-X
establish	B-X
that	B-X
the	B-X
pineal	B-X
gland	B-X
contains	B-X
an	B-X
arylamine	B-X
N-acetyltransferase	B-X
and	B-X
a	B-X
second	B-X
,	B-X
independently	B-X
regulated	B-X
arylalkylamine	B-X
N-acetyltransferase	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
primarily	B-X
responsible	B-X
for	B-X
the	B-X
physiological	B-X
conversion	B-X
of	B-X
serotonin	B-X
to	B-X
melatonin	B-X
via	B-X
the	B-X
intermediate	B-X
N-acetylserotonin	B-X
.	B-X

Third	O
,	O
arylamine	O
N	O
-	O
acetyltransferase	O
and	O
arylalkylamine	B-Protein
N	I-Protein
-	I-Protein
acetyltransferase	I-Protein
inactivated	O
at	O
different	O
rates	O
at	O
4	O
degrees	O
C	O
.	O
<EOS>	B-X
Amine	B-X
N-acetylation	B-X
in	B-X
the	B-X
pineal	B-X
gland	B-X
is	B-X
of	B-X
special	B-X
importance	B-X
because	B-X
it	B-X
is	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
melatonin	B-X
from	B-X
serotonin	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
N-acetylation	B-X
of	B-X
arylamines	B-X
and	B-X
arylalkylamines	B-X
by	B-X
homogenates	B-X
of	B-X
rat	B-X
and	B-X
sheep	B-X
pineal	B-X
glands	B-X
was	B-X
investigated	B-X
.	B-X
The	B-X
arylamines	B-X
studied	B-X
were	B-X
p-phenetidine	B-X
and	B-X
aniline	B-X
;	B-X
the	B-X
arylalkylamines	B-X
studied	B-X
were	B-X
tryptamine	B-X
,	B-X
serotonin	B-X
,	B-X
5-methoxytryptamine	B-X
,	B-X
6-fluorotryptamine	B-X
,	B-X
and	B-X
phenylethylamine	B-X
.	B-X
A	B-X
series	B-X
of	B-X
observations	B-X
in	B-X
both	B-X
species	B-X
indicate	B-X
that	B-X
aromatic	B-X
amine	B-X
N-acetylation	B-X
is	B-X
catalyzed	B-X
by	B-X
two	B-X
distinct	B-X
enzymes	B-X
;	B-X
one	B-X
preferentially	B-X
acetylates	B-X
arylamines	B-X
and	B-X
the	B-X
other	B-X
preferentially	B-X
acetylates	B-X
arylalkylamines	B-X
.	B-X
First	B-X
,	B-X
isoproterenol	B-X
treatment	B-X
of	B-X
the	B-X
rat	B-X
increased	B-X
arylalkylamine	B-X
N-acetylation	B-X
100-fold	B-X
without	B-X
increasing	B-X
arylamine	B-X
N-acetylation	B-X
.	B-X
Second	B-X
,	B-X
cycloheximide	B-X
treatment	B-X
in	B-X
sheep	B-X
reduced	B-X
arylalkylamine	B-X
N-acetylation	B-X
at	B-X
night	B-X
to	B-X
one-tenth	B-X
control	B-X
values	B-X
,	B-X
without	B-X
altering	B-X
arylamine	B-X
N-acetylation	B-X
.	B-X
Third	B-X
,	B-X
arylamine	B-X
N-acetyltransferase	B-X
and	B-X
arylalkylamine	B-X
N-acetyltransferase	B-X
inactivated	B-X
at	B-X
different	B-X
rates	B-X
at	B-X
4	B-X
degrees	B-X
C.	B-X
Fourth	B-X
,	B-X
the	B-X
two	B-X
enzymes	B-X
were	B-X
resolved	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
.	B-X
These	B-X
results	B-X
clearly	B-X
establish	B-X
that	B-X
the	B-X
pineal	B-X
gland	B-X
contains	B-X
an	B-X
arylamine	B-X
N-acetyltransferase	B-X
and	B-X
a	B-X
second	B-X
,	B-X
independently	B-X
regulated	B-X
arylalkylamine	B-X
N-acetyltransferase	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
primarily	B-X
responsible	B-X
for	B-X
the	B-X
physiological	B-X
conversion	B-X
of	B-X
serotonin	B-X
to	B-X
melatonin	B-X
via	B-X
the	B-X
intermediate	B-X
N-acetylserotonin	B-X
.	B-X

Fourth	O
,	O
the	O
two	O
enzymes	O
were	O
resolved	O
by	O
size	O
exclusion	O
chromatography	O
.	O
<EOS>	B-X
With	B-X
mildly	B-X
chaotropic	B-X
detergents	B-X
,	B-X
the	B-X
intact	B-X
complex	B-X
has	B-X
been	B-X
resolved	B-X
into	B-X
various	B-X
subcomplexes	B-X
.	B-X
Their	B-X
subunits	B-X
have	B-X
been	B-X
separated	B-X
by	B-X
three	B-X
independent	B-X
methods	B-X
(	B-X
one-dimensional	B-X
SDS-PAGE	B-X
,	B-X
two-dimensional	B-X
isoelectric	B-X
focusing/SDS-PAGE	B-X
,	B-X
and	B-X
reverse	B-X
phase	B-X
high	B-X
pressure	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
)	B-X
and	B-X
analyzed	B-X
by	B-X
tryptic	B-X
peptide	B-X
mass	B-X
fingerprinting	B-X
and	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
.	B-X
Subunits	B-X
B16.6	B-X
,	B-X
B14.7	B-X
,	B-X
and	B-X
ESSS	B-X
were	B-X
discovered	B-X
in	B-X
the	B-X
SDS-PAGE	B-X
analysis	B-X
of	B-X
subcomplex	B-X
Ilambda	B-X
,	B-X
in	B-X
the	B-X
two-dimensional	B-X
gel	B-X
analysis	B-X
of	B-X
the	B-X
intact	B-X
complex	B-X
,	B-X
and	B-X
in	B-X
the	B-X
HPLC	B-X
analysis	B-X
of	B-X
subcomplex	B-X
Ibeta	B-X
,	B-X
respectively	B-X
.	B-X
Recently	B-X
,	B-X
two	B-X
additional	B-X
subunits	B-X
,	B-X
the	B-X
third	B-X
(	B-X
p68	B-X
)	B-X
and	B-X
fourth	B-X
subunits	B-X
(	B-X
p12	B-X
)	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
The	B-X
heterotetrameric	B-X
human	B-X
pol	B-X
delta	B-X
complex	B-X
was	B-X
reconstituted	B-X
by	B-X
overexpression	B-X
of	B-X
the	B-X
four	B-X
subunits	B-X
in	B-X
Sf9	B-X
cells	B-X
,	B-X
followed	B-X
by	B-X
purification	B-X
to	B-X
near-homogeneity	B-X
using	B-X
FPLC	B-X
chromatography	B-X
.	B-X

These	O
results	O
clearly	O
establish	O
that	O
the	O
pineal	O
gland	O
contains	O
an	O
arylamine	O
N	O
-	O
acetyltransferase	O
and	O
a	O
second	O
,	O
independently	O
regulated	O
arylalkylamine	B-Protein
N	I-Protein
-	I-Protein
acetyltransferase	I-Protein
which	O
appears	O
to	O
be	O
primarily	O
responsible	O
for	O
the	O
physiological	O
conversion	O
of	O
serotonin	O
to	O
melatonin	O
via	O
the	O
intermediate	O
N	O
-	O
acetylserotonin	O
.	O

Undermethylation	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
albumin	B-Protein
gene	O
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
albumin	B-Protein
production	O
by	O
rat	O
hepatoma	O
cells	O
in	O
culture	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
identified	B-X
an	B-X
Msp	B-X
I	B-X
site	B-X
at	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
rat	B-X
albumin	B-X
gene	B-X
whose	B-X
undermethylation	B-X
is	B-X
necessary	B-X
but	B-X
not	B-X
sufficient	B-X
for	B-X
stable	B-X
albumin	B-X
expression	B-X
in	B-X
rat	B-X
hepatoma	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
also	B-X
shown	B-X
that	B-X
the	B-X
extinction	B-X
of	B-X
albumin	B-X
expression	B-X
in	B-X
somatic	B-X
hybrids	B-X
is	B-X
not	B-X
the	B-X
result	B-X
of	B-X
methylation	B-X
at	B-X
this	B-X
site	B-X
,	B-X
since	B-X
for	B-X
two	B-X
different	B-X
crosses	B-X
,	B-X
rapid	B-X
extinction	B-X
was	B-X
found	B-X
to	B-X
occur	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
de	B-X
novo	B-X
methylation	B-X
of	B-X
the	B-X
previously	B-X
active	B-X
gene	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examine	B-X
albumin	B-X
expression	B-X
and	B-X
albumin	B-X
gene	B-X
methylation	B-X
for	B-X
independent	B-X
hybrid	B-X
clones	B-X
isolated	B-X
from	B-X
crosses	B-X
between	B-X
albumin	B-X
expressing	B-X
rat	B-X
hepatoma	B-X
cells	B-X
and	B-X
cells	B-X
of	B-X
two	B-X
different	B-X
non-expressing	B-X
lines	B-X
.	B-X
The	B-X
cells	B-X
from	B-X
hybrid	B-X
clones	B-X
of	B-X
both	B-X
crosses	B-X
are	B-X
characterized	B-X
by	B-X
stable	B-X
extinction	B-X
of	B-X
albumin	B-X
expression	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
find	B-X
that	B-X
de	B-X
novo	B-X
methylation	B-X
of	B-X
the	B-X
``	B-X
extinguished	B-X
''	B-X
albumin	B-X
gene	B-X
can	B-X
occur	B-X
in	B-X
somatic	B-X
hybrids	B-X
,	B-X
but	B-X
only	B-X
some	B-X
weeks	B-X
after	B-X
the	B-X
gene	B-X
has	B-X
ceased	B-X
to	B-X
be	B-X
expressed	B-X
.	B-X

We	O
have	O
measured	O
methylation	O
of	O
the	O
albumin	B-Protein
gene	O
in	O
clones	O
of	O
rat	O
hepatoma	O
cells	O
that	O
vary	O
quantitatively	O
in	O
their	O
rates	O
of	O
synthesis	O
of	O
albumin	B-Protein
and	O
in	O
variant	O
and	O
hybrid	O
cells	O
that	O
produce	O
no	O
albumin	B-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
measured	B-X
methylation	B-X
of	B-X
the	B-X
albumin	B-X
gene	B-X
in	B-X
clones	B-X
of	B-X
rat	B-X
hepatoma	B-X
cells	B-X
that	B-X
vary	B-X
quantitatively	B-X
in	B-X
their	B-X
rates	B-X
of	B-X
synthesis	B-X
of	B-X
albumin	B-X
and	B-X
in	B-X
variant	B-X
and	B-X
hybrid	B-X
cells	B-X
that	B-X
produce	B-X
no	B-X
albumin	B-X
.	B-X
Although	B-X
the	B-X
albumin	B-X
gene	B-X
is	B-X
undermethylated	B-X
for	B-X
its	B-X
entire	B-X
length	B-X
in	B-X
rat	B-X
liver	B-X
,	B-X
only	B-X
the	B-X
5	B-X
'	B-X
end	B-X
is	B-X
ever	B-X
undermethylated	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
undermethylation	B-X
of	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
gene	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
stable	B-X
expression	B-X
of	B-X
the	B-X
albumin	B-X
gene	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
Since	B-X
undermethylation	B-X
of	B-X
this	B-X
region	B-X
is	B-X
found	B-X
in	B-X
some	B-X
variant	B-X
cells	B-X
that	B-X
fail	B-X
to	B-X
produce	B-X
albumin	B-X
,	B-X
it	B-X
is	B-X
not	B-X
a	B-X
sufficient	B-X
condition	B-X
for	B-X
albumin	B-X
gene	B-X
expression	B-X
.	B-X
Despite	B-X
the	B-X
excellent	B-X
correlation	B-X
between	B-X
undermethylation	B-X
of	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
albumin	B-X
gene	B-X
and	B-X
its	B-X
stable	B-X
expression	B-X
,	B-X
the	B-X
results	B-X
argue	B-X
against	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
methylated	B-X
state	B-X
of	B-X
such	B-X
genes	B-X
during	B-X
development	B-X
determines	B-X
whether	B-X
they	B-X
will	B-X
or	B-X
will	B-X
not	B-X
be	B-X
expressed	B-X
.	B-X

Although	O
the	O
albumin	B-Protein
gene	O
is	O
undermethylated	O
for	O
its	O
entire	O
length	O
in	O
rat	O
liver	O
,	O
only	O
the	O
5	O
'	O
end	O
is	O
ever	O
undermethylated	O
in	O
hepatoma	O
cells	O
.	O
<EOS>	B-X
We	B-X
have	B-X
measured	B-X
methylation	B-X
of	B-X
the	B-X
albumin	B-X
gene	B-X
in	B-X
clones	B-X
of	B-X
rat	B-X
hepatoma	B-X
cells	B-X
that	B-X
vary	B-X
quantitatively	B-X
in	B-X
their	B-X
rates	B-X
of	B-X
synthesis	B-X
of	B-X
albumin	B-X
and	B-X
in	B-X
variant	B-X
and	B-X
hybrid	B-X
cells	B-X
that	B-X
produce	B-X
no	B-X
albumin	B-X
.	B-X
Although	B-X
the	B-X
albumin	B-X
gene	B-X
is	B-X
undermethylated	B-X
for	B-X
its	B-X
entire	B-X
length	B-X
in	B-X
rat	B-X
liver	B-X
,	B-X
only	B-X
the	B-X
5	B-X
'	B-X
end	B-X
is	B-X
ever	B-X
undermethylated	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
undermethylation	B-X
of	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
gene	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
stable	B-X
expression	B-X
of	B-X
the	B-X
albumin	B-X
gene	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
Since	B-X
undermethylation	B-X
of	B-X
this	B-X
region	B-X
is	B-X
found	B-X
in	B-X
some	B-X
variant	B-X
cells	B-X
that	B-X
fail	B-X
to	B-X
produce	B-X
albumin	B-X
,	B-X
it	B-X
is	B-X
not	B-X
a	B-X
sufficient	B-X
condition	B-X
for	B-X
albumin	B-X
gene	B-X
expression	B-X
.	B-X
Despite	B-X
the	B-X
excellent	B-X
correlation	B-X
between	B-X
undermethylation	B-X
of	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
albumin	B-X
gene	B-X
and	B-X
its	B-X
stable	B-X
expression	B-X
,	B-X
the	B-X
results	B-X
argue	B-X
against	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
methylated	B-X
state	B-X
of	B-X
such	B-X
genes	B-X
during	B-X
development	B-X
determines	B-X
whether	B-X
they	B-X
will	B-X
or	B-X
will	B-X
not	B-X
be	B-X
expressed	B-X
.	B-X

Moreover	O
,	O
undermethylation	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
appears	O
to	O
be	O
necessary	O
for	O
stable	O
expression	O
of	O
the	O
albumin	B-Protein
gene	O
in	O
hepatoma	O
cells	O
.	O
<EOS>	B-X
We	B-X
have	B-X
measured	B-X
methylation	B-X
of	B-X
the	B-X
albumin	B-X
gene	B-X
in	B-X
clones	B-X
of	B-X
rat	B-X
hepatoma	B-X
cells	B-X
that	B-X
vary	B-X
quantitatively	B-X
in	B-X
their	B-X
rates	B-X
of	B-X
synthesis	B-X
of	B-X
albumin	B-X
and	B-X
in	B-X
variant	B-X
and	B-X
hybrid	B-X
cells	B-X
that	B-X
produce	B-X
no	B-X
albumin	B-X
.	B-X
Although	B-X
the	B-X
albumin	B-X
gene	B-X
is	B-X
undermethylated	B-X
for	B-X
its	B-X
entire	B-X
length	B-X
in	B-X
rat	B-X
liver	B-X
,	B-X
only	B-X
the	B-X
5	B-X
'	B-X
end	B-X
is	B-X
ever	B-X
undermethylated	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
undermethylation	B-X
of	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
gene	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
stable	B-X
expression	B-X
of	B-X
the	B-X
albumin	B-X
gene	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
Since	B-X
undermethylation	B-X
of	B-X
this	B-X
region	B-X
is	B-X
found	B-X
in	B-X
some	B-X
variant	B-X
cells	B-X
that	B-X
fail	B-X
to	B-X
produce	B-X
albumin	B-X
,	B-X
it	B-X
is	B-X
not	B-X
a	B-X
sufficient	B-X
condition	B-X
for	B-X
albumin	B-X
gene	B-X
expression	B-X
.	B-X
Despite	B-X
the	B-X
excellent	B-X
correlation	B-X
between	B-X
undermethylation	B-X
of	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
albumin	B-X
gene	B-X
and	B-X
its	B-X
stable	B-X
expression	B-X
,	B-X
the	B-X
results	B-X
argue	B-X
against	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
methylated	B-X
state	B-X
of	B-X
such	B-X
genes	B-X
during	B-X
development	B-X
determines	B-X
whether	B-X
they	B-X
will	B-X
or	B-X
will	B-X
not	B-X
be	B-X
expressed	B-X
.	B-X

Since	O
undermethylation	O
of	O
this	O
region	O
is	O
found	O
in	O
some	O
variant	O
cells	O
that	O
fail	O
to	O
produce	O
albumin	B-Protein
,	O
it	O
is	O
not	O
a	O
sufficient	O
condition	O
for	O
albumin	B-Protein
gene	O
expression	O
.	O

Despite	O
the	O
excellent	O
correlation	O
between	O
undermethylation	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
albumin	B-Protein
gene	O
and	O
its	O
stable	O
expression	O
,	O
the	O
results	O
argue	O
against	O
the	O
possibility	O
that	O
the	O
methylated	O
state	O
of	O
such	O
genes	O
during	O
development	O
determines	O
whether	O
they	O
will	O
or	O
will	O
not	O
be	O
expressed	O
.	O
<EOS>	B-X
If	B-X
these	B-X
effects	B-X
are	B-X
indeed	B-X
real	B-X
,	B-X
do	B-X
they	B-X
render	B-X
subjects	B-X
'	B-X
decisions	B-X
less	B-X
free	B-X
or	B-X
even	B-X
unfree	B-X
?	B-X
Here	B-X
,	B-X
we	B-X
argue	B-X
that	B-X
,	B-X
while	B-X
unconscious	B-X
influences	B-X
on	B-X
decision-making	B-X
do	B-X
not	B-X
threaten	B-X
the	B-X
existence	B-X
of	B-X
free	B-X
will	B-X
in	B-X
general	B-X
,	B-X
they	B-X
provide	B-X
important	B-X
information	B-X
about	B-X
limitations	B-X
on	B-X
freedom	B-X
in	B-X
specific	B-X
circumstances	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
aspects	B-X
of	B-X
this	B-X
long-lasting	B-X
controversy	B-X
are	B-X
empirically	B-X
testable	B-X
and	B-X
provide	B-X
insight	B-X
into	B-X
their	B-X
bearing	B-X
on	B-X
degrees	B-X
of	B-X
freedom	B-X
,	B-X
laying	B-X
the	B-X
groundwork	B-X
for	B-X
future	B-X
scientific-philosophical	B-X
approaches	B-X
.	B-X
Despite	B-X
this	B-X
diversity	B-X
of	B-X
applications	B-X
,	B-X
most	B-X
decisions	B-X
share	B-X
common	B-X
elements	B-X
including	B-X
deliberation	B-X
and	B-X
commitment	B-X
.	B-X
We	B-X
focus	B-X
on	B-X
simple	B-X
decisions	B-X
that	B-X
can	B-X
be	B-X
studied	B-X
in	B-X
the	B-X
laboratory	B-X
but	B-X
emphasize	B-X
general	B-X
principles	B-X
likely	B-X
to	B-X
extend	B-X
to	B-X
other	B-X
settings	B-X
.	B-X

Hydroxylated	O
aromatic	O
inhibitors	O
of	O
HIV	O
-	O
1	O
integrase	B-Protein
.	O
<EOS>	B-X
Efficient	B-X
replication	B-X
of	B-X
HIV-1	B-X
requires	B-X
integration	B-X
of	B-X
a	B-X
DNA	B-X
copy	B-X
of	B-X
the	B-X
viral	B-X
genome	B-X
into	B-X
a	B-X
chromosome	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
Integration	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
viral	B-X
integrase	B-X
,	B-X
and	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
phenolic	B-X
moieties	B-X
in	B-X
compounds	B-X
such	B-X
as	B-X
flavones	B-X
,	B-X
caffeic	B-X
acid	B-X
phenethyl	B-X
ester	B-X
(	B-X
CAPE	B-X
,	B-X
2	B-X
)	B-X
,	B-X
and	B-X
curcumin	B-X
confer	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-1	B-X
integrase	B-X
.	B-X
Approximately	B-X
30	B-X
compounds	B-X
have	B-X
been	B-X
prepared	B-X
as	B-X
HIV	B-X
integrase	B-X
inhibitors	B-X
based	B-X
on	B-X
the	B-X
structural	B-X
lead	B-X
provided	B-X
by	B-X
CAPE	B-X
,	B-X
which	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
an	B-X
IC50	B-X
value	B-X
of	B-X
7	B-X
microM	B-X
in	B-X
our	B-X
integration	B-X
assay	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
antiviral	B-X
agents	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
acquired	B-X
immune	B-X
deficiency	B-X
syndrome	B-X
can	B-X
be	B-X
based	B-X
upon	B-X
inhibition	B-X
of	B-X
HIV-1	B-X
integrase	B-X
.	B-X

Efficient	O
replication	O
of	O
HIV	O
-	O
1	O
requires	O
integration	O
of	O
a	O
DNA	O
copy	O
of	O
the	O
viral	O
genome	O
into	O
a	O
chromosome	O
of	O
the	O
host	O
cell	O
.	O
<EOS>	B-X
Efficient	B-X
replication	B-X
of	B-X
HIV-1	B-X
requires	B-X
integration	B-X
of	B-X
a	B-X
DNA	B-X
copy	B-X
of	B-X
the	B-X
viral	B-X
genome	B-X
into	B-X
a	B-X
chromosome	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
Integration	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
viral	B-X
integrase	B-X
,	B-X
and	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
phenolic	B-X
moieties	B-X
in	B-X
compounds	B-X
such	B-X
as	B-X
flavones	B-X
,	B-X
caffeic	B-X
acid	B-X
phenethyl	B-X
ester	B-X
(	B-X
CAPE	B-X
,	B-X
2	B-X
)	B-X
,	B-X
and	B-X
curcumin	B-X
confer	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-1	B-X
integrase	B-X
.	B-X
Approximately	B-X
30	B-X
compounds	B-X
have	B-X
been	B-X
prepared	B-X
as	B-X
HIV	B-X
integrase	B-X
inhibitors	B-X
based	B-X
on	B-X
the	B-X
structural	B-X
lead	B-X
provided	B-X
by	B-X
CAPE	B-X
,	B-X
which	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
an	B-X
IC50	B-X
value	B-X
of	B-X
7	B-X
microM	B-X
in	B-X
our	B-X
integration	B-X
assay	B-X
.	B-X
Inhibition	B-X
of	B-X
strand	B-X
transfer	B-X
was	B-X
assayed	B-X
using	B-X
both	B-X
blunt-ended	B-X
and	B-X
``	B-X
precleaved	B-X
''	B-X
DNA	B-X
substrates	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X
Several	B-X
CAPE	B-X
analogues	B-X
were	B-X
also	B-X
tested	B-X
for	B-X
selective	B-X
activity	B-X
against	B-X
transformed	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
antiviral	B-X
agents	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
acquired	B-X
immune	B-X
deficiency	B-X
syndrome	B-X
can	B-X
be	B-X
based	B-X
upon	B-X
inhibition	B-X
of	B-X
HIV-1	B-X
integrase	B-X
.	B-X

Integration	O
is	O
catalyzed	O
by	O
the	O
viral	O
integrase	B-Protein
,	O
and	O
we	O
have	O
previously	O
reported	O
that	O
phenolic	O
moieties	O
in	O
compounds	O
such	O
as	O
flavones	O
,	O
caffeic	O
acid	O
phenethyl	O
ester	O
(	O
CAPE	O
,	O
2	O
)	O
,	O
and	O
curcumin	O
confer	O
inhibitory	O
activity	O
against	O
HIV	O
-	O
1	O
integrase	B-Protein
.	O
<EOS>	B-X
Efficient	B-X
replication	B-X
of	B-X
HIV-1	B-X
requires	B-X
integration	B-X
of	B-X
a	B-X
DNA	B-X
copy	B-X
of	B-X
the	B-X
viral	B-X
genome	B-X
into	B-X
a	B-X
chromosome	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
Integration	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
viral	B-X
integrase	B-X
,	B-X
and	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
phenolic	B-X
moieties	B-X
in	B-X
compounds	B-X
such	B-X
as	B-X
flavones	B-X
,	B-X
caffeic	B-X
acid	B-X
phenethyl	B-X
ester	B-X
(	B-X
CAPE	B-X
,	B-X
2	B-X
)	B-X
,	B-X
and	B-X
curcumin	B-X
confer	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-1	B-X
integrase	B-X
.	B-X
We	B-X
now	B-X
extend	B-X
these	B-X
findings	B-X
by	B-X
performing	B-X
a	B-X
comprehensive	B-X
structure-activity	B-X
relationship	B-X
using	B-X
CAPE	B-X
analogues	B-X
.	B-X
Approximately	B-X
30	B-X
compounds	B-X
have	B-X
been	B-X
prepared	B-X
as	B-X
HIV	B-X
integrase	B-X
inhibitors	B-X
based	B-X
on	B-X
the	B-X
structural	B-X
lead	B-X
provided	B-X
by	B-X
CAPE	B-X
,	B-X
which	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
an	B-X
IC50	B-X
value	B-X
of	B-X
7	B-X
microM	B-X
in	B-X
our	B-X
integration	B-X
assay	B-X
.	B-X
These	B-X
analogues	B-X
were	B-X
designed	B-X
to	B-X
examine	B-X
specific	B-X
features	B-X
of	B-X
the	B-X
parent	B-X
CAPE	B-X
structure	B-X
which	B-X
may	B-X
be	B-X
important	B-X
for	B-X
activity	B-X
.	B-X
Among	B-X
the	B-X
features	B-X
examined	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
inhibitory	B-X
potency	B-X
were	B-X
ring	B-X
substitution	B-X
,	B-X
side	B-X
chain	B-X
length	B-X
and	B-X
composition	B-X
,	B-X
and	B-X
phenyl	B-X
ring	B-X
conformational	B-X
orientation	B-X
.	B-X
In	B-X
an	B-X
assay	B-X
which	B-X
measured	B-X
the	B-X
combined	B-X
effect	B-X
of	B-X
two	B-X
sequential	B-X
steps	B-X
,	B-X
dinucleotide	B-X
cleavage	B-X
and	B-X
strand	B-X
transfer	B-X
,	B-X
several	B-X
analogues	B-X
have	B-X
IC50	B-X
values	B-X
for	B-X
3'-processing	B-X
and	B-X
strand	B-X
transfer	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
CAPE	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X
Several	B-X
CAPE	B-X
analogues	B-X
were	B-X
also	B-X
tested	B-X
for	B-X
selective	B-X
activity	B-X
against	B-X
transformed	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
antiviral	B-X
agents	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
acquired	B-X
immune	B-X
deficiency	B-X
syndrome	B-X
can	B-X
be	B-X
based	B-X
upon	B-X
inhibition	B-X
of	B-X
HIV-1	B-X
integrase	B-X
.	B-X

We	O
now	O
extend	O
these	O
findings	O
by	O
performing	O
a	O
comprehensive	O
structure	O
-	O
activity	O
relationship	O
using	O
CAPE	O
analogues	O
.	O
<EOS>	B-X
Integration	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
viral	B-X
integrase	B-X
,	B-X
and	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
phenolic	B-X
moieties	B-X
in	B-X
compounds	B-X
such	B-X
as	B-X
flavones	B-X
,	B-X
caffeic	B-X
acid	B-X
phenethyl	B-X
ester	B-X
(	B-X
CAPE	B-X
,	B-X
2	B-X
)	B-X
,	B-X
and	B-X
curcumin	B-X
confer	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-1	B-X
integrase	B-X
.	B-X
We	B-X
now	B-X
extend	B-X
these	B-X
findings	B-X
by	B-X
performing	B-X
a	B-X
comprehensive	B-X
structure-activity	B-X
relationship	B-X
using	B-X
CAPE	B-X
analogues	B-X
.	B-X
Approximately	B-X
30	B-X
compounds	B-X
have	B-X
been	B-X
prepared	B-X
as	B-X
HIV	B-X
integrase	B-X
inhibitors	B-X
based	B-X
on	B-X
the	B-X
structural	B-X
lead	B-X
provided	B-X
by	B-X
CAPE	B-X
,	B-X
which	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
an	B-X
IC50	B-X
value	B-X
of	B-X
7	B-X
microM	B-X
in	B-X
our	B-X
integration	B-X
assay	B-X
.	B-X
These	B-X
analogues	B-X
were	B-X
designed	B-X
to	B-X
examine	B-X
specific	B-X
features	B-X
of	B-X
the	B-X
parent	B-X
CAPE	B-X
structure	B-X
which	B-X
may	B-X
be	B-X
important	B-X
for	B-X
activity	B-X
.	B-X
In	B-X
an	B-X
assay	B-X
which	B-X
measured	B-X
the	B-X
combined	B-X
effect	B-X
of	B-X
two	B-X
sequential	B-X
steps	B-X
,	B-X
dinucleotide	B-X
cleavage	B-X
and	B-X
strand	B-X
transfer	B-X
,	B-X
several	B-X
analogues	B-X
have	B-X
IC50	B-X
values	B-X
for	B-X
3'-processing	B-X
and	B-X
strand	B-X
transfer	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
CAPE	B-X
.	B-X
Inhibition	B-X
of	B-X
strand	B-X
transfer	B-X
was	B-X
assayed	B-X
using	B-X
both	B-X
blunt-ended	B-X
and	B-X
``	B-X
precleaved	B-X
''	B-X
DNA	B-X
substrates	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X
Several	B-X
CAPE	B-X
analogues	B-X
were	B-X
also	B-X
tested	B-X
for	B-X
selective	B-X
activity	B-X
against	B-X
transformed	B-X
cells	B-X
.	B-X

Approximately	O
30	O
compounds	O
have	O
been	O
prepared	O
as	O
HIV	O
integrase	B-Protein
inhibitors	O
based	O
on	O
the	O
structural	O
lead	O
provided	O
by	O
CAPE	O
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
exhibit	O
an	O
IC50	O
value	O
of	O
7	O
microM	O
in	O
our	O
integration	O
assay	O
.	O
<EOS>	B-X
Efficient	B-X
replication	B-X
of	B-X
HIV-1	B-X
requires	B-X
integration	B-X
of	B-X
a	B-X
DNA	B-X
copy	B-X
of	B-X
the	B-X
viral	B-X
genome	B-X
into	B-X
a	B-X
chromosome	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
Integration	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
viral	B-X
integrase	B-X
,	B-X
and	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
phenolic	B-X
moieties	B-X
in	B-X
compounds	B-X
such	B-X
as	B-X
flavones	B-X
,	B-X
caffeic	B-X
acid	B-X
phenethyl	B-X
ester	B-X
(	B-X
CAPE	B-X
,	B-X
2	B-X
)	B-X
,	B-X
and	B-X
curcumin	B-X
confer	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-1	B-X
integrase	B-X
.	B-X
We	B-X
now	B-X
extend	B-X
these	B-X
findings	B-X
by	B-X
performing	B-X
a	B-X
comprehensive	B-X
structure-activity	B-X
relationship	B-X
using	B-X
CAPE	B-X
analogues	B-X
.	B-X
Approximately	B-X
30	B-X
compounds	B-X
have	B-X
been	B-X
prepared	B-X
as	B-X
HIV	B-X
integrase	B-X
inhibitors	B-X
based	B-X
on	B-X
the	B-X
structural	B-X
lead	B-X
provided	B-X
by	B-X
CAPE	B-X
,	B-X
which	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
an	B-X
IC50	B-X
value	B-X
of	B-X
7	B-X
microM	B-X
in	B-X
our	B-X
integration	B-X
assay	B-X
.	B-X
These	B-X
analogues	B-X
were	B-X
designed	B-X
to	B-X
examine	B-X
specific	B-X
features	B-X
of	B-X
the	B-X
parent	B-X
CAPE	B-X
structure	B-X
which	B-X
may	B-X
be	B-X
important	B-X
for	B-X
activity	B-X
.	B-X
In	B-X
an	B-X
assay	B-X
which	B-X
measured	B-X
the	B-X
combined	B-X
effect	B-X
of	B-X
two	B-X
sequential	B-X
steps	B-X
,	B-X
dinucleotide	B-X
cleavage	B-X
and	B-X
strand	B-X
transfer	B-X
,	B-X
several	B-X
analogues	B-X
have	B-X
IC50	B-X
values	B-X
for	B-X
3'-processing	B-X
and	B-X
strand	B-X
transfer	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
CAPE	B-X
.	B-X
Inhibition	B-X
of	B-X
strand	B-X
transfer	B-X
was	B-X
assayed	B-X
using	B-X
both	B-X
blunt-ended	B-X
and	B-X
``	B-X
precleaved	B-X
''	B-X
DNA	B-X
substrates	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X
Several	B-X
CAPE	B-X
analogues	B-X
were	B-X
also	B-X
tested	B-X
for	B-X
selective	B-X
activity	B-X
against	B-X
transformed	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
antiviral	B-X
agents	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
acquired	B-X
immune	B-X
deficiency	B-X
syndrome	B-X
can	B-X
be	B-X
based	B-X
upon	B-X
inhibition	B-X
of	B-X
HIV-1	B-X
integrase	B-X
.	B-X

These	O
analogues	O
were	O
designed	O
to	O
examine	O
specific	O
features	O
of	O
the	O
parent	O
CAPE	O
structure	O
which	O
may	O
be	O
important	O
for	O
activity	O
.	O
<EOS>	B-X
Integration	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
viral	B-X
integrase	B-X
,	B-X
and	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
phenolic	B-X
moieties	B-X
in	B-X
compounds	B-X
such	B-X
as	B-X
flavones	B-X
,	B-X
caffeic	B-X
acid	B-X
phenethyl	B-X
ester	B-X
(	B-X
CAPE	B-X
,	B-X
2	B-X
)	B-X
,	B-X
and	B-X
curcumin	B-X
confer	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-1	B-X
integrase	B-X
.	B-X
We	B-X
now	B-X
extend	B-X
these	B-X
findings	B-X
by	B-X
performing	B-X
a	B-X
comprehensive	B-X
structure-activity	B-X
relationship	B-X
using	B-X
CAPE	B-X
analogues	B-X
.	B-X
Approximately	B-X
30	B-X
compounds	B-X
have	B-X
been	B-X
prepared	B-X
as	B-X
HIV	B-X
integrase	B-X
inhibitors	B-X
based	B-X
on	B-X
the	B-X
structural	B-X
lead	B-X
provided	B-X
by	B-X
CAPE	B-X
,	B-X
which	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
an	B-X
IC50	B-X
value	B-X
of	B-X
7	B-X
microM	B-X
in	B-X
our	B-X
integration	B-X
assay	B-X
.	B-X
These	B-X
analogues	B-X
were	B-X
designed	B-X
to	B-X
examine	B-X
specific	B-X
features	B-X
of	B-X
the	B-X
parent	B-X
CAPE	B-X
structure	B-X
which	B-X
may	B-X
be	B-X
important	B-X
for	B-X
activity	B-X
.	B-X
Among	B-X
the	B-X
features	B-X
examined	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
inhibitory	B-X
potency	B-X
were	B-X
ring	B-X
substitution	B-X
,	B-X
side	B-X
chain	B-X
length	B-X
and	B-X
composition	B-X
,	B-X
and	B-X
phenyl	B-X
ring	B-X
conformational	B-X
orientation	B-X
.	B-X
In	B-X
an	B-X
assay	B-X
which	B-X
measured	B-X
the	B-X
combined	B-X
effect	B-X
of	B-X
two	B-X
sequential	B-X
steps	B-X
,	B-X
dinucleotide	B-X
cleavage	B-X
and	B-X
strand	B-X
transfer	B-X
,	B-X
several	B-X
analogues	B-X
have	B-X
IC50	B-X
values	B-X
for	B-X
3'-processing	B-X
and	B-X
strand	B-X
transfer	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
CAPE	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X
Several	B-X
CAPE	B-X
analogues	B-X
were	B-X
also	B-X
tested	B-X
for	B-X
selective	B-X
activity	B-X
against	B-X
transformed	B-X
cells	B-X
.	B-X

Among	O
the	O
features	O
examined	O
for	O
their	O
effects	O
on	O
inhibitory	O
potency	O
were	O
ring	O
substitution	O
,	O
side	O
chain	O
length	O
and	O
composition	O
,	O
and	O
phenyl	O
ring	O
conformational	O
orientation	O
.	O
<EOS>	B-X
Integration	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
viral	B-X
integrase	B-X
,	B-X
and	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
phenolic	B-X
moieties	B-X
in	B-X
compounds	B-X
such	B-X
as	B-X
flavones	B-X
,	B-X
caffeic	B-X
acid	B-X
phenethyl	B-X
ester	B-X
(	B-X
CAPE	B-X
,	B-X
2	B-X
)	B-X
,	B-X
and	B-X
curcumin	B-X
confer	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-1	B-X
integrase	B-X
.	B-X
These	B-X
analogues	B-X
were	B-X
designed	B-X
to	B-X
examine	B-X
specific	B-X
features	B-X
of	B-X
the	B-X
parent	B-X
CAPE	B-X
structure	B-X
which	B-X
may	B-X
be	B-X
important	B-X
for	B-X
activity	B-X
.	B-X
Among	B-X
the	B-X
features	B-X
examined	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
inhibitory	B-X
potency	B-X
were	B-X
ring	B-X
substitution	B-X
,	B-X
side	B-X
chain	B-X
length	B-X
and	B-X
composition	B-X
,	B-X
and	B-X
phenyl	B-X
ring	B-X
conformational	B-X
orientation	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X

In	O
an	O
assay	O
which	O
measured	O
the	O
combined	O
effect	O
of	O
two	O
sequential	O
steps	O
,	O
dinucleotide	O
cleavage	O
and	O
strand	O
transfer	O
,	O
several	O
analogues	O
have	O
IC50	O
values	O
for	O
3	O
'	O
-	O
processing	O
and	O
strand	O
transfer	O
lower	O
than	O
those	O
of	O
CAPE	O
.	O

Inhibition	O
of	O
strand	O
transfer	O
was	O
assayed	O
using	O
both	O
blunt	O
-	O
ended	O
and	O
"	O
precleaved	O
"	O
DNA	O
substrates	O
.	O
<EOS>	B-X
Efficient	B-X
replication	B-X
of	B-X
HIV-1	B-X
requires	B-X
integration	B-X
of	B-X
a	B-X
DNA	B-X
copy	B-X
of	B-X
the	B-X
viral	B-X
genome	B-X
into	B-X
a	B-X
chromosome	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
We	B-X
now	B-X
extend	B-X
these	B-X
findings	B-X
by	B-X
performing	B-X
a	B-X
comprehensive	B-X
structure-activity	B-X
relationship	B-X
using	B-X
CAPE	B-X
analogues	B-X
.	B-X
In	B-X
an	B-X
assay	B-X
which	B-X
measured	B-X
the	B-X
combined	B-X
effect	B-X
of	B-X
two	B-X
sequential	B-X
steps	B-X
,	B-X
dinucleotide	B-X
cleavage	B-X
and	B-X
strand	B-X
transfer	B-X
,	B-X
several	B-X
analogues	B-X
have	B-X
IC50	B-X
values	B-X
for	B-X
3'-processing	B-X
and	B-X
strand	B-X
transfer	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
CAPE	B-X
.	B-X
Inhibition	B-X
of	B-X
strand	B-X
transfer	B-X
was	B-X
assayed	B-X
using	B-X
both	B-X
blunt-ended	B-X
and	B-X
``	B-X
precleaved	B-X
''	B-X
DNA	B-X
substrates	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X

Disintegration	O
using	O
an	O
integrase	B-Protein
mutant	O
lacking	O
the	O
N	O
-	O
terminal	O
zinc	O
finger	O
and	O
C	O
-	O
terminal	O
DNA	O
-	O
binding	O
domains	O
was	O
also	O
inhibited	O
by	O
these	O
analogues	O
,	O
suggesting	O
that	O
the	O
binding	O
site	O
for	O
these	O
compounds	O
resides	O
in	O
the	O
central	O
catalytic	O
core	O
.	O

Several	O
CAPE	O
analogues	O
were	O
also	O
tested	O
for	O
selective	O
activity	O
against	O
transformed	O
cells	O
.	O
<EOS>	B-X
Integration	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
viral	B-X
integrase	B-X
,	B-X
and	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
phenolic	B-X
moieties	B-X
in	B-X
compounds	B-X
such	B-X
as	B-X
flavones	B-X
,	B-X
caffeic	B-X
acid	B-X
phenethyl	B-X
ester	B-X
(	B-X
CAPE	B-X
,	B-X
2	B-X
)	B-X
,	B-X
and	B-X
curcumin	B-X
confer	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-1	B-X
integrase	B-X
.	B-X
We	B-X
now	B-X
extend	B-X
these	B-X
findings	B-X
by	B-X
performing	B-X
a	B-X
comprehensive	B-X
structure-activity	B-X
relationship	B-X
using	B-X
CAPE	B-X
analogues	B-X
.	B-X
Approximately	B-X
30	B-X
compounds	B-X
have	B-X
been	B-X
prepared	B-X
as	B-X
HIV	B-X
integrase	B-X
inhibitors	B-X
based	B-X
on	B-X
the	B-X
structural	B-X
lead	B-X
provided	B-X
by	B-X
CAPE	B-X
,	B-X
which	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
an	B-X
IC50	B-X
value	B-X
of	B-X
7	B-X
microM	B-X
in	B-X
our	B-X
integration	B-X
assay	B-X
.	B-X
These	B-X
analogues	B-X
were	B-X
designed	B-X
to	B-X
examine	B-X
specific	B-X
features	B-X
of	B-X
the	B-X
parent	B-X
CAPE	B-X
structure	B-X
which	B-X
may	B-X
be	B-X
important	B-X
for	B-X
activity	B-X
.	B-X
In	B-X
an	B-X
assay	B-X
which	B-X
measured	B-X
the	B-X
combined	B-X
effect	B-X
of	B-X
two	B-X
sequential	B-X
steps	B-X
,	B-X
dinucleotide	B-X
cleavage	B-X
and	B-X
strand	B-X
transfer	B-X
,	B-X
several	B-X
analogues	B-X
have	B-X
IC50	B-X
values	B-X
for	B-X
3'-processing	B-X
and	B-X
strand	B-X
transfer	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
CAPE	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X
Several	B-X
CAPE	B-X
analogues	B-X
were	B-X
also	B-X
tested	B-X
for	B-X
selective	B-X
activity	B-X
against	B-X
transformed	B-X
cells	B-X
.	B-X

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
development	O
of	O
novel	O
antiviral	O
agents	O
for	O
the	O
treatment	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
can	O
be	O
based	O
upon	O
inhibition	O
of	O
HIV	O
-	O
1	O
integrase	B-Protein
.	O
<EOS>	B-X
Efficient	B-X
replication	B-X
of	B-X
HIV-1	B-X
requires	B-X
integration	B-X
of	B-X
a	B-X
DNA	B-X
copy	B-X
of	B-X
the	B-X
viral	B-X
genome	B-X
into	B-X
a	B-X
chromosome	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
Integration	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
viral	B-X
integrase	B-X
,	B-X
and	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
phenolic	B-X
moieties	B-X
in	B-X
compounds	B-X
such	B-X
as	B-X
flavones	B-X
,	B-X
caffeic	B-X
acid	B-X
phenethyl	B-X
ester	B-X
(	B-X
CAPE	B-X
,	B-X
2	B-X
)	B-X
,	B-X
and	B-X
curcumin	B-X
confer	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-1	B-X
integrase	B-X
.	B-X
Approximately	B-X
30	B-X
compounds	B-X
have	B-X
been	B-X
prepared	B-X
as	B-X
HIV	B-X
integrase	B-X
inhibitors	B-X
based	B-X
on	B-X
the	B-X
structural	B-X
lead	B-X
provided	B-X
by	B-X
CAPE	B-X
,	B-X
which	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
an	B-X
IC50	B-X
value	B-X
of	B-X
7	B-X
microM	B-X
in	B-X
our	B-X
integration	B-X
assay	B-X
.	B-X
Disintegration	B-X
using	B-X
an	B-X
integrase	B-X
mutant	B-X
lacking	B-X
the	B-X
N-terminal	B-X
zinc	B-X
finger	B-X
and	B-X
C-terminal	B-X
DNA-binding	B-X
domains	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
these	B-X
analogues	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
these	B-X
compounds	B-X
resides	B-X
in	B-X
the	B-X
central	B-X
catalytic	B-X
core	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
antiviral	B-X
agents	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
acquired	B-X
immune	B-X
deficiency	B-X
syndrome	B-X
can	B-X
be	B-X
based	B-X
upon	B-X
inhibition	B-X
of	B-X
HIV-1	B-X
integrase	B-X
.	B-X

Effect	O
of	O
modification	O
of	O
carbohydrate	O
side	O
chains	O
on	O
the	O
reactivity	O
of	O
antibodies	O
with	O
core	O
-	O
protein	O
epitopes	O
of	O
the	O
MUC1	B-Protein
gene	O
product	O
.	O
<EOS>	B-X
The	B-X
product	B-X
of	B-X
the	B-X
MUC1	B-X
gene	B-X
,	B-X
the	B-X
polymorphic	B-X
epithelial	B-X
mucin	B-X
(	B-X
PEM	B-X
)	B-X
,	B-X
contains	B-X
a	B-X
large	B-X
domain	B-X
consisting	B-X
of	B-X
tandem	B-X
repeats	B-X
of	B-X
20	B-X
amino	B-X
acids	B-X
.	B-X
Each	B-X
repeat	B-X
contains	B-X
five	B-X
potential	B-X
sites	B-X
for	B-X
O-glycosylation	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
region	B-X
forms	B-X
a	B-X
scaffold	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
the	B-X
O-linked	B-X
carbohydrate	B-X
which	B-X
makes	B-X
up	B-X
more	B-X
than	B-X
50	B-X
%	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
A	B-X
number	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
recognize	B-X
core-protein	B-X
epitopes	B-X
within	B-X
the	B-X
tandem	B-X
repeat	B-X
domain	B-X
.	B-X
Using	B-X
primary	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
HuME	B-X
)	B-X
,	B-X
an	B-X
immortalized	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
HuME	B-X
(	B-X
MTSV1-7	B-X
)	B-X
and	B-X
a	B-X
breast	B-X
carcinoma	B-X
cell	B-X
line	B-X
(	B-X
BT20	B-X
)	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
on	B-X
the	B-X
binding	B-X
of	B-X
antibodies	B-X
to	B-X
core-protein	B-X
epitopes	B-X
has	B-X
been	B-X
investigated	B-X
.	B-X
We	B-X
unequivocally	B-X
show	B-X
that	B-X
the	B-X
masking	B-X
of	B-X
the	B-X
SM3	B-X
epitopes	B-X
in	B-X
normal	B-X
breast	B-X
epithelial	B-X
cells	B-X
is	B-X
due	B-X
to	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
.	B-X
In	B-X
addition	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
two	B-X
other	B-X
antibodies	B-X
(	B-X
HMFG1	B-X
,	B-X
HMFG2	B-X
)	B-X
to	B-X
core-protein	B-X
epitopes	B-X
is	B-X
influenced	B-X
by	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
HMFG-1	B-X
is	B-X
particularly	B-X
affected	B-X
by	B-X
sialic	B-X
acid	B-X
whereas	B-X
the	B-X
binding	B-X
of	B-X
HMFG2	B-X
is	B-X
influenced	B-X
by	B-X
the	B-X
length	B-X
of	B-X
the	B-X
oligosaccharide	B-X
side	B-X
chains	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibited	B-X
elongation	B-X
of	B-X
O-linked	B-X
carbohydrate	B-X
side	B-X
chains	B-X
does	B-X
not	B-X
seem	B-X
to	B-X
interfere	B-X
with	B-X
the	B-X
cell	B-X
trafficking	B-X
of	B-X
the	B-X
mucin	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

The	O
product	O
of	O
the	O
MUC1	B-Protein
gene	O
,	O
the	O
polymorphic	B-Protein
epithelial	I-Protein
mucin	I-Protein
(	O
PEM	B-Protein
)	O
,	O
contains	O
a	O
large	O
domain	O
consisting	O
of	O
tandem	O
repeats	O
of	O
20	O
amino	O
acids	O
.	O
<EOS>	B-X
The	B-X
product	B-X
of	B-X
the	B-X
MUC1	B-X
gene	B-X
,	B-X
the	B-X
polymorphic	B-X
epithelial	B-X
mucin	B-X
(	B-X
PEM	B-X
)	B-X
,	B-X
contains	B-X
a	B-X
large	B-X
domain	B-X
consisting	B-X
of	B-X
tandem	B-X
repeats	B-X
of	B-X
20	B-X
amino	B-X
acids	B-X
.	B-X
Each	B-X
repeat	B-X
contains	B-X
five	B-X
potential	B-X
sites	B-X
for	B-X
O-glycosylation	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
region	B-X
forms	B-X
a	B-X
scaffold	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
the	B-X
O-linked	B-X
carbohydrate	B-X
which	B-X
makes	B-X
up	B-X
more	B-X
than	B-X
50	B-X
%	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
A	B-X
number	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
recognize	B-X
core-protein	B-X
epitopes	B-X
within	B-X
the	B-X
tandem	B-X
repeat	B-X
domain	B-X
.	B-X
One	B-X
such	B-X
antibody	B-X
,	B-X
SM3	B-X
,	B-X
reacts	B-X
with	B-X
the	B-X
mucin	B-X
expressed	B-X
by	B-X
breast	B-X
carcinomas	B-X
but	B-X
shows	B-X
little	B-X
or	B-X
no	B-X
reaction	B-X
with	B-X
normal	B-X
resting	B-X
or	B-X
lactating	B-X
breast	B-X
.	B-X
Using	B-X
primary	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
HuME	B-X
)	B-X
,	B-X
an	B-X
immortalized	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
HuME	B-X
(	B-X
MTSV1-7	B-X
)	B-X
and	B-X
a	B-X
breast	B-X
carcinoma	B-X
cell	B-X
line	B-X
(	B-X
BT20	B-X
)	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
on	B-X
the	B-X
binding	B-X
of	B-X
antibodies	B-X
to	B-X
core-protein	B-X
epitopes	B-X
has	B-X
been	B-X
investigated	B-X
.	B-X
We	B-X
unequivocally	B-X
show	B-X
that	B-X
the	B-X
masking	B-X
of	B-X
the	B-X
SM3	B-X
epitopes	B-X
in	B-X
normal	B-X
breast	B-X
epithelial	B-X
cells	B-X
is	B-X
due	B-X
to	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibited	B-X
elongation	B-X
of	B-X
O-linked	B-X
carbohydrate	B-X
side	B-X
chains	B-X
does	B-X
not	B-X
seem	B-X
to	B-X
interfere	B-X
with	B-X
the	B-X
cell	B-X
trafficking	B-X
of	B-X
the	B-X
mucin	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Each	O
repeat	O
contains	O
five	O
potential	O
sites	O
for	O
O	O
-	O
glycosylation	O
,	O
suggesting	O
that	O
this	O
region	O
forms	O
a	O
scaffold	O
for	O
the	O
attachment	O
of	O
the	O
O	O
-	O
linked	O
carbohydrate	O
which	O
makes	O
up	O
more	O
than	O
50	O
%	O
of	O
the	O
molecule	O
.	O
<EOS>	B-X
The	B-X
product	B-X
of	B-X
the	B-X
MUC1	B-X
gene	B-X
,	B-X
the	B-X
polymorphic	B-X
epithelial	B-X
mucin	B-X
(	B-X
PEM	B-X
)	B-X
,	B-X
contains	B-X
a	B-X
large	B-X
domain	B-X
consisting	B-X
of	B-X
tandem	B-X
repeats	B-X
of	B-X
20	B-X
amino	B-X
acids	B-X
.	B-X
Each	B-X
repeat	B-X
contains	B-X
five	B-X
potential	B-X
sites	B-X
for	B-X
O-glycosylation	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
region	B-X
forms	B-X
a	B-X
scaffold	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
the	B-X
O-linked	B-X
carbohydrate	B-X
which	B-X
makes	B-X
up	B-X
more	B-X
than	B-X
50	B-X
%	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
A	B-X
number	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
recognize	B-X
core-protein	B-X
epitopes	B-X
within	B-X
the	B-X
tandem	B-X
repeat	B-X
domain	B-X
.	B-X
Using	B-X
primary	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
HuME	B-X
)	B-X
,	B-X
an	B-X
immortalized	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
HuME	B-X
(	B-X
MTSV1-7	B-X
)	B-X
and	B-X
a	B-X
breast	B-X
carcinoma	B-X
cell	B-X
line	B-X
(	B-X
BT20	B-X
)	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
on	B-X
the	B-X
binding	B-X
of	B-X
antibodies	B-X
to	B-X
core-protein	B-X
epitopes	B-X
has	B-X
been	B-X
investigated	B-X
.	B-X
We	B-X
unequivocally	B-X
show	B-X
that	B-X
the	B-X
masking	B-X
of	B-X
the	B-X
SM3	B-X
epitopes	B-X
in	B-X
normal	B-X
breast	B-X
epithelial	B-X
cells	B-X
is	B-X
due	B-X
to	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
.	B-X
In	B-X
addition	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
two	B-X
other	B-X
antibodies	B-X
(	B-X
HMFG1	B-X
,	B-X
HMFG2	B-X
)	B-X
to	B-X
core-protein	B-X
epitopes	B-X
is	B-X
influenced	B-X
by	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibited	B-X
elongation	B-X
of	B-X
O-linked	B-X
carbohydrate	B-X
side	B-X
chains	B-X
does	B-X
not	B-X
seem	B-X
to	B-X
interfere	B-X
with	B-X
the	B-X
cell	B-X
trafficking	B-X
of	B-X
the	B-X
mucin	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

A	O
number	O
of	O
monoclonal	O
antibodies	O
have	O
been	O
shown	O
to	O
recognize	O
core	O
-	O
protein	O
epitopes	O
within	O
the	O
tandem	O
repeat	O
domain	O
.	O
<EOS>	B-X
The	B-X
MUC1	B-X
membrane	B-X
mucin	B-X
was	B-X
first	B-X
identified	B-X
as	B-X
the	B-X
molecule	B-X
recognised	B-X
by	B-X
mouse	B-X
monoclonal	B-X
antibodies	B-X
directed	B-X
to	B-X
epithelial	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
cancers	B-X
which	B-X
develop	B-X
from	B-X
them	B-X
.	B-X
Cloning	B-X
the	B-X
gene	B-X
showed	B-X
that	B-X
the	B-X
extracellular	B-X
domain	B-X
is	B-X
made	B-X
up	B-X
of	B-X
highly	B-X
conserved	B-X
repeats	B-X
of	B-X
20	B-X
amino	B-X
acids	B-X
,	B-X
the	B-X
actual	B-X
number	B-X
varying	B-X
between	B-X
25	B-X
and	B-X
100	B-X
depending	B-X
on	B-X
the	B-X
allele	B-X
.	B-X
Each	B-X
tandem	B-X
repeat	B-X
contains	B-X
five	B-X
potential	B-X
glycosylation	B-X
sites	B-X
,	B-X
and	B-X
between	B-X
doublets	B-X
of	B-X
threonines	B-X
and	B-X
serines	B-X
lies	B-X
an	B-X
immunodominant	B-X
region	B-X
which	B-X
contains	B-X
the	B-X
epitopes	B-X
recognised	B-X
by	B-X
most	B-X
of	B-X
the	B-X
mouse	B-X
monoclonal	B-X
antibodies	B-X
.	B-X
The	B-X
O-glycans	B-X
added	B-X
to	B-X
the	B-X
mucin	B-X
produced	B-X
by	B-X
the	B-X
normal	B-X
breast	B-X
are	B-X
core	B-X
2	B-X
based	B-X
and	B-X
can	B-X
be	B-X
complex	B-X
,	B-X
while	B-X
the	B-X
O-glycans	B-X
added	B-X
to	B-X
the	B-X
breast	B-X
cancer	B-X
mucin	B-X
are	B-X
mainly	B-X
core	B-X
1	B-X
based	B-X
.	B-X
This	B-X
means	B-X
that	B-X
some	B-X
core	B-X
protein	B-X
epitopes	B-X
in	B-X
the	B-X
tandem	B-X
repeat	B-X
which	B-X
are	B-X
masked	B-X
in	B-X
the	B-X
normal	B-X
mucin	B-X
are	B-X
exposed	B-X
in	B-X
the	B-X
cancer	B-X
associated	B-X
mucin	B-X
.	B-X
Since	B-X
novel	B-X
carbohydrate	B-X
epitopes	B-X
are	B-X
also	B-X
carried	B-X
on	B-X
the	B-X
breast	B-X
cancer	B-X
mucin	B-X
,	B-X
the	B-X
molecule	B-X
is	B-X
antigenically	B-X
distinct	B-X
from	B-X
the	B-X
normal	B-X
breast	B-X
mucin	B-X
.	B-X
Immune	B-X
responses	B-X
to	B-X
MUC1	B-X
have	B-X
been	B-X
seen	B-X
in	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
patients	B-X
and	B-X
clinical	B-X
studies	B-X
have	B-X
been	B-X
initiated	B-X
to	B-X
evaluate	B-X
the	B-X
use	B-X
of	B-X
antibodies	B-X
to	B-X
MUC1	B-X
and	B-X
of	B-X
immunogens	B-X
based	B-X
on	B-X
MUC1	B-X
for	B-X
immunotherapy	B-X
of	B-X
these	B-X
patients	B-X
.	B-X

One	O
such	O
antibody	O
,	O
SM3	O
,	O
reacts	O
with	O
the	O
mucin	O
expressed	O
by	O
breast	O
carcinomas	O
but	O
shows	O
little	O
or	O
no	O
reaction	O
with	O
normal	O
resting	O
or	O
lactating	O
breast	O
.	O
<EOS>	B-X
Many	B-X
women	B-X
who	B-X
are	B-X
breastfeeding	B-X
also	B-X
want	B-X
to	B-X
participate	B-X
in	B-X
exercise	B-X
,	B-X
but	B-X
have	B-X
concerns	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
their	B-X
newborn	B-X
.	B-X
The	B-X
goals	B-X
of	B-X
the	B-X
chapter	B-X
are	B-X
to	B-X
help	B-X
clinicians	B-X
understand	B-X
the	B-X
benefits	B-X
of	B-X
exercise	B-X
,	B-X
examine	B-X
the	B-X
impact	B-X
of	B-X
postpartum	B-X
exercise	B-X
on	B-X
breastfeeding	B-X
,	B-X
and	B-X
provide	B-X
practical	B-X
recommendations	B-X
for	B-X
exercise	B-X
during	B-X
the	B-X
postpartum	B-X
period	B-X
in	B-X
women	B-X
who	B-X
are	B-X
breastfeeding	B-X
.	B-X
Lactation	B-X
is	B-X
a	B-X
complex	B-X
process	B-X
,	B-X
proper	B-X
to	B-X
the	B-X
mother	B-X
and	B-X
child	B-X
dyad	B-X
,	B-X
and	B-X
including	B-X
numerous	B-X
variables	B-X
ranging	B-X
from	B-X
psychological	B-X
aspects	B-X
to	B-X
the	B-X
secretory	B-X
functioning	B-X
of	B-X
the	B-X
mammary	B-X
epithelial	B-X
cells	B-X
,	B-X
all	B-X
contributing	B-X
to	B-X
a	B-X
successful	B-X
breastfeeding	B-X
.	B-X
Although	B-X
a	B-X
large	B-X
majority	B-X
of	B-X
US	B-X
mothers	B-X
now	B-X
begin	B-X
breastfeeding	B-X
,	B-X
exclusive	B-X
breastfeeding	B-X
rates	B-X
fall	B-X
far	B-X
below	B-X
national	B-X
health	B-X
objectives	B-X
,	B-X
with	B-X
vulnerable	B-X
populations	B-X
being	B-X
least	B-X
likely	B-X
to	B-X
breastfeed	B-X
exclusively	B-X
.	B-X
This	B-X
article	B-X
explores	B-X
common	B-X
personal	B-X
and	B-X
societal	B-X
barriers	B-X
to	B-X
exclusive	B-X
breastfeeding	B-X
and	B-X
offers	B-X
evidence-based	B-X
strategies	B-X
to	B-X
support	B-X
mothers	B-X
to	B-X
breastfeed	B-X
exclusively	B-X
,	B-X
such	B-X
as	B-X
ensuring	B-X
prenatal	B-X
education	B-X
,	B-X
supportive	B-X
maternity	B-X
practices	B-X
,	B-X
timely	B-X
follow-up	B-X
,	B-X
and	B-X
management	B-X
of	B-X
lactation	B-X
challenges	B-X
.	B-X
The	B-X
article	B-X
also	B-X
addresses	B-X
common	B-X
reasons	B-X
nursing	B-X
mothers	B-X
discontinue	B-X
exclusive	B-X
breastfeeding	B-X
,	B-X
including	B-X
the	B-X
perception	B-X
of	B-X
insufficient	B-X
milk	B-X
,	B-X
misinterpretation	B-X
of	B-X
infant	B-X
crying	B-X
,	B-X
returning	B-X
to	B-X
work	B-X
or	B-X
school	B-X
,	B-X
early	B-X
introduction	B-X
of	B-X
solid	B-X
foods	B-X
,	B-X
and	B-X
lack	B-X
of	B-X
support	B-X
.	B-X

Using	O
primary	O
mammary	O
epithelial	O
cells	O
(	O
HuME	O
)	O
,	O
an	O
immortalized	O
cell	O
line	O
derived	O
from	O
HuME	O
(	O
MTSV1	O
-	O
7	O
)	O
and	O
a	O
breast	O
carcinoma	O
cell	O
line	O
(	O
BT20	O
)	O
the	O
influence	O
of	O
the	O
carbohydrate	O
side	O
chains	O
on	O
the	O
binding	O
of	O
antibodies	O
to	O
core	O
-	O
protein	O
epitopes	O
has	O
been	O
investigated	O
.	O

We	O
unequivocally	O
show	O
that	O
the	O
masking	O
of	O
the	O
SM3	O
epitopes	O
in	O
normal	O
breast	O
epithelial	O
cells	O
is	O
due	O
to	O
the	O
carbohydrate	O
side	O
chains	O
.	O

In	O
addition	O
we	O
demonstrate	O
that	O
the	O
binding	O
of	O
two	O
other	O
antibodies	O
(	O
HMFG1	O
,	O
HMFG2	O
)	O
to	O
core	O
-	O
protein	O
epitopes	O
is	O
influenced	O
by	O
the	O
carbohydrate	O
side	O
chains	O
.	O
<EOS>	B-X
Each	B-X
repeat	B-X
contains	B-X
five	B-X
potential	B-X
sites	B-X
for	B-X
O-glycosylation	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
region	B-X
forms	B-X
a	B-X
scaffold	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
the	B-X
O-linked	B-X
carbohydrate	B-X
which	B-X
makes	B-X
up	B-X
more	B-X
than	B-X
50	B-X
%	B-X
of	B-X
the	B-X
molecule	B-X
.	B-X
A	B-X
number	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
recognize	B-X
core-protein	B-X
epitopes	B-X
within	B-X
the	B-X
tandem	B-X
repeat	B-X
domain	B-X
.	B-X
Using	B-X
primary	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
HuME	B-X
)	B-X
,	B-X
an	B-X
immortalized	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
HuME	B-X
(	B-X
MTSV1-7	B-X
)	B-X
and	B-X
a	B-X
breast	B-X
carcinoma	B-X
cell	B-X
line	B-X
(	B-X
BT20	B-X
)	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
on	B-X
the	B-X
binding	B-X
of	B-X
antibodies	B-X
to	B-X
core-protein	B-X
epitopes	B-X
has	B-X
been	B-X
investigated	B-X
.	B-X
We	B-X
unequivocally	B-X
show	B-X
that	B-X
the	B-X
masking	B-X
of	B-X
the	B-X
SM3	B-X
epitopes	B-X
in	B-X
normal	B-X
breast	B-X
epithelial	B-X
cells	B-X
is	B-X
due	B-X
to	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
.	B-X
In	B-X
addition	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
two	B-X
other	B-X
antibodies	B-X
(	B-X
HMFG1	B-X
,	B-X
HMFG2	B-X
)	B-X
to	B-X
core-protein	B-X
epitopes	B-X
is	B-X
influenced	B-X
by	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
HMFG-1	B-X
is	B-X
particularly	B-X
affected	B-X
by	B-X
sialic	B-X
acid	B-X
whereas	B-X
the	B-X
binding	B-X
of	B-X
HMFG2	B-X
is	B-X
influenced	B-X
by	B-X
the	B-X
length	B-X
of	B-X
the	B-X
oligosaccharide	B-X
side	B-X
chains	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibited	B-X
elongation	B-X
of	B-X
O-linked	B-X
carbohydrate	B-X
side	B-X
chains	B-X
does	B-X
not	B-X
seem	B-X
to	B-X
interfere	B-X
with	B-X
the	B-X
cell	B-X
trafficking	B-X
of	B-X
the	B-X
mucin	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

The	O
binding	O
of	O
HMFG	O
-	O
1	O
is	O
particularly	O
affected	O
by	O
sialic	O
acid	O
whereas	O
the	O
binding	O
of	O
HMFG2	O
is	O
influenced	O
by	O
the	O
length	O
of	O
the	O
oligosaccharide	O
side	O
chains	O
.	O
<EOS>	B-X
The	B-X
product	B-X
of	B-X
the	B-X
MUC1	B-X
gene	B-X
,	B-X
the	B-X
polymorphic	B-X
epithelial	B-X
mucin	B-X
(	B-X
PEM	B-X
)	B-X
,	B-X
contains	B-X
a	B-X
large	B-X
domain	B-X
consisting	B-X
of	B-X
tandem	B-X
repeats	B-X
of	B-X
20	B-X
amino	B-X
acids	B-X
.	B-X
Using	B-X
primary	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
HuME	B-X
)	B-X
,	B-X
an	B-X
immortalized	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
HuME	B-X
(	B-X
MTSV1-7	B-X
)	B-X
and	B-X
a	B-X
breast	B-X
carcinoma	B-X
cell	B-X
line	B-X
(	B-X
BT20	B-X
)	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
on	B-X
the	B-X
binding	B-X
of	B-X
antibodies	B-X
to	B-X
core-protein	B-X
epitopes	B-X
has	B-X
been	B-X
investigated	B-X
.	B-X
We	B-X
unequivocally	B-X
show	B-X
that	B-X
the	B-X
masking	B-X
of	B-X
the	B-X
SM3	B-X
epitopes	B-X
in	B-X
normal	B-X
breast	B-X
epithelial	B-X
cells	B-X
is	B-X
due	B-X
to	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
.	B-X
In	B-X
addition	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
two	B-X
other	B-X
antibodies	B-X
(	B-X
HMFG1	B-X
,	B-X
HMFG2	B-X
)	B-X
to	B-X
core-protein	B-X
epitopes	B-X
is	B-X
influenced	B-X
by	B-X
the	B-X
carbohydrate	B-X
side	B-X
chains	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
HMFG-1	B-X
is	B-X
particularly	B-X
affected	B-X
by	B-X
sialic	B-X
acid	B-X
whereas	B-X
the	B-X
binding	B-X
of	B-X
HMFG2	B-X
is	B-X
influenced	B-X
by	B-X
the	B-X
length	B-X
of	B-X
the	B-X
oligosaccharide	B-X
side	B-X
chains	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibited	B-X
elongation	B-X
of	B-X
O-linked	B-X
carbohydrate	B-X
side	B-X
chains	B-X
does	B-X
not	B-X
seem	B-X
to	B-X
interfere	B-X
with	B-X
the	B-X
cell	B-X
trafficking	B-X
of	B-X
the	B-X
mucin	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Furthermore	O
,	O
inhibited	O
elongation	O
of	O
O	O
-	O
linked	O
carbohydrate	O
side	O
chains	O
does	O
not	O
seem	O
to	O
interfere	O
with	O
the	O
cell	O
trafficking	O
of	O
the	O
mucin	O
to	O
the	O
cell	O
surface	O
.	O

Fusing	O
the	O
carboxy	O
-	O
terminal	O
peptide	O
of	O
the	O
chorionic	B-Protein
gonadotropin	I-Protein
(	I-Protein
CG	I-Protein
)	I-Protein
beta	I-Protein
-	I-Protein
subunit	I-Protein
to	O
the	O
common	O
alpha	O
-	O
subunit	O
:	O
retention	O
of	O
O	O
-	O
linked	O
glycosylation	O
and	O
enhanced	O
in	O
vivo	O
bioactivity	O
of	O
chimeric	O
human	O
CG	O
.	O

The	O
hCG	B-Protein
beta	I-Protein
-	I-Protein
subunit	I-Protein
contains	O
a	O
carboxy	O
-	O
terminal	O
extension	O
bearing	O
four	O
serine	O
-	O
linked	O
oligosaccharides	O
[	O
carboxy	O
-	O
terminal	O
peptide	O
(	O
CTP	O
)	O
]	O
,	O
which	O
is	O
important	O
for	O
maintaining	O
its	O
longer	O
half	O
-	O
life	O
compared	O
with	O
the	O
other	O
glycoprotein	O
hormones	O
.	O
<EOS>	B-X
The	B-X
hCG	B-X
beta-subunit	B-X
contains	B-X
a	B-X
carboxy-terminal	B-X
extension	B-X
bearing	B-X
four	B-X
serine-linked	B-X
oligosaccharides	B-X
[	B-X
carboxy-terminal	B-X
peptide	B-X
(	B-X
CTP	B-X
)	B-X
]	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
maintaining	B-X
its	B-X
longer	B-X
half-life	B-X
compared	B-X
with	B-X
the	B-X
other	B-X
glycoprotein	B-X
hormones	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
enhanced	B-X
the	B-X
in	B-X
vivo	B-X
half-life	B-X
of	B-X
FSH	B-X
by	B-X
fusing	B-X
the	B-X
CTP	B-X
to	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
FSH	B-X
beta	B-X
coding	B-X
sequence	B-X
.	B-X
The	B-X
alpha-subunit	B-X
is	B-X
common	B-X
to	B-X
the	B-X
glycoprotein	B-X
family	B-X
.	B-X
We	B-X
constructed	B-X
alpha-subunit	B-X
CTP	B-X
chimeras	B-X
,	B-X
since	B-X
such	B-X
analogs	B-X
with	B-X
the	B-X
appropriate	B-X
O-linked	B-X
glycosylation	B-X
and	B-X
conformation	B-X
would	B-X
increase	B-X
the	B-X
in	B-X
vivo	B-X
stability	B-X
of	B-X
the	B-X
entire	B-X
glycoprotein	B-X
hormone	B-X
family	B-X
.	B-X
Two	B-X
chimeras	B-X
were	B-X
constructed	B-X
using	B-X
overlapping	B-X
polymerase	B-X
chain	B-X
reaction	B-X
mutagenesis	B-X
:	B-X
a	B-X
variant	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
and	B-X
another	B-X
analog	B-X
with	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
subunit	B-X
,	B-X
between	B-X
amino	B-X
acids	B-X
3	B-X
and	B-X
4	B-X
.	B-X
The	B-X
latter	B-X
design	B-X
was	B-X
based	B-X
on	B-X
models	B-X
showing	B-X
that	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
alpha	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
assembly	B-X
with	B-X
the	B-X
beta-subunit	B-X
,	B-X
nor	B-X
is	B-X
it	B-X
essential	B-X
for	B-X
receptor	B-X
binding	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
These	B-X
chimeras	B-X
were	B-X
cotransfected	B-X
with	B-X
the	B-X
hCG	B-X
beta	B-X
gene	B-X
into	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
The	B-X
chimeras	B-X
were	B-X
secreted	B-X
and	B-X
combined	B-X
efficiently	B-X
with	B-X
the	B-X
CG	B-X
beta-subunit	B-X
,	B-X
comparable	B-X
to	B-X
the	B-X
wild	B-X
type	B-X
alpha-subunit	B-X
.	B-X
CG	B-X
dimers	B-X
containing	B-X
the	B-X
alpha-subunit	B-X
chimera	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
had	B-X
a	B-X
much	B-X
lower	B-X
binding	B-X
affinity	B-X
for	B-X
the	B-X
hLH-hCG	B-X
receptor	B-X
in	B-X
vitro	B-X
,	B-X
whereas	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
dimer	B-X
containing	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
amino-terminal	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
was	B-X
similar	B-X
to	B-X
wild	B-X
type	B-X
hCG	B-X
.	B-X
Moreover	B-X
,	B-X
regardless	B-X
of	B-X
the	B-X
two	B-X
insertion	B-X
points	B-X
in	B-X
the	B-X
alpha-subunit	B-X
,	B-X
the	B-X
CTP	B-X
sequence	B-X
was	B-X
O-glycosylated	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
entire	B-X
signal	B-X
for	B-X
O-glycosylation	B-X
is	B-X
primarily	B-X
contained	B-X
within	B-X
the	B-X
CTP	B-X
sequence	B-X
and	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
the	B-X
flanking	B-X
regions	B-X
of	B-X
the	B-X
recipient	B-X
protein	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
CTP	B-X
to	B-X
the	B-X
alpha-subunit	B-X
of	B-X
hCG	B-X
results	B-X
in	B-X
an	B-X
agonist	B-X
with	B-X
prolonged	B-X
biological	B-X
action	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
data	B-X
further	B-X
support	B-X
the	B-X
rationale	B-X
for	B-X
using	B-X
the	B-X
CTP	B-X
as	B-X
a	B-X
general	B-X
target	B-X
to	B-X
increase	B-X
the	B-X
potency	B-X
of	B-X
bioactive	B-X
glycoproteins	B-X
.	B-X

Previously	O
,	O
we	O
enhanced	O
the	O
in	O
vivo	O
half	O
-	O
life	O
of	O
FSH	O
by	O
fusing	O
the	O
CTP	O
to	O
the	O
carboxy	O
end	O
of	O
FSH	B-Protein
beta	I-Protein
coding	O
sequence	O
.	O

The	O
alpha	O
-	O
subunit	O
is	O
common	O
to	O
the	O
glycoprotein	O
family	O
.	O

We	O
constructed	O
alpha	O
-	O
subunit	O
CTP	O
chimeras	O
,	O
since	O
such	O
analogs	O
with	O
the	O
appropriate	O
O	O
-	O
linked	O
glycosylation	O
and	O
conformation	O
would	O
increase	O
the	O
in	O
vivo	O
stability	O
of	O
the	O
entire	O
glycoprotein	O
hormone	O
family	O
.	O
<EOS>	B-X
The	B-X
hCG	B-X
beta-subunit	B-X
contains	B-X
a	B-X
carboxy-terminal	B-X
extension	B-X
bearing	B-X
four	B-X
serine-linked	B-X
oligosaccharides	B-X
[	B-X
carboxy-terminal	B-X
peptide	B-X
(	B-X
CTP	B-X
)	B-X
]	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
maintaining	B-X
its	B-X
longer	B-X
half-life	B-X
compared	B-X
with	B-X
the	B-X
other	B-X
glycoprotein	B-X
hormones	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
enhanced	B-X
the	B-X
in	B-X
vivo	B-X
half-life	B-X
of	B-X
FSH	B-X
by	B-X
fusing	B-X
the	B-X
CTP	B-X
to	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
FSH	B-X
beta	B-X
coding	B-X
sequence	B-X
.	B-X
The	B-X
alpha-subunit	B-X
is	B-X
common	B-X
to	B-X
the	B-X
glycoprotein	B-X
family	B-X
.	B-X
We	B-X
constructed	B-X
alpha-subunit	B-X
CTP	B-X
chimeras	B-X
,	B-X
since	B-X
such	B-X
analogs	B-X
with	B-X
the	B-X
appropriate	B-X
O-linked	B-X
glycosylation	B-X
and	B-X
conformation	B-X
would	B-X
increase	B-X
the	B-X
in	B-X
vivo	B-X
stability	B-X
of	B-X
the	B-X
entire	B-X
glycoprotein	B-X
hormone	B-X
family	B-X
.	B-X
Two	B-X
chimeras	B-X
were	B-X
constructed	B-X
using	B-X
overlapping	B-X
polymerase	B-X
chain	B-X
reaction	B-X
mutagenesis	B-X
:	B-X
a	B-X
variant	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
and	B-X
another	B-X
analog	B-X
with	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
subunit	B-X
,	B-X
between	B-X
amino	B-X
acids	B-X
3	B-X
and	B-X
4	B-X
.	B-X
The	B-X
latter	B-X
design	B-X
was	B-X
based	B-X
on	B-X
models	B-X
showing	B-X
that	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
alpha	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
assembly	B-X
with	B-X
the	B-X
beta-subunit	B-X
,	B-X
nor	B-X
is	B-X
it	B-X
essential	B-X
for	B-X
receptor	B-X
binding	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
These	B-X
chimeras	B-X
were	B-X
cotransfected	B-X
with	B-X
the	B-X
hCG	B-X
beta	B-X
gene	B-X
into	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
The	B-X
chimeras	B-X
were	B-X
secreted	B-X
and	B-X
combined	B-X
efficiently	B-X
with	B-X
the	B-X
CG	B-X
beta-subunit	B-X
,	B-X
comparable	B-X
to	B-X
the	B-X
wild	B-X
type	B-X
alpha-subunit	B-X
.	B-X
CG	B-X
dimers	B-X
containing	B-X
the	B-X
alpha-subunit	B-X
chimera	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
had	B-X
a	B-X
much	B-X
lower	B-X
binding	B-X
affinity	B-X
for	B-X
the	B-X
hLH-hCG	B-X
receptor	B-X
in	B-X
vitro	B-X
,	B-X
whereas	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
dimer	B-X
containing	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
amino-terminal	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
was	B-X
similar	B-X
to	B-X
wild	B-X
type	B-X
hCG	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
in	B-X
vivo	B-X
activity	B-X
of	B-X
this	B-X
analog	B-X
was	B-X
enhanced	B-X
significantly	B-X
.	B-X
Moreover	B-X
,	B-X
regardless	B-X
of	B-X
the	B-X
two	B-X
insertion	B-X
points	B-X
in	B-X
the	B-X
alpha-subunit	B-X
,	B-X
the	B-X
CTP	B-X
sequence	B-X
was	B-X
O-glycosylated	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
entire	B-X
signal	B-X
for	B-X
O-glycosylation	B-X
is	B-X
primarily	B-X
contained	B-X
within	B-X
the	B-X
CTP	B-X
sequence	B-X
and	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
the	B-X
flanking	B-X
regions	B-X
of	B-X
the	B-X
recipient	B-X
protein	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
CTP	B-X
to	B-X
the	B-X
alpha-subunit	B-X
of	B-X
hCG	B-X
results	B-X
in	B-X
an	B-X
agonist	B-X
with	B-X
prolonged	B-X
biological	B-X
action	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
data	B-X
further	B-X
support	B-X
the	B-X
rationale	B-X
for	B-X
using	B-X
the	B-X
CTP	B-X
as	B-X
a	B-X
general	B-X
target	B-X
to	B-X
increase	B-X
the	B-X
potency	B-X
of	B-X
bioactive	B-X
glycoproteins	B-X
.	B-X

Two	O
chimeras	O
were	O
constructed	O
using	O
overlapping	O
polymerase	O
chain	O
reaction	O
mutagenesis	O
:	O
a	O
variant	O
with	O
CTP	O
at	O
the	O
carboxy	O
end	O
and	O
another	O
analog	O
with	O
the	O
CTP	O
at	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
subunit	O
,	O
between	O
amino	O
acids	O
3	O
and	O
4	O
.	O

The	O
latter	O
design	O
was	O
based	O
on	O
models	O
showing	O
that	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
alpha	O
is	O
not	O
involved	O
in	O
assembly	O
with	O
the	O
beta	O
-	O
subunit	O
,	O
nor	O
is	O
it	O
essential	O
for	O
receptor	O
binding	O
and	O
signal	O
transduction	O
.	O

These	O
chimeras	O
were	O
cotransfected	O
with	O
the	O
hCG	B-Protein
beta	I-Protein
gene	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O
<EOS>	B-X
The	B-X
hCG	B-X
beta-subunit	B-X
contains	B-X
a	B-X
carboxy-terminal	B-X
extension	B-X
bearing	B-X
four	B-X
serine-linked	B-X
oligosaccharides	B-X
[	B-X
carboxy-terminal	B-X
peptide	B-X
(	B-X
CTP	B-X
)	B-X
]	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
maintaining	B-X
its	B-X
longer	B-X
half-life	B-X
compared	B-X
with	B-X
the	B-X
other	B-X
glycoprotein	B-X
hormones	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
enhanced	B-X
the	B-X
in	B-X
vivo	B-X
half-life	B-X
of	B-X
FSH	B-X
by	B-X
fusing	B-X
the	B-X
CTP	B-X
to	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
FSH	B-X
beta	B-X
coding	B-X
sequence	B-X
.	B-X
We	B-X
constructed	B-X
alpha-subunit	B-X
CTP	B-X
chimeras	B-X
,	B-X
since	B-X
such	B-X
analogs	B-X
with	B-X
the	B-X
appropriate	B-X
O-linked	B-X
glycosylation	B-X
and	B-X
conformation	B-X
would	B-X
increase	B-X
the	B-X
in	B-X
vivo	B-X
stability	B-X
of	B-X
the	B-X
entire	B-X
glycoprotein	B-X
hormone	B-X
family	B-X
.	B-X
Two	B-X
chimeras	B-X
were	B-X
constructed	B-X
using	B-X
overlapping	B-X
polymerase	B-X
chain	B-X
reaction	B-X
mutagenesis	B-X
:	B-X
a	B-X
variant	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
and	B-X
another	B-X
analog	B-X
with	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
subunit	B-X
,	B-X
between	B-X
amino	B-X
acids	B-X
3	B-X
and	B-X
4	B-X
.	B-X
The	B-X
latter	B-X
design	B-X
was	B-X
based	B-X
on	B-X
models	B-X
showing	B-X
that	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
alpha	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
assembly	B-X
with	B-X
the	B-X
beta-subunit	B-X
,	B-X
nor	B-X
is	B-X
it	B-X
essential	B-X
for	B-X
receptor	B-X
binding	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
These	B-X
chimeras	B-X
were	B-X
cotransfected	B-X
with	B-X
the	B-X
hCG	B-X
beta	B-X
gene	B-X
into	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
The	B-X
chimeras	B-X
were	B-X
secreted	B-X
and	B-X
combined	B-X
efficiently	B-X
with	B-X
the	B-X
CG	B-X
beta-subunit	B-X
,	B-X
comparable	B-X
to	B-X
the	B-X
wild	B-X
type	B-X
alpha-subunit	B-X
.	B-X
CG	B-X
dimers	B-X
containing	B-X
the	B-X
alpha-subunit	B-X
chimera	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
had	B-X
a	B-X
much	B-X
lower	B-X
binding	B-X
affinity	B-X
for	B-X
the	B-X
hLH-hCG	B-X
receptor	B-X
in	B-X
vitro	B-X
,	B-X
whereas	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
dimer	B-X
containing	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
amino-terminal	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
was	B-X
similar	B-X
to	B-X
wild	B-X
type	B-X
hCG	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
CTP	B-X
to	B-X
the	B-X
alpha-subunit	B-X
of	B-X
hCG	B-X
results	B-X
in	B-X
an	B-X
agonist	B-X
with	B-X
prolonged	B-X
biological	B-X
action	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
data	B-X
further	B-X
support	B-X
the	B-X
rationale	B-X
for	B-X
using	B-X
the	B-X
CTP	B-X
as	B-X
a	B-X
general	B-X
target	B-X
to	B-X
increase	B-X
the	B-X
potency	B-X
of	B-X
bioactive	B-X
glycoproteins	B-X
.	B-X

The	O
chimeras	O
were	O
secreted	O
and	O
combined	O
efficiently	O
with	O
the	O
CG	B-Protein
beta	I-Protein
-	I-Protein
subunit	I-Protein
,	O
comparable	O
to	O
the	O
wild	O
type	O
alpha	O
-	O
subunit	O
.	O

CG	O
dimers	O
containing	O
the	O
alpha	O
-	O
subunit	O
chimera	O
with	O
CTP	O
at	O
the	O
carboxy	O
end	O
of	O
the	O
subunit	O
had	O
a	O
much	O
lower	O
binding	O
affinity	O
for	O
the	O
hLH	B-Protein
-	I-Protein
hCG	I-Protein
receptor	I-Protein
in	O
vitro	O
,	O
whereas	O
the	O
binding	O
of	O
the	O
dimer	O
containing	O
the	O
CTP	O
at	O
the	O
amino	O
-	O
terminal	O
end	O
of	O
the	O
subunit	O
was	O
similar	O
to	O
wild	O
type	O
hCG	O
.	O
<EOS>	B-X
The	B-X
hCG	B-X
beta-subunit	B-X
contains	B-X
a	B-X
carboxy-terminal	B-X
extension	B-X
bearing	B-X
four	B-X
serine-linked	B-X
oligosaccharides	B-X
[	B-X
carboxy-terminal	B-X
peptide	B-X
(	B-X
CTP	B-X
)	B-X
]	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
maintaining	B-X
its	B-X
longer	B-X
half-life	B-X
compared	B-X
with	B-X
the	B-X
other	B-X
glycoprotein	B-X
hormones	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
enhanced	B-X
the	B-X
in	B-X
vivo	B-X
half-life	B-X
of	B-X
FSH	B-X
by	B-X
fusing	B-X
the	B-X
CTP	B-X
to	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
FSH	B-X
beta	B-X
coding	B-X
sequence	B-X
.	B-X
The	B-X
alpha-subunit	B-X
is	B-X
common	B-X
to	B-X
the	B-X
glycoprotein	B-X
family	B-X
.	B-X
We	B-X
constructed	B-X
alpha-subunit	B-X
CTP	B-X
chimeras	B-X
,	B-X
since	B-X
such	B-X
analogs	B-X
with	B-X
the	B-X
appropriate	B-X
O-linked	B-X
glycosylation	B-X
and	B-X
conformation	B-X
would	B-X
increase	B-X
the	B-X
in	B-X
vivo	B-X
stability	B-X
of	B-X
the	B-X
entire	B-X
glycoprotein	B-X
hormone	B-X
family	B-X
.	B-X
Two	B-X
chimeras	B-X
were	B-X
constructed	B-X
using	B-X
overlapping	B-X
polymerase	B-X
chain	B-X
reaction	B-X
mutagenesis	B-X
:	B-X
a	B-X
variant	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
and	B-X
another	B-X
analog	B-X
with	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
subunit	B-X
,	B-X
between	B-X
amino	B-X
acids	B-X
3	B-X
and	B-X
4	B-X
.	B-X
The	B-X
latter	B-X
design	B-X
was	B-X
based	B-X
on	B-X
models	B-X
showing	B-X
that	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
alpha	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
assembly	B-X
with	B-X
the	B-X
beta-subunit	B-X
,	B-X
nor	B-X
is	B-X
it	B-X
essential	B-X
for	B-X
receptor	B-X
binding	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
These	B-X
chimeras	B-X
were	B-X
cotransfected	B-X
with	B-X
the	B-X
hCG	B-X
beta	B-X
gene	B-X
into	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
The	B-X
chimeras	B-X
were	B-X
secreted	B-X
and	B-X
combined	B-X
efficiently	B-X
with	B-X
the	B-X
CG	B-X
beta-subunit	B-X
,	B-X
comparable	B-X
to	B-X
the	B-X
wild	B-X
type	B-X
alpha-subunit	B-X
.	B-X
CG	B-X
dimers	B-X
containing	B-X
the	B-X
alpha-subunit	B-X
chimera	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
had	B-X
a	B-X
much	B-X
lower	B-X
binding	B-X
affinity	B-X
for	B-X
the	B-X
hLH-hCG	B-X
receptor	B-X
in	B-X
vitro	B-X
,	B-X
whereas	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
dimer	B-X
containing	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
amino-terminal	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
was	B-X
similar	B-X
to	B-X
wild	B-X
type	B-X
hCG	B-X
.	B-X
Moreover	B-X
,	B-X
regardless	B-X
of	B-X
the	B-X
two	B-X
insertion	B-X
points	B-X
in	B-X
the	B-X
alpha-subunit	B-X
,	B-X
the	B-X
CTP	B-X
sequence	B-X
was	B-X
O-glycosylated	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
entire	B-X
signal	B-X
for	B-X
O-glycosylation	B-X
is	B-X
primarily	B-X
contained	B-X
within	B-X
the	B-X
CTP	B-X
sequence	B-X
and	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
the	B-X
flanking	B-X
regions	B-X
of	B-X
the	B-X
recipient	B-X
protein	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
CTP	B-X
to	B-X
the	B-X
alpha-subunit	B-X
of	B-X
hCG	B-X
results	B-X
in	B-X
an	B-X
agonist	B-X
with	B-X
prolonged	B-X
biological	B-X
action	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
data	B-X
further	B-X
support	B-X
the	B-X
rationale	B-X
for	B-X
using	B-X
the	B-X
CTP	B-X
as	B-X
a	B-X
general	B-X
target	B-X
to	B-X
increase	B-X
the	B-X
potency	B-X
of	B-X
bioactive	B-X
glycoproteins	B-X
.	B-X

Furthermore	O
,	O
the	O
in	O
vivo	O
activity	O
of	O
this	O
analog	O
was	O
enhanced	O
significantly	O
.	O
<EOS>	B-X
Astrocytes	B-X
respond	B-X
to	B-X
neuronal	B-X
activity	B-X
and	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
plasticity	B-X
and	B-X
memory	B-X
.	B-X
To	B-X
test	B-X
whether	B-X
astrocytic	B-X
activity	B-X
is	B-X
also	B-X
sufficient	B-X
to	B-X
generate	B-X
synaptic	B-X
potentiation	B-X
and	B-X
enhance	B-X
memory	B-X
,	B-X
we	B-X
expressed	B-X
the	B-X
Gq-coupled	B-X
receptor	B-X
hM3Dq	B-X
in	B-X
CA1	B-X
astrocytes	B-X
,	B-X
allowing	B-X
their	B-X
activation	B-X
by	B-X
a	B-X
designer	B-X
drug	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
astrocytic	B-X
activation	B-X
enhanced	B-X
memory	B-X
allocation	B-X
;	B-X
i.e.	B-X
,	B-X
it	B-X
increased	B-X
neuronal	B-X
activity	B-X
in	B-X
a	B-X
task-specific	B-X
way	B-X
only	B-X
when	B-X
coupled	B-X
with	B-X
learning	B-X
,	B-X
but	B-X
not	B-X
in	B-X
home-caged	B-X
mice	B-X
.	B-X
Furthermore	B-X
,	B-X
astrocytic	B-X
activation	B-X
using	B-X
either	B-X
a	B-X
chemogenetic	B-X
or	B-X
an	B-X
optogenetic	B-X
tool	B-X
during	B-X
acquisition	B-X
resulted	B-X
in	B-X
memory	B-X
recall	B-X
enhancement	B-X
on	B-X
the	B-X
following	B-X
day	B-X
.	B-X
Conversely	B-X
,	B-X
directly	B-X
increasing	B-X
neuronal	B-X
activity	B-X
resulted	B-X
in	B-X
dramatic	B-X
memory	B-X
impairment	B-X
.	B-X

Moreover	O
,	O
regardless	O
of	O
the	O
two	O
insertion	O
points	O
in	O
the	O
alpha	O
-	O
subunit	O
,	O
the	O
CTP	O
sequence	O
was	O
O	O
-	O
glycosylated	O
.	O
<EOS>	B-X
The	B-X
hCG	B-X
beta-subunit	B-X
contains	B-X
a	B-X
carboxy-terminal	B-X
extension	B-X
bearing	B-X
four	B-X
serine-linked	B-X
oligosaccharides	B-X
[	B-X
carboxy-terminal	B-X
peptide	B-X
(	B-X
CTP	B-X
)	B-X
]	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
maintaining	B-X
its	B-X
longer	B-X
half-life	B-X
compared	B-X
with	B-X
the	B-X
other	B-X
glycoprotein	B-X
hormones	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
enhanced	B-X
the	B-X
in	B-X
vivo	B-X
half-life	B-X
of	B-X
FSH	B-X
by	B-X
fusing	B-X
the	B-X
CTP	B-X
to	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
FSH	B-X
beta	B-X
coding	B-X
sequence	B-X
.	B-X
The	B-X
alpha-subunit	B-X
is	B-X
common	B-X
to	B-X
the	B-X
glycoprotein	B-X
family	B-X
.	B-X
We	B-X
constructed	B-X
alpha-subunit	B-X
CTP	B-X
chimeras	B-X
,	B-X
since	B-X
such	B-X
analogs	B-X
with	B-X
the	B-X
appropriate	B-X
O-linked	B-X
glycosylation	B-X
and	B-X
conformation	B-X
would	B-X
increase	B-X
the	B-X
in	B-X
vivo	B-X
stability	B-X
of	B-X
the	B-X
entire	B-X
glycoprotein	B-X
hormone	B-X
family	B-X
.	B-X
Two	B-X
chimeras	B-X
were	B-X
constructed	B-X
using	B-X
overlapping	B-X
polymerase	B-X
chain	B-X
reaction	B-X
mutagenesis	B-X
:	B-X
a	B-X
variant	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
and	B-X
another	B-X
analog	B-X
with	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
subunit	B-X
,	B-X
between	B-X
amino	B-X
acids	B-X
3	B-X
and	B-X
4	B-X
.	B-X
The	B-X
latter	B-X
design	B-X
was	B-X
based	B-X
on	B-X
models	B-X
showing	B-X
that	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
alpha	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
assembly	B-X
with	B-X
the	B-X
beta-subunit	B-X
,	B-X
nor	B-X
is	B-X
it	B-X
essential	B-X
for	B-X
receptor	B-X
binding	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
The	B-X
chimeras	B-X
were	B-X
secreted	B-X
and	B-X
combined	B-X
efficiently	B-X
with	B-X
the	B-X
CG	B-X
beta-subunit	B-X
,	B-X
comparable	B-X
to	B-X
the	B-X
wild	B-X
type	B-X
alpha-subunit	B-X
.	B-X
CG	B-X
dimers	B-X
containing	B-X
the	B-X
alpha-subunit	B-X
chimera	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
had	B-X
a	B-X
much	B-X
lower	B-X
binding	B-X
affinity	B-X
for	B-X
the	B-X
hLH-hCG	B-X
receptor	B-X
in	B-X
vitro	B-X
,	B-X
whereas	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
dimer	B-X
containing	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
amino-terminal	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
was	B-X
similar	B-X
to	B-X
wild	B-X
type	B-X
hCG	B-X
.	B-X
Moreover	B-X
,	B-X
regardless	B-X
of	B-X
the	B-X
two	B-X
insertion	B-X
points	B-X
in	B-X
the	B-X
alpha-subunit	B-X
,	B-X
the	B-X
CTP	B-X
sequence	B-X
was	B-X
O-glycosylated	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
entire	B-X
signal	B-X
for	B-X
O-glycosylation	B-X
is	B-X
primarily	B-X
contained	B-X
within	B-X
the	B-X
CTP	B-X
sequence	B-X
and	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
the	B-X
flanking	B-X
regions	B-X
of	B-X
the	B-X
recipient	B-X
protein	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
CTP	B-X
to	B-X
the	B-X
alpha-subunit	B-X
of	B-X
hCG	B-X
results	B-X
in	B-X
an	B-X
agonist	B-X
with	B-X
prolonged	B-X
biological	B-X
action	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
data	B-X
further	B-X
support	B-X
the	B-X
rationale	B-X
for	B-X
using	B-X
the	B-X
CTP	B-X
as	B-X
a	B-X
general	B-X
target	B-X
to	B-X
increase	B-X
the	B-X
potency	B-X
of	B-X
bioactive	B-X
glycoproteins	B-X
.	B-X

These	O
data	O
suggest	O
that	O
the	O
entire	O
signal	O
for	O
O	O
-	O
glycosylation	O
is	O
primarily	O
contained	O
within	O
the	O
CTP	O
sequence	O
and	O
is	O
not	O
dependent	O
on	O
the	O
flanking	O
regions	O
of	O
the	O
recipient	O
protein	O
.	O

The	O
transfer	O
of	O
CTP	O
to	O
the	O
alpha	O
-	O
subunit	O
of	O
hCG	O
results	O
in	O
an	O
agonist	O
with	O
prolonged	O
biological	O
action	O
in	O
vivo	O
.	O

These	O
data	O
further	O
support	O
the	O
rationale	O
for	O
using	O
the	O
CTP	O
as	O
a	O
general	O
target	O
to	O
increase	O
the	O
potency	O
of	O
bioactive	O
glycoproteins	O
.	O
<EOS>	B-X
The	B-X
hCG	B-X
beta-subunit	B-X
contains	B-X
a	B-X
carboxy-terminal	B-X
extension	B-X
bearing	B-X
four	B-X
serine-linked	B-X
oligosaccharides	B-X
[	B-X
carboxy-terminal	B-X
peptide	B-X
(	B-X
CTP	B-X
)	B-X
]	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
maintaining	B-X
its	B-X
longer	B-X
half-life	B-X
compared	B-X
with	B-X
the	B-X
other	B-X
glycoprotein	B-X
hormones	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
enhanced	B-X
the	B-X
in	B-X
vivo	B-X
half-life	B-X
of	B-X
FSH	B-X
by	B-X
fusing	B-X
the	B-X
CTP	B-X
to	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
FSH	B-X
beta	B-X
coding	B-X
sequence	B-X
.	B-X
We	B-X
constructed	B-X
alpha-subunit	B-X
CTP	B-X
chimeras	B-X
,	B-X
since	B-X
such	B-X
analogs	B-X
with	B-X
the	B-X
appropriate	B-X
O-linked	B-X
glycosylation	B-X
and	B-X
conformation	B-X
would	B-X
increase	B-X
the	B-X
in	B-X
vivo	B-X
stability	B-X
of	B-X
the	B-X
entire	B-X
glycoprotein	B-X
hormone	B-X
family	B-X
.	B-X
Two	B-X
chimeras	B-X
were	B-X
constructed	B-X
using	B-X
overlapping	B-X
polymerase	B-X
chain	B-X
reaction	B-X
mutagenesis	B-X
:	B-X
a	B-X
variant	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
and	B-X
another	B-X
analog	B-X
with	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
subunit	B-X
,	B-X
between	B-X
amino	B-X
acids	B-X
3	B-X
and	B-X
4	B-X
.	B-X
CG	B-X
dimers	B-X
containing	B-X
the	B-X
alpha-subunit	B-X
chimera	B-X
with	B-X
CTP	B-X
at	B-X
the	B-X
carboxy	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
had	B-X
a	B-X
much	B-X
lower	B-X
binding	B-X
affinity	B-X
for	B-X
the	B-X
hLH-hCG	B-X
receptor	B-X
in	B-X
vitro	B-X
,	B-X
whereas	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
dimer	B-X
containing	B-X
the	B-X
CTP	B-X
at	B-X
the	B-X
amino-terminal	B-X
end	B-X
of	B-X
the	B-X
subunit	B-X
was	B-X
similar	B-X
to	B-X
wild	B-X
type	B-X
hCG	B-X
.	B-X
Moreover	B-X
,	B-X
regardless	B-X
of	B-X
the	B-X
two	B-X
insertion	B-X
points	B-X
in	B-X
the	B-X
alpha-subunit	B-X
,	B-X
the	B-X
CTP	B-X
sequence	B-X
was	B-X
O-glycosylated	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
entire	B-X
signal	B-X
for	B-X
O-glycosylation	B-X
is	B-X
primarily	B-X
contained	B-X
within	B-X
the	B-X
CTP	B-X
sequence	B-X
and	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
the	B-X
flanking	B-X
regions	B-X
of	B-X
the	B-X
recipient	B-X
protein	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
CTP	B-X
to	B-X
the	B-X
alpha-subunit	B-X
of	B-X
hCG	B-X
results	B-X
in	B-X
an	B-X
agonist	B-X
with	B-X
prolonged	B-X
biological	B-X
action	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
data	B-X
further	B-X
support	B-X
the	B-X
rationale	B-X
for	B-X
using	B-X
the	B-X
CTP	B-X
as	B-X
a	B-X
general	B-X
target	B-X
to	B-X
increase	B-X
the	B-X
potency	B-X
of	B-X
bioactive	B-X
glycoproteins	B-X
.	B-X

Glycosylation	O
of	O
IgG	O
during	O
potentially	O
arthritogenic	O
lentiviral	O
infections	O
.	O
<EOS>	B-X
Agalactosyl	B-X
IgG	B-X
[	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
]	B-X
was	B-X
first	B-X
discovered	B-X
in	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Studies	B-X
by	B-X
Western	B-X
blot	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
terminal	B-X
N-acetylglucosamine	B-X
on	B-X
heavy	B-X
chains	B-X
,	B-X
and	B-X
percentages	B-X
of	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
comparable	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
human	B-X
RA	B-X
could	B-X
be	B-X
generated	B-X
by	B-X
exposing	B-X
goat	B-X
IgG	B-X
to	B-X
streptococcal	B-X
beta-galactosidase	B-X
.	B-X

Agalactosyl	O
IgG	O
[	O
Gal	O
(	O
0	O
)	O
]	O
was	O
first	O
discovered	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

However	O
,	O
the	O
proportion	O
of	O
this	O
glycoform	O
is	O
also	O
raised	O
in	O
tuberculosis	O
and	O
leprosy	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
this	B-X
glycoform	B-X
is	B-X
also	B-X
raised	B-X
in	B-X
tuberculosis	B-X
and	B-X
leprosy	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
arthritis	B-X
can	B-X
occur	B-X
in	B-X
mycobacterial	B-X
diseases	B-X
,	B-X
so	B-X
raised	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
could	B-X
be	B-X
associated	B-X
with	B-X
a	B-X
tendency	B-X
to	B-X
arthritis	B-X
,	B-X
rather	B-X
than	B-X
with	B-X
a	B-X
particular	B-X
type	B-X
of	B-X
infection	B-X
.	B-X
Goats	B-X
infected	B-X
with	B-X
CAEV	B-X
or	B-X
Mycobacterium	B-X
paratuberculosis	B-X
(	B-X
used	B-X
as	B-X
a	B-X
control	B-X
mycobacterial	B-X
infection	B-X
)	B-X
had	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
,	B-X
though	B-X
it	B-X
was	B-X
still	B-X
below	B-X
the	B-X
level	B-X
seen	B-X
in	B-X
normal	B-X
humans	B-X
.	B-X

This	O
has	O
helped	O
reinforce	O
the	O
suggestion	O
that	O
RA	O
may	O
be	O
triggered	O
by	O
a	O
mycobacterium	O
-	O
like	O
slow	O
bacterial	O
infection	O
.	O
<EOS>	B-X
Agalactosyl	B-X
IgG	B-X
[	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
]	B-X
was	B-X
first	B-X
discovered	B-X
in	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
This	B-X
has	B-X
helped	B-X
reinforce	B-X
the	B-X
suggestion	B-X
that	B-X
RA	B-X
may	B-X
be	B-X
triggered	B-X
by	B-X
a	B-X
mycobacterium-like	B-X
slow	B-X
bacterial	B-X
infection	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
arthritis	B-X
can	B-X
occur	B-X
in	B-X
mycobacterial	B-X
diseases	B-X
,	B-X
so	B-X
raised	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
could	B-X
be	B-X
associated	B-X
with	B-X
a	B-X
tendency	B-X
to	B-X
arthritis	B-X
,	B-X
rather	B-X
than	B-X
with	B-X
a	B-X
particular	B-X
type	B-X
of	B-X
infection	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
wished	B-X
to	B-X
find	B-X
out	B-X
whether	B-X
the	B-X
percentage	B-X
of	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
[	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
]	B-X
is	B-X
increased	B-X
in	B-X
sheep	B-X
and	B-X
goats	B-X
following	B-X
infection	B-X
with	B-X
maedi	B-X
visna	B-X
virus	B-X
or	B-X
caprine	B-X
arthritis	B-X
encephalitis	B-X
virus	B-X
(	B-X
CAEV	B-X
)	B-X
,	B-X
both	B-X
of	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
inflammatory	B-X
synovitis	B-X
.	B-X
Goats	B-X
infected	B-X
with	B-X
CAEV	B-X
or	B-X
Mycobacterium	B-X
paratuberculosis	B-X
(	B-X
used	B-X
as	B-X
a	B-X
control	B-X
mycobacterial	B-X
infection	B-X
)	B-X
had	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
,	B-X
though	B-X
it	B-X
was	B-X
still	B-X
below	B-X
the	B-X
level	B-X
seen	B-X
in	B-X
normal	B-X
humans	B-X
.	B-X
Studies	B-X
by	B-X
Western	B-X
blot	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
terminal	B-X
N-acetylglucosamine	B-X
on	B-X
heavy	B-X
chains	B-X
,	B-X
and	B-X
percentages	B-X
of	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
comparable	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
human	B-X
RA	B-X
could	B-X
be	B-X
generated	B-X
by	B-X
exposing	B-X
goat	B-X
IgG	B-X
to	B-X
streptococcal	B-X
beta-galactosidase	B-X
.	B-X
The	B-X
rise	B-X
in	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
was	B-X
greatest	B-X
in	B-X
members	B-X
of	B-X
infected	B-X
herds	B-X
that	B-X
were	B-X
just	B-X
starting	B-X
to	B-X
manifest	B-X
arthritis	B-X
,	B-X
and	B-X
tended	B-X
to	B-X
be	B-X
lower	B-X
in	B-X
those	B-X
in	B-X
which	B-X
severe	B-X
carpitis	B-X
had	B-X
developed	B-X
at	B-X
the	B-X
time	B-X
of	B-X
bleeding	B-X
,	B-X
implying	B-X
the	B-X
possibility	B-X
that	B-X
raise	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
may	B-X
be	B-X
an	B-X
early	B-X
or	B-X
predisposing	B-X
event	B-X
for	B-X
the	B-X
development	B-X
of	B-X
arthritis	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

On	O
the	O
other	O
hand	O
,	O
arthritis	O
can	O
occur	O
in	O
mycobacterial	O
diseases	O
,	O
so	O
raised	O
Gal	O
(	O
0	O
)	O
could	O
be	O
associated	O
with	O
a	O
tendency	O
to	O
arthritis	O
,	O
rather	O
than	O
with	O
a	O
particular	O
type	O
of	O
infection	O
.	O

Therefore	O
,	O
we	O
wished	O
to	O
find	O
out	O
whether	O
the	O
percentage	O
of	O
Gal	O
(	O
0	O
)	O
[	O
%	O
Gal	O
(	O
0	O
)	O
]	O
is	O
increased	O
in	O
sheep	O
and	O
goats	O
following	O
infection	O
with	O
maedi	O
visna	O
virus	O
or	O
caprine	O
arthritis	O
encephalitis	O
virus	O
(	O
CAEV	O
)	O
,	O
both	O
of	O
which	O
can	O
lead	O
to	O
inflammatory	O
synovitis	O
.	O
<EOS>	B-X
Agalactosyl	B-X
IgG	B-X
[	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
]	B-X
was	B-X
first	B-X
discovered	B-X
in	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
This	B-X
has	B-X
helped	B-X
reinforce	B-X
the	B-X
suggestion	B-X
that	B-X
RA	B-X
may	B-X
be	B-X
triggered	B-X
by	B-X
a	B-X
mycobacterium-like	B-X
slow	B-X
bacterial	B-X
infection	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
arthritis	B-X
can	B-X
occur	B-X
in	B-X
mycobacterial	B-X
diseases	B-X
,	B-X
so	B-X
raised	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
could	B-X
be	B-X
associated	B-X
with	B-X
a	B-X
tendency	B-X
to	B-X
arthritis	B-X
,	B-X
rather	B-X
than	B-X
with	B-X
a	B-X
particular	B-X
type	B-X
of	B-X
infection	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
wished	B-X
to	B-X
find	B-X
out	B-X
whether	B-X
the	B-X
percentage	B-X
of	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
[	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
]	B-X
is	B-X
increased	B-X
in	B-X
sheep	B-X
and	B-X
goats	B-X
following	B-X
infection	B-X
with	B-X
maedi	B-X
visna	B-X
virus	B-X
or	B-X
caprine	B-X
arthritis	B-X
encephalitis	B-X
virus	B-X
(	B-X
CAEV	B-X
)	B-X
,	B-X
both	B-X
of	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
inflammatory	B-X
synovitis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
normal	B-X
level	B-X
of	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
in	B-X
these	B-X
species	B-X
is	B-X
much	B-X
lower	B-X
than	B-X
in	B-X
humans	B-X
.	B-X
Goats	B-X
infected	B-X
with	B-X
CAEV	B-X
or	B-X
Mycobacterium	B-X
paratuberculosis	B-X
(	B-X
used	B-X
as	B-X
a	B-X
control	B-X
mycobacterial	B-X
infection	B-X
)	B-X
had	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
,	B-X
though	B-X
it	B-X
was	B-X
still	B-X
below	B-X
the	B-X
level	B-X
seen	B-X
in	B-X
normal	B-X
humans	B-X
.	B-X
Studies	B-X
by	B-X
Western	B-X
blot	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
terminal	B-X
N-acetylglucosamine	B-X
on	B-X
heavy	B-X
chains	B-X
,	B-X
and	B-X
percentages	B-X
of	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
comparable	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
human	B-X
RA	B-X
could	B-X
be	B-X
generated	B-X
by	B-X
exposing	B-X
goat	B-X
IgG	B-X
to	B-X
streptococcal	B-X
beta-galactosidase	B-X
.	B-X
The	B-X
rise	B-X
in	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
was	B-X
greatest	B-X
in	B-X
members	B-X
of	B-X
infected	B-X
herds	B-X
that	B-X
were	B-X
just	B-X
starting	B-X
to	B-X
manifest	B-X
arthritis	B-X
,	B-X
and	B-X
tended	B-X
to	B-X
be	B-X
lower	B-X
in	B-X
those	B-X
in	B-X
which	B-X
severe	B-X
carpitis	B-X
had	B-X
developed	B-X
at	B-X
the	B-X
time	B-X
of	B-X
bleeding	B-X
,	B-X
implying	B-X
the	B-X
possibility	B-X
that	B-X
raise	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
may	B-X
be	B-X
an	B-X
early	B-X
or	B-X
predisposing	B-X
event	B-X
for	B-X
the	B-X
development	B-X
of	B-X
arthritis	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

We	O
found	O
that	O
the	O
normal	O
level	O
of	O
Gal	O
(	O
0	O
)	O
in	O
these	O
species	O
is	O
much	O
lower	O
than	O
in	O
humans	O
.	O

Goats	O
infected	O
with	O
CAEV	O
or	O
Mycobacterium	O
paratuberculosis	O
(	O
used	O
as	O
a	O
control	O
mycobacterial	O
infection	O
)	O
had	O
a	O
significant	O
increase	O
in	O
%	O
Gal	O
(	O
0	O
)	O
,	O
though	O
it	O
was	O
still	O
below	O
the	O
level	O
seen	O
in	O
normal	O
humans	O
.	O

Studies	O
by	O
Western	O
blot	O
confirmed	O
the	O
presence	O
of	O
terminal	O
N	O
-	O
acetylglucosamine	O
on	O
heavy	O
chains	O
,	O
and	O
percentages	O
of	O
Gal	O
(	O
0	O
)	O
comparable	O
to	O
those	O
seen	O
in	O
human	O
RA	O
could	O
be	O
generated	O
by	O
exposing	O
goat	O
IgG	O
to	O
streptococcal	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
.	O

The	O
rise	O
in	O
%	O
Gal	O
(	O
0	O
)	O
was	O
greatest	O
in	O
members	O
of	O
infected	O
herds	O
that	O
were	O
just	O
starting	O
to	O
manifest	O
arthritis	O
,	O
and	O
tended	O
to	O
be	O
lower	O
in	O
those	O
in	O
which	O
severe	O
carpitis	O
had	O
developed	O
at	O
the	O
time	O
of	O
bleeding	O
,	O
implying	O
the	O
possibility	O
that	O
raise	O
%	O
Gal	O
(	O
0	O
)	O
may	O
be	O
an	O
early	O
or	O
predisposing	O
event	O
for	O
the	O
development	O
of	O
arthritis	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
<EOS>	B-X
Agalactosyl	B-X
IgG	B-X
[	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
]	B-X
was	B-X
first	B-X
discovered	B-X
in	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
this	B-X
glycoform	B-X
is	B-X
also	B-X
raised	B-X
in	B-X
tuberculosis	B-X
and	B-X
leprosy	B-X
.	B-X
This	B-X
has	B-X
helped	B-X
reinforce	B-X
the	B-X
suggestion	B-X
that	B-X
RA	B-X
may	B-X
be	B-X
triggered	B-X
by	B-X
a	B-X
mycobacterium-like	B-X
slow	B-X
bacterial	B-X
infection	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
arthritis	B-X
can	B-X
occur	B-X
in	B-X
mycobacterial	B-X
diseases	B-X
,	B-X
so	B-X
raised	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
could	B-X
be	B-X
associated	B-X
with	B-X
a	B-X
tendency	B-X
to	B-X
arthritis	B-X
,	B-X
rather	B-X
than	B-X
with	B-X
a	B-X
particular	B-X
type	B-X
of	B-X
infection	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
wished	B-X
to	B-X
find	B-X
out	B-X
whether	B-X
the	B-X
percentage	B-X
of	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
[	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
]	B-X
is	B-X
increased	B-X
in	B-X
sheep	B-X
and	B-X
goats	B-X
following	B-X
infection	B-X
with	B-X
maedi	B-X
visna	B-X
virus	B-X
or	B-X
caprine	B-X
arthritis	B-X
encephalitis	B-X
virus	B-X
(	B-X
CAEV	B-X
)	B-X
,	B-X
both	B-X
of	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
inflammatory	B-X
synovitis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
normal	B-X
level	B-X
of	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
in	B-X
these	B-X
species	B-X
is	B-X
much	B-X
lower	B-X
than	B-X
in	B-X
humans	B-X
.	B-X
Goats	B-X
infected	B-X
with	B-X
CAEV	B-X
or	B-X
Mycobacterium	B-X
paratuberculosis	B-X
(	B-X
used	B-X
as	B-X
a	B-X
control	B-X
mycobacterial	B-X
infection	B-X
)	B-X
had	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
,	B-X
though	B-X
it	B-X
was	B-X
still	B-X
below	B-X
the	B-X
level	B-X
seen	B-X
in	B-X
normal	B-X
humans	B-X
.	B-X
Studies	B-X
by	B-X
Western	B-X
blot	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
terminal	B-X
N-acetylglucosamine	B-X
on	B-X
heavy	B-X
chains	B-X
,	B-X
and	B-X
percentages	B-X
of	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
comparable	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
human	B-X
RA	B-X
could	B-X
be	B-X
generated	B-X
by	B-X
exposing	B-X
goat	B-X
IgG	B-X
to	B-X
streptococcal	B-X
beta-galactosidase	B-X
.	B-X
The	B-X
rise	B-X
in	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
was	B-X
greatest	B-X
in	B-X
members	B-X
of	B-X
infected	B-X
herds	B-X
that	B-X
were	B-X
just	B-X
starting	B-X
to	B-X
manifest	B-X
arthritis	B-X
,	B-X
and	B-X
tended	B-X
to	B-X
be	B-X
lower	B-X
in	B-X
those	B-X
in	B-X
which	B-X
severe	B-X
carpitis	B-X
had	B-X
developed	B-X
at	B-X
the	B-X
time	B-X
of	B-X
bleeding	B-X
,	B-X
implying	B-X
the	B-X
possibility	B-X
that	B-X
raise	B-X
%	B-X
Gal	B-X
(	B-X
0	B-X
)	B-X
may	B-X
be	B-X
an	B-X
early	B-X
or	B-X
predisposing	B-X
event	B-X
for	B-X
the	B-X
development	B-X
of	B-X
arthritis	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

The	O
effects	O
of	O
variable	O
glycosylation	O
on	O
the	O
functional	O
activities	O
of	O
ribonuclease	O
,	O
plasminogen	B-Protein
and	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
.	O
<EOS>	B-X
The	B-X
relatively	B-X
large	B-X
size	B-X
and	B-X
dynamics	B-X
of	B-X
oligosaccharides	B-X
can	B-X
result	B-X
in	B-X
substantial	B-X
shielding	B-X
of	B-X
functionally	B-X
important	B-X
areas	B-X
of	B-X
proteins	B-X
to	B-X
which	B-X
they	B-X
are	B-X
attached	B-X
,	B-X
modulate	B-X
the	B-X
interactions	B-X
of	B-X
glycoconjugates	B-X
with	B-X
other	B-X
molecules	B-X
and	B-X
affect	B-X
the	B-X
rate	B-X
of	B-X
processes	B-X
which	B-X
involve	B-X
conformational	B-X
changes	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
occupancy	B-X
of	B-X
N-linked	B-X
glycosylation	B-X
sites	B-X
on	B-X
three	B-X
enzymes	B-X
,	B-X
ribonuclease	B-X
,	B-X
plasminogen	B-X
and	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
.	B-X
Each	B-X
of	B-X
these	B-X
proteins	B-X
occurs	B-X
naturally	B-X
as	B-X
two	B-X
populations	B-X
of	B-X
molecules	B-X
,	B-X
distinguished	B-X
from	B-X
each	B-X
other	B-X
only	B-X
by	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
an	B-X
oligosaccharide	B-X
at	B-X
one	B-X
glycosylation	B-X
site	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
oligomannose	B-X
sugar	B-X
on	B-X
ribonuclease	B-X
(	B-X
at	B-X
Asn-34	B-X
)	B-X
alters	B-X
its	B-X
overall	B-X
dynamics	B-X
,	B-X
increases	B-X
its	B-X
stability	B-X
towards	B-X
proteinases	B-X
and	B-X
decreases	B-X
its	B-X
functional	B-X
activity	B-X
towards	B-X
double-stranded	B-X
RNA	B-X
.	B-X
The	B-X
N-linked	B-X
sugar	B-X
on	B-X
plasminogen	B-X
(	B-X
at	B-X
Asn-288	B-X
)	B-X
within	B-X
kringle	B-X
3	B-X
reduces	B-X
the	B-X
rate	B-X
of	B-X
the	B-X
beta-	B-X
to	B-X
alpha-conformational	B-X
change	B-X
,	B-X
modulates	B-X
the	B-X
transport	B-X
of	B-X
plasminogen	B-X
into	B-X
the	B-X
extravascular	B-X
compartment	B-X
,	B-X
decreases	B-X
plasminogen	B-X
binding	B-X
to	B-X
U937	B-X
cells	B-X
and	B-X
downregulates	B-X
the	B-X
activation	B-X
of	B-X
plasminogen	B-X
by	B-X
both	B-X
urokinase	B-X
and	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
.	B-X
Additionally	B-X
,	B-X
in	B-X
fibrinolysis	B-X
,	B-X
within	B-X
a	B-X
ternary	B-X
complex	B-X
of	B-X
fibrin	B-X
,	B-X
plasminogen	B-X
and	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
,	B-X
the	B-X
N-linked	B-X
sugar	B-X
of	B-X
plasminogen	B-X
hinders	B-X
the	B-X
initial	B-X
interaction	B-X
with	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
i.e.	B-X
,	B-X
it	B-X
alters	B-X
Km	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
N-linked	B-X
glycan	B-X
(	B-X
at	B-X
Asn-184	B-X
)	B-X
in	B-X
the	B-X
kringle	B-X
2	B-X
domain	B-X
of	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
hinders	B-X
the	B-X
rearrangement	B-X
of	B-X
this	B-X
ternary	B-X
complex	B-X
,	B-X
decreasing	B-X
the	B-X
turnover	B-X
rate	B-X
(	B-X
Kcat	B-X
)	B-X
.	B-X

The	O
relatively	O
large	O
size	O
and	O
dynamics	O
of	O
oligosaccharides	O
can	O
result	O
in	O
substantial	O
shielding	O
of	O
functionally	O
important	O
areas	O
of	O
proteins	O
to	O
which	O
they	O
are	O
attached	O
,	O
modulate	O
the	O
interactions	O
of	O
glycoconjugates	O
with	O
other	O
molecules	O
and	O
affect	O
the	O
rate	O
of	O
processes	O
which	O
involve	O
conformational	O
changes	O
.	O
<EOS>	B-X
The	B-X
relatively	B-X
large	B-X
size	B-X
and	B-X
dynamics	B-X
of	B-X
oligosaccharides	B-X
can	B-X
result	B-X
in	B-X
substantial	B-X
shielding	B-X
of	B-X
functionally	B-X
important	B-X
areas	B-X
of	B-X
proteins	B-X
to	B-X
which	B-X
they	B-X
are	B-X
attached	B-X
,	B-X
modulate	B-X
the	B-X
interactions	B-X
of	B-X
glycoconjugates	B-X
with	B-X
other	B-X
molecules	B-X
and	B-X
affect	B-X
the	B-X
rate	B-X
of	B-X
processes	B-X
which	B-X
involve	B-X
conformational	B-X
changes	B-X
.	B-X
Each	B-X
of	B-X
these	B-X
proteins	B-X
occurs	B-X
naturally	B-X
as	B-X
two	B-X
populations	B-X
of	B-X
molecules	B-X
,	B-X
distinguished	B-X
from	B-X
each	B-X
other	B-X
only	B-X
by	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
an	B-X
oligosaccharide	B-X
at	B-X
one	B-X
glycosylation	B-X
site	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
oligomannose	B-X
sugar	B-X
on	B-X
ribonuclease	B-X
(	B-X
at	B-X
Asn-34	B-X
)	B-X
alters	B-X
its	B-X
overall	B-X
dynamics	B-X
,	B-X
increases	B-X
its	B-X
stability	B-X
towards	B-X
proteinases	B-X
and	B-X
decreases	B-X
its	B-X
functional	B-X
activity	B-X
towards	B-X
double-stranded	B-X
RNA	B-X
.	B-X
The	B-X
N-linked	B-X
sugar	B-X
on	B-X
plasminogen	B-X
(	B-X
at	B-X
Asn-288	B-X
)	B-X
within	B-X
kringle	B-X
3	B-X
reduces	B-X
the	B-X
rate	B-X
of	B-X
the	B-X
beta-	B-X
to	B-X
alpha-conformational	B-X
change	B-X
,	B-X
modulates	B-X
the	B-X
transport	B-X
of	B-X
plasminogen	B-X
into	B-X
the	B-X
extravascular	B-X
compartment	B-X
,	B-X
decreases	B-X
plasminogen	B-X
binding	B-X
to	B-X
U937	B-X
cells	B-X
and	B-X
downregulates	B-X
the	B-X
activation	B-X
of	B-X
plasminogen	B-X
by	B-X
both	B-X
urokinase	B-X
and	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
N-linked	B-X
glycan	B-X
(	B-X
at	B-X
Asn-184	B-X
)	B-X
in	B-X
the	B-X
kringle	B-X
2	B-X
domain	B-X
of	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
hinders	B-X
the	B-X
rearrangement	B-X
of	B-X
this	B-X
ternary	B-X
complex	B-X
,	B-X
decreasing	B-X
the	B-X
turnover	B-X
rate	B-X
(	B-X
Kcat	B-X
)	B-X
.	B-X

This	O
review	O
focuses	O
on	O
the	O
occupancy	O
of	O
N	O
-	O
linked	O
glycosylation	O
sites	O
on	O
three	O
enzymes	O
,	O
ribonuclease	O
,	O
plasminogen	B-Protein
and	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
.	O

Each	O
of	O
these	O
proteins	O
occurs	O
naturally	O
as	O
two	O
populations	O
of	O
molecules	O
,	O
distinguished	O
from	O
each	O
other	O
only	O
by	O
the	O
presence	O
or	O
absence	O
of	O
an	O
oligosaccharide	O
at	O
one	O
glycosylation	O
site	O
.	O
<EOS>	B-X
The	B-X
relatively	B-X
large	B-X
size	B-X
and	B-X
dynamics	B-X
of	B-X
oligosaccharides	B-X
can	B-X
result	B-X
in	B-X
substantial	B-X
shielding	B-X
of	B-X
functionally	B-X
important	B-X
areas	B-X
of	B-X
proteins	B-X
to	B-X
which	B-X
they	B-X
are	B-X
attached	B-X
,	B-X
modulate	B-X
the	B-X
interactions	B-X
of	B-X
glycoconjugates	B-X
with	B-X
other	B-X
molecules	B-X
and	B-X
affect	B-X
the	B-X
rate	B-X
of	B-X
processes	B-X
which	B-X
involve	B-X
conformational	B-X
changes	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
occupancy	B-X
of	B-X
N-linked	B-X
glycosylation	B-X
sites	B-X
on	B-X
three	B-X
enzymes	B-X
,	B-X
ribonuclease	B-X
,	B-X
plasminogen	B-X
and	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
.	B-X
Each	B-X
of	B-X
these	B-X
proteins	B-X
occurs	B-X
naturally	B-X
as	B-X
two	B-X
populations	B-X
of	B-X
molecules	B-X
,	B-X
distinguished	B-X
from	B-X
each	B-X
other	B-X
only	B-X
by	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
an	B-X
oligosaccharide	B-X
at	B-X
one	B-X
glycosylation	B-X
site	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
oligomannose	B-X
sugar	B-X
on	B-X
ribonuclease	B-X
(	B-X
at	B-X
Asn-34	B-X
)	B-X
alters	B-X
its	B-X
overall	B-X
dynamics	B-X
,	B-X
increases	B-X
its	B-X
stability	B-X
towards	B-X
proteinases	B-X
and	B-X
decreases	B-X
its	B-X
functional	B-X
activity	B-X
towards	B-X
double-stranded	B-X
RNA	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
N-linked	B-X
glycan	B-X
(	B-X
at	B-X
Asn-184	B-X
)	B-X
in	B-X
the	B-X
kringle	B-X
2	B-X
domain	B-X
of	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
hinders	B-X
the	B-X
rearrangement	B-X
of	B-X
this	B-X
ternary	B-X
complex	B-X
,	B-X
decreasing	B-X
the	B-X
turnover	B-X
rate	B-X
(	B-X
Kcat	B-X
)	B-X
.	B-X

The	O
presence	O
of	O
an	O
oligomannose	O
sugar	O
on	O
ribonuclease	O
(	O
at	O
Asn	O
-	O
34	O
)	O
alters	O
its	O
overall	O
dynamics	O
,	O
increases	O
its	O
stability	O
towards	O
proteinases	O
and	O
decreases	O
its	O
functional	O
activity	O
towards	O
double	O
-	O
stranded	O
RNA	O
.	O
<EOS>	B-X
The	B-X
relatively	B-X
large	B-X
size	B-X
and	B-X
dynamics	B-X
of	B-X
oligosaccharides	B-X
can	B-X
result	B-X
in	B-X
substantial	B-X
shielding	B-X
of	B-X
functionally	B-X
important	B-X
areas	B-X
of	B-X
proteins	B-X
to	B-X
which	B-X
they	B-X
are	B-X
attached	B-X
,	B-X
modulate	B-X
the	B-X
interactions	B-X
of	B-X
glycoconjugates	B-X
with	B-X
other	B-X
molecules	B-X
and	B-X
affect	B-X
the	B-X
rate	B-X
of	B-X
processes	B-X
which	B-X
involve	B-X
conformational	B-X
changes	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
occupancy	B-X
of	B-X
N-linked	B-X
glycosylation	B-X
sites	B-X
on	B-X
three	B-X
enzymes	B-X
,	B-X
ribonuclease	B-X
,	B-X
plasminogen	B-X
and	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
.	B-X
Each	B-X
of	B-X
these	B-X
proteins	B-X
occurs	B-X
naturally	B-X
as	B-X
two	B-X
populations	B-X
of	B-X
molecules	B-X
,	B-X
distinguished	B-X
from	B-X
each	B-X
other	B-X
only	B-X
by	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
an	B-X
oligosaccharide	B-X
at	B-X
one	B-X
glycosylation	B-X
site	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
oligomannose	B-X
sugar	B-X
on	B-X
ribonuclease	B-X
(	B-X
at	B-X
Asn-34	B-X
)	B-X
alters	B-X
its	B-X
overall	B-X
dynamics	B-X
,	B-X
increases	B-X
its	B-X
stability	B-X
towards	B-X
proteinases	B-X
and	B-X
decreases	B-X
its	B-X
functional	B-X
activity	B-X
towards	B-X
double-stranded	B-X
RNA	B-X
.	B-X
The	B-X
N-linked	B-X
sugar	B-X
on	B-X
plasminogen	B-X
(	B-X
at	B-X
Asn-288	B-X
)	B-X
within	B-X
kringle	B-X
3	B-X
reduces	B-X
the	B-X
rate	B-X
of	B-X
the	B-X
beta-	B-X
to	B-X
alpha-conformational	B-X
change	B-X
,	B-X
modulates	B-X
the	B-X
transport	B-X
of	B-X
plasminogen	B-X
into	B-X
the	B-X
extravascular	B-X
compartment	B-X
,	B-X
decreases	B-X
plasminogen	B-X
binding	B-X
to	B-X
U937	B-X
cells	B-X
and	B-X
downregulates	B-X
the	B-X
activation	B-X
of	B-X
plasminogen	B-X
by	B-X
both	B-X
urokinase	B-X
and	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
.	B-X
Additionally	B-X
,	B-X
in	B-X
fibrinolysis	B-X
,	B-X
within	B-X
a	B-X
ternary	B-X
complex	B-X
of	B-X
fibrin	B-X
,	B-X
plasminogen	B-X
and	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
,	B-X
the	B-X
N-linked	B-X
sugar	B-X
of	B-X
plasminogen	B-X
hinders	B-X
the	B-X
initial	B-X
interaction	B-X
with	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
i.e.	B-X
,	B-X
it	B-X
alters	B-X
Km	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
N-linked	B-X
glycan	B-X
(	B-X
at	B-X
Asn-184	B-X
)	B-X
in	B-X
the	B-X
kringle	B-X
2	B-X
domain	B-X
of	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
hinders	B-X
the	B-X
rearrangement	B-X
of	B-X
this	B-X
ternary	B-X
complex	B-X
,	B-X
decreasing	B-X
the	B-X
turnover	B-X
rate	B-X
(	B-X
Kcat	B-X
)	B-X
.	B-X

The	O
N	O
-	O
linked	O
sugar	O
on	O
plasminogen	B-Protein
(	O
at	O
Asn	O
-	O
288	O
)	O
within	O
kringle	O
3	O
reduces	O
the	O
rate	O
of	O
the	O
beta	O
-	O
to	O
alpha	O
-	O
conformational	O
change	O
,	O
modulates	O
the	O
transport	O
of	O
plasminogen	B-Protein
into	O
the	O
extravascular	O
compartment	O
,	O
decreases	O
plasminogen	B-Protein
binding	O
to	O
U937	O
cells	O
and	O
downregulates	O
the	O
activation	O
of	O
plasminogen	B-Protein
by	O
both	O
urokinase	B-Protein
and	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
.	O

Additionally	O
,	O
in	O
fibrinolysis	O
,	O
within	O
a	O
ternary	O
complex	O
of	O
fibrin	O
,	O
plasminogen	B-Protein
and	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
,	O
the	O
N	O
-	O
linked	O
sugar	O
of	O
plasminogen	B-Protein
hinders	O
the	O
initial	O
interaction	O
with	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
(	O
i	O
.	O
e	O
.	O
,	O
it	O
alters	O
Km	O
)	O
.	O

The	O
presence	O
of	O
an	O
N	O
-	O
linked	O
glycan	O
(	O
at	O
Asn	O
-	O
184	O
)	O
in	O
the	O
kringle	O
2	O
domain	O
of	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
hinders	O
the	O
rearrangement	O
of	O
this	O
ternary	O
complex	O
,	O
decreasing	O
the	O
turnover	O
rate	O
(	O
Kcat	O
)	O
.	O

Production	O
of	O
vampire	O
bat	O
plasminogen	B-Protein
activator	O
DSPA	B-Protein
alpha	I-Protein
1	I-Protein
in	O
CHO	O
and	O
insect	O
cells	O
.	O

Salivary	O
plasminogen	B-Protein
activator	O
from	O
the	O
vampire	O
bat	O
Desmodus	O
rotundus	O
(	O
DSPA	B-Protein
alpha	I-Protein
1	I-Protein
)	O
is	O
a	O
promising	O
new	O
thrombolytic	O
agent	O
.	O
<EOS>	B-X
Salivary	B-X
plasminogen	B-X
activator	B-X
from	B-X
the	B-X
vampire	B-X
bat	B-X
Desmodus	B-X
rotundus	B-X
(	B-X
DSPA	B-X
alpha	B-X
1	B-X
)	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
thrombolytic	B-X
agent	B-X
.	B-X
Continuous	B-X
growth	B-X
of	B-X
a	B-X
stably	B-X
transfected	B-X
,	B-X
methotrexate	B-X
amplified	B-X
,	B-X
dhfr-	B-X
CHO	B-X
cell	B-X
line	B-X
yields	B-X
up	B-X
to	B-X
60	B-X
mg	B-X
l-1	B-X
of	B-X
DSPA	B-X
alpha	B-X
1	B-X
.	B-X
Utilizing	B-X
an	B-X
engineered	B-X
baculovirus	B-X
10	B-X
mg	B-X
l-1	B-X
were	B-X
produced	B-X
in	B-X
batches	B-X
of	B-X
Sf9	B-X
insect	B-X
cells	B-X
.	B-X
Recombinant	B-X
DSPA	B-X
alpha	B-X
1	B-X
is	B-X
purified	B-X
from	B-X
both	B-X
sources	B-X
using	B-X
a	B-X
one-step	B-X
purification	B-X
protocol	B-X
.	B-X
Although	B-X
differences	B-X
in	B-X
glycosylation	B-X
were	B-X
detected	B-X
,	B-X
enzymatic	B-X
activity	B-X
and	B-X
fibrin	B-X
cofactor	B-X
dependency	B-X
are	B-X
unaffected	B-X
when	B-X
DSPA	B-X
alpha	B-X
1	B-X
derived	B-X
from	B-X
the	B-X
two	B-X
expression	B-X
systems	B-X
is	B-X
compared	B-X
.	B-X

Continuous	O
growth	O
of	O
a	O
stably	O
transfected	O
,	O
methotrexate	O
amplified	O
,	O
dhfr	O
-	O
CHO	O
cell	O
line	O
yields	O
up	O
to	O
60	O
mg	O
l	O
-	O
1	O
of	O
DSPA	B-Protein
alpha	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Salivary	B-X
plasminogen	B-X
activator	B-X
from	B-X
the	B-X
vampire	B-X
bat	B-X
Desmodus	B-X
rotundus	B-X
(	B-X
DSPA	B-X
alpha	B-X
1	B-X
)	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
thrombolytic	B-X
agent	B-X
.	B-X
Continuous	B-X
growth	B-X
of	B-X
a	B-X
stably	B-X
transfected	B-X
,	B-X
methotrexate	B-X
amplified	B-X
,	B-X
dhfr-	B-X
CHO	B-X
cell	B-X
line	B-X
yields	B-X
up	B-X
to	B-X
60	B-X
mg	B-X
l-1	B-X
of	B-X
DSPA	B-X
alpha	B-X
1	B-X
.	B-X
Utilizing	B-X
an	B-X
engineered	B-X
baculovirus	B-X
10	B-X
mg	B-X
l-1	B-X
were	B-X
produced	B-X
in	B-X
batches	B-X
of	B-X
Sf9	B-X
insect	B-X
cells	B-X
.	B-X
Recombinant	B-X
DSPA	B-X
alpha	B-X
1	B-X
is	B-X
purified	B-X
from	B-X
both	B-X
sources	B-X
using	B-X
a	B-X
one-step	B-X
purification	B-X
protocol	B-X
.	B-X
Although	B-X
differences	B-X
in	B-X
glycosylation	B-X
were	B-X
detected	B-X
,	B-X
enzymatic	B-X
activity	B-X
and	B-X
fibrin	B-X
cofactor	B-X
dependency	B-X
are	B-X
unaffected	B-X
when	B-X
DSPA	B-X
alpha	B-X
1	B-X
derived	B-X
from	B-X
the	B-X
two	B-X
expression	B-X
systems	B-X
is	B-X
compared	B-X
.	B-X

Utilizing	O
an	O
engineered	O
baculovirus	O
10	O
mg	O
l	O
-	O
1	O
were	O
produced	O
in	O
batches	O
of	O
Sf9	O
insect	O
cells	O
.	O
<EOS>	B-X
Salivary	B-X
plasminogen	B-X
activator	B-X
from	B-X
the	B-X
vampire	B-X
bat	B-X
Desmodus	B-X
rotundus	B-X
(	B-X
DSPA	B-X
alpha	B-X
1	B-X
)	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
thrombolytic	B-X
agent	B-X
.	B-X
Continuous	B-X
growth	B-X
of	B-X
a	B-X
stably	B-X
transfected	B-X
,	B-X
methotrexate	B-X
amplified	B-X
,	B-X
dhfr-	B-X
CHO	B-X
cell	B-X
line	B-X
yields	B-X
up	B-X
to	B-X
60	B-X
mg	B-X
l-1	B-X
of	B-X
DSPA	B-X
alpha	B-X
1	B-X
.	B-X
Utilizing	B-X
an	B-X
engineered	B-X
baculovirus	B-X
10	B-X
mg	B-X
l-1	B-X
were	B-X
produced	B-X
in	B-X
batches	B-X
of	B-X
Sf9	B-X
insect	B-X
cells	B-X
.	B-X
Recombinant	B-X
DSPA	B-X
alpha	B-X
1	B-X
is	B-X
purified	B-X
from	B-X
both	B-X
sources	B-X
using	B-X
a	B-X
one-step	B-X
purification	B-X
protocol	B-X
.	B-X
Although	B-X
differences	B-X
in	B-X
glycosylation	B-X
were	B-X
detected	B-X
,	B-X
enzymatic	B-X
activity	B-X
and	B-X
fibrin	B-X
cofactor	B-X
dependency	B-X
are	B-X
unaffected	B-X
when	B-X
DSPA	B-X
alpha	B-X
1	B-X
derived	B-X
from	B-X
the	B-X
two	B-X
expression	B-X
systems	B-X
is	B-X
compared	B-X
.	B-X

Recombinant	O
DSPA	B-Protein
alpha	I-Protein
1	I-Protein
is	O
purified	O
from	O
both	O
sources	O
using	O
a	O
one	O
-	O
step	O
purification	O
protocol	O
.	O
<EOS>	B-X
Salivary	B-X
plasminogen	B-X
activator	B-X
from	B-X
the	B-X
vampire	B-X
bat	B-X
Desmodus	B-X
rotundus	B-X
(	B-X
DSPA	B-X
alpha	B-X
1	B-X
)	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
thrombolytic	B-X
agent	B-X
.	B-X
Continuous	B-X
growth	B-X
of	B-X
a	B-X
stably	B-X
transfected	B-X
,	B-X
methotrexate	B-X
amplified	B-X
,	B-X
dhfr-	B-X
CHO	B-X
cell	B-X
line	B-X
yields	B-X
up	B-X
to	B-X
60	B-X
mg	B-X
l-1	B-X
of	B-X
DSPA	B-X
alpha	B-X
1	B-X
.	B-X
Utilizing	B-X
an	B-X
engineered	B-X
baculovirus	B-X
10	B-X
mg	B-X
l-1	B-X
were	B-X
produced	B-X
in	B-X
batches	B-X
of	B-X
Sf9	B-X
insect	B-X
cells	B-X
.	B-X
Recombinant	B-X
DSPA	B-X
alpha	B-X
1	B-X
is	B-X
purified	B-X
from	B-X
both	B-X
sources	B-X
using	B-X
a	B-X
one-step	B-X
purification	B-X
protocol	B-X
.	B-X
Although	B-X
differences	B-X
in	B-X
glycosylation	B-X
were	B-X
detected	B-X
,	B-X
enzymatic	B-X
activity	B-X
and	B-X
fibrin	B-X
cofactor	B-X
dependency	B-X
are	B-X
unaffected	B-X
when	B-X
DSPA	B-X
alpha	B-X
1	B-X
derived	B-X
from	B-X
the	B-X
two	B-X
expression	B-X
systems	B-X
is	B-X
compared	B-X
.	B-X

Although	O
differences	O
in	O
glycosylation	O
were	O
detected	O
,	O
enzymatic	O
activity	O
and	O
fibrin	O
cofactor	O
dependency	O
are	O
unaffected	O
when	O
DSPA	B-Protein
alpha	I-Protein
1	I-Protein
derived	O
from	O
the	O
two	O
expression	O
systems	O
is	O
compared	O
.	O
<EOS>	B-X
Salivary	B-X
plasminogen	B-X
activator	B-X
from	B-X
the	B-X
vampire	B-X
bat	B-X
Desmodus	B-X
rotundus	B-X
(	B-X
DSPA	B-X
alpha	B-X
1	B-X
)	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
thrombolytic	B-X
agent	B-X
.	B-X
Continuous	B-X
growth	B-X
of	B-X
a	B-X
stably	B-X
transfected	B-X
,	B-X
methotrexate	B-X
amplified	B-X
,	B-X
dhfr-	B-X
CHO	B-X
cell	B-X
line	B-X
yields	B-X
up	B-X
to	B-X
60	B-X
mg	B-X
l-1	B-X
of	B-X
DSPA	B-X
alpha	B-X
1	B-X
.	B-X
Utilizing	B-X
an	B-X
engineered	B-X
baculovirus	B-X
10	B-X
mg	B-X
l-1	B-X
were	B-X
produced	B-X
in	B-X
batches	B-X
of	B-X
Sf9	B-X
insect	B-X
cells	B-X
.	B-X
Recombinant	B-X
DSPA	B-X
alpha	B-X
1	B-X
is	B-X
purified	B-X
from	B-X
both	B-X
sources	B-X
using	B-X
a	B-X
one-step	B-X
purification	B-X
protocol	B-X
.	B-X
Although	B-X
differences	B-X
in	B-X
glycosylation	B-X
were	B-X
detected	B-X
,	B-X
enzymatic	B-X
activity	B-X
and	B-X
fibrin	B-X
cofactor	B-X
dependency	B-X
are	B-X
unaffected	B-X
when	B-X
DSPA	B-X
alpha	B-X
1	B-X
derived	B-X
from	B-X
the	B-X
two	B-X
expression	B-X
systems	B-X
is	B-X
compared	B-X
.	B-X

Glycosylation	O
of	O
CD4	B-Protein
and	O
Thy	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
site-specific	B-X
glycosylation	B-X
of	B-X
soluble	B-X
recombinant	B-X
variants	B-X
of	B-X
human	B-X
and	B-X
rat	B-X
CD4	B-X
(	B-X
sCD4	B-X
)	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
identical	B-X
oligosaccharides	B-X
at	B-X
the	B-X
conserved	B-X
glycosylation	B-X
site	B-X
in	B-X
domain	B-X
3	B-X
of	B-X
rat	B-X
and	B-X
human	B-X
sCD4	B-X
and	B-X
the	B-X
greater	B-X
abundance	B-X
of	B-X
oligomannose	B-X
and	B-X
hybrid	B-X
type	B-X
glycans	B-X
at	B-X
the	B-X
non-conserved	B-X
glycosylation	B-X
site	B-X
of	B-X
rat	B-X
sCD4	B-X
clearly	B-X
indicate	B-X
that	B-X
the	B-X
protein	B-X
structure	B-X
influences	B-X
oligosaccharide	B-X
processing	B-X
.	B-X
Comparisons	B-X
of	B-X
rat	B-X
sCD4	B-X
glycopeptides	B-X
with	B-X
mutant	B-X
molecules	B-X
with	B-X
only	B-X
single	B-X
glycosylation	B-X
sites	B-X
and	B-X
with	B-X
a	B-X
truncated	B-X
form	B-X
containing	B-X
only	B-X
the	B-X
two	B-X
NH2-terminal	B-X
domains	B-X
,	B-X
indicate	B-X
that	B-X
independent	B-X
processing	B-X
occurs	B-X
at	B-X
each	B-X
glycosylation	B-X
site	B-X
and	B-X
that	B-X
domain	B-X
interactions	B-X
can	B-X
also	B-X
affect	B-X
oligosaccharide	B-X
processing	B-X
.	B-X
These	B-X
and	B-X
other	B-X
analyses	B-X
of	B-X
sCD2	B-X
expressed	B-X
in	B-X
CHO	B-X
cells	B-X
and	B-X
Thy-1	B-X
purified	B-X
from	B-X
various	B-X
tissues	B-X
suggest	B-X
that	B-X
the	B-X
diversity	B-X
of	B-X
oligosaccharide	B-X
structures	B-X
on	B-X
a	B-X
protein	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
location	B-X
of	B-X
the	B-X
glycosylation	B-X
sites	B-X
and	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
target	B-X
protein	B-X
,	B-X
cell	B-X
and	B-X
tissue	B-X
.	B-X

The	O
site	O
-	O
specific	O
glycosylation	O
of	O
soluble	O
recombinant	O
variants	O
of	O
human	O
and	O
rat	O
CD4	B-Protein
(	O
sCD4	B-Protein
)	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
has	O
been	O
characterized	O
.	O
<EOS>	B-X
The	B-X
rat	B-X
and	B-X
human	B-X
forms	B-X
of	B-X
the	B-X
T-cell	B-X
surface	B-X
glycoprotein	B-X
CD4	B-X
share	B-X
a	B-X
common	B-X
glycosylation	B-X
site	B-X
at	B-X
the	B-X
Asn270/271	B-X
position	B-X
but	B-X
differ	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
locations	B-X
of	B-X
the	B-X
second	B-X
glycosylation	B-X
sites	B-X
at	B-X
Asn159	B-X
(	B-X
rat	B-X
)	B-X
and	B-X
Asn300	B-X
(	B-X
human	B-X
)	B-X
.	B-X
The	B-X
glycosylation	B-X
of	B-X
soluble	B-X
recombinant	B-X
forms	B-X
of	B-X
human	B-X
and	B-X
rat	B-X
CD4	B-X
(	B-X
sCD4	B-X
)	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
The	B-X
most	B-X
obvious	B-X
differences	B-X
between	B-X
the	B-X
rat	B-X
and	B-X
human	B-X
sCD4	B-X
oligosaccharides	B-X
were	B-X
the	B-X
greater	B-X
abundance	B-X
of	B-X
oligomannose	B-X
and	B-X
hybrid	B-X
oligosaccharides	B-X
on	B-X
rat	B-X
sCD4	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
oligosaccharides	B-X
carrying	B-X
a	B-X
terminal	B-X
alpha-galactose	B-X
residue	B-X
on	B-X
human	B-X
sCD4	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
the	B-X
occurrence	B-X
of	B-X
alpha-galactose	B-X
residues	B-X
on	B-X
a	B-X
glycoprotein	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
Comparison	B-X
of	B-X
mutant	B-X
rat	B-X
sCD4	B-X
molecules	B-X
with	B-X
single	B-X
glycosylation	B-X
sites	B-X
and	B-X
glycopeptides	B-X
indicated	B-X
that	B-X
site-specific	B-X
and	B-X
independent	B-X
processing	B-X
occurred	B-X
at	B-X
each	B-X
glycosylation	B-X
site	B-X
.	B-X
The	B-X
glycosylation	B-X
at	B-X
the	B-X
conserved	B-X
site	B-X
at	B-X
Asn270	B-X
of	B-X
rat	B-X
sCD4	B-X
was	B-X
identical	B-X
to	B-X
that	B-X
seen	B-X
for	B-X
the	B-X
equivalent	B-X
site	B-X
in	B-X
human	B-X
sCD4	B-X
,	B-X
and	B-X
the	B-X
oligomannose	B-X
and	B-X
hybrid	B-X
structures	B-X
were	B-X
restricted	B-X
to	B-X
the	B-X
nonconserved	B-X
site	B-X
at	B-X
Asn159	B-X
in	B-X
rat	B-X
sCD4	B-X
.	B-X
However	B-X
,	B-X
there	B-X
was	B-X
more	B-X
oligosaccharide	B-X
processing	B-X
at	B-X
this	B-X
site	B-X
in	B-X
a	B-X
truncated	B-X
form	B-X
of	B-X
rat	B-X
sCD4	B-X
consisting	B-X
of	B-X
the	B-X
two	B-X
NH2-terminal	B-X
domains	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
not	B-X
only	B-X
the	B-X
local	B-X
three-dimensional	B-X
structure	B-X
but	B-X
also	B-X
domain	B-X
interactions	B-X
can	B-X
influence	B-X
the	B-X
processing	B-X
at	B-X
individual	B-X
glycosylation	B-X
sites	B-X
.	B-X

The	O
presence	O
of	O
identical	O
oligosaccharides	O
at	O
the	O
conserved	O
glycosylation	O
site	O
in	O
domain	O
3	O
of	O
rat	O
and	O
human	O
sCD4	B-Protein
and	O
the	O
greater	O
abundance	O
of	O
oligomannose	O
and	O
hybrid	O
type	O
glycans	O
at	O
the	O
non	O
-	O
conserved	O
glycosylation	O
site	O
of	O
rat	O
sCD4	B-Protein
clearly	O
indicate	O
that	O
the	O
protein	O
structure	O
influences	O
oligosaccharide	O
processing	O
.	O
<EOS>	B-X
The	B-X
site-specific	B-X
glycosylation	B-X
of	B-X
soluble	B-X
recombinant	B-X
variants	B-X
of	B-X
human	B-X
and	B-X
rat	B-X
CD4	B-X
(	B-X
sCD4	B-X
)	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
identical	B-X
oligosaccharides	B-X
at	B-X
the	B-X
conserved	B-X
glycosylation	B-X
site	B-X
in	B-X
domain	B-X
3	B-X
of	B-X
rat	B-X
and	B-X
human	B-X
sCD4	B-X
and	B-X
the	B-X
greater	B-X
abundance	B-X
of	B-X
oligomannose	B-X
and	B-X
hybrid	B-X
type	B-X
glycans	B-X
at	B-X
the	B-X
non-conserved	B-X
glycosylation	B-X
site	B-X
of	B-X
rat	B-X
sCD4	B-X
clearly	B-X
indicate	B-X
that	B-X
the	B-X
protein	B-X
structure	B-X
influences	B-X
oligosaccharide	B-X
processing	B-X
.	B-X
Comparisons	B-X
of	B-X
rat	B-X
sCD4	B-X
glycopeptides	B-X
with	B-X
mutant	B-X
molecules	B-X
with	B-X
only	B-X
single	B-X
glycosylation	B-X
sites	B-X
and	B-X
with	B-X
a	B-X
truncated	B-X
form	B-X
containing	B-X
only	B-X
the	B-X
two	B-X
NH2-terminal	B-X
domains	B-X
,	B-X
indicate	B-X
that	B-X
independent	B-X
processing	B-X
occurs	B-X
at	B-X
each	B-X
glycosylation	B-X
site	B-X
and	B-X
that	B-X
domain	B-X
interactions	B-X
can	B-X
also	B-X
affect	B-X
oligosaccharide	B-X
processing	B-X
.	B-X
These	B-X
and	B-X
other	B-X
analyses	B-X
of	B-X
sCD2	B-X
expressed	B-X
in	B-X
CHO	B-X
cells	B-X
and	B-X
Thy-1	B-X
purified	B-X
from	B-X
various	B-X
tissues	B-X
suggest	B-X
that	B-X
the	B-X
diversity	B-X
of	B-X
oligosaccharide	B-X
structures	B-X
on	B-X
a	B-X
protein	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
location	B-X
of	B-X
the	B-X
glycosylation	B-X
sites	B-X
and	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
target	B-X
protein	B-X
,	B-X
cell	B-X
and	B-X
tissue	B-X
.	B-X

Comparisons	O
of	O
rat	O
sCD4	B-Protein
glycopeptides	O
with	O
mutant	O
molecules	O
with	O
only	O
single	O
glycosylation	O
sites	O
and	O
with	O
a	O
truncated	O
form	O
containing	O
only	O
the	O
two	O
NH2	O
-	O
terminal	O
domains	O
,	O
indicate	O
that	O
independent	O
processing	O
occurs	O
at	O
each	O
glycosylation	O
site	O
and	O
that	O
domain	O
interactions	O
can	O
also	O
affect	O
oligosaccharide	O
processing	O
.	O
<EOS>	B-X
The	B-X
site-specific	B-X
glycosylation	B-X
of	B-X
soluble	B-X
recombinant	B-X
variants	B-X
of	B-X
human	B-X
and	B-X
rat	B-X
CD4	B-X
(	B-X
sCD4	B-X
)	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
identical	B-X
oligosaccharides	B-X
at	B-X
the	B-X
conserved	B-X
glycosylation	B-X
site	B-X
in	B-X
domain	B-X
3	B-X
of	B-X
rat	B-X
and	B-X
human	B-X
sCD4	B-X
and	B-X
the	B-X
greater	B-X
abundance	B-X
of	B-X
oligomannose	B-X
and	B-X
hybrid	B-X
type	B-X
glycans	B-X
at	B-X
the	B-X
non-conserved	B-X
glycosylation	B-X
site	B-X
of	B-X
rat	B-X
sCD4	B-X
clearly	B-X
indicate	B-X
that	B-X
the	B-X
protein	B-X
structure	B-X
influences	B-X
oligosaccharide	B-X
processing	B-X
.	B-X
Comparisons	B-X
of	B-X
rat	B-X
sCD4	B-X
glycopeptides	B-X
with	B-X
mutant	B-X
molecules	B-X
with	B-X
only	B-X
single	B-X
glycosylation	B-X
sites	B-X
and	B-X
with	B-X
a	B-X
truncated	B-X
form	B-X
containing	B-X
only	B-X
the	B-X
two	B-X
NH2-terminal	B-X
domains	B-X
,	B-X
indicate	B-X
that	B-X
independent	B-X
processing	B-X
occurs	B-X
at	B-X
each	B-X
glycosylation	B-X
site	B-X
and	B-X
that	B-X
domain	B-X
interactions	B-X
can	B-X
also	B-X
affect	B-X
oligosaccharide	B-X
processing	B-X
.	B-X
These	B-X
and	B-X
other	B-X
analyses	B-X
of	B-X
sCD2	B-X
expressed	B-X
in	B-X
CHO	B-X
cells	B-X
and	B-X
Thy-1	B-X
purified	B-X
from	B-X
various	B-X
tissues	B-X
suggest	B-X
that	B-X
the	B-X
diversity	B-X
of	B-X
oligosaccharide	B-X
structures	B-X
on	B-X
a	B-X
protein	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
location	B-X
of	B-X
the	B-X
glycosylation	B-X
sites	B-X
and	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
target	B-X
protein	B-X
,	B-X
cell	B-X
and	B-X
tissue	B-X
.	B-X

These	O
and	O
other	O
analyses	O
of	O
sCD2	B-Protein
expressed	O
in	O
CHO	O
cells	O
and	O
Thy	B-Protein
-	I-Protein
1	I-Protein
purified	O
from	O
various	O
tissues	O
suggest	O
that	O
the	O
diversity	O
of	O
oligosaccharide	O
structures	O
on	O
a	O
protein	O
is	O
regulated	O
by	O
the	O
location	O
of	O
the	O
glycosylation	O
sites	O
and	O
the	O
nature	O
of	O
the	O
target	O
protein	O
,	O
cell	O
and	O
tissue	O
.	O

The	O
functional	O
significance	O
of	O
this	O
control	O
remains	O
to	O
be	O
determined	O
.	O
<EOS>	B-X
A	B-X
thorough	B-X
PubMed	B-X
search	B-X
was	B-X
performed	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
meta-analyses	B-X
and	B-X
randomized	B-X
controlled	B-X
trials	B-X
when	B-X
available	B-X
.	B-X
Starting	B-X
feeds	B-X
later	B-X
rather	B-X
than	B-X
earlier	B-X
,	B-X
advancing	B-X
feeds	B-X
slowly	B-X
and	B-X
continuous	B-X
feeds	B-X
have	B-X
not	B-X
been	B-X
shown	B-X
to	B-X
prevent	B-X
NEC	B-X
and	B-X
breast	B-X
milk	B-X
remains	B-X
the	B-X
only	B-X
effective	B-X
prevention	B-X
strategy	B-X
.	B-X
Following	B-X
resection	B-X
,	B-X
intestinal	B-X
adaptation	B-X
occurs	B-X
,	B-X
during	B-X
which	B-X
villi	B-X
lengthen	B-X
and	B-X
crypts	B-X
deepen	B-X
to	B-X
increase	B-X
the	B-X
functional	B-X
capacity	B-X
of	B-X
remaining	B-X
bowel	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
systematic	B-X
review	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
use	B-X
of	B-X
exercise	B-X
versus	B-X
waiting	B-X
list	B-X
control	B-X
groups	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
anxiety	B-X
and	B-X
also	B-X
to	B-X
assess	B-X
the	B-X
benefit	B-X
of	B-X
high	B-X
intensity	B-X
exercise	B-X
vs	B-X
low	B-X
intensity	B-X
exercise	B-X
.	B-X
The	B-X
comparison	B-X
groups	B-X
were	B-X
either	B-X
a	B-X
waiting	B-X
list	B-X
control	B-X
group	B-X
or	B-X
low	B-X
intensity	B-X
exercise	B-X
.	B-X

Protein	O
carboxyl	O
methylation	O
in	O
Saccharomyces	O
cerevisiae	O
:	O
evidence	O
for	O
STE14	B-Protein
-	O
dependent	O
and	O
STE14	B-Protein
-	O
independent	O
pathways	O
.	O
<EOS>	B-X
We	B-X
incubated	B-X
yeast	B-X
cells	B-X
(	B-X
Saccharomyces	B-X
cerevisiae	B-X
)	B-X
with	B-X
the	B-X
methyl	B-X
donor	B-X
S-adenosyl-L-	B-X
[	B-X
methyl-3H	B-X
]	B-X
methionine	B-X
and	B-X
then	B-X
fractionated	B-X
their	B-X
cellular	B-X
components	B-X
by	B-X
gel	B-X
electrophoresis	B-X
in	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
.	B-X
The	B-X
38-	B-X
,	B-X
33-	B-X
,	B-X
31-	B-X
,	B-X
and	B-X
26-kDa	B-X
polypeptides	B-X
were	B-X
not	B-X
methyl-esterified	B-X
in	B-X
an	B-X
isogenic	B-X
yeast	B-X
strain	B-X
lacking	B-X
the	B-X
STE14	B-X
gene	B-X
encoding	B-X
a	B-X
C-terminal	B-X
isoprenylcysteine	B-X
methyltransferase	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
are	B-X
substrates	B-X
for	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
amount	B-X
of	B-X
the	B-X
methylated	B-X
49-kDa	B-X
polypeptide	B-X
is	B-X
reduced	B-X
in	B-X
the	B-X
ste14	B-X
mutant	B-X
,	B-X
indicating	B-X
that	B-X
at	B-X
least	B-X
two	B-X
methylated	B-X
polypeptides	B-X
are	B-X
present	B-X
--	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
and	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
The	B-X
35-kDa	B-X
polypeptide	B-X
also	B-X
appears	B-X
to	B-X
be	B-X
methylated	B-X
by	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
When	B-X
cells	B-X
were	B-X
incubated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
cycloheximide	B-X
,	B-X
little	B-X
or	B-X
no	B-X
methylation	B-X
of	B-X
the	B-X
STE14-dependent	B-X
species	B-X
was	B-X
detected	B-X
while	B-X
the	B-X
methylation	B-X
of	B-X
the	B-X
STE14-independent	B-X
substrates	B-X
was	B-X
unaffected	B-X
.	B-X

We	O
incubated	O
yeast	O
cells	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
with	O
the	O
methyl	O
donor	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
[	O
methyl	O
-	O
3H	O
]	O
methionine	O
and	O
then	O
fractionated	O
their	O
cellular	O
components	O
by	O
gel	O
electrophoresis	O
in	O
sodium	O
dodecyl	O
sulfate	O
.	O

By	O
analyzing	O
gel	O
slices	O
for	O
[	O
3H	O
]	O
methyl	O
esters	O
by	O
a	O
vapor	O
-	O
phase	O
diffusion	O
assay	O
,	O
we	O
detect	O
major	O
methyl	O
-	O
esterified	O
species	O
that	O
migrate	O
at	O
apparent	O
polypeptide	O
sizes	O
of	O
24	O
and	O
22	O
kDa	O
and	O
minor	O
species	O
of	O
49	O
,	O
38	O
,	O
35	O
,	O
33	O
,	O
31	O
,	O
and	O
26	O
kDa	O
.	O
<EOS>	B-X
We	B-X
incubated	B-X
yeast	B-X
cells	B-X
(	B-X
Saccharomyces	B-X
cerevisiae	B-X
)	B-X
with	B-X
the	B-X
methyl	B-X
donor	B-X
S-adenosyl-L-	B-X
[	B-X
methyl-3H	B-X
]	B-X
methionine	B-X
and	B-X
then	B-X
fractionated	B-X
their	B-X
cellular	B-X
components	B-X
by	B-X
gel	B-X
electrophoresis	B-X
in	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
.	B-X
By	B-X
analyzing	B-X
gel	B-X
slices	B-X
for	B-X
[	B-X
3H	B-X
]	B-X
methyl	B-X
esters	B-X
by	B-X
a	B-X
vapor-phase	B-X
diffusion	B-X
assay	B-X
,	B-X
we	B-X
detect	B-X
major	B-X
methyl-esterified	B-X
species	B-X
that	B-X
migrate	B-X
at	B-X
apparent	B-X
polypeptide	B-X
sizes	B-X
of	B-X
24	B-X
and	B-X
22	B-X
kDa	B-X
and	B-X
minor	B-X
species	B-X
of	B-X
49	B-X
,	B-X
38	B-X
,	B-X
35	B-X
,	B-X
33	B-X
,	B-X
31	B-X
,	B-X
and	B-X
26	B-X
kDa	B-X
.	B-X
Incubation	B-X
of	B-X
extracts	B-X
from	B-X
labeled	B-X
cells	B-X
with	B-X
ribonuclease	B-X
A	B-X
or	B-X
proteinase	B-X
K	B-X
revealed	B-X
that	B-X
the	B-X
24-	B-X
and	B-X
22-kDa	B-X
species	B-X
represent	B-X
methyl-esterified	B-X
RNAs	B-X
,	B-X
whereas	B-X
the	B-X
other	B-X
species	B-X
are	B-X
methyl-esterified	B-X
polypeptides	B-X
.	B-X
The	B-X
38-	B-X
,	B-X
33-	B-X
,	B-X
31-	B-X
,	B-X
and	B-X
26-kDa	B-X
polypeptides	B-X
were	B-X
not	B-X
methyl-esterified	B-X
in	B-X
an	B-X
isogenic	B-X
yeast	B-X
strain	B-X
lacking	B-X
the	B-X
STE14	B-X
gene	B-X
encoding	B-X
a	B-X
C-terminal	B-X
isoprenylcysteine	B-X
methyltransferase	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
are	B-X
substrates	B-X
for	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
amount	B-X
of	B-X
the	B-X
methylated	B-X
49-kDa	B-X
polypeptide	B-X
is	B-X
reduced	B-X
in	B-X
the	B-X
ste14	B-X
mutant	B-X
,	B-X
indicating	B-X
that	B-X
at	B-X
least	B-X
two	B-X
methylated	B-X
polypeptides	B-X
are	B-X
present	B-X
--	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
and	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
The	B-X
35-kDa	B-X
polypeptide	B-X
also	B-X
appears	B-X
to	B-X
be	B-X
methylated	B-X
by	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
When	B-X
cells	B-X
were	B-X
incubated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
cycloheximide	B-X
,	B-X
little	B-X
or	B-X
no	B-X
methylation	B-X
of	B-X
the	B-X
STE14-dependent	B-X
species	B-X
was	B-X
detected	B-X
while	B-X
the	B-X
methylation	B-X
of	B-X
the	B-X
STE14-independent	B-X
substrates	B-X
was	B-X
unaffected	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
revealed	B-X
significant	B-X
turnover	B-X
of	B-X
all	B-X
of	B-X
the	B-X
methylated	B-X
species	B-X
in	B-X
a	B-X
4-h	B-X
period	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
38-kDa	B-X
polypeptide	B-X
.	B-X

Incubation	O
of	O
extracts	O
from	O
labeled	O
cells	O
with	O
ribonuclease	B-Protein
A	I-Protein
or	O
proteinase	B-Protein
K	I-Protein
revealed	O
that	O
the	O
24	O
-	O
and	O
22	O
-	O
kDa	O
species	O
represent	O
methyl	O
-	O
esterified	O
RNAs	O
,	O
whereas	O
the	O
other	O
species	O
are	O
methyl	O
-	O
esterified	O
polypeptides	O
.	O
<EOS>	B-X
Onconase	B-X
,	B-X
or	B-X
P-30	B-X
,	B-X
is	B-X
a	B-X
protein	B-X
initially	B-X
purified	B-X
from	B-X
extracts	B-X
of	B-X
Rana	B-X
pipiens	B-X
oocytes	B-X
and	B-X
early	B-X
embryos	B-X
based	B-X
upon	B-X
its	B-X
anticancer	B-X
activity	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
cultured	B-X
9L	B-X
glioma	B-X
cells	B-X
,	B-X
onconase	B-X
inhibits	B-X
protein	B-X
synthesis	B-X
with	B-X
an	B-X
IC50	B-X
of	B-X
about	B-X
10	B-X
(	B-X
-7	B-X
)	B-X
M.	B-X
The	B-X
inhibition	B-X
of	B-X
protein	B-X
synthesis	B-X
correlates	B-X
with	B-X
cell	B-X
death	B-X
determined	B-X
by	B-X
clonogenic	B-X
assays	B-X
.	B-X
125I-Labeled	B-X
onconase	B-X
binds	B-X
to	B-X
specific	B-X
sites	B-X
on	B-X
cultured	B-X
9L	B-X
glioma	B-X
cells	B-X
.	B-X
Scatchard	B-X
analysis	B-X
of	B-X
the	B-X
binding	B-X
data	B-X
shows	B-X
that	B-X
onconase	B-X
appears	B-X
to	B-X
bind	B-X
to	B-X
cells	B-X
with	B-X
two	B-X
different	B-X
affinities	B-X
,	B-X
one	B-X
with	B-X
a	B-X
Kd	B-X
of	B-X
6.2	B-X
x	B-X
10	B-X
(	B-X
-8	B-X
)	B-X
and	B-X
another	B-X
of	B-X
2.5	B-X
x	B-X
10	B-X
(	B-X
-7	B-X
)	B-X
M.	B-X
Each	B-X
cell	B-X
could	B-X
bind	B-X
about	B-X
3	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
molecules	B-X
of	B-X
onconase	B-X
at	B-X
each	B-X
of	B-X
the	B-X
two	B-X
affinity	B-X
sites	B-X
.	B-X
The	B-X
low	B-X
affinity	B-X
Kd	B-X
is	B-X
similar	B-X
to	B-X
the	B-X
IC50	B-X
for	B-X
onconase	B-X
toxicity	B-X
.	B-X
Incubation	B-X
at	B-X
4	B-X
degrees	B-X
C	B-X
increased	B-X
the	B-X
binding	B-X
of	B-X
onconase	B-X
to	B-X
cells	B-X
relative	B-X
to	B-X
37	B-X
degrees	B-X
C	B-X
binding	B-X
and	B-X
also	B-X
increased	B-X
the	B-X
sensitivity	B-X
of	B-X
cells	B-X
to	B-X
onconase	B-X
toxicity	B-X
,	B-X
indicating	B-X
that	B-X
receptor	B-X
binding	B-X
may	B-X
be	B-X
an	B-X
initial	B-X
step	B-X
in	B-X
cell	B-X
toxicity	B-X
.	B-X
Ribonuclease	B-X
activity	B-X
appears	B-X
necessary	B-X
for	B-X
onconase	B-X
toxicity	B-X
because	B-X
alkylated	B-X
onconase	B-X
,	B-X
which	B-X
only	B-X
retains	B-X
2	B-X
%	B-X
of	B-X
the	B-X
ribonuclease	B-X
activity	B-X
,	B-X
was	B-X
at	B-X
least	B-X
100-fold	B-X
less	B-X
potent	B-X
in	B-X
inhibiting	B-X
protein	B-X
synthesis	B-X
in	B-X
cells	B-X
.	B-X
Onconase	B-X
inhibition	B-X
of	B-X
protein	B-X
synthesis	B-X
in	B-X
9L	B-X
cells	B-X
coincides	B-X
with	B-X
the	B-X
degradation	B-X
of	B-X
cellular	B-X
28	B-X
S	B-X
and	B-X
18	B-X
S	B-X
rRNA	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
RNase	B-X
A	B-X
,	B-X
onconase	B-X
is	B-X
resistant	B-X
to	B-X
two	B-X
RNase	B-X
inhibitors	B-X
,	B-X
placental	B-X
ribonuclease	B-X
inhibitor	B-X
and	B-X
Inhibit-Ace	B-X
.	B-X
Northern	B-X
hybridization	B-X
with	B-X
placental	B-X
ribonuclease	B-X
inhibitor	B-X
cDNA	B-X
probe	B-X
indicates	B-X
that	B-X
9L	B-X
glioma	B-X
cells	B-X
contain	B-X
endogenous	B-X
placental	B-X
ribonuclease	B-X
inhibitor	B-X
mRNA	B-X
.	B-X

The	O
38	O
-	O
,	O
33	O
-	O
,	O
31	O
-	O
,	O
and	O
26	O
-	O
kDa	O
polypeptides	O
were	O
not	O
methyl	O
-	O
esterified	O
in	O
an	O
isogenic	O
yeast	O
strain	O
lacking	O
the	O
STE14	B-Protein
gene	O
encoding	O
a	O
C	O
-	O
terminal	O
isoprenylcysteine	O
methyltransferase	O
,	O
suggesting	O
that	O
they	O
are	O
substrates	O
for	O
the	O
STE14	B-Protein
methyltransferase	O
.	O
<EOS>	B-X
We	B-X
incubated	B-X
yeast	B-X
cells	B-X
(	B-X
Saccharomyces	B-X
cerevisiae	B-X
)	B-X
with	B-X
the	B-X
methyl	B-X
donor	B-X
S-adenosyl-L-	B-X
[	B-X
methyl-3H	B-X
]	B-X
methionine	B-X
and	B-X
then	B-X
fractionated	B-X
their	B-X
cellular	B-X
components	B-X
by	B-X
gel	B-X
electrophoresis	B-X
in	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
.	B-X
By	B-X
analyzing	B-X
gel	B-X
slices	B-X
for	B-X
[	B-X
3H	B-X
]	B-X
methyl	B-X
esters	B-X
by	B-X
a	B-X
vapor-phase	B-X
diffusion	B-X
assay	B-X
,	B-X
we	B-X
detect	B-X
major	B-X
methyl-esterified	B-X
species	B-X
that	B-X
migrate	B-X
at	B-X
apparent	B-X
polypeptide	B-X
sizes	B-X
of	B-X
24	B-X
and	B-X
22	B-X
kDa	B-X
and	B-X
minor	B-X
species	B-X
of	B-X
49	B-X
,	B-X
38	B-X
,	B-X
35	B-X
,	B-X
33	B-X
,	B-X
31	B-X
,	B-X
and	B-X
26	B-X
kDa	B-X
.	B-X
Incubation	B-X
of	B-X
extracts	B-X
from	B-X
labeled	B-X
cells	B-X
with	B-X
ribonuclease	B-X
A	B-X
or	B-X
proteinase	B-X
K	B-X
revealed	B-X
that	B-X
the	B-X
24-	B-X
and	B-X
22-kDa	B-X
species	B-X
represent	B-X
methyl-esterified	B-X
RNAs	B-X
,	B-X
whereas	B-X
the	B-X
other	B-X
species	B-X
are	B-X
methyl-esterified	B-X
polypeptides	B-X
.	B-X
The	B-X
38-	B-X
,	B-X
33-	B-X
,	B-X
31-	B-X
,	B-X
and	B-X
26-kDa	B-X
polypeptides	B-X
were	B-X
not	B-X
methyl-esterified	B-X
in	B-X
an	B-X
isogenic	B-X
yeast	B-X
strain	B-X
lacking	B-X
the	B-X
STE14	B-X
gene	B-X
encoding	B-X
a	B-X
C-terminal	B-X
isoprenylcysteine	B-X
methyltransferase	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
are	B-X
substrates	B-X
for	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
amount	B-X
of	B-X
the	B-X
methylated	B-X
49-kDa	B-X
polypeptide	B-X
is	B-X
reduced	B-X
in	B-X
the	B-X
ste14	B-X
mutant	B-X
,	B-X
indicating	B-X
that	B-X
at	B-X
least	B-X
two	B-X
methylated	B-X
polypeptides	B-X
are	B-X
present	B-X
--	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
and	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
The	B-X
35-kDa	B-X
polypeptide	B-X
also	B-X
appears	B-X
to	B-X
be	B-X
methylated	B-X
by	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
When	B-X
cells	B-X
were	B-X
incubated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
cycloheximide	B-X
,	B-X
little	B-X
or	B-X
no	B-X
methylation	B-X
of	B-X
the	B-X
STE14-dependent	B-X
species	B-X
was	B-X
detected	B-X
while	B-X
the	B-X
methylation	B-X
of	B-X
the	B-X
STE14-independent	B-X
substrates	B-X
was	B-X
unaffected	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
revealed	B-X
significant	B-X
turnover	B-X
of	B-X
all	B-X
of	B-X
the	B-X
methylated	B-X
species	B-X
in	B-X
a	B-X
4-h	B-X
period	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
38-kDa	B-X
polypeptide	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

On	O
the	O
other	O
hand	O
,	O
the	O
amount	O
of	O
the	O
methylated	O
49	O
-	O
kDa	O
polypeptide	O
is	O
reduced	O
in	O
the	O
ste14	B-Protein
mutant	O
,	O
indicating	O
that	O
at	O
least	O
two	O
methylated	O
polypeptides	O
are	O
present	O
-	O
-	O
one	O
a	O
substrate	O
of	O
the	O
STE14	B-Protein
methyltransferase	O
and	O
one	O
a	O
substrate	O
of	O
a	O
STE14	B-Protein
-	O
independent	O
methyltransferase	O
.	O

The	O
35	O
-	O
kDa	O
polypeptide	O
also	O
appears	O
to	O
be	O
methylated	O
by	O
a	O
STE14	B-Protein
-	O
independent	O
methyltransferase	O
.	O
<EOS>	B-X
By	B-X
analyzing	B-X
gel	B-X
slices	B-X
for	B-X
[	B-X
3H	B-X
]	B-X
methyl	B-X
esters	B-X
by	B-X
a	B-X
vapor-phase	B-X
diffusion	B-X
assay	B-X
,	B-X
we	B-X
detect	B-X
major	B-X
methyl-esterified	B-X
species	B-X
that	B-X
migrate	B-X
at	B-X
apparent	B-X
polypeptide	B-X
sizes	B-X
of	B-X
24	B-X
and	B-X
22	B-X
kDa	B-X
and	B-X
minor	B-X
species	B-X
of	B-X
49	B-X
,	B-X
38	B-X
,	B-X
35	B-X
,	B-X
33	B-X
,	B-X
31	B-X
,	B-X
and	B-X
26	B-X
kDa	B-X
.	B-X
Incubation	B-X
of	B-X
extracts	B-X
from	B-X
labeled	B-X
cells	B-X
with	B-X
ribonuclease	B-X
A	B-X
or	B-X
proteinase	B-X
K	B-X
revealed	B-X
that	B-X
the	B-X
24-	B-X
and	B-X
22-kDa	B-X
species	B-X
represent	B-X
methyl-esterified	B-X
RNAs	B-X
,	B-X
whereas	B-X
the	B-X
other	B-X
species	B-X
are	B-X
methyl-esterified	B-X
polypeptides	B-X
.	B-X
The	B-X
38-	B-X
,	B-X
33-	B-X
,	B-X
31-	B-X
,	B-X
and	B-X
26-kDa	B-X
polypeptides	B-X
were	B-X
not	B-X
methyl-esterified	B-X
in	B-X
an	B-X
isogenic	B-X
yeast	B-X
strain	B-X
lacking	B-X
the	B-X
STE14	B-X
gene	B-X
encoding	B-X
a	B-X
C-terminal	B-X
isoprenylcysteine	B-X
methyltransferase	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
are	B-X
substrates	B-X
for	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
amount	B-X
of	B-X
the	B-X
methylated	B-X
49-kDa	B-X
polypeptide	B-X
is	B-X
reduced	B-X
in	B-X
the	B-X
ste14	B-X
mutant	B-X
,	B-X
indicating	B-X
that	B-X
at	B-X
least	B-X
two	B-X
methylated	B-X
polypeptides	B-X
are	B-X
present	B-X
--	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
and	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
The	B-X
35-kDa	B-X
polypeptide	B-X
also	B-X
appears	B-X
to	B-X
be	B-X
methylated	B-X
by	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
When	B-X
cells	B-X
were	B-X
incubated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
cycloheximide	B-X
,	B-X
little	B-X
or	B-X
no	B-X
methylation	B-X
of	B-X
the	B-X
STE14-dependent	B-X
species	B-X
was	B-X
detected	B-X
while	B-X
the	B-X
methylation	B-X
of	B-X
the	B-X
STE14-independent	B-X
substrates	B-X
was	B-X
unaffected	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
revealed	B-X
significant	B-X
turnover	B-X
of	B-X
all	B-X
of	B-X
the	B-X
methylated	B-X
species	B-X
in	B-X
a	B-X
4-h	B-X
period	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
38-kDa	B-X
polypeptide	B-X
.	B-X

When	O
cells	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
little	O
or	O
no	O
methylation	O
of	O
the	O
STE14	B-Protein
-	O
dependent	O
species	O
was	O
detected	O
while	O
the	O
methylation	O
of	O
the	O
STE14	B-Protein
-	O
independent	O
substrates	O
was	O
unaffected	O
.	O
<EOS>	B-X
We	B-X
incubated	B-X
yeast	B-X
cells	B-X
(	B-X
Saccharomyces	B-X
cerevisiae	B-X
)	B-X
with	B-X
the	B-X
methyl	B-X
donor	B-X
S-adenosyl-L-	B-X
[	B-X
methyl-3H	B-X
]	B-X
methionine	B-X
and	B-X
then	B-X
fractionated	B-X
their	B-X
cellular	B-X
components	B-X
by	B-X
gel	B-X
electrophoresis	B-X
in	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
.	B-X
By	B-X
analyzing	B-X
gel	B-X
slices	B-X
for	B-X
[	B-X
3H	B-X
]	B-X
methyl	B-X
esters	B-X
by	B-X
a	B-X
vapor-phase	B-X
diffusion	B-X
assay	B-X
,	B-X
we	B-X
detect	B-X
major	B-X
methyl-esterified	B-X
species	B-X
that	B-X
migrate	B-X
at	B-X
apparent	B-X
polypeptide	B-X
sizes	B-X
of	B-X
24	B-X
and	B-X
22	B-X
kDa	B-X
and	B-X
minor	B-X
species	B-X
of	B-X
49	B-X
,	B-X
38	B-X
,	B-X
35	B-X
,	B-X
33	B-X
,	B-X
31	B-X
,	B-X
and	B-X
26	B-X
kDa	B-X
.	B-X
Incubation	B-X
of	B-X
extracts	B-X
from	B-X
labeled	B-X
cells	B-X
with	B-X
ribonuclease	B-X
A	B-X
or	B-X
proteinase	B-X
K	B-X
revealed	B-X
that	B-X
the	B-X
24-	B-X
and	B-X
22-kDa	B-X
species	B-X
represent	B-X
methyl-esterified	B-X
RNAs	B-X
,	B-X
whereas	B-X
the	B-X
other	B-X
species	B-X
are	B-X
methyl-esterified	B-X
polypeptides	B-X
.	B-X
The	B-X
38-	B-X
,	B-X
33-	B-X
,	B-X
31-	B-X
,	B-X
and	B-X
26-kDa	B-X
polypeptides	B-X
were	B-X
not	B-X
methyl-esterified	B-X
in	B-X
an	B-X
isogenic	B-X
yeast	B-X
strain	B-X
lacking	B-X
the	B-X
STE14	B-X
gene	B-X
encoding	B-X
a	B-X
C-terminal	B-X
isoprenylcysteine	B-X
methyltransferase	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
are	B-X
substrates	B-X
for	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
amount	B-X
of	B-X
the	B-X
methylated	B-X
49-kDa	B-X
polypeptide	B-X
is	B-X
reduced	B-X
in	B-X
the	B-X
ste14	B-X
mutant	B-X
,	B-X
indicating	B-X
that	B-X
at	B-X
least	B-X
two	B-X
methylated	B-X
polypeptides	B-X
are	B-X
present	B-X
--	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
STE14	B-X
methyltransferase	B-X
and	B-X
one	B-X
a	B-X
substrate	B-X
of	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
The	B-X
35-kDa	B-X
polypeptide	B-X
also	B-X
appears	B-X
to	B-X
be	B-X
methylated	B-X
by	B-X
a	B-X
STE14-independent	B-X
methyltransferase	B-X
.	B-X
When	B-X
cells	B-X
were	B-X
incubated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
cycloheximide	B-X
,	B-X
little	B-X
or	B-X
no	B-X
methylation	B-X
of	B-X
the	B-X
STE14-dependent	B-X
species	B-X
was	B-X
detected	B-X
while	B-X
the	B-X
methylation	B-X
of	B-X
the	B-X
STE14-independent	B-X
substrates	B-X
was	B-X
unaffected	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
revealed	B-X
significant	B-X
turnover	B-X
of	B-X
all	B-X
of	B-X
the	B-X
methylated	B-X
species	B-X
in	B-X
a	B-X
4-h	B-X
period	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
38-kDa	B-X
polypeptide	B-X
.	B-X

Pulse	O
-	O
chase	O
studies	O
revealed	O
significant	O
turnover	O
of	O
all	O
of	O
the	O
methylated	O
species	O
in	O
a	O
4	O
-	O
h	O
period	O
,	O
with	O
the	O
exception	O
of	O
the	O
38	O
-	O
kDa	O
polypeptide	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Reconstitution	O
of	O
the	O
folding	O
pathway	O
of	O
collagen	O
in	O
a	O
cell	O
-	O
free	O
system	O
:	O
formation	O
of	O
correctly	O
aligned	O
and	O
hydroxylated	O
triple	O
helices	O
.	O

We	O
describe	O
here	O
a	O
cell	O
-	O
free	O
system	O
which	O
will	O
carry	O
out	O
the	O
initial	O
stages	O
in	O
the	O
synthesis	O
,	O
post	O
-	O
translational	O
modification	O
and	O
assembly	O
of	O
type	B-Protein
-	I-Protein
X	I-Protein
collagen	I-Protein
.	O

The	O
mRNA	O
coding	O
for	O
bovine	O
type	B-Protein
-	I-Protein
X	I-Protein
collagen	I-Protein
was	O
synthesized	O
in	O
vitro	O
and	O
translated	O
in	O
a	O
rabbit	O
reticulocyte	O
lysate	O
to	O
yield	O
a	O
protein	O
that	O
was	O
collagenase	O
sensitive	O
and	O
could	O
be	O
immunoprecipitated	O
with	O
antibodies	O
raised	O
to	O
purified	O
avian	O
type	B-Protein
-	I-Protein
X	I-Protein
collagen	I-Protein
.	O

When	O
type	B-Protein
-	I-Protein
X	I-Protein
collagen	I-Protein
was	O
synthesized	O
in	O
the	O
absence	O
of	O
added	O
microsomes	O
or	O
in	O
the	O
presence	O
of	O
canine	O
pancreas	O
microsomes	O
,	O
the	O
translation	O
products	O
showed	O
partial	O
resistance	O
to	O
digestion	O
with	O
pepsin	O
but	O
were	O
completely	O
degraded	O
with	O
a	O
mixture	O
of	O
chymotrypsin	O
and	O
trypsin	O
,	O
suggesting	O
that	O
only	O
incorrectly	O
aligned	O
non	O
-	O
native	O
collagen	O
molecules	O
were	O
synthesized	O
under	O
these	O
conditions	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
here	B-X
a	B-X
cell-free	B-X
system	B-X
which	B-X
will	B-X
carry	B-X
out	B-X
the	B-X
initial	B-X
stages	B-X
in	B-X
the	B-X
synthesis	B-X
,	B-X
post-translational	B-X
modification	B-X
and	B-X
assembly	B-X
of	B-X
type-X	B-X
collagen	B-X
.	B-X
The	B-X
mRNA	B-X
coding	B-X
for	B-X
bovine	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
vitro	B-X
and	B-X
translated	B-X
in	B-X
a	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
to	B-X
yield	B-X
a	B-X
protein	B-X
that	B-X
was	B-X
collagenase	B-X
sensitive	B-X
and	B-X
could	B-X
be	B-X
immunoprecipitated	B-X
with	B-X
antibodies	B-X
raised	B-X
to	B-X
purified	B-X
avian	B-X
type-X	B-X
collagen	B-X
.	B-X
When	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
added	B-X
microsomes	B-X
or	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
canine	B-X
pancreas	B-X
microsomes	B-X
,	B-X
the	B-X
translation	B-X
products	B-X
showed	B-X
partial	B-X
resistance	B-X
to	B-X
digestion	B-X
with	B-X
pepsin	B-X
but	B-X
were	B-X
completely	B-X
degraded	B-X
with	B-X
a	B-X
mixture	B-X
of	B-X
chymotrypsin	B-X
and	B-X
trypsin	B-X
,	B-X
suggesting	B-X
that	B-X
only	B-X
incorrectly	B-X
aligned	B-X
non-native	B-X
collagen	B-X
molecules	B-X
were	B-X
synthesized	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
microsomes	B-X
derived	B-X
from	B-X
avian	B-X
fibroblasts	B-X
or	B-X
a	B-X
human	B-X
fibrosarcoma	B-X
cell	B-X
line	B-X
,	B-X
the	B-X
translocated	B-X
product	B-X
migrated	B-X
as	B-X
a	B-X
diffuse	B-X
band	B-X
characteristic	B-X
of	B-X
hydroxylated	B-X
collagen	B-X
.	B-X
The	B-X
synthesized	B-X
polypeptides	B-X
were	B-X
also	B-X
resistant	B-X
to	B-X
both	B-X
pepsin	B-X
and	B-X
trypsin/chymotrypsin	B-X
digestion	B-X
,	B-X
demonstrating	B-X
the	B-X
formation	B-X
of	B-X
correctly	B-X
aligned	B-X
native	B-X
collagen	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
collagen	B-X
polypeptides	B-X
assembled	B-X
into	B-X
higher-order	B-X
structures	B-X
,	B-X
possibly	B-X
trimers	B-X
,	B-X
which	B-X
were	B-X
stabilized	B-X
by	B-X
interchain	B-X
disulphide	B-X
bonds	B-X
.	B-X
The	B-X
collagen	B-X
helix	B-X
synthesized	B-X
in	B-X
vitro	B-X
had	B-X
a	B-X
melting	B-X
temperature	B-X
of	B-X
41	B-X
degrees	B-X
C	B-X
which	B-X
is	B-X
comparable	B-X
with	B-X
the	B-X
protein	B-X
synthesized	B-X
in	B-X
vivo	B-X
,	B-X
further	B-X
demonstrating	B-X
that	B-X
the	B-X
polypeptides	B-X
were	B-X
hydroxylated	B-X
and	B-X
that	B-X
the	B-X
triple	B-X
helix	B-X
formed	B-X
was	B-X
correctly	B-X
aligned	B-X
.	B-X

When	O
the	O
protein	O
was	O
synthesized	O
in	O
the	O
presence	O
of	O
microsomes	O
derived	O
from	O
avian	O
fibroblasts	O
or	O
a	O
human	O
fibrosarcoma	O
cell	O
line	O
,	O
the	O
translocated	O
product	O
migrated	O
as	O
a	O
diffuse	O
band	O
characteristic	O
of	O
hydroxylated	O
collagen	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
here	B-X
a	B-X
cell-free	B-X
system	B-X
which	B-X
will	B-X
carry	B-X
out	B-X
the	B-X
initial	B-X
stages	B-X
in	B-X
the	B-X
synthesis	B-X
,	B-X
post-translational	B-X
modification	B-X
and	B-X
assembly	B-X
of	B-X
type-X	B-X
collagen	B-X
.	B-X
The	B-X
mRNA	B-X
coding	B-X
for	B-X
bovine	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
vitro	B-X
and	B-X
translated	B-X
in	B-X
a	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
to	B-X
yield	B-X
a	B-X
protein	B-X
that	B-X
was	B-X
collagenase	B-X
sensitive	B-X
and	B-X
could	B-X
be	B-X
immunoprecipitated	B-X
with	B-X
antibodies	B-X
raised	B-X
to	B-X
purified	B-X
avian	B-X
type-X	B-X
collagen	B-X
.	B-X
When	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
added	B-X
microsomes	B-X
or	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
canine	B-X
pancreas	B-X
microsomes	B-X
,	B-X
the	B-X
translation	B-X
products	B-X
showed	B-X
partial	B-X
resistance	B-X
to	B-X
digestion	B-X
with	B-X
pepsin	B-X
but	B-X
were	B-X
completely	B-X
degraded	B-X
with	B-X
a	B-X
mixture	B-X
of	B-X
chymotrypsin	B-X
and	B-X
trypsin	B-X
,	B-X
suggesting	B-X
that	B-X
only	B-X
incorrectly	B-X
aligned	B-X
non-native	B-X
collagen	B-X
molecules	B-X
were	B-X
synthesized	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
microsomes	B-X
derived	B-X
from	B-X
avian	B-X
fibroblasts	B-X
or	B-X
a	B-X
human	B-X
fibrosarcoma	B-X
cell	B-X
line	B-X
,	B-X
the	B-X
translocated	B-X
product	B-X
migrated	B-X
as	B-X
a	B-X
diffuse	B-X
band	B-X
characteristic	B-X
of	B-X
hydroxylated	B-X
collagen	B-X
.	B-X
The	B-X
synthesized	B-X
polypeptides	B-X
were	B-X
also	B-X
resistant	B-X
to	B-X
both	B-X
pepsin	B-X
and	B-X
trypsin/chymotrypsin	B-X
digestion	B-X
,	B-X
demonstrating	B-X
the	B-X
formation	B-X
of	B-X
correctly	B-X
aligned	B-X
native	B-X
collagen	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
collagen	B-X
polypeptides	B-X
assembled	B-X
into	B-X
higher-order	B-X
structures	B-X
,	B-X
possibly	B-X
trimers	B-X
,	B-X
which	B-X
were	B-X
stabilized	B-X
by	B-X
interchain	B-X
disulphide	B-X
bonds	B-X
.	B-X
The	B-X
collagen	B-X
helix	B-X
synthesized	B-X
in	B-X
vitro	B-X
had	B-X
a	B-X
melting	B-X
temperature	B-X
of	B-X
41	B-X
degrees	B-X
C	B-X
which	B-X
is	B-X
comparable	B-X
with	B-X
the	B-X
protein	B-X
synthesized	B-X
in	B-X
vivo	B-X
,	B-X
further	B-X
demonstrating	B-X
that	B-X
the	B-X
polypeptides	B-X
were	B-X
hydroxylated	B-X
and	B-X
that	B-X
the	B-X
triple	B-X
helix	B-X
formed	B-X
was	B-X
correctly	B-X
aligned	B-X
.	B-X

The	O
synthesized	O
polypeptides	O
were	O
also	O
resistant	O
to	O
both	O
pepsin	O
and	O
trypsin	O
/	O
chymotrypsin	O
digestion	O
,	O
demonstrating	O
the	O
formation	O
of	O
correctly	O
aligned	O
native	O
collagen	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
here	B-X
a	B-X
cell-free	B-X
system	B-X
which	B-X
will	B-X
carry	B-X
out	B-X
the	B-X
initial	B-X
stages	B-X
in	B-X
the	B-X
synthesis	B-X
,	B-X
post-translational	B-X
modification	B-X
and	B-X
assembly	B-X
of	B-X
type-X	B-X
collagen	B-X
.	B-X
The	B-X
mRNA	B-X
coding	B-X
for	B-X
bovine	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
vitro	B-X
and	B-X
translated	B-X
in	B-X
a	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
to	B-X
yield	B-X
a	B-X
protein	B-X
that	B-X
was	B-X
collagenase	B-X
sensitive	B-X
and	B-X
could	B-X
be	B-X
immunoprecipitated	B-X
with	B-X
antibodies	B-X
raised	B-X
to	B-X
purified	B-X
avian	B-X
type-X	B-X
collagen	B-X
.	B-X
When	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
added	B-X
microsomes	B-X
or	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
canine	B-X
pancreas	B-X
microsomes	B-X
,	B-X
the	B-X
translation	B-X
products	B-X
showed	B-X
partial	B-X
resistance	B-X
to	B-X
digestion	B-X
with	B-X
pepsin	B-X
but	B-X
were	B-X
completely	B-X
degraded	B-X
with	B-X
a	B-X
mixture	B-X
of	B-X
chymotrypsin	B-X
and	B-X
trypsin	B-X
,	B-X
suggesting	B-X
that	B-X
only	B-X
incorrectly	B-X
aligned	B-X
non-native	B-X
collagen	B-X
molecules	B-X
were	B-X
synthesized	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
microsomes	B-X
derived	B-X
from	B-X
avian	B-X
fibroblasts	B-X
or	B-X
a	B-X
human	B-X
fibrosarcoma	B-X
cell	B-X
line	B-X
,	B-X
the	B-X
translocated	B-X
product	B-X
migrated	B-X
as	B-X
a	B-X
diffuse	B-X
band	B-X
characteristic	B-X
of	B-X
hydroxylated	B-X
collagen	B-X
.	B-X
The	B-X
synthesized	B-X
polypeptides	B-X
were	B-X
also	B-X
resistant	B-X
to	B-X
both	B-X
pepsin	B-X
and	B-X
trypsin/chymotrypsin	B-X
digestion	B-X
,	B-X
demonstrating	B-X
the	B-X
formation	B-X
of	B-X
correctly	B-X
aligned	B-X
native	B-X
collagen	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
collagen	B-X
polypeptides	B-X
assembled	B-X
into	B-X
higher-order	B-X
structures	B-X
,	B-X
possibly	B-X
trimers	B-X
,	B-X
which	B-X
were	B-X
stabilized	B-X
by	B-X
interchain	B-X
disulphide	B-X
bonds	B-X
.	B-X
The	B-X
collagen	B-X
helix	B-X
synthesized	B-X
in	B-X
vitro	B-X
had	B-X
a	B-X
melting	B-X
temperature	B-X
of	B-X
41	B-X
degrees	B-X
C	B-X
which	B-X
is	B-X
comparable	B-X
with	B-X
the	B-X
protein	B-X
synthesized	B-X
in	B-X
vivo	B-X
,	B-X
further	B-X
demonstrating	B-X
that	B-X
the	B-X
polypeptides	B-X
were	B-X
hydroxylated	B-X
and	B-X
that	B-X
the	B-X
triple	B-X
helix	B-X
formed	B-X
was	B-X
correctly	B-X
aligned	B-X
.	B-X

Furthermore	O
,	O
the	O
collagen	O
polypeptides	O
assembled	O
into	O
higher	O
-	O
order	O
structures	O
,	O
possibly	O
trimers	O
,	O
which	O
were	O
stabilized	O
by	O
interchain	O
disulphide	O
bonds	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
here	B-X
a	B-X
cell-free	B-X
system	B-X
which	B-X
will	B-X
carry	B-X
out	B-X
the	B-X
initial	B-X
stages	B-X
in	B-X
the	B-X
synthesis	B-X
,	B-X
post-translational	B-X
modification	B-X
and	B-X
assembly	B-X
of	B-X
type-X	B-X
collagen	B-X
.	B-X
The	B-X
mRNA	B-X
coding	B-X
for	B-X
bovine	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
vitro	B-X
and	B-X
translated	B-X
in	B-X
a	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
to	B-X
yield	B-X
a	B-X
protein	B-X
that	B-X
was	B-X
collagenase	B-X
sensitive	B-X
and	B-X
could	B-X
be	B-X
immunoprecipitated	B-X
with	B-X
antibodies	B-X
raised	B-X
to	B-X
purified	B-X
avian	B-X
type-X	B-X
collagen	B-X
.	B-X
When	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
added	B-X
microsomes	B-X
or	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
canine	B-X
pancreas	B-X
microsomes	B-X
,	B-X
the	B-X
translation	B-X
products	B-X
showed	B-X
partial	B-X
resistance	B-X
to	B-X
digestion	B-X
with	B-X
pepsin	B-X
but	B-X
were	B-X
completely	B-X
degraded	B-X
with	B-X
a	B-X
mixture	B-X
of	B-X
chymotrypsin	B-X
and	B-X
trypsin	B-X
,	B-X
suggesting	B-X
that	B-X
only	B-X
incorrectly	B-X
aligned	B-X
non-native	B-X
collagen	B-X
molecules	B-X
were	B-X
synthesized	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
microsomes	B-X
derived	B-X
from	B-X
avian	B-X
fibroblasts	B-X
or	B-X
a	B-X
human	B-X
fibrosarcoma	B-X
cell	B-X
line	B-X
,	B-X
the	B-X
translocated	B-X
product	B-X
migrated	B-X
as	B-X
a	B-X
diffuse	B-X
band	B-X
characteristic	B-X
of	B-X
hydroxylated	B-X
collagen	B-X
.	B-X
The	B-X
synthesized	B-X
polypeptides	B-X
were	B-X
also	B-X
resistant	B-X
to	B-X
both	B-X
pepsin	B-X
and	B-X
trypsin/chymotrypsin	B-X
digestion	B-X
,	B-X
demonstrating	B-X
the	B-X
formation	B-X
of	B-X
correctly	B-X
aligned	B-X
native	B-X
collagen	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
collagen	B-X
polypeptides	B-X
assembled	B-X
into	B-X
higher-order	B-X
structures	B-X
,	B-X
possibly	B-X
trimers	B-X
,	B-X
which	B-X
were	B-X
stabilized	B-X
by	B-X
interchain	B-X
disulphide	B-X
bonds	B-X
.	B-X
The	B-X
collagen	B-X
helix	B-X
synthesized	B-X
in	B-X
vitro	B-X
had	B-X
a	B-X
melting	B-X
temperature	B-X
of	B-X
41	B-X
degrees	B-X
C	B-X
which	B-X
is	B-X
comparable	B-X
with	B-X
the	B-X
protein	B-X
synthesized	B-X
in	B-X
vivo	B-X
,	B-X
further	B-X
demonstrating	B-X
that	B-X
the	B-X
polypeptides	B-X
were	B-X
hydroxylated	B-X
and	B-X
that	B-X
the	B-X
triple	B-X
helix	B-X
formed	B-X
was	B-X
correctly	B-X
aligned	B-X
.	B-X

The	O
collagen	O
helix	O
synthesized	O
in	O
vitro	O
had	O
a	O
melting	O
temperature	O
of	O
41	O
degrees	O
C	O
which	O
is	O
comparable	O
with	O
the	O
protein	O
synthesized	O
in	O
vivo	O
,	O
further	O
demonstrating	O
that	O
the	O
polypeptides	O
were	O
hydroxylated	O
and	O
that	O
the	O
triple	O
helix	O
formed	O
was	O
correctly	O
aligned	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
here	B-X
a	B-X
cell-free	B-X
system	B-X
which	B-X
will	B-X
carry	B-X
out	B-X
the	B-X
initial	B-X
stages	B-X
in	B-X
the	B-X
synthesis	B-X
,	B-X
post-translational	B-X
modification	B-X
and	B-X
assembly	B-X
of	B-X
type-X	B-X
collagen	B-X
.	B-X
The	B-X
mRNA	B-X
coding	B-X
for	B-X
bovine	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
vitro	B-X
and	B-X
translated	B-X
in	B-X
a	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
to	B-X
yield	B-X
a	B-X
protein	B-X
that	B-X
was	B-X
collagenase	B-X
sensitive	B-X
and	B-X
could	B-X
be	B-X
immunoprecipitated	B-X
with	B-X
antibodies	B-X
raised	B-X
to	B-X
purified	B-X
avian	B-X
type-X	B-X
collagen	B-X
.	B-X
When	B-X
type-X	B-X
collagen	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
added	B-X
microsomes	B-X
or	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
canine	B-X
pancreas	B-X
microsomes	B-X
,	B-X
the	B-X
translation	B-X
products	B-X
showed	B-X
partial	B-X
resistance	B-X
to	B-X
digestion	B-X
with	B-X
pepsin	B-X
but	B-X
were	B-X
completely	B-X
degraded	B-X
with	B-X
a	B-X
mixture	B-X
of	B-X
chymotrypsin	B-X
and	B-X
trypsin	B-X
,	B-X
suggesting	B-X
that	B-X
only	B-X
incorrectly	B-X
aligned	B-X
non-native	B-X
collagen	B-X
molecules	B-X
were	B-X
synthesized	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
synthesized	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
microsomes	B-X
derived	B-X
from	B-X
avian	B-X
fibroblasts	B-X
or	B-X
a	B-X
human	B-X
fibrosarcoma	B-X
cell	B-X
line	B-X
,	B-X
the	B-X
translocated	B-X
product	B-X
migrated	B-X
as	B-X
a	B-X
diffuse	B-X
band	B-X
characteristic	B-X
of	B-X
hydroxylated	B-X
collagen	B-X
.	B-X
The	B-X
synthesized	B-X
polypeptides	B-X
were	B-X
also	B-X
resistant	B-X
to	B-X
both	B-X
pepsin	B-X
and	B-X
trypsin/chymotrypsin	B-X
digestion	B-X
,	B-X
demonstrating	B-X
the	B-X
formation	B-X
of	B-X
correctly	B-X
aligned	B-X
native	B-X
collagen	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
collagen	B-X
polypeptides	B-X
assembled	B-X
into	B-X
higher-order	B-X
structures	B-X
,	B-X
possibly	B-X
trimers	B-X
,	B-X
which	B-X
were	B-X
stabilized	B-X
by	B-X
interchain	B-X
disulphide	B-X
bonds	B-X
.	B-X
The	B-X
collagen	B-X
helix	B-X
synthesized	B-X
in	B-X
vitro	B-X
had	B-X
a	B-X
melting	B-X
temperature	B-X
of	B-X
41	B-X
degrees	B-X
C	B-X
which	B-X
is	B-X
comparable	B-X
with	B-X
the	B-X
protein	B-X
synthesized	B-X
in	B-X
vivo	B-X
,	B-X
further	B-X
demonstrating	B-X
that	B-X
the	B-X
polypeptides	B-X
were	B-X
hydroxylated	B-X
and	B-X
that	B-X
the	B-X
triple	B-X
helix	B-X
formed	B-X
was	B-X
correctly	B-X
aligned	B-X
.	B-X

Structural	O
requirements	O
for	O
the	O
binding	O
of	O
modified	O
proteins	O
to	O
the	O
scavenger	O
receptor	O
of	O
macrophages	O
.	O

Oxidized	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
and	O
certain	O
chemically	O
modified	O
LDL	O
are	O
recognized	O
by	O
the	O
scavenger	O
receptor	O
of	O
macrophages	O
.	O
<EOS>	B-X
Macrophages	B-X
express	B-X
a	B-X
specific	B-X
receptor	B-X
that	B-X
recognizes	B-X
acetylated	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
and	B-X
certain	B-X
other	B-X
chemically	B-X
modified	B-X
forms	B-X
of	B-X
LDL	B-X
but	B-X
not	B-X
native	B-X
LDL	B-X
.	B-X
LDL	B-X
oxidatively	B-X
modified	B-X
either	B-X
by	B-X
incubation	B-X
with	B-X
endothelial	B-X
cells	B-X
in	B-X
Ham	B-X
's	B-X
F-10	B-X
medium	B-X
or	B-X
by	B-X
incubation	B-X
with	B-X
5	B-X
microM	B-X
copper	B-X
(	B-X
II	B-X
)	B-X
ion	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cells	B-X
is	B-X
recognized	B-X
by	B-X
this	B-X
same	B-X
receptor	B-X
.	B-X
This	B-X
oxidative	B-X
modification	B-X
,	B-X
whether	B-X
cell-induced	B-X
or	B-X
copper-catalyzed	B-X
,	B-X
is	B-X
accompanied	B-X
by	B-X
many	B-X
changes	B-X
in	B-X
the	B-X
physical	B-X
and	B-X
chemical	B-X
properties	B-X
of	B-X
LDL	B-X
,	B-X
including	B-X
an	B-X
increase	B-X
in	B-X
density	B-X
,	B-X
conversion	B-X
of	B-X
phosphatidylcholine	B-X
to	B-X
lysophosphatidylcholine	B-X
,	B-X
generation	B-X
of	B-X
lipid	B-X
peroxides	B-X
,	B-X
and	B-X
degradation	B-X
of	B-X
apolipoprotein	B-X
B-100	B-X
.	B-X
Which	B-X
changes	B-X
are	B-X
essential	B-X
for	B-X
eliciting	B-X
the	B-X
recognition	B-X
by	B-X
the	B-X
receptor	B-X
is	B-X
not	B-X
known	B-X
.	B-X
In	B-X
the	B-X
present	B-X
paper	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
fragments	B-X
of	B-X
the	B-X
degraded	B-X
apolipoprotein	B-X
from	B-X
delipidated	B-X
,	B-X
oxidized	B-X
LDL	B-X
can	B-X
be	B-X
almost	B-X
quantitatively	B-X
resolubilized	B-X
using	B-X
n-octyl	B-X
beta-D-glucopyranoside	B-X
.	B-X
These	B-X
125I-labeled	B-X
,	B-X
solubilized	B-X
apoproteins	B-X
were	B-X
degraded	B-X
rapidly	B-X
by	B-X
mouse	B-X
peritoneal	B-X
macrophages	B-X
,	B-X
and	B-X
that	B-X
degradation	B-X
was	B-X
competitively	B-X
inhibited	B-X
by	B-X
unlabeled	B-X
acetyl-LDL	B-X
and	B-X
endothelial	B-X
cell-modified	B-X
LDL	B-X
but	B-X
not	B-X
by	B-X
native	B-X
LDL	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
the	B-X
acetyl-LDL	B-X
receptor	B-X
recognizes	B-X
an	B-X
epitope	B-X
on	B-X
the	B-X
apoprotein	B-X
moiety	B-X
,	B-X
either	B-X
newly	B-X
generated	B-X
or	B-X
exposed	B-X
as	B-X
a	B-X
result	B-X
of	B-X
oxidative	B-X
modification	B-X
,	B-X
rather	B-X
than	B-X
some	B-X
oxidized	B-X
lipid	B-X
moiety	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
lipids	B-X
of	B-X
oxidatively	B-X
modified	B-X
LDL	B-X
do	B-X
not	B-X
play	B-X
an	B-X
obligatory	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
conformation	B-X
of	B-X
that	B-X
epitope	B-X
.	B-X

All	O
of	O
these	O
modifications	O
involve	O
charge	O
-	O
neutralizing	O
derivatization	O
of	O
lysine	O
amino	O
groups	O
.	O
<EOS>	B-X
Several	B-X
chemical	B-X
modifications	B-X
of	B-X
LDL	B-X
also	B-X
lead	B-X
to	B-X
recognition	B-X
by	B-X
this	B-X
receptor	B-X
;	B-X
all	B-X
of	B-X
these	B-X
involve	B-X
derivatization	B-X
of	B-X
lysine	B-X
residues	B-X
of	B-X
apolipoprotein	B-X
B	B-X
by	B-X
adducts	B-X
that	B-X
neutralize	B-X
the	B-X
positively	B-X
charged	B-X
epsilon-amino	B-X
group	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
show	B-X
that	B-X
oxidation	B-X
also	B-X
results	B-X
in	B-X
derivatization	B-X
of	B-X
LDL	B-X
lysine	B-X
residues	B-X
.	B-X
Analysis	B-X
of	B-X
amino	B-X
acid	B-X
composition	B-X
indicated	B-X
that	B-X
32	B-X
%	B-X
of	B-X
lysine	B-X
residues	B-X
were	B-X
modified	B-X
after	B-X
oxidation	B-X
of	B-X
LDL	B-X
by	B-X
exposure	B-X
to	B-X
5	B-X
microM	B-X
CuSO4	B-X
for	B-X
20	B-X
h.	B-X
About	B-X
one-half	B-X
of	B-X
the	B-X
derivatized	B-X
lysines	B-X
were	B-X
labile	B-X
under	B-X
the	B-X
conditions	B-X
of	B-X
acid	B-X
hydrolysis	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
oxidation	B-X
of	B-X
LDL	B-X
is	B-X
accompanied	B-X
by	B-X
derivatization	B-X
of	B-X
lysine	B-X
epsilon-amino	B-X
groups	B-X
by	B-X
lipid	B-X
products	B-X
and	B-X
that	B-X
these	B-X
adducts	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
interaction	B-X
of	B-X
oxidized	B-X
LDL	B-X
with	B-X
the	B-X
acetyl-LDL	B-X
receptor	B-X
.	B-X

However	O
,	O
it	O
remains	O
controversial	O
whether	O
recognition	O
of	O
modified	O
LDL	O
by	O
this	O
receptor	O
is	O
due	O
to	O
the	O
modification	O
per	O
se	O
,	O
or	O
to	O
other	O
factors	O
such	O
as	O
a	O
conformational	O
change	O
of	O
apoB	B-Protein
.	O
<EOS>	B-X
Electronegative	B-X
LDL	B-X
(	B-X
LDL	B-X
(	B-X
-	B-X
)	B-X
)	B-X
is	B-X
a	B-X
minor	B-X
form	B-X
of	B-X
LDL	B-X
present	B-X
in	B-X
blood	B-X
for	B-X
which	B-X
proportions	B-X
are	B-X
increased	B-X
in	B-X
pathologies	B-X
with	B-X
increased	B-X
cardiovascular	B-X
risk	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
LDL	B-X
(	B-X
-	B-X
)	B-X
presents	B-X
pro-atherogenic	B-X
properties	B-X
,	B-X
including	B-X
a	B-X
high	B-X
susceptibility	B-X
to	B-X
aggregation	B-X
,	B-X
the	B-X
ability	B-X
to	B-X
induce	B-X
inflammation	B-X
and	B-X
apoptosis	B-X
,	B-X
and	B-X
increased	B-X
binding	B-X
to	B-X
arterial	B-X
proteoglycans	B-X
;	B-X
however	B-X
,	B-X
it	B-X
also	B-X
shows	B-X
some	B-X
anti-atherogenic	B-X
properties	B-X
,	B-X
which	B-X
suggest	B-X
a	B-X
role	B-X
in	B-X
controlling	B-X
the	B-X
atherosclerotic	B-X
process	B-X
.	B-X
One	B-X
of	B-X
the	B-X
distinctive	B-X
features	B-X
of	B-X
LDL	B-X
(	B-X
-	B-X
)	B-X
is	B-X
that	B-X
it	B-X
has	B-X
enzymatic	B-X
activities	B-X
with	B-X
the	B-X
ability	B-X
to	B-X
degrade	B-X
different	B-X
lipids	B-X
.	B-X
For	B-X
example	B-X
,	B-X
LDL	B-X
(	B-X
-	B-X
)	B-X
transports	B-X
platelet-activating	B-X
factor	B-X
acetylhydrolase	B-X
(	B-X
PAF-AH	B-X
)	B-X
,	B-X
which	B-X
degrades	B-X
oxidized	B-X
phospholipids	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
two	B-X
other	B-X
enzymatic	B-X
activities	B-X
are	B-X
exhibited	B-X
by	B-X
LDL	B-X
(	B-X
-	B-X
)	B-X
.	B-X
The	B-X
first	B-X
is	B-X
type	B-X
C	B-X
phospholipase	B-X
activity	B-X
,	B-X
which	B-X
degrades	B-X
both	B-X
lysophosphatidylcholine	B-X
(	B-X
LysoPLC-like	B-X
activity	B-X
)	B-X
and	B-X
sphingomyelin	B-X
(	B-X
SMase-like	B-X
activity	B-X
)	B-X
.	B-X
The	B-X
second	B-X
is	B-X
ceramidase	B-X
activity	B-X
(	B-X
CDase-like	B-X
)	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
complementarity	B-X
of	B-X
the	B-X
products	B-X
and	B-X
substrates	B-X
of	B-X
these	B-X
different	B-X
activities	B-X
,	B-X
this	B-X
review	B-X
speculates	B-X
on	B-X
the	B-X
possibility	B-X
that	B-X
LDL	B-X
(	B-X
-	B-X
)	B-X
may	B-X
act	B-X
as	B-X
a	B-X
sort	B-X
of	B-X
multienzymatic	B-X
complex	B-X
in	B-X
which	B-X
these	B-X
enzymatic	B-X
activities	B-X
exert	B-X
a	B-X
concerted	B-X
action	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
LysoPLC/SMase	B-X
and	B-X
CDase	B-X
activities	B-X
could	B-X
be	B-X
generated	B-X
by	B-X
conformational	B-X
changes	B-X
in	B-X
apoB-100	B-X
and	B-X
that	B-X
both	B-X
activities	B-X
occur	B-X
in	B-X
proximity	B-X
to	B-X
PAF-AH	B-X
,	B-X
making	B-X
it	B-X
feasible	B-X
to	B-X
discern	B-X
a	B-X
coordinated	B-X
action	B-X
among	B-X
them	B-X
.	B-X

In	O
this	O
study	O
,	O
LDL	O
and	O
other	O
proteins	O
including	O
bovine	O
serum	B-Protein
albumin	I-Protein
,	O
human	O
high	O
density	O
lipoprotein	O
,	O
and	O
murine	O
IgG	O
were	O
derivatized	O
with	O
oxidation	O
products	O
generated	O
from	O
arachidonic	O
acid	O
by	O
thermal	O
autoxidation	O
.	O
<EOS>	B-X
Oxidized	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
and	B-X
certain	B-X
chemically	B-X
modified	B-X
LDL	B-X
are	B-X
recognized	B-X
by	B-X
the	B-X
scavenger	B-X
receptor	B-X
of	B-X
macrophages	B-X
.	B-X
However	B-X
,	B-X
it	B-X
remains	B-X
controversial	B-X
whether	B-X
recognition	B-X
of	B-X
modified	B-X
LDL	B-X
by	B-X
this	B-X
receptor	B-X
is	B-X
due	B-X
to	B-X
the	B-X
modification	B-X
per	B-X
se	B-X
,	B-X
or	B-X
to	B-X
other	B-X
factors	B-X
such	B-X
as	B-X
a	B-X
conformational	B-X
change	B-X
of	B-X
apoB	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
LDL	B-X
and	B-X
other	B-X
proteins	B-X
including	B-X
bovine	B-X
serum	B-X
albumin	B-X
,	B-X
human	B-X
high	B-X
density	B-X
lipoprotein	B-X
,	B-X
and	B-X
murine	B-X
IgG	B-X
were	B-X
derivatized	B-X
with	B-X
oxidation	B-X
products	B-X
generated	B-X
from	B-X
arachidonic	B-X
acid	B-X
by	B-X
thermal	B-X
autoxidation	B-X
.	B-X
Modified	B-X
proteins	B-X
had	B-X
increased	B-X
negative	B-X
charge	B-X
,	B-X
and	B-X
showed	B-X
a	B-X
more	B-X
than	B-X
10-fold	B-X
enhancement	B-X
of	B-X
degradation	B-X
by	B-X
mouse	B-X
peritoneal	B-X
macrophages	B-X
via	B-X
the	B-X
scavenger	B-X
receptor	B-X
pathway	B-X
.	B-X
Modification	B-X
was	B-X
prevented	B-X
by	B-X
blocking	B-X
lysine	B-X
residues	B-X
of	B-X
the	B-X
proteins	B-X
by	B-X
prior	B-X
reductive	B-X
methylation	B-X
.	B-X
Amino	B-X
acid	B-X
analysis	B-X
revealed	B-X
dose-dependent	B-X
modification	B-X
of	B-X
lysine	B-X
residues	B-X
with	B-X
no	B-X
significant	B-X
effects	B-X
on	B-X
any	B-X
other	B-X
amino	B-X
acid	B-X
.	B-X
Fab	B-X
fragments	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
specific	B-X
for	B-X
adducts	B-X
of	B-X
oxidation	B-X
products	B-X
with	B-X
lysine	B-X
prevented	B-X
the	B-X
uptake	B-X
of	B-X
oxidation	B-X
product-modified	B-X
LDL	B-X
and	B-X
oxidized	B-X
LDL	B-X
by	B-X
macrophages	B-X
.	B-X
Chromatography	B-X
of	B-X
oxidation	B-X
product-modified	B-X
LDL	B-X
over	B-X
Sepharose	B-X
CL-4B	B-X
showed	B-X
that	B-X
uptake	B-X
by	B-X
macrophages	B-X
did	B-X
not	B-X
require	B-X
LDL	B-X
aggregation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
relatively	B-X
simple	B-X
domain	B-X
consisting	B-X
of	B-X
a	B-X
cluster	B-X
of	B-X
suitably	B-X
derivatized	B-X
lysine	B-X
residues	B-X
is	B-X
sufficient	B-X
for	B-X
recognition	B-X
by	B-X
the	B-X
scavenger	B-X
receptor	B-X
of	B-X
macrophages	B-X
.	B-X

Modified	O
proteins	O
had	O
increased	O
negative	O
charge	O
,	O
and	O
showed	O
a	O
more	O
than	O
10	O
-	O
fold	O
enhancement	O
of	O
degradation	O
by	O
mouse	O
peritoneal	O
macrophages	O
via	O
the	O
scavenger	O
receptor	O
pathway	O
.	O

Modification	O
was	O
prevented	O
by	O
blocking	O
lysine	O
residues	O
of	O
the	O
proteins	O
by	O
prior	O
reductive	O
methylation	O
.	O
<EOS>	B-X
All	B-X
of	B-X
these	B-X
modifications	B-X
involve	B-X
charge-neutralizing	B-X
derivatization	B-X
of	B-X
lysine	B-X
amino	B-X
groups	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
LDL	B-X
and	B-X
other	B-X
proteins	B-X
including	B-X
bovine	B-X
serum	B-X
albumin	B-X
,	B-X
human	B-X
high	B-X
density	B-X
lipoprotein	B-X
,	B-X
and	B-X
murine	B-X
IgG	B-X
were	B-X
derivatized	B-X
with	B-X
oxidation	B-X
products	B-X
generated	B-X
from	B-X
arachidonic	B-X
acid	B-X
by	B-X
thermal	B-X
autoxidation	B-X
.	B-X
Modified	B-X
proteins	B-X
had	B-X
increased	B-X
negative	B-X
charge	B-X
,	B-X
and	B-X
showed	B-X
a	B-X
more	B-X
than	B-X
10-fold	B-X
enhancement	B-X
of	B-X
degradation	B-X
by	B-X
mouse	B-X
peritoneal	B-X
macrophages	B-X
via	B-X
the	B-X
scavenger	B-X
receptor	B-X
pathway	B-X
.	B-X
Modification	B-X
was	B-X
prevented	B-X
by	B-X
blocking	B-X
lysine	B-X
residues	B-X
of	B-X
the	B-X
proteins	B-X
by	B-X
prior	B-X
reductive	B-X
methylation	B-X
.	B-X
Amino	B-X
acid	B-X
analysis	B-X
revealed	B-X
dose-dependent	B-X
modification	B-X
of	B-X
lysine	B-X
residues	B-X
with	B-X
no	B-X
significant	B-X
effects	B-X
on	B-X
any	B-X
other	B-X
amino	B-X
acid	B-X
.	B-X
Fab	B-X
fragments	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
specific	B-X
for	B-X
adducts	B-X
of	B-X
oxidation	B-X
products	B-X
with	B-X
lysine	B-X
prevented	B-X
the	B-X
uptake	B-X
of	B-X
oxidation	B-X
product-modified	B-X
LDL	B-X
and	B-X
oxidized	B-X
LDL	B-X
by	B-X
macrophages	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
relatively	B-X
simple	B-X
domain	B-X
consisting	B-X
of	B-X
a	B-X
cluster	B-X
of	B-X
suitably	B-X
derivatized	B-X
lysine	B-X
residues	B-X
is	B-X
sufficient	B-X
for	B-X
recognition	B-X
by	B-X
the	B-X
scavenger	B-X
receptor	B-X
of	B-X
macrophages	B-X
.	B-X

Amino	O
acid	O
analysis	O
revealed	O
dose	O
-	O
dependent	O
modification	O
of	O
lysine	O
residues	O
with	O
no	O
significant	O
effects	O
on	O
any	O
other	O
amino	O
acid	O
.	O
<EOS>	B-X
All	B-X
of	B-X
these	B-X
modifications	B-X
involve	B-X
charge-neutralizing	B-X
derivatization	B-X
of	B-X
lysine	B-X
amino	B-X
groups	B-X
.	B-X
However	B-X
,	B-X
it	B-X
remains	B-X
controversial	B-X
whether	B-X
recognition	B-X
of	B-X
modified	B-X
LDL	B-X
by	B-X
this	B-X
receptor	B-X
is	B-X
due	B-X
to	B-X
the	B-X
modification	B-X
per	B-X
se	B-X
,	B-X
or	B-X
to	B-X
other	B-X
factors	B-X
such	B-X
as	B-X
a	B-X
conformational	B-X
change	B-X
of	B-X
apoB	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
LDL	B-X
and	B-X
other	B-X
proteins	B-X
including	B-X
bovine	B-X
serum	B-X
albumin	B-X
,	B-X
human	B-X
high	B-X
density	B-X
lipoprotein	B-X
,	B-X
and	B-X
murine	B-X
IgG	B-X
were	B-X
derivatized	B-X
with	B-X
oxidation	B-X
products	B-X
generated	B-X
from	B-X
arachidonic	B-X
acid	B-X
by	B-X
thermal	B-X
autoxidation	B-X
.	B-X
Modification	B-X
was	B-X
prevented	B-X
by	B-X
blocking	B-X
lysine	B-X
residues	B-X
of	B-X
the	B-X
proteins	B-X
by	B-X
prior	B-X
reductive	B-X
methylation	B-X
.	B-X
Amino	B-X
acid	B-X
analysis	B-X
revealed	B-X
dose-dependent	B-X
modification	B-X
of	B-X
lysine	B-X
residues	B-X
with	B-X
no	B-X
significant	B-X
effects	B-X
on	B-X
any	B-X
other	B-X
amino	B-X
acid	B-X
.	B-X
Fab	B-X
fragments	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
specific	B-X
for	B-X
adducts	B-X
of	B-X
oxidation	B-X
products	B-X
with	B-X
lysine	B-X
prevented	B-X
the	B-X
uptake	B-X
of	B-X
oxidation	B-X
product-modified	B-X
LDL	B-X
and	B-X
oxidized	B-X
LDL	B-X
by	B-X
macrophages	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
relatively	B-X
simple	B-X
domain	B-X
consisting	B-X
of	B-X
a	B-X
cluster	B-X
of	B-X
suitably	B-X
derivatized	B-X
lysine	B-X
residues	B-X
is	B-X
sufficient	B-X
for	B-X
recognition	B-X
by	B-X
the	B-X
scavenger	B-X
receptor	B-X
of	B-X
macrophages	B-X
.	B-X

Fab	O
fragments	O
of	O
monoclonal	O
antibodies	O
specific	O
for	O
adducts	O
of	O
oxidation	O
products	O
with	O
lysine	O
prevented	O
the	O
uptake	O
of	O
oxidation	O
product	O
-	O
modified	O
LDL	O
and	O
oxidized	O
LDL	O
by	O
macrophages	O
.	O
<EOS>	B-X
Oxidized	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
and	B-X
certain	B-X
chemically	B-X
modified	B-X
LDL	B-X
are	B-X
recognized	B-X
by	B-X
the	B-X
scavenger	B-X
receptor	B-X
of	B-X
macrophages	B-X
.	B-X
All	B-X
of	B-X
these	B-X
modifications	B-X
involve	B-X
charge-neutralizing	B-X
derivatization	B-X
of	B-X
lysine	B-X
amino	B-X
groups	B-X
.	B-X
However	B-X
,	B-X
it	B-X
remains	B-X
controversial	B-X
whether	B-X
recognition	B-X
of	B-X
modified	B-X
LDL	B-X
by	B-X
this	B-X
receptor	B-X
is	B-X
due	B-X
to	B-X
the	B-X
modification	B-X
per	B-X
se	B-X
,	B-X
or	B-X
to	B-X
other	B-X
factors	B-X
such	B-X
as	B-X
a	B-X
conformational	B-X
change	B-X
of	B-X
apoB	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
LDL	B-X
and	B-X
other	B-X
proteins	B-X
including	B-X
bovine	B-X
serum	B-X
albumin	B-X
,	B-X
human	B-X
high	B-X
density	B-X
lipoprotein	B-X
,	B-X
and	B-X
murine	B-X
IgG	B-X
were	B-X
derivatized	B-X
with	B-X
oxidation	B-X
products	B-X
generated	B-X
from	B-X
arachidonic	B-X
acid	B-X
by	B-X
thermal	B-X
autoxidation	B-X
.	B-X
Modified	B-X
proteins	B-X
had	B-X
increased	B-X
negative	B-X
charge	B-X
,	B-X
and	B-X
showed	B-X
a	B-X
more	B-X
than	B-X
10-fold	B-X
enhancement	B-X
of	B-X
degradation	B-X
by	B-X
mouse	B-X
peritoneal	B-X
macrophages	B-X
via	B-X
the	B-X
scavenger	B-X
receptor	B-X
pathway	B-X
.	B-X
Modification	B-X
was	B-X
prevented	B-X
by	B-X
blocking	B-X
lysine	B-X
residues	B-X
of	B-X
the	B-X
proteins	B-X
by	B-X
prior	B-X
reductive	B-X
methylation	B-X
.	B-X
Amino	B-X
acid	B-X
analysis	B-X
revealed	B-X
dose-dependent	B-X
modification	B-X
of	B-X
lysine	B-X
residues	B-X
with	B-X
no	B-X
significant	B-X
effects	B-X
on	B-X
any	B-X
other	B-X
amino	B-X
acid	B-X
.	B-X
Fab	B-X
fragments	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
specific	B-X
for	B-X
adducts	B-X
of	B-X
oxidation	B-X
products	B-X
with	B-X
lysine	B-X
prevented	B-X
the	B-X
uptake	B-X
of	B-X
oxidation	B-X
product-modified	B-X
LDL	B-X
and	B-X
oxidized	B-X
LDL	B-X
by	B-X
macrophages	B-X
.	B-X
Chromatography	B-X
of	B-X
oxidation	B-X
product-modified	B-X
LDL	B-X
over	B-X
Sepharose	B-X
CL-4B	B-X
showed	B-X
that	B-X
uptake	B-X
by	B-X
macrophages	B-X
did	B-X
not	B-X
require	B-X
LDL	B-X
aggregation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
relatively	B-X
simple	B-X
domain	B-X
consisting	B-X
of	B-X
a	B-X
cluster	B-X
of	B-X
suitably	B-X
derivatized	B-X
lysine	B-X
residues	B-X
is	B-X
sufficient	B-X
for	B-X
recognition	B-X
by	B-X
the	B-X
scavenger	B-X
receptor	B-X
of	B-X
macrophages	B-X
.	B-X

Chromatography	O
of	O
oxidation	O
product	O
-	O
modified	O
LDL	O
over	O
Sepharose	O
CL	O
-	O
4B	O
showed	O
that	O
uptake	O
by	O
macrophages	O
did	O
not	O
require	O
LDL	O
aggregation	O
.	O

These	O
results	O
suggest	O
that	O
a	O
relatively	O
simple	O
domain	O
consisting	O
of	O
a	O
cluster	O
of	O
suitably	O
derivatized	O
lysine	O
residues	O
is	O
sufficient	O
for	O
recognition	O
by	O
the	O
scavenger	O
receptor	O
of	O
macrophages	O
.	O
<EOS>	B-X
Oxidized	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
and	B-X
certain	B-X
chemically	B-X
modified	B-X
LDL	B-X
are	B-X
recognized	B-X
by	B-X
the	B-X
scavenger	B-X
receptor	B-X
of	B-X
macrophages	B-X
.	B-X
All	B-X
of	B-X
these	B-X
modifications	B-X
involve	B-X
charge-neutralizing	B-X
derivatization	B-X
of	B-X
lysine	B-X
amino	B-X
groups	B-X
.	B-X
However	B-X
,	B-X
it	B-X
remains	B-X
controversial	B-X
whether	B-X
recognition	B-X
of	B-X
modified	B-X
LDL	B-X
by	B-X
this	B-X
receptor	B-X
is	B-X
due	B-X
to	B-X
the	B-X
modification	B-X
per	B-X
se	B-X
,	B-X
or	B-X
to	B-X
other	B-X
factors	B-X
such	B-X
as	B-X
a	B-X
conformational	B-X
change	B-X
of	B-X
apoB	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
LDL	B-X
and	B-X
other	B-X
proteins	B-X
including	B-X
bovine	B-X
serum	B-X
albumin	B-X
,	B-X
human	B-X
high	B-X
density	B-X
lipoprotein	B-X
,	B-X
and	B-X
murine	B-X
IgG	B-X
were	B-X
derivatized	B-X
with	B-X
oxidation	B-X
products	B-X
generated	B-X
from	B-X
arachidonic	B-X
acid	B-X
by	B-X
thermal	B-X
autoxidation	B-X
.	B-X
Modified	B-X
proteins	B-X
had	B-X
increased	B-X
negative	B-X
charge	B-X
,	B-X
and	B-X
showed	B-X
a	B-X
more	B-X
than	B-X
10-fold	B-X
enhancement	B-X
of	B-X
degradation	B-X
by	B-X
mouse	B-X
peritoneal	B-X
macrophages	B-X
via	B-X
the	B-X
scavenger	B-X
receptor	B-X
pathway	B-X
.	B-X
Modification	B-X
was	B-X
prevented	B-X
by	B-X
blocking	B-X
lysine	B-X
residues	B-X
of	B-X
the	B-X
proteins	B-X
by	B-X
prior	B-X
reductive	B-X
methylation	B-X
.	B-X
Amino	B-X
acid	B-X
analysis	B-X
revealed	B-X
dose-dependent	B-X
modification	B-X
of	B-X
lysine	B-X
residues	B-X
with	B-X
no	B-X
significant	B-X
effects	B-X
on	B-X
any	B-X
other	B-X
amino	B-X
acid	B-X
.	B-X
Fab	B-X
fragments	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
specific	B-X
for	B-X
adducts	B-X
of	B-X
oxidation	B-X
products	B-X
with	B-X
lysine	B-X
prevented	B-X
the	B-X
uptake	B-X
of	B-X
oxidation	B-X
product-modified	B-X
LDL	B-X
and	B-X
oxidized	B-X
LDL	B-X
by	B-X
macrophages	B-X
.	B-X
Chromatography	B-X
of	B-X
oxidation	B-X
product-modified	B-X
LDL	B-X
over	B-X
Sepharose	B-X
CL-4B	B-X
showed	B-X
that	B-X
uptake	B-X
by	B-X
macrophages	B-X
did	B-X
not	B-X
require	B-X
LDL	B-X
aggregation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
relatively	B-X
simple	B-X
domain	B-X
consisting	B-X
of	B-X
a	B-X
cluster	B-X
of	B-X
suitably	B-X
derivatized	B-X
lysine	B-X
residues	B-X
is	B-X
sufficient	B-X
for	B-X
recognition	B-X
by	B-X
the	B-X
scavenger	B-X
receptor	B-X
of	B-X
macrophages	B-X
.	B-X

Adenosine	O
stimulation	O
of	O
AMP	O
deaminase	O
activity	O
in	O
adult	O
rat	O
cardiac	O
myocytes	O
.	O
<EOS>	B-X
Using	B-X
an	B-X
in	B-X
situ	B-X
assay	B-X
for	B-X
analyzing	B-X
AMP	B-X
deaminase	B-X
activity	B-X
in	B-X
isolated	B-X
adult	B-X
rat	B-X
ventricular	B-X
myocytes	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
IMP	B-X
production	B-X
is	B-X
stimulated	B-X
approximately	B-X
twofold	B-X
in	B-X
cardiac	B-X
cells	B-X
incubated	B-X
with	B-X
10	B-X
microM	B-X
adenosine	B-X
.	B-X
This	B-X
effect	B-X
of	B-X
adenosine	B-X
was	B-X
not	B-X
blocked	B-X
by	B-X
the	B-X
adenosine	B-X
A1-receptor	B-X
antagonist	B-X
8-cyclophenyl-1,3-dipropylaxanthine	B-X
(	B-X
0.01-1	B-X
microM	B-X
)	B-X
except	B-X
at	B-X
a	B-X
concentration	B-X
(	B-X
100	B-X
microM	B-X
)	B-X
that	B-X
may	B-X
inhibit	B-X
adenosine	B-X
transport	B-X
.	B-X
Similarly	B-X
,	B-X
in	B-X
situ	B-X
AMP	B-X
deaminase	B-X
activity	B-X
was	B-X
not	B-X
enhanced	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
specific	B-X
adenosine	B-X
A1-receptor	B-X
agonists	B-X
N6-phenylisopropyl	B-X
adenosine	B-X
or	B-X
cyclopentyladenosine	B-X
,	B-X
nor	B-X
was	B-X
it	B-X
sensitive	B-X
to	B-X
prior	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
.	B-X
Modulation	B-X
of	B-X
enzyme	B-X
activity	B-X
via	B-X
the	B-X
transmethylation	B-X
pathway	B-X
could	B-X
not	B-X
be	B-X
implicated	B-X
since	B-X
incubation	B-X
of	B-X
cardiac	B-X
cells	B-X
under	B-X
conditions	B-X
known	B-X
to	B-X
elevate	B-X
intracellular	B-X
S-adenosyl-L-homocysteine	B-X
had	B-X
no	B-X
demonstrable	B-X
effect	B-X
on	B-X
AMP	B-X
deaminase	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
direct	B-X
allosteric	B-X
effect	B-X
of	B-X
adenosine	B-X
on	B-X
the	B-X
partially	B-X
purified	B-X
rat	B-X
cardiac	B-X
enzyme	B-X
was	B-X
not	B-X
observed	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
intracellular	B-X
adenosine	B-X
modulates	B-X
rat	B-X
cardiac	B-X
AMP	B-X
deaminase	B-X
by	B-X
an	B-X
unknown	B-X
mechanism	B-X
.	B-X

Using	O
an	O
in	O
situ	O
assay	O
for	O
analyzing	O
AMP	O
deaminase	O
activity	O
in	O
isolated	O
adult	O
rat	O
ventricular	O
myocytes	O
,	O
we	O
have	O
shown	O
that	O
IMP	O
production	O
is	O
stimulated	O
approximately	O
twofold	O
in	O
cardiac	O
cells	O
incubated	O
with	O
10	O
microM	O
adenosine	O
.	O

This	O
effect	O
of	O
adenosine	O
was	O
not	O
blocked	O
by	O
the	O
adenosine	B-Protein
A1	I-Protein
-	I-Protein
receptor	I-Protein
antagonist	O
8	O
-	O
cyclophenyl	O
-	O
1	O
,	O
3	O
-	O
dipropylaxanthine	O
(	O
0	O
.	O
01	O
-	O
1	O
microM	O
)	O
except	O
at	O
a	O
concentration	O
(	O
100	O
microM	O
)	O
that	O
may	O
inhibit	O
adenosine	O
transport	O
.	O

Similarly	O
,	O
in	O
situ	O
AMP	O
deaminase	O
activity	O
was	O
not	O
enhanced	O
by	O
treatment	O
with	O
the	O
specific	O
adenosine	B-Protein
A1	I-Protein
-	I-Protein
receptor	I-Protein
agonists	O
N6	O
-	O
phenylisopropyl	O
adenosine	O
or	O
cyclopentyladenosine	O
,	O
nor	O
was	O
it	O
sensitive	O
to	O
prior	O
treatment	O
of	O
cells	O
with	O
pertussis	O
toxin	O
.	O
<EOS>	B-X
Using	B-X
an	B-X
in	B-X
situ	B-X
assay	B-X
for	B-X
analyzing	B-X
AMP	B-X
deaminase	B-X
activity	B-X
in	B-X
isolated	B-X
adult	B-X
rat	B-X
ventricular	B-X
myocytes	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
IMP	B-X
production	B-X
is	B-X
stimulated	B-X
approximately	B-X
twofold	B-X
in	B-X
cardiac	B-X
cells	B-X
incubated	B-X
with	B-X
10	B-X
microM	B-X
adenosine	B-X
.	B-X
This	B-X
effect	B-X
of	B-X
adenosine	B-X
was	B-X
not	B-X
blocked	B-X
by	B-X
the	B-X
adenosine	B-X
A1-receptor	B-X
antagonist	B-X
8-cyclophenyl-1,3-dipropylaxanthine	B-X
(	B-X
0.01-1	B-X
microM	B-X
)	B-X
except	B-X
at	B-X
a	B-X
concentration	B-X
(	B-X
100	B-X
microM	B-X
)	B-X
that	B-X
may	B-X
inhibit	B-X
adenosine	B-X
transport	B-X
.	B-X
Similarly	B-X
,	B-X
in	B-X
situ	B-X
AMP	B-X
deaminase	B-X
activity	B-X
was	B-X
not	B-X
enhanced	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
specific	B-X
adenosine	B-X
A1-receptor	B-X
agonists	B-X
N6-phenylisopropyl	B-X
adenosine	B-X
or	B-X
cyclopentyladenosine	B-X
,	B-X
nor	B-X
was	B-X
it	B-X
sensitive	B-X
to	B-X
prior	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
.	B-X
The	B-X
nucleoside	B-X
transport	B-X
blockers	B-X
S-4-nitrobenzyl-6-thioinosine	B-X
,	B-X
dipyridamole	B-X
,	B-X
and	B-X
papaverine	B-X
inhibited	B-X
adenosine-induced	B-X
increases	B-X
in	B-X
IMP	B-X
production	B-X
by	B-X
75-85	B-X
%	B-X
,	B-X
suggesting	B-X
an	B-X
intracellular	B-X
site	B-X
of	B-X
action	B-X
.	B-X
Modulation	B-X
of	B-X
enzyme	B-X
activity	B-X
via	B-X
the	B-X
transmethylation	B-X
pathway	B-X
could	B-X
not	B-X
be	B-X
implicated	B-X
since	B-X
incubation	B-X
of	B-X
cardiac	B-X
cells	B-X
under	B-X
conditions	B-X
known	B-X
to	B-X
elevate	B-X
intracellular	B-X
S-adenosyl-L-homocysteine	B-X
had	B-X
no	B-X
demonstrable	B-X
effect	B-X
on	B-X
AMP	B-X
deaminase	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
direct	B-X
allosteric	B-X
effect	B-X
of	B-X
adenosine	B-X
on	B-X
the	B-X
partially	B-X
purified	B-X
rat	B-X
cardiac	B-X
enzyme	B-X
was	B-X
not	B-X
observed	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
intracellular	B-X
adenosine	B-X
modulates	B-X
rat	B-X
cardiac	B-X
AMP	B-X
deaminase	B-X
by	B-X
an	B-X
unknown	B-X
mechanism	B-X
.	B-X

The	O
nucleoside	O
transport	O
blockers	O
S	O
-	O
4	O
-	O
nitrobenzyl	O
-	O
6	O
-	O
thioinosine	O
,	O
dipyridamole	O
,	O
and	O
papaverine	O
inhibited	O
adenosine	O
-	O
induced	O
increases	O
in	O
IMP	O
production	O
by	O
75	O
-	O
85	O
%	O
,	O
suggesting	O
an	O
intracellular	O
site	O
of	O
action	O
.	O
<EOS>	B-X
Using	B-X
an	B-X
in	B-X
situ	B-X
assay	B-X
for	B-X
analyzing	B-X
AMP	B-X
deaminase	B-X
activity	B-X
in	B-X
isolated	B-X
adult	B-X
rat	B-X
ventricular	B-X
myocytes	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
IMP	B-X
production	B-X
is	B-X
stimulated	B-X
approximately	B-X
twofold	B-X
in	B-X
cardiac	B-X
cells	B-X
incubated	B-X
with	B-X
10	B-X
microM	B-X
adenosine	B-X
.	B-X
This	B-X
effect	B-X
of	B-X
adenosine	B-X
was	B-X
not	B-X
blocked	B-X
by	B-X
the	B-X
adenosine	B-X
A1-receptor	B-X
antagonist	B-X
8-cyclophenyl-1,3-dipropylaxanthine	B-X
(	B-X
0.01-1	B-X
microM	B-X
)	B-X
except	B-X
at	B-X
a	B-X
concentration	B-X
(	B-X
100	B-X
microM	B-X
)	B-X
that	B-X
may	B-X
inhibit	B-X
adenosine	B-X
transport	B-X
.	B-X
Similarly	B-X
,	B-X
in	B-X
situ	B-X
AMP	B-X
deaminase	B-X
activity	B-X
was	B-X
not	B-X
enhanced	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
specific	B-X
adenosine	B-X
A1-receptor	B-X
agonists	B-X
N6-phenylisopropyl	B-X
adenosine	B-X
or	B-X
cyclopentyladenosine	B-X
,	B-X
nor	B-X
was	B-X
it	B-X
sensitive	B-X
to	B-X
prior	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
.	B-X
The	B-X
nucleoside	B-X
transport	B-X
blockers	B-X
S-4-nitrobenzyl-6-thioinosine	B-X
,	B-X
dipyridamole	B-X
,	B-X
and	B-X
papaverine	B-X
inhibited	B-X
adenosine-induced	B-X
increases	B-X
in	B-X
IMP	B-X
production	B-X
by	B-X
75-85	B-X
%	B-X
,	B-X
suggesting	B-X
an	B-X
intracellular	B-X
site	B-X
of	B-X
action	B-X
.	B-X
Modulation	B-X
of	B-X
enzyme	B-X
activity	B-X
via	B-X
the	B-X
transmethylation	B-X
pathway	B-X
could	B-X
not	B-X
be	B-X
implicated	B-X
since	B-X
incubation	B-X
of	B-X
cardiac	B-X
cells	B-X
under	B-X
conditions	B-X
known	B-X
to	B-X
elevate	B-X
intracellular	B-X
S-adenosyl-L-homocysteine	B-X
had	B-X
no	B-X
demonstrable	B-X
effect	B-X
on	B-X
AMP	B-X
deaminase	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
direct	B-X
allosteric	B-X
effect	B-X
of	B-X
adenosine	B-X
on	B-X
the	B-X
partially	B-X
purified	B-X
rat	B-X
cardiac	B-X
enzyme	B-X
was	B-X
not	B-X
observed	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
intracellular	B-X
adenosine	B-X
modulates	B-X
rat	B-X
cardiac	B-X
AMP	B-X
deaminase	B-X
by	B-X
an	B-X
unknown	B-X
mechanism	B-X
.	B-X

Modulation	O
of	O
enzyme	O
activity	O
via	O
the	O
transmethylation	O
pathway	O
could	O
not	O
be	O
implicated	O
since	O
incubation	O
of	O
cardiac	O
cells	O
under	O
conditions	O
known	O
to	O
elevate	O
intracellular	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
homocysteine	O
had	O
no	O
demonstrable	O
effect	O
on	O
AMP	O
deaminase	O
.	O
<EOS>	B-X
Adenosine	B-X
kinase	B-X
(	B-X
ADK	B-X
)	B-X
is	B-X
a	B-X
major	B-X
enzyme	B-X
regulating	B-X
intracellular	B-X
adenosine	B-X
levels	B-X
but	B-X
is	B-X
function	B-X
in	B-X
VSMC	B-X
remains	B-X
unclear	B-X
.	B-X

Furthermore	O
,	O
a	O
direct	O
allosteric	O
effect	O
of	O
adenosine	O
on	O
the	O
partially	O
purified	O
rat	O
cardiac	O
enzyme	O
was	O
not	O
observed	O
.	O

The	O
results	O
indicate	O
that	O
intracellular	O
adenosine	O
modulates	O
rat	O
cardiac	O
AMP	O
deaminase	O
by	O
an	O
unknown	O
mechanism	O
.	O
<EOS>	B-X
Using	B-X
an	B-X
in	B-X
situ	B-X
assay	B-X
for	B-X
analyzing	B-X
AMP	B-X
deaminase	B-X
activity	B-X
in	B-X
isolated	B-X
adult	B-X
rat	B-X
ventricular	B-X
myocytes	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
IMP	B-X
production	B-X
is	B-X
stimulated	B-X
approximately	B-X
twofold	B-X
in	B-X
cardiac	B-X
cells	B-X
incubated	B-X
with	B-X
10	B-X
microM	B-X
adenosine	B-X
.	B-X
This	B-X
effect	B-X
of	B-X
adenosine	B-X
was	B-X
not	B-X
blocked	B-X
by	B-X
the	B-X
adenosine	B-X
A1-receptor	B-X
antagonist	B-X
8-cyclophenyl-1,3-dipropylaxanthine	B-X
(	B-X
0.01-1	B-X
microM	B-X
)	B-X
except	B-X
at	B-X
a	B-X
concentration	B-X
(	B-X
100	B-X
microM	B-X
)	B-X
that	B-X
may	B-X
inhibit	B-X
adenosine	B-X
transport	B-X
.	B-X
Similarly	B-X
,	B-X
in	B-X
situ	B-X
AMP	B-X
deaminase	B-X
activity	B-X
was	B-X
not	B-X
enhanced	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
specific	B-X
adenosine	B-X
A1-receptor	B-X
agonists	B-X
N6-phenylisopropyl	B-X
adenosine	B-X
or	B-X
cyclopentyladenosine	B-X
,	B-X
nor	B-X
was	B-X
it	B-X
sensitive	B-X
to	B-X
prior	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
.	B-X
The	B-X
nucleoside	B-X
transport	B-X
blockers	B-X
S-4-nitrobenzyl-6-thioinosine	B-X
,	B-X
dipyridamole	B-X
,	B-X
and	B-X
papaverine	B-X
inhibited	B-X
adenosine-induced	B-X
increases	B-X
in	B-X
IMP	B-X
production	B-X
by	B-X
75-85	B-X
%	B-X
,	B-X
suggesting	B-X
an	B-X
intracellular	B-X
site	B-X
of	B-X
action	B-X
.	B-X
Modulation	B-X
of	B-X
enzyme	B-X
activity	B-X
via	B-X
the	B-X
transmethylation	B-X
pathway	B-X
could	B-X
not	B-X
be	B-X
implicated	B-X
since	B-X
incubation	B-X
of	B-X
cardiac	B-X
cells	B-X
under	B-X
conditions	B-X
known	B-X
to	B-X
elevate	B-X
intracellular	B-X
S-adenosyl-L-homocysteine	B-X
had	B-X
no	B-X
demonstrable	B-X
effect	B-X
on	B-X
AMP	B-X
deaminase	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
direct	B-X
allosteric	B-X
effect	B-X
of	B-X
adenosine	B-X
on	B-X
the	B-X
partially	B-X
purified	B-X
rat	B-X
cardiac	B-X
enzyme	B-X
was	B-X
not	B-X
observed	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
intracellular	B-X
adenosine	B-X
modulates	B-X
rat	B-X
cardiac	B-X
AMP	B-X
deaminase	B-X
by	B-X
an	B-X
unknown	B-X
mechanism	B-X
.	B-X

Purification	O
and	O
characterization	O
of	O
Saccharomyces	O
cerevisiae	O
DNA	B-Protein
damage	I-Protein
-	I-Protein
responsive	I-Protein
protein	I-Protein
48	I-Protein
(	O
DDRP	B-Protein
48	I-Protein
)	O
.	O
<EOS>	B-X
A	B-X
yeast	B-X
protein	B-X
was	B-X
purified	B-X
from	B-X
wild	B-X
type	B-X
Saccharomyces	B-X
cerevisiae	B-X
(	B-X
S.	B-X
cerevisiae	B-X
)	B-X
to	B-X
near	B-X
homogeneity	B-X
using	B-X
an	B-X
ethanolamine	B-X
affinity	B-X
chromatography	B-X
procedure	B-X
.	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
analyses	B-X
identified	B-X
this	B-X
protein	B-X
as	B-X
the	B-X
product	B-X
of	B-X
the	B-X
second	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
S.	B-X
cerevisiae	B-X
DNA	B-X
Damage-responsive	B-X
gene	B-X
48	B-X
(	B-X
DDR48	B-X
)	B-X
(	B-X
Treger	B-X
,	B-X
J.M.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1990	B-X
)	B-X
Mol	B-X
.	B-X
10	B-X
,	B-X
3174-3184	B-X
)	B-X
The	B-X
first	B-X
methionine	B-X
residue	B-X
encoded	B-X
by	B-X
the	B-X
translation	B-X
starting	B-X
codon	B-X
was	B-X
not	B-X
present	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
which	B-X
is	B-X
designated	B-X
as	B-X
DDRP	B-X
48	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
negatively	B-X
charged	B-X
and	B-X
highly	B-X
hydrophilic	B-X
glycoprotein	B-X
.	B-X
The	B-X
glycosidase	B-X
cleavage	B-X
analyses	B-X
suggested	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
mainly	B-X
N-link-glycosylated	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
DDRP	B-X
48	B-X
was	B-X
estimated	B-X
to	B-X
be	B-X
approximately	B-X
65	B-X
kilodaltons	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
able	B-X
to	B-X
hydrolyze	B-X
ATP	B-X
and	B-X
GTP	B-X
yielding	B-X
PPi	B-X
.	B-X
The	B-X
Western	B-X
blot	B-X
analysis	B-X
demonstrated	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
expressed	B-X
to	B-X
various	B-X
concentrations	B-X
in	B-X
different	B-X
S.	B-X
cerevisiae	B-X
strains	B-X
.	B-X
Increased	B-X
DDRP	B-X
48	B-X
abundance	B-X
was	B-X
observed	B-X
after	B-X
yeast	B-X
cells	B-X
carrying	B-X
the	B-X
wild	B-X
type	B-X
RAD	B-X
52	B-X
gene	B-X
were	B-X
exposed	B-X
to	B-X
either	B-X
ethylmethane	B-X
sulfonate	B-X
or	B-X
heat	B-X
shock	B-X
treatments	B-X
.	B-X
After	B-X
similar	B-X
DNA-damaging	B-X
treatments	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
inductions	B-X
of	B-X
DDRP	B-X
48	B-X
were	B-X
found	B-X
in	B-X
a	B-X
rad	B-X
52	B-X
mutant	B-X
strain	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
predictions	B-X
resulting	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
DDR	B-X
48	B-X
gene	B-X
(	B-X
Maga	B-X
,	B-X
J.A.	B-X
,	B-X
McClanahan	B-X
,	B-X
T.A.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1986	B-X
)	B-X
Mol	B-X
.	B-X

A	O
yeast	O
protein	O
was	O
purified	O
from	O
wild	O
type	O
Saccharomyces	O
cerevisiae	O
(	O
S	O
.	O
cerevisiae	O
)	O
to	O
near	O
homogeneity	O
using	O
an	O
ethanolamine	O
affinity	O
chromatography	O
procedure	O
.	O
<EOS>	B-X
A	B-X
yeast	B-X
protein	B-X
was	B-X
purified	B-X
from	B-X
wild	B-X
type	B-X
Saccharomyces	B-X
cerevisiae	B-X
(	B-X
S.	B-X
cerevisiae	B-X
)	B-X
to	B-X
near	B-X
homogeneity	B-X
using	B-X
an	B-X
ethanolamine	B-X
affinity	B-X
chromatography	B-X
procedure	B-X
.	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
analyses	B-X
identified	B-X
this	B-X
protein	B-X
as	B-X
the	B-X
product	B-X
of	B-X
the	B-X
second	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
S.	B-X
cerevisiae	B-X
DNA	B-X
Damage-responsive	B-X
gene	B-X
48	B-X
(	B-X
DDR48	B-X
)	B-X
(	B-X
Treger	B-X
,	B-X
J.M.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1990	B-X
)	B-X
Mol	B-X
.	B-X
10	B-X
,	B-X
3174-3184	B-X
)	B-X
The	B-X
first	B-X
methionine	B-X
residue	B-X
encoded	B-X
by	B-X
the	B-X
translation	B-X
starting	B-X
codon	B-X
was	B-X
not	B-X
present	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
which	B-X
is	B-X
designated	B-X
as	B-X
DDRP	B-X
48	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
negatively	B-X
charged	B-X
and	B-X
highly	B-X
hydrophilic	B-X
glycoprotein	B-X
.	B-X
The	B-X
Western	B-X
blot	B-X
analysis	B-X
demonstrated	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
expressed	B-X
to	B-X
various	B-X
concentrations	B-X
in	B-X
different	B-X
S.	B-X
cerevisiae	B-X
strains	B-X
.	B-X
Increased	B-X
DDRP	B-X
48	B-X
abundance	B-X
was	B-X
observed	B-X
after	B-X
yeast	B-X
cells	B-X
carrying	B-X
the	B-X
wild	B-X
type	B-X
RAD	B-X
52	B-X
gene	B-X
were	B-X
exposed	B-X
to	B-X
either	B-X
ethylmethane	B-X
sulfonate	B-X
or	B-X
heat	B-X
shock	B-X
treatments	B-X
.	B-X

The	O
N	O
-	O
terminal	O
amino	O
acid	O
sequencing	O
and	O
the	O
amino	O
acid	O
composition	O
analyses	O
identified	O
this	O
protein	O
as	O
the	O
product	O
of	O
the	O
second	O
open	O
reading	O
frame	O
of	O
S	O
.	O
cerevisiae	O
DNA	B-Protein
Damage	I-Protein
-	I-Protein
responsive	I-Protein
gene	I-Protein
48	I-Protein
(	O
DDR48	B-Protein
)	O
(	O
Treger	O
,	O
J	O
.	O
M	O
.	O
,	O
and	O
McEntee	O
,	O
K	O
.	O
(	O
1990	O
)	O
Mol	O
.	O
Cell	O
.	O
Biol	O
.	O
10	O
,	O
3174	O
-	O
3184	O
)	O
The	O
first	O
methionine	O
residue	O
encoded	O
by	O
the	O
translation	O
starting	O
codon	O
was	O
not	O
present	O
in	O
the	O
mature	O
protein	O
which	O
is	O
designated	O
as	O
DDRP	B-Protein
48	I-Protein
.	O

DDRP	B-Protein
48	I-Protein
was	O
found	O
to	O
be	O
a	O
negatively	O
charged	O
and	O
highly	O
hydrophilic	O
glycoprotein	O
.	O
<EOS>	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
analyses	B-X
identified	B-X
this	B-X
protein	B-X
as	B-X
the	B-X
product	B-X
of	B-X
the	B-X
second	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
S.	B-X
cerevisiae	B-X
DNA	B-X
Damage-responsive	B-X
gene	B-X
48	B-X
(	B-X
DDR48	B-X
)	B-X
(	B-X
Treger	B-X
,	B-X
J.M.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1990	B-X
)	B-X
Mol	B-X
.	B-X
10	B-X
,	B-X
3174-3184	B-X
)	B-X
The	B-X
first	B-X
methionine	B-X
residue	B-X
encoded	B-X
by	B-X
the	B-X
translation	B-X
starting	B-X
codon	B-X
was	B-X
not	B-X
present	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
which	B-X
is	B-X
designated	B-X
as	B-X
DDRP	B-X
48	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
negatively	B-X
charged	B-X
and	B-X
highly	B-X
hydrophilic	B-X
glycoprotein	B-X
.	B-X
The	B-X
glycosidase	B-X
cleavage	B-X
analyses	B-X
suggested	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
mainly	B-X
N-link-glycosylated	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
DDRP	B-X
48	B-X
was	B-X
estimated	B-X
to	B-X
be	B-X
approximately	B-X
65	B-X
kilodaltons	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
able	B-X
to	B-X
hydrolyze	B-X
ATP	B-X
and	B-X
GTP	B-X
yielding	B-X
PPi	B-X
.	B-X
The	B-X
Western	B-X
blot	B-X
analysis	B-X
demonstrated	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
expressed	B-X
to	B-X
various	B-X
concentrations	B-X
in	B-X
different	B-X
S.	B-X
cerevisiae	B-X
strains	B-X
.	B-X
Increased	B-X
DDRP	B-X
48	B-X
abundance	B-X
was	B-X
observed	B-X
after	B-X
yeast	B-X
cells	B-X
carrying	B-X
the	B-X
wild	B-X
type	B-X
RAD	B-X
52	B-X
gene	B-X
were	B-X
exposed	B-X
to	B-X
either	B-X
ethylmethane	B-X
sulfonate	B-X
or	B-X
heat	B-X
shock	B-X
treatments	B-X
.	B-X
After	B-X
similar	B-X
DNA-damaging	B-X
treatments	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
inductions	B-X
of	B-X
DDRP	B-X
48	B-X
were	B-X
found	B-X
in	B-X
a	B-X
rad	B-X
52	B-X
mutant	B-X
strain	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
predictions	B-X
resulting	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
DDR	B-X
48	B-X
gene	B-X
(	B-X
Maga	B-X
,	B-X
J.A.	B-X
,	B-X
McClanahan	B-X
,	B-X
T.A.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1986	B-X
)	B-X
Mol	B-X
.	B-X

The	O
glycosidase	O
cleavage	O
analyses	O
suggested	O
that	O
DDRP	B-Protein
48	I-Protein
was	O
mainly	O
N	O
-	O
link	O
-	O
glycosylated	O
.	O
<EOS>	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
analyses	B-X
identified	B-X
this	B-X
protein	B-X
as	B-X
the	B-X
product	B-X
of	B-X
the	B-X
second	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
S.	B-X
cerevisiae	B-X
DNA	B-X
Damage-responsive	B-X
gene	B-X
48	B-X
(	B-X
DDR48	B-X
)	B-X
(	B-X
Treger	B-X
,	B-X
J.M.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1990	B-X
)	B-X
Mol	B-X
.	B-X
10	B-X
,	B-X
3174-3184	B-X
)	B-X
The	B-X
first	B-X
methionine	B-X
residue	B-X
encoded	B-X
by	B-X
the	B-X
translation	B-X
starting	B-X
codon	B-X
was	B-X
not	B-X
present	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
which	B-X
is	B-X
designated	B-X
as	B-X
DDRP	B-X
48	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
negatively	B-X
charged	B-X
and	B-X
highly	B-X
hydrophilic	B-X
glycoprotein	B-X
.	B-X
The	B-X
glycosidase	B-X
cleavage	B-X
analyses	B-X
suggested	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
mainly	B-X
N-link-glycosylated	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
DDRP	B-X
48	B-X
was	B-X
estimated	B-X
to	B-X
be	B-X
approximately	B-X
65	B-X
kilodaltons	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
able	B-X
to	B-X
hydrolyze	B-X
ATP	B-X
and	B-X
GTP	B-X
yielding	B-X
PPi	B-X
.	B-X
The	B-X
Western	B-X
blot	B-X
analysis	B-X
demonstrated	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
expressed	B-X
to	B-X
various	B-X
concentrations	B-X
in	B-X
different	B-X
S.	B-X
cerevisiae	B-X
strains	B-X
.	B-X
Increased	B-X
DDRP	B-X
48	B-X
abundance	B-X
was	B-X
observed	B-X
after	B-X
yeast	B-X
cells	B-X
carrying	B-X
the	B-X
wild	B-X
type	B-X
RAD	B-X
52	B-X
gene	B-X
were	B-X
exposed	B-X
to	B-X
either	B-X
ethylmethane	B-X
sulfonate	B-X
or	B-X
heat	B-X
shock	B-X
treatments	B-X
.	B-X
After	B-X
similar	B-X
DNA-damaging	B-X
treatments	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
inductions	B-X
of	B-X
DDRP	B-X
48	B-X
were	B-X
found	B-X
in	B-X
a	B-X
rad	B-X
52	B-X
mutant	B-X
strain	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
predictions	B-X
resulting	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
DDR	B-X
48	B-X
gene	B-X
(	B-X
Maga	B-X
,	B-X
J.A.	B-X
,	B-X
McClanahan	B-X
,	B-X
T.A.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1986	B-X
)	B-X
Mol	B-X
.	B-X

The	O
apparent	O
molecular	O
mass	O
of	O
DDRP	B-Protein
48	I-Protein
was	O
estimated	O
to	O
be	O
approximately	O
65	O
kilodaltons	O
.	O
<EOS>	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
analyses	B-X
identified	B-X
this	B-X
protein	B-X
as	B-X
the	B-X
product	B-X
of	B-X
the	B-X
second	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
S.	B-X
cerevisiae	B-X
DNA	B-X
Damage-responsive	B-X
gene	B-X
48	B-X
(	B-X
DDR48	B-X
)	B-X
(	B-X
Treger	B-X
,	B-X
J.M.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1990	B-X
)	B-X
Mol	B-X
.	B-X
10	B-X
,	B-X
3174-3184	B-X
)	B-X
The	B-X
first	B-X
methionine	B-X
residue	B-X
encoded	B-X
by	B-X
the	B-X
translation	B-X
starting	B-X
codon	B-X
was	B-X
not	B-X
present	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
which	B-X
is	B-X
designated	B-X
as	B-X
DDRP	B-X
48	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
negatively	B-X
charged	B-X
and	B-X
highly	B-X
hydrophilic	B-X
glycoprotein	B-X
.	B-X
The	B-X
glycosidase	B-X
cleavage	B-X
analyses	B-X
suggested	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
mainly	B-X
N-link-glycosylated	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
DDRP	B-X
48	B-X
was	B-X
estimated	B-X
to	B-X
be	B-X
approximately	B-X
65	B-X
kilodaltons	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
able	B-X
to	B-X
hydrolyze	B-X
ATP	B-X
and	B-X
GTP	B-X
yielding	B-X
PPi	B-X
.	B-X
The	B-X
Western	B-X
blot	B-X
analysis	B-X
demonstrated	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
expressed	B-X
to	B-X
various	B-X
concentrations	B-X
in	B-X
different	B-X
S.	B-X
cerevisiae	B-X
strains	B-X
.	B-X
Increased	B-X
DDRP	B-X
48	B-X
abundance	B-X
was	B-X
observed	B-X
after	B-X
yeast	B-X
cells	B-X
carrying	B-X
the	B-X
wild	B-X
type	B-X
RAD	B-X
52	B-X
gene	B-X
were	B-X
exposed	B-X
to	B-X
either	B-X
ethylmethane	B-X
sulfonate	B-X
or	B-X
heat	B-X
shock	B-X
treatments	B-X
.	B-X
After	B-X
similar	B-X
DNA-damaging	B-X
treatments	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
inductions	B-X
of	B-X
DDRP	B-X
48	B-X
were	B-X
found	B-X
in	B-X
a	B-X
rad	B-X
52	B-X
mutant	B-X
strain	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
predictions	B-X
resulting	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
DDR	B-X
48	B-X
gene	B-X
(	B-X
Maga	B-X
,	B-X
J.A.	B-X
,	B-X
McClanahan	B-X
,	B-X
T.A.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1986	B-X
)	B-X
Mol	B-X
.	B-X

DDRP	B-Protein
48	I-Protein
was	O
found	O
able	O
to	O
hydrolyze	O
ATP	O
and	O
GTP	O
yielding	O
PPi	O
.	O
<EOS>	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
analyses	B-X
identified	B-X
this	B-X
protein	B-X
as	B-X
the	B-X
product	B-X
of	B-X
the	B-X
second	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
S.	B-X
cerevisiae	B-X
DNA	B-X
Damage-responsive	B-X
gene	B-X
48	B-X
(	B-X
DDR48	B-X
)	B-X
(	B-X
Treger	B-X
,	B-X
J.M.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1990	B-X
)	B-X
Mol	B-X
.	B-X
10	B-X
,	B-X
3174-3184	B-X
)	B-X
The	B-X
first	B-X
methionine	B-X
residue	B-X
encoded	B-X
by	B-X
the	B-X
translation	B-X
starting	B-X
codon	B-X
was	B-X
not	B-X
present	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
which	B-X
is	B-X
designated	B-X
as	B-X
DDRP	B-X
48	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
negatively	B-X
charged	B-X
and	B-X
highly	B-X
hydrophilic	B-X
glycoprotein	B-X
.	B-X
The	B-X
glycosidase	B-X
cleavage	B-X
analyses	B-X
suggested	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
mainly	B-X
N-link-glycosylated	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
DDRP	B-X
48	B-X
was	B-X
estimated	B-X
to	B-X
be	B-X
approximately	B-X
65	B-X
kilodaltons	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
able	B-X
to	B-X
hydrolyze	B-X
ATP	B-X
and	B-X
GTP	B-X
yielding	B-X
PPi	B-X
.	B-X
The	B-X
Km	B-X
values	B-X
for	B-X
ATP	B-X
and	B-X
GTP	B-X
are	B-X
0.29	B-X
mM	B-X
and	B-X
0.58	B-X
mM	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
Western	B-X
blot	B-X
analysis	B-X
demonstrated	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
expressed	B-X
to	B-X
various	B-X
concentrations	B-X
in	B-X
different	B-X
S.	B-X
cerevisiae	B-X
strains	B-X
.	B-X
Increased	B-X
DDRP	B-X
48	B-X
abundance	B-X
was	B-X
observed	B-X
after	B-X
yeast	B-X
cells	B-X
carrying	B-X
the	B-X
wild	B-X
type	B-X
RAD	B-X
52	B-X
gene	B-X
were	B-X
exposed	B-X
to	B-X
either	B-X
ethylmethane	B-X
sulfonate	B-X
or	B-X
heat	B-X
shock	B-X
treatments	B-X
.	B-X
After	B-X
similar	B-X
DNA-damaging	B-X
treatments	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
inductions	B-X
of	B-X
DDRP	B-X
48	B-X
were	B-X
found	B-X
in	B-X
a	B-X
rad	B-X
52	B-X
mutant	B-X
strain	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
predictions	B-X
resulting	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
DDR	B-X
48	B-X
gene	B-X
(	B-X
Maga	B-X
,	B-X
J.A.	B-X
,	B-X
McClanahan	B-X
,	B-X
T.A.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1986	B-X
)	B-X
Mol	B-X
.	B-X

The	O
Km	O
values	O
for	O
ATP	O
and	O
GTP	O
are	O
0	O
.	O
29	O
mM	O
and	O
0	O
.	O
58	O
mM	O
,	O
respectively	O
.	O

The	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
DDRP	B-Protein
48	I-Protein
was	O
expressed	O
to	O
various	O
concentrations	O
in	O
different	O
S	O
.	O
cerevisiae	O
strains	O
.	O
<EOS>	B-X
A	B-X
yeast	B-X
protein	B-X
was	B-X
purified	B-X
from	B-X
wild	B-X
type	B-X
Saccharomyces	B-X
cerevisiae	B-X
(	B-X
S.	B-X
cerevisiae	B-X
)	B-X
to	B-X
near	B-X
homogeneity	B-X
using	B-X
an	B-X
ethanolamine	B-X
affinity	B-X
chromatography	B-X
procedure	B-X
.	B-X
The	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
analyses	B-X
identified	B-X
this	B-X
protein	B-X
as	B-X
the	B-X
product	B-X
of	B-X
the	B-X
second	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
S.	B-X
cerevisiae	B-X
DNA	B-X
Damage-responsive	B-X
gene	B-X
48	B-X
(	B-X
DDR48	B-X
)	B-X
(	B-X
Treger	B-X
,	B-X
J.M.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1990	B-X
)	B-X
Mol	B-X
.	B-X
10	B-X
,	B-X
3174-3184	B-X
)	B-X
The	B-X
first	B-X
methionine	B-X
residue	B-X
encoded	B-X
by	B-X
the	B-X
translation	B-X
starting	B-X
codon	B-X
was	B-X
not	B-X
present	B-X
in	B-X
the	B-X
mature	B-X
protein	B-X
which	B-X
is	B-X
designated	B-X
as	B-X
DDRP	B-X
48	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
negatively	B-X
charged	B-X
and	B-X
highly	B-X
hydrophilic	B-X
glycoprotein	B-X
.	B-X
The	B-X
glycosidase	B-X
cleavage	B-X
analyses	B-X
suggested	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
mainly	B-X
N-link-glycosylated	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
DDRP	B-X
48	B-X
was	B-X
estimated	B-X
to	B-X
be	B-X
approximately	B-X
65	B-X
kilodaltons	B-X
.	B-X
DDRP	B-X
48	B-X
was	B-X
found	B-X
able	B-X
to	B-X
hydrolyze	B-X
ATP	B-X
and	B-X
GTP	B-X
yielding	B-X
PPi	B-X
.	B-X
The	B-X
Western	B-X
blot	B-X
analysis	B-X
demonstrated	B-X
that	B-X
DDRP	B-X
48	B-X
was	B-X
expressed	B-X
to	B-X
various	B-X
concentrations	B-X
in	B-X
different	B-X
S.	B-X
cerevisiae	B-X
strains	B-X
.	B-X
Increased	B-X
DDRP	B-X
48	B-X
abundance	B-X
was	B-X
observed	B-X
after	B-X
yeast	B-X
cells	B-X
carrying	B-X
the	B-X
wild	B-X
type	B-X
RAD	B-X
52	B-X
gene	B-X
were	B-X
exposed	B-X
to	B-X
either	B-X
ethylmethane	B-X
sulfonate	B-X
or	B-X
heat	B-X
shock	B-X
treatments	B-X
.	B-X
After	B-X
similar	B-X
DNA-damaging	B-X
treatments	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
inductions	B-X
of	B-X
DDRP	B-X
48	B-X
were	B-X
found	B-X
in	B-X
a	B-X
rad	B-X
52	B-X
mutant	B-X
strain	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
predictions	B-X
resulting	B-X
from	B-X
previous	B-X
studies	B-X
on	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
DDR	B-X
48	B-X
gene	B-X
(	B-X
Maga	B-X
,	B-X
J.A.	B-X
,	B-X
McClanahan	B-X
,	B-X
T.A.	B-X
,	B-X
and	B-X
McEntee	B-X
,	B-X
K.	B-X
(	B-X
1986	B-X
)	B-X
Mol	B-X
.	B-X

Increased	O
DDRP	B-Protein
48	O
abundance	O
was	O
observed	O
after	O
yeast	O
cells	O
carrying	O
the	O
wild	B-Protein
type	I-Protein
RAD	I-Protein
52	I-Protein
gene	I-Protein
were	O
exposed	O
to	O
either	O
ethylmethane	O
sulfonate	O
or	O
heat	O
shock	O
treatments	O
.	O
<EOS>	B-X
Repeated	B-X
sauna	B-X
use	B-X
acclimates	B-X
the	B-X
body	B-X
to	B-X
heat	B-X
and	B-X
optimizes	B-X
the	B-X
body	B-X
's	B-X
response	B-X
to	B-X
future	B-X
exposures	B-X
,	B-X
likely	B-X
due	B-X
to	B-X
the	B-X
biological	B-X
phenomenon	B-X
known	B-X
as	B-X
hormesis	B-X
.	B-X
This	B-X
review	B-X
presents	B-X
an	B-X
overview	B-X
of	B-X
sauna	B-X
practices	B-X
;	B-X
elucidates	B-X
the	B-X
body	B-X
's	B-X
physiological	B-X
response	B-X
to	B-X
heat	B-X
stress	B-X
and	B-X
the	B-X
molecular	B-X
mechanisms	B-X
that	B-X
drive	B-X
the	B-X
response	B-X
;	B-X
enumerates	B-X
the	B-X
myriad	B-X
health	B-X
benefits	B-X
associated	B-X
with	B-X
sauna	B-X
use	B-X
;	B-X
and	B-X
describes	B-X
sauna	B-X
use	B-X
concerns	B-X
.	B-X
The	B-X
heat	B-X
shock	B-X
transcription	B-X
factors	B-X
(	B-X
HSFs	B-X
)	B-X
were	B-X
discovered	B-X
over	B-X
30	B-X
years	B-X
ago	B-X
as	B-X
direct	B-X
transcriptional	B-X
activators	B-X
of	B-X
genes	B-X
regulated	B-X
by	B-X
thermal	B-X
stress	B-X
,	B-X
encoding	B-X
heat	B-X
shock	B-X
proteins	B-X
.	B-X
The	B-X
accepted	B-X
paradigm	B-X
posited	B-X
that	B-X
HSFs	B-X
exclusively	B-X
activate	B-X
the	B-X
expression	B-X
of	B-X
protein	B-X
chaperones	B-X
in	B-X
response	B-X
to	B-X
conditions	B-X
that	B-X
cause	B-X
protein	B-X
misfolding	B-X
by	B-X
recognizing	B-X
a	B-X
simple	B-X
promoter	B-X
binding	B-X
site	B-X
referred	B-X
to	B-X
as	B-X
a	B-X
heat	B-X
shock	B-X
element	B-X
.	B-X
However	B-X
,	B-X
we	B-X
now	B-X
realize	B-X
that	B-X
the	B-X
mammalian	B-X
family	B-X
of	B-X
HSFs	B-X
comprises	B-X
proteins	B-X
that	B-X
independently	B-X
or	B-X
in	B-X
concert	B-X
drive	B-X
combinatorial	B-X
gene	B-X
regulation	B-X
events	B-X
that	B-X
activate	B-X
or	B-X
repress	B-X
transcription	B-X
in	B-X
different	B-X
contexts	B-X
.	B-X
Advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
HSF	B-X
structure	B-X
,	B-X
post-translational	B-X
modifications	B-X
and	B-X
the	B-X
breadth	B-X
of	B-X
HSF-regulated	B-X
target	B-X
genes	B-X
have	B-X
revealed	B-X
exciting	B-X
new	B-X
mechanisms	B-X
that	B-X
modulate	B-X
HSFs	B-X
and	B-X
shed	B-X
new	B-X
light	B-X
on	B-X
their	B-X
roles	B-X
in	B-X
physiology	B-X
and	B-X
pathology	B-X
.	B-X
For	B-X
example	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
HSF1	B-X
to	B-X
protect	B-X
cells	B-X
from	B-X
proteotoxicity	B-X
and	B-X
cell	B-X
death	B-X
is	B-X
impaired	B-X
in	B-X
neurodegenerative	B-X
diseases	B-X
but	B-X
can	B-X
be	B-X
exploited	B-X
by	B-X
cancer	B-X
cells	B-X
to	B-X
support	B-X
their	B-X
growth	B-X
,	B-X
survival	B-X
and	B-X
metastasis	B-X
.	B-X

After	O
similar	O
DNA	O
-	O
damaging	O
treatments	O
,	O
however	O
,	O
no	O
significant	O
inductions	O
of	O
DDRP	B-Protein
48	I-Protein
were	O
found	O
in	O
a	O
rad	O
52	O
mutant	O
strain	O
.	O

These	O
observations	O
are	O
consistent	O
with	O
the	O
predictions	O
resulting	O
from	O
previous	O
studies	O
on	O
transcriptional	O
regulation	O
of	O
the	O
DDR	B-Protein
48	I-Protein
gene	O
(	O
Maga	O
,	O
J	O
.	O
A	O
.	O
,	O
McClanahan	O
,	O
T	O
.	O
A	O
.	O
,	O
and	O
McEntee	O
,	O
K	O
.	O
(	O
1986	O
)	O
Mol	O
.	O
&	O
Gen	O
.	O
Genet	O
.	O
205	O
,	O
276	O
-	O
284	O
;	O
McClanahan	O
,	O
T	O
.	O
,	O
and	O
McEntee	O
,	O
K	O
.	O
(	O
1986	O
)	O
Mol	O
.	O
Cell	O
.	O
Biol	O
.	O
6	O
,	O
90	O
-	O
96	O
)	O
.	O

Control	O
of	O
IgG	O
/	O
Fc	B-Protein
glycosylation	O
:	O
a	O
comparison	O
of	O
oligosaccharides	O
from	O
chimeric	O
human	O
/	O
mouse	O
and	O
mouse	O
subclass	O
immunoglobulin	O
Gs	O
.	O
<EOS>	B-X
Oligosaccharide	B-X
profiles	B-X
were	B-X
obtained	B-X
for	B-X
chimeric	B-X
mouse-human	B-X
antibodies	B-X
corresponding	B-X
to	B-X
each	B-X
of	B-X
the	B-X
human	B-X
IgG	B-X
subclasses	B-X
1-4	B-X
,	B-X
and	B-X
mouse	B-X
IgG2b	B-X
antibodies	B-X
each	B-X
expressed	B-X
in	B-X
the	B-X
mouse	B-X
J558L	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
antibodies	B-X
have	B-X
specificity	B-X
for	B-X
the	B-X
NIP	B-X
hapten	B-X
and	B-X
form	B-X
a	B-X
matched	B-X
set	B-X
of	B-X
IgGs	B-X
.	B-X
An	B-X
IgG4	B-X
chimeric	B-X
antibody	B-X
(	B-X
B72.3	B-X
)	B-X
produced	B-X
in	B-X
the	B-X
chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO-K1	B-X
)	B-X
cell	B-X
line	B-X
was	B-X
also	B-X
analysed	B-X
for	B-X
carbohydrate	B-X
.	B-X
Additionally	B-X
aglycosylated	B-X
mutants	B-X
of	B-X
this	B-X
IgG4	B-X
(	B-X
B72.3	B-X
)	B-X
and	B-X
anti-NIP	B-X
mouse	B-X
IgG2b	B-X
were	B-X
analysed	B-X
.	B-X
The	B-X
total	B-X
lack	B-X
of	B-X
carbohydrate	B-X
found	B-X
in	B-X
the	B-X
aglycosylated	B-X
site-directed	B-X
mutants	B-X
human	B-X
chimeric	B-X
IgG4	B-X
B72.3	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Gln	B-X
)	B-X
and	B-X
mouse	B-X
IgG2b	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Ala	B-X
)	B-X
demonstrates	B-X
that	B-X
there	B-X
are	B-X
no	B-X
N-glycosylation	B-X
sites	B-X
other	B-X
than	B-X
Asn	B-X
297	B-X
.	B-X
Therefore	B-X
glycosylation	B-X
profiles	B-X
for	B-X
all	B-X
the	B-X
IgGs	B-X
analysed	B-X
reflect	B-X
carbohydrate	B-X
attached	B-X
to	B-X
this	B-X
site	B-X
.	B-X
Factors	B-X
such	B-X
as	B-X
cell	B-X
type	B-X
(	B-X
A	B-X
)	B-X
,	B-X
template	B-X
direction	B-X
by	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
(	B-X
B	B-X
)	B-X
and	B-X
culture	B-X
conditions	B-X
(	B-X
C	B-X
)	B-X
are	B-X
shown	B-X
to	B-X
influence	B-X
IgG	B-X
glycosylation	B-X
profiles	B-X
.	B-X
(	B-X
A	B-X
)	B-X
The	B-X
anti-NIP	B-X
IgG	B-X
antibodies	B-X
expressed	B-X
by	B-X
the	B-X
J558L	B-X
cell	B-X
line	B-X
may	B-X
have	B-X
one	B-X
or	B-X
two	B-X
Gal	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
Gal	B-X
residues	B-X
per	B-X
oligosaccharide	B-X
unit	B-X
,	B-X
indicative	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
galactosyl	B-X
transferase	B-X
in	B-X
the	B-X
J558L	B-X
mouse	B-X
cell	B-X
line	B-X
.	B-X
(	B-X
B	B-X
)	B-X
The	B-X
galactosylation	B-X
profiles	B-X
obtained	B-X
for	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
preference	B-X
for	B-X
galactosylation	B-X
of	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
6	B-X
)	B-X
arm	B-X
rather	B-X
than	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
arm	B-X
,	B-X
contrary	B-X
to	B-X
the	B-X
beta-galactosyltransferase	B-X
specificity	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
polypeptide	B-X
chain	B-X
may	B-X
act	B-X
as	B-X
a	B-X
template	B-X
to	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
galactosylation	B-X
and	B-X
hence	B-X
the	B-X
proportions	B-X
of	B-X
each	B-X
oligosaccharide	B-X
incorporated	B-X
.	B-X
The	B-X
IgG2	B-X
antibody	B-X
does	B-X
not	B-X
display	B-X
this	B-X
galactosylation	B-X
preference	B-X
.	B-X
(	B-X
C	B-X
)	B-X
The	B-X
extent	B-X
of	B-X
galactosylation	B-X
appears	B-X
to	B-X
be	B-X
influenced	B-X
by	B-X
the	B-X
growth	B-X
conditions	B-X
,	B-X
with	B-X
the	B-X
highest	B-X
levels	B-X
of	B-X
galactosylation	B-X
being	B-X
found	B-X
for	B-X
IgG	B-X
produced	B-X
by	B-X
cells	B-X
grown	B-X
in	B-X
still	B-X
cultures	B-X
,	B-X
rather	B-X
than	B-X
cells	B-X
grown	B-X
as	B-X
ascites	B-X
or	B-X
in	B-X
hollow	B-X
fibre	B-X
bioreactors	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
though	B-X
the	B-X
profile	B-X
of	B-X
glycosylation	B-X
is	B-X
controlled	B-X
predominantly	B-X
by	B-X
the	B-X
glycosylation	B-X
activity	B-X
of	B-X
the	B-X
cell	B-X
in	B-X
which	B-X
the	B-X
IgG	B-X
is	B-X
expressed	B-X
,	B-X
differences	B-X
between	B-X
the	B-X
IgG	B-X
heavy	B-X
chain	B-X
templates	B-X
of	B-X
the	B-X
various	B-X
subclasses	B-X
and	B-X
culture	B-X
conditions	B-X
can	B-X
also	B-X
influence	B-X
glycosylation	B-X
.	B-X

Oligosaccharide	O
profiles	O
were	O
obtained	O
for	O
chimeric	O
mouse	O
-	O
human	O
antibodies	O
corresponding	O
to	O
each	O
of	O
the	O
human	O
IgG	O
subclasses	O
1	O
-	O
4	O
,	O
and	O
mouse	O
IgG2b	O
antibodies	O
each	O
expressed	O
in	O
the	O
mouse	O
J558L	O
cell	O
line	O
.	O
<EOS>	B-X
Oligosaccharide	B-X
profiles	B-X
were	B-X
obtained	B-X
for	B-X
chimeric	B-X
mouse-human	B-X
antibodies	B-X
corresponding	B-X
to	B-X
each	B-X
of	B-X
the	B-X
human	B-X
IgG	B-X
subclasses	B-X
1-4	B-X
,	B-X
and	B-X
mouse	B-X
IgG2b	B-X
antibodies	B-X
each	B-X
expressed	B-X
in	B-X
the	B-X
mouse	B-X
J558L	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
antibodies	B-X
have	B-X
specificity	B-X
for	B-X
the	B-X
NIP	B-X
hapten	B-X
and	B-X
form	B-X
a	B-X
matched	B-X
set	B-X
of	B-X
IgGs	B-X
.	B-X
An	B-X
IgG4	B-X
chimeric	B-X
antibody	B-X
(	B-X
B72.3	B-X
)	B-X
produced	B-X
in	B-X
the	B-X
chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO-K1	B-X
)	B-X
cell	B-X
line	B-X
was	B-X
also	B-X
analysed	B-X
for	B-X
carbohydrate	B-X
.	B-X
Additionally	B-X
aglycosylated	B-X
mutants	B-X
of	B-X
this	B-X
IgG4	B-X
(	B-X
B72.3	B-X
)	B-X
and	B-X
anti-NIP	B-X
mouse	B-X
IgG2b	B-X
were	B-X
analysed	B-X
.	B-X
The	B-X
total	B-X
lack	B-X
of	B-X
carbohydrate	B-X
found	B-X
in	B-X
the	B-X
aglycosylated	B-X
site-directed	B-X
mutants	B-X
human	B-X
chimeric	B-X
IgG4	B-X
B72.3	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Gln	B-X
)	B-X
and	B-X
mouse	B-X
IgG2b	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Ala	B-X
)	B-X
demonstrates	B-X
that	B-X
there	B-X
are	B-X
no	B-X
N-glycosylation	B-X
sites	B-X
other	B-X
than	B-X
Asn	B-X
297	B-X
.	B-X
Therefore	B-X
glycosylation	B-X
profiles	B-X
for	B-X
all	B-X
the	B-X
IgGs	B-X
analysed	B-X
reflect	B-X
carbohydrate	B-X
attached	B-X
to	B-X
this	B-X
site	B-X
.	B-X
Factors	B-X
such	B-X
as	B-X
cell	B-X
type	B-X
(	B-X
A	B-X
)	B-X
,	B-X
template	B-X
direction	B-X
by	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
(	B-X
B	B-X
)	B-X
and	B-X
culture	B-X
conditions	B-X
(	B-X
C	B-X
)	B-X
are	B-X
shown	B-X
to	B-X
influence	B-X
IgG	B-X
glycosylation	B-X
profiles	B-X
.	B-X
(	B-X
A	B-X
)	B-X
The	B-X
anti-NIP	B-X
IgG	B-X
antibodies	B-X
expressed	B-X
by	B-X
the	B-X
J558L	B-X
cell	B-X
line	B-X
may	B-X
have	B-X
one	B-X
or	B-X
two	B-X
Gal	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
Gal	B-X
residues	B-X
per	B-X
oligosaccharide	B-X
unit	B-X
,	B-X
indicative	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
galactosyl	B-X
transferase	B-X
in	B-X
the	B-X
J558L	B-X
mouse	B-X
cell	B-X
line	B-X
.	B-X
(	B-X
B	B-X
)	B-X
The	B-X
galactosylation	B-X
profiles	B-X
obtained	B-X
for	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
preference	B-X
for	B-X
galactosylation	B-X
of	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
6	B-X
)	B-X
arm	B-X
rather	B-X
than	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
arm	B-X
,	B-X
contrary	B-X
to	B-X
the	B-X
beta-galactosyltransferase	B-X
specificity	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
polypeptide	B-X
chain	B-X
may	B-X
act	B-X
as	B-X
a	B-X
template	B-X
to	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
galactosylation	B-X
and	B-X
hence	B-X
the	B-X
proportions	B-X
of	B-X
each	B-X
oligosaccharide	B-X
incorporated	B-X
.	B-X
The	B-X
IgG2	B-X
antibody	B-X
does	B-X
not	B-X
display	B-X
this	B-X
galactosylation	B-X
preference	B-X
.	B-X
(	B-X
C	B-X
)	B-X
The	B-X
extent	B-X
of	B-X
galactosylation	B-X
appears	B-X
to	B-X
be	B-X
influenced	B-X
by	B-X
the	B-X
growth	B-X
conditions	B-X
,	B-X
with	B-X
the	B-X
highest	B-X
levels	B-X
of	B-X
galactosylation	B-X
being	B-X
found	B-X
for	B-X
IgG	B-X
produced	B-X
by	B-X
cells	B-X
grown	B-X
in	B-X
still	B-X
cultures	B-X
,	B-X
rather	B-X
than	B-X
cells	B-X
grown	B-X
as	B-X
ascites	B-X
or	B-X
in	B-X
hollow	B-X
fibre	B-X
bioreactors	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
though	B-X
the	B-X
profile	B-X
of	B-X
glycosylation	B-X
is	B-X
controlled	B-X
predominantly	B-X
by	B-X
the	B-X
glycosylation	B-X
activity	B-X
of	B-X
the	B-X
cell	B-X
in	B-X
which	B-X
the	B-X
IgG	B-X
is	B-X
expressed	B-X
,	B-X
differences	B-X
between	B-X
the	B-X
IgG	B-X
heavy	B-X
chain	B-X
templates	B-X
of	B-X
the	B-X
various	B-X
subclasses	B-X
and	B-X
culture	B-X
conditions	B-X
can	B-X
also	B-X
influence	B-X
glycosylation	B-X
.	B-X

These	O
antibodies	O
have	O
specificity	O
for	O
the	O
NIP	O
hapten	O
and	O
form	O
a	O
matched	O
set	O
of	O
IgGs	O
.	O

An	O
IgG4	O
chimeric	O
antibody	O
(	O
B72	O
.	O
3	O
)	O
produced	O
in	O
the	O
chinese	O
hamster	O
ovary	O
(	O
CHO	O
-	O
K1	O
)	O
cell	O
line	O
was	O
also	O
analysed	O
for	O
carbohydrate	O
.	O
<EOS>	B-X
Oligosaccharide	B-X
profiles	B-X
were	B-X
obtained	B-X
for	B-X
chimeric	B-X
mouse-human	B-X
antibodies	B-X
corresponding	B-X
to	B-X
each	B-X
of	B-X
the	B-X
human	B-X
IgG	B-X
subclasses	B-X
1-4	B-X
,	B-X
and	B-X
mouse	B-X
IgG2b	B-X
antibodies	B-X
each	B-X
expressed	B-X
in	B-X
the	B-X
mouse	B-X
J558L	B-X
cell	B-X
line	B-X
.	B-X
An	B-X
IgG4	B-X
chimeric	B-X
antibody	B-X
(	B-X
B72.3	B-X
)	B-X
produced	B-X
in	B-X
the	B-X
chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO-K1	B-X
)	B-X
cell	B-X
line	B-X
was	B-X
also	B-X
analysed	B-X
for	B-X
carbohydrate	B-X
.	B-X
Additionally	B-X
aglycosylated	B-X
mutants	B-X
of	B-X
this	B-X
IgG4	B-X
(	B-X
B72.3	B-X
)	B-X
and	B-X
anti-NIP	B-X
mouse	B-X
IgG2b	B-X
were	B-X
analysed	B-X
.	B-X
The	B-X
total	B-X
lack	B-X
of	B-X
carbohydrate	B-X
found	B-X
in	B-X
the	B-X
aglycosylated	B-X
site-directed	B-X
mutants	B-X
human	B-X
chimeric	B-X
IgG4	B-X
B72.3	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Gln	B-X
)	B-X
and	B-X
mouse	B-X
IgG2b	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Ala	B-X
)	B-X
demonstrates	B-X
that	B-X
there	B-X
are	B-X
no	B-X
N-glycosylation	B-X
sites	B-X
other	B-X
than	B-X
Asn	B-X
297	B-X
.	B-X
Therefore	B-X
glycosylation	B-X
profiles	B-X
for	B-X
all	B-X
the	B-X
IgGs	B-X
analysed	B-X
reflect	B-X
carbohydrate	B-X
attached	B-X
to	B-X
this	B-X
site	B-X
.	B-X
Factors	B-X
such	B-X
as	B-X
cell	B-X
type	B-X
(	B-X
A	B-X
)	B-X
,	B-X
template	B-X
direction	B-X
by	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
(	B-X
B	B-X
)	B-X
and	B-X
culture	B-X
conditions	B-X
(	B-X
C	B-X
)	B-X
are	B-X
shown	B-X
to	B-X
influence	B-X
IgG	B-X
glycosylation	B-X
profiles	B-X
.	B-X
(	B-X
A	B-X
)	B-X
The	B-X
anti-NIP	B-X
IgG	B-X
antibodies	B-X
expressed	B-X
by	B-X
the	B-X
J558L	B-X
cell	B-X
line	B-X
may	B-X
have	B-X
one	B-X
or	B-X
two	B-X
Gal	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
Gal	B-X
residues	B-X
per	B-X
oligosaccharide	B-X
unit	B-X
,	B-X
indicative	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
galactosyl	B-X
transferase	B-X
in	B-X
the	B-X
J558L	B-X
mouse	B-X
cell	B-X
line	B-X
.	B-X
(	B-X
B	B-X
)	B-X
The	B-X
galactosylation	B-X
profiles	B-X
obtained	B-X
for	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
preference	B-X
for	B-X
galactosylation	B-X
of	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
6	B-X
)	B-X
arm	B-X
rather	B-X
than	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
arm	B-X
,	B-X
contrary	B-X
to	B-X
the	B-X
beta-galactosyltransferase	B-X
specificity	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
polypeptide	B-X
chain	B-X
may	B-X
act	B-X
as	B-X
a	B-X
template	B-X
to	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
galactosylation	B-X
and	B-X
hence	B-X
the	B-X
proportions	B-X
of	B-X
each	B-X
oligosaccharide	B-X
incorporated	B-X
.	B-X
The	B-X
IgG2	B-X
antibody	B-X
does	B-X
not	B-X
display	B-X
this	B-X
galactosylation	B-X
preference	B-X
.	B-X
(	B-X
C	B-X
)	B-X
The	B-X
extent	B-X
of	B-X
galactosylation	B-X
appears	B-X
to	B-X
be	B-X
influenced	B-X
by	B-X
the	B-X
growth	B-X
conditions	B-X
,	B-X
with	B-X
the	B-X
highest	B-X
levels	B-X
of	B-X
galactosylation	B-X
being	B-X
found	B-X
for	B-X
IgG	B-X
produced	B-X
by	B-X
cells	B-X
grown	B-X
in	B-X
still	B-X
cultures	B-X
,	B-X
rather	B-X
than	B-X
cells	B-X
grown	B-X
as	B-X
ascites	B-X
or	B-X
in	B-X
hollow	B-X
fibre	B-X
bioreactors	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
though	B-X
the	B-X
profile	B-X
of	B-X
glycosylation	B-X
is	B-X
controlled	B-X
predominantly	B-X
by	B-X
the	B-X
glycosylation	B-X
activity	B-X
of	B-X
the	B-X
cell	B-X
in	B-X
which	B-X
the	B-X
IgG	B-X
is	B-X
expressed	B-X
,	B-X
differences	B-X
between	B-X
the	B-X
IgG	B-X
heavy	B-X
chain	B-X
templates	B-X
of	B-X
the	B-X
various	B-X
subclasses	B-X
and	B-X
culture	B-X
conditions	B-X
can	B-X
also	B-X
influence	B-X
glycosylation	B-X
.	B-X

Additionally	O
aglycosylated	O
mutants	O
of	O
this	O
IgG4	O
(	O
B72	O
.	O
3	O
)	O
and	O
anti	O
-	O
NIP	O
mouse	O
IgG2b	O
were	O
analysed	O
.	O
<EOS>	B-X
Oligosaccharide	B-X
profiles	B-X
were	B-X
obtained	B-X
for	B-X
chimeric	B-X
mouse-human	B-X
antibodies	B-X
corresponding	B-X
to	B-X
each	B-X
of	B-X
the	B-X
human	B-X
IgG	B-X
subclasses	B-X
1-4	B-X
,	B-X
and	B-X
mouse	B-X
IgG2b	B-X
antibodies	B-X
each	B-X
expressed	B-X
in	B-X
the	B-X
mouse	B-X
J558L	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
antibodies	B-X
have	B-X
specificity	B-X
for	B-X
the	B-X
NIP	B-X
hapten	B-X
and	B-X
form	B-X
a	B-X
matched	B-X
set	B-X
of	B-X
IgGs	B-X
.	B-X
An	B-X
IgG4	B-X
chimeric	B-X
antibody	B-X
(	B-X
B72.3	B-X
)	B-X
produced	B-X
in	B-X
the	B-X
chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO-K1	B-X
)	B-X
cell	B-X
line	B-X
was	B-X
also	B-X
analysed	B-X
for	B-X
carbohydrate	B-X
.	B-X
Additionally	B-X
aglycosylated	B-X
mutants	B-X
of	B-X
this	B-X
IgG4	B-X
(	B-X
B72.3	B-X
)	B-X
and	B-X
anti-NIP	B-X
mouse	B-X
IgG2b	B-X
were	B-X
analysed	B-X
.	B-X
The	B-X
total	B-X
lack	B-X
of	B-X
carbohydrate	B-X
found	B-X
in	B-X
the	B-X
aglycosylated	B-X
site-directed	B-X
mutants	B-X
human	B-X
chimeric	B-X
IgG4	B-X
B72.3	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Gln	B-X
)	B-X
and	B-X
mouse	B-X
IgG2b	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Ala	B-X
)	B-X
demonstrates	B-X
that	B-X
there	B-X
are	B-X
no	B-X
N-glycosylation	B-X
sites	B-X
other	B-X
than	B-X
Asn	B-X
297	B-X
.	B-X
Therefore	B-X
glycosylation	B-X
profiles	B-X
for	B-X
all	B-X
the	B-X
IgGs	B-X
analysed	B-X
reflect	B-X
carbohydrate	B-X
attached	B-X
to	B-X
this	B-X
site	B-X
.	B-X
(	B-X
A	B-X
)	B-X
The	B-X
anti-NIP	B-X
IgG	B-X
antibodies	B-X
expressed	B-X
by	B-X
the	B-X
J558L	B-X
cell	B-X
line	B-X
may	B-X
have	B-X
one	B-X
or	B-X
two	B-X
Gal	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
Gal	B-X
residues	B-X
per	B-X
oligosaccharide	B-X
unit	B-X
,	B-X
indicative	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
galactosyl	B-X
transferase	B-X
in	B-X
the	B-X
J558L	B-X
mouse	B-X
cell	B-X
line	B-X
.	B-X
(	B-X
B	B-X
)	B-X
The	B-X
galactosylation	B-X
profiles	B-X
obtained	B-X
for	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
preference	B-X
for	B-X
galactosylation	B-X
of	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
6	B-X
)	B-X
arm	B-X
rather	B-X
than	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
arm	B-X
,	B-X
contrary	B-X
to	B-X
the	B-X
beta-galactosyltransferase	B-X
specificity	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
polypeptide	B-X
chain	B-X
may	B-X
act	B-X
as	B-X
a	B-X
template	B-X
to	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
galactosylation	B-X
and	B-X
hence	B-X
the	B-X
proportions	B-X
of	B-X
each	B-X
oligosaccharide	B-X
incorporated	B-X
.	B-X
The	B-X
IgG2	B-X
antibody	B-X
does	B-X
not	B-X
display	B-X
this	B-X
galactosylation	B-X
preference	B-X
.	B-X

The	O
total	O
lack	O
of	O
carbohydrate	O
found	O
in	O
the	O
aglycosylated	O
site	O
-	O
directed	O
mutants	O
human	O
chimeric	O
IgG4	O
B72	O
.	O
3	O
(	O
Asn	O
297	O
-	O
-	O
>	O
Gln	O
)	O
and	O
mouse	O
IgG2b	O
(	O
Asn	O
297	O
-	O
-	O
>	O
Ala	O
)	O
demonstrates	O
that	O
there	O
are	O
no	O
N	O
-	O
glycosylation	O
sites	O
other	O
than	O
Asn	O
297	O
.	O

Therefore	O
glycosylation	O
profiles	O
for	O
all	O
the	O
IgGs	O
analysed	O
reflect	O
carbohydrate	O
attached	O
to	O
this	O
site	O
.	O
<EOS>	B-X
Oligosaccharide	B-X
profiles	B-X
were	B-X
obtained	B-X
for	B-X
chimeric	B-X
mouse-human	B-X
antibodies	B-X
corresponding	B-X
to	B-X
each	B-X
of	B-X
the	B-X
human	B-X
IgG	B-X
subclasses	B-X
1-4	B-X
,	B-X
and	B-X
mouse	B-X
IgG2b	B-X
antibodies	B-X
each	B-X
expressed	B-X
in	B-X
the	B-X
mouse	B-X
J558L	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
antibodies	B-X
have	B-X
specificity	B-X
for	B-X
the	B-X
NIP	B-X
hapten	B-X
and	B-X
form	B-X
a	B-X
matched	B-X
set	B-X
of	B-X
IgGs	B-X
.	B-X
An	B-X
IgG4	B-X
chimeric	B-X
antibody	B-X
(	B-X
B72.3	B-X
)	B-X
produced	B-X
in	B-X
the	B-X
chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO-K1	B-X
)	B-X
cell	B-X
line	B-X
was	B-X
also	B-X
analysed	B-X
for	B-X
carbohydrate	B-X
.	B-X
Additionally	B-X
aglycosylated	B-X
mutants	B-X
of	B-X
this	B-X
IgG4	B-X
(	B-X
B72.3	B-X
)	B-X
and	B-X
anti-NIP	B-X
mouse	B-X
IgG2b	B-X
were	B-X
analysed	B-X
.	B-X
The	B-X
total	B-X
lack	B-X
of	B-X
carbohydrate	B-X
found	B-X
in	B-X
the	B-X
aglycosylated	B-X
site-directed	B-X
mutants	B-X
human	B-X
chimeric	B-X
IgG4	B-X
B72.3	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Gln	B-X
)	B-X
and	B-X
mouse	B-X
IgG2b	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Ala	B-X
)	B-X
demonstrates	B-X
that	B-X
there	B-X
are	B-X
no	B-X
N-glycosylation	B-X
sites	B-X
other	B-X
than	B-X
Asn	B-X
297	B-X
.	B-X
Therefore	B-X
glycosylation	B-X
profiles	B-X
for	B-X
all	B-X
the	B-X
IgGs	B-X
analysed	B-X
reflect	B-X
carbohydrate	B-X
attached	B-X
to	B-X
this	B-X
site	B-X
.	B-X
Factors	B-X
such	B-X
as	B-X
cell	B-X
type	B-X
(	B-X
A	B-X
)	B-X
,	B-X
template	B-X
direction	B-X
by	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
(	B-X
B	B-X
)	B-X
and	B-X
culture	B-X
conditions	B-X
(	B-X
C	B-X
)	B-X
are	B-X
shown	B-X
to	B-X
influence	B-X
IgG	B-X
glycosylation	B-X
profiles	B-X
.	B-X
(	B-X
B	B-X
)	B-X
The	B-X
galactosylation	B-X
profiles	B-X
obtained	B-X
for	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
preference	B-X
for	B-X
galactosylation	B-X
of	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
6	B-X
)	B-X
arm	B-X
rather	B-X
than	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
arm	B-X
,	B-X
contrary	B-X
to	B-X
the	B-X
beta-galactosyltransferase	B-X
specificity	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
polypeptide	B-X
chain	B-X
may	B-X
act	B-X
as	B-X
a	B-X
template	B-X
to	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
galactosylation	B-X
and	B-X
hence	B-X
the	B-X
proportions	B-X
of	B-X
each	B-X
oligosaccharide	B-X
incorporated	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
though	B-X
the	B-X
profile	B-X
of	B-X
glycosylation	B-X
is	B-X
controlled	B-X
predominantly	B-X
by	B-X
the	B-X
glycosylation	B-X
activity	B-X
of	B-X
the	B-X
cell	B-X
in	B-X
which	B-X
the	B-X
IgG	B-X
is	B-X
expressed	B-X
,	B-X
differences	B-X
between	B-X
the	B-X
IgG	B-X
heavy	B-X
chain	B-X
templates	B-X
of	B-X
the	B-X
various	B-X
subclasses	B-X
and	B-X
culture	B-X
conditions	B-X
can	B-X
also	B-X
influence	B-X
glycosylation	B-X
.	B-X

Factors	O
such	O
as	O
cell	O
type	O
(	O
A	O
)	O
,	O
template	O
direction	O
by	O
the	O
IgG	O
heavy	O
chains	O
(	O
B	O
)	O
and	O
culture	O
conditions	O
(	O
C	O
)	O
are	O
shown	O
to	O
influence	O
IgG	O
glycosylation	O
profiles	O
.	O

(	O
A	O
)	O
The	O
anti	O
-	O
NIP	O
IgG	O
antibodies	O
expressed	O
by	O
the	O
J558L	O
cell	O
line	O
may	O
have	O
one	O
or	O
two	O
Gal	O
(	O
alpha	O
1	O
-	O
-	O
>	O
3	O
)	O
Gal	O
residues	O
per	O
oligosaccharide	O
unit	O
,	O
indicative	O
of	O
the	O
presence	O
of	O
(	O
alpha	O
1	O
-	O
-	O
>	O
3	O
)	O
galactosyl	O
transferase	O
in	O
the	O
J558L	O
mouse	O
cell	O
line	O
.	O
<EOS>	B-X
Oligosaccharide	B-X
profiles	B-X
were	B-X
obtained	B-X
for	B-X
chimeric	B-X
mouse-human	B-X
antibodies	B-X
corresponding	B-X
to	B-X
each	B-X
of	B-X
the	B-X
human	B-X
IgG	B-X
subclasses	B-X
1-4	B-X
,	B-X
and	B-X
mouse	B-X
IgG2b	B-X
antibodies	B-X
each	B-X
expressed	B-X
in	B-X
the	B-X
mouse	B-X
J558L	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
antibodies	B-X
have	B-X
specificity	B-X
for	B-X
the	B-X
NIP	B-X
hapten	B-X
and	B-X
form	B-X
a	B-X
matched	B-X
set	B-X
of	B-X
IgGs	B-X
.	B-X
An	B-X
IgG4	B-X
chimeric	B-X
antibody	B-X
(	B-X
B72.3	B-X
)	B-X
produced	B-X
in	B-X
the	B-X
chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO-K1	B-X
)	B-X
cell	B-X
line	B-X
was	B-X
also	B-X
analysed	B-X
for	B-X
carbohydrate	B-X
.	B-X
Additionally	B-X
aglycosylated	B-X
mutants	B-X
of	B-X
this	B-X
IgG4	B-X
(	B-X
B72.3	B-X
)	B-X
and	B-X
anti-NIP	B-X
mouse	B-X
IgG2b	B-X
were	B-X
analysed	B-X
.	B-X
The	B-X
total	B-X
lack	B-X
of	B-X
carbohydrate	B-X
found	B-X
in	B-X
the	B-X
aglycosylated	B-X
site-directed	B-X
mutants	B-X
human	B-X
chimeric	B-X
IgG4	B-X
B72.3	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Gln	B-X
)	B-X
and	B-X
mouse	B-X
IgG2b	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Ala	B-X
)	B-X
demonstrates	B-X
that	B-X
there	B-X
are	B-X
no	B-X
N-glycosylation	B-X
sites	B-X
other	B-X
than	B-X
Asn	B-X
297	B-X
.	B-X
Therefore	B-X
glycosylation	B-X
profiles	B-X
for	B-X
all	B-X
the	B-X
IgGs	B-X
analysed	B-X
reflect	B-X
carbohydrate	B-X
attached	B-X
to	B-X
this	B-X
site	B-X
.	B-X
Factors	B-X
such	B-X
as	B-X
cell	B-X
type	B-X
(	B-X
A	B-X
)	B-X
,	B-X
template	B-X
direction	B-X
by	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
(	B-X
B	B-X
)	B-X
and	B-X
culture	B-X
conditions	B-X
(	B-X
C	B-X
)	B-X
are	B-X
shown	B-X
to	B-X
influence	B-X
IgG	B-X
glycosylation	B-X
profiles	B-X
.	B-X
(	B-X
A	B-X
)	B-X
The	B-X
anti-NIP	B-X
IgG	B-X
antibodies	B-X
expressed	B-X
by	B-X
the	B-X
J558L	B-X
cell	B-X
line	B-X
may	B-X
have	B-X
one	B-X
or	B-X
two	B-X
Gal	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
Gal	B-X
residues	B-X
per	B-X
oligosaccharide	B-X
unit	B-X
,	B-X
indicative	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
galactosyl	B-X
transferase	B-X
in	B-X
the	B-X
J558L	B-X
mouse	B-X
cell	B-X
line	B-X
.	B-X
(	B-X
B	B-X
)	B-X
The	B-X
galactosylation	B-X
profiles	B-X
obtained	B-X
for	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
preference	B-X
for	B-X
galactosylation	B-X
of	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
6	B-X
)	B-X
arm	B-X
rather	B-X
than	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
arm	B-X
,	B-X
contrary	B-X
to	B-X
the	B-X
beta-galactosyltransferase	B-X
specificity	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
polypeptide	B-X
chain	B-X
may	B-X
act	B-X
as	B-X
a	B-X
template	B-X
to	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
galactosylation	B-X
and	B-X
hence	B-X
the	B-X
proportions	B-X
of	B-X
each	B-X
oligosaccharide	B-X
incorporated	B-X
.	B-X
The	B-X
IgG2	B-X
antibody	B-X
does	B-X
not	B-X
display	B-X
this	B-X
galactosylation	B-X
preference	B-X
.	B-X
(	B-X
C	B-X
)	B-X
The	B-X
extent	B-X
of	B-X
galactosylation	B-X
appears	B-X
to	B-X
be	B-X
influenced	B-X
by	B-X
the	B-X
growth	B-X
conditions	B-X
,	B-X
with	B-X
the	B-X
highest	B-X
levels	B-X
of	B-X
galactosylation	B-X
being	B-X
found	B-X
for	B-X
IgG	B-X
produced	B-X
by	B-X
cells	B-X
grown	B-X
in	B-X
still	B-X
cultures	B-X
,	B-X
rather	B-X
than	B-X
cells	B-X
grown	B-X
as	B-X
ascites	B-X
or	B-X
in	B-X
hollow	B-X
fibre	B-X
bioreactors	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
though	B-X
the	B-X
profile	B-X
of	B-X
glycosylation	B-X
is	B-X
controlled	B-X
predominantly	B-X
by	B-X
the	B-X
glycosylation	B-X
activity	B-X
of	B-X
the	B-X
cell	B-X
in	B-X
which	B-X
the	B-X
IgG	B-X
is	B-X
expressed	B-X
,	B-X
differences	B-X
between	B-X
the	B-X
IgG	B-X
heavy	B-X
chain	B-X
templates	B-X
of	B-X
the	B-X
various	B-X
subclasses	B-X
and	B-X
culture	B-X
conditions	B-X
can	B-X
also	B-X
influence	B-X
glycosylation	B-X
.	B-X

(	O
B	O
)	O
The	O
galactosylation	O
profiles	O
obtained	O
for	O
the	O
IgG	O
heavy	O
chains	O
,	O
in	O
particular	O
the	O
preference	O
for	O
galactosylation	O
of	O
the	O
Man	O
(	O
alpha	O
1	O
-	O
-	O
>	O
6	O
)	O
arm	O
rather	O
than	O
the	O
Man	O
(	O
alpha	O
1	O
-	O
-	O
>	O
3	O
)	O
arm	O
,	O
contrary	O
to	O
the	O
beta	O
-	O
galactosyltransferase	O
specificity	O
,	O
suggest	O
that	O
the	O
polypeptide	O
chain	O
may	O
act	O
as	O
a	O
template	O
to	O
influence	O
the	O
extent	O
of	O
galactosylation	O
and	O
hence	O
the	O
proportions	O
of	O
each	O
oligosaccharide	O
incorporated	O
.	O

The	O
IgG2	O
antibody	O
does	O
not	O
display	O
this	O
galactosylation	O
preference	O
.	O
<EOS>	B-X
The	B-X
evolution	B-X
of	B-X
IgG	B-X
subclass	B-X
switches	B-X
is	B-X
regulated	B-X
by	B-X
interaction	B-X
with	B-X
T	B-X
cells	B-X
and	B-X
follows	B-X
a	B-X
1-way	B-X
direction	B-X
(	B-X
IgG3	B-X
→	B-X
IgG1	B-X
→	B-X
IgG2	B-X
→	B-X
IgG4	B-X
)	B-X
.	B-X
Using	B-X
current	B-X
assays	B-X
for	B-X
HLA	B-X
antibody	B-X
detection	B-X
as	B-X
a	B-X
template	B-X
and	B-X
replacing	B-X
the	B-X
generic	B-X
reporter	B-X
antibody	B-X
with	B-X
IgG	B-X
subclass-specific	B-X
reporter	B-X
antibodies	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
investigate	B-X
the	B-X
IgG	B-X
subclasses	B-X
of	B-X
HLA	B-X
antibodies	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
capability	B-X
to	B-X
activate	B-X
the	B-X
complement	B-X
system	B-X
and	B-X
the	B-X
class	B-X
switch	B-X
direction	B-X
,	B-X
3	B-X
arbitrary	B-X
patterns	B-X
can	B-X
be	B-X
defined	B-X
(	B-X
ie	B-X
,	B-X
only	B-X
complement-binding	B-X
subclasses	B-X
[	B-X
IgG3	B-X
and/or	B-X
IgG1	B-X
]	B-X
,	B-X
expansion	B-X
to	B-X
noncomplement-binding	B-X
subclasses	B-X
[	B-X
IgG3	B-X
and/or	B-X
IgG1	B-X
plus	B-X
IgG2	B-X
and/or	B-X
IgG4	B-X
]	B-X
,	B-X
and	B-X
switch	B-X
to	B-X
noncomplement-binding	B-X
subclasses	B-X
[	B-X
IgG2	B-X
and/or	B-X
IgG4	B-X
]	B-X
)	B-X
.	B-X
In	B-X
the	B-X
past	B-X
5	B-X
years	B-X
,	B-X
several	B-X
studies	B-X
correlated	B-X
the	B-X
IgG	B-X
subclass	B-X
pattern	B-X
with	B-X
occurrence	B-X
of	B-X
antibody-mediated	B-X
rejection	B-X
and	B-X
allograft	B-X
outcomes	B-X
.	B-X

(	O
C	O
)	O
The	O
extent	O
of	O
galactosylation	O
appears	O
to	O
be	O
influenced	O
by	O
the	O
growth	O
conditions	O
,	O
with	O
the	O
highest	O
levels	O
of	O
galactosylation	O
being	O
found	O
for	O
IgG	O
produced	O
by	O
cells	O
grown	O
in	O
still	O
cultures	O
,	O
rather	O
than	O
cells	O
grown	O
as	O
ascites	O
or	O
in	O
hollow	O
fibre	O
bioreactors	O
.	O
<EOS>	B-X
Among	B-X
the	B-X
reactors	B-X
,	B-X
hollow	B-X
fiber	B-X
bioreactors	B-X
contribute	B-X
to	B-X
a	B-X
major	B-X
part	B-X
of	B-X
high-density	B-X
cell	B-X
culture	B-X
as	B-X
they	B-X
can	B-X
provide	B-X
a	B-X
tremendous	B-X
amount	B-X
of	B-X
surface	B-X
area	B-X
in	B-X
a	B-X
small	B-X
volume	B-X
for	B-X
cell	B-X
growth	B-X
.	B-X
As	B-X
an	B-X
alternative	B-X
to	B-X
hollow	B-X
fiber	B-X
reactors	B-X
,	B-X
a	B-X
novel	B-X
disposable	B-X
bioreactor	B-X
has	B-X
been	B-X
developed	B-X
,	B-X
which	B-X
consists	B-X
of	B-X
a	B-X
polymer-based	B-X
supermacroporous	B-X
material	B-X
,	B-X
cryogel	B-X
,	B-X
as	B-X
a	B-X
matrix	B-X
for	B-X
cell	B-X
growth	B-X
.	B-X
Packed	B-X
bed	B-X
systems	B-X
and	B-X
disposable	B-X
wave	B-X
bioreactors	B-X
have	B-X
also	B-X
been	B-X
introduced	B-X
for	B-X
high	B-X
cell	B-X
density	B-X
culture	B-X
.	B-X
Membrane	B-X
bioreactors	B-X
,	B-X
as	B-X
efficient	B-X
gas-liquid	B-X
contactors	B-X
,	B-X
are	B-X
a	B-X
promising	B-X
configuration	B-X
for	B-X
overcoming	B-X
this	B-X
gas-to-liquid	B-X
mass	B-X
transfer	B-X
limitation	B-X
,	B-X
so	B-X
that	B-X
sufficient	B-X
productivity	B-X
can	B-X
be	B-X
achieved	B-X
.	B-X

It	O
is	O
concluded	O
that	O
though	O
the	O
profile	O
of	O
glycosylation	O
is	O
controlled	O
predominantly	O
by	O
the	O
glycosylation	O
activity	O
of	O
the	O
cell	O
in	O
which	O
the	O
IgG	O
is	O
expressed	O
,	O
differences	O
between	O
the	O
IgG	O
heavy	O
chain	O
templates	O
of	O
the	O
various	O
subclasses	O
and	O
culture	O
conditions	O
can	O
also	O
influence	O
glycosylation	O
.	O
<EOS>	B-X
Oligosaccharide	B-X
profiles	B-X
were	B-X
obtained	B-X
for	B-X
chimeric	B-X
mouse-human	B-X
antibodies	B-X
corresponding	B-X
to	B-X
each	B-X
of	B-X
the	B-X
human	B-X
IgG	B-X
subclasses	B-X
1-4	B-X
,	B-X
and	B-X
mouse	B-X
IgG2b	B-X
antibodies	B-X
each	B-X
expressed	B-X
in	B-X
the	B-X
mouse	B-X
J558L	B-X
cell	B-X
line	B-X
.	B-X
These	B-X
antibodies	B-X
have	B-X
specificity	B-X
for	B-X
the	B-X
NIP	B-X
hapten	B-X
and	B-X
form	B-X
a	B-X
matched	B-X
set	B-X
of	B-X
IgGs	B-X
.	B-X
An	B-X
IgG4	B-X
chimeric	B-X
antibody	B-X
(	B-X
B72.3	B-X
)	B-X
produced	B-X
in	B-X
the	B-X
chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO-K1	B-X
)	B-X
cell	B-X
line	B-X
was	B-X
also	B-X
analysed	B-X
for	B-X
carbohydrate	B-X
.	B-X
Additionally	B-X
aglycosylated	B-X
mutants	B-X
of	B-X
this	B-X
IgG4	B-X
(	B-X
B72.3	B-X
)	B-X
and	B-X
anti-NIP	B-X
mouse	B-X
IgG2b	B-X
were	B-X
analysed	B-X
.	B-X
The	B-X
total	B-X
lack	B-X
of	B-X
carbohydrate	B-X
found	B-X
in	B-X
the	B-X
aglycosylated	B-X
site-directed	B-X
mutants	B-X
human	B-X
chimeric	B-X
IgG4	B-X
B72.3	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Gln	B-X
)	B-X
and	B-X
mouse	B-X
IgG2b	B-X
(	B-X
Asn	B-X
297	B-X
--	B-X
>	B-X
Ala	B-X
)	B-X
demonstrates	B-X
that	B-X
there	B-X
are	B-X
no	B-X
N-glycosylation	B-X
sites	B-X
other	B-X
than	B-X
Asn	B-X
297	B-X
.	B-X
Therefore	B-X
glycosylation	B-X
profiles	B-X
for	B-X
all	B-X
the	B-X
IgGs	B-X
analysed	B-X
reflect	B-X
carbohydrate	B-X
attached	B-X
to	B-X
this	B-X
site	B-X
.	B-X
Factors	B-X
such	B-X
as	B-X
cell	B-X
type	B-X
(	B-X
A	B-X
)	B-X
,	B-X
template	B-X
direction	B-X
by	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
(	B-X
B	B-X
)	B-X
and	B-X
culture	B-X
conditions	B-X
(	B-X
C	B-X
)	B-X
are	B-X
shown	B-X
to	B-X
influence	B-X
IgG	B-X
glycosylation	B-X
profiles	B-X
.	B-X
(	B-X
A	B-X
)	B-X
The	B-X
anti-NIP	B-X
IgG	B-X
antibodies	B-X
expressed	B-X
by	B-X
the	B-X
J558L	B-X
cell	B-X
line	B-X
may	B-X
have	B-X
one	B-X
or	B-X
two	B-X
Gal	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
Gal	B-X
residues	B-X
per	B-X
oligosaccharide	B-X
unit	B-X
,	B-X
indicative	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
galactosyl	B-X
transferase	B-X
in	B-X
the	B-X
J558L	B-X
mouse	B-X
cell	B-X
line	B-X
.	B-X
(	B-X
B	B-X
)	B-X
The	B-X
galactosylation	B-X
profiles	B-X
obtained	B-X
for	B-X
the	B-X
IgG	B-X
heavy	B-X
chains	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
preference	B-X
for	B-X
galactosylation	B-X
of	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
6	B-X
)	B-X
arm	B-X
rather	B-X
than	B-X
the	B-X
Man	B-X
(	B-X
alpha	B-X
1	B-X
--	B-X
>	B-X
3	B-X
)	B-X
arm	B-X
,	B-X
contrary	B-X
to	B-X
the	B-X
beta-galactosyltransferase	B-X
specificity	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
polypeptide	B-X
chain	B-X
may	B-X
act	B-X
as	B-X
a	B-X
template	B-X
to	B-X
influence	B-X
the	B-X
extent	B-X
of	B-X
galactosylation	B-X
and	B-X
hence	B-X
the	B-X
proportions	B-X
of	B-X
each	B-X
oligosaccharide	B-X
incorporated	B-X
.	B-X
The	B-X
IgG2	B-X
antibody	B-X
does	B-X
not	B-X
display	B-X
this	B-X
galactosylation	B-X
preference	B-X
.	B-X
(	B-X
C	B-X
)	B-X
The	B-X
extent	B-X
of	B-X
galactosylation	B-X
appears	B-X
to	B-X
be	B-X
influenced	B-X
by	B-X
the	B-X
growth	B-X
conditions	B-X
,	B-X
with	B-X
the	B-X
highest	B-X
levels	B-X
of	B-X
galactosylation	B-X
being	B-X
found	B-X
for	B-X
IgG	B-X
produced	B-X
by	B-X
cells	B-X
grown	B-X
in	B-X
still	B-X
cultures	B-X
,	B-X
rather	B-X
than	B-X
cells	B-X
grown	B-X
as	B-X
ascites	B-X
or	B-X
in	B-X
hollow	B-X
fibre	B-X
bioreactors	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
though	B-X
the	B-X
profile	B-X
of	B-X
glycosylation	B-X
is	B-X
controlled	B-X
predominantly	B-X
by	B-X
the	B-X
glycosylation	B-X
activity	B-X
of	B-X
the	B-X
cell	B-X
in	B-X
which	B-X
the	B-X
IgG	B-X
is	B-X
expressed	B-X
,	B-X
differences	B-X
between	B-X
the	B-X
IgG	B-X
heavy	B-X
chain	B-X
templates	B-X
of	B-X
the	B-X
various	B-X
subclasses	B-X
and	B-X
culture	B-X
conditions	B-X
can	B-X
also	B-X
influence	B-X
glycosylation	B-X
.	B-X

Regulation	O
of	O
CD44	B-Protein
binding	O
to	O
hyaluronan	O
by	O
glycosylation	O
of	O
variably	O
spliced	O
exons	O
.	O
<EOS>	B-X
The	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
-binding	B-X
function	B-X
(	B-X
lectin	B-X
function	B-X
)	B-X
of	B-X
the	B-X
leukocyte	B-X
homing	B-X
receptor	B-X
,	B-X
CD44	B-X
,	B-X
is	B-X
tightly	B-X
regulated	B-X
.	B-X
Herein	B-X
we	B-X
address	B-X
possible	B-X
mechanisms	B-X
that	B-X
regulate	B-X
CD44	B-X
isoform-specific	B-X
HA	B-X
binding	B-X
.	B-X
Binding	B-X
studies	B-X
with	B-X
melanoma	B-X
transfectants	B-X
expressing	B-X
CD44H	B-X
,	B-X
CD44E	B-X
,	B-X
or	B-X
with	B-X
soluble	B-X
immunoglobulin	B-X
fusions	B-X
of	B-X
CD44H	B-X
and	B-X
CD44E	B-X
(	B-X
CD44H-Rg	B-X
,	B-X
CD44E-Rg	B-X
)	B-X
showed	B-X
that	B-X
although	B-X
both	B-X
CD44	B-X
isoforms	B-X
can	B-X
bind	B-X
HA	B-X
,	B-X
CD44H	B-X
binds	B-X
HA	B-X
more	B-X
efficiently	B-X
than	B-X
CD44E	B-X
.	B-X
Using	B-X
CD44-Rg	B-X
fusion	B-X
proteins	B-X
we	B-X
show	B-X
that	B-X
the	B-X
variably	B-X
spliced	B-X
exons	B-X
in	B-X
CD44E	B-X
,	B-X
V8-V10	B-X
,	B-X
specifically	B-X
reduce	B-X
the	B-X
lectin	B-X
function	B-X
of	B-X
CD44	B-X
,	B-X
while	B-X
replacement	B-X
of	B-X
V8-V10	B-X
by	B-X
an	B-X
ICAM-1	B-X
immunoglobulin	B-X
domain	B-X
restores	B-X
binding	B-X
to	B-X
a	B-X
level	B-X
comparable	B-X
to	B-X
that	B-X
of	B-X
CD44H	B-X
.	B-X
Conversely	B-X
,	B-X
CD44	B-X
bound	B-X
HA	B-X
very	B-X
weakly	B-X
when	B-X
exons	B-X
V8-V10	B-X
were	B-X
replaced	B-X
with	B-X
a	B-X
CD34	B-X
mucin	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
heavily	B-X
modified	B-X
by	B-X
O-linked	B-X
glycans	B-X
.	B-X
Production	B-X
of	B-X
CD44E-Rg	B-X
or	B-X
incubation	B-X
of	B-X
CD44E-expressing	B-X
transfectants	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
inhibitor	B-X
restored	B-X
HA	B-X
binding	B-X
to	B-X
CD44H-Rg	B-X
and	B-X
to	B-X
cell	B-X
surface	B-X
CD44H	B-X
levels	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
differential	B-X
splicing	B-X
provides	B-X
a	B-X
regulatory	B-X
mechanism	B-X
for	B-X
CD44	B-X
lectin	B-X
function	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
O-linked	B-X
carbohydrate	B-X
moieties	B-X
which	B-X
are	B-X
added	B-X
to	B-X
the	B-X
Ser/Thr	B-X
rich	B-X
regions	B-X
encoded	B-X
by	B-X
the	B-X
variably	B-X
spliced	B-X
CD44	B-X
exons	B-X
.	B-X
Alternative	B-X
splicing	B-X
resulting	B-X
in	B-X
changes	B-X
in	B-X
protein	B-X
glycosylation	B-X
provide	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
lectin	B-X
activity	B-X
.	B-X

The	O
hyaluronan	O
(	O
HA	O
)	O
-	O
binding	O
function	O
(	O
lectin	O
function	O
)	O
of	O
the	O
leukocyte	O
homing	O
receptor	O
,	O
CD44	B-Protein
,	O
is	O
tightly	O
regulated	O
.	O
<EOS>	B-X
The	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
-binding	B-X
function	B-X
(	B-X
lectin	B-X
function	B-X
)	B-X
of	B-X
the	B-X
leukocyte	B-X
homing	B-X
receptor	B-X
,	B-X
CD44	B-X
,	B-X
is	B-X
tightly	B-X
regulated	B-X
.	B-X
Herein	B-X
we	B-X
address	B-X
possible	B-X
mechanisms	B-X
that	B-X
regulate	B-X
CD44	B-X
isoform-specific	B-X
HA	B-X
binding	B-X
.	B-X
Binding	B-X
studies	B-X
with	B-X
melanoma	B-X
transfectants	B-X
expressing	B-X
CD44H	B-X
,	B-X
CD44E	B-X
,	B-X
or	B-X
with	B-X
soluble	B-X
immunoglobulin	B-X
fusions	B-X
of	B-X
CD44H	B-X
and	B-X
CD44E	B-X
(	B-X
CD44H-Rg	B-X
,	B-X
CD44E-Rg	B-X
)	B-X
showed	B-X
that	B-X
although	B-X
both	B-X
CD44	B-X
isoforms	B-X
can	B-X
bind	B-X
HA	B-X
,	B-X
CD44H	B-X
binds	B-X
HA	B-X
more	B-X
efficiently	B-X
than	B-X
CD44E	B-X
.	B-X
Using	B-X
CD44-Rg	B-X
fusion	B-X
proteins	B-X
we	B-X
show	B-X
that	B-X
the	B-X
variably	B-X
spliced	B-X
exons	B-X
in	B-X
CD44E	B-X
,	B-X
V8-V10	B-X
,	B-X
specifically	B-X
reduce	B-X
the	B-X
lectin	B-X
function	B-X
of	B-X
CD44	B-X
,	B-X
while	B-X
replacement	B-X
of	B-X
V8-V10	B-X
by	B-X
an	B-X
ICAM-1	B-X
immunoglobulin	B-X
domain	B-X
restores	B-X
binding	B-X
to	B-X
a	B-X
level	B-X
comparable	B-X
to	B-X
that	B-X
of	B-X
CD44H	B-X
.	B-X
Conversely	B-X
,	B-X
CD44	B-X
bound	B-X
HA	B-X
very	B-X
weakly	B-X
when	B-X
exons	B-X
V8-V10	B-X
were	B-X
replaced	B-X
with	B-X
a	B-X
CD34	B-X
mucin	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
heavily	B-X
modified	B-X
by	B-X
O-linked	B-X
glycans	B-X
.	B-X
Production	B-X
of	B-X
CD44E-Rg	B-X
or	B-X
incubation	B-X
of	B-X
CD44E-expressing	B-X
transfectants	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
inhibitor	B-X
restored	B-X
HA	B-X
binding	B-X
to	B-X
CD44H-Rg	B-X
and	B-X
to	B-X
cell	B-X
surface	B-X
CD44H	B-X
levels	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
differential	B-X
splicing	B-X
provides	B-X
a	B-X
regulatory	B-X
mechanism	B-X
for	B-X
CD44	B-X
lectin	B-X
function	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
O-linked	B-X
carbohydrate	B-X
moieties	B-X
which	B-X
are	B-X
added	B-X
to	B-X
the	B-X
Ser/Thr	B-X
rich	B-X
regions	B-X
encoded	B-X
by	B-X
the	B-X
variably	B-X
spliced	B-X
CD44	B-X
exons	B-X
.	B-X
Alternative	B-X
splicing	B-X
resulting	B-X
in	B-X
changes	B-X
in	B-X
protein	B-X
glycosylation	B-X
provide	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
lectin	B-X
activity	B-X
.	B-X

Herein	O
we	O
address	O
possible	O
mechanisms	O
that	O
regulate	O
CD44	B-Protein
isoform	O
-	O
specific	O
HA	O
binding	O
.	O
<EOS>	B-X
The	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
-binding	B-X
function	B-X
(	B-X
lectin	B-X
function	B-X
)	B-X
of	B-X
the	B-X
leukocyte	B-X
homing	B-X
receptor	B-X
,	B-X
CD44	B-X
,	B-X
is	B-X
tightly	B-X
regulated	B-X
.	B-X
Herein	B-X
we	B-X
address	B-X
possible	B-X
mechanisms	B-X
that	B-X
regulate	B-X
CD44	B-X
isoform-specific	B-X
HA	B-X
binding	B-X
.	B-X
Binding	B-X
studies	B-X
with	B-X
melanoma	B-X
transfectants	B-X
expressing	B-X
CD44H	B-X
,	B-X
CD44E	B-X
,	B-X
or	B-X
with	B-X
soluble	B-X
immunoglobulin	B-X
fusions	B-X
of	B-X
CD44H	B-X
and	B-X
CD44E	B-X
(	B-X
CD44H-Rg	B-X
,	B-X
CD44E-Rg	B-X
)	B-X
showed	B-X
that	B-X
although	B-X
both	B-X
CD44	B-X
isoforms	B-X
can	B-X
bind	B-X
HA	B-X
,	B-X
CD44H	B-X
binds	B-X
HA	B-X
more	B-X
efficiently	B-X
than	B-X
CD44E	B-X
.	B-X
Using	B-X
CD44-Rg	B-X
fusion	B-X
proteins	B-X
we	B-X
show	B-X
that	B-X
the	B-X
variably	B-X
spliced	B-X
exons	B-X
in	B-X
CD44E	B-X
,	B-X
V8-V10	B-X
,	B-X
specifically	B-X
reduce	B-X
the	B-X
lectin	B-X
function	B-X
of	B-X
CD44	B-X
,	B-X
while	B-X
replacement	B-X
of	B-X
V8-V10	B-X
by	B-X
an	B-X
ICAM-1	B-X
immunoglobulin	B-X
domain	B-X
restores	B-X
binding	B-X
to	B-X
a	B-X
level	B-X
comparable	B-X
to	B-X
that	B-X
of	B-X
CD44H	B-X
.	B-X
Conversely	B-X
,	B-X
CD44	B-X
bound	B-X
HA	B-X
very	B-X
weakly	B-X
when	B-X
exons	B-X
V8-V10	B-X
were	B-X
replaced	B-X
with	B-X
a	B-X
CD34	B-X
mucin	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
heavily	B-X
modified	B-X
by	B-X
O-linked	B-X
glycans	B-X
.	B-X
Production	B-X
of	B-X
CD44E-Rg	B-X
or	B-X
incubation	B-X
of	B-X
CD44E-expressing	B-X
transfectants	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
inhibitor	B-X
restored	B-X
HA	B-X
binding	B-X
to	B-X
CD44H-Rg	B-X
and	B-X
to	B-X
cell	B-X
surface	B-X
CD44H	B-X
levels	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
differential	B-X
splicing	B-X
provides	B-X
a	B-X
regulatory	B-X
mechanism	B-X
for	B-X
CD44	B-X
lectin	B-X
function	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
O-linked	B-X
carbohydrate	B-X
moieties	B-X
which	B-X
are	B-X
added	B-X
to	B-X
the	B-X
Ser/Thr	B-X
rich	B-X
regions	B-X
encoded	B-X
by	B-X
the	B-X
variably	B-X
spliced	B-X
CD44	B-X
exons	B-X
.	B-X

Binding	O
studies	O
with	O
melanoma	O
transfectants	O
expressing	O
CD44H	B-Protein
,	O
CD44E	B-Protein
,	O
or	O
with	O
soluble	O
immunoglobulin	O
fusions	O
of	O
CD44H	B-Protein
and	O
CD44E	B-Protein
(	O
CD44H	B-Protein
-	O
Rg	O
,	O
CD44E	B-Protein
-	O
Rg	O
)	O
showed	O
that	O
although	O
both	O
CD44	B-Protein
isoforms	O
can	O
bind	O
HA	O
,	O
CD44H	B-Protein
binds	O
HA	O
more	O
efficiently	O
than	O
CD44E	B-Protein
.	O
<EOS>	B-X
The	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
-binding	B-X
function	B-X
(	B-X
lectin	B-X
function	B-X
)	B-X
of	B-X
the	B-X
leukocyte	B-X
homing	B-X
receptor	B-X
,	B-X
CD44	B-X
,	B-X
is	B-X
tightly	B-X
regulated	B-X
.	B-X
Herein	B-X
we	B-X
address	B-X
possible	B-X
mechanisms	B-X
that	B-X
regulate	B-X
CD44	B-X
isoform-specific	B-X
HA	B-X
binding	B-X
.	B-X
Binding	B-X
studies	B-X
with	B-X
melanoma	B-X
transfectants	B-X
expressing	B-X
CD44H	B-X
,	B-X
CD44E	B-X
,	B-X
or	B-X
with	B-X
soluble	B-X
immunoglobulin	B-X
fusions	B-X
of	B-X
CD44H	B-X
and	B-X
CD44E	B-X
(	B-X
CD44H-Rg	B-X
,	B-X
CD44E-Rg	B-X
)	B-X
showed	B-X
that	B-X
although	B-X
both	B-X
CD44	B-X
isoforms	B-X
can	B-X
bind	B-X
HA	B-X
,	B-X
CD44H	B-X
binds	B-X
HA	B-X
more	B-X
efficiently	B-X
than	B-X
CD44E	B-X
.	B-X
Using	B-X
CD44-Rg	B-X
fusion	B-X
proteins	B-X
we	B-X
show	B-X
that	B-X
the	B-X
variably	B-X
spliced	B-X
exons	B-X
in	B-X
CD44E	B-X
,	B-X
V8-V10	B-X
,	B-X
specifically	B-X
reduce	B-X
the	B-X
lectin	B-X
function	B-X
of	B-X
CD44	B-X
,	B-X
while	B-X
replacement	B-X
of	B-X
V8-V10	B-X
by	B-X
an	B-X
ICAM-1	B-X
immunoglobulin	B-X
domain	B-X
restores	B-X
binding	B-X
to	B-X
a	B-X
level	B-X
comparable	B-X
to	B-X
that	B-X
of	B-X
CD44H	B-X
.	B-X
Conversely	B-X
,	B-X
CD44	B-X
bound	B-X
HA	B-X
very	B-X
weakly	B-X
when	B-X
exons	B-X
V8-V10	B-X
were	B-X
replaced	B-X
with	B-X
a	B-X
CD34	B-X
mucin	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
heavily	B-X
modified	B-X
by	B-X
O-linked	B-X
glycans	B-X
.	B-X
Production	B-X
of	B-X
CD44E-Rg	B-X
or	B-X
incubation	B-X
of	B-X
CD44E-expressing	B-X
transfectants	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
inhibitor	B-X
restored	B-X
HA	B-X
binding	B-X
to	B-X
CD44H-Rg	B-X
and	B-X
to	B-X
cell	B-X
surface	B-X
CD44H	B-X
levels	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
differential	B-X
splicing	B-X
provides	B-X
a	B-X
regulatory	B-X
mechanism	B-X
for	B-X
CD44	B-X
lectin	B-X
function	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
O-linked	B-X
carbohydrate	B-X
moieties	B-X
which	B-X
are	B-X
added	B-X
to	B-X
the	B-X
Ser/Thr	B-X
rich	B-X
regions	B-X
encoded	B-X
by	B-X
the	B-X
variably	B-X
spliced	B-X
CD44	B-X
exons	B-X
.	B-X

Using	O
CD44	B-Protein
-	O
Rg	O
fusion	O
proteins	O
we	O
show	O
that	O
the	O
variably	O
spliced	O
exons	O
in	O
CD44E	B-Protein
,	O
V8	O
-	O
V10	O
,	O
specifically	O
reduce	O
the	O
lectin	O
function	O
of	O
CD44	B-Protein
,	O
while	O
replacement	O
of	O
V8	O
-	O
V10	O
by	O
an	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
immunoglobulin	O
domain	O
restores	O
binding	O
to	O
a	O
level	O
comparable	O
to	O
that	O
of	O
CD44H	B-Protein
.	O
<EOS>	B-X
The	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
-binding	B-X
function	B-X
(	B-X
lectin	B-X
function	B-X
)	B-X
of	B-X
the	B-X
leukocyte	B-X
homing	B-X
receptor	B-X
,	B-X
CD44	B-X
,	B-X
is	B-X
tightly	B-X
regulated	B-X
.	B-X
Herein	B-X
we	B-X
address	B-X
possible	B-X
mechanisms	B-X
that	B-X
regulate	B-X
CD44	B-X
isoform-specific	B-X
HA	B-X
binding	B-X
.	B-X
Binding	B-X
studies	B-X
with	B-X
melanoma	B-X
transfectants	B-X
expressing	B-X
CD44H	B-X
,	B-X
CD44E	B-X
,	B-X
or	B-X
with	B-X
soluble	B-X
immunoglobulin	B-X
fusions	B-X
of	B-X
CD44H	B-X
and	B-X
CD44E	B-X
(	B-X
CD44H-Rg	B-X
,	B-X
CD44E-Rg	B-X
)	B-X
showed	B-X
that	B-X
although	B-X
both	B-X
CD44	B-X
isoforms	B-X
can	B-X
bind	B-X
HA	B-X
,	B-X
CD44H	B-X
binds	B-X
HA	B-X
more	B-X
efficiently	B-X
than	B-X
CD44E	B-X
.	B-X
Using	B-X
CD44-Rg	B-X
fusion	B-X
proteins	B-X
we	B-X
show	B-X
that	B-X
the	B-X
variably	B-X
spliced	B-X
exons	B-X
in	B-X
CD44E	B-X
,	B-X
V8-V10	B-X
,	B-X
specifically	B-X
reduce	B-X
the	B-X
lectin	B-X
function	B-X
of	B-X
CD44	B-X
,	B-X
while	B-X
replacement	B-X
of	B-X
V8-V10	B-X
by	B-X
an	B-X
ICAM-1	B-X
immunoglobulin	B-X
domain	B-X
restores	B-X
binding	B-X
to	B-X
a	B-X
level	B-X
comparable	B-X
to	B-X
that	B-X
of	B-X
CD44H	B-X
.	B-X
Conversely	B-X
,	B-X
CD44	B-X
bound	B-X
HA	B-X
very	B-X
weakly	B-X
when	B-X
exons	B-X
V8-V10	B-X
were	B-X
replaced	B-X
with	B-X
a	B-X
CD34	B-X
mucin	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
heavily	B-X
modified	B-X
by	B-X
O-linked	B-X
glycans	B-X
.	B-X
Production	B-X
of	B-X
CD44E-Rg	B-X
or	B-X
incubation	B-X
of	B-X
CD44E-expressing	B-X
transfectants	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
inhibitor	B-X
restored	B-X
HA	B-X
binding	B-X
to	B-X
CD44H-Rg	B-X
and	B-X
to	B-X
cell	B-X
surface	B-X
CD44H	B-X
levels	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
differential	B-X
splicing	B-X
provides	B-X
a	B-X
regulatory	B-X
mechanism	B-X
for	B-X
CD44	B-X
lectin	B-X
function	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
O-linked	B-X
carbohydrate	B-X
moieties	B-X
which	B-X
are	B-X
added	B-X
to	B-X
the	B-X
Ser/Thr	B-X
rich	B-X
regions	B-X
encoded	B-X
by	B-X
the	B-X
variably	B-X
spliced	B-X
CD44	B-X
exons	B-X
.	B-X
Alternative	B-X
splicing	B-X
resulting	B-X
in	B-X
changes	B-X
in	B-X
protein	B-X
glycosylation	B-X
provide	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
lectin	B-X
activity	B-X
.	B-X

Conversely	O
,	O
CD44	B-Protein
bound	O
HA	O
very	O
weakly	O
when	O
exons	O
V8	O
-	O
V10	O
were	O
replaced	O
with	O
a	O
CD34	B-Protein
mucin	O
domain	O
,	O
which	O
is	O
heavily	O
modified	O
by	O
O	O
-	O
linked	O
glycans	O
.	O
<EOS>	B-X
The	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
-binding	B-X
function	B-X
(	B-X
lectin	B-X
function	B-X
)	B-X
of	B-X
the	B-X
leukocyte	B-X
homing	B-X
receptor	B-X
,	B-X
CD44	B-X
,	B-X
is	B-X
tightly	B-X
regulated	B-X
.	B-X
Herein	B-X
we	B-X
address	B-X
possible	B-X
mechanisms	B-X
that	B-X
regulate	B-X
CD44	B-X
isoform-specific	B-X
HA	B-X
binding	B-X
.	B-X
Binding	B-X
studies	B-X
with	B-X
melanoma	B-X
transfectants	B-X
expressing	B-X
CD44H	B-X
,	B-X
CD44E	B-X
,	B-X
or	B-X
with	B-X
soluble	B-X
immunoglobulin	B-X
fusions	B-X
of	B-X
CD44H	B-X
and	B-X
CD44E	B-X
(	B-X
CD44H-Rg	B-X
,	B-X
CD44E-Rg	B-X
)	B-X
showed	B-X
that	B-X
although	B-X
both	B-X
CD44	B-X
isoforms	B-X
can	B-X
bind	B-X
HA	B-X
,	B-X
CD44H	B-X
binds	B-X
HA	B-X
more	B-X
efficiently	B-X
than	B-X
CD44E	B-X
.	B-X
Using	B-X
CD44-Rg	B-X
fusion	B-X
proteins	B-X
we	B-X
show	B-X
that	B-X
the	B-X
variably	B-X
spliced	B-X
exons	B-X
in	B-X
CD44E	B-X
,	B-X
V8-V10	B-X
,	B-X
specifically	B-X
reduce	B-X
the	B-X
lectin	B-X
function	B-X
of	B-X
CD44	B-X
,	B-X
while	B-X
replacement	B-X
of	B-X
V8-V10	B-X
by	B-X
an	B-X
ICAM-1	B-X
immunoglobulin	B-X
domain	B-X
restores	B-X
binding	B-X
to	B-X
a	B-X
level	B-X
comparable	B-X
to	B-X
that	B-X
of	B-X
CD44H	B-X
.	B-X
Conversely	B-X
,	B-X
CD44	B-X
bound	B-X
HA	B-X
very	B-X
weakly	B-X
when	B-X
exons	B-X
V8-V10	B-X
were	B-X
replaced	B-X
with	B-X
a	B-X
CD34	B-X
mucin	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
heavily	B-X
modified	B-X
by	B-X
O-linked	B-X
glycans	B-X
.	B-X
Production	B-X
of	B-X
CD44E-Rg	B-X
or	B-X
incubation	B-X
of	B-X
CD44E-expressing	B-X
transfectants	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
inhibitor	B-X
restored	B-X
HA	B-X
binding	B-X
to	B-X
CD44H-Rg	B-X
and	B-X
to	B-X
cell	B-X
surface	B-X
CD44H	B-X
levels	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
differential	B-X
splicing	B-X
provides	B-X
a	B-X
regulatory	B-X
mechanism	B-X
for	B-X
CD44	B-X
lectin	B-X
function	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
O-linked	B-X
carbohydrate	B-X
moieties	B-X
which	B-X
are	B-X
added	B-X
to	B-X
the	B-X
Ser/Thr	B-X
rich	B-X
regions	B-X
encoded	B-X
by	B-X
the	B-X
variably	B-X
spliced	B-X
CD44	B-X
exons	B-X
.	B-X

Production	O
of	O
CD44E	B-Protein
-	O
Rg	O
or	O
incubation	O
of	O
CD44E	B-Protein
-	O
expressing	O
transfectants	O
in	O
the	O
presence	O
of	O
an	O
O	O
-	O
linked	O
glycosylation	O
inhibitor	O
restored	O
HA	O
binding	O
to	O
CD44H	B-Protein
-	O
Rg	O
and	O
to	O
cell	O
surface	O
CD44H	O
levels	O
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
-binding	B-X
function	B-X
(	B-X
lectin	B-X
function	B-X
)	B-X
of	B-X
the	B-X
leukocyte	B-X
homing	B-X
receptor	B-X
,	B-X
CD44	B-X
,	B-X
is	B-X
tightly	B-X
regulated	B-X
.	B-X
Herein	B-X
we	B-X
address	B-X
possible	B-X
mechanisms	B-X
that	B-X
regulate	B-X
CD44	B-X
isoform-specific	B-X
HA	B-X
binding	B-X
.	B-X
Binding	B-X
studies	B-X
with	B-X
melanoma	B-X
transfectants	B-X
expressing	B-X
CD44H	B-X
,	B-X
CD44E	B-X
,	B-X
or	B-X
with	B-X
soluble	B-X
immunoglobulin	B-X
fusions	B-X
of	B-X
CD44H	B-X
and	B-X
CD44E	B-X
(	B-X
CD44H-Rg	B-X
,	B-X
CD44E-Rg	B-X
)	B-X
showed	B-X
that	B-X
although	B-X
both	B-X
CD44	B-X
isoforms	B-X
can	B-X
bind	B-X
HA	B-X
,	B-X
CD44H	B-X
binds	B-X
HA	B-X
more	B-X
efficiently	B-X
than	B-X
CD44E	B-X
.	B-X
Using	B-X
CD44-Rg	B-X
fusion	B-X
proteins	B-X
we	B-X
show	B-X
that	B-X
the	B-X
variably	B-X
spliced	B-X
exons	B-X
in	B-X
CD44E	B-X
,	B-X
V8-V10	B-X
,	B-X
specifically	B-X
reduce	B-X
the	B-X
lectin	B-X
function	B-X
of	B-X
CD44	B-X
,	B-X
while	B-X
replacement	B-X
of	B-X
V8-V10	B-X
by	B-X
an	B-X
ICAM-1	B-X
immunoglobulin	B-X
domain	B-X
restores	B-X
binding	B-X
to	B-X
a	B-X
level	B-X
comparable	B-X
to	B-X
that	B-X
of	B-X
CD44H	B-X
.	B-X
Conversely	B-X
,	B-X
CD44	B-X
bound	B-X
HA	B-X
very	B-X
weakly	B-X
when	B-X
exons	B-X
V8-V10	B-X
were	B-X
replaced	B-X
with	B-X
a	B-X
CD34	B-X
mucin	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
heavily	B-X
modified	B-X
by	B-X
O-linked	B-X
glycans	B-X
.	B-X
Production	B-X
of	B-X
CD44E-Rg	B-X
or	B-X
incubation	B-X
of	B-X
CD44E-expressing	B-X
transfectants	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
inhibitor	B-X
restored	B-X
HA	B-X
binding	B-X
to	B-X
CD44H-Rg	B-X
and	B-X
to	B-X
cell	B-X
surface	B-X
CD44H	B-X
levels	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
differential	B-X
splicing	B-X
provides	B-X
a	B-X
regulatory	B-X
mechanism	B-X
for	B-X
CD44	B-X
lectin	B-X
function	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
O-linked	B-X
carbohydrate	B-X
moieties	B-X
which	B-X
are	B-X
added	B-X
to	B-X
the	B-X
Ser/Thr	B-X
rich	B-X
regions	B-X
encoded	B-X
by	B-X
the	B-X
variably	B-X
spliced	B-X
CD44	B-X
exons	B-X
.	B-X
Alternative	B-X
splicing	B-X
resulting	B-X
in	B-X
changes	B-X
in	B-X
protein	B-X
glycosylation	B-X
provide	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
lectin	B-X
activity	B-X
.	B-X

We	O
conclude	O
that	O
differential	O
splicing	O
provides	O
a	O
regulatory	O
mechanism	O
for	O
CD44	B-Protein
lectin	O
function	O
and	O
that	O
this	O
effect	O
is	O
due	O
in	O
part	O
to	O
O	O
-	O
linked	O
carbohydrate	O
moieties	O
which	O
are	O
added	O
to	O
the	O
Ser	O
/	O
Thr	O
rich	O
regions	O
encoded	O
by	O
the	O
variably	O
spliced	O
CD44	B-Protein
exons	O
.	O

Alternative	O
splicing	O
resulting	O
in	O
changes	O
in	O
protein	O
glycosylation	O
provide	O
a	O
novel	O
mechanism	O
for	O
the	O
regulation	O
of	O
lectin	O
activity	O
.	O
<EOS>	B-X
The	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
-binding	B-X
function	B-X
(	B-X
lectin	B-X
function	B-X
)	B-X
of	B-X
the	B-X
leukocyte	B-X
homing	B-X
receptor	B-X
,	B-X
CD44	B-X
,	B-X
is	B-X
tightly	B-X
regulated	B-X
.	B-X
Herein	B-X
we	B-X
address	B-X
possible	B-X
mechanisms	B-X
that	B-X
regulate	B-X
CD44	B-X
isoform-specific	B-X
HA	B-X
binding	B-X
.	B-X
Using	B-X
CD44-Rg	B-X
fusion	B-X
proteins	B-X
we	B-X
show	B-X
that	B-X
the	B-X
variably	B-X
spliced	B-X
exons	B-X
in	B-X
CD44E	B-X
,	B-X
V8-V10	B-X
,	B-X
specifically	B-X
reduce	B-X
the	B-X
lectin	B-X
function	B-X
of	B-X
CD44	B-X
,	B-X
while	B-X
replacement	B-X
of	B-X
V8-V10	B-X
by	B-X
an	B-X
ICAM-1	B-X
immunoglobulin	B-X
domain	B-X
restores	B-X
binding	B-X
to	B-X
a	B-X
level	B-X
comparable	B-X
to	B-X
that	B-X
of	B-X
CD44H	B-X
.	B-X
Production	B-X
of	B-X
CD44E-Rg	B-X
or	B-X
incubation	B-X
of	B-X
CD44E-expressing	B-X
transfectants	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
O-linked	B-X
glycosylation	B-X
inhibitor	B-X
restored	B-X
HA	B-X
binding	B-X
to	B-X
CD44H-Rg	B-X
and	B-X
to	B-X
cell	B-X
surface	B-X
CD44H	B-X
levels	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
differential	B-X
splicing	B-X
provides	B-X
a	B-X
regulatory	B-X
mechanism	B-X
for	B-X
CD44	B-X
lectin	B-X
function	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
O-linked	B-X
carbohydrate	B-X
moieties	B-X
which	B-X
are	B-X
added	B-X
to	B-X
the	B-X
Ser/Thr	B-X
rich	B-X
regions	B-X
encoded	B-X
by	B-X
the	B-X
variably	B-X
spliced	B-X
CD44	B-X
exons	B-X
.	B-X
Alternative	B-X
splicing	B-X
resulting	B-X
in	B-X
changes	B-X
in	B-X
protein	B-X
glycosylation	B-X
provide	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
lectin	B-X
activity	B-X
.	B-X

Recombinant	O
fish	O
neurotrophin	B-Protein
-	I-Protein
6	I-Protein
is	O
a	O
heparin	O
-	O
binding	O
glycoprotein	O
:	O
implications	O
for	O
a	O
role	O
in	O
axonal	O
guidance	O
.	O
<EOS>	B-X
Neurotrophin-6	B-X
(	B-X
NT-6	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
teleost	B-X
fish	B-X
Xiphophorus	B-X
as	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
neurotrophin	B-X
gene	B-X
family	B-X
.	B-X
NT-6	B-X
binds	B-X
specifically	B-X
the	B-X
glycosaminoglycan	B-X
heparin	B-X
.	B-X
In	B-X
this	B-X
study	B-X
NT-6	B-X
was	B-X
expressed	B-X
in	B-X
a	B-X
stably	B-X
transfected	B-X
mammalian	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
insect	B-X
cells	B-X
via	B-X
a	B-X
recombinant	B-X
baculovirus	B-X
.	B-X
NT-6	B-X
from	B-X
both	B-X
expression	B-X
systems	B-X
was	B-X
proteolytically	B-X
processed	B-X
at	B-X
one	B-X
of	B-X
two	B-X
protease	B-X
cleavage	B-X
motifs	B-X
and	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
.	B-X
Furthermore	B-X
,	B-X
NT-6	B-X
elicited	B-X
neurite	B-X
outgrowth	B-X
in	B-X
explanted	B-X
embryonic	B-X
dorsal	B-X
root	B-X
ganglia	B-X
.	B-X
Addition	B-X
of	B-X
heparin	B-X
into	B-X
the	B-X
medium	B-X
did	B-X
not	B-X
potentiate	B-X
the	B-X
activity	B-X
of	B-X
NT-6	B-X
in	B-X
survival	B-X
assays	B-X
.	B-X
However	B-X
,	B-X
when	B-X
a	B-X
sensory	B-X
ganglion	B-X
explant	B-X
was	B-X
cultured	B-X
in	B-X
a	B-X
collagen	B-X
gel	B-X
matrix	B-X
assay	B-X
adjacent	B-X
to	B-X
a	B-X
heparin	B-X
bead	B-X
coated	B-X
with	B-X
NT-6	B-X
,	B-X
neurite	B-X
outgrowth	B-X
directed	B-X
towards	B-X
the	B-X
bead	B-X
was	B-X
observed	B-X
.	B-X
This	B-X
indicated	B-X
that	B-X
NT-6	B-X
was	B-X
slowly	B-X
released	B-X
from	B-X
the	B-X
heparin	B-X
bead	B-X
generating	B-X
a	B-X
concentration	B-X
gradient	B-X
of	B-X
NT-6	B-X
instrumental	B-X
for	B-X
axonal	B-X
guidance	B-X
in	B-X
vitro	B-X
.	B-X
Thus	B-X
the	B-X
interaction	B-X
of	B-X
NT-6	B-X
with	B-X
heparin	B-X
might	B-X
not	B-X
be	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
receptor	B-X
for	B-X
NT-6	B-X
on	B-X
responsive	B-X
cells	B-X
but	B-X
rather	B-X
may	B-X
serve	B-X
to	B-X
control	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
distribution	B-X
of	B-X
NT-6	B-X
.	B-X

Neurotrophin	B-Protein
-	I-Protein
6	I-Protein
(	O
NT	B-Protein
-	I-Protein
6	I-Protein
)	O
was	O
identified	O
in	O
the	O
teleost	O
fish	O
Xiphophorus	O
as	O
a	O
new	O
member	O
of	O
the	O
neurotrophin	O
gene	O
family	O
.	O
<EOS>	B-X
Neurotrophin-6	B-X
(	B-X
NT-6	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
teleost	B-X
fish	B-X
Xiphophorus	B-X
as	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
neurotrophin	B-X
gene	B-X
family	B-X
.	B-X
NT-6	B-X
binds	B-X
specifically	B-X
the	B-X
glycosaminoglycan	B-X
heparin	B-X
.	B-X
In	B-X
this	B-X
study	B-X
NT-6	B-X
was	B-X
expressed	B-X
in	B-X
a	B-X
stably	B-X
transfected	B-X
mammalian	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
insect	B-X
cells	B-X
via	B-X
a	B-X
recombinant	B-X
baculovirus	B-X
.	B-X
It	B-X
was	B-X
purified	B-X
to	B-X
homogeneity	B-X
and	B-X
characterized	B-X
by	B-X
MS	B-X
and	B-X
N-terminal	B-X
sequencing	B-X
.	B-X
NT-6	B-X
from	B-X
both	B-X
expression	B-X
systems	B-X
was	B-X
proteolytically	B-X
processed	B-X
at	B-X
one	B-X
of	B-X
two	B-X
protease	B-X
cleavage	B-X
motifs	B-X
and	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
.	B-X
Furthermore	B-X
,	B-X
NT-6	B-X
elicited	B-X
neurite	B-X
outgrowth	B-X
in	B-X
explanted	B-X
embryonic	B-X
dorsal	B-X
root	B-X
ganglia	B-X
.	B-X
Addition	B-X
of	B-X
heparin	B-X
into	B-X
the	B-X
medium	B-X
did	B-X
not	B-X
potentiate	B-X
the	B-X
activity	B-X
of	B-X
NT-6	B-X
in	B-X
survival	B-X
assays	B-X
.	B-X
However	B-X
,	B-X
when	B-X
a	B-X
sensory	B-X
ganglion	B-X
explant	B-X
was	B-X
cultured	B-X
in	B-X
a	B-X
collagen	B-X
gel	B-X
matrix	B-X
assay	B-X
adjacent	B-X
to	B-X
a	B-X
heparin	B-X
bead	B-X
coated	B-X
with	B-X
NT-6	B-X
,	B-X
neurite	B-X
outgrowth	B-X
directed	B-X
towards	B-X
the	B-X
bead	B-X
was	B-X
observed	B-X
.	B-X
This	B-X
indicated	B-X
that	B-X
NT-6	B-X
was	B-X
slowly	B-X
released	B-X
from	B-X
the	B-X
heparin	B-X
bead	B-X
generating	B-X
a	B-X
concentration	B-X
gradient	B-X
of	B-X
NT-6	B-X
instrumental	B-X
for	B-X
axonal	B-X
guidance	B-X
in	B-X
vitro	B-X
.	B-X
Thus	B-X
the	B-X
interaction	B-X
of	B-X
NT-6	B-X
with	B-X
heparin	B-X
might	B-X
not	B-X
be	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
receptor	B-X
for	B-X
NT-6	B-X
on	B-X
responsive	B-X
cells	B-X
but	B-X
rather	B-X
may	B-X
serve	B-X
to	B-X
control	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
distribution	B-X
of	B-X
NT-6	B-X
.	B-X

NT	B-Protein
-	I-Protein
6	I-Protein
binds	O
specifically	O
the	O
glycosaminoglycan	O
heparin	O
.	O
<EOS>	B-X
Neurotrypsin	B-X
(	B-X
NT	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
specific	B-X
nervous	B-X
system	B-X
multi-domain	B-X
serine	B-X
protease	B-X
best	B-X
known	B-X
for	B-X
its	B-X
selective	B-X
processing	B-X
of	B-X
the	B-X
potent	B-X
synaptic	B-X
organizer	B-X
agrin	B-X
.	B-X
These	B-X
biological	B-X
effects	B-X
are	B-X
likely	B-X
to	B-X
stem	B-X
from	B-X
NT-based	B-X
regulation	B-X
of	B-X
agrin	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
dissecting	B-X
the	B-X
exact	B-X
biological	B-X
implications	B-X
of	B-X
NT-agrin	B-X
interplay	B-X
is	B-X
difficult	B-X
,	B-X
due	B-X
to	B-X
the	B-X
scarce	B-X
molecular	B-X
detail	B-X
regarding	B-X
NT	B-X
activity	B-X
and	B-X
NT-agrin	B-X
interactions	B-X
.	B-X
We	B-X
developed	B-X
a	B-X
strategy	B-X
to	B-X
reliably	B-X
produce	B-X
and	B-X
purify	B-X
a	B-X
catalytically	B-X
competent	B-X
engineered	B-X
variant	B-X
of	B-X
NT	B-X
called	B-X
``	B-X
NT-mini	B-X
''	B-X
and	B-X
a	B-X
library	B-X
of	B-X
C-terminal	B-X
agrin	B-X
fragments	B-X
,	B-X
with	B-X
which	B-X
we	B-X
performed	B-X
a	B-X
thorough	B-X
biochemical	B-X
and	B-X
biophysical	B-X
characterization	B-X
of	B-X
NT	B-X
enzyme	B-X
functionality	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
regulatory	B-X
effects	B-X
of	B-X
calcium	B-X
ions	B-X
and	B-X
heparin	B-X
,	B-X
identified	B-X
NT	B-X
's	B-X
heparin-binding	B-X
domain	B-X
,	B-X
and	B-X
discovered	B-X
how	B-X
zinc	B-X
ions	B-X
induce	B-X
modulation	B-X
of	B-X
enzymatic	B-X
activity	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
investigated	B-X
myotube	B-X
differentiation	B-X
and	B-X
hippocampal	B-X
neuron	B-X
excitability	B-X
,	B-X
evidencing	B-X
a	B-X
dose-dependent	B-X
increase	B-X
in	B-X
neuronal	B-X
activity	B-X
alongside	B-X
a	B-X
negative	B-X
impact	B-X
on	B-X
myoblast	B-X
fusion	B-X
when	B-X
using	B-X
the	B-X
active	B-X
NT	B-X
enzyme	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
in	B-X
vitro	B-X
and	B-X
cellular	B-X
foundations	B-X
to	B-X
unravel	B-X
the	B-X
molecular	B-X
underpinnings	B-X
and	B-X
biological	B-X
significance	B-X
of	B-X
NT-agrin	B-X
interactions	B-X
.	B-X

In	O
this	O
study	O
NT	B-Protein
-	I-Protein
6	I-Protein
was	O
expressed	O
in	O
a	O
stably	O
transfected	O
mammalian	O
cell	O
line	O
,	O
and	O
in	O
insect	O
cells	O
via	O
a	O
recombinant	O
baculovirus	O
.	O

It	O
was	O
purified	O
to	O
homogeneity	O
and	O
characterized	O
by	O
MS	O
and	O
N	O
-	O
terminal	O
sequencing	O
.	O

NT	B-Protein
-	I-Protein
6	I-Protein
from	O
both	O
expression	O
systems	O
was	O
proteolytically	O
processed	O
at	O
one	O
of	O
two	O
protease	O
cleavage	O
motifs	O
and	O
was	O
found	O
to	O
be	O
glycosylated	O
.	O
<EOS>	B-X
Neurotrophin-6	B-X
(	B-X
NT-6	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
teleost	B-X
fish	B-X
Xiphophorus	B-X
as	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
neurotrophin	B-X
gene	B-X
family	B-X
.	B-X
NT-6	B-X
binds	B-X
specifically	B-X
the	B-X
glycosaminoglycan	B-X
heparin	B-X
.	B-X
In	B-X
this	B-X
study	B-X
NT-6	B-X
was	B-X
expressed	B-X
in	B-X
a	B-X
stably	B-X
transfected	B-X
mammalian	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
insect	B-X
cells	B-X
via	B-X
a	B-X
recombinant	B-X
baculovirus	B-X
.	B-X
NT-6	B-X
from	B-X
both	B-X
expression	B-X
systems	B-X
was	B-X
proteolytically	B-X
processed	B-X
at	B-X
one	B-X
of	B-X
two	B-X
protease	B-X
cleavage	B-X
motifs	B-X
and	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
.	B-X
Furthermore	B-X
,	B-X
NT-6	B-X
elicited	B-X
neurite	B-X
outgrowth	B-X
in	B-X
explanted	B-X
embryonic	B-X
dorsal	B-X
root	B-X
ganglia	B-X
.	B-X
Addition	B-X
of	B-X
heparin	B-X
into	B-X
the	B-X
medium	B-X
did	B-X
not	B-X
potentiate	B-X
the	B-X
activity	B-X
of	B-X
NT-6	B-X
in	B-X
survival	B-X
assays	B-X
.	B-X
However	B-X
,	B-X
when	B-X
a	B-X
sensory	B-X
ganglion	B-X
explant	B-X
was	B-X
cultured	B-X
in	B-X
a	B-X
collagen	B-X
gel	B-X
matrix	B-X
assay	B-X
adjacent	B-X
to	B-X
a	B-X
heparin	B-X
bead	B-X
coated	B-X
with	B-X
NT-6	B-X
,	B-X
neurite	B-X
outgrowth	B-X
directed	B-X
towards	B-X
the	B-X
bead	B-X
was	B-X
observed	B-X
.	B-X
This	B-X
indicated	B-X
that	B-X
NT-6	B-X
was	B-X
slowly	B-X
released	B-X
from	B-X
the	B-X
heparin	B-X
bead	B-X
generating	B-X
a	B-X
concentration	B-X
gradient	B-X
of	B-X
NT-6	B-X
instrumental	B-X
for	B-X
axonal	B-X
guidance	B-X
in	B-X
vitro	B-X
.	B-X
Thus	B-X
the	B-X
interaction	B-X
of	B-X
NT-6	B-X
with	B-X
heparin	B-X
might	B-X
not	B-X
be	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
receptor	B-X
for	B-X
NT-6	B-X
on	B-X
responsive	B-X
cells	B-X
but	B-X
rather	B-X
may	B-X
serve	B-X
to	B-X
control	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
distribution	B-X
of	B-X
NT-6	B-X
.	B-X

It	O
supported	O
the	O
survival	O
of	O
embryonic	O
chick	O
sensory	O
neurons	O
;	O
half	O
-	O
maximal	O
survival	O
was	O
observed	O
at	O
100	O
ng	O
/	O
ml	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
the	B-X
sensory	B-X
nervous	B-X
system	B-X
is	B-X
the	B-X
result	B-X
of	B-X
fine-tuned	B-X
waves	B-X
of	B-X
neurogenesis	B-X
and	B-X
apoptosis	B-X
which	B-X
control	B-X
the	B-X
appropriate	B-X
number	B-X
of	B-X
precursors	B-X
and	B-X
newly	B-X
generated	B-X
neurons	B-X
and	B-X
orient	B-X
them	B-X
toward	B-X
a	B-X
specific	B-X
lineage	B-X
.	B-X
They	B-X
have	B-X
long	B-X
been	B-X
in	B-X
the	B-X
scope	B-X
of	B-X
the	B-X
neurotrophic	B-X
theory	B-X
which	B-X
established	B-X
that	B-X
a	B-X
neuron	B-X
is	B-X
committed	B-X
to	B-X
die	B-X
unless	B-X
a	B-X
trophic	B-X
factor	B-X
generated	B-X
by	B-X
its	B-X
target	B-X
provides	B-X
it	B-X
with	B-X
a	B-X
survival	B-X
signal	B-X
.	B-X
The	B-X
neural	B-X
death	B-X
has	B-X
thus	B-X
always	B-X
been	B-X
described	B-X
as	B-X
a	B-X
``	B-X
default	B-X
''	B-X
program	B-X
,	B-X
survival	B-X
being	B-X
the	B-X
major	B-X
player	B-X
to	B-X
control	B-X
the	B-X
number	B-X
of	B-X
cells	B-X
.	B-X
In	B-X
order	B-X
to	B-X
address	B-X
the	B-X
role	B-X
of	B-X
TrkC	B-X
pro-apoptotic	B-X
activity	B-X
in	B-X
the	B-X
control	B-X
of	B-X
sensory	B-X
neurons	B-X
number	B-X
,	B-X
we	B-X
generated	B-X
a	B-X
TrkC	B-X
gene-trap	B-X
mutant	B-X
mice	B-X
.	B-X
We	B-X
found	B-X
out	B-X
that	B-X
this	B-X
new	B-X
murine	B-X
model	B-X
recapitulates	B-X
the	B-X
sensory	B-X
phenotype	B-X
of	B-X
TrkC	B-X
constitutive	B-X
mutants	B-X
,	B-X
with	B-X
reduced	B-X
DRG	B-X
size	B-X
and	B-X
reduced	B-X
number	B-X
of	B-X
DRG	B-X
neurons	B-X
.	B-X
We	B-X
engineered	B-X
these	B-X
mice	B-X
strain	B-X
with	B-X
a	B-X
lacZ	B-X
reporter	B-X
in	B-X
order	B-X
to	B-X
follow	B-X
the	B-X
fate	B-X
of	B-X
neurons	B-X
committed	B-X
to	B-X
a	B-X
TrkC	B-X
lineage	B-X
and	B-X
observed	B-X
that	B-X
they	B-X
are	B-X
specifically	B-X
protected	B-X
from	B-X
NT-3	B-X
mediated	B-X
apoptosis	B-X
in	B-X
NT-3/TrkC	B-X
double	B-X
knock-out	B-X
embryos	B-X
.	B-X
Finally	B-X
,	B-X
using	B-X
a	B-X
chicken	B-X
model	B-X
we	B-X
demonstrated	B-X
that	B-X
silencing	B-X
NT-3	B-X
emanating	B-X
from	B-X
the	B-X
ventral	B-X
neural	B-X
tube	B-X
induced	B-X
apoptosis	B-X
in	B-X
the	B-X
DRG	B-X
anlage	B-X
.	B-X
This	B-X
apoptosis	B-X
was	B-X
inhibited	B-X
by	B-X
silencing	B-X
TrkC	B-X
.	B-X
This	B-X
work	B-X
thus	B-X
demonstrates	B-X
that	B-X
,	B-X
during	B-X
in	B-X
vivo	B-X
DRG	B-X
development	B-X
,	B-X
TrkC	B-X
behaves	B-X
as	B-X
a	B-X
two-sided	B-X
receptor	B-X
transducing	B-X
positive	B-X
signals	B-X
of	B-X
neuronal	B-X
survival	B-X
in	B-X
response	B-X
to	B-X
NT-3	B-X
,	B-X
but	B-X
actively	B-X
inducing	B-X
neuronal	B-X
cell	B-X
death	B-X
when	B-X
unbound	B-X
.	B-X
This	B-X
functional	B-X
duality	B-X
sets	B-X
adequate	B-X
number	B-X
of	B-X
neurons	B-X
committed	B-X
to	B-X
a	B-X
TrkC	B-X
identity	B-X
in	B-X
the	B-X
forming	B-X
DRG	B-X
.	B-X

Furthermore	O
,	O
NT	B-Protein
-	I-Protein
6	I-Protein
elicited	O
neurite	O
outgrowth	O
in	O
explanted	O
embryonic	O
dorsal	O
root	O
ganglia	O
.	O
<EOS>	B-X
Neurotrophin-6	B-X
(	B-X
NT-6	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
teleost	B-X
fish	B-X
Xiphophorus	B-X
as	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
neurotrophin	B-X
gene	B-X
family	B-X
.	B-X
NT-6	B-X
binds	B-X
specifically	B-X
the	B-X
glycosaminoglycan	B-X
heparin	B-X
.	B-X
In	B-X
this	B-X
study	B-X
NT-6	B-X
was	B-X
expressed	B-X
in	B-X
a	B-X
stably	B-X
transfected	B-X
mammalian	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
insect	B-X
cells	B-X
via	B-X
a	B-X
recombinant	B-X
baculovirus	B-X
.	B-X
NT-6	B-X
from	B-X
both	B-X
expression	B-X
systems	B-X
was	B-X
proteolytically	B-X
processed	B-X
at	B-X
one	B-X
of	B-X
two	B-X
protease	B-X
cleavage	B-X
motifs	B-X
and	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
.	B-X
It	B-X
supported	B-X
the	B-X
survival	B-X
of	B-X
embryonic	B-X
chick	B-X
sensory	B-X
neurons	B-X
;	B-X
half-maximal	B-X
survival	B-X
was	B-X
observed	B-X
at	B-X
100	B-X
ng/ml	B-X
.	B-X
Furthermore	B-X
,	B-X
NT-6	B-X
elicited	B-X
neurite	B-X
outgrowth	B-X
in	B-X
explanted	B-X
embryonic	B-X
dorsal	B-X
root	B-X
ganglia	B-X
.	B-X
Addition	B-X
of	B-X
heparin	B-X
into	B-X
the	B-X
medium	B-X
did	B-X
not	B-X
potentiate	B-X
the	B-X
activity	B-X
of	B-X
NT-6	B-X
in	B-X
survival	B-X
assays	B-X
.	B-X
However	B-X
,	B-X
when	B-X
a	B-X
sensory	B-X
ganglion	B-X
explant	B-X
was	B-X
cultured	B-X
in	B-X
a	B-X
collagen	B-X
gel	B-X
matrix	B-X
assay	B-X
adjacent	B-X
to	B-X
a	B-X
heparin	B-X
bead	B-X
coated	B-X
with	B-X
NT-6	B-X
,	B-X
neurite	B-X
outgrowth	B-X
directed	B-X
towards	B-X
the	B-X
bead	B-X
was	B-X
observed	B-X
.	B-X
This	B-X
indicated	B-X
that	B-X
NT-6	B-X
was	B-X
slowly	B-X
released	B-X
from	B-X
the	B-X
heparin	B-X
bead	B-X
generating	B-X
a	B-X
concentration	B-X
gradient	B-X
of	B-X
NT-6	B-X
instrumental	B-X
for	B-X
axonal	B-X
guidance	B-X
in	B-X
vitro	B-X
.	B-X
Thus	B-X
the	B-X
interaction	B-X
of	B-X
NT-6	B-X
with	B-X
heparin	B-X
might	B-X
not	B-X
be	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
receptor	B-X
for	B-X
NT-6	B-X
on	B-X
responsive	B-X
cells	B-X
but	B-X
rather	B-X
may	B-X
serve	B-X
to	B-X
control	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
distribution	B-X
of	B-X
NT-6	B-X
.	B-X

Addition	O
of	O
heparin	O
into	O
the	O
medium	O
did	O
not	O
potentiate	O
the	O
activity	O
of	O
NT	B-Protein
-	I-Protein
6	I-Protein
in	O
survival	O
assays	O
.	O
<EOS>	B-X
Low	B-X
molecular	B-X
weight	B-X
heparin	B-X
(	B-X
LMWH	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
as	B-X
effective	B-X
as	B-X
unfractionated	B-X
heparin	B-X
(	B-X
UFH	B-X
)	B-X
in	B-X
peripheral	B-X
vascular	B-X
surgery	B-X
,	B-X
but	B-X
with	B-X
fewer	B-X
adverse	B-X
effects	B-X
.	B-X
An	B-X
alternative	B-X
approach	B-X
is	B-X
to	B-X
produce	B-X
a	B-X
defined	B-X
serum-free	B-X
culture	B-X
medium	B-X
supplemented	B-X
with	B-X
growth	B-X
factors	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
addition	B-X
of	B-X
Leukaemia	B-X
Inhibitory	B-X
Factor	B-X
increased	B-X
blastocyst	B-X
formation	B-X
from	B-X
18.4-43.6	B-X
%	B-X
but	B-X
none	B-X
of	B-X
these	B-X
embryos	B-X
developed	B-X
beyond	B-X
day	B-X
7	B-X
or	B-X
hatched	B-X
,	B-X
suggesting	B-X
that	B-X
additional	B-X
factors	B-X
are	B-X
required	B-X
.	B-X
Development	B-X
to	B-X
the	B-X
blastocyst	B-X
stage	B-X
was	B-X
significantly	B-X
increased	B-X
to	B-X
71.0	B-X
%	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
100	B-X
nM	B-X
heparin-binding	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
HB-EGF	B-X
)	B-X
and	B-X
81.0	B-X
%	B-X
of	B-X
these	B-X
embryos	B-X
went	B-X
on	B-X
to	B-X
hatch	B-X
.	B-X

However	O
,	O
when	O
a	O
sensory	O
ganglion	O
explant	O
was	O
cultured	O
in	O
a	O
collagen	O
gel	O
matrix	O
assay	O
adjacent	O
to	O
a	O
heparin	O
bead	O
coated	O
with	O
NT	B-Protein
-	I-Protein
6	I-Protein
,	O
neurite	O
outgrowth	O
directed	O
towards	O
the	O
bead	O
was	O
observed	O
.	O

This	O
indicated	O
that	O
NT	B-Protein
-	I-Protein
6	I-Protein
was	O
slowly	O
released	O
from	O
the	O
heparin	O
bead	O
generating	O
a	O
concentration	O
gradient	O
of	O
NT	B-Protein
-	I-Protein
6	I-Protein
instrumental	O
for	O
axonal	O
guidance	O
in	O
vitro	O
.	O
<EOS>	B-X
Neurotrophin-6	B-X
(	B-X
NT-6	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
teleost	B-X
fish	B-X
Xiphophorus	B-X
as	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
neurotrophin	B-X
gene	B-X
family	B-X
.	B-X
NT-6	B-X
binds	B-X
specifically	B-X
the	B-X
glycosaminoglycan	B-X
heparin	B-X
.	B-X
In	B-X
this	B-X
study	B-X
NT-6	B-X
was	B-X
expressed	B-X
in	B-X
a	B-X
stably	B-X
transfected	B-X
mammalian	B-X
cell	B-X
line	B-X
,	B-X
and	B-X
in	B-X
insect	B-X
cells	B-X
via	B-X
a	B-X
recombinant	B-X
baculovirus	B-X
.	B-X
NT-6	B-X
from	B-X
both	B-X
expression	B-X
systems	B-X
was	B-X
proteolytically	B-X
processed	B-X
at	B-X
one	B-X
of	B-X
two	B-X
protease	B-X
cleavage	B-X
motifs	B-X
and	B-X
was	B-X
found	B-X
to	B-X
be	B-X
glycosylated	B-X
.	B-X
Furthermore	B-X
,	B-X
NT-6	B-X
elicited	B-X
neurite	B-X
outgrowth	B-X
in	B-X
explanted	B-X
embryonic	B-X
dorsal	B-X
root	B-X
ganglia	B-X
.	B-X
Addition	B-X
of	B-X
heparin	B-X
into	B-X
the	B-X
medium	B-X
did	B-X
not	B-X
potentiate	B-X
the	B-X
activity	B-X
of	B-X
NT-6	B-X
in	B-X
survival	B-X
assays	B-X
.	B-X
However	B-X
,	B-X
when	B-X
a	B-X
sensory	B-X
ganglion	B-X
explant	B-X
was	B-X
cultured	B-X
in	B-X
a	B-X
collagen	B-X
gel	B-X
matrix	B-X
assay	B-X
adjacent	B-X
to	B-X
a	B-X
heparin	B-X
bead	B-X
coated	B-X
with	B-X
NT-6	B-X
,	B-X
neurite	B-X
outgrowth	B-X
directed	B-X
towards	B-X
the	B-X
bead	B-X
was	B-X
observed	B-X
.	B-X
This	B-X
indicated	B-X
that	B-X
NT-6	B-X
was	B-X
slowly	B-X
released	B-X
from	B-X
the	B-X
heparin	B-X
bead	B-X
generating	B-X
a	B-X
concentration	B-X
gradient	B-X
of	B-X
NT-6	B-X
instrumental	B-X
for	B-X
axonal	B-X
guidance	B-X
in	B-X
vitro	B-X
.	B-X
Thus	B-X
the	B-X
interaction	B-X
of	B-X
NT-6	B-X
with	B-X
heparin	B-X
might	B-X
not	B-X
be	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
receptor	B-X
for	B-X
NT-6	B-X
on	B-X
responsive	B-X
cells	B-X
but	B-X
rather	B-X
may	B-X
serve	B-X
to	B-X
control	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
distribution	B-X
of	B-X
NT-6	B-X
.	B-X

Thus	O
the	O
interaction	O
of	O
NT	B-Protein
-	I-Protein
6	I-Protein
with	O
heparin	O
might	O
not	O
be	O
required	O
for	O
the	O
activation	O
of	O
the	O
cellular	O
receptor	O
for	O
NT	B-Protein
-	I-Protein
6	I-Protein
on	O
responsive	O
cells	O
but	O
rather	O
may	O
serve	O
to	O
control	O
,	O
in	O
vivo	O
,	O
the	O
distribution	O
of	O
NT	B-Protein
-	I-Protein
6	I-Protein
.	O
<EOS>	B-X
Drug-drug	B-X
interactions	B-X
are	B-X
undesirable	B-X
,	B-X
as	B-X
they	B-X
reduce	B-X
drug	B-X
bioavailability	B-X
.	B-X
Drug-reagent	B-X
interactions	B-X
in	B-X
biochemical	B-X
tests	B-X
may	B-X
directly	B-X
affect	B-X
the	B-X
accuracy	B-X
of	B-X
test	B-X
results	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
described	B-X
multilayer	B-X
nanoparticles	B-X
(	B-X
nanotraps	B-X
)	B-X
with	B-X
heparin	B-X
surface	B-X
and	B-X
cationic	B-X
peptides	B-X
comprising	B-X
the	B-X
N-terminal	B-X
tail	B-X
(	B-X
Nt	B-X
)	B-X
and	B-X
the	B-X
second	B-X
extracellular	B-X
loop	B-X
(	B-X
ECL2	B-X
)	B-X
of	B-X
CCR5	B-X
receptor	B-X
,	B-X
which	B-X
could	B-X
bind	B-X
with	B-X
high	B-X
affinity	B-X
some	B-X
inflammatory	B-X
chemokines	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
Rantes	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
similarity	B-X
of	B-X
the	B-X
binding	B-X
determinants	B-X
in	B-X
CCR5	B-X
structure	B-X
,	B-X
both	B-X
for	B-X
chemokines	B-X
and	B-X
gp120	B-X
HIV	B-X
protein	B-X
,	B-X
here	B-X
we	B-X
expand	B-X
this	B-X
approach	B-X
to	B-X
the	B-X
study	B-X
of	B-X
the	B-X
interactions	B-X
of	B-X
these	B-X
biomimetic	B-X
nanosystems	B-X
and	B-X
their	B-X
components	B-X
with	B-X
the	B-X
peptide	B-X
representing	B-X
the	B-X
V3	B-X
loop	B-X
of	B-X
the	B-X
activated	B-X
form	B-X
of	B-X
gp120	B-X
.	B-X

Study	O
of	O
biochemical	O
substrate	O
and	O
role	O
of	O
metalloproteinases	O
in	O
fascia	O
transversalis	O
from	O
hernial	O
processes	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
fascia	B-X
transversalis	B-X
(	B-X
FT	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
direct	B-X
and	B-X
indirect	B-X
hernia	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
possible	B-X
differences	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
We	B-X
have	B-X
analysed	B-X
the	B-X
ultrastructure	B-X
of	B-X
the	B-X
fascia	B-X
surrounding	B-X
the	B-X
hernial	B-X
lesions	B-X
,	B-X
the	B-X
proline	B-X
and	B-X
lysine	B-X
hydroxylation	B-X
in	B-X
the	B-X
tissue	B-X
,	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
ratio	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
metalloproteinases	B-X
.	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
fascia	O
transversalis	O
(	O
FT	O
)	O
from	O
patients	O
with	O
direct	O
and	O
indirect	O
hernia	O
in	O
an	O
attempt	O
to	O
identify	O
possible	O
differences	O
between	O
each	O
type	O
of	O
hernia	O
.	O

FT	O
samples	O
were	O
obtained	O
from	O
36	O
patients	O
presenting	O
inguinal	O
hernia	O
(	O
23	O
indirect	O
hernia	O
and	O
13	O
direct	O
hernia	O
)	O
who	O
underwent	O
surgery	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
fascia	B-X
transversalis	B-X
(	B-X
FT	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
direct	B-X
and	B-X
indirect	B-X
hernia	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
possible	B-X
differences	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
FT	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
36	B-X
patients	B-X
presenting	B-X
inguinal	B-X
hernia	B-X
(	B-X
23	B-X
indirect	B-X
hernia	B-X
and	B-X
13	B-X
direct	B-X
hernia	B-X
)	B-X
who	B-X
underwent	B-X
surgery	B-X
.	B-X
We	B-X
have	B-X
analysed	B-X
the	B-X
ultrastructure	B-X
of	B-X
the	B-X
fascia	B-X
surrounding	B-X
the	B-X
hernial	B-X
lesions	B-X
,	B-X
the	B-X
proline	B-X
and	B-X
lysine	B-X
hydroxylation	B-X
in	B-X
the	B-X
tissue	B-X
,	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
ratio	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
metalloproteinases	B-X
.	B-X
We	B-X
have	B-X
not	B-X
detected	B-X
ultrastructural	B-X
differences	B-X
in	B-X
the	B-X
collagen	B-X
fibrils	B-X
from	B-X
FT	B-X
in	B-X
direct	B-X
and	B-X
indirect	B-X
hernias	B-X
.	B-X
However	B-X
,	B-X
the	B-X
interfibrillar	B-X
matrix	B-X
was	B-X
more	B-X
abundant	B-X
in	B-X
direct	B-X
hernias	B-X
,	B-X
showing	B-X
abundant	B-X
electron-dense	B-X
particles	B-X
.	B-X
No	B-X
differences	B-X
in	B-X
proline	B-X
hydroxylation	B-X
were	B-X
observed	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
A	B-X
small	B-X
decrease	B-X
in	B-X
lysine	B-X
hydroxylation	B-X
was	B-X
detected	B-X
in	B-X
patients	B-X
with	B-X
direct	B-X
hernia	B-X
.	B-X
FT	B-X
from	B-X
patients	B-X
presenting	B-X
direct	B-X
hernia	B-X
showed	B-X
a	B-X
very	B-X
strong	B-X
staining	B-X
vs.	B-X
metalloproteinase-2	B-X
when	B-X
compared	B-X
with	B-X
that	B-X
observed	B-X
in	B-X
indirect	B-X
hernia	B-X
.	B-X

We	O
have	O
analysed	O
the	O
ultrastructure	O
of	O
the	O
fascia	O
surrounding	O
the	O
hernial	O
lesions	O
,	O
the	O
proline	O
and	O
lysine	O
hydroxylation	O
in	O
the	O
tissue	O
,	O
the	O
type	O
I	O
-	O
type	B-Protein
III	I-Protein
collagen	I-Protein
ratio	O
and	O
the	O
presence	O
of	O
metalloproteinases	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
fascia	B-X
transversalis	B-X
(	B-X
FT	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
direct	B-X
and	B-X
indirect	B-X
hernia	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
possible	B-X
differences	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
We	B-X
have	B-X
analysed	B-X
the	B-X
ultrastructure	B-X
of	B-X
the	B-X
fascia	B-X
surrounding	B-X
the	B-X
hernial	B-X
lesions	B-X
,	B-X
the	B-X
proline	B-X
and	B-X
lysine	B-X
hydroxylation	B-X
in	B-X
the	B-X
tissue	B-X
,	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
ratio	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
metalloproteinases	B-X
.	B-X
We	B-X
have	B-X
not	B-X
detected	B-X
ultrastructural	B-X
differences	B-X
in	B-X
the	B-X
collagen	B-X
fibrils	B-X
from	B-X
FT	B-X
in	B-X
direct	B-X
and	B-X
indirect	B-X
hernias	B-X
.	B-X
No	B-X
differences	B-X
in	B-X
proline	B-X
hydroxylation	B-X
were	B-X
observed	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
A	B-X
small	B-X
decrease	B-X
in	B-X
lysine	B-X
hydroxylation	B-X
was	B-X
detected	B-X
in	B-X
patients	B-X
with	B-X
direct	B-X
hernia	B-X
.	B-X
Enzyme-linked	B-X
immunosorbent	B-X
assays	B-X
(	B-X
ELISAs	B-X
)	B-X
showed	B-X
no	B-X
statistically	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
absorbance	B-X
ratios	B-X
.	B-X

We	O
have	O
not	O
detected	O
ultrastructural	O
differences	O
in	O
the	O
collagen	O
fibrils	O
from	O
FT	O
in	O
direct	O
and	O
indirect	O
hernias	O
.	O

However	O
,	O
the	O
interfibrillar	O
matrix	O
was	O
more	O
abundant	O
in	O
direct	O
hernias	O
,	O
showing	O
abundant	O
electron	O
-	O
dense	O
particles	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
fascia	B-X
transversalis	B-X
(	B-X
FT	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
direct	B-X
and	B-X
indirect	B-X
hernia	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
possible	B-X
differences	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
FT	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
36	B-X
patients	B-X
presenting	B-X
inguinal	B-X
hernia	B-X
(	B-X
23	B-X
indirect	B-X
hernia	B-X
and	B-X
13	B-X
direct	B-X
hernia	B-X
)	B-X
who	B-X
underwent	B-X
surgery	B-X
.	B-X
We	B-X
have	B-X
not	B-X
detected	B-X
ultrastructural	B-X
differences	B-X
in	B-X
the	B-X
collagen	B-X
fibrils	B-X
from	B-X
FT	B-X
in	B-X
direct	B-X
and	B-X
indirect	B-X
hernias	B-X
.	B-X
However	B-X
,	B-X
the	B-X
interfibrillar	B-X
matrix	B-X
was	B-X
more	B-X
abundant	B-X
in	B-X
direct	B-X
hernias	B-X
,	B-X
showing	B-X
abundant	B-X
electron-dense	B-X
particles	B-X
.	B-X
A	B-X
small	B-X
decrease	B-X
in	B-X
lysine	B-X
hydroxylation	B-X
was	B-X
detected	B-X
in	B-X
patients	B-X
with	B-X
direct	B-X
hernia	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
no	B-X
differences	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
matrix	B-X
metalloproteinase-1	B-X
.	B-X
FT	B-X
from	B-X
patients	B-X
presenting	B-X
direct	B-X
hernia	B-X
showed	B-X
a	B-X
very	B-X
strong	B-X
staining	B-X
vs.	B-X
metalloproteinase-2	B-X
when	B-X
compared	B-X
with	B-X
that	B-X
observed	B-X
in	B-X
indirect	B-X
hernia	B-X
.	B-X

No	O
differences	O
in	O
proline	O
hydroxylation	O
were	O
observed	O
between	O
each	O
type	O
of	O
hernia	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
fascia	B-X
transversalis	B-X
(	B-X
FT	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
direct	B-X
and	B-X
indirect	B-X
hernia	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
possible	B-X
differences	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
FT	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
36	B-X
patients	B-X
presenting	B-X
inguinal	B-X
hernia	B-X
(	B-X
23	B-X
indirect	B-X
hernia	B-X
and	B-X
13	B-X
direct	B-X
hernia	B-X
)	B-X
who	B-X
underwent	B-X
surgery	B-X
.	B-X
We	B-X
have	B-X
analysed	B-X
the	B-X
ultrastructure	B-X
of	B-X
the	B-X
fascia	B-X
surrounding	B-X
the	B-X
hernial	B-X
lesions	B-X
,	B-X
the	B-X
proline	B-X
and	B-X
lysine	B-X
hydroxylation	B-X
in	B-X
the	B-X
tissue	B-X
,	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
ratio	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
metalloproteinases	B-X
.	B-X
We	B-X
have	B-X
not	B-X
detected	B-X
ultrastructural	B-X
differences	B-X
in	B-X
the	B-X
collagen	B-X
fibrils	B-X
from	B-X
FT	B-X
in	B-X
direct	B-X
and	B-X
indirect	B-X
hernias	B-X
.	B-X
However	B-X
,	B-X
the	B-X
interfibrillar	B-X
matrix	B-X
was	B-X
more	B-X
abundant	B-X
in	B-X
direct	B-X
hernias	B-X
,	B-X
showing	B-X
abundant	B-X
electron-dense	B-X
particles	B-X
.	B-X
No	B-X
differences	B-X
in	B-X
proline	B-X
hydroxylation	B-X
were	B-X
observed	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
A	B-X
small	B-X
decrease	B-X
in	B-X
lysine	B-X
hydroxylation	B-X
was	B-X
detected	B-X
in	B-X
patients	B-X
with	B-X
direct	B-X
hernia	B-X
.	B-X
Enzyme-linked	B-X
immunosorbent	B-X
assays	B-X
(	B-X
ELISAs	B-X
)	B-X
showed	B-X
no	B-X
statistically	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
absorbance	B-X
ratios	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
no	B-X
differences	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
matrix	B-X
metalloproteinase-1	B-X
.	B-X
FT	B-X
from	B-X
patients	B-X
presenting	B-X
direct	B-X
hernia	B-X
showed	B-X
a	B-X
very	B-X
strong	B-X
staining	B-X
vs.	B-X
metalloproteinase-2	B-X
when	B-X
compared	B-X
with	B-X
that	B-X
observed	B-X
in	B-X
indirect	B-X
hernia	B-X
.	B-X

A	O
small	O
decrease	O
in	O
lysine	O
hydroxylation	O
was	O
detected	O
in	O
patients	O
with	O
direct	O
hernia	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
fascia	B-X
transversalis	B-X
(	B-X
FT	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
direct	B-X
and	B-X
indirect	B-X
hernia	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
possible	B-X
differences	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
FT	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
36	B-X
patients	B-X
presenting	B-X
inguinal	B-X
hernia	B-X
(	B-X
23	B-X
indirect	B-X
hernia	B-X
and	B-X
13	B-X
direct	B-X
hernia	B-X
)	B-X
who	B-X
underwent	B-X
surgery	B-X
.	B-X
We	B-X
have	B-X
analysed	B-X
the	B-X
ultrastructure	B-X
of	B-X
the	B-X
fascia	B-X
surrounding	B-X
the	B-X
hernial	B-X
lesions	B-X
,	B-X
the	B-X
proline	B-X
and	B-X
lysine	B-X
hydroxylation	B-X
in	B-X
the	B-X
tissue	B-X
,	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
ratio	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
metalloproteinases	B-X
.	B-X
We	B-X
have	B-X
not	B-X
detected	B-X
ultrastructural	B-X
differences	B-X
in	B-X
the	B-X
collagen	B-X
fibrils	B-X
from	B-X
FT	B-X
in	B-X
direct	B-X
and	B-X
indirect	B-X
hernias	B-X
.	B-X
However	B-X
,	B-X
the	B-X
interfibrillar	B-X
matrix	B-X
was	B-X
more	B-X
abundant	B-X
in	B-X
direct	B-X
hernias	B-X
,	B-X
showing	B-X
abundant	B-X
electron-dense	B-X
particles	B-X
.	B-X
No	B-X
differences	B-X
in	B-X
proline	B-X
hydroxylation	B-X
were	B-X
observed	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
A	B-X
small	B-X
decrease	B-X
in	B-X
lysine	B-X
hydroxylation	B-X
was	B-X
detected	B-X
in	B-X
patients	B-X
with	B-X
direct	B-X
hernia	B-X
.	B-X
FT	B-X
from	B-X
patients	B-X
presenting	B-X
direct	B-X
hernia	B-X
showed	B-X
a	B-X
very	B-X
strong	B-X
staining	B-X
vs.	B-X
metalloproteinase-2	B-X
when	B-X
compared	B-X
with	B-X
that	B-X
observed	B-X
in	B-X
indirect	B-X
hernia	B-X
.	B-X

Enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
showed	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
type	O
I	O
-	O
type	B-Protein
III	I-Protein
collagen	I-Protein
absorbance	O
ratios	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
fascia	B-X
transversalis	B-X
(	B-X
FT	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
direct	B-X
and	B-X
indirect	B-X
hernia	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
possible	B-X
differences	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
We	B-X
have	B-X
analysed	B-X
the	B-X
ultrastructure	B-X
of	B-X
the	B-X
fascia	B-X
surrounding	B-X
the	B-X
hernial	B-X
lesions	B-X
,	B-X
the	B-X
proline	B-X
and	B-X
lysine	B-X
hydroxylation	B-X
in	B-X
the	B-X
tissue	B-X
,	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
ratio	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
metalloproteinases	B-X
.	B-X
We	B-X
have	B-X
not	B-X
detected	B-X
ultrastructural	B-X
differences	B-X
in	B-X
the	B-X
collagen	B-X
fibrils	B-X
from	B-X
FT	B-X
in	B-X
direct	B-X
and	B-X
indirect	B-X
hernias	B-X
.	B-X
No	B-X
differences	B-X
in	B-X
proline	B-X
hydroxylation	B-X
were	B-X
observed	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
Enzyme-linked	B-X
immunosorbent	B-X
assays	B-X
(	B-X
ELISAs	B-X
)	B-X
showed	B-X
no	B-X
statistically	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
absorbance	B-X
ratios	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
no	B-X
differences	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
matrix	B-X
metalloproteinase-1	B-X
.	B-X
FT	B-X
from	B-X
patients	B-X
presenting	B-X
direct	B-X
hernia	B-X
showed	B-X
a	B-X
very	B-X
strong	B-X
staining	B-X
vs.	B-X
metalloproteinase-2	B-X
when	B-X
compared	B-X
with	B-X
that	B-X
observed	B-X
in	B-X
indirect	B-X
hernia	B-X
.	B-X

Immunohistochemistry	O
revealed	O
no	O
differences	O
in	O
the	O
expression	O
of	O
matrix	B-Protein
metalloproteinase	I-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
compare	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMP	B-X
)	B-X
in	B-X
primary	B-X
CNS	B-X
lymphoma	B-X
(	B-X
PCNSL	B-X
)	B-X
with	B-X
that	B-X
of	B-X
nodal	B-X
lymphoma	B-X
(	B-X
NL	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
performed	B-X
quantitative	B-X
analysis	B-X
of	B-X
mRNA	B-X
expression	B-X
of	B-X
MMP1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
7	B-X
and	B-X
9	B-X
in	B-X
lymphoma	B-X
cells	B-X
from	B-X
10	B-X
cases	B-X
of	B-X
PCNSL	B-X
,	B-X
all	B-X
of	B-X
which	B-X
were	B-X
diagnosed	B-X
as	B-X
diffuse	B-X
large	B-X
B-cell	B-X
lymphoma	B-X
(	B-X
DLBCL	B-X
)	B-X
,	B-X
and	B-X
14	B-X
cases	B-X
of	B-X
nodal	B-X
DLBCL	B-X
.	B-X
Immunohistochemistry	B-X
was	B-X
also	B-X
performed	B-X
for	B-X
phenotyping	B-X
of	B-X
lymphoma	B-X
cells	B-X
and	B-X
for	B-X
examining	B-X
the	B-X
localization	B-X
of	B-X
MMPs	B-X
.	B-X
The	B-X
expression	B-X
level	B-X
of	B-X
MMP7	B-X
in	B-X
PCNSL	B-X
(	B-X
median	B-X
ratio	B-X
to	B-X
normal	B-X
lymophocytes	B-X
,	B-X
45.6	B-X
)	B-X
was	B-X
significantly	B-X
higher	B-X
than	B-X
the	B-X
level	B-X
in	B-X
NL	B-X
(	B-X
median	B-X
,	B-X
7.55	B-X
)	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
MMP2	B-X
(	B-X
median	B-X
,	B-X
31.7	B-X
)	B-X
and	B-X
MMP9	B-X
(	B-X
median	B-X
,	B-X
1.30	B-X
)	B-X
in	B-X
PCNSL	B-X
were	B-X
significantly	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
NL	B-X
(	B-X
median	B-X
,	B-X
120	B-X
and	B-X
16.5	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
MMP1	B-X
and	B-X
MMP3	B-X
were	B-X
very	B-X
low	B-X
and	B-X
not	B-X
different	B-X
between	B-X
PCNSL	B-X
and	B-X
NL	B-X
(	B-X
almost	B-X
comparable	B-X
to	B-X
those	B-X
in	B-X
normal	B-X
lymphocytes	B-X
)	B-X
.	B-X
Immunohistochemical	B-X
phenotyping	B-X
revealed	B-X
that	B-X
the	B-X
frequency	B-X
of	B-X
non-germinal	B-X
center	B-X
type	B-X
DLBCL	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
PCNSL	B-X
than	B-X
in	B-X
NL	B-X
.	B-X
These	B-X
results	B-X
,	B-X
notably	B-X
the	B-X
significantly	B-X
increased	B-X
expression	B-X
of	B-X
MMP7	B-X
in	B-X
PCNSL	B-X
,	B-X
suggest	B-X
the	B-X
involvement	B-X
of	B-X
this	B-X
MMP	B-X
in	B-X
the	B-X
characteristic	B-X
infiltration	B-X
pattern	B-X
of	B-X
PCNSL	B-X
.	B-X

FT	O
from	O
patients	O
presenting	O
direct	O
hernia	O
showed	O
a	O
very	O
strong	O
staining	O
vs	O
.	O
metalloproteinase	B-Protein
-	I-Protein
2	I-Protein
when	O
compared	O
with	O
that	O
observed	O
in	O
indirect	O
hernia	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
fascia	B-X
transversalis	B-X
(	B-X
FT	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
direct	B-X
and	B-X
indirect	B-X
hernia	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
possible	B-X
differences	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
FT	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
36	B-X
patients	B-X
presenting	B-X
inguinal	B-X
hernia	B-X
(	B-X
23	B-X
indirect	B-X
hernia	B-X
and	B-X
13	B-X
direct	B-X
hernia	B-X
)	B-X
who	B-X
underwent	B-X
surgery	B-X
.	B-X
We	B-X
have	B-X
analysed	B-X
the	B-X
ultrastructure	B-X
of	B-X
the	B-X
fascia	B-X
surrounding	B-X
the	B-X
hernial	B-X
lesions	B-X
,	B-X
the	B-X
proline	B-X
and	B-X
lysine	B-X
hydroxylation	B-X
in	B-X
the	B-X
tissue	B-X
,	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
ratio	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
metalloproteinases	B-X
.	B-X
We	B-X
have	B-X
not	B-X
detected	B-X
ultrastructural	B-X
differences	B-X
in	B-X
the	B-X
collagen	B-X
fibrils	B-X
from	B-X
FT	B-X
in	B-X
direct	B-X
and	B-X
indirect	B-X
hernias	B-X
.	B-X
However	B-X
,	B-X
the	B-X
interfibrillar	B-X
matrix	B-X
was	B-X
more	B-X
abundant	B-X
in	B-X
direct	B-X
hernias	B-X
,	B-X
showing	B-X
abundant	B-X
electron-dense	B-X
particles	B-X
.	B-X
No	B-X
differences	B-X
in	B-X
proline	B-X
hydroxylation	B-X
were	B-X
observed	B-X
between	B-X
each	B-X
type	B-X
of	B-X
hernia	B-X
.	B-X
A	B-X
small	B-X
decrease	B-X
in	B-X
lysine	B-X
hydroxylation	B-X
was	B-X
detected	B-X
in	B-X
patients	B-X
with	B-X
direct	B-X
hernia	B-X
.	B-X
Enzyme-linked	B-X
immunosorbent	B-X
assays	B-X
(	B-X
ELISAs	B-X
)	B-X
showed	B-X
no	B-X
statistically	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
type	B-X
I-type	B-X
III	B-X
collagen	B-X
absorbance	B-X
ratios	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
no	B-X
differences	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
matrix	B-X
metalloproteinase-1	B-X
.	B-X
FT	B-X
from	B-X
patients	B-X
presenting	B-X
direct	B-X
hernia	B-X
showed	B-X
a	B-X
very	B-X
strong	B-X
staining	B-X
vs.	B-X
metalloproteinase-2	B-X
when	B-X
compared	B-X
with	B-X
that	B-X
observed	B-X
in	B-X
indirect	B-X
hernia	B-X
.	B-X

Porcine	O
submaxillary	B-Protein
mucin	I-Protein
forms	O
disulfide	O
-	O
linked	O
multimers	O
through	O
its	O
amino	O
-	O
terminal	O
D	O
-	O
domains	O
.	O
<EOS>	B-X
COS-7	B-X
cells	B-X
expressing	B-X
1,360	B-X
residues	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
porcine	B-X
submaxillary	B-X
mucin	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
whether	B-X
this	B-X
region	B-X
,	B-X
containing	B-X
the	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
and	B-X
D3	B-X
domains	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
forming	B-X
mucin	B-X
multimers	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
proteins	B-X
immunoprecipitated	B-X
from	B-X
the	B-X
medium	B-X
of	B-X
transfected	B-X
cells	B-X
by	B-X
reducing	B-X
SDS-gel	B-X
electrophoresis	B-X
showed	B-X
a	B-X
single	B-X
N-glycosylated	B-X
protein	B-X
with	B-X
no	B-X
indication	B-X
of	B-X
proteolytically	B-X
processed	B-X
forms	B-X
.	B-X
Without	B-X
prior	B-X
reduction	B-X
,	B-X
only	B-X
two	B-X
proteins	B-X
,	B-X
corresponding	B-X
to	B-X
monomeric	B-X
and	B-X
disulfide-linked	B-X
trimeric	B-X
species	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
The	B-X
expressed	B-X
protein	B-X
devoid	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
also	B-X
formed	B-X
trimers	B-X
,	B-X
but	B-X
was	B-X
secreted	B-X
from	B-X
cells	B-X
in	B-X
significantly	B-X
less	B-X
amounts	B-X
than	B-X
glycosylated	B-X
trimers	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
disulfide-linked	B-X
trimers	B-X
were	B-X
assembled	B-X
inside	B-X
the	B-X
cells	B-X
no	B-X
earlier	B-X
than	B-X
30	B-X
min	B-X
after	B-X
protein	B-X
synthesis	B-X
commenced	B-X
and	B-X
after	B-X
the	B-X
intracellular	B-X
precursors	B-X
were	B-X
N-glycosylated	B-X
.	B-X
Coexpression	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
and	B-X
the	B-X
disulfide-rich	B-X
carboxyl-terminal	B-X
domain	B-X
of	B-X
the	B-X
mucin	B-X
showed	B-X
that	B-X
these	B-X
structures	B-X
were	B-X
not	B-X
disulfide-linked	B-X
with	B-X
one	B-X
another	B-X
.	B-X
Cells	B-X
expressing	B-X
a	B-X
DNA	B-X
construct	B-X
encoding	B-X
a	B-X
fusion	B-X
protein	B-X
between	B-X
the	B-X
amino-	B-X
and	B-X
carboxyl-terminal	B-X
regions	B-X
of	B-X
the	B-X
mucin	B-X
secreted	B-X
disulfide-linked	B-X
dimeric	B-X
and	B-X
high	B-X
molecular	B-X
weight	B-X
multimeric	B-X
species	B-X
of	B-X
the	B-X
recombinant	B-X
mucin	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
monensin	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
dimerization	B-X
,	B-X
but	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
disulfide-linked	B-X
dimers	B-X
of	B-X
mucin	B-X
are	B-X
subsequently	B-X
assembled	B-X
into	B-X
disulfide-linked	B-X
multimers	B-X
by	B-X
the	B-X
amino-terminal	B-X
regions	B-X
.	B-X
They	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
porcine	B-X
mucin	B-X
forms	B-X
branched	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
This	B-X
ability	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
mucin	B-X
to	B-X
aid	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
multimers	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
amino	B-X
acid	B-X
identities	B-X
to	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
human	B-X
von	B-X
Willebrand	B-X
factor	B-X
,	B-X
which	B-X
also	B-X
serves	B-X
to	B-X
form	B-X
disulfide-linked	B-X
multimers	B-X
of	B-X
this	B-X
protein	B-X
.	B-X

COS	O
-	O
7	O
cells	O
expressing	O
1	O
,	O
360	O
residues	O
from	O
the	O
amino	O
terminus	O
of	O
porcine	O
submaxillary	B-Protein
mucin	I-Protein
were	O
used	O
to	O
determine	O
whether	O
this	O
region	O
,	O
containing	O
the	O
D1	O
,	O
D2	O
,	O
and	O
D3	O
domains	O
,	O
is	O
involved	O
in	O
forming	O
mucin	O
multimers	O
.	O
<EOS>	B-X
COS-7	B-X
cells	B-X
expressing	B-X
1,360	B-X
residues	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
porcine	B-X
submaxillary	B-X
mucin	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
whether	B-X
this	B-X
region	B-X
,	B-X
containing	B-X
the	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
and	B-X
D3	B-X
domains	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
forming	B-X
mucin	B-X
multimers	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
proteins	B-X
immunoprecipitated	B-X
from	B-X
the	B-X
medium	B-X
of	B-X
transfected	B-X
cells	B-X
by	B-X
reducing	B-X
SDS-gel	B-X
electrophoresis	B-X
showed	B-X
a	B-X
single	B-X
N-glycosylated	B-X
protein	B-X
with	B-X
no	B-X
indication	B-X
of	B-X
proteolytically	B-X
processed	B-X
forms	B-X
.	B-X
The	B-X
expressed	B-X
protein	B-X
devoid	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
also	B-X
formed	B-X
trimers	B-X
,	B-X
but	B-X
was	B-X
secreted	B-X
from	B-X
cells	B-X
in	B-X
significantly	B-X
less	B-X
amounts	B-X
than	B-X
glycosylated	B-X
trimers	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
disulfide-linked	B-X
trimers	B-X
were	B-X
assembled	B-X
inside	B-X
the	B-X
cells	B-X
no	B-X
earlier	B-X
than	B-X
30	B-X
min	B-X
after	B-X
protein	B-X
synthesis	B-X
commenced	B-X
and	B-X
after	B-X
the	B-X
intracellular	B-X
precursors	B-X
were	B-X
N-glycosylated	B-X
.	B-X
Trimer	B-X
formation	B-X
was	B-X
inhibited	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
brefeldin	B-X
A	B-X
,	B-X
monensin	B-X
,	B-X
chloroquine	B-X
,	B-X
or	B-X
bafilomycin	B-X
A1	B-X
,	B-X
although	B-X
only	B-X
brefeldin	B-X
A	B-X
prevented	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Coexpression	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
and	B-X
the	B-X
disulfide-rich	B-X
carboxyl-terminal	B-X
domain	B-X
of	B-X
the	B-X
mucin	B-X
showed	B-X
that	B-X
these	B-X
structures	B-X
were	B-X
not	B-X
disulfide-linked	B-X
with	B-X
one	B-X
another	B-X
.	B-X
Cells	B-X
expressing	B-X
a	B-X
DNA	B-X
construct	B-X
encoding	B-X
a	B-X
fusion	B-X
protein	B-X
between	B-X
the	B-X
amino-	B-X
and	B-X
carboxyl-terminal	B-X
regions	B-X
of	B-X
the	B-X
mucin	B-X
secreted	B-X
disulfide-linked	B-X
dimeric	B-X
and	B-X
high	B-X
molecular	B-X
weight	B-X
multimeric	B-X
species	B-X
of	B-X
the	B-X
recombinant	B-X
mucin	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
monensin	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
dimerization	B-X
,	B-X
but	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
disulfide-linked	B-X
dimers	B-X
of	B-X
mucin	B-X
are	B-X
subsequently	B-X
assembled	B-X
into	B-X
disulfide-linked	B-X
multimers	B-X
by	B-X
the	B-X
amino-terminal	B-X
regions	B-X
.	B-X
They	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
porcine	B-X
mucin	B-X
forms	B-X
branched	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
This	B-X
ability	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
mucin	B-X
to	B-X
aid	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
multimers	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
amino	B-X
acid	B-X
identities	B-X
to	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
human	B-X
von	B-X
Willebrand	B-X
factor	B-X
,	B-X
which	B-X
also	B-X
serves	B-X
to	B-X
form	B-X
disulfide-linked	B-X
multimers	B-X
of	B-X
this	B-X
protein	B-X
.	B-X

Analysis	O
of	O
the	O
proteins	O
immunoprecipitated	O
from	O
the	O
medium	O
of	O
transfected	O
cells	O
by	O
reducing	O
SDS	O
-	O
gel	O
electrophoresis	O
showed	O
a	O
single	O
N	O
-	O
glycosylated	O
protein	O
with	O
no	O
indication	O
of	O
proteolytically	O
processed	O
forms	O
.	O

Without	O
prior	O
reduction	O
,	O
only	O
two	O
proteins	O
,	O
corresponding	O
to	O
monomeric	O
and	O
disulfide	O
-	O
linked	O
trimeric	O
species	O
,	O
were	O
observed	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
proteins	B-X
immunoprecipitated	B-X
from	B-X
the	B-X
medium	B-X
of	B-X
transfected	B-X
cells	B-X
by	B-X
reducing	B-X
SDS-gel	B-X
electrophoresis	B-X
showed	B-X
a	B-X
single	B-X
N-glycosylated	B-X
protein	B-X
with	B-X
no	B-X
indication	B-X
of	B-X
proteolytically	B-X
processed	B-X
forms	B-X
.	B-X
Without	B-X
prior	B-X
reduction	B-X
,	B-X
only	B-X
two	B-X
proteins	B-X
,	B-X
corresponding	B-X
to	B-X
monomeric	B-X
and	B-X
disulfide-linked	B-X
trimeric	B-X
species	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
The	B-X
expressed	B-X
protein	B-X
devoid	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
also	B-X
formed	B-X
trimers	B-X
,	B-X
but	B-X
was	B-X
secreted	B-X
from	B-X
cells	B-X
in	B-X
significantly	B-X
less	B-X
amounts	B-X
than	B-X
glycosylated	B-X
trimers	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
disulfide-linked	B-X
trimers	B-X
were	B-X
assembled	B-X
inside	B-X
the	B-X
cells	B-X
no	B-X
earlier	B-X
than	B-X
30	B-X
min	B-X
after	B-X
protein	B-X
synthesis	B-X
commenced	B-X
and	B-X
after	B-X
the	B-X
intracellular	B-X
precursors	B-X
were	B-X
N-glycosylated	B-X
.	B-X
Coexpression	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
and	B-X
the	B-X
disulfide-rich	B-X
carboxyl-terminal	B-X
domain	B-X
of	B-X
the	B-X
mucin	B-X
showed	B-X
that	B-X
these	B-X
structures	B-X
were	B-X
not	B-X
disulfide-linked	B-X
with	B-X
one	B-X
another	B-X
.	B-X
Cells	B-X
expressing	B-X
a	B-X
DNA	B-X
construct	B-X
encoding	B-X
a	B-X
fusion	B-X
protein	B-X
between	B-X
the	B-X
amino-	B-X
and	B-X
carboxyl-terminal	B-X
regions	B-X
of	B-X
the	B-X
mucin	B-X
secreted	B-X
disulfide-linked	B-X
dimeric	B-X
and	B-X
high	B-X
molecular	B-X
weight	B-X
multimeric	B-X
species	B-X
of	B-X
the	B-X
recombinant	B-X
mucin	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
monensin	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
dimerization	B-X
,	B-X
but	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
disulfide-linked	B-X
dimers	B-X
of	B-X
mucin	B-X
are	B-X
subsequently	B-X
assembled	B-X
into	B-X
disulfide-linked	B-X
multimers	B-X
by	B-X
the	B-X
amino-terminal	B-X
regions	B-X
.	B-X
They	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
porcine	B-X
mucin	B-X
forms	B-X
branched	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
This	B-X
ability	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
mucin	B-X
to	B-X
aid	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
multimers	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
amino	B-X
acid	B-X
identities	B-X
to	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
human	B-X
von	B-X
Willebrand	B-X
factor	B-X
,	B-X
which	B-X
also	B-X
serves	B-X
to	B-X
form	B-X
disulfide-linked	B-X
multimers	B-X
of	B-X
this	B-X
protein	B-X
.	B-X

The	O
expressed	O
protein	O
devoid	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
also	O
formed	O
trimers	O
,	O
but	O
was	O
secreted	O
from	O
cells	O
in	O
significantly	O
less	O
amounts	O
than	O
glycosylated	O
trimers	O
.	O

Pulse	O
-	O
chase	O
studies	O
showed	O
that	O
the	O
disulfide	O
-	O
linked	O
trimers	O
were	O
assembled	O
inside	O
the	O
cells	O
no	O
earlier	O
than	O
30	O
min	O
after	O
protein	O
synthesis	O
commenced	O
and	O
after	O
the	O
intracellular	O
precursors	O
were	O
N	O
-	O
glycosylated	O
.	O

Trimer	O
formation	O
was	O
inhibited	O
in	O
cells	O
treated	O
with	O
brefeldin	O
A	O
,	O
monensin	O
,	O
chloroquine	O
,	O
or	O
bafilomycin	O
A1	O
,	O
although	O
only	O
brefeldin	O
A	O
prevented	O
the	O
secretion	O
of	O
the	O
protein	O
.	O
<EOS>	B-X
COS-7	B-X
cells	B-X
expressing	B-X
1,360	B-X
residues	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
porcine	B-X
submaxillary	B-X
mucin	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
whether	B-X
this	B-X
region	B-X
,	B-X
containing	B-X
the	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
and	B-X
D3	B-X
domains	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
forming	B-X
mucin	B-X
multimers	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
proteins	B-X
immunoprecipitated	B-X
from	B-X
the	B-X
medium	B-X
of	B-X
transfected	B-X
cells	B-X
by	B-X
reducing	B-X
SDS-gel	B-X
electrophoresis	B-X
showed	B-X
a	B-X
single	B-X
N-glycosylated	B-X
protein	B-X
with	B-X
no	B-X
indication	B-X
of	B-X
proteolytically	B-X
processed	B-X
forms	B-X
.	B-X
Without	B-X
prior	B-X
reduction	B-X
,	B-X
only	B-X
two	B-X
proteins	B-X
,	B-X
corresponding	B-X
to	B-X
monomeric	B-X
and	B-X
disulfide-linked	B-X
trimeric	B-X
species	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
The	B-X
expressed	B-X
protein	B-X
devoid	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
also	B-X
formed	B-X
trimers	B-X
,	B-X
but	B-X
was	B-X
secreted	B-X
from	B-X
cells	B-X
in	B-X
significantly	B-X
less	B-X
amounts	B-X
than	B-X
glycosylated	B-X
trimers	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
disulfide-linked	B-X
trimers	B-X
were	B-X
assembled	B-X
inside	B-X
the	B-X
cells	B-X
no	B-X
earlier	B-X
than	B-X
30	B-X
min	B-X
after	B-X
protein	B-X
synthesis	B-X
commenced	B-X
and	B-X
after	B-X
the	B-X
intracellular	B-X
precursors	B-X
were	B-X
N-glycosylated	B-X
.	B-X
Trimer	B-X
formation	B-X
was	B-X
inhibited	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
brefeldin	B-X
A	B-X
,	B-X
monensin	B-X
,	B-X
chloroquine	B-X
,	B-X
or	B-X
bafilomycin	B-X
A1	B-X
,	B-X
although	B-X
only	B-X
brefeldin	B-X
A	B-X
prevented	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Coexpression	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
and	B-X
the	B-X
disulfide-rich	B-X
carboxyl-terminal	B-X
domain	B-X
of	B-X
the	B-X
mucin	B-X
showed	B-X
that	B-X
these	B-X
structures	B-X
were	B-X
not	B-X
disulfide-linked	B-X
with	B-X
one	B-X
another	B-X
.	B-X
Cells	B-X
expressing	B-X
a	B-X
DNA	B-X
construct	B-X
encoding	B-X
a	B-X
fusion	B-X
protein	B-X
between	B-X
the	B-X
amino-	B-X
and	B-X
carboxyl-terminal	B-X
regions	B-X
of	B-X
the	B-X
mucin	B-X
secreted	B-X
disulfide-linked	B-X
dimeric	B-X
and	B-X
high	B-X
molecular	B-X
weight	B-X
multimeric	B-X
species	B-X
of	B-X
the	B-X
recombinant	B-X
mucin	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
monensin	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
dimerization	B-X
,	B-X
but	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
This	B-X
ability	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
mucin	B-X
to	B-X
aid	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
multimers	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
amino	B-X
acid	B-X
identities	B-X
to	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
human	B-X
von	B-X
Willebrand	B-X
factor	B-X
,	B-X
which	B-X
also	B-X
serves	B-X
to	B-X
form	B-X
disulfide-linked	B-X
multimers	B-X
of	B-X
this	B-X
protein	B-X
.	B-X

These	O
results	O
suggest	O
that	O
trimerization	O
takes	O
place	O
in	O
compartments	O
of	O
the	O
Golgi	O
complex	O
in	O
which	O
the	O
vacuolar	O
H	O
+	O
-	O
ATPase	O
maintains	O
an	O
acidic	O
pH	O
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
trimerization	B-X
takes	B-X
place	B-X
in	B-X
compartments	B-X
of	B-X
the	B-X
Golgi	B-X
complex	B-X
in	B-X
which	B-X
the	B-X
vacuolar	B-X
H+-ATPase	B-X
maintains	B-X
an	B-X
acidic	B-X
pH	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
disulfide-linked	B-X
dimers	B-X
of	B-X
mucin	B-X
are	B-X
subsequently	B-X
assembled	B-X
into	B-X
disulfide-linked	B-X
multimers	B-X
by	B-X
the	B-X
amino-terminal	B-X
regions	B-X
.	B-X
They	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
porcine	B-X
mucin	B-X
forms	B-X
branched	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X

Coexpression	O
in	O
the	O
same	O
cells	O
of	O
the	O
amino	O
-	O
terminal	O
region	O
and	O
the	O
disulfide	O
-	O
rich	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
mucin	O
showed	O
that	O
these	O
structures	O
were	O
not	O
disulfide	O
-	O
linked	O
with	O
one	O
another	O
.	O

Cells	O
expressing	O
a	O
DNA	O
construct	O
encoding	O
a	O
fusion	O
protein	O
between	O
the	O
amino	O
-	O
and	O
carboxyl	O
-	O
terminal	O
regions	O
of	O
the	O
mucin	O
secreted	O
disulfide	O
-	O
linked	O
dimeric	O
and	O
high	O
molecular	O
weight	O
multimeric	O
species	O
of	O
the	O
recombinant	O
mucin	O
.	O
<EOS>	B-X
COS-7	B-X
cells	B-X
expressing	B-X
1,360	B-X
residues	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
porcine	B-X
submaxillary	B-X
mucin	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
whether	B-X
this	B-X
region	B-X
,	B-X
containing	B-X
the	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
and	B-X
D3	B-X
domains	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
forming	B-X
mucin	B-X
multimers	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
proteins	B-X
immunoprecipitated	B-X
from	B-X
the	B-X
medium	B-X
of	B-X
transfected	B-X
cells	B-X
by	B-X
reducing	B-X
SDS-gel	B-X
electrophoresis	B-X
showed	B-X
a	B-X
single	B-X
N-glycosylated	B-X
protein	B-X
with	B-X
no	B-X
indication	B-X
of	B-X
proteolytically	B-X
processed	B-X
forms	B-X
.	B-X
Without	B-X
prior	B-X
reduction	B-X
,	B-X
only	B-X
two	B-X
proteins	B-X
,	B-X
corresponding	B-X
to	B-X
monomeric	B-X
and	B-X
disulfide-linked	B-X
trimeric	B-X
species	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
The	B-X
expressed	B-X
protein	B-X
devoid	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
also	B-X
formed	B-X
trimers	B-X
,	B-X
but	B-X
was	B-X
secreted	B-X
from	B-X
cells	B-X
in	B-X
significantly	B-X
less	B-X
amounts	B-X
than	B-X
glycosylated	B-X
trimers	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
disulfide-linked	B-X
trimers	B-X
were	B-X
assembled	B-X
inside	B-X
the	B-X
cells	B-X
no	B-X
earlier	B-X
than	B-X
30	B-X
min	B-X
after	B-X
protein	B-X
synthesis	B-X
commenced	B-X
and	B-X
after	B-X
the	B-X
intracellular	B-X
precursors	B-X
were	B-X
N-glycosylated	B-X
.	B-X
Trimer	B-X
formation	B-X
was	B-X
inhibited	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
brefeldin	B-X
A	B-X
,	B-X
monensin	B-X
,	B-X
chloroquine	B-X
,	B-X
or	B-X
bafilomycin	B-X
A1	B-X
,	B-X
although	B-X
only	B-X
brefeldin	B-X
A	B-X
prevented	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Coexpression	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
and	B-X
the	B-X
disulfide-rich	B-X
carboxyl-terminal	B-X
domain	B-X
of	B-X
the	B-X
mucin	B-X
showed	B-X
that	B-X
these	B-X
structures	B-X
were	B-X
not	B-X
disulfide-linked	B-X
with	B-X
one	B-X
another	B-X
.	B-X
Cells	B-X
expressing	B-X
a	B-X
DNA	B-X
construct	B-X
encoding	B-X
a	B-X
fusion	B-X
protein	B-X
between	B-X
the	B-X
amino-	B-X
and	B-X
carboxyl-terminal	B-X
regions	B-X
of	B-X
the	B-X
mucin	B-X
secreted	B-X
disulfide-linked	B-X
dimeric	B-X
and	B-X
high	B-X
molecular	B-X
weight	B-X
multimeric	B-X
species	B-X
of	B-X
the	B-X
recombinant	B-X
mucin	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
monensin	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
dimerization	B-X
,	B-X
but	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
disulfide-linked	B-X
dimers	B-X
of	B-X
mucin	B-X
are	B-X
subsequently	B-X
assembled	B-X
into	B-X
disulfide-linked	B-X
multimers	B-X
by	B-X
the	B-X
amino-terminal	B-X
regions	B-X
.	B-X
They	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
porcine	B-X
mucin	B-X
forms	B-X
branched	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
This	B-X
ability	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
mucin	B-X
to	B-X
aid	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
multimers	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
amino	B-X
acid	B-X
identities	B-X
to	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
human	B-X
von	B-X
Willebrand	B-X
factor	B-X
,	B-X
which	B-X
also	B-X
serves	B-X
to	B-X
form	B-X
disulfide-linked	B-X
multimers	B-X
of	B-X
this	B-X
protein	B-X
.	B-X

The	O
presence	O
of	O
monensin	O
in	O
the	O
medium	O
was	O
without	O
effect	O
on	O
dimerization	O
,	O
but	O
inhibited	O
the	O
formation	O
of	O
disulfide	O
-	O
linked	O
multimers	O
.	O
<EOS>	B-X
COS-7	B-X
cells	B-X
expressing	B-X
1,360	B-X
residues	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
porcine	B-X
submaxillary	B-X
mucin	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
whether	B-X
this	B-X
region	B-X
,	B-X
containing	B-X
the	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
and	B-X
D3	B-X
domains	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
forming	B-X
mucin	B-X
multimers	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
proteins	B-X
immunoprecipitated	B-X
from	B-X
the	B-X
medium	B-X
of	B-X
transfected	B-X
cells	B-X
by	B-X
reducing	B-X
SDS-gel	B-X
electrophoresis	B-X
showed	B-X
a	B-X
single	B-X
N-glycosylated	B-X
protein	B-X
with	B-X
no	B-X
indication	B-X
of	B-X
proteolytically	B-X
processed	B-X
forms	B-X
.	B-X
Without	B-X
prior	B-X
reduction	B-X
,	B-X
only	B-X
two	B-X
proteins	B-X
,	B-X
corresponding	B-X
to	B-X
monomeric	B-X
and	B-X
disulfide-linked	B-X
trimeric	B-X
species	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
The	B-X
expressed	B-X
protein	B-X
devoid	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
also	B-X
formed	B-X
trimers	B-X
,	B-X
but	B-X
was	B-X
secreted	B-X
from	B-X
cells	B-X
in	B-X
significantly	B-X
less	B-X
amounts	B-X
than	B-X
glycosylated	B-X
trimers	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
disulfide-linked	B-X
trimers	B-X
were	B-X
assembled	B-X
inside	B-X
the	B-X
cells	B-X
no	B-X
earlier	B-X
than	B-X
30	B-X
min	B-X
after	B-X
protein	B-X
synthesis	B-X
commenced	B-X
and	B-X
after	B-X
the	B-X
intracellular	B-X
precursors	B-X
were	B-X
N-glycosylated	B-X
.	B-X
Trimer	B-X
formation	B-X
was	B-X
inhibited	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
brefeldin	B-X
A	B-X
,	B-X
monensin	B-X
,	B-X
chloroquine	B-X
,	B-X
or	B-X
bafilomycin	B-X
A1	B-X
,	B-X
although	B-X
only	B-X
brefeldin	B-X
A	B-X
prevented	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Coexpression	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
and	B-X
the	B-X
disulfide-rich	B-X
carboxyl-terminal	B-X
domain	B-X
of	B-X
the	B-X
mucin	B-X
showed	B-X
that	B-X
these	B-X
structures	B-X
were	B-X
not	B-X
disulfide-linked	B-X
with	B-X
one	B-X
another	B-X
.	B-X
Cells	B-X
expressing	B-X
a	B-X
DNA	B-X
construct	B-X
encoding	B-X
a	B-X
fusion	B-X
protein	B-X
between	B-X
the	B-X
amino-	B-X
and	B-X
carboxyl-terminal	B-X
regions	B-X
of	B-X
the	B-X
mucin	B-X
secreted	B-X
disulfide-linked	B-X
dimeric	B-X
and	B-X
high	B-X
molecular	B-X
weight	B-X
multimeric	B-X
species	B-X
of	B-X
the	B-X
recombinant	B-X
mucin	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
monensin	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
dimerization	B-X
,	B-X
but	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
disulfide-linked	B-X
dimers	B-X
of	B-X
mucin	B-X
are	B-X
subsequently	B-X
assembled	B-X
into	B-X
disulfide-linked	B-X
multimers	B-X
by	B-X
the	B-X
amino-terminal	B-X
regions	B-X
.	B-X
They	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
porcine	B-X
mucin	B-X
forms	B-X
branched	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
This	B-X
ability	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
mucin	B-X
to	B-X
aid	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
multimers	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
amino	B-X
acid	B-X
identities	B-X
to	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
human	B-X
von	B-X
Willebrand	B-X
factor	B-X
,	B-X
which	B-X
also	B-X
serves	B-X
to	B-X
form	B-X
disulfide-linked	B-X
multimers	B-X
of	B-X
this	B-X
protein	B-X
.	B-X

These	O
studies	O
suggest	O
that	O
disulfide	O
-	O
linked	O
dimers	O
of	O
mucin	O
are	O
subsequently	O
assembled	O
into	O
disulfide	O
-	O
linked	O
multimers	O
by	O
the	O
amino	O
-	O
terminal	O
regions	O
.	O
<EOS>	B-X
COS-7	B-X
cells	B-X
expressing	B-X
1,360	B-X
residues	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
porcine	B-X
submaxillary	B-X
mucin	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
whether	B-X
this	B-X
region	B-X
,	B-X
containing	B-X
the	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
and	B-X
D3	B-X
domains	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
forming	B-X
mucin	B-X
multimers	B-X
.	B-X
Without	B-X
prior	B-X
reduction	B-X
,	B-X
only	B-X
two	B-X
proteins	B-X
,	B-X
corresponding	B-X
to	B-X
monomeric	B-X
and	B-X
disulfide-linked	B-X
trimeric	B-X
species	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
The	B-X
expressed	B-X
protein	B-X
devoid	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
also	B-X
formed	B-X
trimers	B-X
,	B-X
but	B-X
was	B-X
secreted	B-X
from	B-X
cells	B-X
in	B-X
significantly	B-X
less	B-X
amounts	B-X
than	B-X
glycosylated	B-X
trimers	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
disulfide-linked	B-X
trimers	B-X
were	B-X
assembled	B-X
inside	B-X
the	B-X
cells	B-X
no	B-X
earlier	B-X
than	B-X
30	B-X
min	B-X
after	B-X
protein	B-X
synthesis	B-X
commenced	B-X
and	B-X
after	B-X
the	B-X
intracellular	B-X
precursors	B-X
were	B-X
N-glycosylated	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
trimerization	B-X
takes	B-X
place	B-X
in	B-X
compartments	B-X
of	B-X
the	B-X
Golgi	B-X
complex	B-X
in	B-X
which	B-X
the	B-X
vacuolar	B-X
H+-ATPase	B-X
maintains	B-X
an	B-X
acidic	B-X
pH	B-X
.	B-X
Coexpression	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
and	B-X
the	B-X
disulfide-rich	B-X
carboxyl-terminal	B-X
domain	B-X
of	B-X
the	B-X
mucin	B-X
showed	B-X
that	B-X
these	B-X
structures	B-X
were	B-X
not	B-X
disulfide-linked	B-X
with	B-X
one	B-X
another	B-X
.	B-X
Cells	B-X
expressing	B-X
a	B-X
DNA	B-X
construct	B-X
encoding	B-X
a	B-X
fusion	B-X
protein	B-X
between	B-X
the	B-X
amino-	B-X
and	B-X
carboxyl-terminal	B-X
regions	B-X
of	B-X
the	B-X
mucin	B-X
secreted	B-X
disulfide-linked	B-X
dimeric	B-X
and	B-X
high	B-X
molecular	B-X
weight	B-X
multimeric	B-X
species	B-X
of	B-X
the	B-X
recombinant	B-X
mucin	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
monensin	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
dimerization	B-X
,	B-X
but	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
disulfide-linked	B-X
dimers	B-X
of	B-X
mucin	B-X
are	B-X
subsequently	B-X
assembled	B-X
into	B-X
disulfide-linked	B-X
multimers	B-X
by	B-X
the	B-X
amino-terminal	B-X
regions	B-X
.	B-X
They	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
porcine	B-X
mucin	B-X
forms	B-X
branched	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
This	B-X
ability	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
mucin	B-X
to	B-X
aid	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
multimers	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
amino	B-X
acid	B-X
identities	B-X
to	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
human	B-X
von	B-X
Willebrand	B-X
factor	B-X
,	B-X
which	B-X
also	B-X
serves	B-X
to	B-X
form	B-X
disulfide-linked	B-X
multimers	B-X
of	B-X
this	B-X
protein	B-X
.	B-X

They	O
also	O
suggest	O
that	O
the	O
porcine	O
mucin	O
forms	O
branched	O
disulfide	O
-	O
linked	O
multimers	O
.	O
<EOS>	B-X
COS-7	B-X
cells	B-X
expressing	B-X
1,360	B-X
residues	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
porcine	B-X
submaxillary	B-X
mucin	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
whether	B-X
this	B-X
region	B-X
,	B-X
containing	B-X
the	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
and	B-X
D3	B-X
domains	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
forming	B-X
mucin	B-X
multimers	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
proteins	B-X
immunoprecipitated	B-X
from	B-X
the	B-X
medium	B-X
of	B-X
transfected	B-X
cells	B-X
by	B-X
reducing	B-X
SDS-gel	B-X
electrophoresis	B-X
showed	B-X
a	B-X
single	B-X
N-glycosylated	B-X
protein	B-X
with	B-X
no	B-X
indication	B-X
of	B-X
proteolytically	B-X
processed	B-X
forms	B-X
.	B-X
Without	B-X
prior	B-X
reduction	B-X
,	B-X
only	B-X
two	B-X
proteins	B-X
,	B-X
corresponding	B-X
to	B-X
monomeric	B-X
and	B-X
disulfide-linked	B-X
trimeric	B-X
species	B-X
,	B-X
were	B-X
observed	B-X
.	B-X
The	B-X
expressed	B-X
protein	B-X
devoid	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
also	B-X
formed	B-X
trimers	B-X
,	B-X
but	B-X
was	B-X
secreted	B-X
from	B-X
cells	B-X
in	B-X
significantly	B-X
less	B-X
amounts	B-X
than	B-X
glycosylated	B-X
trimers	B-X
.	B-X
Pulse-chase	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
disulfide-linked	B-X
trimers	B-X
were	B-X
assembled	B-X
inside	B-X
the	B-X
cells	B-X
no	B-X
earlier	B-X
than	B-X
30	B-X
min	B-X
after	B-X
protein	B-X
synthesis	B-X
commenced	B-X
and	B-X
after	B-X
the	B-X
intracellular	B-X
precursors	B-X
were	B-X
N-glycosylated	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
trimerization	B-X
takes	B-X
place	B-X
in	B-X
compartments	B-X
of	B-X
the	B-X
Golgi	B-X
complex	B-X
in	B-X
which	B-X
the	B-X
vacuolar	B-X
H+-ATPase	B-X
maintains	B-X
an	B-X
acidic	B-X
pH	B-X
.	B-X
Coexpression	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
and	B-X
the	B-X
disulfide-rich	B-X
carboxyl-terminal	B-X
domain	B-X
of	B-X
the	B-X
mucin	B-X
showed	B-X
that	B-X
these	B-X
structures	B-X
were	B-X
not	B-X
disulfide-linked	B-X
with	B-X
one	B-X
another	B-X
.	B-X
Cells	B-X
expressing	B-X
a	B-X
DNA	B-X
construct	B-X
encoding	B-X
a	B-X
fusion	B-X
protein	B-X
between	B-X
the	B-X
amino-	B-X
and	B-X
carboxyl-terminal	B-X
regions	B-X
of	B-X
the	B-X
mucin	B-X
secreted	B-X
disulfide-linked	B-X
dimeric	B-X
and	B-X
high	B-X
molecular	B-X
weight	B-X
multimeric	B-X
species	B-X
of	B-X
the	B-X
recombinant	B-X
mucin	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
monensin	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
dimerization	B-X
,	B-X
but	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
disulfide-linked	B-X
dimers	B-X
of	B-X
mucin	B-X
are	B-X
subsequently	B-X
assembled	B-X
into	B-X
disulfide-linked	B-X
multimers	B-X
by	B-X
the	B-X
amino-terminal	B-X
regions	B-X
.	B-X
They	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
porcine	B-X
mucin	B-X
forms	B-X
branched	B-X
disulfide-linked	B-X
multimers	B-X
.	B-X
This	B-X
ability	B-X
of	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
mucin	B-X
to	B-X
aid	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
multimers	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
amino	B-X
acid	B-X
identities	B-X
to	B-X
the	B-X
amino-terminal	B-X
region	B-X
of	B-X
human	B-X
von	B-X
Willebrand	B-X
factor	B-X
,	B-X
which	B-X
also	B-X
serves	B-X
to	B-X
form	B-X
disulfide-linked	B-X
multimers	B-X
of	B-X
this	B-X
protein	B-X
.	B-X

This	O
ability	O
of	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
mucin	O
to	O
aid	O
in	O
the	O
assembly	O
of	O
multimers	O
is	O
consistent	O
with	O
its	O
amino	O
acid	O
identities	O
to	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
human	O
von	B-Protein
Willebrand	I-Protein
factor	I-Protein
,	O
which	O
also	O
serves	O
to	O
form	O
disulfide	O
-	O
linked	O
multimers	O
of	O
this	O
protein	O
.	O

A	O
link	O
between	O
secretion	O
and	O
pre	O
-	O
mRNA	O
processing	O
defects	O
in	O
Saccharomyces	O
cerevisiae	O
and	O
the	O
identification	O
of	O
a	O
novel	O
splicing	O
gene	O
,	O
RSE1	B-Protein
.	O
<EOS>	B-X
We	B-X
screened	B-X
a	B-X
collection	B-X
of	B-X
temperature-sensitive	B-X
mutants	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
for	B-X
defects	B-X
in	B-X
ER-to-Golgi	B-X
transport	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
genes	B-X
identified	B-X
in	B-X
this	B-X
screen	B-X
were	B-X
PRP2	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
known	B-X
pre-mRNA	B-X
splicing	B-X
factor	B-X
,	B-X
and	B-X
RSE1	B-X
,	B-X
a	B-X
novel	B-X
gene	B-X
that	B-X
we	B-X
show	B-X
to	B-X
be	B-X
important	B-X
for	B-X
pre-mRNA	B-X
splicing	B-X
.	B-X
The	B-X
secretion	B-X
defect	B-X
in	B-X
each	B-X
mutant	B-X
can	B-X
be	B-X
suppressed	B-X
by	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
SAR1	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
small	B-X
GTPase	B-X
essential	B-X
for	B-X
COPII	B-X
vesicle	B-X
formation	B-X
from	B-X
the	B-X
ER	B-X
,	B-X
or	B-X
by	B-X
deleting	B-X
the	B-X
intron	B-X
from	B-X
the	B-X
SAR1	B-X
gene	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
a	B-X
failure	B-X
to	B-X
splice	B-X
SAR1	B-X
pre-mRNA	B-X
is	B-X
the	B-X
specific	B-X
cause	B-X
of	B-X
the	B-X
secretion	B-X
defects	B-X
in	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
.	B-X
Moreover	B-X
,	B-X
these	B-X
data	B-X
imply	B-X
that	B-X
Sar1p	B-X
is	B-X
a	B-X
limiting	B-X
component	B-X
of	B-X
the	B-X
ER-to-Golgi	B-X
transport	B-X
machinery	B-X
and	B-X
suggest	B-X
a	B-X
way	B-X
that	B-X
secretory	B-X
pathway	B-X
function	B-X
might	B-X
be	B-X
coordinated	B-X
with	B-X
the	B-X
amount	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
cell	B-X
.	B-X

Secretory	O
proteins	O
in	O
eukaryotic	O
cells	O
are	O
transported	O
to	O
the	O
cell	O
surface	O
via	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
the	O
Golgi	O
apparatus	O
by	O
membrane	O
-	O
bounded	O
vesicles	O
.	O

We	O
screened	O
a	O
collection	O
of	O
temperature	O
-	O
sensitive	O
mutants	O
of	O
Saccharomyces	O
cerevisiae	O
for	O
defects	O
in	O
ER	O
-	O
to	O
-	O
Golgi	O
transport	O
.	O
<EOS>	B-X
Nuclear	B-X
pore	B-X
complexes	B-X
(	B-X
NPCs	B-X
)	B-X
are	B-X
essential	B-X
for	B-X
facilitated	B-X
,	B-X
directional	B-X
nuclear	B-X
transport	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
~30	B-X
different	B-X
nucleoporins	B-X
(	B-X
nups	B-X
)	B-X
are	B-X
assembled	B-X
into	B-X
NPCs	B-X
is	B-X
unknown	B-X
.	B-X
We	B-X
combined	B-X
a	B-X
genetic	B-X
strategy	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
with	B-X
Green	B-X
Fluorescence	B-X
Protein	B-X
(	B-X
GFP	B-X
)	B-X
technology	B-X
to	B-X
identify	B-X
mutants	B-X
in	B-X
NPC	B-X
structure	B-X
,	B-X
assembly	B-X
,	B-X
and	B-X
localization	B-X
.	B-X
To	B-X
identify	B-X
such	B-X
mutants	B-X
,	B-X
a	B-X
bank	B-X
of	B-X
temperature	B-X
sensitive	B-X
strains	B-X
was	B-X
generated	B-X
and	B-X
examined	B-X
by	B-X
fluorescence	B-X
microscopy	B-X
for	B-X
mislocalization	B-X
of	B-X
GFP-tagged	B-X
nups	B-X
at	B-X
the	B-X
non-permissive	B-X
temperature	B-X
.	B-X
Secretory	B-X
proteins	B-X
in	B-X
eukaryotic	B-X
cells	B-X
are	B-X
transported	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
via	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
the	B-X
Golgi	B-X
apparatus	B-X
by	B-X
membrane-bounded	B-X
vesicles	B-X
.	B-X
We	B-X
screened	B-X
a	B-X
collection	B-X
of	B-X
temperature-sensitive	B-X
mutants	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
for	B-X
defects	B-X
in	B-X
ER-to-Golgi	B-X
transport	B-X
.	B-X
Both	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
mutants	B-X
accumulate	B-X
the	B-X
ER	B-X
forms	B-X
of	B-X
invertase	B-X
and	B-X
the	B-X
vacuolar	B-X
protease	B-X
CPY	B-X
at	B-X
restrictive	B-X
temperature	B-X
.	B-X
The	B-X
secretion	B-X
defect	B-X
in	B-X
each	B-X
mutant	B-X
can	B-X
be	B-X
suppressed	B-X
by	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
SAR1	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
small	B-X
GTPase	B-X
essential	B-X
for	B-X
COPII	B-X
vesicle	B-X
formation	B-X
from	B-X
the	B-X
ER	B-X
,	B-X
or	B-X
by	B-X
deleting	B-X
the	B-X
intron	B-X
from	B-X
the	B-X
SAR1	B-X
gene	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
a	B-X
failure	B-X
to	B-X
splice	B-X
SAR1	B-X
pre-mRNA	B-X
is	B-X
the	B-X
specific	B-X
cause	B-X
of	B-X
the	B-X
secretion	B-X
defects	B-X
in	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
.	B-X
Moreover	B-X
,	B-X
these	B-X
data	B-X
imply	B-X
that	B-X
Sar1p	B-X
is	B-X
a	B-X
limiting	B-X
component	B-X
of	B-X
the	B-X
ER-to-Golgi	B-X
transport	B-X
machinery	B-X
and	B-X
suggest	B-X
a	B-X
way	B-X
that	B-X
secretory	B-X
pathway	B-X
function	B-X
might	B-X
be	B-X
coordinated	B-X
with	B-X
the	B-X
amount	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
cell	B-X
.	B-X

Two	O
of	O
the	O
genes	O
identified	O
in	O
this	O
screen	O
were	O
PRP2	B-Protein
,	O
which	O
encodes	O
a	O
known	O
pre	O
-	O
mRNA	O
splicing	O
factor	O
,	O
and	O
RSE1	B-Protein
,	O
a	O
novel	O
gene	O
that	O
we	O
show	O
to	O
be	O
important	O
for	O
pre	O
-	O
mRNA	O
splicing	O
.	O
<EOS>	B-X
We	B-X
screened	B-X
a	B-X
collection	B-X
of	B-X
temperature-sensitive	B-X
mutants	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
for	B-X
defects	B-X
in	B-X
ER-to-Golgi	B-X
transport	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
genes	B-X
identified	B-X
in	B-X
this	B-X
screen	B-X
were	B-X
PRP2	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
known	B-X
pre-mRNA	B-X
splicing	B-X
factor	B-X
,	B-X
and	B-X
RSE1	B-X
,	B-X
a	B-X
novel	B-X
gene	B-X
that	B-X
we	B-X
show	B-X
to	B-X
be	B-X
important	B-X
for	B-X
pre-mRNA	B-X
splicing	B-X
.	B-X
The	B-X
secretion	B-X
defect	B-X
in	B-X
each	B-X
mutant	B-X
can	B-X
be	B-X
suppressed	B-X
by	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
SAR1	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
small	B-X
GTPase	B-X
essential	B-X
for	B-X
COPII	B-X
vesicle	B-X
formation	B-X
from	B-X
the	B-X
ER	B-X
,	B-X
or	B-X
by	B-X
deleting	B-X
the	B-X
intron	B-X
from	B-X
the	B-X
SAR1	B-X
gene	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
a	B-X
failure	B-X
to	B-X
splice	B-X
SAR1	B-X
pre-mRNA	B-X
is	B-X
the	B-X
specific	B-X
cause	B-X
of	B-X
the	B-X
secretion	B-X
defects	B-X
in	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
.	B-X
Moreover	B-X
,	B-X
these	B-X
data	B-X
imply	B-X
that	B-X
Sar1p	B-X
is	B-X
a	B-X
limiting	B-X
component	B-X
of	B-X
the	B-X
ER-to-Golgi	B-X
transport	B-X
machinery	B-X
and	B-X
suggest	B-X
a	B-X
way	B-X
that	B-X
secretory	B-X
pathway	B-X
function	B-X
might	B-X
be	B-X
coordinated	B-X
with	B-X
the	B-X
amount	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
cell	B-X
.	B-X

Both	O
prp2	B-Protein
-	O
13	O
and	O
rse1	B-Protein
-	O
1	O
mutants	O
accumulate	O
the	O
ER	O
forms	O
of	O
invertase	O
and	O
the	O
vacuolar	O
protease	O
CPY	B-Protein
at	O
restrictive	O
temperature	O
.	O
<EOS>	B-X
Secretory	B-X
proteins	B-X
in	B-X
eukaryotic	B-X
cells	B-X
are	B-X
transported	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
via	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
the	B-X
Golgi	B-X
apparatus	B-X
by	B-X
membrane-bounded	B-X
vesicles	B-X
.	B-X
We	B-X
screened	B-X
a	B-X
collection	B-X
of	B-X
temperature-sensitive	B-X
mutants	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
for	B-X
defects	B-X
in	B-X
ER-to-Golgi	B-X
transport	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
genes	B-X
identified	B-X
in	B-X
this	B-X
screen	B-X
were	B-X
PRP2	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
known	B-X
pre-mRNA	B-X
splicing	B-X
factor	B-X
,	B-X
and	B-X
RSE1	B-X
,	B-X
a	B-X
novel	B-X
gene	B-X
that	B-X
we	B-X
show	B-X
to	B-X
be	B-X
important	B-X
for	B-X
pre-mRNA	B-X
splicing	B-X
.	B-X
Both	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
mutants	B-X
accumulate	B-X
the	B-X
ER	B-X
forms	B-X
of	B-X
invertase	B-X
and	B-X
the	B-X
vacuolar	B-X
protease	B-X
CPY	B-X
at	B-X
restrictive	B-X
temperature	B-X
.	B-X
The	B-X
secretion	B-X
defect	B-X
in	B-X
each	B-X
mutant	B-X
can	B-X
be	B-X
suppressed	B-X
by	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
SAR1	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
small	B-X
GTPase	B-X
essential	B-X
for	B-X
COPII	B-X
vesicle	B-X
formation	B-X
from	B-X
the	B-X
ER	B-X
,	B-X
or	B-X
by	B-X
deleting	B-X
the	B-X
intron	B-X
from	B-X
the	B-X
SAR1	B-X
gene	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
a	B-X
failure	B-X
to	B-X
splice	B-X
SAR1	B-X
pre-mRNA	B-X
is	B-X
the	B-X
specific	B-X
cause	B-X
of	B-X
the	B-X
secretion	B-X
defects	B-X
in	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
.	B-X
Moreover	B-X
,	B-X
these	B-X
data	B-X
imply	B-X
that	B-X
Sar1p	B-X
is	B-X
a	B-X
limiting	B-X
component	B-X
of	B-X
the	B-X
ER-to-Golgi	B-X
transport	B-X
machinery	B-X
and	B-X
suggest	B-X
a	B-X
way	B-X
that	B-X
secretory	B-X
pathway	B-X
function	B-X
might	B-X
be	B-X
coordinated	B-X
with	B-X
the	B-X
amount	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
cell	B-X
.	B-X

The	O
secretion	O
defect	O
in	O
each	O
mutant	O
can	O
be	O
suppressed	O
by	O
increasing	O
the	O
amount	O
of	O
SAR1	B-Protein
,	O
which	O
encodes	O
a	O
small	O
GTPase	O
essential	O
for	O
COPII	O
vesicle	O
formation	O
from	O
the	O
ER	O
,	O
or	O
by	O
deleting	O
the	O
intron	O
from	O
the	O
SAR1	B-Protein
gene	O
.	O
<EOS>	B-X
Secretory	B-X
proteins	B-X
in	B-X
eukaryotic	B-X
cells	B-X
are	B-X
transported	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
via	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
the	B-X
Golgi	B-X
apparatus	B-X
by	B-X
membrane-bounded	B-X
vesicles	B-X
.	B-X
We	B-X
screened	B-X
a	B-X
collection	B-X
of	B-X
temperature-sensitive	B-X
mutants	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
for	B-X
defects	B-X
in	B-X
ER-to-Golgi	B-X
transport	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
genes	B-X
identified	B-X
in	B-X
this	B-X
screen	B-X
were	B-X
PRP2	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
known	B-X
pre-mRNA	B-X
splicing	B-X
factor	B-X
,	B-X
and	B-X
RSE1	B-X
,	B-X
a	B-X
novel	B-X
gene	B-X
that	B-X
we	B-X
show	B-X
to	B-X
be	B-X
important	B-X
for	B-X
pre-mRNA	B-X
splicing	B-X
.	B-X
Both	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
mutants	B-X
accumulate	B-X
the	B-X
ER	B-X
forms	B-X
of	B-X
invertase	B-X
and	B-X
the	B-X
vacuolar	B-X
protease	B-X
CPY	B-X
at	B-X
restrictive	B-X
temperature	B-X
.	B-X
The	B-X
secretion	B-X
defect	B-X
in	B-X
each	B-X
mutant	B-X
can	B-X
be	B-X
suppressed	B-X
by	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
SAR1	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
small	B-X
GTPase	B-X
essential	B-X
for	B-X
COPII	B-X
vesicle	B-X
formation	B-X
from	B-X
the	B-X
ER	B-X
,	B-X
or	B-X
by	B-X
deleting	B-X
the	B-X
intron	B-X
from	B-X
the	B-X
SAR1	B-X
gene	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
a	B-X
failure	B-X
to	B-X
splice	B-X
SAR1	B-X
pre-mRNA	B-X
is	B-X
the	B-X
specific	B-X
cause	B-X
of	B-X
the	B-X
secretion	B-X
defects	B-X
in	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
.	B-X
Moreover	B-X
,	B-X
these	B-X
data	B-X
imply	B-X
that	B-X
Sar1p	B-X
is	B-X
a	B-X
limiting	B-X
component	B-X
of	B-X
the	B-X
ER-to-Golgi	B-X
transport	B-X
machinery	B-X
and	B-X
suggest	B-X
a	B-X
way	B-X
that	B-X
secretory	B-X
pathway	B-X
function	B-X
might	B-X
be	B-X
coordinated	B-X
with	B-X
the	B-X
amount	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
cell	B-X
.	B-X

These	O
data	O
indicate	O
that	O
a	O
failure	O
to	O
splice	O
SAR1	B-Protein
pre	O
-	O
mRNA	O
is	O
the	O
specific	O
cause	O
of	O
the	O
secretion	O
defects	O
in	O
prp2	B-Protein
-	O
13	O
and	O
rse1	B-Protein
-	O
1	O
.	O
<EOS>	B-X
We	B-X
screened	B-X
a	B-X
collection	B-X
of	B-X
temperature-sensitive	B-X
mutants	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
for	B-X
defects	B-X
in	B-X
ER-to-Golgi	B-X
transport	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
genes	B-X
identified	B-X
in	B-X
this	B-X
screen	B-X
were	B-X
PRP2	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
known	B-X
pre-mRNA	B-X
splicing	B-X
factor	B-X
,	B-X
and	B-X
RSE1	B-X
,	B-X
a	B-X
novel	B-X
gene	B-X
that	B-X
we	B-X
show	B-X
to	B-X
be	B-X
important	B-X
for	B-X
pre-mRNA	B-X
splicing	B-X
.	B-X
Both	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
mutants	B-X
accumulate	B-X
the	B-X
ER	B-X
forms	B-X
of	B-X
invertase	B-X
and	B-X
the	B-X
vacuolar	B-X
protease	B-X
CPY	B-X
at	B-X
restrictive	B-X
temperature	B-X
.	B-X
The	B-X
secretion	B-X
defect	B-X
in	B-X
each	B-X
mutant	B-X
can	B-X
be	B-X
suppressed	B-X
by	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
SAR1	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
small	B-X
GTPase	B-X
essential	B-X
for	B-X
COPII	B-X
vesicle	B-X
formation	B-X
from	B-X
the	B-X
ER	B-X
,	B-X
or	B-X
by	B-X
deleting	B-X
the	B-X
intron	B-X
from	B-X
the	B-X
SAR1	B-X
gene	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
a	B-X
failure	B-X
to	B-X
splice	B-X
SAR1	B-X
pre-mRNA	B-X
is	B-X
the	B-X
specific	B-X
cause	B-X
of	B-X
the	B-X
secretion	B-X
defects	B-X
in	B-X
prp2-13	B-X
and	B-X
rse1-1	B-X
.	B-X
Moreover	B-X
,	B-X
these	B-X
data	B-X
imply	B-X
that	B-X
Sar1p	B-X
is	B-X
a	B-X
limiting	B-X
component	B-X
of	B-X
the	B-X
ER-to-Golgi	B-X
transport	B-X
machinery	B-X
and	B-X
suggest	B-X
a	B-X
way	B-X
that	B-X
secretory	B-X
pathway	B-X
function	B-X
might	B-X
be	B-X
coordinated	B-X
with	B-X
the	B-X
amount	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
cell	B-X
.	B-X

Moreover	O
,	O
these	O
data	O
imply	O
that	O
Sar1p	B-Protein
is	O
a	O
limiting	O
component	O
of	O
the	O
ER	O
-	O
to	O
-	O
Golgi	O
transport	O
machinery	O
and	O
suggest	O
a	O
way	O
that	O
secretory	O
pathway	O
function	O
might	O
be	O
coordinated	O
with	O
the	O
amount	O
of	O
gene	O
expression	O
in	O
a	O
cell	O
.	O

Comparative	O
methylation	O
analysis	O
of	O
murine	O
transgenes	O
that	O
undergo	O
or	O
escape	O
X	O
-	O
chromosome	O
inactivation	O
.	O
<EOS>	B-X
X-chromosome	B-X
inactivation	B-X
,	B-X
which	B-X
was	B-X
discovered	B-X
by	B-X
Mary	B-X
Lyon	B-X
in	B-X
1961	B-X
results	B-X
in	B-X
random	B-X
silencing	B-X
of	B-X
one	B-X
X	B-X
chromosome	B-X
in	B-X
female	B-X
mammals	B-X
.	B-X
She	B-X
predicted	B-X
many	B-X
of	B-X
the	B-X
features	B-X
of	B-X
X	B-X
inactivation	B-X
,	B-X
for	B-X
e.g.	B-X
,	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
X	B-X
inactivation	B-X
center	B-X
,	B-X
the	B-X
role	B-X
of	B-X
L1	B-X
elements	B-X
in	B-X
spreading	B-X
of	B-X
silencing	B-X
and	B-X
the	B-X
existence	B-X
of	B-X
genes	B-X
that	B-X
escape	B-X
X	B-X
inactivation	B-X
.	B-X
X-chromosome	B-X
inactivation	B-X
(	B-X
XCI	B-X
)	B-X
is	B-X
a	B-X
process	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
several	B-X
diseases	B-X
.	B-X
In	B-X
this	B-X
mini	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
known	B-X
mechanisms	B-X
associated	B-X
with	B-X
XCI	B-X
,	B-X
when	B-X
and	B-X
how	B-X
does	B-X
it	B-X
initiate	B-X
,	B-X
spreads	B-X
and	B-X
maintain	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
mechanisms	B-X
that	B-X
allow	B-X
some	B-X
genes	B-X
to	B-X
escape	B-X
from	B-X
it	B-X
.	B-X
We	B-X
address	B-X
the	B-X
skewed	B-X
XCI	B-X
,	B-X
condition	B-X
in	B-X
which	B-X
the	B-X
process	B-X
are	B-X
not	B-X
fully	B-X
randomized	B-X
and	B-X
its	B-X
consequences	B-X
to	B-X
the	B-X
phenotype	B-X
of	B-X
some	B-X
pathologies	B-X
.	B-X
We	B-X
debate	B-X
about	B-X
the	B-X
known	B-X
pathologies	B-X
implicated	B-X
,	B-X
including	B-X
X	B-X
unbalanced	B-X
rearrangements	B-X
,	B-X
X-autosomal	B-X
balanced	B-X
translocations	B-X
,	B-X
Turner	B-X
and	B-X
Klinefelter	B-X
syndromes	B-X
and	B-X
also	B-X
for	B-X
X-linked	B-X
diseases	B-X
and	B-X
its	B-X
consequences	B-X
in	B-X
males	B-X
and	B-X
females	B-X
.	B-X
Some	B-X
pathologies	B-X
are	B-X
discussed	B-X
more	B-X
in	B-X
detail	B-X
such	B-X
as	B-X
intellectual	B-X
disability	B-X
with	B-X
a	B-X
recognized	B-X
relationship	B-X
with	B-X
XCI	B-X
.	B-X

We	O
analyzed	O
an	O
X	O
-	O
linked	O
metallothionein	O
-	O
vasopressin	B-Protein
(	O
MTVP	B-Protein
)	O
fusion	O
transgene	O
that	O
undergoes	O
X	O
-	O
chromosome	O
inactivation	O
(	O
X	O
inactivation	O
)	O
and	O
an	O
X	O
-	O
linked	O
transferrin	B-Protein
(	O
TFN	B-Protein
)	O
transgene	O
that	O
escapes	O
X	O
inactivation	O
with	O
respect	O
to	O
methylation	O
in	O
the	O
5	O
'	O
regulatory	O
regions	O
.	O

The	O
MTVP	B-Protein
transgene	O
promoter	O
region	O
is	O
unmethylated	O
when	O
the	O
transgene	O
is	O
on	O
the	O
active	O
X	O
chromosome	O
and	O
methylated	O
when	O
on	O
the	O
inactive	O
X	O
chromosome	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
an	B-X
X-linked	B-X
metallothionein-vasopressin	B-X
(	B-X
MTVP	B-X
)	B-X
fusion	B-X
transgene	B-X
that	B-X
undergoes	B-X
X-chromosome	B-X
inactivation	B-X
(	B-X
X	B-X
inactivation	B-X
)	B-X
and	B-X
an	B-X
X-linked	B-X
transferrin	B-X
(	B-X
TFN	B-X
)	B-X
transgene	B-X
that	B-X
escapes	B-X
X	B-X
inactivation	B-X
with	B-X
respect	B-X
to	B-X
methylation	B-X
in	B-X
the	B-X
5	B-X
'	B-X
regulatory	B-X
regions	B-X
.	B-X
The	B-X
MTVP	B-X
transgene	B-X
promoter	B-X
region	B-X
is	B-X
unmethylated	B-X
when	B-X
the	B-X
transgene	B-X
is	B-X
on	B-X
the	B-X
active	B-X
X	B-X
chromosome	B-X
and	B-X
methylated	B-X
when	B-X
on	B-X
the	B-X
inactive	B-X
X	B-X
chromosome	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
MTVP	B-X
transgene	B-X
is	B-X
not	B-X
detectably	B-X
transcribed	B-X
from	B-X
the	B-X
male	B-X
X	B-X
chromosome	B-X
,	B-X
although	B-X
it	B-X
is	B-X
unmethylated	B-X
,	B-X
consistent	B-X
with	B-X
its	B-X
availability	B-X
for	B-X
transcription	B-X
.	B-X
The	B-X
TFN	B-X
transgene	B-X
promoter	B-X
region	B-X
is	B-X
hypomethylated	B-X
on	B-X
both	B-X
the	B-X
active	B-X
and	B-X
inactive	B-X
X	B-X
chromosomes	B-X
,	B-X
consistent	B-X
with	B-X
its	B-X
expression	B-X
from	B-X
both	B-X
chromosomes	B-X
.	B-X
The	B-X
TFN	B-X
and	B-X
MTVP	B-X
transgenes	B-X
have	B-X
been	B-X
mapped	B-X
to	B-X
chromosomal	B-X
regions	B-X
D	B-X
and	B-X
C	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
fluorescence	B-X
in	B-X
situ	B-X
hybridization	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
discussed	B-X
in	B-X
the	B-X
context	B-X
of	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
spread	B-X
and	B-X
maintenance	B-X
of	B-X
X-chromosome	B-X
inactivation	B-X
.	B-X

Interestingly	O
,	O
the	O
MTVP	B-Protein
transgene	O
is	O
not	O
detectably	O
transcribed	O
from	O
the	O
male	O
X	O
chromosome	O
,	O
although	O
it	O
is	O
unmethylated	O
,	O
consistent	O
with	O
its	O
availability	O
for	O
transcription	O
.	O

The	O
TFN	B-Protein
transgene	O
promoter	O
region	O
is	O
hypomethylated	O
on	O
both	O
the	O
active	O
and	O
inactive	O
X	O
chromosomes	O
,	O
consistent	O
with	O
its	O
expression	O
from	O
both	O
chromosomes	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
an	B-X
X-linked	B-X
metallothionein-vasopressin	B-X
(	B-X
MTVP	B-X
)	B-X
fusion	B-X
transgene	B-X
that	B-X
undergoes	B-X
X-chromosome	B-X
inactivation	B-X
(	B-X
X	B-X
inactivation	B-X
)	B-X
and	B-X
an	B-X
X-linked	B-X
transferrin	B-X
(	B-X
TFN	B-X
)	B-X
transgene	B-X
that	B-X
escapes	B-X
X	B-X
inactivation	B-X
with	B-X
respect	B-X
to	B-X
methylation	B-X
in	B-X
the	B-X
5	B-X
'	B-X
regulatory	B-X
regions	B-X
.	B-X
The	B-X
MTVP	B-X
transgene	B-X
promoter	B-X
region	B-X
is	B-X
unmethylated	B-X
when	B-X
the	B-X
transgene	B-X
is	B-X
on	B-X
the	B-X
active	B-X
X	B-X
chromosome	B-X
and	B-X
methylated	B-X
when	B-X
on	B-X
the	B-X
inactive	B-X
X	B-X
chromosome	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
MTVP	B-X
transgene	B-X
is	B-X
not	B-X
detectably	B-X
transcribed	B-X
from	B-X
the	B-X
male	B-X
X	B-X
chromosome	B-X
,	B-X
although	B-X
it	B-X
is	B-X
unmethylated	B-X
,	B-X
consistent	B-X
with	B-X
its	B-X
availability	B-X
for	B-X
transcription	B-X
.	B-X
The	B-X
TFN	B-X
transgene	B-X
promoter	B-X
region	B-X
is	B-X
hypomethylated	B-X
on	B-X
both	B-X
the	B-X
active	B-X
and	B-X
inactive	B-X
X	B-X
chromosomes	B-X
,	B-X
consistent	B-X
with	B-X
its	B-X
expression	B-X
from	B-X
both	B-X
chromosomes	B-X
.	B-X
The	B-X
TFN	B-X
and	B-X
MTVP	B-X
transgenes	B-X
have	B-X
been	B-X
mapped	B-X
to	B-X
chromosomal	B-X
regions	B-X
D	B-X
and	B-X
C	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
fluorescence	B-X
in	B-X
situ	B-X
hybridization	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
discussed	B-X
in	B-X
the	B-X
context	B-X
of	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
spread	B-X
and	B-X
maintenance	B-X
of	B-X
X-chromosome	B-X
inactivation	B-X
.	B-X

The	O
TFN	B-Protein
and	O
MTVP	B-Protein
transgenes	O
have	O
been	O
mapped	O
to	O
chromosomal	O
regions	O
D	O
and	O
C	O
,	O
respectively	O
,	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
an	B-X
X-linked	B-X
metallothionein-vasopressin	B-X
(	B-X
MTVP	B-X
)	B-X
fusion	B-X
transgene	B-X
that	B-X
undergoes	B-X
X-chromosome	B-X
inactivation	B-X
(	B-X
X	B-X
inactivation	B-X
)	B-X
and	B-X
an	B-X
X-linked	B-X
transferrin	B-X
(	B-X
TFN	B-X
)	B-X
transgene	B-X
that	B-X
escapes	B-X
X	B-X
inactivation	B-X
with	B-X
respect	B-X
to	B-X
methylation	B-X
in	B-X
the	B-X
5	B-X
'	B-X
regulatory	B-X
regions	B-X
.	B-X
The	B-X
MTVP	B-X
transgene	B-X
promoter	B-X
region	B-X
is	B-X
unmethylated	B-X
when	B-X
the	B-X
transgene	B-X
is	B-X
on	B-X
the	B-X
active	B-X
X	B-X
chromosome	B-X
and	B-X
methylated	B-X
when	B-X
on	B-X
the	B-X
inactive	B-X
X	B-X
chromosome	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
MTVP	B-X
transgene	B-X
is	B-X
not	B-X
detectably	B-X
transcribed	B-X
from	B-X
the	B-X
male	B-X
X	B-X
chromosome	B-X
,	B-X
although	B-X
it	B-X
is	B-X
unmethylated	B-X
,	B-X
consistent	B-X
with	B-X
its	B-X
availability	B-X
for	B-X
transcription	B-X
.	B-X
The	B-X
TFN	B-X
transgene	B-X
promoter	B-X
region	B-X
is	B-X
hypomethylated	B-X
on	B-X
both	B-X
the	B-X
active	B-X
and	B-X
inactive	B-X
X	B-X
chromosomes	B-X
,	B-X
consistent	B-X
with	B-X
its	B-X
expression	B-X
from	B-X
both	B-X
chromosomes	B-X
.	B-X
The	B-X
TFN	B-X
and	B-X
MTVP	B-X
transgenes	B-X
have	B-X
been	B-X
mapped	B-X
to	B-X
chromosomal	B-X
regions	B-X
D	B-X
and	B-X
C	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
fluorescence	B-X
in	B-X
situ	B-X
hybridization	B-X
.	B-X

These	O
observations	O
are	O
discussed	O
in	O
the	O
context	O
of	O
our	O
understanding	O
of	O
the	O
role	O
of	O
DNA	O
methylation	O
in	O
the	O
spread	O
and	O
maintenance	O
of	O
X	O
-	O
chromosome	O
inactivation	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
an	B-X
X-linked	B-X
metallothionein-vasopressin	B-X
(	B-X
MTVP	B-X
)	B-X
fusion	B-X
transgene	B-X
that	B-X
undergoes	B-X
X-chromosome	B-X
inactivation	B-X
(	B-X
X	B-X
inactivation	B-X
)	B-X
and	B-X
an	B-X
X-linked	B-X
transferrin	B-X
(	B-X
TFN	B-X
)	B-X
transgene	B-X
that	B-X
escapes	B-X
X	B-X
inactivation	B-X
with	B-X
respect	B-X
to	B-X
methylation	B-X
in	B-X
the	B-X
5	B-X
'	B-X
regulatory	B-X
regions	B-X
.	B-X
The	B-X
MTVP	B-X
transgene	B-X
promoter	B-X
region	B-X
is	B-X
unmethylated	B-X
when	B-X
the	B-X
transgene	B-X
is	B-X
on	B-X
the	B-X
active	B-X
X	B-X
chromosome	B-X
and	B-X
methylated	B-X
when	B-X
on	B-X
the	B-X
inactive	B-X
X	B-X
chromosome	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
MTVP	B-X
transgene	B-X
is	B-X
not	B-X
detectably	B-X
transcribed	B-X
from	B-X
the	B-X
male	B-X
X	B-X
chromosome	B-X
,	B-X
although	B-X
it	B-X
is	B-X
unmethylated	B-X
,	B-X
consistent	B-X
with	B-X
its	B-X
availability	B-X
for	B-X
transcription	B-X
.	B-X
The	B-X
TFN	B-X
transgene	B-X
promoter	B-X
region	B-X
is	B-X
hypomethylated	B-X
on	B-X
both	B-X
the	B-X
active	B-X
and	B-X
inactive	B-X
X	B-X
chromosomes	B-X
,	B-X
consistent	B-X
with	B-X
its	B-X
expression	B-X
from	B-X
both	B-X
chromosomes	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
discussed	B-X
in	B-X
the	B-X
context	B-X
of	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
DNA	B-X
methylation	B-X
in	B-X
the	B-X
spread	B-X
and	B-X
maintenance	B-X
of	B-X
X-chromosome	B-X
inactivation	B-X
.	B-X

